PMID- 40063960 OWN - NLM STAT- MEDLINE DCOM- 20250512 LR - 20250512 IS - 1539-3704 (Electronic) IS - 0003-4819 (Linking) VI - 178 IP - 3 DP - 2025 Mar TI - Gout. PG - ITC33-ITC48 LID - 10.7326/ANNALS-24-03951 [doi] AB - Gout is characterized by deposition of monosodium urate (MSU) crystals in or around joints, tendons, bursae, and other tissues, resulting in painful recurrent flares and tissue damage. Gout is the most common form of inflammatory arthritis, with a prevalence of 5.1% in the United States, affecting 12.1 million adults. When urate levels exceed the limit of solubility (6.8 mg/dL [400 μmol/L]), MSU crystals may form or grow. Gout flares are the result of inflammatory responses to MSU crystals. The primary method to prevent and reduce gout flares, tophi, chronic inflammatory arthritis, and joint damage is to reduce urate levels below the saturation threshold. The pathophysiology of gout is well understood, and inexpensive and effective therapies are available. However, outcomes for patients with gout remain poorly optimized. FAU - FitzGerald, John D AU - FitzGerald JD AD - University of California, Los Angeles, Los Angeles, California (J.D.F.). LA - eng PT - Journal Article PT - Review DEP - 20250311 PL - United States TA - Ann Intern Med JT - Annals of internal medicine JID - 0372351 RN - 268B43MJ25 (Uric Acid) RN - 0 (Gout Suppressants) SB - IM MH - Humans MH - *Gout/drug therapy/therapy/diagnosis/physiopathology/epidemiology/etiology MH - Uric Acid/metabolism/blood MH - Gout Suppressants/therapeutic use COIS- Disclosures: All relevant financial relationships have been mitigated. Disclosure forms are available with the article online. EDAT- 2025/03/10 18:26 MHDA- 2025/03/25 12:39 CRDT- 2025/03/10 17:03 PHST- 2025/03/25 12:39 [medline] PHST- 2025/03/10 18:26 [pubmed] PHST- 2025/03/10 17:03 [entrez] AID - 10.7326/ANNALS-24-03951 [doi] PST - ppublish SO - Ann Intern Med. 2025 Mar;178(3):ITC33-ITC48. doi: 10.7326/ANNALS-24-03951. Epub 2025 Mar 11. PMID- 39216481 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20251203 IS - 1878-1551 (Electronic) IS - 1534-5807 (Print) IS - 1534-5807 (Linking) VI - 59 IP - 23 DP - 2024 Dec 2 TI - A conserved transcription factor regulatory program promotes tendon fate. PG - 3106-3123.e12 LID - S1534-5807(24)00489-1 [pii] LID - 10.1016/j.devcel.2024.08.006 [doi] AB - Tendons, which transmit force from muscles to bones, are highly prone to injury. Understanding the mechanisms driving tendon fate would impact efforts to improve tendon healing, yet this knowledge is limited. To find direct regulators of tendon progenitor emergence, we performed a zebrafish high-throughput chemical screen. We established forskolin as a tenogenic inducer across vertebrates, functioning through Creb1a, which is required and sufficient for tendon fate. Putative enhancers containing cyclic AMP (cAMP) response elements (CREs) in humans, mice, and fish drove specific expression in zebrafish cranial and fin tendons. Analysis of these genomic regions identified motifs for early B cell factor (Ebf/EBF) transcription factors. Mutation of CRE or Ebf/EBF motifs significantly disrupted enhancer activity and specificity in tendons. Zebrafish ebf1a/ebf3a mutants displayed defects in tendon formation. Notably, Creb1a/CREB1 and Ebf1a/Ebf3a/EBF1 overexpression facilitated tenogenic induction in zebrafish and human pluripotent stem cells. Together, our work identifies the functional conservation of two transcription factors in promoting tendon fate. CI - Copyright © 2024 Elsevier Inc. All rights reserved. FAU - Niu, Xubo AU - Niu X AD - Center for Regenerative Medicine, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. FAU - Melendez, Delmy L AU - Melendez DL AD - Department of Orthopaedic Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Raj, Suyash AU - Raj S AD - Department of Orthopaedic Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Cai, Junming AU - Cai J AD - Department of Orthopaedic Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Senadeera, Dulanjalee AU - Senadeera D AD - Department of Orthopaedic Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Mandelbaum, Joseph AU - Mandelbaum J AD - Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Shestopalov, Ilya A AU - Shestopalov IA AD - Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Martin, Scott D AU - Martin SD AD - Department of Sports Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. FAU - Zon, Leonard I AU - Zon LI AD - Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Boston, MA, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. FAU - Schlaeger, Thorsten M AU - Schlaeger TM AD - Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. FAU - Lai, Lick Pui AU - Lai LP AD - Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. FAU - McMahon, Andrew P AU - McMahon AP AD - Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. FAU - Craft, April M AU - Craft AM AD - Department of Orthopaedic Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: april.craft@childrens.harvard.edu. FAU - Galloway, Jenna L AU - Galloway JL AD - Center for Regenerative Medicine, Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address: jenna_galloway@hms.harvard.edu. LA - eng GR - R03 DE024771/DE/NIDCR NIH HHS/United States GR - R00 HD069533/HD/NICHD NIH HHS/United States GR - R01 AR074541/AR/NIAMS NIH HHS/United States GR - R01 AR079495/AR/NIAMS NIH HHS/United States GR - R01 AR073821/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240830 PL - United States TA - Dev Cell JT - Developmental cell JID - 101120028 RN - 0 (Zebrafish Proteins) RN - 0 (Transcription Factors) RN - 0 (Cyclic AMP Response Element-Binding Protein) RN - 1F7A44V6OU (Colforsin) RN - E0399OZS9N (Cyclic AMP) SB - IM MH - *Zebrafish/genetics/metabolism MH - Animals MH - *Tendons/metabolism MH - Humans MH - *Zebrafish Proteins/metabolism/genetics MH - *Transcription Factors/metabolism/genetics MH - *Cyclic AMP Response Element-Binding Protein/metabolism/genetics MH - *Cell Differentiation/genetics MH - Mice MH - Gene Expression Regulation, Developmental MH - Colforsin/pharmacology MH - Cyclic AMP/metabolism MH - Pluripotent Stem Cells/metabolism/cytology MH - Enhancer Elements, Genetic/genetics PMC - PMC11781300 MID - NIHMS2021519 OTO - NOTNLM OT - Creb1a/CREB1 OT - Ebf1a/Ebf3a/EBF1 OT - cAMP OT - chemical screen OT - enhancer OT - forskolin/colforsin OT - scxa OT - tendon OT - zebrafish COIS- Declaration of interests L.I.Z. is a founder and stockholder of Fate Therapeutics, CAMP4 Therapeutics, Amagma Therapeutics, and Scholar Rock and is a consultant for Celularity. EDAT- 2024/09/01 16:21 MHDA- 2024/12/04 00:23 PMCR- 2025/12/02 CRDT- 2024/08/31 18:42 PHST- 2023/04/03 00:00 [received] PHST- 2024/01/24 00:00 [revised] PHST- 2024/08/08 00:00 [accepted] PHST- 2024/12/04 00:23 [medline] PHST- 2024/09/01 16:21 [pubmed] PHST- 2024/08/31 18:42 [entrez] PHST- 2025/12/02 00:00 [pmc-release] AID - S1534-5807(24)00489-1 [pii] AID - 10.1016/j.devcel.2024.08.006 [doi] PST - ppublish SO - Dev Cell. 2024 Dec 2;59(23):3106-3123.e12. doi: 10.1016/j.devcel.2024.08.006. Epub 2024 Aug 30. PMID- 39012676 OWN - NLM STAT- MEDLINE DCOM- 20250519 LR - 20250524 IS - 2152-5250 (Electronic) IS - 2152-5250 (Linking) VI - 16 IP - 3 DP - 2024 Jun 24 TI - Therapeutic Potential of Quercetin as an Antioxidant for Bone-Muscle-Tendon Regeneration and Aging. PG - 1414-1437 LID - 10.14336/AD.2024.0282 [doi] AB - Quercetin (QC), a naturally occurring bioflavonoid found in various fruits and vegetables, possesses many potential health benefits, primarily attributed to its robust antioxidant properties. The generation of oxidative stress in bone cells is a key modulator of their physiological behavior. Moreover, oxidative stress status influences the pathophysiology of mineralized tissues. Increasing scientific evidence demonstrates that manipulating the redox balance in bone cells might be an effective technique for developing bone disease therapies. The QC antioxidant abilities in skeletal muscle significantly enhance muscle regeneration and reduce muscle atrophy. In addition, QC has been shown to have protective effects against oxidative stress, inflammation, apoptosis, and matrix degradation in tendons, helping to maintain the structural integrity and functionality of tendons. Thus, the antioxidant properties of QC might be crucial for addressing age-related musculoskeletal disorders like osteoporosis, sarcopenia, and tendon-related inflammatory conditions. Understanding how QC influences redox signaling pathways involved in musculoskeletal disorders, including their effect on bone, muscle, and tendon differentiation, might provide insights into the diverse advantages of QC in promoting tissue regeneration and preventing cellular damage. Therefore, this study reviewed the intricate relationship among oxidative stress, inflammation, and tissue repair, affected by the antioxidative abilities of QC, in age-related musculoskeletal tissues to improve the overall health of bones, muscles, and tendons of the skeletal system. Also, reviewing the ongoing clinical trials of QC for musculoskeletal systems is encouraging. Given the positive effect of QC on musculoskeletal health, further scientific investigations and controlled human intervention studies are necessary to explore the therapeutic potential to its optimum strength. FAU - Kim, Jae Gyu AU - Kim JG AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. FAU - Sharma, Ashish Ranjan AU - Sharma AR AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. FAU - Lee, Yeon-Hee AU - Lee YH AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. FAU - Chatterjee, Srijan AU - Chatterjee S AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. FAU - Choi, Yean Jung AU - Choi YJ AD - Department of Food and Nutrition, Sahmyook University, Seoul 01795, Korea. FAU - Rajvansh, Roshani AU - Rajvansh R AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. FAU - Chakraborty, Chiranjib AU - Chakraborty C AD - Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Barasat-Barrackpore Road, Kolkata, West Bengal 700126, India. FAU - Lee, Sang-Soo AU - Lee SS AD - Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Gangwon-do, Korea. LA - eng PT - Journal Article PT - Review DEP - 20240624 PL - United States TA - Aging Dis JT - Aging and disease JID - 101540533 RN - 0 (Antioxidants) RN - 9IKM0I5T1E (Quercetin) SB - IM MH - Humans MH - *Antioxidants/pharmacology/therapeutic use MH - *Quercetin/pharmacology/therapeutic use MH - *Aging/drug effects MH - *Muscle, Skeletal/drug effects/physiology MH - *Tendons/drug effects/physiology MH - *Regeneration/drug effects MH - Oxidative Stress/drug effects MH - Animals MH - *Bone and Bones/drug effects MH - *Bone Regeneration/drug effects PMC - PMC12096925 COIS- The authors have declared no conflict of interest regarding the publication of this paper. EDAT- 2024/07/16 12:43 MHDA- 2025/05/20 00:29 PMCR- 2025/05/17 CRDT- 2024/07/16 11:53 PHST- 2024/03/12 00:00 [received] PHST- 2024/06/24 00:00 [accepted] PHST- 2025/05/20 00:29 [medline] PHST- 2024/07/16 12:43 [pubmed] PHST- 2024/07/16 11:53 [entrez] PHST- 2025/05/17 00:00 [pmc-release] AID - AD.2024.0282 [pii] AID - ad-16-3-1414 [pii] AID - 10.14336/AD.2024.0282 [doi] PST - epublish SO - Aging Dis. 2024 Jun 24;16(3):1414-1437. doi: 10.14336/AD.2024.0282. PMID- 30451771 OWN - NLM STAT- MEDLINE DCOM- 20181217 LR - 20181217 IS - 1542-538X (Electronic) IS - 0744-6020 (Linking) VI - 37 IP - 6 DP - 2018 Nov/Dec TI - Snapping Hip Syndrome. PG - 357-360 LID - 10.1097/NOR.0000000000000499 [doi] AB - Coxa saltans, or snapping hip syndrome, is a common orthopaedic problem that can easily be diagnosed and treated when the proper evaluation and management are utilized. It is often seen in growing adolescents, athletes, and people with sudden increase in physical activity. A thorough physical examination will help decipher whether the snapping hip is intra-articular or extra-articular and will help guide treatment options. This article reviews how to perform a physical assessment and treatment options such as medications, stretching, physical therapy, articular injections, and possible surgical interventions. Complications from conservative treatments are rare, but weakness, infection, nerve damage, and atrophy may occur following surgical procedures. FAU - Badowski, Elizabeth AU - Badowski E AD - Elizabeth Badowski, MSN, RN, CRNP, Department of Orthopedics, Nationwide Children's Hospital, Columbus, OH. LA - eng PT - Journal Article PL - United States TA - Orthop Nurs JT - Orthopedic nursing JID - 8409486 RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) RN - Y8335394RO (Bupivacaine) MH - Adolescent MH - Bupivacaine/administration & dosage MH - Female MH - *Hip Joint/diagnostic imaging MH - Humans MH - Joint Diseases/diagnostic imaging/*surgery/*therapy MH - Lidocaine/administration & dosage MH - Orthopedic Nursing MH - Radiology, Interventional/methods MH - Tendons MH - Triamcinolone Acetonide/administration & dosage MH - Ultrasonography, Interventional/methods EDAT- 2018/11/20 06:00 MHDA- 2018/12/18 06:00 CRDT- 2018/11/20 06:00 PHST- 2018/11/20 06:00 [entrez] PHST- 2018/11/20 06:00 [pubmed] PHST- 2018/12/18 06:00 [medline] AID - 00006416-201811000-00007 [pii] AID - 10.1097/NOR.0000000000000499 [doi] PST - ppublish SO - Orthop Nurs. 2018 Nov/Dec;37(6):357-360. doi: 10.1097/NOR.0000000000000499. PMID- 27535254 OWN - NLM STAT- MEDLINE DCOM- 20171205 LR - 20171205 IS - 0065-2598 (Print) IS - 0065-2598 (Linking) VI - 920 DP - 2016 TI - Hyperuricemia in Tendons. PG - 123-32 LID - 10.1007/978-3-319-33943-6_11 [doi] AB - Hyperuricemia, particularly gout, and the immune inflammatory response are highly integrated. Both, long standing hyperuricemia and monosodium urate (MSU) crystal deposition can challenge tendon homeostasis because of their potential to cause inflammation to the host. Knowledge is emerging from clinical imaging research depicting where MSU crystals deposit, including patellar tendon, triceps and quadriceps tendons. Remarkably, subclinical tendon inflammation and damage are also present in asymptomatic hyperuricemia. Monosodium urate crystals act as danger activating molecular patterns (DAMPs), activating the inflammasome and inducing the secretion of IL-1beta, a key mediator of the inflammatory response. The crucial role of IL-1beta in driving the inflammatory events during gout attacks is supported by the clinical efficacy of IL-1beta blockade. Some data implicating IL-1beta as an initiator of tendinopathy exist, but the link between hyperuricemia and the development of tendinopathy remains to be validated. Further knowledge about the interactions of uric acid with both innate immune and tendon cells, and their consequences may help to determine if there is a subclass of hyperuricemic-tendinopathy. FAU - Andia, Isabel AU - Andia I AD - Regenerative Medicine Laboratory, BioCruces Health Research Institute, Cruces University Hospital, 48903, Barakaldo, Spain. iandia2010@hotmail.com. FAU - Abate, Michele AU - Abate M AD - Department of Medicine and Science of Aging, University G. d'Annunzio, Via dei Vestini 31, Chieti-Pescara, 66013, Chieti Scalo (CH), Italy. LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Exp Med Biol JT - Advances in experimental medicine and biology JID - 0121103 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - Hyperuricemia/diagnosis/*etiology MH - Tendinopathy/*complications/metabolism MH - Tendons/*physiopathology MH - Uric Acid/*metabolism EDAT- 2016/08/19 06:00 MHDA- 2017/12/06 06:00 CRDT- 2016/08/19 06:00 PHST- 2016/08/19 06:00 [entrez] PHST- 2016/08/19 06:00 [pubmed] PHST- 2017/12/06 06:00 [medline] AID - 10.1007/978-3-319-33943-6_11 [doi] PST - ppublish SO - Adv Exp Med Biol. 2016;920:123-32. doi: 10.1007/978-3-319-33943-6_11. PMID- 31361101 OWN - NLM STAT- MEDLINE DCOM- 20200403 LR - 20200403 IS - 1532-0650 (Electronic) IS - 0002-838X (Linking) VI - 100 IP - 3 DP - 2019 Aug 1 TI - Management of Chronic Tendon Injuries. PG - 147-157 AB - Chronic tendon injuries are common athletic and occupational injuries that account for many physician visits. Tendons have a complex biology that provides a unique combination of strength, flexibility, and elasticity but also predisposes them to injury. The term tendinopathy is preferred to tendinitis because of the presence of a disordered and degenerative healing process-not inflammation-in the pathologic tendon. Insidious onset of pain and dysfunction is a common presentation for most tendinopathies, and patients typically report that a change in activity affected the use of the tendon. Diagnosis is typically based on history and physical examination findings, but radiography is an acceptable initial imaging modality. Ultrasonography and magnetic resonance imaging may be useful when the diagnosis is unclear. The mainstays of treatment are activity modification, relative rest, pain control, and protection. Early initiation of rehabilitative exercises that emphasize eccentric loading is also beneficial. Despite a lack of high-quality evidence, cryotherapy has a role in controlling pain. Nonsteroidal anti-inflammatorydrugs and corticosteroids have a role in treatment despite the lack of histologic evidence of inflammation. Short-term use of these drugs reduces pain and increases range of motion, which can assist patients in completing rehabilitative exercises. Care should be taken when injecting corticosteroids into and near major load-bearing tendons because of the risk of rupture. Topical nitroglycerin, extracorporeal shock wave therapy, and platelet-rich plasma injections have varying levels of evidence in certain tendinopathies and are additional nonsurgical treatment options. FAU - Kane, Shawn F AU - Kane SF AD - University of North Carolina School of Medicine, Chapel Hill, NC, USA. FAU - Olewinski, Lucianne H AU - Olewinski LH AD - University of Tennessee College of Medicine, Knoxville, TN, USA. FAU - Tamminga, Kyle S AU - Tamminga KS AD - University of North Carolina School of Medicine, Chapel Hill, NC, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Am Fam Physician JT - American family physician JID - 1272646 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Vasodilator Agents) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Adrenal Cortex Hormones/administration & dosage MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Chronic Disease MH - Cryotherapy MH - Exercise Therapy/*methods MH - Extracorporeal Shockwave Therapy MH - Humans MH - Nitroglycerin/administration & dosage MH - *Pain Management MH - Platelet-Rich Plasma MH - Rest MH - Tendinopathy/*therapy MH - Tendon Injuries/therapy MH - Vasodilator Agents/administration & dosage EDAT- 2019/07/31 06:00 MHDA- 2020/04/04 06:00 CRDT- 2019/07/31 06:00 PHST- 2019/07/31 06:00 [entrez] PHST- 2019/07/31 06:00 [pubmed] PHST- 2020/04/04 06:00 [medline] AID - d14440 [pii] PST - ppublish SO - Am Fam Physician. 2019 Aug 1;100(3):147-157. PMID- 19137124 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20170427 IS - 1699-3993 (Print) IS - 1699-3993 (Linking) VI - 44 IP - 9 DP - 2008 Sep TI - Celecoxib, NSAIDs and the skeleton. PG - 693-709 LID - 10.1358/dot.2008.44.9.1251573 [doi] AB - Treating acute and chronic musculoskeletal pain is essential for improving healing of traumatic injuries and surgical procedures, and for improving patient quality of life. Physicians are limited primarily to treating musculoskeletal pain with nonsteroidal antiinflammatory drugs (NSAIDs), cyclooxygenase type 2 (COX-2)-selective NSAIDs such as celecoxib, or narcotics. Patients often treat their pain with over-the-counter NSAIDs. Unlike narcotics that target the central nervous system to alleviate pain, NSAIDs inhibit cyclooxygenase activity within the central nervous system and at the peripheral pain site to prevent the conversion of arachidonic acid into prostaglandins. Thus, NSAID use can and does alter certain fundamental processes involved in the normal healing of injured tissues. Cyclooxygenase activity and prostaglandin signaling are critical regulators of normal skeletal metabolism and inflammation related to injury or disease. Since most people only use NSAIDs sporadically to treat pain, few data indicate that short-term or repeated occasional use of NSAIDs is deleterious to skeletal health. However, clinical data suggest that chronic use of celecoxib, may impair normal skeletal function leading to decreased bone mineral density in older male patients. Experimental studies also have documented the negative effects of NSAIDs on healing of skeletal tissues. Fracture healing and tendon-to-bone healing appear to be particularly susceptible to inhibition by celecoxib. Limited retrospective clinical data tends to support the experimental data that COX-2 function is critical for normal bone healing. In contrast, NSAID use and perhaps COX-2-selective NSAID use may be beneficial for healing of other skeletal injuries. In particular, NSAID use does not appear to have a long-term negative effect on the ultimate healing of tendons and ligaments. Indeed, NSAID therapy may inhibit adhesion formation during tendon healing, which leads to a better functional recovery. Certainly, NSAID therapy following acetabular fractures, other hip fractures, or following hip replacement surgery is beneficial for reducing heterotopic ossification that can limit joint mobility. The effects of NSAID or celecoxib therapy on healing of other skeletal tissues is less clear. For instance, clinical data indicates that celecoxib therapy does not impair spinal fusion but experimental data indicates the opposite. Similarly, some reports suggest that NSAID therapy may prevent further erosion of cartilage in certain arthritic conditions while other reports indicate that NSAID treatment will exacerbate cartilage damage. The difference in effects caused by NSAID or celecoxib therapy likely relate to the role cyclooxygenase has in the biology of the injured tissue or its healing response. Differences in pharmacology between NSAIDs, treatment regimens, experimental models and potential off-target effects also may confuse many of these issues. It is clear, however, that cyclooxygenase activity is involved in the healing of many skeletal tissues, either directly or indirectly through modulation of the inflammatory response. Consequently, pharmacological manipulation of cyclooxygenase using NSAIDs or celecoxib can profoundly affect skeletal health. CI - Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved. FAU - O'Connor, J Patrick AU - O'Connor JP AD - UMDNJ-New Jersey Medical School, Newark, New Jersey 07103, USA. oconnojp@umdnj.edu FAU - Lysz, Thomas AU - Lysz T LA - eng PT - Journal Article PT - Review PL - Spain TA - Drugs Today (Barc) JT - Drugs of today (Barcelona, Spain : 1998) JID - 101160518 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use MH - Arthritis/drug therapy/physiopathology MH - Bone Regeneration/drug effects MH - Bone and Bones/*drug effects/metabolism MH - Celecoxib MH - Humans MH - Ossification, Heterotopic/drug therapy MH - Osteoporosis/physiopathology MH - Pain/drug therapy MH - Pyrazoles/*adverse effects/pharmacology/therapeutic use MH - Spinal Fusion/methods MH - Sulfonamides/*adverse effects/pharmacology/therapeutic use MH - Tendon Injuries/drug therapy/physiopathology RF - 132 EDAT- 2009/01/13 09:00 MHDA- 2009/02/12 09:00 CRDT- 2009/01/13 09:00 PHST- 2009/01/13 09:00 [entrez] PHST- 2009/01/13 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] AID - 1251573 [pii] AID - 10.1358/dot.2008.44.9.1251573 [doi] PST - ppublish SO - Drugs Today (Barc). 2008 Sep;44(9):693-709. doi: 10.1358/dot.2008.44.9.1251573. PMID- 40325895 OWN - NLM STAT- MEDLINE DCOM- 20250520 LR - 20250520 IS - 1936-086X (Electronic) IS - 1936-0851 (Linking) VI - 19 IP - 19 DP - 2025 May 20 TI - Remodeling the Senescent Microenvironment for Promoting Osteoporotic Tendon-to-Bone Healing via Synergizing Senolytic Quercetin and Aligned Nanowire-Structured Hydrogels. PG - 18364-18385 LID - 10.1021/acsnano.5c01332 [doi] AB - Osteoporotic tendon-to-bone healing remains a major challenge, as cellular senescence disrupts tissue regeneration and impairs repair outcomes. Although the role of cellular senescence in rotator cuff repair is increasingly recognized, current strategies often overlook the complex pathological context, particularly the dual impacts of senescence on both bone marrow-derived mesenchymal stem cells (BMSCs) and tendon-derived stem cells (TDSCs). This gap hampers effective tendon-to-bone healing and integration, especially under osteoporotic conditions. Herein, a composite hydrogel system, quercetin-loaded aligned ultralong hydroxyapatite nanowire/gelatin-hyaluronic acid hydrogel (Que-AHNW/GH), has been developed to address these challenges. By integrating senolytic quercetin as a biological cue with highly aligned ultralong hydroxyapatite (HAP) nanowires as a topographical cue, the system remodels the senescent microenvironment, alleviating senescence in both BMSCs and TDSCs and promoting osteogenesis and tenogenesis. Que-AHNW/GH suppresses the PI3K/AKT pathway, enhances autophagy, and reduces senescence in both cell types. In vivo, Que-AHNW/GH improves bone tunnel regeneration, tendon repair, and tendon-to-bone integration in osteoporotic rats with rotator cuff injury. This system enhances biomechanical strength and gait performance and demonstrates excellent biosafety. These findings highlight the promising potential of Que-AHNW/GH as a multifunctional biomaterial for effectively promoting senescence-related tendon-to-bone healing, offering a promising solution for treating osteoporotic tendon-to-bone injuries. FAU - Song, Wei AU - Song W AUID- ORCID: 0000-0003-2588-6621 AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Liu, Wencai AU - Liu W AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Li, Si-Yi AU - Li SY AD - State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, PR China. FAU - Yu, Yuhao AU - Yu Y AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Xu, Hui AU - Xu H AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Shi, Tingwang AU - Shi T AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Yu, Han-Ping AU - Yu HP AUID- ORCID: 0000-0002-0291-109X AD - State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, PR China. FAU - He, Yaohua AU - He Y AUID- ORCID: 0000-0001-8260-7161 AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. FAU - Zhu, Ying-Jie AU - Zhu YJ AUID- ORCID: 0000-0002-5044-5046 AD - State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, PR China. FAU - Yu, Weilin AU - Yu W AUID- ORCID: 0009-0007-5203-3073 AD - Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, PR China. LA - eng PT - Journal Article DEP - 20250505 PL - United States TA - ACS Nano JT - ACS nano JID - 101313589 RN - 0 (Hydrogels) RN - 9IKM0I5T1E (Quercetin) RN - 0 (Senotherapeutics) RN - 91D9GV0Z28 (Durapatite) SB - IM MH - *Hydrogels/chemistry/pharmacology MH - Animals MH - *Quercetin/pharmacology/chemistry MH - Rats MH - Cellular Senescence/drug effects MH - *Osteoporosis/drug therapy/pathology MH - *Nanowires/chemistry MH - Mesenchymal Stem Cells/drug effects MH - Rats, Sprague-Dawley MH - *Tendons/drug effects/pathology MH - Osteogenesis/drug effects MH - *Wound Healing/drug effects MH - *Senotherapeutics/pharmacology/chemistry MH - Durapatite/chemistry MH - Humans OTO - NOTNLM OT - aligned hydroxyapatite nanowire OT - autophagy modulation OT - cellular senescence OT - senolytic quercetin OT - tendon-to-bone healing EDAT- 2025/05/06 06:29 MHDA- 2025/05/20 06:28 CRDT- 2025/05/06 02:03 PHST- 2025/05/20 06:28 [medline] PHST- 2025/05/06 06:29 [pubmed] PHST- 2025/05/06 02:03 [entrez] AID - 10.1021/acsnano.5c01332 [doi] PST - ppublish SO - ACS Nano. 2025 May 20;19(19):18364-18385. doi: 10.1021/acsnano.5c01332. Epub 2025 May 5. PMID- 38123271 OWN - NLM STAT- MEDLINE DCOM- 20231222 LR - 20240226 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 40 IP - 1 DP - 2024 Jan TI - Editorial Commentary: Dasatinib With Quercetin Shows Promise in Decreasing Age-Related Senescence in the Rotator Cuff Tendon-Can It Work Elsewhere? PG - 45-46 LID - S0749-8063(23)00528-5 [pii] LID - 10.1016/j.arthro.2023.06.038 [doi] AB - Cellular senescence is a fundamental mechanism seen in all age-related diseases. Human supraspinatus tendon and adjacent bursal specimens evaluated for cellular senescence by immunohistochemistry and gene expression show more senescent cells in older patients. This confirms the observation that older patients are more likely to have rotator cuff pathology, and older age is associated with lower rates of rotator cuff healing and more frequent tendon retears. Senolytic drugs can selectively eliminate senescent cells without a localized or systemic impact. Tendon and bursal specimens co-cultured and then incubated with dasatinib and quercetin for 48 hours show a significant decrease in senescent cells. This suggests that these drugs may slow biological aging in rotator cuff tendons and offer the possibility of a clinically effective treatment for the aging rotator cuff tendon. Moreover, this concept is promising for the development of future effective therapies addressing tissue senescence. CI - Copyright © 2023 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Barber, F Alan AU - Barber FA LA - eng PT - Comment PT - Editorial PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - RBZ1571X5H (Dasatinib) RN - 9IKM0I5T1E (Quercetin) SB - IM CON - Arthroscopy. 2024 Jan;40(1):34-44. doi: 10.1016/j.arthro.2023.05.036. PMID: 37356505 MH - Humans MH - Aged MH - *Rotator Cuff/pathology MH - Dasatinib/pharmacology/therapeutic use MH - Quercetin/pharmacology/therapeutic use MH - *Rotator Cuff Injuries/drug therapy/pathology MH - Tendons/pathology EDAT- 2023/12/21 00:41 MHDA- 2023/12/22 06:42 CRDT- 2023/12/20 21:02 PHST- 2023/06/20 00:00 [received] PHST- 2023/06/22 00:00 [accepted] PHST- 2023/12/22 06:42 [medline] PHST- 2023/12/21 00:41 [pubmed] PHST- 2023/12/20 21:02 [entrez] AID - S0749-8063(23)00528-5 [pii] AID - 10.1016/j.arthro.2023.06.038 [doi] PST - ppublish SO - Arthroscopy. 2024 Jan;40(1):45-46. doi: 10.1016/j.arthro.2023.06.038. PMID- 2939096 OWN - NLM STAT- MEDLINE DCOM- 19860613 LR - 20051117 IS - 0749-0712 (Print) IS - 0749-0712 (Linking) VI - 2 IP - 2 DP - 1986 May TI - Silicone implants. PG - 271-90 AB - Infection has not been considered in this article with each individual implant. The incidence is low indeed. In the only publication concerned primarily with the topic of infection following silicone implant surgery, Millender et al. reviewed 2105 implants of varying kinds. There were ten infections, seven of which were with Staphylococcus aureus. The onset was remarkably late--17 days after surgery on average. In seven cases the implant had to be removed and the eventual result was good, being likened to that obtained after an excisional arthroplasty. Reviewing the complications that occur with the various implants, it becomes evident that there are three primary concerns--fracture, subluxation, and synovitis. Fracture occurs primarily in the wrist and the metacarpophalangeal implants. The incidence of fracture in the wrist implant is 8.6, 9.4, and 19.8 per cent, giving an average of the means of 12.6 per cent. In the metacarpophalangeal joint, the incidence with the Swanson design is variously 1.9, 26.2 and 21 per cent, the average of the means being 16.4 per cent. The Niebauer design is reported as having a fracture rate of 29.7 and 38 per cent, for an average of the means of 33.9 per cent. The somewhat lower incidence of fracture of the wrist implant is offset by the fact that, in contrast to the situation with the smaller joint, the fracture is almost always symptomatic, requiring treatment. Largely for this reason, silicone wrist arthroplasty is limited mainly to the rheumatoid patient, being little used for post-traumatic arthritis. Subluxation of implants occurs mainly with the carpal replacements. The incidence in independent reports are 56.5 and 50 per cent, for an average of the means of 53.3 per cent with the scaphoid; 20, 20, and 50 per cent for an average of the means of 30 per cent with the lunate; and 5.3, 10, 11.2, 29, and 32 per cent for an average of the means of 17.5 per cent with the trapezium. In the case of the trapezium, excision of a portion of the trapezoid, supplemented where necessary by ligament reconstruction to support the first metacarpal, appears to give the hope of lowering the incidence of subluxation to an acceptable level. With the lunate, preservation of an anterior shell may give satisfactory results but judgment should await longer term studies of larger groups. The scaphoid implant gives most cause for concern, both because the incidence is high and because the solutions offered have either failed or are too recent to judge and perhaps too radical to accept.(ABSTRACT TRUNCATED AT 400 WORDS) FAU - Kleinert, J M AU - Kleinert JM FAU - Lister, G D AU - Lister GD LA - eng PT - Journal Article PT - Review PL - United States TA - Hand Clin JT - Hand clinics JID - 8510415 RN - 0 (Polyethylene Terephthalates) RN - 0 (Silicones) SB - IM MH - Arthritis, Rheumatoid/*surgery MH - Carpal Bones/surgery MH - Finger Joint/*surgery MH - Humans MH - *Joint Prosthesis MH - Lunate Bone/surgery MH - Osteoarthritis/*surgery MH - Polyethylene Terephthalates MH - Prostheses and Implants MH - *Silicones/adverse effects MH - Synovitis/etiology MH - Tendons/surgery MH - Ulna/surgery MH - Wrist Joint/*surgery RF - 71 EDAT- 1986/05/01 00:00 MHDA- 1986/05/01 00:01 CRDT- 1986/05/01 00:00 PHST- 1986/05/01 00:00 [pubmed] PHST- 1986/05/01 00:01 [medline] PHST- 1986/05/01 00:00 [entrez] PST - ppublish SO - Hand Clin. 1986 May;2(2):271-90. PMID- 37764339 OWN - NLM STAT- MEDLINE DCOM- 20231004 LR - 20231004 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 28 IP - 18 DP - 2023 Sep 11 TI - Phytochemistry and Pharmacology of Eleutherococcus sessiliflorus (Rupr. & Maxim.) S.Y.Hu: A Review. LID - 10.3390/molecules28186564 [doi] LID - 6564 AB - Eleutherococcus sessiliflorus (Rupr. & Maxim.) S.Y.Hu (E. sessiliflorus), a member of the Araliaceae family, is a valuable plant widely used for medicinal and dietary purposes. The tender shoots of E. sessiliflorus are commonly consumed as a staple wild vegetable. The fruits of E. sessiliflorus, known for their rich flavor, play a crucial role in the production of beverages and fruit wines. The root barks of E. sessiliflorus are renowned for their therapeutic effects, including dispelling wind and dampness, strengthening tendons and bones, promoting blood circulation, and removing stasis. To compile a comprehensive collection of information on E. sessiliflorus, extensive searches were conducted in databases such as Web of Science, PubMed, ProQuest, and CNKI. This review aims to provide a detailed exposition of E. sessiliflorus from various perspectives, including phytochemistry and pharmacological effects, to lay a solid foundation for further investigations into its potential uses. Moreover, this review aims to introduce innovative ideas for the rational utilization of E. sessiliflorus resources and the efficient development of related products. To date, a total of 314 compounds have been isolated and identified from E. sessiliflorus, encompassing terpenoids, phenylpropanoids, flavonoids, volatile oils, organic acids and their esters, nitrogenous compounds, quinones, phenolics, and carbohydrates. Among these, triterpenoids and phenylpropanoids are the primary bioactive components, with E. sessiliflorus containing unique 3,4-seco-lupane triterpenoids. These compounds have demonstrated promising properties such as anti-oxidative stress, anti-aging, antiplatelet aggregation, and antitumor effects. Additionally, they show potential in improving glucose metabolism, cardiovascular systems, and immune systems. Despite some existing basic research on E. sessiliflorus, further investigations are required to enhance our understanding of its mechanisms of action, quality assessment, and formulation studies. A more comprehensive investigation into E. sessiliflorus is warranted to delve deeper into its mechanisms of action and potentially expand its pharmaceutical resources, thus facilitating its development and utilization. FAU - Sun, Hui AU - Sun H AUID- ORCID: 0000-0003-3571-8752 AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. FAU - Feng, Jiaxin AU - Feng J AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. AD - College of Pharmacy, Yanbian University, Yanji 133000, China. FAU - Sun, Yue AU - Sun Y AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. AD - College of Pharmacy, Yanbian University, Yanji 133000, China. FAU - Sun, Shuang AU - Sun S AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. AD - College of Pharmacy, Yanbian University, Yanji 133000, China. FAU - Li, Li AU - Li L AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. FAU - Zhu, Junyi AU - Zhu J AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. AD - Key Laboratory of Evaluation and Application of Changbai Mountain Biological Gerplasm Resources of Jilin Province, Tonghua 134002, China. FAU - Zang, Hao AU - Zang H AUID- ORCID: 0000-0001-8357-2888 AD - Green Medicinal Chemistry Laboratory, School of Pharmacy and Medicine, Tonghua Normal University, Tonghua 134002, China. AD - College of Pharmacy, Yanbian University, Yanji 133000, China. AD - Key Laboratory of Evaluation and Application of Changbai Mountain Biological Gerplasm Resources of Jilin Province, Tonghua 134002, China. LA - eng GR - YDZJ202301ZYTS171/Science and Technology Development Plan Project of Jilin Province/ GR - YDZJ202201ZYTS186/Science and Technology Development Plan Project of Jilin Province/ PT - Journal Article PT - Review DEP - 20230911 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (Plant Extracts) RN - 0 (Triterpenes) RN - 0 (Esters) RN - 0 (Phytochemicals) SB - IM MH - *Eleutherococcus/chemistry MH - Plant Extracts/chemistry MH - *Triterpenes/chemistry MH - Fruit/chemistry MH - Esters/analysis MH - Phytochemicals/analysis MH - Ethnopharmacology PMC - PMC10536541 OTO - NOTNLM OT - Eleutherococcus sessiliflorus (Rupr. & Maxim.) S.Y.Hu OT - herbal metabolites OT - pharmacological effects OT - triterpenoids COIS- The authors declare no conflict of interest. EDAT- 2023/09/28 06:42 MHDA- 2023/10/04 06:44 PMCR- 2023/09/11 CRDT- 2023/09/28 01:32 PHST- 2023/08/23 00:00 [received] PHST- 2023/09/07 00:00 [revised] PHST- 2023/09/09 00:00 [accepted] PHST- 2023/10/04 06:44 [medline] PHST- 2023/09/28 06:42 [pubmed] PHST- 2023/09/28 01:32 [entrez] PHST- 2023/09/11 00:00 [pmc-release] AID - molecules28186564 [pii] AID - molecules-28-06564 [pii] AID - 10.3390/molecules28186564 [doi] PST - epublish SO - Molecules. 2023 Sep 11;28(18):6564. doi: 10.3390/molecules28186564. PMID- 36641105 OWN - NLM STAT- MEDLINE DCOM- 20230228 LR - 20250626 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 306 DP - 2023 Apr 24 TI - Botany, traditional usages, phytochemistry, pharmaceutical analysis, and pharmacology of Eleutherococcus nodiflorus (Dunn) S.Y.Hu: A systematic review. PG - 116152 LID - S0378-8741(23)00020-X [pii] LID - 10.1016/j.jep.2023.116152 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Eleutherococcus nodiflorus (Dunn) S.Y.Hu (Araliaceae), also called Eleutherococcus gracilistylus, Acanthopanax gracilistylus, and Xi-zhu-wu-jia (Wujiapi or Nan Wujiapi) in Chinese, is a widely used traditional Chinese herb with the effects of dispelling pathogenic wind and eliminating dampness, nourishing liver and kidney, diuresis and detumescence, promoting blood circulation for removing blood stasis, and strengthening the bones and tendons according to the theory of Traditional Chinese Medicine (TCM). It has been used as medicine for the treatment of paralysis, arthritis, rheumatism, lameness, body asthenia, fatigue, edema, beriberi, and liver diseases. Meanwhile, E. nodiflorus (EN, thereafter) has ginseng-like activities known as "ginseng-like herb". AIMS OF THE REVIEW: This review aims to present comprehensive information for the research progress of EN, including taxonomic position, botany, traditional usages, phytochemistry, pharmaceutical analysis, pharmacology and toxicology. Among them, phytochemical and pharmacological studies are mainly focused. MATERIALS AND METHODS: Relevant literature was acquired from scientific databases including Web of Science, PubMed, Google Scholar, Baidu Scholar, SciFinder and Chinese national knowledge infrastructure (CNKI). Monographs and Chinese pharmacopeia were also utilized as references. RESULTS: In the past decade, a great number of phytochemical and pharmaceutical analyses, as well as pharmacological studies on EN have been carried out. Several kinds of chemical compositions have been reported, including essential oil, sesquiterpenes, diterpenes, triterpenes, phenylpropanoids, lignans, caffeoyl quinic acids, flavonoids, steroids, fatty acids, ceramides as well as other compounds, among which, diterpenes and triterpenes were considered to be the most active components. The fingerprint chromatography, qualitative and quantitative analysis were used for the methods of quality control of EN. Considerable pharmacological experiments in vitro and in vivo have demonstrated that EN possessed hypoglycemic, anti-inflammatory, anticancer, anti-ageing, anti-fatigue, immunomodulatory, hepatoprotective, antioxidant, anti-AChE, anti-BuChE, anti-hyaluronidase, and antiobesity activities. CONCLUSIONS: As an important TCM, a large number of investigations have proved that EN and terpenoids isolated from EN have markedly therapeutic efficacy on diabetes, inflammation, and cancer disorders. These research findings provide modern scientific evidence for the traditional uses of EN. Moreover, more novel and active secondary metabolites from EN, as well as the in vivo and clinical in-depth tests are required in the future. CI - Copyright © 2023 Elsevier B.V. All rights reserved. FAU - Li, Xiaojun AU - Li X AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine, Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, 341000, China. Electronic address: xjli@gmu.edu.cn. FAU - Tang, Siqi AU - Tang S AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine, Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, 341000, China. Electronic address: sugarysiqi@163.com. FAU - Luo, Jiao AU - Luo J AD - School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China. Electronic address: luojiaojiao@stu.hnucm.edu.cn. FAU - Zhang, Xiaodan AU - Zhang X AD - College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, 310018, China. Electronic address: zxd_211@aliyun.com. FAU - Yook, Changsoo AU - Yook C AD - School of Pharmacy, KyungHee University, Seoul, 130-701, South Korea. Electronic address: yookcs@khu.ac.kr. FAU - Huang, Hao AU - Huang H AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine, Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi, 341000, China. Electronic address: huanghao_26@163.com. FAU - Liu, Xiangqian AU - Liu X AD - School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China. Electronic address: lxq0001cn@163.com. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230111 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Phytochemicals) RN - 0 (Triterpenes) SB - IM MH - *Eleutherococcus MH - Medicine, Chinese Traditional/methods MH - *Drugs, Chinese Herbal/pharmacology MH - *Botany MH - Phytochemicals/pharmacology MH - *Triterpenes MH - Ethnopharmacology OTO - NOTNLM OT - Eleutherococcus nodiflorus OT - Pharmaceutical analysis OT - Pharmacology OT - Phytochemistry OT - Toxicology OT - Traditional uses COIS- Declaration of interest statement We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled. EDAT- 2023/01/15 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/01/14 19:28 PHST- 2022/11/03 00:00 [received] PHST- 2023/01/01 00:00 [revised] PHST- 2023/01/04 00:00 [accepted] PHST- 2023/01/15 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/01/14 19:28 [entrez] AID - S0378-8741(23)00020-X [pii] AID - 10.1016/j.jep.2023.116152 [doi] PST - ppublish SO - J Ethnopharmacol. 2023 Apr 24;306:116152. doi: 10.1016/j.jep.2023.116152. Epub 2023 Jan 11. PMID- 19825471 OWN - NLM STAT- MEDLINE DCOM- 20100319 LR - 20161125 IS - 1527-330X (Electronic) IS - 1090-820X (Linking) VI - 29 IP - 5 DP - 2009 Sep-Oct TI - Combination hand rejuvenation procedures. PG - 409-13 LID - 10.1016/j.asj.2009.08.003 [doi] AB - Although the hands age at the same rate as the face, the aging process differs and requires a combination treatment approach for optimal rejuvenation. Photoaging causes epidermal changes such as lentigines, actinic keratoses, fine wrinkles, and crepe-like textural change. Thinning of the dermis and subcutaneous fat occurs as a result of both ultraviolet light exposure and intrinsic aging. This process can lead to a skeletal appearance of the hands, with prominent veins and bulging tendons. The combination approach addresses all of these issues, employing lasers, intense pulsed light devices, fractional devices, fillers, peels, vein sclerotherapy, and an effective at-home skin care program as indicated for individual needs and concerns. FAU - Shamban, Ava T AU - Shamban AT AD - Dermatology at the David Geffen - UCLA School of Medicine, USA. melissacary@shambanmd.com LA - eng PT - Journal Article PL - England TA - Aesthet Surg J JT - Aesthetic surgery journal JID - 9707469 RN - 0 (Caustics) RN - 0 (Glycolates) RN - 0 (Keratolytic Agents) RN - 0 (Polyesters) RN - 0 (Polymers) RN - 0WT12SX38S (glycolic acid) RN - 33X04XA5AT (Lactic Acid) RN - 459TN2L5F5 (poly(lactide)) RN - 5688UTC01R (Tretinoin) RN - 5V2JDO056X (Trichloroacetic Acid) RN - 9004-61-9 (Hyaluronic Acid) RN - S270N0TRQY (Restylane) SB - IM MH - Aging MH - Caustics/therapeutic use MH - Combined Modality Therapy/methods MH - Dermis/physiology/physiopathology MH - Epidermis/physiology/physiopathology MH - Female MH - Glycolates/therapeutic use MH - *Hand MH - Humans MH - Hyaluronic Acid/analogs & derivatives/therapeutic use MH - Keratolytic Agents/therapeutic use MH - Lactic Acid/therapeutic use MH - Laser Therapy MH - Medical Illustration MH - Middle Aged MH - Photochemotherapy MH - Polyesters MH - Polymers/therapeutic use MH - *Rejuvenation MH - Skin Aging/*physiology MH - Skin Diseases/*therapy MH - Tretinoin/therapeutic use MH - Trichloroacetic Acid/therapeutic use EDAT- 2009/10/15 06:00 MHDA- 2010/03/20 06:00 CRDT- 2009/10/15 06:00 PHST- 2008/09/15 00:00 [received] PHST- 2009/05/22 00:00 [accepted] PHST- 2009/10/15 06:00 [entrez] PHST- 2009/10/15 06:00 [pubmed] PHST- 2010/03/20 06:00 [medline] AID - S1090-820X(09)00314-8 [pii] AID - 10.1016/j.asj.2009.08.003 [doi] PST - ppublish SO - Aesthet Surg J. 2009 Sep-Oct;29(5):409-13. doi: 10.1016/j.asj.2009.08.003. PMID- 30919780 OWN - NLM STAT- MEDLINE DCOM- 20200423 LR - 20200423 IS - 1875-6360 (Electronic) IS - 1573-3971 (Linking) VI - 15 IP - 4 DP - 2019 TI - Analgesic Herbal Medicines in the Treatment of Knee Osteoarthritis: A Systematic Review. PG - 290-303 LID - 10.2174/1573397115666190328150203 [doi] AB - BACKGROUND: Osteoarthritis (OA) is a type of progressive rheumatoid disease, which leads to the degeneration of the articular cartilage, synovium, subchondral bone, tendons, and the surrounding ligaments.There are various treatments for knee OA, including pharmaceutical, nonpharmaceutical, and surgical treatments. Considering the chronic nature of the disease as well as the necessity for the long-term use of chemical medications, various side effects could occur that include gastrointestinal bleeding, hypertension, congestive heart failure, hyperkalemia, and kidney failure. Therefore, suitable treatments with fewer side effects should be recommended. Recent investigations suggest increased tendency in people to use Complementary and Alternative Medicine (CAM) for knee OA treatment. OBJECTIVE: This systematic review aimed to assess the effectiveness and safety of herbal preparations for the treatment of OA. METHODS: The searched databases were Cochrane, Scopus, and PubMed. All the selected papers pertained to randomized controlled trials until August 8, 2017 in English in which one or several specific herbs had been used in knee OA treatment. RESULTS: We included 24 randomized trials (involving 2399 women and men). There were several different herbal medicines used within the included trials. CONCLUSION: The results show that the methods used in these trials may reduce symptoms and the extent of NSAID consumption and enhance the quality of life. Additional trials are suggested to investigate the safety and efficacy of herbs for the treatment of patients with OA. CI - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Teymouri, Soudeh AU - Teymouri S AD - Ph.D Candidate of Persian Medicine, Student Research Committee, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Rakhshandeh, Hasan AU - Rakhshandeh H AD - Pharm.D, Assistant Professor, Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Baghdar, Hamideh Naghedi AU - Baghdar HN AD - Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Yousefi, Mahdi AU - Yousefi M AD - Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Salari, Roshanak AU - Salari R AD - Assistant Professor of Drug Control, Department of Pharmaceutical Sciences in Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. LA - eng PT - Journal Article PT - Systematic Review PL - United Arab Emirates TA - Curr Rheumatol Rev JT - Current rheumatology reviews JID - 101261938 RN - 0 (Analgesics) RN - 0 (Plant Extracts) SB - IM MH - Analgesics/*therapeutic use MH - Humans MH - Osteoarthritis, Knee/*drug therapy MH - *Phytotherapy MH - Plant Extracts/*therapeutic use OTO - NOTNLM OT - Knee osteoarthritis OT - herbal medicines OT - medicine OT - osteoarthritis OT - randomized controlled trials OT - symptoms OT - systematic review. EDAT- 2019/03/29 06:00 MHDA- 2020/04/24 06:00 CRDT- 2019/03/29 06:00 PHST- 2018/03/14 00:00 [received] PHST- 2018/11/22 00:00 [revised] PHST- 2019/03/20 00:00 [accepted] PHST- 2019/03/29 06:00 [pubmed] PHST- 2020/04/24 06:00 [medline] PHST- 2019/03/29 06:00 [entrez] AID - CRR-EPUB-97612 [pii] AID - 10.2174/1573397115666190328150203 [doi] PST - ppublish SO - Curr Rheumatol Rev. 2019;15(4):290-303. doi: 10.2174/1573397115666190328150203. PMID- 40858887 OWN - NLM STAT- MEDLINE DCOM- 20250827 LR - 20250829 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Aug 26 TI - Metformin lotion as a novel approach to prevent tendinopathy induced by mechanical overuse. PG - 31474 LID - 10.1038/s41598-025-16279-9 [doi] LID - 31474 AB - Tendinopathy is a common overuse injury with limited preventive options. This study evaluated a novel topical metformin lotion (ML) for its ability to prevent Achilles tendinopathy induced by intensive treadmill running (ITR) in mice. ML at concentrations of 3% and 6% was topically applied daily to the skin overlying the Achilles tendons for four weeks prior to the initiation of ITR. After the four-week topical ML pretreatment period prior to ITR induction, blood samples were collected for ELISA-based analysis of inflammatory markers (HMGB1, IL-1β, and PGE(2)), and tendons were examined using histological and immunofluorescent methods. ML inhibited the release of HMGB1 from cell nuclei into the tendon matrix, reduced serum levels of HMGB1, IL-1β, and PGE(2), and exerted anti-degenerative effects by decreasing chondroid metaplasia, lowering the number of rounded cells, and enhancing collagen fiber organization. These beneficial effects of ML appeared to be mediated through increased AMPK activity, reduced TGF-β1 expression, decreased myofibroblast presence, lower collagen III levels, and elevated collagen I production. In conclusion, ML effectively prevents tendinopathy development, primarily by inhibiting HMGB1 and activating AMPK. These findings suggest that ML may serve as a convenient, effective, and non-invasive strategy to prevent tendinopathy in at-risk populations-such as athletes and military personnel-while minimizing systemic side effects. CI - © 2025. The Author(s). FAU - Zhang, Jianying AU - Zhang J AUID- ORCID: 0000-0002-9004-9910 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. FAU - Maloney, Derek AU - Maloney D AUID- ORCID: 0000-0002-1825-3757 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. FAU - Pastukh, Vasyl AU - Pastukh V AUID- ORCID: 0000-0002-9854-8212 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. FAU - Hattori, Soichi AU - Hattori S AUID- ORCID: 0000-0003-3818-8988 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. FAU - Hogan, MaCalus V AU - Hogan MV AUID- ORCID: 0000-0002-6598-1095 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Wang, James H-C AU - Wang JH AUID- ORCID: 0000-0001-7279-0679 AD - MechanoBiology Laboratory, Bethel Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, E1640 BST, 200 Lothrop Street, Pittsburgh, PA, 15213, USA. wanghc@pitt.edu. AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. wanghc@pitt.edu. AD - Department Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. wanghc@pitt.edu. LA - eng GR - W81XWH2290016/Department of Defense/Medical technology Enterprise Consortium( DOD/MTEC)/ GR - W81XWH2290016/Department of Defense/Medical technology Enterprise Consortium( DOD/MTEC)/ GR - AD2021-120112, AD2022-130408, AD2023-134256/Pittsburgh Foundation/ GR - AD2021-120112, AD2022-130408, AD2023-134256/Pittsburgh Foundation/ GR - HT9425-23-1-0617/Congressionally Directed Medical Research Programs/ PT - Journal Article DEP - 20250826 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 9100L32L2N (Metformin) RN - 0 (HMGB1 Protein) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Interleukin-1beta) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) SB - IM MH - Animals MH - *Metformin/pharmacology/administration & dosage MH - *Tendinopathy/prevention & control/etiology/pathology/metabolism MH - Mice MH - *Cumulative Trauma Disorders/complications/drug therapy/prevention & control MH - Male MH - HMGB1 Protein/metabolism/blood MH - Achilles Tendon/drug effects/pathology/metabolism MH - Transforming Growth Factor beta1/metabolism MH - Interleukin-1beta/blood MH - AMP-Activated Protein Kinases/metabolism MH - Disease Models, Animal PMC - PMC12381261 OTO - NOTNLM OT - Degeneration OT - Inflammation OT - Mechanical overuse OT - Metformin lotion OT - Tendinopathy COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval: The protocol for animal use was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh (protocol #22091904). The study is reported in accordance with ARRIVE guidelines. EDAT- 2025/08/28 04:45 MHDA- 2025/08/28 04:46 PMCR- 2025/08/26 CRDT- 2025/08/26 23:37 PHST- 2025/04/08 00:00 [received] PHST- 2025/08/13 00:00 [accepted] PHST- 2025/08/28 04:46 [medline] PHST- 2025/08/28 04:45 [pubmed] PHST- 2025/08/26 23:37 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - 10.1038/s41598-025-16279-9 [pii] AID - 16279 [pii] AID - 10.1038/s41598-025-16279-9 [doi] PST - epublish SO - Sci Rep. 2025 Aug 26;15(1):31474. doi: 10.1038/s41598-025-16279-9. PMID- 37544344 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20250626 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 318 IP - Pt B DP - 2024 Jan 10 TI - A systematic review of traditional uses, phytochemistry, pharmacology and toxicity of Epimedium koreanum Nakai. PG - 116957 LID - S0378-8741(23)00825-5 [pii] LID - 10.1016/j.jep.2023.116957 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Epimedium koreanum Nakai (E. koreanum), a member of the genus Epimedium in the family Berberidaceae, is a well-known and well-liked traditional herb used as a "kidney tonic". For thousands of years, it has been utilized for renal yang deficiency, impotence, spermatorrhea, impotence, weakness of tendons and bones, rheumatic paralysis and discomfort, numbness, and constriction. AIM OF THE STUDY: The paper aims to comprehensively in-depth, and methodically review the most recent research on the traditional uses, phytochemistry, pharmacology, and toxicity of E. koreanum. MATERIALS AND METHODS: Scientific databases including Web of Science, PubMed, Google Scholar, Elsevier, Springer, ScienceDirect, Baidu Scholar, and CNKI and medicine books in China were searched for relevant information on E. koreanum. RESULTS: In traditional uses, E. koreanum is frequently used to treat various diseases like erectile dysfunction, infertility, rheumatoid arthritis, osteoporosis, asthma, kidney-yang deficiency syndrome, etc. To date, more than 379 compounds have been discovered from various parts of E. koreanum, including flavonoids, lignans, organic acids, terpenoids, hydrocarbons, dihydrophenanthrene derivatives, alkaloids, and others. Research has revealed that the compounds and crude extracts have a wide range of pharmacological effects on the reproductive, cardiovascular, and nervous systems, as well as anti-osteoporosis, anti-tumor, antioxidant, anti-inflammatory, immunomodulatory, hepatoprotective, and antiviral properties. Besides, the crude extracts show potential hepatotoxicity. CONCLUSION: Based on recent domestic and international research investigations, E. koreanum contains a wealth of chemical components with pronounced pharmacological activities. Its traditional uses are numerous, and the majority of these traditional uses have been supported by contemporary pharmacological investigations. Crude extracts, on the other hand, can result in hepatotoxicity. Therefore, additional in vivo and in vitro experimental research on the pharmacology and toxicology of E. koreanum are required in the future to assess its safety and efficacy. This will give a firmer scientific foundation for its safe application and the development of new drugs in the future. CI - Copyright © 2023 Elsevier B.V. All rights reserved. FAU - Qian, Hui-Qin AU - Qian HQ AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Wu, Dou-Can AU - Wu DC AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Li, Chun-Yan AU - Li CY AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Liu, Xin-Ran AU - Liu XR AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Han, Xin-Ke AU - Han XK AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Peng, Yuan AU - Peng Y AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Zhang, Han AU - Zhang H AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Zhao, Bing-Yan AU - Zhao BY AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. FAU - Zhao, Yuan AU - Zhao Y AD - Sanquan College of Xinxiang Medical University, Xinxiang, 453000, China. Electronic address: 13552082@sqmc.edu.cn. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230806 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Phytochemicals) RN - 0 (Plant Extracts) SB - IM MH - Male MH - Humans MH - Phytotherapy MH - *Epimedium MH - Yang Deficiency/drug therapy MH - *Erectile Dysfunction/drug therapy MH - *Chemical and Drug Induced Liver Injury/drug therapy MH - Phytochemicals/therapeutic use/toxicity MH - Ethnopharmacology MH - Plant Extracts/therapeutic use/toxicity MH - Medicine, Chinese Traditional OTO - NOTNLM OT - Epimedium koreanum Nakai OT - Pharmacology OT - Phytochemistry OT - Toxicity OT - Traditional uses COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/08/07 00:42 MHDA- 2023/09/18 12:44 CRDT- 2023/08/06 19:12 PHST- 2023/04/06 00:00 [received] PHST- 2023/07/08 00:00 [revised] PHST- 2023/07/21 00:00 [accepted] PHST- 2023/09/18 12:44 [medline] PHST- 2023/08/07 00:42 [pubmed] PHST- 2023/08/06 19:12 [entrez] AID - S0378-8741(23)00825-5 [pii] AID - 10.1016/j.jep.2023.116957 [doi] PST - ppublish SO - J Ethnopharmacol. 2024 Jan 10;318(Pt B):116957. doi: 10.1016/j.jep.2023.116957. Epub 2023 Aug 6. PMID- 37571349 OWN - NLM STAT- MEDLINE DCOM- 20230814 LR - 20230814 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 15 DP - 2023 Jul 31 TI - Resveratrol, a Multitasking Molecule That Improves Skeletal Muscle Health. LID - 10.3390/nu15153413 [doi] LID - 3413 AB - Resveratrol is a natural polyphenol utilized in Chinese traditional medicine and thought to be one of the determinants of the "French Paradox". More recently, some groups evidenced its properties as a calorie-restriction mimetic, suggesting that its action passes through the modulation of skeletal muscle metabolism. Accordingly, the number of studies reporting the beneficial effects of resveratrol on skeletal muscle form and function, in both experimental models and humans, is steadily increasing. Although studies on animal models confer to resveratrol a good potential to ameliorate skeletal muscle structure, function and performance, clinical trials still do not provide clear-cut information. Here, we first summarize the effects of resveratrol on the distinct components of the skeletal muscle, such as myofibers, the neuromuscular junction, tendons, connective sheaths and the capillary bed. Second, we review clinical trials focused on the analysis of skeletal muscle parameters. We suggest that the heterogeneity in the response to resveratrol in humans could depend on sample characteristics, treatment modalities and parameters analyzed; as well, this heterogeneity could possibly reside in the complexity of skeletal muscle physiology. A systematic programming of treatment protocols and analyses could be helpful to obtain consistent results in clinical trials involving resveratrol administration. FAU - Toniolo, Luana AU - Toniolo L AUID- ORCID: 0000-0001-7160-5638 AD - Laboratory of Muscle Biophysics, Department of Biomedical Sciences, University of Padova, 35131 Padova, Italy. FAU - Concato, Monica AU - Concato M AUID- ORCID: 0000-0003-1026-3106 AD - Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. FAU - Giacomello, Emiliana AU - Giacomello E AUID- ORCID: 0000-0003-3329-6269 AD - Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 Trieste, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230731 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - Q369O8926L (Resveratrol) RN - 0 (Polyphenols) RN - 0 (Stilbenes) SB - IM MH - Animals MH - Humans MH - Resveratrol/pharmacology/metabolism MH - *Muscle, Skeletal/metabolism MH - Polyphenols/pharmacology MH - Caloric Restriction MH - *Stilbenes/therapeutic use PMC - PMC10421121 OTO - NOTNLM OT - clinical trials OT - resveratrol OT - skeletal muscle COIS- The authors declare no conflict of interest. EDAT- 2023/08/12 10:47 MHDA- 2023/08/14 06:42 PMCR- 2023/07/31 CRDT- 2023/08/12 01:21 PHST- 2023/07/10 00:00 [received] PHST- 2023/07/29 00:00 [revised] PHST- 2023/07/30 00:00 [accepted] PHST- 2023/08/14 06:42 [medline] PHST- 2023/08/12 10:47 [pubmed] PHST- 2023/08/12 01:21 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - nu15153413 [pii] AID - nutrients-15-03413 [pii] AID - 10.3390/nu15153413 [doi] PST - epublish SO - Nutrients. 2023 Jul 31;15(15):3413. doi: 10.3390/nu15153413. PMID- 22303530 OWN - NLM STAT- MEDLINE DCOM- 20140428 LR - 20220409 IS - 0048-7449 (Print) IS - 0048-7449 (Linking) VI - 63 IP - 4 DP - 2012 Jan 19 TI - Clinical features of gout. PG - 238-45 LID - 10.4081/reumatismo.2011.238 [doi] AB - Gout is a metabolic disease characterized by hyperuricemia and the deposition of monosodium urate (MSU) crystals in the joints and soft tissues, consisting of a self-limited acute phase characterized by recurrent attacks of synovitis and a chronic phase in which inflammatory and structural changes of the joints and periarticular tissues may lead to persistent symptoms. Acute gout is characterized by a sudden monoarthritis of rapid onset, with intense pain, mostly affecting the big toe (50% of initial attacks), the foot, ankle, midtarsal, knee, wrist, finger, and elbow. Acute flares also occur in periarticular structures, including bursae and tendons. The presence of characteristic MSU crystals in the joint fluid, appearing needle-like and showing strong negative birefringence by polarized microscopy, is pivotal to confirm the diagnosis of gout. The time interval separating the first attack from subsequent episodes of acute synovitis may be widely variable, ranging from a few days to several years. During the period between acute attacks the patient is asymptomatic even if MSU deposition may continue to increase silently. The factors that control the rate, location, and degree of ongoing deposition in gouty patients are not well defined. Chronic gout is the natural evolution of untreated hyperuricemia in patients with gouty attacks followed by pain-free intercritical periods. It is characterized by the deposition of solid MSU crystal aggregates in a variety of tissues including joints, bursae and tendons. Tophi can occur in a variety of locations including the helix of the ear, olecranon bursa, and over the interphalangeal joints. Their development is usually related with both the degree and the duration of hyperuricemia. About 20% of patients with gout have urinary tract stones and can develop an interstitial urate nephropathy. There is a strong association between hyperuricaemia and the metabolic syndrome (the constellation of insulin resistance, hypertension, obesity and dyslipidaemia), and gouty patients often have a medical history of kidney disease, diabetes mellitus and signs of vascular illness such as coronary artery disease, heart failure and stroke, resulting with a poor overall quality of life. FAU - Grassi, W AU - Grassi W AD - Clinica Reumatologica, Università Politecnica delle Marche, Ancona, Italy. walter.grassi@univpm.it FAU - De Angelis, R AU - De Angelis R LA - eng PT - Journal Article PT - Review DEP - 20120119 PL - Italy TA - Reumatismo JT - Reumatismo JID - 0401302 RN - 0 (Biomarkers) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Acute Disease MH - Arthritis, Gouty/diagnosis MH - Biomarkers/metabolism MH - Chronic Disease MH - Crystallization MH - Diagnosis, Differential MH - Gout/*diagnosis/etiology/metabolism MH - Humans MH - Hyperuricemia/*diagnosis/metabolism MH - Joints/metabolism MH - Quality of Life MH - Risk Factors MH - Synovial Fluid/metabolism MH - Uric Acid/*metabolism EDAT- 2012/02/04 06:00 MHDA- 2014/04/29 06:00 CRDT- 2012/02/04 06:00 PHST- 2012/01/19 00:00 [received] PHST- 2012/01/19 00:00 [accepted] PHST- 2012/02/04 06:00 [entrez] PHST- 2012/02/04 06:00 [pubmed] PHST- 2014/04/29 06:00 [medline] AID - reumatismo.2011.238 [pii] AID - 10.4081/reumatismo.2011.238 [doi] PST - epublish SO - Reumatismo. 2012 Jan 19;63(4):238-45. doi: 10.4081/reumatismo.2011.238. PMID- 22268976 OWN - NLM STAT- MEDLINE DCOM- 20121001 LR - 20220410 IS - 1524-4725 (Electronic) IS - 1076-0512 (Linking) VI - 38 IP - 7 Pt 2 DP - 2012 Jul TI - Hand rejuvenation: a review and our experience. PG - 1112-27 LID - 10.1111/j.1524-4725.2011.02291.x [doi] AB - BACKGROUND: The aged hand is characterized by cutaneous and dermal atrophy, with deep intermetacarpal spaces, prominent bones and tendons, and bulging reticular veins. Epidermal changes include solar lentigines, seborrheic keratoses, actinic keratoses, skin laxity, rhytides, tactile roughness, and telangiectasia. STUDY DESIGN: A Medline search was performed on hand rejuvenation from 1989 to 2011, and results are summarized. Practical applications of these procedures are also discussed. RESULTS: Reports of injectable hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, autologous fat transfer, vein treatment, and chemical peels, along with lasers and light sources such as Q-switched laser, intense pulsed light, photodynamic therapy, nonablative resurfacing lasers, and ablative resurfacing lasers, in the rejuvenation of hands were found. CONCLUSION: Review of the literature revealed options for minimally invasive treatment for rejuvenation of the skin and volume restoration of the dorsal hand. These treatments include injectables and fat transfer for volume restoration; sclerotherapy or vein ablation for dorsal hand vein treatment; and chemical peels, lasers, light, and energies for the treatment of epidermal and dermal changes. CI - © 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc. FAU - Fabi, Sabrina G AU - Fabi SG AD - Goldman, Butterwick, Fitzpatrick, and Groff Cosmetic Laser Dermatology, San Diego, CA 92121, USA. sgfabi@gmail.com FAU - Goldman, Mitchel P AU - Goldman MP LA - eng PT - Journal Article PT - Review DEP - 20120123 PL - United States TA - Dermatol Surg JT - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JID - 9504371 RN - 0 (Biocompatible Materials) RN - 0 (Polyesters) RN - 0 (Polymers) RN - 0 (Tissue Adhesives) RN - 0AWH8BFG9A (Polidocanol) RN - 33X04XA5AT (Lactic Acid) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 459TN2L5F5 (poly(lactide)) RN - 9004-61-9 (Hyaluronic Acid) RN - 91D9GV0Z28 (Durapatite) RN - S270N0TRQY (Restylane) SB - IM MH - Adipose Tissue/pathology/transplantation MH - Atrophy MH - Biocompatible Materials/administration & dosage MH - *Cosmetic Techniques MH - Durapatite/administration & dosage MH - *Hand/pathology/physiology/surgery MH - Humans MH - Hyaluronic Acid/administration & dosage/analogs & derivatives MH - Injections MH - Lactic Acid/therapeutic use MH - Laser Therapy MH - Photochemotherapy MH - Polidocanol MH - Polyesters MH - Polyethylene Glycols/administration & dosage MH - Polymers/therapeutic use MH - *Rejuvenation/physiology MH - Sclerotherapy MH - *Skin Aging/physiology MH - Tissue Adhesives/administration & dosage EDAT- 2012/01/25 06:00 MHDA- 2012/10/02 06:00 CRDT- 2012/01/25 06:00 PHST- 2012/01/25 06:00 [entrez] PHST- 2012/01/25 06:00 [pubmed] PHST- 2012/10/02 06:00 [medline] AID - 10.1111/j.1524-4725.2011.02291.x [doi] PST - ppublish SO - Dermatol Surg. 2012 Jul;38(7 Pt 2):1112-27. doi: 10.1111/j.1524-4725.2011.02291.x. Epub 2012 Jan 23. PMID- 29363262 OWN - NLM STAT- MEDLINE DCOM- 20180919 LR - 20220409 IS - 1756-185X (Electronic) IS - 1756-1841 (Linking) VI - 21 IP - 4 DP - 2018 Apr TI - Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. PG - 772-787 LID - 10.1111/1756-185X.13266 [doi] AB - Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long-term urate-lowering treatment. Urate-lowering drugs should be used during the inter-critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate-lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia. CI - © 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. FAU - Yu, Kuang-Hui AU - Yu KH AUID- ORCID: 0000-0001-6251-0231 AD - Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. FAU - Chen, Der-Yuan AU - Chen DY AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. AD - Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. AD - Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan. FAU - Chen, Jiunn-Horng AU - Chen JH AD - Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. AD - School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. FAU - Chen, Shih-Yang AU - Chen SY AD - Center of Gout, Country Hospital, Taipei, Taiwan. FAU - Chen, Shyh-Ming AU - Chen SM AD - Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan. FAU - Cheng, Tien-Tsai AU - Cheng TT AD - Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan. FAU - Hsieh, Song-Chou AU - Hsieh SC AD - Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Hsinchu, Taiwan. FAU - Hsieh, Tsu-Yi AU - Hsieh TY AD - Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. AD - Ph.D. Program of Business, Institute of Business, Feng-Chia University, Taichung, Taiwan. FAU - Hsu, Pai-Feng AU - Hsu PF AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. AD - Department of Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Kuo, Chang-Fu AU - Kuo CF AD - Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. FAU - Kuo, Mei-Chuan AU - Kuo MC AD - Division of Nephrology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - Faculty of Renal Care, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Lam, Hing-Chung AU - Lam HC AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan. FAU - Lee, I-Te AU - Lee IT AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. AD - Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. FAU - Liang, Toong-Hua AU - Liang TH AD - Rheumatology Section, Renai Branch, Taipei City Hospital, Taipei, Taiwan. FAU - Lin, Hsiao-Yi AU - Lin HY AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. AD - Division of Allergy, Immunology and Rheumatology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan. FAU - Lin, Shih-Chang AU - Lin SC AD - Division of Rheumatology and Immunology, Cathay General Hospital, Taipei, Taiwan. AD - Department of Medicine, College of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan. FAU - Tsai, Wen-Pin AU - Tsai WP AD - Department of Immunology and Rheumatology, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan. FAU - Tsay, Gregory J AU - Tsay GJ AD - Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan. AD - School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan. FAU - Wei, James Cheng-Chung AU - Wei JC AD - Division of Allergy, Immunology and Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan. AD - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. FAU - Yang, Chung-Han AU - Yang CH AD - Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan. AD - Department of Internal Medicine, Landseed Hospital, Taoyuan, Taiwan. FAU - Tsai, Wen-Chan AU - Tsai WC AD - Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. LA - eng PT - Consensus Development Conference PT - Journal Article PT - Practice Guideline PT - Review DEP - 20180124 PL - England TA - Int J Rheum Dis JT - International journal of rheumatic diseases JID - 101474930 RN - 0 (Biomarkers) RN - 0 (Gout Suppressants) RN - 0 (Uricosuric Agents) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Biomarkers/blood MH - Comorbidity MH - Consensus MH - Down-Regulation MH - Gout/blood/diagnosis/*drug therapy/epidemiology MH - Gout Suppressants/adverse effects/*therapeutic use MH - Humans MH - Hyperuricemia/blood/diagnosis/*drug therapy/epidemiology MH - Interdisciplinary Communication MH - Risk Factors MH - Taiwan/epidemiology MH - Treatment Outcome MH - Uric Acid/*blood MH - Uricosuric Agents/therapeutic use OTO - NOTNLM OT - gout OT - hyperuricemia OT - urate-lowering agents EDAT- 2018/01/25 06:00 MHDA- 2018/09/20 06:00 CRDT- 2018/01/25 06:00 PHST- 2018/01/25 06:00 [pubmed] PHST- 2018/09/20 06:00 [medline] PHST- 2018/01/25 06:00 [entrez] AID - 10.1111/1756-185X.13266 [doi] PST - ppublish SO - Int J Rheum Dis. 2018 Apr;21(4):772-787. doi: 10.1111/1756-185X.13266. Epub 2018 Jan 24. PMID- 30617190 OWN - NLM STAT- MEDLINE DCOM- 20190417 LR - 20210111 IS - 1757-790X (Electronic) IS - 1757-790X (Linking) VI - 12 IP - 1 DP - 2019 Jan 7 TI - SAPHO syndrome with enthesopathy. LID - 10.1136/bcr-2018-225929 [doi] LID - e225929 AB - Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome was first described as chronic recurrent multifocal osteomyelitis. Because of its rarity, a thorough description of its clinical manifestations is lacking. Herein, we describe the clinical manifestations and imaging features, especially the enthesopathy in bilateral Achilles tendons, of a middle-aged Asian woman with SAPHO syndrome, who improved after diclofenac treatment. CI - © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Su, Chin-Fang AU - Su CF AD - Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Shen, Yu-Chuan AU - Shen YC AD - Division of Rheumatology, Tao-Yuan General Hospital, Ministry of Health & Welfare, Tao-Yuan, Taiwan. FAU - Liao, Hsien-Tzung AU - Liao HT AD - Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. FAU - Tsai, Chang-Youh AU - Tsai CY AUID- ORCID: 0000-0002-4154-4018 AD - Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. LA - eng PT - Case Reports PT - Journal Article DEP - 20190107 PL - England TA - BMJ Case Rep JT - BMJ case reports JID - 101526291 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 144O8QL0L1 (Diclofenac) SB - IM MH - Achilles Tendon/diagnostic imaging/pathology MH - Acquired Hyperostosis Syndrome/*diagnostic imaging/drug therapy/*pathology MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use MH - Chronic Pain/*diagnosis/etiology MH - Diagnosis, Differential MH - Diclofenac/administration & dosage/therapeutic use MH - Enthesopathy/*diagnostic imaging/pathology MH - Female MH - Humans MH - Magnetic Resonance Imaging/methods MH - Middle Aged MH - Osteomyelitis/diagnostic imaging MH - Tomography, X-Ray Computed/methods MH - Treatment Outcome MH - Ultrasonography/methods MH - Whole Body Imaging/methods PMC - PMC6326313 OTO - NOTNLM OT - musculoskeletal and joint disorders OT - musculoskeletal syndromes OT - radiology (diagnostics) COIS- Competing interests: None declared. EDAT- 2019/01/09 06:00 MHDA- 2019/04/18 06:00 PMCR- 2021/01/07 CRDT- 2019/01/09 06:00 PHST- 2019/01/09 06:00 [entrez] PHST- 2019/01/09 06:00 [pubmed] PHST- 2019/04/18 06:00 [medline] PHST- 2021/01/07 00:00 [pmc-release] AID - 12/1/e225929 [pii] AID - bcr-2018-225929 [pii] AID - 10.1136/bcr-2018-225929 [doi] PST - epublish SO - BMJ Case Rep. 2019 Jan 7;12(1):e225929. doi: 10.1136/bcr-2018-225929. PMID- 33516929 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20220421 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 271 DP - 2021 May 10 TI - A review on traditional usages, chemical constituents and pharmacological activities of periploca forrestii schltr. PG - 113892 LID - S0378-8741(21)00118-5 [pii] LID - 10.1016/j.jep.2021.113892 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Periploca forrestii Schltr. was listed as a classical medicinal plant in "Miao medicine", which is a branch of traditional Chinese medicine (TCM). According to the theory of TCM, P. forrestii has the efficacy of relaxing tendons and activating collaterals, and dispelling wind and eliminating dampness. Hence, it was often used for the therapy of rheumatoid arthritis and traumatic injury in clinical practice. AIMS OF THE REVIEW: This review aims to present comprehensive information for the research progress of P. forrestii. The researches on botany, traditional uses, phytochemistry, pharmacology and toxicology of the plant are summarized. We mainly focus on the phytochemical and pharmacological investigations. As a representative class of phytochemicals in P. forrestii, more attention is paid to cardiac glycosides. The insights into potential action of mechanisms and possible future studies on P. forrestii are also discussed. MATERIALS AND METHODS: Relevant literature was acquired from scientific databases including Google Scholar, Web of Science, Scifinder, Baidu Scholar, PubMed and Chinese national knowledge infrastructure. Monographs and Chinese pharmacopoeia were also utilized as references. RESULTS: To date, all kinds of phytochemical constituents have been isolated and identified from this plant including cardiac glycosides, steroids, terpenoids, flavonoids, phenylpropanoids, quinones, organic phenolic acids and others. Among these, cardiac glycosides were considered as the major ingredients and bioactive materials. Modern pharmacological studies demonstrated that the plant possessed extensive bioactivity, such as anti-inflammatory and analgesic effects, immunosuppressive action, wound healing activity, antioxidant, anti-tumor and, cardiotonic properties. CONCLUSIONS: As an important medicinal plant, lots of studies have proved that P. forrestii has significant therapeutical effects, especially on rheumatoid arthritis and traumatic injury. These results provide modern scientific evidence for traditional use and contribute to the development of novel remedies for chronic diseases. However, the exact mechanism of action remains to be elucidated. Furthermore, the long-term in vivo toxicity and clinical efficacy also require in-depth exploration in the future. CI - Copyright © 2021 Elsevier B.V. All rights reserved. FAU - Chen, Lei AU - Chen L AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Tang, Siqi AU - Tang S AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Li, Xiaojun AU - Li X AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Kuang, Ying AU - Kuang Y AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Huang, Hao AU - Huang H AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Fan, Pinglong AU - Fan P AD - National Engineering Research Center for Modernization of Traditional Chinese Medicine- Hakka Medical Resources Branch, School of Pharmacy, Gannan Medical University,Ganzhou, 341000, China. FAU - Feng, Feng AU - Feng F AD - Jiangsu Food and Pharmaceutical Science College, Huaian, 223003, China. Electronic address: fengfeng@cpu.edu.cn. FAU - Liu, Wenyuan AU - Liu W AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: liuwenyuan8506@163.com. LA - eng PT - Journal Article PT - Review DEP - 20210129 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Phytochemicals) SB - IM MH - Animals MH - Drugs, Chinese Herbal/*chemistry/*pharmacology/therapeutic use/toxicity MH - Humans MH - Medicine, Chinese Traditional MH - Periploca/*chemistry MH - Phytochemicals/*chemistry/*pharmacology/therapeutic use/toxicity MH - Plants, Medicinal/chemistry/toxicity OTO - NOTNLM OT - Periploca forrestii schlecht. OT - Pharmacology OT - Phytochemistry OT - Toxicology OT - Traditional uses EDAT- 2021/02/01 06:00 MHDA- 2021/09/16 06:00 CRDT- 2021/01/31 20:27 PHST- 2020/05/13 00:00 [received] PHST- 2021/01/13 00:00 [revised] PHST- 2021/01/26 00:00 [accepted] PHST- 2021/02/01 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2021/01/31 20:27 [entrez] AID - S0378-8741(21)00118-5 [pii] AID - 10.1016/j.jep.2021.113892 [doi] PST - ppublish SO - J Ethnopharmacol. 2021 May 10;271:113892. doi: 10.1016/j.jep.2021.113892. Epub 2021 Jan 29. PMID- 39680093 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 1615-7109 (Electronic) IS - 1203-4754 (Linking) VI - 29 IP - 3 DP - 2025 May-Jun TI - Investigating the Real Effects of Isotretinoin on Enthesopathy in Acne Vulgaris Patients: A Prospective, Controlled Study. PG - 254-258 LID - 10.1177/12034754241303074 [doi] AB - BACKGROUND: Isotretinoin is frequently used for treating severe, treatment-resistant, and scarring acne. A wide range of musculoskeletal side effects are reported due to isotretinoin, and one of them is enthesopathy. OBJECTIVES: In this study, we used ultrasound to evaluate tendon thickness and the presence of enthesophytes, erosions, calcifications, and bursitis. Overall, the main objective was to determine the effects of isotretinoin on enthesopathy. METHODS: The study included 30 patients diagnosed with acne vulgaris (AV) and on isotretinoin treatment for ≥3 months. Thirty patients with AV without treatment or on topical treatments were included as the control group. In both groups, 5 areas in the lower limb were examined bilaterally for tendon thickness, erosion, calcifications, enthesophytes, and bursitis and compared among themselves. Moreover, the Glasgow Ultrasonographic Enthesitis Scoring System (GUESS) scores were also calculated and compared between the 2 groups. RESULTS: The quadriceps tendon, distal patellar ligament, and right Achilles tendon thicknesses were statistically higher in the isotretinoin group than in the control group (P = .02, P = .03, P = .04). The GUESS score was also statistically higher in the isotretinoin group (P = .02). CONCLUSION: This study showed that isotretinoin has certain effects on tendon thickness. Clinicians should be alert that patients under isotretinoin treatment may develop enthesopathy even with no clinical signs. FAU - Orenay, Ozge Mine AU - Orenay OM AUID- ORCID: 0000-0001-5848-7323 AD - Specialist of Dermatology, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Karaosmanoglu, Nermin AU - Karaosmanoglu N AUID- ORCID: 0000-0002-3462-1628 AD - Associate Professor of Dermatology,Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Mulkoglu, Cevriye AU - Mulkoglu C AD - Associate Professor of Physical Medicine and Rehabilitation, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Genc, Hakan AU - Genc H AD - Professor of Physical Medicine and Rehabilitation, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Temel, Berkay AU - Temel B AUID- ORCID: 0000-0001-5528-9006 AD - Specialist of Dermatology, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. FAU - Tiftik, Tulay AU - Tiftik T AD - Professor of Physical Medicine and Rehabilitation, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20241216 PL - United States TA - J Cutan Med Surg JT - Journal of cutaneous medicine and surgery JID - 9614685 RN - EH28UP18IF (Isotretinoin) RN - 0 (Dermatologic Agents) SB - IM MH - Humans MH - *Acne Vulgaris/drug therapy MH - *Isotretinoin/adverse effects/therapeutic use MH - Female MH - *Enthesopathy/chemically induced/diagnostic imaging MH - Male MH - Prospective Studies MH - *Dermatologic Agents/adverse effects/therapeutic use MH - Adult MH - Young Adult MH - Ultrasonography MH - Adolescent MH - Achilles Tendon/diagnostic imaging/drug effects MH - Tendons/diagnostic imaging/drug effects MH - Patellar Ligament/diagnostic imaging/drug effects OTO - NOTNLM OT - GUESS score OT - acne vulgaris OT - enthesopathy OT - isotretinoin OT - ultrasonography COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/12/16 12:29 MHDA- 2025/06/24 11:10 CRDT- 2024/12/16 11:14 PHST- 2025/06/24 11:10 [medline] PHST- 2024/12/16 12:29 [pubmed] PHST- 2024/12/16 11:14 [entrez] AID - 10.1177/12034754241303074 [doi] PST - ppublish SO - J Cutan Med Surg. 2025 May-Jun;29(3):254-258. doi: 10.1177/12034754241303074. Epub 2024 Dec 16. PMID- 40763479 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20250916 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 163 DP - 2025 Oct 10 TI - Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy. PG - 115302 LID - S1567-5769(25)01293-7 [pii] LID - 10.1016/j.intimp.2025.115302 [doi] AB - BACKGROUND: Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. METHODS: This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. RESULTS: In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. CONCLUSIONS: SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy. CI - Copyright © 2025 Elsevier B.V. All rights reserved. FAU - Zhang, Wang AU - Zhang W AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: 2023283030152@whu.edu.cn. FAU - Fang, Xue AU - Fang X AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: 2022283030094@whu.edu.cn. FAU - Liu, Yuping AU - Liu Y AD - Department of anesthesiology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610066, China. Electronic address: 2856804540@qq.com. FAU - Liu, Changhuan AU - Liu C AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: 2024283030162@whu.edu.cn. FAU - Yao, Can AU - Yao C AD - Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan 430071, China. Electronic address: 2023305233088@whu.edu.cn. FAU - Guo, Jiahui AU - Guo J AD - Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan 430071, China. Electronic address: 2023305233098@whu.edu.cn. FAU - Wu, Peilong AU - Wu P AD - Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan 430071, China. Electronic address: 2023305233111@whu.edu.cn. FAU - Tan, Wei AU - Tan W AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: 2428631967@qq.com. FAU - Zhu, Lekai AU - Zhu L AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: 2050144456@qq.com. FAU - Gao, Wei AU - Gao W AD - Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Electronic address: znyycg@126.com. FAU - Wang, Zheng AU - Wang Z AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan 430071, China. Electronic address: wangzhengemail@whu.edu.cn. FAU - Wang, Xin AU - Wang X AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan 430071, China. Electronic address: wangxinznyy@whu.edu.cn. LA - eng PT - Journal Article DEP - 20250805 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (Isothiocyanates) RN - 0 (STAT1 Transcription Factor) RN - GA49J4310U (sulforaphane) RN - EC 2.7.10.2 (Janus Kinase 1) RN - 0 (Sulfoxides) RN - 0 (Stat1 protein, mouse) RN - EC 2.7.10.2 (Jak1 protein, mouse) RN - 0 (STAT1 protein, human) RN - 0 (Anti-Inflammatory Agents) SB - IM MH - Animals MH - *Isothiocyanates/pharmacology/therapeutic use MH - *STAT1 Transcription Factor/metabolism/antagonists & inhibitors MH - *Macrophages/drug effects/immunology MH - *Janus Kinase 1/metabolism MH - Humans MH - Mice MH - *Sulfoxides/pharmacology/therapeutic use MH - *Tendinopathy/drug therapy/immunology/chemically induced/pathology MH - Disease Models, Animal MH - Male MH - Mice, Inbred C57BL MH - Signal Transduction/drug effects MH - *Tendons/drug effects/pathology MH - Macrophage Activation/drug effects MH - *Anti-Inflammatory Agents/pharmacology/therapeutic use OTO - NOTNLM OT - Inflammation OT - JAK/STAT signaling pathway OT - Macrophage polarization OT - Sulforaphane OT - Tendinopathy COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/08/06 00:27 MHDA- 2025/09/16 18:31 CRDT- 2025/08/05 18:08 PHST- 2025/07/12 00:00 [received] PHST- 2025/07/26 00:00 [revised] PHST- 2025/07/28 00:00 [accepted] PHST- 2025/09/16 18:31 [medline] PHST- 2025/08/06 00:27 [pubmed] PHST- 2025/08/05 18:08 [entrez] AID - S1567-5769(25)01293-7 [pii] AID - 10.1016/j.intimp.2025.115302 [doi] PST - ppublish SO - Int Immunopharmacol. 2025 Oct 10;163:115302. doi: 10.1016/j.intimp.2025.115302. Epub 2025 Aug 5. PMID- 15682880 OWN - NLM STAT- MEDLINE DCOM- 20050315 LR - 20191109 IS - 0744-6020 (Print) IS - 0744-6020 (Linking) VI - 23 IP - 6 DP - 2004 Nov-Dec TI - Diffuse idiopathic skeletal hyperostosis: Forestier's disease. PG - 375-82; quiz 383-4 AB - Diffuse idiopathic skeletal hyperostosis (DISH) or Forestier's disease is characterized by calcification and ossification of soft tissue entheses of ligaments and tendons. DISH is believed to be a variant of osteoarthritis (OA) without the degenerative intervertebral disc and joint degenerative qualities seen in classic OA. The likely pathoetiologic causes of DISH are presented. FAU - Childs, Sharon G AU - Childs SG LA - eng PT - Journal Article PT - Review PL - United States TA - Orthop Nurs JT - Orthopedic nursing JID - 8409486 RN - 11103-57-4 (Vitamin A) MH - Comorbidity MH - Coronary Disease/etiology MH - Deglutition Disorders/etiology MH - Disease Progression MH - Dyspnea/etiology MH - Fluoride Poisoning/complications MH - Genetic Predisposition to Disease/genetics MH - Gout/etiology MH - Humans MH - Hyperinsulinism/etiology MH - *Hyperostosis, Diffuse Idiopathic Skeletal/diagnosis/epidemiology/etiology/therapy MH - Hypertension/etiology MH - Obesity/etiology MH - Osteoarthritis/etiology MH - Pain/etiology MH - Physical Examination MH - Range of Motion, Articular MH - Risk Factors MH - Vitamin A/adverse effects RF - 47 EDAT- 2005/02/03 09:00 MHDA- 2005/03/16 09:00 CRDT- 2005/02/03 09:00 PHST- 2005/02/03 09:00 [pubmed] PHST- 2005/03/16 09:00 [medline] PHST- 2005/02/03 09:00 [entrez] AID - 10.1097/00006416-200411000-00006 [doi] PST - ppublish SO - Orthop Nurs. 2004 Nov-Dec;23(6):375-82; quiz 383-4. doi: 10.1097/00006416-200411000-00006. PMID- 14584314 OWN - NLM STAT- MEDLINE DCOM- 20031212 LR - 20131121 IS - 0009-4749 (Print) IS - 0009-4749 (Linking) VI - 88 IP - 1 DP - 2003 Jan-Mar TI - Hip surgery in cerebral palsy. PG - 23-32 AB - The authors report the importance of hip dislocation and pelvic imbalance in patients with cerebral palsy, as the cause of pain, decubitus, and severe secondary deformities of the vertebral column. They report their experience in the surgical treatment of spastic hip, based on 231 cases with a mean follow-up of 5.4 years. The authors emphasize the importance of obtaining a balanced pelvis to allow for walking and sitting in the severest patients, and in order to avoid severe deformity of the vertebral column. The surgical methods used, with particular interest in the importance of stabilizing reduction by intertrochanteric osteotomies of the femur and/or acetabular roof osteotomies, are described. Results obtained, positive in 88% of cases, are also reported. FAU - Cigala, F AU - Cigala F AD - Dipartimento di Ortopedia, Università Federico II, Napoli. FAU - Marmo, C AU - Marmo C FAU - Lotito, F M AU - Lotito FM FAU - Cigala, M AU - Cigala M FAU - Lombari, P AU - Lombari P LA - eng LA - ita PT - Journal Article PL - Italy TA - Chir Organi Mov JT - La Chirurgia degli organi di movimento JID - 0372573 RN - 3K9958V90M (Ethanol) SB - IM MH - Acetabulum/pathology/surgery MH - Bone Diseases, Metabolic/prevention & control MH - Cerebral Palsy/*complications MH - Child, Preschool MH - Ethanol/administration & dosage/therapeutic use MH - Femur/surgery MH - Gait Disorders, Neurologic/physiopathology/prevention & control MH - Hip Dislocation/etiology/*prevention & control/surgery MH - Hip Joint/*surgery MH - Humans MH - Infant MH - Injections, Intramuscular MH - Muscle Spasticity/complications/therapy MH - Muscle, Skeletal/surgery MH - *Osteotomy MH - Posture MH - Sclerotherapy MH - Tendons/surgery MH - Treatment Outcome EDAT- 2003/10/31 05:00 MHDA- 2003/12/13 05:00 CRDT- 2003/10/31 05:00 PHST- 2003/10/31 05:00 [pubmed] PHST- 2003/12/13 05:00 [medline] PHST- 2003/10/31 05:00 [entrez] PST - ppublish SO - Chir Organi Mov. 2003 Jan-Mar;88(1):23-32. PMID- 39708936 OWN - NLM STAT- MEDLINE DCOM- 20250428 LR - 20250519 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 340 DP - 2025 Jan 31 TI - Tinospora crispa (L.) Hook.f. & Thomson vines ameliorates hyperuricemia by inhibiting synthesis and promoting excretion of uric acid through targeting NLRP3/caspase-1/IL-1β pathway. PG - 119271 LID - S0378-8741(24)01570-8 [pii] LID - 10.1016/j.jep.2024.119271 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Tinospora crispa (L.) Hook.f. & Thomson (T. crispa), is widely distributed in Xishuangbanna, Yunnan Province, China. According to the "Selected Medicinal Plants of Yunnan", T. crispa is recognized for its versatile medicinal properties, including promoting diuresis, reducing swelling, relieving pain, relaxing tendons, and promoting blood circulation, suggesting that their extracts can be used to exhibit a range of beneficial activities such as immune regulation, blood sugar reduction, and anti-inflammatory effects. In the Dai ethnic areas of China, T. crispa is commonly employed in the herbal prescription of treatment of hyperuricemia and gouty arthritis. However, further study is needed to enucleate the potential pharmacological mechanism of T. crispa. AIM OF THE STUDY: This study aimed to investigate the effects and mechanisms of T. crispa vines extract (TC) in alleviating hyperuricemia. MATERIALS AND METHODS: A hyperuricemia mouse model was established through intraperitoneal injection of potassium oxonate to evaluate the hypouricemic effects of TC. To explore the underlying mechanisms of TC, network pharmacology analysis was employed. Additionally, a series of experimental approaches-including serum biomarker assays, ELISA, reverse transcription-quantitative PCR (RT-qPCR), histopathological staining, metabolomics analysis and western blotting-were performed to assess the capability of TC in modulating uric acid levels. RESULTS: TC treatment markedly lowered serum biomarkers by inhibiting xanthine oxidase (XOD) activity and modulating the expression of urate transporters, while also alleviating renal injury in hyperuricemic mice. Through bioinformatics and network pharmacology analyses, the NOD-like receptor signaling pathway was identified as a critical mechanism underlying the therapeutic impact of TC. Metabolomics analysis uncovered 14 differential metabolites and seven metabolic pathways linked to the anti-hyperuricemic action of TC. Further experimental validation confirmed that TC attenuated renal inflammation and suppressed activation of the NLRP3/caspase-1/IL-1β signaling pathway. CONCLUSION: Our findings demonstrate that TC exerts a significant uric acid-lowering effect in hyperuricemic mice. This therapeutic effect can be attributed to the suppression of uric acid synthesis and the modulation of urate transporters. Moreover, the inhibition of the NLRP3/caspase-1/IL-1βsignaling pathway further contributes to the regulatory action of TC on uric acid homeostasis. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Chen, Nuoshi AU - Chen N AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China. FAU - Liu, Dandan AU - Liu D AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China. FAU - He, Zelin AU - He Z AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China. FAU - Zhang, Yuping AU - Zhang Y AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China. FAU - Lai, Yongzhi AU - Lai Y AD - School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China. FAU - Wang, Shaoran AU - Wang S AD - School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China. FAU - He, Fei AU - He F AD - School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China. Electronic address: hefei8131@smu.edu.cn. FAU - Jie, Ligang AU - Jie L AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China. Electronic address: Jieligang1976@smu.edu.cn. FAU - Du, Hongyan AU - Du H AD - Department of Rheumatology and Immunology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, 510280, China; School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China; Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China. Electronic address: dhy48321@smu.edu.cn. LA - eng PT - Journal Article DEP - 20241220 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 268B43MJ25 (Uric Acid) RN - 0 (NLR Family, Pyrin Domain-Containing 3 Protein) RN - 0 (Plant Extracts) RN - 0 (Interleukin-1beta) RN - EC 3.4.22.36 (Caspase 1) RN - 0 (Nlrp3 protein, mouse) SB - IM MH - Animals MH - *Hyperuricemia/drug therapy/metabolism MH - *Uric Acid/metabolism/blood MH - NLR Family, Pyrin Domain-Containing 3 Protein/metabolism MH - Mice MH - Male MH - *Plant Extracts/pharmacology/therapeutic use/isolation & purification MH - *Tinospora/chemistry MH - Interleukin-1beta/metabolism MH - Caspase 1/metabolism MH - Signal Transduction/drug effects MH - Mice, Inbred C57BL MH - Disease Models, Animal OTO - NOTNLM OT - Hyperuricemia OT - Metabolomics analysis OT - Tinospora crispa (L.) Hook.f. & Thomson OT - Urate transporters OT - Xanthine oxidase COIS- Declaration of competing interest The authors declare that there are no conflicts of interest. EDAT- 2024/12/22 00:27 MHDA- 2025/01/22 06:26 CRDT- 2024/12/21 19:14 PHST- 2024/10/11 00:00 [received] PHST- 2024/12/06 00:00 [revised] PHST- 2024/12/19 00:00 [accepted] PHST- 2025/01/22 06:26 [medline] PHST- 2024/12/22 00:27 [pubmed] PHST- 2024/12/21 19:14 [entrez] AID - S0378-8741(24)01570-8 [pii] AID - 10.1016/j.jep.2024.119271 [doi] PST - ppublish SO - J Ethnopharmacol. 2025 Jan 31;340:119271. doi: 10.1016/j.jep.2024.119271. Epub 2024 Dec 20. PMID- 39881382 OWN - NLM STAT- MEDLINE DCOM- 20250504 LR - 20250524 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 20 IP - 1 DP - 2025 Jan 29 TI - Mechanisms and new advances in the efficacy of plant active ingredients in tendon-bone healing. PG - 106 LID - 10.1186/s13018-025-05483-y [doi] LID - 106 AB - The tendon-bone interface, known as the tenosynovial union or attachment, can be easily damaged by excessive exercise or trauma. Tendon-bone healing is a significant research topic in orthopedics, encompassing various aspects of sports injuries and postoperative recovery. Surgery is the most common treatment; however, it has limited efficacy in promoting tendon-bone healing and carries a risk of postoperative recurrence, necessitating the search for more effective treatments. Recently, plant-active ingredients such as tanshinone IIA, astragaloside, ginsenoside Rb1, and resveratrol have garnered significant attention due to their unique advantages in promoting tendon-bone healing. This review outlines the various mechanisms and research progress of these four plant-active ingredients, as well as compound ingredients, in promoting tendon-bone healing. For instance, tanshinone IIA significantly accelerates the healing rate and improves healing quality through anti-inflammatory, antioxidant, and cell proliferation-promoting mechanisms. Astragaloside expedites tendon-bone healing and enhances the mechanical strength of healing tissues primarily through anti-inflammatory, antioxidant, and immunoregulatory effects. Ginsenoside Rb1 enhances local blood supply and facilitates tendon-bone tissue repair through angiogenesis, anti-inflammatory, and antioxidant pathways. Resveratrol protects cellular function and accelerates tissue healing due to its potent antioxidant and anti-inflammatory effects. Additionally, the mechanisms and progress of certain Chinese herbal compound components in tendon-bone healing are outlined. This review concludes that these four plant-active ingredients and herbal compound components promote tendon-bone healing through various mechanisms. The efficacy mechanisms and research progress of these plant-active ingredients are summarized to provide references for clinical treatment and related research. CI - © 2025. The Author(s). FAU - Li, Yuan AU - Li Y AD - The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, No.41 Linyin Road, Baotou, Inner Mongolia, 014010, China. FAU - Wang, Wei AU - Wang W AD - The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, No.41 Linyin Road, Baotou, Inner Mongolia, 014010, China. FAU - Xu, Wensheng AU - Xu W AD - The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, No.41 Linyin Road, Baotou, Inner Mongolia, 014010, China. xwsoye@126.com. LA - eng PT - Journal Article PT - Review DEP - 20250129 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Ginsenosides) RN - Q369O8926L (Resveratrol) RN - 7413S0WMH6 (ginsenoside Rb1) SB - IM MH - Humans MH - *Wound Healing/drug effects/physiology MH - Animals MH - Ginsenosides/pharmacology/therapeutic use MH - Resveratrol/pharmacology/therapeutic use MH - *Bone and Bones/drug effects/physiology MH - *Tendon Injuries/drug therapy MH - *Tendons/drug effects/physiology PMC - PMC11776161 OTO - NOTNLM OT - Efficacy OT - Mechanisms OT - New advances OT - Plant-active ingredients OT - Tendon-bone healing COIS- Declarations. Ethics approval and consent to participate: Not applicable. Informed consent: Not applicable. Conflict of interest: There is no conflict of interest in this paper. Competing interests: The authors declare no competing interests. EDAT- 2025/01/30 00:19 MHDA- 2025/01/30 11:06 PMCR- 2025/01/29 CRDT- 2025/01/29 23:41 PHST- 2024/10/29 00:00 [received] PHST- 2025/01/09 00:00 [accepted] PHST- 2025/01/30 11:06 [medline] PHST- 2025/01/30 00:19 [pubmed] PHST- 2025/01/29 23:41 [entrez] PHST- 2025/01/29 00:00 [pmc-release] AID - 10.1186/s13018-025-05483-y [pii] AID - 5483 [pii] AID - 10.1186/s13018-025-05483-y [doi] PST - epublish SO - J Orthop Surg Res. 2025 Jan 29;20(1):106. doi: 10.1186/s13018-025-05483-y. PMID- 32726027 OWN - NLM STAT- MEDLINE DCOM- 20200917 LR - 20240729 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 45 IP - 13 DP - 2020 Jul TI - [Chemome profiling and comparison of three Orobanche medicinal plants]. PG - 3175-3182 LID - 10.19540/j.cnki.cjcmm.20200408.201 [doi] AB - Several Orobanche medicinal plants sometimes served as alternative sources of Cistanches Herba, attributing to the benefits such as tonifying kidney, strengthening tendons and bones. Among them, O. coerulescens, O. cernua and O. pycnostachya have been widely utilized in northern China for treatments of pains in the loins and knees, impotence, and spermatorrhea. However, their chemical profiles haven't been elucidated. In the present study, UHPLC-IT-TOF-MS was implemented to conduct in-depth chemome profiling of O. coerulescens, O. cernua and O. pycnostachya, aiming to achieve a comprehensive chemical characterization and to provide pronounced information for the quality control and clinical applications. An ACE Ultra-Core 2.5 Super C_(18)(3.0 mm×150 mm, 2.5 μm) column was deployed for chromatographic separations, and high-resolution MS~n spectra were recorded by IT-TOF-MS. Forty-eight components, in total, were observed, and thirty-eight ones were structurally annotated according to proposing mass fragmentation patterns, matching with relevant databases. Particularly, nine ones were confirmed by reference compounds. Overall, the chemical compositions of O. coerulescens and O. cernua are quite similar, and differences occur between O. pycnostachya and the prior two ones; primary chemical family is phenylethanoid glycosides, and several lignan glycosides as well as iridoid glycosides are also observed; the primary components include acteoside, isoacteoside, crenatoside and 2'-acetylacteoside, etc. FAU - Zhang, Ke AU - Zhang K AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Gong, Xing-Cheng AU - Gong XC AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Cao, Li-Bo AU - Cao LB AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Jia, Jin-Ru AU - Jia JR AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Tu, Peng-Fei AU - Tu PF AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Song, Qing-Qing AU - Song QQ AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China. FAU - Song, Yue-Lin AU - Song YL AD - School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 100029, China Beijing Key Laboratory for Quality Evaluation of Chinese Materia Medica Beijing 100029, China. LA - chi PT - Journal Article PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Glycosides) SB - IM MH - China MH - *Cistanche MH - Glycosides MH - *Orobanche MH - *Plants, Medicinal OTO - NOTNLM OT - Orobanche OT - chemical profile comparison OT - phenylethanoid glycosides EDAT- 2020/07/30 06:00 MHDA- 2020/09/18 06:00 CRDT- 2020/07/30 06:00 PHST- 2020/07/30 06:00 [entrez] PHST- 2020/07/30 06:00 [pubmed] PHST- 2020/09/18 06:00 [medline] AID - 10.19540/j.cnki.cjcmm.20200408.201 [doi] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2020 Jul;45(13):3175-3182. doi: 10.19540/j.cnki.cjcmm.20200408.201. PMID- 38739298 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20240707 IS - 1534-6307 (Electronic) IS - 1523-3774 (Print) IS - 1523-3774 (Linking) VI - 26 IP - 8 DP - 2024 Aug TI - Review: The Role of Dual-Energy Computed Tomography in Detecting Monosodium Urate Deposits in Vascular Tissues. PG - 302-310 LID - 10.1007/s11926-024-01151-y [doi] AB - PURPOSE OF REVIEW: To highlight novel findings in the detection of monosodium urate deposits in vessels using dual energy computed tomography, and to discuss the potential clinical implications for gout and hyperuricemia patients. RECENT FINDINGS: Gout is an independent risk factor for cardiovascular disease. However, classical risk calculators do not take into account these hazards, and parameters to identify patients at risk are lacking. Monosodium urate measured by dual energy computed tomography is a well-established technology for the detection and quantification of monosodium urate deposits in peripheral joints and tendons. Recent findings also suggest its applicability to identify vascular urate deposits. Dual energy computed tomography is a promising tool for detection of cardiovascular monosodium urate deposits in gout patients, to better delineate individuals at increased risk for cardiovascular disease. CI - © 2024. The Author(s). FAU - Held, Julia AU - Held J AD - Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria. FAU - Haschka, David AU - Haschka D AD - Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria. david.haschka@i-med.ac.at. FAU - Lacaita, Pietro G AU - Lacaita PG AD - Department of Radiology, Medical University Innsbruck, Innsbruck, Austria. FAU - Feuchtner, Gudrun M AU - Feuchtner GM AD - Department of Radiology, Medical University Innsbruck, Innsbruck, Austria. FAU - Klotz, Werner AU - Klotz W AD - Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria. FAU - Stofferin, Hannes AU - Stofferin H AD - Division of Clinical and Functional Anatomy, Department of Anatomy, Histology and Embryology, Medical University Innsbruck, Innsbruck, Austria. FAU - Duftner, Christina AU - Duftner C AD - Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria. FAU - Weiss, Günter AU - Weiss G AD - Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria. FAU - Klauser, Andrea S AU - Klauser AS AD - Department of Radiology, Medical University Innsbruck, Innsbruck, Austria. LA - eng PT - Journal Article PT - Review DEP - 20240513 PL - United States TA - Curr Rheumatol Rep JT - Current rheumatology reports JID - 100888970 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - *Uric Acid/analysis MH - *Tomography, X-Ray Computed/methods MH - *Gout/diagnostic imaging MH - Hyperuricemia/diagnostic imaging MH - Cardiovascular Diseases/diagnostic imaging PMC - PMC11224090 OTO - NOTNLM OT - Cardiovascular OT - Dual Energy Computed Tomography OT - Gout OT - Hyperuricemia OT - Monosodium Urate COIS- The authors declare no competing interests. The authors have no conflicts of interest to disclose. EDAT- 2024/05/13 12:53 MHDA- 2024/07/04 12:43 PMCR- 2024/05/13 CRDT- 2024/05/13 11:15 PHST- 2024/05/01 00:00 [accepted] PHST- 2024/07/04 12:43 [medline] PHST- 2024/05/13 12:53 [pubmed] PHST- 2024/05/13 11:15 [entrez] PHST- 2024/05/13 00:00 [pmc-release] AID - 10.1007/s11926-024-01151-y [pii] AID - 1151 [pii] AID - 10.1007/s11926-024-01151-y [doi] PST - ppublish SO - Curr Rheumatol Rep. 2024 Aug;26(8):302-310. doi: 10.1007/s11926-024-01151-y. Epub 2024 May 13. PMID- 26330947 OWN - NLM STAT- MEDLINE DCOM- 20160526 LR - 20220316 IS - 2005-4408 (Electronic) IS - 2005-291X (Print) IS - 2005-291X (Linking) VI - 7 IP - 3 DP - 2015 Sep TI - Wide-Awake Primary Flexor Tendon Repair, Tenolysis, and Tendon Transfer. PG - 275-81 LID - 10.4055/cios.2015.7.3.275 [doi] AB - Tendon surgery is unique because it should ensure tendon gliding after surgery. Tendon surgery now can be performed under local anesthesia without tourniquet, by injecting epinephrine mixed with lidocaine, to achieve vasoconstriction in the area of surgery. This method allows the tendon to move actively during surgery to test tendon function intraoperatively and to ensure the tendon is properly repaired before leaving the operating table. I applied this method to primary flexor tendon repair in zone 1 or 2, tenolysis, and tendon transfer, and found this approach makes tendon surgery easier and more reliable. This article describes the method that I have used for tendon surgery. FAU - Tang, Jin Bo AU - Tang JB AD - Department of Hand Surgery, The Hand Surgery Research Center, Affiliated Hospital of Nantong University, Nantong, China. LA - eng PT - Journal Article PT - Review DEP - 20150813 PL - Korea (South) TA - Clin Orthop Surg JT - Clinics in orthopedic surgery JID - 101505087 RN - 0 (Anesthetics, Local) RN - 0 (Vasoconstrictor Agents) RN - YKH834O4BH (Epinephrine) SB - IM MH - Anesthetics, Local/administration & dosage/therapeutic use MH - Epinephrine/administration & dosage/therapeutic use MH - Humans MH - Range of Motion, Articular MH - Suture Techniques MH - *Tendon Injuries/rehabilitation/surgery MH - Tendon Transfer/*methods MH - Tendons/*surgery MH - Vasoconstrictor Agents/administration & dosage/therapeutic use PMC - PMC4553273 OTO - NOTNLM OT - Anesthesia OT - Rehabilitation OT - Surgical repair OT - Tendon COIS- CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported. EDAT- 2015/09/04 06:00 MHDA- 2016/05/27 06:00 PMCR- 2015/09/01 CRDT- 2015/09/03 06:00 PHST- 2015/05/06 00:00 [received] PHST- 2015/06/17 00:00 [accepted] PHST- 2015/09/03 06:00 [entrez] PHST- 2015/09/04 06:00 [pubmed] PHST- 2016/05/27 06:00 [medline] PHST- 2015/09/01 00:00 [pmc-release] AID - 10.4055/cios.2015.7.3.275 [doi] PST - ppublish SO - Clin Orthop Surg. 2015 Sep;7(3):275-81. doi: 10.4055/cios.2015.7.3.275. Epub 2015 Aug 13. PMID- 32548773 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20210915 IS - 1724-6059 (Electronic) IS - 1121-8428 (Linking) VI - 34 IP - 4 DP - 2021 Aug TI - Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). PG - 1081-1090 LID - 10.1007/s40620-020-00776-3 [doi] AB - This review is devoted to rheumatologic diseases mainly characterized by different types of arthritis. They may involve also different organs, including the kidney, but renal disease is more frequently caused by the nephrotoxicity of drugs to relieve pain or to interfere with the pathophysiology of the underlying disease. Rheumatoid arthritis is the prototype of arthropathies. This autoimmune disease mainly attacks joints, tendons and ligaments but can also involve internal organs including the kidney. Psoriatic arthritis is a complex disease in which psoriasis, a chronic inflammatory disease, is associated with the development of peripheral arthritis or spondylitis. The disease or its treatment may lead to kidney complications. Gout is a form of inflammatory arthritis which is characterized by an increase in the serum uric acid deposits in and around the joints of the extremities, the so called tophi. The disease is often associated with a metabolic syndrome with diabetes, obesity, hypertension, and cardiovascular disease. Kidney injury is frequent. It may be caused by kidney stones, urinary tract obstruction, tubulointerstitial and vascular lesions leading to CKD and renal failure. CI - © 2020. Italian Society of Nephrology. FAU - Ponticelli, Claudio AU - Ponticelli C AUID- ORCID: 0000-0001-6060-965X AD - , Via Ampere 126, 20131, Milano, Italy. ponticelli.claudio@gmail.com. FAU - Doria, Andrea AU - Doria A AD - Division of Rheumatology, Department of Medicine, DIMED, University of Padova, Padova, Italy. FAU - Moroni, Gabriella AU - Moroni G AD - Division of Nephrology, Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico Milano, Milano, Italy. LA - eng PT - Journal Article PT - Review DEP - 20200616 PL - Italy TA - J Nephrol JT - Journal of nephrology JID - 9012268 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Arthritis, Rheumatoid MH - Chronic Disease MH - *Gout MH - Humans MH - *Kidney Calculi MH - Uric Acid OTO - NOTNLM OT - Drug toxicity OT - Gout OT - Kidney and arthritis OT - Psoriatic arthritis OT - Rheumatoid arthritis OT - Urate and kidney EDAT- 2020/06/18 06:00 MHDA- 2021/09/16 06:00 CRDT- 2020/06/18 06:00 PHST- 2020/04/27 00:00 [received] PHST- 2020/06/06 00:00 [accepted] PHST- 2020/06/18 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2020/06/18 06:00 [entrez] AID - 10.1007/s40620-020-00776-3 [pii] AID - 10.1007/s40620-020-00776-3 [doi] PST - ppublish SO - J Nephrol. 2021 Aug;34(4):1081-1090. doi: 10.1007/s40620-020-00776-3. Epub 2020 Jun 16. PMID- 27010973 OWN - NLM STAT- MEDLINE DCOM- 20170531 LR - 20170817 IS - 1442-9071 (Electronic) IS - 1442-6404 (Linking) VI - 45 IP - 1 DP - 2017 Jan TI - Review of the ophthalmic manifestations of gout and uric acid crystal deposition. PG - 73-80 LID - 10.1111/ceo.12749 [doi] AB - Gout is a clinical disorder that is characterized by the deposition of monosodium urate crystals (MSU) in joints and tendons, usually in the presence of prolonged hyperuricaemia. Following an asymptomatic phase of hyperuricaemia, gout usually presents as acute monoarthritis followed by periods of remission and exacerbation. Conjunctival hyperaemia and subconjunctival haemorrhage exacerbated by purine intake are two of the more common manifestations that may go unrecognized. Other ocular and adnexal structures can be affected by urate crystal deposition and associated inflammation, with potentially vision-threatening consequences; however, ocular manifestations of gout are rare and may have been over-reported in the older literature, but our understanding of the clinic-pathological features of ocular urate deposits remains limited. CI - © 2016 Royal Australian and New Zealand College of Ophthalmologists. FAU - Ao, Jack AU - Ao J AD - South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, South Australia, Australia. FAU - Goldblatt, Fiona AU - Goldblatt F AD - Department of Rheumatology, The Repatriation General Hospital, Adelaide, South Australia, Australia. AD - Flinders Medical Centre, Adelaide, South Australia, Australia. FAU - Casson, Robert J AU - Casson RJ AD - South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, South Australia, Australia. LA - eng PT - Journal Article PT - Review DEP - 20160501 PL - Australia TA - Clin Exp Ophthalmol JT - Clinical & experimental ophthalmology JID - 100896531 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Eye Diseases/diagnosis/etiology/metabolism MH - Gout/blood/*complications MH - Humans MH - Hyperuricemia/blood/*complications MH - Uric Acid/*blood OTO - NOTNLM OT - eyes OT - gout OT - manifestations OT - ocular OT - ophthalmic EDAT- 2016/03/25 06:00 MHDA- 2017/06/01 06:00 CRDT- 2016/03/25 06:00 PHST- 2015/12/17 00:00 [received] PHST- 2016/03/03 00:00 [revised] PHST- 2016/03/18 00:00 [accepted] PHST- 2016/03/25 06:00 [pubmed] PHST- 2017/06/01 06:00 [medline] PHST- 2016/03/25 06:00 [entrez] AID - 10.1111/ceo.12749 [doi] PST - ppublish SO - Clin Exp Ophthalmol. 2017 Jan;45(1):73-80. doi: 10.1111/ceo.12749. Epub 2016 May 1. PMID- 39676463 OWN - NLM STAT- MEDLINE DCOM- 20241216 LR - 20241216 IS - 1756-185X (Electronic) IS - 1756-1841 (Linking) VI - 27 IP - 12 DP - 2024 Dec TI - Ultrasonographic Evaluation of Urate Crystal Deposition in Tendons With Gout Patients. PG - e70006 LID - 10.1111/1756-185X.70006 [doi] AB - OBJECTIVE: To use ultrasound technology to assess the deposition of urate crystals in the common lower limb tendons of patients with gout, providing additional imaging information for the management of these patients. METHODS: High-frequency ultrasound was retrospectively used to evaluate urate crystal deposition in common lower limb tendons-quadriceps, patellar, and Achilles-in patients with gouty arthritis. Comparative statistical analysis was conducted among asymptomatic hyperuricemia patients and healthy individuals during the same period. RESULTS: Aggregates were detected in the tendons of all three groups, whereas tophi were found exclusively in tendons of asymptomatic hyperuricemia and gout groups. The prevalence of intratendinous aggregates and tophi in gout was significantly higher than the other groups (p < 0.05). The Achilles tendon showed the highest involvement, followed by the quadriceps and patellar tendons. CONCLUSION: Tendons are common sites of urate deposition in patients with gout and asymptomatic hyperuricemia. Aggregates and tophi are frequently observed in and around large tendons such as the quadriceps, patellar, and Achilles tendons in gout patients. Ultrasonography proves useful in highly sensitive and specific evaluation of urate deposition within and around tendons. CI - © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. FAU - Deng, Si-Hui AU - Deng SH AUID- ORCID: 0009-0000-8627-5299 AD - Department of Ultrasound, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. FAU - Wang, Jie AU - Wang J AD - Department of Ultrasound, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. FAU - Hu, Jing AU - Hu J AD - Department of Ultrasound, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. FAU - Tu, Bin AU - Tu B AD - Department of Ultrasound, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. FAU - Dang, Wan-Tai AU - Dang WT AUID- ORCID: 0000-0001-9499-2626 AD - Department of Rheumatology and Immunology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. FAU - Liu, Jian AU - Liu J AD - Department of Ultrasound, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. LA - eng GR - 19ZD004/Health Commission of Sichuan Province/ GR - 2022NSFSC0692/Sichuan Science and Technology Department/ GR - 2022-YF05-01414-SN/Key Research and Development Projects Chengdu/ GR - CYFY-GQ18/the First Affiliated Hospital of Chengdu Medical College/ GR - CYFY-GQ11/the First Affiliated Hospital of Chengdu Medical College/ PT - Journal Article PL - England TA - Int J Rheum Dis JT - International journal of rheumatic diseases JID - 101474930 RN - 268B43MJ25 (Uric Acid) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *Uric Acid MH - Male MH - Middle Aged MH - Retrospective Studies MH - Female MH - *Ultrasonography MH - *Predictive Value of Tests MH - Adult MH - *Patellar Ligament/diagnostic imaging/metabolism MH - Achilles Tendon/diagnostic imaging MH - Gout/diagnostic imaging/metabolism MH - Aged MH - Hyperuricemia/diagnostic imaging MH - Biomarkers MH - Arthritis, Gouty/diagnostic imaging/metabolism MH - Quadriceps Muscle/diagnostic imaging/metabolism MH - Crystallization MH - Tendons/diagnostic imaging/metabolism OTO - NOTNLM OT - aggregates OT - enthesis OT - gout OT - tendon OT - tophus OT - ultrasound EDAT- 2024/12/16 11:35 MHDA- 2024/12/16 11:36 CRDT- 2024/12/16 02:43 PHST- 2024/11/04 00:00 [revised] PHST- 2024/08/08 00:00 [received] PHST- 2024/12/02 00:00 [accepted] PHST- 2024/12/16 11:36 [medline] PHST- 2024/12/16 11:35 [pubmed] PHST- 2024/12/16 02:43 [entrez] AID - 10.1111/1756-185X.70006 [doi] PST - ppublish SO - Int J Rheum Dis. 2024 Dec;27(12):e70006. doi: 10.1111/1756-185X.70006. PMID- 25276832 OWN - NLM STAT- MEDLINE DCOM- 20150616 LR - 20211021 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2014 DP - 2014 TI - Hyperuricemic PRP in tendon cells. PG - 926481 LID - 10.1155/2014/926481 [doi] LID - 926481 AB - Platelet-rich plasma (PRP) is injected within tendons to stimulate healing. Metabolic alterations such as the metabolic syndrome, diabetes, or hyperuricemia could hinder the therapeutic effect of PRP. We hypothesise that tendon cells sense high levels of uric acid and this could modify their response to PRP. Tendon cells were treated with allogeneic PRPs for 96 hours. Hyperuricemic PRP did not hinder the proliferative actions of PRP. The gene expression pattern of inflammatory molecules in response to PRP showed absence of IL-1b and COX1 and modest expression of IL6, IL8, COX2, and TGF-b1. IL8 and IL6 proteins were secreted by tendon cells treated with PRP. The synthesis of IL6 and IL8 proteins induced by PRP is decreased significantly in the presence of hyperuricemia (P = 0.017 and P = 0.012, resp.). Concerning extracellular matrix, PRP-treated tendon cells displayed high type-1 collagen, moderate type-3 collagen, decorin, and hyaluronan synthase-2 expression and modest expression of scleraxis. Hyperuricemia modified the expression pattern of extracellular matrix proteins, upregulating COL1 (P = 0.036) and COMP (P = 0.012) and downregulating HAS2 (P = 0.012). Positive correlations between TGF-b1 and type-1 collagen (R = 0.905, P = 0.002) and aggrecan (R = 0.833, P = 0.010) and negative correlations between TGF-b1 and IL6 synthesis (R = -0.857, P = 0.007) and COX2 (R = -0.810, P = 0.015) were found. FAU - Andia, I AU - Andia I AD - Regenerative Medicine Laboratory, BioCruces, Cruces University Hospital, 48903 Barakaldo, Spain. FAU - Rubio-Azpeitia, E AU - Rubio-Azpeitia E AD - Regenerative Medicine Laboratory, BioCruces, Cruces University Hospital, 48903 Barakaldo, Spain. FAU - Maffulli, N AU - Maffulli N AD - Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, 89100 Salerno, Italy ; Queen Mary University of London, Barts and the London School of Medicine and Dentistry Centre for Sports and Exercise Medicine, Mile End Hospital, 275 Bancroft Road, London E1 4DG, UK. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140908 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Extracellular Matrix Proteins) RN - 0 (Interleukins) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Cell Proliferation MH - Extracellular Matrix/metabolism MH - Extracellular Matrix Proteins/genetics/metabolism MH - Gene Expression Regulation MH - Humans MH - Inflammation/genetics/pathology MH - Interleukins/biosynthesis/genetics MH - Male MH - Platelet-Rich Plasma/*metabolism MH - Real-Time Polymerase Chain Reaction MH - Tendons/*cytology MH - Uric Acid/*blood PMC - PMC4170825 EDAT- 2014/10/03 06:00 MHDA- 2015/06/17 06:00 PMCR- 2014/09/08 CRDT- 2014/10/03 06:00 PHST- 2014/05/30 00:00 [received] PHST- 2014/07/31 00:00 [revised] PHST- 2014/08/04 00:00 [accepted] PHST- 2014/10/03 06:00 [entrez] PHST- 2014/10/03 06:00 [pubmed] PHST- 2015/06/17 06:00 [medline] PHST- 2014/09/08 00:00 [pmc-release] AID - 10.1155/2014/926481 [doi] PST - ppublish SO - Biomed Res Int. 2014;2014:926481. doi: 10.1155/2014/926481. Epub 2014 Sep 8. PMID- 40466361 OWN - NLM STAT- MEDLINE DCOM- 20250710 LR - 20250710 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 775 DP - 2025 Aug 15 TI - Mechanistic insights into the anti-rheumatoid arthritis effects of ursolic acid from Periploca forrestii Schltr. via network pharmacology, molecular docking, and experimental Validation. PG - 152111 LID - S0006-291X(25)00825-3 [pii] LID - 10.1016/j.bbrc.2025.152111 [doi] AB - BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovitis and systemic inflammation. Periploca forrestii Schltr., one of the "three treasures of Miao medicine", is traditionally used for RA treatment due to its reputed effects in relaxing tendons, activating collaterals, and dispelling wind and dampness. This study investigates the mechanisms by which Ursolic Acid (UA), a triterpenoid from Periploca forrestii, exerts anti-inflammatory effects in treating RA. METHODS: Network pharmacology was used to identify potential targets of UA in RA treatment by integrating data from the Traditional Chinese Medicine System Pharmacology (TCMSP) Database, PubChem, and SwissTargetPrediction. Key targets were refined through protein-protein interaction (PPI) network analysis, and relevant signaling pathways were identified via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Molecular docking was employed to validate the predicted interactions. The anti-inflammatory efficacy of UA was assessed in vitro using an LPS-induced RAW264.7 macrophage model and in vivo using a collagen-induced arthritis (CIA) rat model. RESULTS: A total of 15 key targets were identified, primarily involved in inflammation response, cell proliferation and apoptosis, and bone resorption and remodeling. GO and KEGG enrichment analyses highlighted the TNF signaling pathway as a central mechanism. In vitro experiments demonstrated that UA significantly inhibited the production of inflammatory mediators, including NO, TNF-α, IL-6, and MMP9, and reduced intracellular reactive oxygen species (ROS) levels in LPS-induced RAW264.7 cells. In the CIA rat model, UA markedly decreased joint swelling, arthritis scores, articular erosion, and TNF-α and IL-6 levels in spleen and serum. CONCLUSION: Our findings suggest that UA exerts therapeutic effects on RA by modulating key inflammatory pathways, particularly the TNF signaling pathway. This study highlights the potential of UA as a therapeutic agent for RA and provides a pharmacological basis for the traditional use of P. forrestii in RA management, thus supporting the development of ethnopharmacological approached in modern medicine. CI - Copyright © 2025 Elsevier Inc. All rights reserved. FAU - Wu, Xiaoqian AU - Wu X AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Teng, Kangdi AU - Teng K AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - He, Yanjun AU - He Y AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Cai, Xu AU - Cai X AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Zhu, Jiaxin AU - Zhu J AD - Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Han, Lingfei AU - Han L AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Feng, Feng AU - Feng F AD - Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China. FAU - Liu, Wenyuan AU - Liu W AD - Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 211198, PR China; Institute of Innovative Medicine, China Pharmaceutical University, Hangzhou, 310018, PR China. Electronic address: liuwenyuan8506@163.com. FAU - Qu, Wei AU - Qu W AD - Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 211198, PR China. Electronic address: popoqzh@126.com. LA - eng PT - Journal Article DEP - 20250528 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - P3M2575F3F (Ursolic Acid) RN - 0 (Triterpenes) RN - 0 (Anti-Inflammatory Agents) SB - IM MH - Animals MH - Ursolic Acid MH - *Triterpenes/pharmacology/chemistry/therapeutic use MH - Molecular Docking Simulation MH - *Arthritis, Rheumatoid/drug therapy/metabolism/pathology MH - Mice MH - Network Pharmacology MH - RAW 264.7 Cells MH - Rats MH - *Anti-Inflammatory Agents/pharmacology/chemistry/therapeutic use MH - Protein Interaction Maps/drug effects MH - Male MH - Rats, Sprague-Dawley MH - Signal Transduction/drug effects MH - Arthritis, Experimental/drug therapy OTO - NOTNLM OT - Network pharmacology OT - Periploca forrestii schltr. OT - Rheumatoid arthritis OT - TNF-α OT - Ursolic acid COIS- Declaration of competing interest ☑ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/06/05 00:28 MHDA- 2025/07/11 00:26 CRDT- 2025/06/04 18:17 PHST- 2025/02/20 00:00 [received] PHST- 2025/05/11 00:00 [revised] PHST- 2025/05/27 00:00 [accepted] PHST- 2025/07/11 00:26 [medline] PHST- 2025/06/05 00:28 [pubmed] PHST- 2025/06/04 18:17 [entrez] AID - S0006-291X(25)00825-3 [pii] AID - 10.1016/j.bbrc.2025.152111 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2025 Aug 15;775:152111. doi: 10.1016/j.bbrc.2025.152111. Epub 2025 May 28. PMID- 26369610 OWN - NLM STAT- MEDLINE DCOM- 20160323 LR - 20220410 IS - 1759-4804 (Electronic) IS - 1759-4790 (Linking) VI - 11 IP - 12 DP - 2015 Dec TI - Mechanisms of crystal formation in gout-a structural approach. PG - 725-30 LID - 10.1038/nrrheum.2015.125 [doi] AB - The mechanisms and sites of monosodium urate monohydrate (MSU) crystal deposition in gout have received little attention from the scientific community to date. Formalin fixation of tissues leads to the dissolution of MSU crystals, resulting in their absence from routinely processed pathological samples and hence neglect. However, modern imaging techniques-especially ultrasonography but also conventional CT and dual-energy CT-reveal that MSU crystals form at the cartilage surface as well as inside tendons and ligaments, often at insertion sites. Tophi comprise round white formations of different sizes surrounded by inflammatory tissue. Studies of fibres recovered from gouty synovial fluid indicate that these fibres are likely to be a primary site of crystal formation by templated nucleation, with crystals deposited parallel to the fibres forming transverse bands. In tophi, two areas can be distinguished: one where crystals are formed on cellular tissues and another consisting predominantly of crystals, where secondary nucleation seems to take place; this organization could explain how tophi can grow rapidly. From these observations based on a crystallographic approach, it seems that initial templated nucleation on structural fibres-probably collagen-followed at some sites by secondary nucleation could explain MSU crystal deposition in gout. FAU - Pascual, Eliseo AU - Pascual E AD - Department of Medicine, Rheumatology Section, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Pintor Baeza 12, Alicante 03010, Spain. FAU - Addadi, Lia AU - Addadi L AD - Department of Structural Biology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 7610001, Israel. FAU - Andrés, Mariano AU - Andrés M AD - Department of Medicine, Rheumatology Section, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Pintor Baeza 12, Alicante 03010, Spain. FAU - Sivera, Francisca AU - Sivera F AD - Rheumatology Unit, Hospital General Universitario de Elda, Carretera Elda-Sax SN, Elda 03600, Spain. LA - eng PT - Journal Article PT - Review DEP - 20150915 PL - United States TA - Nat Rev Rheumatol JT - Nature reviews. Rheumatology JID - 101500080 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Crystallization MH - Gout/*etiology/metabolism MH - Humans MH - Uric Acid/metabolism EDAT- 2015/09/16 06:00 MHDA- 2016/03/24 06:00 CRDT- 2015/09/16 06:00 PHST- 2015/09/16 06:00 [entrez] PHST- 2015/09/16 06:00 [pubmed] PHST- 2016/03/24 06:00 [medline] AID - nrrheum.2015.125 [pii] AID - 10.1038/nrrheum.2015.125 [doi] PST - ppublish SO - Nat Rev Rheumatol. 2015 Dec;11(12):725-30. doi: 10.1038/nrrheum.2015.125. Epub 2015 Sep 15. PMID- 35816119 OWN - NLM STAT- MEDLINE DCOM- 20230123 LR - 20240102 IS - 1607-8438 (Electronic) IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 64 IP - 1 DP - 2023 Jan TI - Post-injury tendon mechanics are not affected by tamoxifen treatment. PG - 75-81 LID - 10.1080/03008207.2022.2097907 [doi] AB - PURPOSE: A growing interest in the mechanisms that govern tendon healing has resulted in the develop-ment of tools, such as the tamoxifen-inducible mouse knockdown model, to address these questions. However, tamoxifen is a selective estrogen receptor modulator and may interfere with the tendon healing process. The objective of this study was to evaluate the effects of tamoxifen on post-injury tendon mechanics in wild-type mice. METHODS: The mice underwent treatment at the time of injury using an established mouse injury model and the injured tendons were evaluated 3 weeks post-injury. The treatment contained tamoxifen suspended in corn oil and was compared to a treatment with only corn oil, as well as mice with no treatment. Tendons were evaluated by measuring the quasi-static and viscoelastic mechanics, collagen fiber realignment, cellularity, and nuclear morphology. RESULTS: Mechanical testing of the tendons post-injury revealed no changes to viscoelastic mechanics, quasi-static mechanics, or collagen realignment during loading after tamoxifen treatment with the dosage regimen utilized (three daily injections of 4.5 mg/40 g body weight). Additionally, histological analysis revealed no changes to cellularity or cell nuclear shape. CONCLUSION: Overall, this study revealed that tamoxifen treatment at the time of tendon injury did not result in changes to tendon mechanics or the histological parameters at 3 weeks post-injury. FAU - Beach, Zakary M AU - Beach ZM AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Fung, Ashley K AU - Fung AK AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Weiss, Stephanie N AU - Weiss SN AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Soslowsky, Louis J AU - Soslowsky LJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. LA - eng GR - P30 AR069619/AR/NIAMS NIH HHS/United States GR - R01 AR068057/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220711 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 094ZI81Y45 (Tamoxifen) RN - 8001-30-7 (Corn Oil) RN - 9007-34-5 (Collagen) SB - IM MH - Mice MH - Animals MH - *Tamoxifen/pharmacology MH - Corn Oil MH - Tendons/pathology MH - *Tendon Injuries/pathology MH - Collagen MH - Disease Models, Animal PMC - PMC9832173 MID - NIHMS1821191 OTO - NOTNLM OT - Tendon OT - injury OT - mechanics OT - mouse OT - tamoxifen EDAT- 2022/07/12 06:00 MHDA- 2023/01/24 06:00 PMCR- 2024/01/01 CRDT- 2022/07/11 10:25 PHST- 2022/07/12 06:00 [pubmed] PHST- 2023/01/24 06:00 [medline] PHST- 2022/07/11 10:25 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.1080/03008207.2022.2097907 [doi] PST - ppublish SO - Connect Tissue Res. 2023 Jan;64(1):75-81. doi: 10.1080/03008207.2022.2097907. Epub 2022 Jul 11. PMID- 4131739 OWN - NLM STAT- MEDLINE DCOM- 19740522 LR - 20190701 IS - 0024-3205 (Print) IS - 0024-3205 (Linking) VI - 13 IP - 4 DP - 1973 Aug 16 TI - Biology of wound repair. PG - I-IX FAU - Peacock, E E Jr AU - Peacock EE Jr LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 151-18-8 (Aminopropionitrile) RN - 1CC1JFE158 (Dactinomycin) RN - 4A6ZS6Q2CL (Puromycin) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 1.- (Oxidoreductases) RN - K3Z4F929H6 (Lysine) SB - IM MH - Aminopropionitrile/therapeutic use MH - Cicatrix/prevention & control MH - Collagen/biosynthesis MH - Connective Tissue/metabolism MH - Dactinomycin/pharmacology MH - Epithelium/metabolism MH - Fibroblasts/metabolism MH - Humans MH - Lathyrism/chemically induced/metabolism MH - Lysine MH - Oxidoreductases/metabolism MH - Proline/pharmacology MH - Puromycin/pharmacology MH - Skin/drug effects/immunology/metabolism MH - Solubility MH - Tendons/surgery MH - *Wound Healing RF - 21 EDAT- 1973/08/16 00:00 MHDA- 2001/03/28 10:01 CRDT- 1973/08/16 00:00 PHST- 1973/08/16 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1973/08/16 00:00 [entrez] AID - 0024-3205(73)90218-X [pii] AID - 10.1016/0024-3205(73)90218-x [doi] PST - ppublish SO - Life Sci. 1973 Aug 16;13(4):I-IX. doi: 10.1016/0024-3205(73)90218-x. PMID- 22244067 OWN - NLM STAT- MEDLINE DCOM- 20120516 LR - 20161018 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 21 IP - 2 DP - 2012 Feb TI - The role of nitric oxide in tendon healing. PG - 238-44 LID - 10.1016/j.jse.2011.11.001 [doi] AB - Nitric oxide (NO) is a small free radical that is generated by a family of enzymes called the nitric oxide synthases (NOS). There are 3 isoforms of NOS: endothelial NOS (eNOS), brain or neuronal NOS (bNOS), and inducible NOS (iNOS). In experiments performed during the last 20 years, we have shown that NO is induced by all 3 isoforms of NOS after tendon injury and that NOS activity is upregulated in tendinopathy. In normal uninjured tendons, there is very little NOS activity. In injured rat and human tendons, NOS activity was found in healing fibroblasts in a temporal fashion. In animal models, competitive inhibition of NOS resulted in reduced tendon healing, whereas the addition of NO resulted in enhanced tendon healing. In cultured human cells, the addition of NO via chemical means and adenovirus transfection resulted in enhanced collagen synthesis. We performed 3 randomized, double-blinded clinical trials that demonstrated a significant positive beneficial effect of NO treatment on clinical symptoms and function in patients with Achilles tendinopathy, tennis elbow, and supraspinatus tendonitis. NO was delivered via glyceryl trinitrate (GTN) patches. We also conducted a 3-year prospective follow-up that demonstrated significant long-term efficacy of GTN patches in treating noninsertional Achilles tendinopathy. In a 5-year prospective comparison treating lateral epicondylitis, we found no additional benefits of GTN vs placebo at 5 years. The use of a new GTN patch, OrthoDerm, demonstrated no evidence for efficacy in treating chronic lateral epicondylitis. CI - Copyright © 2012 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Mosby, Inc. All rights reserved. FAU - Bokhari, Ali R AU - Bokhari AR AD - Orthopaedic Research Institute, University of New South Wales, The St George Hospital, Sydney, NSW, Australia. a.bokhari33@gmail.com FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Comparative Study PT - Journal Article PT - Review PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase) SB - IM MH - Administration, Topical MH - Animals MH - Disease Models, Animal MH - Extracellular Matrix/drug effects/metabolism MH - Humans MH - Nitric Oxide/*administration & dosage/*metabolism MH - Nitric Oxide Synthase/antagonists & inhibitors/metabolism MH - Randomized Controlled Trials as Topic MH - Rats MH - Tendinopathy/*drug therapy/*metabolism/pathology MH - Tendon Injuries/*drug therapy/*metabolism/pathology MH - Wound Healing/*drug effects/physiology EDAT- 2012/01/17 06:00 MHDA- 2012/05/17 06:00 CRDT- 2012/01/17 06:00 PHST- 2011/09/28 00:00 [received] PHST- 2011/11/08 00:00 [revised] PHST- 2011/11/08 00:00 [accepted] PHST- 2012/01/17 06:00 [entrez] PHST- 2012/01/17 06:00 [pubmed] PHST- 2012/05/17 06:00 [medline] AID - S1058-2746(11)00560-X [pii] AID - 10.1016/j.jse.2011.11.001 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2012 Feb;21(2):238-44. doi: 10.1016/j.jse.2011.11.001. PMID- 30928195 OWN - NLM STAT- MEDLINE DCOM- 20200317 LR - 20200317 IS - 1464-3405 (Electronic) IS - 0960-894X (Linking) VI - 29 IP - 10 DP - 2019 May 15 TI - Further sesquiterpenoids from the rhizomes of Homalomena occulta and their anti-inflammatory activity. PG - 1162-1167 LID - S0960-894X(19)30170-2 [pii] LID - 10.1016/j.bmcl.2019.03.031 [doi] AB - The rhizomes of Homalomena occulta are called Qian-nian-jian in Traditional Chinese Medicine (TCM), which is widely consumed in China owing to its health benefits for the treatment of rheumatoid arthritis and for strengthening tendons and bones. A phytochemical investigation on this famous TCM yielded 19 sesquiterpenoids (1-19) with various carbocyclic skeletons including isodaucane (2, 8, and 9), guaiane (3), eudesmane (4 and 10-15), oppositane (5, 16, and 17), and aromadendrane (18 and 19) types. The structures of new compounds, Homalomenins A-E (1-5), were determined by diverse spectroscopic data. Compound 1 possessed a rare sesquiterpenoid skeleton and compound 5 represented the first example of 1,4-oxa-oppositane sesquiterpenoid. These isolates were evaluated for their inhibitory effects on COX-2 mRNA, COX-2 protein expression, and prostaglandin E2 (PGE2) production in Raw264.7 cells, which demonstrated that compounds 5, 18, 19 showed potent anti-inflammatory activity by suppressing LPS-induced COX-2 expression and PGE2 production in a dose-dependent manner. CI - Copyright © 2019 Elsevier Ltd. All rights reserved. FAU - Yang, Jun-Li AU - Yang JL AD - CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou 730000, People's Republic of China. FAU - Dao, Trong Tuan AU - Dao TT AD - Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark; National Institute of Medicinal Materials, 3B Quang Trung, Hanoi, Viet Nam. FAU - Hien, Tran Thi AU - Hien TT AD - Department of Pharmacy, Thai Binh Medical and Pharmacy University, 373 Ly Bon, Thai Binh, Viet Nam. FAU - Zhao, Ya-Min AU - Zhao YM AD - CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou 730000, People's Republic of China. FAU - Shi, Yan-Ping AU - Shi YP AD - CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou 730000, People's Republic of China. Electronic address: shiyp@licp.cas.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190322 PL - England TA - Bioorg Med Chem Lett JT - Bioorganic & medicinal chemistry letters JID - 9107377 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Plant Extracts) RN - 0 (RNA, Messenger) RN - 0 (Sesquiterpenes) RN - 0 (Sesquiterpenes, Eudesmane) RN - 0 (Sesquiterpenes, Guaiane) RN - 0 (aromadendrane) RN - 0 (guaiane) RN - 473-11-0 (eudesmane) RN - EC 1.14.99.- (Ptgs2 protein, mouse) RN - EC 1.14.99.1 (Cyclooxygenase 2) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*chemistry/pharmacology MH - Araceae/*chemistry MH - Cyclooxygenase 2/metabolism MH - Drug Evaluation, Preclinical/methods MH - Gene Expression Regulation MH - Medicine, Chinese Traditional MH - Mice MH - Molecular Structure MH - Plant Extracts/*chemistry/pharmacology MH - RAW 264.7 Cells MH - RNA, Messenger/genetics MH - Rhizome/*chemistry MH - Sesquiterpenes/*chemistry/pharmacology MH - Sesquiterpenes, Eudesmane/chemistry MH - Sesquiterpenes, Guaiane/chemistry MH - Structure-Activity Relationship OTO - NOTNLM OT - Anti-inflammatory activity OT - Araceae OT - COX-2 OT - Homalomena occulta OT - PGE2 OT - Sesquiterpenoids EDAT- 2019/04/01 06:00 MHDA- 2020/03/18 06:00 CRDT- 2019/04/01 06:00 PHST- 2019/01/28 00:00 [received] PHST- 2019/03/14 00:00 [revised] PHST- 2019/03/22 00:00 [accepted] PHST- 2019/04/01 06:00 [pubmed] PHST- 2020/03/18 06:00 [medline] PHST- 2019/04/01 06:00 [entrez] AID - S0960-894X(19)30170-2 [pii] AID - 10.1016/j.bmcl.2019.03.031 [doi] PST - ppublish SO - Bioorg Med Chem Lett. 2019 May 15;29(10):1162-1167. doi: 10.1016/j.bmcl.2019.03.031. Epub 2019 Mar 22. PMID- 39197079 OWN - NLM STAT- MEDLINE DCOM- 20241126 LR - 20250115 IS - 1940-5480 (Electronic) IS - 1067-151X (Linking) VI - 32 IP - 23 DP - 2024 Dec 1 TI - Management of Xylazine-Induced Soft-Tissue Necrosis: A Review of 20 Cases. PG - e1219-e1225 LID - 10.5435/JAAOS-D-24-00125 [doi] AB - PURPOSE: The illicit injection of xylazine has recently been designated as an emerging public health threat. The use of this drug is associated with devastating soft-tissue necrosis that may lead to limb amputation. This study aimed to (1) report cases of soft-tissue injury from xylazine and (2) describe a staging and management algorithm for wounds related to xylazine use. METHODS: A retrospective review was conducted to identify patients treated for xylazine-related soft-tissue necrosis at a trauma center. Clinical cases, treatment strategy, and available outcomes were presented. In addition, a comprehensive literature search was conducted using the keywords "xylazine" and "soft tissue." RESULTS: The management of seven patients with xylazine-related upper extremity soft-tissue necrosis was included, in addition to summarizing findings of five studies reporting on 13 additional cases. These cases were managed with local wound care (2 patients), soft-tissue reconstruction (4 patient), osseous reconstruction (1 patient), and limb amputation (10 patients). DISCUSSION: Acute treatment of xylazine-related soft-tissue necrosis is ideal to minimize morbidity and prevent limb loss. Management strategies of these wounds should be based on the depth of tissue involvement. Superficial ulceration involving the skin and subcutaneous tissue (Stage 1) should be managed with local wound care. Deeper ulceration involving tendons and/or muscle (Stage 2) requires surgical débridement and soft-tissue reconstruction. Deeper ulceration involving bone (Stage 3) requires osseous débridement and reconstruction. Finally, when all tissues in the extremity are involved (Stage 4), amputation is often necessary. CI - Copyright © 2024 by the American Academy of Orthopaedic Surgeons. FAU - Retrouvey, Helene AU - Retrouvey H AUID- ORCID: 0000-0001-5215-0404 AD - From the Department of Orthopedic Surgery, Hand & Upper Extremity Service, Denver Health Medical Center, Denver, CO. FAU - Meyer, Maximilian A AU - Meyer MA FAU - Ipaktchi, Kyros AU - Ipaktchi K FAU - Maertens, Andrew AU - Maertens A FAU - Folchert, Matthew AU - Folchert M FAU - Lauder, Alexander AU - Lauder A LA - eng PT - Journal Article DEP - 20240823 PL - United States TA - J Am Acad Orthop Surg JT - The Journal of the American Academy of Orthopaedic Surgeons JID - 9417468 RN - 2KFG9TP5V8 (Xylazine) SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - Middle Aged MH - Young Adult MH - Amputation, Surgical MH - Debridement MH - *Necrosis/chemically induced MH - Retrospective Studies MH - *Soft Tissue Injuries MH - *Xylazine/adverse effects EDAT- 2024/08/29 08:03 MHDA- 2024/11/26 18:23 CRDT- 2024/08/28 15:32 PHST- 2024/01/30 00:00 [received] PHST- 2024/06/25 00:00 [accepted] PHST- 2024/11/26 18:23 [medline] PHST- 2024/08/29 08:03 [pubmed] PHST- 2024/08/28 15:32 [entrez] AID - 00124635-202412010-00013 [pii] AID - 10.5435/JAAOS-D-24-00125 [doi] PST - ppublish SO - J Am Acad Orthop Surg. 2024 Dec 1;32(23):e1219-e1225. doi: 10.5435/JAAOS-D-24-00125. Epub 2024 Aug 23. PMID- 35689230 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220716 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 23 IP - 1 DP - 2022 Jun 10 TI - Quercetin treatment protects the Achilles tendons of rats from oxidative stress induced by hyperglycemia. PG - 563 LID - 10.1186/s12891-022-05513-4 [doi] LID - 563 AB - BACKGROUND: Quercetin, a flavonoid abundantly in vegetables and fruits, exerts antioxidant and anti-inflammatory effects. We investigated the protective effects of quercetin against oxidative stress in the Achilles tendons of diabetic rats. METHODS: Cells were collected from the Achilles tendons of Sprague-Dawley rats and cultured under four conditions: regular glucose (RG) without quercetin (Quer-), RG with quercetin (Quer +), high-glucose (HG) Quer-, and HG Quer + . The expression of genes related to NADPH oxidase (NOX) and inflammation, reactive oxygen species accumulation, and apoptosis rates was analyzed. Additionally, diabetic rats were divided into two groups and subjected to quercetin (group Q) or no quercetin (group C) treatment. Histological evaluation and expression analysis of relevant genes in the Achilles tendon were performed. RESULTS: In rat tendon-derived cells, the expression of Nox1, Nox4, and Il6; reactive oxygen species accumulation; and apoptosis rates were significantly decreased by quercetin treatment in the HG group. The collagen fiber arrangement was significantly disorganized in the diabetic rat Achilles tendons in group C compared with that in group Q. The mRNA and protein expression levels of NOX1 and NOX4 were significantly decreased upon quercetin treatment. Furthermore, the expression of Il6, type III collagen, Mmp2, and Timp2 was significantly decreased, whereas that of type I collagen was significantly increased in group Q compared with that in group C. CONCLUSIONS: Quercetin treatment decreases NOX expression and thus exerts antioxidant and anti-inflammatory effects in the Achilles tendons of diabetic rats. Quercetin treatment may be effective against diabetic tendinopathy. CI - © 2022. The Author(s). FAU - Yoshikawa, Tomoya AU - Yoshikawa T AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Mifune, Yutaka AU - Mifune Y AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. m-ship@kf7.so-net.ne.jp. FAU - Inui, Atsuyuki AU - Inui A AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Nishimoto, Hanako AU - Nishimoto H AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Yamaura, Kohei AU - Yamaura K AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Mukohara, Shintaro AU - Mukohara S AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Shinohara, Issei AU - Shinohara I AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Kuroda, Ryosuke AU - Kuroda R AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. LA - eng PT - Journal Article DEP - 20220610 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antioxidants) RN - 0 (Interleukin-6) RN - 0 (Reactive Oxygen Species) RN - 9IKM0I5T1E (Quercetin) RN - EC 1.6.3.- (NADPH Oxidases) RN - IY9XDZ35W2 (Glucose) SB - IM MH - *Achilles Tendon/pathology MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Antioxidants/pharmacology/therapeutic use MH - *Diabetes Mellitus, Experimental/drug therapy/metabolism/pathology MH - Glucose/metabolism MH - Humans MH - *Hyperglycemia/drug therapy/metabolism/pathology MH - Interleukin-6/metabolism MH - NADPH Oxidases/metabolism MH - Oxidative Stress MH - Quercetin/metabolism/pharmacology/therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism PMC - PMC9188208 OTO - NOTNLM OT - Antioxidant effect OT - Diabetic tendinopathy OT - Oxidative stress OT - Quercetin OT - Rat diabetic model COIS- The authors declare that they have no competing interests. EDAT- 2022/06/11 06:00 MHDA- 2022/06/15 06:00 PMCR- 2022/06/10 CRDT- 2022/06/10 23:38 PHST- 2022/03/16 00:00 [received] PHST- 2022/06/01 00:00 [accepted] PHST- 2022/06/10 23:38 [entrez] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/06/10 00:00 [pmc-release] AID - 10.1186/s12891-022-05513-4 [pii] AID - 5513 [pii] AID - 10.1186/s12891-022-05513-4 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2022 Jun 10;23(1):563. doi: 10.1186/s12891-022-05513-4. PMID- 14758788 OWN - NLM STAT- MEDLINE DCOM- 20040219 LR - 20191108 IS - 0012-6667 (Print) IS - 0012-6667 (Linking) VI - 63 Spec No 2 DP - 2003 TI - [Paracetamol in the treatment of osteoarthritis pain]. PG - 23-41 AB - Osteoarthritis (OA) is the most common joint disease and OA of the knee, in particular, is the major cause of chronic disability among people > 65 years. Because nonsteroidal anti-inflammatory drugs (NSAIDs) improve symptoms in many patients with OA, it is widely considered that OA pain is due to synovial inflammation. However, OA pain may arise also from subchondral bone, the joint capsule ligaments, tendons, entheses and periarticular muscle spasm. In many patients, the relief of OA pain and overall satisfaction with therapy may be as great with paracetamol (acetaminophen [APAP]) as with an NSAID. Cyclo-oxygenase (COX)-1-sparing NSAIDs (coxibs) are no more effective in the treatment of OA pain than non-selective NSAIDs and, although they may significantly decrease the risk of serious adverse effects related to gastrointestinal ulcers (GI) and ulcer complications, their gastroprotective effect may be reduced by concomitant administration of low-dose aspirin. Also, they may increase the risk of myocardial infarction in predisposed individuals. Because coxibs do not inhibit platelet aggregation, if prophylaxis against thromboembolic disease is required in patients being treated with a selective COX-2 inhibitor, low-dose aspirin should be used in conjunction with the coxib. Furthermore, nonselective NSAIDs and coxibs may have adverse effects on the kidney, fracture healing and salt and water homeostasis. This paper discusses the relative positioning of APAP, NSAIDs and coxibs in the management of OA, on the basis of considerations of tolerability, efficacy and costs. FAU - Brandt, Kenneth AU - Brandt K AD - Départements de Rhumatologie et de Chirurgie Orthopédique, Faculté de Médecine de l'Université d'Indiana et Centre pluridisciplinaire des maladies rhumatismales et ostéoarticulaires de l'Université d'Indiana, Etats-Unis. kbrandt@iupui.edu LA - fre PT - English Abstract PT - Journal Article PT - Review TT - Le paracétamol dans le traitement des douleurs arthrosiques. PL - New Zealand TA - Drugs JT - Drugs JID - 7600076 RN - 0 (Analgesics, Non-Narcotic) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Protective Agents) RN - 362O9ITL9D (Acetaminophen) RN - R16CO5Y76E (Aspirin) SB - IM MH - Acetaminophen/adverse effects/*pharmacology MH - Analgesics, Non-Narcotic/adverse effects/*pharmacology MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Aspirin/administration & dosage MH - Cyclooxygenase Inhibitors/pharmacology/*therapeutic use MH - Duodenal Ulcer/chemically induced MH - Humans MH - Inflammation MH - Kidney Diseases/chemically induced MH - Osteoarthritis/*complications MH - Pain/*drug therapy/*etiology MH - Protective Agents MH - Risk Factors MH - Stomach Ulcer/chemically induced MH - Water-Electrolyte Balance RF - 61 EDAT- 2004/02/05 05:00 MHDA- 2004/02/20 05:00 CRDT- 2004/02/05 05:00 PHST- 2004/02/05 05:00 [pubmed] PHST- 2004/02/20 05:00 [medline] PHST- 2004/02/05 05:00 [entrez] AID - 10.2165/00003495-200363992-00005 [doi] PST - ppublish SO - Drugs. 2003;63 Spec No 2:23-41. doi: 10.2165/00003495-200363992-00005. PMID- 39760277 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20251205 IS - 1537-2677 (Electronic) IS - 0740-9303 (Linking) VI - 41 IP - 6 DP - 2025 Nov-Dec 01 TI - Laudable Pus, Cocaine, and the Evolution of Wound Management. PG - 607-615 LID - 10.1097/IOP.0000000000002893 [doi] AB - PURPOSE: To review the long history of wound management, including the methods of skin closure, asepsis, and anesthesia. Periocular techniques will be emphasized. METHODS: Literature searches and cross-referencing were used to identify historic reports addressing the management of wounds. Foreign language manuscripts were translated using online resources. RESULTS: The first written description of suturing dates to around 3000 BC and involved the repair of an eyebrow wound. A wide variety of materials have since been used as ligatures or stitches, including animal intestines, tendons, hair, silk, linen, plant fibers, and metal wire. For much of recorded history, sutures were a primary cause of wound infection and morbidity. There was a time when the resultant drainage was viewed as being beneficial (laudable pus). Many of the discoveries that ultimately led to the practice of asepsis were coincidental. Prior to the development of infiltrative anesthesia in 1894, patients had to endure the discomfort of surgery, occasionally with the sedative effects of wine or cannabis. CONCLUSIONS: The history of wound closure is a fascinating tale. While there has been a constant evolution, silk and catgut sutures, ligatures, surgical knots, and layered closure have been used for several millennium. Advances in asepsis, in addition to the development of anesthesia, antibiotics, and synthetic sutures, ushered in the modern age of surgery. A knowledge of the past will give us, as oculofacial surgeons, a greater understanding and appreciation of the techniques we use today. CI - Copyright © 2025 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc. FAU - Custer, Philip L AU - Custer PL AD - John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, U.S.A. LA - eng PT - Historical Article PT - Journal Article PT - Review DEP - 20250106 PL - United States TA - Ophthalmic Plast Reconstr Surg JT - Ophthalmic plastic and reconstructive surgery JID - 8508431 RN - I5Y540LHVR (Cocaine) SB - IM MH - Humans MH - *Cocaine/history MH - History, 15th Century MH - History, 16th Century MH - History, 17th Century MH - History, 18th Century MH - History, 19th Century MH - History, 20th Century MH - History, 21st Century MH - History, Ancient MH - History, Medieval MH - *Ophthalmologic Surgical Procedures/history MH - Suture Techniques/history MH - *Wound Closure Techniques/history MH - Wound Healing COIS- The authors have no financial or conflicts of interest to disclose. EDAT- 2025/01/06 12:23 MHDA- 2025/11/04 12:27 CRDT- 2025/01/06 07:03 PHST- 2025/11/04 12:27 [medline] PHST- 2025/01/06 12:23 [pubmed] PHST- 2025/01/06 07:03 [entrez] AID - 00002341-202511000-00001 [pii] AID - 10.1097/IOP.0000000000002893 [doi] PST - ppublish SO - Ophthalmic Plast Reconstr Surg. 2025 Nov-Dec 01;41(6):607-615. doi: 10.1097/IOP.0000000000002893. Epub 2025 Jan 6. PMID- 38398534 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20240227 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 29 IP - 4 DP - 2024 Feb 8 TI - Hypolipidemic and Antithrombotic Effect of 6'-O-Caffeoylarbutin from Vaccinium dunalianum Based on Zebrafish Model, Network Pharmacology, and Molecular Docking. LID - 10.3390/molecules29040780 [doi] LID - 780 AB - Vaccinium dunalianum leaf buds make one of the most commonly used herbal teas of the Yi people in China, which is used to treat articular rheumatism, relax tendons, and stimulates blood circulation in the body. In addition, 6'-O-caffeoylarbutin (CA) is a standardized extract of V. dunalianum, which has been found in dried leaf buds, reaching levels of up to 31.76%. Because of the uncommon phenomenon, it is suggested that CA may have a potential therapeutic role in hyperlipidemia and thrombosis. This study was designed to study the efficacy of CA on treating hyperlipidemia and thrombosis and the possible mechanisms behind these effects. Hyperlipidemia and thrombosis zebrafish models were treated with CA to observe variations of the integrated optical density within the vessels and the intensity of erythrocyte staining within the hearts. The possible mechanisms were explored using network pharmacology and molecular docking. The results demonstrate that CA exhibits an excellent hypolipidemic effect on zebrafish at concentrations ranging from 3.0 to 30.0 μg/mL and shows thrombosis inhibitory activity in zebrafish at a concentration of 30.0 μg/mL, with an inhibition rate of 44%. Moreover, network pharmacological research shows that MMP9, RELA, MMP2, PRKCA, HSP90AA1, and APP are major targets of CA for therapy of hyperlipidemia and thrombosis, and may relate to pathways in cancer, chemical carcinogenesis-receptor activation, estrogen signaling pathway, and the AGE-RAGE signaling pathway in diabetic complications. FAU - Wu, Boxiao AU - Wu B AD - Key Laboratory of Forest Resources Conservation and Utilization in the Southwest Mountains of China Ministry of Education, Southwest Forestry University, Kunming 650224, China. AD - Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming 650224, China. FAU - Li, Churan AU - Li C AD - Key Laboratory of Forest Resources Conservation and Utilization in the Southwest Mountains of China Ministry of Education, Southwest Forestry University, Kunming 650224, China. AD - Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming 650224, China. FAU - Kan, Huan AU - Kan H AD - Key Laboratory of Forest Resources Conservation and Utilization in the Southwest Mountains of China Ministry of Education, Southwest Forestry University, Kunming 650224, China. FAU - Zhang, Yingjun AU - Zhang Y AUID- ORCID: 0000-0002-0295-337X AD - State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650224, China. FAU - Rao, Xiaoping AU - Rao X AUID- ORCID: 0000-0001-5115-8260 AD - Academy of Advanced Carbon Conversion Technology, Huaqiao University, Xiamen 361021, China. FAU - Liu, Yun AU - Liu Y AUID- ORCID: 0000-0002-8947-3482 AD - Key Laboratory of Forest Resources Conservation and Utilization in the Southwest Mountains of China Ministry of Education, Southwest Forestry University, Kunming 650224, China. AD - Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming 650224, China. FAU - Zhao, Ping AU - Zhao P AD - Key Laboratory of Forest Resources Conservation and Utilization in the Southwest Mountains of China Ministry of Education, Southwest Forestry University, Kunming 650224, China. AD - Key Laboratory of State Forestry and Grassland Administration on Highly-Efficient Utilization of Forestry Biomass Resources in Southwest China, Southwest Forestry University, Kunming 650224, China. LA - eng GR - 32060107/National Natural Science Foundation of China/ GR - 32060327/National Natural Science Foundation of China/ PT - Journal Article DEP - 20240208 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (6'-O-caffeoylarbutin) RN - C5INA23HXF (Arbutin) RN - 0 (Caffeic Acids) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Fibrinolytic Agents) SB - IM MH - Animals MH - *Arbutin/analogs & derivatives MH - *Caffeic Acids MH - *Drugs, Chinese Herbal MH - Fibrinolytic Agents/pharmacology MH - *Hyperlipidemias/drug therapy MH - Molecular Docking Simulation MH - Network Pharmacology MH - *Thrombosis/drug therapy MH - Zebrafish PMC - PMC10893483 OTO - NOTNLM OT - 6′-O-Caffeoylarbutin OT - Vaccinium dunalianum Wight OT - antithrombotic OT - hypolipidemic OT - molecular docking OT - network pharmacology COIS- The authors declare no conflicts of interest. EDAT- 2024/02/24 11:45 MHDA- 2024/02/26 06:45 PMCR- 2024/02/08 CRDT- 2024/02/24 01:13 PHST- 2023/11/22 00:00 [received] PHST- 2024/02/04 00:00 [revised] PHST- 2024/02/06 00:00 [accepted] PHST- 2024/02/26 06:45 [medline] PHST- 2024/02/24 11:45 [pubmed] PHST- 2024/02/24 01:13 [entrez] PHST- 2024/02/08 00:00 [pmc-release] AID - molecules29040780 [pii] AID - molecules-29-00780 [pii] AID - 10.3390/molecules29040780 [doi] PST - epublish SO - Molecules. 2024 Feb 8;29(4):780. doi: 10.3390/molecules29040780. PMID- 22522111 OWN - NLM STAT- MEDLINE DCOM- 20130228 LR - 20220409 IS - 1532-866X (Electronic) IS - 0049-0172 (Linking) VI - 42 IP - 2 DP - 2012 Oct TI - The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. PG - 146-54 LID - S0049-0172(12)00081-9 [pii] LID - 10.1016/j.semarthrit.2012.03.007 [doi] AB - OBJECTIVES: Gout is typically described as an inflammatory arthropathy that affects the peripheral joints. Our aim was to describe atypical and rare clinical presentations of gouty tophi to help increase physician awareness and aid in patient care. METHODS: The relevant English literature of unusual gout manifestations was searched using the keywords gout, toph*, monosodium urate, uric acid, unusual, and rare. Well-described case reports, case series, and review articles were evaluated and included, if relevant, in the literature review. RESULTS: Review of the literature revealed many unusual manifestations of gouty tophi involving the head and neck, skin, viscera, bones, tendons, ligaments, nerves, and axial skeleton. Transplant recipients, women, and elderly people are particularly susceptible to developing tophi. Furthermore, gout can cause diagnostic dilemmas, as it can be a great mimicker of and can coexist with infection, malignancy, and other connective tissue diseases. Imaging modalities can help detect tophi in atypical locations. CONCLUSIONS: Tophi can present in unexpected locations, even as the first sign of gout, and vigilance is required when unusual symptoms or signs occur in a patient with gout. CI - Copyright © 2012 Elsevier Inc. All rights reserved. FAU - Forbess, Lindsy J AU - Forbess LJ AD - Rheumatology Fellow, Hospital for Special Surgery, New York, NY 10021, USA. lforbess@gmail.com FAU - Fields, Theodore R AU - Fields TR LA - eng PT - Journal Article PT - Review DEP - 20120421 PL - United States TA - Semin Arthritis Rheum JT - Seminars in arthritis and rheumatism JID - 1306053 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Arthritis, Gouty/*diagnosis/metabolism MH - Crystallization MH - Diagnosis, Differential MH - Female MH - Humans MH - Joints/pathology MH - Male MH - Sex Factors MH - Uric Acid/chemistry/*metabolism EDAT- 2012/04/24 06:00 MHDA- 2013/03/01 06:00 CRDT- 2012/04/24 06:00 PHST- 2012/02/16 00:00 [received] PHST- 2012/03/07 00:00 [revised] PHST- 2012/03/18 00:00 [accepted] PHST- 2012/04/24 06:00 [entrez] PHST- 2012/04/24 06:00 [pubmed] PHST- 2013/03/01 06:00 [medline] AID - S0049-0172(12)00081-9 [pii] AID - 10.1016/j.semarthrit.2012.03.007 [doi] PST - ppublish SO - Semin Arthritis Rheum. 2012 Oct;42(2):146-54. doi: 10.1016/j.semarthrit.2012.03.007. Epub 2012 Apr 21. PMID- 22875366 OWN - NLM STAT- MEDLINE DCOM- 20121024 LR - 20181201 IS - 1755-5248 (Electronic) IS - 0012-6543 (Linking) VI - 50 IP - 8 DP - 2012 Aug TI - Management of chronic Achilles tendinopathy. PG - 93-6 LID - 10.1136/dtb.2012.08.0124 [doi] AB - Tendons transmit force between muscles and bones and, when stretched, store elastic energy that contributes to movement.(1) The tendinous portion of the gastrocnemius and soleus muscles merge to form the Achilles tendon, which is the largest and strongest in the body, but one of the most frequently injured.(2,3) Conservative management options for chronic Achilles tendinopathy include eccentric (lengthening) exercises, extracorporeal shockwave therapy (ESWT), topical nitroglycerin, low level laser therapy, orthoses, splints or injections (e.g. corticosteroids, hyperosmolar dextrose, polidocanol, platelet-rich plasma), while a minority of patients require surgery (using open, percutaneous or endoscopic methods).(4-8) Here we assess the management options for patients with chronic Achilles tendinopathy (lasting over 6 weeks). LA - eng PT - Journal Article PL - England TA - Drug Ther Bull JT - Drug and therapeutics bulletin JID - 0112037 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Analgesics) RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - G59M7S0WS3 (Nitroglycerin) RN - IY9XDZ35W2 (Glucose) SB - IM EIN - Drug Ther Bull. 2012 Nov;50(11):132 MH - *Achilles Tendon MH - Administration, Cutaneous MH - Adrenal Cortex Hormones/administration & dosage MH - Adult MH - Analgesics/administration & dosage MH - Blood Transfusion, Autologous/methods MH - Chronic Disease MH - Exercise Therapy/methods MH - Glucose/administration & dosage MH - Humans MH - Injections, Intramuscular MH - Low-Level Light Therapy/methods MH - Middle Aged MH - Nitroglycerin/administration & dosage MH - Orthotic Devices MH - Platelet-Rich Plasma MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Randomized Controlled Trials as Topic MH - Sclerosing Solutions/therapeutic use MH - Splints MH - Tendinopathy/*therapy MH - Ultrasonic Therapy/methods MH - Young Adult EDAT- 2012/08/10 06:00 MHDA- 2012/10/25 06:00 CRDT- 2012/08/10 06:00 PHST- 2012/08/10 06:00 [entrez] PHST- 2012/08/10 06:00 [pubmed] PHST- 2012/10/25 06:00 [medline] AID - dtb.2012.08.0124 [pii] AID - 10.1136/dtb.2012.08.0124 [doi] PST - ppublish SO - Drug Ther Bull. 2012 Aug;50(8):93-6. doi: 10.1136/dtb.2012.08.0124. PMID- 17924516 OWN - NLM STAT- MEDLINE DCOM- 20071012 LR - 20161124 IS - 1661-8157 (Print) IS - 1661-8157 (Linking) VI - 96 IP - 34 DP - 2007 Aug 22 TI - [Involvement of the foot in metabolic diseases]. PG - 1251-6 AB - In the acute stage of gout, the hallux is most commonly involved followed by the mediotarsal joints and the Achilles tendons. Diagnosis of gout is established when typical monosodium urate crystals can be identified. Apart from NSAIDs, colchicine can be used when there is no renal impairment. Hypouricemic agents (allopurinol or uricosuric drugs) must be initiated one or two weeks after the acute attack of gout because there are risks of exacerbation. Losartan as well as fenofibrate have uricosuric properties. Chondrocalcinosis of the foot can be observed in hemochromatosis. Diffuse idiopathic skeletal hyperostosis (DISH) can cause severe talagia. Hypercholesterolemia can induce xanthomas of the Achilles tendons. Apatite rheumatism can be observed in chronic dialysis patients. FAU - Gerster, J-C AU - Gerster JC AD - Service de rhumatologie, Centre Hospitalier Universitaire Vaudois, CHU, 1011 Lausanne. Jean-Charles.Gerster@chuv.ch LA - fre PT - Comparative Study PT - Journal Article PT - Review TT - Atteintes du pied dans les maladies métaboliques. PL - Switzerland TA - Praxis (Bern 1994) JT - Praxis JID - 101468093 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Apatites) RN - 0 (Gout Suppressants) RN - 0 (Hypolipidemic Agents) RN - 63CZ7GJN5I (Allopurinol) RN - JMS50MPO89 (Losartan) RN - SML2Y3J35T (Colchicine) RN - U202363UOS (Fenofibrate) SB - IM MH - Achilles Tendon/diagnostic imaging/pathology MH - Acute Disease MH - Allopurinol/administration & dosage/therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Apatites/metabolism MH - Chondrocalcinosis/*complications MH - Colchicine/administration & dosage/therapeutic use MH - Fenofibrate/administration & dosage/therapeutic use MH - Foot Diseases/diagnostic imaging/drug therapy/*etiology/pathology MH - Gout/*complications/diagnosis/diagnostic imaging/drug therapy MH - Gout Suppressants/administration & dosage/therapeutic use MH - Hallux/pathology MH - Hemochromatosis/*complications/diagnosis MH - Humans MH - Hypercholesterolemia/*complications/pathology MH - Hyperostosis, Diffuse Idiopathic Skeletal/*complications MH - Hypolipidemic Agents/administration & dosage/therapeutic use MH - Losartan/administration & dosage/therapeutic use MH - Radiography MH - Renal Dialysis/adverse effects MH - Time Factors MH - Xanthomatosis/complications/drug therapy RF - 16 EDAT- 2007/10/11 09:00 MHDA- 2007/10/13 09:00 CRDT- 2007/10/11 09:00 PHST- 2007/10/11 09:00 [pubmed] PHST- 2007/10/13 09:00 [medline] PHST- 2007/10/11 09:00 [entrez] AID - 10.1024/1661-8157.96.34.1251 [doi] PST - ppublish SO - Praxis (Bern 1994). 2007 Aug 22;96(34):1251-6. doi: 10.1024/1661-8157.96.34.1251. PMID- 26484371 OWN - NLM STAT- MEDLINE DCOM- 20160516 LR - 20191113 IS - 1435-1250 (Electronic) IS - 0340-1855 (Linking) VI - 74 IP - 6 DP - 2015 Aug TI - [Not Available]. PG - 486 FAU - Müller-Ladner, U AU - Müller-Ladner U LA - ger PT - Comment PT - Journal Article TT - Kristalline Harnsäureablagerungen in den Sehnen bei Gicht. PL - Germany TA - Z Rheumatol JT - Zeitschrift fur Rheumatologie JID - 0414162 RN - 268B43MJ25 (Uric Acid) SB - IM CON - Ann Rheum Dis. 2014 Sep;73(9):1737-41. doi: 10.1136/annrheumdis-2013-204657. PMID: 24709860 MH - Animals MH - Gout/*pathology MH - Humans MH - Tendons/*drug effects MH - Uric Acid/*pharmacology EDAT- 2015/10/21 06:00 MHDA- 2016/05/18 06:00 CRDT- 2015/10/21 06:00 PHST- 2015/10/21 06:00 [entrez] PHST- 2015/10/21 06:00 [pubmed] PHST- 2016/05/18 06:00 [medline] AID - 10.1007/s00393-015-1635-9 [doi] PST - ppublish SO - Z Rheumatol. 2015 Aug;74(6):486. doi: 10.1007/s00393-015-1635-9. PMID- 39010213 OWN - NLM STAT- MEDLINE DCOM- 20240716 LR - 20240715 IS - 1347-5223 (Electronic) IS - 0009-2363 (Linking) VI - 72 IP - 7 DP - 2024 TI - Galangin Promotes Tendon Repair Mediated by Tendon-Derived Stem Cells through Activating the TGF-β1/Smad3 Signaling Pathway. PG - 669-675 LID - 10.1248/cpb.c24-00117 [doi] AB - Tendon injury is a prevalent orthopedic disease that currently lacks effective treatment. Galangin (GLN) is a vital flavonoid found abundantly in galangal and is known for its natural activity. This study aimed to investigate the GLN-mediated molecular mechanism of tendon-derived stem cells (TDSCs) in tendon repair. The TDSCs were characterized using alkaline phosphatase staining, alizarin red S staining, oil red O staining, and flow cytometry. The effect of GLN treatment on collagen deposition was evaluated using Sirius red staining and quantitative (q)PCR, while a Western bot was used to assess protein levels and analyze pathways. Results showed that GLN treatment not only increased the collagen deposition but also elevated the mRNA expression and protein levels of multiple tendon markers like collagen type I alpha 1 (COL1A1), decorin (DCN) and tenomodulin (TNMD) in TDSCs. Moreover, GLN was also found to upregulate the protein levels of transforming growth factor β1 (TGF-β1) and p-Smad3 to activate the TGF-β1/Smad3 signaling pathway, while GLN mediated collagen deposition in TDSCs was reversed by LY3200882, a TGF-β receptor inhibitor. The study concluded that GLN-mediated TDSCs enhanced tendon repair by activating the TGF-β1/Smad3 signaling pathway, suggesting a novel therapeutic option in treating tendon repair. FAU - Deng, Xiongwei AU - Deng X AD - Department of Foot and Ankle Surgery, Nanchang Hongdu Hospital of Traditional Chinese Medicine. FAU - Li, Qiang AU - Li Q AD - Department of Foot and Ankle Surgery, Nanchang Hongdu Hospital of Traditional Chinese Medicine. FAU - Yuan, Haitao AU - Yuan H AD - Department of Foot and Ankle Surgery, Nanchang Hongdu Hospital of Traditional Chinese Medicine. FAU - Hu, Hejun AU - Hu H AD - Department of Foot and Ankle Surgery, Nanchang Hongdu Hospital of Traditional Chinese Medicine. FAU - Fan, Shaoyong AU - Fan S AD - Department of Foot and Ankle Surgery, Nanchang Hongdu Hospital of Traditional Chinese Medicine. LA - eng PT - Journal Article PL - Japan TA - Chem Pharm Bull (Tokyo) JT - Chemical & pharmaceutical bulletin JID - 0377775 RN - 0 (Flavonoids) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Smad3 Protein) RN - 142FWE6ECS (galangin) RN - 0 (Smad3 protein, rat) SB - IM MH - *Flavonoids/pharmacology/chemistry MH - *Transforming Growth Factor beta1/metabolism MH - *Signal Transduction/drug effects MH - Animals MH - *Smad3 Protein/metabolism/antagonists & inhibitors MH - *Stem Cells/drug effects/metabolism/cytology MH - *Tendons/cytology/metabolism/drug effects MH - Rats MH - Cells, Cultured MH - Rats, Sprague-Dawley MH - Tendon Injuries/drug therapy/metabolism OTO - NOTNLM OT - Smad3 OT - galangin OT - tendon injury OT - tendon repair OT - tendon-derived stem cell OT - transforming growth factor β1 (TGF-β1) EDAT- 2024/07/16 00:41 MHDA- 2024/07/16 06:42 CRDT- 2024/07/15 23:46 PHST- 2024/07/16 06:42 [medline] PHST- 2024/07/16 00:41 [pubmed] PHST- 2024/07/15 23:46 [entrez] AID - 10.1248/cpb.c24-00117 [doi] PST - ppublish SO - Chem Pharm Bull (Tokyo). 2024;72(7):669-675. doi: 10.1248/cpb.c24-00117. PMID- 36678255 OWN - NLM STAT- MEDLINE DCOM- 20230124 LR - 20250130 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 15 IP - 2 DP - 2023 Jan 12 TI - Is Curcumine Useful in the Treatment and Prevention of the Tendinopathy and Myotendinous Junction Injury? A Scoping Review. LID - 10.3390/nu15020384 [doi] LID - 384 AB - Physical activity in general and sports in particular, is a mechanism that produces stress and generates great force in the tendon and in the muscle-tendon unit, which increases the risk of injury (tendinopathies). Eccentric and repetitive contraction of the muscle precipitates persistent microtraumatism in the tendon unit. In the development of tendinopathies, the cellular process includes inflammation, apoptosis, vascular, and neuronal changes. Currently, treatments with oral supplements are frequently used. Curcumin seems to preserve, and even repair, damaged tendons. In this systematic review, we focus more especially on the benefits of curcumin. The biological actions of curcumin are diverse, but act around three systems: (a) inflammatory, (b) nuclear factor B (NF-κB) related apoptosis pathways, and (c) oxidative stress systems. A bibliographic search is conducted under the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) as a basis for reporting reliable systematic reviews to perform a Scoping review. After analysing the manuscripts, we can conclude that curcumin is a product that demonstrates a significant biological antialgic, anti-inflammatory, and antioxidant power. Therefore, supplementation has a positive effect on the inflammatory and regenerative response in tendinopathies. In addition, curcumin decreases and modulates the cell infiltration, activation, and maturation of leukocytes, as well as the production of pro-inflammatory mediators at the site of inflammation. FAU - Córdova, Alfredo AU - Córdova A AUID- ORCID: 0000-0003-0236-2817 AD - Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, GIR Physical Exercise and Aging, University of Valladolid, Campus Duques de Soria, 42004 Soria, Spain. FAU - Drobnic, Franchek AU - Drobnic F AD - Medical Department, Wolverhampton Wanderers FC, Wolverhampton WV1 4QR, UK. FAU - Noriega-González, David AU - Noriega-González D AD - Department of Surgery, Ophthalmology, Otorhinolaryngology and Physiotherapy, Faculty of Medicine, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain. FAU - Caballero-García, Alberto AU - Caballero-García A AUID- ORCID: 0000-0002-9131-0615 AD - Department of Anatomy and Radiology, Faculty of Health Sciences, GIR Physical Exercise and Aging, University of Valladolid, Campus Los Pajaritos, 42004 Soria, Spain. FAU - Roche, Enrique AU - Roche E AUID- ORCID: 0000-0001-5128-1672 AD - CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain. AD - Department of Applied Biology-Nutrition, Institute of Bioengineering, University Miguel Hernández, 03202 Elche, Spain. AD - Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain. FAU - Alvarez-Mon, Melchor AU - Alvarez-Mon M AUID- ORCID: 0000-0003-1309-7510 AD - Department of Medicine and Medical Specialty, Faculty of Medicine and Health Sciences, University of Alcalá, 28871 Alcalá de Henares, Spain. AD - Immune System Diseases-Rheumatology and Oncology Service, University Hospital "Príncipe de Asturias", 28871 Alcalá de Henares, Spain. LA - eng PT - Journal Article PT - Scoping Review DEP - 20230112 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - IT942ZTH98 (Curcumin) SB - IM MH - Humans MH - *Curcumin/pharmacology/therapeutic use MH - Myotendinous Junction MH - *Tendinopathy/drug therapy/prevention & control MH - Tendons MH - Inflammation/metabolism PMC - PMC9860696 OTO - NOTNLM OT - curcumine OT - cytokines OT - exercise OT - inflammation OT - nutrition OT - tendinopathies COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/25 06:00 PMCR- 2023/01/12 CRDT- 2023/01/21 01:47 PHST- 2022/11/22 00:00 [received] PHST- 2023/01/04 00:00 [revised] PHST- 2023/01/10 00:00 [accepted] PHST- 2023/01/21 01:47 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2023/01/12 00:00 [pmc-release] AID - nu15020384 [pii] AID - nutrients-15-00384 [pii] AID - 10.3390/nu15020384 [doi] PST - epublish SO - Nutrients. 2023 Jan 12;15(2):384. doi: 10.3390/nu15020384. PMID- 39933547 OWN - NLM STAT- MEDLINE DCOM- 20250212 LR - 20250211 IS - 1098-898X (Electronic) IS - 1089-7860 (Linking) VI - 29 IP - 1 DP - 2025 Feb TI - Tophaceous Gout Mimicking a Neoplasm of the Patella. PG - 134-138 LID - 10.1055/s-0044-1800845 [doi] AB - Tophaceous gout of the patella and extensor apparatus of the knee can mimic a musculoskeletal neoplasm. Considering gout, correlation with clinical history and presentation, and meticulous analysis of imaging semiology are key to a correct diagnosis. The most useful signs are periarticular erosion with overhanging edges, increased soft tissue on radiography and computed tomography, the "snowstorm sign" on ultrasound, variable signal and enhancement, bandlike infiltration of tendons, and osseous erosions with no or little bone marrow edema on magnetic resonance imaging. Dual-energy computed tomography is both a sensitive and specific tool for noninvasive characterization of gout and for differentiating other crystal arthropathies. CI - Thieme. All rights reserved. FAU - Vuurberg, Gwendolyn AU - Vuurberg G AUID- ORCID: 0000-0001-5008-890X AD - Department of Imaging, Radboud University Medical Centre, Nijmegen, the Netherlands. AD - Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, the Netherlands. FAU - Rooy, Jacky W J de AU - Rooy JWJ AD - Department of Imaging, Radboud University Medical Centre, Nijmegen, the Netherlands. FAU - Vanhoenacker, Filip M AU - Vanhoenacker FM AD - Faculty of Medicine, KU Leuven, Leuven, Belgium. AD - Department of Radiology, AZ Sint-Maarten, Mechelen, Belgium. AD - Department of Diagnostic Sciences, UZ Gent, Faculty of Medicine and Health Sciences, Ghent, Belgium. AD - Department of Radiology, UZ Antwerpen, Faculty of Medicine and Health Sciences University of Antwerp, Edegem, Belgium. LA - eng PT - Case Reports PT - Journal Article PT - Review DEP - 20250211 PL - United States TA - Semin Musculoskelet Radiol JT - Seminars in musculoskeletal radiology JID - 9717520 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Patella/diagnostic imaging/pathology MH - *Bone Neoplasms/diagnostic imaging/pathology MH - *Gout/diagnostic imaging/pathology MH - Humans MH - Male MH - Adult MH - Tomography, X-Ray Computed MH - Radiography MH - Ultrasonography MH - Magnetic Resonance Imaging MH - Patellar Ligament/diagnostic imaging/pathology MH - Diagnosis, Differential MH - Uric Acid/metabolism COIS- None declared. EDAT- 2025/02/12 00:20 MHDA- 2025/02/12 00:21 CRDT- 2025/02/11 18:43 PHST- 2025/02/12 00:21 [medline] PHST- 2025/02/12 00:20 [pubmed] PHST- 2025/02/11 18:43 [entrez] AID - 10.1055/s-0044-1800845 [doi] PST - ppublish SO - Semin Musculoskelet Radiol. 2025 Feb;29(1):134-138. doi: 10.1055/s-0044-1800845. Epub 2025 Feb 11. PMID- 30017488 OWN - NLM STAT- MEDLINE DCOM- 20190128 LR - 20190128 IS - 2589-1294 (Electronic) IS - 1017-995X (Print) IS - 1017-995X (Linking) VI - 52 IP - 5 DP - 2018 Sep TI - Isotretinoin induced achilles tendinopathy: Histopathological and biomechanical evaluation on rats. PG - 387-391 LID - S1017-995X(17)30567-9 [pii] LID - 10.1016/j.aott.2018.06.006 [doi] AB - OBJECTIVE: The aim of the present study was to evaluate histopathological and biomechanical effects of isotretinoin on Achilles tendon. MATERIALS & METHODS: Sixteen rats were divided into two groups including the control group (n = 8) and isotretinoin group (n = 8). The control group received 1.42 ml/kg soy oil per day whereas the isotretinoin group received 15 mg/kg/day (gavage dose 1.42 ml/kg) isotretinoin dissolved in soy oil through gavage method for 6 weeks. Achilles tendons were excised at the end of week 6. The tendon samples were evaluated by hematoxylin-eosin under a light microscope. Quantitative evaluation was performed via Movin and Bonar scoring. A computer-monitored tensile testing machine was utilised for biomechanical testing. Biomechanical characteristics of the tendon samples (elastic modulus, yield force, ultimate tensile force) were measured. RESULTS: Histopathological evaluation revealed a significantly higher Movin and Bonar scores in histopathological evaluation. Movin score in isotretinoin group was 4.1 ± 2.5 and it was 2.3 ± 1.0 in control group (p = 0.032). Bonar score in isotretinoin group was 2.9 ± 1.4 and it was 1.6 ± 0.7 in control group (p = 0.022). In line with histopathological evaluation, biomechanical measurements in isotretinoin group (elastic modulus, yield force, ultimate tensile force) were significantly lower than the control group. Elastic modulus in isotretinoin group was 227 ± 27.7 N/mm(2) and in control group it was 281.7 ± 38.7 N/mm(2) (p = 0.006). In isotretinoin group; yield force was 33.7 ± 4.3 Pa and in control group it was 40.8 ± 5.9 Pa (p = 0.021). Ultimate tensile force in isotretinoin group was 35.7 ± 4.2 Pa and in control group it was 44 ± 7 Pa (p = 0.009). CONCLUSION: The present study detected histopathological and biomechanical negative effect of isotretinoin on Achilles tendon. Therefore, isotretinoin should be questioned in medical history of patients with tendinopathy. CI - Copyright © 2018 Turkish Association of Orthopaedics and Traumatology. All rights reserved. FAU - Beytemür, Ozan AU - Beytemür O AD - Bağcılar Training and Research Hospital, Department of Orthopedics and Traumatology, İstanbul, Turkey. Electronic address: beytemur@yahoo.com. FAU - Yüksel, Serdar AU - Yüksel S AD - Bağcılar Training and Research Hospital, Department of Orthopedics and Traumatology, İstanbul, Turkey. Electronic address: serdar84yuksel@gmail.com. FAU - Tetikkurt, Ümit Seza AU - Tetikkurt ÜS AD - Bağcılar Training and Research Hospital, Department of Pathology, İstanbul, Turkey. Electronic address: umitseza@gmail.com. FAU - Genç, Erdinç AU - Genç E AD - Bağcılar Training and Research Hospital, Department of Orthopedics and Traumatology, İstanbul, Turkey. Electronic address: erdincgenc@hotmail.com. FAU - Olcay, Ercan AU - Olcay E AD - İstanbul Kanuni Sultan Süleyman Training and Research Hospital, Department of Orthopedics and Traumatology, İstanbul, Turkey. Electronic address: ercanolcay@superonline.com.tr. FAU - Güleç, Akif AU - Güleç A AD - Bağcılar Training and Research Hospital, Department of Orthopedics and Traumatology, İstanbul, Turkey. Electronic address: akifgulec@beh.gov.tr. LA - eng PT - Journal Article DEP - 20180713 PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Dermatologic Agents) RN - EH28UP18IF (Isotretinoin) SB - IM MH - *Achilles Tendon/drug effects/pathology MH - Animals MH - Biomechanical Phenomena MH - Dermatologic Agents/pharmacology MH - Isotretinoin/*pharmacology MH - Rats MH - *Tendinopathy/chemically induced/pathology/physiopathology PMC - PMC6204476 OTO - NOTNLM OT - Biomechanic OT - Isotretinoin OT - Rat OT - Tendinopathy OT - Tendon EDAT- 2018/07/19 06:00 MHDA- 2019/01/29 06:00 PMCR- 2018/07/13 CRDT- 2018/07/19 06:00 PHST- 2017/10/04 00:00 [received] PHST- 2018/06/13 00:00 [revised] PHST- 2018/06/19 00:00 [accepted] PHST- 2018/07/19 06:00 [pubmed] PHST- 2019/01/29 06:00 [medline] PHST- 2018/07/19 06:00 [entrez] PHST- 2018/07/13 00:00 [pmc-release] AID - S1017-995X(17)30567-9 [pii] AID - 10.1016/j.aott.2018.06.006 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2018 Sep;52(5):387-391. doi: 10.1016/j.aott.2018.06.006. Epub 2018 Jul 13. PMID- 22587563 OWN - NLM STAT- MEDLINE DCOM- 20121113 LR - 20250529 IS - 1474-9726 (Electronic) IS - 1474-9718 (Print) IS - 1474-9718 (Linking) VI - 11 IP - 4 DP - 2012 Aug TI - Rapamycin slows aging in mice. PG - 675-82 LID - 10.1111/j.1474-9726.2012.00832.x [doi] AB - Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action. CI - © 2012 The Authors. Aging Cell © 2012 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland. FAU - Wilkinson, John E AU - Wilkinson JE AD - Unit for Laboratory Animal Medicine and Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA. FAU - Burmeister, Lisa AU - Burmeister L FAU - Brooks, Susan V AU - Brooks SV FAU - Chan, Chi-Chao AU - Chan CC FAU - Friedline, Sabrina AU - Friedline S FAU - Harrison, David E AU - Harrison DE FAU - Hejtmancik, James F AU - Hejtmancik JF FAU - Nadon, Nancy AU - Nadon N FAU - Strong, Randy AU - Strong R FAU - Wood, Lauren K AU - Wood LK FAU - Woodward, Maria A AU - Woodward MA FAU - Miller, Richard A AU - Miller RA LA - eng GR - AG022303/AG/NIA NIH HHS/United States GR - ZIC EY000461/ImNIH/Intramural NIH HHS/United States GR - ZIA EY000222/ImNIH/Intramural NIH HHS/United States GR - P30 AG013283/AG/NIA NIH HHS/United States GR - U01 AG022303/AG/NIA NIH HHS/United States GR - P30 AG024824/AG/NIA NIH HHS/United States GR - AG013283/AG/NIA NIH HHS/United States GR - AG007996/AG/NIA NIH HHS/United States GR - P01 AG007996/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20120604 PL - England TA - Aging Cell JT - Aging cell JID - 101130839 RN - EC 2.7.1.1 (mTOR protein, mouse) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Adrenal Gland Neoplasms/chemically induced MH - Aging/*drug effects/*pathology/physiology MH - Animals MH - Cataract/chemically induced MH - Endometrium/drug effects/pathology MH - Female MH - Liver/drug effects/pathology MH - Longevity/drug effects/physiology MH - Male MH - Mice MH - Mice, 129 Strain MH - Mice, Inbred C3H MH - Mice, Inbred C57BL MH - Mice, Inbred DBA MH - Motor Activity/drug effects MH - Myocytes, Cardiac/drug effects/pathology MH - Organ Specificity MH - Sirolimus/blood/*pharmacology/toxicity MH - TOR Serine-Threonine Kinases/antagonists & inhibitors MH - Tendons/drug effects/pathology MH - Testis/drug effects/pathology PMC - PMC3434687 MID - NIHMS400561 EDAT- 2012/05/17 06:00 MHDA- 2012/11/14 06:00 PMCR- 2013/08/01 CRDT- 2012/05/17 06:00 PHST- 2012/05/17 06:00 [entrez] PHST- 2012/05/17 06:00 [pubmed] PHST- 2012/11/14 06:00 [medline] PHST- 2013/08/01 00:00 [pmc-release] AID - 10.1111/j.1474-9726.2012.00832.x [doi] PST - ppublish SO - Aging Cell. 2012 Aug;11(4):675-82. doi: 10.1111/j.1474-9726.2012.00832.x. Epub 2012 Jun 4. PMID- 30301735 OWN - NLM STAT- MEDLINE DCOM- 20190515 LR - 20250530 IS - 1473-0480 (Electronic) IS - 0306-3674 (Print) IS - 0306-3674 (Linking) VI - 53 IP - 4 DP - 2019 Feb TI - Topical glyceryl trinitrate for the treatment of tendinopathies: a systematic review. PG - 251-262 LID - 10.1136/bjsports-2018-099552 [doi] AB - OBJECTIVE: To produce a best evidence synthesis of the clinical effects of topical glyceryl trinitrate (GTN) in the treatment of tendinopathies. DESIGN: A systematic review of published randomised controlled trials (RCTs) of the use of GTN in patients with tendinopathy. DATA SOURCES: MEDLINE, Embase, Scopus and CINAHL from database inception to January 2018. METHODS: We examined RCTs comparing the effects of topical GTN with either placebo or other treatments on tendinopathy. Overall quality of each eligible study was determined based on a combined assessment of internal validity, external validity and precision. The level of evidence for each assessed parameter was rated based on the system by van Tulder et al. RESULTS: A total of 10 eligible RCTs were identified including patients with tendinopathy of the rotator cuff (n=4), wrist extensors (n=3), Achilles (n=2) and patellar (n=1) tendons. For all tendinopathies, improvements in pain were significant when comparing GTN versus placebo in the short term (<8 weeks; poor evidence). Significant improvements in midterm outcomes for treatment with GTN versus placebo included the following: patient satisfaction (strong evidence); chances of being asymptomatic with activities of daily living (strong evidence); range of movement (moderate evidence); strength (moderate evidence); pain (at night and with activity; poor evidence) and local tenderness (poor evidence). Patients treated with topical GTN reported a higher incidence of headaches than those who received placebo (moderate evidence). CONCLUSIONS AND RELEVANCE: Treatment of tendinopathies with topical GTN for up to 6 months appears to be superior to placebo and may therefore be a useful adjunct to the treating healthcare professions. CI - © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. FAU - Challoumas, Dimitris AU - Challoumas D AD - Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Kirwan, Paul D AU - Kirwan PD AD - School of Physiotherapy, Royal College of Surgeons in Ireland, Dublin, Ireland. AD - Physiotherapy Department, Connolly Hospital, Dublin, Ireland. FAU - Borysov, Dmytro AU - Borysov D AD - Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Clifford, Christopher AU - Clifford C AD - Physiotherapy Department, West Glasgow Acute Care Hospital, Glasgow, UK. FAU - McLean, Michael AU - McLean M AD - Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. FAU - Millar, Neal L AU - Millar NL AUID- ORCID: 0000-0001-9251-9907 AD - Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. LA - eng GR - 21346/VAC_/Versus Arthritis/United Kingdom GR - MR/R020515/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Systematic Review DEP - 20181009 PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Achilles Tendon/pathology MH - Activities of Daily Living MH - Administration, Cutaneous MH - Cumulative Trauma Disorders/drug therapy MH - Humans MH - Nitroglycerin/*administration & dosage/therapeutic use MH - Pain/*drug therapy MH - Patient Satisfaction MH - Randomized Controlled Trials as Topic MH - Rotator Cuff/pathology MH - Tendinopathy/*drug therapy PMC - PMC6362607 OTO - NOTNLM OT - overuse injury OT - tendinopathy OT - tendinosis OT - tendon OT - treatment COIS- Competing interests: None declared. EDAT- 2018/10/12 06:00 MHDA- 2019/05/16 06:00 PMCR- 2019/02/05 CRDT- 2018/10/11 06:00 PHST- 2018/08/21 00:00 [accepted] PHST- 2018/10/12 06:00 [pubmed] PHST- 2019/05/16 06:00 [medline] PHST- 2018/10/11 06:00 [entrez] PHST- 2019/02/05 00:00 [pmc-release] AID - bjsports-2018-099552 [pii] AID - 10.1136/bjsports-2018-099552 [doi] PST - ppublish SO - Br J Sports Med. 2019 Feb;53(4):251-262. doi: 10.1136/bjsports-2018-099552. Epub 2018 Oct 9. PMID- 34093537 OWN - NLM STAT- MEDLINE DCOM- 20210927 LR - 20210927 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 12 DP - 2021 TI - Quercetin Attenuates Trauma-Induced Heterotopic Ossification by Tuning Immune Cell Infiltration and Related Inflammatory Insult. PG - 649285 LID - 10.3389/fimmu.2021.649285 [doi] LID - 649285 AB - Heterotopic ossification (HO) is one of the most intractable disorders following musculoskeletal injury and is characterized by the ectopic presence of bone tissue in the soft tissue leading to severe loss of function in the extremities. Recent studies have indicated that immune cell infiltration and inflammation are involved in aberrant bone formation. In this study, we found increased monocyte/macrophage and mast cell accumulation during early HO progression. Macrophage depletion by clodronate liposomes and mast cell stabilization by cromolyn sodium significantly impeded HO formation. Therefore, we proposed that the dietary phytochemical quercetin could also suppress immune cell recruitment and related inflammatory responses to prevent HO. As expected, quercetin inhibited the monocyte-to-macrophage transition, macrophage polarization, and mast cell activation in vitro in a dose-dependent manner. Using a murine burn/tenotomy model, we also demonstrated that quercetin attenuated inflammatory responses and HO in vivo. Furthermore, elevated SIRT1 and decreased acetylated NFκB p65 expression were responsible for the mechanism of quercetin, and the beneficial effects of quercetin were reversed by the SIRT1 antagonist EX527 and mimicked by the SIRT agonist SRT1720. The findings in this study suggest that targeting monocyte/macrophage and mast cell activities may represent an attractive approach for therapeutic intervention of HO and that quercetin may serve as a promising therapeutic candidate for the treatment of trauma-induced HO by modulating SIRT1/NFκB signaling. CI - Copyright © 2021 Li, Sun, Luo, Wang, Cui, Yao, Xiong, He, Qian and Fan. FAU - Li, Juehong AU - Li J AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Sun, Ziyang AU - Sun Z AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Luo, Gang AU - Luo G AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Shuo AU - Wang S AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Cui, Haomin AU - Cui H AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Yao, Zhixiao AU - Yao Z AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xiong, Hao AU - Xiong H AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - He, Yunwei AU - He Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Qian, Yun AU - Qian Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. AD - Youth Science and Technology Innovation Studio of Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210520 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide) RN - 0 (Carbazoles) RN - 0 (Heterocyclic Compounds, 4 or More Rings) RN - 0 (Rela protein, mouse) RN - 0 (SRT1720) RN - 0 (Transcription Factor RelA) RN - 9IKM0I5T1E (Quercetin) RN - EC 3.5.1.- (Sirt1 protein, mouse) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - Animals MH - Burns/*complications/immunology MH - Carbazoles/administration & dosage MH - Cells, Cultured MH - Disease Models, Animal MH - Heterocyclic Compounds, 4 or More Rings/administration & dosage MH - Humans MH - Macrophages/drug effects/immunology/metabolism MH - Male MH - Mast Cells/drug effects/immunology/metabolism MH - Mice MH - Monocytes/drug effects/immunology/metabolism MH - Ossification, Heterotopic/diagnosis/*drug therapy/immunology/pathology MH - Primary Cell Culture MH - Quercetin/*administration & dosage MH - Signal Transduction/drug effects/immunology MH - Sirtuin 1/antagonists & inhibitors/metabolism MH - THP-1 Cells MH - Tendon Injuries/*complications/immunology MH - Tendons/pathology MH - Tenotomy/adverse effects MH - Transcription Factor RelA/metabolism MH - X-Ray Microtomography PMC - PMC8173182 OTO - NOTNLM OT - SIRT1 OT - heterotopic ossification OT - macrophages OT - mast cells OT - quercetin COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/06/08 06:00 MHDA- 2021/09/28 06:00 PMCR- 2021/01/01 CRDT- 2021/06/07 05:50 PHST- 2021/01/04 00:00 [received] PHST- 2021/04/13 00:00 [accepted] PHST- 2021/06/07 05:50 [entrez] PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/09/28 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2021.649285 [doi] PST - epublish SO - Front Immunol. 2021 May 20;12:649285. doi: 10.3389/fimmu.2021.649285. eCollection 2021. PMID- 27077593 OWN - NLM STAT- MEDLINE DCOM- 20170111 LR - 20170112 IS - 1098-898X (Electronic) IS - 1089-7860 (Linking) VI - 20 IP - 1 DP - 2016 Feb TI - Dual-Energy Computed Tomography of the Knee, Ankle, and Foot: Noninvasive Diagnosis of Gout and Quantification of Monosodium Urate in Tendons and Ligaments. PG - 130-6 LID - 10.1055/s-0036-1579709 [doi] AB - Gout is a true crystal deposition arthropathy caused by the precipitation of monosodium urate into joints and periarticular soft tissues. It is the most common inflammatory arthropathy in men and women of older age with a male-to-female ratio of 3 to 8:1. The disease may progress from asymptomatic hyperuricemia through symptomatic acute gout attacks with asymptomatic periods into chronic symptomatic tophaceous gout. Although invasive arthrocentesis and demonstration of monosodium urate crystals on polarized light microscopy is definitive for the diagnosis of gout, dual-energy computed tomography (CT) allows for noninvasive visualization and reproducible volume quantification of monosodium urate crystals. Based on the high diagnostic performance, dual-energy CT has been included in the 2015 American College of Rheumatology/European League Against Rheumatism Collaborative Initiative Classification Criteria for Gout. Increasing evidence indicates the usefulness of dual-energy CT to guide the management of patients with suspected gout and monitor the effectiveness of urate-lowering medical therapy. CI - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. FAU - Fritz, Jan AU - Fritz J AD - Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Henes, Joerg C AU - Henes JC AD - Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases, Department of Internal Medicine II (Oncology, Hematology, Immunology, Rheumatology, Pulmonology), Eberhard Karls-University Tübingen, Tübingen, Germany. FAU - Fuld, Matthew K AU - Fuld MK AD - Siemens Medical Solutions, Malvern, Pennsylvania. FAU - Fishman, Elliot K AU - Fishman EK AD - Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. FAU - Horger, Marius S AU - Horger MS AD - Department of Diagnostic and Interventional Radiology, Eberhard Karls-University Tübingen, Tübingen, Germany. LA - eng PT - Journal Article PT - Review DEP - 20160414 PL - United States TA - Semin Musculoskelet Radiol JT - Seminars in musculoskeletal radiology JID - 9717520 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Ankle Joint/*diagnostic imaging MH - Foot/*diagnostic imaging MH - Gout/*diagnostic imaging MH - Humans MH - Knee Joint/*diagnostic imaging MH - Ligaments, Articular/diagnostic imaging MH - Radiography, Dual-Energy Scanned Projection/methods MH - Tendons/diagnostic imaging MH - Tomography, X-Ray Computed/*methods MH - Uric Acid/*analysis EDAT- 2016/04/15 06:00 MHDA- 2017/01/12 06:00 CRDT- 2016/04/15 06:00 PHST- 2016/04/15 06:00 [entrez] PHST- 2016/04/15 06:00 [pubmed] PHST- 2017/01/12 06:00 [medline] AID - 10.1055/s-0036-1579709 [doi] PST - ppublish SO - Semin Musculoskelet Radiol. 2016 Feb;20(1):130-6. doi: 10.1055/s-0036-1579709. Epub 2016 Apr 14. PMID- 39357289 OWN - NLM STAT- MEDLINE DCOM- 20241203 LR - 20241203 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 181 DP - 2024 Dec TI - Application of improved urate analysis algorithm based on spectral parameters in Podagra: A prospective study. PG - 111769 LID - S0720-048X(24)00485-6 [pii] LID - 10.1016/j.ejrad.2024.111769 [doi] AB - OBJECTIVES: To explore whether the improved urate analysis (IUA) algorithm based on spectral parameters can reduce false positives in CT gout images compared with current urate analysis (CUA) algorithm. MATERIALS AND METHODS: This prospective study was performed from May 2022 to May 2023. Spectral feet CT images of suspected gout participants were reconstructed by IUA and CUA algorithm. Qualitative diagnosis of IUA and CUA images was recorded and compared with the reference standard (ultrasound + conventional CT). Artifacts on IUA and CUA images of non-gout participants were recorded and compared; the maximum cross-sectional area of the maximum tophi (S(IT-max)) on IUA and CUA images of participants with gout were measured and compared. RESULTS: There are 65 participants (mean age, 43.9 years ± 13.1 [SD]; 65 men) with 114 feet studies in the gout group, and 33 participants (mean age, 43.4 years ± 15.0 [SD]; 30 men) with 65 feet studies in the non-gout group. For all 179 feet studies, IUA images had higher specificity (19.2-86.6 % vs. 1.3-44.3 %) and accuracy (63.1-88.8 % vs. 41.3-57.0 %) than CUA images (P < 0.001). In the non-gout group, the reduction rates of artifacts from the nail bed, skin, beam hardening, vascular structures, tendons, and total artifacts on the IUA images compared to the CUA images was 40.5 %, 48.9 %, 74.3 %, 99.2 %, 99.6 %, and 80.0 %, respectively (P < 0.001). For 82 feet studies with tophi, S(IT-max) was higher on CUA images than IUA images (P < 0.05). CONCLUSION: The improved urate analysis algorithm based on spectral parameters can reduce image artifacts and improve diagnostic efficacy. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Zhang, Yiteng AU - Zhang Y AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Liu, Yi AU - Liu Y AD - Department of Rheumatism and Immunology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Zhao, Yi AU - Zhao Y AD - Department of Rheumatism and Immunology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Zhang, Yu AU - Zhang Y AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Xia, Chunchao AU - Xia C AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Ye, Zheng AU - Ye Z AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Li, Hanyu AU - Li H AD - Department of Purchasing and Supply, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. FAU - Romman, Zimam AU - Romman Z AD - Philips Healthcare, Haifa, Israel. FAU - Yao, Hui AU - Yao H AD - Philips Healthcare Suzhou Co Ltd., Suzhou, China. FAU - Li, Zhenlin AU - Li Z AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. Electronic address: HX_lizhenlin@126.com. FAU - Tang, Jing AU - Tang J AD - Department of Radiology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu 610041, China. Electronic address: tangjing@wchscu.cn. LA - eng PT - Journal Article DEP - 20240930 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - Prospective Studies MH - *Algorithms MH - Male MH - Female MH - *Uric Acid/blood MH - Adult MH - *Gout/diagnostic imaging MH - *Sensitivity and Specificity MH - *Tomography, X-Ray Computed/methods MH - Middle Aged MH - Artifacts MH - Reproducibility of Results MH - Radiographic Image Interpretation, Computer-Assisted/methods OTO - NOTNLM OT - Artifacts OT - Foot OT - Gout OT - Tomography, X-ray computed COIS- Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Zhenlin Li reports financial support was provided by Key Technologies Research and Development Program. Zhenlin Li reports financial support was provided by Key R&D Projects of Sichuan Science and Technology Program. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/10/03 00:42 MHDA- 2024/12/03 06:24 CRDT- 2024/10/02 18:07 PHST- 2024/06/25 00:00 [received] PHST- 2024/09/06 00:00 [revised] PHST- 2024/09/27 00:00 [accepted] PHST- 2024/12/03 06:24 [medline] PHST- 2024/10/03 00:42 [pubmed] PHST- 2024/10/02 18:07 [entrez] AID - S0720-048X(24)00485-6 [pii] AID - 10.1016/j.ejrad.2024.111769 [doi] PST - ppublish SO - Eur J Radiol. 2024 Dec;181:111769. doi: 10.1016/j.ejrad.2024.111769. Epub 2024 Sep 30. PMID- 28759732 OWN - NLM STAT- MEDLINE DCOM- 20180306 LR - 20181202 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 45 IP - 12 DP - 2017 Oct TI - Therapeutic Effects of Doxycycline on the Quality of Repaired and Unrepaired Achilles Tendons. PG - 2872-2881 LID - 10.1177/0363546517716637 [doi] AB - BACKGROUND: Achilles tendon tears are devastating injuries, especially to athletes. Elevated matrix metalloproteinase (MMP) activity after a tendon injury has been associated with deterioration of the collagen network and can be inhibited with doxycycline (Doxy). HYPOTHESIS: Daily oral administration of Doxy will enhance the histological, molecular, and biomechanical quality of transected Achilles tendons. Additionally, suture repair will further enhance the quality of repaired tendons. STUDY DESIGN: Controlled laboratory study. METHODS: Randomized unilateral Achilles tendon transection was performed in 288 adult male Sprague-Dawley rats. The injured tendons were either unrepaired (groups 1 and 2) or surgically repaired (groups 3 and 4). Animals from groups 2 and 4 received Doxy daily through oral gavage, and animals from groups 1 and 3 served as controls (no Doxy). Tendons were harvested at 1.5, 3, 6, and 9 weeks after the injury (n = 18 per group and time point). The quality of tendon repair was evaluated based on the histological grading score, collagen fiber orientation, gene expression, and biomechanical properties. RESULTS: In surgically repaired samples, Doxy enhanced the quality of tendon repair compared with no Doxy ( P = .0014). Doxy had a significant effect on collagen fiber dispersion, but not principal fiber angle. There was a significant effect of time on the gene expression of MMP-3, MMP-9 and TIMP1, and Doxy significantly decreased MMP-3 expression at 9 weeks. Doxy treatment with surgical repair increased the dynamic modulus at 6 weeks but not at 9 weeks after the injury ( P < .001). Doxy also increased the equilibrium modulus and decreased creep strain irrespective of the repair group. Doxy did not have a significant effect on the histology or biomechanics of unrepaired tendons. CONCLUSION: The findings indicate that daily oral administration of Doxy accelerated matrix remodeling and the dynamic and equilibrium biomechanics of surgically repaired Achilles tendons, although such enhancements were most evident at the 3- to 6-week time points. CLINICAL RELEVANCE: The inhibition of MMPs at the optimal stage of the repair process may accelerate Achilles tendon repair and improve biomechanical properties, especially when paired with surgical management. FAU - Nguyen, Quynhhoa T AU - Nguyen QT AD - Bioengineering-Biomechanics Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. FAU - Norelli, Jolanta B AU - Norelli JB AD - Orthopaedic Research Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. AD - Hofstra Northwell School of Medicine, Hofstra University, Hempstead, New York, USA. FAU - Graver, Adam AU - Graver A AD - Department of Orthopaedic Surgery, Long Island Jewish Medical Center, New Hyde Park, New York, USA. FAU - Ekstein, Charles AU - Ekstein C AD - Department of Orthopaedic Surgery, Long Island Jewish Medical Center, New Hyde Park, New York, USA. FAU - Schwartz, Johnathan AU - Schwartz J AD - Orthopaedic Research Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. FAU - Chowdhury, Farzana AU - Chowdhury F AD - Bioengineering-Biomechanics Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. FAU - Drakos, Mark C AU - Drakos MC AD - Department of Orthopaedic Surgery, Long Island Jewish Medical Center, New Hyde Park, New York, USA. AD - Hospital for Special Surgery, New York, New York, USA. FAU - Grande, Daniel A AU - Grande DA AD - Orthopaedic Research Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. AD - Hofstra Northwell School of Medicine, Hofstra University, Hempstead, New York, USA. AD - Department of Orthopaedic Surgery, Long Island Jewish Medical Center, New Hyde Park, New York, USA. FAU - Chahine, Nadeen O AU - Chahine NO AD - Bioengineering-Biomechanics Laboratory, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. AD - Hofstra Northwell School of Medicine, Hofstra University, Hempstead, New York, USA. LA - eng PT - Journal Article DEP - 20170731 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - N12000U13O (Doxycycline) SB - IM MH - Achilles Tendon/drug effects/*injuries/metabolism/*surgery MH - Animals MH - Biomechanical Phenomena MH - Doxycycline/*administration & dosage MH - Gene Expression/drug effects MH - Male MH - Matrix Metalloproteinase 3/genetics MH - Matrix Metalloproteinase 9/genetics MH - Rats, Sprague-Dawley MH - Tissue Inhibitor of Metalloproteinase-1/genetics MH - Wound Healing/*drug effects OTO - NOTNLM OT - Achilles tendon OT - MMP inhibition OT - doxycycline EDAT- 2017/08/02 06:00 MHDA- 2018/03/07 06:00 CRDT- 2017/08/01 06:00 PHST- 2017/08/02 06:00 [pubmed] PHST- 2018/03/07 06:00 [medline] PHST- 2017/08/01 06:00 [entrez] AID - 10.1177/0363546517716637 [doi] PST - ppublish SO - Am J Sports Med. 2017 Oct;45(12):2872-2881. doi: 10.1177/0363546517716637. Epub 2017 Jul 31. PMID- 40178650 OWN - NLM STAT- MEDLINE DCOM- 20250403 LR - 20250605 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 45 IP - 4 DP - 2025 Apr 3 TI - Gouty finger flexor tenosynovitis with urate milk remarkably similar to infection: a case-based review. PG - 86 LID - 10.1007/s00296-025-05841-3 [doi] AB - Gout attacks and tophi due to hyperuricemia are common, but rarely occur in extraarticular flexor tendons. Milky white fluid containing urate crystals, referred to as urate milk, may incidentally accumulate in the joint cavity and tophus of patients with gout. We report a rare case of gouty flexor tenosynovitis in the finger, characterized by urate milk, which closely resembled pyogenic tenosynovitis. A 54-year-old man with a history of gout attacks presented unprovoked right ring finger pain with marked erythema, swelling, and limited range of motion of the palmar side of the proximal interphalangeal (PIP) joint. He experienced gout attacks without tophus in both feet once a year since the age of 30 years. At the time of the initial onset, the patient took uric acid-lowering drug just for one month for hyperuricemia, but then stopped outpatient treatment and had been using non-steroidal anti-inflammatory drugs (NSAIDs) only during attacks. No abnormalities were observed on radiographs, and magnetic resonance imaging (MRI) showed T1-low and T2-very high-intensity regions from precisely above the flexor tendon to subcutaneously at the PIP joint level. Blood examination revealed C-reactive protein level of 2.5 mg/L, white blood cell count of 8.1 × 10(9) /L, and uric acid level of 666 µmol/L (normal range ≦ 360 µmol/L). The operation was performed for the patient suspected of suppurative flexor tenosynovitis. A milky white fluid overflowed subcutaneously, and multiple gouty tophi were observed on the tendon sheath. The diagnosis of gouty flexor tenosynovitis was made based on the absence of bacteria on culture and uric acid crystals on optical microscopy. Histopathological examination revealed an accumulation of multinucleated giant cells around the amorphous deposits characteristic of gouty tophi. Gouty tenosynovitis with urate milk should be considered in cases presenting a history of gout attacks, hyperuricemia, and high T2 signal intensity on MRI, such as subcutaneous pus accumulation in the clinical picture of infection. CI - © 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kubo, Yusuke AU - Kubo Y AUID- ORCID: 0000-0003-0741-4647 AD - Department of Orthopaedic Surgery, Iizuka Hospital, 3-83, Yoshiomachi, Iizuka, 820-8505, Japan. y.kubokku@gmail.com. FAU - Sonoda, Kazuhiko AU - Sonoda K AUID- ORCID: 0000-0002-0425-5532 AD - Department of Orthopaedic Surgery, Iizuka Hospital, 3-83, Yoshiomachi, Iizuka, 820-8505, Japan. FAU - Ushijima, Takahiro AU - Ushijima T AUID- ORCID: 0009-0002-3523-4889 AD - Department of Orthopaedic Surgery, Iizuka Hospital, 3-83, Yoshiomachi, Iizuka, 820-8505, Japan. FAU - Hara, Toshihiko AU - Hara T AUID- ORCID: 0000-0001-9871-018X AD - Department of Orthopaedic Surgery, Iizuka Hospital, 3-83, Yoshiomachi, Iizuka, 820-8505, Japan. LA - eng PT - Case Reports PT - Journal Article PT - Review DEP - 20250403 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - Middle Aged MH - Male MH - *Uric Acid/metabolism MH - *Tenosynovitis/diagnosis/pathology/diagnostic imaging MH - *Gout/diagnosis/complications MH - Magnetic Resonance Imaging MH - *Fingers/pathology MH - Diagnosis, Differential MH - Hyperuricemia/complications/drug therapy OTO - NOTNLM OT - Gout OT - Hyperuricemia OT - Pyogenic OT - Tenosynovitis OT - Urate milk OT - Uric acid crystal COIS- Declarations. Ethical approval: This study was approved by the Research Ethics Committee of Iizuka Hospital (no. R24006). Informed consent: The patient was informed that data from the research would be submitted for publication, and provided his consent. Disclaimer statement: We declare that no part of this manuscript, including text and graphics, will be copied or published elsewhere, in whole or in part, and that no AI has been used for writing and editing. Conflict of interest: All authors have no competing interests to declare. EDAT- 2025/04/03 12:24 MHDA- 2025/04/03 18:25 CRDT- 2025/04/03 11:16 PHST- 2024/12/18 00:00 [received] PHST- 2025/03/19 00:00 [accepted] PHST- 2025/04/03 18:25 [medline] PHST- 2025/04/03 12:24 [pubmed] PHST- 2025/04/03 11:16 [entrez] AID - 10.1007/s00296-025-05841-3 [pii] AID - 10.1007/s00296-025-05841-3 [doi] PST - epublish SO - Rheumatol Int. 2025 Apr 3;45(4):86. doi: 10.1007/s00296-025-05841-3. PMID- 17509903 OWN - NLM STAT- MEDLINE DCOM- 20071024 LR - 20161124 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 16 IP - 5 Suppl DP - 2007 Sep-Oct TI - Oxygen free radicals and tendon healing. PG - S208-14 AB - Nitric oxide is a small free radical generated by a family of enzymes, the nitric oxide synthases (NOSs). In a series of experiments performed over the last 15 years, we showed that nitric oxide is induced by all 3 isoforms of NOS during tendon healing and that it plays a crucial beneficial role in restoring tendon function. In normal tendons, very little NOS activity was found, whereas in injured rat and human tendons, NOS activity was expressed in healing fibroblasts in a temporal fashion. In healing rat Achilles tendon fibroblasts, the first isoform to be expressed was endothelial NOS, followed by inducible NOS and then brain or neuronal NOS. Systemic inhibition of NOS activity decreased the cross-sectional area and mechanical properties of the healing rodent Achilles tendons. The addition of nitric oxide via nitric oxide-flurbiprofen enhanced rat Achilles tendon healing. The addition of nitric oxide to cultured human tendon cells via chemical means and via adenoviral transfection enhanced collagen synthesis, suggesting that one mechanism for the beneficial effect of nitric oxide on tendon healing might be via matrix synthesis. Most recently, 3 randomized, double-blind clinical trials evaluated the efficacy of nitric oxide donation via a patch in the management of the tendinopathy. In all 3 clinical trials, there was a significant positive beneficial effect of nitric oxide donation to the clinical symptoms and function of patients with Achilles tendinopathy, tennis elbow, and supraspinatus tendinitis. FAU - Murrell, George A C AU - Murrell GA AD - Orthopaedic Research Institute, St George Hospital Campus, University of New South Wales, Sydney, Australia. admin@ori.org.au LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20070516 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Reactive Oxygen Species) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Achilles Tendon/injuries/*physiopathology MH - Administration, Topical MH - Adult MH - Aged MH - Animals MH - Cumulative Trauma Disorders/physiopathology MH - Disease Models, Animal MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Mice MH - Middle Aged MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase/genetics/metabolism MH - Nitroglycerin/administration & dosage MH - Rats MH - Reactive Oxygen Species/administration & dosage/*metabolism MH - Rotator Cuff/*physiopathology/surgery MH - Rotator Cuff Injuries MH - Tendinopathy/therapy MH - Tendon Injuries/*physiopathology/surgery MH - Tennis Elbow/physiopathology/therapy MH - Wound Healing/*physiology EDAT- 2007/05/19 09:00 MHDA- 2007/10/25 09:00 CRDT- 2007/05/19 09:00 PHST- 2006/11/07 00:00 [received] PHST- 2007/02/23 00:00 [revised] PHST- 2007/03/13 00:00 [accepted] PHST- 2007/05/19 09:00 [pubmed] PHST- 2007/10/25 09:00 [medline] PHST- 2007/05/19 09:00 [entrez] AID - S1058-2746(07)00205-4 [pii] AID - 10.1016/j.jse.2007.03.007 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2007 Sep-Oct;16(5 Suppl):S208-14. doi: 10.1016/j.jse.2007.03.007. Epub 2007 May 16. PMID- 30497327 OWN - NLM STAT- MEDLINE DCOM- 20200121 LR - 20200121 IS - 2043-6289 (Electronic) IS - 0266-7681 (Linking) VI - 44 IP - 2 DP - 2019 Feb TI - Wide awake surgery for Linburg-Comstock syndrome. PG - 215-216 LID - 10.1177/1753193418813773 [doi] FAU - Mermod, T AU - Mermod T AD - Department of Plastic and Hand surgery, University Hospital Center of the Canton of Vaud (CHUV), Lausanne, Switzerland. FAU - Müller, C AU - Müller C AD - Department of Plastic and Hand surgery, University Hospital Center of the Canton of Vaud (CHUV), Lausanne, Switzerland. FAU - Durand, S AU - Durand S AD - Department of Plastic and Hand surgery, University Hospital Center of the Canton of Vaud (CHUV), Lausanne, Switzerland. LA - eng PT - Case Reports PT - Letter PT - Video-Audio Media DEP - 20181129 PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Anesthetics, Local) RN - 0 (Vasoconstrictor Agents) RN - 98PI200987 (Lidocaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Anesthetics, Local/*administration & dosage MH - Epinephrine/administration & dosage MH - Hand Deformities, Congenital/physiopathology/*surgery MH - Humans MH - Lidocaine/administration & dosage MH - Magnetic Resonance Imaging MH - Male MH - Syndrome MH - Tendons/*abnormalities/diagnostic imaging/*surgery MH - Vasoconstrictor Agents/administration & dosage MH - Young Adult EDAT- 2018/12/01 06:00 MHDA- 2020/01/22 06:00 CRDT- 2018/12/01 06:00 PHST- 2018/12/01 06:00 [pubmed] PHST- 2020/01/22 06:00 [medline] PHST- 2018/12/01 06:00 [entrez] AID - 10.1177/1753193418813773 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2019 Feb;44(2):215-216. doi: 10.1177/1753193418813773. Epub 2018 Nov 29. PMID- 37750272 OWN - NLM STAT- MEDLINE DCOM- 20230927 LR - 20231005 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 34 IP - 3 DP - 2023 Aug 22 TI - The effect of caffeic acid on tendon healing in rats with an Achilles tendon injury model. PG - 669-678 LID - jdrs.2023.1248 [pii] LID - 10.52312/jdrs.2023.1248 [doi] AB - OBJECTIVES: This study aims to examine the effect of caffeic acid on tendon healing histopathologically and biomechanically in rats with an Achilles tendon injury model. MATERIALS AND METHODS: Twenty male Wistar-albino rats were used in this study. The rats were divided into two groups as the experimental group and control group. All rats underwent a bilateral achillotomy injury model and then surgical repair. Postoperatively, for four weeks, the experimental group was given intraperitoneal caffeic acid (100 mg/kg/day suspended in saline), while the control group was given only intraperitoneal saline. At the end of four weeks, after sacrificing each rat, right Achilles tendons were subjected to biomechanical analysis and the Achilles tendons were subjected to histopathological analysis. Bonar and Movin scores were used for histopathological analysis. In biomechanical analysis, tensile test was applied to Achilles tendons until rupture. For each tendon, failure load, displacement, cross-sectional area, maximum energy, total energy, length, stiffness, ultimate stress and strain parameters were recorded. RESULTS: According to Bonar and Movin scoring, the experimental group had lower scoring values than the control group (p=0.002 and p=0.002, respectively). Bonar scoring parameters were analyzed separately. Vascularity, collagen, and ground substance scores were lower in the experimental group compared to the control group (p=0.001, p=0.003, and p=0.047, respectively). No significant difference was found for tenocyte (p=0.064). In biomechanical analysis, failure load, displacement, ultimate stress, strain, and stiffness values were found to be higher in the experimental group compared to the control group (p=0.049, p=0.005, p=0.028, p=0.021, and p=0.049, respectively). CONCLUSION: The caffeic acid contributed positively to tendon healing histopathologically and biomechanically in rats with an Achilles tendon injury model. FAU - Yurteri, Ahmet AU - Yurteri A AD - Konya Şehir Hastanesi Ortopedi ve Travmatoloji Kliniği, 42020 Karatay, Konya. op.drahmetyurteri@gmail.com. FAU - Mercan, Numan AU - Mercan N FAU - Çelik, Murat AU - Çelik M FAU - Doğar, Fatih AU - Doğar F FAU - Kılıç, Mehmet AU - Kılıç M FAU - Yıldırım, Ahmet AU - Yıldırım A LA - eng PT - Journal Article DEP - 20230822 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - U2S3A33KVM (caffeic acid) RN - 0 (Caffeic Acids) SB - IM MH - Male MH - Rats MH - Animals MH - *Achilles Tendon MH - Rats, Wistar MH - *Tendon Injuries/drug therapy MH - Caffeic Acids/pharmacology/therapeutic use MH - *Ankle Injuries PMC - PMC10546862 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2023/09/26 06:44 MHDA- 2023/09/27 06:42 PMCR- 2023/08/22 CRDT- 2023/09/26 04:33 PHST- 2023/09/27 06:42 [medline] PHST- 2023/09/26 06:44 [pubmed] PHST- 2023/09/26 04:33 [entrez] PHST- 2023/08/22 00:00 [pmc-release] AID - jdrs.2023.1248 [pii] AID - 10.52312/jdrs.2023.1248 [doi] PST - epublish SO - Jt Dis Relat Surg. 2023 Aug 22;34(3):669-678. doi: 10.52312/jdrs.2023.1248. PMID- 15216906 OWN - NLM STAT- MEDLINE DCOM- 20040809 LR - 20190911 IS - 1389-4501 (Print) IS - 1389-4501 (Linking) VI - 5 IP - 5 DP - 2004 Jul TI - Chronic tendon pain--implications for treatment: an update. PG - 407-10 AB - In previous studies we found high concentrations of the neurotransmitter glutamate in chronic painful tendons. To evaluate the possible importance, the high intra-tendinous glutamate concentrations had for the pain suffered in chronic Achilles tendinosis, microdialysis was performed before and after treatment. The results showed that in patients that were pain-free after treatment there were no significant differences in the glutamate levels before compared to after treatment. With this finding in mind, also other possibly pain-related mechanisms were evaluated. Using ultrasonography and colour doppler technique, we found that in chronic painful tendinosis tendons, but not in normal pain-free tendons, there was a neovascularisation inside and outside the area with structural tendon changes and pain. To test the hypothesis that there was an association between neovascularisation and pain, in a pilot study, under ultrasound and colour doppler guidance the area with neovascularisation was destroyed by injecting the sclerosing agent Polidocanol. The clinical results showed that 8/10 patients were pain-free and had no remaining neovessels. The 2 patients that were not pain-free had remaining neovessels. In a following investigation combining ultrasonography + colour doppler, immunohistochemical analyses of biopsies, and diagnostic injections, the results showed that in the area with tendon changes and neovascularisation, biopsies showed nerve structures in close relation to the blood vessels, and injections of local anaesthesia temporarily cured the pain in all patients. Altogether, the findings indicate that the area with neovascularisation (neovessels and nerves) might be responsible for the pain suffered in chronic Achilles tendinosis, and that a locally administrated (in the area with neovascularisation) sclerosing drug (Polidocanol) has the potential to cure the pain. FAU - Alfredson, Håkan AU - Alfredson H AD - Umeå University, Department of Surgical and Perioperative Science, Sports Medicine, Umeå, Sweden. hakan.alfredson@idrott.umu.se LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Drug Targets JT - Current drug targets JID - 100960531 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Achilles Tendon/blood supply/diagnostic imaging/innervation MH - Chronic Disease MH - Humans MH - Neovascularization, Pathologic/complications/diagnostic imaging/*therapy MH - Pain/etiology MH - *Pain Management MH - Polidocanol MH - Polyethylene Glycols/administration & dosage/*therapeutic use MH - Sclerosing Solutions/administration & dosage/*therapeutic use MH - Tendinopathy/complications/diagnostic imaging/*therapy MH - Ultrasonography RF - 26 EDAT- 2004/06/26 05:00 MHDA- 2004/08/10 05:00 CRDT- 2004/06/26 05:00 PHST- 2004/06/26 05:00 [pubmed] PHST- 2004/08/10 05:00 [medline] PHST- 2004/06/26 05:00 [entrez] AID - 10.2174/1389450043345353 [doi] PST - ppublish SO - Curr Drug Targets. 2004 Jul;5(5):407-10. doi: 10.2174/1389450043345353. PMID- 34908488 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220501 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 50 IP - 2 DP - 2022 Feb TI - Evaluation of Therapeutic Effects of Quercetin Against Achilles Tendinopathy in Rats via Oxidative Stress, Inflammation, Apoptosis, Autophagy, and Metalloproteinases. PG - 486-498 LID - 10.1177/03635465211059821 [doi] AB - BACKGROUND: Achilles tendinopathy, seen in athletes and manual labor workers, is an inflammatory condition characterized by chronic tendon pain. Owing to the toxicity that develops in various organs attributed to the use of anti-inflammatory drugs, there is a need for new therapeutic agents. PURPOSE: In the present study, the effects of quercetin (Que), the one that attracted the most attention of researchers studying this group of flavonoids, were investigated against collagenase-induced tendinopathy. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 35 Sprague-Dawley rats were used in the study. Tendinopathy was created by injecting a single dose of collagenase (10 μL; 10 mg/mL) into the tendons of rats. Thirty minutes after the injection, Que was administered at doses of 25 or 50 mg/kg. Que administration was carried out for 7 days. Animals underwent a motility test at the end of the study. In addition, markers of oxidative stress, inflammation, apoptosis, and autophagy, as well as the expression levels of matrix metalloproteinases (MMPs 2, 3, 9, and 13), ICAM-1, and STAT3, were measured in tendon tissues with biochemical, molecular, and Western blot techniques. RESULTS: The results showed that oxidative stress, inflammation, apoptosis, and autophagy were triggered by the injection of collagenase. In addition, MMPs, ICAM-1, and STAT3 were activated to participate in the development of tendinopathy. Que was found to reduce ICAM-1 levels in tendon tissue. Moreover, Que showed antioxidant, anti-inflammatory, antiapoptotic, and antiautophagic effects on tendons against tendinopathy. More important, Que suppressed the expression of MMPs in the tendon tissues. CONCLUSION: Que has protective properties against collagenase-induced tendon damage in rats. CLINICAL RELEVANCE: We believe that with further study, Que may be shown to be an alternative treatment option for athletes or others who experience tendon injuries. FAU - Semis, Halil Sezgin AU - Semis HS AD - Department of Orthopedics and Traumatology, Private Buhara Hospital, Erzurum, Turkey. FAU - Gur, Cihan AU - Gur C AD - Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey. FAU - Ileriturk, Mustafa AU - Ileriturk M AD - Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey. FAU - Kandemir, Fatih Mehmet AU - Kandemir FM AD - Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey. FAU - Kaynar, Ozgur AU - Kaynar O AD - Department of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey. LA - eng PT - Journal Article DEP - 20211215 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 9IKM0I5T1E (Quercetin) RN - EC 3.4.24.- (Collagenases) SB - IM MH - *Achilles Tendon/metabolism MH - Animals MH - Apoptosis MH - Autophagy MH - Collagenases/adverse effects MH - Humans MH - Inflammation/drug therapy/metabolism MH - Oxidative Stress MH - Quercetin/adverse effects MH - Rats MH - Rats, Sprague-Dawley MH - *Tendinopathy/chemically induced/drug therapy/metabolism OTO - NOTNLM OT - *collagenase OT - *inflammation OT - *metalloproteinases OT - *quercetin OT - *tendinopathy EDAT- 2021/12/16 06:00 MHDA- 2022/04/08 06:00 CRDT- 2021/12/15 12:19 PHST- 2021/12/16 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] PHST- 2021/12/15 12:19 [entrez] AID - 10.1177/03635465211059821 [doi] PST - ppublish SO - Am J Sports Med. 2022 Feb;50(2):486-498. doi: 10.1177/03635465211059821. Epub 2021 Dec 15. PMID- 26511510 OWN - NLM STAT- MEDLINE DCOM- 20160916 LR - 20250529 IS - 1946-6242 (Electronic) IS - 1946-6234 (Print) IS - 1946-6234 (Linking) VI - 7 IP - 311 DP - 2015 Oct 28 TI - Inflammation activation and resolution in human tendon disease. PG - 311ra173 LID - 10.1126/scitranslmed.aac4269 [doi] AB - Improved understanding of the role of inflammation in tendon disease is required to facilitate therapeutic target discovery. We studied supraspinatus tendons from patients experiencing pain before and after surgical subacromial decompression treatment. Tendons were classified as having early, intermediate, or advanced disease, and inflammation was characterized through activation of pathways mediated by interferon (IFN), nuclear factor κB (NF-κB), glucocorticoid receptor, and signal transducer and activator of transcription 6 (STAT-6). Inflammation signatures revealed expression of genes and proteins induced by IFN and NF-κB in early-stage disease and genes and proteins induced by STAT-6 and glucocorticoid receptor activation in advanced-stage disease. The proresolving proteins FPR2/ALX and ChemR23 were increased in early-stage disease compared to intermediate- to advanced-stage disease. Patients who were pain-free after treatment had tendons with increased expression of CD206 and ALOX15 mRNA compared to tendons from patients who continued to experience pain after treatment, suggesting that these genes and their pathways may moderate tendon pain. Stromal cells from diseased tendons cultured in vitro showed increased expression of NF-κB and IFN target genes after treatment with lipopolysaccharide or IFNγ compared to stromal cells derived from healthy tendons. We identified 15-epi lipoxin A4, a stable lipoxin isoform derived from aspirin treatment, as potentially beneficial in the resolution of tendon inflammation. CI - Copyright © 2015, American Association for the Advancement of Science. FAU - Dakin, Stephanie G AU - Dakin SG AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Martinez, Fernando O AU - Martinez FO AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. FAU - Yapp, Clarence AU - Yapp C AD - Structural Genomics Consortium, University of Oxford, Old Road Campus, Headington OX3 7DQ, UK. FAU - Wells, Graham AU - Wells G AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. FAU - Oppermann, Udo AU - Oppermann U AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. Structural Genomics Consortium, University of Oxford, Old Road Campus, Headington OX3 7DQ, UK. FAU - Dean, Benjamin J F AU - Dean BJ AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Smith, Richard D J AU - Smith RD AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Wheway, Kim AU - Wheway K AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Watkins, Bridget AU - Watkins B AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Roche, Lucy AU - Roche L AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. FAU - Carr, Andrew J AU - Carr AJ AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Headington OX3 7LD, UK. NIHR Oxford Biomedical Research Unit, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK. LA - eng GR - CAPMC/CIHR/Canada GR - 20522/VAC_/Versus Arthritis/United Kingdom GR - 106169/WT_/Wellcome Trust/United Kingdom GR - 20506/ARC_/Arthritis Research UK/United Kingdom GR - 20506/VAC_/Versus Arthritis/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Sci Transl Med JT - Science translational medicine JID - 101505086 RN - 0 (CMKLR1 protein, human) RN - 0 (FPR2 protein, human) RN - 0 (Lectins, C-Type) RN - 0 (Lipopolysaccharides) RN - 0 (Lipoxins) RN - 0 (Mannose Receptor) RN - 0 (Mannose-Binding Lectins) RN - 0 (NF-kappa B) RN - 0 (Receptors, Cell Surface) RN - 0 (Receptors, Chemokine) RN - 0 (Receptors, Formyl Peptide) RN - 0 (Receptors, Lipoxin) RN - 0 (STAT6 Transcription Factor) RN - 0 (lipoxin A4) RN - 82115-62-6 (Interferon-gamma) RN - 9008-11-1 (Interferons) RN - EC 1.13.11.33 (ALOX15 protein, human) RN - EC 1.13.11.33 (Arachidonate 15-Lipoxygenase) RN - R16CO5Y76E (Aspirin) SB - IM MH - Adolescent MH - Adult MH - Arachidonate 15-Lipoxygenase/metabolism MH - Aspirin/therapeutic use MH - Female MH - Humans MH - Immunohistochemistry MH - In Vitro Techniques MH - Inflammation/drug therapy/*metabolism/pathology MH - Interferon-gamma/therapeutic use MH - Interferons/metabolism MH - Lectins, C-Type/metabolism MH - Lipopolysaccharides/therapeutic use MH - Lipoxins/metabolism MH - Male MH - Mannose Receptor MH - Mannose-Binding Lectins/metabolism MH - NF-kappa B/metabolism MH - Receptors, Cell Surface/metabolism MH - Receptors, Chemokine/metabolism MH - Receptors, Formyl Peptide/metabolism MH - Receptors, Lipoxin/metabolism MH - STAT6 Transcription Factor/metabolism MH - Tendinopathy/drug therapy/immunology/metabolism/pathology MH - Tendons/immunology/*metabolism/*pathology MH - Young Adult PMC - PMC4883654 MID - EMS68087 OID - NLM: EMS68087 COIS- Competing interests: The authors declare that they have no competing interests. EDAT- 2015/10/30 06:00 MHDA- 2016/09/17 06:00 PMCR- 2016/05/27 CRDT- 2015/10/30 06:00 PHST- 2015/10/30 06:00 [entrez] PHST- 2015/10/30 06:00 [pubmed] PHST- 2016/09/17 06:00 [medline] PHST- 2016/05/27 00:00 [pmc-release] AID - 7/311/311ra173 [pii] AID - 10.1126/scitranslmed.aac4269 [doi] PST - ppublish SO - Sci Transl Med. 2015 Oct 28;7(311):311ra173. doi: 10.1126/scitranslmed.aac4269. PMID- 40142139 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20250514 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 30 IP - 6 DP - 2025 Mar 18 TI - Eucommiae cortex Comprehensive Phytochemical Analysis Connected with Its In Vitro Anti-Inflammatory Activity in Human Immune Cells. LID - 10.3390/molecules30061364 [doi] LID - 1364 AB - Eucommia ulmoides Oliv., commonly known as "plant gold", is a species of the Eucommiaceae family, native to East Asia and widely utilized in medicine, food, and the chemical industry. In Traditional Chinese Medicine, the bark of E. ulmoides plays a special role, used to nourish the liver and kidneys and to strengthen tendons and bones. Due to its extensive pharmacological profile, including anti-inflammatory, antioxidant, hypoglycemic, hypotensive, and cardio- and neuroprotective effects, there has been growing interest in elucidating the molecular mechanisms underlying its biological effects. However, many of these mechanisms remain poorly understood to date. This study analyzed the phytochemical composition of E. ulmoides bark infusions and tinctures and their dominant compounds using the HPLC-DAD-MS/MS method, and evaluated their anti-inflammatory effects in human immune cell models. The analysis identified lignans, iridoids, and caffeic acid derivatives as the dominant constituents of the tested samples. The extracts significantly inhibited the secretion of pro-inflammatory cytokines (TNF-α, IL-6, IL-8, MCP-1) in neutrophils, PBMC-derived monocytes/macrophages, and THP-1 cells. The results presented herein offer significant insights into the detailed phytochemical composition of E. ulmoides bark, and contribute to a deeper understanding of its anti-inflammatory mechanisms in human immune cells. FAU - Kołtun-Jasion, Małgorzata AU - Kołtun-Jasion M AUID- ORCID: 0000-0001-9501-5325 AD - Department of Pharmaceutical Biology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. FAU - Dudek, Marta Katarzyna AU - Dudek MK AUID- ORCID: 0000-0003-3412-0177 AD - Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza H. 112, 90-001 Łódź, Poland. FAU - Kiss, Anna Karolina AU - Kiss AK AUID- ORCID: 0000-0001-8258-2849 AD - Department of Pharmaceutical Biology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland. LA - eng GR - F/MB/03/22/Medical University of Warsaw/ PT - Journal Article DEP - 20250318 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Phytochemicals) RN - 0 (Plant Extracts) RN - 0 (Cytokines) RN - 0 (Iridoids) RN - 0 (eucommiae cortex) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Anti-Inflammatory Agents/pharmacology/chemistry MH - *Phytochemicals/pharmacology/chemistry MH - *Eucommiaceae/chemistry MH - *Plant Extracts/pharmacology/chemistry MH - Cytokines/metabolism MH - Neutrophils/drug effects/metabolism MH - Macrophages/drug effects/metabolism MH - THP-1 Cells MH - Tandem Mass Spectrometry MH - Monocytes/drug effects MH - Plant Bark/chemistry MH - Chromatography, High Pressure Liquid MH - Iridoids/chemistry/pharmacology MH - Drugs, Chinese Herbal PMC - PMC11944357 OTO - NOTNLM OT - Eucommia ulmoides OT - inflammation OT - iridoids OT - lignans OT - macrophages OT - monocytes OT - neutrophils COIS- The authors declare no conflicts of interest. EDAT- 2025/03/27 06:28 MHDA- 2025/03/27 06:29 PMCR- 2025/03/18 CRDT- 2025/03/27 01:10 PHST- 2025/01/10 00:00 [received] PHST- 2025/03/11 00:00 [revised] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/03/27 06:29 [medline] PHST- 2025/03/27 06:28 [pubmed] PHST- 2025/03/27 01:10 [entrez] PHST- 2025/03/18 00:00 [pmc-release] AID - molecules30061364 [pii] AID - molecules-30-01364 [pii] AID - 10.3390/molecules30061364 [doi] PST - epublish SO - Molecules. 2025 Mar 18;30(6):1364. doi: 10.3390/molecules30061364. PMID- 22341940 OWN - NLM STAT- MEDLINE DCOM- 20120809 LR - 20151119 IS - 1532-2777 (Electronic) IS - 0306-9877 (Linking) VI - 78 IP - 5 DP - 2012 May TI - Can snus (Swedish moist snuff) be used as a treatment of Pyoderma gangrenosum? PG - 619-20 LID - 10.1016/j.mehy.2012.01.039 [doi] AB - Pyoderma gangrenosum (PG) is a rare dermatological condition belonging to the group of deep neutrophilic dermatoses. It can display a protracted and refractory course. The list of treatments which have been tried and proved their efficacy is long, but none of them provide constant efficacy. In the absence of gold standard, the choice of the treatment relies on the physician's experience and review of the literature based upon case reports, small series or retrospective studies. Localized lesion has first to be managed with application of topical ointments and wound dressings while multiple or disseminated lesions, failure of local therapy, involvement of muscle and tendons or existence of an underlying disease will prompt to use systemic immunosuppressive therapies in association with local therapy and wound management. Among the local treatment, nicotine has been reported on very few occasions on localized PG under the form of nicotine gums, patches and topical applications. We hypothesized that Swedish oral-type moist snuff (or snus), a form of smokeless tobacco, could be an affordable alternative for the management of patients with chronic resistant PG to conventional therapies through the release and mucosal absorption of nicotine. It could be used only on a short-time basis to obtain healing of PG in selected patients. CI - Copyright © 2012 Elsevier Ltd. All rights reserved. FAU - Kluger, Nicolas AU - Kluger N AD - Department of Dermatology, Allergology and Venereology, Institute of Clinical Medicine, University of Helsinki, Skin and Allergies Hospital, Helsinki University Central Hospital, Meilahdentie 2, P.O. Box 160, 00029 HUS, Finland. nicolaskluger@yahoo.fr LA - eng PT - Journal Article PT - Review DEP - 20120215 PL - United States TA - Med Hypotheses JT - Medical hypotheses JID - 7505668 RN - 6M3C89ZY6R (Nicotine) SB - IM MH - Administration, Topical MH - Humans MH - Nicotine/administration & dosage MH - Pyoderma Gangrenosum/drug therapy/*therapy MH - Sweden MH - *Tobacco, Smokeless EDAT- 2012/02/22 06:00 MHDA- 2012/08/10 06:00 CRDT- 2012/02/21 06:00 PHST- 2011/11/01 00:00 [received] PHST- 2012/01/23 00:00 [accepted] PHST- 2012/02/21 06:00 [entrez] PHST- 2012/02/22 06:00 [pubmed] PHST- 2012/08/10 06:00 [medline] AID - S0306-9877(12)00060-6 [pii] AID - 10.1016/j.mehy.2012.01.039 [doi] PST - ppublish SO - Med Hypotheses. 2012 May;78(5):619-20. doi: 10.1016/j.mehy.2012.01.039. Epub 2012 Feb 15. PMID- 36815784 OWN - NLM STAT- MEDLINE DCOM- 20230404 LR - 20230424 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 51 IP - 5 DP - 2023 Apr TI - Histological and Biomechanical Effects of Local Anesthetics and Steroids on Achilles Tendon: A Study in Rats. PG - 1319-1327 LID - 10.1177/03635465231153640 [doi] AB - BACKGROUND: Peritendinous injection of local anesthetics, alone or in combination with corticosteroids, is widely used in the treatment of tendinopathies. Toxicity of local anesthetics has been demonstrated in many cells, including myocytes, chondrocytes, and neurons. Bupivacaine and lidocaine are known to have time- and dose-dependent cytotoxicity in these cells. The effects of these agents on the tendon remain unknown. PURPOSE: To show histological and biomechanical effects after the injection of different local anesthetics and steroids, both single and combined, at different concentrations into the peritendinous sheath of rat Achilles tendon. STUDY DESIGN: Controlled laboratory study. METHODS: In the study, 100 rats were divided into 10 groups with equal body weights. Inflammation was induced in both Achilles tendons of each rat by means of the ball drop technique; 7 hours later, injections were made into the peritendinous sheaths of both Achilles tendons using lidocaine, bupivacaine, and dexamethasone as appropriate for the rat's group. At the end of the first week, the right Achilles tendons of the rats were removed for histological study. Left Achilles tendons were evaluated in terms of biomechanics. RESULTS: Histological findings demonstrated that the group with the most toxicity to the tendon was the group that received injection of dexamethasone alone. The groups with the least toxicity were those receiving dexamethasone combined with low- or high-dose bupivacaine. Biomechanical findings showed that the experimental groups had similar results to each other with the exception of the groups receiving 0.25% bupivacaine alone and dexamethasone alone, in which tendons revealed higher tensile strength. CONCLUSION: Local anesthetic and steroid applications have different histological and biomechanical effects on the tendon. Although the dexamethasone-injected group was the most affected in terms of histology, these changes could not be demonstrated biomechanically. CLINICAL RELEVANCE: In future clinical studies, the effect of steroids on the tendon should be investigated more comprehensively. Whether biomechanical results overlap with histological results should be investigated further. FAU - Kafa, Baris AU - Kafa B AUID- ORCID: 0000-0003-4548-534X AD - Hand Surgery Unit, Department of Orthopaedics and Traumatology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey. FAU - Cakmak, Gokhan AU - Cakmak G AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Yuksek Ihtisas University, Liv Hospital, Ankara, Turkey. FAU - Sahin, Mehmet Sukru AU - Sahin MS AD - Department of Orthopaedics and Traumatology, Baskent University Alanya Research and Practice Center, Alanya, Antalya, Turkey. FAU - Helvacioglu, Fatma AU - Helvacioglu F AD - Department of Histology and Embryology, Faculty of Medicine, Baskent University, Ankara, Turkey. FAU - Fidan, Pinar Ayran AU - Fidan PA AD - Department of Histology and Embryology, Faculty of Medicine, Baskent University, Ankara, Turkey. FAU - Demir, Teyfik AU - Demir T AD - Department of Mechanical Engineering, TOBB University of Economics and Technology, Ankara, Turkey. FAU - Guvercin, Ayse Canan Yazici AU - Guvercin ACY AD - Department of Biostatistics and Medical Informatics, Faculty of Medicine, Izmir Tinaztepe University, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20230223 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anesthetics, Local) RN - Y8335394RO (Bupivacaine) RN - 0 (Steroids) RN - 98PI200987 (Lidocaine) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Rats MH - Animals MH - *Anesthetics, Local/pharmacology/therapeutic use MH - *Achilles Tendon MH - Bupivacaine/pharmacology MH - Steroids MH - Lidocaine/pharmacology/therapeutic use MH - Dexamethasone/pharmacology/therapeutic use MH - Biomechanical Phenomena OTO - NOTNLM OT - Achilles tendon OT - biomechanics of tendon OT - histological labeling OT - local anesthetics OT - steroids OT - tendon EDAT- 2023/02/24 06:00 MHDA- 2023/04/04 06:42 CRDT- 2023/02/23 09:04 PHST- 2023/04/04 06:42 [medline] PHST- 2023/02/24 06:00 [pubmed] PHST- 2023/02/23 09:04 [entrez] AID - 10.1177/03635465231153640 [doi] PST - ppublish SO - Am J Sports Med. 2023 Apr;51(5):1319-1327. doi: 10.1177/03635465231153640. Epub 2023 Feb 23. PMID- 16183110 OWN - NLM STAT- MEDLINE DCOM- 20060104 LR - 20220310 IS - 0141-8130 (Print) IS - 0141-8130 (Linking) VI - 37 IP - 1-2 DP - 2005 Oct 30 TI - Stabilization of collagen using plant polyphenol: role of catechin. PG - 47-53 AB - Collagen, a unique connective tissue protein finds extensive application as biocompatible biomaterial in wound healing, as drug carriers, cosmetics, etc. A work has been undertaken to study the stabilization of type I collagen using the plant polyphenol catechin. Catechin treated collagen fibres showed a shrinkage temperature around 70 degrees C implying that catechin is able to impart thermal stability to collagen. Catechin treated collagen fibres has been found to be stable even after treatment with high concentration of the secondary structural destabilizer, urea. Circular dichroism studies revealed that there is no major alteration in the structure of collagen on treatment with catechin. The study has demonstrated the involvement of hydrogen bonding and hydrophobic interactions as the major forces involved in the stabilization of collagen by the plant polyphenol, catechin. FAU - Madhan, B AU - Madhan B AD - Centre for Human and Organizational Resources Development, Central Leather Research Institute, Adyar, Chennai 600 020, India. FAU - Subramanian, V AU - Subramanian V FAU - Rao, J Raghava AU - Rao JR FAU - Nair, Balachandran Unni AU - Nair BU FAU - Ramasami, T AU - Ramasami T LA - eng PT - Journal Article DEP - 20050923 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (Biocompatible Materials) RN - 0 (Drug Carriers) RN - 0 (Flavonoids) RN - 0 (Phenols) RN - 0 (Plant Proteins) RN - 0 (Polymers) RN - 0 (Polyphenols) RN - 0 (Tannins) RN - 8R1V1STN48 (Catechin) RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Binding Sites MH - Biocompatible Materials/chemistry MH - Catechin/*chemistry MH - Collagen/*chemistry MH - Dose-Response Relationship, Drug MH - Drug Carriers MH - Extracellular Matrix/metabolism MH - Flavonoids/*chemistry MH - Hot Temperature MH - Hydrogen Bonding MH - Male MH - Models, Molecular MH - Molecular Conformation MH - Phenols/*chemistry MH - Plant Proteins/chemistry MH - Polymers/chemistry MH - Polyphenols MH - Protein Binding MH - Protein Conformation MH - Protein Structure, Secondary MH - Rats MH - Rats, Wistar MH - Software MH - Spectroscopy, Fourier Transform Infrared MH - Tannins/chemistry MH - Temperature MH - Tendons/pathology MH - Urea/chemistry MH - Wound Healing EDAT- 2005/09/27 09:00 MHDA- 2006/01/05 09:00 CRDT- 2005/09/27 09:00 PHST- 2005/07/04 00:00 [received] PHST- 2005/08/18 00:00 [revised] PHST- 2005/08/18 00:00 [accepted] PHST- 2005/09/27 09:00 [pubmed] PHST- 2006/01/05 09:00 [medline] PHST- 2005/09/27 09:00 [entrez] AID - S0141-8130(05)00178-9 [pii] AID - 10.1016/j.ijbiomac.2005.08.005 [doi] PST - ppublish SO - Int J Biol Macromol. 2005 Oct 30;37(1-2):47-53. doi: 10.1016/j.ijbiomac.2005.08.005. Epub 2005 Sep 23. PMID- 28859517 OWN - NLM STAT- MEDLINE DCOM- 20180201 LR - 20181202 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 45 IP - 14 DP - 2017 Dec TI - A Novel Approach for Meniscal Regeneration Using Kartogenin-Treated Autologous Tendon Graft. PG - 3289-3297 LID - 10.1177/0363546517721192 [doi] AB - BACKGROUND: The meniscus is one of the most commonly injured parts of the body, and meniscal healing is difficult. HYPOTHESIS: Kartogenin (KGN) induces tendon stem cells (TSCs) to differentiate into cartilage cells in vitro and form meniscus-like tissue in vivo. A damaged meniscus can be replaced with a KGN-treated autologous tendon graft. STUDY DESIGN: Controlled laboratory study. METHODS: In the in vitro experiments, TSCs were isolated from rabbit patellar tendons and cultured with various concentrations of KGN, from 0 to 1000 µM. The effect of KGN on the chondrogenesis of TSCs in vitro was investigated by histochemical staining and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). The in vivo experiments were carried out on 6 New Zealand White rabbits by removing a meniscus from the rabbit knee and implanting an autologous tendon graft treated with KGN or saline. The meniscus formation in vivo was examined by histological analysis and immune staining. RESULTS: The proliferation of TSCs was promoted by KGN in a concentration-dependent manner. Both histochemical staining and qRT-PCR showed that the chondrogenic differentiation of TSCs was increased with KGN concentration. After 3 months of implantation, the tendon graft treated with KGN formed a meniscus-like tissue with a white and glistening appearance, while the saline-treated tendon graft retained tendon-like tissue and appeared yellowish and unhealthy. Histochemical staining showed that after 3 months of implantation, the KGN-treated tendon graft had a structure similar to that of normal meniscus. Many cartilage-like cells and fibrocartilage-like tissues were found in the KGN-treated tendon graft. However, no cartilage-like cells were found in the saline-treated tendon graft after 3 months of implantation. Furthermore, the KGN-treated tendon graft was positively stained by both anti-collagen type I and type II antibodies, but the saline-treated tendon graft was not stained by collagen type II. CONCLUSION: The findings indicated that KGN can induce the differentiation of TSCs into cartilage-like cells in vitro and in vivo. The results suggest that KGN-treated tendon graft may be a good substitute for meniscal repair and regeneration. CLINICAL RELEVANCE: This study revealed the direct effects of KGN on the chondrogenic differentiation of TSCs in vitro and in vivo. A KGN-treated autologous tendon graft induced formation of a meniscus-like tissue in vivo. This study provides a new cartilage regenerating technology for the treatment of damaged meniscus. FAU - Huang, He AU - Huang H AD - Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. FAU - Xu, Hongyao AU - Xu H AD - Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. FAU - Zhao, Jianning AU - Zhao J AD - Department of Orthopaedics, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. AD - Jinling Hospital, Nanjing University School of Medicine, Nanjing, China. LA - eng PT - Journal Article DEP - 20170901 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anilides) RN - 0 (Phthalic Acids) RN - Q93BBN11CP (kartogenin) SB - IM MH - Anilides/*administration & dosage/pharmacology MH - Animals MH - Autografts MH - Cartilage/drug effects/*surgery MH - Cell Differentiation/drug effects MH - Chondrogenesis MH - Connective Tissue Cells MH - Disease Models, Animal MH - Meniscus/*surgery MH - Phthalic Acids/*administration & dosage/pharmacology MH - Rabbits MH - Regeneration MH - Tendons/drug effects/*transplantation MH - Transplantation, Autologous OTO - NOTNLM OT - kartogenin OT - meniscus regeneration OT - tendon graft OT - tendon stem cell OT - tissue engineering EDAT- 2017/09/02 06:00 MHDA- 2018/02/02 06:00 CRDT- 2017/09/02 06:00 PHST- 2017/09/02 06:00 [pubmed] PHST- 2018/02/02 06:00 [medline] PHST- 2017/09/02 06:00 [entrez] AID - 10.1177/0363546517721192 [doi] PST - ppublish SO - Am J Sports Med. 2017 Dec;45(14):3289-3297. doi: 10.1177/0363546517721192. Epub 2017 Sep 1. PMID- 24985041 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20211021 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 34 IP - 7 DP - 2015 Jul TI - Effects of isotretinoin treatment on cartilage and tendon thicknesses: an ultrasonographic study. PG - 1255-8 LID - 10.1007/s10067-014-2733-9 [doi] AB - Effects of retinoic acid on collagen synthesis and cartilage have previously been shown. However, its effects on cartilage and tendons in humans have not been studied yet. Therefore, in order to provide a morphologic insight, the aim of this study was to measure femoral cartilage, Achilles and supraspinatus tendon thicknesses in patients under systemic isotretinoin treatment by using ultrasound. Fifteen patients (nine F, six M) who used isotretinoin for their acnes were included. All patients were treated with isotretinoin 0.5 mg/kg/day for the first month, and the dosage was escalated up to 1 mg/kg/day thereafter. Distal femoral cartilage, supraspinatus, and Achilles tendons thicknesses have been evaluated both before the treatment and at the end of the third month. Femoral cartilage thicknesses were assessed from three midpoints bilaterally; medial condyle, lateral condyle, and intercondylar area. Short/long-axis diameters and cross-sectional area of the Achilles tendons and axial tendon thicknesses of supraspinatus tendon were evaluated from the nondominant side. The mean age of the patients was 20.1 ± 4.9 years, and body mass index was 21.7 ± 2.5 kg/m(2). Although posttreatment cartilage measurements of 30 knees were lower for the three midpoints, it reached significance only for lateral condyle (p = 0.05). In addition, posttreatment tendon measurements were not statistically significant compared with pretreatment values (all p > 0.05). Systemic isotretinoin treatment seems to make cartilage thinner. Further studies considering histological and molecular evaluations with more sample sizes are awaited. FAU - Yıldızgören, Mustafa Turgut AU - Yıldızgören MT AD - Department of Physical Medicine and Rehabilitation, Ankara Occupational Diseases Hospital, Ankara, Turkey, ftr.mustafaturgut@hotmail.com. FAU - Karataş Toğral, Arzu AU - Karataş Toğral A FAU - Baki, Ali Erdem AU - Baki AE FAU - Ekiz, Timur AU - Ekiz T LA - eng PT - Journal Article DEP - 20140702 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Dermatologic Agents) RN - 5688UTC01R (Tretinoin) RN - EH28UP18IF (Isotretinoin) SB - IM MH - Achilles Tendon/diagnostic imaging/drug effects MH - Adolescent MH - Adult MH - Cartilage, Articular/*diagnostic imaging/*drug effects MH - Dermatologic Agents/therapeutic use MH - Female MH - Femur/drug effects MH - Humans MH - Isotretinoin/*therapeutic use MH - Knee Joint/diagnostic imaging/drug effects MH - Male MH - Tendons/*diagnostic imaging/*drug effects MH - Tretinoin/chemistry MH - Ultrasonography MH - Young Adult EDAT- 2014/07/06 06:00 MHDA- 2016/04/19 06:00 CRDT- 2014/07/03 06:00 PHST- 2014/04/13 00:00 [received] PHST- 2014/06/18 00:00 [accepted] PHST- 2014/06/15 00:00 [revised] PHST- 2014/07/03 06:00 [entrez] PHST- 2014/07/06 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] AID - 10.1007/s10067-014-2733-9 [doi] PST - ppublish SO - Clin Rheumatol. 2015 Jul;34(7):1255-8. doi: 10.1007/s10067-014-2733-9. Epub 2014 Jul 2. PMID- 35343961 OWN - NLM STAT- MEDLINE DCOM- 20220407 LR - 20220407 IS - 1940-087X (Electronic) IS - 1940-087X (Linking) IP - 181 DP - 2022 Mar 11 TI - Alleviation of Diabetic Tendon Injury via Activation of Tendon Fibroblasts Autophagy under Berberine Treatment. LID - 10.3791/63224 [doi] AB - Berberine (BBR) is an isoquinoline alkaloid isolated from Coptis chinensis and possesses valuable pharmacological activities, including anti-inflammatory, anti-tumor, and alleviating several complications of type 2 diabetes mellitus (T2DM). However, the role of BBR in regulating diabetic tendon injury remains poorly understood. In this study, a rat model of T2DM was constructed, and cell apoptosis and autophagy were assessed in tendon tissues after BBR treatment through TdT-Mediated dUTP nick-end labeling (TUNEL) assay and immunohistochemical analysis. Tendon fibroblasts were obtained from the rat Achilles tendon, and the role of BBR in regulating cell apoptosis, the production of inflammatory cytokines, and autophagy activation were assessed using flow cytometry, quantitative real-time PCR (qRT-PCR), and western blot analysis. We demonstrated that BBR treatment significantly increased autophagy activation and decreased cell apoptosis in tendon tissues of T2DM rats. In tendon fibroblasts, BBR repressed High glucose (HG)-induced cell apoptosis and production of proinflammatory cytokines. HG treatment resulted in a decrease of autophagy activation in tendon fibroblasts, whereas BBR restored autophagy activation. More important, pharmacological inhibition of autophagy by 3-MA weakened the protective effects of BBR against HG-induced tendon fibroblasts injury. Taken together, the current results demonstrate that BBR helps relieve diabetic tendon injury by activating autophagy of tendon fibroblasts. FAU - Zhu, Mei-Dong AU - Zhu MD AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine. FAU - Li, Qi AU - Li Q AD - Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine. FAU - Yuan, Jia-Qin AU - Yuan JQ AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine. FAU - Song, Fu-Chen AU - Song FC AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine. FAU - Liu, Sheng-Hua AU - Liu SH AD - Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine. FAU - Zhang, Lei AU - Zhang L AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; zhanglei@shutcm.edu.cn. FAU - Zhao, Cheng AU - Zhao C AD - Department of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine; chengzhao_79@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Video-Audio Media DEP - 20220311 PL - United States TA - J Vis Exp JT - Journal of visualized experiments : JoVE JID - 101313252 RN - 0I8Y3P32UF (Berberine) SB - IM MH - Animals MH - Apoptosis MH - Autophagy MH - *Berberine/pharmacology MH - *Diabetes Mellitus, Type 2 MH - Fibroblasts MH - Rats MH - *Tendon Injuries MH - Tendons EDAT- 2022/03/29 06:00 MHDA- 2022/04/08 06:00 CRDT- 2022/03/28 12:16 PHST- 2022/03/28 12:16 [entrez] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/04/08 06:00 [medline] AID - 10.3791/63224 [doi] PST - epublish SO - J Vis Exp. 2022 Mar 11;(181). doi: 10.3791/63224. PMID- 38727117 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20240529 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 35 IP - 2 DP - 2024 Apr 26 TI - The effect of papaverine on tendon healing and adhesion in rats following Achilles tendon repair. PG - 368-376 LID - jdrs.2024.1656 [pii] LID - 10.52312/jdrs.2024.1656 [doi] AB - OBJECTIVES: The study aimed to examine the histopathological and biomechanical effects of papaverine administered intraperitoneally and locally on Achilles tendon healing in a rat model. MATERIALS AND METHODS: Forty-eight adult male Sprague-Dawley rats (range, 300 to 400 g) were used in this study conducted between October and November 2022. The rats were divided into three groups, with each group further subdivided into two for sacrifice on either the 15(th) (early period) or 30(th) (late period) day after surgery. The first (control) group received no treatment following Achilles tendon repair, while papaverine was intraperitoneally administered every other day for 10 days in the second group and locally in the third group after surgery. On the 15(th) and 30(th) days, the rats were sacrificed, and their Achilles tendons were subjected to biomechanical testing and histopathological evaluation. RESULTS: Histopathologically, there were no significant differences among the groups on the 15(th) day. However, on the 30(th) day, the locally applied papaverine group exhibited superior histopathological outcomes compared to the control group (p<0.05). Concerning the highest tensile strength values before rupture, the biomechanical assessment showed that the group receiving local papaverine treatment in the early period and both the group with systemic papaverine treatment and the one with local papaverine treatment in the late period displayed a statistically significant advantage compared to the control group (p<0.05). CONCLUSION: Locally administered papaverine has positive biomechanical effects in the early period and exhibits a positive correlation both histopathologically and biomechanically in the late period. Novel therapeutic options may be provided for patients through these findings. FAU - Can, Erdem AU - Can E AD - Erciş Şehit Rıdvan Çevik Devlet Hastanesi, Ortopedi ve Travmatoloji Kliniği, 65400 Erciş, Van, Türkiye. erdemcan.md@gmail.com. FAU - Dincel, Yasar Mahsut AU - Dincel YM FAU - Karabulut, Derya AU - Karabulut D FAU - Karabag, Sevil AU - Karabag S FAU - Arslan, Yunus Ziya AU - Arslan YZ LA - eng PT - Journal Article DEP - 20240426 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - DAA13NKG2Q (Papaverine) SB - IM MH - Animals MH - *Achilles Tendon/injuries/drug effects/pathology/surgery MH - *Papaverine/pharmacology/administration & dosage/therapeutic use MH - *Rats, Sprague-Dawley MH - Male MH - Tissue Adhesions/drug therapy/pathology MH - *Wound Healing/drug effects MH - *Tendon Injuries/drug therapy/pathology/surgery MH - Rats MH - Tensile Strength/drug effects MH - Injections, Intraperitoneal MH - Biomechanical Phenomena/drug effects MH - Disease Models, Animal PMC - PMC11128969 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2024/05/10 12:42 MHDA- 2024/05/10 12:43 PMCR- 2024/04/26 CRDT- 2024/05/10 08:13 PHST- 2024/02/05 00:00 [received] PHST- 2024/03/02 00:00 [accepted] PHST- 2024/05/10 12:43 [medline] PHST- 2024/05/10 12:42 [pubmed] PHST- 2024/05/10 08:13 [entrez] PHST- 2024/04/26 00:00 [pmc-release] AID - jdrs.2024.1656 [pii] AID - 10.52312/jdrs.2024.1656 [doi] PST - ppublish SO - Jt Dis Relat Surg. 2024 Apr 26;35(2):368-376. doi: 10.52312/jdrs.2024.1656. Epub 2024 Apr 26. PMID- 38148369 OWN - NLM STAT- MEDLINE DCOM- 20240228 LR - 20240228 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 144 IP - 3 DP - 2024 Mar TI - The effect of Sildenafil, a phosphodiesterase-5 inhibitor, on tendon healing: an experimental study in rat model of achilles tendon injury. PG - 1107-1115 LID - 10.1007/s00402-023-05178-1 [doi] AB - INTRODUCTION: Sildenafil Citrate has various effects on the body, including widening blood vessels, inhibiting platelet aggregation, promoting the growth of blood vessels, stimulating apoptosis and adhesion of fibroblasts, and reducing inflammation. This research aims to explore how Sildenafil Citrate affects surgically treated Achilles tendons, both in terms of tissue structure and mechanical properties. MATERIALS AND METHODS: Forty-eight Wistar-albino rats weighing 350-400 g were randomly divided into groups, 6 in each group, as the study group was given Sildenafil Citrate and the control group given saline, respectively. The Achilles tendon rupture model was created under ketamine and xylazine anesthesia. During the entire experiment, rats were housed in eight separate cages, six of them each. The study group and control group of the first group were sacrificed at the end of 1 week, and Achilles tendon samples were taken. After that, Achilles tendon samples were taken after sacrificing the second group at 14 days, the third group at 21 days, and the fourth group at 28 days, respectively. Neovascularization, inflammation, fibrosis and fibroblastic activities of the harvested Achilles tendons were evaluated histopathologically. Biomechanically, stretching was applied to the Achilles tendons and continued until the tendon ruptured. the maximum force values at the moment of rupture were calculated. RESULTS: The mean maximum strength value of group T21, which was given sildenafil citrate for 21 days, was 31.1 ± 4.36 N, and the mean maximum strength value of group C21, which was the control group, was 20.56 ± 6.92 N. A significant difference was observed between the groups (p: 0.008). Group T28 (45.17 ± 5.54 N) also demonstrated greater strength than group C28 (34.62 ± 3.21 N) in the comparison (p: 0.004). The study also noted significant differences between the groups in neovascularization, in the first week, 1 mild, 3 moderate and 2 prominent neovascularization was observed in group T7, in group T28, moderate neovascularization was observed in 4 specimens and prominent neovascularization was observed in 2 specimens (p: 0.001). Furthermore, the groups showed significant differences in their levels of fibrosis, inflammation and fibroblastic proliferation (p: 0.017, p: 0.036, (p: 0.035) respectively). CONCLUSIONS: Study has demonstrated that sildenafil citrate can enhance the biomechanical and histopathological aspects of tendon healing, resulting in a stronger tendon. CI - © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kurt, Vahap AU - Kurt V AUID- ORCID: 0000-0003-0532-4357 AD - Department of Orthopedics and Traumatology, Abdulkadir Yuksel State Hospital, Perilikaya, Havaalanıyolu Cd. No: 302, 27100, Şahinbey/Gaziantep, Turkey. vahapkurt@hotmail.com. FAU - Guner, Savaş AU - Guner S AD - Department of Orthopedics and Traumatology, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey. FAU - Kayacan, Ahmet Mesut AU - Kayacan AM AD - Department of Orthopedics and Traumatology, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey. FAU - Eronat, Omer AU - Eronat O AD - Department of Pathology, Faculty of Medicine, Gaziantep University, 27310, Gaziantep, Turkey. LA - eng GR - TF.UT.21.25/Gaziantep Üniversitesi/ PT - Journal Article DEP - 20231226 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - BW9B0ZE037 (Sildenafil Citrate) RN - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5) RN - 0 (Phosphodiesterase 5 Inhibitors) SB - IM MH - Rats MH - Animals MH - Sildenafil Citrate/pharmacology/therapeutic use MH - *Achilles Tendon/injuries MH - Cyclic Nucleotide Phosphodiesterases, Type 5/pharmacology MH - Rats, Wistar MH - Phosphodiesterase 5 Inhibitors/pharmacology MH - Biomechanical Phenomena MH - *Tendon Injuries/drug therapy MH - Rupture MH - *Ankle Injuries MH - Inflammation MH - Fibrosis OTO - NOTNLM OT - Achilles tendon OT - PDE-5 OT - Rat OT - Sildenafil EDAT- 2023/12/27 00:41 MHDA- 2024/02/28 06:44 CRDT- 2023/12/26 23:16 PHST- 2023/06/14 00:00 [received] PHST- 2023/12/06 00:00 [accepted] PHST- 2024/02/28 06:44 [medline] PHST- 2023/12/27 00:41 [pubmed] PHST- 2023/12/26 23:16 [entrez] AID - 10.1007/s00402-023-05178-1 [pii] AID - 10.1007/s00402-023-05178-1 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2024 Mar;144(3):1107-1115. doi: 10.1007/s00402-023-05178-1. Epub 2023 Dec 26. PMID- 34087778 OWN - NLM STAT- MEDLINE DCOM- 20210720 LR - 20210720 IS - 1873-4367 (Electronic) IS - 0927-7765 (Linking) VI - 205 DP - 2021 Sep TI - Sustained-Release Hydrogel-Based Rhynchophylline Delivery System Improved Injured Tendon Repair. PG - 111876 LID - S0927-7765(21)00320-9 [pii] LID - 10.1016/j.colsurfb.2021.111876 [doi] AB - During the injured flexor tendon healing process, tendon tissue is easy to form extremely dense adhesion with the surrounding tissue, which causes the serious influence of hand function recovery. Uncaria is widely used in clinic and its main composition, Rhynchophylline (Rhy), has been reported on its good therapeutic effect, which could effectively inhibit the intra-abdominal adhesion formation. However, the therapeutic effect of Rhy on tendon healing and adhesion formation is still unclear. Due to the short half-life of Rhy, hyaluronic acid (HA) sustained-release system for Rhy delivery was constructed and it could also avoid drug from the undesired loss during the transit. After Rhy delivery system was applied around the injured tendons, adhesion formation, gliding function and healing strength of tendons were evaluated. Our results showed that the gliding excursion and healing strength of repaired tendons were both significantly increased, as well as the adhesion was inhibited. From in vivo experiments, Rhy could be able to increase the expression of Col Ⅰ/Col Ⅲ and helped fibroblasts to ordered organization for tendon tissues. But for adhesion tissues, Rhy promoted the apoptosis and accelerated the degradation of extracellular matrix. In vitro study showed Rhy could help tenocytes stimulated with TGF-β1 to recover to normal cell functions involving cell proliferation and apoptosis level. Through high-throughput sequencing, we found that Rhy was involved in the regulation of Extracellular Matrix (ECM) signaling pathway. We draw a conclusion that Rhy enhanced the tendon healing and prevented adhesion formation through inhibiting the phosphorylation of Smad2. In a word, this sustained release system of Rhy may be a promising strategy for the treatment of injured tendons. CI - Copyright © 2021 Elsevier B.V. All rights reserved. FAU - Yang, Qian Qian AU - Yang QQ AD - The Nanomedicine Research Laboratory, Research for Frontier Medicine and Hand Surgery Research Center, Department of Hand Surgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, PR China; Medical School of Nantong University, Nantong, 226001, Jiangsu Province, PR China. FAU - Zhang, Luzhong AU - Zhang L AD - The Nanomedicine Research Laboratory, Research for Frontier Medicine and Hand Surgery Research Center, Department of Hand Surgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, PR China. FAU - Ju, Fei AU - Ju F AD - The Nanomedicine Research Laboratory, Research for Frontier Medicine and Hand Surgery Research Center, Department of Hand Surgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, PR China. FAU - Zhou, You Lang AU - Zhou YL AD - The Nanomedicine Research Laboratory, Research for Frontier Medicine and Hand Surgery Research Center, Department of Hand Surgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu Province, PR China. Electronic address: youlangzhou@163.com. LA - eng PT - Journal Article DEP - 20210523 PL - Netherlands TA - Colloids Surf B Biointerfaces JT - Colloids and surfaces. B, Biointerfaces JID - 9315133 RN - 0 (Delayed-Action Preparations) RN - 0 (Hydrogels) RN - 0 (Oxindoles) RN - 46BQ79VJ8D (rhyncophylline) SB - IM MH - Delayed-Action Preparations MH - Humans MH - *Hydrogels MH - Oxindoles MH - *Tendons/pathology MH - Tissue Adhesions/drug therapy/pathology OTO - NOTNLM OT - Healing strength OT - Injured tendon OT - Rhynchophylline OT - Sustained-release hydrogel OT - Tendon adhesion EDAT- 2021/06/05 06:00 MHDA- 2021/07/21 06:00 CRDT- 2021/06/04 20:30 PHST- 2021/02/23 00:00 [received] PHST- 2021/04/25 00:00 [revised] PHST- 2021/05/19 00:00 [accepted] PHST- 2021/06/05 06:00 [pubmed] PHST- 2021/07/21 06:00 [medline] PHST- 2021/06/04 20:30 [entrez] AID - S0927-7765(21)00320-9 [pii] AID - 10.1016/j.colsurfb.2021.111876 [doi] PST - ppublish SO - Colloids Surf B Biointerfaces. 2021 Sep;205:111876. doi: 10.1016/j.colsurfb.2021.111876. Epub 2021 May 23. PMID- 41213157 OWN - NLM STAT- MEDLINE DCOM- 20251204 LR - 20251204 IS - 1522-1601 (Electronic) IS - 0161-7567 (Linking) VI - 139 IP - 6 DP - 2025 Dec 1 TI - Caffeine decreases muscle and tendon protein synthesis and engineered ligament strength in vitro and attenuates adaptation to exercise in mice. PG - 1569-1580 LID - 10.1152/japplphysiol.00512.2025 [doi] AB - Caffeine is a well-known stimulant that is widely used to increase alertness and performance. However, there is little information on the effect of chronic caffeine consumption on exercise adaptations. We first sought to characterize the effect of caffeine on protein synthesis in vitro using immortalized C2C12 and TTD6 muscle and tendon cells. Total protein synthesis, as measured by puromycin incorporation, decreased 31% in TTD6 cells with 4 mM caffeine (P < 0.05) and 41% in C2C12 cells with 0.5 mM caffeine (P < 0.01). The structure and function of in vitro engineered ligaments were also reduced with caffeine, including a 45% reduction in maximal tensile load (P = 0.0128) and 30% reduction in collagen content (P = 0.0038) with 1 mM caffeine. To assess the effect of caffeine in vivo, sedentary and running mice were provided with a moderately high dose of caffeine (0.22 mg/mL, roughly equivalent to 5.7 mg/kg for a human) or water as a placebo control. Free access to a running wheel was effective in increasing gastrocnemius, soleus, and heart muscle mass relative to body weight, oxidative phosphorylation proteins, and Achilles tendon collagen concentration and Col1a1 gene expression. Mice that consumed caffeine while exercising did not gain skeletal muscle mass (gastrocnemius and soleus) to the same extent as the noncaffeinated exercising mice. Together, these data suggest that high caffeine consumption can dampen the molecular signals associated with protein synthesis and in excess may limit exercise-induced skeletal muscle adaptations.NEW & NOTEWORTHY It is possible for high doses of caffeine to dampen the adaptive response to exercise. In cell culture, muscle and tendon cells have lower protein synthesis with caffeine. Caffeine also reduced the mechanical properties of engineered ligaments. In mice, muscle mass gains with 6 wk of exercise are limited with a high physiological dose of caffeine (roughly equivalent to a human dose of 5.7 mg/kg). FAU - Steffen, Danielle AU - Steffen D AUID- ORCID: 0000-0002-5333-8406 AD - Department of Neurobiology, Physiology and Behavior, University of California, Davis, California, United States. AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. AD - Center for Healthy Aging, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Paulussen, Kevin J M AU - Paulussen KJM AD - Physiology and Membrane Biology, University of California, Davis, California, United States. FAU - Crone, Ryman AU - Crone R AUID- ORCID: 0009-0007-8373-9095 AD - Department of Neurobiology, Physiology and Behavior, University of California, Davis, California, United States. FAU - Tucker, Benjamin AU - Tucker B AD - Department of Neurobiology, Physiology and Behavior, University of California, Davis, California, United States. FAU - Pathak, Suraj AU - Pathak S AUID- ORCID: 0000-0002-0009-1972 AD - Department of Neurobiology, Physiology and Behavior, University of California, Davis, California, United States. FAU - Baar, Keith AU - Baar K AUID- ORCID: 0000-0001-9337-6186 AD - Department of Neurobiology, Physiology and Behavior, University of California, Davis, California, United States. AD - Physiology and Membrane Biology, University of California, Davis, California, United States. LA - eng GR - Clara Wu and Joe Tsai Foundation/ PT - Journal Article DEP - 20251110 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 3G6A5W338E (Caffeine) RN - 0 (Muscle Proteins) RN - 9007-34-5 (Collagen) SB - IM MH - *Caffeine/pharmacology MH - Animals MH - Mice MH - *Physical Conditioning, Animal/physiology MH - *Adaptation, Physiological/drug effects MH - *Muscle, Skeletal/drug effects/metabolism/physiology MH - *Tendons/drug effects/metabolism/physiology MH - Male MH - *Protein Biosynthesis/drug effects MH - *Ligaments/drug effects/physiology/metabolism MH - *Muscle Proteins/biosynthesis/metabolism MH - Mice, Inbred C57BL MH - Cell Line MH - Collagen/metabolism OTO - NOTNLM OT - caffeine OT - exercise OT - mice OT - muscle OT - tendon EDAT- 2025/11/10 18:23 MHDA- 2025/12/04 19:37 CRDT- 2025/11/10 17:12 PHST- 2025/12/04 19:37 [medline] PHST- 2025/11/10 18:23 [pubmed] PHST- 2025/11/10 17:12 [entrez] AID - 10.1152/japplphysiol.00512.2025 [doi] PST - ppublish SO - J Appl Physiol (1985). 2025 Dec 1;139(6):1569-1580. doi: 10.1152/japplphysiol.00512.2025. Epub 2025 Nov 10. PMID- 32917186 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 21 IP - 1 DP - 2020 Sep 11 TI - Quercetin reduces tendon adhesion in rat through suppression of oxidative stress. PG - 608 LID - 10.1186/s12891-020-03618-2 [doi] LID - 608 AB - BACKGROUND: Tendon adhesion is one of the most common clinical problems, which poses a considerable challenge to orthopedics doctors. Quercetin (QUE) as a popular drug at present, it has various biological functions, including anti-inflammatory, anti-ischemic, anti-peroxidation, and antioxidant. The purpose of this study was to investigate the effect of quercetin on tendon adhesion and whether quercetin can inhibit oxidative stress. METHOD: Thirty-six rats were randomly divided into three groups, including control group, low QUE (50 mg/kg/day) group, and high QUE (100 mg/kg/day) group. After 1 week, the levels of SOD, MDA and GPx were measured. The degree of tendon adhesion was assessed by macroscopic evaluation and histological evaluation. After 4 weeks. Besides, the pharmacological toxicity of quercetin to main organs were evaluated by histological analysis. RESULTS: The extent of superoxide dismutase (SOD) and glutathione peroxidase (GPx) of tendon tissue in high QUE group was significantly higher than those of low QUE group and control group. And the extent of malondialdehyde (MDA) of tendon tissue in high QUE group was significantly lower than that of low QUE group and control group. By macroscopic evaluation and histological analysis, the extent of tendon adhesion in high QUE group was lower than low QUE group and control group. However, there were no significant changes of the major organs through histological analysis. CONCLUSIONS: Quercetin may be a good and safe strategy in preventing tendon adhesion. But further clinical research is needed before its recommendation in the prevention and treatment of tendon adhesion. FAU - Liang, Yuan AU - Liang Y AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Xu, Keteng AU - Xu K AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Zhang, Pei AU - Zhang P AD - Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China. FAU - Zhang, Jiale AU - Zhang J AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Chen, Pengtao AU - Chen P AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - He, Jinshan AU - He J AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Fang, Yongchao AU - Fang Y AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Zhou, Yuelai AU - Zhou Y AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. FAU - Wang, Jingcheng AU - Wang J AD - Department of Orthopedics, Clinical Medical College of Yangzhou University, Subei People's Hospital, Nantong West Road 98, Yangzhou, 225001, China. wangjcyangzhou@163.com. FAU - Bai, Jianzhong AU - Bai J AD - Department of Orthopedics, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, 233000, China. jianzhongb@163.com. LA - eng GR - No: 81772332/National Natural Science Foundation of China/ GR - No: CXTDB2017004/Graduate Research and Innovation Projects of Jiangsu Province/ PT - Journal Article DEP - 20200911 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Antioxidants) RN - 9IKM0I5T1E (Quercetin) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Antioxidants/pharmacology MH - *Oxidative Stress MH - *Quercetin/pharmacology MH - Rats MH - Superoxide Dismutase MH - Tendons PMC - PMC7488677 OTO - NOTNLM OT - Oxidative stress OT - Quercetin OT - Tendon adhesions COIS- The authors declare that they have no competing interests. EDAT- 2020/09/13 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/09/11 CRDT- 2020/09/12 05:23 PHST- 2020/03/26 00:00 [received] PHST- 2020/08/31 00:00 [accepted] PHST- 2020/09/12 05:23 [entrez] PHST- 2020/09/13 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/09/11 00:00 [pmc-release] AID - 10.1186/s12891-020-03618-2 [pii] AID - 3618 [pii] AID - 10.1186/s12891-020-03618-2 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2020 Sep 11;21(1):608. doi: 10.1186/s12891-020-03618-2. PMID- 31447123 OWN - NLM STAT- MEDLINE DCOM- 20191212 LR - 20191217 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 28 IP - 9 DP - 2019 Sep TI - Iontophoresis in lateral epicondylitis: a randomized, double-blind clinical trial. PG - 1743-1749 LID - S1058-2746(19)30355-6 [pii] LID - 10.1016/j.jse.2019.05.020 [doi] AB - BACKGROUND: Lateral epicondylitis (LE) is a painful condition typically caused by excessive use of tendons, resulting in tendinopathy, inflammation, pain, and sensitivity changes in the lateral elbow. Iontophoresis is a noninvasive method of systemic and local drug delivery by means of a current. The study aimed to evaluate the effects of iontophoresis in patients with LE. METHODS: We performed a randomized, double-blind clinical trial. Twenty-four patients with LE, randomized into an iontophoresis group and a galvanic current group. The iontophoresis group received a solution of dexamethasone (4 mg/mL) and gel lidocaine-applied on the negative electrode by means of a continuous current at 5 mA for 15 minutes-and the positive electrode received a base gel solution. Patients in the galvanic current group received the same protocol but using a base gel solution on both electrodes. RESULTS: Both groups showed a significant improvement in pain on exertion and rest; increased handgrip strength in elbow extension and flexion; and improved function, as evaluated by the Patient-Rated Tennis Elbow Evaluation scale (P < .05). Iontophoresis showed superior results compared with galvanic current in pain on exertion and rest and in the function of individuals with tennis elbow. CONCLUSION: Iontophoresis proved to be an effective technique in reducing pain and improving strength and function in individuals with LE (tennis elbow). CI - Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. FAU - da Luz, Dionei C AU - da Luz DC AD - Department of Physiotherapy, Lutheran University of Brazil, Torres, Rio Grande do Sul, Brazil. FAU - de Borba, Yacom AU - de Borba Y AD - Department of Physiotherapy, Lutheran University of Brazil, Torres, Rio Grande do Sul, Brazil. FAU - Ravanello, Emerson M AU - Ravanello EM AD - Private practice, Torres, Rio Grande do Sul, Brazil. FAU - Daitx, Rodrigo B AU - Daitx RB AD - Department of Physiotherapy, Lutheran University of Brazil, Torres, Rio Grande do Sul, Brazil. FAU - Döhnert, Marcelo B AU - Döhnert MB AD - Department of Physiotherapy, Lutheran University of Brazil, Torres, Rio Grande do Sul, Brazil. Electronic address: mdohnert@hotmail.com. LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Gels) RN - 7S5I7G3JQL (Dexamethasone) RN - 98PI200987 (Lidocaine) SB - IM MH - Anesthetics, Local/administration & dosage MH - Anti-Inflammatory Agents/administration & dosage MH - Dexamethasone/administration & dosage MH - Double-Blind Method MH - Female MH - Gels MH - Hand Strength MH - Humans MH - *Iontophoresis MH - Lidocaine/administration & dosage MH - Male MH - Middle Aged MH - Patient Reported Outcome Measures MH - Tennis Elbow/*therapy OTO - NOTNLM OT - Iontophoresis OT - dexamethasone OT - direct electrical current OT - epicondylitis OT - lidocaine OT - physical therapy OT - tennis elbow EDAT- 2019/08/27 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/08/27 06:00 PHST- 2019/03/27 00:00 [received] PHST- 2019/05/08 00:00 [revised] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/08/27 06:00 [entrez] PHST- 2019/08/27 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] AID - S1058-2746(19)30355-6 [pii] AID - 10.1016/j.jse.2019.05.020 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2019 Sep;28(9):1743-1749. doi: 10.1016/j.jse.2019.05.020. PMID- 34156566 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20211019 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 40 IP - 11 DP - 2021 Nov TI - Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study. PG - 4649-4657 LID - 10.1007/s10067-021-05826-0 [doi] AB - OBJECTIVE: The aim of this study was to explore the prevalence and distribution of lower extremity entheseal abnormities by musculoskeletal ultrasound (US) in a cohort of gout patients, taking spondyloarthritis (SpA) patients and asymptomatic hyperuricemia (HUA) patients as controls. METHOD: One hundred participants with gout, fifty patients with SpA, and twenty-nine patients with asymptomatic HUA were recruited. US was used to assess the bilateral quadriceps, patellar and Achilles tendons, and plantar fascia entheses according to the Outcome Measures in Rheumatology (OMERACT) definitions. RESULTS: The US examination revealed the presence of one or more abnormalities in at least one enthesis in 45 out of 100 subjects (45.0%) and 152 out of 1000 entheses (15.2%) in the gout patients. Among the affected entheses, the patellar insertion of the quadriceps tendon was the most commonly involved area (38.0% in the gout patients versus 48.0% in the SpA patients with at least one pathological US finding, p = 0.241). There were no significant group differences in entheseal power Doppler (PD) signals, bone erosion, or enthesophytes. The patients with lower limb entheseal involvement in the gout group had an older age, longer disease duration, higher percentage of chronic tophaceous gout, and higher levels of inflammatory biomarkers of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Multivariate logistic regression analysis revealed that age (OR = 1.052, p = 0.001) and the ESR (OR = 1.023, p = 0.028) were correlated with lower limb enthesopathy in gout patients. In the subgroup analysis of gout patients without active inflammation, age (OR = 1.119, p = 0.001) and serum uric acid (UA, OR = 1.012, p = 0.002) were correlated with lower limb enthesopathy in gout. CONCLUSION: Lower extremity entheseal involvement might be neglected but should be considered as an important element in the evaluation of gout patients. Enthesopathy most frequently involves in the patellar insertion of the quadriceps tendon and is characterized by entheseal hypoechogenicity and/or thickening. Key Points • Lower extremity enthesopathy might be neglected as an important element in gout. • Enthesopathy is most frequently involved in the patellar insertion of the quadriceps tendon in gout. • Age and ESR are correlated with lower limb enthesopathy in gout patients. CI - © 2021. International League of Associations for Rheumatology (ILAR). FAU - Xu, Guanhua AU - Xu G AD - Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Road Qingchun, Hangzhou, 310003, Zhejiang Province, China. FAU - Lin, Jin AU - Lin J AD - Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Road Qingchun, Hangzhou, 310003, Zhejiang Province, China. FAU - Liang, Junyu AU - Liang J AD - Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Road Qingchun, Hangzhou, 310003, Zhejiang Province, China. FAU - Yang, Yang AU - Yang Y AD - Zhejiang University School of Medicine, Hangzhou, China. FAU - Ye, Zi AU - Ye Z AD - The First People's Hospital of Linhai, Linhai, China. FAU - Zhu, Guohui AU - Zhu G AD - The First People's Hospital of Linhai, Linhai, China. FAU - Cao, Heng AU - Cao H AUID- ORCID: 0000-0002-2435-049X AD - Department of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Road Qingchun, Hangzhou, 310003, Zhejiang Province, China. caohengzju@zju.edu.cn. LA - eng GR - 81701602/National Natural Science Foundation of China/ GR - Y201738127/Scientific research project of Education Department Zhejiang Province/ PT - Journal Article PT - Observational Study DEP - 20210622 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Achilles Tendon/diagnostic imaging MH - Aged MH - *Enthesopathy/diagnostic imaging/epidemiology MH - *Gout/complications/diagnostic imaging/epidemiology MH - Humans MH - Lower Extremity MH - Severity of Illness Index MH - Ultrasonography MH - Uric Acid OTO - NOTNLM OT - Enthesopathy OT - Gout OT - Spondyloarthropathy OT - Ultrasonography EDAT- 2021/06/23 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/06/22 12:21 PHST- 2021/01/26 00:00 [received] PHST- 2021/06/15 00:00 [accepted] PHST- 2021/06/06 00:00 [revised] PHST- 2021/06/23 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/06/22 12:21 [entrez] AID - 10.1007/s10067-021-05826-0 [pii] AID - 10.1007/s10067-021-05826-0 [doi] PST - ppublish SO - Clin Rheumatol. 2021 Nov;40(11):4649-4657. doi: 10.1007/s10067-021-05826-0. Epub 2021 Jun 22. PMID- 14971669 OWN - NLM STAT- MEDLINE DCOM- 20040520 LR - 20220321 IS - 1538-8506 (Print) IS - 1538-8506 (Linking) VI - 17 IP - 1 DP - 2004 Jan TI - Postoperative pain management after anterior cruciate ligament reconstruction. PG - 18-23 AB - This study compared pain and its management in four groups of patients after anterior cruciate ligament (ACL) surgery. Group 1 consisted of primary ACL reconstruction, group 2 primary ACL reconstruction with meniscal repair, group 3 primary ACL reconstruction with meniscal resection, and group 4 revision ACL reconstruction with patellar tendon allograft. Each patient was instructed to record his or her pain level on a visual analog pain scale (VAS) prior to the procedure and for 7 days postoperatively. All patients received a prescribed narcotic to be taken orally as needed every 4-6 hours. Each patient was instructed to taper its use and supplement with non-narcotic as symptoms allowed. The VAS score for all groups peaked at postoperative day 1 and remained elevated at postoperative day 2. At postoperative day 7, the VAS scores for groups 1, 2, and 3 began to show signs of further decline, whereas group 4 persisted at postoperative day 5 levels. A general trend of decreasing narcotic use over time and increasing non-narcotic use was noted in each group; however, these findings were not statistically significant. All four groups had nearly identical mean VAS scores and corresponding narcotic use for each postoperative day despite the differing levels of complexity of surgical intervention in each group. FAU - Beck, Paul R AU - Beck PR AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Ill, USA. FAU - Nho, Shane J AU - Nho SJ FAU - Balin, Jefferson AU - Balin J FAU - Badrinath, Shyamala K AU - Badrinath SK FAU - Bush-Joseph, Charles A AU - Bush-Joseph CA FAU - Bach, Bernard R Jr AU - Bach BR Jr FAU - Hayden, Jennifer K AU - Hayden JK LA - eng PT - Journal Article PL - Germany TA - J Knee Surg JT - The journal of knee surgery JID - 101137599 RN - 0 (Analgesics, Opioid) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 6YKS4Y3WQ7 (Hydrocodone) SB - IM MH - Adult MH - Ambulatory Surgical Procedures MH - Analgesics, Opioid/*therapeutic use MH - Anterior Cruciate Ligament/*surgery MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Case-Control Studies MH - Cryotherapy MH - Female MH - Humans MH - Hydrocodone/*therapeutic use MH - Male MH - Menisci, Tibial/surgery MH - Pain Measurement MH - Pain, Postoperative/*therapy MH - Tendons/transplantation EDAT- 2004/02/20 05:00 MHDA- 2004/05/21 05:00 CRDT- 2004/02/20 05:00 PHST- 2004/02/20 05:00 [pubmed] PHST- 2004/05/21 05:00 [medline] PHST- 2004/02/20 05:00 [entrez] AID - 10.1055/s-0030-1247142 [doi] PST - ppublish SO - J Knee Surg. 2004 Jan;17(1):18-23. doi: 10.1055/s-0030-1247142. PMID- 32021169 OWN - NLM STAT- MEDLINE DCOM- 20200518 LR - 20220412 IS - 1178-2013 (Electronic) IS - 1176-9114 (Print) IS - 1176-9114 (Linking) VI - 15 DP - 2020 TI - Doxycycline-Embedded Nanofibrous Membranes Help Promote Healing of Tendon Rupture. PG - 125-136 LID - 10.2147/IJN.S217697 [doi] AB - BACKGROUND: Despite recent advancements in surgical techniques, the repair of tendon rupture remains a challenge for surgeons. The purpose of this study was to develop novel doxycycline-loaded biodegradable nanofibrous membranes and evaluate their efficacy for the repair of Achilles tendon rupture in a rat model. MATERIALS AND METHODS: The drug-loaded nanofibers were prepared using the electrospinning process and drug release from the prepared membranes was investigated both in vitro and in vivo. Furthermore, the safety and efficacy of the drug-loaded nanofibrous membranes were evaluated in rats that underwent tendon surgeries. An animal behavior cage was employed to monitor the post-surgery activity of the animals. RESULTS: The experimental results demonstrated that poly(D,L-lactide-co-glycolide) (PLGA) nanofibers released effective concentrations of doxycycline for more than 40 days post-surgery, and the systemic plasma drug concentration was low. Rats receiving implantation of doxycycline-loaded nanofibers also showed greater activities and stronger tendons post-operation. CONCLUSION: Nanofibers loaded with doxycycline may have great potential in the repair of Achilles tendon rupture. CI - © 2020 Weng et al. FAU - Weng, Chun-Jui AU - Weng CJ AD - Department of Orthopedic Surgery, Musculoskeletal Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan. AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. FAU - Lee, Demei AU - Lee D AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. FAU - Ho, Jui AU - Ho J AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. FAU - Liu, Shih-Jung AU - Liu SJ AUID- ORCID: 0000-0003-2083-4865 AD - Department of Orthopedic Surgery, Musculoskeletal Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan. AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20200109 PL - New Zealand TA - Int J Nanomedicine JT - International journal of nanomedicine JID - 101263847 RN - 0 (Membranes, Artificial) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - N12000U13O (Doxycycline) SB - IM MH - Absorbable Implants MH - Achilles Tendon/injuries MH - Animals MH - Doxycycline/administration & dosage/pharmacokinetics/*pharmacology MH - Drug Delivery Systems/*methods MH - Drug Liberation MH - Membranes, Artificial MH - Nanofibers/*administration & dosage/chemistry/therapeutic use MH - Polylactic Acid-Polyglycolic Acid Copolymer/chemistry MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/*therapy MH - Wound Healing PMC - PMC6966150 OTO - NOTNLM OT - doxycycline OT - nanofibrous membrane OT - tendon COIS- The authors declare that there are no conflicts of interest in this work. EDAT- 2020/02/06 06:00 MHDA- 2020/05/19 06:00 PMCR- 2020/01/09 CRDT- 2020/02/06 06:00 PHST- 2019/05/30 00:00 [received] PHST- 2019/11/15 00:00 [accepted] PHST- 2020/02/06 06:00 [entrez] PHST- 2020/02/06 06:00 [pubmed] PHST- 2020/05/19 06:00 [medline] PHST- 2020/01/09 00:00 [pmc-release] AID - 217697 [pii] AID - 10.2147/IJN.S217697 [doi] PST - epublish SO - Int J Nanomedicine. 2020 Jan 9;15:125-136. doi: 10.2147/IJN.S217697. eCollection 2020. PMID- 25829359 OWN - NLM STAT- MEDLINE DCOM- 20151019 LR - 20250214 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 74 IP - 9 DP - 2015 Sep TI - Ungoutedly time for a change. PG - e50 LID - 10.1136/annrheumdis-2015-207534 [doi] FAU - Reid, Graham AU - Reid G LA - eng PT - Comment PT - Letter DEP - 20150331 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 268B43MJ25 (Uric Acid) SB - IM CON - Ann Rheum Dis. 2015 May;74(5):908-11. doi: 10.1136/annrheumdis-2014-206397. PMID: 25637002 MH - Female MH - Foot Joints/*diagnostic imaging MH - Gout/*diagnostic imaging MH - Humans MH - Hyperuricemia/*diagnostic imaging MH - Male MH - Radiography MH - Tendons/*diagnostic imaging MH - Uric Acid/*blood OTO - NOTNLM OT - Disease Activity OT - Early Rheumatoid Arthritis OT - Rheumatoid Arthritis EDAT- 2015/04/02 06:00 MHDA- 2015/10/20 06:00 CRDT- 2015/04/02 06:00 PHST- 2015/03/02 00:00 [received] PHST- 2015/03/04 00:00 [accepted] PHST- 2015/04/02 06:00 [entrez] PHST- 2015/04/02 06:00 [pubmed] PHST- 2015/10/20 06:00 [medline] AID - S0003-4967(24)02594-9 [pii] AID - 10.1136/annrheumdis-2015-207534 [doi] PST - ppublish SO - Ann Rheum Dis. 2015 Sep;74(9):e50. doi: 10.1136/annrheumdis-2015-207534. Epub 2015 Mar 31. PMID- 12182376 OWN - NLM STAT- MEDLINE DCOM- 20030109 LR - 20190818 IS - 0891-3668 (Print) IS - 0891-3668 (Linking) VI - 21 IP - 6 DP - 2002 Jun TI - Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. PG - 525-9 AB - BACKGROUND: Fluoroquinolones (FQs) have been infrequently used in children, largely because of concern that these agents can cause lesions of the cartilage in juvenile animals. However, the relevance of this laboratory observation to children treated with FQs is unknown. A retrospective, observational study was conducted to assess the incidence and relative risk of tendon or joint disorders (TJDs) that occur after use of selected FQs compared with azithromycin (AZ), a drug with no known effect on cartilage or tendons in humans or animals. METHODS: An automated database was searched to identify patients younger than 19 years who had been prescribed ofloxacin (OFX), levofloxacin, ciprofloxacin (CPX), or AZ. Potential cases of TJD occurring within 60 days of a prescription of one of the study drugs were identified based on assignment of a claims diagnosis consistent with a TJD within this period. Verified cases were identified by a blinded review of abstracts of medical records from subjects identified as potential cases. RESULTS: The incidence of verified TJD was 0.82% for OFX (13 of 1593) and CPX (37 of 4531) and was 0.78% for AZ (118 of 15,073). The relative risk of TJD for OFX and CPX compared with AZ was 1.04 (95% confidence interval, 0.55 to 1.84) and 1.04 (95% confidence interval, 0.72 to 1.51), respectively. The distributions of claims diagnoses and time to onset of TJD were comparable for all groups. The most frequently reported category of TJD involved the joint followed by tendon, cartilage and gait disorder. CONCLUSIONS: In this observational study involving more than 6000 FQ-treated children, the incidence of TJD associated with selected FQ use in children was <1% and was comparable with that of the reference group, children treated with AZ. FAU - Yee, Chuen L AU - Yee CL AD - Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, NJ 08869, USA. FAU - Duffy, Ciaran AU - Duffy C FAU - Gerbino, Peter G AU - Gerbino PG FAU - Stryker, Scott AU - Stryker S FAU - Noel, Gary J AU - Noel GJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Pediatr Infect Dis J JT - The Pediatric infectious disease journal JID - 8701858 RN - 0 (Fluoroquinolones) RN - 83905-01-5 (Azithromycin) SB - IM MH - Adolescent MH - Azithromycin/adverse effects/pharmacology/*therapeutic use MH - Child MH - Child, Preschool MH - Cohort Studies MH - Female MH - Fluoroquinolones/adverse effects/pharmacology/*therapeutic use MH - Humans MH - Incidence MH - Joint Diseases/*drug therapy MH - Joints/drug effects MH - Male MH - Muscular Diseases/*drug therapy MH - Retrospective Studies MH - Risk Factors MH - Tendinopathy/drug therapy MH - Tendons/*drug effects MH - Time Factors EDAT- 2002/08/17 10:00 MHDA- 2003/01/10 04:00 CRDT- 2002/08/17 10:00 PHST- 2002/08/17 10:00 [pubmed] PHST- 2003/01/10 04:00 [medline] PHST- 2002/08/17 10:00 [entrez] AID - 10.1097/00006454-200206000-00009 [doi] PST - ppublish SO - Pediatr Infect Dis J. 2002 Jun;21(6):525-9. doi: 10.1097/00006454-200206000-00009. PMID- 19393566 OWN - NLM STAT- MEDLINE DCOM- 20090625 LR - 20131121 IS - 1532-1770 (Electronic) IS - 1521-6942 (Linking) VI - 23 IP - 2 DP - 2009 Apr TI - How to perform local soft-tissue glucocorticoid injections. PG - 193-219 LID - 10.1016/j.berh.2008.11.002 [doi] AB - Inflammation of periarticular soft-tissue structures such as tendons, tendon sheaths, entheses, bursae, ligaments and fasciae are the hallmark of many inflammatory rheumatic diseases, but inflammation - or rather irritation - of these structures also occurs in the absence of an underlying rheumatic disease. In both these primary and secondary soft-tissue lesions, local glucocorticoid injection often is beneficial, although evidence in literature is limited. This chapter reviews local injection therapy for these lesions and for nerve compression syndromes. FAU - Jacobs, J W AU - Jacobs JW AD - Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands. j.w.g.jacobs@umcutrecht.nl LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Best Pract Res Clin Rheumatol JT - Best practice & research. Clinical rheumatology JID - 101121149 RN - 0 (Anesthetics, Local) RN - 0 (Glucocorticoids) RN - 98PI200987 (Lidocaine) SB - IM MH - Anesthetics, Local/administration & dosage MH - Bursitis/*drug therapy MH - Glucocorticoids/*administration & dosage MH - Humans MH - Injections, Intra-Articular/*methods MH - Lidocaine/administration & dosage MH - Nerve Compression Syndromes/*drug therapy MH - Tendinopathy/*drug therapy RF - 105 EDAT- 2009/04/28 09:00 MHDA- 2009/06/26 09:00 CRDT- 2009/04/28 09:00 PHST- 2009/04/28 09:00 [entrez] PHST- 2009/04/28 09:00 [pubmed] PHST- 2009/06/26 09:00 [medline] AID - S1521-6942(08)00131-9 [pii] AID - 10.1016/j.berh.2008.11.002 [doi] PST - ppublish SO - Best Pract Res Clin Rheumatol. 2009 Apr;23(2):193-219. doi: 10.1016/j.berh.2008.11.002. PMID- 39527887 OWN - NLM STAT- MEDLINE DCOM- 20241207 LR - 20241207 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 143 IP - Pt 3 DP - 2024 Dec 25 TI - Inhibition of peritendinous adhesion through targeting JAK2-STAT3 signaling pathway: The therapeutic potential of AG490. PG - 113582 LID - S1567-5769(24)02104-0 [pii] LID - 10.1016/j.intimp.2024.113582 [doi] AB - Peritendinous adhesion is a common complication following tendon injury repair, posing a significant clinical challenge that requires urgent attention. The primary cause of peritendinous adhesion is the excessive deposition of collagen matrix due to the abnormal proliferation of fibroblasts in an inflammatory state. Janus kinase2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) are key signaling molecules involved in cell proliferation and fibrosis development in various organs. However, the role of the JAK-2 and STAT3 signaling pathways in peritendinous adhesion fibrosis remains unclear. In our study, we first observed upregulation of p-JAK2 and p-STAT3 proteins in human peritendinous adhesion specimens and rat peritendinous adhesion models. In vitro, the JAK2/STAT3 pathway inhibitor AG490 effectively inhibited TGF-β1-induced fibroblast proliferation. Wound healing and transwell assays demonstrated that AG490 suppressed TGF-β1-induced fibroblast migration. Furthermore, we found that AG490 decreased the expression of pro-inflammatory factors, including IL-1β and TNF-α, as well as extracellular matrix (ECM) proteins in fibroblasts under TGF-β1 stimulation. In vivo, histological staining showed that AG490 prevented fibrous tissue formation in a rat model of tendon injury. Moreover, AG490 inhibited the overexpression of pro-inflammatory factors IL-1β and TNF-α, as well as ECM in the peritendinous adhesions. In conclusion, AG490 inhibited fibrosis and inflammation in injured tendons by targeting the JAK2-STAT3 signaling pathway, presenting a promising strategy for the prophylaxis of peritendinous adhesions. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Fang, Xue AU - Fang X AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China. FAU - Zhang, Wang AU - Zhang W AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China. FAU - Liu, Changhuan AU - Liu C AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China. FAU - Liu, Yuping AU - Liu Y AD - Sichuan University West China Second University Hospital, Department of Anesthesiology, Chengdu, Sichuan, China. FAU - Tan, Wei AU - Tan W AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China. FAU - Wang, Zheng AU - Wang Z AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China. Electronic address: wangzhengemail@whu.edu.cn. FAU - Wang, Xin AU - Wang X AD - Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China; Hubei Clinical Medical Research Center of Trauma and Microsurgery, Wuhan, Hubei, China; Elderly Hip Fracture Diagnosis and Treatment Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Electronic address: wangxinznyy@whu.edu.cn. LA - eng PT - Journal Article DEP - 20241112 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - EC 2.7.10.2 (Janus Kinase 2) RN - 0 (STAT3 Transcription Factor) RN - 0 (alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide) RN - 0 (Tyrphostins) RN - 0 (Transforming Growth Factor beta1) RN - EC 2.7.10.2 (JAK2 protein, human) RN - 0 (STAT3 protein, human) SB - IM MH - Animals MH - *Janus Kinase 2/metabolism/antagonists & inhibitors MH - *STAT3 Transcription Factor/metabolism MH - Humans MH - *Signal Transduction/drug effects MH - *Tyrphostins/pharmacology/therapeutic use MH - Male MH - *Fibroblasts/drug effects/metabolism MH - Rats MH - *Rats, Sprague-Dawley MH - Tissue Adhesions/drug therapy/prevention & control/metabolism MH - Transforming Growth Factor beta1/metabolism MH - Cell Proliferation/drug effects MH - Cell Movement/drug effects MH - Tendons/pathology/drug effects/metabolism MH - Female MH - Cells, Cultured MH - Tendon Injuries/drug therapy OTO - NOTNLM OT - AG490 OT - JAK2-STAT3 signaling pathway OT - Peritendinous adhesion OT - Proliferation COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/13 14:01 MHDA- 2024/12/07 14:46 CRDT- 2024/11/11 18:02 PHST- 2024/09/11 00:00 [received] PHST- 2024/11/04 00:00 [revised] PHST- 2024/11/05 00:00 [accepted] PHST- 2024/12/07 14:46 [medline] PHST- 2024/11/13 14:01 [pubmed] PHST- 2024/11/11 18:02 [entrez] AID - S1567-5769(24)02104-0 [pii] AID - 10.1016/j.intimp.2024.113582 [doi] PST - ppublish SO - Int Immunopharmacol. 2024 Dec 25;143(Pt 3):113582. doi: 10.1016/j.intimp.2024.113582. Epub 2024 Nov 12. PMID- 32917279 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20210621 IS - 1478-6362 (Electronic) IS - 1478-6354 (Print) IS - 1478-6354 (Linking) VI - 22 IP - 1 DP - 2020 Sep 11 TI - Dual-energy CT in gout patients: Do all colour-coded lesions actually represent monosodium urate crystals? PG - 212 LID - 10.1186/s13075-020-02283-z [doi] LID - 212 AB - BACKGROUND: Dual-energy CT (DECT) can acknowledge differences in tissue compositions and can colour-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating gout patients, DECT frequently colour-codes material not truly representing MSU crystals and this might lead to misinterpretations. The characteristics of and variations in properties of colour-coded DECT lesions in gout patients have not yet been systematically investigated. The objective of this study was to evaluate the properties and locations of colour-coded DECT lesions in gout patients. METHODS: DECT of the hands, knees and feet were performed in patients with suspected gout using factory default gout settings, and colour-coded DECT lesions were registered. For each lesion, properties [mean density (mean of Hounsfield Units (HU) at 80 kV and Sn150kV), mean DECT ratio and size] and location were determined. Subgroup analysis was performed post hoc evaluating differences in locations of lesions when divided into definite MSU depositions and possibly other lesions. RESULTS: In total, 4033 lesions were registered in 27 patients (23 gout patients, 3918 lesions; 4 non-gout patients, 115 lesions). In gout patients, lesions had a median density of 160.6 HU and median size of 6 voxels, and DECT ratios showed an approximated normal distribution (mean 1.06, SD 0.10), but with a right heavy tail consistent with the presence of smaller amounts of high effective atomic number lesions (e.g. calcium-containing lesions). The most common locations of lesions were 1st metatarsophalangeal (MTP1), knee and midtarsal joints along with quadriceps and patella tendons. Subgroup analyses showed that definite MSU depositions (large volume, low DECT ratio, high density) had a similar distribution pattern, whereas possible calcium-containing material (high DECT ratio) and non-gout MSU-imitating lesions (properties as definite MSU depositions in non-gout patients) were primarily found in some larger joints (knee, midtarsal and talocrural) and tendons (Achilles and quadriceps). MTP1 joints and patella tendons showed only definite MSU depositions. CONCLUSION: Colour-coded DECT lesions in gout patients showed heterogeneity in properties and distribution. MTP1 joints and patella tendons exclusively showed definite MSU depositions. Hence, a sole focus on these regions in the evaluation of gout patients may improve the specificity of DECT scans. FAU - Christiansen, Sara Nysom AU - Christiansen SN AUID- ORCID: 0000-0002-5063-9932 AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600, Glostrup, Denmark. sara.nysom.christiansen@regionh.dk. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. sara.nysom.christiansen@regionh.dk. FAU - Müller, Felix Christoph AU - Müller FC AD - Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark. AD - Siemens Healthineers, Ballerup, Denmark. FAU - Østergaard, Mikkel AU - Østergaard M AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600, Glostrup, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Slot, Ole AU - Slot O AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600, Glostrup, Denmark. FAU - Møller, Jakob M AU - Møller JM AD - Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark. FAU - Børgesen, Henrik F AU - Børgesen HF AD - Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark. FAU - Gosvig, Kasper Kjærulf AU - Gosvig KK AD - Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark. FAU - Terslev, Lene AU - Terslev L AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Valdemar Hansens Vej 17, 2600, Glostrup, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200911 PL - England TA - Arthritis Res Ther JT - Arthritis research & therapy JID - 101154438 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Color MH - *Gout/diagnostic imaging MH - Humans MH - Tendons MH - Tomography, X-Ray Computed MH - *Uric Acid PMC - PMC7488422 OTO - NOTNLM OT - Artefacts OT - Dual-energy CT OT - Gout OT - MSU crystals OT - Property analysis OT - Specificity COIS- Sara Christiansen has received speaker fees from Bristol Myers Squibb (BMS) and General Electric (GE). Felix Müller is an employee of Siemens Healthineers. Lene Terslev has received speaker fees from AbbVie, MSD, Novartis, Roche, Pfizer, General Electric (GE), Bristol Myers Squibb (BMS) and Janssen. Mikkel Østergaard has received research support and/or consultancy/speaker fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth. Ole Slot, Jakob Møller, Henrik Børgesen and Kasper Gosvig have no potential conflicts of interests. EDAT- 2020/09/13 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/09/11 CRDT- 2020/09/12 05:24 PHST- 2020/05/06 00:00 [received] PHST- 2020/07/31 00:00 [accepted] PHST- 2020/09/12 05:24 [entrez] PHST- 2020/09/13 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/09/11 00:00 [pmc-release] AID - 10.1186/s13075-020-02283-z [pii] AID - 2283 [pii] AID - 10.1186/s13075-020-02283-z [doi] PST - epublish SO - Arthritis Res Ther. 2020 Sep 11;22(1):212. doi: 10.1186/s13075-020-02283-z. PMID- 30526453 OWN - NLM STAT- MEDLINE DCOM- 20200925 LR - 20200925 IS - 1875-533X (Electronic) IS - 0929-8673 (Linking) VI - 27 IP - 30 DP - 2020 TI - Mechanistic Insights of Soluble Uric Acid-related Kidney Disease. PG - 5056-5066 LID - 10.2174/0929867326666181211094421 [doi] AB - Hyperuricemia, defined as the presence of elevated serum uric acid (sUA), could lead to urate deposit in joints, tendons, kidney and other tissues. Hyperuricemia as an independent risk factor was common in patients during the causation and progression of kidney disease. Uric acid is a soluble final product of endogenous and dietary purine metabolism, which is freely filtered in kidney glomeruli where approximately 90% of filtered uric acid is reabsorbed. Considerable studies have demonstrated that soluble uric acid was involved in the pathophysiology of renal arteriolopathy, tubule injury, tubulointerstitial fibrosis, as well as glomerular hypertrophy and glomerulosclerosis. In the review, we summarized the mechanistic insights of soluble uric acid related renal diseases. CI - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Pan, Jing AU - Pan J AD - Kidney Research Laboratory, Division of Nephrology, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China. FAU - Shi, Min AU - Shi M AD - Kidney Research Laboratory, Division of Nephrology, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China. FAU - Ma, Liang AU - Ma L AD - Kidney Research Laboratory, Division of Nephrology, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China. FAU - Fu, Ping AU - Fu P AD - Kidney Research Laboratory, Division of Nephrology, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China. LA - eng PT - Journal Article PL - United Arab Emirates TA - Curr Med Chem JT - Current medicinal chemistry JID - 9440157 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - *Hyperuricemia MH - Kidney MH - *Kidney Diseases/etiology MH - Risk Factors MH - *Uric Acid OTO - NOTNLM OT - Soluble uric acid OT - Uric acid (UA) OT - hyperuricemia OT - kidney injury OT - renal arteriolopathy OT - uric acid-induced kidney injury EDAT- 2018/12/12 06:00 MHDA- 2020/09/26 06:00 CRDT- 2018/12/12 06:00 PHST- 2018/10/30 00:00 [received] PHST- 2018/11/21 00:00 [revised] PHST- 2018/12/03 00:00 [accepted] PHST- 2018/12/12 06:00 [pubmed] PHST- 2020/09/26 06:00 [medline] PHST- 2018/12/12 06:00 [entrez] AID - CMC-EPUB-95135 [pii] AID - 10.2174/0929867326666181211094421 [doi] PST - ppublish SO - Curr Med Chem. 2020;27(30):5056-5066. doi: 10.2174/0929867326666181211094421. PMID- 39018873 OWN - NLM STAT- MEDLINE DCOM- 20240727 LR - 20240727 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 177 DP - 2024 Aug TI - Matrine reduces traumatic heterotopic ossification in mice by inhibiting M2 macrophage polarization through the MAPK pathway. PG - 117130 LID - S0753-3322(24)01014-X [pii] LID - 10.1016/j.biopha.2024.117130 [doi] AB - In this study, the role of matrine, a component derived from traditional Chinese medicine, in modulating macrophage polarization and its effects on traumatic heterotopic ossification (HO) in mice was investigated. Traumatic HO is a pathological condition characterized by abnormal bone formation in nonskeletal tissues, often following severe trauma or surgery. The mechanisms underlying HO involve an enhanced inflammatory response and abnormal bone formation, with macrophages playing a crucial role. Our study demonstrated that matrine effectively inhibits the polarization of bone marrow-derived macrophages (BMDMs) toward the M2 phenotype, a subtype associated with anti-inflammatory processes and implicated in the progression of HO. Using in vitro assays, we showed that matrine suppresses key M2 markers and inhibits the MAPK signaling pathway in BMDMs. Furthermore, in vivo experiments revealed that matrine treatment significantly reduced HO formation in the Achilles tendons of mice and downregulated the expression of markers associated with M2 macrophages and the MAPK pathway. Our findings suggest that the ability of matrine to modulate macrophage polarization and inhibit the MAPK pathway has therapeutic potential for treating traumatic HO, providing a novel approach to managing this complex condition. CI - Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Wang, Hui AU - Wang H AD - Orthopedic Disease Center of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250000, China. FAU - Wang, Xiaofei AU - Wang X AD - Pediatric Surgery department, People's Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province 271100, China. FAU - Zhang, Qingkun AU - Zhang Q AD - Orthopedic Disease Center of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250000, China. FAU - Liang, Yanchen AU - Liang Y AD - Orthopedic Disease Center of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250000, China. Electronic address: 185492453@qq.com. FAU - Wu, Hong AU - Wu H AD - Department of Radiation Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province 250000, China. Electronic address: banbu.duo@163.com. LA - eng PT - Journal Article DEP - 20240717 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Matrines) RN - 0 (Quinolizines) RN - 0 (Alkaloids) SB - IM MH - Animals MH - *Matrines MH - *Quinolizines/pharmacology MH - *Alkaloids/pharmacology MH - *Ossification, Heterotopic/drug therapy/pathology MH - *Macrophages/drug effects/metabolism MH - Mice MH - *MAP Kinase Signaling System/drug effects MH - Male MH - *Mice, Inbred C57BL MH - Cell Polarity/drug effects OTO - NOTNLM OT - Heterotopic osssification OT - M2 macrophages OT - MAPK OT - Matrine OT - Phenotype COIS- Declaration of Competing Interest All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/07/18 00:42 MHDA- 2024/07/28 14:46 CRDT- 2024/07/17 18:09 PHST- 2024/05/22 00:00 [received] PHST- 2024/07/05 00:00 [revised] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/07/28 14:46 [medline] PHST- 2024/07/18 00:42 [pubmed] PHST- 2024/07/17 18:09 [entrez] AID - S0753-3322(24)01014-X [pii] AID - 10.1016/j.biopha.2024.117130 [doi] PST - ppublish SO - Biomed Pharmacother. 2024 Aug;177:117130. doi: 10.1016/j.biopha.2024.117130. Epub 2024 Jul 17. PMID- 21934587 OWN - NLM STAT- MEDLINE DCOM- 20120118 LR - 20141009 IS - 1542-538X (Electronic) IS - 0744-6020 (Linking) VI - 30 IP - 5 DP - 2011 Sep-Oct TI - Gout: no longer the disease of kings. PG - 322-30; quiz 331-2 LID - 10.1097/NOR.0b013e31822c5aa7 [doi] AB - Once described as the disease of kings, gout has developed a much greater incidence and prevalence. The incidence of gout is on the rise predominantly in the elderly. There appears to be a greater risk of developing gout with hyperuricemia, hypertension, and renal disease. High fructose drinks, red meat, organ meats, fatty seafood, and beer or liquor also appear to increase the risk of developing gout. Gout can lead to inflammation and damage to cartilage, bone, bursa, tendons, heart, or kidneys. Patients with gout will have many years of asymptomatic hyperuricemia followed by episodes of acute gouty inflammation and asymptomatic periods. Some people with gout will progress to chronic gout with tophi deposits, pain, deformity, and bone and cartilage destruction. FAU - Zychowicz, Michael E AU - Zychowicz ME AD - Duke University School of Nursing, Durham, NC, USA. LA - eng PT - Journal Article PL - United States TA - Orthop Nurs JT - Orthopedic nursing JID - 8409486 RN - 268B43MJ25 (Uric Acid) MH - Education, Continuing MH - Gout/epidemiology/*physiopathology/therapy MH - Humans MH - Risk Factors MH - Uric Acid/blood EDAT- 2011/09/22 06:00 MHDA- 2012/01/19 06:00 CRDT- 2011/09/22 06:00 PHST- 2011/09/22 06:00 [entrez] PHST- 2011/09/22 06:00 [pubmed] PHST- 2012/01/19 06:00 [medline] AID - 00006416-201109000-00011 [pii] AID - 10.1097/NOR.0b013e31822c5aa7 [doi] PST - ppublish SO - Orthop Nurs. 2011 Sep-Oct;30(5):322-30; quiz 331-2. doi: 10.1097/NOR.0b013e31822c5aa7. PMID- 22088932 OWN - NLM STAT- MEDLINE DCOM- 20120515 LR - 20200205 IS - 1778-7254 (Electronic) IS - 1297-319X (Linking) VI - 79 IP - 1 DP - 2012 Jan TI - Supraclavicular nerve entrapment syndrome. PG - 88-9 LID - 10.1016/j.jbspin.2011.09.009 [doi] AB - Supraclavicular nerve entrapment syndrome, although rare, should be considered among the causes of anterior shoulder girdle pain. This syndrome is usually related to anatomic variants (involving the bone structures, fibrous bands, or muscles and tendons). Computed tomography is the most useful investigation. Medications used to treat neuropathic pain may provide relief. Otherwise, a local glucocorticoid injection or even surgical decompression should be considered. CI - Copyright © 2011 Société française de rhumatologie. All rights reserved. FAU - Douchamps, Frédéric AU - Douchamps F AD - Service de médecine physique et réadaptation, CHU du Sart Tilman, ULG, B35, Sart Tilman, 4000 Liège, Belgium. freddouchamps@yahoo.fr FAU - Courtois, Anne-Catherine AU - Courtois AC FAU - Bruyère, Pierre-Julien AU - Bruyère PJ FAU - Crielaard, Jean-Michel AU - Crielaard JM LA - eng PT - Case Reports PT - Journal Article DEP - 20111115 PL - France TA - Joint Bone Spine JT - Joint bone spine JID - 100938016 RN - 0 (Analgesics) RN - 0 (Antirheumatic Agents) RN - 98PI200987 (Lidocaine) RN - X66NSO3N35 (Thiamine) SB - IM MH - Analgesics/therapeutic use MH - Antirheumatic Agents/therapeutic use MH - Brachial Plexus/*pathology/physiopathology MH - Clavicle/*innervation/pathology MH - Humans MH - Lidocaine/administration & dosage/therapeutic use MH - Male MH - Middle Aged MH - Nerve Compression Syndromes/complications/*diagnosis/therapy MH - Neuralgia/diagnosis/etiology/therapy MH - Osteoarthritis/complications/diagnosis/therapy MH - Physical Therapy Modalities MH - Shoulder Pain/diagnosis/etiology/therapy MH - Syndrome MH - Thiamine/therapeutic use MH - Tomography, X-Ray Computed MH - Transdermal Patch MH - Treatment Outcome EDAT- 2011/11/18 06:00 MHDA- 2012/05/16 06:00 CRDT- 2011/11/18 06:00 PHST- 2011/07/22 00:00 [accepted] PHST- 2011/11/18 06:00 [entrez] PHST- 2011/11/18 06:00 [pubmed] PHST- 2012/05/16 06:00 [medline] AID - S1297-319X(11)00229-6 [pii] AID - 10.1016/j.jbspin.2011.09.009 [doi] PST - ppublish SO - Joint Bone Spine. 2012 Jan;79(1):88-9. doi: 10.1016/j.jbspin.2011.09.009. Epub 2011 Nov 15. PMID- 17432134 OWN - NLM STAT- MEDLINE DCOM- 20080424 LR - 20220408 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 32 IP - 3 DP - 2007 Feb TI - [Advances on study of treatment of lumbar disk herniation by Chinese medicinal herbs]. PG - 186-91 AB - Lumbar disk herniation (LDH) is a common orthopaedic disorder. Many clinical and basic science researches have been conducted recently on using Chinese medicinal herbs to treat LDH. Literature review reveals that the common basic formulas include Duhuo Jisheng decoction (DHJST), Buyang Huanwu decoction (HYBWT), Shentong Zhuyu decoction (STZYT), Taohong Siwu decoction (THSWT), Yanghe decoction (YHT) and Tongdu Huoxue decoction (TDHXT). A basic formula can be modified by adding more herbs or removing some herbs from the formula according to clinical symptoms and traditional Chinese medicine (TCM) syndrome differentiation. Literatures show that herbal treatment have better clinical effects, the medicinal herbs make low-back pain, sciatica and low limb numbness disappeared or alleviated; and restore normal low limb sensation, muscle strength and daily activity. These formulas have also been used to treat LDH postoperative remaining pain, postoperative discitis, postoperative recurrent LDH, and to prevent epidural scar formation and dura mata adhesion. Herbs in these formulas include 5 categories of drugs classified by TCM. They are blood circulation promoting herbs for relieving pain; liver and kidney nourishing and tendons and bones strengthening herbs; blood circulation promoting herbs for unblocking collaterals; pathogenic wind and dampness expelling herbs; and qi invigorating herbs. These herbs have actions of analgesia, anti-inflammation, immunomodulation, phagocytosis of macrophages enhancement, blood circulation improvement, nerve protection, collagen synthesis enhancement. Future research needs to focus on the effects of herbs on four aspects: to enhance collagen synthesis in the disks and inhibit disk degeneration; to promote the resorption of herniated nucleus pulposus and epidural hemorrhage; to prevent nerve cell apoptosis and promote nerve cell regeneration, and to inhibit nociception in the nerve system. FAU - Lin, Xue-juan AU - Lin XJ AD - Institute of Basic Medicine, Guzhou University of Traditional Chinese Medicine, Guangzhou 510405, China. lxj-llxxjj@yahoo.com.cn FAU - Chen, Chao-yang AU - Chen CY LA - chi PT - English Abstract PT - Journal Article PT - Review PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Drug Combinations) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Diagnosis, Differential MH - Drug Combinations MH - Drugs, Chinese Herbal/isolation & purification/*therapeutic use MH - Humans MH - Intervertebral Disc Displacement/*drug therapy MH - *Lumbar Vertebrae MH - Medicine, Chinese Traditional MH - *Phytotherapy MH - Plants, Medicinal/chemistry RF - 52 EDAT- 2007/04/17 09:00 MHDA- 2008/04/25 09:00 CRDT- 2007/04/17 09:00 PHST- 2007/04/17 09:00 [pubmed] PHST- 2008/04/25 09:00 [medline] PHST- 2007/04/17 09:00 [entrez] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2007 Feb;32(3):186-91. PMID- 22982344 OWN - NLM STAT- MEDLINE DCOM- 20130107 LR - 20131121 IS - 1879-0631 (Electronic) IS - 0024-3205 (Linking) VI - 91 IP - 17-18 DP - 2012 Oct 29 TI - Structural and biochemical alterations during the healing process of tendons treated with Aloe vera. PG - 885-93 LID - S0024-3205(12)00486-9 [pii] LID - 10.1016/j.lfs.2012.09.002 [doi] AB - AIMS: The tendon is composed of highly organized collagen fibers that form a complex supramolecular structure. After lesions, the organization and composition of the tendon are not completely restored. Our purpose was to evaluate if the application of Aloe vera improves tendon healing, considering the effectiveness in the stimulus of collagen synthesis. MAIN METHODS: The calcaneal tendon of male Wistar rats was partially transected with subsequent topical application of A. vera ointment at the injury. The animals were separated into groups with tendons treated with the A. vera extract for 7days and excised on the 7th, 14th and 21st days after surgery; control rats received only ointment base without plant extract. KEY FINDINGS: Morphological analysis using polarization microscopy showed that the entire tendon undergoes a remodeling process, with disorganized collagen fibers by days 7 and 14 in plant-treated and non-treated groups and with a higher birefringence in tendons of the plant-treated group on the 21st day. A higher concentration of hydroxyproline was found in plant-treated tendons on days 7 and 14 compared with their controls. Western blots showed lower amounts of type I collagen in the plant-treated group on day 14 compared with the control. MMP-9 diminished 14days after lesion and the active isoform of MMP-2 increased on day 21 in plant-treated groups. SIGNIFICANCE: The present study indicates a beneficial effect of A. vera in the tissue reorganization in the transected region of the tendon 21days after injury and is supported by an increase of active MMP-2. CI - Copyright © 2012 Elsevier Inc. All rights reserved. FAU - Aro, A A AU - Aro AA AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas-UNICAMP, Campinas-SP, Brazil. andreaaro@ig.com.br FAU - Nishan, U AU - Nishan U FAU - Perez, M O AU - Perez MO FAU - Rodrigues, R A AU - Rodrigues RA FAU - Foglio, M A AU - Foglio MA FAU - Carvalho, J E AU - Carvalho JE FAU - Gomes, L AU - Gomes L FAU - Vidal, B C AU - Vidal BC FAU - Pimentel, E R AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120912 PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Ointments) RN - 0 (Plant Preparations) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - *Aloe/chemistry MH - Animals MH - Collagen/metabolism/ultrastructure MH - Hydroxyproline/analysis MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Ointments MH - *Phytotherapy/methods MH - Plant Preparations/administration & dosage/*therapeutic use MH - Rats MH - Rats, Wistar MH - Tendon Injuries/drug therapy MH - Tendons/*drug effects/metabolism/pathology MH - Wound Healing/*drug effects EDAT- 2012/09/18 06:00 MHDA- 2013/01/08 06:00 CRDT- 2012/09/18 06:00 PHST- 2012/06/08 00:00 [received] PHST- 2012/08/11 00:00 [revised] PHST- 2012/09/04 00:00 [accepted] PHST- 2012/09/18 06:00 [entrez] PHST- 2012/09/18 06:00 [pubmed] PHST- 2013/01/08 06:00 [medline] AID - S0024-3205(12)00486-9 [pii] AID - 10.1016/j.lfs.2012.09.002 [doi] PST - ppublish SO - Life Sci. 2012 Oct 29;91(17-18):885-93. doi: 10.1016/j.lfs.2012.09.002. Epub 2012 Sep 12. PMID- 38053726 OWN - NLM STAT- MEDLINE DCOM- 20231207 LR - 20240304 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 14 DP - 2023 TI - Untargeted metabolomics reveals dynamic changes in metabolic profiles of rat supraspinatus tendon at three different time points after diabetes induction. PG - 1292103 LID - 10.3389/fendo.2023.1292103 [doi] LID - 1292103 AB - OBJECTIVE: To investigate the dynamic changes of metabolite composition in rat supraspinatus tendons at different stages of diabetes by untargeted metabolomics analysis. METHODS: A total of 80 Sprague-Dawley rats were randomly divided into normal (NG, n = 20) and type 2 diabetes mellitus groups (T2DM, n = 60) and subdivided into three groups according to the duration of diabetes: T2DM-4w, T2DM-12w, and T2DM-24w groups; the duration was calculated from the time point of T2DM rat model establishment. The three comparison groups were set up in this study, T2DM-4w group vs. NG, T2DM-12w group vs. T2DM-4w group, and T2DM-24w group vs. T2DM-12w group. The metabolite profiles of supraspinatus tendon were obtained using tandem mass spectrometry. Metabolomics multivariate statistics were used for metabolic data analysis and differential metabolite (DEM) determination. The intersection of the three comparison groups' DEMs was defined as key metabolites that changed consistently in the supraspinatus tendon after diabetes induction; then, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed. RESULTS: T2DM-4w group vs. NG, T2DM-12w group vs. T2DM-4w group, and T2DM-24w group vs. T2DM-12w group detected 94 (86 up-regulated and 8 down-regulated), 36 (13 up-regulated and 23 down-regulated) and 86 (24 up-regulated and 62 down-regulated) DEMs, respectively. Seven key metabolites of sustained changes in the supraspinatus tendon following induction of diabetes include D-Lactic acid, xanthine, O-acetyl-L-carnitine, isoleucylproline, propoxycarbazone, uric acid, and cytidine, which are the first identified biomarkers of the supraspinatus tendon as it progresses through the course of diabetes. The results of KEGG pathway enrichment analysis showed that the main pathway of supraspinatus metabolism affected by diabetes (p < 0.05) was purine metabolism. The results of the KEGG metabolic pathway vs. DEMs correlation network graph revealed that uric acid and xanthine play a role in more metabolic pathways. CONCLUSION: Untargeted metabolomics revealed the dynamic changes of metabolite composition in rat supraspinatus tendons at different stages of diabetes, and the newly discovered seven metabolites, especially uric acid and xanthine, may provide novel research to elucidate the mechanism of diabetes-induced tendinopathy. CI - Copyright © 2023 Xu, Zhang, Wang, Ren, Yu, Zhang and Zhao. FAU - Xu, Kuishuai AU - Xu K AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Zhang, Liang AU - Zhang L AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Wang, Tianrui AU - Wang T AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Ren, Zhongkai AU - Ren Z AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Yu, Tengbo AU - Yu T AD - Department of Sports Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Zhang, Yingze AU - Zhang Y AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. FAU - Zhao, Xia AU - Zhao X AD - Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, China. LA - eng PT - Comment PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231120 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - 268B43MJ25 (Uric Acid) SB - IM CON - J Orthop Res. 2022 Apr;40(4):965-976. doi: 10.1002/jor.25112. PMID: 34081345 MH - Rats MH - Animals MH - *Rotator Cuff/chemistry/metabolism MH - *Diabetes Mellitus, Type 2/metabolism MH - Rats, Sprague-Dawley MH - Uric Acid MH - Metabolome PMC - PMC10694349 OTO - NOTNLM OT - biomarker discovery OT - diabetes mellitus OT - metabolomics OT - progression OT - rotator cuff OT - supraspinatus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/12/06 06:42 MHDA- 2023/12/07 12:42 PMCR- 2023/01/01 CRDT- 2023/12/06 04:09 PHST- 2023/09/11 00:00 [received] PHST- 2023/11/01 00:00 [accepted] PHST- 2023/12/07 12:42 [medline] PHST- 2023/12/06 06:42 [pubmed] PHST- 2023/12/06 04:09 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2023.1292103 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2023 Nov 20;14:1292103. doi: 10.3389/fendo.2023.1292103. eCollection 2023. PMID- 36828196 OWN - NLM STAT- MEDLINE DCOM- 20230327 LR - 20230327 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 309 DP - 2023 Jun 12 TI - Exploring active ingredients of anti-osteoarthritis in raw and wine-processed Dipsaci Radix based on spectrum-effect relationship combined with chemometrics. PG - 116281 LID - S0378-8741(23)00149-6 [pii] LID - 10.1016/j.jep.2023.116281 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Dipsaci Radix (DR) is the dry root of the Dipsacus asper Wall. ex DC., which has the function of tonifying the liver and kidney, continuing tendons and bones, and regulating blood vessels. However, there are few reports on the main active ingredients. AIM OF THE STUDY: This study aimed to find the main active components of DR in the treatment of osteoarthritis (OA) by spectrum-effect relationship and compare the differences between RDR and WDR. MATERIALS AND METHODS: Firstly, the high-performance liquid chromatography (HPLC) method was used to establish the fingerprint of DR, and 10 peaks of them were determined by UPLC-Q-TOF/MS. Then, the OA rat model was established by injecting sodium iodoacetate to study the effect of DR on OA. The spectrum-effect relationship was analyzed by grey relational analysis (GRA) and Pearson correlation analysis. RESULTS: According to the pharmacological results, compared with the model group, the cartilage score, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), and Mankin score of rats in low, medium and high dose groups were decreased, and the therapeutic effect of wine-processed DR tended to be better than raw DR at the same dose. Finally, the active components of DR were preliminarily determined as 4 (loganic acid), 6 (chlorogenic acid), 8 (caffeic acid), 14 (dipsanoside B), 16, and 17 (asperosaponin VI) which had a large correlation in GRA and Pearson correlation analysis. CONCLUSION: This study established the spectrum-effect relationship between the raw and wine-processed DR for the first time, which provided a theoretical basis for the study of the pharmacodynamic substance basis of DR before and after processing. This research provided a reference for the subsequent study of DR. CI - Copyright © 2023 Elsevier B.V. All rights reserved. FAU - Lv, Yue AU - Lv Y AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. Electronic address: 1132126021@qq.com. FAU - Wu, Hangsha AU - Wu H AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. Electronic address: whs540412@163.com. FAU - Hong, Zhihui AU - Hong Z AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. FAU - Wei, Feiyang AU - Wei F AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. FAU - Zhao, Mingfang AU - Zhao M AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. FAU - Tang, Rui AU - Tang R AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. FAU - Li, Yafei AU - Li Y AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China. FAU - Ge, Weihong AU - Ge W AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China; Research Center of TCM Processing Technology, Zhejiang Chinese Medical University, Hangzhou, 311401, PR China; Zhejiang Chinese Medical University Chinese Medicine Yinpian Co., Ltd., Hangzhou, 311401, PR China. Electronic address: geweihong@hotmail.com. FAU - Li, Changyu AU - Li C AD - Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, PR China. FAU - Du, Weifeng AU - Du W AD - School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 311400, PR China; Research Center of TCM Processing Technology, Zhejiang Chinese Medical University, Hangzhou, 311401, PR China; Zhejiang Chinese Medical University Chinese Medicine Yinpian Co., Ltd., Hangzhou, 311401, PR China. Electronic address: duweifeng_200158@sohu.com. LA - eng PT - Journal Article DEP - 20230223 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Rats MH - Animals MH - *Drugs, Chinese Herbal/pharmacology/therapeutic use/analysis MH - *Wine/analysis MH - Chemometrics MH - *Dipsacaceae/chemistry MH - Chromatography, High Pressure Liquid/methods OTO - NOTNLM OT - Dipsaci Radix OT - HPLC-Fingerprint OT - Osteoarthritis OT - Spectrum-effect relationship OT - Wine-processed COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/02/25 06:00 MHDA- 2023/03/28 06:00 CRDT- 2023/02/24 19:27 PHST- 2022/10/24 00:00 [received] PHST- 2023/01/31 00:00 [revised] PHST- 2023/02/12 00:00 [accepted] PHST- 2023/02/25 06:00 [pubmed] PHST- 2023/03/28 06:00 [medline] PHST- 2023/02/24 19:27 [entrez] AID - S0378-8741(23)00149-6 [pii] AID - 10.1016/j.jep.2023.116281 [doi] PST - ppublish SO - J Ethnopharmacol. 2023 Jun 12;309:116281. doi: 10.1016/j.jep.2023.116281. Epub 2023 Feb 23. PMID- 9973973 OWN - NLM STAT- MEDLINE DCOM- 19990225 LR - 20131121 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 358 DP - 1999 Jan TI - Marginal excision for osteosarcoma with caffeine assisted chemotherapy. PG - 27-35 AB - The authors report on intentional marginal excision for osteosarcoma in conjunction with caffeine assisted chemotherapy for the purpose of preservation of good limb function. Twenty-seven patients with osteosarcoma (22 patients with Stage IIB and five with Stage IIIB) preoperatively were given three-to-five courses of intraarterial cisplatin and caffeine without or with doxorubicin. For 26 (96%) responders to the chemotherapy, limb salvage surgery was conducted by means of an intentional marginal procedure, which led to the preservation of important structures such as major neurovascular bundles, tendons, ligaments, muscles, and the epiphysis. Tumors were located in the distal femur in 11 patients, the proximal tibia in eight, the proximal fibula in four, the proximal humerus in two, and the proximal femur in one patient. The histologic response of these 26 patients to the preoperative chemotherapy showed no viable cells in 19 patients with Stage IIB osteosarcoma and only scattered foci of viable cells in two patients with Stage IIB and five patients with Stage IIIB osteosarcoma. As for reconstruction, distraction osteogenesis was performed in eight patients, allograft or autoclaved bone and prosthesis composite in four, autoclaved bone in two, osteochondral allograft in two, megaprosthesis in six, and resection alone in four patients. The average functional evaluation of the 26 patients was 91% of normal. Local tumor recurrence was seen in one patient, whereas 18 patients with Stage IIB osteosarcoma remain diseasefree with a mean followup of 61 months. Two patients with Stage IIB osteosarcoma and four patients with osteosarcoma Stage IIIB died of the disease. Intentional marginal excision for osteosarcoma in conjunction with caffeine assisted chemotherapy is advantageous because it results in the preservation of healthy important structures, with joint preservation possible in selected cases. This approach should help to improve the success rate of limb salvage surgery for osteosarcoma and to preserve the function of the affected limb. FAU - Tsuchiya, H AU - Tsuchiya H AD - Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Japan. FAU - Tomita, K AU - Tomita K FAU - Mori, Y AU - Mori Y FAU - Asada, N AU - Asada N FAU - Yamamoto, N AU - Yamamoto N LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Antineoplastic Agents) RN - 0 (Phosphodiesterase Inhibitors) RN - 3G6A5W338E (Caffeine) RN - 80168379AG (Doxorubicin) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adolescent MH - Adult MH - Antineoplastic Agents/*therapeutic use MH - Bone Neoplasms/drug therapy/mortality/*surgery MH - Bone Transplantation MH - Caffeine/*therapeutic use MH - Child MH - Cisplatin/*therapeutic use MH - Doxorubicin/therapeutic use MH - Drug Synergism MH - Female MH - Femoral Neoplasms/drug therapy/surgery MH - Fibula MH - Humans MH - Humerus MH - Infusions, Intra-Arterial MH - Male MH - Osteosarcoma/drug therapy/mortality/*surgery MH - Phosphodiesterase Inhibitors/*therapeutic use MH - *Premedication MH - Survival Analysis MH - Tibia MH - Treatment Outcome EDAT- 1999/02/12 00:00 MHDA- 1999/02/12 00:01 CRDT- 1999/02/12 00:00 PHST- 1999/02/12 00:00 [pubmed] PHST- 1999/02/12 00:01 [medline] PHST- 1999/02/12 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1999 Jan;(358):27-35. PMID- 11285785 OWN - NLM STAT- MEDLINE DCOM- 20010419 LR - 20161209 IS - 0755-4982 (Print) IS - 0755-4982 (Linking) VI - 30 IP - 9 DP - 2001 Mar 10 TI - [Gait disorders in Parkinson disease. Clinical description, analysis of posture, initiation of stabilized gait]. PG - 452-9 AB - A WELL INFORMED DESCRIPTION: The parkinsonian posture is generally described as a stooped one. At the beginning of the disease, the gait troubles remain moderate; gradually the gait is composed of small steps without a wide base; the patient tends to run after his centre of gravity by accelerating the step (festination phenomenon). Difficulties occurs for starting up (delay of gait initiation), for about-turn or for clearing obstacles. Kinetic jammings and standing around (freezing) can last several seconds and be responsible for falls. POSTURAL INSTABILITY, A MAJOR SYMPTOM IN PARKINSON'S DISEASE: This symptom is little improved by therapies and is responsible for serious disability. Postural instability induces a disequilibrium and is partially due to a simultaneous antagonist muscles contraction and to the impossibility of modifying postural responses to changing support conditions. The passive viscoelastic properties of muscles and tendons constitute a first line of defence against the disequilibrium and contribute to postural stability in the case of medium disturbances. Automatic and voluntary postural responses which come into play in the case of major disturbances can also be impaired (delay or defect of the responses). GAIT INITIATION FAILURE ARE FREQUENT: They result from an increase of the postural phase and a decrease of the propulsion forces, depending on a deficit of the postural anticipation mechanisms and also the sequential organization and the integration of two different motor programs, postural and locomotor. They can be controlled partially with sensory stimuli, notably visual inputs. DATA CONCERNING STABILIZED WALKING AND ITS PATHOPHYSIOLOGY REMAINS TO BE CLARIFIED: Spatial and temporal parameters are impaired: speed, step length and swing phase are reduced, while cadence increases to compensate these troubles. These modifications are the consequence of an incapacity to produce internal marks to generate regular steps. When the parkinsonian patient is supplied with external marks, these parameters can be normalized. From a pathophysiological point of view, gait disorders could result from defective central integration of proprioceptive information during movement within the basal ganglia, associated with a visual perceptive deficit linked with a retinal dopaminergic cells dysfunction and finally from an impairment of the proprioceptive feedback of the load receptors in the leg extensor muscles. FAU - Kemoun, G AU - Kemoun G AD - Service de Neurologie et Pathologie du Mouvement, Hôpital Salengro, CHRU F 59037 Lille. FAU - Defebvre, L AU - Defebvre L LA - fre PT - English Abstract PT - Journal Article PT - Review TT - Troubles de la marche dans la maladie de Parkinson. Description clinique, analyse de la posture, de l'initiation et de la marche stabilisée. PL - France TA - Presse Med JT - Presse medicale (Paris, France : 1983) JID - 8302490 RN - 0 (Antiparkinson Agents) RN - 46627O600J (Levodopa) SB - IM MH - Antiparkinson Agents/adverse effects/therapeutic use MH - Basal Ganglia/drug effects MH - *Gait/drug effects MH - Humans MH - Levodopa/adverse effects/therapeutic use MH - Parkinson Disease/*diagnosis/drug therapy MH - Postural Balance/drug effects MH - *Posture MH - *Walking RF - 48 EDAT- 2001/04/05 10:00 MHDA- 2001/04/21 10:01 CRDT- 2001/04/05 10:00 PHST- 2001/04/05 10:00 [pubmed] PHST- 2001/04/21 10:01 [medline] PHST- 2001/04/05 10:00 [entrez] PST - ppublish SO - Presse Med. 2001 Mar 10;30(9):452-9. PMID- 21490198 OWN - NLM STAT- MEDLINE DCOM- 20110613 LR - 20211020 IS - 1529-2401 (Electronic) IS - 0270-6474 (Print) IS - 0270-6474 (Linking) VI - 31 IP - 15 DP - 2011 Apr 13 TI - Extra forces evoked during electrical stimulation of the muscle or its nerve are generated and modulated by a length-dependent intrinsic property of muscle in humans and cats. PG - 5579-88 LID - 10.1523/JNEUROSCI.6641-10.2011 [doi] AB - Extra forces or torques are defined as forces or torques that are larger than would be expected from the input or stimuli, which can be mediated by properties intrinsic to motoneurons and/or to the muscle. The purpose of this study was to determine whether extra forces/torques evoked during electrical stimulation of the muscle or its nerve with variable frequency stimulation are modulated by muscle length/joint angle. A secondary aim was to determine whether extra forces/torques are generated by an intrinsic neuronal or muscle property. Experiments were conducted in 14 able-bodied human subjects and in eight adult decerebrate cats. Torque and force were measured in human and cat experiments, respectively. Extra forces/torques were evoked by stimulating muscles with surface electrodes (human experiments) or by stimulating the nerve with cuff electrodes (cat experiments). In humans and cats, extra forces/torques were larger at short muscle lengths, indicating that a similar regulatory mechanism is involved. In decerebrate cats, extra forces and length-dependent modulation were unaffected by intrathecal methoxamine injections, despite evidence of increased spinal excitability, and by transecting the sciatic nerve proximal to the nerve stimulations. Anesthetic nerve block experiments in two human subjects also failed to abolish extra torques and the length-dependent modulation. Therefore, these data indicate that extra forces/torques evoked during electrical stimulation of the muscle or nerve are muscle length-dependent and primarily mediated by an intrinsic muscle property. FAU - Frigon, Alain AU - Frigon A AD - Department of Physiology and Biophysics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada J1H 5N4. frigon.alain@gmail.com FAU - Thompson, Christopher K AU - Thompson CK FAU - Johnson, Michael D AU - Johnson MD FAU - Manuel, Marin AU - Manuel M FAU - Hornby, T George AU - Hornby TG FAU - Heckman, C J AU - Heckman CJ LA - eng GR - R01 NS034382/NS/NINDS NIH HHS/United States GR - NS034382/NS/NINDS NIH HHS/United States GR - CAPMC/CIHR/Canada PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Neurosci JT - The Journal of neuroscience : the official journal of the Society for Neuroscience JID - 8102140 RN - 0 (Adrenergic alpha-Agonists) RN - HUQ1KC1YLI (Methoxamine) SB - IM MH - Adrenergic alpha-Agonists/administration & dosage/pharmacology MH - Animals MH - Ankle/innervation/physiology MH - Cats MH - Data Interpretation, Statistical MH - Decerebrate State/physiopathology MH - Electric Stimulation MH - Female MH - Humans MH - Joints/innervation/physiology MH - Laminectomy MH - Male MH - Methoxamine/administration & dosage/pharmacology MH - Motor Neurons/physiology MH - Muscle Contraction/physiology MH - Muscle Denervation MH - Muscle, Skeletal/*innervation/*physiology MH - Nerve Block MH - Peripheral Nerves/*physiology MH - Sciatic Nerve/drug effects/physiology MH - Spinal Cord/cytology/physiology MH - Tendons/physiology MH - Vibration PMC - PMC4115248 MID - NIHMS606368 EDAT- 2011/04/15 06:00 MHDA- 2011/06/15 06:00 PMCR- 2011/10/13 CRDT- 2011/04/15 06:00 PHST- 2011/04/15 06:00 [entrez] PHST- 2011/04/15 06:00 [pubmed] PHST- 2011/06/15 06:00 [medline] PHST- 2011/10/13 00:00 [pmc-release] AID - 31/15/5579 [pii] AID - 3684713 [pii] AID - 10.1523/JNEUROSCI.6641-10.2011 [doi] PST - ppublish SO - J Neurosci. 2011 Apr 13;31(15):5579-88. doi: 10.1523/JNEUROSCI.6641-10.2011. PMID- 32532323 OWN - NLM STAT- MEDLINE DCOM- 20210305 LR - 20210305 IS - 1756-0500 (Electronic) IS - 1756-0500 (Linking) VI - 13 IP - 1 DP - 2020 Jun 12 TI - Determination of efficacy and toxicity of diclofenac microemulsion formulation for musculoskeletal pain: an observational study. PG - 285 LID - 10.1186/s13104-020-05120-3 [doi] LID - 285 AB - OBJECTIVE: Musculoskeletal pain is often caused by injury to the bones, muscles, tendons, ligaments or nerves. Symptoms can be localized or generalized. Mild-moderate symptoms are treated with topical/oral over the counter drugs. Microemulsion delivery formulations are thermodynamically stable, have superior bioavailability and better penetration of lipophilic and hydrophilic drug into the dermis. A prospective observational study in patients: 18 years or older, with mild-moderate musculoskeletal pain; with severe pain without adequate pain control; with severe pain and could not tolerate oral agents; with renal impairment were invited to try diclofenac 2% in microemulsion foam. They were followed up at 2 and 4 weeks. A 50% reduction on a visual analog pain scale was considered success. Adverse events were defined as irritation, gastrointestinal upset/bleed, rectal bleed, and hematemesis. The objective was to determine the efficacy and toxicity of diclofenac 2% in microemulsion foam. RESULTS: Thirteen consecutive patients with musculoskeletal pain consented to participate. Two patients were lost to follow up. Two of the 11 patients reported minimal improvement, while nine patients reported minimum 50% reduction. No adverse effects were reported. Diclofenac 2% in microemulsion foam is effective in the treatment of mild to moderate musculoskeletal pain and well tolerated. FAU - Banh, Hoan Linh AU - Banh HL AUID- ORCID: 0000-0003-1997-7156 AD - Department of Family Medicine/Faculty of Medicine and Dentistry, University of Alberta, 6-10 University Terrace, Edmonton, AB, T6G 2T4, Canada. hoan@ualberta.ca. FAU - Cave, Andrew AU - Cave A AD - Department of Family Medicine/Faculty of Medicine and Dentistry, University of Alberta, 6-10 University Terrace, Edmonton, AB, T6G 2T4, Canada. LA - eng PT - Journal Article PT - Observational Study DEP - 20200612 PL - England TA - BMC Res Notes JT - BMC research notes JID - 101462768 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Emulsions) RN - 144O8QL0L1 (Diclofenac) SB - IM MH - Administration, Topical MH - Aged MH - Aged, 80 and over MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/toxicity MH - Diclofenac/*administration & dosage/toxicity MH - Drug Compounding MH - Emulsions MH - Female MH - Humans MH - Male MH - Middle Aged MH - Musculoskeletal Pain/*drug therapy MH - *Outcome Assessment, Health Care MH - Prospective Studies PMC - PMC7291466 OTO - NOTNLM OT - Diclofenac OT - Microemulsion OT - Pain OT - Topical foam OT - Transdermal formulation COIS- Both authors have no conflict of interest to declare. EDAT- 2020/06/14 06:00 MHDA- 2021/03/06 06:00 PMCR- 2020/06/12 CRDT- 2020/06/14 06:00 PHST- 2020/01/16 00:00 [received] PHST- 2020/05/30 00:00 [accepted] PHST- 2020/06/14 06:00 [entrez] PHST- 2020/06/14 06:00 [pubmed] PHST- 2021/03/06 06:00 [medline] PHST- 2020/06/12 00:00 [pmc-release] AID - 10.1186/s13104-020-05120-3 [pii] AID - 5120 [pii] AID - 10.1186/s13104-020-05120-3 [doi] PST - epublish SO - BMC Res Notes. 2020 Jun 12;13(1):285. doi: 10.1186/s13104-020-05120-3. PMID- 35666137 OWN - NLM STAT- MEDLINE DCOM- 20220718 LR - 20250728 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 50 IP - 9 DP - 2022 Jul TI - Celecoxib, Beyond Anti-inflammation, Alleviates Tendon-Derived Stem Cell Senescence in Degenerative Rotator Cuff Tendinopathy. PG - 2488-2496 LID - 10.1177/03635465221098133 [doi] AB - BACKGROUND: Degenerative rotator cuff tendinopathy (RCT) is associated with the senescence of tendon-derived stem cells (TDSCs). Nonsteroidal anti-inflammatory drugs have been demonstrated to alleviate age-associated inflammation (inflamm-aging)-induced cellular senescence of skeletal stem/progenitor cells. However, whether they can alleviate degenerative RCT through reducing inflamm-aging-related TDSC senescence is still unknown. PURPOSE: To assess whether celecoxib can prevent the inflamm-aging-related cellular senescence of TDSCs. STUDY DESIGN: Controlled laboratory study. METHODS: TDSCs were isolated from degenerative RCT tendons (S-TDSCs) and healthy hamstring tendons (Y-TDSCs), and the cellular senescence of TDSCs was evaluated. Thereafter, the senescent TDSC-conditioned medium (SEN-CM) was collected to culture Y-TDSCs with or without celecoxib. The effects of celecoxib on TDSC senescence were examined by assaying the expression of aging-related markers. Furthermore, the level of the NF-κB pathway was determined by Western blot analysis to explore the underlying mechanism. Its effects on preventing dysfunction of inflamm-aging-induced senescent TDSCs were also determined using multilineage differentiation assay. RESULTS: S-TDSCs showed increased senescence-associated β-galactosidase activity and enhanced expression of γ-H2AX, p21(CIP1A), p16(INK4A), and senescence-associated secretory phenotype factors. SEN-CM accelerated the senescence progress of Y-TDSCs, resulting in an increase in senescence markers. To some extent, celecoxib treatment could prevent the detrimental effects of inflamm-aging on Y-TDSCs. The level of the NF-κB pathway was increased in the SEN-CM group but decreased with the use of celecoxib. Moreover, the reduced senescence of TDSCs resulted in preservation of the TDSC tenogenic potential. CONCLUSION: Celecoxib treatment can prevent inflamm-aging-induced TDSC senescence, which holds potential for alleviating the development of degenerative RCT. CLINICAL RELEVANCE: In addition to relieving the symptoms of patients with RCT, treatment with celecoxib, a common nonsteroidal anti-inflammatory drug, may defer the development of RCT and prevent rotator cuff tears by delaying TDSC senescence. FAU - Cai, Zhuochang AU - Cai Z AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Zhang, Yao AU - Zhang Y AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Liu, Shen AU - Liu S AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Liu, Xudong AU - Liu X AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220606 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents) RN - 0 (NF-kappa B) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Anti-Inflammatory Agents/pharmacology/therapeutic use MH - *Celecoxib/metabolism/pharmacology/therapeutic use MH - Cell Differentiation MH - *Cellular Senescence/drug effects MH - Humans MH - NF-kappa B/metabolism/pharmacology MH - Rotator Cuff/pathology MH - *Stem Cells/drug effects/metabolism MH - *Tendinopathy/drug therapy/metabolism MH - Tendons/drug effects/pathology OTO - NOTNLM OT - celecoxib OT - cellular senescence OT - nonsteroidal anti-inflammatory drugs OT - rotator cuff tendinopathy OT - tendon-derived stem cells EDAT- 2022/06/07 06:00 MHDA- 2022/07/19 06:00 CRDT- 2022/06/06 15:21 PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/07/19 06:00 [medline] PHST- 2022/06/06 15:21 [entrez] AID - 10.1177/03635465221098133 [doi] PST - ppublish SO - Am J Sports Med. 2022 Jul;50(9):2488-2496. doi: 10.1177/03635465221098133. Epub 2022 Jun 6. PMID- 26742649 OWN - NLM STAT- MEDLINE DCOM- 20170919 LR - 20171201 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 34 IP - 9 DP - 2016 Sep TI - Effects of lidocaine on torn rotator cuff tendons. PG - 1620-7 LID - 10.1002/jor.23153 [doi] AB - We determined lidocaine's action on torn rotator cuff tendons in vitro and in vivo. For in vitro experiments, cell proliferation and viability assays were performed using tenocytes derived from human torn rotator cuff tendons. For in vivo experiments, acute rotator cuff tears were made on the supraspinatus tendons in the rats' bilateral shoulders; before closure, lidocaine was injected into the shoulder and saline into the contralateral shoulder (control). After sacrifice, the specimens underwent biomechanical testing or histological analysis at 24 h and at 2, 4, and 8 weeks after surgery. The extent of collagen organization and apoptosis were semi-quantitatively evaluated using collagen picrosirius red staining. Apoptosis was examined using TUNEL staining and electron microscopy. Cell proliferation decreased dose-dependently. After exposure to 0.1% lidocaine for 24 h, cell viability decreased. Two and 4 weeks after surgery, the ultimate load to failure decreased more in the lidocaine group than in the control group, with significantly reduced stiffness in the lidocaine group 2 weeks after surgery. Collagen organization significantly decreased in the lidocaine group by 4 weeks after surgery but returned to baseline at 8 weeks. TUNEL staining detected numerous apoptotic tenocytes at the torn tendon edge exposed to lidocaine 24 h after surgery; electron microscopy confirmed the condensed cell nuclei. These changes were not observed in controls. Lidocaine caused cytotoxicity to tenocytes under both conditions, decreased biomechanical properties, and induced apoptosis and delay of collagen organization in this model. Subacromial lidocaine injections in patients with rotator cuff tears should be performed carefully. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1620-1627, 2016. CI - © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Honda, Hirokazu AU - Honda H AD - Department of Orthopedic Surgery, Kurume University, Fukuoka, Japan. FAU - Gotoh, Masafumi AU - Gotoh M AD - Department of Orthopedic Surgery, Kurume University Medical Center, Fukuoka, Japan. FAU - Kanazawa, Tomonoshin AU - Kanazawa T AD - Department of Orthopedic Surgery, Kurume University, Fukuoka, Japan. AD - Division of Microscopic and Developmental Anatomy, Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan. FAU - Nakamura, Hidehiro AU - Nakamura H AD - Department of Orthopedic Surgery, Kurume University, Fukuoka, Japan. FAU - Ohta, Keisuke AU - Ohta K AD - Division of Microscopic and Developmental Anatomy, Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan. FAU - Nakamura, Kei-Ichiro AU - Nakamura K AD - Division of Microscopic and Developmental Anatomy, Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan. FAU - Shiba, Naoto AU - Shiba N AD - Department of Orthopedic Surgery, Kurume University, Fukuoka, Japan. LA - eng PT - Journal Article DEP - 20160211 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Aged MH - Anesthetics, Local/*adverse effects MH - Animals MH - Apoptosis/drug effects MH - Cell Proliferation/drug effects MH - Female MH - Humans MH - Lidocaine/*adverse effects MH - Male MH - Middle Aged MH - Rats, Sprague-Dawley MH - Rotator Cuff/*drug effects MH - *Rotator Cuff Injuries MH - Tenocytes/*drug effects/ultrastructure OTO - NOTNLM OT - lidocaine OT - rotator cuff OT - tendons OT - tenocytes EDAT- 2016/01/09 06:00 MHDA- 2017/09/20 06:00 CRDT- 2016/01/09 06:00 PHST- 2015/10/02 00:00 [received] PHST- 2016/01/04 00:00 [accepted] PHST- 2016/01/09 06:00 [entrez] PHST- 2016/01/09 06:00 [pubmed] PHST- 2017/09/20 06:00 [medline] AID - 10.1002/jor.23153 [doi] PST - ppublish SO - J Orthop Res. 2016 Sep;34(9):1620-7. doi: 10.1002/jor.23153. Epub 2016 Feb 11. PMID- 23982408 OWN - NLM STAT- MEDLINE DCOM- 20140911 LR - 20220331 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 472 IP - 8 DP - 2014 Aug TI - The detrimental effects of systemic Ibuprofen delivery on tendon healing are time-dependent. PG - 2433-9 LID - 10.1007/s11999-013-3258-2 [doi] AB - BACKGROUND: Current clinical treatment after tendon repairs often includes prescribing NSAIDs to limit pain and inflammation. The negative influence of NSAIDs on bone repair is well documented, but their effects on tendon healing are less clear. While NSAIDs may be detrimental to early tendon healing, some evidence suggests that they may improve healing if administered later in the repair process. QUESTIONS/PURPOSES: We asked whether the biomechanical and histologic effects of systemic ibuprofen administration on tendon healing are influenced by either immediate or delayed drug administration. METHODS: After bilateral supraspinatus detachment and repair surgeries, rats were divided into groups and given ibuprofen orally for either Days 0 to 7 (early) or Days 8 to 14 (delayed) after surgery; a control group did not receive ibuprofen. Healing was evaluated at 1, 2, and 4 weeks postsurgery through biomechanical testing and histologic assessment. RESULTS: Biomechanical evaluation resulted in decreased stiffness and modulus at 4 weeks postsurgery for early ibuprofen delivery (mean ± SD [95% CI]: 10.8 ± 6.4 N/mm [6.7-14.8] and 8.9 ± 5.9 MPa [5.4-12.3]) when compared to control repair (20.4 ± 8.6 N/mm [16.3-24.5] and 15.7 ± 7.5 MPa [12.3-19.2]) (p = 0.003 and 0.013); however, there were no differences between the delayed ibuprofen group (18.1 ± 7.4 N/mm [14.2-22.1] and 11.5 ± 5.6 MPa [8.2-14.9]) and the control group. Histology confirmed mechanical results with reduced fiber reorganization over time in the early ibuprofen group. CONCLUSIONS: Early administration of ibuprofen in the postoperative period was detrimental to tendon healing, while delayed administration did not affect tendon healing. CLINICAL RELEVANCE: Historically, clinicians have often prescribed ibuprofen after tendon repair, but this study suggests that the timing of ibuprofen administration is critical to adequate tendon healing. This research necessitates future clinical studies investigating the use of ibuprofen for pain control after rotator cuff repair and other tendon injuries. FAU - Connizzo, Brianne K AU - Connizzo BK AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, 424 Stemmler Hall, 34th and Hamilton Walk, Philadelphia, PA, 19104, USA. FAU - Yannascoli, Sarah M AU - Yannascoli SM FAU - Tucker, Jennica J AU - Tucker JJ FAU - Caro, Adam C AU - Caro AC FAU - Riggin, Corinne N AU - Riggin CN FAU - Mauck, Robert L AU - Mauck RL FAU - Soslowsky, Louis J AU - Soslowsky LJ FAU - Steinberg, David R AU - Steinberg DR FAU - Bernstein, Joseph AU - Bernstein J LA - eng GR - I01 RX000979/RX/RRD VA/United States GR - P30 AR050950/AR/NIAMS NIH HHS/United States GR - R25 OD010986/OD/NIH HHS/United States GR - T32 AR007132/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Administration, Oral MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*toxicity MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Drug Administration Schedule MH - Elastic Modulus MH - Ibuprofen/*administration & dosage/*toxicity MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/pathology/physiopathology/*surgery MH - Tendons/*drug effects/pathology/physiopathology/*surgery MH - *Tenotomy MH - Time Factors MH - Wound Healing/*drug effects PMC - PMC4079885 EDAT- 2013/08/29 06:00 MHDA- 2014/09/12 06:00 PMCR- 2015/08/01 CRDT- 2013/08/29 06:00 PHST- 2013/08/29 06:00 [entrez] PHST- 2013/08/29 06:00 [pubmed] PHST- 2014/09/12 06:00 [medline] PHST- 2015/08/01 00:00 [pmc-release] AID - 3258 [pii] AID - 10.1007/s11999-013-3258-2 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2014 Aug;472(8):2433-9. doi: 10.1007/s11999-013-3258-2. PMID- 30378129 OWN - NLM STAT- MEDLINE DCOM- 20191114 LR - 20191114 IS - 1097-0096 (Electronic) IS - 0091-2751 (Linking) VI - 47 IP - 2 DP - 2019 Feb TI - Accuracy and efficacy of ultrasound-guided pes anserinus bursa injection. PG - 77-82 LID - 10.1002/jcu.22661 [doi] AB - PURPOSE: To compare the accuracy and efficacy of ultrasound (US)-guided versus blind pes anserinus bursa (PAB) injection in patients with pes anserinus tendinobursitis (PATB). METHODS: Forty-seven patients with clinically diagnosed PATB were randomly assigned to a US-guided group or a blind group of steroid injection. In the US-guided group, the injectate was delivered under sonographic visualization. In the blind group, the conventional technique was used without any visual guidance. After the PAB injection, the injectate location was identified using US in both groups. Treatment effects were assessed using the visual analogue scale (VAS) of knee tenderness. Outcomes were measured before, 1 week and 4 weeks after the injection. RESULTS: Both groups showed pain relieving at 1 week and 4 weeks after the injection. The injectate in the US guided group were found to be accurately at the PAB in all subjects, whereas blind group were found to be just in 4 of 22 subjects. The US-guided group showed significant improvement of both of VAS scores compared to the blind group at 1 week and 4 weeks after the injection (P < .05). CONCLUSION: Our results suggest that US-guided PAB injection is more accurate and effective than blind injection in patients with PATB. CI - © 2018 Wiley Periodicals, Inc. FAU - Lee, Jong H AU - Lee JH AUID- ORCID: 0000-0003-2489-358X AD - Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Busan, Republic of Korea. FAU - Lee, Jae U AU - Lee JU AD - Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Busan, Republic of Korea. FAU - Yoo, Seung W AU - Yoo SW AD - Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Busan, Republic of Korea. LA - eng GR - Dong-A University/ PT - Journal Article PT - Randomized Controlled Trial DEP - 20181030 PL - United States TA - J Clin Ultrasound JT - Journal of clinical ultrasound : JCU JID - 0401663 RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Adult MH - Aged MH - Anesthetics, Local/administration & dosage MH - Anti-Inflammatory Agents/administration & dosage MH - Bursa, Synovial/*diagnostic imaging MH - Bursitis/diagnostic imaging/physiopathology MH - Female MH - Humans MH - Injections, Intra-Articular MH - Knee Joint/diagnostic imaging MH - Lidocaine/*administration & dosage MH - Male MH - Middle Aged MH - Pain/diagnostic imaging/drug therapy MH - Pain Measurement MH - Tendons/diagnostic imaging MH - Triamcinolone Acetonide/*administration & dosage MH - Ultrasonography, Interventional OTO - NOTNLM OT - bursa injection OT - pes anserinus tendinobursitis OT - ultrasound EDAT- 2018/11/01 06:00 MHDA- 2019/11/15 06:00 CRDT- 2018/11/01 06:00 PHST- 2018/02/15 00:00 [received] PHST- 2018/09/03 00:00 [revised] PHST- 2018/09/27 00:00 [accepted] PHST- 2018/11/01 06:00 [pubmed] PHST- 2019/11/15 06:00 [medline] PHST- 2018/11/01 06:00 [entrez] AID - 10.1002/jcu.22661 [doi] PST - ppublish SO - J Clin Ultrasound. 2019 Feb;47(2):77-82. doi: 10.1002/jcu.22661. Epub 2018 Oct 30. PMID- 32396518 OWN - NLM STAT- MEDLINE DCOM- 20210419 LR - 20210419 IS - 2056-5933 (Electronic) IS - 2056-5933 (Linking) VI - 6 IP - 1 DP - 2020 Jan TI - Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy. LID - 10.1136/rmdopen-2019-001144 [doi] LID - e001144 AB - OBJECTIVES: To evaluate the sensitivity to change of ultrasound structural gout lesions, as defined by the Outcome Measures in Rheumatology (OMERACT) ultrasound group, in patients with gout during urate-lowering therapy (ULT). METHODS: Ultrasound (28 joints, 26 tendons) was performed in patients with microscopically verified gout initiating or increasing ULT and repeated after 3 and 6 months. Joints and tendons were evaluated by ultrasound for presence of the OMERACT structural gout lesions-double contour sign (DC), tophus, aggregates and erosion-scored binarily. A sum score was calculated at patient and lesion level. Changes at 3 and 6 months in patient sum scores and lesion scores at different locations were evaluated. RESULTS: 50 patients (48 men), mean age 68.9 (range, 30-88) years, were included. Ultrasound showed a statistically significant decrease in DC and tophus sum scores from 0 months (3.16 and 2.68, respectively) to 3 months (2.33 and 2.43) and 6 months (1.34 and 1.83) (all p<0.002). The aggregate sum score only decreased significantly from 3 to 6 months (6.02 to 5.02, p=0.002), whereas erosion sum score remained almost unchanged. All four structural lesions were most commonly found in metatarsophalangeal (MTP) 1 joints (>1 lesions bilaterally), and furthermore MTP2-4 and knee joints were common sites especially for DC. Likewise, these regions were the locations with most pronounced changes in scores. CONCLUSION: Ultrasound assessment of the OMERACT structural gout lesions scored binarily seems to be a useful tool for monitoring urate depositions during ULT. Particularly DC and tophus showed sensitivity to change after only 3 months of treatment. CI - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Christiansen, Sara Nysom AU - Christiansen SN AUID- ORCID: 0000-0002-5063-9932 AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark sara.nysom.christiansen@regionh.dk. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Østergaard, Mikkel AU - Østergaard M AUID- ORCID: 0000-0003-3690-467X AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Slot, Ole AU - Slot O AUID- ORCID: 0000-0003-4721-907X AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark. FAU - Keen, Helen AU - Keen H AD - School of Medicine and Pharmacology Fiona Stanley Hospital Unit, University of Western Australia, Perth, Western Australia, Australia. FAU - Bruyn, George A W AU - Bruyn GAW AD - Department of Rheumatology, MC Hospital Group, Lelystad, The Netherlands. FAU - D'Agostino, Maria Antonietta AU - D'Agostino MA AUID- ORCID: 0000-0002-5347-0060 AD - Rheumatology, Ambroise Paré Hospital, APHP, Université Versailles-Saint-Quentin en Yvelines, Boulogne-Billancourt, France. FAU - Terslev, Lene AU - Terslev L AUID- ORCID: 0000-0001-8193-9471 AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Glostrup, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article PT - Observational Study PL - England TA - RMD Open JT - RMD open JID - 101662038 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Female MH - Gout/*diagnostic imaging MH - Humans MH - Joints/diagnostic imaging MH - Male MH - Middle Aged MH - Musculoskeletal System/chemistry MH - *Outcome Assessment, Health Care MH - Predictive Value of Tests MH - Prospective Studies MH - Tendons/diagnostic imaging MH - *Ultrasonography MH - Uric Acid/analysis PMC - PMC6999691 OTO - NOTNLM OT - OMERACT OT - double contour sign OT - gout OT - tophus OT - ultrasound COIS- Competing interests: SNC has received speaker fees from Bristol Myers Squibb (BMS) and General Electric (GE). LT has received speakers’ fees from AbbVie, MSD, Novartis, Roche, Pfizer, General Electric (GE), Bristol Myers Squibb (BMS) and Janssen. MØ has received research support and/or consultancy/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth. EDAT- 2020/05/13 06:00 MHDA- 2021/04/20 06:00 PMCR- 2020/01/27 CRDT- 2020/05/13 06:00 PHST- 2019/11/06 00:00 [received] PHST- 2019/12/19 00:00 [revised] PHST- 2020/01/07 00:00 [accepted] PHST- 2020/05/13 06:00 [entrez] PHST- 2020/05/13 06:00 [pubmed] PHST- 2021/04/20 06:00 [medline] PHST- 2020/01/27 00:00 [pmc-release] AID - rmdopen-2019-001144 [pii] AID - 10.1136/rmdopen-2019-001144 [doi] PST - ppublish SO - RMD Open. 2020 Jan;6(1):e001144. doi: 10.1136/rmdopen-2019-001144. PMID- 32507170 OWN - NLM STAT- MEDLINE DCOM- 20210120 LR - 20210120 IS - 1879-1344 (Electronic) IS - 0144-8617 (Linking) VI - 241 DP - 2020 Aug 1 TI - Enhanced tendon restoration effects of anti-inflammatory, lactoferrin-immobilized, heparin-polymeric nanoparticles in an Achilles tendinitis rat model. PG - 116284 LID - S0144-8617(20)30458-6 [pii] LID - 10.1016/j.carbpol.2020.116284 [doi] AB - Gradual wear and tear can cause a local inflammatory response in tendons. The trauma and inflammatory reaction eventually impair the biomechanical properties of the tendon. In this study, we prepared lactoferrin-immobilized, heparin-anchored, poly(lactic-co-glycolic acid) nanoparticles (LF/Hep-PLGA NPs) and evaluated their in vitro anti-inflammatory effects on interleukin-1β (IL-1β)-treated tenocytes and in vivo tendon healing effects in a rat model of Achilles tendinitis. Long-term LF-deliverable NPs (LF/Hep-PLGA NPs) remarkably decreased mRNA levels of pro-inflammatory factors [cyclooxygenase-2 (COX-2), IL-1β, matrix metalloproteinase-3 (MMP-3), MMP-13, IL-6, and tumor necrosis factor-α (TNF-α)] and increased mRNA levels of anti-inflammatory cytokines (IL-4 and IL-10) in both IL-1β-treated tenocytes and the Achilles tendons of a collagenase-induced Achilles tendinitis rat model. Interestingly, anti-inflammatory LF/Hep-PLGA NPs greatly enhanced collagen content, mRNA levels of tenogenic markers [collagen type I (COL1A1), decorin (DCN), tenascin-C (TNC)], and biomechanical properties such as tendon stiffness and tensile strength. These results suggest that anti-inflammatory LF/Hep-PLGA NPs are effective at restoring tendons in Achilles tendinitis. CI - Copyright © 2020 Elsevier Ltd. All rights reserved. FAU - Choi, Hong Joon AU - Choi HJ AD - Department of Orthopedic Surgery, College of Medicine Korea University, Anam-dong, Seongbuk-gu, Seoul, 02841, Republic of Korea; Yonsei gunwoo Hospital, #1814, Nambusunhwan-ro, Gwanak-gu, Seoul, 08787, Republic of Korea. FAU - Choi, Somang AU - Choi S AD - Department of Biomedical Science, College of Medicine Korea University, Anam-dong, Seongbuk-gu, Seoul, 02841, Republic of Korea. FAU - Kim, Jae Gyoon AU - Kim JG AD - Department of Orthopedic Surgery, Korea University, College of Medicine, Korea University Ansan Hospital 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, 15355, Republic of Korea. FAU - Song, Mi Hyun AU - Song MH AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #80, Guro-dong, Guro-gu, Seoul, 08308, Republic of Korea. FAU - Shim, Kyu-Sik AU - Shim KS AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #80, Guro-dong, Guro-gu, Seoul, 08308, Republic of Korea. FAU - Lim, Youn-Mook AU - Lim YM AD - Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, 1266 Sinjeong-dong, Jeongeup-si, Jeollabuk-do, 56212, Republic of Korea. FAU - Kim, Hak-Jun AU - Kim HJ AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #80, Guro-dong, Guro-gu, Seoul, 08308, Republic of Korea. Electronic address: dakjul@korea.ac.kr. FAU - Park, Kyeongsoon AU - Park K AD - Department of Systems Biotechnology, Chung-Ang University, Anseong, Gyeonggi, 17546, Republic of Korea. Electronic address: kspark1223@cau.ac.kr. FAU - Kim, Sung Eun AU - Kim SE AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University Guro Hospital, #80, Guro-dong, Guro-gu, Seoul, 08308, Republic of Korea. Electronic address: sekim10@korea.ac.kr. LA - eng PT - Journal Article DEP - 20200426 PL - England TA - Carbohydr Polym JT - Carbohydrate polymers JID - 8307156 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Cytokines) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 9005-49-6 (Heparin) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.- (Lactoferrin) SB - IM MH - Achilles Tendon/*drug effects/metabolism/pathology/physiology MH - Animals MH - Anti-Inflammatory Agents/*administration & dosage/chemistry MH - Collagen/metabolism MH - Cytokines/genetics MH - Disease Models, Animal MH - Heparin/*administration & dosage/chemistry MH - Lactoferrin/*administration & dosage/chemistry MH - Male MH - Nanoparticles/*administration & dosage/chemistry MH - Polylactic Acid-Polyglycolic Acid Copolymer/*administration & dosage/chemistry MH - Rats, Sprague-Dawley MH - Tendinopathy/*drug therapy/genetics/metabolism/pathology MH - Tenocytes/drug effects MH - Tensile Strength OTO - NOTNLM OT - 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (PubChem CID: 2723939) OT - 2-(N-morpholino)-ethanesulfonic acid (PubChem CID:4478249) OT - Dichloromethane (DCM) (PubChem CID: 6344) OT - Dopamine hydrochloride (PubChem CID:65340) OT - Heparin sodium (PubChem CID: 22833565) OT - Lactoferrin (PubChem CID: 126456119, Mw: 3128.8 g/mol) OT - N-hydroxysuccinimide (NHS) (PubChem CID: 80170) OT - Poly (lactic-co-glycolic acid) (PLGA) (PubChem CID: 23111554) OT - Polyvinyl Alcohol (PVA) (PubChem CID: 11199) OT - Sodium Chloride (PubChem CID:5234) OT - inflammatory factors OT - nanoparticles OT - sustained lactoferrin delivery OT - tendon healing OT - tenocytes EDAT- 2020/06/09 06:00 MHDA- 2021/01/21 06:00 CRDT- 2020/06/09 06:00 PHST- 2020/01/29 00:00 [received] PHST- 2020/04/07 00:00 [revised] PHST- 2020/04/09 00:00 [accepted] PHST- 2020/06/09 06:00 [entrez] PHST- 2020/06/09 06:00 [pubmed] PHST- 2021/01/21 06:00 [medline] AID - S0144-8617(20)30458-6 [pii] AID - 10.1016/j.carbpol.2020.116284 [doi] PST - ppublish SO - Carbohydr Polym. 2020 Aug 1;241:116284. doi: 10.1016/j.carbpol.2020.116284. Epub 2020 Apr 26. PMID- 35298610 OWN - NLM STAT- MEDLINE DCOM- 20221201 LR - 20230109 IS - 1462-0332 (Electronic) IS - 1462-0324 (Linking) VI - 61 IP - 12 DP - 2022 Nov 28 TI - Retrospective longitudinal assessment of ultrasound gout lesions using the OMERACT semi-quantitative scoring system. PG - 4711-4721 LID - 10.1093/rheumatology/keac179 [doi] AB - OBJECTIVES: The objectives of this study were (i) to evaluate the responsiveness of gout-specific US lesions representing urate deposition in patients receiving treat-to-target urate-lowering therapy using a binary and the OMERACT-defined semi-quantitative scoring systems; (ii) to determine the most responsive US measure for urate deposition and the optimal joint/tendon set for monitoring this. METHODS: US (28 joints, 14 tendons) was performed in microscopically verified gout patients initiating/increasing urate-lowering therapy and repeated after 6 and 12 months. Static images/videos of pathologies were stored and scored binarily and semi-quantitatively for tophus, double contour sign (DC) and aggregates. Lesion scores were calculated at patient level, as were combined crystal sum scores. Responsiveness of lesions-scored binarily and semi-quantitatively-was calculated at both patient and joint/tendon levels. RESULTS: Sixty-three patients underwent longitudinal evaluation. The static images/videos assessed retrospectively showed statistically significant decreases in tophus and DC, when scored binarily and semi-quantitatively, whereas aggregates were almost unchanged during follow-up. The responsiveness of the semi-quantitative tophus and DC sum scores were markedly higher than when using binary scoring. The most responsive measure for urate deposition was a combined semi-quantitative tophus-DC-sum score. A feasible joint/tendon set for monitoring included knee and first-second MTP joints and peroneus and distal patella tendons (all bilateral), representing the most prevalent and responsive sites. CONCLUSION: The OMERACT consensus-based semi-quantitative US gout scoring system showed longitudinal validity with both tophus and DC being highly responsive to treatment when assessed in static images/videos. A responsive US measure for urate deposition and a feasible joint/tendon set for monitoring were proposed and may prove valuable in future longitudinal studies. CI - © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Christiansen, Sara Nysom AU - Christiansen SN AUID- ORCID: 0000-0002-5063-9932 AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup. FAU - Østergaard, Mikkel AU - Østergaard M AUID- ORCID: 0000-0003-3690-467X AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Slot, Ole AU - Slot O AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup. FAU - Fana, Viktoria AU - Fana V AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup. FAU - Terslev, Lene AU - Terslev L AUID- ORCID: 0000-0001-8193-9471 AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Rigshospitalet, Glostrup. AD - Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - Retrospective Studies MH - Uric Acid MH - *Gout/diagnostic imaging/drug therapy/pathology MH - Ultrasonography MH - *Arthritis, Gouty OTO - NOTNLM OT - OMERACT OT - aggregates OT - double contour OT - gout OT - longitudinal validity OT - monitoring OT - tophus OT - ultrasound EDAT- 2022/03/18 06:00 MHDA- 2022/12/02 06:00 CRDT- 2022/03/17 17:18 PHST- 2021/12/20 00:00 [received] PHST- 2022/03/07 00:00 [revised] PHST- 2022/03/18 06:00 [pubmed] PHST- 2022/12/02 06:00 [medline] PHST- 2022/03/17 17:18 [entrez] AID - 6550054 [pii] AID - 10.1093/rheumatology/keac179 [doi] PST - ppublish SO - Rheumatology (Oxford). 2022 Nov 28;61(12):4711-4721. doi: 10.1093/rheumatology/keac179. PMID- 40862690 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20250916 IS - 2576-6422 (Electronic) IS - 2576-6422 (Linking) VI - 8 IP - 9 DP - 2025 Sep 15 TI - Artificial Tendons' Responsiveness to Mechanical Stress and Biological Performance Following Cork Extract Functionalization. PG - 7652-7671 LID - 10.1021/acsabm.5c00449 [doi] AB - Hand tendon ruptures have increased due to mechanical stress, degeneration, trauma, and repetitive motion. This study proposes an artificial tendon engineered from polymeric braids made of lyocell, biodegradable polyester, and polyethylene terephthalate, functionalized with natural cork extract. Cork extract 2, obtained by cork powder using hydroethanolic solvent in a planetary mixture, exhibited a phenolic content of 508.35 ± 82.26 mg GAE/g, flavonoid content of 607.32 ± 63.96 mg EQ/g, strong antioxidant activity (EC(50) = 0.21 ± 0.02 mg/mL), and antimicrobial efficacy, with minimum bactericidal concentrations of 0.16 mg/mL against Staphylococcus aureus and 0.64 mg/mL against Pseudomonas aeruginosa. Single-polymer braids were processed with a core-shell structure, in which the core was formed of loose strands. The mechanical characterization of the braids showed the three polymers to exhibit an elongation at break of 8.72 ± 2.05-18.72 ± 6.58% and tensile strength of 44.22 ± 12.02-53.15 ± 12.62 MPa, all within desirable ranges for hand tendon repair/substitution. Braids were functionalized via physical adsorption of cork extract 2 (1.60 mg/mL), achieving loading values between 0.33 ± 0.16 and 0.55 ± 0.14 mg/mL. The presence of extract in the braids was confirmed via infrared spectroscopy and through thermal characterization, thermogravimetry, and differential scanning calorimetry. Functionalized braids exhibited controlled release of the cork extract 2, ranging from 1.57 ± 4.14 to 13.90 ± 2.02% within 24 h, ensuring sustained bioactivity, demonstrating as well strong antioxidant activity (87.42 ± 1.18 reduced 2,2-diphenyl-1-picrylhydrazyl), antimicrobial activity (achieving up to 99% reduction in S. aureus and 80% reduction in P. aeruginosa), and low cytotoxicity (>70% metabolic activity); with the functionalized lyocell presenting the best overall performance. In general, the proposed strategy demonstrated promise for hand tendon repair, offering a potential innovative solution to improve patients' quality of life. FAU - Oliveira, Bruna A S AU - Oliveira BAS AD - Centre for Textile Science and Technology (2C2T), University of Minho, Campus of Azurém, 4800-058 Guimarães, Portugal. AD - Centre of Biological Engineering (CEB), University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal. FAU - Teixeira, Marta O AU - Teixeira MO AD - Centre for Textile Science and Technology (2C2T), University of Minho, Campus of Azurém, 4800-058 Guimarães, Portugal. FAU - Gonçalves, Sónia P AU - Gonçalves SP AD - Centre for Textile Science and Technology (2C2T), University of Minho, Campus of Azurém, 4800-058 Guimarães, Portugal. FAU - Ribeiro, Artur AU - Ribeiro A AUID- ORCID: 0000-0003-3298-5564 AD - Centre of Biological Engineering (CEB), University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal. AD - LABBELS-Associate Laboratory, 4710-057 Braga, Guimarães, Portugal. FAU - Silva, Carla AU - Silva C AD - Centre of Biological Engineering (CEB), University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal. AD - LABBELS-Associate Laboratory, 4710-057 Braga, Guimarães, Portugal. FAU - Felgueiras, Helena P AU - Felgueiras HP AUID- ORCID: 0000-0002-4354-0256 AD - Centre for Textile Science and Technology (2C2T), University of Minho, Campus of Azurém, 4800-058 Guimarães, Portugal. LA - eng PT - Journal Article DEP - 20250827 PL - United States TA - ACS Appl Bio Mater JT - ACS applied bio materials JID - 101729147 RN - 0 (Plant Extracts) RN - 0 (Biocompatible Materials) RN - 0 (Anti-Bacterial Agents) RN - 0 (Antioxidants) SB - IM MH - *Plant Extracts/chemistry/pharmacology MH - *Biocompatible Materials/chemistry/pharmacology/chemical synthesis MH - Staphylococcus aureus/drug effects MH - Pseudomonas aeruginosa/drug effects MH - *Anti-Bacterial Agents/pharmacology/chemistry/chemical synthesis MH - *Quercus/chemistry MH - Materials Testing MH - Microbial Sensitivity Tests MH - Stress, Mechanical MH - Antioxidants/chemistry/pharmacology MH - *Tendons/drug effects MH - Tensile Strength MH - Particle Size MH - Humans OTO - NOTNLM OT - artificial tendons for hands OT - biodegradable and nonbiodegradable polymers OT - core−shell braiding OT - cork extract OT - multifunctional activity EDAT- 2025/08/27 12:46 MHDA- 2025/09/16 18:31 CRDT- 2025/08/27 09:53 PHST- 2025/09/16 18:31 [medline] PHST- 2025/08/27 12:46 [pubmed] PHST- 2025/08/27 09:53 [entrez] AID - 10.1021/acsabm.5c00449 [doi] PST - ppublish SO - ACS Appl Bio Mater. 2025 Sep 15;8(9):7652-7671. doi: 10.1021/acsabm.5c00449. Epub 2025 Aug 27. PMID- 30345583 OWN - NLM STAT- MEDLINE DCOM- 20191104 LR - 20200309 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 37 IP - 1 DP - 2019 Jan TI - Nicotine impairs intra-substance tendon healing after full thickness injury in a rat model. PG - 94-103 LID - 10.1002/jor.24167 [doi] AB - Nicotine is harmful to many bodily systems; however, the effects of nicotine on intra-substance tendon healing remain largely unexplored. The purpose of this study was to examine the functional, structural, and biomechanical effects of nicotine on the healing of Achilles tendons in rats after an acute full-thickness injury. Sixty Sprague-Dawley rats were enrolled in this study. Half were exposed to 0.9% saline and half to 61 ng/mL of nicotine for 3 months via subcutaneous osmotic pumps. At 3 months, all rats underwent blunt full thickness transection of the left Achilles tendon and were immobilized for one week in plantarflexion. In-vivo assays were conducted prior to injury, at 21 days, and at 42 days post-injury and included the following: Functional limb assessment, passive joint mechanics, and vascular evaluation. Rats were sacrificed at 21 and 42 days for biomechanical testing and histologic evaluation. Rats exposed to nicotine demonstrated decreased vascularity, greater alteration in gait mechanics, and increased passive ROM of the ankle joint. Biomechanically, the nicotine tendons failed at lower maximum loads, were less stiff, had smaller cross-sectional areas and had altered viscoelastic properties. Histologically, nicotine tendons demonstrated decreased vessel density at the injury site. This study demonstrates that nicotine leads to worse functional outcomes and biomechanical properties in tendons. The decreased vascularity in the nicotine group may suggest an underlying mechanism for inferior tendon healing. Patients should be counseled that using nicotine products increase their risk of poor tendon healing and may predispose them to tendon re-rupture. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res. CI - © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Cheema, Adnan N AU - Cheema AN AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Newton, Joseph B AU - Newton JB AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Boorman-Padgett, James F AU - Boorman-Padgett JF AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Weiss, Stephanie N AU - Weiss SN AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Nuss, Courtney A AU - Nuss CA AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Gittings, Daniel J AU - Gittings DJ AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Farber, Daniel C AU - Farber DC AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. FAU - Soslowsky, Louis J AU - Soslowsky LJ AD - McKay Orthopaedic Research Laboratory University of Pennsylvania, 3450 Hamilton Walk, 110 Stemmler Hall, Philadelphia, Pennsylvania, 19104-6081. LA - eng GR - P30 AR069619/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20181130 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Ganglionic Stimulants) RN - 6M3C89ZY6R (Nicotine) SB - IM MH - Achilles Tendon/*drug effects/injuries/pathology MH - Animals MH - Ganglionic Stimulants/*adverse effects MH - Male MH - Nicotine/*adverse effects MH - Rats, Sprague-Dawley MH - Regeneration/*drug effects MH - *Tendon Injuries PMC - PMC6411046 MID - NIHMS1006242 OTO - NOTNLM OT - biomechanical properties OT - nicotine OT - tendon healing OT - tendon structure OT - vascularity EDAT- 2018/10/23 06:00 MHDA- 2019/11/05 06:00 PMCR- 2020/01/01 CRDT- 2018/10/23 06:00 PHST- 2018/06/27 00:00 [received] PHST- 2018/10/11 00:00 [accepted] PHST- 2018/10/23 06:00 [pubmed] PHST- 2019/11/05 06:00 [medline] PHST- 2018/10/23 06:00 [entrez] PHST- 2020/01/01 00:00 [pmc-release] AID - 10.1002/jor.24167 [doi] PST - ppublish SO - J Orthop Res. 2019 Jan;37(1):94-103. doi: 10.1002/jor.24167. Epub 2018 Nov 30. PMID- 10574173 OWN - NLM STAT- MEDLINE DCOM- 19991207 LR - 20190915 IS - 0894-9115 (Print) IS - 0894-9115 (Linking) VI - 78 IP - 6 DP - 1999 Nov-Dec TI - Greater trochanter enthesopathy: an example of "short course retinoid enthesopathy": a case report. PG - 571-6 AB - Irreversible skeletal changes have been described in patients with dermatologic disorders treated with isotretinoin (Accutane), a synthetic vitamin A derivative. Although retinoids were developed to avoid toxicity associated with vitamin A, skeletal lesions and rheumatologic consequences are possible hazards of isotretinoin treatment. Enthesopathy is one of the potential musculoskeletal sequelae and is characterized by pathologic, sometimes painful changes at the insertion sites (entheses) of tendons, ligaments, and articular capsules into bone. We report a patient who was referred secondary to an extended history of bilateral hip region pain. She was subsequently found to have a greater trochanteric enthesopathy. A detailed patient history revealed past use of Accutane for cystic acne. The subsequent treatment course, including medications, corticosteroid injections, physical therapy, and activity modifications, is described and the pertinent literature is reviewed. We believe that patients who are prescribed isotretinoin should be warned about this potential pathologic condition at the initiation of treatment and that physicians who are treating patients with a history of Accutane use should be suspicious of underlying enthesopathies as the etiology behind pain of musculoskeletal origin. FAU - Stitik, T P AU - Stitik TP AD - Department of Physical Medicine and Rehabilitation, UMDNJ-New Jersey Medical School, West Orange, New Jersey, USA. FAU - Nadler, S F AU - Nadler SF FAU - Foye, P M AU - Foye PM FAU - Juvan, L AU - Juvan L LA - eng PT - Case Reports PT - Journal Article PT - Review PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Keratolytic Agents) RN - 144O8QL0L1 (Diclofenac) RN - EH28UP18IF (Isotretinoin) SB - IM MH - Acne Vulgaris/drug therapy MH - Adrenal Cortex Hormones/therapeutic use MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Diagnosis, Differential MH - Diclofenac/therapeutic use MH - Female MH - Hip Joint/*pathology MH - Humans MH - Isotretinoin/*adverse effects MH - Keratolytic Agents/*adverse effects MH - Physical Therapy Modalities MH - Posture/physiology MH - Rheumatic Diseases/*chemically induced/drug therapy/rehabilitation MH - Sports/physiology RF - 32 EDAT- 1999/11/26 00:00 MHDA- 1999/11/26 00:01 CRDT- 1999/11/26 00:00 PHST- 1999/11/26 00:00 [pubmed] PHST- 1999/11/26 00:01 [medline] PHST- 1999/11/26 00:00 [entrez] AID - 10.1097/00002060-199911000-00015 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 1999 Nov-Dec;78(6):571-6. doi: 10.1097/00002060-199911000-00015. PMID- 34552033 OWN - NLM STAT- MEDLINE DCOM- 20220217 LR - 20220225 IS - 1543-3072 (Electronic) IS - 1056-6716 (Linking) VI - 31 IP - 1 DP - 2022 Jan 1 TI - Menthol-Based Topical Analgesic Induces Similar Upper and Lower Body Pain Pressure Threshold Values: A Randomized Trial. PG - 24-30 LID - jsr.2021-0144 [pii] LID - 10.1123/jsr.2021-0144 [doi] AB - CONTEXT: Both health professionals and consumers use menthol-based topical analgesics extensively for the temporary relief of pain from musculoskeletal ailments or injury. However, there are no reports of differences in the pain pressure threshold (PPT) or the relative effectiveness of topical analgesics to reduce pain in the upper and lower body muscles and tendons. The objective of this study was to investigate whether differences existed in PPT and relative pain attenuation associated with a menthol-based topical analgesic over a variety of upper and lower body muscles and tendons. DESIGN: Randomized allocation, controlled, intervention study. METHODS: Sixteen participants (10 females and 6 males) were tested on their dominant or nondominant side. The order of specific muscle/tendon testing was also randomized, which included upper body (middle deltoid, biceps brachii, and lateral epicondylar tendon) and lower body locations (quadriceps, hamstrings, gastrocnemius, lumbosacral erector spinae muscles, and patellar and Achilles tendons). The PPT was monitored before and 15 minutes following the application of a menthol-based topical analgesic. RESULTS: A menthol-based topical analgesic increased PPT (decreased pain sensitivity) overall (P = .05; 11.6% [2.4%]; d = 1.05) and PPT was higher (P < .0001; 31.5%-44.2%; d = 1.03-1.8) for lower versus upper body locations. CONCLUSIONS: Health professionals and the public can be assured of similar reductions in pain sensitivity independent of the location of application of a menthol-based topical analgesic. FAU - Behm, David G AU - Behm DG FAU - Herat, Nehara AU - Herat N FAU - Power, Gerard M J AU - Power GMJ FAU - Brosky, Joseph A AU - Brosky JA FAU - Page, Phil AU - Page P FAU - Alizadeh, Shahab AU - Alizadeh S LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20210922 PL - United States TA - J Sport Rehabil JT - Journal of sport rehabilitation JID - 9206500 RN - 0 (Analgesics) RN - 1490-04-6 (Menthol) SB - IM MH - *Achilles Tendon MH - Analgesics/pharmacology/therapeutic use MH - Female MH - Humans MH - Male MH - *Menthol/pharmacology MH - Pain MH - Pain Threshold OTO - NOTNLM OT - lower back OT - musculoskeletal OT - tendons EDAT- 2021/09/24 06:00 MHDA- 2022/02/19 06:00 CRDT- 2021/09/23 05:58 PHST- 2021/04/20 00:00 [received] PHST- 2021/06/23 00:00 [accepted] PHST- 2021/09/24 06:00 [pubmed] PHST- 2022/02/19 06:00 [medline] PHST- 2021/09/23 05:58 [entrez] AID - jsr.2021-0144 [pii] AID - 10.1123/jsr.2021-0144 [doi] PST - ppublish SO - J Sport Rehabil. 2022 Jan 1;31(1):24-30. doi: 10.1123/jsr.2021-0144. Epub 2021 Sep 22. PMID- 27236513 OWN - NLM STAT- MEDLINE DCOM- 20170213 LR - 20181113 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 35 IP - 8 DP - 2016 Aug TI - Tendon involvement in patients with gout: an ultrasound study of prevalence. PG - 2039-2044 LID - 10.1007/s10067-016-3309-7 [doi] AB - The objective of the present study is to evaluate, by ultrasonography (US), the prevalence in the quadriceps, patellar, and Achilles tendon involvement of gout compared to that of patients with osteoarthritis and asymptomatic marathon runners. This is a multicenter, multinational, transverse cross-sectional, and comparative study comprising 80 patients with the diagnosis of gout according to the American College of Rheumatology (ACR) criteria, compared with two control groups: 35 patients with generalized osteoarthritis according to the ACR criteria and 35 subjects who were healthy marathon runners. Demographics and clinical characteristics, such as age, gender, comorbidity, disease duration, pain at the enthesis in the knee and ankle, frequency of disease exacerbations, uric acid level more than 7.2 mg at the time of evaluation, and type of treatment, were recorded. All participants were examined by ultrasound at the quadriceps, the patellar at its proximal and distal insertion, and the Achilles tendon to detect intra-tendinous tophus or aggregates according to the OMERACT definitions. Descriptive statistics and differences between groups were analyzed by chi-square test. Sensitivity and specificity by US were calculated. The prevalence of intra-tendinous aggregates and tophi in gout was significant compared with the other groups. Both lesions were the most frequent at the distal patellar insertion, followed by the quadriceps, Achilles, and proximal patellar insertion ones. In patients with osteoarthritis (OA), intra-tendinous hyperechoic aggregates were observed in 20 % of quadriceps tendons and in 11 % of patellar tendons at its proximal insertion, while in the healthy marathon runner group, the Achilles tendon had this kind of lesion in 17 % of the subjects. Neither the OA nor the healthy marathon runners had intra-tendinous tophi. The sensitivity and specificity of US to detect tophi or aggregates were 69.6 and 92 %, respectively, tendon involvement at the lower limbs in gout is very frequent, particularly in the patellar tendon, and US possesses good sensitivity and specificity for detecting intra-tendinous tophi. FAU - Ventura-Ríos, Lucio AU - Ventura-Ríos L AD - Musculoskeletal Ultrasound Laboratory, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, México City, México. venturarioslucio@gmail.com. FAU - Sánchez-Bringas, Guadalupe AU - Sánchez-Bringas G AD - Spine Surgery Service, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, Mexico City, Mexico. FAU - Pineda, Carlos AU - Pineda C AD - Research Direction, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, México City, México. FAU - Hernández-Díaz, Cristina AU - Hernández-Díaz C AD - Musculoskeletal Ultrasound Laboratory, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, México City, México. FAU - Reginato, Anthony AU - Reginato A AD - Rheumatology Research and Musculoskeletal Ultrasound, Brown University, Providence VAMC, University Medicine Foundation/RIH, Providence, RI, USA. FAU - Alva, Magaly AU - Alva M AD - Rheumatology Unit, Hospital Edgardo Rebagliati Martins, Lima, Perú. FAU - Audisio, Marcelo AU - Audisio M AD - Rheumatology Unit, Facultad de Ciencias Médicas, Hospital Nacional de Clínicas, Córdoba, Argentina. FAU - Bertoli, Ana AU - Bertoli A AD - Rheumatology Unit, Instituto Reumatológico Strusberg, Córdoba, Argentina. FAU - Cazenave, Tomas AU - Cazenave T AD - Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina. FAU - Gutiérrez, Marwin AU - Gutiérrez M AD - División de Enfermedades Musculoesqueléticas y Reumáticas, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, México City, México. FAU - Mora, Claudia AU - Mora C AD - Rheumatology Unit, Hospital Edgardo Rebagliati Martins, Lima, Perú. FAU - Py, Guillermo AU - Py G AD - Rheumatology Unit, Facultad de Ciencias Médicas, Hospital Nacional de Clínicas, Córdoba, Argentina. FAU - Sedano, Oscar AU - Sedano O AD - Rheumatology Lima, Hospital Marino Molina Scippa ESSALUD, Lima, Peru. FAU - Solano, Carla AU - Solano C AD - Rheumatology Unit, Hospital Nacional Rosales, San Salvador, El Salvador. FAU - de Miguel, Eugenio AU - de Miguel E AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20160528 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Achilles Tendon/*diagnostic imaging MH - Adult MH - Aged MH - Case-Control Studies MH - Comorbidity MH - Cross-Sectional Studies MH - Female MH - Gout/*complications MH - Humans MH - International Cooperation MH - Male MH - Middle Aged MH - Patellar Ligament/*diagnostic imaging MH - Sensitivity and Specificity MH - Tendinopathy/*diagnostic imaging MH - Ultrasonography MH - Uric Acid/blood OTO - NOTNLM OT - Gout OT - Tendinopathy OT - Ultrasound EDAT- 2016/05/30 06:00 MHDA- 2017/02/14 06:00 CRDT- 2016/05/30 06:00 PHST- 2016/04/10 00:00 [received] PHST- 2016/05/11 00:00 [accepted] PHST- 2016/05/06 00:00 [revised] PHST- 2016/05/30 06:00 [entrez] PHST- 2016/05/30 06:00 [pubmed] PHST- 2017/02/14 06:00 [medline] AID - 10.1007/s10067-016-3309-7 [pii] AID - 10.1007/s10067-016-3309-7 [doi] PST - ppublish SO - Clin Rheumatol. 2016 Aug;35(8):2039-2044. doi: 10.1007/s10067-016-3309-7. Epub 2016 May 28. PMID- 21601885 OWN - NLM STAT- MEDLINE DCOM- 20110912 LR - 20131121 IS - 1095-8673 (Electronic) IS - 0022-4804 (Linking) VI - 169 IP - 2 DP - 2011 Aug TI - An experimental study on the effect of safflower yellow on tendon injury-repair in chickens. PG - e175-84 LID - 10.1016/j.jss.2011.03.079 [doi] AB - BACKGROUND: The present study sought to investigate pathologic changes in tendon, expression of basic fibroblast growth factor (bFGF) and collagen type I, and effects of safflower yellow (SY) on the process of tendon injury-repair. MATERIALS AND METHODS: A tendon injury-repair model was used, and stereology, biomechanics, and immunohistochemistry were employed to assess the benefits of local application of SY for the repair. In this model, the flexor digitorum profundus muscle tendon of the third digit was transected bilaterally, and the transected ends sutured. Data were analyzed with SPSS ver. 10.0 software (SPSS Inc., Chicago, IL). RESULTS: The adhesion to surrounding tissues and tensile strength gradually increased after the injury and repair in control (no-SY) tendons, and were significantly greater by the sixth wk than any other time. In the SY tendons, adhesion was significantly lower, and tensile strength significantly higher than in no-SY tendons at the same post-injury-suture time points. An inflammatory reaction was observed in the injury-repair areas of the tendon by the end of first wk post-injury-suture, and reached its peak by the end of second wk. The inflammatory reaction was significantly less in SY tendons than in controls. Immunostaining for bFGF occurred in the tendon injury-repair areas by the end of first wk, and the number of bFGF positive cells reached a peak by the end of second wk, with a greater abundance in SY than control tendons from the second to sixth wk. Expression of collagen type I protein was observed in the injury-repair areas as well, coincident with bFGF, and was remarkably higher in SY than in controls. CONCLUSIONS: Tendon adhesion and tensile strength increased with time post-injury-suture repair, as did expression of bFGF and collagen type I protein in the injured area. SY enhanced expression of bFGF and collagen type I protein, enhanced the tensile strength of the injured tendon, and alleviated the injured tendon adhesion and inflammatory reaction. The results indicated that SY promoted the repair of injured tendon by up-regulating expression of bFGF and collagen type I protein. CI - Copyright © 2011 Elsevier Inc. All rights reserved. FAU - Liu, Bingbing AU - Liu B AD - Department of Anatomy, Zhongshan School of Medicine, SUN Yat-sen University, Guangzhou, China. FAU - Luo, Cheng AU - Luo C FAU - Ouyang, Lisi AU - Ouyang L FAU - Mu, Shuhua AU - Mu S FAU - Zhu, Yaxi AU - Zhu Y FAU - Li, Keyi AU - Li K FAU - Zhan, Mali AU - Zhan M FAU - Liu, Zongwei AU - Liu Z FAU - Jia, Yu AU - Jia Y FAU - Lei, Wanlong AU - Lei W LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110429 PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 RN - 0 (Collagen Type I) RN - 0 (Plant Extracts) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - 1401-20-3 (safflower yellow) RN - 5S5A2Q39HX (Chalcone) SB - IM MH - Animals MH - *Carthamus tinctorius MH - Chalcone/*analogs & derivatives/pharmacology/therapeutic use MH - Chickens MH - Collagen Type I/metabolism MH - Fibroblast Growth Factor 2/metabolism MH - Male MH - Models, Animal MH - Phytotherapy/methods MH - Plant Extracts/pharmacology/therapeutic use MH - Regeneration/*drug effects/physiology MH - Tendon Injuries/*drug therapy/metabolism/*pathology MH - Tendons/drug effects/pathology/*physiology MH - Tensile Strength/drug effects MH - Up-Regulation/drug effects/physiology MH - Wound Healing/*drug effects/physiology EDAT- 2011/05/24 06:00 MHDA- 2011/09/13 06:00 CRDT- 2011/05/24 06:00 PHST- 2010/11/26 00:00 [received] PHST- 2011/03/28 00:00 [revised] PHST- 2011/03/31 00:00 [accepted] PHST- 2011/05/24 06:00 [entrez] PHST- 2011/05/24 06:00 [pubmed] PHST- 2011/09/13 06:00 [medline] AID - S0022-4804(11)00314-3 [pii] AID - 10.1016/j.jss.2011.03.079 [doi] PST - ppublish SO - J Surg Res. 2011 Aug;169(2):e175-84. doi: 10.1016/j.jss.2011.03.079. Epub 2011 Apr 29. PMID- 22433782 OWN - NLM STAT- MEDLINE DCOM- 20130114 LR - 20250529 IS - 1872-8294 (Electronic) IS - 0169-409X (Print) IS - 0169-409X (Linking) VI - 64 IP - 12 DP - 2012 Sep TI - Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues. PG - 1177-88 LID - 10.1016/j.addr.2012.03.002 [doi] AB - Non-invasive treatment of injuries and disorders affecting bone and connective tissue remains a significant challenge facing the medical community. A treatment route that has recently been proposed is nitric oxide (NO) therapy. Nitric oxide plays several important roles in physiology with many conditions lacking adequate levels of NO. As NO is a radical, localized delivery via NO donors is essential to promoting biological activity. Herein, we review current literature related to therapeutic NO delivery in the treatment of bone, skin and tendon repair. CI - Copyright © 2012 Elsevier B.V. All rights reserved. FAU - Nichols, Scott P AU - Nichols SP AD - Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. snichols@unc.edu FAU - Storm, Wesley L AU - Storm WL FAU - Koh, Ahyeon AU - Koh A FAU - Schoenfisch, Mark H AU - Schoenfisch MH LA - eng GR - R01 EB000708/EB/NIBIB NIH HHS/United States GR - EB000708/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20120310 PL - Netherlands TA - Adv Drug Deliv Rev JT - Advanced drug delivery reviews JID - 8710523 RN - 0 (Nitric Oxide Donors) RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Animals MH - Bone and Bones/metabolism/pathology MH - Connective Tissue/metabolism/pathology MH - *Drug Delivery Systems MH - Humans MH - Nitric Oxide/*administration & dosage/metabolism/therapeutic use MH - Nitric Oxide Donors/*administration & dosage/therapeutic use MH - Skin/metabolism/pathology MH - Tendons/metabolism/pathology MH - Wound Healing/drug effects PMC - PMC3383916 MID - NIHMS363451 EDAT- 2012/03/22 06:00 MHDA- 2013/01/15 06:00 PMCR- 2013/09/01 CRDT- 2012/03/22 06:00 PHST- 2011/09/15 00:00 [received] PHST- 2012/02/17 00:00 [revised] PHST- 2012/03/05 00:00 [accepted] PHST- 2012/03/22 06:00 [entrez] PHST- 2012/03/22 06:00 [pubmed] PHST- 2013/01/15 06:00 [medline] PHST- 2013/09/01 00:00 [pmc-release] AID - S0169-409X(12)00098-1 [pii] AID - 10.1016/j.addr.2012.03.002 [doi] PST - ppublish SO - Adv Drug Deliv Rev. 2012 Sep;64(12):1177-88. doi: 10.1016/j.addr.2012.03.002. Epub 2012 Mar 10. PMID- 19826139 OWN - NLM STAT- MEDLINE DCOM- 20100902 LR - 20131121 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 38 IP - 2 DP - 2010 Feb TI - Doxycycline-mediated inhibition of matrix metalloproteinases improves healing after rotator cuff repair. PG - 308-17 LID - 10.1177/0363546509347366 [doi] AB - BACKGROUND: Recent studies demonstrate a potentially critical role of matrix metalloproteinases (MMPs) and their inhibitors in the pathophysiology of rotator cuff tears. HYPOTHESIS: Doxycycline-mediated MMP inhibition after rotator cuff repair will improve tendon-to-bone healing. STUDY DESIGN: Controlled laboratory study. METHODS: Rats (n = 183) underwent acute detachment and repair of the supraspinatus tendon and the animals were divided into 4 groups: In controls (n = 66), the supraspinatus was repaired to its anatomical footprint. In experimental groups, an identical surgery was performed with doxycycline (130 mg/kg/d) administered orally at (1) preoperative day 1 (n = 66), (2) postoperative day (POD) 5 (n = 28), or (3) POD 14 (n = 23). Animals were sacrificed at 5 days, 8 days, 2 weeks, and 4 weeks. Tendon-bone interface was evaluated with histomorphometry. Enzyme-linked immunosorbent assay for local MMP-13 activity was performed at 8 days and 4 weeks. Biomechanical testing of the healing enthesis was performed at 8 days, 2 weeks, and 4 weeks. Serum doxycycline levels were measured at sacrifice. Statistical analysis was performed using unpaired t tests and 2-way analysis of variance (P < .05). RESULTS: Serum doxycycline levels were significantly higher in all treated groups compared with controls (1830 +/- 835 vs 3 +/- 3 ng/mL, respectively; P < .001). Doxycycline-treated animals demonstrated greater metachromasia and improved collagen organization at the healing enthesis at POD 5 (P < .06), POD 8 (P < .03), and 2 weeks (P < .04). The MMP-13 activity was significantly reduced in doxycycline-treated compared with control animals at POD 8 (6740 +/- 2770 vs 10400 +/- 2930 relative fluorescent units [RFU], respectively; P < .02) but not at 4 weeks (3600 +/- 3280 vs 4530 +/- 2720 RFU, respectively). The healing enthesis of animals started on doxycycline preoperatively or at POD 5 had an increased load to failure compared to controls at 2 weeks (13.6 +/- 1.8 and 13.2 +/- 1.94 N vs 9.1 +/- 2.5 N, respectively; P < .01). CONCLUSION/CLINICAL RELEVANCE: Modulation of MMP-13 activity after rotator cuff repair may offer a novel biological pathway to augment tendon-to-bone healing. FAU - Bedi, Asheesh AU - Bedi A AD - Laboratory for Soft Tissue Research, Hospital For Special Surgery, 535 East 70th Street, New York City, NY 10021, USA. bedia@hss.edu FAU - Fox, Alice J S AU - Fox AJ FAU - Kovacevic, David AU - Kovacevic D FAU - Deng, Xeng-Hua AU - Deng XH FAU - Warren, Russell F AU - Warren RF FAU - Rodeo, Scott A AU - Rodeo SA LA - eng PT - Journal Article DEP - 20091013 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Bacterial Agents) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - N12000U13O (Doxycycline) SB - IM MH - Animals MH - Anti-Bacterial Agents/administration & dosage/blood/*pharmacology MH - Biomechanical Phenomena MH - Bone and Bones/drug effects MH - Doxycycline/administration & dosage/*analogs & derivatives/blood/pharmacology MH - Male MH - *Matrix Metalloproteinase Inhibitors MH - Matrix Metalloproteinases/drug effects MH - Postoperative Care MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*surgery MH - Tendons/drug effects MH - Wound Healing/drug effects EDAT- 2009/10/15 06:00 MHDA- 2010/09/03 06:00 CRDT- 2009/10/15 06:00 PHST- 2009/10/15 06:00 [entrez] PHST- 2009/10/15 06:00 [pubmed] PHST- 2010/09/03 06:00 [medline] AID - 0363546509347366 [pii] AID - 10.1177/0363546509347366 [doi] PST - ppublish SO - Am J Sports Med. 2010 Feb;38(2):308-17. doi: 10.1177/0363546509347366. Epub 2009 Oct 13. PMID- 33182831 OWN - NLM STAT- MEDLINE DCOM- 20210412 LR - 20210412 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 12 IP - 11 DP - 2020 Nov 10 TI - Anti-Vascular Inflammatory Effect of Ethanol Extract from Securinega suffruticosa in Human Umbilical Vein Endothelial Cells. LID - 10.3390/nu12113448 [doi] LID - 3448 AB - Securiniga suffruticosa is known as a drug that has the effect of improving the blood circulation and relaxing muscles and tendons, thereby protects and strengthen kidney and spleen. Therefore, in this study, treatment of Securiniga suffruticosa showed protective effect of inhibiting the vascular inflammation in human umbilical vein endothelial cells (HUVECs) by inducing nitric oxide (NO) production and endothelial nitric oxide synthase (eNOS) coupling pathway. In this study, Securiniga suffruticosa suppressed TNF-α (Tumor necrosis factor-α) induced protein and mRNA levels of cell adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and Interleukin-6 (IL-6). Pretreatment of HUVEC with Securiniga suffruticosa decreased the adhesion of HL-60 cells to Ox-LDL (Oxidized Low-Density-Lipoprotein)-induced HUVEC. Moreover, Securiniga suffruticosa inhibited TNF-α induced intracellular reactive oxygen species (ROS) production. Securiniga suffruticosa also inhibited phosphorylation of IκB-α in cytoplasm and translocation of NF-κB (Nuclear factor-kappa B) p65 to the nucleus. Securiniga suffruticosa increased NO production, as well increased the phosphorylation of eNOS and Akt (protein kinase B) which are related with NO production. In addition, Securiniga suffruticosa increased the protein expression of GTPCH (Guanosine triphosphate cyclohydrolase Ⅰ) and the production of BH4 in HUVEC which are related with eNOS coupling pathway. In conclusion, Securiniga suffruticosa has a protective effect against vascular inflammation and can be a potential therapeutic agent for early atherosclerosis. FAU - Han, Byung Hyuk AU - Han BH AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Song, Chun Ho AU - Song CH AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Yoon, Jung Joo AU - Yoon JJ AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Kim, Hye Yoom AU - Kim HY AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Seo, Chang Seob AU - Seo CS AUID- ORCID: 0000-0002-8156-446X AD - Herbal Medicine Research Division, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, Korea. FAU - Kang, Dae Gill AU - Kang DG AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Lee, Yun Jung AU - Lee YJ AUID- ORCID: 0000-0002-9347-8606 AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. FAU - Lee, Ho Sub AU - Lee HS AD - Hanbang Cardio-Renal Syndrome Research Center, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. AD - College of Oriental Medicine and Professional Graduate School of Oriental Medicine, Wonkwang University, 460, Iksan-daero, Iksan 54538, Jeonbuk, Korea. LA - eng GR - 2017R1A5A2015805/National Research Foundation of Korea (NRF)/ GR - 2019R1A2C1085650/National Research Foundation of Korea (NRF)/ GR - 2018R1A6A3A11050510/National Research Foundation of Korea (NRF)/ PT - Journal Article DEP - 20201110 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Lipoproteins, LDL) RN - 0 (NF-kappa B) RN - 0 (Plant Extracts) RN - 0 (Reactive Oxygen Species) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (Vascular Cell Adhesion Molecule-1) RN - 0 (oxidized low density lipoprotein) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 3K9958V90M (Ethanol) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type III) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM MH - Anti-Inflammatory Agents/*pharmacology MH - Ethanol/isolation & purification MH - Human Umbilical Vein Endothelial Cells/cytology/*drug effects/metabolism MH - Humans MH - Inflammation/metabolism/*prevention & control MH - Intercellular Adhesion Molecule-1/genetics/metabolism MH - Lipoproteins, LDL MH - NF-kappa B/metabolism MH - Nitric Oxide Synthase Type III/metabolism MH - Plant Extracts/chemistry/*pharmacology MH - Proto-Oncogene Proteins c-akt/metabolism MH - Reactive Oxygen Species/metabolism MH - Securinega/*chemistry MH - Tumor Necrosis Factor-alpha/metabolism MH - Vascular Cell Adhesion Molecule-1/genetics/metabolism PMC - PMC7697010 OTO - NOTNLM OT - HUVECs OT - NO OT - Securiniga suffruticosa OT - TNF-α OT - adhesion molecules OT - vascular inflammation COIS- The authors report no conflict of interest. EDAT- 2020/11/14 06:00 MHDA- 2021/04/13 06:00 PMCR- 2020/11/01 CRDT- 2020/11/13 01:04 PHST- 2020/09/22 00:00 [received] PHST- 2020/11/06 00:00 [revised] PHST- 2020/11/07 00:00 [accepted] PHST- 2020/11/13 01:04 [entrez] PHST- 2020/11/14 06:00 [pubmed] PHST- 2021/04/13 06:00 [medline] PHST- 2020/11/01 00:00 [pmc-release] AID - nu12113448 [pii] AID - nutrients-12-03448 [pii] AID - 10.3390/nu12113448 [doi] PST - epublish SO - Nutrients. 2020 Nov 10;12(11):3448. doi: 10.3390/nu12113448. PMID- 17805438 OWN - NLM STAT- MEDLINE DCOM- 20071113 LR - 20181201 IS - 0379-0355 (Print) IS - 0379-0355 (Linking) VI - 29 IP - 5 DP - 2007 Jun TI - Comparison between newer local anesthetics for myofascial pain syndrome management. PG - 353-7 AB - Myofascial pain syndromes are characterized by the presence of painful loci within muscles, tendons or ligaments, called trigger points. Infiltration of these points with local anesthetics is often used as a treatment modality. The aim of the study was to comparatively evaluate 0.25% levobupivacaine and 0.25% ropivacaine for trigger point injection regarding pain on injection, treatment efficacy and duration of symptoms remission. Sixty-eight patients, suffering from myofascial pain syndromes, were randomly assigned to two groups to receive either levobupivacaine or ropivacaine for trigger-point injection. After completion of the procedure, patients were asked to rate pain during injection and efficacy of the treatment, based on immediate relief. Two weeks later, they were asked about the duration of this relief. Statistical analysis did not reveal significant differences between groups with respect to pain during injection, efficacy of the treatment and duration of pain relief. The two local anesthetics seem to be equally effective for trigger point infiltration. CI - (c) 2007 Prous Science. All rights reserved. FAU - Zaralidou, A Th AU - Zaralidou AT AD - Department of Anesthesiology, Pain Clinic, AHEPA University Hospital, Thessaloniki, Greece. FAU - Amaniti, E N AU - Amaniti EN FAU - Maidatsi, P G AU - Maidatsi PG FAU - Gorgias, N K AU - Gorgias NK FAU - Vasilakos, D F AU - Vasilakos DF LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - Spain TA - Methods Find Exp Clin Pharmacol JT - Methods and findings in experimental and clinical pharmacology JID - 7909595 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 7IO5LYA57N (Ropivacaine) RN - A5H73K9U3W (Levobupivacaine) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adult MH - Amides/administration & dosage/*therapeutic use MH - Anesthetics, Local/administration & dosage/*therapeutic use MH - Bupivacaine/administration & dosage/analogs & derivatives/therapeutic use MH - Double-Blind Method MH - Female MH - Humans MH - Injections, Intramuscular MH - Levobupivacaine MH - Male MH - Middle Aged MH - Myofascial Pain Syndromes/*drug therapy MH - Pain Measurement MH - Ropivacaine EDAT- 2007/09/07 09:00 MHDA- 2007/11/14 09:00 CRDT- 2007/09/07 09:00 PHST- 2007/09/07 09:00 [pubmed] PHST- 2007/11/14 09:00 [medline] PHST- 2007/09/07 09:00 [entrez] AID - 1075364 [pii] AID - 10.1358/mf.2007.29.5.1075364 [doi] PST - ppublish SO - Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):353-7. doi: 10.1358/mf.2007.29.5.1075364. PMID- 31784541 OWN - NLM STAT- MEDLINE DCOM- 20201106 LR - 20210110 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 9 IP - 1 DP - 2019 Nov 29 TI - Statin treatment increases the clinical risk of tendinopathy through matrix metalloproteinase release - a cohort study design combined with an experimental study. PG - 17958 LID - 10.1038/s41598-019-53238-7 [doi] LID - 17958 AB - Recent experimental evidence indicates potential adverse effects of statin treatment on tendons but previous clinical studies are few and inconclusive. The aims of our study were, first, to determine whether statin use in a cohort design is associated with tendinopathy disorders, and second, to experimentally understand the pathogenesis of statin induced tendinopathy. We studied association between statin use and different tendon injuries in two population-based Swedish cohorts by time-dependent Cox regression analysis. Additionally, we tested simvastatin in a 3D cell culture model with human tenocytes. Compared with never-users, current users of statins had a higher incidence of trigger finger with adjusted hazard ratios (aHRs) of 1.50 for men (95% confidence interval [CI] 1.21-1.85) and 1.21 (1.02-1.43) for women. We also found a higher incidence of shoulder tendinopathy in both men (aHR 1.43; 1.24-1.65) and women (aHR 1.41; 0.97-2.05). Former users did not confer a higher risk of tendinopathies. In vitro experiments revealed an increased release of matrix metalloproteinase (MMP)-1 and MMP-13 and a weaker, disrupted matrix after simvastatin exposure. Current statin use seems to increase the risk of trigger finger and shoulder tendinopathy, possibly through increased MMP release, and subsequently, a weakened tendon matrix which will be more prone to injuries. FAU - Eliasson, Pernilla AU - Eliasson P AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. pernilla.eliasson@gmail.com. FAU - Dietrich-Zagonel, Franciele AU - Dietrich-Zagonel F AUID- ORCID: 0000-0003-4871-8268 AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. FAU - Lundin, Anna-Carin AU - Lundin AC AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. FAU - Aspenberg, Per AU - Aspenberg P AD - Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden. FAU - Wolk, Alicja AU - Wolk A AD - National Institute of Environmental Medicine, Division of Nutritional Epidemiology, Karolinska Institute, Stockholm, Sweden. FAU - Michaëlsson, Karl AU - Michaëlsson K AD - Section of Orthopedics, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191129 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - AGG2FN16EV (Simvastatin) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Aged MH - Cells, Cultured MH - Cohort Studies MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use MH - Male MH - Matrix Metalloproteinases/*metabolism MH - Middle Aged MH - Simvastatin/*adverse effects/therapeutic use MH - Tendinopathy/*chemically induced/metabolism PMC - PMC6884518 COIS- The authors declare no competing interests. EDAT- 2019/12/01 06:00 MHDA- 2020/11/11 06:00 PMCR- 2019/11/29 CRDT- 2019/12/01 06:00 PHST- 2019/06/19 00:00 [received] PHST- 2019/10/30 00:00 [accepted] PHST- 2019/12/01 06:00 [entrez] PHST- 2019/12/01 06:00 [pubmed] PHST- 2020/11/11 06:00 [medline] PHST- 2019/11/29 00:00 [pmc-release] AID - 10.1038/s41598-019-53238-7 [pii] AID - 53238 [pii] AID - 10.1038/s41598-019-53238-7 [doi] PST - epublish SO - Sci Rep. 2019 Nov 29;9(1):17958. doi: 10.1038/s41598-019-53238-7. PMID- 18310707 OWN - NLM STAT- MEDLINE DCOM- 20080327 LR - 20220408 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 90 IP - 3 DP - 2008 Mar TI - The role of macrophages in early healing of a tendon graft in a bone tunnel. PG - 565-79 LID - 10.2106/JBJS.F.00531 [doi] AB - BACKGROUND: Macrophages accumulate following tendon-to-bone repair and may contribute to the formation of a scar-tissue interface rather than to the reformation of a normal insertion site. We hypothesized that macrophage depletion may lead to improved insertion site regeneration, in a form of "scar-less" healing rather than reactive scar-tissue formation. METHODS: One hundred and ninety-two Sprague-Dawley rats underwent anterior cruciate ligament reconstruction with use of a flexor tendon autograft and were divided into a control group (ninety-six rats) and a liposomal clodronate-injected group (ninety-six rats). Clodronate is a bisphosphonate that selectively induces macrophage apoptosis. Animals in the liposomal clodronate group received weekly intraperitoneal injections of liposomal clodronate (1.33 mL/100 g of body weight). Rats were killed at serial time points from three to forty-two days. Immunostaining identified macrophages and transforming growth factor-beta (TGF-beta) at the tendon-bone interface. Fibrous interface width, osteoid formation, and collagen fiber continuity were evaluated with use of histomorphometry. Serial fluorochrome labeling was used to measure mineral apposition rate. Additional rats were killed for biomechanical testing at seven, fourteen, twenty-eight, and forty-two days. RESULTS: Liposomal clodronate significantly decreased macrophages and TGF-beta accumulation at the tendon-bone interface (p < 0.05). Specimens from rats that received liposomal clodronate exhibited a significantly narrower fibrous tissue interface between tendon and bone at all time points compared with specimens from controls (p < 0.05). In specimens from the liposomal clodronate group, healing proceeded at an accelerated rate, characterized by enhanced collagen fiber continuity and a greater degree of interface remodeling between tendon and bone. There were significant increases in osteoid formation (p < 0.05) and mineral apposition rates (p < 0.05) among experimental specimens. At forty-two days, the specimens from the liposomal clodronate group had significantly greater increases than the control specimens with respect to load to failure (mean and standard deviation, 13.5 +/- 4.2 N and 9.7 +/- 3.9 N, respectively; p < 0.05) and stiffness (mean, 11.5 +/- 5.0 N/mm and 7.5 +/- 3.2 N/mm; p < 0.05). CONCLUSIONS: Macrophage depletion following anterior cruciate ligament reconstruction resulted in significantly improved morphologic and biomechanical properties at the healing tendon-bone interface, which we hypothesize are due to diminished macrophage-induced TGF-beta production. FAU - Hays, Peyton L AU - Hays PL AD - The Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. FAU - Kawamura, Sumito AU - Kawamura S FAU - Deng, Xiang-Hua AU - Deng XH FAU - Dagher, Elias AU - Dagher E FAU - Mithoefer, Kai AU - Mithoefer K FAU - Ying, Liang AU - Ying L FAU - Rodeo, Scott A AU - Rodeo SA LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Bone Density Conservation Agents) RN - 0 (Liposomes) RN - 0 (Transforming Growth Factor beta) RN - 0813BZ6866 (Clodronic Acid) SB - IM MH - Animals MH - Anterior Cruciate Ligament/physiopathology/*surgery MH - Anterior Cruciate Ligament Injuries MH - Apoptosis/drug effects MH - Biomechanical Phenomena MH - Bone Density Conservation Agents/administration & dosage/pharmacology MH - Bone Remodeling/physiology MH - Clodronic Acid/administration & dosage/pharmacology MH - Immunohistochemistry MH - Liposomes MH - Macrophages/drug effects/metabolism/*physiology MH - Male MH - Models, Animal MH - Orthopedic Procedures MH - Rats MH - Rats, Sprague-Dawley MH - Recovery of Function MH - Tendons/*transplantation MH - Time Factors MH - Transforming Growth Factor beta/metabolism MH - Transplantation, Autologous MH - Wound Healing/*physiology EDAT- 2008/03/04 09:00 MHDA- 2008/03/28 09:00 CRDT- 2008/03/04 09:00 PHST- 2008/03/04 09:00 [pubmed] PHST- 2008/03/28 09:00 [medline] PHST- 2008/03/04 09:00 [entrez] AID - 90/3/565 [pii] AID - 10.2106/JBJS.F.00531 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2008 Mar;90(3):565-79. doi: 10.2106/JBJS.F.00531. PMID- 23334212 OWN - NLM STAT- MEDLINE DCOM- 20131017 LR - 20250214 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 72 IP - 9 DP - 2013 Sep 1 TI - Tendon involvement in the feet of patients with gout: a dual-energy CT study. PG - 1545-8 LID - 10.1136/annrheumdis-2012-202786 [doi] AB - OBJECTIVES: To examine the frequency and patterns of monosodium urate (MSU) crystal deposition in tendons and ligaments in patients with gout using dual-energy CT (DECT). METHODS: Ninety-two patients with tophaceous gout had DECT scanning of both feet. Two readers scored the DECT scans for MSU crystal deposition at 20 tendon/ligament sites and 42 bone sites (total 1840 tendon/ligament sites and 3864 bone sites). RESULTS: MSU crystal deposition was observed by both readers in 199/1840 (10.8%) tendon/ligament sites and in 399/3864 (10.3%) bone sites (p=0.60). The Achilles tendon was the most commonly involved tendon/ligament site (39.1% of all Achilles tendons), followed by the peroneal tendons (18.1%). Tibialis anterior and the extensor tendons were involved less commonly (7.6-10.3%), and the other flexor tendons, plantar fascia and deltoid ligaments were rarely involved (<5%) (p<0.0001 between sites). Involvement of the enthesis alone was more common in the Achilles tendon (OR (95% CI) 74.5 (4.4 to 1264), p<0.0001), as was any involvement of the enthesis (OR (95% CI) 6.8 (3.6 to 13.0), p<0.0001). CONCLUSIONS: Tendons are commonly affected by MSU crystal deposition in patients with tophaceous gout. The patterns of MSU crystal deposition suggest that biomechanical strain or other local factors may contribute to deposition of MSU crystals. FAU - Dalbeth, Nicola AU - Dalbeth N AD - Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.dalbeth@auckland.ac.nz FAU - Kalluru, Ramanamma AU - Kalluru R FAU - Aati, Opetaia AU - Aati O FAU - Horne, Anne AU - Horne A FAU - Doyle, Anthony J AU - Doyle AJ FAU - McQueen, Fiona M AU - McQueen FM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130119 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Absorptiometry, Photon MH - Achilles Tendon/diagnostic imaging/metabolism/*pathology MH - Crystallization MH - Female MH - Gout/complications/metabolism/*pathology MH - Humans MH - Ligaments/diagnostic imaging/metabolism/pathology MH - Male MH - Middle Aged MH - Tendinopathy/complications/metabolism/*pathology MH - Tomography, X-Ray Computed/*methods MH - Uric Acid/*metabolism OTO - NOTNLM OT - Gout OT - Inflammation OT - Tendinitis EDAT- 2013/01/22 06:00 MHDA- 2013/10/18 06:00 CRDT- 2013/01/22 06:00 PHST- 2013/01/22 06:00 [entrez] PHST- 2013/01/22 06:00 [pubmed] PHST- 2013/10/18 06:00 [medline] AID - S0003-4967(24)21377-7 [pii] AID - 10.1136/annrheumdis-2012-202786 [doi] PST - ppublish SO - Ann Rheum Dis. 2013 Sep 1;72(9):1545-8. doi: 10.1136/annrheumdis-2012-202786. Epub 2013 Jan 19. PMID- 38051506 OWN - NLM STAT- MEDLINE DCOM- 20240117 LR - 20240117 IS - 2239-253X (Electronic) IS - 0003-469X (Linking) VI - 94 DP - 2023 TI - Efficacy and safety of Dynavisc® gel in prevention of scar adhesions recurrence after flexor tendons tenolysis in zone 2. Multicenter retrospective cohort study. PG - 529-536 LID - S0003469X23039180 [pii] AB - AIM: Dynavisc® is a novel surgical product made of carboxymethylcellulose (CMC) and Polyethylene Oxide (PEO) designed to reduce post-surgical adhesions in tendons surgery. A multicenter retrospective cohort study was performed to investigate the clinical safety and efficacy of the Dynavisc® gel in reducing post-surgical adhesions after flexor tenolysis in zone 2. MATERIAL OF STUDY: Thirty-one patients suffering from stiff finger after flexor tendon repairs in zone 2 treated with standard release with (18 Dynavisc®-treated group) or without (13 controls) anti-adhesion gel application into the flexor tendon sheath and around the site of the tenolysis, were collected in five different hand surgery units. Safety profile and functional outcomes (based on TAM test and the The Quick-DASH questionnaire) were examined from patients' charts and analyzed. RESULTS: The application of Dynavisc® posed no safety concerns and it was not related to any additional complication. The Dynavisc®-treated group showed greater progressive improvement of TAM value in all visits with superior TAM value at T(90) and T(180) compared to the control group. DISCUSSION: Tendon adhesions are the main cause of flexor tendon surgery failure. Multiple strategies (i.e. robust tendon repair, early rehabilitation and lubricant or barrier agents) have been proposed to minimize their formation. Among different products described in the literature Dynavisc® showed a significant role in limiting adhesions formation in a recent experimental study. CONCLUSIONS: This clinical study confirm the safety of Dynavisc® gel application in hand surgery demonstrating its potential long-term benefits after flexor tendon tenolysis. KEY WORDS: Flexor Tendon Repair, Tendon Adhesions, Tenolysis. FAU - Bassetto, Franco AU - Bassetto F FAU - Pajardi, Giorgio AU - Pajardi G FAU - Battiston, Bruno AU - Battiston B FAU - Corain, Massimo AU - Corain M FAU - Sargenti, Silvia AU - Sargenti S FAU - Scarpa, Carlotta AU - Scarpa C FAU - Novelli, Chiara AU - Novelli C FAU - Tiengo, Cesare AU - Tiengo C FAU - Vitali, Andrea AU - Vitali A FAU - Facchin, Federico AU - Facchin F FAU - Bertolini, Maddalena AU - Bertolini M FAU - Cara, Luciano AU - Cara L FAU - Caruso, Giancarlo AU - Caruso G LA - eng PT - Journal Article PT - Multicenter Study PL - Italy TA - Ann Ital Chir JT - Annali italiani di chirurgia JID - 0372343 RN - K679OBS311 (Carboxymethylcellulose Sodium) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 0 (Antifibrotic Agents) RN - 0 (Drug Combinations) RN - 0 (Gels) SB - IM MH - Humans MH - *Cicatrix/etiology/prevention & control MH - Retrospective Studies MH - Tendon Injuries/surgery/complications MH - *Tendons/surgery MH - *Tissue Adhesions/etiology/prevention & control MH - *Carboxymethylcellulose Sodium/administration & dosage/therapeutic use MH - *Polyethylene Glycols/administration & dosage/therapeutic use MH - *Antifibrotic Agents/administration & dosage/therapeutic use MH - Drug Combinations MH - Gels EDAT- 2023/12/05 17:45 MHDA- 2023/12/07 12:41 CRDT- 2023/12/05 11:13 PHST- 2023/12/07 12:41 [medline] PHST- 2023/12/05 17:45 [pubmed] PHST- 2023/12/05 11:13 [entrez] AID - S0003469X23039180 [pii] PST - ppublish SO - Ann Ital Chir. 2023;94:529-536. PMID- 38908755 OWN - NLM STAT- MEDLINE DCOM- 20240728 LR - 20240728 IS - 1873-4995 (Electronic) IS - 0168-3659 (Linking) VI - 372 DP - 2024 Aug TI - Uni-directional release of ibuprofen from an asymmetric fibrous membrane enables effective peritendinous anti-adhesion. PG - 251-264 LID - S0168-3659(24)00403-6 [pii] LID - 10.1016/j.jconrel.2024.06.046 [doi] AB - Drug-loaded porous membranes have been deemed to be effective physicochemical barriers to separate postoperative adhesion-prone tissues in tendon healing. However, cell viability and subsequent tissue regeneration might be severely interfered with the unrestricted release and the locally excessive concentration of anti-inflammatory drugs. Herein, we report a double-layered membrane with sustained and uni-directional drug delivery features to prevent peritendinous adhesion without hampering the healing outcome. A vortex-assisted electrospinning system in combination with ibuprofen (IBU)-in-water emulsion was utilized to fabricate IBU-loaded poly-ʟ-lactic-acid (PLLA) fiber bundle membrane (PFB-IBU) as the anti-adhesion layer. The resultant highly porous structure, oleophilic and hydrophobic nature of PLLA fibers enabled in situ loading of IBU with a concentration gradient across the membrane thickness. Aligned collagen nanofibers were further deposited at the low IBU concentration side of the membrane for regulating cell growth and achieving uni-directional release of IBU. Drug release kinetics showed that the release amount of IBU from the high concentration side reached 79.32% at 14 d, while it was only 0.35% at the collagen side. Therefore, fibroblast proliferation at the high concentration side was successfully inhibited without affecting the oriented growth of tendon-derived stem cells at the other side. In vivo evaluation of the rat Achilles adhesion model confirmed the successful peritendinous anti-adhesion of our double-layered membrane, in that the macrophage recruitment, the inflammatory factor secretion and the deposition of pathological adhesion markers such as α-SMA and COL-III were all inhibited, which greatly improved the peritendinous fibrosis and restored the motor function of tendon. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Deng, Jixia AU - Deng J AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Yao, Zhixiao AU - Yao Z AD - Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. FAU - Wang, Shikun AU - Wang S AD - Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. FAU - Zhang, Xinyu AU - Zhang X AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Zhan, Lei AU - Zhan L AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Wang, Tongyu AU - Wang T AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Yu, Wenhua AU - Yu W AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Zeng, Jiamei AU - Zeng J AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Wu, Jinglei AU - Wu J AD - Biomaterials and Tissue Engineering Laboratory, College of Chemistry and Chemical Engineering and Biological Engineering, Donghua University, Shanghai 201620, China. FAU - Fu, Shaoju AU - Fu S AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. FAU - Wu, Shihao AU - Wu S AD - School of Medicine, Yunnan University, Kunming, Yunnan 650091, China. Electronic address: brad-315@163.com. FAU - Ouyang, Yuanming AU - Ouyang Y AD - Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China. Electronic address: ouyangyuanming@163.com. FAU - Huang, Chen AU - Huang C AD - Shanghai Frontiers Science Center of Advanced Textiles, College of Textiles, Donghua University, Shanghai 201620, China. Electronic address: hc@dhu.edu.cn. LA - eng PT - Journal Article DEP - 20240624 PL - Netherlands TA - J Control Release JT - Journal of controlled release : official journal of the Controlled Release Society JID - 8607908 RN - WK2XYI10QM (Ibuprofen) RN - 0 (Polyesters) RN - 459TN2L5F5 (poly(lactide)) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Membranes, Artificial) RN - 0 (Delayed-Action Preparations) SB - IM MH - Animals MH - *Ibuprofen/administration & dosage/pharmacology/chemistry MH - *Polyesters/chemistry MH - *Drug Liberation MH - *Rats, Sprague-Dawley MH - Tissue Adhesions/prevention & control MH - *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology/chemistry MH - Male MH - Membranes, Artificial MH - Fibroblasts/drug effects MH - Nanofibers/chemistry MH - Rats MH - Tendons/drug effects MH - Cell Proliferation/drug effects MH - Delayed-Action Preparations MH - Achilles Tendon/drug effects MH - Porosity OTO - NOTNLM OT - Ibuprofen OT - Peritendinous anti-adhesion OT - Physical barrier OT - Porous PLLA fiber bundle OT - Uni-directional drug release EDAT- 2024/06/23 00:42 MHDA- 2024/07/28 14:51 CRDT- 2024/06/22 19:30 PHST- 2023/12/16 00:00 [received] PHST- 2024/05/31 00:00 [revised] PHST- 2024/06/19 00:00 [accepted] PHST- 2024/07/28 14:51 [medline] PHST- 2024/06/23 00:42 [pubmed] PHST- 2024/06/22 19:30 [entrez] AID - S0168-3659(24)00403-6 [pii] AID - 10.1016/j.jconrel.2024.06.046 [doi] PST - ppublish SO - J Control Release. 2024 Aug;372:251-264. doi: 10.1016/j.jconrel.2024.06.046. Epub 2024 Jun 24. PMID- 1761977 OWN - NLM STAT- MEDLINE DCOM- 19920213 LR - 20171213 IS - 0022-3077 (Print) IS - 0022-3077 (Linking) VI - 66 IP - 4 DP - 1991 Oct TI - Mechanical analysis of heterogenic inhibition between soleus muscle and the pretibial flexors in the cat. PG - 1139-55 AB - 1. The role of proprioceptive pathways linking the direct antagonists soleus (S) and tibialis anterior (TA) muscles in governing the mechanical properties of the ankle joint were studied in the decerebrate cat. Actions of these heterogenic pathways were compared with those between S and extensor digitorum longus (EDL), a muscle that also acts at the metatarsophalangeal joint. These neurally mediated interactions between S and either TA or EDL were studied by applying controlled length changes to the isolated tendons of pairs of these muscles and recording the resulting changes in force. The muscles were activated with the use of electrically evoked crossed-extension reflexes, flexion reflexes, and brain stem stimulation. 2. Heterogenic inhibition from TA or EDL onto S was well developed whether S was initially quiescent or activated by a crossed-extension reflex. The inhibition persisted for the duration of the stretch of TA or EDL. During a crossed-extension reflex, TA did not generate background force, but brief stretch reflexes could be obtained. During flexion reflexes, stretch reflexes in S were usually abolished, and heterogenic inhibition from S to TA was weak or absent. 3. The strength of the heterogenic inhibition onto S was dependent on the initial length and activation level of TA and EDL. Changes in flexor length or activation level per se did not alter the background force or strength of the stretch reflex in S. Even taking into account the variation of strength of inhibition with the initial state of the muscle of origin, the strength of the inhibition was stronger from TA to S than the other way around. 4. The contributions of heterogenic inhibition from TA and EDL to S were independent in the sense that these components summed linearly with each other and with the autogenic reflex in S. In addition, the magnitude of the inhibition from TA to S was proportional to the amplitude of stretch for low to intermediate levels of initial force in S. The inhibition appeared to affect the mechanical responses of S essentially as rapidly as the stretch reflex in this muscle. 5. The heterogenic inhibition from TA to S was reduced or abolished by intravenous injections of strychnine but unaffected by injections of picrotoxin or bicuculline. These results, together with the observation that the inhibition sums linearly with the stretch reflex, suggest that the mechanism of this heterogenic inhibition is glycinergic and postsynaptic and, therefore, may include Ia-disynaptic reciprocal inhibition.(ABSTRACT TRUNCATED AT 400 WORDS) FAU - Nichols, T R AU - Nichols TR AD - Department of Physiology, Emory University School of Medicine, Atlanta, Georgia 30322. FAU - Koffler-Smulevitz, D AU - Koffler-Smulevitz D LA - eng GR - NS-20855/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Neurophysiol JT - Journal of neurophysiology JID - 0375404 RN - 0 (Amino Acids) RN - 124-87-8 (Picrotoxin) RN - 76726-92-6 (2-Amino-5-phosphonovalerate) RN - H9Y79VD43J (Strychnine) RN - P34K80CUSM (2-amino-7-phosphonoheptanoic acid) RN - Y37615DVKC (Bicuculline) SB - IM MH - *2-Amino-5-phosphonovalerate/*analogs & derivatives MH - Amino Acids/pharmacology MH - Animals MH - Bicuculline/pharmacology MH - Cats MH - Electric Stimulation MH - Electromyography/drug effects MH - Female MH - Hindlimb/innervation/physiology MH - Injections, Intravenous MH - Isometric Contraction/drug effects MH - Joints/physiology MH - Male MH - Muscles/innervation/*physiology MH - Neural Pathways/physiology MH - Picrotoxin/pharmacology MH - Proprioception/*physiology MH - Reflex/drug effects MH - Strychnine/administration & dosage/pharmacology EDAT- 1991/10/01 00:00 MHDA- 1991/10/01 00:01 CRDT- 1991/10/01 00:00 PHST- 1991/10/01 00:00 [pubmed] PHST- 1991/10/01 00:01 [medline] PHST- 1991/10/01 00:00 [entrez] AID - 10.1152/jn.1991.66.4.1139 [doi] PST - ppublish SO - J Neurophysiol. 1991 Oct;66(4):1139-55. doi: 10.1152/jn.1991.66.4.1139. PMID- 32490900 OWN - NLM STAT- MEDLINE DCOM- 20200612 LR - 20211204 IS - 1678-2674 (Electronic) IS - 0102-8650 (Print) IS - 0102-8650 (Linking) VI - 35 IP - 3 DP - 2020 TI - Effect of low intensity photobiomodulation associated with norbixin-based poly (hydroxybutyrate) membrane on post-tenotomy tendon repair. In vivo study. PG - e202000303 LID - S0102-86502020000300204 [pii] LID - 10.1590/s0102-865020200030000003 [doi] LID - e202000303 AB - PURPOSE: To evaluate the in vivo response of photobiomodulation therapy associated with norbixin-based poly(hydroxybutyrate) membrane (PHB) in tenotomized calcaneal tendon. METHODS: Thirty rats were randomly allocated to six groups (n=5 each): LED groups (L1, L2 and L3) and membrane + LED groups (ML1, ML2 and ML3). The right calcaneal tendons of all animals were sectioned transversely and were irradiated with LED daily, one hour after surgery every 24 hours, until the day of euthanasia. At the end of the experiments the tendons were removed for histological analysis. RESULTS: The histological analysis showed a significant reduction in inflammatory cells in the ML1, ML2 and ML3 groups (p=0.0056, p=0.0018 and p<0.0001, respectively) compared to those in the LED group. There was greater proliferation of fibroblasts in the ML1 (p<0.0001) and L3 (p<0.0001) groups. A higher concentration of type I collagen was also observed in the ML1 group (p=0.0043) replacing type III collagen. CONCLUSION: Photobiomodulation in association with norbixin-based PHB membrane led to control of the inflammatory process. However, it did not favor fibroblast proliferation and did not optimize type I collagen formation in the expected stage of the repair process. FAU - Nascimento, Lízia Daniela E Silva AU - Nascimento LDES AUID- ORCID: 0000-0001-5837-8311 AD - Health Sciences Center, Universidade do Vale do Paraíba, Teresina, PI, Brazil. FAU - Nicolau, Renata Amadei AU - Nicolau RA AUID- ORCID: 0000-0002-7687-7963 AD - Postgraduate Program in Biomedical Engineering of the Research and Development Institute, Research and Development Institute, UNIVAP, Sao Jose dos Campos, SP, Brazil. FAU - Maia Filho, Antônio Luiz Martins AU - Maia Filho ALM AUID- ORCID: 0000-0001-6184-8003 AD - Health Sciences Center, Researcher of the Biotechnology and Biodiversity Core, UESPI, Teresina, PI, Brazil. FAU - Nascimento, Kárita Francisca E Silva AU - Nascimento KFES AUID- ORCID: 0000-0003-2985-6032 AD - Department of Social Assistance, SASC, Teresina, PI, Brazil. FAU - Santos, José Zilton Lima Verde AU - Santos JZLV AUID- ORCID: 0000-0001-9877-1994 AD - Center of Health Sciences, Medicine and Physical Therapy, UESPI, Brazil. FAU - Sousa, Rayssilane Cardoso de AU - Sousa RC AUID- ORCID: 0000-0003-4244-1560 AD - Postgraduate Program in Biotechnology, Universidade Federal do Piauí, Teresina, PI, Brazil. FAU - Carvalho, Luiz Fernando Meneses AU - Carvalho LFM AUID- ORCID: 0000-0002-1032-0230 AD - Postgraduate Program in Material Engineering, Federal Institute of Education, Science and Technology of Piaui, Teresina, PI, Brazil. FAU - Viana, Vicente Galber Freitas AU - Viana VGF AUID- ORCID: 0000-0002-3863-6974 AD - Postgraduate Program in Material Engineering (PPGEM), IFPI, Teresina, PI, Brazil. LA - eng PT - Journal Article DEP - 20200522 PL - Brazil TA - Acta Cir Bras JT - Acta cirurgica brasileira JID - 9103983 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Hydroxybutyrates) RN - 0 (Phb protein, rat) RN - 0 (Prohibitins) RN - 36-88-4 (Carotenoids) RN - 9007-34-5 (Collagen) RN - E8M59E17AI (norbixin) SB - IM MH - Achilles Tendon/drug effects/*radiation effects/surgery MH - Animals MH - Carotenoids/*pharmacology MH - Collagen/pharmacology MH - Collagen Type I/analysis/drug effects MH - Collagen Type III/analysis/drug effects MH - Drug Evaluation, Preclinical MH - Fibroblasts/chemistry/drug effects MH - Hydroxybutyrates/*pharmacology MH - Low-Level Light Therapy/*methods MH - Male MH - Prohibitins MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Tendinopathy/*radiotherapy MH - Tenotomy/*methods MH - Wound Healing/drug effects/radiation effects PMC - PMC7357841 COIS- Conflict of interest: none EDAT- 2020/06/04 06:00 MHDA- 2020/06/13 06:00 PMCR- 2020/05/22 CRDT- 2020/06/04 06:00 PHST- 2019/11/16 00:00 [received] PHST- 2020/02/15 00:00 [accepted] PHST- 2020/06/04 06:00 [entrez] PHST- 2020/06/04 06:00 [pubmed] PHST- 2020/06/13 06:00 [medline] PHST- 2020/05/22 00:00 [pmc-release] AID - S0102-86502020000300204 [pii] AID - 10.1590/s0102-865020200030000003 [doi] PST - ppublish SO - Acta Cir Bras. 2020;35(3):e202000303. doi: 10.1590/s0102-865020200030000003. Epub 2020 May 22. PMID- 10368466 OWN - NLM STAT- MEDLINE DCOM- 19990715 LR - 20190615 IS - 0002-9378 (Print) IS - 0002-9378 (Linking) VI - 180 IP - 6 Pt 1 DP - 1999 Jun TI - Risk factors for abruptio placentae and eclampsia: analysis of 445 consecutively managed women with severe preeclampsia and eclampsia. PG - 1322-9 AB - OBJECTIVE: Our purpose was to characterize the clinical presentation or laboratory variables predictive of either abruptio placentae or eclampsia in women with severe preeclampsia. STUDY DESIGN: Prospective collection of perinatal data from 445 consecutively managed women with severe preeclampsia and eclampsia. Univariate analysis was used to determine which of the independent variables were significantly different between the groups (abruptio placentae vs no abruptio placentae; eclampsia vs no eclampsia). Those with significant differences were then entered into multiple logistic regression analysis to determine those characteristics that were independently related to the outcome variable (abruptio placentae or eclampsia). Before multivariate analysis, the independent variables with an interval scale of measurement were converted to a dichotomous scale, with the receiver-operator characteristic curve used to determine a cutoff level. RESULTS: Univariate analysis revealed statistical significance for the following variables associated with eclampsia: uric acid concentration, > 8.1 mg/dL; proteinuria (>3+); headache; visual symptoms; deep tendon reflexes >3+; serum albumin concentration, <3 mg/dL; and serum creatinine concentration, >1.3 mg/dL. However, with subsequent multivariate analysis, only headache and deep tendon reflexes >3+ remained significant. Univariate analysis for variables associated with abruptio placentae revealed an association between bleeding and platelet count <60,000/mm3. There was no association between abruptio placentae and eclampsia and systolic, diastolic, or mean arterial pressure, quantitative proteinuria, epigastric pain, bleeding, gestational age at delivery, history of preeclampsia, or chronic hypertension. CONCLUSION: Quantitative proteinuria and degree of blood pressure elevation were not predictive of either abruptio placentae or eclampsia, as has previously been suggested. The greatest morbidity associated with eclampsia occurred in women with preterm gestations not receiving medical attention. FAU - Witlin, A G AU - Witlin AG AD - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, USA. FAU - Saade, G R AU - Saade GR FAU - Mattar, F AU - Mattar F FAU - Sibai, B M AU - Sibai BM LA - eng PT - Journal Article PL - United States TA - Am J Obstet Gynecol JT - American journal of obstetrics and gynecology JID - 0370476 RN - 0 (Serum Albumin) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Abruptio Placentae/complications/*diagnosis/physiopathology MH - Adolescent MH - Adult MH - Blood Pressure MH - Eclampsia/complications/*diagnosis/physiopathology MH - Female MH - Headache MH - Humans MH - Logistic Models MH - Pre-Eclampsia/*complications/physiopathology MH - Pregnancy MH - Prospective Studies MH - Proteinuria/urine MH - ROC Curve MH - Reflex MH - Risk Factors MH - Seizures MH - Serum Albumin/analysis MH - Tendons/physiopathology MH - Uric Acid/blood EDAT- 1999/06/16 00:00 MHDA- 1999/06/16 00:01 CRDT- 1999/06/16 00:00 PHST- 1999/06/16 00:00 [pubmed] PHST- 1999/06/16 00:01 [medline] PHST- 1999/06/16 00:00 [entrez] AID - S0002-9378(99)70014-1 [pii] AID - 10.1016/s0002-9378(99)70014-1 [doi] PST - ppublish SO - Am J Obstet Gynecol. 1999 Jun;180(6 Pt 1):1322-9. doi: 10.1016/s0002-9378(99)70014-1. PMID- 2017502 OWN - NLM STAT- MEDLINE DCOM- 19910522 LR - 20190712 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 87 IP - 5 DP - 1991 May TI - Biomechanical analysis of intrinsic tendon healing in vitro and the effects of vitamins A and E. PG - 925-30; discussion 931-2 AB - This in vitro study was designed to test the hypothesis that flexor tendons have an intrinsic capability to heal as judged by rigorously defined biomechanical criteria. Rabbit forepaw flexor tendons (n = 114) were transected and repaired in zone II and cultured in standard media or media supplemented with vitamin A or E. Tenorrhaphies were disrupted at 0, 2, 8, and 12 weeks after repair by fixed-speed tensiometry. The following parameters were calculated: true stress, true strain, and normalized energy absorption. Statistical analysis was by Student's t test. Peak stress (strength) increased equally in all groups over time (p less than 0.05), while normalized energy absorption (toughness) was markedly higher in the vitamin E-treated group after 2 weeks' incubation (p less than 0.05). These data represent the first biomechanical evidence of intrinsic tendon healing in vitro. Biomechanical methodology and vitamin effects are discussed in detail. FAU - Greenwald, D AU - Greenwald D AD - Section of Plastic Surgery, University of Chicago Pritzker School of Medicine, Ill. FAU - Mass, D AU - Mass D FAU - Gottlieb, L AU - Gottlieb L FAU - Tuel, R AU - Tuel R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 11103-57-4 (Vitamin A) RN - 1406-18-4 (Vitamin E) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Culture Techniques MH - Rabbits MH - Random Allocation MH - Tendons/drug effects/*physiology MH - Vitamin A/*pharmacology MH - Vitamin E/*pharmacology MH - Wound Healing/drug effects EDAT- 1991/05/01 00:00 MHDA- 1991/05/01 00:01 CRDT- 1991/05/01 00:00 PHST- 1991/05/01 00:00 [pubmed] PHST- 1991/05/01 00:01 [medline] PHST- 1991/05/01 00:00 [entrez] AID - 10.1097/00006534-199105000-00018 [doi] PST - ppublish SO - Plast Reconstr Surg. 1991 May;87(5):925-30; discussion 931-2. doi: 10.1097/00006534-199105000-00018. PMID- 39956454 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20250416 IS - 2059-7762 (Electronic) IS - 2059-7754 (Linking) VI - 11 DP - 2025 Apr TI - Efficacy of peri-articular and peri-hamstring injections for post-operative pain management in anterior cruciate ligament reconstruction with hamstring autograft: a double-blinded, randomized controlled trial. PG - 100842 LID - S2059-7754(25)00459-6 [pii] LID - 10.1016/j.jisako.2025.100842 [doi] AB - OBJECTIVES: This study aimed to evaluate the efficacy of combining multimodal cocktail drug local injection with adductor canal block versus adductor canal block alone for postoperative pain management following anterior cruciate ligament (ACL) reconstruction with hamstring autograft. METHODS: A randomized controlled trial was conducted with 40 patients undergoing ACL reconstruction. Participants were assigned to two groups: one received a multimodal cocktail drug injection into the peri-articular and peri-hamstring regions combined with an adductor canal block (study group), while the other received only the adductor canal block (control group). Pain was assessed using the numeric rating scale (NRS) overall and at the posteromedial thigh. Additional data included morphine consumption, postoperative nausea and vomiting (PONV), knee range of motion, and patient-reported outcomes. Statistical comparisons were performed using the unpaired t-test or Mann-Whitney U test, as appropriate, with significance set at P ​< ​0.05. RESULTS: The multimodal cocktail group reported statistically significantly lower overall NRS pain scores at 6, 12, and 24 ​h postoperatively compared to the control group (P ​< ​0.001 for all). At the posteromedial thigh, NRS scores were statistically significantly lower at 6 and 12 ​h (P ​< ​0.001) but not at 24 ​h or later time points. Morphine consumption was statistically significantly lower in the multimodal cocktail group at 12 and 24 ​h (P ​= ​0.004 and P ​= ​0.008, respectively), and PONV scores were reduced (P ​= ​0.04). No statistically significant differences were observed between the groups in knee flexion (P ​= ​0.656) or patient-reported outcomes at 6 weeks (P ​> ​0.05). CONCLUSIONS: The findings of this study suggest that multimodal cocktail injections may enhance early postoperative pain control, reduce opioid consumption, and minimize PONV without compromising short-term functional recovery. These findings support its potential role in pain management following ACL reconstruction, though larger studies are warranted to confirm these results. LEVEL OF EVIDENCE: Level I - randomized controlled trial. CI - Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Thamrongskulsiri, Napatpong AU - Thamrongskulsiri N AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Chancharoenchai, Phanusorn AU - Chancharoenchai P AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tanpowpong, Thanathep AU - Tanpowpong T AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Kuptniratsaikul, Somsak AU - Kuptniratsaikul S AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Itthipanichpong, Thun AU - Itthipanichpong T AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Limskul, Danaithep AU - Limskul D AD - Department of Orthopaedic, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address: danaithep.l@chula.ac.th. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20250214 PL - England TA - J ISAKOS JT - Journal of ISAKOS : joint disorders & orthopaedic sports medicine JID - 101680867 RN - 0 (Anesthetics, Local) RN - 76I7G6D29C (Morphine) RN - 0 (Analgesics, Opioid) SB - IM MH - Humans MH - *Anterior Cruciate Ligament Reconstruction/adverse effects/methods MH - *Pain, Postoperative/drug therapy/diagnosis/etiology MH - Male MH - Female MH - Adult MH - Double-Blind Method MH - *Pain Management/methods MH - Pain Measurement MH - Young Adult MH - *Nerve Block/methods MH - Treatment Outcome MH - *Hamstring Tendons/transplantation MH - *Anesthetics, Local/administration & dosage MH - Morphine/administration & dosage MH - Range of Motion, Articular MH - Injections, Intra-Articular MH - Postoperative Nausea and Vomiting MH - Transplantation, Autologous MH - Autografts MH - Analgesics, Opioid/administration & dosage MH - Hamstring Muscles/transplantation OTO - NOTNLM OT - Analgesia OT - Anterior cruciate ligament OT - Multimodal OT - Peri-articular OT - Peri-hamstring OT - Reconstruction COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/02/17 00:21 MHDA- 2025/04/10 00:20 CRDT- 2025/02/16 19:34 PHST- 2025/01/08 00:00 [received] PHST- 2025/02/07 00:00 [revised] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/04/10 00:20 [medline] PHST- 2025/02/17 00:21 [pubmed] PHST- 2025/02/16 19:34 [entrez] AID - S2059-7754(25)00459-6 [pii] AID - 10.1016/j.jisako.2025.100842 [doi] PST - ppublish SO - J ISAKOS. 2025 Apr;11:100842. doi: 10.1016/j.jisako.2025.100842. Epub 2025 Feb 14. PMID- 16951120 OWN - NLM STAT- MEDLINE DCOM- 20061031 LR - 20220408 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 88 IP - 9 DP - 2006 Sep TI - Nicotine delays tendon-to-bone healing in a rat shoulder model. PG - 2027-34 AB - BACKGROUND: Many studies have shown that nicotine negatively impacts fracture healing and bone fusion processes. However, very little is known about its effect on tendon and ligament healing. The goal of the present study was to evaluate the effect of nicotine on tendon-to-bone healing. METHODS: Supraspinatus tendons in both shoulders of seventy-two rats were transected and repaired to the humeral head. Osmotic pumps were implanted subcutaneously, and nicotine or saline solution was delivered for ten, twenty-eight, or fifty-six days. Cell morphology was evaluated with use of histologic sections. Cells were counted, and proliferating cell nuclear antigen (PCNA) immunohistochemistry was performed to assess cellular proliferation. In situ hybridization was performed to measure type-I collagen mRNA expression. Biomechanical and geometric properties were assessed. RESULTS: Inflammation persisted longer in the nicotine group than in the saline solution group. Cellular proliferation was higher in the saline solution group than in the nicotine group at the early time-points. Type-I collagen expression was higher in the saline solution group at twenty-eight days. Mechanical properties increased over time in both groups. Maximum stress was significantly lower in the nicotine group than in the saline solution group at ten days. Maximum force was significantly lower in the nicotine group than in the saline solution group at twenty-eight days. Maximum force was significantly higher in the nicotine group than in the saline solution group at fifty-six days. Stiffness was not different between the groups at any time-point. CONCLUSIONS: Nicotine caused a delay in tendon-to-bone healing in a rat rotator cuff animal model. Mechanical properties increased over time in both groups, but the properties in the nicotine group lagged behind those in the saline solution group. Chronic inflammation and decreased cell proliferation may partly explain the inferior biomechanical properties in the nicotine group as compared with the saline solution group. CLINICAL RELEVANCE: Failure of rotator cuff repair is a major clinical problem. The adverse effect of nicotine on rotator cuff healing noted in this clinically appropriate animal model may be an important clinical consideration. FAU - Galatz, L M AU - Galatz LM AD - Department of Orthopaedic Research, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8233, St. Louis, MO 63110, USA. galatzl@wustl.edu FAU - Silva, M J AU - Silva MJ FAU - Rothermich, S Y AU - Rothermich SY FAU - Zaegel, M A AU - Zaegel MA FAU - Havlioglu, N AU - Havlioglu N FAU - Thomopoulos, S AU - Thomopoulos S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Nicotinic Agonists) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 6M3C89ZY6R (Nicotine) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Cell Proliferation MH - Disease Models, Animal MH - Immunohistochemistry MH - Male MH - Nicotine/*pharmacology MH - Nicotinic Agonists/*pharmacology MH - Proliferating Cell Nuclear Antigen/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - *Rotator Cuff Injuries MH - Wound Healing/*drug effects EDAT- 2006/09/05 09:00 MHDA- 2006/11/01 09:00 CRDT- 2006/09/05 09:00 PHST- 2006/09/05 09:00 [pubmed] PHST- 2006/11/01 09:00 [medline] PHST- 2006/09/05 09:00 [entrez] AID - 88/9/2027 [pii] AID - 10.2106/JBJS.E.00899 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2006 Sep;88(9):2027-34. doi: 10.2106/JBJS.E.00899. PMID- 19139865 OWN - NLM STAT- MEDLINE DCOM- 20090423 LR - 20211020 IS - 1432-1106 (Electronic) IS - 0014-4819 (Linking) VI - 194 IP - 2 DP - 2009 Apr TI - Glutamate and capsaicin-induced pain, hyperalgesia and modulatory interactions in human tendon tissue. PG - 173-82 LID - 10.1007/s00221-008-1683-3 [doi] AB - Experimental glutamate and capsaicin-induced pain has not been described in tendon tissue despite the implications of addressing these receptors in pain management strategies. This study investigated pain induction and modulatory interactions by injecting glutamate (0.5 ml, 1 M) and capsaicin (0.5 ml, 5 microg, 33 microM) to human tendon tissue. Following the initial glutamate or capsaicin injection, a second injection of either glutamate (following capsaicin), capsaicin (following glutamate) or hypertonic saline (after both glutamate and capsaicin) was given. Twelve male volunteers participated. Subjects had four sequences of injections to tibialis anterior tendon over two sessions 1 week apart. Pain intensity responses were scored on a visual analogue scale (VAS). Pressure pain thresholds (PPTs) were assessed before, during and after pain induction. Capsaicin caused significantly higher peak pain scores compared to glutamate (P < 0.003) whilst glutamate pain was of significantly longer duration (P < 0.0003). Capsaicin following glutamate resulted in significantly higher average VAS scores 180-450 s after injection compared to capsaicin as primary injection (P < 0.05). PPTs were significantly reduced during capsaicin pain (72 +/- 5 and 80 +/- 6% of pre-pain values at the injection site and 2 cm proximal, P < 0.002). Following capsaicin, hypertonic saline and glutamate showed significant reductions in PPT at the same sites and to a similar degree compared to baseline (P < 0.002). The results indicate in tendon tissue a facilitation of response to capsaicin injection following glutamate injection. PPTs were only reliably reduced by capsaicin injection. These results emphasize the possible importance of peripheral glutamate receptor antagonists in pain management in musculoskeletal conditions. FAU - Gibson, William AU - Gibson W AD - Laboratory for Experimental Pain Research, Center for Sensory-Motor Interaction, Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7D-3, 9220, Aalborg, Denmark. w.gibson@curtin.edu.au FAU - Arendt-Nielsen, Lars AU - Arendt-Nielsen L FAU - Sessle, Barry J AU - Sessle BJ FAU - Graven-Nielsen, Thomas AU - Graven-Nielsen T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090113 PL - Germany TA - Exp Brain Res JT - Experimental brain research JID - 0043312 RN - 3KX376GY7L (Glutamic Acid) RN - S07O44R1ZM (Capsaicin) SB - IM MH - Adult MH - Analysis of Variance MH - Capsaicin/*administration & dosage MH - Drug Interactions MH - Glutamic Acid/*administration & dosage MH - Humans MH - Hyperalgesia/*chemically induced/physiopathology MH - Male MH - Pain/*chemically induced/physiopathology MH - Pain Measurement MH - Pain Threshold/drug effects MH - Physical Stimulation MH - Tendons/drug effects/*physiopathology MH - Young Adult EDAT- 2009/01/14 09:00 MHDA- 2009/04/25 09:00 CRDT- 2009/01/14 09:00 PHST- 2006/12/22 00:00 [received] PHST- 2008/12/05 00:00 [accepted] PHST- 2009/01/14 09:00 [entrez] PHST- 2009/01/14 09:00 [pubmed] PHST- 2009/04/25 09:00 [medline] AID - 10.1007/s00221-008-1683-3 [doi] PST - ppublish SO - Exp Brain Res. 2009 Apr;194(2):173-82. doi: 10.1007/s00221-008-1683-3. Epub 2009 Jan 13. PMID- 17923056 OWN - NLM STAT- MEDLINE DCOM- 20080227 LR - 20220408 IS - 1071-1007 (Print) IS - 1071-1007 (Linking) VI - 28 IP - 10 DP - 2007 Oct TI - Three-year followup study of topical glyceryl trinitrate treatment of chronic noninsertional Achilles tendinopathy. PG - 1064-8 AB - BACKGROUND: Topical glyceryl trinitrate treatment has demonstrated short-term efficacy in chronic noninsertional Achilles tendinopathy. No long-term followup is reported. We aimed to assess if the demonstrated efficacy of this treatment persisted 3 years after discontinuation of therapy. METHODS: A follow-up study of 52 patients (68 tendons) treated with 6 months of glyceryl trinitrate therapy or placebo was performed 3 years after cessation of therapy. Assessment included pain scores, return to previous activity, the Victorian Institute of Sport Achilles tendon scale (VISA-A), asymptomatic patient outcomes, clinical assessment of tendon tenderness, and functional hop test. RESULTS: Patients treated with topical glyceryl trinitrate had significantly less Achilles tendon tenderness (p = 0.03), and improved VISA-A scores (p = 0.04) than those in the placebo group; 88% (28 of 32 tendons) of patients were completely asymptomatic at 3 years (VISA-A score of 100) compared to 67% (24 of 36 tendons) of patients treated with rehabilitation alone (p = 0.03 with Chi square analysis). Other outcome measures showed nonsignificant trends towards improvement in the glyceryl trinitrate group (pain scores p = 0.07, functional hop test p = 0.07, and return to sport p = 0.16). The mean estimated effect size for all outcome measures was 0.21. CONCLUSIONS: Topical glyceryl trinitrate treatment has demonstrated efficacy in treating chronic noninsertional Achilles tendinopathy, and the treatment benefits continue at 3 years. Significant differences in asymptomatic patient outcomes for the glyceryl trinitrate group continue at 3 years, and this is confirmed by the effect size estimate. This suggests that the mechanism of action of topical glyceryl trinitrate on chronic tendinopathies is more than an analgesic effect. FAU - Paoloni, Justin Alan AU - Paoloni JA AD - University of New South Wales, Orthopaedic Research Institute, 2nd Floor, 4-10 South St, Kogarah, Sydney, NSW, Australia. jpaoloni@bigpond.net.au FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Foot Ankle Int JT - Foot & ankle international JID - 9433869 RN - 0 (Vasodilator Agents) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Achilles Tendon/*drug effects/pathology MH - Administration, Topical MH - Adult MH - Aged MH - Chronic Disease MH - Double-Blind Method MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Nitroglycerin/administration & dosage/*therapeutic use MH - Tendinopathy/*drug therapy MH - Time Factors MH - Treatment Outcome MH - Vasodilator Agents/administration & dosage/*therapeutic use EDAT- 2007/10/10 09:00 MHDA- 2008/02/28 09:00 CRDT- 2007/10/10 09:00 PHST- 2007/10/10 09:00 [pubmed] PHST- 2008/02/28 09:00 [medline] PHST- 2007/10/10 09:00 [entrez] AID - 961829 [pii] AID - 10.3113/FAI.2007.1064 [doi] PST - ppublish SO - Foot Ankle Int. 2007 Oct;28(10):1064-8. doi: 10.3113/FAI.2007.1064. PMID- 25528374 OWN - NLM STAT- MEDLINE DCOM- 20151026 LR - 20181113 IS - 1432-1017 (Electronic) IS - 0175-7571 (Linking) VI - 44 IP - 1-2 DP - 2015 Feb TI - Capsaicin inhibits collagen fibril formation and increases the stability of collagen fibers. PG - 69-76 LID - 10.1007/s00249-014-1002-9 [doi] AB - Capsaicin is a versatile plant product which has been ascribed several health benefits and anti-inflammatory and analgesic properties. We have investigated the effect of capsaicin on the molecular stability, self-assembly, and fibril stability of type-I collagen. It was found that capsaicin suppresses collagen fibril formation, increases the stability of collagen fibers in tendons, and has no effect on the molecular stability of collagen. Turbidity assay data show that capsaicin does not promote disassembly of collagen fibrils. However, capsaicin moderately protects collagen fibrils from enzymatic degradation. Computational studies revealed the functions of the aromatic group and amide region of capsaicin in the collagen-capsaicin interaction. The results may have significant implications for capsaicin-based therapeutics that target excess collagen accumulation-linked pathology, for example thrombosis, fibrosis, and sclerosis. FAU - Perumal, Sathiamurthi AU - Perumal S AD - CSIR-Central Leather Research Institute, Adyar, Chennai, 600020, Tamil Nadu, India. FAU - Dubey, Kriti AU - Dubey K FAU - Badhwar, Rahul AU - Badhwar R FAU - George, Kodimattan Joseph AU - George KJ FAU - Sharma, Rakesh Kumar AU - Sharma RK FAU - Bagler, Ganesh AU - Bagler G FAU - Madhan, Balaraman AU - Madhan B FAU - Kar, Karunakar AU - Kar K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141221 PL - Germany TA - Eur Biophys J JT - European biophysics journal : EBJ JID - 8409413 RN - 0 (Fibrillar Collagens) RN - S07O44R1ZM (Capsaicin) SB - IM MH - Amino Acid Sequence MH - Animals MH - Capsaicin/chemistry/*pharmacology MH - Fibrillar Collagens/*chemistry/metabolism MH - Male MH - Molecular Docking Simulation MH - Molecular Sequence Data MH - Protein Binding MH - Protein Stability MH - Proteolysis MH - Rats MH - Rats, Wistar EDAT- 2014/12/22 06:00 MHDA- 2015/10/27 06:00 CRDT- 2014/12/22 06:00 PHST- 2014/09/21 00:00 [received] PHST- 2014/11/27 00:00 [accepted] PHST- 2014/11/23 00:00 [revised] PHST- 2014/12/22 06:00 [entrez] PHST- 2014/12/22 06:00 [pubmed] PHST- 2015/10/27 06:00 [medline] AID - 10.1007/s00249-014-1002-9 [doi] PST - ppublish SO - Eur Biophys J. 2015 Feb;44(1-2):69-76. doi: 10.1007/s00249-014-1002-9. Epub 2014 Dec 21. PMID- 38539076 OWN - NLM STAT- MEDLINE DCOM- 20240329 LR - 20241108 IS - 1471-2253 (Electronic) IS - 1471-2253 (Linking) VI - 24 IP - 1 DP - 2024 Mar 27 TI - The value of local dexmedetomidine as an adjuvant to ultrasound-guided wide awake local anesthesia no tourniquet (WALANT) in flexor tendon repair surgeries: a randomized controlled trial. PG - 120 LID - 10.1186/s12871-024-02504-x [doi] LID - 120 AB - BACKGROUND: The Wide-Awake Local Anesthesia No Tourniquet (WALANT) technique allows intraoperative motor assessment of tendon repair integrity of the hand compared with general anesthesia or brachial plexus block. No studies have tested the effect of adding dexmedetomidine to lidocaine on the analgesic properties of the WALANT technique, which is the aim of our study. METHODS: A total of 128 patients aged more than 18 years were scheduled for surgical flexor tendon injury repair using WALANT technique. Patients were divided into two equal groups. Ultrasound-guided subcutaneous injection of lidocaine 1% with dexmedetomidine (1 µg/kg), Group D, or without dexmedetomidine, Group C, was performed at four points: proximal to the wrist joint, the distal forearm, palm region, and proximal phalanges. The primary outcome was total morphine consumption throughout the first postoperative day. Secondary outcomes included number of patients requiring rescue analgesia, time to first analgesic request, and pain score. RESULTS: Total morphine consumption was significantly (P < 0.001) lower in group D (2.66 ± 0.998) than in group C (3.66 ± 1.144) mg. Number of patients requiring rescue analgesia was significantly (P < 0.001) lower in group D (54.7% (35)) than group C (100.0% (64)). The time for first request for analgesia was significantly (P < 0.001) longer in group D (11.31 ± 6.944) than in group C (5.91 ± 4.839) h. Pain score was significantly higher in group C than D at three (P < 0.001), and six (P = 0.001) hours (P = 0.001) postoperatively. CONCLUSION: Dexmedetomidine significantly improves the analgesic quality of WALANT when added to lidocaine with less opioid consumption. TRIAL REGISTRATION: (ID: PACTR202203906027106; Date: 31/07/2023). CI - © 2024. The Author(s). FAU - Alseoudy, Mahmoud Mohammed AU - Alseoudy MM AD - Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Abdelsalam Aref St., Mansoura City, El-Dakahliya Governorate, Egypt. drs3ody.mansora@mans.edu.eg. FAU - Abdelkarime, Elsayed Mohamed AU - Abdelkarime EM AD - Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Abdelsalam Aref St., Mansoura City, El-Dakahliya Governorate, Egypt. FAU - Nour, Khaled AU - Nour K AD - Department of Orthopedic Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt. FAU - Badr, May Elsherbiny AU - Badr ME AD - Department of Anesthesia and Surgical Intensive Care, Faculty of Medicine, Mansoura University, Abdelsalam Aref St., Mansoura City, El-Dakahliya Governorate, Egypt. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20240327 PL - England TA - BMC Anesthesiol JT - BMC anesthesiology JID - 100968535 RN - 0 (Analgesics) RN - 0 (Anesthetics, Local) RN - 67VB76HONO (Dexmedetomidine) RN - 98PI200987 (Lidocaine) RN - 76I7G6D29C (Morphine) SB - IM MH - Humans MH - Analgesics MH - *Anesthesia, Local/methods MH - Anesthetics, Local MH - *Dexmedetomidine MH - Lidocaine MH - Morphine MH - Pain, Postoperative/drug therapy MH - Tendons MH - Ultrasonography, Interventional MH - Adolescent MH - Young Adult PMC - PMC10967158 OTO - NOTNLM OT - Analgesia OT - Dexmedetomidine OT - Flexor tendon repair OT - Morphine OT - Ultrasound OT - WALANT COIS- The authors declare no competing interests. EDAT- 2024/03/28 06:44 MHDA- 2024/03/29 06:46 PMCR- 2024/03/27 CRDT- 2024/03/28 00:43 PHST- 2024/01/18 00:00 [received] PHST- 2024/03/19 00:00 [accepted] PHST- 2024/03/29 06:46 [medline] PHST- 2024/03/28 06:44 [pubmed] PHST- 2024/03/28 00:43 [entrez] PHST- 2024/03/27 00:00 [pmc-release] AID - 10.1186/s12871-024-02504-x [pii] AID - 2504 [pii] AID - 10.1186/s12871-024-02504-x [doi] PST - epublish SO - BMC Anesthesiol. 2024 Mar 27;24(1):120. doi: 10.1186/s12871-024-02504-x. PMID- 31560698 OWN - NLM STAT- MEDLINE DCOM- 20200312 LR - 20210630 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 14 IP - 9 DP - 2019 TI - HMGB1 mediates the development of tendinopathy due to mechanical overloading. PG - e0222369 LID - 10.1371/journal.pone.0222369 [doi] LID - e0222369 AB - Mechanical overloading is a major cause of tendinopathy, but the underlying pathogenesis of tendinopathy is unclear. Here we report that high mobility group box1 (HMGB1) is released to the tendon extracellular matrix and initiates an inflammatory cascade in response to mechanical overloading in a mouse model. Moreover, administration of glycyrrhizin (GL), a naturally occurring triterpene and a specific inhibitor of HMGB1, inhibits the tendon's inflammatory reactions. Also, while prolonged mechanical overloading in the form of long-term intensive treadmill running induces Achilles tendinopathy in mice, administration of GL completely blocks the tendinopathy development. Additionally, mechanical overloading of tendon cells in vitro induces HMGB1 release to the extracellular milieu, thereby eliciting inflammatory and catabolic responses as marked by increased production of prostaglandin E2 (PGE2) and matrix metalloproteinase-3 (MMP-3) in tendon cells. Application of GL abolishes the cellular inflammatory/catabolic responses. Collectively, these findings point to HMGB1 as a key molecule that is responsible for the induction of tendinopathy due to mechanical overloading placed on the tendon. FAU - Zhao, Guangyi AU - Zhao G AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. FAU - Zhang, Jianying AU - Zhang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. FAU - Nie, Daibang AU - Nie D AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. FAU - Zhou, Yiqin AU - Zhou Y AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. AD - Joint Surgery and Sports Medicine Department, Shanghai Changzheng Hospital, Second Military Medical University, Huangpu, Shanghai, China. FAU - Li, Feng AU - Li F AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. FAU - Onishi, Kentaro AU - Onishi K AD - Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. FAU - Billiar, Timothy AU - Billiar T AD - Department of Surgery, University of Pittsburgh, Pennsylvania, United States of America. FAU - Wang, James H-C AU - Wang JH AUID- ORCID: 0000-0001-7279-0679 AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. AD - Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America. LA - eng GR - P30 AG024827/AG/NIA NIH HHS/United States GR - R21 AR070340/AR/NIAMS NIH HHS/United States GR - P30 DK120531/DK/NIDDK NIH HHS/United States GR - R01 AR065949/AR/NIAMS NIH HHS/United States GR - R01 AR061395/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20190927 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (HMGB1 Protein) RN - 0 (HMGB1 protein, mouse) RN - 6FO62043WK (Glycyrrhizic Acid) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Animals MH - Blotting, Western MH - Dinoprostone/metabolism MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Glycyrrhizic Acid/pharmacology MH - HMGB1 Protein/antagonists & inhibitors/metabolism/*physiology MH - Matrix Metalloproteinase 3/metabolism MH - Mice MH - Mice, Inbred C57BL MH - Rats, Sprague-Dawley MH - Tendinopathy/etiology/*metabolism/physiopathology MH - Tendons/cytology/metabolism/physiopathology MH - Weight-Bearing/physiology PMC - PMC6764662 COIS- The authors have declared that no competing interests exist. EDAT- 2019/09/29 06:00 MHDA- 2020/03/13 06:00 PMCR- 2019/09/27 CRDT- 2019/09/28 06:00 PHST- 2019/08/21 00:00 [received] PHST- 2019/09/16 00:00 [accepted] PHST- 2019/09/28 06:00 [entrez] PHST- 2019/09/29 06:00 [pubmed] PHST- 2020/03/13 06:00 [medline] PHST- 2019/09/27 00:00 [pmc-release] AID - PONE-D-19-23610 [pii] AID - 10.1371/journal.pone.0222369 [doi] PST - epublish SO - PLoS One. 2019 Sep 27;14(9):e0222369. doi: 10.1371/journal.pone.0222369. eCollection 2019. PMID- 24004657 OWN - NLM STAT- MEDLINE DCOM- 20140707 LR - 20220408 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 8 DP - 2013 Sep 2 TI - Diclofenac and triamcinolone acetonide impair tenocytic differentiation and promote adipocytic differentiation of mesenchymal stem cells. PG - 30 LID - 10.1186/1749-799X-8-30 [doi] AB - BACKGROUND: Tendinopathies are often empirically treated with oral/topical nonsteroidal anti-inflammatory medications and corticosteroid injections despite their unclear effects on tendon regeneration. Recent studies indicate that tendon progenitors exhibit stem cell-like properties, i.e., differentiation to osteoblasts, adipocytes, and chondrocytes, in addition to tenocytes. Our present study aims at understanding the effects of triamcinolone acetonide and diclofenac on tenocytic differentiation of mesenchymal stem cells. METHODS: The murine fibroblast C3H10T1/2 cell line was induced to tenocytic differentiation by growth differentiation factor-7. Cell proliferation and differentiation with the exposure of different concentrations of triamcinolone acetonide and diclofenac were measured by WST-1 assay and real-time polymerase chain reaction analysis, respectively. RESULTS: Cell proliferation was decreased in a concentration-dependent manner when exposed to triamcinolone acetonide and diclofenac. In addition to tenocytic differentiation, adipocyte formation was observed, both at gene expression and microscopic level, when the cells were exposed to triamcinolone acetonide or high concentrations of diclofenac. CONCLUSIONS: Our results indicate that triamcinolone acetonide and diclofenac might alter mesenchymal stem cell differentiation in a nonfavorable way regarding tendon regeneration; therefore, these medications should be used with more caution clinically. FAU - Fredriksson, Maritha AU - Fredriksson M AD - Department of Clinical Intervention, Technology and Science, Karolinska Institutet, Stockholm 141 86, Sweden. Maritha.Fredrission@ki.se. FAU - Li, Yan AU - Li Y FAU - Stålman, Anders AU - Stålman A FAU - Haldosén, Lars-Arne AU - Haldosén LA FAU - Felländer-Tsai, Li AU - Felländer-Tsai L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130902 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Fabp4 protein, mouse) RN - 0 (Fatty Acid-Binding Proteins) RN - 0 (Gdf7 protein, mouse) RN - 0 (Glucocorticoids) RN - 0 (Growth Differentiation Factors) RN - 144O8QL0L1 (Diclofenac) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Adipocytes/*drug effects MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology MH - Bone Morphogenetic Proteins/pharmacology MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Diclofenac/administration & dosage/*pharmacology MH - Dose-Response Relationship, Drug MH - Fatty Acid-Binding Proteins/biosynthesis/genetics MH - Gene Expression Regulation/drug effects MH - Glucocorticoids/administration & dosage/pharmacology MH - Growth Differentiation Factors/pharmacology MH - Mesenchymal Stem Cells/cytology/*drug effects/metabolism MH - Mice MH - Tendons/cytology/*drug effects MH - Triamcinolone Acetonide/administration & dosage/*pharmacology PMC - PMC3766711 EDAT- 2013/09/06 06:00 MHDA- 2014/07/08 06:00 PMCR- 2013/09/02 CRDT- 2013/09/06 06:00 PHST- 2012/09/30 00:00 [received] PHST- 2013/08/12 00:00 [accepted] PHST- 2013/09/06 06:00 [entrez] PHST- 2013/09/06 06:00 [pubmed] PHST- 2014/07/08 06:00 [medline] PHST- 2013/09/02 00:00 [pmc-release] AID - 1749-799X-8-30 [pii] AID - 10.1186/1749-799X-8-30 [doi] PST - epublish SO - J Orthop Surg Res. 2013 Sep 2;8:30. doi: 10.1186/1749-799X-8-30. PMID- 6150636 OWN - NLM STAT- MEDLINE DCOM- 19850109 LR - 20131121 IS - 0002-9289 (Print) IS - 0002-9289 (Linking) VI - 41 IP - 11 DP - 1984 Nov TI - Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. PG - 2410-4 AB - The pathophysiology and mechanisms of toxicity of anthracycline-induced skin damage are reviewed, and the various available therapeutic interventions are discussed. Skin ulcers caused by the vesicant antineoplastic agents doxorubicin hydrochloride and daunorubicin hydrochloride begin slowly, and the extent of the tissue damage produced is often underestimated. Within a week, untreated infiltrations of these agents can advance to serious indurations and ulcerations, causing extensive damage to underlying structures such as tendons and bones. Two theories have been proposed to explain the mechanism of action of anthrocycline-induced tissue damage; one holds that doxorubicin-DNA complexes form causing cell death, and the other holds that these agents are reduced to free radicals that can cause cell-membrane damage. Nonpharmacologic treatment of extravasation consists of stopping the infusion at the first sign of a problem and attempting to aspirate fluid and drug back through the same needle. The application of ice packs for the next 24-72 hours is recommended. A variety of pharmacologic approaches have been evaluated to ameliorate tissue damage. Corticosteroids, sodium bicarbonate, beta-adrenergic agents, and dimethyl sulfoxide have been used with some success. Patients who do not respond to initial conservative treatments should be referred to a plastic surgeon for skin grafting and reconstruction. The best treatment for anthracycline toxicity is prevention. FAU - Cox, R F AU - Cox RF LA - eng PT - Journal Article PL - United States TA - Am J Hosp Pharm JT - American journal of hospital pharmacy JID - 0370474 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Adrenergic beta-Antagonists) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Bicarbonates) RN - 1406-18-4 (Vitamin E) RN - 80168379AG (Doxorubicin) RN - 8MDF5V39QO (Sodium Bicarbonate) RN - YOW8V9698H (Dimethyl Sulfoxide) RN - ZS7284E0ZP (Daunorubicin) SB - IM MH - Administration, Topical MH - Adrenal Cortex Hormones/therapeutic use MH - Adrenergic beta-Antagonists/therapeutic use MH - Anti-Inflammatory Agents/therapeutic use MH - Bicarbonates/therapeutic use MH - Daunorubicin/*adverse effects MH - Dimethyl Sulfoxide/therapeutic use MH - Doxorubicin/*adverse effects MH - Extravasation of Diagnostic and Therapeutic Materials/complications MH - Humans MH - Skin Diseases/*chemically induced/drug therapy MH - Sodium Bicarbonate MH - Vitamin E/therapeutic use EDAT- 1984/11/01 00:00 MHDA- 1984/11/01 00:01 CRDT- 1984/11/01 00:00 PHST- 1984/11/01 00:00 [pubmed] PHST- 1984/11/01 00:01 [medline] PHST- 1984/11/01 00:00 [entrez] PST - ppublish SO - Am J Hosp Pharm. 1984 Nov;41(11):2410-4. PMID- 29442150 OWN - NLM STAT- MEDLINE DCOM- 20180924 LR - 20181113 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 38 IP - 5 DP - 2018 May TI - Ultrasound scans and dual energy CT identify tendons as preferred anatomical location of MSU crystal depositions in gouty joints. PG - 801-811 LID - 10.1007/s00296-018-3994-4 [doi] AB - OBJECTIVE: The present study was performed to localize the articular deposition of monosodium urate (MSU) crystal in joints. We compare the detection efficiencies of dual-energy CT (DECT) and ultrasound scans. METHODS: Analyses by DECT and ultrasound were performed with 184 bilateral joints of the lower limbs of 54 consecutive gout patients. All joints were categorized into (1) knee, (2) ankle, (3) MTP1, and (4) MTP2, and sorted into those with and those without detectable MSU deposition. The comparison of the positive rate between DECT and ultrasound and the agreement was performed using the McNemar test and the Cohen's κ coefficient, respectively. Next, we listed the MSU crystal deposition as assessed by ultrasound between the DECT-positive and -negative joints according to their interior structure. We included tendons, synovia, cartilage, subcutaneous tissue, etc. RESULTS: Among all joints, the percentages with MSU crystal deposition detected by DECT (99/184, 53.8%) and ultrasound (106/184, 57.6%) were comparable (P = 0.530 > 0.05). For MTP1 (21/34, 61.8%; 12/34, 35.3%; P < 0.05) and MTP2-5 (17/34, 50.0%; 10/34, 29.4%, P < 0.05), ultrasound and DECT were more efficient, respectively. The data concordance in 46 of 50 joints (92.00%; κ = 0.769, P < 0.05) for knee; and 27 of 34 joints (79.41%; κ = 0.588, P < 0.05) for MTP2-5 and suggested that tendons were the most frequent anatomical location of MSU crystal deposition. CONCLUSIONS: The tendons are the most frequent anatomical location of MSU crystal depositions. The concordance rate of knee joints and MTP2-5 joints shows good agreement between DECT and ultrasound depending on the location. FAU - Yuan, Yuan AU - Yuan Y AD - Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 610041, Chengdu, China. AD - Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, 646000, Luzhou, China. FAU - Liu, Chang AU - Liu C AD - Department of Medical Imaging, West China Hospital, Sichuan University, 610041, Chengdu, China. FAU - Xiang, Xi AU - Xiang X AD - Department of Musculoskeletal Ultrasound, West China Hospital, Sichuan University, 610041, Chengdu, China. FAU - Yuan, Tong-Ling AU - Yuan TL AD - Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 610041, Chengdu, China. FAU - Qiu, Li AU - Qiu L AD - Department of Musculoskeletal Ultrasound, West China Hospital, Sichuan University, 610041, Chengdu, China. FAU - Liu, Yi AU - Liu Y AD - Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 610041, Chengdu, China. AD - Department of Rheumatology and Immunology, Affiliated Hospital of Southwest Medical University, 646000, Luzhou, China. FAU - Luo, Yu-Bin AU - Luo YB AD - Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 610041, Chengdu, China. FAU - Zhao, Y AU - Zhao Y AD - Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 610041, Chengdu, China. zhao.y1977@163.com. FAU - Herrmann, Martin AU - Herrmann M AD - Department of Internal Medicine 3, University of Erlangen-Nuremberg, 91054, Erlangen, Germany. LA - eng GR - 81273286/the National Natural Science Foundation of China/ GR - 2015HH0050/International Collaborative Project in Science and Technology of the Sichuan province/ PT - Comparative Study PT - Journal Article DEP - 20180213 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Ankle Joint/chemistry/*diagnostic imaging MH - Crystallization MH - Female MH - Gout/*diagnostic imaging/metabolism MH - Humans MH - Knee Joint/chemistry/*diagnostic imaging MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Reproducibility of Results MH - Tendons/chemistry/*diagnostic imaging MH - *Tomography, X-Ray Computed MH - *Ultrasonography MH - Uric Acid/*analysis MH - Young Adult OTO - NOTNLM OT - Concordance rate OT - Detection efficiency OT - Dual-energy CT (DECT) OT - MSU crystal deposition OT - Ultrasound EDAT- 2018/02/15 06:00 MHDA- 2018/09/25 06:00 CRDT- 2018/02/15 06:00 PHST- 2017/09/09 00:00 [received] PHST- 2018/02/05 00:00 [accepted] PHST- 2018/02/15 06:00 [pubmed] PHST- 2018/09/25 06:00 [medline] PHST- 2018/02/15 06:00 [entrez] AID - 10.1007/s00296-018-3994-4 [pii] AID - 10.1007/s00296-018-3994-4 [doi] PST - ppublish SO - Rheumatol Int. 2018 May;38(5):801-811. doi: 10.1007/s00296-018-3994-4. Epub 2018 Feb 13. PMID- 37017249 OWN - NLM STAT- MEDLINE DCOM- 20230502 LR - 20230502 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 51 IP - 6 DP - 2023 May TI - The Effect of Vitamin C and N-Acetylcysteine on Tendon-to-Bone Healing in a Rodent Model of Rotator Cuff Repair. PG - 1596-1607 LID - 10.1177/03635465231160772 [doi] AB - BACKGROUND: Oxidative stress inhibits tendon-to-bone healing after rotator cuff repair. Regulation of oxidative stress has the potential to accelerate this healing, but its mechanism remains unclear. PURPOSE: To investigate the effects of reducing oxidative stress by applying antioxidants, such as N-acetylcysteine (NAC) and vitamin C (VC), on rotator cuff repair in a rat rotator cuff repair model. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 48 Sprague Dawley rats underwent bilateral surgery to repair the infraspinatus tendon to its insertion site 1 week after detachment. Rats were assigned to either the NAC group, the VC group, or a control group. Histological evaluation was performed via hematoxylin-eosin or toluidine blue staining, and oxidative stress was assessed via dihydroethidium intensity and protein carbonyl concentration at 3 and 6 weeks. Superoxide dismutase 1 (SOD1), SOD2, SOD3, peroxiredoxin 5, collagen type I (COL1), COL3, matrix metalloproteinase 1 (MMP-1), MMP-3, and MMP-13 expression and SOD activity were determined at 3 and 6 weeks. Biomechanical tests were performed at 6 and 12 weeks. RESULTS: Histological evaluation showed that the number of chondrocytes in the NAC group at 6 weeks and in the VC group at 3 and 6 weeks, the area of fibrocartilage at 6 weeks in the VC group, and collagen fibers at 6 weeks in the NAC and VC groups were significantly increased compared with those in the control group. Dihydroethidium intensity at 3 and 6 weeks and protein carbonyls at 6 weeks in the NAC and VC groups were significantly decreased. SOD1 expression and SOD activity at 3 weeks in the VC group and peroxiredoxin 5 expression at 6 weeks in the NAC group were significantly upregulated compared with that in the control group. COL3 expression was significantly upregulated at 6 weeks in the VC group, and MMP-13 expression was significantly decreased at 6 weeks in the NAC and VC groups. The biomechanical strength showed no significant difference. CONCLUSION: Antioxidant treatment, via NAC or VC administration, reduced oxidative stress in the rotator cuff repair site and accelerated healing. CLINICAL RELEVANCE: These findings provide essential indications to develop clinical strategies for improved healing after rotator cuff surgical repair in patients. FAU - Uehara, Hirohisa AU - Uehara H AD - Department of Orthopaedic Surgery, Juntendo University Urayasu Hospital, Chiba, Japan. AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Itoigawa, Yoshiaki AU - Itoigawa Y AUID- ORCID: 0000-0002-5793-9655 AD - Department of Orthopaedic Surgery, Juntendo University Urayasu Hospital, Chiba, Japan. AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Morikawa, Daichi AU - Morikawa D AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Koga, Akihisa AU - Koga A AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Tsurukami, Hironori AU - Tsurukami H AD - Department of Orthopaedic Surgery, Juntendo University Urayasu Hospital, Chiba, Japan. AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. FAU - Maruyama, Yuichiro AU - Maruyama Y AD - Department of Orthopaedic Surgery, Juntendo University Urayasu Hospital, Chiba, Japan. FAU - Ishijima, Muneaki AU - Ishijima M AUID- ORCID: 0000-0002-0920-0805 AD - Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230405 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - WYQ7N0BPYC (Acetylcysteine) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) RN - EC 1.15.1.1 (Superoxide Dismutase-1) SB - IM MH - Rats MH - Animals MH - *Rotator Cuff/physiology MH - Acetylcysteine/pharmacology/therapeutic use MH - Matrix Metalloproteinase 13 MH - Wound Healing/physiology MH - Collagen/metabolism MH - Rodentia/metabolism MH - Rats, Sprague-Dawley MH - Ascorbic Acid/pharmacology/therapeutic use MH - Superoxide Dismutase-1/pharmacology MH - Tendons/surgery MH - *Rotator Cuff Injuries/drug therapy/surgery/pathology MH - Biomechanical Phenomena OTO - NOTNLM OT - N-acetylcysteine OT - oxidative stress OT - rotator cuff healing OT - vitamin C EDAT- 2023/04/06 06:00 MHDA- 2023/05/02 06:42 CRDT- 2023/04/05 07:12 PHST- 2023/05/02 06:42 [medline] PHST- 2023/04/06 06:00 [pubmed] PHST- 2023/04/05 07:12 [entrez] AID - 10.1177/03635465231160772 [doi] PST - ppublish SO - Am J Sports Med. 2023 May;51(6):1596-1607. doi: 10.1177/03635465231160772. Epub 2023 Apr 5. PMID- 38382264 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20240325 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 130 DP - 2024 Mar 30 TI - Evaluation of Anti-Nociceptive, Anti-Inflammatory, and Anti-Fibrotic effects of noscapine against a rat model of Achilles tendinopathy. PG - 111704 LID - S1567-5769(24)00222-4 [pii] LID - 10.1016/j.intimp.2024.111704 [doi] AB - During tendinopathy, prolonged inflammation results in fibrosis and the adherence of tendons to the adjacent tissues, causing discomfort and movement disorders. As a natural compound, noscapine has several anti-inflammatory and anti-fibrotic properties. Therefore, we aimed to investigate the effects of noscapine against a rat model of tendinopathy. We created a surgical rat model of Achilles tendon damage to emulate tendinopathy. Briefly, an incision was made on the Achilles tendon, and it was then sutured using an absorbable surgical thread. Immediately, the injured area was topically treated with the vehicle, noscapine (0.2, 0.6, and 1.8 mg/kg), or dexamethasone (0.1 mg/kg) as a positive control. During the 19-day follow-up period, animals were assessed for weight, behavior, pain, and motor coordination testing. On day 20th, the rats were sacrificed, and the tendon tissue was isolated for macroscopic scoring, microscopic (H&E, Masson's trichrome, Ki67, p53) analyses, and cytokine secretion levels. The levels of macroscopic parameters, including thermal hyperalgesia, mechanical and cold allodynia, deterioration of motor coordination, tendon adhesion score, and microscopic indices, namely histological adhesion, vascular prominence and angiogenesis, and Ki67 and p53 levels, as well as fibrotic and inflammatory biomarkers (IL-6, TNF-α, TGF-β, VEGF) were significantly increased in the vehicle group compared to the sham group (P < 0.05-0.001 for all cases). In contrast, the administration of noscapine (0.2, 0.6, and 1.8 mg/kg) attenuated the pain, fibrosis, and inflammatory indices in a dose-dependent manner compared to the vehicle group (P < 0.05-0.001). Histological research indicated that noscapine 0.6 and 1.8 mg/kg had the most remarkable healing effects. Interestingly, two higher doses of noscapine had impacts similar to those of the positive control group in both clinical and paraclinical assessments. Taken together, our findings suggested that noscapine could be a promising medicine for treating tendinopathies. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Najafi, Zohreh AU - Najafi Z AD - Division of Biotechnology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran; Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Moosavi, Zahra AU - Moosavi Z AD - Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran. FAU - Baradaran Rahimi, Vafa AU - Baradaran Rahimi V AD - Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: vafa_br@yahoo.com. FAU - Hashemitabar, Gholamreza AU - Hashemitabar G AD - Division of Biotechnology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran. Electronic address: hashemit@um.ac.ir. FAU - Askari, Vahid Reza AU - Askari VR AD - Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: askariv@mums.ac.ir. LA - eng PT - Journal Article DEP - 20240220 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 8V32U4AOQU (Noscapine) RN - 0 (Ki-67 Antigen) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (Anti-Inflammatory Agents) SB - IM MH - Rats MH - Animals MH - *Tendinopathy/drug therapy MH - *Achilles Tendon/pathology MH - *Noscapine MH - Ki-67 Antigen MH - Tumor Suppressor Protein p53 MH - Anti-Inflammatory Agents/therapeutic use MH - Pain/pathology MH - Hyperalgesia/drug therapy/pathology MH - Fibrosis OTO - NOTNLM OT - Anti-Fibrotic OT - Immunomodulatory OT - Noscapine OT - Pain OT - Tendinopathy OT - Tendon Repair EDAT- 2024/02/22 00:42 MHDA- 2024/03/25 06:44 CRDT- 2024/02/21 18:08 PHST- 2023/12/12 00:00 [received] PHST- 2024/02/06 00:00 [revised] PHST- 2024/02/13 00:00 [accepted] PHST- 2024/03/25 06:44 [medline] PHST- 2024/02/22 00:42 [pubmed] PHST- 2024/02/21 18:08 [entrez] AID - S1567-5769(24)00222-4 [pii] AID - 10.1016/j.intimp.2024.111704 [doi] PST - ppublish SO - Int Immunopharmacol. 2024 Mar 30;130:111704. doi: 10.1016/j.intimp.2024.111704. Epub 2024 Feb 20. PMID- 32485026 OWN - NLM STAT- MEDLINE DCOM- 20210907 LR - 20240226 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 39 IP - 7 DP - 2021 Jul TI - Effects of tamoxifen on tendon homeostasis and healing: Considerations for the use of tamoxifen-inducible mouse models. PG - 1572-1580 LID - 10.1002/jor.24767 [doi] AB - The use of tamoxifen-inducible models of Cre recombinase in the tendon field is rapidly expanding, resulting in an enhanced understanding of tendon homeostasis and healing. However, the effects of tamoxifen on the tendon are not well-defined, which is particularly problematic given that tamoxifen can have both profibrotic and antifibrotic effects in a tissue-specific manner. Therefore, in the present study, we examined the effects of tamoxifen on tendon homeostasis and healing in male and female C57Bl/6J mice. Tamoxifen-treated mice were compared to corn oil (vehicle)-treated mice. In the "washout" treatment regimen, mice were treated with tamoxifen or corn oil for 3 days beginning 1 week prior to undergoing complete transection and surgical repair of the flexor digitorum longus tendon. In the second regimen, mice were treated with tamoxifen or corn oil beginning on the day of surgery, daily through day 2 postsurgery, and every 48 hours thereafter (D0-2q48) until harvest. All repaired tendons and uninjured contralateral control tendons were harvested at day 14 postsurgery. Tamoxifen treatment had no effect on tendon healing in male mice, regardless of the treatment regimen, while Max load was significantly decreased in female repairs in the Tamoxifen washout group, relative to corn oil. In contrast, D0-2q48 corn oil treatment in female mice led to substantial disruptions in tendon homeostasis, relative to washout corn oil treatment. Collectively, these data clearly define the functional effects of tamoxifen and corn oil treatment in the tendon and inform future use of tamoxifen-inducible genetic models. CI - © 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC. FAU - Best, Katherine T AU - Best KT AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Studentsova, Valentina AU - Studentsova V AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Ackerman, Jessica E AU - Ackerman JE AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Nichols, Anne E C AU - Nichols AEC AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Myers, Marlin AU - Myers M AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Cobb, Justin AU - Cobb J AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Knapp, Emma AU - Knapp E AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Awad, Hani A AU - Awad HA AUID- ORCID: 0000-0003-2197-2610 AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. AD - Department of Biomedical Engineering, University of Rochester, Rochester, New York. FAU - Loiselle, Alayna E AU - Loiselle AE AUID- ORCID: 0000-0002-7548-6653 AD - Department of Orthopaedics and Rehabilitation, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. LA - eng GR - F31 AR074815/AR/NIAMS NIH HHS/United States GR - K01 AR068386/AR/NIAMS NIH HHS/United States GR - P30 AR069655/AR/NIAMS NIH HHS/United States GR - F31 AR077398/AR/NIAMS NIH HHS/United States GR - R01 AR056696/AR/NIAMS NIH HHS/United States GR - T32 AR076950/AR/NIAMS NIH HHS/United States GR - R01 AR073169/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20200609 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Selective Estrogen Receptor Modulators) RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Animals MH - Disease Models, Animal MH - Drug Evaluation, Preclinical MH - Female MH - Homeostasis/drug effects MH - Male MH - Mice, Inbred C57BL MH - Mice, Transgenic MH - Selective Estrogen Receptor Modulators/*adverse effects MH - Tamoxifen/*adverse effects MH - *Tendon Injuries MH - Tendons/*drug effects MH - Wound Healing/*drug effects MH - Mice PMC - PMC7708438 MID - NIHMS1615236 OTO - NOTNLM OT - fibrosis OT - mouse model OT - tamoxifen OT - tendon healing OT - tendon homeostasis EDAT- 2020/06/03 06:00 MHDA- 2021/09/08 06:00 PMCR- 2022/07/01 CRDT- 2020/06/03 06:00 PHST- 2020/04/07 00:00 [revised] PHST- 2019/11/04 00:00 [received] PHST- 2020/05/28 00:00 [accepted] PHST- 2020/06/03 06:00 [pubmed] PHST- 2021/09/08 06:00 [medline] PHST- 2020/06/03 06:00 [entrez] PHST- 2022/07/01 00:00 [pmc-release] AID - 10.1002/jor.24767 [doi] PST - ppublish SO - J Orthop Res. 2021 Jul;39(7):1572-1580. doi: 10.1002/jor.24767. Epub 2020 Jun 9. PMID- 29922838 OWN - NLM STAT- MEDLINE DCOM- 20190909 LR - 20190909 IS - 1432-5195 (Electronic) IS - 0341-2695 (Linking) VI - 42 IP - 8 DP - 2018 Aug TI - Effect of curcumin on tendon healing: an experimental study in a rat model of Achilles tendon injury. PG - 1905-1910 LID - 10.1007/s00264-018-4017-5 [doi] AB - PURPOSE: This in vivo study aims to investigate the effects of curcumin which is recently developed for tendon healing using a rat Achilles tendon injury model. MATERIALS AND METHODS: Eighteen male Wistar albino rats weighing 300-400 g were used in this study. Under anesthesia, Achilles tendon injuries were created and repaired surgically. Nine rats of the study group received curcumin (suspended in saline at a dose of 200 mg/kg orally) and eight rats of the control group received only saline solution by oral gavage for a period of 28 days. Animals were euthanized on the 28th post-operative day, and all the Achilles tendons were removed and transferred immediately for biomechanic and histological analysis. RESULTS: Macroscopically, all the tendons were fully healed. Total mean Bonar score was higher in the control group. When the parameters of Bonar score were analysed separately, tenocyte morphology, collogen, and ground substance scores were statistically lower than the control group (p = 0.03, 0.041, 0.049, respectively). Vascularity parameter did not show any statistical difference (p > 0.05). Of the nine biomechanical parameters, five of them (failure load, cross-sectional area, length, ultimate stress, strain) showed better results which were also statistically significant (p = 0.046, 0.027, 0.011, 0.021, 0.002, respectively). When the remaining four parameters were examined, the study group also had better results, but this difference was not statistically significant. CONCLUSION: Curcumin had better results for total tendon healing not only histologically but also biomechanically. Curcumin could be an additional agent in the management of surgically repaired tendon injuries. FAU - Güleç, Ali AU - Güleç A AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. FAU - Türk, Yılmaz AU - Türk Y AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. FAU - Aydin, Bahattin Kerem AU - Aydin BK AUID- ORCID: 0000-0002-0973-3249 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. bkaydin@yahoo.com. FAU - Erkoçak, Ömer Faruk AU - Erkoçak ÖF AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. FAU - Safalı, Selim AU - Safalı S AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. FAU - Ugurluoglu, Ceyhan AU - Ugurluoglu C AD - Department of Pathology, Faculty of Medicine, Selcuk University, Alaeddin Keykubat Campus, 42130, Konya, Turkey. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180619 PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - 0 (Antioxidants) RN - IT942ZTH98 (Curcumin) SB - IM MH - Achilles Tendon/*drug effects/injuries/pathology/surgery MH - Administration, Oral MH - Animals MH - Antioxidants/*administration & dosage/therapeutic use MH - Biomechanical Phenomena MH - Curcumin/*administration & dosage/therapeutic use MH - Disease Models, Animal MH - Male MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy/pathology/physiopathology/*surgery MH - Wound Healing/*drug effects/physiology OTO - NOTNLM OT - Achilles tendon OT - Antioxidant OT - Curcumin OT - Rat OT - Tendon injuries EDAT- 2018/06/21 06:00 MHDA- 2019/09/10 06:00 CRDT- 2018/06/21 06:00 PHST- 2018/01/02 00:00 [received] PHST- 2018/06/04 00:00 [accepted] PHST- 2018/06/21 06:00 [pubmed] PHST- 2019/09/10 06:00 [medline] PHST- 2018/06/21 06:00 [entrez] AID - 10.1007/s00264-018-4017-5 [pii] AID - 10.1007/s00264-018-4017-5 [doi] PST - ppublish SO - Int Orthop. 2018 Aug;42(8):1905-1910. doi: 10.1007/s00264-018-4017-5. Epub 2018 Jun 19. PMID- 28112540 OWN - NLM STAT- MEDLINE DCOM- 20170606 LR - 20181202 IS - 1205-7541 (Electronic) IS - 0008-4212 (Linking) VI - 95 IP - 4 DP - 2017 Apr TI - Do different tendons exhibit the same response following chronic exposure to statins? PG - 333-339 LID - 10.1139/cjpp-2016-0133 [doi] AB - Over the past few years, a number of cases of tendon injuries associated with statin therapy have been reported. In this study, we assessed whether statins can affect the extracellular matrix (ECM) of the deep digital flexor tendon (DDFT) and patellar tendon (PT). Wistar rats were assigned to groups treated with atorvastatin (A20, A80), treated with simvastatin (S20, S80), and control. Zymography, Western blotting for collagen I, non-collagenous proteins (NCP), glycosaminoglycans (GAGs), and hydroxyproline quantifications were performed. DDFT findings: NCP were increased in A20 and A80; higher concentration of hydroxyproline was found in S80; levels of GAGs was increased in all statin-treated groups; collagen I was increased in S80 and pro-MMP-2 activity was reduced in A80, S20, and S80. PT findings: NCP were reduced in A20, A80, and S80; GAGs was reduced in A80 and S20; collagen I was increased in A20 and pro-MMP-2 activity was reduced in the S20. Both the statins provoked marked changes in both tendons. All these changes may make the tendons more prone to microdamage and ruptures. Therefore, a better understanding of the behavior of the tendon ECM components under statin therapy may provide important insights into the mechanisms behind statin-induced tendon injuries. FAU - Oliveira, L P AU - Oliveira LP AD - a Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. FAU - Vieira, C P AU - Vieira CP AD - b Department of Pharmacology, Medical Sciences College, University of Campinas - UNICAMP, Campinas, SP, Brazil. FAU - Marques, P P AU - Marques PP AD - c Department of Biochemistry, Federal University of Alfenas - Unifal, Alfenas, MG, Brazil. FAU - Pimentel, E R AU - Pimentel ER AD - a Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. LA - eng PT - Journal Article DEP - 20161004 PL - Canada TA - Can J Physiol Pharmacol JT - Canadian journal of physiology and pharmacology JID - 0372712 RN - 0 (Collagen Type I) RN - 0 (Enzyme Precursors) RN - 0 (Glycosaminoglycans) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) RN - EC 3.4.24.- (Gelatinases) RN - EC 3.4.24.- (progelatinase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Atorvastatin/*adverse effects/therapeutic use MH - Collagen Type I/metabolism MH - Enzyme Precursors/metabolism MH - Extracellular Matrix/*drug effects MH - Gelatinases/metabolism MH - Glycosaminoglycans/metabolism MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use MH - Hydroxyproline/metabolism MH - Hyperlipidemias/*drug therapy MH - Male MH - Rats MH - Rats, Wistar MH - Simvastatin/*adverse effects/therapeutic use MH - Tendon Injuries/*chemically induced MH - Tendons/*drug effects OTO - NOTNLM OT - ECM OT - atorvastatin OT - atorvastatine OT - deep digital flexor tendon OT - matrice extracellulaire OT - patellar tendon OT - simvastatin OT - simvastatine OT - tendon du muscle fléchisseur profond des doigts OT - tendon rotulien EDAT- 2017/01/24 06:00 MHDA- 2017/06/07 06:00 CRDT- 2017/01/24 06:00 PHST- 2017/01/24 06:00 [pubmed] PHST- 2017/06/07 06:00 [medline] PHST- 2017/01/24 06:00 [entrez] AID - 10.1139/cjpp-2016-0133 [doi] PST - ppublish SO - Can J Physiol Pharmacol. 2017 Apr;95(4):333-339. doi: 10.1139/cjpp-2016-0133. Epub 2016 Oct 4. PMID- 33940121 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20211025 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 37 IP - 10 DP - 2021 Oct TI - Nicotine Exposure Via Electronic Cigarettes Significantly Impedes Biomechanical Healing Properties of Tendon Healing in a Rat Model. PG - 3170-3176 LID - S0749-8063(21)00337-6 [pii] LID - 10.1016/j.arthro.2021.03.071 [doi] AB - PURPOSE: To evaluate the biomechanical and histologic effects on Achilles tendon repair of inhaled combusted tobacco versus nicotine exposure via electronic cigarette versus a control group in a small-animal model (Sprague-Dawley rat). METHODS: Fifty-four Sprague-Dawley rats were randomized into 3 groups: combusted tobacco, e-cigarettes, or control. Experimental rats were exposed to research cigarettes or e-cigarette vapor in a smoking chamber for 4 weeks. Surgical transection and repair of the Achilles tendon were then completed, followed by 2 additional weeks of exposure. Achilles tendons were harvested, and biomechanical tensile testing was performed. Histologic evaluation was completed, including hematoxylin-eosin staining, trichrome staining, and immunohistochemistry analysis for type I and type III collagen. RESULTS: The control group showed the highest mean tensile load to failure, at 41.0 ± 10.4 N (range, 18.3-55.1 N); the cigarette cohort had the second highest mean, at 37.3 ± 11.1 N (range, 14.0-54.7 N); and finally, the vaping group had the lowest mean, at 32.3 ± 8.4 N (range, 17.8-45.1 N). One-way analysis of variance showed a significant difference in load to failure when comparing the control group with the e-cigarette group (P = .026). No statistical difference was detected between the control group and cigarette group (P = .35) or between the e-cigarette group and cigarette group (P = .23). Stiffness and qualitative histologic analysis showed no difference among groups. CONCLUSIONS: This investigation shows that in a rat model, nicotine exposure via e-cigarette significantly impedes the biomechanical healing properties of Achilles tendon surgical repair. CLINICAL RELEVANCE: The results indicate that although e-cigarettes are often used as a perceived "safer" alternative to smoking, their use may have a detrimental effect on tendon load to failure. CI - Copyright © 2021 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Kennedy, Patrick AU - Kennedy P AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A.. Electronic address: pmkennedy86@gmail.com. FAU - Saloky, Kaitlin AU - Saloky K AD - Geisinger Commonwealth School of Medicine, Geisinger Health System, Scranton, Pennsylvania, U.S.A. FAU - Yadavalli, Aditya AU - Yadavalli A AD - Department of Anesthesia and Perioperative Medicine, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. (d)Department of Emergency Medicine, Zucker School of Medicine, Northwell Southside Hospital, Bay Shore, New York, U.S.A. FAU - Barlow, Erin AU - Barlow E AD - Department of Anesthesia and Perioperative Medicine, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. (d)Department of Emergency Medicine, Zucker School of Medicine, Northwell Southside Hospital, Bay Shore, New York, U.S.A. FAU - Aynardi, Michael AU - Aynardi M AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. FAU - Garner, Matthew AU - Garner M AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. FAU - Bible, Jesse AU - Bible J AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. FAU - Lewis, Gregory S AU - Lewis GS AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. FAU - Dhawan, Aman AU - Dhawan A AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, U.S.A. LA - eng PT - Journal Article DEP - 20210430 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 6M3C89ZY6R (Nicotine) SB - IM MH - *Achilles Tendon/surgery MH - Animals MH - *Electronic Nicotine Delivery Systems MH - Nicotine MH - Rats MH - Rats, Sprague-Dawley MH - Wound Healing EDAT- 2021/05/04 06:00 MHDA- 2021/10/26 06:00 CRDT- 2021/05/03 20:13 PHST- 2020/07/23 00:00 [received] PHST- 2021/03/28 00:00 [revised] PHST- 2021/03/30 00:00 [accepted] PHST- 2021/05/04 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/05/03 20:13 [entrez] AID - S0749-8063(21)00337-6 [pii] AID - 10.1016/j.arthro.2021.03.071 [doi] PST - ppublish SO - Arthroscopy. 2021 Oct;37(10):3170-3176. doi: 10.1016/j.arthro.2021.03.071. Epub 2021 Apr 30. PMID- 38963583 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20241015 IS - 1590-9999 (Electronic) IS - 1590-9921 (Print) IS - 1590-9921 (Linking) VI - 25 IP - 1 DP - 2024 Jul 4 TI - Comparing autologous blood, corticosteroid, and a combined injection of both for treating lateral epicondylitis: a randomized clinical trial. PG - 34 LID - 10.1186/s10195-024-00772-4 [doi] LID - 34 AB - BACKGROUND: Because lateral epicondylitis is a common musculoskeletal disorder that affects the forearm's extensor tendons, an effective therapeutic approach should reverse the degeneration and promote regeneration. This study aimed to compare the efficacies of autologous blood (AB) injection, corticosteroid (CS) injection, and a combined injection of both in treating lateral epicondylitis (LE), hypothesizing that the combined approach might offer immediate symptom resolution and a lower recurrence. MATERIALS AND METHODS: A total of 120 patients diagnosed with lateral epicondylitis were systematically distributed among three distinct therapeutic injection groups. Those in the AB group were administered 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl. Participants in the CS category were given 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl. Meanwhile, patients in the combined group received a mixture containing 1 ml each of autologous venous blood and 40 mg methylprednisolone acetate along with 1 ml of 2% prilocaine HCl. Prior to receiving their respective injections, a comprehensive assessment of all participants was carried out. Follow-up assessments were subsequently conducted on days 15, 30, and 90 utilizing metrics of the patient-rated tennis elbow evaluation (PRTEE) and measurements of hand grip strength (HGS). RESULTS: One patient dropped out from the combined group, and 119 patients completed the trial. No complications were recorded during the course of follow-up. By day 15, all groups had demonstrated significant PRTEE improvement, with CS showing the most pronounced reduction (p = 0.001). However, the benefits of CS had deteriorated by day 30 and had deteriorated further by day 90. The AB and AB + CS groups demonstrated sustained improvement, with AB + CS revealing the most effective treatment, achieving a clinically significant improvement in 97.4% of the patients. The improved HGS parallelled the functional enhancements, as it was more substantial in the AB and AB + CS groups (p = 0.001), corroborating the sustained benefits of these treatments. CONCLUSIONS: The study concluded that while AB and CS individually offer distinct benefits, a combined AB + CS approach optimizes therapeutic outcomes, providing swift and sustained functional improvement with a lower recurrence rate. These findings have substantial clinical implications, suggesting a balanced, multimodal treatment strategy for enhanced patient recovery in LE. LEVEL OF EVIDENCE: Randomized clinical trial, level 1 evidence. TRIAL REGISTRATION: NCT06236178. CI - © 2024. The Author(s). FAU - Cakar, Albert AU - Cakar A AD - Department of Orthopedics and Traumatology, Istanbul Training and Research Hospital, Istanbul, Turkey. dralbertcakar@gmail.com. FAU - Gozlu, Ozgur Dogus AU - Gozlu OD AD - Department of Orthopedics and Traumatology, Istanbul Training and Research Hospital, Istanbul, Turkey. LA - eng SI - ClinicalTrials.gov/NCT06236178 PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20240704 PL - Italy TA - J Orthop Traumatol JT - Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology JID - 101090931 RN - X4W7ZR7023 (Methylprednisolone) RN - 046O35D44R (Prilocaine) RN - 43502P7F0P (Methylprednisolone Acetate) RN - 0 (Anesthetics, Local) RN - 0 (Glucocorticoids) SB - IM MH - Humans MH - *Tennis Elbow/therapy/drug therapy MH - Male MH - Female MH - *Blood Transfusion, Autologous/methods MH - Middle Aged MH - Adult MH - *Methylprednisolone/administration & dosage MH - Treatment Outcome MH - *Prilocaine/administration & dosage MH - *Methylprednisolone Acetate/administration & dosage MH - Anesthetics, Local/administration & dosage MH - Glucocorticoids/administration & dosage MH - Pain Measurement PMC - PMC11224188 OTO - NOTNLM OT - Autologous blood OT - Corticosteroid OT - Lateral epicondylitis OT - Tennis elbow COIS- The authors declare no competing interests. EDAT- 2024/07/04 12:43 MHDA- 2024/07/04 12:44 PMCR- 2024/07/04 CRDT- 2024/07/04 11:15 PHST- 2024/03/08 00:00 [received] PHST- 2024/05/25 00:00 [accepted] PHST- 2024/07/04 12:44 [medline] PHST- 2024/07/04 12:43 [pubmed] PHST- 2024/07/04 11:15 [entrez] PHST- 2024/07/04 00:00 [pmc-release] AID - 10.1186/s10195-024-00772-4 [pii] AID - 772 [pii] AID - 10.1186/s10195-024-00772-4 [doi] PST - epublish SO - J Orthop Traumatol. 2024 Jul 4;25(1):34. doi: 10.1186/s10195-024-00772-4. PMID- 34825499 OWN - NLM STAT- MEDLINE DCOM- 20220314 LR - 20220314 IS - 1756-185X (Electronic) IS - 1756-1841 (Linking) VI - 25 IP - 2 DP - 2022 Feb TI - Characteristics of monosodium urate crystal deposition in the foot in the different stages of gout by dual-energy computed tomography. PG - 147-153 LID - 10.1111/1756-185X.14249 [doi] AB - OBJECTIVE: To compare the characteristics of monosodium urate (MSU) crystal deposition at specific anatomical sites of the foot detected by dual-energy computed tomography in patients with different stages of gout. MATERIALS AND METHODS: This study included 101 patients with gout, 64 had early gout (<3 years) and 37 had late gout (>3 years). We retrospectively compared the total volumes of MSU crystals, the detection rates, and the morphology of MSU crystals at specific anatomical sites in the foot of the patients with different gout durations. RESULTS: The total volume of MSU crystals in patients with early gout was significantly smaller than that in patients with late gout (P < 0.05). The detection rates and morphology of MSU crystals in the anterior calf tendons, ankle joints, tarsometatarsal joints, and metatarsophalangeal joints differed significantly between the patients with early and late gout (P < 0.05). There were no significant differences in the detection rates of submillimeter MSU crystals at the other specific anatomical sites, except for the tendons of the anterior calf, the ankle joint, and the metatarsal joint (P > 0.05). The submillimeter MSU crystal deposition was most common in the tendons of the posterior calf, the proportions in patients with early gout and late gout were 85.9% and 70.3%. Only submillimeter deposition existed in 52 patients (81.3%) with early gout and 11 patients (29.7%) with late gout at all sites of the foot. CONCLUSION: Dual-energy computed tomography detection of submillimeter MSU crystal deposits in the foot is of great significance for the diagnosis of gout, especially along tendons. CI - © 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. FAU - Zhang, Yan AU - Zhang Y AUID- ORCID: 0000-0003-4214-2536 AD - Department of Radiology, Peking University Third Hospital, Beijing, China. FAU - Di, Aihui AU - Di A AD - Department of Radiology, Peking University Third Hospital, Beijing, China. FAU - Yuan, Huishu AU - Yuan H AD - Department of Radiology, Peking University Third Hospital, Beijing, China. LA - eng PT - Journal Article DEP - 20211126 PL - England TA - Int J Rheum Dis JT - International journal of rheumatic diseases JID - 101474930 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Arthritis, Gouty/blood/*diagnostic imaging/physiopathology MH - Disease Progression MH - Female MH - Foot/diagnostic imaging MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Tendons/diagnostic imaging MH - Tomography, X-Ray Computed MH - Uric Acid/*blood OTO - NOTNLM OT - dual-energy computed tomography OT - duration OT - gout OT - monosodium urate OT - sensitivity EDAT- 2021/11/27 06:00 MHDA- 2022/03/15 06:00 CRDT- 2021/11/26 07:19 PHST- 2021/11/04 00:00 [revised] PHST- 2021/09/16 00:00 [received] PHST- 2021/11/07 00:00 [accepted] PHST- 2021/11/27 06:00 [pubmed] PHST- 2022/03/15 06:00 [medline] PHST- 2021/11/26 07:19 [entrez] AID - 10.1111/1756-185X.14249 [doi] PST - ppublish SO - Int J Rheum Dis. 2022 Feb;25(2):147-153. doi: 10.1111/1756-185X.14249. Epub 2021 Nov 26. PMID- 19470813 OWN - NLM STAT- MEDLINE DCOM- 20090709 LR - 20191210 IS - 1550-9613 (Electronic) IS - 0278-4297 (Linking) VI - 28 IP - 6 DP - 2009 Jun TI - Ultrasound-guided first annular pulley injection for trigger finger. PG - 737-43 AB - OBJECTIVE: The purpose of this study was to develop an ultrasound-guided first annular (A1) pulley injection technique for trigger finger with documentation of outcomes at 1 year. METHODS: We performed a short-axis injection into a triangle bordered by the A1 pulley, the flexor digitorum superficialis and profundus tendons and volar plate, and the distal metacarpal bone with a 10-mg median dose of triamcinolone acetonide and 2% lidocaine. This was a prospective study of 50 of 52 consecutive trigger fingers from 24 patients recruited from a physical medicine and rehabilitation private practice. RESULTS: All patients were available for follow-up, with 94% (47 of 50) of fingers having complete resolution of symptoms at 6 months, 90% (37 of 41) at 1 year, 65% (17 of 26) at 18 months, and 71% (12 of 17) at 3 years after a single injection. CONCLUSIONS: Our ultrasound-guided A1 pulley injection technique is a highly effective and minimally invasive treatment option for trigger finger with a 90% success rate at 1 year for complete resolution of symptoms after a single injection. Assuming similar patient populations, our results were statistically significant (P < .01) compared with the 56% to 57% success rates recently reported for blind injections. FAU - Bodor, Marko AU - Bodor M AD - Queen of the Valley Medical Center, 3421 Villa Ln, Suite 2B, Napa, CA 94558, USA. mbodormd@sbcglobal.net FAU - Flossman, Tiffany AU - Flossman T LA - eng PT - Evaluation Study PT - Journal Article PL - England TA - J Ultrasound Med JT - Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine JID - 8211547 RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Chi-Square Distribution MH - Female MH - Fingers/diagnostic imaging MH - Follow-Up Studies MH - Humans MH - Injections, Intra-Articular/methods MH - Lidocaine/*administration & dosage/therapeutic use MH - Male MH - Middle Aged MH - Palmar Plate/diagnostic imaging MH - Treatment Outcome MH - Triamcinolone Acetonide/*administration & dosage/therapeutic use MH - Trigger Finger Disorder/*diagnostic imaging/drug therapy MH - Ultrasonography, Interventional/*methods EDAT- 2009/05/28 09:00 MHDA- 2009/07/10 09:00 CRDT- 2009/05/28 09:00 PHST- 2009/05/28 09:00 [entrez] PHST- 2009/05/28 09:00 [pubmed] PHST- 2009/07/10 09:00 [medline] AID - 28/6/737 [pii] AID - 10.7863/jum.2009.28.6.737 [doi] PST - ppublish SO - J Ultrasound Med. 2009 Jun;28(6):737-43. doi: 10.7863/jum.2009.28.6.737. PMID- 11019707 OWN - NLM STAT- MEDLINE DCOM- 20001114 LR - 20190910 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 217 IP - 7 DP - 2000 Oct 1 TI - Evaluation of transdermal fentanyl patches for analgesia in cats undergoing onychectomy. PG - 1013-20 AB - OBJECTIVE: To evaluate efficacy and safety of using transdermal fentanyl patches (TFP) for analgesia in cats undergoing onychectomy. DESIGN: Randomized controlled clinical trial. ANIMALS: 45 client-owned cats weighing > or = 2.7 kg (5.9 lb) undergoing onychectomy, onychectomy and ovariohysterectomy, or onychectomy and castration. PROCEDURE: Cats were randomly assigned to be treated with a TFP (25 micrograms/h) or butorphanol; TFP were applied a minimum of 4 hours before surgery (approx 8 hours prior to extubation). Rectal temperature, heart rate, respiratory rate, force applied by the forelimbs, and serum fentanyl concentration were measured, and temperament, recovery, degree of sedation, severity of pain, severity of lameness, and appetite were scored before and periodically for up to 40 hours after surgery. RESULTS: Cats treated with a TFP had better recovery scores at 2 of 4 evaluation times, lower sedation scores at 2 of 8 evaluation times, and lower pain scores at 6 of 8 evaluation times, compared with cats treated with butorphanol. Use of a pressure-sensitive mat to evaluate force applied by the forelimbs did not reveal any differences between groups but did reveal a significant difference between preoperative and postoperative values. Mean +/- SD serum fentanyl concentrations were 1.56 +/- 1.08, 4.85 +/- 2.38, 4.87 +/- 1.56, and 4.35 +/- 2.97 ng/ml approximately 8, 24, 32, and 48 hours, respectively, after TFP placement. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that use of a TFP (25 micrograms/h) for postoperative analgesia in cats undergoing onychectomy with or without surgical sterilization is safe and effective. FAU - Franks, J N AU - Franks JN AD - Department of Small Animal Medicine, College of Veterinary Medicine, Texas A&M University, College Station 77843, USA. FAU - Boothe, H W AU - Boothe HW FAU - Taylor, L AU - Taylor L FAU - Geller, S AU - Geller S FAU - Carroll, G L AU - Carroll GL FAU - Cracas, V AU - Cracas V FAU - Boothe, D M AU - Boothe DM LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - QV897JC36D (Butorphanol) RN - UF599785JZ (Fentanyl) SB - IM MH - Administration, Cutaneous MH - Analgesia/economics/*veterinary MH - Animals MH - Body Temperature/drug effects MH - Butorphanol/blood/therapeutic use MH - Cats/*surgery MH - Fentanyl/administration & dosage/blood/*therapeutic use MH - Hoof and Claw/*surgery MH - Postoperative Complications/drug therapy/etiology/*veterinary MH - Tendons/*surgery EDAT- 2000/10/06 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/10/06 11:00 PHST- 2000/10/06 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/10/06 11:00 [entrez] AID - 10.2460/javma.2000.217.1013 [doi] PST - ppublish SO - J Am Vet Med Assoc. 2000 Oct 1;217(7):1013-20. doi: 10.2460/javma.2000.217.1013. PMID- 21913532 OWN - NLM STAT- MEDLINE DCOM- 20111005 LR - 20131121 IS - 0189-2657 (Print) IS - 0189-2657 (Linking) VI - 20 IP - 4 DP - 2010 Oct-Dec TI - The role of aqueous extract of pineapple fruit parts on the healing of acute crush tendon injury. PG - 223-7 AB - BACKGROUND: The Pineapple plant contains the enzyme bromelain which has been acclaimed to reduce pain and swellings following acute muscle injuries as well as carotenoids and polyphenols which are powerful antioxidants. It is yet to be determined if these constituents are distributed throughout the plant and what effect they have on the healing of acute tendon injuries. OBJECTIVE: This study therefore investigated the effects of the aqueous extract of different parts of the pineapple plant on tenoblast proliferation and the tendon Malondialdehyde (MDA) level in the early stage of healing in a crush injury to the achilles tendon of Sprague-Dawley rats. METHODS: Forty male rats were divided randomly into five groups; all had induced crush injury to the left Achilles tendon. Group 1; injury and nil treatment, Group 2; leaves extract, Group 3; fruit flesh extract, Group 4; bark extract, Group 5; core extract. The extract was given at a dosage of 30 mg/kg body weight daily over the first 14 days post-injury. On the 15th day post injury, the animals were sacrificed and the tendons excised and processed for histological study and MDA assay. RESULTS: The flesh and bark extract induced a proliferation of tenoblasts which however was not significantly different from that of the untreated tendon while the leaves and core extracts reduced the population of the tenocytes. The flesh extract significantly (p < 0.05) reduced the MDA level while the leaves and core extract significantly (p < 0.001) increased it. The bark extract had no significant impact on the MDA level compared with the untreated tendon. CONCLUSION: This study suggests that the anti-oxidant constituents of the pineapple plant are concentrated in the flesh while the bark and flesh extracts have the potential to promote healing by stimulating tenoblast proliferation. FAU - Aiyegbusi, A I AU - Aiyegbusi AI AD - Department of Anatomy, College of Medicine, University of Lagos, Lagos. bogphysio@yahoo.com FAU - Duru, F I O AU - Duru FI FAU - Awelimobor, D AU - Awelimobor D FAU - Noronha, C C AU - Noronha CC FAU - Okanlawon, A O AU - Okanlawon AO LA - eng PT - Journal Article PL - Nigeria TA - Nig Q J Hosp Med JT - Nigerian quarterly journal of hospital medicine JID - 9713944 RN - 0 (Plant Extracts) RN - 059QF0KO0R (Water) RN - 4Y8F71G49Q (Malondialdehyde) RN - 9001-00-7 (Bromelains) SB - IM MH - Achilles Tendon/*drug effects/*injuries MH - Acute Disease MH - Administration, Oral MH - Ananas/*chemistry MH - Animals MH - Bromelains/pharmacology MH - Dose-Response Relationship, Drug MH - Fruit/chemistry MH - Male MH - Malondialdehyde/analysis MH - *Phytotherapy MH - Plant Bark/chemistry MH - Plant Extracts/pharmacology/*therapeutic use MH - Plant Leaves/chemistry MH - Rats MH - Rats, Sprague-Dawley MH - Water MH - Wound Healing/drug effects EDAT- 2011/09/15 06:00 MHDA- 2011/10/06 06:00 CRDT- 2011/09/15 06:00 PHST- 2011/09/15 06:00 [entrez] PHST- 2011/09/15 06:00 [pubmed] PHST- 2011/10/06 06:00 [medline] PST - ppublish SO - Nig Q J Hosp Med. 2010 Oct-Dec;20(4):223-7. PMID- 32696059 OWN - NLM STAT- MEDLINE DCOM- 20210416 LR - 20210416 IS - 1462-0332 (Electronic) IS - 1462-0324 (Linking) VI - 60 IP - 1 DP - 2021 Jan 5 TI - Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group. PG - 239-249 LID - 10.1093/rheumatology/keaa366 [doi] AB - OBJECTIVE: To evaluate ultrasound for diagnosing gout using consensus-based Outcome Measures in Rheumatology ultrasound definitions of gout lesions. METHODS: Ultrasound was performed in patients with clinically suspected gout. Joints (28) and tendons (26) were binarily evaluated for the Outcome Measures in Rheumatology gout lesions-double contour (DC), tophus, aggregates and erosions. Ultrasound assessment was compared with two reference standards: (i) presence of MSU crystals in joint/tophus aspirate (primary outcome) and (ii) ACR/EULAR 2015 gout classification criteria (secondary outcome). Both reference standards were evaluated by rheumatologists blinded to ultrasound findings. Sensitivity, specificity, accuracy, positive predictive value and negative predictive value of each ultrasound lesion against both reference standards were determined. RESULTS: Eighty-two patients (70 men), mean age 62.4 (range 19-88) years, were included. Fifty-seven patients were MSU-positive whereas 25 patients were MSU-negative (no MSU crystals: 23; aspiration unsuccessful: 2). Of these 25 patients, three patients were classified as ACR/EULAR-positive (i.e. totally 60 ACR/EULAR-positive patients). All ultrasound lesions had high sensitivities for gout (0.77-0.95). DC and tophus showed high specificities (0.88-0.95), positive predictive values (0.94-0.98) and accuracies (0.82-0.84) when both reference standards were used. In contrast, low specificities were found for aggregates and erosions (0.32-0.59). Ultrasound of MTP joints for DC or tophus, knee joint for DC and peroneus tendons for tophus was sufficient to identify all MSU-positive patients with ultrasound signs of gout at any location. CONCLUSION: Ultrasound-visualized DC and tophus, as defined by the Outcome Measures in Rheumatology ultrasound group, show high specificities, positive predictive values and accuracies for diagnosing gout and are therefore valid tools in clinical practice. CI - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Christiansen, Sara Nysom AU - Christiansen SN AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Østergaard, Mikkel AU - Østergaard M AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. FAU - Slot, Ole AU - Slot O AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. FAU - Fana, Viktoria AU - Fana V AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. FAU - Terslev, Lene AU - Terslev L AD - Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup. AD - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cross-Sectional Studies MH - Female MH - Gout/*diagnostic imaging MH - Humans MH - Joints/diagnostic imaging MH - Logistic Models MH - Male MH - Middle Aged MH - Musculoskeletal System/chemistry MH - *Outcome Assessment, Health Care MH - Predictive Value of Tests MH - Reference Standards MH - Rheumatology MH - Sensitivity and Specificity MH - Tendons/diagnostic imaging MH - Ultrasonography MH - Uric Acid/analysis MH - Young Adult OTO - NOTNLM OT - ACR/EULAR classification criteria OT - MSU crystal microscopy OT - diagnostic accuracy OT - gout OT - sensitivity and specificity OT - ultrasound EDAT- 2020/07/23 06:00 MHDA- 2021/04/17 06:00 CRDT- 2020/07/23 06:00 PHST- 2020/02/08 00:00 [received] PHST- 2020/05/25 00:00 [revised] PHST- 2020/07/23 06:00 [pubmed] PHST- 2021/04/17 06:00 [medline] PHST- 2020/07/23 06:00 [entrez] AID - 5874633 [pii] AID - 10.1093/rheumatology/keaa366 [doi] PST - ppublish SO - Rheumatology (Oxford). 2021 Jan 5;60(1):239-249. doi: 10.1093/rheumatology/keaa366. PMID- 31926548 OWN - NLM STAT- MEDLINE DCOM- 20201119 LR - 20201119 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 21 IP - 1 DP - 2020 Jan 11 TI - In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon. PG - 19 LID - 10.1186/s12891-019-3014-1 [doi] LID - 19 AB - BACKGROUND: Bone mineral density of the humeral head is an independent determining factor for postoperative rotator cuff tendon healing. Bisphosphonates, which are commonly used to treat osteoporosis, have raised concerns regarding their relationships to osteonecrosis of the jaw and to atypical fracture of the femur. In view of the prevalence of rotator cuff tear in osteoporotic elderly people, it is important to determine whether bisphosphonates affect rotator cuff tendon healing. However, no studies have investigated bisphosphonates' cytotoxicity to human rotator cuff tendon fibroblasts (HRFs) or bisphosphonates' effects on rotator cuff tendon healing. The purpose of this study was to evaluate the cytotoxicity of alendronate (Ald), a bisphosphonate, and its effects on HRF wound healing. METHODS: HRFs were obtained from human supraspinatus tendons, using primary cell cultures. The experimental groups were control, 0.1 μM Ald, 1 μM Ald, 10 μM Ald, and 100 μM Ald. Alendronate exposure was for 48 h, except during a cell viability analysis with durations from 1 day to 6 days. The experimental groups were evaluated for cell viability, cell cycle and cell proliferation, type of cell death, caspase activity, and wound-healing ability. RESULTS: The following findings regarding the 100 μM Ald group contrasted with those for all the other experimental groups: a significantly lower rate of live cells (p < 0.01), a higher rate of subG1 population, a lower rate of Ki-67 positive cells, higher rates of apoptosis and necrosis, a higher number of cells with DNA fragmentation, higher caspase-3/7 activity (p < 0.001), and a higher number of caspase-3 positive staining cells. In scratch-wound healing analyses of all the experimental groups, all the wounds healed within 48 h, except in the 100 μM Ald group (p < 0.001). CONCLUSIONS: Low concentrations of alendronate appear to have little effect on HRF viability, proliferation, migration, and wound healing. However, high concentrations are significantly cytotoxic, impairing cellular proliferation, cellular migration, and wound healing in vitro. FAU - Sung, Chang-Meen AU - Sung CM AD - Department of Orthopaedic Surgery, Gyeongsang National University College of Medicine, Jinju, South Korea. FAU - Kim, Ra Jeong AU - Kim RJ AD - Department of Convergence Medical Science, Gyeongsang National University, Jinju, South Korea. FAU - Hah, Young-Sool AU - Hah YS AD - Institute of Health Sciences, Gyeongsang National University School of Medicine and Biomedical Research Institute, Gyeongsang National University Hospital, Jinju, South Korea. FAU - Gwark, Ji-Yong AU - Gwark JY AD - Department of Orthopaedic Surgery, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea, 51472. FAU - Park, Hyung Bin AU - Park HB AUID- ORCID: 0000-0001-9468-6282 AD - Department of Orthopaedic Surgery, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea, 51472. hbinpark@gnu.ac.kr. LA - eng PT - Journal Article DEP - 20200111 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Bone Density Conservation Agents) RN - X1J18R4W8P (Alendronate) SB - IM MH - Alendronate/*adverse effects MH - Bone Density Conservation Agents/*adverse effects MH - Drug Evaluation, Preclinical MH - Female MH - Fibroblasts/*drug effects MH - Humans MH - Male MH - Middle Aged MH - Primary Cell Culture MH - Rotator Cuff/*cytology MH - Wound Healing/*drug effects PMC - PMC6955091 OTO - NOTNLM OT - Alendronate OT - Human rotator cuff tendon fibroblasts OT - Wound healing COIS- The authors declare that they have no conflicts of interest with the contents of this article. EDAT- 2020/01/14 06:00 MHDA- 2020/11/20 06:00 PMCR- 2020/01/11 CRDT- 2020/01/14 06:00 PHST- 2019/07/08 00:00 [received] PHST- 2019/12/19 00:00 [accepted] PHST- 2020/01/14 06:00 [entrez] PHST- 2020/01/14 06:00 [pubmed] PHST- 2020/11/20 06:00 [medline] PHST- 2020/01/11 00:00 [pmc-release] AID - 10.1186/s12891-019-3014-1 [pii] AID - 3014 [pii] AID - 10.1186/s12891-019-3014-1 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2020 Jan 11;21(1):19. doi: 10.1186/s12891-019-3014-1. PMID- 34247224 OWN - NLM STAT- MEDLINE DCOM- 20220420 LR - 20220716 IS - 1462-0332 (Electronic) IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 61 IP - SI DP - 2022 Apr 18 TI - Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. PG - SI81-SI85 LID - 10.1093/rheumatology/keab533 [doi] AB - OBJECTIVES: There is a lack of large longitudinal studies of urate deposition measured by dual-energy CT (DECT) during urate lowering therapy (ULT) in people with gout. We explored longitudinal changes in DECT urate depositions during a treat-to-target strategy with ULT in gout. METHODS: Patients with a recent gout flare and serum-urate (sUA) >360 µmol/l attended tight-control visits during escalating ULT. The treatment target was sUA <360 µmol/l, and <300 µmol/l if presence of tophi. A DECT scanner (General Electric Discovery CT750 HD) acquired data from bilateral forefeet and ankles at baseline and after one and two years. Images were scored in known order, using the semi-quantitative Bayat method, by one experienced radiologist who was blinded to serum urate and clinical data. Four regions were scored: the first metatarsophalangeal (MTP1) joint, the other joints of the toes, the ankles and midfeet, and all tendons in the feet and ankles. RESULTS: DECT was measured at baseline in 187 of 211 patients. The mean (s.d.) serum urate level (μmol/l) decreased from 501 (80) at baseline to 311 (48) at 12 months, and 322 (67) at 24 months. DECT scores at all locations decreased during both the first and the second year (P <0.001 for all comparisons vs baseline), both for patients achieving and not achieving the sUA treatment target. CONCLUSIONS: In patients with gout, urate depositions in ankles and feet as measured by DECT decreased both in the first and the second year, when patients were treated using a treat-to-target ULT strategy. CI - © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. FAU - Uhlig, Till AU - Uhlig T AUID- ORCID: 0000-0002-6881-9552 AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. AD - Faculty of Medicine, University of Oslo. FAU - Eskild, Tron AU - Eskild T AD - Division for Clinical Service, Radiology, Diakonhjemmet Hospital, Oslo, Norway. FAU - Karoliussen, Lars F AU - Karoliussen LF AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. FAU - Sexton, Joe AU - Sexton J AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. FAU - Kvien, Tore K AU - Kvien TK AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. AD - Faculty of Medicine, University of Oslo. FAU - Haavardsholm, Espen A AU - Haavardsholm EA AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. AD - Faculty of Medicine, University of Oslo. FAU - Dalbeth, Nicola AU - Dalbeth N AD - Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. FAU - Hammer, Hilde Berner AU - Hammer HB AUID- ORCID: 0000-0001-7317-8991 AD - Division of Rheumatology and Research, Diakonhjemmet Hospital. AD - Faculty of Medicine, University of Oslo. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Gout Suppressants) RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Arthritis, Gouty/drug therapy MH - *Gout/diagnostic imaging/drug therapy MH - Gout Suppressants/therapeutic use MH - Humans MH - Longitudinal Studies MH - Symptom Flare Up MH - Tomography, X-Ray Computed/methods MH - Uric Acid PMC - PMC9015021 OTO - NOTNLM OT - DECT OT - deposition OT - gout OT - treat to target OT - urate lowering treatment EDAT- 2021/07/12 06:00 MHDA- 2022/04/21 06:00 PMCR- 2021/07/11 CRDT- 2021/07/11 20:57 PHST- 2021/04/20 00:00 [received] PHST- 2021/06/21 00:00 [accepted] PHST- 2021/07/12 06:00 [pubmed] PHST- 2022/04/21 06:00 [medline] PHST- 2021/07/11 20:57 [entrez] PHST- 2021/07/11 00:00 [pmc-release] AID - 6319035 [pii] AID - keab533 [pii] AID - 10.1093/rheumatology/keab533 [doi] PST - ppublish SO - Rheumatology (Oxford). 2022 Apr 18;61(SI):SI81-SI85. doi: 10.1093/rheumatology/keab533. PMID- 12209043 OWN - NLM STAT- MEDLINE DCOM- 20021028 LR - 20190513 IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 41 IP - 9 DP - 2002 Sep TI - Recurrent tenosynovitis in Sweet's syndrome. PG - 1067-9 FAU - Brown, A M E AU - Brown AM FAU - Davies, M G AU - Davies MG FAU - Hickling, P AU - Hickling P LA - eng PT - Case Reports PT - Letter PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 8W5C518302 (Dapsone) RN - SML2Y3J35T (Colchicine) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Colchicine/therapeutic use MH - Dapsone/therapeutic use MH - Drug Therapy, Combination MH - Female MH - Humans MH - Middle Aged MH - Sweet Syndrome/*complications/drug therapy/pathology MH - Synovial Membrane/diagnostic imaging/pathology MH - Tendons/diagnostic imaging/pathology MH - Tenosynovitis/drug therapy/*etiology/pathology MH - Treatment Outcome MH - Ultrasonography MH - Wrist/diagnostic imaging EDAT- 2002/09/05 10:00 MHDA- 2002/10/29 04:00 CRDT- 2002/09/05 10:00 PHST- 2002/09/05 10:00 [pubmed] PHST- 2002/10/29 04:00 [medline] PHST- 2002/09/05 10:00 [entrez] AID - 10.1093/rheumatology/41.9.1067 [doi] PST - ppublish SO - Rheumatology (Oxford). 2002 Sep;41(9):1067-9. doi: 10.1093/rheumatology/41.9.1067. PMID- 15118032 OWN - NLM STAT- MEDLINE DCOM- 20040629 LR - 20220227 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 86 IP - 5 DP - 2004 May TI - Topical glyceryl trinitrate treatment of chronic noninsertional achilles tendinopathy. A randomized, double-blind, placebo-controlled trial. PG - 916-22 AB - BACKGROUND: Noninsertional Achilles tendinopathy is a degenerative overuse disorder. No method has been universally successful in treating this condition. Topically applied nitric oxide has been shown, in animal models, to be effective for the treatment of fractures and cutaneous wounds through mechanisms that may include stimulation of collagen synthesis in fibroblasts. The goal of the present study was to determine if topical glyceryl trinitrate improves clinical outcome measures in patients with Achilles tendinopathy. METHODS: A prospective, randomized, double-blind, placebo-controlled trial involving a total of sixty-five patients (eighty-four Achilles tendons) was performed to compare continuous application of topical glyceryl trinitrate (at a dosage of 1.25 mg per twenty-four hours) with rehabilitation alone for the treatment of noninsertional Achilles tendinopathy. RESULTS: Compared with the control group, the glyceryl trinitrate group showed reduced pain with activity at twelve weeks (p = 0.02) and twenty-four weeks (p = 0.03), reduced night pain at twelve weeks (p = 0.04), reduced tenderness at twelve weeks (p = 0.02), decreased pain scores after the hop test at twenty-four weeks (p = 0.005), and increased ankle plantar flexor mean total work compared with the baseline level at twenty-four weeks (p = 0.04). Twenty-eight (78%) of thirty-six tendons in the glyceryl trinitrate group were asymptomatic with activities of daily living at six months, compared with twenty (49%) of forty-one tendons in the placebo group (p = 0.001, chi-square analysis). The mean effect size for all outcome measures was 0.14. CONCLUSIONS: Topical glyceryl trinitrate significantly reduced pain with activity and at night, improved functional measures, and improved outcomes in patients with Achilles tendinopathy. FAU - Paoloni, Justin A AU - Paoloni JA AD - Orthopaedic Research Institute, St George Hospital Campus, University of New South Wales, New South Wales, Australia. pao_26@hotmail.com FAU - Appleyard, Richard C AU - Appleyard RC FAU - Nelson, Janis AU - Nelson J FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Vasodilator Agents) RN - G59M7S0WS3 (Nitroglycerin) SB - IM CIN - Clin J Sport Med. 2005 Mar;15(2):116-7. doi: 10.1097/01.jsm.0000151866.75684.3d. PMID: 15782065 MH - Achilles Tendon/*drug effects MH - Administration, Topical MH - Adult MH - Aged MH - Chronic Disease MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Nitroglycerin/*administration & dosage MH - Physical Therapy Modalities MH - Prospective Studies MH - Tendinopathy/*drug therapy/therapy MH - Vasodilator Agents/*administration & dosage EDAT- 2004/05/01 05:00 MHDA- 2004/06/30 05:00 CRDT- 2004/05/01 05:00 PHST- 2004/05/01 05:00 [pubmed] PHST- 2004/06/30 05:00 [medline] PHST- 2004/05/01 05:00 [entrez] AID - 10.2106/00004623-200405000-00005 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2004 May;86(5):916-22. doi: 10.2106/00004623-200405000-00005. PMID- 10976300 OWN - NLM STAT- MEDLINE DCOM- 20011004 LR - 20190910 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 217 IP - 5 DP - 2000 Sep 1 TI - Subjective and objective measurements of postoperative pain in cats. PG - 685-90 AB - OBJECTIVE: To evaluate the ability of various subjective and objective measurements to determine the presence and degree of postoperative pain in cats. DESIGN: Randomized controlled prospective clinical study. ANIMALS: 18 healthy client-owned cats. PROCEDURE: Cats were randomly assigned to 3 groups of 6: control, tenectomy, and onychectomy. Jugular catheters were placed the day prior to surgery. All surgeries were performed by the same surgeon, and all observations were made by the same blinded trained observer. One hour prior to surgery and at assigned intervals for 36 hours after surgery, heart rate, respiratory rate, and rectal temperature were measured. Scores were assigned for 3 interaction responses, including response to palpation, by use of simple descriptive scales, and to 2 pain assessments by use of visual analogue scales. Blood was collected to measure plasma beta-endorphin and cortisol concentrations. Butorphanol was administered to all cats before surgery and to any cat subjectively assessed to be experiencing pain after surgery. RESULTS: Only visual analogue scale scores and response to palpation scores differed significantly between control and surgical groups. CONCLUSIONS AND CLINICAL RELEVANCE: Determination of the presence of pain in cats can be made on the basis of observation and interaction by a trained observer. Physiologic measurements, including plasma cortisol and beta-endorphin concentrations, did not differentiate between control cats and cats that underwent surgery. FAU - Cambridge, A J AU - Cambridge AJ AD - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman 99164, USA. FAU - Tobias, K M AU - Tobias KM FAU - Newberry, R C AU - Newberry RC FAU - Sarkar, D K AU - Sarkar DK LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Analgesics, Opioid) RN - 60617-12-1 (beta-Endorphin) RN - QV897JC36D (Butorphanol) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Analgesics, Opioid/administration & dosage MH - Animals MH - Body Temperature MH - Butorphanol/administration & dosage MH - Cat Diseases/*diagnosis/physiopathology MH - Cats/*surgery MH - Heart Rate MH - Hoof and Claw/surgery MH - Hydrocortisone/blood MH - Pain Measurement/methods/*veterinary MH - Pain, Postoperative/diagnosis/physiopathology/*veterinary MH - Palpation/veterinary MH - Prospective Studies MH - Respiration MH - Tendons/surgery MH - Time Factors MH - beta-Endorphin/blood EDAT- 2000/09/08 11:00 MHDA- 2001/10/05 10:01 CRDT- 2000/09/08 11:00 PHST- 2000/09/08 11:00 [pubmed] PHST- 2001/10/05 10:01 [medline] PHST- 2000/09/08 11:00 [entrez] AID - 10.2460/javma.2000.217.685 [doi] PST - ppublish SO - J Am Vet Med Assoc. 2000 Sep 1;217(5):685-90. doi: 10.2460/javma.2000.217.685. PMID- 32852773 OWN - NLM STAT- MEDLINE DCOM- 20201023 LR - 20201023 IS - 1652-7518 (Electronic) IS - 0023-7205 (Linking) VI - 117 DP - 2020 Aug 25 TI - [Gout - a common and well known disease]. LID - F3M3 [pii] AB - Hyperuricemia is defined by a blood urate level > 405 µmol/L, the cut-off value at which urate forms crystals in vivo. In 15-20% these individuals develop gout, clinically characterized by attacks of acute arthritis, initially and most commonly affecting MTP 1 or other joints, tendons and soft tissues of the foot. These attacks usually subside within 1 to 2 weeks. Over time attacks occur more frequently and can transform into chronic arthritis characterized by tophi. The gold standard for diagnosis relies on identification of urate crystals by polarization microscopy in aspirated joint fluid. This procedure is rarely performed in primary care where the majority of patients are seen, and gout is usually diagnosed by clinical criteria. New imaging technologies (ultrasound, dual-energy CT) can be helpful when aspiration is not available and when the diagnosis is unclear. Gout has a prevalence of 1.7% and incidence rate of approximately 200 per 100000 person-years in Sweden, figures that increase over time. FAU - Sigurdardottir, Valgerdur AU - Sigurdardottir V AD - specialistläkare, Falu lasarett; Centrum för klinisk forskning Dalarna, Uppsala universitet; institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet. FAU - Svärd, Anna AU - Svärd A AD - med dr, överläkare, Falu lasarett; Centrum för klinisk forskning Dalarna, Uppsala universitet; institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet. FAU - Bengtsson Boström, Kristina AU - Bengtsson Boström K AD - adjungerad professor, distriktsläkare, institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet. FAU - Wändell, Per AU - Wändell P AD - . FAU - Jacobsson, Lennart AU - Jacobsson L AD - . FAU - Forsblad d'Elia, Helena AU - Forsblad d'Elia H AD - . FAU - Kapetanovic, Meliha AU - Kapetanovic M AD - . FAU - Dehlin, Mats AU - Dehlin M AD - . LA - swe PT - Journal Article TT - Gikt – en känd och vanlig sjukdom. DEP - 20200825 PL - Sweden TA - Lakartidningen JT - Lakartidningen JID - 0027707 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Gout/diagnostic imaging/drug therapy MH - Humans MH - *Hyperuricemia MH - Sweden MH - Ultrasonography MH - Uric Acid EDAT- 2020/08/28 06:00 MHDA- 2020/10/24 06:00 CRDT- 2020/08/28 06:00 PHST- 2020/08/28 06:00 [entrez] PHST- 2020/08/28 06:00 [pubmed] PHST- 2020/10/24 06:00 [medline] AID - F3M3 [pii] PST - epublish SO - Lakartidningen. 2020 Aug 25;117:F3M3. PMID- 25637002 OWN - NLM STAT- MEDLINE DCOM- 20150702 LR - 20250214 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 74 IP - 5 DP - 2015 May TI - Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. PG - 908-11 LID - 10.1136/annrheumdis-2014-206397 [doi] AB - BACKGROUND: The aim of this study was to compare the frequency and volume of dual energy CT (DECT) urate deposits in people with asymptomatic hyperuricaemia and symptomatic gout. METHODS: We analysed DECT scans of the feet from asymptomatic individuals with serum urate ≥540 µmol/L (n=25) and those with crystal proven gout without clinically apparent tophi (n=33). RESULTS: DECT urate deposits were observed in 6/25 (24%) participants with asymptomatic hyperuricaemia, 11/14 (79%) with early gout (predefined as disease duration ≤3 years) and 16/19 (84%) with late gout (p<0.001). DECT urate deposition was observed in both joints and tendons in the asymptomatic hyperuricaemia group, but significantly less frequently than in those with gout (p≤0.001 for both joint and tendon sites). The volume of urate deposition was also significantly lower in those with asymptomatic hyperuricaemia, compared with the early and the late gout groups (p<0.01 for both comparisons). Similar urate volumes were observed in the early and late gout groups. CONCLUSIONS: Although subclinical urate deposition can occur in people with asymptomatic hyperuricaemia, these deposits occur more frequently and at higher volumes in those with symptomatic gout. These data suggest that a threshold of urate crystal volume may be required before symptomatic disease occurs. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. FAU - Dalbeth, Nicola AU - Dalbeth N AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - House, Meaghan E AU - House ME AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Aati, Opetaia AU - Aati O AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Tan, Paul AU - Tan P AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Franklin, Christopher AU - Franklin C AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Horne, Anne AU - Horne A AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Gamble, Gregory D AU - Gamble GD AD - Faculty of Medical and Health Sciences, Department of Medicine, Bone and Joint Research Group, University of Auckland, Auckland, New Zealand. FAU - Stamp, Lisa K AU - Stamp LK AD - Department of Medicine, University of Otago, Christchurch, New Zealand. FAU - Doyle, Anthony J AU - Doyle AJ AD - Faculty of Medical and Health Sciences, Department of Anatomy with Radiology, University of Auckland, Auckland, New Zealand. FAU - McQueen, Fiona M AU - McQueen FM AD - Faculty of Medical and Health Sciences, Department of Molecular Medicine, University of Auckland, Auckland, New Zealand. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150130 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 268B43MJ25 (Uric Acid) SB - IM CIN - Ann Rheum Dis. 2015 Sep;74(9):e50. doi: 10.1136/annrheumdis-2015-207534. PMID: 25829359 MH - Absorptiometry, Photon MH - Aged MH - Asymptomatic Diseases MH - Cross-Sectional Studies MH - Female MH - Foot/diagnostic imaging MH - Foot Joints/*diagnostic imaging MH - Gout/blood/*diagnostic imaging MH - Humans MH - Hyperuricemia/blood/*diagnostic imaging MH - Male MH - Middle Aged MH - Prospective Studies MH - Tendons/*diagnostic imaging MH - Tomography, X-Ray Computed MH - Uric Acid/*blood OTO - NOTNLM OT - Arthritis OT - Gout OT - Inflammation EDAT- 2015/02/01 06:00 MHDA- 2015/07/03 06:00 CRDT- 2015/02/01 06:00 PHST- 2014/07/31 00:00 [received] PHST- 2015/01/13 00:00 [accepted] PHST- 2015/02/01 06:00 [entrez] PHST- 2015/02/01 06:00 [pubmed] PHST- 2015/07/03 06:00 [medline] AID - S0003-4967(24)03207-2 [pii] AID - 10.1136/annrheumdis-2014-206397 [doi] PST - ppublish SO - Ann Rheum Dis. 2015 May;74(5):908-11. doi: 10.1136/annrheumdis-2014-206397. Epub 2015 Jan 30. PMID- 20720072 OWN - NLM STAT- MEDLINE DCOM- 20100930 LR - 20211203 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 256 IP - 3 DP - 2010 Sep TI - Do patients with structural abnormalities of the shoulder experience pain after MR arthrography of the shoulder? PG - 870-8 LID - 10.1148/radiol.10091671 [doi] AB - PURPOSE: To assess the pain course after intraarticular injection of a gadolinium-containing contrast material admixed with anesthetic for magnetic resonance (MR) arthrography of the shoulder in relation to internal derangements of the shoulder. MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained for this study. The study sample consisted of 655 consecutive patients (249 female, 406 male; median age, 54 years) referred for MR arthrography of the shoulder. Pain level was measured at baseline, directly after intraarticular injection of the gadolinium-containing contrast material admixed with anesthetic, 4 hours after injection, 1 day (18-30 hours) after injection, and 1 week (6-8 days) after injection with a visual analog scale (range, 0-10). MR arthrography was used to assess the following internal derangements: lesions of the rotator cuff tendons and long biceps tendon, adhesive capsulitis (frozen shoulder), fluid in the subacromial bursa, labral tears, and osteoarthritis of the glenohumeral joint. History of shoulder surgery was recorded. Linear regression models were calculated for the dependent variable (difference between follow-up pain and baseline pain), with the independent variable grouping adjusted for age and sex. RESULTS: There was no significant association between pain level over time and internal derangements of the shoulder, nor was there significant association between pain level over time in patients with a history of shoulder surgery and patients without a history of shoulder surgery. CONCLUSION: Neither internal derangements nor prior surgery have an apparent effect on the pain course after MR arthrography of the shoulder. CI - (c) RSNA, 2010. FAU - Steurer-Dober, Isabelle AU - Steurer-Dober I AD - Department of Radiology, University Hospital Balgrist, Zurich, Switzerland. Isabelle.Steurer@ksl.ch FAU - Rufibach, Kaspar AU - Rufibach K FAU - Hodler, Juerg AU - Hodler J FAU - Saupe, Nadja AU - Saupe N FAU - Zanetti, Marco AU - Zanetti M FAU - Fucentese, Sandro F AU - Fucentese SF FAU - Pfirrmann, Christian W A AU - Pfirrmann CW LA - eng PT - Journal Article PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Anesthetics, Local) RN - 0 (Contrast Media) RN - B6E06QE59J (Mepivacaine) RN - JR13W81H44 (Iopamidol) RN - K2I13DR72L (Gadolinium DTPA) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anesthetics, Local/administration & dosage/adverse effects MH - Arthralgia/*etiology MH - Contrast Media/administration & dosage/adverse effects MH - Female MH - Gadolinium DTPA/administration & dosage/adverse effects MH - Humans MH - Injections, Intra-Articular/*adverse effects MH - Iopamidol/administration & dosage/adverse effects MH - Linear Models MH - Magnetic Resonance Imaging/*methods MH - Male MH - Mepivacaine/administration & dosage/adverse effects MH - Middle Aged MH - Pain Measurement MH - Risk Factors MH - Shoulder Injuries MH - Shoulder Joint/*abnormalities EDAT- 2010/08/20 06:00 MHDA- 2010/10/01 06:00 CRDT- 2010/08/20 06:00 PHST- 2010/08/20 06:00 [entrez] PHST- 2010/08/20 06:00 [pubmed] PHST- 2010/10/01 06:00 [medline] AID - 256/3/870 [pii] AID - 10.1148/radiol.10091671 [doi] PST - ppublish SO - Radiology. 2010 Sep;256(3):870-8. doi: 10.1148/radiol.10091671. PMID- 28281462 OWN - NLM STAT- MEDLINE DCOM- 20171120 LR - 20171128 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 35 IP - 5 DP - 2017 Sep-Oct TI - Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment. PG - 746-751 AB - OBJECTIVES: The goals of our study are to evaluate the urate-lowering therapy (ULT) effect on gout ultrasound (US) lesions and to explore US sensitivity to change in gout patients. METHODS: Patients with chronic and symptomatic gout, confirmed by crystal identification, were prospectively included. Clinical and US assessments were performed at baseline and after 6, 12 and 24 months of ULT. The presence of double contour sign (DCS) and US- detectable tophi were assessed in the first metatarsophalangeals, the knees and patellar tendons. The mean and standard deviation were calculated for each parameter. The correlation between the clinical and US parameters was assessed by calculating Pearson's correlation coefficient. Sensitivity to change in the US examinations was assessed by estimating the smallest detectable difference (SDD). RESULTS: Twenty-three consecutive patients were included (96% men; mean age 59 ± 11 years). DCS and US tophi were detected in 73.9% and 91.3% of patients at baseline. A significant parallel improvement in the serum urate, clinical parameters and US lesions was found at the follow-up assessment. The SDD values for the global DCS and tophi were 0.52 and 0.69, respectively, which were smaller than the differences achieved over the course of the two years. A significant correlation between DCS and clinical parameters was observed (r =0.49, p=0.038). CONCLUSIONS: Ultrasound findings in gout patients show sensitivity to change and concurrent validity with uric acid reduction after ULT in gout patients. US can be a useful tool for gout tophus burden monitoring. FAU - Peiteado, Diana AU - Peiteado D AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. diapeitead@gmail.com. FAU - Villalba, Alejandro AU - Villalba A AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - Martín-Mola, Emilio AU - Martín-Mola E AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - Balsa, Alejandro AU - Balsa A AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - De Miguel, Eugenio AU - De Miguel E AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. LA - eng PT - Journal Article DEP - 20170303 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Biomarkers) RN - 0 (Gout Suppressants) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Biomarkers/blood MH - Chronic Disease MH - Down-Regulation MH - Female MH - Gout/blood/*diagnostic imaging/*drug therapy MH - Gout Suppressants/*therapeutic use MH - Humans MH - Joints/*diagnostic imaging/*drug effects/metabolism MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prospective Studies MH - Time Factors MH - Treatment Outcome MH - *Ultrasonography, Doppler MH - Uric Acid/blood EDAT- 2017/03/11 06:00 MHDA- 2017/11/29 06:00 CRDT- 2017/03/11 06:00 PHST- 2016/10/11 00:00 [received] PHST- 2017/01/23 00:00 [accepted] PHST- 2017/03/11 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/03/11 06:00 [entrez] AID - 11214 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2017 Sep-Oct;35(5):746-751. Epub 2017 Mar 3. PMID- 23514060 OWN - NLM STAT- MEDLINE DCOM- 20140411 LR - 20190116 IS - 1521-0553 (Electronic) IS - 0894-1939 (Linking) VI - 26 IP - 5 DP - 2013 Oct TI - The role of antibiotics after surgical treatment of simple hand infections: a prospective pilot study. PG - 229-34 LID - 10.3109/08941939.2012.747576 [doi] AB - BACKGROUND: Manifested hand infections are usually treated by sufficient debridement and drainage followed by splinting and elevation of the corresponding upper extremity. The role of antibiotics in the postoperative prognosis of hand infections is contradictory. METHODS: Three groups of 30 patients each with subcutaneous or subfascial localized hand infections without infiltration of tendons, joints, or bones, have been treated in a different way regarding the use of antibiotics postoperatively. Group 1 was treated with systemic cephalosporins as well as locally inserted Gentamycin bead chains in the wound after debridement. Group 2 was only treated locally with Gentamycin bead chains but no systemic antibiots, while Group 3 did not receive any antibiotics at all. RESULTS: No substantial differences could be observed between the three patient groups regarding the convalescence in terms of duration of splinting and recovery of hand function in relation to hand mobility as assessed by the sum of finger-palm distance and to the disabilities of the arm, shoulder, and hand score. CONCLUSIONS: The use of antibiotics after surgical treatment of simple hand infections seems to be unnecessary. FAU - Manoli, Theodora AU - Manoli T AD - Department of Hand, Plastic and Reconstructive Surgery with Burn Unit, Eberhard-Karls-University of Tuebingen , BG Trauma Centre Tuebingen , Germany. FAU - Rahmanian-Schwarz, Ashin AU - Rahmanian-Schwarz A FAU - Konheiser, Kathrin AU - Konheiser K FAU - Gonser, Phillipp AU - Gonser P FAU - Schaller, Hans-Eberhard AU - Schaller HE LA - eng PT - Journal Article DEP - 20130320 PL - United States TA - J Invest Surg JT - Journal of investigative surgery : the official journal of the Academy of Surgical Research JID - 8809255 RN - 0 (Anti-Bacterial Agents) RN - 0 (Cephalosporins) RN - 0 (Gentamicins) RN - 9011-14-7 (Polymethyl Methacrylate) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Bacterial Agents/*therapeutic use MH - Bacterial Infections/*drug therapy MH - Cephalosporins/*administration & dosage MH - Gentamicins/administration & dosage MH - Hand/microbiology/*surgery MH - Humans MH - Middle Aged MH - Pilot Projects MH - Polymethyl Methacrylate MH - Prospective Studies MH - Splints MH - Treatment Outcome EDAT- 2013/03/22 06:00 MHDA- 2014/04/12 06:00 CRDT- 2013/03/22 06:00 PHST- 2013/03/22 06:00 [entrez] PHST- 2013/03/22 06:00 [pubmed] PHST- 2014/04/12 06:00 [medline] AID - 10.3109/08941939.2012.747576 [doi] PST - ppublish SO - J Invest Surg. 2013 Oct;26(5):229-34. doi: 10.3109/08941939.2012.747576. Epub 2013 Mar 20. PMID- 22350064 OWN - NLM STAT- MEDLINE DCOM- 20130805 LR - 20220309 IS - 1573-6814 (Electronic) IS - 1389-9333 (Print) IS - 1389-9333 (Linking) VI - 14 IP - 1 DP - 2013 Mar TI - Differential cross-linking and radio-protective effects of genipin on mature bovine and human patella tendons. PG - 21-32 LID - 10.1007/s10561-012-9295-3 [doi] AB - Gamma irradiation is a proven sterilization method, but is not widely used on allografts for anterior cruciate ligament reconstruction (e.g., patella tendon) due to radiation-induced decreases in mechanical strength. Addressing this drawback would improve the safety and supply of allografts to meet current and future demand. It was hypothesized that genipin-induced collagen cross-linking would increase the tensile modulus of patella tendon tissue such that 5 MRad gamma irradiation would not reduce the tissue mechanical strength below the original untreated values. Optimized genipin treatment increased the tensile modulus of bovine tendons by ~2.4-fold. After irradiation, genipin treated tissue did not significantly differ from native tissue, proving the hypothesis. Optimized genipin treatment of human tendons increased the tensile modulus by ~1.3-fold. After irradiation, both control and genipin-treated tissues possessed ~50-60% of their native tendon modulus, disproving the hypothesis. These results highlight possible age- and species- dependent effects of genipin cross-linking on tendon tissue. Cross-linking of human allografts may be beneficial only in younger donor tissues. Future research is warranted to better understand the mechanisms and applications of collagen cross-linking for clinical use. FAU - Ng, Kenneth W AU - Ng KW AD - Hospital for Special Surgery, 535 E. 70th Street, New York, NY, 10021, USA. FAU - Wanivenhaus, Florian AU - Wanivenhaus F FAU - Chen, Tony AU - Chen T FAU - Abrams, Valarian D AU - Abrams VD FAU - Torzilli, Peter A AU - Torzilli PA FAU - Warren, Russell F AU - Warren RF FAU - Maher, Suzanne A AU - Maher SA LA - eng GR - T32 AR007281/AR/NIAMS NIH HHS/United States GR - TL1 RR024998/RR/NCRR NIH HHS/United States GR - AR046121/AR/NIAMS NIH HHS/United States GR - P30 AR046121/AR/NIAMS NIH HHS/United States GR - C06 RR012538/RR/NCRR NIH HHS/United States GR - TL1RR024998/RR/NCRR NIH HHS/United States GR - UL1 TR000457/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120221 PL - Netherlands TA - Cell Tissue Bank JT - Cell and tissue banking JID - 100965121 RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 0 (Radiation-Protective Agents) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Cattle MH - Cell Death/drug effects MH - Cross-Linking Reagents/*pharmacology MH - Female MH - Humans MH - Iridoids/*pharmacology MH - Male MH - Middle Aged MH - Patellar Ligament/cytology/*drug effects/*growth & development MH - Radiation-Protective Agents/*pharmacology MH - Tensile Strength/drug effects MH - Time Factors PMC - PMC3705212 MID - NIHMS480756 EDAT- 2012/02/22 06:00 MHDA- 2013/08/06 06:00 PMCR- 2013/07/09 CRDT- 2012/02/22 06:00 PHST- 2011/11/28 00:00 [received] PHST- 2012/01/24 00:00 [accepted] PHST- 2012/02/22 06:00 [entrez] PHST- 2012/02/22 06:00 [pubmed] PHST- 2013/08/06 06:00 [medline] PHST- 2013/07/09 00:00 [pmc-release] AID - 10.1007/s10561-012-9295-3 [doi] PST - ppublish SO - Cell Tissue Bank. 2013 Mar;14(1):21-32. doi: 10.1007/s10561-012-9295-3. Epub 2012 Feb 21. PMID- 930858 OWN - NLM STAT- MEDLINE DCOM- 19780127 LR - 20131121 IS - 0002-9106 (Print) IS - 0002-9106 (Linking) VI - 150 IP - 3 DP - 1977 Nov TI - The role of movement in the development of a digital flexor tendon. PG - 443-59 AB - D-tubocurarine was injected into the air sac of 8-day chick embryos to prevent movement of the digits of the hind limb. The embryos were paralyzed from the tenth to the eighteenth day, when the experiment was terminated. The immobilization of the flexor digitorum profundus tendons in the tarsus resulted in a loss of specialized structures around and on this tendon, as determined by light and electron microscopy. Specialized areas observed in the normal chick (synovial cavity, fibrocartilaginous area, and elastic vinculum) failed to form, as a result of the paralysis of the digit. Several authors have shown previously that movement is a requirement for the molding and maintenance of joint cavities in vivo, in ovo and in vitro (see text for references). We have shown that movement of the tendon is required to produce a functional tendon apparatus in the embryo and predict that movement is also required for regeneration after injury. FAU - Beckham, C AU - Beckham C FAU - Dimond, R AU - Dimond R FAU - Greenlee, T K Jr AU - Greenlee TK Jr LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Anat JT - The American journal of anatomy JID - 0376312 RN - W9YXS298BM (Tubocurarine) SB - IM MH - Animals MH - Chick Embryo MH - Foot MH - *Movement MH - Paralysis/chemically induced/embryology MH - Synovial Membrane/embryology/ultrastructure MH - Tendons/*embryology/ultrastructure MH - Tubocurarine EDAT- 1977/11/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1977/11/01 00:00 PHST- 1977/11/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1977/11/01 00:00 [entrez] AID - 10.1002/aja.1001500306 [doi] PST - ppublish SO - Am J Anat. 1977 Nov;150(3):443-59. doi: 10.1002/aja.1001500306. PMID- 31150601 OWN - NLM STAT- MEDLINE DCOM- 20200318 LR - 20200318 IS - 1532-821X (Electronic) IS - 0003-9993 (Linking) VI - 100 IP - 11 DP - 2019 Nov TI - Ultrasound-Guided Standard vs Dual-Target Subacromial Corticosteroid Injections for Shoulder Impingement Syndrome: A Randomized Controlled Trial. PG - 2119-2128 LID - S0003-9993(19)30381-8 [pii] LID - 10.1016/j.apmr.2019.04.016 [doi] AB - OBJECTIVE: To compare dual-target injection with standard ultrasound (US)-guided subacromial injection in patients with subacromial impingement syndrome (SIS) and possible disorders of the biceps long-head tendons. DESIGN: Double-blind, randomized controlled trial. SETTING: Rehabilitation outpatient clinic. PARTICIPANTS: Patients with SIS (N=60). INTERVENTION: (1) US-guided standard subacromial bursa; (2) dual-target (subacromial bursa plus proximal biceps long-head tendon) injection, with 40-mg triamcinolone acetonide administered to patients in each group. MAIN OUTCOME MEASURES: Clinical assessments were performed at baseline. The outcomes, including results from a self-administered questionnaire, the Shoulder Pain and Disability Index (SPADI), and a self-pain report, the visual analog scale (VAS) scores for pain at rest, at night, and during overhead activities, were evaluated at baseline and at the first and third months postintervention. RESULTS: No significant difference was observed in baseline evaluations between groups (n=30 in each treatment arm) prior to injections. Both groups exhibited significant SPADI and VAS-score improvements after the first month. The dual-target injection group had less rebounding pain at the 3-month follow-up. The standard injection group had more patients reporting worsening pain within 1 day postinjection. CONCLUSION: US-guided dual-target corticosteroid injection showed similar short-term efficacy to standard subacromial injections, but with an extended duration of symptom relief. Therefore, dual-target corticosteroid injections may be useful for shoulder pain treatment in patients with SIS. CI - Copyright © 2019 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved. FAU - Wang, Jia-Chi AU - Wang JC AD - Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Chang, Ke-Vin AU - Chang KV AD - Department of Physical Medicine and Rehabilitation, National Taiwan University, Hospital, Bei-Hu Branch and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: pattap@pchome.com.tw. FAU - Wu, Wei-Ting AU - Wu WT AD - Department of Physical Medicine and Rehabilitation, National Taiwan University, Hospital, Bei-Hu Branch and National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Han, Der-Sheng AU - Han DS AD - Department of Physical Medicine and Rehabilitation, National Taiwan University, Hospital, Bei-Hu Branch and National Taiwan University College of Medicine, Taipei, Taiwan. FAU - Özçakar, Levent AU - Özçakar L AD - Department of Physical and Rehabilitation Medicine, Hacettepe University Medical School, Ankara, Turkey. LA - eng SI - ClinicalTrials.gov/NCT03148353 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20190529 PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Anesthetics, Local/administration & dosage/*therapeutic use MH - Anti-Inflammatory Agents/administration & dosage/*therapeutic use MH - Bursa, Synovial MH - Double-Blind Method MH - Drug Therapy, Combination MH - Female MH - Humans MH - Injections, Intra-Articular/*methods MH - Lidocaine/administration & dosage/*therapeutic use MH - Male MH - Middle Aged MH - Pain Measurement MH - Range of Motion, Articular MH - Shoulder Impingement Syndrome/*drug therapy MH - Tendons MH - Time Factors MH - Triamcinolone Acetonide/administration & dosage/*therapeutic use MH - Ultrasonography, Interventional/methods OTO - NOTNLM OT - Pain OT - Rehabilitation OT - Shoulder OT - Ultrasonography EDAT- 2019/06/01 06:00 MHDA- 2020/03/19 06:00 CRDT- 2019/06/01 06:00 PHST- 2019/03/05 00:00 [received] PHST- 2019/04/20 00:00 [revised] PHST- 2019/04/25 00:00 [accepted] PHST- 2019/06/01 06:00 [pubmed] PHST- 2020/03/19 06:00 [medline] PHST- 2019/06/01 06:00 [entrez] AID - S0003-9993(19)30381-8 [pii] AID - 10.1016/j.apmr.2019.04.016 [doi] PST - ppublish SO - Arch Phys Med Rehabil. 2019 Nov;100(11):2119-2128. doi: 10.1016/j.apmr.2019.04.016. Epub 2019 May 29. PMID- 20179487 OWN - NLM STAT- MEDLINE DCOM- 20100521 LR - 20131121 IS - 1536-3708 (Electronic) IS - 0148-7043 (Linking) VI - 64 IP - 3 DP - 2010 Mar TI - Effects of a single application of extractum cepae on the peritendinous adhesion: an experimental study in rabbits. PG - 338-41 LID - 10.1097/SAP.0b013e3181afa428 [doi] AB - Peritendinous adhesion is an important cause of poor functional outcome after flexor tendon repair. The objective of this study was to investigate the effect of a single intraoperative application of extractum cepae, an extract of dietary onion, on the peritendinous adhesion, using a rabbit model of flexor tendon injury. The first, second, and third digits of the right hind paw of 18 rabbits were used for tendon operations. A standard partial division of the synovial sheath and flexor tendon was done at zone II to stimulate the adhesion formation. In the treatment group (n = 9 rabbits, 27 tendons), the flexor tendon sheath was treated with 50 mg/mL of extractum cepae which was applied locally and allowed to infiltrate for 5 minutes, the skin was sutured without suturing the sheath and the tendons. The same operation was done for the control group (n = 9 rabbits, 27 tendons) and 1 mL of normal saline solution was applied locally. Biomechanical and histologic evaluations of the specimens were done after 3 weeks. Tendons from the first toes were used for biomechanical studies. The second and third toe tendons were used for histopathologic evaluation. We have compared the peritendinous adhesions and the ultimate forces in the control and treated tendons. There were no statistically significant differences between the 2 groups with respect to the ultimate loads. Adhesion formation was absent in 1 tendon (5.5%), slight in 8 (44.4%), moderate in 6 (33.3), and severe in 3 tendons (16.7%) in the extractum cepae treated group (n = 18); while in the control group (n = 18), it was absent in 1 tendon (5.5%), slight in 1 tendon (5.5%), moderate in 3 (16.6%), and severe in 13 (72.4%) tendons. There was a significant reduction (P = 0.01) in the peritendinous adhesion in the treated group comparing to the control group. The problem of adhesion formation may be minimized using a single intraoperative application of extractum cepae. FAU - Dogramaci, Yunus AU - Dogramaci Y AD - Department of Orthopaedics and Traumatology, Mustafa Kemal University, 31100 Antakya, Hatay, Turkey. yunus_latif@yahoo.com FAU - Kalac, Aydner AU - Kalac A FAU - Atik, Esin AU - Atik E FAU - Esen, Erdinc AU - Esen E FAU - Altuğ, Muhammet Enes AU - Altuğ ME FAU - Onel, Ercument AU - Onel E FAU - Koç, Ahmet AU - Koç A FAU - Yanat, Ahmetnedim AU - Yanat A LA - eng PT - Journal Article PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 SB - IM MH - Animals MH - Biomechanical Phenomena MH - *Phytotherapy MH - Rabbits MH - Tendons/*physiology MH - *Tissue Adhesions MH - Wound Healing EDAT- 2010/02/25 06:00 MHDA- 2010/05/22 06:00 CRDT- 2010/02/25 06:00 PHST- 2010/02/25 06:00 [entrez] PHST- 2010/02/25 06:00 [pubmed] PHST- 2010/05/22 06:00 [medline] AID - 00000637-201003000-00021 [pii] AID - 10.1097/SAP.0b013e3181afa428 [doi] PST - ppublish SO - Ann Plast Surg. 2010 Mar;64(3):338-41. doi: 10.1097/SAP.0b013e3181afa428. PMID- 15296944 OWN - NLM STAT- MEDLINE DCOM- 20050218 LR - 20220224 IS - 0945-053X (Print) IS - 0945-053X (Linking) VI - 23 IP - 3 DP - 2004 Jun TI - Inhibition of interleukin-1beta-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. PG - 163-9 AB - The medicinal benefits of green tea (Camellia sinensis) consumption have been attributed to bioavailable polyphenols, notably epigallocatechin gallate (EGCG). We have assessed the effects of EGCG and its non-esterified counterpart EGC on the expression of the collagenases, matrix metalloproteinases (MMP)-1 and -13, and the stromelysin, MMP-3, in human tendon-derived fibroblasts. Interleukin (IL)-1beta increased MMP-1, -3 and -13 mRNA and output at least 30-fold. EGCG reduced this stimulation, by 20-30% at 2.5 microM and more than 80% at 25 microM, and had a smaller effect on MMP-2 mRNA expression, which was not stimulated by IL-1beta. In all experiments EGCG was at least 10-fold more potent than EGC. EGCG reduced the stimulation of p54 JNK/SAPK phosphorylation by IL-1beta but did not affect p38 MAPK phosphorylation, the degradation of IkappaB or the activating phosphorylation of NFkappaB. We conclude that EGCG reduces the IL-1-stimulated expression of both collagenase and stromelysin mRNA species, an effect which may be mediated by inhibition of the JNK/SAPK pathway. Taken together with previous reports of EGCG effects on the expression and/or activity of gelatinases and aggrecanases, our results underline the importance of extracellular matrix breakdown as a potential target for the actions of green tea polyphenols. FAU - Corps, Anthony N AU - Corps AN AD - Rheumatology Research Unit, Box 194, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. anc@mole.bio.cam.ac.uk FAU - Curry, Valerie A AU - Curry VA FAU - Buttle, David J AU - Buttle DJ FAU - Hazleman, Brian L AU - Hazleman BL FAU - Riley, Graham P AU - Riley GP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Interleukin-1) RN - 0 (NF-kappa B) RN - 0 (RNA, Messenger) RN - 8R1V1STN48 (Catechin) RN - BQM438CTEL (epigallocatechin gallate) RN - EC 2.7.1.- (Mitogen-Activated Protein Kinase 10) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Catechin/*analogs & derivatives/*pharmacology MH - Collagenases/genetics/*metabolism MH - Fibroblasts/*drug effects/metabolism MH - Gene Expression Regulation, Enzymologic/*drug effects MH - Humans MH - Interleukin-1/*antagonists & inhibitors/pharmacology MH - Matrix Metalloproteinase 3/genetics/*metabolism MH - Mitogen-Activated Protein Kinase 10/metabolism MH - NF-kappa B/metabolism MH - Phosphorylation/drug effects MH - RNA, Messenger/metabolism MH - Signal Transduction/drug effects MH - Tendons/*cytology MH - p38 Mitogen-Activated Protein Kinases/metabolism EDAT- 2004/08/07 05:00 MHDA- 2005/02/19 09:00 CRDT- 2004/08/07 05:00 PHST- 2004/01/07 00:00 [received] PHST- 2004/04/30 00:00 [revised] PHST- 2004/05/04 00:00 [accepted] PHST- 2004/08/07 05:00 [pubmed] PHST- 2005/02/19 09:00 [medline] PHST- 2004/08/07 05:00 [entrez] AID - S0945053X04000496 [pii] AID - 10.1016/j.matbio.2004.05.001 [doi] PST - ppublish SO - Matrix Biol. 2004 Jun;23(3):163-9. doi: 10.1016/j.matbio.2004.05.001. PMID- 9539603 OWN - NLM STAT- MEDLINE DCOM- 19980422 LR - 20220311 IS - 0003-2999 (Print) IS - 0003-2999 (Linking) VI - 86 IP - 4 DP - 1998 Apr TI - The dose-response relationship of ketorolac as a component of intravenous regional anesthesia with lidocaine. PG - 791-3 AB - Ketorolac (K) is a useful addition to lidocaine for i.v. regional anesthesia (IVRA). However, the minimal dose of K that is effective for this purpose has not been established. We added 0, 5, 10, 15, 20, 30, and 60 mg of K to 0.5% lidocaine IVRA for either carpal tunnel release or tenolysis. Pain was assessed in the postanesthesia care unit by using a visual analog scale. The duration of analgesia (time to first request for pain relief) and the use of Tylenol No. 3 tablets (T3) were measured. A linear dose-response relationship was observed between the dose of K and the duration of analgesia (r = 0.988) up to 20 mg of K. Similarly, the number of T3 tablets used was inversely related to the dose of K (r = 0.960) over the same range. There were no significant differences among the groups who received 20, 30, or 60 mg of K. We conclude that 20 mg of K is the optimal dose for inclusion with 0.5% lidocaine for IVRA under the conditions of our study. IMPLICATIONS: The antiinflammatory drug ketorolac is a useful addition to lidocaine for i.v. regional anesthesia. This study showed that 20 mg of ketorolac is equally effective as 60 mg in this context. However, smaller doses provided less effective pain relief, and a linear dose-response relationship was demonstrated. FAU - Steinberg, R B AU - Steinberg RB AD - Department of Anesthesiology, Baystate Medical Center, Springfield, Massachusetts 01199, USA. FAU - Reuben, S S AU - Reuben SS FAU - Gardner, G AU - Gardner G LA - eng PT - Journal Article PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 RN - 0 (Analgesics, Non-Narcotic) RN - 0 (Analgesics, Opioid) RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Tablets) RN - 362O9ITL9D (Acetaminophen) RN - 98PI200987 (Lidocaine) RN - D8K2JPN18B (Tolmetin) RN - UF599785JZ (Fentanyl) RN - YZI5105V0L (Ketorolac) SB - IM MH - Acetaminophen/administration & dosage/therapeutic use MH - Analgesia MH - Analgesics, Non-Narcotic/*administration & dosage MH - Analgesics, Opioid/administration & dosage/therapeutic use MH - *Anesthesia, Conduction MH - Anesthetics, Local/*administration & dosage MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage MH - Carpal Tunnel Syndrome/surgery MH - Dose-Response Relationship, Drug MH - Double-Blind Method MH - Fentanyl/administration & dosage/therapeutic use MH - Humans MH - Injections, Intravenous MH - Ketorolac MH - Lidocaine/*administration & dosage MH - Linear Models MH - Middle Aged MH - Pain Measurement MH - Pain, Postoperative/prevention & control MH - Tablets MH - Tendons/surgery MH - Time Factors MH - Tolmetin/administration & dosage/*analogs & derivatives EDAT- 1998/04/16 00:00 MHDA- 1998/04/16 00:01 CRDT- 1998/04/16 00:00 PHST- 1998/04/16 00:00 [pubmed] PHST- 1998/04/16 00:01 [medline] PHST- 1998/04/16 00:00 [entrez] AID - 10.1097/00000539-199804000-00021 [doi] PST - ppublish SO - Anesth Analg. 1998 Apr;86(4):791-3. doi: 10.1097/00000539-199804000-00021. PMID- 24709860 OWN - NLM STAT- MEDLINE DCOM- 20141016 LR - 20250214 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 73 IP - 9 DP - 2014 Sep TI - Interactions between tenocytes and monosodium urate monohydrate crystals: implications for tendon involvement in gout. PG - 1737-41 LID - 10.1136/annrheumdis-2013-204657 [doi] AB - OBJECTIVES: Advanced imaging studies have demonstrated that urate deposition in periarticular structures, such as tendons, is common in gout. The aim of this study was to investigate the effects of monosodium urate monohydrate (MSU) crystals on tenocyte viability and function. METHODS: The histological appearance of tendons in joints affected by advanced gout was examined using light microscopy. In vitro, colorimetric assays and flow cytometry were used to assess cell viability in primary rat and primary human tenocytes cultured with MSU crystals. Real-time PCR was used to determine changes in the relative mRNA expression levels of tendon-related genes, and Sirius red staining was used to measure changes in collagen deposition in primary rat tenocytes. RESULTS: In joint samples from patients with gout, MSU crystals were identified within the tendon, adjacent to and invading into tendon, and at the enthesis. MSU crystals reduced tenocyte viability in a dose-dependent manner. MSU crystals decreased the mRNA expression of tendon collagens, matrix proteins and degradative enzymes and reduced collagen protein deposition by tenocytes. CONCLUSIONS: These data indicate that MSU crystals directly interact with tenocytes to reduce cell viability and function. These interactions may contribute to tendon damage in people with advanced gout. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. FAU - Chhana, Ashika AU - Chhana A AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Callon, Karen E AU - Callon KE AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Dray, Michael AU - Dray M AD - Department of Histology, Waikato Hospital, Hamilton, New Zealand. FAU - Pool, Bregina AU - Pool B AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Naot, Dorit AU - Naot D AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Gamble, Greg D AU - Gamble GD AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Coleman, Brendan AU - Coleman B AD - Department of Orthopaedic Surgery, Middlemore Hospital, Auckland, New Zealand. FAU - McCarthy, Geraldine AU - McCarthy G AD - Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland. FAU - McQueen, Fiona M AU - McQueen FM AD - Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand. FAU - Cornish, Jillian AU - Cornish J AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. FAU - Dalbeth, Nicola AU - Dalbeth N AD - Bone & Joint Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140407 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (RNA, Messenger) RN - 268B43MJ25 (Uric Acid) RN - 9007-34-5 (Collagen) RN - EC 3.4.- (Metalloproteases) SB - IM CIN - Nat Rev Rheumatol. 2014 Jun;10(6):321. doi: 10.1038/nrrheum.2014.65. PMID: 24752181 CIN - Z Rheumatol. 2015 Aug;74(6):486. doi: 10.1007/s00393-015-1635-9. PMID: 26484371 MH - Animals MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/biosynthesis/genetics MH - Crystallization MH - Dose-Response Relationship, Drug MH - Gene Expression Regulation/drug effects MH - Gout/metabolism/*pathology MH - Humans MH - Metalloproteases/biosynthesis/genetics MH - RNA, Messenger/genetics MH - Rats MH - Rats, Wistar MH - Tendons/chemistry/cytology/*drug effects MH - Uric Acid/administration & dosage/analysis/*pharmacology OTO - NOTNLM OT - Disease Activity OT - Gout OT - Tendinitis EDAT- 2014/04/09 06:00 MHDA- 2014/10/17 06:00 CRDT- 2014/04/09 06:00 PHST- 2014/04/09 06:00 [entrez] PHST- 2014/04/09 06:00 [pubmed] PHST- 2014/10/17 06:00 [medline] AID - S0003-4967(24)09899-6 [pii] AID - 10.1136/annrheumdis-2013-204657 [doi] PST - ppublish SO - Ann Rheum Dis. 2014 Sep;73(9):1737-41. doi: 10.1136/annrheumdis-2013-204657. Epub 2014 Apr 7. PMID- 38176264 OWN - NLM STAT- MEDLINE DCOM- 20240129 LR - 20240206 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 124 DP - 2024 Feb TI - Chronopharmacology of diuresis via metabolic profiling and key biomarker discovery of the traditional Chinese prescription Ji-Ming-San using tandem mass spectrometry in rat models. PG - 155260 LID - S0944-7113(23)00618-9 [pii] LID - 10.1016/j.phymed.2023.155260 [doi] AB - BACKGROUND: Ji-Ming-Shan (JMS) is a traditional prescription used for patients with rheumatism, tendons swelling, relief of foot pain, athlete's foot, diuresis, gout. Although many studies have investigated the active compounds in each herb, the functional mechanism behind its therapeutic effect remains unclear. STUDY DESIGN: Metabolic cages for sample collection. The serum components obtained from the experimental animals were analyzed using LC-MS/MS. Furthermore, cross-analysis using the software MetaboAnalyst and Venn diagrams were used to investigate chronopharmacology of JMS in the animal models. PURPOSE: The aim of this study is to analyze the diuretic effects of JMS and to explore their chronopharmacology involved in organ regulation through four-quarter periods from serum samples of rat models. METHODS: Metabolic cages were used for collecting the urine samples and PocketChem UA PU-4010, Fuji DRI-CHEM 800 were used to examine the urine biochemical parameters. The serum components were identified through ultra-performance liquid chromatography-quadrupole time-of-flight (UPLC-Q-TOF) with a new developed method. Cross analysis, Venn diagram, MetaboAnalyst were used to investigate the key biomarker and major metabolism route with the oral administration of the drug. RESULT: JMS significantly changed the 6 h urine volume with no observed kidney toxicity. Urine pH value ranges from 7.0 to 7.5. The chronopharmacology of JMS diuresis activity were 0-6 and 6-12 groups. UPLC-Q-TOF analyses identified 243 metabolites which were determined in positive mode and negative mode respectively. With cross analysis in the Venn diagram, one key biomarker naringenin-7-O-glucoside has been identified. Major metabolic pathways such as 1: Glycerophospholipid metabolism, 2: Primary bile acid biosynthesis, 3: Sphingolipid metabolism, 4: Riboflavin metabolism, 5: Linoleic acid metabolism, 6: Butanoate metabolism. CONCLUSION: JMS significantly changed the urine output of animals in the 0-6 and 6-12 groups. No change in urine pH was observed and also kidney toxicity. A new UPLC-Q-TOF method was developed for the detection of the metabolites of JMS after oral administration. The cross analysis with Venn diagram and identified the key biomarker of JMS namely naringenin-7-O-glucoside. The results showed that six major pathways are involved in the gastrointestinal system and the liver. This study demonstrated the capability of JMS prescription in the regulation of diuresis and identified a key biomarker that is responsible for its therapeutic effect. CI - Copyright © 2023 Elsevier GmbH. All rights reserved. FAU - Hsieh, Cheng-Yang AU - Hsieh CY AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Postal address: Teaching & research building, 250 Wu-Hsing Street, Taipei 110, Taiwan; Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai Japan. FAU - Tsai, Po-Wei AU - Tsai PW AD - Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan 711, Taiwan. FAU - Tomioka, Yoshihisa AU - Tomioka Y AD - Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai Japan. FAU - Matsumoto, Yotaro AU - Matsumoto Y AD - Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai Japan. FAU - Akiyama, Yasutoshi AU - Akiyama Y AD - Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai Japan. FAU - Wang, Ching-Chiung AU - Wang CC AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Postal address: Teaching & research building, 250 Wu-Hsing Street, Taipei 110, Taiwan; Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan. FAU - Tayo, Lemmuel L AU - Tayo LL AD - School of Chemical, Biological, Materials Engineering and Sciences, Mapúa University, Intramuros, 1002 Metro Manila, Manila, Philippines; Department of Biology, School of Medicine and Health Sciences Mapua University, Makati, Philippines. FAU - Lee, Chia-Jung AU - Lee CJ AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Postal address: Teaching & research building, 250 Wu-Hsing Street, Taipei 110, Taiwan; Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan. Electronic address: cjlee@tmu.edu.tw. LA - eng PT - Journal Article DEP - 20231206 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Biomarkers) SB - IM MH - Rats MH - Humans MH - Animals MH - *Tandem Mass Spectrometry/methods MH - Rats, Sprague-Dawley MH - Chromatography, Liquid MH - Chromatography, High Pressure Liquid/methods MH - *Drugs, Chinese Herbal/analysis MH - Diuresis MH - Biomarkers MH - China OTO - NOTNLM OT - Hesperidin OT - Ji-Ming-Shan OT - Naringenin-7-O-glucoside OT - Narirutin OT - Traditional prescription OT - UPLC-Q-TOF COIS- Declaration of Competing Interest The authors have no conflicts of interest to disclose in relation to this article. EDAT- 2024/01/05 00:42 MHDA- 2024/01/29 06:44 CRDT- 2024/01/04 18:11 PHST- 2023/10/11 00:00 [received] PHST- 2023/11/14 00:00 [revised] PHST- 2023/12/04 00:00 [accepted] PHST- 2024/01/29 06:44 [medline] PHST- 2024/01/05 00:42 [pubmed] PHST- 2024/01/04 18:11 [entrez] AID - S0944-7113(23)00618-9 [pii] AID - 10.1016/j.phymed.2023.155260 [doi] PST - ppublish SO - Phytomedicine. 2024 Feb;124:155260. doi: 10.1016/j.phymed.2023.155260. Epub 2023 Dec 6. PMID- 40234966 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20250418 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 20 IP - 1 DP - 2025 Apr 15 TI - Investigation on the role of Icariin in tendon injury repair: focusing on tendon stem cell differentiation. PG - 379 LID - 10.1186/s13018-025-05784-2 [doi] LID - 379 AB - OBJECTIVE: Tendon injury is a common and frequent disease in the field of sports medicine, and tendon repair after injury is a common clinical difficulty. Repair strategy based on tendon stem cells (TDSCs) therapy is considered a promising therapeutic option for the treatment of tendon injuries. Icariin (ICA) has been shown to be an effective herbal monomer for the treatment of tendon-bone healing and may be effective in the repair of tendon injuries. METHODS: In vitro, TDSCs isolated from C57 mice were treated with ICA (0.01-100 µM) to assess proliferation (CCK-8 assay) and tendonogenic differentiation (qRT-PCR). In vivo, 42 C57 mice with surgically induced patellar tendon defects were randomized into three groups (n = 14/group): (1) 20 mg/kg ICA, (2) 40 mg/kg ICA, and (3) control group (DMSO), administered intraperitoneally for 14 days. Half of each group (n = 7) underwent histopathological (hematoxylin-eosin staining, Masson staining) and molecular (qRT-PCR) analyses at 2 and 4 weeks post-surgery. RESULTS: In vitro, after 7 days of ICA intervention in TDSC, the expression of Mohawk (MKX), Scleraxis (SCX), fibromodulin (FMOD), and Tenomodulin (TNC) were higher in the ICA group than in the control group. In vivo, the expression of MKX, SCX, FMOD, and TNC was higher in the 20 mg/kg ICA group and 40 mg/kg ICA group than in the control group at 2 and 4 weeks after surgery. Histological evaluation revealed superior tendon repair in both ICA-treated groups compared to controls at both 2 and 4 weeks postoperative intervals. The 20 mg/kg ICA group demonstrated a significant enhancement in tissue continuity and collagen fiber organization, exhibiting greater defect filling, fewer interstitial gaps, and reduced vascular infiltration. In contrast, control specimens exhibited disorganized collagen architecture with prominent interstitial gaps. The 40 mg/kg ICA group showed intermediate repair outcomes between the 20 mg/kg ICA and control groups. CONCLUSION: ICA can improve tendon injury repair by enhancing tendonogenic differentiation of TDSC. CI - © 2025. The Author(s). FAU - He, Zhenhong AU - He Z AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. AD - School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. FAU - Zeng, Shengqiang AU - Zeng S AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. FAU - Qin, Bo AU - Qin B AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. FAU - Liu, Gang AU - Liu G AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. FAU - Liu, Huan AU - Liu H AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. 20016040@163.com. AD - School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. 20016040@163.com. FAU - Bao, Dingsu AU - Bao D AD - Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, Sichuan, China. 332639420@qq.com. AD - School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. 332639420@qq.com. AD - Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan, China. 332639420@qq.com. LA - eng GR - 2023M732927/the China Postdoctoral Science Foundation/ GR - 2021-SYF-25/the Science and Technology Project of Luzhou/ GR - 2021ZKMS051/the Research Project of Southwest Medical University/ PT - Journal Article DEP - 20250415 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - VNM47R2QSQ (icariin) RN - 0 (Flavonoids) SB - IM MH - Animals MH - *Cell Differentiation/drug effects/physiology MH - *Flavonoids/pharmacology/therapeutic use MH - *Tendon Injuries/pathology/drug therapy/therapy MH - Mice MH - Mice, Inbred C57BL MH - *Stem Cells/drug effects/physiology MH - Male MH - Cells, Cultured MH - *Tendons/cytology/drug effects MH - *Wound Healing/drug effects/physiology MH - Cell Proliferation/drug effects PMC - PMC12001499 OTO - NOTNLM OT - Icariin OT - Tendon repair OT - Tendon stem cell OT - Tendonogenic differentiation COIS- Declarations. Ethics approval and consent to participate: The Animal Research Ethics Committee of Traditional Chinese Medicine Hospital of Southwest Medical University in China had approved all experiments (SWMU20210053). Competing interests: The authors declare no competing interests. EDAT- 2025/04/16 00:24 MHDA- 2025/04/16 06:19 PMCR- 2025/04/15 CRDT- 2025/04/15 23:52 PHST- 2025/02/22 00:00 [received] PHST- 2025/04/03 00:00 [accepted] PHST- 2025/04/16 06:19 [medline] PHST- 2025/04/16 00:24 [pubmed] PHST- 2025/04/15 23:52 [entrez] PHST- 2025/04/15 00:00 [pmc-release] AID - 10.1186/s13018-025-05784-2 [pii] AID - 5784 [pii] AID - 10.1186/s13018-025-05784-2 [doi] PST - epublish SO - J Orthop Surg Res. 2025 Apr 15;20(1):379. doi: 10.1186/s13018-025-05784-2. PMID- 19409915 OWN - NLM STAT- MEDLINE DCOM- 20090623 LR - 20131121 IS - 1879-0631 (Electronic) IS - 0024-3205 (Linking) VI - 84 IP - 25-26 DP - 2009 Jun 19 TI - New insight into the non-neuronal cholinergic system via studies on chronically painful tendons and inflammatory situations. PG - 865-70 LID - 10.1016/j.lfs.2009.04.014 [doi] AB - For certain parts of the body, it is nowadays accepted that there is a cholinergic system that is not related to cholinergic innervation, i.e. a non-neuronal cholinergic system. It might be argued that this system is of minor importance. New information obtained shows, however, that the non-neuronal cholinergic system is more widely distributed in the body than what is previously recognised. In recent studies, the existence of such a system has thus been shown for human tendons, especially in chronically painful situations (tendinopathy/tendinosis), in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis, and in the mucosa of ulcerative colitis patients. There is evidence of both acetylcholine (ACh) production and a marked existence of muscarinic (M2) ACh receptors in these situations. The non-neuronal cholinergic system may be involved in the establishment of a 'cholinergic anti-inflammatory pathway' and in proliferative and tissue reorganisation processes via autocrine/paracrine effects. The new information obtained suggests that this system plays an important functional role in chronically painful tendons and in inflammatory conditions. The findings of such a system in various parts of the body, when taken together, show that not only should the classical neuronal cholinergic system be considered in discussion of the cholinergic influences in the body. Additionally, the production of ACh in local cells in the tissues represents an important extra supply of the transmitter. ACh effects can be obtained whether or not there is a cholinergic innervation in the tissue. FAU - Forsgren, Sture AU - Forsgren S AD - Department of Integrative Medical Biology, Section for Anatomy, Umeå University, SE-901 87 Umeå, Sweden. Sture.Forsgren@Anatomy.umu.se FAU - Grimsholm, Ola AU - Grimsholm O FAU - Jönsson, Maria AU - Jönsson M FAU - Alfredson, Håkan AU - Alfredson H FAU - Danielson, Patrik AU - Danielson P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20090503 PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Receptors, Muscarinic) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*genetics/immunology/*metabolism MH - Animals MH - Arthritis, Rheumatoid/genetics/immunology/*metabolism MH - Colitis, Ulcerative/genetics/immunology/*metabolism MH - Humans MH - Receptors, Muscarinic/immunology/metabolism MH - Tendinopathy/genetics/immunology/*metabolism RF - 68 EDAT- 2009/05/05 09:00 MHDA- 2009/06/24 09:00 CRDT- 2009/05/05 09:00 PHST- 2009/02/03 00:00 [received] PHST- 2009/04/14 00:00 [revised] PHST- 2009/04/17 00:00 [accepted] PHST- 2009/05/05 09:00 [entrez] PHST- 2009/05/05 09:00 [pubmed] PHST- 2009/06/24 09:00 [medline] AID - S0024-3205(09)00180-5 [pii] AID - 10.1016/j.lfs.2009.04.014 [doi] PST - ppublish SO - Life Sci. 2009 Jun 19;84(25-26):865-70. doi: 10.1016/j.lfs.2009.04.014. Epub 2009 May 3. PMID- 32345111 OWN - NLM STAT- MEDLINE DCOM- 20210305 LR - 20211203 IS - 1557-7600 (Electronic) IS - 1096-620X (Print) IS - 1096-620X (Linking) VI - 23 IP - 12 DP - 2020 Dec TI - The Impact of Genistein Supplementation on Tendon Functional Properties and Gene Expression in Estrogen-Deficient Rats. PG - 1266-1274 LID - 10.1089/jmf.2019.0293 [doi] AB - Tendinopathy risk increases with menopause. The phytoestrogen genistein prevents collagen loss during estrogen deficiency (ovariectomy [OVX]). The influence of genistein on tendon function and extracellular matrix (ECM) regulation is not well known. We determined the impact of genistein on tendon function and the expression of several genes important for the regulation of tendon ECM. Eight-week-old rats (n = 42) were divided into three groups: intact, OVX, or OVX-genistein (6 mg/kg/day) for 6 weeks. Tail fascicles were assessed with a Deben tensile stage. Achilles tendon mRNA expression was determined with digital droplet polymerase chain reaction. Compared to intact, fascicle stress tended to be lower in untreated OVX rats (P = .022). Furthermore, fascicle modulus and energy density were greater in genistein-treated rats (P < .05) compared to intact. Neither OVX nor genistein altered expression of Col1a1, Col3a1, Casp3, Casp8, Mmp1a, Mmp2, or Mmp9 (P > .05). Compared to intact, Tnmd and Esr1 expression were greater and Pcna and Timp1 expression were lower in OVX rats (P < .05). Genistein treatment returned Tnmd, Pcna, and Timp1 to levels of intact-vehicle (P < .05), but did not alter Scx or Esr1 (P > .05). Several β-catenin/Wnt signaling-related molecules were not altered by OVX or genistein (P > .05). Our findings demonstrate that genistein improves tendon function in estrogen-deficient rats. The effect of genistein in vivo was predominately on genes related to cell proliferation rather than collagen remodeling. FAU - Carroll, Chad C AU - Carroll CC AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. AD - Department of Physiology, Midwestern University, Glendale, Arizona, USA. FAU - Patel, Shivam H AU - Patel SH AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. FAU - Simmons, Jessica AU - Simmons J AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. FAU - Gordon, Ben Dh AU - Gordon BD AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina, USA. FAU - Olson, Jay F AU - Olson JF AD - Department of Physiology, Midwestern University, Glendale, Arizona, USA. FAU - Chemelewski, Kali AU - Chemelewski K AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. FAU - Saw, Shannon AU - Saw S AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana, USA. FAU - Hale, Taben M AU - Hale TM AD - Department of Basic Medical Sciences, College of Medicine-Phoenix, University of Arizona, Phoenix, Arizona, USA. FAU - Howden, Reuben AU - Howden R AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina, USA. FAU - Sabbaghi, Arman AU - Sabbaghi A AD - Department of Statistics, Purdue University, West Lafayette, Indiana, USA. LA - eng PT - Journal Article DEP - 20200427 PL - United States TA - J Med Food JT - Journal of medicinal food JID - 9812512 RN - DH2M523P0H (Genistein) SB - IM MH - Animals MH - *Dietary Supplements MH - Female MH - Gene Expression MH - Genistein/*pharmacology MH - Ovariectomy MH - Rats MH - Tendons/*drug effects/*physiology PMC - PMC7757587 OTO - NOTNLM OT - collagen OT - estrogen deficiency OT - extracellular matrix OT - genistein OT - rat OT - tendon COIS- No competing financial interests exist. EDAT- 2020/04/30 06:00 MHDA- 2021/03/06 06:00 PMCR- 2021/12/01 CRDT- 2020/04/30 06:00 PHST- 2020/04/30 06:00 [pubmed] PHST- 2021/03/06 06:00 [medline] PHST- 2020/04/30 06:00 [entrez] PHST- 2021/12/01 00:00 [pmc-release] AID - 10.1089/jmf.2019.0293 [pii] AID - 10.1089/jmf.2019.0293 [doi] PST - ppublish SO - J Med Food. 2020 Dec;23(12):1266-1274. doi: 10.1089/jmf.2019.0293. Epub 2020 Apr 27. PMID- 36905095 OWN - NLM STAT- MEDLINE DCOM- 20230331 LR - 20230331 IS - 1532-4109 (Electronic) IS - 0360-1234 (Linking) VI - 58 IP - 3 DP - 2023 TI - Improving meat qualities of pigs after deworming against ascariasis with administered glycyrrhizic acid. PG - 239-246 LID - 10.1080/03601234.2023.2186669 [doi] AB - The present paper describes the effect of glycyrrhizic acid contained in licorice roots on the quality of pork produced. The study uses advanced research methods as ion-exchange chromatography, inductively coupled plasma mass spectrometry, drying of an average sample of muscle, and pressing method. The paper set out to investigate the effect of glycyrrhizic acid on the pig meat quality after deworming. Of particular concern is the animal body restoration after deworming that results in metabolic disorders. The nutrient content of meat reduces, the output of bones and tendons rises. This is the first report on the use of glycyrrhizic acid to increase the meat quality of pigs after deworming. The findings from this study indicated higher pork quality resulted from a favorable effect of GA on the chemical and amino acid composition of meat. The resulting data demonstrated that glycyrrhizic acid in the piglets' diet had a beneficial effect on the biochemical processes in their body. The main scientific provisions of this paper and its findings have several practical implications for veterinary specialists. They can also be recommended for the educational process. Another possible implication is the development of new drugs, methods, and treatment plans. FAU - Bazekin, Georgii AU - Bazekin G AD - Department of Morphology, Pathology, Pharmacy and Non-Communicable Diseases, Federal State Budget Educational Institution of Higher Education "Bashkir State Agrarian University", Ufa, Russia. FAU - Gatiyatullin, Ildar AU - Gatiyatullin I AD - Department of Morphology, Pathology, Pharmacy and Non-Communicable Diseases, Federal State Budget Educational Institution of Higher Education "Bashkir State Agrarian University", Ufa, Russia. FAU - Skovorodin, Evgeny AU - Skovorodin E AD - Department of Morphology, Pathology, Pharmacy and Non-Communicable Diseases, Federal State Budget Educational Institution of Higher Education "Bashkir State Agrarian University", Ufa, Russia. FAU - Chudov, Ivan AU - Chudov I AD - Department of Morphology, Pathology, Pharmacy and Non-Communicable Diseases, Federal State Budget Educational Institution of Higher Education "Bashkir State Agrarian University", Ufa, Russia. FAU - Ezhkov, Vladimir AU - Ezhkov V AD - Department for the Development of Nano- and Biotechnologies in Agriculture and Animal Husbandry, Tatar Research Institute of Agrochemistry and Soil Science-A Separate Structural Subdivision of the Federal Research Center "Kazan Scientific Center of the Russian Academy of Sciences", Kazan, Russia. LA - eng PT - Journal Article DEP - 20230310 PL - England TA - J Environ Sci Health B JT - Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes JID - 7607167 RN - 6FO62043WK (Glycyrrhizic Acid) SB - IM MH - Swine MH - Animals MH - *Glycyrrhizic Acid/pharmacology/chemistry MH - *Ascariasis MH - Diet/veterinary MH - Muscles MH - Meat/analysis OTO - NOTNLM OT - Food OT - glycyrrhizic acid OT - meat production OT - pork EDAT- 2023/03/12 06:00 MHDA- 2023/03/31 06:42 CRDT- 2023/03/11 01:37 PHST- 2023/03/31 06:42 [medline] PHST- 2023/03/12 06:00 [pubmed] PHST- 2023/03/11 01:37 [entrez] AID - 10.1080/03601234.2023.2186669 [doi] PST - ppublish SO - J Environ Sci Health B. 2023;58(3):239-246. doi: 10.1080/03601234.2023.2186669. Epub 2023 Mar 10. PMID- 20027940 OWN - NLM STAT- MEDLINE DCOM- 20100112 LR - 20131121 IS - 1545-9616 (Print) IS - 1545-9616 (Linking) VI - 8 IP - 12 DP - 2009 Dec TI - A novel approach to treatment of the aging hand with Radiesse. PG - 1122-6 AB - The ideal dermal filler for treatment of the aging had needs to have inherent bulk and longevity of effect. The filler calcium hydroxylapatite (CaHA) provides a texture that lends itself to injection and then to subsequent massage, without losing control of where the product is placed. In the recent past, delivery of CaHA to the hands has been accomplished by mixing lidocaine with the dermal filler prior to injection into the dorsum of the hand. The author suggests that an alternative way to deliver CaHA is to administer a large bolus of lidocaine immediately prior to injection of the dermal filler itself, followed by firm massage to disseminate the CaHA microspheres and carrier gel into the areas around and above the tendons and veins of the hand. FAU - Bank, David E AU - Bank DE AD - Columbia Presbyterian Medical Center, New York, NY, USA. office@thecenterforderm.com LA - eng PT - Journal Article PL - United States TA - J Drugs Dermatol JT - Journal of drugs in dermatology : JDD JID - 101160020 RN - 91D9GV0Z28 (Durapatite) RN - 98PI200987 (Lidocaine) SB - IM MH - *Cosmetic Techniques MH - Durapatite/*administration & dosage MH - *Hand MH - Humans MH - Lidocaine/*administration & dosage MH - *Skin Aging EDAT- 2009/12/24 06:00 MHDA- 2010/01/13 06:00 CRDT- 2009/12/24 06:00 PHST- 2009/12/24 06:00 [entrez] PHST- 2009/12/24 06:00 [pubmed] PHST- 2010/01/13 06:00 [medline] PST - ppublish SO - J Drugs Dermatol. 2009 Dec;8(12):1122-6. PMID- 24901928 OWN - NLM STAT- MEDLINE DCOM- 20150728 LR - 20181023 IS - 2589-1294 (Electronic) IS - 1017-995X (Linking) VI - 48 IP - 3 DP - 2014 TI - The effect of organic silicon injection on Achilles tendon healing in rats. PG - 346-54 LID - 10.3944/AOTT.2014.3162 [doi] AB - OBJECTIVE: The aim of this study was to assess the efficacy of a soluble absorbable silicon compound on healing of the Achilles tendon. METHODS: The Achilles tendons of 21 Wistar albino rats were cut and repaired. A 0.01 ml organic silicon solution (silanol) was injected peri/intratendinously into the left leg of all rats and the same dose of saline into the right leg postoperatively. Rats were randomly divided into 3 groups for biomechanical testing on Day 10 (7 rats) and Day 20 (7 rats) and histological and immunohistochemical assessment on Day 20 (7 rats). Fibroblast cell count and diameter, tissue vascularity and blood vessel diameter were evaluated by histomorphometry. Basic fibroblast growth factor (bFGF) immunoreactivity was analyzed with immunohistochemistry on Day 20. Failure load and stiffness of the repaired tendons were measured on Days 10 and 20. RESULTS: The number of fibroblasts per area, average fibroblast diameter, number of vessels parallel to collagen bundles per area and average vessel diameter were significantly higher in the organic silicon group than in the control group (p<0.05). Strong immunoreactivity of bFGF in the silicon group was detected. Failure load was significantly higher in the silicon group than in the control group on Day 10 (p=0.041). On Day 20, while a difference still existed, this difference was not significant. There was no effect of the silicon injection on stiffness of healing tendons. CONCLUSION: Organic silicon appears to have a positive effect on tendon healing and is suitable for further studies on host healing response modification. FAU - Gereli, Arel AU - Gereli A AD - Department of Orthopedics and Traumatology, Acıbadem University, Faculty of Medicine, İstanbul, Turkey. arelgereli@gmail.com. FAU - Akgün, Umut AU - Akgün U AD - Department of Orthopedics and Traumatology, Acıbadem University, Faculty of Medicine, İstanbul, Turkey. FAU - Uslu, Serap AU - Uslu S AD - Vocational School of Health Services, Acıbadem University, İstanbul, Turkey. FAU - Ağır, Ismail AU - Ağır I AD - Department of Orthopedics and Traumatology, Adıyaman University, Faculty of Medicine, Adıyaman, Turkey. FAU - Ateş, Filiz AU - Ateş F AD - Institute of Biomedical Sciences, Boğaziçi University, İstanbul, Turkey. FAU - Nalbantoğlu, Ufuk AU - Nalbantoğlu U AD - Department of Orthopedics and Traumatology, Acıbadem University, Faculty of Medicine, İstanbul, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Silicones) SB - IM MH - Achilles Tendon/*drug effects/*injuries MH - Animals MH - Disease Models, Animal MH - Injections, Intralesional MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Silicones/*administration & dosage MH - Tensile Strength MH - Wound Healing EDAT- 2014/06/06 06:00 MHDA- 2015/07/29 06:00 CRDT- 2014/06/06 06:00 PHST- 2014/06/06 06:00 [entrez] PHST- 2014/06/06 06:00 [pubmed] PHST- 2015/07/29 06:00 [medline] AID - 10.3944/AOTT.2014.3162 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2014;48(3):346-54. doi: 10.3944/AOTT.2014.3162. PMID- 34916683 OWN - NLM STAT- MEDLINE DCOM- 20211220 LR - 20220105 IS - 1671-167X (Print) IS - 1671-167X (Linking) VI - 53 IP - 6 DP - 2021 Dec 18 TI - [Clinical characteristics of crystal deposits in joints and tendons in patients with gout]. PG - 1067-1071 AB - OBJECTIVE: To explore the abnormal manifestations and clinical features of patients with gout according to the location of crystal deposits: in articulars or in tendons. METHODS: A total of 105 patients with gout who were continuously treated in the Department of Rheumatology and Immunology of Peking University People's Hospital from June 2019 to December 2019 were selected and their knees, ankles, toes and painful joints and tendons were examined by high-frequency ultrasound. Then we grouped them according to the presence or absence of sodium urate crystals and the location of the crystals, collected their clinical data, and analyzed the clinical characteristics. RESULTS: Among the 105 patients, 25 patients had no crystal deposits in the joints or tendons (as the non-crystal group), 43 patients had intra-articular crystals (as the joint group), and 37 patients had intra-tendon crystals with or without intra-articular crystals (as the tendon group). Among them, the most involved part of sodium urate crystals deposited in the joints was the metatarsophalangeal joint (29 cases, 67.4%), followed by knee joints (10 cases, 23.2%), ankle joints (9 cases, 20.9%). The most involved part of sodium urate crystals deposited in the tendon was the quadriceps tendon (16 cases, 43.2%), followed by the Achilles tendon (13 cases, 35.1%), the patellar tendon (12 cases, 32.4%), and the three heads of brachii tendons (5 cases, 13.5%). The three groups were compared using multi-sample analysis of variance/multi-sample rank sum test. Age, age of first increase in uric acid (UA), serum glucose (Glu) level and C reactive protein (CRP) were all significantly different. After multiple comparisons, compared with the non-crystal group, age, the age of first increase in uric acid, and CRP were significantly higher in the tendon group. There was no significant difference between the non-crystal group and the joint group. There was no significant difference between the tendon group and the joint group. CONCLUSION: In patients with gout, it is common for ultrasound to find crystals deposited in joints or tendons. The most commonly affected parts include the metatarsophalangeal joint, knee joint, ankle joint, quadriceps tendon, Achilles tendon, patellar tendon, and triceps tendon. There were significant differences among the three groups in age, age of first increase in uric acid, CRP and blood glucose, and the proportion of urinary calculi in patients with crystal deposits was significantly higher than those without crystal deposits. FAU - Peng, Z AU - Peng Z AD - Department of Rheumatology, Peking University People's Hospital, Beijing 100044, China. FAU - Ding, Y M AU - Ding YM AD - Department of Rheumatology, Peking University People's Hospital, Beijing 100044, China. FAU - Pei, L AU - Pei L AD - Department of Laboratory Medicine, Peking University People's Hospital, Beijing 100044, China. FAU - Yao, H H AU - Yao HH AD - Department of Rheumatology, Peking University People's Hospital, Beijing 100044, China. FAU - Zhang, X W AU - Zhang XW AD - Department of Rheumatology, Peking University People's Hospital, Beijing 100044, China. FAU - Tang, S M AU - Tang SM AD - Department of Rheumatology, Peking University People's Hospital, Beijing 100044, China. LA - chi PT - Journal Article PL - China TA - Beijing Da Xue Xue Bao Yi Xue Ban JT - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences JID - 101125284 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Achilles Tendon MH - *Gout MH - Humans MH - Knee Joint MH - *Metatarsophalangeal Joint/diagnostic imaging MH - Uric Acid PMC - PMC8695156 OTO - NOTNLM OT - Gout OT - Joint OT - Sodium urate crystal deposition OT - Tendon OT - Ultrasound EDAT- 2021/12/18 06:00 MHDA- 2021/12/21 06:00 PMCR- 2021/12/18 CRDT- 2021/12/17 06:49 PHST- 2021/12/17 06:49 [entrez] PHST- 2021/12/18 06:00 [pubmed] PHST- 2021/12/21 06:00 [medline] PHST- 2021/12/18 00:00 [pmc-release] AID - bjdxxbyxb-53-6-1067 [pii] AID - 10.19723/j.issn.1671-167X.2021.06.010 [doi] PST - ppublish SO - Beijing Da Xue Xue Bao Yi Xue Ban. 2021 Dec 18;53(6):1067-1071. doi: 10.19723/j.issn.1671-167X.2021.06.010. PMID- 22264830 OWN - NLM STAT- MEDLINE DCOM- 20120822 LR - 20191210 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 28 IP - 5 DP - 2012 May TI - Corticosteroids and local anesthetics decrease positive effects of platelet-rich plasma: an in vitro study on human tendon cells. PG - 711-9 LID - 10.1016/j.arthro.2011.09.013 [doi] AB - PURPOSE: To determine the effects of mixing anesthetics or corticosteroids with platelet-rich plasma (PRP) on human tenocytes in vitro. METHODS: Two separate protocols (double spin and single spin) were used to obtain homologous PRP from the blood of 8 healthy volunteers. Discarded tendon acquired during biceps tenodesis served as tendon specimens for all experiments. After cell isolation, tenocytes were treated in culture with PRP alone or in combination with corticosteroids and/or anesthetics. Fetal bovine serum in concentrations of 2% and 10% served as controls. Cell exposure times of 5, 10, and 30 minutes were used. Radioactive thymidine and luminescence assays were obtained to examine cell proliferation and viability. RESULTS: The presence of lidocaine, bupivacaine, or methylprednisolone resulted in significantly less proliferation than the negative 2% fetal bovine serum control (P < .05). When we compared groups, both lidocaine and bupivacaine had a greater inhibitory effect than methylprednisolone (P < .05). At all time points, viability was significantly decreased in the presence of lidocaine, bupivacaine, or methylprednisolone compared with the negative control (P < .05). CONCLUSIONS: The addition of either anesthetics or corticosteroids to PRP resulted in statistically significant decreases in tenocyte proliferation and cell viability. These results suggest that incorporation of anesthetics or corticosteroids, either alone or in combination, with PRP injection may compromise the potentially beneficial in vitro effects of isolated PRP on tendon cells and compromise cell viability at the site of tendon injury. CLINICAL RELEVANCE: Anesthetics or corticosteroids either alone or in combination should be used carefully to preserve the proposed positive effects of PRP in the treatment of tendon injury. CI - Copyright © 2012 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Carofino, Bradley AU - Carofino B AD - Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, Connecticut 06030, USA. FAU - Chowaniec, David M AU - Chowaniec DM FAU - McCarthy, Mary Beth AU - McCarthy MB FAU - Bradley, James P AU - Bradley JP FAU - Delaronde, Steve AU - Delaronde S FAU - Beitzel, Knut AU - Beitzel K FAU - Cote, Mark P AU - Cote MP FAU - Arciero, Robert A AU - Arciero RA FAU - Mazzocca, Augustus D AU - Mazzocca AD LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120121 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) RN - X4W7ZR7023 (Methylprednisolone) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adrenal Cortex Hormones/administration & dosage/*adverse effects MH - Adult MH - Anesthetics, Local/administration & dosage/*adverse effects MH - Bupivacaine/administration & dosage/*adverse effects MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Female MH - Humans MH - Lidocaine/administration & dosage/*adverse effects MH - Male MH - Methylprednisolone/administration & dosage/*adverse effects MH - *Platelet-Rich Plasma MH - Tendons/cytology/*drug effects EDAT- 2012/01/24 06:00 MHDA- 2012/08/23 06:00 CRDT- 2012/01/24 06:00 PHST- 2011/02/22 00:00 [received] PHST- 2011/09/19 00:00 [revised] PHST- 2011/09/24 00:00 [accepted] PHST- 2012/01/24 06:00 [entrez] PHST- 2012/01/24 06:00 [pubmed] PHST- 2012/08/23 06:00 [medline] AID - S0749-8063(11)01193-5 [pii] AID - 10.1016/j.arthro.2011.09.013 [doi] PST - ppublish SO - Arthroscopy. 2012 May;28(5):711-9. doi: 10.1016/j.arthro.2011.09.013. Epub 2012 Jan 21. PMID- 15041714 OWN - NLM STAT- MEDLINE DCOM- 20041221 LR - 20220223 IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 10 IP - 6 DP - 2004 Mar 15 TI - A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. PG - 1971-5 AB - PURPOSE: This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase inhibitor (MMPI), into adjuvant breast cancer therapy. EXPERIMENTAL DESIGN: Patients with stage I (T1c)-IIIA breast cancer were eligible if planned adjuvant therapy consisted of either tamoxifen alone, doxorubicin + cyclophosphamide every 21 days for four cycles (AC), or AC followed by paclitaxel every 21 days for 4 cycles (AC>T). Patients were stratified by planned adjuvant therapy and randomized (2:1 ratio) to BMS-275291 (1200 mg/day) or matched placebo for 1 year. RESULTS: Seventy-two patients were recruited from March 2001 to July 2002. Grade >or=2 musculoskeletal toxicity, generally reversible arthralgia, was reported by 36.2% of patients receiving BMS-275291 compared with 16.7% of patients receiving placebo; difference = 19.5% (95% confidence interval: -0.06, 0.44; P = NS). Two patients receiving BMS-275291 developed palpable nodules along tendons. Grade >or=3 rash was reported by 8.5% of patients receiving BMS-275291 compared with 4.2% of patients receiving placebo; difference = 4.3% (95% confidence interval: -0.18, 0.3; P = NS). Overall, 33% of BMS-275291 patients and 21% of placebo patients discontinued treatment due to adverse events. BMS-275291 trough levels tended to decrease over time; 9 of 47 (19%) had >or=50% of trough concentrations > 124 ng/ml (IC(90) for matrix metalloproteinase-9). CONCLUSIONS: The pattern of arthralgia in BMS-275291-treated patients was consistent with matrix metalloproteinase inhibitor toxicity. Although the differential incidence of arthralgia did not reach statistical significance, the trial was terminated. An adjuvant trial in this patient population is not feasible. FAU - Miller, Kathy D AU - Miller KD AD - Indiana University, Indianapolis, Indiana, USA. kathmill@iupui.edu FAU - Saphner, Thomas J AU - Saphner TJ FAU - Waterhouse, David M AU - Waterhouse DM FAU - Chen, T-T AU - Chen TT FAU - Rush-Taylor, Anita AU - Rush-Taylor A FAU - Sparano, Joseph A AU - Sparano JA FAU - Wolff, Antonio C AU - Wolff AC FAU - Cobleigh, Melody A AU - Cobleigh MA FAU - Galbraith, Susan AU - Galbraith S FAU - Sledge, George W AU - Sledge GW LA - eng PT - Clinical Trial PT - Clinical Trial, Phase II PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Antineoplastic Agents) RN - 0 (Imidazoles) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (Organic Chemicals) RN - 094ZI81Y45 (Tamoxifen) RN - 259188-38-0 (N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide) RN - 80168379AG (Doxorubicin) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Aged MH - Antineoplastic Agents/blood/*therapeutic use/toxicity MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use/toxicity MH - Breast Neoplasms/*drug therapy/pathology MH - Chemotherapy, Adjuvant MH - Cyclophosphamide/administration & dosage MH - Doxorubicin/administration & dosage MH - Female MH - Humans MH - Imidazoles MH - *Matrix Metalloproteinase Inhibitors MH - Middle Aged MH - Neoplasm Staging MH - Organic Chemicals/*therapeutic use/*toxicity MH - Tamoxifen/therapeutic use EDAT- 2004/03/26 05:00 MHDA- 2004/12/22 09:00 CRDT- 2004/03/26 05:00 PHST- 2004/03/26 05:00 [pubmed] PHST- 2004/12/22 09:00 [medline] PHST- 2004/03/26 05:00 [entrez] AID - 10.1158/1078-0432.ccr-03-0968 [doi] PST - ppublish SO - Clin Cancer Res. 2004 Mar 15;10(6):1971-5. doi: 10.1158/1078-0432.ccr-03-0968. PMID- 21705172 OWN - NLM STAT- MEDLINE DCOM- 20120126 LR - 20181201 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 27 IP - 10 DP - 2011 Oct TI - Evaluation of tumor necrosis factor α blockade on early tendon-to-bone healing in a rat rotator cuff repair model. PG - 1351-7 LID - 10.1016/j.arthro.2011.03.076 [doi] AB - PURPOSE: The purpose was to determine whether systemic tumor necrosis factor α (TNF-α) blockade can improve rotator cuff healing in a rat model. METHODS: One hundred twenty Lewis rats underwent unilateral detachment and repair of the supraspinatus. Rats were randomized into 2 groups. The experimental group received injections of pegylated soluble tumor necrosis factor receptor type I (3.0 mg/kg every other day for 3 doses). The control group received saline solution on the same dosing schedule. At 2, 4, and 8 weeks, 20 animals in each group were killed (4 for histologic assessment and 16 for biomechanical testing). Outcomes included qualitative histologic assessment to determine new fibrocartilage formation and collagen fiber organization. Immunohistochemical staining was performed to localize TNF-α, ED1 and ED2 macrophages, and tartrate-resistant acidic phosphatase. Biomechanical testing was performed to determine the ultimate load to failure, stiffness, cross-sectional area, and ultimate stress to failure. RESULTS: Qualitative assessments of histology showed that the experimental group had more cartilage formation at 4 weeks but not at 2 or 8 weeks. There was less TNF-α staining in the experimental group at 4 and 8 weeks, and there were fewer ED1 macrophages at 4 weeks compared with controls. The ultimate load to failure was greater in the experimental group compared with controls at 2 weeks (13.3 ± 2.6 N v 11.2 ± 2.7 N, P = .05) and at 4 weeks (21.7 ± 4.6 N v 18.5 ± 2.1 N, P = .04). The experimental group also had a higher stiffness at 2 weeks (7.2 ± 2.3 N/mm v 5.8 ± 1.4 N/mm, P = .04) and at 4 weeks (10.5 ± 2.7 N/mm v 8.4 ± 1.7 N/mm, P = .01). There were no differences in any biomechanical variable at 8 weeks. CONCLUSIONS: TNF-α blockade can improve the biomechanical strength of tendon-bone healing in a rat rotator cuff model at early time points, which corresponded with modest qualitative improvements in histology. However, these differences were not maintained at 8 weeks. CLINICAL RELEVANCE: TNF-α blockade may influence rotator cuff tendon healing. CI - Copyright © 2011 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Gulotta, Lawrence V AU - Gulotta LV AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York 10021, USA. gulottal@hss.edu FAU - Kovacevic, David AU - Kovacevic D FAU - Cordasco, Frank AU - Cordasco F FAU - Rodeo, Scott A AU - Rodeo SA LA - eng PT - Journal Article DEP - 20110625 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Ectodysplasins) RN - 0 (PEGylated tumor necrosis factor alpha receptor 1) RN - 0 (Receptors, Tumor Necrosis Factor, Type I) RN - 0 (Tumor Necrosis Factor-alpha) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Cicatrix/prevention & control MH - Drug Evaluation, Preclinical MH - Ectodysplasins/analysis MH - Fibrocartilage/physiology MH - Humerus/pathology MH - Macrophages/chemistry/pathology MH - Polyethylene Glycols/administration & dosage/*therapeutic use MH - Random Allocation MH - Rats MH - Rats, Inbred Lew MH - Receptors, Tumor Necrosis Factor, Type I/administration & dosage/*therapeutic use MH - Regeneration/drug effects MH - Rotator Cuff/pathology/*surgery MH - Single-Blind Method MH - Suture Techniques MH - Tendons/pathology MH - Tumor Necrosis Factor-alpha/analysis/*antagonists & inhibitors MH - Wound Healing/*drug effects EDAT- 2011/06/28 06:00 MHDA- 2012/01/27 06:00 CRDT- 2011/06/28 06:00 PHST- 2010/08/10 00:00 [received] PHST- 2011/03/09 00:00 [revised] PHST- 2011/03/10 00:00 [accepted] PHST- 2011/06/28 06:00 [entrez] PHST- 2011/06/28 06:00 [pubmed] PHST- 2012/01/27 06:00 [medline] AID - S0749-8063(11)00336-7 [pii] AID - 10.1016/j.arthro.2011.03.076 [doi] PST - ppublish SO - Arthroscopy. 2011 Oct;27(10):1351-7. doi: 10.1016/j.arthro.2011.03.076. Epub 2011 Jun 25. PMID- 31482998 OWN - NLM STAT- MEDLINE DCOM- 20190918 LR - 20200225 IS - 1414-431X (Electronic) IS - 0100-879X (Print) IS - 0100-879X (Linking) VI - 52 IP - 9 DP - 2019 TI - Local treatment with ascorbic acid accelerates recovery of post-sutured Achilles tendon in male Wistar rats. PG - e8290 LID - S0100-879X2019000900608 [pii] LID - 10.1590/1414-431X20198290 [doi] LID - e8290 AB - Tendon rupture is a very frequent accident involving average people and high-performance athletes. Clinical studies describe tendon recovery as a painful and slow process involving different biochemical and histological events. Ascorbic acid (AA) is a potent antioxidant as well as an important cofactor for collagen synthesis. In the current study, we evaluated if local treatment with AA is able to promote tendon repair in tenotomized rats. Animals were submitted to Achilles tendon rupture followed by surgical suture. Control and AA groups received in loco injection of saline solution (0.9% NaCl) and 30 mM AA, respectively. Histological and functional recovery of Achilles tendon tissue was evaluated at 7, 14, and 21 days post-surgery. Hematoxylin/eosin staining and collagen fluorescence analysis showed intense disarrangement of tendon tissue in the saline group. Tenotomized animals also showed hypercellularity in tendon tissue compared with non-tenotomized animals. The Achilles functional index (AFI) showed a significant decrease of tendon functionality in tenotomized animals at 7, 14, and 21 days post-surgery. AA accelerated tissue organization and the recovery of function of the Achilles tendons. The beneficial effect of AA treatment was also observed in the organization of the collagen network. Data presented in the current work showed that in loco treatment with AA accelerated the recovery of injured Achilles tendon post-surgery. FAU - Souza, M AU - Souza M AUID- ORCID: 0000-0001-8021-4583 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. FAU - Moraes, S A S AU - Moraes SAS AUID- ORCID: 0000-0001-8616-6885 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. AD - Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brasil. FAU - de Paula, D R AU - de Paula DR AUID- ORCID: 0000-0001-6979-6682 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. AD - Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brasil. FAU - Maciel, A A AU - Maciel AA AUID- ORCID: 0000-0002-2444-5771 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. AD - Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brasil. FAU - Batista, E J O AU - Batista EJO AUID- ORCID: 0000-0001-5181-6833 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. AD - Núcleo de Medicina Tropical, Universidade Federal do Pará, Belém, Pará, Brasil. FAU - Silva, D G F AU - Silva DGF AUID- ORCID: 0000-0002-2109-614X AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. FAU - Bahia, C P AU - Bahia CP AUID- ORCID: 0000-0003-3794-4710 AD - Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Pará, Brasil. FAU - Oliveira, K R H M AU - Oliveira KRHM AUID- ORCID: 0000-0001-7888-1141 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. FAU - Herculano, A M AU - Herculano AM AUID- ORCID: 0000-0003-4022-8096 AD - Laboratório de Neurofarmacologia Experimental, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. LA - eng PT - Journal Article DEP - 20190902 PL - Brazil TA - Braz J Med Biol Res JT - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica JID - 8112917 RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Achilles Tendon/*drug effects/injuries/pathology MH - Animals MH - Ascorbic Acid/*administration & dosage MH - Collagen/*drug effects/physiology MH - Disease Models, Animal MH - Male MH - Rats MH - Rats, Wistar MH - Recovery of Function/drug effects MH - Tendon Injuries/*surgery MH - Tenotomy MH - Wound Healing/drug effects PMC - PMC6719343 EDAT- 2019/09/05 06:00 MHDA- 2019/09/19 06:00 PMCR- 2019/09/02 CRDT- 2019/09/05 06:00 PHST- 2019/02/11 00:00 [received] PHST- 2019/07/04 00:00 [accepted] PHST- 2019/09/05 06:00 [entrez] PHST- 2019/09/05 06:00 [pubmed] PHST- 2019/09/19 06:00 [medline] PHST- 2019/09/02 00:00 [pmc-release] AID - S0100-879X2019000900608 [pii] AID - 10.1590/1414-431X20198290 [doi] PST - ppublish SO - Braz J Med Biol Res. 2019;52(9):e8290. doi: 10.1590/1414-431X20198290. Epub 2019 Sep 2. PMID- 25760389 OWN - NLM STAT- MEDLINE DCOM- 20151006 LR - 20181202 IS - 1099-1573 (Electronic) IS - 0951-418X (Linking) VI - 29 IP - 6 DP - 2015 Jun TI - A Clinical Trial with Brazilian Arnica (Solidago chilensis Meyen) Glycolic Extract in the Treatment of Tendonitis of Flexor and Extensor Tendons of Wrist and Hand. PG - 864-9 LID - 10.1002/ptr.5323 [doi] AB - One of the Brazilian arnicas, Solidago chilensis Meyen, is a species of the Asteraceae family. This plant is known by this common name because it shares remarkably similar organoleptic properties with the genus Arnica L., also within the family Asteraceae. We examined the effectiveness of the S. chilensis fluid extract used externally for treating tendinitis of flexor and extensor tendons of wrist and hand in placebo-controlled double-blind clinical pharmacological studies. This study was approved by the Ethical Committee for Scientific Research in Human Beings at University Vila Velha-UVV. Two daily skin applications on the arm skin of a gel cream containing a 5% glycolic plant extract were administered to eight volunteers for 21 days. Among the volunteers, one of their arms was used as the placebo group, and the other one was used as a test group. Statistical data analyses demonstrated a significant reduction in the perception of pain in the arms in the test group, when it was compared to those receiving only the placebo. CI - Copyright © 2015 John Wiley & Sons, Ltd. FAU - da Silva, Ary Gomes AU - da Silva AG AD - Laboratory of Functional Ecology, University of Vila Velha-UVV, Brazil. FAU - Machado, Elbe Rodrigues AU - Machado ER AD - Department of Pharmacy, University of Vila Velha-UVV-ES, Brazil. FAU - de Almeida, Leonardo Mendes AU - de Almeida LM AD - Department of Pharmacy, University of Vila Velha-UVV-ES, Brazil. FAU - Nunes, Ricardo Marcelo Menezes AU - Nunes RM AD - Department of Pharmacy, University of Vila Velha-UVV-ES, Brazil. FAU - Giesbrecht, Patrícia Caldeira Pena AU - Giesbrecht PC AD - Department of Physiotherapy, University of Vila Velha-UVV-ES, Brazil. FAU - Costa, Regina Mamed AU - Costa RM AD - Doctoral Program in Biotechnology, Northeastern Web of Biotechnology-RENORBIO, Federal University of Espírito Santo-UFES, Brazil. FAU - Costa, Helber B AU - Costa HB AD - Petroleomic and Forensic Laboratory, Department of Chemistry, Federal University of Espírito Santo-UFES, Brazil. FAU - Romão, Wanderson AU - Romão W AD - Petroleomic and Forensic Laboratory, Department of Chemistry, Federal University of Espírito Santo-UFES, Brazil. AD - Federal Institute of Espírito Santo, Vila Velha, IFES-ES, Brazil. FAU - Kuster, Ricardo Machado AU - Kuster RM AD - Laboratory of Phytochemistry of Medicinal Plants, Institute of Natural Products Research, Federal University of Rio de Janeiro-IPPN-UFRJ, Brazil. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150311 PL - England TA - Phytother Res JT - Phytotherapy research : PTR JID - 8904486 RN - 0 (Gels) RN - 0 (Plant Extracts) SB - IM MH - Administration, Cutaneous MH - Brazil MH - Double-Blind Method MH - Gels MH - Humans MH - Pain Measurement MH - Phytotherapy MH - Plant Extracts/chemistry/*pharmacology MH - Skin Cream MH - Solidago/*chemistry MH - Tendinopathy/*drug therapy MH - Tendons/physiopathology MH - Wrist/physiopathology OTO - NOTNLM OT - Asteraceae OT - antiinflammatory OT - antinociception activity OT - pain OT - phytotherapy OT - repetitive strain injury EDAT- 2015/03/12 06:00 MHDA- 2015/10/07 06:00 CRDT- 2015/03/12 06:00 PHST- 2014/07/06 00:00 [received] PHST- 2015/02/08 00:00 [revised] PHST- 2015/02/16 00:00 [accepted] PHST- 2015/03/12 06:00 [entrez] PHST- 2015/03/12 06:00 [pubmed] PHST- 2015/10/07 06:00 [medline] AID - 10.1002/ptr.5323 [doi] PST - ppublish SO - Phytother Res. 2015 Jun;29(6):864-9. doi: 10.1002/ptr.5323. Epub 2015 Mar 11. PMID- 36262012 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20240603 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 41 IP - 6 DP - 2023 Jun TI - Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice. PG - 1162-1176 LID - 10.1002/jor.25470 [doi] AB - This study aimed to characterize aging-induced tendinopathy in mouse Achilles tendon and also to assess the treatment effects of metformin (Met) on aging tendon. We showed that compared to young tendon, aging tendon was in an inflammatory and senescent state as shown by increased expression of inflammatory disulfide HMGB1 (dsHMGB1), inflammatory macrophage marker CD68, and senescent cell markers SA-β-gal, p53, and p16. Moreover, aging tendon was degenerated marked by accumulation of proteoglycans and lipids in its interior. However, treatment of aging tendon by intraperitoneal (IP) injection of Met, a specific inhibitor of HMGB1, reduced dsHMGB1 levels, decreased the expression of CD68, SA-β-gal, CCN1, and p16 in vitro and in vivo. Furthermore, Met treatment also increased the number of NS, SSEA-1, and CD73 positive stem cells in culture and improved the tendon structure in aging mouse. These findings of this study indicate that Met exerts anti-inflammatory and anti-senescent effects on aging tendon. CI - © 2022 Orthopaedic Research Society. Published by Wiley Periodicals LLC. FAU - Zhang, Jianying AU - Zhang J AUID- ORCID: 0000-0002-9004-9910 AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Brown, Roshawn AU - Brown R AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Hogan, MaCalus V AU - Hogan MV AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Onishi, Kentaro AU - Onishi K AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. FAU - Wang, James H-C AU - Wang JH AUID- ORCID: 0000-0001-7279-0679 AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. AD - Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. LA - eng GR - R21 AR070340/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20221107 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 9100L32L2N (Metformin) RN - 0 (HMGB1 Protein) SB - IM MH - Mice MH - Animals MH - Cellular Senescence MH - *Metformin/pharmacology/therapeutic use MH - *HMGB1 Protein/metabolism MH - Aging/metabolism MH - Inflammation/drug therapy MH - Tendons/metabolism PMC - PMC10113400 MID - NIHMS1844060 OTO - NOTNLM OT - HMGB1 OT - aging OT - degeneration OT - inflammation OT - metformin OT - senescence OT - tendon EDAT- 2022/10/21 06:00 MHDA- 2023/05/08 06:42 PMCR- 2024/06/01 CRDT- 2022/10/20 01:07 PHST- 2022/08/29 00:00 [revised] PHST- 2022/02/27 00:00 [received] PHST- 2022/10/18 00:00 [accepted] PHST- 2023/05/08 06:42 [medline] PHST- 2022/10/21 06:00 [pubmed] PHST- 2022/10/20 01:07 [entrez] PHST- 2024/06/01 00:00 [pmc-release] AID - 10.1002/jor.25470 [doi] PST - ppublish SO - J Orthop Res. 2023 Jun;41(6):1162-1176. doi: 10.1002/jor.25470. Epub 2022 Nov 7. PMID- 40957132 OWN - NLM STAT- MEDLINE DCOM- 20251009 LR - 20251009 IS - 1873-2380 (Electronic) IS - 0021-9290 (Linking) VI - 192 DP - 2025 Nov TI - The effect of the collagen crosslinker genipin on early healing in a rat model of Achilles tendinopathy. PG - 112962 LID - S0021-9290(25)00474-9 [pii] LID - 10.1016/j.jbiomech.2025.112962 [doi] AB - Achilles tendinopathy is characterized by deterioration of tissue integrity and biomechanical properties. Reduced tendon stiffness is detrimental to its function. Previous studies found that increased body mass is a risk factor for Achilles tendinopathy. We aimed to determine whether increasing the stiffness of damaged Achilles tendon by the collagen crosslinker genipin can improve early healing outcomes in an animal model of collagenase-induced tendinopathy, and whether the effect depends on body mass. Male and female Sprague-Dawley rats were allocated to normal diet (ND) or high-fat diet (HFD) at weaning. At 17 weeks, each sex and diet group was divided into three treatment groups (n = 15): collagenase (CT), collagenase-genipin (CT-GT), and genipin (GT). Collagenase and genipin were injected into the Achilles tendons; contralateral tendons served as controls. After 10 days, Achilles tendons were collected for biomechanical and histological evaluation. At the time of tendinopathy induction, animals fed HFD weighed on average, 14.5 % more than animals on ND. Biomechanical and histological changes characteristic of tendinopathy were observed in Achilles tendons of all animals treated with collagenase. Genipin had no effect on tendon biomechanical and histological properties: we found no differences between the GT and the control group, or between the CT-GT and the CT group. In conclusion, 1 mM genipin did not improve the biomechanical properties of tendinopathic Achilles, and had no effect on early tendon healing in this rat model of collagenase-induced Achilles tendinopathy, irrespective of animal sex and weight. This is an important pre-clinical finding and can be used to direct future research, and prevent possible research wastage. One potential future direction is exploring innovative delivery systems to maintain higher local concentrations of genipin, that may be required to realize the potential of this molecule in tendon healing. CI - Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Konar, Subhajit AU - Konar S AD - Department of Nutrition and Dietetics, University of Auckland, New Zealand. FAU - Bolam, Scott M AU - Bolam SM AD - Department of Surgery, University of Auckland, Auckland, New Zealand. FAU - Leung, Sophia AU - Leung S AD - Department of Anatomy and Medical Imaging, University of Auckland, New Zealand. FAU - Vickers, Mark H AU - Vickers MH AD - Liggins Institute, University of Auckland, New Zealand. FAU - Cornish, Jillian AU - Cornish J AD - Department of Medicine, University of Auckland, New Zealand. FAU - Naot, Dorit AU - Naot D AD - Department of Nutrition and Dietetics, University of Auckland, New Zealand. FAU - Musson, David S AU - Musson DS AD - Department of Nutrition and Dietetics, University of Auckland, New Zealand. Electronic address: d.musson@auckland.ac.nz. LA - eng PT - Journal Article DEP - 20250912 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - A3V2NE52YG (genipin) RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - 0 (Cross-Linking Reagents) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Animals MH - *Iridoids/pharmacology MH - *Achilles Tendon/drug effects/pathology/physiopathology/injuries MH - Rats, Sprague-Dawley MH - Male MH - *Tendinopathy/drug therapy/physiopathology/pathology MH - Rats MH - Female MH - *Wound Healing/drug effects MH - Disease Models, Animal MH - *Collagen/metabolism MH - *Cross-Linking Reagents/pharmacology MH - Collagenases MH - Biomechanical Phenomena OTO - NOTNLM OT - Achilles tendinopathy OT - Biomechanics OT - Genipin OT - Histology OT - Obesity COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/09/17 00:30 MHDA- 2025/10/10 00:29 CRDT- 2025/09/16 18:11 PHST- 2025/03/26 00:00 [received] PHST- 2025/08/03 00:00 [revised] PHST- 2025/09/11 00:00 [accepted] PHST- 2025/10/10 00:29 [medline] PHST- 2025/09/17 00:30 [pubmed] PHST- 2025/09/16 18:11 [entrez] AID - S0021-9290(25)00474-9 [pii] AID - 10.1016/j.jbiomech.2025.112962 [doi] PST - ppublish SO - J Biomech. 2025 Nov;192:112962. doi: 10.1016/j.jbiomech.2025.112962. Epub 2025 Sep 12. PMID- 29274126 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1740-8261 (Electronic) IS - 1058-8183 (Linking) VI - 59 IP - 3 DP - 2018 May TI - Computed tomographic contrast tenography of the digital flexor tendon sheath of the equine hindlimb. PG - 279-288 LID - 10.1111/vru.12586 [doi] AB - Pre-surgical investigation of digital flexor tendon sheath pathology remains challenging with current standard imaging techniques. The aim of this prospective, anatomical, pilot study was to describe the anatomy of the equine hind limb digital flexor tendon sheath using a combination of computed tomography (CT) and computed tomographic contrast tenography in clinically normal cadaver limbs. Ten pairs of hind limbs with no external abnormalities were examined from the level of the tarsometatarsal joint distally. Limbs initially underwent non-contrast CT examination using 120 kVp, 300 mAs, and 1.5 mm slice thickness. Sixty millilitres of ioversol iodinated contrast media and saline (final concentration 100 mg/ml) were injected using a basilar sesamoidean approach. The computed tomographic contrast tenography examination was then repeated, before dissection of the specimens to compare gross and imaging findings. The combined CT and computed tomographic contrast tenography examinations provided excellent anatomical detail of intra-thecal structures. The borders of the superficial and deep digital flexor tendons, and the manica flexoria were consistently identifiable in all limbs. Detailed anatomy including that of the mesotenons, two of which are previously undescribed, and the plantar annular ligament were also consistently identifiable. Dissection of all 10 pairs of limbs revealed there to be no pathology, in accordance with the imaging findings. In conclusion, the combination of CT and computed tomographic contrast tenography may be useful adjunctive diagnostic techniques to define digital flexor tendon sheath pathology prior to surgical exploration in horses. CI - © 2017 American College of Veterinary Radiology. FAU - Agass, Rachel AU - Agass R AUID- ORCID: 0000-0002-7715-4820 AD - Rainbow Equine Hospital, York, North, Yorkshire, YO17 6SG. FAU - Dixon, Jonathon AU - Dixon J AD - Rainbow Equine Hospital, York, North, Yorkshire, YO17 6SG. FAU - Fraser, Barny AU - Fraser B AD - Rainbow Equine Hospital, York, North, Yorkshire, YO17 6SG. LA - eng PT - Journal Article DEP - 20171222 PL - England TA - Vet Radiol Ultrasound JT - Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association JID - 9209635 RN - 0 (Contrast Media) RN - 0 (Triiodobenzoic Acids) RN - N3RIB7X24K (ioversol) SB - IM MH - Animals MH - Cadaver MH - Contrast Media/administration & dosage MH - Hindlimb/*drug effects MH - Horses MH - Pilot Projects MH - Prospective Studies MH - Reference Values MH - Tendons/*diagnostic imaging MH - Tomography, X-Ray Computed/*veterinary MH - Triiodobenzoic Acids/administration & dosage OTO - NOTNLM OT - CT OT - effusion OT - horse OT - lameness OT - tendon sheath EDAT- 2017/12/24 06:00 MHDA- 2018/12/12 06:00 CRDT- 2017/12/24 06:00 PHST- 2017/07/18 00:00 [received] PHST- 2017/10/04 00:00 [revised] PHST- 2017/10/16 00:00 [accepted] PHST- 2017/12/24 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2017/12/24 06:00 [entrez] AID - 10.1111/vru.12586 [doi] PST - ppublish SO - Vet Radiol Ultrasound. 2018 May;59(3):279-288. doi: 10.1111/vru.12586. Epub 2017 Dec 22. PMID- 25201739 OWN - NLM STAT- MEDLINE DCOM- 20150603 LR - 20220321 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 35 IP - 37 DP - 2014 Dec TI - Down-regulating ERK1/2 and SMAD2/3 phosphorylation by physical barrier of celecoxib-loaded electrospun fibrous membranes prevents tendon adhesions. PG - 9920-9929 LID - S0142-9612(14)00953-3 [pii] LID - 10.1016/j.biomaterials.2014.08.028 [doi] AB - Peritendinous adhesions, as a major problem in hand surgery, may be due to the proliferation of fibroblasts and excessive collagen synthesis, in which ERK1/2 and SMAD2/3 plays crucial roles. In this study, we hypothesized that the complication progression could be inhibited by down-regulating ERK1/2 and SMAD2/3 phosphorylation of exogenous fibroblasts with celecoxib. Celecoxib was incorporated in poly(l-lactic acid)-polyethylene glycol (PELA) diblock copolymer fibrous membranes via electrospinning. Results of an in vitro drug release study showed celecoxib-loaded membrane had excellent continuous drug release capability. It was found that celecoxib-loaded PELA membranes were not favorable for the rabbit fibroblast and tenocyte adhesion and proliferation. In a rabbit tendon repair model, we first identified ERK1/2 and SMAD2/3 phosphorylation as a critical driver of early adhesion formation progression. Celecoxib released from PELA membrane was found to down-regulate ERK1/2 and SMAD2/3 phosphorylation, leading to reduced collagen I and collagen Ⅲ expression, inflammation reaction, and fibroblast proliferation. Importantly, the celecoxib-loaded PELA membranes successfully prevented tissue adhesion compared with control treatment and unloaded membranes treatment. This approach offers a novel barrier strategy to block tendon adhesion through targeted down-regulating of ERK1/2 and SMAD2/3 phosphorylation directly within peritendinous adhesion tissue. CI - Copyright © 2014 Elsevier Ltd. All rights reserved. FAU - Jiang, Shichao AU - Jiang S AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: mailjsc@163.com. FAU - Zhao, Xin AU - Zhao X AD - Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China. Electronic address: Xinzhao1@mit.edu. FAU - Chen, Shuai AU - Chen S AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: 723997068@qq.com. FAU - Pan, Guoqing AU - Pan G AD - Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China; Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou, Jiangsu 215006, PR China. Electronic address: yueer@suda.edu.cn. FAU - Song, Jialin AU - Song J AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: songjialinsjtu@126.com. FAU - He, Ning AU - He N AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: desmask@163.com. FAU - Li, Fengfeng AU - Li F AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: fengmale@yahoo.com.cn. FAU - Cui, Wenguo AU - Cui W AD - Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China; Department of Orthopedics, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou, Jiangsu 215006, PR China. Electronic address: wgcui80@hotmail.com. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedics, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: fancunyi888@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140915 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Lactates) RN - 0 (Membranes, Artificial) RN - 0 (Pyrazoles) RN - 0 (Smad Proteins) RN - 0 (Smad2 Protein) RN - 0 (Smad3 Protein) RN - 0 (Sulfonamides) RN - 0 (poly(lactic acid-ethylene glycol)) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Animals MH - Celecoxib MH - Cyclooxygenase 2 Inhibitors/*administration & dosage/therapeutic use MH - *Drug Delivery Systems MH - Extracellular Signal-Regulated MAP Kinases/*metabolism MH - Fibroblasts/*drug effects/metabolism MH - Lactates/chemistry MH - Membranes, Artificial MH - Mitogen-Activated Protein Kinase 1/metabolism MH - Mitogen-Activated Protein Kinase 3/metabolism MH - Phosphorylation/drug effects MH - Polyethylene Glycols/chemistry MH - Pyrazoles/*administration & dosage/therapeutic use MH - Rabbits MH - Smad Proteins/*metabolism MH - Smad2 Protein/metabolism MH - Smad3 Protein/metabolism MH - Sulfonamides/*administration & dosage/therapeutic use MH - Tendons/drug effects/metabolism MH - Tissue Adhesions/metabolism/*prevention & control OTO - NOTNLM OT - Celecoxib OT - ERK OT - Electrospun fiber OT - Phosphorylation OT - SMAD OT - Tendon adhesions EDAT- 2014/09/10 06:00 MHDA- 2015/06/04 06:00 CRDT- 2014/09/10 06:00 PHST- 2014/07/13 00:00 [received] PHST- 2014/08/18 00:00 [accepted] PHST- 2014/09/10 06:00 [entrez] PHST- 2014/09/10 06:00 [pubmed] PHST- 2015/06/04 06:00 [medline] AID - S0142-9612(14)00953-3 [pii] AID - 10.1016/j.biomaterials.2014.08.028 [doi] PST - ppublish SO - Biomaterials. 2014 Dec;35(37):9920-9929. doi: 10.1016/j.biomaterials.2014.08.028. Epub 2014 Sep 15. PMID- 4330245 OWN - NLM STAT- MEDLINE DCOM- 19720121 LR - 20191030 IS - 0515-2720 (Print) IS - 0515-2720 (Linking) VI - 40 DP - 1971 TI - Intravenous regional anaesthesia. PG - 1-35 FAU - Thorn-Alquist, A M AU - Thorn-Alquist AM LA - eng PT - Journal Article PL - England TA - Acta Anaesthesiol Scand Suppl JT - Acta anaesthesiologica Scandinavica. Supplementum JID - 0370271 RN - 046O35D44R (Prilocaine) RN - 98PI200987 (Lidocaine) RN - B6E06QE59J (Mepivacaine) SB - IM MH - Action Potentials/drug effects MH - *Anesthesia, Conduction MH - Anesthesia, Local MH - Arm/surgery MH - Humans MH - Leg/surgery MH - Lidocaine/administration & dosage MH - Mepivacaine/administration & dosage MH - Muscle Tonus MH - Muscles/drug effects MH - Preanesthetic Medication MH - Prilocaine/administration & dosage MH - Synaptic Transmission/drug effects MH - Tendons/transplantation MH - Tourniquets EDAT- 1971/01/01 00:00 MHDA- 1971/01/01 00:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 1971/01/01 00:01 [medline] PHST- 1971/01/01 00:00 [entrez] AID - 10.1111/j.1399-6576.1971.tb00820.x [doi] PST - ppublish SO - Acta Anaesthesiol Scand Suppl. 1971;40:1-35. doi: 10.1111/j.1399-6576.1971.tb00820.x. PMID- 22102295 OWN - NLM STAT- MEDLINE DCOM- 20120522 LR - 20220309 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 30 IP - 6 DP - 2012 Jun TI - Exogenous collagen cross-linking recovers tendon functional integrity in an experimental model of partial tear. PG - 973-81 LID - 10.1002/jor.22014 [doi] AB - We investigated the hypothesis that exogenous collagen cross-linking can augment intact regions of tendon to mitigate mechanical propagation of partial tears. We first screened the low toxicity collagen cross-linkers genipin, methylglyoxal and ultra-violet (UV) light for their ability to augment tendon stiffness and failure load in rat tail tendon fascicles (RTTF). We then investigated cross-linking effects in load bearing equine superficial digital flexor tendons (SDFT). Data indicated that all three cross-linking agents augmented RTTF mechanical properties but reduced native viscoelasticity. In contrast to effects observed in fascicles, methylglyoxal treatment of SDFT detrimentally affected tendon mechanical integrity, and in the case of UV did not alter tendon mechanics. As in the RTTF experiments, genipin cross-linking of SDFT resulted in increased stiffness, higher failure loads and reduced viscoelasticity. Based on this result we assessed the efficacy of genipin in arresting tendon tear propagation in cyclic loading to failure. Genipin cross-linking secondary to a mid-substance biopsy-punch significantly reduced tissue strains, increased elastic modulus and increased resistance to fatigue failure. We conclude that genipin cross-linking of injured tendons holds potential for arresting tendon tear progression, and that implications of the treatment on matrix remodeling in living tendons should now be investigated. CI - Copyright © 2011 Orthopaedic Research Society. FAU - Fessel, Gion AU - Fessel G AD - Department of Orthopedics, University Hospital Zurich, Balgrist, Forchstrasse 340, 8008 Zurich, Switzerland. FAU - Wernli, Jeremy AU - Wernli J FAU - Li, Yufei AU - Li Y FAU - Gerber, Christian AU - Gerber C FAU - Snedeker, Jess G AU - Snedeker JG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20111118 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 722KLD7415 (Pyruvaldehyde) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Collagen/metabolism/*pharmacology MH - Cross-Linking Reagents/metabolism/*pharmacology MH - Disease Models, Animal MH - Elasticity/drug effects/radiation effects MH - Horses MH - Iridoids/metabolism/*pharmacology MH - Lacerations/metabolism/therapy MH - Pyruvaldehyde/metabolism/*pharmacology MH - Rats MH - Recovery of Function MH - Tendon Injuries/metabolism/pathology/*therapy MH - *Tendons/drug effects/pathology/radiation effects MH - *Ultraviolet Therapy MH - Wound Healing/physiology EDAT- 2011/11/22 06:00 MHDA- 2012/05/23 06:00 CRDT- 2011/11/22 06:00 PHST- 2011/06/01 00:00 [received] PHST- 2011/10/31 00:00 [accepted] PHST- 2011/11/22 06:00 [entrez] PHST- 2011/11/22 06:00 [pubmed] PHST- 2012/05/23 06:00 [medline] AID - 10.1002/jor.22014 [doi] PST - ppublish SO - J Orthop Res. 2012 Jun;30(6):973-81. doi: 10.1002/jor.22014. Epub 2011 Nov 18. PMID- 16002437 OWN - NLM STAT- MEDLINE DCOM- 20051223 LR - 20191210 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 567 IP - Pt 3 DP - 2005 Sep 15 TI - Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. PG - 1021-33 AB - We hypothesized that an acute bout of strenuous, non-damaging exercise would increase rates of protein synthesis of collagen in tendon and skeletal muscle but these would be less than those of muscle myofibrillar and sarcoplasmic proteins. Two groups (n = 8 and 6) of healthy young men were studied over 72 h after 1 h of one-legged kicking exercise at 67% of maximum workload (W(max)). To label tissue proteins in muscle and tendon primed, constant infusions of [1-(13)C]leucine or [1-(13)C]valine and flooding doses of [(15)N] or [(13)C]proline were given intravenously, with estimation of labelling in target proteins by gas chromatography-mass spectrometry. Patellar tendon and quadriceps biopsies were taken in exercised and rested legs at 6, 24, 42 or 48 and 72 h after exercise. The fractional synthetic rates of all proteins were elevated at 6 h and rose rapidly to peak at 24 h post exercise (tendon collagen (0.077% h(-1)), muscle collagen (0.054% h(-1)), myofibrillar protein (0.121% h(-1)), and sarcoplasmic protein (0.134% h(-1))). The rates decreased toward basal values by 72 h although rates of tendon collagen and myofibrillar protein synthesis remained elevated. There was no tissue damage of muscle visible on histological evaluation. Neither tissue microdialysate nor serum concentrations of IGF-I and IGF binding proteins (IGFBP-3 and IGFBP-4) or procollagen type I N-terminal propeptide changed from resting values. Thus, there is a rapid increase in collagen synthesis after strenuous exercise in human tendon and muscle. The similar time course of changes of protein synthetic rates in different cell types supports the idea of coordinated musculotendinous adaptation. FAU - Miller, Benjamin F AU - Miller BF AD - Institute of Sports Medicine, Copenhagen, Bispebjerg Hospital, Denmark. FAU - Olesen, Jens L AU - Olesen JL FAU - Hansen, Mette AU - Hansen M FAU - Døssing, Simon AU - Døssing S FAU - Crameri, Regina M AU - Crameri RM FAU - Welling, Rasmus J AU - Welling RJ FAU - Langberg, Henning AU - Langberg H FAU - Flyvbjerg, Allan AU - Flyvbjerg A FAU - Kjaer, Michael AU - Kjaer M FAU - Babraj, John A AU - Babraj JA FAU - Smith, Kenneth AU - Smith K FAU - Rennie, Michael J AU - Rennie MJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20050707 PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (Carbon Radioisotopes) RN - 0 (Hemiterpenes) RN - 0 (Keto Acids) RN - 0 (Muscle Proteins) RN - 0 (Nitrogen Radioisotopes) RN - 759-05-7 (alpha-ketoisovalerate) RN - 816-66-0 (alpha-ketoisocaproic acid) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - GMW67QNF9C (Leucine) RN - HG18B9YRS7 (Valine) SB - IM MH - Adult MH - Carbon Radioisotopes MH - Collagen/*biosynthesis MH - Exercise/*physiology MH - Hemiterpenes MH - Humans MH - Keto Acids/blood MH - Leucine/blood MH - Male MH - Muscle Proteins/*biosynthesis MH - Muscle, Skeletal/anatomy & histology/*metabolism/physiology MH - Myofibrils/metabolism MH - Nitrogen Radioisotopes MH - Patella MH - Proline/blood/pharmacology MH - Sarcoplasmic Reticulum/metabolism MH - Tendons/*metabolism/physiology MH - Thigh MH - Valine/blood PMC - PMC1474228 EDAT- 2005/07/09 09:00 MHDA- 2005/12/24 09:00 PMCR- 2006/09/15 CRDT- 2005/07/09 09:00 PHST- 2005/07/09 09:00 [pubmed] PHST- 2005/12/24 09:00 [medline] PHST- 2005/07/09 09:00 [entrez] PHST- 2006/09/15 00:00 [pmc-release] AID - jphysiol.2005.093690 [pii] AID - 10.1113/jphysiol.2005.093690 [doi] PST - ppublish SO - J Physiol. 2005 Sep 15;567(Pt 3):1021-33. doi: 10.1113/jphysiol.2005.093690. Epub 2005 Jul 7. PMID- 17356796 OWN - NLM STAT- MEDLINE DCOM- 20070730 LR - 20181113 IS - 1436-6207 (Print) IS - 1436-6207 (Linking) VI - 46 IP - 3 DP - 2007 Apr TI - Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. PG - 139-46 AB - BACKGROUND: Glycoxidation of collagens contributes to development of vascular complications in diabetes. AIM OF THE STUDY: Since flavonoids are potent antioxidants present in vegetal foods, it was interesting to examine their effect on the formation of a cross-linking advanced glycation endproduct, pentosidine, in collagens. METHODS: Collagen was incubated with glucose (250 mM), in the presence of different flavonoids. Pentosidine was measured by HPLC, hydroxyproline colorimetrically. RESULTS: Monomeric flavonoids (25 and 250 microM) markedly reduced pentosidine/hydroxyproline values in a concentration- and structure-dependent manner. In decreasing order of their specific inhibitory activity, they rank as follows: myricetin > or = quercetin > rutin > (+)catechin > kaempferol. Thus 3'-OH or 4-oxo + Delta(2-3) increase the inhibitory activity; conjugation by Rha-Glc on 3-OH decreases it. Procyanidin oligomers from grape seed were more active than pine bark procyanidin oligomers: this may be related to the galloyl residues present in grape seed oligomers only. Procyanidin oligomers are known to be cleaved into monomers in the gastric milieu and monomeric flavonoids to be absorbed and recovered at micromolar concentrations (with a long plasmatic half-life) in extracellular fluids, in contact with collagens. CONCLUSION: Flavonoids are very potent inhibitors of pentosidine formation in collagens. They are active at micromolar concentrations; these might be achieved in plasma of diabetic patients after oral intake of natural flavonoids. FAU - Urios, Paul AU - Urios P AD - Equipe de recherche "Protéines modifiées, protéases et physiopathologie de l'endothélium vasculaire", Dépt. de Biochimie, Faculté de Médecine and Laboratoire de Pharmacologie, Faculté de Pharmacie, Université René Descartes, Paris, France. FAU - Grigorova-Borsos, Anne-Marie AU - Grigorova-Borsos AM FAU - Sternberg, Michel AU - Sternberg M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070313 PL - Germany TA - Eur J Nutr JT - European journal of nutrition JID - 100888704 RN - 0 (Antioxidants) RN - 0 (Cross-Linking Reagents) RN - 0 (Flavonoids) RN - 0 (Glycation End Products, Advanced) RN - 94ZLA3W45F (Arginine) RN - BJ4I2X2CQJ (pentosidine) RN - IY9XDZ35W2 (Glucose) RN - K3Z4F929H6 (Lysine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Antioxidants/pharmacology MH - Arginine/*analogs & derivatives/analysis/antagonists & inhibitors MH - Cattle MH - Chromatography, High Pressure Liquid MH - Cross-Linking Reagents/analysis MH - Dose-Response Relationship, Drug MH - Flavonoids/*pharmacology MH - Glucose/metabolism MH - Glycation End Products, Advanced/analysis/*antagonists & inhibitors MH - *Glycosylation MH - Humans MH - Hydroxyproline/analysis/pharmacology MH - Lysine/*analogs & derivatives/analysis/antagonists & inhibitors MH - Oxidation-Reduction MH - Tendons MH - Tissue Culture Techniques EDAT- 2007/03/16 09:00 MHDA- 2007/07/31 09:00 CRDT- 2007/03/16 09:00 PHST- 2006/03/27 00:00 [received] PHST- 2007/01/23 00:00 [accepted] PHST- 2007/03/16 09:00 [pubmed] PHST- 2007/07/31 09:00 [medline] PHST- 2007/03/16 09:00 [entrez] AID - 10.1007/s00394-007-0644-0 [doi] PST - ppublish SO - Eur J Nutr. 2007 Apr;46(3):139-46. doi: 10.1007/s00394-007-0644-0. Epub 2007 Mar 13. PMID- 34332919 OWN - NLM STAT- MEDLINE DCOM- 20220124 LR - 20220124 IS - 1879-0712 (Electronic) IS - 0014-2999 (Linking) VI - 909 DP - 2021 Oct 15 TI - Pharmacological activation of SIRT1 by metformin prevented trauma-induced heterotopic ossification through inhibiting macrophage mediated inflammation. PG - 174386 LID - S0014-2999(21)00539-2 [pii] LID - 10.1016/j.ejphar.2021.174386 [doi] AB - Trauma-induced heterotopic ossification (HO) is the aberrant extra-skeletal bone formation that severely incapacitates patient's daily life. Inflammation is the first stage of this progression, becoming an appealing target of early therapeutic intervention. Metformin, a widely used antidiabetic drug, also poses the therapeutic potential to modulate various inflammatory-related diseases. Therefore, this study aimed to investigate the preventive effect of metformin on trauma-induced HO progression, and unveil the underlying molecular mechanisms. A murine burn/tenotomy model was established to mimic trauma-induced HO in vivo. The anti-inflammation and anti-ossification effects of metformin were evaluated by histological staining and micro-CT. The inhibitory effects of metformin on macrophages activation in vitro were examined by ELISA and qRT-PCR. The underlying molecular mechanisms were further explored by immunofluorescence staining and western-blotting in vivo. Increased macrophages infiltration and inflammatory responses were found at early stage during HO progression. However, metformin dose-dependently attenuated the macrophage-mediated inflammatory responses both in vivo and vitro, which might account for the inhibitory effect of metformin on chondrogenesis and HO formation after trauma. Furthermore, elevated SIRT1 expression and decreased NF-κB p65 acetylation were found in the beneficial effects of metformin. Moreover, similar preventive effects were also found in SRT1720 HCI, a specific SIRT1 activator, while were remarkably reversed after the administration of EX527 (a specific SIRT1 inhibitor) with metformin. Taken together, our results provide a novel evidence that metformin can effectively attenuate trauma-induced HO by mitigating macrophage inflammatory responses through inhibiting NF-κB signaling via SIRT1-dependent mechanisms, which favors future therapeutic investigations for trauma-related disease. CI - Copyright © 2021 Elsevier B.V. All rights reserved. FAU - Sun, Ziyang AU - Sun Z AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - Li, Juehong AU - Li J AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - Luo, Gang AU - Luo G AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - Liu, Weixuan AU - Liu W AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - He, Yunwei AU - He Y AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - Wang, Feiyan AU - Wang F AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. FAU - Qian, Yun AU - Qian Y AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. Electronic address: lollipopcloudland@foxmail.com. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, PR China; Shanghai Engineering Research Center for Orthopaedic Material Innovation and Tissue Regeneration, Shanghai, 201306, PR China. Electronic address: cyfan@sjtu.edu.cn. LA - eng PT - Journal Article DEP - 20210729 PL - Netherlands TA - Eur J Pharmacol JT - European journal of pharmacology JID - 1254354 RN - 9100L32L2N (Metformin) RN - EC 3.5.1.- (Sirt1 protein, mouse) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - Animals MH - Burns/complications/*drug therapy/immunology/pathology MH - Disease Models, Animal MH - Humans MH - Inflammation/drug therapy/immunology/pathology MH - Macrophages/drug effects/immunology/metabolism MH - Male MH - Metformin/*pharmacology/therapeutic use MH - Mice MH - Ossification, Heterotopic/immunology/pathology/*prevention & control MH - Sirtuin 1/*metabolism MH - Tendon Injuries/complications/*drug therapy/pathology MH - Tendons/drug effects/pathology MH - Tenotomy/adverse effects OTO - NOTNLM OT - Heterotopic ossification OT - Inflammation OT - Macrophage OT - Metformin OT - NF-κB OT - SIRT1 EDAT- 2021/08/02 06:00 MHDA- 2022/01/27 06:00 CRDT- 2021/08/01 20:39 PHST- 2021/02/21 00:00 [received] PHST- 2021/07/24 00:00 [revised] PHST- 2021/07/26 00:00 [accepted] PHST- 2021/08/02 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2021/08/01 20:39 [entrez] AID - S0014-2999(21)00539-2 [pii] AID - 10.1016/j.ejphar.2021.174386 [doi] PST - ppublish SO - Eur J Pharmacol. 2021 Oct 15;909:174386. doi: 10.1016/j.ejphar.2021.174386. Epub 2021 Jul 29. PMID- 27432081 OWN - NLM STAT- MEDLINE DCOM- 20180524 LR - 20200930 IS - 1552-4981 (Electronic) IS - 1552-4973 (Linking) VI - 105 IP - 8 DP - 2017 Nov TI - Genipin crosslinker releasing sutures for improving the mechanical/repair strength of damaged connective tissue. PG - 2199-2205 LID - 10.1002/jbm.b.33753 [doi] AB - The most common mode of surgical repair of ruptured tendons and ligaments involves the use of sutures for reattachment. However, there is a high incidence of rerupture and repair failure due to pulling out of the suture material from the damaged connective tissue. The main goal of this research was to achieve a localized delivery of crosslinking agent genipin (GP) from rapid-release biodegradable coatings on sutures, for strengthening the repair of ruptured connective tissue. Our hypothesis is that GP released from the suture coating will lead to exogenous crosslinking of native connective tissue resulting in beneficial effects on clinically relevant mechanical parameters such as tear resistance, tissue strength, and energy required to rupture the tissue (toughness). Sutures were successfully coated with a biodegradable polymer layer loaded with the crosslinking agent genipin, without compromising the mechanical properties of the suture. The rapid-release of genipin was achieved under both in vitro and ex vivo conditions. Exogenous crosslinking using these genipin releasing sutures was demonstrated using equine tendons. The tendons treated with genipin releasing sutures showed significant improvement in failure load, energy required for pull-out failure, and stiffness. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 2199-2205, 2017. CI - © 2016 Wiley Periodicals, Inc. FAU - Sundararaj, Sharath AU - Sundararaj S AD - Orthopeutics, L.P., Lexington, Kentucky. FAU - Slusarewicz, Paul AU - Slusarewicz P AD - Orthopeutics, L.P., Lexington, Kentucky. FAU - Brown, Matt AU - Brown M AD - Orthopeutics, L.P., Lexington, Kentucky. FAU - Hedman, Thomas AU - Hedman T AD - Orthopeutics, L.P., Lexington, Kentucky. AD - Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky. LA - eng PT - Journal Article DEP - 20160719 PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - *Coated Materials, Biocompatible MH - Cross-Linking Reagents/chemistry/pharmacokinetics/pharmacology MH - Iridoids/chemistry/pharmacokinetics/pharmacology MH - *Sutures MH - Tendon Injuries/*metabolism/pathology/*therapy MH - Tendons/*metabolism/pathology OTO - NOTNLM OT - bioresorbable OT - coating(s) OT - connective tissue OT - controlled release OT - drug delivery/release EDAT- 2016/07/20 06:00 MHDA- 2018/05/25 06:00 CRDT- 2016/07/20 06:00 PHST- 2016/02/09 00:00 [received] PHST- 2016/05/31 00:00 [revised] PHST- 2016/06/26 00:00 [accepted] PHST- 2016/07/20 06:00 [pubmed] PHST- 2018/05/25 06:00 [medline] PHST- 2016/07/20 06:00 [entrez] AID - 10.1002/jbm.b.33753 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2017 Nov;105(8):2199-2205. doi: 10.1002/jbm.b.33753. Epub 2016 Jul 19. PMID- 29304843 OWN - NLM STAT- MEDLINE DCOM- 20180810 LR - 20181113 IS - 2047-783X (Electronic) IS - 0949-2321 (Print) IS - 0949-2321 (Linking) VI - 23 IP - 1 DP - 2018 Jan 5 TI - Effect of COX-2 inhibition on tendon-to-bone healing and PGE2 concentration after anterior cruciate ligament reconstruction. PG - 1 LID - 10.1186/s40001-017-0297-2 [doi] LID - 1 AB - BACKGROUND: Non-steroidal anti-inflammatory drugs are commonly used to reduce pain and inflammation in orthopaedic patients. Selective cyclooxygenase-2 (COX-2) inhibitors have been developed to minimize drug-specific side effects. However, they are suspected to impair both bone and tendon healing. The objective of this study is to evaluate the effect of COX-2 inhibitor administration on tendon-to-bone healing and prostaglandin E (PGE2) concentration. METHODS: Thirty-two New Zealand white rabbits underwent reconstructions of the anterior cruciate ligaments and were randomized into four groups: Two groups postoperatively received a selective COX-2 inhibitor (Celecoxib) on a daily basis for 3 weeks, the two other groups received no postoperative COX-2 inhibitors at all and were examined after three or 6 weeks. The PGE2 concentration of the synovial fluid, the osseous integration of the tendon graft at tunnel aperture and midtunnel section, as well as the stability of the tendon graft were examined via biomechanic testing. RESULTS: After 3 weeks, the PGE2 content of the synovial fluid in the COX-2 inhibitor recipients was significantly lower than that of the control group (p = 0.018). At the same time, the COX-2 inhibitor recipients had a significantly lower bone density and lower amount of new bone formation than the control group (p = 0.020; p = 0.028) in the tunnel aperture. At the 6-week examination, there was a significant increase in the PGE2 content within synovial fluid of the COX-2 inhibitor recipients (p = 0.022), whose treatment with COX-2 inhibitors had ended 3 weeks earlier; in contrast, the transplant stability decreased and was reduced by 37% compared to the controls. CONCLUSIONS: Selective COX-2 inhibitors cause impaired tendon-to-bone healing, weaken mechanical stability and decrease PGE2 content of the synovial fluid. The present study suggests a reluctant use of COX-2 inhibitors when tendon-to-bone healing is intended. FAU - Sauerschnig, Martin AU - Sauerschnig M AUID- ORCID: 0000-0003-0690-2892 AD - Center for Musculoskeletal Surgery, University Hospital Charité, Charitéplatz 1, 10117, Berlin, Germany. sauerschnig@gmail.com. AD - Department of Experimental Trauma Surgery, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany. sauerschnig@gmail.com. AD - Department of Orthopaedic Sports Medicine, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany. sauerschnig@gmail.com. AD - Trauma Hospital Graz, Unfallkrankenhaus der Allgemeinen Unfallversicherungsanstalt (AUVA), Göstinger Straße 24, 8020, Graz, Austria. sauerschnig@gmail.com. FAU - Stolberg-Stolberg, Josef AU - Stolberg-Stolberg J AD - Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. FAU - Schmidt, Carmen AU - Schmidt C AD - Center for Musculoskeletal Surgery, University Hospital Charité, Charitéplatz 1, 10117, Berlin, Germany. FAU - Wienerroither, Valerie AU - Wienerroither V AD - Department of Experimental Trauma Surgery, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany. FAU - Plecko, Michael AU - Plecko M AD - Trauma Hospital Graz, Unfallkrankenhaus der Allgemeinen Unfallversicherungsanstalt (AUVA), Göstinger Straße 24, 8020, Graz, Austria. FAU - Schlichting, Karin AU - Schlichting K AD - Center for Musculoskeletal Surgery, University Hospital Charité, Charitéplatz 1, 10117, Berlin, Germany. FAU - Perka, Carsten AU - Perka C AD - Center for Musculoskeletal Surgery, University Hospital Charité, Charitéplatz 1, 10117, Berlin, Germany. FAU - Dynybil, Christian AU - Dynybil C AD - Center for Musculoskeletal Surgery, University Hospital Charité, Charitéplatz 1, 10117, Berlin, Germany. LA - eng PT - Journal Article DEP - 20180105 PL - England TA - Eur J Med Res JT - European journal of medical research JID - 9517857 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Cyclooxygenase 2 Inhibitors) RN - JCX84Q7J1L (Celecoxib) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Animals MH - Anterior Cruciate Ligament/*surgery MH - Anti-Inflammatory Agents/*adverse effects/therapeutic use MH - Bone and Bones/*physiology/surgery MH - Celecoxib/*adverse effects/therapeutic use MH - Cyclooxygenase 2 Inhibitors/*adverse effects/therapeutic use MH - Dinoprostone/*metabolism MH - Female MH - *Osseointegration MH - Rabbits MH - Synovial Fluid/metabolism MH - Tendons/*physiology/surgery PMC - PMC5756348 OTO - NOTNLM OT - Anterior cruciate ligament OT - Cyclooxygenase-2 inhibitor OT - Prostaglandin E2 OT - Tendon-to-bone healing EDAT- 2018/01/07 06:00 MHDA- 2018/08/11 06:00 PMCR- 2018/01/05 CRDT- 2018/01/07 06:00 PHST- 2017/04/26 00:00 [received] PHST- 2017/12/12 00:00 [accepted] PHST- 2018/01/07 06:00 [entrez] PHST- 2018/01/07 06:00 [pubmed] PHST- 2018/08/11 06:00 [medline] PHST- 2018/01/05 00:00 [pmc-release] AID - 10.1186/s40001-017-0297-2 [pii] AID - 297 [pii] AID - 10.1186/s40001-017-0297-2 [doi] PST - epublish SO - Eur J Med Res. 2018 Jan 5;23(1):1. doi: 10.1186/s40001-017-0297-2. PMID- 29693006 OWN - NLM STAT- MEDLINE DCOM- 20180918 LR - 20220317 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2018 DP - 2018 TI - Baicalein Accelerates Tendon-Bone Healing via Activation of Wnt/β-Catenin Signaling Pathway in Rats. PG - 3849760 LID - 10.1155/2018/3849760 [doi] LID - 3849760 AB - BACKGROUND: Tendon-bone healing is a reconstructive procedure which requires a tendon graft healing to a bone tunnel or to the surface of bone after the junction injury between tendon, ligament, and bone. The surgical reattachment of tendon to bone often fails due to regeneration failure of the specialized tendon-bone junction. MATERIALS AND METHODS: An extra-articular tendon-bone healing rat model was established to discuss the effect of the baicalein 10 mg/(kg·d) in accelerating tendon-bone healing progress. Also, tendon-derived stem cells (TDSCs) were treated with various concentrations of baicalein or dickkopf-1 (DKK-1) to stimulate differentiation for 14 days. RESULTS: In vivo, tendon-bone healing strength of experiment group was obviously stronger than the control group in 3 weeks as well as in 6 weeks. And there were more mature fibroblasts, more Sharpey fibers, and larger new bone formation area treated intragastrically with baicalein compared with rats that were treated with vehicle for 3 weeks and 6 weeks. In vitro, after induction for 14 days, the expressions of osteoblast differentiation markers, that is, alkaline phosphatase (ALP), runt-related transcription factor 2 (Runx2), osteocalcin (OCN), osterix (OSX), and collagen I, were upregulated and Wnt/β-catenin signaling pathway was enhanced in TDSCs. The effect of DKK-1 significantly reduced the effect of baicalein on the osteogenic differentiation. CONCLUSION: These data suggest that baicalein may stimulate TDSCs osteogenic differentiation via activation of Wnt/β-catenin signaling pathway to accelerate tendon-bone healing. FAU - Tian, Xinggui AU - Tian X AD - Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China. AD - Department of Spine Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China. FAU - Jiang, Huaji AU - Jiang H AD - Department of Pain, Yue Bei People's Hospital, Shaoguan, Guangdong 512000, China. FAU - Chen, Yuhui AU - Chen Y AD - Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China. FAU - Ao, Xiang AU - Ao X AD - Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China. FAU - Chen, Chuan AU - Chen C AD - Department of Orthopedics, The First People's Hospital of Guangyuan, Guangyuan, Sichuan 628017, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518000, China. FAU - He, Feilin AU - He F AD - Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518000, China. FAU - Liao, Xiaoqing AU - Liao X AD - Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518000, China. FAU - Jiang, Xiaocheng AU - Jiang X AD - Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518000, China. FAU - Li, Tao AU - Li T AUID- ORCID: 0000-0002-5427-3181 AD - Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China. FAU - Zhang, Zhongmin AU - Zhang Z AUID- ORCID: 0000-0002-8044-0326 AD - Department of Orthopedics, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510515, China. FAU - Zhang, Xintao AU - Zhang X AUID- ORCID: 0000-0001-9926-3756 AD - Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518000, China. LA - eng PT - Journal Article DEP - 20180306 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (Flavanones) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (beta Catenin) RN - 104982-03-8 (Osteocalcin) RN - 49QAH60606 (baicalein) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Alkaline Phosphatase/metabolism MH - Animals MH - Bone and Bones/*drug effects/metabolism MH - Cell Differentiation/drug effects MH - Cells, Cultured MH - Core Binding Factor Alpha 1 Subunit/metabolism MH - Fibroblasts/drug effects/metabolism MH - Flavanones/*pharmacology MH - Intercellular Signaling Peptides and Proteins/metabolism MH - Male MH - Mesenchymal Stem Cells/drug effects/metabolism MH - Osteoblasts/drug effects/metabolism MH - Osteocalcin/drug effects/metabolism MH - Osteogenesis/drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cells/drug effects/metabolism MH - Tendons/*drug effects/metabolism MH - Wnt Signaling Pathway/*drug effects MH - Wound Healing/*drug effects MH - beta Catenin/*metabolism PMC - PMC5859801 EDAT- 2018/04/26 06:00 MHDA- 2018/09/19 06:00 PMCR- 2018/03/06 CRDT- 2018/04/26 06:00 PHST- 2017/03/11 00:00 [received] PHST- 2017/07/26 00:00 [accepted] PHST- 2018/04/26 06:00 [entrez] PHST- 2018/04/26 06:00 [pubmed] PHST- 2018/09/19 06:00 [medline] PHST- 2018/03/06 00:00 [pmc-release] AID - 10.1155/2018/3849760 [doi] PST - epublish SO - Biomed Res Int. 2018 Mar 6;2018:3849760. doi: 10.1155/2018/3849760. eCollection 2018. PMID- 23454166 OWN - NLM STAT- MEDLINE DCOM- 20130520 LR - 20130401 IS - 1879-0631 (Electronic) IS - 0024-3205 (Linking) VI - 92 IP - 13 DP - 2013 Apr 19 TI - Effect of the Arrabidaea chica extract on collagen fiber organization during healing of partially transected tendon. PG - 799-807 LID - S0024-3205(13)00116-1 [pii] LID - 10.1016/j.lfs.2013.02.011 [doi] AB - AIMS: After undergoing lesions, tendons have disorganized collagen fibers compared to undamaged tendons. Arrabidaea chica leaves have the aglycones carajurin and carajurone, components of the antocyanins, with a strong pharmacological potential due to their healing properties. Thus, the aim of this study was to investigate the effect of topical application of A. chica extract during tendon healing. MAIN METHODS: The calcaneal tendon of Wistar rats was partially transected with subsequent treatment with A. chica extract (2.13 g/mL) followed by excision on the 7th, 14th and 21st days. Control rats received only saline treatment. KEY FINDINGS: Transmission electron microscopy analysis showed the presence of a large amount of small segments of collagen fibrils in the transected region of the tendons on the 7th day in both the control and plant-treated groups. Considering the organization of the collagen fibers, higher values of birefringence were observed under polarization microscopy in the tendons of the plant-treated group on the 14th day compared to the control group. A larger quantity of dermatan sulfate was also detected after plant treatment in the same period. However, lesser dermatan and chondroitin sulfate were detected in the plant-treated group than in the control group on the 21st day. No differences were found in the values of birefringence between these groups. Intense metachromasy was observed in both transected groups on the 21st day. SIGNIFICANCE: In conclusion, the use of A. chica extract improves collagen organization and increases the quantity of dermatan sulfate on the 14th day of the tendon healing. CI - Copyright © 2013 Elsevier Inc. All rights reserved. FAU - Aro, A A AU - Aro AA AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas, UNICAMP, Campinas-SP, Brazil. andreaaro@ig.com.br FAU - Freitas, K M AU - Freitas KM FAU - Foglio, M A AU - Foglio MA FAU - Carvalho, J E AU - Carvalho JE FAU - Dolder, H AU - Dolder H FAU - Gomes, L AU - Gomes L FAU - Vidal, B C AU - Vidal BC FAU - Pimentel, E R AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130227 PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Bignoniaceae/*chemistry MH - Collagen/*analysis/ultrastructure MH - Male MH - Phytotherapy MH - Plant Extracts/chemistry/isolation & purification/*therapeutic use MH - Plant Leaves/chemistry MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy/pathology MH - Tendons/*drug effects/*pathology MH - Wound Healing/drug effects EDAT- 2013/03/05 06:00 MHDA- 2013/05/22 06:00 CRDT- 2013/03/05 06:00 PHST- 2012/11/24 00:00 [received] PHST- 2013/01/31 00:00 [revised] PHST- 2013/02/13 00:00 [accepted] PHST- 2013/03/05 06:00 [entrez] PHST- 2013/03/05 06:00 [pubmed] PHST- 2013/05/22 06:00 [medline] AID - S0024-3205(13)00116-1 [pii] AID - 10.1016/j.lfs.2013.02.011 [doi] PST - ppublish SO - Life Sci. 2013 Apr 19;92(13):799-807. doi: 10.1016/j.lfs.2013.02.011. Epub 2013 Feb 27. PMID- 31225686 OWN - NLM STAT- MEDLINE DCOM- 20190802 LR - 20220409 IS - 1365-2184 (Electronic) IS - 0960-7722 (Print) IS - 0960-7722 (Linking) VI - 52 IP - 4 DP - 2019 Jul TI - Aspirin inhibits inflammation and scar formation in the injury tendon healing through regulating JNK/STAT-3 signalling pathway. PG - e12650 LID - 10.1111/cpr.12650 [doi] LID - e12650 AB - OBJECTIVELY: Tendinopathy is a common problem in sports medicine which can lead to severe morbidity. Aspirin, as the classical representative of non-steroidal anti-inflammatory drugs (NSAIDs) for its anti-inflammatory and analgesic actions, has been commonly used in treating tendinopathy. While its treatment effects on injury tendon healing are lacking, illuminating the underlying mechanism may provide scientific basis for clinical treatment. MATERIALS AND METHODS: Firstly, we used immunohistochemistry and qRT-PCR to detect changes in CD14, CD206, iNOS, IL-6, IL-10, MMP-3, TIMP-3, Col-1a1, biglycan, Comp, Fibronectin, TGF-β1，ACAN，EGR-1 and FMOD. Next, Western blot was used to measure the protein levels (IL-6, IL-10, TGF-β1, COMP, TIMP-3, STAT-3/P-STAT-3 and JNK/P-JNK) in TSCs. Then, migration and proliferation of TSCs were measured through wound healing test and BrdU staining. Finally, the mechanical properties of injury tendon were detected. RESULTS: After aspirin treatment, the inflammation and scar formation in injury tendon were significantly inhibited by aspirin. Still, tendon's ECM was positively balanced. Increasing migration and proliferation ability of TSCs induced by IL-1β were significantly reversed. JNK/STAT-3 signalling pathway participated in the process above. In addition, biomechanical properties of injury tendon were significantly improved. CONCLUSIONS: Taken together, the findings suggested that aspirin inhibited inflammation and scar formation via regulation of JNK/STAT-3 signalling and decreased rerupture risk of injury tendon. Aspirin could be an ideal therapeutic strategy in tendon injury healing. CI - © 2019 The Authors. Cell Proliferation published by John Wiley & Sons Ltd. FAU - Wang, Yunjiao AU - Wang Y AUID- ORCID: 0000-0003-1108-7079 AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - He, Gang AU - He G AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Tang, Hong AU - Tang H AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Shi, Youxing AU - Shi Y AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Kang, Xia AU - Kang X AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Lyu, Jingtong AU - Lyu J AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhu, Min AU - Zhu M AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhou, Mei AU - Zhou M AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Yang, Mingyu AU - Yang M AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Mu, Miduo AU - Mu M AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Chen, Wan AU - Chen W AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhou, Binghua AU - Zhou B AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhang, Jiqiang AU - Zhang J AD - Department of Neurology, Third Military Medical University, Chongqing, China. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopeadics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. LA - eng GR - 81601943/National Science Foundation for Young Scientists of China/ GR - cstc2015shmszx0471/Chongqing Science & Technology Commission/ GR - 81230040/National Natural Science Foundation of China/ GR - 81572133/National Natural Science Foundation of China/ GR - 2016YFC1100500/National Key Research and Development of China/ PT - Journal Article DEP - 20190621 PL - England TA - Cell Prolif JT - Cell proliferation JID - 9105195 RN - 0 (Interleukin-1beta) RN - 0 (STAT3 Transcription Factor) RN - 0 (Stat3 protein, rat) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Aspirin/*pharmacology MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Cicatrix/*drug therapy/metabolism MH - Inflammation/*drug therapy/metabolism MH - Interleukin-1beta/metabolism MH - MAP Kinase Signaling System/*drug effects MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - STAT3 Transcription Factor/*metabolism MH - Signal Transduction/drug effects MH - Tendon Injuries/*drug therapy/metabolism MH - Tendons/*drug effects/metabolism MH - Wound Healing/drug effects PMC - PMC6668964 OTO - NOTNLM OT - aspirin OT - inflammation OT - tendinopathy OT - tendon stem cells EDAT- 2019/06/22 06:00 MHDA- 2019/08/03 06:00 PMCR- 2019/06/21 CRDT- 2019/06/22 06:00 PHST- 2019/03/05 00:00 [received] PHST- 2019/05/05 00:00 [revised] PHST- 2019/05/17 00:00 [accepted] PHST- 2019/06/22 06:00 [pubmed] PHST- 2019/08/03 06:00 [medline] PHST- 2019/06/22 06:00 [entrez] PHST- 2019/06/21 00:00 [pmc-release] AID - CPR12650 [pii] AID - 10.1111/cpr.12650 [doi] PST - ppublish SO - Cell Prolif. 2019 Jul;52(4):e12650. doi: 10.1111/cpr.12650. Epub 2019 Jun 21. PMID- 23125003 OWN - NLM STAT- MEDLINE DCOM- 20130417 LR - 20151119 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 31 IP - 4 DP - 2013 Apr TI - Nicotine reduced MMP-9 expression in the primary porcine tenocytes exposed to cyclic stretch. PG - 645-50 LID - 10.1002/jor.22259 [doi] AB - Nicotine is one of the major chemical components of the cigarette smoke, which has been known as a risk factor for tendon ruptures including rotator cuff tears. This study investigated the effect of nicotine on tenocytes under cyclic-stretched condition. Particularly, we focused on the morphologic changes of tenocytes and their expression of MMPs. Primary porcine tenocytes were obtained from the infraspinatus tendon. The cells were cultured on elastic chambers under static or cyclic-stretched condition for 24 h in the existence of nicotine (0, 1, 10, and 100 µM). Cell shape, gene expression of collagen type I and III, MMPs (-1, -2, -3, -9, and -13) and TIMPs (-1, -2, and -3) and enzyme activity of MMP-9 were analyzed using immunohistochemistry, RT-PCR, and zymography. Tenocytes exposed to nicotine represented significantly decreased gene expressions in MMP-9 (p < 0.001) and TIMP-3 (p < 0.05) under the cyclic stretch. Enzymatic activity of MMP-9 was also reduced by nicotine exposure in a dose-dependent manner (p < 0.001). The down-regulation of MMP and TIMP expression by nicotine shown in our in vitro experiment might deteriorate normal metabolism of the tendon. These mechanisms might affect the mechanical properties of the extracellular matrix of the rotator cuff tendon. CI - Copyright © 2012 Orthopaedic Research Society. FAU - Hatta, Taku AU - Hatta T AD - Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. FAU - Sano, Hirotaka AU - Sano H FAU - Sakamoto, Naoya AU - Sakamoto N FAU - Kishimoto, Koshi N AU - Kishimoto KN FAU - Sato, Masaaki AU - Sato M FAU - Itoi, Eiji AU - Itoi E LA - eng PT - Journal Article DEP - 20121101 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 6M3C89ZY6R (Nicotine) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Animals MH - Cells, Cultured MH - Collagen Type I/biosynthesis MH - Collagen Type III/biosynthesis MH - Down-Regulation MH - Matrix Metalloproteinase 9/*biosynthesis/metabolism MH - Nicotine/*pharmacology MH - Rotator Cuff/cytology MH - *Stress, Mechanical MH - Swine MH - Tendons/cytology/*metabolism MH - Tissue Inhibitor of Metalloproteinase-3/biosynthesis EDAT- 2012/11/06 06:00 MHDA- 2013/04/19 06:00 CRDT- 2012/11/06 06:00 PHST- 2012/06/07 00:00 [received] PHST- 2012/10/11 00:00 [accepted] PHST- 2012/11/06 06:00 [entrez] PHST- 2012/11/06 06:00 [pubmed] PHST- 2013/04/19 06:00 [medline] AID - 10.1002/jor.22259 [doi] PST - ppublish SO - J Orthop Res. 2013 Apr;31(4):645-50. doi: 10.1002/jor.22259. Epub 2012 Nov 1. PMID- 11557674 OWN - NLM STAT- MEDLINE DCOM- 20011004 LR - 20220224 IS - 1524-4636 (Electronic) IS - 1079-5642 (Linking) VI - 21 IP - 9 DP - 2001 Sep TI - Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. PG - 1470-6 AB - Hyperhomocysteinemia is an independent risk factor for atherothrombosis. However, causality is unproven, and it remains unknown whether hyperhomocysteinemia promotes atherosclerosis, plaque rupture, and/or thrombosis. We evaluated the short- and long-term effects of hyperhomocysteinemia on plaque size and structure in 99 atherosclerosis-prone apolipoprotein E-deficient mice. Hyperhomocysteinemia was induced by methionine (Met) or homocysteine (HcyH) supplementation: low Met (+11 g Met/kg food), high Met (+33 g Met/kg food), low HcyH (0.9 g HcyH/L drinking water), and high HcyH (1.8 g HcyH/L drinking water). Met and HcyH supplementation significantly raised plasma total homocysteine levels by 4- to 16-fold above those observed in mice fed a control diet (up to 146.1 micromol/L). Compared with controls, aortic root plaque size was significantly larger in supplemented groups after 3 months (56% and 173% larger in high-Met and high-HcyH, respectively) but not after 12 months. Hyperhomocysteinemia was associated with an increase in the amount of collagen in plaques after both 3 and 12 months. Mechanical testing of the tail tendons revealed no weakening of collagen after 12 months of hyperhomocysteinemia. Many plaques in both control and supplemented mice appeared rupture prone morphologically, but all aortic root plaques and all but 1 coronary plaque had an intact surface without rupture or thrombosis. Thus, diet-induced hyperhomocysteinemia promotes early atherosclerosis and plaque fibrosis but does not, even in the long term, weaken collagen or induce plaque rupture. FAU - Zhou, J AU - Zhou J AD - Department of Cardiology, Institute of Experimental Clinical Research, Aarhus University Hospital, Denmark. FAU - Møller, J AU - Møller J FAU - Danielsen, C C AU - Danielsen CC FAU - Bentzon, J AU - Bentzon J FAU - Ravn, H B AU - Ravn HB FAU - Austin, R C AU - Austin RC FAU - Falk, E AU - Falk E LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology JID - 9505803 RN - 0 (Apolipoproteins E) RN - 0 (Lipids) RN - 0LVT1QZ0BA (Homocysteine) RN - 9007-34-5 (Collagen) RN - AE28F7PNPL (Methionine) SB - IM CIN - Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1385-6. PMID: 11557659 CIN - Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1387-8. PMID: 11557660 MH - Animals MH - Aortic Diseases/etiology/pathology MH - Apolipoproteins E/*genetics MH - Arteriosclerosis/blood/*etiology/pathology MH - Collagen/ultrastructure MH - Coronary Artery Disease/etiology/pathology MH - Dietary Supplements MH - Female MH - Homocysteine/blood/*pharmacology MH - Hyperhomocysteinemia/blood/*complications/etiology MH - Lipids/blood MH - Methionine/*pharmacology MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Thrombosis/*etiology/pathology EDAT- 2001/09/15 10:00 MHDA- 2001/10/05 10:01 CRDT- 2001/09/15 10:00 PHST- 2001/09/15 10:00 [pubmed] PHST- 2001/10/05 10:01 [medline] PHST- 2001/09/15 10:00 [entrez] AID - 10.1161/hq0901.096582 [doi] PST - ppublish SO - Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1470-6. doi: 10.1161/hq0901.096582. PMID- 36529246 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20230206 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 304 DP - 2023 Mar 25 TI - Pilose antler (Cervus elaphus Linnaeus) polysaccharide and polypeptide extract inhibits bone resorption in high turnover type osteoporosis by stimulating the MAKP and MMP-9 signaling pathways. PG - 116052 LID - S0378-8741(22)01091-1 [pii] LID - 10.1016/j.jep.2022.116052 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Pilose antler is a traditional Chinese medicine used to improve kidney function, strengthen tendons and bones, and prolong life, among other uses. It is widely employed in the treatment of osteoporosis. However, the molecular mechanisms underlying the treatment of high turnover osteoporosis are not fully understood. AIM OF THE STUDY: The present study aimed to investigate the molecular mechanism underlying pilose antler polysaccharide and polypeptide extracts in inhibiting bone resorption in high turnover osteoporosis, and compare the effects of the two components alone and in combination to explore whether they could produce synergistic enhancement effects. MATERIALS AND METHODS: The quantitative and qualitative characteristics of pilose antler polysaccharide and polypeptide extracts were detected by UV-visible spectrophotometry and high-performance liquid chromatography. A rat model of retinoic acid-induced osteoporosis was used to evaluate the inhibitory effect of the extracts on bone resorption. Enzyme-linked immunosorbent assay (ELISA) was used to detect the activity of factors related to high turnover type osteoporosis in rat serum. Western blotting was used to detect the expression of proteins related to the MAKP and MMP-9 signaling pathways in rat femurs. Fluorescence quantitative PCR was used to detect the transcription levels of genes related to the MAKP and MMP-9 signaling pathways in rat femur tissues. Hematoxylin and eosin staining were used to observe the osteoprotective effects of pilose antler polysaccharides and polypeptides. RESULTS: The yield of pilose antler polysaccharides was 8.3%, and was mainly composed of mannose, glucosamine hydrochloride, glucuronic acid, Galacturonic acid, Galactose hydrochloride, glucose, and galactose. The yield of the polypeptides was 26.2%, and eighty percent of the molecular weight of the antler polypeptides was 1.6 kDa-7kD, among which, the molecular weight of 7kD peptide accounted for 52% of the total. Both polysaccharides and peptides could reduce the activities of TRACP, OCN, ERK1, JNK, and MMP-9 in rat serum and reduce both the protein expression and gene transcription levels of ERK1, JNK, and MMP-9 in rat femur tissue with significant differences compared with the model group. Both extracts exerted significant protective effects on rat femur tissue. The effect of pilose antler polypeptides alone was better than that of polysaccharides either alone or in combination. CONCLUSIONS: Pilose antler polysaccharides, polypeptides, and their mixtures could inhibit the occurrence of bone resorption of high turnover osteoporosis by stimulating the MAKP and MMP-9 signaling pathways to reduce the expression of the ERK1, JNK, and MMP-9 genes and proteins, and could help alleviate bone loss caused by retinoic acid. Pilose antler polypeptides had a stronger effect on inhibiting bone resorption. The combination of the two components did not show synergistic enhancement effect, and the polysaccharide tended to moderate the inhibitory enhancement effect of the polypeptide. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Liu, Yuan-Yuan AU - Liu YY AD - School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, PR China; Jinzhou Medical University, Jinzhou, 121001, PR China. Electronic address: liuyuanyuan5237@163.com. FAU - Ding, Yun-Feng AU - Ding YF AD - Department of Pharmacy, Liaoning Shang Yao Science and Technology Development Co. LTD, 117000, PR China. Electronic address: 18340852962@163.com. FAU - Sui, Hai-Juan AU - Sui HJ AD - Jinzhou Medical University, Jinzhou, 121001, PR China. Electronic address: 493623428@qq.com. FAU - Liu, Wei AU - Liu W AD - School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, PR China. Electronic address: 651682538@qq.com. FAU - Zhang, Zhen-Qiu AU - Zhang ZQ AD - School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, PR China. Electronic address: zhangzhenqiu@sina.com. FAU - Li, Feng AU - Li F AD - School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, 116600, PR China. Electronic address: zhanglijiayi@163.com. LA - eng PT - Journal Article DEP - 20221216 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - X2RN3Q8DNE (Galactose) RN - 0 (Peptides) RN - 0 (Proteins) RN - 0 (Polysaccharides) RN - 5688UTC01R (Tretinoin) SB - IM MH - Rats MH - Animals MH - Matrix Metalloproteinase 9/genetics/metabolism MH - Galactose MH - *Osteoporosis/metabolism MH - Peptides/pharmacology/therapeutic use MH - Proteins/pharmacology MH - Polysaccharides/pharmacology/therapeutic use MH - *Bone Resorption/drug therapy MH - Signal Transduction MH - Tretinoin/pharmacology/therapeutic use MH - *Deer OTO - NOTNLM OT - Bone resorption OT - Cervi cornu pantotrichum OT - Osteoporosis OT - Pilose antler OT - Polypeptide OT - Polysaccharide COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/19 06:00 MHDA- 2023/02/07 06:00 CRDT- 2022/12/18 19:14 PHST- 2022/08/29 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/09 00:00 [accepted] PHST- 2022/12/19 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] PHST- 2022/12/18 19:14 [entrez] AID - S0378-8741(22)01091-1 [pii] AID - 10.1016/j.jep.2022.116052 [doi] PST - ppublish SO - J Ethnopharmacol. 2023 Mar 25;304:116052. doi: 10.1016/j.jep.2022.116052. Epub 2022 Dec 16. PMID- 17599460 OWN - NLM STAT- MEDLINE DCOM- 20070816 LR - 20151119 IS - 0002-9149 (Print) IS - 0002-9149 (Linking) VI - 100 IP - 1 DP - 2007 Jul 1 TI - Tendon rupture associated with simvastatin/ezetimibe therapy. PG - 152-3 AB - A case of spontaneous biceps tendon rupture in a physician during therapy with the combination of simvastatin and ezetimibe (Vytorin) is reported. Rechallenge produced tendinopathy in the contralateral biceps tendon that abated with drug discontinuation. Tendon rupture generally occurs in injured tendons. Physiological repair of an injured tendon requires degradation and remodeling of the extracellular matrix through matrix metalloproteinases (MMPs). Statins are known to inhibit MMPs. It was hypothesized that statins may increase the risk of tendon rupture by altering MMP activity. In conclusion, statins may increase the risk of tendon rupture by altering MMP activity. FAU - Pullatt, Raja C AU - Pullatt RC AD - Department of Internal Medicine, University of Connecticut, Farmington, Connecticut, USA. FAU - Gadarla, Mamatha Reddy AU - Gadarla MR FAU - Karas, Richard H AU - Karas RH FAU - Alsheikh-Ali, Alawi A AU - Alsheikh-Ali AA FAU - Thompson, Paul D AU - Thompson PD LA - eng PT - Case Reports PT - Journal Article DEP - 20070521 PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Anticholesteremic Agents) RN - 0 (Azetidines) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - AGG2FN16EV (Simvastatin) RN - EC 3.4.- (Metalloproteases) RN - EOR26LQQ24 (Ezetimibe) SB - IM MH - Anticholesteremic Agents/*adverse effects MH - Azetidines/*adverse effects MH - Ezetimibe MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects MH - Magnetic Resonance Imaging MH - Male MH - Metalloproteases/metabolism MH - Middle Aged MH - Simvastatin/*adverse effects MH - Tendon Injuries/*chemically induced/diagnosis/metabolism MH - Tendons/drug effects EDAT- 2007/06/30 09:00 MHDA- 2007/08/19 09:00 CRDT- 2007/06/30 09:00 PHST- 2007/01/31 00:00 [received] PHST- 2007/02/12 00:00 [revised] PHST- 2007/02/12 00:00 [accepted] PHST- 2007/06/30 09:00 [pubmed] PHST- 2007/08/19 09:00 [medline] PHST- 2007/06/30 09:00 [entrez] AID - S0002-9149(07)00624-8 [pii] AID - 10.1016/j.amjcard.2007.02.068 [doi] PST - ppublish SO - Am J Cardiol. 2007 Jul 1;100(1):152-3. doi: 10.1016/j.amjcard.2007.02.068. Epub 2007 May 21. PMID- 40552989 OWN - NLM STAT- MEDLINE DCOM- 20251115 LR - 20251115 IS - 1557-7600 (Electronic) IS - 1096-620X (Linking) VI - 28 IP - 11 DP - 2025 Nov TI - Phlomis umbrosa Turcz. Water Extract Attenuates Dexamethasone-Induced Muscle Atrophy by Regulating PI3K/Akt/mTOR Pathway. PG - 1159-1167 LID - 10.1089/jmf.2025.k.0050 [doi] AB - Skeletal muscles, attached to bones via tendons, enable physical movement in animals. Muscle atrophy is associated with a decline in muscle mass and function and can detrimentally impact quality of life, leading to muscle weakness, altered fiber properties, and, ultimately, sarcopenia. Phlomis umbrosa Turcz. (Korean name: Han-Sok-Dan) has been used as a herbal medicine in Southeast Asia since ancient times. Although several studies have explored the properties of Han-Sok-Dan, further research is warranted to establish its therapeutic benefits for muscle function. This study investigated the effects of Phlomis umbrosa Turcz. water extract (PUW) in mice subjected to dexamethasone-induced muscle atrophy. Mice exhibiting dexamethasone-induced muscle atrophy experienced weight loss, reduced muscle mass, and functional decline. However, PUW administration effectively reversed these effects by maintaining muscle mass and strength, decreasing protein degradation-related marker expression, and enhancing signaling for protein synthesis. Notably, phosphorylations of mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase beta-1, and eukaryotic translation initiation factor 4E-binding protein 1 were significantly enhanced in the PUW group, indicating the activation of anabolic signaling. Overall, PUW alleviates muscle atrophy induced by dexamethasone by modulating the balance between protein degradation and synthesis through regulation of the ubiquitin-proteasome system and phosphoinositide 3-kinase/protein kinase B/mTOR pathway. These findings reveal the potential of PUW as a natural therapeutic agent for preventing or managing muscle wasting. FAU - Lee, Yeonhwa AU - Lee Y AD - Division of Food and Nutrition, Chonnam National University, Gwangju, Korea. FAU - Park, Jeongjin AU - Park J AD - Division of Food and Nutrition, Chonnam National University, Gwangju, Korea. AD - Research Institute for Human Ecology, Chonnam National University, Gwangju, Korea. FAU - Jun, Woojin AU - Jun W AD - Division of Food and Nutrition, Chonnam National University, Gwangju, Korea. AD - Research Institute for Human Ecology, Chonnam National University, Gwangju, Korea. LA - eng PT - Journal Article DEP - 20250624 PL - United States TA - J Med Food JT - Journal of medicinal food JID - 9812512 RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 7S5I7G3JQL (Dexamethasone) RN - 0 (Plant Extracts) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - EC 2.7.1.1 (mTOR protein, mouse) SB - IM MH - Animals MH - *TOR Serine-Threonine Kinases/metabolism/genetics MH - *Muscular Atrophy/drug therapy/chemically induced/metabolism/genetics MH - Dexamethasone/adverse effects MH - *Plant Extracts/administration & dosage MH - *Proto-Oncogene Proteins c-akt/metabolism/genetics MH - *Phosphatidylinositol 3-Kinases/metabolism/genetics MH - Mice MH - Male MH - Signal Transduction/drug effects MH - Muscle, Skeletal/drug effects/metabolism MH - Humans MH - Mice, Inbred C57BL OTO - NOTNLM OT - Phlomis umbrosa Turcz. OT - dexamethasone-induced muscle atrophy OT - protein degradation OT - protein synthesis OT - sarcopenia EDAT- 2025/06/24 13:15 MHDA- 2025/11/15 06:29 CRDT- 2025/06/24 10:03 PHST- 2025/11/15 06:29 [medline] PHST- 2025/06/24 13:15 [pubmed] PHST- 2025/06/24 10:03 [entrez] AID - 10.1089/jmf.2025.k.0050 [doi] PST - ppublish SO - J Med Food. 2025 Nov;28(11):1159-1167. doi: 10.1089/jmf.2025.k.0050. Epub 2025 Jun 24. PMID- 29601380 OWN - NLM STAT- MEDLINE DCOM- 20190530 LR - 20200306 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 476 IP - 5 DP - 2018 May TI - Can Genipin-coated Sutures Deliver a Collagen Crosslinking Agent to Improve Suture Pullout in Degenerated Tendon? An Ex Vivo Animal Study. PG - 1104-1113 LID - 10.1007/s11999.0000000000000247 [doi] AB - BACKGROUND: The suture-tendon interface is often the weakest link in tendon-to-tendon or tendon-to-bone repair. Genipin is an exogenous collagen crosslink agent derived from the gardenia fruit that can enhance suture force to failure of the tendon-suture interface. Viable methods for intraoperative clinical delivery of genipin could be of clinical utility, but to our knowledge have not yet been extensively studied. QUESTIONS/PURPOSES: The purposes of this study were (1) to evaluate whether sutures precoated with genipin can augment the suture-tendon interface to improve force to failure, stiffness, and work to failure in healthy and degenerated tendons; and (2) to determine the effect of genipin on the extent and distribution of crosslinking. METHODS: Single-stitch suture pullout tests were performed ex vivo on 25 bovine superficial digital flexor tendons. To assess effects on native tissue, one group of 12 tendons was cut in proximal and distal halves and randomized to treatment (n = 12) and control groups (n = 12) in a matched-pair design. One simple stitch with a loop with either a normal suture or genipin-coated suture was applied to tendons in both groups. To simulate a degenerative tendon condition, a second group of 13 tendons was cut in proximal and distal halves, injected with 0.2 mL of collagenase D (8 mg/mL) and incubated for 24 hours before suturing with either a genipin-coated suture (n = 13) or their matched controls (n = 13). Sutures from all groups then were loaded to failure on a universal materials testing machine 24 hours after suturing. Suture pullout force, stiffness, and work to failure were calculated from force-displacement data and compared between the groups. Additionally, fluorescence was measured to determine the degree of crosslinking quantitatively and a qualitative analysis of the distribution pattern was performed by microscopy. RESULTS: In healthy tendon pairs, the median maximum pullout force was greater with genipin-coated sutures than with control sutures (median, 42 N [range, 24-73 N] versus 29 N [range, 13-48 N]; difference of medians, 13 N; p = 0.003) with corresponding increases in the required work to failure (median, 275 mJ [range, 48-369 mJ] versus 148 mJ [range, 83-369 mJ]; difference of medians, 127 mJ; p = 0.025) but not stiffness (median, 4.1 N/mm [range, 2.3-8.1 N/mm] versus 3.3 N/mm [range, 1.1-9.6 N/mm]; difference of medians, 0.8 N/mm; p = 0.052). In degenerated tendons, median maximum pullout force was greater with genipin-coated sutures than with control sutures (median, 16 N [range, 9-36 N] versus 13 N [range, 5-28 N]; difference of medians, 3 N; p = 0.034) with no differences in work to failure (median, 75 mJ [range, 11-249 mJ] versus 53 mJ [range, 14-143 mJ]; difference of medians, 22 mJ; p = 0.636) or stiffness (median, 1.9 N/mm [range, 0.7-13.4 N/mm] versus 1.6 N/mm [range, 0.5-5.6 N/mm]; difference of medians, 0.3 N/mm; p = 0.285). Fluorescence was higher in tendons treated with genipin-coated sutures compared with the control group, whereas higher fluorescence was observed in the treated healthy compared with the degenerated tendons (difference of means -3.16; standard error 1.08; 95% confidence interval [CI], 0.97-5.34; p = 0.006/healthy genipin: mean 13.04; standard error 0.78; 95% CI, 11.47-14.62; p < 0.001/degenerated genipin: mean 9.88; SD 0.75; 95% CI, 8.34-11.40; p < 0.001). CONCLUSIONS: Genipin-coated sutures improved force to failure of a simple stitch at the tendon-suture interface in healthy and degenerated tendons in an ex vivo animal model. Fluorescence was higher in tendons treated with genipin-coated sutures compared with the control group. CLINICAL RELEVANCE: A genipin-coated suture represents a potential delivery vehicle for exogenous crosslink agents to augment suture retention properties. In vivo animal studies are the next logical step to assess safety and efficacy of the approach. FAU - Camenzind, Roland S AU - Camenzind RS AD - R. S. Camenzind, T. O. Tondelli, T. Götschi, C. Holenstein, J. G. Snedeker, Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland T. Götschi, C. Holenstein, J. G. Snedeker, Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Tondelli, Timo O AU - Tondelli TO FAU - Götschi, Tobias AU - Götschi T FAU - Holenstein, Claude AU - Holenstein C FAU - Snedeker, Jess G AU - Snedeker JG LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Cattle MH - *Coated Materials, Biocompatible MH - Collagen/*metabolism MH - Cross-Linking Reagents/administration & dosage/*pharmacology MH - Equipment Design MH - Equipment Failure MH - In Vitro Techniques MH - Iridoids/administration & dosage/*pharmacology MH - Materials Testing MH - Suture Techniques/*instrumentation MH - *Sutures MH - Tendons/metabolism/pathology/*surgery PMC - PMC5916599 COIS- All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research® editors and board members are on file with the publication and can be viewed on request. EDAT- 2018/03/31 06:00 MHDA- 2019/05/31 06:00 PMCR- 2019/05/01 CRDT- 2018/03/31 06:00 PHST- 2018/03/31 06:00 [pubmed] PHST- 2019/05/31 06:00 [medline] PHST- 2018/03/31 06:00 [entrez] PHST- 2019/05/01 00:00 [pmc-release] AID - CORR-D-17-01296 [pii] AID - 10.1007/s11999.0000000000000247 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2018 May;476(5):1104-1113. doi: 10.1007/s11999.0000000000000247. PMID- 17061044 OWN - NLM STAT- MEDLINE DCOM- 20070913 LR - 20220330 IS - 0167-6806 (Print) IS - 0167-6806 (Linking) VI - 104 IP - 1 DP - 2007 Jul TI - Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. PG - 87-91 AB - OBJECTIVE: Arthralgia, skeletal and muscle pain have been reported in postmenopausal women under treatment with third generation aromatase inhibitors (AIs). However, the pathogenesis and anatomic correlate of musculoskeletal pains have not been thoroughly evaluated. Moreover, the impact of AI-induced musculoskeletal symptoms on normal daily functioning needs to be further explored. PATIENTS AND METHODS: We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane. Clinical rheumatological examination and serum biochemistry were performed. Radiological evaluation of the hand/wrist joints were performed using ultrasound (US) and/or magnetic resonance imaging (MRI). RESULTS: The most common reported symptom was severe early morning stiffness and hand/wrist pain causing impaired ability to completely close/stretch the hand/fingers and to perform daily activities and work-related skills. Six patients had to discontinue treatment due to severe symptoms. Trigger finger and carpal tunnel syndrome were the most frequently reported clinical signs. US showed fluid in the tendon sheath surrounding the digital flexor tendons. On MRI, an enhancement and thickening of the tendon sheath was a constant finding in all 12 patients. CONCLUSIONS: Musculoskeletal pains in breast cancer patients under third generation AIs can be severe, debilitating, and can limit compliance. Characteristic tenosynovial, and in some patients joint changes on US and MRI were observed in this series and have not been reported before. FAU - Morales, Leilani AU - Morales L AD - Department of General Medical Oncology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. FAU - Pans, Steven AU - Pans S FAU - Paridaens, Robert AU - Paridaens R FAU - Westhovens, Rene AU - Westhovens R FAU - Timmerman, Dirk AU - Timmerman D FAU - Verhaeghe, Johan AU - Verhaeghe J FAU - Wildiers, Hans AU - Wildiers H FAU - Leunen, Karin AU - Leunen K FAU - Amant, Frederic AU - Amant F FAU - Berteloot, Patrick AU - Berteloot P FAU - Smeets, Ann AU - Smeets A FAU - Van Limbergen, Erik AU - Van Limbergen E FAU - Weltens, Caroline AU - Weltens C FAU - Van den Bogaert, Walter AU - Van den Bogaert W FAU - De Smet, Luc AU - De Smet L FAU - Vergote, Ignace AU - Vergote I FAU - Christiaens, Marie-Rose AU - Christiaens MR FAU - Neven, Patrick AU - Neven P LA - eng PT - Journal Article DEP - 20061024 PL - Netherlands TA - Breast Cancer Res Treat JT - Breast cancer research and treatment JID - 8111104 RN - 0 (Androstadienes) RN - 0 (Aromatase Inhibitors) RN - 0 (Nitriles) RN - 0 (Triazoles) RN - 7LKK855W8I (Letrozole) RN - NY22HMQ4BX (exemestane) SB - IM MH - Aged MH - Androstadienes/*adverse effects MH - Aromatase Inhibitors/*adverse effects MH - Breast Neoplasms/*drug therapy/pathology MH - Carpal Tunnel Syndrome/chemically induced/diagnostic imaging/pathology MH - Female MH - Humans MH - Letrozole MH - Magnetic Resonance Imaging MH - Middle Aged MH - Musculoskeletal Diseases/*chemically induced/diagnostic imaging/pathology MH - Nitriles/*adverse effects MH - Pain/chemically induced/pathology MH - Severity of Illness Index MH - Triazoles/*adverse effects MH - Ultrasonography MH - Wrist Joint/diagnostic imaging/pathology EDAT- 2006/10/25 09:00 MHDA- 2007/09/14 09:00 CRDT- 2006/10/25 09:00 PHST- 2006/08/22 00:00 [received] PHST- 2006/08/23 00:00 [accepted] PHST- 2006/10/25 09:00 [pubmed] PHST- 2007/09/14 09:00 [medline] PHST- 2006/10/25 09:00 [entrez] AID - 10.1007/s10549-006-9394-6 [doi] PST - ppublish SO - Breast Cancer Res Treat. 2007 Jul;104(1):87-91. doi: 10.1007/s10549-006-9394-6. Epub 2006 Oct 24. PMID- 30690843 OWN - NLM STAT- MEDLINE DCOM- 20200304 LR - 20200304 IS - 1521-6551 (Electronic) IS - 1521-6543 (Linking) VI - 71 IP - 5 DP - 2019 May TI - Hydroxycamptothecin Prevents Fibrotic Pathways in Fibroblasts In Vitro. PG - 653-662 LID - 10.1002/iub.2013 [doi] AB - Peritendinous fibrosis, which leads to impaired tendon function, is a clinical problem worldwide, and it is urgent to explore potential ways to reduce the formation of peritendinous adhesion. Several studies have demonstrated the biological roles of hydroxycamptothecin (HCPT) in inhibiting fibrosis in different tissues. In this study, we investigated whether HCPT could inhibit tendon fibrosis in vitro. Our results revealed that HCPT inhibited transforming growth factor (TGF)-β1-induced cell viability of human fibroblasts, decreased excessive cell hyperproliferation and promoted fibroblasts apoptosis. In addition, HCPT treatment also inhibited expression of fibrosis genes COL3A1 and α-smooth muscle actin (α-SMA). In terms of mechanism, we pretreated fibroblasts with the endoplasmic reticulum stress (ER) inhibitor salubrinal and RNA-dependent protein kinase-like ER kinase (PERK) short hairpin RNA, these treatments abolished the inhibitory effects of HCPT on fibrosis, thereby suggesting that HCPT's inhibition of TGF-β1-induced tendon fibrosis might be mediated by the PERK signaling pathway in vitro. In conclusion, our results suggested that HCPT had protective effects on peritendinous tissue fibrosis and might be promising in future clinical applications. © 2019 IUBMB Life, 71(5):653-662, 2019. CI - © 2019 International Union of Biochemistry and Molecular Biology. FAU - Yao, Zhixiao AU - Yao Z AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Zheng, Wei AU - Zheng W AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Zhang, Xiangqi AU - Zhang X AD - Department of Pharmacy, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Xiong, Hao AU - Xiong H AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Qian, Yun AU - Qian Y AUID- ORCID: 0000-0003-1600-5693 AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190128 PL - England TA - IUBMB Life JT - IUBMB life JID - 100888706 RN - 0 (hydroxycamptothecinum) RN - EC 2.7.11.1 (EIF2AK3 protein, human) RN - EC 2.7.11.1 (eIF-2 Kinase) RN - XT3Z54Z28A (Camptothecin) SB - IM MH - Apoptosis/*drug effects MH - Camptothecin/*analogs & derivatives/pharmacology MH - Cell Adhesion MH - Cell Proliferation/*drug effects MH - Cells, Cultured MH - Endoplasmic Reticulum Stress/drug effects MH - Fibroblasts/cytology/*drug effects/metabolism MH - Fibrosis/metabolism/pathology/*prevention & control MH - Humans MH - In Vitro Techniques MH - Signal Transduction/*drug effects MH - Tendons/cytology/*drug effects/metabolism MH - eIF-2 Kinase/metabolism OTO - NOTNLM OT - PERK signaling pathway OT - TGF-β1 OT - endoplasmic reticulum stress OT - hydroxycamptothecin OT - peritendinous fibrosis EDAT- 2019/01/29 06:00 MHDA- 2020/03/05 06:00 CRDT- 2019/01/29 06:00 PHST- 2018/10/13 00:00 [received] PHST- 2018/12/12 00:00 [revised] PHST- 2018/12/29 00:00 [accepted] PHST- 2019/01/29 06:00 [pubmed] PHST- 2020/03/05 06:00 [medline] PHST- 2019/01/29 06:00 [entrez] AID - 10.1002/iub.2013 [doi] PST - ppublish SO - IUBMB Life. 2019 May;71(5):653-662. doi: 10.1002/iub.2013. Epub 2019 Jan 28. PMID- 32194057 OWN - NLM STAT- MEDLINE DCOM- 20201022 LR - 20201022 IS - 1873-2968 (Electronic) IS - 0006-2952 (Linking) VI - 175 DP - 2020 May TI - Alda-1, an activator of ALDH2, ameliorates Achilles tendinopathy in cellular and mouse models. PG - 113919 LID - S0006-2952(20)30147-7 [pii] LID - 10.1016/j.bcp.2020.113919 [doi] AB - Achilles tendinopathy has a high re-injury rate and poor prognosis. Development of effective therapy for Achilles tendinopathy is important. Excessive accumulation of ROS and resulting oxidative stress are believed to cause tendinopathy. Overproduction of hydrogen peroxide (H(2)O(2)), the most common ROS, could lead to the tendinopathy by causing oxidative damage, activation of endoplasmic reticulum (ER) stress and apoptotic death of tenocytes. Activation of mitochondrial aldehyde dehydrogenase 2 (ALDH2) is expected to alleviate oxidative stress and ER stress. Alda-1 is a selective and potent activator of ALDH2. In this study, we examined the cytoprotective benefit of Alda-1, an activator of ALDH2, on H(2)O(2)-induced Achilles tendinopathy in cellular and mouse models. We prepared cellular and mouse models of Achilles tendinopathy by treating cultured Achilles tenocytes and Achilles tendons with oxidative stressor H(2)O(2). Subsequently, we studied the protective benefit of Alda-1 on H(2)O(2)-induced Achilles tendinopathy. Alda-1 pretreatment attenuated H(2)O(2)-induced cell death of cultured Achilles tenocytes. Treatment of Alda-1 prevented H(2)O(2)-induced oxidative stress and depolarization of mitochondrial membrane potential in tenocytes. Application of Alda-1 attenuated H(2)O(2)-triggered mitochondria- and ER stress-mediated apoptotic cascades in cultured tenocytes. Alda-1 treatment ameliorated the severity of H(2)O(2)-induced Achilles tendinopathy in vivo by preventing H(2)O(2)-induced pathological histological features of Achilles tendons, apoptotic death of Achilles tenocytes and upregulated expression of inflammatory cytokines IL-1β and TNF-α. Our results provide the evidence that ALDH2 activator Alda-1 ameliorates H(2)O(2)-induced Achilles tendinopathy. Alda-1 could be used for preventing and treating Achilles tendinopathy. CI - Copyright © 2020 Elsevier Inc. All rights reserved. FAU - Liu, Yu-Chuan AU - Liu YC AD - Landseed Sports Medicine Center, Landseed International Hospital, Taoyuan, Taiwan. FAU - Wang, Hung-Li AU - Wang HL AD - Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Healthy Aging Research Center, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Huang, Ying-Zu AU - Huang YZ AD - Healthy Aging Research Center, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Institute of Cognitive Neuroscience, National Central University, Taoyuan, Taiwan. FAU - Weng, Yi-Hsin AU - Weng YH AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Chen, Rou-Shayn AU - Chen RS AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. FAU - Tsai, Wen-Chung AU - Tsai WC AD - College of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Yeh, Tu-Hsueh AU - Yeh TH AD - Department of Neurology, Taipei Medical University Hospital, Taiwan. FAU - Lu, Chin-Song AU - Lu CS AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Chen, Ying-Ling AU - Chen YL AD - Department of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. FAU - Lin, Yan-Wei AU - Lin YW AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Chen, Yu-Jie AU - Chen YJ AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Hsu, Chia-Chen AU - Hsu CC AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Chiu, Chi-Han AU - Chiu CH AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Chiu, Ching-Chi AU - Chiu CC AD - Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Division of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Department of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. Electronic address: ccchei@cgmh.org.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200317 PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Benzamides) RN - 0 (Benzodioxoles) RN - 0 (N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 1.2.1.3 (ALDH2 protein, mouse) RN - EC 1.2.1.3 (Aldehyde Dehydrogenase, Mitochondrial) SB - IM MH - Achilles Tendon/drug effects/*metabolism/pathology MH - Aldehyde Dehydrogenase, Mitochondrial/*metabolism MH - Animals MH - Benzamides/pharmacology/*therapeutic use MH - Benzodioxoles/pharmacology/*therapeutic use MH - Cell Survival/drug effects/physiology MH - Cells, Cultured MH - *Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Hydrogen Peroxide/toxicity MH - Mice MH - Mice, Inbred C57BL MH - Tendinopathy/*drug therapy/*metabolism/pathology MH - Tenocytes/drug effects/metabolism/pathology OTO - NOTNLM OT - ALDH2 OT - Alda-1 OT - Apoptosis OT - ER stress OT - Mitochondria OT - Oxidative stress OT - Tendinopathy OT - Tenocytes EDAT- 2020/03/21 06:00 MHDA- 2020/10/23 06:00 CRDT- 2020/03/21 06:00 PHST- 2020/02/19 00:00 [received] PHST- 2020/03/13 00:00 [accepted] PHST- 2020/03/21 06:00 [pubmed] PHST- 2020/10/23 06:00 [medline] PHST- 2020/03/21 06:00 [entrez] AID - S0006-2952(20)30147-7 [pii] AID - 10.1016/j.bcp.2020.113919 [doi] PST - ppublish SO - Biochem Pharmacol. 2020 May;175:113919. doi: 10.1016/j.bcp.2020.113919. Epub 2020 Mar 17. PMID- 19370185 OWN - NLM STAT- MEDLINE DCOM- 20090529 LR - 20191111 IS - 0048-7449 (Print) IS - 0048-7449 (Linking) VI - 61 IP - 1 DP - 2009 Jan-Mar TI - Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. PG - 27-33 AB - BACKGROUND: Two generic bioequivalent copies of the same drug sometimes do not achieve therapeutic equivalence. This may produce adverse events in clinical practice if the therapeutic index of that drug is narrow. OBJECTIVE: To compare the efficacy and safety of two generic copies of nimesulide Nimulid (N) and Tenaprost (T). METHODS: 60 out-patients with symptomatic low back pain or knee osteoarthritis were randomized to take T or N (100 mg 2 x/day for 20 days) in a prospective double-blinded randomized phase four clinical trial conducted at the Institute of Rheumatology, Belgrade, Serbia. Pain was evaluated by VAS. Paravertebral muscle spasm (PVM), sagittal mobility, and the Lasegue's test (LT) were estimated in low back pain. In knee osteoarthritis, knee circumference, motion, and knee tendons sensitivity (KTS) to palpation were assessed. Adverse events reported by the patients, or observed by the investigators were recorded. RESULTS: T and N significantly reduced pain levels in patients with low back pain and knee osteoarthritis (p<0.001) as well as knee circumference and KTS to palpation (p<0.05). Compared to N, T showed slightly better effects on the Lequesne functional index (p<0.05) and PVM spasm in patients with lower back pain, but that was not of clinical relevance. Tolerability of T and N was good. CONCLUSION: T and N are equally effective and safe forms of nimesulide for pain management in low back pain and knee osteoarthritis. Price per daily dose is a relevant parameter for making a choice. However, regulations regarding drug bioequivalence criteria should be met for drug marketing authorization submission. FAU - Ilic, K V AU - Ilic KV AD - Department of Pharmacology, School of Pharmacy, University of Belgrade, Belgrade, Republic of Serbia. katarina.v.ilic@gmail.com FAU - Sefik-Bukilica, M AU - Sefik-Bukilica M FAU - Jankovic, S AU - Jankovic S FAU - Vujasinovic-Stupar, N AU - Vujasinovic-Stupar N LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - Italy TA - Reumatismo JT - Reumatismo JID - 0401302 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Drugs, Generic) RN - 0 (Sulfonamides) RN - V4TKW1454M (nimesulide) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Cyclooxygenase 2 Inhibitors/administration & dosage/*therapeutic use MH - Data Interpretation, Statistical MH - Drugs, Generic/administration & dosage/pharmacokinetics/*therapeutic use MH - Female MH - Humans MH - Low Back Pain/diagnosis/*drug therapy MH - Male MH - Middle Aged MH - Osteoarthritis, Knee/diagnosis/*drug therapy MH - Pain Measurement MH - Prospective Studies MH - Safety MH - Sulfonamides/administration & dosage/pharmacokinetics/*therapeutic use MH - Therapeutic Equivalency MH - Time Factors EDAT- 2009/04/17 09:00 MHDA- 2009/05/30 09:00 CRDT- 2009/04/17 09:00 PHST- 2009/04/17 09:00 [entrez] PHST- 2009/04/17 09:00 [pubmed] PHST- 2009/05/30 09:00 [medline] AID - 10.4081/reumatismo.2009.27 [doi] PST - ppublish SO - Reumatismo. 2009 Jan-Mar;61(1):27-33. doi: 10.4081/reumatismo.2009.27. PMID- 7114353 OWN - NLM STAT- MEDLINE DCOM- 19821012 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 10 IP - 3 DP - 1982 May-Jun TI - Dimethyl sulfoxide. Biomechanical effects on tendons. PG - 177-9 AB - Forty-eight mice were treated for 12 time periods from 0 days through 28 days at 24-hour intervals by rinsing the skin area of the Achilles tendon of each hindleg with 100 microliters of a solution of 70% drug grade dimethyl sulfoxide in 30% sterile water. After the treatment period the mice were killed and the Achilles tendons were subjected to separation force analysis to determine tensile strength. The mean separation force was shown to be a function of the treatment period (P = 0.0294) with a significant linear component (P = 0.0049), a significant quadratic component (P = 0.0036), and a significant cubic component (P = 0.0049). The model identified an initial area of decreasing mean separation force (0 to 7 days), an area of increasing mean separation force (7 to 22 days), and a subsequent area of decreasing mean separation force (22 to 28 days). The maximum decrease in the group mean separation force was 20.2% and was observed in the 7-day treatment group. The clinical significance of the results of this study was that the topical application of dimethyl sulfoxide was associated with periods of decreased mean separation forces in tendons. The avoidance of vigorous muscular activity is recommended during therapy with dimethyl sulfoxide. FAU - Albrechtsen, S J AU - Albrechtsen SJ FAU - Harvey, J S Jr AU - Harvey JS Jr LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Administration, Topical MH - Animals MH - Biomechanical Phenomena MH - Dimethyl Sulfoxide/administration & dosage/metabolism/*pharmacology MH - Female MH - Mice MH - Skin Absorption MH - Tendons/*drug effects/physiology EDAT- 1982/05/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1982/05/01 00:00 PHST- 1982/05/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1982/05/01 00:00 [entrez] AID - 10.1177/036354658201000310 [doi] PST - ppublish SO - Am J Sports Med. 1982 May-Jun;10(3):177-9. doi: 10.1177/036354658201000310. PMID- 26135547 OWN - NLM STAT- MEDLINE DCOM- 20160222 LR - 20151030 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 33 IP - 12 DP - 2015 Dec TI - Effect of highly purified capsaicin on articular cartilage and rotator cuff tendon healing: An in vivo rabbit study. PG - 1854-60 LID - 10.1002/jor.22971 [doi] AB - Highly purified capsaicin has emerged as a promising injectable compound capable of providing sustained pain relief following a single localized treatment during orthopedic surgical procedures. To further assess its reliability for clinical use, the potential effect of highly purified capsaicin on articular cartilage metabolism as well as tendon structure and function warrants clarification. In the current study, rabbits received unilateral supraspinatus transection and repair with a single 1 ml injection of capsaicin (R+C), PEG-only placebo (R+P), or saline (R+S) into the glenohumeral joint (GHJ). An additional group received 1 ml capsaicin onto an intact rotator cuff (I+C). At 18 weeks post-op, cartilage proteoglycan (PG) synthesis and content as well as cell viability were similar (p>0.05) across treatment groups. Biomechanical testing revealed no differences (p>0.05) among tendon repair treatment groups. Similarly, histologic features of both cartilage and repaired tendons showed minimal differences across groups. Hence, in this rabbit model, a single injection of highly purified capsaicin into the GHJ does not induce a deleterious response with regard to cartilage matrix metabolism and cell viability, or rotator cuff healing. These data provide further evidence supporting the use of injectable, highly purified capsaicin as a safe alternative for management of postoperative pain following GHJ surgery. CI - © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Friel, Nicole A AU - Friel NA AD - Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - McNickle, Allison G AU - McNickle AG AD - Department of Surgery, Mount Sinai Hospital Medical Center, Chicago, Illinois. FAU - DeFranco, Michael J AU - DeFranco MJ AD - CGH Medical Center, Sterling, Illinois. FAU - Wang, FanChia AU - Wang F AD - BioCare Corporation, Lujhu Township, Taiwan. FAU - Shewman, Elizabeth F AU - Shewman EF AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. FAU - Verma, Nikhil N AU - Verma NN AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. FAU - Cole, Brian J AU - Cole BJ AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. FAU - Bach, Bernard R Jr AU - Bach BR Jr AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. FAU - Chubinskaya, Susan AU - Chubinskaya S AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. AD - Department of Biochemistry, Rush University Medical Center, Chicago, Illinois. FAU - Kramer, Susan M AU - Kramer SM AD - Annexon Bioscience, South San Francisco, California. FAU - Wang, Vincent M AU - Wang VM AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150707 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Proteoglycans) RN - S07O44R1ZM (Capsaicin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Capsaicin/*therapeutic use MH - Cartilage, Articular/*drug effects/surgery MH - Cell Survival MH - Male MH - Pain, Postoperative MH - Pressure MH - Proteoglycans/metabolism MH - Rabbits MH - Rotator Cuff/*drug effects/surgery MH - Shoulder Joint/pathology MH - Stress, Mechanical MH - Tendon Injuries/*drug therapy/surgery MH - Tendons/*drug effects/surgery OTO - NOTNLM OT - anesthetic OT - capsaicin OT - cartilage OT - rotator cuff OT - tendon EDAT- 2015/07/03 06:00 MHDA- 2016/02/24 06:00 CRDT- 2015/07/03 06:00 PHST- 2015/01/06 00:00 [received] PHST- 2015/06/16 00:00 [accepted] PHST- 2015/07/03 06:00 [entrez] PHST- 2015/07/03 06:00 [pubmed] PHST- 2016/02/24 06:00 [medline] AID - 10.1002/jor.22971 [doi] PST - ppublish SO - J Orthop Res. 2015 Dec;33(12):1854-60. doi: 10.1002/jor.22971. Epub 2015 Jul 7. PMID- 34127225 OWN - NLM STAT- MEDLINE DCOM- 20211018 LR - 20211018 IS - 1879-1344 (Electronic) IS - 0144-8617 (Linking) VI - 268 DP - 2021 Sep 15 TI - Chitosan/gelatin-tannic acid decorated porous tape suture with multifunctionality for tendon healing. PG - 118246 LID - S0144-8617(21)00633-0 [pii] LID - 10.1016/j.carbpol.2021.118246 [doi] AB - The inferior tendon healing after surgery is inextricably linked to the surgical suture. Poor load transfer along the suture often results in a high tendon re-tear rate. Besides, the severe inflammation and infection induced by sutures even cause a second surgery. Herein, to alleviate the above-mentioned issues, a multifunctional suture was fabricated by decorating chitosan/gelatin-tannic acid (CS/GE-TA) on the porous tape suture. The porous tape suture ensured the required mechanical properties and sufficient space for tissue integration. Compared to the pristine suture, the CS/GE-TA decorated suture (TA100) presented a 332% increase in pull-out force from the tendon, indicating potentially decreased re-tear rates. Meanwhile, TA100 showed superior anti-inflammatory and antibacterial performances. In vivo experiments further proved that TA100 could not only reduce inflammatory action but also facilitate collagen deposition and blood vessel formation. These results indicate that the multifunctional sutures are promising candidates for accelerating tendon healing. CI - Copyright © 2021 Elsevier Ltd. All rights reserved. FAU - Zhang, Qian AU - Zhang Q AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. FAU - Qiao, Yansha AU - Qiao Y AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. FAU - Li, Chaojing AU - Li C AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. FAU - Lin, Jing AU - Lin J AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. FAU - Han, Hui AU - Han H AD - Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China. FAU - Li, Xiaoli AU - Li X AD - Key Laboratory of Biomedical Materials and Implants, Research Institute of Tsinghua University in Shenzhen, Shenzhen 518057, China. FAU - Mao, Jifu AU - Mao J AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. Electronic address: jifu.mao@dhu.edu.cn. FAU - Wang, Fujun AU - Wang F AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. FAU - Wang, Lu AU - Wang L AD - Key Laboratory of Textile Science and Technology of Ministry of Education, College of Textiles, Donghua University, Shanghai 201620, China; Key Laboratory of Textile Industry for Biomedical Textile Materials and Technology, Donghua University, Shanghai 201620, China. Electronic address: wanglu@dhu.edu.cn. LA - eng PT - Journal Article DEP - 20210525 PL - England TA - Carbohydr Polym JT - Carbohydrate polymers JID - 8307156 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Indoles) RN - 0 (Polymers) RN - 0 (Tannins) RN - 0 (polydopamine) RN - 9000-70-8 (Gelatin) RN - 9012-76-4 (Chitosan) SB - IM MH - Animals MH - Anti-Bacterial Agents/chemistry/pharmacology/*therapeutic use MH - Anti-Inflammatory Agents/chemistry/pharmacology/*therapeutic use MH - Chitosan/chemistry/pharmacology/therapeutic use MH - Escherichia coli/drug effects MH - Gelatin/chemistry/pharmacology/therapeutic use MH - Indoles/chemistry/pharmacology/therapeutic use MH - Inflammation/*drug therapy/pathology MH - Male MH - Mice MH - Microbial Sensitivity Tests MH - Polymers/chemistry/pharmacology/therapeutic use MH - Porosity MH - RAW 264.7 Cells MH - Staphylococcus aureus/drug effects MH - *Sutures MH - Swine MH - Tannins/chemistry/pharmacology/therapeutic use MH - Tendons/*drug effects/pathology MH - Tensile Strength MH - Wound Healing/*drug effects OTO - NOTNLM OT - Anti-inflammatory OT - Antibacterial OT - Load transfer OT - Porous tape suture OT - Tendon healing EDAT- 2021/06/16 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/06/15 05:59 PHST- 2021/02/03 00:00 [received] PHST- 2021/03/31 00:00 [revised] PHST- 2021/05/19 00:00 [accepted] PHST- 2021/06/15 05:59 [entrez] PHST- 2021/06/16 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] AID - S0144-8617(21)00633-0 [pii] AID - 10.1016/j.carbpol.2021.118246 [doi] PST - ppublish SO - Carbohydr Polym. 2021 Sep 15;268:118246. doi: 10.1016/j.carbpol.2021.118246. Epub 2021 May 25. PMID- 922655 OWN - NLM STAT- MEDLINE DCOM- 19780127 LR - 20190619 IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 40 IP - 5 DP - 1977 Nov TI - Clinical course and management of accidental adriamycin extravasation. PG - 2053-6 AB - Adriamycin infiltration into subcutaneous tissues during intravenous administration results in an intense inflammatory response, which may progress to full-thickness skin ioss and irreversible damage to underlying tendons and neurovascular structures. An analysis of 10 patients seen with Adriamycin in filtration indicated that healing of ulcerated lesions is often prolnged and associated with significant morbidity. Seven patients suffered skin ulcerations and three had severe functional impairment due to joint contractures. Adriamycin should not be infused near joints if possible . Surgical excision of ulcers is advocated if healing is prolonged. Proper local therapy, as well as early attention to proper splinting and physical therapy, can help reduce ultimate functional disability. FAU - Reilly, J J AU - Reilly JJ FAU - Neifeld, J P AU - Neifeld JP FAU - Rosenberg, S A AU - Rosenberg SA LA - eng PT - Journal Article PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 80168379AG (Doxorubicin) SB - IM MH - Adolescent MH - Adult MH - Doxorubicin/*adverse effects MH - Female MH - Humans MH - Inflammation/chemically induced/therapy MH - Injections, Intravenous/*adverse effects MH - Joints/drug effects MH - Male MH - Middle Aged MH - Necrosis/chemically induced/therapy MH - Skin Ulcer/chemically induced/therapy EDAT- 1977/11/01 00:00 MHDA- 1977/11/01 00:01 CRDT- 1977/11/01 00:00 PHST- 1977/11/01 00:00 [pubmed] PHST- 1977/11/01 00:01 [medline] PHST- 1977/11/01 00:00 [entrez] AID - 10.1002/1097-0142(197711)40:5<2053::aid-cncr2820400509>3.0.co;2-a [doi] PST - ppublish SO - Cancer. 1977 Nov;40(5):2053-6. doi: 10.1002/1097-0142(197711)40:5<2053::aid-cncr2820400509>3.0.co;2-a. PMID- 23047299 OWN - NLM STAT- MEDLINE DCOM- 20140417 LR - 20130610 IS - 1879-0267 (Electronic) IS - 0020-1383 (Linking) VI - 44 IP - 7 DP - 2013 Jul TI - Arrabidaea chica extract improves gait recovery and changes collagen content during healing of the Achilles tendon. PG - 884-92 LID - S0020-1383(12)00366-X [pii] LID - 10.1016/j.injury.2012.08.055 [doi] AB - INTRODUCTION: Tendon lesions are still a serious clinical problem. The leaves of the Bignoniaceae Arrabidaea chica (Humb. & Bonpl.) B. Verlot. (syn. Bignonia chica (Bonpl.)) have been used in traditional medicine and described in the literature for its healing properties. However, no study has shown the effects of A. chica during tendon healing. The aim of this study was to investigate the healing properties of the A. chica leaves extract on tendons after partial transection. METHODS: A partial transection in the tension region of the Achilles tendon of rats was performed with subsequent posterior topical application of A. chica extract (2.13g/mL in 0.85% saline solution) at the site of the injury. The animals (n=154) were separated into 7 groups: N - rats with tendons without transection; S7, S14 and S21 - rats with tendons treated with topical applications of saline for 7 days and sacrificed on the 7th, 14th and 21st days after surgery, respectively; A7, A14 and A21 - rats with tendons treated with topical applications of the plant extract. The transected regions of the tendons were analyzed through biochemical, morphological and functional analyses. To evaluate the type and concentration of collagen, Western blotting for collagen types I and III was performed, and the hydroxyproline concentration was determined. The participation of metalloproteinases (MMP)-2 and -9 during tendon remodelling was investigated through zymography. Gait recovery was analyzed using the catwalk system. The organization of the extracellular matrix and morphometry were detected in sections stained with haematoxylin-eosin. RESULTS: The application of A. chica extract in the region of tendon injury led to an increase in the amount of hydroxyproline (mg/g tissue) on the 7th (91.5±18.9) and 21st (95.8±11.9) days after the tendon lesion relative to the control groups treated with saline (S7: 75.2±7.2; and S21: 71.9±7.9). There were decreases in collagen types I and III (as determined by densitometry) in the groups treated with the plant extract 7 days after injury (type I: 103.9±15.9; type III: 206.3±8.1) compared to the saline-treated groups (type I: 165.2±31.1; type III: 338.6±48.8). The plant extract stimulated the synthesis of MMP-2 on the 21st day after the lesion and decreased the amount of latent and active isoforms of MMP-9 on the 14th day. Analysis by the catwalk system (max contact intensity) showed that the A. chica extract improved the gait of rats on the 7th day of the healing process when compared to the saline group. CONCLUSIONS: The use of A. chica extract during the healing process of the tendon leads to an increase in collagen content and improved gait recovery. Further studies will be performed to analyze the effect of this plant extract on the organization of the collagen bundles of tendons after lesions and to study its probable anti-inflammatory effect. CI - Copyright © 2012 Elsevier Ltd. All rights reserved. FAU - Aro, A A AU - Aro AA AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas, UNICAMP, Campinas, SP, Brazil. andreaaro@ig.com.br FAU - Simões, G F AU - Simões GF FAU - Esquisatto, M A M AU - Esquisatto MA FAU - Foglio, M A AU - Foglio MA FAU - Carvalho, J E AU - Carvalho JE FAU - Oliveira, A L R AU - Oliveira AL FAU - Gomes, L AU - Gomes L FAU - Pimentel, E R AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121007 PL - Netherlands TA - Injury JT - Injury JID - 0226040 RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Bignoniaceae/*chemistry MH - Blotting, Western MH - Collagen MH - Disease Models, Animal MH - *Gait MH - Phytotherapy MH - Plant Extracts/*pharmacology/therapeutic use MH - Plant Leaves/chemistry MH - Rats MH - Rats, Wistar MH - Tendon Injuries/pathology/*therapy MH - Wound Healing/drug effects/physiology EDAT- 2012/10/11 06:00 MHDA- 2014/04/18 06:00 CRDT- 2012/10/11 06:00 PHST- 2012/04/06 00:00 [received] PHST- 2012/08/29 00:00 [accepted] PHST- 2012/10/11 06:00 [entrez] PHST- 2012/10/11 06:00 [pubmed] PHST- 2014/04/18 06:00 [medline] AID - S0020-1383(12)00366-X [pii] AID - 10.1016/j.injury.2012.08.055 [doi] PST - ppublish SO - Injury. 2013 Jul;44(7):884-92. doi: 10.1016/j.injury.2012.08.055. Epub 2012 Oct 7. PMID- 33550349 OWN - NLM STAT- MEDLINE DCOM- 20210209 LR - 20210218 IS - 1671-167X (Print) IS - 1671-167X (Linking) VI - 53 IP - 1 DP - 2020 Dec 25 TI - [Risk factors and diagnostic value for ultrasound-detected tendon monosodium urate crystal deposition in patients with gout]. PG - 143-149 AB - OBJECTIVE: To evaluate frequency and patterns, risk factors of MSU (monosodium urate) crystal deposition at lower extremity tendon by ultrasonography in gout patients, and to explore diagnostic value by ultrasonography. METHODS: Patients diagnosed with gout and age matched healthy controls had ultrasound scanning of both feet and knees including joints and tendons (achilles, quadriceps, and patellar tendon). Readers who scored the ultrasound scans for MSU crystal deposition were blinded to the patients' clinical diagnoses. Clinical characteristics were compared between positive and negative crystal deposition groups by US, and risk factors of MSU deposition in tendons were analyzed. Diagnostic values of MSU deposition were evaluated by ultrasonography according with positive MSU crystal in synovial fluid or tophi by polarized microscopy. RESULTS: Eighty patients and eighty healthy controls were included. Thity-three patients (47.5%) had tophi by physical examination. The achilles tendon was the most commonly involved tendon site 41(51.2%), followed by the quadriceps tendons 22(27.5%), and patella tendon 10(12.5%). There were no MSU deposition in healthy control group at tendon by ultrasonography. Compared with negative MSU deposition at tendon site by ultrasonography, tendon MSU positive patients had longer mean gout duration [(87.3±40.9) months vs. (7.7±2.6) months, P=0.001];higher frequency of gout flare [2(1, 2) /year vs. 1(1, 1) /year, P=0.001]; higher BMI [(26.3±2.5) kg/m(2)vs. (23.3±2.1) kg/m(2), P=0.05]. Also, the mean serum uric acid and creatinine levels were higher in tendon MSU positive group [(584.6±87.6) μmol/L vs. (460.4±96.7) μmol/L, P=0.001] and [(90.9±33.3) μmol/L vs. (70.6±40.2) μmol/L, P=0.02] separately. Logistic regression analysis showed gout duration and flare frequency were independent risk factors for MSU deposition at tendon by ultrasonography (P < 0.01). Joint or tophi aspirations were performed in all the eighty gout patients, and positive MSU crystals in synovial fluid analysis by polarized microscopy were defined as the golden standard of gout diagnosis. When compared with the golden standard, the sensitivity and specificity were 94.0% and 78.0% separately for MSU deposition at tendon by ultrasonography. CONCLUSION: Tendon involvement at the lower extremity tendons in gout is very common. Long gout disease duration and high frequency of gout flare are both independent risk factors of tendon MSU deposition by ultrasonography. Ultrasonography had good sensitivity and specificity for detecting tendinous tophi and aggregates. FAU - Wang, Y AU - Wang Y AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. FAU - Deng, X R AU - Deng XR AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. FAU - Ji, L L AU - Ji LL AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. FAU - Zhang, X H AU - Zhang XH AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. FAU - Geng, Y AU - Geng Y AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. FAU - Zhang, Z L AU - Zhang ZL AD - Department of Rheumatology and Immunology, Peking University First Hospital, Beijing 100034, China. LA - chi PT - Journal Article PL - China TA - Beijing Da Xue Xue Bao Yi Xue Ban JT - Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences JID - 101125284 RN - 268B43MJ25 (Uric Acid) SB - IM MH - *Gout/diagnostic imaging MH - Humans MH - Risk Factors MH - Symptom Flare Up MH - Ultrasonography MH - *Uric Acid PMC - PMC7867977 OTO - NOTNLM OT - Diagnostic value OT - Gout OT - Sodium urate monohydrate OT - Tendon OT - Ultrasonography EDAT- 2021/02/08 06:00 MHDA- 2021/02/10 06:00 PMCR- 2021/02/18 CRDT- 2021/02/07 20:51 PHST- 2021/02/07 20:51 [entrez] PHST- 2021/02/08 06:00 [pubmed] PHST- 2021/02/10 06:00 [medline] PHST- 2021/02/18 00:00 [pmc-release] AID - bjdxxbyxb-53-1-143 [pii] AID - 10.19723/j.issn.1671-167X.2021.01.022 [doi] PST - ppublish SO - Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Dec 25;53(1):143-149. doi: 10.19723/j.issn.1671-167X.2021.01.022. PMID- 29534523 OWN - NLM STAT- MEDLINE DCOM- 20180905 LR - 20181114 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 3 DP - 2018 Mar 12 TI - Exploring the In Vivo Anti-Inflammatory Actions of Simvastatin-Loaded Porous Microspheres on Inflamed Tenocytes in a Collagenase-Induced Animal Model of Achilles Tendinitis. LID - 10.3390/ijms19030820 [doi] LID - 820 AB - Tendon rupture induces an inflammatory response characterized by release of pro-inflammatory cytokines and impaired tendon performance. This study sought to investigate the therapeutic effects of simvastatin-loaded porous microspheres (SIM/PMSs) on inflamed tenocytes in vitro and collagenase-induced Achilles tendinitis in vivo. The treatment of SIM/PMSs in lipopolysaccharide (LPS)-treated tenocytes reduced the mRNA expressions of pro-inflammatory cytokines (Matrix metalloproteinase-3 (MMP-3), cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)). In addition, the local injection of SIM/PMSs into the tendons of collagenase-induced Achilles tendinitis rat models suppressed pro-inflammatory cytokines (MMP-3, COX-2, IL-6, TNF-α, and MMP-13). This local treatment also upregulated anti-inflammatory cytokines (IL-4, IL-10, and IL-13). Furthermore, treatment with SIM/PMSs also improved the alignment of collagen fibrils and effectively prevented collagen disruption in a dose-dependent manner. Therefore, SIM/PMSs treatment resulted in an incremental increase in the collagen content, stiffness, and tensile strength in tendons. This study suggests that SIM/PMSs have great potential for tendon healing and restoration in Achilles tendinitis. FAU - Jeong, Chandong AU - Jeong C AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University College of Medicine, Guro Hospital, Guro-dong, Guro-gu, Seoul 08308, Korea. cdjeong85@gmail.com. AD - Department of Biomedical Science, Korea University College of Medicine, Anam-dong, Seongbuk-gu, Seoul 02841, Korea. cdjeong85@gmail.com. FAU - Kim, Sung Eun AU - Kim SE AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University College of Medicine, Guro Hospital, Guro-dong, Guro-gu, Seoul 08308, Korea. sekim10@korea.ac.kr. FAU - Shim, Kyu-Sik AU - Shim KS AD - Department of Biomedical Science, Korea University College of Medicine, Anam-dong, Seongbuk-gu, Seoul 02841, Korea. breakdown88@nate.com. FAU - Kim, Hak-Jun AU - Kim HJ AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University College of Medicine, Guro Hospital, Guro-dong, Guro-gu, Seoul 08308, Korea. dakjul@korea.ac.kr. FAU - Song, Mi Hyun AU - Song MH AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University College of Medicine, Guro Hospital, Guro-dong, Guro-gu, Seoul 08308, Korea. wwiiw@naver.com. FAU - Park, Kyeongsoon AU - Park K AUID- ORCID: 0000-0003-3625-4128 AD - Department of Systems Biotechnology, Chung-Ang University, Anseong, Gyeonggi-do 17546, Korea. kspark1223@cau.ac.kr. FAU - Song, Hae-Ryong AU - Song HR AD - Department of Orthopedic Surgery and Rare Diseases Institute, Korea University College of Medicine, Guro Hospital, Guro-dong, Guro-gu, Seoul 08308, Korea. songhae@korea.ac.kr. LA - eng PT - Journal Article DEP - 20180312 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Interleukins) RN - 0 (Lipopolysaccharides) RN - 0 (Tumor Necrosis Factor-alpha) RN - 9007-34-5 (Collagen) RN - AGG2FN16EV (Simvastatin) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Achilles Tendon/pathology MH - Animals MH - Anti-Inflammatory Agents/administration & dosage/*pharmacology MH - Cells, Cultured MH - Collagen/genetics/metabolism MH - Collagenases/toxicity MH - Cyclooxygenase 2/genetics/metabolism MH - Interleukins/genetics/metabolism MH - Lipopolysaccharides/toxicity MH - Matrix Metalloproteinases/genetics/metabolism MH - *Microspheres MH - Rats MH - Rats, Sprague-Dawley MH - Simvastatin/administration & dosage/*pharmacology MH - Tendinopathy/*drug therapy/etiology MH - Tenocytes/*drug effects/metabolism MH - Tumor Necrosis Factor-alpha/genetics/metabolism PMC - PMC5877681 OTO - NOTNLM OT - Achilles tendinitis OT - anti-inflammation OT - porous microspheres OT - simvastatin OT - tendon healing COIS- The authors declare no conflict of interest. EDAT- 2018/03/15 06:00 MHDA- 2018/09/06 06:00 PMCR- 2018/03/01 CRDT- 2018/03/15 06:00 PHST- 2018/01/18 00:00 [received] PHST- 2018/02/25 00:00 [revised] PHST- 2018/03/08 00:00 [accepted] PHST- 2018/03/15 06:00 [entrez] PHST- 2018/03/15 06:00 [pubmed] PHST- 2018/09/06 06:00 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - ijms19030820 [pii] AID - ijms-19-00820 [pii] AID - 10.3390/ijms19030820 [doi] PST - epublish SO - Int J Mol Sci. 2018 Mar 12;19(3):820. doi: 10.3390/ijms19030820. PMID- 22822997 OWN - NLM STAT- MEDLINE DCOM- 20120925 LR - 20211021 IS - 0003-3006 (Print) IS - 0003-3006 (Linking) VI - 59 IP - 2 DP - 2012 Summer TI - Anesthetic considerations for masticatory muscle tendon-aponeurosis hyperplasia: a report of 24 cases. PG - 87-9 LID - 10.2344/11-27.1 [doi] AB - Masticatory muscle tendon-aponeurosis hyperplasia (MMTAH) is a new disease entity characterized by limited mouth opening due to contracture of the masticatory muscles, resulting from hyperplasia of tendons and aponeuroses. In this case series, we report what methods of airway establishment were conclusively chosen after rapid induction of anesthesia. We had 24 consecutive patients with MMTAH who underwent surgical release of its contracture under general anesthesia. Rapid induction of anesthesia with propofol and rocuronium was chosen for all the cases. In 7 cases, intubation using the Macintosh laryngoscopy was attempted; however, 2 of those cases failed to be intubated on the first attempt. Finally, intubation using the McCoy laryngoscopy or fiber-optic intubation was alternatively used in these 2 cases. In 7 cases, the Trachlight was used. In the remaining 10 cases, fiber-optic intubation was used. Limited mouth opening in patients with MMTAH did not improve with muscular relaxation. "Square mandible" has been reported to be one of the clinical features in this disease; however, half of these 24 patients lacked this characteristic, which might affect a definitive diagnosis of this disease for anesthesiologists. An airway problem in patients with MMTAH should not be underestimated, which means that other intubation methods rather than direct laryngoscopy had better be considered. FAU - Yamamoto, Ikumi AU - Yamamoto I AD - Department of Anesthesiology, Nara Medical University, Kashihara, Japan. FAU - Inoue, Satoki AU - Inoue S FAU - Kawaguchi, Masahiko AU - Kawaguchi M FAU - Kawakami, Tetsuji AU - Kawakami T FAU - Kirita, Tadaaki AU - Kirita T FAU - Furuya, Hitoshi AU - Furuya H LA - eng PT - Journal Article PL - United States TA - Anesth Prog JT - Anesthesia progress JID - 0043533 RN - 0 (Androstanols) RN - 0 (Anesthetics, Intravenous) RN - 0 (Neuromuscular Nondepolarizing Agents) RN - WRE554RFEZ (Rocuronium) RN - YI7VU623SF (Propofol) MH - Androstanols/administration & dosage MH - Anesthesia, Dental/*methods MH - Anesthesia, General/*methods MH - Anesthetics, Intravenous/administration & dosage MH - Connective Tissue/surgery MH - Contracture/surgery MH - Fiber Optic Technology MH - Humans MH - Hyperplasia MH - Intubation, Intratracheal/*instrumentation/*methods MH - Laryngoscopy/adverse effects MH - Mandible/pathology MH - Masseter Muscle/*pathology/surgery MH - Neuromuscular Nondepolarizing Agents/administration & dosage MH - Nose MH - Oral Surgical Procedures/methods MH - Propofol/administration & dosage MH - Rocuronium MH - Tendons/*pathology/surgery PMC - PMC3403588 EDAT- 2012/07/25 06:00 MHDA- 2012/09/26 06:00 PMCR- 2012/12/01 CRDT- 2012/07/25 06:00 PHST- 2012/07/25 06:00 [entrez] PHST- 2012/07/25 06:00 [pubmed] PHST- 2012/09/26 06:00 [medline] PHST- 2012/12/01 00:00 [pmc-release] AID - 11-27 [pii] AID - 10.2344/11-27.1 [doi] PST - ppublish SO - Anesth Prog. 2012 Summer;59(2):87-9. doi: 10.2344/11-27.1. PMID- 30415260 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20220408 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 50 IP - 6 DP - 2018 TI - High Concentration of Aspirin Induces Apoptosis in Rat Tendon Stem Cells via Inhibition of the Wnt/β-Catenin Pathway. PG - 2046-2059 LID - 10.1159/000495050 [doi] AB - BACKGROUND/AIMS: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in clinical practice to relieve fever and pain. Aspirin, as a representative NSAID, has been widely used in the treatment of tendinopathy. Some reports have demonstrated that aspirin can induce apoptosis in cancer cells. However, evidence regarding aspirin treatment for tendinopathy, especially the effect of this treatment on tendon stem cells (TSCs), is lacking. Understanding the effect of aspirin on tendinopathy may provide a basis for the rational use of NSAIDs in clinical practice. The aim of our study was to determine whether aspirin induces apoptosis in rat TSCs via the Wnt/β-catenin pathway. METHODS: First, we used flow cytometry and fluorescence to detect TSC apoptosis. Protein expression of the apoptosis-related caspase-3 pathway was investigated via western blot analysis. Next, we used western blotting to determine the effect of aspirin on the Wnt/β-catenin pathway. We used immunostaining to detect the levels of Bcl2, cleaved caspase-3, and P-β-catenin in the Achilles tendon. Finally, we used flow cytometry, fluorescence, and western blotting to investigate the aspirin-induced apoptosis of TSCs via the Wnt/β-catenin pathway. RESULTS: Aspirin induced morphological apoptosis in rat TSCs via the mitochondrial/caspase-3 pathway and induced cellular apoptosis in the Achilles tendon. Apoptosis was partly reversed after adding the Wnt signaling activator Wnt3a and lithium chloride (LiCl, a GSK-3β inhibitor). Aspirin administration led to a dose-dependent increase in COX-2 expression. Apoptosis was promoted after adding the COX-2 inhibitor NS398. CONCLUSION: The Wnt/β-catenin pathway plays a vital role in aspirin-induced apoptosis by regulating mitochondrial/caspase-3 function. Elevating COX-2 levels may protect cells against apoptosis. More importantly, the results remind us to consider the apoptotic effect of aspirin on TSCs and tendon cells when aspirin is administered to treat tendinopathy. The relationship between the positive and negative effects of aspirin remains a subject for future study. CI - © 2018 The Author(s). Published by S. Karger AG, Basel. FAU - Wang, Yunjiao AU - Wang Y AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Tang, Hong AU - Tang H AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - He, Gang AU - He G AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Shi, Youxing AU - Shi Y AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Kang, Xia AU - Kang X AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Lyu, Jingtong AU - Lyu J AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhou, Mei AU - Zhou M AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhu, Min AU - Zhu M AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhang, Jiqiang AU - Zhang J AD - Department of Neurology, Third Military Medical University, Chongqing, China. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopeadics, Southwest Hospital, Third Military Medical University, Chongqing, Chinatangkanglai@hotmail.com. LA - eng PT - Journal Article DEP - 20181109 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Nitrobenzenes) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Sulfonamides) RN - 0 (Wnt3A Protein) RN - 0 (beta Catenin) RN - 123653-11-2 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (Ptgs2 protein, rat) RN - EC 2.7.11.26 (Glycogen Synthase Kinase 3) RN - EC 3.4.22.- (Caspase 3) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Apoptosis/*drug effects MH - Aspirin/*pharmacology MH - Caspase 3/metabolism MH - Cyclooxygenase 2/chemistry/metabolism MH - Gene Expression Regulation/drug effects MH - Glycogen Synthase Kinase 3/metabolism MH - Male MH - Mitochondria/drug effects/metabolism MH - Nitrobenzenes/pharmacology MH - Proto-Oncogene Proteins c-bcl-2/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cells/cytology/drug effects/metabolism MH - Sulfonamides/pharmacology MH - Tendons/cytology MH - Wnt Signaling Pathway/*drug effects MH - Wnt3A Protein/metabolism MH - beta Catenin/metabolism OTO - NOTNLM OT - Apoptosis OT - Aspirin OT - Tendon stem cells OT - Wnt/β-catenin pathway EDAT- 2018/11/12 06:00 MHDA- 2018/12/12 06:00 CRDT- 2018/11/12 06:00 PHST- 2017/12/28 00:00 [received] PHST- 2018/11/02 00:00 [accepted] PHST- 2018/11/12 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2018/11/12 06:00 [entrez] AID - 000495050 [pii] AID - 10.1159/000495050 [doi] PST - ppublish SO - Cell Physiol Biochem. 2018;50(6):2046-2059. doi: 10.1159/000495050. Epub 2018 Nov 9. PMID- 4355999 OWN - NLM STAT- MEDLINE DCOM- 19740105 LR - 20181113 IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 52 IP - 11 DP - 1973 Nov TI - The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis. PG - 2822-35 AB - The metabolism of cholesterol and its 5-dihydro derivative, cholestanol, was investigated by means of sterol balance and isotope kinetic techniques in 3 subjects with cerebrotendinous xanthomatosis (CTX) and 11 other individuals. All subjects were hospitalized on a metabolic ward and were fed diets practically free of cholesterol and cholestanol. After the intravenous administration of [1,2-(3)H]cholestanol, the radioactive sterol was transported and esterified in plasma lipoproteins in an identical manner to cholesterol. In these short-term experiments, the specific activity-time curves of plasma cholestanol conformed to two-pool models in both the CTX and control groups. However, cholestanol plasma concentrations, total body miscible pools, and daily synthesis rates were two to five times greater in the CTX than control individuals. The short-term specific activity decay curves of plasma [4-(14)C]cholesterol also conformed to two-pool models in both groups. However, in the CTX subjects the decay was more rapid, and daily cholesterol synthesis was nearly double that of the control subjects. Plasma concentrations and the sizes of the rapidly turning over pool of exchangeable cholesterol were apparently small in the CTX subjects, and these measurements did not correlate with the large cholesterol deposits found in tendon and tuberous xanthomas. Despite active cholesterol synthesis, bile acid formation was subnormal in the CTX subjects. However, bile acid sequestration was accompanied by a rise in plasma cholestanol levels and greatly augmented fecal cholestanol outputs. In contrast, the administration of clofibrate lowered plasma cholesterol levels 50% and presumably reduced synthesis in the CTX subjects. Plasma cholesterol concentrations and fecal steroid excretion did not change significantly during this therapy. These findings indicate that the excessive tissue deposits of cholesterol and cholestanol that characterize CTX were associated with hyperactive neutral sterol synthesis. The demonstration of subnormal bile acid formation suggests that defective bile acid synthesis may predispose to the neutral sterol abnormalities. FAU - Salen, G AU - Salen G FAU - Grundy, S M AU - Grundy SM LA - eng PT - Journal Article PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Bile Acids and Salts) RN - 0 (Carbon Radioisotopes) RN - 0 (Esters) RN - 0 (Lipoproteins, HDL) RN - 0 (Lipoproteins, LDL) RN - 0 (Lipoproteins, VLDL) RN - 10028-17-8 (Tritium) RN - 11041-12-6 (Cholestyramine Resin) RN - 8M308U816E (Cholestanol) RN - 97C5T2UQ7J (Cholesterol) RN - HPN91K7FU3 (Clofibrate) SB - IM MH - Adult MH - Aged MH - Bile Acids and Salts/*metabolism MH - Brain Diseases/*metabolism MH - Carbon Radioisotopes MH - Cholestanol/administration & dosage/blood/metabolism MH - Cholesterol/administration & dosage/blood/*metabolism MH - Cholestyramine Resin/pharmacology MH - Clofibrate/pharmacology MH - Diet MH - Esters/blood MH - Feces/analysis MH - Female MH - Humans MH - Injections, Intravenous MH - Lipoproteins, HDL/blood MH - Lipoproteins, LDL/blood MH - Lipoproteins, VLDL/blood MH - Male MH - Middle Aged MH - *Tendons MH - Tritium MH - Xanthomatosis/*metabolism PMC - PMC302550 EDAT- 1973/11/01 00:00 MHDA- 1973/11/01 00:01 PMCR- 1973/11/01 CRDT- 1973/11/01 00:00 PHST- 1973/11/01 00:00 [pubmed] PHST- 1973/11/01 00:01 [medline] PHST- 1973/11/01 00:00 [entrez] PHST- 1973/11/01 00:00 [pmc-release] AID - 10.1172/JCI107478 [doi] PST - ppublish SO - J Clin Invest. 1973 Nov;52(11):2822-35. doi: 10.1172/JCI107478. PMID- 24953691 OWN - NLM STAT- MEDLINE DCOM- 20140921 LR - 20220113 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 450 IP - 1 DP - 2014 Jul 18 TI - Effects of celecoxib on proliferation and tenocytic differentiation of tendon-derived stem cells. PG - 762-6 LID - S0006-291X(14)01132-2 [pii] LID - 10.1016/j.bbrc.2014.06.058 [doi] AB - NSAIDs are often ingested to reduce the pain and improve regeneration of tendon after tendon injury. Although the effects of NSAIDs in tendon healing have been reported, the data and conclusions are not consistent. Recently, tendon-derived stem cells (TDSCs) have been isolated from tendon tissues and has been suggested involved in tendon repair. Our study aims to determine the effects of COX-2 inhibitor (celecoxib) on the proliferation and tenocytic differentiation of TDSCs. TDSCs were isolated from mice Achilles tendon and exposed to celecoxib. Cell proliferation rate was investigated at various concentrations (0.1, 1, 10 and 100 μg/ml) of celecoxib by using hemocytometer. The mRNA expression of tendon associated transcription factors, tendon associated collagens and tendon associated molecules were determined by reverse transcription-polymerase chain reaction. The protein expression of Collagen I, Collagen III, Scleraxis and Tenomodulin were determined by Western blotting. The results showed that celecoxib has no effects on TDSCs cell proliferation in various concentrations (p>0.05). The levels of most tendon associated transcription factors, tendon associated collagens and tendon associated molecules genes expression were significantly decreased in celecoxib (10 μg/ml) treated group (p<0.05). Collagen I, Collagen III, Scleraxis and Tenomodulin protein expression were also significantly decreased in celecoxib (10 μg/ml) treated group (p<0.05). In conclusion, celecoxib inhibits tenocytic differentiation of tendon-derived stem cells but has no effects on cell proliferation. CI - Copyright © 2014 Elsevier Inc. All rights reserved. FAU - Zhang, Kairui AU - Zhang K AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. FAU - Zhang, Sheng AU - Zhang S AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. FAU - Li, Qianqian AU - Li Q AD - Cancer Research Institute, Southern Medical University, Guangzhou 510515, China. FAU - Yang, Jun AU - Yang J AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Department of Orthopaedics, 421 Hospital of PLA, Guangzhou 510318, China. FAU - Dong, Weiqiang AU - Dong W AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Department of Orthopaedics, The First Affiliated Hospital to Guangzhou Medical University, Guangzhou 510120, China. FAU - Wang, Shengnan AU - Wang S AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. FAU - Cheng, Yirong AU - Cheng Y AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. FAU - Al-Qwbani, Mohammed AU - Al-Qwbani M AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. FAU - Wang, Qiang AU - Wang Q AD - Department of Orthopaedics, Subei People's Hospital of Jiangsu Province (Clinical Medical College of Yangzhou University), Yangzhou, Jiangsu Province 225001, China. Electronic address: 1780468505@qq.com. FAU - Yu, Bin AU - Yu B AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: carryzhang1985@live.com. LA - eng PT - Journal Article DEP - 20140619 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - 9007-34-5 (Collagen) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Animals MH - Celecoxib MH - Cell Differentiation/drug effects/physiology MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Collagen/*metabolism MH - Cyclooxygenase 2 Inhibitors/administration & dosage MH - Dose-Response Relationship, Drug MH - Mice MH - Mice, Inbred C57BL MH - Pyrazoles/*administration & dosage MH - Stem Cells/*cytology/*physiology MH - Sulfonamides/*administration & dosage MH - Tendons/*cytology/*physiology OTO - NOTNLM OT - Celecoxib OT - Cell proliferation OT - Tendon-derived stem cells OT - Tenocytic differentiation EDAT- 2014/06/24 06:00 MHDA- 2014/09/23 06:00 CRDT- 2014/06/24 06:00 PHST- 2014/05/28 00:00 [received] PHST- 2014/06/11 00:00 [accepted] PHST- 2014/06/24 06:00 [entrez] PHST- 2014/06/24 06:00 [pubmed] PHST- 2014/09/23 06:00 [medline] AID - S0006-291X(14)01132-2 [pii] AID - 10.1016/j.bbrc.2014.06.058 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2014 Jul 18;450(1):762-6. doi: 10.1016/j.bbrc.2014.06.058. Epub 2014 Jun 19. PMID- 29202812 OWN - NLM STAT- MEDLINE DCOM- 20180720 LR - 20211204 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 8 IP - 1 DP - 2017 Dec 4 TI - Celastrol improves self-renewal and differentiation of human tendon-derived stem cells by suppressing Smad7 through hypoxia. PG - 274 LID - 10.1186/s13287-017-0724-x [doi] LID - 274 AB - BACKGROUND: We aimed to evaluate the potential enhancing effect of celastrol on the stemness of human tendon-derived stem cells (hTSCs) in vitro and the underlying molecular mechanisms. METHODS: The capability of hTSC self-renewal was assessed by cell proliferation and colony formation as determined with the CCK-8 kit. Adipogenesis, chondrogenesis, and osteogenesis were determined by Oil Red O, Alcian Blue, and Alizarin Red staining, respectively. The relative mRNA levels of Sox9, PPARγ, Runx2, Smad7, and HIF1α were determined by real-time polymerase chain reaction (PCR). The levels of Smad7 and HIF1α protein were measured by immunoblotting. The chromatin immunoprecipitation (ChIP) assay was used to assess the direct binding of HIF1α to the Smad7 promoter. Suppression of Smad7 induced by hypoxia was examined using the luciferase reporter assay. RESULTS: We found that treatment with celastrol resulted in improvement in both the multi-differentiation potential and self-renewal capability of hTSCs. Celastrol elicited hypoxia and subsequently suppressed the expression of Smad7 through direct association with the hypoxia response element consensus sequence. Further, we demonstrated that both Smad7 and HIF1α were involved in the beneficial effects of celastrol on the differentiation and self-renewal of hTSCs. CONCLUSIONS: We demonstrated the positive effect of celastrol on the stemness of hTSCs and elucidated the essential role of the HIF1α-Smad7 pathway in this process. FAU - Wu, Tianyi AU - Wu T AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. FAU - Liu, Shenghe AU - Liu S AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. FAU - Wen, Gen AU - Wen G AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. FAU - Xu, Jia AU - Xu J AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. FAU - Yu, Yaling AU - Yu Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. FAU - Chai, Yimin AU - Chai Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200033, People's Republic of China. ymchai@sjtu.edu.cn. LA - eng PT - Journal Article DEP - 20171204 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (PPAR gamma) RN - 0 (Pentacyclic Triterpenes) RN - 0 (RUNX2 protein, human) RN - 0 (SMAD7 protein, human) RN - 0 (SOX9 Transcription Factor) RN - 0 (SOX9 protein, human) RN - 0 (Smad7 Protein) RN - 0 (Triterpenes) RN - L8GG98663L (celastrol) SB - IM MH - Adipogenesis/drug effects/genetics MH - Cell Differentiation/*drug effects MH - Cell Hypoxia/drug effects MH - Cell Proliferation/*drug effects MH - Chondrogenesis/drug effects/genetics MH - Core Binding Factor Alpha 1 Subunit/genetics/metabolism MH - Gene Expression Regulation MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*genetics/metabolism MH - Osteogenesis/drug effects/genetics MH - PPAR gamma/genetics/metabolism MH - Pentacyclic Triterpenes MH - Promoter Regions, Genetic MH - Protein Binding MH - Response Elements MH - SOX9 Transcription Factor/genetics/metabolism MH - Smad7 Protein/antagonists & inhibitors/*genetics/metabolism MH - Stem Cells/cytology/*drug effects/metabolism MH - Tendons/cytology/drug effects/metabolism MH - Triterpenes/*pharmacology PMC - PMC5715986 OTO - NOTNLM OT - Celastrol OT - Human tendon-derived stem cells OT - Hypoxia OT - Multi-differentiation OT - Smad7 COIS- AUTHORS’ INFORMATION: All authors are from Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. CONSENT FOR PUBLICATION: All authors have approved the publication of this paper. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2017/12/06 06:00 MHDA- 2018/07/22 06:00 PMCR- 2017/12/04 CRDT- 2017/12/06 06:00 PHST- 2017/09/14 00:00 [received] PHST- 2017/11/10 00:00 [accepted] PHST- 2017/10/29 00:00 [revised] PHST- 2017/12/06 06:00 [entrez] PHST- 2017/12/06 06:00 [pubmed] PHST- 2018/07/22 06:00 [medline] PHST- 2017/12/04 00:00 [pmc-release] AID - 10.1186/s13287-017-0724-x [pii] AID - 724 [pii] AID - 10.1186/s13287-017-0724-x [doi] PST - epublish SO - Stem Cell Res Ther. 2017 Dec 4;8(1):274. doi: 10.1186/s13287-017-0724-x. PMID- 26412512 OWN - NLM STAT- MEDLINE DCOM- 20160526 LR - 20181202 IS - 1532-2661 (Electronic) IS - 0034-5288 (Linking) VI - 102 DP - 2015 Oct TI - Epinephrine-enhanced computed tomographic arthrography of the canine shoulder. PG - 15-21 LID - S0034-5288(15)30002-3 [pii] LID - 10.1016/j.rvsc.2015.06.009 [doi] AB - The aim of this study was to investigate the effect of epinephrine-enhanced computed tomographic arthrography (CTA) on the image sharpness of the lateral and medial glenohumeral ligaments (LGHL and MGHL, respectively), biceps tendon (BT) and joint cartilage (JC) in the canine shoulder. The shoulders of eight normal dogs were examined using a 4-slice helical CT scanner. The right shoulders were injected with Iohexol and the left shoulders with a mixture of Iohexol and epinephrine. CTA images were obtained after 1, 3, 5, 9, 13, 20 and 30 min and the image sharpness of the intra-articular structures in both shoulders was graded for visibility. The attenuation values were measured to examine the persistence of contrast appearance. Admixture of epinephrine and Iohexol significantly improved the image sharpness of the LGHL and the BT, especially on delayed CTA images. The use of epinephrine did not negatively affect post-CTA recovery. CI - Copyright © 2015 Elsevier Ltd. All rights reserved. FAU - De Rycke, Lieve AU - De Rycke L AD - Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. Electronic address: lieve.de.rycke@skynet.be. FAU - van Bree, Henri AU - van Bree H AD - Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. FAU - Van Caelenberg, Annemie AU - Van Caelenberg A AD - Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. FAU - Polis, Ingeborgh AU - Polis I AD - Department of Medicine and Clinical Biology of Small Animals, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. FAU - Duchateau, Luc AU - Duchateau L AD - Department of Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. FAU - Gielen, Ingrid AU - Gielen I AD - Department of Veterinary Medical Imaging and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium. LA - eng PT - Journal Article DEP - 20150625 PL - England TA - Res Vet Sci JT - Research in veterinary science JID - 0401300 RN - 0 (Contrast Media) RN - 0 (Vasoconstrictor Agents) RN - 4419T9MX03 (Iohexol) RN - YKH834O4BH (Epinephrine) SB - IM MH - Animals MH - Arthrography/methods/*veterinary MH - Cartilage, Articular/diagnostic imaging MH - Contrast Media/administration & dosage/pharmacology MH - Dogs/*anatomy & histology MH - Epinephrine/administration & dosage/*pharmacology MH - Iohexol/administration & dosage/pharmacology MH - Shoulder/*diagnostic imaging MH - Shoulder Joint/*diagnostic imaging MH - Tendons MH - Tomography, X-Ray Computed/methods/*veterinary MH - Vasoconstrictor Agents/administration & dosage/pharmacology OTO - NOTNLM OT - Arthrography OT - Canine OT - Computed tomography OT - Epinephrine OT - Shoulder EDAT- 2015/09/29 06:00 MHDA- 2016/05/27 06:00 CRDT- 2015/09/29 06:00 PHST- 2014/01/08 00:00 [received] PHST- 2015/05/06 00:00 [revised] PHST- 2015/06/21 00:00 [accepted] PHST- 2015/09/29 06:00 [entrez] PHST- 2015/09/29 06:00 [pubmed] PHST- 2016/05/27 06:00 [medline] AID - S0034-5288(15)30002-3 [pii] AID - 10.1016/j.rvsc.2015.06.009 [doi] PST - ppublish SO - Res Vet Sci. 2015 Oct;102:15-21. doi: 10.1016/j.rvsc.2015.06.009. Epub 2015 Jun 25. PMID- 19428542 OWN - NLM STAT- MEDLINE DCOM- 20090804 LR - 20131121 IS - 1872-678X (Electronic) IS - 0165-0270 (Linking) VI - 179 IP - 2 DP - 2009 May 15 TI - The use of motion analysis to measure pain-related behaviour in a rat model of degenerative tendon injuries. PG - 309-18 LID - 10.1016/j.jneumeth.2009.02.011 [doi] AB - Chronic tendinopathy is characterized with longstanding activity-related pain with degenerative tendon injuries. An objective tool to measure painful responses in animal models is essential for the development of effective treatment for tendinopathy. Gait analysis has been developed to monitor the inflammatory pain in small animals. We reported the use of motion analysis to monitor gait changes in a rat model of degenerative tendon injury. Intratendinous injection of collagenase into the left patellar tendon of Sprague Dawley rat was used to induce degenerative tendon injury, while an equal volume of saline was injected in the control groups. Motion analyses with a high speed video camera were performed on all rats at pre-injury, 2, 4, 8, 12 or 16 weeks post injection. In the end-point study, the rats were sacrificed to obtain tendon samples for histological examination after motion analyses. In the follow-up study, repeated motion analyses were performed on another group of collagenase-treated and saline-treated rats. The results showed that rats with injured patellar tendon exhibited altered walking gait as compared to the controls. The change in double stance duration in the collagenase-treated rats was reversible by administration of buprenorphrine (p=0.029), it suggested that the detected gait changes were associated with pain. Comparisons of end-point and follow-up studies revealed the confounding effects of training, which led to higher gait velocities and probably a different adaptive response to tendon pain in the trained rats. The results showed that motion analysis could be used to measure activity-related chronic tendon pain. FAU - Fu, Sai-Chuen AU - Fu SC AD - Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. FAU - Chan, Kai-Ming AU - Chan KM FAU - Chan, Lai-Shan AU - Chan LS FAU - Fong, Daniel Tik-Pui AU - Fong DT FAU - Lui, Po-Yee Pauline AU - Lui PY LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090304 PL - Netherlands TA - J Neurosci Methods JT - Journal of neuroscience methods JID - 7905558 RN - 0 (Analgesics, Opioid) RN - 40D3SCR4GZ (Buprenorphine) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Analgesics, Opioid/pharmacology MH - Animals MH - Behavior, Animal/*physiology MH - Biomechanical Phenomena/physiology MH - Buprenorphine/pharmacology MH - Chronic Disease MH - Collagenases MH - Disease Models, Animal MH - Gait/physiology MH - Lameness, Animal/*diagnosis/etiology/physiopathology MH - Male MH - Pain/*diagnosis/etiology/physiopathology MH - Pain Measurement/*methods MH - Predictive Value of Tests MH - Rats MH - Rats, Sprague-Dawley MH - Sensitivity and Specificity MH - Tendon Injuries/chemically induced/*complications/physiopathology MH - Tendons/drug effects/innervation/physiopathology MH - Video Recording/*methods MH - Walking/physiology EDAT- 2009/05/12 09:00 MHDA- 2009/08/06 09:00 CRDT- 2009/05/12 09:00 PHST- 2008/12/03 00:00 [received] PHST- 2009/02/09 00:00 [revised] PHST- 2009/02/19 00:00 [accepted] PHST- 2009/05/12 09:00 [entrez] PHST- 2009/05/12 09:00 [pubmed] PHST- 2009/08/06 09:00 [medline] AID - S0165-0270(09)00113-7 [pii] AID - 10.1016/j.jneumeth.2009.02.011 [doi] PST - ppublish SO - J Neurosci Methods. 2009 May 15;179(2):309-18. doi: 10.1016/j.jneumeth.2009.02.011. Epub 2009 Mar 4. PMID- 36812821 OWN - NLM STAT- MEDLINE DCOM- 20230322 LR - 20230506 IS - 1879-1271 (Electronic) IS - 0268-0033 (Linking) VI - 103 DP - 2023 Mar TI - Improved suture pullout through genipin-coated sutures in human biceps tendons with spatially confined changes in cell viability. PG - 105907 LID - S0268-0033(23)00038-4 [pii] LID - 10.1016/j.clinbiomech.2023.105907 [doi] AB - BACKGROUND: The suture-tendon interface often constitutes the point of failure in tendon suture repair. In the present study, we investigated the mechanical benefit of coating the suture with a cross-linking agent to strengthen the nearby tissue after suture placement in human tendons and we assessed the biological implications regarding tendon cell survival in-vitro. METHODS: Freshly harvested human biceps long head tendons were randomly allocated to control (n = 17) or intervention (n = 19) group. According to the assigned group, either an untreated or a genipin-coated suture was inserted into the tendon. 24 h after suturing, mechanical testing composed of cyclic and ramp-to-failure loading was performed. Additionally, 11 freshly harvested tendons were used for short-term in vitro cell viability assessment in response to genipin-loaded suture placement. These specimens were analyzed in a paired-sample setting as stained histological sections using combined fluorescent/light microscopy. FINDINGS: Tendons stitched with a genipin-coated suture sustained higher forces to failure. Cyclic and ultimate displacement of the tendon-suture construct remained unaltered by the local tissue crosslinking. Tissue crosslinking resulted in significant cytotoxicity in the direct vicinity of the suture (<3 mm). At larger distances from the suture, however, no difference in cell viability between the test and the control group was discernable. INTERPRETATION: The repair strength of a tendon-suture construct can be augmented by loading the suture with genipin. At this mechanically relevant dosage, crosslinking-induced cell death is confined to a radius of <3 mm from the suture in the short-term in-vitro setting. These promising results warrant further examination in-vivo. CI - Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Götschi, Tobias AU - Götschi T AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Scheibler, Anne-Gita AU - Scheibler AG AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Jaeger, Patrick AU - Jaeger P AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Wieser, Karl AU - Wieser K AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland. FAU - Holenstein, Claude AU - Holenstein C AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Snedeker, Jess G AU - Snedeker JG AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Camenzind, Roland S AU - Camenzind RS AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland; Department of Orthopedic and Trauma Surgery, Cantonal Hospital Lucerne, Lucerne, Switzerland. Electronic address: roland.camenzind@luks.ch. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20230215 PL - England TA - Clin Biomech (Bristol) JT - Clinical biomechanics (Bristol, Avon) JID - 8611877 RN - A3V2NE52YG (genipin) RN - 0 (Iridoids) SB - IM MH - Humans MH - Biomechanical Phenomena MH - Cell Survival MH - Iridoids/metabolism/pharmacology MH - Suture Techniques MH - *Sutures MH - *Tendons/surgery MH - Tensile Strength OTO - NOTNLM OT - Cell viability OT - Collagen crosslinking OT - Mechanical testing OT - Soft tissue repair OT - Suture OT - Tendon COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/02/23 06:00 MHDA- 2023/03/15 06:00 CRDT- 2023/02/22 18:14 PHST- 2022/11/24 00:00 [received] PHST- 2023/02/10 00:00 [revised] PHST- 2023/02/13 00:00 [accepted] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/02/22 18:14 [entrez] AID - S0268-0033(23)00038-4 [pii] AID - 10.1016/j.clinbiomech.2023.105907 [doi] PST - ppublish SO - Clin Biomech (Bristol). 2023 Mar;103:105907. doi: 10.1016/j.clinbiomech.2023.105907. Epub 2023 Feb 15. PMID- 24474613 OWN - NLM STAT- MEDLINE DCOM- 20141023 LR - 20220317 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 134 IP - 4 DP - 2014 Apr TI - Timing matters: NSAIDs interfere with the late proliferation stage of a repaired rotator cuff tendon healing in rats. PG - 515-20 LID - 10.1007/s00402-014-1928-5 [doi] AB - INTRODUCTION: Rotator cuff (RC) tear is a common problem that causes pain and can limit shoulder function. Non-steroidal anti-inflammatory drugs (NSAIDs) are often prescribed for musculoskeletal pain, including the pain subsequent to RC repair. NSAIDs have been reported to affect bone metabolism and fracture healing(,) but there is little evidence about their effect on tendon healing. We investigated the effect of meloxicam (non-steroidal anti-inflammatory drug) on the healing of RC tendons when given immediately after surgical repair. MATERIALS AND METHODS: Thirty-nine rats underwent acute RC tear and repair. Group A (n = 13) received daily intraperitoneal (IP) injections of meloxicam for the first 10 postoperative days. Group B (n = 13) received IP injections of meloxicam starting from postoperative day 11. Group C (n = 13, controls) received daily IP injections of saline for 3 weeks. The animals were killed 3 weeks after surgery and the RC was evaluated by gross inspection, biomechanical testing and histological examination. RESULTS: Group B displayed a significantly lower mean maximal load at 3 weeks than group C (P = 0.02) and group A (P = 0.05). Stiffness was significantly lower in B group as compared to A group (P = 0.05). Qualitative examination of histology specimens did not disclose any apparent differences with respect to cellularity, vascularity, healing, and collagen orientation. CONCLUSIONS: We conclude that meloxicam decreases the biomechanical strength of repaired rat RCs when administered between 11 and 20 days after the repair. FAU - Chechik, Ofir AU - Chechik O AD - Shoulder Unit, Division of Orthopedic Surgery, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. FAU - Dolkart, Oleg AU - Dolkart O FAU - Mozes, Gavriel AU - Mozes G FAU - Rak, Ofer AU - Rak O FAU - Alhajajra, Fadi AU - Alhajajra F FAU - Maman, Eran AU - Maman E LA - eng PT - Journal Article DEP - 20140129 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Thiazines) RN - 0 (Thiazoles) RN - VG2QF83CGL (Meloxicam) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*adverse effects MH - Biomechanical Phenomena MH - Drug Administration Schedule MH - Male MH - Meloxicam MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Rotator Cuff/physiology/*surgery MH - Tendons/physiology/*surgery MH - Thiazines/*administration & dosage/*adverse effects MH - Thiazoles/*administration & dosage/*adverse effects MH - Wound Healing/*drug effects EDAT- 2014/01/30 06:00 MHDA- 2014/10/24 06:00 CRDT- 2014/01/30 06:00 PHST- 2013/06/26 00:00 [received] PHST- 2014/01/30 06:00 [entrez] PHST- 2014/01/30 06:00 [pubmed] PHST- 2014/10/24 06:00 [medline] AID - 10.1007/s00402-014-1928-5 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2014 Apr;134(4):515-20. doi: 10.1007/s00402-014-1928-5. Epub 2014 Jan 29. PMID- 40306310 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250702 IS - 1536-3678 (Electronic) IS - 1077-4114 (Linking) VI - 47 IP - 5 DP - 2025 Jul 1 TI - Hyperbaric Oxygen Therapy in Doxorubicin Extravasation: A Promising Future Treatment?: A Case Report. PG - e177-e180 LID - 10.1097/MPH.0000000000003038 [doi] AB - Doxorubicin extravasation is a serious complication that can lead to severe local necrosis, aesthetic damage, and injury to underlying nerves, tendons, and muscles. Its management has been the subject of numerous studies, but the optimal treatment remains controversial. The limited access to dexrazoxane makes the management even more challenging. We report the case of a 17-month-old infant treated for an alveolar rhabdomyosarcoma of the soft tissues in the gluteal region, who experienced doxorubicin extravasation in the forearm. This incident was successfully managed with initial fasciotomy followed by hyperbaric oxygen therapy. We highlight the beneficial effects of hyperbaric oxygen therapy as a complementary treatment in cases of doxorubicin extravasation, supported by current data from the literature. CI - Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved. FAU - Belcadi, Khadija AU - Belcadi K AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - Isfaoun, Zineb AU - Isfaoun Z AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - El Ansari, Naoual AU - El Ansari N AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - Lakhrissi, Meryem AU - Lakhrissi M AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - Fejjal, Naoufal AU - Fejjal N AD - Surgery Department C, Children's Hospital of Rabat. FAU - El Kababri, Maria AU - El Kababri M AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - El Khorassani, Mohamed AU - El Khorassani M AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - Hessissen, Laila AU - Hessissen L AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. FAU - Kili, Amina AU - Kili A AD - Department of pediatric Hematology and Oncology, Children's Hospital of Rabat, Mohamed V University, Rabat, Morocco. LA - eng GR - nn/no/ PT - Case Reports PT - Journal Article DEP - 20250429 PL - United States TA - J Pediatr Hematol Oncol JT - Journal of pediatric hematology/oncology JID - 9505928 RN - 0 (Antibiotics, Antineoplastic) RN - 80168379AG (Doxorubicin) SB - IM MH - Humans MH - Infant MH - *Antibiotics, Antineoplastic/adverse effects MH - *Doxorubicin/adverse effects/administration & dosage MH - *Extravasation of Diagnostic and Therapeutic Materials/therapy MH - *Hyperbaric Oxygenation/methods MH - *Rhabdomyosarcoma, Alveolar/drug therapy/pathology OTO - NOTNLM OT - dexrazoxane OT - doxorubicin OT - extravasation OT - hyperbaric oxygen therapy COIS- The authors declare no conflict of interest. EDAT- 2025/05/01 00:27 MHDA- 2025/06/24 11:10 CRDT- 2025/04/30 19:03 PHST- 2024/10/16 00:00 [received] PHST- 2025/03/26 00:00 [accepted] PHST- 2025/06/24 11:10 [medline] PHST- 2025/05/01 00:27 [pubmed] PHST- 2025/04/30 19:03 [entrez] AID - 00043426-990000000-00573 [pii] AID - 10.1097/MPH.0000000000003038 [doi] PST - ppublish SO - J Pediatr Hematol Oncol. 2025 Jul 1;47(5):e177-e180. doi: 10.1097/MPH.0000000000003038. Epub 2025 Apr 29. PMID- 9565233 OWN - NLM STAT- MEDLINE DCOM- 19980618 LR - 20200313 IS - 0032-5791 (Print) IS - 0032-5791 (Linking) VI - 77 IP - 4 DP - 1998 Apr TI - Effects of roxarsone and monensin on digital flexoral tendons of broiler chickens. PG - 523-8 AB - Roxarsone and monensin are common poultry feed additives that are used alone or in combination with other drugs to improve growth and feed utilization in young birds. The effects of monensin and roxarsone on the physiology of flexoral tendons of broiler chickens were examined to understand their relationships to leg weakness that have been occasionally associated with these drugs. Day-old chickens were fed either roxarsone or monensin for a period of 6 wk with two regimens of each of the drugs (roxarsone, 45.4 or 90.8 g/ton feed; monensin, 100 or 150 g/ton feed). None of the treatments had any adverse effect on the growth of the birds or caused any significant leg problem. Roxarsone at 45.4 g/ton caused a significant gain in body weight. The biomechanical strength of digital flexoral tendons was measured in several ways. There were no statistical differences in load at break, the modulus of elasticity, or stress or strain levels between different treatment groups and birds that received no medication. There were no differences in collagen, proteoglycan, and pyridinoline content of tendons. Sequential extraction of tendons with different solvents revealed a significant increase in the percentage of guanidine HCl extractible collagens in monensin-treated birds, and a decrease in the acid extractible collagen in both roxarsone- and monensin-treated groups. The relative content of collagen in acid extractible collagens were significantly small relative to total collagen content. Majority of collagen (84 to 90%) was extractible with pepsin. About 8 to 11% of total collagen was resistant to pepsin that was extractible with collagenase; this did not differ between treatment groups. Roxarsone treatment had no effect on the guanidine soluble collagen pool. The effect of monensin on the increase in guanidine soluble pool of collagen may relate to its disruptive effects on cellular secretory processes, which may be of significance in modulating connective tissue function in conjunction with other factors. However, in the present study, neither roxarsone nor monensin alone produced any significant leg problems nor caused any significant differences in the physiology of flexoral tendons or altered their biomechanical properties. FAU - Rath, N C AU - Rath NC AD - USDA, Agricultural Research Service, University of Arkansas, Fayetteville 72701, USA. nrath@comp.uark.edu FAU - Chapman, H D AU - Chapman HD FAU - Fitz-Coy, S H AU - Fitz-Coy SH FAU - Balog, J M AU - Balog JM FAU - Huff, G R AU - Huff GR FAU - Huff, W E AU - Huff WE LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Poult Sci JT - Poultry science JID - 0401150 RN - 0 (Amino Acids) RN - 0 (Anti-Bacterial Agents) RN - 0 (Coccidiostats) RN - 0 (Food Additives) RN - 0 (Glycosaminoglycans) RN - 63800-01-1 (pyridinoline) RN - 9007-34-5 (Collagen) RN - 906O0YJ6ZP (Monensin) RN - H5GU9YQL7L (Roxarsone) SB - IM MH - Amino Acids/analysis/drug effects MH - Animal Feed MH - Animals MH - Anti-Bacterial Agents/administration & dosage/*toxicity MH - Biomechanical Phenomena MH - Body Weight/drug effects/physiology MH - Chickens/*physiology MH - Coccidiostats/administration & dosage/*toxicity MH - Cohort Studies MH - Collagen/analysis/drug effects MH - Dose-Response Relationship, Drug MH - Food Additives/toxicity MH - Glycosaminoglycans/analysis MH - Male MH - Monensin/administration & dosage/*toxicity MH - Roxarsone/administration & dosage/*toxicity MH - Tendons/chemistry/*drug effects/physiology EDAT- 1998/06/20 00:00 MHDA- 1998/06/20 00:01 CRDT- 1998/06/20 00:00 PHST- 1998/06/20 00:00 [pubmed] PHST- 1998/06/20 00:01 [medline] PHST- 1998/06/20 00:00 [entrez] AID - S0032-5791(19)40842-0 [pii] AID - 10.1093/ps/77.4.523 [doi] PST - ppublish SO - Poult Sci. 1998 Apr;77(4):523-8. doi: 10.1093/ps/77.4.523. PMID- 14634028 OWN - NLM STAT- MEDLINE DCOM- 20041214 LR - 20131121 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 96 IP - 5 DP - 2004 May TI - Neuromuscular rehabilitation by treadmill running or electrical stimulation after peripheral nerve injury and repair. PG - 1988-95 AB - Numerous studies have been devoted to the regeneration of the motor pathway toward a denervated muscle after nerve injury. However, the regeneration of sensory muscle endings after repair by self-anastomosis are little studied. In previous electrophysiological studies, our laboratory showed that the functional characteristics of tibialis anterior muscle afferents are differentially affected after injury and repair of the peroneal nerve with and without chronic electrostimulation. The present study focuses on the axonal regeneration of mechano- (fibers I and II) and metabosensitive (fibers III and IV) muscle afferents by evaluating the recovery of their response to different test agents after nerve injury and repair by self-anastomosis during 10 wk of treadmill running (LSR). Data were compared with control animals (C), animals with nerve lesion and suture (LS), and animals with lesion, suture, and chronic muscle rehabilitation by electrostimulation (LSE) with a biphasic current modulated in pulse duration and frequency, eliciting a pattern mimicking the activity delivered by the nerve to the muscle. Compared with the C group, results indicated that 1) muscle weight was smaller in LS and LSR groups, 2) the fatigue index was greater in the LS group and smaller in the LSE group, 3) metabosensibility remained altered in the LS and LSE groups, and 4) mechanosensitivity presented a large increase of the activation pattern in the LS and LSE groups. Our data indicated that chronic muscle electrostimulation partially favors the recovery of muscle properties (i.e., muscle weight and twitch response were close to the C group) and that rehabilitation by treadmill running also efficiently induced a better functional muscle afferent recovery (i.e., the discharge pattern was similar to the C group). The effectiveness of the chronic electromyostimulation and the treadmill exercise on afferent recovery is discussed with regard to parameters listed above. FAU - Marqueste, Tanguy AU - Marqueste T AD - Laboratoire des Déterminants Physiologiques de l'Activité Physique, Institut Fédératif de Recherches Etienne-Jules MAREY, Faculté des Sciences du Sport de Marseille-Luminy, Université de la Méditerranée, 13288 Marseille Cedex 09, France. FAU - Alliez, Jean-Roch AU - Alliez JR FAU - Alluin, Olivier AU - Alluin O FAU - Jammes, Yves AU - Jammes Y FAU - Decherchi, Patrick AU - Decherchi P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20031121 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 33X04XA5AT (Lactic Acid) RN - 660YQ98I10 (Potassium Chloride) SB - IM MH - Action Potentials MH - Animals MH - Axons MH - Electric Stimulation MH - Female MH - Injections MH - Lactic Acid/administration & dosage/pharmacology MH - *Motor Activity MH - Muscle Contraction MH - Muscle Fatigue MH - Muscle, Skeletal/innervation/pathology/physiopathology MH - Nerve Regeneration MH - Neuromuscular Junction/*physiopathology MH - Neurons, Afferent MH - Organ Size MH - *Peripheral Nerve Injuries MH - Potassium Chloride/administration & dosage/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/physiopathology MH - Vibration MH - *Wound Healing MH - Wounds and Injuries/physiopathology EDAT- 2003/11/25 05:00 MHDA- 2004/12/16 09:00 CRDT- 2003/11/25 05:00 PHST- 2003/11/25 05:00 [pubmed] PHST- 2004/12/16 09:00 [medline] PHST- 2003/11/25 05:00 [entrez] AID - 00775.2003 [pii] AID - 10.1152/japplphysiol.00775.2003 [doi] PST - ppublish SO - J Appl Physiol (1985). 2004 May;96(5):1988-95. doi: 10.1152/japplphysiol.00775.2003. Epub 2003 Nov 21. PMID- 31264048 OWN - NLM STAT- MEDLINE DCOM- 20200110 LR - 20200309 IS - 1613-2254 (Electronic) IS - 1346-4523 (Linking) VI - 46 IP - 4 DP - 2019 Oct TI - Ultrasound-guided injection and the pie crust technique for the treatment of symptomatic bipartite patella. PG - 497-502 LID - 10.1007/s10396-019-00960-4 [doi] AB - PURPOSE: This study aimed to investigate the results of a new treatment procedure (ultrasound-guided injection and the "pie crust" technique for lengthening of capsular tendon structures) for symptomatic bipartite patella. METHODS: We retrospectively investigated patient outcomes following the treatment of symptomatic type III bipartite patella with our new technique. Fifteen knees in 14 boys (mean age, 13.0 ± 1.7 years) were included. The procedure involved the injection of 1% lidocaine (2 mL) and triamcinolone acetonide (5 mg) between the patella and fragment. We then punctured 10 sites from one skin puncture to extend lateral capsular tendon structures. The patients were clinically assessed using the Victorian Institute of Sports Assessment (VISA) score before and 1 week, 1 month, and 3 months after the procedure. Patients were also evaluated for complications. RESULTS: The average VISA score was 45.7 ± 4.7 before treatment, 70.6 ± 7.3 at 1 week post-treatment, 84.4 ± 16.6 at 1 month post-treatment, and 88.6 ± 18.3 at 3 months post-treatment. The VISA score improvement from before the procedure to 1 week after the procedure was significant (P < 0.01). There were no complications in any of the patients, who returned to sports at a mean of 4.2 ± 2.1 weeks after the procedure. However, two patients (three knees) had poor results and could not return to action; thus, they underwent surgical treatment 4 months after the ultrasonographic procedure. CONCLUSIONS: This novel method is a potential treatment option for the management of symptomatic bipartite patella in outpatient clinics. FAU - Nakase, Junsuke AU - Nakase J AUID- ORCID: 0000-0002-9286-5276 AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. nakase1007@yahoo.co.jp. FAU - Oshima, Takeshi AU - Oshima T AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. FAU - Takata, Yasushi AU - Takata Y AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. FAU - Shimozaki, Kengo AU - Shimozaki K AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. FAU - Asai, Kazuki AU - Asai K AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. FAU - Toyooka, Kazu AU - Toyooka K AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. FAU - Tsuchiya, Hiroyuki AU - Tsuchiya H AD - Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan. LA - eng PT - Journal Article DEP - 20190701 PL - Japan TA - J Med Ultrason (2001) JT - Journal of medical ultrasonics (2001) JID - 101128385 RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Adolescent MH - Anesthetics, Local/administration & dosage MH - Anti-Inflammatory Agents/administration & dosage MH - Follow-Up Studies MH - Humans MH - Lidocaine/administration & dosage MH - Male MH - Patella/*abnormalities/diagnostic imaging/*surgery MH - Punctures MH - Retrospective Studies MH - Tendons/*diagnostic imaging/*surgery MH - Treatment Outcome MH - Triamcinolone Acetonide/administration & dosage MH - Ultrasonography, Interventional/*methods OTO - NOTNLM OT - Bipartite patella OT - Pie crust technique OT - Ultrasound-guided injection EDAT- 2019/07/03 06:00 MHDA- 2020/01/11 06:00 CRDT- 2019/07/03 06:00 PHST- 2019/04/10 00:00 [received] PHST- 2019/06/07 00:00 [accepted] PHST- 2019/07/03 06:00 [pubmed] PHST- 2020/01/11 06:00 [medline] PHST- 2019/07/03 06:00 [entrez] AID - 10.1007/s10396-019-00960-4 [pii] AID - 10.1007/s10396-019-00960-4 [doi] PST - ppublish SO - J Med Ultrason (2001). 2019 Oct;46(4):497-502. doi: 10.1007/s10396-019-00960-4. Epub 2019 Jul 1. PMID- 34097540 OWN - NLM STAT- MEDLINE DCOM- 20230929 LR - 20230929 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 49 IP - 9 DP - 2021 Jul TI - Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model: A Pilot Study. PG - 2522-2527 LID - 10.1177/03635465211016840 [doi] AB - BACKGROUND: The use of cannabis is common among athletes and the US population at large. Cannabinoids are currently being evaluated as alternatives to opioid medications for chronic pain management. However, the effects of recreational and/or medical use of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on musculoskeletal injury and healing remain largely unknown. HYPOTHESIS/PURPOSE: The purpose of this study was to evaluate the biomechanical effects of CBD and THC on tendon-to-tendon healing in a rat Achilles tendon repair model. The hypothesis was that rats administered CBD would demonstrate decreased tensile load to failure of surgically repaired Achilles tendons compared with the THC and control groups. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 33 Sprague Dawley rats underwent Achilles tendon surgical transection and repair and were randomized to receive subcutaneous injection of THC, CBD, or vehicle once daily starting on the day of surgery and for 5 total days. After sacrifice, biomechanical tensile load-displacement testing was performed to determine Achilles tendon load to failure and stiffness. Data were analyzed by 1-way analysis of variance. RESULTS: The THC group demonstrated the highest median load to failure, 18.7 N (95% CI, 15.3-19.2 N); the CBD group had the second highest at 16.9 N (95% CI, 15.1-19.8 N), and the control group had the lowest at 14.4 N (95% CI, 12.1-18.3 N). Stiffness was highest in the THC group at 4.1 N/mm (95% CI, 2.7-5.1 N/mm) compared with 3.6 N/mm (95% CI, 2.9-4.1 N/mm) for the CBD group and 3.6 N/mm (95% CI, 2.8-4.3 N/mm) for the control group. No statistically significant differences for strength and stiffness were observed between the groups. CONCLUSION: In this pilot study using an animal tendon-to-tendon repair model, neither THC nor CBD resulted in altered biomechanical characteristics compared to control. CLINICAL RELEVANCE: Cannabinoids do not appear to adversely affect Achilles tendon healing. FAU - Stauch, Christopher M AU - Stauch CM AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Ammerman, Brittany AU - Ammerman B AD - Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Sepulveda, Diana AU - Sepulveda D AD - Department of Anesthesia and Perioperative Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Aynardi, Michael C AU - Aynardi MC AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Garner, Matthew R AU - Garner MR AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Lewis, Gregory AU - Lewis G AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Morgan, Daniel AU - Morgan D AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Dhawan, Aman AU - Dhawan A AD - Department of Orthopedics and Rehabilitation, Center for Orthopedic Research and Translational Sciences (CORTS), Penn State Hershey Medical Center, Hershey, Pennsylvania, USA. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20210607 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 19GBJ60SN5 (Cannabidiol) RN - 7J8897W37S (Dronabinol) SB - IM MH - Animals MH - Rats MH - *Achilles Tendon/surgery MH - *Cannabidiol/pharmacology MH - *Cannabis MH - Dronabinol/pharmacology MH - Pilot Projects MH - Rats, Sprague-Dawley OTO - NOTNLM OT - biological healing enhancement OT - biomechanics OT - cannabis OT - rat OT - tendon EDAT- 2021/06/08 06:00 MHDA- 2021/08/10 06:00 CRDT- 2021/06/07 17:13 PHST- 2021/06/08 06:00 [pubmed] PHST- 2021/08/10 06:00 [medline] PHST- 2021/06/07 17:13 [entrez] AID - 10.1177/03635465211016840 [doi] PST - ppublish SO - Am J Sports Med. 2021 Jul;49(9):2522-2527. doi: 10.1177/03635465211016840. Epub 2021 Jun 7. PMID- 3082875 OWN - NLM STAT- MEDLINE DCOM- 19860514 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 261 IP - 11 DP - 1986 Apr 15 TI - Tyrosine sulfation in precursors of collagen V. PG - 5034-40 AB - Radioactive labeling of p-collagens V, collagens V, and, to a small extent, of procollagen V occurred when [35S]sulfate was incubated with tendons or primary tendon cell cultures, or blood vessels and crops of 17- to 19-day-old chick embryos, or with lung slices from neonatal rats. Most or all of this label is in the form of 1 or more sulfated tyrosine residues/chain of p alpha 1(V), alpha 1(V), p alpha 1'(V), alpha 1'(V), p alpha 2(V), and alpha 2(V), and it remains attached through purification by dialysis, ammonium sulfate precipitation, CsCl-GdnCl2 equilibrium buoyant density and velocity sedimentations, ion-exchange chromatography, and sodium dodecyl sulfate gel electrophoresis. Radioactive tyrosine sulfate was identified in alkaline hydrolysates of these collagen V chains, after labeling the tissues with either [35S]sulfate or [3H]tyrosine, by electrophoretic and chromatographic comigration with a tyrosine sulfate standard. Tunicamycin A1, which inhibits the attachment of N-linked complex carbohydrate, did not interfere with the sulfation process. The tyrosine sulfate is located in a noncollagenous domain, which is probably adjacent to the amino end of the collagen helix, and is retained throughout the physiological proteolytic processing of procollagens V. After digestion with Staphylococcus aureus V8 protease, 35S-labeled p alpha 1(V) and alpha 1(V) chains gave the same map of labeled peptides, and this differed from the map given by p alpha 1'(V) and alpha 1'(V) chains. Little sulfation of p alpha 2(V) and alpha 2(V) chains occurs. The implications of these observations for the structure and properties of procollagens V and their derivatives are considered. FAU - Fessler, L I AU - Fessler LI FAU - Brosh, S AU - Brosh S FAU - Chapin, S AU - Chapin S FAU - Fessler, J H AU - Fessler JH LA - eng GR - AG02128/AG/NIA NIH HHS/United States GR - AM13748/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Peptide Fragments) RN - 0 (Procollagen) RN - 0 (Sulfates) RN - 0 (Sulfur Radioisotopes) RN - 04079A1RDZ (Cytarabine) RN - 42HK56048U (Tyrosine) RN - 5J49Q6B70F (Vincristine) RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.21.- (Serine Endopeptidases) RN - EC 3.4.21.19 (glutamyl endopeptidase) RN - EC 3.4.23.1 (Pepsin A) RN - ZS7284E0ZP (Daunorubicin) RN - CROP protocol SB - IM MH - Animals MH - *Antineoplastic Combined Chemotherapy Protocols MH - Blood Vessels/metabolism MH - Centrifugation, Density Gradient MH - Chemical Precipitation MH - Chick Embryo MH - Chromatography, DEAE-Cellulose MH - Collagen/*metabolism MH - Cytarabine/metabolism MH - Daunorubicin/metabolism MH - Electrophoresis, Polyacrylamide Gel MH - Endopeptidases/metabolism MH - Lung/metabolism MH - Pepsin A/metabolism MH - Peptide Fragments/metabolism MH - Prednisolone/metabolism MH - Procollagen/*metabolism MH - Rats MH - *Serine Endopeptidases MH - Sulfates/*metabolism MH - Sulfur Radioisotopes MH - Tendons/metabolism MH - Tyrosine/*metabolism MH - Vincristine/metabolism EDAT- 1986/04/15 00:00 MHDA- 1986/04/15 00:01 CRDT- 1986/04/15 00:00 PHST- 1986/04/15 00:00 [pubmed] PHST- 1986/04/15 00:01 [medline] PHST- 1986/04/15 00:00 [entrez] AID - S0021-9258(19)89211-6 [pii] PST - ppublish SO - J Biol Chem. 1986 Apr 15;261(11):5034-40. PMID- 31557405 OWN - NLM STAT- MEDLINE DCOM- 20200910 LR - 20210110 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 23 IP - 11 DP - 2019 Nov TI - Aspirin inhibits adipogenesis of tendon stem cells and lipids accumulation in rat injury tendon through regulating PTEN/PI3K/AKT signalling. PG - 7535-7544 LID - 10.1111/jcmm.14622 [doi] AB - Tendon injury repairs are big challenges in sports medicine, and fatty infiltration after tendon injury is very common and hampers tendon injury healing process. Tendon stem cells (TSCs), as precursors of tendon cells, have shown promising effect on injury tendon repair for their tenogenesis and tendon extracellular matrix formation. Adipocytes and lipids accumulation is a landmark event in pathological process of tendon injury, and this may induce tendon rupture in clinical practice. Based on this, it is important to inhibit TSCs adipogenesis and lipids infiltration to restore structure and function of injury tendon. Aspirin, as the representative of non-steroidal anti-inflammatory drugs (NSAIDs), has been widely used in tendon injury for its anti-inflammatory and analgesic actions, but effect of aspirin on TSCs adipogenesis and fatty infiltration is still unclear. Under adipogenesis conditions, TSCs were treated with concentration gradient of aspirin. Oil red O staining was performed to observe changes of lipids accumulation. Next, we used RNA sequencing to compare profile changes of gene expression between induction group and aspirin-treated group. Then, we verified the effect of filtrated signalling on TSCs adipogenesis. At last, we established rat tendon injury model and compared changes of biomechanical properties after aspirin treatment. The results showed that aspirin decreased lipids accumulation in injury tendon and inhibited TSCs adipogenesis. RNA sequencing filtrated PTEN/PI3K/AKT signalling as our target. After adding the signalling activators of VO-Ohpic and IGF-1, inhibited adipogenesis of TSCs was reversed. Still, aspirin promoted maximum loading, ultimate stress and breaking elongation of injury tendon. In conclusion, by down-regulating PTEN/PI3K/AKT signalling, aspirin inhibited adipogenesis of TSCs and fatty infiltration in injury tendon, promoted biomechanical properties and decreased rupture risk of injury tendon. All these provided new therapeutic potential and medicine evidence of aspirin in treating tendon injury and tendinopathy. CI - © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Wang, Yunjiao AU - Wang Y AUID- ORCID: 0000-0003-1108-7079 AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - He, Gang AU - He G AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Wang, Feng AU - Wang F AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhang, Chenke AU - Zhang C AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Ge, Zilu AU - Ge Z AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zheng, Xiaolong AU - Zheng X AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Deng, Honghao AU - Deng H AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Yuan, Chengsong AU - Yuan C AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhou, Binghua AU - Zhou B AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Tao, Xu AU - Tao X AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. FAU - Zhang, Jiqiang AU - Zhang J AD - Department of Neurology, Third Military Medical University, Chongqing, China. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopaedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190926 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Lipids) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - EC 3.1.3.67 (Pten protein, rat) RN - R16CO5Y76E (Aspirin) SB - IM MH - Adipocytes/drug effects/metabolism MH - Adipogenesis/*drug effects MH - Animals MH - Aspirin/*pharmacology MH - Cell Differentiation/drug effects MH - Cells, Cultured MH - Insulin-Like Growth Factor I/metabolism MH - Lipids MH - PTEN Phosphohydrolase/*metabolism MH - Phosphatidylinositol 3-Kinases/*metabolism MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Rats MH - Signal Transduction/drug effects MH - Stem Cells/*drug effects/metabolism MH - Tendon Injuries/*drug therapy/metabolism MH - Tendons/drug effects/metabolism PMC - PMC6815914 OTO - NOTNLM OT - adipogenesis OT - aspirin OT - tendinopathy OT - tendon stem cells COIS- The authors declare that there are no any conflicts of competing financial interests with the contents of this article. EDAT- 2019/09/27 06:00 MHDA- 2020/09/12 06:00 PMCR- 2019/11/01 CRDT- 2019/09/27 06:00 PHST- 2019/06/18 00:00 [received] PHST- 2019/07/16 00:00 [revised] PHST- 2019/08/04 00:00 [accepted] PHST- 2019/09/27 06:00 [pubmed] PHST- 2020/09/12 06:00 [medline] PHST- 2019/09/27 06:00 [entrez] PHST- 2019/11/01 00:00 [pmc-release] AID - JCMM14622 [pii] AID - 10.1111/jcmm.14622 [doi] PST - ppublish SO - J Cell Mol Med. 2019 Nov;23(11):7535-7544. doi: 10.1111/jcmm.14622. Epub 2019 Sep 26. PMID- 23709244 OWN - NLM STAT- MEDLINE DCOM- 20140916 LR - 20250214 IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 73 IP - 8 DP - 2014 Aug TI - Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? PG - 1522-8 LID - 10.1136/annrheumdis-2013-203487 [doi] AB - OBJECTIVE: The primary objective of this prospective case-control study was to assess the diagnostic value of several intra-articular and periarticular ultrasound (US)-detected abnormalities in the upper and lower limbs in gout. The secondary objective was to test the concurrent validity of US abnormalities using as gold standard the microscopic demonstration of monosodium urate (MSU) crystals. METHODS: Ninety-one men with gout and 42 age-matched controls were prospectively recruited. All patients with gout and controls underwent US assessment of several US abnormalities in 26 joints, six bursae, eight tendons, 20 tendon compartments, four ligaments, and 18 articular cartilages by experts in US blinded to the patients' group. Patients with gout and controls with US abnormalities were asked to undergo US-guided aspiration for microscopic identification of MSU crystals. Interobserver and intraobserver reliability of the US assessment was evaluated in a web-based exercise. RESULTS: The assessment of one joint (ie, radiocarpal joint) for hyperechoic aggregates (HAGs), two tendons (ie, patellar tendon and triceps tendon) for HAGs and three articular cartilages (ie, first metatarsal, talar and second metacarpal/femoral) for double contour sign showed the best balance between sensitivity and specificity (84.6% and 83.3%, respectively). Intraobserver reliability was good (mean κ 0.75) and interobserver reliability was moderate (κ 0.52). The aspirated material from HAGs was positive for MSU crystals in 77.6% of patients with gout and negative in all controls. CONCLUSIONS: Our results suggest that US bilateral assessment of one joint, three articular cartilages and two tendons may be valid for diagnosing gout with acceptable sensitivity and specificity. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. FAU - Naredo, Esperanza AU - Naredo E AD - Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Complutense University, Madrid, Spain Department of Rheumatology, Hospìtal Universitario Severo Ochoa, Madrid, Spain. FAU - Uson, Jacqueline AU - Uson J AD - Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain. FAU - Jiménez-Palop, Mercedes AU - Jiménez-Palop M AD - Department of Rheumatology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Martínez, Agustín AU - Martínez A AD - Department of Rheumatology, Hospital Universitario de Alicante, Alicante, Spain. FAU - Vicente, Esther AU - Vicente E AD - Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain. FAU - Brito, Elia AU - Brito E AD - Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain. FAU - Rodríguez, Ana AU - Rodríguez A AD - Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain. FAU - Cornejo, Francisco Javier AU - Cornejo FJ AD - C.S. Mendiguchia Carriche, Leganés, Madrid. FAU - Castañeda, Santos AU - Castañeda S AD - Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain. FAU - Martínez, María Jesús AU - Martínez MJ AD - Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain. FAU - Sanz, Jesús AU - Sanz J AD - Department of Rheumatology, Hospital Puerta de Hierro, Madrid, Spain. FAU - Möller, Ingrid AU - Möller I AD - Department of Rheumatology, Instituto Poal, Barcelona, Spain. FAU - Batlle-Gualda, Enrique AU - Batlle-Gualda E AD - Department of Rheumatology, Hospital Clínico de San Juan, Alicante, Spain. FAU - Garrido, Jesús AU - Garrido J AD - Department of Social Psychology and Methodology, Faculty of Psychology, Autonoma University, Madrid, Spain. FAU - Pascual, Eliseo AU - Pascual E AD - Department of Rheumatology, Hospital Universitario de Alicante, Alicante, Spain. LA - eng PT - Clinical Trial PT - Journal Article PT - Validation Study DEP - 20130524 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Cartilage, Articular/diagnostic imaging/metabolism MH - Case-Control Studies MH - Crystallization MH - Female MH - Gout/complications/*diagnostic imaging/metabolism MH - Humans MH - Joints/diagnostic imaging/metabolism MH - Male MH - Metacarpal Bones/diagnostic imaging/metabolism MH - Metatarsal Bones/diagnostic imaging/metabolism MH - Middle Aged MH - Musculoskeletal Diseases/*diagnostic imaging/etiology/metabolism MH - Observer Variation MH - Prospective Studies MH - Reference Standards MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Tendons/diagnostic imaging/metabolism MH - Ultrasonography/methods/*standards/statistics & numerical data MH - Uric Acid/chemistry/*metabolism OTO - NOTNLM OT - Arthritis OT - Gout OT - Ultrasonography EDAT- 2013/05/28 06:00 MHDA- 2014/09/17 06:00 CRDT- 2013/05/28 06:00 PHST- 2013/05/28 06:00 [entrez] PHST- 2013/05/28 06:00 [pubmed] PHST- 2014/09/17 06:00 [medline] AID - S0003-4967(24)09924-2 [pii] AID - 10.1136/annrheumdis-2013-203487 [doi] PST - ppublish SO - Ann Rheum Dis. 2014 Aug;73(8):1522-8. doi: 10.1136/annrheumdis-2013-203487. Epub 2013 May 24. PMID- 26952552 OWN - NLM STAT- MEDLINE DCOM- 20170105 LR - 20170106 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 184 DP - 2016 May 26 TI - Structure, cytotoxic activity and mechanism of protoilludane sesquiterpene aryl esters from the mycelium of Armillaria mellea. PG - 119-27 LID - S0378-8741(16)30088-5 [pii] LID - 10.1016/j.jep.2016.02.044 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Armillaria mellea (Vahl. ex. Fr.) Karst is an important traditional Chinese medicine used in dispelling wind and removing obstruction in the meridians, and strengthening tendons and bones. Armillaria mellea has been recorded in the book Caobenshiyi which was written by ancestor for the function of suppressing hyderactive liver for calming endogenous wind medicine. The aim of this study is to investigate the cytotoxic activity for liver cell lines (normal and cancerous) of protoilludane sesquiterpene aryl esters from the mycelium of A. mellea. MATERIALS AND METHODS: A systemic fractionation of the mycelium extracts of A. mellea and relative activity mechanisms were studied. RESULTS: Two new protoilludane sesquiterpene aryl esters named 5'-methoxy-armillasin (1) and 5-hydroxyl-armillarivin (2) were isolated. In addition, eight known protoilludane sesquiterpene aryl esters armillaridin (3), armillartin (4), armillarin (5), melleolide B (6), armillarilin (7), armillasin (8), armillarigin (9) and melleolide (10) were also isolated from the mycelium of A. mellea. The relative configurations of the two new compounds were confirmed by NOESY spectra. Among ten protoilludane sesquiterpene aryl esters, compounds 2, 3, 4, 7, 8, 9 and 10 were active constituents with highly cytotoxic activity against HepG2 cells (4.95-37.65μg/mL). We reported here for the time, that compound 10 (melleolide) showed anti-tumor ability on hepatoma cell. The relative mechanism was assessed on HepG2 cells. CONCLUSIONS: Among all the ten protoilludane sesquiterpene aryl esters, melleolide (10) showed the best cytotoxic activity for HepG2 cells (4.95μg/mL) and lower activity for L02 cells (16.05μg/mL). Mechanism study showed that melleolide decreased the viability of the cancer cells with varying levels of cleaved-caspase 3, caspase 8, caspase 9, Bax and Ki67 expression. On the other hand, melleolide induced HepG2 cell cycle arrest at the G2/M phase. CI - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. FAU - Li, Zhijin AU - Li Z AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Wang, Yunchao AU - Wang Y AD - Shijiazhuang No.4 Pharmaceutical Co., ltd, Shijiazhuang 050000, China. FAU - Jiang, Bin AU - Jiang B AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Li, Wenliang AU - Li W AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China; School of Pharmaceutical Science, Jilin Medical University, Jilin 132013, China. Electronic address: liwl100@nenu.edu.cn. FAU - Zheng, Lihua AU - Zheng L AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Yang, Xiaoguang AU - Yang X AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Bao, Yongli AU - Bao Y AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Sun, Luguo AU - Sun L AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Huang, Yanxin AU - Huang Y AD - National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University, Changchun 130024, China. FAU - Li, Yuxin AU - Li Y AD - Jilin Province Key Laboratory on Chemistry and Biology of Natural Drugs in Changbai Mountain, School of life Sciences, Northeast Normal University, Changchun 130024, China. Electronic address: yxli486@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160304 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Antineoplastic Agents) RN - 0 (Esters) RN - 0 (Sesquiterpenes) SB - IM MH - Antineoplastic Agents/chemistry/isolation & purification/*pharmacology MH - Apoptosis/drug effects MH - *Armillaria MH - Cell Cycle/drug effects MH - Cell Line MH - Cell Line, Tumor MH - Cell Survival/drug effects MH - Esters MH - Humans MH - Molecular Structure MH - Mycelium/chemistry MH - Sesquiterpenes/chemistry/isolation & purification/*pharmacology OTO - NOTNLM OT - Armillaria mellea OT - Armillaridin (PubChem CID: 126031) OT - Armillarigin (PubChem CID: 51351607) OT - Armillarilin (PubChem CID: 195529) OT - Armillarin (PubChem CID: 134206) OT - Armillartin (PubChem CID: 131866) OT - Armillasin (PubChem CID: 134206) OT - Cytotoxic activity OT - Melleolide OT - Melleolide (PubChem CID: 435402) OT - Protoilludane Sesquiterpene aryl esters EDAT- 2016/03/10 06:00 MHDA- 2017/01/06 06:00 CRDT- 2016/03/09 06:00 PHST- 2015/09/12 00:00 [received] PHST- 2016/01/28 00:00 [revised] PHST- 2016/02/28 00:00 [accepted] PHST- 2016/03/09 06:00 [entrez] PHST- 2016/03/10 06:00 [pubmed] PHST- 2017/01/06 06:00 [medline] AID - S0378-8741(16)30088-5 [pii] AID - 10.1016/j.jep.2016.02.044 [doi] PST - ppublish SO - J Ethnopharmacol. 2016 May 26;184:119-27. doi: 10.1016/j.jep.2016.02.044. Epub 2016 Mar 4. PMID- 27418121 OWN - NLM STAT- MEDLINE DCOM- 20170320 LR - 20190609 IS - 1941-5923 (Electronic) IS - 1941-5923 (Linking) VI - 17 DP - 2016 Jul 15 TI - Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT). PG - 494-8 AB - BACKGROUND Gout is characterized by deposition of uric acid crystals (monosodium urate) in tissues and fluids. This can cause acute inflammatory arthritis. The 2015 ACR/EULAR criteria for the diagnosis of gout include dual energy computed tomography (DECT)-demonstrated monosodium urate crystals as a new criterion. DECT is a spectral decomposition that permits recognition of different types of tissues based on their characteristic energy-dependent photon attenuation. A positive scan is defined as the presence of urate at articular or periarticular sites. CASE REPORT We describe a 51-year-old woman known to have anorexia nervosa. During our clinical examination, we detected plenty of tophi on both hands, but no swollen joints. The diagnosis of gout was made by visualizing crystals in a biopsy from a tophus. The first line of treatment was allopurinol, the second line was rasburicase, and the current treatment is febuxostat 80 mg/day, allopurinol 300 mg twice a day, and colchicine 0.5 mg twice a day. The patient has unchanged arthralgia and the size and number of tophi remain the same as before treatment in spite of active treatment for 3 years. Previously the patient had problems with adherence, but now she claims that she follows the proposed treatment. The last plasma urate (P-urate) was 0.57 mmol/L. Following two years of treatment, DECT of hands visualized monosodium urate crystal deposits in the tophi, as seen on the clinical photos, but also crystals in relation to the tendons and soft tissue.  CONCLUSIONS DECT is an imaging modality useful to assess urate crystal deposits at diagnosis of gout and could be considered during treatment evaluation. Lack of adherence to treatment should be considered when P-urate values vary significantly and when DECT scans over years persistently visualize monosodium urate crystals. FAU - Christensen, Heidi Dahl AU - Christensen HD AD - Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark. FAU - Sheta, Hussam Mahmoud AU - Sheta HM AD - Department of Medical Research, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark. FAU - Morillon, Melanie Birger AU - Morillon MB AD - Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark. FAU - Hansen, Inger Marie Jensen AU - Hansen IM AD - Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark. LA - eng PT - Case Reports PT - Journal Article DEP - 20160715 PL - United States TA - Am J Case Rep JT - The American journal of case reports JID - 101489566 RN - 0 (Biomarkers) RN - 0 (Gout Suppressants) RN - 08GY9K1EUO (rasburicase) RN - 101V0R1N2E (Febuxostat) RN - 268B43MJ25 (Uric Acid) RN - 63CZ7GJN5I (Allopurinol) RN - EC 1.7.3.3 (Urate Oxidase) RN - SML2Y3J35T (Colchicine) SB - IM MH - *Absorptiometry, Photon/methods MH - Allopurinol/therapeutic use MH - Anorexia Nervosa/*complications MH - Biomarkers/blood MH - Biopsy MH - Colchicine/therapeutic use MH - Drug Therapy, Combination MH - Febuxostat/therapeutic use MH - Female MH - Gout/blood/complications/*diagnosis/*drug therapy MH - Gout Suppressants/therapeutic use MH - Humans MH - Middle Aged MH - Patient Compliance MH - Predictive Value of Tests MH - Sensitivity and Specificity MH - Urate Oxidase/therapeutic use MH - Uric Acid/blood PMC - PMC4948657 EDAT- 2016/07/16 06:00 MHDA- 2017/03/21 06:00 PMCR- 2016/07/15 CRDT- 2016/07/16 06:00 PHST- 2016/07/16 06:00 [entrez] PHST- 2016/07/16 06:00 [pubmed] PHST- 2017/03/21 06:00 [medline] PHST- 2016/07/15 00:00 [pmc-release] AID - 898542 [pii] AID - 10.12659/ajcr.898542 [doi] PST - epublish SO - Am J Case Rep. 2016 Jul 15;17:494-8. doi: 10.12659/ajcr.898542. PMID- 19882141 OWN - NLM STAT- MEDLINE DCOM- 20100927 LR - 20211020 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 18 IP - 7 DP - 2010 Jul TI - Microcirculatory effects of topical glyceryl trinitrate on the Achilles tendon microcirculation in patients with previous Achilles tendon rupture. PG - 977-81 LID - 10.1007/s00167-009-0958-y [doi] AB - Topical glyceryl trinitrate treatment has demonstrated short- to mid-term efficacy in chronic noninsertional Achilles tendinopathy. However, the underlying mechanisms are far from being understood. We hypothetized that Achilles tendon capillary blood flow changes immediately after topical glyceryl trinitrate treatment. Fifteen patients (55 + or - 15 years, VAS 5.8 + or - 2.3) with current mid-portion Achilles tendon pain 36 months after open surgical Achilles tendon repair for tendon rupture were included. On the Achilles mid-portion, 1.2 mg topical glyceryl trinitrate was sprayed. Microcirculatory monitoring included capillary blood flow, tendon oxygen saturation and postcapillary venous filling pressures at the insertion and 2, 4 and 6 cm above the insertion using a combined laser Doppler and spectrophotometry system. Baseline capillary blood-flows of the painful versus the uninjured tendon were increased [108 + or - 46 vs. 81 + or - 20 (2 cm above the insertion), 104 + or - 40 vs. 76 + or - 20 (4 cm above the insertion), 111 + or - 53 vs. 90 + or - 21 (6 cm above the insertion, P < 0.05)]. However, topical glyceryl trinitrate did not change capillary blood-flow at 2 and 8-mm tissue depths at the painful Achilles tendon or the healthy tendon. Tendon oxygenation was not changed at the painful or the healthy Achilles tendon. Postcapillary venous filling pressure was reduced at 8 mm at the mid-portion in the painful Achilles tendon only (113 + or - 37 vs. 95 + or - 31, P = 0.030). Acute topical glyceryl trinitrate facilitates capillary venous outflow in painful Achilles tendons. However, capillary blood-flow and tendon oxygenation remain unchanged following acute topical glyceryl trinitrate application. Elevated capillary blood-flow at the entire mid-portion is encountered at baseline in previously ruptured painful Achilles tendons even 3 years after surgical repair of the Achilles tendon indicating an altered microcirculatory flow pattern. FAU - Osadnik, Rafal AU - Osadnik R AD - Plastic, Hand and Reconstructive Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. FAU - Redeker, Joern AU - Redeker J FAU - Kraemer, Robert AU - Kraemer R FAU - Vogt, Peter M AU - Vogt PM FAU - Knobloch, Karsten AU - Knobloch K LA - eng PT - Journal Article DEP - 20091031 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Vasodilator Agents) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Achilles Tendon/*blood supply/injuries MH - Administration, Topical MH - Adult MH - Aged MH - Blood Flow Velocity/*drug effects MH - Blood Gas Analysis MH - Humans MH - Male MH - Microcirculation/*drug effects MH - Middle Aged MH - Nitroglycerin/*administration & dosage MH - Pain/drug therapy MH - Rupture, Spontaneous MH - Vasodilator Agents/*administration & dosage EDAT- 2009/11/03 06:00 MHDA- 2010/09/29 06:00 CRDT- 2009/11/03 06:00 PHST- 2008/12/06 00:00 [received] PHST- 2009/10/05 00:00 [accepted] PHST- 2009/11/03 06:00 [entrez] PHST- 2009/11/03 06:00 [pubmed] PHST- 2010/09/29 06:00 [medline] AID - 10.1007/s00167-009-0958-y [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2010 Jul;18(7):977-81. doi: 10.1007/s00167-009-0958-y. Epub 2009 Oct 31. PMID- 32294117 OWN - NLM STAT- MEDLINE DCOM- 20200715 LR - 20200715 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 15 IP - 4 DP - 2020 TI - Assessing the effects of intratendinous genipin injections: Mechanical augmentation and spatial distribution in an ex vivo degenerative tendon model. PG - e0231619 LID - 10.1371/journal.pone.0231619 [doi] LID - e0231619 AB - BACKGROUND: Tendinopathy is a common musculoskeletal disorder and current treatment options show limited success. Genipin is an effective collagen crosslinker with low cytotoxicity and a promising therapeutic strategy for stabilizing an intratendinous lesion. PURPOSE: This study examined the mechanical effect and delivery of intratendinous genipin injection in healthy and degenerated tendons. STUDY DESIGN: Controlled laboratory study. METHODS: Bovine superficial digital flexor tendons were randomized into four groups: Healthy control (N = 25), healthy genipin (N = 25), degenerated control (N = 45) and degenerated genipin (N = 45). Degeneration was induced by Collagenase D injection. After 24h, degenerated tendons were subsequently injected with either 0.2ml of 80mM genipin or buffer only. 24h post-treatment, samples were cyclically loaded for 500 cycles and then ramp loaded to failure. Fluorescence and absorption assays were performed to analyze genipin crosslink distribution and estimate tissue concentration after injection. RESULTS: Compared to controls, genipin treatment increased ultimate force by 19% in degenerated tendons (median control 530 N vs. 633 N; p = 0.0078). No significant differences in mechanical properties were observed in healthy tendons, while degenerated tendons showed a significant difference in ultimate stress (+23%, p = 0.049), stiffness (+27%, p = 0.037), work to failure (+42%, p = 0.009), and relative stress relaxation (-11%, p < 0.001) after genipin injection. Fluorescence and absorption were significantly higher in genipin treated tendons compared to control groups. A higher degree of crosslinking (+45%, p < 0.001) and a more localized distribution were observed in the treated healthy compared to degenerated tendons, with higher genipin tissue concentrations in healthy (7.9 mM) than in degenerated tissue (2.3 mM). CONCLUSION: Using an ex-vivo tendinopathy model, intratendinous genipin injections recovered mechanical strength to the level of healthy tendons. Measured by genipin tissue distribution, injection is an effective method for local delivery. CLINICAL RELEVANCE: This study provides a proof of concept for the use of intratendinous genipin injection in the treatment of tendinopathy. The results demonstrate that a degenerated tendon can be mechanically augmented by a clinically viable method of local genipin delivery. This warrants further in vivo studies towards the development of a clinically applicable treatment based on genipin. FAU - Tondelli, Timo AU - Tondelli T AUID- ORCID: 0000-0003-0177-3550 AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland. AD - Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Götschi, Tobias AU - Götschi T AUID- ORCID: 0000-0002-1641-6401 AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland. AD - Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Camenzind, Roland S AU - Camenzind RS AUID- ORCID: 0000-0002-9096-2910 AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland. FAU - Snedeker, Jess G AU - Snedeker JG AD - Department of Orthopedics, Balgrist University Hospital, Zurich, Switzerland. AD - Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. LA - eng SI - figshare/10.6084/m9.figshare.11498568 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200415 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Adhesives) RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM EIN - PLoS One. 2020 Nov 30;15(11):e0243256. doi: 10.1371/journal.pone.0243256. PMID: 33253301 MH - Adhesives/*administration & dosage MH - Animals MH - Cattle MH - Collagen/*drug effects/metabolism MH - Humans MH - Injections, Intralesional MH - Iridoids/*administration & dosage MH - Tendinopathy/*drug therapy/pathology MH - Tendons/*drug effects/pathology MH - Tensile Strength PMC - PMC7159246 COIS- The authors have declared that no competing interests exist. EDAT- 2020/04/16 06:00 MHDA- 2020/07/16 06:00 PMCR- 2020/04/15 CRDT- 2020/04/16 06:00 PHST- 2019/03/21 00:00 [received] PHST- 2020/03/29 00:00 [accepted] PHST- 2020/04/16 06:00 [entrez] PHST- 2020/04/16 06:00 [pubmed] PHST- 2020/07/16 06:00 [medline] PHST- 2020/04/15 00:00 [pmc-release] AID - PONE-D-19-08022 [pii] AID - 10.1371/journal.pone.0231619 [doi] PST - epublish SO - PLoS One. 2020 Apr 15;15(4):e0231619. doi: 10.1371/journal.pone.0231619. eCollection 2020. PMID- 22905628 OWN - NLM STAT- MEDLINE DCOM- 20150515 LR - 20120821 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 26 IP - 7 DP - 2012 Jul TI - [Effect of triptolide on allogenic tendon transplantation in repairing tendon defect in chicken]. PG - 869-73 AB - OBJECTIVE: Triptolide can suppress immunological rejection reaction. To investigate the effect of triptolide on allogenic tendon transplantation in repairing tendon defect in chicken. METHODS: The defect model of the third toes tendon was established in 64 healthy-cleaning male Leghorn chickens (4-month-old, weighing 1.9-2.3 kg), which underwent allogenic tendon transplantation for repairing and were divided into 2 groups randomly (n=32). Triptolide feeding [100 microg/(kg x d)] was given for 3 weeks in the experimental group and normal feeding in the control group. General condition of the chickens was observed after operation. The transplanted tendons were harvested from 4 chickens in each group for gross observation at 1, 2, 3, and 4 weeks after operation; the histological observation was performed at 1 and 3 weeks, and transmission electron microscope observation at 2 and 4 weeks. The blood and tendon were harvested from another 8 chickens in each group for flow cytometry and biomechanical tests respectively at 3 and 6 weeks. RESULTS: All chickens survived to the experiment end. Gross observation: with time extending, hyperemia and edema around transplanted tendon were relieved. Rarefaction adhering zone was seen in experimental group, and pyknotic adhering zone in control group. Histological observation: inflammatory reaction in experimental group was slighter than that in control group at 1 and 3 weeks. Transmission electron microscope observation: at 2 and 4 weeks, fibroblasts had big cell nucleus, more euchromatin, and little heterochromatin in experimental group; however, there were small amount of rough endocytoplasmic reticulums with gentle expanded capsular space in control group, which contained sparse content. Flow cytometry test: at 3 and 6 weeks, peripheral blood contained less CD4+ and CD8+ T lymphocytes in experimental group than in control group, and the ratio of CD4+ to CD8+ T lymphocyte significantly decreased in experimental group when compared with control group (P < 0.05). Biomechanical examination: at 3 and 6 weeks, the maximum tensile strength in experimental group was bigger than that in control group, and tensile adhesion power in experimental group was smaller than that in control group. There were significant differences in the indexes between 2 groups (P < 0.05). CONCLUSION: Triptolide can suppress immunological rejection reaction, strengthen tendon healing strength, and reduce tendon adhesion in allogenic tendon transplantation. FAU - Dou, Bo AU - Dou B AD - Department of Orthopaedics, Lulong Hospital, Lulong Hebei, PR China. FAU - Wang, Jiangyong AU - Wang J FAU - Zhang, Yingze AU - Zhang Y FAU - Tian, Dehu AU - Tian D FAU - Bai, Jiangbo AU - Bai J FAU - Feng, Jianshu AU - Feng J FAU - Ni, Huawei AU - Ni H LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - 0 (Diterpenes) RN - 0 (Epoxy Compounds) RN - 0 (Immunosuppressive Agents) RN - 0 (Phenanthrenes) RN - 19ALD1S53J (triptolide) SB - IM MH - Animals MH - Chickens MH - Diterpenes/*administration & dosage/therapeutic use MH - Epoxy Compounds/administration & dosage/therapeutic use MH - Immunosuppressive Agents/*administration & dosage/therapeutic use MH - Male MH - Phenanthrenes/*administration & dosage/therapeutic use MH - Tendon Injuries/*surgery MH - Tendons/surgery/*transplantation MH - Tensile Strength MH - Tissue Adhesions/*prevention & control MH - Toes MH - Transplantation, Autologous MH - *Wound Healing EDAT- 2012/08/22 06:00 MHDA- 2015/05/16 06:00 CRDT- 2012/08/22 06:00 PHST- 2012/08/22 06:00 [entrez] PHST- 2012/08/22 06:00 [pubmed] PHST- 2015/05/16 06:00 [medline] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012 Jul;26(7):869-73. PMID- 7609771 OWN - NLM STAT- MEDLINE DCOM- 19950817 LR - 20131121 IS - 0028-4793 (Print) IS - 0028-4793 (Linking) VI - 333 IP - 6 DP - 1995 Aug 10 TI - Colchicine therapy for palmar fibromatosis. PG - 393 FAU - Pitts, F N Jr AU - Pitts FN Jr LA - eng PT - Case Reports PT - Letter PL - United States TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 RN - SML2Y3J35T (Colchicine) SB - IM MH - Colchicine/*therapeutic use MH - Fibroma/*drug therapy MH - *Fingers MH - Humans MH - Male MH - Muscular Diseases/drug therapy MH - *Tendons EDAT- 1995/08/10 00:00 MHDA- 2001/03/28 10:01 CRDT- 1995/08/10 00:00 PHST- 1995/08/10 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1995/08/10 00:00 [entrez] AID - 10.1056/NEJM199508103330620 [doi] PST - ppublish SO - N Engl J Med. 1995 Aug 10;333(6):393. doi: 10.1056/NEJM199508103330620. PMID- 23509029 OWN - NLM STAT- MEDLINE DCOM- 20131017 LR - 20161125 IS - 2151-4658 (Electronic) IS - 2151-464X (Linking) VI - 65 IP - 8 DP - 2013 Aug TI - Ultrasound learning curve in gout: a disease-oriented training program. PG - 1265-74 LID - 10.1002/acr.22009 [doi] AB - OBJECTIVE: To describe the learning curve of rheumatologists with limited experience using ultrasound (US) attending an intensive disease-oriented training program focusing on the skills required to obtain and interpret US signs of monosodium urate (MSU) crystal deposits in joint and periarticular tissues. METHODS: Three investigators participated in a 7-day training program involving 12 men with gout. The agreement between the expert and beginners was calculated in 4 sessions involving 8 patients with gout. The US assessment was performed at the second and third metacarpophalangeal joints, knee, tibiotalar and first metatarsophalangeal joints, second and third finger flexors, quadriceps and patellar posterior tibialis, peroneus longus and brevis, and Achilles tendons. The presence or absence of synovial fluid/synovial hypertrophy, double contour sign, intra- or periarticular and intratendinous tophi, bursitis, bone erosions, and tendon tears was recorded. RESULTS: A total of 416 anatomic sites were studied. Kappa values and overall agreement percentages of qualitative assessments of US gout findings at the end of the exercise both showed moderate to excellent agreement, while in the first session they showed poor/fair agreement. At the end of the training session, sensitivity, specificity, and capability of the beginners were also improved. CONCLUSION: After 1 week of the disease-oriented training program, rheumatologists with limited experience in US were satisfactorily able to detect and interpret the main US signs indicative of MSU crystal deposits at different tissues in patients with gout. CI - Copyright © 2013 by the American College of Rheumatology. FAU - Gutiérrez, Marwin AU - Gutiérrez M AD - Università Politecnica delle Marche, Jesi, Ancona, Italy. dr.gmarwin@gmail.com FAU - Di Geso, Luca AU - Di Geso L FAU - Rovisco, João AU - Rovisco J FAU - Di Carlo, Marco AU - Di Carlo M FAU - Ariani, Alarico AU - Ariani A FAU - Filippucci, Emilio AU - Filippucci E FAU - Grassi, Walter AU - Grassi W LA - eng PT - Journal Article PL - United States TA - Arthritis Care Res (Hoboken) JT - Arthritis care & research JID - 101518086 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Gout/*diagnostic imaging MH - Humans MH - Joints/diagnostic imaging MH - Learning Curve MH - Male MH - Middle Aged MH - Rheumatology/*education MH - Ultrasonography MH - Uric Acid/analysis EDAT- 2013/03/20 06:00 MHDA- 2013/10/18 06:00 CRDT- 2013/03/20 06:00 PHST- 2012/09/13 00:00 [received] PHST- 2013/02/26 00:00 [accepted] PHST- 2013/03/20 06:00 [entrez] PHST- 2013/03/20 06:00 [pubmed] PHST- 2013/10/18 06:00 [medline] AID - 10.1002/acr.22009 [doi] PST - ppublish SO - Arthritis Care Res (Hoboken). 2013 Aug;65(8):1265-74. doi: 10.1002/acr.22009. PMID- 31488012 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 62 IP - 2 DP - 2021 Mar TI - Ascorbic acid mitigates the deleterious effects of nicotine on tendon stem cells. PG - 183-193 LID - 10.1080/03008207.2019.1663349 [doi] AB - Purpose: Nicotine causes tendon degeneration, whereas ascorbic acid imparts beneficial effects on tendon cells. Tendon stem cells (TSCs) play a vital role in maintaining tissue integrity and promoting restoration of structure and function after tendon injury. In the present study, cell culture experiments were performed to determine the effects of nicotine on TSCs and whether ascorbic acid supplementation could antagonize the action of high concentration nicotine. Methods: After treatment with nicotine and ascorbic acid, TSC proliferation, migration, stemness, apoptosis, and differentiation were analyzed. Results: TSC proliferation and expression of stem cell markers were significantly impaired by a high concentration of nicotine (1000 ng/mL), but a lower concentration (100 ng/mL) induced proliferative effects in TSCs. Moreover, the highest concentration of nicotine tested (1000 ng/mL) significantly inhibited the migratory ability of TSCs, while relatively high concentrations (100 and 1000 ng/mL) significantly (p < 0.05) up-regulated non-tenocyte genes. When ascorbic acid was added, the inhibitory effects of nicotine on the proliferation, migration, and stemness of TSCs were reversed. In addition, flow cytometry analysis showed that these nicotine concentrations could induce cell apoptosis, while the addition of ascorbic acid inhibited apoptosis. Conclusion: Addition of ascorbic acid partially reversed the inhibitory effect of a high concentration of nicotine. These findings indicate that while nicotine impairs the biological characteristics of TSCs, ascorbic acid can mitigate these deleterious effects and, therefore, may be useful for decreasing nicotine-induced tendon degeneration. FAU - Shi, Zhengzhou AU - Shi Z AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine , Shanghai, China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine , Shanghai, China. FAU - Jiang, Dapeng AU - Jiang D AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine , Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190905 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 6M3C89ZY6R (Nicotine) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Ascorbic Acid/pharmacology MH - Cell Differentiation MH - Nicotine/adverse effects MH - *Stem Cells MH - *Tendons OTO - NOTNLM OT - Ascorbic acid OT - nicotine OT - proliferation OT - stemness OT - tendon stem cells EDAT- 2019/09/07 06:00 MHDA- 2022/02/03 06:00 CRDT- 2019/09/07 06:00 PHST- 2019/09/07 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2019/09/07 06:00 [entrez] AID - 10.1080/03008207.2019.1663349 [doi] PST - ppublish SO - Connect Tissue Res. 2021 Mar;62(2):183-193. doi: 10.1080/03008207.2019.1663349. Epub 2019 Sep 5. PMID- 1428073 OWN - NLM STAT- MEDLINE DCOM- 19921215 LR - 20200515 IS - 0019-5359 (Print) IS - 0019-5359 (Linking) VI - 46 IP - 6 DP - 1992 Jun TI - Treatment of intractable spasticity in spinal cord injured patients. PG - 169-73 AB - Spasticity and flexor spasms can be most incapacitating in SCI victims. Muscle relaxants, physiotherapy and elimination of triggering factors must be tried before opting for peripheral surgery or alcohol block. The choice of alcohol block or peripheral surgery depends in whether damage to the spinal cord is complete or incomplete. Results of both the procedures are satisfactory in rightly chosen patients. Alcohol block is a simple, safe and effective method of treating spasticity in the patients of complete paraplegia. The effect is immediate and almost permanent. However, alcohol block is contra-indicated in the patients of incomplete paraplegia where peripheral surgery is a better choice. FAU - Sangwan, S S AU - Sangwan SS AD - Dept. of Orthopaedics, Medical College, Rohtak, Haryana. FAU - Chand, S AU - Chand S FAU - Siwach, R C AU - Siwach RC FAU - Gupta, I S AU - Gupta IS LA - eng PT - Journal Article PL - India TA - Indian J Med Sci JT - Indian journal of medical sciences JID - 0373023 RN - 3K9958V90M (Ethanol) SB - IM MH - Achilles Tendon/*surgery MH - Ethanol/administration & dosage/*therapeutic use MH - Hip/innervation/*surgery MH - Humans MH - Injections, Spinal MH - Knee/*surgery MH - Muscle Spasticity/etiology/*therapy MH - Muscles/*surgery MH - Spinal Cord Injuries/*complications MH - Tendons/*surgery MH - Treatment Outcome EDAT- 1992/06/01 00:00 MHDA- 1992/06/01 00:01 CRDT- 1992/06/01 00:00 PHST- 1992/06/01 00:00 [pubmed] PHST- 1992/06/01 00:01 [medline] PHST- 1992/06/01 00:00 [entrez] PST - ppublish SO - Indian J Med Sci. 1992 Jun;46(6):169-73. PMID- 37889023 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20240108 IS - 1307-7945 (Electronic) IS - 1306-696X (Print) IS - 1306-696X (Linking) VI - 29 IP - 11 DP - 2023 Oct 27 TI - Investigation of the effects of umbilical cord-derived mesenchymal stem cells and curcumin on Achilles tendon healing - can they act synergistically? PG - 1218-1227 LID - 10.14744/tjtes.2023.04203 [doi] AB - BACKGROUND: It is known that curcumin and umbilical cord-derived mesenchymal stem cells (UC-MSCs) positively affect experi-mental tendon injury healing. This study investigated individual effects and potential synergistic effects of using curcumin and UC-MSCs alone and together. METHODS: Eighty female Wistar albino rats were randomly divided into five groups: Control, curcumin, sesame oil, MSCs, and Curcumin+MSCs groups. In all rats, punch tendon defect was created in both right and left Achilles tendons. While no additional treatment was applied to the control group, curcumin, sesame oil used as a solvent for curcumin, MSCs, and MSCs and curcumin com-bination were applied locally to the injury site, respectively, in the other groups. Curcumin was solved in sesame oil before application. In each group, half of the animals were euthanized in the post-operative 2nd week while the other half were euthanized in the post-operative 4th week. The right Achilles was used for biomechanical testing, while the left Achilles was used for histological evaluation and immunohistochemical analysis of type I, Type III collagen, and tenomodulin. RESULTS: Histologically, significant improvement was observed in the curcumin, MSCs, and Curcumin+ MSCs groups compared to the control Group in the 2nd week. In the 2nd and 4th weeks, Type III collagen was significantly increased in the curcumin group com-pared to the control group. In week 4, tenomodulin increased significantly in the curcumin and MSCs groups compared to the control group. Tendon tensile strength increased significantly in MSCs and Curcumin+MSCs groups compared to the control group in the 4th week. No superiority was observed between the treatment groups regarding their positive effects on recovery. CONCLUSION: Locally used curcumin and UC-MSCs showed positive effects that were not superior to each other in the healing of injury caused by a punch in the Achilles tendons of rats. However, synergistic effects on healing were not observed when they were applied together. FAU - Öztürk, Tuğçe Merve AU - Öztürk TM AD - Afyonkarahisar State Hospital, Afyonkarahisar-Türkiye. FAU - Özyazgan, İrfan AU - Özyazgan İ AD - Department of Plastic Reconstructive and Aesthetic Surgery, Erciyes University, Faculty of Medicine, Kayseri-Türkiye. FAU - Sezer, Gülay AU - Sezer G AD - Department of Pharmacology, Erciyes University, Faculty of Medicine, Kayseri-Türkiye. FAU - Yalçın, Betül AU - Yalçın B AD - Department of Histology and Embryology, Adıyaman University, Faculty of Medicine, Adıyaman-Türkiye. FAU - Göç, Rümeysa AU - Göç R AD - Department of Histology and Embryology, Cumhuriyet University, Faculty of Medicine, Sivas-Türkiye. FAU - Ülger, Menekşe AU - Ülger M AD - Department of Histology and Embryology, Erciyes University, Faculty of Medicine, Kayseri-Türkiye. FAU - Özocak, Hakan AU - Özocak H AD - Private Practice, İstanbul-Türkiye. FAU - Yakan, Birkan AU - Yakan B AD - Department of Histology and Embryology, Erciyes University, Faculty of Medicine, Kayseri-Türkiye. LA - eng PT - Journal Article TT - Aşil tendonu iyileşmesinde umbilikal kord-kaynaklı mezenkimal kök hücre ve kurkuminin etkilerinin incelenmesi - sinerjistik etkileri olabilir mi? PL - Turkey TA - Ulus Travma Acil Cerrahi Derg JT - Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES JID - 101274231 RN - IT942ZTH98 (Curcumin) RN - 0 (Collagen Type III) RN - 8008-74-0 (Sesame Oil) SB - IM MH - Rats MH - Female MH - Animals MH - *Achilles Tendon/injuries/pathology/surgery MH - *Curcumin/pharmacology MH - Rats, Wistar MH - Collagen Type III MH - Sesame Oil MH - *Mesenchymal Stem Cell Transplantation MH - *Mesenchymal Stem Cells PMC - PMC10771245 COIS- Conflict of Interest: None declared. EDAT- 2023/10/27 12:43 MHDA- 2023/10/30 06:46 PMCR- 2023/10/27 CRDT- 2023/10/27 09:13 PHST- 2023/10/30 06:46 [medline] PHST- 2023/10/27 12:43 [pubmed] PHST- 2023/10/27 09:13 [entrez] PHST- 2023/10/27 00:00 [pmc-release] AID - TJTES-29-1218 [pii] AID - 10.14744/tjtes.2023.04203 [doi] PST - ppublish SO - Ulus Travma Acil Cerrahi Derg. 2023 Oct 27;29(11):1218-1227. doi: 10.14744/tjtes.2023.04203. PMID- 30668918 OWN - NLM STAT- MEDLINE DCOM- 20200311 LR - 20200311 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 47 IP - 3 DP - 2019 Mar TI - Simvastatin With PRP Promotes Chondrogenesis of Bone Marrow Stem Cells In Vitro and Wounded Rat Achilles Tendon-Bone Interface Healing In Vivo. PG - 729-739 LID - 10.1177/0363546518819108 [doi] AB - BACKGROUND: Tendons and ligaments are joined to bone in a specialized interface that transmits force from muscle to bone and permits body movement. Tendon/ligament injuries always occur in the interface areas, and injured tendons/ligaments have a limited healing response because the insertion site is composed of a fibrocartilaginous zone. PURPOSE: To study the effect of simvastatin with platelet-rich plasma (PRP) on chondrogenesis of rat bone marrow stem cells (BMSCs) in vitro and wounded rat Achilles tendon-bone interface healing in vivo. STUDY DESIGN: Controlled laboratory study. METHODS: The in vitro model was performed by the culture of rat BMSCs with various concentrations of simvastatin (0, 10, 50, 100 nM) for 2 weeks. The effect of simvastatin on the chondrogenic differentiation of the BMSCs was examined by histochemical analysis and real-time quantitative reverse transcription polymerase chain reaction. The in vivo model was carried out by testing the healing effect of simvastatin with PRP on 12 wounded rat Achilles tendon-bone interfaces. RESULTS: Simvastatin induced chondrogenic differentiation of rat BMSCs in a concentration-dependent manner as evidenced by histological staining and real-time quantitative reverse transcription polymerase chain reaction. The wounds treated with simvastatin alone or with simvastatin-containing PRP gel healed much faster than the wounds treated with saline alone or PRP alone. Histological analysis showed that higher percentages of healed tissues were positively stained with safranin O and fast green in wounds treated with simvastatin-containing PRP gel than in the other 3 groups. Immunohistochemical analysis further demonstrated these findings, as evidenced by more positively stained healed tissues with collagen I and II antibodies in the wound areas treated with simvastatin-containing PRP gel than the other 3 groups. CONCLUSION: The combination of simvastatin with PRP induced chondrogenesis of BMSCs in vitro and enhanced fibrocartilage formation in vivo. The simvastatin-PRP gel treatment promotes wounded tendon-bone interface healing in clinical treatment. CLINICAL RELEVANCE: The combination of simvastatin with PRP may be a good clinical treatment for wounded tendon/ligament junction healing, especially for acute sports-related tendon/ligament injuries. FAU - Zhang, Ying AU - Zhang Y AD - Department of Orthopedics, Jinan Central Hospital Affiliated to Shandong University Medical School, Jinan, China. FAU - Yu, Jing AU - Yu J AD - Department of Anesthesiology, Jinan Central Hospital Affiliated to Shandong University Medical School, Jinan, China. FAU - Zhang, Jiefeng AU - Zhang J AD - Department of Trauma Surgery, Taian City Central Hospital, Taian, China. FAU - Hua, Yongxin AU - Hua Y AD - Department of Orthopedics, Jinan Central Hospital Affiliated to Shandong University Medical School, Jinan, China. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20190122 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Collagen Type I) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Achilles Tendon/drug effects/injuries/pathology MH - Animals MH - Bone Marrow Cells/drug effects/metabolism MH - Bone and Bones/injuries/pathology MH - Cell Differentiation/drug effects MH - Chondrogenesis/*drug effects MH - Collagen Type I MH - Drug Evaluation, Preclinical MH - Female MH - Fibrocartilage MH - *Platelet-Rich Plasma MH - Rats MH - Rats, Sprague-Dawley MH - Simvastatin/pharmacology/*therapeutic use MH - Stem Cells/drug effects/metabolism MH - Tendon Injuries/pathology/*therapy MH - Wound Healing/*drug effects OTO - NOTNLM OT - chondrogenesis OT - fibrocartilage OT - platelet-rich plasma OT - simvastatin OT - tendon-bone interface EDAT- 2019/01/23 06:00 MHDA- 2020/03/12 06:00 CRDT- 2019/01/23 06:00 PHST- 2019/01/23 06:00 [pubmed] PHST- 2020/03/12 06:00 [medline] PHST- 2019/01/23 06:00 [entrez] AID - 10.1177/0363546518819108 [doi] PST - ppublish SO - Am J Sports Med. 2019 Mar;47(3):729-739. doi: 10.1177/0363546518819108. Epub 2019 Jan 22. PMID- 25147000 OWN - NLM STAT- MEDLINE DCOM- 20151023 LR - 20141125 IS - 1097-0029 (Electronic) IS - 1059-910X (Linking) VI - 77 IP - 12 DP - 2014 Dec TI - Effect of Aloe vera application on the content and molecular arrangement of glycosaminoglycans during calcaneal tendon healing. PG - 964-73 LID - 10.1002/jemt.22422 [doi] AB - Although several treatments for tendon lesions have been proposed, successful tendon repair remains a great challenge for orthopedics, especially considering the high incidence of re-rupture of injured tendons. Our aim was to evaluate the pharmacological potential of Aloe vera on the content and arrangement of glycosaminoglycans (GAGs) during tendon healing, which was based on the effectiveness of A. vera on collagen organization previously observed by our group. In rats, a partial calcaneal tendon transection was performed with subsequent topical A. vera application at the injury site. The tendons were treated with A. vera ointment for 7 days and excised on the 7(th) , 14(th) , or 21(st) day post-surgery. Control rats received ointment without A. vera. A higher content of GAGs and a lower amount of dermatan sulfate were detected in the A. vera-treated group on the 14(th) day compared with the control. Also at 14 days post-surgery, a lower dichroic ratio in toluidine blue stained sections was observed in A. vera-treated tendons compared with the control. No differences were observed in the chondroitin-6-sulfate and TGF-β1 levels between the groups, and higher amount of non-collagenous proteins was detected in the A. vera-treated group on the 21(st) day, compared with the control group. No differences were observed in the number of fibroblasts, inflammatory cells and blood vessels between the groups. The application of A. vera during tendon healing modified the arrangement of GAGs and increased the content of GAGs and non-collagenous proteins. CI - © 2014 Wiley Periodicals, Inc. FAU - Aro, Andrea Aparecida de AU - Aro AA AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil. FAU - Esquisatto, Marcelo Augusto Marretto AU - Esquisatto MA FAU - Nishan, Umar AU - Nishan U FAU - Perez, Mylena Oliveira AU - Perez MO FAU - Rodrigues, Rodney Alexandre Ferreira AU - Rodrigues RA FAU - Foglio, Mary Ann AU - Foglio MA FAU - Carvalho, João Ernesto de AU - Carvalho JE FAU - Gomes, Laurecir AU - Gomes L FAU - Vidal, Benedicto De Campos AU - Vidal Bde C FAU - Pimentel, Edson Rosa AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140822 PL - United States TA - Microsc Res Tech JT - Microscopy research and technique JID - 9203012 RN - 0 (Glycosaminoglycans) RN - 0 (Plant Preparations) SB - IM MH - Administration, Topical MH - *Aloe MH - Animals MH - Enzyme-Linked Immunosorbent Assay MH - Glycosaminoglycans/*metabolism MH - Male MH - *Phytotherapy MH - Plant Preparations/administration & dosage/*therapeutic use MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy/metabolism MH - Tendons/*drug effects/metabolism MH - Wound Healing/*drug effects OTO - NOTNLM OT - dichroic ratio OT - injury OT - non-collagenous proteins OT - ointment OT - proteoglycans EDAT- 2014/08/26 06:00 MHDA- 2015/10/24 06:00 CRDT- 2014/08/23 06:00 PHST- 2014/05/13 00:00 [received] PHST- 2014/07/31 00:00 [accepted] PHST- 2014/08/23 06:00 [entrez] PHST- 2014/08/26 06:00 [pubmed] PHST- 2015/10/24 06:00 [medline] AID - 10.1002/jemt.22422 [doi] PST - ppublish SO - Microsc Res Tech. 2014 Dec;77(12):964-73. doi: 10.1002/jemt.22422. Epub 2014 Aug 22. PMID- 17260615 OWN - NLM STAT- MEDLINE DCOM- 20070220 LR - 20131121 IS - 0001-6462 (Print) IS - 0001-6462 (Linking) VI - 72 IP - 6 DP - 2006 Dec TI - Doxycycline impairs tendon repair in rats. PG - 756-60 AB - Doxycycline exhibits various effects apart from its antimicrobial activity, such as inhibition of matrix metalloproteinases (MMPs). MMPs, mainly collagenases and gelatinases, are capable of degrading virtually all constituents of the extracellular matrix and are critical to connective tissue remodelling and healing. We therefore hypothesised that doxycycline would negatively influence the rat tendon healing process and impede tendon regeneration. The Achilles tendon of 60 Sprague Dawley rats was transected transversely. The animals were treated with doxycycline, 130 mg/kg body weight/day. The healing tendons were evaluated mechanically at 5, 8 and 14 days. Doxycycline significantly decreased force at failure (p < 0.005) and energy uptake (p < 0.001). Doxycycline serum concentration was 3.4 (SD 1.0) microg/ml. In conclusion, tendon healing can be affected by doxycycline at clinically relevant serum concentrations. This observation might be of relevance to further studies exploring effects of MMP-inhibitors on tendon tissue. FAU - Pasternak, Björn AU - Pasternak B AD - Division of Orthopaedics, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linköping University, Sweden. bjopa266@student.liu.se FAU - Fellenius, Mårten AU - Fellenius M FAU - Aspenberg, Per AU - Aspenberg P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Belgium TA - Acta Orthop Belg JT - Acta orthopaedica Belgica JID - 2985165R RN - 0 (Matrix Metalloproteinase Inhibitors) RN - N12000U13O (Doxycycline) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Doxycycline/adverse effects/blood/*pharmacology MH - Female MH - *Matrix Metalloproteinase Inhibitors MH - Rats MH - Rats, Sprague-Dawley MH - Time Factors MH - Wound Healing/*drug effects EDAT- 2007/01/31 09:00 MHDA- 2007/02/21 09:00 CRDT- 2007/01/31 09:00 PHST- 2007/01/31 09:00 [pubmed] PHST- 2007/02/21 09:00 [medline] PHST- 2007/01/31 09:00 [entrez] PST - ppublish SO - Acta Orthop Belg. 2006 Dec;72(6):756-60. PMID- 29600676 OWN - NLM STAT- MEDLINE DCOM- 20180817 LR - 20211204 IS - 1003-0034 (Print) IS - 1003-0034 (Linking) VI - 31 IP - 3 DP - 2018 Mar 25 TI - [Osteopractic total flavone promoting rat extra-articular tendon-bone healing through mTOR pathway]. PG - 248-253 LID - 10.3969/j.issn.1003-0034.2018.03.011 [doi] AB - OBJECTIVE: To explore function and related molecular mechanism of osteopractic total flavone (OTF) on tendon healing in rats. METHODS: Ten male rats aged for 8 weeks were collected and weighted from 180 to 220 g. Tendon stem cells were cultivated, the third tendon stem cells were used for experiment. OTP treated with 0, 0.1, 1, 10 ng/ml were added into tendon stem cells, and expression change of ALP, Runx2, OCN, VEGF, P-S6, P-4E/BP1 were detected after 14 days. Forty male rats aged for 8 weeks (weighted 180 to 220 g) were established extra-articular tendon-bone transplanting healing model, and divided into experimental group and control group. Experimental group were treated with OTF(100 mg·kg⁻¹·d⁻¹), while control group was treated by normal saline with the same volume. Tendon-bone healing degree were detected by biomechanical testing at 3 and 6 weeks after surgery, histological detection were applied to detect tendon-bone healing and number of new vessles. RESULTS: After treated by OTP, ALP staining and active index detection showed there were statistical differences among 0, 0.1, 1, 10 ng/ml group. After 14 days' cultivation, western blotting results showed mTOR downstream marker protein P-S6 protein expression were gradually increased with increase of density of OTP, expression of P-4E/BP1 was reduced, while expression of Runx2, OCN, VEGF were increased. Biological detection results showed that there was no significant difference in mechanical strength between experimental group(0.78±0.05) N/mm and control group (0.51±0.02) N/mm at 3 weeks after surgery, while mechanical strength in experimental group (1.36±0.09) N/mm was higher than control group (1.01±0.08) N/mm at 6 weeks after surgery. Histological results showed maturity of tendon-bone surface cell were higher at 3 and 6 weeks in experimental group, sharpey fiber growth more density, calcification extent of mesenchyme was high, and new bone, vessels were increased. CONCLUSIONS: OTF could promote osteogenic differentiation of tendon stem cells through mTOR signaling in vitro, and stimulate tendon-bone healing in bone tunnel and enhance connection quality between tendon and bone. CI - Copyright© 2018 by the China Journal of Orthopaedics and Traumatology Press. FAU - Zhang, Xin-Tao AU - Zhang XT AD - Department of Sports medicine and rehabilitation, Shenzhen Hospital of Peking University, Shenzhen 518036, Guangdong, China; zhangxintao@sina.com. FAU - Jiang, Hua-Ji AU - Jiang HJ FAU - Liang, Zu-Ru AU - Liang ZR FAU - He, Fei-Lin AU - He FL FAU - Liao, Xiao-Qing AU - Liao XQ FAU - Ren, Yu-Xiang AU - Ren YX FAU - Zhang, Wen-Tao AU - Zhang WT LA - chi PT - Journal Article PL - China TA - Zhongguo Gu Shang JT - Zhongguo gu shang = China journal of orthopaedics and traumatology JID - 9815790 RN - 0 (Flavones) RN - EC 2.7.1.1 (mTOR protein, rat) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Animals MH - Biomechanical Phenomena MH - *Bone Transplantation MH - Cell Differentiation MH - Cells, Cultured MH - Flavones/*pharmacology MH - Male MH - *Osteogenesis MH - Rats MH - Stem Cells/*cytology MH - TOR Serine-Threonine Kinases/*metabolism MH - Tendons/cytology/transplantation MH - *Wound Healing OTO - NOTNLM OT - Achilles tendon OT - Drynaria fortunei OT - Flavone OT - Rats COIS- The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. EDAT- 2018/03/31 06:00 MHDA- 2018/08/18 06:00 CRDT- 2018/03/31 06:00 PHST- 2017/04/17 00:00 [received] PHST- 2018/03/31 06:00 [entrez] PHST- 2018/03/31 06:00 [pubmed] PHST- 2018/08/18 06:00 [medline] AID - 10.3969/j.issn.1003-0034.2018.03.011 [doi] PST - ppublish SO - Zhongguo Gu Shang. 2018 Mar 25;31(3):248-253. doi: 10.3969/j.issn.1003-0034.2018.03.011. PMID- 27090262 OWN - NLM STAT- MEDLINE DCOM- 20170223 LR - 20220309 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 474 IP - 8 DP - 2016 Aug TI - Tendon Collagen Crosslinking Offers Potential to Improve Suture Pullout in Rotator Cuff Repair: An Ex Vivo Sheep Study. PG - 1778-85 LID - 10.1007/s11999-016-4838-8 [doi] AB - BACKGROUND: The suture-tendon interface is often the weakest link in tendon to bone repair of massive rotator cuff tears. Genipin is a low-toxicity collagen crosslinker derived from the gardenia fruit that has been shown to augment collagen tissue strength and mechanically arrest tendon-tear progression. QUESTION/PURPOSE: The purpose of the current study was to evaluate whether genipin crosslinking can sufficiently augment the suture-tendon interface to improve suture pullout strength using simple single-loop sutures and the modified Mason-Allen technique. The study also aimed to assess whether time of genipin treatment is a relevant factor in efficacy. METHODS: In an ex vivo (cadaveric) sheep rotator cuff tendon model, a total of 142 suture pullout tests were performed on 32 infraspinatus tendons. Each tendon was prepared with three single-loop stitches. Two groups were pretreated by incubation in genipin solution for either 4 hours or 24 hours. Two corresponding control groups were incubated in phosphate buffered saline for the same periods. The same test protocol was applied to tendons using modified Mason-Allen technique stitch patterns. Each suture was loaded to failure on a universal materials testing machine. Suture pullout force, stiffness, and work to failure were calculated from force-displacement data, and then compared among the groups. RESULTS: Median single-loop pullout force on tendons incubated for 24 hours in genipin yielded an approximately 30% increase in maximum pullout force for single-loop stitches with a median of 73 N (range, 56-114 N) compared with 56 N (range, 40-69 N; difference of medians = 17 N; p = 0.028), with corresponding increases in the required work to failure but not stiffness. Genipin treatment for 4 hours showed no added benefit for suture-pullout behavior (46 N, [range, 35-95 N] versus 45 N, [range, 28-63 N]; difference of medians, 1 N; p = 1). No tested genipin crosslinking conditions indicated benefit for tendons grasped using the modified Mason-Allen technique after 4 hours (162 N, [range, 143-193 N] versus 140 N, [range, 129-151 N]; difference of medians, 22 N; p = 0.114) or after 24 hours of crosslinking (172 N, [range, 42-183 N] versus 164 N [range, 151-180 N]; difference of medians, 8 N; p = 0.886). CONCLUSION: Exogenous collagen crosslinking in genipin can markedly improve resistance to pullout at the tendon-suture interface for simple stitch patterns while the modified Mason-Allen stitch showed no benefit in an ex vivo animal model. CLINICAL RELEVANCE: Tendon strength augmentation by genipin pretreatment offers the potential to improve suture retention properties. Future studies are warranted for the development of clinically viable intraoperative delivery strategies and in vivo testing for safety and efficacy. FAU - Camenzind, Roland S AU - Camenzind RS AD - Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland. FAU - Wieser, Karl AU - Wieser K AD - Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland. FAU - Fessel, Gion AU - Fessel G AD - Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland. AD - Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. FAU - Meyer, Dominik C AU - Meyer DC AD - Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland. FAU - Snedeker, Jess G AU - Snedeker JG AD - Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland. snedeker@ethz.ch. AD - Institute for Biomechanics, ETH Zurich, Zurich, Switzerland. snedeker@ethz.ch. LA - eng PT - Journal Article DEP - 20160418 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM CIN - Clin Orthop Relat Res. 2016 Aug;474(8):1786-7. doi: 10.1007/s11999-016-4914-0. PMID: 27245770 MH - Animals MH - Biomechanical Phenomena MH - Collagen/*metabolism MH - Cross-Linking Reagents/*pharmacology MH - Disease Models, Animal MH - Equipment Failure MH - Iridoids/*pharmacology MH - Materials Testing MH - Orthopedic Procedures/*instrumentation MH - Rotator Cuff Injuries/metabolism/physiopathology/*surgery MH - Sheep MH - Stress, Mechanical MH - Suture Techniques/*instrumentation MH - *Sutures PMC - PMC4925414 EDAT- 2016/04/20 06:00 MHDA- 2017/02/24 06:00 PMCR- 2017/08/01 CRDT- 2016/04/20 06:00 PHST- 2015/11/08 00:00 [received] PHST- 2016/04/11 00:00 [accepted] PHST- 2016/04/20 06:00 [entrez] PHST- 2016/04/20 06:00 [pubmed] PHST- 2017/02/24 06:00 [medline] PHST- 2017/08/01 00:00 [pmc-release] AID - 10.1007/s11999-016-4838-8 [pii] AID - 4838 [pii] AID - 10.1007/s11999-016-4838-8 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2016 Aug;474(8):1778-85. doi: 10.1007/s11999-016-4838-8. Epub 2016 Apr 18. PMID- 27071839 OWN - NLM STAT- MEDLINE DCOM- 20171016 LR - 20221207 IS - 1616-5195 (Electronic) IS - 1616-5187 (Linking) VI - 16 IP - 7 DP - 2016 Jul TI - Bioactive, Elastic, and Biodegradable Emulsion Electrospun DegraPol Tube Delivering PDGF-BB for Tendon Rupture Repair. PG - 1048-63 LID - 10.1002/mabi.201500455 [doi] AB - Healing of tendon ruptures represents a major challenge in musculoskeletal injuries and combinations of biomaterials with biological factors are suggested as viable option for improved healing. The standard approach of repair by conventional suture leads to incomplete healing or rerupture. Here, a new elastic type of DegraPol® (DP), a polyester urethane, is explored as a delivery device for platelet-derived growth factor-BB (PDGF-BB) to promote tendon healing. Using emulsion electrospinning as an easy method for incorporation of biomolecules within polymers, DegraPol® supports loading and release of PDGF-BB. Morphological, mechanical and delivery device properties of the bioactive DP scaffolds, as well as differences arising due to different electrospinning parameters are studied. Emulsion electrospun DP scaffolds result in thinner fibers than pure DP scaffolds and experience decreased strain at break [%], but high enough for successful surgeon handling. PDGF-BB is released in a sustained manner from emulsion electrospun DP, but not completely, with still large amount of it being inside the polymeric fibers after 30 d. In vitro studies show that the bioactive scaffolds promote tenocyte proliferation in serum free and serum(+) conditions, demonstrating the potential of this surgeon-friendly bioactive delivery device to be used for tendon repair. CI - © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. FAU - Evrova, Olivera AU - Evrova O AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. AD - Laboratory of Applied Mechanobiology, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, 8093, Zürich, Switzerland. FAU - Houska, Joanna AU - Houska J AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. FAU - Welti, Manfred AU - Welti M AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. FAU - Bonavoglia, Eliana AU - Bonavoglia E AD - ab medica, Via J. F. Kennedy 10/12, 20023, Cerro Maggiore (Milan), Italy. FAU - Calcagni, Maurizio AU - Calcagni M AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. FAU - Giovanoli, Pietro AU - Giovanoli P AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. FAU - Vogel, Viola AU - Vogel V AD - Laboratory of Applied Mechanobiology, ETH Zürich, Vladimir-Prelog-Weg 1-5/10, 8093, Zürich, Switzerland. FAU - Buschmann, Johanna AU - Buschmann J AD - Division of Plastic Surgery and Hand Surgery, University Hospital Zürich, Sternwartstrasse 14, 8091, Zürich, Switzerland. LA - eng PT - Journal Article DEP - 20160413 PL - Germany TA - Macromol Biosci JT - Macromolecular bioscience JID - 101135941 RN - 0 (Biocompatible Materials) RN - 0 (DegraPol) RN - 0 (Emulsions) RN - 0 (Polyesters) RN - 0 (Polyurethanes) RN - 0 (Proto-Oncogene Proteins c-sis) RN - 1B56C968OA (Becaplermin) SB - IM MH - Becaplermin MH - Biocompatible Materials/administration & dosage/chemistry MH - Emulsions/administration & dosage/chemistry MH - Humans MH - Polyesters/*administration & dosage/chemistry MH - Polyurethanes/*administration & dosage MH - Proto-Oncogene Proteins c-sis/*administration & dosage/chemistry MH - Plastic Surgery Procedures MH - Rupture/*drug therapy/physiopathology/surgery MH - Tendon Injuries/*drug therapy/physiopathology/surgery MH - Tendons/physiopathology/surgery MH - Wound Healing/drug effects OTO - NOTNLM OT - PDGF-BB release OT - block copolymers OT - drug delivery systems OT - emulsion electrospining OT - rabbit tenocytes EDAT- 2016/04/14 06:00 MHDA- 2017/10/17 06:00 CRDT- 2016/04/14 06:00 PHST- 2015/12/14 00:00 [received] PHST- 2016/03/04 00:00 [revised] PHST- 2016/04/14 06:00 [entrez] PHST- 2016/04/14 06:00 [pubmed] PHST- 2017/10/17 06:00 [medline] AID - 10.1002/mabi.201500455 [doi] PST - ppublish SO - Macromol Biosci. 2016 Jul;16(7):1048-63. doi: 10.1002/mabi.201500455. Epub 2016 Apr 13. PMID- 27863377 OWN - NLM STAT- MEDLINE DCOM- 20180221 LR - 20181113 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 51 DP - 2016 Dec 20 TI - Variable patterns of ectopic mineralization in Enpp1asj-2J mice, a model for generalized arterial calcification of infancy. PG - 83837-83842 LID - 10.18632/oncotarget.13335 [doi] AB - Generalized arterial calcification of infancy (GACI) is an autosomal recessive disorder characterized by early onset of extensive mineralization of the cardiovascular system. The classical forms of GACI are caused by mutations in the ENPP1 gene, encoding a membrane-bound pyrophosphatase/phosphodiesterase that hydrolyzes ATP to AMP and inorganic pyrophosphate. The asj-2J mouse harboring a spontaneous mutation in the Enpp1 gene has been characterized as a model for GACI. These mutant mice develop ectopic mineralization in skin and vascular connective tissues as well as in cartilage and collagen-rich tendons and ligaments. This study examined in detail the temporal ectopic mineralization phenotype of connective tissues in this mouse model, utilizing a novel cryo-histological method that does not require decalcification of bones. The wild type, heterozygous, and homozygous mice were administered fluorescent mineralization labels at 4 weeks (calcein), 10 weeks (alizarin complexone), and 11 weeks of age (demeclocycline). Twenty-four hours later, outer ears, muzzle skin, trachea, aorta, shoulders, and vertebrae were collected from these mice and examined for progression of mineralization. The results revealed differential timeline for disease initiation and progression in various tissues of this mouse model. It also highlights the advantages of cryo-histological fluorescent imaging technique to study mineral deposition in mouse models of ectopic mineralization disorders. FAU - Siu, Sarah Y AU - Siu SY AD - Department of Dermatology and Cutaneous Biology, The Sidney Kimmel Medical College and The PXE International Center of Excellence in Research and Clinical Care, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Dyment, Nathaniel A AU - Dyment NA AD - Center for Regenerative Medicine and Skeletal Development, University of Connecticut Health Center, Farmington, CT, USA. FAU - Rowe, David W AU - Rowe DW AD - Center for Regenerative Medicine and Skeletal Development, University of Connecticut Health Center, Farmington, CT, USA. FAU - Sundberg, John P AU - Sundberg JP AD - The Jackson Laboratory, Bar Harbor, ME, USA. FAU - Uitto, Jouni AU - Uitto J AD - Department of Dermatology and Cutaneous Biology, The Sidney Kimmel Medical College and The PXE International Center of Excellence in Research and Clinical Care, Thomas Jefferson University, Philadelphia, PA, USA. AD - Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Li, Qiaoli AU - Li Q AD - Department of Dermatology and Cutaneous Biology, The Sidney Kimmel Medical College and The PXE International Center of Excellence in Research and Clinical Care, Thomas Jefferson University, Philadelphia, PA, USA. AD - Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA. LA - eng GR - K01 AR064766/AR/NIAMS NIH HHS/United States GR - P30 CA056036/CA/NCI NIH HHS/United States GR - R01 AR055225/AR/NIAMS NIH HHS/United States PT - Comparative Study PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Anthraquinones) RN - 0 (Fluoresceins) RN - 0 (Fluorescent Dyes) RN - 3952-78-1 (alizarin complexone) RN - 5R5W9ICI6O (Demeclocycline) RN - EC 3.1.4.- (Phosphoric Diester Hydrolases) RN - EC 3.1.4.1 (ectonucleotide pyrophosphatase phosphodiesterase 1) RN - EC 3.6.1.- (Pyrophosphatases) RN - V0YM2B16TS (fluorexon) RN - Arterial calcification of infancy SB - IM MH - Animals MH - Anthraquinones/administration & dosage MH - Connective Tissue/enzymology/*pathology MH - Demeclocycline/administration & dosage MH - Disease Progression MH - Fluoresceins/administration & dosage MH - Fluorescent Dyes/administration & dosage MH - Genetic Predisposition to Disease MH - Heterozygote MH - Homozygote MH - Mice, Inbred BALB C MH - Mice, Mutant Strains MH - Microscopy, Fluorescence/methods MH - *Mutation MH - Phenotype MH - Phosphoric Diester Hydrolases/*genetics/metabolism MH - Pyrophosphatases/*genetics/metabolism MH - Time Factors MH - Vascular Calcification/enzymology/*genetics/*pathology PMC - PMC5341293 OTO - NOTNLM OT - Pathology Section OT - cryohistology OT - ectopic mineralization OT - generalized arterial calcification of infancy OT - mouse models COIS- CONFLICTS OF INTEREST Dr. Sundberg has sponsored research with BIOCON which has no relevance to this project. All other authors state no conflict of interests. EDAT- 2016/11/20 06:00 MHDA- 2018/02/22 06:00 PMCR- 2016/12/20 CRDT- 2016/11/19 06:00 PHST- 2016/10/07 00:00 [received] PHST- 2016/11/02 00:00 [accepted] PHST- 2016/11/20 06:00 [pubmed] PHST- 2018/02/22 06:00 [medline] PHST- 2016/11/19 06:00 [entrez] PHST- 2016/12/20 00:00 [pmc-release] AID - 13335 [pii] AID - 10.18632/oncotarget.13335 [doi] PST - ppublish SO - Oncotarget. 2016 Dec 20;7(51):83837-83842. doi: 10.18632/oncotarget.13335. PMID- 2992893 OWN - NLM STAT- MEDLINE DCOM- 19851015 LR - 20190903 IS - 0300-5208 (Print) IS - 0300-5208 (Linking) VI - 113 DP - 1985 TI - Effect of retinoids on rheumatoid arthritis, a proliferative and invasive non-malignant disease. PG - 191-211 AB - In rheumatoid arthritis synovial tissue proliferates and destroys articular cartilage, bone and tendons. Collagenase is a major mediator of the connective tissue degradation. This enzyme is produced in large quantities by rheumatoid tissue and its synthesis can be inhibited by retinoids. However, knowledge of mechanisms controlling retinoid inhibition of collagenase production and of factors possibly controlling synovial cell proliferation is limited. We found that transforming growth factor beta in combination with epidermal growth factor, epidermal growth factor alone and immune interferon increased proliferation of cultured human and rabbit synovial fibroblasts. Only transforming growth factor beta caused a piling up of cells into foci resembling those seen in primary cultures of human rheumatoid tissue. All the factors were antagonized by retinoids but not by glucocorticoids or indomethacin. Adding retinoids or glucocorticoids to collagenase-producing cells decreased hybridizable collagenase mRNA by 50% within 24 h. Oral administration of retinoids to rats with experimental arthritis decreased clinical disease without toxicity, and inhibited collagenase synthesis by synovial cells taken from treated animals. Retinoids are both antiproliferative and anti-invasive, and therefore may be potential therapeutic agents in the treatment of rheumatoid arthritis. FAU - Brinckerhoff, C E AU - Brinckerhoff CE FAU - Sheldon, L A AU - Sheldon LA FAU - Benoit, M C AU - Benoit MC FAU - Burgess, D R AU - Burgess DR FAU - Wilder, R L AU - Wilder RL LA - eng GR - AM-31643/AM/NIADDK NIH HHS/United States GR - CA 32476/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - Ciba Found Symp JT - Ciba Foundation symposium JID - 0356636 RN - 0 (Growth Inhibitors) RN - 0 (Retinoids) RN - EC 3.4.24.3 (Microbial Collagenase) SB - IM MH - Administration, Oral MH - Animals MH - Arthritis, Infectious/drug therapy MH - Arthritis, Rheumatoid/*drug therapy/enzymology MH - Cells, Cultured MH - Disease Models, Animal MH - Fibroblasts/drug effects MH - Growth Inhibitors MH - Humans MH - Microbial Collagenase/antagonists & inhibitors MH - Rabbits MH - Rats MH - Retinoids/administration & dosage/*pharmacology MH - Streptococcal Infections/drug therapy MH - Synovial Membrane/drug effects MH - Time Factors EDAT- 1985/01/01 00:00 MHDA- 1985/01/01 00:01 CRDT- 1985/01/01 00:00 PHST- 1985/01/01 00:00 [pubmed] PHST- 1985/01/01 00:01 [medline] PHST- 1985/01/01 00:00 [entrez] AID - 10.1002/9780470720943.ch12 [doi] PST - ppublish SO - Ciba Found Symp. 1985;113:191-211. doi: 10.1002/9780470720943.ch12. PMID- 2660711 OWN - NLM STAT- MEDLINE DCOM- 19890714 LR - 20131121 IS - 0151-9638 (Print) IS - 0151-9638 (Linking) VI - 116 IP - 2 DP - 1989 TI - [Rheumatologic effects of etretinate]. PG - 95-102 AB - The effects of chronic hypervitaminosis A and long-term isotretinoin treatment on bone include cortical hyperostosis, ligament calcification and premature epiphyseal closure. Similar effects have now been reported in patients under maintenance treatment with etretinate in high doses. Etretinate, an oral, aromatic, synthetic vitamin A derivative, is widely used in Europe for disorders of keratinization. We report the cases of two patients--one with lamellar ichthyosis, the other with pachyonychia congenita--who developed such bone diseases during treatment with etretinate over 2 and 6 years respectively. The doses ranged from 0.5 to 1 mg/kg/day. Two years after starting treatment (total dose 25 g), the patient with lamellar ichthyosis complained of mechanical pain in the lumbar region and hips. Radiography showed calcification of the extraspinal tendons and ligaments and hyperostosis of the calcaneus bone at the insertion of the plantar ligament. After six years of etretinate treatment (total dose 50 g), the patient with pachyonychia congenita presented with scoliosis and limb length discrepancy. The musculoskeletal abnormalities resembled chronic hypervitaminosis A, with such osseous changes as demineralization, thinning and increased curvature of long bones with osteopenia, and premature closure of the epiphyses. Acroosteolysis was also present. Etretinate has been implicated in the formation of spinal hyperostoses and calcification of extraspinal ligaments in patients who had taken the drug for many years. The occurrence of premature epiphyseal closure in children certainly is a consequence of therapy with relatively high doses of etretinate for six years. But premature epiphyseal closure may also result from trauma to a fragile bone.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Cuny, J F AU - Cuny JF AD - Clinique Dermatologique, Hôpital Fournier, Nancy. FAU - Schmutz, J L AU - Schmutz JL FAU - Terver, M N AU - Terver MN FAU - Aussedat, R AU - Aussedat R FAU - Cointin, M AU - Cointin M FAU - Weber, M AU - Weber M FAU - Beurey, J AU - Beurey J LA - fre PT - Case Reports PT - English Abstract PT - Journal Article PT - Review TT - Effets rhumatologiques de l'étrétinate. PL - France TA - Ann Dermatol Venereol JT - Annales de dermatologie et de venereologie JID - 7702013 RN - 65M2UDR9AG (Etretinate) SB - IM MH - Adolescent MH - Bone Diseases/*chemically induced MH - Bone Diseases, Metabolic/chemically induced MH - Calcinosis/chemically induced MH - Cartilage Diseases/*chemically induced MH - Etretinate/*adverse effects MH - Female MH - Humans RF - 61 EDAT- 1989/01/01 00:00 MHDA- 1989/01/01 00:01 CRDT- 1989/01/01 00:00 PHST- 1989/01/01 00:00 [pubmed] PHST- 1989/01/01 00:01 [medline] PHST- 1989/01/01 00:00 [entrez] PST - ppublish SO - Ann Dermatol Venereol. 1989;116(2):95-102. PMID- 24033590 OWN - NLM STAT- MEDLINE DCOM- 20150123 LR - 20161125 IS - 2042-3306 (Electronic) IS - 0425-1644 (Linking) VI - 46 IP - 4 DP - 2014 Jul TI - Distal limb desensitisation following analgesia of the digital flexor tendon sheath in horses using four different techniques. PG - 488-93 LID - 10.1111/evj.12186 [doi] AB - REASONS FOR PERFORMING STUDY: Controversy exists about the desensitisation obtained after diagnostic analgesia of the digital flexor tendon sheath (DFTS) during lameness examinations. OBJECTIVES: To determine whether DFTS analgesia results in inadvertent desensitisation of the palmar/plantar digital nerves and whether this depends on the injection technique used. STUDY DESIGN: Crossover experimental study. METHODS: The DFTS of 9 horses were injected with local anaesthetic solution and radiodense contrast medium using one of the following techniques: Proximal (at lateral proximal recess of the DFTS), Axial (axial to the lateral proximal sesamoid bone), Base (at base of the lateral proximal sesamoid bone), and Distal (at palmar/plantar mid-pastern). In total, 72 injections were performed. Skin desensitisation at the heel bulbs was tested with a dynamometer before and at 15, 30, 90 and 120 min after injection. RESULTS: Overall, complete desensitisation of a heel bulb at one or more time points after injection occurred in 22 limbs (30.6%). An additional 7 limbs were partially desensitised. Complete skin desensitisation occurred in 10, 3, 4 and 5 limbs using the Proximal, Axial, Base and Distal techniques respectively. Significant differences between techniques were only found at T30. The probability of skin desensitisation at the heel bulbs was 4 times higher when using the Proximal compared with the Axial and Base techniques in the forelimbs, and 3 times higher compared with the Axial and Distal techniques in the hindlimbs. Skin desensitisation nearly always occurred exclusively on the lateral heel bulb. Bilateral desensitisation only occurred in 5 limbs. CONCLUSIONS: Anaesthesia of the palmar/plantar digital nerves with distal limb desensitisation often occurs after DFTS analgesia. A higher chance of desensitisation exists when injecting the proximal DFTS recess. It is advisable to verify skin sensitivity at the heel bulbs after DFTS analgesia to avoid false interpretations about the origin of pain causing lameness. CI - © 2013 EVJ Ltd. FAU - Jordana, M AU - Jordana M AD - Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. FAU - Martens, A AU - Martens A FAU - Duchateau, L AU - Duchateau L FAU - Vanderperren, K AU - Vanderperren K FAU - Saunders, J AU - Saunders J FAU - Oosterlinck, M AU - Oosterlinck M FAU - Pille, F AU - Pille F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131121 PL - United States TA - Equine Vet J JT - Equine veterinary journal JID - 0173320 RN - 0 (Analgesics) RN - 0 (Anesthetics, Local) RN - 0 (Triiodobenzoic Acids) RN - B6E06QE59J (Mepivacaine) RN - HW8W27HTXX (iodixanol) SB - IM MH - Analgesics MH - Anesthesia, Local/methods/*veterinary MH - Anesthetics, Local/administration & dosage/*pharmacology MH - Animals MH - Cross-Over Studies MH - Female MH - *Horses MH - Injections/methods/*veterinary MH - Male MH - Mepivacaine/administration & dosage/*pharmacology MH - Tendons MH - Triiodobenzoic Acids/administration & dosage/pharmacology OTO - NOTNLM OT - diagnostic analgesia OT - digital flexor tendon sheath OT - horse OT - local anaesthesia OT - palmar/plantar digital nerve OT - synoviocentesis EDAT- 2013/09/17 06:00 MHDA- 2015/01/24 06:00 CRDT- 2013/09/17 06:00 PHST- 2013/03/01 00:00 [received] PHST- 2013/08/27 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2015/01/24 06:00 [medline] AID - 10.1111/evj.12186 [doi] PST - ppublish SO - Equine Vet J. 2014 Jul;46(4):488-93. doi: 10.1111/evj.12186. Epub 2013 Nov 21. PMID- 32559842 OWN - NLM STAT- MEDLINE DCOM- 20210216 LR - 20221207 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 127 DP - 2020 Jul TI - Matrine attenuates heterotopic ossification by suppressing TGF-β induced mesenchymal stromal cell migration and osteogenic differentiation. PG - 110152 LID - S0753-3322(20)30344-9 [pii] LID - 10.1016/j.biopha.2020.110152 [doi] AB - PURPOSE OF THE STUDY: Heterotopic ossification (HO) is a debilitating disease characterized by extraskeletal bone formation. Active TGF-β recruits mesenchymal stromal cells (MSCs), which contribute to trauma-induced HO. Inhibiting TGF-β induced MSC migration and osteogenic differentiation could be a promising treatment for HO. Matrine is an alkaloid from the genus Sophora that can suppress pancreatic and hepatic fibrosis by regulating TGF-β/Smad signaling. We conducted this study to evaluate the effects of matrine on HO and explore the mechanisms, we carried out this study. MATERIALS AND METHODS: Achilles tendon puncture was performed in C57BL/6J male mice to establish the HO model. Following treatment with matrine for 3, 6, 9, and 15 weeks, mice were sacrificed and tendons were collected. In vivo, micro-CT, hematoxylin and eosin staining, CD73 and CD90 immunofluorescence, and osteocalcin staining were used to evaluate the development of HO. In vitro, a transwell migration assay was used to evaluate MSC migration. Immunohistochemistry, immunofluorescence and western blotting were used to evaluate the TGF-β/Smad2/3 pathway. Real-time PCR was conducted to analyze the transcription of alkaline phosphatase (Alp), runt-related transcription factor-2 (Runx2), osteocalcin (Ocn), osteopontin (Opn), and type I collagen (Col1). ALP activity and alizarin red staining were used to assess MSC osteogenic differentiation. RESULTS: In vivo, matrine significantly reduced ossification and inhibited HO progression. In vitro, matrine significantly suppressed MSC migration, ALP activity, and mineralization of MSCs. Mechanistically, matrine inhibited TGF-β induced Smad2/3 phosphorylation and transcription of Runx2, Alp, and Ocn after osteoinduction. CONCLUSIONS: Matrine inhibited HO by suppressing the migration and osteogenic differentiation of TGF-β-induced-MSCsin mice. CI - Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. FAU - Mao, Dong AU - Mao D AD - Orthopaedic Institute, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, 214062, China. FAU - Pan, Xiaoyun AU - Pan X AD - Orthopaedic Institute, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, 214062, China. FAU - Rui, Yongjun AU - Rui Y AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, 214062, China. FAU - Li, Fengfeng AU - Li F AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, 214062, China. Electronic address: fengmale@foxmail.com. LA - eng PT - Journal Article DEP - 20200518 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Alkaloids) RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (Quinolizines) RN - 0 (Runx2 protein, mouse) RN - 0 (Transforming Growth Factor beta) RN - 104982-03-8 (Osteocalcin) RN - EC 3.1.3.1 (Alkaline Phosphatase) RN - 0 (Matrines) SB - IM MH - Alkaline Phosphatase/metabolism MH - Alkaloids/*pharmacology MH - Animals MH - Cell Differentiation/*physiology MH - Cell Movement/*physiology MH - Cells, Cultured MH - Core Binding Factor Alpha 1 Subunit/metabolism MH - Male MH - Mesenchymal Stem Cells/*physiology MH - Mice MH - Ossification, Heterotopic/*prevention & control MH - Osteocalcin/metabolism MH - Osteogenesis/*physiology MH - Quinolizines/*pharmacology MH - Transforming Growth Factor beta/*physiology MH - Matrines OTO - NOTNLM OT - Heterotopic ossification OT - Matrine OT - Mesenchymal stromal cells OT - Osteogenic differentiation OT - TGF-β COIS- Declaration of Competing Interest The authors declare no competing interests. EDAT- 2020/06/21 06:00 MHDA- 2021/02/17 06:00 CRDT- 2020/06/21 06:00 PHST- 2019/12/07 00:00 [received] PHST- 2020/03/30 00:00 [revised] PHST- 2020/04/04 00:00 [accepted] PHST- 2020/06/21 06:00 [entrez] PHST- 2020/06/21 06:00 [pubmed] PHST- 2021/02/17 06:00 [medline] AID - S0753-3322(20)30344-9 [pii] AID - 10.1016/j.biopha.2020.110152 [doi] PST - ppublish SO - Biomed Pharmacother. 2020 Jul;127:110152. doi: 10.1016/j.biopha.2020.110152. Epub 2020 May 18. PMID- 26577051 OWN - NLM STAT- MEDLINE DCOM- 20161102 LR - 20220113 IS - 1096-0929 (Electronic) IS - 1096-0929 (Linking) VI - 149 IP - 2 DP - 2016 Feb TI - Prevention of Simvastatin-Induced Inhibition of Tendon Cell Proliferation and Cell Cycle Progression by Geranylgeranyl Pyrophosphate. PG - 326-34 LID - 10.1093/toxsci/kfv239 [doi] AB - Statins have been reported to induce tendinopathy and even tendon rupture. The present study was designed to investigate the potential molecular mechanism underlying the adverse effect of simvastatin on tendon cells. An in vitro tendon healing model was performed using tendon cells isolated from rat Achilles tendons. The viability of tendon cells and cell cycle progression were examined by the MTT assay and flow cytometric analysis, respectively. Immunofluorescent staining for Ki-67 was used to assess the proliferation activity of tendon cells. Western blot analysis and coimmunoprecipitation was used to determine the protein expression of cell cycle-related proteins. To investigate the potential mechanism underlying the effect of statins on tendon cells, mevalonate, farnesyl pyrophosphate (FPP), or geranylgeranyl pyrophosphate (GGPP) was added to simvastatin-treated tendon cells. Simvastatin inhibited the in vitro tendon healing model and tendon cell proliferation in a dose-dependent manner. Immunofluorescent staining demonstrated reduced ki-67 expression in simvastatin-treated tendon cells. Furthermore, simvastatin induced cell cycle arrest at the G1 phase. The expression levels of cdk1, cdk2, cyclin A, and cyclin E were downregulated by simvastatin in a dose-dependent manner. The inhibitory effect of simvastatin was proved to mediate the reduction of mevalonate, and the addition of exogenous GGPP completely prevented the inhibitory effect of simvastatin on tendon cells. The present study demonstrated, for the first time, the molecular mechanism underlying simvastatin-induced tendinopathy or tendon rupture. GGPP was shown to prevent the adverse effect of simvastatin in tendon cells without interfering with its cholesterol-reducing efficacy. CI - © The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. FAU - Tsai, Wen-Chung AU - Tsai WC AD - *Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City, Taiwan; College of Medicine, Chang Gung University, Taoyuan City, Taiwan; FAU - Yu, Tung-Yang AU - Yu TY AD - *Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City, Taiwan; FAU - Lin, Li-Ping AU - Lin LP AD - *Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City, Taiwan; FAU - Cheng, Mei-Ling AU - Cheng ML AD - Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan; FAU - Chen, Cheng-Lun AU - Chen CL AD - *Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City, Taiwan; FAU - Pang, Jong-Hwei S AU - Pang JH AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City, Taiwan jonghwei@mail.cgu.edu.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151116 PL - United States TA - Toxicol Sci JT - Toxicological sciences : an official journal of the Society of Toxicology JID - 9805461 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Polyisoprenyl Phosphates) RN - AGG2FN16EV (Simvastatin) RN - N21T0D88LX (geranylgeranyl pyrophosphate) RN - S5UOB36OCZ (Mevalonic Acid) SB - IM MH - Animals MH - Cell Cycle/*drug effects MH - Cell Proliferation/*drug effects MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Mevalonic Acid/pharmacology MH - Polyisoprenyl Phosphates/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Simvastatin/*pharmacology MH - Tendons/cytology/*drug effects OTO - NOTNLM OT - geranylgeranyl pyrophosphate OT - proliferation OT - simvastatin OT - tendon cell EDAT- 2015/11/19 06:00 MHDA- 2016/11/03 06:00 CRDT- 2015/11/19 06:00 PHST- 2015/11/19 06:00 [entrez] PHST- 2015/11/19 06:00 [pubmed] PHST- 2016/11/03 06:00 [medline] AID - kfv239 [pii] AID - 10.1093/toxsci/kfv239 [doi] PST - ppublish SO - Toxicol Sci. 2016 Feb;149(2):326-34. doi: 10.1093/toxsci/kfv239. Epub 2015 Nov 16. PMID- 11103693 OWN - NLM STAT- MEDLINE DCOM- 20001220 LR - 20171116 IS - 0722-1819 (Print) IS - 0722-1819 (Linking) VI - 32 IP - 5 DP - 2000 Sep TI - [Chronic paronychia and synovialitis of extensor tendons due to Mycobacterium marinum. Is diagnosis or treatment the problem?]. PG - 343-6 AB - Most infections of the upper extremity are caused by staphylococcus or streptococcus and respond well to beta-lactam antibiotics. Hand surgeons should be aware of the possible diagnosis of Mycobacterium marinum infection: 90% of the lesions are found in the upper extremity. We present a case of a chronic, cutaneous lesion of the right middle finger with synovialitis of the extensor tendons observed in a 35-year-old woman. Routine cultures from tissue of the infected finger led to the diagnosis of paronychia due to staphylococcus aureus. Despite surgical and antibacterial treatment, the lesion persisted and the patient developed multiple raised, non-tender satellite lesions to the right hand and elbow. Based on the clinical aspect and a detailed history (she kept fish and had suffered a chicken bone stab to her middle finger 12 weeks earlier), we suspected a Mycobacterium marinum infection. Tissue was obtained mainly by synovialectomy. Culture of the biopsy tissue for Mycobacterium marinum confirmed the diagnosis. The patient responded to a triple therapy (rifabutin, ethambutol and clarithromycin) and had an uncomplicated recovery. The importance of a high index of suspicion, adequate examination and a complete patient's history for a correct diagnosis is stressed. Culture for Mycobacterium marinum is not routinely performed and ought to be initiated once an infection is suspected. We also discuss the best timing for the onset of medical treatment. FAU - Witthaut, J AU - Witthaut J AD - Abteilung für Handchirurgie, St. Josef Hospitale, Katholische Kliniken Ruhrhalbinsel gGmbH, Essen. webmaster@Handchirurgie-online.de FAU - Möhlen, S AU - Möhlen S LA - ger PT - Case Reports PT - Journal Article TT - Chronische Nagelwallinfektion und Synovialitis der Strecksehnen durch Mycobacterium marinum. Ist die Diagnose oder die Therapie das Problem? PL - Germany TA - Handchir Mikrochir Plast Chir JT - Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... JID - 8302815 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antibiotics, Antitubercular) RN - 0 (Antitubercular Agents) RN - 1W306TDA6S (Rifabutin) RN - 8G167061QZ (Ethambutol) RN - H1250JIK0A (Clarithromycin) SB - IM MH - Adult MH - Anti-Bacterial Agents/administration & dosage MH - Antibiotics, Antitubercular/administration & dosage MH - Antitubercular Agents/administration & dosage MH - Biopsy MH - Chronic Disease MH - Clarithromycin/administration & dosage MH - Drug Therapy, Combination MH - Elbow Joint MH - Ethambutol/administration & dosage MH - Female MH - Humans MH - *Mycobacterium Infections, Nontuberculous/diagnosis/drug therapy MH - *Mycobacterium marinum/isolation & purification MH - Paronychia/diagnosis/drug therapy/*etiology MH - Rifabutin/administration & dosage MH - Synovectomy MH - Synovial Membrane/microbiology MH - Synovitis/diagnosis/drug therapy/*etiology EDAT- 2000/12/05 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/12/05 11:00 PHST- 2000/12/05 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/12/05 11:00 [entrez] AID - 10.1055/s-2000-10942 [doi] PST - ppublish SO - Handchir Mikrochir Plast Chir. 2000 Sep;32(5):343-6. doi: 10.1055/s-2000-10942. PMID- 11945005 OWN - NLM STAT- MEDLINE DCOM- 20021018 LR - 20031114 IS - 0021-9975 (Print) IS - 0021-9975 (Linking) VI - 126 IP - 2-3 DP - 2002 Feb-Apr TI - Effect of beta-aminopropionitrile and hyaluronic acid on repair of collagenase-induced injury of the rabbit Achilles tendon. PG - 161-70 AB - Collagenase was injected into the Achilles tendon of both hind legs of 10 clinically normal adult male New Zealand white rabbits. One month after induction of the injury, beta-aminoproprionitrile (BAPN) or hyaluronic acid (HA) was injected into the tendon core of the right hind leg of each rabbit, the left hind leg being left untreated. The treatment effects were evaluated by electron microscopy and analysis of the glycosaminoglycan (GAG) content of samples at 2 and 6 months post-treatment. At 2 months, collagen fibrils in tendons from both hind legs were relatively small in diameter, irregularly arranged, and interspersed with abundant active tenocytes as compared with those in normal tendon uninjured by collagenase. In the matrix, the amount of HA increased, but chondroitin-6-sulphate was eliminated. At 6 months, BAPN-treated tendons had small-diameter, regularly arranged collagen fibrils. HA-treated tendons, on the other hand, had large diameters, as well as regularly arranged collagen fibrils by comparison with non-treated tendon. The results suggest that HA, unlike BAPN, promoted healing. CI - Copyright Harcourt Publishers Ltd. FAU - Yamamoto, E AU - Yamamoto E AD - Department of Veterinary Anatomy, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido 069-8501, Japan. FAU - Hata, D AU - Hata D FAU - Kobayashi, A AU - Kobayashi A FAU - Ueda, H AU - Ueda H FAU - Tangkawattana, P AU - Tangkawattana P FAU - Oikawa, M AU - Oikawa M FAU - Takehana, K AU - Takehana K LA - eng PT - Journal Article PL - England TA - J Comp Pathol JT - Journal of comparative pathology JID - 0102444 RN - 0 (Fibrillar Collagens) RN - 0 (Glycosaminoglycans) RN - 151-18-8 (Aminopropionitrile) RN - 9004-61-9 (Hyaluronic Acid) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Achilles Tendon/drug effects/metabolism/*pathology MH - Aminopropionitrile/administration & dosage/*therapeutic use MH - Animals MH - Collagenases/*pharmacology MH - Disease Models, Animal MH - Extracellular Matrix/drug effects/metabolism/ultrastructure MH - Fibrillar Collagens/drug effects/metabolism/ultrastructure MH - Glycosaminoglycans/metabolism MH - Hyaluronic Acid/administration & dosage/*therapeutic use MH - Injections, Intralesional MH - Male MH - Microscopy, Electron, Scanning MH - Rabbits MH - Tendon Injuries/chemically induced/*drug therapy/metabolism MH - *Wound Healing/drug effects/physiology EDAT- 2002/04/12 10:00 MHDA- 2002/10/19 04:00 CRDT- 2002/04/12 10:00 PHST- 2002/04/12 10:00 [pubmed] PHST- 2002/10/19 04:00 [medline] PHST- 2002/04/12 10:00 [entrez] AID - S0021997501905389 [pii] AID - 10.1053/jcpa.2001.0538 [doi] PST - ppublish SO - J Comp Pathol. 2002 Feb-Apr;126(2-3):161-70. doi: 10.1053/jcpa.2001.0538. PMID- 17932681 OWN - NLM STAT- MEDLINE DCOM- 20080414 LR - 20211020 IS - 0340-1855 (Print) IS - 0340-1855 (Linking) VI - 66 IP - 7 DP - 2007 Nov TI - [Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy]. PG - 573-4, 576-8 AB - Calcium pyrophosphate dihydrate deposition (CPPDD) disease is the term used to describe a group of common and potentially severe metabolic arthropathies. In these, CPPD crystals form and are deposited in the cartilage matrix (chondrocalcinosis) and induce inflammatory and/or destructive mechanisms. Most cases are idiopathic, but hyperparathyroidism, hemochromatosis, hypomagnesemia and hypophosphatemia can promote or cause chondrocalcinosis. Early disease (with onset before the age of 60 years) thus requires that the patient be examined for these metabolic conditions, particularly hemochromatosis. The prevalence of CPPDD disease in the general population increases with age, being 10-15% in the age group 65-75 years and more than 40% in the over-80s. Although frequently asymptomatic, chondrocalcinosis can involve severe acute attacks of inflammatory arthritis (pseudogout) and also various types of chronic arthropathy including pseudorheumatoid arthritis, pseudo-osteoarthritis, and pseudoneuropathic joint disease. CPPD crystals can also be deposited in the bursae, ligaments, and tendons and generate inflammation and/or ruptures. The diagnosis is based on synovial fluid analysis (positively birefringent CPPD crystals visualized by compensated polarized light microscopy) and X-rays (punctate and linear radiodense areas in fibrocartilage and hyaline cartilage). Treatment is primarily symptomatic, since there is no known drug that can prevent progression of the joint destruction). Nonsteroid anti-inflammatory drugs (NSAIDs) and intra-articular or systemic glucocorticoids (amounts must be only small if use is prolonged) are the most useful treatments. Colchicine can be effective in recurring pseudogout, and magnesium can be used prophylactically. In a small uncontrolled series methotrexate was effective and aroused interest; it can be used when other treatments fail. FAU - Announ, N AU - Announ N AD - Division de Rhumatologie, Hôpital Universitaire de Genève, 26 Avenaue de Beau-Séjour, 1211, Genève, Schweiz. FAU - Guerne, P-A AU - Guerne PA LA - ger PT - English Abstract PT - Journal Article TT - Diagnose und Therapie der Kalziumpyrophosphatkristall-induzierten Arthropathie. PL - Germany TA - Z Rheumatol JT - Zeitschrift fur Rheumatologie JID - 0414162 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Glucocorticoids) RN - 0 (Gout Suppressants) RN - 0 (Interleukin-1beta) RN - SML2Y3J35T (Colchicine) RN - X69NU20D19 (Calcium Pyrophosphate) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Aged MH - Aged, 80 and over MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Calcium Pyrophosphate/metabolism MH - Cartilage, Articular/metabolism MH - Chondrocalcinosis/*diagnosis/etiology/therapy MH - Colchicine/therapeutic use MH - Diagnosis, Differential MH - Disease Progression MH - Glucocorticoids/therapeutic use MH - Gout Suppressants/therapeutic use MH - Humans MH - Injections, Intra-Articular MH - Interleukin-1beta/antagonists & inhibitors MH - Methotrexate/therapeutic use MH - Middle Aged MH - Risk Factors MH - Synovial Membrane/metabolism EDAT- 2007/10/13 09:00 MHDA- 2008/04/15 09:00 CRDT- 2007/10/13 09:00 PHST- 2007/10/13 09:00 [pubmed] PHST- 2008/04/15 09:00 [medline] PHST- 2007/10/13 09:00 [entrez] AID - 10.1007/s00393-007-0221-1 [doi] PST - ppublish SO - Z Rheumatol. 2007 Nov;66(7):573-4, 576-8. doi: 10.1007/s00393-007-0221-1. PMID- 30777116 OWN - NLM STAT- MEDLINE DCOM- 20190607 LR - 20200225 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 14 IP - 1 DP - 2019 Feb 18 TI - Combined ascorbic acid and T(3) produce better healing compared to bone marrow mesenchymal stem cells in an Achilles tendon injury rat model: a proof of concept study. PG - 54 LID - 10.1186/s13018-019-1098-9 [doi] LID - 54 AB - BACKGROUND: This pilot study aimed to ascertain whether the local application of ascorbic acid (AA), of T(3), and of rat (r) bone marrow mesenchymal stem cells (BMSCs), alone or in all possible combinations, promoted healing after an Achilles tendon injury in a rat model. METHODS: An Achilles tendon defect was produced in 24 6-8-week-old male inbred Lewis rats. The animals were then randomly divided into eight groups of three rats each. The tendon defect was filled with 50 μL of phosphate-buffered saline (PBS) containing (1) 50 μg/mL AA (AA group), (2) 10(-7) M T(3) (T(3) group), (3) 4 × 10(6) rBMSCs (rBMSC group), (4) 50 μg/mL AA + 10(-7) M T(3) (AA + T(3) group), (5) 4 × 10(6) rBMSCs + 50 μg/mL AA (rBMSC + AA group), (6) 4 × 10(6) rBMSCs + 10(-7) M T(3) (rBMSC + T(3) group), (7) 4 × 10(6) rBMSCS + 50 μg/mL AA + 10(-7) M T(3) (rBMSC + AA + T(3) group), and (8) PBS only (control group: CTRL). All treatments were administered by local injection immediately after the tendons had been damaged; additionally, AA was injected also on the second and fourth day from the first injection (for groups 1, 4, 5, and 7), and T(3) was injected again every day for 4 days (for groups 2, 4, 6, and 7). At 30 days from initial treatment, tendon samples were harvested, and the quality of tendon repair was evaluated using histological and histomorphological analysis. The structure and morphology of the injured Achilles tendons were evaluated using the modified Svensson, Soslowsky, and Cook score, and the collagen type I and III ratio was calculated. RESULTS: The group treated with AA combined with T(3) displayed the lowest Svensson, Soslowsky, and Cook total score value of all tissue sections at histopathological examination, with fiber structure close to regular orientation, normal-like tendon vasculature, and no cartilage formation. AA + T(3) also showed the highest collagen I and the lowest collagen III values compared to all other treatments including the CTRL. CONCLUSION: There are potential benefits using a combination of AA and T(3) to accelerate tendon healing. FAU - Oliva, Francesco AU - Oliva F AD - Department of Orthopaedics and Traumatology, Surgery and Dentistry, Azienda Ospedaliera San Giovanni di Dio e Ruggi d'Aragona, University of Salerno School of Medicine, Salerno, Italy. FAU - Maffulli, Nicola AU - Maffulli N AUID- ORCID: 0000-0002-5327-3702 AD - Department of Orthopaedics and Traumatology, Surgery and Dentistry, Azienda Ospedaliera San Giovanni di Dio e Ruggi d'Aragona, University of Salerno School of Medicine, Salerno, Italy. n.maffulli@qmul.ac.uk. AD - Centre for Sports and Exercise Medicine, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Mile End Hospital, London, UK. n.maffulli@qmul.ac.uk. AD - Institute of Science and Technology in Medicine, Keele University Medical School, Stoke on Trent, UK. n.maffulli@qmul.ac.uk. FAU - Gissi, Clarissa AU - Gissi C AD - U.O.C. of Immunohaematology and Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, Pescara, Italy. FAU - Veronesi, Francesca AU - Veronesi F AD - Laboratory of Preclinical and Surgical Studies, Research Innovation and Technology Department (RIT), IRCCS Rizzoli Orthopedic Institute, Via di Barbiano 1/10, 40136, Bologna, Italy. FAU - Calciano, Lucia AU - Calciano L AD - Dipartimento di Sanità Pubblica e Medicina di Comunità, Sezione di Epidemiologia e Statistica Medica, Università di Verona, 37134, Verona, Italy. FAU - Fini, Milena AU - Fini M AD - Laboratory of Preclinical and Surgical Studies, Research Innovation and Technology Department (RIT), IRCCS Rizzoli Orthopedic Institute, Via di Barbiano 1/10, 40136, Bologna, Italy. FAU - Brogini, Silvia AU - Brogini S AD - Laboratory of Preclinical and Surgical Studies, Research Innovation and Technology Department (RIT), IRCCS Rizzoli Orthopedic Institute, Via di Barbiano 1/10, 40136, Bologna, Italy. FAU - Gallorini, Marialucia AU - Gallorini M AD - Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy. FAU - Antonetti Lamorgese Passeri, Cristina AU - Antonetti Lamorgese Passeri C AD - U.O.C. of Immunohaematology and Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, Pescara, Italy. FAU - Bernardini, Roberta AU - Bernardini R AD - Interdepartmental Service Centre - Station for Animal Technology, University of Rome "Tor Vergata", Rome, Italy. FAU - Cicconi, Rosella AU - Cicconi R AD - Interdepartmental Service Centre - Station for Animal Technology, University of Rome "Tor Vergata", Rome, Italy. FAU - Mattei, Maurizio AU - Mattei M AD - Interdepartmental Service Centre - Station for Animal Technology, University of Rome "Tor Vergata", Rome, Italy. AD - Department of Biology, University of Rome "Tor Vergata", Rome, Italy. FAU - Berardi, Anna Concetta AU - Berardi AC AD - U.O.C. of Immunohaematology and Transfusion Medicine, Laboratory of Stem Cells, Spirito Santo Hospital, Pescara, Italy. LA - eng GR - PCFF-2017-27.3/PCFF Foundation, Pescara, Italy/ PT - Comparative Study PT - Journal Article DEP - 20190218 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 06LU7C9H1V (Triiodothyronine) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Achilles Tendon/drug effects/*injuries/pathology MH - Animals MH - Ascorbic Acid/*administration & dosage MH - Cells, Cultured MH - Disease Models, Animal MH - Drug Therapy, Combination MH - Male MH - Mesenchymal Stem Cell Transplantation/*methods MH - Pilot Projects MH - *Proof of Concept Study MH - Rats MH - Rats, Inbred Lew MH - Rupture/pathology/*therapy MH - Triiodothyronine/*administration & dosage MH - Wound Healing/drug effects/physiology PMC - PMC6380036 OTO - NOTNLM OT - Ascorbic acid OT - T3, bone marrow mesenchymal stem cells OT - Tendon OT - Thyroid hormones COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Ethical approval was obtained from Italian Health Ministry approval n°513/2016-PR. Not applicable. Consent was not necessary for our study. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/02/20 06:00 MHDA- 2019/06/08 06:00 PMCR- 2019/02/18 CRDT- 2019/02/20 06:00 PHST- 2018/06/10 00:00 [received] PHST- 2019/02/07 00:00 [accepted] PHST- 2019/02/20 06:00 [entrez] PHST- 2019/02/20 06:00 [pubmed] PHST- 2019/06/08 06:00 [medline] PHST- 2019/02/18 00:00 [pmc-release] AID - 10.1186/s13018-019-1098-9 [pii] AID - 1098 [pii] AID - 10.1186/s13018-019-1098-9 [doi] PST - epublish SO - J Orthop Surg Res. 2019 Feb 18;14(1):54. doi: 10.1186/s13018-019-1098-9. PMID- 23131435 OWN - NLM STAT- MEDLINE DCOM- 20140326 LR - 20161125 IS - 1873-1600 (Electronic) IS - 1466-853X (Linking) VI - 14 IP - 3 DP - 2013 Aug TI - High volume image guided injections for the management of chronic tendinopathy of the main body of the Achilles tendon. PG - 163-7 LID - S1466-853X(12)00078-8 [pii] LID - 10.1016/j.ptsp.2012.07.002 [doi] AB - OBJECTIVES: Several substances are routinely injected in and around tendons. The present study evaluated the long term effects of high volume image guided injection (HVIGI) of normal saline, local anaesthetic and aprotinin in athletic patients with resistant tendinopathy of the main body of the Achilles tendon. DESIGN: Case series. METHODS: The study included a series of 94 athletes (69 men and 25 women; average age 37.5 years, range 22-63) with ultrasound confirmed tendinopathy of the main body of the Achilles tendon. All the patients had not improved after at least three months of conservative management. Patients were injected with 10 mL of 0.5% Bupivacaine Hydrochloride, 25 mg aprotinin, and up to 40 mL of injectable normal saline. We prospectively administered the Victorian Institute of Sport Assessment-Achilles tendon (VISA-A) to assess the short- and long-term pain and functional improvement. RESULTS: At baseline (n = 94), the VISA-A score was 41.7 ± 23.2 (range 11-60), and had improved to 74.6 ± 21.4 (range 71-100) by 12 months (n = 87) (p = 0.003), with no significant difference between sexes. CONCLUSION: HVIGI with aprotinin significantly reduces pain and improves function in patients with chronic Achilles tendinopathy in the short- and long-term follow up. CI - Copyright © 2012 Elsevier Ltd. All rights reserved. FAU - Maffulli, Nicola AU - Maffulli N AD - Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry, Mile End Hospital, 275 Bancroft Road, London E1 4DG, UK. n.maffulli@qmul.ac.uk FAU - Spiezia, Filippo AU - Spiezia F FAU - Longo, Umile Giuseppe AU - Longo UG FAU - Denaro, Vincenzo AU - Denaro V FAU - Maffulli, Gayle D AU - Maffulli GD LA - eng PT - Journal Article DEP - 20121104 PL - England TA - Phys Ther Sport JT - Physical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine JID - 100940513 RN - 0 (Anesthetics, Local) RN - 0 (Hemostatics) RN - 9087-70-1 (Aprotinin) RN - Y8335394RO (Bupivacaine) SB - IM MH - Achilles Tendon/diagnostic imaging/*drug effects MH - Adult MH - Anesthetics, Local/*administration & dosage MH - Aprotinin/*administration & dosage MH - Athletic Injuries/diagnostic imaging/*drug therapy MH - Bupivacaine/*administration & dosage MH - Female MH - Hemostatics/*administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Tendinopathy/diagnostic imaging/*drug therapy MH - Ultrasonography, Doppler, Color MH - *Ultrasonography, Interventional OTO - NOTNLM OT - Achilles tendon OT - Athletes OT - Injections OT - Neovascularization OT - Sports EDAT- 2012/11/08 06:00 MHDA- 2014/03/29 06:00 CRDT- 2012/11/08 06:00 PHST- 2011/12/22 00:00 [received] PHST- 2012/04/19 00:00 [revised] PHST- 2012/07/02 00:00 [accepted] PHST- 2012/11/08 06:00 [entrez] PHST- 2012/11/08 06:00 [pubmed] PHST- 2014/03/29 06:00 [medline] AID - S1466-853X(12)00078-8 [pii] AID - 10.1016/j.ptsp.2012.07.002 [doi] PST - ppublish SO - Phys Ther Sport. 2013 Aug;14(3):163-7. doi: 10.1016/j.ptsp.2012.07.002. Epub 2012 Nov 4. PMID- 24186775 OWN - NLM STAT- MEDLINE DCOM- 20151208 LR - 20211021 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 29 IP - 3 DP - 2014 May TI - Analysis of the effect of phototherapy in model with traumatic Achilles tendon injury in rats. PG - 1075-81 LID - 10.1007/s10103-013-1468-1 [doi] AB - The aim of this study was to investigate the effect of low-intensity laser (LILT) infrared (830 nm) therapy in tendon inflammation, tendinitis induced by mechanical trauma in rat Achilles tendon. For this, we used 65 young male Wistar rats, weighing ± 300 g divided into different groups: C = control (n = 5) and experimental (n = 10/group), with two different times of sacrifice such as treated with L = laser, D = treated with diclofenac, and T = untreated injured. The tendon inflammation was induced by controlled contusion in the medial region of the Achilles tendon of the animals. The treated groups received some kind of intervention every 24 h, all groups were sacrificed on the 7th or 14th day after the trauma. The tendons were dissected, extracted, and sent for analysis. Histological analysis of the L group showed a decrease in the number of inflammatory cells in relation to other groups in both periods studied. The comparative results between the number of inflammatory cells in the control and treated groups at 7 and 14 days showed statistically significant differences. Qualitative analysis findings obtained by the picrosirius red technique under polarized light showed that in 7 days, the T group presented collagen types I and III in the same proportion; group D presented a predominance of type III fibers, while in group L, type I collagen predominated. The 14-day group D showed collagen types I and III in the same proportion, while in group L, there was a predominance of type I fibers. Biomechanical analysis showed that 7-day groups L and C showed similar stiffness and increased breaking strength. The 14-day groups L and C showed greater rupturing strength as well as increased stiffness angle. Group D showed a decrease of maximum traction strength and degree of rigidity. It was concluded that treatment with LIL in the parameters used and the times studied reduces migration of inflammatory cells and improves the quality of repair while reducing the functional limitations. FAU - Casalechi, Heliodora Leão AU - Casalechi HL AD - Post Graduate Program in Rehabilitation Sciences, Universidade Nove de Julho (UNINOVE), Rua Vergueiro, 235, São Paulo, SP, 01504-001, Brazil. FAU - de Farias Marques, Anna Cristina AU - de Farias Marques AC FAU - da Silva, Evela Aparecida Pereira AU - da Silva EA FAU - Aimbire, Flávio AU - Aimbire F FAU - Marcos, Rodrigo Labat AU - Marcos RL FAU - Lopes-Martins, Rodrigo A B AU - Lopes-Martins RA FAU - de Carvalho, Paulo de Tarso Camilo AU - de Carvalho Pde T FAU - Albertini, Regiane AU - Albertini R LA - eng PT - Journal Article DEP - 20131102 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Collagen Type I) RN - 144O8QL0L1 (Diclofenac) SB - IM MH - Achilles Tendon/injuries/physiopathology/radiation effects MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use MH - Biomechanical Phenomena MH - Collagen Type I/metabolism MH - Diclofenac/pharmacology/therapeutic use MH - *Low-Level Light Therapy MH - Male MH - Rats, Wistar MH - Tendinopathy/immunology/*radiotherapy MH - Tendon Injuries/immunology/*radiotherapy MH - Wound Healing/radiation effects EDAT- 2013/11/05 06:00 MHDA- 2015/12/15 06:00 CRDT- 2013/11/05 06:00 PHST- 2013/06/05 00:00 [received] PHST- 2013/10/13 00:00 [accepted] PHST- 2013/11/05 06:00 [entrez] PHST- 2013/11/05 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] AID - 10.1007/s10103-013-1468-1 [doi] PST - ppublish SO - Lasers Med Sci. 2014 May;29(3):1075-81. doi: 10.1007/s10103-013-1468-1. Epub 2013 Nov 2. PMID- 12666206 OWN - NLM STAT- MEDLINE DCOM- 20031229 LR - 20131121 IS - 1058-8388 (Print) IS - 1058-8388 (Linking) VI - 226 IP - 4 DP - 2003 Apr TI - Expression and regulation of eHAND during limb development. PG - 690-701 AB - eHAND is a bHLH transcription factor with important functions during embryogenesis. Here, we report that eHAND has a dynamic pattern of expression during limb development. In chick embryos, eHAND expression is first observed in the ventral mesoderm of the emerging limb. Its expression is then restricted to an anteroventral area of mesoderm at mid-level in the proximodistal axis. At later stages, expression is observed in the autopod encompassing the ventral tendons of the digits. In mouse embryos, only the anteroventral domain of expression is conserved, the early ventral expression not being detectable and the late pattern of expression differing clearly from that in the chick. A constant feature of all areas of expression is their ventral and anterior localization. Respecification of the anterior mesoderm as occurs secondarily to Sonic hedgehog (SHH) or retinoic acid application to the anterior border leads to down-regulation of eHAND expression. Accordingly, eHAND expression is not detectable in talpid(2) mutant limbs, which are considered to be posteriorized limbs. However, eHAND expression is little modified in oligozeugodactyly, a chick mutant that lacks Shh signaling in the limb but retains certain anteroposterior polarity. Interestingly, eHAND expression is also linked to the ventral identity of the mesoderm and is repressed by the dorsal ectoderm. It is also positively regulated by bone morphogenetic protein signaling, which is also known to participate in dorsoventral patterning. We suggest that eHAND expression may be related to the anteroventral identity of the mesoderm. However, in overexpression experiments using retroviral vectors, only a low percentage of cases (5%) showed phenotypic alterations, consisting of a duplication of digit 2. CI - Copyright 2003 Wiley-Liss, Inc. FAU - Fernandez-Teran, Marian AU - Fernandez-Teran M AD - Departamento de Anatomía y Biología Celular, Universidad de Cantabria, Spain. FAU - Piedra, M Elisa AU - Piedra ME FAU - Rodriguez-Rey, Jose C AU - Rodriguez-Rey JC FAU - Talamillo, Ana AU - Talamillo A FAU - Ros, Maria A AU - Ros MA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Dev Dyn JT - Developmental dynamics : an official publication of the American Association of Anatomists JID - 9201927 RN - 0 (Antineoplastic Agents) RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (DNA-Binding Proteins) RN - 0 (Hand1 protein, mouse) RN - 0 (Hedgehog Proteins) RN - 0 (Trans-Activators) RN - 0 (Transcription Factors) RN - 0 (helix-loop-helix protein, eHAND) RN - 5688UTC01R (Tretinoin) RN - 62031-54-3 (Fibroblast Growth Factors) SB - IM MH - Animals MH - Antineoplastic Agents/pharmacology MH - Basic Helix-Loop-Helix Transcription Factors MH - Body Patterning/physiology MH - Chick Embryo MH - Chickens MH - DNA-Binding Proteins/*genetics MH - Extremities/*embryology/*physiology MH - Female MH - Fibroblast Growth Factors/pharmacology MH - Gene Expression Regulation, Developmental/drug effects/physiology MH - Hedgehog Proteins MH - Mice MH - Mutation/physiology MH - Polydactyly/genetics/physiopathology MH - Pregnancy MH - Signal Transduction/drug effects/physiology MH - Trans-Activators/metabolism MH - Transcription Factors/*genetics MH - Tretinoin/pharmacology EDAT- 2003/04/01 05:00 MHDA- 2003/12/31 05:00 CRDT- 2003/04/01 05:00 PHST- 2003/04/01 05:00 [pubmed] PHST- 2003/12/31 05:00 [medline] PHST- 2003/04/01 05:00 [entrez] AID - 10.1002/dvdy.10271 [doi] PST - ppublish SO - Dev Dyn. 2003 Apr;226(4):690-701. doi: 10.1002/dvdy.10271. PMID- 40328831 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250509 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 May 6 TI - Pharmacological alternatives to oxytetracycline as potential treatment of flexural limb deformities in foals: a preliminary in vitro cell viability and proliferation study. PG - 15762 LID - 10.1038/s41598-025-00311-z [doi] LID - 15762 AB - Flexural limb deformities are a widespread condition in foals. Oxytetracycline is a common conservative treatment option with relaxing effects on the muscle-tendon-unit, potentially mediated through a matrix-metalloproteinase (MMP)-inhibitor mechanism. Its high therapeutic dose for this indication, potential negative side effects, and the guidelines for prudent use of antimicrobials make investigating alternatives desirable. In this study, the influence of substances with potentially similar mechanisms of action, however without antimicrobial properties, on viability and proliferation of juvenile myofibroblasts was assessed in vitro. Myofibroblasts from forelimb superficial digital flexor tendons and accessory ligaments of the deep digital flexor tendon from 6 foals, euthanized for reasons unrelated to this study, were cultured and characterized. The myofibroblasts were incubated with oxytetracycline, the MMP-inhibitors incyclinide, ilomastat, aprotinin, pentoxifylline, the lathyrogenic agent β-aminopropionitrile fumarate and Dulbecco's modified eagle medium as control. Colorimetric cell viability (MTS) and crystal violet assays assessed their viability and proliferation capacities. The morphology and immunohistochemistry profile of the cultured cells was consistent with tendon and ligament myofibroblasts. All test substances were biocompatible, shown by the absence of significant differences with cells incubated with medium, demonstrating the absence of cytotoxic or anti-proliferative effect on juvenile myofibroblasts in the tested concentrations in this preliminary study. CI - © 2025. The Author(s). FAU - Cardinaux, Emmanuel Mathieu AU - Cardinaux EM AD - Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. emmanuel.mathieu.cardinaux@tiho-hannover.de. FAU - Oltmanns, Hilke AU - Oltmanns H AD - Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. FAU - Beineke, Andreas AU - Beineke A AD - Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. FAU - Meißner, Jessica AU - Meißner J AD - Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. FAU - Geburek, Florian AU - Geburek F AD - Clinic for Horses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany. LA - eng PT - Journal Article DEP - 20250506 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - X20I9EN955 (Oxytetracycline) SB - IM MH - Animals MH - Horses MH - *Oxytetracycline/pharmacology/therapeutic use MH - Cell Survival/drug effects MH - Cell Proliferation/drug effects MH - *Myofibroblasts/drug effects/cytology MH - Tendons/drug effects MH - Cells, Cultured PMC - PMC12056144 OTO - NOTNLM OT - Flexural limb deformities OT - Foals OT - Matrix-metalloproteinase-inhibitors OT - Oxytetracycline COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics statement: The experiments were approved by the animal welfare officer of the University of Veterinary Medicine Hannover (approval number TVO-2023-V-84). EDAT- 2025/05/07 00:27 MHDA- 2025/05/07 06:27 PMCR- 2025/05/06 CRDT- 2025/05/06 23:19 PHST- 2025/01/02 00:00 [received] PHST- 2025/04/28 00:00 [accepted] PHST- 2025/05/07 06:27 [medline] PHST- 2025/05/07 00:27 [pubmed] PHST- 2025/05/06 23:19 [entrez] PHST- 2025/05/06 00:00 [pmc-release] AID - 10.1038/s41598-025-00311-z [pii] AID - 311 [pii] AID - 10.1038/s41598-025-00311-z [doi] PST - epublish SO - Sci Rep. 2025 May 6;15(1):15762. doi: 10.1038/s41598-025-00311-z. PMID- 8922353 OWN - NLM STAT- MEDLINE DCOM- 19961230 LR - 20190515 IS - 0012-1797 (Print) IS - 0012-1797 (Linking) VI - 45 IP - 12 DP - 1996 Dec TI - Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. PG - 1694-700 AB - Solubility of tail tendon collagen from normal, streptozotocin-induced diabetic Lewis rats, and diabetic animals treated with aminoguanidine and two novel advanced glycosylation end products (AGE)-formation inhibitors was investigated by limited pepsin digestion under acidic conditions. Assays were conducted using tail tendon collagen from Lewis rats obtained from two different vendors, Harlan and Charles River Laboratories. Collagen solubility was assessed by following the kinetics of pepsin digestion. The data revealed that the rate of digestion for diabetic animals is markedly slow relative to that of normals. More strikingly, the kinetics of the diabetic animals showed the feature of a lag in digestion regardless of the animal source. Experiments designed to optimize the difference in solubility between normal and diabetic animals demonstrated that Charles River animals exhibit a greater window of solubility than the Harlan animals. More importantly, a pronounced effect of aminoguanidine, an AGE-formation inhibitor, was observed in Charles River animals, but not in the Harlan animals, presumably because of the larger window of solubility between the normal and the diabetic animals in the former. These data indicated that the Charles River Lewis rats are an animal model that demonstrates greater efficacy in this assay. Analysis of in vivo screens designed to test efficacy of aminoguanidine and two novel AGE-formation inhibitors, ALT 462 and ALT 486, demonstrated that monitoring an in vivo dose response is highly dependent on the enzyme concentration as well as the time of digestion, and that 1.5 h of digestion and 10 microg/ml pepsin (5 pg pepsin/mg collagen) appeared optimal. Under these conditions, a 29% normalization of solubility was observed with aminoguanidine at 100 mg/kg body wt, whereas a similar normalization was observed at 10 mg/kg body wt for both ALT 462 and ALT 486. Thus, on a molar basis, ALT 462 and ALT 486 are at least 20 times more potent than aminoguanidine. This is the first demonstration of dose-dependent efficacy for AGE-formation inhibitors in animal models, and as such, this assay provides a method with which to assess the in vivo efficacy of other such inhibitors. FAU - Kochakian, M AU - Kochakian M AD - Department of Biochemistry, Alteon, Inc., Ramsey, New Jersey, USA. FAU - Manjula, B N AU - Manjula BN FAU - Egan, J J AU - Egan JJ LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Diabetes JT - Diabetes JID - 0372763 RN - 0 (ALT 462) RN - 0 (Aminobenzoates) RN - 0 (Benzoates) RN - 0 (Cross-Linking Reagents) RN - 0 (Enzyme Inhibitors) RN - 0 (Guanidines) RN - 0 (Hydroxybenzoates) RN - 0 (Triazoles) RN - 177960-39-3 (3,5-diamino-4-hydroxybenzoic acid dihydrochloride) RN - 9007-34-5 (Collagen) RN - EC 3.4.23.1 (Pepsin A) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Aminobenzoates MH - Animals MH - Benzoates/pharmacology MH - Collagen/chemistry/*metabolism MH - Cross-Linking Reagents MH - Diabetes Mellitus, Experimental/*metabolism MH - Dose-Response Relationship, Drug MH - Enzyme Inhibitors/pharmacology MH - Glycosylation MH - Guanidines/administration & dosage/*pharmacology MH - *Hydroxybenzoates MH - Kinetics MH - Pepsin A/metabolism MH - Rats MH - Rats, Inbred Lew MH - Solubility MH - Species Specificity MH - *Tail MH - Tendons/*chemistry MH - Triazoles/pharmacology EDAT- 1996/12/01 00:00 MHDA- 1996/12/01 00:01 CRDT- 1996/12/01 00:00 PHST- 1996/12/01 00:00 [pubmed] PHST- 1996/12/01 00:01 [medline] PHST- 1996/12/01 00:00 [entrez] AID - 10.2337/diab.45.12.1694 [doi] PST - ppublish SO - Diabetes. 1996 Dec;45(12):1694-700. doi: 10.2337/diab.45.12.1694. PMID- 37270113 OWN - NLM STAT- MEDLINE DCOM- 20231121 LR - 20231121 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 39 IP - 12 DP - 2023 Dec TI - Losartan in Combination With Bone Marrow Stimulation Showed Synergistic Effects on Load to Failure and Tendon Matrix Organization in a Rabbit Model. PG - 2408-2419 LID - S0749-8063(23)00423-1 [pii] LID - 10.1016/j.arthro.2023.05.020 [doi] AB - PURPOSE: To investigate the effects of combining bone marrow stimulation (BMS) with oral losartan to block transforming growth factor β1 (TGF-β1) on biomechanical repair strength in a rabbit chronic injury model. METHODS: Forty rabbits were randomly allocated into 4 groups (10 in each group). The supraspinatus tendon was detached and left alone for 6 weeks to establish a rabbit chronic injury model and was then repaired in a surgical procedure using a transosseous, linked, crossing repair construct. The animals were divided into the following groups: control group (group C), surgical repair only; BMS group (group B), surgical repair with BMS of the tuberosity; losartan group (group L), surgical repair plus oral losartan (TGF-β1 blocker) for 8 weeks; and BMS-plus-losartan group (group BL), surgical repair plus BMS plus oral losartan for 8 weeks. At 8 weeks after repair, biomechanical and histologic evaluations were performed. RESULTS: The biomechanical testing results showed significantly higher ultimate load to failure in group BL than in group B (P = .029) but not compared with group C or group L. A 2 × 2 analysis-of-variance model found that the effect of losartan on ultimate load significantly depended on whether BMS was performed (interaction term F(1,28) = 5.78, P = .018). No difference was found between the other groups. No difference in stiffness was found between any groups. On histologic assessment, groups B, L, and BL showed improved tendon morphology and an organized type I collagen matrix with less type III collagen compared with group C. Group BL showed the most highly organized tendon matrix with more type I collagen and less type III collagen, which indicates less fibrosis. Similar results were found at the bone-tendon interface. CONCLUSIONS: Rotator cuff repair combined with oral losartan and BMS of the greater tuberosity showed improved pullout strength and a highly organized tendon matrix in this rabbit chronic injury model. CLINICAL RELEVANCE: Tendon healing or scarring is accompanied by the formation of fibrosis, which has been shown to result in compromised biomechanical properties, and is therefore a potential limiting factor in healing after rotator cuff repair. TGF-β1 expression has been shown to play an important role in the formation of fibrosis. Recent studies focusing on muscle healing and cartilage repair have found that the downregulation of TGF-β1 by losartan intake can reduce fibrosis and improve tissue regeneration in animal models. CI - Copyright © 2023. Published by Elsevier Inc. FAU - Lacheta, Lucca AU - Lacheta L AD - Department of Sports Orthopaedics, Technical University of Munich, Munich, Germany; Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Gao, Xueqin AU - Gao X AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Miles, Jon Wesley AU - Miles JW AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Murata, Yoichi AU - Murata Y AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Fukase, Naomasa AU - Fukase N AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Utsunomiya, Hajime AU - Utsunomiya H AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Dornan, Grant AU - Dornan G AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Tashman, Scott AU - Tashman S AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Kashyap, Ritesh AU - Kashyap R AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Altintas, Burak AU - Altintas B AD - Division of Orthopaedic Surgery, NYC Health + Hospitals/Jacobi, Bronx, New York, U.S.A.; Department of Orthopaedic Surgery, Albert Einstein College of Medicine, Bronx, New York, U.S.A. FAU - Ravuri, Sudheer AU - Ravuri S AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A. FAU - Philippon, Marc AU - Philippon M AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A.; The Steadman Clinic, Vail, Colorado, U.S.A. FAU - Huard, Johnny AU - Huard J AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A.; The Steadman Clinic, Vail, Colorado, U.S.A.. Electronic address: jhuard@sprivail.org. FAU - Millett, Peter J AU - Millett PJ AD - Steadman Philippon Research Institute, Vail, Colorado, U.S.A.; The Steadman Clinic, Vail, Colorado, U.S.A. LA - eng PT - Journal Article DEP - 20230602 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - JMS50MPO89 (Losartan) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) SB - IM MH - Animals MH - Rabbits MH - *Bone Marrow MH - *Losartan/pharmacology/therapeutic use MH - Transforming Growth Factor beta1 MH - Collagen Type I MH - Collagen Type III MH - Tendons/surgery MH - Fibrosis EDAT- 2023/06/04 01:08 MHDA- 2023/11/21 06:43 CRDT- 2023/06/03 19:26 PHST- 2022/01/24 00:00 [received] PHST- 2023/05/17 00:00 [revised] PHST- 2023/05/18 00:00 [accepted] PHST- 2023/11/21 06:43 [medline] PHST- 2023/06/04 01:08 [pubmed] PHST- 2023/06/03 19:26 [entrez] AID - S0749-8063(23)00423-1 [pii] AID - 10.1016/j.arthro.2023.05.020 [doi] PST - ppublish SO - Arthroscopy. 2023 Dec;39(12):2408-2419. doi: 10.1016/j.arthro.2023.05.020. Epub 2023 Jun 2. PMID- 24384123 OWN - NLM STAT- MEDLINE DCOM- 20141125 LR - 20220309 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 10 IP - 5 DP - 2014 May TI - Dose- and time-dependent effects of genipin crosslinking on cell viability and tissue mechanics - toward clinical application for tendon repair. PG - 1897-906 LID - S1742-7061(13)00653-3 [pii] LID - 10.1016/j.actbio.2013.12.048 [doi] AB - The crosslinking agent genipin is increasingly invoked for the mechanical augmentation of collagen tissues and implants, and has previously been demonstrated to arrest mechanical damage accumulation in various tissues. This study established an in vitro dose-response baseline for the effects of genipin treatment on tendon cells and their matrix, with a view to in vivo application to the repair of partial tendon tears. Regression models based on a broad range of experimental data were used to delineate the range of concentrations that are likely to achieve functionally effective crosslinking, and predict the corresponding degree of cell loss and diminished metabolic activity that can be expected. On these data, it was concluded that rapid mechanical augmentation of tissue properties can only be achieved by accepting some degree of cytotoxicity, yet that post-treatment cell survival may be adequate to eventually repopulate and stabilize the tissue. On this basis, development of delivery strategies and subsequent in vivo study seems warranted. CI - Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Fessel, Gion AU - Fessel G AD - Department of Orthopedics, Balgrist University Hospital, University of Zurich, Balgrist, Forchstrasse 340, CH-8008 Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Wolfgang Paulistrasse 10, CH-8092 Zurich, Switzerland. FAU - Cadby, Jennifer AU - Cadby J AD - Department of Orthopedics, Balgrist University Hospital, University of Zurich, Balgrist, Forchstrasse 340, CH-8008 Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Wolfgang Paulistrasse 10, CH-8092 Zurich, Switzerland; Department of Equine Sciences, Faculty of Veterinary Medicine, University of Utrecht, Yalelaan 112, 3584 Utrecht, The Netherlands. FAU - Wunderli, Stefania AU - Wunderli S AD - Department of Orthopedics, Balgrist University Hospital, University of Zurich, Balgrist, Forchstrasse 340, CH-8008 Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Wolfgang Paulistrasse 10, CH-8092 Zurich, Switzerland. FAU - van Weeren, René AU - van Weeren R AD - Department of Equine Sciences, Faculty of Veterinary Medicine, University of Utrecht, Yalelaan 112, 3584 Utrecht, The Netherlands. FAU - Snedeker, Jess G AU - Snedeker JG AD - Department of Orthopedics, Balgrist University Hospital, University of Zurich, Balgrist, Forchstrasse 340, CH-8008 Zurich, Switzerland; Institute for Biomechanics, ETH Zurich, Wolfgang Paulistrasse 10, CH-8092 Zurich, Switzerland. Electronic address: jsnedeker@research.balgrist.ch. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131231 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Calorimetry, Differential Scanning MH - Cell Movement/drug effects MH - Cell Survival/drug effects MH - Cross-Linking Reagents/*pharmacology MH - Elastic Modulus/drug effects MH - Gene Expression Regulation/drug effects MH - Horses MH - Iridoids/*pharmacology/toxicity MH - Mechanical Phenomena/drug effects MH - Protein Denaturation/drug effects MH - Reference Standards MH - Regression Analysis MH - Tendons/drug effects/*pathology MH - Time Factors MH - Wound Healing/*drug effects OTO - NOTNLM OT - Collagen OT - Cytotoxicity OT - Tendon injury OT - Tendon tear OT - Tenocytes EDAT- 2014/01/05 06:00 MHDA- 2014/12/15 06:00 CRDT- 2014/01/04 06:00 PHST- 2013/09/12 00:00 [received] PHST- 2013/11/21 00:00 [revised] PHST- 2013/12/18 00:00 [accepted] PHST- 2014/01/04 06:00 [entrez] PHST- 2014/01/05 06:00 [pubmed] PHST- 2014/12/15 06:00 [medline] AID - S1742-7061(13)00653-3 [pii] AID - 10.1016/j.actbio.2013.12.048 [doi] PST - ppublish SO - Acta Biomater. 2014 May;10(5):1897-906. doi: 10.1016/j.actbio.2013.12.048. Epub 2013 Dec 31. PMID- 5305074 OWN - NLM STAT- MEDLINE DCOM- 19690522 LR - 20211203 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 12 IP - 2 DP - 1969 Apr TI - The arthritis of sarcoidosis. PG - 126-37 FAU - Spilberg, I AU - Spilberg I FAU - Siltzbach, L E AU - Siltzbach LE FAU - McEwen, C AU - McEwen C LA - eng PT - Journal Article PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Antibodies, Antinuclear) RN - 268B43MJ25 (Uric Acid) RN - 9009-79-4 (Rheumatoid Factor) SB - IM MH - Adult MH - Age Factors MH - Antibodies, Antinuclear/analysis MH - Arthritis/*complications/diagnostic imaging/etiology/immunology MH - Biopsy MH - Erythema Nodosum/complications MH - Ethnicity MH - Female MH - Humans MH - Male MH - Middle Aged MH - Radiography MH - Rheumatoid Factor/analysis MH - Sarcoidosis/*complications/immunology MH - Sex Factors MH - Tendons/pathology MH - Uric Acid/blood EDAT- 1969/04/01 00:00 MHDA- 1969/04/01 00:01 CRDT- 1969/04/01 00:00 PHST- 1969/04/01 00:00 [pubmed] PHST- 1969/04/01 00:01 [medline] PHST- 1969/04/01 00:00 [entrez] AID - 10.1002/art.1780120209 [doi] PST - ppublish SO - Arthritis Rheum. 1969 Apr;12(2):126-37. doi: 10.1002/art.1780120209. PMID- 24833737 OWN - NLM STAT- MEDLINE DCOM- 20140729 LR - 20220310 IS - 1552-5783 (Electronic) IS - 0146-0404 (Print) IS - 0146-0404 (Linking) VI - 55 IP - 6 DP - 2014 May 15 TI - The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. PG - 3727-36 LID - 10.1167/iovs.13-13699 [doi] AB - PURPOSE: To determine the connections between the ciliary muscle (CM), trabecular meshwork (TM), and Schlemm's canal (SC) and their innervations that allows CM contraction (by pilocarpine) to influence conventional outflow in mice. METHODS: Sequential sections and whole mounts of murine corneoscleral angles were stained for elastin, α-smooth muscle actin (αSMA), vesicular acetylcholine transporter (VAChT), neuronal nitric oxide synthase (nNOS), vasoactive intestinal peptide (VIP), and tyrosine hydroxylase (TH). Elastic (EL) fibers between the CM, TM, and SC were examined in ultrathin, sequential sections from different planes. The effect of pilocarpine (100 μM) on conventional outflow facility was measured by perfusion of enucleated mouse eyes. RESULTS: The mouse TM contains a three-dimensional (3D) net of EL fibers connecting the inner wall of SC to the cornea anteriorly, the ciliary body (CB) internally and the choroid and CM posteriorly. The CM bifurcates near the posterior TM, extending outer tendons to the juxtacanalicular tissue and inner wall of SC and internal connections to the lamellated TM and CB. Ciliary muscle and lamellated TM cells stain with αSMA and are innervated by VAChT-containing nerve fibers, without TH, VIP, or nNOS. Pilocarpine doubled outflow facility. CONCLUSIONS: Mouse eyes resemble primate eyes not only by their well developed SC and TM, but also by their 3D EL net tethering together the TM and SC inner wall and by the tendinous insertion of the CM into this net. The increase in outflow facility following cholinergic stimulation in mice, as in primates, supports using mice for studies of aqueous humor dynamics and glaucoma. CI - Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. FAU - Overby, Darryl R AU - Overby DR AD - Department of Bioengineering, Imperial College London, London, United Kingdom. FAU - Bertrand, Jacques AU - Bertrand J AD - Department of Bioengineering, Imperial College London, London, United Kingdom. FAU - Schicht, Martin AU - Schicht M AD - Department of Anatomy II, University of Erlangen-Nürnberg, Germany. FAU - Paulsen, Friedrich AU - Paulsen F AD - Department of Anatomy II, University of Erlangen-Nürnberg, Germany. FAU - Stamer, W Daniel AU - Stamer WD AD - Department of Ophthalmology, Duke University, Durham, North Carolina, United States. FAU - Lütjen-Drecoll, Elke AU - Lütjen-Drecoll E AD - Department of Anatomy II, University of Erlangen-Nürnberg, Germany. LA - eng GR - R01 EY022359/EY/NEI NIH HHS/United States GR - EY022359/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140515 PL - United States TA - Invest Ophthalmol Vis Sci JT - Investigative ophthalmology & visual science JID - 7703701 RN - 0 (Muscarinic Agonists) RN - 01MI4Q9DI3 (Pilocarpine) SB - IM MH - Animals MH - Aqueous Humor/*metabolism MH - Ciliary Body/drug effects/physiopathology/*ultrastructure MH - Disease Models, Animal MH - Glaucoma/drug therapy/*pathology/physiopathology MH - Imaging, Three-Dimensional MH - Immunohistochemistry MH - Mice MH - Mice, Inbred BALB C MH - Mice, Inbred C57BL MH - Microscopy, Electron MH - Muscarinic Agonists/pharmacology MH - Pilocarpine/*pharmacology MH - Trabecular Meshwork/drug effects/physiopathology/*ultrastructure PMC - PMC4059081 OTO - NOTNLM OT - aqueous humor OT - ciliary muscle OT - glaucoma OT - pilocarpine OT - trabecular meshwork EDAT- 2014/05/17 06:00 MHDA- 2014/07/30 06:00 PMCR- 2014/12/01 CRDT- 2014/05/17 06:00 PHST- 2014/05/17 06:00 [entrez] PHST- 2014/05/17 06:00 [pubmed] PHST- 2014/07/30 06:00 [medline] PHST- 2014/12/01 00:00 [pmc-release] AID - iovs.13-13699 [pii] AID - 10.1167/iovs.13-13699 [doi] PST - epublish SO - Invest Ophthalmol Vis Sci. 2014 May 15;55(6):3727-36. doi: 10.1167/iovs.13-13699. PMID- 3511134 OWN - NLM STAT- MEDLINE DCOM- 19860320 LR - 20220316 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 11 IP - 1 DP - 1986 Jan TI - Oral ibuprofen: evaluation of its effect on peritendinous adhesions and the breaking strength of a tenorrhaphy. PG - 110-20 AB - In a study of 21 primates, treatment with oral ibuprofen significantly reduced the force required for tendon gliding following flexor tendon injury in zone II. Tendons that were partially lacerated but not repaired required less force for tendon motion than those repaired. Ibuprofen also reduced the breaking strength of completely divided and repaired extensor tendons. The addition of a piece of chromic suture buried across the extensor tenorrhaphy site significantly increased the breaking strength of the repair in control and treated animals alike. These findings were observed at 4 and 6 weeks after tendon injury and repair. No adverse reactions to the medication were observed. FAU - Kulick, M I AU - Kulick MI FAU - Smith, S AU - Smith S FAU - Hadler, K AU - Hadler K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Administration, Oral MH - Animals MH - Ibuprofen/administration & dosage/pharmacology/*therapeutic use MH - Macaca fascicularis MH - Male MH - Stress, Mechanical MH - Suture Techniques MH - Tendon Injuries/surgery MH - *Tendons/surgery MH - Tissue Adhesions/*prevention & control MH - Wound Healing/drug effects EDAT- 1986/01/01 00:00 MHDA- 1986/01/01 00:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 1986/01/01 00:01 [medline] PHST- 1986/01/01 00:00 [entrez] AID - S0363-5023(86)80116-2 [pii] AID - 10.1016/s0363-5023(86)80116-2 [doi] PST - ppublish SO - J Hand Surg Am. 1986 Jan;11(1):110-20. doi: 10.1016/s0363-5023(86)80116-2. PMID- 28760374 OWN - NLM STAT- MEDLINE DCOM- 20180518 LR - 20220408 IS - 1877-0568 (Electronic) IS - 1877-0568 (Linking) VI - 103 IP - 7 DP - 2017 Nov TI - Ropivacaine alters the mechanical properties of hamstring tendons: In vitro controlled mechanical testing of tendons from living donors. PG - 1027-1030 LID - S1877-0568(17)30199-8 [pii] LID - 10.1016/j.otsr.2017.05.024 [doi] AB - OBJECTIVE: Intraarticular or periarticular injection of ropivacaine (RI) is an element of current knee surgery practices. The goal of this study was to determine the effects of RI on the mechanical properties of hamstring tendons. We hypothesized that RI would have a detrimental effect on the mechanical properties of periarticular soft tissues METHODS: A tensile test to failure was performed on 120 hamstring tendon segments harvested during ACL reconstruction surgery in 120 patients. Two sets of tensile tests were done. The first evaluated the effect of RI itself on the mechanical properties of tendons: 30 samples were soaked for 1hour in a 2% RI solution and compared to 30 samples soaked in a saline solution (control group). The second evaluated the effect of RI concentration on the mechanical properties of hamstring tendons: 30 samples were soaked for 1hour in a 2% RI solution and 30 samples were soaked in a 7.5% RI solution. RESULTS: In the first test, 29 samples from each group were analyzed as two samples (one in each group) failed at the grip interface. The specimens exposed to 2% RI had lower ultimate tensile strength (Δ=4.4MPa, P=0.001), strain energy (Δ=13MPa, P=0.001) and Young's modulus (Δ=1.6MPa, P=0.02) than the specimens in the control group. There was no significant difference in the strain at failure between groups (Δ=5%, P=0.3). In the second test, one specimen from the 7.5% RI group failed during the preloading and was excluded. There was no significant difference in terms of the load at failure and ultimate tensile stress (Δ=0.45MPa, P=0.6) and strain energy (Δ=0.49MPa, P=0.49) between the two groups. There were significant differences in terms of elongation at failure (Δ=28%, P=0.0003) and Young's modulus (Δ=2.6MPa, P=0.005), with the specimens exposed to 7.5% RI undergoing greater deformation and having a lower Young's modulus. DISCUSSION: While local RI injections are widely performed in clinical practice, the results of this in vitro study point to short-term alterations of the mechanical properties of hamstring tendons. If these results hold in vivo, this could lead to weakness of the soft tissues exposed to this product, particularly the tendons and ligaments around the injection area. LEVEL OF EVIDENCE: Experimental study. Level 1. CI - Copyright © 2017 Elsevier Masson SAS. All rights reserved. FAU - Ollivier, M AU - Ollivier M AD - Institute for movement and locomotion, orthopedic surgery, boulevard Sainte-Marguerite, 13009 Marseille, France. Electronic address: ollivier.matthieu@yahoo.fr. FAU - Sbihi, J AU - Sbihi J AD - ICOS13, institut de chirurgie orthopédique et sportive de Marseille, 13008 Marseille, France. FAU - Sbihi, A AU - Sbihi A AD - ICOS13, institut de chirurgie orthopédique et sportive de Marseille, 13008 Marseille, France. FAU - Pithioux, M AU - Pithioux M AD - Institut des sciences du mouvement UMR 7287, Aix-Marseille université, CNRS, 13288 Marseille, France. FAU - Parratte, S AU - Parratte S AD - Institute for movement and locomotion, orthopedic surgery, boulevard Sainte-Marguerite, 13009 Marseille, France. FAU - Argenson, J-N AU - Argenson JN AD - Institute for movement and locomotion, orthopedic surgery, boulevard Sainte-Marguerite, 13009 Marseille, France. LA - eng PT - Journal Article DEP - 20170729 PL - France TA - Orthop Traumatol Surg Res JT - Orthopaedics & traumatology, surgery & research : OTSR JID - 101494830 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 7IO5LYA57N (Ropivacaine) SB - IM MH - Adolescent MH - Adult MH - Amides/*adverse effects MH - Anesthetics, Local/*adverse effects MH - Biomechanical Phenomena MH - Dose-Response Relationship, Drug MH - Female MH - Hamstring Tendons/*drug effects/physiopathology MH - Humans MH - In Vitro Techniques MH - Living Donors MH - Male MH - Ropivacaine MH - Tensile Strength/*drug effects MH - Young Adult OTO - NOTNLM OT - Hamstring tendons OT - Mechanical properties OT - Mechanical testing OT - Ropivacaine EDAT- 2017/08/02 06:00 MHDA- 2018/05/19 06:00 CRDT- 2017/08/02 06:00 PHST- 2017/01/16 00:00 [received] PHST- 2017/04/17 00:00 [revised] PHST- 2017/05/02 00:00 [accepted] PHST- 2017/08/02 06:00 [pubmed] PHST- 2018/05/19 06:00 [medline] PHST- 2017/08/02 06:00 [entrez] AID - S1877-0568(17)30199-8 [pii] AID - 10.1016/j.otsr.2017.05.024 [doi] PST - ppublish SO - Orthop Traumatol Surg Res. 2017 Nov;103(7):1027-1030. doi: 10.1016/j.otsr.2017.05.024. Epub 2017 Jul 29. PMID- 18216273 OWN - NLM STAT- MEDLINE DCOM- 20080317 LR - 20220317 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 36 IP - 3 DP - 2008 Mar TI - Photoencapsulation of bone morphogenetic protein-2 and periosteal progenitor cells improve tendon graft healing in a bone tunnel. PG - 461-73 LID - 10.1177/0363546507311098 [doi] AB - BACKGROUND: Tissue-engineered solutions for promoting the tendon graft incorporation within the bone tunnel appear to be promising. HYPOTHESIS: To determine the feasibility that conjugation of hyaluronic acid-tethered bone morphogenetic protein-2 can be used to stimulate periosteal progenitor cells direct fibrocartilagenous attachment and new bone formation in an extra-articular tendon-bone healing model. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 42 mature New Zealand White rabbits were used. The long digitorum extensor tendon was transplanted into a bone tunnel of the proximal tibia. The tendon was pulled through a drill hole in the proximal tibia and attached to the medial aspect of the tibia. Photopolymerizable hydrogel based on poly (ethylene glycol) diacrylate with hyaluronic acid-tethered bone morphogenetic protein-2 was injected and photogelated in a bone tunnel. Histological and biomechanical examination of the tendon-bone interface was evaluated at postoperative weeks 3 and 6. RESULTS: Histological analysis showed an interface fibrocartilage and new bone formed by photoencapsulation of bone morphogenetic protein-2 and periosteal progenitor cells at 6 weeks. Biomechanical testing revealed higher maximum pullout strength and stiffness in experimental groups with a statistically significant difference at 3 and 6 weeks after tendon transplantation. CONCLUSION: The healing tendon-bone interface undergoes a gradual remodeling process; it appears that photoencapsulation of bone morphogenetic protein-2 and periosteal progenitor cells possesses a powerful inductive ability between the tendon and the bone to incorporate the healing in a rabbit model. CLINICAL RELEVANCE: Novel technologies, such as those described in this study, including photopolymerization and tissue engineering, may provide minimally invasive therapeutic procedures via arthroscopy to enhance biological healing after reconstruction of the anterior cruciate ligament. FAU - Chen, Chih-Hwa AU - Chen CH AD - Department of Orthopaedic Surgery, College of Medicine, Chang Gung Memorial Hospital-Keelung, Chang Gung University, Keelung, Taiwan. FAU - Liu, Hsia-Wei AU - Liu HW FAU - Tsai, Ching-Lin AU - Tsai CL FAU - Yu, Chung-Ming AU - Yu CM FAU - Lin, I-Hsuan AU - Lin IH FAU - Hsiue, Ging-Ho AU - Hsiue GH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080123 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Hydrogels) RN - 0 (Transforming Growth Factor beta) RN - 0 (poly(ethylene glycol)diacrylate) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Bone Morphogenetic Protein 2 MH - Bone Morphogenetic Proteins/*administration & dosage MH - Bone Remodeling/*drug effects MH - Cell Survival MH - Hyaluronic Acid/administration & dosage MH - Hydrogels/administration & dosage MH - Injections, Intralesional MH - Microscopy, Fluorescence MH - Periosteum/cytology MH - Polyethylene Glycols/administration & dosage MH - Rabbits MH - Reverse Transcriptase Polymerase Chain Reaction MH - Stem Cell Transplantation/*methods MH - Stem Cells/physiology/radiation effects MH - Tendon Injuries/pathology/*therapy MH - Tendons/pathology/*transplantation MH - Transforming Growth Factor beta/*administration & dosage MH - Ultraviolet Rays EDAT- 2008/01/25 09:00 MHDA- 2008/03/18 09:00 CRDT- 2008/01/25 09:00 PHST- 2008/01/25 09:00 [pubmed] PHST- 2008/03/18 09:00 [medline] PHST- 2008/01/25 09:00 [entrez] AID - 0363546507311098 [pii] AID - 10.1177/0363546507311098 [doi] PST - ppublish SO - Am J Sports Med. 2008 Mar;36(3):461-73. doi: 10.1177/0363546507311098. Epub 2008 Jan 23. PMID- 30037570 OWN - NLM STAT- MEDLINE DCOM- 20190918 LR - 20200306 IS - 1526-3231 (Electronic) IS - 0749-8063 (Print) IS - 0749-8063 (Linking) VI - 34 IP - 9 DP - 2018 Sep TI - Kartogenin Enhances Collagen Organization and Mechanical Strength of the Repaired Enthesis in a Murine Model of Rotator Cuff Repair. PG - 2579-2587 LID - S0749-8063(18)30382-7 [pii] LID - 10.1016/j.arthro.2018.04.022 [doi] AB - PURPOSE: To investigate the use of kartogenin (KGN) in augmenting healing of the repaired enthesis after rotator cuff repair in a murine model. METHODS: Seventy-two C57BL/6 wild-type mice underwent unilateral detachment and transosseous repair of the supraspinatus tendon augmented with either fibrin sealant (control group; n = 36) or fibrin sealant containing 100 μmol/L of KGN (experimental group; n = 36) applied at the repair site. Postoperatively, mice were allowed free cage activity without immobilization. Mice were humanely killed at 2 and 4 weeks postoperatively. Repair site integrity was evaluated histologically through fibrocartilage formation and collagen fiber organization and biomechanically through load-to-failure testing of the supraspinatus tendon-bone construct. RESULTS: At 2 weeks, no differences were noted in percent area of fibrocartilage, collagen organization, or ultimate strength between groups. At 4 weeks, superior collagen fiber organization (based on collagen birefringence [17.3 ± 2.0 vs 7.0 ± 6.5 integrated density/μm(2); P < .01]) and higher ultimate failure loads (3.5 ± 0.6 N vs 2.3 ± 1.1 N; P = .04) were seen in the KGN group. The percent area of fibrocartilage (13.2 ± 8.4% vs 4.4 ± 5.4%; P = .04) was higher in the control group compared with the KGN group. CONCLUSIONS: Rotator cuff repair augmentation with KGN improved the collagen fiber organization and biomechanical strength of the tendon-bone interface at 4 weeks in a murine model. CLINICAL RELEVANCE: These findings have implications for improving the structural integrity of the repaired enthesis and potentially reducing the retear rate after rotator cuff repair, which can ultimately lead to improvements in clinical outcomes. CI - Copyright © 2018 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Wang, Dean AU - Wang D AD - Sports Medicine and Shoulder Service, New York, New York, U.S.A.; Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A.. Electronic address: deanwangmd@gmail.com. FAU - Tan, Hongbo AU - Tan H AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Lebaschi, Amir H AU - Lebaschi AH AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Nakagawa, Yusuke AU - Nakagawa Y AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Wada, Susumu AU - Wada S AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Donnelly, Patrick E AU - Donnelly PE AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Ying, Liang AU - Ying L AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Deng, Xiang-Hua AU - Deng XH AD - Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. FAU - Rodeo, Scott A AU - Rodeo SA AD - Sports Medicine and Shoulder Service, New York, New York, U.S.A.; Laboratory for Joint Tissue Repair and Regeneration, Hospital for Special Surgery, New York, New York, U.S.A. LA - eng GR - T32 AR007281/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20180720 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Anilides) RN - 0 (Fibrin Tissue Adhesive) RN - 0 (Phthalic Acids) RN - 9007-34-5 (Collagen) RN - Q93BBN11CP (kartogenin) SB - IM CIN - Arthroscopy. 2018 Sep;34(9):2588-2589. doi: 10.1016/j.arthro.2018.06.040. PMID: 30173798 MH - Anilides/*administration & dosage MH - Animals MH - Arthroplasty MH - Biomechanical Phenomena MH - Chondrogenesis/*drug effects MH - Collagen/drug effects/*physiology MH - Disease Models, Animal MH - Fibrin Tissue Adhesive MH - Fibrocartilage/physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Phthalic Acids/*administration & dosage MH - Rotator Cuff Injuries/physiopathology/*surgery MH - Tendons/surgery MH - Tensile Strength MH - Wound Healing/*physiology PMC - PMC6371391 MID - NIHMS1004116 COIS- The authors report that they have no conflicts of interest in the authorship and publication of this article. Full ICMJE author disclosure forms are available for this article online, as supplementary material. Investigation performed at the Hospital for Special Surgery, New York, New York, U.S.A. EDAT- 2018/07/25 06:00 MHDA- 2019/09/19 06:00 PMCR- 2019/02/12 CRDT- 2018/07/25 06:00 PHST- 2018/01/31 00:00 [received] PHST- 2018/04/18 00:00 [revised] PHST- 2018/04/24 00:00 [accepted] PHST- 2018/07/25 06:00 [pubmed] PHST- 2019/09/19 06:00 [medline] PHST- 2018/07/25 06:00 [entrez] PHST- 2019/02/12 00:00 [pmc-release] AID - S0749-8063(18)30382-7 [pii] AID - 10.1016/j.arthro.2018.04.022 [doi] PST - ppublish SO - Arthroscopy. 2018 Sep;34(9):2579-2587. doi: 10.1016/j.arthro.2018.04.022. Epub 2018 Jul 20. PMID- 22852581 OWN - NLM STAT- MEDLINE DCOM- 20130207 LR - 20211021 IS - 1600-0838 (Electronic) IS - 0905-7188 (Print) IS - 0905-7188 (Linking) VI - 22 IP - 5 DP - 2012 Oct TI - The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats. PG - e108-14 LID - 10.1111/j.1600-0838.2012.01516.x [doi] AB - The objective of this study was to evaluate the effects of genistein and moderate intensity exercise on Achilles tendon collagen and cross-linking in intact and ovariectomized (OVX) female Sprague-Dawley rats. Rats were separated into eight groups (n = 9/group): intact or OVX, treadmill exercised or sedentary, genistein-treated (300 mg/kg/day) or vehicle. After 6 weeks, tendons were assayed for the collagen-specific amino acid hydroxyproline and hydroxylyslpyridinoline (HP). Collagen content was not influenced by exercise (P = 0.40) but was lower (P < 0.001) in OVX-vehicle rats compared with intact vehicle rats (OVX: 894 ± 35 μg collagen/mg dry weight; intact: 1185 ± 72 μg collagen/mg dry weight). In contrast, collagen content in OVX rats treated with genistein was greater (P = 0.010, 1198 ± 121 μg collagen/mg dry weight) when compared with untreated rats and was not different from intact rats (P = 0.89). HP content was lower in OVX genistein-treated rats when compared with intact genistein-treated rats, but only within the sedentary animals (P = 0.05, intact-treated: 232 ± 39 mmol/mol collagen; OVX-treated: 144 ± 21 mmol/mol collagen). Our findings suggest that ovariectomy leads to a reduction in tendon collagen, which is prevented by genistein. HP content, however, may not have increased in proportion to the addition of collagen. Genistein may be useful for improving tendon collagen content in conditions of estrogen deficiency. CI - © 2012 John Wiley & Sons A/S. FAU - Ramos, J E AU - Ramos JE AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, USA. FAU - Al-Nakkash, L AU - Al-Nakkash L FAU - Peterson, A AU - Peterson A FAU - Gump, B S AU - Gump BS FAU - Janjulia, T AU - Janjulia T FAU - Moore, M S AU - Moore MS FAU - Broderick, T L AU - Broderick TL FAU - Carroll, C C AU - Carroll CC LA - eng GR - R15 DK071625/DK/NIDDK NIH HHS/United States GR - 1R15DK071625-01A2/DK/NIDDK NIH HHS/United States GR - ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20120801 PL - Denmark TA - Scand J Med Sci Sports JT - Scandinavian journal of medicine & science in sports JID - 9111504 RN - 0 (Phytoestrogens) RN - 9007-34-5 (Collagen) RN - DH2M523P0H (Genistein) SB - IM MH - Achilles Tendon/drug effects/*metabolism MH - Animals MH - Collagen/drug effects/*metabolism MH - Disease Models, Animal MH - Female MH - Genistein/*pharmacology MH - *Ovariectomy MH - Physical Conditioning, Animal/*physiology MH - Phytoestrogens/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Statistics as Topic PMC - PMC3482002 MID - NIHMS393650 EDAT- 2012/08/03 06:00 MHDA- 2013/02/08 06:00 PMCR- 2013/10/01 CRDT- 2012/08/03 06:00 PHST- 2012/07/02 00:00 [accepted] PHST- 2012/08/03 06:00 [entrez] PHST- 2012/08/03 06:00 [pubmed] PHST- 2013/02/08 06:00 [medline] PHST- 2013/10/01 00:00 [pmc-release] AID - 10.1111/j.1600-0838.2012.01516.x [doi] PST - ppublish SO - Scand J Med Sci Sports. 2012 Oct;22(5):e108-14. doi: 10.1111/j.1600-0838.2012.01516.x. Epub 2012 Aug 1. PMID- 22619518 OWN - NLM STAT- MEDLINE DCOM- 20120926 LR - 20211021 IS - 1178-2013 (Electronic) IS - 1176-9114 (Print) IS - 1176-9114 (Linking) VI - 7 DP - 2012 TI - Gold nanoparticles and diclofenac diethylammonium administered by iontophoresis reduce inflammatory cytokines expression in Achilles tendinitis. PG - 1651-7 LID - 10.2147/IJN.S25164 [doi] AB - INTRODUCTION: Tendinitis affects a substantial number of people in several occupations involving repetitive work or direct trauma. Iontophoresis is a therapeutic alternative used in the treatment of injury during the inflammatory phase. In recent years, gold nanoparticles (GNP) have been studied due to their therapeutic anti-inflammatory capacity and as an alternative to the transport of several proteins. PURPOSE: This study evaluates the therapeutic effects of iontophoresis using GNPs and diclofenac diethylammonium on inflammatory parameters in rats challenged with traumatic tendinitis. METHODS: Wistar rats were divided in three treatment groups (n = 15): (1) iontophoresis + diclofenac diethylammonium; (2) iontophoresis + GNP; and (3) iontophoresis + diclofenac diethylammonium + GNP. External control was formed by challenged tendons without treatment (n = 15). Iontophoresis was administered using 0.3 mA direct current on 1.5 cm(2) electrodes. RESULTS: The levels of both inflammatory cytokines were significantly higher in untreated challenged rats, when compared with the control (5.398 ± 234 for interleukin 1 beta and 6.411 ± 432 for tumor necrosis factor alpha), which confirms the occurrence of an inflammatory stage in injury (P < 0.05). A significant decrease was observed in expression of cytokines interleukin 1 beta in the three treatment groups, in comparison with untreated challenged tendons, although, in the group treated with diclofenac and GNP, results were similar to the control (1.732 ± 239) (P < 0.05). Concerning tumor necrosis factor alpha, only the group treated with the association diclofenac and GNPs presented decreased levels, compared with the control (3.221 ± 369) (P < 0.05). CONCLUSION: The results show the efficacy of drug administration using direct current to treat tendinitis in an animal model, and the potential anti-inflammatory, carrier, and enhancing effects of GNPs in iontophoresis. FAU - Dohnert, Marcelo B AU - Dohnert MB AD - Postgraduation Program in Health Sciences, Programa de Pós-graduação em Ciências da Saúde PPGCS, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina, Brazil. FAU - Venâncio, Mirelli AU - Venâncio M FAU - Possato, Jonathann C AU - Possato JC FAU - Zeferino, Rodrigo C AU - Zeferino RC FAU - Dohnert, Luciana H AU - Dohnert LH FAU - Zugno, Alexandra I AU - Zugno AI FAU - De Souza, Cláudio T AU - De Souza CT FAU - Paula, Marcos M S AU - Paula MM FAU - Luciano, Thais F AU - Luciano TF LA - eng PT - Journal Article DEP - 20120326 PL - New Zealand TA - Int J Nanomedicine JT - International journal of nanomedicine JID - 101263847 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cytokines) RN - 0 (Interleukin-1beta) RN - 0 (Tumor Necrosis Factor-alpha) RN - 144O8QL0L1 (Diclofenac) RN - 7440-57-5 (Gold) SB - IM MH - Achilles Tendon MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage MH - Cytokines/metabolism MH - Diclofenac/*administration & dosage MH - Disease Models, Animal MH - Gold MH - Humans MH - Interleukin-1beta/metabolism MH - *Iontophoresis MH - Male MH - Metal Nanoparticles/*administration & dosage MH - Nanomedicine MH - Rats MH - Rats, Wistar MH - Tendinopathy/*drug therapy/immunology MH - Tumor Necrosis Factor-alpha/metabolism PMC - PMC3356204 OTO - NOTNLM OT - electrophoresis OT - iontophoresis OT - nanoparticles OT - proinflammatory cytokines OT - tendinous injury EDAT- 2012/05/24 06:00 MHDA- 2012/09/27 06:00 PMCR- 2012/03/26 CRDT- 2012/05/24 06:00 PHST- 2012/05/24 06:00 [entrez] PHST- 2012/05/24 06:00 [pubmed] PHST- 2012/09/27 06:00 [medline] PHST- 2012/03/26 00:00 [pmc-release] AID - ijn-7-1651 [pii] AID - 10.2147/IJN.S25164 [doi] PST - ppublish SO - Int J Nanomedicine. 2012;7:1651-7. doi: 10.2147/IJN.S25164. Epub 2012 Mar 26. PMID- 27775780 OWN - NLM STAT- MEDLINE DCOM- 20170804 LR - 20180318 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 20 IP - 19 DP - 2016 Oct TI - A novel lecithin based delivery form of Boswellic acids (Casperome®) for the management of osteo-muscular pain: a registry study in young rugby players. PG - 4156-4161 LID - 11541 [pii] AB - OBJECTIVE: Several experimental studies and clinical trials support the potential of Boswellia serrata extracts (BSE) for the treatment of various inflammatory diseases. The aim of this registry study was to assess the safety and the efficacy of a novel lecithin-based delivery form of Boswellia serrata extract (Casperome®) in the supportive management of osteo-muscular pain. PATIENTS AND METHODS: 52 healthy young rugby players with acute knee pain and inflammation were recruited. Informed participants freely decided to follow either a standard management (SM) to control joint pain (control group = 27) or SM associated with oral daily supplementation with Casperome® (supplement group =25). Parameters associated with osteo-muscular pain and inflammation, and measurements of joint health and functions were assessed at the inclusion and after a 4-week supplementation. RESULTS: A significant beneficial effect of Casperome® vs SM alone was observed for all the parameters evaluated, namely: local pain on effort; pain-free walking distance (treadmill test); minimal joint effusion; structural damage (joint, tendons, muscles) and intramuscular hematomas; thermal imaging of the anterior knee; Visual Analog Scale for Pain (VAS Pain); need for concomitant drugs and medical attention; measurement of inflammatory biomarkers. CONCLUSIONS: Our registry study suggests that Casperome® supplementation could represent an effective and safe, integrated approach for the treatment of osteo-muscular pain and inflammation. FAU - Franceschi, F AU - Franceschi F AD - Indena SpA, Milan, Italy. cardres@abol.it. FAU - Togni, S AU - Togni S FAU - Belcaro, G AU - Belcaro G FAU - Dugall, M AU - Dugall M FAU - Luzzi, R AU - Luzzi R FAU - Ledda, A AU - Ledda A FAU - Pellegrini, L AU - Pellegrini L FAU - Eggenhoffner, R AU - Eggenhoffner R FAU - Giacomelli, L AU - Giacomelli L LA - eng PT - Journal Article PL - Italy TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - 0 (Lecithins) RN - 0 (Plant Extracts) RN - 0 (Triterpenes) RN - 631-69-6 (boswellic acid) SB - IM MH - Adolescent MH - Adult MH - Boswellia/*chemistry MH - *Football MH - Humans MH - Knee MH - *Lecithins MH - Male MH - *Pain Management MH - Plant Extracts/administration & dosage MH - *Registries MH - Triterpenes/*therapeutic use MH - Young Adult EDAT- 2016/10/25 06:00 MHDA- 2017/08/05 06:00 CRDT- 2016/10/25 06:00 PHST- 2016/10/25 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] PHST- 2016/10/25 06:00 [entrez] AID - 11541 [pii] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4156-4161. PMID- 25898174 OWN - NLM STAT- MEDLINE DCOM- 20150818 LR - 20170112 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 33 IP - 3 DP - 2015 May-Jun TI - Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment? PG - 385-90 AB - OBJECTIVES: We undertook this study to evaluate the responsiveness of Doppler ultrasound (US) to urate lowering therapy (ULT) in gout patients. METHODS: Twenty-four consecutive patients were prospectively included from an outpatient clinic. The patients underwent clinical, and US assessment at baseline and after 6, 12 and 24 months of ULT. The US assessment was made by another rheumatologist blinded to the clinical data. Standardised examinations were performed in four joints (both first metatarso-phalangeals and knees) and the patellar tendons. The Doppler signals were scored. The mean and standard deviation were calculated for each parameter. The comparison between the quantitative values was performed by Student's t-test. Sensitivity to change in the US examinations was assessed by estimating the smallest detectable difference (SDD) in the total Doppler score. RESULTS: A Doppler signal was detected in 95.8% of the patients at the baseline. A significant parallel improvement in the serum urate level, clinical parameters and in Doppler scores was found at the follow-up assessment. 62% of the patients had achieved a uric concentration level below 6 mg/dl at one year. At two years, persistence of a Doppler signal was found in 72.7% of the patients. The SDD in the Doppler score at 2 years was 1.92, lower than the difference achieved. CONCLUSIONS: The Doppler US findings show significant improvement and responsiveness after ULT in gout patients. The Doppler signal persistence after two years of treatment is marked. This finding introduces a reflection on the accuracy of the current outcome measures and treatments. FAU - Peiteado, Diana AU - Peiteado D AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - Villalba, Alejandro AU - Villalba A AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - Martín-Mola, Emilio AU - Martín-Mola E AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. FAU - de Miguel, Eugenio AU - de Miguel E AD - Rheumatology Unit, Hospital Universitario La Paz, Madrid, Spain. LA - eng PT - Journal Article DEP - 20150416 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Biomarkers) RN - 0 (Gout Suppressants) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Biomarkers/blood MH - Drug Monitoring MH - Female MH - Gout/blood/*diagnostic imaging/*drug therapy MH - Gout Suppressants/*therapeutic use MH - Humans MH - Joints/*diagnostic imaging/*drug effects MH - Male MH - Middle Aged MH - Predictive Value of Tests MH - Prospective Studies MH - Remission Induction MH - Severity of Illness Index MH - Time Factors MH - Treatment Outcome MH - *Ultrasonography, Doppler MH - Uric Acid/blood EDAT- 2015/04/22 06:00 MHDA- 2015/08/19 06:00 CRDT- 2015/04/22 06:00 PHST- 2014/09/19 00:00 [received] PHST- 2015/01/19 00:00 [accepted] PHST- 2015/04/22 06:00 [entrez] PHST- 2015/04/22 06:00 [pubmed] PHST- 2015/08/19 06:00 [medline] AID - 8674 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2015 May-Jun;33(3):385-90. Epub 2015 Apr 16. PMID- 15587384 OWN - NLM STAT- MEDLINE DCOM- 20050114 LR - 20140729 VI - 69 IP - 4 DP - 2004 TI - [Shoulder pain and limited mobility in the course of algodystrophy of the hand]. PG - 273-7 AB - Algodystrophy typically affects distal parts of upper extremity: the hand and the wrist. Some patients, however, complain of pain and limited mobility in shoulder joint and these symptoms are not related to predisposed injury but appear secondary in the course of the condition. Cause and pathogenesis of this disorder in unknown. The objectives of the study were to investigate incidence of shoulder complains in the patients suffered of algodystrophy of the hand and to evaluate results of the treatment with local steroid injections of proximal insertion of the tendon of biceps muscle. Based on notes of 78 patients with algodystrophy within the hand, the incidence of shoulder complains was analysed. Evaluation of the results of the treatment of 18 patients was performed. RESULTS: 24 patients (31%) complained of pain and limited mobility in shoulder joint. In 17 of these patients (71%) algodystrophy was proceeded by fracture of the distal radius. In 16 patients shoulder complains appeared at the same time with algodystrophy of the hand and in 8 they delayed for 1-3 months. X-rays performed in all patients revealed in 3 only mild osteopenia within proximal part of humerus. All patients had proximal part of bicipital tendons of the biceps muscle tender for palpation suggesting inflammation of this tendon. In 18 patients methylprednisolone and lignocaine was injected 1-3 times locally in the vicinity of the painful tendon. In 15 of these patients (83%) treatment was successful and relief of the pain was achieved within the period from 2 days to 4 weeks. Final assessment of the treatment of algodystrophy was done mean at 13 months after the treatment was completed. Shoulder complaints disappeared in 17 from 24 patients (71%), and in 7 features persisted but were of milder intensity. These 7 patients had significantly worse final result of the treatment of the algodystrophy of the hand than rest of the group. FAU - Zyluk, Andrzej AU - Zyluk A AD - Klinika Chirurgii Ogólnej i Chirurgii Reki, Pomorska Akademia Medyczna w Szczecinie. FAU - Puchalski, Piotr AU - Puchalski P FAU - Zyluk, Beata AU - Zyluk B LA - pol PT - English Abstract PT - Journal Article TT - Ból i ograniczenie ruchomości w stawie ramiennym w przebiegu algodystrofii reki. PL - Poland TA - Chir Narzadow Ruchu Ortop Pol JT - Chirurgia narzadow ruchu i ortopedia polska JID - 2985137R RN - 0 (Anesthetics, Local) RN - 0 (Glucocorticoids) RN - 0 (Neuroprotective Agents) RN - 98PI200987 (Lidocaine) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Adult MH - Aged MH - Anesthetics, Local/administration & dosage MH - Female MH - Glucocorticoids/administration & dosage MH - *Hand/physiopathology MH - Humans MH - Incidence MH - Lidocaine/administration & dosage MH - Male MH - Methylprednisolone/administration & dosage MH - Middle Aged MH - Neuroprotective Agents/administration & dosage MH - Poland/epidemiology MH - Radius Fractures/complications MH - *Range of Motion, Articular MH - Reflex Sympathetic Dystrophy/*complications/epidemiology/physiopathology MH - Retrospective Studies MH - Shoulder Joint/physiopathology MH - Shoulder Pain/*drug therapy/epidemiology/*etiology MH - Time Factors EDAT- 2004/12/14 09:00 MHDA- 2005/01/15 09:00 CRDT- 2004/12/14 09:00 PHST- 2004/12/14 09:00 [pubmed] PHST- 2005/01/15 09:00 [medline] PHST- 2004/12/14 09:00 [entrez] PST - ppublish SO - Chir Narzadow Ruchu Ortop Pol. 2004;69(4):273-7. PMID- 12580652 OWN - NLM STAT- MEDLINE DCOM- 20030523 LR - 20220321 IS - 1064-8011 (Print) IS - 1064-8011 (Linking) VI - 17 IP - 1 DP - 2003 Feb TI - Creatine supplementation and its effect on musculotendinous stiffness and performance. PG - 26-33 AB - Anecdotal reports suggesting that creatine (Cr) supplementation may cause side effects, such as an increased incidence of muscle strains or tears, require scientific examination. In this study, it was hypothesized that the rapid fluid retention and "dry matter growth" evident after Cr supplementation may cause an increase in musculotendinous stiffness. Intuitively, an increase in musculotendinous stiffness would increase the chance of injury during exercise. Twenty men were randomly allocated to a control or an experimental group and were examined for musculotendinous stiffness of the triceps surae and for numerous performance indices before and after Cr ingestion. The Cr group achieved a significant increase in body mass (79.7 +/- 10.8 kg vs. 80.9 +/- 10.7 kg), counter movement jump height (40.2 +/- 4.8 cm vs. 42.7 +/- 5.9 cm), and 20-cm drop jump height (32.3 +/- 3.3 cm vs. 35.1 +/- 4.8 cm) after supplementation. No increase was found for musculotendinous stiffness at any assessment load. There were no significant changes in any variables within the control group. These findings have both performance- and injury-related implications. Primarily, anecdotal evidence suggesting that Cr supplementation causes muscular strain injuries is not supported by this study. In addition, the increase in jump performance is indicative of performance enhancement in activities requiring maximal power output. FAU - Watsford, Mark L AU - Watsford ML AD - Human Movement Department, School of Leisure, Sport, and Tourism, University of Technology, Sydney, Australia 2070. mark.watsford@uts.edu.au FAU - Murphy, Aron J AU - Murphy A FAU - Spinks, Warwick L AU - Spinks WL FAU - Walshe, Andrew D AU - Walshe AD LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Strength Cond Res JT - Journal of strength and conditioning research JID - 9415084 RN - MU72812GK0 (Creatine) SB - IM MH - Adult MH - Body Mass Index MH - Creatine/administration & dosage/*adverse effects MH - Dietary Supplements/*adverse effects MH - Elasticity MH - Humans MH - Leg MH - Male MH - Muscle Contraction/*drug effects MH - Muscle, Skeletal/drug effects/*physiology MH - Tendons/drug effects/*physiology EDAT- 2003/02/13 04:00 MHDA- 2003/05/24 05:00 CRDT- 2003/02/13 04:00 PHST- 2003/02/13 04:00 [pubmed] PHST- 2003/05/24 05:00 [medline] PHST- 2003/02/13 04:00 [entrez] AID - 10.1519/1533-4287(2003)017<0026:csaieo>2.0.co;2 [doi] PST - ppublish SO - J Strength Cond Res. 2003 Feb;17(1):26-33. doi: 10.1519/1533-4287(2003)017<0026:csaieo>2.0.co;2. PMID- 21254908 OWN - NLM STAT- MEDLINE DCOM- 20110712 LR - 20110329 IS - 1557-7600 (Electronic) IS - 1096-620X (Linking) VI - 14 IP - 4 DP - 2011 Apr TI - A comparative study of the effects of bromelain and fresh pineapple juice on the early phase of healing in acute crush achilles tendon injury. PG - 348-52 LID - 10.1089/jmf.2010.0078 [doi] AB - Bromelain, an enzyme extracted from the stem of the pineapple plant, has been reported to reduce pain and swelling in acute soft tissue injuries, but no study has been done to compare its effect with that of fresh pineapple juice on the healing of acute tendon injuries. This study compared the effects of commercial bromelain and fresh pineapple juice on tenocyte proliferation and the malondialdehyde (MDA) level in the early stage of healing in a crush injury to the Achilles tendon of Sprague-Dawley rats. Twenty-four male rats were divided randomly into three groups of eight rats each; all the rats had induced crush injury to the Achilles tendon: Group 1 (control), no treatment; Group 2, oral bromelain treatment at a dosage of 7 mg/kg of body weight daily; and Group 3, fresh diluted pineapple juice at a dosage of 30 mg/kg of body weight. Treatment was given over the first 14 days post-injury. On day 15 post-injury, the animals were sacrificed, and the tendons were excised and processed for histological study and MDA assay. Results show a significant difference in the tenocyte population between the bromelain group and the control (P < .05), whereas pineapple juice also increased the tenocyte population, although not significantly (P = .36). Pineapple juice, however, significantly lowered the MDA level compared with both the control and bromelain-treated groups. Based on this study, 600 GDU bromelain given at a dosage of 7 mg/kg had a better effect on tenocyte proliferation than fresh pineapple juice given once daily in acute tendon injury. FAU - Aiyegbusi, Ayoola I AU - Aiyegbusi AI AD - Department of Anatomy, College of Medicine, University of Lagos, Lagos, Nigeria. bogphysio@yahoo.com FAU - Olabiyi, Olaleye O AU - Olabiyi OO FAU - Duru, Francis I O AU - Duru FI FAU - Noronha, Cressie C AU - Noronha CC FAU - Okanlawon, Abayomi O AU - Okanlawon AO LA - eng PT - Comparative Study PT - Journal Article DEP - 20110123 PL - United States TA - J Med Food JT - Journal of medicinal food JID - 9812512 RN - 0 (Plant Extracts) RN - 9001-00-7 (Bromelains) SB - IM MH - Achilles Tendon/*drug effects/*injuries MH - Acute Disease/therapy MH - Administration, Oral MH - Ananas/*chemistry MH - Animals MH - Beverages/analysis MH - Bromelains/*pharmacology MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Fruit/chemistry MH - Male MH - Pain/drug therapy MH - *Phytotherapy MH - Plant Extracts/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/*drug therapy MH - Wound Healing/drug effects EDAT- 2011/01/25 06:00 MHDA- 2011/07/13 06:00 CRDT- 2011/01/25 06:00 PHST- 2011/01/25 06:00 [entrez] PHST- 2011/01/25 06:00 [pubmed] PHST- 2011/07/13 06:00 [medline] AID - 10.1089/jmf.2010.0078 [doi] PST - ppublish SO - J Med Food. 2011 Apr;14(4):348-52. doi: 10.1089/jmf.2010.0078. Epub 2011 Jan 23. PMID- 22875200 OWN - NLM STAT- MEDLINE DCOM- 20140226 LR - 20161125 IS - 1573-6814 (Electronic) IS - 1389-9333 (Linking) VI - 14 IP - 3 DP - 2013 Sep TI - Sporicidal efficacy of genipin: a potential theoretical alternative for biomaterial and tissue graft sterilization. PG - 381-93 LID - 10.1007/s10561-012-9335-z [doi] AB - Terminal sterilization of musculoskeletal allografts by gamma radiation minimizes the risk of disease transmission but impairs allograft mechanical properties. Commonly employed crosslinking agents can sterilize tissues without affecting mechanical properties adversely; however, these agents are toxic. Genipin is reported to be a benign crosslinking agent that strengthens mechanical properties of tissues; however, the antimicrobial capacity of genipin is largely unknown. The present study's aims were: (1) to assess the sporicidal potential of genipin, (2) to improve antimicrobial capacity by changing chemical and physical treatment conditions. To establish genipin's sterilization potential Bacillus subtilis var. niger spore strips were treated with 0-10% genipin in PBS or in 1:1 DMSO:PBS up to 72 h at room temperature (RT). Sterilizing doses and concentrations of genipin were used to treat B. pumilus and Geobacillus stearothermophilus spores to assess broader spectrum sporicidal activity of genipin. Scanning electron microscopy (SEM) was performed to evaluate gross morphological changes after genipin treatment. Optimal sterilization conditions were determined by evaluating the effects of temperature (RT-50 °C), DMSO:PBS ratio (0:100-100:0), and treatment duration (24-72 h) on B. subtilis. Genipin penetration of full thickness bovine patellar tendon and cortical bone specimens was observed to assess the feasibility of the agent for treating grafts. Initial studies showed that after 72 h of treatment at RT with 0.63-10% genipin/DMSO:PBS B. subtilis spore strips were sterilized; 0.63% genipin/PBS did not sterilize spore strips at 72 h at RT. Genipin doses and concentrations that sterilized B. subtilis spore strips sterilized B. pumilus and G. stearothermophilus spore strips. SEM revealed no gross morphological differences between untreated and treated spores. Treatment optimization resulted in sterilization within 24 h with 100% PBS, and DMSO facilitated sporicidal activity. Genipin penetrated full thickness patellar tendon specimens and 3.72 ± 0.58 mm in cortical bone specimens. Genipin sterilizes B. subtilis, B. pumilus, and G. stearothermophilus spore strips. It penetrates soft and hard tissues at doses previously shown to be non-toxic and to improve mechanical strength in collagen-rich soft tissues. Further studies are indicated to assess genipin's effects on the mechanical properties of genipin-sterilized grafts, the ability of genipin to eradicate infectious species other than spores, and to assess whether sterilant activity persists after penetrating tissues and biomaterials. FAU - Reich, Michael S AU - Reich MS AD - Department of Orthopaedic Surgery, Case Western Reserve University, 11100 Euclid Ave, Mail Stop UH 5043, Cleveland, OH 44106, USA. FAU - Akkus, Ozan AU - Akkus O LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120809 PL - Netherlands TA - Cell Tissue Bank JT - Cell and tissue banking JID - 100965121 RN - 0 (Biocompatible Materials) RN - 0 (Iridoids) RN - A3V2NE52YG (genipin) SB - IM MH - Allografts/*drug effects MH - Animals MH - Bacillus subtilis/drug effects/*physiology/ultrastructure MH - Biocompatible Materials/*pharmacology MH - Cattle MH - Geobacillus stearothermophilus/drug effects/*physiology MH - Iridoids/*pharmacology MH - Spores, Bacterial/drug effects/ultrastructure MH - *Sterilization MH - Tendons/drug effects EDAT- 2012/08/10 06:00 MHDA- 2014/02/27 06:00 CRDT- 2012/08/10 06:00 PHST- 2012/03/14 00:00 [received] PHST- 2012/07/25 00:00 [accepted] PHST- 2012/08/10 06:00 [entrez] PHST- 2012/08/10 06:00 [pubmed] PHST- 2014/02/27 06:00 [medline] AID - 10.1007/s10561-012-9335-z [doi] PST - ppublish SO - Cell Tissue Bank. 2013 Sep;14(3):381-93. doi: 10.1007/s10561-012-9335-z. Epub 2012 Aug 9. PMID- 25996412 OWN - NLM STAT- MEDLINE DCOM- 20160302 LR - 20220410 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 61 DP - 2015 Aug TI - Optimization of intrinsic and extrinsic tendon healing through controllable water-soluble mitomycin-C release from electrospun fibers by mediating adhesion-related gene expression. PG - 61-74 LID - S0142-9612(15)00462-7 [pii] LID - 10.1016/j.biomaterials.2015.05.012 [doi] AB - To balance intrinsic and extrinsic healing during tendon repair is challenging in tendon surgery. We hypothesized that by mediating apoptotic gene and collagen synthesis of exogenous fibroblasts, the adhesion formation induced by extrinsic healing could be inhibited. With the maintenance of intrinsic healing, the tendon could be healed with proper function with no adhesion. In this study, we loaded hydrophilic mitomycin-C (MMC) into hyaluronan (HA) hydrosols, which were then encapsulated in poly(L-lactic acid) (PLLA) fibers by micro-sol electrospinning. This strategy successfully provided a controlled release of MMC to inhibit adhesion formations with no detrimental effect on intrinsic healing. We found that micro-sol electrospinning was an effective and facile approach to incorporate and control hydrophilic drug release from hydrophobic polyester fibers. MMC exhibited an initially rapid, and gradually steadier release during 40 days, and the release rates could be tuned by its concentration. In vitro studies revealed that low concentrations of MMC could inhibit fibroblast adhesion and proliferation. When lacerate tendons were healed using the MMC-HA loaded PLLA fibers in vivo, they exhibited comparable mechanical strength to the naturally healed tendons but with no significant presence of adhesion formation. We further identified the up-regulation of apoptotic protein Bax expression and down-regulation of proteins Bcl2, collage I, collagen III and α-SMA during the healing process associated with minimum adhesion formations. This approach presented here leverages new advances in drug delivery and nanotechnology and offers a promising strategy to balance intrinsic and extrinsic tendon healing through modulating genes associated with fibroblast apoptosis and collagen synthesis. CI - Copyright © 2015 Elsevier Ltd. All rights reserved. FAU - Zhao, Xin AU - Zhao X AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge 02139, MA, USA. FAU - Jiang, Shichao AU - Jiang S AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Rd, Shanghai 200233, PR China. FAU - Liu, Shen AU - Liu S AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Rd, Shanghai 200233, PR China. FAU - Chen, Shuai AU - Chen S AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Rd, Shanghai 200233, PR China. FAU - Lin, Zhi Yuan William AU - Lin ZY AD - Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge 02139, MA, USA. FAU - Pan, Guoqing AU - Pan G AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China. FAU - He, Fan AU - He F AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China. FAU - Li, Fengfeng AU - Li F AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Rd, Shanghai 200233, PR China. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Rd, Shanghai 200233, PR China. Electronic address: fancunyi888@hotmail.com. FAU - Cui, Wenguo AU - Cui W AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, PR China; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge 02139, MA, USA. Electronic address: wgcui80@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150515 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Cell Adhesion Molecules) RN - 0 (Delayed-Action Preparations) RN - 0 (Nanocapsules) RN - 059QF0KO0R (Water) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Animals MH - Cell Adhesion Molecules/metabolism MH - Delayed-Action Preparations/administration & dosage/*chemical synthesis MH - Diffusion MH - Electroplating/methods MH - Gene Expression Regulation/drug effects MH - Male MH - Mice MH - Mitomycin/*administration & dosage/chemistry MH - NIH 3T3 Cells MH - Nanocapsules/*chemistry/ultrastructure MH - Nanofibers/*chemistry/ultrastructure MH - Particle Size MH - Rats MH - Rats, Sprague-Dawley MH - Solubility MH - Tendinopathy/*drug therapy/*metabolism/pathology MH - Tissue Adhesions/metabolism/prevention & control MH - Treatment Outcome MH - Water/chemistry MH - Wound Healing/drug effects OTO - NOTNLM OT - Adhesion formation OT - Electrospun fibers OT - Micro-sol OT - Tendon healing OT - Water-soluble drug EDAT- 2015/05/23 06:00 MHDA- 2016/03/05 06:00 CRDT- 2015/05/22 06:00 PHST- 2015/02/21 00:00 [received] PHST- 2015/05/02 00:00 [revised] PHST- 2015/05/14 00:00 [accepted] PHST- 2015/05/22 06:00 [entrez] PHST- 2015/05/23 06:00 [pubmed] PHST- 2016/03/05 06:00 [medline] AID - S0142-9612(15)00462-7 [pii] AID - 10.1016/j.biomaterials.2015.05.012 [doi] PST - ppublish SO - Biomaterials. 2015 Aug;61:61-74. doi: 10.1016/j.biomaterials.2015.05.012. Epub 2015 May 15. PMID- 9584049 OWN - NLM STAT- MEDLINE DCOM- 19980513 LR - 20220318 IS - 0250-7005 (Print) IS - 0250-7005 (Linking) VI - 18 IP - 1B DP - 1998 Jan-Feb TI - Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. PG - 657-66 AB - Osteosarcoma is usually treated with intensive preoperative and postoperative chemotherapy and wide tumor resection, resulting in a 60% to 70% 5-year survival rate. Caffeine has a DNA-repair inhibiting effect. We therefore investigated the impact of caffeine given in conjunction with chemotherapy and limb-sparing surgery on survival and local tumor control in patients with nonmetastatic, high-grade osteosarcoma. Twenty-two patients were given 3 to 5 preoperative courses of intra-arterial cisplatin (120 mg/m2, 1 to 2 hours) and caffeine (1.5 g/m2/day x 3 days) with or without doxorubicin (30 mg/m2/day x 2 days). Following this treatment, limb-sparing surgery was performed by means of intentional marginal excision aiming at preservation of important structures such as major neurovascular bundles, tendons, ligaments and the epiphysis. Three courses of cisplatin and doxorubicin combined with caffeine, and high-dose methotrexate with vincristine and citrovorum factor rescue were given intravenously as postoperative chemotherapy for 21 patients and three courses of high-dose methotrexate and combination of ifosfamide, etoposide and methotrexate for 1 patient. Following the preoperative chemotherapy, there were no viable tumor cells in 19 patients, only scattered foci of viable cells in 2 patients, and some areas of viable tumor cells in 1. The 21 patients with a good chemotherapeutic response on radiographs underwent minimized marginal excision. Functional evaluation of the affected limbs was excellent for 17 patients, good for 3, fair for 1, and poor for 1. No local tumor recurrence was seen in this series. Eighteen patients remain disease-free with a mean follow-up of 61 months. Two patients died of metastatic disease, 1 died of chemotherapy-related complications, and 1 died of unknown causes. The overall 5-year cumulative survival rate was 90%, and the 5-year event-free survival rate was 75%. Chemotherapeutic caffeine enhanced tumor necrosis and improved the success rate of limb-sparing surgery using marginal procedure without any adverse impact on survival. The results of our limited clinical trial appear to justify further prospective, multicenter randomized trials of the benefits of caffeine combined with chemotherapy for nonmetastatic osteosarcoma and other malignant neoplasms. FAU - Tsuchiya, H AU - Tsuchiya H AD - Department of Orthopaedic Surgery, School of Medicine, Kanazawa University, Japan. FAU - Tomita, K AU - Tomita K FAU - Mori, Y AU - Mori Y FAU - Asada, N AU - Asada N FAU - Morinaga, T AU - Morinaga T FAU - Kitano, S AU - Kitano S FAU - Yamamoto, N AU - Yamamoto N LA - eng PT - Clinical Trial PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 3G6A5W338E (Caffeine) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bone Neoplasms/*drug therapy/mortality/surgery MH - Caffeine/*therapeutic use MH - Child MH - Cisplatin/administration & dosage MH - Combined Modality Therapy MH - Drug Administration Schedule MH - Female MH - Humans MH - Male MH - Middle Aged MH - Osteosarcoma/*drug therapy/mortality/surgery EDAT- 1998/05/16 00:00 MHDA- 1998/05/16 00:01 CRDT- 1998/05/16 00:00 PHST- 1998/05/16 00:00 [pubmed] PHST- 1998/05/16 00:01 [medline] PHST- 1998/05/16 00:00 [entrez] PST - ppublish SO - Anticancer Res. 1998 Jan-Feb;18(1B):657-66. PMID- 22525485 OWN - NLM STAT- MEDLINE DCOM- 20121123 LR - 20131121 IS - 1878-1519 (Electronic) IS - 1569-9048 (Linking) VI - 181 IP - 3 DP - 2012 May 31 TI - Effect of sublingual nitrate on respiratory reflexes arising from stimulation of juxta-pulmonary capillary (J) receptors by i.v. lobeline and short duration exercise. PG - 259-66 LID - 10.1016/j.resp.2012.03.020 [doi] AB - Juxta-pulmonary capillary (J or pulmonary C fiber) receptors are stimulated by an increase in pulmonary blood flow and give rise to respiratory acceleration and related sensations and inhibit exercise. However, the reverse, i.e., the effect of reducing pulmonary blood flow on their reflexes, is as yet not known. This was investigated by carrying out a placebo-controlled study on the acute effects of a single dose (0.4 mg) of sublingual glyceryl nitrate (GTN), known to shift blood from the central to the peripheral circulation, on the respiratory parameters of exercising healthy subjects and on their responses to i.v. lobeline. In 10 subjects, GTN use delayed the first appearance of respiratory sensations from 9.08 ± 0.9 min to 11 min (P=0.002), reduced the increase in minute ventilation by the end of 10 min of exercise (P=0.003) and increased its duration by 1-4s and doubled it in the remaining one subject. In a majority of 8 of them, the effect of GTN on i.v. lobeline-induced respiratory reflexes and sensations was a significant increase in the dose required (P=0.006) for producing threshold effects and in the latency of their appearance (P=0.003). The latter feature points to a reduction in blood flow in the lung parenchyma where these receptors are located and to which they are sensitive. As this would have led to a reduced stimulation of these receptors, it would account for the delayed appearance of respiratory symptoms, a reduction in ventilatory increase and prolongation of exercise duration. We demonstrated a mechanism of reducing the stimulus level of J receptors by reducing pulmonary blood flow by means of pharmacological sequestration with GTN use, which then led to a reduction in the magnitude of respiratory and viscerosomatic reflexes, while noting at the same time that changes in blood flow in the pulmonary bed do not directly influence limb muscles, tendons and joints which also determine exercise output. CI - Copyright © 2012 Elsevier B.V. All rights reserved. FAU - Anand, Ashima AU - Anand A AD - Exertional Breathlessness Studies Laboratory (DST), Vallabhbhai Patel Chest Institute, Delhi University, Delhi 110007, India. FAU - Srivastava, Niraj AU - Srivastava N FAU - Raj, Hans AU - Raj H LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120412 PL - Netherlands TA - Respir Physiol Neurobiol JT - Respiratory physiology & neurobiology JID - 101140022 RN - 0 (Respiratory System Agents) RN - 0 (Vasodilator Agents) RN - D0P25S3P81 (Lobeline) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Adaptation, Physiological/drug effects MH - Administration, Sublingual MH - Adult MH - Blood Pressure MH - Dose-Response Relationship, Drug MH - Dyspnea/*prevention & control MH - Exercise/*physiology MH - Humans MH - Lobeline/administration & dosage MH - Lung/blood supply/drug effects/innervation MH - Male MH - Nitroglycerin/*pharmacology MH - Reference Values MH - Reflex/drug effects MH - Regional Blood Flow/drug effects MH - Respiration/*drug effects MH - Respiratory System Agents/administration & dosage MH - Sensory Receptor Cells/*drug effects MH - Vasodilator Agents/*pharmacology MH - Young Adult EDAT- 2012/04/25 06:00 MHDA- 2012/12/10 06:00 CRDT- 2012/04/25 06:00 PHST- 2011/12/20 00:00 [received] PHST- 2012/03/27 00:00 [revised] PHST- 2012/03/29 00:00 [accepted] PHST- 2012/04/25 06:00 [entrez] PHST- 2012/04/25 06:00 [pubmed] PHST- 2012/12/10 06:00 [medline] AID - S1569-9048(12)00081-X [pii] AID - 10.1016/j.resp.2012.03.020 [doi] PST - ppublish SO - Respir Physiol Neurobiol. 2012 May 31;181(3):259-66. doi: 10.1016/j.resp.2012.03.020. Epub 2012 Apr 12. PMID- 11020082 OWN - NLM STAT- MEDLINE DCOM- 20010111 LR - 20200313 IS - 0032-5791 (Print) IS - 0032-5791 (Linking) VI - 79 IP - 9 DP - 2000 Sep TI - Relationship between mechanical properties and pentosidine in tendon: effects of age, diet restriction, and aminoguanidine in broiler breeder hens. PG - 1338-44 AB - Nonenzymatic glycosylation contributes to the formation of crosslinks, which leads to the structural and functional deterioration of tissue protein. The accumulation of these crosslinks in tissue proteins has been implicated in the alteration of biomechanical properties of connective tissues. The objective of this study was to determine whether tendon breaking time (TBT) and tendon breaking strength (TBS) of the flexor perforans et perforatus digiti iii tendon were related to concentrations of pentosidine in tendons (Pt) of broiler breeder hens from 8 to 125 wk of age. In addition, effects of diet restriction (DR) and a crosslinking inhibitor, aminoguanidine (AG) on Pt, TBS, and TBT were determined. Female chicks (n = 450) were randomly assigned to four treatment groups immediately after hatch: ad libitum-fed (AL); diet-restricted (DR; 60% of AL); and AL and DR groups supplemented with 1.35 mg/kg BW per day AG in the feed (AL+AG and DR+AG, respectively). In AL hens, Pt increased with increasing age (P < or = 0.0001). Concurrently, an age-related parallel increase was found for TBS (P < or = 0.0001) and TBT (P < or = 0.0001). Rate of Pt accumulation was lower in DR (P < or = 0.001), TBS (P < or = 0.01), and TBT (P < or = 0.02) hens compared with AL hens. Concentration of Pt in the AL + AG group was lower (P < or = 0.0002) than in the AL group; TBS and TBT (P < or = 0.01) followed a similar pattern. Supplementation of DR with AG did not affect Pt, TBS, or TBT. The age-related increase in Pt and loss of elasticity in the tendon was retarded by diet restriction and AG. FAU - Iqbal, M AU - Iqbal M AD - Division of Animal and Veterinary Sciences, College of Agriculture, Forestry, and Consumer Sciences, West Virginia University, Morgantown 26506-6108, USA. FAU - Kenney, P B AU - Kenney PB FAU - Al-Humadi, N H AU - Al-Humadi NH FAU - Klandorf, H AU - Klandorf H LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Poult Sci JT - Poultry science JID - 0401150 RN - 0 (Guanidines) RN - 94ZLA3W45F (Arginine) RN - BJ4I2X2CQJ (pentosidine) RN - K3Z4F929H6 (Lysine) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Aging MH - Animals MH - Arginine/*analogs & derivatives/*analysis MH - Biomechanical Phenomena MH - Chickens/*physiology MH - Diet MH - Elasticity MH - Female MH - *Food Deprivation MH - Guanidines/*administration & dosage MH - Lysine/*analogs & derivatives/*analysis MH - Regression Analysis MH - Tendons/*chemistry/*physiology MH - Tensile Strength EDAT- 2000/10/06 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/10/06 11:00 PHST- 2000/10/06 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/10/06 11:00 [entrez] AID - S0032-5791(19)41632-5 [pii] AID - 10.1093/ps/79.9.1338 [doi] PST - ppublish SO - Poult Sci. 2000 Sep;79(9):1338-44. doi: 10.1093/ps/79.9.1338. PMID- 10036251 OWN - NLM STAT- MEDLINE DCOM- 19990817 LR - 20171213 IS - 0022-3077 (Print) IS - 0022-3077 (Linking) VI - 81 IP - 2 DP - 1999 Feb TI - Receptor mechanisms underlying heterogenic reflexes among the triceps surae muscles of the cat. PG - 467-78 AB - The soleus (S), medial gastrocnemius (MG), and lateral gastrocnemius (LG) muscles of the cat are interlinked by rapid spinal reflex pathways. In the decerebrate state, these heterogenic reflexes are either excitatory and length dependent or inhibitory and force dependent. Mechanographic analysis was used to obtain additional evidence that the muscle spindle primary ending and the Golgi tendon organ provide the major contributions to these reflexes, respectively. The tendons of the triceps surae muscles were separated and connected to independent force transducers and servo-controlled torque motors in unanesthetized, decerebrate cats. The muscles were activated as a group using crossed-extension reflexes. Electrical stimulation of the caudal cutaneous sural nerve was used to provide a particularly strong activation of MG and decouple the forces of the triceps surae muscles. During either form of activation, the muscles were stretched either individually or in various combinations to determine the strength and characteristics of autogenic and heterogenic feedback. The corresponding force responses, including both active and passive components, were measured during the changing background tension. During activation of the entire group, the excitatory, heterogenic feedback linking the three muscles was found to be strongest onto LG and weakest onto MG, in agreement with previous results concerning the strengths of heteronymous Ia excitatory postsynaptic potentials among the triceps surae muscles. The inhibition, which is known to affect only the soleus muscle, was dependent on active contractile force and was detected essentially as rapidly as length dependent excitation. The inhibition outlasted the excitation and was blocked by intravenous strychnine. These results indicate that the excitatory and inhibitory effects are dominated by feedback from primary spindle receptors and Golgi tendon organs. The interactions between these two feedback pathways potentially can influence both the mechanical coupling between ankle and knee. FAU - Nichols, T R AU - Nichols TR AD - Department of Physiology, Emory University, Atlanta, Georgia 30322, USA. LA - eng GR - NS-20855/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Neurophysiol JT - Journal of neurophysiology JID - 0375404 RN - 0 (Glycine Agents) RN - H9Y79VD43J (Strychnine) SB - IM MH - Animals MH - Cats MH - Decerebrate State MH - Electric Stimulation MH - Electromyography MH - Excitatory Postsynaptic Potentials/drug effects/physiology MH - Feedback/physiology MH - Female MH - Glycine Agents/pharmacology MH - Male MH - Mechanoreceptors/*physiology MH - Muscle Contraction/physiology MH - Muscle, Skeletal/*physiology MH - Neural Inhibition/drug effects/physiology MH - Reflex, Stretch/drug effects/*physiology MH - Stress, Mechanical MH - Strychnine/pharmacology MH - Sural Nerve/physiology EDAT- 1999/02/26 00:00 MHDA- 1999/02/26 00:01 CRDT- 1999/02/26 00:00 PHST- 1999/02/26 00:00 [pubmed] PHST- 1999/02/26 00:01 [medline] PHST- 1999/02/26 00:00 [entrez] AID - 10.1152/jn.1999.81.2.467 [doi] PST - ppublish SO - J Neurophysiol. 1999 Feb;81(2):467-78. doi: 10.1152/jn.1999.81.2.467. PMID- 32914364 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20220210 IS - 1573-2576 (Electronic) IS - 0360-3997 (Linking) VI - 43 IP - 6 DP - 2020 Dec TI - Screen the Effective Components of Lycopodii herba on Rheumatoid Arthritis with the Aid of Spectrum-Effect Relationship and Uncover its Potential Mechanism. PG - 2087-2097 LID - 10.1007/s10753-020-01276-z [doi] AB - Lycopodii herba (SJC), a traditional Chinese medicine, has the effect of dispelling wind and eliminating dampness (a therapeutic principle and method of traditional Chinese medicine for rheumatoid arthritis), relaxing tendon and activating collaterals. However, the major effective components and its therapeutic mechanism were unclear. In this study, different SJC samples with slightly different compositions were prepared by extracting with different concentrations of ethanol. Then, the therapeutic effects on rheumatoid arthritis (RA) of different SJC samples were evaluated. Finally, the spectrum-effect relationship between UPLC-Q-TOF/MS fingerprints and the effect of RA was explored to screen the effective components. Western blotting was used to study the potential mechanism. The volume of hind paw and the level of RF, TNF-α, and IL-1β were lower after administrating with different SJC samples, compared with the model group. Histopathological findings also confirmed that SJC could relieve the symptoms of RA. Combined with identification of the components in plasm from SJC, lycojaponicumin C, des-N-methyl-α-obscurine, 8β-acetoxy-12β-hydroxy-lycopodine or 8β-acetoxy-11α-hydroxy-lycopodine or 8β-hydroxy-11α-acetoxylycopodine were considered to be the major effective components. The mechanism may be related to AChE/NF-κB signaling pathway. This work provides a general method to screen the potential effective components of herb medicines and would be benefit to understand the mechanism of SJC for the treatment of RA. FAU - Yang, Zhen AU - Yang Z AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Yin, Qingsheng AU - Yin Q AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Ma, Jing AU - Ma J AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Yang, Changshuo AU - Yang C AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Sheng, Yuanyuan AU - Sheng Y AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Song, Lili AU - Song L AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Pang, Tan AU - Pang T AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Zhuang, Pengwei AU - Zhuang P AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. AD - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Guo, Hong AU - Guo H AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. cacti1983@163.com. FAU - Zhang, Yanjun AU - Zhang Y AUID- ORCID: 0000-0003-2176-6657 AD - Chinese Materia Medica College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. zyjsunye@163.com. AD - Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. zyjsunye@163.com. LA - eng GR - 2017KJ132/Tianjin Education Commission Research Project in China/ GR - 8180141249/the National Natural Science Foundation of China/ PT - Journal Article PL - United States TA - Inflammation JT - Inflammation JID - 7600105 RN - 0 (Alkaloids) RN - 0 (Azabicyclo Compounds) RN - 0 (Drugs, Chinese Herbal) RN - 0 (IL1B protein, rat) RN - 0 (Interleukin-1beta) RN - 0 (Plant Extracts) RN - 0 (Quinolizines) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (lycojaponicumin C) RN - 0 (lycopodii herba) RN - 2P5MU968XW (lycopodine) RN - 3K9958V90M (Ethanol) RN - 9009-79-4 (Rheumatoid Factor) SB - IM MH - Alkaloids/analysis MH - Animals MH - Arthritis, Rheumatoid/*drug therapy MH - Azabicyclo Compounds/analysis MH - Drugs, Chinese Herbal/*pharmacology/therapeutic use MH - Ethanol MH - Interleukin-1beta/biosynthesis MH - Male MH - Medicine, Chinese Traditional MH - Plant Extracts/*pharmacology/therapeutic use MH - Quinolizines MH - Rats MH - Rats, Sprague-Dawley MH - Rats, Wistar MH - Rheumatoid Factor/metabolism MH - Signal Transduction MH - Tendons/drug effects MH - Tumor Necrosis Factor-alpha/metabolism OTO - NOTNLM OT - Lycopodii herba OT - rheumatoid arthritis OT - spectrum–effect relationship EDAT- 2020/09/12 06:00 MHDA- 2021/09/22 06:00 CRDT- 2020/09/11 05:47 PHST- 2020/09/12 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] PHST- 2020/09/11 05:47 [entrez] AID - 10.1007/s10753-020-01276-z [pii] AID - 10.1007/s10753-020-01276-z [doi] PST - ppublish SO - Inflammation. 2020 Dec;43(6):2087-2097. doi: 10.1007/s10753-020-01276-z. PMID- 27329776 OWN - NLM STAT- MEDLINE DCOM- 20161226 LR - 20181202 IS - 1744-8069 (Electronic) IS - 1744-8069 (Linking) VI - 12 DP - 2016 TI - Further observations on the behavioral and neural effects of bone marrow stromal cells in rodent pain models. LID - 10.1177/1744806916658043 [doi] LID - 1744806916658043 AB - BACKGROUND: Bone marrow stromal cells (BMSCs) have shown potential to treat chronic pain, although much still needs to be learned about their efficacy and mechanisms of action under different pain conditions. Here, we provide further convergent evidence on the effects of BMSCs in rodent pain models. RESULTS: In an orofacial pain model involving injury of a tendon of the masseter muscle, BMSCs attenuated behavioral pain conditions assessed by von Frey filaments and a conditioned place avoidance test in female Sprague-Dawley rats. The antihyperalgesia of BMSCs in females lasted for <8 weeks, which is shorter than that seen in males. To relate preclinical findings to human clinical conditions, we used human BMSCs. Human BMSCs (1.5 M cells, i.v.) attenuated mechanical and thermal hyperalgesia induced by spinal nerve ligation and suppressed spinal nerve ligation-induced aversive behavior, and the effect persisted through the 8-week observation period. In a trigeminal slice preparation, BMSC-treated and nerve-injured C57B/L mice showed reduced amplitude and frequency of spontaneous excitatory postsynaptic currents, as well as excitatory synaptic currents evoked by electrical stimulation of the trigeminal nerve root, suggesting inhibition of trigeminal neuronal hyperexcitability and primary afferent input by BMSCs. Finally, we observed that GluN2A (N-methyl-D-aspartate receptor subunit 2A) tyrosine phosphorylation and protein kinase Cgamma (PKCg) immunoreactivity in rostral ventromedial medulla was suppressed at 8 weeks after BMSC in tendon-injured rats. CONCLUSIONS: Collectively, the present work adds convergent evidence supporting the use of BMSCs in pain control. As PKCg activity related to N-methyl-D-aspartate receptor activation is critical in opioid tolerance, these results help to understand the mechanisms of BMSC-produced long-term antihyperalgesia, which requires opioid receptors in rostral ventromedial medulla and apparently lacks the development of tolerance. FAU - Guo, Wei AU - Guo W AD - University of Maryland School of Denstistry. FAU - Chu, Yu-Xia AU - Chu YX AD - University of Maryland School of DenstistryUniversity of Maryland School of DentistryUniversity of Maryland School of DentristryUniversity of Maryland School of DentistryUniversity of Maryland School of Dentistry. FAU - Imai, Satoshi AU - Imai S AD - University of Maryland School of DenstistryUniversity of Maryland School of DentistryUniversity of Maryland School of DentristryUniversity of Maryland School of DentistryUniversity of Maryland School of Dentistry. FAU - Yang, Jia-Le AU - Yang JL AD - University of Maryland School of Dentistry. FAU - Zou, Shiping AU - Zou S AD - University of Maryland School of Dentristry. FAU - Mohammad, Zaid AU - Mohammad Z AD - University of Maryland School of Dentistry. FAU - Wei, Feng AU - Wei F AD - University of Maryland School of DenstistryUniversity of Maryland School of DentistryUniversity of Maryland School of DentristryUniversity of Maryland School of DentistryUniversity of Maryland School of Dentistry. FAU - Dubner, Ronald AU - Dubner R AD - University of Maryland School of Dentistry. FAU - Ren, Ke AU - Ren K AD - University of Maryland School of DenstistryUniversity of Maryland School of DentistryUniversity of Maryland School of DentristryUniversity of Maryland School of DentistryUniversity of Maryland School of Dentistry kren@umaryland.edu. LA - eng GR - R01 DE025137/DE/NIDCR NIH HHS/United States GR - DE021804/DE/NIDCR NIH HHS/United States GR - DE025137/DE/NIDCR NIH HHS/United States GR - NS019296/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160621 PL - United States TA - Mol Pain JT - Molecular pain JID - 101242662 RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 36B82AMQ7N (Naloxone) RN - EC 2.7.1.- (protein kinase C gamma) RN - EC 2.7.11.13 (Protein Kinase C) SB - IM MH - Animals MH - *Behavior, Animal MH - Brain/*pathology MH - Disease Models, Animal MH - Excitatory Postsynaptic Potentials/drug effects MH - Female MH - Humans MH - Male MH - *Mesenchymal Stem Cell Transplantation MH - Mesenchymal Stem Cells/*cytology/drug effects/metabolism MH - Mice, Inbred C57BL MH - Naloxone/pharmacology MH - Neuralgia/metabolism/pathology/*therapy MH - Phosphorylation/drug effects MH - Protein Kinase C/metabolism MH - Rats, Sprague-Dawley MH - Receptors, N-Methyl-D-Aspartate/metabolism MH - Synapses/drug effects/pathology MH - Tendons/drug effects/pathology MH - Trigeminal Nerve/drug effects/pathology PMC - PMC4956005 EDAT- 2016/06/23 06:00 MHDA- 2016/12/27 06:00 PMCR- 2016/06/21 CRDT- 2016/06/23 06:00 PHST- 2016/06/23 06:00 [entrez] PHST- 2016/06/23 06:00 [pubmed] PHST- 2016/12/27 06:00 [medline] PHST- 2016/06/21 00:00 [pmc-release] AID - 12/0/1744806916658043 [pii] AID - 10.1177_1744806916658043 [pii] AID - 10.1177/1744806916658043 [doi] PST - epublish SO - Mol Pain. 2016 Jun 21;12:1744806916658043. doi: 10.1177/1744806916658043. Print 2016. PMID- 32294907 OWN - NLM STAT- MEDLINE DCOM- 20210107 LR - 20210107 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 8 DP - 2020 Apr 13 TI - Recovery of Tendon Characteristics by Inhibition of Aberrant Differentiation of Tendon-Derived Stem Cells from Degenerative Tendinopathy. LID - 10.3390/ijms21082687 [doi] LID - 2687 AB - The inhibition of the aberrant differentiation of tendon-derived stem cells (TDSCs) is a major target for the regeneration of damaged tendon tissues, as tendinopathy can be caused by the aberrant differentiation of TDSCs. We investigated whether the possible aberrant differentiation of TDSCs can be prevented by using adequate inhibitors. TDSCs extracted from chemically induced tendinopathy and injury-with-overuse tendinopathy models were cultured with 18α-glycyrrhetinic acid (AGA) and T0070907 to block osteogenic differentiation and adipogenic differentiation, respectively. The optimal dose of AGA decreased the osteogenic-specific marker Runx2 (Runt-related transcription factor 2), and T0070907 blocked the adipogenic-specific marker peroxisome proliferator-activated receptor gamma (PPARγ) in mRNA levels. We also found that AGA induced tenogenic differentiation in mRNA levels. However, T0070907 did not affect the tenogenic differentiation and regenerative capacity of TDSCs. We expect that optimal doses of AGA and T0070907 can prevent tendinopathy by inhibiting osteogenic and adipogenic differentiation, respectively. In addition, AGA and T0070907 may play important roles in the treatment of tendinopathy. FAU - Kim, Sun Jeong AU - Kim SJ AUID- ORCID: 0000-0003-2344-4176 AD - Department of Physical and Rehabilitation Medicine, Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea. AD - R&D Center, ENCell Co. Ltd., Seoul 06072, Korea. FAU - Oh, Hae Won AU - Oh HW AUID- ORCID: 0000-0001-5615-6205 AD - Division of Health Policy and Administration, School of Public Health, University of Illinois, Chicago, IL 60612, USA. FAU - Chang, Jong Wook AU - Chang JW AD - R&D Center, ENCell Co. Ltd., Seoul 06072, Korea. AD - Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea. AD - Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul 06351, Korea. FAU - Kim, Sang Jun AU - Kim SJ AD - Seoul Jun Research Center, Seoul Jun Rehabilitation Clinic, Seoul 06737, Korea. LA - eng PT - Journal Article DEP - 20200413 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (PPAR gamma) RN - P540XA09DR (Glycyrrhetinic Acid) SB - IM MH - Adipogenesis/genetics MH - Animals MH - *Cell Differentiation/drug effects/genetics MH - Cells, Cultured MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Gene Expression MH - Glycyrrhetinic Acid/pharmacology MH - Immunohistochemistry MH - PPAR gamma/genetics/metabolism MH - Rats MH - Regeneration MH - *Stem Cell Transplantation MH - Stem Cells/*cytology/drug effects/metabolism MH - Tendinopathy/etiology/*pathology/*therapy MH - Tendons/*cytology MH - Treatment Outcome PMC - PMC7215446 OTO - NOTNLM OT - 18α-glycyrrhetinic acid OT - PPARγ OT - Runx2 OT - T0070907 OT - adipogenic differentiation OT - osteogenic differentiation COIS- The authors declare no conflict of interest. EDAT- 2020/04/17 06:00 MHDA- 2021/01/08 06:00 PMCR- 2020/04/01 CRDT- 2020/04/17 06:00 PHST- 2020/03/12 00:00 [received] PHST- 2020/04/09 00:00 [revised] PHST- 2020/04/10 00:00 [accepted] PHST- 2020/04/17 06:00 [entrez] PHST- 2020/04/17 06:00 [pubmed] PHST- 2021/01/08 06:00 [medline] PHST- 2020/04/01 00:00 [pmc-release] AID - ijms21082687 [pii] AID - ijms-21-02687 [pii] AID - 10.3390/ijms21082687 [doi] PST - epublish SO - Int J Mol Sci. 2020 Apr 13;21(8):2687. doi: 10.3390/ijms21082687. PMID- 19226039 OWN - NLM STAT- MEDLINE DCOM- 20090428 LR - 20220318 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 32 IP - 1 DP - 2009 Jan TI - Effect of bupivacaine on cultured tenocytes. PG - 26 AB - Proliferation of cultured human fibroblasts and other types of cells has been shown to be hindered by exposure to local anesthetics, which are widely used in musculoskeletal medicine for their use in regional anesthesia, selective nerve blocks, bursography, and brisement. We hypothesized that bupivacaine would decrease cell proliferation and production of extracellular matrix components collagen and proteoglycan in healthy human tenocytes in culture. Primary human tenocyte cultures were prepared from samples of normal tendons obtained from healthy tissue that would otherwise have been discarded during lower extremity tendon transfer surgery. Samples were obtained from 6 patients, 5 women and 1 man with an average age of 69 years (range, 17-73 years). Five flexor digitorum longus tendon samples and 1 peroneus longus tendon sample were used. Harvested tendon tissues (5 mm(3)) were used as explants for primary cell cultures. To measure the proliferative response to bupivacaine, seeded cells were exposed to saline control or to various concentrations of bupivacaine in 1% fetal bovine serum DMEM/F12 or 10% fetal bovine serum DMEM/F12. The 1% fetal bovine serum medium demonstrated the pure bupivacaine effect, and 10% fetal bovine serum more closely approximated the in vivo environment. Seeded cells were starved of fetal bovine serum for 12 hours before exposure to phosphate-buffered saline (control group) and 500 microM bupivacaine (experimental group). This concentration of bupivacaine was selected because it was found to significantly hinder proliferation in both the 1% and 10% fetal bovine serum groups in our proliferation assay. Tenocyte proliferation and extracellular matrix component production were significantly lower (Por=1 time points up to 6 days in bupivacaine-treated groups as compared with controls. FAU - Scherb, Michael B AU - Scherb MB AD - Department of Orthopedic Surgery, Union Memorial Hospital, Baltimore, MD 21218, USA. FAU - Han, Seung-Hwan AU - Han SH FAU - Courneya, Jean-Paul AU - Courneya JP FAU - Guyton, Gregory P AU - Guyton GP FAU - Schon, Lew C AU - Schon LC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Anesthetics, Local) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Anesthetics, Local/administration & dosage MH - Bupivacaine/*administration & dosage MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - Female MH - Humans MH - Male MH - Middle Aged MH - Tendons/*cytology/drug effects/*physiology MH - Young Adult EDAT- 2009/02/20 09:00 MHDA- 2009/04/29 09:00 CRDT- 2009/02/20 09:00 PHST- 2009/02/20 09:00 [entrez] PHST- 2009/02/20 09:00 [pubmed] PHST- 2009/04/29 09:00 [medline] AID - orthopedics.33725 [pii] AID - 10.3928/01477447-20090101-19 [doi] PST - ppublish SO - Orthopedics. 2009 Jan;32(1):26. doi: 10.3928/01477447-20090101-19. PMID- 21547683 OWN - NLM STAT- MEDLINE DCOM- 20110907 LR - 20171116 IS - 1976-3786 (Electronic) IS - 0253-6269 (Linking) VI - 34 IP - 3 DP - 2011 Mar TI - Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. PG - 495-500 LID - 10.1007/s12272-011-0319-5 [doi] AB - Advanced glycation end products (AGEs) play an important role in the development of chronic diabetic complications. Chlorogenic acid (CGA) is a phenolic compound formed by the esterification of caffeic and quinic acids. In this study, we evaluated the inhibitory effects of CGA against the formation of AGEs and AGEs protein cross-linking in vitro. An in vitro assay for glycation of bovine serum albumin by high glucose showed that CGA inhibited AGEs formation with an IC(50) value of 148.32 μM and was found to be more effective than aminoguanidine, a well-known AGEs inhibitor (IC(50); 807.67 μM). In an indirect AGE-ELISA assay, the CGA exhibited more potent inhibitory activity on the cross-linking of AGEs to collagen than aminoguanidine. In addition, the inhibitory effects of CGA on AGEs formation and on its cross-linking with collagen might be caused by its interactions with reactive decarbonyl compounds, such as methylglyoxal. These results suggest that CGA could be beneficial in the prevention of AGEs progression in patients with diabetes because CGA can attenuate AGEs deposition in glucose. FAU - Kim, Junghyun AU - Kim J AD - Diabetic Complications Research Center, Division of Traditional Korean Medicine Integrated Research, Korea Institute of Oriental Medicine, Daejeon, Korea. FAU - Jeong, Il-Ha AU - Jeong IH FAU - Kim, Chan-Sik AU - Kim CS FAU - Lee, Yun Mi AU - Lee YM FAU - Kim, Jong Min AU - Kim JM FAU - Kim, Jin Sook AU - Kim JS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110506 PL - Korea (South) TA - Arch Pharm Res JT - Archives of pharmacal research JID - 8000036 RN - 0 (Cross-Linking Reagents) RN - 0 (Glycation End Products, Advanced) RN - 0 (Hypoglycemic Agents) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 318ADP12RI (Chlorogenic Acid) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cattle MH - Chlorogenic Acid/*chemistry/pharmacology MH - Collagen/*chemistry MH - Cross-Linking Reagents/*chemistry MH - Glycation End Products, Advanced/*antagonists & inhibitors/chemistry MH - Hypoglycemic Agents/*chemistry/pharmacology MH - Protein Binding MH - Protein Carbonylation MH - Rats MH - Serum Albumin, Bovine/*chemistry MH - Tendons/chemistry EDAT- 2011/05/07 06:00 MHDA- 2011/09/08 06:00 CRDT- 2011/05/07 06:00 PHST- 2010/10/04 00:00 [received] PHST- 2010/12/03 00:00 [accepted] PHST- 2010/11/08 00:00 [revised] PHST- 2011/05/07 06:00 [entrez] PHST- 2011/05/07 06:00 [pubmed] PHST- 2011/09/08 06:00 [medline] AID - 10.1007/s12272-011-0319-5 [doi] PST - ppublish SO - Arch Pharm Res. 2011 Mar;34(3):495-500. doi: 10.1007/s12272-011-0319-5. Epub 2011 May 6. PMID- 40618971 OWN - NLM STAT- MEDLINE DCOM- 20250824 LR - 20250824 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 203 DP - 2025 Sep 1 TI - A hydrated fibrous gene patch codelivers TGF-β1 siRNA/TAT and berberine for the treatment of peritendinous antiadhesion. PG - 277-290 LID - S1742-7061(25)00508-2 [pii] LID - 10.1016/j.actbio.2025.07.014 [doi] AB - Bacterial infections, oxidative stress and inflammatory responses after tendon surgery are highly associated with peritendinous adhesion formation. Although drug-loaded anti-adhesion barriers have been extensively studied, most of them lack control over the process of drug release from the anti-adhesion barrier and fail to coordinate with the tendon's own biological mechanisms. Here, inspired by the mechanisms of tendon adhesion development, an anti-peritendon adhesion hydrated fibrous gene patch with antimicrobial antioxidant and anti-inflammatory activity was developed. First, hydrazinylated hyaluronic acid and dialdehyde polyethylene glycol were crosslinked to prepare a self-healing hydrogel (DHP). Then, the hydrogel loaded with transforming growth factor-β1 siRNA/TAT conjugate was attached to a Poly(L-lactide-co-ε-caprolactone) electrospun fiber membrane containing berberine to form a composite bilayer patch. The encapsulated TGF-β1 siRNA complex in the siRNA@DHP-PB patch responds to the microenvironment by releasing to the outer gel side, blocking the key fibrosis pathway and inhibiting the formation of tendon adhesion tissue; the loaded Ber is released to the inner fiber side, with antioxidant, anti-inflammatory and antimicrobial properties, providing a good microenvironment for tendon regeneration. This design fills the therapeutic gap between transient anti-inflammatory treatment and delayed antifibrotic intervention, offering a paradigm shift in the field of regenerative medicine that transcends tendon repair and holds potential for chronotherapeutic applications and multimodal anti-adhesion strategies. STATEMENT OF SIGNIFICANCE: Peritendinous adhesions are a critical post-tendon-injury complication. Conventional anti-adhesion barriers (e.g., drug-loaded hydrogels/fibers) lack microenvironment-responsive drug control and tendon-specific biointegration. We developed a multifunctional siRNA@DHP-PB patch with antimicrobial, antioxidant, and anti-inflammatory properties. Its outer layer is a self-healing hydrogel (crosslinked hydrazide-hyaluronic acid/aldehyde-polyglycol) encapsulating TGF-β1 siRNA/TAT, while the inner PLCL electrospun membrane is loaded with berberine. The siRNA complex is released toward the gel interface to suppress early-stage inflammatory TGF-β1, minimizing tendon toxicity. Berberine, released at the fiber interface, scavenges ROS, prevents infections, and inhibits oxidative damage. This bidirectional, biodegradable system enables targeted, adhesion-free tendon repair. CI - Copyright © 2025. Published by Elsevier Inc. FAU - Jiang, Yingxue AU - Jiang Y AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China. FAU - Liu, Taishan AU - Liu T AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China. FAU - Duan, Zhiguang AU - Duan Z AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China. FAU - Qu, Linlin AU - Qu L AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China; Xi'an Giant Biotechnology Co. Ltd., Xi'an 710100, China. FAU - Liu, Lin AU - Liu L AD - Xi'an Giant Biotechnology Co. Ltd., Xi'an 710100, China. FAU - Fan, Yanru AU - Fan Y AD - The college of life sciences, Northwest University, Xi'an 710069, China. FAU - Zhu, Chenhui AU - Zhu C AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China. Electronic address: zch2005@nwu.edu.cn. FAU - Ma, Xiaoxuan AU - Ma X AD - Engineering Research Center of Western Resource Innovation Medicine Green Manufacturing, Ministry of Education, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Shaanxi Key Laboratory of Degradable Biomedical Materials and Shaanxi R&D Center of Biomaterials and Fermentation Engineering, School of Chemical Engineering, Northwest University, Xi'an, 710069, China; Biotech. & Biomed. Research Institute, Northwest University, Xi'an, 710069, China; Xi'an Synthetic Biology Technology and Biomaterials International Science and Technology Cooperation Base, School of Chemical Engineering, Northwest University, Xi'an, 710127, China. Electronic address: xiaoxuanma@nwu.edu.cn. LA - eng PT - Journal Article DEP - 20250705 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Transforming Growth Factor beta1) RN - 0 (RNA, Small Interfering) RN - 0I8Y3P32UF (Berberine) RN - 0 (Hydrogels) SB - IM MH - *Transforming Growth Factor beta1/genetics/metabolism MH - Tissue Adhesions/pathology/metabolism/drug therapy MH - *RNA, Small Interfering/pharmacology/genetics/chemistry MH - Animals MH - *Berberine/pharmacology/chemistry/pharmacokinetics MH - *Tendons/pathology/metabolism MH - Hydrogels/chemistry/pharmacology MH - Humans OTO - NOTNLM OT - Berberine OT - Bidirectional delivery OT - Hydrated fibrous gene patch OT - Peritendinous antiadhesion OT - Tendon microenvironment COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/07/07 00:26 MHDA- 2025/08/31 20:03 CRDT- 2025/07/06 19:38 PHST- 2025/04/04 00:00 [received] PHST- 2025/06/27 00:00 [revised] PHST- 2025/07/03 00:00 [accepted] PHST- 2025/08/31 20:03 [medline] PHST- 2025/07/07 00:26 [pubmed] PHST- 2025/07/06 19:38 [entrez] AID - S1742-7061(25)00508-2 [pii] AID - 10.1016/j.actbio.2025.07.014 [doi] PST - ppublish SO - Acta Biomater. 2025 Sep 1;203:277-290. doi: 10.1016/j.actbio.2025.07.014. Epub 2025 Jul 5. PMID- 1810931 OWN - NLM STAT- MEDLINE DCOM- 19920603 LR - 20181113 IS - 0021-8782 (Print) IS - 1469-7580 (Electronic) IS - 0021-8782 (Linking) VI - 178 DP - 1991 Oct TI - Prostaglandin synthetase and prostacyclin synthetase in mature rat skeletal muscles: immunohistochemical localisation to arterioles, tendons and connective tissues. PG - 243-53 AB - Mature skeletal muscles produce appreciable quantities of prostacyclin (PGI2) and smaller amounts of PGF2 alpha and PGE2, but the sources of these prostaglandins within skeletal muscle are unknown. Monoclonal antibodies to prostaglandin synthetase and prostacyclin synthetase were used to determine which muscle cells produce prostaglandins. The antibody to prostacyclin synthetase stained the tendon, fascia, epimysium and the arteries leading to the muscles. The endothelia of arterioles were also stained in the tibialis anterior and cremaster but not in the soleus muscles. Only trace levels of immunoreactivity were observed with the antibody to prostaglandin synthetase in normal muscles. However, immunoreactivity was observed in the muscles of rats that had been pretreated with aspirin, a drug that inhibits and stabilises prostaglandin synthetase. In muscles of the aspirin-treated rats, all cell types that were stained by the antiprostacyclin synthetase also reacted weakly with the antibody to prostaglandin synthetase. In addition, some cells in the endomysium were strongly stained with the antiprostaglandin synthetase but not with the antiprostacyclin synthetase. We conclude that (1) at least one aspect of the regulation of blood flow in the microcirculation of slow muscles is different from that of fast muscles, (2) that the tendon and connective tissue is the major source of PGI2 in mature skeletal muscles, and (3) that the prostaglandin-dependent effects of insulin and some other stimuli on skeletal muscle may be mediated by the muscle's arterioles or connective tissue. FAU - McLennan, I S AU - McLennan IS AD - Department of Anatomy, University of Otago Medical School, Dunedin, New Zealand. FAU - Macdonald, R E AU - Macdonald RE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Anat JT - Journal of anatomy JID - 0137162 RN - 9035-51-2 (Cytochrome P-450 Enzyme System) RN - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases) RN - EC 5.- (Isomerases) RN - EC 5.3.- (Intramolecular Oxidoreductases) RN - EC 5.3.99.4 (prostacyclin synthetase) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Arterioles/*enzymology MH - Aspirin/pharmacology MH - Connective Tissue/*enzymology MH - Cytochrome P-450 Enzyme System/*analysis MH - Female MH - Immunohistochemistry MH - *Intramolecular Oxidoreductases MH - Isomerases/*analysis MH - Male MH - Muscles/anatomy & histology/blood supply/drug effects/*enzymology MH - Prostaglandin-Endoperoxide Synthases/*analysis MH - Rats MH - Rats, Inbred Strains MH - Tendons/*enzymology PMC - PMC1260550 EDAT- 1991/10/01 00:00 MHDA- 1991/10/01 00:01 PMCR- 1991/10/01 CRDT- 1991/10/01 00:00 PHST- 1991/10/01 00:00 [pubmed] PHST- 1991/10/01 00:01 [medline] PHST- 1991/10/01 00:00 [entrez] PHST- 1991/10/01 00:00 [pmc-release] PST - ppublish SO - J Anat. 1991 Oct;178:243-53. PMID- 9600555 OWN - NLM STAT- MEDLINE DCOM- 19980707 LR - 20121115 IS - 0271-6798 (Print) IS - 0271-6798 (Linking) VI - 18 IP - 3 DP - 1998 May-Jun TI - Muscle and tendon size relationships in a paralyzed chick embryo model of clubfoot. PG - 314-8 AB - Clubfoot is a birth defect that may be related to muscle weakness or imbalance. The purpose of this study was to examine the relationships among muscle and tendon size and embryonic motility in a paralyzed chick embryo model of clubfoot and arthrogryposis. Decamethonium bromide, a neuromuscular blocking agent, was administered to a series of embryos in five dosage groups, producing a cohort of embryos with various degrees of paralysis and atrophy of tendons and muscle. Embryonic movement frequency was monitored, and after death in late gestation, the cross-sectional areas of the calf musculature and the gastrocnemius tendon proximal to the ankle were measured histologically. Significant correlations were found between embryonic motility and both muscle (r2 = 0.52) and tendon (r2 = 0.77) areas. In addition, a significant correlation (r2 = 0.74) was found between muscle and tendon areas, suggesting that a measurement of one may be used to predict the other. FAU - Germiller, J A AU - Germiller JA AD - Section of Orthopaedic Surgery, University of Michigan, Ann Arbor, USA. FAU - Lerner, A L AU - Lerner AL FAU - Pacifico, R J AU - Pacifico RJ FAU - Loder, R T AU - Loder RT FAU - Hensinger, R N AU - Hensinger RN LA - eng GR - AR20557/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Pediatr Orthop JT - Journal of pediatric orthopedics JID - 8109053 RN - 0 (Decamethonium Compounds) RN - 0 (Neuromuscular Blocking Agents) RN - C1CG1S3T2W (decamethonium) SB - IM MH - Animals MH - Chick Embryo MH - Clubfoot/*etiology MH - Decamethonium Compounds/administration & dosage MH - Disease Models, Animal MH - Hindlimb/*pathology MH - Movement MH - Muscle, Skeletal/*pathology MH - Muscular Atrophy/etiology/*pathology/physiopathology MH - Neuromuscular Blocking Agents/administration & dosage MH - Paralysis/chemically induced/*pathology/physiopathology MH - Tendons/*pathology EDAT- 1998/05/26 00:00 MHDA- 1998/05/26 00:01 CRDT- 1998/05/26 00:00 PHST- 1998/05/26 00:00 [pubmed] PHST- 1998/05/26 00:01 [medline] PHST- 1998/05/26 00:00 [entrez] PST - ppublish SO - J Pediatr Orthop. 1998 May-Jun;18(3):314-8. PMID- 9195442 OWN - NLM STAT- MEDLINE DCOM- 19970724 LR - 20151119 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 22 IP - 2 DP - 1997 Mar TI - Modified transthecal digital block. PG - 361-3 FAU - Whetzel, T P AU - Whetzel TP AD - Department of Surgery, University of California, Davis, Medical Center, Sacramento 95817-2282, USA. FAU - Mabourakh, S AU - Mabourakh S FAU - Barkhordar, R AU - Barkhordar R LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Anesthetics, Local) RN - 0 (Coloring Agents) RN - 0 (chinese ink) RN - 7440-44-0 (Carbon) RN - 98PI200987 (Lidocaine) SB - IM MH - Anesthetics, Local/*administration & dosage MH - Cadaver MH - *Carbon MH - Coloring Agents MH - Fingers/*surgery MH - Humans MH - Injections, Intramuscular/methods MH - Lidocaine/*administration & dosage MH - Nerve Block/*methods MH - Tendons EDAT- 1997/03/01 00:00 MHDA- 1997/03/01 00:01 CRDT- 1997/03/01 00:00 PHST- 1997/03/01 00:00 [pubmed] PHST- 1997/03/01 00:01 [medline] PHST- 1997/03/01 00:00 [entrez] AID - S0363-5023(97)80179-7 [pii] AID - 10.1016/S0363-5023(97)80179-7 [doi] PST - ppublish SO - J Hand Surg Am. 1997 Mar;22(2):361-3. doi: 10.1016/S0363-5023(97)80179-7. PMID- 28617199 OWN - NLM STAT- MEDLINE DCOM- 20180427 LR - 20181113 IS - 1473-2300 (Electronic) IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 45 IP - 4 DP - 2017 Aug TI - An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study. PG - 1417-1429 LID - 10.1177/0300060517706800 [doi] AB - Objective To identify the optimal sites for classification of early gout by ultrasonography. Methods Sixty patients with monosodium urate crystal-proven gout (25 with early gout [≤2-year symptom duration], 35 with late gout [>2-year symptom duration], and 36 normouricemic healthy controls) from one centre were prospectively evaluated. Standardized blinded ultrasound examination of 36 joints and the triceps and patellar tendons was performed to identify tophi and the double contour (DC) sign. Results Ultrasonographic sensitivity was lower in early than late gout. Binary logistic regression analysis showed that two ultrasonographic signs (tophi in the first metatarsophalangeal joint [odds ratio, 16.46] and the DC sign in the ankle [odds ratio, 25.18]) significantly contributed to the final model for early gout diagnosis (sensitivity and specificity of 84% and 81%, respectively). The inter-reader reliability kappa value for the DC sign and tophi was 0.712. Conclusions Four-joint investigation (both first metatarsophalangeal joints for tophi and both ankles for the DC sign) is feasible and reliable and could be proposed as a screening test for early ultrasonographic gout classification in daily practice. FAU - Norkuviene, Eleonora AU - Norkuviene E AD - 1 Rheumatology Department, Medical academy Lithuanian University of Health Sciences, Mickeviciaus, Kaunas, Lithuania. FAU - Petraitis, Mykolas AU - Petraitis M AD - 1 Rheumatology Department, Medical academy Lithuanian University of Health Sciences, Mickeviciaus, Kaunas, Lithuania. AD - 2 Rheumatology Department, Hospital of Lithuanian University of Health Sciences Kauno Clinic's, Eiveniu, Kaunas, Lithuania. FAU - Apanaviciene, Indre AU - Apanaviciene I AD - 1 Rheumatology Department, Medical academy Lithuanian University of Health Sciences, Mickeviciaus, Kaunas, Lithuania. FAU - Virviciute, Dalia AU - Virviciute D AD - 3 Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu pr, Kaunas, Lithuania. FAU - Baranauskaite, Asta AU - Baranauskaite A AD - 1 Rheumatology Department, Medical academy Lithuanian University of Health Sciences, Mickeviciaus, Kaunas, Lithuania. LA - eng PT - Journal Article DEP - 20170615 PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Ankle Joint/diagnostic imaging/metabolism MH - Case-Control Studies MH - Early Diagnosis MH - Female MH - Gout/*diagnostic imaging/metabolism MH - Humans MH - Knee Joint/diagnostic imaging/metabolism MH - Male MH - Middle Aged MH - Prospective Studies MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Ultrasonography MH - Uric Acid/metabolism MH - Wrist Joint/diagnostic imaging/metabolism PMC - PMC5625526 OTO - NOTNLM OT - Gout OT - diagnostic test OT - double contour sign OT - tophus OT - ultrasound EDAT- 2017/06/16 06:00 MHDA- 2018/04/28 06:00 PMCR- 2017/08/01 CRDT- 2017/06/16 06:00 PHST- 2017/06/16 06:00 [pubmed] PHST- 2018/04/28 06:00 [medline] PHST- 2017/06/16 06:00 [entrez] PHST- 2017/08/01 00:00 [pmc-release] AID - 10.1177_0300060517706800 [pii] AID - 10.1177/0300060517706800 [doi] PST - ppublish SO - J Int Med Res. 2017 Aug;45(4):1417-1429. doi: 10.1177/0300060517706800. Epub 2017 Jun 15. PMID- 22588406 OWN - NLM STAT- MEDLINE DCOM- 20120920 LR - 20220330 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 35 IP - 5 DP - 2012 May TI - Effect of PEEK polymer on tunnel widening after hamstring ACL reconstruction. PG - e654-9 LID - 10.3928/01477447-20120426-18 [doi] AB - The purpose of this study was to evaluate the effect of the AperFix device (Cayenne Medical, Inc, Scottsdale, Arizona), composed of polyetheretherketone (PEEK) polymer, on tunnel widening after hamstring anterior cruciate ligament (ACL) reconstruction as compared with 2 other fixation devices: the TransFix (Arthrex, Inc, Naples, Florida) and the EndoButton (Smith & Nephew Endoscopy, Mansfield, Massachusetts). Sixty-seven patients with isolated total ACL ruptures who underwent arthroscopically assisted reconstruction using hamstring autografts at the authors' institution were included in the study. Patients were assigned into 1 of 3 groups in a nonrandomized fashion: AperFix (n=18), TransFix (n=29), and EndoButton (n=20). Mean follow-up was 30 months. Tunnel widening measurements were performed on anteroposterior and lateral digital plain radiographs taken in postoperative week 1 and at final follow-up. Laxity testing, Lysholm scoring, and arthrometric evaluation were performed.All 3 graft fixation devices resulted in significant tunnel widening in both tibial and femoral tunnels at final follow-up when compared with the immediate postoperative period. Tunnel widening between groups was not significantly different in terms of coronal and sagittal femoral tunnel diameters. Tibial tunnel diameter increase in the sagittal plane in the EndoButton group was significantly smaller than that in the TransFix and AperFix groups. No correlation was found between the amount of tunnel enlargement and clinical outcomes of ACL surgery. This study's findings suggest that tunnel enlargement after ACL reconstruction is influenced by the type of graft fixation on the tibial side irrespective of clinical outcome, and PEEK polymer does not have an effect on tunnel widening after hamstring ACL reconstruction. CI - Copyright 2012, SLACK Incorporated. FAU - Uzumcugil, Onat AU - Uzumcugil O AD - Department of Orthopaedics and Traumatology, H.M. Istanbul Education and Research Hospita, Istanbul, Turkey. FAU - Yalcinkaya, Merter AU - Yalcinkaya M FAU - Ozturkmen, Yusuf AU - Ozturkmen Y FAU - Dikmen, Goksel AU - Dikmen G FAU - Caniklioglu, Mustafa AU - Caniklioglu M LA - eng PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Benzophenones) RN - 0 (Biocompatible Materials) RN - 0 (Ketones) RN - 0 (Polymers) RN - 31694-16-3 (polyetheretherketone) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adult MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Injuries MH - Anterior Cruciate Ligament Reconstruction/adverse effects/*methods MH - Arthroscopy MH - Benzophenones MH - Biocompatible Materials/*administration & dosage MH - Female MH - Femur/drug effects/pathology/surgery MH - Humans MH - Ketones/*administration & dosage MH - Knee Injuries/surgery MH - Knee Joint/drug effects/pathology/surgery MH - Male MH - Polyethylene Glycols/*administration & dosage MH - Polymers MH - Postoperative Complications/*prevention & control MH - Retrospective Studies MH - Rupture MH - Tendons/*transplantation MH - Tibia/drug effects/pathology/surgery EDAT- 2012/05/17 06:00 MHDA- 2012/09/21 06:00 CRDT- 2012/05/17 06:00 PHST- 2012/05/17 06:00 [entrez] PHST- 2012/05/17 06:00 [pubmed] PHST- 2012/09/21 06:00 [medline] AID - 10.3928/01477447-20120426-18 [doi] PST - ppublish SO - Orthopedics. 2012 May;35(5):e654-9. doi: 10.3928/01477447-20120426-18. PMID- 8620841 OWN - NLM STAT- MEDLINE DCOM- 19960617 LR - 20220215 IS - 0950-1991 (Print) IS - 0950-1991 (Linking) VI - 122 IP - 4 DP - 1996 Apr TI - Expression and regulation of Cek-8, a cell to cell signalling receptor in developing chick limb buds. PG - 1147-55 AB - The Eph-related receptor tyrosine kinase gene, Cek-8, is expressed in mesenchyme at the tip of chick limb buds, with high levels of transcripts posteriorly and apically but fading out anteriorly. Expression of Cek-8 in distal mesenchyme is regulated by apical ridge- and FGF-polarising signals and retinoic acid, and is uniform across the anteroposterior axis in talpid3 mutants. These data indicate that Cek-8 expression responds to regulatory signals during limb patterning and suggest that this receptor tyrosine kinase may have a role in coordinating responses to signals in the progress zone of early buds. Later on in limb development, Cek-8 expression is associated with cell condensations that form tendons and their attachments to cartilage rudiments and then in developing feather buds. FAU - Patel, K AU - Patel K AD - Division of Developmental Neurobiology, National Institute for Medical Research, London, UK. FAU - Nittenberg, R AU - Nittenberg R FAU - D'Souza, D AU - D'Souza D FAU - Irving, C AU - Irving C FAU - Burt, D AU - Burt D FAU - Wilkinson, D G AU - Wilkinson DG FAU - Tickle, C AU - Tickle C LA - eng GR - Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Development JT - Development (Cambridge, England) JID - 8701744 RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Growth Substances) RN - 0 (Neuropeptides) RN - 0 (Proteins) RN - 0 (RNA, Messenger) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - 5688UTC01R (Tretinoin) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) RN - EC 2.7.10.1 (Receptor, EphA4) SB - IM MH - Animals MH - Bone Morphogenetic Proteins MH - Cell Communication MH - Chick Embryo MH - Feathers/embryology MH - Fibroblast Growth Factor 2/pharmacology MH - Gene Expression Regulation, Developmental/drug effects/*physiology MH - Growth Substances/pharmacology MH - Limb Buds/cytology/growth & development/*physiology MH - Mesoderm/chemistry MH - Mice MH - Mice, Inbred C57BL MH - Microspheres MH - Mutation MH - Neuropeptides/*genetics MH - Proteins/pharmacology MH - RNA, Messenger/analysis MH - Receptor Protein-Tyrosine Kinases/*genetics MH - Receptor, EphA4 MH - Tendons/chemistry/embryology MH - Tretinoin/pharmacology EDAT- 1996/04/01 00:00 MHDA- 1996/04/01 00:01 CRDT- 1996/04/01 00:00 PHST- 1996/04/01 00:00 [pubmed] PHST- 1996/04/01 00:01 [medline] PHST- 1996/04/01 00:00 [entrez] AID - 10.1242/dev.122.4.1147 [doi] PST - ppublish SO - Development. 1996 Apr;122(4):1147-55. doi: 10.1242/dev.122.4.1147. PMID- 23261247 OWN - NLM STAT- MEDLINE DCOM- 20130906 LR - 20181202 IS - 1873-2380 (Electronic) IS - 0021-9290 (Linking) VI - 46 IP - 4 DP - 2013 Feb 22 TI - Fractionation of 50kGy electron beam irradiation: effects on biomechanics of human flexor digitorum superficialis tendons treated with ascorbate. PG - 658-61 LID - S0021-9290(12)00701-4 [pii] LID - 10.1016/j.jbiomech.2012.11.049 [doi] AB - The electron beam (Ebeam) irradiation has begun to be considered as an efficient alternative to gamma irradiation in the sterilization of allografts in the reconstruction of anterior cruciate ligament. The purpose of this study was to evaluate the biomechanical properties of human tendons after exposure to electron beam and free radical scavenger ascorbate. Forty human flexor digitorum superficialis tendons were prepared from five fresh cadavers and divided randomly into four groups: A, fresh (0kGy); B, 50kGy Ebeam irradiation; C, fractionated 50kGy Ebeam irradiation; D, fractionated 50kGy Ebeam on ascorbate-treated tendons. The fractionation of 50kGy was achieved by repeated irradiation of 2.5kGy for 20 repetitions. Biomechanical properties were analyzed during load-to-failure testing. The fresh tendons were found to be significant different in ultimate load, ultimate elongation relative to tendons in group B. Statistical differences were found between group B and C in ultimate load. No differences were detected between group A and C in all the parameters. Compare tendons in group C and D, significant differences were found in ultimate load and ultimate stress. It is recommended that fractionated 50kGy electron beam irradiation and free radical scavenger ascorbate should be applied in the sterilization of allografts tendons. CI - Copyright © 2012 Elsevier Ltd. All rights reserved. FAU - Wei, Wei AU - Wei W AD - Department of Orthopedics, the Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China. weiwei_qy@yahoo.com.cn FAU - Liu, Yujie AU - Liu Y FAU - Yang, Xu AU - Yang X FAU - Tian, Shaoqi AU - Tian S FAU - Liu, Chao AU - Liu C FAU - Zhang, Yang AU - Zhang Y FAU - Xu, Zhaoning AU - Xu Z FAU - Hu, Baiqiang AU - Hu B FAU - Tian, Zhen AU - Tian Z FAU - Sun, Kang AU - Sun K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121220 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Free Radical Scavengers) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adult MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Injuries MH - Anterior Cruciate Ligament Reconstruction/methods MH - Ascorbic Acid/administration & dosage MH - Biomechanical Phenomena MH - Dose Fractionation, Radiation MH - Electrons/therapeutic use MH - Female MH - Free Radical Scavengers/administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Sterilization/methods MH - Tendons/drug effects/*physiology/*radiation effects MH - Transplantation, Homologous MH - Weight-Bearing/physiology EDAT- 2012/12/25 06:00 MHDA- 2013/09/07 06:00 CRDT- 2012/12/25 06:00 PHST- 2012/09/25 00:00 [received] PHST- 2012/11/23 00:00 [revised] PHST- 2012/11/25 00:00 [accepted] PHST- 2012/12/25 06:00 [entrez] PHST- 2012/12/25 06:00 [pubmed] PHST- 2013/09/07 06:00 [medline] AID - S0021-9290(12)00701-4 [pii] AID - 10.1016/j.jbiomech.2012.11.049 [doi] PST - ppublish SO - J Biomech. 2013 Feb 22;46(4):658-61. doi: 10.1016/j.jbiomech.2012.11.049. Epub 2012 Dec 20. PMID- 971346 OWN - NLM STAT- MEDLINE DCOM- 19761121 LR - 20190718 IS - 0021-9150 (Print) IS - 0021-9150 (Linking) VI - 24 IP - 3 DP - 1976 Sep TI - Ischaemic disease in men and women with familial hypercholesterolaemia and xanthomatosis. A comparative study of genetic and environmental factors in 274 heterozygous cases. PG - 441-50 AB - The incidence of ischaemic diseases in familial hypercholesterolaemia and xanthomatosis (familial Type II) was studied in a group of 158 men and 116 women. (1) Men and women did not differ with regard to the inherited metabolic disease. Levels of serum cholesterol, the marker of the genetic defect, were not statistically different, and cholesterol deposition in tissues, visualized by skin tendon xanthomas, was not sex related. (2) Men and women were different with regard to ischaemic diseases. The incidence was much lower in women, and the mean age of onset 9 years later. Moreover, there was a sex difference in the nature of the ischaemic disease, with a high male predominance of myocardial infarction. (3) Since the major risk factor hypercholesterolaemia could not explain such a difference, the role of other risk factors was investigated. It was shown that the incidence of ischaemic diseases was increased in women by cigarette smoking and hypertension, and that the difference in age of onset between males and females was no longer seen in smoking women. It is suggested that the genetic factor is responsible for the atherosclerotic lesion in both sexes and that other factors playing a role in ischaemic complications including tobacco and hypertension may explain the difference between men and women. FAU - Beaumont, V AU - Beaumont V FAU - Jacotot, B AU - Jacotot B FAU - Beaumont, J L AU - Beaumont JL LA - eng PT - Journal Article PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 RN - 0 (Triglycerides) RN - 268B43MJ25 (Uric Acid) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Adult MH - Cholesterol/blood MH - Coronary Disease/*complications/genetics MH - Female MH - *Heterozygote MH - Humans MH - Hypercholesterolemia/*complications/genetics MH - Hypertension/complications MH - Male MH - Middle Aged MH - Muscular Diseases/complications MH - Myocardial Infarction/complications MH - Obesity/complications MH - Risk MH - Sex Factors MH - Smoking MH - Tendons MH - Triglycerides/blood MH - Uric Acid/blood MH - Xanthomatosis/*complications/genetics EDAT- 1976/09/01 00:00 MHDA- 1976/09/01 00:01 CRDT- 1976/09/01 00:00 PHST- 1976/09/01 00:00 [pubmed] PHST- 1976/09/01 00:01 [medline] PHST- 1976/09/01 00:00 [entrez] AID - 0021-9150(76)90136-2 [pii] AID - 10.1016/0021-9150(76)90136-2 [doi] PST - ppublish SO - Atherosclerosis. 1976 Sep;24(3):441-50. doi: 10.1016/0021-9150(76)90136-2. PMID- 24938519 OWN - NLM STAT- MEDLINE DCOM- 20140926 LR - 20211021 IS - 1552-5783 (Electronic) IS - 0146-0404 (Print) IS - 0146-0404 (Linking) VI - 55 IP - 7 DP - 2014 Jun 17 TI - Morphological alterations within the peripheral fixation of the iris dilator muscle in eyes with pigmentary glaucoma. PG - 4541-51 LID - 10.1167/iovs.13-13765 [doi] AB - PURPOSE: To analyze the peripheral fixation of the iris dilator muscle in normal eyes and in eyes with pigmentary glaucoma (PG). METHODS: Using 63 control eyes (age 18 months-99 years), the peripheral iris dilator was investigated by light microscopy, immunohistochemistry, and electron microscopy. Development was studied using 18 differently aged fetal eyes stained immunohistochemically against α-smooth muscle (SM) actin. The peripheral iris dilator muscle in PG was analyzed using semithin and ultrathin sections of six glutaraldehyde-fixed eyes from three donors aged 38, 62, and 74 years. RESULTS: In normal eyes, the peripheral end of the iris dilator muscle is arranged in a sphincter-like manner. Arcade-shaped tendinous connections associated with myofibroblasts (iridial strands) anchor the iris dilator within the elastic-fibromuscular ciliary meshwork that also serves as fixation area for the elastic tendons of the inner ciliary muscle portions. The iridial strands are innervated and can adapt their length during accommodation. The PG eyes show incomplete circular bundles and iridial strands that are mainly anchored to the iris stroma and the flexible uveal parts of the trabecular meshwork. CONCLUSIONS: The normal anchorage of the peripheral iris dilator and its presumably neuronally regulated length adaptation stabilize the peripheral iris during accommodation. Insufficient fixation in PG could promote posterior bowing of the iris with rubbing against the zonular fibers and pigment liberation from the iris pigmented epithelium. CI - Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc. FAU - Flügel-Koch, Cassandra M AU - Flügel-Koch CM AD - Department of Anatomy II, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. FAU - Tektas, Ozan Y AU - Tektas OY AD - Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. FAU - Kaufman, Paul L AU - Kaufman PL AD - Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States. FAU - Paulsen, Friedrich P AU - Paulsen FP AD - Department of Anatomy II, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. FAU - Lütjen-Drecoll, Elke AU - Lütjen-Drecoll E AD - Department of Anatomy II, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. LA - eng GR - P30 EY016665/EY/NEI NIH HHS/United States PT - Journal Article DEP - 20140617 PL - United States TA - Invest Ophthalmol Vis Sci JT - Investigative ophthalmology & visual science JID - 7703701 RN - 0 (Biomarkers) RN - 0 (Miotics) RN - 0 (Mydriatics) RN - 0 (Nerve Tissue Proteins) RN - 01MI4Q9DI3 (Pilocarpine) RN - 7C0697DR9I (Atropine) SB - IM MH - Accommodation, Ocular MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Atropine/pharmacology MH - Biomarkers/metabolism MH - Child MH - Child, Preschool MH - Female MH - *Fixation, Ocular MH - Glaucoma, Open-Angle/metabolism/*pathology MH - Healthy Volunteers MH - Humans MH - Immunohistochemistry MH - Infant MH - Iris/embryology/metabolism/*pathology MH - Male MH - Middle Aged MH - Miotics/pharmacology MH - Muscle, Smooth/innervation/metabolism/*pathology MH - Mydriatics/pharmacology MH - Nerve Tissue Proteins/metabolism MH - Pilocarpine/pharmacology MH - Tendons/innervation/metabolism/*pathology MH - Tissue Donors MH - Young Adult PMC - PMC4453212 OTO - NOTNLM OT - anchorage OT - immunohistochemistry OT - iris dilator muscle OT - morphology OT - pigmentary glaucoma EDAT- 2014/06/19 06:00 MHDA- 2014/09/27 06:00 PMCR- 2015/01/01 CRDT- 2014/06/19 06:00 PHST- 2014/06/19 06:00 [entrez] PHST- 2014/06/19 06:00 [pubmed] PHST- 2014/09/27 06:00 [medline] PHST- 2015/01/01 00:00 [pmc-release] AID - iovs.13-13765 [pii] AID - 10.1167/iovs.13-13765 [doi] PST - epublish SO - Invest Ophthalmol Vis Sci. 2014 Jun 17;55(7):4541-51. doi: 10.1167/iovs.13-13765. PMID- 26275370 OWN - NLM STAT- MEDLINE DCOM- 20180108 LR - 20181202 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 25 IP - 6 DP - 2017 Jun TI - Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin. PG - 1884-1891 LID - 10.1007/s00167-015-3728-z [doi] AB - PURPOSE: Accumulating clinical evidence indicates the risk of tendinopathy and spontaneous and/or simultaneous tendon ruptures associated with statin use. This experimental study was designed to evaluate and compare the biomechanical and histopathological effects of the three most commonly prescribed statins (simvastatin, atorvastatin and rosuvastatin) on the Achilles tendon in rats. METHODS: Statins were administered by gavage to rats at daily doses of 20 and 40 mg/kg for 3 weeks. One week later, the Achilles tendons were dissected and their biomechanical properties, including ultimate tensile force, yield force and elastic modulus, were determined. The samples were stained with haematoxylin-eosin and examined under a light microscope. The biomechanical properties of the tibia were tested by three-point bending test. Bone mineral density (BMD) and the lengths of tibias were measured by computed tomography. RESULTS: All the statins caused deterioration of the biomechanical parameters of the Achilles tendon. Histopathological analysis demonstrated foci of dystrophic calcification only in the statin-treated groups. However, the number and the total area of calcific deposits were similar between the statin groups. The biomechanical parameters of tibias were improved in all the statin groups. BMD in the statin-treated groups was not significantly different from the control group. CONCLUSION: All the statins tested are associated with calcific tendinopathy risk of which full awareness is required during everyday medical practice. However, statin-associated improvement of bone biomechanical properties is a favourable feature which may add to their beneficial effects in atherosclerotic cardiovascular disease, especially in the elderly. FAU - Kaleağasıoğlu, Ferda AU - Kaleağasıoğlu F AD - Department of Pharmacology, Faculty of Medicine, University of Yeditepe, Istanbul, Turkey. FAU - Olcay, Ercan AU - Olcay E AD - Department of Orthopaedic Surgery, Faculty of Medicine, University of Kafkas, Kars, Turkey. ercan.olcay3809@gmail.com. AD - Department of Orthopaedic Surgery, Kanuni Sultan Suleyman Educational Hospital, Istanbul, Turkey. ercan.olcay3809@gmail.com. FAU - Olgaç, Vakur AU - Olgaç V AD - Department of Pathology, Institute of Oncology, University of Istanbul, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20150815 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 83MVU38M7Q (Rosuvastatin Calcium) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Achilles Tendon/*pathology/*physiopathology MH - Aged, 80 and over MH - Animals MH - Atorvastatin/adverse effects MH - Biomechanical Phenomena MH - Bone Density MH - Calcinosis/*pathology MH - Disease Models, Animal MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects MH - Rats, Wistar MH - Risk Factors MH - Rosuvastatin Calcium/adverse effects MH - Rupture, Spontaneous MH - Simvastatin/adverse effects MH - Tendinopathy/chemically induced/*pathology/*physiopathology OTO - NOTNLM OT - Achilles tendon OT - Atorvastatin OT - Biomechanics OT - Bone density OT - Calcific tendinopathy OT - Rosuvastatin OT - Simvastatin EDAT- 2015/08/16 06:00 MHDA- 2018/01/09 06:00 CRDT- 2015/08/16 06:00 PHST- 2015/03/25 00:00 [received] PHST- 2015/07/17 00:00 [accepted] PHST- 2015/08/16 06:00 [pubmed] PHST- 2018/01/09 06:00 [medline] PHST- 2015/08/16 06:00 [entrez] AID - 10.1007/s00167-015-3728-z [pii] AID - 10.1007/s00167-015-3728-z [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2017 Jun;25(6):1884-1891. doi: 10.1007/s00167-015-3728-z. Epub 2015 Aug 15. PMID- 28905585 OWN - NLM STAT- MEDLINE DCOM- 20180521 LR - 20181202 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 41 IP - 13 DP - 2016 Jul TI - [Analysis of clinical medication rules in 48 398 patients with limb fractures based on hospital information system]. PG - 2555-2560 LID - 10.4268/cjcmm20161331 [doi] AB - To explore the clinical medication rules in the patients with limb fractures, and provide guidance for clinical practice. Data of 48 398 patients with limb fractures from 2001 to 2011 was extracted from the hospital information system(HIS) established by the institute of basic research in clinical medicine, China academy of Chinese medical sciences. The gender and age distribution of patients and clinical medication characteristics were described. Apriori algorithm was adopted to analyze the common drug combinations of Chinese medicine(CM) and western medicine(WM). The study results showed that the ratio of included males and females was 1.83∶1. There was a high peak of incidence for the patients from 18 to 44 years. Apriori algorithm showed that the usage of WM was more frequent than that of CM. The most commonly used CM was Lugua polypeptide and sodium aescinate injection. Blood-activating and stasis-resolving medicines, as well as tendons and bones-strengthening medicines were the commonly used CM types. In addition, WM antibiotics plus blood-activating and stasis-resolving CM, or antibiotics plus tendons and bones-strengthening CM was the most commonly used drug combination. Based on the analysis of available data, the prevalence of limb fracture was higher in men than in women; more in young and middle-aged patients; the common drug combination was antibiotics plus blood-activating and stasis-resolving CM, or antibiotics plus tendons and bones-strengthening CM. More prospective and high-quality clinical trials are necessary to evaluate the effect of CM or integrative medicine treatment for limb fracture in the future research. CI - Copyright© by the Chinese Pharmaceutical Association. FAU - Jia, Cheng-Hui AU - Jia CH AD - Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. AD - Beijing Zhongguancun Hospital, China Academy of Sciences, Beijing 100190, China. FAU - Zhang, Yin AU - Zhang Y AD - Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. FAU - Xie, Yan-Ming AU - Xie YM AD - Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. FAU - Wei, Xu AU - Wei X AD - Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. AD - Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China. FAU - Yin, He AU - Yin H AD - Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China. FAU - Feng, Bo AU - Feng B AD - School of Statistics, Renmin University of China, Beijing 100872, China. FAU - Zhuang, Yan AU - Zhuang Y AD - The PLA Navy General Hospital, Beijing 100048, China. LA - chi PT - Journal Article PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Adolescent MH - Adult MH - China MH - Drugs, Chinese Herbal MH - Female MH - Fractures, Bone/*drug therapy MH - *Hospital Information Systems MH - Humans MH - Male MH - Medicine, Chinese Traditional MH - Prospective Studies MH - Young Adult OTO - NOTNLM OT - apriori algorithm OT - clinical medication OT - hospital information system OT - limb fracture COIS- The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose. EDAT- 2016/07/01 00:00 MHDA- 2018/05/22 06:00 CRDT- 2017/09/15 06:00 PHST- 2016/03/03 00:00 [received] PHST- 2017/09/15 06:00 [entrez] PHST- 2016/07/01 00:00 [pubmed] PHST- 2018/05/22 06:00 [medline] AID - 10.4268/cjcmm20161331 [doi] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2016 Jul;41(13):2555-2560. doi: 10.4268/cjcmm20161331. PMID- 16555106 OWN - NLM STAT- MEDLINE DCOM- 20061208 LR - 20181113 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 14 IP - 7 DP - 2006 Jul TI - Extensor origin vascularity related to pain in patients with Tennis elbow. PG - 659-63 AB - Tennis elbow, extensor carpi radialis brevis (ECRB) tendinosis, is a condition with unknown etiology and pathogenesis, known to be difficult to treat. The pain mechanisms have not been fully clarified, but involvement of a neurogenic inflammation mediated via the neuropeptide Substance-P (SP), has been suggested. In this investigation, grey-scale ultrasonography (US) and colour Doppler (CD) was used to examine the common extensor origin in 17 patients with the diagnose Tennis elbow in altogether 22 elbows, and in 11 controls with 22 pain-free elbows. In 21/22 elbows with chronic pain from the extensor origin, but only in 2/22 pain-free elbows, vascularity was demonstrated in the extensor origin. After US and CD-guided injection of a local anaesthetic, targeting the area with vessels, the patients were pain-free during extensor-loading activity. The area with vascularity found in the extensor origin seems to be related to pain. Most likely, the findings correspond with the vasculo-neural in growth that has been demonstrated in the chronic painful Achilles tendon, and possibly have implications for treatment. FAU - Zeisig, Eva AU - Zeisig E AD - Department of Surgical and Perioperative Science Sports Medicine, University of Umeå, 90187, Umeå, Sweden. eva.zeisig@vll.se FAU - Ohberg, Lars AU - Ohberg L FAU - Alfredson, Håkan AU - Alfredson H LA - eng PT - Journal Article DEP - 20060323 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Anesthetics, Local/administration & dosage MH - Blood Flow Velocity MH - Case-Control Studies MH - Female MH - Hand Strength MH - Humans MH - Injections, Intra-Articular MH - Lidocaine/administration & dosage MH - Male MH - Middle Aged MH - Pain Measurement MH - Tendons/*blood supply/*diagnostic imaging MH - Tennis Elbow/*diagnostic imaging/*physiopathology MH - Ultrasonography/methods MH - Weight-Bearing EDAT- 2006/03/24 09:00 MHDA- 2006/12/12 09:00 CRDT- 2006/03/24 09:00 PHST- 2005/06/13 00:00 [received] PHST- 2005/08/26 00:00 [accepted] PHST- 2006/03/24 09:00 [pubmed] PHST- 2006/12/12 09:00 [medline] PHST- 2006/03/24 09:00 [entrez] AID - 10.1007/s00167-006-0060-7 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2006 Jul;14(7):659-63. doi: 10.1007/s00167-006-0060-7. Epub 2006 Mar 23. PMID- 32819060 OWN - NLM STAT- MEDLINE DCOM- 20200824 LR - 20200824 IS - 0376-2491 (Print) IS - 0376-2491 (Linking) VI - 100 IP - 31 DP - 2020 Aug 18 TI - [Study on the deposition of monosodium urate in patients with first-episode of acute gouty arthritis by dual energy CT]. PG - 2441-2445 LID - 10.3760/cma.j.cn112137-20200325-00925 [doi] AB - Objectives: To investigate the characteristics of monosodium urate (MSU) deposition in patients with the first-episode of acute gouty arthritis (Gout) by using dual energy CT (DECT) imaging technique. Methods: A total of 70 first-episode patients with acute Gout diagnosed in Peking University Third Hospital in 2019 were collected as the case group, including 69 males and 1 female, aged 17-65 (39±14) years. During the same period, a total of 15 male patients aged 19-56 (33±12) years were collected as the control group. They were admitted to the hospital due to sports injuries and were excluded from gout. The DECT data of the first-affected or the most painful joints of gout in the case group and the surgical ankle joints in the control group were retrospectively analyzed. The crystal morphology, volume and deposition location of MSU in the measured joints were evaluated and recorded, and the degree of MSU deposition in the joints of the first-episode patients with Gout and its coincidence with clinical symptoms were summarized. The χ(2) test, and Kruskal-walls were used for statistical analysis. Results: The detection rate of MSU by DECT in the case group was 97.1% (68/70), and 0 in the control group. The first-affected joints of Gout included 52 cases of ankles (74.3%), 13 cases of knees (18.6%), and 5 cases of wrists (7.1%). The three joints were mainly deposited with scattered submillimeter MCU. There was no significant difference in MSU morphology and volume between the three joints. The locations with the most MCU deposits among the three joints were 78.8% (41/52) of the posterior calf tendons (including Achilles tendon), 76.9% (10/15) of the knee articular cartilages, and 60.0% (3/5) of the palmaris tendons, while the distribution of the first metatarsophalangeal joint was less than 13.5% (7/52). The number of MSU deposited joints detected by DECT was 37 cases more than that of symptomatic joints, accounting for 52.8%. Conclusions: DECT is highly sensitive in detecting MCU in the first-episode of acute Gout, which helps to improve the early diagnosis rate of gout. FAU - Zhang, Y AU - Zhang Y AD - Department of Radiology, Peking University Third Hospital, Beijing 100191, China. FAU - Dong, X Z AU - Dong XZ AD - Department of Radiology, Peking University Third Hospital, Beijing 100191, China. FAU - Yuan, H S AU - Yuan HS AD - Department of Radiology, Peking University Third Hospital, Beijing 100191, China. LA - chi GR - 2017YFC0113403/2017 National Key Research Project of the Ministry of Science and Technology/ PT - Journal Article PL - China TA - Zhonghua Yi Xue Za Zhi JT - Zhonghua yi xue za zhi JID - 7511141 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adolescent MH - Adult MH - Aged MH - *Arthritis, Gouty MH - Female MH - *Gout MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Tomography, X-Ray Computed MH - Uric Acid MH - Young Adult OTO - NOTNLM OT - Diagnosis OT - Dual-energy CT OT - First attack OT - Gout OT - Tomography, X ray computed EDAT- 2020/08/21 06:00 MHDA- 2020/08/25 06:00 CRDT- 2020/08/22 06:00 PHST- 2020/08/22 06:00 [entrez] PHST- 2020/08/21 06:00 [pubmed] PHST- 2020/08/25 06:00 [medline] AID - 10.3760/cma.j.cn112137-20200325-00925 [doi] PST - ppublish SO - Zhonghua Yi Xue Za Zhi. 2020 Aug 18;100(31):2441-2445. doi: 10.3760/cma.j.cn112137-20200325-00925. PMID- 2279404 OWN - NLM STAT- MEDLINE DCOM- 19910313 LR - 20220318 IS - 0149-7944 (Print) IS - 0149-7944 (Linking) VI - 47 IP - 6 DP - 1990 Nov-Dec TI - Intrinsic tendon healing in vitro: biomechanical analysis and effects of vitamins A and E. PG - 440-3 FAU - Greenwald, D AU - Greenwald D AD - Department of Surgery, University of Chicago, IL 60637. FAU - Mass, D AU - Mass D FAU - Gottlieb, L AU - Gottlieb L FAU - Tuel, R AU - Tuel R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Curr Surg JT - Current surgery JID - 7802123 RN - 11103-57-4 (Vitamin A) RN - 1406-18-4 (Vitamin E) SB - IM MH - Animals MH - Biomechanical Phenomena MH - In Vitro Techniques MH - Rabbits MH - Rupture MH - Stress, Mechanical MH - Tendon Injuries/*physiopathology MH - Tendons/drug effects/physiopathology MH - Vitamin A/*pharmacology MH - Vitamin E/*pharmacology EDAT- 1990/11/01 00:00 MHDA- 1990/11/01 00:01 CRDT- 1990/11/01 00:00 PHST- 1990/11/01 00:00 [pubmed] PHST- 1990/11/01 00:01 [medline] PHST- 1990/11/01 00:00 [entrez] PST - ppublish SO - Curr Surg. 1990 Nov-Dec;47(6):440-3. PMID- 12849938 OWN - NLM STAT- MEDLINE DCOM- 20031209 LR - 20190906 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 28 IP - 4 DP - 2003 Aug TI - Local anaesthetic infusion for postoperative pain. PG - 300-6 AB - The role of continuous bupivacaine infusion either into the wound or as a local nerve block, following hand surgery was investigated in 100 patients. After excluding six patients with complex pain problems in whom neither the bupivacaine infusion nor any other conventional analgesic techniques provided adequate analgesia post-operatively, 86 of 94 (91%) patients were adequately treated for post-operative pain by this system during the first night after surgery when pain is presumed to be greatest. This system also provided adequate on-going analgesia for up to 1 week after surgery, controlling nerve pain and allowing mobilization of tendons after tenolysis. Continuous bupivacaine infusion is of particular use in these two groups of patients and after major hand injuries, when considerable pain can be anticipated. Pain during the first night was not controlled adequately by the bupivacaine infusion system in eight of the 94 patients (8%). All eight had a technical failure of the system, which was rectified in six cases to restore adequate analgesia by the infusion system. Two patients developed infection at the infusion cannula insertion site, which occurred only after 1 week and was successfully treated by removal of the cannula and oral antibiotics. FAU - Kulkarni, M AU - Kulkarni M AD - Hand Surgery Department, St Andrew's Centre for Plastic Surgery, Broomfield Hospital, Chelmsford, Essex, UK. FAU - Elliot, D AU - Elliot D LA - eng PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Analgesics, Opioid) RN - 0 (Anesthetics, Local) RN - 76I7G6D29C (Morphine) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adult MH - Aged MH - Analgesia, Patient-Controlled MH - Analgesics, Opioid/administration & dosage MH - Anesthetics, Local/*administration & dosage MH - Bupivacaine/*administration & dosage MH - Catheters, Indwelling MH - Female MH - Hand/*surgery MH - Humans MH - Infusion Pumps MH - Infusions, Intravenous MH - Male MH - Middle Aged MH - Morphine/administration & dosage MH - Nerve Block/methods MH - Pain Measurement MH - Pain, Postoperative/*prevention & control MH - Treatment Outcome EDAT- 2003/07/10 05:00 MHDA- 2003/12/11 05:00 CRDT- 2003/07/10 05:00 PHST- 2003/07/10 05:00 [pubmed] PHST- 2003/12/11 05:00 [medline] PHST- 2003/07/10 05:00 [entrez] AID - S0266768103000159 [pii] AID - 10.1016/s0266-7681(03)00015-9 [doi] PST - ppublish SO - J Hand Surg Br. 2003 Aug;28(4):300-6. doi: 10.1016/s0266-7681(03)00015-9. PMID- 35178155 OWN - NLM STAT- MEDLINE DCOM- 20220318 LR - 20220318 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2022 DP - 2022 TI - Eugenol-Preconditioned Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Antioxidant Capacity of Tendon Stem Cells In Vitro and In Vivo. PG - 3945195 LID - 10.1155/2022/3945195 [doi] LID - 3945195 AB - Tendon stem cells (TSCs) are often exposed to oxidative stress at tendon injury sites, which impairs their physiological effect as well as therapeutic application. Recently, extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (BMSCs) were shown to mediate cell protection and survival under stress conditions. The function of BMSC-EVs may be affected by pretreatment with various factors such as eugenol (EUG)-a powerful antioxidant. In our previous study, we found that H(2)O(2) significantly impaired TSC proliferation and tenogenic differentiation capabilities. Apoptosis and intracellular ROS accumulation in TSCs were induced by H(2)O(2). However, such H(2)O(2)-induced damage was prevented by treatment with EUG-BMSC-EVs. Furthermore, EUG-BMSC-EVs activated the Nrf2/HO-1 pathway to counteract H(2)O(2)-induced damage in TSCs. In a rat patellar tendon injury model, the ROS level was significantly higher than that in the normal tendon and TSCs not pretreated showed a poor therapeutic effect. However, EUG-BMSC-EV-pretreated TSCs significantly improved tenogenesis and matrix regeneration during tendon healing. Additionally, the EUG-BMSC-EV group had a significantly improved fiber arrangement. Overall, EUG-BMSC-EVs protected TSCs against oxidative stress and enhanced their functions in tendon injury. These findings provide a basis for potential clinical use of EUG-BMSC-EVs as a new therapeutic vehicle to facilitate TSC therapies for tendon regeneration. CI - Copyright © 2022 Xiangze Li et al. FAU - Li, Xiangze AU - Li X AD - Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Su, Zhan AU - Su Z AD - Department of Orthopaedics, Heilongjiang Red Cross Sengong General Hospital, Heilongjiang, China. FAU - Shen, Kaiying AU - Shen K AD - Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Qi AU - Wang Q AD - Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xu, Chencheng AU - Xu C AD - Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Wang, Fuqiang AU - Wang F AD - Department of Pediatric Surgery, Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, China. FAU - Zhang, Yuchi AU - Zhang Y AD - Department of Pediatric Surgery, Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, China. FAU - Jiang, Dapeng AU - Jiang D AUID- ORCID: 0000-0002-7360-1662 AD - Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article DEP - 20220208 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 RN - 0 (Anti-Infective Agents) RN - 0 (Antioxidants) RN - 3T8H1794QW (Eugenol) SB - IM MH - Animals MH - Anti-Infective Agents/pharmacology/*therapeutic use MH - Antioxidants/*metabolism MH - Cell Differentiation MH - Eugenol/pharmacology/*therapeutic use MH - Extracellular Vesicles/*metabolism MH - Humans MH - Mesenchymal Stem Cells/*metabolism MH - Oxidative Stress MH - Rats MH - Tendons/*physiopathology PMC - PMC8847013 COIS- The authors declare that they have no competing interests. EDAT- 2022/02/19 06:00 MHDA- 2022/03/19 06:00 PMCR- 2022/02/08 CRDT- 2022/02/18 05:49 PHST- 2021/11/05 00:00 [received] PHST- 2022/01/06 00:00 [revised] PHST- 2022/01/12 00:00 [accepted] PHST- 2022/02/18 05:49 [entrez] PHST- 2022/02/19 06:00 [pubmed] PHST- 2022/03/19 06:00 [medline] PHST- 2022/02/08 00:00 [pmc-release] AID - 10.1155/2022/3945195 [doi] PST - epublish SO - Oxid Med Cell Longev. 2022 Feb 8;2022:3945195. doi: 10.1155/2022/3945195. eCollection 2022. PMID- 652049 OWN - NLM STAT- MEDLINE DCOM- 19780715 LR - 20190725 IS - 0028-1298 (Print) IS - 0028-1298 (Linking) VI - 302 IP - 1 DP - 1978 Mar TI - In vivo method for quantitation for anti-platelet potency of drugs. PG - 25-30 AB - Aortic strips from atherosclerotic rabbits or Achilles tendons from healthy rabbits were superfused with blood (3 ml/min) from anaesthetized and heparinized cats, while blood was returned to the venous system of animals. The superfused tissues gained in weight because of deposition of platelet thrombi on their surface. This gain in weight was continuously monitored and quantified. Forty minutes after intravenous administration of indomethacin (14 mg/kg), aspirin (7 mg/kg) or nictindole (2 mg/kg) the formation of platelet depostis was reduced by half. Three hours after i.v. administration of each drug at a dose of 20 m;/kg the remaining anti-platelet activities were 92% for aspirin, 59% for indomethacin and 18% for nictindole as compared to their antithrombotic action, which was recorded 40 min after their administration. Thrombogenesis was also prevented by a direct infusion of nictindole (50 ng/ml) or indomethacin (2000 ng/ml) into a stream of superfusing blood. Thereby our method enables us to quantify in vivo anti-aggregating potency of drug, to estimate the duration of this action, and to compare their in vitro and in vivo aggregation-inhibitory activities. FAU - Gryglewski, R J AU - Gryglewski RJ FAU - Korbut, R AU - Korbut R FAU - Ocetkiewicz, A AU - Ocetkiewicz A FAU - Stachura, J AU - Stachura J LA - eng PT - Journal Article PL - Germany TA - Naunyn Schmiedebergs Arch Pharmacol JT - Naunyn-Schmiedeberg's archives of pharmacology JID - 0326264 RN - 0 (Fibrinolytic Agents) RN - 0 (Indoles) RN - 0 (Pyridines) RN - R16CO5Y76E (Aspirin) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Aspirin/pharmacology MH - Blood Coagulation/drug effects MH - Cats MH - Fibrinolytic Agents/*pharmacology MH - In Vitro Techniques MH - Indoles/pharmacology MH - Indomethacin/pharmacology MH - Platelet Aggregation/*drug effects MH - Pyridines/pharmacology MH - Rabbits MH - Time Factors EDAT- 1978/03/16 00:00 MHDA- 1978/03/16 00:01 CRDT- 1978/03/16 00:00 PHST- 1978/03/16 00:00 [pubmed] PHST- 1978/03/16 00:01 [medline] PHST- 1978/03/16 00:00 [entrez] AID - 10.1007/BF00586592 [doi] PST - ppublish SO - Naunyn Schmiedebergs Arch Pharmacol. 1978 Mar;302(1):25-30. doi: 10.1007/BF00586592. PMID- 10954446 OWN - NLM STAT- MEDLINE DCOM- 20001003 LR - 20131121 IS - 0361-803X (Print) IS - 0361-803X (Linking) VI - 175 IP - 3 DP - 2000 Sep TI - Carpal tunnel syndrome caused by tophaceous gout: CT and MR imaging features in 20 patients. PG - 655-9 AB - OBJECTIVE: The objective of this study is to describe the CT and MR imaging findings of gouty tophi in the wrist and present this entity as a cause of carpal tunnel syndrome. MATERIALS AND METHODS: Retrospective review of the CT (n = 18) and MR imaging (n = 20) studies of the wrist in patients with a documented diagnosis of gout who presented with gout-related carpal tunnel syndrome was performed; images of 24 wrists were collected over a 5-year period. Patient population included 20 men, who ranged in age from 35 to 76 years. All images were reviewed by two musculoskeletal radiologists who reached a consensus opinion. Surgical correlation was available in 12 patients. RESULTS: Tophi were found in the floor of the carpal tunnel (n = 18), carpal bones (n = 17), radiocarpal joint (n = 17), and extensor tendons or tendon sheaths (n = 16) of the wrist. All tophi showed similar signal characteristics (from low to intermediate signal intensity on T1-weighted images with heterogeneous signal intensity on T2-weighted images) with the exception of tophi in the floor of the carpal tunnel (low signal intensity on T2-weighted images). Varying degrees of calcification were noted on CT and MR imaging studies. Gadolinium-enhanced MR studies showed heterogeneous enhancement. CONCLUSION: Gouty tophi should be entertained as a cause of carpal tunnel syndrome in the appropriate patient population. Familiarity with this entity and its imaging characteristics may prove helpful in diagnosis and preoperative planning. FAU - Chen, C K AU - Chen CK AD - Department of Radiology, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Rd. Kaohsiung, 813 Taiwan. FAU - Chung, C B AU - Chung CB FAU - Yeh, L AU - Yeh L FAU - Pan, H B AU - Pan HB FAU - Yang, C F AU - Yang CF FAU - Lai, P H AU - Lai PH FAU - Liang, H L AU - Liang HL FAU - Resnick, D AU - Resnick D LA - eng PT - Journal Article PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Carpal Tunnel Syndrome/*diagnosis/*etiology MH - Female MH - Gout/*complications MH - Humans MH - *Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Retrospective Studies MH - *Tomography, X-Ray Computed MH - Uric Acid EDAT- 2000/08/23 11:00 MHDA- 2000/10/07 11:01 CRDT- 2000/08/23 11:00 PHST- 2000/08/23 11:00 [pubmed] PHST- 2000/10/07 11:01 [medline] PHST- 2000/08/23 11:00 [entrez] AID - 10.2214/ajr.175.3.1750655 [doi] PST - ppublish SO - AJR Am J Roentgenol. 2000 Sep;175(3):655-9. doi: 10.2214/ajr.175.3.1750655. PMID- 18551276 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20211020 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 16 IP - 9 DP - 2008 Sep TI - Sclerosing injections in midportion Achilles tendinopathy: a retrospective study of 25 patients. PG - 887-90 LID - 10.1007/s00167-008-0568-0 [doi] AB - Sclerosing injections under ultrasonographic guidance is a new method of treatment for persistent pain in Achilles tendinosis. Good results, even superior to those of surgery, have been described. We report the outcome of 25 patients with midportion tendinosis receiving sclerosing treatment. Twenty-eight consecutive patients (29 tendons) with ultrasonographical findings of midportion tendinosis examined during the period November 2004 to November 2005 were identified in the database of the Department of Radiology, Malmö University Hospital. Twenty-five patients (26 tendons) were found suitable for treatment. Follow-up consisted of self-assessment questionnaire or phone interview. In 19 patients (20 tendons), results were good or excellent. Complications were few and mild. We conclude that sclerosing injections is a promising alternative to surgery in chronic Achilles midportion tendinosis. Our results are comparable to those obtained with surgery, but the procedure is less invasive. However, a few cases of tendinosis lack detectable neovessels and may still be candidates for surgery. FAU - Clementson, Martin AU - Clementson M AD - Department of Orthopedics, Malmö University Hospital, 205 02, Malmö, Sweden. martin.j.clementson@skane.se FAU - Lorén, Ingemar AU - Lorén I FAU - Dahlberg, Leif AU - Dahlberg L FAU - Aström, Mats AU - Aström M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080613 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CIN - Knee Surg Sports Traumatol Arthrosc. 2008 Nov;16(11):1061-2; author reply 1063. doi: 10.1007/s00167-008-0613-z. PMID: 18791700 MH - *Achilles Tendon MH - Adult MH - Aged MH - Aged, 80 and over MH - Cohort Studies MH - Female MH - Humans MH - Injections, Intralesional MH - Male MH - Middle Aged MH - Polidocanol MH - Polyethylene Glycols/*administration & dosage MH - Retrospective Studies MH - Sclerosing Solutions/*administration & dosage MH - Tendinopathy/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography, Doppler, Color EDAT- 2008/06/14 09:00 MHDA- 2009/02/12 09:00 CRDT- 2008/06/14 09:00 PHST- 2007/12/30 00:00 [received] PHST- 2008/05/06 00:00 [accepted] PHST- 2008/06/14 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] PHST- 2008/06/14 09:00 [entrez] AID - 10.1007/s00167-008-0568-0 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2008 Sep;16(9):887-90. doi: 10.1007/s00167-008-0568-0. Epub 2008 Jun 13. PMID- 24797812 OWN - NLM STAT- MEDLINE DCOM- 20151222 LR - 20220331 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 23 IP - 8 DP - 2015 Aug TI - Sclerosing injections and ultrasound-guided arthroscopic shaving for patellar tendinopathy: good clinical results and decreased tendon thickness after surgery-a medium-term follow-up study. PG - 2259-2268 LID - 10.1007/s00167-014-3028-z [doi] AB - PURPOSE: Treatment of patellar tendinopathy/jumper's knee with ultrasound-guided sclerosing injections or ultrasound-guided arthroscopic shaving has shown good clinical short-term results. Former studies indicate that the tendon thickness and structure stays unaffected after successful treatment. The aim of this study was to evaluate the sonographic findings and clinical outcome 3-5 years after treatment of patellar tendinopathy with ultrasound-guided sclerosing injections or arthroscopic shaving. METHODS: Fifty-seven patellar tendons (43 patients) with chronic patellar tendinopathy were evaluated, with ultrasound, colour Doppler (CD) and visual analogue scale (VAS) for pain and satisfaction with treatment, 3-5 years after treatment. Functional status was evaluated with a single question-"Back in full loading activity?" yes or no. RESULTS: At endpoint (mean 46 months), there was a significant decrease in anteroposterior thickness of the proximal patellar tendon in patients treated with ultrasound-guided arthroscopic shaving but not after sclerosing injections. Tendon structure had improved, and CD local blood flow had diminished significantly in both groups. There were good clinical results with a significant decrease in VAS for pain after sclerosing injections (VAS 64 ± 18 → 17 ± 23) with 74 % satisfied patients and also after arthroscopic shaving (VAS 77 ± 16 → 13 ± 23) with 80 % satisfied patients. There were no significant differences in VAS between groups. A significant correlation between low local blood flow and high patient satisfaction was found. CONCLUSIONS: Tendon thickness decreased over time after ultrasound-guided arthroscopic shaving, and tendon structure and local blood flow decreased after both treatments. There were good, and similar, clinical results with both methods. LEVEL OF EVIDENCE: III. FAU - Sunding, Kerstin AU - Sunding K AD - Stockholm Sports Trauma Research Centre/Karolinska Institutet, Capio Artro Clinic AB, Box 5605, 114 86, Stockholm, Sweden. kerstin.sunding@capio.se. FAU - Willberg, Lotta AU - Willberg L AD - Stockholm Sports Trauma Research Centre/Karolinska Institutet, Capio Artro Clinic AB, Box 5605, 114 86, Stockholm, Sweden. AD - Sports Medicine Unit, Department of Surgical and Perioperative Science, Umeå University, 901 87, Umeå, Sweden. FAU - Werner, Suzanne AU - Werner S AD - Stockholm Sports Trauma Research Centre/Karolinska Institutet, Capio Artro Clinic AB, Box 5605, 114 86, Stockholm, Sweden. FAU - Alfredson, Håkan AU - Alfredson H AD - Sports Medicine Unit, Department of Surgical and Perioperative Science, Umeå University, 901 87, Umeå, Sweden. FAU - Forssblad, Magnus AU - Forssblad M AD - Stockholm Sports Trauma Research Centre/Karolinska Institutet, Capio Artro Clinic AB, Box 5605, 114 86, Stockholm, Sweden. FAU - Fahlström, Martin AU - Fahlström M AD - Department of Community Medicine and Rehabilitation, Rehabilitation Medicine, Umeå University, 901 87, Umeå, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140506 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adolescent MH - Adult MH - Arthroscopy MH - Athletic Injuries/therapy MH - Chronic Disease MH - Female MH - Follow-Up Studies MH - Humans MH - Injections MH - Male MH - Patellar Ligament/diagnostic imaging/drug effects/*surgery MH - Polidocanol MH - Polyethylene Glycols/*administration & dosage MH - Randomized Controlled Trials as Topic MH - Recovery of Function MH - Sclerosing Solutions/*administration & dosage MH - Tendinopathy/diagnostic imaging/drug therapy/*surgery MH - Ultrasonography, Doppler, Color MH - Ultrasonography, Interventional MH - Young Adult EDAT- 2014/05/07 06:00 MHDA- 2015/12/23 06:00 CRDT- 2014/05/07 06:00 PHST- 2013/11/12 00:00 [received] PHST- 2014/04/19 00:00 [accepted] PHST- 2014/05/07 06:00 [entrez] PHST- 2014/05/07 06:00 [pubmed] PHST- 2015/12/23 06:00 [medline] AID - 10.1007/s00167-014-3028-z [pii] AID - 10.1007/s00167-014-3028-z [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2015 Aug;23(8):2259-2268. doi: 10.1007/s00167-014-3028-z. Epub 2014 May 6. PMID- 24796842 OWN - NLM STAT- MEDLINE DCOM- 20140630 LR - 20140506 IS - 1460-9584 (Electronic) IS - 1268-7731 (Linking) VI - 20 IP - 2 DP - 2014 Jun TI - Foreign body granulomatous reaction associated with polyethelene 'Fiberwire(®)' suture material used in Achilles tendon repair. PG - e27-9 LID - S1268-7731(14)00026-5 [pii] LID - 10.1016/j.fas.2014.01.006 [doi] AB - Repair of acute Achilles tendon rupture is a common procedure. There are many accepted surgical techniques; suture selection is largely due to surgeon preference. We present a case report of a granulomatous reaction to suture material following Achilles tendon repair. 'Fiberwire(®)' is an increasingly popular suture material for the repair of tendons and ligamentous structures; the polyethelene braided structure with silicone and polyester coating provides high tensile strengths and good handling characteristics. Eight months following uneventful Achilles tendon repair surgery in an otherwise fit and well patient, pain, swelling and loss of function was noted. She required revision surgery with debridement and reconstruction of the tendo Achillis with flexor hallucis longus tendon transfer. Histology revealed a granulomatous reaction with giant cell response surrounding sections of the suture. Both the silicone coating of Fiberwire(®) and polyethylene core have the potential to cause a severe granulomatous reaction. We would advise caution in the use of this suture for tendo Achillis repair, and use the readily available alternatives. CI - Copyright © 2014 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved. FAU - Ollivere, Ben J AU - Ollivere BJ AD - Queens Medical Centre, Nottingham NG7 2UH, UK. FAU - Bosman, Hilary A AU - Bosman HA AD - Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. FAU - Bearcroft, Philip W P AU - Bearcroft PW AD - Addenbrooke's Hospital, Cambridge, UK. FAU - Robinson, Andrew H N AU - Robinson AH AD - Addenbrooke's Hospital, Cambridge, UK. Electronic address: fred.robinson@addenbrookes.nhs.uk. LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140215 PL - France TA - Foot Ankle Surg JT - Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons JID - 9609647 RN - 9002-88-4 (Polyethylene) SB - IM MH - Achilles Tendon/*surgery MH - Device Removal MH - Female MH - Foreign-Body Reaction/*etiology/surgery MH - Humans MH - Middle Aged MH - Polyethylene/*adverse effects MH - Reoperation MH - Rupture MH - Sutures/*adverse effects MH - Tendon Injuries/*surgery MH - *Tendon Transfer OTO - NOTNLM OT - Achilles OT - Fiberwire OT - Tendo Achillis OT - Tendon repair EDAT- 2014/05/07 06:00 MHDA- 2014/07/01 06:00 CRDT- 2014/05/07 06:00 PHST- 2013/07/18 00:00 [received] PHST- 2013/11/27 00:00 [revised] PHST- 2014/01/24 00:00 [accepted] PHST- 2014/05/07 06:00 [entrez] PHST- 2014/05/07 06:00 [pubmed] PHST- 2014/07/01 06:00 [medline] AID - S1268-7731(14)00026-5 [pii] AID - 10.1016/j.fas.2014.01.006 [doi] PST - ppublish SO - Foot Ankle Surg. 2014 Jun;20(2):e27-9. doi: 10.1016/j.fas.2014.01.006. Epub 2014 Feb 15. PMID- 33032804 OWN - NLM STAT- MEDLINE DCOM- 20211013 LR - 20240902 IS - 2352-2291 (Electronic) IS - 0104-0014 (Print) IS - 0104-0014 (Linking) VI - 70 IP - 6 DP - 2020 Nov-Dec TI - [Comparison between subarachnoid morphine and femoral nerve block for analgesia after knee ligament reconstruction: a randomized clinical trial]. PG - 613-619 LID - S0034-7094(19)30151-5 [pii] LID - 10.1016/j.bjan.2019.08.006 [doi] AB - BACKGROUND AND OBJECTIVES: There are no consensus of the ideal technique to provide analgesia in knee ligament reconstructions. The aim of this study was to compare the intensity of postoperative pain in these patients under different modalities of analgesia. METHOD: Randomized and controlled clinical trial of patients undergoing reconstruction of the Anterior Cruciate Ligament (ACL) with flexor tendons between December 2013 and 2014. All patients underwent spinal anesthesia and rescue analgesia with tramadol. The groups C, M, R0,375 and R0,25 was compared with only the previously described technique, subarachnoid morphine (100░μg), or Femoral Nerve Block (BNF) with 25░mL of 0.375% ropivacaine and 0.25%, respectively. Pain intensity at 6, 12 and 24░hours, age, sex, rescue analgesia, adverse reactions and satisfaction were evaluated. RESULTS: Among the 83 eligible patients, a predominance of males (85.7%) was observed, between 28 and 31 years. The group C requested more opioid (27.3%) than the other groups, without significance when compared. There were no significant differences in pain intensity at 6, 12 and 24░hours. There was a higher incidence of urinary retention in the M group (23.8%) than in the R0,375 (0%) and prolonged quadriceps motor block in the R0,375 group (30%) than in the M and C groups (0%), with statistical significance (p░<░0.05). CONCLUSION: There was no difference in the intensity of postoperative pain in patients submitted to ACL reconstruction with flexor tendons under the analgesic modalities evaluated, despite the predominance of urinary retention in the M group and motor block in the R0,375 group. CI - Copyright © 2019 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. All rights reserved. FAU - Fiorentin, Joana Zulian AU - Fiorentin JZ AD - Hospital Universitário Cajuru, Serviço de Anestesiologia, Curitiba, PR, Brasil; Hospital Universitário Cajuru, Departamento de Residência Médica, Curitiba, PR, Brasil; Universidade Federal do Paraná (UFPR), Programa de Pós-Graduação em Clínica Cirúrgica, Curitiba, Paraná, Brasil. Electronic address: joanafiorentin@yahoo.com.br. FAU - Martins, Alexandre Vieira AU - Martins AV AD - Hospital Universitário Cajuru, Serviço de Anestesiologia, Curitiba, PR, Brasil; Hospital Universitário Cajuru, Departamento de Residência Médica, Curitiba, PR, Brasil. FAU - Cañola, Juan Manuel Vélez AU - Cañola JMV AD - Hospital Universitário Cajuru, Serviço de Anestesiologia, Curitiba, PR, Brasil; Hospital Universitário Cajuru, Departamento de Residência Médica, Curitiba, PR, Brasil. FAU - Gutierrez, Linda Cecilia AU - Gutierrez LC AD - Hospital Universitário Cajuru, Serviço de Anestesiologia, Curitiba, PR, Brasil; Hospital Universitário Cajuru, Departamento de Residência Médica, Curitiba, PR, Brasil. FAU - Perches, Fábio AU - Perches F AD - Hospital Universitário Cajuru, Serviço de Anestesiologia, Curitiba, PR, Brasil; Hospital Universitário Cajuru, Departamento de Residência Médica, Curitiba, PR, Brasil. FAU - Sakae, Thiago Mamôru AU - Sakae TM AD - Universidade do Sul de Santa Catarina (Unisul), Florianópolis, SC, Brasil. FAU - Tenório, Sérgio Bernardo AU - Tenório SB AD - Universidade Federal do Paraná (UFPR), Programa de Pós-Graduação em Clínica Cirúrgica, Curitiba, Paraná, Brasil; Sociedade Brasileira de Anestesiologia, Rio de Janeiro, RJ, Brasil. LA - por PT - Journal Article PT - Randomized Controlled Trial TT - Comparação entre morfina subaracnoidea e bloqueio do nervo femoral para analgesia após reconstrução ligamentar de joelho: estudo clínico randomizado. DEP - 20201005 PL - Brazil TA - Braz J Anesthesiol JT - Brazilian journal of anesthesiology (Elsevier) JID - 101624623 RN - 0 (Analgesics, Opioid) RN - 0 (Anesthetics, Local) RN - 39J1LGJ30J (Tramadol) RN - 76I7G6D29C (Morphine) RN - 7IO5LYA57N (Ropivacaine) SB - IM MH - Acute Pain/drug therapy MH - Adult MH - Analgesia/methods MH - Analgesics, Opioid/*administration & dosage MH - Anesthesia, Spinal/*methods MH - Anesthetics, Local/administration & dosage MH - *Anterior Cruciate Ligament Reconstruction MH - Female MH - *Femoral Nerve MH - Humans MH - Male MH - Morphine/*administration & dosage MH - Nerve Block/*methods MH - Pain Measurement MH - Pain, Postoperative/*drug therapy MH - Quadriceps Muscle/drug effects MH - Ropivacaine/administration & dosage MH - Time Factors MH - Tramadol/administration & dosage MH - Urinary Retention/chemically induced PMC - PMC9373337 OAB - BACKGROUND AND OBJECTIVES: There is no consensus of the ideal technique to provide analgesia in knee ligament reconstructions. The aim of this study was to compare the intensity of postoperative pain in these patients under different modalities of analgesia. METHOD: Randomized and controlled clinical trial of patients undergoing reconstruction of the anterior cruciate ligament (ACL) with flexor tendons between December 2013 and 2014. All patients underwent spinal anesthesia and rescue analgesia with tramadol. The Groups C, M, R0,375 and R0,25 were compared with only the previously described technique, subarachnoid morphine (100 μg) or femoral nerve block with 25 mL of 0.375% ropivacaine and 0.25%, respectively. Pain intensity at 6, 12 and 24hours, age, sex, rescue analgesia, adverse reactions and satisfaction were evaluated. RESULTS: Among the 83 eligible patients, a predominance of males (85.7%) was observed, between 28 and 31 years. The Group C requested more opioid (27.3%) than the other groups, without significance when compared. There were no significant differences in pain intensity at 6, 12 and 24hours. There was a higher incidence of urinary retention in the Group M (23.8%) than in the R0,375 (0%) and prolonged quadriceps motor block in the R0,375 Group (30%) than in the M and C Groups (0%), with statistical significance (p < 0.05). CONCLUSION: There was no difference in the intensity of postoperative pain in patients submitted to anterior cruciate ligament reconstruction with flexor tendons under the analgesic modalities evaluated, despite the predominance of urinary retention in the M Group and motor block in the R0,375 Group. OABL- eng OTO - NOTNLM OT - Acute pain OT - Anestesia espinhal OT - Anterior cruciate ligament reconstruction OT - Bloqueio do nervo femoral OT - Dor aguda OT - Femoral nerve block OT - Reconstrução do ligamento cruzado anterior OT - Spinal anesthesia EDAT- 2020/10/10 06:00 MHDA- 2021/10/14 06:00 PMCR- 2020/09/18 CRDT- 2020/10/09 05:29 PHST- 2019/03/12 00:00 [received] PHST- 2019/08/12 00:00 [revised] PHST- 2019/08/13 00:00 [accepted] PHST- 2020/10/10 06:00 [pubmed] PHST- 2021/10/14 06:00 [medline] PHST- 2020/10/09 05:29 [entrez] PHST- 2020/09/18 00:00 [pmc-release] AID - S0034-7094(19)30151-5 [pii] AID - 10.1016/j.bjan.2019.08.006 [doi] PST - ppublish SO - Braz J Anesthesiol. 2020 Nov-Dec;70(6):613-619. doi: 10.1016/j.bjan.2019.08.006. Epub 2020 Oct 5. PMID- 4149367 OWN - NLM STAT- MEDLINE DCOM- 19740328 LR - 20190623 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 23 IP - 1 DP - 1974 Jan 1 TI - Aggregation of blood platelets by biogenic amines and its inhibition by antiadrenergic and antiserotoninergic agents. PG - 37-45 FAU - Barthel, W AU - Barthel W FAU - Markwardt, F AU - Markwardt F LA - eng PT - Journal Article PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Adrenergic alpha-Antagonists) RN - 0 (Biogenic Amines) RN - 0 (Serotonin Antagonists) RN - 0 (Sympatholytics) RN - 0 (Tissue Extracts) RN - 2Y49VWD90Q (Yohimbine) RN - 333DO1RDJY (Serotonin) RN - 43EXU2S56H (Dibenzylchlorethamine) RN - 8NA5SWF92O (Lysergic Acid Diethylamide) RN - 9Y8NXQ24VQ (Propranolol) RN - DAA13NKG2Q (Papaverine) RN - L628TT009W (Isoproterenol) RN - PR834Q503T (Ergotamine) RN - X4W3ENH1CV (Norepinephrine) RN - YKH834O4BH (Epinephrine) RN - Z468598HBV (Phentolamine) SB - IM MH - Adrenergic alpha-Antagonists/pharmacology MH - Animals MH - Binding, Competitive MH - Biogenic Amines/*pharmacology MH - Densitometry MH - Depression, Chemical MH - Dibenzylchlorethamine/pharmacology MH - Dose-Response Relationship, Drug MH - Drug Synergism MH - Epinephrine/pharmacology MH - Ergotamine/pharmacology MH - In Vitro Techniques MH - Isoproterenol/pharmacology MH - Lysergic Acid Diethylamide/pharmacology MH - Norepinephrine/pharmacology MH - Papaverine/pharmacology MH - Phentolamine/pharmacology MH - Platelet Adhesiveness/*drug effects MH - Propranolol/pharmacology MH - Rabbits MH - Serotonin/pharmacology MH - *Serotonin Antagonists MH - Sympatholytics/*pharmacology MH - Tendons MH - Time Factors MH - Tissue Extracts/pharmacology MH - Yohimbine/pharmacology EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 0006-2952(74)90311-6 [pii] AID - 10.1016/0006-2952(74)90311-6 [doi] PST - ppublish SO - Biochem Pharmacol. 1974 Jan 1;23(1):37-45. doi: 10.1016/0006-2952(74)90311-6. PMID- 4735997 OWN - NLM STAT- MEDLINE DCOM- 19730731 LR - 20131121 IS - 0003-2999 (Print) IS - 0003-2999 (Linking) VI - 52 IP - 3 DP - 1973 May-Jun TI - Sensory disturbances following ketamine anesthesia: recurrent hallucinations. PG - 428-30 FAU - Fine, J AU - Fine J FAU - Finestone, S C AU - Finestone SC LA - eng PT - Journal Article PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 RN - 0 (Hallucinogens) RN - 690G0D6V8H (Ketamine) SB - IM MH - Adult MH - Anesthesia, Intravenous/*adverse effects MH - Curettage MH - Dilatation MH - Dreams MH - Female MH - Hallucinations/*chemically induced MH - Hallucinogens MH - Humans MH - Ketamine/*adverse effects MH - Male MH - Middle Aged MH - Recurrence MH - Tendons/surgery MH - Urinary Bladder Neoplasms/surgery EDAT- 1973/05/01 00:00 MHDA- 1973/05/01 00:01 CRDT- 1973/05/01 00:00 PHST- 1973/05/01 00:00 [pubmed] PHST- 1973/05/01 00:01 [medline] PHST- 1973/05/01 00:00 [entrez] PST - ppublish SO - Anesth Analg. 1973 May-Jun;52(3):428-30. PMID- 12368782 OWN - NLM STAT- MEDLINE DCOM- 20021121 LR - 20190916 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 18 IP - 8 DP - 2002 Oct TI - The efficacy of continuous bupivacaine infiltration following anterior cruciate ligament reconstruction. PG - 854-8 AB - PURPOSE: The purpose of this study was to determine whether continuous infiltration of a local anesthetic into the surgical wound for 48 hours will diminish the need for narcotics and improve the postoperative pain experience for patients undergoing anterior cruciate ligament (ACL) reconstruction using a patellar tendon autograft. TYPE OF STUDY: Prospective, randomized, double-blind study with a placebo and an experimental group. METHODS: Twenty-six patients were randomly assigned to receive either normal saline (placebo) or bupivacaine (experimental) for 48 hours. Both groups received a single intra-articular bolus injection of 35 mL of 0.25% bupivacaine and 5 mg. of morphine at the conclusion of surgery. The placebo group received an infusion of 2 mL/h of normal saline and the experimental group received an infusion of 2 mL/h of 0.25% bupivacaine, both for 48 hours. The anesthetic was infused using a disposable elastomeric pump (Baxter Healthcare, Deerfield, IL). Patients were evaluated using a pain and pain relief assessment questionnaire and visual analogue scale (VAS). Narcotic consumption was also documented. The pump was discontinued either by the patient at home or by a physical therapist. RESULTS: There was a statistically significant (P <.05) difference in VAS pain and pain relief scores reported by patients receiving the infusion of 0.25% bupivacaine. Patients in the treatment group also consumed 37% less narcotics than the placebo group. The operating room time, tourniquet time, weight, and age of this population were similar in the 2 groups. There were no complications with the catheter technique. CONCLUSION: This report of a new technique suggests that surgical knee patients receiving local anesthetic infusion postoperatively experience less pain and require less narcotics. The disposable pump allowed administration of the medication on an outpatient basis. FAU - Hoenecke, Heinz R Jr AU - Hoenecke HR Jr AD - Division of Orthopaedics, Scripps Clinic, La Jolla, California 92037, USA. hhoenecke@aol.com FAU - Pulido, Pamela A AU - Pulido PA FAU - Morris, Beverly A AU - Morris BA FAU - Fronek, Jan AU - Fronek J LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Anesthetics, Combined) RN - 0 (Anesthetics, Local) RN - 76I7G6D29C (Morphine) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adult MH - Anesthetics, Combined/administration & dosage MH - Anesthetics, Local/*administration & dosage MH - Anterior Cruciate Ligament/*surgery MH - Bupivacaine/*administration & dosage MH - Catheterization/methods MH - Double-Blind Method MH - Female MH - Humans MH - Infusion Pumps, Implantable MH - Injections, Subcutaneous/adverse effects MH - Male MH - Middle Aged MH - Morphine/administration & dosage MH - Pain Measurement MH - Pain, Postoperative/*drug therapy MH - Prospective Studies MH - Tendons/transplantation MH - Transplantation, Autologous EDAT- 2002/10/09 04:00 MHDA- 2002/11/26 04:00 CRDT- 2002/10/09 04:00 PHST- 2002/10/09 04:00 [pubmed] PHST- 2002/11/26 04:00 [medline] PHST- 2002/10/09 04:00 [entrez] AID - S0749806302000506 [pii] AID - 10.1053/jars.2002.36139 [doi] PST - ppublish SO - Arthroscopy. 2002 Oct;18(8):854-8. doi: 10.1053/jars.2002.36139. PMID- 12489253 OWN - NLM STAT- MEDLINE DCOM- 20030110 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 52 IP - 11 DP - 2002 TI - Tissue absorption and distribution of ketoprofen after patch application in subjects undergoing knee arthroscopy or endoscopic carpal ligament release. PG - 822-7 AB - The diffusion into the target tissues of ketoprofen (CAS 22071-15-4), a widely used nonsteroidal anti-inflammatory drug, from a new topical patch has been studied after repeated patch application in comparison with its plasma level. Ten patients (5 women and 5 men) with a mean age of 45.0 +/- 12.3 years (mean +/- SD), scheduled for arthroscopic meniscectomy (5 subjects) or endoscopic carpal tunnel decompression (5 subjects), were asked to apply one patch with 100 mg ketoprofen on the affected body site once a day during the 6 days before the scheduled surgery. The last patch was kept for 6 h, and removed just a few minutes before surgery, when venous blood was drawn. Biopsies of the synovial tissue of the medial compartment and of the anterior fat pad (Hoffa's tissue) or of the ulnar bursa were taken during knee arthroscopy or endoscopic carpal tunnel release, respectively. An average plasma value of 52.8 +/- 30.1 (SD) ng/ml of ketoprofen was obtained in the 10 patients. The tissue concentrations of ketoprofen in the 5 subjects undergoing knee arthroscopy were 27.9 +/- 26.1 ng/g (range 7.2-67.1 ng/g) in the anterior fat pad and 239.0 +/- 163.0 ng/g (range 20.0-430.5 ng/g) in the synovial tissue. Drug concentrations up to 1000 times higher were found in the tendon sheath tissue of the ulnar bursa of the five patients undergoing endoscopic carpal tunnel release: average values of 20,107 +/- 7359 ng/g (range 13,004-32,578 ng/g) were obtained in this tissue. Data observed in this trial are consistent with those previously published by other authors, and demonstrate that ketoprofen applied on the skin is able to enter the subcutaneous and intra-articular tissues, reaching concentrations markedly higher than in plasma, and is further able to produce the desired pharmacological activity in situ, whereas plasma concentrations are too low to produce any systemic activity or side effect. FAU - Osterwalder, Andreas AU - Osterwalder A AD - Ars Medica Clinic S. A., Gravesano, Switzerland. FAU - Reiner, Valentina AU - Reiner V FAU - Reiner, Giorgio AU - Reiner G FAU - Lualdi, Paolo AU - Lualdi P LA - eng PT - Clinical Trial PT - Journal Article PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 90Y4QC304K (Ketoprofen) SB - IM MH - Absorption MH - Adipose Tissue/metabolism MH - Administration, Cutaneous MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics MH - *Arthroscopy MH - Bursa, Synovial/metabolism MH - Carpal Tunnel Syndrome/*surgery MH - Cartilage, Articular/*metabolism MH - Chromatography, High Pressure Liquid MH - *Endoscopy MH - Female MH - Humans MH - Ketoprofen/administration & dosage/*pharmacokinetics MH - Knee/*surgery MH - Male MH - Middle Aged MH - Synovial Membrane/metabolism MH - Tendons/metabolism EDAT- 2002/12/20 04:00 MHDA- 2003/01/11 04:00 CRDT- 2002/12/20 04:00 PHST- 2002/12/20 04:00 [pubmed] PHST- 2003/01/11 04:00 [medline] PHST- 2002/12/20 04:00 [entrez] AID - 10.1055/s-0031-1299974 [doi] PST - ppublish SO - Arzneimittelforschung. 2002;52(11):822-7. doi: 10.1055/s-0031-1299974. PMID- 772430 OWN - NLM STAT- MEDLINE DCOM- 19760706 LR - 20131121 IS - 0028-4793 (Print) IS - 0028-4793 (Linking) VI - 294 IP - 23 DP - 1976 Jun 3 TI - Massive resection and allograft transplantation in the treatment of malignant bone tumors. PG - 1247-55 AB - Nineteen massive resections and allograft transplantations have been performed for malignant or aggressive bone tumors. Allograft procurment technic uses freezing of the segment to decrease immunogenicity of the bony portion and glycinerization of the cartilage to maintain chondrocyte viability during freezing and thawing. Fifteen Fifteen of the patients have been followed for an average of almost two years and were evaluated for early results by serial follow-up studies, including clinical, laboratoy, x-ray and scan data. Despite numerous complications (related to both tumor and operation) none have metastases, local recurrence, or major functional impairment except for two whose grafts became infected. We conclude that, although still experimental, allograft replacement may in the future serve as an important approach to certain neoplastic conditions of bones and joints. FAU - Mankin, H J AU - Mankin HJ FAU - Fogelson, F S AU - Fogelson FS FAU - Thrasher, A Z AU - Thrasher AZ FAU - Jaffer, F AU - Jaffer F LA - eng PT - Case Reports PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 RN - PDC6A3C0OX (Glycerol) SB - IM MH - Adenocarcinoma/surgery MH - Adolescent MH - Adult MH - Bone Neoplasms/*surgery MH - *Bone Transplantation MH - Cadaver MH - Cartilage, Articular/transplantation MH - Chondrosarcoma/surgery MH - Female MH - Femoral Neoplasms/surgery MH - Fibrosarcoma/surgery MH - Follow-Up Studies MH - Giant Cell Tumors/surgery MH - Glycerol/administration & dosage MH - Humans MH - Ligaments/transplantation MH - Male MH - Middle Aged MH - Postoperative Complications MH - Surgical Wound Infection MH - Tendons/transplantation MH - Tibia MH - Time Factors MH - Tissue Preservation/methods MH - Transplantation, Homologous EDAT- 1976/06/03 00:00 MHDA- 1976/06/03 00:01 CRDT- 1976/06/03 00:00 PHST- 1976/06/03 00:00 [pubmed] PHST- 1976/06/03 00:01 [medline] PHST- 1976/06/03 00:00 [entrez] AID - 10.1056/NEJM197606032942301 [doi] PST - ppublish SO - N Engl J Med. 1976 Jun 3;294(23):1247-55. doi: 10.1056/NEJM197606032942301. PMID- 28818476 OWN - NLM STAT- MEDLINE DCOM- 20180716 LR - 20180716 IS - 1542-2224 (Electronic) IS - 1067-2516 (Linking) VI - 56 IP - 6 DP - 2017 Nov-Dec TI - Complex Anatomic Abnormalities of the Lower Leg Muscles and Tendons Associated With Phocomelia: A Case Report. PG - 1335-1338 LID - S1067-2516(17)30407-6 [pii] LID - 10.1053/j.jfas.2017.06.008 [doi] AB - Musculoskeletal anatomy is widely known to have components that stray from the norm in the form of variant muscle and tendon presence, absence, origin, insertion, and bifurcation. Although these variant muscles and tendons might be deemed incidental and insignificant findings by most, they can be important contributors to pathologic physiology or, more importantly, an option for effective treatment. In the present case report, we describe a patient with phocomelia and Müllerian abnormalities secondary to in utero thalidomide exposure. The patient had experienced recurrent bilateral foot pain accompanied by numbness, stiffness, swelling, and longstanding pes planus. These symptoms persisted despite conservative treatment with orthotics, steroids, and nonsteroidal anti-inflammatory drugs. Radiographic imaging showed dysmorphic and degenerative changes of the ankle and foot joints. Further investigation with magnetic resonance imaging revealed complex anatomic abnormalities, including the absence of the posterior tibialis and peroneus brevis, lateralization of the peroneus longus, and the presence of a variant anterior compartment muscle. The variant structure was likely a previously described anterior compartment variant, anterior fibulocalcaneus, and might have been a source of the recurrent pain. Also, the absence of the posterior tibialis might have caused the pes planus in the present patient, considering that posterior tibialis tendon dysfunction is the most common cause of acquired pes planus. Although thalidomide infrequently affects the lower extremities, its effects on growth and development were likely the cause of this rare array of anatomic abnormalities and resulting ankle and foot pathologic features. CI - Copyright © 2017 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Hodo, Thomas AU - Hodo T AD - Medical Student, Medical College of Georgia at Augusta University, Augusta, GA. FAU - Hamrick, Mark AU - Hamrick M AD - Professor, Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA. FAU - Melenevsky, Yulia AU - Melenevsky Y AD - Radiologist, Department of Radiology, Medical College of Georgia at Augusta University, Augusta, GA. Electronic address: ymelenevsky@augusta.edu. LA - eng PT - Case Reports PT - Journal Article DEP - 20170814 PL - United States TA - J Foot Ankle Surg JT - The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons JID - 9308427 RN - 4Z8R6ORS6L (Thalidomide) SB - IM MH - Abnormalities, Drug-Induced/*diagnostic imaging/physiopathology MH - Ankle Joint/abnormalities/diagnostic imaging MH - Ectromelia/complications/*diagnosis MH - Female MH - Follow-Up Studies MH - Foot Joints/abnormalities/diagnostic imaging MH - Humans MH - Lower Extremity/physiopathology MH - Magnetic Resonance Imaging/methods MH - Middle Aged MH - Muscle, Skeletal/*abnormalities/anatomy & histology MH - Rare Diseases MH - Risk Assessment MH - Severity of Illness Index MH - Tendons/*abnormalities/anatomy & histology MH - Thalidomide/administration & dosage/*adverse effects OTO - NOTNLM OT - anterior fibulocalcaneus OT - peroneus longus OT - pes planus OT - phocomelia OT - posterior tibialis OT - thalidomide EDAT- 2017/08/19 06:00 MHDA- 2018/07/17 06:00 CRDT- 2017/08/19 06:00 PHST- 2017/04/15 00:00 [received] PHST- 2017/08/19 06:00 [pubmed] PHST- 2018/07/17 06:00 [medline] PHST- 2017/08/19 06:00 [entrez] AID - S1067-2516(17)30407-6 [pii] AID - 10.1053/j.jfas.2017.06.008 [doi] PST - ppublish SO - J Foot Ankle Surg. 2017 Nov-Dec;56(6):1335-1338. doi: 10.1053/j.jfas.2017.06.008. Epub 2017 Aug 14. PMID- 86372 OWN - NLM STAT- MEDLINE DCOM- 19790716 LR - 20151119 IS - 0007-1285 (Print) IS - 0007-1285 (Linking) VI - 52 IP - 615 DP - 1979 Mar TI - Clear cell sarcoma of tendons and aponeuroses treated with bleomycin and vincristine. PG - 238-41 FAU - Radstone, D J AU - Radstone DJ FAU - Revell, P A AU - Revell PA FAU - Mantell, B S AU - Mantell BS LA - eng PT - Case Reports PT - Journal Article PL - England TA - Br J Radiol JT - The British journal of radiology JID - 0373125 RN - 11056-06-7 (Bleomycin) RN - 5J49Q6B70F (Vincristine) SB - IM MH - Adult MH - Bleomycin/*therapeutic use MH - Drug Therapy, Combination MH - Female MH - Humans MH - Sarcoma/*drug therapy MH - Soft Tissue Neoplasms/*drug therapy MH - *Tendons MH - Vincristine/*therapeutic use EDAT- 1979/03/01 00:00 MHDA- 1979/03/01 00:01 CRDT- 1979/03/01 00:00 PHST- 1979/03/01 00:00 [pubmed] PHST- 1979/03/01 00:01 [medline] PHST- 1979/03/01 00:00 [entrez] AID - 10.1259/0007-1285-52-615-238 [doi] PST - ppublish SO - Br J Radiol. 1979 Mar;52(615):238-41. doi: 10.1259/0007-1285-52-615-238. PMID- 24883319 OWN - NLM STAT- MEDLINE DCOM- 20150105 LR - 20211021 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2014 DP - 2014 TI - Does the addition of tramadol and ketamine to ropivacaine prolong the axillary brachial plexus block? PG - 686287 LID - 10.1155/2014/686287 [doi] LID - 686287 AB - BACKGROUND AND OBJECTIVES: A prospective, randomized, controlled, double-blind clinical trial to assess the effect of tramadol and ketamine, 50 mg, added to ropivacaine in brachial plexus anesthesia. METHODS: Thirty-six ASA physical statuses I and II patients, between 18 and 60 years of age, scheduled for forearm and hand surgery under axillary brachial plexus block, were allocated to 3 groups. Group R received 0.375% ropivacaine in 40 mL, group RT received 0.375% ropivacaine in 40 mL with 50 mg tramadol, and group RK received 0.375% ropivacaine in 40 mL with 50 mg ketamine for axillary brachial plexus block. The onset times and the duration of sensory and motor blocks, duration of analgesia, hemodynamic parameters, and adverse events (nausea, vomiting, and feeling uncomfortable) were recorded. RESULTS: The onset time of sensorial block was the fastest in ropivacaine + tramadol group. Duration of sensorial and motor block was the shortest in the ropivacaine + tramadol group. Duration of analgesia was significantly longer in ropivacaine + tramadol group. CONCLUSION: We conclude that when added to brachial plexus analgesia at a dose of 50 mg, tramadol extends the onset and duration time of the block and improves the quality of postoperative analgesia without any side effects. FAU - Senel, Ahmet Can AU - Senel AC AD - Department of Anesthesiology, Medical Faculty of Karadeniz Technical University, 61080 Trabzon, Turkey. FAU - Ukinc, Ozlem AU - Ukinc O AD - Department of Anesthesiology, Medical Faculty of Karadeniz Technical University, 61080 Trabzon, Turkey. FAU - Timurkaynak, Alper AU - Timurkaynak A AD - Department of Orthopedics, Medical Faculty of Karadeniz Technical University, 61080 Trabzon, Turkey. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20140506 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (Amides) RN - 0 (Analgesics, Opioid) RN - 39J1LGJ30J (Tramadol) RN - 690G0D6V8H (Ketamine) RN - 7IO5LYA57N (Ropivacaine) SB - IM MH - Adult MH - Amides/administration & dosage MH - Analgesics, Opioid/administration & dosage MH - Anesthesia/*methods MH - Brachial Plexus/drug effects MH - Brachial Plexus Block/*methods MH - Double-Blind Method MH - Drug-Related Side Effects and Adverse Reactions MH - Female MH - Humans MH - Ketamine/*administration & dosage/adverse effects MH - Male MH - Ropivacaine MH - Tendons/pathology/surgery MH - Tramadol/*administration & dosage/adverse effects PMC - PMC4032708 EDAT- 2014/06/03 06:00 MHDA- 2015/01/06 06:00 PMCR- 2014/05/06 CRDT- 2014/06/03 06:00 PHST- 2013/12/10 00:00 [received] PHST- 2014/03/25 00:00 [revised] PHST- 2014/04/07 00:00 [accepted] PHST- 2014/06/03 06:00 [entrez] PHST- 2014/06/03 06:00 [pubmed] PHST- 2015/01/06 06:00 [medline] PHST- 2014/05/06 00:00 [pmc-release] AID - 10.1155/2014/686287 [doi] PST - ppublish SO - Biomed Res Int. 2014;2014:686287. doi: 10.1155/2014/686287. Epub 2014 May 6. PMID- 18633599 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20211020 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 16 IP - 9 DP - 2008 Sep TI - Sclerosing injections to treat midportion Achilles tendinosis: a randomised controlled study evaluating two different concentrations of Polidocanol. PG - 859-64 LID - 10.1007/s00167-008-0579-x [doi] AB - Two to three ultrasound (US) and colour Doppler (CD)-guided injections of the sclerosing substance Polidocanol (5 mg/ml) have been demonstrated to give good clinical results in patients with chronic midportion Achilles tendinopathy. This study aimed to investigate if a higher concentration of Polidocanol (10 mg/ml) would lead to a less number of treatments, and lower volumes, needed for good clinical results. Fifty-two consecutive Achilles tendons (48 patients, mean age 49.6 years) with chronic painful midportion Achilles tendinopathy, were randomised to treatment with Polidocanol 5 mg/ml (group A) or 10 mg/ml (group B). The patients and treating physician were blinded to the concentration of Polidocanol injected. All patients had structural tendon changes and neovascularisation in the Achilles midportion. Treatment was US + CD-guided injections targeting the region with neovascularisation (outside ventral tendon). A maximum of three treatments (6-8 weeks in between) were given before evaluation. Patients not satisfied after three treatments were given additional treatment with Polidocanol 10 mg/ml, up to five treatments. For evaluation, the patients recorded the severity of Achilles tendon pain during activity on a visual analogue scale (VAS), before and after treatment. Patient satisfaction with treatment was also assessed. At follow-up (mean 14 months) after three treatments, 18/26 patients in group A and 19/26 patients in group B were satisfied with the treatment and had a significantly reduced level of tendon pain (P < 0.05). After completion of the study, additional treatments with Polidocanol 10 mg/ml in the not satisfied patients resulted in 26/26 satisfied patients in both groups A and B. In summary, we found no significant differences in the number of satisfied patients, number of injections or volumes given, between patients treated with 5 or 10 mg/ml Polidocanol. FAU - Willberg, Lotta AU - Willberg L AD - Capio Artro Clinic, Stockholm Sports Trauma Research Centre, Karolinska Institute, 114 86, Stockholm, Sweden. FAU - Sunding, Kerstin AU - Sunding K FAU - Ohberg, Lars AU - Ohberg L FAU - Forssblad, Magnus AU - Forssblad M FAU - Fahlström, Martin AU - Fahlström M FAU - Alfredson, Håkan AU - Alfredson H LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20080717 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CIN - Knee Surg Sports Traumatol Arthrosc. 2009 Jan;17(1):111-2; author reply 113-4. doi: 10.1007/s00167-008-0687-7. PMID: 19099292 MH - *Achilles Tendon MH - Adult MH - Aged MH - Dose-Response Relationship, Drug MH - Double-Blind Method MH - Drug Administration Schedule MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pain Measurement MH - Patient Satisfaction MH - Polidocanol MH - Polyethylene Glycols/*administration & dosage MH - Radiography MH - Sclerosing Solutions/*administration & dosage MH - Tendinopathy/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography EDAT- 2008/07/18 09:00 MHDA- 2009/02/12 09:00 CRDT- 2008/07/18 09:00 PHST- 2008/01/07 00:00 [received] PHST- 2008/06/16 00:00 [accepted] PHST- 2008/07/18 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] PHST- 2008/07/18 09:00 [entrez] AID - 10.1007/s00167-008-0579-x [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2008 Sep;16(9):859-64. doi: 10.1007/s00167-008-0579-x. Epub 2008 Jul 17. PMID- 10360289 OWN - NLM STAT- MEDLINE DCOM- 19990727 LR - 20181113 IS - 0065-9533 (Print) IS - 1545-6110 (Electronic) IS - 0065-9533 (Linking) VI - 96 DP - 1998 TI - Acute and chronic structural effects of pilocarpine on monkey outflow tissues. PG - 171-91; discussion 192-5 AB - PURPOSE: Determine the effects of supraclinical topical doses of pilocarpine on the structure of the trabecular meshwork (TM), ciliary muscle (CM), and ciliary processes in monkeys. METHODS: Cynomolgus monkeys received topical pilocarpine hydrochloride doses of 1 to 2 mg unilaterally once or twice daily for 1 to 211 days. Both eyes were examined by light and electron microscopy. RESULTS: After 1 dose, the TM was expanded and the flow pathways open. Some elastic anterior CM tendons were disconnected from the muscle tips and/or the tips themselves were disrupted; macrophage-like cells accumulated in these regions. In eyes that had long-term treatment, scar tissue at the muscle tips and disruption of myofibrils within muscle cells indicated regions of previous disconnection. Most collagen tendons inserting into the peripheral cornea were unaffected. With increasing treatment duration in younger monkeys, there was anteroposterior shortening of Schlemm's canal, TM densification due to collapse, and increased cellularity in the subendothelial region of Schlemm's canal. TM densification and Schlemm's canal shortening were not found in older monkeys, implicating posterior movement of the elastic young limbal region induced by strong CM contraction, rather than pilocarpine toxicity. In the ciliary body we found vasodilation, Greeff's vesicles, and blood-aqueous barrier breakdown in the anterior ciliary processes and vasodilation, edema, and round-cell infiltration in the posterior pars plana. CONCLUSIONS: Large pilocarpine doses induce morphologic changes in the monkey anterior segment, likely consequent to intense CM contraction. Changes in the TM and Schlemm's canal are seen only in young monkeys, apparently owing to mechanical deformation of the elastic limbal region. FAU - Lütjen-Drecoll, E AU - Lütjen-Drecoll E AD - Department of Anatomy II, University of Erlangen-Nürnberg, Germany. FAU - Wiendl, H AU - Wiendl H FAU - Kaufman, P L AU - Kaufman PL LA - eng GR - EY 02698/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Trans Am Ophthalmol Soc JT - Transactions of the American Ophthalmological Society JID - 7506106 RN - 01MI4Q9DI3 (Pilocarpine) SB - IM MH - Animals MH - Ciliary Body/*drug effects/pathology MH - Dose-Response Relationship, Drug MH - Macaca fascicularis MH - Microscopy, Electron MH - Muscle, Smooth/drug effects/pathology MH - Pilocarpine/*administration & dosage/pharmacology MH - Time Factors MH - Trabecular Meshwork/*drug effects/pathology PMC - PMC1298395 EDAT- 1999/06/09 00:00 MHDA- 1999/06/09 00:01 PMCR- 1998/01/01 CRDT- 1999/06/09 00:00 PHST- 1999/06/09 00:00 [pubmed] PHST- 1999/06/09 00:01 [medline] PHST- 1999/06/09 00:00 [entrez] PHST- 1998/01/01 00:00 [pmc-release] PST - ppublish SO - Trans Am Ophthalmol Soc. 1998;96:171-91; discussion 192-5. PMID- 15261372 OWN - NLM STAT- MEDLINE DCOM- 20041209 LR - 20131121 IS - 0369-8114 (Print) IS - 0369-8114 (Linking) VI - 52 IP - 6 DP - 2004 Jul TI - [Anethole dithiolethione: an antioxidant agent against tenotoxicity induced by fluoroquinolones]. PG - 308-13 AB - Tendinopathy and tendon rupture are the adverse effects observed with fluoroquinolone antibiotics in old patients. The aim of this study was to investigate the effect of anethole dithiolethione (5-[p-methoxyphenyl]3H-1,2-dithiole-3-thione) on the oxidative stress induced by three fluoroquinolones (pefloxacin, ofloxacin, ciprofloxacin) incubated with rabbit tenocyte cell line. Anethole dithiolethione is a well known antioxidant and glutathione inducer. Anethole dithiolethione is widely used in human therapy for its choleretic, sialogogic properties and recently proposed as cytoprotective agent in lung precancerous lesions prevention in smokers. In this purpose, protection against oxidative stress induced by fluoroquinolones has been assessed using cytofluorimetric probes to quantify cytotoxicity and reactive oxygen species production. Fluorescence signal was quantified in 96-well microplates, using cold light cytofluorometer. Significant reactive oxygen species production was detected after 45 minutes for all fluoroquinolones tested. Anethole dithiolethione has been evaluated on this parameter. Anethole dithiolethione significantly (*: P<0.05) reduces and normalizes reactive oxygen species induced by fluoroquinolones. So, anethole dithiolethione (Sulfarlem), well known for its antioxidant and glutathione inducing properties, good tissue diffusion and good tolerance in humans, could be beneficially associated to fluoroquinolones, and be proposed as a therapeutic adjuvant to prevent oxidative stress and tendinous adverse effects induced by xenobiotics and more precisely by fluoroquinolones. FAU - Pouzaud, F AU - Pouzaud F AD - Laboratoires Solvay-Pharma, 92151 Suresnes, France. FAU - Christen, M-O AU - Christen MO FAU - Warnet, J-M AU - Warnet JM FAU - Rat, P AU - Rat P LA - fre PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't TT - L'anethole dithiolethione: un agent cytoprotecteur contre la ténotoxicité induite par les fluoroquinolones. PL - France TA - Pathol Biol (Paris) JT - Pathologie-biologie JID - 0265365 RN - 0 (Anticarcinogenic Agents) RN - 0 (Reactive Oxygen Species) RN - QUY32964DJ (Anethole Trithione) SB - IM MH - Anethole Trithione/*pharmacology/therapeutic use MH - Animals MH - Anticarcinogenic Agents/therapeutic use MH - Cell Line MH - Cell Survival/drug effects MH - Cells, Cultured MH - Humans MH - Lung Neoplasms/prevention & control MH - Oxidative Stress/drug effects/*physiology MH - Precancerous Conditions/prevention & control MH - Rabbits MH - Reactive Oxygen Species/antagonists & inhibitors/metabolism MH - Tendons/cytology/drug effects/*physiology EDAT- 2004/07/21 05:00 MHDA- 2004/12/16 09:00 CRDT- 2004/07/21 05:00 PHST- 2003/10/29 00:00 [received] PHST- 2003/11/17 00:00 [accepted] PHST- 2004/07/21 05:00 [pubmed] PHST- 2004/12/16 09:00 [medline] PHST- 2004/07/21 05:00 [entrez] AID - S036981140300292X [pii] AID - 10.1016/j.patbio.2003.11.001 [doi] PST - ppublish SO - Pathol Biol (Paris). 2004 Jul;52(6):308-13. doi: 10.1016/j.patbio.2003.11.001. PMID- 33857874 OWN - NLM STAT- MEDLINE DCOM- 20210521 LR - 20210521 IS - 1878-0180 (Electronic) IS - 1878-0180 (Linking) VI - 119 DP - 2021 Jul TI - Effects of genipin crosslinking on mechanical cell-matrix interaction in 3D engineered tendon constructs. PG - 104508 LID - S1751-6161(21)00193-4 [pii] LID - 10.1016/j.jmbbm.2021.104508 [doi] AB - It is well known that cells can generate endogenous forces onto the extracellular matrix, but to what extent the mechanical properties of the matrix influences these endogenous cellular forces remains unclear. We therefore sought to quantify the influence of matrix rigidity on cell-matrix interactions by inducing cross-links using increasing concentrations of genipin (0.01-1 mM) or by blocking cross-link formation using beta-aminopropionitrile (BAPN) in engineered human tendon tissue constructs. The cell-matrix mechanics of the tendon constructs were evaluated as cell-generated tissue re-tensioning and stress-relaxation responses using a novel custom-made force monitor, which can apply and detect tensional forces in real-time in addition to mechanical failure testing. Genipin treatment had no influence on the biochemical profile (hydroxyproline, glycosaminoglycan and DNA content) of the constructs and cell viability was comparable between genipin-treated and control constructs, except at the highest genipin concentration. Endogenous re-tension after unloading was significantly decreased with increasing genipin concentrations compared to controls. Mechanical failure testing of tendon constructs showed increased (56%) peak stress at the highest genipin concentration but decreased (72%) with BAPN treatment when compared to controls. Tendon construct stiffness increased with high genipin concentrations (0.1 and 1 mM) and decreased by 70% in BAPN-treated constructs, relative to the controls. These data demonstrate that human tendon fibroblasts regulate their force exertion inversely proportional to increased cross-link capacity but did so independently of matrix stiffness. Overall, these findings support the notion of an interaction between cell force generation and cross-linking, and thus a role for this interplay in mechanical homeostasis of the tissue. CI - Copyright © 2021 Elsevier Ltd. All rights reserved. FAU - Giannopoulos, A AU - Giannopoulos A AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Denmark. Electronic address: antonios.giannopoulos@umu.se. FAU - Svensson, R B AU - Svensson RB AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Denmark. FAU - Yeung, C Y C AU - Yeung CYC AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Denmark. FAU - Kjaer, M AU - Kjaer M AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Denmark. FAU - Magnusson, S P AU - Magnusson SP AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery, Bispebjerg-Frederiksberg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Denmark; Department of Physical and Occupational Therapy, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210412 PL - Netherlands TA - J Mech Behav Biomed Mater JT - Journal of the mechanical behavior of biomedical materials JID - 101322406 RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - *Collagen MH - Cross-Linking Reagents MH - Humans MH - *Iridoids/pharmacology MH - Tendons MH - Tissue Engineering OTO - NOTNLM OT - Cellular forces OT - Cross-linking OT - Engineered tendon OT - Genipin OT - Matrix stiffness OT - Tissue mechanics EDAT- 2021/04/16 06:00 MHDA- 2021/05/22 06:00 CRDT- 2021/04/15 20:26 PHST- 2020/06/06 00:00 [received] PHST- 2021/03/31 00:00 [revised] PHST- 2021/04/01 00:00 [accepted] PHST- 2021/04/16 06:00 [pubmed] PHST- 2021/05/22 06:00 [medline] PHST- 2021/04/15 20:26 [entrez] AID - S1751-6161(21)00193-4 [pii] AID - 10.1016/j.jmbbm.2021.104508 [doi] PST - ppublish SO - J Mech Behav Biomed Mater. 2021 Jul;119:104508. doi: 10.1016/j.jmbbm.2021.104508. Epub 2021 Apr 12. PMID- 20601592 OWN - NLM STAT- MEDLINE DCOM- 20110412 LR - 20181201 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 38 IP - 11 DP - 2010 Nov TI - Less promising results with sclerosing ethoxysclerol injections for midportion achilles tendinopathy: a retrospective study. PG - 2226-32 LID - 10.1177/0363546510373467 [doi] AB - BACKGROUND: Local injections of the sclerosing substance polidocanol (Ethoxysclerol) have shown good clinical results in patients with chronic midportion Achilles tendinopathy. After training by the inventors of the technique, sclerosing Ethoxysclerol injections were applied on a group of patients in our center. HYPOTHESIS: Sclerosing Ethoxysclerol injections will yield good results in the majority of patients. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: In 113 patients (140 tendons) with Achilles tendinopathy, we identified 62 patients (70 tendons) showing neovascularization on color Doppler ultrasound. Fifty-three Achilles tendons (48 patients) were treated with sclerosing Ethoxysclerol injections, with intervals of 6 weeks and a maximum of 5 sessions. Treatment was completed when neovascularization or pain had disappeared, or when there was no positive treatment effect after 3 to 4 sessions. RESULTS: Forty-eight patients (20 women and 28 men) with a median age of 45 years, (range, 33-68 years) were treated. Median symptom duration was 23 months (range, 3-300 months). Fifty-three tendons were treated with a median of 3 sessions of Ethoxysclerol injections. Six weeks after the last injection, 35% of patients had no complaints, 9% had minimal symptoms, 42% were the same, and 14% had more complaints. Women were 3.8 times (95% confidence interval: 1.1-13.8) more likely to have unsatisfactory outcome than men. Pain correlated positively with neovessels on ultrasound (P < .01). At 2.7 to 5.1 year follow-up, 53% had received additional (surgical/conservative) treatment; 3 of these patients (7.5%) still had complaints of Achilles tendinopathy. In 6 patients, complaints that were still present 6 weeks after treatment had resolved spontaneously by final follow-up. CONCLUSION: Our study did not confirm the high beneficial value of sclerosing neovascularization in patients with midportion Achilles tendinopathy. Despite the retrospective design of our study, we consider it important to stress that injection of Ethoxysclerol may not be as promising as was thought. FAU - van Sterkenburg, Maayke N AU - van Sterkenburg MN AD - Academic Medical Center, Department of Orthopaedic Surgery, G4-262, PO Box 22700, 1100 DE Amsterdam, The Netherlands. m.n.vansterkenburg@amc.uva.nl FAU - de Jonge, Milko C AU - de Jonge MC FAU - Sierevelt, Inger N AU - Sierevelt IN FAU - van Dijk, C Niek AU - van Dijk CN LA - eng PT - Journal Article DEP - 20100702 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CIN - Am J Sports Med. 2011 Jan;39(1):NP2; author reply NP2-3. doi: 10.1177/0363546510390752. PMID: 21205976 MH - Achilles Tendon/diagnostic imaging/drug effects/*pathology MH - Adult MH - Aged MH - Confidence Intervals MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neovascularization, Physiologic/*drug effects MH - Pain Measurement MH - Polidocanol MH - Polyethylene Glycols/administration & dosage/*therapeutic use MH - Retrospective Studies MH - Sclerosing Solutions/administration & dosage/*therapeutic use MH - Statistics, Nonparametric MH - Surveys and Questionnaires MH - Tendinopathy/diagnostic imaging/*drug therapy/pathology MH - Treatment Outcome MH - Ultrasonography, Doppler, Color EDAT- 2010/07/06 06:00 MHDA- 2011/04/13 06:00 CRDT- 2010/07/06 06:00 PHST- 2010/07/06 06:00 [entrez] PHST- 2010/07/06 06:00 [pubmed] PHST- 2011/04/13 06:00 [medline] AID - 0363546510373467 [pii] AID - 10.1177/0363546510373467 [doi] PST - ppublish SO - Am J Sports Med. 2010 Nov;38(11):2226-32. doi: 10.1177/0363546510373467. Epub 2010 Jul 2. PMID- 19540671 OWN - NLM STAT- MEDLINE DCOM- 20091117 LR - 20250529 IS - 1872-6623 (Electronic) IS - 0304-3959 (Print) IS - 0304-3959 (Linking) VI - 145 IP - 1-2 DP - 2009 Sep TI - Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. PG - 96-104 LID - 10.1016/j.pain.2009.05.020 [doi] AB - Fibromyalgia (FM) syndrome is characterized by pain and widespread hyperalgesia to mechanical, thermal, and electrical stimuli. Despite convincing evidence for central sensitization of nociceptive pain pathways, the role of peripheral tissue impulse input in the initiation and maintenance of FM is unclear. Therefore this randomized, double-blind, placebo-controlled trial of 22 female normal controls (NCs) and 28 female FM subjects tested the effects of trapezius muscle (TrapM) tender point injections with 1% lidocaine on local pain thresholds as well as on remote heat hyperalgesia at the forearm. Prior to muscle injections shoulder pain was standardized by tonic mechanical muscle stimulation, resulting in local pain ratings of 4.0+/-0.5 VAS units. Tonic muscle stimulation was interrupted for the TrapM injections but was continued afterwards at the same level. NC as well as FM subjects experienced significant increases of TrapM pressure pain thresholds from lidocaine injections but not from placebo injections (p<0.001). Additionally, heat hyperalgesia of FM participants was significantly reduced at areas remote from the injection site (forearm) by lidocaine but not by placebo (p=0.02). Neither lidocaine nor saline injections significantly affected clinical FM pain ratings, a result most likely due to the very low dose of lidocaine (50mg) used in this trial. CONCLUSION: Lidocaine injections increased local pain thresholds and decreased remote secondary heat hyperalgesia in FM patients, emphasizing the important role of peripheral impulse input in maintaining central sensitization in this chronic pain syndrome; similar to other persistent pain conditions such as irritable bowel syndrome and complex regional pain syndrome. FAU - Staud, Roland AU - Staud R AD - Department of Medicine, University of Florida, Gainesville, FL 32610, USA. staudr@ufl.edu FAU - Nagel, Susann AU - Nagel S FAU - Robinson, Michael E AU - Robinson ME FAU - Price, Donald D AU - Price DD LA - eng GR - R01 AR053541/AR/NIAMS NIH HHS/United States GR - R01 NS038767/NS/NINDS NIH HHS/United States GR - NS-38767/NS/NINDS NIH HHS/United States GR - AR053541/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20090621 PL - United States TA - Pain JT - Pain JID - 7508686 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - Afferent Pathways/drug effects/*physiopathology MH - Analysis of Variance MH - Anesthetics, Local/administration & dosage/pharmacology MH - Arm/innervation MH - Double-Blind Method MH - Female MH - Fibromyalgia/*complications/drug therapy MH - Hot Temperature/adverse effects MH - Humans MH - Hyperalgesia/drug therapy/*etiology MH - Lidocaine/administration & dosage/pharmacology MH - Middle Aged MH - Muscle, Skeletal/drug effects/innervation MH - Pain/drug therapy/*etiology MH - Pain Measurement/methods MH - Pain Threshold/drug effects/*physiology MH - Pressure/adverse effects MH - Tendons/innervation PMC - PMC2751583 MID - NIHMS119962 COIS- The authors have no financial or other relationships to report that might result in a conflict of interest. EDAT- 2009/06/23 09:00 MHDA- 2009/11/18 06:00 PMCR- 2010/09/01 CRDT- 2009/06/23 09:00 PHST- 2009/02/24 00:00 [received] PHST- 2009/05/21 00:00 [revised] PHST- 2009/05/21 00:00 [accepted] PHST- 2009/06/23 09:00 [entrez] PHST- 2009/06/23 09:00 [pubmed] PHST- 2009/11/18 06:00 [medline] PHST- 2010/09/01 00:00 [pmc-release] AID - S0304-3959(09)00306-6 [pii] AID - 10.1016/j.pain.2009.05.020 [doi] PST - ppublish SO - Pain. 2009 Sep;145(1-2):96-104. doi: 10.1016/j.pain.2009.05.020. Epub 2009 Jun 21. PMID- 1342225 OWN - NLM STAT- MEDLINE DCOM- 19940210 LR - 20161018 IS - 0100-879X (Print) IS - 0100-879X (Linking) VI - 25 IP - 5 DP - 1992 TI - Type I collagen synthesis by rats fed beans (Phaseolus vulgaris, L.) as the protein source. PG - 499-501 AB - Type I collagen synthesis was studied in 12 female Wistar rats weighing 60 +/- 5 g at the beginning of the experiment. The animals were fasted for 24 h and then injected ip with 10 microCi uniformly labeled [14C]-glycine. Two hours later, groups of 4 animals each were fed balanced diets (10.7 +/- 0.4% protein) containing raw beans (Phaseolus vulgaris, L.), cooked beans or casein (control) as the single protein source, ad libitum. The animals were killed after 4 days and collagen was extracted from the tail and calcaneal tendons. Food intake and weight gain of rats fed raw beans (22 g, 0 g) were considerably less than rats fed cooked beans (38 g, 9 g) and casein (44 g, 22 g). Collagen was quantitated on the basis of hydroxyproline and corresponded to 0.1, 0.2 and 0.2% rat body weight, with specific radioactivity of 1.2, 1.6 and 4.2 microCi/g, for the rats fed raw beans, cooked beans and casein, respectively. The results indicate that rats fed either bean protein synthesized less collagen than those fed casein (P < 0.05). Although the food intake and extractable collagen of rats fed cooked beans were similar to those of casein-fed rats, weight gain and collagen specific radioactivity were less. FAU - Oliveira, A C AU - Oliveira AC AD - Departamento de Planejamento Alimentar e Nutrição, Faculdade de Engenharia de Alimentos, Universidade Estadual de Campinas, SP, Brasil. FAU - Vidal, B C AU - Vidal BC LA - eng PT - Comparative Study PT - Journal Article PL - Brazil TA - Braz J Med Biol Res JT - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica JID - 8112917 RN - 0 (Carbon Radioisotopes) RN - 0 (Caseins) RN - 0 (Dietary Proteins) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Caseins/administration & dosage MH - Collagen/analysis/*biosynthesis MH - Cooking MH - Dietary Proteins/*administration & dosage MH - *Fabaceae MH - Female MH - *Plants, Medicinal MH - Rats MH - Rats, Wistar MH - Tail/chemistry MH - Tendons/chemistry EDAT- 1992/01/01 00:00 MHDA- 1992/01/01 00:01 CRDT- 1992/01/01 00:00 PHST- 1992/01/01 00:00 [pubmed] PHST- 1992/01/01 00:01 [medline] PHST- 1992/01/01 00:00 [entrez] PST - ppublish SO - Braz J Med Biol Res. 1992;25(5):499-501. PMID- 23553304 OWN - NLM STAT- MEDLINE DCOM- 20130527 LR - 20220331 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 95 IP - 7 DP - 2013 Apr 3 TI - Local vitamin-C injection reduced tendon adhesion in a chicken model of flexor digitorum profundus tendon injury. PG - e41 LID - 10.2106/JBJS.K.00988 [doi] AB - BACKGROUND: Adhesion formation is a complication of hand flexor tendon repair. Normal gliding function of flexor tendons can be impaired by an excessive fibrotic response, which may be caused by intraoperative and postoperative hemorrhage. As tissue damage and hemorrhage can disturb redox regulation, thereby favoring fibrotic responses, the purpose of this study was to investigate if antioxidants can reduce tendon adhesion by antagonizing oxidative stress. METHODS: Flexor digitorum profundus tendon injury was induced in fifty-seven chickens. In twelve chickens, oxidative stress preinjury, immediately after injury, and two and six weeks postinjury (n = 3 at each time period) was estimated by measuring tissue levels of the reduced form of glutathione (GSH) and oxidized glutathione (glutathione disulfide [GSSG]) in the proximal interphalangeal joint. In the remaining chickens, 50 μL of saline solution or vitamin-C solution (5 or 50 mg/mL) was injected into the wound immediately after closure of the tendon sheath. Samples were harvested at two weeks (n = 6 in each group) or six weeks (n = 6 in each group) postinjury for a gliding test, ultrasound imaging, and histological examination. Three chickens from each group were killed at two weeks postinjury for GSH and GSSG measurements to evaluate the treatment effects on postoperative oxidative stress. RESULTS: The GSH level was significantly decreased at two and six weeks postinjury, and the GSSG level was significantly increased at six weeks postinjury. Both 5 and 50-mg/mL vitamin C led to higher tissue levels of GSH at two weeks postinjury, as compared with that in the saline solution group, but no significant change in the GSSG level was detected. Chickens with vitamin-C supplementation showed no significant improvement in gliding resistance and no significant reduction of the fibrotic size at two weeks postinjury, but they did show significant improvement in gliding resistance at six weeks postinjury and the 5-mg/mL vitamin-C group showed a significant reduction of the fibrotic size at six weeks. Histological examination showed less peritendinous adhesion in the vitamin-C groups. CONCLUSIONS: Our results suggest that local injection of vitamin-C solution can reduce the extent of adhesion of healing tendons, probably by redox modulation, in a chicken model. FAU - Hung, Leung-Kim AU - Hung LK AD - Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong SAR, China. E-mail address for L.-K. Hung: leungkimhung@cuhk.edu.hk. FAU - Fu, Sai-Chuen AU - Fu SC FAU - Lee, Yuk-Wa AU - Lee YW FAU - Mok, Tsui-Yu AU - Mok TY FAU - Chan, Kai-Ming AU - Chan KM LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - GAN16C9B8O (Glutathione) RN - PQ6CK8PD0R (Ascorbic Acid) RN - ULW86O013H (Glutathione Disulfide) SB - IM MH - Animals MH - Ascorbic Acid/administration & dosage/*pharmacology MH - Chickens MH - Disease Models, Animal MH - Female MH - Glutathione/metabolism MH - Glutathione Disulfide/metabolism MH - Injections, Intra-Articular MH - Oxidative Stress MH - Statistics, Nonparametric MH - Tendon Injuries/*surgery MH - Tissue Adhesions/*prevention & control MH - Toes MH - Wound Healing/drug effects EDAT- 2013/04/05 06:00 MHDA- 2013/05/29 06:00 CRDT- 2013/04/05 06:00 PHST- 2013/04/05 06:00 [entrez] PHST- 2013/04/05 06:00 [pubmed] PHST- 2013/05/29 06:00 [medline] AID - 1668932 [pii] AID - 10.2106/JBJS.K.00988 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2013 Apr 3;95(7):e41. doi: 10.2106/JBJS.K.00988. PMID- 29201913 OWN - NLM STAT- MEDLINE DCOM- 20180730 LR - 20181113 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2017 DP - 2017 TI - Proanthocyanidins Attenuation of H(2)O(2)-Induced Oxidative Damage in Tendon-Derived Stem Cells via Upregulating Nrf-2 Signaling Pathway. PG - 7529104 LID - 10.1155/2017/7529104 [doi] LID - 7529104 AB - Proanthocyanidins (PCs) have shown inhibition of oxidative damage by improving Nrf-2 expression in many tissues. However, the cytoprotective effects of PCs on H(2)O(2)-induced tendon damage have not been verified. The current study was aimed at assessing the cytoprotection of PCs on the oxidative cellular toxicity of tendon-derived stem cells (TDSCs) induced by H(2)O(2). The TDSCs were isolated from patellar tendons of Sprague Dawley (SD) rats, and the cells after third passage were used for subsequent experiments. The isolated cells were identified by flow cytometry assay and multidifferentiation potential assay. Cell Counting Kit-8 assay was performed to examine cell viability. Real-Time PCR and Western Blot were employed to, respectively, assess the mRNA and protein expressions of Nrf-2, GCLM, NQO-1, and HO-1. PCs significantly improved the cell viability of TDSCs. Furthermore, H(2)O(2) upregulated Nrf-2, GCLM, NQO-1, and HO-1 without significant difference, while the proteins expressions were increased with significant difference in PCs group and PCs + H(2)O(2) cotreated group. All the findings indicated that PCs could protect against the oxidative damage induced by H(2)O(2) in TDSCs, and the cytoprotective effects might be due to the ability of PCs to activate the expressions of GCLM, HO-1, and NQO-1 via upregulating Nrf-2 signaling pathway. FAU - Sun, Wenshuang AU - Sun W AUID- ORCID: 0000-0002-9433-6589 AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Meng, Jia AU - Meng J AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Wang, Zhenheng AU - Wang Z AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Yuan, Tao AU - Yuan T AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Qian, Hong AU - Qian H AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Chen, Wenxiang AU - Chen W AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Tong, Jian AU - Tong J AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Xie, Yu AU - Xie Y AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Zhang, Ya AU - Zhang Y AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Zhao, Jianning AU - Zhao J AUID- ORCID: 0000-0001-9454-409X AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. FAU - Bao, Nirong AU - Bao N AUID- ORCID: 0000-0003-3048-714X AD - Department of Orthopedics, Nanjing Jinling Hospital, No. 305 Zhongshan East Road, Nanjing 210000, China. LA - eng PT - Journal Article DEP - 20171022 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 0 (NF-E2-Related Factor 2) RN - 0 (Nfe2l2 protein, rat) RN - 0 (Proanthocyanidins) RN - 0 (RNA, Messenger) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 1.14.14.18 (Heme Oxygenase-1) RN - EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone)) RN - EC 1.6.5.2 (NQO1 protein, rat) RN - EC 6.3.2.2 (GCLM protein, rat) RN - EC 6.3.2.2 (Glutamate-Cysteine Ligase) SB - IM MH - Animals MH - Gene Expression Regulation, Developmental/drug effects MH - Glutamate-Cysteine Ligase/genetics MH - Heme Oxygenase-1/genetics MH - Hydrogen Peroxide/toxicity MH - NAD(P)H Dehydrogenase (Quinone)/genetics MH - NF-E2-Related Factor 2/*genetics MH - Oxidative Stress/*drug effects MH - Patellar Ligament/cytology/drug effects MH - Proanthocyanidins/*administration & dosage MH - RNA, Messenger/genetics MH - Rats MH - Signal Transduction/drug effects MH - Stem Cells/cytology/*drug effects PMC - PMC5671684 EDAT- 2017/12/05 06:00 MHDA- 2018/07/31 06:00 PMCR- 2017/10/22 CRDT- 2017/12/05 06:00 PHST- 2017/06/12 00:00 [received] PHST- 2017/08/13 00:00 [revised] PHST- 2017/09/27 00:00 [accepted] PHST- 2017/12/05 06:00 [entrez] PHST- 2017/12/05 06:00 [pubmed] PHST- 2018/07/31 06:00 [medline] PHST- 2017/10/22 00:00 [pmc-release] AID - 10.1155/2017/7529104 [doi] PST - ppublish SO - Biomed Res Int. 2017;2017:7529104. doi: 10.1155/2017/7529104. Epub 2017 Oct 22. PMID- 3463863 OWN - NLM STAT- MEDLINE DCOM- 19861119 LR - 20220310 IS - 0028-4793 (Print) IS - 0028-4793 (Linking) VI - 315 IP - 19 DP - 1986 Nov 6 TI - Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. PG - 1177-82 AB - Isotretinoin, a synthetic retinoid that has been prescribed for over 500,000 patients with cystic acne, has been associated with both spinal hyperostosis and a disorder similar to diffuse idiopathic skeletal hyperostosis. We describe a syndrome of tendon and ligament calcification, primarily in extraspinal locations, that we have observed after long-term therapy for psoriasis and disorders of keratinization with etretinate, another synthetic retinoid. Of 38 patients who had received etretinate (average dose, 0.8 mg per kilogram of body weight per day; average duration, 60 months), 32 (84 percent) had radiographic evidence of extraspinal tendon and ligament calcification. The most common sites of involvement were the ankles (29 patients [76 percent]), pelvis (20 patients [53 percent]), and knees (16 patients [42 percent]); spine involvement was uncommon in this group of etretinate-treated patients. Involvement tended to be bilateral and multifocal. Fifteen (47 percent) of the 32 affected patients had no bone or joint symptoms at the sites of radiographic abnormality. Thus, tendon and ligament calcification can occur without vertebral involvement as well as in association with it (for example, as part of the spectrum of diffuse idiopathic skeletal hyperostosis). We have identified extraspinal tendon and ligament calcification as a toxic effect that is commonly associated with long-term etretinate therapy. FAU - DiGiovanna, J J AU - DiGiovanna JJ FAU - Helfgott, R K AU - Helfgott RK FAU - Gerber, L H AU - Gerber LH FAU - Peck, G L AU - Peck GL LA - eng PT - Journal Article PL - United States TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 RN - 5688UTC01R (Tretinoin) RN - 65M2UDR9AG (Etretinate) RN - EH28UP18IF (Isotretinoin) SB - IM MH - Adult MH - Aged MH - Calcinosis/*chemically induced/diagnostic imaging MH - Etretinate/*adverse effects MH - Female MH - Humans MH - Isotretinoin MH - Knee Joint/diagnostic imaging MH - Ligaments/diagnostic imaging/*pathology MH - Lupus Erythematosus, Systemic/diagnostic imaging MH - Male MH - Middle Aged MH - Pelvis/diagnostic imaging MH - Prospective Studies MH - Psoriasis/drug therapy MH - Radiography MH - Skin Diseases/drug therapy MH - Spinal Diseases/chemically induced/diagnostic imaging MH - Tendons/diagnostic imaging/*pathology MH - Tretinoin/adverse effects EDAT- 1986/11/06 00:00 MHDA- 1986/11/06 00:01 CRDT- 1986/11/06 00:00 PHST- 1986/11/06 00:00 [pubmed] PHST- 1986/11/06 00:01 [medline] PHST- 1986/11/06 00:00 [entrez] AID - 10.1056/NEJM198611063151901 [doi] PST - ppublish SO - N Engl J Med. 1986 Nov 6;315(19):1177-82. doi: 10.1056/NEJM198611063151901. PMID- 17884275 OWN - NLM STAT- MEDLINE DCOM- 20080311 LR - 20171116 IS - 0278-6915 (Print) IS - 0278-6915 (Linking) VI - 46 IP - 1 DP - 2008 Jan TI - Effect of green tea extract on advanced glycation and cross-linking of tail tendon collagen in streptozotocin induced diabetic rats. PG - 280-5 AB - Diabetes leads to modification of collagen such as advanced glycation and cross-linking which play an important role in the pathogenesis of diabetes mellitus. We have investigated the effect of green tea on modification of collagen in streptozotocin (60 mg/kg body weight) induced diabetic rats. To investigate the therapeutic effect of green tea, treatment was begun six weeks after the onset of diabetes and green tea extract (300 mg/kg body weight) was given orally for 4 weeks. The collagen content, extent of advanced glycation, advanced glycation end products (AGE) and cross-linking of tail tendon collagen were investigated. Green tea reduced the tail tendon collagen content which increased in diabetic rats. Accelerated advanced glycation and AGE in diabetic animals, as detected by Ehrlich's-positive material and collagen linked fluorescence respectively were reduced significantly by green tea. The solubility of tail tendon collagen decreased significantly in diabetic rats indicating a remarkable increase in the cross-linking, whereas green tea increases the solubility of collagen in diabetic rats. The present study reveals that green tea is effective in reducing the modification of tail tendon collagen in diabetic rats. Thus green tea may have a therapeutic effect in the treatment of glycation induced complications of diabetes. FAU - Babu, Pon Velayutham Anandh AU - Babu PV AD - Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, India. FAU - Sabitha, Kuruvimalai Ekambaram AU - Sabitha KE FAU - Shyamaladevi, Chennam Srinivasulu AU - Shyamaladevi CS LA - eng PT - Journal Article DEP - 20070815 PL - England TA - Food Chem Toxicol JT - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association JID - 8207483 RN - 0 (Blood Glucose) RN - 0 (Glycation End Products, Advanced) RN - 0 (Plant Extracts) RN - 0 (Tea) RN - 3G6A5W338E (Caffeine) RN - 8R1V1STN48 (Catechin) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Blood Glucose/metabolism MH - Caffeine/analysis/pharmacology MH - Catechin/analysis/metabolism/pharmacology MH - Collagen/chemistry/*metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Fluorescence MH - Glycation End Products, Advanced/*metabolism MH - Male MH - Plant Extracts/pharmacology MH - Rats MH - Rats, Wistar MH - Solubility MH - Tea/*chemistry MH - Tendons/*metabolism EDAT- 2007/09/22 09:00 MHDA- 2008/03/12 09:00 CRDT- 2007/09/22 09:00 PHST- 2005/09/06 00:00 [received] PHST- 2006/08/29 00:00 [revised] PHST- 2007/08/08 00:00 [accepted] PHST- 2007/09/22 09:00 [pubmed] PHST- 2008/03/12 09:00 [medline] PHST- 2007/09/22 09:00 [entrez] AID - S0278-6915(07)00294-3 [pii] AID - 10.1016/j.fct.2007.08.005 [doi] PST - ppublish SO - Food Chem Toxicol. 2008 Jan;46(1):280-5. doi: 10.1016/j.fct.2007.08.005. Epub 2007 Aug 15. PMID- 12558622 OWN - NLM STAT- MEDLINE DCOM- 20030425 LR - 20190901 IS - 0307-6938 (Print) IS - 0307-6938 (Linking) VI - 28 IP - 1 DP - 2003 Jan TI - Complete remission of metastatic clear cell sarcoma with DAV chemotherapy. PG - 22-4 AB - We report the first case of metastatic clear cell sarcoma with dramatic response to DAV treatment (DTIC + ACNU + VCR). Clear cell sarcoma of tendons and aponeuroses, or malignant melanoma of soft parts, is a rare tumour that occurs predominantly in the extremities of young adults. It tends to recur locally or metastasize and the prognosis is poor. Although the importance of surgery has been established, the role of adjuvant chemotherapy has yet to be determined. DAV should be considered as a first-line palliative treatment in disseminated disease as well as adjuvant therapy after surgery of primary clear cell sarcoma. FAU - Fujimoto, M AU - Fujimoto M AD - Department of Dermatology, Jichi Medical School, Minami-Kawachi-machi, Japan. dermat@jichi.ac.jp FAU - Hiraga, M AU - Hiraga M FAU - Kiyosawa, T AU - Kiyosawa T FAU - Murakami, T AU - Murakami T FAU - Murata, S AU - Murata S FAU - Ohtsuki, M AU - Ohtsuki M FAU - Nakagawa, H AU - Nakagawa H LA - eng PT - Case Reports PT - Journal Article PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 RN - 0S726V972K (Nimustine) RN - 5J49Q6B70F (Vincristine) RN - 7GR28W0FJI (Dacarbazine) RN - DAV protocol SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use MH - Dacarbazine/administration & dosage MH - Humans MH - Lung Neoplasms/secondary MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/drug therapy MH - Nimustine/administration & dosage MH - Sarcoma, Clear Cell/*drug therapy/secondary MH - Skin Neoplasms/*drug therapy/pathology MH - Treatment Outcome MH - Vincristine/administration & dosage EDAT- 2003/02/01 04:00 MHDA- 2003/04/26 05:00 CRDT- 2003/02/01 04:00 PHST- 2003/02/01 04:00 [pubmed] PHST- 2003/04/26 05:00 [medline] PHST- 2003/02/01 04:00 [entrez] AID - 1109 [pii] AID - 10.1046/j.1365-2230.2003.01109.x [doi] PST - ppublish SO - Clin Exp Dermatol. 2003 Jan;28(1):22-4. doi: 10.1046/j.1365-2230.2003.01109.x. PMID- 27792147 OWN - NLM STAT- MEDLINE DCOM- 20170328 LR - 20220321 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 17 IP - 11 DP - 2016 Oct 25 TI - Icariin Promotes Tendon-Bone Healing during Repair of Rotator Cuff Tears: A Biomechanical and Histological Study. LID - 1780 AB - To investigate whether the systematic administration of icariin (ICA) promotes tendon-bone healing after rotator cuff reconstruction in vivo, a total of 64 male Sprague Dawley rats were used in a rotator cuff injury model and underwent rotator cuff reconstruction (bone tunnel suture fixation). Rats from the ICA group (n = 32) were gavage-fed daily with ICA at 0.125 mg/g, while rats in the control group (n = 32) received saline only. Micro-computed tomography, biomechanical tests, serum ELISA (calcium; Ca, alkaline phosphatase; AP, osteocalcin; OCN) and histological examinations (Safranin O and Fast Green staining, type I, II and III collagen (Col1, Col2, and Col3), CD31, and vascular endothelial growth factor (VEGF)) were analyzed two and four weeks after surgery. In the ICA group, the serum levels of AP and OCN were higher than in the control group. More Col1-, Col2-, CD31-, and VEGF-positive cells, together with a greater degree of osteogenesis, were detected in the ICA group compared with the control group. During mechanical testing, the ICA group showed a significantly higher ultimate failure load than the control group at both two and four weeks. Our results indicate that the systematic administration of ICA could promote angiogenesis and tendon-bone healing after rotator cuff reconstruction, with superior mechanical strength compared with the controls. Treatment for rotator cuff injury using systematically-administered ICA could be a promising strategy. FAU - Ye, Chenyi AU - Ye C AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. yechenyi@zju.edu.cn. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. yechenyi@zju.edu.cn. FAU - Zhang, Wei AU - Zhang W AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. zhangweilook@zju.edu.cn. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. zhangweilook@zju.edu.cn. FAU - Wang, Shengdong AU - Wang S AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 21518572@zju.edu.cn. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 21518572@zju.edu.cn. FAU - Jiang, Shuai AU - Jiang S AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 3090103847@zju.edu.cn. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 3090103847@zju.edu.cn. AD - Department of Hand Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou 310009, China. 3090103847@zju.edu.cn. FAU - Yu, Yuanbin AU - Yu Y AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. yybbyy@hotmail.com. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. yybbyy@hotmail.com. FAU - Chen, Erman AU - Chen E AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 21318096@zju.edu.cn. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. 21318096@zju.edu.cn. FAU - Xue, Deting AU - Xue D AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. blueskine@hotmail.com. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. blueskine@hotmail.com. FAU - Chen, Jianzhong AU - Chen J AD - Institute of Immunology, School of Basic Medical Sciences, Zhejiang University, No. 866, Yuhangtang Road, Hangzhou 310000, China. chenjianzhong@zju.edu.cn. FAU - He, Rongxin AU - He R AD - Department of Orthopedic Surgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. herongxin666@hotmail.com. AD - Orthopedics Research Institute of Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China. herongxin666@hotmail.com. LA - eng PT - Journal Article DEP - 20161025 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Flavonoids) RN - 0 (Vascular Endothelial Growth Factor A) RN - 9007-34-5 (Collagen) RN - VNM47R2QSQ (icariin) SB - IM MH - Animals MH - Collagen/biosynthesis MH - Disease Models, Animal MH - Flavonoids/*administration & dosage MH - Humans MH - Male MH - Osteogenesis/*drug effects MH - Rats MH - Rotator Cuff/drug effects/pathology MH - Rotator Cuff Injuries/*drug therapy/pathology MH - Tendons/drug effects/pathology MH - Vascular Endothelial Growth Factor A MH - Wound Healing/drug effects MH - X-Ray Microtomography PMC - PMC5133781 OTO - NOTNLM OT - icariin OT - rotator cuff tears OT - tendon-bone healing COIS- The authors declare that they have no competing interests. EDAT- 2016/10/30 06:00 MHDA- 2017/03/30 06:00 PMCR- 2016/11/01 CRDT- 2016/10/30 06:00 PHST- 2016/08/06 00:00 [received] PHST- 2016/09/14 00:00 [revised] PHST- 2016/09/21 00:00 [accepted] PHST- 2016/10/30 06:00 [pubmed] PHST- 2017/03/30 06:00 [medline] PHST- 2016/10/30 06:00 [entrez] PHST- 2016/11/01 00:00 [pmc-release] AID - ijms17111780 [pii] AID - ijms-17-01780 [pii] AID - 10.3390/ijms17111780 [doi] PST - epublish SO - Int J Mol Sci. 2016 Oct 25;17(11):1780. doi: 10.3390/ijms17111780. PMID- 32962576 OWN - NLM STAT- MEDLINE DCOM- 20210208 LR - 20210208 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 31 IP - 3 DP - 2020 TI - Tranexamic acid has positive effect in early period of tendon healing by stimulating the tumor necrosis factor-alpha and matrix metalloproteinase-3 expression levels. PG - 463-469 LID - ehc.2020.74265 [pii] LID - 10.5606/ehc.2020.74265 [doi] AB - OBJECTIVES: This study aims to evaluate the effect of tranexamic acid (TXA) application in tendon healing by using its immunohistochemical effects on tumor necrosis factor-alpha (TNF-α), matrix metalloproteinase-3 (MMP-3), and transforming growth factor-beta (TGF-β) expression; and to identify if TNF-α, MMP-3, and TGF-β can be used to monitor and evaluate tendon healing or not in tenotomized rat Achilles tendons. MATERIALS AND METHODS: Twelve male Wistar-Albino rats (age 6-7-month-old; weighing 300-350 g) were used in this retrospective study conducted between November 2016 and May 2017. The rats were divided into two groups with similar weights. The right legs of the rats were determined as the study group (TXA), and the left legs as the control serum physiologic (SP) group. Under anesthesia, bilateral Achilles tenotomy was performed and surgically repaired. 1 mL of TXA was applied locally for the right side and 1 mL of SP was locally applied for the left side. Half of the rats were sacrificed at the third week (right leg-TXA3, left leg-SP3) and the other half at sixth week (right leg-TXA6, left leg-SP6) and tendon samples were taken from the extremities. Immunohistochemical findings of TNF-α, MMP-3, and TGF-β were evaluated on the basis of the frequency and intensity of staining. RESULTS: In TNF-α and MMP-3 and TXA groups, there was a significant difference in staining compared to SP groups (p<0.05). Regarding TNF-α expression, the total index score in the TXA6 subgroup was higher than the TXA3, SP6, and SP3 subgroups (8, 7, 3, and 4, respectively). Overall scores of TNF-α showed that TXA groups had significantly higher scores when compared to SP groups (p<0.05). In addition, total MMP-3 expression scores were significantly higher in TXA groups than in SP groups, respectively; TXA3: 14, TXA6: 11, SP3: 10, and SP6: 9 (p<0.05). However, the degree of staining with TNF-α was found to be significantly lower than MMP-3 (p<0.05). Immunohistochemical reactivity was not observed with TGF-β. CONCLUSION: Tranexamic acid has positive effect in early period of tendon healing by stimulating the TNF-α and MMP-3 expression levels. TNF-α and MMP-3 can be used to monitor and evaluate tendon healing. FAU - Çıraklı, Alper AU - Çıraklı A FAU - Gürgör, Pınar Naile AU - Gürgör PN FAU - Uzun, Erdal AU - Uzun E FAU - Erdem, Havva AU - Erdem H FAU - Şahin, Abdullah Alper AU - Şahin AA AD - Ordu Üniversitesi Eğitim ve Araştırma Hastanesi Ortopedi ve Travmatoloji Kliniği, 52200 Altınordu, Ordu, Türkiye. dr.a.alpersahin@gmail.com. FAU - Baş, Orhan AU - Baş O LA - eng PT - Journal Article PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - 0 (Transforming Growth Factor beta) RN - 0 (Tumor Necrosis Factor-alpha) RN - 6T84R30KC1 (Tranexamic Acid) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - *Achilles Tendon/metabolism/surgery MH - Administration, Topical MH - Animals MH - Male MH - Matrix Metalloproteinase 3/*metabolism MH - Rats MH - Rats, Wistar MH - Retrospective Studies MH - *Surgical Wound/drug therapy/metabolism MH - Tenotomy/methods MH - *Tranexamic Acid/administration & dosage/pharmacokinetics MH - Transforming Growth Factor beta/*metabolism MH - Treatment Outcome MH - Tumor Necrosis Factor-alpha/*metabolism MH - *Wound Healing/drug effects/physiology PMC - PMC7607962 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2020/09/24 06:00 MHDA- 2021/02/09 06:00 PMCR- 2020/09/11 CRDT- 2020/09/23 05:55 PHST- 2020/09/23 05:55 [entrez] PHST- 2020/09/24 06:00 [pubmed] PHST- 2021/02/09 06:00 [medline] PHST- 2020/09/11 00:00 [pmc-release] AID - ehc.2020.74265 [pii] AID - 10.5606/ehc.2020.74265 [doi] PST - ppublish SO - Jt Dis Relat Surg. 2020;31(3):463-469. doi: 10.5606/ehc.2020.74265. PMID- 3980949 OWN - NLM STAT- MEDLINE DCOM- 19850523 LR - 20190829 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 10 IP - 2 DP - 1985 Mar TI - Gouty tenosynovitis in the hand. PG - 291-5 AB - Gouty tenosynovitis can present as an infection, tendon rupture, nerve compression, or digital stiffness. In ten patients, extensive urate deposition was encountered in the extensor tendons at both the wrist and digital levels in addition to involvement of the flexor tendons in the carpal canal and digital theca. Direct nerve or muscle involvement was not observed in the hand. Medical therapy, which is now the cornerstone of treatment for most aspects of gout, may not be the best treatment for tophaceous deposits in the hand. Operative treatment may be required to debulk tophaceous deposits, improve tendon gliding, decompress nerves, allow increased range of motion of joints, and ameliorate pain. FAU - Moore, J R AU - Moore JR FAU - Weiland, A J AU - Weiland AJ LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Arthritis/etiology MH - Carpal Tunnel Syndrome/etiology MH - Female MH - Gout/*complications/surgery MH - *Hand MH - Humans MH - Male MH - Middle Aged MH - Tenosynovitis/*etiology MH - Uric Acid/metabolism MH - Wrist EDAT- 1985/03/01 00:00 MHDA- 1985/03/01 00:01 CRDT- 1985/03/01 00:00 PHST- 1985/03/01 00:00 [pubmed] PHST- 1985/03/01 00:01 [medline] PHST- 1985/03/01 00:00 [entrez] AID - S0363-5023(85)80127-1 [pii] AID - 10.1016/s0363-5023(85)80127-1 [doi] PST - ppublish SO - J Hand Surg Am. 1985 Mar;10(2):291-5. doi: 10.1016/s0363-5023(85)80127-1. PMID- 29903498 OWN - NLM STAT- MEDLINE DCOM- 20181015 LR - 20181015 IS - 1872-7565 (Electronic) IS - 0169-2607 (Linking) VI - 162 DP - 2018 Aug TI - Betti number ratios as quantitative indices for bone morphometry in three dimensions. PG - 93-98 LID - S0169-2607(18)30069-5 [pii] LID - 10.1016/j.cmpb.2018.05.012 [doi] AB - BACKGROUND AND OBJECTIVE: Computational homology is an emerging mathematical tool for characterizing shapes of data. In this work, we present a methodology using computational homology for obtaining quantitative measurements of the connectivity in bone morphometry. We introduce the Betti number ratios as novel morphological descriptor for the classification of bone fine structures in three dimensions. METHODS: A total of 51 Japanese white rabbits were used to investigate the connectivity of bone trabeculae after the administration of alendronate in a tendon graft model in rabbits. They were divided into a control group C and an experimental group A. Knee joints specimens were harvested for examination of their bone trabecular structure by micro-CT. Applying the computational homology software to the reconstructed 3D image data, we extract the morphological feature of a steric bone structure as the Betti numbers set (β(0), β(1), β(2)). The zeroth Betti number β(0) indicates the number of the connected components corresponding to isolated bone fragments. The first and second Betti numbers, β(1) and β(2), indicate the numbers of open pores and closed pores of bone trabeculae, corresponding to a 2D empty space enclosed by a 1D curve and a 3D empty space enclosed by a 2D surface, respectively. RESULTS: We define the Betti number ratios β(1)/β(0) and β(2)/β(0) to better distinguish the two groups A and C in the scatter plots. Testing the discriminant function line for 29 data points of A (22 data points of C), the 17 points (resp. 18 points) are correctly classified into group A (resp. C). The accuracy rate is 35/51. The classification results in terms of the Betti number ratios are consistent with the histomorphometric measurements observed by medical doctors. CONCLUSIONS: This study is the first application of computational homology to bone morphometry in three dimensions. We show the mathematical basis of the Betti numbers index which are useful in a statistical description of the topological features of sponge-like structures. The potential benefits associated with our method include both improved quantification and reproducibility for the stereology. CI - Copyright © 2018 Elsevier B.V. All rights reserved. FAU - Teramoto, Takashi AU - Teramoto T AD - Department of Mathematics, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan. Electronic address: teramoto@asahikawa-med.ac.jp. FAU - Kamiya, Takeshi AU - Kamiya T AD - Department of Orthopedic Surgery, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan. FAU - Sakurai, Taira AU - Sakurai T AD - Hokkaido Kitami Technical Highschool, 602 Higashi-Ainonai, Kitami 099-0878, Japan. FAU - Kanaya, Fuminori AU - Kanaya F AD - Department of Orthopedic Surgery, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan. LA - eng PT - Journal Article DEP - 20180505 PL - Ireland TA - Comput Methods Programs Biomed JT - Computer methods and programs in biomedicine JID - 8506513 RN - X1J18R4W8P (Alendronate) SB - IM MH - Alendronate/*administration & dosage MH - Algorithms MH - Animals MH - Bone Density MH - *Bone Transplantation MH - Bone and Bones/*diagnostic imaging/*pathology MH - Computational Biology MH - Image Processing, Computer-Assisted MH - *Imaging, Three-Dimensional MH - Programming Languages MH - Rabbits MH - Reproducibility of Results MH - Software MH - Tendons/diagnostic imaging MH - *X-Ray Microtomography OTO - NOTNLM OT - Bone morphometry OT - Computational homology OT - Image processing EDAT- 2018/06/16 06:00 MHDA- 2018/10/16 06:00 CRDT- 2018/06/16 06:00 PHST- 2018/01/15 00:00 [received] PHST- 2018/04/24 00:00 [revised] PHST- 2018/05/03 00:00 [accepted] PHST- 2018/06/16 06:00 [entrez] PHST- 2018/06/16 06:00 [pubmed] PHST- 2018/10/16 06:00 [medline] AID - S0169-2607(18)30069-5 [pii] AID - 10.1016/j.cmpb.2018.05.012 [doi] PST - ppublish SO - Comput Methods Programs Biomed. 2018 Aug;162:93-98. doi: 10.1016/j.cmpb.2018.05.012. Epub 2018 May 5. PMID- 23038762 OWN - NLM STAT- MEDLINE DCOM- 20130702 LR - 20240229 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 24 IP - 2 DP - 2013 Feb TI - Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. PG - 350-355 LID - S0923-7534(19)36848-6 [pii] LID - 10.1093/annonc/mds290 [doi] AB - BACKGROUND: Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data. PATIENTS AND METHODS: A prospective cohort study of 33 postmenopausal breast cancer patients received adjuvant endocrine therapy; 27 received an AI and 6 received tamoxifen. At baseline, 6 and 24 months patients had a rheumatologic examination, including a grip strength test, and magnetic resonance imaging of both hands and wrists. The primary end point was tenosynovial changes; secondary end points were changes in morning stiffness, grip strength and IAF. RESULTS: Twenty-three AI and 5 tamoxifen patients completed all investigations. Between month 6 and 24, IAF further increased in AI users (P = 0.04) but not in tamoxifen users, and grip strength further decreased in both groups. The worsened tenosynovial changes were strongly correlated with a decrease in grip strength. At 24 months, morning stiffness continued to be present in over a third of AI users. CONCLUSION: AIMSS represents a substantial problem in breast cancer patients. It is associated with tenosynovial changes, IAF retention, joint stiffness and loss of grip strength that do not improve with prolonged use. FAU - Lintermans, A AU - Lintermans A AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven. Electronic address: patrick.neven@uzleuven.be. FAU - Laenen, A AU - Laenen A AD - Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven, Leuven; Leuven Cancer Institute (LKI), KU Leuven, Leuven. FAU - Van Calster, B AU - Van Calster B AD - Leuven Cancer Institute (LKI), KU Leuven, Leuven; Department of Development and Regeneration, KU Leuven, Leuven. FAU - Van Hoydonck, M AU - Van Hoydonck M AD - Department of Rheumatology, KU Leuven, Leuven. FAU - Pans, S AU - Pans S AD - Department of Radiology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. FAU - Verhaeghe, J AU - Verhaeghe J AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven. FAU - Westhovens, R AU - Westhovens R AD - Department of Rheumatology, KU Leuven, Leuven. FAU - Henry, N L AU - Henry NL AD - Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA. FAU - Wildiers, H AU - Wildiers H AD - Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven; Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. FAU - Paridaens, R AU - Paridaens R AD - Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven; Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. FAU - Dieudonné, A S AU - Dieudonné AS AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven. FAU - Leunen, K AU - Leunen K AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven; Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. FAU - Morales, L AU - Morales L AD - Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. FAU - Verschueren, K AU - Verschueren K AD - Department of Rheumatology, KU Leuven, Leuven. FAU - Timmerman, D AU - Timmerman D AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven. FAU - De Smet, L AU - De Smet L AD - Orthopedic Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium. FAU - Vergote, I AU - Vergote I AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven; Leuven Cancer Institute (LKI), KU Leuven, Leuven. FAU - Christiaens, M R AU - Christiaens MR AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven; Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. FAU - Neven, P AU - Neven P AD - Department of Obstetrics and Gynecology, KU Leuven, Leuven; Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven. LA - eng PT - Journal Article DEP - 20121004 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - 0 (Antineoplastic Agents, Hormonal) RN - 0 (Aromatase Inhibitors) RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Aged MH - Antineoplastic Agents, Hormonal/adverse effects/pharmacology/therapeutic use MH - *Aromatase Inhibitors/adverse effects/pharmacology/therapeutic use MH - Breast Neoplasms/*drug therapy MH - Chemotherapy, Adjuvant/adverse effects MH - Cohort Studies MH - Female MH - Follow-Up Studies MH - Hand Strength MH - Humans MH - Middle Aged MH - Musculoskeletal Diseases MH - Postmenopause MH - Prospective Studies MH - Synovial Membrane/*drug effects MH - *Tamoxifen/adverse effects/pharmacology/therapeutic use MH - Tendons/*drug effects EDAT- 2012/10/06 06:00 MHDA- 2013/07/03 06:00 CRDT- 2012/10/06 06:00 PHST- 2012/10/06 06:00 [entrez] PHST- 2012/10/06 06:00 [pubmed] PHST- 2013/07/03 06:00 [medline] AID - S0923-7534(19)36848-6 [pii] AID - 10.1093/annonc/mds290 [doi] PST - ppublish SO - Ann Oncol. 2013 Feb;24(2):350-355. doi: 10.1093/annonc/mds290. Epub 2012 Oct 4. PMID- 12845372 OWN - NLM STAT- MEDLINE DCOM- 20040120 LR - 20190605 IS - 0100-879X (Print) IS - 0100-879X (Linking) VI - 36 IP - 7 DP - 2003 Jul TI - Effect of an aqueous extract of Phaseolus vulgaris on the properties of tail tendon collagen of rats with streptozotocin-induced diabetes. PG - 861-70 AB - Changes in the structural and functional properties of collagen caused by advanced glycation might be of importance for the etiology of late complications in diabetes. The present study was undertaken to investigate the influence of oral administration of aqueous pod extract (200 mg/kg body weight) of Phaseolus vulgaris, an indigenous plant used in Ayurvedic Medicine in India, on collagen content and characteristics in the tail tendon of streptozotocin-diabetic rats. In diabetic rats, collagen content (117.01 6.84 mg/100 mg tissue) as well as its degree of cross-linking was increased, as shown by increased extent of glycation (21.70 0.90 g glucose/mg collagen), collagen-linked fluorescence (52.8 3.0 AU/ mol hydroxyproline), shrinkage temperature (71.50 2.50 C) and decreased acid (1.878 0.062 mg hydroxyproline/100 mg tissue) and pepsin solubility (1.77 0.080 mg hydroxyproline/100 mg tissue). The alpha/ ratio of acid- (1.69) and pepsin-soluble (2.00) collagen was significantly decreased in streptozotocin-diabetic rats. Administration of P. vulgaris for 45 days to streptozotocin-diabetic rats significantly reduced the accumulation and cross-linking of collagen. The effect of P. vulgaris was compared with that of glibenclamide, a reference drug administered to streptozotocin-diabetic rats at the dose of 600 g/kg body weight for 45 days by gavage. The effects of P. vulgaris (collagen content, 64.18 1.97; extent of glycation, 12.00 0.53; collagen-linked fluorescence, 33.6 1.9; shrinkage temperature, 57.0 1.0; extent of cross-linking - acid-soluble collagen, 2.572 0.080, and pepsin-soluble collagen, 2.28 0.112) were comparable with those of glibenclamide (collagen content, 71.5 2.04; extent of glycation, 13.00 0.60; collagen-linked fluorescence, 38.9 2.0; shrinkage temperature, 59.0 1.5; extent of cross-linking - acid-soluble collagen, 2.463 0.078, and pepsin-soluble collagen, 2.17 0.104). In conclusion, administration of P. vulgaris pods had a positive influence on the content of collagen and its properties in streptozotocin-diabetic rats. FAU - Pari, L AU - Pari L AD - Department of Biochemistry, Faculty of Science, Annamalai University, Tamil Nadu, India. paribala@sancharnet.in FAU - Venkateswaran, S AU - Venkateswaran S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20030626 PL - Brazil TA - Braz J Med Biol Res JT - Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica JID - 8112917 RN - 0 (Blood Glucose) RN - 0 (Cross-Linking Reagents) RN - 0 (Glycation End Products, Advanced) RN - 0 (Insulin) RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Blood Glucose/metabolism MH - Collagen/*drug effects/metabolism MH - Cross-Linking Reagents/metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Electrophoresis, Polyacrylamide Gel MH - Glycation End Products, Advanced/metabolism MH - Insulin/blood MH - Male MH - *Phaseolus MH - Plant Extracts/*pharmacology MH - Rats MH - Rats, Wistar MH - Tail/*drug effects/metabolism MH - Tendons/*drug effects/metabolism EDAT- 2003/07/08 05:00 MHDA- 2004/01/21 05:00 CRDT- 2003/07/08 05:00 PHST- 2003/07/08 05:00 [pubmed] PHST- 2004/01/21 05:00 [medline] PHST- 2003/07/08 05:00 [entrez] AID - S0100-879X2003000700006 [pii] AID - 10.1590/s0100-879x2003000700006 [doi] PST - ppublish SO - Braz J Med Biol Res. 2003 Jul;36(7):861-70. doi: 10.1590/s0100-879x2003000700006. Epub 2003 Jun 26. PMID- 24122676 OWN - NLM STAT- MEDLINE DCOM- 20150511 LR - 20140303 IS - 1099-081X (Electronic) IS - 0142-2782 (Linking) VI - 35 IP - 2 DP - 2014 Mar TI - Biodistribution of diclofenac following repeated topical applications of two diclofenac sodium formulations to minipigs. PG - 87-96 LID - 10.1002/bdd.1867 [doi] AB - This study evaluated diclofenac concentrations in plasma, selected hind limb tissues and synovial fluid after repeated topical applications of two diclofenac formulations. Group 1 Gottingen minipigs (n = 18) were administered diclofenac sodium 2.0% topical solution twice daily on days 1-6 and once on day 7. Group 2 minipigs (n = 18) were administered diclofenac sodium 1.5% topical solution four times daily on days 1-6 and twice on day 7. Approximately 20 mg of diclofenac was applied daily to a 10 × 15 cm dosing site centered over the patella of the right knee. Plasma and tissue samples were collected throughout and analysed for diclofenac concentrations using liquid chromatography with tandem mass spectrometry. On day 1, diclofenac sodium 2.0% topical solution produced higher plasma concentrations compared with the 1.5% formulation; however, after 24 h and throughout the remainder of the dosing period, plasma concentrations appeared similar, except at the 72 h time point. Twenty-four hours after the final application, skin treated with diclofenac sodium 2.0% topical solution retained a significantly (p < 0.02) greater amount of diclofenac than the 1.5% formulation. Generally, both formulations produced similar diclofenac concentrations in synovial fluid, underlying muscle, tendon and bone 24 h after the last application. The 2.0% diclofenac formulation applied twice daily delivered similar amounts of diclofenac as the 1.5% formulation administered four times daily. The skin retained a significant portion of the applied dose to serve as a depot for continuous diffusion of diclofenac into underlying tissues and systemic circulation. CI - Copyright © 2013 John Wiley & Sons, Ltd. FAU - Wible, James H Jr AU - Wible JH Jr AD - Mallinckrodt Pharmaceuticals, Hazelwood, MO, USA. FAU - Barrett, Thomas AU - Barrett T FAU - Devarakonda, Krishna AU - Devarakonda K FAU - Giuliani, Michael AU - Giuliani M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131204 PL - England TA - Biopharm Drug Dispos JT - Biopharmaceutics & drug disposition JID - 7911226 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 144O8QL0L1 (Diclofenac) SB - IM MH - Administration, Cutaneous MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics MH - Bone and Bones/metabolism MH - Diclofenac/blood/*pharmacokinetics MH - Female MH - Lower Extremity MH - Muscle, Skeletal/metabolism MH - Skin/metabolism MH - Swine MH - Swine, Miniature MH - Synovial Fluid/metabolism MH - Tendons/metabolism MH - Tissue Distribution OTO - NOTNLM OT - biodistribution OT - diclofenac OT - knee OT - osteoarthritis OT - topical EDAT- 2013/10/15 06:00 MHDA- 2015/05/12 06:00 CRDT- 2013/10/15 06:00 PHST- 2013/05/06 00:00 [received] PHST- 2013/08/23 00:00 [revised] PHST- 2013/10/08 00:00 [accepted] PHST- 2013/10/15 06:00 [entrez] PHST- 2013/10/15 06:00 [pubmed] PHST- 2015/05/12 06:00 [medline] AID - 10.1002/bdd.1867 [doi] PST - ppublish SO - Biopharm Drug Dispos. 2014 Mar;35(2):87-96. doi: 10.1002/bdd.1867. Epub 2013 Dec 4. PMID- 18485147 OWN - NLM STAT- MEDLINE DCOM- 20080612 LR - 20221207 IS - 1472-8206 (Electronic) IS - 0767-3981 (Linking) VI - 22 IP - 3 DP - 2008 Jun TI - Effect of succinic acid monoethyl ester on hemoglobin glycation and tail tendon collagen properties in type 2 diabetic rats. PG - 291-8 LID - 10.1111/j.1472-8206.2008.00581.x [doi] AB - Succinic acid monoethyl ester (EMS) was recently proposed as an insulinotropic agent for the treatment of type 2 diabetes. The aim of the study was to investigate the effect of EMS and metformin administration on tail collagen content and its characteristics in streptozotocin-nicotinamide-induced type 2 diabetic rats. EMS was administered intraperitoneally for 30 days to normal and diabetic rats. In the diabetic rats, a significant increase in the levels of glucose, glycated hemoglobin, hydroxyproline, collagen content, extent glycation, fluorescence, neutral salt, acid and pepsin soluble collagen content was absorbed with a significant decrease in the level of insulin, hemoglobin in streptozotocin-nicotinamide diabetic rats. Moreover, a daily administration of nonglucidic nutrient EMS and metformin significantly decreased the levels of glucose, glycated hemoglobin, hydroxyproline, collagen content, extent glycation, fluorescence, neutral salt, acid and pepsin soluble collagen content, whereas it increased insulin, hemoglobin levels in diabetic rats. The positive influence of nonglucidic nutrient on both collagen content and its properties suggests a potential mechanism for the ability of EMS to delay diabetic complications. FAU - Saravanan, Ramalingam AU - Saravanan R AD - Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu 608002, India. FAU - Pari, Leelavinothan AU - Pari L LA - eng PT - Journal Article PL - England TA - Fundam Clin Pharmacol JT - Fundamental & clinical pharmacology JID - 8710411 RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin A) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) RN - 0 (Succinates) RN - 0 (monoethyl succinate) RN - 25X51I8RD4 (Niacinamide) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) RN - 9100L32L2N (Metformin) SB - IM MH - Animals MH - Blood Glucose/metabolism MH - Collagen/*metabolism MH - Diabetes Mellitus, Experimental/chemically induced/drug therapy/metabolism MH - Diabetes Mellitus, Type 2/chemically induced/drug therapy/*metabolism MH - Glycated Hemoglobin/*analysis MH - Hypoglycemic Agents/*pharmacology/therapeutic use MH - Injections, Intraperitoneal MH - Insulin/blood MH - Male MH - Metformin/pharmacokinetics/therapeutic use MH - Niacinamide MH - Rats MH - Rats, Wistar MH - Streptozocin MH - Succinates/*pharmacology/therapeutic use MH - Tail MH - Tendons/*drug effects/metabolism EDAT- 2008/05/20 09:00 MHDA- 2008/06/13 09:00 CRDT- 2008/05/20 09:00 PHST- 2008/05/20 09:00 [pubmed] PHST- 2008/06/13 09:00 [medline] PHST- 2008/05/20 09:00 [entrez] AID - FCP581 [pii] AID - 10.1111/j.1472-8206.2008.00581.x [doi] PST - ppublish SO - Fundam Clin Pharmacol. 2008 Jun;22(3):291-8. doi: 10.1111/j.1472-8206.2008.00581.x. PMID- 15823472 OWN - NLM STAT- MEDLINE DCOM- 20050801 LR - 20061115 IS - 1350-4533 (Print) IS - 1350-4533 (Linking) VI - 27 IP - 4 DP - 2005 May TI - Total flavones of Hippophae rhamnoides promotes early restoration of ultimate stress of healing patellar tendon in a rat model. PG - 313-21 AB - Traditional Chinese herbal medicine has long been used for treatment of tendon injuries. Comparing to the modern way of treatments, Traditional Chinese medicine also stresses on strategies to promote the inherent healing capacity of tendons. Hippophae rhamnoides, known as Shaji, is one of Chinese herbal drugs that are traditionally used to promote tendon and ligament injuries. The total flavones of H. rhamnoides (TFH), with major constituents including quercetin, isorhamnetin and kaempferol, have been demonstrated with most of the bioactive properties of Shaji. In the present study, we evaluated the potential effect of TFH in the restoration of ultimate stress of healing patellar tendon in a well-established gap wound model in rats. A 0.1 mg TFH was injected to wound 1 day after the injury, and the ultimate stress of the healing tendon was measured at day 14 post-injury. The results showed that the ultimate stress of the healing tendon was significantly promoted by injection of TFH, increasing from 30 to 50% as compared to saline control. Excessive fibrotic response was not found in TFH-treated animals, but an enhanced collagen deposition and a better fibre alignment were observed. The results suggest that TFH may improve the ultimate stress of healing tendons at early stages, which implies possible earlier rehabilitation programme and better recovery. FAU - Fu, S C AU - Fu SC AD - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, China. FAU - Hui, C W C AU - Hui CW FAU - Li, L C AU - Li LC FAU - Cheuk, Y C AU - Cheuk YC FAU - Qin, L AU - Qin L FAU - Gao, J AU - Gao J FAU - Chan, K-M AU - Chan KM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Med Eng Phys JT - Medical engineering & physics JID - 9422753 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Flavones) SB - IM MH - Animals MH - Disease Models, Animal MH - Drugs, Chinese Herbal/*administration & dosage MH - Elasticity MH - Flavones/*administration & dosage MH - Hippophae/*metabolism MH - Injections, Intralesional MH - Male MH - Phytotherapy/methods MH - Rats MH - Rats, Sprague-Dawley MH - Stress, Mechanical MH - Tendon Injuries/diagnosis/*drug therapy/pathology/*physiopathology MH - Tendons/drug effects/pathology/physiopathology MH - Tensile Strength MH - Treatment Outcome MH - Wound Healing/drug effects/*physiology EDAT- 2005/04/13 09:00 MHDA- 2005/08/02 09:00 CRDT- 2005/04/13 09:00 PHST- 2004/06/24 00:00 [received] PHST- 2004/12/13 00:00 [revised] PHST- 2004/12/21 00:00 [accepted] PHST- 2005/04/13 09:00 [pubmed] PHST- 2005/08/02 09:00 [medline] PHST- 2005/04/13 09:00 [entrez] AID - S1350-4533(05)00031-7 [pii] AID - 10.1016/j.medengphy.2004.12.011 [doi] PST - ppublish SO - Med Eng Phys. 2005 May;27(4):313-21. doi: 10.1016/j.medengphy.2004.12.011. PMID- 15756611 OWN - NLM STAT- MEDLINE DCOM- 20050714 LR - 20220316 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 13 IP - 2 DP - 2005 Mar TI - Neovascularisation in chronic painful patellar tendinosis--promising results after sclerosing neovessels outside the tendon challenge the need for surgery. PG - 74-80 AB - Sclerosing injections targeting neovascularisation have been demonstrated to give promising clinical results in patients with chronic painful Achilles tendinosis. In this study, fifteen elite or recreational athletes (12 men and three women) with the diagnosis patellar tendinosis/Jumper's knee in 15 patellar tendons were included. All the patients had a long duration of pain symptoms (mean = 23 months) from the patellar tendon, and ultra-sonography + colour doppler examination showed structural tendon changes with hypo-echoic areas and a neovascularisation, corresponding to the painful area. The patients were treated with ultrasound and colour doppler-guided injections of the sclerosing substance Polidocanol, targeting the area with neovascularisation. At follow-up (mean = 6 months) after a mean amount of three treatments, there was a good clinical result in 12/15 tendons. The patients were back to their previous (before injury) sport activity level, and the amount of pain recorded on a VAS-scale had decreased significantly (VAS from 81 to 10). Our findings indicate that treatment with sclerosing injections, targeting the area with neovessels in patellar tendinosis, has the potential to cure the pain in the tendons and also allow the patients to go back to full patellar-tendon loading activity. FAU - Alfredson, Håkan AU - Alfredson H AD - Sports Medicine Unit, Department of Surgical and Perioperative Science, University of Umeå, 90187 Umea, Sweden. hakan.alfredson@idrott.umu.se FAU - Ohberg, Lars AU - Ohberg L LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20041126 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adult MH - Chronic Disease MH - Female MH - Follow-Up Studies MH - Humans MH - Injections, Intra-Articular MH - Knee Injuries/*complications/diagnostic imaging MH - Knee Joint/diagnostic imaging MH - Male MH - Neovascularization, Pathologic/diagnostic imaging/*drug therapy/etiology MH - Pain/diagnosis/etiology MH - Pain Measurement MH - Patella MH - Patient Satisfaction MH - Polidocanol MH - Polyethylene Glycols/*administration & dosage MH - Sclerosing Solutions/*administration & dosage MH - Tendinopathy/*complications/diagnostic imaging/pathology MH - Tendons/*blood supply MH - Treatment Outcome MH - Ultrasonography EDAT- 2005/03/10 09:00 MHDA- 2005/07/15 09:00 CRDT- 2005/03/10 09:00 PHST- 2004/01/22 00:00 [received] PHST- 2004/05/12 00:00 [accepted] PHST- 2005/03/10 09:00 [pubmed] PHST- 2005/07/15 09:00 [medline] PHST- 2005/03/10 09:00 [entrez] AID - 10.1007/s00167-004-0549-x [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2005 Mar;13(2):74-80. doi: 10.1007/s00167-004-0549-x. Epub 2004 Nov 26. PMID- 3392821 OWN - NLM STAT- MEDLINE DCOM- 19880818 LR - 20170214 IS - 0148-6071 (Print) IS - 0148-6071 (Linking) VI - 12 IP - 3 DP - 1988 May-Jun TI - Infusion of a branched-chain amino acid-enriched solution and alpha-ketoisocaproic acid in septic rats: effects on nitrogen balance and skeletal muscle protein turnover. PG - 244-9 AB - Sepsis was induced by cecal ligation and puncture in male Sprague-Dawley rats weighing approximately 70 g and the animals were intravenously infused with one of four isocaloric solutions: group I (N = 16), 8.5% dextrose solution; group II (N = 16), alpha-ketoisocaproic acid (KIA, 5.1 mg/ml) in 8.5% dextrose; group III (N = 16), FreAmine HBC (containing 45% branched-chain amino acids) in 2.5% dextrose; and group IV (N = 17), FreAmine HBC in 2.5% dextrose + KIA (5.1 mg/ml). Eighteen hr after induction of sepsis, extensor digitorum longus (EDL) and soleus (SOL) muscles were dissected with intact tendons and incubated for the study of protein synthesis and degradation, which were measured as incorporation of 14C-phenylalanine into protein and release of tyrosine into incubation medium, respectively. Urine was collected for determination of nitrogen balance. Nitrogen balance, which was equally negative in groups I and II, was significantly improved in groups III and IV and became equally positive in these groups. Protein synthesis and degradation rates in incubated EDL and SOL muscles were similar to those which we have reported previously in septic rats. Except for a higher synthetic rate in SOL in group II, no other differences in protein synthesis or degradation rates between the four experimental groups were found. Thus, the present study showed that infusion of a branched-chain amino acid-enriched solution improved nitrogen balance in septic rats. KIA alone or administered with the amino acid solution did not affect nitrogen balance.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Hasselgren, P O AU - Hasselgren PO AD - Dept. of Surgery, University of Cincinnati Medical Center, OH 45267-0558. FAU - LaFrance, R AU - LaFrance R FAU - Pedersen, P AU - Pedersen P FAU - James, J H AU - James JH FAU - Fischer, J E AU - Fischer JE LA - eng PT - Journal Article PL - United States TA - JPEN J Parenter Enteral Nutr JT - JPEN. Journal of parenteral and enteral nutrition JID - 7804134 RN - 0 (Amino Acids) RN - 0 (Amino Acids, Branched-Chain) RN - 0 (Keto Acids) RN - 0 (Muscle Proteins) RN - 0 (Solutions) RN - 816-66-0 (alpha-ketoisocaproic acid) RN - N762921K75 (Nitrogen) SB - IM MH - Amino Acids/blood MH - Amino Acids, Branched-Chain/administration & dosage/blood/*therapeutic use MH - Animals MH - Infusions, Intravenous MH - Keto Acids/administration & dosage/blood/*therapeutic use MH - Kinetics MH - Male MH - Muscle Proteins/*metabolism MH - Nitrogen/*metabolism MH - Rats MH - Rats, Inbred Strains MH - Sepsis/*drug therapy/metabolism MH - Solutions EDAT- 1988/05/01 00:00 MHDA- 1988/05/01 00:01 CRDT- 1988/05/01 00:00 PHST- 1988/05/01 00:00 [pubmed] PHST- 1988/05/01 00:01 [medline] PHST- 1988/05/01 00:00 [entrez] AID - 10.1177/0148607188012003244 [doi] PST - ppublish SO - JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):244-9. doi: 10.1177/0148607188012003244. PMID- 6469345 OWN - NLM STAT- MEDLINE DCOM- 19841022 LR - 20190821 IS - 0020-1383 (Print) IS - 0020-1383 (Linking) VI - 16 IP - 2 DP - 1984 Sep TI - The relationship between Achilles tendon rupture and serum uric acid level. PG - 94-5 AB - The serum uric acid level of 30 patients with a rupture of the Achilles tendon was compared with that of 30 healthy control subjects matched for age and sex. In patients with a ruptured Achilles tendon the serum uric acid level was significantly higher than in the control subjects. This finding was not dependent on sex or race. It is possible that hyperuricaemia is a contributing factor in rupture of the Achilles tendon and warrants further study. It is suggested that this finding might be related to an adverse effect on the tendon's nutrition. FAU - Dodds, W N AU - Dodds WN FAU - Burry, H C AU - Burry HC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Injury JT - Injury JID - 0226040 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Achilles Tendon/*injuries MH - Adult MH - Europe/ethnology MH - Female MH - Humans MH - Male MH - New Zealand MH - Polynesia/ethnology MH - Rupture, Spontaneous MH - Uric Acid/*blood EDAT- 1984/09/01 00:00 MHDA- 1984/09/01 00:01 CRDT- 1984/09/01 00:00 PHST- 1984/09/01 00:00 [pubmed] PHST- 1984/09/01 00:01 [medline] PHST- 1984/09/01 00:00 [entrez] AID - S0020-1383(84)80006-6 [pii] AID - 10.1016/s0020-1383(84)80006-6 [doi] PST - ppublish SO - Injury. 1984 Sep;16(2):94-5. doi: 10.1016/s0020-1383(84)80006-6. PMID- 8294534 OWN - NLM STAT- MEDLINE DCOM- 19940225 LR - 20190630 VI - 621 IP - 2 DP - 1993 Nov 24 TI - Reversed-phase high-performance liquid chromatographic analysis of hydroxyproline and proline from collagen by derivatization with dabsyl chloride. PG - 133-8 AB - A high-performance liquid chromatographic method for the analysis of hydroxyproline and proline has been developed. The method is based on the derivatization of the secondary amino group with dabsyl-chloride after blocking of the primary amino group with o-phthalaldehyde. Dabsyl-hydroxyproline and dabsyl-proline were separated from other amino acids by high-performance liquid chromatography in the gradient elution mode, and eluted at 10.27 and 16.02 min, respectively. The correlations between the peak areas of dabsyl-hydroxyproline and dabsyl-proline were linear in the range from 20-200 pmol, with equations y = 1.10x - 0.80 (r = 0.999) and y = 1.12x - 0.52 (r = 0.999), respectively. The method was applied to the analysis of rat tail collagen, and the contents of hydroxyproline and proline were 1.55 +/- 0.04 and 2.03 +/- 0.04 nmol/micrograms, respectively. FAU - Ikeda, M AU - Ikeda M AD - Laboratory of Medical Science, Dokkyo University School of Medicine, Tochigi, Japan. FAU - Sorimachi, K AU - Sorimachi K FAU - Akimoto, K AU - Akimoto K FAU - Yasumura, Y AU - Yasumura Y LA - eng PT - Journal Article PL - Netherlands TA - J Chromatogr JT - Journal of chromatography JID - 0427043 RN - 0 (Indicators and Reagents) RN - 56512-49-3 (4-N,N-dimethylaminoazobenzene-4'-sulfonyl chloride) RN - 643-79-8 (o-Phthalaldehyde) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - A49L8E13FD (p-Dimethylaminoazobenzene) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Chromatography, High Pressure Liquid/*methods MH - Collagen/*analysis MH - Hydrogen-Ion Concentration MH - Hydroxyproline/*analysis MH - Indicators and Reagents MH - Proline/*analysis MH - Rats MH - Tail MH - Tendons/chemistry MH - o-Phthalaldehyde/administration & dosage/pharmacology MH - p-Dimethylaminoazobenzene/*analogs & derivatives EDAT- 1993/11/24 00:00 MHDA- 1993/11/24 00:01 CRDT- 1993/11/24 00:00 PHST- 1993/11/24 00:00 [pubmed] PHST- 1993/11/24 00:01 [medline] PHST- 1993/11/24 00:00 [entrez] AID - 10.1016/0378-4347(93)80088-l [doi] PST - ppublish SO - J Chromatogr. 1993 Nov 24;621(2):133-8. doi: 10.1016/0378-4347(93)80088-l. PMID- 29182386 OWN - NLM STAT- MEDLINE DCOM- 20180321 LR - 20181202 IS - 1943-5681 (Electronic) IS - 0002-9645 (Linking) VI - 78 IP - 12 DP - 2017 Dec TI - In vivo evaluation of effects of sedation on results of acoustoelastography of the superficial digital flexor tendons in clinically normal horses. PG - 1421-1425 LID - 10.2460/ajvr.78.12.1421 [doi] AB - OBJECTIVE To assess the effects of sedation on results of acoustoelastography of the superficial digital flexor tendons (SDFTs) in clinically normal horses. ANIMALS 27 clinically normal horses. PROCEDURES For each horse, the pathology index (PI) for the SDFT of each thoracic limb was determined by use of acoustoelastography at 4 locations (5, 10, 15, and 20 cm distal to the accessory carpal bone). Horses were evaluated before and after they were sedated with a combination of detomidine hydrochloride (0.01 mg/kg, IV) and butorphanol tartrate (0.01 mg/kg, IV). A repeated-measures ANOVA was used for statistical analysis. RESULTS Overall, the PI was lower after sedation than before sedation. In addition, the PI was lower at more distal locations than at more proximal locations. There was not a significant effect of limb (left or right). Differences among individual horses accounted for the largest variance effect. CONCLUSIONS AND CLINICAL RELEVANCE Sedation with detomidine and butorphanol facilitated acoustoelastography; however, it decreased the SDFT PI in clinically normal horses and should be used consistently in prospective studies. Variance associated with each individual horse in the sample population had the greatest effect on the PI. FAU - De Gasperi, Diego AU - De Gasperi D FAU - Dzierzak, Samantha L AU - Dzierzak SL FAU - Muir, Peter AU - Muir P FAU - Vanderby, Ray Jr AU - Vanderby R Jr FAU - Brounts, Sabrina H AU - Brounts SH LA - eng PT - Clinical Trial PT - Journal Article PL - United States TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Hypnotics and Sedatives) RN - 0 (Imidazoles) RN - 7N8K34P2XH (detomidine) RN - QV897JC36D (Butorphanol) SB - IM MH - Animals MH - Butorphanol/*pharmacology MH - Elasticity Imaging Techniques/methods/*veterinary MH - Female MH - Forelimb/drug effects MH - *Horses MH - Hypnotics and Sedatives/*pharmacology MH - Imidazoles/administration & dosage/*pharmacology MH - Male MH - Prospective Studies MH - Tendons/*diagnostic imaging/*drug effects EDAT- 2017/11/29 06:00 MHDA- 2018/03/22 06:00 CRDT- 2017/11/29 06:00 PHST- 2017/11/29 06:00 [entrez] PHST- 2017/11/29 06:00 [pubmed] PHST- 2018/03/22 06:00 [medline] AID - 10.2460/ajvr.78.12.1421 [doi] PST - ppublish SO - Am J Vet Res. 2017 Dec;78(12):1421-1425. doi: 10.2460/ajvr.78.12.1421. PMID- 17277302 OWN - NLM STAT- MEDLINE DCOM- 20070320 LR - 20191210 IS - 0042-4900 (Print) IS - 0042-4900 (Linking) VI - 160 IP - 5 DP - 2007 Feb 3 TI - Effect of infusion of 60 mg/kg oxytetracycline on forelimb flexor tendon contracture in calves. PG - 166-7 FAU - Metzner, M AU - Metzner M AD - Clinic for Ruminants, University of Munich, Sonnenstrasse 16, 85764 Oberschleissheim, Germany. FAU - Baumgart, I AU - Baumgart I FAU - Klee, W AU - Klee W LA - eng PT - Evaluation Study PT - Journal Article PL - England TA - Vet Rec JT - The Veterinary record JID - 0031164 RN - 0 (Anti-Bacterial Agents) RN - X20I9EN955 (Oxytetracycline) SB - IM MH - Animals MH - Animals, Newborn MH - Anti-Bacterial Agents/administration & dosage/*therapeutic use MH - Cattle MH - Cattle Diseases/*drug therapy/pathology MH - Contracture/drug therapy/*veterinary MH - Female MH - *Forelimb/pathology MH - Infusions, Intravenous/veterinary MH - Male MH - Oxytetracycline/administration & dosage/*therapeutic use MH - Range of Motion, Articular MH - *Tendons/pathology EDAT- 2007/02/06 09:00 MHDA- 2007/03/21 09:00 CRDT- 2007/02/06 09:00 PHST- 2007/02/06 09:00 [pubmed] PHST- 2007/03/21 09:00 [medline] PHST- 2007/02/06 09:00 [entrez] AID - 160/5/166 [pii] AID - 10.1136/vr.160.5.166 [doi] PST - ppublish SO - Vet Rec. 2007 Feb 3;160(5):166-7. doi: 10.1136/vr.160.5.166. PMID- 16199947 OWN - NLM STAT- MEDLINE DCOM- 20051115 LR - 20220317 IS - 0271-6798 (Print) IS - 0271-6798 (Linking) VI - 25 IP - 5 DP - 2005 Sep-Oct TI - Responsiveness and uniqueness of the pediatric outcomes data collection instrument compared to the gross motor function measure for measuring orthopaedic and neurosurgical outcomes in cerebral palsy. PG - 641-5 AB - The Pediatrics Outcomes Data Collection Instrument (PODCI) is a valid and reliable measure of functional health status in children with acute and chronic musculoskeletal disorders, including cerebral palsy (CP), but its responsiveness has not been documented specifically for this population. The Gross Motor Function Measure (GMFM) and the Pediatric Evaluation of Disability Inventory (PEDI) are the only two instruments validated specifically as evaluative measures for CP, and while widely used, they are limited by a ceiling effect when assessing higher-functioning children. The PEDI is further restricted to children who are 7 years old or less. The goal of this study was to evaluate the responsiveness, and secondarily the uniqueness, of the PODCI compared with the GMFM for evaluating surgical outcomes in CP. Changes in the GMFM and PODCI Parent forms were assessed at two time points in 64 children with spastic CP who underwent muscle-tendon lengthenings (MT; n = 22) or neurosurgical spasticity reduction consisting of either selective dorsal rhizotomy (SDR; n = 18) or intrathecal baclofen pump implantation (ITB; n = 11) or who had no surgery between assessments (n = 13). The GMFM Total score was responsive to change after both MT surgery and SDR, with a nearly equivalent magnitude of change in both groups. However, the PODCI Global Function Scale was responsive to changes only after MT surgery, with improvement in the Sports and Physical Function subscale particularly prominent. No significant changes were noted in the ITB group for either measure. FAU - Damiano, Diane L AU - Damiano DL AD - Department of Neurology, Washington University, St Louis, MO 63110, USA. damianod@neuro.wustl.edu FAU - Gilgannon, Marc D AU - Gilgannon MD FAU - Abel, Mark F AU - Abel MF LA - eng GR - 5R29HD36516-5/HD/NICHD NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Pediatr Orthop JT - Journal of pediatric orthopedics JID - 8109053 RN - 0 (Muscle Relaxants, Central) RN - H789N3FKE8 (Baclofen) SB - IM MH - Adolescent MH - Adult MH - Baclofen/administration & dosage MH - Cerebral Palsy/*complications/surgery MH - Child MH - Child, Preschool MH - Disability Evaluation MH - Health Status MH - Humans MH - Muscle Relaxants, Central/administration & dosage MH - Muscle Spasticity/complications/physiopathology/*therapy MH - Muscle, Skeletal/physiopathology/surgery MH - Reproducibility of Results MH - Rhizotomy MH - *Surveys and Questionnaires/standards MH - Tendons/surgery MH - *Treatment Outcome EDAT- 2005/10/04 09:00 MHDA- 2005/11/16 09:00 CRDT- 2005/10/04 09:00 PHST- 2005/10/04 09:00 [pubmed] PHST- 2005/11/16 09:00 [medline] PHST- 2005/10/04 09:00 [entrez] AID - 01241398-200509000-00016 [pii] AID - 10.1097/01.bpo.0000167079.83835.22 [doi] PST - ppublish SO - J Pediatr Orthop. 2005 Sep-Oct;25(5):641-5. doi: 10.1097/01.bpo.0000167079.83835.22. PMID- 10231101 OWN - NLM STAT- MEDLINE DCOM- 19990616 LR - 20220408 IS - 0749-8063 (Print) IS - 0749-8063 (Linking) VI - 15 IP - 3 DP - 1999 Apr TI - Internal impingement of the shoulder: comparison of findings between the throwing and nonthrowing shoulders of college baseball players. PG - 253-8 AB - The authors evaluated and compared the findings of gadolinium-enhanced magnetic resonance imaging (MRI) studies of throwing and nonthrowing shoulders in college baseball athletes and contrasted these findings with the clinical examination results. Ten throwing college baseball athletes were prospectively clinically examined for instability, range of motion, impingement signs, and relocation testing, then evaluated with bilateral gadolinium enhanced MRI using the nonthrowing shoulder as a control. All MRIs were performed on a 1.5-Tesla magnet and included routine adduction images and images obtained in abduction and external rotation (ABER). Studies were interpreted by a musculoskeletal radiologist and an orthopaedic surgeon specializing in shoulder surgery. In all shoulders, ABER imaging showed physical contact between the undersurface of the rotator cuff and the posterior superior glenoid. No imaging or physical examination abnormalities were identified in the nonthrowing shoulders. Three of 10 throwing shoulders had superior labral tears and adjacent paralabral cysts extending toward or into the spinoglenoid notch. Four of 10 throwing shoulders had abnormal signal change in the rotator cuff tendons. No correlation was identified between positive MRI findings and instability on physical examination. Physical contact between the rotator cuff undersurface and the subjacent labrum can be seen normally in the ABER position. Abnormalities of the rotator cuff and superior labrum are seen in asymptomatic throwing shoulders but not nonthrowing shoulders. MRI abnormalities consistent with internal impingement can be seen in asymptomatic patients. Treatment of these abnormalities in young throwing athletes should be approached with caution. FAU - Halbrecht, J L AU - Halbrecht JL AD - California Pacific Medical Center, San Francisco 94115, USA. FAU - Tirman, P AU - Tirman P FAU - Atkin, D AU - Atkin D LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Contrast Media) RN - K2I13DR72L (Gadolinium DTPA) SB - IM MH - Adult MH - *Baseball MH - Contrast Media/administration & dosage MH - Follow-Up Studies MH - Gadolinium DTPA/administration & dosage MH - Humans MH - Injections, Intravenous MH - Magnetic Resonance Imaging MH - Male MH - Prospective Studies MH - *Range of Motion, Articular MH - Rotator Cuff/pathology/physiopathology MH - Shoulder Impingement Syndrome/*diagnosis/physiopathology MH - Shoulder Joint/pathology/physiopathology EDAT- 1999/05/07 00:00 MHDA- 1999/05/07 00:01 CRDT- 1999/05/07 00:00 PHST- 1999/05/07 00:00 [pubmed] PHST- 1999/05/07 00:01 [medline] PHST- 1999/05/07 00:00 [entrez] AID - S074980639900033X [pii] AID - 10.1016/s0749-8063(99)70030-7 [doi] PST - ppublish SO - Arthroscopy. 1999 Apr;15(3):253-8. doi: 10.1016/s0749-8063(99)70030-7. PMID- 7721555 OWN - NLM STAT- MEDLINE DCOM- 19950525 LR - 20061115 IS - 0021-2180 (Print) IS - 0021-2180 (Linking) VI - 31 IP - 4 DP - 1995 Apr TI - The relativity of biocompatibility. A critique of the concept of biocompatibility. PG - 203-9 AB - The concept of biocompatibility of the materials used in surgical reconstruction of joints, ligaments, and tendons is controversial, as evinced by the conflicting definitions proposed by the many authors who have studied the host reaction to the presence of implants and their breakdown products. We propose that biocompatibility of contemporary medical implants is not a property of the chemical composition of the biomaterials but depends rather on their physical attributes. The histological reaction patterns of tissue to the presence of polyethylene in diverse physical states are described. The inflammatory response evoked by the implants is laudable in so far as it precedes and accompanies the adequate tissular incorporation of the devices used. On the other hand, the granulomatous reaction induced by small, irregularly shaped and edgy breakdown products adversely affects the life span of the implants. Thus the manner in which the host handles the biomaterials is determined primarily by the physical state of the biomaterials (rather than their chemical composition), which in turn determines the success or failure of reconstructive surgery. It logically follows that biocompatibility constitutes a relativistic concept. FAU - Boss, J H AU - Boss JH AD - Department of Pathology, Bnai Zion Medical Center, Haifa, Israel. FAU - Shajrawi, I AU - Shajrawi I FAU - Aunullah, J AU - Aunullah J FAU - Mendes, D G AU - Mendes DG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Israel TA - Isr J Med Sci JT - Israel journal of medical sciences JID - 0013105 RN - 0 (Biocompatible Materials) RN - 0 (Bone Cements) RN - 0 (Polyethylenes) SB - IM MH - Animals MH - *Biocompatible Materials MH - Bone Cements/adverse effects MH - Granuloma, Foreign-Body/*etiology/pathology MH - Humans MH - Joint Diseases/*surgery MH - Joint Prosthesis/adverse effects MH - Ligaments, Articular/*surgery MH - Macrophages/pathology MH - Polyethylenes/*adverse effects MH - Prostheses and Implants/*adverse effects MH - Prosthesis Failure MH - Reoperation MH - Synovitis/etiology/pathology MH - Tendons/*surgery EDAT- 1995/04/01 00:00 MHDA- 1995/04/01 00:01 CRDT- 1995/04/01 00:00 PHST- 1995/04/01 00:00 [pubmed] PHST- 1995/04/01 00:01 [medline] PHST- 1995/04/01 00:00 [entrez] PST - ppublish SO - Isr J Med Sci. 1995 Apr;31(4):203-9. PMID- 351418 OWN - NLM STAT- MEDLINE DCOM- 19780828 LR - 20190617 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 273 IP - 5665 DP - 1978 Jun 29 TI - Prostacyclin is a circulating hormone. PG - 767-8 FAU - Moncada, S AU - Moncada S FAU - Korbut, R AU - Korbut R FAU - Bunting, S AU - Bunting S FAU - Vane, J R AU - Vane JR LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Antibodies) RN - 0 (Prostaglandins) RN - DCR9Z582X0 (Epoprostenol) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Antibodies MH - Antigen-Antibody Reactions MH - Aspirin/pharmacology MH - *Blood Coagulation/drug effects MH - Epoprostenol/*blood/immunology MH - Lung/metabolism MH - Organ Size MH - *Platelet Aggregation/drug effects MH - Prostaglandins/*blood MH - Rabbits MH - Tendons/anatomy & histology/blood supply EDAT- 1978/06/29 00:00 MHDA- 1978/06/29 00:01 CRDT- 1978/06/29 00:00 PHST- 1978/06/29 00:00 [pubmed] PHST- 1978/06/29 00:01 [medline] PHST- 1978/06/29 00:00 [entrez] AID - 10.1038/273767a0 [doi] PST - ppublish SO - Nature. 1978 Jun 29;273(5665):767-8. doi: 10.1038/273767a0. PMID- 21572279 OWN - NLM STAT- MEDLINE DCOM- 20110915 LR - 20131121 IS - 1539-2570 (Electronic) IS - 0271-6798 (Linking) VI - 31 IP - 4 DP - 2011 Jun TI - Distraction osteogenesis-induced muscle fibrosis may not be associated with TGF-β1. PG - 413-20 LID - 10.1097/BPO.0b013e31821adc8d [doi] AB - BACKGROUND: Transforming growth factor-β 1 (TGF-β1) participates in the synthesis and deposition of collagen. It has been implicated in fibrosis of tendons in wound-healing models but has never been studied in muscles with respect to distraction osteogenesis. METHODS: Using a rabbit model of distraction osteogenesis, we distracted the left tibias of 36 New Zealand white rabbits at 0.75 mm/d for 20 days. To determine whether suramin, an antagonist of TGF-β, could aid in the prevention of fibrosis, we injected it into the anterior tibialis muscle [12 rabbits received low-dose suramin (50 mg), 12 received high-dose suramin (100 mg), and 12 received sham injections]. Half of each group was killed at the end of distraction (day 24) and the other half at day 60. At the time of killing the rabbits, joint range of motion was measured, and strength and morphometric measures of the muscle were taken. Muscle was harvested and immunolabeled for TGF-β1. All findings were compared between study limbs and control (right) limbs. RESULTS: The comparison failed to demonstrate improvements in the range of motion, and in strength or morphometric muscle development. Immunolabeling for TGF-β1 failed to show any staining in the intramuscular fibrosis. Paradoxically, muscle injected with high-dose suramin had the highest degree of fibrosis. CONCLUSIONS: We conclude that TGF-β1 may not be the primary mediator of muscle fibrosis in distraction osteogenesis. CLINICAL RELEVANCE: Injection of suramin may not prevent contracture formation after distraction osteogenesis. FAU - Koplin, Stephanie Ann AU - Koplin SA AD - Department of Pathology, University of Wisconsin School of Medicine and Public Health, Highland Avenue, Madison, WI 53215, USA. stephanie.koplin@aurora.org FAU - Su, Lillian AU - Su L FAU - Salamat, Shahriar AU - Salamat S FAU - Torrealba, Jose AU - Torrealba J FAU - McCarthy, James AU - McCarthy J FAU - Mitchell, Jean AU - Mitchell J FAU - Olabisi, Ronke AU - Olabisi R FAU - Noonan, Kenneth J AU - Noonan KJ LA - eng PT - Journal Article PL - United States TA - J Pediatr Orthop JT - Journal of pediatric orthopedics JID - 8109053 RN - 0 (Transforming Growth Factor beta1) RN - 6032D45BEM (Suramin) SB - IM MH - Animals MH - Ankle Joint/*pathology MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Fibrosis MH - Immunohistochemistry MH - Muscle, Skeletal/*pathology MH - Osteogenesis, Distraction/*adverse effects/methods MH - Postoperative Complications/etiology MH - Rabbits MH - Range of Motion, Articular MH - Suramin/administration & dosage/pharmacology MH - Transforming Growth Factor beta1/antagonists & inhibitors/*metabolism EDAT- 2011/05/17 06:00 MHDA- 2011/09/16 06:00 CRDT- 2011/05/17 06:00 PHST- 2011/05/17 06:00 [entrez] PHST- 2011/05/17 06:00 [pubmed] PHST- 2011/09/16 06:00 [medline] AID - 01241398-201106000-00009 [pii] AID - 10.1097/BPO.0b013e31821adc8d [doi] PST - ppublish SO - J Pediatr Orthop. 2011 Jun;31(4):413-20. doi: 10.1097/BPO.0b013e31821adc8d. PMID- 6622669 OWN - NLM STAT- MEDLINE DCOM- 19831123 LR - 20161123 IS - 0033-832X (Print) IS - 0033-832X (Linking) VI - 23 IP - 8 DP - 1983 Aug TI - [The spine and polytopic hyperostoses in gout and hyperuricemia]. PG - 371-4 AB - Investigations were made on a total of 92 patients with gout and hyperuricemia. 30% had no clinical signs of spinal involvement. The remaining 70% were examined radiologically and by xero-radiography. Examination revealed signs of erosion of vertebral bodies, spondylodiscitis, osteopenia, manifestations of Forestier's disease and changes on sacroiliac joints. In 35% of subjects there were polytopic hyperostoses including an increased incidence of calcifications around the large joints and periosteal appositions at the periphery, particularly on the finger and toe tips. The hypothesis was raised that massive calcifications and manifestations of hyperostosis and ossification of the ligaments and tendons (osteodesmosis) in gout may correlate with a latent glycide metabolism disorder like in Forestier's disease. FAU - Stĕpán, J AU - Stĕpán J FAU - Sváb, V AU - Sváb V FAU - Kolár, J AU - Kolár J FAU - Susta, A AU - Susta A FAU - Cáp, F AU - Cáp F LA - ger PT - Journal Article TT - Die Wirbelsäule und polytope Hyperostosen bei Gicht und Hyperurikämie. PL - Germany TA - Radiologe JT - Der Radiologe JID - 0401257 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Female MH - Gout/*diagnosis MH - Humans MH - Male MH - Middle Aged MH - Spinal Osteophytosis/*diagnostic imaging MH - Uric Acid/*blood MH - Xeroradiography EDAT- 1983/08/01 00:00 MHDA- 1983/08/01 00:01 CRDT- 1983/08/01 00:00 PHST- 1983/08/01 00:00 [pubmed] PHST- 1983/08/01 00:01 [medline] PHST- 1983/08/01 00:00 [entrez] PST - ppublish SO - Radiologe. 1983 Aug;23(8):371-4. PMID- 16722279 OWN - NLM STAT- MEDLINE DCOM- 20060630 LR - 20181113 IS - 0003-3006 (Print) IS - 0003-3006 (Linking) VI - 53 IP - 1 DP - 2006 Spring TI - Uvular edema secondary to snoring under deep sedation. PG - 13-6 AB - A 57-year-old male with a documented history of obstructive sleep apnea with loud snoring received deep intravenous sedation with midazolam, fentanyl, ketamine, and propofol infusion and a left interscalene brachial plexus nerve block for a left biceps tendon repair. Loud snoring during the case was noted. On the second postoperative day, he was observed to have significant uvular edema. After due consideration of the various elements in the differential diagnosis, it was concluded that negative pressure trauma from deep snoring during the sedation was the most likely etiology. FAU - Miller, Robert J AU - Miller RJ AD - Department of Surgery, Wright State University, Dayton, Ohio, USA. FAU - Gerhardt, Mark A AU - Gerhardt MA LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Anesth Prog JT - Anesthesia progress JID - 0043533 RN - 0 (Anesthetics, Dissociative) RN - 0 (Anesthetics, Intravenous) RN - 0 (Hypnotics and Sedatives) RN - 690G0D6V8H (Ketamine) RN - R60L0SM5BC (Midazolam) RN - UF599785JZ (Fentanyl) RN - YI7VU623SF (Propofol) MH - Anesthetics, Dissociative/administration & dosage MH - Anesthetics, Intravenous/administration & dosage MH - Arm MH - Brachial Plexus MH - Edema/*etiology MH - Fentanyl/administration & dosage MH - Humans MH - Hypnotics and Sedatives/*administration & dosage MH - Ketamine/administration & dosage MH - Male MH - Midazolam/administration & dosage MH - Middle Aged MH - Nerve Block MH - *Postoperative Complications MH - Propofol/administration & dosage MH - Sleep Apnea, Obstructive/complications MH - Snoring/*complications MH - Tendons/surgery MH - Uvula/*pathology PMC - PMC1586864 EDAT- 2006/05/26 09:00 MHDA- 2006/07/01 09:00 PMCR- 2006/09/01 CRDT- 2006/05/26 09:00 PHST- 2006/05/26 09:00 [pubmed] PHST- 2006/07/01 09:00 [medline] PHST- 2006/05/26 09:00 [entrez] PHST- 2006/09/01 00:00 [pmc-release] AID - 10.2344/0003-3006(2006)53[13:UESTSU]2.0.CO;2 [doi] PST - ppublish SO - Anesth Prog. 2006 Spring;53(1):13-6. doi: 10.2344/0003-3006(2006)53[13:UESTSU]2.0.CO;2. PMID- 3976557 OWN - NLM STAT- MEDLINE DCOM- 19850402 LR - 20180330 IS - 0002-9165 (Print) IS - 0002-9165 (Linking) VI - 41 IP - 3 DP - 1985 Mar TI - Effects of supplemental pantothenic acid on wound healing: experimental study in rabbit. PG - 578-89 AB - The effect of pantothenic acid supplementation and deficiency on wound healing was investigated over a one month postoperative period in rabbits. The supplemented group was injected with pentothenate (20 mg/kg of body weight/24 h) for three weeks and compared to a placebo group (0.5 ml of distilled water). Deficient animals were fed with a pantothenate free diet also for three weeks. These three experimental groups were matched against a control group. The degree of wound healing was determined by the mean of postoperative breaking strength and wound fibroblast population changes. Pantothenic acid urinary excretion measured by gas chromatography served as control of pantothenate consumption. With regard to these three parameters no significant difference has been found between placebo and controls. The average urinary elimination in the pantothenic acid group was significantly higher as far as the pantothenate supplemented group was concerned, while the deficient group showed no significant decrease when compared to controls. Chronic pre- and postoperative pantothenic acid supplementation significantly increased aponeurosis strength after surgery; it improved slightly, but not significantly the strength of the skin. Furthermore, the fibroblast content of the scar became significantly greater during the fibroblast proliferation phase after pantothenic supplementation. These data suggest that pantothenic acid induces an accelerating effect of the normal healing process. The mechanism responsible for this improvement seems to be an increase in cellular multiplication during the first postoperative period. But the exact intimate mechanism of the beneficial effect of pantothenate remains unclear. FAU - Aprahamian, M AU - Aprahamian M FAU - Dentinger, A AU - Dentinger A FAU - Stock-Damgé, C AU - Stock-Damgé C FAU - Kouassi, J C AU - Kouassi JC FAU - Grenier, J F AU - Grenier JF LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Clin Nutr JT - The American journal of clinical nutrition JID - 0376027 RN - 19F5HK2737 (Pantothenic Acid) SB - IM MH - Animals MH - Body Weight MH - Cell Count MH - Drug Resistance MH - Female MH - Fibroblasts/cytology MH - Male MH - Pantothenic Acid/*pharmacology/urine MH - Rabbits MH - Skin/cytology MH - Tendons/cytology MH - Tensile Strength MH - Wound Healing/*drug effects EDAT- 1985/03/01 00:00 MHDA- 1985/03/01 00:01 CRDT- 1985/03/01 00:00 PHST- 1985/03/01 00:00 [pubmed] PHST- 1985/03/01 00:01 [medline] PHST- 1985/03/01 00:00 [entrez] AID - 10.1093/ajcn/41.3.578 [doi] PST - ppublish SO - Am J Clin Nutr. 1985 Mar;41(3):578-89. doi: 10.1093/ajcn/41.3.578. PMID- 19609505 OWN - NLM STAT- MEDLINE DCOM- 20100513 LR - 20220311 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 18 IP - 1 DP - 2010 Jan TI - Tibial tunnel widening after bioresorbable poly-lactide calcium carbonate interference screw usage in ACL reconstruction. PG - 79-84 LID - 10.1007/s00167-009-0865-2 [doi] AB - Developing bio-absorbable interference screws for anterior cruciate ligament (ACL) reconstruction has proven to be a challenging task. The aim of this study was to investigate the osteogenetic response of poly-lactide carbonate (PLC) interference screws in ACL reconstruction in humans. Ten patients (median age, 28 years) underwent arthroscopic ACL reconstruction with semitendinosus/gracilis tendon graft and a PLC interference screw. The patients were scanned with a multi-slice CT scanner 2 weeks and 1 year postoperatively. Fourteen days postoperatively a mean tunnel widening of 78% [52%; 110%] was observed. At 1-year follow-up, the mean tunnel widening was 128% [84%; 180%]. No sign of bone replacement or bone ingrowth was observed. Factors such as accelerated rehabilitation, micro-motions, and early screw degradation might be responsible for this large tunnel widening. Our results demonstrate the difficulty in translation of preclinical data. This study illustrates the need for extensive preclinical investigation of new materials for clinical purposes. FAU - Foldager, Casper AU - Foldager C AD - Sports Trauma Clinic, Aarhus University Hospital, Aarhus, Denmark. foldager@ki.au.dk FAU - Jakobsen, Bent W AU - Jakobsen BW FAU - Lund, Bent AU - Lund B FAU - Christiansen, Svend Erik AU - Christiansen SE FAU - Kashi, Lotte AU - Kashi L FAU - Mikkelsen, Lone R AU - Mikkelsen LR FAU - Lind, Martin AU - Lind M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090716 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Polyesters) RN - 0 (Polymers) RN - 33X04XA5AT (Lactic Acid) RN - 459TN2L5F5 (poly(lactide)) RN - H0G9379FGK (Calcium Carbonate) SB - IM MH - Absorbable Implants/*adverse effects MH - Adult MH - Anterior Cruciate Ligament/*surgery MH - Anterior Cruciate Ligament Injuries MH - Bone Screws/adverse effects MH - Calcium Carbonate MH - *Equipment Failure MH - Follow-Up Studies MH - Humans MH - Lactic Acid/*adverse effects MH - Middle Aged MH - Orthopedic Procedures/adverse effects/*instrumentation MH - Polyesters MH - Polymers/*adverse effects MH - Tendons/transplantation MH - Tibia/*surgery MH - Transplantation, Autologous MH - Young Adult EDAT- 2009/07/18 09:00 MHDA- 2010/05/14 06:00 CRDT- 2009/07/18 09:00 PHST- 2009/02/15 00:00 [received] PHST- 2009/06/18 00:00 [accepted] PHST- 2009/07/18 09:00 [entrez] PHST- 2009/07/18 09:00 [pubmed] PHST- 2010/05/14 06:00 [medline] AID - 10.1007/s00167-009-0865-2 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2010 Jan;18(1):79-84. doi: 10.1007/s00167-009-0865-2. Epub 2009 Jul 16. PMID- 2696292 OWN - NLM STAT- MEDLINE DCOM- 19900319 LR - 20121115 IS - 0340-1855 (Print) IS - 0340-1855 (Linking) VI - 48 IP - 6 DP - 1989 Nov-Dec TI - [Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint]. PG - 317-22 AB - In an randomised study 30 patients were treated during one week before undergoing an elective surgery of the knee joint with 1 or 2 g respectively of 3% Felbinac gel (biphenylacetic acid gel) or oral 300 mg Fenbufen thrice daily. Biphenylacetic acid (BPAA) is the therapeutically active metabolite of the non-steroid anti-inflammatory drug Fenbufen. Plasma concentrations were measured before, during therapy and at the time of the operation. During the surgery of the knee joint specimens of synovial fluid and -membrane, of cartilage, muscle and tendons as well as of the skin and the subcutaneous fatty tissue were obtained and the BPAA concentrations measured. There was a large variance of the obtained values in all groups. It seems that mainly methodical problems are responsible for this. At the time of surgery, the plasma concentrations following oral administration were with 10,080 ng/ml 20 to 50 times higher than those after topical administration. The tissue concentrations reached 1/8 to 1/2 of the plasma concentrations. The relation of tissue concentrations to plasma concentrations of BPAA was smaller in patients treated with oral administration than in patients treated with topical administration. Therefore a partial direct penetration of Felbinac into the deeper tissue compartments can be assumed. There was no significant difference in plasma-, synovial- or tissue concentrations between the two groups treated with the topical administration. The tissue concentrations were 1 to 2 orders of magnitude lower than those after oral administration. Only in the skin the concentrations were with 9160 respectively 3830 ng/g higher than those obtained after oral application (2110 ng/g). FAU - Bolten, W AU - Bolten W AD - Rheumaklinik II Wiesbaden, Wiesbaden. FAU - Salzmann, G AU - Salzmann G FAU - Goldmann, R AU - Goldmann R FAU - Miehlke, K AU - Miehlke K LA - ger PT - Clinical Trial PT - Comparative Study PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial TT - Plasma- und Gewebekonzentrationen von Biphenylessigsäure nach einwöchiger oraler Fenbufenmedikation bzw. topischer Anwendung von Felbinac-Gel am Kniegelenk. PL - Germany TA - Z Rheumatol JT - Zeitschrift fur Rheumatologie JID - 0414162 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Phenylacetates) RN - 0 (Phenylbutyrates) RN - 51317-25-0 (biphenylylacetic acid) RN - 9815R1WR9B (fenbufen) SB - IM MH - Administration, Oral MH - Administration, Topical MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacokinetics MH - Arthritis, Rheumatoid/*drug therapy MH - Female MH - Humans MH - Knee Joint/*drug effects/metabolism MH - Male MH - Middle Aged MH - Osteoarthritis/*drug therapy MH - Phenylacetates/*administration & dosage/pharmacokinetics MH - Phenylbutyrates/*administration & dosage/pharmacokinetics MH - Randomized Controlled Trials as Topic EDAT- 1989/11/01 00:00 MHDA- 1989/11/01 00:01 CRDT- 1989/11/01 00:00 PHST- 1989/11/01 00:00 [pubmed] PHST- 1989/11/01 00:01 [medline] PHST- 1989/11/01 00:00 [entrez] PST - ppublish SO - Z Rheumatol. 1989 Nov-Dec;48(6):317-22. PMID- 3715908 OWN - NLM STAT- MEDLINE DCOM- 19860716 LR - 20190820 IS - 0041-0101 (Print) IS - 0041-0101 (Linking) VI - 24 IP - 5 DP - 1986 TI - Differential effects of trichothecenes on the canine cardiac action potential. PG - 467-72 AB - We investigated the hypothesis that trichothecenes directly alter cardiac electrical activity. Action potentials were recorded from electrically stimulated canine false tendons before, during and after exposure to trichothecenes (1.0 mg/l). Action potentials recorded prior to and 60 min after exposure to trichothecenes were compared statistically. T-2 toxin decreased resting potentials in interventricular septum cells (7%), decreased action potential durations in papillary muscle cells (19%) and decreased both in false tendon cells (11% and 27%, respectively). Scirpentriol shortened durations of action potentials recorded in false tendon cells (24%), but had no other effects on any of the cell types tested. T-2 tetraol shortened the duration of interventricular septum cell action potentials (35%), but had no significant effects on other cardiac cells. Adenosine-5'-triphosphate (ATP) (final concentration 1100 mg/l) reversed all the effects of the trichothecenes on canine cardiac action potentials. These action potential changes may reflect a deficit of high energy phosphate and directly contribute to trichothecene-induced arrhythmias. FAU - Bubien, J K AU - Bubien JK FAU - Woods, W T Jr AU - Woods WT Jr LA - eng GR - HL 30486/HL/NHLBI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Toxicon JT - Toxicon : official journal of the International Society on Toxinology JID - 1307333 RN - 0 (Sesquiterpenes) RN - 0 (Trichothecenes) RN - 8L70Q75FXE (Adenosine Triphosphate) SB - IM MH - Action Potentials/drug effects MH - Adenosine Triphosphate/pharmacology MH - Animals MH - Dogs MH - Electric Stimulation MH - Female MH - Heart/*drug effects MH - In Vitro Techniques MH - Male MH - Myocardium/cytology MH - Purkinje Fibers/drug effects/physiopathology MH - Sesquiterpenes/*pharmacology MH - Structure-Activity Relationship MH - Trichothecenes/antagonists & inhibitors/*pharmacology EDAT- 1986/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1986/01/01 00:00 [entrez] AID - 0041-0101(86)90078-4 [pii] AID - 10.1016/0041-0101(86)90078-4 [doi] PST - ppublish SO - Toxicon. 1986;24(5):467-72. doi: 10.1016/0041-0101(86)90078-4. PMID- 21782470 OWN - NLM STAT- MEDLINE DCOM- 20120126 LR - 20220409 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 20 IP - 7 DP - 2011 Oct TI - Accuracy of the biceps tendon sheath injection: ultrasound-guided or unguided injection? A randomized controlled trial. PG - 1069-73 LID - 10.1016/j.jse.2011.04.004 [doi] AB - BACKGROUND: Patients often localize pain in the anterior shoulder; however, this patient-localized pain does not necessarily correlate to the location of disease. Unguided shoulder injections are common in clinical practice. The accuracy of unguided biceps tendon sheath injections has not been studied. Patient management may be aided by the knowledge of injection accuracy. This study compared the accuracy of ultrasound-guided biceps tendon sheath injection with unguided injection. MATERIALS AND METHODS: The study comprised 30 patients (30 shoulders) with reported anterior shoulder pain who had a primary diagnosis of tenosynovitis or tendinitis of the biceps tendon, or both. Shoulders were randomly allocated into ultrasound-guided and unguided injection groups. Computed tomography (CT) imaging was performed immediately after a contrast agent was injected into the biceps tendon sheath. The locations of contrast seen on CT scan were classified into 3 types: only within the tendon sheath (type 1); inside the tendon, tendon sheath, and surrounding area (type 2); and only the area outside the tendon sheath (type 3). RESULTS: Ultrasound-guided injections resulted in 86.7% type 1 and 13.3% type 2 locations. Unguided injections resulted in 26.7% type 1, 40.0% type 2, and 33.3% type 3 locations. The difference for each location type was significant (P < .05). CONCLUSION: Injection into the tendon sheath of the long head of the biceps brachii can be more accurately performed using ultrasound guidance than by the blind method. CI - Copyright © 2011 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Mosby, Inc. All rights reserved. FAU - Hashiuchi, Tomohisa AU - Hashiuchi T AD - Department of Orthopaedic Surgery, Nishinara Central Hospital, Nara City, Nara, Japan. thashiuchi@aol.com FAU - Sakurai, Goro AU - Sakurai G FAU - Morimoto, Mitsutoshi AU - Morimoto M FAU - Komei, Tatsuya AU - Komei T FAU - Takakura, Yoshinori AU - Takakura Y FAU - Tanaka, Yasuhito AU - Tanaka Y LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20110722 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anesthetics, Local/*administration & dosage MH - Female MH - Humans MH - Injections, Intra-Articular/methods MH - Lidocaine/*administration & dosage MH - Male MH - Middle Aged MH - Shoulder Joint/*diagnostic imaging MH - Tendinopathy/diagnosis MH - Tendons/*diagnostic imaging MH - Tenosynovitis/diagnosis MH - *Ultrasonography, Interventional EDAT- 2011/07/26 06:00 MHDA- 2012/01/27 06:00 CRDT- 2011/07/26 06:00 PHST- 2010/11/06 00:00 [received] PHST- 2011/03/28 00:00 [revised] PHST- 2011/04/06 00:00 [accepted] PHST- 2011/07/26 06:00 [entrez] PHST- 2011/07/26 06:00 [pubmed] PHST- 2012/01/27 06:00 [medline] AID - S1058-2746(11)00161-3 [pii] AID - 10.1016/j.jse.2011.04.004 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2011 Oct;20(7):1069-73. doi: 10.1016/j.jse.2011.04.004. Epub 2011 Jul 22. PMID- 9795814 OWN - NLM STAT- MEDLINE DCOM- 19981217 LR - 20190515 IS - 0341-2695 (Print) IS - 1432-5195 (Electronic) IS - 0341-2695 (Linking) VI - 22 IP - 4 DP - 1998 TI - Ethanol treatment of tendon allografts: a potential HIV inactivating procedure. PG - 252-4 AB - The penetration rate of ethanol in human tendons was studied to in order to define the conditions which were necessary to achieve an inactivating concentration against the Human Immunodeficiency Virus (HIV) within the tendon. The rate of alcohol penetration was found to be slow and did not differ with different types of tendons. An average ethanol concentration of 14% (v/v) was measured in human tendons after they had been immersed for 2 h in 70% (v/v) ethanol, and a concentration of 19% (v/v) was reached after 3 h. Ethanol immersion of human tendons may represent an additional safety procedure in inactivating the HIV virus provided the duration is at least 3 h. FAU - Anastasescou, M AU - Anastasescou M AD - Orthopaedic Research Laboratory, Catholic University of Louvain, Brussels, Belgium. FAU - Cornu, O AU - Cornu O FAU - Banse, X AU - Banse X FAU - König, J AU - König J FAU - Hassoun, A AU - Hassoun A FAU - Delloye, C AU - Delloye C LA - eng PT - Journal Article PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - 0 (Anti-Infective Agents, Local) RN - 3K9958V90M (Ethanol) SB - IM MH - *Anti-Infective Agents, Local/analysis/pharmacokinetics MH - Drug Evaluation, Preclinical MH - *Ethanol/analysis/pharmacokinetics MH - HIV/*drug effects MH - Humans MH - Infection Control/methods MH - Tendons/chemistry/drug effects/*transplantation/*virology MH - Time Factors MH - Tissue Distribution MH - Tissue Preservation/*methods MH - Transplantation, Homologous PMC - PMC3619604 EDAT- 1998/10/31 00:00 MHDA- 1998/10/31 00:01 PMCR- 1999/09/01 CRDT- 1998/10/31 00:00 PHST- 1998/10/31 00:00 [pubmed] PHST- 1998/10/31 00:01 [medline] PHST- 1998/10/31 00:00 [entrez] PHST- 1999/09/01 00:00 [pmc-release] AID - 80220252.264 [pii] AID - 10.1007/s002640050253 [doi] PST - ppublish SO - Int Orthop. 1998;22(4):252-4. doi: 10.1007/s002640050253. PMID- 3021169 OWN - NLM STAT- MEDLINE DCOM- 19861113 LR - 20190623 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 35 IP - 19 DP - 1986 Oct 1 TI - Demonstration of cellular retinoic acid binding protein (CRABP) in chick embryo tendon cells and effects of retinoids on collagen synthesis in tendon and sterna. PG - 3393-400 AB - The binding of all-trans-retinoic acid (all-trans RA) to specific cytosol proteins and the effects of retinoids on procollagen synthesis were studied in chick-embryo tendon cells. For the receptor assay, tendon cytosols were incubated with [3H]all-trans-RA in the presence or absence of 100-fold excess of nonlabeled all-trans-RA up to 20 hr at +4 degrees and unbound retinoid was removed by charcoal-dextran treatment or by gel filtration chromatography. The results indicated that chick-embryo tendon cells contained cellular retinoic acid binding protein (CRABP). The binding of [3H]all-trans-RA could be displaced by 13-cis-retinoic acid, but not by retinol or etretinate. In contrast no CRABP could be found in cartilage cells isolated from sterna or in whole sterna. The treatment of tendon cytosol with proteases (pronase, trypsin, chymotrypsin) abolished the specific binding of [3H]all-trans-RA. Gel filtration studies on Sephadex G-100 indicated an apparent molecular weight of 14,500-15,000 daltons for the all-trans-retinoic acid binding protein. All-trans-RA markedly decreased procollagen synthesis in isolated chick-embryo tendon cells, the inhibition being concentration dependent; the decrease was about 58% of the control in the presence of 10(-5) M all-trans-RA. Similar decrease was noted with 13-cis-RA and etretinate, while retinol was less effective. In isolated cartilage cells the dose of 10(-5) M of all-trans-retinoic acid decreased drastically total protein and collagen synthesis. The mannosylation of procollagen, the conversion of procollagen to collagen and the size of procollagen chains were not significantly affected. The results of the present study indicate that CRABP is not expressed in sterna of chick-embryos, and in contrast high levels of CRABP could be found in tendons. However, retinoids modulated collagen synthesis in both tissues. Thus it is possible that retinoids can affect the metabolism of different collagen types also in clinical use. FAU - Oikarinen, A I AU - Oikarinen AI FAU - Oikarinen, H AU - Oikarinen H FAU - Uitto, J AU - Uitto J LA - eng GR - AM-28450/AM/NIADDK NIH HHS/United States GR - AM-35297/AM/NIADDK NIH HHS/United States GR - GM-28833/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Carrier Proteins) RN - 0 (Procollagen) RN - 0 (Receptors, Retinoic Acid) RN - 0 (Retinoids) RN - 9007-34-5 (Collagen) RN - PHA4727WTP (Mannose) SB - IM MH - Animals MH - Carrier Proteins/*analysis MH - Cartilage/metabolism MH - Chick Embryo MH - Collagen/*biosynthesis MH - In Vitro Techniques MH - Mannose/metabolism MH - Molecular Weight MH - Procollagen/metabolism MH - Receptors, Retinoic Acid MH - Retinoids/*pharmacology MH - Sternum/*metabolism MH - Tendons/*metabolism EDAT- 1986/10/01 00:00 MHDA- 1986/10/01 00:01 CRDT- 1986/10/01 00:00 PHST- 1986/10/01 00:00 [pubmed] PHST- 1986/10/01 00:01 [medline] PHST- 1986/10/01 00:00 [entrez] AID - 0006-2952(86)90441-7 [pii] AID - 10.1016/0006-2952(86)90441-7 [doi] PST - ppublish SO - Biochem Pharmacol. 1986 Oct 1;35(19):3393-400. doi: 10.1016/0006-2952(86)90441-7. PMID- 20087696 OWN - NLM STAT- MEDLINE DCOM- 20100713 LR - 20221207 IS - 1530-9932 (Electronic) IS - 1530-9932 (Linking) VI - 11 IP - 1 DP - 2010 Mar TI - Ketoprofen absorption by muscle and tendon after topical or oral administration in patients undergoing anterior cruciate ligament reconstruction. PG - 154-8 LID - 10.1208/s12249-009-9367-2 [doi] AB - Topical ketoprofen patches are widely used in the treatment of musculoskeletal pain, but the pharmacokinetics of ketoprofen following topical application remain unclear. This open-label, single-dose pharmacokinetic study was designed to determine the concentrations of ketoprofen in the semitendinosus muscle/tendon and plasma after topical application or oral administration to patients scheduled for anterior cruciate ligament reconstruction. Two ketoprofen patches (20 mg each) were applied over the semitendinosus muscle/tendon for 1, 6, 14, or 20 h before surgery in 21 patients, while one sustained-release 150 mg ketoprofen capsule was administered to six patients 14 h before surgery. Ten untreated patients served as the control group. The main outcome measures were the semitendinosus muscle/tendon and plasma concentrations of ketoprofen at 1, 6, 14, and 20 h. Ketoprofen was detected in the semitendinosus muscle/tendon from about 1 h after topical application. The peak concentration was reached at 6 h, and it decreased gradually until 20 h, although the concentration at 20 h was still higher than that at 1 h. Unlike the tissue concentration, the plasma concentration of ketoprofen increased gradually after topical application. At 14 h, there was no significant difference of the tissue concentration between the topical and oral groups, although the plasma concentration was about 17-fold higher in the oral group than in the topical group. In conclusion, following topical application in a patch, ketoprofen shows rapid and sustained delivery to the underlying tissues without a significant increase of the plasma drug concentration. FAU - Sekiya, Ichiro AU - Sekiya I AD - Section of Cartilage Regeneration, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. sekiya.orj@tmd.ac.jp FAU - Morito, Toshiyuki AU - Morito T FAU - Hara, Kenji AU - Hara K FAU - Yamazaki, Junya AU - Yamazaki J FAU - Ju, Young-Jin AU - Ju YJ FAU - Yagishita, Kazuyoshi AU - Yagishita K FAU - Mochizuki, Tomoyuki AU - Mochizuki T FAU - Tsuji, Kunikazu AU - Tsuji K FAU - Muneta, Takeshi AU - Muneta T LA - eng PT - Journal Article DEP - 20100120 PL - United States TA - AAPS PharmSciTech JT - AAPS PharmSciTech JID - 100960111 RN - 90Y4QC304K (Ketoprofen) SB - IM MH - Absorption MH - Administration, Cutaneous MH - Administration, Oral MH - Administration, Topical MH - Adolescent MH - Adult MH - Anterior Cruciate Ligament/*surgery MH - Arthroscopy MH - Female MH - Humans MH - *Ketoprofen/administration & dosage/pharmacokinetics/therapeutic use MH - Male MH - Middle Aged MH - Muscle, Skeletal/*surgery MH - Muscular Diseases/drug therapy/metabolism/surgery MH - Pain/drug therapy/metabolism/surgery MH - Plastic Surgery Procedures/*methods MH - Tendons/*surgery MH - Young Adult PMC - PMC2850498 EDAT- 2010/01/21 06:00 MHDA- 2010/07/14 06:00 PMCR- 2011/01/20 CRDT- 2010/01/21 06:00 PHST- 2009/06/16 00:00 [received] PHST- 2009/12/09 00:00 [accepted] PHST- 2010/01/21 06:00 [entrez] PHST- 2010/01/21 06:00 [pubmed] PHST- 2010/07/14 06:00 [medline] PHST- 2011/01/20 00:00 [pmc-release] AID - 9367 [pii] AID - 10.1208/s12249-009-9367-2 [doi] PST - ppublish SO - AAPS PharmSciTech. 2010 Mar;11(1):154-8. doi: 10.1208/s12249-009-9367-2. Epub 2010 Jan 20. PMID- 18465958 OWN - NLM STAT- MEDLINE DCOM- 20080820 LR - 20190930 IS - 1083-3668 (Print) IS - 1083-3668 (Linking) VI - 13 IP - 2 DP - 2008 Mar-Apr TI - Quantitative second harmonic generation imaging and modeling of the optical clearing mechanism in striated muscle and tendon. PG - 021109 LID - 10.1117/1.2907207 [doi] AB - We have investigated the mechanisms and capabilities of optical clearing in conjunction with second harmonic generation (SHG) imaging in tendon and striated muscle. Our approach combines three-dimensional (3-D) SHG imaging of the axial attenuation and directional response with Monte Carlo simulation (based on measured bulk optical properties) of the creation intensity and propagation through the tissues. Through these experiments and simulations, we show that reduction of the primary filter following glycerol treatment dominates the axial attenuation response in both muscle and tendon. However, these disparate tissue types are shown to clear through different mechanisms of the glycerol-tissue interaction. In the acellular tendon, glycerol application reduces scattering by both index matching as well as increasing the interfibril separation. This results in an overall enhancement of the 3-D SHG intensity, where good agreement is found between experiment and simulation. Through analysis of the axial response as a function of glycerol concentration in striated muscle, we conclude that the mechanism in this tissue arises from matching of the refractive index of the cytoplasm of the muscle cells with that of the surrounding higher-index collagenous perimysium. We further show that the proportional decrease in the scattering coefficient mu(s) with increasing glycerol fraction can be well-approximated by Mie theory. FAU - LaComb, Ronald AU - LaComb R AD - University of Connecticut Health Center, Department of Cell Biology, Center for Cell Analysis and Modeling, Farmington, Connecticut 06030, USA. FAU - Nadiarnykh, Oleg AU - Nadiarnykh O FAU - Carey, Shawn AU - Carey S FAU - Campagnola, Paul J AU - Campagnola PJ LA - eng GR - EB-01842/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Biomed Opt JT - Journal of biomedical optics JID - 9605853 RN - PDC6A3C0OX (Glycerol) SB - IM MH - Animals MH - Glycerol/*administration & dosage MH - Image Interpretation, Computer-Assisted/*methods MH - Imaging, Three-Dimensional/*methods MH - In Vitro Techniques MH - Mice MH - Muscle, Skeletal/*drug effects/*physiology MH - Refractometry MH - Tendons/*drug effects/*physiology EDAT- 2008/05/10 09:00 MHDA- 2008/08/21 09:00 CRDT- 2008/05/10 09:00 PHST- 2008/05/10 09:00 [pubmed] PHST- 2008/08/21 09:00 [medline] PHST- 2008/05/10 09:00 [entrez] AID - 10.1117/1.2907207 [doi] PST - ppublish SO - J Biomed Opt. 2008 Mar-Apr;13(2):021109. doi: 10.1117/1.2907207. PMID- 28774233 OWN - NLM STAT- MEDLINE DCOM- 20190701 LR - 20190701 IS - 2424-8363 (Electronic) VI - 22 IP - 3 DP - 2017 Sep TI - Disruption of Flexor Tendon after Intrasheath Triamcinolone Acetonide Injection for Trigger Digits: Two Case Reports. PG - 380-383 LID - 10.1142/S0218810417720285 [doi] AB - We experienced two cases of flexor tendons rupture after triamcinolone acetate (TA) injection for trigger finger. A 45-year-old man underwent injection of 40 mg of TA and 1 mL of 1% lidocaine solution into his little finger. While playing golf 3 months after the injection, he heard a popping sound, and was unable to flex it. A 57-year-old female nurse had undergone injection of 40 mg of TA and 1 mL of 1% lidocaine solution into her thumb twice at a 2-month interval. Two months after the second injection, she was unable to flex it. Both cases had high concentrated TA injection at trigger digits. The present and previous cases illustrate that when TA is injected into trigger digits, the dose should be low, the safety interval should be long, and refuse injection into the tendon proper. FAU - Tanaka, Toshikazu AU - Tanaka T AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. FAU - Ogawa, Takeshi AU - Ogawa T AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. FAU - Yanai, Takaji AU - Yanai T AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. FAU - Okano, Eriko AU - Okano E AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. FAU - Kohyama, Sho AU - Kohyama S AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. FAU - Ochiai, Naoyuki AU - Ochiai N AD - 1 Department of Orthopedic Surgery, Kikkoman General Hospital, Chiba, Japan. LA - eng PT - Case Reports PT - Journal Article PL - Singapore TA - J Hand Surg Asian Pac Vol JT - The journal of hand surgery Asian-Pacific volume JID - 101688432 RN - 0 (Glucocorticoids) RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Female MH - Glucocorticoids/*administration & dosage MH - Humans MH - Injections, Intra-Articular MH - Lidocaine/administration & dosage MH - Male MH - Middle Aged MH - Rupture MH - Tendon Injuries/*etiology MH - Triamcinolone Acetonide/*administration & dosage MH - Trigger Finger Disorder/*drug therapy OTO - NOTNLM OT - Disruption OT - Flexor tendon OT - Injection OT - Triamcinolone acetonide OT - Trigger digit EDAT- 2017/08/05 06:00 MHDA- 2019/07/02 06:00 CRDT- 2017/08/05 06:00 PHST- 2017/08/05 06:00 [entrez] PHST- 2017/08/05 06:00 [pubmed] PHST- 2019/07/02 06:00 [medline] AID - 10.1142/S0218810417720285 [doi] PST - ppublish SO - J Hand Surg Asian Pac Vol. 2017 Sep;22(3):380-383. doi: 10.1142/S0218810417720285. PMID- 21851304 OWN - NLM STAT- MEDLINE DCOM- 20111209 LR - 20181201 IS - 0048-0169 (Print) IS - 0048-0169 (Linking) VI - 59 IP - 5 DP - 2011 Sep TI - Probable avulsion of the infraspinatus tendon of insertion in a Rottweiler. PG - 253-7 LID - 10.1080/00480169.2011.596259 [doi] AB - CASE HISTORY: An 8.5-month-old male Rottweiler was presented with chronic, non-localisable, right forelimb lameness. CLINICAL FINDINGS: Survey radiographs revealed panosteitis in the right antebrachium and an irregularly marginated radiolucency on the lateral aspect of the proximal left humerus. The tendon of insertion of the left infraspinatus muscle was enlarged, some tendon fibres ended prematurely in a cluster of mineralised particles, and there was a large bony defect at the point of insertion. DIAGNOSIS: Probable avulsion of the left infraspinatus tendon. CLINICAL RELEVANCE: This case was particularly unusual due to the marked prominence of the lesion without lameness of the left forelimb. Avulsion of the infraspinatus tendon is poorly described in the veterinary and medical literature. FAU - Thompson, D J AU - Thompson DJ AD - Institute of Veterinary, Animal and Biomedical Sciences, Massey University, Private Bag 11222, Palmerston North 4442, New Zealand. d.j.thompson@massey.ac.nz FAU - Leitch, B J AU - Leitch BJ FAU - Hartman, A C AU - Hartman AC FAU - Breshears, L A AU - Breshears LA LA - eng PT - Case Reports PT - Journal Article PL - England TA - N Z Vet J JT - New Zealand veterinary journal JID - 0021406 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Thiazines) RN - 0 (Thiazoles) RN - VG2QF83CGL (Meloxicam) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage MH - Dogs MH - Humerus/*diagnostic imaging/*pathology MH - Lameness, Animal/*diagnosis/drug therapy MH - Male MH - Meloxicam MH - Radiography MH - Tendons/*diagnostic imaging/*pathology MH - Thiazines/administration & dosage MH - Thiazoles/administration & dosage MH - Treatment Outcome EDAT- 2011/08/20 06:00 MHDA- 2011/12/14 06:00 CRDT- 2011/08/20 06:00 PHST- 2011/08/20 06:00 [entrez] PHST- 2011/08/20 06:00 [pubmed] PHST- 2011/12/14 06:00 [medline] AID - 10.1080/00480169.2011.596259 [doi] PST - ppublish SO - N Z Vet J. 2011 Sep;59(5):253-7. doi: 10.1080/00480169.2011.596259. PMID- 38604839 OWN - NLM STAT- MEDLINE DCOM- 20240702 LR - 20240910 IS - 0219-3108 (Electronic) IS - 1015-9584 (Linking) VI - 47 IP - 7 DP - 2024 Jul TI - Carpal tunnel syndrome due to urate crystals in the tendon of flexor carpi radialis: A case report. PG - 3310-3311 LID - S1015-9584(24)00593-1 [pii] LID - 10.1016/j.asjsur.2024.03.166 [doi] FAU - Jin, Hailong AU - Jin H AD - Bone and Hand Microsurgery, Shandong Wendeng Osteopathic Hospital, Weihai, 264400, China. FAU - Ng, Liqi AU - Ng L AD - Institute of Orthopaedic and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital, Stanmore, London, HA7 4LP, UK. FAU - He, Rong AU - He R AD - Bone and Hand Microsurgery, Shandong Wendeng Osteopathic Hospital, Weihai, 264400, China; College of Integrated Chinese and Western Medicin, Changchun University of Chinese Medicine, Changchun, 130117, China. Electronic address: rhe168@126.com. FAU - Zhou, Yu AU - Zhou Y AD - Postdoctoral Research Workstation, Chongqing Orthopedic Hospital of Traditional Chinese Medicine, Chongqing, 400012, China; Orthopedic Laboratory of Chongqing Medical University, Chongqing, 400016, China. Electronic address: zyhenry123@163.com. LA - eng PT - Case Reports PT - Letter DEP - 20240410 PL - Netherlands TA - Asian J Surg JT - Asian journal of surgery JID - 8900600 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Humans MH - *Carpal Tunnel Syndrome/etiology/surgery MH - *Uric Acid/analysis MH - *Tendons MH - Male MH - Middle Aged MH - Gout/complications MH - Crystallization COIS- Declaration of competing interest Declaration of competing interest: The authors declare that they have no conflict of interest. EDAT- 2024/04/12 00:43 MHDA- 2024/07/02 06:42 CRDT- 2024/04/11 21:57 PHST- 2024/02/15 00:00 [received] PHST- 2024/03/18 00:00 [revised] PHST- 2024/03/22 00:00 [accepted] PHST- 2024/07/02 06:42 [medline] PHST- 2024/04/12 00:43 [pubmed] PHST- 2024/04/11 21:57 [entrez] AID - S1015-9584(24)00593-1 [pii] AID - 10.1016/j.asjsur.2024.03.166 [doi] PST - ppublish SO - Asian J Surg. 2024 Jul;47(7):3310-3311. doi: 10.1016/j.asjsur.2024.03.166. Epub 2024 Apr 10. PMID- 32073328 OWN - NLM STAT- MEDLINE DCOM- 20201211 LR - 20201214 IS - 1930-8264 (Electronic) IS - 1930-8264 (Linking) VI - 110 IP - 1 DP - 2020 Jan TI - Gout in the Flexor Hallucis Longus Tendon Mimicking Cellulitis: A Case Report. PG - Article8 LID - 10.7547/18-161 [doi] AB - A 65-year-old Japanese man was admitted to our hospital with fever and inflammation of the right ankle. We initiated antibiotics on suspicion of cellulitis. After no clinical improvement, we performed magnetic resonance imaging, which showed a fluid collection in the flexor hallucis longus (FHL) tendon sheath. Synovial fluid analysis revealed monosodium uric crystals. Final diagnosis was FHL tendonitis secondary to gout proven by synovial fluid analysis. To our knowledge, this is the first case report of FHL tendonitis caused by gout. When ankle inflammation is examined in clinical situations, FHL tendonitis caused by gout should be considered. FAU - Ohnishi, Jun AU - Ohnishi J FAU - Ishimaru, Naoto AU - Ishimaru N FAU - Seto, Hiroyuki AU - Seto H FAU - Kanzawa, Yohei AU - Kanzawa Y FAU - Kinami, Saori AU - Kinami S LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Podiatr Med Assoc JT - Journal of the American Podiatric Medical Association JID - 8501423 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Ankle MH - Cellulitis/*diagnosis MH - Diagnosis, Differential MH - Foot MH - Gout/complications/*diagnosis MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Synovial Fluid/chemistry MH - Tendinopathy/*etiology MH - Tendons/diagnostic imaging MH - Uric Acid/analysis EDAT- 2020/02/20 06:00 MHDA- 2020/12/15 06:00 CRDT- 2020/02/20 06:00 PHST- 2020/02/20 06:00 [entrez] PHST- 2020/02/20 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] AID - 10.7547/18-161 [doi] PST - ppublish SO - J Am Podiatr Med Assoc. 2020 Jan;110(1):Article8. doi: 10.7547/18-161. PMID- 18034669 OWN - NLM STAT- MEDLINE DCOM- 20080215 LR - 20131121 IS - 0767-3981 (Print) IS - 0767-3981 (Linking) VI - 21 IP - 6 DP - 2007 Dec TI - Influence of tetrahydrocurcumin on tail tendon collagen contents and its properties in rats with streptozotocin-nicotinamide-induced type 2 diabetes. PG - 665-71 AB - Changes in the structural and functional properties of collagen caused by advanced glycation might be of importance for the etiology of late-stage complications in diabetics. Curcumin is the most active component of turmeric. It is believed that curcumin is a potent antioxidant and anti-inflammatory agent. Tetrahydrocurcumin (THC) is one of the major metabolites of curcumin, exhibiting many of the same physiological and pharmacological activities of curcumin and in some systems may exert greater antioxidant activity than curcumin. In diabetic rats, hydroxyproline and collagen content as well as its degree of cross-linking were increased, as shown by increased extent of glycation, collagen-linked fluorescence, neutral salt collagen, and decreased acid and pepsin solubility. Administration of THC for 45 days to diabetic rats significantly reduced the accumulation and cross-linking of collagen. The effects of THC were comparable with those of curcumin. In conclusion, administration of THC had a positive influence on the content of collagen and its properties in streptozotocin- and nicotinamide-induced diabetic rats. THC was found to be more effective than curcumin. FAU - Pari, Leelavinothan AU - Pari L AD - Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalai Nagar - 608 002, Tamil Nadu, India. paribalaji@gmail.com FAU - Murugan, Pidaran AU - Murugan P LA - eng PT - Journal Article PL - England TA - Fundam Clin Pharmacol JT - Fundamental & clinical pharmacology JID - 8710411 RN - 00U0645U03 (tetrahydrocurcumin) RN - 25X51I8RD4 (Niacinamide) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) RN - IT942ZTH98 (Curcumin) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Collagen/*analysis MH - Curcumin/*analogs & derivatives/pharmacology/therapeutic use MH - Diabetes Mellitus, Experimental/*drug therapy/metabolism MH - Diabetes Mellitus, Type 2/*drug therapy/metabolism MH - Hydroxyproline/analysis MH - Male MH - Niacinamide MH - Rats MH - Rats, Wistar MH - Streptozocin MH - Tail MH - Tendons/*chemistry EDAT- 2007/11/24 09:00 MHDA- 2008/02/19 09:00 CRDT- 2007/11/24 09:00 PHST- 2007/11/24 09:00 [pubmed] PHST- 2008/02/19 09:00 [medline] PHST- 2007/11/24 09:00 [entrez] AID - FCP542 [pii] AID - 10.1111/j.1472-8206.2007.00542.x [doi] PST - ppublish SO - Fundam Clin Pharmacol. 2007 Dec;21(6):665-71. doi: 10.1111/j.1472-8206.2007.00542.x. PMID- 24752181 OWN - NLM STAT- MEDLINE DCOM- 20141016 LR - 20211021 IS - 1759-4804 (Electronic) IS - 1759-4790 (Linking) VI - 10 IP - 6 DP - 2014 Jun TI - Crystal arthritis: Tendon damage in gout--a role for MSU crystals? PG - 321 LID - 10.1038/nrrheum.2014.65 [doi] FAU - Ray, Katrina AU - Ray K LA - eng PT - Comment PT - Journal Article DEP - 20140422 PL - United States TA - Nat Rev Rheumatol JT - Nature reviews. Rheumatology JID - 101500080 RN - 268B43MJ25 (Uric Acid) SB - IM CON - Ann Rheum Dis. 2014 Sep;73(9):1737-41. doi: 10.1136/annrheumdis-2013-204657. PMID: 24709860 MH - Animals MH - Gout/*pathology MH - Humans MH - Tendons/*drug effects MH - Uric Acid/*pharmacology EDAT- 2014/04/23 06:00 MHDA- 2014/10/17 06:00 CRDT- 2014/04/23 06:00 PHST- 2014/04/23 06:00 [entrez] PHST- 2014/04/23 06:00 [pubmed] PHST- 2014/10/17 06:00 [medline] AID - nrrheum.2014.65 [pii] AID - 10.1038/nrrheum.2014.65 [doi] PST - ppublish SO - Nat Rev Rheumatol. 2014 Jun;10(6):321. doi: 10.1038/nrrheum.2014.65. Epub 2014 Apr 22. PMID- 7443438 OWN - NLM STAT- MEDLINE DCOM- 19810224 LR - 20131121 IS - 0301-1518 (Print) IS - 0301-1518 (Linking) VI - 9 IP - 40 DP - 1980 Oct 30 TI - [Effects of probucol on skin cholesterol concentrations in patients with type II hyperlipoproteineamia (author's transl)]. PG - 2995-3000 AB - Twenty patients (14 male and 6 female) with hyperlipoproteineamia (type IIa in 10 and type IIb in 10) were given probucol 500 mg b.d. during 6 months. Eleven patients had xanthoma tendinosum and 4 had xanthelasma. The mean plasma cholesterol and plasma triglyceride levels were 435 +/- 100 mg/dl and 210 +/- 138 mg/dl respectively. Normal diet was continued throughout. Skin biopsies were performed on the forearm before and after treatment. The skin fragments were freeze-dried, and free (FCh) and esterified (ECh) cholesterol concentrations were measured by gas chromatography after preliminary thin layer chromatography on silica gel. FCh and ECh were found to be significantly increased before treatment when compared with skin concentrations in 10 control subjects; FCh ranged from 2.25 to 1.58 microgram/mg (p < 0.001) and ECh from 0.44 to 0.16 microgram/mg of dry tissue (p < 0.001). After 6 months' treatment with probucol, there was no significant change in FCh (2.25 to 2.16 microgram/mg), but a significant rise was observed in ECh (0.44 to 0.66 microgram/mg; p < 0.01). This effect suggests that probucol interferes with cholesterol synthesis and transport in human tissues, which might help to comprehend the action of this and other drugs on xanthelasma, xanthoma tendinosum and atherosclerosis. In one of the patients, a xanthelasma was considerably reduced in size following probucol treatment. FAU - Beaumont, J L AU - Beaumont JL FAU - Jacotot, B AU - Jacotot B FAU - Buxtorf, J C AU - Buxtorf JC FAU - Meliço-Silvestre, A A AU - Meliço-Silvestre AA FAU - Beaumont, V AU - Beaumont V LA - fre PT - English Abstract PT - Journal Article TT - Effets du probucol sur la teneur en cholestérol de la peau dans les hyperlipoprotéinémies de type II. PL - France TA - Nouv Presse Med JT - La Nouvelle presse medicale JID - 0312552 RN - 0 (Lipids) RN - 0 (Phenols) RN - 97C5T2UQ7J (Cholesterol) RN - P3CTH044XJ (Probucol) SB - IM MH - Adult MH - Cholesterol/*metabolism MH - Female MH - Humans MH - Hyperlipoproteinemia Type II/*drug therapy/metabolism MH - Lipids/blood MH - Male MH - Middle Aged MH - Phenols/*pharmacology MH - Probucol/*pharmacology/therapeutic use MH - Skin/drug effects/*metabolism MH - Tendons MH - Xanthomatosis/drug therapy EDAT- 1980/10/30 00:00 MHDA- 1980/10/30 00:01 CRDT- 1980/10/30 00:00 PHST- 1980/10/30 00:00 [pubmed] PHST- 1980/10/30 00:01 [medline] PHST- 1980/10/30 00:00 [entrez] PST - ppublish SO - Nouv Presse Med. 1980 Oct 30;9(40):2995-3000. PMID- 21722500 OWN - NLM STAT- MEDLINE DCOM- 20110824 LR - 20170112 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 29 IP - 3 DP - 2011 May-Jun TI - Imaging of tophi with an extremity-dedicated MRI system. PG - 519-26 AB - OBJECTIVES: To describe the MRI features of gout tophi in the soft-tissues or joints of the limbs by low-field extremity-dedicated MRI. METHODS: Nine consecutive patients, 8M/1W, affected by chronic tophaceous gout were studied. Mean patients' age was 71.3±11.5 years, mean disease duration 98.1±44.9 months, and mean serum uric acid concentration 9.2±2.8 mg/L. Diagnosis was based on the ACR classification criteria for gout, and by identification of MSU crystals in the tophi and synovial fluid. Conventional radiograms and MRI with an extremity-dedicated system were obtained of the joint areas involved by tophi. RESULTS: At T1 weighted MRI images, all tophi showed a homogeneous intermediate signal intensity, similar to that of muscle. Conversely, in T2 weighted images, a wide spectrum of signal intensity patterns was observed. The pattern of contrast enhancement was variable from intense homogeneous to peripheral and heterogeneous. Capsulo-ligamentous structures were often thickened and degenerated and, on occasion, could be recognised as inhomogeneous, hypointense ribbon-shaped elements in the context of the tophus. In only two cases, tendons were infiltrated by tophaceous matter. Bone marrow oedema (BME) and erosions were seen in 8 out of 10 bones adjacent to tophi. CONCLUSIONS: The MRI appearance of gout tophi using an extremity-dedicated machine is similar to that described in the literature using whole body machines. BME adjacent to the tophus was a frequent finding. This technique may occasionally help in the differential diagnosis of nodules and in the follow-up of the disease. It also represents a useful tool to investigate the pathogenesis of gout and to better understand its clinical progression. FAU - Paparo, F AU - Paparo F AD - Sezione di Diagnostica per Immagini, Dipartimento di Medicina Interna, Università di Genova, Italy. FAU - Zampogna, G AU - Zampogna G FAU - Fabbro, E AU - Fabbro E FAU - Parodi, M AU - Parodi M FAU - Andracco, R AU - Andracco R FAU - Ferrero, G AU - Ferrero G FAU - Garlaschi, G AU - Garlaschi G FAU - Cimmino, M A AU - Cimmino MA LA - eng PT - Journal Article DEP - 20110629 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Aged, 80 and over MH - Bone Marrow/pathology MH - Bone Marrow Diseases/diagnosis/pathology MH - Diagnosis, Differential MH - Edema/diagnosis/pathology MH - Female MH - Gout/blood/*diagnosis/*pathology MH - Humans MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Retrospective Studies MH - Uric Acid/blood EDAT- 2011/07/05 06:00 MHDA- 2011/08/25 06:00 CRDT- 2011/07/05 06:00 PHST- 2010/09/02 00:00 [received] PHST- 2011/02/11 00:00 [accepted] PHST- 2011/07/05 06:00 [entrez] PHST- 2011/07/05 06:00 [pubmed] PHST- 2011/08/25 06:00 [medline] AID - 4300 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2011 May-Jun;29(3):519-26. Epub 2011 Jun 29. PMID- 580153 OWN - NLM STAT- MEDLINE DCOM- 19780417 LR - 20190827 IS - 0001-6683 (Print) IS - 0001-6683 (Linking) VI - 42 IP - 2 DP - 1978 Feb TI - Reversibility of the effects of cyclophosphamide on collagen: biochemical studies on skin and granulation tissue and determination of thermal stability of tail tendons of rats. PG - 103-9 AB - Granulation tissue was produced in rats by subcutaneous implantation of viscose cellulose sponges. Treatment with cyclophosphamide in a dose of 10 mg/kg/day for 14 days caused an increase in acid soluble OH-proline and a decrease in alpha/beta ratio of acid soluble collagen of granulation tissue. Forty-two days of continuous cyclophosphamide treatment caused a decrease in dry weight, in free OH-proline, and in salt soluble OH-proline in granulation tissue. These findings are in accordance with previous observations of a decreased collagen synthesis and an inhibited collagen degradation in granulation tissue after cyclophosphamide treatment. In skin, the only change after cyclophosphamide was a decrease in total content of OH-proline and an increase in alpha/beta ratio of acid soluble collagen after 42 days of treatment. No effect of the subcutaneous sponge implantation was observed on the collagen variables in the skin. In comparison with unstarved controls, a reduction in dry weight and in free OH-proline in granulation tissue, as well as an increase in salt soluble OH-proline in the skin were observed 28 days after a 14-day treatment with cyclophosphamide. These observations indicate a sustained effect of cyclophosphamide on collagen 28 days after cessation of treatment. In addition the thermal stability of rat tail tendons was decreased 28 days after withdrawal of cyclophosphamide to the same extent as after starvation for 42 days and after 42 days of continuous cyclophosphamide treatment. It is concluded that the cyclophosphamide-induced collagen alterations, which may be of importance in the anti-inflammatory action of cyclophosphamide, are only in part reversible, 28 days after cessation of 14 days of cyclophosphamide treatment. FAU - Hansen, T M AU - Hansen TM FAU - Andreassen, T T AU - Andreassen TT FAU - Lorenzen, I AU - Lorenzen I LA - eng PT - Journal Article PL - Denmark TA - Acta Pharmacol Toxicol (Copenh) JT - Acta pharmacologica et toxicologica JID - 0370572 RN - 8N3DW7272P (Cyclophosphamide) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Body Temperature/*drug effects MH - Collagen/*metabolism MH - Cyclophosphamide/administration & dosage/*pharmacology MH - Granulation Tissue/*metabolism MH - Hydroxyproline/metabolism MH - Male MH - Rats MH - Skin/*metabolism MH - Starvation MH - Tail MH - Tendons/*drug effects MH - Time Factors EDAT- 1978/02/01 00:00 MHDA- 1978/02/01 00:01 CRDT- 1978/02/01 00:00 PHST- 1978/02/01 00:00 [pubmed] PHST- 1978/02/01 00:01 [medline] PHST- 1978/02/01 00:00 [entrez] AID - 10.1111/j.1600-0773.1978.tb02176.x [doi] PST - ppublish SO - Acta Pharmacol Toxicol (Copenh). 1978 Feb;42(2):103-9. doi: 10.1111/j.1600-0773.1978.tb02176.x. PMID- 8305101 OWN - NLM STAT- MEDLINE DCOM- 19940317 LR - 20190914 IS - 0749-8063 (Print) IS - 0749-8063 (Linking) VI - 9 IP - 6 DP - 1993 TI - Comparison of ketorolac and opioid analgesics in postoperative ACL reconstruction outpatient pain control. PG - 653-61 AB - Pain control is an important postoperative consideration with any surgical procedure. Technological and procedural improvements have contributed to the reduction in both the degree of surgical difficulty and the postsurgical complications associated with intricate surgeries. As a result, certain surgeries have potential for being performed on an outpatient basis, dependent upon appropriate pain-management regimens and the degree of potential for postoperative complications. Arthroscopic anterior cruciate ligament (ACL) reconstruction is a common procedure. Because of the reduction in invasiveness that arthroscopy provides, outpatient surgery is now routinely employed for ACL patients. The arguments against ACL outpatient surgery have included the reluctance to use ambulatory, indwelling, intravenous pain-pump delivery systems for opioid pain medication. The purpose of this study was to determine the efficacy of a ketorolac tromethamine used for the management of the postoperative pain produced as a result of outpatient ACL reconstruction. When the ketorolac pain management regimen is compared in this setting with meperidine or morphine, pain control is as good as, or in some cases better than, either of the opioid drugs. Additionally, the adverse side effects associated with opioid drugs are significantly reduced at a substantially lower direct cost to the patient. FAU - McGuire, D A AU - McGuire DA AD - Knee and Arthroscopic Surgery, Anchorage, Alaska. FAU - Sanders, K AU - Sanders K FAU - Hendricks, S D AU - Hendricks SD LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Analgesics) RN - 023C2WHX2V (Tromethamine) RN - 4EVE5946BQ (Ketorolac Tromethamine) RN - 76I7G6D29C (Morphine) RN - 9E338QE28F (Meperidine) RN - D8K2JPN18B (Tolmetin) SB - IM MH - Adolescent MH - Adult MH - Ambulatory Surgical Procedures MH - Analgesics/*therapeutic use MH - Anterior Cruciate Ligament/*surgery MH - Arthroscopy MH - Female MH - Follow-Up Studies MH - Humans MH - Ketorolac Tromethamine MH - Male MH - Meperidine/*therapeutic use MH - Middle Aged MH - Morphine/*therapeutic use MH - Pain, Postoperative/*prevention & control MH - Retrospective Studies MH - Tendons/*transplantation MH - Tolmetin/*analogs & derivatives/therapeutic use MH - Tromethamine/*analogs & derivatives/therapeutic use EDAT- 1993/01/01 00:00 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PHST- 1993/01/01 00:00 [pubmed] PHST- 1993/01/01 00:01 [medline] PHST- 1993/01/01 00:00 [entrez] AID - S0749-8063(05)80501-8 [pii] AID - 10.1016/s0749-8063(05)80501-8 [doi] PST - ppublish SO - Arthroscopy. 1993;9(6):653-61. doi: 10.1016/s0749-8063(05)80501-8. PMID- 18658201 OWN - NLM STAT- MEDLINE DCOM- 20081204 LR - 20131121 IS - 1462-0332 (Electronic) IS - 1462-0324 (Linking) VI - 47 IP - 10 DP - 2008 Oct TI - Frequency of successful intra-articular puncture of finger joints: influence of puncture position and physician experience. PG - 1503-5 LID - 10.1093/rheumatology/ken295 [doi] AB - OBJECTIVE: Physicians and specialists routinely perform IA punctures and injections on patients with joint injuries, chronic arthritis and arthrosis to release joint effusion or to inject drugs. The purpose of this study was to investigate the frequencies of intra- and peri-articular cannula positioning during this procedure. METHODS: A total of 300 cadaveric finger joints were injected with a methyl blue-containing solution and subsequently dissected to distinguish intra- from peri-articular injections. To assess the influence of puncture position on successful injection, half of the joints were injected dorsally and the other half dorso-radially. To assess the importance of practical experience for a positive outcome, half of the injections were performed by an inexperienced resident and half by a skilled specialist. RESULTS: The overall frequency of occurrence of peri-articular injections was much higher than expected (overall: 23%, specialist: 15%, resident: 32%) The failure rate was significantly higher than the average with the joints of the little finger and the DIP joints of each phalanx. CONCLUSIONS: Even skilled specialists cannot guarantee to insert the cannula into the joint in every case. Unintended peri-articular drug injection moreover may affect the surrounding ligaments or tendons, leading to serious complications. Correct positioning of the needle in the joint may be facilitated by fluoroscopy in doubtful cases. FAU - Pichler, W AU - Pichler W AD - Department of Traumatology, Medical University of Graz (MUG), Auenbruggerplatz 7a, A - 8036 Graz, Austria. wolfgang.pichler@klinikum-graz.at FAU - Grechenig, W AU - Grechenig W FAU - Grechenig, S AU - Grechenig S FAU - Anderhuber, F AU - Anderhuber F FAU - Clement, H AU - Clement H FAU - Weinberg, A M AU - Weinberg AM LA - eng PT - Journal Article DEP - 20080725 PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Coloring Agents) RN - T42P99266K (Methylene Blue) SB - IM MH - Aged MH - Aged, 80 and over MH - *Clinical Competence MH - Coloring Agents/administration & dosage MH - *Finger Joint MH - Humans MH - Injections, Intra-Articular/methods/*standards MH - Methylene Blue/administration & dosage MH - Middle Aged MH - Punctures/methods/standards MH - Treatment Failure EDAT- 2008/07/29 09:00 MHDA- 2008/12/17 09:00 CRDT- 2008/07/29 09:00 PHST- 2008/07/29 09:00 [pubmed] PHST- 2008/12/17 09:00 [medline] PHST- 2008/07/29 09:00 [entrez] AID - ken295 [pii] AID - 10.1093/rheumatology/ken295 [doi] PST - ppublish SO - Rheumatology (Oxford). 2008 Oct;47(10):1503-5. doi: 10.1093/rheumatology/ken295. Epub 2008 Jul 25. PMID- 8180457 OWN - NLM STAT- MEDLINE DCOM- 19940616 LR - 20211203 IS - 1053-1807 (Print) IS - 1053-1807 (Linking) VI - 4 IP - 2 DP - 1994 Mar-Apr TI - Distribution of normal and abnormal fluid collections in the glenohumeral joint: implications for MR arthrography. PG - 173-7 AB - Although magnetic resonance (MR) images of the glenohumeral joint frequently demonstrate intraarticular fluid, no specific criteria have, to the authors' knowledge, been published that allow accurate assessment of the amount of fluid present. Also, despite the increasing use of MR arthrography of the shoulder, the optimal amount of intraarticular fluid that should be used with this technique has not been determined. The authors progressively distended the glenohumeral joint in six cadaveric shoulder specimens with a dilute gadopentetate dimeglumine solution and obtained MR images after injection of 2, 5, 10, 15, and 20 mL of the solution. The pattern of fluid distribution was evaluated, and these results were then used to estimate the amount of fluid that was present in the glenohumeral joint on MR images of 20 shoulders obtained in 12 asymptomatic volunteers. In 14 of these shoulders, intraarticular fluid was present; however, in none was more than 2 mL evident. Results of the cadaveric study also indicated that 15 mL of intraarticular fluid appears to be the optimal amount for MR arthrography. FAU - Recht, M P AU - Recht MP AD - Department of Radiology, Veterans Administration Medical Center, San Diego, CA 92161. FAU - Kramer, J AU - Kramer J FAU - Petersilge, C A AU - Petersilge CA FAU - Yu, J AU - Yu J FAU - Pathria, M AU - Pathria M FAU - Trudell, D AU - Trudell D FAU - Sartoris, D J AU - Sartoris DJ FAU - Resnick, D AU - Resnick D LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Magn Reson Imaging JT - Journal of magnetic resonance imaging : JMRI JID - 9105850 RN - 0 (Contrast Media) RN - 0 (Drug Combinations) RN - 0 (Organometallic Compounds) RN - 6HG8UB2MUY (Meglumine) RN - 7A314HQM0I (Pentetic Acid) RN - AU0V1LM3JT (Gadolinium) RN - K2I13DR72L (Gadolinium DTPA) SB - IM MH - Adult MH - Contrast Media/administration & dosage MH - Drug Combinations MH - Female MH - Gadolinium/administration & dosage MH - Gadolinium DTPA MH - Humans MH - Humerus/anatomy & histology/pathology MH - Ligaments, Articular/anatomy & histology MH - *Magnetic Resonance Imaging/methods MH - Male MH - Meglumine/administration & dosage MH - Organometallic Compounds/administration & dosage MH - Pentetic Acid/administration & dosage/analogs & derivatives MH - Rotator Cuff/anatomy & histology/pathology MH - Rotator Cuff Injuries MH - Shoulder Injuries MH - Shoulder Joint/*anatomy & histology/pathology MH - *Synovial Fluid MH - Tendon Injuries MH - Tendons/anatomy & histology/pathology EDAT- 1994/03/01 00:00 MHDA- 1994/03/01 00:01 CRDT- 1994/03/01 00:00 PHST- 1994/03/01 00:00 [pubmed] PHST- 1994/03/01 00:01 [medline] PHST- 1994/03/01 00:00 [entrez] AID - 10.1002/jmri.1880040214 [doi] PST - ppublish SO - J Magn Reson Imaging. 1994 Mar-Apr;4(2):173-7. doi: 10.1002/jmri.1880040214. PMID- 22936996 OWN - NLM STAT- MEDLINE DCOM- 20130425 LR - 20220321 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 8 DP - 2012 TI - A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PG - e42866 LID - 10.1371/journal.pone.0042866 [doi] LID - e42866 AB - BACKGROUND: Cholesterol management drugs known as statins are widely used and often well tolerated; however, a variety of muscle-related side effects can arise. These adverse events (AEs) can have serious impact, and form a significant barrier to therapy adherence. Surveillance of post-marketing AEs is of vital importance to understand real-world AEs and reporting differences between individual statin drugs. We conducted a review of post-approval muscle and tendon AE reports in association with statin use, to assess differences within the drug class. METHODS: We analyzed all case reports from the FDA AE Reporting System (AERS) database linking muscle-related AEs to statin use (07/01/2005-03/31/2011). Drugs examined were: atorvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin, and fluvastatin. RESULTS: Relative risk rates for rosuvastatin were consistently higher than other statins. Atorvastatin and simvastatin showed intermediate risks, while pravastatin and lovastatin appeared to have the lowest risk rates. Relative risk of muscle-related AEs, therefore, approximately tracked with per milligram LDL-lowering potency, with fluvastatin an apparent exception. Incorporating all muscle categories, rates for atorvastatin, simvastatin, pravastatin, and lovastatin were, respectively, 55%, 26%, 17%, and 7.5% as high, as rosuvastatin, approximately tracking per milligram potency (Rosuvastatin>Atorvastatin>Simvastatin>Pravastatin ≈ Lovastatin) and comporting with findings of other studies. Relative potency, therefore, appears to be a fundamental predictor of muscle-related AE risk, with fluvastatin, the least potent statin, an apparent exception (risk 74% vs rosuvastatin). INTERPRETATION: AE reporting rates differed strikingly for drugs within the statin class, with relative reporting aligning substantially with potency. The data presented in this report offer important reference points for the selection of statins for cholesterol management in general and, especially, for the rechallenge of patients who have experienced muscle-related AEs (for whom agents of lower expected potency should be preferred). FAU - Hoffman, Keith B AU - Hoffman KB AD - AdverseEvents, Inc, Healdsburg, California, United States of America. FAU - Kraus, Christina AU - Kraus C FAU - Dimbil, Mo AU - Dimbil M FAU - Golomb, Beatrice A AU - Golomb BA LA - eng PT - Journal Article DEP - 20120822 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Fatty Acids, Monounsaturated) RN - 0 (Fluorobenzenes) RN - 0 (Heptanoic Acids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Indoles) RN - 0 (Pyrimidines) RN - 0 (Pyrroles) RN - 0 (Sulfonamides) RN - 4L066368AS (Fluvastatin) RN - 83MVU38M7Q (Rosuvastatin Calcium) RN - 9LHU78OQFD (Lovastatin) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) RN - KXO2KT9N0G (Pravastatin) SB - IM MH - Atorvastatin MH - Databases, Factual MH - Fatty Acids, Monounsaturated/adverse effects MH - Fluorobenzenes/adverse effects MH - Fluvastatin MH - Heptanoic Acids/adverse effects MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects MH - Indoles/adverse effects MH - Lovastatin/adverse effects MH - Muscle, Skeletal/*drug effects MH - Pravastatin/adverse effects MH - Pyrimidines/adverse effects MH - Pyrroles/adverse effects MH - Risk Factors MH - Rosuvastatin Calcium MH - Simvastatin/adverse effects MH - Sulfonamides/adverse effects MH - Tendons/*drug effects MH - United States MH - United States Food and Drug Administration PMC - PMC3425581 COIS- Competing Interests: Authors Keith Hoffman, Christina Kraus, and Mo Dimbil work for Adverse Events, Inc. which produced the RxFilter software used in this paper. There is no financial conflict regarding the focus of the paper: That there are adverse event reports for statins within the FDA AERS database is not in dispute; and there is no rationale by which this company affiliation would bias a comparative analysis of agents within a class, such as that presented. Although the software will not be made available, the methods have been elucidated by which the results can be replicated without this software. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. EDAT- 2012/09/01 06:00 MHDA- 2013/04/26 06:00 PMCR- 2012/08/22 CRDT- 2012/09/01 06:00 PHST- 2012/03/20 00:00 [received] PHST- 2012/07/12 00:00 [accepted] PHST- 2012/09/01 06:00 [entrez] PHST- 2012/09/01 06:00 [pubmed] PHST- 2013/04/26 06:00 [medline] PHST- 2012/08/22 00:00 [pmc-release] AID - PONE-D-12-09227 [pii] AID - 10.1371/journal.pone.0042866 [doi] PST - ppublish SO - PLoS One. 2012;7(8):e42866. doi: 10.1371/journal.pone.0042866. Epub 2012 Aug 22. PMID- 9609295 OWN - NLM STAT- MEDLINE DCOM- 19980619 LR - 20131121 IS - 0022-3085 (Print) IS - 0022-3085 (Linking) VI - 88 IP - 6 DP - 1998 Jun TI - Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. PG - 1009-13 AB - Intrathecal baclofen infusion (IBI) is an effective treatment for spasticity secondary to cerebral palsy (CP). OBJECT: To assess the need for orthopedic surgery of the lower extremities in such cases, the authors retrospectively reviewed the outcome in 48 patients with spastic CP who were treated with IBI. METHODS: Pumps were placed in 40 patients (84%) suffering from spastic quadriplegia and eight patients (16%) with spastic diplegia. The patients' ages ranged from 5 to 43 years (mean 15 years). The mean follow-up period was 53 months (range 24-94 months). The mean baclofen dosage was 306 microg/day (range 25-1350 microg/day). At the time of pump placement, subsequent orthopedic surgery was planned in 28 patients (58%); however, only 10 (21%) underwent surgery after IBI therapy. In all 10 cases, the surgical procedure was planned at the time of initial evaluation for IBI therapy. In the remaining 18 patients, who did not subsequently undergo their planned orthopedic operation, it was believed that their lower-extremity spasticity had improved to the degree that intervention was no longer indicated. In addition, although six patients had undergone multiple orthopedic operations before their spasticity was treated, no patient required more than one operation after IBI treatment for spasticity. CONCLUSIONS: The authors conclude that IBI for treatment of spastic CP reduces the need for subsequent orthopedic surgery for the effects of lower-extremity spasticity. In patients with spastic CP and lower-extremity contractures, spasticity should be treated before orthopedic procedures are performed. FAU - Gerszten, P C AU - Gerszten PC AD - Department of Neurosurgery, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA. FAU - Albright, A L AU - Albright AL FAU - Johnstone, G F AU - Johnstone GF LA - eng PT - Journal Article PL - United States TA - J Neurosurg JT - Journal of neurosurgery JID - 0253357 RN - 0 (GABA Agonists) RN - 0 (Muscle Relaxants, Central) RN - H789N3FKE8 (Baclofen) SB - IM MH - Adolescent MH - Adult MH - Baclofen/administration & dosage/*therapeutic use MH - Cerebral Palsy/drug therapy/*surgery MH - Child MH - Child, Preschool MH - Contracture/drug therapy/surgery MH - Femur/surgery MH - Follow-Up Studies MH - GABA Agonists/administration & dosage/*therapeutic use MH - Hemiplegia/drug therapy/surgery MH - Humans MH - Infusion Pumps MH - Injections, Spinal MH - Leg/*surgery MH - Muscle Relaxants, Central/administration & dosage/*therapeutic use MH - Muscle Spasticity/drug therapy/surgery MH - Muscle, Skeletal/surgery MH - Patient Care Planning MH - Quadriplegia/drug therapy/surgery MH - Retrospective Studies MH - Tendons/surgery MH - Treatment Outcome EDAT- 1998/06/03 00:00 MHDA- 1998/06/03 00:01 CRDT- 1998/06/03 00:00 PHST- 1998/06/03 00:00 [pubmed] PHST- 1998/06/03 00:01 [medline] PHST- 1998/06/03 00:00 [entrez] AID - 10.3171/jns.1998.88.6.1009 [doi] PST - ppublish SO - J Neurosurg. 1998 Jun;88(6):1009-13. doi: 10.3171/jns.1998.88.6.1009. PMID- 1775906 OWN - NLM STAT- MEDLINE DCOM- 19920303 LR - 20131121 IS - 0035-2659 (Print) IS - 0035-2659 (Linking) VI - 58 IP - 9 DP - 1991 Oct TI - [Hip and spinal ossification enthesopathies induced by etretinate therapy in peripheral psoriatic arthritis]. PG - 595-9 AB - The occurrence of ossifying enthesopathy during treatment with synthetic retinoids (etretinate, isotretinoin and acitretin) is a side-effect more and more frequently recorded. The authors report here a new case in a patient with a severe psoriatic arthritis. This observation is characterized by the size of ossifications on hips and lumbar spine which appeared after two years of etretinate therapy. The interest of this observation lies in the fact that ossifications occurred while the patient was treated with long-term corticotherapy. The disease for which retinoids are prescribed does not seem to influence the occurrence of those lesions and it is likely that the responsibility of these molecules is entire. Lesions are enthesitis ossification. They are frequent during these treatments (average of 70%) after an average time of 24 to 36 months for etretinate and of 10 months for isotretinoin. Lesions are asymptomatic in about 50% of the cases. After discontinuation of treatment, lesions become quiescent and does not disappear. Growth hormone or abnormalities in vitamin A metabolism could play a role in the physiopathology of lesions. FAU - Bologna, C AU - Bologna C AD - Service de Rhumatologie, Hôpital Lapeyronie, Montpellier. FAU - Poirier, J L AU - Poirier JL FAU - Hérisson, C AU - Hérisson C FAU - Simon, L AU - Simon L LA - fre PT - Case Reports PT - English Abstract PT - Journal Article TT - Enthésopathies ossifiantes des hanches et du rachis induites par l'étrétinate au cours d'un rheumatisme psoriasique périphérique. PL - France TA - Rev Rhum Mal Osteoartic JT - Revue du rhumatisme et des maladies osteo-articulaires JID - 0407211 RN - 65M2UDR9AG (Etretinate) SB - IM MH - Arthritis, Psoriatic/*drug therapy MH - Etretinate/*adverse effects/therapeutic use MH - Female MH - Hip Joint/drug effects MH - Humans MH - Hyperostosis/*chemically induced/physiopathology MH - Hyperostosis, Diffuse Idiopathic Skeletal/*chemically induced MH - Middle Aged MH - Tendons/drug effects EDAT- 1991/10/01 00:00 MHDA- 1991/10/01 00:01 CRDT- 1991/10/01 00:00 PHST- 1991/10/01 00:00 [pubmed] PHST- 1991/10/01 00:01 [medline] PHST- 1991/10/01 00:00 [entrez] PST - ppublish SO - Rev Rhum Mal Osteoartic. 1991 Oct;58(9):595-9. PMID- 4415848 OWN - NLM STAT- MEDLINE DCOM- 19741210 LR - 20190516 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 104 DP - 1974 Oct TI - Spasticity in the upper extremity. PG - 80-91 FAU - Caldwell, C AU - Caldwell C FAU - Braun, R M AU - Braun RM LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Phenols) SB - IM MH - *Arm MH - Arthrodesis MH - Contracture/rehabilitation/surgery MH - Elbow/surgery MH - Exercise Therapy MH - Hand Deformities, Acquired/surgery MH - Hemiplegia/physiopathology/rehabilitation/therapy MH - Humans MH - Motor Activity MH - Muscle Spasticity/physiopathology/rehabilitation/*therapy MH - Nerve Block MH - Orthopedics MH - Phenols/administration & dosage MH - Shoulder/surgery MH - Splints MH - Tendon Transfer MH - Tendons/surgery EDAT- 1974/10/01 00:00 MHDA- 1974/10/01 00:01 CRDT- 1974/10/01 00:00 PHST- 1974/10/01 00:00 [pubmed] PHST- 1974/10/01 00:01 [medline] PHST- 1974/10/01 00:00 [entrez] AID - 10.1097/00003086-197410000-00009 [doi] PST - ppublish SO - Clin Orthop Relat Res. 1974 Oct;(104):80-91. doi: 10.1097/00003086-197410000-00009. PMID- 9187728 OWN - NLM STAT- MEDLINE DCOM- 19971015 LR - 20220318 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 210 IP - 12 DP - 1997 Jun 15 TI - Use of yohimbine to reverse prolonged effects of xylazine hydrochloride in a horse being treated with chloramphenicol. PG - 1771-3 AB - A 1-year-old Standardbred gelding had received xylazine hydrochloride (0.75 to 1.00 mg/kg [0.34 to 0.45 mg/lb] of body weight, IV) during 2 surgeries for debridement of a wound. The horse was given chloramphenicol (55 mg/kg [25 mg/lb], PO, q 6 h) for 5 days, and was anesthetized a third time with xylazine (0.75 mg/kg, IM). Five hours after administration of xylazine, the horse remained markedly sedated and had clinical signs of gaseous distention of the large bowel (bloat) requiring trocharization. Administration of yohimbine (0.03 mg/kg [0.01 mg/lb], i.v.) eliminated signs of sedation within 5 minutes. Moderate flatulence developed, and gastrointestinal sounds could be heard within all 4 abdominal quadrants within 15 minutes of yohimbine administration. The remainder of recovery was unremarkable. Xylazine induces bradycardia and decreases gastrointestinal motility in addition to causing sedation, muscle relaxation, and analgesia. Chloramphenicol can inhibit oxidase activity of cytochrome P-450 and inhibit metabolism and elimination of drugs such as xylazine. FAU - Grubb, T L AU - Grubb TL AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, Ohio State University, Columbus 43202, USA. FAU - Muir, W W 3rd AU - Muir WW 3rd FAU - Bertone, A L AU - Bertone AL FAU - Beluche, L A AU - Beluche LA FAU - Garcia-Calderon, M AU - Garcia-Calderon M LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Anesthetics) RN - 0 (Anti-Bacterial Agents) RN - 0 (Cytochrome P-450 Enzyme Inhibitors) RN - 0 (Sympatholytics) RN - 2KFG9TP5V8 (Xylazine) RN - 2Y49VWD90Q (Yohimbine) RN - 66974FR9Q1 (Chloramphenicol) SB - IM MH - Anesthesia, Intravenous/methods/veterinary MH - Anesthetics/*antagonists & inhibitors/metabolism/pharmacology MH - Animals MH - Anti-Bacterial Agents/pharmacology/*therapeutic use MH - Chloramphenicol/pharmacology/*therapeutic use MH - Cytochrome P-450 Enzyme Inhibitors MH - Debridement/methods/veterinary MH - Drug Interactions MH - Gastrointestinal Motility/drug effects/physiology MH - Horses/metabolism/*physiology/surgery MH - Male MH - Sympatholytics/*pharmacology MH - Tendons/surgery MH - Wound Healing/drug effects/physiology MH - Xylazine/*antagonists & inhibitors/metabolism/pharmacology MH - Yohimbine/*pharmacology EDAT- 1997/06/15 00:00 MHDA- 2001/03/28 10:01 CRDT- 1997/06/15 00:00 PHST- 1997/06/15 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1997/06/15 00:00 [entrez] PST - ppublish SO - J Am Vet Med Assoc. 1997 Jun 15;210(12):1771-3. PMID- 6329981 OWN - NLM STAT- MEDLINE DCOM- 19840822 LR - 20131121 IS - 0020-8868 (Print) IS - 0020-8868 (Linking) VI - 69 IP - 1 DP - 1984 Jan-Mar TI - Recall phenomenon or severe skin and muscle necrosis following Adriamycin extravasation in the hand. PG - 73-4 AB - A 56-year-old male, following pneumonectomy for oat cell carcinoma, was receiving Adriamycin intravenously. Early in his treatment schedule, the intravenous Adriamycin was alleged to have infiltrated, and was promptly stopped. However, treatment was continued through the veins of the other arm at three week intervals. The patient developed an extensive slough of the dorsum of the hand and forearm, including the extensor tendons and muscle, over a seven week period from the initial extravasation. Numerous debridements and skin grafting procedures were required to salvage the hand. It is suggested that the continued Adriamycin treatments had an additive effect in the already devitalized tissue, resulting in recall phenomenon, which further aggravated and enhanced the extent of necrosis. Ameliorative efforts to treat the extravasation in experimental and clinical settings have been ineffective. Care in the intravenous drug administration and dilution of Adriamycin are the best means of preventing the sequela of Adriamycin extravasation. FAU - Mamakos, M S AU - Mamakos MS LA - eng PT - Case Reports PT - Journal Article PL - Italy TA - Int Surg JT - International surgery JID - 0043524 RN - 80168379AG (Doxorubicin) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Carcinoma, Small Cell/*therapy MH - Combined Modality Therapy MH - Debridement MH - Doxorubicin/*adverse effects MH - Humans MH - Infusions, Parenteral MH - Lung Neoplasms/*therapy MH - Male MH - Middle Aged MH - Muscles/*drug effects MH - Necrosis MH - Pneumonectomy MH - Skin/*drug effects EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] PST - ppublish SO - Int Surg. 1984 Jan-Mar;69(1):73-4. PMID- 12172717 OWN - NLM STAT- MEDLINE DCOM- 20020927 LR - 20221207 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 10 IP - 4 DP - 2002 Jul TI - Comparison of analgesic effects of intra-articular tenoxicam and morphine in anterior cruciate ligament reconstruction. PG - 229-32 AB - This study compared the analgesic effect of intra-articular injection of tenoxicam with that of morphine on postoperative pain after anterior cruciate ligament (ACL) reconstruction. Forty-two patients undergoing arthroscopically ACL reconstructions using hamstring tendons underwent the same anesthetic protocol. The patients were randomized to receive 25 ml normal saline, 20 mg tenoxicam in 25 ml normal saline, or 2 mg morphine in 25 ml normal saline. Postoperative pain was assessed using a visual analogue scale and measuring analgesic requirements. We found both that both intra-articular tenoxicam and intra-articular morphine provided better analgesia than that in the control group. Although pain scores were similar between tenoxicam and morphine groups 30 min postoperative, the analgesic requirements in with tenoxicam were significantly lower than those with morphine group 3-6 h postoperatively. FAU - Guler, Gulen AU - Guler G AD - Department of Anesthesiology, Medical School, Erciyes University, 38039 Kayseri, Turkey. FAU - Karaoglu, Sinan AU - Karaoglu S FAU - Velibasoglu, Hediye AU - Velibasoglu H FAU - Ramazanogullari, Nesrin AU - Ramazanogullari N FAU - Boyaci, Adem AU - Boyaci A LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20020327 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Analgesics, Opioid) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 13T4O6VMAM (Piroxicam) RN - 76I7G6D29C (Morphine) RN - Z1R9N0A399 (tenoxicam) SB - IM MH - Adult MH - *Analgesia MH - Analgesics, Opioid/*administration & dosage/*therapeutic use MH - Anterior Cruciate Ligament/*surgery MH - *Anterior Cruciate Ligament Injuries MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/*therapeutic use MH - Arthroscopy/*adverse effects MH - Double-Blind Method MH - Female MH - Humans MH - Injections, Intra-Articular MH - Male MH - Morphine/*administration & dosage/*therapeutic use MH - Pain Measurement MH - Pain, Postoperative/*etiology/*prevention & control MH - Piroxicam/*administration & dosage/*analogs & derivatives/*therapeutic use MH - Prospective Studies MH - Plastic Surgery Procedures/*adverse effects EDAT- 2002/08/13 10:00 MHDA- 2002/09/28 04:00 CRDT- 2002/08/13 10:00 PHST- 2001/07/01 00:00 [received] PHST- 2002/01/29 00:00 [accepted] PHST- 2002/08/13 10:00 [pubmed] PHST- 2002/09/28 04:00 [medline] PHST- 2002/08/13 10:00 [entrez] AID - 10.1007/s00167-002-0286-y [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2002 Jul;10(4):229-32. doi: 10.1007/s00167-002-0286-y. Epub 2002 Mar 27. PMID- 15043631 OWN - NLM STAT- MEDLINE DCOM- 20040826 LR - 20161124 IS - 0905-7188 (Print) IS - 0905-7188 (Linking) VI - 14 IP - 2 DP - 2004 Apr TI - Preliminary results of colour Doppler-guided intratendinous glucocorticoid injection for Achilles tendonitis in five patients. PG - 100-6 AB - BACKGROUND: It is debated as to whether Achilles tendonitis (AT) has an inflammatory component. The intratendinous hyperaemia demonstrated with colour Doppler has been interpreted as neovascularisation. Glucocorticoid injection around the tendon is a common therapeutic procedure. HYPOTHESES: The intratendinous hyperaemia seen with ultrasound (US) colour Doppler represents an inflammatory background. Glucocorticoid injections will be effective if administered inside the tendon where the inflammation seems to be. STUDY DESIGN: An uncontrolled, prospective study with a minimum follow-up of 3 months. METHODS: Six tendons in five patients were evaluated with grey-scale US and colour Doppler before and after US-guided intratendinous glucocorticoid injection. Pain at rest and at activity was evaluated on a visual analogue scale. RESULTS: With colour Doppler all tendons had intratendinous flow. Pain and colour Doppler activity decreased during a mean follow-up of 182 days (range 92-309 days). One tendon relapsed after 199 days. CONCLUSION: Intratendinous glucocorticoid injections seem to have a marked effect on both symptoms and colour Doppler findings, which may be taken as an indication of an inflammatory component in the disease. Colour Doppler adds significant information to grey-scale US with regard to diagnosis, location and follow-up of AT. FAU - Koenig, M J AU - Koenig MJ AD - The Parker Institute, Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark. FAU - Torp-Pedersen, S AU - Torp-Pedersen S FAU - Qvistgaard, E AU - Qvistgaard E FAU - Terslev, L AU - Terslev L FAU - Bliddal, H AU - Bliddal H LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Denmark TA - Scand J Med Sci Sports JT - Scandinavian journal of medicine & science in sports JID - 9111504 RN - 0 (Drug Combinations) RN - 0 (Glucocorticoids) RN - 98PI200987 (Lidocaine) RN - X4W7ZR7023 (Methylprednisolone) SB - IM CIN - Scand J Med Sci Sports. 2004 Apr;14(2):69-71. doi: 10.1111/j.1600-0838.2004.00291.x. PMID: 15043628 CIN - Scand J Med Sci Sports. 2004 Aug;14(4):269-70; author reply 270. doi: 10.1111/j.1600-0838.2004.404.x. PMID: 15265149 MH - Achilles Tendon/diagnostic imaging/*pathology MH - Adult MH - Aged MH - Chronic Disease MH - Drug Combinations MH - Drug Therapy, Computer-Assisted/methods MH - Echocardiography, Doppler, Color MH - Female MH - Glucocorticoids/administration & dosage/*therapeutic use MH - Humans MH - Injections, Intralesional/methods MH - Lidocaine/administration & dosage/therapeutic use MH - Male MH - Methylprednisolone/administration & dosage/therapeutic use MH - Middle Aged MH - Neovascularization, Pathologic/drug therapy MH - Pain/etiology MH - Prospective Studies MH - Tendinopathy/*diagnostic imaging/*drug therapy/physiopathology EDAT- 2004/03/27 05:00 MHDA- 2004/08/27 05:00 CRDT- 2004/03/27 05:00 PHST- 2004/03/27 05:00 [pubmed] PHST- 2004/08/27 05:00 [medline] PHST- 2004/03/27 05:00 [entrez] AID - SMS364 [pii] AID - 10.1046/j.1600-0838.2003.00364.x [doi] PST - ppublish SO - Scand J Med Sci Sports. 2004 Apr;14(2):100-6. doi: 10.1046/j.1600-0838.2003.00364.x. PMID- 1585165 OWN - NLM STAT- MEDLINE DCOM- 19920612 LR - 20161123 VI - 45 IP - 3 DP - 1992 Mar TI - Hand lacerations of the combined interdigital-intermetacarpal region (split hand). PG - 69-71 AB - Longitudinal lacerations involving the finger commissures and adjacent intermetacarpal clefts (including the adjacent tendons, the intrinsic muscles, the deep transverse metacarpal ligament, adjacent arteries, nerves, bones and joints), present multiple problems not seen in the unusual hand lacerations. Thorough cleansing, delayed closure, accurate repair of all injured structures with prompt appropriate rehabilitation results in excellent appearance and early function. FAU - Van Demark, R E Sr AU - Van Demark RE Sr LA - eng PT - Case Reports PT - Journal Article PL - United States TA - S D J Med JT - South Dakota journal of medicine JID - 0040162 RN - IHS69L0Y4T (Cefazolin) SB - IM MH - Adult MH - Cefazolin/administration & dosage MH - Combined Modality Therapy MH - Debridement MH - Finger Injuries/diagnostic imaging/*surgery MH - Fracture Fixation, Internal MH - Hand Injuries/diagnostic imaging/*surgery MH - Humans MH - Male MH - Metacarpus/*injuries MH - Radiography MH - Wound Healing/physiology EDAT- 1992/03/11 19:15 MHDA- 2001/03/28 10:01 CRDT- 1992/03/11 19:15 PHST- 1992/03/11 19:15 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1992/03/11 19:15 [entrez] PST - ppublish SO - S D J Med. 1992 Mar;45(3):69-71. PMID- 8214634 OWN - NLM STAT- MEDLINE DCOM- 19931104 LR - 20190904 IS - 0340-2061 (Print) IS - 0340-2061 (Linking) VI - 188 IP - 2 DP - 1993 Aug TI - Modification of the phalangeal pattern of the digits in the chick embryo leg bud by local microinjection of RA, staurosporin and TGF beta's. PG - 201-8 AB - Many experimental studies show that in the avian chick limb the digits are specified at early stages of development by characteristic concentrations within the limb mesoderm of a still unidentified morphogen diffusing from the posterior margin of the bud, linked with a specific pattern of homeobox gene expression. In all these studies, digits are distinguished by their size, morphology and phalangeal pattern rather than by their position within the autopodium. In this work we report the induction of digits that have otherwise normal morphology but lack an interphalangeal joint. This suggests that the patterning of these joints is not necessarily linked to the control of the outgrowth of the digital rays. Missing interphalangeal joints were induced by microinjection into the third interdigital space of the leg bud of stage 28 to 31 chick embryos of retinoic Acid (RA), staurosporine and TGF beta 1 and beta 2, but not by microinjection of FGF or EGF. Our results also suggest that the pattern of insertion of the long tendons and the formation of the flexor cutaneous pad at the plantar surface of the digits are both linked to the establishment of the interphalangeal joints. FAU - Macias, D AU - Macias D AD - Departamento de Ciencias Morfológicas, Facultad de Medicina, Universidad de Extremadura, Badajoz, Spain. FAU - Gañan, Y AU - Gañan Y FAU - Hurlé, J M AU - Hurlé JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Anat Embryol (Berl) JT - Anatomy and embryology JID - 7505194 RN - 0 (Alkaloids) RN - 0 (Transforming Growth Factor beta) RN - 5688UTC01R (Tretinoin) RN - H88EPA0A3N (Staurosporine) SB - IM MH - Alkaloids/*administration & dosage MH - Animals MH - Chick Embryo MH - Hindlimb/abnormalities/drug effects/embryology MH - Microscopy, Electron, Scanning MH - Staurosporine MH - Toes/abnormalities/*embryology MH - Transforming Growth Factor beta/*administration & dosage MH - Tretinoin/*administration & dosage EDAT- 1993/08/01 00:00 MHDA- 1993/08/01 00:01 CRDT- 1993/08/01 00:00 PHST- 1993/08/01 00:00 [pubmed] PHST- 1993/08/01 00:01 [medline] PHST- 1993/08/01 00:00 [entrez] AID - 10.1007/BF00186253 [doi] PST - ppublish SO - Anat Embryol (Berl). 1993 Aug;188(2):201-8. doi: 10.1007/BF00186253. PMID- 20073985 OWN - NLM STAT- MEDLINE DCOM- 20100713 LR - 20181201 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 51 IP - 3 DP - 2010 Jun TI - Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast. PG - 179-87 LID - 10.3109/03008200903204669 [doi] AB - The selective estrogen receptor modulator raloxifene is therapeutically beneficial for postmenopausal connective tissue degradation, such as osteoporosis, vascular sclerosis, and dermal degradation; however, the effects of raloxifene on postmenopausal tendon metabolism have not been clarified. In this study, we investigated the effects of raloxifene analogue (LY117018) on cell proliferation and collagen metabolism using cultured rat Achilles tendon fibroblasts. 17beta-Estradiol (E(2); 10(-11)-10(-9) M) and LY117018 (10(-9)-10(-7) M) had no significant effects on tendon fibroblast proliferation, based on a BrdU (5-bromo-2'-deoxyuridine) incorporation assay (24 hr) and a WST-8 colorimetric assay (2 or 6 days). Neither E(2) nor LY117018 significantly altered the expression of type I collagen, which is a main component of the tendon extracellular matrix (ECM), whereas both E(2) and LY117018 significantly increased the expression of matrix metalloproteinase (MMP)-13, which is responsible for tendon collagen degradation in rat. Also, both E(2) and LY117018 increased the expression of type III collagen and elastin, which are minor components of tendon ECM, but are considered to govern the elastic properties of tendons. These changes in collagen and MMP induced by either E(2) or LY117018 were attenuated by the estrogen receptor alpha blocker ICI 182,780. The results of this study suggest that postmenopausal estrogen deficiency might downregulate tendon collagen turnover and decrease tendon elasticity. Further, raloxifene treatment might restore these changes to premenopausal levels. FAU - Irie, Toru AU - Irie T AD - Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. FAU - Takahata, Masahiko AU - Takahata M FAU - Majima, Tokifumi AU - Majima T FAU - Abe, Yuichiro AU - Abe Y FAU - Komatsu, Miki AU - Komatsu M FAU - Iwasaki, Norimasa AU - Iwasaki N FAU - Minami, Akio AU - Minami A LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazolium monosodium salt) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Estrogen Antagonists) RN - 0 (Pyrrolidines) RN - 0 (Selective Estrogen Receptor Modulators) RN - 0 (Tetrazolium Salts) RN - 0 (Thiophenes) RN - 22X328QOC4 (Fulvestrant) RN - 4F86W47BR6 (Raloxifene Hydrochloride) RN - 4TI98Z838E (Estradiol) RN - 63676-25-5 (LY 117018) RN - 9007-58-3 (Elastin) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Achilles Tendon/cytology/*drug effects MH - Animals MH - Bromodeoxyuridine/metabolism MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen Type I/metabolism MH - Collagen Type III/metabolism MH - Elastin/metabolism MH - Estradiol/analogs & derivatives/pharmacology MH - Estrogen Antagonists/pharmacology MH - Extracellular Matrix/drug effects/metabolism MH - Female MH - Fibroblasts/*drug effects/metabolism/pathology MH - Fulvestrant MH - Matrix Metalloproteinase 13/metabolism MH - Pyrrolidines/antagonists & inhibitors/*pharmacology MH - Raloxifene Hydrochloride/*analogs & derivatives MH - Rats MH - Selective Estrogen Receptor Modulators/*pharmacology MH - Tetrazolium Salts/metabolism MH - Thiophenes/antagonists & inhibitors/*pharmacology EDAT- 2010/01/16 06:00 MHDA- 2010/07/14 06:00 CRDT- 2010/01/16 06:00 PHST- 2010/01/16 06:00 [entrez] PHST- 2010/01/16 06:00 [pubmed] PHST- 2010/07/14 06:00 [medline] AID - 10.3109/03008200903204669 [doi] PST - ppublish SO - Connect Tissue Res. 2010 Jun;51(3):179-87. doi: 10.3109/03008200903204669. PMID- 8645359 OWN - NLM STAT- MEDLINE DCOM- 19960718 LR - 20190718 IS - 0021-9150 (Print) IS - 0021-9150 (Linking) VI - 120 IP - 1-2 DP - 1996 Feb TI - Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. PG - 181-7 AB - A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years. This treatment has produced significant reductions in the cholesterol levels of his serum, low density lipoprotein (LDL), and high density lipoprotein (HDL) from 237 +/- 20 mg/dl (mean +/- S.D.) to 156 +/- 15, from 175 +/- 8 to 111 +/- 16 mg/dl, and from 23 +/- 4 to 19 +/- 2 mg/dl, respectively. These reductions have been maintained for eight years. Serum triglyceride levels also decreased, from 220 +/- 54 to 146 +/- 36 md/dl. During this period, marked regression of xanthomas on the eyelids and finger extensor tendons was observed, while thickness of the Achilles tendons was reduced from 21.0 mm to 13.0 mm. On other hand, effort-induced anginal symptoms requiring additional antianginal medication have been noticed, and angiographically-demonstrated coronary atherosclerosis has progressed significantly during these eight years. These observations lead us to suggest that maintaining low levels of HDL cholesterol with probucol, even though resulting in satisfactory reduction of LDL cholesterol and marked regression of xanthomas, appears to be associated with the progression of atherosclerosis in the coronary arteries. FAU - Kajinami, K AU - Kajinami K AD - Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan. FAU - Nishitsuji, M AU - Nishitsuji M FAU - Takeda, Y AU - Takeda Y FAU - Shimizu, M AU - Shimizu M FAU - Koizumi, J AU - Koizumi J FAU - Mabuchi, H AU - Mabuchi H LA - eng PT - Case Reports PT - Journal Article PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 RN - 0 (Anticholesteremic Agents) RN - 0 (Cholesterol, HDL) RN - 0 (Cholesterol, LDL) RN - 0 (Lipids) RN - P3CTH044XJ (Probucol) SB - IM MH - Aged MH - Anticholesteremic Agents/administration & dosage/*adverse effects/therapeutic use MH - Cholesterol, HDL/blood MH - Cholesterol, LDL/blood MH - Coronary Angiography MH - Coronary Artery Disease/diagnostic imaging/*etiology MH - Disease Progression MH - Eyelid Diseases/*drug therapy/etiology/pathology MH - Heterozygote MH - Humans MH - Hyperlipoproteinemia Type II/blood/complications/*drug therapy MH - Lipids/blood MH - Male MH - Probucol/administration & dosage/*adverse effects/therapeutic use MH - *Tendons/pathology MH - Xanthomatosis/*drug therapy/etiology/pathology EDAT- 1996/02/01 00:00 MHDA- 1996/02/01 00:01 CRDT- 1996/02/01 00:00 PHST- 1996/02/01 00:00 [pubmed] PHST- 1996/02/01 00:01 [medline] PHST- 1996/02/01 00:00 [entrez] AID - 0021-9150(95)05699-8 [pii] AID - 10.1016/0021-9150(95)05699-8 [doi] PST - ppublish SO - Atherosclerosis. 1996 Feb;120(1-2):181-7. doi: 10.1016/0021-9150(95)05699-8. PMID- 998795 OWN - NLM STAT- MEDLINE DCOM- 19770129 LR - 20171213 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 231 IP - 5 Pt. 1 DP - 1976 Nov TI - Calcium-dependent resistance to stretch and stress relaxation in resting smooth muscles. PG - 1501-8 AB - Mechanical responses to stretch and length-tension relations were examined in rabbit taenia coli, mesenteric vein, aorta, and myometrium and in guinea pig taenia coli made atonic by incubation in Krebs-bicarbonate solution at 20-22 degrees C. When stretched 10% of the length at which maximum active tension is observed (Lo) in 0.5 s, the muscles showed a transient large force (resistance to stretch) that decayed to a new constant level within minutes (stress relaxation). The resistance to stretch decreased markedly in Ca2+-free [disodium ethylene glycolbis-(beta-aminoethylether)-N,N-tetraacetic acid (EGTA)] Krebs but was restored in normal Krebs solution. Calcium removal did not affect the passive length-tension curve. The absence of Ca2+ did not change the steady-state force maintained by the muscle; thus stretch resistance was not due to tone. Blockade of Ca2+ influx associated with electrical activity with 5-[3,4-dimethoxyphenethyl)methylamino]-2-(3,4,5-trimethoxyphenyl-2-isopropylvaleronitrile (D-600) and of Ca2+ release from intracellular sites with thymol (1 mM) completely blocked contraction but did not alter the responses to stretch, thus dissociating the responses to stretch from these processes and tension development. The Ca2+-dependent stress relaxation showed a dependence on muscle length similar to that for active tension development. Except at long muscle lengths, where connective tissue markedly affects length-tension relations, most of the "viscoelasticity" of these smooth muscles is dependent on calcium and may be largely due to the straining of crossbridges that are attached, but not generating a net force, in the resting state. FAU - Siegman, M J AU - Siegman MJ FAU - Butler, T M AU - Butler TM FAU - Mooers, S U AU - Mooers SU FAU - Davies, R E AU - Davies RE LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 3J50XA376E (Thymol) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Aorta MH - Calcium/*metabolism MH - Cats MH - Colon MH - Elasticity MH - Female MH - Guinea Pigs MH - Male MH - Mesenteric Veins MH - *Muscle Contraction MH - *Muscle Relaxation MH - Muscle, Smooth/*physiology MH - Myometrium MH - Rabbits MH - Rats MH - Tendons/physiology MH - Thymol/pharmacology EDAT- 1976/11/01 00:00 MHDA- 1976/11/01 00:01 CRDT- 1976/11/01 00:00 PHST- 1976/11/01 00:00 [pubmed] PHST- 1976/11/01 00:01 [medline] PHST- 1976/11/01 00:00 [entrez] AID - 10.1152/ajplegacy.1976.231.5.1501 [doi] PST - ppublish SO - Am J Physiol. 1976 Nov;231(5 Pt. 1):1501-8. doi: 10.1152/ajplegacy.1976.231.5.1501. PMID- 23176422 OWN - NLM STAT- MEDLINE DCOM- 20130430 LR - 20131121 IS - 1943-5681 (Electronic) IS - 0002-9645 (Linking) VI - 73 IP - 12 DP - 2012 Dec TI - Age-dependent effects of systemic administration of oxytetracycline on the viscoelastic properties of rat tail tendons as a mechanistic basis for pharmacological treatment of flexural limb deformities in foals. PG - 1951-6 LID - 10.2460/ajvr.73.12.1951 [doi] AB - OBJECTIVE: To describe the effect of systemically administered oxytetracycline on the viscoelastic properties of rat tail tendon fascicles (TTfs) to provide a mechanistic rationale for pharmacological treatment of flexural limb deformities in foals. SAMPLE: TTfs from ten 1-month-old and ten 6-month-old male Sprague-Dawley rats. PROCEDURES: 5 rats in each age group were administered oxytetracycline (50 mg/kg, IP, q 24 h) for 4 days. The remaining 5 rats in each age group served as untreated controls. Five days after initiation of oxytetracycline treatment, TTfs were collected and their viscoelastic properties were evaluated via a stress-relaxation protocol. Maximum modulus and equilibrium modulus were compared via a 2-way ANOVA. Collagen fibril size, density, and orientation in TTfs were compared between treated and control rats. RESULTS: Viscoelastic properties were significantly decreased in TTfs from 1-month-old oxytetracycline-treated rats, compared with those in TTfs from 1-month-old control rats. Oxytetracycline had no effect on the viscoelastic properties of TTfs from 6-month-old rats. Collagen fibril size, density, and orientation in TTfs from 1-month-old rats did not differ between oxytetracycline-treated and control rats. CONCLUSIONS AND CLINICAL RELEVANCE: Results confirmed that systemically administered oxytetracycline decreased the viscoelastic properties of TTfs from 1-month-old rats but not those of TTfs from 6-month-old rats. The decrease in viscoelastic properties associated with oxytetracycline treatment does not appear to be caused by altered collagen fibril diameter or organization. The age-dependent effect of oxytetracycline on the viscoelastic properties of tendons may be related to its effect on the maturation of the extracellular matrix of developing tendons. FAU - Wintz, Leslie R AU - Wintz LR AD - Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA. FAU - Lavagnino, Michael AU - Lavagnino M FAU - Gardner, Keri L AU - Gardner KL FAU - Sedlak, Aleksa M AU - Sedlak AM FAU - Arnoczky, Steven P AU - Arnoczky SP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Anti-Bacterial Agents) RN - 9007-34-5 (Collagen) RN - X20I9EN955 (Oxytetracycline) SB - IM MH - Age Factors MH - Analysis of Variance MH - Animals MH - Anti-Bacterial Agents/*administration & dosage MH - Biomechanical Phenomena/drug effects MH - Collagen/*drug effects/metabolism MH - Elasticity/drug effects MH - Extracellular Matrix/*drug effects MH - Horses MH - Male MH - Microscopy, Electron, Transmission MH - Oxytetracycline/*administration & dosage MH - Rats MH - Rats, Sprague-Dawley MH - Tail/*drug effects/physiology MH - Tendons/*drug effects/physiology EDAT- 2012/11/28 06:00 MHDA- 2013/05/01 06:00 CRDT- 2012/11/27 06:00 PHST- 2012/11/27 06:00 [entrez] PHST- 2012/11/28 06:00 [pubmed] PHST- 2013/05/01 06:00 [medline] AID - 10.2460/ajvr.73.12.1951 [doi] PST - ppublish SO - Am J Vet Res. 2012 Dec;73(12):1951-6. doi: 10.2460/ajvr.73.12.1951. PMID- 19862652 OWN - NLM STAT- MEDLINE DCOM- 20100322 LR - 20161125 IS - 1438-9010 (Electronic) IS - 1438-9010 (Linking) VI - 182 IP - 3 DP - 2010 Mar TI - [Dual energy CT--a new perspective in the diagnosis of gout]. PG - 261-6 LID - 10.1055/s-0028-1109820 [doi] AB - PURPOSE: To describe the first experience with dual energy CT (DECT) for the diagnosis of gout and to evaluate its potential for the clinical routine. MATERIALS AND METHODS: DECT examinations acquired with a dual source CT of 71 regions from 41 patients were evaluated with respect to image quality, amount of urate deposits and their location. The amount of urate deposits was described using a 4-stage scale: none (1), minimal punctual (up to 2 mm) (2), at least moderate (bigger than 2 mm) (3), soft tissue or osseus tophi (4). The DECT results were compared with the findings of the diagnostic tools currently in use. RESULTS: The DECTs of peripheral regions showed excellent image quality, while the image quality was poor in the regions of the trunk. Patients (n) and regions (r) with a score of 3 (n = 23, r = 44), 4 (n = 5, r = 8) and 1 (n = 2, r = 2) showed a highly significant correlation (p < 0.01) with the currently available diagnostic tools. In patients or regions with a score of 2 (n = 7, r = 11), the urate deposits were asymptomatic, the serum urate levels were partly elevated (43 %) and partly normal (57 %). The symptoms were ultimately able to be associated with a differential diagnosis. The urate deposits were found in tendons (57), articular synovia (25), cartilage (17), soft tissue tophi (8), osseus tophi (5), cruciate ligaments (7) and menisci (7). CONCLUSION: DECT allows specific and quantitative visualization of urate deposits in peripheral regions. Taking into account the amount of urate deposits shown in DECT, the diagnosis of gout can be stated reliably. Based on our experience and results, DECT greatly benefits the routine diagnosis of gout in peripheral regions. CI - Georg Thieme Verlag KG Stuttgart New York. FAU - Artmann, A AU - Artmann A AD - Radiologie II, Klinikum Wels Grieskirchen, Osterreich. andreas.artmann@klinikum-wegr.at FAU - Ratzenböck, M AU - Ratzenböck M FAU - Noszian, I AU - Noszian I FAU - Trieb, K AU - Trieb K LA - ger PT - Journal Article TT - Dual Energy CT--eine neue Perspektive in der Gicht-Diagnostik. DEP - 20091027 PL - Germany TA - Rofo JT - RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin JID - 7507497 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Arthrography/methods MH - Cervical Vertebrae/diagnostic imaging MH - Extremities/diagnostic imaging MH - Gout/blood/*diagnostic imaging MH - Humans MH - Lumbar Vertebrae/diagnostic imaging MH - Radiography, Dual-Energy Scanned Projection/*methods MH - Retrospective Studies MH - Sensitivity and Specificity MH - Tomography, X-Ray Computed/*methods MH - Uric Acid/blood EDAT- 2009/10/29 06:00 MHDA- 2010/03/23 06:00 CRDT- 2009/10/29 06:00 PHST- 2009/10/29 06:00 [entrez] PHST- 2009/10/29 06:00 [pubmed] PHST- 2010/03/23 06:00 [medline] AID - 10.1055/s-0028-1109820 [doi] PST - ppublish SO - Rofo. 2010 Mar;182(3):261-6. doi: 10.1055/s-0028-1109820. Epub 2009 Oct 27. PMID- 30631915 OWN - NLM STAT- MEDLINE DCOM- 20190410 LR - 20190410 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 139 IP - 3 DP - 2019 Mar TI - Acute atraumatic carpal tunnel syndrome due to flexor tendon rupture following palmar plate osteosynthesis in a patient taking rivaroxaban. PG - 435-438 LID - 10.1007/s00402-019-03116-8 [doi] AB - INTRODUCTION: Few case reports describe the development of a hematoma under oral anticoagulation as the cause of an atraumatic carpal tunnel syndrome. CASE REPORT: A 76 years old woman presented an acute atraumatic carpal tunnel syndrome of her left hand under oral anticoagulation with rivaroxaban due to atrial fibrillation. 12 years ago, palmar plate osteosynthesis of a distal radius fracture had been performed on the affected wrist. Open decompression of the carpal canal was performed due to persistent severe pain under intense pain therapy and progressive neurological symptoms. The cause of the pain was a hematoma due to a rupture of the flexor pollicis longus and the second flexor digitorum profundus tendon with concomitant synovitis at the plate's distal rim. After decompression, pain relieved and neurological deficits improved rapidly. DISCUSSION: Ruptures of the flexor tendons occur in palmar plate osteosynthesis in up to 1.5% in the long term postoperative course. Very distal plate positions, like in this case, increase that risk. Under anticoagulation, the rupture induced a hematoma increasing local pressure resulting in an acute carpal tunnel syndrome. Acute nerve compression syndromes should be treated surgically without delay. CONCLUSION: Therapy with anticoagulants may increase hematoma after tendon rupture, thus supporting the development of an atraumatic acute carpal tunnel syndrome and complicating the surgical therapy. Hardware removal after fracture healing should be advised in patients with Soong grade 2 plate positions especially those taking anticoagulants. FAU - Weschenfelder, Wolfram AU - Weschenfelder W AUID- ORCID: 0000-0002-4828-1812 AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. wolfram.weschenfelder@med.uni-jena.de. FAU - Friedel, Reinhard AU - Friedel R AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. FAU - Hofmann, Gunther O AU - Hofmann GO AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. FAU - Lenz, Mark AU - Lenz M AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany. LA - eng PT - Journal Article DEP - 20190110 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 0 (Factor Xa Inhibitors) RN - 9NDF7JZ4M3 (Rivaroxaban) SB - IM MH - Aged MH - *Carpal Tunnel Syndrome/diagnosis/etiology/surgery MH - Decompression, Surgical MH - Factor Xa Inhibitors/adverse effects MH - Female MH - Fracture Fixation, Internal MH - *Hematoma/chemically induced/complications MH - Humans MH - Palmar Plate/*surgery MH - Radius Fractures/surgery MH - Rivaroxaban/*adverse effects MH - Rupture MH - Tendon Injuries/*complications OTO - NOTNLM OT - Carpal tunnel syndrome OT - Oral anticoagulants OT - Palmar plate osteosynthesis OT - Tendon rupture EDAT- 2019/01/12 06:00 MHDA- 2019/04/11 06:00 CRDT- 2019/01/12 06:00 PHST- 2018/06/26 00:00 [received] PHST- 2019/01/12 06:00 [pubmed] PHST- 2019/04/11 06:00 [medline] PHST- 2019/01/12 06:00 [entrez] AID - 10.1007/s00402-019-03116-8 [pii] AID - 10.1007/s00402-019-03116-8 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2019 Mar;139(3):435-438. doi: 10.1007/s00402-019-03116-8. Epub 2019 Jan 10. PMID- 3816088 OWN - NLM STAT- MEDLINE DCOM- 19870420 LR - 20190820 IS - 0143-5221 (Print) IS - 0143-5221 (Linking) VI - 72 IP - 3 DP - 1987 Mar TI - The effect of muscle paralysis on the radial growth of collagen fibrils in developing tendon. PG - 359-63 AB - Voluntary muscle activity in chick embryos was paralysed by administration in ovo of tubocurarine hydrochloride, administered in single or multiple doses, from day 9 to day 13 after fertilization. Control eggs were given saline instead of tubocurarine or were simply incubated without operative interference. Embryos were killed at 9, 13, 14, 16 and 19 days after fertilization. Flexor digitorum tendons were removed, fixed in glutaraldehyde, embedded in plastic, sectioned, and stained with phosphotungstic acid for electron microscopy. The diameters of the tendon collagen fibrils were measured, on electron micrographs, using a Magiscan Mk II programme. Tendon collagen fibril expansion was not inhibited by tubocurarine treatment. It is concluded that the rapid increase of collagen fibril diameters, which coincides in the normal embryo with the first onset of use of the associated muscle, is not dependent on muscle activity. There remains a possibility that other ways of producing tension in the tendon could provide sufficient stimulus to fibril expansion. FAU - Scott, J E AU - Scott JE FAU - Haigh, M AU - Haigh M FAU - Neo, G E AU - Neo GE FAU - Gibson, S AU - Gibson S LA - eng PT - Journal Article PL - England TA - Clin Sci (Lond) JT - Clinical science (London, England : 1979) JID - 7905731 RN - 9007-34-5 (Collagen) RN - W9YXS298BM (Tubocurarine) SB - IM MH - Animals MH - Chick Embryo MH - Collagen/*biosynthesis MH - Movement/drug effects MH - Muscles/*embryology MH - Reflex/drug effects MH - Tendons/anatomy & histology/*embryology MH - Tubocurarine/pharmacology EDAT- 1987/03/01 00:00 MHDA- 1987/03/01 00:01 CRDT- 1987/03/01 00:00 PHST- 1987/03/01 00:00 [pubmed] PHST- 1987/03/01 00:01 [medline] PHST- 1987/03/01 00:00 [entrez] AID - 10.1042/cs0720359 [doi] PST - ppublish SO - Clin Sci (Lond). 1987 Mar;72(3):359-63. doi: 10.1042/cs0720359. PMID- 3394648 OWN - NLM STAT- MEDLINE DCOM- 19880825 LR - 20190622 IS - 0002-9149 (Print) IS - 0002-9149 (Linking) VI - 62 IP - 3 DP - 1988 Jul 25 TI - Prevention of atherosclerotic progression in Watanabe rabbits by probucol. PG - 13B-19B AB - The foam cell has been recognized as a characteristic feature of xanthomas in skin and tendons, and also of atheromas. Many foam cells in these lesions share properties characteristic of the macrophages. Therefore macrophages may be the progenitor of certain foam cells that are involved in atherogenesis. Several investigators demonstrated in vitro that macrophages can ingest large amounts of certain chemically modified lipoproteins, such as acetylated low-density lipoprotein (LDL) and malondialdehyde-treated LDL, through the process of receptor-mediated endocytosis. By this process, macrophages become foam cells. But this process has not been demonstrated in vivo. Recently, oxidized LDL has been suggested to play an important role in atherogenesis by facilitating the accumulation of lipids in macrophages in vitro. Probucol, originally developed as an antioxidant, prevents this oxidative modification of LDL in vitro. Moreover, there are some clinical reports that probucol induces regression of cutaneous and tendon xanthomas in patients with homozygous familial hypercholesterolemia. A question was posed whether in vivo probucol could prevent the progression of atherosclerosis in homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model for familial hypercholesterolemia. At age 2 months, 8 WHHL rabbits were classified into 2 groups: group A rabbits were controls and group B rabbits were treated with 1% probucol. After 6 months of treatment, average plasma concentrations of cholesterol were 704 +/- 121 mg/dl in group A and 584 +/- 61 mg/dl in group B. The percentage of surface area of total thoracic aorta with visible plaques in group A vs group B was 54.2 +/- 18.8% vs 7.0 +/- 6.3%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Kita, T AU - Kita T AD - Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan. FAU - Nagano, Y AU - Nagano Y FAU - Yokode, M AU - Yokode M FAU - Ishii, K AU - Ishii K FAU - Kume, N AU - Kume N FAU - Narumiya, S AU - Narumiya S FAU - Kawai, C AU - Kawai C LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Cardiol JT - The American journal of cardiology JID - 0207277 RN - 0 (Lipid Peroxides) RN - 0 (Lipoproteins) RN - 0 (Phenols) RN - P3CTH044XJ (Probucol) SB - IM MH - Animals MH - Arteriosclerosis/blood/*prevention & control MH - Cells, Cultured MH - Drug Evaluation, Preclinical MH - Female MH - Foam Cells/drug effects/metabolism MH - Hyperlipidemias/blood/*drug therapy/genetics MH - Lipid Peroxides/blood MH - Lipoproteins/blood MH - Male MH - Mice MH - Mice, Inbred Strains MH - Oxidation-Reduction/drug effects MH - Phenols/*therapeutic use MH - Probucol/*therapeutic use MH - Rabbits EDAT- 1988/07/25 00:00 MHDA- 1988/07/25 00:01 CRDT- 1988/07/25 00:00 PHST- 1988/07/25 00:00 [pubmed] PHST- 1988/07/25 00:01 [medline] PHST- 1988/07/25 00:00 [entrez] AID - S0002-9149(88)80045-6 [pii] AID - 10.1016/s0002-9149(88)80045-6 [doi] PST - ppublish SO - Am J Cardiol. 1988 Jul 25;62(3):13B-19B. doi: 10.1016/s0002-9149(88)80045-6. PMID- 2746589 OWN - NLM STAT- MEDLINE DCOM- 19890825 LR - 20220410 IS - 0315-162X (Print) IS - 0315-162X (Linking) VI - 16 IP - 4 DP - 1989 Apr TI - Tendinous laxity and Jaccoud's syndrome in patients with systemic lupus erythematosus. Possible role of secondary hyperparathyroidism. PG - 494-8 AB - Fourteen of 52 unselected patients with systemic lupus erythematosus (SLE) (27%) had ligamentous derangement demonstrated by either Jaccoud's syndrome and/or patellar tendon elongation. Three cases had only Jaccoud's syndrome, 4 isolated patellar tendinous laxity, while the remaining 7 presented both findings. Jaccoud's syndrome and/or tendinous laxity were not associated to an increased frequency of arthritis, corticosteroid therapy or a longer disease duration, but significantly associated with increased serum PTH levels secondary to chronic renal failure. Hyperparathyroidism secondary to chronic renal failure should, therefore, be considered a potential factor contributing to the development of Jaccoud's syndrome and/or tendinous laxity in patients with SLE. FAU - Babini, S M AU - Babini SM AD - Section of Rheumatology, Instituto Nacional de Rehabilitación, Buenos Aires, Argentina. FAU - Cocco, J A AU - Cocco JA FAU - de la Sota, M AU - de la Sota M FAU - Babini, J C AU - Babini JC FAU - Arturi, A AU - Arturi A FAU - Marcos, J C AU - Marcos JC FAU - Morteo, O G AU - Morteo OG LA - eng PT - Journal Article PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Parathyroid Hormone) RN - 268B43MJ25 (Uric Acid) RN - 27YLU75U4W (Phosphorus) RN - AYI8EX34EU (Creatinine) RN - SY7Q814VUP (Calcium) SB - IM MH - Adolescent MH - Adult MH - Arthritis/*physiopathology MH - Calcium/blood MH - Child MH - Creatinine/urine MH - Female MH - Foot Deformities, Congenital MH - Hand Deformities, Congenital MH - Humans MH - Hyperparathyroidism, Secondary/*physiopathology MH - Joint Instability/*physiopathology MH - Knee Joint/physiopathology MH - Lupus Erythematosus, Systemic/*physiopathology MH - Male MH - Middle Aged MH - Parathyroid Hormone/blood MH - Phosphorus/blood MH - Tendons/*physiopathology MH - Uric Acid/blood EDAT- 1989/04/01 00:00 MHDA- 1989/04/01 00:01 CRDT- 1989/04/01 00:00 PHST- 1989/04/01 00:00 [pubmed] PHST- 1989/04/01 00:01 [medline] PHST- 1989/04/01 00:00 [entrez] PST - ppublish SO - J Rheumatol. 1989 Apr;16(4):494-8. PMID- 8039 OWN - NLM STAT- MEDLINE DCOM- 19760925 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 156 IP - 1 DP - 1976 Apr 15 TI - The route of secretion of procollagen. The influence of alphaalpha'-bipyridyl, colchicine and antimycin A on the secretory process in embryonic-chick tendon and cartilage cells. PG - 81-90 AB - I. Embryonic-chick tendon cells were pulse-labelled for 4 min with [14C]proline and the 14C-labelled polypeptides were chased with unlabelled proline for up to 30 min. Isolation of subcellular fractions during the chase period and their subsequent analysis for bacterial collagenase-susceptible 14C-labelled peptides demonstrated the transfer of procollagen polypeptides from rough to smooth microsomal fractions and thence to the extracellular medium. Parallel analyses of Golgi-enriched fractions indicated the involvement of this organelle in the secretory pathway of procollagen. Sodium dodecylsulphate/polyacrylamide-gel electrophoresis of the 14C-labelled polypeptides present in the Golgi-enriched fractions demonstrated that the procollagen polypeptides were all present as disulphide-linked pro-gamma components. 2. When similar kinetic studies of the intracellular transport of procollagen were conducted with embryonic-chick cartilage cells almost identical results were obtained, but the rate of translocation of cartilage procollagen was significantly slower than that observed for tendon procollagen. 3. When hydroxylation of procollagen polypeptides was inhibited by alphaalpha'-bipyridyl, the nascent polypeptides accumulated in the rough microsomal fraction. 4. When cells were pulse-labelled for 4min with [14C)proline and the label was chased in the presence of colchicine, secretion of procollagen was inhibited and an intracellular accumulation of procollagen 14C-labelled polypeptides was observed in the Golgi-enriched fractions. 5. The energy-dependence of the intracellular transport of procollagen was demonstrated in experiments in which antimycin A was found to inhibit the transfer of procollagen polypeptides from rough to smooth endoplasmic reticulum. 6. It is concluded that procollagen follows the classical route of secretion taken by other extracellular proteins. FAU - Harwood, R AU - Harwood R FAU - Grant, M E AU - Grant ME FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Protein Precursors) RN - 0 (Pyridines) RN - 551W113ZEP (2,2'-Dipyridyl) RN - 642-15-9 (Antimycin A) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - SML2Y3J35T (Colchicine) SB - IM MH - 2,2'-Dipyridyl/*pharmacology MH - Animals MH - Antimycin A/*pharmacology MH - Cartilage/*metabolism MH - Chick Embryo MH - Colchicine/*pharmacology MH - Collagen/biosynthesis/*metabolism MH - Hydroxylation MH - In Vitro Techniques MH - Proline/metabolism MH - Protein Precursors/metabolism MH - Pyridines/*pharmacology MH - Subcellular Fractions/metabolism MH - Tendons/*metabolism PMC - PMC1163719 EDAT- 1976/04/15 00:00 MHDA- 1976/04/15 00:01 PMCR- 1976/04/15 CRDT- 1976/04/15 00:00 PHST- 1976/04/15 00:00 [pubmed] PHST- 1976/04/15 00:01 [medline] PHST- 1976/04/15 00:00 [entrez] PHST- 1976/04/15 00:00 [pmc-release] AID - 10.1042/bj1560081 [doi] PST - ppublish SO - Biochem J. 1976 Apr 15;156(1):81-90. doi: 10.1042/bj1560081. PMID- 10477870 OWN - NLM STAT- MEDLINE DCOM- 19991007 LR - 20190822 IS - 0022-4790 (Print) IS - 0022-4790 (Linking) VI - 72 IP - 1 DP - 1999 Sep TI - Use of subatmospheric pressure to prevent doxorubicin extravasation ulcers in a swine model. PG - 14-7 AB - Application of subatmospheric pressure to sites injected with doxorubicin prevented ulcer formation in treated sites (0 ulcers/16 sites) compared to control wounds (10 ulcers/16 sites) in a pig model. BACKGROUND AND OBJECTIVES: Extravasation of doxorubicin hydrochloride (Adriamycin) frequently causes chronic ulcers, which usually progress and expose underlying structures such as tendons and bone. The exact mechanism of action that causes cell death and the chronic ulcers is unknown. METHODS: Eight sites were injected intradermally with doxorubicin on each of 4 pigs. Four sites on each animal served as untreated controls. The remaining four sites were exposed to 125 mm Hg subatmospheric pressure applied 1 h after injection. The sites were observed on a three times per week schedule. Sites that did not develop ulcers were re-injected up to a total of four injections. The animals were observed for 5 weeks. RESULTS: Ten of sixteen control sites developed ulcers. No subatmospheric pressure treated sites developed ulcers. The incidence of ulcer formation was significantly less for treated wounds compared to control wounds at P < 0.001 by Fisher's exact test. CONCLUSIONS: This physical modality appears to successfully prevent ulcer formation after doxorubicin injection. CI - Copyright 1999 Wiley-Liss, Inc. FAU - Morykwas, M J AU - Morykwas MJ AD - Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1075, USA. mmorykwa@wfubmc.edu FAU - Kennedy, A AU - Kennedy A FAU - Argenta, J P AU - Argenta JP FAU - Argenta, L C AU - Argenta LC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 RN - 80168379AG (Doxorubicin) SB - IM MH - Animals MH - Chronic Disease MH - Disease Models, Animal MH - Doxorubicin/*adverse effects MH - Extravasation of Diagnostic and Therapeutic Materials/*complications MH - Swine MH - Ulcer/etiology/*prevention & control MH - Vacuum EDAT- 1999/09/09 00:00 MHDA- 1999/09/09 00:01 CRDT- 1999/09/09 00:00 PHST- 1999/09/09 00:00 [pubmed] PHST- 1999/09/09 00:01 [medline] PHST- 1999/09/09 00:00 [entrez] AID - 10.1002/(SICI)1096-9098(199909)72:1<14::AID-JSO4>3.0.CO;2-3 [pii] AID - 10.1002/(sici)1096-9098(199909)72:1<14::aid-jso4>3.0.co;2-3 [doi] PST - ppublish SO - J Surg Oncol. 1999 Sep;72(1):14-7. doi: 10.1002/(sici)1096-9098(199909)72:1<14::aid-jso4>3.0.co;2-3. PMID- 16141733 OWN - NLM STAT- MEDLINE DCOM- 20051229 LR - 20131121 IS - 1017-995X (Print) IS - 1017-995X (Linking) VI - 39 IP - 3 DP - 2005 TI - [The use of N-butyl-2-cyanoacrylate (Histoacryl) in primary tendon repair: a biomechanical study with sheep flexor tendons]. PG - 258-62 AB - OBJECTIVES: In this study, the biomechanical properties of peripheral tendon repair with the use of epitendinous suture technique and N-butyl-2-cyanoacrylate (Histoacryl) (NBSA), a biodegradable glue, were compared. METHODS: Twenty-four flexor tendons were harvested from sheep hind limbs. Following transection of the tendons, 12 tendons (group 1) were repaired with modified Kessler core sutures using no 2 prolene and epitendinous running sutures with 3/0 prolene. In the other 12 tendons (group 2), NBSA was applied between the cut surfaces before placing modified Kessler core sutures. Placed on an hydrolic test machine, half of the tendons from each group were subjected to load to failure with a tensile force of 20 mm/min and the other half to cyclic loading with a tensile loading between 1-15 N at a rate of 20 cycles/min. Observation of a gap of 1 mm between the tendon ends in each test was regarded as repair failure. RESULTS: The mean load to failure was 27.3 N (range 25 to 32 N) for group 1 and 50.4 N (range 32 to 63 N) for group 2 (p=0.022). The mean number of cycles at failure was 140 (range 45 to 250) in group 1 and 350 (range 150 to 600) in group 2 (p=0.032). CONCLUSION: Our results showed that peripheral tendon repair with the use of NBSA has biomechanical advantages over repair with the epitendinous running suture technique. FAU - Oztuna, Volkan AU - Oztuna V AD - Department of Orthopedics and Traumatology (Ortopedi ve Travmatoloji Anabilim Dali), Medicine Faculty of Mersin University, Mersin, Turkey. oztuna67@mersin.edu.tr FAU - Yilmaz, Ali AU - Yilmaz A FAU - Yilmaz, Cengiz AU - Yilmaz C FAU - Eskandari, Metin M AU - Eskandari MM FAU - Ayan, Irfan AU - Ayan I FAU - Milcan, Abtullah AU - Milcan A FAU - Kuyurtar, Fehmi AU - Kuyurtar F LA - tur PT - English Abstract PT - Journal Article TT - Tendon onariminda N-butil-2-siyanoakrilat (Histoakril) kullanimi: Koyun fleksör tendonuyla biyomekanik çalişma. PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Tissue Adhesives) RN - F8CEP82QNP (Enbucrilate) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Enbucrilate/administration & dosage/*analogs & derivatives MH - Hindlimb MH - Sheep MH - *Suture Techniques MH - Tendon Injuries/*surgery MH - Tissue Adhesives/*administration & dosage EDAT- 2005/09/06 09:00 MHDA- 2005/12/31 09:00 CRDT- 2005/09/06 09:00 PHST- 2005/09/06 09:00 [pubmed] PHST- 2005/12/31 09:00 [medline] PHST- 2005/09/06 09:00 [entrez] PST - ppublish SO - Acta Orthop Traumatol Turc. 2005;39(3):258-62. PMID- 24226553 OWN - NLM STAT- MEDLINE DCOM- 20140915 LR - 20231213 IS - 2567-6911 (Electronic) IS - 0932-0814 (Linking) VI - 27 IP - 1 DP - 2014 TI - Hinged circular fixator construct for correction of congenital metatarsal deformity in a foal. PG - 74-9 LID - 10.3415/VCOT-13-01-0007 [doi] AB - A five-week-old American Quarter Horse colt was presented for evaluation of a left hindlimb deformity and lameness. Radiographs of the left hindlimb revealed a varus deformity with recurvatum originating in the mid-diaphysis of the third metatarsal bone. Surgical correction was undertaken by performing an osteotomy through the centre of rotation of angulation located within the mid-diaphysis of the third metatarsal bone, and a four-ring hinged circular external fixator construct was applied. Distraction of the osteotomy site was performed over an 11 day period. Notable complications included failure of a fixation pin, infection of the surgical site, and temporary laxity of the supporting tendons and ligaments of the contralateral metatarsophalangeal joint. The fixator was maintained until there was sufficient bone formation to allow frame removal, 152 days after the initial surgery. Use of a hinged circular construct allowed for partial correction of the deformity with resultant lengthening and resolution of the lameness in this colt. FAU - Porter, E G AU - Porter EG AD - Erin G. Porter, DVM, DACVT, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, 2016 SW 16th Ave, Gainesville, FL 32610, United States, Phone: +1 352 318 0633, Fax: +1 352 392 2235, E-mail: Gordone@ufl.edu. FAU - Cuddy, L C AU - Cuddy LC FAU - Graham, A S AU - Graham AS FAU - Reese, D J AU - Reese DJ FAU - Porter, M B AU - Porter MB FAU - Morton, A J AU - Morton AJ FAU - Lewis, D D AU - Lewis DD LA - eng PT - Case Reports PT - Journal Article DEP - 20131113 PL - Germany TA - Vet Comp Orthop Traumatol JT - Veterinary and comparative orthopaedics and traumatology : V.C.O.T JID - 8906319 RN - 0 (Anti-Bacterial Agents) RN - C43C467DPE (Ceftizoxime) SB - IM MH - Animals MH - Anti-Bacterial Agents/administration & dosage/therapeutic use MH - Ceftizoxime/administration & dosage/analogs & derivatives/therapeutic use MH - Enterobacter cloacae MH - Enterobacteriaceae Infections/drug therapy/etiology/veterinary MH - External Fixators/*veterinary MH - Horse Diseases/*congenital/surgery MH - Horses MH - Male MH - Metatarsal Bones/*abnormalities/surgery MH - Surgical Wound Infection/drug therapy/veterinary MH - Treatment Outcome MH - Cefpodoxime OTO - NOTNLM OT - Distraction osteogenesis OT - congenital metatarsal deformity OT - external fixator OT - horse EDAT- 2013/11/15 06:00 MHDA- 2014/09/16 06:00 CRDT- 2013/11/15 06:00 PHST- 2013/01/11 00:00 [received] PHST- 2013/10/01 00:00 [accepted] PHST- 2013/11/15 06:00 [entrez] PHST- 2013/11/15 06:00 [pubmed] PHST- 2014/09/16 06:00 [medline] AID - 13-01-0007 [pii] AID - 10.3415/VCOT-13-01-0007 [doi] PST - ppublish SO - Vet Comp Orthop Traumatol. 2014;27(1):74-9. doi: 10.3415/VCOT-13-01-0007. Epub 2013 Nov 13. PMID- 8351815 OWN - NLM STAT- MEDLINE DCOM- 19930914 LR - 20191023 IS - 0161-3499 (Print) IS - 0161-3499 (Linking) VI - 22 IP - 4 DP - 1993 Jul-Aug TI - Epidural morphine in goats after hindlimb orthopedic surgery. PG - 307-10 AB - Morphine (0.1 mg/kg) diluted with 0.9% saline to a volume of 0.13 mL/kg was administered into the epidural space at the lumbosacral junction in 10 halothane-anesthetized goats immediately before discontinuation of halothane. The same volume of 0.9% saline was given to control group of eight anesthetized goats. Both groups had undergone an orthopedic procedure that replaced the anterior cruciate ligament with a patellar tendon autograft. The appearance and unprovoked behavior of goats in the morphine group were significantly different (p < .05) from the saline groups. The goats in the morphine group were more sedate and struggled less during recovery. Epidural morphine did not produce respiratory depression or bloat during a 9 hour observation period. Heart rate, respiratory rate, and blood pressure (mean, systolic, and diastolic) of the morphine group did not differ from those of the control group. FAU - Pablo, L S AU - Pablo LS AD - Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610-0136. LA - eng PT - Journal Article PL - United States TA - Vet Surg JT - Veterinary surgery : VS JID - 8113214 RN - 76I7G6D29C (Morphine) RN - UQT9G45D1P (Halothane) SB - IM MH - Analgesia, Epidural/*veterinary MH - Animals MH - Anterior Cruciate Ligament/surgery MH - Goats/*physiology MH - Halothane MH - Hemodynamics/*drug effects MH - Hindlimb MH - Morphine/*pharmacology MH - Pain, Postoperative/physiopathology/prevention & control/*veterinary MH - Respiration/drug effects MH - Tendons/transplantation EDAT- 1993/07/01 00:00 MHDA- 1993/07/01 00:01 CRDT- 1993/07/01 00:00 PHST- 1993/07/01 00:00 [pubmed] PHST- 1993/07/01 00:01 [medline] PHST- 1993/07/01 00:00 [entrez] AID - 10.1111/j.1532-950x.1993.tb00405.x [doi] PST - ppublish SO - Vet Surg. 1993 Jul-Aug;22(4):307-10. doi: 10.1111/j.1532-950x.1993.tb00405.x. PMID- 6240008 OWN - NLM STAT- MEDLINE DCOM- 19850221 LR - 20190726 IS - 0161-6420 (Print) IS - 0161-6420 (Linking) VI - 91 IP - 11 DP - 1984 Nov TI - Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. PG - 1411-9 AB - The exenterated orbital contents obtained post mortem from a 47-year-old man who had an eight-month history of treated hyperthyroidism and a two-month history of visual complaints were examined histopathologically, immunohistochemically, and by electron microscopy. All of the extraocular muscles were massively enlarged, due to early diffuse endomysial fibrosis, mucopolysaccharide deposition, and a predominantly perivascular lymphocytic and plasmacytic infiltration. Histochemical stains revealed that the intramuscular mucopolysaccharides were weakly sulfated and polycarboxylated, establishing that they were products of fibroblastic activation rather than derived from mast cells. Subsarcolemmal deposits in the myofibers were shown by electron microscopy to be collections of glycogen rosettes with intermixed lipid deposits. These inclusions were interpreted as secondary phenomena due to abnormal muscle energetics from restrictions in contractility, and not as evidence of a primary degeneration of the extraocular muscle fibers themselves. The sarcomeric organization of the striated muscle cells was undisturbed, and therefore the pathologic changes occurred int he interstitial space of the endomysium. A monoclonal antibody specific for neurofilaments (antibody 4.3 F9) revealed, in comparison with normal controls, a preferential loss of large-type axons of the proximal segment of the orbital portion of the optic nerve as well as in the intracanalicular portion. The axonal loss was associated with a mildly increased number of astrocytes as demonstrated by an antibody against glial fibrillary acidic protein. The meninges of the optic nerve, the orbital fat, and the tendons of the extraocular muscles were uninflamed. The foregoing findings are compatible with a compressive optic neuropathy mediated by the massively swollen extraocular muscles impinging upon the optic nerve at the orbital apex. FAU - Hufnagel, T J AU - Hufnagel TJ FAU - Hickey, W F AU - Hickey WF FAU - Cobbs, W H AU - Cobbs WH FAU - Jakobiec, F A AU - Jakobiec FA FAU - Iwamoto, T AU - Iwamoto T FAU - Eagle, R C AU - Eagle RC LA - eng GR - 5T3 2EYO 7041/EY/NEI NIH HHS/United States GR - EYO-3357/EY/NEI NIH HHS/United States PT - Case Reports PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Ophthalmology JT - Ophthalmology JID - 7802443 RN - 0 (Antibodies, Monoclonal) RN - 0 (Glycosaminoglycans) RN - 5B2658E0N2 (Aminosalicylic Acid) SB - IM MH - Aminosalicylic Acid MH - Antibodies, Monoclonal MH - Atrophy MH - Glycosaminoglycans/metabolism MH - Graves Disease/metabolism/*pathology MH - Histocytochemistry MH - Humans MH - Immunochemistry MH - Male MH - Middle Aged MH - Oculomotor Muscles/pathology MH - Optic Nerve/pathology MH - Orbit/*pathology/ultrastructure MH - Tomography, X-Ray Computed EDAT- 1984/11/01 00:00 MHDA- 1984/11/01 00:01 CRDT- 1984/11/01 00:00 PHST- 1984/11/01 00:00 [pubmed] PHST- 1984/11/01 00:01 [medline] PHST- 1984/11/01 00:00 [entrez] AID - S0161-6420(84)34152-5 [pii] AID - 10.1016/s0161-6420(84)34152-5 [doi] PST - ppublish SO - Ophthalmology. 1984 Nov;91(11):1411-9. doi: 10.1016/s0161-6420(84)34152-5. PMID- 9441558 OWN - NLM STAT- MEDLINE DCOM- 19980121 LR - 20221207 IS - 0001-6462 (Print) IS - 0001-6462 (Linking) VI - 63 IP - 3 DP - 1997 Sep TI - [Mri and surgical indications in perforating ulcer in diabetic patients]. PG - 156-64 AB - The authors report a series of thirty-six perforating ulcers of the foot in diabetic patients, evaluated using M.R.I. M.R.I. showed osteomyelitis in 16 cases, cellulitis in 15 cases, osteoarthropathies in 21 cases, tenosynovitis of flexor tendons in 2 cases, oedema in 2 cases and abscess in one case. In 19 cases, M.R.I. was used to improve diagnostic accuracy. The medical treatment made use of thermo-moulded soles allowing for the recovery of walking, with a hole facing the perforating ulcer of the foot. The application of insulin-soaked sponges in the event of clean perforating ulcer of the foot and iodized solution in the event of infected perforating ulcer of the foot promoted healing. The treatment was only conservative, when the lesions were limited to the soft tissues. Surgical treatment was performed in 19 cases due to a global involvement of soft and osteoarticular tissues. In fourteen cases the surgical treatment was limited and was performed through the perforating ulcer. Resection of metatarsal heads or metatarso-phalangeal joints was performed in 10 cases, with resection of surrounding pathologic tissue. The surgical treatment was limited to the soft tissues in 6 cases. In 4 cases, M.R.I. findings resulted into a transmetatarsal amputation because the vascular plexus was of poor quality and infection spread from the perforating ulcer to the dorsal aspect of the foot. In our opinion, dorsal infectious involvement in a perforating ulcer of the foot, is a factor of poor prognosis. A below-knee amputation has been performed in one patient. FAU - Jarde, O AU - Jarde O AD - Service d'orthopédie-taumatologie, Hôpital Nord, AMIENS, France. FAU - Filloux, V AU - Filloux V FAU - Filloux, J F AU - Filloux JF FAU - Remond, A AU - Remond A FAU - Vives, P AU - Vives P LA - fre PT - Journal Article TT - IRM et indications chirurgicales, dans le mal performant chez le diabétique. PL - Belgium TA - Acta Orthop Belg JT - Acta orthopaedica Belgica JID - 2985165R RN - 0 (Anti-Infective Agents, Local) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) RN - 85H0HZU99M (Povidone-Iodine) SB - IM MH - Abscess/diagnosis/drug therapy/surgery MH - Administration, Cutaneous MH - Adult MH - Aged MH - Amputation, Surgical MH - Anti-Infective Agents, Local/administration & dosage/therapeutic use MH - Bacterial Infections/surgery MH - Cellulitis/diagnosis/drug therapy/surgery MH - Diabetic Foot/*diagnosis/drug therapy/surgery MH - Edema/diagnosis/drug therapy/surgery MH - Equipment Design MH - Follow-Up Studies MH - Foot Diseases/diagnosis/drug therapy/surgery MH - Humans MH - Hypoglycemic Agents/administration & dosage/therapeutic use MH - Insulin/administration & dosage/therapeutic use MH - *Magnetic Resonance Imaging MH - Metatarsal Bones/surgery MH - Metatarsophalangeal Joint/surgery MH - Middle Aged MH - Osteoarthritis/diagnosis/drug therapy/surgery MH - Osteomyelitis/diagnosis/drug therapy/surgery MH - Povidone-Iodine/administration & dosage/therapeutic use MH - Prognosis MH - Shoes MH - Tenosynovitis/diagnosis/drug therapy/surgery MH - Walking MH - Wound Healing EDAT- 1998/01/24 00:00 MHDA- 1998/01/24 00:01 CRDT- 1998/01/24 00:00 PHST- 1998/01/24 00:00 [pubmed] PHST- 1998/01/24 00:01 [medline] PHST- 1998/01/24 00:00 [entrez] PST - ppublish SO - Acta Orthop Belg. 1997 Sep;63(3):156-64. PMID- 21357497 OWN - NLM STAT- MEDLINE DCOM- 20110613 LR - 20161125 IS - 1945-1997 (Electronic) IS - 0098-6151 (Linking) VI - 111 IP - 2 DP - 2011 Feb TI - Management of Dupuytren contracture with ultrasound-guided lidocaine injection and needle aponeurotomy coupled with osteopathic manipulative treatment. PG - 113-6 AB - Dupuytren contracture is a debilitating disease that characteristically presents as a firm nodularity on the palmar surface of the hand with coalescing cords of soft tissue on the webs and digits. With few nonsurgical modalities providing clinical benefits, open surgical procedures are the standard of care for patients with this condition. However, recent studies have associated surgical intervention with many complications, necessitating further exploration of nonsurgical treatment options. We describe the case of a 64-year-old woman who presented with decreased extension of the fourth and fifth digits on the upper extremities bilaterally; previous conservative treatment regimens had been unsuccessful. After a diagnostic ultrasound, the patient was diagnosed as having Dupuytren contracture and underwent 5 treatments consisting of ultrasound-guided dry-needle aponeurotomy, lidocaine injections, and osteopathic manipulative treatment. During the fifth treatment session, the patient experienced dramatic relief of her symptoms after a palpable release during the manual manipulation portion of her therapeutic regimen. At 2-week follow-up, the patient was symptom-free. Based on this desirable outcome, the authors suggest future research be directed at minimally invasive therapeutic options in the management of Dupuytren contracture. FAU - Sampson, Steven AU - Sampson S AD - The Orthohealing Center, 10780 Santa Monica Blvd Suite 440, Los Angeles, CA 90025, USA. drsampson@orthohealing.com FAU - Meng, Michael AU - Meng M FAU - Schulte, Adam AU - Schulte A FAU - Trainor, Drew AU - Trainor D FAU - Montenegro, Roberto AU - Montenegro R FAU - Aufiero, Danielle AU - Aufiero D LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Osteopath Assoc JT - The Journal of the American Osteopathic Association JID - 7503065 RN - 98PI200987 (Lidocaine) SB - IM MH - Dupuytren Contracture/diagnostic imaging/*drug therapy/surgery MH - Fascia/ultrastructure MH - Fasciotomy MH - Female MH - Humans MH - Injections, Intramuscular MH - Lidocaine/administration & dosage/*therapeutic use MH - *Manipulation, Osteopathic MH - Middle Aged MH - Minimally Invasive Surgical Procedures MH - *Needles MH - Tendons/diagnostic imaging/surgery MH - Treatment Outcome MH - *Ultrasonography, Interventional EDAT- 2011/03/02 06:00 MHDA- 2011/06/15 06:00 CRDT- 2011/03/02 06:00 PHST- 2011/03/02 06:00 [entrez] PHST- 2011/03/02 06:00 [pubmed] PHST- 2011/06/15 06:00 [medline] AID - 111/2/113 [pii] PST - ppublish SO - J Am Osteopath Assoc. 2011 Feb;111(2):113-6. PMID- 3958966 OWN - NLM STAT- MEDLINE DCOM- 19860515 LR - 20141120 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 237 IP - 1 DP - 1986 Apr TI - Comparative electropharmacology of mexiletine, lidocaine and quinidine in a canine Purkinje fiber model. PG - 232-6 AB - Although said to be lidocaine-like, there is evidence that mexiletine has some properties similar to those of quinidine. To evaluate the relationship between the effects of these three drugs we analyzed their effects on action potentials of Purkinje fibers from canine false tendons. Experiments with each drug were done on single preparations from each of six dogs over the concentration range 0.31 to 10.0 X 10(-5) M. Lidocaine shortened action potential duration and effective refractory period with a log concentration-response relationship. The maximum velocity of phase "0" (Vmax) was unaffected at low concentrations and only slightly depressed at high concentrations. Quinidine also shortened action potential duration and effective refractory period but the effect levelled off at midrange and was reversed at higher concentrations. Quinidine depressed Vmax throughout the concentration range studied. Mexiletine shortened action potential duration with a log concentration response relationship. Effective refractory period was shortened at low concentrations but the effect levelled off and then reversed at higher concentrations of the drug. Mexiletine had no effect on Vmax at the lower end of the concentration curve but did suppress this parameter at higher concentrations. Mexiletine resembled lidocaine in its effect on Vmax and action potential duration whereas the effects of quinidine on these two parameters were distinct. On the other hand, the effects of mexiletine on effective refractory period were more akin to quinidine than lidocaine. FAU - Burke, G H AU - Burke GH FAU - Loukides, J E AU - Loukides JE FAU - Berman, N D AU - Berman ND LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Propylamines) RN - 1U511HHV4Z (Mexiletine) RN - 98PI200987 (Lidocaine) RN - 9NEZ333N27 (Sodium) RN - ITX08688JL (Quinidine) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Dogs MH - Dose-Response Relationship, Drug MH - Electric Conductivity MH - Heart/*drug effects MH - In Vitro Techniques MH - Lidocaine/*pharmacology MH - Membrane Potentials/drug effects MH - Mexiletine/*pharmacology MH - Propylamines/*pharmacology MH - Purkinje Fibers/drug effects/physiology MH - Quinidine/*pharmacology MH - Sodium/physiology MH - Time Factors EDAT- 1986/04/01 00:00 MHDA- 1986/04/01 00:01 CRDT- 1986/04/01 00:00 PHST- 1986/04/01 00:00 [pubmed] PHST- 1986/04/01 00:01 [medline] PHST- 1986/04/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1986 Apr;237(1):232-6. PMID- 6091602 OWN - NLM STAT- MEDLINE DCOM- 19841121 LR - 20151119 IS - 0005-2086 (Print) IS - 0005-2086 (Linking) VI - 28 IP - 3 DP - 1984 Jul-Sep TI - Severity of tenosynovitis in reovirus-infected chickens fed various dietary levels of choline, folic acid, manganese, biotin, or niacin. PG - 562-73 AB - Five experiments were conducted to determine the incidence and severity of tenosynovitis in tendons distal to the tarsal joint in 4-, 6-, and 8-week-old reovirus WVU 2937-infected chickens fed diets containing 20%, 100%, or 200% of the 1977 National Research Council nutrient requirements (NCR-77) of manganese, biotin, niacin, choline, or folic acid. Male chickens, but not female chickens, fed 20% or 100% or the NRC-77 level of folic acid had consistently higher lesion scores of tenosynovitis than male chickens fed the 200% NRC-77 level of folic acid. Increasing dietary manganese levels from 20% to 200% NRC-77 reduced the severity of tendon swelling in 6- and 8-week-old male chickens and appeared to increase the severity of tendon swelling in 8-week-old female chickens. Male chickens fed 20% of the NRC-77 required level of biotin had numerically more severe tenosynovitis at 6 weeks of age and significantly more severe tenosynovitis at 8 weeks of age than male chickens fed 100% and 200% of the NRC-77 level of biotin. Increasing dietary choline levels from 20% to 200% of the NCR-77 required level increased the severity of tenosynovitis numerically at 6 weeks of age and significantly at 8 weeks of age. When data were pooled across diet, male chickens had significantly more severe tenosynovitis than female chickens at 4, 6, and 8 weeks of age in the choline experiment and at 4 and 6 weeks of age in the folic acid experiment. Differences in the severity of tenosynovitis of individual treatment means (sex X diet X infection interaction means) occurred at only the 20% or 100% NRC-77 level of choline or folic acid. Male chickens also had more severe tenosynovitis than female chickens when fed 20% of the NRC-77 required level of manganese for 6 or 8 weeks. FAU - Cook, M E AU - Cook ME FAU - Springer, W T AU - Springer WT FAU - Kerr, K M AU - Kerr KM FAU - Hebert, J A AU - Hebert JA LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Avian Dis JT - Avian diseases JID - 0370617 RN - 2679MF687A (Niacin) RN - 42Z2K6ZL8P (Manganese) RN - 6SO6U10H04 (Biotin) RN - 935E97BOY8 (Folic Acid) RN - N91BDP6H0X (Choline) SB - IM MH - Age Factors MH - Animals MH - Biotin/*administration & dosage MH - *Chickens MH - Choline/*administration & dosage MH - Female MH - Folic Acid/*administration & dosage MH - Male MH - Manganese/*administration & dosage MH - Niacin/*administration & dosage MH - Nutritional Requirements MH - Poultry Diseases/*pathology MH - Reoviridae Infections/pathology/*veterinary MH - Sex Factors MH - Tenosynovitis/pathology/*veterinary EDAT- 1984/07/01 00:00 MHDA- 1984/07/01 00:01 CRDT- 1984/07/01 00:00 PHST- 1984/07/01 00:00 [pubmed] PHST- 1984/07/01 00:01 [medline] PHST- 1984/07/01 00:00 [entrez] PST - ppublish SO - Avian Dis. 1984 Jul-Sep;28(3):562-73. PMID- 23404939 OWN - NLM STAT- MEDLINE DCOM- 20131217 LR - 20211021 IS - 1552-4930 (Electronic) IS - 1552-4922 (Print) IS - 1552-4922 (Linking) VI - 83 IP - 6 DP - 2013 Jun TI - Col-F, a fluorescent probe for ex vivo confocal imaging of collagen and elastin in animal tissues. PG - 533-9 LID - 10.1002/cyto.a.22264 [doi] AB - A new low-molecular-weight fluorescent probe, Col-F, that exhibits affinity to collagen and elastin, was used successfully in imaging of extracellular matrix in freshly excised animal tissues. Col-F readily penetrates between live cells into tissues and binds to fibers of collagen and elastin by a noncovalent mechanism. Fibers of collagen and elastin have been stained in a variety of tissues, including tendon, skeletal muscle, connective tissue, and arteries. Cells migrating in a Col-F-stained collagenous biomaterial were also imaged. No phototoxic effects were detected when live keratocytes were imaged in the in vitro culture in the presence of Col-F. In conclusion, Col-F provides a simple and convenient tool for fluorescence three-dimensional imaging of intricate collagenous and elastic structures in live and fixed animal tissues, as well as in collagen-containing biomaterials. CI - Copyright © 2013 International Society for Advancement of Cytometry. FAU - Biela, Ewa AU - Biela E AD - Division of Cell Biophysics, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Kraków, Poland. FAU - Galas, Jerzy AU - Galas J FAU - Lee, Brian AU - Lee B FAU - Johnson, Gary L AU - Johnson GL FAU - Darzynkiewicz, Zbigniew AU - Darzynkiewicz Z FAU - Dobrucki, Jurek W AU - Dobrucki JW LA - eng GR - R01 CA028704/CA/NCI NIH HHS/United States GR - CA 28704/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20130212 PL - United States TA - Cytometry A JT - Cytometry. Part A : the journal of the International Society for Analytical Cytology JID - 101235694 RN - 0 (Col-F compound) RN - 0 (Fluoresceins) RN - 0 (Fluorescent Dyes) RN - 9007-34-5 (Collagen) RN - 9007-58-3 (Elastin) RN - 9U1VM840SP (Physostigmine) SB - IM MH - Animals MH - Arteries/chemistry/ultrastructure MH - Biological Transport MH - Collagen/chemistry/*ultrastructure MH - Connective Tissue/chemistry/ultrastructure MH - Elastin/chemistry/*ultrastructure MH - Extracellular Matrix/chemistry/*ultrastructure MH - Fluoresceins/*chemical synthesis/metabolism MH - Fluorescent Dyes/*chemical synthesis/metabolism MH - HeLa Cells MH - Humans MH - Imaging, Three-Dimensional/*methods MH - Mice MH - Microscopy, Fluorescence MH - Muscle, Skeletal/chemistry/ultrastructure MH - Physostigmine/*analogs & derivatives/chemical synthesis/metabolism MH - Tendons/chemistry/ultrastructure PMC - PMC3671577 MID - NIHMS468348 COIS- Conflict of interests. The authors declare a conflict of interests; BJ and GLJ represent the manufacturer of Col-F. EDAT- 2013/02/14 06:00 MHDA- 2013/12/18 06:00 PMCR- 2014/06/01 CRDT- 2013/02/14 06:00 PHST- 2012/07/02 00:00 [received] PHST- 2013/01/12 00:00 [revised] PHST- 2013/01/15 00:00 [accepted] PHST- 2013/02/14 06:00 [entrez] PHST- 2013/02/14 06:00 [pubmed] PHST- 2013/12/18 06:00 [medline] PHST- 2014/06/01 00:00 [pmc-release] AID - 10.1002/cyto.a.22264 [doi] PST - ppublish SO - Cytometry A. 2013 Jun;83(6):533-9. doi: 10.1002/cyto.a.22264. Epub 2013 Feb 12. PMID- 28444753 OWN - NLM STAT- MEDLINE DCOM- 20170831 LR - 20170831 IS - 1751-0813 (Electronic) IS - 0005-0423 (Linking) VI - 95 IP - 5 DP - 2017 May TI - Examination of toxicity and collagen linearity after the administration of the protein cross-linker genipin in equine tendon and dermis: a pilot study. PG - 167-173 LID - 10.1111/avj.12583 [doi] AB - OBJECTIVE: Collagen cross-linking is an attractive therapeutic route aimed at supplementing natural collagen stabilisation. In this study the toxicity of the cross-linker genipin (GP) was examined in avascular (tendon) and vascular (dermis) tissue. METHODS: High doses of GP were injected intratendinously into three yearling horses and evaluated at various time points up to 30 days. A second group of three yearlings were injected into the dermis and evaluated at various time points up to 1 year. Metrics used included lameness, circumferential swelling, ultrasound evaluation, microscopic morphology, collagen production and systemic effect on blood parameters. RESULTS: The tendon injection sites exhibited mild lameness and swelling with no apparent systemic toxicity or stabilisation defects. Treated tendons exhibited increased linear collagen microscopically. Dermal injections showed similar results, with mild swelling at the injection site. Microscopic morphology resulted in a decrease in dermal collagen at 30 days post-injection. Dermis injected at the high dose of 355 mmol/L examined 1 year post-treatment appeared similar to the untreated biopsies; however, there was an increase in mature collagen. CONCLUSION: GP injection appeared to be well tolerated, with transient lameness and mild circumferential swelling when injected into the tendon and local tissue swelling when injected into the dermis. No systemic hypersensitivities or toxicities were observed. Microscopically, GP resulted in increased linear collagen in tendons at 30 days post-injection and overall increased collagen in dermal tissue when evaluated 1 year post-injection. CI - © 2017 Australian Veterinary Association. FAU - Bellefeuille, M AU - Bellefeuille M AD - Equine Sports Medicine & Surgery, Weatherford, Texas, USA. FAU - Peters, D F AU - Peters DF AD - College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. FAU - Nolin, M AU - Nolin M AD - Equinext LLC, Lexington, Kentucky, USA. FAU - Slusarewicz, P AU - Slusarewicz P AD - Equinext LLC, Lexington, Kentucky, USA. FAU - Telgenhoff, D AU - Telgenhoff D AD - Medical Laboratory Science Department, Tarleton State University, 1501 Enderly Place, Fort Worth, Texas 76104, USA. LA - eng PT - Journal Article PL - England TA - Aust Vet J JT - Australian veterinary journal JID - 0370616 RN - 0 (Iridoids) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Collagen/*drug effects MH - Dermis/*drug effects/pathology MH - Horses/injuries MH - Injections, Intradermal/veterinary MH - Iridoids/*metabolism/*toxicity MH - Lameness, Animal/chemically induced MH - Male MH - Pilot Projects MH - Tendon Injuries/drug therapy/veterinary MH - Tendons/*drug effects MH - Wound Healing OTO - NOTNLM OT - collagen OT - cross-linking OT - genipin OT - histology OT - horses EDAT- 2017/04/27 06:00 MHDA- 2017/09/01 06:00 CRDT- 2017/04/27 06:00 PHST- 2014/12/30 00:00 [received] PHST- 2016/06/26 00:00 [revised] PHST- 2016/06/29 00:00 [accepted] PHST- 2017/04/27 06:00 [entrez] PHST- 2017/04/27 06:00 [pubmed] PHST- 2017/09/01 06:00 [medline] AID - 10.1111/avj.12583 [doi] PST - ppublish SO - Aust Vet J. 2017 May;95(5):167-173. doi: 10.1111/avj.12583. PMID- 30019701 OWN - NLM STAT- MEDLINE DCOM- 20181101 LR - 20181101 IS - 1689-0035 (Electronic) IS - 0065-1400 (Linking) VI - 78 IP - 2 DP - 2018 TI - Fos immunoreactivity in the intermediolateral nucleus induced by tendon vibration of the m. triceps surae in rats pretreated with a nitric oxide blocker or precursor. PG - 82-91 AB - We investigated neuronal activation of the rat intermediolateral (IML) nucleus of the thoracolumbar spinal cord, initiated by Achilles tendon vibration, after intramuscular (m. triceps surae) administration of 7‑nitroindazole (7‑NI) or L‑arginine (LA). The spindle afferent response to vibratory stimuli induced a distinct bilateral increase in the activation of c‑Fos immunoreactivity in the spinal neurons in three groups of rats (tendon‑vibrated, tendon‑vibrated + 7‑NI and tendon‑vibrated + LA). The T5/T13 segments in tendon‑vibrated +7‑NI animals showed the highest increase of Fos‑immunoreactive neurons. This increase was two times higher than that in tendon only‑vibrated control rats and endon‑vibrated + LA animals. The highest mean number of labelled neurons were observed in the IML nucleus and in layers 4 and 7 of the T5-L3 segments in tendon‑vibrated and tendon‑vibrated + 7‑NI animals, and in the IML nucleus and layer 4 in tendon‑vibrated + LA rats. The highest mean number of activated neurons was found ipsilaterally in the IML nucleus of the T5/T13 segment. These results indicate that decreased nitric oxide release after injection of 7‑NI was accompanied by a potentiation of the early c‑fos gene expression induced by muscle proprioceptive activity within the thoracolumbar region of the rat spinal cord. Thus, enhanced c‑Fos immunoreactivity in the IML nucleus indicated that the sympathetic nervous system can exert a direct influence on the muscle spindles. FAU - Vereshchaka, Inna V AU - Vereshchaka IV AD - University of Physical Education and Sport, Gdansk, Poland, inna.vereshchaka@awf.gda.pl. FAU - Maznychenko, Andriy V AU - Maznychenko AV AD - Department of Movement Physiology, Bogomoletz Institute of Physiology, Kyiv, Ukraine. FAU - Mankivska, Olena P AU - Mankivska OP AD - Department of Cytology, Bogomoletz Institute of Physiology, Kyiv, Ukraine. FAU - Maisky, Volodymyr O AU - Maisky VO AD - Department of Cytology, Bogomoletz Institute of Physiology, Kyiv, Ukraine. FAU - Vlasenko, Oleh V AU - Vlasenko OV AD - Laboratory of Experimental Neurophysiology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine. FAU - Dovgan', Olexandr V AU - Dovgan' OV AD - Laboratory of Experimental Neurophysiology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine. FAU - Ocheretna, Olga L AU - Ocheretna OL AD - Laboratory of Experimental Neurophysiology, National Pirogov Memorial Medical University, Vinnytsya, Ukraine. FAU - Tomiak, Tomasz AU - Tomiak T AD - University of Physical Education and Sport, Gdansk, Poland. FAU - Kostyukov, Alexander I AU - Kostyukov AI AD - Department of Movement Physiology, Bogomoletz Institute of Physiology, Kyiv, Ukraine. LA - eng PT - Journal Article PL - Poland TA - Acta Neurobiol Exp (Wars) JT - Acta neurobiologiae experimentalis JID - 1246675 RN - 0 (Proto-Oncogene Proteins c-fos) RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Animals MH - *Immunohistochemistry MH - Male MH - Muscle, Skeletal/metabolism MH - Neurons/*metabolism MH - Nitric Oxide/antagonists & inhibitors MH - Proto-Oncogene Proteins c-fos/*metabolism MH - Rats, Wistar MH - Spinal Cord/metabolism MH - Spinal Cord Lateral Horn/*metabolism MH - Tendons/*metabolism MH - Vibration EDAT- 2018/07/19 06:00 MHDA- 2018/11/02 06:00 CRDT- 2018/07/19 06:00 PHST- 2018/07/19 06:00 [entrez] PHST- 2018/07/19 06:00 [pubmed] PHST- 2018/11/02 06:00 [medline] AID - 7812 [pii] PST - ppublish SO - Acta Neurobiol Exp (Wars). 2018;78(2):82-91. PMID- 6747425 OWN - NLM STAT- MEDLINE DCOM- 19840911 LR - 20220311 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 9 IP - 2 DP - 1984 Jun TI - The dangers of sclerotherapy in the treatment of ganglia. PG - 181-4 AB - Sixteen ganglia were treated by injection with sclerosant (Sodium Tetradecyl Disulphate), fifteen failed to respond. We present radiological and electron microscopical data together with animal studies to explain the failure and to show the inherent dangers of this therapy. FAU - Mackie, I G AU - Mackie IG FAU - Howard, C B AU - Howard CB FAU - Wilkins, P AU - Wilkins P LA - eng PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Fatty Alcohols) RN - 0 (Sclerosing Solutions) RN - Q1SUG5KBD6 (Sodium Tetradecyl Sulfate) SB - IM MH - Animals MH - Chickens MH - Fatty Alcohols/*adverse effects MH - Fibroblasts/pathology MH - Humans MH - Knee Joint/*pathology MH - Plasma Cells/pathology MH - Rats MH - Sclerosing Solutions/*adverse effects/therapeutic use MH - Sodium Tetradecyl Sulfate/*adverse effects/therapeutic use MH - Synovial Cyst/*therapy/ultrastructure MH - Tendons/*pathology MH - *Wrist EDAT- 1984/06/01 00:00 MHDA- 1984/06/01 00:01 CRDT- 1984/06/01 00:00 PHST- 1984/06/01 00:00 [pubmed] PHST- 1984/06/01 00:01 [medline] PHST- 1984/06/01 00:00 [entrez] PST - ppublish SO - J Hand Surg Br. 1984 Jun;9(2):181-4. PMID- 3978911 OWN - NLM STAT- MEDLINE DCOM- 19850503 LR - 20220419 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 194 DP - 1985 Apr TI - Gouty infiltration of a flexor tendon simulating rupture. PG - 172-5 AB - A 28-year-old hyperuricemic man injured his left long finger and presented with a possible rupture of the flexor digitorum profundus. Operative exploration revealed gouty infiltration of the flexor tendon within its fibrous synovial sheath. Urate crystal deposition in tendons is rare. Superimposed trauma was a possible predisposing factor. FAU - Hankin, F M AU - Hankin FM FAU - Mayhew, D E AU - Mayhew DE FAU - Coapman, R A AU - Coapman RA FAU - Snedden, M AU - Snedden M FAU - Schneider, L H AU - Schneider LH LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - *Fingers MH - Gout/diagnosis/*pathology MH - Humans MH - Male MH - Rupture MH - Tendon Injuries/diagnosis MH - Tendons/*pathology MH - Uric Acid/metabolism EDAT- 1985/04/01 00:00 MHDA- 1985/04/01 00:01 CRDT- 1985/04/01 00:00 PHST- 1985/04/01 00:00 [pubmed] PHST- 1985/04/01 00:01 [medline] PHST- 1985/04/01 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1985 Apr;(194):172-5. PMID- 6417973 OWN - NLM STAT- MEDLINE DCOM- 19840107 LR - 20190829 IS - 0001-6683 (Print) IS - 0001-6683 (Linking) VI - 53 IP - 4 DP - 1983 Oct TI - Fenflumizole: interactions with the arachidonic acid cascade. PG - 297-303 AB - Fenflumizole (2-(2,4-difluorophenyl)-4,5-bis(4-methoxyphenyl)imidazole), a new non-steroidal anti-inflammatory agent, was investigated for interference with cyclo-oxygenase activity in vivo, ex vivo and in vitro in comparison with indomethacin (and aspirin). Fenflumizole was comparable to indomethacin ex vivo in inhibition of thromboxane (TX)A2 production in rabbit platelets and inhibition of prostaglandin (PG)I2 (approximately prostacyclin) generation in rabbit mesenteric arteries and in vivo as an inhibitor of PGE2 formation in inflammatory exudates in rats. Fenflumizole was 18 times less active than indomethacin in inhibition of PGE2 synthesis in vitro and 170 times weaker as an inhibitor of PGI2 generation in the rat stomach mucosa ex vivo. Fenflumizole was 20-50 times more potent than indomethacin in vivo in inhibition of arachidonic acid induced bronchoconstriction in guinea-pigs, in inhibition of platelet aggregation on tendons superfused with blood from rabbits and in vitro in inhibition of aggregation of human and rabbit platelets. Neither fenflumizole nor indomethacin inhibited TXA2-synthetase in vitro. Aspirin-when tested-was less potent than fenflumizole and indomethacin. It is concluded that fenflumizole is a potent cyclo-oxygenase inhibitor. The very potent activity of fenflumizole against platelet aggregation and bronchoconstriction suggests a selectivity in the mode of action. The weak inhibition of gastric PGI2 generation may account for the previously observed weak gastro-ulcerogenicity of fenflumizole. FAU - Corell, T AU - Corell T FAU - Hasselmann, G AU - Hasselmann G FAU - Splawinski, J AU - Splawinski J FAU - Wojtaszek, B AU - Wojtaszek B LA - eng PT - Comparative Study PT - Journal Article PL - Denmark TA - Acta Pharmacol Toxicol (Copenh) JT - Acta pharmacologica et toxicologica JID - 0370572 RN - 0 (Arachidonic Acids) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Imidazoles) RN - 0 (Prostaglandins E) RN - 57576-52-0 (Thromboxane A2) RN - DCR9Z582X0 (Epoprostenol) RN - K7Q1JQR04M (Dinoprostone) RN - PD0931191Q (fenflumizole) RN - R16CO5Y76E (Aspirin) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Arachidonic Acids/*pharmacology MH - Aspirin/pharmacology MH - Blood Platelets/metabolism MH - Cattle MH - *Cyclooxygenase Inhibitors MH - Dinoprostone MH - Drug Interactions MH - Epoprostenol/biosynthesis MH - Exudates and Transudates/metabolism MH - Guinea Pigs MH - Imidazoles/*pharmacology MH - In Vitro Techniques MH - Indomethacin/pharmacology MH - Inflammation/metabolism MH - Male MH - Platelet Aggregation/drug effects MH - Prostaglandins E/biosynthesis MH - Rabbits MH - Rats MH - Rats, Inbred Strains MH - Thromboxane A2/biosynthesis EDAT- 1983/10/01 00:00 MHDA- 1983/10/01 00:01 CRDT- 1983/10/01 00:00 PHST- 1983/10/01 00:00 [pubmed] PHST- 1983/10/01 00:01 [medline] PHST- 1983/10/01 00:00 [entrez] AID - 10.1111/j.1600-0773.1983.tb03426.x [doi] PST - ppublish SO - Acta Pharmacol Toxicol (Copenh). 1983 Oct;53(4):297-303. doi: 10.1111/j.1600-0773.1983.tb03426.x. PMID- 5652883 OWN - NLM STAT- MEDLINE DCOM- 19680725 LR - 20190511 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 196 IP - 2 DP - 1968 May TI - On the increase in rate of heat production caused by stretch in frog's skeletal muscle. PG - 397-414 AB - 1. The increase in rate of heat production caused by stretch in the unstimulated frog's sartorius (stretch response) has been measured using a conventional thermopile technique.2. The rate of heat production was found constant between l(0) (the distance in vivo between the tendons when the legs were in a straight line) and 1.2 l(0), and rose rapidly above this length to reach 3-5 times the basal rate at 1.3 l(0). Stretching to greater lengths appeared to damage the muscles.3. The stretch response is increased by several substances which increase the duration of the active state.4. Unlike the rate of heat production at l(0), the stretch response is increased by procaine; while the presence of CO(2) greatly reduces it.5. Evidence is presented supporting the hypothesis that the stretch response is associated with the appearance of tension in the sarcolemma. FAU - Clinch, N F AU - Clinch NF LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (Imidazoles) RN - 0 (Sulfates) RN - 0 (Thiocyanates) RN - 142M471B3J (Carbon Dioxide) RN - 3G6A5W338E (Caffeine) RN - 451W47IQ8X (Sodium Chloride) RN - 4Z8Y51M438 (Procaine) RN - A7V27PHC7A (Quinine) RN - J41CSQ7QDS (Zinc) SB - IM MH - Animals MH - Anura MH - Body Temperature Regulation/*physiology MH - Caffeine/pharmacology MH - Carbon Dioxide/pharmacology MH - Electrophysiology MH - Hydrogen-Ion Concentration MH - Imidazoles/pharmacology MH - In Vitro Techniques MH - Methods MH - Muscles/*physiology MH - Procaine/pharmacology MH - Quinine/pharmacology MH - Sarcolemma MH - Sodium Chloride/pharmacology MH - Species Specificity MH - Sulfates/pharmacology MH - Thiocyanates/pharmacology MH - Zinc/pharmacology PMC - PMC1351719 EDAT- 1968/05/01 00:00 MHDA- 1968/05/01 00:01 PMCR- 1969/05/01 CRDT- 1968/05/01 00:00 PHST- 1968/05/01 00:00 [pubmed] PHST- 1968/05/01 00:01 [medline] PHST- 1968/05/01 00:00 [entrez] PHST- 1969/05/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1968.sp008514 [doi] PST - ppublish SO - J Physiol. 1968 May;196(2):397-414. doi: 10.1113/jphysiol.1968.sp008514. PMID- 22561379 OWN - NLM STAT- MEDLINE DCOM- 20120925 LR - 20161018 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 91 IP - 7 DP - 2012 Jul TI - Simultaneous and spontaneous bilateral quadriceps tendons rupture. PG - 631-4 LID - 10.1097/PHM.0b013e3182555dbb [doi] AB - Simultaneous and spontaneous bilateral quadriceps tendon rupture is an uncommon injury that is usually seen in association with multiple medical conditions and some medications. We report a case of simultaneous and spontaneous bilateral quadriceps tendon rupture that may be related to the long-term use of a statin. FAU - Celik, Evrim Coşkun AU - Celik EC AD - Physical Medicine and Rehabilitation Department, Faculty of Medicine, Başkent University, Istanbul, Turkey. FAU - Ozbaydar, Mehmet AU - Ozbaydar M FAU - Ofluoglu, Demet AU - Ofluoglu D FAU - Demircay, Emre AU - Demircay E LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 0 (Fluorobenzenes) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Pyrimidines) RN - 0 (Sulfonamides) RN - 83MVU38M7Q (Rosuvastatin Calcium) SB - IM CIN - Am J Phys Med Rehabil. 2014 Jan;93(1):97-8. doi: 10.1097/PHM.0b013e318296e2d7. PMID: 23739272 CIN - Am J Phys Med Rehabil. 2014 Jan;93(1):98-9. doi: 10.1097/PHM.0b013e318296d97f. PMID: 24355998 MH - Fluorobenzenes/adverse effects MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects MH - Knee Injuries/diagnosis/*etiology/*surgery MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Pyrimidines/adverse effects MH - Rosuvastatin Calcium MH - Rupture/diagnosis/etiology/surgery MH - Sulfonamides/adverse effects MH - Tendon Injuries/diagnosis/*etiology/*surgery EDAT- 2012/05/09 06:00 MHDA- 2012/09/26 06:00 CRDT- 2012/05/08 06:00 PHST- 2012/05/08 06:00 [entrez] PHST- 2012/05/09 06:00 [pubmed] PHST- 2012/09/26 06:00 [medline] AID - 10.1097/PHM.0b013e3182555dbb [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2012 Jul;91(7):631-4. doi: 10.1097/PHM.0b013e3182555dbb. PMID- 1538103 OWN - NLM STAT- MEDLINE DCOM- 19920402 LR - 20190827 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 17 IP - 1 DP - 1992 Jan TI - Tenosynovial injection for carpal tunnel syndrome. PG - 178-81 AB - Although local steroid injection into the tenosynovium is a frequent treatment for carpal tunnel syndrome, it involves some risk and is not always effective. We simulated injection on 16 fresh cadaver forearms, instilling 1 ml (group 1) or 2 ml (group 2) of methylene blue at 1 cm or 3 cm proximal to the most distal wrist crease. Passive flexion and extension were simulated 2 minutes after injection by application of traction to the appropriate digital tendons. Specimens were dissected under loupe magnification from midpalm to midforearm, dye diffusion was quantified and photographed, sections of the carpal tunnel and contents were graded for presence of dye, and average values were determined for each of the four groups. Diffusion of dye was best in group 2B in which 2 ml was injected 3 cm proximal to the distal wrist flexion crease. FAU - Minamikawa, Y AU - Minamikawa Y AD - Department of Orthopaedic Surgery, State University of New York, School of Medicine and Biomedical Sciences, Buffalo. FAU - Peimer, C A AU - Peimer CA FAU - Kambe, K AU - Kambe K FAU - Wheeler, D R AU - Wheeler DR FAU - Sherwin, F S AU - Sherwin FS LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Steroids) RN - T42P99266K (Methylene Blue) SB - IM MH - Cadaver MH - Carpal Tunnel Syndrome/*drug therapy MH - Humans MH - Injections, Intralesional/*methods MH - Methylene Blue/administration & dosage MH - Steroids/administration & dosage/therapeutic use EDAT- 1992/01/01 00:00 MHDA- 1992/01/01 00:01 CRDT- 1992/01/01 00:00 PHST- 1992/01/01 00:00 [pubmed] PHST- 1992/01/01 00:01 [medline] PHST- 1992/01/01 00:00 [entrez] AID - 0363-5023(92)90137-E [pii] AID - 10.1016/0363-5023(92)90137-e [doi] PST - ppublish SO - J Hand Surg Am. 1992 Jan;17(1):178-81. doi: 10.1016/0363-5023(92)90137-e. PMID- 23430345 OWN - NLM STAT- MEDLINE DCOM- 20150110 LR - 20211203 IS - 1776-260X (Electronic) IS - 1776-2596 (Linking) VI - 9 IP - 1 DP - 2014 Mar TI - Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor. PG - 73-9 LID - 10.1007/s11523-013-0267-8 [doi] FAU - Sikaria, Swati AU - Sikaria S AD - Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SCCT Mezzanine MS 35, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA. FAU - Heim-Hall, Josefine AU - Heim-Hall J FAU - Diaz, Elizabeth H AU - Diaz EH FAU - Williams, Ronald AU - Williams R FAU - Sankhala, Kamelesh AU - Sankhala K FAU - Laabs, Brenda AU - Laabs B FAU - Mita, Monica AU - Mita M LA - eng PT - Case Reports PT - Journal Article DEP - 20130221 PL - France TA - Target Oncol JT - Targeted oncology JID - 101270595 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Receptors, Somatomedin) RN - 9HW64Q8G6G (Everolimus) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - V983921H3B (robatumumab) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Antibodies, Monoclonal/*administration & dosage MH - Antibodies, Monoclonal, Humanized MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Everolimus MH - Giant Cell Tumors/diagnosis/*drug therapy/pathology MH - Humans MH - Joint Capsule/pathology MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Receptors, Somatomedin/antagonists & inhibitors/immunology MH - Shoulder Joint/*pathology MH - Sirolimus/administration & dosage/*analogs & derivatives MH - Soft Tissue Neoplasms/diagnosis/*drug therapy/pathology MH - TOR Serine-Threonine Kinases/antagonists & inhibitors MH - Tendons/pathology MH - Treatment Outcome EDAT- 2013/02/23 06:00 MHDA- 2015/01/13 06:00 CRDT- 2013/02/23 06:00 PHST- 2012/10/01 00:00 [received] PHST- 2013/02/01 00:00 [accepted] PHST- 2013/02/23 06:00 [entrez] PHST- 2013/02/23 06:00 [pubmed] PHST- 2015/01/13 06:00 [medline] AID - 10.1007/s11523-013-0267-8 [doi] PST - ppublish SO - Target Oncol. 2014 Mar;9(1):73-9. doi: 10.1007/s11523-013-0267-8. Epub 2013 Feb 21. PMID- 17274335 OWN - NLM STAT- MEDLINE DCOM- 20070227 LR - 20200114 IS - 0191-3913 (Print) IS - 0191-3913 (Linking) VI - 44 IP - 1 DP - 2007 Jan-Feb TI - Trypan blue-assisted posterior tenectomy of the superior oblique. PG - 45-6 LID - 10.3928/01913913-20070101-06 [doi] AB - Posterior tenectomy of the superior oblique tendon can be difficult, particularly for inexperienced surgeons, due to problems in visualization and anatomic peculiarities. Trypan blue can be used to stain the superior oblique tendon for easy identification and delineation of it at its insertion, making the current surgical technique less difficult. FAU - Saxena, Rohit AU - Saxena R AD - Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. FAU - Sinha, Ankur AU - Sinha A FAU - Sethi, Harinder AU - Sethi H FAU - Menon, Vimla AU - Menon V LA - eng PT - Journal Article PL - United States TA - J Pediatr Ophthalmol Strabismus JT - Journal of pediatric ophthalmology and strabismus JID - 7901143 RN - 0 (Coloring Agents) RN - I2ZWO3LS3M (Trypan Blue) SB - IM MH - Administration, Topical MH - *Coloring Agents/administration & dosage MH - Humans MH - Intraoperative Period MH - Oculomotor Muscles/anatomy & histology/*surgery MH - Ophthalmologic Surgical Procedures/*methods MH - Strabismus/*surgery MH - Tendons/anatomy & histology/*surgery MH - *Trypan Blue/administration & dosage EDAT- 2007/02/06 09:00 MHDA- 2007/02/28 09:00 CRDT- 2007/02/06 09:00 PHST- 2007/02/06 09:00 [pubmed] PHST- 2007/02/28 09:00 [medline] PHST- 2007/02/06 09:00 [entrez] AID - 10.3928/01913913-20070101-06 [doi] PST - ppublish SO - J Pediatr Ophthalmol Strabismus. 2007 Jan-Feb;44(1):45-6. doi: 10.3928/01913913-20070101-06. PMID- 8441038 OWN - NLM STAT- MEDLINE DCOM- 19930331 LR - 20161123 IS - 0161-5505 (Print) IS - 0161-5505 (Linking) VI - 34 IP - 3 DP - 1993 Mar TI - Enthesopathy of the patellar tendon insertion associated with isotretinoin therapy. PG - 455-7 AB - A 99mTc-MDP bone scan performed on a 34-yr-old female for suspected osteomyelitis of the proximal tibia revealed focally increased activity in both tibial tuberosities due to enthesopathies secondary to chronic isotretinoin therapy. Physicians should be aware that isotretinoin therapy can cause abnormal bone scans and not mistake these abnormalities for other diseases such as osteomyelitis. Second, bone scans may be helpful in diagnosing and following isotretinoin bone toxicity. FAU - Scuderi, A J AU - Scuderi AJ AD - Division of Nuclear Medicine, University of Utah School of Medicine, Salt Lake City. FAU - Datz, F L AU - Datz FL FAU - Valdivia, S AU - Valdivia S FAU - Morton, K A AU - Morton KA LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Nucl Med JT - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JID - 0217410 RN - EH28UP18IF (Isotretinoin) SB - IM MH - Adult MH - Diagnosis, Differential MH - Female MH - Humans MH - Hyperostosis/chemically induced MH - Isotretinoin/*adverse effects MH - Knee Joint/*diagnostic imaging MH - Muscular Diseases/chemically induced/diagnostic imaging MH - Osteomyelitis/diagnostic imaging MH - Radionuclide Imaging MH - Spinal Diseases/chemically induced MH - Tendons/*diagnostic imaging EDAT- 1993/03/01 00:00 MHDA- 1993/03/01 00:01 CRDT- 1993/03/01 00:00 PHST- 1993/03/01 00:00 [pubmed] PHST- 1993/03/01 00:01 [medline] PHST- 1993/03/01 00:00 [entrez] PST - ppublish SO - J Nucl Med. 1993 Mar;34(3):455-7. PMID- 8302889 OWN - NLM STAT- MEDLINE DCOM- 19940307 LR - 20131121 IS - 0361-7742 (Print) IS - 0361-7742 (Linking) VI - 383A DP - 1993 TI - In vivo experimental induction of interdigital tissue chondrogenesis in the avian limb bud results in the formation of extradigits. Effects of local microinjection of staurosporine, zinc chloride and growth factors. PG - 127-39 AB - In previous studies we had found that at late stages of development, when the early patterning control mechanism have ceased to act, the chick limb bud is able to form fully differentiated extradigits by subjecting the interdigital spaces to ectoderm removal. In this study we attempted to mimic this phenomenon by using local microinjections of substances which presumably have a biological action on the interdigital mesenchyme. Microinjection of staurosporine results in the formation of fully differentiated extradigits. The action of this drug appears to be due to the induction of chondrogenesis after the inhibition of the protein kinase C. Zinc chloride administration also causes ectopic chondrogenesis but it seems to act by arresting the interdigital cell death program through endonuclease inhibition. A clear differentiation of the zinc-induced cartilages into extradigits was no detected. This can be explained by the accompanying damage caused by zinc in the growing limb mesenchyme as deduced by the high incidence of hypophalangy in the normal digits. Both TGF beta 1 and TGF beta 2 have a weak effect as inducers of interdigital chondrogenesis; presumably they act by inducing chondrogenetic differentiation. Neither FGF nor EGF has any effect when administered by local microinjection. These results show that ectopic interdigital chondrogenesis induced by drug administration results in the differentiation of extradigits. This suggests that once a cartilage is formed in the autopodium it triggers a new signalling stage which leads to the morphogenesis of a digit. This morphogenetic process involves the patterning of skeleton, joints and tendons. In accordance with these observations, it can be proposed that early patterning of the limb results in the establishment of an autopodium with a defined but still plastic skeletal distribution pattern, while morphogenesis of each autopodial element would take place at a second stage by the activation of new signalling processes. FAU - Gañan, Y AU - Gañan Y AD - Department of Morphological Sciences, University of Extremadura, Badajoz, Spain. FAU - Macias, D AU - Macias D FAU - Garcia-Martinez, V AU - Garcia-Martinez V FAU - Hurle, J M AU - Hurle JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Prog Clin Biol Res JT - Progress in clinical and biological research JID - 7605701 RN - 0 (Alkaloids) RN - 0 (Chlorides) RN - 0 (Transforming Growth Factor beta) RN - 0 (Zinc Compounds) RN - 62229-50-9 (Epidermal Growth Factor) RN - 86Q357L16B (zinc chloride) RN - EC 2.7.11.13 (Protein Kinase C) RN - H88EPA0A3N (Staurosporine) SB - IM MH - Alkaloids/*pharmacology MH - Animals MH - Cartilage/drug effects/embryology MH - Chick Embryo MH - Chlorides/*pharmacology MH - Epidermal Growth Factor/pharmacology MH - Hindlimb/drug effects/*embryology MH - Mesoderm/drug effects MH - Microinjections MH - Protein Kinase C/antagonists & inhibitors MH - Staurosporine MH - Toes/abnormalities/embryology MH - Transforming Growth Factor beta/pharmacology MH - Zinc Compounds/*pharmacology EDAT- 1993/01/01 00:00 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PHST- 1993/01/01 00:00 [pubmed] PHST- 1993/01/01 00:01 [medline] PHST- 1993/01/01 00:00 [entrez] PST - ppublish SO - Prog Clin Biol Res. 1993;383A:127-39. PMID- 21169306 OWN - NLM STAT- MEDLINE DCOM- 20110425 LR - 20131121 IS - 2043-6289 (Electronic) IS - 0266-7681 (Linking) VI - 36 IP - 1 DP - 2011 Jan TI - Rupture of the flexor digitorum profundus tendon after injections of insoluble steroid for a trigger finger. PG - 77-8 LID - 10.1177/1753193410382377 [doi] FAU - Yamada, Katsuhisa AU - Yamada K FAU - Masuko, Tatsuya AU - Masuko T FAU - Iwasaki, Norimasa AU - Iwasaki N LA - eng PT - Case Reports PT - Letter PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Anti-Inflammatory Agents) RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Adult MH - Anti-Inflammatory Agents/administration & dosage/*adverse effects MH - Female MH - Finger Injuries/*chemically induced/surgery MH - Humans MH - Injections/*adverse effects MH - Lidocaine/*administration & dosage/*adverse effects MH - Recurrence MH - Reoperation MH - Rupture MH - Tendon Injuries/*chemically induced/surgery MH - Tendon Transfer MH - Tendons/*drug effects/surgery MH - Triamcinolone Acetonide/administration & dosage/*adverse effects MH - Trigger Finger Disorder/*drug therapy/surgery EDAT- 2010/12/21 06:00 MHDA- 2011/04/26 06:00 CRDT- 2010/12/21 06:00 PHST- 2010/12/21 06:00 [entrez] PHST- 2010/12/21 06:00 [pubmed] PHST- 2011/04/26 06:00 [medline] AID - 36/1/77 [pii] AID - 10.1177/1753193410382377 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2011 Jan;36(1):77-8. doi: 10.1177/1753193410382377. PMID- 285913 OWN - NLM STAT- MEDLINE DCOM- 19790716 LR - 20190827 IS - 0015-5691 (Print) IS - 0015-5691 (Linking) VI - 75 IP - 1 DP - 1979 Jan TI - [Possible mechanism of morphine-induced Straub tail reaction (STR) (author's transl)]. PG - 73-89 AB - Mechanical contraction of the dorsal sarco-cocygeus muscle and electrical stimulation of spinal cord elicited tail elevation such as straub tail reaction (STR). When morphine, 0.25 approximately 0.5 microgram, was injected into the lumbothecal space, STR was produced dose-dependently and such was the same as that produced by systemic injection of morphine. STR was not observed, when morphine was injected into the lumbo-thecal space in spinal mice. STR was antagonized by tubocurarine given subcutaneously and by naloxone injected into the lumbothecal space. STR was not antagonized by the right, left or both dorsal spinal lesion at C5 approximately 6 as well as by the right or both dorsal spinal lesion at T11 approximately 12. However, STR was antagonized by the spinal transection at T11 approximately 12. The lesion of spinal serotonergic neurons enhanced STR. These results suggest that morphine acts on both the lumbo-sacral nerve cell bodies and the nerve terminals descending via the spinal ventral horn, by which the morphine-induced contraction of dorsal sarco-coccygeus muscle tendons produce STR. FAU - Kameyama, T AU - Kameyama T FAU - Nabeshima, T AU - Nabeshima T FAU - Yamaguchi, K AU - Yamaguchi K LA - jpn PT - English Abstract PT - Journal Article PL - Japan TA - Nihon Yakurigaku Zasshi JT - Nihon yakurigaku zasshi. Folia pharmacologica Japonica JID - 0420550 RN - 0 (Analgesics) RN - 76I7G6D29C (Morphine) RN - W9YXS298BM (Tubocurarine) SB - IM MH - Analgesics MH - Animals MH - Cordotomy MH - Electric Stimulation MH - Lumbosacral Region/drug effects/innervation MH - Mice MH - Morphine/antagonists & inhibitors/*pharmacology MH - Neurons/drug effects MH - Reflex, Stretch/*drug effects MH - Spinal Cord/*physiology MH - *Tail MH - Tubocurarine/pharmacology EDAT- 1979/01/01 00:00 MHDA- 1979/01/01 00:01 CRDT- 1979/01/01 00:00 PHST- 1979/01/01 00:00 [pubmed] PHST- 1979/01/01 00:01 [medline] PHST- 1979/01/01 00:00 [entrez] AID - 10.1254/fpj.75.73 [doi] PST - ppublish SO - Nihon Yakurigaku Zasshi. 1979 Jan;75(1):73-89. doi: 10.1254/fpj.75.73. PMID- 1173779 OWN - NLM STAT- MEDLINE DCOM- 19751011 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 25 IP - 2A DP - 1975 Feb TI - [Experiences with the effect of naproxen in chronic and degenerative diseases as in overload conditions of the postural and locomotor system]. PG - 321-3 AB - At the Orthopaedic University Clinic, Homburg, a total of 127 patients was treated with d-2-(6'-methoxy-2'-naphthyl)-propionic acid (naproxen) from June 1973 up to June 1974. The indications were chronic degenerative changes of the joints, muscles and tendons. In the first series naproxen was administered orally. In these 45 cases a very low rate of side effects was observed. Only 4 times nausea or vomiting occurred, which in one case had been caused by an overdosage. Generally tolerance was excellent and there was a very good relief of symptoms in early all patients. Particularly in those patients whose arthrotic alterations did not yet require surgical intervention the effect as to symptomatology was extremely good. In a second series initially 63 patients and, later on, another 19 patients were treated with naproxen suppositories. As before, concomitant medication was avoided. The therapeutic results were mostly very good to good, and only in a few cases no success was seen. It should be mentioned, however, that after application of the suppositories, a few patients noted a slight local burning after insertion of the suppository. Also blood in the feces and circulatory symptoms were reported. We believe that naproxen can achieve a very good improvement of subjective symptoms, particularly when combined with other therapeutic measures such as physiotherapy and intra- or periarticular injections. This drug should not only be used in the conservative treatment of degenerative joint diseases, but also -- as shown by our experience -- after palliative surgical procedures employed in the treatment of severe arthroses. Also in these cases a positive influence on the symptoms can be achieved. FAU - Biehl, G AU - Biehl G LA - ger PT - English Abstract PT - Journal Article TT - Erfahrungsbericht über die Wirking von Naproxen bei chronischen und degenerativen Erkrankungen sowie bei Uberlastungszuständen des Haltungs- und Bewegungsapparates. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Capsules) RN - 0 (Naphthaleneacetic Acids) RN - 0 (Suppositories) RN - 57Y76R9ATQ (Naproxen) SB - IM MH - Adult MH - Aged MH - Arthritis, Rheumatoid/*drug therapy MH - Capsules MH - Chronic Disease MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Naphthaleneacetic Acids/*therapeutic use MH - Naproxen/administration & dosage/*therapeutic use MH - Osteoarthritis/drug therapy MH - Periarthritis/drug therapy MH - Suppositories MH - Tendinopathy/drug therapy EDAT- 1975/02/01 00:00 MHDA- 1975/02/01 00:01 CRDT- 1975/02/01 00:00 PHST- 1975/02/01 00:00 [pubmed] PHST- 1975/02/01 00:01 [medline] PHST- 1975/02/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1975 Feb;25(2A):321-3. PMID- 20919810 OWN - NLM STAT- MEDLINE DCOM- 20101014 LR - 20220330 IS - 1745-3682 (Electronic) IS - 1745-3674 (Print) IS - 1745-3674 (Linking) VI - 81 IP - 5 DP - 2010 Oct TI - Alteration of the material properties of the normal supraspinatus tendon by nicotine treatment in a rat model. PG - 634-8 LID - 10.3109/17453674.2010.524595 [doi] AB - BACKGROUND AND PURPOSE: Several studies have shown that nicotine has a detrimental effect on the development of rotator cuff tear. However, little is known about its mechanism. We evaluated the effect of nicotine on the maximum tensile load, the maximum tensile stress, and the elastic modulus of the supraspinatus tendon in a rat model. METHODS: 27 rats were randomly assigned to 3 groups. Subcutaneously implanted osmotic pumps delivered two different concentrations of nicotine solution (high dose: 45 ng/mL; low dose: 22.5 ng/mL) or saline solution (controls) over a 12-week period. The level of serum cotinine, a breakdown product of nicotine, was evaluated. We performed tensile testing using the left supraspinatus tendon in each rat. The maximum load of the supraspinatus tendon was measured, and the maximum tensile stress and elastic modulus were calculated. RESULTS: Serum cotinine levels showed controlled systemic release of nicotine. The maximum tensile load and stress were similar in the three groups. The elastic modulus was, however, higher in the nicotine groups than in the control group. INTERPRETATION: In a rat model, nicotine caused a change in the material properties of the supraspinatus tendon. This change may predispose to a tear in the supraspinatus tendon. FAU - Ichinose, Ryogo AU - Ichinose R AD - Department of Orthopaedic Surgery, School of Medicine, Tohoku University, Sendai, Japan. FAU - Sano, Hirotaka AU - Sano H FAU - Kishimoto, Koshi N AU - Kishimoto KN FAU - Sakamoto, Naoya AU - Sakamoto N FAU - Sato, Masaaki AU - Sato M FAU - Itoi, Eiji AU - Itoi E LA - eng PT - Journal Article PL - Sweden TA - Acta Orthop JT - Acta orthopaedica JID - 101231512 RN - 6M3C89ZY6R (Nicotine) RN - K5161X06LL (Cotinine) SB - IM MH - Animals MH - Cotinine/blood MH - Elastic Modulus/*drug effects MH - Male MH - Nicotine/*administration & dosage/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Risk Factors MH - Rotator Cuff/*drug effects MH - Rotator Cuff Injuries MH - Tendons/*drug effects MH - Tensile Strength/*drug effects MH - Wound Healing/drug effects PMC - PMC3214755 EDAT- 2010/10/06 06:00 MHDA- 2010/10/15 06:00 PMCR- 2010/10/01 CRDT- 2010/10/06 06:00 PHST- 2010/10/06 06:00 [entrez] PHST- 2010/10/06 06:00 [pubmed] PHST- 2010/10/15 06:00 [medline] PHST- 2010/10/01 00:00 [pmc-release] AID - ORT_A_524595_O [pii] AID - 10.3109/17453674.2010.524595 [doi] PST - ppublish SO - Acta Orthop. 2010 Oct;81(5):634-8. doi: 10.3109/17453674.2010.524595. PMID- 953958 OWN - NLM STAT- MEDLINE DCOM- 19761101 LR - 20190619 IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 38 IP - 3 DP - 1976 Sep TI - Skin ulcers due to adriamycin. PG - 1087-94 AB - Local skin necrosis at the site of intravenous or intra-arterial adriamycin infusion is an infrequent, but serious complication. Ulcers secondary to adriamycin have insidious beginnings, but progress to a much deeper extent than would be expected from their initial appearance. Deep structures, such as tendon or bone, may become exposed. The ulcers are indolent and do not develop a granulation tissue response or epithelialization, as might be expected from their early appearance. Injections of adriamycin in the dorsum of the hand should be avoided when possible, since tendons have little skin cover and the area is difficult to cover with local tissue if there is skin loss. While prevention is important, early surgical treatment may prevent progressive deep involvement and seems warranted when the patient has a life expectancy of months or years. Wide excision of all inflamed tissue is the treatment of choice, with split-thickness skin grafting or flap coverage. FAU - Rudolph, R AU - Rudolph R FAU - Stein, R S AU - Stein RS FAU - Pattillo, R A AU - Pattillo RA LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 80168379AG (Doxorubicin) SB - IM MH - Aged MH - Doxorubicin/administration & dosage/*adverse effects MH - Female MH - Humans MH - Injections, Intra-Arterial MH - Male MH - Middle Aged MH - Skin Ulcer/*chemically induced/pathology/surgery EDAT- 1976/09/01 00:00 MHDA- 1976/09/01 00:01 CRDT- 1976/09/01 00:00 PHST- 1976/09/01 00:00 [pubmed] PHST- 1976/09/01 00:01 [medline] PHST- 1976/09/01 00:00 [entrez] AID - 10.1002/1097-0142(197609)38:3<1087::aid-cncr2820380308>3.0.co;2-x [doi] PST - ppublish SO - Cancer. 1976 Sep;38(3):1087-94. doi: 10.1002/1097-0142(197609)38:3<1087::aid-cncr2820380308>3.0.co;2-x. PMID- 5795976 OWN - NLM STAT- MEDLINE DCOM- 19690904 LR - 20201114 IS - 0025-729X (Print) IS - 0025-729X (Linking) VI - 1 IP - 20 DP - 1969 May 17 TI - Gouty tenosynovitis and the carpal tunnel syndrome. PG - 1030-2 FAU - Champion, D AU - Champion D LA - eng PT - Journal Article PL - Australia TA - Med J Aust JT - The Medical journal of Australia JID - 0400714 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Carpal Tunnel Syndrome/diagnostic imaging/*etiology MH - Diagnosis, Differential MH - Gout/*complications/diagnostic imaging MH - Humans MH - Male MH - Median Nerve MH - Middle Aged MH - Radiography MH - Tendons/analysis MH - Tenosynovitis/*complications/diagnostic imaging MH - Uric Acid/analysis MH - Wrist/diagnostic imaging EDAT- 1969/05/17 00:00 MHDA- 1969/05/17 00:01 CRDT- 1969/05/17 00:00 PHST- 1969/05/17 00:00 [pubmed] PHST- 1969/05/17 00:01 [medline] PHST- 1969/05/17 00:00 [entrez] AID - 10.5694/j.1326-5377.1969.tb49870.x [doi] PST - ppublish SO - Med J Aust. 1969 May 17;1(20):1030-2. doi: 10.5694/j.1326-5377.1969.tb49870.x. PMID- 6793925 OWN - NLM STAT- MEDLINE DCOM- 19811222 LR - 20161123 IS - 0375-9393 (Print) IS - 0375-9393 (Linking) VI - 47 IP - 5 DP - 1981 May TI - [Lysine acetylsalicylate by subcutaneous administration in therapy of postoperative pain. Preliminary note]. PG - 241-5 FAU - Amato, G AU - Amato G LA - ita PT - Journal Article TT - L'acetilsalicilato di lisina per via sottocutanea nella terapia antalgica post-operatoria. Nota preliminare. PL - Italy TA - Minerva Anestesiol JT - Minerva anestesiologica JID - 0375272 RN - K3Z4F929H6 (Lysine) RN - R16CO5Y76E (Aspirin) RN - XAN4V337CI (acetylsalicylic acid lysinate) SB - IM MH - Adult MH - Aspirin/administration & dosage/*analogs & derivatives/therapeutic use MH - Bone and Bones/surgery MH - Female MH - Fracture Fixation MH - Herniorrhaphy MH - Humans MH - Infusions, Parenteral MH - Lysine/administration & dosage/*analogs & derivatives/therapeutic use MH - Male MH - Middle Aged MH - Pain, Postoperative/*drug therapy MH - Tendons/surgery EDAT- 1981/05/01 00:00 MHDA- 1981/05/01 00:01 CRDT- 1981/05/01 00:00 PHST- 1981/05/01 00:00 [pubmed] PHST- 1981/05/01 00:01 [medline] PHST- 1981/05/01 00:00 [entrez] PST - ppublish SO - Minerva Anestesiol. 1981 May;47(5):241-5. PMID- 4459908 OWN - NLM STAT- MEDLINE DCOM- 19750714 LR - 20131121 IS - 0302-7600 (Print) IS - 0302-7600 (Linking) VI - 9 IP - 3 DP - 1974 Jun TI - A comparative study of carticaine and prilocaine in regional intravenous analgesia. PG - 171-5 FAU - Eerola, R AU - Eerola R LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - Germany TA - Prakt Anaesth JT - Praktische Anasthesie, Wiederbelebung und Intensivtherapie JID - 0417656 RN - 0 (Anesthetics, Local) RN - 0 (Propylamines) RN - 0 (Thiophenes) RN - 046O35D44R (Prilocaine) SB - IM MH - Analgesia MH - *Anesthesia, Conduction MH - Anesthesia, Intravenous MH - Anesthetics, Local/*administration & dosage/adverse effects MH - Arm Injuries/surgery MH - Electrocardiography MH - Female MH - Fractures, Bone/surgery MH - Humans MH - Leg Injuries/surgery MH - Ligaments/surgery MH - Male MH - Monitoring, Physiologic MH - Prilocaine/*administration & dosage/adverse effects MH - Propylamines/administration & dosage/adverse effects MH - Tendons/surgery MH - Thiophenes/*administration & dosage/adverse effects EDAT- 1974/06/01 00:00 MHDA- 1974/06/01 00:01 CRDT- 1974/06/01 00:00 PHST- 1974/06/01 00:00 [pubmed] PHST- 1974/06/01 00:01 [medline] PHST- 1974/06/01 00:00 [entrez] PST - ppublish SO - Prakt Anaesth. 1974 Jun;9(3):171-5. PMID- 373478 OWN - NLM STAT- MEDLINE DCOM- 19790626 LR - 20190627 IS - 0002-9610 (Print) IS - 0002-9610 (Linking) VI - 137 IP - 3 DP - 1979 Mar TI - The management of inadvertent subcutaneous adriamycin infiltration. PG - 408-12 AB - Once the inadvertent infiltration of Adriamycin occurs, it is recommended to immediately treat the problem. This has been accomplished by wide excision and meshed split thickness skin grafting for resurfacing of the defect. Obtaining a healed wound alleviates the stiffness from lack of motion or ruptured tendons. Pain from the open ulcer, which is prone to infection in the immunosuppressed patient, is lessened. An analogy between pit viper envenomization and Adriamycin infiltration is discussed. FAU - Laughlin, R A AU - Laughlin RA FAU - Landeen, J M AU - Landeen JM FAU - Habal, M B AU - Habal MB LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Surg JT - American journal of surgery JID - 0370473 RN - 80168379AG (Doxorubicin) SB - IM MH - Adenocarcinoma/drug therapy MH - Breast Neoplasms/drug therapy MH - Cellulitis/*chemically induced MH - Child MH - Doxorubicin/*adverse effects MH - Female MH - Humans MH - Leukemia/drug therapy MH - Male MH - Middle Aged MH - Skin Transplantation MH - Skin Ulcer/*chemically induced EDAT- 1979/03/01 00:00 MHDA- 1979/03/01 00:01 CRDT- 1979/03/01 00:00 PHST- 1979/03/01 00:00 [pubmed] PHST- 1979/03/01 00:01 [medline] PHST- 1979/03/01 00:00 [entrez] AID - 0002-9610(79)90077-1 [pii] AID - 10.1016/0002-9610(79)90077-1 [doi] PST - ppublish SO - Am J Surg. 1979 Mar;137(3):408-12. doi: 10.1016/0002-9610(79)90077-1. PMID- 15875233 OWN - NLM STAT- MEDLINE DCOM- 20051004 LR - 20220410 IS - 0936-8051 (Print) IS - 0936-8051 (Linking) VI - 125 IP - 4 DP - 2005 May TI - Spontaneous rupture of extensor pollicis longus tendon with tophaceous gout infiltration. PG - 281-4 AB - INTRODUCTION: Spontaneous rupture of the extensor pollicis longus (EPL) tendon has been reported in the literature. Various mechanisms have been proposed to account for this problem, but gouty infiltration is a rare mechanism. Here we report a patient with a long-standing history of gout who presented with sudden loss of interphalangeal extension of the left thumb. Spontaneous rupture of the EPL tendon caused by gout was discovered. MATERIALS AND METHODS: The successful treatment done involved surgical exploration and extensor indicis proprius tendon transfer. Postoperative thumb spica immobilization for 6 weeks was applied. RESULTS: Pathology disclosed urate crystals deposited within the ruptured EPL tendon. The functional recovery is satisfactory at the 1-year follow-up. CONCLUSION: Spontaneous rupture of the EPL tendon caused by gout is rare. Successful treatment was done with surgical management. Life-long medical follow-up to prevent a repeated acute attack can lower the risk of a large amount of tophaceous gout infiltration in tendons and may possibly prevent acute spontaneous tendon rupture. FAU - Hung, Jui-Yuan AU - Hung JY AD - Department of Orthopedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China. FAU - Wang, Shyu-Jye AU - Wang SJ FAU - Wu, Shing-Sheng AU - Wu SS LA - eng PT - Case Reports PT - Journal Article DEP - 20040615 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Crystallization MH - Gout/*complications/*physiopathology MH - Humans MH - Male MH - Rupture, Spontaneous/diagnosis/etiology/surgery MH - *Tendon Injuries/diagnosis/*etiology/surgery MH - Tendons/chemistry/physiopathology/surgery MH - Uric Acid/analysis MH - Wrist Joint/*physiopathology EDAT- 2005/05/06 09:00 MHDA- 2005/10/05 09:00 CRDT- 2005/05/06 09:00 PHST- 2003/08/29 00:00 [received] PHST- 2005/05/06 09:00 [pubmed] PHST- 2005/10/05 09:00 [medline] PHST- 2005/05/06 09:00 [entrez] AID - 10.1007/s00402-004-0670-9 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2005 May;125(4):281-4. doi: 10.1007/s00402-004-0670-9. Epub 2004 Jun 15. PMID- 3475997 OWN - NLM STAT- MEDLINE DCOM- 19870831 LR - 20190616 IS - 0077-8923 (Print) IS - 0077-8923 (Linking) VI - 498 DP - 1987 TI - Ascorbate can act as an inducer of the collagen pathway because most steps are tightly coupled. PG - 172-85 FAU - Schwarz, R I AU - Schwarz RI FAU - Kleinman, P AU - Kleinman P FAU - Owens, N AU - Owens N LA - eng GR - CA37958/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 RN - 0 (Procollagen) RN - 0 (RNA, Messenger) RN - 551W113ZEP (2,2'-Dipyridyl) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - 2,2'-Dipyridyl/pharmacology MH - Animals MH - Ascorbic Acid/antagonists & inhibitors/*pharmacology MH - Chick Embryo MH - Collagen/*biosynthesis MH - Endoplasmic Reticulum/metabolism MH - Hydroxylation MH - Kinetics MH - Procollagen/*biosynthesis MH - Proline/metabolism MH - Protein Biosynthesis/drug effects MH - RNA, Messenger/metabolism MH - Ribosomes/metabolism MH - Tendons/metabolism EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] AID - 10.1111/j.1749-6632.1987.tb23760.x [doi] PST - ppublish SO - Ann N Y Acad Sci. 1987;498:172-85. doi: 10.1111/j.1749-6632.1987.tb23760.x. PMID- 8784810 OWN - NLM STAT- MEDLINE DCOM- 19970114 LR - 20191024 IS - 0960-8966 (Print) IS - 0960-8966 (Linking) VI - 6 IP - 3 DP - 1996 May TI - Role of nicotinic acetylcholine receptors at the vertebrate myotendinous junction: a hypothesis. PG - 211-4 AB - It has long been known that nicotinic acetycholine receptors (nAChRs) are present in muscle fibres not only at the end plate region but also at the myotendinous junction (MTJ). Their function at the MTJ, however, is yet unknown. Recent experiments in our laboratory lead us to suggest that nAChRs at this site might be involved in muscle repair. MTJ is subject to high mechanical stress and therefore is easily damaged. We found in pure cultures of human myogenic cells that (1) the density of nAChRs in myoblasts increases markedly just before cell fusion, (2) the fusion of human myoblasts is accelerated by the presence of a cholinergic agonist acting on nAChRs and (3) human myoblasts and myotubes spontaneously release an ACh-like compound. Based on these observations we propose that in damaged muscles the nAChRs at the MTJ and those of myogenic cells are activated by the ACh-like compound these cells release. This leads to fusion of myogenic cells with damaged muscle fibres and hence promotes repair. FAU - Bernheim, L AU - Bernheim L AD - Division de Recherche Clinique Neuro-Musculaire, Hôpital Cantonal Universitaire, Genève, Switzerland. FAU - Hamann, M AU - Hamann M FAU - Liu, J H AU - Liu JH FAU - Fischer-Lougheed, J AU - Fischer-Lougheed J FAU - Bader, C R AU - Bader CR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Neuromuscul Disord JT - Neuromuscular disorders : NMD JID - 9111470 RN - 0 (Culture Media, Conditioned) RN - 0 (Receptors, Nicotinic) RN - N9YNS0M02X (Acetylcholine) RN - W9YXS298BM (Tubocurarine) SB - IM MH - Acetylcholine/analysis MH - Adolescent MH - Cell Fusion MH - Cells, Cultured MH - Child MH - Child, Preschool MH - Culture Media, Conditioned MH - Evoked Potentials/drug effects MH - Humans MH - Kinetics MH - Middle Aged MH - Muscle, Skeletal/cytology/*physiology MH - Patch-Clamp Techniques MH - Receptors, Nicotinic/analysis/*physiology MH - Tendons/cytology/*physiology MH - Time Factors MH - Tubocurarine/pharmacology EDAT- 1996/05/01 00:00 MHDA- 1996/05/01 00:01 CRDT- 1996/05/01 00:00 PHST- 1996/05/01 00:00 [pubmed] PHST- 1996/05/01 00:01 [medline] PHST- 1996/05/01 00:00 [entrez] AID - 096089669600020X [pii] AID - 10.1016/0960-8966(96)00020-x [doi] PST - ppublish SO - Neuromuscul Disord. 1996 May;6(3):211-4. doi: 10.1016/0960-8966(96)00020-x. PMID- 3378580 OWN - NLM STAT- MEDLINE DCOM- 19880725 LR - 20190707 IS - 0014-4827 (Print) IS - 0014-4827 (Linking) VI - 176 IP - 2 DP - 1988 Jun TI - High serum levels interfere with the normal differentiated state of avian tendon cells by altering translational regulation. PG - 268-80 AB - In low serum (0.2%) medium, ascorbate stimulates primary avian tendon cells to increase procollagen synthesis from 12 to 50% of total protein synthesis. This is reversibly blocked by an increase of serum levels from 0.2 to 3%. Ascorbate in low serum medium has been shown previously to stimulate the procollagen pathway by sequentially increasing by sixfold the secretion rate constant, then translation rates, and finally mRNA levels. We now show that addition of ascorbate to cultures containing 3% serum induces a sixfold increase in the secretion rate constant but translation rates and mRNA levels remain unchanged. In fully induced cells, an increase in serum levels causes a down-regulation of procollagen synthesis. In this case, the translational products of the induced cell are rapidly altered (less than 1 h), with noncollagen protein synthesis being stimulated preferentially over procollagen synthesis. This change is not reflected in procollagen mRNA levels since they remain constant for at least 6 h following addition of high serum. After 48 h in high serum, the induction of procollagen synthesis by ascorbate is reversed and the level of procollagen mRNA drops to that of uninduced cells. The data are consistent with the model that serum acts primarily at the translational level. High serum levels break the coupling in the ascorbate induction process that ties the stimulation of procollagen secretion rates to the increase in procollagen translation rates, and this prevents the maintenance of the induced state. FAU - Valmassoi, J AU - Valmassoi J AD - Laboratory of Cell Biology, University of California, Berkeley 94720. FAU - Schwarz, R I AU - Schwarz RI LA - eng GR - CA37958/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Culture Media) RN - 0 (Procollagen) RN - 0 (RNA, Messenger) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*antagonists & inhibitors MH - *Blood MH - Cell Differentiation/drug effects MH - Chick Embryo MH - Culture Media/pharmacology MH - Endoplasmic Reticulum/physiology MH - Models, Genetic MH - Procollagen/biosynthesis MH - Protein Biosynthesis/*drug effects MH - RNA, Messenger/biosynthesis/drug effects MH - Tendons/*cytology/drug effects EDAT- 1988/06/01 00:00 MHDA- 1988/06/01 00:01 CRDT- 1988/06/01 00:00 PHST- 1988/06/01 00:00 [pubmed] PHST- 1988/06/01 00:01 [medline] PHST- 1988/06/01 00:00 [entrez] AID - 10.1016/0014-4827(88)90330-8 [doi] PST - ppublish SO - Exp Cell Res. 1988 Jun;176(2):268-80. doi: 10.1016/0014-4827(88)90330-8. PMID- 17114532 OWN - NLM STAT- MEDLINE DCOM- 20061206 LR - 20131121 IS - 1546-3141 (Electronic) IS - 0361-803X (Linking) VI - 187 IP - 6 DP - 2006 Dec TI - A novel approach to flexor hallucis longus tenography. PG - 1432-5 AB - OBJECTIVE: This article presents a technically simple and more accurate approach to flexor hallucis longus (FHL) tenography than any we found reported in the literature. CONCLUSION: Tenography is used to evaluate and treat tenosynovitis. Standard FHL tenography protocol involves either direct percutaneous access of the FHL synovial sheath posterior to the medial malleolus or indirect filling of the FHL sheath from an injection of the flexor digitorum longus (FDL) tendon sheath, which often communicates with the FHL tendon sheath. However, with these methods, difficulty entering the FHL sheath may be encountered. We adapted our technique to access the FHL sheath as it courses below the sustentaculum talus. Our early experience with five cases using this technique reflects a 100% success rate with accurate needle placement within the FHL tendon sheath, thereby improving procedural efficiency. FAU - Gelbart, Michael S AU - Gelbart MS AD - Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd., St. Louis, MO 63110, USA. FAU - Parikh, Ashesh AU - Parikh A FAU - Chong, Wincha AU - Chong W FAU - Gilula, Louis A AU - Gilula LA LA - eng PT - Journal Article PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 RN - 0 (Contrast Media) RN - XUW72GOP7W (Iothalamate Meglumine) SB - IM MH - Adult MH - Ankle Injuries/*diagnosis MH - Contrast Media/administration & dosage MH - Female MH - Fluoroscopy/*methods MH - Humans MH - Iothalamate Meglumine/administration & dosage MH - Magnetic Resonance Imaging MH - Pain/etiology MH - Retrospective Studies MH - Tendons/pathology MH - Tenosynovitis/*diagnosis EDAT- 2006/11/23 09:00 MHDA- 2006/12/09 09:00 CRDT- 2006/11/23 09:00 PHST- 2006/11/23 09:00 [pubmed] PHST- 2006/12/09 09:00 [medline] PHST- 2006/11/23 09:00 [entrez] AID - 187/6/1432 [pii] AID - 10.2214/AJR.05.0345 [doi] PST - ppublish SO - AJR Am J Roentgenol. 2006 Dec;187(6):1432-5. doi: 10.2214/AJR.05.0345. PMID- 1016244 OWN - NLM STAT- MEDLINE DCOM- 19770321 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 160 IP - 3 DP - 1976 Dec 15 TI - Effect of L-azetidine-2-carboxylic acid on glycosylations of collagen in chick-embryo tendon cells. PG - 639-45 AB - The glycosylations of hydroxylysine during collagen biosynthesis in isolated chick-embryo tendon cells were studied by using pulse-chase labelling experiments with [14C]-lysine. The hydroxylation of lysine and the glycosylations of hydroxylysine continued after a 5 min pulse label for up to about 10 min during the chase period. These data differ from those obtained previously in isolated chick-embryo cartilage cells, in which, after a similar 5 min pulse label, these reactions continued during the chase period for up to about 20 min. The collagen synthesized by the isolated chick-embryo tendon cells differed markedly from the type I collagen of adult tissues in its degree of hydroxylation of lysine residues and glycosylations of hydroxylysine residues. When the isolated tendon cells were incubated in the presence of L-azetidine-2-carboxylic acid, the degree of glycosylations of hydroxylysine during the first 10 min of the chase period was identical with that in cells incubated without thcarboxylic acid for at least 60 min, whereas no additional glycosylations took place in the control cells after the 10 min time-point. As a consequence, the collagen synthesized in the presence of this compound contained more carbohydrate than did the collagen synthesized by the control cells. Additional experiments indicated that azetidine-2-carboxylic acid did not increase the collagen glycosyltransferase activities in the tendon cells or the rate of glycosylation reactions when added directly to the enzyme incubation mixture. Control experiments with colchicine indicated that the delay in the rate of collagen secretion, which was observed in the presence of azetidine-2-carboxylic acid, did not in itself affect the degree of glycosylations of collagen. The results thus suggest that the increased glycosylations were due to inhibition of the collagen triple-helix formation, which is known to occur in the presence of azetidine-2-carboxylic acid. FAU - Oikarinen, A AU - Oikarinen A FAU - Anttinen, H AU - Anttinen H FAU - Kivirikko, K I AU - Kivirikko KI LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Azetines) RN - 2GQB349IUB (Hydroxylysine) RN - 5GZ3E0L9ZU (Azetidinecarboxylic Acid) RN - 9007-34-5 (Collagen) RN - EC 2.4.1.- (Glucosyltransferases) RN - SML2Y3J35T (Colchicine) SB - IM MH - Animals MH - Azetidinecarboxylic Acid/*metabolism MH - Azetines/*metabolism MH - Chick Embryo MH - Colchicine/pharmacology MH - Collagen/*biosynthesis MH - Glucosyltransferases/metabolism MH - Hydroxylation MH - Hydroxylysine/analogs & derivatives/biosynthesis MH - In Vitro Techniques MH - Tendons/*cytology/metabolism PMC - PMC1164281 EDAT- 1976/12/15 00:00 MHDA- 1976/12/15 00:01 PMCR- 1977/06/15 CRDT- 1976/12/15 00:00 PHST- 1976/12/15 00:00 [pubmed] PHST- 1976/12/15 00:01 [medline] PHST- 1976/12/15 00:00 [entrez] PHST- 1977/06/15 00:00 [pmc-release] AID - 10.1042/bj1600639 [doi] PST - ppublish SO - Biochem J. 1976 Dec 15;160(3):639-45. doi: 10.1042/bj1600639. PMID- 4829760 OWN - NLM STAT- MEDLINE DCOM- 19740719 LR - 20220318 IS - 0003-9977 (Print) IS - 0003-9977 (Linking) VI - 99 IP - 6 DP - 1974 Jun TI - Patulous eustachian tube syndrome. Preliminary report of the use of the tensor veli palatini transposition procedure. PG - 419-21 FAU - Stroud, M H AU - Stroud MH FAU - Spector, G J AU - Spector GJ FAU - Maisel, R H AU - Maisel RH LA - eng PT - Journal Article PL - United States TA - Arch Otolaryngol JT - Archives of otolaryngology (Chicago, Ill. : 1960) JID - 0376526 RN - 0 (Boric Acids) RN - 0 (Salicylates) SB - IM MH - Adult MH - Aged MH - Anesthesia, Local MH - Body Weight MH - Boric Acids/therapeutic use MH - Ear Diseases/complications/etiology/*surgery/therapy MH - Eustachian Tube/anatomy & histology/*surgery MH - Female MH - Hearing Disorders/etiology MH - Humans MH - Middle Aged MH - Palate/surgery MH - Posture MH - Pressure MH - Salicylates/therapeutic use MH - Sphenoid Bone/surgery MH - Tendons/*surgery MH - Therapeutic Irrigation MH - Tinnitus/etiology EDAT- 1974/06/01 00:00 MHDA- 1974/06/01 00:01 CRDT- 1974/06/01 00:00 PHST- 1974/06/01 00:00 [pubmed] PHST- 1974/06/01 00:01 [medline] PHST- 1974/06/01 00:00 [entrez] AID - 10.1001/archotol.1974.00780030433006 [doi] PST - ppublish SO - Arch Otolaryngol. 1974 Jun;99(6):419-21. doi: 10.1001/archotol.1974.00780030433006. PMID- 4810651 OWN - NLM STAT- MEDLINE DCOM- 19740322 LR - 20161123 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 55 IP - 2 DP - 1974 Feb TI - Shoulder arthrography in hemiplegic patients. PG - 49-51 FAU - Nepomuceno, C S AU - Nepomuceno CS FAU - Miller, J M 3rd AU - Miller JM 3rd LA - eng PT - Journal Article PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 0 (Amino Sugars) RN - 0 (Contrast Media) RN - 117-96-4 (Diatrizoate) RN - 4Z8Y51M438 (Procaine) RN - 506T60A25R (Sorbitol) SB - IM MH - Adult MH - Aged MH - Amino Sugars/administration & dosage MH - Contrast Media/administration & dosage MH - Diatrizoate/administration & dosage MH - Female MH - Hemiplegia/*complications MH - Humans MH - Injections, Intra-Articular MH - Male MH - Middle Aged MH - Pain/complications MH - Procaine/administration & dosage MH - Radiography MH - Shoulder Dislocation/complications/*diagnostic imaging/physiopathology MH - Sorbitol/administration & dosage MH - Tendons/diagnostic imaging EDAT- 1974/02/01 00:00 MHDA- 1974/02/01 00:01 CRDT- 1974/02/01 00:00 PHST- 1974/02/01 00:00 [pubmed] PHST- 1974/02/01 00:01 [medline] PHST- 1974/02/01 00:00 [entrez] PST - ppublish SO - Arch Phys Med Rehabil. 1974 Feb;55(2):49-51. PMID- 4963601 OWN - NLM STAT- MEDLINE DCOM- 19671214 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 140 IP - 3 DP - 1967 Aug 15 TI - The effect of chelating agents on collagen interfibrillar matrix interactions in connective tissue. PG - 522-8 FAU - Steven, F S AU - Steven FS LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Acetates) RN - 0 (Amino Acids) RN - 0 (Chelating Agents) RN - 0 (Ethylenediamines) RN - 0 (Polymers) RN - 9007-34-5 (Collagen) RN - 9G34HU7RV0 (Edetic Acid) RN - GNN1DV99GX (Penicillamine) RN - SY7Q814VUP (Calcium) RN - WIQ1H85SYP (Sodium Salicylate) SB - IM MH - Acetates MH - Amino Acids/analysis MH - Animals MH - Calcium/*pharmacology MH - Cattle MH - Chelating Agents/*pharmacology MH - *Collagen/analysis MH - Connective Tissue/*drug effects MH - Edetic Acid/*pharmacology MH - Ethylenediamines/*pharmacology MH - Hydrogen-Ion Concentration MH - In Vitro Techniques MH - Penicillamine/*pharmacology MH - Polymers MH - Sodium Salicylate/*pharmacology MH - Tendons EDAT- 1967/08/15 00:00 MHDA- 1967/08/15 00:01 CRDT- 1967/08/15 00:00 PHST- 1967/08/15 00:00 [pubmed] PHST- 1967/08/15 00:01 [medline] PHST- 1967/08/15 00:00 [entrez] AID - 0005-2795(67)90526-0 [pii] AID - 10.1016/0005-2795(67)90526-0 [doi] PST - ppublish SO - Biochim Biophys Acta. 1967 Aug 15;140(3):522-8. doi: 10.1016/0005-2795(67)90526-0. PMID- 15481424 OWN - NLM STAT- MEDLINE DCOM- 20041130 LR - 20161124 IS - 0001-6462 (Print) IS - 0001-6462 (Linking) VI - 70 IP - 4 DP - 2004 Aug TI - Gouty flexor tenosynovitis mimicking infection: a case report emphasising the value of ultrasound in diagnosis. PG - 368-70 AB - Tenosynovitis of the flexor tendons of the hand is a rare manifestation of gout. We present an unusual case of gouty tenosynovitis mimicking infection. The role of ultrasound in the management of this condition is emphasised. FAU - Aslam, Nadim AU - Aslam N AD - Nuffield Orthopaedic Centre, Oxford, UK. nadimaslam@hotmail.com FAU - Lo, Steven AU - Lo S FAU - McNab, Ian AU - McNab I LA - eng PT - Case Reports PT - Journal Article PT - Review PL - Belgium TA - Acta Orthop Belg JT - Acta orthopaedica Belgica JID - 2985165R RN - 268B43MJ25 (Uric Acid) RN - SML2Y3J35T (Colchicine) SB - IM MH - Adult MH - Colchicine/therapeutic use MH - Female MH - Fingers MH - Follow-Up Studies MH - Gout/diagnosis/*diagnostic imaging/drug therapy MH - Humans MH - Pain Measurement MH - Risk Assessment MH - Severity of Illness Index MH - Tenosynovitis/diagnosis/*diagnostic imaging/drug therapy MH - Treatment Outcome MH - Ultrasonography MH - Uric Acid/analysis RF - 8 EDAT- 2004/10/16 09:00 MHDA- 2004/12/16 09:00 CRDT- 2004/10/16 09:00 PHST- 2004/10/16 09:00 [pubmed] PHST- 2004/12/16 09:00 [medline] PHST- 2004/10/16 09:00 [entrez] PST - ppublish SO - Acta Orthop Belg. 2004 Aug;70(4):368-70. PMID- 15858517 OWN - NLM STAT- MEDLINE DCOM- 20060307 LR - 20131121 IS - 1097-6787 (Electronic) IS - 0190-9622 (Linking) VI - 52 IP - 5 Suppl 1 DP - 2005 May TI - Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. PG - S86-9 AB - Xanthomas most often occur in conjunction with a primary or secondary disorder of lipid metabolism. A range of metabolic disturbances has been described in association with protease inhibitors, including lipodystrophy, hyperglycemia, and hyperlipidemia. Ritonavir has been repeatedly shown to be the most common protease inhibitor to induce these metabolic abnormalities. This report highlights a case of both tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia. FAU - Brown, Chad A AU - Brown CA AD - Section of Dermatology, Department of Medicine, Medical College of Georgia, Augusta 30912, USA. FAU - Lesher, Jack L Jr AU - Lesher JL Jr FAU - Peterson, Christopher M AU - Peterson CM LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Acad Dermatol JT - Journal of the American Academy of Dermatology JID - 7907132 RN - 0 (HIV Protease Inhibitors) RN - O3J8G9O825 (Ritonavir) SB - IM MH - HIV Infections/*drug therapy MH - HIV Protease Inhibitors/*adverse effects MH - Histiocytes/pathology MH - Humans MH - Hyperlipidemias/*chemically induced/*complications MH - Male MH - Middle Aged MH - Ritonavir/*adverse effects MH - Skin/pathology MH - Tendons/pathology MH - Xanthomatosis/*etiology/pathology EDAT- 2005/04/29 09:00 MHDA- 2006/03/08 09:00 CRDT- 2005/04/29 09:00 PHST- 2005/04/29 09:00 [pubmed] PHST- 2006/03/08 09:00 [medline] PHST- 2005/04/29 09:00 [entrez] AID - S019096220403662X [pii] AID - 10.1016/j.jaad.2004.11.018 [doi] PST - ppublish SO - J Am Acad Dermatol. 2005 May;52(5 Suppl 1):S86-9. doi: 10.1016/j.jaad.2004.11.018. PMID- 21656083 OWN - NLM STAT- MEDLINE DCOM- 20111130 LR - 20220408 IS - 1937-6995 (Electronic) IS - 1556-9039 (Print) IS - 1556-9039 (Linking) VI - 7 IP - 3 DP - 2011 Sep TI - Case files of the medical toxicology fellowship at Drexel University. Rhabdomyolysis and compartment syndrome following acute diphenhydramine overdose. PG - 213-9 LID - 10.1007/s13181-011-0157-3 [doi] FAU - Vearrier, David AU - Vearrier D AD - Division of Medical Toxicology, Department of Emergency Medicine, Drexel University College of Medicine, Philadelphia, PA 19102, USA. david.vearrier@drexelmed.edu FAU - Curtis, John A AU - Curtis JA LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Med Toxicol JT - Journal of medical toxicology : official journal of the American College of Medical Toxicology JID - 101284598 RN - 0 (Central Nervous System Depressants) RN - 0 (Histamine H1 Antagonists) RN - 0 (Xenobiotics) RN - 3K9958V90M (Ethanol) RN - 8GTS82S83M (Diphenhydramine) SB - IM MH - Adult MH - Blood Chemical Analysis MH - Central Nervous System Depressants/poisoning MH - Compartment Syndromes/*chemically induced MH - Depressive Disorder, Major/complications MH - Diphenhydramine/pharmacology/*poisoning MH - Drug Overdose MH - Emergency Medical Services MH - Ethanol/poisoning MH - Female MH - Histamine H1 Antagonists/pharmacology/*poisoning MH - Humans MH - Muscle, Skeletal/surgery MH - Rhabdomyolysis/*chemically induced/surgery/therapy MH - Suicide, Attempted MH - Tendons/surgery MH - Xenobiotics/adverse effects PMC - PMC3550207 EDAT- 2011/06/10 06:00 MHDA- 2011/12/13 00:00 PMCR- 2012/09/01 CRDT- 2011/06/10 06:00 PHST- 2011/06/10 06:00 [entrez] PHST- 2011/06/10 06:00 [pubmed] PHST- 2011/12/13 00:00 [medline] PHST- 2012/09/01 00:00 [pmc-release] AID - 157 [pii] AID - 10.1007/s13181-011-0157-3 [doi] PST - ppublish SO - J Med Toxicol. 2011 Sep;7(3):213-9. doi: 10.1007/s13181-011-0157-3. PMID- 20707847 OWN - NLM STAT- MEDLINE DCOM- 20101116 LR - 20161018 IS - 0891-6640 (Print) IS - 0891-6640 (Linking) VI - 24 IP - 5 DP - 2010 Sep-Oct TI - Cutaneous and tendon sheath mastocytomas with eosinophilic joint and tendon sheath effusions in a horse. PG - 1233-6 LID - 10.1111/j.1939-1676.2010.0570.x [doi] FAU - Uehlinger, F D AU - Uehlinger FD AD - Department of Health Management, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada. fuehlinger@upei.ca FAU - Burton, S A AU - Burton SA FAU - Riley, C B AU - Riley CB FAU - Wichtel, M E G AU - Wichtel ME FAU - Bourque, A C AU - Bourque AC LA - eng PT - Case Reports PT - Journal Article DEP - 20100812 PL - United States TA - J Vet Intern Med JT - Journal of veterinary internal medicine JID - 8708660 RN - 0 (Analgesics) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 76I7G6D29C (Morphine) RN - 7S5I7G3JQL (Dexamethasone) RN - GN5P7K3T8S (Phenylbutazone) RN - QV897JC36D (Butorphanol) SB - IM MH - Analgesics/therapeutic use MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Butorphanol/therapeutic use MH - Dexamethasone/therapeutic use MH - Eosinophilia/pathology/veterinary MH - Horse Diseases/*pathology MH - Horses MH - Joint Diseases/drug therapy/pathology/*veterinary MH - Male MH - Mastocytoma/pathology/*veterinary MH - Morphine/therapeutic use MH - Phenylbutazone/therapeutic use MH - Skin Neoplasms/pathology/*veterinary MH - Tendons/*pathology EDAT- 2010/08/17 06:00 MHDA- 2010/11/17 06:00 CRDT- 2010/08/17 06:00 PHST- 2010/08/17 06:00 [entrez] PHST- 2010/08/17 06:00 [pubmed] PHST- 2010/11/17 06:00 [medline] AID - JVIM570 [pii] AID - 10.1111/j.1939-1676.2010.0570.x [doi] PST - ppublish SO - J Vet Intern Med. 2010 Sep-Oct;24(5):1233-6. doi: 10.1111/j.1939-1676.2010.0570.x. Epub 2010 Aug 12. PMID- 142610 OWN - NLM STAT- MEDLINE DCOM- 19771028 LR - 20190918 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 5 IP - 2 DP - 1977 TI - Mechanical and chemical properties of various connective tissue organs in rats as influenced by non-steroidal antirheumatic drugs. PG - 91-5 FAU - Vogel, H G AU - Vogel HG LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 9007-34-5 (Collagen) RN - GN5P7K3T8S (Phenylbutazone) RN - R16CO5Y76E (Aspirin) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Aspirin/*pharmacology MH - Biomechanical Phenomena MH - Bone and Bones/drug effects MH - Cartilage/drug effects MH - Collagen/metabolism MH - Connective Tissue/*drug effects/metabolism MH - Granuloma/physiopathology MH - Indomethacin/*pharmacology MH - Phenylbutazone/*pharmacology MH - Rats MH - Skin/drug effects MH - Tendons/drug effects MH - Tensile Strength/drug effects EDAT- 1977/01/01 00:00 MHDA- 1977/01/01 00:01 CRDT- 1977/01/01 00:00 PHST- 1977/01/01 00:00 [pubmed] PHST- 1977/01/01 00:01 [medline] PHST- 1977/01/01 00:00 [entrez] AID - 10.3109/03008207709152235 [doi] PST - ppublish SO - Connect Tissue Res. 1977;5(2):91-5. doi: 10.3109/03008207709152235. PMID- 15293303 OWN - NLM STAT- MEDLINE DCOM- 20041202 LR - 20220311 IS - 0091-2751 (Print) IS - 0091-2751 (Linking) VI - 32 IP - 7 DP - 2004 Sep TI - Sonographically guided injection of anesthetic for iliopsoas tendinopathy after total hip arthroplasty. PG - 354-7 AB - We report 2 patients who developed pain in the region of the iliopsoas tendon after undergoing total hip arthroplasty. The pain was temporarily relieved by sonographically guided injection of steroid and anesthetic and was subsequently treated by surgical release of the tendon. CI - Copyright 2004 Wiley Periodicals, Inc. FAU - Wank, Ross AU - Wank R AD - Department of Radiology, North Shore University Hospital, 825 Northern Blvd., Great Neck, NY 11021, USA. FAU - Miller, Theodore T AU - Miller TT FAU - Shapiro, Jeffrey F AU - Shapiro JF LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Clin Ultrasound JT - Journal of clinical ultrasound : JCU JID - 0401663 RN - 0 (Anesthetics, Local) RN - 1ZK20VI6TY (Triamcinolone) RN - 9842X06Q6M (Betamethasone) RN - 98PI200987 (Lidocaine) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adult MH - Anesthetics, Local/*administration & dosage MH - Arthroplasty, Replacement, Hip/*adverse effects MH - Betamethasone/administration & dosage MH - Bupivacaine/administration & dosage MH - Female MH - Groin MH - Humans MH - Injections, Intra-Articular MH - Lidocaine/administration & dosage MH - Middle Aged MH - Pain/*etiology/*prevention & control MH - Psoas Muscles/physiopathology MH - Tendons/physiopathology MH - Triamcinolone/administration & dosage MH - *Ultrasonography, Interventional EDAT- 2004/08/05 05:00 MHDA- 2004/12/16 09:00 CRDT- 2004/08/05 05:00 PHST- 2004/08/05 05:00 [pubmed] PHST- 2004/12/16 09:00 [medline] PHST- 2004/08/05 05:00 [entrez] AID - 10.1002/jcu.20043 [doi] PST - ppublish SO - J Clin Ultrasound. 2004 Sep;32(7):354-7. doi: 10.1002/jcu.20043. PMID- 6520044 OWN - NLM STAT- MEDLINE DCOM- 19850227 LR - 20171213 IS - 0161-7567 (Print) IS - 0161-7567 (Linking) VI - 57 IP - 5 DP - 1984 Nov TI - Canine gastrocnemius disuse atrophy: resistance to paralysis by dimethyl tubocurarine. PG - 1502-6 AB - Ten dogs developed unilateral gastrocnemius disuse atrophy after unilateral hindlimb immobilization in a cast for 25 days. Dose-response curves to dimethyl tubocurarine (MTC) were determined during anesthesia with pentobarbital sodium-N2O. Bolus and continuous infusion increments of MTC every 30 min provided steady-state blood levels at each stage of paralysis. Both gastrocnemius tendons were sectioned and attached to transducers. Both sciatic nerves were stimulated every 30 min: 2 Hz for 2 s, a 15-s pause, 50 Hz for 2 s. Dose-response curves, computer calculated by nonlinear regression using a sigmoid maximal effect model of the Hill equation, were parallel for the data relating blocking of tetanus to dose of MTC. The 50% paralyzing dose (tetanus) for control vs. casted gastrocnemius muscle was 64 vs. 813 mg/kg; corresponding plasma concentrations were 0.12 vs. 2.0 micrograms/ml. Thus in vivo simultaneous tension measurements of both gastrocnemius muscles, one casted and one uncasted, demonstrated resistance to paralysis by MTC in muscle with disuse atrophy. FAU - Gronert, G A AU - Gronert GA FAU - Matteo, R S AU - Matteo RS FAU - Perkins, S AU - Perkins S LA - eng GR - GM-21729/GM/NIGMS NIH HHS/United States GR - GM-26745/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Appl Physiol Respir Environ Exerc Physiol JT - Journal of applied physiology: respiratory, environmental and exercise physiology JID - 7801242 RN - 947TXZ810I (dimethyltubocurarine) RN - W9YXS298BM (Tubocurarine) SB - IM MH - Animals MH - Dogs MH - Dose-Response Relationship, Drug MH - Drug Resistance MH - *Immobilization MH - Leg MH - Muscular Atrophy/etiology/*physiopathology MH - Paralysis/*chemically induced MH - Tubocurarine/*analogs & derivatives/blood/pharmacology OID - NASA: 85104463 EDAT- 1984/11/01 00:00 MHDA- 1984/11/01 00:01 CRDT- 1984/11/01 00:00 PHST- 1984/11/01 00:00 [pubmed] PHST- 1984/11/01 00:01 [medline] PHST- 1984/11/01 00:00 [entrez] AID - 10.1152/jappl.1984.57.5.1502 [doi] PST - ppublish SO - J Appl Physiol Respir Environ Exerc Physiol. 1984 Nov;57(5):1502-6. doi: 10.1152/jappl.1984.57.5.1502. PMID- 16514850 OWN - NLM STAT- MEDLINE DCOM- 20060323 LR - 20220408 IS - 0001-5547 (Print) IS - 0001-5547 (Linking) VI - 50 IP - 1 DP - 2006 Jan-Feb TI - Diagnostic value of fine needle aspiration cytology in gouty tophi: a report of 7 cases. PG - 101-4 AB - BACKGROUND The diagnosis of gout can be problematic when the presentation is atypical and serum uric acid is borderline elevated. Demonstration of monosodium urate (MSU) crystals in fine needle aspiration (FNA) smears from nodular masses clinically suspected to be tophi establishes the diagnosis unequivocally. CASES: Of the 7 cases in this study, 4 were suspected clinically to have gouty tophi. Giant cell tumor of tendon sheath, giant cell tumor of bone and metastatic tumor with multicentric involvement of bone were the clinical diagnoses in 1 case each. Serum uric acid levels high enough to be in the diagnostic range for gout were reported in 3 cases, within normal limits in 3 cases and low in 1 chronic alcoholic patient. Bright field microscopy of FNA smears revealed singly scattered or stacks of MSU crystals with variable number of inflammatory cells, with or without foreign body giant cells in 6 cases. In 1 patient, FNA showed stacks of MSU crystals only. Characteristic birefringence of MSU crystals was observed on polarizing microscopy. CONCLUSION: FNA demonstration of MSU crystals on polarizing microscopy can easily establish the nature of the nodules in and around the joints and in soft tissue as gouty tophi and is thus an investigation differentiating this lesion from other masses clinically simulating it. FAU - Bhadani, Punam Prasad AU - Bhadani PP AD - Department of Pathology, BP Koirala Institute of Health Sciences, Dharan, Nepal. ukbhadani275@yahoo.com FAU - Sah, Shatrughan Prasad AU - Sah SP FAU - Sen, Rajeev AU - Sen R FAU - Singh, Ranjit Kumar AU - Singh RK LA - eng PT - Case Reports PT - Journal Article PL - Switzerland TA - Acta Cytol JT - Acta cytologica JID - 0370307 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Aged MH - Arthritis, Gouty/*diagnosis/pathology MH - Biopsy, Fine-Needle MH - Bone Neoplasms/diagnosis MH - Crystallization MH - Diagnosis, Differential MH - Giant Cell Tumors/diagnosis MH - Humans MH - Male MH - Microscopy, Polarization MH - Middle Aged MH - Neoplasm Metastasis MH - Soft Tissue Neoplasms/diagnosis MH - Tendons MH - Uric Acid/analysis EDAT- 2006/03/07 09:00 MHDA- 2006/03/24 09:00 CRDT- 2006/03/07 09:00 PHST- 2006/03/07 09:00 [pubmed] PHST- 2006/03/24 09:00 [medline] PHST- 2006/03/07 09:00 [entrez] AID - 10.1159/000325904 [doi] PST - ppublish SO - Acta Cytol. 2006 Jan-Feb;50(1):101-4. doi: 10.1159/000325904. PMID- 4047446 OWN - NLM STAT- MEDLINE DCOM- 19851030 LR - 20071115 IS - 0026-4806 (Print) IS - 0026-4806 (Linking) VI - 76 IP - 36 DP - 1985 Sep 22 TI - [Phytopack Ispex in the treatment of degenerative arthropathies and insertion tendinopathies. Telethermographic study]. PG - 1597-604 AB - The authors have studied the antiflogistic properties of a fitotherapic agent used in course of rheumatic and degenerative joint and tendon disease. The control of the therapeutic activity of the agent has been checked out by mean of telethermography. The best results were mainly obtained in cases of osteoarthritis and tendonitis, in which a real reduction of the stermic value showed a parallel decrease of the flogistic process involving joints and tendons. FAU - Pizzetti, M AU - Pizzetti M FAU - Martini, G AU - Martini G FAU - Ippolito, E AU - Ippolito E LA - ita PT - English Abstract PT - Journal Article TT - Il Phitopack Ispex nel trattamento delle artropatie degenerative e delle tendinopatie inserzionali. Studio teletermografico. PL - Italy TA - Minerva Med JT - Minerva medica JID - 0400732 RN - 0 (Plant Extracts) SB - IM MH - Adult MH - Aged MH - Evaluation Studies as Topic MH - Female MH - Humans MH - Joint Diseases/*therapy MH - Male MH - Middle Aged MH - Plant Extracts/*therapeutic use MH - Plants, Medicinal MH - Tendinopathy/*therapy MH - Thermography EDAT- 1985/09/22 00:00 MHDA- 1985/09/22 00:01 CRDT- 1985/09/22 00:00 PHST- 1985/09/22 00:00 [pubmed] PHST- 1985/09/22 00:01 [medline] PHST- 1985/09/22 00:00 [entrez] PST - ppublish SO - Minerva Med. 1985 Sep 22;76(36):1597-604. PMID- 6016267 OWN - NLM STAT- MEDLINE DCOM- 19670318 LR - 20190704 IS - 0004-0010 (Print) IS - 0004-0010 (Linking) VI - 94 IP - 2 DP - 1967 Feb TI - The regional use of muscle relaxants. PG - 199-201 FAU - Torda, T A AU - Torda TA FAU - Klonymus, D H AU - Klonymus DH LA - eng PT - Journal Article PL - United States TA - Arch Surg JT - Archives of surgery (Chicago, Ill. : 1960) JID - 9716528 RN - 0 (Adjuvants, Anesthesia) RN - 0 (Decamethonium Compounds) RN - J2R869A8YF (Succinylcholine) RN - Q3254X40X2 (Gallamine Triethiodide) RN - W9YXS298BM (Tubocurarine) SB - IM MH - Adjuvants, Anesthesia MH - Decamethonium Compounds/administration & dosage MH - Forearm/*surgery MH - Gallamine Triethiodide/administration & dosage MH - Hand/*surgery MH - Humans MH - Joints/surgery MH - Muscles/*administration & dosage MH - Succinylcholine/administration & dosage MH - Tendons/surgery MH - Tourniquets MH - Tubocurarine/administration & dosage EDAT- 1967/02/01 00:00 MHDA- 1967/02/01 00:01 CRDT- 1967/02/01 00:00 PHST- 1967/02/01 00:00 [pubmed] PHST- 1967/02/01 00:01 [medline] PHST- 1967/02/01 00:00 [entrez] AID - 10.1001/archsurg.1967.01330080037012 [doi] PST - ppublish SO - Arch Surg. 1967 Feb;94(2):199-201. doi: 10.1001/archsurg.1967.01330080037012. PMID- 4473958 OWN - NLM STAT- MEDLINE DCOM- 19750127 LR - 20190629 IS - 0003-9861 (Print) IS - 0003-9861 (Linking) VI - 164 IP - 1 DP - 1974 Sep TI - Hydroxylation of peptide-bound proline and lysine before and after chain completion of the polypeptide chains of procollagen. PG - 210-7 FAU - Uitto, J AU - Uitto J FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Arch Biochem Biophys JT - Archives of biochemistry and biophysics JID - 0372430 RN - 0 (Carbon Radioisotopes) RN - 0 (Culture Media) RN - 2GQB349IUB (Hydroxylysine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - K3Z4F929H6 (Lysine) RN - RMB44WO89X (Hydroxyproline) RN - SML2Y3J35T (Colchicine) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Chick Embryo MH - Chromatography, Gel MH - Colchicine/pharmacology MH - Collagen/*biosynthesis MH - Culture Media MH - Electrophoresis, Polyacrylamide Gel MH - Hydroxylysine/biosynthesis MH - Hydroxyproline/biosynthesis MH - Lysine/*metabolism MH - Proline/*metabolism MH - *Protein Biosynthesis/drug effects MH - Tendons/drug effects/metabolism EDAT- 1974/09/01 00:00 MHDA- 1974/09/01 00:01 CRDT- 1974/09/01 00:00 PHST- 1974/09/01 00:00 [pubmed] PHST- 1974/09/01 00:01 [medline] PHST- 1974/09/01 00:00 [entrez] AID - 0003-9861(74)90024-1 [pii] AID - 10.1016/0003-9861(74)90024-1 [doi] PST - ppublish SO - Arch Biochem Biophys. 1974 Sep;164(1):210-7. doi: 10.1016/0003-9861(74)90024-1. PMID- 5365743 OWN - NLM STAT- MEDLINE DCOM- 19700305 LR - 20131121 IS - 0035-2659 (Print) IS - 0035-2659 (Linking) VI - 36 IP - 10 DP - 1969 Oct TI - [Articular manifestations in hyperlipidemia]. PG - 555-8 FAU - Khachadurian, A AU - Khachadurian A LA - fre PT - Journal Article TT - Les manifestations articulaires dans les hyperlipidémies. PL - France TA - Rev Rhum Mal Osteoartic JT - Revue du rhumatisme et des maladies osteo-articulaires JID - 0407211 RN - 0 (Triglycerides) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Arthritis/*complications MH - Arthritis, Rheumatoid/complications MH - Child MH - Child, Preschool MH - Female MH - Gout/complications MH - Humans MH - Hyperlipidemias/*complications/genetics MH - Male MH - Middle Aged MH - Tendons/pathology MH - Triglycerides/blood MH - Uric Acid/blood MH - Xanthomatosis/*complications EDAT- 1969/10/01 00:00 MHDA- 1969/10/01 00:01 CRDT- 1969/10/01 00:00 PHST- 1969/10/01 00:00 [pubmed] PHST- 1969/10/01 00:01 [medline] PHST- 1969/10/01 00:00 [entrez] PST - ppublish SO - Rev Rhum Mal Osteoartic. 1969 Oct;36(10):555-8. PMID- 2348068 OWN - NLM STAT- MEDLINE DCOM- 19900709 LR - 20190828 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 15 IP - 3 DP - 1990 May TI - Transthecal digital block: flexor tendon sheath used for anesthetic infusion. PG - 471-7 AB - A new approach to achieve digital block by use of the flexor tendon sheath as an avenue introducing anesthetics to the core of the digit is described. Through centrifugal anesthetic diffusion all four digital nerves are anesthetized rapidly. This technique involves palmar percutaneous injection of 2 ml of lidocaine (Xylocaine) into the potential space of the flexor tendon sheath at the level of the palmar flexion crease with a 3 ml syringe and a No. 25-gauge hypodermic needle. Over the last 5 years, I have used this technique on 420 patients with no observable anesthetic complication. A repeat injection or local infiltration as a supplement was necessary only in four instances. FAU - Chiu, D T AU - Chiu DT AD - Department of Plastic Surgery, New York University Medical Center, New York. LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 98PI200987 (Lidocaine) SB - IM MH - Fingers/*innervation MH - Humans MH - Injections, Intradermal MH - Lidocaine/administration & dosage MH - Metacarpophalangeal Joint MH - Nerve Block/*methods MH - Tendons EDAT- 1990/05/01 00:00 MHDA- 1990/05/01 00:01 CRDT- 1990/05/01 00:00 PHST- 1990/05/01 00:00 [pubmed] PHST- 1990/05/01 00:01 [medline] PHST- 1990/05/01 00:00 [entrez] AID - 0363-5023(90)90063-W [pii] AID - 10.1016/0363-5023(90)90063-w [doi] PST - ppublish SO - J Hand Surg Am. 1990 May;15(3):471-7. doi: 10.1016/0363-5023(90)90063-w. PMID- 2301680 OWN - NLM STAT- MEDLINE DCOM- 19900313 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 18 IP - 1 DP - 1990 Jan-Feb TI - Intraarticular reaction associated with the use of freeze-dried, ethylene oxide-sterilized bone-patella tendon-bone allografts in the reconstruction of the anterior cruciate ligament. PG - 1-10; discussion 10-1 AB - One hundred nine patients over a 3 year period underwent reconstruction for chronic ACL ruptures using a freeze-dried, ethylene oxide-sterilized bone-patella tendon-bone allograft. Seven patients (6.4%) developed a characteristic persistent intraarticular reaction. This reaction was characterized by persistent synovial effusion with collagenous particulates and cellular inflammatory response. Synovial biopsies in all cases showed a similar chronic inflammatory process, characterized by fibrin, collagen, and phagocytic cells. The intraarticular white cells were predominantly lymphocytes. Removal of the allograft resulted in resolution of the reaction in all of the patients. Three of the seven patients showed HLA conversion. Gas chromatography demonstrated detectable levels of ethylene chlorohydrin, a toxic reaction product of ethylene oxide, within the allograft and synovium 14 months following implantation of one graft. These seven cases presented strongly suggest a nonspecific or immune mediated response that must be further delineated. The use of freeze-dried, ethylene oxide-sterilized allografts using standard techniques cannot be recommended for reconstruction of the ACL. FAU - Jackson, D W AU - Jackson DW AD - Southern California Center for Sports Medicine, Long Beach 90806. FAU - Windler, G E AU - Windler GE FAU - Simon, T M AU - Simon TM LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - JJH7GNN18P (Ethylene Oxide) SB - IM MH - Adolescent MH - Adult MH - *Bone Transplantation MH - Ethylene Oxide/*adverse effects MH - Female MH - Freeze Drying MH - Humans MH - Knee Injuries/surgery MH - Knee Joint/*surgery MH - Ligaments, Articular/injuries/*surgery MH - Male MH - Patella/*transplantation MH - *Postoperative Complications MH - Prospective Studies MH - Rupture MH - Sterilization/*methods MH - Synovitis/*etiology MH - Tendons/*transplantation MH - Transplantation, Homologous EDAT- 1990/01/01 00:00 MHDA- 1990/01/01 00:01 CRDT- 1990/01/01 00:00 PHST- 1990/01/01 00:00 [pubmed] PHST- 1990/01/01 00:01 [medline] PHST- 1990/01/01 00:00 [entrez] AID - 10.1177/036354659001800101 [doi] PST - ppublish SO - Am J Sports Med. 1990 Jan-Feb;18(1):1-10; discussion 10-1. doi: 10.1177/036354659001800101. PMID- 4337621 OWN - NLM STAT- MEDLINE DCOM- 19720727 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 264 IP - 2 DP - 1972 Apr 21 TI - Time lag in the secretion of collagen by matrix-free tendon cells and inhibition of the secretory process by colchicine and vinblastine. PG - 375-82 FAU - Dehm, P AU - Dehm P FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Butyrates) RN - 0 (Carbon Isotopes) RN - 5V9KLZ54CY (Vinblastine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - E0399OZS9N (Cyclic AMP) RN - EC 3.4.21.4 (Trypsin) RN - EC 3.4.24.3 (Microbial Collagenase) RN - RMB44WO89X (Hydroxyproline) RN - SML2Y3J35T (Colchicine) SB - IM MH - Animals MH - Butyrates/pharmacology MH - Carbon Isotopes MH - Cells/drug effects/metabolism MH - Chick Embryo MH - Colchicine/*pharmacology MH - Collagen/biosynthesis/*metabolism MH - Cyclic AMP/pharmacology MH - Depression, Chemical MH - Hydroxyproline/biosynthesis MH - Kinetics MH - Microbial Collagenase MH - Proline/metabolism MH - Stimulation, Chemical MH - Tendons/cytology/drug effects/*metabolism MH - Trypsin MH - Vinblastine/*pharmacology EDAT- 1972/04/21 00:00 MHDA- 1972/04/21 00:01 CRDT- 1972/04/21 00:00 PHST- 1972/04/21 00:00 [pubmed] PHST- 1972/04/21 00:01 [medline] PHST- 1972/04/21 00:00 [entrez] AID - 0304-4165(72)90302-9 [pii] AID - 10.1016/0304-4165(72)90302-9 [doi] PST - ppublish SO - Biochim Biophys Acta. 1972 Apr 21;264(2):375-82. doi: 10.1016/0304-4165(72)90302-9. PMID- 171653 OWN - NLM STAT- MEDLINE DCOM- 19760116 LR - 20190501 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 72 IP - 8 DP - 1975 Aug TI - Human synoviocytes: activation and desensitization by prostaglandins and 1-epinephrine. PG - 3124-8 AB - The human synoviocyte increases its intracellular adenosine 3':5'-cyclic monophosphate (cAMP) concentration significantly after incubation with prostaglandin E1, prostaglandin E2, or l-epinephrine. The cells can be desensitized to these same hormones. Hormone-induced desensitization is receptor site specific and associated with a significant increase in intracellular 3':5'-cyclic AMP phosphodiesterase (EC 3.1.4. 17; 3':5'-cyclic AMP 5'-nucleotidohydrolase) activity, whereas cAMP-induced desensitization is not hormone specific. FAU - Newcombe, D S AU - Newcombe DS FAU - Ciosek, C P Jr AU - Ciosek CP Jr FAU - Ishikawa, Y AU - Ishikawa Y FAU - Fahey, J V AU - Fahey JV LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Prostaglandins E) RN - C137DTR5RG (Theophylline) RN - E0399OZS9N (Cyclic AMP) RN - EC 3.1.4.17 (3',5'-Cyclic-AMP Phosphodiesterases) RN - YKH834O4BH (Epinephrine) SB - IM MH - 3',5'-Cyclic-AMP Phosphodiesterases/metabolism MH - Cells, Cultured MH - Cyclic AMP/metabolism MH - Enzyme Activation/drug effects MH - Epinephrine/*pharmacology MH - Humans MH - Prostaglandins E/*pharmacology MH - Synovial Membrane/cytology/drug effects/*metabolism MH - Tendons/cytology/drug effects/metabolism MH - Theophylline/pharmacology PMC - PMC432933 EDAT- 1975/08/01 00:00 MHDA- 2001/03/28 10:01 PMCR- 1976/02/01 CRDT- 1975/08/01 00:00 PHST- 1975/08/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1975/08/01 00:00 [entrez] PHST- 1976/02/01 00:00 [pmc-release] AID - 10.1073/pnas.72.8.3124 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 1975 Aug;72(8):3124-8. doi: 10.1073/pnas.72.8.3124. PMID- 6635344 OWN - NLM STAT- MEDLINE DCOM- 19831220 LR - 20031114 IS - 0034-5288 (Print) IS - 0034-5288 (Linking) VI - 35 IP - 2 DP - 1983 Sep TI - Forms of leg abnormality observed in male broilers fed on a diet containing 12.5 percent rapeseed meal. PG - 182-9 AB - The incidence of leg abnormalities was studied in 216 male Ross I broilers, fed for 10 weeks on a diet containing 12.5 per cent extracted rapeseed. Regular serological examination showed that the birds remained free from Mycoplasma gallisepticum, Mycoplasma synoviae and avian reovirus throughout the period of investigation. Post mortem examination and radiographs were performed when birds were culled due to leg deformities or at the end of the experiment. Leg abnormalities were seen in 19.4 per cent of the birds which represents a very significant increase above that currently seen in commercial flocks. They consisted of a large range of skeletal deformities including valgus and varus deformities, dyschondroplasia, slipped gastrocnemius tendons, dislocated condyles, rotation and penetration of the distal tibiotarsus and fractured fibulas. Multiple forms of leg abnormality were often observed in individual birds and their association is briefly discussed. FAU - Timms, L M AU - Timms LM LA - eng PT - Journal Article PL - England TA - Res Vet Sci JT - Research in veterinary science JID - 0401300 RN - 36-88-4 (Carotenoids) SB - IM MH - Animal Feed/adverse effects MH - Animals MH - Body Weight MH - Bone Diseases/etiology/metabolism/*veterinary MH - *Brassica MH - Carotenoids/blood MH - *Chickens MH - Diet MH - Hindlimb MH - Male MH - Poultry Diseases/*etiology/metabolism EDAT- 1983/09/01 00:00 MHDA- 1983/09/01 00:01 CRDT- 1983/09/01 00:00 PHST- 1983/09/01 00:00 [pubmed] PHST- 1983/09/01 00:01 [medline] PHST- 1983/09/01 00:00 [entrez] PST - ppublish SO - Res Vet Sci. 1983 Sep;35(2):182-9. PMID- 19158520 OWN - NLM STAT- MEDLINE DCOM- 20090505 LR - 20131121 IS - 1536-3708 (Electronic) IS - 0148-7043 (Linking) VI - 62 IP - 2 DP - 2009 Feb TI - Crystal deposition disease masquerading as proliferative tenosynovitis and its associated sequelae. PG - 128-33 LID - 10.1097/SAP.0b013e3181788e98 [doi] AB - Extra-articular crystalline deposition secondary to gout, and less commonly, pseudogout is a well known phenomenon. Despite this well-documented entity of extra-articular deposition, there have been few reports of infiltration of the flexor tendon sheath of the hand. Here, we present a case series of this unique occurrence, including surgical techniques, pathology, and the clinical outcomes of 5 patients. We encountered 2 cases of calcium pyrophosphate and 3 cases of uric acid deposition into the flexor tendon sheath masquerading as common tendonopathies. These include cases of carpal tunnel syndrome, nonsuppurative flexor tenosynovitis, trigger finger, and attrition rupture of the flexor tendons. Although, medical therapy is the cornerstone of treatment for diseases that result in crystal deposition, these cases emphasize the potential need for surgical therapy in the armamentarium of their management. This case series demonstrates the importance of inclusion of crystal deposition into the flexor tendon sheath in the differential diagnosis in patients that present with uncharacteristic symptomatology of common flexor tendonopathies. FAU - Bullocks, Jamal M AU - Bullocks JM AD - Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. bullocks@bcm.tmc.edu FAU - Downey, Cara R AU - Downey CR FAU - Gibler, D Patricio González AU - Gibler DP FAU - Netscher, David T AU - Netscher DT LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 RN - 268B43MJ25 (Uric Acid) RN - X69NU20D19 (Calcium Pyrophosphate) SB - IM MH - Aged MH - *Calcium Pyrophosphate MH - Crystallization MH - Diagnosis, Differential MH - *Finger Joint MH - Humans MH - Joint Diseases/*diagnosis/pathology MH - Male MH - Middle Aged MH - Tenosynovitis/*diagnosis/pathology MH - *Uric Acid EDAT- 2009/01/23 09:00 MHDA- 2009/05/06 09:00 CRDT- 2009/01/23 09:00 PHST- 2009/01/23 09:00 [entrez] PHST- 2009/01/23 09:00 [pubmed] PHST- 2009/05/06 09:00 [medline] AID - 00000637-200902000-00008 [pii] AID - 10.1097/SAP.0b013e3181788e98 [doi] PST - ppublish SO - Ann Plast Surg. 2009 Feb;62(2):128-33. doi: 10.1097/SAP.0b013e3181788e98. PMID- 4411633 OWN - NLM STAT- MEDLINE DCOM- 19741210 LR - 20131121 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 104 DP - 1974 Oct TI - A dynamic approach to problems of hand function using local anesthesia supplemented by intravenous fentanyl-droperidol. PG - 112-5 FAU - Hunter, J M AU - Hunter JM FAU - Schneider, L H AU - Schneider LH FAU - Dumont, J AU - Dumont J FAU - Erickson, J C 3rd AU - Erickson JC 3rd LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Drug Combinations) RN - O9U0F09D5X (Droperidol) RN - UF599785JZ (Fentanyl) SB - IM MH - *Anesthesia, Local MH - Droperidol/*administration & dosage MH - Drug Combinations MH - *Fentanyl/administration & dosage MH - Fingers/surgery MH - Hand/*surgery MH - Hand Deformities, Acquired/surgery MH - Humans MH - *Neuroleptanalgesia MH - Tendons/surgery EDAT- 1974/10/01 00:00 MHDA- 1974/10/01 00:01 CRDT- 1974/10/01 00:00 PHST- 1974/10/01 00:00 [pubmed] PHST- 1974/10/01 00:01 [medline] PHST- 1974/10/01 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1974 Oct;(104):112-5. PMID- 1720975 OWN - NLM STAT- MEDLINE DCOM- 19920123 LR - 20191028 IS - 1153-2424 (Print) IS - 1153-2424 (Linking) VI - 10 IP - 4 DP - 1991 TI - [Sarcoid synovitis. A case report of localization at the level of the flexor tendons of the fingers]. PG - 360-3 AB - Sarcoidosis without bone involvement or sarcoid dactylitis, is a very unusual cause of flexor synovitis. Our reported patient initially presented with chronic arthralgia of the knees and ankles. The initial diagnosis of rheumatoid arthritis was incorrect. A surgical flexor synovectomy was performed to release painful compression of the median nerve due to the synovitis. The correct diagnosis was suggested by the histopathological examination showing noncaseating epithelioid granulomas. The diagnosis was confirmed by the association of a negative tuberculin test and raised angiotensin converting enzyme. No recurrence of synovitis occurred after surgical excision and colchicine therapy but arthralgia persisted. FAU - Bleton, R AU - Bleton R AD - Service de Chirurgie orthopédique et reconstructrice, Hôpital Bichat, Paris. FAU - Alnot, J Y AU - Alnot JY FAU - Kahn, M F AU - Kahn MF FAU - Bocquet, L AU - Bocquet L LA - fre PT - Case Reports PT - English Abstract PT - Journal Article TT - Synovite sarcoïdosique. A propos d'un cas de localisation au niveau des tendons fléchisseurs des doigts. PL - France TA - Ann Chir Main Memb Super JT - Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery JID - 9011039 RN - EC 3.4.15.1 (Peptidyl-Dipeptidase A) RN - SML2Y3J35T (Colchicine) SB - IM MH - Colchicine/therapeutic use MH - Combined Modality Therapy MH - Diagnostic Errors MH - Female MH - *Fingers MH - Humans MH - Peptidyl-Dipeptidase A/blood MH - Sarcoidosis/diagnosis/*pathology/surgery MH - Sarcoma, Synovial/diagnosis/*pathology/surgery MH - *Tendons MH - Tuberculin Test EDAT- 1991/01/01 00:00 MHDA- 1991/01/01 00:01 CRDT- 1991/01/01 00:00 PHST- 1991/01/01 00:00 [pubmed] PHST- 1991/01/01 00:01 [medline] PHST- 1991/01/01 00:00 [entrez] AID - 10.1016/s0753-9053(05)80145-0 [doi] PST - ppublish SO - Ann Chir Main Memb Super. 1991;10(4):360-3. doi: 10.1016/s0753-9053(05)80145-0. PMID- 7511915 OWN - NLM STAT- MEDLINE DCOM- 19940512 LR - 20191031 IS - 1153-2424 (Print) IS - 1153-2424 (Linking) VI - 13 IP - 1 DP - 1994 TI - [Simplified anesthesia for the surgical treatment of severe sprains of the metacarpophalangeal joint of the thumb]. PG - 60-3 AB - A series a 40 patients with severe sprain of the medial collateral ligament of the metacarpophalangeal joint of the thumb is reported. Anesthesia was performed by infiltration of the superficial branch of the radial nerve and the palmar collateral nerves of the thumb via of the flexor tendon sheath, with 0.5% bupivacaine without adrenaline, 3-4 ml each. This technique, easy and reliable (complete success) with a prolonged analgesia, is useful in the operating room and for stress examination or dynamic X rays. FAU - Chevaleraud, E AU - Chevaleraud E AD - Institut Francais de la Main, Paris. FAU - Lenoble, E AU - Lenoble E LA - fre PT - English Abstract PT - Journal Article TT - Anesthésie simplifiée pour le traitement chirurgical des entorses graves de l'articulation métacarpophalangienne du pouce. PL - France TA - Ann Chir Main Memb Super JT - Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery JID - 9011039 RN - Y8335394RO (Bupivacaine) SB - IM MH - Analgesia MH - Bupivacaine/administration & dosage MH - Collateral Ligaments/injuries/surgery MH - Humans MH - Injections, Subcutaneous MH - Metacarpophalangeal Joint/*injuries/*surgery MH - *Nerve Block MH - Pain, Postoperative/prevention & control MH - *Radial Nerve MH - Sprains and Strains/*surgery MH - Tendons/innervation MH - Thumb/*injuries/innervation/*surgery EDAT- 1994/01/01 00:00 MHDA- 1994/01/01 00:01 CRDT- 1994/01/01 00:00 PHST- 1994/01/01 00:00 [pubmed] PHST- 1994/01/01 00:01 [medline] PHST- 1994/01/01 00:00 [entrez] AID - 10.1016/s0753-9053(05)80363-1 [doi] PST - ppublish SO - Ann Chir Main Memb Super. 1994;13(1):60-3. doi: 10.1016/s0753-9053(05)80363-1. PMID- 19292358 OWN - NLM STAT- MEDLINE DCOM- 20090422 LR - 20131121 IS - 0147-7447 (Print) IS - 0147-7447 (Linking) VI - 31 IP - 6 DP - 2008 Jun TI - The effects of suramin in prevention of peritendinous adhesions following flexor tendon injury in a chicken model. PG - 542 AB - Peritendinous adhesions are the most common complication of flexor tendon injuries. Overproduction of transforming growth factor Beta has been reported as a major cause of tissue fibrosis. This study investigated the effects of suramin, a known inhibitor of transforming growth factor Beta, on the formation of flexor tendon adhesions in a chicken model. Forty-two chicken flexor tendons that were divided partially were repaired using a modified Kessler technique. The chickens were divided into 3 groups. In group 1 (control), no suramin was administered to the tendon repair site; in group 2, 1 mg of suramin was injected around the tendon repair site; and in group 3, 2 mg of suramin was injected around the tendon repair site. At 6 weeks postoperatively, the animals were sacrificed, and functional, histologic, and biomechanical examinations were performed. There was no difference between the groups in terms of tendon excursion. Histologic evaluation showed adhesions were decreased in the groups treated with suramin. In the biomechanical evaluation, a statistically significant difference was present only between the group treated with 2 mg of suramin and the control group. Although suramin is effective in preventing peritendinous adhesions, it can reduce tendon strength as dose-dependent. Future studies should be performed with different doses to determine clinical application. FAU - Sener, Muhittin AU - Sener M AD - Orthopedics and Traumatology, Izmir Atatürk Research and Training Hospital, Balçova, Izmir, Turkey. FAU - Akhan, Serkan AU - Akhan S FAU - Kazimoglu, Cemal AU - Kazimoglu C FAU - Karapinar, Hasan AU - Karapinar H FAU - Tuna, Burcin AU - Tuna B FAU - Cecen, Berivan AU - Cecen B LA - eng PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 6032D45BEM (Suramin) SB - IM MH - Animals MH - Chickens MH - *Disease Models, Animal MH - Female MH - Humans MH - Suramin/*administration & dosage MH - Tendon Injuries/*complications/*drug therapy MH - Tissue Adhesions/*etiology/*prevention & control MH - Treatment Outcome EDAT- 2009/03/19 09:00 MHDA- 2009/04/23 09:00 CRDT- 2009/03/19 09:00 PHST- 2009/03/19 09:00 [entrez] PHST- 2009/03/19 09:00 [pubmed] PHST- 2009/04/23 09:00 [medline] AID - orthopedics.28240 [pii] PST - ppublish SO - Orthopedics. 2008 Jun;31(6):542. PMID- 16933725 OWN - NLM STAT- MEDLINE DCOM- 20061017 LR - 20131121 IS - 0377-4929 (Print) IS - 0377-4929 (Linking) VI - 49 IP - 2 DP - 2006 Apr TI - Fine needle aspiration of tophi in asymptomatic gout--a case report. PG - 244-5 AB - Gout, a chronic hyperuricemic crystal induced arthropathy, may produce soft tissue masses (tophi). Tophi may be found in synovial membranes, periarticular ligaments, tendons, soft tissues as well as internal organs. We present a case in which diagnosis of gout was made by fine needle aspiration of tophus. The patient had a painless nodule over right ankle which was progressively increasing in size. He gave a past history of painful arthropathy, but serum uric acid levels were within normal limits. At this juncture, FNAC of the ankle tophus was performed which revealed aggregated and innumerable dissociated needle-shaped negatively birefringent crystals of monosodium urate (MSU) on polarization microscopy. FAU - Rao, Seema AU - Rao S AD - Department of Pathology, VMMC & Safdarjung Hospital. csydr@rediffmail.com FAU - Gupta, Kusum AU - Gupta K FAU - Arora, Rashmi AU - Arora R FAU - Arulselvi, S AU - Arulselvi S LA - eng PT - Case Reports PT - Journal Article PL - India TA - Indian J Pathol Microbiol JT - Indian journal of pathology & microbiology JID - 7605904 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Ankle MH - Biopsy, Fine-Needle MH - Birefringence MH - Crystallization MH - Gout/*diagnosis/metabolism MH - Humans MH - Male MH - Middle Aged MH - Uric Acid/blood/metabolism EDAT- 2006/08/29 09:00 MHDA- 2006/10/18 09:00 CRDT- 2006/08/29 09:00 PHST- 2006/08/29 09:00 [pubmed] PHST- 2006/10/18 09:00 [medline] PHST- 2006/08/29 09:00 [entrez] PST - ppublish SO - Indian J Pathol Microbiol. 2006 Apr;49(2):244-5. PMID- 19902750 OWN - NLM STAT- MEDLINE DCOM- 20091208 LR - 20161125 IS - 1003-0034 (Print) IS - 1003-0034 (Linking) VI - 22 IP - 10 DP - 2009 Oct TI - [Treatment of Zone II flexor tendon injury]. PG - 749-50 FAU - Cao, Qi-bin AU - Cao QB AD - Ningyang Hospital of TCM, Ningyang 271400, Shandong, China. LA - chi PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Zhongguo Gu Shang JT - Zhongguo gu shang = China journal of orthopaedics and traumatology JID - 9815790 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Adolescent MH - Adult MH - Combined Modality Therapy MH - Drugs, Chinese Herbal/therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Radiography MH - Tendon Injuries/diagnostic imaging/drug therapy/surgery/*therapy MH - Tendons/diagnostic imaging/drug effects/surgery MH - Young Adult EDAT- 2009/11/12 06:00 MHDA- 2009/12/16 06:00 CRDT- 2009/11/12 06:00 PHST- 2009/11/12 06:00 [entrez] PHST- 2009/11/12 06:00 [pubmed] PHST- 2009/12/16 06:00 [medline] PST - ppublish SO - Zhongguo Gu Shang. 2009 Oct;22(10):749-50. PMID- 5772368 OWN - NLM STAT- MEDLINE DCOM- 19690708 LR - 20131121 IS - 0300-8673 (Print) IS - 0300-8673 (Linking) VI - 45 IP - 1 DP - 1969 Jan 10 TI - [Tendomyopathy or periostosis following abdominal surgery]. PG - 29 FAU - Möller, E AU - Möller E LA - ger PT - Journal Article TT - Tendomyopathie bzw. Periostose nach Bauchoperation. PL - Germany TA - Z Allgemeinmed JT - Zeitschrift fur Allgemeinmedizin JID - 7700691 RN - 4Z8Y51M438 (Procaine) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 3.2.1.35 (Hyaluronoglucosaminidase) SB - IM MH - Abdomen/surgery MH - Dexamethasone/*administration & dosage MH - Humans MH - Hyaluronoglucosaminidase/*administration & dosage MH - Muscular Diseases/*drug therapy MH - Periostitis/*drug therapy MH - Postoperative Complications/*drug therapy MH - Procaine/*administration & dosage MH - *Tendons EDAT- 1969/01/10 00:00 MHDA- 1969/01/10 00:01 CRDT- 1969/01/10 00:00 PHST- 1969/01/10 00:00 [pubmed] PHST- 1969/01/10 00:01 [medline] PHST- 1969/01/10 00:00 [entrez] PST - ppublish SO - Z Allgemeinmed. 1969 Jan 10;45(1):29. PMID- 178654 OWN - NLM STAT- MEDLINE DCOM- 19760802 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 251 IP - 7 DP - 1976 Apr 10 TI - Termination of procollagen chain synthesis by puromycin. Evidence that assembly and secretion require a COOH-terminal extension. PG - 2070-6 AB - Embryonic chick fibroblasts were incubated with [14C]proline and puromycin in the low concentrations of 1 to 3 mug/ml. The molecular weight of the synthesized procollagen chains, as measured by polyacrylamide gel electrophoresis in sodium dodecyl sulfate, was progressively reduced by increasing concentrations of puromycin in this range. For example, at 3 mug/ml the great majority of the [14C]proline was contained in procollagen chains having an average molecular weight of about 95,000 instead of the control value of 125,000. Associated with this decrease in molecular weight there was a marked decrease in the incorporation of cysteine although [14C]proline incorporation was relatively unaffedted. Disulfide bond formation was drastically inhibited as was triple helix formation as measured by resistance of the procollagen to pepsin digestion. Although the shortened procollagen chains were of normal hydroxyproline content, they nevertheless were secreted much more slowly than normal procollagen. Based upon these findings, we postulate that: (a) low concentrations of puromycin terminate procollagen chains before a COOH-terminal extension is completed, (b) these COOH-terminal extensions are required for normal assembly of the three individual procollagen chains and for triple helix formation, and (c) only assembled, triple helical procollagen molecules are selected for normal secretion. FAU - Rosenbloom, J AU - Rosenbloom J FAU - Endo, R AU - Endo R FAU - Harsch, M AU - Harsch M LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Disulfides) RN - 0 (Macromolecular Substances) RN - 0 (Protein Precursors) RN - 4A6ZS6Q2CL (Puromycin) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - EC 3.4.23.1 (Pepsin A) RN - EC 3.4.24.3 (Microbial Collagenase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*biosynthesis MH - Disulfides/analysis MH - Fibroblasts/metabolism MH - Hydroxyproline/metabolism MH - Macromolecular Substances MH - Microbial Collagenase MH - Pepsin A MH - Peptide Chain Termination, Translational/*drug effects MH - Procollagen-Proline Dioxygenase/metabolism MH - Proline/metabolism MH - Protein Precursors/*biosynthesis MH - Puromycin/*pharmacology MH - Tendons/*metabolism EDAT- 1976/04/10 00:00 MHDA- 1976/04/10 00:01 CRDT- 1976/04/10 00:00 PHST- 1976/04/10 00:00 [pubmed] PHST- 1976/04/10 00:01 [medline] PHST- 1976/04/10 00:00 [entrez] AID - S0021-9258(17)33656-6 [pii] PST - ppublish SO - J Biol Chem. 1976 Apr 10;251(7):2070-6. PMID- 1941681 OWN - NLM STAT- MEDLINE DCOM- 19911213 LR - 20190711 IS - 0022-3913 (Print) IS - 0022-3913 (Linking) VI - 66 IP - 1 DP - 1991 Jul TI - Hyoid bone syndrome: a degenerative injury of the middle pharyngeal constrictor muscle with photomicroscopic evidence of insertion tendinosis. PG - 78-83 AB - This article describes the condition known as hyoid bone syndrome, its diagnosis by exclusion, and the histopathologic evidence of focal, degenerative muscle injury. The injury involves the origin fibers of the middle pharyngeal constrictor muscle on the greater cornu of the hyoid bone. The importance of the dentist and physician in recognizing the condition is emphasized, because dental and nondental pain reference sites make up the syndrome. FAU - Ernest, E A 3rd AU - Ernest EA 3rd AD - Department of Cell Biology and Anatomy, University of Alabama Medical Center, Birmingham. FAU - Salter, E G AU - Salter EG LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Prosthet Dent JT - The Journal of prosthetic dentistry JID - 0376364 RN - Y8335394RO (Bupivacaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Adult MH - Bupivacaine/administration & dosage MH - Diagnosis, Differential MH - Epinephrine/administration & dosage MH - Facial Pain/*etiology MH - Female MH - Humans MH - Hyoid Bone/*pathology MH - Pharyngeal Muscles/*injuries/pathology/surgery MH - Syndrome MH - Tendons/*physiopathology EDAT- 1991/07/01 00:00 MHDA- 1991/07/01 00:01 CRDT- 1991/07/01 00:00 PHST- 1991/07/01 00:00 [pubmed] PHST- 1991/07/01 00:01 [medline] PHST- 1991/07/01 00:00 [entrez] AID - 0022-3913(91)90357-3 [pii] AID - 10.1016/0022-3913(91)90357-3 [doi] PST - ppublish SO - J Prosthet Dent. 1991 Jul;66(1):78-83. doi: 10.1016/0022-3913(91)90357-3. PMID- 4719617 OWN - NLM STAT- MEDLINE DCOM- 19730926 LR - 20131121 IS - 0012-0472 (Print) IS - 0012-0472 (Linking) VI - 98 IP - 30 DP - 1973 Jul 27 TI - [Acquired knee joint contracture in infancy]. PG - 1427-9 FAU - Lachmann, D AU - Lachmann D FAU - Meznik, F AU - Meznik F FAU - Rosenkranz, A AU - Rosenkranz A FAU - Zweymüller, E AU - Zweymüller E LA - ger PT - Journal Article TT - Die erworbene Kniestreckkontraktur im Säuglingsalter. PL - Germany TA - Dtsch Med Wochenschr JT - Deutsche medizinische Wochenschrift (1946) JID - 0006723 RN - Q42T66VG0C (Penicillin G) SB - IM MH - Child, Preschool MH - Contracture/chemically induced/rehabilitation/*surgery MH - Female MH - Humans MH - Infant MH - Injections, Intramuscular/*adverse effects MH - *Knee Joint MH - Male MH - Penicillin G/adverse effects/therapeutic use MH - Tendons/surgery MH - Thigh EDAT- 1973/07/27 00:00 MHDA- 1973/07/27 00:01 CRDT- 1973/07/27 00:00 PHST- 1973/07/27 00:00 [pubmed] PHST- 1973/07/27 00:01 [medline] PHST- 1973/07/27 00:00 [entrez] AID - 10.1055/s-0028-1107047 [doi] PST - ppublish SO - Dtsch Med Wochenschr. 1973 Jul 27;98(30):1427-9. doi: 10.1055/s-0028-1107047. PMID- 16011105 OWN - NLM STAT- MEDLINE DCOM- 20060302 LR - 20080206 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 30 IP - 7 DP - 2005 Apr TI - [Ameliorative effect of ginseng glycopeptide on cross-linking of rat tail tendon collagen]. PG - 544-7 AB - OBJECTIVE: To investigate the ameliorative effect of ginseng glycopeptide on cross-linking of rat tail tendon collagen. METHOD: ELISA was used to determine the inhibitory effect of ginseng glycopeptide on cross-linking of rat tail tendon collagen in vitro. After ginseng glycopeptide was intraperitoneally administrated to streptozotocin-induced diabetic rats for 12 weeks, the acid solubility, limited pepsin degradation properties and solubility in SDS-2-mercaptoethanol of the rat tail tendon collagen were determined, and the effect of ginseng glycopeptide on the tail tendon collagen cross-linking was evaluated. RESULT: Ginseng glycopeptide inhibited significantly the cross-linking of rat tail tendon collagen in vitro. The solubility of the tail tendon collagen (in acid, pepsin and SDS-2-mercaptoethanol) was markedly decreased in diabetic rats and ginseng glycopeptide-treated diabetic rats had significantly an increase in the collagen solubility in the above-mentioned solutions, suggesting that ginseng glycopeptide decreased severity of the collagen cross-linking. CONCLUSION: Ginsengglycopeptide exhibits an significantly ameliorative effect on cross-linking of rat tail tendon collagen. FAU - Li, Cai AU - Li C AD - Institute of Frontier Medical Science, Jilin University, Changchun 130021, China. licaijia@public.cc.jl.cn FAU - Li, Xiang-jun AU - Li XJ FAU - Miao, Chun-sheng AU - Miao CS FAU - Zhang, Xiu-yun AU - Zhang XY LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Glycopeptides) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Collagen/*metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Female MH - Glycopeptides/isolation & purification/*pharmacology MH - Male MH - *Panax/chemistry MH - Plants, Medicinal/chemistry MH - Rats MH - Rats, Wistar MH - Solubility MH - Tail MH - Tendons/*metabolism EDAT- 2005/07/14 09:00 MHDA- 2006/03/03 09:00 CRDT- 2005/07/14 09:00 PHST- 2005/07/14 09:00 [pubmed] PHST- 2006/03/03 09:00 [medline] PHST- 2005/07/14 09:00 [entrez] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2005 Apr;30(7):544-7. PMID- 2634827 OWN - NLM STAT- MEDLINE DCOM- 19900607 LR - 20150216 IS - 0028-3843 (Print) IS - 0028-3843 (Linking) VI - 23 IP - 3 DP - 1989 May-Jun TI - [A case of tophus situated in the optic nerve]. PG - 250-2 AB - Tophi are a characteristic sign of gout. They are situated usually around joints, on tendons, in the skin, intestine and renal tubules. The authors report a rare case of tophus situated in the optic nerve and coexisting with aneurysm of the anterior communicating artery. FAU - Bazowski, P AU - Bazowski P AD - Katedry i Kliniki Neurochirurgii S1. AM w Katowicach. FAU - Kopera, M AU - Kopera M LA - pol PT - Case Reports PT - English Abstract PT - Journal Article TT - Przypadek guzka dnawego wewnatrz nerwu wzrokowego. PL - Poland TA - Neurol Neurochir Pol JT - Neurologia i neurochirurgia polska JID - 0101265 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Calculi/diagnosis/*etiology MH - Gout/*complications MH - Humans MH - Male MH - Middle Aged MH - Optic Nerve Diseases/diagnosis/*etiology MH - *Uric Acid EDAT- 1989/05/01 00:00 MHDA- 1989/05/01 00:01 CRDT- 1989/05/01 00:00 PHST- 1989/05/01 00:00 [pubmed] PHST- 1989/05/01 00:01 [medline] PHST- 1989/05/01 00:00 [entrez] PST - ppublish SO - Neurol Neurochir Pol. 1989 May-Jun;23(3):250-2. PMID- 4788754 OWN - NLM STAT- MEDLINE DCOM- 19740626 LR - 20131121 IS - 0340-5338 (Print) IS - 0340-5338 (Linking) VI - 30 IP - 1 DP - 1973 Sep 15 TI - Leucocytes and thrombosis. 3. Effect on white cell behaviour of substances which induce or inhibit platelet aggregation. PG - 62-71 FAU - Banks, D C AU - Banks DC FAU - Mitchell, J R AU - Mitchell JR LA - eng PT - Journal Article PL - Germany TA - Thromb Diath Haemorrh JT - Thrombosis et diathesis haemorrhagica JID - 7608420 RN - 0 (Catecholamines) RN - 333DO1RDJY (Serotonin) RN - 64ALC7F90C (Dipyridamole) RN - 9007-34-5 (Collagen) RN - K72T3FS567 (Adenosine) RN - L628TT009W (Isoproterenol) RN - R16CO5Y76E (Aspirin) RN - X4W3ENH1CV (Norepinephrine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Adenosine/pharmacology MH - Aspirin/pharmacology MH - Catecholamines/*pharmacology MH - Collagen/pharmacology MH - Dipyridamole/pharmacology MH - Epinephrine/pharmacology MH - Isoproterenol/pharmacology MH - Leukocytes/*drug effects MH - Norepinephrine/pharmacology MH - Serotonin/*pharmacology MH - Tendons MH - Thrombosis/*blood EDAT- 1973/09/15 00:00 MHDA- 1973/09/15 00:01 CRDT- 1973/09/15 00:00 PHST- 1973/09/15 00:00 [pubmed] PHST- 1973/09/15 00:01 [medline] PHST- 1973/09/15 00:00 [entrez] PST - ppublish SO - Thromb Diath Haemorrh. 1973 Sep 15;30(1):62-71. PMID- 4770405 OWN - NLM STAT- MEDLINE DCOM- 19740307 LR - 20141120 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 187 IP - 3 DP - 1973 Dec TI - Inhibition of platelet aggregation and of experimental thrombosis by sudoxicam. PG - 653-65 FAU - Constantine, J W AU - Constantine JW FAU - Purcell, I M AU - Purcell IM LA - eng PT - Journal Article PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Amides) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Thiazines) RN - 0 (Thiazoles) RN - 0 (Tissue Extracts) RN - 61D2G4IYVH (Adenosine Diphosphate) SB - IM MH - Adenosine Diphosphate/metabolism MH - Administration, Oral MH - Amides/administration & dosage/pharmacology MH - Animals MH - Anti-Inflammatory Agents/*pharmacology MH - Blood Platelets/metabolism MH - Dogs MH - Guinea Pigs MH - In Vitro Techniques MH - Injections, Intravenous MH - Models, Biological MH - Platelet Adhesiveness/*drug effects MH - Rabbits MH - Tendons MH - Thiazines/administration & dosage/*pharmacology MH - Thiazoles/administration & dosage/pharmacology MH - Thrombosis/*prevention & control MH - Time Factors MH - Tissue Extracts/pharmacology EDAT- 1973/12/01 00:00 MHDA- 1973/12/01 00:01 CRDT- 1973/12/01 00:00 PHST- 1973/12/01 00:00 [pubmed] PHST- 1973/12/01 00:01 [medline] PHST- 1973/12/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1973 Dec;187(3):653-65. PMID- 4677730 OWN - NLM STAT- MEDLINE DCOM- 19721110 LR - 20191210 IS - 0027-2973 (Print) IS - 0027-2973 (Linking) VI - 114 IP - 32 DP - 1972 Aug 11 TI - [Experiences with concentrin special in general medicine]. PG - 1420-2 FAU - Götz, K AU - Götz K LA - ger PT - Journal Article TT - Erfahrungen mit Concentrin Spezial in der Allgemeinmedizin. PL - Germany TA - Munch Med Wochenschr JT - Munchener medizinische Wochenschrift (1950) JID - 7801802 RN - 0 (Anticholesteremic Agents) RN - 0 (Drug Combinations) RN - 0 (Flavonoids) RN - 0 (Glycosides) RN - 0 (Phospholipids) RN - 0 (Saponins) RN - 0 (escin, flavonoid, phospholipid drug combination) RN - 6805-41-0 (Escin) SB - IM MH - Anticholesteremic Agents/therapeutic use MH - Capillaries/drug effects MH - Capillary Permeability MH - Drug Combinations MH - Edema MH - Escin MH - Family Practice MH - Flavonoids/*therapeutic use MH - Glycosides MH - Humans MH - Joint Diseases/drug therapy MH - Leg Ulcer/drug therapy MH - Muscular Diseases/drug therapy MH - Phospholipids/*therapeutic use MH - Saponins/*therapeutic use MH - Tendons MH - Vascular Diseases/drug therapy MH - Veins EDAT- 1972/08/11 00:00 MHDA- 1972/08/11 00:01 CRDT- 1972/08/11 00:00 PHST- 1972/08/11 00:00 [pubmed] PHST- 1972/08/11 00:01 [medline] PHST- 1972/08/11 00:00 [entrez] PST - ppublish SO - Munch Med Wochenschr. 1972 Aug 11;114(32):1420-2. PMID- 9186088 OWN - NLM STAT- MEDLINE DCOM- 19970627 LR - 20190815 IS - 0272-6386 (Print) IS - 0272-6386 (Linking) VI - 29 IP - 6 DP - 1997 Jun TI - Spontaneous tendon ruptures in patients on chronic dialysis. PG - 982 FAU - Donck, J AU - Donck J FAU - Vanrenterghem, Y AU - Vanrenterghem Y LA - eng PT - Case Reports PT - Comment PT - Letter PL - United States TA - Am J Kidney Dis JT - American journal of kidney diseases : the official journal of the National Kidney Foundation JID - 8110075 RN - 0 (Morphinans) RN - 102578-49-4 (perdolan) SB - IM CON - Am J Kidney Dis. 1996 Dec;28(6):861-6. doi: 10.1016/s0272-6386(96)90386-8. PMID: 8957038 MH - Humans MH - Male MH - Middle Aged MH - Morphinans/*adverse effects MH - Muscular Diseases/*etiology MH - Renal Dialysis/*adverse effects MH - Rupture, Spontaneous/etiology MH - *Tendons EDAT- 1997/06/01 00:00 MHDA- 1997/06/01 00:01 CRDT- 1997/06/01 00:00 PHST- 1997/06/01 00:00 [pubmed] PHST- 1997/06/01 00:01 [medline] PHST- 1997/06/01 00:00 [entrez] AID - S0272-6386(97)90477-7 [pii] AID - 10.1016/s0272-6386(97)90477-7 [doi] PST - ppublish SO - Am J Kidney Dis. 1997 Jun;29(6):982. doi: 10.1016/s0272-6386(97)90477-7. PMID- 2396799 OWN - NLM STAT- MEDLINE DCOM- 19901011 LR - 20171116 IS - 0002-9645 (Print) IS - 0002-9645 (Linking) VI - 51 IP - 9 DP - 1990 Sep TI - Effect of antimicrobial solution lavage on the palmar digital tendon sheath in horses. PG - 1488-94 AB - Sixteen horses were allotted to 4 groups of 4 horses each to evaluate the effect of tendon sheath lavage with 4 solutions (balanced electrolyte solution, 0.1% povidone-iodine, 0.5% povidone-iodine, and 0.5% chlorhexidine). The synovitis caused by 0.1% povidone-iodine lavage was not appreciably worse than that caused by balanced electrolyte solution lavage, but the 0.5% povidone-iodine and chlorhexidine lavages caused severe synovitis, and, therefore, should not be used for tendon sheath lavage. FAU - Baird, A N AU - Baird AN AD - Department of Large Animal Medicine and Surgery, Texas Veterinary Medical Center, Texas A&M University, College Station 77843. FAU - Scruggs, D W AU - Scruggs DW FAU - Watkins, J P AU - Watkins JP FAU - Taylor, T S AU - Taylor TS LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Electrolytes) RN - 0 (Solutions) RN - 85H0HZU99M (Povidone-Iodine) RN - FZ989GH94E (Povidone) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Animals MH - Chlorhexidine/*adverse effects MH - Electrolytes/*pharmacology MH - Forelimb MH - *Horses MH - Povidone/*adverse effects MH - Povidone-Iodine/*adverse effects MH - Random Allocation MH - Solutions MH - Tendons/*drug effects/pathology MH - Therapeutic Irrigation/veterinary EDAT- 1990/09/01 00:00 MHDA- 1990/09/01 00:01 CRDT- 1990/09/01 00:00 PHST- 1990/09/01 00:00 [pubmed] PHST- 1990/09/01 00:01 [medline] PHST- 1990/09/01 00:00 [entrez] PST - ppublish SO - Am J Vet Res. 1990 Sep;51(9):1488-94. PMID- 233561 OWN - NLM STAT- MEDLINE DCOM- 19810922 LR - 20131121 IS - 0344-7618 (Print) IS - 0344-7618 (Linking) VI - 63 DP - 1978 TI - Collagen requirements for initiation of platelet aggregation. PG - 255-67 FAU - Simons, E R AU - Simons ER LA - eng GR - 8T01 AG00020-07/AG/NIA NIH HHS/United States GR - HL-15335/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - Germany TA - Suppl Thromb Haemost JT - Supplementum ... ad Thrombosis and haemostasis JID - 8106612 RN - 0 (Macromolecular Substances) RN - 10450-60-9 (Periodic Acid) RN - 9007-34-5 (Collagen) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Aspirin/pharmacology MH - Blood Platelets/*physiology MH - Collagen/*physiology MH - Drug Stability MH - Humans MH - Kinetics MH - Macromolecular Substances MH - Microscopy, Electron MH - Periodic Acid/pharmacology MH - *Platelet Aggregation MH - Protein Conformation MH - Rats MH - Tendons/ultrastructure EDAT- 1978/01/01 00:00 MHDA- 1978/01/01 00:01 CRDT- 1978/01/01 00:00 PHST- 1978/01/01 00:00 [pubmed] PHST- 1978/01/01 00:01 [medline] PHST- 1978/01/01 00:00 [entrez] PST - ppublish SO - Suppl Thromb Haemost. 1978;63:255-67. PMID- 5769056 OWN - NLM STAT- MEDLINE DCOM- 19690629 LR - 20141120 IS - 0340-5338 (Print) IS - 0340-5338 (Linking) VI - 21 IP - 2 DP - 1969 Apr 30 TI - Effect of inhibitors of aggregation on platelet ultrastructure in vitro. PG - 354-61 FAU - Mannucci, P M AU - Mannucci PM FAU - Sirigu, F AU - Sirigu F LA - eng PT - Journal Article PL - Germany TA - Thromb Diath Haemorrh JT - Thrombosis et diathesis haemorrhagica JID - 7608420 RN - 0 (Adenine Nucleotides) RN - 0 (Nucleosides) RN - 0 (Tissue Extracts) RN - 0 (Tryptamines) RN - 8B1QWR724A (Reserpine) RN - 8GTS82S83M (Diphenhydramine) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - EC 3.4.21.5 (Thrombin) RN - FF28EJQ494 (Promethazine) RN - I5Y540LHVR (Cocaine) RN - X4W3ENH1CV (Norepinephrine) RN - YKH834O4BH (Epinephrine) RN - Z468598HBV (Phentolamine) SB - IM MH - Adenine Nucleotides/*pharmacology MH - Adenosine Triphosphate/*pharmacology MH - Blood Platelets/*drug effects MH - Cocaine/pharmacology MH - Diphenhydramine/pharmacology MH - Epinephrine/pharmacology MH - Humans MH - In Vitro Techniques MH - Microscopy, Electron MH - Norepinephrine/*pharmacology MH - Nucleosides/*pharmacology MH - Phentolamine/pharmacology MH - Promethazine/pharmacology MH - Reserpine/pharmacology MH - Tendons MH - Thrombin/pharmacology MH - Tissue Extracts MH - Tryptamines/pharmacology EDAT- 1969/04/30 00:00 MHDA- 1969/04/30 00:01 CRDT- 1969/04/30 00:00 PHST- 1969/04/30 00:00 [pubmed] PHST- 1969/04/30 00:01 [medline] PHST- 1969/04/30 00:00 [entrez] PST - ppublish SO - Thromb Diath Haemorrh. 1969 Apr 30;21(2):354-61. PMID- 7486283 OWN - NLM STAT- MEDLINE DCOM- 19951128 LR - 20180623 IS - 0750-7658 (Print) IS - 0750-7658 (Linking) VI - 14 IP - 2 DP - 1995 TI - [Delayed low back pain after spinal anesthesia]. PG - 230-2 AB - A 50-year-old man had an inguinal hernia repair under spinal anaesthesia with bupivacaine. On the 2nd postoperative day, he complained of backache and paresis at the posterior part of the lower extremities, well relieved by non-steroidal anti-inflammatory drugs. On the 6th postoperative day, he came back to hospital, because of low back pain associated with a heavy feet sensation. The hypothesis of a neurological complication of the spinal anaesthesia was considered. The interview of the patient revealed a history of lumbar disk disease, not reported during the preoperative visit. After an in depth clinical examination, two causes seemed possible: subarachnoid haematoma and lumbar disk protusion. Against the first diagnosis were the initial clinical signs. However, in many cases, objective neurological deficit arise too late to allow efficient neurosurgical treatment. Thus, a MRI examination was performed which is non invasive in comparison with a computed tomography myelogram. In our patient, it did not detect a true lumbar disk protusion, but a simple degenerative disease of the L5-S1 disk. In suppressing the lumbar lordosis, spinal anaesthesia probably allowed a distension of spinal capsules and tendons, responsible for the troubles. FAU - Sardin, B AU - Sardin B AD - Département d'Anesthésie-Réanimation Chirurgicale, CHRU Dupuytren, Limoges. FAU - Boncoeur, M P AU - Boncoeur MP FAU - Desport, J C AU - Desport JC FAU - Abderrazak, M AU - Abderrazak M FAU - Guillaume, A AU - Guillaume A LA - fre PT - Case Reports PT - English Abstract PT - Journal Article TT - Lombalgies retardées après rachianesthésie. PL - France TA - Ann Fr Anesth Reanim JT - Annales francaises d'anesthesie et de reanimation JID - 8213275 RN - 0 (Anesthetics, Local) RN - Y8335394RO (Bupivacaine) SB - IM MH - Anesthesia, Spinal/*adverse effects MH - Anesthetics, Local/administration & dosage MH - Bupivacaine/*administration & dosage MH - Hernia, Inguinal/*surgery MH - Humans MH - Low Back Pain/*etiology MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Sciatica/complications MH - Time Factors EDAT- 1995/01/01 00:00 MHDA- 1995/01/01 00:01 CRDT- 1995/01/01 00:00 PHST- 1995/01/01 00:00 [pubmed] PHST- 1995/01/01 00:01 [medline] PHST- 1995/01/01 00:00 [entrez] AID - S0750-7658(95)70024-7 [pii] PST - ppublish SO - Ann Fr Anesth Reanim. 1995;14(2):230-2. PMID- 7309101 OWN - NLM STAT- MEDLINE DCOM- 19820225 LR - 20131121 IS - 0301-1208 (Print) IS - 0301-1208 (Linking) VI - 18 IP - 3 DP - 1981 Jun TI - Effect of bioflavonoids on the mechanical & thermal properties of skin & tendon. PG - 224-8 FAU - Rao, C N AU - Rao CN FAU - Rao, V H AU - Rao VH FAU - Sanjeevi, R AU - Sanjeevi R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - India TA - Indian J Biochem Biophys JT - Indian journal of biochemistry & biophysics JID - 0310774 RN - 0 (Flavonoids) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Flavonoids/*pharmacology MH - Male MH - Rats MH - Skin/*drug effects MH - Tendons/*drug effects MH - Thermodynamics EDAT- 1981/06/01 00:00 MHDA- 1981/06/01 00:01 CRDT- 1981/06/01 00:00 PHST- 1981/06/01 00:00 [pubmed] PHST- 1981/06/01 00:01 [medline] PHST- 1981/06/01 00:00 [entrez] PST - ppublish SO - Indian J Biochem Biophys. 1981 Jun;18(3):224-8. PMID- 10857342 OWN - NLM STAT- MEDLINE DCOM- 20000822 LR - 20161018 IS - 0023-2130 (Print) IS - 0023-2130 (Linking) IP - 4 DP - 2000 TI - [The use of vobenzym in the comprehensive treatment of patients with digital flexor tendon injury]. PG - 39-40 AB - The results of treatment of 56 patients with tendons of digital flexors were analyzed. In 28 of them in complex of treatment vobenzim was included, and an early active mobilization as well. Considerable antiinflammatory, antioedematous, secondarily analgetic effect of preparation, its application in early period permitted to realize active movements, to reach high functional result of treatment of patients' were noted. FAU - Strafun, S S AU - Strafun SS FAU - Tovmasian, V V AU - Tovmasian VV LA - rus PT - English Abstract PT - Journal Article TT - Primenenie preparata vobénzim v komplekse lecheniia bol'nykh s povrezhdeniem sukhozhiliĭ sgibateleĭ pal'tsev kisti. PL - Ukraine TA - Klin Khir JT - Klinichna khirurhiia JID - 9516872 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Drug Combinations) RN - 5G06TVY3R7 (Rutin) RN - 72506-65-1 (Wobenzym) RN - EC 3.- (Hydrolases) SB - IM MH - Adolescent MH - Adult MH - Anti-Inflammatory Agents/*therapeutic use MH - Drug Combinations MH - Edema/*drug therapy MH - Female MH - Finger Injuries/*rehabilitation/*surgery MH - Humans MH - Hydrolases/*therapeutic use MH - Male MH - Middle Aged MH - Postoperative Care MH - *Postoperative Complications MH - Rutin/*therapeutic use MH - Tendon Injuries/*rehabilitation/*surgery EDAT- 2000/06/17 09:00 MHDA- 2000/08/29 11:01 CRDT- 2000/06/17 09:00 PHST- 2000/06/17 09:00 [pubmed] PHST- 2000/08/29 11:01 [medline] PHST- 2000/06/17 09:00 [entrez] PST - ppublish SO - Klin Khir. 2000;(4):39-40. PMID- 4310819 OWN - NLM STAT- MEDLINE DCOM- 19700102 LR - 20181130 IS - 0003-9780 (Print) IS - 0003-9780 (Linking) VI - 181 IP - 1 DP - 1969 Sep TI - Neuromuscular blocking activity of gentamicin in cats and mice. PG - 109-17 FAU - Barnett, A AU - Barnett A FAU - Ackermann, E AU - Ackermann E LA - eng PT - Journal Article PL - Belgium TA - Arch Int Pharmacodyn Ther JT - Archives internationales de pharmacodynamie et de therapie JID - 0405353 RN - 0 (Gentamicins) RN - 0 (Neuromuscular Depolarizing Agents) RN - 3982TWQ96G (Neostigmine) RN - 59-01-8 (Kanamycin) RN - 8063-06-7 (Curare) RN - I16QD7X297 (Neomycin) SB - IM MH - Animals MH - Blood Pressure/drug effects MH - Cats MH - Curare/pharmacology MH - Drug Antagonism MH - Drug Synergism MH - Female MH - Gentamicins/*pharmacology/toxicity MH - Kanamycin/pharmacology/toxicity MH - Male MH - Mice MH - Muscle Contraction/drug effects MH - Neomycin/pharmacology/toxicity MH - Neostigmine/pharmacology MH - Neuromuscular Depolarizing Agents/*pharmacology MH - Reflex/drug effects MH - Synapses/drug effects MH - Synaptic Transmission/drug effects MH - Tendons/drug effects EDAT- 1969/09/01 00:00 MHDA- 1969/09/01 00:01 CRDT- 1969/09/01 00:00 PHST- 1969/09/01 00:00 [pubmed] PHST- 1969/09/01 00:01 [medline] PHST- 1969/09/01 00:00 [entrez] PST - ppublish SO - Arch Int Pharmacodyn Ther. 1969 Sep;181(1):109-17. PMID- 6288520 OWN - NLM STAT- MEDLINE DCOM- 19821202 LR - 20191031 IS - 0072-968X (Print) IS - 0072-968X (Linking) VI - 14 IP - 2 DP - 1982 Jun TI - Effect of the immunological antigenicity of the allogeneic tendons on tendon grafting. PG - 111-9 FAU - Minami, A AU - Minami A FAU - Ishii, S AU - Ishii S FAU - Ogino, T AU - Ogino T FAU - Oikawa, T AU - Oikawa T FAU - Kobayashi, H AU - Kobayashi H LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Hand JT - The Hand JID - 0231601 RN - 0 (Histocompatibility Antigens) RN - 0 (Mitomycins) RN - 1HG84L3525 (Formaldehyde) RN - 50SG953SK6 (Mitomycin) RN - EC 3.4.21.4 (Trypsin) RN - EC 3.4.24.3 (Microbial Collagenase) RN - T3C89M417N (Glutaral) SB - IM MH - Achilles Tendon/drug effects/immunology/*transplantation MH - Animals MH - Complement Fixation Tests MH - Cytotoxicity Tests, Immunologic MH - Formaldehyde/immunology MH - Freezing MH - Glutaral/immunology MH - *Graft Rejection MH - Histocompatibility Antigens/*immunology MH - Lymph Nodes/immunology MH - Microbial Collagenase/pharmacology MH - Mitomycin MH - Mitomycins/immunology MH - Radiation MH - Rats MH - Rats, Inbred Strains MH - Sarcoma, Experimental/immunology MH - Spleen/immunology MH - Transplantation, Homologous MH - Trypsin/pharmacology EDAT- 1982/06/01 00:00 MHDA- 1982/06/01 00:01 CRDT- 1982/06/01 00:00 PHST- 1982/06/01 00:00 [pubmed] PHST- 1982/06/01 00:01 [medline] PHST- 1982/06/01 00:00 [entrez] AID - 10.1016/s0072-968x(82)80001-6 [doi] PST - ppublish SO - Hand. 1982 Jun;14(2):111-9. doi: 10.1016/s0072-968x(82)80001-6. PMID- 4325294 OWN - NLM STAT- MEDLINE DCOM- 19710714 LR - 20131121 IS - 0340-5338 (Print) IS - 0340-5338 (Linking) VI - 25 IP - 1 DP - 1971 TI - [Collagen induced 5-HT- liberation in blood platelets]. PG - 47-52 FAU - Barthel, W AU - Barthel W FAU - Markwardt, F AU - Markwardt F LA - ger PT - Journal Article TT - Untersuchungen über die durch Kollagen ausgelöste 5-HT-Freisetzung aus Blutplättchen. PL - Germany TA - Thromb Diath Haemorrh JT - Thrombosis et diathesis haemorrhagica JID - 7608420 RN - 0 (Isoquinolines) RN - 0 (Tissue Extracts) RN - 333DO1RDJY (Serotonin) RN - 9007-34-5 (Collagen) RN - 9NEZ333N27 (Sodium) RN - DAA13NKG2Q (Papaverine) RN - EC 3.4.24.3 (Microbial Collagenase) RN - O3C74ACM9V (Ethylmaleimide) RN - R16CO5Y76E (Aspirin) SB - IM MH - Animals MH - Aspirin/pharmacology MH - Blood Platelets/drug effects/*metabolism MH - Collagen/*pharmacology MH - Ethylmaleimide/pharmacology MH - Isoquinolines/pharmacology MH - Microbial Collagenase/pharmacology MH - Papaverine/pharmacology MH - Rabbits MH - Serotonin/*metabolism MH - Sodium MH - Tendons MH - Tissue Extracts EDAT- 1971/01/01 00:00 MHDA- 1971/01/01 00:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 1971/01/01 00:01 [medline] PHST- 1971/01/01 00:00 [entrez] PST - ppublish SO - Thromb Diath Haemorrh. 1971;25(1):47-52. PMID- 4538529 OWN - NLM STAT- MEDLINE DCOM- 19721125 LR - 20131121 IS - 0001-6772 (Print) IS - 0001-6772 (Linking) VI - 85 IP - 4 DP - 1972 Aug TI - Effects of chlorpromazine, imipramine, and quinidine on the mechanical activity of single skeletal muscle fibres of the frog. PG - 532-46 FAU - Andersson, K E AU - Andersson KE LA - eng PT - Journal Article PL - England TA - Acta Physiol Scand JT - Acta physiologica Scandinavica JID - 0370362 RN - 3G6A5W338E (Caffeine) RN - ITX08688JL (Quinidine) RN - OGG85SX4E4 (Imipramine) RN - RWP5GA015D (Potassium) RN - U42B7VYA4P (Chlorpromazine) SB - IM MH - Animals MH - Anura MH - Caffeine/pharmacology MH - Chlorpromazine/*pharmacology MH - Drug Synergism MH - Electric Stimulation MH - Imipramine/*pharmacology MH - Methods MH - Muscle Contraction/*drug effects MH - Myofibrils/*drug effects MH - Potassium/pharmacology MH - Quinidine/*pharmacology MH - Rana temporaria MH - Tendons EDAT- 1972/08/01 00:00 MHDA- 1972/08/01 00:01 CRDT- 1972/08/01 00:00 PHST- 1972/08/01 00:00 [pubmed] PHST- 1972/08/01 00:01 [medline] PHST- 1972/08/01 00:00 [entrez] AID - 10.1111/j.1748-1716.1971.tb05292.x [doi] PST - ppublish SO - Acta Physiol Scand. 1972 Aug;85(4):532-46. doi: 10.1111/j.1748-1716.1971.tb05292.x. PMID- 2498862 OWN - NLM STAT- MEDLINE DCOM- 19890627 LR - 20190903 IS - 0901-9928 (Print) IS - 0901-9928 (Linking) VI - 64 IP - 3 DP - 1989 Mar TI - Increased thermal stability of collagen after 2,5-hexanedione intoxication in rats. PG - 252-6 AB - The present study examined the ability of 2,5-hexanedione (2,5-HD) to cross-link the fibrillary protein, collagen, in vivo. The thermal stability of collagen measured as the isometric contraction-relaxation force was studied in tail tendons from rats, receiving 2,5-HD intraperitoneally for 2 or 6 weeks (1 g/kg/week, divided into 3 doses). The maximum contraction force was significantly increased after 6 weeks of intoxication as compared to controls, indicating an increase in covalent cross-linking between collagen molecules. Likewise, in vitro incubation of rat tail tendons in 2,5-HD for 24 hr induced an increase in thermal isometric contraction force. FAU - Braendgaard, H AU - Braendgaard H AD - Department of Neurology, Diabetes Research Laboratory, Aarhus, Denmark. FAU - Andreassen, T T AU - Andreassen TT LA - eng PT - Journal Article PL - Denmark TA - Pharmacol Toxicol JT - Pharmacology & toxicology JID - 8702180 RN - 0 (Hexanones) RN - 0 (Ketones) RN - 059QF0KO0R (Water) RN - 9007-34-5 (Collagen) RN - C0Z8884J3P (2,5-hexanedione) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Body Weight/drug effects MH - Collagen/*analysis MH - Glutaral/pharmacology MH - Hexanones/*poisoning MH - Hot Temperature MH - Isometric Contraction/drug effects MH - Ketones/*poisoning MH - Male MH - Rats MH - Rats, Inbred Strains MH - Water/analysis EDAT- 1989/03/01 00:00 MHDA- 1989/03/01 00:01 CRDT- 1989/03/01 00:00 PHST- 1989/03/01 00:00 [pubmed] PHST- 1989/03/01 00:01 [medline] PHST- 1989/03/01 00:00 [entrez] AID - 10.1111/j.1600-0773.1989.tb00641.x [doi] PST - ppublish SO - Pharmacol Toxicol. 1989 Mar;64(3):252-6. doi: 10.1111/j.1600-0773.1989.tb00641.x. PMID- 4741940 OWN - NLM STAT- MEDLINE DCOM- 19731211 LR - 20190706 IS - 0009-7330 (Print) IS - 0009-7330 (Linking) VI - 33 IP - 4 DP - 1973 Oct TI - Role of muscular contraction in the reflex vascular responses to stimulation of muscle afferents in the dog. PG - 386-92 FAU - Clement, D L AU - Clement DL FAU - Pelletier, C L AU - Pelletier CL FAU - Shepherd, J T AU - Shepherd JT LA - eng PT - Journal Article PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 0TTZ664R7Z (Phenoxybenzamine) RN - 3C5ORO99TY (Tripelennamine) RN - 7C0697DR9I (Atropine) RN - 9Y8NXQ24VQ (Propranolol) RN - Q3254X40X2 (Gallamine Triethiodide) SB - IM MH - Animals MH - Aorta MH - Atropine/pharmacology MH - Blood Pressure/drug effects MH - Dogs MH - Electric Stimulation MH - Femoral Nerve/physiology MH - Gallamine Triethiodide/pharmacology MH - Hindlimb/physiology MH - Iliac Artery/physiology MH - *Muscle Contraction MH - Neurons/*physiology MH - Neurons, Afferent MH - Obturator Nerve/physiology MH - Paralysis/physiopathology MH - Perfusion MH - Phenoxybenzamine/pharmacology MH - Propranolol/pharmacology MH - *Reflex MH - Sciatic Nerve/physiology MH - Stimulation, Chemical MH - Sympathectomy MH - Tendons/physiology MH - Tripelennamine/pharmacology EDAT- 1973/10/01 00:00 MHDA- 1973/10/01 00:01 CRDT- 1973/10/01 00:00 PHST- 1973/10/01 00:00 [pubmed] PHST- 1973/10/01 00:01 [medline] PHST- 1973/10/01 00:00 [entrez] AID - 10.1161/01.res.33.4.386 [doi] PST - ppublish SO - Circ Res. 1973 Oct;33(4):386-92. doi: 10.1161/01.res.33.4.386. PMID- 5514926 OWN - NLM STAT- MEDLINE DCOM- 19711117 LR - 20081121 IS - 0071-8041 (Print) IS - 0071-8041 (Linking) VI - 21 DP - 1970 TI - Effect of beta-aminioproprionitrile on adhesions following digital flexor tendon repair in chickens. PG - 509-11 FAU - Herzog, M AU - Herzog M FAU - Lindsay, W K AU - Lindsay WK FAU - McCain, W G AU - McCain WG LA - eng PT - Journal Article PL - United States TA - Surg Forum JT - Surgical forum JID - 0337723 RN - 0 (Nitriles) RN - 151-18-8 (Aminopropionitrile) SB - IM MH - Aminopropionitrile/pharmacology/therapeutic use MH - Animals MH - Chickens MH - Foot MH - Injections, Intraperitoneal MH - Nitriles/*therapeutic use MH - Tendons/*surgery MH - Time Factors MH - Tissue Adhesions/*drug therapy MH - Wound Healing EDAT- 1970/01/01 00:00 MHDA- 1970/01/01 00:01 CRDT- 1970/01/01 00:00 PHST- 1970/01/01 00:00 [pubmed] PHST- 1970/01/01 00:01 [medline] PHST- 1970/01/01 00:00 [entrez] PST - ppublish SO - Surg Forum. 1970;21:509-11. PMID- 3982018 OWN - NLM STAT- MEDLINE DCOM- 19850429 LR - 20190817 IS - 0022-4804 (Print) IS - 0022-4804 (Linking) VI - 38 IP - 3 DP - 1985 Mar TI - The control of peritendinous adhesions using topical beta-aminopropionitrile base. PG - 252-7 AB - The Lindsay chicken foot tendon model was utilized to test the effect of topically applied beta-aminopropionitrile base upon the tensile strength of peritendinous adhesions following tenolysis of a scarified flexor tendon. The agent reduced by one-third the force required to effect tendon gliding and flexion of the joints in the involved digit. The results show that topical beta-aminopropionitrile is effective in the control of peritendinous adhesions and, therefore, achieves sufficient depth of penetration topically to affect the peritendinous location. No adverse effects of the topically applied agent were demonstrated. The principle of topical therapeutics that may have significant benefits to patients with tendon injuries is demonstrated. FAU - Speer, D P AU - Speer DP FAU - Feldman, S AU - Feldman S FAU - Chvapil, M AU - Chvapil M LA - eng PT - Journal Article PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) SB - IM MH - Administration, Topical MH - Aminopropionitrile/*administration & dosage MH - Animals MH - Biomechanical Phenomena MH - Chickens MH - Cicatrix MH - Collagen MH - Female MH - Male MH - Movement MH - Postoperative Complications/drug therapy/physiopathology MH - Tendon Injuries/physiopathology MH - Tendons/*drug effects/physiopathology/surgery MH - Tensile Strength MH - Tissue Adhesions/*drug therapy/etiology/physiopathology EDAT- 1985/03/01 00:00 MHDA- 1985/03/01 00:01 CRDT- 1985/03/01 00:00 PHST- 1985/03/01 00:00 [pubmed] PHST- 1985/03/01 00:01 [medline] PHST- 1985/03/01 00:00 [entrez] AID - 0022-4804(85)90034-4 [pii] AID - 10.1016/0022-4804(85)90034-4 [doi] PST - ppublish SO - J Surg Res. 1985 Mar;38(3):252-7. doi: 10.1016/0022-4804(85)90034-4. PMID- 564348 OWN - NLM STAT- MEDLINE DCOM- 19780426 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 253 IP - 5 DP - 1978 Mar 10 TI - Role of molecular conformation on secretion of chick tendon procollagen. PG - 1420-6 FAU - Jimenez, S A AU - Jimenez SA FAU - Yankowski, R AU - Yankowski R LA - eng PT - Journal Article PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Azetidines) RN - 0 (Procollagen) RN - 551W113ZEP (2,2'-Dipyridyl) RN - Z01IVE25KI (Demecolcine) SB - IM MH - 2,2'-Dipyridyl/pharmacology MH - Animals MH - Azetidines/pharmacology MH - Cells, Cultured MH - Chick Embryo MH - Demecolcine/pharmacology MH - Fibroblasts/drug effects/metabolism MH - Kinetics MH - *Procollagen/metabolism MH - Protein Conformation MH - Tendons/drug effects/*metabolism EDAT- 1978/03/10 00:00 MHDA- 1978/03/10 00:01 CRDT- 1978/03/10 00:00 PHST- 1978/03/10 00:00 [pubmed] PHST- 1978/03/10 00:01 [medline] PHST- 1978/03/10 00:00 [entrez] AID - S0021-9258(17)34883-4 [pii] PST - ppublish SO - J Biol Chem. 1978 Mar 10;253(5):1420-6. PMID- 4908059 OWN - NLM STAT- MEDLINE DCOM- 19700510 LR - 20131121 IS - 0003-3014 (Print) IS - 0003-3014 (Linking) VI - 26 IP - 6 DP - 1969 Nov-Dec TI - [Per- and post-operative emetic action of halothane]. PG - 845-52 FAU - Deret, C AU - Deret C LA - fre PT - Journal Article TT - Etude sur l'effet émétisant per- et post-opératoire de l'halothane. PL - France TA - Anesth Analg (Paris) JT - Anesthesie, analgesie, reanimation JID - 0404017 RN - 0 (Emetics) RN - UQT9G45D1P (Halothane) SB - IM MH - Adult MH - Anesthesia, Inhalation MH - Bone and Bones/surgery MH - Cerebral Angiography MH - Child MH - Dermatologic Surgical Procedures MH - Emergencies/surgery MH - *Emetics MH - Halothane/*adverse effects MH - Humans MH - Methods MH - Skin Transplantation MH - Tendons/surgery EDAT- 1969/11/01 00:00 MHDA- 1969/11/01 00:01 CRDT- 1969/11/01 00:00 PHST- 1969/11/01 00:00 [pubmed] PHST- 1969/11/01 00:01 [medline] PHST- 1969/11/01 00:00 [entrez] PST - ppublish SO - Anesth Analg (Paris). 1969 Nov-Dec;26(6):845-52. PMID- 4354903 OWN - NLM STAT- MEDLINE DCOM- 19731204 LR - 20181113 IS - 0035-9157 (Print) IS - 0035-9157 (Linking) VI - 66 IP - 7 DP - 1973 Jul TI - Pollicization for congenital deformities of the hand. PG - 634-7 FAU - Harrison, S H AU - Harrison SH LA - eng PT - Journal Article PL - England TA - Proc R Soc Med JT - Proceedings of the Royal Society of Medicine JID - 7505890 RN - 4Z8R6ORS6L (Thalidomide) SB - IM MH - Abnormalities, Drug-Induced/physiopathology/*surgery MH - Child MH - Child, Preschool MH - Fingers/physiopathology/*surgery MH - Humans MH - Syndactyly/physiopathology/*surgery MH - Tendons/transplantation MH - Thalidomide/adverse effects MH - Thumb/*abnormalities MH - Transplantation, Autologous PMC - PMC1645045 EDAT- 1973/07/01 00:00 MHDA- 1973/07/01 00:01 PMCR- 1973/07/01 CRDT- 1973/07/01 00:00 PHST- 1973/07/01 00:00 [pubmed] PHST- 1973/07/01 00:01 [medline] PHST- 1973/07/01 00:00 [entrez] PHST- 1973/07/01 00:00 [pmc-release] AID - 10.1177/003591577306600716 [doi] PST - ppublish SO - Proc R Soc Med. 1973 Jul;66(7):634-7. doi: 10.1177/003591577306600716. PMID- 8318974 OWN - NLM STAT- MEDLINE DCOM- 19930803 LR - 20131121 IS - 1067-2516 (Print) IS - 1067-2516 (Linking) VI - 32 IP - 2 DP - 1993 Mar-Apr TI - Tophaceous gout of the foot: an unusual presentation of severe chronic gout in an undiagnosed patient. PG - 167-70 AB - Tophaceous deposits are frequently noted within articular cartilage, synovium, tendons, tendon sheaths, pinnae and the soft tissue on the extensor surface of the forearms, feet, and bursae in patients with a history of chronic gout. The authors describe an unusual case of severe chronic tophaceous gout without prior diagnostic history or presence of acute attacks. They describe the procedure for the excision of these masses as well as the radiographic and pathological findings. FAU - Kerman, B L AU - Kerman BL AD - Department of Podiatric Surgery, Straith Hospital for Special Surgery, Southfield, Michigan. FAU - Mack, G AU - Mack G FAU - Moshirfar, M M AU - Moshirfar MM LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Foot Ankle Surg JT - The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons JID - 9308427 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Aged MH - Chronic Disease MH - Female MH - Foot Diseases/complications/*diagnosis/surgery/urine MH - Gout/complications/*diagnosis/surgery/urine MH - Humans MH - Kidney Diseases/complications/urine MH - Uric Acid/urine EDAT- 1993/03/01 00:00 MHDA- 1993/03/01 00:01 CRDT- 1993/03/01 00:00 PHST- 1993/03/01 00:00 [pubmed] PHST- 1993/03/01 00:01 [medline] PHST- 1993/03/01 00:00 [entrez] PST - ppublish SO - J Foot Ankle Surg. 1993 Mar-Apr;32(2):167-70. PMID- 4408393 OWN - NLM STAT- MEDLINE DCOM- 19741108 LR - 20161123 IS - 0008-2902 (Print) IS - 0008-2902 (Linking) VI - 25 IP - 2 DP - 1974 Jun TI - Value of delayed films in knee arthrography. PG - 144-6 FAU - O'Malley, B P AU - O'Malley BP LA - eng PT - Journal Article PL - Canada TA - J Can Assoc Radiol JT - Journal of the Canadian Association of Radiologists JID - 7505589 RN - 117-96-4 (Diatrizoate) SB - IM MH - Diatrizoate/administration & dosage MH - Humans MH - Injections, Spinal MH - Knee/*diagnostic imaging MH - *Knee Joint MH - Menisci, Tibial/diagnostic imaging MH - Methods MH - Radiography MH - Tendons/diagnostic imaging MH - Tibial Meniscus Injuries EDAT- 1974/06/01 00:00 MHDA- 1974/06/01 00:01 CRDT- 1974/06/01 00:00 PHST- 1974/06/01 00:00 [pubmed] PHST- 1974/06/01 00:01 [medline] PHST- 1974/06/01 00:00 [entrez] PST - ppublish SO - J Can Assoc Radiol. 1974 Jun;25(2):144-6. PMID- 5802519 OWN - NLM STAT- MEDLINE DCOM- 19690930 LR - 20221207 IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 65 DP - 1969 Jul-Aug TI - Intravenous regional anesthesia in peripheral extremity surgery. PG - 138-42 FAU - Lucas, G L AU - Lucas GL LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 98PI200987 (Lidocaine) SB - IM MH - Adolescent MH - Adult MH - Amputation, Surgical MH - *Anesthesia, Conduction/adverse effects MH - Arthrodesis MH - Child MH - Child, Preschool MH - Debridement MH - Female MH - Foot/*surgery MH - Fracture Fixation MH - Hallux Valgus/surgery MH - Hand/*surgery MH - Humans MH - Injections, Intravenous MH - Lidocaine/*administration & dosage MH - Ligaments/surgery MH - Male MH - Middle Aged MH - *Military Medicine MH - Neuroma/surgery MH - Osteotomy MH - Synovectomy MH - Tendons/surgery MH - Tourniquets EDAT- 1969/07/01 00:00 MHDA- 1969/07/01 00:01 CRDT- 1969/07/01 00:00 PHST- 1969/07/01 00:00 [pubmed] PHST- 1969/07/01 00:01 [medline] PHST- 1969/07/01 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1969 Jul-Aug;65:138-42. PMID- 14254334 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20181201 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 146 DP - 1964 Dec TI - A COMPARISON BETWEEN ACUTE AND CHRONIC PHYSICAL DEPENDENCE IN THE CHRONIC SPINAL DOG. PG - 385-94 FAU - MARTIN, W R AU - MARTIN WR FAU - EADES, C G AU - EADES CG LA - eng PT - Journal Article PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - U59WB2WRY2 (Nalorphine) SB - OM MH - *Body Temperature MH - *Cordotomy MH - Dogs MH - *Drug Tolerance MH - *Heart Rate MH - *Morphine Dependence MH - *Nalorphine MH - *Neurophysiology MH - *Pharmacology MH - *Physiology MH - *Pulse MH - *Pupil MH - *Reflex MH - *Reflex, Stretch MH - *Research MH - *Respiration MH - *Spinal Cord MH - *Substance Withdrawal Syndrome MH - *Tendons MH - *Toxicology OTO - NLM OT - *BODY TEMPERATURE OT - *CHORDOTOMY OT - *DOGS OT - *DRUG TOLERANCE OT - *DRUG WITHDRAWAL SYMPTOMS OT - *EXPERIMENTAL LAB STUDY OT - *MORPHINE ADDICTION OT - *NALORPHINE OT - *NEUROPHYSIOLOGY OT - *PHARMACOLOGY OT - *PHYSIOLOGY OT - *PULSE OT - *PUPIL OT - *REFLEX OT - *REFLEX, TENDON OT - *RESPIRATION OT - *SPINAL CORD OT - *TOXICOLOGIC REPORT EDAT- 1964/12/01 00:00 MHDA- 1964/12/01 00:01 CRDT- 1964/12/01 00:00 PHST- 1964/12/01 00:00 [pubmed] PHST- 1964/12/01 00:01 [medline] PHST- 1964/12/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1964 Dec;146:385-94. PMID- 14203117 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20181201 IS - 0003-9780 (Print) IS - 0003-9780 (Linking) VI - 150 DP - 1964 Aug 1 TI - EFFECTS OF TREMORINE ON MONOSYNAPTIC AND POLYSYNAPTIC MOTOR REFLEXES IN THE INTACT ANESTHETIZED CAT. PG - 401-12 FAU - BAKER, W W AU - BAKER WW FAU - TRIOLO, A J AU - TRIOLO AJ LA - eng PT - Journal Article PL - Belgium TA - Arch Int Pharmacodyn Ther JT - Archives internationales de pharmacodynamie et de therapie JID - 0405353 RN - 0 (Heterocyclic Compounds) RN - 7C0697DR9I (Atropine) RN - U817VZ1URQ (Tremorine) SB - OM MH - *Atropine MH - Cats MH - *Heterocyclic Compounds MH - *Motor Neurons MH - *Neuromuscular Junction MH - *Pharmacology MH - *Reflex MH - *Reflex, Stretch MH - *Research MH - *Reticular Formation MH - *Sciatic Nerve MH - *Sensory Receptor Cells MH - *Sympathetic Nervous System MH - *Tendons MH - *Toxicology MH - *Tremorine OTO - NLM OT - *ATROPINE OT - *CATS OT - *EXPERIMENTAL LAB STUDY OT - *HETEROCYCLIC COMPOUNDS OT - *MOTOR NEURONS OT - *NEUROMUSCULAR JUNCTION OT - *PHARMACOLOGY OT - *RECEPTORS, NEURAL OT - *REFLEX OT - *REFLEX, TENDON OT - *RETICULAR FORMATION OT - *SCIATIC NERVE OT - *SYMPATHETIC NERVOUS SYSTEM OT - *TOXICOLOGIC REPORT EDAT- 1964/08/01 00:00 MHDA- 1964/08/01 00:01 CRDT- 1964/08/01 00:00 PHST- 1964/08/01 00:00 [pubmed] PHST- 1964/08/01 00:01 [medline] PHST- 1964/08/01 00:00 [entrez] PST - ppublish SO - Arch Int Pharmacodyn Ther. 1964 Aug 1;150:401-12. PMID- 743614 OWN - NLM STAT- MEDLINE DCOM- 19790516 LR - 20161013 IS - 0008-4182 (Print) IS - 0008-4182 (Linking) VI - 13 IP - 4 DP - 1978 Oct TI - Silicone augmentation of the enophthalmic socket. A 14 year review. PG - 294-8 AB - We injected Silastic RTV S-5392 to increase the obrital volume in 25 enophthalmic patients with enophthalmus. Once the technique had been perfected, the complication rate was nil. Seven patients examined 12-14 years later had no later complications and uniformly satisfactory results. FAU - Hill, J C AU - Hill JC FAU - Savar, D AU - Savar D LA - eng PT - Case Reports PT - Journal Article PL - England TA - Can J Ophthalmol JT - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie JID - 0045312 RN - 0 (Dimethylpolysiloxanes) RN - 0 (Silicones) SB - IM MH - Adult MH - Chemical Phenomena MH - Chemistry MH - Dimethylpolysiloxanes/*administration & dosage/therapeutic use MH - *Eye, Artificial MH - Eyelids MH - Follow-Up Studies MH - Humans MH - Injections, Intramuscular MH - Male MH - Middle Aged MH - *Orbit MH - Postoperative Complications/*prevention & control MH - Silicones/*administration & dosage MH - Tendons MH - Time Factors EDAT- 1978/10/01 00:00 MHDA- 1978/10/01 00:01 CRDT- 1978/10/01 00:00 PHST- 1978/10/01 00:00 [pubmed] PHST- 1978/10/01 00:01 [medline] PHST- 1978/10/01 00:00 [entrez] PST - ppublish SO - Can J Ophthalmol. 1978 Oct;13(4):294-8. PMID- 1497694 OWN - NLM STAT- MEDLINE DCOM- 19920910 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 42 IP - 3 DP - 1992 Mar TI - [Binding affinity of ibuprofen in human tissues]. PG - 325-7 AB - In vitro binding of ibuprofen (CAS 15687-27-1) to various human tissues was studied to explain differences in tissue concentration after local application of ibuprofen cream. Radioactive ibuprofen, was incubated with human skin, subcutaneous tissue, muscle, tendon, joint capsule for 2 h at 37 degrees C. Tissue specimens were washed and radioactivity was measured by a liquid scintillation counter. The results show specific binding of ibuprofen to the various tissues of different degrees. Despite of interindividual differences muscle tissues showed the highest, tendons the lowest concentrations of ibuprofen. These findings may explain the in vivo results, where higher concentrations of ibuprofen were found in muscle tissue compared with subcutaneous tissue. FAU - Menzel, J AU - Menzel J AD - Institut für Immunologie, Universität Wien. FAU - Kolarz, G AU - Kolarz G LA - ger PT - English Abstract PT - Journal Article TT - Bindungsvermögen von Ibuprofen an humanes Gewebe. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Ointments) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Aged MH - Female MH - Humans MH - Ibuprofen/administration & dosage/*pharmacokinetics MH - Male MH - Ointments MH - Tissue Distribution EDAT- 1992/03/01 00:00 MHDA- 1992/03/01 00:01 CRDT- 1992/03/01 00:00 PHST- 1992/03/01 00:00 [pubmed] PHST- 1992/03/01 00:01 [medline] PHST- 1992/03/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1992 Mar;42(3):325-7. PMID- 5950182 OWN - NLM STAT- MEDLINE DCOM- 19661130 LR - 20071112 IS - 0002-7154 (Print) IS - 0002-7154 (Linking) VI - 70 IP - 2 DP - 1966 Mar-Apr TI - Absorbable collagen implants and encircling elements in retinal detachment surgery. PG - 212-34 FAU - L'Esperance, F A Jr AU - L'Esperance FA Jr LA - eng PT - Journal Article PL - United States TA - Trans Am Acad Ophthalmol Otolaryngol JT - Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology JID - 7506085 RN - 0 (Silicones) RN - 9007-34-5 (Collagen) SB - IM MH - Absorption MH - Animals MH - Cattle MH - *Collagen MH - Dogs MH - Humans MH - Postoperative Complications/prevention & control MH - Retinal Detachment/*surgery MH - Silicones/adverse effects MH - Tendons/transplantation MH - Transplantation, Heterologous EDAT- 1966/03/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1966/03/01 00:00 PHST- 1966/03/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1966/03/01 00:00 [entrez] PST - ppublish SO - Trans Am Acad Ophthalmol Otolaryngol. 1966 Mar-Apr;70(2):212-34. PMID- 2256641 OWN - NLM STAT- MEDLINE DCOM- 19910124 LR - 20161123 IS - 0066-2097 (Print) IS - 0066-2097 (Linking) VI - 37 IP - 7 DP - 1990 Sep TI - [Bone complications from chronic etretinate intoxication in children]. PG - 458-60 AB - Clinical, roentgenographic and biologic features of etretinate bone toxicity in a 13-year-old girl with pachyonychia congenita syndrome are reported. Etretinate is a synthetic derivative of vitamin A that infrequently induces bone and joint abnormalities in children. The following manifestations can be observed: cortical hyperostosis, pain, calcification of tendons, thinning of long bones, demineralization, premature closure of epiphyses, or abnormal remodelling. Onset of these anomalies is often delayed since etretinate has a long half-life. Mechanisms are unknown. We advocate use of the minimum effective dosage and regular monitoring of patients. FAU - Cointin, M AU - Cointin M AD - Centre de Convalescence Pédiatrique St Lambert-Lioux, Gordes. FAU - Sommelet-Olive, D AU - Sommelet-Olive D FAU - Cuny, J F AU - Cuny JF FAU - Bretagne, M C AU - Bretagne MC LA - fre PT - Case Reports PT - Journal Article TT - Complications osseuses de l'intoxication chronique par l'étrétinate chez l'enfant. PL - France TA - Ann Pediatr (Paris) JT - Annales de pediatrie JID - 2984696R RN - 65M2UDR9AG (Etretinate) SB - IM MH - Adolescent MH - Bone Diseases/*chemically induced/diagnostic imaging/pathology MH - Etretinate/administration & dosage/*adverse effects/therapeutic use MH - Female MH - Humans MH - Nail Diseases/congenital/*drug therapy MH - Radiography EDAT- 1990/09/01 00:00 MHDA- 1990/09/01 00:01 CRDT- 1990/09/01 00:00 PHST- 1990/09/01 00:00 [pubmed] PHST- 1990/09/01 00:01 [medline] PHST- 1990/09/01 00:00 [entrez] PST - ppublish SO - Ann Pediatr (Paris). 1990 Sep;37(7):458-60. PMID- 15635746 OWN - NLM STAT- MEDLINE DCOM- 20050111 LR - 20131121 IS - 0035-8843 (Print) IS - 1478-7083 (Electronic) IS - 0035-8843 (Linking) VI - 86 IP - 6 DP - 2004 Nov TI - Technical tips. The use of lignocaine antiseptic gel to facilitate the passing of a quadrupled semitendinosus tendon graft in anterior cruciate ligament reconstruction (ACLR). PG - 476 FAU - Vincent, M J AU - Vincent MJ FAU - Godsiff, S P AU - Godsiff SP LA - eng PT - Journal Article PL - England TA - Ann R Coll Surg Engl JT - Annals of the Royal College of Surgeons of England JID - 7506860 RN - 0 (Anesthetics, Local) RN - 0 (Gels) RN - 98PI200987 (Lidocaine) SB - IM MH - Anesthetics, Local/*administration & dosage MH - Anterior Cruciate Ligament/*surgery MH - Gels MH - Humans MH - Lidocaine/*administration & dosage MH - Tendons/*transplantation PMC - PMC1964295 EDAT- 2005/01/07 09:00 MHDA- 2005/01/12 09:00 PMCR- 2005/11/01 CRDT- 2005/01/07 09:00 PHST- 2005/01/07 09:00 [pubmed] PHST- 2005/01/12 09:00 [medline] PHST- 2005/01/07 09:00 [entrez] PHST- 2005/11/01 00:00 [pmc-release] PST - ppublish SO - Ann R Coll Surg Engl. 2004 Nov;86(6):476. PMID- 5300882 OWN - NLM STAT- MEDLINE DCOM- 19680704 LR - 20131121 IS - 0008-9176 (Print) IS - 0008-9176 (Linking) VI - 14 IP - 1 DP - 1968 Jan TI - Xanthoma tendinosum. The influence of anaemia on plasma cholesterol levels. PG - 1-4 FAU - Jacobs, P AU - Jacobs P FAU - Bloom, J R AU - Bloom JR FAU - Suzman, M M AU - Suzman MM LA - eng PT - Journal Article PL - Zimbabwe TA - Cent Afr J Med JT - The Central African journal of medicine JID - 0372566 RN - 0 (Salicylates) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Adult MH - Anemia/*etiology MH - Cholesterol/*blood MH - Female MH - Gastrointestinal Hemorrhage/chemically induced/complications MH - Humans MH - Hypercholesterolemia/etiology MH - Salicylates/adverse effects MH - *Tendons MH - *Xanthomatosis EDAT- 1968/01/01 00:00 MHDA- 1968/01/01 00:01 CRDT- 1968/01/01 00:00 PHST- 1968/01/01 00:00 [pubmed] PHST- 1968/01/01 00:01 [medline] PHST- 1968/01/01 00:00 [entrez] PST - ppublish SO - Cent Afr J Med. 1968 Jan;14(1):1-4. PMID- 14150112 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20181201 IS - 0258-2589 (Print) IS - 0258-2589 (Linking) VI - 10 DP - 1964 TI - THE STRUCTURAL STABILITY OF COLLAGEN FIBRES ISOLATED FROM RAT TAIL TENDON DURING THE TREATMENT WITH ANTIRHEUMATIC DRUGS. PRELIMINARY REPORT. PG - 225-31 FAU - TRNAVSKY, K AU - TRNAVSKY K FAU - TRNAVSKA, Z AU - TRNAVSKA Z LA - eng PT - Journal Article PL - Switzerland TA - Med Exp Int J Exp Med JT - Medicina experimentalis : International journal of experimental medicine JID - 1246320 RN - 0 (Antirheumatic Agents) RN - 886U3H6UFF (Chloroquine) RN - 9007-34-5 (Collagen) RN - GN5P7K3T8S (Phenylbutazone) RN - WI4X0X7BPJ (Hydrocortisone) RN - WIQ1H85SYP (Sodium Salicylate) SB - OM MH - *Antirheumatic Agents MH - *Chloroquine MH - *Collagen MH - *Hydrocortisone MH - *Pharmacology MH - *Phenylbutazone MH - Rats MH - *Research MH - *Sodium Salicylate MH - *Tendons OTO - NLM OT - *CHLOROQUINE OT - *COLLAGEN OT - *EXPERIMENTAL LAB STUDY OT - *HYDROCORTISONE OT - *PHARMACOLOGY OT - *PHENYLBUTAZONE OT - *RATS OT - *SODIUM SALICYLATE OT - *TENDONS EDAT- 1964/01/01 00:00 MHDA- 1964/01/01 00:01 CRDT- 1964/01/01 00:00 PHST- 1964/01/01 00:00 [pubmed] PHST- 1964/01/01 00:01 [medline] PHST- 1964/01/01 00:00 [entrez] PST - ppublish SO - Med Exp Int J Exp Med. 1964;10:225-31. PMID- 5071522 OWN - NLM STAT- MEDLINE DCOM- 19721116 LR - 20131121 IS - 0032-2938 (Print) IS - 0032-2938 (Linking) VI - 11 IP - 2 DP - 1972 TI - Gouty tophus. (Analysis of 132 cases of gout). PG - 340-53 FAU - Kawenoki-Minc, E AU - Kawenoki-Minc E FAU - Maldyk, E AU - Maldyk E FAU - Eyman, E AU - Eyman E FAU - Leo, W AU - Leo W FAU - Dabrowski, W AU - Dabrowski W LA - eng PT - Journal Article PL - Poland TA - Pol Med J JT - Polish medical journal JID - 0376721 RN - 268B43MJ25 (Uric Acid) SB - IM MH - Adult MH - Crystallization MH - Female MH - Gout/*complications/metabolism/pathology MH - Granuloma/etiology MH - Humans MH - Male MH - Middle Aged MH - Tendons/pathology MH - Time Factors MH - Uric Acid/metabolism EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PST - ppublish SO - Pol Med J. 1972;11(2):340-53. PMID- 5788377 OWN - NLM STAT- MEDLINE DCOM- 19690806 LR - 20041117 IS - 0039-6060 (Print) IS - 0039-6060 (Linking) VI - 66 IP - 1 DP - 1969 Jul TI - Some studies on the effects of beta-aminopropionitrile in patients with injured flexor tendons. PG - 215-23 FAU - Peacock, E E Jr AU - Peacock EE Jr FAU - Madden, J W AU - Madden JW LA - eng PT - Journal Article PL - United States TA - Surgery JT - Surgery JID - 0417347 RN - 0 (Nitriles) RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) SB - IM MH - Aminopropionitrile/adverse effects/therapeutic use MH - Collagen/*biosynthesis MH - Humans MH - *Lathyrism MH - Nitriles/adverse effects/*therapeutic use MH - Tendon Injuries/*surgery MH - Wound Healing/*drug effects EDAT- 1969/07/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1969/07/01 00:00 PHST- 1969/07/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1969/07/01 00:00 [entrez] AID - 0039-6060(69)90245-1 [pii] PST - ppublish SO - Surgery. 1969 Jul;66(1):215-23. PMID- 4343246 OWN - NLM STAT- MEDLINE DCOM- 19730103 LR - 20161122 IS - 0368-3966 (Print) IS - 0368-3966 (Linking) VI - 53 IP - 5 DP - 1972 May TI - [Radiological aspects of calcification in multiple tendinous calcifications and chondrocalcinosis]. PG - 444-8 FAU - Amor, B AU - Amor B FAU - Guidet, P AU - Guidet P FAU - Delrieu, F AU - Delrieu F LA - fre PT - Journal Article TT - Aspects radiologiques des calcifications dans la maladie des calcifications tendineuses multiples et la chondro-calcinose. PL - France TA - J Radiol Electrol Med Nucl JT - Journal de radiologie, d'electrologie, et de medecine nucleaire JID - 7610508 RN - 0 (Calcium Phosphates) RN - 0 (Diphosphates) RN - 0 (Hydroxyapatites) RN - 268B43MJ25 (Uric Acid) SB - IM MH - Calcinosis/*diagnostic imaging MH - Calcium Phosphates MH - Chondrocalcinosis/*diagnostic imaging MH - Diphosphates MH - Elbow Joint MH - Hip Joint MH - Humans MH - Hydroxyapatites MH - Intervertebral Disc MH - Knee Joint MH - Pubic Symphysis MH - Radiography MH - Shoulder Joint MH - Tarsal Joints MH - Tendinopathy/*diagnostic imaging MH - Tendons/diagnostic imaging MH - Toe Joint MH - Uric Acid MH - Wrist Joint EDAT- 1972/05/01 00:00 MHDA- 1972/05/01 00:01 CRDT- 1972/05/01 00:00 PHST- 1972/05/01 00:00 [pubmed] PHST- 1972/05/01 00:01 [medline] PHST- 1972/05/01 00:00 [entrez] PST - ppublish SO - J Radiol Electrol Med Nucl. 1972 May;53(5):444-8. PMID- 19032570 OWN - NLM STAT- MEDLINE DCOM- 20090326 LR - 20181201 IS - 1399-6576 (Electronic) IS - 0001-5172 (Linking) VI - 53 IP - 2 DP - 2009 Feb TI - Ultrasound-guided ulnar nerve catheter placement in the forearm for postoperative pain relief and physiotherapy. PG - 261-3 LID - 10.1111/j.1399-6576.2008.01762.x [doi] AB - Consistent identification of peripheral nerves as well as placement of catheters for post-operative pain relief is possible with the aid of ultrasound. By blocking a single nerve rather than the entire extremity, pain can be eliminated without impairing motor function of the entire extremity, providing greater patient comfort. This report describes a case in which ultrasound-guided ulnar nerve catheter placement was performed in the forearm for post-operative pain relief following arthrolysis and tenolysis of the fifth finger. The ulnar nerve catheter allowed for excellent pain relief and completely painless physiotherapy without impairing motor function of the operated finger. FAU - Lurf, M AU - Lurf M AD - Anaesthesia and Critical Care, Trauma Center Lorenz Boehler, Vienna, Australia. monika.lurf@auva.at FAU - Leixnering, M AU - Leixnering M LA - eng PT - Case Reports PT - Journal Article DEP - 20081022 PL - England TA - Acta Anaesthesiol Scand JT - Acta anaesthesiologica Scandinavica JID - 0370270 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 046O35D44R (Prilocaine) RN - 7IO5LYA57N (Ropivacaine) SB - IM MH - Adult MH - Amides/administration & dosage MH - Analgesia, Patient-Controlled/*instrumentation MH - Anesthetics, Local/administration & dosage MH - Catheterization/*methods MH - Contracture/etiology/*surgery MH - Finger Injuries/complications/rehabilitation MH - Finger Joint/*surgery MH - Forearm MH - Fractures, Bone/complications MH - Humans MH - Male MH - Pain, Postoperative/*therapy MH - Physical Therapy Modalities MH - Prilocaine/administration & dosage MH - Ropivacaine MH - Tendons/*surgery MH - Ulnar Nerve/drug effects/*physiopathology MH - *Ultrasonography, Interventional EDAT- 2008/11/27 09:00 MHDA- 2009/03/27 09:00 CRDT- 2008/11/27 09:00 PHST- 2008/11/27 09:00 [pubmed] PHST- 2009/03/27 09:00 [medline] PHST- 2008/11/27 09:00 [entrez] AID - AAS1762 [pii] AID - 10.1111/j.1399-6576.2008.01762.x [doi] PST - ppublish SO - Acta Anaesthesiol Scand. 2009 Feb;53(2):261-3. doi: 10.1111/j.1399-6576.2008.01762.x. Epub 2008 Oct 22. PMID- 4906336 OWN - NLM STAT- MEDLINE DCOM- 19700410 LR - 20131121 IS - 0020-8868 (Print) IS - 0020-8868 (Linking) VI - 53 IP - 2 DP - 1970 Feb TI - Repair of tendons with cutis grafts. An experimental study. PG - 115-8 FAU - Grewal, R S AU - Grewal RS FAU - Mittal, V K AU - Mittal VK LA - eng PT - Journal Article PL - Italy TA - Int Surg JT - International surgery JID - 0043524 RN - 17R794ESYN (Penicillin G Procaine) SB - IM MH - Achilles Tendon/pathology/physiology/*surgery MH - Animals MH - Dogs MH - Injections, Intramuscular MH - Methods MH - Penicillin G Procaine/administration & dosage MH - *Skin Transplantation MH - Transplantation, Homologous EDAT- 1970/02/01 00:00 MHDA- 1970/02/01 00:01 CRDT- 1970/02/01 00:00 PHST- 1970/02/01 00:00 [pubmed] PHST- 1970/02/01 00:01 [medline] PHST- 1970/02/01 00:00 [entrez] PST - ppublish SO - Int Surg. 1970 Feb;53(2):115-8. PMID- 14230029 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20181201 IS - 0021-7743 (Print) IS - 0021-7743 (Linking) VI - 13 DP - 1964 Sep TI - [CUTANEOUS AND TENDINOUS TUBEROUS XANTHOMATOSIS THROUGH 3 GENERATIONS]. PG - 185-206 FAU - DODINVAL, P AU - DODINVAL P FAU - AMMANN, F AU - AMMANN F FAU - KLEIN, D AU - KLEIN D FAU - MACH, R AU - MACH R LA - fre PT - Journal Article TT - XANTHOMATOSE TUB'EREUSE CUTAN'EE ET TENDINEUSE 'A TRAVERS TROIS G'EN'ERATIONS. PL - Switzerland TA - J Genet Hum JT - Journal de genetique humaine JID - 2983308R RN - 268B43MJ25 (Uric Acid) SB - OM MH - *Angina Pectoris MH - *Blood MH - *Eyelids MH - *Genetics, Medical MH - *Hyperlipidemias MH - *Hyperlipoproteinemia Type I MH - *Hyperlipoproteinemia Type III MH - *Tendons MH - *Uric Acid MH - *Xanthomatosis OTO - NLM OT - *ANGINA PECTORIS OT - *BLOOD OT - *EYELIDS OT - *GENETICS, HUMAN OT - *HYPERLIPEMIA, ESSENTIAL FAMILIAL OT - *TENDONS OT - *URIC ACID OT - *XANTHOMATOSIS EDAT- 1964/09/01 00:00 MHDA- 1964/09/01 00:01 CRDT- 1964/09/01 00:00 PHST- 1964/09/01 00:00 [pubmed] PHST- 1964/09/01 00:01 [medline] PHST- 1964/09/01 00:00 [entrez] PST - ppublish SO - J Genet Hum. 1964 Sep;13:185-206. PMID- 4157614 OWN - NLM STAT- MEDLINE DCOM- 19651120 LR - 20131121 IS - 0001-5423 (Print) IS - 0001-5423 (Linking) VI - 7 IP - 3 DP - 1965 TI - The effects of an antihistamine (promethazine) on the reaction of tendons to trauma (a histological study). PG - 171-86 FAU - Walker, F G AU - Walker FG FAU - Bensley, S H AU - Bensley SH FAU - Lindsay, W K AU - Lindsay WK LA - eng PT - Journal Article PL - Czech Republic TA - Acta Chir Plast JT - Acta chirurgiae plasticae JID - 0370301 RN - FF28EJQ494 (Promethazine) SB - IM MH - Animals MH - Poultry MH - Promethazine/*administration & dosage/*pharmacology MH - Tendon Injuries/*physiopathology EDAT- 1965/01/01 00:00 MHDA- 1965/01/01 00:01 CRDT- 1965/01/01 00:00 PHST- 1965/01/01 00:00 [pubmed] PHST- 1965/01/01 00:01 [medline] PHST- 1965/01/01 00:00 [entrez] PST - ppublish SO - Acta Chir Plast. 1965;7(3):171-86. PMID- 5709777 OWN - NLM STAT- MEDLINE DCOM- 19690401 LR - 20131121 IS - 0003-9780 (Print) IS - 0003-9780 (Linking) VI - 176 IP - 1 DP - 1968 Nov TI - [Development of the activity of cholinesterases and their functional capacity at the level of frog neuromuscular and musculotendinous junctions after section of the motor nerve]. PG - 118-33 FAU - Pécot-Dechavassine, M AU - Pécot-Dechavassine M LA - fre PT - Journal Article TT - Evolution de l'activité des cholinestérases et de leur capacité fonctionnelle au niveau des jonctions neuromusculaires et musculotendineuses de la grenoluille après section du nerf moteur. PL - Belgium TA - Arch Int Pharmacodyn Ther JT - Archives internationales de pharmacodynamie et de therapie JID - 0405353 RN - 0 (Butyrates) RN - 3982TWQ96G (Neostigmine) RN - 9U1VM840SP (Physostigmine) RN - EC 3.1.1.7 (Acetylcholinesterase) RN - EC 3.1.1.8 (Cholinesterases) SB - IM MH - Acetylcholinesterase/physiology MH - Animals MH - Anura MH - Atrophy MH - Butyrates MH - Cholinesterases/*physiology MH - Iontophoresis MH - Microscopy MH - Muscle Denervation MH - Neostigmine/pharmacology MH - Neuromuscular Junction/*enzymology MH - Physostigmine/pharmacology MH - Tendons/*enzymology MH - Time Factors EDAT- 1968/11/01 00:00 MHDA- 1968/11/01 00:01 CRDT- 1968/11/01 00:00 PHST- 1968/11/01 00:00 [pubmed] PHST- 1968/11/01 00:01 [medline] PHST- 1968/11/01 00:00 [entrez] PST - ppublish SO - Arch Int Pharmacodyn Ther. 1968 Nov;176(1):118-33. PMID- 2401930 OWN - NLM STAT- MEDLINE DCOM- 19901023 LR - 20131121 IS - 0096-1736 (Print) IS - 0096-1736 (Linking) VI - 32 IP - 8 DP - 1990 Aug TI - Medical management of hydrofluoric acid exposure. PG - 726-31 AB - Hydrofluoric acid burns are usually due to accidental exposure. Deep tissue injury may result, damaging nerves, blood vessels, tendons, and bone. Concentrated hydrofluoric acid may cause immediate pain; dilute solutions may result in a delay of symptoms for many hours. Symptoms are usually out of proportion to the observed injury. Appropriate first aid and medical management can dramatically affect the prognosis. Local treatment consists of copious water lavage and the application of topical neutralization agents. For more severe exposures, calcium gluconate injection or intraarterial infusion of calcium gluconate may be indicated as well. Life-threatening alterations of electrolytes can occur, with ensuing arrhythmias. Inhalation, ingestion, and ocular exposures require specialized treatment and referral. FAU - Upfal, M AU - Upfal M AD - Department of Family Medicine, Wayne State University, Detroit, MI 48201. FAU - Doyle, C AU - Doyle C LA - eng PT - Journal Article PL - United States TA - J Occup Med JT - Journal of occupational medicine. : official publication of the Industrial Medical Association JID - 7502807 RN - 0 (Amines) RN - RGL5YE86CZ (Hydrofluoric Acid) RN - SQE6VB453K (Calcium Gluconate) SB - IM MH - *Accidents, Occupational MH - Administration, Topical MH - Amines/administration & dosage/therapeutic use MH - Burns, Chemical/etiology/*therapy MH - Calcium Gluconate/administration & dosage/therapeutic use MH - *First Aid MH - Humans MH - Hydrofluoric Acid/adverse effects/*toxicity MH - Therapeutic Irrigation EDAT- 1990/08/01 00:00 MHDA- 1990/08/01 00:01 CRDT- 1990/08/01 00:00 PHST- 1990/08/01 00:00 [pubmed] PHST- 1990/08/01 00:01 [medline] PHST- 1990/08/01 00:00 [entrez] PST - ppublish SO - J Occup Med. 1990 Aug;32(8):726-31. PMID- 41137000 OWN - NLM STAT- MEDLINE DCOM- 20251025 LR - 20251027 IS - 2662-7671 (Electronic) IS - 2662-7671 (Linking) VI - 25 IP - 1 DP - 2025 Oct 24 TI - Therapeutic effects of cinnamic acid in a rat model of collagenase-induced Achilles tendinopathy. PG - 401 LID - 10.1186/s12906-025-05152-x [doi] LID - 401 AB - BACKGROUND: Achilles tendinopathy is a common degenerative disorder characterized by pain, impaired function, and poor tissue regeneration. Effective treatment remains a challenge due to the tendon's limited healing capacity. Cinnamic acid, a naturally occurring phenolic compound, has demonstrated anti-inflammatory and antioxidant effects in various tissue repair models. However, its therapeutic potential in tendon injury remains unexplored, and this study represents the first study to evaluate its effects in an experimental Achilles tendinopathy model. METHODS: In this experimental study, tendinopathy was induced in male rats via ultrasound-guided collagenase injection into the right Achilles tendon. Animals were randomly assigned to six groups (n = 7 each): Sham, Injury Control, vehicle control (Tendinopathy + DMSO), and three cinnamic acid treatment groups (10, 30, and 90 mg/kg). Cinnamic acid was administered intraperitoneally once daily for four weeks, starting on day 7 post-injury. Tendon healing was evaluated on days 21 and 35 using ultrasound imaging and histological analysis based on semi-quantitative scoring systems. RESULTS: Cinnamic acid treatment led to dose-dependent improvements in tendon healing. Ultrasound scores significantly decreased in the 30 mg/kg group, indicating preservation of echogenicity and reduced neovascularization. Modest improvement was observed with 10 mg/kg, whereas 90 mg/kg showed no significant benefit. Histological findings paralleled the ultrasound results, with the 30 mg/kg group displaying improved collagen fiber organization, normalized nuclear morphology, and reduced inflammation. Both 10 mg/kg and 90 mg/kg groups showed improvements over the injury control group, but the difference between these two doses was not statistically significant. A strong correlation (ρ = 0.794, p < 0.001) between ultrasound and histological scores confirmed the consistency of imaging-based assessment. CONCLUSIONS: These findings support the utility of ultrasound as a non-invasive monitoring tool and highlight cinnamic acid as a promising therapeutic agent for tendinopathy. CLINICAL TRIAL NUMBER: Not applicable. CI - © 2025. The Author(s). FAU - Capkin, Sercan AU - Capkin S AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Izmir Bakırçay University, Izmir, Turkey. sercancapkn@gmail.com. FAU - Kilic, Ali Ihsan AU - Kilic AI AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, Izmir Bakırçay University, Izmir, Turkey. FAU - Dizakar, Saadet Ozen Akarca AU - Dizakar SOA AD - Department of Histology and Embryology, Faculty of Medicine, Izmir Bakırçay University, Izmir, Turkey. FAU - Isin, Yagmur AU - Isin Y AD - Department of Orthopaedics and Traumatology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, Izmir, Turkey. LA - eng GR - BBAP.2025.001/Izmir Bakircay University, Office of Scientific Research Projects/ GR - BBAP.2025.001/Izmir Bakircay University, Office of Scientific Research Projects/ GR - BBAP.2025.001/Izmir Bakircay University, Office of Scientific Research Projects/ GR - BBAP.2025.001/Izmir Bakircay University, Office of Scientific Research Projects/ PT - Journal Article DEP - 20251024 PL - England TA - BMC Complement Med Ther JT - BMC complementary medicine and therapies JID - 101761232 RN - 0 (Cinnamates) RN - 140-10-3 (cinnamic acid) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Animals MH - *Cinnamates/pharmacology/therapeutic use MH - *Achilles Tendon/drug effects/injuries MH - Rats MH - *Tendinopathy/drug therapy/chemically induced MH - Male MH - Disease Models, Animal MH - Collagenases MH - Rats, Sprague-Dawley MH - Wound Healing/drug effects PMC - PMC12553171 OTO - NOTNLM OT - Achilles tendinopathy OT - Cinnamic acid OT - Collagenase OT - Rat model OT - Tendon healing OT - Ultrasound imaging COIS- Declarations. Ethics approval and consent to participate: All experimental procedures were approved by the Dokuz Eylul University Animal Experiments Local Ethics Committee (Approval No: 36/2024). All animal procedures were conducted in accordance with the ARRIVE guidelines and the Guide for the Care and Use of Laboratory Animals. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/10/25 00:30 MHDA- 2025/10/25 06:31 PMCR- 2025/10/24 CRDT- 2025/10/24 23:46 PHST- 2025/05/17 00:00 [received] PHST- 2025/10/02 00:00 [accepted] PHST- 2025/10/25 06:31 [medline] PHST- 2025/10/25 00:30 [pubmed] PHST- 2025/10/24 23:46 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - 10.1186/s12906-025-05152-x [pii] AID - 5152 [pii] AID - 10.1186/s12906-025-05152-x [doi] PST - epublish SO - BMC Complement Med Ther. 2025 Oct 24;25(1):401. doi: 10.1186/s12906-025-05152-x. PMID- 23325540 OWN - NLM STAT- MEDLINE DCOM- 20130603 LR - 20191112 IS - 1473-2262 (Electronic) IS - 1473-2262 (Linking) VI - 25 DP - 2013 Jan 16 TI - Alendronate reduced peri-tunnel bone loss and enhanced tendon graft to bone tunnel healing in anterior cruciate ligament reconstruction. PG - 78-96 AB - Peri-tunnel bone loss after anterior cruciate ligament (ACL) reconstruction is commonly observed, both clinically and experimentally. We aimed to study the effect and mechanisms of different doses of alendronate in the reduction of peri-tunnel bone loss and promotion of graft-bone tunnel healing in ACL reconstruction. Eighty-four ACL-reconstructed rats were divided into 4 groups. Alendronate at different dosages, or saline, were injected subcutaneously weekly, for 2 or 6 weeks post-reconstruction, for vivaCT (computed tomography) imaging, biomechanical tests, histology and immunohistochemistry. Alendronate significantly increased bone mass and density of tissue inside bone tunnels except at the epiphyseal region of tibial tunnel. The femoral tunnel diameter decreased significantly in the mid-dose and high-dose alendronate groups compared to that in the saline group at week 6. Alendronate significantly increased the peri-tunnel bone mass and density along all tunnel regions at week 6. Better graft-bone tunnel integration and intra-tunnel graft integrity were observed in the alendronate groups. The ultimate load was significantly higher in the mid-dose and high-dose alendronate groups at week 2, but not at week 6. There was a reduction in matrix metalloprotein (MMP)1, MMP13 and CD68-positive cells at the peri-tunnel region and graft-bone interface in the alendronate-treated group compared to the saline group. Alendronate reduced peri-tunnel bone resorption, increased mineralised tissue inside bone tunnel as well as histologically and biomechanically promoted graft-bone tunnel healing, probably by reducing the expression of MMP1, MMP13 and CD68-positive cells. Alendronate might be used for reducing peri-tunnel bone loss and promoting graft-bone tunnel healing at early stage post-ACL reconstruction. FAU - Lui, P P Y AU - Lui PP AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. paulinelui00@gmail.com FAU - Lee, Y W AU - Lee YW FAU - Mok, T Y AU - Mok TY FAU - Cheuk, Y C AU - Cheuk YC FAU - Chan, K M AU - Chan KM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130116 PL - United States TA - Eur Cell Mater JT - European cells & materials JID - 100973416 RN - 0 (Bone Density Conservation Agents) RN - X1J18R4W8P (Alendronate) SB - IM MH - Alendronate/*administration & dosage MH - Animals MH - Anterior Cruciate Ligament/physiopathology/*surgery MH - *Anterior Cruciate Ligament Reconstruction MH - Bone Density/drug effects MH - Bone Density Conservation Agents/*administration & dosage MH - Bone Regeneration/*drug effects MH - Dose-Response Relationship, Drug MH - Femur/drug effects/physiopathology/surgery MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/*transplantation MH - Tibia/drug effects/physiopathology/surgery MH - Wound Healing/drug effects EDAT- 2013/01/18 06:00 MHDA- 2013/06/05 06:00 CRDT- 2013/01/18 06:00 PHST- 2013/01/18 06:00 [entrez] PHST- 2013/01/18 06:00 [pubmed] PHST- 2013/06/05 06:00 [medline] AID - vol025a06 [pii] AID - 10.22203/ecm.v025a06 [doi] PST - epublish SO - Eur Cell Mater. 2013 Jan 16;25:78-96. doi: 10.22203/ecm.v025a06. PMID- 11447546 OWN - NLM STAT- MEDLINE DCOM- 20011212 LR - 20190915 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 17 IP - 6 DP - 2001 Jul TI - Bone tunnel remodeling at the site of biodegradable interference screws used for anterior cruciate ligament reconstruction: 5-year follow-up. PG - 597-602 AB - PURPOSE: The purpose of this prospective study was to review, using expanded clinical-assessment tools, the long-term results of the local effects of a bioabsorbable interference screw (copolymer 85/15 D,L lactide/glycolide) in anterior cruciate ligament (ACL) reconstruction. TYPE OF STUDY: This prospective study was initiated in May 1993. The inclusion criteria for patient selection included rupture of the ACL in athletic patients without involvement of the collateral ligaments, arthroscopic ACL reconstruction using middle third of the ligamentum patella, and magnetic resonance imaging (MRI) and plain radiographic examinations of the knee joint during follow-up. MATERIALS: Between May 1993 and October 1994, 32 patients were enlisted in the study; 48 patients did not fit the inclusion criteria. There were 25 men 7 women. The average age was 29.1 years (range, 19 to 50 years). There were 21 right knees and 11 left knees. The follow-up examinations were performed by an independent examiner. There were 28 patients available for follow-up at a medium of 5.2 years (range, 4.1 to 6.4 years). The evaluation included various testing systems (i.e., OAK, IKDC, Lysholm) as well as MRI and plain radiographic studies to investigate the longevity of the implant and potential adverse effects of this new bioabsorbable material. RESULTS: The clinical results were good. The OAK score (Orthopädische Arbeitsgruppe Knie) showed 93% excellent and good results, and 7% fair results. The IKDC and Lysholm scores were 92% and 96% good and excellent results, respectively. MRI showed bone remodeling and new bone formations at the site of the implant in the femoral as well as in the tibial bone tunnel at follow-up. No cystic or osteolytic changes where seen on MRI or plain radiographs. CONCLUSIONS: This study showed the correlation between histology and MRI: there was minimal surgical-site edema, minimal reaction to this material, and complete replacement by new bone formation of the previous site of this implant. At 5 years, this bioabsorbable interference screw appeared clinically safe and effective for fixation of bone blocks during ACL reconstruction and MRI showed complete absorption and replacement with new bone. FAU - Lajtai, G AU - Lajtai G AD - Departments of Traumatology and Radiology, AKH-Wels, Wels, Austria. laj@shoulder.org FAU - Schmiedhuber, G AU - Schmiedhuber G FAU - Unger, F AU - Unger F FAU - Aitzetmüller, G AU - Aitzetmüller G FAU - Klein, M AU - Klein M FAU - Noszian, I AU - Noszian I FAU - Orthner, E AU - Orthner E LA - eng PT - Clinical Trial PT - Journal Article PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Polymers) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - *Absorbable Implants/adverse effects MH - Adult MH - Anterior Cruciate Ligament/*surgery MH - Anterior Cruciate Ligament Injuries MH - Bone Screws MH - Female MH - Follow-Up Studies MH - Humans MH - Knee Joint/diagnostic imaging/pathology MH - *Lactic Acid/adverse effects MH - Magnetic Resonance Imaging MH - Male MH - *Materials Testing MH - Middle Aged MH - *Polyglycolic Acid/adverse effects MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - *Polymers/adverse effects MH - Prospective Studies MH - Radiography MH - Reoperation MH - Rupture MH - Tendons/*transplantation EDAT- 2001/07/12 10:00 MHDA- 2002/01/05 10:01 CRDT- 2001/07/12 10:00 PHST- 2001/07/12 10:00 [pubmed] PHST- 2002/01/05 10:01 [medline] PHST- 2001/07/12 10:00 [entrez] AID - S0749806301800980 [pii] AID - 10.1053/jars.2001.21535 [doi] PST - ppublish SO - Arthroscopy. 2001 Jul;17(6):597-602. doi: 10.1053/jars.2001.21535. PMID- 19095873 OWN - NLM STAT- MEDLINE DCOM- 20090121 LR - 20181201 IS - 1526-7598 (Electronic) IS - 0003-2999 (Linking) VI - 108 IP - 1 DP - 2009 Jan TI - A randomized comparison of a modified intertendinous and classic posterior approach to popliteal sciatic nerve block. PG - 359-63 LID - 10.1213/ane.0b013e31818c9452 [doi] AB - INTRODUCTION: In this prospective randomized study, we compared a single-injection modified intertendinous (n = 55) with the classic posterior (n = 54) popliteal sciatic nerve block for patients undergoing ankle/foot surgery. METHODS: Nerve stimulator-guided blocks were performed 7-8 cm (classic posterior) or 12-14 cm (modified intertendinous) above the popliteal crease. Levobupivacaine 0.625% with epinephrine 1:300,000 (Chirocaine(R), Purdue Pharma, Stamford, CT), was injected in 5 mL aliquots to a total volume of 0.4 mL/kg (range, 25-35 mL). The needle position was considered acceptable if an evoked motor response of plantar flexion, inversion, eversion or a dorsiflexion of the ipsilateral foot was elicited at 0.05). After the ligament reconstruction during operation, corresponding MDC (consisting of ropivacaine, tranexamic acid, and betamethasone in group A, and ropivacaine, betamethasone, and saline in group B) or saline (group C) were injected into the joint and tendon site, respectively. The length of hospital stay, postoperative tramadol injection volume, incidence of complications, degree of knee joint swelling and range of motion, visual analogue scale (VAS) score, International Knee Documentation Committee (IKDC) score, Lyshlom score, and Hospital for Special Surgery (HSS) score were recorded and compared between groups. The T2 (*) values in different cartilage regions were detected by MRI examination and the levels of TNF-α, IL-6, IL-1, MMP-3, MMP-13, and ACAN in synovial fluid were detected by ELISA method. RESULTS: The patients in group A, B, and C were followed up (12.53±3.24), (13.14±2.87), and (12.82±3.32) months, respectively. All incisions healed by first intention. Compared with group C, group A and group B had shorter length of hospital stay, less tramadol injection volume, and lower incidence of complications, showing significant differences ( P<0.05); there was no significant difference between group A and group B ( P>0.05). The degree of knee swelling in group A was significantly less than that in group B and group C ( P<0.05), but there was no significant difference between group B and group C ( P>0.05). At 3, 6, 12, 24, and 48 hours after operation, VAS scores of group A and group B were significantly lower than those of group C ( P<0.05); at 72 hours after operation, there was no significant difference among the three groups ( P>0.05). At 3 days, 14 days, and 1 month after operation, the range of motion of knee joint in group A were significantly better than those in group C ( P<0.05), and there was no significant difference between the other groups ( P>0.05). At 1 month after operation, the IKDC score of group A and group B was significantly higher than that of group C ( P<0.05); there was no significant difference among the three groups at other time points ( P>0.05). There was no significant difference in Lyshlom score and HSS score among the three groups at each time point ( P>0.05). At 14 days after operation, the levels of IL-1 and IL-6 in the synovial fluid in groups A and B were significantly lower than those in group C ( P<0.05). There was no significant difference in the levels of TNF-α, MMP-3, MMP-13, and ACAN between groups A and B ( P>0.05). At 1 month after operation, there was no significant difference in the above indicators among the three groups ( P>0.05). At 3, 6, and 12 months after operation, there was no significant difference in the T2 (*) values of different cartilage regions among the three groups ( P>0.05). CONCLUSION: Injecting MDC (ropivacaine, tranexamic acid, betamethasone) into the joint and tendon site during ACLR can achieve good early effectiveness without significant impact on cartilage. FAU - Yu, Hong AU - Yu H AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Dong, Zhenlin AU - Dong Z AD - Department of Imaging, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Shi, Zhengliang AU - Shi Z AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Li, Li AU - Li L AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Dong, Kaiyan AU - Dong K AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Liu, Haolong AU - Liu H AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. FAU - Li, Yanlin AU - Li Y AD - Department of Sports Medicine, First Affiliated Hospital of Kunming Medical University, Kunming Yunnan, 650032, P. R. China. LA - chi PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 SB - IM MH - Humans MH - *Anterior Cruciate Ligament Reconstruction/methods MH - *Ropivacaine/administration & dosage MH - Male MH - *Betamethasone/administration & dosage MH - Female MH - Adult MH - Matrix Metalloproteinase 3/metabolism MH - Anesthetics, Local/administration & dosage MH - Arthroscopy MH - Anterior Cruciate Ligament Injuries/surgery MH - Aggrecans/metabolism MH - Matrix Metalloproteinase 13/metabolism MH - Anterior Cruciate Ligament/surgery MH - Treatment Outcome MH - Tendons/transplantation MH - Cartilage/metabolism MH - Tumor Necrosis Factor-alpha/metabolism PMC - PMC11096880 OTO - NOTNLM OT - Anterior cruciate ligament reconstruction OT - cartilage OT - early effectiveness OT - local injection OT - multimodal drug cocktail COIS- 利益冲突　在课题研究和文章撰写过程中不存在利益冲突；经费支持没有影响文章观点和对研究数据客观结果的统计分析及其报道 EDAT- 2024/05/16 06:42 MHDA- 2024/05/16 06:43 PMCR- 2024/05/01 CRDT- 2024/05/16 04:02 PHST- 2024/05/16 06:43 [medline] PHST- 2024/05/16 06:42 [pubmed] PHST- 2024/05/16 04:02 [entrez] PHST- 2024/05/01 00:00 [pmc-release] AID - zgxfcjwkzz-38-5-562 [pii] AID - 10.7507/1002-1892.202402054 [doi] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 May 15;38(5):562-569. doi: 10.7507/1002-1892.202402054. PMID- 20349070 OWN - NLM STAT- MEDLINE DCOM- 20120821 LR - 20211020 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 32 IP - 5 DP - 2012 May TI - Fibrodysplasia ossificans progressiva without characteristic skeletal anomalies. PG - 1379-82 LID - 10.1007/s00296-010-1426-1 [doi] AB - Fibrodysplasia ossificans progressiva (FOP) is a rare but extremely disabling genetic disease of the skeletal system. This disease is characterized by progression of heterotopic ossification within skeletal muscles, ligaments and tendons. Most patients with FOP are misdiagnosed early in life before the appearance of heterotopic ossification and undergo diagnostic procedures such as biopsy that can cause lifelong disability. Almost all of the patients have some peculiar congenital anomalies, including short great toes, hallux valgus, short thumbs and hypoplasia of digital phalanges. These congenital defects support the diagnosis of FOP, but are not constantly observed in the totality of patients. If necessary, genetic studies can be performed to confirm the diagnosis. Once diagnosed, patients should be advised in order to avoid unnecessary traumas, surgical procedures, biopsies, intramuscular injections and vaccinations. Here, we describe a patient with FOP without characteristic congenital skeletal anomalies. FAU - Ulusoy, Hasan AU - Ulusoy H AD - Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University, Elazig, Turkey. ulusoyh@mynet.com LA - eng PT - Case Reports PT - Journal Article DEP - 20100327 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 0 (Bone Density Conservation Agents) RN - M2F465ROXU (Etidronic Acid) SB - IM CIN - Rheumatol Int. 2012 May;32(5):1475-6; author reply 1477-8. doi: 10.1007/s00296-011-1904-0. PMID: 21437684 MH - Adult MH - Biomechanical Phenomena MH - Bone Density Conservation Agents/administration & dosage MH - Bone and Bones/*abnormalities/diagnostic imaging MH - Drug Administration Schedule MH - Etidronic Acid/administration & dosage MH - Humans MH - Male MH - Muscle Strength MH - Muscle, Skeletal/diagnostic imaging/*pathology/physiopathology MH - Myositis Ossificans/*diagnosis/genetics/physiopathology/therapy MH - *Ossification, Heterotopic MH - Physical Therapy Modalities MH - Predictive Value of Tests MH - Radiography MH - Treatment Outcome EDAT- 2010/03/30 06:00 MHDA- 2012/08/22 06:00 CRDT- 2010/03/30 06:00 PHST- 2009/11/10 00:00 [received] PHST- 2010/03/10 00:00 [accepted] PHST- 2010/03/30 06:00 [entrez] PHST- 2010/03/30 06:00 [pubmed] PHST- 2012/08/22 06:00 [medline] AID - 10.1007/s00296-010-1426-1 [doi] PST - ppublish SO - Rheumatol Int. 2012 May;32(5):1379-82. doi: 10.1007/s00296-010-1426-1. Epub 2010 Mar 27. PMID- 19458428 OWN - NLM STAT- MEDLINE DCOM- 20090820 LR - 20131121 IS - 1053-8135 (Print) IS - 1053-8135 (Linking) VI - 24 IP - 3 DP - 2009 TI - A novel method improving motor disturbance in Parkinson disease: application of glycerin poultice to the flexor digitorum profundus in the middle phalanx of the little finger. PG - 219-23 LID - 10.3233/NRE-2009-0471 [doi] AB - OBJECTIVE: To investigate whether the application of glycerin poultice to the flexor digitorum profundus in the middle phalanx of the little finger (GFML) improves motor disturbance in Parkinson Disease (PD). METHODS: Dorsiflexion of the little finger and diameter of the pupil in 22 patients with PD and 23 control subjects was evaluated before and after application of GFML. Motor disturbance in patients with PD was evaluated before and after application of GFML. RESULTS: The application of GFML increased dorsiflexion of the little finger and constricted the pupil in all subjects, which suggests that application of GFML caused the decreased tension of the flexor digitorum profundus and lowered sympathetic nerve activity. With application of GFML, motor disturbance in patients with PD was improved. CONCLUSIONS: The application of GFML improves motor disturbance in PD which might be caused by reversing the mechanism of the muscle mechanosensitive reflex. FAU - Yasuda, Yuzuru AU - Yasuda Y AD - Department of Neurology, Yasuda Clinic, Kyoto, Japan. yuzuru-yasuda@mra.biglobe.ne.jp LA - eng PT - Controlled Clinical Trial PT - Journal Article PL - United States TA - NeuroRehabilitation JT - NeuroRehabilitation JID - 9113791 RN - 0 (Solvents) RN - PDC6A3C0OX (Glycerol) SB - IM MH - Administration, Cutaneous MH - Aged MH - Bandages MH - Female MH - Fingers MH - Glycerol/*administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Motor Skills/*drug effects MH - Muscle Tonus/drug effects MH - Parkinson Disease/complications/*physiopathology/*rehabilitation MH - Range of Motion, Articular/drug effects MH - Reflex, Pupillary/drug effects MH - Solvents/*administration & dosage MH - *Tendons EDAT- 2009/05/22 09:00 MHDA- 2009/08/21 09:00 CRDT- 2009/05/22 09:00 PHST- 2009/05/22 09:00 [entrez] PHST- 2009/05/22 09:00 [pubmed] PHST- 2009/08/21 09:00 [medline] AID - K41W25411VG214H0 [pii] AID - 10.3233/NRE-2009-0471 [doi] PST - ppublish SO - NeuroRehabilitation. 2009;24(3):219-23. doi: 10.3233/NRE-2009-0471. PMID- 29205374 OWN - NLM STAT- MEDLINE DCOM- 20181114 LR - 20181114 IS - 1097-0096 (Electronic) IS - 0091-2751 (Linking) VI - 46 IP - 2 DP - 2018 Feb TI - Ethyl chloride spray for musculoskeletal ultrasound-guided injections: An alternative to subcutaneous injection of local anesthetic solution. PG - 129-131 LID - 10.1002/jcu.22561 [doi] AB - Ultrasound-guided injections such as steroid injections are common procedures involving the musculoskeletal system. They are usually performed after a subcutaneous injection of local anesthetic (LA), which can be painful. In 126 consecutive patients, local anesthesia was performed using ethyl chloride spray prior to a therapeutic ultrasound-guided injection in joints, tendons, or bursae. Ninety-nine (78.5%) patients found the use of ethyl chloride spray helpful. The use of ethyl chloride spray is an effective, patient-friendly alternative to the standard injection of local aesthetic for ultrasound-guided therapeutic musculoskeletal injections with the advantage of a lower cost of $0.18 per procedure. CI - © 2017 Wiley Periodicals, Inc. FAU - Shah, Amit AU - Shah A AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. FAU - Vidoni, Alessandro AU - Vidoni A AUID- ORCID: 0000-0003-1394-1400 AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. FAU - McGarry, Sharon AU - McGarry S AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. FAU - Davies, Mark AU - Davies M AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. FAU - James, Steven AU - James S AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. FAU - Botchu, Rajesh AU - Botchu R AD - Department of Musculoskeletal Radiology, Royal Orthopaedic Hospital, Birmingham, B31 2AP, United Kingdom. LA - eng PT - Journal Article DEP - 20171204 PL - United States TA - J Clin Ultrasound JT - Journal of clinical ultrasound : JCU JID - 0401663 RN - 0 (Anesthetics, Local) RN - 46U771ERWK (Ethyl Chloride) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anesthesia, Local/*methods MH - Anesthetics, Local/*administration & dosage/therapeutic use MH - Ethyl Chloride/*administration & dosage/therapeutic use MH - Female MH - Humans MH - Injections/adverse effects MH - Injections, Subcutaneous MH - Male MH - Middle Aged MH - Musculoskeletal System/diagnostic imaging MH - Pain/*prevention & control MH - Prospective Studies MH - *Ultrasonography, Interventional OTO - NOTNLM OT - ethyl chloride spray OT - local anesthetic OT - musculoskeletal system OT - ultrasound guided injections EDAT- 2017/12/06 06:00 MHDA- 2018/11/15 06:00 CRDT- 2017/12/06 06:00 PHST- 2017/03/29 00:00 [received] PHST- 2017/10/24 00:00 [revised] PHST- 2017/10/29 00:00 [accepted] PHST- 2017/12/06 06:00 [pubmed] PHST- 2018/11/15 06:00 [medline] PHST- 2017/12/06 06:00 [entrez] AID - 10.1002/jcu.22561 [doi] PST - ppublish SO - J Clin Ultrasound. 2018 Feb;46(2):129-131. doi: 10.1002/jcu.22561. Epub 2017 Dec 4. PMID- 20725821 OWN - NLM STAT- MEDLINE DCOM- 20110125 LR - 20220309 IS - 1433-044X (Electronic) IS - 0177-5537 (Linking) VI - 113 IP - 9 DP - 2010 Sep TI - [Conservative treatment of Achilles tendinopathy]. PG - 705-11 LID - 10.1007/s00113-010-1808-6 [doi] AB - Hind foot tendinopathies mainly involve the Achilles tendon. Color and Power-Doppler ultrasound visualizes pathological neovessels in painful tendons, which are associated with pain mediating nerve fibres. These neovessels are characterized by an increased capillary blood flow at the point of pain. Painful eccentric training can significantly reduce pain and improve function in Achilles tendinopathy (evidence level Ib). Shock wave therapy in combination with eccentric training is superior to eccentric training alone (evidence level Ib). Long-term results suggest a collagen induction and reduced pain following topical application of glyceryl trinitrate (NO) (evidence level Ib). Color and Power-Doppler-guided sclerosing therapy using polidocanol reduces pain, improves function and may lead to tendon remodeling (evidence level Ib). Pain-restricted sport up to a visual analogue scale (VAS) score 5/10 during therapy is recommended (evidence level Ib). Cryotherapy sessions of 3-times 10 min of reduce pain and capillary blood flow (evidence level Ib). The role of proprioceptive training in tendinopathy has to be determined in future trials (evidence level II). Anecdotical treatment of hindfoot tendinopathies has been replaced by evidence-based recommendations. FAU - Knobloch, K AU - Knobloch K AD - Klinik für Plastische, Hand- und Wiederherstellungschirurgie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. knobloch.karsten@mh-hannover.de FAU - Hüfner, T AU - Hüfner T LA - ger PT - Journal Article TT - Konservative Behandlung der Achillestendinopathie. PL - Germany TA - Unfallchirurg JT - Der Unfallchirurg JID - 8502736 RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Achilles Tendon/diagnostic imaging/*injuries MH - Administration, Topical MH - Arthralgia/*prevention & control MH - Cryotherapy MH - Evidence-Based Medicine MH - Humans MH - Nitroglycerin/administration & dosage MH - Physical Therapy Modalities MH - Tendinopathy/*therapy MH - Tendon Injuries/diagnostic imaging/*therapy MH - *Ultrasonic Therapy MH - Ultrasonography EDAT- 2010/08/21 06:00 MHDA- 2011/01/28 06:00 CRDT- 2010/08/21 06:00 PHST- 2010/08/21 06:00 [entrez] PHST- 2010/08/21 06:00 [pubmed] PHST- 2011/01/28 06:00 [medline] AID - 10.1007/s00113-010-1808-6 [doi] PST - ppublish SO - Unfallchirurg. 2010 Sep;113(9):705-11. doi: 10.1007/s00113-010-1808-6. PMID- 11845085 OWN - NLM STAT- MEDLINE DCOM- 20020318 LR - 20220409 IS - 0035-1040 (Print) IS - 0035-1040 (Linking) VI - 87 IP - 8 DP - 2001 Dec TI - [Anterior iliopsoas impingement after total hip arthroplasty: diagnosis and conservative treatment in 9 cases]. PG - 815-9 AB - PURPOSE OF THE STUDY: Impingement of the iliopsoas muscle due to a protruding acetabular component is an uncommon cause of pain after total hip arthroplasty. Diagnostic signs may be misleading and therapeutic management has varied, leading to divergent findings reported in the literature. The purpose of this prospective work was to determine the frequency of groin pain due to iliopsoas impingement (with or without an identified causal mechanism) in patients with painful total hip arthroplasties and to identify diagnostic criteria that can be used to determine the appropriate therapeutic strategy. MATERIAL AND METHODS: This prospective study was conducted between 1998 and 2000 and included 206 painful total hip arthroplasties. From this series, we excluded cases where pain was related to loosening (139 cases, 67%), infection (45 cases, 21.7%), bursitis on trochanteric sutures (2 cases, 1%), and aortic aneurysm with gluteal claudication and resulting from a lumbosacral disorder (10 cases, 4.8%). This left 9 cases (4.3%) with a clinical picture suggestive of iliopsoas impingement. These 9 patients (mean age 50 years, age range 38 - 65) had 8 uncemented press-fix cups and 1 cemented cup with an acetabular mesh. Mean delay to the development of pain after the arthroplasty procedure was 7.3 months (1 - 48 months). The most suggestive clinical sign was groin pain triggered by active flexion of the hip and flexion of the hip against force with a painful arc measuring 30 degrees to 70 degrees. None of these 9 patients had any sign of material loosening and puncture aspiration ruled out infection. The final diagnosis was confirmed by sedation of pain after extra-articular infiltration at the anterior border of the cup (overhanging cup in 6/9 cases) under computed tomographic guidance. RESULTS: Infiltrations with xylocaine and long-release corticosteroids led to complete sedation of pain in 4 out of 9 patients and partial sedation in 1 other. Recurrent pain led to terminal tenotomy of the iliopsoas in 4 patients, that provided total sedation in 3 and partial sedation in 1. In all, successful pain relief was achieved in 7 out of 9 cases: 4 after infiltration (repeated in 1 cases) and 3 after tenotomy. At last follow-up physical examination has not identified any loss of flexion force. DISCUSSION AND CONCLUSION: Irritation of the iliopsoas muscle can be the cause of pain in 4.3% of patients experiencing pain after total hip arthroplasty. The delay to symptom onset is variable but there appears to be a pain-free period after implantation. An anatomic element (anterior cup overhang) is not necessary for diagnosis since the infiltration test was positive in 1 out of 3 cases without any identified acetabular factor. The infiltration test is an important element for positive diagnosis and should be the first therapeutic measure taken. We achieved success in 4 out of 9 cases. Tenotomy is indicated in case of recurrence, providing complete cure in 3 out of 4 cases in our series. Cure may be achieved without changing the cup by simple infiltration or tenotomy of the iliopsoas that led to complete cure in 7 out of 9 cases in our series, even in patients with an overhanging cup (6 out of 9 cases). An elective procedure might be indicated if a specific anomaly is identified (overly long screw, cement leakage) or for a screwed cup. The infiltration test should however be performed beforehand to confirm the diagnosis. FAU - Ala Eddine, T AU - Ala Eddine T AD - Service d'Orthopédie B, Hôpital Salengro, CHRU de Lille, 59037 Lille Cedex, France. FAU - Remy, F AU - Remy F FAU - Chantelot, C AU - Chantelot C FAU - Giraud, F AU - Giraud F FAU - Migaud, H AU - Migaud H FAU - Duquennoy, A AU - Duquennoy A LA - fre PT - Comparative Study PT - Journal Article TT - Douleur inguinale isolée après prothèse totale de hanche et souffrance de l'ilio-psoas. PL - France TA - Rev Chir Orthop Reparatrice Appar Mot JT - Revue de chirurgie orthopedique et reparatrice de l'appareil moteur JID - 1272427 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Adult MH - Anesthetics, Local/administration & dosage/therapeutic use MH - Arthroplasty, Replacement, Hip/*adverse effects MH - Female MH - Groin MH - Humans MH - Lidocaine/administration & dosage/therapeutic use MH - Male MH - Middle Aged MH - Pain/drug therapy/*etiology MH - Prospective Studies MH - *Psoas Muscles/diagnostic imaging MH - Recurrence MH - Tendons/surgery MH - Time Factors MH - Tomography, X-Ray Computed EDAT- 2002/02/15 10:00 MHDA- 2002/03/19 10:01 CRDT- 2002/02/15 10:00 PHST- 2002/02/15 10:00 [pubmed] PHST- 2002/03/19 10:01 [medline] PHST- 2002/02/15 10:00 [entrez] AID - MDOI-RCO-12-2001-87-8-0035-1040-101019-ART8 [pii] PST - ppublish SO - Rev Chir Orthop Reparatrice Appar Mot. 2001 Dec;87(8):815-9. PMID- 20401480 OWN - NLM STAT- MEDLINE DCOM- 20110204 LR - 20211020 IS - 1432-2161 (Electronic) IS - 0364-2348 (Linking) VI - 39 IP - 12 DP - 2010 Dec TI - Unusual variation of the rotator interval: insertional abnormality of the pectoralis minor tendon and absence of the coracohumeral ligament. PG - 1205-9 LID - 10.1007/s00256-010-0926-0 [doi] AB - OBJECTIVE: To evaluate the anomalous insertion of the pectoralis minor tendon with absence of the coracohumeral ligament on MR arthrography and to demonstrate the associated findings seen with this anatomical variation. MATERIALS AND METHODS: We retrospectively reviewed the 335 MR arthrograms of the shoulder joint (mean age 37.8 years) performed from March 2000 to February 2008. Images were evaluated with attention to anomalous insertion of the pectoralis minor tendon and the coracohumeral ligament. RESULTS: Anomalous insertion of the pectoralis minor tendon was demonstrated in 5 out of 335 shoulders (1.5%). The pectoralis minor tendons crossed over the coracoid process and attached directly to a glenohumeral joint capsule, and the coracohumeral ligament was absent in these 5 patients. In these patients, injected contrast material was noted to extend over the coracoid process along the course of the pectoralis minor tendon. Among 5 patients, 3 patients (60%) were diagnosed with SLAP (superior labrum anterior to posterior) lesions. CONCLUSION: Anomalous insertion of the pectoralis minor tendon to the glenohumeral joint capsule and associated absence of the coracohumeral ligament is well demonstrated on MR arthrography. It is an unusual variant of the pectoralis minor muscle insertion, and may be a possible contributing factor in the development of a SLAP lesion. FAU - Lee, Shin Jae AU - Lee SJ AD - Department of Radiology, CHA Bundang Medical Center, CHA University, Bundang-gu, Seongnam-si, Korea. FAU - Ha, Doo Hoe AU - Ha DH FAU - Lee, Sang Min AU - Lee SM LA - eng PT - Journal Article DEP - 20100417 PL - Germany TA - Skeletal Radiol JT - Skeletal radiology JID - 7701953 RN - 0 (Contrast Media) RN - 0 (Organometallic Compounds) RN - 0 (Triiodobenzoic Acids) RN - 6HG8UB2MUY (Meglumine) RN - L0ND3981AG (gadoterate meglumine) RN - N3RIB7X24K (ioversol) RN - RLM74T3Z9D (gadoversetamide) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Contrast Media/administration & dosage MH - Female MH - Humans MH - Humerus/*abnormalities MH - Ligaments, Articular/*abnormalities MH - Magnetic Resonance Imaging/*methods MH - Male MH - Meglumine/administration & dosage MH - Middle Aged MH - Organometallic Compounds/administration & dosage MH - Pectoralis Muscles/*abnormalities MH - Retrospective Studies MH - Rotator Cuff/*abnormalities MH - Triiodobenzoic Acids/administration & dosage EDAT- 2010/04/20 06:00 MHDA- 2011/02/05 06:00 CRDT- 2010/04/20 06:00 PHST- 2009/10/08 00:00 [received] PHST- 2010/03/29 00:00 [accepted] PHST- 2010/01/20 00:00 [revised] PHST- 2010/04/20 06:00 [entrez] PHST- 2010/04/20 06:00 [pubmed] PHST- 2011/02/05 06:00 [medline] AID - 10.1007/s00256-010-0926-0 [doi] PST - ppublish SO - Skeletal Radiol. 2010 Dec;39(12):1205-9. doi: 10.1007/s00256-010-0926-0. Epub 2010 Apr 17. PMID- 8420520 OWN - NLM STAT- MEDLINE DCOM- 19930211 LR - 20180106 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 74 IP - 1 DP - 1993 Jan TI - Effects of TENS and topical skin anesthesia on soleus H-reflex and the concomitant influence of skin/muscle temperature. PG - 48-53 AB - The purpose of this study was to determine, in ten healthy subjects, the extent of soleus motoneuronal excitability during conditions of increased (transcutaneous electrical nerve stimulation [TENS]), decreased (Xylocaine [lidocaine]a anaesthesia) and normal (placebo anaesthesia) cutaneous inputs. Increased cutaneous activity was evoked using a TENS unit, with the two pairs of electrodes placed respectively over the Achilles (S2 dermatome) and tibialis anterior (L5 dermatome) tendons. Experimental and placebo topical anaesthesia were obtained after rubbing Xylocaine (5%) and Vaselineb ointment, respectively, on the skin surface overlying the Achilles tendon. Sets of ten H-responses (Hmax/2) were evoked at a frequency of 1 shock/30s and averaged at regular time intervals before, during and after the testing conditions. The results showed a gradual increase (up to 40% after 20 minutes) of H-reflex amplitude during TENS regardless of whether it was applied on the L5 or S2 dermatome. Furthermore, placebo anesthesia (Vaseline) caused the same gradual facilitatory response (up to 100% after 50 minutes) as that obtained during Xylocaine anaesthesia. Power spectral analysis of the H-responses obtained over time showed that the increase in the peak-to-peak H-response value was accompanied by a shift of the spectral content toward low frequencies. This shift occurred concomitantly with a cooling of the skin overlying the soleus muscle. FAU - Arsenault, A B AU - Arsenault AB AD - School of Rehabilitation, Faculty of Medicine, University of Montreal, Canada. FAU - Bélanger, A Y AU - Bélanger AY FAU - Durand, M J AU - Durand MJ FAU - De Serres, S J AU - De Serres SJ FAU - Fortin, L AU - Fortin L FAU - Kemp, F AU - Kemp F LA - eng PT - Clinical Trial PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 98PI200987 (Lidocaine) SB - IM MH - Administration, Topical MH - Adult MH - *Anesthesia, Local MH - Body Temperature MH - Female MH - H-Reflex/*physiology MH - Humans MH - Leg MH - Lidocaine/administration & dosage MH - Male MH - Muscle Contraction/*physiology MH - Skin Temperature MH - *Transcutaneous Electric Nerve Stimulation EDAT- 1993/01/01 00:00 MHDA- 1993/01/01 00:01 CRDT- 1993/01/01 00:00 PHST- 1993/01/01 00:00 [pubmed] PHST- 1993/01/01 00:01 [medline] PHST- 1993/01/01 00:00 [entrez] AID - 0003-9993(93)90382-K [pii] PST - ppublish SO - Arch Phys Med Rehabil. 1993 Jan;74(1):48-53. PMID- 26222558 OWN - NLM STAT- MEDLINE DCOM- 20150814 LR - 20220409 IS - 1533-4406 (Electronic) IS - 0028-4793 (Linking) VI - 373 IP - 5 DP - 2015 Jul 30 TI - Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. PG - 428-37 LID - 10.1056/NEJMoa1411366 [doi] AB - BACKGROUND: Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors. This observation has led to the discovery and clinical development of therapy targeting the CSF1 receptor (CSF1R). METHODS: Using x-ray co-crystallography to guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps the kinase in the autoinhibited conformation. We then conducted a multicenter, phase 1 trial in two parts to analyze this compound. In the first part, we evaluated escalations in the dose of PLX3397 that was administered orally in patients with solid tumors (dose-escalation study). In the second part, we evaluated PLX3397 at the chosen phase 2 dose in an extension cohort of patients with tenosynovial giant-cell tumors (extension study). Pharmacokinetic and tumor responses in the enrolled patients were assessed, and CSF1 in situ hybridization was performed to confirm the mechanism of action of PLX3397 and that the pattern of CSF1 expression was consistent with the pathological features of tenosynovial giant-cell tumor. RESULTS: A total of 41 patients were enrolled in the dose-escalation study, and an additional 23 patients were enrolled in the extension study. The chosen phase 2 dose of PLX3397 was 1000 mg per day. In the extension study, 12 patients with tenosynovial giant-cell tumors had a partial response and 7 patients had stable disease. Responses usually occurred within the first 4 months of treatment, and the median duration of response exceeded 8 months. The most common adverse events included fatigue, change in hair color, nausea, dysgeusia, and periorbital edema; adverse events rarely led to discontinuation of treatment. CONCLUSIONS: Treatment of tenosynovial giant-cell tumors with PLX3397 resulted in a prolonged regression in tumor volume in most patients. (Funded by Plexxikon; ClinicalTrials.gov number, NCT01004861.). FAU - Tap, William D AU - Tap WD AD - From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.). FAU - Wainberg, Zev A AU - Wainberg ZA FAU - Anthony, Stephen P AU - Anthony SP FAU - Ibrahim, Prabha N AU - Ibrahim PN FAU - Zhang, Chao AU - Zhang C FAU - Healey, John H AU - Healey JH FAU - Chmielowski, Bartosz AU - Chmielowski B FAU - Staddon, Arthur P AU - Staddon AP FAU - Cohn, Allen Lee AU - Cohn AL FAU - Shapiro, Geoffrey I AU - Shapiro GI FAU - Keedy, Vicki L AU - Keedy VL FAU - Singh, Arun S AU - Singh AS FAU - Puzanov, Igor AU - Puzanov I FAU - Kwak, Eunice L AU - Kwak EL FAU - Wagner, Andrew J AU - Wagner AJ FAU - Von Hoff, Daniel D AU - Von Hoff DD FAU - Weiss, Glen J AU - Weiss GJ FAU - Ramanathan, Ramesh K AU - Ramanathan RK FAU - Zhang, Jiazhong AU - Zhang J FAU - Habets, Gaston AU - Habets G FAU - Zhang, Ying AU - Zhang Y FAU - Burton, Elizabeth A AU - Burton EA FAU - Visor, Gary AU - Visor G FAU - Sanftner, Laura AU - Sanftner L FAU - Severson, Paul AU - Severson P FAU - Nguyen, Hoa AU - Nguyen H FAU - Kim, Marie J AU - Kim MJ FAU - Marimuthu, Adhirai AU - Marimuthu A FAU - Tsang, Garson AU - Tsang G FAU - Shellooe, Rafe AU - Shellooe R FAU - Gee, Carolyn AU - Gee C FAU - West, Brian L AU - West BL FAU - Hirth, Peter AU - Hirth P FAU - Nolop, Keith AU - Nolop K FAU - van de Rijn, Matt AU - van de Rijn M FAU - Hsu, Henry H AU - Hsu HH FAU - Peterfy, Charles AU - Peterfy C FAU - Lin, Paul S AU - Lin PS FAU - Tong-Starksen, Sandra AU - Tong-Starksen S FAU - Bollag, Gideon AU - Bollag G LA - eng SI - ClinicalTrials.gov/NCT01004861 PT - Clinical Trial, Phase I PT - Clinical Trial, Phase II PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 RN - 0 (Aminopyridines) RN - 0 (Pyrroles) RN - 6783M2LV5X (pexidartinib) RN - EC 2.7.10.1 (Receptor, Macrophage Colony-Stimulating Factor) SB - IM CIN - N Engl J Med. 2015 Jul 30;373(5):402-3. doi: 10.1056/NEJMp1503567. PMID: 26222556 CIN - Lancet. 2019 Aug 10;394(10197):446-448. doi: 10.1016/S0140-6736(19)30947-X. PMID: 31229239 MH - Adult MH - Aged MH - Aminopyridines/*administration & dosage/adverse effects/pharmacokinetics MH - Crystallography, X-Ray MH - Dose-Response Relationship, Drug MH - Drug Discovery MH - Female MH - Giant Cell Tumors/*drug therapy/pathology MH - Humans MH - Male MH - Middle Aged MH - Pyrroles/*administration & dosage/adverse effects/pharmacokinetics MH - Receptor, Macrophage Colony-Stimulating Factor/*antagonists & inhibitors/metabolism MH - Soft Tissue Neoplasms/*drug therapy/pathology MH - Tendons/pathology MH - Tumor Burden EDAT- 2015/07/30 06:00 MHDA- 2015/08/15 06:00 CRDT- 2015/07/30 06:00 PHST- 2015/07/30 06:00 [entrez] PHST- 2015/07/30 06:00 [pubmed] PHST- 2015/08/15 06:00 [medline] AID - 10.1056/NEJMoa1411366 [doi] PST - ppublish SO - N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366. PMID- 39833604 OWN - NLM STAT- MEDLINE DCOM- 20250421 LR - 20250424 IS - 1179-6901 (Electronic) IS - 1174-5886 (Print) IS - 1174-5886 (Linking) VI - 25 IP - 1 DP - 2025 Mar TI - Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases. PG - 35-55 LID - 10.1007/s40268-024-00499-x [doi] AB - INTRODUCTION: In November 2018, the European Medicines Agency (EMA) restricted the use of fluoroquinolones (used by mouth, injections or inhalation) in the context of a referral due to long-lasting and potentially irreversible adverse drug reactions (ADRs). Fluoroquinolones should no longer be used to treat mild or moderate bacterial infections unless other antibacterials cannot be used. OBJECTIVES: The first aim of our study was to analyze whether in the period before compared with after the referral the characteristics of spontaneous ADR reports related to fluoroquinolones differed and whether specific ADRs were more frequently reported for fluoroquinolones compared with cotrimoxazole. Secondly, we analyzed whether the ADR profile differed between individual fluoroquinolones. Finally, the number of fluoroquinolone reports was considered in relation to the number of outpatient drug prescriptions. METHODS: All spontaneous ADR reports from Germany received before the referral (01/2014-12/2019) and after the referral (01/2020-12/2022) for adults in which fluoroquinolones (n = 2575; n = 967) or cotrimoxazole (n = 299, n = 275) were reported as suspected/interacting were identified in the European ADR database, EudraVigilance. The ADR reports were descriptively analyzed concerning the reported characteristics. Odds ratios (ORs) and their 95% confidence intervals (CIs) were estimated by logistic regression analyses, which were performed to investigate whether aortic aneurysms, retinal detachments, cardiac arrhythmias, peripheral polyneuropathies, nervous system disorders, toxic liver diseases and non-traumatic injuries of muscles, tendons and synovialis were more frequently reported for fluoroquinolones compared with cotrimoxazole. Stratified analyses between fluoroquinolones were conducted by calculating ORs and their 95% CIs by using two-by-two tables. Reporting rates were calculated by dividing the number of fluoroquinolone reports by the number of fluoroquinolone prescriptions. RESULTS: Reporting rates of fluoroquinolones clearly increased until 2019 and decreased afterward. Only minor differences in the characteristics of fluoroquinolone reports (e.g., regarding the indications) were observed in reports received before and after the referral. In both periods, peripheral neuropathies, nervous system, and muscle and tendon disorders were more often reported for fluoroquinolones than cotrimoxazole. In the pooled fluoroquinolone-stratified analyses, (i) peripheral neuropathies and nervous system disorders were more frequently reported for ciprofloxacin, (ii) non-traumatic injuries of muscle, tendon, and synovialis were more often reported for levofloxacin, and (iii) cardiac arrhythmias and toxic liver diseases were more frequently reported for moxifloxacin compared with the other fluoroquinolones. CONCLUSION: In accordance with a reminder sent by the EMA referring to prescribing trends for fluoroquinolones, our study showed that the characteristics of spontaneous ADR reports for fluoroquinolones after the referral were similar to those before the referral, underlining the importance of adhering to the recommended restrictions issued by the EMA. In addition, we observed individual differences between ciprofloxacin, levofloxacin, and moxifloxacin with regard to their ADR profile. Further studies are needed to confirm our results. CI - © 2024. The Author(s). FAU - Dubrall, Diana AU - Dubrall D AUID- ORCID: 0000-0002-8763-051X AD - Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. Diana.Dubrall@bfarm.de. AD - Research Division, Federal Institute of Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. Diana.Dubrall@bfarm.de. FAU - Wicherski, Julia AU - Wicherski J AUID- ORCID: 0000-0001-9630-6239 AD - Research Division, Federal Institute of Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. FAU - Below, Maike AU - Below M AD - Central Research Institute for Ambulatory Health Care in Germany, Salzufer 8, 10587, Berlin, Germany. FAU - Görtzen-Patin, Jan AU - Görtzen-Patin J AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Venusberg-campus 1, 53127, Bonn, Germany. AD - Staff Unit for Medical and Scientific Technology Development and Coordination (MWTek), University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Schmid, Matthias AU - Schmid M AUID- ORCID: 0000-0002-0788-0317 AD - Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Zenker, Sven AU - Zenker S AUID- ORCID: 0000-0003-0774-0725 AD - Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. AD - Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, Venusberg-campus 1, 53127, Bonn, Germany. AD - Staff Unit for Medical and Scientific Technology Development and Coordination (MWTek), University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Haenisch, Britta AU - Haenisch B AUID- ORCID: 0000-0002-4828-6058 AD - Research Division, Federal Institute of Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) e. V., Venusberg-Campus 1/99, 53127, Bonn, Germany. AD - Germany Center for Translational Medicine, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. FAU - Sachs, Bernhardt AU - Sachs B AUID- ORCID: 0000-0001-8260-0891 AD - Research Division, Federal Institute of Drugs and Medical Devices (BfArM), Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. AD - Department for Dermatology and Allergy, University Hospital RWTH Aachen, Morillenhang 27, 52074, Aachen, Germany. LA - eng GR - V-2020.2/68502/2020-2024/Bundesinstitut für Arzneimittel und Medizinprodukte/ GR - V-2020.2/68502/2020-2024/University Hospital Bonn/ PT - Journal Article DEP - 20250121 PL - New Zealand TA - Drugs R D JT - Drugs in R&D JID - 100883647 RN - 0 (Fluoroquinolones) RN - 0 (Anti-Bacterial Agents) RN - 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination) SB - IM MH - Humans MH - *Fluoroquinolones/adverse effects MH - *Anti-Bacterial Agents/adverse effects MH - Male MH - Middle Aged MH - Female MH - *Adverse Drug Reaction Reporting Systems/statistics & numerical data MH - Adult MH - Referral and Consultation MH - Germany/epidemiology MH - Aged MH - Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects MH - *Drug-Related Side Effects and Adverse Reactions/epidemiology MH - Pharmacovigilance MH - Databases, Factual PMC - PMC12011694 COIS- Declarations. Funding: ANKA is funded by own resources from the German Federal Institute for Drugs and Medical Devices’ (BfArM) and the Institute for Medical Biometry, Informatics, and Epidemiology (IMBIE), University Hospital Bonn, Germany (V-2020.2/68502/2020-2024). The data provisioning services provided by the data integration center (DIC) Bonn were created with and/or are currently supported, in part, via funding by the Federal Ministry of Education and Science (BMBF) under grant numbers (FKZ): 01ZZ1602C, 01ZZ1803Q, 01ZZ2303G, and 01KX2121. Competing interests: DD and MS are supported by the ANKA project, which is founded by the Federal Institute for Drugs and Medical Devices and the Institute for Medical Biometry, Informatics and Epidemiology at the University Hospital Bonn. Ethics approval: The ethics committee of the Medical Faculty of Bonn waved the need for approval since this is not required for retrospective analyses based on pseudonymized spontaneous reports from EudraVigilance and clinical routine data from the University Hospital Bonn and stated that fthere are no ethical concerns (file no. 458/20 and 100/21). Thus, consent to participate is not required and was not obtained. Consent to participate: Not applicable. Consent for publication: Not applicable. Availability of data and materials: The pseudonymized ADR reports from EudraVigilance are not publicly accessible due to data protection requirements. Distinct levels of access are provided for various stakeholders ( https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/access-eudravigilance-data ). Being one of the competent authorities in Germany, the highest level of access is granted to the Federal Institute for Drugs and Medical Devices (BfArM). Nevertheless, even with the lowest access level, researchers can perform the same analysis in EudraVigilance (EV) with aggregated data (public access: http://www.adrreports.eu/en/index.html ). For further information regarding processing personal data in the context of the operation of EudraVigilance Human we refer to the European Medicines Agency’s Data Protection Notice for EudraVigilance Human. Code availability: Not applicable. Author's contributions: DD, JW, BH, and BS contributed to the conception and design of the study. DD selected the statistical methods, performed the analysis and created all tables and figures. The results were discussed by all authors. The first draft of the manuscript was written by DD. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. EDAT- 2025/01/21 09:02 MHDA- 2025/04/21 12:28 PMCR- 2025/01/21 CRDT- 2025/01/20 23:32 PHST- 2024/11/03 00:00 [accepted] PHST- 2025/04/21 12:28 [medline] PHST- 2025/01/21 09:02 [pubmed] PHST- 2025/01/20 23:32 [entrez] PHST- 2025/01/21 00:00 [pmc-release] AID - 10.1007/s40268-024-00499-x [pii] AID - 499 [pii] AID - 10.1007/s40268-024-00499-x [doi] PST - ppublish SO - Drugs R D. 2025 Mar;25(1):35-55. doi: 10.1007/s40268-024-00499-x. Epub 2025 Jan 21. PMID- 21393261 OWN - NLM STAT- MEDLINE DCOM- 20111207 LR - 20220331 IS - 1473-0480 (Electronic) IS - 0306-3674 (Linking) VI - 45 IP - 5 DP - 2011 Apr TI - Sclerosing polidocanol injections or arthroscopic shaving to treat patellar tendinopathy/jumper's knee? A randomised controlled study. PG - 411-5 LID - 10.1136/bjsm.2010.082446 [doi] AB - BACKGROUND: Proximal patellar tendinopathy/jumper's knee (PT/JK) is well known to be difficult to treat. Recent studies using an ultrasound and colour Doppler-based treatment approach on the dorsal side of the tendon, sclerosing polidocanol injections and ultrasound-guided arthroscopic shaving, have shown promising clinical results. OBJECTIVES: To compare the clinical effects after treatment with sclerosing polidocanol injections and arthroscopic shaving. MATERIAL AND METHODS: 52 patellar tendons (43 men and two women) with ultrasound and colour Doppler-verified diagnosis of PT/JK were randomly assigned to treatment with ultrasound and colour Doppler-guided sclerosing polidocanol injections (group A) or ultrasound and colour Doppler-guided arthroscopic shaving (group B). All patients were involved in patellar tendon loading sports or recreational activities, and had had a long duration of pain symptoms from the proximal patellar tendon. Pain during patellar tendon loading activity, and at rest, before and after treatment (visual analogue scale; VAS), and patient satisfaction with the result of the treatment, was registered. RESULTS: After treatment, the patients treated with arthroscopic shaving had a significantly lower VAS score at rest and during activity, and were significantly more satisfied compared with the patients in the sclerosing injection group. CONCLUSIONS: Both treatment with ultrasound and colour Doppler-guided sclerosing polidocanol injections and arthroscopic shaving showed good clinical results, but patients treated with arthroscopic shaving had less pain and were more satisfied with the treatment result. Because surgical treatment is a one-stage treatment return to sports was faster in this group. FAU - Willberg, Lotta AU - Willberg L AD - Capio Artro Clinic, Stockholm Sports Trauma Research Centre, Karolinska Institutet, Stockholm, Sweden. lotta.willberg@capio.se FAU - Sunding, Kerstin AU - Sunding K FAU - Forssblad, Magnus AU - Forssblad M FAU - Fahlström, Martin AU - Fahlström M FAU - Alfredson, Håkan AU - Alfredson H LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adolescent MH - Adult MH - Arthroscopy/*methods MH - Chronic Disease MH - Female MH - Humans MH - Male MH - *Patellar Ligament MH - Polidocanol MH - Polyethylene Glycols/*administration & dosage MH - Recovery of Function MH - Sclerosing Solutions/*administration & dosage MH - Tendinopathy/*therapy MH - *Track and Field MH - Treatment Outcome MH - Ultrasonography, Doppler, Color MH - Ultrasonography, Interventional MH - Young Adult EDAT- 2011/03/12 06:00 MHDA- 2011/12/13 00:00 CRDT- 2011/03/12 06:00 PHST- 2011/03/12 06:00 [entrez] PHST- 2011/03/12 06:00 [pubmed] PHST- 2011/12/13 00:00 [medline] AID - 45/5/411 [pii] AID - 10.1136/bjsm.2010.082446 [doi] PST - ppublish SO - Br J Sports Med. 2011 Apr;45(5):411-5. doi: 10.1136/bjsm.2010.082446. PMID- 18359821 OWN - NLM STAT- MEDLINE DCOM- 20080611 LR - 20131121 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 36 IP - 6 DP - 2008 Jun TI - Topical glyceryl trinitrate and noninsertional Achilles tendinopathy: a clinical and cellular investigation. PG - 1160-3 LID - 10.1177/0363546508314423 [doi] AB - BACKGROUND: Topical glyceryl trinitrate (GTN) therapy has been advocated in the treatment of Achilles tendinopathy. The mechanism of action is unknown but may be related to modulation of local nitric oxide levels. HYPOTHESIS: Topical GTN therapy for noninsertional Achilles tendinopathy will significantly enhance clinical improvement and will be associated with increased collagen synthesis within the tendon. STUDY DESIGN: Randomized controlled clinical trial; Level of evidence, 1. METHODS: Forty patients were recruited. Twenty underwent standard nonoperative physical therapy, and 20 underwent physical therapy and topical GTN daily. Clinical outcome was assessed using the Ankle Osteoarthritis Scale (AOS) visual analog score. Patients who failed to improve with conservative measures and who underwent surgical decompression had histological and immunohistochemical examination of samples from the Achilles tendon. RESULTS: Glyceryl trinitrate did not offer any additional clinical benefit over standard nonoperative treatment for noninsertional Achilles tendinopathy. After 6 months of treatment, there was no significant difference in scores between the groups for pain (3.0 vs 3.1, P = .42) or disability (2.15 vs 2.25, P = .38). Histological examination did not show any difference in neovascularization, collagen synthesis, or stimulated fibroblasts between the 2 groups. There was no evidence of modulation of nitric oxide synthase, a marker of nitric oxide production, in those tendons treated with GTN. CONCLUSION AND CLINICAL RELEVANCE: This study has failed to support the clinical benefit of GTN patches previously described in the literature. In the available tissue samples, there did not appear to be any histological or immunohistochemical change in Achilles tendinopathy treated with GTN compared with those undergoing standard nonoperative therapy. FAU - Kane, Timothy P C AU - Kane TP AD - North Hampshire Hospital, Basingstoke, Hampshire, United Kingdom. kanetimothy@yahoo.com FAU - Ismail, Muhammad AU - Ismail M FAU - Calder, James D F AU - Calder JD LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20080321 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - *Achilles Tendon/pathology MH - Administration, Topical MH - Adult MH - Aged MH - Combined Modality Therapy MH - Humans MH - Middle Aged MH - Nitroglycerin/*administration & dosage MH - Physical Therapy Modalities MH - Statistics, Nonparametric MH - Tendinopathy/*drug therapy/pathology/rehabilitation EDAT- 2008/03/25 09:00 MHDA- 2008/06/12 09:00 CRDT- 2008/03/25 09:00 PHST- 2008/03/25 09:00 [pubmed] PHST- 2008/06/12 09:00 [medline] PHST- 2008/03/25 09:00 [entrez] AID - 0363546508314423 [pii] AID - 10.1177/0363546508314423 [doi] PST - ppublish SO - Am J Sports Med. 2008 Jun;36(6):1160-3. doi: 10.1177/0363546508314423. Epub 2008 Mar 21. PMID- 30850078 OWN - NLM STAT- MEDLINE DCOM- 20190320 LR - 20190320 IS - 1558-1373 (Electronic) IS - 0030-5898 (Linking) VI - 50 IP - 2 DP - 2019 Apr TI - Osteogenesis Imperfecta: A Pediatric Orthopedic Perspective. PG - 193-209 LID - S0030-5898(18)30177-9 [pii] LID - 10.1016/j.ocl.2018.10.003 [doi] AB - Osteogenesis imperfecta is a genetically and phenotypically heterogeneous disorder related to a defect or deficiency in the production of type I collagen. It is characterized by brittle bones, fractures, spine and extremity deformity, and a host of extraskeletal manifestations. Type I collagen is present in bone, tendons, ligaments, skin, dentin, and the sclera of the eye and other connective tissues. Osteogenesis imperfecta includes a multitude of disease manifestations that may be present at birth or develop over time and vary depending on the severity of the disease. This article describes the disease presentation and management considerations from a pediatric orthopedic perspective. CI - Copyright © 2018 Elsevier Inc. All rights reserved. FAU - Franzone, Jeanne M AU - Franzone JM AD - Department of Orthopaedic Surgery, Nemours Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA. Electronic address: Jeanne.Franzone@nemours.org. FAU - Shah, Suken A AU - Shah SA AD - Department of Orthopaedic Surgery, Nemours Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA. FAU - Wallace, Maegen J AU - Wallace MJ AD - Department of Orthopaedic Surgery, University of Nebraska Medical Center, Children's Hospital and Medical Center, 8200 Dodge Street, Omaha, NE 68114, USA. FAU - Kruse, Richard W AU - Kruse RW AD - Department of Orthopaedic Surgery, Nemours Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Orthop Clin North Am JT - The Orthopedic clinics of North America JID - 0254463 RN - 0 (Diphosphonates) RN - 1406-16-2 (Vitamin D) RN - SY7Q814VUP (Calcium) SB - IM MH - Adolescent MH - Bone Diseases, Developmental/*genetics/pathology/physiopathology MH - Calcium/administration & dosage/therapeutic use MH - Child MH - Child, Preschool MH - Diphosphonates/administration & dosage/therapeutic use MH - Exercise/physiology MH - Female MH - Foot Orthoses/standards MH - Fractures, Bone/complications/therapy MH - Humans MH - Infant MH - Interdisciplinary Communication MH - Limb Deformities, Congenital/*diagnosis/etiology/surgery/therapy MH - Male MH - Osteogenesis Imperfecta/*diagnosis/drug therapy/*genetics/pathology MH - Scoliosis/pathology/surgery MH - Spine/abnormalities/pathology MH - Vitamin D/therapeutic use OTO - NOTNLM OT - Brittle bones OT - Extremity deformity OT - Osteogenesis imperfecta OT - Spine deformity EDAT- 2019/03/10 06:00 MHDA- 2019/03/21 06:00 CRDT- 2019/03/10 06:00 PHST- 2019/03/10 06:00 [entrez] PHST- 2019/03/10 06:00 [pubmed] PHST- 2019/03/21 06:00 [medline] AID - S0030-5898(18)30177-9 [pii] AID - 10.1016/j.ocl.2018.10.003 [doi] PST - ppublish SO - Orthop Clin North Am. 2019 Apr;50(2):193-209. doi: 10.1016/j.ocl.2018.10.003. PMID- 18446422 OWN - NLM STAT- MEDLINE DCOM- 20080626 LR - 20250623 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 466 IP - 7 DP - 2008 Jul TI - Treatment of tendinopathy: what works, what does not, and what is on the horizon. PG - 1539-54 LID - 10.1007/s11999-008-0260-1 [doi] AB - Tendinopathy is a broad term encompassing painful conditions occurring in and around tendons in response to overuse. Recent basic science research suggests little or no inflammation is present in these conditions. Thus, traditional treatment modalities aimed at controlling inflammation such as corticosteroid injections and nonsteroidal antiinflammatory medications (NSAIDS) may not be the most effective options. We performed a systematic review of the literature to determine the best treatment options for tendinopathy. We evaluated the effectiveness of NSAIDS, corticosteroid injections, exercise-based physical therapy, physical therapy modalities, shock wave therapy, sclerotherapy, nitric oxide patches, surgery, growth factors, and stem cell treatment. NSAIDS and corticosteroids appear to provide pain relief in the short term, but their effectiveness in the long term has not been demonstrated. We identified inconsistent results with shock wave therapy and physical therapy modalities such as ultrasound, iontophoresis and low-level laser therapy. Current data support the use of eccentric strengthening protocols, sclerotherapy, and nitric oxide patches, but larger, multicenter trials are needed to confirm the early results with these treatments. Preliminary work with growth factors and stem cells is promising, but further study is required in these fields. Surgery remains the last option due to the morbidity and inconsistent outcomes. The ideal treatment for tendinopathy remains unclear. LEVEL OF EVIDENCE: Level II, systematic review. FAU - Andres, Brett M AU - Andres BM AD - Orthopaedic Research Institute, St George Hospital, University of New South Wales, Level 2 Research and Education Building, 4-10 South Street, Kogarah, Sydney, NSW, 2217, Australia. bandres@yahoo.com FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Journal Article PT - Systematic Review DEP - 20080430 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Glucocorticoids) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Combined Modality Therapy MH - Glucocorticoids/therapeutic use MH - Humans MH - Intercellular Signaling Peptides and Proteins/therapeutic use MH - Nitroglycerin/administration & dosage MH - Orthopedic Procedures MH - Physical Therapy Modalities MH - Sclerotherapy MH - Stem Cell Transplantation MH - Tendinopathy/*therapy MH - Ultrasonic Therapy PMC - PMC2505250 EDAT- 2008/05/01 09:00 MHDA- 2008/06/27 09:00 PMCR- 2009/07/01 CRDT- 2008/05/01 09:00 PHST- 2007/12/20 00:00 [received] PHST- 2008/04/03 00:00 [accepted] PHST- 2008/05/01 09:00 [pubmed] PHST- 2008/06/27 09:00 [medline] PHST- 2008/05/01 09:00 [entrez] PHST- 2009/07/01 00:00 [pmc-release] AID - 260 [pii] AID - 10.1007/s11999-008-0260-1 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2008 Jul;466(7):1539-54. doi: 10.1007/s11999-008-0260-1. Epub 2008 Apr 30. PMID- 10796930 OWN - NLM STAT- MEDLINE DCOM- 20000523 LR - 20211203 IS - 0033-8419 (Print) IS - 0033-8419 (Linking) VI - 215 IP - 2 DP - 2000 May TI - Direct MR arthrography of the shoulder: is exercise prior to imaging beneficial or detrimental? PG - 491-6 AB - PURPOSE: To define the beneficial and detrimental effects of adding exercise to direct magnetic resonance (MR) shoulder arthrography. MATERIALS AND METHODS: Direct, intraarticular, gadolinium arthrography of the shoulder was performed in 41 patients, who underwent 1.5-T MR imaging before and after 1 minute of arm swinging. Fourteen milliliters of dilute gadolinium solution was injected. Two readers blinded to exercise independently graded the randomly distributed images with a five-point scale for capsular contrast material resorption; extraarticular contrast material leakage; rotator cuff, glenoid labrum, and anterior capsule conspicuity; and partial-thickness or full-thickness rotator cuff tear and labral tear detectability. The sign test was performed to evaluate the significance of differences between preexercise and postexercise grading for each reader. A second review was performed, with direct side-by-side comparison of preexercise and postexercise images. RESULTS: There was evidence of increased capsular resorption after exercise but no alteration in the depiction of the rotator cuff tendons or glenoid labrum. There was no significant extraarticular contrast material leakage after exercise and no alteration in depiction of the anterior capsule. There was no difference in the detectability of rotator cuff or labral tears. CONCLUSION: Exercise with direct shoulder MR arthrography has no beneficial or detrimental effect on image quality or on the depiction of rotator cuff or labral tears. FAU - Brenner, M L AU - Brenner ML AD - Department of Radiology, Orthopedic Surgery, Wilford Hall Medical Center, 759th MDTS/MTRD, 2200 Bergquist Dr, Suite 1, Lackland AFB, TX 78236-5300, USA. FAU - Morrison, W B AU - Morrison WB FAU - Carrino, J A AU - Carrino JA FAU - Nusser, C A AU - Nusser CA FAU - Sanders, T G AU - Sanders TG FAU - Howard, R F AU - Howard RF FAU - Meier, P AU - Meier P LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Contrast Media) RN - K2I13DR72L (Gadolinium DTPA) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Contrast Media/administration & dosage MH - Extravasation of Diagnostic and Therapeutic Materials MH - Female MH - Gadolinium DTPA/administration & dosage MH - Humans MH - Image Enhancement/methods MH - Injections, Intra-Articular MH - Joint Capsule/pathology MH - *Magnetic Resonance Imaging/methods MH - Male MH - Middle Aged MH - Physical Exertion/*physiology MH - Retrospective Studies MH - Rotator Cuff/pathology MH - Rotator Cuff Injuries MH - Scapula/pathology MH - Shoulder Injuries MH - Shoulder Joint/*pathology MH - Single-Blind Method EDAT- 2000/05/05 09:00 MHDA- 2000/06/08 09:00 CRDT- 2000/05/05 09:00 PHST- 2000/05/05 09:00 [pubmed] PHST- 2000/06/08 09:00 [medline] PHST- 2000/05/05 09:00 [entrez] AID - 10.1148/radiology.215.2.r00ma14491 [doi] PST - ppublish SO - Radiology. 2000 May;215(2):491-6. doi: 10.1148/radiology.215.2.r00ma14491. PMID- 21458143 OWN - NLM STAT- MEDLINE DCOM- 20110815 LR - 20220409 IS - 1879-291X (Electronic) IS - 0301-5629 (Linking) VI - 37 IP - 5 DP - 2011 May TI - Ultrasound-guided injection for the biceps brachii tendinitis: results and experience. PG - 729-33 LID - 10.1016/j.ultrasmedbio.2011.02.014 [doi] AB - The purpose of this study was to identify the results of ultrasound-guided injection of corticosteroid for biceps brachii tendinitis. In this randomized and prospective study, we evaluated 45 patients who were treated by free-hand injection without ultrasound guidance (group A) and 53 patients who were treated by ultrasound-guided injection (group B). The mean age was 47 y (range, 28 to 72). The average follow-up was 33 weeks (range, 24 to 56). The visual analog scale score decreased from 7.1 ± 2.3 before injection to 4.2 ± 3.1 at follow-up in group A and from 6.9 ± 2.6 to 2.1 ± 1.9 in group B (p < 0.05). The Constant-Murley score improved from 31.4 ± 11.6 before injection to 73.5 ± 19.2 at follow-up in group A and from 32.5 ± 14.7 to 85.5 ± 10.3 (p < 0.01). The ultrasound-guided injection therefore demonstrated a statistically significantly greater degree of pain relief. However, the outcome of injection was not satisfactory for the patients who demonstrated severely frayed tendons at arthroscopy. There were no complications related to the injection in both groups. Corticosteroid injection under ultrasound guidance is a safe and well-tolerated procedure with a satisfactory rate of symptom relief in patients with biceps brachii tendinitis. CI - Copyright © 2011 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved. FAU - Zhang, Jingwei AU - Zhang J AD - Department of Orthopaedic Surgery, Sixth Hospital of Ningbo, China. awei3@sohu.com FAU - Ebraheim, Nabil AU - Ebraheim N FAU - Lause, Gregory E AU - Lause GE LA - eng PT - Clinical Trial PT - Journal Article DEP - 20110331 PL - England TA - Ultrasound Med Biol JT - Ultrasound in medicine & biology JID - 0410553 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - Aged MH - Anesthetics, Local/administration & dosage/pharmacology MH - Female MH - Follow-Up Studies MH - Humans MH - Lidocaine/*administration & dosage/pharmacology MH - Male MH - Middle Aged MH - Prospective Studies MH - Shoulder Injuries MH - *Shoulder Joint/diagnostic imaging/drug effects MH - Tendinopathy/*therapy MH - *Ultrasonography, Interventional EDAT- 2011/04/05 06:00 MHDA- 2011/08/16 06:00 CRDT- 2011/04/05 06:00 PHST- 2010/12/02 00:00 [received] PHST- 2011/02/16 00:00 [revised] PHST- 2011/02/21 00:00 [accepted] PHST- 2011/04/05 06:00 [entrez] PHST- 2011/04/05 06:00 [pubmed] PHST- 2011/08/16 06:00 [medline] AID - S0301-5629(11)00109-8 [pii] AID - 10.1016/j.ultrasmedbio.2011.02.014 [doi] PST - ppublish SO - Ultrasound Med Biol. 2011 May;37(5):729-33. doi: 10.1016/j.ultrasmedbio.2011.02.014. Epub 2011 Mar 31. PMID- 24346815 OWN - NLM STAT- MEDLINE DCOM- 20140401 LR - 20220331 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 32 IP - 4 DP - 2014 Apr TI - Enhancement of Achilles tendon repair mediated by matrix metalloproteinase inhibition via systemic administration of doxycycline. PG - 500-6 LID - 10.1002/jor.22564 [doi] AB - Collagenases or matrix metalloproteinases (MMPs) have been shown to play an important role in the matrix degradation cascade associated with Achilles tendon rupture and disease. The goal of this study was to examine the effects of daily administration of doxycycline (Doxy) through oral gavage on MMP activity and on the repair quality of Achilles tendons in vivo. Our findings indicate that Achilles tendon transection resulted in increasing MMP-8 activity from 2 to 6 weeks post-injury, with peak increases in activity occurring at 4 weeks post-injury. Doxy adiministration at clinically relevant serum concentrations was found to significantly inhibit MMP activity after continuous treatment for 4 weeks, but not for continuous administration for shorter durations (96 h or 2 weeks). Extended doxy administration was also associated with improved collagen fibril organization, and enhanced biomechanical properties (stiffness, ultimate tensile strength, maximum load to failure, and elastic toughness). Our findings indicate that a temporal delay exists between Achilles tendon transection and associated increases in MMP-8 activity in situ. Our findings suggest that inhibition of MMP-8 at its peak activity levels ameliorates fibrosis development and improves biomechanical properties of the Achilles tendon. CI - © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Kessler, Michael W AU - Kessler MW AD - Orthopaedic Research Lab, The Feinstein Institute for Medical Research, Manhasset, New York; Georgetown University Hospital, Washington, District of Columbia. FAU - Barr, Jerome AU - Barr J FAU - Greenwald, Robert AU - Greenwald R FAU - Lane, Lewis B AU - Lane LB FAU - Dines, Joshua S AU - Dines JS FAU - Dines, David M AU - Dines DM FAU - Drakos, Mark C AU - Drakos MC FAU - Grande, Daniel A AU - Grande DA FAU - Chahine, Nadeen O AU - Chahine NO LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131218 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.34 (Matrix Metalloproteinase 8) RN - N12000U13O (Doxycycline) SB - IM MH - Achilles Tendon/drug effects/injuries/*surgery MH - Administration, Oral MH - Animals MH - Collagen/metabolism MH - Doxycycline/*administration & dosage MH - Male MH - Matrix Metalloproteinase 8/*metabolism MH - Matrix Metalloproteinase Inhibitors/*administration & dosage MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/*drug therapy MH - Wound Healing/drug effects OTO - NOTNLM OT - achilles tendon OT - doxycycline OT - matrix metalloproteinase OT - tendon rupture and repair EDAT- 2013/12/19 06:00 MHDA- 2014/04/02 06:00 CRDT- 2013/12/19 06:00 PHST- 2013/06/04 00:00 [received] PHST- 2013/11/19 00:00 [accepted] PHST- 2013/12/19 06:00 [entrez] PHST- 2013/12/19 06:00 [pubmed] PHST- 2014/04/02 06:00 [medline] AID - 10.1002/jor.22564 [doi] PST - ppublish SO - J Orthop Res. 2014 Apr;32(4):500-6. doi: 10.1002/jor.22564. Epub 2013 Dec 18. PMID- 8414420 OWN - NLM STAT- MEDLINE DCOM- 19931108 LR - 20190726 IS - 0161-6420 (Print) IS - 0161-6420 (Linking) VI - 100 IP - 10 DP - 1993 Oct TI - Prospective study of sub-Tenon's versus retrobulbar anesthesia for inpatient and day-surgery trabeculectomy. PG - 1585-9 AB - PURPOSE: Several retrospective studies have demonstrated the safety and efficacy of sub-Tenon's anesthesia in ocular surgery. This is the first prospective randomized study comparing sub-Tenon's versus retrobulbar anesthesia for glaucoma surgery. METHODS: Thirty-nine patients undergoing both inpatient and day surgery trabeculectomy were randomized to receive retrobulbar or sub-Tenon's anesthesia. Retrobulbar anesthesia consisted of a 1.5-ml injection of a 1:1 mixture of 2% lidocaine without epinephrine and 0.5% plain bupivacaine with hyaluronidase. Sub-Tenon's anesthesia consisted of 2% lidocaine without epinephrine injected over the superior, medial and lateral recti muscles. Both groups received a van Lint lid block and a standardized sedative. Outcome parameters evaluated included patient demographics, operative complications, intraoperative and postoperative patient comfort, and volume of anesthetic. RESULTS: Seventeen patients were randomized to the retrobulbar group and 22 to the sub-Tenon's group. Patient discomfort was statistically similar between the groups. There was no statistical difference between groups with respect to quantity of sedative received, surgical exposure, eye movements, or operative complications. A retrobulbar hemorrhage, however, developed at the time of retrobulbar anesthesia in one patient, requiring cancellation of surgery. A larger volume of local anesthetic was required in the retrobulbar group versus the sub-Tenon's group (1.8 versus 1.1 ml; P < 0.01). Patients receiving retrobulbar injections were more likely to require additional anesthesia (P < 0.01) and postoperative analgesics (P < 0.05) compared with patients undergoing sub-Tenon's injection. There was no significant difference between the groups with respect to age, sex, or operated eye. CONCLUSIONS: Sub-Tenon's anesthesia is safe and effective for patients undergoing either inpatient or day-surgery trabeculectomies, and it requires less local anesthetic than retrobulbar anesthesia. FAU - Buys, Y M AU - Buys YM AD - Department of Ophthalmology, Toronto Hospital, Ontario, Canada. FAU - Trope, G E AU - Trope GE LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - Ophthalmology JT - Ophthalmology JID - 7802443 RN - 98PI200987 (Lidocaine) RN - EC 3.2.1.35 (Hyaluronoglucosaminidase) RN - Y8335394RO (Bupivacaine) SB - IM MH - Ambulatory Surgical Procedures MH - Anesthesia, Local/*methods MH - Bupivacaine/administration & dosage MH - Female MH - Hospitalization MH - Humans MH - Hyaluronoglucosaminidase/administration & dosage MH - Lidocaine/administration & dosage MH - Male MH - Middle Aged MH - Orbit MH - Postoperative Complications MH - Prospective Studies MH - Tendons MH - *Trabeculectomy MH - Treatment Outcome EDAT- 1993/10/01 00:00 MHDA- 1993/10/01 00:01 CRDT- 1993/10/01 00:00 PHST- 1993/10/01 00:00 [pubmed] PHST- 1993/10/01 00:01 [medline] PHST- 1993/10/01 00:00 [entrez] AID - S0161-6420(93)31440-5 [pii] AID - 10.1016/s0161-6420(93)31440-5 [doi] PST - ppublish SO - Ophthalmology. 1993 Oct;100(10):1585-9. doi: 10.1016/s0161-6420(93)31440-5. PMID- 29769829 OWN - NLM STAT- MEDLINE DCOM- 20190904 LR - 20231112 IS - 1303-2968 (Electronic) IS - 1303-2968 (Linking) VI - 17 IP - 2 DP - 2018 Jun TI - Creatine Supplementation Supports the Rehabilitation of Adolescent Fin Swimmers in Tendon Overuse Injury Cases. PG - 279-288 AB - Our purpose was to investigate the effect of creatine (Cr) supplementation on regeneration periods in tendon overuse injury rehabilitation of adolescent fin swimmers. The participants of this study were injured adolescent competitive fin swimmers (n = 18). The subjects were randomly assigned the creatine (CR) or placebo (PL) groups with a double-blind research design. The subjects were given Cr supplementation or received the placebo as part of the conservative treatment of the tendinopathy. We measured the segmental lean mass (SLM;kg), the ankle plantar flexion peak torque (PFT;N·m), the pain intensity (NRS;values), prior to immobilization, after immobilization (R2) and after the 2nd (R4) and 4th (R6) weeks of the rehabilitation period of the injured limb. The creatine kinase (CK; U/L) enzyme levels were measured before immobilization, and then every 24 hours for four days. There was a significant decrease in SLM (CR by 5.6% vs. PL by 8.9%; p < 0.03) after two weeks of immobilization in both groups (p < 0.001). After four weeks rehabilitation the SLM significantly increased in both groups (CR by 5.5% vs. PL by 3.8%; p < 0.01). The percent changes in PFT after supplementation in R4 (p < 0.001) and R6 (p < 0.03) were significantly different between groups. There was a significant percent increase measured in the CR group (R4 by 10.4%; p < 0.001; R6 by 16.8%; p < 0.001), whereas significant, but lower growth found in the PL group also took place (R4 by 7.1%; p < 0.001; R6 by 14.7%; p < 0.001) after four weeks of rehabilitation. Significantly faster decrease were found in NRS of CR versus PL group during treatment (p < 0.02). We detected significantly lower CK levels increase at the CR group compared to the PL group. The results of this study indicate that Cr supplementation combined with therapeutic strategy effectively supports the rehabilitation of tendon overuse injury of adolescent fin swimmers. FAU - Juhasz, Imre AU - Juhasz I AD - University of Physical Education, School of Doctoral Studies, Hungary. FAU - Kopkane, Judit Plachy AU - Kopkane JP AD - University of Miskolc, Faculty of Health Care, Hungary. FAU - Hajdu, Pal AU - Hajdu P AD - Eszterhazy Karoly University of Applied Sciences, Institute of Sport Sciences, Hungary. FAU - Szalay, Gabor AU - Szalay G AD - Eszterhazy Karoly University of Applied Sciences, Institute of Sport Sciences, Hungary. FAU - Kopper, Bence AU - Kopper B AD - University of Physical Education, Department of Biomechanics, Hungary. FAU - Tihanyi, Jozsef AU - Tihanyi J AD - University of Physical Education, Department of Biomechanics, Hungary. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20180514 PL - Turkey TA - J Sports Sci Med JT - Journal of sports science & medicine JID - 101174629 RN - EC 2.7.3.2 (Creatine Kinase) RN - MU72812GK0 (Creatine) SB - IM MH - Adolescent MH - Child MH - Creatine/*administration & dosage MH - Creatine Kinase/blood MH - Cumulative Trauma Disorders/*rehabilitation MH - Dietary Supplements MH - Double-Blind Method MH - Electric Impedance MH - Female MH - Humans MH - Immobilization MH - Male MH - *Sports Nutritional Physiological Phenomena MH - Swimming/*injuries MH - Tendinopathy/rehabilitation MH - Tendon Injuries/*rehabilitation MH - Tendons MH - Torque PMC - PMC5950745 OTO - NOTNLM OT - Tendinopathy OT - pain OT - therapeutic strategy EDAT- 2018/05/18 06:00 MHDA- 2019/09/05 06:00 PMCR- 2018/05/14 CRDT- 2018/05/18 06:00 PHST- 2018/01/22 00:00 [received] PHST- 2018/04/10 00:00 [accepted] PHST- 2018/05/18 06:00 [entrez] PHST- 2018/05/18 06:00 [pubmed] PHST- 2019/09/05 06:00 [medline] PHST- 2018/05/14 00:00 [pmc-release] AID - jssm-17-279 [pii] PST - epublish SO - J Sports Sci Med. 2018 May 14;17(2):279-288. eCollection 2018 Jun. PMID- 19944642 OWN - NLM STAT- MEDLINE DCOM- 20100730 LR - 20161125 IS - 1878-1861 (Electronic) IS - 1878-1861 (Linking) VI - 13 IP - 3 DP - 2010 May TI - The short-term effects of high volume image guided injections in resistant non-insertional Achilles tendinopathy. PG - 295-8 LID - 10.1016/j.jsams.2009.09.007 [doi] AB - We investigated neovascularisation, tendon thickness and clinical function in chronic resistant Achilles tendinopathy following high volume image guided injections (HVIGI). The subjects involved 11 athletes (mean age 43.5 years+/-11.6, range 22-59) with resistant tendinopathy of the main body of the Achilles tendon for a mean of 51.4 months (+/-55.56, range 4-144) who failed to improve with an eccentric loading program (mean 11.8 months+/-2.6, range 8-16). The morphological features, neovascularisation and maximal tendon thickness were assessed with power Doppler ultrasound. Clinical function was measured with the Victorian Institute of Sports Assessment-Achilles tendon (VISA-A) questionnaire. All the tendinopathic Achilles tendons were injected with 10 mL of 0.5% bupivacaine hydrochloride, 25 mg of hydrocortisone acetate, and 40 mL of 0.9% NaCl saline solution under real time ultrasound guidance. All outcome measures were recorded at baseline and after a short-term follow-up (mean 2.9 weeks, range 2-4). The results showed a statistically significant difference between baseline and 3-week follow-up in all the outcome measures after HVIGI. The grade of neovascularisation reduced (3-1.1, p=0.003), the maximal tendon diameter decreased (8.7-7.6 mm, p<0.001), and the VISA-A scores improved (46.3-84.1, p<0.001). In conclusion, HVIGI for resistant tendinopathy of the main body of the Achilles tendon is effective to improve symptoms, reduce neovascularisation, and decrease maximal tendon thickness at short-term follow-up. CI - 2009 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved. FAU - Humphrey, Joel AU - Humphrey J AD - Centre for Sports and Exercise Medicine, Mile End Hospital, London, UK. FAU - Chan, Otto AU - Chan O FAU - Crisp, Tom AU - Crisp T FAU - Padhiar, Nat AU - Padhiar N FAU - Morrissey, Dylan AU - Morrissey D FAU - Twycross-Lewis, Richard AU - Twycross-Lewis R FAU - King, John AU - King J FAU - Maffulli, Nicola AU - Maffulli N LA - eng PT - Journal Article DEP - 20091127 PL - Australia TA - J Sci Med Sport JT - Journal of science and medicine in sport JID - 9812598 RN - 0 (Anesthetics, Local) RN - WI4X0X7BPJ (Hydrocortisone) RN - Y8335394RO (Bupivacaine) SB - IM MH - Achilles Tendon/diagnostic imaging/*drug effects/physiopathology MH - Adult MH - Anesthetics, Local/administration & dosage/pharmacology/*therapeutic use MH - Bupivacaine/administration & dosage/pharmacology/*therapeutic use MH - Female MH - Humans MH - Hydrocortisone/administration & dosage/pharmacology/*therapeutic use MH - Injections/*methods MH - Male MH - Middle Aged MH - Tendinopathy/diagnostic imaging/*drug therapy/physiopathology MH - *Ultrasonography, Interventional MH - Young Adult EDAT- 2009/12/01 06:00 MHDA- 2010/07/31 06:00 CRDT- 2009/12/01 06:00 PHST- 2009/01/16 00:00 [received] PHST- 2009/09/24 00:00 [revised] PHST- 2009/09/25 00:00 [accepted] PHST- 2009/12/01 06:00 [entrez] PHST- 2009/12/01 06:00 [pubmed] PHST- 2010/07/31 06:00 [medline] AID - S1440-2440(09)00223-0 [pii] AID - 10.1016/j.jsams.2009.09.007 [doi] PST - ppublish SO - J Sci Med Sport. 2010 May;13(3):295-8. doi: 10.1016/j.jsams.2009.09.007. Epub 2009 Nov 27. PMID- 36789824 OWN - NLM STAT- MEDLINE DCOM- 20230216 LR - 20230216 IS - 1011-601X (Print) IS - 1011-601X (Linking) VI - 35 IP - 6 DP - 2022 Nov TI - Flavonoids accelerate wound healing of pressure sore by promoting angiogenesis: Potential mechanism. PG - 1647-1654 AB - Pressure ulcers can progress in four stages based on the level of tissue damage from discoloration of the upper layer of skin to the ulcers of the deep skin. These sores extend below the subcutaneous fat into your deep tissues like muscle, tendons and ligaments. Pressure ulcers bed sores, are the most common complications after surgery and are difficult to treat. Flavonoids Liquid is a typical traditional Chinese medicine, which composed of Rheum officinale and Abelmoschus manihot. Recent study showed that the aqueous extract of Rheum officinale (da huang) possesses cytoprotective, antioxidant and wound healing effects. In this study, we investigated the role of flavonoids on pressure ulcer wound healing and its potential mechanism. A rat model mimicking pressure ulcer was developed and used to test the efficacy of flavonoids in ulcer healing. It was found that flavonoids significantly increase wound healing of pressure ulcer. Moreover, flavonoids promoted the expression of biomarkers related to angiogenesis in the rat model. In conclusion, flavonoids could increase the vasculature in wounds and could be used for treatment of pressure ulcer or bed sores. FAU - Liu, Chang AU - Liu C AD - Department of Emergency Surgery, Ezhou Central Hospital, Ezhou City, Hubei Province, PR China. FAU - Yang, Qiubao AU - Yang Q AD - Department of Emergency Surgery, Ezhou Central Hospital, Ezhou City, Hubei Province, PR China. FAU - Hu, Wenchang AU - Hu W AD - Department of Emergency Surgery, Ezhou Central Hospital, Ezhou City, Hubei Province, PR China. LA - eng PT - Journal Article PL - Pakistan TA - Pak J Pharm Sci JT - Pakistan journal of pharmaceutical sciences JID - 9426356 RN - 0 (Flavonoids) SB - IM MH - Rats MH - Animals MH - *Pressure Ulcer/drug therapy MH - Flavonoids/pharmacology/therapeutic use MH - Wound Healing MH - Skin MH - Ulcer EDAT- 2023/02/16 06:00 MHDA- 2023/02/17 06:00 CRDT- 2023/02/15 05:32 PHST- 2023/02/15 05:32 [entrez] PHST- 2023/02/16 06:00 [pubmed] PHST- 2023/02/17 06:00 [medline] PST - ppublish SO - Pak J Pharm Sci. 2022 Nov;35(6):1647-1654. PMID- 32043642 OWN - NLM STAT- MEDLINE DCOM- 20210902 LR - 20210902 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 39 IP - 6 DP - 2021 Jun TI - Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling. PG - 1297-1304 LID - 10.1002/jor.24625 [doi] AB - Heterotopic ossification (HO) is a pathological condition in which ectopic bone forms within soft tissues such as skeletal muscle. Human platelet-derived growth factor receptor α positive (PDGFRα+) cells, which were proved to be the original cells of HO were incubated in osteogenic differentiation medium with Food and Drug Administration-approved compounds. Alkaline phosphatase activity was measured as a screening to inhibit osteogenic differentiation. For the compounds which inhibited osteogenic differentiation of PDGFRα+ cells, we examined dose dependency of its effect using alizarin red S staining and its cell toxicity using WST-8. In addition, regulation of bone morphogenetic proteins (BMP)-Smad signaling which is the major signal of osteogenic differentiation was investigated by Western blotting to elucidate the mechanism of osteogenesis inhibitory effect by the compound. In vivo experiment, complete transverse incision of Achilles tendons in mice was made and mice were fed the compound by mixing with drinking water after operation. Ten weeks after operation, we assessed and quantified HO by micro-computed tomography scan. Intriguingly, we discovered desloratadine inhibited osteogenic differentiation of PDGFRα+ cells using the drug repositioning method. Desloratadine inhibited osteogenic differentiation of the cells dose dependently without cell toxicity. Desloratadine suppressed phosphorylation of Smad1/5/8 induced by BMP2 in PDGFRα+ cells. In Achilles tenotomy mice model, desloratadine treatment significantly inhibited ectopic bone formation compared with control. In conclusion, we discovered desloratadine inhibited osteogenic differentiation using human PDGFRα+ cells and proved its efficacy using Achilles tenotomy ectopic bone formation model in vivo. Our study paved the way to inhibit HO in early clinical use because of its guaranteed safety. CI - © 2020 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Kusano, Taiki AU - Kusano T AUID- ORCID: 0000-0001-5021-0629 AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. AD - Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan. AD - Division of Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Nakatani, Masashi AU - Nakatani M AD - Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan. FAU - Ishiguro, Naoki AU - Ishiguro N AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Ohno, Kinji AU - Ohno K AD - Division of Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Yamamoto, Naoki AU - Yamamoto N AD - Center for Joint Research Facilities Support, Fujita Health University, Research Promotion and Support Headquarters, Toyoake, Japan. FAU - Morita, Mitsuhiro AU - Morita M AD - Department of Orthopaedic Surgery, Fujita Health University, Toyoake, Japan. FAU - Yamada, Harumoto AU - Yamada H AD - Department of Orthopaedic Surgery, Fujita Health University, Toyoake, Japan. FAU - Uezumi, Akiyoshi AU - Uezumi A AD - Department of Geriatric Medicine, Tokyo Metropolitan Institute of Gerontology, Itabashi, Tokyo, Japan. FAU - Tsuchida, Kunihiro AU - Tsuchida K AUID- ORCID: 0000-0002-3983-5756 AD - Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200221 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Smad Proteins) RN - 7AJO3BO7QN (Loratadine) RN - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha) RN - FVF865388R (desloratadine) SB - IM MH - Animals MH - Bone Morphogenetic Protein 2/*physiology MH - Cell Differentiation/drug effects MH - Loratadine/*analogs & derivatives/pharmacology/therapeutic use MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Ossification, Heterotopic/*prevention & control MH - Osteogenesis/drug effects MH - Receptor, Platelet-Derived Growth Factor alpha/analysis MH - Signal Transduction/drug effects MH - Smad Proteins/*physiology OTO - NOTNLM OT - Achilles tenotomy mice OT - BMP-Smad signaling OT - PDGFRα+ cells OT - bone QCT/μCT OT - heterotopic ossification EDAT- 2020/02/12 06:00 MHDA- 2021/09/03 06:00 CRDT- 2020/02/12 06:00 PHST- 2019/05/20 00:00 [received] PHST- 2020/01/30 00:00 [accepted] PHST- 2020/02/12 06:00 [pubmed] PHST- 2021/09/03 06:00 [medline] PHST- 2020/02/12 06:00 [entrez] AID - 10.1002/jor.24625 [doi] PST - ppublish SO - J Orthop Res. 2021 Jun;39(6):1297-1304. doi: 10.1002/jor.24625. Epub 2020 Feb 21. PMID- 19160256 OWN - NLM STAT- MEDLINE DCOM- 20090319 LR - 20251204 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 2009 IP - 1 DP - 2009 Jan 21 TI - Corticosteroid injection for trigger finger in adults. PG - CD005617 LID - 10.1002/14651858.CD005617.pub2 [doi] LID - CD005617 AB - BACKGROUND: Trigger finger is a disease of the tendons of the hand leading to triggering (locking) of affected fingers, dysfunction and pain. Available treatments include local injection with corticosteroids, surgery, or splinting. OBJECTIVES: To summarize the evidence on the efficacy and safety of corticosteroid injections for trigger finger in adults using the following endpoints: treatment success, frequency of triggering or locking, functional status of the affected fingers, and severity of pain of the fingers. SEARCH STRATEGY: The databases CENTRAL, DARE, MEDLINE (1966 to November 2007), EMBASE (1956 to November 2007), CINAHL (1982 to November 2007), AMED (1985 to November 2007) and PEDro (a physiotherapy evidence database) were searched. SELECTION CRITERIA: We selected randomized and controlled clinical trials evaluating efficacy and safety of corticosteroid injections for trigger finger in adults. DATA COLLECTION AND ANALYSIS: The databases were searched for titles of eligible studies. After screening abstracts of these studies, full text articles of studies which fulfilled the selection criteria were obtained. Data were extracted using a predefined electronic form. The methodological quality of included trials was assessed by using items from the checklist developed by Jadad and the Delphi list. We planned to extract data regarding information on the primary outcome measures: treatment success, frequency of triggering or locking, and functional impairment of fingers, severity of the trigger finger; and the secondary outcome measures: proportion of patients with side effects, types of side effects, and patient satisfaction with injection. MAIN RESULTS: Two randomized controlled studies were found that involved 63 participants: 34 were allocated to corticosteroids and lidocaine, and 29 were allocated to lidocaine alone. Corticosteroid injection with lidocaine was more effective than lidocaine alone on treatment success at four weeks (relative risk 3.15, 95% CI 1.34 to 7.40). The number needed to treat to benefit was 3. No adverse events or side effects were reported. AUTHORS' CONCLUSIONS: The effectiveness of local corticosteroid injections was studied in only two small randomized controlled trials of poor methodological quality. Both studies showed better short-term effects of corticosteroid injection combined with lidocaine compared to lidocaine alone on the treatment success outcome. In one study the effects of corticosteroid injections lasted up to four months. No adverse effects were observed. The available evidence for the effectiveness of intra-tendon sheath corticosteroid injection for trigger finger can be graded as a silver level evidence for superiority of corticosteroid injections combined with lidocaine over injections with lidocaine alone. FAU - Peters-Veluthamaningal, Cyriac AU - Peters-Veluthamaningal C AD - Department of General Practice, University Medical Center Groningen, Antonius Deusinglaan 1, Groningen, Netherlands, 9713 AV. raju@dds.nl. FAU - van der Windt, Daniëlle A W M AU - van der Windt DA FAU - Winters, Jan C AU - Winters JC FAU - Meyboom-de Jong, Betty AU - Meyboom-de Jong B LA - eng PT - Journal Article PT - Systematic Review DEP - 20090121 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM UOF - doi: 10.1002/14651858.CD005617 MH - Adrenal Cortex Hormones/*administration & dosage MH - Adult MH - Anesthetics, Local/*administration & dosage MH - Humans MH - Lidocaine/*administration & dosage MH - Randomized Controlled Trials as Topic MH - Trigger Finger Disorder/*drug therapy PMC - PMC12671840 COIS- CP has conducted an RCT (Groningen Hand and Wrist Injection Therapy Trial ‐ HAWITT) assessing the efficacy and safety of corticosteroid injections for trigger finger, De Quervain's tenosynovitis, and carpal tunnel syndrome in a primary care population. The HAWITT trial was sponsored by an unrestricted educational grant from the pharmaceutical company Bristol‐Myers Squibb. EDAT- 2009/01/23 09:00 MHDA- 2009/03/20 09:00 PMCR- 2010/01/21 CRDT- 2009/01/23 09:00 PHST- 2009/01/23 09:00 [entrez] PHST- 2009/01/23 09:00 [pubmed] PHST- 2009/03/20 09:00 [medline] PHST- 2010/01/21 00:00 [pmc-release] AID - CD005617.pub2 [pii] AID - 10.1002/14651858.CD005617.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD005617. doi: 10.1002/14651858.CD005617.pub2. PMID- 18056491 OWN - NLM STAT- MEDLINE DCOM- 20080122 LR - 20221207 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 89 IP - 12 DP - 2007 Dec TI - Corticosteroid injection in diabetic patients with trigger finger. A prospective, randomized, controlled double-blinded study. PG - 2604-11 AB - BACKGROUND: It is generally accepted that the initial treatment for trigger finger is injection of corticosteroid into the flexor tendon sheath. In this study, the efficacy of corticosteroid injections for the treatment of trigger finger in patients with diabetes mellitus was evaluated in a prospective, randomized, controlled, double-blinded fashion and the efficacy in nondiabetic patients was evaluated in a prospective, unblinded fashion. METHODS: Thirty diabetic patients (thirty-five digits) and twenty-nine nondiabetic patients (twenty-nine digits) were enrolled. The nondiabetic patients were given corticosteroid injections in an unblinded manner. The cohort with diabetes was randomized into a corticosteroid group (twenty digits) or a placebo group (fifteen digits). Both of these groups were double-blinded. Additional injections, surgical intervention, and recurrent symptoms of trigger finger were recorded. Treatment success was defined as complete or nearly complete resolution of trigger finger symptoms such that surgical intervention was not required. RESULTS: After one or two injections, twenty-five of the twenty-nine digits in the nondiabetic group had a successful outcome compared with twelve of the nineteen in the diabetic corticosteroid group (p = 0.03) and eight of the fifteen in the diabetic placebo group (p = 0.006). With the numbers studied, no significant difference was found between the diabetic groups. Surgery was performed in three of the twenty-nine digits in the nondiabetic group compared with seven of the nineteen in the diabetic corticosteroid group and six of the fifteen in the diabetic placebo group. There was a significant difference in the prevalence of surgery between the nondiabetic group and both the diabetic corticosteroid group and the diabetic placebo group (p = 0.035 and p = 0.020, respectively). With the numbers studied, no difference was found between the diabetic groups with regard to the persistence of symptoms. Nephropathy and neuropathy were significantly associated with the need for surgery (p = 0.008 and p = 0.03, respectively). CONCLUSIONS: Corticosteroid injections were significantly more effective in the digits of nondiabetic patients than in those of diabetic patients. In patients with diabetes, corticosteroid injections did not decrease the surgery rate or improve symptom relief compared with the placebo. The use of corticosteroid injections for the treatment of trigger finger may be less effective in patients with systemic manifestations of diabetes mellitus. FAU - Baumgarten, Keith M AU - Baumgarten KM AD - Sports Medicine and Shoulder Surgery Section, The Orthopedic Institute, 810 East 23rd Street, Sioux Falls, SD 57108, USA. Kbaumga@yahoo.com FAU - Gerlach, David AU - Gerlach D FAU - Boyer, Martin I AU - Boyer MI LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Anesthetics, Local) RN - 0 (Drug Combinations) RN - 0 (Glucocorticoids) RN - 0 (Glycated Hemoglobin A) RN - 52081-45-5 (betamethasone acetate phosphate) RN - 9842X06Q6M (Betamethasone) RN - 98PI200987 (Lidocaine) SB - IM MH - Aged MH - Anesthetics, Local/administration & dosage MH - Betamethasone/administration & dosage/*analogs & derivatives MH - Diabetes Complications/blood/*complications MH - Diabetes Mellitus/blood MH - Double-Blind Method MH - Drug Combinations MH - Female MH - Follow-Up Studies MH - Glucocorticoids/*administration & dosage MH - Glycated Hemoglobin/metabolism MH - Humans MH - Injections MH - Lidocaine/administration & dosage MH - Male MH - Middle Aged MH - Prospective Studies MH - Tendons MH - Treatment Outcome MH - Trigger Finger Disorder/complications/*drug therapy EDAT- 2007/12/07 09:00 MHDA- 2008/01/23 09:00 CRDT- 2007/12/07 09:00 PHST- 2007/12/07 09:00 [pubmed] PHST- 2008/01/23 09:00 [medline] PHST- 2007/12/07 09:00 [entrez] AID - 89/12/2604 [pii] AID - 10.2106/JBJS.G.00230 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2007 Dec;89(12):2604-11. doi: 10.2106/JBJS.G.00230. PMID- 32000816 OWN - NLM STAT- MEDLINE DCOM- 20201123 LR - 20201123 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 15 IP - 1 DP - 2020 Jan 30 TI - A new improvement: subperiosteal cocktail application to effectively reduce pain and blood loss after total knee arthroplasty. PG - 33 LID - 10.1186/s13018-020-1563-5 [doi] LID - 33 AB - BACKGROUND: Pain and blood loss after total knee arthroplasty (TKA) are unsolved clinical problems. Some studies reported that periarticular cocktail injection can effectively reduce pain and blood loss. However, there was no gold standard about the cocktail ingredient and injection location. More osteotomy and less soft tissue release in TKA with mild deformity; besides, plenty of nerves and blood vessels are contained in the periosteums and bone marrow. In this study, we aimed to detect the clinical results of subperiosteal cocktail application in TKA. METHODS: Two groups were included according to the different injection location in our study. In group 1, cocktails were injected into the muscles, tendons, suprapatellar bursa, and subpatellar bursa surrounding knee joint. In group 2, cocktail injection was performed under the periosteum of the distal femur and proximal tibia. Our primary outcomes were visual analogue scale (VAS) and hemoglobin (Hb), and the secondary outcomes were wound healing, infection, deep vein thrombosis (DVT), operation time, and hospitalization. RESULTS: At the first operative day, the mean (standard deviation) VAS score in a state of static was lower in group 2 compared with group 1 (0.98 ± 0.27 in group 1 and 0.86 ± 0.60 in group 2, p < 0.05). In the state of flexion and extension, the mean (standard deviation) VAS was 1.61 ± 0.66 in group 1 and 1.10 ± 0.57 in group 2 (p < 0.05). The mean (standard deviation) blood loss was higher in group 1 than in group 2 at the first postoperative day (440.19 (167.68) ml in group 1 and 333.67 (205.99) ml in group 2, p < 0.05). At the third day after surgery, the mean (standard deviation) blood loss was 686.44 (140.29) ml in group 1 and 609.19 (260.30) ml in group 2, and there was significant difference between these two groups (p < 0.05). CONCLUSIONS: We concluded that subperiosteal cocktail injection can significantly reduce pain and blood loss compared with periarticular cocktail injection after TKA. FAU - Wang, Yanxin AU - Wang Y AD - Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing, 400016, China. FAU - Zhou, Aiguo AU - Zhou A AUID- ORCID: 0000-0003-1717-101X AD - Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuzhong District, Chongqing, 400016, China. zhouaiguo@hospital.cqmu.edu.cn. LA - eng PT - Controlled Clinical Trial PT - Journal Article DEP - 20200130 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Vasoconstrictor Agents) RN - 6T84R30KC1 (Tranexamic Acid) RN - 7IO5LYA57N (Ropivacaine) RN - X4W7ZR7023 (Methylprednisolone) RN - YKH834O4BH (Epinephrine) SB - IM MH - Aged MH - Anesthetics, Local/administration & dosage MH - Anti-Inflammatory Agents/administration & dosage MH - Arthroplasty, Replacement, Knee/adverse effects/*methods MH - Blood Loss, Surgical/*prevention & control MH - Drug Therapy, Combination/methods MH - Epinephrine/administration & dosage MH - Female MH - Humans MH - Knee Joint/*drug effects/surgery MH - Male MH - Methylprednisolone/administration & dosage MH - Middle Aged MH - Pain Management/*methods MH - Pain, Postoperative/etiology/*prevention & control MH - Periosteum/*drug effects/surgery MH - Prospective Studies MH - Ropivacaine/administration & dosage MH - Tranexamic Acid/administration & dosage MH - Treatment Outcome MH - Vasoconstrictor Agents/administration & dosage PMC - PMC6993367 OTO - NOTNLM OT - Blood loss OT - Cocktail injection OT - Pain OT - Periarticular OT - Subperiosteal OT - Total knee arthroplasty COIS- The authors declare that they have no competing interests. EDAT- 2020/02/01 06:00 MHDA- 2020/11/24 06:00 PMCR- 2020/01/30 CRDT- 2020/02/01 06:00 PHST- 2019/03/22 00:00 [received] PHST- 2020/01/16 00:00 [accepted] PHST- 2020/02/01 06:00 [entrez] PHST- 2020/02/01 06:00 [pubmed] PHST- 2020/11/24 06:00 [medline] PHST- 2020/01/30 00:00 [pmc-release] AID - 10.1186/s13018-020-1563-5 [pii] AID - 1563 [pii] AID - 10.1186/s13018-020-1563-5 [doi] PST - epublish SO - J Orthop Surg Res. 2020 Jan 30;15(1):33. doi: 10.1186/s13018-020-1563-5. PMID- 31140714 OWN - NLM STAT- MEDLINE DCOM- 20200211 LR - 20200211 IS - 1526-968X (Electronic) IS - 1526-954X (Linking) VI - 57 IP - 9 DP - 2019 Sep TI - Ferulic acid improves self-renewal and differentiation of human tendon-derived stem cells by upregulating early growth response 1 through hypoxia. PG - e23291 LID - 10.1002/dvg.23291 [doi] AB - We aimed to investigate the potential beneficial effect of ferulic acid (FA) on stemness of human tendon-derived stem cells (hTSCs) in vitro and to elucidate the underlying molecular mechanism. The self-renewal ability of hTSCs was evaluated by colony formation and cell proliferation was determined by CCK-8 kit. Adipogenesis, osteogenesis, and chondrogenesis were determined by Oil Red O, Alizarin Red, and Alcian Blue stainings, respectively. Relative mRNA levels of PPARγ, Col2A1, Acan, Runx2, HIF1α, and EGR1 were measured with real-time PCR. Protein levels of HIF1α and EGR1 were detected by western blot. Direct binding of HIF1α with EGR1 promoter was analyzed by ChIP assay. Hypoxia-induced expression of EGR1 was interrogated by luciferase reporter assay. We demonstrated that FA treatment improved both self-renewal ability and multi-differentiation potential of hTSCs. FA induced hypoxia which in turn upregulated EGR1 expression via direct association with its hypoxia response element consensus sequence. Furthermore, we showed that both HIF1α and EGR1 were required for the enhancing effects of FA on hTSC self-renewal and differentiation. We hereby characterize the beneficial effect of FA on the stemness of hTSCs and highlight the critical role of HIF1α-EGR1 axis in this process. CI - © 2019 Wiley Periodicals, Inc. FAU - Qiu, Shuo AU - Qiu S AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Sun, Yunchu AU - Sun Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Xu, Jia AU - Xu J AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Wen, Gen AU - Wen G AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Yu, Yaling AU - Yu Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Wu, Tianyi AU - Wu T AUID- ORCID: 0000-0002-7167-3419 AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Chai, Yimin AU - Chai Y AD - Department of Orthopaedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. LA - eng PT - Journal Article DEP - 20190529 PL - United States TA - Genesis JT - Genesis (New York, N.Y. : 2000) JID - 100931242 RN - 0 (Angiogenesis Inducing Agents) RN - 0 (Coumaric Acids) RN - 0 (EGR1 protein, human) RN - 0 (Early Growth Response Protein 1) RN - 0 (HIF1A protein, human) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - AVM951ZWST (ferulic acid) SB - IM MH - Angiogenesis Inducing Agents/*pharmacology MH - Cell Differentiation/*drug effects MH - *Cell Hypoxia MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Coumaric Acids/*pharmacology MH - Early Growth Response Protein 1/genetics/*metabolism MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism MH - Stem Cells/*drug effects/metabolism MH - Tendons/*cytology/drug effects/metabolism MH - Up-Regulation/drug effects OTO - NOTNLM OT - EGR1 OT - ferulic acid OT - human tendon-derived stem cells OT - hypoxia OT - multi-differentiation EDAT- 2019/05/30 06:00 MHDA- 2020/02/12 06:00 CRDT- 2019/05/30 06:00 PHST- 2018/12/12 00:00 [received] PHST- 2019/02/27 00:00 [revised] PHST- 2019/02/28 00:00 [accepted] PHST- 2019/05/30 06:00 [pubmed] PHST- 2020/02/12 06:00 [medline] PHST- 2019/05/30 06:00 [entrez] AID - 10.1002/dvg.23291 [doi] PST - ppublish SO - Genesis. 2019 Sep;57(9):e23291. doi: 10.1002/dvg.23291. Epub 2019 May 29. PMID- 17070795 OWN - NLM STAT- MEDLINE DCOM- 20070306 LR - 20131121 IS - 0012-1606 (Print) IS - 0012-1606 (Linking) VI - 302 IP - 1 DP - 2007 Feb 1 TI - Tendon-muscle crosstalk controls muscle bellies morphogenesis, which is mediated by cell death and retinoic acid signaling. PG - 267-80 AB - Vertebrate muscle morphogenesis is a complex developmental process, which remains quite yet unexplored at cellular and molecular level. In this work, we have found that sculpturing programmed cell death is a key morphogenetic process responsible for the formation of individual foot muscles in the developing avian limb. Muscle fibers are produced in excess in the precursor dorsal and ventral muscle masses of the limb bud and myofibers lacking junctions with digital tendons are eliminated via apoptosis. Microsurgical experiments to isolate the developing muscles from their specific tendons are consistent with a role for tendons in regulating survival of myogenic cells. Analysis of the expression of Raldh2 and local treatments with retinoic acid indicate that this signaling pathway mediates apoptosis in myogenic cells, appearing also involved in tendon maturation. Retinoic acid inhibition experiments led to defects in muscle belly segmentation and myotendinous junction formation. It is proposed that heterogeneous local distribution of retinoids controlled through Raldh2 and Cyp26A1 is responsible for matching the fleshy and the tendinous components of each muscle belly. FAU - Rodriguez-Guzman, Maria AU - Rodriguez-Guzman M AD - Departamento de Anatomía y Biología Celular, Facultad de Medicina, Universidad de Cantabria, C/Cardenal Herrera Oria s/n, Santander, Spain. FAU - Montero, Juan A AU - Montero JA FAU - Santesteban, Elena AU - Santesteban E FAU - Gañan, Yolanda AU - Gañan Y FAU - Macias, Domingo AU - Macias D FAU - Hurle, Juan M AU - Hurle JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060926 PL - United States TA - Dev Biol JT - Developmental biology JID - 0372762 RN - 5688UTC01R (Tretinoin) SB - IM MH - Animals MH - *Apoptosis MH - Chick Embryo MH - Extremities/embryology MH - *Morphogenesis MH - Muscle Development MH - Muscle Fibers, Skeletal/cytology MH - Muscle, Skeletal/anatomy & histology/*embryology/metabolism MH - *Signal Transduction MH - Tendons/*embryology/metabolism MH - Tretinoin/*metabolism EDAT- 2006/10/31 09:00 MHDA- 2007/03/07 09:00 CRDT- 2006/10/31 09:00 PHST- 2006/05/31 00:00 [received] PHST- 2006/08/16 00:00 [revised] PHST- 2006/09/19 00:00 [accepted] PHST- 2006/10/31 09:00 [pubmed] PHST- 2007/03/07 09:00 [medline] PHST- 2006/10/31 09:00 [entrez] AID - S0012-1606(06)01235-8 [pii] AID - 10.1016/j.ydbio.2006.09.034 [doi] PST - ppublish SO - Dev Biol. 2007 Feb 1;302(1):267-80. doi: 10.1016/j.ydbio.2006.09.034. Epub 2006 Sep 26. PMID- 20681309 OWN - NLM STAT- MEDLINE DCOM- 20110203 LR - 20131121 IS - 1001-4454 (Print) IS - 1001-4454 (Linking) VI - 33 IP - 3 DP - 2010 Mar TI - [Effects of deer tendons collagen on osteoporosis rats induced by retinoic acid]. PG - 411-4 AB - OBJECTIVE: To study the effects of deer tendons collagen on osteoporosis rats induced by retinoic acid. METHODS: Male Wistar rats were randomly divided into normal control group, model control group, deer tendons collagen high, medium and low-dose groups, osteoporosis rats of retinoic acid-induced were set up. Changes of body weight, bone weight, bone mineral density, bone histomorphometry, plasma phosphorus, calcium, alkaline phosphatase (ALP), bone mechanics were measured before and after treatment of deer tendons collagen. RESULTS: Compared with model control group,after treated by deer tendons collagen, body weight, bone mineral density, bone weight was increased in varying degrees, bone histomorphometry parameters were significantly different, the ALP in plasma was significantly reduced, contents of Ca, P were increased, all indicators of bone mechanics were significantly higher. CONCLUSION: Deer tendons collagen can prevent and treat retinoic acid-induced osteoporosis of rats. FAU - Zhang, He AU - Zhang H AD - Changchun University of Traditional Chinese Medicine, Changchun 130117, China. FAU - Zhao, Yu AU - Zhao Y FAU - Li, Yin-Qing AU - Li YQ FAU - Sun, Xiao-Di AU - Sun XD FAU - Bai, Xue-Yuan AU - Bai XY FAU - Zhao, Da-Qing AU - Zhao DQ LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Zhong Yao Cai JT - Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials JID - 9426370 RN - 0 (Materia Medica) RN - 5688UTC01R (Tretinoin) RN - 9007-34-5 (Collagen) RN - EC 3.1.3.1 (Alkaline Phosphatase) RN - SY7Q814VUP (Calcium) SB - IM MH - Alkaline Phosphatase/blood/metabolism MH - Animals MH - Biomechanical Phenomena MH - Bone Density/*drug effects MH - Calcium/blood MH - Collagen/isolation & purification/pharmacology/*therapeutic use MH - *Deer MH - Disease Models, Animal MH - Femur/*drug effects/metabolism MH - Male MH - Materia Medica/pharmacology/*therapeutic use MH - Osteoporosis/chemically induced/*drug therapy/prevention & control MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Tendons MH - Tretinoin EDAT- 2010/08/05 06:00 MHDA- 2011/02/04 06:00 CRDT- 2010/08/05 06:00 PHST- 2010/08/05 06:00 [entrez] PHST- 2010/08/05 06:00 [pubmed] PHST- 2011/02/04 06:00 [medline] PST - ppublish SO - Zhong Yao Cai. 2010 Mar;33(3):411-4. PMID- 39072972 OWN - NLM STAT- MEDLINE DCOM- 20240729 LR - 20240731 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 28 IP - 14 DP - 2024 Jul TI - Functions of Epimedin C in a zebrafish model of glucocorticoid-induced osteoporosis. PG - e18569 LID - 10.1111/jcmm.18569 [doi] LID - e18569 AB - Epimedium is thought to enhance the integrity of tendons and bones, ease joint discomfort and rigidity and enhance kidney function. Although glucocorticoids are commonly used in clinical practice, the mechanism by which the active compound Epimedin C (EC) alleviates glucocorticoid-induced osteoporosis (GIOP) is not well understood. The therapeutic potential of EC in treating GIOP was evaluated using alizarin red S staining, calcein immersion and fluorescence imaging, and bone mineralization, bone mass accumulation and bone density in zebrafish larvae were determined. Using the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, the key signalling pathways related to bone development were identified. A protein-protein interaction network (PPIN) was constructed to identify osteoclast characteristic genes and the findings were verified using real-time quantitative PCR (RT-qPCR). The bone tissue damage caused by prednisolone was reduced by EC. It also altered physiological processes, improved bone density, boosted mineralization and increased bone mass and activity. Subsequent empirical investigations showed that EC impacted the major signalling pathways involved in bone development, such as osteoclast differentiation, oestrogen, MAPK, insulin resistance, PPAR and AMPK signalling pathways. It also decreased the expression of genes typical of osteoclasts. The results of our study uncover a previously unknown function of EC in controlling bone formation and emphasize the potential of EC as a therapeutic target. The osteoprotective effect of EC indicates its potential as a cost-effective strategy for treating GIOP. CI - © 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Zhou, Xiaoyang AU - Zhou X AD - Department of Orthopedics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. AD - Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City, Department of Obstetrics and Gynaecology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Lian, Kai AU - Lian K AUID- ORCID: 0009-0004-8117-114X AD - Department of Orthopedics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Jia, Junjie AU - Jia J AD - Department of Orthopedics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Zhao, Xue AU - Zhao X AD - Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City, Department of Obstetrics and Gynaecology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Duan, Peng AU - Duan P AD - Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City, Department of Obstetrics and Gynaecology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Huang, Jiaolong AU - Huang J AD - Key Laboratory of Zebrafish Modeling and Drug Screening for Human Diseases of Xiangyang City, Department of Obstetrics and Gynaecology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. FAU - Shi, Yihua AU - Shi Y AD - Department of Orthopedics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, China. LA - eng GR - 2022YL24A/Scientific and Technological Project of Xiangyang City of Hubei Province/ GR - 2022BCE021/Hubei Province Key Research and Development Program/ GR - 2022CFD010/Hubei Province Key Research and Development Program/ GR - WJ2023M162/Foundation of Health Commission of Hubei Province/ PT - Journal Article PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Flavonoids) RN - 0 (Glucocorticoids) RN - 110642-44-9 (epimedin C) SB - IM MH - Animals MH - *Zebrafish MH - *Osteoporosis/chemically induced/metabolism/genetics/pathology/drug therapy MH - *Flavonoids/pharmacology MH - *Glucocorticoids/adverse effects/pharmacology MH - *Disease Models, Animal MH - *Osteoclasts/metabolism/drug effects MH - *Signal Transduction/drug effects MH - Bone Density/drug effects MH - Protein Interaction Maps MH - Osteogenesis/drug effects/genetics MH - Calcification, Physiologic/drug effects PMC - PMC11284123 OTO - NOTNLM OT - Epimedin C OT - bone mineralization OT - glucocorticoid‐induced osteoporosis OT - osteoprotective effect OT - traditional Chinese medicine OT - zebrafish model COIS- The authors declare no competing interest. EDAT- 2024/07/29 12:43 MHDA- 2024/07/29 12:44 PMCR- 2024/07/28 CRDT- 2024/07/29 09:59 PHST- 2024/07/13 00:00 [revised] PHST- 2024/03/08 00:00 [received] PHST- 2024/07/18 00:00 [accepted] PHST- 2024/07/29 12:44 [medline] PHST- 2024/07/29 12:43 [pubmed] PHST- 2024/07/29 09:59 [entrez] PHST- 2024/07/28 00:00 [pmc-release] AID - JCMM18569 [pii] AID - 10.1111/jcmm.18569 [doi] PST - ppublish SO - J Cell Mol Med. 2024 Jul;28(14):e18569. doi: 10.1111/jcmm.18569. PMID- 37602483 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20240813 IS - 1098-1128 (Electronic) IS - 0198-6325 (Linking) VI - 44 IP - 2 DP - 2024 Mar TI - Rheumatoid arthritis molecular targets and their importance to flavonoid-based therapy. PG - 497-538 LID - 10.1002/med.21990 [doi] AB - Rheumatoid arthritis (RA) is a progressive, chronic, autoimmune, inflammatory, and systemic condition that primarily affects the synovial joints and adjacent tissues, including bone, muscle, and tendons. The World Health Organization recognizes RA as one of the most prevalent chronic inflammatory diseases. In the last decade, there was an expansion on the available RA therapeutic options which aimed to improve patient's quality of life. Despite the extensive research and the emergence of new therapeutic approaches and drugs, there are still significant unwanted side effects associated to these drugs and still a vast number of patients that do not respond positively to the existing therapeutic strategies. Over the years, several references to the use of flavonoids in the quest for new treatments for RA have emerged. This review aimed to summarize the existing literature about the flavonoids' effects on the major pathogenic/molecular targets of RA and their potential use as lead compounds for the development of new effective molecules for RA treatment. It is demonstrated that flavonoids can modulate various players in synovial inflammation, regulate immune cell function, decrease synoviocytes proliferation and balance the apoptotic process, decrease angiogenesis, and stop/prevent bone and cartilage degradation, which are all dominant features of RA. Although further investigation is necessary to determine the effectiveness of flavonoids in humans, the available data from in vitro and in vivo models suggest their potential as new disease-modifying anti-rheumatic drugs. This review highlights the use of flavonoids as a promising avenue for future research in the treatment of RA. CI - © 2023 Wiley Periodicals LLC. FAU - Rufino, Ana T AU - Rufino AT AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. FAU - Freitas, Marisa AU - Freitas M AUID- ORCID: 0000-0001-9114-9967 AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. FAU - Proença, Carina AU - Proença C AUID- ORCID: 0000-0003-0859-6526 AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. FAU - Ferreira de Oliveira, José M P AU - Ferreira de Oliveira JMP AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. FAU - Fernandes, Eduarda AU - Fernandes E AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. FAU - Ribeiro, Daniela AU - Ribeiro D AUID- ORCID: 0000-0001-9733-7934 AD - LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. AD - Faculty of Agrarian Sciences and Environment, University of the Azores, Açores, Portugal. LA - eng GR - UIDB/50006/2020/FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior/ GR - UIDP/50006/2020/FCT/MCTES, Fundação para a Ciência e Tecnologia and Ministério da Ciência, Tecnologia e Ensino Superior/ GR - POCI-01-0145- FEDER-029253-Project PTDC/MED-QUI/29253/2017/FEDER funds through the Operational Competitiveness Program [COMPETE2020]/ GR - EXPL/MED-QUI/0815/2021/ GR - SFRH/BPD/74868/2010/DL 57/2016-Norma transitória/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230821 PL - United States TA - Med Res Rev JT - Medicinal research reviews JID - 8103150 RN - 0 (Flavonoids) SB - IM MH - Humans MH - *Flavonoids/pharmacology/therapeutic use MH - Quality of Life MH - *Arthritis, Rheumatoid/drug therapy MH - Inflammation OTO - NOTNLM OT - drug discovery OT - flavonoids OT - rheumatoid arthritis pathophysiology OT - rheumatoid arthritis treatment EDAT- 2023/08/21 12:42 MHDA- 2024/02/07 06:42 CRDT- 2023/08/21 07:26 PHST- 2023/04/18 00:00 [revised] PHST- 2022/02/28 00:00 [received] PHST- 2023/08/05 00:00 [accepted] PHST- 2024/02/07 06:42 [medline] PHST- 2023/08/21 12:42 [pubmed] PHST- 2023/08/21 07:26 [entrez] AID - 10.1002/med.21990 [doi] PST - ppublish SO - Med Res Rev. 2024 Mar;44(2):497-538. doi: 10.1002/med.21990. Epub 2023 Aug 21. PMID- 11744378 OWN - NLM STAT- MEDLINE DCOM- 20020510 LR - 20190910 IS - 0925-4773 (Print) IS - 0925-4773 (Linking) VI - 110 IP - 1-2 DP - 2002 Jan TI - Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. PG - 173-7 AB - We recently cloned the murine homologue of Cyp26B1, a novel retinoic acid (RA)-metabolizing enzyme and showed that its gene expression pattern is unique from that of Cyp26A1 during early embryogenesis. Here, we complete this comparative expression analysis from embryonic day (E) 12 to postnatal stages. Cyp26B1 expression was found in developing tendons and precartilaginous elements and in perichondrium by E14.5, while Cyp26A1 expression was restricted to extremities of rib and vertebral cartilage. Cyp26A1 and Cyp26B1 were expressed, in the distal epithelium and mesenchyme of the limbs and genital tubercle, respectively. High Cyp26B1 expression was found in craniofacial areas undergoing morphogenetic growth, whereas Cyp26A1 message was restricted to the mouth and dental epithelium. Cyp26A1 alone was expressed in the developing neural retina, while both genes were co-expressed in the retinal pigment epithelium. Cyp26B1 was specifically expressed in the developing hindbrain (pons, cerebellum) and forebrain (striatum, hippocampus), with forebrain expression persisting postnatally. In addition, Cyp26B1 was expressed at specific levels of the differentiating upper and lower thoracic spinal cord, adjacent to the cervical and lumbar regions that express the RA-synthesizing enzyme RALDH-2. In viscera, Cyp26B1 transcripts were detected in the developing lung, kidney, spleen, thymus and testis, whereas Cyp26A1 transcripts were found in the diaphragm and outer stomach mesenchyme. Cyp26B1 was also specifically expressed in dermis surrounding the developing hair follicles. Regulated RA metabolism may therefore be required in many developing systems. FAU - Abu-Abed, Suzan AU - Abu-Abed S AD - Department of Pathology, Queen's University, Kingston, Ontario, K7L 3N6, Canada. FAU - MacLean, Glenn AU - MacLean G FAU - Fraulob, Valérie AU - Fraulob V FAU - Chambon, Pierre AU - Chambon P FAU - Petkovich, Martin AU - Petkovich M FAU - Dollé, Pascal AU - Dollé P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Ireland TA - Mech Dev JT - Mechanisms of development JID - 9101218 RN - 5688UTC01R (Tretinoin) RN - 9035-51-2 (Cytochrome P-450 Enzyme System) RN - EC 1.- (Mixed Function Oxygenases) RN - EC 1.14.14.1 (Cyp26a1 protein, mouse) RN - EC 1.14.14.1 (Cyp26b1 protein, mouse) RN - EC 1.14.14.1 (Retinoic Acid 4-Hydroxylase) SB - IM MH - Animals MH - Bone Development/genetics MH - Brain/embryology/enzymology/growth & development MH - Cytochrome P-450 Enzyme System/*genetics MH - Extremities/embryology/growth & development MH - Gene Expression Regulation, Developmental MH - Gene Expression Regulation, Enzymologic MH - Male MH - Mice MH - Mixed Function Oxygenases/*genetics MH - Retinoic Acid 4-Hydroxylase MH - Spinal Cord/embryology/enzymology/growth & development MH - Tendons/embryology/enzymology/growth & development MH - Tretinoin/*metabolism EDAT- 2001/12/18 10:00 MHDA- 2002/05/11 10:01 CRDT- 2001/12/18 10:00 PHST- 2001/12/18 10:00 [pubmed] PHST- 2002/05/11 10:01 [medline] PHST- 2001/12/18 10:00 [entrez] AID - S092547730100572X [pii] AID - 10.1016/s0925-4773(01)00572-x [doi] PST - ppublish SO - Mech Dev. 2002 Jan;110(1-2):173-7. doi: 10.1016/s0925-4773(01)00572-x. PMID- 41303871 OWN - NLM STAT- MEDLINE DCOM- 20251127 LR - 20251130 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 61 IP - 11 DP - 2025 Nov 14 TI - Avocado-Soybean Unsaponifiables Enhance Tendon Healing via Anti-Inflammatory and Antioxidant Mechanisms in a Rat Achilles Injury Model. LID - 10.3390/medicina61112035 [doi] LID - 2035 AB - Background and Objectives: Tendon healing is a multifactorial process influenced by inflammation and oxidative stress. Avocado-soybean unsaponifiables (ASU), recognized for their anti-inflammatory and antioxidant properties in osteoarthritis, have not yet been evaluated in tendon repair. This study aimed to investigate the effects of systemic ASU administration on histological, biomechanical, and biochemical parameters of tendon healing in a rat Achilles tendon injury model. Materials and Methods: Twenty male Wistar rats underwent bilateral Achilles tendon transection and repair. The ASU group received intraperitoneal ASU (300 mg/kg/day) for four weeks; controls received saline. Right tendons were analyzed histologically using a semiquantitative scoring system adapted from Curtis-DeLee, Bonar, and Modified Soslowsky criteria. Left tendons were tested biomechanically for maximum force, displacement, stress, stiffness, and energy parameters. Serum interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), total antioxidant status (TAS), total oxidant status (TOS), and oxidative stress index (OSI) were measured by ELISA. Results: ASU markedly improved histological healing with better collagen alignment, reduced inflammation, and normalized tenocyte morphology (p < 0.001). Biomechanical strength increased, with higher maximum force (p = 0.002), displacement (p = 0.004), stress (p = 0.001), and total energy to failure (p = 0.001). Serum IL-1β, IL-6, and TNF-α levels were lower (p < 0.001), while TAS increased and TOS/OSI decreased (p < 0.001). Conclusions: Systemic ASU administration enhances tendon healing by improving tissue organization, increasing mechanical strength, and modulating systemic inflammation and oxidative stress. These findings suggest that ASU may serve as a safe, clinically relevant adjunct therapy to promote tendon regeneration. FAU - Dinç, Mustafa AU - Dinç M AUID- ORCID: 0000-0002-3002-5028 AD - Orthopedics and Traumatology Clinics, Bursa City Hospital, Bursa 16250, Turkey. FAU - Soydemir, Ömer Cevdet AU - Soydemir ÖC AUID- ORCID: 0000-0001-8493-8562 AD - Orthopedics and Traumatology Clinics, Bursa City Hospital, Bursa 16250, Turkey. FAU - Bayrak, Hünkar Çağdaş AU - Bayrak HÇ AUID- ORCID: 0009-0003-4963-9980 AD - Orthopedics and Traumatology Clinics, Çekirge State Hospital, Bursa 16090, Turkey. FAU - Karasu, Recep AU - Karasu R AUID- ORCID: 0000-0002-0628-5794 AD - Orthopedics and Traumatology Clinics, Bursa City Hospital, Bursa 16250, Turkey. FAU - Aykaç, Bilal AU - Aykaç B AUID- ORCID: 0000-0002-6180-2467 AD - Orthopedics and Traumatology Clinics, Bursa City Hospital, Bursa 16250, Turkey. FAU - Topcu, Mehmet Emre AU - Topcu ME AUID- ORCID: 0009-0007-1631-8805 AD - Department of Pathology, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa 16059, Turkey. LA - eng PT - Journal Article DEP - 20251114 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 RN - 0 (Antioxidants) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Plant Extracts) SB - IM MH - Animals MH - Rats MH - Rats, Wistar MH - *Antioxidants/therapeutic use/pharmacology MH - Male MH - *Persea/chemistry MH - *Achilles Tendon/injuries/drug effects/physiopathology MH - *Anti-Inflammatory Agents/therapeutic use/pharmacology MH - *Glycine max/chemistry MH - *Wound Healing/drug effects MH - *Tendon Injuries/drug therapy MH - Disease Models, Animal MH - Oxidative Stress/drug effects MH - *Plant Extracts/therapeutic use/pharmacology PMC - PMC12654124 OTO - NOTNLM OT - Achilles tendon injury OT - avocado–soybean unsaponifiables OT - inflammation OT - oxidative stress OT - tendon healing COIS- The authors declare no conflicts of interest. EDAT- 2025/11/27 06:29 MHDA- 2025/11/27 06:30 PMCR- 2025/11/14 CRDT- 2025/11/27 01:16 PHST- 2025/10/15 00:00 [received] PHST- 2025/11/03 00:00 [revised] PHST- 2025/11/12 00:00 [accepted] PHST- 2025/11/27 06:30 [medline] PHST- 2025/11/27 06:29 [pubmed] PHST- 2025/11/27 01:16 [entrez] PHST- 2025/11/14 00:00 [pmc-release] AID - medicina61112035 [pii] AID - medicina-61-02035 [pii] AID - 10.3390/medicina61112035 [doi] PST - epublish SO - Medicina (Kaunas). 2025 Nov 14;61(11):2035. doi: 10.3390/medicina61112035. PMID- 22722667 OWN - NLM STAT- MEDLINE DCOM- 20130312 LR - 20161125 IS - 1422-6421 (Electronic) IS - 1422-6405 (Linking) VI - 196 IP - 5 DP - 2012 TI - Novel application of Theranekron® enhanced the structural and functional performance of the tenotomized tendon in rabbits. PG - 442-55 LID - 10.1159/000337860 [doi] AB - The effects of Tarantula cubensis extract (TC; Theranekron®) on the experimentally induced rupture of the superficial digital flexor tendon (SDFT) 28 days post-injury (DPI) was studied in rabbits. Forty mature White New Zealand male rabbits were randomly divided into two groups. TC was repeatedly injected subcutaneously over the lesion 3, 7 and 10 days after tenotomy and surgical anastomosis. Clinical and ultrasonographic evaluations were conducted at weekly intervals. The animals were euthanized 28 DPI and the tendons were investigated for macroscopic, histopathologic, ultrastructural, biomechanical and percent dry weight parameters. Treatment reduced signs of acute inflammation and strongly ameliorated clinical symptoms, structural organization and biomechanical properties (p < 0.05). Apparently, TC is effective in restoring the clinical, morphological and biomechanical properties of the injured SDFT in rabbits and may be valuable in human and veterinary medicine. CI - Copyright © 2012 S. Karger AG, Basel. FAU - Oryan, Ahmad AU - Oryan A AD - Department of Pathology, School of Veterinary Medicine, Shiraz University, Shiraz, Iran. FAU - Moshiri, Ali AU - Moshiri A FAU - Raayat, Ali Reza AU - Raayat AR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120619 PL - Switzerland TA - Cells Tissues Organs JT - Cells, tissues, organs JID - 100883360 RN - 0 (Plant Extracts) SB - IM MH - Animals MH - Male MH - Plant Extracts/*therapeutic use MH - Rabbits MH - Radiography MH - Random Allocation MH - Tendons/diagnostic imaging/drug effects/*surgery MH - *Tenotomy MH - Ultrasonography EDAT- 2012/06/23 06:00 MHDA- 2013/03/13 06:00 CRDT- 2012/06/23 06:00 PHST- 2012/03/07 00:00 [accepted] PHST- 2012/06/23 06:00 [entrez] PHST- 2012/06/23 06:00 [pubmed] PHST- 2013/03/13 06:00 [medline] AID - 000337860 [pii] AID - 10.1159/000337860 [doi] PST - ppublish SO - Cells Tissues Organs. 2012;196(5):442-55. doi: 10.1159/000337860. Epub 2012 Jun 19. PMID- 26447005 OWN - NLM STAT- MEDLINE DCOM- 20180116 LR - 20220317 IS - 2202-4433 (Electronic) IS - 2202-4433 (Linking) VI - 13 IP - 1 DP - 2015 Jan TI - Effectiveness of ondansetron as an adjunct to lidocaine intravenous regional anesthesia on tourniquet pain and postoperative pain in patients undergoing elective hand surgery: a systematic review protocol. PG - 27-38 LID - 10.11124/jbisrir-2015-1768 [doi] AB - REVIEW QUESTION/OBJECTIVE: The objective of this quantitative systematic review is to determine the effects of ondansetron as an adjunct to lidocaine on the tourniquet pain and postoperative pain of American Society of Anesthesiologists (ASA) class 1 or 2 adult patients undergoing elective hand surgery with intravenous regional anesthesia. BACKGROUND: Both injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain. Hand injuries and deformities encompass an area of upper extremity surgery, wherein isolation and accessibility to peripheral nerves allows for a wide range of anesthesia techniques. Common hand surgeries include carpal tunnel or trigger finger release, Dupuytren's contracture fasciectomy, tendon repair, and ganglion cyst removal. According to the extent of injury or deformity, a general anesthetic, regional anesthetic, monitored anesthetic care (MAC) or local anesthetic may be used for these hand surgeries. Depending on the injury or deformity, local anesthesia may not provide sufficient anesthesia, but a general anesthesia may not be completely warranted either. Typical elective hand surgeries performed under regional anesthesia and MAC may be the ideal anesthetic plan that balances adequate sedation and analgesia. Intravenous regional anesthesia (IVRA), commonly known as a bier block, is a safe and effective anesthetic and is typically utilized in uncomplicated hand or forearm surgeries lasting less than an hour. Intravenous regional anesthesia was first developed by August Bier in 1908 for anesthesia of the hand and forearm. It is a regional anesthetic technique that is easy to perform, with success rates up to 98%. Intravenous regional anesthesia is a simple, reliable and cost-effective anesthesia technique for short ambulatory hand surgery. The IVRA technique is ideal for American Society of Anesthesiologists (ASA) class 1 or 2 patients, which according to ASA classification, are individuals who are healthy with well controlled to no comorbidities.The IVRA technique consists of inserting an intravenous catheter into a peripheral vein of the affected extremity. A double pneumatic tourniquet is applied to the same arm. The extremity is lifted and exsanguinated from distal to proximal with an Esmarch bandage. The proximal cuff of the tourniquet is then inflated to the appropriate pressure; standard 250mmHg for an upper extremity followed by the distal cuff. Insufflation times are limited to a maximum of one and a half to two hours, whereas the total insufflation time should never be less than 20 minutes. The Esmarch bandage is removed, and the local anesthetic is injected via the intravenous catheter to promote anesthesia in the operative area. In addition to the advantages of IVRA, there are disadvantages as well. These disadvantages include, but are not limited to, local anesthetic (LA) toxicity, delayed onset of action, poor muscle relaxation, tourniquet pain, and minimal postoperative analgesia. A method for improving analgesia and IVRA is to add medications to the IVRA solution. The ideal IVRA should include rapid onset of sensory and motor block, reduced LA dose, reduced intraoperative and tourniquet pain, prolonged postoperative analgesia, and minimal side effects.Adjuncts to LA can help offset some of the disadvantages mentioned above. In a systematic review of adjuncts for intravenous regional anesthesia conducted by Choyce and Peng, 29 studies were systematically reviewed to include various adjuncts to LA in IVRA. Adjuncts studied in this review included opioids, tramadol, non-steroidal anti-inflammatory drugs (NSAIDs), clonidine, muscle relaxants, sodium bicarbonate and potassium. The results of this systematic review suggest that NSAIDs have the most potential to offer as adjuncts to IVRA, while opioid adjuncts to IVRA proved to be disappointing as a form of postoperative analgesia. The search for the optimal IVRA adjunct that improves analgesia but has limited side effects is ongoing. More recent studies on adjuncts to IVRA have included medications such as neostigmine, dexmetomidine, nitroglycerin, and ondansetron.Ondansetron is a specific 5-hydroxytryptamine-3 (5-HT3 or serotonin) antagonist, commonly used as an antiemetic drug for prevention or treatment of postoperative nausea and vomiting. Used in the recommended dose range, there are minimal reported side effects, with constipation, dizziness and headache being the most common. 5-HT3 antagonists such as ondansetron possess anti-inflammatory, anesthetic, and analgesic properties which may have a potential role in decreasing pain. 5-HT3 antagonists participate in the pathway of nociception by interfering with peripheral effects of serotonin on nociception. By binding to opioid mu receptors and acting as a potential opioid agonist, the result is a peripheral nociceptive analgesic effect. A study by Deegan shows that there are 5-HT3 receptors on the central spinal terminal, which suggests that ondansetron could have both peripheral and central nociceptive effects. Ambesh et al. found that pain during injection of propofol can be successfully prevented by the administration of 4 mg of ondansetron. In a study performed by Reddy et al., it was shown that 4 mg of ondansetron could significantly reduce pain during the intravenous (IV) injection of rocuronium and propofol.Ondansetron may be useful for its potential anti-in-ammatory effect as an adjunct to medication to reduce acute inflammation. Ondansetron can block sodium channels similar to local anesthetics and produce a local anesthetic effect. It has been shown to be approximately fifteen times more potent than lidocaine. A study by Farouk suggests the addition of ondansetron to lidocaine may improve the quality of IVRA and prolong postoperative analgesia in patients undergoing hand surgery. A study conducted by Honarmand, concluded that the addition of ondansetron to lidocaine for IVRA reduced intraoperative and postoperative analgesic use.Tourniquet pain, which is described as a dull and aching pain sensation, is caused by the nerve compression from the tourniquet. Neuropathic pain produced by nerve compression plays an important role in the etiology of this discomfort. Tourniquet pain is thought to be mediated by impulse propagation via small, unmyelinated, slow-conducting C fibers. The duration of the tourniquet time is directly proportional to the onset of tourniquet pain. In a study by Asik, onset of tourniquet pain ranged from eight to fifteen minutes. Tourniquet pain is a well-known limitation of IVRA and is a factor that can limit the number of times which IVRA can be used for extremity surgery. Lidocaine is one of the most frequently used LAs for IVRA. It has a relatively brief duration of action which may limit the postoperative analgesia. Duration of postoperative analgesia, measured as time to first analgesic requirement ranged from 34 to 45 minutes (median) with LA alone.Outcome measures will include pain assessment for intraoperative tourniquet pain and postoperative pain measured by first analgesic requirement time (the time elapsed after tourniquet release to the first request by the patient for analgesic). Pain will be assessed with a visual analog scale (VAS) (0 = no pain and 10 = worst pain imaginable). A VAS score of more than three would indicate pain threshold has been exceeded.A preliminary search of the Joanna Briggs Database of Systematic Reviews and Implementation Reports, the Cochrane Library, CINAHL, PubMed and PROSPERO has revealed that there are currently no systematic reviews (either published or underway) on the topic of ondansetron as an adjunct to lidocaine intravenous regional anesthesia. Search terms included Zofran, ondansetron, intravenous regional anesthesia, and IVRA. Outcomes of this review will determine if ondansetron, admixed with lidocaine, has an effect on tourniquet pain, and secondly to determine if ondansetron, admixed with lidocaine, has an effect on the duration of postoperative analgesia. FAU - Badeaux, Jennifer AU - Badeaux J AD - 1 The Louisiana Center for Evidence-Based Nursing at LSUHSC School of Nursing: an Affiliate Center of the Joanna Briggs Institute. FAU - Bonanno, Laura AU - Bonanno L FAU - Au, Henry AU - Au H LA - eng PT - Journal Article PL - Australia TA - JBI Database System Rev Implement Rep JT - JBI database of systematic reviews and implementation reports JID - 101648258 RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Serotonin Antagonists) RN - 4AF302ESOS (Ondansetron) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - Anesthesia, Conduction/methods MH - Anesthesia, Intravenous/*methods MH - Anesthetics, Local/therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Elective Surgical Procedures/adverse effects MH - Hand/*surgery MH - Hand Injuries MH - Humans MH - Lidocaine/*administration & dosage MH - Ondansetron/administration & dosage/*pharmacology MH - Orthopedic Procedures/adverse effects MH - Pain Measurement/drug effects MH - Pain, Postoperative/drug therapy MH - Serotonin Antagonists/therapeutic use MH - Systematic Reviews as Topic MH - Tourniquets/*adverse effects EDAT- 2015/10/09 06:00 MHDA- 2015/10/09 06:01 CRDT- 2015/10/09 06:00 PHST- 2015/10/09 06:00 [entrez] PHST- 2015/10/09 06:00 [pubmed] PHST- 2015/10/09 06:01 [medline] AID - 10.11124/jbisrir-2015-1768 [doi] PST - ppublish SO - JBI Database System Rev Implement Rep. 2015 Jan;13(1):27-38. doi: 10.11124/jbisrir-2015-1768. PMID- 13398797 OWN - NLM STAT- MEDLINE DCOM- 20020501 LR - 20181201 IS - 0099-9695 (Print) IS - 0099-9695 (Linking) VI - 24 IP - 1 DP - 1957 Jan-Feb TI - Abolition of mass femoral muscular contractions during transurethral resection. PG - 23-5 FAU - LIEF, P A AU - LIEF PA FAU - NARINS, L AU - NARINS L LA - eng PT - Journal Article PL - United States TA - J Mt Sinai Hosp N Y JT - Journal of the Mount Sinai Hospital, New York JID - 0242260 RN - 8063-06-7 (Curare) SB - OM MH - Curare/*therapeutic use MH - Humans MH - *Leg MH - Male MH - *Muscle Contraction MH - *Muscle, Skeletal MH - *Muscles MH - Prostate/*surgery MH - *Reflex MH - *Tendons OID - CLML: 5731:45420 OTO - NLM OT - *CURARE/therapeutic use OT - *LEG/muscles and tendons OT - *PROSTATE/surgery OT - *REFLEX EDAT- 1957/01/01 00:00 MHDA- 1957/01/01 00:01 CRDT- 1957/01/01 00:00 PHST- 1957/01/01 00:00 [pubmed] PHST- 1957/01/01 00:01 [medline] PHST- 1957/01/01 00:00 [entrez] PST - ppublish SO - J Mt Sinai Hosp N Y. 1957 Jan-Feb;24(1):23-5. PMID- 13429456 OWN - NLM STAT- MEDLINE DCOM- 20020501 LR - 20181201 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 119 IP - 4 DP - 1957 Apr TI - The effect of neuromuscular blocking agents on isolated human intercostal muscles. PG - 485-94 FAU - CREESE, R AU - CREESE R FAU - DILLON, J B AU - DILLON JB FAU - MARSHALL, J AU - MARSHALL J FAU - SABAWALA, P B AU - SABAWALA PB FAU - SCHNEIDER, D J AU - SCHNEIDER DJ FAU - TAYLOR, D B AU - TAYLOR DB FAU - ZINN, D E AU - ZINN DE LA - eng PT - Journal Article PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Muscle Relaxants, Central) RN - 0 (Neuromuscular Blocking Agents) RN - 8063-06-7 (Curare) SB - OM MH - Curare/*pharmacology MH - Humans MH - *Intercostal Muscles MH - Muscle Relaxants, Central/*pharmacology MH - *Muscles MH - *Neuromuscular Blocking Agents MH - *Ribs MH - *Tendons OID - CLML: 5732:27636 OTO - NLM OT - *CURARE/effects OT - *MUSCLE RELAXANTS/effects OT - *RIBS/muscles and tendons EDAT- 1957/04/01 00:00 MHDA- 1957/04/01 00:01 CRDT- 1957/04/01 00:00 PHST- 1957/04/01 00:00 [pubmed] PHST- 1957/04/01 00:01 [medline] PHST- 1957/04/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1957 Apr;119(4):485-94. PMID- 21711561 OWN - NLM STAT- MEDLINE DCOM- 20120113 LR - 20211020 IS - 1472-6882 (Electronic) IS - 1472-6882 (Linking) VI - 11 DP - 2011 Jun 28 TI - More resistant tendons obtained from the association of Heteropterys aphrodisiaca and endurance training. PG - 51 LID - 10.1186/1472-6882-11-51 [doi] AB - BACKGROUND: Popular Brazilian medicine uses Heteropterys aphrodisiaca infusion as a tonic or stimulant, for the treatment of nervous debility and breakdown and for muscle and bone weakness. This study investigated the effects of Heteropterys aphrodisiaca infusion on the tendon properties and extracellular matrix of rats under endurance training. METHODS: Wistar rats were grouped as follows: CS- control sedentary, HS- H. aphrodisiaca sedentary, CT-control trained, HT- H. aphrodisiaca trained. The training protocol consisted in running on a motorized treadmill, five times a week, with weekly increase in treadmill speed and duration. Control groups received water while the HS and HT groups received H. aphrodisiaca infusion, daily, by gavage for the 8 weeks of training. Achilles tendons were frozen for biochemical and biomechanical analysis or preserved in Karnovsky's fixative, then processed for histomorphological analysis with light microscopy. RESULTS: Biomechanical analysis showed significant increase in maximum load, maximum stress, modulus of elasticity and stiffness of the HT animals' tendons. The metalloproteinase-2 activity was reduced in the HT group. The compression region of HT animals' tendons had a stronger and more intense metachromasy, which suggests an increase in glycosaminoglycan concentration in this region of the tendon. The most intense birefringence was observed in both compression and tension regions of HT animals' tendons, which may indicate a higher organizational level of collagen bundles. The hydroxyproline content increased in the HT group. CONCLUSIONS: The association of endurance training with H. aphrodisiaca resulted in more organized collagen bundles and more resistant tendons to support higher loads from intense muscle contraction. Despite the clear anabolic effects of Heteropterys aphrodisiaca and the endurance exercise association, no side effects were observed, such as those found for synthetic anabolic androgenic steroids. FAU - Monteiro, Juliana C AU - Monteiro JC AD - Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, SP, Brazil. FAU - Gomes, Marcos L M AU - Gomes ML FAU - Tomiosso, Tatiana C AU - Tomiosso TC FAU - Nakagaki, Wilson R AU - Nakagaki WR FAU - Sbervelheri, Mariana M AU - Sbervelheri MM FAU - Ferrucci, Danilo L AU - Ferrucci DL FAU - Pimentel, Edson R AU - Pimentel ER FAU - Dolder, Heidi AU - Dolder H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110628 PL - England TA - BMC Complement Altern Med JT - BMC complementary and alternative medicine JID - 101088661 RN - 0 (Glycosaminoglycans) RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Achilles Tendon/*drug effects/physiology MH - Animals MH - Brazil MH - Collagen/*metabolism MH - Elasticity/drug effects MH - Extracellular Matrix/drug effects MH - Glycosaminoglycans/metabolism MH - Hydroxyproline/metabolism MH - Male MH - *Malpighiaceae MH - Matrix Metalloproteinase 2/metabolism MH - Medicine, Traditional MH - Physical Endurance MH - Plant Extracts/*pharmacology MH - Plant Roots MH - Rats MH - Rats, Wistar MH - Running/*physiology MH - Stress, Mechanical PMC - PMC3146459 EDAT- 2011/06/30 06:00 MHDA- 2012/01/14 06:00 PMCR- 2011/06/28 CRDT- 2011/06/30 06:00 PHST- 2011/02/21 00:00 [received] PHST- 2011/06/28 00:00 [accepted] PHST- 2011/06/30 06:00 [entrez] PHST- 2011/06/30 06:00 [pubmed] PHST- 2012/01/14 06:00 [medline] PHST- 2011/06/28 00:00 [pmc-release] AID - 1472-6882-11-51 [pii] AID - 10.1186/1472-6882-11-51 [doi] PST - epublish SO - BMC Complement Altern Med. 2011 Jun 28;11:51. doi: 10.1186/1472-6882-11-51. PMID- 34244516 OWN - NLM STAT- MEDLINE DCOM- 20210720 LR - 20231107 IS - 2041-1723 (Electronic) IS - 2041-1723 (Linking) VI - 12 IP - 1 DP - 2021 Jul 9 TI - Transcriptional profiling of mESC-derived tendon and fibrocartilage cell fate switch. PG - 4208 LID - 10.1038/s41467-021-24535-5 [doi] LID - 4208 AB - The transcriptional regulators underlying induction and differentiation of dense connective tissues such as tendon and related fibrocartilaginous tissues (meniscus and annulus fibrosus) remain largely unknown. Using an iterative approach informed by developmental cues and single cell RNA sequencing (scRNA-seq), we establish directed differentiation models to generate tendon and fibrocartilage cells from mouse embryonic stem cells (mESCs) by activation of TGFβ and hedgehog pathways, achieving 90% induction efficiency. Transcriptional signatures of the mESC-derived cells recapitulate embryonic tendon and fibrocartilage signatures from the mouse tail. scRNA-seq further identify retinoic acid signaling as a critical regulator of cell fate switch between TGFβ-induced tendon and fibrocartilage lineages. Trajectory analysis by RNA sequencing define transcriptional modules underlying tendon and fibrocartilage fate induction and identify molecules associated with lineage-specific differentiation. Finally, we successfully generate 3-dimensional engineered tissues using these differentiation protocols and show activation of mechanotransduction markers with dynamic tensile loading. These findings provide a serum-free approach to generate tendon and fibrocartilage cells and tissues at high efficiency for modeling development and disease. CI - © 2021. The Author(s). FAU - Kaji, Deepak A AU - Kaji DA AD - Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Montero, Angela M AU - Montero AM AD - Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Patel, Roosheel AU - Patel R AD - Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Huang, Alice H AU - Huang AH AUID- ORCID: 0000-0002-5037-6829 AD - Department of Orthopaedics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ah364@cumc.columbia.edu. LA - eng GR - F31 AR073626/AR/NIAMS NIH HHS/United States GR - R01 AR069537/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20210709 PL - England TA - Nat Commun JT - Nature communications JID - 101528555 RN - 0 (Hedgehog Proteins) RN - 0 (Transforming Growth Factor beta) RN - 5688UTC01R (Tretinoin) SB - IM MH - Animals MH - Cell Differentiation/genetics MH - Embryo, Mammalian MH - Fibrocartilage/cytology/*growth & development MH - Gene Expression Regulation, Developmental MH - Hedgehog Proteins/metabolism MH - Mechanotransduction, Cellular/genetics MH - Mice MH - Mouse Embryonic Stem Cells/*physiology MH - RNA-Seq MH - Signal Transduction/genetics MH - Single-Cell Analysis MH - Tendons/cytology/*growth & development MH - Tissue Engineering/*methods MH - *Transcriptional Activation MH - Transforming Growth Factor beta/metabolism MH - Tretinoin/metabolism PMC - PMC8270956 COIS- The authors have no competing interests to declare. EDAT- 2021/07/11 06:00 MHDA- 2021/07/21 06:00 PMCR- 2021/07/09 CRDT- 2021/07/10 05:49 PHST- 2020/07/18 00:00 [received] PHST- 2021/06/24 00:00 [accepted] PHST- 2021/07/10 05:49 [entrez] PHST- 2021/07/11 06:00 [pubmed] PHST- 2021/07/21 06:00 [medline] PHST- 2021/07/09 00:00 [pmc-release] AID - 10.1038/s41467-021-24535-5 [pii] AID - 24535 [pii] AID - 10.1038/s41467-021-24535-5 [doi] PST - epublish SO - Nat Commun. 2021 Jul 9;12(1):4208. doi: 10.1038/s41467-021-24535-5. PMID- 23650387 OWN - NLM STAT- MEDLINE DCOM- 20130806 LR - 20231213 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 110 IP - 21 DP - 2013 May 21 TI - Kif7 is required for the patterning and differentiation of the diaphragm in a model of syndromic congenital diaphragmatic hernia. PG - E1898-905 LID - 10.1073/pnas.1222797110 [doi] AB - Congenital diaphragmatic hernia (CDH) is a common birth defect that results in a high degree of neonatal morbidity and mortality, but its pathological mechanisms are largely unknown. Therefore, we performed a forward genetic screen in mice to identify unique genes, models, and mechanisms of abnormal diaphragm development. We identified a mutant allele of kinesin family member 7 (Kif7), the disorganized diaphragm (dd). Embryos homozygous for the dd allele possess communicating diaphragmatic hernias, central tendon patterning defects, and increased cell proliferation with diaphragmatic tissue hyperplasia. Because the patterning of the central tendon is undescribed, we analyzed the expression of genes regulating tendonogenesis in dd/dd mutant embryos, and we determined that retinoic acid (RA) signaling was misregulautted. To further investigate the role of Kif7 and RA signaling in the development of the embryonic diaphragm, we established primary mesenchymal cultures of WT embryonic day 13.5 diaphragmatic cells. We determined that RA signaling is necessary for the expression of tendon markers as well as the expression of other CDH-associated genes. Knockdown of Kif7, and retinoic acid receptors alpha (Rara), beta (Rarb), and gamma (Rarg) indicated that RA signaling is dependent on these genes to promote tendonogenesis within the embryonic diaphragm. Taken together, our results provide evidence for a model in which inhibition of RA receptor signaling promotes CDH pathogenesis through a complex gene network. FAU - Coles, Garry L AU - Coles GL AD - Department of Biomedical Genetics, Center for Pediatric Biomedical Research, University of Rochester Medical Center, Rochester, NY 14642, USA. FAU - Ackerman, Kate G AU - Ackerman KG LA - eng GR - R01 HL085459/HL/NHLBI NIH HHS/United States GR - T32 HL066988/HL/NHLBI NIH HHS/United States GR - HL066988/HL/NHLBI NIH HHS/United States GR - R01HL085459/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20130506 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Muscle Proteins) RN - 0 (Rara protein, mouse) RN - 0 (Receptors, Retinoic Acid) RN - 0 (Retinoic Acid Receptor alpha) RN - 0 (retinoic acid receptor beta) RN - 5688UTC01R (Tretinoin) RN - EC 3.6.1.- (Kif7 protein, mouse) RN - EC 3.6.4.4 (Kinesins) SB - IM MH - Alleles MH - Animals MH - *Body Patterning MH - *Cell Differentiation MH - Cell Line MH - Diaphragm/*embryology/pathology MH - Gene Expression Regulation, Developmental/genetics MH - Hernia, Diaphragmatic/embryology/genetics/pathology MH - *Hernias, Diaphragmatic, Congenital MH - Kinesins/genetics/*metabolism MH - Mice MH - Mice, Mutant Strains MH - Muscle Proteins/genetics/*metabolism MH - Receptors, Retinoic Acid/genetics/metabolism MH - Retinoic Acid Receptor alpha MH - *Signal Transduction MH - Tendons/embryology/pathology MH - Tretinoin/metabolism MH - Retinoic Acid Receptor gamma PMC - PMC3666741 OTO - NOTNLM OT - Gli transcription factors OT - myotendonous junction OT - tendon differentiation COIS- The authors declare no conflict of interest. EDAT- 2013/05/08 06:00 MHDA- 2013/08/07 06:00 PMCR- 2013/11/21 CRDT- 2013/05/08 06:00 PHST- 2013/05/08 06:00 [entrez] PHST- 2013/05/08 06:00 [pubmed] PHST- 2013/08/07 06:00 [medline] PHST- 2013/11/21 00:00 [pmc-release] AID - 1222797110 [pii] AID - 201222797 [pii] AID - 10.1073/pnas.1222797110 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2013 May 21;110(21):E1898-905. doi: 10.1073/pnas.1222797110. Epub 2013 May 6. PMID- 29140140 OWN - NLM STAT- MEDLINE DCOM- 20180808 LR - 20250623 IS - 1543-2742 (Electronic) IS - 1526-484X (Linking) VI - 28 IP - 3 DP - 2018 May 1 TI - The Physiological Mechanisms of Effect of Vitamins and Amino Acids on Tendon and Muscle Healing: A Systematic Review. PG - 294-311 LID - 10.1123/ijsnem.2017-0267 [doi] AB - AIMS/OBJECTIVES: To evaluate the current literature via systematic review to ascertain whether amino acids/vitamins provide any influence on musculotendinous healing and if so, by which physiological mechanisms. METHODS: EBSCO, PubMed, ScienceDirect, Embase Classic/Embase, and MEDLINE were searched using terms including "vitamins," "amino acids," "healing," "muscle," and "tendon." The primary search had 479 citations, of which 466 were excluded predominantly due to nonrandomized design. Randomized human and animal studies investigating all supplement types/forms of administration were included. Critical appraisal of internal validity was assessed using the Cochrane risk of Bias Tool or the Systematic Review Centre for Laboratory Animal Experimentation Risk of Bias Tool for human and animal studies, respectively. Two reviewers performed duel data extraction. RESULTS: Twelve studies met criteria for inclusion: eight examined tendon healing and four examined muscle healing. All studies used animal models, except two human trials using a combined integrator. Narrative synthesis was performed via content analysis of demonstrated statistically significant effects and thematic analysis of proposed physiological mechanisms of intervention. Vitamin C/taurine demonstrated indirect effects on tendon healing through antioxidant activity. Vitamin A/glycine showed direct effects on extracellular matrix tissue synthesis. Vitamin E shows an antiproliferative influence on collagen deposition. Leucine directly influences signaling pathways to promote muscle protein synthesis. DISCUSSION: Preliminary evidence exists, demonstrating that vitamins and amino acids may facilitate multilevel changes in musculotendinous healing; however, recommendations on clinical utility should be made with caution. All animal studies and one human study showed high risk of bias with moderate interobserver agreement (k = 0.46). Currently, there is limited evidence to support the use of vitamins and amino acids for musculotendinous injury. Both high-quality animal experimentation of the proposed mechanisms confirming the physiological influence of supplementation and human studies evaluating effects on tissue morphology and biochemistry are required before practical application. FAU - Tack, Christopher AU - Tack C AD - 1 University of Hertfordshire. AD - 2 Guy's Hospital. FAU - Shorthouse, Faye AU - Shorthouse F AD - 2 Guy's Hospital. FAU - Kass, Lindsy AU - Kass L AD - 1 University of Hertfordshire. LA - eng PT - Journal Article PT - Systematic Review DEP - 20180601 PL - United States TA - Int J Sport Nutr Exerc Metab JT - International journal of sport nutrition and exercise metabolism JID - 100939812 RN - 0 (Amino Acids) RN - 0 (Vitamins) RN - 11103-57-4 (Vitamin A) RN - 1406-18-4 (Vitamin E) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Amino Acids/*pharmacology MH - Animals MH - Ascorbic Acid MH - Humans MH - Muscle, Skeletal/*drug effects/injuries MH - Randomized Controlled Trials as Topic MH - Tendon Injuries/drug therapy MH - Tendons/*drug effects MH - Vitamin A MH - Vitamin E MH - Vitamins/*pharmacology MH - Wound Healing/*drug effects OTO - NOTNLM OT - musculoskeletal tissue OT - nutrition OT - rehabilitation OT - supplementation EDAT- 2017/11/16 06:00 MHDA- 2018/08/09 06:00 CRDT- 2017/11/16 06:00 PHST- 2017/11/16 06:00 [pubmed] PHST- 2018/08/09 06:00 [medline] PHST- 2017/11/16 06:00 [entrez] AID - 10.1123/ijsnem.2017-0267 [doi] PST - ppublish SO - Int J Sport Nutr Exerc Metab. 2018 May 1;28(3):294-311. doi: 10.1123/ijsnem.2017-0267. Epub 2018 Jun 1. PMID- 33201874 OWN - NLM STAT- MEDLINE DCOM- 20210104 LR - 20210104 IS - 1545-7885 (Electronic) IS - 1544-9173 (Print) IS - 1544-9173 (Linking) VI - 18 IP - 11 DP - 2020 Nov TI - Local retinoic acid signaling directs emergence of the extraocular muscle functional unit. PG - e3000902 LID - 10.1371/journal.pbio.3000902 [doi] LID - e3000902 AB - Coordinated development of muscles, tendons, and their attachment sites ensures emergence of functional musculoskeletal units that are adapted to diverse anatomical demands among different species. How these different tissues are patterned and functionally assembled during embryogenesis is poorly understood. Here, we investigated the morphogenesis of extraocular muscles (EOMs), an evolutionary conserved cranial muscle group that is crucial for the coordinated movement of the eyeballs and for visual acuity. By means of lineage analysis, we redefined the cellular origins of periocular connective tissues interacting with the EOMs, which do not arise exclusively from neural crest mesenchyme as previously thought. Using 3D imaging approaches, we established an integrative blueprint for the EOM functional unit. By doing so, we identified a developmental time window in which individual EOMs emerge from a unique muscle anlage and establish insertions in the sclera, which sets these muscles apart from classical muscle-to-bone type of insertions. Further, we demonstrate that the eyeballs are a source of diffusible all-trans retinoic acid (ATRA) that allow their targeting by the EOMs in a temporal and dose-dependent manner. Using genetically modified mice and inhibitor treatments, we find that endogenous local variations in the concentration of retinoids contribute to the establishment of tendon condensations and attachment sites that precede the initiation of muscle patterning. Collectively, our results highlight how global and site-specific programs are deployed for the assembly of muscle functional units with precise definition of muscle shapes and topographical wiring of their tendon attachments. FAU - Comai, Glenda Evangelina AU - Comai GE AUID- ORCID: 0000-0003-3244-3378 AD - Stem Cells & Development Unit, Institut Pasteur, Paris, France. AD - CNRS UMR 3738, Institut Pasteur, Paris, France. FAU - Tesařová, Markéta AU - Tesařová M AUID- ORCID: 0000-0002-5200-7365 AD - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic. FAU - Dupé, Valérie AU - Dupé V AUID- ORCID: 0000-0003-4859-0612 AD - Université de Rennes, CNRS, IGDR, Rennes, France. FAU - Rhinn, Muriel AU - Rhinn M AD - IGBMC-Institut de Génétique et de Biologie Moleculaire et Cellulaire, Illkirch, France. FAU - Vallecillo-García, Pedro AU - Vallecillo-García P AUID- ORCID: 0000-0001-6833-5972 AD - Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. FAU - da Silva, Fabio AU - da Silva F AD - Université Côte d'Azur, INSERM, CNRS, iBV, Nice, France. AD - Division of Molecular Embryology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Feret, Betty AU - Feret B AD - IGBMC-Institut de Génétique et de Biologie Moleculaire et Cellulaire, Illkirch, France. FAU - Exelby, Katherine AU - Exelby K AD - The Francis Crick Institute, London, United Kingdom. FAU - Dollé, Pascal AU - Dollé P AD - IGBMC-Institut de Génétique et de Biologie Moleculaire et Cellulaire, Illkirch, France. FAU - Carlsson, Leif AU - Carlsson L AD - Umeå Center for Molecular Medicine, Umeå University, Umeå, Sweden. FAU - Pryce, Brian AU - Pryce B AD - Research Division, Shriners Hospital for Children, Portland, United States of America. FAU - Spitz, François AU - Spitz F AD - Genomics of Animal Development Unit, Institut Pasteur, Paris, France. FAU - Stricker, Sigmar AU - Stricker S AUID- ORCID: 0000-0002-7174-5363 AD - Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. FAU - Zikmund, Tomáš AU - Zikmund T AUID- ORCID: 0000-0003-2948-5198 AD - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic. FAU - Kaiser, Jozef AU - Kaiser J AUID- ORCID: 0000-0002-7397-125X AD - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic. FAU - Briscoe, James AU - Briscoe J AUID- ORCID: 0000-0002-1020-5240 AD - The Francis Crick Institute, London, United Kingdom. FAU - Schedl, Andreas AU - Schedl A AUID- ORCID: 0000-0001-9380-7396 AD - Université Côte d'Azur, INSERM, CNRS, iBV, Nice, France. FAU - Ghyselinck, Norbert B AU - Ghyselinck NB AUID- ORCID: 0000-0003-4042-6818 AD - IGBMC-Institut de Génétique et de Biologie Moleculaire et Cellulaire, Illkirch, France. FAU - Schweitzer, Ronen AU - Schweitzer R AUID- ORCID: 0000-0002-7425-5028 AD - Research Division, Shriners Hospital for Children, Portland, United States of America. FAU - Tajbakhsh, Shahragim AU - Tajbakhsh S AUID- ORCID: 0000-0003-1809-7202 AD - Stem Cells & Development Unit, Institut Pasteur, Paris, France. AD - CNRS UMR 3738, Institut Pasteur, Paris, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201117 PL - United States TA - PLoS Biol JT - PLoS biology JID - 101183755 RN - 5688UTC01R (Tretinoin) SB - IM MH - Animals MH - Connective Tissue/physiology MH - Embryonic Development MH - Eye MH - Imaging, Three-Dimensional/methods MH - Mice/embryology MH - Mice, Inbred C57BL MH - Mice, Inbred DBA MH - Morphogenesis MH - Oculomotor Muscles/*embryology/*growth & development MH - Signal Transduction MH - Tendons/physiology MH - Tretinoin/*metabolism/physiology PMC - PMC7707851 COIS- The authors have declared that no competing interests exist. EDAT- 2020/11/18 06:00 MHDA- 2021/01/05 06:00 PMCR- 2020/11/17 CRDT- 2020/11/17 17:11 PHST- 2020/01/07 00:00 [received] PHST- 2020/10/01 00:00 [accepted] PHST- 2020/12/01 00:00 [revised] PHST- 2020/11/18 06:00 [pubmed] PHST- 2021/01/05 06:00 [medline] PHST- 2020/11/17 17:11 [entrez] PHST- 2020/11/17 00:00 [pmc-release] AID - PBIOLOGY-D-20-00048 [pii] AID - 10.1371/journal.pbio.3000902 [doi] PST - epublish SO - PLoS Biol. 2020 Nov 17;18(11):e3000902. doi: 10.1371/journal.pbio.3000902. eCollection 2020 Nov. PMID- 20451573 OWN - NLM STAT- MEDLINE DCOM- 20101103 LR - 20240109 IS - 1873-6351 (Electronic) IS - 0278-6915 (Linking) VI - 48 IP - 8-9 DP - 2010 Aug-Sep TI - Antihyperglycemic activity and inhibition of advanced glycation end product formation by Cuminum cyminum in streptozotocin induced diabetic rats. PG - 2030-6 LID - 10.1016/j.fct.2010.04.048 [doi] AB - Cuminum cyminum is widely used as a spice in many countries. The aim of the present study was to investigate the effect of methanolic extract of seeds of C. cyminum (CC) on diabetes, oxidative stress and formation of advanced glycated end products (AGE) and obtain comparison with glibenclamide. In vitro studies indicated that CC inhibited free radicals and AGE formation. Treatment of streptozotocin-diabetic rats with CC and glibenclamide for 28 days caused a reduction in blood glucose, glycosylated hemoglobin, creatinine, blood urea nitrogen and improved serum insulin and glycogen (liver and skeletal muscle) content when compared to diabetic control rats. Significant reduction in renal oxidative stress and AGE was observed with CC when compared to diabetic control and glibenclamide. CC and glibenclamide improved antioxidant status in kidney and pancreas of diabetic rats. Diabetic rats showed increase in rat tail tendon collagen, glycated collagen, collagen linked fluorescence and reduction in pepsin digestion. Treatment with CC significantly improved these parameters when compared to diabetic control and glibenclamide group. Though the antidiabetic effect of CC was comparable to glibenclamide it had better effect in controlling oxidative stress and inhibiting the AGE formation, which are implicated in the pathogenesis of diabetic microvascular complications. CI - Copyright (c) 2010 Elsevier Ltd. All rights reserved. FAU - Jagtap, A G AU - Jagtap AG AD - Department of Pharmacology, Bombay College of Pharmacy, Mumbai 400068, Maharashtra, India. jagtaparti@gmail.com FAU - Patil, P B AU - Patil PB LA - eng PT - Journal Article DEP - 20100506 PL - England TA - Food Chem Toxicol JT - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association JID - 8207483 RN - 0 (Blood Glucose) RN - 0 (Free Radical Scavengers) RN - 0 (Glycation End Products, Advanced) RN - 0 (Hypoglycemic Agents) RN - 0 (Insulin) RN - 0 (Plant Extracts) RN - 0 (Thiobarbituric Acid Reactive Substances) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 9005-79-2 (Glycogen) RN - AYI8EX34EU (Creatinine) SB - IM MH - Animals MH - Blood Glucose/metabolism MH - Blood Urea Nitrogen MH - Body Weight/drug effects MH - Creatinine/blood MH - Cuminum/*chemistry MH - Diabetes Mellitus, Experimental/blood/*drug therapy MH - Female MH - Free Radical Scavengers/chemistry/pharmacology MH - Glycation End Products, Advanced/*antagonists & inhibitors/metabolism MH - Glycogen/metabolism MH - Hypoglycemic Agents/isolation & purification/*pharmacology/*therapeutic use MH - Insulin/blood MH - Kidney/drug effects/metabolism MH - Male MH - Plant Extracts/chemistry/pharmacology MH - Rats MH - Rats, Wistar MH - Serum Albumin, Bovine/chemistry MH - Tendons/chemistry/drug effects MH - Thiobarbituric Acid Reactive Substances/metabolism EDAT- 2010/05/11 06:00 MHDA- 2010/11/04 06:00 CRDT- 2010/05/11 06:00 PHST- 2009/11/12 00:00 [received] PHST- 2010/04/01 00:00 [revised] PHST- 2010/04/30 00:00 [accepted] PHST- 2010/05/11 06:00 [entrez] PHST- 2010/05/11 06:00 [pubmed] PHST- 2010/11/04 06:00 [medline] AID - S0278-6915(10)00275-9 [pii] AID - 10.1016/j.fct.2010.04.048 [doi] PST - ppublish SO - Food Chem Toxicol. 2010 Aug-Sep;48(8-9):2030-6. doi: 10.1016/j.fct.2010.04.048. Epub 2010 May 6. PMID- 37313565 OWN - NLM STAT- MEDLINE DCOM- 20230615 LR - 20230615 IS - 0255-2930 (Print) IS - 0255-2930 (Linking) VI - 43 IP - 6 DP - 2023 Jun 12 TI - [Application of "Sancai principle" for needle-knife treatment of bi syndrome of neck region]. PG - 697-700 LID - 10.13703/j.0255-2930.20220814-k0003 [doi] AB - Under the guidance of the "Sancai principle", based on the understanding of the etiology and pathogenesis of the imbalance of muscles and bones in bi syndrome of neck region, holistic treatment should be used. The needle-knife release therapy is applied at corresponding acupoints in the three parts i.e. head, neck and back including Tiancai points (Naohu [GV 17] and Naokong [GB 19]), Rencai points (neck Jiaji [EX-B 2]), and Dicai points (Dazhui [GV 14], Quyuan [SI 13] and Tianzong [SI 11]). According to the layers of the lesion's meridians and muscles, the needle-knife is inserted into skin, muscle and bone to relax the tendons and treat bone disorders, and restore the normal mechanical balance of neck. FAU - Zhang, Xin AU - Zhang X AD - College of Acupuncture-Moxibustion and Tuina, Shandong University of TCM, Jinan 250355, China. FAU - Yang, Wen-Long AU - Yang WL AD - Department of Pain, First Affiliated Hospital of Shandong First Medical University, Jinan 250014. FAU - Liu, Fang-Ming AU - Liu FM AD - College of Acupuncture-Moxibustion and Tuina, Shandong University of TCM, Jinan 250355, China; Department of Pain, First Affiliated Hospital of Shandong First Medical University, Jinan 250014. LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhongguo Zhen Jiu JT - Zhongguo zhen jiu = Chinese acupuncture & moxibustion JID - 8600658 RN - 0 (sancai) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - *Needles MH - *Drugs, Chinese Herbal MH - Muscles MH - Tendons OTO - NOTNLM OT - Sancai principle OT - bi syndrome of neck region OT - muscles and bones OT - needle-knife EDAT- 2023/06/14 06:42 MHDA- 2023/06/15 06:42 CRDT- 2023/06/14 04:00 PHST- 2023/06/15 06:42 [medline] PHST- 2023/06/14 06:42 [pubmed] PHST- 2023/06/14 04:00 [entrez] AID - 10.13703/j.0255-2930.20220814-k0003 [doi] PST - ppublish SO - Zhongguo Zhen Jiu. 2023 Jun 12;43(6):697-700. doi: 10.13703/j.0255-2930.20220814-k0003. PMID- 31527569 OWN - NLM STAT- MEDLINE DCOM- 20200210 LR - 20200210 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 25 DP - 2019 Sep 17 TI - Retinoic Acid Promotes Retinoic Acid Signaling by Suppression of Pitx1 In Tendon Cells: A Possible Mechanism of a Clubfoot-Like Phenotype Induced by Retinoic Acid. PG - 6980-6989 LID - 10.12659/MSM.917740 [doi] AB - BACKGROUND The pathogenesis of idiopathic congenital clubfoot (CCF) is unknown. Although some familial patients have Pitx1 mutations, and the Pitx1+/- genotype causes a clubfoot-like phenotype in mice, the mechanism of Pitx1-induced CCF is unknown. MATERIAL AND METHODS We used tibialis anterior tendon samples to detect the expression of Pitx1 in idiopathic and neurogenic clubfoot patients. After obtaining Sprague-Dawley (SD) rat Achilles tendon cells, the expression of Pitx1 was knocked down by SiRNA. After 48 h of culture, mass spectrometry was used to quantitatively analyze proteins. Then, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to assess the downstream pathway of PITX1. The relationship between Pitx1 and the promoter region of deacetylase 1 (Sirtuin-1 and Sirt1) was examined by luciferase and ChIP assays. RESULTS We found that Pitx1 expression in the tendon samples of idiopathic CCF patients was downregulated. Mass spectrometry analysis revealed that the inhibition of Pitx1 induced the downregulation of Sirt1 expression in tendon cells. Luciferase and ChIP assays confirmed that Pitx1 binds to the promoter region of SIRT1 and promotes Sirt1 gene transcription. Further results showed that, after the inhibition of Pitx1 in tendon cells, CRABP2 acetylation increased, the nuclear import of CRABP2 was enhanced, and the expression of RARß2 increased. After the inhibition of Pitx1, RARß2 expression was further increased by RA treatment in tendon cells. In the presence of retinoic acid, the expression of Pitx1 was inhibited in tendon cells. CONCLUSIONS Pitx1 binds to the promoter region of SIRT1 and promotes the transcription of SIRT1. Positive feedback occurs between RA signaling and Pitx1. FAU - Zhao, Xiang AU - Zhao X AD - Department of Pediatric Orthopaedics, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (mainland). FAU - Yang, Xuan AU - Yang X AD - Department of Pediatric Orthopaedics, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (mainland). LA - eng PT - Journal Article DEP - 20190917 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (Paired Box Transcription Factors) RN - 0 (homeobox protein PITX1) RN - 5688UTC01R (Tretinoin) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - Animals MH - Animals, Newborn MH - Biological Transport MH - Child MH - Child, Preschool MH - Clubfoot/*metabolism/*pathology MH - Feedback, Physiological MH - Humans MH - Male MH - Paired Box Transcription Factors/*metabolism MH - Promoter Regions, Genetic/genetics MH - Rats, Sprague-Dawley MH - *Signal Transduction MH - Sirtuin 1/genetics/metabolism MH - Tendons/*pathology MH - Tretinoin/*metabolism PMC - PMC6761847 COIS- Conflict of interest None. EDAT- 2019/09/19 06:00 MHDA- 2020/02/11 06:00 PMCR- 2019/09/17 CRDT- 2019/09/19 06:00 PHST- 2019/09/19 06:00 [entrez] PHST- 2019/09/19 06:00 [pubmed] PHST- 2020/02/11 06:00 [medline] PHST- 2019/09/17 00:00 [pmc-release] AID - 917740 [pii] AID - 10.12659/MSM.917740 [doi] PST - epublish SO - Med Sci Monit. 2019 Sep 17;25:6980-6989. doi: 10.12659/MSM.917740. PMID- 39321186 OWN - NLM STAT- MEDLINE DCOM- 20240925 LR - 20250619 IS - 2053-1095 (Electronic) IS - 2053-1095 (Linking) VI - 10 IP - 6 DP - 2024 Nov TI - Effect of hydroalcoholic extract of Sambucus nigra on superficial digital flexor tendon repair in rabbit by ultrasonography and histopathology. PG - e1581 LID - 10.1002/vms3.1581 [doi] LID - e1581 AB - BACKGROUND: Adult tendon tissue has limited and slow regenerative capacity. Sambucus nigra plant possesses antioxidant and anti-inflammatory attributes. OBJECTIVES: This study aimed to evaluate the effect of hydroalcoholic extract of this plant's fruit on superficial digital flexor tendon repair in rabbits (SDFT). METHODS: Twenty-five male New Zealand white rabbits weighing 1.5-2 kg were selected, quarantined and randomly divided into four groups of six. By performing a partial left posterior limb tenotomy, differentiating the SDFT and creating multiple scrapes were performed. During 3 consecutive days post-surgery, the positive control group was injected with 0.5 mg/kg dexamethasone, whereas the treatment groups received extract doses of 200 and 400 mg/kg, respectively. The negative control group did not receive any medication. Evaluation of sonographic and histopathological parameters was conducted on days 0, 7 and 28 post-surgeries. Findings were analysed and compared using SPSS22. RESULTS: Both treatment groups showed significant differences in echogenicity, and collagen fibre alignment compared to the control and positive control groups, in sonographic evaluation. Histopathological examination revealed fewer inflammatory cells and increased collagen fibre formation in the treatment groups compared to the other two groups. No significant difference in angiogenesis was observed among the groups on days 7 and 28 (p value <0.05). CONCLUSIONS: The results indicate that the S. nigra fruit extract, by stimulating collagen synthesis and reducing inflammation, effectively accelerates the healing process of injured tendons. CI - © 2024 The Author(s). Veterinary Medicine and Science published by John Wiley & Sons Ltd. FAU - Asgari, Niusha AU - Asgari N AUID- ORCID: 0009-0009-0858-9036 AD - Graduated of Veterinary Medicine, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. FAU - Moghtadaei-Khorasgani, Elham AU - Moghtadaei-Khorasgani E AUID- ORCID: 0000-0002-8666-5104 AD - Department of Pathobiology, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. FAU - Yadegari, Mehrdad AU - Yadegari M AUID- ORCID: 0000-0001-5515-1357 AD - Department of Veterinary Clinical Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. FAU - Taheri-Boroujeni, Omid AU - Taheri-Boroujeni O AUID- ORCID: 0000-0003-1861-8629 AD - Faculty of Veterinary Medicine, Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran. LA - eng PT - Journal Article PL - England TA - Vet Med Sci JT - Veterinary medicine and science JID - 101678837 RN - 0 (Plant Extracts) SB - IM MH - Animals MH - Rabbits MH - *Plant Extracts/pharmacology/administration & dosage MH - Male MH - *Sambucus nigra/chemistry MH - *Tendon Injuries/veterinary/drug therapy MH - Ultrasonography MH - Random Allocation MH - Tendons/drug effects PMC - PMC11423904 OTO - NOTNLM OT - Sambucus nigra OT - collagen OT - dexamethasone OT - inflammation OT - tendon COIS- The authors declare no conflicts of interest. EDAT- 2024/09/25 22:18 MHDA- 2024/09/25 22:19 PMCR- 2024/09/25 CRDT- 2024/09/25 13:34 PHST- 2024/03/27 00:00 [received] PHST- 2024/07/26 00:00 [accepted] PHST- 2024/09/25 22:19 [medline] PHST- 2024/09/25 22:18 [pubmed] PHST- 2024/09/25 13:34 [entrez] PHST- 2024/09/25 00:00 [pmc-release] AID - VMS31581 [pii] AID - 10.1002/vms3.1581 [doi] PST - ppublish SO - Vet Med Sci. 2024 Nov;10(6):e1581. doi: 10.1002/vms3.1581. PMID- 24273976 OWN - NLM STAT- MEDLINE DCOM- 20150105 LR - 20161018 IS - 1003-5370 (Print) IS - 1003-5370 (Linking) VI - 33 IP - 9 DP - 2013 Sep TI - [Danhong injection, ligustrazine injection, combined adsorbable biomembranes prevented adhesion of tendons after the repair operation: a clinical research]. PG - 1212-5 AB - OBJECTIVE: To explore the effect and the mechanism of Danhong Injection (DI), Ligustrazine Injection (LI), and adsorbable biomembranes in preventing the adhesion of tendons and tissues. METHODS: Totally 120 patients all suffering from simple flexor digitorum tendon rupture on the hand zone two damaged by sharp weapons were randomly assigned to Group A (Dikang adsorbable biomembrane), Group B (Tianxinfu adsorbable biomembrane), Group C (Tianxinfu adsorbable biomembrane + Ligustrazine group), and Group D (Tianxinfu adsorbable biomembrane + DI group) in accordance with random digit table, 30 cases in each group. Indicators such as total active movement (TAM) of the hand tendon, Minnesota manual dexterity test (MMDT), and finger flex strength test (FFST) were observed. RESULTS: The TAM and the favorable rate were higher in Group C and D than in Group A and B at post-operative 4 and 8 week (P < 0.05, P < 0.01). There was no statistical difference between Group C and D (P > 0.05). Each index of MMDT was lower in Group C and D than in Group A and B (P < 0.05). There was no statistical difference in FFST among all the 4 groups (P > 0.05). CONCLUSIONS: Combined application of LI or DI with Tianxinfu adsorbable biomembranes could effectively prevent the adhesion of tendons. DI showed equivalent effect as LI did. Besides, the combined application was superior in preventing adhesion to using Xintianfu adsorbable biomembrane or Dikan adsorbable biomembrane alone. FAU - Zhao, Zhi-Wei AU - Zhao ZW AD - Luoyang Orthopedics Hospital, Henan 471002, China. zhaozhiwei999@126.com FAU - Cheng, Chun-Sheng AU - Cheng CS FAU - Ma, Wen-Long AU - Ma WL FAU - Shan, Hai-Min AU - Shan HM FAU - Cheng, Zhen-Zhen AU - Cheng ZZ FAU - Song, Guan-Peng AU - Song GP LA - chi PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - China TA - Zhongguo Zhong Xi Yi Jie He Za Zhi JT - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine JID - 9211576 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Membranes, Artificial) RN - 0 (Pyrazines) RN - 0 (danhong) RN - V80F4IA5XG (tetramethylpyrazine) SB - IM MH - Absorbable Implants MH - Adult MH - Drugs, Chinese Herbal/administration & dosage/*therapeutic use MH - Female MH - Humans MH - Male MH - Membranes, Artificial MH - Middle Aged MH - Musculoskeletal Diseases/*prevention & control MH - Pyrazines/administration & dosage/*therapeutic use MH - Tendon Injuries/*surgery MH - Tissue Adhesions/*prevention & control MH - Wound Healing EDAT- 2013/11/28 06:00 MHDA- 2015/01/06 06:00 CRDT- 2013/11/27 06:00 PHST- 2013/11/27 06:00 [entrez] PHST- 2013/11/28 06:00 [pubmed] PHST- 2015/01/06 06:00 [medline] PST - ppublish SO - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Sep;33(9):1212-5. PMID- 41017607 OWN - NLM STAT- MEDLINE DCOM- 20250929 LR - 20250929 IS - 1661-8157 (Print) IS - 1661-8157 (Linking) VI - 114 IP - 8-9 DP - 2025 Sep TI - [Fluoroquinolone-associated disability after taking ciprofloxacin]. PG - 326-330 LID - 10.23785/PRAXIS.2025.08_09.005 [doi] AB - Ciprofloxacin is among the most commonly prescribed Fluoroquinolones. Side effects of Fluoroquinolones include tendinopathies, ar-rhythmias, gastrointestinal discomfort, and neurological symptoms. The definition of a "Fluoroquinolone-associated disability" includes dis-ability, symptoms in several body systems and duration of symptoms after discontinuation of the antibiotic. The pathophysiology of this disease is probably due to a damage to the redox system. We report on a 41-year-old patient who felt pain in his Achilles tendons three days after starting to take ciprofloxacin (of a total of 3 g) and presented as an emergency. In the course of the disease, the pain became chronically disabling and the patient developed paresthesia of both extremities and intermittent heart palpitations. The only tolerated pain medication was Pregabalin. Several MRI examinations showed minimal peritendinitis and irritation of the Achilles tendons. Blood samples indicated probable intracellular damage at low intracellular ATP and coenzyme Q10 values. CI - © 2025 Aerzteverlag medinfo AG. FAU - Piazza, Raffaele AU - Piazza R AD - Institut für Hausarztmedizin, UniversitätsSpital Zürich, Zürich. FAU - Weiss, Katja AU - Weiss K AD - Institut für Hausarztmedizin, UniversitätsSpital Zürich, Zürich. FAU - Rosemann, Thomas AU - Rosemann T AD - Institut für Hausarztmedizin, UniversitätsSpital Zürich, Zürich. FAU - Knechtle, Beat AU - Knechtle B AD - Institut für Hausarztmedizin, UniversitätsSpital Zürich, Zürich. AD - Medbase, St. Gallen. AD - beat.knechtle@hispeed.ch. LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Fluoroquinolone-Associated Disability nach Einnahme von Ciprofloxacin. PL - Switzerland TA - Praxis (Bern 1994) JT - Praxis JID - 101468093 RN - 5E8K9I0O4U (Ciprofloxacin) RN - 1339-63-5 (Ubiquinone) RN - EJ27X76M46 (coenzyme Q10) RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Infective Agents) SB - IM MH - Humans MH - *Ciprofloxacin/adverse effects/therapeutic use MH - Adult MH - Male MH - *Achilles Tendon/drug effects/pathology MH - Ubiquinone/analogs & derivatives/blood MH - *Tendinopathy/chemically induced/diagnosis MH - Magnetic Resonance Imaging MH - Diagnosis, Differential MH - *Anti-Bacterial Agents/adverse effects/therapeutic use MH - *Anti-Infective Agents/adverse effects/therapeutic use OTO - NOTNLM OT - Ciprofloxacin OT - FQAD OT - Fluorchinolones OT - achillopathy OT - disability EDAT- 2025/09/29 09:27 MHDA- 2025/09/29 09:28 CRDT- 2025/09/29 05:33 PHST- 2025/09/29 09:28 [medline] PHST- 2025/09/29 09:27 [pubmed] PHST- 2025/09/29 05:33 [entrez] AID - 10.23785/PRAXIS.2025.08_09.005 [doi] PST - ppublish SO - Praxis (Bern 1994). 2025 Sep;114(8-9):326-330. doi: 10.23785/PRAXIS.2025.08_09.005. PMID- 33973686 OWN - NLM STAT- MEDLINE DCOM- 20211020 LR - 20211020 IS - 1097-0029 (Electronic) IS - 1059-910X (Linking) VI - 84 IP - 11 DP - 2021 Nov TI - Acmella oleracea extract increases collagen content and organization in partially transected tendons. PG - 2588-2597 LID - 10.1002/jemt.23809 [doi] AB - Acmella oleracea contains spilanthol as the main active compound, which possesses analgesic and anti-inflammatory effects that can favor tendon reorganization. To analyze the effect of A. oleracea on the content and organization of collagen in injured tendons, the calcaneal tendon of male Lewis rats was partially transected and treated at the site of injury with a topical application of 20% A. oleracea ointment (AO group) or with the ointment base without the plant extract (B group). The animals were euthanized 21 days after partial transection. Higher collagen concentration was observed in the AO group than in the B group, and morphological analysis using polarization microscopy showed higher birefringence in the AO group than in the B group, indicating higher collagen organization. No difference was observed in the number of fibroblasts, blood vessels, proteoglycan distribution, and maximum load between the B and AO groups. In conclusion, topical application of 20% A. oleracea ointment increased the molecular organization and content of collagen, thus indicating a potential application in tendon repair. Studies on the later phases of the tendon healing process are necessary to demonstrate the possible biomechanical changes after the application of A. oleracea ointment. CI - © 2021 Wiley Periodicals LLC. FAU - Moro, Selma Delgado de Souza AU - Moro SDS AD - Biomedical Sciences Graduate Program, University Center of Herminio Ometto Foundation/FHO, São Paulo, Brazil. FAU - de Oliveira Fujii, Lucas AU - de Oliveira Fujii L AD - Biomedical Sciences Graduate Program, University Center of Herminio Ometto Foundation/FHO, São Paulo, Brazil. FAU - Teodoro, Luis Felipe Rodrigues AU - Teodoro LFR AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas-UNICAMP, São Paulo, Brazil. FAU - Frauz, Katleen AU - Frauz K AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas-UNICAMP, São Paulo, Brazil. FAU - Mazoni, Alysson Fernandes AU - Mazoni AF AD - Faculty of Mechanical Engineering, University of Campinas-UNICAMP, São Paulo, Brazil. FAU - Esquisatto, Marcelo Augusto Maretto AU - Esquisatto MAM AD - Biomedical Sciences Graduate Program, University Center of Herminio Ometto Foundation/FHO, São Paulo, Brazil. FAU - Rodrigues, Rodney Alexandre Ferreira AU - Rodrigues RAF AD - Chemical, Biological and Agricultural Pluridisciplinary Research Center (CPQBA), University of Campinas-UNICAMP, São Paulo, Brazil. FAU - Pimentel, Edson Rosa AU - Pimentel ER AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas-UNICAMP, São Paulo, Brazil. FAU - de Aro, Andrea Aparecida AU - de Aro AA AUID- ORCID: 0000-0003-2895-0000 AD - Biomedical Sciences Graduate Program, University Center of Herminio Ometto Foundation/FHO, São Paulo, Brazil. AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas-UNICAMP, São Paulo, Brazil. LA - eng GR - Herminio Ometto Foundation/FHO/ PT - Journal Article DEP - 20210511 PL - United States TA - Microsc Res Tech JT - Microscopy research and technique JID - 9203012 RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) SB - IM MH - *Achilles Tendon MH - Animals MH - Collagen MH - Male MH - Plant Extracts/pharmacology MH - Rats MH - Rats, Inbred Lew MH - Rats, Wistar MH - *Tendon Injuries/drug therapy OTO - NOTNLM OT - Acmella oleracea OT - birefringence OT - calcaneal tendon OT - repair EDAT- 2021/05/12 06:00 MHDA- 2021/10/21 06:00 CRDT- 2021/05/11 09:35 PHST- 2021/02/18 00:00 [revised] PHST- 2020/12/03 00:00 [received] PHST- 2021/04/19 00:00 [accepted] PHST- 2021/05/12 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/05/11 09:35 [entrez] AID - 10.1002/jemt.23809 [doi] PST - ppublish SO - Microsc Res Tech. 2021 Nov;84(11):2588-2597. doi: 10.1002/jemt.23809. Epub 2021 May 11. PMID- 3861262 OWN - NLM STAT- MEDLINE DCOM- 19851024 LR - 20250306 IS - 0272-4340 (Print) IS - 1573-6830 (Electronic) IS - 0272-4340 (Linking) VI - 5 IP - 1-2 DP - 1985 Jun TI - Activity and synapse elimination at the neuromuscular junction. PG - 167-82 AB - The neuromuscular junction undergoes a loss of synaptic connections during early development. This loss converts the innervation of each muscle fiber from polyneuronal to single. During this change the number of motor neurons remains constant but the number of muscle fibers innervated by each motor neuron is reduced. Evidence indicates that a local competition among the inputs on each muscle fiber determines which inputs are eliminated. The role of synapse elimination in the development of neuromuscular circuits, other than ensuring a single innervation of each fiber, is unclear. Most evidence suggests that the elimination plays little or no role in correcting for errant connections. Rather, it seems that connections are initially highly specific, in terms of both which motor neurons connect to which muscles and which neurons connect to which particular fibers within these muscles. A number of attempts have been made to determine the importance of neuromuscular activity during early development for this rearrangement of synaptic connections. Experiments reducing neuromuscular activity by muscle tenotomy, deafferentation and spinal cord section, block of nerve impulse conduction with tetrodotoxin, and the use of postsynaptic and presynaptic blocking agents have all shown that normal activity is required for normal synapse elimination. Most experiments in which complete muscle paralysis has been achieved show that activity may be essential for the occurrence of synapse elimination. Furthermore, experiments in which neuromuscular activity has been augmented by external stimulation show that synapse elimination is accelerated. A plausible hypothesis to explain the activity dependence of neuromuscular synapse elimination is that a neuromuscular trophic agent is produced by the muscle fibers and that this production is controlled by muscle-fiber activity. The terminals on each fiber compete for the substance produced by that fiber. Inactive fibers produce large quantities of this substance; on the other hand, muscle activity suppresses the level of synthesis of this agent to the point where only a single synaptic terminal can be maintained. Inactive muscle fibers would be expected to be able to maintain more nerve terminals. The attractiveness of this scheme is that it provides a simple feedback mechanism to ensure that each fiber retains a single effective input. FAU - Thompson, W J AU - Thompson WJ LA - eng PT - Journal Article PL - Netherlands TA - Cell Mol Neurobiol JT - Cellular and molecular neurobiology JID - 8200709 RN - 0 (Bungarotoxins) RN - 4368-28-9 (Tetrodotoxin) RN - 8063-06-7 (Curare) RN - EC 3.4.24.69 (Botulinum Toxins) SB - IM MH - Animals MH - Botulinum Toxins/pharmacology MH - Bungarotoxins/pharmacology MH - Cats MH - Cordotomy MH - Curare/pharmacology MH - Electromyography MH - Mice MH - Muscle Denervation MH - *Muscle Development MH - Neuromuscular Junction/drug effects/*physiology MH - Rats MH - Spinal Cord/physiology MH - Tendons/surgery MH - Tetrodotoxin/pharmacology PMC - PMC11572775 EDAT- 1985/06/01 00:00 MHDA- 1985/06/01 00:01 PMCR- 1985/06/01 CRDT- 1985/06/01 00:00 PHST- 1985/06/01 00:00 [pubmed] PHST- 1985/06/01 00:01 [medline] PHST- 1985/06/01 00:00 [entrez] PHST- 1985/06/01 00:00 [pmc-release] AID - BF00711091 [pii] AID - 10.1007/BF00711091 [doi] PST - ppublish SO - Cell Mol Neurobiol. 1985 Jun;5(1-2):167-82. doi: 10.1007/BF00711091. PMID- 6678242 OWN - NLM STAT- MEDLINE DCOM- 19840830 LR - 20131121 IS - 0019-5499 (Print) IS - 0019-5499 (Linking) VI - 27 IP - 4 DP - 1983 Oct-Dec TI - Creatine of tenotomised muscle under influence of prednisolone treatment. PG - 334-6 AB - The prednisolone has got a devastating effect on the creatine content of muscle when it is tenotomised. In non-tenotomised muscle, prednisolone reduces the creatine content. The reduction of creatine content in prednisolone treated muscle which are tenotomised is due to perhaps the catabolic effect of glucocorticoid analogue on muscle protein together with inactivity of the muscle. FAU - Mandal, S K AU - Mandal SK FAU - Dastidar, A G AU - Dastidar AG LA - eng PT - Journal Article PL - India TA - Indian J Physiol Pharmacol JT - Indian journal of physiology and pharmacology JID - 0374707 RN - 0 (Muscle Proteins) RN - 9PHQ9Y1OLM (Prednisolone) RN - MU72812GK0 (Creatine) SB - IM MH - Animals MH - Creatine/*analysis MH - Male MH - Muscle Proteins/metabolism MH - Muscle, Smooth/*drug effects/metabolism MH - Organ Size MH - Prednisolone/*pharmacology MH - Rats MH - Tendons/*physiology/surgery OID - NASA: 84263416 EDAT- 1983/10/01 00:00 MHDA- 1983/10/01 00:01 CRDT- 1983/10/01 00:00 PHST- 1983/10/01 00:00 [pubmed] PHST- 1983/10/01 00:01 [medline] PHST- 1983/10/01 00:00 [entrez] PST - ppublish SO - Indian J Physiol Pharmacol. 1983 Oct-Dec;27(4):334-6. PMID- 40825698 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20250826 IS - 0255-2930 (Print) IS - 0255-2930 (Linking) VI - 45 IP - 8 DP - 2025 Aug 12 TI - [WANG Jihong's experience in treatment of post-stroke hypermyotonia with "trinity" approach of Lai's tongyuan therapy]. PG - 1134-1140 LID - 10.13703/j.0255-2930.20240822-k0003 [doi] AB - This article introduces the clinical experience of Professor WANG Jihong in treatment of post-stroke hypermyotonia with Lai's tongyuan therapy (therapy for removing obstruction and consolidating vital essence). Regarding the pathogenesis of this disease, Professor WANG Jihong emphasizes a "trinity" approach, "the mind disturbed, qi and blood unbalanced, and yuan (vital essence) not consolidated". In treatment, "the unblocking, conducting and nourishing are taken as the fundamental" to "prevent from over-dredging, balancing yin and yang, and avoiding over-replenishing". In clinical practice, the combined measure is adopted with acupuncture, tuina and herbal medicine. In acupuncture, the acupoints are selected according to the front-back combination of the points of the conception vessel and the governor vessel (basic prescription: Yintang [GV24(+)], Baihui [GV20] and Niesanzhen; prescription for promoting the governor vessel: Dazhui (GV14), Jinsuo [GV8], Xinshu [BL15], Pishu [BL20] and etc.; and the prescription for consolidating the vital essence: Danzhong (CV17), Zhongwan [CV12], Tianshu [ST25], Qihai [CV6]) and etc., as well as those on the four limbs for "opening, closing and pivoting of yin and yang" (on the upper limbs of the affected side: Jiquan [HT1], Jianyu [LI15], Quchi [LI11], Quze [PC3] and etc.; on the lower limbs of the affected side: Huantiao [GB30], Liangqiu [ST34], Xuehai [SP10], Yanglingquan [GB34]) and etc. The above points co-act on regulating the conception vessel and the governor vessel, and balancing yin and yang. Tuina is delivered on the governor vessel, the bladder meridian of foot-taiyang and wind points on the area between the head and nape, so as to promote the governor vessel, benefit the orifices, strengthen the spine and relax tendons. Herbal medicine works on nourishing the liver to soften tendons, nourishing blood to remove wind, regulating qi to replenish the spleen, consolidating the root to cultivate the vital essence, activating blood circulation to unblock meridians, and removing stasis to resolve phlegm. Tongyuan therapy provides a certain instruction in treatment of post-stroke hypermyotonia. FAU - Huang, Zhikai AU - Huang Z AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. FAU - Pan, Qi AU - Pan Q AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. FAU - Li, Aining AU - Li A AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. FAU - Wang, Jihong AU - Wang J AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. FAU - Wang, Yulian AU - Wang Y AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. FAU - Hou, Jialu AU - Hou J AD - Clinical Medical College of Acupuncture-Moxibustion and Rehabilitation, Guangzhou University of CM, Guangzhou 510006, Guangdong Province, China. LA - chi PT - English Abstract PT - Journal Article DEP - 20250519 PL - China TA - Zhongguo Zhen Jiu JT - Zhongguo zhen jiu = Chinese acupuncture & moxibustion JID - 8600658 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Acupuncture Therapy MH - Acupuncture Points MH - *Stroke/complications MH - Male MH - Female MH - Middle Aged MH - Aged MH - *Drugs, Chinese Herbal MH - Adult OTO - NOTNLM OT - WANG Jihong OT - acupuncture OT - famous doctor's experience OT - herbal medicine OT - post-stroke hypermyotonia OT - tongyuan therapy OT - tuina EDAT- 2025/08/19 00:28 MHDA- 2025/08/31 20:08 CRDT- 2025/08/18 21:43 PHST- 2024/08/22 00:00 [received] PHST- 2025/08/31 20:08 [medline] PHST- 2025/08/19 00:28 [pubmed] PHST- 2025/08/18 21:43 [entrez] AID - 10.13703/j.0255-2930.20240822-k0003 [doi] PST - ppublish SO - Zhongguo Zhen Jiu. 2025 Aug 12;45(8):1134-1140. doi: 10.13703/j.0255-2930.20240822-k0003. Epub 2025 May 19. PMID- 40603128 OWN - NLM STAT- MEDLINE DCOM- 20250702 LR - 20250702 IS - 1003-0034 (Print) IS - 1003-0034 (Linking) VI - 38 IP - 6 DP - 2025 Jun 25 TI - [Mechanism of traditional Chinese medicine monomers on regulating bone marrow mesenchymal stem cells to promote tendon-bone healing]. PG - 645-50 LID - 10.12200/j.issn.1003-0034.20240899 [doi] AB - The healing of the tendon-bone interface is a complex dynamic process involving the interaction of multiple cellular and molecular signaling pathways. Bone mesenchymal stem cells (BMSCs) have the potential to differentiate into various types of cells, including osteoblasts, chondrocytes and adipocytes, etc., and have the potential to regenerate damaged tissues. They are potential seed cells for promoting tendon-bone healing. How to precisely regulate the proliferation and differentiation of BMSCs to accelerate the process of tendon-bone healing is a current research hotspot. Monomers of traditional Chinese medicine can promote tendon-bone healing by regulating signaling pathways such as Wnt/β-catenin and BMP/Smad to induce osteogenic and chondrogenic differentiation of BMSCs. This article reviews from several aspects such as the regulatory role of related signaling pathways on tendine-bone healing, traditional Chinese medicine monomers and their mechanism of regulating BMSCs to promote tendine-bone healing in order to providing new ideas for promoting tendine-bone healing. FAU - Meng, Xiang-Zhe AU - Meng XZ AD - Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 311201, Zhejiang, China. FAU - Tian, Guan-Ming AU - Tian GM AD - Xiaoshan Yongxin Hospital, Hangzhou 311223, Zhejiang, China. FAU - Han, Lei AU - Han L AD - Department of Orthopaedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine, Hangzhou 311201, Zhejiang, China. FAU - Wang, Tuo AU - Wang T AD - Department of Orthopaedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine, Hangzhou 311201, Zhejiang, China. LA - chi PT - English Abstract PT - Journal Article PT - Review PL - China TA - Zhongguo Gu Shang JT - Zhongguo gu shang = China journal of orthopaedics and traumatology JID - 9815790 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - *Mesenchymal Stem Cells/drug effects/cytology MH - Humans MH - Animals MH - *Bone Marrow Cells/drug effects/cytology MH - *Bone and Bones/drug effects MH - *Wound Healing/drug effects MH - *Medicine, Chinese Traditional MH - *Tendons/drug effects MH - *Drugs, Chinese Herbal/pharmacology MH - Signal Transduction/drug effects MH - Cell Differentiation/drug effects OTO - NOTNLM OT - Bone mesenchymal stem cells OT - Review OT - Tendon-bone healing OT - Traditional Chinese medicine OT - Traditional Chinese medicine monomer EDAT- 2025/07/03 00:27 MHDA- 2025/07/03 00:28 CRDT- 2025/07/02 21:44 PHST- 2025/07/03 00:28 [medline] PHST- 2025/07/03 00:27 [pubmed] PHST- 2025/07/02 21:44 [entrez] AID - 10.12200/j.issn.1003-0034.20240899 [doi] PST - ppublish SO - Zhongguo Gu Shang. 2025 Jun 25;38(6):645-50. doi: 10.12200/j.issn.1003-0034.20240899. PMID- 14291394 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20190823 IS - 0001-5180 (Print) IS - 0001-5180 (Linking) VI - 60 DP - 1965 TI - HISTOCHEMISTRY AND CYTOCHEMISTRY OF EXPERIMENTALLY DENERVATED GUINEA PIG MUSCLE. I. HISTOCHEMISTRY. PG - 39-65 FAU - HOGENHUIS, L A AU - HOGENHUIS LA FAU - ENGEL, W K AU - ENGEL WK LA - eng PT - Journal Article PL - Switzerland TA - Acta Anat (Basel) JT - Acta anatomica JID - 0370272 RN - 0U46U6E8UK (NAD) RN - 12001-79-5 (Vitamin K) RN - 53-59-8 (NADP) RN - 9005-79-2 (Glycogen) RN - EC 1.- (Oxidoreductases) RN - EC 1.1.- (Alcohol Oxidoreductases) RN - EC 1.1.- (Glycerolphosphate Dehydrogenase) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - EC 1.3.5.1 (Electron Transport Complex II) RN - EC 1.3.99.1 (Succinate Dehydrogenase) RN - EC 1.9.3.1 (Electron Transport Complex IV) RN - EC 2.7.- (Phosphotransferases) RN - EC 3.6.1.- (Adenosine Triphosphatases) SB - OM MH - *Adenosine Triphosphatases MH - *Alcohol Oxidoreductases MH - *Anatomy MH - Animals MH - *Biopsy MH - *Denervation MH - *Electron Transport Complex II MH - *Electron Transport Complex IV MH - *Glycerolphosphate Dehydrogenase MH - *Glycogen MH - Guinea Pigs MH - *Histocytochemistry MH - *L-Lactate Dehydrogenase MH - *Muscles MH - *Myofibrils MH - *NAD MH - *NADP MH - *Oxidoreductases MH - *Phosphotransferases MH - *Research MH - *Succinate Dehydrogenase MH - *Tendons MH - *Vitamin K OTO - NLM OT - *ADENOSINE TRIPHOSPHATASE OT - *ALCOHOL OXIDOREDUCTASES OT - *ANATOMY OT - *BIOPSY OT - *CYTOCHROME OXIDASE OT - *DENERVATION OT - *EXPERIMENTAL LAB STUDY OT - *GLYCEROLPHOSPHATE DEHYDROGENASE OT - *GLYCOGEN OT - *GUINEA PIGS OT - *HISTOCYTOCHEMISTRY OT - *LACTATE DEHYDROGENASE OT - *MUSCLES OT - *MYOFIBRILS OT - *NAD OT - *NADP OT - *OXIDOREDUCTASES OT - *PHOSPHOTRANSFERASES OT - *SUCCINATE DEHYDROGENASE OT - *TENDONS OT - *VITAMIN K EDAT- 1965/01/01 00:00 MHDA- 1965/01/01 00:01 CRDT- 1965/01/01 00:00 PHST- 1965/01/01 00:00 [pubmed] PHST- 1965/01/01 00:01 [medline] PHST- 1965/01/01 00:00 [entrez] AID - 10.1159/000142635 [doi] PST - ppublish SO - Acta Anat (Basel). 1965;60:39-65. doi: 10.1159/000142635. PMID- 37586334 OWN - NLM STAT- MEDLINE DCOM- 20240807 LR - 20240807 IS - 1422-6421 (Electronic) IS - 1422-6405 (Linking) VI - 213 IP - 4 DP - 2024 TI - Momordica charantia Enhances Tendon Healing in Rats: An Experimental Study. PG - 304-315 LID - 10.1159/000533644 [doi] AB - Momordica charantia (MC) is a traditional plant widely used since ancient times for wound healing. This study evaluated its potential effects on tendon healing. Adult male Wistar albino rats (n = 32, 8 rats in each group) were anesthetized, and their Achilles tendons were prepared for surgical procedures. Group 1 (Cont = control group) was not subjected to any surgery and was used as a control group for baseline values. Group 2 (PR = primary repair group) underwent primary repair (PR) with a monofilament suture after a full-thickness incision of the Achilles tendon. A full-thickness incision was also made to the Achilles tendon of group 3 (CT = collagen tube-administered group), followed by PR and collagen tube insertion. In group 4 (MC = M. charantia-administered group), 1 mL of MC extract was applied locally on the collagen tube in addition to the surgical procedure applied to group 3. The Achilles tendons were excised on the postoperative 40th day and examined stereologically, histologically, and bioinformatically. Data showed that the total volume of the collagen fibers was higher in MC and CT groups than in the PR group. The total volume of the tendon was decreased in MC and CT groups than in the Cont group. The ratios between the volumes of the collagen fibers and total tendon in the MC and CT groups were significantly different from PR, but not different from the Cont group. Additionally, MC improved tenoblastic activity, collagen production, and neovascularization. Bioinformatic interactions showed that the proteases of MC could trigger the signals playing a role on vasculogenesis, reducing inflammation, and contributing to tenoblast activation and collagen remodeling. MC extract ameliorates the healing of injured tendon and can provide satisfactory tendon repair. Further works are recommended to explore the healing capacity of MC. CI - © 2023 S. Karger AG, Basel. FAU - Erdoğan, Furkan AU - Erdoğan F AD - Clinic of Orthopaedic and Traumatology, Sabuncuoğlu Şerafeddin Training and Research Hospital, Amasya, Turkey. FAU - Kaplan, Arife Ahsen AU - Kaplan AA AD - Department of Histology and Embryology, Faculty of Medicine, İstanbul Medipol University, Samsun, Turkey. FAU - Coşkun, Hüseyin Sina AU - Coşkun HS AD - Department of Orthopaedic and Traumatology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. FAU - Altun, Gamze AU - Altun G AD - Department of Histology and Embryology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. FAU - Altunkaynak, Berrin Zuhal AU - Altunkaynak BZ AD - Department of Histology and Embryology, Faculty of Medicine, İstanbul Okan University, Istanbul, Turkey. FAU - Kelsaka, Ebru AU - Kelsaka E AD - Department of Anaesthesia and Reanimation, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. FAU - Kaplan, Suleyman AU - Kaplan S AD - Department of Histology and Embryology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. AD - Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania. FAU - Pişkin, Ahmet AU - Pişkin A AD - Department of Orthopaedic and Traumatology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. LA - eng PT - Journal Article DEP - 20230816 PL - Switzerland TA - Cells Tissues Organs JT - Cells, tissues, organs JID - 100883360 RN - 0 (Plant Extracts) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - *Momordica charantia/chemistry MH - *Rats, Wistar MH - Male MH - *Wound Healing/drug effects MH - *Achilles Tendon/drug effects/surgery/injuries MH - *Plant Extracts/pharmacology MH - Rats MH - Tendon Injuries/drug therapy/pathology MH - Collagen/metabolism OTO - NOTNLM OT - Bioinformatics OT - Momordica charantia OT - Rat OT - Stereology OT - Tendon healing EDAT- 2023/08/17 00:42 MHDA- 2024/08/08 00:42 CRDT- 2023/08/16 18:23 PHST- 2023/02/13 00:00 [received] PHST- 2023/08/14 00:00 [accepted] PHST- 2024/08/08 00:42 [medline] PHST- 2023/08/17 00:42 [pubmed] PHST- 2023/08/16 18:23 [entrez] AID - 000533644 [pii] AID - 10.1159/000533644 [doi] PST - ppublish SO - Cells Tissues Organs. 2024;213(4):304-315. doi: 10.1159/000533644. Epub 2023 Aug 16. PMID- 24390370 OWN - NLM STAT- MEDLINE DCOM- 20140926 LR - 20211021 IS - 1560-2281 (Electronic) IS - 1083-3668 (Print) IS - 1083-3668 (Linking) VI - 19 IP - 1 DP - 2014 Jan TI - Functional assessment of gap junctions in monolayer and three-dimensional cultures of human tendon cells using fluorescence recovery after photobleaching. PG - 15001 LID - 10.1117/1.JBO.19.1.015001 [doi] LID - 015001 AB - Gap junction-mediated intercellular communication influences a variety of cellular activities. In tendons, gap junctions modulate collagen production, are involved in strain-induced cell death, and are involved in the response to mechanical stimulation. The aim of the present study was to investigate gap junction-mediated intercellular communication in healthy human tendon-derived cells using fluorescence recovery after photobleaching (FRAP). The FRAP is a noninvasive technique that allows quantitative measurement of gap junction function in living cells. It is based on diffusion-dependent redistribution of a gap junction-permeable fluorescent dye. Using FRAP, we showed that human tenocytes form functional gap junctions in monolayer and three-dimensional (3-D) collagen I culture. Fluorescently labeled tenocytes following photobleaching rapidly reacquired the fluorescent dye from neighboring cells, while HeLa cells, which do not communicate by gap junctions, remained bleached. Furthermore, both 18 β-glycyrrhetinic acid and carbenoxolone, standard inhibitors of gap junction activity, impaired fluorescence recovery in tendon cells. In both monolayer and 3-D cultures, intercellular communication in isolated cells was significantly decreased when compared with cells forming many cell-to-cell contacts. In this study, we used FRAP as a tool to quantify and experimentally manipulate the function of gap junctions in human tenocytes in both two-dimensional (2-D) and 3-D cultures. FAU - Kuzma-Kuzniarska, Maria AU - Kuzma-Kuzniarska M AD - University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford OX3 7LD, United Kingdom. FAU - Yapp, Clarence AU - Yapp C AD - University of Oxford, Structural Genomics Consortium, Oxford OX3 7DQ, United Kingdom. FAU - Pearson-Jones, Thomas W AU - Pearson-Jones TW AD - University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford OX3 7LD, United Kingdom. FAU - Jones, Andrew K AU - Jones AK AD - Oxford Brookes University, Faculty of Health and Life Sciences, Department of Biological and Medical Sciences Oxford OX3 0BP, United Kingdom. FAU - Hulley, Philippa A AU - Hulley PA AD - University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford OX3 7LD, United Kingdom. LA - eng GR - R01 EB009100/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Biomed Opt JT - Journal of biomedical optics JID - 9605853 RN - 1449-05-4 (18alpha-glycyrrhetinic acid) RN - 9007-34-5 (Collagen) RN - MM6384NG73 (Carbenoxolone) RN - P540XA09DR (Glycyrrhetinic Acid) SB - IM MH - Adult MH - Carbenoxolone/chemistry MH - Cell Communication MH - Cell Culture Techniques MH - Cells, Cultured MH - Collagen/chemistry MH - Diffusion MH - Female MH - Fluorescence Recovery After Photobleaching/*methods MH - Gap Junctions/*pathology MH - Glycyrrhetinic Acid/analogs & derivatives/chemistry MH - HeLa Cells MH - Humans MH - Imaging, Three-Dimensional MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Tendons/*cytology/*pathology PMC - PMC4019415 EDAT- 2014/01/07 06:00 MHDA- 2014/09/27 06:00 PMCR- 2015/01/03 CRDT- 2014/01/07 06:00 PHST- 2013/07/31 00:00 [received] PHST- 2013/12/03 00:00 [accepted] PHST- 2014/01/07 06:00 [entrez] PHST- 2014/01/07 06:00 [pubmed] PHST- 2014/09/27 06:00 [medline] PHST- 2015/01/03 00:00 [pmc-release] AID - 1812766 [pii] AID - 130544R [pii] AID - 10.1117/1.JBO.19.1.015001 [doi] PST - ppublish SO - J Biomed Opt. 2014 Jan;19(1):15001. doi: 10.1117/1.JBO.19.1.015001. PMID- 23225770 OWN - NLM STAT- MEDLINE DCOM- 20130904 LR - 20220309 IS - 1616-5195 (Electronic) IS - 1616-5187 (Linking) VI - 13 IP - 3 DP - 2013 Mar TI - Biocompatible fibrous networks of cellulose nanofibres and collagen crosslinked using genipin: potential as artificial ligament/tendons. PG - 289-98 LID - 10.1002/mabi.201200317 [doi] AB - Bio-based fibrous nanocomposites of cellulose nanofibres and non-crosslinked/crosslinked collagen were prepared by in situ pH-induced fibrillation of collagen phase and sterilized using gamma rays at 25 KGy. Collagen phase is crosslinked using genipin, a bio-based crosslinker that introduces flexible crosslinks. Microscopy studies of the prepared materials showed nanostructured fibrous collagen and cellulose dispersed in collagen matrix. Mechanical performance of the sterilized nanocomposites was close to that of natural ligament and tendon, in simulated body conditions. Cytocompatibility studies indicated that these nanocomposites allowed human ligament cell and human endothelial cell adhesion, growth, and differentiation; which is eminently favourable to ligament tissue engineering. CI - Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. FAU - Mathew, Aji P AU - Mathew AP AD - Division of Materials Science, Luleå University of Technology, 97187-Luleå, Sweden. aji.mathew@ltu.se FAU - Oksman, Kristiina AU - Oksman K FAU - Pierron, Dorothée AU - Pierron D FAU - Harmand, Marie-Françoise AU - Harmand MF LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121206 PL - Germany TA - Macromol Biosci JT - Macromolecular bioscience JID - 101135941 RN - 0 (Biocompatible Materials) RN - 0 (Cross-Linking Reagents) RN - 0 (Iridoids) RN - 9004-34-6 (Cellulose) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - Animals MH - Biocompatible Materials/*chemical synthesis/pharmacology MH - Cell Adhesion/drug effects MH - Cell Differentiation/drug effects MH - Cellulose/*chemistry MH - Collagen/*chemistry MH - Cross-Linking Reagents/*chemistry MH - Gamma Rays MH - Hydrogen-Ion Concentration MH - Iridoids/*chemistry MH - Ligaments/chemistry MH - Materials Testing MH - Mice MH - Microscopy, Electron, Scanning MH - NIH 3T3 Cells MH - Nanofibers/*chemistry/ultrastructure MH - Tendons/chemistry MH - Tissue Engineering/methods MH - Tissue Scaffolds EDAT- 2012/12/12 06:00 MHDA- 2013/09/05 06:00 CRDT- 2012/12/11 06:00 PHST- 2012/08/23 00:00 [received] PHST- 2012/10/10 00:00 [revised] PHST- 2012/12/11 06:00 [entrez] PHST- 2012/12/12 06:00 [pubmed] PHST- 2013/09/05 06:00 [medline] AID - 10.1002/mabi.201200317 [doi] PST - ppublish SO - Macromol Biosci. 2013 Mar;13(3):289-98. doi: 10.1002/mabi.201200317. Epub 2012 Dec 6. PMID- 23032437 OWN - NLM STAT- MEDLINE DCOM- 20130510 LR - 20220310 IS - 1878-0180 (Electronic) IS - 1878-0180 (Linking) VI - 15 DP - 2012 Nov TI - Genipin crosslinking elevates the strength of electrochemically aligned collagen to the level of tendons. PG - 176-89 LID - S1751-6161(12)00178-6 [pii] LID - 10.1016/j.jmbbm.2012.06.012 [doi] AB - Collagen-based tissue mimics are important in clinical research because collagen is the main structural element in tendons. The current study aimed to improve the mechanical strength of Electronically Aligned Collagen (ELAC) threads by optimizing several crosslinking parameters. The results indicated that elevating the concentration of genipin to 2% and the solvent to 90% ethanol significantly enhanced the wet ultimate tensile stress of ELAC threads to 109 MPa with a crosslinking degree of 65%. Furthermore, significantly higher adhesion and proliferation of hMSCs was observed in ELAC threads crosslinked with 2% genipin in 90% ethanol compared to 0.625% genipin in 1X PBS. In conclusion, ELAC threads with mechanical strength on par with native tendon have significant potential to be used as scaffolds in tendon tissue engineering applications. CI - Copyright © 2012 Elsevier Ltd. All rights reserved. FAU - Alfredo Uquillas, Jorge AU - Alfredo Uquillas J AD - Weldon School of Biomedical Engineering, Purdue University, 206 S. Martin Jischke Drive, West Lafayette, IN 47907-2032, United States of America. juquilla@purdue.edu FAU - Kishore, Vipuil AU - Kishore V FAU - Akkus, Ozan AU - Akkus O LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120720 PL - Netherlands TA - J Mech Behav Biomed Mater JT - Journal of the mechanical behavior of biomedical materials JID - 101322406 RN - 0 (Iridoids) RN - 3K9958V90M (Ethanol) RN - 9007-34-5 (Collagen) RN - A3V2NE52YG (genipin) SB - IM MH - Biomechanical Phenomena MH - Biomimetic Materials/*chemistry/pharmacology MH - Cell Adhesion/drug effects MH - Cell Proliferation/drug effects MH - Collagen/*chemistry/pharmacology MH - Electrochemistry MH - Ethanol/chemistry MH - Humans MH - Iridoids/*chemistry MH - *Mechanical Phenomena MH - Mesenchymal Stem Cells/cytology/drug effects MH - *Tendons MH - Time Factors EDAT- 2012/10/04 06:00 MHDA- 2013/05/11 06:00 CRDT- 2012/10/04 06:00 PHST- 2012/03/16 00:00 [received] PHST- 2012/06/21 00:00 [revised] PHST- 2012/06/22 00:00 [accepted] PHST- 2012/10/04 06:00 [entrez] PHST- 2012/10/04 06:00 [pubmed] PHST- 2013/05/11 06:00 [medline] AID - S1751-6161(12)00178-6 [pii] AID - 10.1016/j.jmbbm.2012.06.012 [doi] PST - ppublish SO - J Mech Behav Biomed Mater. 2012 Nov;15:176-89. doi: 10.1016/j.jmbbm.2012.06.012. Epub 2012 Jul 20. PMID- 35932974 OWN - NLM STAT- MEDLINE DCOM- 20220913 LR - 20250728 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 298 DP - 2022 Nov 15 TI - Pyrolae herba: A review on its botany, traditional uses, phytochemistry, pharmacology and quality control. PG - 115584 LID - S0378-8741(22)00623-7 [pii] LID - 10.1016/j.jep.2022.115584 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Pyrolae herba is the dried whole plant of Pyrola calliantha H. Andres or Pyrola decorata H. Andres (Pyrolaceae). Pyrolae herba has a long history of medicinal use in China. In ancient times, it was often used to treat pain in tendons and bones, swollen sore, cough, expectoration, bleeding, and other diseases. and was commonly used in ancient times to treat pain in the tendons and bones, swollen sore, cough, expectoration, bleeding and other diseases. AIM OF THE REVIEW: This paper summarizes the botany, traditional uses, phytochemistry, pharmacology, quality control and toxicology of Pyrolae herba, with a view to providing reference for further development and research. MATERIALS AND METHODS: The relevant information on Pyrolae herba was collected from the scientific databases including PubMed, CNKI, ScienceDirect, Wiley, Springer, Web of Science, Google Scholar, Baidu Scholar, Pharmacopoeia of the People's Republic of China and Flora Republicae Popularis Sinicae, etc. RESULTS: At present, more than 70 compounds have been identified from Pyrolae herba, including flavonoids, phenolic glycosides, quinones, terpenoids, volatile oils and other compounds. Pharmacological studies have shown that Pyrolae herba has a variety of pharmacological activities, such as anti-inflammatory, anti-bacterial, anti-viral, anti-tumor, anti-oxidation, reducing blood lipids, protective on cardiovascular and cerebrovascular, promoting osteoblast proliferation, and so on. It is used clinically in modern times to treat rheumatic arthritis, rheumatoid arthritis, bone hyperplasia, sciatica, cervical spondylosis, lumbar spondylosis, acute and chronic bronchitis, mammary gland hyperplasia, tumor, hypertension, coronary heart disease and bleeding diseases. CONCLUSIONS: Pyrolae herba is rich in chemical constituents, diverse in pharmacological activities and abundant in resources, which is widely used in clinics from traditional to modern. However, there is a lack of research on the relationship between chemical constituents and pharmacodynamics of Pyrolae herba. In addition, the existing clinical applications suggest that Pyrolae herba has a certain therapeutic potential in the treatment of hemorrhagic diseases, but there is a lack of information on experimental studies. It is worthwhile to further investigate the Pyrolae herba in depth in the hope of making discoveries and breakthroughs. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - He, Chunjiao AU - He C AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Liu, Junyu AU - Liu J AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Ke, Tongwei AU - Ke T AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Luo, Yawen AU - Luo Y AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Zhang, Shaowu AU - Zhang S AD - College of Acupuncture and Massage, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Mao, Ting AU - Mao T AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Li, Zulun AU - Li Z AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. FAU - Qin, Xuhua AU - Qin X AD - College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. Electronic address: Xuhuaqin0028@126.com. FAU - Jin, Shenrui AU - Jin S AD - College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China. Electronic address: J15184436539@163.com. LA - eng PT - Journal Article PT - Review DEP - 20220804 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Phytochemicals) SB - IM MH - *Botany MH - Cough/drug therapy MH - *Drugs, Chinese Herbal/chemistry/pharmacology/therapeutic use MH - Ethnopharmacology MH - Humans MH - Hyperplasia/drug therapy MH - Medicine, Chinese Traditional MH - Pain/drug therapy MH - Phytochemicals/pharmacology/therapeutic use MH - Quality Control OTO - NOTNLM OT - Botany OT - Pharmacology OT - Phytochemistry OT - Pyrolae herba OT - Quality control OT - Traditional uses COIS- Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/08/07 06:00 MHDA- 2022/09/14 06:00 CRDT- 2022/08/06 19:25 PHST- 2022/03/22 00:00 [received] PHST- 2022/06/20 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/08/07 06:00 [pubmed] PHST- 2022/09/14 06:00 [medline] PHST- 2022/08/06 19:25 [entrez] AID - S0378-8741(22)00623-7 [pii] AID - 10.1016/j.jep.2022.115584 [doi] PST - ppublish SO - J Ethnopharmacol. 2022 Nov 15;298:115584. doi: 10.1016/j.jep.2022.115584. Epub 2022 Aug 4. PMID- 35343169 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20241219 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 47 IP - 5 DP - 2022 Mar TI - [Expert opinion on clinical application of Baimai Ointment]. PG - 1403-1408 LID - 10.19540/j.cnki.cjcmm.20220129.501 [doi] AB - Baimai Ointment, derived from Tibetan classics, is indicated for Baimai diseases(nervous system diseases) with the effects of relaxing tendons and activating collaterals. It is included in the National Basic Medical Insurance Drugs Catalogue and is widely used for neurological rehabilitation and musculoskeletal system diseases, showing efficacy and safety. Nevertheless, the description of indications, usage, and dosage in the instructions of Baimai Ointment is unclear. There has been no standard for the application of Baimai Ointment. To give full play to its effect and to guide and standardize the clinical medication, this research group organized 23 experts specializing in Tibetan medicine, traditional Chinese medicine, western medicine, evidence-based medicine, methodology, pharmacy, and bibliography from 14 organizations jointly developed this Expert opinion on clinical application of Baimai Ointment. Due to the lack of clinical evidence, this expert consensus is innovatively combined with massive ancient classics, abundant experts' experience, and comprehensive clinical evidence. After discussion and in-depth interview, the consensus on the indications, usage, dosage, duration, frequency, course, and combination protocol of Baimai Ointment has been achieved. Safety and contraindications have been clearly stated. This expert opinion can provide guidance and references for clinicians at all levels to use Baimai Ointment in a reasonable and standardized way. LA - chi PT - Journal Article PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Drugs, Chinese Herbal) RN - 0 (baimai ointment) SB - IM MH - *Drugs, Chinese Herbal/adverse effects MH - Medicine, Chinese Traditional MH - Medicine, Tibetan Traditional OTO - NOTNLM OT - Baimai Ointment OT - clinical application OT - expert opinion EDAT- 2022/03/29 06:00 MHDA- 2022/04/01 06:00 CRDT- 2022/03/28 05:34 PHST- 2022/03/28 05:34 [entrez] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] AID - 10.19540/j.cnki.cjcmm.20220129.501 [doi] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2022 Mar;47(5):1403-1408. doi: 10.19540/j.cnki.cjcmm.20220129.501. PMID- 6528180 OWN - NLM STAT- MEDLINE DCOM- 19850326 LR - 20191023 IS - 0172-8172 (Print) IS - 0172-8172 (Linking) VI - 5 IP - 1 DP - 1984 TI - Pristane-induced arthritis in Balb/c mice. I. Clinical and histological features of the arthropathy. PG - 21-8 AB - Intraperitoneal injection of pristane induced a clinical peripheral arthritis and/or tenosynovitis in 40% of 40 Balb/cJ/Ola mice. Hind paws were always affected first and fore paws were frequently involved. Involvement of knee joints was only apparent histologically. Some clinically unaffected animals and apparently uninvolved joints from arthritic mice were also shown to have a synovitis histologically. The time of onset and pattern of arthritis was variable. The development of arthritis was not related to plasmacytoma or ascites induction, which occurred in a similar percentage of mice over a similar period. The earliest change was synoviocyte hyperplasia and polymorphonuclear infiltration in the subintima. There was no obvious mononuclear cell infiltration. In the later stages there was erosion of cartilage and sclerosis of underlying bone. These features resemble the joint changes seen in osteoarthritis. FAU - Hopkins, S J AU - Hopkins SJ FAU - Freemont, A J AU - Freemont AJ FAU - Jayson, M I AU - Jayson MI LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 0 (Terpenes) RN - 26HZV48DT1 (pristane) SB - IM MH - Animals MH - Arthritis/*chemically induced/pathology MH - Cartilage, Articular/drug effects MH - Female MH - Joints/drug effects MH - Mice MH - Mice, Inbred BALB C MH - Synovial Membrane/drug effects MH - Tendons/drug effects MH - *Terpenes MH - Time Factors EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] AID - 10.1007/BF00541361 [doi] PST - ppublish SO - Rheumatol Int. 1984;5(1):21-8. doi: 10.1007/BF00541361. PMID- 4550120 OWN - NLM STAT- MEDLINE DCOM- 19720303 LR - 20181113 IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 51 IP - 1 DP - 1972 Jan TI - Biosynthesis of 5 -cholestan-3 -ol in cerebrotendinous xanthomatosis. PG - 134-40 AB - Cerebrotendinous Xanthomatosis is a rare, inherited disease characterized by an extraordinary accumulation of cholestanol in all tissues, xanthomatous deposits in the brain, lungs, and Achilles tendons, premature atherosclerosis, and low plasma cholesterol concentrations. In two patients with the disease, the biosynthesis of cholestanol was examined by different techniques. After cholesterol-4-(14)C was injected intravenously into one patient, cholestanol and cholesterol isolated from the bile on 3 different days over the ensuing week contained significant radioactivity. The specific radioactivity-time curves for cholesterol-(14)C and cholestanol-(14)C suggested a precursor product relationship and provided additional evidence for the transformation of cholesterol into cholestanol. The second patient received intravenously a mixture of mevalonate-2-(14)C and stereospecifically labeled mevalonate-3R,4R-(3)H. Again cholesterol and cholestanol were isolated from the bile, and the (3)H/(14)C ratio in both sterols was almost the same. This experiment again demonstrated that the biosynthetic path of cholestanol proceeded through cholesterol and not directly from earlier 5alpha-H-saturated precursors. These two independent lines of evidence indicate that the extraordinary deposition of cholestanol in Cerebrotendinous Xanthomatosis arises from cholesterol presumably through the accentuation of the normal biosynthetic pathway. FAU - Salen, G AU - Salen G FAU - Polito, A AU - Polito A LA - eng PT - Journal Article PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Carbon Isotopes) RN - 0 (Cholestanes) RN - 0 (Sterols) RN - 10028-17-8 (Tritium) RN - 7QWM220FJH (Squalene) RN - 8M308U816E (Cholestanol) RN - 97C5T2UQ7J (Cholesterol) RN - S5UOB36OCZ (Mevalonic Acid) SB - IM MH - Adult MH - Autoradiography MH - Bile/analysis MH - Brain Diseases/*metabolism MH - Carbon Isotopes MH - Cholestanes/*biosynthesis MH - Cholestanol/biosynthesis MH - Cholesterol/metabolism MH - Female MH - Humans MH - Male MH - Mevalonic Acid/metabolism MH - Middle Aged MH - Squalene/metabolism MH - Sterols/metabolism MH - *Tendons MH - Tritium MH - Xanthomatosis/*metabolism PMC - PMC332938 EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 PMCR- 1972/01/01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PHST- 1972/01/01 00:00 [pmc-release] AID - 10.1172/JCI106783 [doi] PST - ppublish SO - J Clin Invest. 1972 Jan;51(1):134-40. doi: 10.1172/JCI106783. PMID- 960742 OWN - NLM STAT- MEDLINE DCOM- 19761101 LR - 20141010 IS - 0044-2224 (Print) IS - 0044-2224 (Linking) VI - 31 IP - 1 DP - 1976 TI - [Ageing-changes in collagen -- biosynthesis of collagen (part II) (author's transl)]. PG - 73-90 AB - In the present three parts of the survey on ageing-changes in collagen physical and chemical qualities are discussed at first. Further a summary on questions of the biosynthesis of collagen, changes of the collagen metabolism in the ageing organism organism and changes of the ripening collagen in the living organism is given. Following in vitro-ageing-changes of collagen and causes of the changes of the ageing organism are described. A summarizing appreciation of the ageing-changes in the collagen finishes the survey. FAU - Georgi, G R AU - Georgi GR FAU - Schmidt, U J AU - Schmidt UJ FAU - Weber, R AU - Weber R FAU - Reinhardt, C AU - Reinhardt C FAU - Kalbe, I AU - Kalbe I LA - ger PT - English Abstract PT - Journal Article TT - Alternsveränderungen am Kollagen -- Biosynthese des Kollagens (Teil II). PL - Germany TA - Z Alternsforsch JT - Zeitschrift fur Alternsforschung JID - 0414005 RN - 0 (Hormones) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - *Aging MH - Aorta MH - Ascorbic Acid/analysis MH - Bone and Bones MH - Collagen/*metabolism MH - Connective Tissue MH - Heart Valves MH - Hormones MH - Humans MH - Hydroxyproline/analysis MH - Lung MH - Methods MH - Myocardium MH - Nutritional Physiological Phenomena MH - Temperature MH - Tendons MH - Wound Healing EDAT- 1976/01/01 00:00 MHDA- 1976/01/01 00:01 CRDT- 1976/01/01 00:00 PHST- 1976/01/01 00:00 [pubmed] PHST- 1976/01/01 00:01 [medline] PHST- 1976/01/01 00:00 [entrez] PST - ppublish SO - Z Alternsforsch. 1976;31(1):73-90. PMID- 17329138 OWN - NLM STAT- MEDLINE DCOM- 20071213 LR - 20131121 IS - 1096-4959 (Print) IS - 1096-4959 (Linking) VI - 147 IP - 2 DP - 2007 Jun TI - Protective effect of Withania somnifera (Solanaceae) on collagen glycation and cross-linking. PG - 308-13 AB - Modification of collagen such as non-enzymatic glycation and cross-linking plays an important role in diabetic complications and age-related diseases. We evaluate the effect of Withania somnifera on glucose-mediated collagen glycation and cross-linking in vitro. Extent of glycation, viscosity, collagen-linked fluorescence and pepsin solubility were assessed in different experimental procedures to investigate the effect of W. somnifera. Tail tendons obtained from rats (Rattus norvegicus) weighing 250-275 g were incubated with 50 mM glucose and 100 mg of metformin or Withania root powder or ethanolic extract of Withania under physiological conditions of temperature and pH for 30 days. Formation of advanced glycation end products (AGE) was measured by fluorescent method whereas the cross-linking of collagen was assessed by pepsin digestion and viscosity measurements. Tendon collagen incubated with glucose showed an increase in glycation, AGE and cross-linking of collagen. The collagen incubated with W. somnifera and metformin ameliorates these modifications. The ethanolic extract of Withania showed more prominent effect than Withania root powder. The activity of ethanolic extract of Withania is comparable to metformin, a known antiglycating agent. In conclusion, Withania could have therapeutic role in the prevention of glycation induced pathogenesis in diabetes mellitus and aging. FAU - Babu, Pon Velayutham Anandh AU - Babu PV AD - Department of Biochemistry, Islamiah College, Vaniyambadi 635 752, Tamil Nadu, India. pvanandhbabu@gmail.com FAU - Gokulakrishnan, Adikesavan AU - Gokulakrishnan A FAU - Dhandayuthabani, Rajendra AU - Dhandayuthabani R FAU - Ameethkhan, Dowlath AU - Ameethkhan D FAU - Kumar, Chandrasekara Vimal Pradeep AU - Kumar CV FAU - Ahamed, Md Iqbal Niyas AU - Ahamed MI LA - eng PT - Comparative Study PT - Journal Article DEP - 20070131 PL - England TA - Comp Biochem Physiol B Biochem Mol Biol JT - Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology JID - 9516061 RN - 0 (Cross-Linking Reagents) RN - 0 (Plant Extracts) RN - EC 3.4.23.1 (Pepsin A) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Analysis of Variance MH - Animals MH - Cartilage/*drug effects MH - Cross-Linking Reagents/chemistry/pharmacology MH - Glucose MH - Glycosylation/drug effects MH - Microscopy, Fluorescence MH - Pepsin A/chemistry MH - Plant Extracts/chemistry/*pharmacology MH - Plant Roots/*chemistry MH - Rats MH - Solubility MH - Viscosity MH - Withania/*chemistry EDAT- 2007/03/03 09:00 MHDA- 2007/12/14 09:00 CRDT- 2007/03/03 09:00 PHST- 2006/07/10 00:00 [received] PHST- 2007/01/24 00:00 [revised] PHST- 2007/01/24 00:00 [accepted] PHST- 2007/03/03 09:00 [pubmed] PHST- 2007/12/14 09:00 [medline] PHST- 2007/03/03 09:00 [entrez] AID - S1096-4959(07)00056-5 [pii] AID - 10.1016/j.cbpb.2007.01.011 [doi] PST - ppublish SO - Comp Biochem Physiol B Biochem Mol Biol. 2007 Jun;147(2):308-13. doi: 10.1016/j.cbpb.2007.01.011. Epub 2007 Jan 31. PMID- 40328511 OWN - NLM STAT- MEDLINE DCOM- 20250702 LR - 20250702 IS - 2042-7158 (Electronic) IS - 0022-3573 (Linking) VI - 77 IP - 7 DP - 2025 Jul 1 TI - Shaoyao Gancao decoction, an Ancient Classical Prescription: a review on its chemical composition, pharmacology, pharmacokinetics, clinical applications, and toxicology. PG - 845-865 LID - 10.1093/jpp/rgaf017 [doi] AB - OBJECTIVES: Shaoyao Gancao decoction (SGD) is a famous Ancient Classical Prescription (ACP) from "Treatise on Febrile Diseases." It has been clinically used for spasm- and pain-related disorders induced by insufficiency of Qi and blood and malnutrition of tendons and vessels for thousands of years. To expand comprehensive understanding and to highlight the importance of more effective utilization, this study aimed to provide a comprehensive review of SGD covering multiple research fields. METHODS: Some databases, including PubMed, Web of Science, Google Scholar, and China National Knowledge Infrastructure, were used to collect the related information with "Shaoyao Gancao decoction" and similar ones as the keywords. KEY FINDINGS: Phytochemical researches revealed that flavonoids and monoterpenoids were the predominant components in SGD. It was documented that SGD had demonstrated a variety of effects, such as analgesic and anti-inflammatory activity, neuroprotection, antispasmodic activity, gastrointestinal protection, hepatoprotection, anti-asthma activity, and effects on gynecological diseases. As for its toxicology, pseudoaldosteronism occasionally occurred and 18β-glycyrrhetyl-3-O-sulfate was believed to be a causative agent. CONCLUSIONS: As a whole, many valuable achievements have been made, exhibiting great attraction and potential of SGD as a famous ACP. This review is also expected to facilitate SGD application and research in the future. CI - © The Author(s) 2025. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. FAU - Facheng, Zhang AU - Facheng Z AD - Polifarma (Nanjing) Co., Ltd., Nanjing, 210038, PR China. FAU - Rongli, Qiu AU - Rongli Q AD - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. AD - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. FAU - Li, Zhang AU - Li Z AD - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. AD - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. FAU - Baoxiang, Wu AU - Baoxiang W AD - Polifarma (Nanjing) Co., Ltd., Nanjing, 210038, PR China. FAU - Sheng, Yu AU - Sheng Y AD - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. AD - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. FAU - Mingqiu, Shan AU - Mingqiu S AUID- ORCID: 0000-0002-3029-7074 AD - Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. AD - School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. LA - eng PT - Journal Article PT - Review PL - England TA - J Pharm Pharmacol JT - The Journal of pharmacy and pharmacology JID - 0376363 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Phytochemicals) SB - IM MH - Humans MH - *Drugs, Chinese Herbal/pharmacology/pharmacokinetics/chemistry/therapeutic use/toxicity/adverse effects MH - Animals MH - Medicine, Chinese Traditional/methods MH - Phytochemicals/pharmacology OTO - NOTNLM OT - Shaoyao Gancao decoction OT - chemical composition OT - pharmacokinetics OT - pharmacology OT - toxicology EDAT- 2025/05/07 00:27 MHDA- 2025/07/02 12:28 CRDT- 2025/05/06 21:43 PHST- 2024/10/14 00:00 [received] PHST- 2025/03/27 00:00 [accepted] PHST- 2025/07/02 12:28 [medline] PHST- 2025/05/07 00:27 [pubmed] PHST- 2025/05/06 21:43 [entrez] AID - 8126039 [pii] AID - 10.1093/jpp/rgaf017 [doi] PST - ppublish SO - J Pharm Pharmacol. 2025 Jul 1;77(7):845-865. doi: 10.1093/jpp/rgaf017. PMID- 37622715 OWN - NLM STAT- MEDLINE DCOM- 20240606 LR - 20240606 IS - 1875-5704 (Electronic) IS - 1567-2018 (Linking) VI - 21 IP - 8 DP - 2024 TI - Nano-platform Strategies of Herbal Components for the Management of Rheumatoid Arthritis: A Review on the Battle for Next-Generation Formulations. PG - 1082-1105 LID - 10.2174/1567201821666230825102748 [doi] AB - INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that initially affects small joints and then spreads to the bigger joints. It also affects other organs of the body such as lungs, eyes, kidneys, heart, and skin. In RA, there is destruction of cartilage and joints, and ligaments and tendons become brittle. Damage to the joints leads to abnormalities and bone degradation, which may be quite painful for the patient. METHOD: The nano-carriers such as liposomes, phytosomes, nanoparticles, microcapsules, and niosomes are developed to deliver the encapsulated phytoconstituents to targeted sites for the better management of RA. RESULTS: The phytoconstituents loaded nano-carriers have been used in order to increase bioavailability, stability and reduce the dose of an active compound. In one study, the curcumin-loaded phytosomes increase the bioavailability of curcumin and also provides relief from RA symptoms. The drug-loaded nano-carriers are the better option for the management of RA. CONCLUSION: In conclusion, there are many anti-arthritic herbal and synthetic medicine available in the market that are currently used in the treatment of RA. However, chronic use of these medications may result in a variety of side effects. Because therapy for RA is frequently necessary for the rest of ones life. The use of natural products may be a better option for RA management. These phytoconstituents, however, have several disadvantages, including limited bioavailability, low stability, and the need for a greater dosage. These problems can be rectified by using nano-technology. CI - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Prabha, Jyoti AU - Prabha J AUID- ORCID: 0000-0003-4895-5781 AD - Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda, 151001, Punjab, India. FAU - Kumar, Mohit AU - Kumar M AD - Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda, 151001, Punjab, India. FAU - Kumar, Devesh AU - Kumar D AD - Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda, 151001, Punjab, India. FAU - Chopra, Shruti AU - Chopra S AD - Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh - 201313, India. FAU - Bhatia, Amit AU - Bhatia A AD - Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda, 151001, Punjab, India. LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Drug Deliv JT - Current drug delivery JID - 101208455 RN - 0 (Antirheumatic Agents) RN - 0 (Drug Carriers) RN - 0 (Plant Preparations) SB - IM MH - *Arthritis, Rheumatoid/drug therapy MH - Humans MH - Nanoparticles/chemistry/administration & dosage MH - Antirheumatic Agents/administration & dosage/chemistry/pharmacokinetics/therapeutic use MH - Animals MH - Drug Carriers/chemistry MH - Plant Preparations/chemistry/administration & dosage MH - Drug Delivery Systems MH - Drug Compounding/methods MH - Biological Availability OTO - NOTNLM OT - Rheumatoid arthritis OT - epidemiology. OT - liposomes OT - nanoparticles OT - phytoconstituents OT - phytosomes EDAT- 2023/08/25 12:42 MHDA- 2024/06/06 12:44 CRDT- 2023/08/25 08:13 PHST- 2023/03/10 00:00 [received] PHST- 2023/06/01 00:00 [revised] PHST- 2023/07/06 00:00 [accepted] PHST- 2024/06/06 12:44 [medline] PHST- 2023/08/25 12:42 [pubmed] PHST- 2023/08/25 08:13 [entrez] AID - CDD-EPUB-134041 [pii] AID - 10.2174/1567201821666230825102748 [doi] PST - ppublish SO - Curr Drug Deliv. 2024;21(8):1082-1105. doi: 10.2174/1567201821666230825102748. PMID- 10546388 OWN - NLM STAT- MEDLINE DCOM- 19991124 LR - 20191103 IS - 0001-4001 (Print) IS - 0001-4001 (Linking) VI - 124 IP - 4 DP - 1999 Sep TI - [The first transplantation of a hand in humans. Early results]. PG - 358-65; discussion 365-7 AB - The first hand allograft was performed on September 23, 1998. The right distal forearm and hand of a brain dead donor was transplanted to a 48 year old recipient who had undergone a traumatic amputation of the distal third of his right forearm. The donor's arm was irrigated with organ preservation solution (UW) and transported to Lyon in a cool container. Two teams simultaneously dissected the donor's limb and the recipient's stump to identify anatomical structures. Transplantation involved bone fixation, arterial and venous anastomoses, nerve sutures, joining of the muscles and tendons, and skin closure. Immunosuppression consisted of anti-lymphocyte, polyclonal and monoclonal antibodies, tacrolimus, mycophenolic acid, and prednisone. Mild clinical and histological signs of rejection occurred at week 9 after surgery. They disappeared with adjustments of the immunosuppressant doses. Seven months after surgery the patient was in good general condition. Intensive physiotherapy led to satisfactory progress of motor function. Sensory progress is excellent, reaching the fingertips. A longer follow-up is necessary to appreciate the final result. In the absence of further rejection, the functional prognosis of the graft should be similar to that reported after successful autoreconstruction. FAU - Dubernard, J M AU - Dubernard JM AD - Service de chirurgie de la transplantation et d'urologie, hôpital Edouard-Herriot, Lyon, France. FAU - Owen, E AU - Owen E FAU - Herzberg, G AU - Herzberg G FAU - Martin, X AU - Martin X FAU - Guigal, V AU - Guigal V FAU - Dawahra, M AU - Dawahra M FAU - Pasticier, G AU - Pasticier G FAU - Mongin-Long, D AU - Mongin-Long D FAU - Kopp, C AU - Kopp C FAU - Ostapetz, A AU - Ostapetz A FAU - Lanzetta, M AU - Lanzetta M FAU - Kapila, H AU - Kapila H FAU - Hakim, N AU - Hakim N LA - fre PT - Case Reports PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't TT - Première transplantation de main chez l'homme. Résultats précoces. PL - France TA - Chirurgie JT - Chirurgie; memoires de l'Academie de chirurgie JID - 0236600 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antilymphocyte Serum) RN - 0 (Enzyme Inhibitors) RN - 0 (Immunosuppressive Agents) RN - 0 (Insulin) RN - 0 (Organ Preservation Solutions) RN - 0 (University of Wisconsin-lactobionate solution) RN - 63CZ7GJN5I (Allopurinol) RN - GAN16C9B8O (Glutathione) RN - HU9DX48N0T (Mycophenolic Acid) RN - K72T3FS567 (Adenosine) RN - N5O3QU595M (Raffinose) RN - VB0R961HZT (Prednisone) RN - WM0HAQ4WNM (Tacrolimus) SB - IM MH - Adenosine/therapeutic use MH - Allopurinol/therapeutic use MH - Amputation, Traumatic/surgery MH - Anastomosis, Surgical MH - Anti-Inflammatory Agents/therapeutic use MH - Antibodies, Monoclonal/therapeutic use MH - Antilymphocyte Serum/therapeutic use MH - Arteriovenous Shunt, Surgical MH - Enzyme Inhibitors/therapeutic use MH - Follow-Up Studies MH - Forearm Injuries/surgery MH - Glutathione/therapeutic use MH - Graft Rejection/etiology MH - Hand/blood supply/innervation MH - *Hand Transplantation MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Insulin/therapeutic use MH - Internal Fixators MH - Male MH - Middle Aged MH - Muscle, Skeletal/surgery MH - Mycophenolic Acid/therapeutic use MH - Organ Preservation Solutions/therapeutic use MH - Physical Therapy Modalities MH - Prednisone/therapeutic use MH - Raffinose/therapeutic use MH - Tacrolimus/therapeutic use MH - Tendons/surgery MH - Transplantation, Homologous EDAT- 1999/11/05 00:00 MHDA- 1999/11/05 00:01 CRDT- 1999/11/05 00:00 PHST- 1999/11/05 00:00 [pubmed] PHST- 1999/11/05 00:01 [medline] PHST- 1999/11/05 00:00 [entrez] AID - S0001400100800070 [pii] AID - 10.1016/s0001-4001(00)80007-0 [doi] PST - ppublish SO - Chirurgie. 1999 Sep;124(4):358-65; discussion 365-7. doi: 10.1016/s0001-4001(00)80007-0. PMID- 5567515 OWN - NLM STAT- MEDLINE DCOM- 19711103 LR - 20121115 IS - 0021-2180 (Print) IS - 0021-2180 (Linking) VI - 7 IP - 3 DP - 1971 Mar TI - The intermolecular cross-link precursors in collagens as related to function. Identification of -hydroxy -amino adipic semialdehyde in tendon collagen. PG - 458-62 FAU - Mechanic, G L AU - Mechanic GL LA - eng PT - Journal Article PL - Israel TA - Isr J Med Sci JT - Israel journal of medical sciences JID - 0013105 RN - 0 (Adipates) RN - 0 (Aldehydes) RN - 0 (Amino Alcohols) RN - 9007-34-5 (Collagen) SB - IM MH - Adipates/*isolation & purification MH - Age Factors MH - Aldehydes/isolation & purification MH - Amino Alcohols/isolation & purification MH - Chromatography MH - Collagen/*analysis/metabolism MH - Mass Spectrometry MH - Skin/analysis/metabolism MH - Skin Physiological Phenomena MH - Spectrum Analysis MH - Tendons/analysis/metabolism/physiology EDAT- 1971/03/01 00:00 MHDA- 1971/03/01 00:01 CRDT- 1971/03/01 00:00 PHST- 1971/03/01 00:00 [pubmed] PHST- 1971/03/01 00:01 [medline] PHST- 1971/03/01 00:00 [entrez] PST - ppublish SO - Isr J Med Sci. 1971 Mar;7(3):458-62. PMID- 40321094 OWN - NLM STAT- MEDLINE DCOM- 20250505 LR - 20250505 IS - 1552-4981 (Electronic) IS - 1552-4973 (Linking) VI - 113 IP - 5 DP - 2025 May TI - Comparison of Collagen and Polylactic Acid Multifilament Yarns for Developing Textile Scaffolds for Tendon Tissue Engineering Applications. PG - e35583 LID - 10.1002/jbm.b.35583 [doi] AB - This study is the first to compare the mechanical properties and biocompatibility of multifilament yarns made from a natural biopolymer, collagen, and from a synthetic polymer, polylactic acid (PLA), with a view toward evaluating the suitability of these two yarns for fabricating tendon tissue engineering scaffolds. Genipin, the natural plant-based anti-inflammatory and antioxidant crosslinking agent, was used to stabilize the collagen structure. A range of different genipin concentrations, crosslinking temperatures, and crosslinking times were studied, and based on higher degrees of crosslinking, reduced swelling ratio, and greater tensile strength, the recommended conditions are crosslinking the wet-spun collagen yarns with 1.0% genipin at 37°C for 72 h. During a 6-week enzymatic degradation study, the PLA yarns were more resistant to degradation and retained greater tensile strength than the genipin-crosslinked collagen yarns under both dry (4.0 ± 0.2 N vs. 2.2 ± 0.4 N) and hydrated (3.7 ± 0.3 N vs. 0.4 ± 0.1 N) conditions. After coating the PLA yarns with collagen, their biocompatibility improved, and they were able to support tendon cell growth and proliferation. In conclusion, the selection of multifilament PLA yarns coated with collagen is recommended as a promising scaffold material for tendon tissue engineering applications. CI - © 2025 The Author(s). Journal of Biomedical Materials Research Part B: Applied Biomaterials published by Wiley Periodicals LLC. FAU - Huang, Yihan AU - Huang Y AD - Wilson College of Textiles, North Carolina State University, Raleigh, North Carolina, USA. FAU - Tonndorf, Robert AU - Tonndorf R AD - Institute of Textile Machinery and High Performance Material Technology, Technische Universität Dresden, Dresden, Germany. FAU - Gluck, Jessica M AU - Gluck JM AUID- ORCID: 0000-0002-6908-0809 AD - Wilson College of Textiles, North Carolina State University, Raleigh, North Carolina, USA. FAU - Cadet, Edwin R AU - Cadet ER AD - Raleigh Orthopaedic Clinic, Raleigh, North Carolina, USA. FAU - King, Martin W AU - King MW AD - Wilson College of Textiles, North Carolina State University, Raleigh, North Carolina, USA. AD - College of Textiles, Donghua University, Shanghai, China. FAU - Cole, Jacqueline H AU - Cole JH AUID- ORCID: 0000-0002-0233-9425 AD - Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina, USA. LA - eng GR - AATCC Foundation/ PT - Comparative Study PT - Journal Article PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 459TN2L5F5 (poly(lactide)) RN - 0 (Polyesters) RN - 9007-34-5 (Collagen) RN - 0 (Polymers) RN - A3V2NE52YG (genipin) RN - 33X04XA5AT (Lactic Acid) RN - 0 (Iridoids) SB - IM MH - Polyesters/chemistry MH - *Tissue Engineering/methods MH - *Tissue Scaffolds/chemistry MH - *Tendons/cytology MH - *Collagen/chemistry MH - Animals MH - Materials Testing MH - *Polymers/chemistry MH - *Lactic Acid/chemistry MH - Iridoids/chemistry MH - Tensile Strength MH - *Textiles OTO - NOTNLM OT - collagen OT - genipin OT - polylactic acid OT - tendon repair OT - tissue engineering OT - yarn EDAT- 2025/05/05 06:26 MHDA- 2025/05/05 12:41 CRDT- 2025/05/05 04:33 PHST- 2025/03/13 00:00 [revised] PHST- 2024/11/06 00:00 [received] PHST- 2025/04/05 00:00 [accepted] PHST- 2025/05/05 12:41 [medline] PHST- 2025/05/05 06:26 [pubmed] PHST- 2025/05/05 04:33 [entrez] AID - 10.1002/jbm.b.35583 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2025 May;113(5):e35583. doi: 10.1002/jbm.b.35583. PMID- 9973181 OWN - NLM STAT- MEDLINE DCOM- 19990212 LR - 20220321 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 56 IP - 12 DP - 1998 Dec 15 TI - Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. PG - 1607-14 AB - A close association between increased oxidative stress and hyperglycemia has been postulated to contribute significantly to the accelerated accumulation of advanced glycation end products (AGEs) and the cross-linking of collagen in diabetes mellitus. In the present work, we report the influence of curcumin, an efficient antioxidant, on the level of AGEs and the cross-linking of collagen in diabetic rats. Diabetic rats were given curcumin (200 mg/kg body wt) orally for a duration of 8 weeks. The antioxidant status in serum and the level of AGEs, cross-linking and browning of collagen in tail tendons and skin were investigated. The oxidative stress observed in diabetic rats was reduced significantly by curcumin administration. Nonenzymic antioxidants such as vitamin C, vitamin E, and glutathione were maintained at near normal values in curcumin-treated diabetic animals. Similarly, the accumulation of lipid peroxidation products in diabetic serum was reduced significantly by curcumin. Accelerated accumulation of AGE-collagen in diabetic animals, as detected by ELISA, was prevented by curcumin. Extensive cross-linking of collagen in the tail tendon and skin of diabetic animals was also prevented to a greater extent by curcumin treatment. A correlation between the level of AGEs and collagen cross-linking was noted, suggesting the involvement of advanced glycation in cross-linking. It was also noted that the preventive effect of curcumin on the advanced glycation and cross-linking of collagen was more pronounced than its therapeutic effect. However, the Maillard reaction fluorescence in both tail and skin collagen remained unaltered by curcumin. This study confirms the significance of free radicals in the accumulation of AGEs and cross-linking of collagen in diabetes. It supports curcumin administration for the prevention of AGE-induced complications of diabetes mellitus. FAU - Sajithlal, G B AU - Sajithlal GB AD - Department of Biochemistry, Central Leather Research Institute, Adyar, Chennai, India. FAU - Chithra, P AU - Chithra P FAU - Chandrakasan, G AU - Chandrakasan G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Antioxidants) RN - 0 (Glycation End Products, Advanced) RN - 9007-34-5 (Collagen) RN - EC 3.1.- (Ribonucleases) RN - IT942ZTH98 (Curcumin) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Antioxidants/analysis/*therapeutic use MH - Collagen/chemistry/immunology/*metabolism MH - Curcumin/*therapeutic use MH - Diabetes Mellitus, Experimental/complications/*drug therapy/metabolism MH - Enzyme-Linked Immunosorbent Assay MH - Glycation End Products, Advanced/chemistry/immunology/*metabolism MH - Lipid Peroxidation MH - Male MH - Rats MH - Rats, Wistar MH - Ribonucleases/immunology MH - Skin/metabolism MH - Tendons/metabolism EDAT- 1999/02/11 00:00 MHDA- 1999/02/11 00:01 CRDT- 1999/02/11 00:00 PHST- 1999/02/11 00:00 [pubmed] PHST- 1999/02/11 00:01 [medline] PHST- 1999/02/11 00:00 [entrez] AID - S0006-2952(98)00237-8 [pii] AID - 10.1016/s0006-2952(98)00237-8 [doi] PST - ppublish SO - Biochem Pharmacol. 1998 Dec 15;56(12):1607-14. doi: 10.1016/s0006-2952(98)00237-8. PMID- 4232353 OWN - NLM STAT- MEDLINE DCOM- 19680827 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 158 IP - 3 DP - 1968 Jun 24 TI - Application of cetylpyridinium-complex elution methods to analysis of glycosaminoglycans of tendon. PG - 336-43 FAU - Dorner, R W AU - Dorner RW FAU - Antonopoulos, C A AU - Antonopoulos CA FAU - Gardell, S AU - Gardell S LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Glycosaminoglycans) RN - 0 (Hexosamines) RN - 0 (Pyridinium Compounds) RN - 0 (Sulfates) RN - 0 (Uronic Acids) RN - 9007-27-6 (Chondroitin) SB - IM MH - Achilles Tendon/analysis/metabolism MH - Animals MH - Cattle MH - Chondroitin MH - Chromatography MH - Chromatography, Ion Exchange MH - Chromatography, Paper MH - Glycosaminoglycans/*analysis MH - Hexosamines/analysis MH - Pyridinium Compounds MH - Rabbits MH - Regeneration MH - Spectrophotometry MH - Sulfates/analysis MH - Tendons/*analysis/metabolism/physiology MH - Uronic Acids/analysis EDAT- 1968/06/24 00:00 MHDA- 1968/06/24 00:01 CRDT- 1968/06/24 00:00 PHST- 1968/06/24 00:00 [pubmed] PHST- 1968/06/24 00:01 [medline] PHST- 1968/06/24 00:00 [entrez] AID - 0304-4165(68)90287-0 [pii] AID - 10.1016/0304-4165(68)90287-0 [doi] PST - ppublish SO - Biochim Biophys Acta. 1968 Jun 24;158(3):336-43. doi: 10.1016/0304-4165(68)90287-0. PMID- 35039256 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220315 IS - 1011-601X (Print) IS - 1011-601X (Linking) VI - 34 IP - 6(Special) DP - 2021 Nov TI - Study on the effect of extra capsular arthroscopy plus analgesic tincture in the treatment of external humeral epicondylitis. PG - 2437-2440 AB - External humeral epicondylitis (EHE) is an inflammation and pain of the lateral tendons of the elbow with poor clinical efficacy. In this study, we aim to observe the effect of extra capsular arthroscopy (ECA) plus Traditional Chinese medicine (TCM) analgesic tincture in the treatment of EHE. A retrospective analysis was performed on the follow-up data of 58 patients with intractable EHE treated by ECA plus TCM analgesic tincture over 2 years from January 2017 to October 2018. All patients were followed up during the operation, with a mean follow-up duration of 17.6 months. There were no complications such as infection, nerve injury, wound nonunion and joint stiffness. The postoperative and pronation angles were statistically different from preoperative. The visual analogue scale (VAS) score during rest and movement of the elbow joint after operation was significantly different from that before operation. Postoperative Mayo elbow joint function score was significantly different from preoperative. Postoperative elbow joint function and brachial and shoulder dysfunction scores were statistically significant compared with those before surgery. Postoperative elbow joint function and brachial and shoulder dysfunction scores were statistically significant compared with those before surgery. The satisfaction rate of patients was 100%, with 52 cases of completely satisfied, 6 cases of basically satisfied and no dissatisfied cases. The curative effect of external capsular arthroscopy plus analgesic tincture in the treatment of external humeral epicondylitis was promising, which was worthy of clinical promotion. FAU - Yu, Bo AU - Yu B AD - The First Hospital of Jilin University, Jilin, China. FAU - Li, Dongsong AU - Li D AD - The First Hospital of Jilin University, Jilin, China. FAU - Xu, Yan AU - Xu Y AD - The First Hospital of Jilin University, Jilin, China. LA - eng PT - Journal Article PL - Pakistan TA - Pak J Pharm Sci JT - Pakistan journal of pharmaceutical sciences JID - 9426356 RN - 0 (Analgesics) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Adult MH - Analgesics/adverse effects/*therapeutic use MH - *Arthroscopy/adverse effects MH - Drugs, Chinese Herbal/adverse effects/*therapeutic use MH - Female MH - Humans MH - Male MH - Pain Measurement MH - Pain, Postoperative/diagnosis/etiology/physiopathology/*prevention & control MH - Patient Satisfaction MH - Recovery of Function MH - Retrospective Studies MH - Tennis Elbow/diagnostic imaging/physiopathology/*therapy MH - Time Factors MH - Treatment Outcome EDAT- 2022/01/19 06:00 MHDA- 2022/03/16 06:00 CRDT- 2022/01/18 05:44 PHST- 2022/01/18 05:44 [entrez] PHST- 2022/01/19 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PST - ppublish SO - Pak J Pharm Sci. 2021 Nov;34(6(Special)):2437-2440. PMID- 25360832 OWN - NLM STAT- MEDLINE DCOM- 20150910 LR - 20220316 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 56 IP - 1 DP - 2015 Feb TI - Green tea and glycine aid in the recovery of tendinitis of the Achilles tendon of rats. PG - 50-8 LID - 10.3109/03008207.2014.983270 [doi] AB - PURPOSE: Green tea (GT) is widely used due to its anti-inflammatory properties. Previous studies have shown beneficial effects of a glycine diet on the remodeling process in inflamed tendons. Tendinitis is commonly observed in athletes and is of concern to surgeons due to the slowness of the recovery process. Our hypothesis is that GT + a glycine diet may improve tendinitis. AIM OF THE STUDY: To analyze the effect of GT and/or glycine in the diet on tendinitis. MATERIALS AND METHODS: Wistar rats were divided into seven groups (G): control group (C); G1 and G4, tendinitis; G2 and G5, tendinitis supplied with GT; and G3 and G6, tendinitis supplied with GT and a glycine diet for 7 or 21 days, respectively. We performed zymography for metalloproteinase, biochemical, morphological and biomechanics tests. RESULTS: G2, G3 and G5 showed high levels of hydroxyproline in relation to G1, while G4 showed high levels of glycosaminoglycans. High activity of metalloproteinase-2 was detected in G3. The organization of collagen bundles was better in G2 and G3. G5 showed similar birefringence measurements compared with C. G5 withstood a larger load compared with G4. CONCLUSIONS: The presence of metalloproteinase-2 indicates that a tissue is undergoing a remodeling process. High birefringence suggests a better organization of collagen bundles. After 21 days, G5 sustained a high load before rupture, unlike G4. The results suggest that GT + a glycine diet has beneficial effects that aid in the recovery process of the tendon after tendinitis. FAU - Vieira, C P AU - Vieira CP AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas , Campinas, SP , Brazil and. FAU - Guerra, F Da Ré AU - Guerra Fda R FAU - de Oliveira, L P AU - de Oliveira LP FAU - Almeida, M S AU - Almeida MS FAU - Marcondes, Maria Cristina Cintra AU - Marcondes MC FAU - Pimentell, E R AU - Pimentell ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141121 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Plant Extracts) RN - 0 (Tea) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - TE7660XO1C (Glycine) SB - IM MH - Achilles Tendon/drug effects/*pathology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Birefringence MH - Cell Shape MH - Densitometry MH - Extracellular Matrix/drug effects/metabolism MH - Glycine/pharmacology/*therapeutic use MH - Male MH - Matrix Metalloproteinases/metabolism MH - Plant Extracts/pharmacology/*therapeutic use MH - Rats, Wistar MH - Tea/*chemistry MH - Tendinopathy/*drug therapy/pathology OTO - NOTNLM OT - Achilles tendon OT - biomechanics OT - extracellular matrix OT - metalloproteinase OT - tendinitis EDAT- 2014/11/02 06:00 MHDA- 2015/09/12 06:00 CRDT- 2014/11/01 06:00 PHST- 2014/11/01 06:00 [entrez] PHST- 2014/11/02 06:00 [pubmed] PHST- 2015/09/12 06:00 [medline] AID - 10.3109/03008207.2014.983270 [doi] PST - ppublish SO - Connect Tissue Res. 2015 Feb;56(1):50-8. doi: 10.3109/03008207.2014.983270. Epub 2014 Nov 21. PMID- 25266273 OWN - NLM STAT- MEDLINE DCOM- 20150914 LR - 20220331 IS - 1932-8494 (Electronic) IS - 1932-8486 (Linking) VI - 298 IP - 2 DP - 2015 Feb TI - Effect of Calendula officinalis cream on achilles tendon healing. PG - 428-35 LID - 10.1002/ar.23057 [doi] AB - In recent years, the scientific community has undertaken research on plant extracts, searching for compounds with pharmacological activities that can be used in diverse fields of medicine. Calendula officinalis L. is known to have antioxidant, anti-inflammatory, antibacterial, and wound healing properties when used to treat skin burns. Therefore, the purpose of this study was to analyze the effects of C. officinalis on the initial phase of Achilles tendon healing. Wistar rats were separated in three groups: Calendula (Cal)-rats with a transected tendon were treated with topical applications of C. officinalis cream and then euthanized 7 days after injury; Control (C)-rats were treated with only vehicle after transection; and Normal (N)-rats without tenotomy. Higher concentrations of hydroxyproline (an indicator of total collagen) and non-collagenous proteins were observed in the Cal group in relation to the C group. Zymography showed no difference in the amount of the isoforms of metalloproteinase-2 and of metalloproteinase-9, between C and Cal groups. Polarization microscopy images analysis showed that the Cal group presented a slightly higher birefringence compared with the C group. In sections of tendons stained with toluidine blue, the transected groups presented higher metachromasy as compared with the N group. Immunocytochemistry analysis for chondroitin-6-sulfate showed no difference between the C and Cal groups. In conclusion, the topical application of C. officinalis after tendon transection increases the concentrations of collagen and non-collagenous proteins, as well as the collagen organization in the initial phase of healing. CI - © 2014 Wiley Periodicals, Inc. FAU - Aro, A A AU - Aro AA AD - Department of Structural and Functional Biology, Institute of Biology, State University of Campinas-UNICAMP, Campinas, São Paulo, Brazil. FAU - Perez, M O AU - Perez MO FAU - Vieira, C P AU - Vieira CP FAU - Esquisatto, M A M AU - Esquisatto MA FAU - Rodrigues, R A F AU - Rodrigues RA FAU - Gomes, L AU - Gomes L FAU - Pimentel, E R AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141012 PL - United States TA - Anat Rec (Hoboken) JT - Anatomical record (Hoboken, N.J. : 2007) JID - 101292775 RN - 0 (Plant Extracts) SB - IM MH - Achilles Tendon/*drug effects/metabolism/pathology MH - Administration, Topical MH - Animals MH - *Calendula MH - Male MH - Plant Extracts/*administration & dosage/isolation & purification MH - Rats MH - Rats, Wistar MH - Skin Cream/*administration & dosage/isolation & purification MH - Treatment Outcome MH - Wound Healing/*drug effects/physiology OTO - NOTNLM OT - Calendula officinalis OT - hydroxyproline OT - metalloproteinase OT - non-collagenous proteins OT - tendon repair EDAT- 2014/10/01 06:00 MHDA- 2015/09/15 06:00 CRDT- 2014/10/01 06:00 PHST- 2014/03/03 00:00 [received] PHST- 2014/08/12 00:00 [accepted] PHST- 2014/10/01 06:00 [entrez] PHST- 2014/10/01 06:00 [pubmed] PHST- 2015/09/15 06:00 [medline] AID - 10.1002/ar.23057 [doi] PST - ppublish SO - Anat Rec (Hoboken). 2015 Feb;298(2):428-35. doi: 10.1002/ar.23057. Epub 2014 Oct 12. PMID- 27744069 OWN - NLM STAT- MEDLINE DCOM- 20171020 LR - 20240324 IS - 1878-7568 (Electronic) IS - 1742-7061 (Print) IS - 1742-7061 (Linking) VI - 48 DP - 2017 Jan 15 TI - Model polymer system for investigating the generation of hydrogen peroxide and its biological responses during the crosslinking of mussel adhesive moiety. PG - 144-156 LID - S1742-7061(16)30543-8 [pii] LID - 10.1016/j.actbio.2016.10.016 [doi] AB - Mussel adhesive moiety, catechol, has been utilized to design a wide variety of biomaterials. However, the biocompatibility and biological responses associated with the byproducts generated during the curing process of catechol has never been characterized. An in situ curable polymer model system, 4-armed polyethylene glycol polymer end-capped with dopamine (PEG-D4), was used to characterize the production of hydrogen peroxide (H(2)O(2)) during the oxidative crosslinking of catechol. Although PEG-D4 cured rapidly (under 30s), catechol continues to polymerize over several hours to form a more densely crosslinked network over time. PEG-D4 hydrogels were examined at two different time points; 5min and 16h after initiation of crosslinking. Catechol in the 5min-cured PEG-D4 retained the ability to continue to crosslink and generated an order of magnitude higher H(2)O(2) (40μM) over 6h when compared to 16h-cured samples that ceased to crosslink. H(2)O(2) generated during catechol crosslinking exhibited localized cytotoxicity in culture and upregulated the expression of an antioxidant enzyme, peroxiredoxin 2, in primary dermal and tendon fibroblasts. Subcutaneous implantation study indicated that H(2)O(2) released during oxidative crosslinking of PEG-D4 hydrogel promoted superoxide generation, macrophage recruitment, and M2 macrophage polarization in tissues surrounding the implant. Given the multitude of biological responses associated with H(2)O(2), it is important to monitor and tailor the production of H(2)O(2) generated from catechol-containing biomaterials for a given application. STATEMENT OF SIGNIFICANCE: Remarkable underwater adhesion strategy employed by mussels has been utilized to design a wide variety of biomaterials ranging from tissue adhesives to drug carrier and tissue engineering scaffolds. Catechol is the main adhesive moiety that is widely incorporated to create an injectable biomaterials and bioadhesives. However, the biocompatibility and biological responses associated with the byproducts generated during the curing process of catechol has never been characterized. In this manuscript, we design a model system to systemically characterize the release of hydrogen peroxide (H(2)O(2)) during the crosslinking of catechol. Given the multitude of biological responses associated with H(2)O(2) (i.e., wound healing, antimicrobial, chronic inflammation), its release from catechol-containing biomaterials need to be carefully monitored and controlled for a desired application. CI - Copyright © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Meng, Hao AU - Meng H AD - Department of Biomedical Engineering, Michigan Technological University, Houghton, MI 49931, USA. FAU - Liu, Yuan AU - Liu Y AD - Department of Biomedical Engineering, Michigan Technological University, Houghton, MI 49931, USA. FAU - Lee, Bruce P AU - Lee BP AD - Department of Biomedical Engineering, Michigan Technological University, Houghton, MI 49931, USA. Electronic address: bplee@mtu.edu. LA - eng GR - R15 GM104846/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20161012 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Adhesives) RN - 0 (Antioxidants) RN - 0 (Cross-Linking Reagents) RN - 0 (Polymers) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 1.11.1.15 (Peroxiredoxins) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Adhesives/*pharmacology MH - Animals MH - Antioxidants/metabolism MH - Bivalvia/*chemistry MH - Cell Survival/drug effects MH - Cross-Linking Reagents/*pharmacology MH - Dermis/cytology MH - Dopamine/chemistry MH - Fibroblasts/cytology/drug effects MH - Fluorescent Antibody Technique MH - Hydrogen Peroxide/*analysis MH - Macrophages/metabolism MH - Mice MH - Molecular Weight MH - Peroxiredoxins/metabolism MH - Polyethylene Glycols/chemistry MH - Polymers/*chemistry MH - Rats, Sprague-Dawley MH - Rheology MH - Staining and Labeling MH - Subcutaneous Tissue/metabolism MH - Tendons/cytology PMC - PMC5235946 MID - NIHMS823474 OTO - NOTNLM OT - Cytotoxicity OT - Hydrogen peroxide OT - Macrophage polarization OT - Mussel adhesive protein OT - Oxidative crosslinking EDAT- 2016/10/19 06:00 MHDA- 2017/10/21 06:00 PMCR- 2018/01/15 CRDT- 2016/10/17 06:00 PHST- 2016/08/03 00:00 [received] PHST- 2016/09/25 00:00 [revised] PHST- 2016/10/11 00:00 [accepted] PHST- 2016/10/19 06:00 [pubmed] PHST- 2017/10/21 06:00 [medline] PHST- 2016/10/17 06:00 [entrez] PHST- 2018/01/15 00:00 [pmc-release] AID - S1742-7061(16)30543-8 [pii] AID - 10.1016/j.actbio.2016.10.016 [doi] PST - ppublish SO - Acta Biomater. 2017 Jan 15;48:144-156. doi: 10.1016/j.actbio.2016.10.016. Epub 2016 Oct 12. PMID- 38728461 OWN - NLM STAT- MEDLINE DCOM- 20240510 LR - 20250503 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 103 IP - 19 DP - 2024 May 10 TI - Clinical use and efficacy of Chinese patent medicines for external use containing pyritum, a mineral medicine mainly used for oral administration: A systematic review. PG - e37881 LID - 10.1097/MD.0000000000037881 [doi] LID - e37881 AB - BACKGROUND: Pyritum, a mineral drug, has been used primarily orally in traditional medicine to treat traumatic injuries, broken tendons, and fractures. Due to growing concerns about the accumulation of heavy metals in the body, this systematic review aims to evaluate the efficacy and safety of Chinese patent medicine containing pyritum for external use (CPMPE) to determine the effectiveness of external use of pyritum. METHODS: A literature search was performed through China National Knowledge Infrastructure, Wanfang, EMBASE, Cochrane Library, and PubMed from inception to February 2023. "Pyrite," "pyritum," "zirantong," "traditional medicine," "oriental medicine," etc, were the keywords from the database. In this systematic review, RCTs and case reports were referred to analyze the efficacy rate and clinical status of CPMPE. RESULTS: About 36 studies were reviewed. Of 36 studies, 23 were RCTs and 13 were case reports. The total effective rate in 34 studies was used to evaluate the efficacy of CPMPE for various disease classifications. The effectiveness of CPMPE was confirmed in case reports, and RCTs showed that using CPMPE as a single or combined treatment had a more significant effect than not using CPMPE in anorectal diseases, orthopedic diseases, obstetrics and gynecology diseases, and skin diseases. CONCLUSIONS: This review concluded that CPMPE might be a safe and effective alternative treatment method for various diseases and has potential benefits in preventing postoperative complications, reducing pain, relieving symptoms, and accelerating healing compared to the control group, which employs unused CPMPE. CI - Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Hwang, Ji Hye AU - Hwang JH AUID- ORCID: 0000-0002-6304-1972 AD - Department of Acupuncture & Moxibustion Medicine, College of Korean Medicine, Gachon University, Seongnam, Republic of Korea. FAU - Choi, Su Hyeon AU - Choi SH AD - College of Korean Medicine, Gachon University, Seongnam, Republic of Korea. LA - eng PT - Journal Article PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Nonprescription Drugs) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Medicine, Chinese Traditional/methods MH - Administration, Oral MH - Nonprescription Drugs/therapeutic use MH - Drugs, Chinese Herbal/therapeutic use/administration & dosage PMC - PMC11081566 COIS- The authors have no conflicts of interest to disclose. EDAT- 2024/05/10 18:42 MHDA- 2024/05/10 18:43 PMCR- 2024/05/10 CRDT- 2024/05/10 14:13 PHST- 2024/05/10 18:43 [medline] PHST- 2024/05/10 18:42 [pubmed] PHST- 2024/05/10 14:13 [entrez] PHST- 2024/05/10 00:00 [pmc-release] AID - 00005792-202405100-00017 [pii] AID - MD-D-23-08320 [pii] AID - 10.1097/MD.0000000000037881 [doi] PST - ppublish SO - Medicine (Baltimore). 2024 May 10;103(19):e37881. doi: 10.1097/MD.0000000000037881. PMID- 4141357 OWN - NLM STAT- MEDLINE DCOM- 19750505 LR - 20190829 IS - 0301-5564 (Print) IS - 0301-5564 (Linking) VI - 42 IP - 2 DP - 1974 TI - Selective proteolytic sensitivity of sulfate-collagen and basement membranes. PG - 199-209 FAU - Romhányi, G AU - Romhányi G FAU - Bukovinszky, A AU - Bukovinszky A FAU - Deák, G AU - Deák G LA - eng PT - Journal Article PL - Germany TA - Histochemistry JT - Histochemistry JID - 0411300 RN - 0 (Sulfuric Acids) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.4 (Trypsin) SB - IM MH - Animals MH - Autopsy MH - Basement Membrane/*analysis/ultrastructure MH - Biopsy MH - Collagen/*analysis MH - Humans MH - Methods MH - Rats MH - Staining and Labeling MH - Sulfuric Acids/analysis MH - Tendons/analysis/ultrastructure MH - Trypsin EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 10.1007/BF00533271 [doi] PST - ppublish SO - Histochemistry. 1974;42(2):199-209. doi: 10.1007/BF00533271. PMID- 19772810 OWN - NLM STAT- MEDLINE DCOM- 20091112 LR - 20170112 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 27 IP - 4 DP - 2009 Jul-Aug TI - Joint and tendineous involvement in ochronosis: clinical history and imaging of a case. PG - 696-7 FAU - Iannuccelli, C AU - Iannuccelli C FAU - Coari, G AU - Coari G FAU - Mastantuono, M AU - Mastantuono M FAU - Osimani, M AU - Osimani M FAU - Valesini, G AU - Valesini G FAU - Di Franco, M AU - Di Franco M LA - eng PT - Case Reports PT - Letter PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - NP8UE6VF08 (Homogentisic Acid) SB - IM MH - Arthritis, Rheumatoid/diagnosis MH - Diagnosis, Differential MH - Drug Therapy, Combination MH - Homogentisic Acid/urine MH - Humans MH - Knee Joint/diagnostic imaging/*pathology MH - Male MH - Middle Aged MH - Ochronosis/complications/*diagnosis/drug therapy MH - Synovitis/diagnosis/etiology MH - Tendinopathy/complications/*diagnosis MH - Tendons/diagnostic imaging/*pathology MH - Ultrasonography EDAT- 2009/09/24 06:00 MHDA- 2009/11/13 06:00 CRDT- 2009/09/24 06:00 PHST- 2009/09/24 06:00 [entrez] PHST- 2009/09/24 06:00 [pubmed] PHST- 2009/11/13 06:00 [medline] AID - 2701 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2009 Jul-Aug;27(4):696-7. PMID- 14504722 OWN - NLM STAT- MEDLINE DCOM- 20040805 LR - 20220330 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 12 IP - 2 DP - 2004 Mar TI - Tunnel enlargement and changes in synovial fluid cytokine profile following anterior cruciate ligament reconstruction with patellar tendon and hamstring tendon autografts. PG - 98-103 AB - There is growing evidence that cytokines such as tumor necrosis factor (TNF) alpha, interleukin (IL) 1beta, IL-6, bone morphogenetic proteins (BMP), and nitric oxide (NO) play an important role in the pathogenesis of bone tunnel enlargement following anterior cruciate ligament (ACL) reconstruction. Furthermore, the release of these mediators has been considered a possible reason for the higher incidence of bone tunnel enlargement following hamstring tendon (HST) than following patellar tendon (PT) ACL reconstruction observed in several studies. In this investigation synovial fluid samples from 13 patients were collected immediately before (24+/-7 days after ACL rupture) and 7 days after ACL surgery and values of TNF-alpha, IL-1beta, IL-6, NO, and BMP-2 were analyzed. Furthermore, the incidence of bone tunnel enlargement was assessed using radiographs 38+/-7 weeks after surgery. Six patients underwent autologous HST ACL reconstruction, and in seven patients an PT autograft was used. In the overall patient population there were significantly higher synovial fluid concentrations of IL-6 and BMP-2 postoperatively than preoperatively; TNF-alpha showed a trend towards lower postoperative levels while IL-1beta and NO remained unchanged. The concentrations of NO, TNF-alpha, and IL-6 found in the present study were clearly higher than normal values given in the literature. Assessment of bone tunnel enlargement revealed an average increase in tibial tunnel width of 28.4+/-3.1% with comparable values for HST and PT ACL reconstructions. There was no significant correlation between bone tunnel enlargement and postoperative synovial fluid concentrations of TNF-alpha, IL-1beta, IL-6, NO, and BMP-2. However, all patients with bone tunnel enlargement had higher postoperative concentrations of TNF-alpha, IL-6, and NO in the synovial fluid. There were no significant differences in concentrations between HST and PT groups. In conclusion, we observed an association between tibial bone tunnel enlargement and elevated synovial fluid concentrations of IL-6, TNF-alpha, and NO 7 days after ACL surgery indicating the potential involvement of these biological mediators in the pathogenesis of bone tunnel enlargement. However, there was no difference between HST and PT ACL reconstructions regarding synovial fluid contents of IL-6, TNF-alpha, IL-1beta, NO, and BMP-2, suggesting a comparable biological response between these autografts following their use in ACL reconstruction. FAU - Zysk, S P AU - Zysk SP AD - Department of Orthopedics, Klinikum Grosshadern, Ludwig Maximilian University of Munich, Marchioninistrasse 15, 81377 Munich, Germany. szysk@helios.med.uni-muenchen.de FAU - Fraunberger, P AU - Fraunberger P FAU - Veihelmann, A AU - Veihelmann A FAU - Dörger, M AU - Dörger M FAU - Kalteis, T AU - Kalteis T FAU - Maier, M AU - Maier M FAU - Pellengahr, C AU - Pellengahr C FAU - Refior, H J AU - Refior HJ LA - eng PT - Comparative Study PT - Journal Article DEP - 20030920 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (BMP2 protein, human) RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Interleukin-6) RN - 0 (Transforming Growth Factor beta) RN - 0 (Tumor Necrosis Factor-alpha) RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Adult MH - Anterior Cruciate Ligament/*surgery MH - Arthroscopy MH - Bone Morphogenetic Protein 2 MH - Bone Morphogenetic Proteins/analysis MH - Female MH - Humans MH - Interleukin-6/*analysis MH - Male MH - Nitric Oxide/analysis MH - Patella/surgery MH - Prospective Studies MH - Radiography MH - Reference Values MH - Synovial Fluid/*chemistry/immunology MH - Tendons/*transplantation MH - Tibia/diagnostic imaging/surgery MH - *Transforming Growth Factor beta MH - Transplantation, Autologous MH - Tumor Necrosis Factor-alpha/*analysis EDAT- 2003/09/25 05:00 MHDA- 2004/08/06 05:00 CRDT- 2003/09/25 05:00 PHST- 2003/02/04 00:00 [received] PHST- 2003/06/01 00:00 [accepted] PHST- 2003/09/25 05:00 [pubmed] PHST- 2004/08/06 05:00 [medline] PHST- 2003/09/25 05:00 [entrez] AID - 10.1007/s00167-003-0426-z [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2004 Mar;12(2):98-103. doi: 10.1007/s00167-003-0426-z. Epub 2003 Sep 20. PMID- 17240172 OWN - NLM STAT- MEDLINE DCOM- 20070709 LR - 20070504 IS - 1065-6995 (Print) IS - 1065-6995 (Linking) VI - 31 IP - 6 DP - 2007 Jun TI - The effect of age on the structure and composition of rat tendon fibrocartilage. PG - 570-7 AB - Biochemical and morphological aspects of fibrocartilages of calcaneal and deep digital flexor tendons in rats aged 30, 180 and 730 days were analyzed. In both tendons a stronger staining with Alcian blue, indicating the presence of proteoglycans, was detected in rats of 30 and 180 days. In animals 730 days old, it was restricted to the pericellular area. Ultrastructural analysis showed a more prominent pericellular matrix in calcaneal tendon compared to the deep digital flexor tendon. The biochemical analysis showed higher levels of proteins and glycosaminoglycans in the calcaneal tendon of 30-day-old rats compared to older rats. In the deep digital flexor tendon, no significant differences were observed between ages. The small proteoglycan, fibromodulin, was detected in both tendons of all ages, but in young rats it appeared to be running as a 210 kDa component, probably due to the association with collagen chains or self-association. FAU - Esquisatto, M A M AU - Esquisatto MA AD - Department of Morphology, University of Araras (UNIARARAS), 13600-970 Araras, SP, Brazil. FAU - Joazeiro, P P AU - Joazeiro PP FAU - Pimentel, E R AU - Pimentel ER FAU - Gomes, L AU - Gomes L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20061203 PL - England TA - Cell Biol Int JT - Cell biology international JID - 9307129 RN - 0 (Glycosaminoglycans) RN - 0 (Proteins) RN - 0 (Uronic Acids) SB - IM MH - Aging/*physiology MH - Animals MH - Calcaneus/cytology/ultrastructure MH - Electrophoresis, Polyacrylamide Gel MH - Fibrocartilage/*chemistry/*cytology/ultrastructure MH - Glycosaminoglycans/analysis MH - Male MH - Proteins/analysis MH - Rats MH - Rats, Wistar MH - Tendons/*chemistry/*cytology MH - Uronic Acids/analysis EDAT- 2007/01/24 09:00 MHDA- 2007/07/10 09:00 CRDT- 2007/01/24 09:00 PHST- 2005/11/01 00:00 [received] PHST- 2006/11/20 00:00 [revised] PHST- 2006/11/29 00:00 [accepted] PHST- 2007/01/24 09:00 [pubmed] PHST- 2007/07/10 09:00 [medline] PHST- 2007/01/24 09:00 [entrez] AID - S1065-6995(06)00296-4 [pii] AID - 10.1016/j.cellbi.2006.11.030 [doi] PST - ppublish SO - Cell Biol Int. 2007 Jun;31(6):570-7. doi: 10.1016/j.cellbi.2006.11.030. Epub 2006 Dec 3. PMID- 32502650 OWN - NLM STAT- MEDLINE DCOM- 20210218 LR - 20210218 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 260 DP - 2020 Oct 5 TI - Metabolomics profiling reveals Echinops latifolius Tausch improves the trabecular micro-architecture of ovariectomized rats mainly via intervening amino acids and glycerophospholipids metabolism. PG - 113018 LID - S0378-8741(20)30939-9 [pii] LID - 10.1016/j.jep.2020.113018 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Echinops latifolius Tausch (ELT) is traditional Mongolian medicine in China, and often used to against osteoporosis, strengthen tendons and bones, clear bones heat. AIM OF THE STUDY: To study efficacy of ELT on ovariectomized (OVX) rats and underly metabolic pathways related to trabecular micro-architecture changing of OVX. MATERIALS AND METHODS: Three-month-old female Wistar rats were randomly divided into 4 groups (n = 6) including normal group (without surgery), sham group (bilateral laparotomy), OVX group (bilateral ovariectomy), and ELT-treated groups (ELT-treated after bilateral ovariectomy). The effects of ELT on trabecular micro-architecture and biochemical markers of OVX rat were investigated by dual-energy X-ray absorptiometry machine and Enzyme-linked immunosorbent assay (ELISA), respectively. Untargeted metabolomics strategy was applied to discover the potential biomarkers and related metabolic pathways involving the progression of OVX-induced osteoporosis. RESULTS: The trabecular micro-architecture and biochemical markers of OVX rats were improved by ELT. We found 36 potential biomarkers and 21 related metabolic pathways were involved in progression of OVX-induced osteoporosis. Amino acids metabolism and glycerophospholipids metabolism were mainly intervened in ELT treatment on ovariectomized rats. The disordered amino acids and glycerophospholipids metabolism closely related to the imbalance between bone resorption and formation were reversed by administration of ELT, indicating that the influences of ELT on OVX rats' trabecular micro-architecture may possible be associated with intervening amino acids and glycerophospholipids metabolism. CONCLUSIONS: This approach may provide the metabolomic perspective to link metabolic alterations and anti-osteoporosis action of ELT, to further explain how ELT works in postmenopausal patients with bone loss. CI - Copyright © 2020 Elsevier B.V. All rights reserved. FAU - Wang, Jiaqi AU - Wang J AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Dong, Xin AU - Dong X AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Ma, Feixiang AU - Ma F AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Li, Chunyan AU - Li C AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Bu, Ren AU - Bu R AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Lu, Jingkun AU - Lu J AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. FAU - Gao, Jianping AU - Gao J AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. Electronic address: 1067429131@qq.com. FAU - Xue, Peifeng AU - Xue P AD - Department of Pharmacy, Inner Mongolia Medical University, Jinshan Development Zone, Hohhot, 010110, China. Electronic address: Xpfdc153@163.com. LA - eng PT - Journal Article DEP - 20200602 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Amino Acids) RN - 0 (Biomarkers) RN - 0 (Glycerophospholipids) RN - 0 (Plant Extracts) SB - IM MH - Amino Acids/metabolism MH - Animals MH - Biomarkers/metabolism MH - Disease Models, Animal MH - Disease Progression MH - Echinops Plant/*chemistry MH - Female MH - Glycerophospholipids/metabolism MH - Humans MH - Medicine, Chinese Traditional MH - *Metabolomics MH - Osteoporosis, Postmenopausal/*drug therapy/metabolism/pathology MH - Ovariectomy MH - Plant Extracts/*pharmacology MH - Rats MH - Rats, Wistar OTO - NOTNLM OT - Echinops latifolius Tausch OT - Metabolomics OT - Ovariectomized OT - Trabecular micro-architecture EDAT- 2020/06/06 06:00 MHDA- 2021/02/20 06:00 CRDT- 2020/06/06 06:00 PHST- 2020/02/28 00:00 [received] PHST- 2020/05/22 00:00 [revised] PHST- 2020/05/24 00:00 [accepted] PHST- 2020/06/06 06:00 [pubmed] PHST- 2021/02/20 06:00 [medline] PHST- 2020/06/06 06:00 [entrez] AID - S0378-8741(20)30939-9 [pii] AID - 10.1016/j.jep.2020.113018 [doi] PST - ppublish SO - J Ethnopharmacol. 2020 Oct 5;260:113018. doi: 10.1016/j.jep.2020.113018. Epub 2020 Jun 2. PMID- 31486703 OWN - NLM STAT- MEDLINE DCOM- 20200901 LR - 20231213 IS - 1557-7600 (Electronic) IS - 1096-620X (Linking) VI - 23 IP - 2 DP - 2020 Feb TI - Avocado/Soybean Unsaponifiables, Glucosamine and Chondroitin Sulfate Combination Inhibits Proinflammatory COX-2 Expression and Prostaglandin E2 Production in Tendon-Derived Cells. PG - 139-146 LID - 10.1089/jmf.2019.0022 [doi] AB - Tendinopathy, a common disorder in man and horses, is characterized by pain, dysfunction, and tendon degeneration. Inflammation plays a key role in the pathogenesis of tendinopathy. Tendon cells produce proinflammatory molecules that induce pain and tissue deterioration. Currently used nonsteroidal anti-inflammatory drugs are palliative but have been associated with adverse side effects prompting the search for safe, alternative compounds. This study determined whether tendon-derived cells' expression of proinflammatory cyclooxygenase (COX)-2 and production of prostaglandin E2 (PGE(2)) could be attenuated by the combination of avocado/soybean unsaponifiables (ASU), glucosamine (GLU), and chondroitin sulfate (CS). ASU, GLU, and CS have been used in the management of osteoarthritis-associated joint inflammation. Tenocytes in monolayer and microcarrier spinner cultures were incubated with media alone, or with the combination of ASU (8.3 μg/mL), GLU (11 μg/mL), and CS (20 μg/mL). Cultures were next incubated with media alone, or stimulated with interleukin-1β (IL-1β; 10 ng/mL) for 1 h to measure COX-2 gene expression, or for 24 h to measure PGE(2) production, respectively. Tenocyte phenotype was analyzed by phase-contrast microscopy, immunocytochemistry, and Western blotting. Tendon-derived cells proliferated and produced extracellular matrix component type I collagen in monolayer and microcarrier spinner cultures. IL-1β-induced COX-2 gene expression and PGE(2) production were significantly reduced by the combination of (ASU+GLU+CS). The suppression of IL-1β-induced inflammatory response suggests that (ASU+GLU+CS) may help attenuate deleterious inflammation in tendons. FAU - Grzanna, Mark W AU - Grzanna MW AD - Nutramax Laboratories, Inc., Edgewood, Maryland, USA. FAU - Au, Rebecca Y AU - Au RY AD - Nutramax Laboratories, Inc., Edgewood, Maryland, USA. FAU - Au, Angela Y AU - Au AY AD - Nutramax Laboratories, Inc., Edgewood, Maryland, USA. FAU - Rashmir, Ann M AU - Rashmir AM AD - College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. FAU - Frondoza, Carmelita G AU - Frondoza CG AD - Nutramax Laboratories, Inc., Edgewood, Maryland, USA. AD - Department of Orthopedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA. AD - College of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi, USA. LA - eng PT - Journal Article DEP - 20190905 PL - United States TA - J Med Food JT - Journal of medicinal food JID - 9812512 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Interleukin-1beta) RN - 0 (Phytochemicals) RN - 0 (Plant Preparations) RN - 9007-28-7 (Chondroitin Sulfates) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - K7Q1JQR04M (Dinoprostone) RN - N08U5BOQ1K (Glucosamine) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Cells, Cultured MH - Chondroitin Sulfates/*pharmacology MH - Cyclooxygenase 2/metabolism MH - Dinoprostone/*metabolism MH - Glucosamine/*pharmacology MH - Horses MH - Interleukin-1beta/pharmacology MH - Persea/*chemistry MH - Phytochemicals/pharmacology MH - Plant Preparations/therapeutic use MH - Glycine max/*chemistry MH - Tendinopathy MH - Tenocytes/*drug effects OTO - NOTNLM OT - COX-2 OT - PGE2 OT - avocado/soybean unsaponifiables OT - chondroitin sulfate OT - glucosamine OT - microcarrier spinner culture OT - tendinopathy EDAT- 2019/09/06 06:00 MHDA- 2020/09/02 06:00 CRDT- 2019/09/06 06:00 PHST- 2019/09/06 06:00 [pubmed] PHST- 2020/09/02 06:00 [medline] PHST- 2019/09/06 06:00 [entrez] AID - 10.1089/jmf.2019.0022 [doi] PST - ppublish SO - J Med Food. 2020 Feb;23(2):139-146. doi: 10.1089/jmf.2019.0022. Epub 2019 Sep 5. PMID- 26591540 OWN - NLM STAT- MEDLINE DCOM- 20151217 LR - 20151120 IS - 1001-5302 (Print) IS - 1001-5302 (Linking) VI - 40 IP - 12 DP - 2015 Jun TI - [Efficacy of compound Xiatianwu tablets in elderly patients with osteoporotic distal radius fractures]. PG - 2445-8 AB - Xiatianwu tablet is based on the theory of traditional Chinese medicine (TCM), combined with modern TCM pharmacology and selected 33 famous traditional Chinese crude drugs to compose. Its recipe helps cure rheumatism, relax tendons, promote blood circulation to relieve pain, et al. Although Xiatianwu tablets are widely applied to clinical remedy such as rheumatic arthritis, lumbar disc hernia, osteoarthritis and so on, there is no report about its application in fracture. This article is to observe the efficacy of compound Xiatianwu tablets in elderly patients with osteoporotic distal radius fractures and its impact on the wrist function and complications. 180 elderly patients with osteoporotic distal radius fractures, from January 2011 to June 2014, were divided into observation group and control group by the method of random number table, each group had 90 cases. The control group were gave Caltrate D after manipulative reduction and plaster immobilization, observation group were treated with compound Xiatianwu tablets in the basis of the control group. Efficacy, wrist function and complication rates were observed in two groups after treatment. The excellent and good rate was 95.56% in observation group better than 77.78% in control group, the difference was statistically significant (χ2 = 4.712, P < 0.05). The complication rate in observation group was significantly lower compared with the control group (P < 0.05). This study shows that compound Xiatianwu tablets can improve the efficacy in elderly patients with osteoporotic distal radius fractures, reduce the incidence of complications and relieve the pain of patients which plays a significant role in improving the quality of life. FAU - Zhang, Bin AU - Zhang B FAU - Chen, Gang AU - Chen G FAU - Li, Hai-long AU - Li HL FAU - Ren, Hai-peng AU - Ren HP FAU - Yang, Tao AU - Yang T FAU - Chen, Min AU - Chen M FAU - Guo, Li-gang AU - Guo LG LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Zhongguo Zhong Yao Za Zhi JT - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica JID - 8913656 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Tablets) SB - IM MH - Aged MH - Aged, 80 and over MH - Drugs, Chinese Herbal/*administration & dosage MH - Female MH - Fractures, Bone/*drug therapy MH - Humans MH - Male MH - Middle Aged MH - Osteoarthritis/*drug therapy MH - Radius Fractures/*drug therapy MH - Tablets/administration & dosage MH - Treatment Outcome EDAT- 2015/11/26 06:00 MHDA- 2015/12/19 06:00 CRDT- 2015/11/24 06:00 PHST- 2015/11/24 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2015/12/19 06:00 [medline] PST - ppublish SO - Zhongguo Zhong Yao Za Zhi. 2015 Jun;40(12):2445-8. PMID- 3002430 OWN - NLM STAT- MEDLINE DCOM- 19860228 LR - 20191210 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 24 IP - 21 DP - 1985 Oct 8 TI - Biosynthesis of prolyl hydroxylase: evidence for two separate dolichol-media pathways of glycosylation. PG - 5960-7 AB - Prolyl hydroxylase is a glycoprotein containing two nonidentical subunits, alpha and beta. The alpha subunit of prolyl hydroxylase isolated from 13-day-old chick embryos contains a single high mannose oligosaccharide having seven mannosyl residues. Two forms of alpha subunit have been shown to exist in enzyme purified from tendon cells of 17-day-old chick embryos, one of which (alpha) appears to be identical in molecular weight and carbohydrate content with the single alpha of enzyme from 13-day-old chick embryos, as well as another form (alpha') that contains two oligosaccharides, each containing eight mannosyl units [see Kedersha, N. L., Tkacz, J. S., & Berg, R. A. (1985) Biochemistry (preceding paper in this issue)]. Biosynthetic labeling studies were performed with chick tendon cells using [2-3H]mannose, [6-3H]glucosamine, [14C(U)]mannose, and [14C(U)]glucose. Analysis of the labeled products using polyacrylamide gel electrophoresis in sodium dodecyl sulfate showed that only the oligosaccharides on alpha' incorporated measurable mannose or glucosamine isotopes; however, both alpha subunits incorporated 14C amino acid mix and [14C(U)]glucose [metabolically converted to [14C(U)]mannose] under similar conditions. Pulse-chase labeling studies using 14C amino acid mix demonstrated that both glycosylated polypeptide chains alpha and alpha' were synthesized simultaneously and that no precursor product relationship between alpha and alpha' was apparent. In the presence of tunicamycin, neither alpha nor alpha' was detected; a single polypeptide of greater mobility appeared instead. Incubation of the cells with inhibitory concentrations of glucosamine partially depressed the glycosylation of alpha' but allowed the glycosylation of alpha.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Kedersha, N L AU - Kedersha NL FAU - Tkacz, J S AU - Tkacz JS FAU - Berg, R A AU - Berg RA LA - eng GR - AM 16516/AM/NIADDK NIH HHS/United States GR - AM 31839/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Amino Acids) RN - 0 (Carbon Radioisotopes) RN - 0 (Diterpenes) RN - 0 (Dolichols) RN - 0 (Glycoproteins) RN - 10028-17-8 (Tritium) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - EC 3.2.1.- (Glycoside Hydrolases) RN - IY9XDZ35W2 (Glucose) RN - N08U5BOQ1K (Glucosamine) RN - PHA4727WTP (Mannose) SB - IM MH - Amino Acids/metabolism MH - Animals MH - Carbon Radioisotopes MH - Chick Embryo MH - Chromatography, Affinity MH - Chromatography, Paper MH - Diterpenes/*metabolism MH - Dolichols/*metabolism MH - Glucosamine/metabolism MH - Glucose/metabolism MH - Glycoproteins/biosynthesis MH - Glycoside Hydrolases MH - Immunodiffusion MH - Mannose/metabolism MH - Organ Culture Techniques MH - Procollagen-Proline Dioxygenase/*biosynthesis/isolation & purification MH - Tendons/enzymology MH - Tritium EDAT- 1985/10/08 00:00 MHDA- 1985/10/08 00:01 CRDT- 1985/10/08 00:00 PHST- 1985/10/08 00:00 [pubmed] PHST- 1985/10/08 00:01 [medline] PHST- 1985/10/08 00:00 [entrez] AID - 10.1021/bi00342a041 [doi] PST - ppublish SO - Biochemistry. 1985 Oct 8;24(21):5960-7. doi: 10.1021/bi00342a041. PMID- 4672181 OWN - NLM STAT- MEDLINE DCOM- 19721110 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 278 IP - 1 DP - 1972 Aug 31 TI - Characterization of the precursor forms of the 1 and 2 chains of collagen from matrix-free tendon cells. PG - 198-205 FAU - Uitto, J AU - Uitto J FAU - Jimenez, S A AU - Jimenez SA FAU - Dehm, P AU - Dehm P FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Amino Acids) RN - 0 (Carbon Isotopes) RN - 10028-17-8 (Tritium) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 48TCX9A1VT (Cystine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - K848JZ4886 (Cysteine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Amino Acids/analysis MH - Animals MH - Carbon Isotopes MH - Chick Embryo MH - *Collagen/biosynthesis MH - Cysteine/analysis MH - Cystine/analysis MH - Electrophoresis, Polyacrylamide Gel MH - Hydroxyproline/analysis MH - Proline/analysis MH - Sodium Dodecyl Sulfate MH - Tendons/*analysis/cytology MH - Tritium EDAT- 1972/08/31 00:00 MHDA- 1972/08/31 00:01 CRDT- 1972/08/31 00:00 PHST- 1972/08/31 00:00 [pubmed] PHST- 1972/08/31 00:01 [medline] PHST- 1972/08/31 00:00 [entrez] AID - 0005-2795(72)90123-7 [pii] AID - 10.1016/0005-2795(72)90123-7 [doi] PST - ppublish SO - Biochim Biophys Acta. 1972 Aug 31;278(1):198-205. doi: 10.1016/0005-2795(72)90123-7. PMID- 1156429 OWN - NLM STAT- MEDLINE DCOM- 19751107 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 65 IP - 3 DP - 1975 Aug 4 TI - Age-related changes in aldehyde location on rat tail tendon collagen. PG - 983-9 FAU - Davison, P F AU - Davison PF FAU - Patel, A AU - Patel A LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Aldehydes) RN - 0 (Amino Acids) RN - 0 (Borohydrides) RN - 0 (Peptide Fragments) RN - 9007-34-5 (Collagen) RN - OS382OHJ8P (Cyanogen Bromide) SB - IM MH - *Aging MH - Aldehydes/analysis MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Borohydrides MH - Chromatography, Gel MH - Chromatography, Ion Exchange MH - *Collagen MH - Cyanogen Bromide MH - Oxidation-Reduction MH - Peptide Fragments/analysis MH - Rats MH - Tail MH - Tendons/*analysis/growth & development EDAT- 1975/08/04 00:00 MHDA- 1975/08/04 00:01 CRDT- 1975/08/04 00:00 PHST- 1975/08/04 00:00 [pubmed] PHST- 1975/08/04 00:01 [medline] PHST- 1975/08/04 00:00 [entrez] AID - S0006-291X(75)80482-7 [pii] AID - 10.1016/s0006-291x(75)80482-7 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1975 Aug 4;65(3):983-9. doi: 10.1016/s0006-291x(75)80482-7. PMID- 39666275 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20241230 IS - 2224-6614 (Electronic) IS - 1021-9498 (Print) VI - 31 IP - 3 DP - 2023 Aug 31 TI - Identification for metabolism profiles and pharmacokinetic studies of tradition Chinese prescription Ji-Ming-San and its major metabolites in rats by UHPLC-Q-TOF-MS/MS and UHPLC-MS/MS. PG - 502-518 LID - 10.38212/2224-6614.3473 [doi] AB - Ji-Ming-Shan (JMS) is a traditional prescription use for patients with rheumatism, tendons swelling, athlete's foot, diuresis and even gout. This study developed a rapid and sensitive method for the analysis of JMS chemical components in the Traditional Chinese medicine (TCM) prescription and in the serum samples of rats which were administered with the herbal extract. Two mass spectrometric approaches were used namely Ultra-performance liquid chromatography-quadrupole time-of-flight-mass spectrometry (UPLC-Q-TOF-MS) method for the major metabolites of the JMS extract while Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was employed for the detection of the JMS metabolites in the sera of rats. It was revealed that the major components in the JMS extract were identified to be narirutin and hesperidin. It was confirmed that 17 compounds were determined in JMS prescription extract and 16 metabolites resulting from the biotransformation of narirutin and hesperidin were identified in the serum samples. In silico analyses also revealed that the metabolite hersperidin-7-glucoside exhibited the best binding ability with respect to the Cyclooxygenase-2 (COX-2) enzyme target. This study showcased the possible biochemical mechanism involved in the therapeutic efficiency of JMS components and their biotransformation products. FAU - Hsieh, Cheng-Yang AU - Hsieh CY AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. AD - Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan. FAU - Wang, Ching-Chiung AU - Wang CC AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. AD - Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. AD - Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan. AD - School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. FAU - Tayo, Lemmuel L AU - Tayo LL AD - School of Chemical, Biological, Materials Engineering and Sciences, Mapúa University, Intramuros, Manila, 1002, Metro Manila, Philippines. FAU - Tsai, Po-Wei AU - Tsai PW AD - Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan, 711, Taiwan. FAU - Lee, Chia-Jung AU - Lee CJ AD - Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. AD - Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. AD - Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan. LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China (Republic : 1949- ) TA - J Food Drug Anal JT - Journal of food and drug analysis JID - 101630927 RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Animals MH - *Drugs, Chinese Herbal/pharmacokinetics/administration & dosage/chemistry MH - Chromatography, High Pressure Liquid/methods MH - *Tandem Mass Spectrometry/methods MH - Rats MH - Male MH - *Rats, Sprague-Dawley MH - Medicine, Chinese Traditional PMC - PMC10629916 COIS- Conflict of interest The authors declare that there are no conflicts of interest. EDAT- 2023/08/31 00:00 MHDA- 2023/08/31 00:01 PMCR- 2023/08/31 CRDT- 2024/12/12 11:28 PHST- 2023/04/07 00:00 [received] PHST- 2023/07/30 00:00 [accepted] PHST- 2023/08/31 00:01 [medline] PHST- 2023/08/31 00:00 [pubmed] PHST- 2024/12/12 11:28 [entrez] PHST- 2023/08/31 00:00 [pmc-release] AID - jfda-31-03-502 [pii] AID - 10.38212/2224-6614.3473 [doi] PST - ppublish SO - J Food Drug Anal. 2023 Aug 31;31(3):502-518. doi: 10.38212/2224-6614.3473. PMID- 38801026 OWN - NLM STAT- MEDLINE DCOM- 20240821 LR - 20250730 IS - 1612-1880 (Electronic) IS - 1612-1872 (Linking) VI - 21 IP - 8 DP - 2024 Aug TI - Epimedium Linn: A Comprehensive Review of Phytochemistry, Pharmacology, Clinical Applications and Quality Control. PG - e202400846 LID - 10.1002/cbdv.202400846 [doi] AB - Epimedium genus is a traditional Chinese medicine, which has functions of tonifying kidney and yang, strengthening tendons and bones, dispelling wind and emoving dampness. It is mainly used for the treatment of impotence and spermatorrhea, osteoporosis, Parkinson's, Alzheimer's, and cardiovascular diseases. The aim of this review is to provide a systematic summary of the phytochemistry, pharmacology, and clinical applications of the Epimedium Linn. In this paper, the relevant literature on Epimedium Linn. was collected from 1987 to the present day, and more than 274 chemical constituents, including flavonoids, phenylpropanoids, lignans, phenanthrenes, and others, were isolated from this genus. Modern pharmacological studies have shown that Epimedium Linn. has osteoprotective, neuroprotective, cardiovascular protective, and immune enhancing pharmacological effects. In addition, Epimedium Linn. has been commonly used to treat osteoporosis, erectile dysfunction, hypertension and cardiovascular disease. In this paper, the distribution of resources, chemical compositions, pharmacological effects, clinical applications and quality control of Epimedium Linn. are progressed to provide a reference for further research and development of the resources of this genus. CI - © 2024 Wiley-VHCA AG, Zurich, Switzerland. FAU - Chen, Xiao-Lin AU - Chen XL AUID- ORCID: 0009-0006-6332-1495 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. FAU - Li, Shi-Xing AU - Li SX AUID- ORCID: 0009-0009-4205-9696 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. FAU - Ge, Teng AU - Ge T AUID- ORCID: 0009-0003-7465-156X AD - Shaanxi Province Key Laboratory of Integrated Traditional Chinese and Western Medicine for the Prevention and Treatment of Cardiovascular Diseases, Xianyang, 712046, P. R. China. FAU - Zhang, Dong-Dong AU - Zhang DD AUID- ORCID: 0000-0003-0956-1261 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. FAU - Wang, Hai-Fang AU - Wang HF AUID- ORCID: 0000-0002-3320-4398 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. FAU - Wang, Wei AU - Wang W AUID- ORCID: 0000-0002-4699-0498 AD - Shaanxi Province Key Laboratory of Integrated Traditional Chinese and Western Medicine for the Prevention and Treatment of Cardiovascular Diseases, Xianyang, 712046, P. R. China. FAU - Li, Yu-Ze AU - Li YZ AUID- ORCID: 0000-0001-7571-3214 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. FAU - Song, Xiao-Mei AU - Song XM AUID- ORCID: 0000-0003-1906-1578 AD - School of Pharmacy, Shaanxi Key Laboratory of Research and Application of "Taibai Qi Yao", Shaanxi University of Chinese Medicine, Xianyang, 712046, P. R. China. LA - eng GR - 2024JC-YBQN-0860/Shaanxi Provincial Science and Technology Department/ GR - 82104368/National Natural Science Foundation of China/ GR - 2021GP27/Shaanxi University of Chinese Medicine/ GR - 2019-YL12/Shaanxi University of Chinese Medicine Science and Technology/ GR - 2023-CXTD-05/Shaanxi University of Chinese Medicine/ GR - 22JK0344/Department of Education of Shaanxi Province/ PT - Journal Article PT - Review DEP - 20240709 PL - Switzerland TA - Chem Biodivers JT - Chemistry & biodiversity JID - 101197449 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Phytochemicals) SB - IM MH - *Epimedium/chemistry MH - Humans MH - Quality Control MH - Drugs, Chinese Herbal/chemistry/pharmacology/isolation & purification MH - Animals MH - Medicine, Chinese Traditional MH - Phytochemicals/pharmacology/chemistry/isolation & purification OTO - NOTNLM OT - Epimedium Linn. OT - clinical application OT - pharmacological OT - phytochemistry OT - quality control EDAT- 2024/05/27 12:42 MHDA- 2024/08/21 11:41 CRDT- 2024/05/27 06:13 PHST- 2024/04/03 00:00 [received] PHST- 2024/05/27 00:00 [accepted] PHST- 2024/08/21 11:41 [medline] PHST- 2024/05/27 12:42 [pubmed] PHST- 2024/05/27 06:13 [entrez] AID - 10.1002/cbdv.202400846 [doi] PST - ppublish SO - Chem Biodivers. 2024 Aug;21(8):e202400846. doi: 10.1002/cbdv.202400846. Epub 2024 Jul 9. PMID- 3403480 OWN - NLM STAT- MEDLINE DCOM- 19880921 LR - 20171213 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 65 IP - 1 DP - 1988 Jul TI - Adaptation of bone and tendon to prolonged hindlimb suspension in rats. PG - 373-6 AB - The rat hindlimb suspension model was used to ascertain the importance of ground reaction forces in maintaining bone and tendon homeostasis. Young female Sprague-Dawley rats were randomly assigned to either a suspended or a nonsuspended group. After 28 days, femur bones and patellar tendons were obtained for morphological and biochemical analyses. Prolonged suspension induced a significant change in the geometric configuration of the femur middiaphysis by increasing the minimum diameter (12%) without any significant alterations in cortical area, density, mineral, and collagen concentrations. Femur wet weight, length, DNA, and uronic acid concentrations of suspended animals were not significantly different from bones of nonsuspended rats. However, the collagen and proteoglycan concentrations in patellar tendons of suspended rats were 28% lower than the concentrations of matrix proteins in tissues obtained from nonsuspended animals. These data suggest that elimination of ground reaction forces induces alterations in tendon composition and femur diaphyseal shape by changing regional rates in bone remodeling and localized tendon strain. Therefore it appears that ground reaction forces are an important factor in the maintenance of cortical bone and patellar tendon homeostasis during weight-bearing conditions. FAU - Vailas, A C AU - Vailas AC AD - Department of Kinesiology, University of California, Los Angeles 90024-1568. FAU - Deluna, D M AU - Deluna DM FAU - Lewis, L L AU - Lewis LL FAU - Curwin, S L AU - Curwin SL FAU - Roy, R R AU - Roy RR FAU - Alford, E K AU - Alford EK LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Uronic Acids) RN - 27YLU75U4W (Phosphorus) RN - RMB44WO89X (Hydroxyproline) RN - SY7Q814VUP (Calcium) SB - IM MH - *Adaptation, Physiological MH - Animals MH - Bone and Bones/analysis/*physiology MH - Calcium/analysis MH - Connective Tissue/physiology MH - Female MH - Hindlimb/*physiology MH - Homeostasis MH - Hydroxyproline/analysis MH - Phosphorus/analysis MH - Rats MH - Rats, Inbred Strains MH - Stress, Mechanical MH - Tendons/analysis/*physiology MH - Uronic Acids/analysis OID - NASA: 88298576 EDAT- 1988/07/01 00:00 MHDA- 1988/07/01 00:01 CRDT- 1988/07/01 00:00 PHST- 1988/07/01 00:00 [pubmed] PHST- 1988/07/01 00:01 [medline] PHST- 1988/07/01 00:00 [entrez] AID - 10.1152/jappl.1988.65.1.373 [doi] PST - ppublish SO - J Appl Physiol (1985). 1988 Jul;65(1):373-6. doi: 10.1152/jappl.1988.65.1.373. PMID- 869913 OWN - NLM STAT- MEDLINE DCOM- 19770723 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 163 IP - 1 DP - 1977 Apr 1 TI - The proteoglycan content and the axial periodicity of collagen in tendon. PG - 145-51 AB - The glycosaminoglycan content and the axial periodicity of collagen was determined in various regions of the rabbit flexor digitorum profundus tendon. This tendon, which passes from the calf to the toes round the inner side of the ankle, contains a thickened sesamoid-like pad where it is subjected to friction and pressure. Other regions of the tendon are subject only to longitudinal tension. In tensional areas the axial periodicity of collagen was of the order of 62 nm and the tissue contained less than 0.2% proteoglycan on a dry weight basis. In the sesamoid-like region, however, the axial periodicity was a significant 13-15% less, and the proteoglycan constituted about 3.5% of the dry weight. Also, in the tensional areas the predominant glycosaminoglycan was dermatan sulphate, whereas in the sesamoid the predominant glycosaminoglycan was chondroitin sulphate. The possible interrelationships between collagen axial peroidicity and proteoglycan content in this tissue are discussed. FAU - Gillard, G C AU - Gillard GC FAU - Merrilees, M J AU - Merrilees MJ FAU - Bell-Booth, P G AU - Bell-Booth PG FAU - Reilly, H C AU - Reilly HC FAU - Flint, M H AU - Flint MH LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Glycosaminoglycans) RN - 0 (Hexosamines) RN - 0 (Hexuronic Acids) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Collagen/*analysis MH - Female MH - Glycosaminoglycans/*analysis MH - Hexosamines/analysis MH - Hexuronic Acids/analysis MH - Male MH - Periodicity MH - Protein Conformation MH - Rabbits MH - Tendons/*analysis/ultrastructure PMC - PMC1164670 EDAT- 1977/04/01 00:00 MHDA- 1977/04/01 00:01 PMCR- 1977/10/01 CRDT- 1977/04/01 00:00 PHST- 1977/04/01 00:00 [pubmed] PHST- 1977/04/01 00:01 [medline] PHST- 1977/04/01 00:00 [entrez] PHST- 1977/10/01 00:00 [pmc-release] AID - 10.1042/bj1630145 [doi] PST - ppublish SO - Biochem J. 1977 Apr 1;163(1):145-51. doi: 10.1042/bj1630145. PMID- 12497576 OWN - NLM STAT- MEDLINE DCOM- 20030409 LR - 20131121 IS - 0738-1085 (Print) IS - 0738-1085 (Linking) VI - 22 IP - 8 DP - 2002 TI - Biochemical evaluation of serum and flexor tenosynovium in carpal tunnel syndrome. PG - 378-85 AB - In total, 41 consecutive patients with "idiopathic carpal tunnel syndrome" and abnormal electrophysiologic findings who underwent carpal tunnel release were studied prospectively. The focus of this investigation was the evaluation of the levels of specific chemical mediators within the serum and flexor tenosynovium of these patients. Blood was collected from these patients within 1 week prior to carpal tunnel release, and flexor tenosynovium was obtained at time of surgery. Specimens were then analyzed to determine the levels of interleukins 1 and 6, prostaglandin E(2) (PGE(2)), and malondialdehyde bis diethyl acetal. These values were compared to those of controls who had no evidence of carpal tunnel syndrome. A significant increase was noted in the serum malondialdehyde and tenosynovial levels of malondialdehyde, interleukin 6, and prostaglandin PGE(2) compared to controls. The elevated levels of these biologic factors and the absence of interleukin 1 elevation support a noninflammatory ischemia-reperfusion etiology for so-called "idiopathic carpal tunnel syndrome" that causes progressive edema and fibrosis of the tissues within the carpal canal. These findings correlate with previous histopathology reports. We believe that "idiopathic carpal tunnel syndrome" is an "-osis" not an "-itis." CI - Copyright 2002 Wiley-Liss, Inc. MICROSURGERY 22:378-385 2002 FAU - Freeland, Alan E AU - Freeland AE AD - Department of Orthopedic Surgery, University of Mississippi Medical Center, Jackson, MS 39216, USA. afreeland@orthopedics.umsmed.edu FAU - Tucci, Michelle A AU - Tucci MA FAU - Barbieri, Rocco A AU - Barbieri RA FAU - Angel, Michael F AU - Angel MF FAU - Nick, Todd G AU - Nick TG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Microsurgery JT - Microsurgery JID - 8309230 RN - 0 (Interleukin-1) RN - 0 (Interleukin-6) RN - 0 (Oxytocics) RN - 4Y8F71G49Q (Malondialdehyde) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Carpal Tunnel Syndrome/*metabolism/pathology/surgery MH - Dinoprostone/*analysis/*blood MH - Female MH - Humans MH - Interleukin-1/*analysis/*blood MH - Interleukin-6/*analysis/*blood MH - Male MH - Malondialdehyde/*analysis/*blood MH - Median Nerve/metabolism/pathology/surgery MH - Middle Aged MH - Oxytocics/*analysis/*blood MH - Synovial Fluid/*metabolism MH - Tendons/*metabolism/pathology/surgery EDAT- 2002/12/24 04:00 MHDA- 2003/04/10 05:00 CRDT- 2002/12/24 04:00 PHST- 2002/12/24 04:00 [pubmed] PHST- 2003/04/10 05:00 [medline] PHST- 2002/12/24 04:00 [entrez] AID - 10.1002/micr.10065 [doi] PST - ppublish SO - Microsurgery. 2002;22(8):378-85. doi: 10.1002/micr.10065. PMID- 10716287 OWN - NLM STAT- MEDLINE DCOM- 20000323 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 18 IP - 1 DP - 2000 Jan TI - An in vivo model for load-modulated remodeling in the rabbit flexor tendon. PG - 116-25 AB - This study tested the hypothesis that eliminating in vivo compression to the wrap-around, fibrocartilage-rich zone of the flexor digitorum profundus tendon results in rapid depletion of fibrocartilage and changes in its mechanical properties, microstructure, extracellular matrix composition, and cellularity. The right flexor digitorum profundus tendons of 2.5-3-year-old rabbits were translocated anteriorly to eliminate in vivo compression and shear to the fibrocartilage zone and, at 4 weeks after surgery, were compared with tendons that had sham surgery and with untreated tendons. The translocated tissue showed a significant increase in equilibrium strain under a compressive creep load (p < 0.05). The thickness and area of the fibrocartilage zone also decreased significantly (p < 0.05). The nuclear density decreased by 40% in the fibrocartilage zone (p < 0.005); however, nuclear shape and orientation were not significantly altered. Glycosaminoglycan content in the fibrocartilage zone was also depleted by 40% (p < 0.02). The tightly woven basket weave-like mesh of collagen fibers in the zone appeared more loosely organized, suggesting matrix reorganization due to translocation. Moreover, immunoreactive type-II collagen and link protein in the fibrocartilage zone also decreased. With use of this unique in vivo model, this research clearly elucidates how changing tissue function (by removing compressive forces) rapidly alters tissue form. FAU - Malaviya, P AU - Malaviya P AD - Noyes-Giannestras Biomechanics Laboratories, University of Cincinnati, Ohio 45221-0070, USA. FAU - Butler, D L AU - Butler DL FAU - Boivin, G P AU - Boivin GP FAU - Smith, F N AU - Smith FN FAU - Barry, F P AU - Barry FP FAU - Murphy, J M AU - Murphy JM FAU - Vogel, K G AU - Vogel KG LA - eng GR - RR07075-18/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Glycosaminoglycans) RN - 0 (Uronic Acids) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Cartilage/physiology MH - Collagen/analysis/immunology MH - Glycosaminoglycans/analysis MH - Rabbits MH - Tendons/chemistry/*physiology MH - Uronic Acids/analysis EDAT- 2000/03/15 09:00 MHDA- 2000/03/25 09:00 CRDT- 2000/03/15 09:00 PHST- 2000/03/15 09:00 [pubmed] PHST- 2000/03/25 09:00 [medline] PHST- 2000/03/15 09:00 [entrez] AID - 10.1002/jor.1100180117 [doi] PST - ppublish SO - J Orthop Res. 2000 Jan;18(1):116-25. doi: 10.1002/jor.1100180117. PMID- 4277976 OWN - NLM STAT- MEDLINE DCOM- 19741206 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 2 IP - 2 DP - 1974 TI - A comparative study of the crosslinking precursors present in rat skin and tail tendon collagen. PG - 95-100 FAU - Deshmukh, K AU - Deshmukh K LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Aldehydes) RN - 0 (Peptides) RN - 0 (Protein Precursors) RN - 10028-17-8 (Tritium) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Age Factors MH - Aldehydes/*analysis MH - Animals MH - Chromatography MH - Collagen/*analysis MH - Hydroxyproline/analysis MH - Molecular Weight MH - Peptides/analysis MH - Protein Denaturation MH - Protein Precursors/*analysis MH - Rats MH - Scintillation Counting MH - Skin/*analysis MH - Spectrophotometry MH - Tendons/*analysis MH - Tritium EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 10.3109/03008207409152094 [doi] PST - ppublish SO - Connect Tissue Res. 1974;2(2):95-100. doi: 10.3109/03008207409152094. PMID- 25490945 OWN - NLM STAT- MEDLINE DCOM- 20150522 LR - 20150326 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 33 IP - 4 DP - 2015 Apr TI - Characterization of deposits in patients with calcific tendinopathy of the supraspinatus. Role of phytate and osteopontin. PG - 475-82 LID - 10.1002/jor.22801 [doi] AB - Calcific tendinopathy of the tendons of the rotator cuff is common in adults. These calcifications tend to be reabsorbed after a period of acute pain. This study evaluated the morphologic characteristics of calcific deposits and the participation of phytate and osteopontin (OPN) in their development. Calcific deposits were removed from 21 patients with calcific tendinopathy by ultrasound-guided needle puncture under local anesthesia. The removed deposits were evaluated by scanning electron microscopy, X-ray diffraction and Fourier transform infrared spectroscopy. The amounts of calcium and phosphorus in the deposits were semi-quantitatively determined by energy dispersive X-ray analysis. Phytate was determined in 2 h urine samples, and OPN was extracted from a pool of deposits. The calcific deposits consisted of amorphous and poorly crystalline carbonated hydroxyapatite containing molecular water and organic matter. OPN was associated with the hydroxyapatite deposits. Phytate concentrations were significantly lower in the urine of patients with calcific tendinopathy than in healthy controls. The deficit in crystallization inhibitors such as phytate, and the presence of regulators such as OPN, may play important roles in the development of calcific tendinopathy. CI - © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Grases, Felix AU - Grases F AD - Laboratory of Renal Lithiasis Research, University Institute of Health Sciences Research (IUNICS-IdISPa), Universitat de les Illes Balears, Palma de Mallorca, Spain; CIBERobn (CB06/03), Instituto de Salud Carlos III, Spain. FAU - Muntaner-Gimbernat, Lorenzo AU - Muntaner-Gimbernat L FAU - Vilchez-Mira, Mar AU - Vilchez-Mira M FAU - Costa-Bauzá, Antonia AU - Costa-Bauzá A FAU - Tur, Fernando AU - Tur F FAU - Prieto, Rafel Maria AU - Prieto RM FAU - Torrens-Mas, Margalida AU - Torrens-Mas M FAU - Vega, Fabiana Gisela AU - Vega FG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150121 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 106441-73-0 (Osteopontin) RN - 7IGF0S7R8I (Phytic Acid) RN - 91D9GV0Z28 (Durapatite) SB - IM MH - Adult MH - Aged MH - Calcinosis/complications/*metabolism/pathology MH - Durapatite/metabolism MH - Female MH - Humans MH - Male MH - Middle Aged MH - Osteopontin/*metabolism MH - Phytic Acid/*metabolism/urine MH - Reference Values MH - Rotator Cuff/*metabolism/ultrastructure MH - Tendinopathy/complications/*metabolism/pathology MH - Tendons/*metabolism/ultrastructure OTO - NOTNLM OT - calcific deposits OT - osteopontin OT - phytate OT - tendinopathy EDAT- 2014/12/11 06:00 MHDA- 2015/05/23 06:00 CRDT- 2014/12/11 06:00 PHST- 2014/07/10 00:00 [received] PHST- 2014/12/04 00:00 [accepted] PHST- 2014/12/11 06:00 [entrez] PHST- 2014/12/11 06:00 [pubmed] PHST- 2015/05/23 06:00 [medline] AID - 10.1002/jor.22801 [doi] PST - ppublish SO - J Orthop Res. 2015 Apr;33(4):475-82. doi: 10.1002/jor.22801. Epub 2015 Jan 21. PMID- 1093363 OWN - NLM STAT- MEDLINE DCOM- 19750718 LR - 20191028 IS - 0065-258X (Print) VI - 42 DP - 1975 TI - Procollagen. PG - 167-91 FAU - Martin, G R AU - Martin GR FAU - Byers, P H AU - Byers PH FAU - Piez, K A AU - Piez KA LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Enzymol Relat Areas Mol Biol JT - Advances in enzymology and related areas of molecular biology JID - 0337243 RN - 0 (Amino Acids) RN - 0 (Disulfides) RN - 0 (Protein Precursors) RN - 9007-34-5 (Collagen) SB - IM MH - Amino Acids/analysis MH - Animals MH - Binding Sites MH - Biological Transport MH - Bone and Bones/analysis MH - Cartilage/analysis MH - *Collagen/biosynthesis MH - Disulfides/analysis MH - Molecular Weight MH - Protein Binding MH - Protein Conformation MH - *Protein Precursors/metabolism MH - Rats MH - Skin/analysis MH - Tendons/analysis RF - 101 EDAT- 1975/01/01 00:00 MHDA- 1975/01/01 00:01 CRDT- 1975/01/01 00:00 PHST- 1975/01/01 00:00 [pubmed] PHST- 1975/01/01 00:01 [medline] PHST- 1975/01/01 00:00 [entrez] AID - 10.1002/9780470122877.ch3 [doi] PST - ppublish SO - Adv Enzymol Relat Areas Mol Biol. 1975;42:167-91. doi: 10.1002/9780470122877.ch3. PMID- 5111799 OWN - NLM STAT- MEDLINE DCOM- 19711221 LR - 20190908 IS - 0531-5565 (Print) IS - 0531-5565 (Linking) VI - 6 IP - 3 DP - 1971 Jun TI - Aging of the connective tissue: collagen cross linking in animals of different species and equal age. PG - 227-33 FAU - Deyl, Z AU - Deyl Z FAU - Juricová, M AU - Juricová M FAU - Rosmus, J AU - Rosmus J FAU - Adam, M AU - Adam M LA - eng PT - Journal Article PL - England TA - Exp Gerontol JT - Experimental gerontology JID - 0047061 RN - 0 (Acetates) RN - 0 (Polymers) RN - 451W47IQ8X (Sodium Chloride) RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Acetates/analysis MH - Age Factors MH - Aged MH - *Aging MH - Animals MH - Cats MH - Cattle MH - Child, Preschool MH - Chromatography MH - Collagen/*analysis MH - Cyprinidae MH - Densitometry MH - Dogs MH - Electrophoresis, Disc MH - Humans MH - Hydroxyproline/analysis MH - Polymers/analysis MH - Rats MH - Skin/*analysis MH - Sodium Chloride/analysis MH - Solubility MH - Species Specificity MH - Temperature MH - Tendons/*analysis MH - Urea EDAT- 1971/06/01 00:00 MHDA- 1971/06/01 00:01 CRDT- 1971/06/01 00:00 PHST- 1971/06/01 00:00 [pubmed] PHST- 1971/06/01 00:01 [medline] PHST- 1971/06/01 00:00 [entrez] AID - 0531-5565(71)90035-0 [pii] AID - 10.1016/0531-5565(71)90035-0 [doi] PST - ppublish SO - Exp Gerontol. 1971 Jun;6(3):227-33. doi: 10.1016/0531-5565(71)90035-0. PMID- 26761345 OWN - NLM STAT- MEDLINE DCOM- 20160919 LR - 20160202 IS - 1520-6882 (Electronic) IS - 0003-2700 (Linking) VI - 88 IP - 3 DP - 2016 Feb 2 TI - Is the Collagen Primed for Mineralization in Specific Regions of the Turkey Tendon? An Investigation of the Protein-Mineral Interface Using Raman Spectroscopy. PG - 1559-63 LID - 10.1021/acs.analchem.5b00406 [doi] AB - The tendons in the turkey leg have specific well-defined areas which become mineralized as the animal ages and they are a thoroughly characterized model system for studying the mineralization process of bone. In this study, nondestructive Raman spectroscopic analysis was used to explore the hypothesis that regions of the turkey tendon that are associated with mineralization exhibit distinct and observable chemical modifications of the collagen prior to the onset of mineralization. The Raman spectroscopy features associated with mineralization were identified by probing (on the micrometer scale) the transition zone between mineralized and nonmineralized regions of turkey leg tendons. These features were then measured in whole tendons and identified in regions of tendon which are destined to become rapidly mineralized around 14 weeks of age. The data show there is a site-specific difference in collagen prior to the deposition of mineral, specifically the amide III band at 1270 cm(-1) increases as the collagen becomes more ordered (increased amide III:amide I ratio) in regions that become mineralized compared to collagen destined to remain nonmineralized. If this mechanism were present in materials of different mineral fraction (and thus material properties), it could provide a target for controlling mineralization in metabolic bone disease. FAU - Kerns, Jemma G AU - Kerns JG AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. AD - Lancaster Medical School, Faculty of Health and Medicine, Lancaster University , Lancaster, Lancashire LA1 4YW, U.K. FAU - Buckley, Kevin AU - Buckley K AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. AD - Central Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory , Harwell Oxford, Oxfordshire OX11 0QX, U.K. FAU - Churchwell, John AU - Churchwell J AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. FAU - Parker, Anthony W AU - Parker AW AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. AD - Central Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory , Harwell Oxford, Oxfordshire OX11 0QX, U.K. FAU - Matousek, Pavel AU - Matousek P AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. AD - Central Laser Facility, Research Complex at Harwell, STFC Rutherford Appleton Laboratory , Harwell Oxford, Oxfordshire OX11 0QX, U.K. FAU - Goodship, Allen E AU - Goodship AE AD - Institute of Orthopaedics and Musculoskeletal Science, University College London, Royal National Orthopaedic Hospital , Stanmore, Middlesex HA7 4LP, U.K. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160113 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 RN - 0 (Amides) RN - 0 (Minerals) RN - 0 (Proteins) RN - 9007-34-5 (Collagen) SB - IM MH - Amides/analysis/chemistry MH - Animals MH - Collagen/*chemistry MH - Minerals/*chemistry MH - Proteins/*chemistry MH - Spectrum Analysis, Raman MH - Tendons/*chemistry MH - Turkeys/*anatomy & histology EDAT- 2016/01/14 06:00 MHDA- 2016/09/20 06:00 CRDT- 2016/01/14 06:00 PHST- 2016/01/14 06:00 [entrez] PHST- 2016/01/14 06:00 [pubmed] PHST- 2016/09/20 06:00 [medline] AID - 10.1021/acs.analchem.5b00406 [doi] PST - ppublish SO - Anal Chem. 2016 Feb 2;88(3):1559-63. doi: 10.1021/acs.analchem.5b00406. Epub 2016 Jan 13. PMID- 7730387 OWN - NLM STAT- MEDLINE DCOM- 19950601 LR - 20190821 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 28 IP - 3 DP - 1995 Mar TI - The influence of tendon Youngs modulus, dimensions and instantaneous moment arms on the efficiency of human movement. PG - 281-91 AB - The purpose of the study was to examine the influence of passive tendon work on the gross mechanical efficiency of human whole body movement. Seven male subjects participated in the study. They performed repetitive jumps (like skipping) of three different intensities. Metabolic costs and work rates were recorded to obtain mechanical efficiencies. Net joint moments were calculated from film recordings using inverse dynamics. A general stress-strain relationship for tendons was modelled using a quadratic function, including Youngs elastic modulus of tendon tissue and tendon dimensions. Instantaneous tendon moment arms for the largest leg extensor muscles (m. triceps surae and m. quadriceps femoris) were calculated using joint angle-moment arm transfer functions obtained from the literature (cadaver studies) and the tendon work was calculated from the net joint moments. Gross efficiency values of 0.65-0.69 and efficiency values of 0.77-0.80 at the approximate level of the muscle-tendon complexes were observed. The tendons performed 52-60% of the total work. The enhancement of the muscle-tendon efficiency over the maximal theoretical efficiency of the contractile machinery (0.30) could exclusively be explained by the contribution of the tendon work. A clear negative relationship between repetitive jumping with high mechanical efficiency and running economy at 12 km h-1 was found. Using model calculations the gross efficiency and the muscle-tendon efficiency were shown to be sensitive to tendon Youngs modulus, dimensions and moment arms. The efficiencies were most sensitive to changes in the tendon moment arms. A 10% decrease in tendon moment arms resulted in a 13% increase in the gross efficiency. Optimization or minimisation of the mechanical efficiency by changing the tendon variables 5% was followed by changes in mechanical efficiency of +14% and -10%, respectively. FAU - Voigt, M AU - Voigt M AD - Department of Medical Anatomy, Panum Institute, University of Copenhagen, Denmark. FAU - Bojsen-Møller, F AU - Bojsen-Møller F FAU - Simonsen, E B AU - Simonsen EB FAU - Dyhre-Poulsen, P AU - Dyhre-Poulsen P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Lactates) SB - IM MH - Adult MH - Algorithms MH - Efficiency/physiology MH - Elasticity MH - Energy Metabolism/physiology MH - Humans MH - Joints/physiology MH - Lactates/blood MH - Male MH - Movement/physiology MH - Muscle Contraction/physiology MH - Muscle, Skeletal/anatomy & histology/physiology MH - Oxygen Consumption/physiology MH - Running/physiology MH - Stress, Mechanical MH - Tendons/*anatomy & histology/*physiology MH - Weight-Bearing/physiology MH - Work/physiology EDAT- 1995/03/01 00:00 MHDA- 1995/03/01 00:01 CRDT- 1995/03/01 00:00 PHST- 1995/03/01 00:00 [pubmed] PHST- 1995/03/01 00:01 [medline] PHST- 1995/03/01 00:00 [entrez] AID - 0021-9290(94)00071-B [pii] AID - 10.1016/0021-9290(94)00071-b [doi] PST - ppublish SO - J Biomech. 1995 Mar;28(3):281-91. doi: 10.1016/0021-9290(94)00071-b. PMID- 38593963 OWN - NLM STAT- MEDLINE DCOM- 20240522 LR - 20240522 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 329 DP - 2024 Jul 15 TI - Aqueous extract of Epimedium sagittatum (Sieb. et Zucc.) Maxim. induces liver injury in mice via pyroptosis. PG - 118164 LID - S0378-8741(24)00463-X [pii] LID - 10.1016/j.jep.2024.118164 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Epimedium sagittatum (Sieb. et Zucc.) Maxim. has been used traditionally in Asia. It can dispel wind and cold, tonify the kidney, and strengthen bones and tendons. However, adverse effects of E. sagittatum have been reported, and the underlying mechanisms remain unclear. AIM OF THE STUDY: This study aimed to investigate liver injury caused by an aqueous extract of E. sagittatum in Institute of Cancer Research (ICR) mice and explore its potential mechanisms. MATERIALS AND METHODS: Dried E. sagittatum leaves were decocted in water to prepare aqueous extracts for ultra-high performance liquid chromatography analysis. Mice were administered an aqueous extract of E. sagittatum equivalent to either 3 g raw E. sagittatum/kg or 10 g raw E. sagittatum/kg once daily via intragastric injection for three months. The liver weights and levels of the serum biochemical parameters including alanine transaminase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), total bilirubin (TBIL), and alkaline phosphatase were measured. Hematoxylin-eosin staining was performed for histopathology. Apoptosis was detected using the TUNEL apoptosis assay kit. IL-1β was detected using ELISA kits. Proteomics was used to identify the differentially expressed proteins. Western blot analysis was performed to determine the levels of proteins significantly affected by the aqueous extract of E. sagittatum. RESULTS: E. sagittatum treatment increased the liver weights and liver coefficients, and ALT and AST levels significantly increased (p < 0.05). A high dose of E. sagittatum significantly increased LDH and TBIL levels (p < 0.05). Ruptured cell membranes and multiple sites of inflammatory cell infiltration were also observed. No evidence of apoptosis was observed. IL-1β levels were significantly increased (p < 0.05). The expressions of PIK3R1, p-MAP2K4, p-Jun N-terminal kinase (JNK)/JNK, p-c-Jun, VDAC2, Bax, and CYC were upregulated, whereas that of Bcl-2 was inhibited by E. sagittatum. The expression of cleaved caspase-1 was significantly increased; however, its effects on GSDMD and GSDMD-N were significantly decreased. The expression levels of cleaved caspase-3 and its effector proteins GSDME and GSDME-N significantly increased. CONCLUSIONS: Our results suggest that the aqueous extract of E. sagittatum induces liver injury in ICR mice after three months of intragastric injection via inflammatory pyroptosis. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Song, Lei AU - Song L AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin, 301617, China. FAU - Wang, Dongyu AU - Wang D AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Zhai, Yuxia AU - Zhai Y AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Zhang, Xiaoying AU - Zhang X AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Zhang, Yue AU - Zhang Y AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin, 301617, China. FAU - Yu, Yingli AU - Yu Y AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin, 301617, China. FAU - Sun, Likang AU - Sun L AD - School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. FAU - Zhou, Kun AU - Zhou K AD - Center of Drug Safety Evaluation, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin, 301617, China. Electronic address: z.k.ken@263.net. LA - eng PT - Journal Article DEP - 20240407 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Plant Extracts) SB - IM MH - Animals MH - *Plant Extracts/pharmacology/chemistry MH - *Chemical and Drug Induced Liver Injury/pathology/drug therapy MH - Male MH - Mice MH - *Pyroptosis/drug effects MH - *Mice, Inbred ICR MH - *Epimedium/chemistry MH - *Liver/drug effects/pathology/metabolism MH - Plant Leaves/chemistry OTO - NOTNLM OT - Intragastric injection OT - Liver injury OT - Mice OT - Pyroptosis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/04/10 00:42 MHDA- 2024/05/23 00:42 CRDT- 2024/04/09 19:20 PHST- 2023/12/25 00:00 [received] PHST- 2024/04/04 00:00 [revised] PHST- 2024/04/06 00:00 [accepted] PHST- 2024/05/23 00:42 [medline] PHST- 2024/04/10 00:42 [pubmed] PHST- 2024/04/09 19:20 [entrez] AID - S0378-8741(24)00463-X [pii] AID - 10.1016/j.jep.2024.118164 [doi] PST - ppublish SO - J Ethnopharmacol. 2024 Jul 15;329:118164. doi: 10.1016/j.jep.2024.118164. Epub 2024 Apr 7. PMID- 3868946 OWN - NLM STAT- MEDLINE DCOM- 19860512 LR - 20190616 IS - 0077-8923 (Print) IS - 0077-8923 (Linking) VI - 460 DP - 1985 TI - Biosynthesis and properties of procollagens V. PG - 181-6 FAU - Fessler, J H AU - Fessler JH FAU - Shigaki, N AU - Shigaki N FAU - Fessler, L I AU - Fessler LI LA - eng GR - AG02128/AG/NIA NIH HHS/United States GR - AM13748/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 RN - 0 (Disulfides) RN - 0 (Macromolecular Substances) RN - 0 (Procollagen) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Chick Embryo MH - Collagen/biosynthesis MH - Disulfides/analysis MH - Macromolecular Substances MH - Procollagen/*biosynthesis MH - Tendons/metabolism EDAT- 1985/01/01 00:00 MHDA- 1985/01/01 00:01 CRDT- 1985/01/01 00:00 PHST- 1985/01/01 00:00 [pubmed] PHST- 1985/01/01 00:01 [medline] PHST- 1985/01/01 00:00 [entrez] AID - 10.1111/j.1749-6632.1985.tb51166.x [doi] PST - ppublish SO - Ann N Y Acad Sci. 1985;460:181-6. doi: 10.1111/j.1749-6632.1985.tb51166.x. PMID- 4293591 OWN - NLM STAT- MEDLINE DCOM- 19680112 LR - 20190629 IS - 0003-9861 (Print) IS - 0003-9861 (Linking) VI - 121 IP - 2 DP - 1967 Aug TI - Studies on acellular bovine glomeruli. Isolation, chemical composition, and demonstration of collagen with an unusual hydroxylysine: hydroxyproline ratio. PG - 491-501 FAU - Lidsky, M D AU - Lidsky MD FAU - Sharp, J T AU - Sharp JT FAU - Rudee, M L AU - Rudee ML LA - eng PT - Journal Article PL - United States TA - Arch Biochem Biophys JT - Archives of biochemistry and biophysics JID - 0372430 RN - 0 (Amino Acids) RN - 0 (Carbohydrates) RN - 0 (Lipids) RN - 0 (Neuraminic Acids) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.4 (Trypsin) RN - EC 3.4.24.3 (Microbial Collagenase) RN - K3Z4F929H6 (Lysine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Amino Acids/analysis MH - Animals MH - Biochemistry/instrumentation MH - Carbohydrates/analysis MH - Cattle MH - Centrifugation, Density Gradient MH - Chemical Phenomena MH - Chemistry, Physical MH - Collagen/*analysis MH - Hydroxyproline/*analysis MH - Kidney Glomerulus/*analysis/cytology MH - Lipids/analysis MH - Lysine/*analysis MH - Microbial Collagenase MH - Neuraminic Acids/analysis MH - Tendons/analysis MH - Trypsin EDAT- 1967/08/01 00:00 MHDA- 1967/08/01 00:01 CRDT- 1967/08/01 00:00 PHST- 1967/08/01 00:00 [pubmed] PHST- 1967/08/01 00:01 [medline] PHST- 1967/08/01 00:00 [entrez] AID - 0003-9861(67)90104-X [pii] AID - 10.1016/0003-9861(67)90104-x [doi] PST - ppublish SO - Arch Biochem Biophys. 1967 Aug;121(2):491-501. doi: 10.1016/0003-9861(67)90104-x. PMID- 29620898 OWN - NLM STAT- MEDLINE DCOM- 20180427 LR - 20180427 IS - 1520-5118 (Electronic) IS - 0021-8561 (Linking) VI - 66 IP - 15 DP - 2018 Apr 18 TI - Analysis of Advanced Glycation Endproducts in Rat Tail Collagen and Correlation to Tendon Stiffening. PG - 3957-3965 LID - 10.1021/acs.jafc.8b00937 [doi] AB - Methylglyoxal is a major 1,2-dicarbonyl compound in vivo and leads to nonenzymatic protein modifications, known as advanced glycation endproducts. Especially long-lived proteins like collagen are prone to changes of the mechanical or biological function, respectively, by accumulation of Maillard-derived modifications. Specifically, the resulting nonenzymatic cross-link structures in parallel to the natural maturation process of collagen fibrils lead to complications with age or during disease. A novel lysine-lysine amide cross-link derived from methylglyoxal, 2,15-diamino-8-methyl-9-oxo-7,10-diaza-1,16-hexadecanedioic acid, named MOLA, was synthesized and identified in vitro and in vivo. Tail tendons of young, adult, and old rats (3, 12, and 22 months) were enzymatically digested prior to analysis of acid-labile glycation products via liquid chromatography-tandem mass spectrometry (LC-MS/MS). As a result, nine monovalent amino acid modifications, mostly originating from methylglyoxal (36 μmol/mol leucine-equivalents in total), and four glycation cross-links (0.72 μmol/mol glucosepane, 0.24 μmol/mol DODIC (3-deoxyglucosone-derived imidazoline cross-link), 0.04 μmol/mol MODIC (methylglyoxal-derived imidazoline cross-link), 0.34 μmol/mol MOLA) were quantitated in senescent tendon collagen. The results correlated with increased tail tendon breaking time from 10 to 190 min and indicate that methylglyoxal is a major player in the aging process of connective tissue. FAU - Jost, Tobias AU - Jost T AUID- ORCID: 0000-0001-7871-1345 AD - Institute of Chemistry-Food Chemistry , Martin-Luther-University Halle-Wittenberg , Kurt-Mothes-Strasse 2 , D-06120 Halle , Germany. FAU - Zipprich, Alexander AU - Zipprich A AD - Department of Internal Medicine I , Martin-Luther-University Halle-Wittenberg , Ernst-Grube-Strasse 40 , D-06120 Halle , Germany. FAU - Glomb, Marcus A AU - Glomb MA AUID- ORCID: 0000-0001-8826-0808 AD - Institute of Chemistry-Food Chemistry , Martin-Luther-University Halle-Wittenberg , Kurt-Mothes-Strasse 2 , D-06120 Halle , Germany. LA - eng PT - Journal Article DEP - 20180405 PL - United States TA - J Agric Food Chem JT - Journal of agricultural and food chemistry JID - 0374755 RN - 0 (Glycation End Products, Advanced) RN - 722KLD7415 (Pyruvaldehyde) RN - 9007-34-5 (Collagen) SB - IM MH - Aging/*metabolism MH - Animals MH - Collagen/*chemistry/metabolism MH - Glycation End Products, Advanced/*analysis/metabolism MH - Male MH - Mass Spectrometry MH - Pyruvaldehyde/*analysis/metabolism MH - Rats MH - Rats, Wistar MH - Tail/chemistry/*metabolism MH - Tendons/*chemistry/metabolism OTO - NOTNLM OT - Maillard reaction OT - advanced glycation endproducts OT - collagen OT - connective tissue stiffening OT - glycation cross-links OT - methylglyoxal EDAT- 2018/04/06 06:00 MHDA- 2018/04/28 06:00 CRDT- 2018/04/06 06:00 PHST- 2018/04/06 06:00 [pubmed] PHST- 2018/04/28 06:00 [medline] PHST- 2018/04/06 06:00 [entrez] AID - 10.1021/acs.jafc.8b00937 [doi] PST - ppublish SO - J Agric Food Chem. 2018 Apr 18;66(15):3957-3965. doi: 10.1021/acs.jafc.8b00937. Epub 2018 Apr 5. PMID- 4333046 OWN - NLM STAT- MEDLINE DCOM- 19720404 LR - 20190501 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 69 IP - 1 DP - 1972 Jan TI - A transport form of collagen from embryonic tendon: electron microscopic demonstration of an NH 2 -terminal extension and evidence suggesting the presence of cystine in the molecule (chick embryo-tropocollagen-gel filtration). PG - 60-4 AB - When cells were isolated from chickembryo tendons and incubated in vitro for 2-6 hr, essentially all the newly-synthesized collagen was recovered from the incubation medium as a transport form larger than tropocollagen. Experiments in which cells were incubated with [(14)C]cystine suggested that the transport form contained cystine and that it was, in part, stabilized by disulfide bonds. Electron microscopy of segment-long-spacing aggregates prepared from the transport form of collagen showed that the native molecule differed from tropocollagen in that it had an extension of about 13 nm (130 A) at the NH(2)-terminal end. FAU - Dehm, P AU - Dehm P FAU - Jimenez, S A AU - Jimenez SA FAU - Olsen, B R AU - Olsen BR FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Carbon Isotopes) RN - 0 (Carrier Proteins) RN - 0 (Detergents) RN - 0 (Sulfates) RN - 0 (Tropocollagen) RN - 48TCX9A1VT (Cystine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 3.4.21.4 (Trypsin) RN - EC 3.4.23.1 (Pepsin A) RN - EC 3.4.24.3 (Microbial Collagenase) RN - SU46BAM238 (Ammonium Sulfate) SB - IM MH - Ammonium Sulfate MH - Animals MH - Anura MH - Biological Transport MH - Carbon Isotopes MH - Carrier Proteins/analysis/metabolism MH - Chick Embryo MH - Chromatography, Gel MH - Collagen/*biosynthesis/isolation & purification MH - Cystine/*isolation & purification MH - Detergents MH - Microbial Collagenase MH - Microscopy, Electron MH - Pepsin A MH - Proline MH - Protein Conformation MH - Sulfates MH - Tendons/*metabolism MH - Tropocollagen/biosynthesis/isolation & purification MH - Trypsin PMC - PMC427544 EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 PMCR- 1972/07/01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PHST- 1972/07/01 00:00 [pmc-release] AID - 10.1073/pnas.69.1.60 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 1972 Jan;69(1):60-4. doi: 10.1073/pnas.69.1.60. PMID- 9731366 OWN - NLM STAT- MEDLINE DCOM- 19980924 LR - 20131121 IS - 0067-8856 (Print) IS - 0067-8856 (Linking) VI - 33 DP - 1997 TI - Biochemical and histological analysis of the flexor tenosynovium in patients with carpal tunnel syndrome. PG - 246-51 AB - Carpal tunnel release is the most common hand operation performed in this country. In the absence of specific systemic diseases, the etiology and persistence of pain and dysfunction even after surgical decompression is poorly understood. The focus of this investigation was to investigate the biological factors present within the patients serum that may lead to increased sensitivity to pain. Tissue was collected from patients during surgery. The tissue was homogenized and the homogenate analyzed for the presence of IL-1, IL-6, prostaglandin E series (PGE2). The levels were compared with volunteers that had no evidence of carpal tunnel syndrome or pain. The results showed similar levels of IL-1 (range 42-26 ng/ml) in tissue homogenates, and a significant increase in levels of IL-6 and malionaldehyde bis-(diethyl acetal) in CTS patients in comparison to control tissues. This increase may be associated with oxidative changes occurring as a result of ischemia and reperfusion. Tissue homogenates were also evaluated for PGE2. The CTS tissues showed a five fold elevation in PGE2 compared to control tissues. Levels of PGE2 in CTS tissues were statistically different using a two-tailed student T-test. Increased levels of PGE2 can enhance vascular permeability at the site of injury, and can play an important role in activating adenylate cyclase which increases intracellular cyclic adenosine monophosphate (cAMP). This increase in cAMP levels can inhibit functional responses to other inflammatory stimuli. Increases in PGE2 can also cause sensitization of the nerve endings so that a normal stimulus that would not necessarily cause pain will now be experienced as painful. The results of this study demonstrate that arachidonic acid metabolites PGE2 may be responsible for both the pathological changes and clinical symptomatology in carpal tunnel syndrome. FAU - Tucci, M A AU - Tucci MA AD - Department of Orthopaedic Surgery, University of Mississippi Medical Center, Jackson 39216, USA. FAU - Barbieri, R A AU - Barbieri RA FAU - Freeland, A E AU - Freeland AE LA - eng PT - Journal Article PL - United States TA - Biomed Sci Instrum JT - Biomedical sciences instrumentation JID - 0140524 RN - 0 (Interleukin-1) RN - 0 (Interleukin-6) RN - 4Y8F71G49Q (Malondialdehyde) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Carpal Tunnel Syndrome/*metabolism/pathology MH - Dinoprostone/analysis MH - Female MH - Humans MH - Immunohistochemistry MH - Interleukin-1/analysis MH - Interleukin-6/analysis MH - Male MH - Malondialdehyde/analysis MH - Middle Aged MH - Synovial Membrane/*chemistry/pathology MH - Tendons/*chemistry/pathology EDAT- 1997/01/01 00:00 MHDA- 1998/09/10 00:01 CRDT- 1997/01/01 00:00 PHST- 1997/01/01 00:00 [pubmed] PHST- 1998/09/10 00:01 [medline] PHST- 1997/01/01 00:00 [entrez] PST - ppublish SO - Biomed Sci Instrum. 1997;33:246-51. PMID- 10906747 OWN - NLM STAT- MEDLINE DCOM- 20001019 LR - 20151119 IS - 0362-2525 (Print) IS - 0022-2887 (Linking) VI - 245 IP - 2 DP - 2000 Aug TI - Examination of intrafascicular muscle fiber terminations: implications for tension delivery in series-fibered muscles. PG - 130-45 AB - Mammalian skeletal muscles with long fascicle lengths are predominantly composed of short muscle fibers that terminate midbelly with no direct connection to the muscle origin or insertion. The manner in which these short fibers terminate and transmit tension through the muscle to their tendons is poorly understood. We made an extensive morphological study of a series-fibered muscle, the guinea pig sternomastoid, in order to define the full range of structural specializations for tension transmission from short fibers within this muscle. Terminations were examined in single fibers, teased small bundles of fibers, and in sections at both the light and electron microscopic level. In many cases, sites of fiber termination were defined by reactivity for the enzyme acetylcholinesterase, which also marks myotendinous junctions. Additionally, transport of the lipophilic fluorescent dye, DiI, or injection of Lucifer Yellow were used to visualize undisturbed fiber terminations in whole muscles using confocal and fluorescence microscopy. At the light microscopic level, we find that intrafascicularly terminating fibers end about equally often in either a long progressive taper, or in a series of small or larger blunt steps. Combinations of these two morphologies are also seen. However, when analyzed at higher resolution with confocal or electron microscopy, the apparently smooth progressive tapers appear also to be predominantly composed of a series of fine stepped terminations. Stepwise terminations in most cases join face-to-face with complementary endings of neighboring muscle fibers, some via an extended collagenous bridge and others at close interdigitating myomyonal junctions. These muscle-to-muscle junctions show many of the features of myotendinous junctions, including dense subsarcolemmal plaques in regions of myofibrillar termination and we suggest that they serve to pass tension from fiber to fiber along the longitudinal axis of the muscle. In addition, we observe regions of apparent side-to-side adhesion between neighboring fibers at sites where there is no apparent fiber tapering or structural specialization typical of myofibril termination. These sites show acetylcholinesterase reactivity, and large numbers of collagen fibers passing laterally from fiber to fiber. These latter connections seem most likely to be involved in lateral transmission of tension, either from fiber to fiber, or from fiber to endomysium. Overall, our results suggest that tension from intrafascicularly terminating fibers is likely to be passed along the muscle to the tendon using both in-series and in-parallel arrangements. The results are discussed in light of current theories of tension delivery within the series-fibered muscles typical of large, nonprimate mammals. CI - Copyright 2000 Wiley-Liss, Inc. FAU - Young, M AU - Young M AD - Department of Anatomy and Structural Biology, University of Otago School of Medical Sciences, Dunedin, New Zealand. FAU - Paul, A AU - Paul A FAU - Rodda, J AU - Rodda J FAU - Duxson, M AU - Duxson M FAU - Sheard, P AU - Sheard P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Morphol JT - Journal of morphology JID - 0406125 RN - 0 (Carbocyanines) RN - 0 (Fluorescent Dyes) RN - 0 (Isoquinolines) RN - 0 (Muscle Proteins) RN - 40957-95-7 (3,3'-dioctadecylindocarbocyanine) RN - 9007-34-5 (Collagen) RN - 9654F8OVKE (lucifer yellow) RN - EC 3.1.1.7 (Acetylcholinesterase) SB - IM MH - Acetylcholinesterase/analysis MH - Animals MH - Carbocyanines/analysis MH - Collagen/analysis MH - Female MH - Fluorescent Dyes/analysis MH - Guinea Pigs MH - Hydrogen-Ion Concentration MH - Isoquinolines/analysis MH - Microscopy, Confocal MH - Microscopy, Electron MH - Microscopy, Electron, Scanning MH - Muscle Contraction/*physiology MH - Muscle Fibers, Skeletal/physiology/*ultrastructure MH - Muscle Proteins/analysis MH - Neck Muscles/physiology/*ultrastructure MH - Tendons/physiology/ultrastructure EDAT- 2000/07/25 11:00 MHDA- 2000/10/21 11:01 CRDT- 2000/07/25 11:00 PHST- 2000/07/25 11:00 [pubmed] PHST- 2000/10/21 11:01 [medline] PHST- 2000/07/25 11:00 [entrez] AID - 10.1002/1097-4687(200008)245:2<130::AID-JMOR4>3.0.CO;2-R [pii] AID - 10.1002/1097-4687(200008)245:2<130::AID-JMOR4>3.0.CO;2-R [doi] PST - ppublish SO - J Morphol. 2000 Aug;245(2):130-45. doi: 10.1002/1097-4687(200008)245:2<130::AID-JMOR4>3.0.CO;2-R. PMID- 23575360 OWN - NLM STAT- MEDLINE DCOM- 20140915 LR - 20220321 IS - 1533-4287 (Electronic) IS - 1064-8011 (Linking) VI - 28 IP - 1 DP - 2014 Jan TI - Acute effects of self-myofascial release using a foam roller on arterial function. PG - 69-73 LID - 10.1519/JSC.0b013e31829480f5 [doi] AB - Flexibility is associated with arterial distensibility. Many individuals involved in sport, exercise, and/or fitness perform self-myofascial release (SMR) using a foam roller, which restores muscles, tendons, ligaments, fascia, and/or soft-tissue extensibility. However, the effect of SMR on arterial stiffness and vascular endothelial function using a foam roller is unknown. This study investigates the acute effect of SMR using a foam roller on arterial stiffness and vascular endothelial function. Ten healthy young adults performed SMR and control (CON) trials on separate days in a randomized controlled crossover fashion. Brachial-ankle pulse wave velocity (baPWV), blood pressure, heart rate, and plasma nitric oxide (NO) concentration were measured before and 30 minutes after both SMR and CON trials. The participants performed SMR of the adductor, hamstrings, quadriceps, iliotibial band, and trapezius. Pressure was self-adjusted during myofascial release by applying body weight to the roller and using the hands and feet to offset weight as required. The roller was placed under the target tissue area, and the body was moved back and forth across the roller. In the CON trial, SMR was not performed. The baPWV significantly decreased (from 1,202 ± 105 to 1,074 ± 110 cm·s-1) and the plasma NO concentration significantly increased (from 20.4 ± 6.9 to 34.4 ± 17.2 μmol·L-1) after SMR using a foam roller (both p < 0.05), but neither significantly differed after CON trials. These results indicate that SMR using a foam roller reduces arterial stiffness and improves vascular endothelial function. FAU - Okamoto, Takanobu AU - Okamoto T AD - 11Department of Exercise Physiology, Nippon Sport Science University, Tokyo, Japan; 2Department of Exercise Physiology and Biochemistry, Osaka University of Health and Sport Sciences, Osaka, Japan; and 3Department of Health and Child Sciences, Osaka Aoyama University, Osaka, Japan. FAU - Masuhara, Mitsuhiko AU - Masuhara M FAU - Ikuta, Komei AU - Ikuta K LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - J Strength Cond Res JT - Journal of strength and conditioning research JID - 9415084 RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Ankle MH - Blood Pressure MH - Brachial Artery/physiology MH - Cross-Over Studies MH - Endothelium, Vascular/*physiology MH - Fascia/*physiology MH - Female MH - Heart Rate MH - Humans MH - Male MH - Massage/instrumentation/*methods MH - Muscle, Skeletal/*physiology MH - Nitric Oxide/blood MH - Pulse Wave Analysis MH - Vascular Stiffness/*physiology MH - Young Adult EDAT- 2013/04/12 06:00 MHDA- 2014/09/16 06:00 CRDT- 2013/04/12 06:00 PHST- 2013/04/12 06:00 [entrez] PHST- 2013/04/12 06:00 [pubmed] PHST- 2014/09/16 06:00 [medline] AID - 10.1519/JSC.0b013e31829480f5 [doi] PST - ppublish SO - J Strength Cond Res. 2014 Jan;28(1):69-73. doi: 10.1519/JSC.0b013e31829480f5. PMID- 30236221 OWN - NLM STAT- MEDLINE DCOM- 20190930 LR - 20190930 IS - 1866-0452 (Electronic) IS - 1866-0452 (Linking) VI - 115 IP - 35-36 DP - 2018 Sep 3 TI - Tendon Swelling After Kidney Transplantation. PG - 595 LID - arztebl.2018.0595 [pii] LID - 10.3238/arztebl.2018.0595 [doi] FAU - Reuter, Stefan AU - Reuter S FAU - Backhaus, Philipp AU - Backhaus P FAU - Becker, Heidemarie AU - Becker H LA - eng PT - Case Reports PT - Journal Article PL - Germany TA - Dtsch Arztebl Int JT - Deutsches Arzteblatt international JID - 101475967 RN - 0 (Enzyme Inhibitors) RN - 0 (Immunosuppressive Agents) RN - 7D0YB67S97 (Abatacept) RN - HU9DX48N0T (Mycophenolic Acid) SB - IM MH - Abatacept/therapeutic use MH - Enzyme Inhibitors/therapeutic use MH - Glomerulonephritis, IGA/complications MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Inflammation/*diagnosis/physiopathology MH - Kidney Transplantation/*adverse effects/methods MH - Male MH - Middle Aged MH - Mycophenolic Acid/therapeutic use MH - Tendons/abnormalities/*physiopathology PMC - PMC6206247 EDAT- 2018/09/22 06:00 MHDA- 2019/10/01 06:00 PMCR- 2018/09/01 CRDT- 2018/09/22 06:00 PHST- 2018/09/22 06:00 [entrez] PHST- 2018/09/22 06:00 [pubmed] PHST- 2019/10/01 06:00 [medline] PHST- 2018/09/01 00:00 [pmc-release] AID - arztebl.2018.0595 [pii] AID - 10.3238/arztebl.2018.0595 [doi] PST - ppublish SO - Dtsch Arztebl Int. 2018 Sep 3;115(35-36):595. doi: 10.3238/arztebl.2018.0595. PMID- 29338716 OWN - NLM STAT- MEDLINE DCOM- 20190530 LR - 20250530 IS - 1472-6750 (Electronic) IS - 1472-6750 (Linking) VI - 18 IP - 1 DP - 2018 Jan 16 TI - Donor age affects proteome composition of tenocyte-derived engineered tendon. PG - 2 LID - 10.1186/s12896-018-0414-5 [doi] LID - 2 AB - BACKGROUND: The concept of tissue engineering is to deliver to the injury site biological scaffolds carrying functional cells that will enhance healing response. The preferred cell source is autologous in order to reduce immune response in the treated individual. However, in elderly patients age-related changes in synthetic activity of the implanted cells and subsequent alterations in tissue protein content may affect therapeutic outcomes. In this study we investigated the effect of donor age on proteome composition of tenocyte-derived tendon tissue-engineered constructs. RESULTS: Liquid chromatography tandem mass spectrometry was used to assess the proteome of tissue-engineered constructs derived from young and old equine tenocytes. Ageing was associated with altered extracellular matrix composition, especially accumulation of collagens (type I, III and XIV), and lower cytoskeletal turnover. Proteins involved in cell responsiveness to mechanical stimuli and cell-extracellular matrix interaction (calponin 1, palladin, caldesmon 1, cortactin) were affected. CONCLUSIONS: This study demonstrated significant changes in proteome of engineered tendon derived from young and old tenocytes, indicating the impact of donor age on composition of autologous constructs. FAU - Turlo, Agnieszka J AU - Turlo AJ AD - Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Science, ul. Nowoursynowska 159c, 02-776, Warsaw, Poland. a_turlo@op.pl. FAU - Ashraf Kharaz, Yalda AU - Ashraf Kharaz Y AD - Institute of Ageing and Chronic Disease, University of Liverpool, William Duncan Building, 6 West Derby Street, Liverpool, L7 8TX, UK. FAU - Clegg, Peter D AU - Clegg PD AD - Institute of Ageing and Chronic Disease, University of Liverpool, William Duncan Building, 6 West Derby Street, Liverpool, L7 8TX, UK. FAU - Anderson, James AU - Anderson J AD - Institute of Ageing and Chronic Disease, University of Liverpool, William Duncan Building, 6 West Derby Street, Liverpool, L7 8TX, UK. FAU - Peffers, Mandy J AU - Peffers MJ AD - Institute of Ageing and Chronic Disease, University of Liverpool, William Duncan Building, 6 West Derby Street, Liverpool, L7 8TX, UK. LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - MR/P020941/1/MRC_/Medical Research Council/United Kingdom GR - ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180116 PL - England TA - BMC Biotechnol JT - BMC biotechnology JID - 101088663 RN - 0 (Proteome) RN - 5KV86114PT (Ethanolamine) SB - IM MH - Age Factors MH - Animals MH - Cells, Cultured MH - Ethanolamine/analysis MH - Extracellular Matrix/physiology MH - Horses MH - Immunohistochemistry/methods MH - Proteome/analysis/*metabolism MH - Proteomics/methods MH - Tendons/*cytology/physiology MH - Tenocytes/cytology/*physiology MH - Tissue Engineering/*methods PMC - PMC5771075 OTO - NOTNLM OT - Ageing OT - Engineered tendon OT - Label-free quantification OT - Tenocytes COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Equine tendon samples were collected as a by-product of the agricultural industry. Specifically, the Animal (Scientific Procedures) Act 1986, Schedule 2, does not define collection from these sources as scientific procedures. Ethical approval was therefore not required for this study. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/01/18 06:00 MHDA- 2019/05/31 06:00 PMCR- 2018/01/16 CRDT- 2018/01/18 06:00 PHST- 2017/03/29 00:00 [received] PHST- 2018/01/03 00:00 [accepted] PHST- 2018/01/18 06:00 [entrez] PHST- 2018/01/18 06:00 [pubmed] PHST- 2019/05/31 06:00 [medline] PHST- 2018/01/16 00:00 [pmc-release] AID - 10.1186/s12896-018-0414-5 [pii] AID - 414 [pii] AID - 10.1186/s12896-018-0414-5 [doi] PST - epublish SO - BMC Biotechnol. 2018 Jan 16;18(1):2. doi: 10.1186/s12896-018-0414-5. PMID- 518916 OWN - NLM STAT- MEDLINE DCOM- 19800317 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 581 IP - 2 DP - 1979 Dec 14 TI - The presence of gamma-carboxyglutamic acid-containing protein in atheromatous aortae. PG - 307-15 AB - It has been established that a gamma-carboxyglutamic acid-containing protein is present in rat aortae after long term atherogenic diet administration. A similar protein was proven to be present in turkey tibial tendons that are predisposed to undergo physiological calcification. The molecular weight and amino acid composition of both proteins were identical. They contained six glutamic acid residues per molecule, three of which were gamma-carboxylated. The proteins studied were also identical in their N-terminal sequence over six residues. This sequence was fully coincident with that published for osteocalcin (Price, P.A., Poser, J.W. and Raman, N. (1976) Proc. Natl. Acad. Sci. U.S.A. 73, 3374--3375). In the region corresponding to residues 20--26 in osteocalcin, a single replacement of valine for isoleucine was found in turkey tendon protein. From the physiological point of view it should be mentioned that the level of the gamma-carboxyglutamic acid containing protein in atherogenic diet fet rat aortae exceeds that found normally in bone or in tissues predisposed for physiological calcification. FAU - Deyl, Z AU - Deyl Z FAU - Macek, K AU - Macek K FAU - Vancikova, O AU - Vancikova O FAU - Adam, M AU - Adam M LA - eng PT - Comparative Study PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Amino Acids) RN - 0 (Dietary Fats) RN - 0 (Glutamates) RN - 0 (Peptides) RN - 0 (Proteins) RN - 53445-96-8 (1-Carboxyglutamic Acid) SB - IM MH - 1-Carboxyglutamic Acid/*analysis MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Aorta/*analysis MH - Arteriosclerosis/*metabolism MH - Bone and Bones/analysis MH - Cattle MH - Dietary Fats MH - Glutamates/*analysis MH - Male MH - Molecular Weight MH - Peptides/analysis MH - *Proteins/isolation & purification MH - Rats MH - Tendons/analysis MH - Turkeys EDAT- 1979/12/14 00:00 MHDA- 1979/12/14 00:01 CRDT- 1979/12/14 00:00 PHST- 1979/12/14 00:00 [pubmed] PHST- 1979/12/14 00:01 [medline] PHST- 1979/12/14 00:00 [entrez] AID - 0005-2795(79)90250-2 [pii] AID - 10.1016/0005-2795(79)90250-2 [doi] PST - ppublish SO - Biochim Biophys Acta. 1979 Dec 14;581(2):307-15. doi: 10.1016/0005-2795(79)90250-2. PMID- 5773752 OWN - NLM STAT- MEDLINE DCOM- 19690427 LR - 20170915 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 176 IP - 1 DP - 1969 Jan 21 TI - [Qualitative and quantitative estimation of free and esterified sterols in whole rat and in 23 of its tissues and organs]. PG - 146-62 FAU - d' Hollander, F AU - d' Hollander F FAU - Chevallier, F AU - Chevallier F LA - fre PT - Journal Article TT - Estimation qualitative et quantitative des stérols libres et estérifiés du rat in toto et de 23 de ses tissus ou organes. PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Cholestanes) RN - 0 (Dietary Fats) RN - 0 (Esters) RN - 0 (Sterols) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Adipose Tissue/analysis MH - Adrenal Glands/*analysis MH - Animals MH - Aorta/analysis MH - Bone Marrow/analysis MH - Bone and Bones/analysis MH - Brain Chemistry MH - Cholestanes/analysis MH - Cholesterol/analysis MH - Chromatography, Gas MH - Dietary Fats MH - Erythrocytes/*analysis MH - Esters/analysis MH - Intestines/analysis MH - Kidney/analysis MH - Liver/*analysis MH - Lung/analysis MH - Male MH - Muscles/analysis MH - Myocardium/analysis MH - Rats MH - Skin/*analysis MH - Spinal Cord/analysis MH - Spleen/analysis MH - Sterols/*analysis/*blood MH - Stomach/analysis MH - Tail/analysis MH - Tendons/analysis MH - Testis/*analysis EDAT- 1969/01/21 00:00 MHDA- 1969/01/21 00:01 CRDT- 1969/01/21 00:00 PHST- 1969/01/21 00:00 [pubmed] PHST- 1969/01/21 00:01 [medline] PHST- 1969/01/21 00:00 [entrez] AID - 0005-2760(69)90083-6 [pii] PST - ppublish SO - Biochim Biophys Acta. 1969 Jan 21;176(1):146-62. PMID- 39668791 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20241213 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 113 IP - 1 DP - 2025 Jan TI - Injectable Nano-Micron AKBA Delivery Platform for Treatment of Tendinopathy in a Rat Model. PG - e37844 LID - 10.1002/jbm.a.37844 [doi] AB - Tendinopathy is a disorder characterized by pain and reduced function due to a series of changes in injured or diseased tendons. Inflammation and collagen degeneration are key contributors to the onset and chronic nature of tendinopathy. Acetyl-11-keto-β-boswellic acid (AKBA) is an effective anti-inflammatory agent widely used in chronic inflammatory disorders and holds potential for tendinopathy treatment; however, its therapeutic efficacy is limited by poor aqueous solubility. Here, we fabricated AKBA-encapsulated cationic liposome-gelatin methacrylamide (GelMA) microspheres (GM-Lipo-AKBA) using thin-film hydration and microfluidic technology for drug delivery therapy. GM-Lipo-AKBA exhibited high encapsulation efficiency, extended AKBA release for over 4 weeks, and prolonged degradation. In vitro and in vivo experiments demonstrated its effectiveness in improving inflammation and ECM remodeling in tendinopathy. In summary, the injectable nano-micron drug delivery platform provides a promising strategy for the sustained and localized delivery of AKBA for tendinopathy treatment. CI - © 2024 Wiley Periodicals LLC. FAU - Han, Qibin AU - Han Q AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. AD - Research Institute of Clinical Medicine, Department of Orthopedic Surgery and Biochemistry, Jeonbuk National University Medical School, Jeonju, Republic of Korea. FAU - Qian, Yinhua AU - Qian Y AD - Department of Orthopedics, Kunshan Hospital of Traditional Chinese Medicine, Suzhou, P. R. China. FAU - Bai, Lang AU - Bai L AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. FAU - Zhou, Jing AU - Zhou J AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. FAU - Hao, Yuefeng AU - Hao Y AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. FAU - Hu, Dan AU - Hu D AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. FAU - Zhang, Zhouzhou AU - Zhang Z AD - Department of Urology Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. FAU - Yang, Xing AU - Yang X AUID- ORCID: 0000-0002-1809-3810 AD - Department of Orthopedics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, P. R. China. LA - eng GR - BE2022737/Program of Jiangsu Science and Technology Department/ GR - H2023120/Program of Jiangsu Province Department of Health/ GR - GSWS2020078/Program of Suzhou Health Committee/ GR - SZXK202111/Program of Suzhou Health Committee/ GR - LCZX202110/Program of Suzhou Health Committee/ GR - SKY2023062/Program of Suzhou Health Committee/ PT - Journal Article PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (acetyl-11-ketoboswellic acid) RN - 0 (Liposomes) RN - 9000-70-8 (Gelatin) RN - 0 (Triterpenes) SB - IM MH - Animals MH - *Tendinopathy/drug therapy/pathology MH - *Rats, Sprague-Dawley MH - *Disease Models, Animal MH - Rats MH - Liposomes/chemistry MH - Male MH - Drug Delivery Systems MH - Gelatin/chemistry MH - Microspheres MH - Injections MH - Triterpenes OTO - NOTNLM OT - AKBA OT - GelMA OT - liposome OT - tendinopathy EDAT- 2024/12/13 11:32 MHDA- 2024/12/13 11:33 CRDT- 2024/12/13 04:33 PHST- 2024/11/01 00:00 [revised] PHST- 2024/06/12 00:00 [received] PHST- 2024/11/25 00:00 [accepted] PHST- 2024/12/13 11:33 [medline] PHST- 2024/12/13 11:32 [pubmed] PHST- 2024/12/13 04:33 [entrez] AID - 10.1002/jbm.a.37844 [doi] PST - ppublish SO - J Biomed Mater Res A. 2025 Jan;113(1):e37844. doi: 10.1002/jbm.a.37844. PMID- 6202699 OWN - NLM STAT- MEDLINE DCOM- 19840719 LR - 20190508 IS - 0021-9525 (Print) IS - 1540-8140 (Electronic) IS - 0021-9525 (Linking) VI - 98 IP - 6 DP - 1984 Jun TI - Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. PG - 1937-46 AB - This report describes the biochemical characterization of a novel extracellular matrix component, " myotendinous antigen," which appears early in chick limb morphogenesis at sites connecting developing muscle fibers, tendons, and bone ( Chiquet , M., and D. Fambrough , 1984; J. Cell Biol., 98:1926-1936). This extracellular matrix antigen is a major component of the secretory proteins released into the medium by fibroblast and muscle cultures; the soluble form is characterized here. This form of myotendinous antigen is a large glycoprotein complex consisting of several disulfide linked subunits (Mr approximately 150,000-240,000). The differently sized antigen subunits are related, since they yielded very similar proteolytic cleavage patterns. M1 antibody can bind to the denatured subunits. The antigen subunits, as well as a Mr approximately 80,000 pepsin-resistant antigenic domain derived from them, are resistant to bacterial collagenase. Despite possessing subunits similar in size to fibronectin, myotendinous antigen appears to be both structurally and antigenically unrelated to fibronectin or to other known extracellular matrix components. About seven times more M1 antigen per cell nucleus was released into the medium in fibroblast as compared to muscle cultures. In muscle conditioned medium, myotendinous antigen is noncovalently complexed to very high molecular weight material that could be heavily labeled by [3H]glucosamine and [35S]sulfate. This material is sensitive to chondroitinase ABC and hence appears to contain sulfated glycosaminoglycans. We speculate that myotendinous antigen might interact with proteoglycans on the surface of muscle fibers, thereby acting as a link to tendons. FAU - Chiquet, M AU - Chiquet M FAU - Fambrough, D M AU - Fambrough DM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Cell Biol JT - The Journal of cell biology JID - 0375356 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antigens, Surface) RN - 0 (Disulfides) RN - 0 (Epitopes) RN - 0 (Fibronectins) RN - 0 (Glycoproteins) RN - 0 (Macromolecular Substances) RN - EC 3.4.24.3 (Microbial Collagenase) SB - IM MH - Animals MH - Antibodies, Monoclonal MH - Antigens, Surface/*analysis MH - Cells, Cultured MH - Chick Embryo MH - Disulfides/analysis MH - Epitopes/analysis MH - Extracellular Matrix/*analysis MH - Fibroblasts/analysis MH - Fibronectins/analysis MH - Glycoproteins/*analysis MH - Macromolecular Substances MH - Microbial Collagenase MH - Molecular Weight MH - Morphogenesis MH - Muscles/*embryology MH - *Osteogenesis MH - Tendons/*embryology PMC - PMC2113072 EDAT- 1984/06/01 00:00 MHDA- 1984/06/01 00:01 PMCR- 1984/12/01 CRDT- 1984/06/01 00:00 PHST- 1984/06/01 00:00 [pubmed] PHST- 1984/06/01 00:01 [medline] PHST- 1984/06/01 00:00 [entrez] PHST- 1984/12/01 00:00 [pmc-release] AID - 84212761 [pii] AID - 10.1083/jcb.98.6.1937 [doi] PST - ppublish SO - J Cell Biol. 1984 Jun;98(6):1937-46. doi: 10.1083/jcb.98.6.1937. PMID- 15260224 OWN - NLM STAT- MEDLINE DCOM- 20050311 LR - 20191108 IS - 0098-0331 (Print) IS - 0098-0331 (Linking) VI - 30 IP - 4 DP - 2004 Apr TI - A stingless bee (Melipona seminigra) marks food sources with a pheromone from its claw retractor tendons. PG - 793-804 AB - By depositing scent marks on flowers, bees reduce both the search time and the time spent with the handling of nonrewarding flowers. They thereby improve the efficiency of foraging. Whereas in honey bees the source of these scent marks is unknown, it is assumed to be the tarsal glands in bumble bees. According to histological studies, however, the tarsal glands lack any openings to the outside. Foragers of the stingless bee Melipona seminigra have previously been shown to deposit an attractant pheromone at sugar solution feeders, which is secreted at the tips of their tarsi. Here we show that the claw retractor tendons have specialized glandular epithelia within the femur and tibia of all legs that produce this pheromone. The secretion accumulates within the hollow tendon, which also serves as the duct to the outside, and is released from an opening at the base of the unguitractor plate. In choice experiments, M. seminigra was attracted by feeders baited with pentane extracts of the claw retractor tendons in the same way as it was attracted by feeders previously scent marked by foragers. Our results resolve the seeming contradiction between the importance of foot print secretions and the lack of openings of the tarsal glands. FAU - Jarau, Stefan AU - Jarau S AD - Institute of Zoology, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria. stefan.jarau@biologie.uni-ulm.de FAU - Hrncir, Michael AU - Hrncir M FAU - Ayasse, Manfred AU - Ayasse M FAU - Schulz, Claudia AU - Schulz C FAU - Francke, Wittko AU - Francke W FAU - Zucchi, Ronaldo AU - Zucchi R FAU - Barth, Friedrich G AU - Barth FG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Chem Ecol JT - Journal of chemical ecology JID - 7505563 RN - 0 (Complex Mixtures) RN - 0 (Hydrocarbons) RN - 0 (Pheromones) SB - IM MH - Animals MH - Bees/anatomy & histology/*physiology MH - Brazil MH - Complex Mixtures/analysis MH - Feeding Behavior MH - Hydrocarbons/analysis MH - Pheromones/chemistry/*physiology MH - Scent Glands/anatomy & histology/chemistry/*physiology EDAT- 2004/07/21 05:00 MHDA- 2005/03/12 09:00 CRDT- 2004/07/21 05:00 PHST- 2004/07/21 05:00 [pubmed] PHST- 2005/03/12 09:00 [medline] PHST- 2004/07/21 05:00 [entrez] AID - 10.1023/b:joec.0000028432.29759.ed [doi] PST - ppublish SO - J Chem Ecol. 2004 Apr;30(4):793-804. doi: 10.1023/b:joec.0000028432.29759.ed. PMID- 20683611 OWN - NLM STAT- MEDLINE DCOM- 20110228 LR - 20211020 IS - 1439-6327 (Electronic) IS - 1439-6319 (Linking) VI - 110 IP - 5 DP - 2010 Nov TI - Changes in tendon stiffness and running economy in highly trained distance runners. PG - 1037-46 LID - 10.1007/s00421-010-1582-8 [doi] AB - The purpose of this study was to determine if changes in triceps-surae tendon stiffness (TST K) could affect running economy (RE) in highly trained distance runners. The intent was to induce increased TST K in a subgroup of runners by an added isometric training program. If TST K is a primary determinant of RE, then the energy cost of running (EC) should decrease in the trained subjects. EC was measured via open-circuit spirometry in 12 highly trained male distance runners, and TST K was measured using ultrasonography and dynamometry. Runners were randomly assigned to either a training or control group. The training group performed 4 × 20 s isometric contractions at 80% of maximum voluntary plantarflexion moment three times per week for 8 weeks. All subjects (V(O)₂(max)) = 67.4 ± 4.6 ml kg(-1) min(-1)) continued their usual training for running. TST K was measured every 2 weeks. EC was measured in both training and control groups before and after the 8 weeks at three submaximal velocities, corresponding to 75, 85 and 95% of the speed at lactate threshold (sLT). Isometric training did neither result in a mean increase in TST K (0.9 ± 25.8%) nor a mean improvement in RE (0.1 ± 3.6%); however, there was a significant relationship (r(2) = 0.43, p = 0.02) between the change in TST K and change in EC, regardless of the assigned group. It was concluded that TST K and EC are somewhat labile and change together. FAU - Fletcher, Jared R AU - Fletcher JR AD - Human Performance Laboratory, Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada. FAU - Esau, Shane P AU - Esau SP FAU - MacIntosh, Brian R AU - MacIntosh BR LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20100804 PL - Germany TA - Eur J Appl Physiol JT - European journal of applied physiology JID - 100954790 RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Adult MH - *Athletes MH - Athletic Performance/physiology MH - Elasticity/*physiology MH - Energy Metabolism/physiology MH - Exercise Test MH - Humans MH - Isometric Contraction/physiology MH - Lactic Acid/blood MH - Male MH - Muscle, Skeletal/diagnostic imaging/physiology MH - Oxygen Consumption/physiology MH - Physical Endurance/physiology MH - Random Allocation MH - Running/*physiology MH - Tendons/diagnostic imaging/*physiology MH - Ultrasonography MH - Young Adult EDAT- 2010/08/05 06:00 MHDA- 2011/03/01 06:00 CRDT- 2010/08/05 06:00 PHST- 2010/07/13 00:00 [accepted] PHST- 2010/08/05 06:00 [entrez] PHST- 2010/08/05 06:00 [pubmed] PHST- 2011/03/01 06:00 [medline] AID - 10.1007/s00421-010-1582-8 [doi] PST - ppublish SO - Eur J Appl Physiol. 2010 Nov;110(5):1037-46. doi: 10.1007/s00421-010-1582-8. Epub 2010 Aug 4. PMID- 865281 OWN - NLM STAT- MEDLINE DCOM- 19770729 LR - 20190725 IS - 0026-0495 (Print) IS - 0026-0495 (Linking) VI - 26 IP - 7 DP - 1977 Jul TI - Evidence for the early reduction of the 24,25 double bond in the conversion of lanosterol to cholesterol in cerebrotendinous xanthomatosis. PG - 721-9 AB - The metabolism of lanosterol and 24,25-dihydrolanosterol (DL) was examined in a patient with cerebrotendinous xanthomatosis after intravenous pulse labeling with a mixture of DL-2-14C and 3S,4S,3R,4R-(4-3H)mevalonate. Sterols were isolated from the feces and purified by silver nitrate thin-layer chromatography, and their identities were confirmed by gas-liquid chromatography and mass spectrometry. Their specific activities were then determined and plotted as a function of time. These isotope ratio measurements and specific activity decay curves were consistent with 24,25-dihydrolanosterol and delta7-cholestenol being intermediates in the synthesis of cholesterol from mevalonate and lanosterol, and they suggested that reduction of the lanosterol side chain may occur as an early step in the synthesis of cholesterol. These results are in contrast to the results reported after the administration of triparanol, a delta24-reductase inhibitor. FAU - Tint, G S AU - Tint GS FAU - Salen, G AU - Salen G LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (Carbon Radioisotopes) RN - 0 (Sterols) RN - 10028-17-8 (Tritium) RN - 1J05Z83K3M (Lanosterol) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Brain Diseases, Metabolic/*metabolism MH - Carbon Radioisotopes MH - Cholesterol/*biosynthesis MH - Chromatography, Gas MH - Chromatography, Thin Layer MH - Feces/analysis MH - Female MH - Humans MH - Isotope Labeling MH - Lanosterol/*metabolism MH - Mass Spectrometry MH - Middle Aged MH - Oxidation-Reduction MH - Sterols/metabolism MH - *Tendons MH - Time Factors MH - Tritium MH - Xanthomatosis/*metabolism EDAT- 1977/07/01 00:00 MHDA- 1977/07/01 00:01 CRDT- 1977/07/01 00:00 PHST- 1977/07/01 00:00 [pubmed] PHST- 1977/07/01 00:01 [medline] PHST- 1977/07/01 00:00 [entrez] AID - 0026-0495(77)90059-2 [pii] AID - 10.1016/0026-0495(77)90059-2 [doi] PST - ppublish SO - Metabolism. 1977 Jul;26(7):721-9. doi: 10.1016/0026-0495(77)90059-2. PMID- 3088796 OWN - NLM STAT- MEDLINE DCOM- 19860815 LR - 20131121 IS - 0042-4625 (Print) IS - 0042-4625 (Linking) VI - 136 IP - 3 DP - 1986 Mar TI - [Methods of sterilizing and preserving tendon transplants]. PG - 85-8 AB - The authors describe three methods for making tendon transplants by using chemical sterilizing and preserving means having no unfavorable effect on their biological and plasty properties. The methods are simple, reliable and fairly suitable for a wide supply of clinical institutions with tendon transplants. FAU - Savel'ev, V I AU - Savel'ev VI FAU - Roskov, R V AU - Roskov RV FAU - Stakheev, I A AU - Stakheev IA FAU - Plotnikova, V A AU - Plotnikova VA FAU - Katochikova, L D AU - Katochikova LD LA - rus PT - Comparative Study PT - English Abstract PT - Journal Article TT - Sposoby sterilizatsii sukhozhil'nykh transplantatov. PL - Russia (Federation) TA - Vestn Khir Im I I Grek JT - Vestnik khirurgii imeni I. I. Grekova JID - 0411377 RN - 1014KSJ86F (Erythromycin Ethylsuccinate) RN - 1364PS73AF (Acetone) RN - 1HG84L3525 (Formaldehyde) RN - 9PHQ9Y1OLM (Prednisolone) RN - JJH7GNN18P (Ethylene Oxide) RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Acetone/pharmacology MH - Animals MH - Bacteria/isolation & purification MH - Dimethyl Sulfoxide/pharmacology MH - Dogs MH - Erythromycin Ethylsuccinate/pharmacology MH - Ethylene Oxide/pharmacology MH - Formaldehyde/pharmacology MH - Humans MH - Prednisolone/pharmacology MH - Sterilization/*methods MH - Tendons/microbiology/*transplantation MH - Tissue Preservation/*methods EDAT- 1986/03/01 00:00 MHDA- 1986/03/01 00:01 CRDT- 1986/03/01 00:00 PHST- 1986/03/01 00:00 [pubmed] PHST- 1986/03/01 00:01 [medline] PHST- 1986/03/01 00:00 [entrez] PST - ppublish SO - Vestn Khir Im I I Grek. 1986 Mar;136(3):85-8. PMID- 114291 OWN - NLM STAT- MEDLINE DCOM- 19791218 LR - 20190827 IS - 0171-967X (Print) IS - 0171-967X (Linking) VI - 27 IP - 3 DP - 1979 Jul 3 TI - Phosphopeptides and gamma-carboxyglutamic acid-containing peptides in calcified turkey tendon: their absence in uncalcified tendon. PG - 281-4 AB - Uncalcified samples of turkey tendon obtained prior to calcification, and other samples from areas of tendon that never calcify, contain little or no O-phosphoserine [Ser(P)], O-phosphothreonine [Thr(P)] and gamma-carboxyglutamic acid (Gla). Significant amounts of all three of these Ca2+-binding amino acids, which are found in EDTA-extractable, non-collagenous proteins, are detected coincident with the onset of mineralization of a tendon and increase in concentration as mineralization proceeds. FAU - Glimcher, M J AU - Glimcher MJ FAU - Brickley-Parsons, D AU - Brickley-Parsons D FAU - Kossiva, D AU - Kossiva D LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Calcif Tissue Int JT - Calcified tissue international JID - 7905481 RN - 0 (Glutamates) RN - 0 (Organophosphorus Compounds) RN - 0 (Peptides) RN - 0 (Phosphopeptides) RN - 2ZD004190S (Threonine) RN - 452VLY9402 (Serine) RN - 53445-96-8 (1-Carboxyglutamic Acid) SB - IM MH - 1-Carboxyglutamic Acid/*analysis MH - Aging MH - Animals MH - Female MH - Glutamates/*analysis MH - Organophosphorus Compounds/analysis MH - *Peptides/analysis MH - Phosphopeptides/*analysis MH - Serine/analysis MH - Tendons/*growth & development MH - Threonine/analysis MH - Turkeys EDAT- 1979/07/03 00:00 MHDA- 1979/07/03 00:01 CRDT- 1979/07/03 00:00 PHST- 1979/07/03 00:00 [pubmed] PHST- 1979/07/03 00:01 [medline] PHST- 1979/07/03 00:00 [entrez] AID - 10.1007/BF02441198 [doi] PST - ppublish SO - Calcif Tissue Int. 1979 Jul 3;27(3):281-4. doi: 10.1007/BF02441198. PMID- 36584922 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20230206 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 305 DP - 2023 Apr 6 TI - In vitro and in vivo anti-osteoarthritis effects of tradition Chinese prescription Ji-Ming-San. PG - 116084 LID - S0378-8741(22)01123-0 [pii] LID - 10.1016/j.jep.2022.116084 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Ji-Ming-Shan (JMS) is a traditional herbal prescription consisting of seven herbs including Areca cathechu Burm.f., Citrus reticulata Blanco, Chaenomeles speciosa (Sweet) Nakai, Euodia ruticarpa (A. Juss.) Benth., Perilla frutescens (L.) Britton, Zingiber officinale Roscoe, Platycodon grandiflorus (Jacq.). It was first recorded during the Song dynasty and has been used extensively for protection against rheumatism, treatment of swelling of tendons, relief from foot pain, gout and diuresis and other forms of inflammation. AIM OF THE STUDY: The aim of this study is to evaluate the anti-inflammatory and anti-osteoarthritis activity of JMS extracts with the use of different cell lines (RAW 264.7 cells, SW1353 cells and primary cultured rat chondrocytes). MIA-induced rat animal models were used to assess the anti-osteoarthritis activity of the extract. MATERIALS AND METHODS: This study investigated the anti-inflammatory activity of JMS-95E on LPS-induced RAW 264.7 macrophages and IL-1β-stimulated chondrocytes. For the in vivo study, male Wistar rats were used and they were randomly assigned in different groups: blank, control, positive control and three different JMS-95E treatment groups (200, 400, 800 mg/kg/d). Paw edema, hind-limb weight bearing, serum inflammatory cytokines including hematoxylin and eosin (HE) staining experiments were used to assess the efficacy of the extract in the rat model. RESULT: JMS 95% ethanol extract (JMS-95E, marker substance: narirutin (5.10 mg/g) and hesperidin (11.33 mg/g) has been identified in the extract using high pressure liquid chromatography. For in vitro assays, JMS-95E did not exhibit cytotoxicity and was able to downregulate the protein expression of iNOS, COX-2 and MMP-13. The production of inflammatory mediators such as NO and PGE(2) were also reduced with an increase in dose-dependent manner in various cell lines. Inhibitory activity on the key enzyme xanthine oxidase was also observed in this study. In rat animal models, JMS-95E reduced the inflammatory responses such as acute swelling, chondrocyte degradation and pain section of paw edema in rat model. Molecular marker studies of inflammation demonstrated that JMS-95E significantly decrease PGE(2) expression in MIA model. CONCLUSION: JMS-95E inhibited the inflammatory pathway leading to the production or expression levels of NO, iNOS, COX-2 and PGE(2) in macrophage cells. In primary cultured rat chondrocytes iNOS and SW1353 MMP-13 expression were downregulated after JMS-95E treatment. For the in vivo study JMS-95E significantly reduced the paw volume of carrageenan-induced rat paw edema through each dose and significantly inhibited paw volume, counterweight the distribution of hind-paw weight bearing through the MIA model which means JMS-95E could promote recovery of the acute swelling and chondrocyte degradation of the ankle joints. The above results provided the multiple mechanism of JMS-95E in OA treatment of the scientific founding which supported the description of JMS in traditional use. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Hsieh, Cheng-Yang AU - Hsieh CY AD - Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. Electronic address: d339108001@tmu.edu.tw. FAU - Wang, Ching-Chiung AU - Wang CC AD - Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. Electronic address: crystal@tmu.edu.tw. FAU - Tayo, Lemmuel L AU - Tayo LL AD - School of Chemical, Biological, Materials Engineering and Sciences, Mapúa University, Intramuros, Manila, 1002, Metro Manila, Philippines. Electronic address: lltayo@mapua.edu.ph. FAU - Deng, Shun-Xin AU - Deng SX AD - Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan. Electronic address: d339107003@tmu.edu.tw. FAU - Tsai, Po-Wei AU - Tsai PW AD - Department of Medical Science Industries, College of Health Sciences, Chang Jung Christian University, Tainan, 711, Taiwan. Electronic address: powei@mail.cjcu.edu.tw. FAU - Lee, Chia-Jung AU - Lee CJ AD - Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 110, Taiwan. Electronic address: cjlee@tmu.edu.tw. LA - eng PT - Journal Article DEP - 20221227 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - 0 (Anti-Inflammatory Agents) RN - 9000-07-1 (Carrageenan) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - 0 (Plant Extracts) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Animals MH - Male MH - Rats MH - Anti-Inflammatory Agents/adverse effects MH - Carrageenan MH - Cyclooxygenase 2/metabolism MH - Disease Models, Animal MH - Edema/chemically induced/drug therapy/prevention & control MH - Inflammation/drug therapy MH - Matrix Metalloproteinase 13 MH - *Osteoarthritis/drug therapy MH - Pain/drug therapy MH - Plant Extracts/adverse effects MH - Rats, Sprague-Dawley MH - Rats, Wistar MH - *Drugs, Chinese Herbal/pharmacology OTO - NOTNLM OT - Anti-inflammatory OT - Hesperidin OT - Ji-Ming-Shan OT - MIA OT - Narirutin OT - Osteoarthritis COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/31 06:00 MHDA- 2023/01/25 06:00 CRDT- 2022/12/30 19:16 PHST- 2022/05/31 00:00 [received] PHST- 2022/12/20 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/25 06:00 [medline] PHST- 2022/12/30 19:16 [entrez] AID - S0378-8741(22)01123-0 [pii] AID - 10.1016/j.jep.2022.116084 [doi] PST - ppublish SO - J Ethnopharmacol. 2023 Apr 6;305:116084. doi: 10.1016/j.jep.2022.116084. Epub 2022 Dec 27. PMID- 188411 OWN - NLM STAT- MEDLINE DCOM- 19770224 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 159 IP - 3 DP - 1976 Dec 1 TI - A comparison of bone matrix and tendon with particular reference to glycoprotein content. PG - 749-55 AB - Bone matrix and tendon are compared in terms of their carbohydrate and non-collagenous protein composition. The collagen content of both tissues was similar (90-91%), but bone matrix had at least three times as much sialic acid (0.28%) as tendon (0.08%). Smaller differences were found in the analysis of hexoses and hexosamines. After digestion with bacterial collagenase, about 9% of the total protein from both tissues was non-diffusible on dialysis, and this contained only 0.15% (bone) and 0.7% (tendon) of the original hydroxyproline; recovery of sialic acid was 86-87%. The collagenase-resistant soluble material amounted to about 9% (bone matrix) and 5% (tendon); the insoluble residues were 1 and 4% respectively. There were clear differences in the carbohydrate contents of the digests, but the amino acid compositions were similar. When the soluble digests were chromatographed on DEAE-cellulose, the elution profiles indicated the presence in each tissue of a variety of glycoproteins and a proteoglycan fraction, and showed clearly that an acidic glycoprotein corresponding to bone sialoprotein was not present in tendon. FAU - Herring, G M AU - Herring GM LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Amino Acids) RN - 0 (Glycoproteins) RN - 0 (Sialic Acids) RN - 0 (Sialoglycoproteins) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.3 (Microbial Collagenase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Amino Acids/analysis MH - Animals MH - Bone and Bones/*analysis MH - Cattle MH - Chromatography, DEAE-Cellulose MH - Collagen/analysis MH - Glycoproteins/*analysis MH - Hydroxyproline/analysis MH - Microbial Collagenase MH - Sialic Acids/analysis MH - Sialoglycoproteins/analysis MH - Tendons/*analysis PMC - PMC1164178 EDAT- 1976/12/01 00:00 MHDA- 1976/12/01 00:01 PMCR- 1977/06/01 CRDT- 1976/12/01 00:00 PHST- 1976/12/01 00:00 [pubmed] PHST- 1976/12/01 00:01 [medline] PHST- 1976/12/01 00:00 [entrez] PHST- 1977/06/01 00:00 [pmc-release] AID - 10.1042/bj1590749 [doi] PST - ppublish SO - Biochem J. 1976 Dec 1;159(3):749-55. doi: 10.1042/bj1590749. PMID- 38364326 OWN - NLM STAT- MEDLINE DCOM- 20240304 LR - 20240304 IS - 2772-9508 (Electronic) IS - 2772-9508 (Linking) VI - 158 DP - 2024 Apr TI - Dual cross-linked COL1/HAp bionic gradient scaffolds containing human amniotic mesenchymal stem cells promote rotator cuff tendon-bone interface healing. PG - 213799 LID - S2772-9508(24)00042-6 [pii] LID - 10.1016/j.bioadv.2024.213799 [doi] AB - The tendon-bone interface heals through scar tissue, while the lack of a natural interface gradient structure and collagen fibre alignment leads to the occurrence of retearing. Therefore, the promotion of tendon healing has become the focus of regenerative medicine. The purpose of this study was to develop a gradient COL1/ hydroxyapatite (HAp) biomaterial loaded with human amniotic mesenchymal stem cells (hAMSCs). The performance of common cross-linking agents, Genipin, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS), and dual cross-linked materials were compared to select the best cross-linking mechanism to optimize the biological and mechanical properties of the scaffold. The optimal COL1/HAp-loaded with hAMSCs were implanted into the tendon-bone rotator cuff interfaces in rats and the effect on the tendon-bone healing was assessed by micro-CT, histological analysis, and biomechanical properties. The results showed that Genipin and EDC/NHS dual cross-linked COL1/HAp had good biological activity and mechanical properties and promoted the proliferation and differentiation of hAMSCs. Animal experiments showed that the group using a scaffold loaded with hAMSCs had excellent continuity and orientation of collagen fibers, increased fibrocartilage and bone formation, and significantly higher biomechanical functions than the control group at the interface at 12 weeks post operation. This study demonstrated that dual cross-linked gradient COL1/HAp-loaded hAMSCs could promote interface healing, thereby providing a feasible strategy for tendon-bone interface regeneration. CI - Copyright © 2024 Elsevier B.V. All rights reserved. FAU - Dai, Xiaomei AU - Dai X AD - School of Nursing and School of Public Health, Yangzhou University, Yangzhou 225001, PR China; Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China. FAU - Yuan, Meijuan AU - Yuan M AD - School of Nursing and School of Public Health, Yangzhou University, Yangzhou 225001, PR China; Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China. FAU - Yang, Yuxia AU - Yang Y AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China; Medical College, Yangzhou University, Yangzhou 225001, PR China. FAU - Dang, Mengbo AU - Dang M AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China; Dalian Medical University, Dalian 116044, PR China. FAU - Yang, Jian AU - Yang J AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China; Medical College, Yangzhou University, Yangzhou 225001, PR China. FAU - Shi, Junli AU - Shi J AD - School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou 225009, PR China. FAU - Liu, Dianwei AU - Liu D AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China; Dalian Medical University, Dalian 116044, PR China. FAU - Li, Mingjun AU - Li M AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China; Dalian Medical University, Dalian 116044, PR China. FAU - Yao, Hang AU - Yao H AD - School of Chemistry and Chemical Engineering, Yangzhou University, Yangzhou 225009, PR China. Electronic address: yaohang@yzu.edu.cn. FAU - Fei, Wenyong AU - Fei W AD - Department of Orthopedics and Sports Medicine, Northern Jiangsu People's Hospital, Affiliated to Yangzhou University, Yangzhou 225001, PR China. Electronic address: sbydyx105@163.com. LA - eng PT - Journal Article DEP - 20240209 PL - Netherlands TA - Biomater Adv JT - Biomaterials advances JID - 9918383886206676 RN - A3V2NE52YG (genipin) RN - 91D9GV0Z28 (Durapatite) RN - 0 (Immunologic Factors) RN - 9007-34-5 (Collagen) RN - 0 (Iridoids) SB - IM MH - Humans MH - Animals MH - Rats MH - *Rotator Cuff MH - Durapatite MH - Bionics MH - Tendons MH - Immunologic Factors MH - *Mesenchymal Stem Cells MH - Collagen MH - *Iridoids OTO - NOTNLM OT - Gradient scaffold OT - Stem cells OT - Tendon-bone regeneration OT - Tissue engineering COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/16 18:43 MHDA- 2024/03/04 06:44 CRDT- 2024/02/16 18:00 PHST- 2023/09/06 00:00 [received] PHST- 2024/01/17 00:00 [revised] PHST- 2024/02/08 00:00 [accepted] PHST- 2024/03/04 06:44 [medline] PHST- 2024/02/16 18:43 [pubmed] PHST- 2024/02/16 18:00 [entrez] AID - S2772-9508(24)00042-6 [pii] AID - 10.1016/j.bioadv.2024.213799 [doi] PST - ppublish SO - Biomater Adv. 2024 Apr;158:213799. doi: 10.1016/j.bioadv.2024.213799. Epub 2024 Feb 9. PMID- 11398848 OWN - NLM STAT- MEDLINE DCOM- 20010621 LR - 20220227 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 19 IP - 3 DP - 2001 May TI - Autonomic innervation of tendons, ligaments and joint capsules. A morphologic and quantitative study in the rat. PG - 372-8 AB - We analyzed the neuronal occurrence of autonomic transmitters; noradrenaline (NA), neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), in the Achilles tendon, medial and lateral collateral ligaments and knee joint capsule in the rat--by immunohistochemistry (IHC). In addition, the tissue concentrations of the sympathetic neuropeptide, NPY, and the parasympathetic peptide, VIP, were determined by radioimmunoassay (RIA). IHC demonstrated nerve fibers containing sympathetic vasoconstrictors--NA and NPY--and the parasympathetic vasodilator, VIP, in all tissues. NPY- and NA-positive nerve fibers were predominantly observed in larger blood vessels, whereas, nerve fibers immunoreactive to VIP were found in smaller vessels. In many nerve fibers a co-localization of the transmitters was seen. RIA showed that the concentration of NPY compared to VIP was 15-times higher in ligaments and twice as high in tendons and capsules. The differences noted may reflect a difference in vulnerability to degenerative conditions. In pathological conditions, dysregulation of autonomic transmitters in hypovascularized tissues subjected to repetitive mechanical load may contribute to tissue hypoxia leading to degeneration and rupture of tendons and ligaments. FAU - Ackermann, P W AU - Ackermann PW AD - Department of Surgical Sciences, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden. paul.ackermann@ks.se FAU - Li, J AU - Li J FAU - Finn, A AU - Finn A FAU - Ahmed, M AU - Ahmed M FAU - Kreicbergs, A AU - Kreicbergs A LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Neuropeptide Y) RN - 37221-79-7 (Vasoactive Intestinal Peptide) RN - X4W3ENH1CV (Norepinephrine) SB - IM MH - Achilles Tendon/chemistry/*innervation MH - Animals MH - Autonomic Nervous System/*anatomy & histology/chemistry MH - Chromatography, High Pressure Liquid MH - Collateral Ligaments/chemistry/*innervation MH - Fluorescent Antibody Technique MH - Fluorescent Antibody Technique, Indirect MH - Joint Capsule/chemistry/*innervation MH - Male MH - Medial Collateral Ligament, Knee/chemistry/*innervation MH - Nerve Fibers/chemistry MH - Neuropeptide Y/analysis MH - Norepinephrine/analysis MH - Radioimmunoassay MH - Rats MH - Rats, Sprague-Dawley MH - Vasoactive Intestinal Peptide/analysis EDAT- 2001/06/12 10:00 MHDA- 2001/06/22 10:01 CRDT- 2001/06/12 10:00 PHST- 2001/06/12 10:00 [pubmed] PHST- 2001/06/22 10:01 [medline] PHST- 2001/06/12 10:00 [entrez] AID - S0736-0266(00)90029-9 [pii] AID - 10.1016/S0736-0266(00)90029-9 [doi] PST - ppublish SO - J Orthop Res. 2001 May;19(3):372-8. doi: 10.1016/S0736-0266(00)90029-9. PMID- 5025627 OWN - NLM STAT- MEDLINE DCOM- 19720720 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 11 IP - 10 DP - 1972 May 9 TI - Studies on the location of intermolecular cross-links in collagen. Isolation of a CNBr peptide containing -hydroxylysinonorleucine. PG - 1828-35 FAU - Kang, A H AU - Kang AH LA - eng PT - Journal Article PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Amino Acids) RN - 0 (Aminocaproates) RN - 0 (Borohydrides) RN - 0 (Macromolecular Substances) RN - 0 (Peptides) RN - 10028-17-8 (Tritium) RN - 2GQB349IUB (Hydroxylysine) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.4 (Trypsin) RN - OS382OHJ8P (Cyanogen Bromide) SB - IM MH - Amino Acids/analysis MH - Aminocaproates/analysis MH - Animals MH - Borohydrides MH - Chromatography, Gel MH - Chromatography, Ion Exchange MH - Collagen/*analysis MH - Cyanogen Bromide MH - Hydrolysis MH - Hydroxylysine/analysis MH - Macromolecular Substances MH - Male MH - Molecular Weight MH - Oxidation-Reduction MH - Peptides/analysis/isolation & purification MH - Rats MH - Tail MH - Tendons MH - Tritium MH - Trypsin EDAT- 1972/05/09 00:00 MHDA- 1972/05/09 00:01 CRDT- 1972/05/09 00:00 PHST- 1972/05/09 00:00 [pubmed] PHST- 1972/05/09 00:01 [medline] PHST- 1972/05/09 00:00 [entrez] AID - 10.1021/bi00760a015 [doi] PST - ppublish SO - Biochemistry. 1972 May 9;11(10):1828-35. doi: 10.1021/bi00760a015. PMID- 39172877 OWN - NLM STAT- MEDLINE DCOM- 20240822 LR - 20240826 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 8 DP - 2024 TI - A SIRT1-independent mechanism mediates protection against steroid-induced senescence by resveralogues in equine tenocytes. PG - e0309301 LID - 10.1371/journal.pone.0309301 [doi] LID - e0309301 AB - Tendinopathy is a common age-related disease which causes significant morbidity for both human athletes and performance horses. In the latter, the superficial digital flexor tendon is an excellent model for human tendinopathies because it is a functional homologue of the human Achilles tendon and a primary site of injuries with strong similarities to the human disease. Corticosteroids have been previously used clinically to treat tendinopathic inflammation, but they upregulate the p53-p21 axis with concomitant reductions in cell proliferation and collagen synthesis in human tenocytes. This phenotype is consistent with the induction of cellular senescence in vitro and in vivo and probably represents an important clinical barrier to their effective use. Because of the many differences in senescence mechanisms between species, this study aimed to evaluate these mechanisms after corticosteroid treatment in equine tenocytes. Exposure to clinically reflective levels of dexamethasone for 48 hours drove equine tenocytes into steroid induced senescence (SIS). This was characterised by permanent growth arrest and upregulation of p53, the cyclin dependent kinase inhibitors p21waf and p16ink4a as well as the matrix degrading enzymes MMP1, MMP2 and MMP13. SIS also induced a distinctive equine senescence associated secretory phenotype (eSASP) characterised by enhanced secretion of IL-8 and MCP-1. Preincubation with resveratrol or the potent SIRT1 activator SRT1720 prevented SIS in equine tenocytes, while treatment with the non-SIRT1 activating resveratrol analogue V29 was equally protective against SIS, consistent with a novel, as yet uncharacterised SIRT1-indendent mechanism which has relevance for the development of future preventative and therapeutic strategies. CI - Copyright: © 2024 Heidari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Heidari, Neda AU - Heidari N AUID- ORCID: 0009-0006-8508-2501 AD - Department of Clinical Sciences and Services, The Royal Veterinary College of University of London, North Mymms, Hertfordshire, United Kingdom. FAU - Faragher, Richard G A AU - Faragher RGA AD - Department of Clinical Sciences and Services, The Royal Veterinary College of University of London, North Mymms, Hertfordshire, United Kingdom. FAU - Pattison, Graham AU - Pattison G AUID- ORCID: 0000-0003-0116-8457 AD - School of Applied Sciences, University of Brighton, Brighton, East Sussex, United Kingdom. FAU - Dudhia, Jayesh AU - Dudhia J AUID- ORCID: 0000-0002-2503-697X AD - School of Chemistry, College of Health and Science, University of Lincoln, Lincoln, United Kingdom. FAU - Smith, Roger K W AU - Smith RKW AD - School of Chemistry, College of Health and Science, University of Lincoln, Lincoln, United Kingdom. LA - eng PT - Journal Article DEP - 20240822 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - EC 3.5.1.- (Sirtuin 1) RN - 7S5I7G3JQL (Dexamethasone) RN - Q369O8926L (Resveratrol) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Animals MH - Horses MH - *Sirtuin 1/metabolism MH - *Cellular Senescence/drug effects MH - *Tenocytes/drug effects/metabolism MH - *Dexamethasone/pharmacology MH - Resveratrol/pharmacology MH - Cell Proliferation/drug effects MH - Tumor Suppressor Protein p53/metabolism MH - Tendinopathy/metabolism/pathology/drug therapy MH - Cells, Cultured MH - Tendons/drug effects/cytology/metabolism PMC - PMC11340939 COIS- NO authors have competing interests. EDAT- 2024/08/22 18:41 MHDA- 2024/08/22 18:42 PMCR- 2024/08/22 CRDT- 2024/08/22 14:13 PHST- 2023/10/07 00:00 [received] PHST- 2024/08/09 00:00 [accepted] PHST- 2024/08/22 18:42 [medline] PHST- 2024/08/22 18:41 [pubmed] PHST- 2024/08/22 14:13 [entrez] PHST- 2024/08/22 00:00 [pmc-release] AID - PONE-D-23-32686 [pii] AID - 10.1371/journal.pone.0309301 [doi] PST - epublish SO - PLoS One. 2024 Aug 22;19(8):e0309301. doi: 10.1371/journal.pone.0309301. eCollection 2024. PMID- 16929845 OWN - NLM STAT- MEDLINE DCOM- 20100707 LR - 20161018 IS - 1000-8713 (Print) IS - 1000-8713 (Linking) VI - 24 IP - 3 DP - 2006 May TI - [Determination of collagen in tendon by reversed-phase high performance liquid chromatography]. PG - 263-6 AB - A method for determining collagen in tendon by reversed-phase high performance liquid chromatography (RP-HPLC) was developed. After hydrolysis with hydrochloric acid, the collagen in samples was decomposed into hydroxyproline which hydroxyproline can be derivatized with 2, 4-dinitrochlorobenzene for the determination by HPLC (reversed-phase C18 column, 0.01 mol/L NaAc-HAc (pH 6.0)-CH3CN (80: 20, v/v) as mobile phase, detection at 360 nm). The factors influencing hydrolysis, derivatization and HPLC analysis were studied and optimized. Sixty samples were analyzed with the proposed method. The linear range was from 3 microg/L to 100 mg/L and the detection limit was 3 microg/L. The relative standard deviation (RSD) of determination was 1.95%. The recoveries of spiked samples were 98.4%-110.8%. The results show that the method is sensitive, accurate and suitable for tendon determination. FAU - Zou, Xiaoli AU - Zou X AD - West China School of Public Health, Sichuan University, Chengdu. FAU - Li, Yuanqian AU - Li Y FAU - Zeng, Hongyan AU - Zeng H FAU - Zhou, Jian AU - Zhou J FAU - Qin, Tingwu AU - Qin T FAU - Mo, Xiangtao AU - Mo X LA - chi PT - English Abstract PT - Journal Article PL - China TA - Se Pu JT - Se pu = Chinese journal of chromatography JID - 9424804 RN - 0 (Propionates) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Chromatography, High Pressure Liquid/*methods MH - Chromatography, Reverse-Phase/*methods MH - Collagen/*analysis MH - Drug Stability MH - Extracellular Matrix/metabolism MH - Flow Injection Analysis MH - Humans MH - Hydroxyproline/analysis MH - Limit of Detection MH - Propionates/analysis MH - Stereoisomerism MH - Tendons/*chemistry EDAT- 2006/08/26 09:00 MHDA- 2010/07/08 06:00 CRDT- 2006/08/26 09:00 PHST- 2006/08/26 09:00 [pubmed] PHST- 2010/07/08 06:00 [medline] PHST- 2006/08/26 09:00 [entrez] PST - ppublish SO - Se Pu. 2006 May;24(3):263-6. PMID- 17284838 OWN - NLM STAT- MEDLINE DCOM- 20070509 LR - 20171116 IS - 0916-8451 (Print) IS - 0916-8451 (Linking) VI - 71 IP - 2 DP - 2007 Feb TI - Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end product in streptozotocin-induced diabetic rats. PG - 442-8 AB - GLAP, glyceraldehyde-derived pyridinium-type advanced glycation end product (AGE), formed by glyceraldehyde-related glycation, was identified in the plasma protein and the tail tendon collagen of streptozotocin (STZ)-induced diabetic rats. It was detected in the plasma protein and the collagen in diabetic rats by LC-MS and LC-MS/MS analysis, but was not detected in normal rats. In addition, GLAP was formed from glyceraldehyde-3-phosphate (GA3P) with lysine as well as glyceraldehyde (GLA) with lysine in vitro. Accordingly, it is suggested that an increase in the GLAP level reflects an increase in the GLA level and the GA3P level. GLAP might be a biomarker for reduced activity of the glyceraldehyde-related enzymes in the metabolic diseases such as diabetic complications. FAU - Usui, Teruyuki AU - Usui T AD - Department of Agricultural Chemistry, Faculty of Agriculture, Meiji University, Kawasaki, Kanagawa, Japan. FAU - Shimohira, Kazuhito AU - Shimohira K FAU - Watanabe, Hirohito AU - Watanabe H FAU - Hayase, Fumitaka AU - Hayase F LA - eng PT - Journal Article DEP - 20070207 PL - England TA - Biosci Biotechnol Biochem JT - Bioscience, biotechnology, and biochemistry JID - 9205717 RN - 0 (Glycation End Products, Advanced) RN - 0 (Indicators and Reagents) RN - 0 (Proteins) RN - 0 (Pyridinium Compounds) RN - 142-10-9 (Glyceraldehyde 3-Phosphate) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 367-47-5 (Glyceraldehyde) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Collagen/analysis MH - Diabetes Mellitus, Experimental/*blood MH - Glycation End Products, Advanced/*blood MH - Glyceraldehyde/*blood MH - Glyceraldehyde 3-Phosphate/analysis MH - Hydrolysis MH - Indicators and Reagents MH - Male MH - Proteins/chemistry MH - Pyridinium Compounds/*blood MH - Rats MH - Rats, Sprague-Dawley MH - Serum Albumin, Bovine/analysis MH - Spectrometry, Fluorescence MH - Tail/chemistry MH - Tendons/chemistry EDAT- 2007/02/08 09:00 MHDA- 2007/05/10 09:00 CRDT- 2007/02/08 09:00 PHST- 2007/02/08 09:00 [pubmed] PHST- 2007/05/10 09:00 [medline] PHST- 2007/02/08 09:00 [entrez] AID - JST.JSTAGE/bbb/60497 [pii] AID - 10.1271/bbb.60497 [doi] PST - ppublish SO - Biosci Biotechnol Biochem. 2007 Feb;71(2):442-8. doi: 10.1271/bbb.60497. Epub 2007 Feb 7. PMID- 25361855 OWN - NLM STAT- MEDLINE DCOM- 20150811 LR - 20191210 IS - 1478-6362 (Electronic) IS - 1478-6354 (Print) IS - 1478-6354 (Linking) VI - 16 IP - 5 DP - 2014 Oct 31 TI - Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). PG - 476 LID - 10.1186/s13075-014-0476-2 [doi] LID - 476 AB - INTRODUCTION: This study was performed to develop ultrasound composite scores for the assessment of inflammatory and structural lesions in Psoriatic Arthritis (PsA). METHODS: We performed a prospective study on 83 PsA patients undergoing two study visits scheduled 6 months apart. B-mode and Power Doppler (PD) findings were semi-quantitatively scored at 68 joints (evaluating synovia, perisynovial tissue, tendons and bone) and 14 entheses. We constructed bilateral and unilateral (focusing the dominant site) ultrasound composite scores selecting relevant sites by a hierarchical approach. We tested convergent construct validity, reliability and feasibility of inflammatory and structural elements of the scores as well as sensitivity to change for inflammatory items. RESULTS: The bilateral score (termed PsASon22) included 22 joints (6 metacarpophalangeal joints (MCPs), 4 proximal interphalangeal joints (PIPs) of hands (H-PIPs), 2 metatarsophalangeal joints (MTPs), 4 distal interphalangeal joints (DIPs) of hands (H-DIPs), 2 DIPs of feet (F-DIPs), 4 large joints) and 4 entheses (bilateral assessment of lateral epicondyle and distal patellar tendon). The unilateral score (PsASon13) compromised 13 joints (2 MCPs, 3 H-PIPs, 1 PIP of feet (F-PIP), 2 MTPs, 1 H-DIP and 2 F-DIPs and 2 large joints) and 2 entheses (unilateral lateral epicondyle and distal patellar tendon). Both composite scores revealed a moderate to high sensitivity (bilateral composite score 43% to 100%, unilateral 36% to 100%) to detect inflammatory and structural lesions compared to the 68-joint/14-entheses score. The inflammatory and structural components of the composite scores correlated weakly with clinical markers of disease activity (corrcoeffs 0 to 0.40) and the health assessment questionnaire (HAQ, corrcoeffs 0 to 0.39), respectively. Patients with active disease achieving remission at follow-up yielded greater reductions of ultrasound inflammatory scores than those with stable clinical activity (Cohen's d effect size ranging from 0 to 0.79). Inter-rater reliability of bi- and unilateral composite scores was moderate to good with ICCs ranging from 0.42 to 0.96 and from 0.36 to 0.71, respectively for inflammatory and structural sub-scores. The PsASon22 and PsASon13 required 16 to 26 and 9 to 13 minutes, respectively to be completed. CONCLUSION: Both new PsA ultrasound composite scores (PsASon22 and PsASon13) revealed sufficient convergent construct validity, sensitivity to change, reliability and feasibility. FAU - Ficjan, Anja AU - Ficjan A FAU - Husic, Rusmir AU - Husic R FAU - Gretler, Judith AU - Gretler J FAU - Lackner, Angelika AU - Lackner A FAU - Graninger, Winfried B AU - Graninger WB FAU - Gutierrez, Marwin AU - Gutierrez M FAU - Duftner, Christina AU - Duftner C FAU - Hermann, Josef AU - Hermann J FAU - Dejaco, Christian AU - Dejaco C LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141031 PL - England TA - Arthritis Res Ther JT - Arthritis research & therapy JID - 101154438 RN - 0 (Antirheumatic Agents) RN - 0 (Isoxazoles) RN - 3XC8GUZ6CB (Sulfasalazine) RN - G162GK9U4W (Leflunomide) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Psoriatic/*diagnostic imaging/drug therapy/pathology MH - Bone and Bones/diagnostic imaging/drug effects/pathology MH - Feasibility Studies MH - Female MH - Follow-Up Studies MH - Humans MH - Inflammation/*diagnostic imaging/drug therapy/pathology MH - Isoxazoles/therapeutic use MH - Joints/diagnostic imaging/drug effects/pathology MH - Leflunomide MH - Male MH - Methotrexate/therapeutic use MH - Middle Aged MH - Outcome Assessment, Health Care MH - Prospective Studies MH - Reproducibility of Results MH - Severity of Illness Index MH - Sulfasalazine/therapeutic use MH - Surveys and Questionnaires MH - Synovial Membrane/diagnostic imaging/drug effects/pathology MH - Tendons/diagnostic imaging/drug effects/pathology MH - Time Factors MH - Ultrasonography, Doppler/*methods PMC - PMC4247751 EDAT- 2014/11/02 06:00 MHDA- 2015/08/12 06:00 PMCR- 2014/10/31 CRDT- 2014/11/02 06:00 PHST- 2014/05/06 00:00 [received] PHST- 2014/10/21 00:00 [accepted] PHST- 2014/11/02 06:00 [entrez] PHST- 2014/11/02 06:00 [pubmed] PHST- 2015/08/12 06:00 [medline] PHST- 2014/10/31 00:00 [pmc-release] AID - s13075-014-0476-2 [pii] AID - 476 [pii] AID - 10.1186/s13075-014-0476-2 [doi] PST - epublish SO - Arthritis Res Ther. 2014 Oct 31;16(5):476. doi: 10.1186/s13075-014-0476-2. PMID- 5529814 OWN - NLM STAT- MEDLINE DCOM- 19710113 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 9 IP - 24 DP - 1970 Nov 24 TI - Isolation and characterization of the cyanogen bromide peptides from the alpha 1 and alpha 2 chains of human skin collagen. PG - 4699-706 FAU - Click, E M AU - Click EM FAU - Bornstein, P AU - Bornstein P LA - eng PT - Journal Article PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Amino Acids) RN - 0 (Cyanides) RN - 0 (Peptides) RN - 9007-34-5 (Collagen) RN - AE28F7PNPL (Methionine) RN - GMW67QNF9C (Leucine) RN - K3Z4F929H6 (Lysine) SB - IM MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Biological Evolution MH - Chickens MH - Chromatography, Gel MH - Chromatography, Ion Exchange MH - *Collagen MH - *Cyanides MH - Humans MH - Leucine/analysis MH - Lysine MH - Methionine/analysis MH - Molecular Weight MH - Peptides/analysis/*isolation & purification MH - Rats MH - Skin MH - Species Specificity MH - Tendons EDAT- 1970/11/24 00:00 MHDA- 1970/11/24 00:01 CRDT- 1970/11/24 00:00 PHST- 1970/11/24 00:00 [pubmed] PHST- 1970/11/24 00:01 [medline] PHST- 1970/11/24 00:00 [entrez] AID - 10.1021/bi00826a012 [doi] PST - ppublish SO - Biochemistry. 1970 Nov 24;9(24):4699-706. doi: 10.1021/bi00826a012. PMID- 4350832 OWN - NLM STAT- MEDLINE DCOM- 19730806 LR - 20131121 IS - 0021-2180 (Print) IS - 0021-2180 (Linking) VI - 9 IP - 4 DP - 1973 Apr TI - Ultrastructural and lipid biochemical comparisons of human eruptive, tuberous and planar xanthomas. PG - 395-423 FAU - Parker, F AU - Parker F FAU - Odland, G F AU - Odland GF LA - eng PT - Journal Article PL - Israel TA - Isr J Med Sci JT - Israel journal of medical sciences JID - 0013105 RN - 0 (Chylomicrons) RN - 0 (Esters) RN - 0 (Fatty Acids) RN - 0 (Linolenic Acids) RN - 0 (Lipids) RN - 0 (Lipoproteins, HDL) RN - 0 (Lipoproteins, LDL) RN - 0 (Lipoproteins, VLDL) RN - 0 (Triglycerides) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Cholesterol/analysis/blood MH - Chylomicrons/blood MH - Diabetes Complications MH - Esters/analysis MH - Fatty Acids/analysis/blood MH - Histocytochemistry MH - Humans MH - Hypercholesterolemia/complications MH - Linolenic Acids/metabolism MH - Lipids/*analysis MH - Lipoproteins, HDL/blood MH - Lipoproteins, LDL/blood MH - Lipoproteins, VLDL/blood MH - Microscopy, Electron MH - *Tendons MH - Triglycerides/analysis/blood MH - Xanthomatosis/etiology/metabolism/*pathology EDAT- 1973/04/01 00:00 MHDA- 1973/04/01 00:01 CRDT- 1973/04/01 00:00 PHST- 1973/04/01 00:00 [pubmed] PHST- 1973/04/01 00:01 [medline] PHST- 1973/04/01 00:00 [entrez] PST - ppublish SO - Isr J Med Sci. 1973 Apr;9(4):395-423. PMID- 16770465 OWN - NLM STAT- MEDLINE DCOM- 20060921 LR - 20181113 IS - 1439-6319 (Print) IS - 1439-6319 (Linking) VI - 97 IP - 3 DP - 2006 Jun TI - Changes in the soleus muscle architecture after exhausting stretch-shortening cycle exercise in humans. PG - 298-306 AB - This study focused on the architectural changes in the muscle-tendon complex during the immediate and secondary (delayed) reductions of performance (bimodal recovery) caused by an exhaustive rebound type stretch-shortening cycle (SSC) exercise. The isometric plantar flexor torque during maximum voluntary contraction (MVC) was measured together with recording of electromyography (EMG) and ultrasonography from the soleus muscle before (BEF), after (AFT), 2 h (2H), 2 and 8 days (2D, 8D) after the SSC exercise (n=8). The performance variables (MVC torque and EMG activation) followed the bimodal recovery patterns. This was not the case in the changes of the fascicle length and muscle thickness. The relative torque changes in MVC correlated positively (R=0.78, P=0.02) to the corresponding averaged EMG changes between BEF and 2H (BEF-->2H); the significance disappeared in the comparison between 2H and 2D (2H-->2D), during which period MVC showed a secondary reduction. The relative torque changes in MVC showed no correlation with the changes in muscle thickness between BEF-2H. However, this correlation between 2H-2D was negative (R=-0.85, P<0.01). The fascicle shortening/average EMG ratio in MVC increased at 2H, and then decreased more at 2D than 2H (P<0.05). Thus, the secondary performance decline was not related to the corresponding EMG reduction but to the increased muscle thickness, which peaked at 2D. The results suggest clearly that the secondary decline in MVC could be related to the increase in muscle volume. FAU - Ishikawa, M AU - Ishikawa M AD - Neuromuscular Research Center, Department of Biology of Physical Activity, University of Jyväskylä, P.O. Box 35 (LL2), 40014, Jyväskylä, Finland. masaki@sport.jyu.fi FAU - Dousset, E AU - Dousset E FAU - Avela, J AU - Avela J FAU - Kyröläinen, H AU - Kyröläinen H FAU - Kallio, J AU - Kallio J FAU - Linnamo, V AU - Linnamo V FAU - Kuitunen, S AU - Kuitunen S FAU - Nicol, C AU - Nicol C FAU - Komi, P V AU - Komi PV LA - eng PT - Comparative Study PT - Journal Article DEP - 20060421 PL - Germany TA - Eur J Appl Physiol JT - European journal of applied physiology JID - 100954790 RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Adult MH - Compliance MH - Electromyography MH - Exercise Test MH - Humans MH - Lactic Acid/blood MH - Male MH - Muscle Contraction MH - *Muscle Fatigue MH - Muscle, Skeletal/*anatomy & histology/diagnostic imaging/*physiology MH - Physical Exertion/*physiology MH - Recovery of Function MH - Tendons/physiology MH - Time Factors MH - Torque MH - Ultrasonography MH - Volition EDAT- 2006/06/14 09:00 MHDA- 2006/09/22 09:00 CRDT- 2006/06/14 09:00 PHST- 2006/03/14 00:00 [accepted] PHST- 2006/06/14 09:00 [pubmed] PHST- 2006/09/22 09:00 [medline] PHST- 2006/06/14 09:00 [entrez] AID - 10.1007/s00421-006-0180-2 [doi] PST - ppublish SO - Eur J Appl Physiol. 2006 Jun;97(3):298-306. doi: 10.1007/s00421-006-0180-2. Epub 2006 Apr 21. PMID- 33608337 OWN - NLM STAT- MEDLINE DCOM- 20210305 LR - 20230220 IS - 1757-790X (Electronic) IS - 1757-790X (Linking) VI - 14 IP - 2 DP - 2021 Feb 19 TI - Isolated multidrug-resistant tubercular tenosynovitis of the flexor tendon of the little finger. LID - 10.1136/bcr-2020-238339 [doi] LID - e238339 AB - Isolated multidrug-resistant (MDR) tubercular tenosynovitis of the flexor tendons of finger without involvement of wrist is a rare presentation. Tenosynovitis of hand is an uncommon manifestation of extrapulmonary tuberculosis. Pyogenic flexor tenosynovitis of hand is frequently seen and is the closest differential. Non-specific clinical signs may lead to delay in diagnosis, which is often made after biopsy. Management includes surgical excision of necrotic tissue and infected synovium along with antitubercular therapy after histopathological diagnosis. MDR tuberculosis of hand is extremely rare and, to the best of our knowledge, has not been reported in the literature so far. We report an interesting case of MDR tubercular flexor tendon tenosynovitis of the little finger without any pulmonary involvement in an immunocompetent patient. The case was managed by complete synovectomy and second-line antitubercular therapy with complete resolution of disease and had no functional limitation. CI - © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Chaudhary, Sunny AU - Chaudhary S AUID- ORCID: 0000-0001-8298-5795 AD - Department of Orthopedics, All India Institute of Medical Sciences - Rishikesh, Rishikesh, India dr.sunny.ortho@gmail.com. FAU - Maji, Subhajit AU - Maji S AD - Department of Orthopedics, All India Institute of Medical Sciences - Rishikesh, Rishikesh, India. FAU - Garg, Varun AU - Garg V AD - Department of Orthopedics, All India Institute of Medical Sciences - Rishikesh, Rishikesh, India. FAU - Singh, Vivek AU - Singh V AD - Department of Orthopedics, All India Institute of Medical Sciences - Rishikesh, Rishikesh, India. LA - eng PT - Case Reports PT - Journal Article DEP - 20210219 PL - England TA - BMJ Case Rep JT - BMJ case reports JID - 101526291 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antitubercular Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - 8G167061QZ (Ethambutol) RN - 95IK5KI84Z (Cycloserine) RN - D959AE5USF (Clofazimine) RN - ISQ9I6J12J (Linezolid) SB - IM MH - Adult MH - Anti-Bacterial Agents/therapeutic use MH - Anti-Inflammatory Agents/therapeutic use MH - Antitubercular Agents/therapeutic use MH - Clofazimine/therapeutic use MH - Cycloserine/therapeutic use MH - Diagnosis, Differential MH - Drug Resistance, Multiple/*drug effects MH - Ethambutol/therapeutic use MH - Female MH - Fingers/*diagnostic imaging/surgery MH - Humans MH - Levofloxacin/therapeutic use MH - Linezolid/therapeutic use MH - Magnetic Resonance Imaging/*methods MH - Tendons/diagnostic imaging MH - Tenosynovitis/*diagnostic imaging/etiology/surgery MH - Tuberculosis/*complications/*drug therapy MH - Young Adult PMC - PMC7896614 OTO - NOTNLM OT - orthopaedics OT - tuberculosis COIS- Competing interests: None declared. EDAT- 2021/02/21 06:00 MHDA- 2021/03/06 06:00 PMCR- 2023/02/19 CRDT- 2021/02/20 05:30 PHST- 2021/02/20 05:30 [entrez] PHST- 2021/02/21 06:00 [pubmed] PHST- 2021/03/06 06:00 [medline] PHST- 2023/02/19 00:00 [pmc-release] AID - 14/2/e238339 [pii] AID - bcr-2020-238339 [pii] AID - 10.1136/bcr-2020-238339 [doi] PST - epublish SO - BMJ Case Rep. 2021 Feb 19;14(2):e238339. doi: 10.1136/bcr-2020-238339. PMID- 3569165 OWN - NLM STAT- MEDLINE DCOM- 19870527 LR - 20191022 IS - 0190-2148 (Print) IS - 0190-2148 (Linking) VI - 12 IP - 2 DP - 1987 TI - Structural crosslinking of lung connective tissue collagen in the blotchy mouse. PG - 109-17 AB - Male mice with the sex-linked mutation Blotchy (Blo) have a defect in copper metabolism which results in deficient activity of a number of copper-containing enzymes. Inbred Blo/y mice spontaneously develop lung abnormalities which resemble emphysema and often die of ruptured aortic aneurysm. Lung, tail tendon, and tibial bone collagens from inbred Blo/y and their normal (+/y) litter mates were reduced with standardized [3H]NaBH4, acid and alkaline hydrolyzed, and chromatographed in order to quantify the aldehydic crosslink precursors, and the labile reducible and nonreducible stable mature covalent intermolecular crosslinks. Reducible lung collagen crosslinks were markedly (60%) decreased in the Blo/y mice and few, if any, mature nonreducible crosslinks were present. Total aldehydes were also decreased (65%) when Blo/y was compared to +/y. In tail tendon and bone, collagen crosslinks were decreased by only 28% and 15%, respectively. Selectively severe lack of activity of the copper-dependent enzyme level oxidase in lung with only partial lack in tendon and bone could account for the results obtained. Alternatively, insufficient reducible crosslinks, coupled with increased collagen turnover in the lung could prevent formation of the more mature stable crosslinks required to provide a proper connective tissue framework for the Blo/y lung. FAU - Mechanic, G L AU - Mechanic GL FAU - Farb, R M AU - Farb RM FAU - Henmi, M AU - Henmi M FAU - Ranga, V AU - Ranga V FAU - Bromberg, P A AU - Bromberg PA FAU - Yamauchi, M AU - Yamauchi M LA - eng GR - AM19969/AM/NIADDK NIH HHS/United States GR - AM30587/AM/NIADDK NIH HHS/United States GR - HL32740/HL/NHLBI NIH HHS/United States GR - etc. PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Exp Lung Res JT - Experimental lung research JID - 8004944 RN - 0 (Aldehydes) RN - 9007-34-5 (Collagen) SB - IM MH - Aldehydes/*analysis MH - Animals MH - Bone and Bones/analysis MH - Collagen/*analysis/genetics MH - Lung/*analysis MH - Mice MH - Mice, Mutant Strains/*metabolism MH - Tendons/analysis OID - NASA: 87190210 EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] AID - 10.3109/01902148709062835 [doi] PST - ppublish SO - Exp Lung Res. 1987;12(2):109-17. doi: 10.3109/01902148709062835. PMID- 20625197 OWN - NLM STAT- MEDLINE DCOM- 20100818 LR - 20220410 IS - 1555-0265 (Print) IS - 1555-0265 (Linking) VI - 5 IP - 2 DP - 2010 Jun TI - Relationship between muscle strength, power and stiffness and running economy in trained male runners. PG - 249-61 AB - PURPOSE: In this study, a comparison was made between muscle strength, power and muscle and tendon (km and kt respectively) stiffness of the triceps surae muscle group and running economy (RE) in trained male runners. METHODS: Twelve well-trained male runners (age = 21 +/- 2.7 y, height = 178.1 +/- 7.1 cm, body mass = 66.7 +/- 3.2 kg, VO2max = 68.3 +/- 4.3 mL x kg(-1) x min(-1), 5000-m time = 15:04 min:s) underwent passive stiffness testing using a free oscillation method. Muscle strength was determined via a maximal isometric squat test and power determined via a maximal countermovement jump (CMJ). On a separate day, subjects performed an incremental treadmill test and their RE, lactate threshold, and VO2max were determined. Fingertip blood lactate was determined at the end of each 3-min stage. Lactate threshold was defined as a nonlinear increase in lactate accumulation. RESULTS: A statistically significant correlation was found between km and VO2 at stage 6 (r = -0.69, P = .01). In addition, statistically significant correlations were observed between CMJ peak force production and VO2 at stage 2 (r = .66, P = .02), stage 3 (r = .70, P = .01), and stage 4 (r = .58, P = .04). No other statistically significant correlations were observed. CONCLUSION: These data suggest that greater muscle stiffness and less power are associated with greater RE. Future study in this area should focus on determining the mechanisms behind this relationship and how to best apply them to a running population through training techniques. FAU - Dumke, Charles L AU - Dumke CL AD - Department of Health and Human Performance, University of Montana, Missoula, Montana, USA. FAU - Pfaffenroth, Christopher M AU - Pfaffenroth CM FAU - McBride, Jeffrey M AU - McBride JM FAU - McCauley, Grant O AU - McCauley GO LA - eng PT - Journal Article PL - United States TA - Int J Sports Physiol Perform JT - International journal of sports physiology and performance JID - 101276430 RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Adult MH - Athletic Performance/*physiology MH - Cross-Sectional Studies MH - Humans MH - Lactic Acid/blood MH - Male MH - Muscle Strength/*physiology MH - Muscle, Skeletal/*physiology MH - Oxygen Consumption/*physiology MH - Physical Endurance/physiology MH - Running/*physiology MH - Tendons/physiology EDAT- 2010/07/14 06:00 MHDA- 2010/08/19 06:00 CRDT- 2010/07/14 06:00 PHST- 2010/07/14 06:00 [entrez] PHST- 2010/07/14 06:00 [pubmed] PHST- 2010/08/19 06:00 [medline] AID - 10.1123/ijspp.5.2.249 [doi] PST - ppublish SO - Int J Sports Physiol Perform. 2010 Jun;5(2):249-61. doi: 10.1123/ijspp.5.2.249. PMID- 15626428 OWN - NLM STAT- MEDLINE DCOM- 20050712 LR - 20191210 IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 26 IP - 18 DP - 2005 Jun TI - The effect of hydrophilic adhesive monomers on the stability of type I collagen. PG - 3801-8 AB - The adsorption effects of adhesive monomers on the structural stability of type I collagen were studied at an acid pH condition for two monomers: 2-hydroxyethyl methacrylate (HEMA), a neutral monomer and N-methacryloyl glycine (NMGly), an acidic monomer. Differential scanning calorimetry (DSC) measurements were done to assess the denaturation temperature (Td), which is a measure of the structural stability of the proteins, including the bovine tendon collagen (BTC). While HEMA lowered the Td of the BTC linearly with HEMA concentrations, NMGly exhibited a two-step decrease of the Td. The rate of decrease in the Td by the NMGly was by far greater than the rate of decrease with the HEMA. The first step had a larger slope than the second step in the Td vs. CNMGly plot. The degree of adsorption of these two monomers to the BTC was estimated from infrared absorption measurements on the monomer solutions of various concentrations, before and after the immersion of the BTC. Both the adsorption of HEMA to the BTC and the Td of the BTC were linearly dependent on HEMA concentrations. Conversely, NMGly was adsorbed to the BTC, again, in a two-step decrease similar to the Td vs. CNMGLy profile. An enhanced adsorption of NMGly, which might be attributed to a strong electrostatic interaction, was observed below 0.013 mol%. Circular dichroism measurements of the collagen of the same type as the BTC, in the absence and in the presence of the monomers, revealed that the native collagen helix structure was scarcely affected by the monomers. From these observations, it was concluded that (1) both of the monomers were adsorbed onto the BTC, which thus destabilized the triple helical collagen structure, and that (2) the effect was higher for NMGly in which the electrostatic attraction with the oppositely charged collagen might be effective at a pH of 3. If compared to HEMA, an acidic NMGly is a potential monomer that binds strongly to collagen and one that is hardly hydrolyzed. FAU - Nezu, Takashi AU - Nezu T AD - Section of Fixed Prosthodontics, Faculty of Dental Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. nezudhd@mbox.nc.kyushu-u.ac.jp FAU - Nishiyama, Norihiro AU - Nishiyama N FAU - Nemoto, Kimiya AU - Nemoto K FAU - Terada, Yoshihiro AU - Terada Y LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Collagen Type I) RN - 0 (Methacrylates) RN - 0 (Resin Cements) RN - 059QF0KO0R (Water) RN - 23578-45-2 (N-methacryloyl glycine) RN - 6E1I4IV47V (hydroxyethyl methacrylate) RN - TE7660XO1C (Glycine) SB - IM MH - Adhesiveness MH - Animals MH - Cattle MH - Circular Dichroism MH - Collagen Type I/analysis/*chemistry MH - Drug Stability MH - Glycine/*analogs & derivatives/analysis/*chemistry MH - Hydrogen-Ion Concentration MH - Materials Testing MH - Methacrylates/analysis/*chemistry MH - Protein Denaturation MH - Resin Cements/analysis/*chemistry MH - Temperature MH - Tendons/metabolism MH - Water/*chemistry EDAT- 2005/01/01 09:00 MHDA- 2005/07/13 09:00 CRDT- 2005/01/01 09:00 PHST- 2004/05/27 00:00 [received] PHST- 2004/10/14 00:00 [accepted] PHST- 2005/01/01 09:00 [pubmed] PHST- 2005/07/13 09:00 [medline] PHST- 2005/01/01 09:00 [entrez] AID - S0142-9612(04)00929-9 [pii] AID - 10.1016/j.biomaterials.2004.10.010 [doi] PST - ppublish SO - Biomaterials. 2005 Jun;26(18):3801-8. doi: 10.1016/j.biomaterials.2004.10.010. PMID- 2016301 OWN - NLM STAT- MEDLINE DCOM- 19910517 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 266 IP - 11 DP - 1991 Apr 15 TI - Type XIV collagen, a new homotrimeric molecule extracted from fetal bovine skin and tendon, with a triple helical disulfide-bonded domain homologous to type IX and type XII collagens. PG - 6853-8 AB - Previously undescribed disulfide-bonded collagenous pepsin-derived fragments have been isolated from fetal calf tendon and skin. One fragment, 10.5 kDa after reduction, was shown to be similar but distinct to the COL1 domain of the recently characterized type XII collagen (64% primary structure identity). The similarity includes important features such as size, location of the cysteine residues, and nature and position of an imperfection of the triple helix. From fetal calf skin, two approximately 34-kDa disulfide-bonded trimeric fragments were isolated in the unreduced form. Amino acid sequencing showed that one fragment contained solely the COL1 domain of type XII collagen while the other one only contained the COL1 domain of the new chain. Like type XII collagen, the new chain is therefore part of a homotrimeric molecule and should thus be considered as a distinct collagen type. We propose to call the molecule from which this fragment is derived, type XIV collagen, with a chain composition (alpha 1 (XIV]3. The presence of a domain similar to the COL1 domain of collagens types IX and XII suggests that type XIV collagen belongs to the group of fibril-associated collagens with interrupted triple helices (FACIT). Two other fragments, 13.5 and 17 kDa after reduction, were also purified. They were shown to contain the same triple helical domain with different pepsin cleavage sites at the amino terminus. Several tryptic peptides were sequenced, and the derived sequences could be aligned with the COL2 domain of type XII collagen or with flanking sequences in the NC2 and NC3 domains (61% sequence identity). These fragments are very likely to be also derived from type XIV collagen. FAU - Dublet, B AU - Dublet B AD - Institute for Biology and Chemistry of Proteins, Centre National de la Recherche Scientifique Unité Propre de Recherche 412), Université Claude Bernard, Villeurbanne, France. FAU - van der Rest, M AU - van der Rest M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Disulfides) RN - 0 (Macromolecular Substances) RN - 0 (Peptide Fragments) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) SB - IM MH - Amino Acid Sequence MH - Animals MH - Cattle MH - Chickens MH - Chromatography, High Pressure Liquid MH - Collagen/chemistry/*genetics/isolation & purification MH - DNA/genetics/isolation & purification MH - Disulfides/analysis MH - Fetus MH - Macromolecular Substances MH - Molecular Sequence Data MH - Molecular Weight MH - Peptide Fragments/isolation & purification MH - Peptide Mapping MH - Protein Conformation MH - Sequence Homology, Nucleic Acid MH - Skin/*chemistry MH - Tendons/*chemistry EDAT- 1991/04/15 00:00 MHDA- 1991/04/15 00:01 CRDT- 1991/04/15 00:00 PHST- 1991/04/15 00:00 [pubmed] PHST- 1991/04/15 00:01 [medline] PHST- 1991/04/15 00:00 [entrez] AID - S0021-9258(20)89579-9 [pii] PST - ppublish SO - J Biol Chem. 1991 Apr 15;266(11):6853-8. PMID- 3451944 OWN - NLM STAT- MEDLINE DCOM- 19880727 LR - 20190828 IS - 0301-4800 (Print) IS - 0301-4800 (Linking) VI - 33 IP - 6 DP - 1987 Dec TI - Blood thiamine levels in outpatients with diabetes mellitus. PG - 421-30 AB - In 46 diabetic outpatients consisting of 20 males and 26 females not given thiamine treatment, the blood thiamine level was 46.9 +/- 28.5 ng/ml (mean +/- SD) and only 23.9% of all cases had a value of more than the normal lower limit (50 ng/ml). Erythrocyte transketolase activity was 443.8 +/- 107.7 micrograms/ml/h and only 20.9% had a value of ore than the normal lower limit (50 micrograms/ml/h), and the erythrocyte TPP effect was 16.6 +/- 13.2%. Moreover, there was a significant positive correlation (r = 0.97) between the blood thiamine level and erythrocyte transketolase activity, and a significant inverse correlation (r = -0.525, r = -0.576) between blood thiamine level and/or erythrocyte transketolase activity and the erythrocyte TPP effect. In 24 diabetic outpatients consisting of 14 males and 10 females given thiamine treatment, the blood thiamine level was 96.5 +/- 44.5 ng/ml/h excluding one case (621.7 ng/ml), and it was higher than the normal lower limit in 83% of all cases. Erythrocyte transketolase activity was 513.9 +/- 133.4 micrograms/ml/h and it was higher than the normal lower limit in 58.3%. Erythrocyte TPP effect was 5.84 +/- 8.39%. There was also a significant positive correlation (r = 0.663) between blood thiamine level and erythrocyte transketolase activity, and a significant inverse correlation (r = 0.0668, r = 0.834) between blood thiamine level and/or erythrocyte transketolase activity and erythrocyte TPP effect. Blood thiamine level and erythrocyte transketolase activity were significantly higher in diabetic outpatients given thiamine treatment than in diabetic outpatients not given thiamine treatment, while the erythrocyte TPP effect was significantly lower in diabetic outpatients given thiamine treatment than in diabetic outpatients not given thiamine treatment. There was no direct relationship between the lowered response of patellar tendon reflex and the biochemical status of thiamine. From the above findings it was concluded that diabetic outpatients tend to have a low blood thiamine level, with low erythrocyte transketolase activity and high erythrocyte TPP effect, and showed marginal thiamine deficiency. FAU - Saito, N AU - Saito N AD - Department of Geriatrics, Kochi Medical University, Japan. FAU - Kimura, M AU - Kimura M FAU - Kuchiba, A AU - Kuchiba A FAU - Itokawa, Y AU - Itokawa Y LA - eng PT - Journal Article PL - Japan TA - J Nutr Sci Vitaminol (Tokyo) JT - Journal of nutritional science and vitaminology JID - 0402640 RN - EC 2.2.1.1 (Transketolase) RN - Q57971654Y (Thiamine Pyrophosphate) RN - X66NSO3N35 (Thiamine) SB - IM MH - Adult MH - Ambulatory Care MH - Diabetes Mellitus/*blood MH - Erythrocytes/enzymology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Reflex MH - Tendons/physiology MH - Thiamine/*blood MH - Thiamine Pyrophosphate/blood MH - Transketolase/blood EDAT- 1987/12/01 00:00 MHDA- 1987/12/01 00:01 CRDT- 1987/12/01 00:00 PHST- 1987/12/01 00:00 [pubmed] PHST- 1987/12/01 00:01 [medline] PHST- 1987/12/01 00:00 [entrez] AID - 10.3177/jnsv.33.421 [doi] PST - ppublish SO - J Nutr Sci Vitaminol (Tokyo). 1987 Dec;33(6):421-30. doi: 10.3177/jnsv.33.421. PMID- 15811148 OWN - NLM STAT- MEDLINE DCOM- 20050718 LR - 20131121 IS - 1462-8902 (Print) IS - 1462-8902 (Linking) VI - 7 IP - 3 DP - 2005 May TI - Lipoic acid prevents collagen abnormalities in tail tendon of high-fructose-fed rats. PG - 294-7 AB - BACKGROUND: Non-enzymatic glycation of proteins, leading to chemical modification and cross-linking are of importance in the pathology of diabetic complications. We studied the effect of alpha-lipoic acid (LA) on the glycation and cross-linking of collagen from tail tendon of high-fructose-fed rats. METHODS: The rats were divided into four groups of six each. Two groups of rats were fed with a high-fructose diet (60/100 g diet) and administered with either LA (35 mg/kg body weight, intraperitoneally) (FRU + LA) or saline (FRU) for 45 days. The other two groups were fed control diet containing starch (60/100 g diet) and administered with either saline (CON) or LA (CON + LA). The rats were maintained for 45 days and then sacrificed. Collagen was isolated from tail tendon and the extent of glycation, fluorescence, aldehyde and peroxidation levels were measured. The tail tendons were separated, and shrinkage temperature was also measured. Acid-soluble collagen was extracted from tail tendon and subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis. RESULTS: Fructose administration caused accumulation of collagen in tail tendon. Glycation, collagen-linked fluorescence, aldehyde and peroxide contents were elevated. The gel pattern of acid-soluble collagen from the fructose-fed rat showed elevated beta-component. These changes were alleviated by the simultaneous administration of LA. CONCLUSION: Administration of LA has a positive influence on tail tendon collagen glycation and other variables in high-fructose-fed rats. FAU - Thirunavukkarasu, V AU - Thirunavukkarasu V AD - Department of Biochemistry, Faculty of Science, Annamalai University, Annamalai Nagar, Tamil Nadu 608-002, India. FAU - Nandhini, A T A AU - Nandhini AT FAU - Anuradha, C V AU - Anuradha CV LA - eng PT - Journal Article PL - England TA - Diabetes Obes Metab JT - Diabetes, obesity & metabolism JID - 100883645 RN - 0 (Dietary Carbohydrates) RN - 30237-26-4 (Fructose) RN - 73Y7P0K73Y (Thioctic Acid) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Collagen/analysis/chemistry/*metabolism MH - Diabetes Complications/*metabolism MH - Dietary Carbohydrates/*administration & dosage MH - Fructose/*administration & dosage MH - Male MH - Models, Animal MH - Rats MH - Rats, Wistar MH - Tail MH - Tendons/chemistry/*metabolism MH - Thioctic Acid/*therapeutic use EDAT- 2005/04/07 09:00 MHDA- 2005/07/19 09:00 CRDT- 2005/04/07 09:00 PHST- 2005/04/07 09:00 [pubmed] PHST- 2005/07/19 09:00 [medline] PHST- 2005/04/07 09:00 [entrez] AID - DOM418 [pii] AID - 10.1111/j.1463-1326.2004.00418.x [doi] PST - ppublish SO - Diabetes Obes Metab. 2005 May;7(3):294-7. doi: 10.1111/j.1463-1326.2004.00418.x. PMID- 33300201 OWN - NLM STAT- MEDLINE DCOM- 20210517 LR - 20210517 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 39 IP - 4 DP - 2021 Apr TI - Vitamin C in orthopedic practices: Current concepts, novel ideas, and future perspectives. PG - 698-706 LID - 10.1002/jor.24947 [doi] AB - Vitamin C (ascorbic acid), is an important antioxidant that has been applied broadly in the field of orthopaedics. Current research on vitamin C examines the molecule's role in bone and tendon physiology, as well as joint replacement and Postoperative pain. Most laboratory and human studies associate the use of vitamin C with improved bone health and tendon healing. Recent literature moderately supports the use of vitamin C to improve functional outcomes, decreased postoperative pain, and prevent complex regional pain syndrome following orthopaedic procedures. The perioperative use of vitamin C in patients undergoing joint replacement surgery and anterior cruciate ligament reconstruction is still under investigation. Overall, there is need for high-quality human trials to confirm whether vitamin C can potentiate the outcomes of orthopaedic procedures and to determine optimal dosage and means of administration to maximize its proposed benefits. The purpose of this review was to summarize the application of vitamin C in orthopaedic practices and to identify potential areas for future study. CI - © 2020 Orthopaedic Research Society. Published by Wiley Periodicals LLC. FAU - Oakes, Bennett AU - Oakes B AD - Department of Orthopaedic Surgery, University of Southern California Los Angeles, Los Angeles, California, USA. FAU - Bolia, Ioanna K AU - Bolia IK AD - Department of Orthopaedic Surgery, University of Southern California Los Angeles, Los Angeles, California, USA. FAU - Weber, Alexander E AU - Weber AE AUID- ORCID: 0000-0002-4957-4334 AD - Department of Orthopaedic Surgery, University of Southern California Los Angeles, Los Angeles, California, USA. FAU - Petrigliano, Frank A AU - Petrigliano FA AD - Department of Orthopaedic Surgery, University of Southern California Los Angeles, Los Angeles, California, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20210104 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Antioxidants) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Injuries/surgery MH - Anterior Cruciate Ligament Reconstruction MH - Antioxidants/*therapeutic use MH - Arthroplasty, Replacement MH - Ascorbic Acid/*therapeutic use MH - Bone and Bones/drug effects/surgery MH - Clinical Trials as Topic MH - Humans MH - Orthopedics/*trends MH - Osteoporosis/therapy MH - Pain, Postoperative/prevention & control MH - Perioperative Period MH - Randomized Controlled Trials as Topic MH - Tendons/drug effects/surgery MH - Treatment Outcome OTO - NOTNLM OT - bone OT - orthopedics OT - pain management OT - tendons OT - vitamin C EDAT- 2020/12/11 06:00 MHDA- 2021/05/18 06:00 CRDT- 2020/12/10 06:01 PHST- 2020/12/01 00:00 [revised] PHST- 2020/09/28 00:00 [received] PHST- 2020/12/07 00:00 [accepted] PHST- 2020/12/11 06:00 [pubmed] PHST- 2021/05/18 06:00 [medline] PHST- 2020/12/10 06:01 [entrez] AID - 10.1002/jor.24947 [doi] PST - ppublish SO - J Orthop Res. 2021 Apr;39(4):698-706. doi: 10.1002/jor.24947. Epub 2021 Jan 4. PMID- 6615580 OWN - NLM STAT- MEDLINE DCOM- 19831028 LR - 20190718 IS - 0021-9150 (Print) IS - 0021-9150 (Linking) VI - 48 IP - 2 DP - 1983 Aug TI - Effects of probucol on homozygous cases of familial hypercholesterolemia. PG - 157-66 AB - A marked reduction of serum cholesterol was obtained by treatment with probucol in heterozygous as well as in homozygous cases of familial hypercholesterolemia. A strict dietary regimen (low-fat, low-calories) intensified the hypocholesterolemic effect of the drug. The drug was also useful in diminishing the rebound of serum cholesterol after plasma exchange. Probucol reduced serum triglycerides in heterozygous cases of familial hypercholesterolemia, but there was a slight increase in triglycerides in homozygous cases. Treatment with probucol resulted in the regression of cutaneous and tendon xanthomas. Although it caused a decrease in HDL, it seems to be very effective in the treatment of familial hypercholesterolemia. FAU - Yamamoto, A AU - Yamamoto A FAU - Matsuzawa, Y AU - Matsuzawa Y FAU - Kishino, B AU - Kishino B FAU - Hayashi, R AU - Hayashi R FAU - Hirobe, K AU - Hirobe K FAU - Kikkawa, T AU - Kikkawa T LA - eng PT - Comparative Study PT - Journal Article PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 RN - 0 (Anticholesteremic Agents) RN - 0 (Naphthalenes) RN - 0 (Phenols) RN - 0 (Triglycerides) RN - 1UQM1K0W9X (mevastatin) RN - 97C5T2UQ7J (Cholesterol) RN - 9LHU78OQFD (Lovastatin) RN - P3CTH044XJ (Probucol) SB - IM MH - Adolescent MH - Adult MH - Anticholesteremic Agents/therapeutic use MH - Cholesterol/blood MH - Energy Intake MH - Female MH - Homozygote MH - Humans MH - Hyperlipoproteinemia Type II/*drug therapy/therapy MH - *Lovastatin/*analogs & derivatives MH - Male MH - Middle Aged MH - Naphthalenes/therapeutic use MH - Phenols/*therapeutic use MH - Plasma Exchange MH - Probucol/*therapeutic use MH - Skin Diseases/drug therapy MH - Tendons MH - Triglycerides/blood MH - Xanthomatosis/drug therapy EDAT- 1983/08/01 00:00 MHDA- 1983/08/01 00:01 CRDT- 1983/08/01 00:00 PHST- 1983/08/01 00:00 [pubmed] PHST- 1983/08/01 00:01 [medline] PHST- 1983/08/01 00:00 [entrez] AID - 0021-9150(83)90102-8 [pii] AID - 10.1016/0021-9150(83)90102-8 [doi] PST - ppublish SO - Atherosclerosis. 1983 Aug;48(2):157-66. doi: 10.1016/0021-9150(83)90102-8. PMID- 5167391 OWN - NLM STAT- MEDLINE DCOM- 19720317 LR - 20190702 IS - 0042-4900 (Print) IS - 0042-4900 (Linking) VI - 89 IP - 16 DP - 1971 Oct 16 TI - Superficial flexor tendon injuries in the greyhound. PG - 437-8 FAU - Prole, J H AU - Prole JH LA - eng PT - Journal Article PL - England TA - Vet Rec JT - The Veterinary record JID - 0031164 RN - 0 (Adrenal Cortex Hormones) RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Animals MH - Cautery MH - Dimethyl Sulfoxide/therapeutic use MH - Dog Diseases/*therapy MH - Dogs MH - Methods MH - Rupture/surgery MH - Sports MH - Tendon Injuries/drug therapy/surgery/therapy/*veterinary MH - Tendons/surgery EDAT- 1971/10/16 00:00 MHDA- 1971/10/16 00:01 CRDT- 1971/10/16 00:00 PHST- 1971/10/16 00:00 [pubmed] PHST- 1971/10/16 00:01 [medline] PHST- 1971/10/16 00:00 [entrez] AID - 10.1136/vr.89.16.437 [doi] PST - ppublish SO - Vet Rec. 1971 Oct 16;89(16):437-8. doi: 10.1136/vr.89.16.437. PMID- 7339868 OWN - NLM STAT- MEDLINE DCOM- 19820614 LR - 20190821 IS - 0036-5513 (Print) IS - 0036-5513 (Linking) VI - 41 IP - 7 DP - 1981 Nov TI - An electrophoretic fraction of urinary glycosaminoglycans reflecting connective tissue turnover. PG - 675-81 AB - In 97 healthy individuals, including 64 children, the excretion of glycosaminoglycan-derived uronic acid, hydroxyproline and creatinine was determined. In 32 of the individuals the glycosaminoglycans were separated into two electrophoretic fractions. The excretion of both were expressed as uronic acid. One of these fractions correlated with the excretion of hydroxyproline producing a peak of excretion at puberty. Constituting up to 30% the other fraction was excreted independently of hydroxyproline and was rather constant throughout life. Regarded as a fraction without any relation to the ground substance of bone, cartilage, tendons and skin, the independent fraction represented a disturbing factor in the investigation of connective tissue by urinary measurements. Due to the correlation above, glycosaminoglycans and hydroxyproline showed identical sex-and age-dependent patterns of excretion. Peak excretions were found at puberty, and when expressed as ratios with creatinine, linear decreases during adolescence were the results. The uronic acid/hydroxproline ratio was constant throughout childhood, but increased a little in adults. FAU - Poulsen, J H AU - Poulsen JH LA - eng PT - Journal Article PL - England TA - Scand J Clin Lab Invest JT - Scandinavian journal of clinical and laboratory investigation JID - 0404375 RN - 0 (Glycosaminoglycans) RN - 0 (Uronic Acids) RN - 9007-34-5 (Collagen) RN - AYI8EX34EU (Creatinine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Bone and Bones/metabolism MH - Child MH - Child, Preschool MH - Collagen/metabolism MH - Connective Tissue/*metabolism MH - Creatinine/urine MH - Electrophoresis, Cellulose Acetate MH - Female MH - Glycosaminoglycans MH - Humans MH - Hydroxyproline/urine MH - Male MH - Puberty MH - Sex Factors MH - *Urine MH - Uronic Acids/urine EDAT- 1981/11/01 00:00 MHDA- 1981/11/01 00:01 CRDT- 1981/11/01 00:00 PHST- 1981/11/01 00:00 [pubmed] PHST- 1981/11/01 00:01 [medline] PHST- 1981/11/01 00:00 [entrez] AID - 10.3109/00365518109090514 [doi] PST - ppublish SO - Scand J Clin Lab Invest. 1981 Nov;41(7):675-81. doi: 10.3109/00365518109090514. PMID- 28825891 OWN - NLM STAT- MEDLINE DCOM- 20171127 LR - 20180416 IS - 1527-1315 (Electronic) IS - 0033-8419 (Linking) VI - 285 IP - 3 DP - 2017 Dec TI - Achilles Tendon Xanthomas: Fat-Water Separation at Baseline and after Treatment. PG - 876-884 LID - 10.1148/radiol.2017161435 [doi] AB - Purpose To investigate the fat-water content of Achilles tendon xanthomas at baseline and after treatment and to compare this assessment with that of ultrasonography (US) and other magnetic resonance (MR) imaging-based parameters. Materials and Methods Forty-eight Achilles tendons with clinically apparent xanthomas in 24 patients with familial hypercholesterolemia (FH) (six men, 18 women; mean age ± standard deviation, 58 years ± 9) were compared with 20 Achilles tendons in 10 control subjects without FH (two men, eight women; mean age, 62 years ± 7). US imaging measurements (thickness, width, cross-sectional area, echogenicity) and 3.0-T MR imaging measurements (thickness, width, cross-sectional area, volume, and fat-water separation) of the Achilles tendons were obtained at baseline and in patients with FH at 3 and 6 months after treatment with probucol, a cholesterol-lowering agent. Nonparametric tests compared baseline data, whereas repeated-measures analyses assessed treatment change. Results At baseline, all US and MR imaging-based parameters were higher in xanthoma tendons compared with those in control tendons (all P < .05). The mean relative water content per unit volume was 71% higher (42.0% ± 6.7) in xanthoma tendons than in control tendons (24.5% 6 5.8; P < .001). After 6 months of cholesterol-lowering treatment, only MR imaging measurements of tendon volume (P = .007), relative fat (P = .041), and relative water content (P < .001) showed significant changes. As relative tendon fat content decreased with treatment, relative water content increased. Conclusion Most of the enlargement of Achilles tendon xanthomas is due to an increase in water content rather than fat. For depicting treatment change, relative tendon water content was the most sensitive parameter, followed by tendon volume and relative tendon fat content. (©) RSNA, 2017 Online supplemental material is available for this article. FAU - Griffith, James F AU - Griffith JF AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Hu, Miao AU - Hu M AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Yeung, David K W AU - Yeung DKW AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Guo, Pei AU - Guo P AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Lam, Sik Lok AU - Lam SL AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Xiao, Fan AU - Xiao F AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Wang, Defeng AU - Wang D AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. FAU - Tomlinson, Brian AU - Tomlinson B AD - From the Departments of Imaging & Interventional Radiology (J.F.G., D.K.W.Y., F.X., D.W.), Medicine & Therapeutics (M.H., B.T.), and Chemistry (P.G., S.L.L.), Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing St, Shatin, NT, Hong Kong. LA - eng PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170821 PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Anticholesteremic Agents) RN - P3CTH044XJ (Probucol) SB - IM MH - Achilles Tendon/*diagnostic imaging/drug effects/pathology MH - Adipose Tissue/*diagnostic imaging/pathology MH - Aged MH - Anticholesteremic Agents/therapeutic use MH - Body Water/*diagnostic imaging MH - Female MH - Humans MH - Magnetic Resonance Imaging/*methods MH - Male MH - Middle Aged MH - Probucol/therapeutic use MH - Reproducibility of Results MH - Sensitivity and Specificity MH - Subtraction Technique MH - Treatment Outcome MH - Xanthomatosis/*diagnostic imaging/*drug therapy/pathology EDAT- 2017/08/22 06:00 MHDA- 2017/11/29 06:00 CRDT- 2017/08/22 06:00 PHST- 2017/08/22 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] PHST- 2017/08/22 06:00 [entrez] AID - 10.1148/radiol.2017161435 [doi] PST - ppublish SO - Radiology. 2017 Dec;285(3):876-884. doi: 10.1148/radiol.2017161435. Epub 2017 Aug 21. PMID- 5472968 OWN - NLM STAT- MEDLINE DCOM- 19701209 LR - 20190617 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 228 IP - 5273 DP - 1970 Nov 21 TI - Decreased binding of 14C-homogentisic acid induced by ascorbic acid in connective tissue of rats with experimental alcaptonuria. PG - 770-1 FAU - Lustberg, T J AU - Lustberg TJ FAU - Schulman, J D AU - Schulman JD FAU - Seegmiller, J E AU - Seegmiller JE LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Carbon Isotopes) RN - 0 (Phenylacetates) RN - 42HK56048U (Tyrosine) RN - GNN1DV99GX (Penicillamine) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Alkaptonuria/drug therapy/*metabolism MH - Ascorbic Acid/*therapeutic use MH - Binding Sites MH - Carbon Isotopes MH - Connective Tissue/*metabolism MH - Disease Models, Animal MH - Ochronosis/metabolism MH - Penicillamine/therapeutic use MH - Phenylacetates/*metabolism MH - Sternum/metabolism MH - Tendons/metabolism MH - Tyrosine/therapeutic use EDAT- 1970/11/21 00:00 MHDA- 1970/11/21 00:01 CRDT- 1970/11/21 00:00 PHST- 1970/11/21 00:00 [pubmed] PHST- 1970/11/21 00:01 [medline] PHST- 1970/11/21 00:00 [entrez] AID - 10.1038/228770a0 [doi] PST - ppublish SO - Nature. 1970 Nov 21;228(5273):770-1. doi: 10.1038/228770a0. PMID- 20513891 OWN - NLM STAT- MEDLINE DCOM- 20100709 LR - 20131121 IS - 2044-5377 (Electronic) IS - 0301-620X (Linking) VI - 92 IP - 6 DP - 2010 Jun TI - Effect of mitomycin-C on post-operative adhesions in tendon surgery: an experimental study in rats. PG - 889-93 LID - 10.1302/0301-620X.92B6.23534 [doi] AB - We investigated the effect of mitomycin-C on the reduction of the formation of peritendinous fibrous adhesions after tendon repair. In 20 Wistar albino rats the tendo Achillis was cut and repaired using a modified Kessler technique. The rats were divided into two equal groups. In group 1, an injection of mitomycin-C was placed between the tendon and skin of the right leg. In group 2, an identical volume of sterile normal saline was injected on the left side in a similar fashion. All the rats received mitomycin-C or saline for four weeks starting from the day of operation. The animals were killed after 30 days. The formation of peritendinous fibrous tissue, the inflammatory reaction and tendon healing were evaluated. The tensile strength of the repaired tendons was measured biomechanically. Microscopic evidence of the formation of adhesions and inflammation was less in group 1. There was no significant difference in the tensile load required to rupture the repaired tendons in the two groups. Mitomycin-C may therefore provide a simple and inexpensive means of preventing of post-operative adhesions. FAU - Kocaoglu, B AU - Kocaoglu B AD - Department of Orthopaedics and Traumatology, Acibadem University, Istanbul, Turkey. bariskocaoglu@gmail.com FAU - Agir, I AU - Agir I FAU - Nalbantoglu, U AU - Nalbantoglu U FAU - Karahan, M AU - Karahan M FAU - Türkmen, M AU - Türkmen M LA - eng PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Nucleic Acid Synthesis Inhibitors) RN - 50SG953SK6 (Mitomycin) SB - IM MH - Achilles Tendon/injuries/pathology/surgery MH - Animals MH - Drug Evaluation, Preclinical/methods MH - Female MH - Mitomycin/*therapeutic use MH - Nucleic Acid Synthesis Inhibitors/*therapeutic use MH - Postoperative Complications/pathology/*prevention & control MH - Rats MH - Rats, Wistar MH - Tendon Injuries/pathology/*surgery MH - Tissue Adhesions/prevention & control MH - Wound Healing EDAT- 2010/06/02 06:00 MHDA- 2010/07/10 06:00 CRDT- 2010/06/02 06:00 PHST- 2010/06/02 06:00 [entrez] PHST- 2010/06/02 06:00 [pubmed] PHST- 2010/07/10 06:00 [medline] AID - 92-B/6/889 [pii] AID - 10.1302/0301-620X.92B6.23534 [doi] PST - ppublish SO - J Bone Joint Surg Br. 2010 Jun;92(6):889-93. doi: 10.1302/0301-620X.92B6.23534. PMID- 17903127 OWN - NLM STAT- MEDLINE DCOM- 20071217 LR - 20161124 IS - 0005-0423 (Print) IS - 0005-0423 (Linking) VI - 85 IP - 10 DP - 2007 Oct TI - Flexor carpi ulnaris tendonopathy in a Weimaraner. PG - 401-4 FAU - Kuan, S Y AU - Kuan SY AD - University Veterinary Centre Sydney, B10 Evelyn Williams Building, University of Sydney NSW 2006, Australia. sooyuin@yahoo.com.au FAU - Smith, B A AU - Smith BA FAU - Fearnside, S M AU - Fearnside SM FAU - Black, A P AU - Black AP FAU - Allan, G S AU - Allan GS LA - eng PT - Case Reports PT - Journal Article PL - England TA - Aust Vet J JT - Australian veterinary journal JID - 0370616 RN - 0 (Anti-Inflammatory Agents) RN - LR3CD8SX89 (Flumethasone) RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*therapeutic use MH - Dimethyl Sulfoxide/therapeutic use MH - Dogs/*injuries MH - Female MH - Flumethasone/therapeutic use MH - Rest MH - Splints/*veterinary MH - Tendon Injuries/diagnostic imaging/drug therapy/therapy/*veterinary MH - Tendons/*pathology MH - Treatment Outcome MH - Ultrasonography EDAT- 2007/10/02 09:00 MHDA- 2007/12/18 09:00 CRDT- 2007/10/02 09:00 PHST- 2007/10/02 09:00 [pubmed] PHST- 2007/12/18 09:00 [medline] PHST- 2007/10/02 09:00 [entrez] AID - AVJ187 [pii] AID - 10.1111/j.1751-0813.2007.00187.x [doi] PST - ppublish SO - Aust Vet J. 2007 Oct;85(10):401-4. doi: 10.1111/j.1751-0813.2007.00187.x. PMID- 31317423 OWN - NLM STAT- MEDLINE DCOM- 20200330 LR - 20200330 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 38 IP - 11 DP - 2019 Nov TI - Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. PG - 3145-3151 LID - 10.1007/s10067-019-04674-3 [doi] AB - INTRODUCTION/OBJECTIVE: Apremilast, PDE4 competitive inhibitor, has been recently introduced in the treatment of adult psoriatic arthritis (PsA) patients, but only preliminary data are available on imaging evaluation. Thus, we evaluated the response to apremilast in PsA patients by ultrasonographic (US) assessment. METHODS: Thirty-four patients (M/F 7/27; median age 61 years, IQR 15; median disease duration 10 years, IQR 13) treated for polyarticular involvement were longitudinally evaluated. All the patients were assessed at baseline (T0), and after 6 (T1), 12 (T2), and 24 weeks (T3) by DAS28, CDAI, SDAI, and DAPSA. At the same time-points, US assessment was performed in 22 sites (wrists, MCPs, PIPs): synovial effusion/hypertrophy and power Doppler were scored with a semi-quantitative scale (0-3). A total score, corresponding to patient's inflammatory status, was obtained by their sum (0-198). We assessed also the presence of tenosynovitis of flexor (tendons) of hands' fingers bilaterally, registering the number of involved tendons (US-tenosynovitis score 0-10). RESULTS: We found a significant reduction in the US inflammatory score values after 6 weeks (T0, median 15 (IQR 11.2); T1, 6 (10.0); P = 0.0002), confirmed at T2 (4.0 (4.0), P = 0.0002) and T3 (4.0 (6.0); P = 0.0003). Finally, US-detected tenosynovitis was observed in 44.1% of patients: a significant improvement in tenosynovitis score was identified at 6 weeks (T0, median 4 (IQR 4); T1, 1 (2); P < 0.0001) and maintained at T2 (0 (IQR 1); P < 0.0001) and T3 ((IQR 1.25); P < 0.0001). CONCLUSIONS: Apremilast is able to induce an early and sustained improvement of ultrasonographic inflammatory status at articular and peri-articular level. Key points •Apremilast induces a significant, early, and sustained improvement of inflammatory joint status in psoriatic arthritis patients. •Ultrasonographic assessment is able to monitor articular and peri-articular response to apremilast. FAU - Ceccarelli, Fulvia AU - Ceccarelli F AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. fulviaceccarelli@gmail.com. FAU - Lucchetti, Ramona AU - Lucchetti R AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Perricone, Carlo AU - Perricone C AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Spinelli, Francesca Romana AU - Spinelli FR AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Cipriano, Enrica AU - Cipriano E AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Truglia, Simona AU - Truglia S AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Miranda, Francesca AU - Miranda F AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Riccieri, Valeria AU - Riccieri V AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Di Franco, Manuela AU - Di Franco M AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Scrivo, Rossana AU - Scrivo R AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Alessandri, Cristiano AU - Alessandri C AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Valesini, Guido AU - Valesini G AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. FAU - Conti, Fabrizio AU - Conti F AD - Sapienza Arthritis Center, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy. LA - eng PT - Journal Article DEP - 20190717 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 4Z8R6ORS6L (Thalidomide) RN - UP7QBP99PN (apremilast) SB - IM MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Arthritis, Psoriatic/diagnostic imaging/*drug therapy MH - Female MH - Humans MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Outcome Assessment, Health Care MH - Prospective Studies MH - Thalidomide/*analogs & derivatives/therapeutic use MH - Ultrasonography OTO - NOTNLM OT - Apremilast OT - Joint inflammation OT - Psoriatic arthritis OT - Treatment response OT - Ultrasonographic assessment EDAT- 2019/07/19 06:00 MHDA- 2020/03/31 06:00 CRDT- 2019/07/19 06:00 PHST- 2019/04/12 00:00 [received] PHST- 2019/07/01 00:00 [accepted] PHST- 2019/06/26 00:00 [revised] PHST- 2019/07/19 06:00 [pubmed] PHST- 2020/03/31 06:00 [medline] PHST- 2019/07/19 06:00 [entrez] AID - 10.1007/s10067-019-04674-3 [pii] AID - 10.1007/s10067-019-04674-3 [doi] PST - ppublish SO - Clin Rheumatol. 2019 Nov;38(11):3145-3151. doi: 10.1007/s10067-019-04674-3. Epub 2019 Jul 17. PMID- 809289 OWN - NLM STAT- MEDLINE DCOM- 19751220 LR - 20131121 IS - 0091-6331 (Print) IS - 0091-6331 (Linking) VI - 3 DP - 1975 TI - Soft tissue injury in sport. PG - 275-301 FAU - Burry, H C AU - Burry HC LA - eng PT - Journal Article PL - United States TA - Exerc Sport Sci Rev JT - Exercise and sport sciences reviews JID - 0375434 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents) RN - EC 3.2.1.35 (Hyaluronoglucosaminidase) RN - EC 3.4.- (Peptide Hydrolases) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Aging MH - Anti-Inflammatory Agents/therapeutic use MH - Ascorbic Acid/therapeutic use MH - *Athletic Injuries/drug therapy/pathology/therapy MH - *Connective Tissue MH - Humans MH - Hyaluronoglucosaminidase/therapeutic use MH - Muscles/*injuries MH - Myositis Ossificans/etiology MH - Ossification, Heterotopic MH - Peptide Hydrolases/therapeutic use MH - Physical Therapy Modalities MH - Rupture MH - *Sports Medicine MH - Tendon Injuries/pathology MH - Tendons/pathology MH - Wound Healing EDAT- 1975/01/01 00:00 MHDA- 1975/01/01 00:01 CRDT- 1975/01/01 00:00 PHST- 1975/01/01 00:00 [pubmed] PHST- 1975/01/01 00:01 [medline] PHST- 1975/01/01 00:00 [entrez] PST - ppublish SO - Exerc Sport Sci Rev. 1975;3:275-301. PMID- 16340790 OWN - NLM STAT- MEDLINE DCOM- 20060112 LR - 20220316 IS - 0041-1337 (Print) IS - 0041-1337 (Linking) VI - 80 IP - 10 DP - 2005 Nov 27 TI - Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. PG - 1447-54 AB - BACKGROUND: Composite tissue allotransplantation (CTA) has been recently introduced as a potential treatment for tissue loss secondary to burns, injuries, or resections. However, the optimal strategies to prevent CTA rejection remain undefined. Presently, no CTA model exists to evaluate human-specific immunosuppressants or the relative immunogenicity of all CTA tissues. METHODS: We established a NHP CTA model utilizing a sensate osteomyocutaneous radial forearm flap that avoids functional impairment even in the case of graft loss. The model was evaluated in19 monkeys that underwent auto- or allotransplantation, with or without subtherapeutic immunosuppression to temporarily characterize rejection. RESULTS: Autografts showed no evidence of rejection. Nonimmunosuppressed allografts were rapidly rejected showing a perivenular T-cell infiltrate. This was associated with subsequent alloantibody formation and led to graft thrombosis without prominent dermal infiltration. Subtherapeutically immunosuppressed animals also developed alloantibody and rejected in a delayed fashion exhibiting a marked dermal lymphocytic infiltrate similar in magnitude and distribution to previously reported human cases. CONCLUSION: Our NHP model for CTA is well tolerated by NHPs, results in allosensitization, is responsive to immunosuppression, allows for the evaluation of CTA histology and can be used for the systematic preclinical evaluation of therapeutic maneuvers to improve allograft survival. FAU - Cendales, Linda C AU - Cendales LC AD - Orthopedic Section, Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892-1102, USA. cendalesl@mail.nih.gov FAU - Xu, He AU - Xu H FAU - Bacher, John AU - Bacher J FAU - Eckhaus, Michael A AU - Eckhaus MA FAU - Kleiner, David E AU - Kleiner DE FAU - Kirk, Allan D AU - Kirk AD LA - eng GR - Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PL - United States TA - Transplantation JT - Transplantation JID - 0132144 RN - 0 (Immunosuppressive Agents) RN - HU9DX48N0T (Mycophenolic Acid) RN - WM0HAQ4WNM (Tacrolimus) RN - X4W7ZR7023 (Methylprednisolone) SB - IM CIN - Transplantation. 2005 Nov 27;80(10):1374-5. doi: 10.1097/01.tp.0000183960.06766.ae. PMID: 16340777 MH - Animals MH - Biopsy MH - Forearm/*surgery MH - Graft Rejection/*prevention & control MH - Immunosuppressive Agents/therapeutic use MH - Macaca fascicularis MH - Methylprednisolone/therapeutic use MH - Models, Animal MH - Muscle, Skeletal/*transplantation MH - Mycophenolic Acid/analogs & derivatives/therapeutic use MH - Radius/*transplantation MH - Surgical Flaps MH - Tacrolimus/therapeutic use MH - Tendons/*transplantation MH - Transplantation, Homologous/immunology/*methods EDAT- 2005/12/13 09:00 MHDA- 2006/01/13 09:00 CRDT- 2005/12/13 09:00 PHST- 2005/12/13 09:00 [pubmed] PHST- 2006/01/13 09:00 [medline] PHST- 2005/12/13 09:00 [entrez] AID - 00007890-200511270-00016 [pii] AID - 10.1097/01.tp.0000183292.57349.27 [doi] PST - ppublish SO - Transplantation. 2005 Nov 27;80(10):1447-54. doi: 10.1097/01.tp.0000183292.57349.27. PMID- 27817975 OWN - NLM STAT- MEDLINE DCOM- 20170209 LR - 20181113 IS - 2589-1294 (Electronic) IS - 1017-995X (Print) IS - 1017-995X (Linking) VI - 50 IP - 5 DP - 2016 Oct TI - Long-term result of arthroplasty in the treatment of a case of ochronotic arthropathy. PG - 584-586 LID - S1017-995X(16)30125-0 [pii] LID - 10.1016/j.aott.2016.08.018 [doi] AB - Alkaptonuria is a rare metabolic disease caused by a partial or total deficiency of homogentisic acid oxidase, which results in excess homogentisic acid (HGA) levels. Homogentisic acid and its oxidation products can accumulate in hyaline cartilage, tendons, and ligaments. A 55-year-old male was admitted complaining of worsening chronic pain in his left knee. A radiographic evaluation showed tricompartmental end- stage osteoarthritis. A cemented total knee replacement was performed. At the 10-year follow-up, he had returned to full activity, had no knee pain, and was very satisfied with the outcome. No abnormality was observed in the femoral, tibial, or patellar components on radiography. We believe that total knee replacement is a good option in a patient with marked degenerative arthritis secondary to ochronotic arthritis. CI - Copyright © 2016. Production and hosting by Elsevier B.V. FAU - Karaoğlu, Sinan AU - Karaoğlu S AD - Acibadem Kayseri Hospital, Kayseri, Turkey. Electronic address: sinankaraoglu@hotmail.com. FAU - Karaaslan, Fatih AU - Karaaslan F AD - Bozok University Faculty of Medicine, Department of Orthopaedics and Traumatology, Turkey. FAU - Mermerkaya, Musa Uğur AU - Mermerkaya MU AD - Bozok University Faculty of Medicine, Department of Orthopaedics and Traumatology, Turkey. LA - eng PT - Case Reports PT - Journal Article DEP - 20161103 PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - NP8UE6VF08 (Homogentisic Acid) SB - IM MH - Alkaptonuria/*complications MH - Arthroplasty, Replacement, Knee/*methods MH - Chronic Pain/etiology MH - Homogentisic Acid/urine MH - Humans MH - Knee Joint/surgery MH - Male MH - Middle Aged MH - Ochronosis/*complications MH - Osteoarthritis, Knee/diagnostic imaging/*surgery MH - Radiography MH - Treatment Outcome PMC - PMC6197303 OTO - NOTNLM OT - Alkaptonuria OT - Arthroplasty OT - Knee joint OT - Ochronotic arthropathy EDAT- 2016/11/08 06:00 MHDA- 2017/02/10 06:00 PMCR- 2016/11/03 CRDT- 2016/11/08 06:00 PHST- 2014/03/24 00:00 [received] PHST- 2014/11/14 00:00 [revised] PHST- 2014/11/15 00:00 [accepted] PHST- 2016/11/08 06:00 [pubmed] PHST- 2017/02/10 06:00 [medline] PHST- 2016/11/08 06:00 [entrez] PHST- 2016/11/03 00:00 [pmc-release] AID - S1017-995X(16)30125-0 [pii] AID - 10.1016/j.aott.2016.08.018 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2016 Oct;50(5):584-586. doi: 10.1016/j.aott.2016.08.018. Epub 2016 Nov 3. PMID- 15922757 OWN - NLM STAT- MEDLINE DCOM- 20050830 LR - 20191210 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 38 IP - 7 DP - 2005 Jul TI - A model for the stability and creep of organic materials. PG - 1459-67 AB - A model is presented for the thermally assisted breaking of a number of bonds arranged in parallel and stressed by an individual soft spring each. Using a simplified potential for the bond it is shown that in equilibrium there are two definite regions of elastic behavior: one with all bonds intact, the other with a variable fraction of bonds broken, therefore with a tangent modulus steadily decreasing with applied stress. Criteria are given for the existence of these regions. Beyond these regions time-dependent creep to rupture is found, limited, in turn, by the theoretical fracture strength, the stress necessary for fracture without any thermal assistance, beyond which a bound state is impossible. The time-to-fracture for creep rupture is calculated and an example of the time evolution of the accelerating creep given. The results of the calculations are applied to experimental data on Wallaby tendons by Wang and Ker (J. Exp. Biol. 198 (1995) 831) and data estimated for the bond potential depth, the theoretical fracture strength and the number density of bonds involved as well as the elastic modulus of the ensemble. Values are derived under the assumption of one deformation mechanism being dominant--e.g., (sub-)fibril sliding or sliding of collagen molecules along one another--but the model cannot definitely distinguish between mechanisms. FAU - Jäger, Ingomar L AU - Jäger IL AD - Department of Metal Physics, University of Leoben, and Erich-Schmid-Institute of Materials Science, Austrian Academy of Sciences, Jahnstr 12, 8700 Leoben, Austria. ingomar@unileoben.ac.at LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Biocompatible Materials) RN - 0 (Organic Chemicals) SB - IM MH - Anisotropy MH - Biocompatible Materials/*analysis/*chemistry MH - Computer Simulation MH - Elasticity MH - Materials Testing/*methods MH - *Models, Chemical MH - Nonlinear Dynamics MH - Organic Chemicals/*analysis/*chemistry MH - Stress, Mechanical MH - Viscosity EDAT- 2005/06/01 09:00 MHDA- 2005/09/01 09:00 CRDT- 2005/06/01 09:00 PHST- 2003/09/12 00:00 [received] PHST- 2004/07/19 00:00 [accepted] PHST- 2005/06/01 09:00 [pubmed] PHST- 2005/09/01 09:00 [medline] PHST- 2005/06/01 09:00 [entrez] AID - S0021-9290(04)00348-3 [pii] AID - 10.1016/j.jbiomech.2004.07.006 [doi] PST - ppublish SO - J Biomech. 2005 Jul;38(7):1459-67. doi: 10.1016/j.jbiomech.2004.07.006. PMID- 9262673 OWN - NLM STAT- MEDLINE DCOM- 19971104 LR - 20131121 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 211 IP - 3 DP - 1997 Aug 1 TI - Sepsis of the common digital extensor tendon sheath secondary to hemicircumferential periosteal transection in a foal. PG - 331-2 AB - A 4-month-old Quarter Horse was admitted for evaluation of infection that developed following bilateral hemicircumferential periosteal transection and elevation. Sepsis of the common digital extensor tendon sheath was diagnosed. Treatment included lavage of the tendon sheath, placement of an indwelling drain for lavage after surgery, establishment of drainage, and administration of antimicrobial and anti-inflammatory drugs. Three months after treatment, the foal was clinically normal. FAU - Hawkins, J F AU - Hawkins JF AD - Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907-1248, USA. FAU - Lescun, T B AU - Lescun TB LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) RN - AN164J8Y0X (Trimethoprim) RN - Q42T66VG0C (Penicillin G) SB - IM MH - Animals MH - Anti-Bacterial Agents/therapeutic use MH - Combined Modality Therapy/veterinary MH - Forelimb/abnormalities/*surgery MH - Gentamicins/therapeutic use MH - Horse Diseases/drug therapy/*etiology MH - Horses MH - Male MH - Penicillin G/therapeutic use MH - Periosteum/*surgery MH - Streptococcal Infections/drug therapy/etiology/*veterinary MH - Streptococcus equi/*isolation & purification MH - Surgical Wound Infection/drug therapy/etiology/*veterinary MH - Tendons/microbiology/pathology/surgery MH - Tenosynovitis/drug therapy/etiology/*veterinary MH - Trimethoprim/therapeutic use EDAT- 1997/08/01 00:00 MHDA- 1997/08/01 00:01 CRDT- 1997/08/01 00:00 PHST- 1997/08/01 00:00 [pubmed] PHST- 1997/08/01 00:01 [medline] PHST- 1997/08/01 00:00 [entrez] PST - ppublish SO - J Am Vet Med Assoc. 1997 Aug 1;211(3):331-2. PMID- 22428411 OWN - NLM STAT- MEDLINE DCOM- 20120405 LR - 20131121 IS - 0270-1367 (Print) IS - 0270-1367 (Linking) VI - 83 IP - 1 DP - 2012 Mar TI - Changes in bone alkaline phosphatase and procollagen type-1 C-peptide after static and dynamic exercises. PG - 49-54 AB - We investigated the effects of two types of nonweight-bearing exercise on changes in bone-specific alkaline phosphatase (BAP) and procollagen type 1 C-peptide (PIP). BAP is a specific marker of bone synthesis, whereas P1P reflects synthesis of type 1 collagen in other organs as well as bone. Eight participants performed static and dynamic unilateral knee extensions. BAP and PIP were measured before, and at 1, 2, 24, 48, and 72 hr after exercise. PIP increased at 24 hr after a static knee extension exercise, whereas BAP did not change during the experimental period. We found no changes in these markers after dynamic exercise. These results imply that type I collagen synthesis in tendons increases after static exercise. FAU - Kubo, Keitaro AU - Kubo K AD - Department of Life Science (Sports Sciences) University of Tokyo, Japan. kubo@idaten.c.u-tokyo.ac.jp FAU - Yuki, Kazuhito AU - Yuki K FAU - Ikebukuro, Toshihiro AU - Ikebukuro T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Res Q Exerc Sport JT - Research quarterly for exercise and sport JID - 8006373 RN - 0 (Peptide Fragments) RN - 0 (Procollagen) RN - 0 (procollagen type I carboxy terminal peptide) RN - 33X04XA5AT (Lactic Acid) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Adult MH - Alkaline Phosphatase/*blood MH - Analysis of Variance MH - Bone and Bones/*metabolism MH - Exercise/*physiology MH - Humans MH - Isometric Contraction MH - Isotonic Contraction MH - Knee/physiology MH - Lactic Acid/blood MH - Male MH - Muscle, Skeletal/anatomy & histology/physiology MH - Patellar Ligament/metabolism MH - Peptide Fragments/*blood MH - Procollagen/*blood EDAT- 2012/03/21 06:00 MHDA- 2012/04/06 06:00 CRDT- 2012/03/21 06:00 PHST- 2012/03/21 06:00 [entrez] PHST- 2012/03/21 06:00 [pubmed] PHST- 2012/04/06 06:00 [medline] AID - 10.1080/02701367.2012.10599824 [doi] PST - ppublish SO - Res Q Exerc Sport. 2012 Mar;83(1):49-54. doi: 10.1080/02701367.2012.10599824. PMID- 22283685 OWN - NLM STAT- MEDLINE DCOM- 20120723 LR - 20120321 IS - 1520-6882 (Electronic) IS - 0003-2700 (Linking) VI - 84 IP - 6 DP - 2012 Mar 20 TI - Deamidation of collagen. PG - 3017-25 LID - 10.1021/ac202980z [doi] AB - Collagen is the major component of skin, tendons, ligaments, teeth, and bones, it provides the framework that holds most multicellular animals together, and collagen type I constitutes the major fibrillar collagen of bone. Because of the complexity of collagen's structure, the study of post-translational modifications such as deamidation for this protein is challenging. Although there is no evidence of this protein being used for age assessment, it has been shown that deamidation of collagen is remarkably increased in old bones from mammals. Nonspectrometric methodologies have been used for the determination of the extent of deamidation as a measure of the amount of amide nitrogen released in ammonia as well as constant rates for deamidation of asparagine in collagen. In general, these methodologies required more sample and separation processes. To understand if collagen plays a significant role in the aging process of fossil materials, a simpler and more accurate method is needed to determine the extent of deamidation at the whole protein level. The present work shows a method to determine the extent of deamidation in collagen using Fourier transform ion cyclotron resonance-mass spectrometry (FTICR-MS) along with collisionally activated dissociation (CAD) and electron capture dissociation (ECD). The measured deamidation half-life for three different tryptic peptides from collagen (I) ranged from 2000 to 6000 s under high temperature conditions (∼62 °C) and pH 7.5. FAU - Hurtado, Pilar Perez AU - Hurtado PP AD - Department of Chemistry, University of Warwick, Coventry, UK. FAU - O'Connor, Peter B AU - O'Connor PB LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120228 PL - United States TA - Anal Chem JT - Analytical chemistry JID - 0370536 RN - 0 (Amides) RN - 0 (Collagen Type I) RN - 0 (Peptides) SB - IM MH - *Aging MH - Amides/analysis/*metabolism MH - Animals MH - Collagen Type I/chemistry/*metabolism MH - Mass Spectrometry MH - Peptides/chemistry/metabolism EDAT- 2012/01/31 06:00 MHDA- 2012/07/24 06:00 CRDT- 2012/01/31 06:00 PHST- 2012/01/31 06:00 [entrez] PHST- 2012/01/31 06:00 [pubmed] PHST- 2012/07/24 06:00 [medline] AID - 10.1021/ac202980z [doi] PST - ppublish SO - Anal Chem. 2012 Mar 20;84(6):3017-25. doi: 10.1021/ac202980z. Epub 2012 Feb 28. PMID- 23198912 OWN - NLM STAT- MEDLINE DCOM- 20130930 LR - 20220409 IS - 1937-335X (Electronic) IS - 1937-3341 (Linking) VI - 19 IP - 9-10 DP - 2013 May TI - Local administration of low-dose simvastatin-conjugated gelatin hydrogel for tendon-bone healing in anterior cruciate ligament reconstruction. PG - 1233-43 LID - 10.1089/ten.TEA.2012.0325 [doi] AB - Anterior cruciate ligament (ACL) reconstruction with the hamstring tendon graft takes a long time, as the tendon graft needs to heal at the site of the bone-tendon integration in the created bone tunnels. Several reports have shown the therapeutic effects of simvastatin on bone formation with neovascularization. The aim of this study was to test the hypothesis that enhanced angiogenesis and osteogenesis by locally applied simvastatin promotes tendon-bone healing after ACL reconstruction. Rabbits received ACL reconstruction with hamstring tendon graft and were implanted with either simvastatin-conjugated gelatin hydrogel or gelatin hydrogel alone in their bone tunnels, and then bone regeneration and neovascularization at tendon-bone interface and biomechanical properties were assessed. Histological analysis at week 2 demonstrated that tendon-bone healing was significantly greater with angiogenesis and osteogenesis in the simvastatin-treated group than in the control group. Computed tomography at weeks 2 and 4 showed a significantly smaller tibial bone tunnel in the simvastatin-treated group. Biomechanical testing at week 2 demonstrated a significant increase in ultimate failure load in the simvastatin-treated group. This study suggested that local administration of low-dose simvastatin-conjugated gelatin hydrogel promotes the tendon-bone healing via its effect on both angiogenesis and osteogenesis at an early phase in a rabbit model, but does not affect biomechanical property in long-term after ACL reconstruction. FAU - Oka, Shinya AU - Oka S AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe- city 650-0017, Japan. FAU - Matsumoto, Tomoyuki AU - Matsumoto T FAU - Kubo, Seiji AU - Kubo S FAU - Matsushita, Takehiko AU - Matsushita T FAU - Sasaki, Hiroshi AU - Sasaki H FAU - Nishizawa, Yuichiro AU - Nishizawa Y FAU - Matsuzaki, Tokio AU - Matsuzaki T FAU - Saito, Takashi AU - Saito T FAU - Nishida, Kotaro AU - Nishida K FAU - Tabata, Yasuhiko AU - Tabata Y FAU - Kurosaka, Masahiro AU - Kurosaka M FAU - Kuroda, Ryosuke AU - Kuroda R LA - eng PT - Journal Article DEP - 20130114 PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 9000-70-8 (Gelatin) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Animals MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Gelatin/*chemistry MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry MH - Rabbits MH - Simvastatin/*chemistry/*therapeutic use MH - Tendons/*cytology/drug effects/surgery MH - Wound Healing/drug effects EDAT- 2012/12/04 06:00 MHDA- 2013/10/01 06:00 CRDT- 2012/12/04 06:00 PHST- 2012/12/04 06:00 [entrez] PHST- 2012/12/04 06:00 [pubmed] PHST- 2013/10/01 06:00 [medline] AID - 10.1089/ten.TEA.2012.0325 [doi] PST - ppublish SO - Tissue Eng Part A. 2013 May;19(9-10):1233-43. doi: 10.1089/ten.TEA.2012.0325. Epub 2013 Jan 14. PMID- 1260004 OWN - NLM STAT- MEDLINE DCOM- 19760706 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 427 IP - 1 DP - 1976 Mar 18 TI - The interaction of collagen with alpha1-acid glycoprotein. PG - 302-14 AB - The influence of alpha1-acid glycoprotein on the formation of fibrous long spacing fibers of collagen has been investigated. It was observed that addition of the glycoprotein to dialyzed collagen solutions caused a significant decrease in the intensity of the circular dichroic spectrum of collagen. This phenomenon, which displays an optimum with respect to glycoprotein, is consistent with previous observations of fibrous long spacing fiber formation. Changes in viscosity of collagen initially dissolved in acetic acid were monitored during dialysis. It was found that a significant increase in viscosity must occur during dialysis of collagen before fibrous long spacing formation could take place. This increase in viscosity can be related directly to removal of acetic acid from the collagen solution. Removal of all sialyl residues from the alpha1-acid glycoprotein with neuraminidase prevents fibrous long spacing formation while removal of up to 35% of the sialyl residues has no effect on the interaction of glycoprotein with collagen. Amino acid composition and radioactivity studies suggest that 45-55% of the insoluble fibrous long spacing fibers is glycoprotein. In contrast to native collagen fibers, reduced fibrous long spacing fibers do not contain histidinohydroxymerodesmosine or hydroxylysinonorleucine. Instead, they contain significant quantities of allysine aldol and epsilon-hydroxynorleucine. FAU - Franzblau, C AU - Franzblau C FAU - Schmid, K AU - Schmid K FAU - Faris, B AU - Faris B FAU - Beldekas, J AU - Beldekas J FAU - Garvin, P AU - Garvin P FAU - Kagan, H M AU - Kagan HM FAU - Baum, B J AU - Baum BJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Amino Acids) RN - 0 (Glycoproteins) RN - 0 (Hexosamines) RN - 0 (Macromolecular Substances) RN - 0 (Sialic Acids) RN - 9007-34-5 (Collagen) SB - IM MH - Amino Acids/analysis MH - Animals MH - Binding Sites MH - Circular Dichroism MH - *Collagen MH - *Glycoproteins/blood MH - Hexosamines/analysis MH - Humans MH - Macromolecular Substances MH - Microscopy, Electron MH - Protein Binding MH - Protein Conformation MH - Rats MH - Sialic Acids/analysis MH - Spectrophotometry, Ultraviolet MH - Structure-Activity Relationship MH - Tail MH - Tendons MH - Viscosity EDAT- 1976/03/18 00:00 MHDA- 1976/03/18 00:01 CRDT- 1976/03/18 00:00 PHST- 1976/03/18 00:00 [pubmed] PHST- 1976/03/18 00:01 [medline] PHST- 1976/03/18 00:00 [entrez] AID - 0005-2795(76)90306-8 [pii] AID - 10.1016/0005-2795(76)90306-8 [doi] PST - ppublish SO - Biochim Biophys Acta. 1976 Mar 18;427(1):302-14. doi: 10.1016/0005-2795(76)90306-8. PMID- 11309788 OWN - NLM STAT- MEDLINE DCOM- 20010830 LR - 20220331 IS - 0021-9304 (Print) IS - 0021-9304 (Linking) VI - 56 IP - 1 DP - 2001 Jul TI - Biocompatibility of NDGA-polymerized collagen fibers. I. Evaluation of cytotoxicity with tendon fibroblasts in vitro. PG - 31-9 AB - The material properties of tendon type I collagen fibers polymerized with nordihydroguaiaretic acid (NDGA) are equivalent to native tendon, suggesting that NDGA crosslinking may provide a viable approach to stabilizing collagenous materials for repairing ruptured, lacerated, or surgically transected fibrous tissues, such as tendon and ligament (Koob & Hernandez, Biomaterials, in press). Using standard cytotoxicity tests, the present study evaluated the biocompatibility of these fibers with cultured bovine tendon fibroblasts. Primary fibroblasts obtained from calf digital extensor tendons were exposed to NDGA, reaction products generated from the polymerization protocol, and the crosslinked fibers. NDGA was cytotoxic to these cells at concentrations above 100 microM. NDGA oxidation products were similarly cytotoxic. At concentrations below 100 microM, fibroblast viability was not affected by NDGA or its oxidation products. At these lower concentrations, fibroblast proliferation was unaffected compared to controls not exposed to NDGA. Fibers crosslinked with NDGA contained no unreacted NDGA, but they did contain soluble reaction products that were cytotoxic to tendon fibroblasts in both the elution and the direct contact tests. Washing the fibers in 70% ethanol and phosphate-buffered saline eliminated cytotoxicity of the fibers. Ethanol simultaneously sterilized the fibers. Tensile tests established that the ethanol/phosphate buffer wash did not adversely affect the material properties of the fibers. The results of these experiments indicate that NDGA-crosslinked fibers can be rendered nontoxic to tendon fibroblasts and may provide a novel approach for producing biologically based, biocompatible, tendon bioprostheses. FAU - Koob, T J AU - Koob TJ AD - Skeletal Biology Section, The Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospital for Children, 12502 North Pine Drive, Tampa, Florida 33612, USA. tkoob@shctampa.usf.edu FAU - Willis, T A AU - Willis TA FAU - Hernandez, D J AU - Hernandez DJ LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Biomed Mater Res JT - Journal of biomedical materials research JID - 0112726 RN - 0 (Biocompatible Materials) RN - 0 (Cross-Linking Reagents) RN - 0 (Polymers) RN - 3K9958V90M (Ethanol) RN - 7BO8G1BYQU (Masoprocol) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Animals, Newborn MH - Biocompatible Materials/*toxicity MH - Cattle MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/biosynthesis/chemical synthesis MH - Cross-Linking Reagents MH - Ethanol/*toxicity MH - Fibroblasts/cytology/*drug effects MH - Masoprocol/*pharmacology MH - Materials Testing MH - Polymers MH - Solubility MH - Tendons/*chemistry/*cytology/surgery EDAT- 2001/04/20 10:00 MHDA- 2001/08/31 10:01 CRDT- 2001/04/20 10:00 PHST- 2001/04/20 10:00 [pubmed] PHST- 2001/08/31 10:01 [medline] PHST- 2001/04/20 10:00 [entrez] AID - 10.1002/1097-4636(200107)56:1<31::AID-JBM1065>3.0.CO;2-N [pii] AID - 10.1002/1097-4636(200107)56:1<31::aid-jbm1065>3.0.co;2-n [doi] PST - ppublish SO - J Biomed Mater Res. 2001 Jul;56(1):31-9. doi: 10.1002/1097-4636(200107)56:1<31::aid-jbm1065>3.0.co;2-n. PMID- 33843069 OWN - NLM STAT- MEDLINE DCOM- 20210524 LR - 20210524 IS - 1749-6632 (Electronic) IS - 0077-8923 (Linking) VI - 1490 IP - 1 DP - 2021 Apr TI - Mitochondrial dysfunction and potential mitochondrial protectant treatments in tendinopathy. PG - 29-41 LID - 10.1111/nyas.14599 [doi] AB - Tendinopathy is a common musculoskeletal condition that affects a wide range of patients, including athletes, laborers, and older patients. Tendinopathy is often characterized by pain, swelling, and impaired performance and function. The etiology of tendinopathy is multifactorial, including both intrinsic and extrinsic mechanisms. Various treatment strategies have been described, but outcomes are often variable, as tendons have poor intrinsic healing potential compared with other tissues. Therefore, several novel targets for tendon regeneration have been identified and are being explored. Mitochondria are organelles that generate adenosine triphosphate, and they are considered to be the power generators of the cell. Recently, mitochondrial dysfunction verified by increased reactive oxygen species (ROS), decreased superoxide dismutase activity, cristae disorganization, and decreased number of mitochondria has been identified as a mechanism that may contribute to tendinopathy. This has provided new insights for studying tendinopathy pathogenesis and potential treatments via antioxidant, metabolic modulation, or ROS inhibition. In this review, we present the current understanding of mitochondrial dysfunction in tendinopathy. The review summarizes the potential mechanism by which mitochondrial dysfunction contributes to the development of tendinopathy, as well as the potential therapeutic benefits of mitochondrial protectants in the treatment of tendinopathy. CI - © 2021 New York Academy of Sciences. FAU - Zhang, Xueying AU - Zhang X AUID- ORCID: 0000-0001-7674-0273 AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York. AD - Department of Sports Medicine & Research Center of Sports Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. FAU - Eliasberg, Claire D AU - Eliasberg CD AUID- ORCID: 0000-0002-4298-5755 AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York. FAU - Rodeo, Scott A AU - Rodeo SA AUID- ORCID: 0000-0002-0745-9880 AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York. LA - eng PT - Journal Article PT - Review DEP - 20210411 PL - United States TA - Ann N Y Acad Sci JT - Annals of the New York Academy of Sciences JID - 7506858 RN - 0 (5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione) RN - 0 (Antioxidants) RN - 0 (Heterocyclic Compounds, 1-Ring) RN - 0 (Oligopeptides) RN - 0 (Reactive Oxygen Species) RN - 0 (Thiones) RN - 0 (arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide) RN - 1094-61-7 (Nicotinamide Mononucleotide) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Adenosine Triphosphate/biosynthesis MH - Animals MH - Antioxidants/therapeutic use MH - Apoptosis/physiology MH - Disease Models, Animal MH - Heterocyclic Compounds, 1-Ring/therapeutic use MH - Humans MH - Mice MH - Mitochondria/*drug effects/*pathology MH - Nicotinamide Mononucleotide/therapeutic use MH - Oligopeptides/therapeutic use MH - Reactive Oxygen Species/metabolism MH - Superoxide Dismutase/metabolism MH - Tendinopathy/*drug therapy/*pathology MH - Tendons/*pathology MH - Thiones/therapeutic use OTO - NOTNLM OT - ROS OT - mitochondria OT - mitochondrial protectants OT - tendinopathy EDAT- 2021/04/13 06:00 MHDA- 2021/05/25 06:00 CRDT- 2021/04/12 06:35 PHST- 2021/03/08 00:00 [revised] PHST- 2020/10/13 00:00 [received] PHST- 2021/03/15 00:00 [accepted] PHST- 2021/04/13 06:00 [pubmed] PHST- 2021/05/25 06:00 [medline] PHST- 2021/04/12 06:35 [entrez] AID - 10.1111/nyas.14599 [doi] PST - ppublish SO - Ann N Y Acad Sci. 2021 Apr;1490(1):29-41. doi: 10.1111/nyas.14599. Epub 2021 Apr 11. PMID- 25860819 OWN - NLM STAT- MEDLINE DCOM- 20160706 LR - 20190114 IS - 1573-2665 (Electronic) IS - 0141-8955 (Linking) VI - 38 IP - 5 DP - 2015 Sep TI - Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria. PG - 791-6 LID - 10.1007/s10545-015-9844-6 [doi] AB - Alkaptonuria (AKU) is caused by deficiency of the enzyme homogentisate 1,2 dioxygenase. It results in an accumulation of homogentisate which oxidizes spontaneously to benzoquinone acetate, a highly oxidant compound, which polymerises to a melanin-like structure, in a process called ochronosis. Asymptomatic during childhood, this accumulation will lead from the second decade of life to a progressive and severe spondylo-arthopathy, associated with multisystem involvement: osteoporosis/fractures, stones (renal, prostatic, gall bladder, salivary glands), ruptures of tendons/muscle/ligaments, renal failure and aortic valve disease. The pathophysiological mechanisms of AKU remain poorly understood, but recent advances lead us to reconsider the treatment strategy in AKU patients. Besides the supporting therapies (pain killers, anti-inflammatory drugs, physiotherapy, joints replacements and others), specific therapies have been considered (anti-oxidant, low protein diet, nitisinone), but clinical studies have failed to prove efficiency on the rheumatological lesions of the disease. Here we propose a treatment strategy for children and adults with AKU, based on a review of the latest findings on AKU and lessons from other aminoacipathies, especially tyrosinemias. FAU - Arnoux, Jean-Baptiste AU - Arnoux JB AD - Reference Centre for Inherited Metabolic Diseases Necker-Enfants Malades Hospital, Assistance Publique - Hôpitaux de Paris, 149 rue de Sèvres, Paris, 75015, France, jean-baptiste.arnoux@nck.aphp.fr. FAU - Le Quan Sang, Kim-Hanh AU - Le Quan Sang KH FAU - Brassier, Anais AU - Brassier A FAU - Grisel, Coraline AU - Grisel C FAU - Servais, Aude AU - Servais A FAU - Wippf, Julien AU - Wippf J FAU - Dubois, Sandrine AU - Dubois S FAU - Sireau, Nicolas AU - Sireau N FAU - Job-Deslandre, Chantal AU - Job-Deslandre C FAU - Ranganath, Lakshminarayan AU - Ranganath L FAU - de Lonlay, Pascale AU - de Lonlay P LA - eng PT - Journal Article PT - Review DEP - 20150410 PL - United States TA - J Inherit Metab Dis JT - Journal of inherited metabolic disease JID - 7910918 RN - 0 (Antioxidants) RN - 0 (Cyclohexanones) RN - 0 (Nitrobenzoates) RN - 42HK56048U (Tyrosine) RN - 47E5O17Y3R (Phenylalanine) RN - K5BN214699 (nitisinone) SB - IM MH - Adult MH - Age Factors MH - Alkaptonuria/diet therapy/*drug therapy/epidemiology MH - Antioxidants/therapeutic use MH - Child MH - Cyclohexanones/therapeutic use MH - Humans MH - Nitrobenzoates/therapeutic use MH - Ochronosis/diet therapy/drug therapy/epidemiology MH - Phenylalanine/administration & dosage MH - Tyrosine/administration & dosage EDAT- 2015/04/11 06:00 MHDA- 2016/07/07 06:00 CRDT- 2015/04/11 06:00 PHST- 2014/11/28 00:00 [received] PHST- 2015/03/18 00:00 [accepted] PHST- 2015/03/06 00:00 [revised] PHST- 2015/04/11 06:00 [entrez] PHST- 2015/04/11 06:00 [pubmed] PHST- 2016/07/07 06:00 [medline] AID - 10.1007/s10545-015-9844-6 [doi] PST - ppublish SO - J Inherit Metab Dis. 2015 Sep;38(5):791-6. doi: 10.1007/s10545-015-9844-6. Epub 2015 Apr 10. PMID- 12395913 OWN - NLM STAT- MEDLINE DCOM- 20030424 LR - 20161124 IS - 0251-1649 (Print) IS - 0251-1649 (Linking) VI - 22 IP - 1 DP - 2002 TI - Changes in size of periarthritis calcifications in patients with painful shoulder treated with injectable disodium-clodronate. PG - 7-12 AB - Calcific periarticular disease is characterized by the deposition of calcium phosphate crystals in many tendons and particularly in the rotator cuff tendons. Calcifications of any size may be accompanied by painful shoulder syndrome and tendon tears. Ecographic assessment of changes in the size of calcifications may be a marker of tissue changes in evolving shoulder periarthropathies. The aim of this study was to compare variations in pain and ultrasound dimensions in the calcifications in the tendons of the rotator cuff in patients treated with disodium-clodronate compared with those treated with paracetamol and nimesulide. In all groups, pain reduction occurred over a 6-month period, but was significantly greater in patients administered disodium-clodronate than in those administered nimesulide or paracetamol. A significant reduction in the size of calcifications was also observed in all three groups, but this reduction was more marked in the disodium-clodronate group. FAU - Monteforte, P AU - Monteforte P AD - Istituto Bruzzone, Rheumatology Medical School, Department of Endocrinological and Metabolic Diseases, University of Genoa, Italy. FAU - Rovetta, G AU - Rovetta G LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PL - Switzerland TA - Int J Clin Pharmacol Res JT - International journal of clinical pharmacology research JID - 8110183 RN - 0 (Analgesics, Non-Narcotic) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Sulfonamides) RN - 0813BZ6866 (Clodronic Acid) RN - 362O9ITL9D (Acetaminophen) RN - V4TKW1454M (nimesulide) SB - IM MH - Acetaminophen/therapeutic use MH - Analgesics, Non-Narcotic/therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Calcinosis/complications/diagnostic imaging/*drug therapy MH - Clodronic Acid/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pain/*drug therapy/etiology MH - Periarthritis/complications/diagnostic imaging/*drug therapy MH - Shoulder Joint/*diagnostic imaging MH - Sulfonamides/therapeutic use MH - Syndrome MH - Tendons/diagnostic imaging MH - Tissue Adhesions/complications/diagnostic imaging/drug therapy MH - Treatment Outcome MH - Ultrasonography EDAT- 2002/10/25 04:00 MHDA- 2003/04/25 05:00 CRDT- 2002/10/25 04:00 PHST- 2002/10/25 04:00 [pubmed] PHST- 2003/04/25 05:00 [medline] PHST- 2002/10/25 04:00 [entrez] PST - ppublish SO - Int J Clin Pharmacol Res. 2002;22(1):7-12. PMID- 37916332 OWN - NLM STAT- MEDLINE DCOM- 20231103 LR - 20251218 IS - 2284-0729 (Electronic) IS - 1128-3602 (Linking) VI - 27 IP - 20 DP - 2023 Oct TI - Curcumin nanoparticles and the therapeutic potential of curcumin for musculoskeletal disorders. PG - 9680-9702 LID - 34139 [pii] LID - 10.26355/eurrev_202310_34139 [doi] AB - Musculoskeletal disorders (MSD) are a collection of degenerative conditions impacting the body's bones, joints, muscles, tendons, ligaments, and nerves. MSDs affect approximately 1.71 billion individuals worldwide and are a significant cause of disability. Curcumin is a polyphenolic compound with anti-inflammatory, antioxidant, and antitumor properties. In this review, we will discuss the research progress of structural analogs, derivatives, and nanomaterials that can improve the bioavailability of this natural drug. Curcumin may potentially retard the progression of osteoporosis, osteoarthritis, and rheumatoid arthritis. These effects may be related to curcumin's targeting of multiple signalling pathways. FAU - Wu, H-Y AU - Wu HY AD - Department of Joint Surgery, The 940th Hospital of Joint Logistics Support Force of The Chinese People's Liberation Army, Lanzhou, Gansu, China. zhanghaoqiang_fmmu@163.com. FAU - Yu, H-T AU - Yu HT FAU - Kang, B AU - Kang B FAU - Xuan, Y-Y AU - Xuan YY FAU - Zhang, H-Q AU - Zhang HQ FAU - Li, X-S AU - Li XS LA - eng PT - Journal Article PT - Review PL - Italy TA - Eur Rev Med Pharmacol Sci JT - European review for medical and pharmacological sciences JID - 9717360 RN - IT942ZTH98 (Curcumin) RN - 0 (Anti-Inflammatory Agents) SB - IM MH - Humans MH - *Curcumin/therapeutic use/chemistry MH - *Musculoskeletal Diseases/drug therapy MH - Anti-Inflammatory Agents/therapeutic use MH - *Osteoarthritis/drug therapy MH - *Nanoparticles EDAT- 2023/11/02 06:42 MHDA- 2023/11/03 06:44 CRDT- 2023/11/02 04:43 PHST- 2023/11/03 06:44 [medline] PHST- 2023/11/02 06:42 [pubmed] PHST- 2023/11/02 04:43 [entrez] AID - 34139 [pii] AID - 10.26355/eurrev_202310_34139 [doi] PST - ppublish SO - Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):9680-9702. doi: 10.26355/eurrev_202310_34139. PMID- 3731582 OWN - NLM STAT- MEDLINE DCOM- 19860916 LR - 20131121 IS - 0147-958X (Print) IS - 0147-958X (Linking) VI - 9 IP - 2 DP - 1986 TI - Tendon xanthomas associated with cholestanolosis and hyperapobetalipoproteinemia. PG - 94-9 AB - Large Achilles tendon xanthomas of the type found in severe familial hypercholesterolemia were the first manifestation of cholestanolosis (cerebrotendinous xanthomatosis) in our patient, an otherwise asymptomatic normolipidemic 21-year-old woman. Extensive laboratory investigation disclosed the presence of hyperapobetalipoproteinemia which did not resolve with the administration of probucol. Immunofluorescent studies revealed marked accumulation of apolipoprotein B in a xanthoma excised from the tricipital area. This was in contrast to the spotty and weak fluorescence observed in a tuberous xanthoma, from the same anatomical area and histologically otherwise identical, obtained from a patient with heterozygous familial hypercholesterolemia. Hyperapobetalipoproteinemia has been reported before in association with sitosterolemia but not with cholestanolosis. We suggest that cholestanol, like sitosterol, may interfere with the normal uptake and degradation of low-density lipoproteins by peripheral cells. FAU - Lussier-Cacan, S AU - Lussier-Cacan S FAU - Cantin, M AU - Cantin M FAU - Roy, C C AU - Roy CC FAU - Sniderman, A D AU - Sniderman AD FAU - Nestruck, A C AU - Nestruck AC FAU - Davignon, J AU - Davignon J LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Canada TA - Clin Invest Med JT - Clinical and investigative medicine. Medecine clinique et experimentale JID - 7804071 RN - 0 (Apolipoproteins B) RN - 0 (Bile Acids and Salts) RN - 0 (Dietary Fats) RN - 0 (Lipoproteins) RN - 0 (Sterols) RN - 0 (Triglycerides) RN - 97C5T2UQ7J (Cholesterol) RN - P3CTH044XJ (Probucol) SB - IM MH - Adult MH - Apolipoproteins B/*blood MH - Bile/analysis MH - Bile Acids and Salts/analysis MH - Cholesterol/blood MH - Dietary Fats MH - Female MH - Humans MH - Hyperlipoproteinemias/blood/*complications/therapy MH - Lipoproteins/blood MH - Probucol/therapeutic use MH - Sterols/analysis MH - Tendons/*pathology MH - Triglycerides/blood MH - Xanthomatosis/blood/*complications/pathology EDAT- 1986/01/01 00:00 MHDA- 1986/01/01 00:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 1986/01/01 00:01 [medline] PHST- 1986/01/01 00:00 [entrez] PST - ppublish SO - Clin Invest Med. 1986;9(2):94-9. PMID- 12379534 OWN - NLM STAT- MEDLINE DCOM- 20021203 LR - 20250214 IS - 0003-4967 (Print) IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 61 IP - 11 DP - 2002 Nov TI - Ultrasonographic diagnosis of de Quervain's tenosynovitis. PG - 1034-5 FAU - Kamel, M AU - Kamel M AD - Al-Azhar University, Cairo, Egypt. mkamel56@hotmail.com FAU - Moghazy, K AU - Moghazy K FAU - Eid, H AU - Eid H FAU - Mansour, R AU - Mansour R LA - eng PT - Journal Article PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (Drug Combinations) RN - 1ZK20VI6TY (Triamcinolone) RN - 98PI200987 (Lidocaine) RN - A73MM2Q32P (triamcinolone diacetate) SB - IM MH - Drug Combinations MH - Humans MH - Injections, Intralesional MH - Lidocaine/therapeutic use MH - Prospective Studies MH - Tendons/diagnostic imaging MH - Tenosynovitis/*diagnostic imaging MH - Triamcinolone/*analogs & derivatives/therapeutic use MH - Ultrasonography PMC - PMC1753934 EDAT- 2002/10/16 04:00 MHDA- 2002/12/04 04:00 PMCR- 2005/11/01 CRDT- 2002/10/16 04:00 PHST- 2002/10/16 04:00 [pubmed] PHST- 2002/12/04 04:00 [medline] PHST- 2002/10/16 04:00 [entrez] PHST- 2005/11/01 00:00 [pmc-release] AID - S0003-4967(24)09201-X [pii] AID - 10.1136/ard.61.11.1034 [doi] PST - ppublish SO - Ann Rheum Dis. 2002 Nov;61(11):1034-5. doi: 10.1136/ard.61.11.1034. PMID- 7571861 OWN - NLM STAT- MEDLINE DCOM- 19951107 LR - 20190920 IS - 0044-3026 (Print) IS - 0044-3026 (Linking) VI - 201 IP - 1 DP - 1995 Jul TI - [B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities]. PG - 20-4 AB - In a comparative slaughter experiment the thiamin, vitamin B6 and pantothenic acid content of lean tissue of foreloin of growing cattle was determined by whole body analyses. 54 bulls, 45 heifers and 45 steers were fed until a live mass of 200 kg, 350 kg, 425 kg (only heifers) 500 kg and 575 kg, 650 kg, respectively (only bulls and steers). One half of each carcass was divided into 13 cuts and afterwards the cuts were each divided into lean, adipose and bone tissue and tendons. The lean tissue of the foreloin was subjected to analysis of thiamin, vitamin B6 and pantothenic acid. The mean thiamin content of 0.75 mg kg-1 fresh matter (200 kg live mass) decreased with rising live mass and under intensive feeding conditions in bulls and steers to 0.53 mg and in heifers to 0.61 mg. Restrictively feeding caused a mean thiamin content of 0.60 mg per kg fresh matter in bulls, steers and heifers. Under both feeding conditions in the lean tissue of the foreloin on average a vitamin B6 content of 2.6 mg (bulls), 3.1 mg (heifers) and 3.0 mg kg-1 fresh matter (steers) was analysed. A mean content of pantothenic acid of 2.6 mg kg-1 fresh matter was determined in bulls independent of live mass and feeding intensity. In heifers the content of pantothenic acid on average was 3.0 mg under intensive feeding system and 2.6 mg under low feeding conditions, whereas steers reached contents of 2.7 mg (high feeding) and 2.2 mg kg-1 fresh matter (low feeding). FAU - Kirchgessner, M AU - Kirchgessner M AD - Institut für Ernährungsphysiologie, TU München, Freising-Weihenstephan, Germany. FAU - Roth-Maier, D A AU - Roth-Maier DA FAU - Heindl, U AU - Heindl U FAU - Schwarz, F J AU - Schwarz FJ LA - ger PT - Comparative Study PT - English Abstract PT - Journal Article TT - B-Vitamine (Thiamin, Vitamin B6 and Pantothensäure) im Muskelgewebe wachsender Rinder der Rasse Deutsches Fleckvieh in Abhängigkeit von Mastendmasse und Fütterungsintensität. PL - Germany TA - Z Lebensm Unters Forsch JT - Zeitschrift fur Lebensmittel-Untersuchung und -Forschung JID - 7509812 RN - 19F5HK2737 (Pantothenic Acid) RN - KV2JZ1BI6Z (Pyridoxine) RN - X66NSO3N35 (Thiamine) SB - IM MH - *Animal Feed MH - Animals MH - Cattle MH - Female MH - Growth MH - Male MH - Meat/*analysis MH - Muscle, Skeletal/*chemistry MH - Orchiectomy MH - Pantothenic Acid/*analysis MH - Pyridoxine/*analysis MH - Thiamine/*analysis EDAT- 1995/07/01 00:00 MHDA- 1995/07/01 00:01 CRDT- 1995/07/01 00:00 PHST- 1995/07/01 00:00 [pubmed] PHST- 1995/07/01 00:01 [medline] PHST- 1995/07/01 00:00 [entrez] AID - 10.1007/BF01193194 [doi] PST - ppublish SO - Z Lebensm Unters Forsch. 1995 Jul;201(1):20-4. doi: 10.1007/BF01193194. PMID- 2402652 OWN - NLM STAT- MEDLINE DCOM- 19901019 LR - 20190702 IS - 0038-4348 (Print) IS - 0038-4348 (Linking) VI - 83 IP - 9 DP - 1990 Sep TI - Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin. PG - 1053-7 AB - Plasma concentrations of total and low-density lipoprotein cholesterol are increased twofold to threefold in patients with heterozygous familial hypercholesterolemia. This sustained increase leads to accelerated rates of cholesterol deposition in the coronary arteries and to the development of tendon xanthomas. To assess whether hypolipidemic therapy with lovastatin, alone and in combination therapy with colestipol hydrochloride or nicotinic acid, results in regression of lipid deposits in the tendons of these patients, we have measured Achilles tendon diameters by xeroradiography before and after treatment. In 20 patients treated for a mean of 43 months (during which time plasma cholesterol concentrations decreased from 430 to 247 mg/dL), the diameter of both the left and right Achilles tendons measured at three different locations decreased by 0.55 to 1.5 mm. Larger reductions were seen in the tendons of seven of these patients who were treated for a mean of 64 months and whose mean concentrations of cholesterol fell from 488 to 279 mg/dL. We conclude that effective long-term hypolipidemic therapy leads to diminution in the size of Achilles tendon xanthomas in patients with heterozygous familial hypercholesterolemia and that such therapy is associated with mobilization of tissue stores of cholesterol in these patients. FAU - Illingworth, D R AU - Illingworth DR AD - Department of Medicine, Oregon Health Sciences University, Portland 97201-3098. FAU - Cope, R AU - Cope R FAU - Bacon, S P AU - Bacon SP LA - eng GR - HL32271/HL/NHLBI NIH HHS/United States GR - HL37940/HL/NHLBI NIH HHS/United States GR - RR334/RR/NCRR NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 RN - 0 (Cholesterol, LDL) RN - 2679MF687A (Niacin) RN - 9LHU78OQFD (Lovastatin) RN - K50N755924 (Colestipol) SB - IM MH - Achilles Tendon/diagnostic imaging/drug effects MH - Adult MH - Cholesterol, LDL/blood MH - Colestipol/therapeutic use MH - Drug Therapy, Combination MH - Female MH - Humans MH - Hyperlipoproteinemia Type II/*drug therapy MH - Lovastatin/*therapeutic use MH - Male MH - Middle Aged MH - Niacin/therapeutic use MH - Radiography MH - Remission Induction MH - Tendons/pathology MH - Wolman Disease/diagnostic imaging/*drug therapy EDAT- 1990/09/01 00:00 MHDA- 1990/09/01 00:01 CRDT- 1990/09/01 00:00 PHST- 1990/09/01 00:00 [pubmed] PHST- 1990/09/01 00:01 [medline] PHST- 1990/09/01 00:00 [entrez] AID - 10.1097/00007611-199009000-00019 [doi] PST - ppublish SO - South Med J. 1990 Sep;83(9):1053-7. doi: 10.1097/00007611-199009000-00019. PMID- 2912433 OWN - NLM STAT- MEDLINE DCOM- 19890222 LR - 20131121 IS - 0276-5047 (Print) IS - 0276-5047 (Linking) VI - 9 IP - 1 Suppl DP - 1989 Jan-Feb TI - Clinical features of familial hypercholesterolemia. PG - I66-74 AB - The clinical consequences of familial hypercholesterolemia (FH) result from its metabolic peculiarities that persist from very early childhood, leading to the accumulation of cholesterol in the form of xanthomas in skin and tendons and atheromatous lesions in the arterial wall, in particular, in the aorta and the stem of coronary arteries. Plasma cholesterol concentration markedly increases during the suckling period, soon attaining a level near 1000 mg/dl in homozygotes and 200 to 400 mg/dl in heterozygotes. By age 50, about 80% of FH males suffer from ischemic heart diseases, while only 20% to 30% of the females are moderately affected by coronary atherosclerosis. In addition to the low density lipoprotein (LDL) cholesterol level, higher triglyceride and lower high density lipoprotein (HDL) cholesterol levels correlate with an increased risk of ischemic heart diseases. A very important problem is that most of these patients do not feel themselves to be seriously ill until a severe myocardial infarction (often leading to sudden death) takes place during the third to fifth decades of life. Among the different types of receptor mutations, the incidence of ischemic heart diseases was much higher and more extensive among patients with the receptor-negative type than among those with the receptor-defective type with a residual receptor activity. FAU - Yamamoto, A AU - Yamamoto A AD - Department of Etiology, National Cardiovascular Center, Osaka, Japan. FAU - Kamiya, T AU - Kamiya T FAU - Yamamura, T AU - Yamamura T FAU - Yokoyama, S AU - Yokoyama S FAU - Horiguchi, Y AU - Horiguchi Y FAU - Funahashi, T AU - Funahashi T FAU - Kawaguchi, A AU - Kawaguchi A FAU - Miyake, Y AU - Miyake Y FAU - Beppu, S AU - Beppu S FAU - Ishikawa, K AU - Ishikawa K AU - et al. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arteriosclerosis JT - Arteriosclerosis (Dallas, Tex.) JID - 8401388 RN - 0 (Lipoproteins) RN - 0 (Receptors, LDL) RN - 11041-12-6 (Cholestyramine Resin) RN - 1UQM1K0W9X (mevastatin) RN - 97C5T2UQ7J (Cholesterol) RN - 9LHU78OQFD (Lovastatin) RN - P3CTH044XJ (Probucol) SB - IM MH - Age Factors MH - Angiography MH - Blood Coagulation MH - Blood Platelets/physiology MH - Cholesterol/blood MH - Cholestyramine Resin/therapeutic use MH - Echocardiography MH - Heterozygote MH - Homozygote MH - Humans MH - Hyperlipoproteinemia Type II/diagnosis/*physiopathology/therapy MH - Lipoproteins/blood MH - Lovastatin/analogs & derivatives/therapeutic use MH - Mutation MH - Plasmapheresis MH - Probucol/therapeutic use MH - Receptors, LDL/genetics MH - Xanthomatosis/complications EDAT- 1989/01/01 00:00 MHDA- 1989/01/01 00:01 CRDT- 1989/01/01 00:00 PHST- 1989/01/01 00:00 [pubmed] PHST- 1989/01/01 00:01 [medline] PHST- 1989/01/01 00:00 [entrez] PST - ppublish SO - Arteriosclerosis. 1989 Jan-Feb;9(1 Suppl):I66-74. PMID- 27932679 OWN - NLM STAT- MEDLINE DCOM- 20171220 LR - 20171220 IS - 1522-1601 (Electronic) IS - 0161-7567 (Linking) VI - 122 IP - 2 DP - 2017 Feb 1 TI - Tendon collagen synthesis declines with immobilization in elderly humans: no effect of anti-inflammatory medication. PG - 273-282 LID - 10.1152/japplphysiol.00809.2015 [doi] AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) are used as pain killers during periods of unloading caused by traumatic occurrences or diseases. However, it is unknown how tendon protein turnover and mechanical properties respond to unloading and subsequent reloading in elderly humans, and whether NSAID treatment would affect the tendon adaptations during such periods. Thus we studied human patellar tendon protein synthesis and mechanical properties during immobilization and subsequent rehabilitating resistance training and the influence of NSAIDs upon these parameters. Nineteen men (range 60-80 yr) were randomly assigned to NSAIDs (ibuprofen 1,200 mg/day; Ibu) or placebo (Plc). One lower limb was immobilized in a cast for 2 wk and retrained for 6 wk. Tendon collagen protein synthesis, mechanical properties, size, expression of genes related to collagen turnover and remodeling, and signal intensity (from magnetic resonance imaging) were investigated. Tendon collagen synthesis decreased (P < 0.001), whereas tendon mechanical properties and size were generally unchanged with immobilization, and NSAIDs did not influence this. Matrix metalloproteinase-2 mRNA tended to increase (P < 0.1) after immobilization in both groups, whereas scleraxis mRNA decreased with inactivity in the Plc group only (P < 0.05). In elderly human tendons, collagen protein synthesis decreased after 2 wk of immobilization, whereas tendon stiffness and modulus were only marginally reduced, and NSAIDs had no influence upon this. This indicates an importance of mechanical loading for maintenance of tendon collagen turnover. However, reduced collagen production induced by short-term unloading may only marginally affect tendon mechanical properties in elderly individuals. NEW & NOTEWORTHY: In elderly humans, 2 wk of inactivity reduces tendon collagen protein synthesis, while tendon stiffness and modulus are only marginally reduced, and NSAID treatment does not affect this. This indicates that mechanical loading is important for maintenance of tendon collagen turnover and that changes in collagen turnover induced by short-term immobilization may only have minor impact on the internal structures that are essential for mechanical properties in elderly tendons. CI - Copyright © 2017 the American Physiological Society. FAU - Dideriksen, Kasper AU - Dideriksen K AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; kasperjuel@hotmail.com. FAU - Boesen, Anders P AU - Boesen AP AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. FAU - Reitelseder, Søren AU - Reitelseder S AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. AD - Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; and. FAU - Couppé, Christian AU - Couppé C AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. AD - Department of Physical Therapy, Musculoskeletal Rehabilitation Research Unit, Bispebjerg Hospital, Denmark. FAU - Svensson, Rene AU - Svensson R AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. FAU - Schjerling, Peter AU - Schjerling P AUID- ORCID: 0000-0001-7138-3211 AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. FAU - Magnusson, S Peter AU - Magnusson SP AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. AD - Department of Physical Therapy, Musculoskeletal Rehabilitation Research Unit, Bispebjerg Hospital, Denmark. FAU - Holm, Lars AU - Holm L AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. AD - Institute of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; and. FAU - Kjaer, Michael AU - Kjaer M AD - Institute of Sports Medicine Copenhagen, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20161208 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (RNA, Messenger) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Collagen/*biosynthesis/*metabolism MH - Humans MH - Ibuprofen/therapeutic use MH - Immobilization/methods MH - Lower Extremity/physiopathology MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Protein Biosynthesis/*drug effects MH - RNA, Messenger/metabolism MH - Resistance Training/methods MH - Tendons/*drug effects/*metabolism OTO - NOTNLM OT - ibuprofen OT - scleraxis OT - tendon mechanical properties OT - tendon reloading OT - tendon unloading EDAT- 2016/12/10 06:00 MHDA- 2017/12/21 06:00 CRDT- 2016/12/10 06:00 PHST- 2015/09/24 00:00 [received] PHST- 2016/11/23 00:00 [revised] PHST- 2016/12/01 00:00 [accepted] PHST- 2016/12/10 06:00 [pubmed] PHST- 2017/12/21 06:00 [medline] PHST- 2016/12/10 06:00 [entrez] AID - japplphysiol.00809.2015 [pii] AID - 10.1152/japplphysiol.00809.2015 [doi] PST - ppublish SO - J Appl Physiol (1985). 2017 Feb 1;122(2):273-282. doi: 10.1152/japplphysiol.00809.2015. Epub 2016 Dec 8. PMID- 4472297 OWN - NLM STAT- MEDLINE DCOM- 19741219 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 59 IP - 3 DP - 1974 Aug 5 TI - Secretion of procollagen: evidence for the transfer of nascent polypeptides across microsomal membranes of tendon cells. PG - 947-54 FAU - Harwood, R AU - Harwood R FAU - Grant, M E AU - Grant ME FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Carbon Radioisotopes) RN - 0 (Peptides) RN - 4A6ZS6Q2CL (Puromycin) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 3.1.- (Ribonucleases) RN - EC 3.4.21.1 (Chymotrypsin) RN - EC 3.4.21.4 (Trypsin) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Biological Transport MH - Carbon Radioisotopes MH - Chick Embryo MH - Chromatography, Gel MH - Chymotrypsin MH - Collagen/*biosynthesis/metabolism MH - Hydroxyproline/metabolism MH - Isotope Labeling MH - Microsomes/drug effects/*metabolism MH - Pancreas/enzymology MH - Peptide Biosynthesis MH - Peptides/*metabolism MH - Proline/metabolism MH - Puromycin/pharmacology MH - Ribonucleases MH - Ribosomes/drug effects/metabolism MH - Tendons/cytology/drug effects/*metabolism MH - Time Factors MH - Trypsin MH - Ultracentrifugation EDAT- 1974/08/05 00:00 MHDA- 1974/08/05 00:01 CRDT- 1974/08/05 00:00 PHST- 1974/08/05 00:00 [pubmed] PHST- 1974/08/05 00:01 [medline] PHST- 1974/08/05 00:00 [entrez] AID - S0006-291X(74)80071-9 [pii] AID - 10.1016/s0006-291x(74)80071-9 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1974 Aug 5;59(3):947-54. doi: 10.1016/s0006-291x(74)80071-9. PMID- 16403491 OWN - NLM STAT- MEDLINE DCOM- 20061101 LR - 20131121 IS - 1569-1993 (Print) IS - 1569-1993 (Linking) VI - 5 IP - 2 DP - 2006 May TI - The systemic inflammatory response to exercise in adults with cystic fibrosis. PG - 105-12 AB - Exercise is associated with release of inflammatory mediators in the circulation and there is evidence that the exercising muscles and tendons are sources of interleukin-6. Due to the catabolic effects of some cytokines, increased release in circulation might contribute to alterations in body composition in adults with cystic fibrosis. We hypothesised that exercise of moderate intensity would generate increased blood concentrations of some inflammatory mediators. We investigated the change in blood concentrations of interleukin-6, tumour necrosis factor alpha and their soluble receptors after a structured exercise (box stepping) of intensity similar to that encountered during activities of daily living in 12 adults with cystic fibrosis and mean (95% confidence interval) FEV1 55.6 (44.4, 66.8)% predicted, body mass index 23.0 (21.3, 24.6) kg/m2 and 12 healthy subjects. The increments post-exercise for all inflammatory mediators and lactate corrected for the work performed until voluntary exhaustion were greater for patients, while the total work was less for patients (all p<0.01). Daytime variability of the inflammatory mediators was assessed in eight patients and was less than the change due to exercise. We report greater increments in circulating concentrations of some cytokines with moderate exercise in adults with cystic fibrosis compared to healthy subjects. FAU - Ionescu, Alina A AU - Ionescu AA AD - Respiratory Medicine, Cardiff University, Academic Centre, Llandough Hospital, Cardiff, CF64 2XX, United Kingdom. ionescuaa@cardiff.ac.uk FAU - Mickleborough, Timothy D AU - Mickleborough TD FAU - Bolton, Charlotte E AU - Bolton CE FAU - Lindley, Martin R AU - Lindley MR FAU - Nixon, Lisette S AU - Nixon LS FAU - Dunseath, Gareth AU - Dunseath G FAU - Luzio, Steve AU - Luzio S FAU - Owens, David R AU - Owens DR FAU - Shale, Dennis J AU - Shale DJ LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060103 PL - Netherlands TA - J Cyst Fibros JT - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society JID - 101128966 RN - 0 (IL6R protein, human) RN - 0 (Interleukin-6) RN - 0 (Receptors, Interleukin-6) RN - 0 (Receptors, Tumor Necrosis Factor) RN - 0 (Tumor Necrosis Factor-alpha) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Adult MH - Anaerobic Threshold MH - Cystic Fibrosis/*blood/physiopathology MH - Exercise/*physiology MH - Female MH - Forced Expiratory Volume MH - Humans MH - Inflammation/*blood/physiopathology MH - Interleukin-6/blood MH - Lactic Acid/blood MH - Male MH - Oxygen Consumption MH - Receptors, Interleukin-6/blood MH - Receptors, Tumor Necrosis Factor/blood MH - Tumor Necrosis Factor-alpha/metabolism EDAT- 2006/01/13 09:00 MHDA- 2006/11/02 09:00 CRDT- 2006/01/13 09:00 PHST- 2005/08/03 00:00 [received] PHST- 2005/11/27 00:00 [revised] PHST- 2005/11/28 00:00 [accepted] PHST- 2006/01/13 09:00 [pubmed] PHST- 2006/11/02 09:00 [medline] PHST- 2006/01/13 09:00 [entrez] AID - S1569-1993(05)00162-1 [pii] AID - 10.1016/j.jcf.2005.11.006 [doi] PST - ppublish SO - J Cyst Fibros. 2006 May;5(2):105-12. doi: 10.1016/j.jcf.2005.11.006. Epub 2006 Jan 3. PMID- 11309789 OWN - NLM STAT- MEDLINE DCOM- 20010830 LR - 20191210 IS - 0021-9304 (Print) IS - 0021-9304 (Linking) VI - 56 IP - 1 DP - 2001 Jul TI - Biocompatibility of NDGA-polymerized collagen fibers. II. Attachment, proliferation, and migration of tendon fibroblasts in vitro. PG - 40-8 AB - The material properties of collagen fibers polymerized with nordihydroguaiaretic acid (NDGA) are equivalent to native tendon, suggesting that NDGA crosslinking may provide a viable approach to stabilizing collagenous materials for use in repairing ruptured, lacerated, or surgically transected fibrous tissues, such as tendons and ligaments (Koob & Hernandez, Biomaterials, in press). The present study evaluated the biocompatibility of these fibers with cultured bovine tendon fibroblasts. Fibroblast attachment, migration, and proliferation on NDGA-crosslinked materials were compared to those on prepolymerized type I tendon collagen constructs as well as on tissue-culture-treated plastic. Fibroblast attachment on NDGA-crosslinked collagen fibrils was equivalent to attachment on plates coated with collagen alone. Over a period of 8 days in culture, attached fibroblasts proliferated on NDGA-crosslinked collagen at a rate identical to that of fibroblasts attached to native collagen. In order for the biomaterial effectively to bridge gaps in fibrous tissues, fibroblasts must be able to migrate and replicate on the bridging fiber. Control and crosslinked fibers were inserted in calf tendon explants, with a portion of the fiber extending out of the sectioned end of the tendon. Explants were cultured for 9 weeks, and the number of cells was measured at weekly intervals. Cells appeared on the fibers after 1 week of culture. By 2 weeks, cells had colonized the entire fiber. The number of cells continued to increase throughout the 9 weeks in culture, forming a layer several cells thick. Histologic analysis indicated that the fibroblasts populating the fibers appeared to originate in the epitenon. There was no difference in the rate of fibroblast migration and replication, nor in the ultimate number of colonizing cells, between control collagen fibers and NDGA-crosslinked fibers. NDGA-crosslinked fibers may provide a means of bridging gaps in ruptured, lacerated, or surgically transected tendons by providing a mechanically competent scaffold on which tendon fibroblasts can migrate, attach, and proliferate. FAU - Koob, T J AU - Koob TJ AD - Skeletal Biology Section, The Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospital for Children, Tampa, Florida 33612, USA. tkoob@shctampa.usf.edu FAU - Willis, T A AU - Willis TA FAU - Qiu, Y S AU - Qiu YS FAU - Hernandez, D J AU - Hernandez DJ LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Biomed Mater Res JT - Journal of biomedical materials research JID - 0112726 RN - 0 (Biocompatible Materials) RN - 0 (Coated Materials, Biocompatible) RN - 0 (Cross-Linking Reagents) RN - 0 (Methylmethacrylates) RN - 0 (Plastics) RN - 0 (Polymers) RN - 25249-16-5 (Polyhydroxyethyl Methacrylate) RN - 26355-01-1 (HTR composite) RN - 7BO8G1BYQU (Masoprocol) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Animals, Newborn MH - Biocompatible Materials/*toxicity MH - Cattle MH - Cell Adhesion/physiology MH - Cell Count MH - Cell Division/physiology MH - Cell Movement/physiology MH - Coated Materials, Biocompatible/*toxicity MH - Collagen/*analysis/biosynthesis/chemical synthesis/chemistry MH - Cross-Linking Reagents MH - Fibroblasts/cytology/physiology MH - Masoprocol/*toxicity MH - Materials Testing MH - Methylmethacrylates/*metabolism MH - Plastics/*analysis/chemistry MH - Polyhydroxyethyl Methacrylate/*metabolism MH - Polymers MH - Surface Properties MH - Tendons/*anatomy & histology/growth & development EDAT- 2001/04/20 10:00 MHDA- 2001/08/31 10:01 CRDT- 2001/04/20 10:00 PHST- 2001/04/20 10:00 [pubmed] PHST- 2001/08/31 10:01 [medline] PHST- 2001/04/20 10:00 [entrez] AID - 10.1002/1097-4636(200107)56:1<40::AID-JBM1066>3.0.CO;2-I [pii] AID - 10.1002/1097-4636(200107)56:1<40::aid-jbm1066>3.0.co;2-i [doi] PST - ppublish SO - J Biomed Mater Res. 2001 Jul;56(1):40-8. doi: 10.1002/1097-4636(200107)56:1<40::aid-jbm1066>3.0.co;2-i. PMID- 4045157 OWN - NLM STAT- MEDLINE DCOM- 19851112 LR - 20190829 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 10 IP - 5 DP - 1985 Sep TI - Candida albicans tenosynovitis of the hand. PG - 719-22 AB - Invasive fungal infections of the hand are extremely rare and usually require an immunocompromised host. We report the first known case of Candida albicans tenosynovitis of the hand presenting as a mass in a boy with Buckley's immunodeficiency. Treatment was successful after radical synovectomy of both the flexor and extensor aspects of the hand after he failed to respond to combined amphotericin B and 5-fluorouracil therapy. Fungal tenosynovitis should be considered when swelling and decreased range of motion occur in the hands or digits of an immunocompromised host, especially if pain is not a prominent symptom. FAU - Yuan, R T AU - Yuan RT FAU - Cohen, M J AU - Cohen MJ LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 7XU7A7DROE (Amphotericin B) RN - U3P01618RT (Fluorouracil) SB - IM MH - Amphotericin B/therapeutic use MH - Candidiasis/*complications/drug therapy MH - Child MH - Fluorouracil/therapeutic use MH - *Hand/microbiology/surgery MH - Humans MH - Hypergammaglobulinemia/complications MH - Male MH - Tendons/surgery MH - Tenosynovitis/drug therapy/*etiology/surgery EDAT- 1985/09/01 00:00 MHDA- 1985/09/01 00:01 CRDT- 1985/09/01 00:00 PHST- 1985/09/01 00:00 [pubmed] PHST- 1985/09/01 00:01 [medline] PHST- 1985/09/01 00:00 [entrez] AID - S0363-5023(85)80217-3 [pii] AID - 10.1016/s0363-5023(85)80217-3 [doi] PST - ppublish SO - J Hand Surg Am. 1985 Sep;10(5):719-22. doi: 10.1016/s0363-5023(85)80217-3. PMID- 3706871 OWN - NLM STAT- MEDLINE DCOM- 19860620 LR - 20190717 IS - 0196-0644 (Print) IS - 0196-0644 (Linking) VI - 15 IP - 6 DP - 1986 Jun TI - Calcific tendinitis of the flexors of the forefoot. PG - 751-3 AB - We report a case of calcific tendinitis in the flexor tendons of the forefoot. A 33-year-old woman presented with a two-day history of foot pain but she recalled no direct trauma to the foot. Physical examination revealed redness, warmth, and tenderness on the plantar surface of the foot near the head of the first metatarsal. Radiographs showed a small focus of calcification in the flexor tendons of the great toe, diagnostic of calcific tendinitis. The patient was treated with supportive therapy and recovered. FAU - Rhodes, R A AU - Rhodes RA FAU - Stelling, C B AU - Stelling CB LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Ann Emerg Med JT - Annals of emergency medicine JID - 8002646 RN - RA33EAC7KY (Fenoprofen) SB - IM MH - Adult MH - Female MH - Fenoprofen/therapeutic use MH - Foot MH - Humans MH - Radiography MH - Tendinopathy/*diagnostic imaging/drug therapy/physiopathology EDAT- 1986/06/01 00:00 MHDA- 1986/06/01 00:01 CRDT- 1986/06/01 00:00 PHST- 1986/06/01 00:00 [pubmed] PHST- 1986/06/01 00:01 [medline] PHST- 1986/06/01 00:00 [entrez] AID - S0196-0644(86)80444-9 [pii] AID - 10.1016/s0196-0644(86)80444-9 [doi] PST - ppublish SO - Ann Emerg Med. 1986 Jun;15(6):751-3. doi: 10.1016/s0196-0644(86)80444-9. PMID- 12835894 OWN - NLM STAT- MEDLINE DCOM- 20040319 LR - 20131121 IS - 1023-3830 (Print) IS - 1023-3830 (Linking) VI - 52 IP - 6 DP - 2003 Jun TI - Addition of nitric oxide via nitroflurbiprofen enhances the material properties of early healing of young rat Achilles tendons. PG - 230-7 AB - OBJECTIVE AND DESIGN: To determine if the addition of nitric oxide (NO) via nitroflurbiprofen (NO-flurbiprofen) would enhance rat Achilles tendon healing. MATERIALS AND METHODS: Sixty-five male Sprague-Dawley rats were randomly divided into NO-flurbiprofen, flurbiprofen and vehicle groups, given drugs or vehicle subcutaneously, and their right Achilles tendon divided. Histological assessment was carried out at day 5, 10, and 15 post-operation. Healing tendon biomechanical properties and hydroxyproline content were measured at day 10. RESULTS: The healing Achilles tendon from the NO-flurbiprofen and flurbiprofen groups showed a better organization of extracellular collagenous matrix than that from the vehicle group. Flurbiprofen and NO-flurbiprofen decreased healing tendon cross-sectional area by 30% and 20%. This reduction was accompanied by a decreased failure load in the flurbiprofen group, but not the NO-flurbiprofen group. NO-flubiprofen prevented the reduction of body weight gain observed in the flubiprofen group. CONCLUSION: Both flurbiprofen and NO-flurbiprofen promoted better collagen reorganization during tendon healing. NO-flurbiprofen further improved tendon healing by increasing tendon stress and reducing the side effects (body weight loss) of flurbiprofen. The enhanced tendon healing by NO-flurbiprofen is likely due to the release of NO from the compound. FAU - Yuan, J AU - Yuan J AD - Orthopaedic Research Institute, St George Hospital Campus, University of New South Wales, 4-10 South Street, Kogarah, Sydney, NSW 2217, Australia. FAU - Murrell, G A C AU - Murrell GA FAU - Wei, A-Q AU - Wei AQ FAU - Appleyard, R C AU - Appleyard RC FAU - Del Soldato, P AU - Del Soldato P FAU - Wang, M-X AU - Wang MX LA - eng PT - Journal Article PL - Switzerland TA - Inflamm Res JT - Inflammation research : official journal of the European Histamine Research Society ... [et al.] JID - 9508160 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Coloring Agents) RN - 158836-71-6 (nitroflurbiprofen) RN - 31C4KY9ESH (Nitric Oxide) RN - 5GRO578KLP (Flurbiprofen) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/*injuries/metabolism/pathology MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Biomechanical Phenomena MH - Body Water/metabolism MH - Collagen/metabolism MH - Coloring Agents MH - Extracellular Space/metabolism MH - Flurbiprofen/*analogs & derivatives/*therapeutic use MH - Male MH - Nitric Oxide/metabolism/*therapeutic use MH - Organ Size/drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Weight Gain/drug effects MH - Wound Healing/*drug effects EDAT- 2003/07/02 05:00 MHDA- 2004/03/20 05:00 CRDT- 2003/07/02 05:00 PHST- 2003/07/02 05:00 [pubmed] PHST- 2004/03/20 05:00 [medline] PHST- 2003/07/02 05:00 [entrez] AID - 10.1007/s00011-003-1167-7 [doi] PST - ppublish SO - Inflamm Res. 2003 Jun;52(6):230-7. doi: 10.1007/s00011-003-1167-7. PMID- 6745758 OWN - NLM STAT- MEDLINE DCOM- 19840912 LR - 20091119 IS - 0722-1819 (Print) IS - 0722-1819 (Linking) VI - 16 IP - 2 DP - 1984 Jun TI - [Treatment of palmar and tendon sheath infections following aponeurectomy with gentamycin PMMA minichains]. PG - 93-6 AB - Soft tissue and bone infections of the hand often require long-term treatment. In most cases this will result in a poor function. In a case of infection after aponeurectomy it is shown that early revision and local therapy with Gentamycin-PMMA-minichains bring very good results, as we have already shown in more than two hundred cases. FAU - Asche, G AU - Asche G LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Behandlung einer Hohlhand- und Sehnenscheiden-Phlegmone nach Aponeurektomie mit Gentamycin-PMMA-Miniketten. PL - Germany TA - Handchir Mikrochir Plast Chir JT - Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... JID - 8302815 RN - 0 (Gentamicins) RN - 0 (Methylmethacrylates) RN - 0 (gentamicin-polymethylmethacrylate bead) SB - IM MH - Drainage MH - Dupuytren Contracture/surgery MH - Finger Injuries/surgery MH - Fingers/surgery MH - Gentamicins/*therapeutic use MH - Hand/*surgery MH - Humans MH - Male MH - Methylmethacrylates/*therapeutic use MH - Middle Aged MH - Surgical Wound Infection/*drug therapy MH - Tendinopathy/*drug therapy MH - Tendons/*surgery MH - Wound Healing/drug effects EDAT- 1984/06/01 00:00 MHDA- 1984/06/01 00:01 CRDT- 1984/06/01 00:00 PHST- 1984/06/01 00:00 [pubmed] PHST- 1984/06/01 00:01 [medline] PHST- 1984/06/01 00:00 [entrez] PST - ppublish SO - Handchir Mikrochir Plast Chir. 1984 Jun;16(2):93-6. PMID- 3829094 OWN - NLM STAT- MEDLINE DCOM- 19870429 LR - 20131121 IS - 0149-2918 (Print) IS - 0149-2918 (Linking) VI - 9 Suppl B DP - 1986 TI - Occupational therapy in the multidisciplinary assessment and management of osteoarthritis. PG - 24-9 AB - As part of the multidisciplinary assessment of osteoarthritis, two occupational therapists evaluated the signs and symptoms of osteoarthritis in the hands of 77 patients. The patients were seen every two weeks for 12 weeks. Initially 58% considered themselves disabled; their mean disability score, on a scale of 0 to 3, was 1.7. Crepitus and pain of the joints and tendons occurred in 36% of the patients. Three hundred fifty-five cysts/nodules, primarily bony, were identified, the mean number being significantly greater (P less than 0.05) for women (8.8) than for men (5.3). Despite considerable disability due to osteoarthritis, none of these patients had ever consulted an occupational therapist. At the end of the study, the mean disability score was 1.2, significantly (P less than 0.05) lower than the initial score. Osteoarthritis of the hand was associated with considerable disability, more so in women than in men, and improvement was evident when an occupational therapist participated in the management of this disease. FAU - Moratz, V AU - Moratz V FAU - Muncie, H L Jr AU - Muncie HL Jr FAU - Miranda-Walsh, H AU - Miranda-Walsh H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Ther JT - Clinical therapeutics JID - 7706726 RN - 184SNS8VUH (Sulindac) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Combined Modality Therapy MH - Disability Evaluation MH - Female MH - Hand/physiopathology MH - Humans MH - Male MH - Middle Aged MH - *Occupational Therapy MH - Osteoarthritis/*rehabilitation/therapy MH - Patient Care Team MH - Sulindac/therapeutic use MH - Time Factors EDAT- 1986/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1986/01/01 00:00 [entrez] PST - ppublish SO - Clin Ther. 1986;9 Suppl B:24-9. PMID- 16237617 OWN - NLM STAT- MEDLINE DCOM- 20060223 LR - 20220331 IS - 0172-4622 (Print) IS - 0172-4622 (Linking) VI - 26 IP - 9 DP - 2005 Nov TI - In vivo measurements of glucose uptake in human Achilles tendon during different exercise intensities. PG - 727-31 AB - Muscular contraction and loading of adjacent tendons has been demonstrated to cause increased blood flow and metabolic activity in the peritendinous region. However, it is poorly known to what extent the human tendon itself takes up glucose during exercise. Thus, the purpose of this study was to measure tendon glucose uptake with increasing exercise intensity and to compare it to muscle glucose uptake at the same intensities. Eight young men were examined on three separate days during which they performed 35 min of cycling at 30, 55 and 75 % of VO2max, respectively. Glucose uptake was measured directly by positron emission tomography (PET) with 2-[ (18)F]fluoro-2-deoxyglucose ([18F]FDG). [18F]FDG was injected after 10 min of exercise that was continued for a further 25 min after the injection. PET scanning of the thigh and Achilles region was performed after the exercise. Glucose uptake of the Achilles tendon (AT) remained unchanged (7.1 +/- 1.5, 6.6 +/- 1.1, and 6.0 +/- 1.1 micromol.kg(-1).min(-1)) with the increasing workload, although the glucose uptake in m. quadriceps femoris simultaneously clearly increased (48 +/- 35, 120 +/- 35, and 152 +/- 74 micromol.kg(-1).min(-1), p < 0.05). In conclusion, the AT takes up glucose during exercise but in significantly smaller amounts than the skeletal muscle does. Furthermore, glucose uptake in the AT is not increased with the increasing exercise intensity. This may be partly explained by the cycle ergometry exercise used in the present study, which probably causes only a little increase in strain to the AT with increasing exercise intensity. FAU - Hannukainen, J AU - Hannukainen J AD - Turku PET Centre, University of Turku, Turku, Finland. jarna.hannukainen@tyks.fi FAU - Kalliokoski, K K AU - Kalliokoski KK FAU - Nuutila, P AU - Nuutila P FAU - Fujimoto, T AU - Fujimoto T FAU - Kemppainen, J AU - Kemppainen J FAU - Viljanen, T AU - Viljanen T FAU - Laaksonen, M S AU - Laaksonen MS FAU - Parkkola, R AU - Parkkola R FAU - Knuuti, J AU - Knuuti J FAU - Kjaer, M AU - Kjaer M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Int J Sports Med JT - International journal of sports medicine JID - 8008349 RN - 33X04XA5AT (Lactic Acid) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Achilles Tendon/*metabolism MH - Adult MH - Exercise/*physiology MH - Exercise Test MH - Glucose/*metabolism MH - Heart Rate MH - Humans MH - Image Processing, Computer-Assisted MH - Lactic Acid/blood MH - Male MH - Muscle, Skeletal/metabolism MH - Positron-Emission Tomography EDAT- 2005/10/21 09:00 MHDA- 2006/02/24 09:00 CRDT- 2005/10/21 09:00 PHST- 2005/10/21 09:00 [pubmed] PHST- 2006/02/24 09:00 [medline] PHST- 2005/10/21 09:00 [entrez] AID - 10.1055/s-2005-837458 [doi] PST - ppublish SO - Int J Sports Med. 2005 Nov;26(9):727-31. doi: 10.1055/s-2005-837458. PMID- 22936809 OWN - NLM STAT- MEDLINE DCOM- 20130123 LR - 20211021 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 287 IP - 45 DP - 2012 Nov 2 TI - Resveratrol modulates interleukin-1β-induced phosphatidylinositol 3-kinase and nuclear factor κB signaling pathways in human tenocytes. PG - 38050-63 LID - 10.1074/jbc.M112.377028 [doi] AB - Resveratrol, an activator of histone deacetylase Sirt-1, has been proposed to have beneficial health effects due to its antioxidant and anti-inflammatory properties. However, the mechanisms underlying the anti-inflammatory effects of resveratrol and the intracellular signaling pathways involved are poorly understood. An in vitro model of human tenocytes was used to examine the mechanism of resveratrol action on IL-1β-mediated inflammatory signaling. Resveratrol suppressed IL-1β-induced activation of NF-κB and PI3K in a dose- and time-dependent manner. Treatment with resveratrol enhanced the production of matrix components collagen types I and III, tenomodulin, and tenogenic transcription factor scleraxis, whereas it inhibited gene products involved in inflammation and apoptosis. IL-1β-induced NF-κB and PI3K activation was inhibited by resveratrol or the inhibitors of PI3K (wortmannin), c-Src (PP1), and Akt (SH-5) through inhibition of IκB kinase, IκBα phosphorylation, and inhibition of nuclear translocation of NF-κB, suggesting that PI3K signaling pathway may be one of the signaling pathways inhibited by resveratrol to abrogate NF-κB activation. Inhibition of PI3K by wortmannin attenuated IL-1β-induced Akt and p65 acetylation, suggesting that p65 is a downstream component of PI3K/Akt in these responses. The modulatory effects of resveratrol on IL-1β-induced activation of NF-κB and PI3K were found to be mediated at least in part by the association between Sirt-1 and scleraxis and deacetylation of NF-κB and PI3K. Overall, these results demonstrate that activated Sirt-1 plays an essential role in the anti-inflammatory effects of resveratrol and this may be mediated at least in part through inhibition/deacetylation of PI3K and NF-κB. FAU - Busch, Franziska AU - Busch F AD - Institute of Anatomy, Ludwig-Maximilian-University Munich, 80336 Munich, Germany. FAU - Mobasheri, Ali AU - Mobasheri A FAU - Shayan, Parviz AU - Shayan P FAU - Lueders, Cora AU - Lueders C FAU - Stahlmann, Ralf AU - Stahlmann R FAU - Shakibaei, Mehdi AU - Shakibaei M LA - eng PT - Journal Article DEP - 20120830 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (1-((1-O-octadecyl-2-O-methylglycero)phospho)-3-deoxy-myo-inositol) RN - 0 (4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine) RN - 0 (Androstadienes) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Inositol Phosphates) RN - 0 (Interleukin-1beta) RN - 0 (NF-kappa B) RN - 0 (Phosphoinositide-3 Kinase Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 0 (Stilbenes) RN - 9007-34-5 (Collagen) RN - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) RN - EC 2.7.10.2 (src-Family Kinases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.5.1.- (SIRT1 protein, human) RN - EC 3.5.1.- (Sirtuin 1) RN - Q369O8926L (Resveratrol) RN - XVA4O219QW (Wortmannin) SB - IM MH - Androstadienes/pharmacology MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Apoptosis/drug effects MH - Blotting, Western MH - Cells, Cultured MH - Collagen/metabolism MH - Dose-Response Relationship, Drug MH - Humans MH - Inositol Phosphates/pharmacology MH - Interleukin-1beta/*pharmacology MH - Male MH - Microscopy, Electron MH - Middle Aged MH - Mitochondria/drug effects/metabolism MH - NF-kappa B/*metabolism MH - Phosphatidylinositol 3-Kinase/*metabolism MH - Phosphoinositide-3 Kinase Inhibitors MH - Phosphorylation/drug effects MH - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/metabolism MH - Pyrazoles/pharmacology MH - Pyrimidines/pharmacology MH - Resveratrol MH - Signal Transduction/*drug effects MH - Sirtuin 1/metabolism MH - Stilbenes/*pharmacology MH - Tendons/cytology/*drug effects/metabolism MH - Time Factors MH - Wortmannin MH - src-Family Kinases/antagonists & inhibitors/metabolism PMC - PMC3488075 EDAT- 2012/09/01 06:00 MHDA- 2013/01/24 06:00 PMCR- 2013/11/02 CRDT- 2012/09/01 06:00 PHST- 2012/09/01 06:00 [entrez] PHST- 2012/09/01 06:00 [pubmed] PHST- 2013/01/24 06:00 [medline] PHST- 2013/11/02 00:00 [pmc-release] AID - S0021-9258(20)62430-9 [pii] AID - M112.377028 [pii] AID - 10.1074/jbc.M112.377028 [doi] PST - ppublish SO - J Biol Chem. 2012 Nov 2;287(45):38050-63. doi: 10.1074/jbc.M112.377028. Epub 2012 Aug 30. PMID- 21107196 OWN - NLM STAT- MEDLINE DCOM- 20110322 LR - 20181201 IS - 1524-4040 (Electronic) IS - 0148-396X (Linking) VI - 67 IP - 6 DP - 2010 Dec TI - Changes in tissue substance P levels in patients with carpal tunnel syndrome. PG - 1655-60; discussion 1660-1 LID - 10.1227/NEU.0b013e3181fa7032 [doi] AB - BACKGROUND: Although carpal tunnel syndrome (CTS) is the most common entrapment neuropathy in adults, its etiology is not completely known. Chronic inflammation, fibrosis of the transverse carpal ligament (TCL), and altered sensory response contribute to the symptoms. OBJECTIVE: Because substance P (SP) is known to be involved in neuropathic pain, chronic inflammation, and fibrosis, the present study evaluated changes in SP levels in patients with CTS. METHODS: TCL, median nerve adventitia, and synovial connective tissue of the middle flexor digitorum superficialis tendon samples from patients (n=42) with CTS and healthy control subjects (n=13) who were operated on for hand wounds were obtained at surgery. A group of these patients with CTS (n=9) had received meloxicam treatment for 10 days before surgery. A 2-step acetic acid extraction was used to determine changes in SP levels in free nerve endings (neuronal) and in nonneuronal cells. RESULTS: Changes in SP levels were observed in both neuronal and nonneuronal tissues. SP levels increased in extracts of the TCL and synovial connective tissue of the middle flexor digitorum superficialis tendon but not in the median nerve adventitia of patients with CTS. Meloxicam pretreatment increased SP levels in nonneuronal components of the TCL. CONCLUSION: These findings suggest that SP contributes to the pain and inflammation associated with CTS. Further studies are required to evaluate the therapeutic potentials of SP receptor (NK1R) antagonists in CTS. FAU - Öztürk, Niyazi AU - Öztürk N AD - 1Department of Orthopedics and Traumatology, School of Medicine, Akdeniz University, Antalya, Turkey 2Department of Medical Pharmacology, School of Medicine, Akdeniz University, Antalya, Turkey. FAU - Erin, Nuray AU - Erin N FAU - Tüzüner, Serdar AU - Tüzüner S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Neurosurgery JT - Neurosurgery JID - 7802914 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Thiazines) RN - 0 (Thiazoles) RN - 33507-63-0 (Substance P) RN - VG2QF83CGL (Meloxicam) SB - IM MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Carpal Tunnel Syndrome/drug therapy/*metabolism/*pathology/surgery MH - Connective Tissue/drug effects/*metabolism MH - Female MH - Humans MH - Male MH - Median Nerve/metabolism/pathology MH - Meloxicam MH - Middle Aged MH - Myelin Sheath/drug effects/metabolism MH - Retrospective Studies MH - Severity of Illness Index MH - Substance P/*metabolism MH - Tendons/drug effects/pathology MH - Thiazines/therapeutic use MH - Thiazoles/therapeutic use MH - Young Adult EDAT- 2010/11/26 06:00 MHDA- 2011/03/23 06:00 CRDT- 2010/11/26 06:00 PHST- 2010/11/26 06:00 [entrez] PHST- 2010/11/26 06:00 [pubmed] PHST- 2011/03/23 06:00 [medline] AID - 00006123-201012000-00031 [pii] AID - 10.1227/NEU.0b013e3181fa7032 [doi] PST - ppublish SO - Neurosurgery. 2010 Dec;67(6):1655-60; discussion 1660-1. doi: 10.1227/NEU.0b013e3181fa7032. PMID- 24739929 OWN - NLM STAT- MEDLINE DCOM- 20141125 LR - 20240404 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 19 IP - 4 DP - 2014 Apr 15 TI - Cornu cervi pantotrichum supplementation improves exercise performance and protects against physical fatigue in mice. PG - 4669-80 LID - 10.3390/molecules19044669 [doi] AB - Cornu cervi pantotrichum (CCP) is a well-known yang-invigorating agent used in traditional Chinese medicine that can nourish the blood, tonify qi, and invigorate bones and tendons with multifunctional bioactivities. However, evidence on the effects of CCP on exercise performance and physical fatigue is limited. We evaluated the potential beneficial effects of ethanolic extract from CCP on ergogenic and antifatigue functions following a physiological challenge. Male ICR mice from four groups (n=8 per group) were orally administered CCP for 14 days at 0, 2054, and 4108 mg/kg/day, and were respectively designated as the vehicle, CCP-1X, and CCP-2X groups. The physical performance and antifatigue function were evaluated using forelimb grip strength and exhaustive swimming time as well as serum levels of lactate, ammonia, glucose, and creatine kinase after a 15-min swimming exercise. The results indicated that CCP-1X supplementation significantly improved grip strength; reduced fatigue-associated biochemical indices, including lactate and ammonia levels; and ameliorated skeletal muscle injury induced by acute exercise challenge. A trend analysis revealed that CCP supplementation significantly increased grip strength and dose-dependently reduced serum alkaline phosphatase, uric acid, triacylglycerol, and glucose levels in healthy mice. Therefore, CCP is a potential agent with an antifatigue pharmacological effect. FAU - Huang, Chi-Chang AU - Huang CC AD - Graduate Institute of Sports Science, College of Exercise and Health Sciences, National Taiwan Sport University, Taoyuan 33301, Taiwan. FAU - Chen, Yi-Ming AU - Chen YM AD - Graduate Institute of Sports Science, College of Exercise and Health Sciences, National Taiwan Sport University, Taoyuan 33301, Taiwan. FAU - Kan, Nai-Wen AU - Kan NW AD - Graduate Institute of Athletics and Coaching Science, College of Sports and Athletics, National Taiwan Sport University, Taoyuan 33301, Taiwan. FAU - Chao, Hui-Ling AU - Chao HL AD - Graduate Institute of Sports Science, College of Exercise and Health Sciences, National Taiwan Sport University, Taoyuan 33301, Taiwan. FAU - Ho, Chin-Shan AU - Ho CS AD - Graduate Institute of Sports Science, College of Exercise and Health Sciences, National Taiwan Sport University, Taoyuan 33301, Taiwan. FAU - Hsu, Mei-Chich AU - Hsu MC AD - Department of Sports Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. meichich@kmu.edu.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140415 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - 0 (Blood Glucose) RN - 0 (Complex Mixtures) RN - 0 (Protective Agents) RN - 0 (Stimulants, Historical) RN - 33X04XA5AT (Lactic Acid) RN - 7664-41-7 (Ammonia) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Administration, Oral MH - Alkaline Phosphatase/blood MH - Ammonia/blood MH - Animals MH - Antlers/*chemistry MH - Blood Glucose/metabolism MH - Complex Mixtures/chemistry MH - Deer MH - Fatigue/blood/*prevention & control MH - Lactic Acid/blood MH - Male MH - Mice MH - Mice, Inbred ICR MH - Muscle Strength/drug effects MH - Muscle, Skeletal/drug effects/metabolism MH - Physical Conditioning, Animal MH - Physical Exertion/*drug effects MH - Protective Agents/isolation & purification/*pharmacology MH - Stimulants, Historical/isolation & purification/*pharmacology MH - Swimming/physiology PMC - PMC6270703 COIS- All authors declare no conflicts of interest. EDAT- 2014/04/18 06:00 MHDA- 2014/12/15 06:00 PMCR- 2014/04/15 CRDT- 2014/04/18 06:00 PHST- 2014/02/24 00:00 [received] PHST- 2014/04/11 00:00 [revised] PHST- 2014/04/11 00:00 [accepted] PHST- 2014/04/18 06:00 [entrez] PHST- 2014/04/18 06:00 [pubmed] PHST- 2014/12/15 06:00 [medline] PHST- 2014/04/15 00:00 [pmc-release] AID - molecules19044669 [pii] AID - molecules-19-04669 [pii] AID - 10.3390/molecules19044669 [doi] PST - epublish SO - Molecules. 2014 Apr 15;19(4):4669-80. doi: 10.3390/molecules19044669. PMID- 12516725 OWN - NLM STAT- MEDLINE DCOM- 20030204 LR - 20221207 IS - 0008-4182 (Print) IS - 0008-4182 (Linking) VI - 37 IP - 7 DP - 2002 Dec TI - Cysticercosis of superior oblique muscle: surgical excision and reconstruction of superior oblique tendon. PG - 423-6 FAU - Bajaj, Mandeep S AU - Bajaj MS AD - Oculoplastic and Paediatric Ophthalmology Services Dr. R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. msbajaj32@hotmail.com FAU - Pushker, Neelam AU - Pushker N FAU - Sen, Seema AU - Sen S FAU - Balasubramanya, Ramamurthy AU - Balasubramanya R LA - eng PT - Case Reports PT - Journal Article PL - England TA - Can J Ophthalmol JT - Canadian journal of ophthalmology. Journal canadien d'ophtalmologie JID - 0045312 RN - 0 (Antiprotozoal Agents) RN - 0 (Glucocorticoids) RN - 9PHQ9Y1OLM (Prednisolone) RN - F4216019LN (Albendazole) SB - IM MH - Albendazole/therapeutic use MH - Animals MH - Antiprotozoal Agents/therapeutic use MH - Child MH - Cysticercosis/diagnostic imaging/pathology/*surgery MH - Cysticercus/isolation & purification MH - Drug Therapy, Combination MH - Eye Infections, Parasitic/diagnostic imaging/pathology/*surgery MH - Glucocorticoids/therapeutic use MH - Humans MH - Male MH - Ocular Motility Disorders/diagnostic imaging/pathology/*surgery MH - Oculomotor Muscles/diagnostic imaging/pathology/*surgery MH - Ophthalmologic Surgical Procedures MH - Orbital Diseases/diagnostic imaging/pathology/*surgery MH - Prednisolone/therapeutic use MH - Plastic Surgery Procedures MH - Tendons/*surgery MH - Tomography, X-Ray Computed EDAT- 2003/01/09 04:00 MHDA- 2003/02/05 04:00 CRDT- 2003/01/09 04:00 PHST- 2003/01/09 04:00 [pubmed] PHST- 2003/02/05 04:00 [medline] PHST- 2003/01/09 04:00 [entrez] AID - S0008-4182(02)80047-3 [pii] AID - 10.1016/s0008-4182(02)80047-3 [doi] PST - ppublish SO - Can J Ophthalmol. 2002 Dec;37(7):423-6. doi: 10.1016/s0008-4182(02)80047-3. PMID- 16394410 OWN - NLM STAT- MEDLINE DCOM- 20060328 LR - 20191109 IS - 0378-6323 (Print) IS - 0378-6323 (Linking) VI - 71 IP - 3 DP - 2005 May-Jun TI - Early detection of alkaptonuria. PG - 189-91 AB - Alkaptonuria is a rare disorder of metabolism characterized by deficiency of homogentisic acid oxidase. This leads to the characteristic features like darkening of urine, ochronosis and arthropathy. Darkening of urine is one of the first symptoms noticed by the parents of the child suffering from this disorder. Ochronosis is seen in various organs like eyes, skin, tendons and joints. A case of 10 year old boy is reported who was brought to this clinic with the presenting complaint of bluish discoloration of sclerae. This discoloration led to eliciting positive history of dark urine off and on. Further investigations confirmed alkaptonuria. FAU - Verma, Shyam B AU - Verma SB AD - vermaderma@rediffmail.com LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Indian J Dermatol Venereol Leprol JT - Indian journal of dermatology, venereology and leprology JID - 7701852 RN - EC 1.13.11.5 (Homogentisate 1,2-Dioxygenase) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Alkaptonuria/*diagnosis/therapy MH - Ascorbic Acid/therapeutic use MH - Child MH - Diet Therapy MH - Early Diagnosis MH - Follow-Up Studies MH - Homogentisate 1,2-Dioxygenase/*deficiency MH - Humans MH - Male MH - Risk Assessment MH - Severity of Illness Index MH - Treatment Outcome EDAT- 2006/01/06 09:00 MHDA- 2006/03/29 09:00 CRDT- 2006/01/06 09:00 PHST- 2006/01/06 09:00 [pubmed] PHST- 2006/03/29 09:00 [medline] PHST- 2006/01/06 09:00 [entrez] AID - 10.4103/0378-6323.16236 [doi] PST - ppublish SO - Indian J Dermatol Venereol Leprol. 2005 May-Jun;71(3):189-91. doi: 10.4103/0378-6323.16236. PMID- 24901929 OWN - NLM STAT- MEDLINE DCOM- 20150728 LR - 20181202 IS - 2589-1294 (Electronic) IS - 1017-995X (Linking) VI - 48 IP - 3 DP - 2014 TI - The effects of resveratrol on tendon healing of diabetic rats. PG - 355-62 LID - 10.3944/AOTT.2014.13.0096 [doi] AB - OBJECTIVE: The aim of this study was to determine the effects of resveratrol on the tendon healing process of streptozotocin-induced diabetic rats. METHODS: The study included 16 male Sprague-Dawley rats. Streptozotocin was administered to induce diabetes and bilateral tenorrhaphy of the Achilles tendons was performed. Intraperitoneal resveratrol was injected in the experimental group (n=8) and saline in the control group (n=8) during the postoperative period. Rats were sacrificed at the 14th day. Right side tendons were evaluated biomechanically and left side tendons histologically. RESULTS: Difference in mean tendon tensile strength was not statistically significant between groups (p>0.05). Histologic evaluations of the repair zones showed greater configuration of the newly synthesized collagen in the experimental group. The ratio of the newly synthesized collagen area to the healing region area was significantly higher in the experimental group then the control group (p<0.01). CONCLUSION: Resveratrol appears to have a positive impact on the process of tendon healing in diabetic conditions in the first 14 days. FAU - Zeytin, Kayhan AU - Zeytin K AD - Department of Plastic Surgery, Manisa State Hospital, Manisa, Turkey. kayhanzeytin@gmail.com. FAU - Ciloğlu, Nesibe Sinem AU - Ciloğlu NS AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey. FAU - Ateş, Filiz AU - Ateş F AD - Institute of Biomedical Engineering, Boğaziçi University, İstanbul, Turkey. FAU - Vardar Aker, Fugen AU - Vardar Aker F AD - Department of Pathology, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey. FAU - Ercan, Feriha AU - Ercan F AD - Department of Histology and Embryology, Marmara University, Faculty of Medicine, İstanbul, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Stilbenes) RN - 9007-34-5 (Collagen) RN - Q369O8926L (Resveratrol) SB - IM MH - Achilles Tendon/*drug effects/injuries MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Collagen/*drug effects MH - *Diabetes Mellitus, Experimental MH - Injections, Intraperitoneal MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Resveratrol MH - Stilbenes/*pharmacology MH - Tensile Strength MH - Treatment Outcome MH - Wound Healing/*drug effects EDAT- 2014/06/06 06:00 MHDA- 2015/07/29 06:00 CRDT- 2014/06/06 06:00 PHST- 2014/06/06 06:00 [entrez] PHST- 2014/06/06 06:00 [pubmed] PHST- 2015/07/29 06:00 [medline] AID - 10.3944/AOTT.2014.13.0096 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2014;48(3):355-62. doi: 10.3944/AOTT.2014.13.0096. PMID- 1779233 OWN - NLM STAT- MEDLINE DCOM- 19920312 LR - 20190724 IS - 0022-510X (Print) IS - 0022-510X (Linking) VI - 106 IP - 1 DP - 1991 Nov TI - A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. PG - 10-8 AB - A study is presented of a 48-year-old female patient and her three siblings with familial hypercholesterolemia. The family members had episodes of cerebral infarction and apparently had atherosclerosis of the internal carotid artery, but no coronary heart disease due to their almost normal level of cholesterol. The laboratory studies of the family members revealed the elevations of serum lipid peroxides, serum lipoprotein(a), leukotriene C4 in blood, the thromboxane B2/6-keto-prostaglandin F1 alpha ratio in plasma and serum hydroxyl radical. Therefore, it is suspected that these factors accelerating atherosclerotic process caused the cerebral infarction. The patient demonstrated corneal opacities, palpebral xanthomas, thickened Achilles tendons, polyneuropathy and the carpal tunnel syndrome. Laboratory studies revealed an elevation in the OKT4/8 ratio, monocyte dysfunction with respect to phagocytosis and chemotaxis, and the presence of the 46XX/45XO mosaic chromosome. Lipid deposits were observed in the Achilles tendon, the transverse carpal ligament, the Schwann's cells and axons of the sural nerve, and in the keratocytes and stroma of the cornea. Following the administration of tocopherol nicotinate and probucol, the patient's serum lipid peroxide normalized and there was improvement in her palpebral xanthomas, thickening of the Achilles tendons and polyneuropathy. We conclude that the lipid deposits in this patient were due to the abnormal oxidative metabolism of low-density lipoprotein and a disturbance of the scavenger pathway due to the monocyte dysfunction. FAU - Ihara, Y AU - Ihara Y AD - Department of Neurology, National Minamiokayama Hospital, Okayama, Japan. FAU - Nobukuni, K AU - Nobukuni K FAU - Namba, R AU - Namba R FAU - Kamisaka, K AU - Kamisaka K FAU - Kibata, M AU - Kibata M FAU - Kajinami, K AU - Kajinami K FAU - Fujita, H AU - Fujita H FAU - Mabuchi, H AU - Mabuchi H FAU - Shirabe, T AU - Shirabe T FAU - Ohshima, K AU - Ohshima K AU - et al. LA - eng PT - Case Reports PT - Journal Article PL - Netherlands TA - J Neurol Sci JT - Journal of the neurological sciences JID - 0375403 RN - 0 (Free Radicals) RN - 0 (Lipoproteins, LDL) RN - 0 (Nicotinic Acids) RN - 1406-18-4 (Vitamin E) RN - 43119-47-7 (alpha-tocopheryl nicotinate) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - P3CTH044XJ (Probucol) SB - IM MH - Arteriosclerosis/genetics MH - Axons/pathology MH - CD4-CD8 Ratio MH - Carpal Tunnel Syndrome/genetics MH - Cerebral Infarction/*genetics MH - Corneal Opacity/genetics MH - Female MH - Free Radicals MH - Hereditary Sensory and Motor Neuropathy/*genetics MH - Humans MH - Hyperlipoproteinemia Type II/blood/drug therapy/*genetics MH - Lipoproteins, LDL/blood MH - Middle Aged MH - Mosaicism MH - Nicotinic Acids/therapeutic use MH - Probucol/therapeutic use MH - Schwann Cells/pathology MH - Superoxide Dismutase/blood MH - Turner Syndrome/genetics MH - Vitamin E/analogs & derivatives/therapeutic use EDAT- 1991/11/01 00:00 MHDA- 1991/11/01 00:01 CRDT- 1991/11/01 00:00 PHST- 1991/11/01 00:00 [pubmed] PHST- 1991/11/01 00:01 [medline] PHST- 1991/11/01 00:00 [entrez] AID - 0022-510X(91)90187-C [pii] AID - 10.1016/0022-510x(91)90187-c [doi] PST - ppublish SO - J Neurol Sci. 1991 Nov;106(1):10-8. doi: 10.1016/0022-510x(91)90187-c. PMID- 7559718 OWN - NLM STAT- MEDLINE DCOM- 19951024 LR - 20131121 IS - 0301-620X (Print) IS - 0301-620X (Linking) VI - 77 IP - 5 DP - 1995 Sep TI - Fibrogenesis imperfecta ossium. PG - 820-9 AB - The clinical features, investigation, treatment and outcome of two adults with fibrogenesis imperfecta ossium are described. In this rare acquired disorder of bone, normal lamellar collagen is replaced by structurally unsound collagen-deficient tissue, which leads to extreme bone fragility and ununited fractures. Transmission microscopy and SEM showed striking ultrastructural changes in bone structure and mineralisation. Both patients had monoclonal IgG paraproteins in the plasma and one excreted monoclonal lambda light chains in the urine. No abnormal plasma cells were found in the bone marrow and there was no evidence of amyloid deposition in the tissues. In both patients initial treatment with 1 alpha-hydroxycholecalciferol appeared to be ineffective, but in one, repeated courses of melphalan and corticosteroids over three years together with 1 alpha-hydroxycholecalciferol produced striking clinical and histological improvement. The findings in these and other patients strongly suggest that paraproteinaemia is an integral feature of fibrogenesis imperfecta ossium, and this needs further investigation. FAU - Carr, A J AU - Carr AJ AD - Nuffield Orthopaedic Centre NHS Trust, Headington, Oxford, UK. FAU - Smith, R AU - Smith R FAU - Athanasou, N AU - Athanasou N FAU - Woods, C G AU - Woods CG LA - eng PT - Case Reports PT - Journal Article PT - Review PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Hydroxycholecalciferols) RN - 9007-34-5 (Collagen) RN - Q41OR9510P (Melphalan) RN - URQ2517572 (alfacalcidol) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Adult MH - Aged MH - Bone Diseases/*diagnosis/drug therapy/etiology MH - Bone and Bones/pathology MH - Child MH - Collagen/ultrastructure MH - Collagen Diseases/*diagnosis/drug therapy/etiology MH - Female MH - Fractures, Bone/etiology MH - Humans MH - Hydroxycholecalciferols/therapeutic use MH - Male MH - Melphalan/therapeutic use MH - Microscopy, Electron MH - Middle Aged MH - Paraproteinemias/complications MH - Tendons/chemistry RF - 22 EDAT- 1995/09/01 00:00 MHDA- 1995/09/01 00:01 CRDT- 1995/09/01 00:00 PHST- 1995/09/01 00:00 [pubmed] PHST- 1995/09/01 00:01 [medline] PHST- 1995/09/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Br. 1995 Sep;77(5):820-9. PMID- 6015667 OWN - NLM STAT- MEDLINE DCOM- 19670304 LR - 20151119 IS - 0008-428X (Print) IS - 0008-428X (Linking) VI - 10 IP - 1 DP - 1967 Jan TI - The effects of dexamethasone, norethandrolone, promethazine and a tension-relieving procedure on collagen synthesis in healing flexor tendons as estimated by tritiated proline uptake studies. PG - 36-46 FAU - Douglas, L G AU - Douglas LG FAU - Jackson, S H AU - Jackson SH FAU - Lindsay, W K AU - Lindsay WK LA - eng PT - Journal Article PL - Canada TA - Can J Surg JT - Canadian journal of surgery. Journal canadien de chirurgie JID - 0372715 RN - 10028-17-8 (Tritium) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - FF28EJQ494 (Promethazine) RN - P7W01638W6 (Norethandrolone) SB - IM MH - Animals MH - Collagen/*biosynthesis MH - Dexamethasone/*therapeutic use MH - In Vitro Techniques MH - Norethandrolone/*therapeutic use MH - Poultry MH - Proline MH - Promethazine/*therapeutic use MH - Radiometry MH - Sutures MH - Tendon Injuries/*drug therapy/surgery MH - Tritium MH - Wound Healing/drug effects EDAT- 1967/01/01 00:00 MHDA- 1967/01/01 00:01 CRDT- 1967/01/01 00:00 PHST- 1967/01/01 00:00 [pubmed] PHST- 1967/01/01 00:01 [medline] PHST- 1967/01/01 00:00 [entrez] PST - ppublish SO - Can J Surg. 1967 Jan;10(1):36-46. PMID- 6407679 OWN - NLM STAT- MEDLINE DCOM- 19830826 LR - 20190501 IS - 0267-0623 (Print) IS - 0267-0623 (Linking) VI - 287 IP - 6384 DP - 1983 Jul 2 TI - Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis. PG - 21-2 FAU - Lewis, B AU - Lewis B FAU - Mitchell, W D AU - Mitchell WD FAU - Marenah, C B AU - Marenah CB FAU - Cortese, C AU - Cortese C FAU - Reynolds, E H AU - Reynolds EH FAU - Shakir, R AU - Shakir R LA - eng PT - Case Reports PT - Journal Article PL - England TA - Br Med J (Clin Res Ed) JT - British medical journal (Clinical research ed.) JID - 8302911 RN - 0 (Anticholesteremic Agents) RN - 0 (Naphthalenes) RN - 9LHU78OQFD (Lovastatin) SB - IM MH - Adult MH - Anticholesteremic Agents/*therapeutic use MH - Brain Diseases, Metabolic/*drug therapy MH - Humans MH - Lovastatin MH - Male MH - Muscular Diseases/*drug therapy MH - Naphthalenes/*therapeutic use MH - Tendons MH - Xanthomatosis/*drug therapy PMC - PMC1548166 EDAT- 1983/07/02 00:00 MHDA- 1983/07/02 00:01 PMCR- 1983/07/02 CRDT- 1983/07/02 00:00 PHST- 1983/07/02 00:00 [pubmed] PHST- 1983/07/02 00:01 [medline] PHST- 1983/07/02 00:00 [entrez] PHST- 1983/07/02 00:00 [pmc-release] AID - 10.1136/bmj.287.6384.21-a [doi] PST - ppublish SO - Br Med J (Clin Res Ed). 1983 Jul 2;287(6384):21-2. doi: 10.1136/bmj.287.6384.21-a. PMID- 20055850 OWN - NLM STAT- MEDLINE DCOM- 20100818 LR - 20131121 IS - 1365-2230 (Electronic) IS - 0307-6938 (Linking) VI - 34 IP - 8 DP - 2009 Dec TI - Endogenous ochronosis. PG - e865-8 LID - 10.1111/j.1365-2230.2009.03618.x [doi] AB - Endogenous ochronosis or alkaptonuria is a rare, autosomal recessive disease of tyrosine metabolism that is caused by a deficiency of the enzyme homogentisic acid oxidase. The disease results in the accumulation and deposition of homogentisic acid in the cartilage, eyelids, forehead, cheeks, axillae, genital region, buccal mucosa, larynx, tympanic membranes, and tendons. The disease generally presents in adults with arthritis and skin abnormalities; occasionally, involvement of other organs may be seen. A 49-year-old man was referred to our clinic with verrucous lesions on his hands. On physical examination, caviar-like ochronotic papules were found around his eyes and the helix cartilage of his ears, and on the dorsa of both hands. There were brown macules on the sclera (Osler's sign). The patient had arthritis and nephrolithiasis, and a sample of his urine darkened upon standing. Histopathological examination showed deposition of ochronotic pigment. High-dose ascorbic acid was given, and the patient showed improvement on follow-up examination 6 months later. FAU - Turgay, E AU - Turgay E AD - Department of Dermatology, Okmeydani Education and Research Hospital, Istanbul, Turkey. evrenturgay@gmail.com FAU - Canat, D AU - Canat D FAU - Gurel, M S AU - Gurel MS FAU - Yuksel, T AU - Yuksel T FAU - Baran, M F AU - Baran MF FAU - Demirkesen, C AU - Demirkesen C LA - eng PT - Case Reports PT - Journal Article PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Ascorbic Acid/*therapeutic use MH - Ear, External/*pathology MH - Female MH - Humans MH - Middle Aged MH - Ochronosis/drug therapy/*pathology MH - Treatment Outcome EDAT- 2010/01/09 06:00 MHDA- 2010/08/19 06:00 CRDT- 2010/01/09 06:00 PHST- 2010/01/09 06:00 [entrez] PHST- 2010/01/09 06:00 [pubmed] PHST- 2010/08/19 06:00 [medline] AID - CED3618 [pii] AID - 10.1111/j.1365-2230.2009.03618.x [doi] PST - ppublish SO - Clin Exp Dermatol. 2009 Dec;34(8):e865-8. doi: 10.1111/j.1365-2230.2009.03618.x. PMID- 22689577 OWN - NLM STAT- MEDLINE DCOM- 20121011 LR - 20220330 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 287 IP - 31 DP - 2012 Jul 27 TI - Sirt-1 is required for the inhibition of apoptosis and inflammatory responses in human tenocytes. PG - 25770-81 LID - 10.1074/jbc.M112.355420 [doi] AB - Tendon overuse injuries and tendinitis are accompanied by catabolic processes and apoptosis of tenocytes. However, the precise molecular mechanisms of the destructive processes in tendon are not fully understood. Sirt-1, a nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase, has been linked to transcriptional silencing and appears to play a key role in inflammation. The purpose of this study was to examine whether down-regulation of Sirt-1 using antisense oligonucleotides (ASO) affects inflammatory and apoptotic signaling in tenocytes. Transient transfection of tenocytes with ASO against Sirt-1 induced expression of Bax and other proteins involved in apoptosis (cleaved caspase-3 and poly(ADP-ribose)polymerase), acetylation of tumor suppressor p53, and mitochondrial degradation. Interestingly, Sirt-1 was found to interact directly with p53. In contrast, Sirt-1 activator resveratrol inhibited interleukin-1β (IL-1β)- and nicotinamide-induced NF-κB activation and p65 acetylation and suppressed the activation of IκB-α kinase. Resveratrol also reversed the IL-1β- or nicotinamide-induced up-regulation of various gene products that mediate inflammation (cyclooxygenase-2) and matrix degradation (matrix metalloproteinase-9) that are known to be regulated by NF-κB. Knockdown of Sirt-1 by using ASO abolished the inhibitory effects of resveratrol on inflammatory and apoptotic signaling including Akt activation and SCAX suppression. Down-regulation of histone deacetylase Sirt-1 by mRNA interference abrogated the effect of resveratrol on NF-κB suppression, thus highlighting the crucial homeostatic role of this enzyme. Overall, these results suggest for the first time that Sirt-1 can regulate p53 and NF-κB signaling via deacetylation, demonstrating a novel role for resveratrol in the treatment of tendinitis/tendinopathy. FAU - Busch, Franziska AU - Busch F AD - Institute of Anatomy, Ludwig-Maximilians-University Munich, Munich 80336 Germany. FAU - Mobasheri, Ali AU - Mobasheri A FAU - Shayan, Parviz AU - Shayan P FAU - Stahlmann, Ralf AU - Stahlmann R FAU - Shakibaei, Mehdi AU - Shakibaei M LA - eng PT - Journal Article DEP - 20120611 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (BAX protein, human) RN - 0 (Enzyme Activators) RN - 0 (Interleukin-1beta) RN - 0 (NF-kappa B) RN - 0 (RNA, Small Interfering) RN - 0 (Stilbenes) RN - 0 (TP53 protein, human) RN - 0 (Tumor Suppressor Protein p53) RN - 0 (bcl-2-Associated X Protein) RN - EC 2.4.2.30 (PARP1 protein, human) RN - EC 2.4.2.30 (Poly (ADP-Ribose) Polymerase-1) RN - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.4.22.- (CASP3 protein, human) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.5.1.- (SIRT1 protein, human) RN - EC 3.5.1.- (Sirtuin 1) RN - Q369O8926L (Resveratrol) SB - IM MH - Acetylation MH - *Apoptosis MH - Caspase 3/metabolism MH - Cell Proliferation MH - Cell Survival MH - Cells, Cultured MH - Enzyme Activation MH - Enzyme Activators/pharmacology MH - Gene Knockdown Techniques MH - Humans MH - Interleukin-1beta/pharmacology/physiology MH - Mitochondria/metabolism MH - NF-kappa B/metabolism MH - Poly (ADP-Ribose) Polymerase-1 MH - Poly(ADP-ribose) Polymerases/metabolism MH - Protein Binding MH - Protein Processing, Post-Translational MH - Proteolysis MH - Proto-Oncogene Proteins c-akt/metabolism MH - RNA Interference MH - RNA, Small Interfering/genetics MH - Resveratrol MH - Signal Transduction MH - Sirtuin 1/genetics/*metabolism/physiology MH - Stilbenes/pharmacology MH - Tendinopathy/enzymology/*metabolism/pathology MH - Tendons/metabolism/*pathology MH - Tumor Suppressor Protein p53/metabolism MH - bcl-2-Associated X Protein/metabolism PMC - PMC3406664 EDAT- 2012/06/13 06:00 MHDA- 2012/10/12 06:00 PMCR- 2013/07/27 CRDT- 2012/06/13 06:00 PHST- 2012/06/13 06:00 [entrez] PHST- 2012/06/13 06:00 [pubmed] PHST- 2012/10/12 06:00 [medline] PHST- 2013/07/27 00:00 [pmc-release] AID - S0021-9258(20)73591-X [pii] AID - M112.355420 [pii] AID - 10.1074/jbc.M112.355420 [doi] PST - ppublish SO - J Biol Chem. 2012 Jul 27;287(31):25770-81. doi: 10.1074/jbc.M112.355420. Epub 2012 Jun 11. PMID- 8771475 OWN - NLM STAT- MEDLINE DCOM- 19961024 LR - 20220331 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 21 IP - 3 DP - 1996 Jun TI - Mycobacterial tenosynovitis of the flexor tendons of the hand. A report of five cases. PG - 351-4 AB - We present five cases of mycobacterial tenosynovitis of the flexor tendons of the fingers. These cases were observed during the last 12 years and treated by the same surgeon. This pathology is uncommon now, but it is becoming more frequent, especially in patients with diminished immunity. The diagnosis was most commonly made after synovectomy in patients presenting with carpal tunnel syndrome associated with slightly painful swelling at the wrist. Histological and bacteriological examinations are very important and revealed tuberculosis in four of our patients and mycobacterium in one, and the treatment consists of synovectomy and appropriate antibiotics. The functional result is usually good, but recurrence is not uncommon. Long-term follow-up is necessary. Local corticosteroid therapy could have a part in the causation of this condition. FAU - Regnard, P J AU - Regnard PJ AD - SOS Mains Dijon, Bourgogne, France. FAU - Barry, P AU - Barry P FAU - Isselin, J AU - Isselin J LA - eng PT - Case Reports PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Antibiotics, Antitubercular) RN - 0 (Antitubercular Agents) RN - 8G167061QZ (Ethambutol) RN - V83O1VOZ8L (Isoniazid) RN - VJT6J7R4TR (Rifampin) SB - IM MH - Adult MH - Aged MH - Antibiotics, Antitubercular/therapeutic use MH - Antitubercular Agents/therapeutic use MH - Carpal Tunnel Syndrome/drug therapy/microbiology/pathology/surgery MH - Combined Modality Therapy MH - Ethambutol/therapeutic use MH - Female MH - Hand/*microbiology/pathology MH - Humans MH - Isoniazid/therapeutic use MH - Male MH - Middle Aged MH - Mycobacterium avium-intracellulare Infection/drug therapy/pathology/surgery MH - Rifampin/therapeutic use MH - Tenosynovitis/drug therapy/*microbiology/pathology/surgery MH - Tuberculosis/drug therapy/*pathology/surgery EDAT- 1996/06/01 00:00 MHDA- 1996/06/01 00:01 CRDT- 1996/06/01 00:00 PHST- 1996/06/01 00:00 [pubmed] PHST- 1996/06/01 00:01 [medline] PHST- 1996/06/01 00:00 [entrez] AID - 10.1016/s0266-7681(05)80201-3 [doi] PST - ppublish SO - J Hand Surg Br. 1996 Jun;21(3):351-4. doi: 10.1016/s0266-7681(05)80201-3. PMID- 608285 OWN - NLM STAT- MEDLINE DCOM- 19780524 LR - 20190516 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 129 DP - 1977 Nov-Dec TI - Coccidioidomycosis of the extensor tenosynovium of the wrist. A case report. PG - 245-7 AB - A 59-year-old man had isolated coccidioidomycosis infestation of the tenosynovium of the wrist extensor tendons resistent to surgical and amphotericin chemotherapy. Some improvement has been noted on Miconazole chemothearapy, but neither the long term side effects nor clinical results are known. FAU - Danzig, L A AU - Danzig LA FAU - Fierer, J AU - Fierer J LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 7NNO0D7S5M (Miconazole) RN - 7XU7A7DROE (Amphotericin B) SB - IM MH - Amphotericin B/therapeutic use MH - *Coccidioidomycosis/diagnosis/therapy MH - Humans MH - Male MH - Miconazole/therapeutic use MH - Middle Aged MH - Tenosynovitis/diagnosis/*etiology/therapy MH - *Wrist EDAT- 1977/11/01 00:00 MHDA- 1977/11/01 00:01 CRDT- 1977/11/01 00:00 PHST- 1977/11/01 00:00 [pubmed] PHST- 1977/11/01 00:01 [medline] PHST- 1977/11/01 00:00 [entrez] AID - 10.1097/00003086-197711000-00036 [doi] PST - ppublish SO - Clin Orthop Relat Res. 1977 Nov-Dec;(129):245-7. doi: 10.1097/00003086-197711000-00036. PMID- 7298680 OWN - NLM STAT- MEDLINE DCOM- 19820128 LR - 20201007 IS - 0301-620X (Print) IS - 0301-620X (Linking) VI - 63B IP - 4 DP - 1981 TI - Non-tuberculous mycobacterial infection of the tendon sheaths in the hand. A report of six cases. PG - 542-4 FAU - Dixon, J H AU - Dixon JH LA - eng PT - Case Reports PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 8G167061QZ (Ethambutol) RN - VJT6J7R4TR (Rifampin) SB - IM MH - Adult MH - Ethambutol/therapeutic use MH - Female MH - *Hand MH - Humans MH - Male MH - Middle Aged MH - Mycobacterium Infections/*diagnosis MH - Mycobacterium Infections, Nontuberculous/*diagnosis/drug therapy MH - Rifampin/therapeutic use MH - *Tendons EDAT- 1981/01/01 00:00 MHDA- 1981/01/01 00:01 CRDT- 1981/01/01 00:00 PHST- 1981/01/01 00:00 [pubmed] PHST- 1981/01/01 00:01 [medline] PHST- 1981/01/01 00:00 [entrez] AID - 10.1302/0301-620X.63B4.7298680 [doi] PST - ppublish SO - J Bone Joint Surg Br. 1981;63B(4):542-4. doi: 10.1302/0301-620X.63B4.7298680. PMID- 19235604 OWN - NLM STAT- MEDLINE DCOM- 20090713 LR - 20250529 IS - 1029-2470 (Electronic) IS - 1029-2470 (Linking) VI - 43 IP - 4 DP - 2009 Apr TI - The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells. PG - 323-8 LID - 10.1080/10715760902736275 [doi] AB - Tendinitis and tendon rupture during treatment with fluoroquinolone antibiotics is thought to be mediated via oxidative stress. This study investigated whether ciprofloxacin and moxifloxacin cause oxidative stress and mitochondrial damage in cultured normal human Achilles' tendon cells and whether an antioxidant targeted to mitochondria (MitoQ) would protect against such damage better than a non-mitochondria targeted antioxidant. Human tendon cells from normal Achilles' tendons were exposed to 0-0.3 mM antibiotic for 24 h and 7 days in the presence of 1 microM MitoQ or an untargeted form, idebenone. Both moxifloxacin and ciprofloxacin resulted in up to a 3-fold increase in the rate of oxidation of dichlorodihydrofluorescein, a marker of general oxidative stress in tenocytes (p<0.0001) and loss of mitochondrial membrane permeability (p<0.001). In cells treated with MitoQ the oxidative stress was less and mitochondrial membrane potential was maintained. Mitochondrial damage to tenocytes during fluoroquinolone treatment may be involved in tendinitis and tendon rupture. FAU - Lowes, Damon A AU - Lowes DA AD - Division of Applied Medicine, School of Medicine & Dentistry, University of Aberdeen, UK. FAU - Wallace, Carol AU - Wallace C FAU - Murphy, Michael P AU - Murphy MP FAU - Webster, Nigel R AU - Webster NR FAU - Galley, Helen F AU - Galley HF LA - eng GR - MC_U105663142/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20090223 PL - England TA - Free Radic Res JT - Free radical research JID - 9423872 RN - 0 (Anti-Infective Agents) RN - 0 (Antioxidants) RN - 0 (Aza Compounds) RN - 0 (Fluoroquinolones) RN - 0 (Organophosphorus Compounds) RN - 0 (Quinolines) RN - 1339-63-5 (Ubiquinone) RN - 47BYS17IY0 (mitoquinone) RN - 5E8K9I0O4U (Ciprofloxacin) RN - U188XYD42P (Moxifloxacin) SB - IM MH - Achilles Tendon/cytology/*drug effects/injuries/*metabolism MH - Anti-Infective Agents/toxicity MH - Antioxidants/*pharmacology MH - Aza Compounds/*toxicity MH - Cell Survival/drug effects MH - Cells, Cultured MH - Ciprofloxacin/*toxicity MH - Fluoroquinolones MH - Humans MH - Intracellular Membranes/drug effects/metabolism MH - Membrane Potential, Mitochondrial/drug effects MH - Mitochondria/drug effects/metabolism MH - Moxifloxacin MH - Organophosphorus Compounds/*pharmacology MH - Oxidative Stress/drug effects MH - Quinolines/*toxicity MH - Rupture/etiology MH - Tendinopathy/etiology MH - Ubiquinone/*analogs & derivatives/pharmacology EDAT- 2009/02/25 09:00 MHDA- 2009/07/14 09:00 CRDT- 2009/02/25 09:00 PHST- 2009/02/25 09:00 [entrez] PHST- 2009/02/25 09:00 [pubmed] PHST- 2009/07/14 09:00 [medline] AID - 908977491 [pii] AID - 10.1080/10715760902736275 [doi] PST - ppublish SO - Free Radic Res. 2009 Apr;43(4):323-8. doi: 10.1080/10715760902736275. Epub 2009 Feb 23. PMID- 3668385 OWN - NLM STAT- MEDLINE DCOM- 19871204 LR - 20210217 IS - 0022-2275 (Print) IS - 0022-2275 (Linking) VI - 28 IP - 8 DP - 1987 Aug TI - Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid. PG - 1006-12 AB - Large quantities of C27 bile alcohols hydroxylated at C-25 are excreted in the bile and urine of patients with cerebrotendinous xanthomatosis, a lipid storage disease that results from defective bile acid synthesis. The presence of both biliary and urinary bile alcohols reflects impaired bile acid synthesis. After treatment of samples with beta-glucuronidase, plasma bile alcohols were quantitated by gas-liquid chromatography-mass spectrometry. 5 beta-Cholestane-3 alpha,7 alpha,12 alpha,25-tetrol (334 micrograms/dl) was found to be the major bile alcohol, followed by 5 beta-cholestane-3 alpha,7 alpha,12 alpha,23R,25-pentol (65 micrograms/dl), and 5 beta-cholestane-3 alpha,7 alpha,12 alpha,24(R and S),25-pentols (62.5 micrograms/dl and 64.5 micrograms/dl, respectively) in the plasma of these patients. When compared to biliary and urinary bile alcohol excretions, the plasma pattern resembled bile where 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol glucuronide predominated. In contrast, urinary bile alcohols were composed chiefly of 5 beta-cholestanepentol glucuronides with only small amounts of 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol glucuronide. Treatment with chenodeoxycholic acid, which suppresses abnormal bile acid synthesis in these patients, reduced plasma bile alcohol concentrations dramatically. These results show that large quantities of bile alcohol glucuronides, particularly 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrolglucuronide, circulate in plasma of patients with cerebrotendinous xanthomatosis. The plasma bile alcohols closely resemble biliary bile alcohols which indicates their hepatic origin. The large quantities of polyhydroxylated bile alcohols in the urine may suggest their formation, at least in part, from 5 beta-cholestane-3 alpha,7 alpha,12 alpha,25-tetrol by renal hydroxylating mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Batta, A K AU - Batta AK AD - Department of Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark 07103. FAU - Salen, G AU - Salen G FAU - Shefer, S AU - Shefer S FAU - Tint, G S AU - Tint GS FAU - Batta, M AU - Batta M LA - eng GR - AM-18707/AM/NIADDK NIH HHS/United States GR - AM-26756/AM/NIADDK NIH HHS/United States GR - HL-17818/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Lipid Res JT - Journal of lipid research JID - 0376606 RN - 0 (Cholestanols) RN - 0 (Glucuronates) RN - 0GEI24LG0J (Chenodeoxycholic Acid) SB - IM MH - Adult MH - Brain Diseases/*blood/drug therapy MH - Chenodeoxycholic Acid/*pharmacology MH - Cholestanols/*blood MH - Female MH - Glucuronates/*blood MH - Humans MH - Male MH - Middle Aged MH - Muscular Diseases/*blood/drug therapy MH - Tendons MH - Xanthomatosis/*blood/drug therapy EDAT- 1987/08/01 00:00 MHDA- 1987/08/01 00:01 CRDT- 1987/08/01 00:00 PHST- 1987/08/01 00:00 [pubmed] PHST- 1987/08/01 00:01 [medline] PHST- 1987/08/01 00:00 [entrez] AID - S0022-2275(20)38632-6 [pii] PST - ppublish SO - J Lipid Res. 1987 Aug;28(8):1006-12. PMID- 5055164 OWN - NLM STAT- MEDLINE DCOM- 19721019 LR - 20160512 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 54 IP - 3 DP - 1972 Apr TI - Histoplasmosis of the common palmar tendon sheath. PG - 676-8 FAU - Perlman, R AU - Perlman R FAU - Jubelirer, R A AU - Jubelirer RA FAU - Schwarz, J AU - Schwarz J LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 7XU7A7DROE (Amphotericin B) SB - IM MH - Adult MH - Amphotericin B/therapeutic use MH - *Hand MH - *Histoplasmosis/drug therapy/pathology/surgery MH - Humans MH - Male MH - Recurrence MH - *Tendons/pathology/surgery MH - Wrist EDAT- 1972/04/01 00:00 MHDA- 1972/04/01 00:01 CRDT- 1972/04/01 00:00 PHST- 1972/04/01 00:00 [pubmed] PHST- 1972/04/01 00:01 [medline] PHST- 1972/04/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Am. 1972 Apr;54(3):676-8. PMID- 3728782 OWN - NLM STAT- MEDLINE DCOM- 19860813 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 14 IP - 4 DP - 1986 Jul-Aug TI - Healing of experimental muscle strains and the effects of nonsteroidal antiinflammatory medication. PG - 303-8 AB - The healing process of muscle strains and the effect of nonsteroidal antiinflammatory medication were studied using an experimental animal model. A standardized strain of the tibialis anterior muscle in adult male rats was produced by a controlled stretch of the muscle. Groups I and II underwent a unilateral strain of the tibialis anterior muscle and were immobilized in the postinjury period. The rats in Group II were fed piroxicam in the postinjury period. Group III underwent a sham procedure and were also immobilized. At 0, 2, 4, and 11 days postinjury both injured and contralateral control muscles were evaluated by determining tensile strength characteristics and histologic appearance. Group I showed a significant drop in maximum failure load to 25.7% of the control leg at Day 2 with a gradual return to the level of Group III at Days 4 and 11 (40.9% and 50.1%). Group II showed a similar drop but was still stronger than Group I at 2 days with 40.8% of the control leg and continued to drop until 4 days postinjury (33.7%). Histology showed a delay in inflammatory reaction and muscle regeneration in Group II. At 11 days both Groups I and II showed regenerated muscle fibers bridging the entire defect and an increase in endomyseal fibrosis. It is concluded that muscle strains continue to weaken in the early postinjury period. Non-steroidal antiinflammatory medication, such as piroxicam, might delay muscle regeneration. FAU - Almekinders, L C AU - Almekinders LC FAU - Gilbert, J A AU - Gilbert JA LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Thiazines) RN - 13T4O6VMAM (Piroxicam) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*therapeutic use MH - Male MH - Muscles/pathology/physiopathology MH - Piroxicam MH - Rats MH - Rats, Inbred Strains MH - Sprains and Strains/drug therapy/pathology/*physiopathology MH - Tendons/pathology MH - Tensile Strength MH - Thiazines/therapeutic use MH - Time Factors MH - Wound Healing/*drug effects EDAT- 1986/07/01 00:00 MHDA- 1986/07/01 00:01 CRDT- 1986/07/01 00:00 PHST- 1986/07/01 00:00 [pubmed] PHST- 1986/07/01 00:01 [medline] PHST- 1986/07/01 00:00 [entrez] AID - 10.1177/036354658601400411 [doi] PST - ppublish SO - Am J Sports Med. 1986 Jul-Aug;14(4):303-8. doi: 10.1177/036354658601400411. PMID- 38069418 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240121 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 23 DP - 2023 Dec 4 TI - Examining the Potential of Vitamin C Supplementation in Tissue-Engineered Equine Superficial Digital Flexor Tendon Constructs. LID - 10.3390/ijms242317098 [doi] LID - 17098 AB - Because equine tendinopathies are slow to heal and often recur, therapeutic strategies are being considered that aid tendon repair. Given the success of utilizing vitamin C to promote tenogenesis in other species, we hypothesized that vitamin C supplementation would produce dose-dependent improvements in the tenogenic properties of tendon proper (TP) and peritenon (PERI) cells of the equine superficial digital flexor tendon (SDFT). Equine TP- and PERI-progenitor-cell-seeded fibrin three-dimensional constructs were supplemented with four concentrations of vitamin C. The gene expression profiles of the constructs were assessed with 3'-Tag-Seq and real-time quantitative polymerase chain reaction (RT-qPCR); collagen content and fibril ultrastructure were also analyzed. Moreover, cells were challenged with dexamethasone to determine the levels of cytoprotection afforded by vitamin C. Expression profiling demonstrated that vitamin C had an anti-inflammatory effect on TP and PERI cell constructs. Moreover, vitamin C supplementation mitigated the degenerative pathways seen in tendinopathy and increased collagen content in tendon constructs. When challenged with dexamethasone in two-dimensional culture, vitamin C had a cytoprotective effect for TP cells but not necessarily for PERI cells. Future studies will explore the effects of vitamin C on these cells during inflammation and within the tendon niche in vivo. FAU - Mienaltowski, Michael J AU - Mienaltowski MJ AUID- ORCID: 0000-0001-6456-9894 AD - Department of Animal Science, College of Agricultural & Environmental Sciences, University of California Davis, Davis, CA 95616, USA. FAU - Callahan, Mitchell AU - Callahan M AD - Department of Animal Science, College of Agricultural & Environmental Sciences, University of California Davis, Davis, CA 95616, USA. FAU - Gonzales, Nicole L AU - Gonzales NL AD - School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA. FAU - Wong, Angelique AU - Wong A AD - Department of Animal Science, College of Agricultural & Environmental Sciences, University of California Davis, Davis, CA 95616, USA. LA - eng GR - T35 OD010956/OD/NIH HHS/United States PT - Journal Article DEP - 20231204 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Animals MH - Horses MH - *Tendons/metabolism MH - Collagen/metabolism MH - Tissue Engineering/methods MH - *Tendinopathy/drug therapy/metabolism MH - Ascorbic Acid/pharmacology/metabolism MH - Dexamethasone/pharmacology/metabolism PMC - PMC10707379 OTO - NOTNLM OT - equine OT - peritenon OT - tendon OT - three-dimensional construct OT - vitamin C COIS- The authors declare no conflict of interest. EDAT- 2023/12/09 10:45 MHDA- 2023/12/17 09:43 PMCR- 2023/12/04 CRDT- 2023/12/09 01:16 PHST- 2023/09/15 00:00 [received] PHST- 2023/11/26 00:00 [revised] PHST- 2023/12/01 00:00 [accepted] PHST- 2023/12/17 09:43 [medline] PHST- 2023/12/09 10:45 [pubmed] PHST- 2023/12/09 01:16 [entrez] PHST- 2023/12/04 00:00 [pmc-release] AID - ijms242317098 [pii] AID - ijms-24-17098 [pii] AID - 10.3390/ijms242317098 [doi] PST - epublish SO - Int J Mol Sci. 2023 Dec 4;24(23):17098. doi: 10.3390/ijms242317098. PMID- 6487059 OWN - NLM STAT- MEDLINE DCOM- 19841114 LR - 20131121 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 65 IP - 10 DP - 1984 Oct TI - Fast walking velocity in health and Duchenne muscular dystrophy: a statistical analysis. PG - 573-8 AB - Fast walking velocity was measured in 335 apparently healthy subjects, 180 males and 155 females, whose ages ranged from 3.5 to 24 years. These velocities increased with age and approached an asymptote of 3.44m/sec in males and 3.17 m/sec in females, a statistically significant difference (p less than 0.001). This parameter was also measured serially over periods of 18 to 132 months in 15 patients with Duchenne muscular dystrophy. A decrease in walking rate began between ages four and six. This decline was found to fit linear and monoexponential decay mode models equally. Average linear decay for all 15 patients was 0.0308 m/sec/month; and the average fractional decay was 0.0349/month. On average, by 10 years, the fast walking rate was reduced to about 29% of normal. This measure of disease progression followed a unique course in each subject, which could be mathematically characterized by a unique decay rate, and a unique walking velocity at age 10 years. Thus, in contrast to natural speed walking, the measurement of fast walking velocity has proved to be a simple and useful index for characterizing disease progression in Duchenne muscular dystrophy, and for evaluating therapeutic interventions. FAU - Cohen, L AU - Cohen L FAU - Morgan, J AU - Morgan J FAU - Babbs, R Jr AU - Babbs R Jr FAU - Karrison, T G AU - Karrison TG FAU - Giacomoni, M AU - Giacomoni M LA - eng GR - 20-2MOIRR00305-16/RR/NCRR NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 731DCA35BT (Diethylstilbestrol) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Braces MH - Child MH - Child, Preschool MH - Diethylstilbestrol/therapeutic use MH - Female MH - Humans MH - *Locomotion MH - Male MH - Muscular Dystrophies/diagnosis/*physiopathology/therapy MH - Prednisolone/therapeutic use MH - Prognosis MH - Tendons/surgery MH - Time Factors EDAT- 1984/10/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1984/10/01 00:00 PHST- 1984/10/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1984/10/01 00:00 [entrez] PST - ppublish SO - Arch Phys Med Rehabil. 1984 Oct;65(10):573-8. PMID- 18550435 OWN - NLM STAT- MEDLINE DCOM- 20090804 LR - 20161020 IS - 1440-2440 (Print) IS - 1878-1861 (Linking) VI - 12 IP - 3 DP - 2009 May TI - Tendinopathy and drugs--potential implications for beneficial and detrimental effects on painful tendons. PG - 423 LID - 10.1016/j.jsams.2008.03.005 [doi] FAU - Knobloch, Karsten AU - Knobloch K LA - eng PT - Comment PT - Letter DEP - 20080611 PL - Australia TA - J Sci Med Sport JT - Journal of science and medicine in sport JID - 9812598 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - N12000U13O (Doxycycline) RN - WK2XYI10QM (Ibuprofen) SB - IM CON - J Sci Med Sport. 2008 Jun;11(3):235-8. doi: 10.1016/j.jsams.2007.09.002. PMID: 18077212 MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Athletic Injuries/*drug therapy MH - Doxycycline/therapeutic use MH - Drug Administration Schedule MH - Drug Therapy, Combination MH - Humans MH - Ibuprofen/therapeutic use MH - Tendinopathy/*drug therapy EDAT- 2008/06/14 09:00 MHDA- 2009/08/06 09:00 CRDT- 2008/06/14 09:00 PHST- 2008/03/06 00:00 [received] PHST- 2008/03/31 00:00 [accepted] PHST- 2008/06/14 09:00 [pubmed] PHST- 2009/08/06 09:00 [medline] PHST- 2008/06/14 09:00 [entrez] AID - S1440-2440(08)00073-X [pii] AID - 10.1016/j.jsams.2008.03.005 [doi] PST - ppublish SO - J Sci Med Sport. 2009 May;12(3):423. doi: 10.1016/j.jsams.2008.03.005. Epub 2008 Jun 11. PMID- 6245095 OWN - NLM STAT- MEDLINE DCOM- 19800625 LR - 20201007 IS - 0301-620X (Print) IS - 0301-620X (Linking) VI - 62-B IP - 2 DP - 1980 May TI - Improvement of gliding function of flexor tendons by topically applied enriched collagen solution. PG - 208-13 AB - The long flexor tendons of the second, third and fourth toes of 94 chickens were cut and sutured. After operation the birds were divided into three groups. To reduce peritendinous adhesions, an aqueous solution of beta-aminopropionitrile (BAPN) was added to a solution of enriched native collagen (ECS) and applied to the cut tendons of one group; untreated controls and controls treated with collagen solution alone comprised the other groups. Chickens from each group were killed one, two, three, four and five weeks after operation. The results were evaluated both biomechanically and biochemically. It was found that the collagen solution alone had the same effect as the treatment with BAPN. It is suggested that the exogenous collagen present at the site of injury binds the collagenase inhibitor released by tendon cells, thus providing enough active collagenase to control the formation of fibrous adhesions. The inefficiency of BAPN in these experiments might have been due to either inadequate dosage or wrong timing, or both. FAU - Porat, S AU - Porat S FAU - Rousso, M AU - Rousso M FAU - Shoshan, S AU - Shoshan S LA - eng PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Proteins) RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) RN - EC 3.4.24.3 (Microbial Collagenase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Aminopropionitrile/*therapeutic use MH - Animals MH - Biomechanical Phenomena MH - Chickens MH - Collagen/*therapeutic use MH - DNA/analysis MH - Foot MH - Hydroxyproline/analysis MH - Microbial Collagenase/antagonists & inhibitors MH - Proteins/analysis MH - Tendon Injuries/physiopathology MH - Tendons/analysis/*drug effects MH - Tissue Adhesions MH - Wound Healing/*drug effects EDAT- 1980/05/01 00:00 MHDA- 1980/05/01 00:01 CRDT- 1980/05/01 00:00 PHST- 1980/05/01 00:00 [pubmed] PHST- 1980/05/01 00:01 [medline] PHST- 1980/05/01 00:00 [entrez] AID - 10.1302/0301-620X.62B2.6245095 [doi] PST - ppublish SO - J Bone Joint Surg Br. 1980 May;62-B(2):208-13. doi: 10.1302/0301-620X.62B2.6245095. PMID- 5593911 OWN - NLM STAT- MEDLINE DCOM- 19680919 LR - 20061115 IS - 0001-5415 (Print) IS - 0001-5415 (Linking) VI - 34 IP - 2 DP - 1967 Apr TI - [Reconstruction of joints and tendons using silicone oils of Czechoslovak production. Experimental study]. PG - 187-90 FAU - Ondrouch, A AU - Ondrouch A FAU - Ruppert, J AU - Ruppert J FAU - Schlupek, A AU - Schlupek A LA - cze PT - Journal Article TT - Plastika kloubů a slach pomocí silikonových olejů nasí výroby. Experimentální studie. PL - Czech Republic TA - Acta Chir Orthop Traumatol Cech JT - Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca JID - 0407123 RN - 0 (Oils) RN - 0 (Silicones) SB - IM MH - Animals MH - Contracture/surgery MH - Fracture Fixation MH - Humans MH - Joint Diseases/*surgery MH - Methods MH - Mice MH - Oils MH - Rabbits MH - Silicones/*therapeutic use MH - Tendons/*surgery EDAT- 1967/04/01 00:00 MHDA- 1967/04/01 00:01 CRDT- 1967/04/01 00:00 PHST- 1967/04/01 00:00 [pubmed] PHST- 1967/04/01 00:01 [medline] PHST- 1967/04/01 00:00 [entrez] PST - ppublish SO - Acta Chir Orthop Traumatol Cech. 1967 Apr;34(2):187-90. PMID- 6114236 OWN - NLM STAT- MEDLINE DCOM- 19810925 LR - 20091111 IS - 0025-0317 (Print) IS - 0025-0317 (Linking) VI - 23 IP - 4 DP - 1980 TI - [Experimental reattachment of tendons with cyano-acryl adhesive (author's transl)]. PG - 296-301 FAU - Endroödi, J AU - Endroödi J FAU - Simonka, A J AU - Simonka AJ FAU - Barabás, K AU - Barabás K FAU - Kiss, G AU - Kiss G FAU - Dósa, G AU - Dósa G LA - hun PT - Comparative Study PT - Journal Article TT - Kísérletes ínragasztás cianoakriláttal. PL - Hungary TA - Magy Traumatol Orthop Helyreallito Seb JT - Magyar traumatologia, orthopaedia es helyreallito sebeszet JID - 0074071 RN - 0 (Cyanoacrylates) RN - 0 (Tissue Adhesives) SB - IM MH - Animals MH - Cyanoacrylates/*therapeutic use MH - Rabbits MH - Suture Techniques MH - Tendons/*transplantation MH - Tissue Adhesives/therapeutic use EDAT- 1980/01/01 00:00 MHDA- 1980/01/01 00:01 CRDT- 1980/01/01 00:00 PHST- 1980/01/01 00:00 [pubmed] PHST- 1980/01/01 00:01 [medline] PHST- 1980/01/01 00:00 [entrez] PST - ppublish SO - Magy Traumatol Orthop Helyreallito Seb. 1980;23(4):296-301. PMID- 16442981 OWN - NLM STAT- MEDLINE DCOM- 20060306 LR - 20220309 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 87 IP - 2 DP - 2006 Feb TI - The effects of substance P on the biomechanic properties of ruptured rat Achilles' tendon. PG - 254-8 AB - OBJECTIVE: To determine whether injection of substance P into the paratendinous region of a ruptured and subsequently sutured rat Achilles' tendon alters the biomechanic properties of the tendon. DESIGN: Interventional animal study. SETTING: Animal laboratory at a university hospital. ANIMALS: Ninety-six 2-month-old, male Sprague-Dawley rats. INTERVENTION: Injection of saline, substance P (10(-6)micromol/kg of body weight [BW] or 10(-8)micromol/kg BW) associated with neutral endopeptidase inhibitors, or neutral endopeptidase inhibitors alone into the paratendinous region of ruptured and subsequently sutured rat Achilles' tendons from the second until the sixth day postoperatively. MAIN OUTCOME MEASURES: Stress at maximal load and work to maximal load and stiffness. RESULTS: Stress at maximal load was higher in the groups injected with substance P than in the saline group in the first, second, and sixth weeks. Work to maximal load was higher from the second until the sixth weeks in the substance P-treated groups than in the saline group. Stiffness did not differ between the 4 groups in any of the weeks. CONCLUSIONS: Injection of substance P into the paratendinous region of ruptured and subsequently sutured rat Achilles' tendons improved tendon healing by enhancing stress at maximal load and work to maximal load. However, stiffness was not significantly affected. FAU - Steyaert, Adelheid E AU - Steyaert AE AD - Department of Physical Medicine and Rehabilitation, Ghent University Hospital, Belgium. Adelheid.Steyaert@Ugent.be FAU - Burssens, Peter J AU - Burssens PJ FAU - Vercruysse, Chris W AU - Vercruysse CW FAU - Vanderstraeten, Guy G AU - Vanderstraeten GG FAU - Verbeeck, Ronald M AU - Verbeeck RM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 0 (Neurotransmitter Agents) RN - 0 (Protease Inhibitors) RN - 33507-63-0 (Substance P) RN - 9G64RSX1XD (Captopril) RN - B79L7B5X3Z (Thiorphan) SB - IM MH - Achilles Tendon/*drug effects/injuries/physiopathology MH - Animals MH - Biomechanical Phenomena MH - Captopril/therapeutic use MH - Male MH - Neurotransmitter Agents/*therapeutic use MH - Protease Inhibitors/therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Rupture MH - Stress, Mechanical MH - Substance P/*therapeutic use MH - Thiorphan/therapeutic use MH - Wound Healing/*drug effects EDAT- 2006/01/31 09:00 MHDA- 2006/03/07 09:00 CRDT- 2006/01/31 09:00 PHST- 2005/04/20 00:00 [received] PHST- 2005/09/29 00:00 [revised] PHST- 2005/10/21 00:00 [accepted] PHST- 2006/01/31 09:00 [pubmed] PHST- 2006/03/07 09:00 [medline] PHST- 2006/01/31 09:00 [entrez] AID - S0003-9993(05)01361-4 [pii] AID - 10.1016/j.apmr.2005.10.025 [doi] PST - ppublish SO - Arch Phys Med Rehabil. 2006 Feb;87(2):254-8. doi: 10.1016/j.apmr.2005.10.025. PMID- 17430133 OWN - NLM STAT- MEDLINE DCOM- 20070503 LR - 20191110 IS - 1871-5257 (Print) IS - 1871-5257 (Linking) VI - 5 IP - 2 DP - 2007 Apr TI - Sclerosing polidocanol injections of small vessels to treat the chronic painful tendon. PG - 97-100 AB - The chronic painful tendon (tendinopathy, tendinosis) is generally considered difficult to treat, not seldom causing long-term disability and sometimes ending the sports or work carreér. Most common sites for tendinopathy are the Achilles-, patellar-, extensor carpi radialis brevis (ERCB)-, and supraspinatus tendons. The origin of pain has for many years been unknown, but recently, by using ultrasound (US) + colour Doppler (CD), immunohistochemical analyses of tendon biopsies, and diagnostic injections of local anaestesia, we found a close relationship between areas with vasculo-neural ingrowth and tendon pain. Sensory nerves (Substance-P-SP and Calcitonin Gene Related Peptide-CGRP) were found inside and outside the vascular wall. In following clinical studies we have demonstrated good short-and mid-term clinical results using treatment with US+CD-guided sclerosing polidocanol injections, targeting the area with neovessels outside the tendon. Two-year follow ups have showed remaining good clinical results, and sonographically signs of remodelling with a significantly thinner tendon with a more normal structure. Whether the effects of polidocanol are mediated through destruction of neovessels, activity on nerves or a combination, is under evaluation. FAU - Alfredson, H AU - Alfredson H AD - Sports Medicine Unit, University of Umeå, 901 87 Umeå, Sweden. hakan.alfredson@idrott.umu.se FAU - Lorentzon, R AU - Lorentzon R LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Cardiovasc Hematol Agents Med Chem JT - Cardiovascular & hematological agents in medicinal chemistry JID - 101266881 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Humans MH - Neovascularization, Pathologic/*drug therapy MH - Pain/*drug therapy MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Tendons/*blood supply/diagnostic imaging/*drug effects MH - Ultrasonography, Doppler, Color RF - 37 EDAT- 2007/04/14 09:00 MHDA- 2007/05/04 09:00 CRDT- 2007/04/14 09:00 PHST- 2007/04/14 09:00 [pubmed] PHST- 2007/05/04 09:00 [medline] PHST- 2007/04/14 09:00 [entrez] AID - 10.2174/187152507780363232 [doi] PST - ppublish SO - Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):97-100. doi: 10.2174/187152507780363232. PMID- 25428204 OWN - NLM STAT- MEDLINE DCOM- 20160218 LR - 20181113 IS - 1573-2576 (Electronic) IS - 0360-3997 (Linking) VI - 38 IP - 3 DP - 2015 TI - Inflammatory cytokines content in Achilles tendinopathy after phonophoresis treatment combined with gold nanoparticles and diclophenac diethylammonium in rats. PG - 1044-9 LID - 10.1007/s10753-014-0069-x [doi] AB - Tendinitis is a painful condition that occurs in tendons in response to repetitive use or direct trauma. The therapeutic approaches commonly employed to modulate inflammation have not achieved complete success in chronic cases of tendinitis. In this scenario, considering the anti-inflammatory properties of pulsed therapeutic ultrasound and gold nanoparticles (GNPs), this study assesses the possible therapeutic effects of phonophoresis in association with diclophenac diethylammonium and GNPs by measuring the inflammatory parameters interleukin 1β and tumor necrosis factor alpha in acute tendinous injury. Wistar rats were randomly divided into three groups and were treated with phonophoresis and diclophenac diethylammonium, GNP gel, and a combination thereof. A significant decrease in interleukin 1β and tumor necrosis factor alpha occurred in tendons treated with phonophoresis+diclophenac+GNPs. The content of both cytokines were similar after combined treatment with phonophoresis+diclophenac+GNPs. Apart from the anti-inflammatory effect, GNPs transported and enhanced drug action when used with phonophoresis. FAU - Dohnert, Marcelo B AU - Dohnert MB AD - Laboratório de Síntese de Complexos Multifuncionais, Programa de Pós-Graduação em Ciências e Engenharia de Materiais, Universidade do Extremo Sul Catarinense, Av. Universitária, 1105 Universitário, P.O. Box 3167, 88806-000, Criciúma, Santa Catarina, Brazil. FAU - Ferreira, Gabriela K AU - Ferreira GK FAU - Silveira, Paulo Cesar Lock AU - Silveira PC FAU - Zanoni, Elton Torres AU - Zanoni ET FAU - Dohnert, Luciana H AU - Dohnert LH FAU - de Souza, Cláudio Teodoro AU - de Souza CT FAU - Paula, Marcos M S AU - Paula MM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Inflammation JT - Inflammation JID - 7600105 RN - 0 (Anti-Inflammatory Agents) RN - 0 (IL1B protein, rat) RN - 0 (Interleukin-1beta) RN - 0 (Tumor Necrosis Factor-alpha) RN - 144O8QL0L1 (Diclofenac) RN - 7440-57-5 (Gold) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Anti-Inflammatory Agents/therapeutic use MH - Diclofenac/therapeutic use MH - Disease Models, Animal MH - Gold/*therapeutic use MH - Inflammation/therapy MH - Interleukin-1beta/metabolism MH - Male MH - Metal Nanoparticles/*therapeutic use MH - *Phonophoresis MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Tendinopathy/immunology/pathology/*therapy MH - Tumor Necrosis Factor-alpha/metabolism EDAT- 2014/11/28 06:00 MHDA- 2016/02/19 06:00 CRDT- 2014/11/28 06:00 PHST- 2014/11/28 06:00 [entrez] PHST- 2014/11/28 06:00 [pubmed] PHST- 2016/02/19 06:00 [medline] AID - 10.1007/s10753-014-0069-x [doi] PST - ppublish SO - Inflammation. 2015;38(3):1044-9. doi: 10.1007/s10753-014-0069-x. PMID- 718997 OWN - NLM STAT- MEDLINE DCOM- 19790212 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 544 IP - 1 DP - 1978 Nov 15 TI - In vitro studies of the interaction between ascorbic acid and rat tail tendon. PG - 62-8 AB - Ascorbic acid (in its normal and oxidised forms) enhances the mechanical and thermal stability of rat tail tendon. Its effectiveness increases with the concentration but levels off at a value approximately 5 times normal physiological concentration (1--2 mg/100 ml). An analogue, D-isoascorbic acid is also effective, but to a lesser extent. There is some evidence that it reduces reducible aldimine links, especially in young tissues. However, for the most part, its effects are reversible. FAU - Rigby, B J AU - Rigby BJ FAU - Mitchell, T W AU - Mitchell TW LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Aging MH - Animals MH - Ascorbic Acid/analogs & derivatives/*pharmacology MH - Rats MH - Stress, Mechanical MH - Tendons/drug effects/growth & development/*physiology EDAT- 1978/11/15 00:00 MHDA- 1978/11/15 00:01 CRDT- 1978/11/15 00:00 PHST- 1978/11/15 00:00 [pubmed] PHST- 1978/11/15 00:01 [medline] PHST- 1978/11/15 00:00 [entrez] AID - 0304-4165(78)90209-X [pii] AID - 10.1016/0304-4165(78)90209-x [doi] PST - ppublish SO - Biochim Biophys Acta. 1978 Nov 15;544(1):62-8. doi: 10.1016/0304-4165(78)90209-x. PMID- 28139720 OWN - NLM STAT- MEDLINE DCOM- 20181024 LR - 20220408 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 7 DP - 2017 Jan 31 TI - Inhibition of PDGFR signaling prevents muscular fatty infiltration after rotator cuff tear in mice. PG - 41552 LID - 10.1038/srep41552 [doi] LID - 41552 AB - Fatty infiltration in muscle is often observed in patients with sizable rotator cuff tear (RCT) and is thought to be an irreversible event that significantly compromises muscle plasticity and contraction strength. These changes in the mechanical properties of the affected muscle render surgical repair of RCT highly formidable. Therefore, it is important to learn more about the pathology of fatty infiltration to prevent this undesired condition. In the present study, we aimed to generate a mouse model that can reliably recapitulate some of the important characteristics of muscular fatty infiltration after RCT in humans. We found that fatty infiltration can be efficiently induced by a combination of the following procedures: denervation of the suprascapular nerve, transection of the rotator cuff tendon, and resection of the humeral head. Using this model, we found that platelet-derived growth factor receptor-α (PDGFRα)-positive mesenchymal stem cells are induced after this intervention and that inhibition of PDGFR signaling by imatinib treatment can significantly suppress fatty infiltration. Taken together, the present study presents a reliable fatty infiltration mouse model and suggests a key role for PDGFRα-positive mesenchymal stem cells in the process of fatty infiltration after RCT in humans. FAU - Shirasawa, Hideyuki AU - Shirasawa H AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Matsumura, Noboru AU - Matsumura N AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Shimoda, Masayuki AU - Shimoda M AD - Department of Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Oki, Satoshi AU - Oki S AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Yoda, Masaki AU - Yoda M AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Tohmonda, Takahide AU - Tohmonda T AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Kanai, Yae AU - Kanai Y AD - Department of Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Matsumoto, Morio AU - Matsumoto M AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Nakamura, Masaya AU - Nakamura M AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. FAU - Horiuchi, Keisuke AU - Horiuchi K AD - Department of Orthopedic Surgery, and Keio University School of Medicine, Tokyo 160-8582, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170131 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers) RN - 0 (Protein Kinase Inhibitors) RN - 8A1O1M485B (Imatinib Mesylate) RN - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor) SB - IM MH - Adipocytes/metabolism MH - Adipose Tissue/*pathology MH - Animals MH - Biomarkers MH - Denervation MH - Disease Models, Animal MH - Gene Expression MH - Gene Expression Profiling MH - Imatinib Mesylate/pharmacology MH - Mice MH - Muscle, Skeletal/metabolism/pathology MH - Protein Kinase Inhibitors/pharmacology MH - Receptors, Platelet-Derived Growth Factor/genetics/*metabolism MH - Rotator Cuff Injuries/diagnostic imaging/genetics/*metabolism/*pathology MH - Signal Transduction/*drug effects MH - Tendons/metabolism/pathology PMC - PMC5282512 COIS- The authors declare no competing financial interests. EDAT- 2017/02/01 06:00 MHDA- 2018/10/26 06:00 PMCR- 2017/01/31 CRDT- 2017/02/01 06:00 PHST- 2016/09/01 00:00 [received] PHST- 2016/12/21 00:00 [accepted] PHST- 2017/02/01 06:00 [entrez] PHST- 2017/02/01 06:00 [pubmed] PHST- 2018/10/26 06:00 [medline] PHST- 2017/01/31 00:00 [pmc-release] AID - srep41552 [pii] AID - 10.1038/srep41552 [doi] PST - epublish SO - Sci Rep. 2017 Jan 31;7:41552. doi: 10.1038/srep41552. PMID- 13110237 OWN - NLM STAT- MEDLINE DCOM- 20030501 LR - 20181201 IS - 0023-9046 (Print) IS - 0023-9046 (Linking) VI - 18 IP - 8 DP - 1953 Oct TI - Experimental surgery for finding a substitute for synovial tissue of tendons. PG - 1042-55 FAU - JOLICOEUR, A AU - JOLICOEUR A LA - eng PT - Journal Article TT - Expériences chirurgicales en vue de trouver un succédané au tissu synovial des tendons. PL - Canada TA - Laval Med JT - Laval medical JID - 2985217R RN - 0 (Sulfanilamides) RN - 0 (Sulfonamides) RN - 21240MF57M (Sulfanilamide) SB - OM MH - Humans MH - *Muscles MH - Sulfanilamide MH - Sulfanilamides MH - Sulfonamides/*therapeutic use MH - *Synovial Membrane MH - *Tendons OID - CLML: 5425:31404:301:447:451 OTO - NLM OT - *MUSCLES OT - *SULFONAMIDES/therapeutic use OT - *SYNOVIAL MEMBRANE EDAT- 1953/10/01 00:00 MHDA- 1953/10/01 00:01 CRDT- 1953/10/01 00:00 PHST- 1953/10/01 00:00 [pubmed] PHST- 1953/10/01 00:01 [medline] PHST- 1953/10/01 00:00 [entrez] PST - ppublish SO - Laval Med. 1953 Oct;18(8):1042-55. PMID- 25263886 OWN - NLM STAT- MEDLINE DCOM- 20151026 LR - 20220321 IS - 1879-1344 (Electronic) IS - 0144-8617 (Linking) VI - 114 DP - 2014 Dec 19 TI - Evaluation of the ability of xanthan gum/gellan gum/hyaluronan hydrogel membranes to prevent the adhesion of postrepaired tendons. PG - 230-237 LID - S0144-8617(14)00733-4 [pii] LID - 10.1016/j.carbpol.2014.07.049 [doi] AB - After tendon-repair surgery, adhesion between the surgical tendon and the synovial sheath is often presented resulting in poor functional repair of the tendon. This may be prevented using a commercially available mechanical barrier implant, Seprafilm, which is composed of hyaluronan (HA) and carboxymethyl cellulose hydrogels. In a rat model, prepared membranes of various compositions of gellan gum (GG), xanthan gum (XG) and HA as well as Seprafilm were wrapped around repaired tendons and the adhesion of the tendons was examined grossly and histologically after 3 weeks of healing. Certain formulations of the XG/GG/HA hydrogel membranes reduced tendon adhesion with equal efficacy but without reducing the tendon strength compared to Seprafilm. The designed membranes swelled rapidly and blanketed onto the tendon tissue more readily and closely than Seprafilm. Also they degraded slowly, which allowed the membranes to function as barriers for extended periods. CI - Copyright © 2014 Elsevier Ltd. All rights reserved. FAU - Kuo, Shyh Ming AU - Kuo SM AD - Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan. FAU - Chang, Shwu Jen AU - Chang SJ AD - Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan. FAU - Wang, Hung-Yi AU - Wang HY AD - Center for General Education, I-Shou University, Kaohsiung, Taiwan. FAU - Tang, Shu Ching AU - Tang SC AD - Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan. FAU - Yang, Shan-Wei AU - Yang SW AD - Department of Orthopedics, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung, Taiwan; School of Nursing, Fooyin University, Kaohsiung, Taiwan. Electronic address: yangshanwei@yahoo.com.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140819 PL - England TA - Carbohydr Polym JT - Carbohydrate polymers JID - 8307156 RN - 0 (Hydrogels) RN - 0 (Polysaccharides, Bacterial) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 7593U09I4D (gellan gum) RN - TTV12P4NEE (xanthan gum) SB - IM MH - Animals MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry/*therapeutic use MH - Hydrogels/*chemistry MH - Male MH - Polysaccharides, Bacterial/*chemistry MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/*cytology/surgery MH - Tissue Adhesions/*prevention & control OTO - NOTNLM OT - Anti-adhesion OT - Gellan gum OT - Hyaluronan OT - Tendon OT - Xanthan gum EDAT- 2014/09/30 06:00 MHDA- 2015/10/27 06:00 CRDT- 2014/09/30 06:00 PHST- 2014/04/08 00:00 [received] PHST- 2014/07/21 00:00 [revised] PHST- 2014/07/22 00:00 [accepted] PHST- 2014/09/30 06:00 [entrez] PHST- 2014/09/30 06:00 [pubmed] PHST- 2015/10/27 06:00 [medline] AID - S0144-8617(14)00733-4 [pii] AID - 10.1016/j.carbpol.2014.07.049 [doi] PST - ppublish SO - Carbohydr Polym. 2014 Dec 19;114:230-237. doi: 10.1016/j.carbpol.2014.07.049. Epub 2014 Aug 19. PMID- 10722483 OWN - NLM STAT- MEDLINE DCOM- 20000501 LR - 20240929 IS - 0066-4804 (Print) IS - 1098-6596 (Electronic) IS - 0066-4804 (Linking) VI - 44 IP - 4 DP - 2000 Apr TI - Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. PG - 867-72 AB - Despite a relatively low incidence of serious side effects, fluoroquinolones and the fluoroquinolone pefloxacin have been reported to occasionally promote tendinopathy that might result in the complication of spontaneous rupture of tendons. In the present study, we investigated in rodents the intrinsic deleterious effect of pefloxacin (400 mg/kg of body weight) on Achilles tendon proteoglycans and collagen. Proteoglycan synthesis was determined by measurement of in vivo and ex vivo radiosulfate incorporation in mice. Collagen oxidative modifications were measured by carbonyl derivative detection by Western blotting. An experimental model of tendinous ischemia (2 h) and reperfusion (3 days) was achieved in rats. Biphasic changes in proteoglycan synthesis were observed after a single administration of pefloxacin, consisting of an early inhibition followed by a repair-like phase. The depletion phase was accompanied by a marked decrease in the endogenous serum sulfate level and a concomitant increase in the level of sulfate excretion in urine. Studies of ex vivo proteoglycan synthesis confirmed the in vivo results that were obtained. The decrease in proteoglycan anabolism seemed to be a direct effect of pefloxacin on tissue metabolism rather than a consequence of the low concentration of sulfate. Pefloxacin treatment for several days induced oxidative damage of type I collagen, with the alterations being identical to those observed in the experimental tendinous ischemia and reperfusion model. Oxidative damage was prevented by coadministration of N-acetylcysteine (150 mg/kg) to the mice. These results provide the first experimental evidence of a pefloxacin-induced oxidative stress in the Achilles tendon that altered proteoglycan anabolism and oxidized collagen. FAU - Simonin, M A AU - Simonin MA AD - Department of Pharmacology, UMR 7561, CNRS-Université Henri Poincaré-Nancy I "Physiopathologie et Pharmacologie Articulaires," Faculté de Médecine, Vandoeuvre-lès-Nancy, France. FAU - Gegout-Pottie, P AU - Gegout-Pottie P FAU - Minn, A AU - Minn A FAU - Gillet, P AU - Gillet P FAU - Netter, P AU - Netter P FAU - Terlain, B AU - Terlain B LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Antimicrob Agents Chemother JT - Antimicrobial agents and chemotherapy JID - 0315061 RN - 0 (Anti-Infective Agents) RN - 0 (Antioxidants) RN - 0 (Proteoglycans) RN - 0 (Sulfur Radioisotopes) RN - 2H52Z9F2Q5 (Pefloxacin) RN - 9007-34-5 (Collagen) RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - Acetylcysteine/pharmacology MH - Achilles Tendon/*drug effects/metabolism/pathology MH - Animals MH - Anti-Infective Agents/*toxicity MH - Antioxidants/pharmacology MH - Collagen/drug effects/*metabolism MH - Male MH - Mice MH - Oxidation-Reduction MH - Oxidative Stress/physiology MH - Pefloxacin/*toxicity MH - Proteoglycans/*biosynthesis MH - Rats MH - Rats, Sprague-Dawley MH - Reperfusion Injury/metabolism/pathology MH - Sulfur Radioisotopes PMC - PMC89784 EDAT- 2000/03/18 09:00 MHDA- 2000/05/08 09:00 PMCR- 2000/04/01 CRDT- 2000/03/18 09:00 PHST- 2000/03/18 09:00 [pubmed] PHST- 2000/05/08 09:00 [medline] PHST- 2000/03/18 09:00 [entrez] PHST- 2000/04/01 00:00 [pmc-release] AID - 0591 [pii] AID - 10.1128/AAC.44.4.867-872.2000 [doi] PST - ppublish SO - Antimicrob Agents Chemother. 2000 Apr;44(4):867-72. doi: 10.1128/AAC.44.4.867-872.2000. PMID- 4620987 OWN - NLM STAT- MEDLINE DCOM- 19891101 LR - 20190701 IS - 0024-3205 (Print) IS - 0024-3205 (Linking) VI - 15 IP - 10 DP - 1974 Nov 15 TI - Description and statistical analysis of fine structural changes in tendon fibrocytes treated with dimethyl sulfoxide. PG - 1749-56 FAU - Stratton, C J AU - Stratton CJ FAU - Grim, J N AU - Grim JN LA - eng PT - Journal Article PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Animals MH - Cell Membrane/drug effects/ultrastructure MH - Cell Nucleus/drug effects/ultrastructure MH - Dimethyl Sulfoxide/*pharmacology MH - Endoplasmic Reticulum/drug effects/ultrastructure MH - Female MH - Intracellular Membranes/drug effects/ultrastructure MH - Mice MH - Mitochondria/drug effects/ultrastructure MH - Tendons/*drug effects/ultrastructure MH - Time Factors EDAT- 1974/11/15 00:00 MHDA- 1974/11/15 00:01 CRDT- 1974/11/15 00:00 PHST- 1974/11/15 00:00 [pubmed] PHST- 1974/11/15 00:01 [medline] PHST- 1974/11/15 00:00 [entrez] AID - 0024-3205(74)90176-3 [pii] AID - 10.1016/0024-3205(74)90176-3 [doi] PST - ppublish SO - Life Sci. 1974 Nov 15;15(10):1749-56. doi: 10.1016/0024-3205(74)90176-3. PMID- 26121952 OWN - NLM STAT- MEDLINE DCOM- 20160222 LR - 20161125 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 33 IP - 12 DP - 2015 Dec TI - Effect of tamoxifen on fatty degeneration and atrophy of rotator cuff muscles in chronic rotator cuff tear: An animal model study. PG - 1846-53 LID - 10.1002/jor.22964 [doi] AB - Fatty degeneration of the rotator cuff muscles is an irreversible change resulting from chronic rotator cuff tear and is associated with poor clinical outcomes following rotator cuff repair. We evaluated the effect of Tamoxifen, a competitive estrogen receptor inhibitor, on fatty degeneration using a mouse model for chronic rotator cuff tear. Sixteen adult mice were divided into two diet groups (Tamoxifen vs. Regular) and subjected to surgical creation of a large rotator cuff tear and suprascapular nerve transection in their left shoulder with the right shoulder serving as a control. The rotator cuff muscles were harvested at 16 weeks and subjected to histology and RT-PCR for adipogenic and myogenic markers. Histology showed substantially decreased atrophy and endomysial inflammation in Tamoxifen group, but no significant differences in the amount of intramuscular adipocytes and lipid droplets compared to the Regular group. With RT-PCR, the operated shoulders showed significant upregulation of myogenin and PPAR-γ, and downregulation of myostatin compared to the nonsurgical shoulder. No significant differences of gene expression were found between the two diet groups. Our study demonstrated that tamoxifen diet leads to decreased muscle atrophy and inflammatory changes following chronic rotator cuff tear, but has no apparent effect on adipogenesis. CI - © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Cho, Edward AU - Cho E AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Hershey, Pennsylvania. FAU - Zhang, Yue AU - Zhang Y AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Hershey, Pennsylvania. FAU - Pruznak, Anne AU - Pruznak A AD - Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, Pennsylvania. FAU - Kim, H Mike AU - Kim HM AD - Department of Orthopaedics and Rehabilitation, Penn State College of Medicine, Hershey, Pennsylvania. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150714 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Lipids) RN - 0 (Myogenin) RN - 0 (Myostatin) RN - 0 (PPAR gamma) RN - 0 (Receptors, Estrogen) RN - 0 (Selective Estrogen Receptor Modulators) RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Adipocytes/cytology MH - Adipogenesis/*drug effects MH - Animals MH - Body Composition MH - Disease Models, Animal MH - Gene Expression Profiling MH - Gene Expression Regulation MH - Inflammation MH - Lipids/chemistry MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Muscular Atrophy/drug therapy/*pathology MH - Myogenin/metabolism MH - Myostatin/metabolism MH - PPAR gamma/metabolism MH - Receptors, Estrogen/antagonists & inhibitors MH - Rotator Cuff/drug effects/*pathology MH - *Rotator Cuff Injuries MH - Selective Estrogen Receptor Modulators/therapeutic use MH - Tamoxifen/*therapeutic use MH - Tendons/pathology OTO - NOTNLM OT - atrophy OT - fatty degeneration OT - mouse model OT - rotator cuff tear OT - tamoxifen EDAT- 2015/07/01 06:00 MHDA- 2016/02/24 06:00 CRDT- 2015/07/01 06:00 PHST- 2015/03/09 00:00 [received] PHST- 2015/06/03 00:00 [accepted] PHST- 2015/07/01 06:00 [entrez] PHST- 2015/07/01 06:00 [pubmed] PHST- 2016/02/24 06:00 [medline] AID - 10.1002/jor.22964 [doi] PST - ppublish SO - J Orthop Res. 2015 Dec;33(12):1846-53. doi: 10.1002/jor.22964. Epub 2015 Jul 14. PMID- 1118604 OWN - NLM STAT- MEDLINE DCOM- 19750609 LR - 20161123 IS - 0033-8419 (Print) IS - 0033-8419 (Linking) VI - 115 IP - 1 DP - 1975 Apr TI - Peroneal tenography in previous calcaneal fractures. PG - 211-3 AB - The evaluation of persistent hindfoot pain in patients with previous calcaneal fractures should include contrast examination of the peroneal tendon sheaths. The identification of extrinsic compression or displacement of the peroneal tendons may indicate that source of pain, the diagnosis being substantiated by temporary relief of discomfort following Xylocaine injection. FAU - Resnick, D AU - Resnick D FAU - Goergen, T G AU - Goergen TG LA - eng PT - Journal Article PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 98PI200987 (Lidocaine) SB - IM MH - Cadaver MH - Calcaneus/*diagnostic imaging MH - Fibula/*diagnostic imaging/pathology MH - Fractures, Bone/*diagnostic imaging MH - Humans MH - Lidocaine/therapeutic use MH - Pain/drug therapy MH - Pressure MH - Radiography MH - Tendons/*diagnostic imaging EDAT- 1975/04/01 00:00 MHDA- 1975/04/01 00:01 CRDT- 1975/04/01 00:00 PHST- 1975/04/01 00:00 [pubmed] PHST- 1975/04/01 00:01 [medline] PHST- 1975/04/01 00:00 [entrez] AID - 10.1148/115.1.211 [doi] PST - ppublish SO - Radiology. 1975 Apr;115(1):211-3. doi: 10.1148/115.1.211. PMID- 4671162 OWN - NLM STAT- MEDLINE DCOM- 19740905 LR - 20031114 IS - 0071-8041 (Print) IS - 0071-8041 (Linking) VI - 23 IP - 0 DP - 1972 TI - Silicone gel coating of a sutured flexor digital tendon within a sheath. PG - 471-2 FAU - Eguro, H AU - Eguro H FAU - Urbaniak, J R AU - Urbaniak JR LA - eng PT - Journal Article PL - United States TA - Surg Forum JT - Surgical forum JID - 0337723 RN - 0 (Gels) RN - 0 (Silicones) SB - IM MH - Animals MH - Dogs MH - Gels MH - Silicones/*therapeutic use MH - *Sutures MH - Tendons/*surgery EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PST - ppublish SO - Surg Forum. 1972;23(0):471-2. PMID- 9680171 OWN - NLM STAT- MEDLINE DCOM- 19981013 LR - 20190826 IS - 0891-5849 (Print) IS - 0891-5849 (Linking) VI - 25 IP - 3 DP - 1998 Aug TI - The role of metal-catalyzed oxidation in the formation of advanced glycation end products: an in vitro study on collagen. PG - 265-9 AB - The present study investigates the role of metal catalysed oxidation in the formation of Advanced Glycation End products (AGEs). Rat tail tendon collagen was incubated with glucose (250 mM) and increasing concentrations of copper ions (5-500 microM) under physiological conditions of temperature and pH. After 1 and 3 weeks of incubation the level of AGEs in collagen samples were estimated by enzyme linked immunoassay, using antibodies raised against AGE ribonuclease. It was observed that the presence of metal ions significantly increased the rate of accumulation of AGEs. The increase was dependent on the concentration of metal ions present in the incubation medium. Free radical scavengers such as mannitol, benzoate, catalase, and the antiglycating agent aminoguanidine almost completely inhibited the formation of AGEs. Incubation of collagen with copper ions alone did not show any increase in crosslinking, as detected by cyanogen bromide digestion, and AGEs formation. Further it was also noted that glycoxidation, i.e., oxidation of glycated collagen, was the major pathway that leads to increased formation of AGEs. These results indicate that metal-catalyzed oxidation and free radicals play a major role in the formation of AGEs. This work also strongly suggests that increased oxidative stress in diabetes may accelerate the formation of AGEs and thus contribute to the pathogenesis of diabetic complications. FAU - Sajithlal, G B AU - Sajithlal GB AD - Department of Biochemistry Central Leather Research Institute, Adyar, Chennai, India. FAU - Chithra, P AU - Chithra P FAU - Chandrakasan, G AU - Chandrakasan G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Free Radic Biol Med JT - Free radical biology & medicine JID - 8709159 RN - 0 (Benzoates) RN - 0 (Free Radical Scavengers) RN - 0 (Glycation End Products, Advanced) RN - 0 (Guanidines) RN - 3352-57-6 (Hydroxyl Radical) RN - 3OWL53L36A (Mannitol) RN - 789U1901C5 (Copper) RN - 8SKN0B0MIM (Benzoic Acid) RN - 9007-34-5 (Collagen) RN - EC 1.11.1.6 (Catalase) RN - IY9XDZ35W2 (Glucose) RN - OS382OHJ8P (Cyanogen Bromide) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Animals MH - Benzoates/pharmacology MH - Benzoic Acid MH - Catalase/pharmacology MH - Collagen/*metabolism MH - Copper/*pharmacology MH - Cyanogen Bromide MH - Free Radical Scavengers/pharmacology MH - Glucose/metabolism MH - Glycation End Products, Advanced/*metabolism MH - Guanidines/pharmacology MH - Hydrogen-Ion Concentration MH - Hydroxyl Radical/metabolism MH - Mannitol/pharmacology MH - Oxidation-Reduction MH - Rats MH - Tail MH - Tendons/chemistry EDAT- 1998/07/29 00:00 MHDA- 1998/07/29 00:01 CRDT- 1998/07/29 00:00 PHST- 1998/07/29 00:00 [pubmed] PHST- 1998/07/29 00:01 [medline] PHST- 1998/07/29 00:00 [entrez] AID - S0891-5849(98)00035-5 [pii] AID - 10.1016/s0891-5849(98)00035-5 [doi] PST - ppublish SO - Free Radic Biol Med. 1998 Aug;25(3):265-9. doi: 10.1016/s0891-5849(98)00035-5. PMID- 3393546 OWN - NLM STAT- MEDLINE DCOM- 19880817 LR - 20200930 IS - 0037-9727 (Print) IS - 0037-9727 (Linking) VI - 188 IP - 3 DP - 1988 Jul TI - Effect of beta-aminopropionitrile and ascorbate on fibroblast migration. PG - 346-52 AB - Ascorbate and beta-aminopropionitrile (BAPN) have direct, but diverse affects on collagen matrix production. Ascorbate is necessary for the intracellular hydroxylation of prolyl and lysyl residues during collagen biosynthesis whereas BAPN inhibits the enzyme lysyl oxidase in the extracellular space thus preventing collagen crosslink formation. To study the influence of these two agents on fibroplasia, an in vitro model was used to analyze fibroblast migration, proliferation, and collagen synthesis. Biopsies of chicken tendon were covered with a fibrin clot to simulate an in vivo wound environment, and then they were exposed to either ascorbate or BAPN for up to 7 days. Fibroblast migration into the fibrin clot was measured using a Zeiss Mopp II planimeter, DNA synthesis by 125IUDR incorporation, and collagen synthesis by [3H]proline incorporation into collagenase-digestible protein. Tendon biopsies treated daily with fresh ascorbate (0.1 mM) had significantly greater fibroblast migration than controls without ascorbate (P less than 0.05). Cellular proliferation, collagen synthesis, and total protein synthesis were not significantly altered by ascorbate treatment. In contrast, BAPN inhibited fibroblast migration in a dose-dependent fashion without inhibiting proliferation (0.25 and 0.5 mM), collagen, and noncollagen protein synthesis. Therefore, the effect of BAPN on migration does not appear to be due to generalized cytotoxicity. These combined studies suggest that compounds such as ascorbate and BAPN which can modify collagen may also modify fibroblast migration. FAU - Nelson, J M AU - Nelson JM AD - Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0629. FAU - Diegelmann, R F AU - Diegelmann RF FAU - Cohen, I K AU - Cohen IK LA - eng GR - GM-20298/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Proc Soc Exp Biol Med JT - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) JID - 7505892 RN - 151-18-8 (Aminopropionitrile) RN - 9001-31-4 (Fibrin) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) RN - 9DLQ4CIU6V (Proline) RN - LGP81V5245 (Idoxuridine) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Aminopropionitrile/*pharmacology MH - Animals MH - Ascorbic Acid/*pharmacology MH - Cell Division/drug effects MH - Cell Movement/drug effects MH - Chickens MH - Collagen/biosynthesis MH - DNA/biosynthesis MH - Fibrin/metabolism MH - Fibroblasts/*cytology MH - Idoxuridine/metabolism MH - Proline/metabolism MH - Protein Biosynthesis MH - Tendons/cytology EDAT- 1988/07/01 00:00 MHDA- 1988/07/01 00:01 CRDT- 1988/07/01 00:00 PHST- 1988/07/01 00:00 [pubmed] PHST- 1988/07/01 00:01 [medline] PHST- 1988/07/01 00:00 [entrez] AID - 10.3181/00379727-188-42745 [doi] PST - ppublish SO - Proc Soc Exp Biol Med. 1988 Jul;188(3):346-52. doi: 10.3181/00379727-188-42745. PMID- 4941819 OWN - NLM STAT- MEDLINE DCOM- 19720209 LR - 20161013 IS - 0065-3411 (Print) IS - 0065-3411 (Linking) VI - 5 DP - 1971 TI - Biologic principles affecting repair of flexor tendons. PG - 145-88 FAU - Weiner, L J AU - Weiner LJ FAU - Peacock, E E Jr AU - Peacock EE Jr LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Surg JT - Advances in surgery JID - 0045335 RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) SB - IM MH - Adult MH - Aminopropionitrile/therapeutic use MH - Blood Vessels/transplantation MH - Child, Preschool MH - Cicatrix/prevention & control/surgery MH - Collagen/biosynthesis MH - Connective Tissue/metabolism/transplantation MH - Connective Tissue Cells MH - Finger Injuries/surgery MH - Fingers/surgery MH - Hand Injuries/*surgery MH - Humans MH - Methods MH - Postoperative Care MH - Postoperative Complications MH - Protein Biosynthesis MH - Tendon Injuries/*surgery MH - Tendon Transfer MH - Tendons/transplantation MH - Thumb/surgery MH - Transplantation, Autologous MH - Transplantation, Homologous MH - Wound Healing RF - 71 EDAT- 1971/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1971/01/01 00:00 [entrez] PST - ppublish SO - Adv Surg. 1971;5:145-88. PMID- 40921515 OWN - NLM STAT- MEDLINE DCOM- 20250908 LR - 20250915 IS - 2173-5743 (Electronic) IS - 2173-5743 (Linking) VI - 21 IP - 7 DP - 2025 Aug-Sep TI - Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index. PG - 501921 LID - S2173-5743(25)00118-2 [pii] LID - 10.1016/j.reumae.2025.501921 [doi] AB - BACKGROUND: Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast. PRIMARY OBJECTIVE: 20% reduction in the US index (UIC) at 12 months. METHODOLOGY: Multicenter, prospective, open-label study. Patients with PsA (≥2 swollen joints) and ≥2 US synovitis in joints and ≥1 US enthesitis at screening were recruited. Follow-up was 52 weeks (baseline and 1, 6, 9, 12 months). US (joint, tendon, and entheses), clinical (SJC, TJC, LEI, PGA, PtGA), and biological (ESR and CRP) parameters were recorded. RESULTS: 48 patients were evaluated, 46 were included in the follow-up and 26 completed the 52-week study. The primary endpoint was achieved, with reductions of up to 40%. All clinical and ultrasound variables decreased significantly after 12 months. 75 adverse events (AEs) were recorded in 33 patients, and only one serious event (SAE). Reasons for withdrawal included AEs (6 patients), lack of efficacy (8 patients), and other reasons (loss to follow-up, withdrawal of consent) for 6 patients. CONCLUSIONS: Changes in different domains of PsA in patients treated with Apremilast can be best identified by ultrasound. Ultrasound is an excellent tool to study joints, tendons, and entheses in PsA. Apremilast is a safe, well-tolerated, and effective treatment for several patterns of PsA (joints, entheses) as demonstrated by ultrasound. Ultrasound can also identify nail diseases in patients with PsA. CI - Copyright © 2025 Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U. All rights reserved. FAU - de Agustin, Juan José AU - de Agustin JJ AD - Rheumatology Unit, Image and Techniques Section, Hospital Universitari Vall Hebron, Spain. Electronic address: jjagor@hotmail.com. FAU - Añez, Gustavo Adolfo AU - Añez GA AD - Rheumatology Unit, Hospital Universitari Arnau de Vilanova, Spain. FAU - Reina, Delia AU - Reina D AD - Complex Hospitalari Moisés Broggi, Spain. FAU - Heredia, Sergi AU - Heredia S AD - Complex Hospitalari Moisés Broggi, Spain. FAU - Ramirez, Julio AU - Ramirez J AD - Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain. FAU - Cuervo, Andrea Mireya AU - Cuervo AM AD - Rheumatology Department, Hospital General Granollers, Spain. FAU - Rodriguez, Jesus AU - Rodriguez J AD - Hospital de Bellvitge, Spain. FAU - Moragues, Carmen AU - Moragues C AD - Hospital de Bellvitge, Spain. FAU - Moya, Patricia AU - Moya P AD - Hospital de la Santa Creu i Sant Pau, Spain. FAU - Laiz Alonso, Ana Maria AU - Laiz Alonso AM AD - Institut de Recerca Sant Pau, Hospital de la Santa Creu i Sant Pau, Spain. FAU - Moreno, Mireia AU - Moreno M AD - Rheumatology Department, Hospital Universitari Parc Tauli I3PT, UAB, Sabadell, Spain. FAU - Arevalo, Marta AU - Arevalo M AD - Rheumatology Department, Hospital Universitari Parc Tauli I3PT, UAB, Sabadell, Spain. FAU - Pujol, Manel AU - Pujol M AD - Hospital Universitari Mutua Terrassa, Spain. FAU - Salvador, Georgina AU - Salvador G AD - Hospital Universitari Mutua Terrassa, Spain. FAU - Busquets, Noemi AU - Busquets N AD - Hospital de Granollers, Spain. FAU - Ponce, Andres AU - Ponce A AD - Department of Rheumatology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain. FAU - Pascual Pastor, Maria AU - Pascual Pastor M AD - Rheumatology Unit, Hospital Universitari Vall Hebron, Spain. LA - eng PT - Clinical Trial, Phase IV PT - Journal Article PT - Multicenter Study PL - Spain TA - Reumatol Clin (Engl Ed) JT - Reumatologia clinica JID - 101717526 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - UP7QBP99PN (apremilast) RN - 4Z8R6ORS6L (Thalidomide) SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - *Arthritis, Psoriatic/drug therapy/diagnostic imaging MH - Enthesopathy/diagnostic imaging/etiology MH - Prospective Studies MH - Severity of Illness Index MH - *Thalidomide/analogs & derivatives/therapeutic use/analogs & derivatives MH - Treatment Outcome MH - Ultrasonography OTO - NOTNLM OT - Apremilast OT - Artritis psoriásica OT - Psoriatic arthritis OT - Ultrasonido OT - Ultrasound EDAT- 2025/09/09 00:33 MHDA- 2025/09/09 00:34 CRDT- 2025/09/08 20:53 PHST- 2024/09/24 00:00 [received] PHST- 2025/05/21 00:00 [revised] PHST- 2025/06/18 00:00 [accepted] PHST- 2025/09/09 00:34 [medline] PHST- 2025/09/09 00:33 [pubmed] PHST- 2025/09/08 20:53 [entrez] AID - S2173-5743(25)00118-2 [pii] AID - 10.1016/j.reumae.2025.501921 [doi] PST - ppublish SO - Reumatol Clin (Engl Ed). 2025 Aug-Sep;21(7):501921. doi: 10.1016/j.reumae.2025.501921. PMID- 28470843 OWN - NLM STAT- MEDLINE DCOM- 20180612 LR - 20181202 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 21 IP - 11 DP - 2017 Nov TI - Combination of biochemical and mechanical cues for tendon tissue engineering. PG - 2711-2719 LID - 10.1111/jcmm.13186 [doi] AB - Tendinopathies negatively affect the life quality of millions of people in occupational and athletic settings, as well as the general population. Tendon healing is a slow process, often with insufficient results to restore complete endurance and functionality of the tissue. Tissue engineering, using tendon progenitors, artificial matrices and bioreactors for mechanical stimulation, could be an important approach for treating rips, fraying and tissue rupture. In our work, C3H10T1/2 murine fibroblast cell line was exposed to a combination of stimuli: a biochemical stimulus provided by Transforming Growth Factor Beta (TGF-β) and Ascorbic Acid (AA); a three-dimensional environment represented by PEGylated-Fibrinogen (PEG-Fibrinogen) biomimetic matrix; and a mechanical induction exploiting a custom bioreactor applying uniaxial stretching. In vitro analyses by immunofluorescence and mechanical testing revealed that the proposed combined approach favours the organization of a three-dimensional tissue-like structure promoting a remarkable arrangement of the cells and the neo-extracellular matrix, reflecting into enhanced mechanical strength. The proposed method represents a novel approach for tendon tissue engineering, demonstrating how the combined effect of biochemical and mechanical stimuli ameliorates biological and mechanical properties of the artificial tissue compared to those obtained with single inducement. CI - © 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. FAU - Testa, Stefano AU - Testa S AD - Department of Biology, Tor Vergata Rome University, Rome, Italy. FAU - Costantini, Marco AU - Costantini M AD - Department of Engineering, Università Campus Bio-Medico di Roma, Rome, Italy. FAU - Fornetti, Ersilia AU - Fornetti E AD - Department of Biology, Tor Vergata Rome University, Rome, Italy. FAU - Bernardini, Sergio AU - Bernardini S AD - Department of Biology, Tor Vergata Rome University, Rome, Italy. FAU - Trombetta, Marcella AU - Trombetta M AD - Department of Engineering, Università Campus Bio-Medico di Roma, Rome, Italy. FAU - Seliktar, Dror AU - Seliktar D AD - Department of Biomedical Engineering, Techion Institute, Haifa, Israel. FAU - Cannata, Stefano AU - Cannata S AD - Department of Biology, Tor Vergata Rome University, Rome, Italy. FAU - Rainer, Alberto AU - Rainer A AD - Department of Engineering, Università Campus Bio-Medico di Roma, Rome, Italy. FAU - Gargioli, Cesare AU - Gargioli C AUID- ORCID: 0000-0003-1742-3969 AD - Department of Biology, Tor Vergata Rome University, Rome, Italy. LA - eng PT - Journal Article DEP - 20170504 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Transforming Growth Factor beta) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9001-32-5 (Fibrinogen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Biomimetic Materials/chemistry/pharmacology MH - Bioreactors MH - Cell Culture Techniques MH - Cell Line MH - Extracellular Matrix/chemistry MH - Fibrinogen/chemistry/pharmacology MH - Fibroblasts/cytology/*drug effects/metabolism MH - Mechanotransduction, Cellular MH - Mice MH - Polyethylene Glycols/chemistry/pharmacology MH - Stress, Mechanical MH - Tendons/cytology/drug effects/growth & development/metabolism MH - Tissue Engineering/*methods MH - Tissue Scaffolds MH - Transforming Growth Factor beta/*pharmacology PMC - PMC5661263 OTO - NOTNLM OT - artificial tendon OT - biomaterial OT - bioreactor OT - mechanical stimulation OT - tissue engineering EDAT- 2017/05/05 06:00 MHDA- 2018/06/13 06:00 PMCR- 2017/11/01 CRDT- 2017/05/05 06:00 PHST- 2016/08/05 00:00 [received] PHST- 2017/02/20 00:00 [accepted] PHST- 2017/05/05 06:00 [pubmed] PHST- 2018/06/13 06:00 [medline] PHST- 2017/05/05 06:00 [entrez] PHST- 2017/11/01 00:00 [pmc-release] AID - JCMM13186 [pii] AID - 10.1111/jcmm.13186 [doi] PST - ppublish SO - J Cell Mol Med. 2017 Nov;21(11):2711-2719. doi: 10.1111/jcmm.13186. Epub 2017 May 4. PMID- 18753682 OWN - NLM STAT- MEDLINE DCOM- 20081023 LR - 20220316 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 36 IP - 9 DP - 2008 Sep TI - Color Doppler ultrasound findings in patellar tendinopathy (jumper's knee). PG - 1813-20 AB - BACKGROUND: Recent studies have revealed structural changes with neovessels in patients with jumper's knee and Achilles tendinopathy, and treatment with sclerosing injections has shown promising clinical results. PURPOSE: To study the prevalence of neovascularization and structural tendon changes on color Doppler ultrasound examination in elite athletes with clinical symptoms of jumper's knee and to examine the ultrasound characteristics of the tendon after sclerosing injection treatment with polidocanol. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: The authors recruited patients among elite athletes with a clinical diagnosis of jumper's knee who participated in a previous randomized clinical trial. The patients recorded knee function using the Victorian Institute of Sport Assessment score. Patients were examined by color Doppler ultrasound at baseline and, for patients with structural changes and neovascularization who received sclerosing treatment, after treatment. RESULTS: Sixty-three patients (11 women and 52 men) with 79 symptomatic tendons were studied. The ultrasound examination revealed that neovascularization was present in 48 of the 79 tendons (60%). Of 33 patients (43 tendons) who received sclerosing injections, 29 patients (37 tendons, 86%) were examined 37 (19 to 53) weeks after their final sclerosing injections. Of these, 7 tendons (18.9%) had no change in neovascularization after treatment, 21 tendons (56.8%) had less neovascularization, and 9 tendons (24.3%) had more visible neovascularization. There were no significant differences in the change in Victorian Institute of Sport Assessment score between patients who had less, more, or unchanged neovascularization after treatment (analysis of variance, P = .9). CONCLUSION: About two thirds of patients with jumper's knee can be expected to have structural tendon changes with neovascularization. There was no relationship between changes in ultrasound characteristic and knee function after sclerosing treatment. FAU - Hoksrud, Aasne AU - Hoksrud A AD - Oslo Sports Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, PO Box 4014 Ullevaal Stadion, 0806 Oslo, Norway. FAU - Ohberg, Lars AU - Ohberg L FAU - Alfredson, Håkan AU - Alfredson H FAU - Bahr, Roald AU - Bahr R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adolescent MH - Adult MH - Cohort Studies MH - Female MH - Humans MH - Male MH - Neovascularization, Pathologic/*diagnostic imaging/drug therapy MH - Patellar Ligament/*diagnostic imaging/pathology MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Randomized Controlled Trials as Topic MH - Sclerosing Solutions/therapeutic use MH - Tendinopathy/*diagnostic imaging/drug therapy/pathology MH - Ultrasonography, Doppler, Color EDAT- 2008/08/30 09:00 MHDA- 2008/10/24 09:00 CRDT- 2008/08/30 09:00 PHST- 2008/08/30 09:00 [pubmed] PHST- 2008/10/24 09:00 [medline] PHST- 2008/08/30 09:00 [entrez] AID - 36/9/1813 [pii] AID - 10.1177/036354650831989 [doi] PST - ppublish SO - Am J Sports Med. 2008 Sep;36(9):1813-20. doi: 10.1177/036354650831989. PMID- 14749998 OWN - NLM STAT- MEDLINE DCOM- 20040519 LR - 20181113 IS - 0770-3198 (Print) IS - 0770-3198 (Linking) VI - 23 IP - 1 DP - 2004 Feb TI - Involvement of an inconstant bursa under the head of the second metatarsal bone in spondyloarthritis. PG - 93-4 FAU - Olivieri, Ignazio AU - Olivieri I FAU - Scarano, Enrico AU - Scarano E FAU - Ciancio, Giovanni AU - Ciancio G FAU - Padula, Angela AU - Padula A FAU - Benjamin, Mike AU - Benjamin M LA - eng PT - Case Reports PT - Letter PT - Research Support, Non-U.S. Gov't DEP - 20040108 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Antirheumatic Agents) RN - 3XC8GUZ6CB (Sulfasalazine) SB - IM MH - Adult MH - Antirheumatic Agents/therapeutic use MH - Bursa, Synovial/diagnostic imaging/*pathology MH - Bursitis/complications/diagnostic imaging/drug therapy/*pathology MH - Humans MH - Male MH - Metatarsal Bones/diagnostic imaging/*pathology MH - Metatarsophalangeal Joint/diagnostic imaging/*pathology MH - Spondylitis, Ankylosing/complications/diagnostic imaging/drug therapy/*pathology MH - Sulfasalazine/therapeutic use MH - Tendons/diagnostic imaging/pathology MH - Treatment Outcome MH - Ultrasonography EDAT- 2004/01/30 05:00 MHDA- 2004/05/20 05:00 CRDT- 2004/01/30 05:00 PHST- 2003/08/04 00:00 [received] PHST- 2003/08/04 00:00 [accepted] PHST- 2004/01/30 05:00 [pubmed] PHST- 2004/05/20 05:00 [medline] PHST- 2004/01/30 05:00 [entrez] AID - 10.1007/s10067-003-0829-8 [doi] PST - ppublish SO - Clin Rheumatol. 2004 Feb;23(1):93-4. doi: 10.1007/s10067-003-0829-8. Epub 2004 Jan 8. PMID- 5346767 OWN - NLM STAT- MEDLINE DCOM- 19691205 LR - 20061115 IS - 0067-8090 (Print) IS - 0067-8090 (Linking) VI - 79 DP - 1969 TI - Lamellar undermining, diathermy and tissue transplantation versus cryotherapy and full-thickness scleral buckling. PG - 554-62 FAU - Okun, E AU - Okun E FAU - Johnston, G P AU - Johnston GP LA - eng PT - Comparative Study PT - Journal Article PL - Switzerland TA - Bibl Ophthalmol JT - Bibliotheca ophthalmologica : supplementa ad ophthalmologica JID - 0400647 RN - 0 (Silicones) SB - IM MH - *Cryosurgery MH - *Diathermy MH - Humans MH - Methods MH - Retinal Detachment/*surgery MH - Sclera/*surgery/transplantation MH - Silicones/therapeutic use MH - Tendons/transplantation MH - Transplantation, Autologous MH - Transplantation, Homologous EDAT- 1969/01/01 00:00 MHDA- 1969/01/01 00:01 CRDT- 1969/01/01 00:00 PHST- 1969/01/01 00:00 [pubmed] PHST- 1969/01/01 00:01 [medline] PHST- 1969/01/01 00:00 [entrez] PST - ppublish SO - Bibl Ophthalmol. 1969;79:554-62. PMID- 19171275 OWN - NLM STAT- MEDLINE DCOM- 20090402 LR - 20220331 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 25 IP - 2 DP - 2009 Feb TI - Prospective randomized study of 2 different techniques for endoscopic iliopsoas tendon release in the treatment of internal snapping hip syndrome. PG - 159-63 LID - 10.1016/j.arthro.2008.08.009 [doi] AB - PURPOSE: To evaluate the short-term results of 2 different techniques of endoscopic iliopsoas tendon release for the treatment of internal snapping hip syndrome. METHODS: Between January 2005 and January 2007, a consecutive series of patients with the diagnosis of internal snapping hip syndrome was treated with endoscopic release of the iliopsoas tendon. The patients were randomized into 2 different groups. Patients in group 1 were treated with endoscopic iliopsoas tendon release at the lesser trochanter, and patients in group 2 were treated with endoscopic transcapsular psoas release from the peripheral compartment. Hip arthroscopy of both the central and peripheral compartments was performed in both groups using the lateral approach. Associated injuries were identified and treated arthroscopically. Postoperative physical therapy was the same for both series, and each patient received 400 mg of celecoxib daily for 21 days after surgery. Preoperative and postoperative Western Ontario MacMaster (WOMAC) scores and imaging studies were evaluated. RESULTS: Nineteen patients were included in the study: 10 in group 1 (5 male and 5 female; average age, 29.5 years) and 9 in group 2 (8 female and 1 male; average age, 32.6 years). No statistical difference was found in group composition. Associated injuries were found and treated in 8 patients in group 1 and 7 patients in group 2. No statistical difference was found between groups in preoperative WOMAC scores, and every patient in both groups had an improvement in the WOMAC score. Improvements in WOMAC scores were statistically significant in both groups, and no difference was found in postoperative WOMAC results between groups. No complications were seen. CONCLUSIONS: Iliopsoas tendon release at the level of the lesser trochanter or at the level of the hip joint using a transcapsular technique is effective and reproducible. We found no clinical difference in the results of both techniques. FAU - Ilizaliturri, Victor M Jr AU - Ilizaliturri VM Jr AD - Adult Joint Reconstruction Service, Hip and Knee, National Rehabilitation Institute of Mexico, Mexico City, Mexico. vichip2002@yahoo.com.mx FAU - Chaidez, Carlos AU - Chaidez C FAU - Villegas, Patricio AU - Villegas P FAU - Briseño, Arcadio AU - Briseño A FAU - Camacho-Galindo, Javier AU - Camacho-Galindo J LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20081010 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Adult MH - Arthroscopy/*methods MH - Celecoxib MH - Combined Modality Therapy MH - Female MH - Hip Joint/*surgery MH - Humans MH - Joint Capsule/surgery MH - Male MH - Prospective Studies MH - Pyrazoles/therapeutic use MH - Severity of Illness Index MH - Sulfonamides/therapeutic use MH - Syndrome MH - Tendon Entrapment/drug therapy/physiopathology/*surgery MH - Tendons/*surgery MH - Young Adult EDAT- 2009/01/28 09:00 MHDA- 2009/04/03 09:00 CRDT- 2009/01/28 09:00 PHST- 2008/04/01 00:00 [received] PHST- 2008/08/20 00:00 [revised] PHST- 2008/08/20 00:00 [accepted] PHST- 2009/01/28 09:00 [entrez] PHST- 2009/01/28 09:00 [pubmed] PHST- 2009/04/03 09:00 [medline] AID - S0749-8063(08)00653-1 [pii] AID - 10.1016/j.arthro.2008.08.009 [doi] PST - ppublish SO - Arthroscopy. 2009 Feb;25(2):159-63. doi: 10.1016/j.arthro.2008.08.009. Epub 2008 Oct 10. PMID- 179471 OWN - NLM STAT- MEDLINE DCOM- 19760802 LR - 20190628 IS - 0003-9861 (Print) IS - 0003-9861 (Linking) VI - 173 IP - 2 DP - 1976 Apr TI - Primary and secondary effects of ascorbate on procollagen synthesis and protein synthesis by primary cultures of tendon fibroblasts. PG - 638-48 FAU - Kao, W W AU - Kao WW FAU - Flaks, J G AU - Flaks JG FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Arch Biochem Biophys JT - Archives of biochemistry and biophysics JID - 0372430 RN - 0 (Protein Precursors) RN - 9007-34-5 (Collagen) RN - EC 3.4.23.1 (Pepsin A) RN - EC 3.4.24.3 (Microbial Collagenase) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/pharmacology MH - Cell Division/drug effects MH - Cell Membrane/metabolism MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*biosynthesis MH - Fibroblasts/drug effects/metabolism MH - Kinetics MH - Microbial Collagenase MH - Pepsin A MH - *Protein Biosynthesis/drug effects MH - Protein Precursors/*biosynthesis MH - Ribosomes/metabolism MH - Tendons/drug effects/*metabolism EDAT- 1976/04/01 00:00 MHDA- 1976/04/01 00:01 CRDT- 1976/04/01 00:00 PHST- 1976/04/01 00:00 [pubmed] PHST- 1976/04/01 00:01 [medline] PHST- 1976/04/01 00:00 [entrez] AID - 0003-9861(76)90301-5 [pii] AID - 10.1016/0003-9861(76)90301-5 [doi] PST - ppublish SO - Arch Biochem Biophys. 1976 Apr;173(2):638-48. doi: 10.1016/0003-9861(76)90301-5. PMID- 2844261 OWN - NLM STAT- MEDLINE DCOM- 19881114 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 950 IP - 3 DP - 1988 Sep 7 TI - Relative content of isoaccepting tRNAs for glycine and proline in avian tendon cells with different rates of procollagen synthesis. PG - 429-34 AB - The relative amounts of iso-tRNAsGly and iso-tRNAsPro existing in chick embryo tendon are indicative of a specialization of the tRNA population for collagen synthesis. These amounts are not modified (i) in primary avian tendon (PAT) cells in culture for which the procollagen production varies from about 10% of total protein synthesis to 60% and (ii) in tendons from immature chicks, which show a 3-fold decrease of procollagen production with increasing age. The characteristic tRNA pattern was not maintained in cells which had lost the ability to make high levels of collagen as observed in the cases of: (i) PAT cells reaching confluency; (ii) virus-transformed PAT cells and (iii) tendon from adult chick. Our data are consistent with the idea that tendon tRNA specialization for collagen synthesis is a differentiation feature independent of the expression level of the collagenic function but related to its maintenance. FAU - Ouenzar, B AU - Ouenzar B AD - Institut Curie, Centre Universitaire, Orsay, France. FAU - Weill, D AU - Weill D FAU - Agoutin, B AU - Agoutin B FAU - Keith, G AU - Keith G FAU - Heyman, T AU - Heyman T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Procollagen) RN - 0 (RNA, Transfer, Amino Acid-Specific) RN - 0 (RNA, Transfer, Pro) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Aging MH - Animals MH - Ascorbic Acid/pharmacology MH - Avian Sarcoma Viruses/genetics MH - Cell Division MH - Cell Transformation, Neoplastic MH - Cells, Cultured MH - Chick Embryo MH - Chickens MH - Kinetics MH - Procollagen/*biosynthesis/genetics MH - RNA, Transfer, Amino Acid-Specific/*genetics MH - RNA, Transfer, Pro/drug effects/*genetics/isolation & purification MH - Tendons/cytology/growth & development/*metabolism EDAT- 1988/09/07 00:00 MHDA- 1988/09/07 00:01 CRDT- 1988/09/07 00:00 PHST- 1988/09/07 00:00 [pubmed] PHST- 1988/09/07 00:01 [medline] PHST- 1988/09/07 00:00 [entrez] AID - 0167-4781(88)90140-6 [pii] AID - 10.1016/0167-4781(88)90140-6 [doi] PST - ppublish SO - Biochim Biophys Acta. 1988 Sep 7;950(3):429-34. doi: 10.1016/0167-4781(88)90140-6. PMID- 18831890 OWN - NLM STAT- MEDLINE DCOM- 20081027 LR - 20220331 IS - 0300-0605 (Print) IS - 0300-0605 (Linking) VI - 36 IP - 5 DP - 2008 Sep-Oct TI - Tramadol as a local anaesthetic in tendon repair surgery of the hand. PG - 971-8 AB - This double-blind pilot study compared the local anaesthetic effects of tramadol plus adrenaline with lidocaine plus adrenaline during surgery to repair hand tendons. Twenty patients were randomly allocated to receive either 5% tramadol plus adrenaline (n = 10) or 2% lidocaine plus adrenaline (n = 10). Injection site pain and local skin reactions were recorded. At 1-min intervals after injection of the anaesthetic agent, the degree of sensory blockade was assessed by the patient reporting the extent to which they felt a pinprick, light touch and a cold sensation. Pain felt during surgical incision was also recorded. There was no difference in the quality of sensory blockade or the incidence of side effects between the two groups. Only patients treated with tramadol did not require additional post-operative analgesia. A combination of tramadol plus adrenaline provided a local anaesthetic effect similar to that of lidocaine plus adrenaline. FAU - Kargi, E AU - Kargi E AD - Department of Plastic and Reconstructive Surgery, School of Medicine, Zonguldak Karaelmas University, Kozlu, Zonguldak, Turkey. eksalk@superonline.com FAU - Babuccu, O AU - Babuccu O FAU - Altunkaya, H AU - Altunkaya H FAU - Hosnuter, M AU - Hosnuter M FAU - Ozer, Y AU - Ozer Y FAU - Babuccu, B AU - Babuccu B FAU - Payasli, C AU - Payasli C LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - England TA - J Int Med Res JT - The Journal of international medical research JID - 0346411 RN - 0 (Adrenergic Agonists) RN - 0 (Analgesics, Opioid) RN - 0 (Anesthetics, Combined) RN - 0 (Anesthetics, Local) RN - 39J1LGJ30J (Tramadol) RN - 98PI200987 (Lidocaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Adolescent MH - Adrenergic Agonists/therapeutic use MH - Adult MH - Analgesics, Opioid/*therapeutic use MH - Anesthetics, Combined/therapeutic use MH - Anesthetics, Local/*therapeutic use MH - Double-Blind Method MH - Epinephrine/therapeutic use MH - Female MH - Hand/anatomy & histology/*surgery MH - Hand Injuries/pathology/*surgery MH - Humans MH - Lidocaine/therapeutic use MH - Male MH - Middle Aged MH - Pilot Projects MH - Tendons/pathology/*surgery MH - Tramadol/*therapeutic use EDAT- 2008/10/04 09:00 MHDA- 2008/10/28 09:00 CRDT- 2008/10/04 09:00 PHST- 2008/10/04 09:00 [pubmed] PHST- 2008/10/28 09:00 [medline] PHST- 2008/10/04 09:00 [entrez] AID - 10.1177/147323000803600513 [doi] PST - ppublish SO - J Int Med Res. 2008 Sep-Oct;36(5):971-8. doi: 10.1177/147323000803600513. PMID- 14520512 OWN - NLM STAT- MEDLINE DCOM- 20040325 LR - 20220409 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 11 IP - 5 DP - 2003 Sep TI - Is vasculo-neural ingrowth the cause of pain in chronic Achilles tendinosis? An investigation using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. PG - 334-8 AB - The purpose of this study was to investigate where the pain comes from in chronic mid-portion Achilles tendinosis, by using ultrasonography and colour Doppler, immunohistochemistry, and diagnostic injections. Twenty-five tendons in 24 patients (mean age 47 years) with the clinical diagnosis of painful chronic mid-portion Achilles tendinosis, and 20 tendons in 14 controls (mean age 48 years) with pain-free Achilles tendons were examined with ultrasonography and colour Doppler. For the 25 painful tendons, a local anaesthetic was injected in the area with neovascularisation outside the ventral part of the tendon. Biopsies taken from tendinosis tissue in six patients were used for PGP 9.5 immunohistochemistry. A neovascularisation, inside and outside the ventral part of the area with tendon changes, was demonstrated in all painful tendinosis tendons, but not in any of the pain-free control tendons. After injection of the local anaesthetic towards the neovessels outside the ventral part of the tendon, the pain during tendon-loading activity was temporarily cured in all patients. The mean VAS-score for heel-raises decreased significantly from 75 mm to 6 mm. In biopsies, PGP 9.5 immunohistochemistry showed nerve structures in the vicinity of blood vessels. In conclusion, we demonstrate findings which support neovessels and accompanying nerves being the possible source of pain in chronic mid-portion Achilles tendinosis. FAU - Alfredson, Håkan AU - Alfredson H AD - Department of Surgical and Perioperative Science, Sports Medicine, University of Umeå, S-90187, Umeå, Sweden. Hakan.Alfredson@idrott.umu.se FAU - Ohberg, Lars AU - Ohberg L FAU - Forsgren, Sture AU - Forsgren S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20030809 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Anesthetics, Local) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - EC 3.4.19.12 (Ubiquitin Thiolesterase) SB - IM MH - Achilles Tendon/*blood supply/diagnostic imaging/pathology MH - Adult MH - Aged MH - Anesthetics, Local/therapeutic use MH - Biopsy MH - Case-Control Studies MH - Female MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Neovascularization, Pathologic/*diagnosis MH - Pain/drug therapy/*pathology MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Tendinopathy/diagnostic imaging/*pathology MH - Ubiquitin Thiolesterase MH - Ultrasonography, Doppler, Color EDAT- 2003/10/02 05:00 MHDA- 2004/03/26 05:00 CRDT- 2003/10/02 05:00 PHST- 2003/01/09 00:00 [received] PHST- 2003/03/21 00:00 [accepted] PHST- 2003/10/02 05:00 [pubmed] PHST- 2004/03/26 05:00 [medline] PHST- 2003/10/02 05:00 [entrez] AID - 10.1007/s00167-003-0391-6 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2003 Sep;11(5):334-8. doi: 10.1007/s00167-003-0391-6. Epub 2003 Aug 9. PMID- 19459021 OWN - NLM STAT- MEDLINE DCOM- 20100208 LR - 20211020 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 468 IP - 2 DP - 2010 Feb TI - Orthopaedic/radiology/pathology conference: Multiple nodular outgrowths in the hands and feet of a 60-year-old man. PG - 637-42 LID - 10.1007/s11999-009-0898-3 [doi] FAU - Kapoor, Sudhir K AU - Kapoor SK AD - Department of Orthopedics, Lady Hardinge Medical College and Dr. Ram Manohar Lohia Hospital & PGIMER, New Delhi, India. FAU - Kataria, Himanshu AU - Kataria H FAU - Patra, Satya Ranjan AU - Patra SR FAU - Boruah, Tankeswar AU - Boruah T LA - eng PT - Clinical Conference PT - Journal Article DEP - 20090521 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 53PF01Q249 (Clofibric Acid) SB - IM MH - Biopsy MH - Clofibric Acid/therapeutic use MH - Combined Modality Therapy MH - Diagnosis, Differential MH - Foot Diseases/*diagnosis/etiology/therapy MH - Hand Deformities, Acquired/*diagnosis/etiology/therapy MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Hyperlipidemia, Familial Combined/complications/*diagnosis/drug therapy MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Orthopedic Procedures MH - Physical Therapy Modalities MH - Tendons/*pathology/surgery MH - Xanthomatosis/*diagnosis/etiology/therapy PMC - PMC2806983 EDAT- 2009/05/22 09:00 MHDA- 2010/02/09 06:00 PMCR- 2011/02/01 CRDT- 2009/05/22 09:00 PHST- 2009/01/14 00:00 [received] PHST- 2009/05/05 00:00 [accepted] PHST- 2009/05/22 09:00 [entrez] PHST- 2009/05/22 09:00 [pubmed] PHST- 2010/02/09 06:00 [medline] PHST- 2011/02/01 00:00 [pmc-release] AID - 898 [pii] AID - 10.1007/s11999-009-0898-3 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2010 Feb;468(2):637-42. doi: 10.1007/s11999-009-0898-3. Epub 2009 May 21. PMID- 2006015 OWN - NLM STAT- MEDLINE DCOM- 19910425 LR - 20190514 IS - 0028-3878 (Print) IS - 0028-3878 (Linking) VI - 41 IP - 3 DP - 1991 Mar TI - Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. PG - 434-6 AB - We report 3 sisters treated for cerebrotendinous xanthomatosis. We treated one, with a severe neurologic form of the illness, with chenodeoxycholic acid, then lovastatin and simvastatin. These drugs had different efficacy and tolerance, but induced no clinical improvement. Her sisters, without neurologic symptoms, received chenodeoxycholic acid, which normalized the cholestanol level. Optimal treatment of this illness must begin before there is significant clinical symptomatology. FAU - Peynet, J AU - Peynet J AD - Laboratoire de Biochimie, Hospital Lariboisière, Paris. FAU - Laurent, A AU - Laurent A FAU - De Liege, P AU - De Liege P FAU - Lecoz, P AU - Lecoz P FAU - Gambert, P AU - Gambert P FAU - Legrand, A AU - Legrand A FAU - Mikol, J AU - Mikol J FAU - Warnet, A AU - Warnet A LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Neurology JT - Neurology JID - 0401060 RN - 0 (Anticholesteremic Agents) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 9LHU78OQFD (Lovastatin) RN - AGG2FN16EV (Simvastatin) SB - IM CIN - Neurology. 1994 Nov;44(11):2218. doi: 10.1212/wnl.44.11.2218. PMID: 7970001 MH - Adult MH - Anticholesteremic Agents/therapeutic use MH - Brain Diseases/diagnostic imaging/*drug therapy/genetics MH - Chenodeoxycholic Acid/*therapeutic use MH - Female MH - Humans MH - Lovastatin/*analogs & derivatives/*therapeutic use MH - Muscular Diseases/diagnostic imaging/drug therapy/genetics MH - Simvastatin MH - *Tendons MH - Tomography, X-Ray Computed MH - Xanthomatosis/diagnostic imaging/*drug therapy/genetics EDAT- 1991/03/01 00:00 MHDA- 1991/03/01 00:01 CRDT- 1991/03/01 00:00 PHST- 1991/03/01 00:00 [pubmed] PHST- 1991/03/01 00:01 [medline] PHST- 1991/03/01 00:00 [entrez] AID - 10.1212/wnl.41.3.434 [doi] PST - ppublish SO - Neurology. 1991 Mar;41(3):434-6. doi: 10.1212/wnl.41.3.434. PMID- 6512382 OWN - NLM STAT- MEDLINE DCOM- 19850215 LR - 20190904 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 9 IP - 3 DP - 1984 Oct TI - Acute calcific periarthritis in a child. PG - 351-2 AB - We wish to present an account of a child who developed acute calcification in his thenar eminence to highlight the difficulty in differentiation between calcific periarthritis, acute infection, on clinical grounds. Calcific periarthritis is due to hydroxyapatite crystal deposits in bursae, tendons and ligaments (Bonavita 1980) with characteristic radiographic appearances of opacities of variable density and shape around joints (Hitchcock 1959). The condition was first described in the shoulder, by Duplay in 1870 (Sandstrom 1938) and this remains the most commonly affected site. The hip, elbow, wrist, knee and ankle may also be involved but involvement of the hand is uncommon. Involvement in this site was first described in 1924 by Cohen (Carroll 1955). The previously reported age span ranged from thirteen years upwards, with an average of forty-five years, both sexes being equally affected (Currey 1970, Hitchcock 1959, Bonavita 1980). FAU - Mercer, N S AU - Mercer NS FAU - Newman, J H AU - Newman JH FAU - Watt, I AU - Watt I LA - eng PT - Case Reports PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 43B2M34G2V (Floxacillin) RN - 59XE10C19C (Fusidic Acid) SB - IM MH - Calcinosis/*diagnostic imaging/drug therapy MH - Child MH - Floxacillin/therapeutic use MH - Follow-Up Studies MH - Fusidic Acid/therapeutic use MH - Hand Injuries/complications MH - Humans MH - Male MH - Periarthritis/*diagnostic imaging/drug therapy MH - Radiography EDAT- 1984/10/01 00:00 MHDA- 1984/10/01 00:01 CRDT- 1984/10/01 00:00 PHST- 1984/10/01 00:00 [pubmed] PHST- 1984/10/01 00:01 [medline] PHST- 1984/10/01 00:00 [entrez] AID - 10.1016/0266-7681(84)90064-0 [doi] PST - ppublish SO - J Hand Surg Br. 1984 Oct;9(3):351-2. doi: 10.1016/0266-7681(84)90064-0. PMID- 31002728 OWN - NLM STAT- MEDLINE DCOM- 20200113 LR - 20200309 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 14 IP - 4 DP - 2019 TI - Cryopreservation of tendon tissue using dimethyl sulfoxide combines conserved cell vitality with maintained biomechanical features. PG - e0215595 LID - 10.1371/journal.pone.0215595 [doi] LID - e0215595 AB - Biomechanical research on tendon tissue evaluating new treatment strategies to frequently occurring clinical problems regarding tendon degeneration or trauma is of expanding scientific interest. In this context, storing tendon tissue deep-frozen is common practice to collect tissue and analyze it under equal conditions. The commonly used freezing medium, phosphate buffered saline, is known to damage cells and extracellular matrix in frozen state. Dimethyl sulfoxide, however, which is used for deep-frozen storage of cells in cell culture preserves cell vitality and reduces damage to the extracellular matrix during freezing. In our study, Achilles tendons of 26 male C57/Bl6 mice were randomized in five groups. Tendons were deep frozen in dimethyl sulfoxide or saline undergoing one or four freeze-thaw-cycles and compared to an unfrozen control group analyzing biomechanical properties, cell viability and collagenous structure. In electron microscopy, collagen fibrils of tendons frozen in saline appeared more irregular in shape, while dimethyl sulfoxide preserved the collagenous structure during freezing. In addition, treatment with dimethyl sulfoxide preserved cell viability visualized with an MTT-Assay, while tendons frozen in saline showed no remaining metabolic activity, indicating total destruction of cells during freezing. The biomechanical results revealed no differences between tendons frozen once in saline or dimethyl sulfoxide. However, tendons frozen four times in saline showed a significantly higher Young's modulus over all strain rates compared to unfrozen tendons. In conclusion, dimethyl sulfoxide preserves the vitality of tendon resident cells and protects the collagenous superstructure during the freezing process resulting in maintained biomechanical properties of the tendon. FAU - Hochstrat, Eva AU - Hochstrat E AD - Department of Regenerative Musculoskeletal Medicine, Institute for Musculoskeletal Medicine, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany. FAU - Müller, Marcus AU - Müller M AD - Department of Trauma-, Hand-, and Reconstructive Surgery, University Hospital Münster, Münster, Germany. FAU - Frank, Andre AU - Frank A AD - Department of Trauma-, Hand-, and Reconstructive Surgery, University Hospital Münster, Münster, Germany. FAU - Michel, Philipp AU - Michel P AD - Department of Regenerative Musculoskeletal Medicine, Institute for Musculoskeletal Medicine, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany. AD - Department of Trauma-, Hand-, and Reconstructive Surgery, University Hospital Münster, Münster, Germany. FAU - Hansen, Uwe AU - Hansen U AD - Department of Molecular Medicine, Institute for Musculoskeletal Medicine, Westfälische Wilhelms-University, Münster, Germany. FAU - Raschke, Michael J AU - Raschke MJ AD - Department of Trauma-, Hand-, and Reconstructive Surgery, University Hospital Münster, Münster, Germany. FAU - Kronenberg, Daniel AU - Kronenberg D AUID- ORCID: 0000-0001-6807-7328 AD - Department of Regenerative Musculoskeletal Medicine, Institute for Musculoskeletal Medicine, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany. FAU - Stange, Richard AU - Stange R AD - Department of Regenerative Musculoskeletal Medicine, Institute for Musculoskeletal Medicine, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190419 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Cryoprotective Agents) RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Achilles Tendon/cytology/*drug effects/physiology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Cell Survival/drug effects MH - Cryopreservation/*methods MH - Cryoprotective Agents/pharmacology MH - Dimethyl Sulfoxide/*pharmacology MH - Elastic Modulus/*drug effects/physiology MH - Male MH - Mice, Inbred C57BL PMC - PMC6474606 COIS- The authors have declared that no competing interests exist. EDAT- 2019/04/20 06:00 MHDA- 2020/01/14 06:00 PMCR- 2019/04/19 CRDT- 2019/04/20 06:00 PHST- 2018/11/08 00:00 [received] PHST- 2019/04/04 00:00 [accepted] PHST- 2019/04/20 06:00 [entrez] PHST- 2019/04/20 06:00 [pubmed] PHST- 2020/01/14 06:00 [medline] PHST- 2019/04/19 00:00 [pmc-release] AID - PONE-D-18-32207 [pii] AID - 10.1371/journal.pone.0215595 [doi] PST - epublish SO - PLoS One. 2019 Apr 19;14(4):e0215595. doi: 10.1371/journal.pone.0215595. eCollection 2019. PMID- 1143471 OWN - NLM STAT- MEDLINE DCOM- 19751008 LR - 20131121 IS - 0028-1298 (Print) IS - 0028-1298 (Linking) VI - 287 Suppl DP - 1975 TI - Proceedings: Antiarthritic properties of cystein derivatives in comparison with D-penicillamin in rats. PG - R65 FAU - Worstmann, W AU - Worstmann W FAU - Kretzschmar, R AU - Kretzschmar R LA - eng PT - Comparative Study PT - Journal Article PL - Germany TA - Naunyn Schmiedebergs Arch Pharmacol JT - Naunyn-Schmiedeberg's archives of pharmacology JID - 0326264 RN - 9007-81-2 (Freund's Adjuvant) RN - GNN1DV99GX (Penicillamine) RN - K848JZ4886 (Cysteine) SB - IM MH - Animals MH - Arthritis, Rheumatoid/*drug therapy MH - Cysteine/*analogs & derivatives/therapeutic use MH - Elasticity MH - Female MH - Freund's Adjuvant MH - Penicillamine/*therapeutic use MH - Rats MH - Tendons/physiology EDAT- 1975/01/01 00:00 MHDA- 1975/01/01 00:01 CRDT- 1975/01/01 00:00 PHST- 1975/01/01 00:00 [pubmed] PHST- 1975/01/01 00:01 [medline] PHST- 1975/01/01 00:00 [entrez] PST - ppublish SO - Naunyn Schmiedebergs Arch Pharmacol. 1975;287 Suppl:R65. PMID- 4711716 OWN - NLM STAT- MEDLINE DCOM- 19730810 LR - 20191030 IS - 0029-6678 (Print) IS - 0029-6678 (Linking) VI - 15 IP - 1 DP - 1973 TI - Reversibility of lipid deposition. PG - 141-3 FAU - Wolfram, G AU - Wolfram G LA - eng PT - Journal Article PL - Switzerland TA - Nutr Metab JT - Nutrition and metabolism JID - 0330472 RN - 0 (Lipids) RN - 0 (Pyridines) RN - 97C5T2UQ7J (Cholesterol) RN - HPN91K7FU3 (Clofibrate) RN - Y4S76JWI15 (Methanol) SB - IM MH - Arteriosclerosis/drug therapy MH - Cholesterol/blood MH - Clofibrate/therapeutic use MH - Cornea/metabolism MH - Coronary Disease/drug therapy MH - Coronary Vessels/metabolism MH - Evaluation Studies as Topic MH - Humans MH - Hypercholesterolemia/drug therapy MH - Hyperlipidemias/drug therapy/*metabolism MH - *Lipid Metabolism MH - Lipids/blood MH - Methanol/therapeutic use MH - Pyridines/therapeutic use MH - Skin/metabolism MH - Tendons/metabolism MH - Xanthomatosis/drug therapy/*metabolism EDAT- 1973/01/01 00:00 MHDA- 1973/01/01 00:01 CRDT- 1973/01/01 00:00 PHST- 1973/01/01 00:00 [pubmed] PHST- 1973/01/01 00:01 [medline] PHST- 1973/01/01 00:00 [entrez] AID - 10.1159/000175432 [doi] PST - ppublish SO - Nutr Metab. 1973;15(1):141-3. doi: 10.1159/000175432. PMID- 28438861 OWN - NLM STAT- MEDLINE DCOM- 20180213 LR - 20181113 IS - 1791-7549 (Electronic) IS - 0258-851X (Print) IS - 0258-851X (Linking) VI - 31 IP - 3 DP - 2017 May-Jun TI - Vitamin C Improves Therapeutic Effects of Adipose-derived Stem Cell Transplantation in Mouse Tendonitis Model. PG - 343-348 AB - BACKGROUND/AIM: We hypothesized that combined therapy using adipose-derived stem cells (ASCs) and vitamin C might improve tendon regeneration in tendonitis. To determine combined effects of ASC transplantation with vitamin C, we used senescence marker protein 30 (SMP30)-knockout (KO) mice that cannot biosynthesize vitamin C by themselves. MATERIALS AND METHODS: SMP30-KO were divided into four groups: Control, vitamin C, ASCs, and vitamin C plus ASCs. Tendonitis was induced in the achilles tendons via injection of collagenase type I. After 1 week, ASCs were injected into the intratendonal region. After 30 days, all mice were sacrificed and Achilles tendons were isolated. RESULTS: Gross and microscopic findings showed mice treated with combination of ASC transplantation and vitamin C showed better tendon regeneration than those in other groups. This combination led to higher serum vitamin C levels than use of vitamin C alone. This indicates that the vitamin C-treated group used more vitamin C as a precursor to collagen synthesis, whereas vitamin C was in excess in the combination group because of the added effect of ASCs on tendon healing. CONCLUSION: This study showed that vitamin C improved the effect of ASC transplantation on tendonitis by inducing a better stem cell niche. CI - Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. FAU - Kang, Kyung-Ku AU - Kang KK AD - Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea. AD - Stem Cell Therapeutic Research Institute, Kyungpook National University, Daegu, Republic of Korea. FAU - Lee, Eun-Joo AU - Lee EJ AD - Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea. AD - Stem Cell Therapeutic Research Institute, Kyungpook National University, Daegu, Republic of Korea. FAU - Kim, Youg-Deuk AU - Kim YD AD - Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea. AD - Stem Cell Therapeutic Research Institute, Kyungpook National University, Daegu, Republic of Korea. FAU - Chung, Myung-Jin AU - Chung MJ AD - Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea. AD - Stem Cell Therapeutic Research Institute, Kyungpook National University, Daegu, Republic of Korea. FAU - Kim, Jun-Young AU - Kim JY AD - Department of Orthopedic Surgery, Kyungpook National University Hospital, Daegu, Republic of Korea. FAU - Kim, Shin-Yoon AU - Kim SY AD - Department of Orthopedic Surgery, Kyungpook National University Hospital, Daegu, Republic of Korea. FAU - Hwang, Su-Kyeung AU - Hwang SK AD - Department of Pediatrics, Kyungpook National University Hospital, Daegu, Republic of Korea. FAU - Jeong, Kyu-Shik AU - Jeong KS AD - Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea jeongks@knu.ac.kr. AD - Stem Cell Therapeutic Research Institute, Kyungpook National University, Daegu, Republic of Korea. LA - eng PT - Journal Article PL - Greece TA - In Vivo JT - In vivo (Athens, Greece) JID - 8806809 RN - EC 3.4.24.- (Collagenases) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adipose Tissue/*drug effects/metabolism MH - Animals MH - Ascorbic Acid/*pharmacology MH - Collagenases/metabolism MH - Disease Models, Animal MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Regeneration/drug effects MH - Stem Cell Transplantation/methods MH - Stem Cells/*drug effects/metabolism MH - Tendinopathy/*drug therapy/metabolism MH - Tendons/*drug effects/metabolism MH - Wound Healing/drug effects PMC - PMC5461443 OTO - NOTNLM OT - SMP30-KO mouse OT - Tendonitis OT - adipose-derived stem cell OT - stem cell therapy OT - vitamin C EDAT- 2017/04/26 06:00 MHDA- 2018/02/14 06:00 PMCR- 2017/05/03 CRDT- 2017/04/26 06:00 PHST- 2017/01/26 00:00 [received] PHST- 2017/03/16 00:00 [revised] PHST- 2017/03/20 00:00 [accepted] PHST- 2017/04/26 06:00 [entrez] PHST- 2017/04/26 06:00 [pubmed] PHST- 2018/02/14 06:00 [medline] PHST- 2017/05/03 00:00 [pmc-release] AID - 31/3/343 [pii] AID - 10.21873/invivo.11065 [doi] PST - ppublish SO - In Vivo. 2017 May-Jun;31(3):343-348. doi: 10.21873/invivo.11065. PMID- 10702841 OWN - NLM STAT- MEDLINE DCOM- 20000323 LR - 20161124 VI - 69 IP - 5-6 DP - 1998 TI - [The treatment of pathologic calcification of shoulder tendons with E.D.T.A. bisodium salt by mesotherapy]. PG - 133-8 AB - The Authors treated at the Physiotherapy Service of the Clinic Orthopedic in Parma, 31 patients affected by shoulder's calcific tendonpathie++ were treated with E.D.T.A. bisodium salt they were painful and showed functional restriction besides they all shared a crystal's hydroxyapatite deposition. It was considered the pain by the Scott-Huskisson analogous--visual scale and the radiographic variation of calcification. It was noticed that with minimum pharmacological doses satisfying therapeutical results were achieved. That was not only as far as pain was concerned (disappeared in 29 patients (93.5%), but it was also obtained a significant reduction (4 patients 13%) or in some cases the disappearing of calcifications (25 patients 80%). FAU - Soncini, G AU - Soncini G AD - Cattedra di Medicina Fisica e Riabilitazione, Università degli Studi di Parma. FAU - Costantino, C AU - Costantino C LA - ita PT - Journal Article TT - Il trattamento delle tendinopatie calcifiche di spalla con E.D.T.A. sale bisodico per via mesoterapica. PL - Italy TA - Acta Biomed Ateneo Parmense JT - Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma JID - 8106323 RN - 0 (Chelating Agents) RN - 9G34HU7RV0 (Edetic Acid) SB - IM MH - Adult MH - Calcinosis/*diagnostic imaging/*drug therapy MH - Chelating Agents/*therapeutic use MH - Edetic Acid/*therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Radiography MH - Shoulder MH - Tendons/*diagnostic imaging MH - Treatment Outcome EDAT- 2000/03/07 09:00 MHDA- 2000/05/02 09:00 CRDT- 2000/03/07 09:00 PHST- 2000/03/07 09:00 [pubmed] PHST- 2000/05/02 09:00 [medline] PHST- 2000/03/07 09:00 [entrez] PST - ppublish SO - Acta Biomed Ateneo Parmense. 1998;69(5-6):133-8. PMID- 9279397 OWN - NLM STAT- MEDLINE DCOM- 19970926 LR - 20210526 IS - 0270-7306 (Print) IS - 1098-5549 (Electronic) IS - 0270-7306 (Linking) VI - 1 IP - 9 DP - 1981 Sep TI - Ascorbate induction of collagen synthesis as a means for elucidating a mechanism of quantitative control of tissue-specific function. PG - 843-53 AB - Ascorbic acid displays the characteristics of an ideal inducer of tissue-specific function in primary avian tendon cells in culture. It is a highly specific, potent stimulator of collagen synthesis, it demonstrates slow reversible kinetics, and it has no effect on growth rate of the cultured cells. Kinetic analysis of ascorbate induction of collagen synthesis was used to determine the critical steps in this complex biosynthetic pathway. Full hydroxylation of the proline residues in collagen, although probably a necessary step for collagen induction, was in itself not sufficient for achieving either increased secretion or increased synthesis. On the other hand, an increase in secretion rate, which required both the presence of ascorbate and a high cell density, did correlate with the later stimulation in procollagen production. The process of procollagen secretion, therefore, meets the minimal requirements for the rate-limiting step. The fact that the cells maintained a large pool of intracellular procollagen despite changes in the rates of translation or secretion led us to postulate a possible feedback between the level of the internal procollagen pool and the rate of procollagen synthesis. FAU - Schwarz, R I AU - Schwarz RI AD - Laboratory of Cell Biology, Lawrence Berkeley Laboratory, University of California, Berkeley 94720, USA. FAU - Mandell, R B AU - Mandell RB FAU - Bissell, M J AU - Bissell MJ LA - eng GR - IF32 CA 05807-91/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Mol Cell Biol JT - Molecular and cellular biology JID - 8109087 RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Cells, Cultured MH - Chickens MH - Collagen/*biosynthesis MH - Hydroxylation MH - Kinetics MH - Models, Biological MH - Proline/metabolism MH - Tendons/cytology/drug effects/metabolism PMC - PMC369368 EDAT- 1981/09/01 00:00 MHDA- 1981/09/01 00:01 PMCR- 1981/09/01 CRDT- 1981/09/01 00:00 PHST- 1981/09/01 00:00 [pubmed] PHST- 1981/09/01 00:01 [medline] PHST- 1981/09/01 00:00 [entrez] PHST- 1981/09/01 00:00 [pmc-release] AID - 10.1128/mcb.1.9.843-853.1981 [doi] PST - ppublish SO - Mol Cell Biol. 1981 Sep;1(9):843-53. doi: 10.1128/mcb.1.9.843-853.1981. PMID- 21669872 OWN - NLM STAT- MEDLINE DCOM- 20120511 LR - 20240109 IS - 1083-351X (Electronic) IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 286 IP - 32 DP - 2011 Aug 12 TI - Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. PG - 28556-66 LID - 10.1074/jbc.M111.256180 [doi] AB - Inflammatory processes play essential roles in the pathogenesis of tendinitis and tendinopathy. These events are accompanied by catabolic processes initiated by pro-inflammatory cytokines such as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Pharmacological treatments for tendinitis are restricted to the use of non-steroidal anti-inflammatory drugs. Recent studies in various cell models have demonstrated that curcumin targets the NF-κB signaling pathway. However, its potential for the treatment of tendinitis has not been explored. Herein, we used an in vitro model of human tenocytes to study the mechanism of curcumin action on IL-1β-mediated inflammatory signaling. Curcumin at concentrations of 5-20 μm inhibited IL-1β-induced inflammation and apoptosis in cultures of human tenocytes. The anti-inflammatory effects of curcumin included down-regulation of gene products that mediate matrix degradation (matrix metalloproteinase-1, -9, and -13), prostanoid production (cyclooxygenase-2), apoptosis (Bax and activated caspase-3), and stimulation of cell survival (Bcl-2), all known to be regulated by NF-κB. Furthermore, curcumin suppressed IL-1β-induced NF-κB activation via inhibition of phosphorylation and degradation of inhibitor of κBα, inhibition of inhibitor of κB-kinase activity, and inhibition of nuclear translocation of NF-κB. Furthermore, the effects of IL-1β were abrogated by wortmannin, suggesting a role for the phosphatidylinositol 3-kinase (PI-3K) pathway in IL-1β signaling. Curcumin suppressed IL-1β-induced PI-3K p85/Akt activation and its association with IKK. These results demonstrate, for the first time, a potential role for curcumin in treating tendon inflammation through modulation of NF-κB signaling, which involves PI-3K/Akt and the tendon-specific transcription factor scleraxis in tenocytes. FAU - Buhrmann, Constanze AU - Buhrmann C AD - Institute of Anatomy, Ludwig-Maximilian-University Munich, 80336 Munich, Germany. FAU - Mobasheri, Ali AU - Mobasheri A FAU - Busch, Franziska AU - Busch F FAU - Aldinger, Constance AU - Aldinger C FAU - Stahlmann, Ralf AU - Stahlmann R FAU - Montaseri, Azadeh AU - Montaseri A FAU - Shakibaei, Mehdi AU - Shakibaei M LA - eng GR - Wellcome Trust/United Kingdom GR - Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110613 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (BAX protein, human) RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (IL1B protein, human) RN - 0 (Interleukin-1beta) RN - 0 (NF-kappa B) RN - 0 (SCX protein, human) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (bcl-2-Associated X Protein) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (PTGS2 protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 3.4.24.- (Collagenases) RN - IT942ZTH98 (Curcumin) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Basic Helix-Loop-Helix Transcription Factors/metabolism MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagenases/metabolism MH - Curcumin/*pharmacology MH - Cyclooxygenase 2/metabolism MH - Dose-Response Relationship, Drug MH - Humans MH - Inflammation/metabolism/pathology MH - Interleukin-1beta/metabolism MH - Male MH - Middle Aged MH - NF-kappa B MH - Phosphatidylinositol 3-Kinases/*metabolism MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Signal Transduction/*drug effects MH - Tendons/*metabolism/pathology MH - Tumor Necrosis Factor-alpha/metabolism MH - bcl-2-Associated X Protein/metabolism PMC - PMC3151097 EDAT- 2011/06/15 06:00 MHDA- 2012/05/12 06:00 PMCR- 2011/06/13 CRDT- 2011/06/15 06:00 PHST- 2011/06/15 06:00 [entrez] PHST- 2011/06/15 06:00 [pubmed] PHST- 2012/05/12 06:00 [medline] PHST- 2011/06/13 00:00 [pmc-release] AID - S0021-9258(20)57569-8 [pii] AID - M111.256180 [pii] AID - 10.1074/jbc.M111.256180 [doi] PST - ppublish SO - J Biol Chem. 2011 Aug 12;286(32):28556-66. doi: 10.1074/jbc.M111.256180. Epub 2011 Jun 13. PMID- 39769123 OWN - NLM STAT- MEDLINE DCOM- 20250108 LR - 20250927 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 25 IP - 24 DP - 2024 Dec 12 TI - Effect of High-Dose Vitamin C on Tendon Cell Degeneration-An In Vitro Study. LID - 10.3390/ijms252413358 [doi] LID - 13358 AB - Tendinopathy is an aging-related disease, often caused by micro-scarring and degeneration due to overuse or trauma. Ascorbic acid (vitamin C) supplementation is reported to be a useful treatment for tendinopathy recovery. We compared the inhibitory effects of various ascorbic acid doses on tendon cell damage. H(2)O(2) was added to human-derived tendon cells in vitro (Group H(2)O(2), control), followed by incubation with 150 µM or 30 mM of ascorbic acid (Group C, Group HC). The oxidative injury degree was evaluated by determining reactive oxygen species levels. The cytoskeletal structure was examined via fluorescence immunostaining of actin filaments. Quantitative polymerase chain reaction (qPCR) was performed to analyze the expressions of mitochondria transcription factor A, adenosine triphosphate 5A, type I collagen, and p16. Cell death was reduced, and oxidative stress was inhibited in C and HC groups. The cytoskeleton was maintained in the HC group but not in the C group. qPCR analysis revealed that p16 expression was inhibited in both the C and HC groups compared to the H(2)O(2) group; other markers had increased expression. The progression of cell death and cytoskeletal disruption was inhibited by the administration of high-dose vitamin C. Hence, high-dose vitamin C is a potential treatment for tendon cell degeneration. FAU - Ueda, Shusuke AU - Ueda S AUID- ORCID: 0000-0003-3385-032X AD - Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Ichiseki, Toru AU - Ichiseki T AD - Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. AD - Division of Translational Research, Department of Life Science, Medical Research Institute, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Shimasaki, Miyako AU - Shimasaki M AD - Department of Pathology 2, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Soma, Daisuke AU - Soma D AD - Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Sakurai, Masaru AU - Sakurai M AD - Social and Environmental Medicine, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Kaneuji, Ayumi AU - Kaneuji A AUID- ORCID: 0000-0001-7224-0722 AD - Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. FAU - Kawahara, Norio AU - Kawahara N AD - Department of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan. LA - eng GR - 19K18511/The Ministry of Education, Culture, Sports, Science, and Technology of Japan./ PT - Journal Article DEP - 20241212 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - PQ6CK8PD0R (Ascorbic Acid) RN - BBX060AN9V (Hydrogen Peroxide) RN - 0 (Reactive Oxygen Species) RN - 0 (Antioxidants) SB - IM EIN - Int J Mol Sci. 2025 Sep 17;26(18):9029. doi: 10.3390/ijms26189029. PMID: 41009825 MH - *Ascorbic Acid/pharmacology MH - Humans MH - *Oxidative Stress/drug effects MH - *Hydrogen Peroxide/pharmacology MH - *Tendons/metabolism/drug effects/pathology MH - *Reactive Oxygen Species/metabolism MH - Cells, Cultured MH - Tendinopathy/drug therapy/metabolism/pathology MH - Antioxidants/pharmacology MH - Cytoskeleton/metabolism/drug effects PMC - PMC11678561 OTO - NOTNLM OT - actin filament OT - cellular senescence OT - high-dose vitamin C OT - mitochondrial damage OT - oxidative injury OT - tendon cell degeneration COIS- The authors declare no conflicts of interest. EDAT- 2025/01/08 06:20 MHDA- 2025/01/08 06:21 PMCR- 2024/12/12 CRDT- 2025/01/08 01:23 PHST- 2024/10/30 00:00 [received] PHST- 2024/12/09 00:00 [revised] PHST- 2024/12/11 00:00 [accepted] PHST- 2025/01/08 06:21 [medline] PHST- 2025/01/08 06:20 [pubmed] PHST- 2025/01/08 01:23 [entrez] PHST- 2024/12/12 00:00 [pmc-release] AID - ijms252413358 [pii] AID - ijms-25-13358 [pii] AID - 10.3390/ijms252413358 [doi] PST - epublish SO - Int J Mol Sci. 2024 Dec 12;25(24):13358. doi: 10.3390/ijms252413358. PMID- 19543778 OWN - NLM STAT- MEDLINE DCOM- 20091202 LR - 20211020 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 467 IP - 11 DP - 2009 Nov TI - Improved tendon radioprotection by combined cross-linking and free radical scavenging. PG - 2994-3001 LID - 10.1007/s11999-009-0934-3 [doi] AB - Allograft safety is a great concern owing to the risk of disease transmission from nonsterile tissues. Radiation sterilization is not used routinely because of deleterious effects on the mechanical integrity and stability of allograft collagen. We previously reported several individual cross-linking or free radical scavenging treatments provided some radioprotective effects for tendons. We therefore asked whether a combination of treatments would provide an improved protective effect after radiation exposure regarding mechanical properties and enzyme resistance. To address this question we treated 90 rabbit Achilles tendons with a combination of cross-linking (1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide [EDC]) and one of three scavenging regimens (mannitol, ascorbate, or riboflavin). Tendons then were exposed to one of three radiation conditions (gamma or electron beam irradiation at 50 kGy or unsterilized). Combination-treated tendons (10 per group) had increases in mechanical properties and higher resistance to collagenase digestion compared with EDC-only and untreated tendons. Irradiated tendons treated with EDC-mannitol, -ascorbate, and -riboflavin combinations had comparable strength to native tendon and had averages of 26%, 39%, and 37% greater, respectively, than those treated with EDC-only. Optimization of a cross-linking protocol and free radical scavenging cocktail is ongoing with the goal of ensuring sterile allografts through irradiation while maintaining their structure and mechanical properties. FAU - Seto, Aaron AU - Seto A AD - Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, UMDNJ-Robert Wood Johnson Medical School, 51 French Street, Orthopaedic Surgery Room 424, PO Box 19, New Brunswick, NJ, 08903, USA. FAU - Gatt, Charles J Jr AU - Gatt CJ Jr FAU - Dunn, Michael G AU - Dunn MG LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090619 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Cross-Linking Reagents) RN - 0 (Free Radical Scavengers) RN - 3OWL53L36A (Mannitol) RN - PQ6CK8PD0R (Ascorbic Acid) RN - TLM2976OFR (Riboflavin) SB - IM MH - Achilles Tendon/*drug effects/*radiation effects MH - Animals MH - Ascorbic Acid/pharmacology MH - Biomechanical Phenomena MH - Cross-Linking Reagents/*pharmacology MH - Disease Models, Animal MH - Free Radical Scavengers/*pharmacology MH - Mannitol/pharmacology MH - Materials Testing MH - Rabbits MH - Radiation Dosage MH - Radiation Injuries/prevention & control MH - Random Allocation MH - Reference Values MH - Riboflavin/pharmacology MH - Sensitivity and Specificity MH - Tendon Transfer/adverse effects/methods MH - Tensile Strength MH - Tissue and Organ Harvesting/methods MH - Transplantation, Homologous PMC - PMC2758987 EDAT- 2009/06/23 09:00 MHDA- 2009/12/16 06:00 PMCR- 2010/11/01 CRDT- 2009/06/23 09:00 PHST- 2008/09/09 00:00 [received] PHST- 2009/06/01 00:00 [accepted] PHST- 2009/06/23 09:00 [entrez] PHST- 2009/06/23 09:00 [pubmed] PHST- 2009/12/16 06:00 [medline] PHST- 2010/11/01 00:00 [pmc-release] AID - 934 [pii] AID - 10.1007/s11999-009-0934-3 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2009 Nov;467(11):2994-3001. doi: 10.1007/s11999-009-0934-3. Epub 2009 Jun 19. PMID- 562877 OWN - NLM STAT- MEDLINE DCOM- 19780127 LR - 20210212 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 252 IP - 23 DP - 1977 Dec 10 TI - Kinetics for the secretion of procollagen by freshly isolated tendon cells. PG - 8391-7 AB - Fibroblasts isolated by enzymic digestion of chick embryo tendons were incubated for several hours in suspension under conditions in which they were in steady state in terms of the synthesis and secretion of procollagen. Under these conditions, the cells synthesized and secreted about 630 microgram of procollagen/10(9) cells/h. The cells were labeled with [14C]proline for 15 to 120 min and then the kinetics of secretion were followed by chasing the label and assaying the 14C-peptides digestible by collagenase in the cells and in the medium. The results demonstrated that secretion of collagenase-digestible peptides did not follow the kinetics of a single first order process but suggested at least two pseudo-first order process with half-times of 14 and 115 min. The [14C]procollagen secreted during 0 to 30 min and 90 to 120 min of chase was the same in terms of the ratio of pro-alpha1 to pro-alpha2 chains, the size of the pro-alpha chains, the extent of interchain disulfide bonding, the extent of prolyl hydroxylation, and the degree of helicity as tested by resistance to pepsin digestion. Addition of ascorbic acid to the incubation medium increased slightly the extent of prolyl hydroxylation but did not alter the kinetics of secretion. The results suggested that the kinetics of secretion are influenced by a two-compartment system in which at least one metabolic pool contributing to the secretory process is present as a "side pocket." FAU - Kao, W W AU - Kao WW FAU - Berg, R A AU - Berg RA FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Procollagen) RN - 9DLQ4CIU6V (Proline) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/pharmacology MH - Cells, Cultured MH - Chick Embryo MH - Fibroblasts/metabolism MH - Kinetics MH - Procollagen/*metabolism MH - Proline/metabolism MH - Tendons/drug effects/*metabolism EDAT- 1977/12/10 00:00 MHDA- 1977/12/10 00:01 CRDT- 1977/12/10 00:00 PHST- 1977/12/10 00:00 [pubmed] PHST- 1977/12/10 00:01 [medline] PHST- 1977/12/10 00:00 [entrez] AID - S0021-9258(19)75231-4 [pii] PST - ppublish SO - J Biol Chem. 1977 Dec 10;252(23):8391-7. PMID- 10336043 OWN - NLM STAT- MEDLINE DCOM- 19990624 LR - 20190915 IS - 0277-3740 (Print) IS - 0277-3740 (Linking) VI - 18 IP - 3 DP - 1999 May TI - Cyanoacrylate tissue adhesive augmented tenoplasty: a new surgical procedure for bilateral severe chemical eye burns. PG - 366-9 AB - PURPOSE: To report on cyanoacrylate tissue adhesive augmented tenoplasty, a new surgical procedure for bilateral severe chemical eye injuries. METHODS: A 26-year-old man presented with bilateral severe (grade IV) chemical burns involving the eye, periorbital tissues, face, and neck. Despite adequate medical therapy, corneal, limbal, and scleral ulceration progressed in both eyes. Secondary Pseudomonas keratitis necessitated therapeutic penetrating keratoplasty in the right eye. Tenoplasty and glued-on rigid gas permeable contact lens were unsuccessful to arrest progression of corneolimboscleral ulceration in the left eye. We applied n-butyl cyanoacrylate tissue adhesive directly on the ulcerating corneal, limbal, and scleral surface to augment tenoplasty. RESULTS: The left ocular surface healed with resultant massive fibrous tissue proliferation and symblepharon on the nasal side. Ocular surface rehabilitation resulted in a vascularized leukomatous corneal opacity with upper temporal clear cornea. The patient achieved visual acuity of 6/36 in the left eye. CONCLUSION: We suggest that cyanoacrylate tissue adhesive-augmented tenoplasty can be undertaken to preserve ocular integrity and retain visual potential in a severe chemical eye injury. FAU - Sharma, A AU - Sharma A AD - Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. eyepgi@chd.vsnl.net.in FAU - Pandey, S AU - Pandey S FAU - Sharma, R AU - Sharma R FAU - Mohan, K AU - Mohan K FAU - Gupta, A AU - Gupta A LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Cornea JT - Cornea JID - 8216186 RN - F8CEP82QNP (Enbucrilate) SB - IM MH - Adult MH - Burns, Chemical/drug therapy/*surgery MH - Combined Modality Therapy MH - Corneal Ulcer/drug therapy/microbiology/*surgery MH - Enbucrilate/*therapeutic use MH - Eye Burns/*chemically induced/drug therapy/surgery MH - Eye Infections, Bacterial/surgery MH - Humans MH - Keratoplasty, Penetrating MH - Male MH - Pseudomonas Infections/surgery MH - Scleral Diseases/drug therapy/*surgery MH - Tendons/drug effects/*surgery EDAT- 1999/05/21 00:00 MHDA- 1999/05/21 00:01 CRDT- 1999/05/21 00:00 PHST- 1999/05/21 00:00 [pubmed] PHST- 1999/05/21 00:01 [medline] PHST- 1999/05/21 00:00 [entrez] AID - 00003226-199905000-00020 [pii] AID - 10.1097/00003226-199905000-00020 [doi] PST - ppublish SO - Cornea. 1999 May;18(3):366-9. doi: 10.1097/00003226-199905000-00020. PMID- 3886259 OWN - NLM STAT- MEDLINE DCOM- 19850528 LR - 20041117 IS - 0094-1298 (Print) IS - 0094-1298 (Linking) VI - 12 IP - 2 DP - 1985 Apr TI - Collagen modifications. PG - 209-20 AB - Collagen, the major structural protein found in all animal tissues, has a variety of uses in the armamentarium of the plastic surgeon. This article discusses the biologic characteristics of collagen that determine its behavior as an implant material. Clinical applications discussed include hemostatic collagen fleece, collagen sponge wound dressing, composite tissue tendon allografts, injectable collagen, and manipulation of scar collagen. FAU - Arem, A AU - Arem A LA - eng PT - Journal Article PT - Review PL - United States TA - Clin Plast Surg JT - Clinics in plastic surgery JID - 0424767 RN - 0 (Antigens) RN - 0 (Biocompatible Materials) RN - 0 (Hemostatics) RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) SB - IM MH - Aminopropionitrile/therapeutic use MH - Animals MH - Antigens MH - Biocompatible Materials MH - Biological Dressings MH - Cicatrix MH - *Collagen/immunology/physiology/therapeutic use MH - Foreign-Body Reaction/etiology MH - Hemostasis, Surgical MH - Hemostatics MH - Humans MH - *Prostheses and Implants MH - *Surgery, Plastic MH - Tendons/transplantation RF - 74 EDAT- 1985/04/01 00:00 MHDA- 1985/04/01 00:01 CRDT- 1985/04/01 00:00 PHST- 1985/04/01 00:00 [pubmed] PHST- 1985/04/01 00:01 [medline] PHST- 1985/04/01 00:00 [entrez] PST - ppublish SO - Clin Plast Surg. 1985 Apr;12(2):209-20. PMID- 24111820 OWN - NLM STAT- MEDLINE DCOM- 20140616 LR - 20181202 IS - 1944-8252 (Electronic) IS - 1944-8244 (Linking) VI - 5 IP - 21 DP - 2013 Nov 13 TI - One-step generation of engineered drug-laden poly(lactic-co-glycolic acid) micropatterned with Teflon chips for potential application in tendon restoration. PG - 10583-90 LID - 10.1021/am402388k [doi] AB - Regulating cellular behaviors such as cellular spatial arrangement and cellular phenotype is critical for managing tissue microstructure and biological function for engineered tissue regeneration. We herein pattern drug-laden poly(lactic-co-glycolic acid) (PLGA) into grooves using novel Teflon stamps (that possess excellent properties of resistance to harsh organic solvents and molecular adsorption) for engineered tendon-repair therapeutics. The drug release and biological properties of melatonin-laden PLGA grooved micropatterns are investigated. The results reveal that fibroblasts cultured on the melatonin-laden PLGA groove micropatterns not only display significant cell alignment that mimics the cell behavior in native tendon, but also promote the secretion of a major extracellular matrix in tendon, type I collagen, indicating great potential for the engineering of functional tendon regeneration. FAU - Shi, Xuetao AU - Shi X AD - WPI Advanced Institute for Materials Research, Tohoku University , 2-1-1 Katahira, Aoba-ku, Sendai, 980-8577, Japan. FAU - Zhao, Yihua AU - Zhao Y FAU - Zhou, Jianhua AU - Zhou J FAU - Chen, Song AU - Chen S FAU - Wu, Hongkai AU - Wu H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131022 PL - United States TA - ACS Appl Mater Interfaces JT - ACS applied materials & interfaces JID - 101504991 RN - 0 (Biocompatible Materials) RN - 0 (Collagen Type I) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) RN - 9002-84-0 (Polytetrafluoroethylene) SB - IM MH - Adsorption MH - Biocompatible Materials/chemistry/therapeutic use MH - Collagen Type I/biosynthesis MH - Fibroblasts/cytology/drug effects/metabolism MH - Humans MH - Lactic Acid/*chemistry/therapeutic use MH - Polyglycolic Acid/*chemistry/therapeutic use MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - Polytetrafluoroethylene/*chemistry/therapeutic use MH - *Regeneration MH - Tendons/pathology/*surgery MH - Tissue Engineering EDAT- 2013/10/12 06:00 MHDA- 2014/06/17 06:00 CRDT- 2013/10/12 06:00 PHST- 2013/10/12 06:00 [entrez] PHST- 2013/10/12 06:00 [pubmed] PHST- 2014/06/17 06:00 [medline] AID - 10.1021/am402388k [doi] PST - ppublish SO - ACS Appl Mater Interfaces. 2013 Nov 13;5(21):10583-90. doi: 10.1021/am402388k. Epub 2013 Oct 22. PMID- 9523961 OWN - NLM STAT- MEDLINE DCOM- 19980512 LR - 20161124 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 23 IP - 1 DP - 1998 Jan TI - Injection accuracy and clinical relief of de Quervain's tendinitis. PG - 89-96 AB - In a controlled, prospective, double-blind study, the incidence of accurate injection of the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) tendon compartments was defined and correlated with clinical relief of de Quervain's tendinitis. X-ray dye was included with steroid and lidocaine injections for 19 patients; dye location was immediately checked by 1 radiologist blinded to the clinical results. Dye was confirmed to be within the first dorsal compartment in 16 of 19 cases. There was relief of symptoms in 11 of 19 patients. Four of 5 patients with dye in both the APL and EPB tendon compartments, experienced relief of symptoms, while all 3 with dye in neither compartment experienced no relief. This suggests that accurate injection of steroids is required for relief of de Quervain's tendinitis. The EPB compartment was often missed (13/19 cases), possibly because it was separate or of small size and deep location. This may be a factor in failed injections, just as surgery can fail if a separate EPB compartment is not released. FAU - Zingas, C AU - Zingas C AD - Department of Orthopaedic Surgery, Henry Ford Hospital, Detroit, MI 48202, USA. FAU - Failla, J M AU - Failla JM FAU - Van Holsbeeck, M AU - Van Holsbeeck M LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Anesthetics, Local) RN - 0 (Contrast Media) RN - 0 (Glucocorticoids) RN - 4419T9MX03 (Iohexol) RN - 9842X06Q6M (Betamethasone) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - Anesthetics, Local/therapeutic use MH - Betamethasone/administration & dosage/*therapeutic use MH - Contrast Media MH - Female MH - Glucocorticoids/administration & dosage/*therapeutic use MH - Humans MH - Iohexol MH - Lidocaine/therapeutic use MH - Male MH - Prospective Studies MH - Radiography MH - Synovial Membrane/anatomy & histology MH - *Tendons/anatomy & histology/diagnostic imaging MH - Tenosynovitis/diagnostic imaging/*drug therapy/pathology MH - Treatment Outcome MH - Wrist Joint/*anatomy & histology/diagnostic imaging EDAT- 1998/04/02 00:00 MHDA- 1998/04/02 00:01 CRDT- 1998/04/02 00:00 PHST- 1998/04/02 00:00 [pubmed] PHST- 1998/04/02 00:01 [medline] PHST- 1998/04/02 00:00 [entrez] AID - S0363-5023(98)80095-6 [pii] AID - 10.1016/S0363-5023(98)80095-6 [doi] PST - ppublish SO - J Hand Surg Am. 1998 Jan;23(1):89-96. doi: 10.1016/S0363-5023(98)80095-6. PMID- 1870035 OWN - NLM STAT- MEDLINE DCOM- 19910913 LR - 20220330 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 9 IP - 5 DP - 1991 Sep TI - Ascorbic acid requirement for optimal flexor tendon repair in vitro. PG - 714-9 AB - Numerous studies from our laboratory have defined aspects of the repair process in a lacerated flexor tendon model, both in vivo and in vitro. Inherent in the development of a viable tissue or cell culture model system is the definition of the optimal media environment. Since our laboratory investigations of in vitro flexor tendon repair encompass the formation of numerous extracellular matrix proteins, we have defined the optimal level of ascorbic acid with which to study the tendon wound healing process. The ascorbic acid requirement for proline and lysine hydroxylase activity during collagen biosynthesis is well known, and the importance of this vitamin for matrix proteoglycan synthesis more recently has been appreciated. This report describes the effect of several levels of ascorbic acid on 3H-thymidine incorporation, collagen and noncollagen protein synthesis, and glucose utilization and lactate production. Profundus flexor tendon segments were obtained from young adult New Zealand white rabbits and maintained in organ culture for periods of 1, 2, or 3 weeks. Ascorbic acid concentrations ranged from 50 to 300 micrograms/ml and were added fresh at each 48-h media change. Tendon protein synthesis, glucose metabolism, and cell permeability/viability were significantly correlated with the level of ascorbic acid in the culture medium. The results suggest that ascorbic acid levels in excess of the traditional 50 micrograms/ml are necessary to optimally maintain flexor tendons from adult animals in organ culture with 48-h media and ascorbate changes. Additionally, it may be necessary to determine the precise ascorbic acid requirement for individual tissues, since the specific tissue/cell and species requirement for ascorbate may vary. FAU - Russell, J E AU - Russell JE AD - Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. FAU - Manske, P R AU - Manske PR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 9007-34-5 (Collagen) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - IY9XDZ35W2 (Glucose) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Collagen/biosynthesis MH - Culture Techniques MH - Glucose/metabolism MH - L-Lactate Dehydrogenase/metabolism MH - Protein Biosynthesis MH - Rabbits MH - Tendons/drug effects/*physiology EDAT- 1991/09/01 00:00 MHDA- 1991/09/01 00:01 CRDT- 1991/09/01 00:00 PHST- 1991/09/01 00:00 [pubmed] PHST- 1991/09/01 00:01 [medline] PHST- 1991/09/01 00:00 [entrez] AID - 10.1002/jor.1100090511 [doi] PST - ppublish SO - J Orthop Res. 1991 Sep;9(5):714-9. doi: 10.1002/jor.1100090511. PMID- 11361235 OWN - NLM STAT- MEDLINE DCOM- 20010712 LR - 20131121 IS - 0037-5675 (Print) IS - 0037-5675 (Linking) VI - 42 IP - 1 DP - 2001 Jan TI - Cerebrotendinous xanthomatosis in three siblings from a Chinese family. PG - 30-2 AB - Cerebrotendinous xanthomatosis (CTX) is exceptionally rare in the Chinese population. We reported a 31-year-old Chinese male in Hong Kong, who has the characteristic features of cerebrotendinous xanthomatosis including the multiple xanthomas of tendons, mental retardation, bilateral cataracts, cerebellar ataxia and spasticity of the left arm, high concentrations of plasma phytosterols and abnormal MR of brain. On screening the family, two other siblings of 27 and 29 respectively, have tendon xanthomas and high plasma phytosterols. An extensive search of the international medical literature, including the Medline, has revealed only one other case report of cerebrotendinous xanthomatosis in Taiwan. CTX is a potentially treatable disease. It is hoped by alertness, early diagnosis and treatment can be made, and hence prevent further progression of the disease. FAU - Ko, K F AU - Ko KF AD - Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong. FAU - Lee, K W AU - Lee KW LA - eng PT - Case Reports PT - Journal Article PL - India TA - Singapore Med J JT - Singapore medical journal JID - 0404516 RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 97C5T2UQ7J (Cholesterol) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Adult MH - Chenodeoxycholic Acid/therapeutic use MH - China MH - Cholesterol/blood MH - Genes, Recessive MH - Humans MH - Intellectual Disability/etiology MH - Magnetic Resonance Imaging MH - Male MH - Nuclear Family MH - Simvastatin/therapeutic use MH - Xanthomatosis, Cerebrotendinous/complications/*diagnosis/drug therapy/*genetics EDAT- 2001/05/22 10:00 MHDA- 2001/07/13 10:01 CRDT- 2001/05/22 10:00 PHST- 2001/05/22 10:00 [pubmed] PHST- 2001/07/13 10:01 [medline] PHST- 2001/05/22 10:00 [entrez] PST - ppublish SO - Singapore Med J. 2001 Jan;42(1):30-2. PMID- 34855112 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20220202 IS - 1559-0291 (Electronic) IS - 0273-2289 (Linking) VI - 194 IP - 1 DP - 2022 Jan TI - Inhibition of Advanced Glycation End Product Formation in Rat Tail Tendons by Polydatin and p-Coumaric acid: an In Vitro Study. PG - 339-353 LID - 10.1007/s12010-021-03762-y [doi] AB - Advanced glycation end products (AGEs) formed through non-enzymatic glycosylation between a protein and sugar molecule are highly harmful to the human body. In hyperglycemic patients, AGE formation is more due to high glucose circulating in the blood, causing inter and intra molecular cross-linking of collagen leading to reduction of collagen elasticity. This cross-linked collagen develops resistance to matrix metalloproteinases leading to impaired collagen turnover. The aim of this work is to determine the anti-glycation effects of polydatin and p-coumaric acid in preventing collagen cross-linking by incubating rat tail tendons (RTTs) as collagen source in high glucose concentration (50 mM) for a week. The RTTs were then characterized for tensile strength, cross-linking efficiency, circular dichroism spectrometry, collagen, glucose, and aldehyde contents. Electrophoresis was carried out to evaluate the level of cross-linking in collagen and the results confirmed the ability of the drugs in preventing complex intermolecular cross-link formation induced by non-enzymatic glycosylation. CD data showed alteration in the secondary structure of collagen where AGE formation had occurred. More collagen was extracted by pepsin from RTTs treated with glucose alone (6.88 mg/10 mg tendon) when compared with drug-treated groups (4.25, 2.56 mg/10 mg tendon for polydatin and p-coumaric acid, respectively). Tensile strength (20.66% and 18.95%), cross-linking percentage (32.5% and 29.84%), and glucose content (2.3 and 1.8 mg/100 mg) of drug-treated groups were similar to the positive control (19.07%, 30.13%, and 2.61 mg/100 mg) thus proving the anti-glycation potential of the drugs. Hence, both polydatin and p-coumaric acid could play a pivotal role in preventing AGE formation. CI - © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Selvakumar, Gopika AU - Selvakumar G AD - Biochemistry and Biotechnology Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai, 600 020, India. AD - University of Madras, Chepauk, Chennai, 600 005, India. FAU - Venu, Dhanalakshmi AU - Venu D AD - Department of Biochemistry, University of Madras, Guindy Campus, Chennai, 600 085, India. FAU - Kuttalam, Iyappan AU - Kuttalam I AD - Chemical Engineering Division, CSIR-Central Leather Research Institute, Adyar, Chennai, 600 020, India. FAU - Lonchin, Suguna AU - Lonchin S AD - Biochemistry and Biotechnology Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai, 600 020, India. slonchin@yahoo.co.uk. LA - eng PT - Journal Article DEP - 20211202 PL - United States TA - Appl Biochem Biotechnol JT - Applied biochemistry and biotechnology JID - 8208561 RN - 0 (Coumaric Acids) RN - 0 (Glucosides) RN - 0 (Glycation End Products, Advanced) RN - 0 (Stilbenes) RN - IBS9D1EU3J (p-coumaric acid) RN - XM261C37CQ (polydatin) SB - IM MH - Animals MH - Coumaric Acids/*pharmacology MH - Glucosides/*pharmacology MH - Glycation End Products, Advanced/*metabolism MH - Glycosylation/drug effects MH - Rats MH - Rats, Wistar MH - Stilbenes/*pharmacology MH - Tail/metabolism MH - Tendons/*metabolism OTO - NOTNLM OT - Advanced glycated end products OT - Collagen OT - Cross-linking OT - Polyphenols OT - Rat tail tendons EDAT- 2021/12/03 06:00 MHDA- 2022/02/03 06:00 CRDT- 2021/12/02 12:27 PHST- 2021/07/28 00:00 [received] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/12/03 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/12/02 12:27 [entrez] AID - 10.1007/s12010-021-03762-y [pii] AID - 10.1007/s12010-021-03762-y [doi] PST - ppublish SO - Appl Biochem Biotechnol. 2022 Jan;194(1):339-353. doi: 10.1007/s12010-021-03762-y. Epub 2021 Dec 2. PMID- 26719200 OWN - NLM STAT- MEDLINE DCOM- 20160829 LR - 20220318 IS - 1477-2566 (Electronic) IS - 1465-3249 (Linking) VI - 18 IP - 1 DP - 2016 Jan TI - Transplantation of tendon-derived stem cells pre-treated with connective tissue growth factor and ascorbic acid in vitro promoted better tendon repair in a patellar tendon window injury rat model. PG - 99-112 LID - S1465-3249(15)01079-8 [pii] LID - 10.1016/j.jcyt.2015.10.005 [doi] AB - BACKGROUND AIMS: Treatment of tendon-derived stem cells (TDSCs) with connective tissue growth factor (CTGF) and ascorbic acid promoted their tenogenic differentiation. We investigated the effects of TDSCs pre-treated with CTGF and ascorbic acid on tendon repair in a patellar tendon window injury rat model. METHODS: Green fluorescent protein-TDSCs (GFP-TDSCs) were pre-treated with or without CTGF and ascorbic acid for 2 weeks before transplantation. The patellar tendons of rats were injured and divided into three groups: fibrin glue-only group (control group), untreated and treated TDSC group. The rats were followed up until week 16. RESULTS: The treated TDSCs accelerated and enhanced the quality of tendon repair compared with untreated TDSCs up to week 8, which was better than that in the controls up to week 16 as shown by histology, ultrasound imaging and biomechanical test. The fibrils in the treated TDSC group showed better alignment and larger size compared with those in the control group at week 8 (P = 0.004). There was lower risk of ectopic mineralization after transplantation of treated or untreated TDSCs (all P ≤ 0.050). The transplanted cells proliferated and could be detected in the window wound up to weeks 2 to 4 and week 8 for the untreated and treated TDSC groups, respectively. CONCLUSIONS: The transplantation of TDSCs promoted tendon repair up to week 16, with CTGF and ascorbic acid pre-treatment showing the best results up to week 8. Pre-treatment of TDSCs with CTGF and ascorbic acid may be used to further enhance the rate and quality of tendon repair after injury. CI - Copyright © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved. FAU - Lui, Pauline Po Yee AU - Lui PP AD - Headquarter, Hospital Authority, Hong Kong SAR, China. Electronic address: paulinelui00@gmail.com. FAU - Wong, On Tik AU - Wong OT AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lee, Yuk Wa AU - Lee YW AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Cytotherapy JT - Cytotherapy JID - 100895309 RN - 0 (Fibrillar Collagens) RN - 0 (Fibrin Tissue Adhesive) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - 147336-22-9 (Green Fluorescent Proteins) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Biomechanical Phenomena/drug effects MH - Calcification, Physiologic/drug effects MH - Cell Differentiation MH - Connective Tissue Growth Factor/*pharmacology MH - Disease Models, Animal MH - Fibrillar Collagens/metabolism/ultrastructure MH - Fibrin Tissue Adhesive/pharmacology MH - Green Fluorescent Proteins/metabolism MH - Immunohistochemistry MH - Male MH - Patellar Ligament/injuries MH - Proliferating Cell Nuclear Antigen/metabolism MH - Rats, Sprague-Dawley MH - *Stem Cell Transplantation MH - Stem Cells/*cytology/drug effects MH - Tendon Injuries/diagnostic imaging/pathology/*therapy MH - Tendons/diagnostic imaging/drug effects/*pathology MH - Tomography, X-Ray Computed MH - Ultrasonography MH - Wound Healing/*drug effects OTO - NOTNLM OT - connective tissue growth factor (CTGF) and ascorbic acid OT - tendon healing OT - tendon repair OT - tendon stem/progenitor cells OT - tendon tissue engineering OT - tendon-derived stem cells (TDSCs) EDAT- 2016/01/01 06:00 MHDA- 2016/08/30 06:00 CRDT- 2016/01/01 06:00 PHST- 2015/07/18 00:00 [received] PHST- 2015/09/26 00:00 [revised] PHST- 2015/10/05 00:00 [accepted] PHST- 2016/01/01 06:00 [entrez] PHST- 2016/01/01 06:00 [pubmed] PHST- 2016/08/30 06:00 [medline] AID - S1465-3249(15)01079-8 [pii] AID - 10.1016/j.jcyt.2015.10.005 [doi] PST - ppublish SO - Cytotherapy. 2016 Jan;18(1):99-112. doi: 10.1016/j.jcyt.2015.10.005. PMID- 172137 OWN - NLM STAT- MEDLINE DCOM- 19760301 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 411 IP - 2 DP - 1975 Dec 5 TI - Ascorbate increases the synthesis of procollagen hydroxyproline by cultured fibroblasts from chick embryo tendons without activation of prolyl hydroxyla. PG - 202-15 AB - An improved procedure was developed to extract prolyl hydroxylase from tendon cells of chick embryos with detergent, and improved assays were developed for both the activity of the enzyme and the amount of enzyme protein. Freshly isolated tendon cells were found to contain approx. 100 mug of enzyme protein per 10(8) cells and 40-50% of the enzyme protein was active. When the cells were cultured, they were found to contain the same amount of enzyme protein but only 15-20% of the enzyme protein was active. Gel filtration of cell extracts indicated that the active form of prolyl hydroxylase in freshly isolated tendon cells and incultured tendon cells had the same apparent size and the same activity per mug of immunoreactive protein as enzyme which was shown to be a tetramer. The inactive form was found to have about the same apparent size as subunits of the enzyme. When freshly isolated cells were incubated for 2 h in the presence of 40 mug per ml of ascorbate, there was a slight increase in the rate of hydroxyproline synthesis. In cultured cells, ascorbate at a concentration of 40 mug per ml caused a 2-fold increase in the rate of hydroxyproline synthesis within 30 min. However, ascorbate did not icrease the activity of prolyl hydroxylase in extracts from either cell system. Therefore it appears that the influence of ascorbate on synthesis of procollagen hydroxyproline by the cells studied here must be ascribed to a cofactor effect on the hydroxylation reaction similar to that observed with purified enzyme, and it does not involve "activation" of inactive enzyme protein to active enzyme as has been observed in cultures of L-929 and 3T6 mouse fibroblasts. FAU - Kao, W W AU - Kao WW FAU - Berg, R A AU - Berg RA FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Detergents) RN - 0 (Protein Precursors) RN - 9007-34-5 (Collagen) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*biosynthesis MH - Detergents/pharmacology MH - Enzyme Activation/drug effects MH - Fibroblasts/drug effects/metabolism MH - Hydroxyproline/*biosynthesis MH - Kinetics MH - Procollagen-Proline Dioxygenase/*metabolism MH - Protein Precursors/*biosynthesis MH - Tendons/drug effects/*metabolism EDAT- 1975/12/05 00:00 MHDA- 1975/12/05 00:01 CRDT- 1975/12/05 00:00 PHST- 1975/12/05 00:00 [pubmed] PHST- 1975/12/05 00:01 [medline] PHST- 1975/12/05 00:00 [entrez] AID - 0304-4165(75)90300-1 [pii] AID - 10.1016/0304-4165(75)90300-1 [doi] PST - ppublish SO - Biochim Biophys Acta. 1975 Dec 5;411(2):202-15. doi: 10.1016/0304-4165(75)90300-1. PMID- 39467998 OWN - NLM STAT- MEDLINE DCOM- 20241029 LR - 20250923 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 28 IP - 20 DP - 2024 Oct TI - Enhancing osteogenic differentiation of diabetic tendon stem/progenitor cells through hyperoxia: Unveiling ROS/HIF-1α signalling axis. PG - e70127 LID - 10.1111/jcmm.70127 [doi] LID - e70127 AB - Diabetic calcific tendinopathy is the leading cause of chronic pain, mobility restriction, and tendon rupture in patients with diabetes. Tendon stem/progenitor cells (TSPCs) have been implicated in the development of diabetic calcified tendinopathy, but the molecular mechanisms remain unclear. This study found that diabetic tendons have a hyperoxic environment, characterized by increased oxygen delivery channels and carriers. In hyperoxic environment, TSPCs showed enhanced osteogenic differentiation and increased levels of reactive oxygen species (ROS). Additionally, hypoxia-inducible factor-1a (HIF-1a), a protein involved in regulating cellular responses to hyperoxia, was decreased in TSPCs by the ubiquitin-proteasome system. By intervening with antioxidant N-acetyl-L-cysteine (NAC) and overexpressing HIF-1a, we discovered that blocking the ROS/HIF-1a signalling axis significantly inhibited the osteogenic differentiation ability of TSPCs. Animal experiments further confirmed that hyperoxic environment could cause calcification in the Achilles tendon tissue of rats, while NAC intervention prevented calcification. These findings demonstrate that hyperoxia in diabetic tendons promotes osteogenic differentiation of TSPCs through the ROS/HIF-1a signalling axis. This study provides a new theoretical basis and research target for preventing and treating diabetic calcified tendinopathy. CI - © 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Zhang, Ming AU - Zhang M AUID- ORCID: 0000-0002-6032-7262 AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Dai, Guang-Chun AU - Dai GC AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Zhang, Yuan-Wei AU - Zhang YW AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Lu, Pan-Pan AU - Lu PP AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Wang, Hao AU - Wang H AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Li, Ying-Juan AU - Li YJ AD - Department of Geriatrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Rui, Yun-Feng AU - Rui YF AD - Department of Orthopedics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - School of Medicine, Southeast University, Nanjing, People's Republic of China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, Nanjing, China. AD - Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. LA - eng GR - BK20221462/Natural Science Foundation of Jiangsu Province/ GR - No.81871812/National Natural Science Foundation of China/ GR - YL20220525/Winfast Charity Foundation Project/ GR - CZXM-GSP-RC46/Research Personnel Cultivation Programme of Zhongda Hospital Southeast University/ PT - Journal Article PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Reactive Oxygen Species) RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - *Osteogenesis MH - Animals MH - *Hypoxia-Inducible Factor 1, alpha Subunit/metabolism/genetics MH - *Reactive Oxygen Species/metabolism MH - *Stem Cells/metabolism/cytology MH - *Signal Transduction MH - *Cell Differentiation MH - Rats MH - *Tendons/metabolism/pathology MH - Male MH - *Diabetes Mellitus, Experimental/metabolism/pathology MH - Rats, Sprague-Dawley MH - Hyperoxia/metabolism MH - Acetylcysteine/pharmacology PMC - PMC11518821 OTO - NOTNLM OT - Hyperoxia OT - N‐acetyl‐L‐cysteine OT - diabetic calcified tendinopathy OT - osteogenic differentiation OT - reactive oxygen species OT - tendon stem/progenitor cells COIS- The authors declare no conflict of interest. This article has already been uploaded to a preprint. (https://www.researchsquare.com/article/rs‐3417115/v1). EDAT- 2024/10/29 06:23 MHDA- 2024/10/29 06:24 PMCR- 2024/10/28 CRDT- 2024/10/29 00:28 PHST- 2024/08/10 00:00 [revised] PHST- 2023/12/08 00:00 [received] PHST- 2024/09/20 00:00 [accepted] PHST- 2024/10/29 06:24 [medline] PHST- 2024/10/29 06:23 [pubmed] PHST- 2024/10/29 00:28 [entrez] PHST- 2024/10/28 00:00 [pmc-release] AID - JCMM70127 [pii] AID - 10.1111/jcmm.70127 [doi] PST - ppublish SO - J Cell Mol Med. 2024 Oct;28(20):e70127. doi: 10.1111/jcmm.70127. PMID- 1660217 OWN - NLM STAT- MEDLINE DCOM- 19920106 LR - 20180504 IS - 0002-9165 (Print) IS - 0002-9165 (Linking) VI - 54 IP - 6 Suppl DP - 1991 Dec TI - Ascorbate stabilizes the differentiated state and reduces the ability of Rous sarcoma virus to replicate and to uniformly transform cell cultures. PG - 1247S-1251S LID - 10.1093/ajcn/54.6.1247s [doi] AB - In primary avian tendon cells, Rous sarcoma virus can coexist or completely take over the cell. Infection, at high multiplicity or under conditions that promote high virus production (no ascorbate and high serum concentrations), results in almost complete oncogenic transformation of the culture. This is indicated in part by a radical change in morphology, growth at high cell density, and a dramatic drop in the production of procollagen from approximately 50% to approximately 3% of total protein synthesis. In contrast, infection at low multiplicity, infection with a replication defective virus, or the presence of ascorbate restrict the ability of the virus to transform the culture. Thus, there appears to be a balance between the normal and transformed states of the cell that can be shifted depending on the cellular environment and the level of infection. Ascorbate stabilizes the normal state by reducing virus production and promoting the synthesis of differentiated proteins. FAU - Schwarz, R I AU - Schwarz RI AD - Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, University of California, Berkeley 94720. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Am J Clin Nutr JT - The American journal of clinical nutrition JID - 0376027 RN - 0 (Culture Media) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Avian Sarcoma Viruses/*drug effects/physiology MH - Blood MH - Cell Differentiation/drug effects MH - Cell Transformation, Neoplastic/drug effects MH - Cells, Cultured MH - Culture Media MH - Sarcoma, Avian/pathology MH - Tendons/embryology/pathology MH - Virus Replication/*drug effects EDAT- 1991/12/01 00:00 MHDA- 1991/12/01 00:01 CRDT- 1991/12/01 00:00 PHST- 1991/12/01 00:00 [pubmed] PHST- 1991/12/01 00:01 [medline] PHST- 1991/12/01 00:00 [entrez] AID - 10.1093/ajcn/54.6.1247s [doi] PST - ppublish SO - Am J Clin Nutr. 1991 Dec;54(6 Suppl):1247S-1251S. doi: 10.1093/ajcn/54.6.1247s. PMID- 20135741 OWN - NLM STAT- MEDLINE DCOM- 20100504 LR - 20131121 IS - 1793-6535 (Electronic) IS - 0218-8104 (Linking) VI - 14 IP - 2-3 DP - 2009 TI - An uncommon cause for a common complaint. PG - 131-4 AB - Infective tenosynovitis is an uncommon cause of a common condition namely carpal tunnel syndrome. Following an extensive review of the literature, we report what we understand to be the first published case of Mycobacterium kansasii (M. kansasii) causing tenosynovitis of flexor tendons resulting in carpal tunnel syndrome in Australia. Our case highlights the need for a high level of suspension, histology and appropriate culture with specific microbiological tests for atypical mycobacteria where tenosynovitis is present at carpal tunnel surgery, even in patients who do not appear to have risk factors. FAU - Rust, P A AU - Rust PA AD - Victorian Hand Surgery Associates, St. Vincent's Hospital, Fitzroy, Australia. philipparust@hotmail.com FAU - Bennett, T AU - Bennett T LA - eng PT - Case Reports PT - Journal Article PL - Singapore TA - Hand Surg JT - Hand surgery : an international journal devoted to hand and upper limb surgery and related research : journal of the Asia-Pacific Federation of Societies for Surgery of the Hand JID - 9602613 RN - 0 (Anti-Bacterial Agents) RN - 0 (DNA, Bacterial) RN - 8G167061QZ (Ethambutol) RN - H1250JIK0A (Clarithromycin) RN - VJT6J7R4TR (Rifampin) SB - IM MH - Anti-Bacterial Agents/therapeutic use MH - Carpal Tunnel Syndrome/*etiology MH - Clarithromycin/therapeutic use MH - DNA, Bacterial/genetics MH - Ethambutol/therapeutic use MH - Humans MH - Male MH - Middle Aged MH - Mycobacterium Infections, Nontuberculous/complications/*diagnosis/drug therapy MH - Mycobacterium kansasii/genetics/*isolation & purification MH - Occupational Exposure MH - Rifampin/therapeutic use MH - Rivers/microbiology MH - Tenosynovitis/complications/*microbiology EDAT- 2010/02/06 06:00 MHDA- 2010/05/05 06:00 CRDT- 2010/02/06 06:00 PHST- 2008/08/21 00:00 [received] PHST- 2009/08/10 00:00 [revised] PHST- 2009/10/19 00:00 [accepted] PHST- 2010/02/06 06:00 [entrez] PHST- 2010/02/06 06:00 [pubmed] PHST- 2010/05/05 06:00 [medline] AID - S0218810409004360 [pii] AID - 10.1142/S0218810409004360 [doi] PST - ppublish SO - Hand Surg. 2009;14(2-3):131-4. doi: 10.1142/S0218810409004360. PMID- 936909 OWN - NLM STAT- MEDLINE DCOM- 19760901 LR - 20151119 IS - 0354-950X (Print) IS - 0354-950X (Linking) VI - 23 IP - 1 Suppl DP - 1976 TI - [Treatment of open war injuries of the limbs in Ethiopia during the 3-year period with regard to 2 cases where a big part of the ulnar bone was missing]. PG - 255-60 AB - I. When a patient with open compound fracture arrives at the hospital he should be given 1500 u TAT, 25000 u Serum Antigangrenosum, one million Penicillin and one gram of Streptomycin, provided that these were not given before. II. Immediate operation of the cases with injury of less than six-eight hours duration is a must here. But still it must not be forgotten that those with shoc need to be left aside for primary treatment of the shoc before they are due for operation. Debridement of the wound should be done perfectly before starting to indulage one self with the operation. Any operation of this kind is not complete if the torn or nut nerves and tendons are primarily sutured after refreshing their ends. If necessary, plastic of the skin should be accomplished at the same time. III. We must be very considerate in dealing with bones. Bones that look dirty should be cleaned by spoon curretage rather than resecting them and facing shortage in bone. Shertage of small length of bone, can be substituted by bone grafting with either method of sliding or transplanting from one bone to another. IV. Up to the time that infection can be controlled, the primary sutture should be postponed and the only cautious debridement must be done. V. Post operative antibiotic treatment should extend from seven to ten days. FAU - Milosevic, V AU - Milosevic V LA - srp PT - Case Reports PT - English Abstract PT - Journal Article TT - Naĉin zbrinjavanja ratnih otvorenih povreda ekstremiteta u Etiopiji za period od tri godine sa osvrtom na dva sluĉaja gde je nedostajao veliki dio kosti ulne. PL - Serbia TA - Acta Chir Iugosl JT - Acta chirurgica Iugoslavica JID - 0372631 RN - 0 (Penicillins) RN - Y45QSO73OB (Streptomycin) SB - IM MH - Bacterial Infections/prevention & control MH - Ethiopia MH - Fractures, Bone/*surgery MH - Fractures, Open/*surgery MH - Humans MH - Methods MH - *Military Medicine MH - Penicillins/therapeutic use MH - Streptomycin/therapeutic use MH - Ulna Fractures/*surgery MH - Warfare EDAT- 1976/01/01 00:00 MHDA- 1976/01/01 00:01 CRDT- 1976/01/01 00:00 PHST- 1976/01/01 00:00 [pubmed] PHST- 1976/01/01 00:01 [medline] PHST- 1976/01/01 00:00 [entrez] PST - ppublish SO - Acta Chir Iugosl. 1976;23(1 Suppl):255-60. PMID- 26809496 OWN - NLM STAT- MEDLINE DCOM- 20170803 LR - 20250529 IS - 1758-535X (Electronic) IS - 1079-5006 (Print) IS - 1079-5006 (Linking) VI - 71 IP - 7 DP - 2016 Jul TI - Rapamycin Attenuates Age-associated Changes in Tibialis Anterior Tendon Viscoelastic Properties. PG - 858-65 LID - 10.1093/gerona/glv307 [doi] AB - Rapamycin extends mouse life span, but the extent to which rapamycin prevents aging-associated changes in specific tissues remains unclear. Stiffness increases and collagen turnover decreases in mouse tendon with aging; thus, our aim was to determine the effect of long-term rapamycin treatment on the mechanical and structural properties of tendons from old mice. Tendons were harvested from female UM-HET3 mice maintained on a standard chow diet for 4 (adult) or 22 (old) months or fed chow containing polymer-encapsulated rapamycin (eRAPA) from 9 to 22 months of age (old RAPA). Stiffness was twofold higher for tendons of old compared with adult mice, but in old RAPA mice, tendon stiffness was maintained at a value not different from that of adults. Additionally, expression of collagen decreased, expression of matrix metalloproteinase-8 increased, and total hydroxyproline content trended toward decreased levels in tendons of old eRAPA-fed mice compared with controls. Finally, age-associated calcification of Achilles tendons and accompanying elevations in expression of chondrocyte and osteoblast markers were all lower in old eRAPA-fed mice. These results suggest that long-term administration of rapamycin alters the molecular pathways responsible for aging of tendon extracellular matrix, resulting in tissue that is structurally and mechanically similar to tendons in adult mice. CI - © The Author 2016. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Zaseck, Lauren Wood AU - Zaseck LW AD - Department of Biomedical Engineering. FAU - Miller, Richard A AU - Miller RA AD - Department of Pathology, and. FAU - Brooks, Susan V AU - Brooks SV AD - Department of Biomedical Engineering, Department of Molecular and Integrative Physiology, The University of Michigan, Ann Arbor. svbrooks@umich.edu. LA - eng GR - P30 AG024824/AG/NIA NIH HHS/United States GR - T32 AG000114/AG/NIA NIH HHS/United States GR - U01 AG022303/AG/NIA NIH HHS/United States GR - Z01 AG000114/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20160124 PL - United States TA - J Gerontol A Biol Sci Med Sci JT - The journals of gerontology. Series A, Biological sciences and medical sciences JID - 9502837 RN - 0 (Immunosuppressive Agents) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.34 (Matrix Metalloproteinase 8) RN - RMB44WO89X (Hydroxyproline) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - *Aging/drug effects/pathology/physiology MH - Animals MH - *Biomechanical Phenomena/drug effects/physiology MH - Collagen/*metabolism MH - *Elasticity/drug effects/physiology MH - Extracellular Matrix/drug effects/metabolism/physiology MH - Female MH - Hydroxyproline/metabolism MH - Immunosuppressive Agents/metabolism/pharmacology MH - *Long Term Adverse Effects/etiology/pathology/physiopathology MH - Matrix Metalloproteinase 8/metabolism MH - Mice MH - Muscle, Skeletal/physiopathology MH - *Sirolimus/metabolism/pharmacology MH - *Tendons/metabolism/pathology/physiopathology PMC - PMC4906327 OTO - NOTNLM OT - Biology of aging OT - Mice OT - mTOR EDAT- 2016/01/27 06:00 MHDA- 2017/08/05 06:00 PMCR- 2017/07/01 CRDT- 2016/01/27 06:00 PHST- 2015/11/05 00:00 [received] PHST- 2015/12/13 00:00 [accepted] PHST- 2016/01/27 06:00 [entrez] PHST- 2016/01/27 06:00 [pubmed] PHST- 2017/08/05 06:00 [medline] PHST- 2017/07/01 00:00 [pmc-release] AID - glv307 [pii] AID - 10.1093/gerona/glv307 [doi] PST - ppublish SO - J Gerontol A Biol Sci Med Sci. 2016 Jul;71(7):858-65. doi: 10.1093/gerona/glv307. Epub 2016 Jan 24. PMID- 29702719 OWN - NLM STAT- MEDLINE DCOM- 20190723 LR - 20191210 IS - 1938-2480 (Electronic) IS - 1538-8506 (Linking) VI - 32 IP - 5 DP - 2019 May TI - Evaluation of a Novel Degradable Synthetic Biomaterial Patch for Augmentation of Tendon Healing in a Large Animal Model. PG - 434-440 LID - 10.1055/s-0038-1646930 [doi] AB - Tendon injury is common in sports. The standard of care (SOC) for tendon repair is surgical treatment. However, restored tendons often lack complete strength and functionality, and surgical repair is often unsuccessful. This controlled laboratory study investigates the healing of an Artelon patch (AP)-augmented tendon versus tendon repair alone in a preclinical canine patellar tendon defect model. Full-thickness proximal and distal flap defects were created in the patella tendons of eight purpose-bred research mongrel dogs. Dogs were randomly allocated into either the AP-augmented repair group or the SOC group (N = 8; four knees per group). Outcomes measures included limb function and pain; range of motion (ROM) and ultrasound assessment at 2, 4, and 8 weeks; and measurements of elongation, biomechanical testing, and histology at 8 weeks. Data were compared for statistically significant differences to preoperative measures and between groups (p < 0.05). The AP group had higher limb function scores compared with the SOC group at 2, 4, and 8 weeks, with statistically significant differences observed at 2 weeks (AP: 7.1 ± 1.4, SOC: 5.5 ± 0.4, p < 0.05) and 8 weeks (AP: 9.5 ± 0.7, SOC: 7.0 ± 0.9, p < 0.05). The ROM was significantly higher for the AP group at 4 weeks (AP: 105 degrees ± 4, SOC: 89 degrees ± 5, p < 0.05). Pain scores were statistically significantly lower in the AP group at 4 (AP: 0.6 ± 0.5, SOC: 2.2 ± 0.5) and 8 weeks (p < 0.05 for both comparisons). All animals in the AP group displayed full bridging tissue at week 4, while most animals of the SOC group displayed full bridging by week 8. Minimal tendon elongation was observed in both groups. Significantly more force was required to elongate tendons in the AP group compared with the SOC group (p < 0.05). Animals with AP-augmented tendon repair show an earlier regain of function, earlier regain of range of movement, less postoperative pain, and improved tendon strength when compared with animals treated with tendon repair alone. CI - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA. FAU - Gersoff, Wayne K AU - Gersoff WK AD - Advanced Orthopedic and Sports Medicine Specialists, Denver, Colorado. FAU - Bozynski, Chantelle C AU - Bozynski CC AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri. AD - Department of Orthopaedic Surgery, University of Missouri, Columbia, Missouri. FAU - Cook, Cristi R AU - Cook CR AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri. AD - Department of Orthopaedic Surgery, University of Missouri, Columbia, Missouri. FAU - Pfeiffer, Ferris M AU - Pfeiffer FM AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri. FAU - Kuroki, Keiichi AU - Kuroki K AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri. FAU - Cook, James L AU - Cook JL AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, Missouri. AD - Department of Orthopaedic Surgery, University of Missouri, Columbia, Missouri. LA - eng PT - Evaluation Study PT - Journal Article DEP - 20180427 PL - Germany TA - J Knee Surg JT - The journal of knee surgery JID - 101137599 RN - 0 (Biocompatible Materials) RN - 0 (Polyurethanes) RN - 97343-15-2 (polyetherurethane urea) MH - Animals MH - Biocompatible Materials MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Dogs MH - Male MH - Patellar Ligament/diagnostic imaging/*surgery MH - Polyurethanes/*therapeutic use MH - Range of Motion, Articular MH - Tendon Injuries/*surgery MH - Tendons/surgery MH - *Wound Healing COIS- None declared. EDAT- 2018/04/28 06:00 MHDA- 2019/07/25 06:00 CRDT- 2018/04/28 06:00 PHST- 2018/04/28 06:00 [pubmed] PHST- 2019/07/25 06:00 [medline] PHST- 2018/04/28 06:00 [entrez] AID - 10.1055/s-0038-1646930 [doi] PST - ppublish SO - J Knee Surg. 2019 May;32(5):434-440. doi: 10.1055/s-0038-1646930. Epub 2018 Apr 27. PMID- 16960741 OWN - NLM STAT- MEDLINE DCOM- 20070227 LR - 20220318 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 14 IP - 11 DP - 2006 Nov TI - Sclerosing polidocanol injections in chronic painful tennis elbow-promising results in a pilot study. PG - 1218-24 AB - Sclerosing polidocanol injections targeting the area with neovessels (vascularity) have been demonstrated to give promising clinical results in patients with chronic painful Achilles and patellar tendinosis. Recently, we demonstrated vascularity in the extensor origin in patients with chronic painful tennis elbow, but not in controls with pain-free elbows. In this pilot study, 11 patients (four men and seven women, mean age 46 years) with the diagnosis of tennis elbow in altogether 13 elbows, were included. All patients had a long duration of pain symptoms (mean 23 months), and ultrasonography (US) + colour Doppler (CD) examination showed structural tendon changes with hypo-echoic areas, and a vascularity, corresponding to the painful area in the extensor origin. All patients were treated with US- and CD-guided injections of the sclerosing substance polidocanol, targeting the area with vascularity. At 8-month follow-up after treatment, there was a good clinical result in 11/13 elbows. Extensor origin pain during wrist loading activities (recorded on a VAS-scale) was significantly reduced (mean VAS from 75 to 34; P < 0.003), and maximal grip strength was significantly increased (from 29 to 40 kg; P < 0.025). Our findings indicate that one treatment with sclerosing polidocanol injections, targeting the area with vascularity in the extensor origin, has a potential to reduce the tendon pain and increase grip strength, in patients with chronic painful tennis elbow. FAU - Zeisig, Eva AU - Zeisig E AD - Sports Medicine Unit, Department of Surgical and Perioperative Science, Umeå University, 901 87 Umeå, Sweden. eva.zeisig@vll.se FAU - Ohberg, Lars AU - Ohberg L FAU - Alfredson, Håkan AU - Alfredson H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060908 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CIN - Knee Surg Sports Traumatol Arthrosc. 2006 Nov;14(11):1037. doi: 10.1007/s00167-006-0217-4. PMID: 17006661 MH - Adult MH - Arthralgia/diagnostic imaging/*therapy MH - Chronic Disease MH - Female MH - Follow-Up Studies MH - Humans MH - Injections, Intra-Articular MH - Male MH - Middle Aged MH - Patient Satisfaction MH - Pilot Projects MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Tendons/blood supply/innervation MH - Tennis Elbow/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography, Doppler, Color MH - Ultrasonography, Interventional EDAT- 2006/09/09 09:00 MHDA- 2007/02/28 09:00 CRDT- 2006/09/09 09:00 PHST- 2005/12/23 00:00 [received] PHST- 2006/04/10 00:00 [accepted] PHST- 2006/09/09 09:00 [pubmed] PHST- 2007/02/28 09:00 [medline] PHST- 2006/09/09 09:00 [entrez] AID - 10.1007/s00167-006-0156-0 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2006 Nov;14(11):1218-24. doi: 10.1007/s00167-006-0156-0. Epub 2006 Sep 8. PMID- 3176615 OWN - NLM STAT- MEDLINE DCOM- 19881122 LR - 20061115 IS - 0044-3220 (Print) IS - 0044-3220 (Linking) VI - 126 IP - 4 DP - 1988 Jul-Aug TI - [Lateral ligament replacement of the ankle joint--cialit graft or tendon graft? A comparative clinical study from the Balgrist Orthopedic University Hospital, Zürich]. PG - 416-9 AB - Of a total of 268 patients who were operated because of ankle instability, 125 who were treated with cialit skin graft and 101 who received a peroneal tendon graft were interrogated. 36 were clinically and radiologically examined. Apart from some very minor disturbances, neither during the period immediately after surgery nor later, were the subjective or objective results significantly different. This observation demands that no surgical technique should be employed that could interfere with the function of proprioceptive or constraining structures. FAU - Waldis, M F AU - Waldis MF AD - Orthopädische Universitätsklinik Balgrist, Zürich. FAU - Zollinger, H AU - Zollinger H LA - ger PT - Comparative Study PT - English Abstract PT - Journal Article TT - Lateraler Bandersatz am Sprunggelenk--Cialithautplastik oder Sehnenplastik? Eine vergleichende klinische Studie aus der Orthopädischen Universitätsklinik Balgrist, Zürich. PL - Germany TA - Z Orthop Ihre Grenzgeb JT - Zeitschrift fur Orthopadie und ihre Grenzgebiete JID - 1256465 RN - 0 (Ethylmercury Compounds) RN - 16509-11-8 (Cialit) SB - IM MH - Adolescent MH - Adult MH - Ankle Joint/*surgery MH - Cialit/*therapeutic use MH - Ethylmercury Compounds/*therapeutic use MH - Female MH - Humans MH - Joint Instability/*surgery MH - Ligaments, Articular/*surgery MH - Male MH - Middle Aged MH - Tendons/*transplantation EDAT- 1988/07/01 00:00 MHDA- 1988/07/01 00:01 CRDT- 1988/07/01 00:00 PHST- 1988/07/01 00:00 [pubmed] PHST- 1988/07/01 00:01 [medline] PHST- 1988/07/01 00:00 [entrez] AID - 10.1055/s-2008-1044461 [doi] PST - ppublish SO - Z Orthop Ihre Grenzgeb. 1988 Jul-Aug;126(4):416-9. doi: 10.1055/s-2008-1044461. PMID- 17211211 OWN - NLM STAT- MEDLINE DCOM- 20070320 LR - 20221207 IS - 1559-047X (Print) IS - 1559-047X (Linking) VI - 28 IP - 1 DP - 2007 Jan-Feb TI - Seven years' experience with Integra as a reconstructive tool. PG - 120-6 AB - The bilayered dermal substitute Integra (Integra Life Sciences Corp., Plainsboro, NJ) was developed and has been widely used as primary coverage for excised acute burns. Our take has been slightly different, finding it most useful in the management of complex soft-tissue loss and threatened extremities as the result of tendon, joint, or bone exposure. Often tasked to fill significant volume loss, we have become adept at stacked multiple-layer applications. Creative use of this material has resulted in unexpected successes with distal limb salvage; the technique takes its place beside adjacent tissue transfer, composite flaps, and vascular pedicle flaps in our burn reconstructive practice. A prospective registry (44 patients) has been kept during the past 7 years that catalogs wounds with complex soft-tissue loss treated with Integra grafts. Many of these patients were at risk of extremity loss because of exposed tendons, joints, or bone. Integra was applied after 1:1 meshing. With profound soft-tissue defects, multiple layers of Integra were serially applied 1 to 2 weeks apart for reconstitution of soft-tissue contours. Local Integra graft infections were managed by silicone unroofing followed by topical sulfamylon liquid dressings. Wounds addressed included fourth-degree burns, necrotizing fasciitis, pit-viper envenomations, and total abdominal wall avulsion in one patient after being run over by a bus. Patients generally were free of pain from their wounds during the maturation phase of the Integra neodermis. Restoration of tissue contour was significantly better when using multiple layers for deep defects. Second and third layers of Integra were successfully applied after an abbreviated first graft maturation period of 7 days. Epithelial autografts on multilayer Integra applications frequently "ghosted"; they would auto-digest to dispersed cells followed subsequently by the reappearance of a confluent epithelial layer. Final grafted skin morphology over palmar and plantar surfaces assumed the type and fingerprint pattern of the original tissues. Infections were readily visible. Early recognition kept them to easily treated circumscribed areas, which did not jeopardize the entire wound. Lengths of stay were long (range, 2-246 days) but not significantly greater than with traditional techniques. The specific reconstructive use of Integra permitted unexpected salvage of several threatened extremities by protecting exposed tendons, bones and joints. Long-term histologic examination revealed unexpected persistence of Integra collagen. Large volume loss wounds benefited from the ability to fill voids with multilayered applications. FAU - Jeng, James C AU - Jeng JC AD - The Burn Center at Washington Hospital Center, Washington, DC 20010, USA. FAU - Fidler, Philip E AU - Fidler PE FAU - Sokolich, Julio C AU - Sokolich JC FAU - Jaskille, Amin D AU - Jaskille AD FAU - Khan, Shaher AU - Khan S FAU - White, Patricia M AU - White PM FAU - Street, James H 3rd AU - Street JH 3rd FAU - Light, Timothy D AU - Light TD FAU - Jordan, Marion H AU - Jordan MH LA - eng PT - Journal Article PL - England TA - J Burn Care Res JT - Journal of burn care & research : official publication of the American Burn Association JID - 101262774 RN - 0 (Acticoat) RN - 0 (Anti-Infective Agents, Local) RN - 0 (Polyesters) RN - 0 (Polyethylenes) RN - 0 (integra artificial skin) RN - 58447S8P4L (Mafenide) RN - 9007-28-7 (Chondroitin Sulfates) RN - 9007-34-5 (Collagen) SB - IM MH - Abdominal Injuries/surgery MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Amputation, Surgical/statistics & numerical data MH - Anti-Infective Agents, Local/therapeutic use MH - Bandages MH - Burns/*surgery MH - Case-Control Studies MH - Chondroitin Sulfates/*therapeutic use MH - Collagen/*therapeutic use MH - Fasciitis, Necrotizing/surgery MH - Humans MH - Length of Stay/statistics & numerical data MH - Mafenide/therapeutic use MH - Middle Aged MH - Polyesters/therapeutic use MH - Polyethylenes/therapeutic use MH - Prospective Studies MH - Registries MH - Skin Transplantation MH - *Skin, Artificial MH - Snake Bites/surgery MH - Surgical Wound Infection/therapy MH - Transplantation, Autologous MH - Treatment Outcome EDAT- 2007/01/11 09:00 MHDA- 2007/03/21 09:00 CRDT- 2007/01/11 09:00 PHST- 2007/01/11 09:00 [pubmed] PHST- 2007/03/21 09:00 [medline] PHST- 2007/01/11 09:00 [entrez] AID - 01253092-200701000-00019 [pii] AID - 10.1097/BCR.0b013E31802CB83F [doi] PST - ppublish SO - J Burn Care Res. 2007 Jan-Feb;28(1):120-6. doi: 10.1097/BCR.0b013E31802CB83F. PMID- 10622494 OWN - NLM STAT- MEDLINE DCOM- 20000113 LR - 20190822 IS - 0001-6470 (Print) IS - 0001-6470 (Linking) VI - 70 IP - 5 DP - 1999 Oct TI - Insertion of the patella tendon after prosthetic replacement of the proximal tibia. PG - 527-9 AB - We describe the technique and the results of a method to reconstruct the patellar tendon insertion to a tumor prosthesis by wrapping an artificial mesh around the prosthesis, followed by suturing the patellar tendon and a gastrocnemius flap to the mesh. FAU - Ozaki, T AU - Ozaki T AD - Department of Orthopaedic Surgery, Okayama University Medical School, Japan. tozaki@med.okayama-u.ac.jp FAU - Kunisada, T AU - Kunisada T FAU - Kawai, A AU - Kawai A FAU - Takahara, Y AU - Takahara Y FAU - Inoue, H AU - Inoue H LA - eng PT - Journal Article PL - England TA - Acta Orthop Scand JT - Acta orthopaedica Scandinavica JID - 0370352 RN - 0 (Bone Substitutes) RN - 0 (Polypropylenes) SB - IM MH - Activities of Daily Living MH - Adult MH - Ameloblastoma/diagnostic imaging/physiopathology/*surgery MH - Bone Neoplasms/diagnostic imaging/physiopathology/*surgery MH - Bone Substitutes/*therapeutic use MH - Child MH - Follow-Up Studies MH - Humans MH - Middle Aged MH - Osteosarcoma/diagnostic imaging/physiopathology/*surgery MH - *Patella MH - Polypropylenes/*therapeutic use MH - Radiography MH - Range of Motion, Articular MH - Replantation/*methods MH - *Surgical Mesh MH - Tendons/*surgery MH - *Tibia MH - Treatment Outcome EDAT- 2000/01/06 00:00 MHDA- 2000/01/06 00:01 CRDT- 2000/01/06 00:00 PHST- 2000/01/06 00:00 [pubmed] PHST- 2000/01/06 00:01 [medline] PHST- 2000/01/06 00:00 [entrez] AID - 10.3109/17453679909000997 [doi] PST - ppublish SO - Acta Orthop Scand. 1999 Oct;70(5):527-9. doi: 10.3109/17453679909000997. PMID- 6502863 OWN - NLM STAT- MEDLINE DCOM- 19850109 LR - 20190630 IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 252 IP - 21 DP - 1984 Dec 7 TI - Suppurative flexor tenosynovitis after accidental self-inoculation with Streptococcus pneumoniae type I. PG - 3003-4 FAU - Little, J S AU - Little JS FAU - O'Reilly, M J AU - O'Reilly MJ FAU - Higbee, J W AU - Higbee JW FAU - Camp, R A AU - Camp RA LA - eng PT - Case Reports PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - JAMA JT - JAMA JID - 7501160 RN - 0 (Penicillins) SB - IM MH - Adult MH - Arthritis, Infectious/etiology MH - Combined Modality Therapy MH - Humans MH - Injections MH - Laboratory Infection/*etiology MH - Male MH - Metacarpophalangeal Joint/microbiology MH - Penicillins/therapeutic use MH - Pneumococcal Infections/drug therapy/*etiology MH - Suppuration MH - Tendons/microbiology MH - Tenosynovitis/drug therapy/*etiology/surgery EDAT- 1984/12/07 00:00 MHDA- 1984/12/07 00:01 CRDT- 1984/12/07 00:00 PHST- 1984/12/07 00:00 [pubmed] PHST- 1984/12/07 00:01 [medline] PHST- 1984/12/07 00:00 [entrez] AID - 10.1001/jama.252.21.3003 [doi] PST - ppublish SO - JAMA. 1984 Dec 7;252(21):3003-4. doi: 10.1001/jama.252.21.3003. PMID- 7308913 OWN - NLM STAT- MEDLINE DCOM- 19820225 LR - 20191031 IS - 0198-0211 (Print) IS - 0198-0211 (Linking) VI - 2 IP - 1 DP - 1981 Jul TI - Stenosing tenosynovitis of the flexor hallucis longus tendon at the great toe. PG - 46-8 AB - The purpose of this paper is to call attention to the previously overlooked entity, stenosing tenosynovitis of the flexor hallucis longus tendon in the sesamoid area of the great toe. Nine patients have been tabulated and successfully treated during the past 4 years, with an average 2 1/2-year follow-up. Trauma seems to be the causative factor. Five cases had accompanying pathology. Three cases responded to inflation of the tendon sheath with 1% lidocaine anesthesia, but the remainder required tenolysis of the sheath plus surgery to the accompanying pathology for relief. Early recognition of this problem and prompt inflation with lidocaine may be the only required treatment if this is the only entity. Chronic cases will respond to tenolysis. A plantar full visualization surgical approach is recommended. FAU - Gould, N AU - Gould N LA - eng PT - Journal Article PL - United States TA - Foot Ankle JT - Foot & ankle JID - 8010104 RN - 98PI200987 (Lidocaine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Constriction, Pathologic MH - Female MH - *Hallux MH - Humans MH - Lidocaine/therapeutic use MH - Male MH - Middle Aged MH - Tendons/surgery MH - Tenosynovitis/diagnosis/*therapy EDAT- 1981/07/01 00:00 MHDA- 1981/07/01 00:01 CRDT- 1981/07/01 00:00 PHST- 1981/07/01 00:00 [pubmed] PHST- 1981/07/01 00:01 [medline] PHST- 1981/07/01 00:00 [entrez] AID - 10.1177/107110078100200108 [doi] PST - ppublish SO - Foot Ankle. 1981 Jul;2(1):46-8. doi: 10.1177/107110078100200108. PMID- 759441 OWN - NLM STAT- MEDLINE DCOM- 19790329 LR - 20161123 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 61 IP - 1 DP - 1979 Jan TI - Replacement of the trapezium for arthritis of the basal articulations: a new technique with stabilization by tenodesis. PG - 76-82 AB - Forty-six patients (fifty hands) had replacement of the trapezium by a silicone implant that incorporated a local tendon strip to stabilize the device. The patients had intractable pain due to degenerative changes of multiple facets of the trapezium. The over-all rate of subluxation and dislocation was 10 per cent. In all hands, pain-free improved movement resulted. The pinch strength approximated the normal, averaging six kilograms for women and eight kilograms for men. FAU - Eaton, R G AU - Eaton RG LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Silicones) SB - IM MH - Adult MH - Aged MH - Arthritis, Rheumatoid/*surgery MH - Arthrodesis/methods MH - Arthroplasty/*methods MH - Carpal Bones/*surgery MH - Female MH - Finger Joint/*surgery MH - Follow-Up Studies MH - Humans MH - Male MH - Metacarpophalangeal Joint/diagnostic imaging/*surgery MH - Middle Aged MH - Osteoarthritis/*surgery MH - Prostheses and Implants/*methods MH - Radiography MH - Silicones/therapeutic use MH - Tendon Transfer/methods MH - Tendons/surgery MH - Thumb/diagnostic imaging/*surgery EDAT- 1979/01/01 00:00 MHDA- 1979/01/01 00:01 CRDT- 1979/01/01 00:00 PHST- 1979/01/01 00:00 [pubmed] PHST- 1979/01/01 00:01 [medline] PHST- 1979/01/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Am. 1979 Jan;61(1):76-82. PMID- 3960762 OWN - NLM STAT- MEDLINE DCOM- 19860425 LR - 20220210 IS - 0147-7447 (Print) IS - 0147-7447 (Linking) VI - 9 IP - 2 DP - 1986 Feb TI - Stalked patellar tendon graft in reconstruction of the anterior cruciate ligament. PG - 205-11 AB - A careful description of the surgical technique in reconstruction of the anterior cruciate using the medial third of the patellar tendon is given. It is pointed out that it is a technical advantage if the drill hole for the patellar tendon enters the knee joint into or just behind the remnants of the normal anterior cruciate ligament. It is also emphasized how important it is that the ligament is anchored to its normal anatomic insertion far back posterolaterally. With the technique suggested about 90% stable knees can be expected at an early follow up. The most common complication was an extension lag and recommendations for how this should be treated are given. FAU - Eriksson, E AU - Eriksson E LA - eng PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - COF19H7WBK (Dicloxacillin) SB - IM MH - Bacterial Infections/prevention & control MH - Dicloxacillin/therapeutic use MH - Follow-Up Studies MH - Humans MH - Knee Joint MH - Ligaments, Articular/injuries/*surgery MH - Movement MH - Patella MH - Physical Therapy Modalities/instrumentation MH - Postoperative Period MH - Surgery, Plastic/*methods MH - Tendons/*transplantation EDAT- 1986/02/01 00:00 MHDA- 1986/02/01 00:01 CRDT- 1986/02/01 00:00 PHST- 1986/02/01 00:00 [pubmed] PHST- 1986/02/01 00:01 [medline] PHST- 1986/02/01 00:00 [entrez] AID - 10.3928/0147-7447-19860201-12 [doi] PST - ppublish SO - Orthopedics. 1986 Feb;9(2):205-11. doi: 10.3928/0147-7447-19860201-12. PMID- 270689 OWN - NLM STAT- MEDLINE DCOM- 19780127 LR - 20220316 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 74 IP - 10 DP - 1977 Oct TI - Dependence of the differentiated state on the cellular environment: modulation of collagen synthesis in tendon cells. PG - 4453-7 AB - In an adequate environment, primary avian tendon cells are capable of retaining both the full expression of differentiated function and a correct morphological orientation for 1 week in culture. At high density and in the presence of ascorbate, they are fully stabilized in that they devote 25-30% of their total protein synthesis to collagen, a level comparable to that in tendon cells in ovo. However, either at low density or in medium without ascorbate, they synthesize collagen at only a third of this level. If plated on a collagen matrix, these cells will orient themselves in a manner similar to that of tendon cells in vivo. Furthermore, they are capable of fully modulating the percentage of collagen synthesis upon addition or removal of ascorbate and serum. The variation in the percentage of collagen produced is a result of alterations in collagen synthesis rather than of changes in total protein synthesis or hydroxylation of proline in collagen. Primary avian tendon cells, therefore, provide a suitable model for understanding the stability of the differentiated state, the mechanism of action of ascorbate, and the regulation of collagen biosynthesis. FAU - Schwarz, R I AU - Schwarz RI FAU - Bissell, M J AU - Bissell MJ LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/pharmacology MH - Cell Differentiation/drug effects MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*biosynthesis MH - Protein Biosynthesis MH - Tendons/cytology/*metabolism MH - Time Factors PMC - PMC431961 EDAT- 1977/10/01 00:00 MHDA- 1977/10/01 00:01 PMCR- 1978/04/01 CRDT- 1977/10/01 00:00 PHST- 1977/10/01 00:00 [pubmed] PHST- 1977/10/01 00:01 [medline] PHST- 1977/10/01 00:00 [entrez] PHST- 1978/04/01 00:00 [pmc-release] AID - 10.1073/pnas.74.10.4453 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 1977 Oct;74(10):4453-7. doi: 10.1073/pnas.74.10.4453. PMID- 3042643 OWN - NLM STAT- MEDLINE DCOM- 19880915 LR - 20131121 IS - 0251-1649 (Print) IS - 0251-1649 (Linking) VI - 8 IP - 3 DP - 1988 TI - Ketoprofen vs etofenamate in a controlled double-blind study: evidence of topical effectiveness in soft tissue rheumatic pain. PG - 157-60 AB - The efficacy and safety of topical application of ketoprofen gel and etofenamate gel were studied in a controlled double-blind clinical trial. Thirty-six patients affected by inflammation of tendons, sheaths and bursae entered the study, and were treated for seven days. The parameters studied were: pain scale, Ritchie index, stiffness, pain on active and passive movement and functional capacity. The results showed that ketoprofen gel and etofenamate gel were able to induce remission of the inflammatory symptoms in soft tissue rheumatic pain. No side-effects were detected in either group. FAU - Matucci-Cerinic, M AU - Matucci-Cerinic M AD - First Institute of Medical Pathology, University of Florence, Italy. FAU - Casini, A AU - Casini A LA - eng PT - Clinical Trial PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article PL - Switzerland TA - Int J Clin Pharmacol Res JT - International journal of clinical pharmacology research JID - 8110183 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Phenylpropionates) RN - 60GCX7Y6BH (Flufenamic Acid) RN - 90Y4QC304K (Ketoprofen) RN - KZF0XM66JC (etofenamate) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Clinical Trials as Topic MH - Double-Blind Method MH - Female MH - Flufenamic Acid/*analogs & derivatives/therapeutic use MH - Humans MH - Ketoprofen/*therapeutic use MH - Male MH - Middle Aged MH - Pain/*drug therapy/etiology MH - Phenylpropionates/*therapeutic use MH - Random Allocation MH - Rheumatic Diseases/*complications MH - Time Factors EDAT- 1988/01/01 00:00 MHDA- 1988/01/01 00:01 CRDT- 1988/01/01 00:00 PHST- 1988/01/01 00:00 [pubmed] PHST- 1988/01/01 00:01 [medline] PHST- 1988/01/01 00:00 [entrez] PST - ppublish SO - Int J Clin Pharmacol Res. 1988;8(3):157-60. PMID- 2692580 OWN - NLM STAT- MEDLINE DCOM- 19900315 LR - 20190503 IS - 0264-4924 (Print) IS - 0264-4924 (Linking) VI - 6 IP - 4 DP - 1989 Dec TI - A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites. PG - 251-6 AB - The value of prophylactic antibiotics in the treatment of animal bites is uncertain. A prospective double blind stratified trial was performed comparing a broad spectrum antibiotic amoxycillin/clavulanate with placebo in full thickness animal bite wounds in a series of 185 consecutive patients. In wounds less than 9 h old, no significant benefit was found with the antibiotic. In older wounds, presenting 9-24 h after injury, the infection rate was reduced significantly (P = 0.023), although the numbers were small. We recommend the use of such an antibiotic on wounds 9-24 h old and query its use in more recent injuries, unless tendons or joints are likely to be involved. FAU - Brakenbury, P H AU - Brakenbury PH AD - Accident and Emergency Department, Middlesbrough General Hospital, England. FAU - Muwanga, C AU - Muwanga C LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Arch Emerg Med JT - Archives of emergency medicine JID - 8500828 RN - 0 (Clavulanic Acids) RN - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination) RN - 804826J2HU (Amoxicillin) SB - IM MH - Adult MH - Amoxicillin/*therapeutic use MH - Amoxicillin-Potassium Clavulanate Combination MH - Animals MH - Bites and Stings/*complications MH - Cats MH - Child MH - Clavulanic Acids/*therapeutic use MH - Dogs MH - Double-Blind Method MH - Drug Therapy, Combination/therapeutic use MH - Female MH - Ferrets MH - Humans MH - Male MH - Prospective Studies MH - Rabbits MH - Randomized Controlled Trials as Topic MH - Wound Infection/drug therapy/etiology/*prevention & control PMC - PMC1285624 EDAT- 1989/12/01 00:00 MHDA- 1989/12/01 00:01 PMCR- 1989/12/01 CRDT- 1989/12/01 00:00 PHST- 1989/12/01 00:00 [pubmed] PHST- 1989/12/01 00:01 [medline] PHST- 1989/12/01 00:00 [entrez] PHST- 1989/12/01 00:00 [pmc-release] AID - 10.1136/emj.6.4.251 [doi] PST - ppublish SO - Arch Emerg Med. 1989 Dec;6(4):251-6. doi: 10.1136/emj.6.4.251. PMID- 22284408 OWN - NLM STAT- MEDLINE DCOM- 20120822 LR - 20220409 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 28 IP - 5 DP - 2012 May TI - Micro-organism colonization and intraoperative contamination in patients undergoing arthroscopic anterior cruciate ligament reconstruction. PG - 667-71 LID - 10.1016/j.arthro.2011.10.023 [doi] AB - PURPOSE: To investigate the status of preoperative micro-organism colonization and intraoperative contamination in patients undergoing anterior cruciate ligament (ACL) reconstruction. METHODS: Fifty patients who underwent scheduled ACL reconstruction were included in the study. At the preoperative checkup, swabs were taken from the skin at the surgical site and the nose. During surgery, swab samples were taken from the skin adjacent to the incision and the surface of the graft and examined for contamination. RESULTS: Preoperative examination for micro-organism colonization showed positive results in 23 of 50 samples (46%) taken from the skin and 45 of 50 samples (90%) taken from the nose. Intraoperative swab samples taken from the skin and the graft showed positive rates of 6% and 2%, respectively, which were significantly lower compared with the preoperative values (P < .05). The most frequently identified organism in both preoperative and postoperative examinations was coagulase-negative Staphylococcus (CNS), representing 93% of the positive results. Among those CNS strains, roughly one-third of the samples were shown to be methicillin resistant. During the study period, surgical-site infection with methicillin-resistant CNS occurred in 1 patient. In this patient the preoperative culture identified methicillin-sensitive CNS, whereas preoperative nasal culture and intraoperative examinations of the skin and the graft were negative. CONCLUSIONS: Preoperative examination of micro-organism colonization in patients undergoing ACL reconstruction showed positive results in 46% and 90% of the samples taken from the skin and the nose, respectively. In the intraoperative examination, 6% and 2% of the swabs taken from the adjacent skin and the graft, respectively, showed positive results. LEVEL OF EVIDENCE: Level IV, therapeutic case series. CI - Copyright © 2012 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Nakayama, Hiroshi AU - Nakayama H AD - Department of Orthopaedic Surgery, Hyogo College of Medicine, Nishinomiya, Japan. hiroshi0273@mac.com FAU - Yagi, Masayoshi AU - Yagi M FAU - Yoshiya, Shinichi AU - Yoshiya S FAU - Takesue, Yoshio AU - Takesue Y LA - eng PT - Journal Article DEP - 20120128 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Anti-Bacterial Agents) RN - IHS69L0Y4T (Cefazolin) SB - IM MH - Adolescent MH - Adult MH - *Anterior Cruciate Ligament Reconstruction/methods MH - Anti-Bacterial Agents/therapeutic use MH - Antibiotic Prophylaxis MH - *Arthroscopy MH - Bacillus/isolation & purification MH - Cefazolin/therapeutic use MH - Cohort Studies MH - Female MH - Humans MH - Intraoperative Period MH - Male MH - Methicillin-Resistant Staphylococcus aureus/isolation & purification MH - Middle Aged MH - Nose/*microbiology MH - Preoperative Period MH - Skin/*microbiology MH - Staphylococcus/isolation & purification MH - Surgical Wound Infection/*microbiology/prevention & control MH - Tendons/*microbiology/transplantation MH - Young Adult EDAT- 2012/01/31 06:00 MHDA- 2012/08/23 06:00 CRDT- 2012/01/31 06:00 PHST- 2011/04/01 00:00 [received] PHST- 2011/10/11 00:00 [revised] PHST- 2011/10/25 00:00 [accepted] PHST- 2012/01/31 06:00 [entrez] PHST- 2012/01/31 06:00 [pubmed] PHST- 2012/08/23 06:00 [medline] AID - S0749-8063(11)01250-3 [pii] AID - 10.1016/j.arthro.2011.10.023 [doi] PST - ppublish SO - Arthroscopy. 2012 May;28(5):667-71. doi: 10.1016/j.arthro.2011.10.023. Epub 2012 Jan 28. PMID- 30609804 OWN - NLM STAT- MEDLINE DCOM- 20190411 LR - 20211204 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 20 IP - 1 DP - 2019 Jan 3 TI - In Vitro Induction of Tendon-Specific Markers in Tendon Cells, Adipose- and Bone Marrow-Derived Stem Cells is Dependent on TGFβ3, BMP-12 and Ascorbic Acid Stimulation. LID - 10.3390/ijms20010149 [doi] LID - 149 AB - Mesenchymal Stem Cells (MSCs) and tissue-specific progenitors have been proposed as useful tools for regenerative medicine approaches in bone, cartilage and tendon-related pathologies. The differentiation of cells towards the desired, target tissue-specific lineage has demonstrated advantages in the application of cell therapies and tissue engineering. Unlike osteogenic and chondrogenic differentiation, there is no consensus on the best tenogenic induction protocol. Many growth factors have been proposed for this purpose, including BMP-12, b-FGF, TGF-β3, CTGF, IGF-1 and ascorbic acid (AA). In this study, different combinations of these growth factors have been tested in the context of a two-step differentiation protocol, in order to define their contribution to the induction and maintenance of tendon marker expression in adipose tissue and bone marrow derived MSCs and tendon cells (TCs), respectively. Our results demonstrate that TGF-β3 is the main inducer of scleraxis, an early expressed tendon marker, while at the same time inhibiting tendon markers normally expressed later, such as decorin. In contrast, we find that decorin is induced by BMP-12, b-FGF and AA. Our results provide new insights into the effect of different factors on the tenogenic induction of MSCs and TCs, highlighting the importance of differential timing in TGF-β3 stimulation. FAU - Perucca Orfei, Carlotta AU - Perucca Orfei C AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. carlotta.perucca@gmail.com. FAU - Viganò, Marco AU - Viganò M AUID- ORCID: 0000-0002-6463-6564 AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. marco.vigano@grupposandonato.it. FAU - Pearson, John R AU - Pearson JR AUID- ORCID: 0000-0002-2267-0844 AD - Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, 29590 Málaga, Spain. jrpearson@bionand.es. FAU - Colombini, Alessandra AU - Colombini A AUID- ORCID: 0000-0002-1800-3424 AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. alessandra.colombini@grupposandonato.it. FAU - De Luca, Paola AU - De Luca P AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. deluca.paola@grupposandonato.it. FAU - Ragni, Enrico AU - Ragni E AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. enrico.ragni@grupposandonato.it. FAU - Santos-Ruiz, Leonor AU - Santos-Ruiz L AUID- ORCID: 0000-0001-6159-6045 AD - Andalusian Centre for Nanomedicine and Biotechnology, BIONAND, 29590 Málaga, Spain. lsantos@uma.es. AD - Network Centre for Biomedical Research ⁻ Biotechnology, Biomaterials and Nanomedicine, CIBER-BBN, 50018 Zaragoza, Spain. lsantos@uma.es. AD - Department of Cell Biology, Genetics and Physiology, Instituto de Investigación University of Málaga, 29016 Malaga, Spain. lsantos@uma.es. FAU - de Girolamo, Laura AU - de Girolamo L AD - IRCCS Istituto Ortopedico Galeazzi, Orthopaedic Biotechnology Lab, 20161 Milan, Italy. laura.degirolamo@grupposandonato.it. LA - eng PT - Journal Article DEP - 20190103 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Biomarkers) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Culture Media) RN - 0 (Decorin) RN - 0 (Homeodomain Proteins) RN - 0 (Mkx protein, human) RN - 0 (SCX protein, human) RN - 0 (Transforming Growth Factor beta3) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adipose Tissue/cytology MH - Ascorbic Acid/*pharmacology MH - Basic Helix-Loop-Helix Transcription Factors/metabolism MH - Biomarkers/*metabolism MH - Bone Marrow Cells/cytology MH - Bone Morphogenetic Proteins/*pharmacology MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - Collagen Type I/metabolism MH - Collagen Type I, alpha 1 Chain MH - Culture Media/chemistry MH - Decorin/metabolism MH - Female MH - Homeodomain Proteins/metabolism MH - Humans MH - Male MH - Mesenchymal Stem Cells/cytology/drug effects/metabolism MH - Microscopy, Fluorescence MH - Middle Aged MH - Tendons/cytology/drug effects/metabolism MH - Transforming Growth Factor beta3/*pharmacology PMC - PMC6337430 OTO - NOTNLM OT - BMP-12 OT - Bone marrow-derived MSCs OT - FGF OT - TGFbeta OT - adipose-derived MSCs OT - ascorbic acid OT - tendon cells OT - tenogenic differentiation COIS- The authors declare no conflict of interest. EDAT- 2019/01/06 06:00 MHDA- 2019/04/12 06:00 PMCR- 2019/01/01 CRDT- 2019/01/06 06:00 PHST- 2018/12/20 00:00 [received] PHST- 2018/12/27 00:00 [accepted] PHST- 2019/01/06 06:00 [entrez] PHST- 2019/01/06 06:00 [pubmed] PHST- 2019/04/12 06:00 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - ijms20010149 [pii] AID - ijms-20-00149 [pii] AID - 10.3390/ijms20010149 [doi] PST - epublish SO - Int J Mol Sci. 2019 Jan 3;20(1):149. doi: 10.3390/ijms20010149. PMID- 31281545 OWN - NLM STAT- MEDLINE DCOM- 20200727 LR - 20240717 IS - 1838-7640 (Electronic) IS - 1838-7640 (Linking) VI - 9 IP - 14 DP - 2019 TI - A Combination of Oxo-M and 4-PPBP as a potential regenerative therapeutics for tendon injury. PG - 4241-4254 LID - 10.7150/thno.35285 [doi] AB - Tendons injuries frequently result in scar-like tissue with poor biochemical structure and mechanical properties. We have recently reported that CD146(+) perivascular originated tendon stem/progenitor cells (TSCs), playing critical roles in tendon healing. Here, we identified highly efficient small molecules that selectively activate endogenous TSCs for tendon regeneration. Methods: From a pool of ERK1/2 and FAK agonists, Oxo-M and 4-PPBP were identified, and their roles in tenogenic differentiation of TSCs and in vivo tendon healing were investigated. Controlled delivery of Oxo-M and 4-PPBP was applied via PLGA µS. Signaling studies were conducted to determine the mechanism for specificity of Oxo-M and 4-PPBP to CD146(+) TSCs. Results: A combination of Oxo-M and 4-PPBP synergistically increased the expressions of tendon-related gene markers in TSCs. In vivo, delivery of Oxo-M and 4-PPBP significantly enhanced healing of fully transected rat patellar tendons (PT), with functional restoration and reorganization of collagen fibrous structure. Our signaling study suggested that Oxo-M and 4-PPBP specifically targets CD146(+) TSCs via non-neuronal muscarinic acetylcholine receptors (AChR) and σ1 receptor (σ1) signaling. Principal conclusions: Our findings demonstrate a significant potential of Oxo-M and 4-PPBP as a regenerative therapeutics for tendon injuries. FAU - Tarafder, Solaiman AU - Tarafder S AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. FAU - Ricupero, Christopher AU - Ricupero C AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. FAU - Minhas, Sumeet AU - Minhas S AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. FAU - Yu, Rebecca J AU - Yu RJ AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. FAU - Alex, Ashleigh D AU - Alex AD AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. FAU - Lee, Chang H AU - Lee CH AD - Columbia University College of Dental Medicine, 630 W. 168th street, Vanderbilt Clinic 12-210, New York, NY 10032. LA - eng GR - R01 AR065023/AR/NIAMS NIH HHS/United States GR - R01 AR071316/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20190531 PL - Australia TA - Theranostics JT - Theranostics JID - 101552395 RN - 0 (CD146 Antigen) RN - 136534-70-8 (4-phenyl-1-(4-phenylbutyl)piperidine) RN - EC 2.7.10.2 (Focal Adhesion Kinase 1) RN - EC 2.7.10.2 (Ptk2 protein, rat) RN - J6292F8L3D (Haloperidol) SB - IM MH - Animals MH - CD146 Antigen/metabolism MH - Cell Differentiation/physiology MH - Cells, Cultured MH - Focal Adhesion Kinase 1/metabolism MH - Haloperidol/*analogs & derivatives/therapeutic use MH - MAP Kinase Signaling System/drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Regeneration/physiology MH - Stem Cells/*cytology MH - Tendon Injuries/*therapy MH - Tendons/*cytology MH - Wound Healing/physiology PMC - PMC6592164 OTO - NOTNLM OT - Endogenous stem/progenitor cells OT - Regenerative Medicine OT - Small molecules OT - Tendon COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2019/07/10 06:00 MHDA- 2020/07/28 06:00 PMCR- 2019/01/01 CRDT- 2019/07/09 06:00 PHST- 2019/03/28 00:00 [received] PHST- 2019/04/21 00:00 [accepted] PHST- 2019/07/09 06:00 [entrez] PHST- 2019/07/10 06:00 [pubmed] PHST- 2020/07/28 06:00 [medline] PHST- 2019/01/01 00:00 [pmc-release] AID - thnov09p4241 [pii] AID - 10.7150/thno.35285 [doi] PST - epublish SO - Theranostics. 2019 May 31;9(14):4241-4254. doi: 10.7150/thno.35285. eCollection 2019. PMID- 6539113 OWN - NLM STAT- MEDLINE DCOM- 19840611 LR - 20141120 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 34 IP - 2 DP - 1984 TI - Influence of desmotropic drugs on viscoelastic properties of rat tail tendons. Hysteresis experiments. PG - 213-6 AB - The influence of several desmotropic drugs (D-penicillamine (D-Pc) at doses of 300 and 1000 mg/kg p.o., a lathyrogenic drug, e.g. aminoacetonitrile (AAN) at doses of 100 and 300 mg/kg p.o. and a glucocorticoid, e.g. prednisolone acetate at doses of 2 and 10 mg/kg s.c.) on viscoelastic properties of rat tail tendons has been studied after 10 days' administration. In this experimental series not only the ultimate values (ultimate load, tensile strength, ultimate load of elasticity, ultimate strain), but also the hysteresis loops after 2, 4, 6 and 8% strain were evaluated. The ultimate values showed similar results as found in earlier experimental series, e.g., an impressive decrease after D-Pc treatment, a less pronounced decrease after AAN and an increase after prednisolone acetate. At extension degrees below rupture the values of stress, modulus of elasticity and energy input showed the same pattern. In contrast, energy dissipation as indicated by the area between the hysteresis loop showed a different pattern. Consequently, the ratio between energy dissipation and energy input, which is the characteristic parameter of the hysteresis phenomenon, was highly increased by D-Pc and only barely influenced by AAN. In contrast, prednisolone acetate reduced this ratio. A similar pattern was found for residual extension. Since the hysteresis phenomenon can be regarded as a parameter of plasticity of tail tendons one can conclude that D-Pc increases plasticity, AAN has only a slight influence and prednisolone acetate decreases plasticity. FAU - Vogel, H G AU - Vogel HG LA - eng PT - Journal Article PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 3739OQ10IJ (Aminoacetonitrile) RN - 9PHQ9Y1OLM (Prednisolone) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Aging MH - Aminoacetonitrile/pharmacology MH - Animals MH - Body Weight/drug effects MH - Connective Tissue/*drug effects MH - Elasticity MH - In Vitro Techniques MH - Male MH - Penicillamine/pharmacology MH - Prednisolone/pharmacology MH - Rats MH - Rats, Inbred Strains MH - Tail MH - Tendons/*drug effects/physiology MH - Tensile Strength MH - Viscosity EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1984;34(2):213-6. PMID- 18589276 OWN - NLM STAT- MEDLINE DCOM- 20080730 LR - 20161124 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 24 IP - 7 DP - 2008 Jul TI - Magnetic resonance imaging appearance of the shoulder after subacromial injection with corticosteroids can mimic a rotator cuff tear. PG - 846-9 LID - 10.1016/j.arthro.2007.01.024 [doi] AB - Subacromial injections have been used to treat rotator cuff problems. Previous studies have noted the difficulty in performing accurate injections into this area. In addition, one must also question the effects that misplaced corticosteroids could have on the surrounding tissues. In this case, a 51-year-old woman presented with several weeks of left shoulder pain and was diagnosed with rotator cuff tendonitis. After a subacromial injection with betamethasone and lidocaine, the patient noted 3 weeks of near complete pain relief, followed by a return of her symptoms. A magnetic resonance imaging scan obtained 7 weeks after the injection showed a full-thickness tear of the supraspinatus tendon. Five weeks later, the patient underwent arthroscopic evaluation of the shoulder and subacromial decompression. The rotator cuff tendons were noted to be intact and normal in appearance. The patient eventually had full resolution of her symptoms. Six months postoperatively, she underwent a new scan that showed a normal supraspinatus tendon. Apparently, the subacromial injection penetrated the anterior half of the supraspinatus tendon, causing a transient effect and signal change. One should use caution in the interpretation of magnetic resonance imaging scans of the shoulder soon after the injection of corticosteroids. FAU - Borick, Jay M AU - Borick JM AD - Southern California Center for Sports Medicine, Long Beach, California, USA. jayborick@hotmail.com FAU - Kurzweil, Peter R AU - Kurzweil PR LA - eng PT - Case Reports PT - Journal Article DEP - 20070424 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Adrenal Cortex Hormones) RN - 9842X06Q6M (Betamethasone) RN - 98PI200987 (Lidocaine) SB - IM CIN - Arthroscopy. 2008 Dec;24(12):1435-6; author reply 1436. doi: 10.1016/j.arthro.2008.09.023. PMID: 19038720 MH - Adrenal Cortex Hormones/*administration & dosage MH - Arthralgia/drug therapy/*etiology/surgery MH - Betamethasone/therapeutic use MH - Diagnosis, Differential MH - Diagnostic Errors MH - Female MH - Humans MH - Injections, Intra-Articular/*adverse effects MH - Lidocaine/therapeutic use MH - Magnetic Resonance Imaging MH - Middle Aged MH - Recurrence MH - Rotator Cuff Injuries MH - Shoulder Impingement Syndrome/drug therapy MH - Shoulder Joint/*pathology MH - Tendinopathy/*diagnosis/drug therapy MH - Tendon Injuries/*diagnosis/etiology MH - Tendons/*pathology EDAT- 2008/07/01 09:00 MHDA- 2008/07/31 09:00 CRDT- 2008/07/01 09:00 PHST- 2006/10/31 00:00 [received] PHST- 2006/12/22 00:00 [revised] PHST- 2007/01/03 00:00 [accepted] PHST- 2008/07/01 09:00 [pubmed] PHST- 2008/07/31 09:00 [medline] PHST- 2008/07/01 09:00 [entrez] AID - S0749-8063(07)00137-5 [pii] AID - 10.1016/j.arthro.2007.01.024 [doi] PST - ppublish SO - Arthroscopy. 2008 Jul;24(7):846-9. doi: 10.1016/j.arthro.2007.01.024. Epub 2007 Apr 24. PMID- 40959984 OWN - NLM STAT- MEDLINE DCOM- 20251222 LR - 20251222 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 67 IP - 1 DP - 2026 Jan TI - Dapagliflozin attenuates lipotoxic tenocyte injury via PPARα activation and irisin-driven antioxidant pathways. PG - 38-50 LID - 10.1080/03008207.2025.2561655 [doi] AB - PURPOSE: Dapagliflozin (DAP), an SGLT2 inhibitor commonly prescribed for type 2 diabetes, has been recognized for its anti-inflammatory and antioxidative effects in various disease contexts. However, its impact on hyperlipidemic tenocytes-particularly within the framework of obesity-induced tendinopathy-remains underexplored. This study investigated the protective role of DAP in palmitate-exposed tenocytes, which simulate lipid-induced tendon degeneration. METHODS: Protein expression was analyzed via Western blotting, while apoptosis was assessed through cell viability assays, caspase-3 activity, and TUNEL staining. Oxidative stress was evaluated through the quantification of H₂O₂, malondialdehyde (MDA), and reactive oxygen species (ROS). PPARα gene silencing was conducted via siRNA transfection. RESULTS: DAP treatment significantly attenuated apoptosis and oxidative stress, restored the extracellular matrix (ECM) balance, and enhanced tenocyte migration. These protective effects were associated with the upregulation of PPARα, PGC1α, and Nrf2, along with increased activities of antioxidant enzymes such as superoxide dismutase (SOD) and catalase. Notably, silencing PPARα negated the beneficial effects of DAP, underscoring its central role. Furthermore, irisin-a myokine upregulated by DAP in myocytes-was also found to reduce oxidative stress and apoptosis in palmitate-treated tenocytes. CONCLUSIONS: This study provides novel insights into the mechanistic actions of DAP in musculoskeletal repair and highlights its potential in mitigating the cellular consequences of metabolic stress. By advancing therapeutic strategies rooted in metabolic regulation and cellular resilience, these findings support the development of safer, more effective interventions for chronic degenerative conditions associated with obesity. FAU - Pyo, Min Kyung AU - Pyo MK AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. AD - Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. FAU - Ko, Jun Hwi AU - Ko JH AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. AD - Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. FAU - Lim, Do Su AU - Lim DS AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. AD - Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. FAU - Gwon, Hyeon Ji AU - Gwon HJ AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. AD - Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. FAU - Abd El-Aty, A M AU - Abd El-Aty AM AD - Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt. AD - Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, Turkey. FAU - Ahmet Aydemir, Hacı AU - Ahmet Aydemir H AD - Department of Family Medicine, Erzurum Regional Training and Research Hospital, Erzurum, Turkey. FAU - Jeong, Ji Hoon AU - Jeong JH AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. AD - Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. FAU - Jung, Tae Woo AU - Jung TW AD - Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20250917 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (PPAR alpha) RN - 0 (Benzhydryl Compounds) RN - 0 (Antioxidants) RN - 0 (Fibronectins) RN - 0 (Glucosides) RN - 1ULL0QJ8UC (dapagliflozin) RN - 0 (FNDC5 protein, mouse) RN - 0 (Palmitates) SB - IM MH - *PPAR alpha/metabolism MH - Animals MH - *Benzhydryl Compounds/pharmacology MH - *Antioxidants/metabolism MH - Oxidative Stress/drug effects MH - *Fibronectins/metabolism MH - *Glucosides/pharmacology MH - Apoptosis/drug effects MH - *Tendons/pathology/metabolism MH - *Signal Transduction/drug effects MH - Extracellular Matrix/metabolism/drug effects MH - Palmitates MH - Cell Movement/drug effects OTO - NOTNLM OT - Dapagliflozin OT - PPARα OT - Tendinopathy OT - apoptosis OT - oxidative stress EDAT- 2025/09/17 06:33 MHDA- 2025/12/22 06:29 CRDT- 2025/09/17 05:53 PHST- 2025/12/22 06:29 [medline] PHST- 2025/09/17 06:33 [pubmed] PHST- 2025/09/17 05:53 [entrez] AID - 10.1080/03008207.2025.2561655 [doi] PST - ppublish SO - Connect Tissue Res. 2026 Jan;67(1):38-50. doi: 10.1080/03008207.2025.2561655. Epub 2025 Sep 17. PMID- 6709500 OWN - NLM STAT- MEDLINE DCOM- 19840502 LR - 20190501 IS - 0305-1048 (Print) IS - 1362-4962 (Electronic) IS - 0305-1048 (Linking) VI - 12 IP - 5 DP - 1984 Mar 12 TI - Ascorbate stimulation of PAT cells causes an increase in transcription rates and a decrease in degradation rates of procollagen mRNA. PG - 2569-79 AB - Procollagen alpha 2 (I) mRNA can be induced congruent to 6-fold in primary avian tendon (PAT) cells on addition of ascorbate to the culture medium. Previously, we have shown that the induction is linear after a 12 h lag and requires a total of 60-72 h to achieve maximum levels. We have now investigated in more detail the changes that have occurred in the metabolism of procollagen mRNA in fully induced cells to account for the observed induction. Ascorbate was found to triple the rate of procollagen gene transcription. In addition, there was a stabilization of the mRNA causing the half-life to increase from 10.5 h to 20 h. The increased stability of the procollagen mRNA, however, did not correlate with its ability to bind to oligo (dT)-cellulose. Since a 3-fold change in transcription rates and a 2-fold increase in half-life would account for the 6-fold overall increase in procollagen mRNA levels, we conclude that these are the primary alterations caused by ascorbate addition that give rise to the specific increase in procollagen mRNA. FAU - Lyons, B L AU - Lyons BL FAU - Schwarz, R I AU - Schwarz RI LA - eng GR - CA 31767/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Nucleic Acids Res JT - Nucleic acids research JID - 0411011 RN - 0 (Procollagen) RN - 0 (RNA, Messenger) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Cells, Cultured MH - Chick Embryo MH - Kinetics MH - Nucleic Acid Hybridization MH - Plasmids MH - Procollagen/*genetics MH - RNA, Messenger/*genetics/isolation & purification MH - Tendons/drug effects/metabolism MH - Transcription, Genetic/*drug effects PMC - PMC318686 EDAT- 1984/03/12 00:00 MHDA- 1984/03/12 00:01 CRDT- 1984/03/12 00:00 PHST- 1984/03/12 00:00 [pubmed] PHST- 1984/03/12 00:01 [medline] PHST- 1984/03/12 00:00 [entrez] AID - 10.1093/nar/12.5.2569 [doi] PST - ppublish SO - Nucleic Acids Res. 1984 Mar 12;12(5):2569-79. doi: 10.1093/nar/12.5.2569. PMID- 15156269 OWN - NLM STAT- MEDLINE DCOM- 20040624 LR - 20170214 IS - 0003-3197 (Print) IS - 0003-3197 (Linking) VI - 55 IP - 3 DP - 2004 May-Jun TI - Regression of Achilles tendon xanthomas evaluated by CT scan after hypolipidemic treatment with simvastatin. A case report. PG - 335-9 AB - Familial hypercholesterolemia (FH) is a relatively common autosomal monogenic disease with dominant inheritance and threefold to fourfold increase in relative risk of cardiovascular death in untreated patients. For a "definitive" clinical diagnosis of FH the Simon Broome Register proposes the presence of tendon xanthomas as a key feature. However, detection of tendon xanthomas by physical examination is subjective and difficult to use for follow-up purposes. Several instrumental methods have been reported to be more sensitive than physical examination for the evaluation of xanthomas. The present case illustrates the usefulness of computed tomography (CT) to detect xanthomas in the Achilles tendons (XAT) and their regression in response to hypolipidemic drug treatment in a heterozygous FH patient. As XAT are atherosclerotic plaque-like depositions of lipids it is likely that their progression or regression follows the behavior of vascular atherosclerotic lesions. FAU - Kolovou, Genovefa AU - Kolovou G AD - 1st Cardiology Department of the Onassis Cardiac Surgery Center, Athens, Greece. g_kolovou@yahoo.co.uk FAU - Daskalova, Deliana AU - Daskalova D FAU - Mastorakou, Irene AU - Mastorakou I FAU - Anagnostopoulou, Katherine AU - Anagnostopoulou K FAU - Cokkinos, Dennis V AU - Cokkinos DV LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Angiology JT - Angiology JID - 0203706 RN - 0 (Anticholesteremic Agents) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Achilles Tendon/*diagnostic imaging MH - Anticholesteremic Agents/*therapeutic use MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use MH - Hyperlipoproteinemia Type II/complications/*drug therapy MH - Male MH - Middle Aged MH - Muscular Diseases/complications/diagnostic imaging MH - Simvastatin/*therapeutic use MH - *Tomography, X-Ray Computed MH - Xanthomatosis/*complications/diagnostic imaging EDAT- 2004/05/25 05:00 MHDA- 2004/06/25 05:00 CRDT- 2004/05/25 05:00 PHST- 2004/05/25 05:00 [pubmed] PHST- 2004/06/25 05:00 [medline] PHST- 2004/05/25 05:00 [entrez] AID - 10.1177/000331970405500314 [doi] PST - ppublish SO - Angiology. 2004 May-Jun;55(3):335-9. doi: 10.1177/000331970405500314. PMID- 2147882 OWN - NLM STAT- MEDLINE DCOM- 19910131 LR - 20181130 IS - 0009-9074 (Print) IS - 0009-9074 (Linking) VI - 133 IP - 6 DP - 1990 Jun 30 TI - [Analgesic and anti-inflammatory effect of nabumetone in osteo-articular diseases in the acute phase]. PG - 379-86 AB - Twenty patients, 7 males, 13 females, age range 27-69, average 46 years, with highly painful and inflammatory osteo-articular pathology were treated with a nabumetone preparation (one 1 g capsule at night before going to bed), for a minimum of 6 and a maximum of 10 days (average 9.70 days). Already during the first days of treatment, pain and joint function were improved and reactive edema diminished. The authors believe the drug to have a preventive analgesic effect which may at first consist in an increased pain threshold at the level of capsular receptors and may subsequently involve algoreceptors situated in the tendons. In addition to its analgesic efficacy, the drug has the advantage of being easy to handle neither general nor local side effects were observed. Only two patients complained of digestive side effects (dyspepsia and minor gastric pain in one case; gastric pain and vomiting in the other: both leading to withdrawal of the drug after 6 days). Five patients had excellent results, 9 reported good results, in 5 the result was fair. FAU - Catalano, F AU - Catalano F AD - Istituto di Clinica Ortopedica, Università cattolica del S. Cuore di Roma. FAU - Fanfani, F AU - Fanfani F FAU - Taccardo, G AU - Taccardo G FAU - Pagliei, A AU - Pagliei A FAU - Vaiani, G AU - Vaiani G LA - ita PT - Journal Article TT - Effetto analgesico ed antiflogistico del nabumetone in patologie osteo-articolari in fase acuta. PL - Italy TA - Clin Ter JT - La Clinica terapeutica JID - 0372604 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Butanones) RN - LW0TIW155Z (Nabumetone) SB - IM MH - Acute Disease MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Bone Diseases/*drug therapy MH - Butanones/*therapeutic use MH - Female MH - Humans MH - Joint Diseases/*drug therapy MH - Male MH - Middle Aged MH - Nabumetone EDAT- 1990/06/30 00:00 MHDA- 1990/06/30 00:01 CRDT- 1990/06/30 00:00 PHST- 1990/06/30 00:00 [pubmed] PHST- 1990/06/30 00:01 [medline] PHST- 1990/06/30 00:00 [entrez] PST - ppublish SO - Clin Ter. 1990 Jun 30;133(6):379-86. PMID- 5244413 OWN - NLM STAT- MEDLINE DCOM- 19681016 LR - 20131121 IS - 0370-632X (Print) IS - 0370-632X (Linking) VI - 24 IP - 5 DP - 1967 Sep-Oct TI - [Acute scapulo-humeral periarthritis and its specific treatment. Apropos of 129 cases]. PG - 418-28 FAU - Badaro, H AU - Badaro H LA - fre PT - Journal Article TT - La périarthrite scapulo-humérale aiguë et son traitement pathogénique. PL - Lebanon TA - Rev Med Moyen Orient JT - Revue medicale du Moyen-Orient JID - 20340240R RN - 4Z8Y51M438 (Procaine) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Acute Disease MH - Humans MH - Hydrocortisone/therapeutic use MH - Movement MH - *Periarthritis/drug therapy MH - Procaine/therapeutic use MH - *Shoulder Joint MH - Tendons EDAT- 1967/09/01 00:00 MHDA- 1967/09/01 00:01 CRDT- 1967/09/01 00:00 PHST- 1967/09/01 00:00 [pubmed] PHST- 1967/09/01 00:01 [medline] PHST- 1967/09/01 00:00 [entrez] PST - ppublish SO - Rev Med Moyen Orient. 1967 Sep-Oct;24(5):418-28. PMID- 5377288 OWN - NLM STAT- MEDLINE DCOM- 19700909 LR - 20121115 IS - 0041-9826 (Print) IS - 0041-9826 (Linking) VI - 35 IP - 4 DP - 1969 Oct-Dec TI - Phonotenography in systemic sclerosis (scleroderma). PG - 211-3 FAU - Zarafonetis, C J AU - Zarafonetis CJ FAU - Dabich, L AU - Dabich L FAU - Shell, W E AU - Shell WE LA - eng PT - Journal Article PL - United States TA - Univ Mich Med Cent J JT - University of Michigan Medical Center journal JID - 0417371 RN - 0 (Aminobenzoates) SB - IM MH - Adult MH - Aminobenzoates/therapeutic use MH - *Auscultation MH - Child MH - Female MH - Humans MH - Methods MH - Oscillometry MH - Scleroderma, Systemic/*diagnosis MH - *Tendons MH - Tenosynovitis/*diagnosis/drug therapy EDAT- 1969/10/01 00:00 MHDA- 1969/10/01 00:01 CRDT- 1969/10/01 00:00 PHST- 1969/10/01 00:00 [pubmed] PHST- 1969/10/01 00:01 [medline] PHST- 1969/10/01 00:00 [entrez] PST - ppublish SO - Univ Mich Med Cent J. 1969 Oct-Dec;35(4):211-3. PMID- 31401128 OWN - NLM STAT- MEDLINE DCOM- 20200313 LR - 20200313 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 29 IP - 1 DP - 2020 Jan TI - A prospective study comparing tendon-to-bone interface healing using an interposition bioresorbable scaffold with a vented anchor for primary rotator cuff repair in sheep. PG - 157-166 LID - S1058-2746(19)30359-3 [pii] LID - 10.1016/j.jse.2019.05.024 [doi] AB - BACKGROUND: The purpose of this study was to evaluate the biomechanical and histologic properties of rotator cuff repairs using a vented anchor attached to a bioresorbable interpositional scaffold composed of aligned PLGA (poly(l-lactide-co-glycoside)) microfibers in an animal model compared to standard anchors in an ovine model. METHODS: Fifty-six (n = 56) skeletally mature sheep were randomly assigned to a repair of an acute infraspinatus tendon detachment using a innovative anchor-PLGA scaffold device (Treatment) or a similar anchor without the scaffold (Control). Animals were humanely euthanized at 7 and 12 weeks post repair. Histologic and biomechanical properties of the repairs were evaluated and compared. RESULTS: The Treatment group had a significantly higher fibroblast count at 7 weeks compared to the Control group. The tendon bone repair distance, percentage perpendicular fibers, new bone formation at the tendon-bone interface, and collagen type III deposition was significantly greater for the Treatment group compared with the Control group at 12 weeks (P ≤ .05). A positive correlation was identified in the Treatment group between increased failure loads at 12 weeks and the following parameters: tendon-bone integration, new bone formation, and collagen type III. No statistically significant differences in biomechanical properties were identified between Treatment and Control Groups (P > .05). CONCLUSIONS: Use of a vented anchor attached to a bioresorbable interpositional scaffold composed of aligned PLGA microfibers improves the histologic properties of rotator cuff repairs in a sheep model. Improved histology was correlated with improved final construct strength at the 12-week time point. CI - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Easley, Jeremiah AU - Easley J AD - Preclinical Surgical Research Laboratory, Colorado State University, Fort Collins, CO, USA. FAU - Puttlitz, Christian AU - Puttlitz C AD - Orthopedic Bioengineering Research Laboratory, Colorado State University, Fort Collins, CO, USA. FAU - Hackett, Eileen AU - Hackett E AD - Preclinical Surgical Research Laboratory, Colorado State University, Fort Collins, CO, USA. FAU - Broomfield, Cecily AU - Broomfield C AD - Orthopedic Bioengineering Research Laboratory, Colorado State University, Fort Collins, CO, USA. FAU - Nakamura, Lucas AU - Nakamura L AD - Orthopedic Bioengineering Research Laboratory, Colorado State University, Fort Collins, CO, USA. FAU - Hawes, Michael AU - Hawes M AD - Charter Preclinical Services, Hudson, MA, USA. FAU - Getz, Charles AU - Getz C AD - Orthopedic Surgery, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Frankle, Mark AU - Frankle M AD - Florida Orthopaedic Institute, Shoulder and Elbow Service, Tampa, FL, USA; Morsani College of Medicine, University of South Florida, Tampa, FL, USA. FAU - St Pierre, Patrick AU - St Pierre P AD - Shoulder and Elbow Service, Desert Orthopedic Center, Eisenhower Health, Rancho Mirage, CA, USA. FAU - Tashjian, Robert AU - Tashjian R AD - University of Utah School of Medicine, Salt Lake City, UT, USA. FAU - Cummings, P Dean AU - Cummings PD AD - The Orthopedic Clinic Association, Phoenix, AZ, USA. FAU - Abboud, Joseph AU - Abboud J AD - The Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. FAU - Harper, Derek AU - Harper D AD - Zimmer Biomet, Warsaw, IN, USA. FAU - McGilvray, Kirk AU - McGilvray K AD - Orthopedic Bioengineering Research Laboratory, Colorado State University, Fort Collins, CO, USA. Electronic address: kirk.mcgilvray@colostate.edu. LA - eng PT - Comparative Study PT - Journal Article DEP - 20190807 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Biocompatible Materials) RN - 0 (Collagen Type III) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) SB - IM MH - Absorbable Implants MH - Animals MH - Biocompatible Materials/therapeutic use MH - Biomechanical Phenomena MH - Bone and Bones/*physiology/surgery MH - Cell Count MH - Collagen Type III/metabolism MH - Disease Models, Animal MH - Female MH - Fibroblasts MH - Osteogenesis MH - Polylactic Acid-Polyglycolic Acid Copolymer/therapeutic use MH - Prospective Studies MH - Rotator Cuff Injuries/pathology/*surgery MH - Sheep MH - Suture Techniques MH - Tendons/*physiology/surgery MH - *Tissue Scaffolds MH - *Wound Healing OTO - NOTNLM OT - PLGA scaffold OT - Rotator cuff repair OT - biomechanics OT - histology OT - ovine OT - rotator cuff tendon OT - suture anchor EDAT- 2019/08/12 06:00 MHDA- 2020/03/14 06:00 CRDT- 2019/08/12 06:00 PHST- 2019/01/02 00:00 [received] PHST- 2019/05/03 00:00 [revised] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/08/12 06:00 [pubmed] PHST- 2020/03/14 06:00 [medline] PHST- 2019/08/12 06:00 [entrez] AID - S1058-2746(19)30359-3 [pii] AID - 10.1016/j.jse.2019.05.024 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2020 Jan;29(1):157-166. doi: 10.1016/j.jse.2019.05.024. Epub 2019 Aug 7. PMID- 21841065 OWN - NLM STAT- MEDLINE DCOM- 20120306 LR - 20220331 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 39 IP - 11 DP - 2011 Nov TI - Ultrasound-guided sclerosing treatment in patients with patellar tendinopathy (jumper's knee). 44-month follow-up. PG - 2377-80 LID - 10.1177/0363546511417097 [doi] AB - BACKGROUND: A randomized controlled study has shown good clinical results after treatment with sclerosing injections into the area with neovessels in patients with patellar tendinopathy, but no study has investigated medium- or long-term outcomes. PURPOSE: This study investigates the effect of sclerosing treatment 44 months (range, 42-47 months) after start of treatment. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Patients with a diagnosis of jumper's knee and neovascularization corresponding to the painful area were recruited and treated with ultrasound-guided sclerosing injections using polidocanol. Primary outcome was Victorian Institute of Sport Assessment (VISA) score, which was recorded before the start of treatment, after 12 months, and 44 months after the start of the study period. RESULTS: Twelve of the 29 patients (14 tendons) who were followed up at 44 months had undergone arthroscopic surgery after sclerosing treatment, either to the patellar tendon (n = 6) or for other intra-articular lesions (n = 8). For patients who did not receive additional treatment after the sclerosing injections (n = 23 tendons), VISA score was 55 (range, 28-71) at baseline and 81 (range, 39-100) at 12-month follow-up (P < .001 vs baseline).Their VISA score at 44 months' follow-up was 89 (range, 73-100; P = .047 vs 12 months). For patients who went through arthroscopic tendon surgery, VISA score was 53 (range, 39-71) at baseline and 71 before surgery (range, 48-98; P = .14 vs baseline). Their VISA score at 44 months was 91 (range, 76-100; P = .0.16 vs 12 months; P = .005 vs baseline). For patients who went through non-tendon surgery, VISA score was 45 (range, 15-69) at baseline and 57 (range, 32-95) before surgery (P = .29 vs baseline). Their VISA score at 44 months was 92 (range, 72-100; P = .006 vs before surgery; P < .001 vs baseline). CONCLUSION: Sclerosing treatment with polidocanol was effective for the majority of the patients. Nevertheless, one-third elected to seek additional treatment through arthroscopic surgery during the 44-month follow-up period. FAU - Hoksrud, Aasne AU - Hoksrud A AD - Oslo Sports Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, Ullevaal Stadion, Oslo, Norway. aasne.hoksrud@nih.no FAU - Bahr, Roald AU - Bahr R LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20110812 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adolescent MH - Adult MH - Athletes MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Patella/*diagnostic imaging/physiopathology MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Sclerosing Solutions/therapeutic use MH - Sclerotherapy/*methods MH - Tendinopathy/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography MH - Young Adult EDAT- 2011/08/16 06:00 MHDA- 2012/03/07 06:00 CRDT- 2011/08/16 06:00 PHST- 2011/08/16 06:00 [entrez] PHST- 2011/08/16 06:00 [pubmed] PHST- 2012/03/07 06:00 [medline] AID - 0363546511417097 [pii] AID - 10.1177/0363546511417097 [doi] PST - ppublish SO - Am J Sports Med. 2011 Nov;39(11):2377-80. doi: 10.1177/0363546511417097. Epub 2011 Aug 12. PMID- 17086383 OWN - NLM STAT- MEDLINE DCOM- 20070816 LR - 20220716 IS - 0770-3198 (Print) IS - 0770-3198 (Linking) VI - 26 IP - 7 DP - 2007 Jul TI - The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. PG - 1104-10 AB - The aim of this study was to evaluate the effects of a 1-year course of sulfasalazine monotherapy on enthesal abnormalities of inflammatory rheumatic diseases (IRDs) using ultrasonography. Thirty-six patients with IRD including 20 patients with rheumatoid arthritis (RA) and 16 patients with ankylosing spondylitis (AS) (22 women, 14 men, mean ages 43.3 +/- 8.8 years), and 18 healthy controls (10 women, 8 men, mean ages 42.5 +/- 9.9 years) matched by age and body mass index were enrolled in this study. For the evaluation of enthesal structures, all patients and controls underwent ultrasonographic (USG) examinations of five enthesal sites of both lower limbs using high-resolution and Doppler USG. An ultrasonographic score of lower limb enthesitis was calculated using Glasgow ultrasound enthesitis scoring system (GUESS). Clinical and laboratory activities of IRD patients were also evaluated. Patient group was made to undergo 2 g/day sulfasalazine monotherapy for 1 year. All evaluations were made at the beginning of the treatment and repeated after 1 year follow-up. Results showed that the frequency of enthesal abnormalities of the IRD group was significantly higher than controls. On USG examination, 301/1,296 (23.2%) enthesal structures were abnormal in IRD patients, and 19/648 (2.93%) structures were abnormal in controls. Mean GUESS score of the IRD group (6.40 +/- 2.41) was also significantly higher than controls (1.79 +/- 1.60) (p < 0.001). Although there was a significant improvement in clinical and laboratory activity parameters of the IRD patients, significant decrease was not observed in enthesal abnormalities (295/1,296 enthesal structures-22.7%) and mean GUESS score (6.20 +/- 2.38) after 1 year sulfasalazine trial. Additionally, there was no significant improvement in enthesal abnormalities and mean GUESS scores of AS and RA subgroups separately. Sulfasalazine treatment was not found effective on enthesal abnormalities of IRD patients. Further studies with larger groups including other IRDs are required to validate our results. FAU - Genc, Hakan AU - Genc H AD - 2nd Department of Physical Medicine and Rehabilitation, Ministry of Health, Ankara Research and Education Hospital, Ankara, Turkey. hakangenc06@hotmail.com FAU - Duyur Cakit, Burcu AU - Duyur Cakit B FAU - Nacir, Baris AU - Nacir B FAU - Saracoglu, Meryem AU - Saracoglu M FAU - Kacar, Mahmut AU - Kacar M FAU - Erdem, Hatice Rana AU - Erdem HR LA - eng PT - Clinical Trial PT - Journal Article DEP - 20061104 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Antirheumatic Agents) RN - 3XC8GUZ6CB (Sulfasalazine) SB - IM MH - Adult MH - Antirheumatic Agents/*therapeutic use MH - Arthritis, Rheumatoid/complications/diagnosis/*drug therapy MH - Disability Evaluation MH - Female MH - Health Status MH - Humans MH - Male MH - Severity of Illness Index MH - Spondylitis, Ankylosing/complications/diagnosis/*drug therapy MH - Sulfasalazine/*therapeutic use MH - Tendinopathy/diagnostic imaging/*drug therapy/etiology MH - Tendons/diagnostic imaging/*pathology MH - Treatment Outcome MH - Ultrasonography EDAT- 2006/11/07 09:00 MHDA- 2007/08/19 09:00 CRDT- 2006/11/07 09:00 PHST- 2006/05/25 00:00 [received] PHST- 2006/09/28 00:00 [accepted] PHST- 2006/09/28 00:00 [revised] PHST- 2006/11/07 09:00 [pubmed] PHST- 2007/08/19 09:00 [medline] PHST- 2006/11/07 09:00 [entrez] AID - 10.1007/s10067-006-0460-6 [doi] PST - ppublish SO - Clin Rheumatol. 2007 Jul;26(7):1104-10. doi: 10.1007/s10067-006-0460-6. Epub 2006 Nov 4. PMID- 5300834 OWN - NLM STAT- MEDLINE DCOM- 19680703 LR - 20131121 IS - 0044-345X (Print) IS - 0044-345X (Linking) VI - 25 IP - 7 DP - 1966 Aug TI - [Clinical picture of tendomyosis]. PG - 226-36 FAU - Gross, D AU - Gross D LA - ger PT - Journal Article TT - Klinik der Tendomyosen. PL - Germany TA - Z Rheumaforsch JT - Zeitschrift fur Rheumaforschung JID - 0415612 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Analgesics) RN - X66NSO3N35 (Thiamine) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Analgesics/therapeutic use MH - Diagnosis, Differential MH - Fibromyalgia/*diagnosis MH - Humans MH - Periostitis/*diagnosis MH - Rheumatic Diseases/therapy MH - Tendinopathy/*diagnosis MH - Tendons MH - Thiamine/therapeutic use EDAT- 1966/08/01 00:00 MHDA- 1966/08/01 00:01 CRDT- 1966/08/01 00:00 PHST- 1966/08/01 00:00 [pubmed] PHST- 1966/08/01 00:01 [medline] PHST- 1966/08/01 00:00 [entrez] PST - ppublish SO - Z Rheumaforsch. 1966 Aug;25(7):226-36. PMID- 13236513 OWN - NLM STAT- MEDLINE DCOM- 20030501 LR - 20191107 IS - 0735-7435 (Print) IS - 0735-7435 (Linking) VI - 35 IP - 2 DP - 1955 Feb TI - Acetic acid ionization; a study of determine the absorptive effects upon calcified tendinitis of the shoulder. PG - 84-7 FAU - PSAKI, C G AU - PSAKI CG FAU - CARROLL, J AU - CARROLL J LA - eng PT - Journal Article PL - United States TA - Phys Ther Rev (1948) JT - The Physical therapy review JID - 19620720R RN - 0 (Acetates) RN - Q40Q9N063P (Acetic Acid) SB - OM MH - *Acetates MH - Acetic Acid/*therapeutic use MH - *Disease MH - Humans MH - *Muscles MH - *Muscular Diseases MH - *Shoulder MH - *Tendinopathy MH - *Tendons OID - CLML: 5527:48676:6:300:420 OTO - NLM OT - *ACETIC ACID/therapeutic use OT - *MUSCLES/diseases OT - *SHOULDER/muscles EDAT- 1955/02/01 00:00 MHDA- 1955/02/01 00:01 CRDT- 1955/02/01 00:00 PHST- 1955/02/01 00:00 [pubmed] PHST- 1955/02/01 00:01 [medline] PHST- 1955/02/01 00:00 [entrez] AID - 10.1093/ptj/35.2.84 [doi] PST - ppublish SO - Phys Ther Rev (1948). 1955 Feb;35(2):84-7. doi: 10.1093/ptj/35.2.84. PMID- 7943524 OWN - NLM STAT- MEDLINE DCOM- 19941110 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 22 IP - 4 DP - 1994 Jul-Aug TI - Biomechanical and histologic assessment of a controlled muscle strain injury treated with piroxicam. PG - 558-61 AB - This study was designed to observe the effect of the nonsteroidal antiinflammatory piroxicam on a controlled muscle strain injury in the rabbit model. The tibialis anterior tendons of 90 New Zealand White rabbits were detached at their distal insertions, and the right tendon was stretched to the yield point of the deformation curve. One group of 50 rabbits received piroxicam treatment and the others received no treatment. At 1, 2, 4, and 7 days the parameters of muscle function, tensile strength, and histology were examined. Muscle contractile force was significantly greater in the piroxicam-treated group at Day 1, but no difference was noted at any other time period. Tensile strength was not significantly different at any time period in either group. Histology revealed delayed degradation of damaged tissue and slowed regeneration of muscle tissue at the injury site in the piroxicam-treated group. Piroxicam and other anti-inflammatories are frequently given to athletes being treated for muscle strain injuries to control pain through their effect on the inflammatory process. This study demonstrates that piroxicam does not adversely influence the recovery of contractile and tensile strength in a followup period of 1 week. Therefore, antiinflammatory treatment may be beneficial early in the course of muscle injury. FAU - Obremsky, W T AU - Obremsky WT AD - Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710. FAU - Seaber, A V AU - Seaber AV FAU - Ribbeck, B M AU - Ribbeck BM FAU - Garrett, W E Jr AU - Garrett WE Jr LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 13T4O6VMAM (Piroxicam) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Hindlimb MH - Muscle Contraction/physiology MH - Piroxicam/*therapeutic use MH - Rabbits MH - Sprains and Strains/*drug therapy/pathology/physiopathology MH - Tendon Injuries/*drug therapy/pathology/physiopathology MH - Tensile Strength MH - Wound Healing EDAT- 1994/07/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1994/07/01 00:00 PHST- 1994/07/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1994/07/01 00:00 [entrez] AID - 10.1177/036354659402200420 [doi] PST - ppublish SO - Am J Sports Med. 1994 Jul-Aug;22(4):558-61. doi: 10.1177/036354659402200420. PMID- 23116933 OWN - NLM STAT- MEDLINE DCOM- 20130823 LR - 20161125 IS - 0736-4679 (Print) IS - 0736-4679 (Linking) VI - 44 IP - 2 DP - 2013 Feb TI - Acute calcific tendinitis of the wrist. PG - 352-4 LID - S0736-4679(12)01094-3 [pii] LID - 10.1016/j.jemermed.2012.08.028 [doi] AB - BACKGROUND: Acute calcific tendinitis, a benign and self-limiting inflammatory condition commonly seen in the shoulder, is also described in many other tendons, including those in the hand and wrist. When involving the wrist, acute calcific tendinitis is often misdiagnosed and mistaken for infection. OBJECTIVE: We present this case to increase familiarity with this condition to avoid errors in diagnosis resulting in inappropriate treatment with antibiotics or even surgery. CASE REPORT: A 27-year-old man presented to the Emergency Department with a 2-week history of volar wrist pain, with sudden increase in pain associated with chills and new onset swelling and redness of the wrist. Plain radiographs showed characteristic soft-tissue calcification overlying the insertion of the flexor carpi ulnaris tendon into the wrist. Treatment with ibuprofen and splinting resulted in complete symptom resolution. CONCLUSION: Acute calcific tendinitis is an important consideration in the differential diagnosis of acute wrist pain. Radiographs are helpful in confirming the diagnosis when symptoms and examination findings are characteristic. CI - Copyright © 2013 Elsevier Inc. All rights reserved. FAU - Torbati, Sam S AU - Torbati SS AD - Department of Emergency Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. FAU - Bral, Daniel AU - Bral D FAU - Geiderman, Joel M AU - Geiderman JM LA - eng PT - Case Reports PT - Journal Article DEP - 20121030 PL - United States TA - J Emerg Med JT - The Journal of emergency medicine JID - 8412174 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Acute Disease MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Arthralgia/etiology MH - Calcinosis/*diagnosis/physiopathology/therapy MH - Chills/etiology MH - Edema/etiology MH - Humans MH - Ibuprofen/therapeutic use MH - Lymphangitis/diagnosis/therapy MH - Male MH - Radiography MH - Splints MH - Tendinopathy/*diagnosis/physiopathology/therapy MH - Wrist Joint/diagnostic imaging/*physiopathology EDAT- 2012/11/03 06:00 MHDA- 2013/08/24 06:00 CRDT- 2012/11/03 06:00 PHST- 2012/02/15 00:00 [received] PHST- 2012/05/14 00:00 [revised] PHST- 2012/08/24 00:00 [accepted] PHST- 2012/11/03 06:00 [entrez] PHST- 2012/11/03 06:00 [pubmed] PHST- 2013/08/24 06:00 [medline] AID - S0736-4679(12)01094-3 [pii] AID - 10.1016/j.jemermed.2012.08.028 [doi] PST - ppublish SO - J Emerg Med. 2013 Feb;44(2):352-4. doi: 10.1016/j.jemermed.2012.08.028. Epub 2012 Oct 30. PMID- 32584721 OWN - NLM STAT- MEDLINE DCOM- 20201113 LR - 20201113 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 31 IP - 2 DP - 2020 TI - Does methylene blue reduce adhesion during the healing process after tendon repair? PG - 246-254 LID - ehc.2020.74405 [pii] LID - 10.5606/ehc.2020.74405 [doi] AB - OBJECTIVES: This study aims to biomechanically and histopathologically investigate the effects of methylene blue (MB) on preventing postoperative adhesion in chickens undergoing full- thickness flexor tendon incision. MATERIALS AND METHODS: This study was performed between June 2017 and June 2018 on Hubbard JA 57 type chickens (age, 6 months; weight, 2.2±0.3 kg). Sixty-four tendons were studied in 32 chickens, including 16 in the control group and 16 in the experimental group. The second and third finger flexor digitorum profundus tendons of the left foot of each chicken were repaired primarily after a full-thickness incision approximately 1 cm proximal to the distal adhesion area. In the control (n=32) and experimental groups (n=32), 0.25 mL of normal saline and 0.25 mL of 1% MB solutions were applied locally to the surgical site, respectively. The operated limb was immobilized using a circular cast. 16 chickens were randomly selected in each group and examined at the fourth week, and the remaining 16 chickens were examined at the sixth week. Thirty-two of these tendons were evaluated using the Tang histopathological adhesion classification system, and the other 32 were evaluated with a biomechanical pull system. RESULTS: Adhesion was found to be less in the experimental group compared to the control group at the end of the fourth and sixth weeks both histopathologically and biomechanically. Furthermore, adhesion was significantly less in the experimental group at the end of the sixth week compared to the fourth week both histopathologically and biomechanically. CONCLUSION: Histopathological and biomechanical results show that MB, which has anti-inflammatory, antiseptic, antimicrobial and antioxidant effects, reduces adhesion during the healing process after tendon repair. We think that local MB application, particularly in surgeries performed after this type of injury, will be beneficial on early rehabilitation and functional results. FAU - Boz, Mehmet AU - Boz M AD - Malatya Eğitim ve Araştırma Hastanesi Ortopedi ve Travmatoloji Kliniği, 44090 Yeşilyurt, Malatya, Türkiye. dr_memoz@hotmail.com. FAU - Çakıcı, Hüsamettin AU - Çakıcı H FAU - Pakdil, Murat AU - Pakdil M FAU - Şahin, Abdullah Alper AU - Şahin AA FAU - Erdoğan Düzcü, Selma AU - Erdoğan Düzcü S FAU - Bala, Mehmet Murat AU - Bala MM FAU - Çelik, Metin AU - Çelik M LA - eng PT - Journal Article DEP - 20200618 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - 0 (Enzyme Inhibitors) RN - T42P99266K (Methylene Blue) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Chickens MH - Enzyme Inhibitors/pharmacology MH - Methylene Blue/*pharmacology MH - Models, Anatomic MH - Orthopedic Procedures/*adverse effects MH - Tendon Injuries/*surgery MH - *Tendons/pathology/physiopathology/surgery MH - *Tissue Adhesions/etiology/prevention & control MH - Wound Healing/*drug effects PMC - PMC7489185 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2020/06/26 06:00 MHDA- 2020/11/18 06:00 PMCR- 2020/06/18 CRDT- 2020/06/26 06:00 PHST- 2020/03/03 00:00 [received] PHST- 2020/04/15 00:00 [accepted] PHST- 2020/06/26 06:00 [entrez] PHST- 2020/06/26 06:00 [pubmed] PHST- 2020/11/18 06:00 [medline] PHST- 2020/06/18 00:00 [pmc-release] AID - ehc.2020.74405 [pii] AID - 10.5606/ehc.2020.74405 [doi] PST - ppublish SO - Jt Dis Relat Surg. 2020;31(2):246-254. doi: 10.5606/ehc.2020.74405. Epub 2020 Jun 18. PMID- 15581769 OWN - NLM STAT- MEDLINE DCOM- 20050408 LR - 20220321 IS - 0968-0160 (Print) IS - 0968-0160 (Linking) VI - 11 IP - 6 DP - 2004 Dec TI - Total knee replacement in patients with multiple sclerosis. PG - 485-7 AB - Total knee replacement was performed on two patients with Multiple sclerosis. Severe hamstring spasticity was encountered in both patients in the immediate post-operative period requiring further surgery. Both patients remain ambulatory at follow-up. The disease, and its implications in patients warranting total joint replacement are discussed. FAU - Shannon, F J AU - Shannon FJ AD - Department of Orthopaedic Surgery, Tullamore Regional Hospital, Tullamore, County Offaly, Ireland. fjshannon@eircom.net FAU - Cogley, D AU - Cogley D FAU - Glynn, M AU - Glynn M LA - eng PT - Case Reports PT - Journal Article PL - Netherlands TA - Knee JT - The Knee JID - 9430798 RN - 0 (Muscle Relaxants, Central) RN - H789N3FKE8 (Baclofen) SB - IM MH - Aged MH - Arthroplasty, Replacement, Knee/*adverse effects/*methods MH - Baclofen/therapeutic use MH - Braces MH - Casts, Surgical MH - Humans MH - Immobilization MH - Knee Joint/physiopathology/surgery MH - Male MH - Multiple Sclerosis/*complications/physiopathology MH - Muscle Relaxants, Central/therapeutic use MH - Muscle Spasticity/*etiology/therapy MH - Osteoarthritis, Knee/complications/physiopathology/*surgery MH - Range of Motion, Articular/physiology MH - Tendons/surgery EDAT- 2004/12/08 09:00 MHDA- 2005/04/09 09:00 CRDT- 2004/12/08 09:00 PHST- 2003/06/01 00:00 [received] PHST- 2003/07/08 00:00 [revised] PHST- 2003/10/31 00:00 [accepted] PHST- 2004/12/08 09:00 [pubmed] PHST- 2005/04/09 09:00 [medline] PHST- 2004/12/08 09:00 [entrez] AID - S0968016003001741 [pii] AID - 10.1016/j.knee.2003.10.006 [doi] PST - ppublish SO - Knee. 2004 Dec;11(6):485-7. doi: 10.1016/j.knee.2003.10.006. PMID- 10386802 OWN - NLM STAT- MEDLINE DCOM- 19990805 LR - 20220210 IS - 0147-7447 (Print) IS - 0147-7447 (Linking) VI - 22 IP - 6 DP - 1999 Jun TI - Sterilization of contaminated bone-tendon autografts using 10% povidone-iodine solution. PG - 601-4 AB - This study evaluates methods of sterilizing contaminated bone-tendon autografts using 10% povidone-iodine solution. Sterile grafts were prepared from human cadavers. Grafts were immersed in a suspension of either Staphylococcus aureus or Pseudomonas aeruginosa, and three sets of sterilization experiments were performed in 10% povidone-iodine for 30 minutes: one each with S. aureus and P. aeruginosa by static soaking and a third with S. aureus by serial washing with agitation. Of grafts inoculated with S. aureus, six of six grew the test organism after soaking at room temperature, as did five of six after soaking at 36 degrees C and also eight of nine after washing with agitation. Of grafts inoculated with P. aeruginosa, five of six grew the test strain after soaking at room temperature, as did six of six after soaking at 36 degrees C. Thirty minutes of exposure to aqueous 10% povidone-iodine does not adequately sterilize an inoculated graft. FAU - Stanford, R AU - Stanford R AD - Department of Orthopedic Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia. FAU - Solomon, M AU - Solomon M FAU - Levick, M AU - Levick M FAU - Kohan, L AU - Kohan L FAU - Bell, S AU - Bell S LA - eng PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Anti-Infective Agents, Local) RN - 85H0HZU99M (Povidone-Iodine) SB - IM MH - Anti-Infective Agents, Local/*therapeutic use MH - *Bone Transplantation MH - Humans MH - Postoperative Complications/prevention & control MH - Povidone-Iodine/*therapeutic use MH - *Sterilization MH - Tendons/*transplantation MH - Transplantation, Autologous EDAT- 1999/07/01 00:00 MHDA- 1999/07/01 00:01 CRDT- 1999/07/01 00:00 PHST- 1999/07/01 00:00 [pubmed] PHST- 1999/07/01 00:01 [medline] PHST- 1999/07/01 00:00 [entrez] AID - 10.3928/0147-7447-19990601-10 [doi] PST - ppublish SO - Orthopedics. 1999 Jun;22(6):601-4. doi: 10.3928/0147-7447-19990601-10. PMID- 9243704 OWN - NLM STAT- MEDLINE DCOM- 19971118 LR - 20220318 IS - 0034-5288 (Print) IS - 0034-5288 (Linking) VI - 62 IP - 2 DP - 1997 Mar-Apr TI - Oxidative energy metabolism in equine tendon cells. PG - 93-7 AB - Hypoxia has been suggested as a possible cause of tissue degeneration and subsequent rupture in equine tendons. To determine whether low oxygen tension is likely to be detrimental to tendon cell function, experiments were designed to investigate oxidative energy metabolism in freshly isolated and cultured equine tendon cells. Freshly isolated tenocytes and cultured fibroblasts possessed activities of the mitochondrial enzyme citrate synthase similar to those of other mammalian cells, with well defined oxidative metabolism. D-[6(-14)C]-glucose oxidation was measurable in both freshly isolated and explant-derived cells. The content of adenosine triphosphate (ATP) in cultured cells was decreased by incubation with a mitochondrial respiratory uncoupler. These data demonstrate that tendon cells are capable of oxidative energy metabolism and rely upon it to maintain cellular ATP levels. Hypoxia must therefore be considered as a possible factor leading to tendon degeneration and subsequent injury. FAU - Birch, H L AU - Birch HL AD - Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield. FAU - Rutter, G A AU - Rutter GA FAU - Goodship, A E AU - Goodship AE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Res Vet Sci JT - Research in veterinary science JID - 0401300 RN - 0 (Carbon Radioisotopes) RN - 0 (Uncoupling Agents) RN - 0U46U6E8UK (NAD) RN - 370-86-5 (Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone) RN - 61D2G4IYVH (Adenosine Diphosphate) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - EC 2.3.3.1 (Citrate (si)-Synthase) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Adenosine Diphosphate/analysis/metabolism MH - Adenosine Triphosphate/analysis/metabolism MH - Animals MH - Carbon Radioisotopes MH - Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone/pharmacology MH - Cells, Cultured MH - Citrate (si)-Synthase/analysis/metabolism/physiology MH - Energy Metabolism/*physiology MH - Fibroblasts/enzymology MH - Glucose/metabolism MH - Glycolysis/physiology MH - Horse Diseases/metabolism/physiopathology MH - Horses/*metabolism/physiology MH - Hypoxia/metabolism/physiopathology/veterinary MH - L-Lactate Dehydrogenase/analysis/metabolism/physiology MH - NAD/metabolism MH - Oxidation-Reduction MH - Oxygen Consumption/physiology MH - Tendons/*cytology/enzymology/*metabolism MH - Time Factors MH - Uncoupling Agents/pharmacology EDAT- 1997/03/01 00:00 MHDA- 1997/03/01 00:01 CRDT- 1997/03/01 00:00 PHST- 1997/03/01 00:00 [pubmed] PHST- 1997/03/01 00:01 [medline] PHST- 1997/03/01 00:00 [entrez] AID - S0034-5288(97)90127-2 [pii] AID - 10.1016/s0034-5288(97)90127-2 [doi] PST - ppublish SO - Res Vet Sci. 1997 Mar-Apr;62(2):93-7. doi: 10.1016/s0034-5288(97)90127-2. PMID- 21622815 OWN - NLM STAT- MEDLINE DCOM- 20120117 LR - 20140730 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 39 IP - 9 DP - 2011 Sep TI - Tibial fixation in anterior cruciate ligament reconstruction: a prospective randomized study comparing metal interference screw and staples with a centrally placed polyethylene screw and sheath. PG - 1858-64 LID - 10.1177/0363546511406234 [doi] AB - BACKGROUND: The use of hamstring tendons for anterior cruciate ligament reconstruction has increased in popularity over recent years. However, concerns with the stability of graft fixation on the tibial side remain. Centrally placed interference screw/sheath implants have demonstrated promising results in biomechanical studies. HYPOTHESIS: Centrally placed, polyethylene screw and sheath implants will provide clinically equivalent fixation to the standard metal interference screw and supplemental staple fixation. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: A total of 113 consecutive patients undergoing isolated, unilateral, primary anterior cruciate ligament reconstruction with hamstring autografts were randomized to tibial fixation with metal interference screw and staples (RCI) or with a centrally placed polyethylene screw and sheath implant (INTRAFIX). Prospective assessment of subjective outcomes was performed using Lysholm, Mohtadi, and International Knee Documentation Committee (IKDC) scores. RESULTS: At minimum 2-year follow-up, there were no significant differences between the 2 groups in terms of instrumented stability testing (KT-1000 arthrometer) or subjective assessment of knee outcomes (IKDC, Lysholm, Mohtadi). Both fixation methods demonstrated a significant, but not different, increase in outcomes scores from preoperative to postoperative evaluation. There were 7 failures (5 INTRAFIX, 2 RCI) caused by reinjury, but no statistically significant differences were observed between the 2 fixation methods. CONCLUSION: The centrally placed polyethylene screw and sheath provided equivalent clinical outcomes at minimum 2-year follow-up to standard tibial fixation with metal interference screw and staples. FAU - De Wall, Mathew AU - De Wall M AD - Sydney Orthopaedic Research Institute, Chatswood NSW, Australia. FAU - Scholes, Corey J AU - Scholes CJ FAU - Patel, Sandeep AU - Patel S FAU - Coolican, Myles R J AU - Coolican MR FAU - Parker, David A AU - Parker DA LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20110527 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Metals) RN - 9002-88-4 (Polyethylene) SB - IM MH - Adult MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Reconstruction/instrumentation/*methods MH - *Bone Screws MH - Female MH - Humans MH - *Internal Fixators MH - Joint Instability/surgery MH - Male MH - Metals/therapeutic use MH - Middle Aged MH - Polyethylene/therapeutic use MH - *Sutures MH - Tendons/transplantation MH - Tibia/*surgery MH - Treatment Outcome MH - Young Adult EDAT- 2011/05/31 06:00 MHDA- 2012/01/18 06:00 CRDT- 2011/05/31 06:00 PHST- 2011/05/31 06:00 [entrez] PHST- 2011/05/31 06:00 [pubmed] PHST- 2012/01/18 06:00 [medline] AID - 0363546511406234 [pii] AID - 10.1177/0363546511406234 [doi] PST - ppublish SO - Am J Sports Med. 2011 Sep;39(9):1858-64. doi: 10.1177/0363546511406234. Epub 2011 May 27. PMID- 26596578 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20250529 IS - 1573-2665 (Electronic) IS - 0141-8955 (Linking) VI - 39 IP - 2 DP - 2016 Mar TI - Acute fatal metabolic complications in alkaptonuria. PG - 203-10 LID - 10.1007/s10545-015-9902-0 [doi] AB - Alkaptonuria (AKU) is a rare inherited metabolic disorder of tyrosine metabolism that results from a defect in an enzyme called homogentisate 1,2-dioxygenase. The result of this is that homogentisic acid (HGA) accumulates in the body. HGA is central to the pathophysiology of this disease and the consequences observed; these include spondyloarthropathy, rupture of ligaments/muscle/tendons, valvular heart disease including aortic stenosis and renal stones. While AKU is considered to be a chronic progressive disorder, it is clear from published case reports that fatal acute metabolic complications can also occur. These include oxidative haemolysis and methaemoglobinaemia. The exact mechanisms underlying the latter are not clear, but it is proposed that disordered metabolism within the red blood cell is responsible for favouring a pro-oxidant environment that leads to the life threatening complications observed. Herein the role of red blood cell in maintaining the redox state of the body is reviewed in the context of AKU. In addition previously reported therapeutic strategies are discussed, specifically with respect to why reported treatments had little therapeutic effect. The potential use of nitisinone for the management of patients suffering from the acute metabolic decompensation in AKU is proposed as an alternative strategy. FAU - Davison, A S AU - Davison AS AD - Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospitals Trust, Liverpool, L7 8XP, UK. andrew.davison@rlbuht.nhs.uk. AD - Bone and Joint Research Group, Musculoskeletal Biology, University of Liverpool, Liverpool, L69 3GA, UK. andrew.davison@rlbuht.nhs.uk. FAU - Milan, A M AU - Milan AM AD - Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospitals Trust, Liverpool, L7 8XP, UK. AD - Bone and Joint Research Group, Musculoskeletal Biology, University of Liverpool, Liverpool, L69 3GA, UK. FAU - Gallagher, J A AU - Gallagher JA AD - Bone and Joint Research Group, Musculoskeletal Biology, University of Liverpool, Liverpool, L69 3GA, UK. FAU - Ranganath, L R AU - Ranganath LR AD - Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Royal Liverpool University Hospitals Trust, Liverpool, L7 8XP, UK. AD - Bone and Joint Research Group, Musculoskeletal Biology, University of Liverpool, Liverpool, L69 3GA, UK. LA - eng GR - HCS DRF-2014-05-009/DH_/Department of Health/United Kingdom PT - Journal Article PT - Review DEP - 20151123 PL - United States TA - J Inherit Metab Dis JT - Journal of inherited metabolic disease JID - 7910918 RN - 0 (Cyclohexanones) RN - 0 (Nitrobenzoates) RN - EC 1.13.11.5 (Homogentisate 1,2-Dioxygenase) RN - K5BN214699 (nitisinone) RN - NP8UE6VF08 (Homogentisic Acid) SB - IM MH - Acute Disease MH - Alkaptonuria/*complications/*metabolism MH - Cyclohexanones/therapeutic use MH - Erythrocytes/drug effects/metabolism MH - Homogentisate 1,2-Dioxygenase/metabolism MH - Homogentisic Acid/metabolism MH - Humans MH - Metabolic Diseases/drug therapy/*etiology/*metabolism MH - Nitrobenzoates/therapeutic use MH - Oxidation-Reduction/drug effects EDAT- 2015/11/26 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/11/25 06:00 PHST- 2015/07/24 00:00 [received] PHST- 2015/11/09 00:00 [accepted] PHST- 2015/11/02 00:00 [revised] PHST- 2015/11/25 06:00 [entrez] PHST- 2015/11/26 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.1007/s10545-015-9902-0 [pii] AID - 10.1007/s10545-015-9902-0 [doi] PST - ppublish SO - J Inherit Metab Dis. 2016 Mar;39(2):203-10. doi: 10.1007/s10545-015-9902-0. Epub 2015 Nov 23. PMID- 12791069 OWN - NLM STAT- MEDLINE DCOM- 20030815 LR - 20211203 IS - 1398-2273 (Print) IS - 1398-2273 (Linking) VI - 5 IP - 1 DP - 2003 Mar TI - Mycobacterial infection after renal transplantation in a Western population. PG - 9-15 AB - Mycobacterial infection is a serious opportunistic infection in renal transplant recipients. The incidence is higher in developing than in developed Western countries. This study is a single-centre retrospective review of the records of 2502 renal transplant recipients in Belgium. Fourteen cases of mycobacterial infection (9 Mycobacterium tuberculosis and 5 atypical mycobacterial infection) were diagnosed. The time interval between transplantation and diagnosis was 64 +/- 80 months (mean +/- SD, range 5-188) for M. tuberculosis and 92 +/- 75 months (range 14-209) for atypical mycobacterial infection. The localisation of M. tuberculosis was pulmonary/pleural in 67% and extrapulmonary in 33%. The atypical mycobacterial infections were located in skin, tendons, and joints. Eight patients received IV prednisolone pulse therapy for acute rejection long before the time of mycobacterial infection. The initial antimycobacterial therapy consisted of a combination of isoniazid, rifampicin, and ethambutol in all patients. In patients with M. tuberculosis infection, a good response to antimycobacterial therapy was obtained. In patients with atypical mycobacterial infection, initial treatment was successful in 3 out of 5 patients, in 1 patient recurrence was diagnosed and in another patient, who is still under treatment at present, the initial treatment was adjusted after identification of the atypical mycobacterium and its antibiogram. The incidence of mycobacterial infection after renal transplantation did not increase with newer immunosuppressive therapy. The major risk factor is the total dose of corticosteroids. All patients responded well without major reductions in immunosuppressive therapy. Chemoprophylaxis for high-risk patients still is recommended. FAU - Vandermarliere, A AU - Vandermarliere A AD - Department of Nephrology, University Hospital, Gasthuisberg, B-3000 Leuven, Belgium. FAU - Van Audenhove, A AU - Van Audenhove A FAU - Peetermans, W E AU - Peetermans WE FAU - Vanrenterghem, Y AU - Vanrenterghem Y FAU - Maes, B AU - Maes B LA - eng PT - Journal Article PL - Denmark TA - Transpl Infect Dis JT - Transplant infectious disease : an official journal of the Transplantation Society JID - 100883688 RN - V83O1VOZ8L (Isoniazid) RN - VJT6J7R4TR (Rifampin) SB - IM MH - Adult MH - Aged MH - Belgium MH - Female MH - Humans MH - Immunosuppression Therapy MH - Isoniazid/therapeutic use MH - Kidney Transplantation/*adverse effects MH - Male MH - Middle Aged MH - Mycobacterium Infections/classification/diagnosis/*etiology/therapy MH - Mycobacterium tuberculosis/isolation & purification MH - Opportunistic Infections/diagnosis/*etiology/therapy MH - Retrospective Studies MH - Rifampin/therapeutic use MH - Treatment Outcome EDAT- 2003/06/07 05:00 MHDA- 2003/08/16 05:00 CRDT- 2003/06/07 05:00 PHST- 2003/06/07 05:00 [pubmed] PHST- 2003/08/16 05:00 [medline] PHST- 2003/06/07 05:00 [entrez] AID - 0010 [pii] AID - 10.1034/j.1399-3062.2003.00010.x [doi] PST - ppublish SO - Transpl Infect Dis. 2003 Mar;5(1):9-15. doi: 10.1034/j.1399-3062.2003.00010.x. PMID- 8539985 OWN - NLM STAT- MEDLINE DCOM- 19960208 LR - 20171116 IS - 0041-1345 (Print) IS - 0041-1345 (Linking) VI - 27 IP - 6 DP - 1995 Dec TI - In vitro advanced glycation end product formation in rat tail tendon fibers: influence of aminoguanidine. PG - 3345-6 FAU - Troncoso, I A AU - Troncoso IA AD - Functional Biology Department, University of Oviedo, Spain. FAU - Esteban, M M AU - Esteban MM FAU - Ruiz, M A AU - Ruiz MA FAU - Flórez, L AU - Flórez L FAU - Barneo, L AU - Barneo L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 RN - 0 (Glycation End Products, Advanced) RN - 0 (Guanidines) RN - 9007-34-5 (Collagen) RN - IY9XDZ35W2 (Glucose) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Animals MH - Collagen/metabolism MH - Diabetes Mellitus, Experimental/drug therapy/metabolism/surgery MH - Glucose/metabolism MH - Glycation End Products, Advanced/*biosynthesis MH - Guanidines/*pharmacology MH - In Vitro Techniques MH - Male MH - Pancreas Transplantation MH - Rats MH - Rats, Inbred Lew MH - Spectrometry, Fluorescence MH - Tendons/drug effects/metabolism EDAT- 1995/12/01 00:00 MHDA- 1995/12/01 00:01 CRDT- 1995/12/01 00:00 PHST- 1995/12/01 00:00 [pubmed] PHST- 1995/12/01 00:01 [medline] PHST- 1995/12/01 00:00 [entrez] PST - ppublish SO - Transplant Proc. 1995 Dec;27(6):3345-6. PMID- 40186777 OWN - NLM STAT- MEDLINE DCOM- 20250405 LR - 20251231 IS - 1434-3916 (Electronic) IS - 0936-8051 (Print) IS - 0936-8051 (Linking) VI - 145 IP - 1 DP - 2025 Apr 5 TI - N-chlorotaurine does not alter structural tendon properties: a comparative biomechanical study. PG - 223 LID - 10.1007/s00402-025-05851-7 [doi] LID - 223 AB - INTRODUCTION: N-chlorotaurine (NCT) is a well-tolerated antiseptic with broad-spectrum microbicidal activity and could therefore be a promising alternative to vancomycin, the current standard of care for the prevention of postoperative septic arthritis (PSA) after anterior cruciate ligament reconstruction (ACLR). MATERIALS AND METHODS: The aim of this study was to evaluate whether soaking bovine extensor tendons in N-chlorotaurine (NCT), vancomycin, or 0.9% saline influences structural tendon properties. In this controlled biomechanical study, fifty bovine extensor tendons were randomized into groups and soaked for 10 min in distilled water solutions containing either 1% vancomycin, 1% NCT, 5% NCT, 5% NCT with 0.1% ammonium chloride, or 0.9% saline. Tendons were then mounted in cryo-clamps and subjected to uniaxial tensile testing until failure. Failure mode, ultimate load, ultimate elongation, and stiffness of the linear region from the load-elongation curve were extracted and compared for each graft. RESULTS: No statistically significant differences were detected across all measured parameters (p > 0.05) and solutions. The mean ultimate load, ultimate elongation, stiffness and elastic modulus were not statistically significantly different between all five tested solutions. CONCLUSIONS: Both NCT and vancomycin even at high concentrations do not impair structural tendon properties compared to 0.9% saline. NCT appears to be safe for clinical use from a biomechanical perspective. CI - © 2025. The Author(s). FAU - Runer, Armin AU - Runer A AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. armin.runer@tum.de. AD - Technical University of Munich, Dept of Sports Orthopedics, Munich, Germany. armin.runer@tum.de. FAU - Schneider, Friedemann AU - Schneider F AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. friedemann.schneider@i-med.ac.at. FAU - Wawer, Karl AU - Wawer K AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. FAU - Gruber, Kerstin AU - Gruber K AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. FAU - Arora, Rohit AU - Arora R AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. FAU - Nagl, Markus AU - Nagl M AD - Medical University of Innsbruck, Institute of Hygiene and Medical Microbiology, Innsbruck, Austria. FAU - Schmoelz, Werner AU - Schmoelz W AD - Medical University of Innsbruck, Dept. of Orthopedics and Trauma Surgery, Innsbruck, Austria. werner.schmoelz@i-med.ac.at. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250405 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 1EQV5MLY3D (Taurine) RN - 51036-13-6 (N-chlorotaurine) RN - 6Q205EH1VU (Vancomycin) RN - 0 (Anti-Infective Agents, Local) SB - IM MH - *Tendons/drug effects/physiology MH - Animals MH - Cattle MH - *Taurine/analogs & derivatives/pharmacology MH - Biomechanical Phenomena/drug effects MH - Vancomycin/pharmacology MH - Tensile Strength/drug effects MH - *Anti-Infective Agents, Local/pharmacology PMC - PMC11972176 OTO - NOTNLM OT - ACLR OT - Anterior cruciate ligament reconstructions OT - N-chlorotaurine OT - Septic arthritis OT - Vancomycin COIS- Declarations. Ethical approval: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/04/05 16:33 MHDA- 2025/04/05 16:34 PMCR- 2025/04/05 CRDT- 2025/04/05 11:13 PHST- 2025/01/28 00:00 [received] PHST- 2025/03/25 00:00 [accepted] PHST- 2025/04/05 16:34 [medline] PHST- 2025/04/05 16:33 [pubmed] PHST- 2025/04/05 11:13 [entrez] PHST- 2025/04/05 00:00 [pmc-release] AID - 10.1007/s00402-025-05851-7 [pii] AID - 5851 [pii] AID - 10.1007/s00402-025-05851-7 [doi] PST - epublish SO - Arch Orthop Trauma Surg. 2025 Apr 5;145(1):223. doi: 10.1007/s00402-025-05851-7. PMID- 4998759 OWN - NLM STAT- MEDLINE DCOM- 19711109 LR - 20131121 IS - 0065-9479 (Print) IS - 0065-9479 (Linking) VI - 95 DP - 1970 TI - Stiff muscles and bony tendons. PG - 169-72 FAU - Trojaborg, W AU - Trojaborg W FAU - Rowland, L P AU - Rowland LP FAU - Katz, R I AU - Katz RI FAU - Wheaton, E A AU - Wheaton EA LA - eng PT - Journal Article PL - United States TA - Trans Am Neurol Assoc JT - Transactions of the American Neurological Association JID - 7506105 RN - 4Z8Y51M438 (Procaine) RN - 63-84-3 (Dihydroxyphenylalanine) RN - 98PI200987 (Lidocaine) RN - GWH6IJ239E (Amobarbital) RN - Q3JTX2Q7TU (Diazepam) SB - IM MH - Adult MH - Affective Symptoms/complications MH - Amobarbital/therapeutic use MH - Diazepam/therapeutic use MH - Dihydroxyphenylalanine/therapeutic use MH - Electromyography MH - Female MH - Fibromyalgia/complications/*diagnosis/drug therapy MH - Humans MH - Lidocaine/therapeutic use MH - *Ossification, Heterotopic MH - Procaine/therapeutic use EDAT- 1970/01/01 00:00 MHDA- 1970/01/01 00:01 CRDT- 1970/01/01 00:00 PHST- 1970/01/01 00:00 [pubmed] PHST- 1970/01/01 00:01 [medline] PHST- 1970/01/01 00:00 [entrez] PST - ppublish SO - Trans Am Neurol Assoc. 1970;95:169-72. PMID- 23720048 OWN - NLM STAT- MEDLINE DCOM- 20130820 LR - 20220408 IS - 1477-9129 (Electronic) IS - 0950-1991 (Linking) VI - 140 IP - 13 DP - 2013 Jul TI - Tendon-bone attachment unit is formed modularly by a distinct pool of Scx- and Sox9-positive progenitors. PG - 2680-90 LID - 10.1242/dev.093906 [doi] AB - The assembly of the musculoskeletal system requires the formation of an attachment unit between a bone and a tendon. Tendons are often inserted into bone eminences, superstructures that improve the mechanical resilience of the attachment of muscles to the skeleton and facilitate movement. Despite their functional importance, little is known about the development of bone eminences and attachment units. Here, we show that bone eminence cells are descendants of a unique set of progenitors and that superstructures are added onto the developing long bone in a modular fashion. First, we show that bone eminences emerge only after the primary cartilage rudiments have formed. Cell lineage analyses revealed that eminence cells are not descendants of chondrocytes. Moreover, eminence progenitors were specified separately and after chondroprogenitors of the primary cartilage. Fields of Sox9-positive, Scx-positive, Col2a1-negative cells identified at presumable eminence sites confirm the identity and specificity of these progenitors. The loss of eminences in limbs in which Sox9 expression was blocked in Scx-positive cells supports the hypothesis that a distinct pool of Sox9- and Scx-positive progenitors forms these superstructures. We demonstrate that TGFβ signaling is necessary for the specification of bone eminence progenitors, whereas the SCX/BMP4 pathway is required for the differentiation of these progenitors to eminence-forming cells. Our findings suggest a modular model for bone development, involving a distinct pool of Sox9- and Scx-positive progenitor cells that form bone eminences under regulation of TGFβ and BMP4 signaling. This model offers a new perspective on bone morphogenesis and on attachment unit development during musculoskeletal assembly. FAU - Blitz, Einat AU - Blitz E AD - Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel. FAU - Sharir, Amnon AU - Sharir A FAU - Akiyama, Haruhiko AU - Akiyama H FAU - Zelzer, Elazar AU - Zelzer E LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130529 PL - England TA - Development JT - Development (Cambridge, England) JID - 8701744 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Bone Morphogenetic Protein 4) RN - 0 (SOX9 Transcription Factor) RN - 0 (Scx protein, mouse) RN - 0 (Sox9 protein, mouse) RN - 0 (Transforming Growth Factor beta) RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Animals MH - Basic Helix-Loop-Helix Transcription Factors/genetics/*metabolism MH - Bone Morphogenetic Protein 4/genetics/metabolism MH - Bone and Bones/*cytology/metabolism MH - Cartilage/cytology MH - Cell Differentiation/drug effects/physiology MH - Cells, Cultured MH - Chondrocytes/cytology MH - Female MH - Gene Expression Regulation, Developmental MH - In Situ Hybridization MH - Mice MH - Mice, Knockout MH - Microscopy, Fluorescence MH - SOX9 Transcription Factor/genetics/*metabolism MH - Stem Cells/*cytology/metabolism MH - Tamoxifen/pharmacology MH - Tendons/*cytology/metabolism MH - Transforming Growth Factor beta/metabolism MH - X-Ray Microtomography OTO - NOTNLM OT - Attachment unit OT - BMP4 OT - Cartilage OT - Modularity OT - Mouse OT - Musculoskeletal system OT - Patterning OT - Progenitors OT - SCX OT - SOX9 OT - Skeleton OT - Specification OT - TGFβ OT - Tendons EDAT- 2013/05/31 06:00 MHDA- 2013/08/21 06:00 CRDT- 2013/05/31 06:00 PHST- 2013/05/31 06:00 [entrez] PHST- 2013/05/31 06:00 [pubmed] PHST- 2013/08/21 06:00 [medline] AID - dev.093906 [pii] AID - 10.1242/dev.093906 [doi] PST - ppublish SO - Development. 2013 Jul;140(13):2680-90. doi: 10.1242/dev.093906. Epub 2013 May 29. PMID- 22615126 OWN - NLM STAT- MEDLINE DCOM- 20130107 LR - 20211203 IS - 1097-4644 (Electronic) IS - 0730-2312 (Linking) VI - 113 IP - 10 DP - 2012 Oct TI - Uniaxial mechanical tension promoted osteogenic differentiation of rat tendon-derived stem cells (rTDSCs) via the Wnt5a-RhoA pathway. PG - 3133-42 LID - 10.1002/jcb.24190 [doi] AB - Chronic tendinopathy is a tendon disorder that is common in athletes and individuals whose tendons are subjected to repetitive strain injuries. The presence of ossification worsened the clinical manifestation of the disorder. The change of tendon loading due to mechanical overload, compression, or disuse have been implicated as the possible etiologies, but the pathological mechanisms of tendinopathy remain unclear. In this study, we demonstrated that ossification in tendon tissue might be due to the osteogenesis of tendon-derived stem cells (TDSCs) induced by uniaxial mechanical tension (UMT) which mimics the mechanical loading in tendon. Rat TDSCs (rTDSCs) could be induced to differentiate into osteogenic lineage after treatment with 2% elongation UMT for 3 days as shown by the increased expression Runx2 mRNA and protein, Alpl mRNA, collagen type 1 alpha 1 (Col1a1) mRNA, ALP activity, and ALP cytochemical staining. RhoA, an osteogenesis regulator, was activated in rTDSCs upon UMT stimulation. Blockage of RhoA activity in rTDSCs by C3 toxin or ROCK activity, a downstream target of RhoA, by Y-27632 inhibited UMT-induced osteogenesis in rTDSCs. UMT up-regulated the mRNA expression of Wnt5a but not the other non-canonical Wnts. The inhibition of Wnt5a expression by siRNA abolished UMT-induced Runx2 mRNA expression and RhoA activation in rTDSCs and the inhibition of Runx2 expression could be rescued by addition of LPA, a RhoA activator. In conclusion, our results showed that UMT induced osteogenic differentiation of rTDSCs via the Wnt5a-RhoA pathway, which might contribute to ectopic ossification in tendon tissue due to mechanical loading. CI - Copyright © 2012 Wiley Periodicals, Inc. FAU - Shi, Yu AU - Shi Y AD - The Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China. FAU - Fu, Yujie AU - Fu Y FAU - Tong, Wenxue AU - Tong W FAU - Geng, Yiyun AU - Geng Y FAU - Lui, Pauline Po Yee AU - Lui PP FAU - Tang, Tingting AU - Tang T FAU - Zhang, Xiaoling AU - Zhang X FAU - Dai, Kerong AU - Dai K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Biochem JT - Journal of cellular biochemistry JID - 8205768 RN - 0 (Amides) RN - 0 (Col1a1 protein, rat) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (Lysophospholipids) RN - 0 (Pyridines) RN - 0 (RNA, Messenger) RN - 0 (Runx2 protein, rat) RN - 0 (Wnt Proteins) RN - 0 (Wnt-5a Protein) RN - 0 (Wnt5a protein, rat) RN - 138381-45-0 (Y 27632) RN - EC 3.1.3.1 (Alkaline Phosphatase) RN - EC 3.6.5.2 (rhoA GTP-Binding Protein) RN - PG6M3969SG (lysophosphatidic acid) SB - IM MH - Alkaline Phosphatase/genetics/metabolism MH - Amides/pharmacology MH - Animals MH - Biomechanical Phenomena MH - *Cell Differentiation MH - Cell Lineage MH - Cells, Cultured MH - Collagen Type I/genetics/metabolism MH - Collagen Type I, alpha 1 Chain MH - Core Binding Factor Alpha 1 Subunit/genetics/metabolism MH - Lysophospholipids/pharmacology MH - Male MH - Ossification, Heterotopic/metabolism/*pathology MH - *Osteogenesis MH - Pyridines/pharmacology MH - RNA, Messenger/genetics/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Staining and Labeling/methods MH - Stem Cells/drug effects/metabolism/*pathology MH - *Stress, Mechanical MH - Tendinopathy/metabolism/pathology MH - Tendons/cytology/drug effects/metabolism/pathology MH - Wnt Proteins/metabolism MH - *Wnt Signaling Pathway MH - Wnt-5a Protein MH - rhoA GTP-Binding Protein/genetics/metabolism EDAT- 2012/05/23 06:00 MHDA- 2013/01/08 06:00 CRDT- 2012/05/23 06:00 PHST- 2012/05/23 06:00 [entrez] PHST- 2012/05/23 06:00 [pubmed] PHST- 2013/01/08 06:00 [medline] AID - 10.1002/jcb.24190 [doi] PST - ppublish SO - J Cell Biochem. 2012 Oct;113(10):3133-42. doi: 10.1002/jcb.24190. PMID- 40550378 OWN - NLM STAT- MEDLINE DCOM- 20250826 LR - 20250826 IS - 1095-564X (Electronic) IS - 0012-1606 (Linking) VI - 526 DP - 2025 Oct TI - Gene dosage-dependent roles of Mkx in postnatal tendon development and maintenance revealed by conditional deletion. PG - 15-25 LID - S0012-1606(25)00181-2 [pii] LID - 10.1016/j.ydbio.2025.06.022 [doi] AB - The transcription factor Mohawk (Mkx) contributes to tendon development and differentiation, as demonstrated by conventional knockout studies. However, the temporal requirements and gene dosage effects of Mkx in postnatal tendon maturation and maintenance remain unclear. To address these questions, we generated a novel conditional knockout mouse model harboring a loxP-flanked allele and a Venus-CreERT2 knock-in allele at the Mkx locus by crossing Mkx(Venus-CreERT2/+) with Mkx(flox/+) lines. Tamoxifen was administered at two distinct stages: early postnatal (P3) and adult (6-week-old). Mkx(Venus-CreERT2/+) mice exhibited mild reductions in tendon thickness and alterations in collagen fibril organization, while conditional deletion of Mkx (Mkx(Venus-CreERT2/flox) with tamoxifen induction) resulted in more pronounced defects. Time-course analysis revealed that both early postnatal and adult Mkx deletion led to progressive changes in tendon morphology, with TEM analysis showing a tendency toward reduced collagen fibril diameters. RNA-seq revealed distinct transcriptional changes associated with ECM organization and tendon homeostasis in Mkx-deficient tendons. These findings reveal previously unrecognized gene dosage effects of Mkx and suggest that maintaining appropriate levels of Mkx may be critical for tendon homeostasis, providing new insights into tendon biology and potential therapeutic strategies for tendon-related pathologies. CI - Copyright © 2025 Elsevier Inc. All rights reserved. FAU - Liu, Lin AU - Liu L AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Chiba, Tomoki AU - Chiba T AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Matsushima, Takahide AU - Matsushima T AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Inotsume, Maiko AU - Inotsume M AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Kato, Tomomi AU - Kato T AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. FAU - Hiraoka, Yuichi AU - Hiraoka Y AD - Department of Molecular Neuroscience, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Tokyo, Japan; Laboratory of Genome Editing for Biomedical Research, Medical Research Institute, Institute of Science Tokyo, Tokyo, Japan. FAU - Asahara, Hiroshi AU - Asahara H AD - Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan; Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, USA. Electronic address: asahara.syst@tmd.ac.jp. LA - eng PT - Journal Article DEP - 20250621 PL - United States TA - Dev Biol JT - Developmental biology JID - 0372762 RN - 0 (mohawk protein, mouse) RN - 094ZI81Y45 (Tamoxifen) RN - 9007-34-5 (Collagen) RN - 0 (Homeodomain Proteins) SB - IM MH - Animals MH - *Tendons/growth & development/metabolism MH - Mice MH - Mice, Knockout MH - *Gene Dosage MH - Tamoxifen/pharmacology MH - Gene Deletion MH - Gene Expression Regulation, Developmental MH - Extracellular Matrix/metabolism MH - Collagen/metabolism MH - Homeodomain Proteins OTO - NOTNLM OT - Conditional knockout mouse OT - Gene dosage effects OT - Haploinsufficiency OT - Mohawk (mkx) OT - Tendon development OT - Tendon homeostasis COIS- Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/06/24 11:08 MHDA- 2025/09/08 08:02 CRDT- 2025/06/23 19:12 PHST- 2025/01/15 00:00 [received] PHST- 2025/06/20 00:00 [revised] PHST- 2025/06/20 00:00 [accepted] PHST- 2025/09/08 08:02 [medline] PHST- 2025/06/24 11:08 [pubmed] PHST- 2025/06/23 19:12 [entrez] AID - S0012-1606(25)00181-2 [pii] AID - 10.1016/j.ydbio.2025.06.022 [doi] PST - ppublish SO - Dev Biol. 2025 Oct;526:15-25. doi: 10.1016/j.ydbio.2025.06.022. Epub 2025 Jun 21. PMID- 11386772 OWN - NLM STAT- MEDLINE DCOM- 20010809 LR - 20131121 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 26 IP - 3 DP - 2001 Jun TI - Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. PG - 224-8 AB - The purpose of this study was to investigate the effects of some commonly used non-steroidal anti-inflammatory drugs (NSAIDs) on human tendon. Explants of human digital flexor and patella tendons were cultured in medium containing pharmacological concentrations of NSAIDs. Cell proliferation was measured by incorporation of 3H-thymidine and glycosaminoglycan synthesis was measured by incorporation of 35S-Sulphate. Diclofenac and aceclofenac had no significant effect either on tendon cell proliferation or glycosaminoglycan synthesis. Indomethacin and naproxen inhibited cell proliferation in patella tendons and inhibited glycosaminoglycan synthesis in both digital flexor and patella tendons. If applicable to the in vivo situation, these NSAIDs should be used with caution in the treatment of pain after tendon injury and surgery. CI - Copyright 2001 The British Society for Surgery of the Hand. FAU - Riley, G P AU - Riley GP AD - Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK FAU - Cox, M AU - Cox M FAU - Harrall, R L AU - Harrall RL FAU - Clements, S AU - Clements S FAU - Hazleman, B L AU - Hazleman BL LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Glycosaminoglycans) RN - 0 (glucosaminoglycans) RN - 144O8QL0L1 (Diclofenac) RN - 57Y76R9ATQ (Naproxen) RN - RPK779R03H (aceclofenac) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Cell Division/*drug effects MH - Culture Techniques MH - Diclofenac/analogs & derivatives/pharmacology MH - Female MH - Glycosaminoglycans/*biosynthesis MH - Humans MH - Indomethacin/pharmacology MH - Male MH - Middle Aged MH - Naproxen/pharmacology MH - Tendons/*cytology MH - Wound Healing/drug effects EDAT- 2001/06/02 10:00 MHDA- 2001/08/10 10:01 CRDT- 2001/06/02 10:00 PHST- 2001/06/02 10:00 [pubmed] PHST- 2001/08/10 10:01 [medline] PHST- 2001/06/02 10:00 [entrez] AID - S0266-7681(01)90560-1 [pii] AID - 10.1054/jhsb.2001.0560 [doi] PST - ppublish SO - J Hand Surg Br. 2001 Jun;26(3):224-8. doi: 10.1054/jhsb.2001.0560. PMID- 1541376 OWN - NLM STAT- MEDLINE DCOM- 19920403 LR - 20190816 IS - 0012-186X (Print) IS - 0012-186X (Linking) VI - 35 IP - 1 DP - 1992 Jan TI - Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. PG - 19-25 AB - Alterations in the biophysical properties of connective tissues in diabetes mellitus have been attributed to the nonenzymatic glycation of the collagens and the subsequent formation of browning products, cross-linking the proteins. Aminoguanidine may bind to carbonyl groups of these nonenzymatic glycation products and thereby block the process. Rats with streptozotocin-induced diabetes were treated with aminoguanidine, 25 mg.kg-1.day-1, for 120 days. The aminoguanidine treatment did not counteract the increase in blood glucose concentrations, nor did it prevent the arrest in weight gain of diabetic rats. The increased stability in 7 mol/l urea and increased tensile strength of tail tendons from the diabetic rats, however, were prevented by the aminoguanidine treatment. Aminoguanidine did not reduce the formation of early nonenzymatic glycation products (aldimine and Amadori rearrangement products), whereas the amount of browning products (fluorescent compounds) was reduced in the tail tendon collagen of the diabetic rats. Aminoguanidine treatment of intact rats did not influence these parameters. These findings indicate that the biophysical alterations of collagens induced by experimental diabetes are caused by cross-links derived from the nonenzymatic glycation, and furthermore, that aminoguanidine treatment may prevent the concomitant changes in biophysical properties of connective tissues. FAU - Oxlund, H AU - Oxlund H AD - Department of Connective Tissue Biology, University of Aarhus, Denmark. FAU - Andreassen, T T AU - Andreassen TT LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Diabetologia JT - Diabetologia JID - 0006777 RN - 0 (Blood Glucose) RN - 0 (Guanidines) RN - 9007-34-5 (Collagen) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Animals MH - Blood Glucose/metabolism MH - Collagen/chemistry/*drug effects/metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Energy Intake MH - Guanidines/*pharmacology MH - Male MH - Rats MH - Rats, Inbred Strains MH - Reference Values MH - Stress, Mechanical MH - Tendons/drug effects/*metabolism EDAT- 1992/01/01 00:00 MHDA- 1992/01/01 00:01 CRDT- 1992/01/01 00:00 PHST- 1992/01/01 00:00 [pubmed] PHST- 1992/01/01 00:01 [medline] PHST- 1992/01/01 00:00 [entrez] AID - 10.1007/BF00400847 [doi] PST - ppublish SO - Diabetologia. 1992 Jan;35(1):19-25. doi: 10.1007/BF00400847. PMID- 30638929 OWN - NLM STAT- MEDLINE DCOM- 20191104 LR - 20191104 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 509 IP - 3 DP - 2019 Feb 12 TI - Age related changes in cell stiffness of tendon stem/progenitor cells and a rejuvenating effect of ROCK-inhibition. PG - 839-844 LID - S0006-291X(19)30035-X [pii] LID - 10.1016/j.bbrc.2019.01.027 [doi] AB - Tendon stem/progenitor cells (TSPC) are potential targets for regenerative medicine and the treatment of tendon injuries. The frequency of such injuries increases in elderly patients while the proportion of functional TSPCs in tendon tissue decreases, protracting tendon repair. Using atomic force microscopy (AFM), we show that cell stiffness and size increase in TSPCs isolated from elderly patients (A-TSPC) compared to TSPCs from younger patients (Y-TSPC). Additionally, two-photon excited fluorescence (TPEF) microscopy revealed a denser, well-structured actin cytoskeleton in A-TSPC, which correlates with the augmented cell stiffness. Treating A-TSPC with ROCK-inhibitor, reverses these age-related changes, and has rejuvenating effect on cell morphology and stiffness. We assume that cellular stiffness is a suitable marker for cell aging and ROCK a potential target for therapeutic applications of cell rejuvenation. CI - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Kiderlen, Stefanie AU - Kiderlen S AD - Center for Applied Tissue Engineering and Regenerative Medicine - CANTER, Munich University of Applied Sciences, Munich, Germany; Faculty of Physics, Soft Condensed Matter, Ludwig-Maximilians-University, Munich, Germany; Center for NanoScience, Ludwig-Maximilians-University, Munich, Germany. FAU - Polzer, Christoph AU - Polzer C AD - Faculty of Physics, Soft Condensed Matter, Ludwig-Maximilians-University, Munich, Germany; Multiphoton Imaging Lab, Munich University of Applied Sciences, Munich, Germany. FAU - Rädler, Joachim O AU - Rädler JO AD - Faculty of Physics, Soft Condensed Matter, Ludwig-Maximilians-University, Munich, Germany; Center for NanoScience, Ludwig-Maximilians-University, Munich, Germany. FAU - Docheva, Denitsa AU - Docheva D AD - Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Center, Regensburg, Germany. FAU - Clausen-Schaumann, Hauke AU - Clausen-Schaumann H AD - Center for Applied Tissue Engineering and Regenerative Medicine - CANTER, Munich University of Applied Sciences, Munich, Germany; Center for NanoScience, Ludwig-Maximilians-University, Munich, Germany. Electronic address: hauke.clausen-schaumann@hm.edu. FAU - Sudhop, Stefanie AU - Sudhop S AD - Center for Applied Tissue Engineering and Regenerative Medicine - CANTER, Munich University of Applied Sciences, Munich, Germany; Center for NanoScience, Ludwig-Maximilians-University, Munich, Germany. Electronic address: stefanie.sudhop@hm.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190111 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Amides) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyridines) RN - 138381-45-0 (Y 27632) RN - EC 2.7.11.1 (rho-Associated Kinases) SB - IM MH - Adult MH - Aged MH - Amides/*pharmacology MH - Biomechanical Phenomena/drug effects MH - Cell Differentiation/drug effects MH - Cell Line MH - Cell Proliferation/drug effects MH - Cell Size/drug effects MH - Cells, Cultured MH - Cellular Senescence/drug effects MH - Elastic Modulus/drug effects MH - Humans MH - Middle Aged MH - Protein Kinase Inhibitors/*pharmacology MH - Pyridines/*pharmacology MH - Rejuvenation MH - Stem Cells/*cytology/drug effects/metabolism MH - Tendons/*cytology/drug effects/metabolism MH - Young Adult MH - rho-Associated Kinases/*antagonists & inhibitors/metabolism OTO - NOTNLM OT - Cell aging OT - Elastic modulus OT - ROCK-inhibition OT - Rejuvenation OT - hTSPC EDAT- 2019/01/15 06:00 MHDA- 2019/11/05 06:00 CRDT- 2019/01/15 06:00 PHST- 2018/12/21 00:00 [received] PHST- 2019/01/05 00:00 [accepted] PHST- 2019/01/15 06:00 [pubmed] PHST- 2019/11/05 06:00 [medline] PHST- 2019/01/15 06:00 [entrez] AID - S0006-291X(19)30035-X [pii] AID - 10.1016/j.bbrc.2019.01.027 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2019 Feb 12;509(3):839-844. doi: 10.1016/j.bbrc.2019.01.027. Epub 2019 Jan 11. PMID- 8791988 OWN - NLM STAT- MEDLINE DCOM- 19970227 LR - 20171116 IS - 0004-5632 (Print) IS - 0004-5632 (Linking) VI - 33 ( Pt 3) DP - 1996 May TI - Comparison of the effect of different inhibitors of the non-enzymatic glycation of rat tail tendons and bovine serum albumin. PG - 241-8 AB - The biomechanical and biochemical properties of collagen are changed by non-enzymatic glycation culminating in increased cross-linking. We have previously shown that dibasic amino acids such as L-arginine inhibit in vitro the non-enzymatic glycation of soluble proteins and insoluble connective tissue macromolecules. In the present in vitro study we obtained evidence that the nucleophilic hydrazine derivative aminoguanidine and the non-steroidal anti-rheumatic drug ibuprofen inhibit the formation of fluorescent advanced glycation end products (AGEs) to a comparable extent, while arginine is ineffective as a consequence of its tendency to form AGEs itself. Periodic replacement of glycated arginine in the rat tail tendon system, however, engendered an inhibition of fluorescence similar to that obtained by the other inhibitors. Long-term glycation of rat tail tendons caused a significant increase in Young's modulus, which could also be inhibited by periodically renewed arginine. In contrast to ibuprofen, aminoguanidine and arginine-lysine inhibited the marked increase in maximum contraction force of long-term glycated rat tail tendons. As opposed to other inhibitors, aminoguanidine also reduced the thermal contraction force of native tendons, shifted the maximum contraction temperature to markedly lower values and solubilized a significant part of the rat tail tendon collagen. These findings indicate that the in vitro alterations of rat tail tendon collagen induced by non-enzymatic glycation can be prevented by arginine, arginine-lysine and aminoguanidine. However, collagen structure is seriously affected by aminoguanidine. FAU - Menzel, E J AU - Menzel EJ AD - Institute of Immunology, University of Vienna, Austria. FAU - Reihsner, R AU - Reihsner R LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Ann Clin Biochem JT - Annals of clinical biochemistry JID - 0324055 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Dipeptides) RN - 0 (Enzyme Inhibitors) RN - 0 (Guanidines) RN - 0 (arginyllysine) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 94ZLA3W45F (Arginine) RN - SCQ4EZQ113 (pimagedine) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Arginine/*pharmacology MH - Dipeptides/*pharmacology MH - Enzyme Inhibitors/*pharmacology MH - Glycosylation MH - Guanidines/pharmacology MH - Ibuprofen/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Serum Albumin, Bovine/*metabolism MH - Solubility MH - Tail MH - Tendons/*metabolism EDAT- 1996/05/01 00:00 MHDA- 1996/05/01 00:01 CRDT- 1996/05/01 00:00 PHST- 1996/05/01 00:00 [pubmed] PHST- 1996/05/01 00:01 [medline] PHST- 1996/05/01 00:00 [entrez] AID - 10.1177/000456329603300311 [doi] PST - ppublish SO - Ann Clin Biochem. 1996 May;33 ( Pt 3):241-8. doi: 10.1177/000456329603300311. PMID- 11068182 OWN - NLM STAT- MEDLINE DCOM- 20010111 LR - 20190610 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1502 IP - 3 DP - 2000 Nov 15 TI - p-Dimethylaminobenzaldehyde-reactive substances in tail tendon collagen of streptozotocin-diabetic rats: temporal relation to biomechanical properties and advanced glycation endproduct (AGE)-related fluorescence. PG - 398-404 AB - In the present work, pepsin digests of tail tendons from streptozotocin-diabetic rats were found to contain material that reacted rapidly at room temperature with p-dimethylaminobenzaldehyde (Ehrlich's reagent) to give an adduct with an absorbance spectrum characteristic of the Ehrlich chromogen of pyrrolic nature determined in ageing collagens. A significant correlation of the Ehrlich adduct with tendon mechanical strength and collagen fluorescence characteristic of advanced glycation endproducts was observed. Collagen content of the Ehrlich-positive material was found to be significantly elevated in tendons of diabetic rats compared with age-matched healthy controls. The results indicate that the p-dimethylaminobenzaldehyde-reactive pyrrole moieties may contribute to the increased cross-linking of diabetic matrix collagen. Profound inhibitory effect of aminoguanidine was observed, underlining the role of non-enzymatic mechanisms of advanced glycation in pyrrolisation and cross-linking of collagen exposed to hyperglycaemia. It is hypothesised that quantification of the p-dimethylaminobenzaldehyde-reactive material in matrix collagen may provide a tissue measure of integrated hyperglycaemia over prolonged periods of time. Further research is to assess the significance of p-dimethylaminobenzaldehyde-reactive substances in diabetic collagen tissues and to reveal their relationship to enzyme-mediated physiological pyrrolisation of ageing collagens. FAU - Stefek, M AU - Stefek M AD - Institute of Experimental Pharmacology, Slovak Academy of Sciences, Dubravska cesta 9, 842 16, Bratislava, Slovakia. exfastfk@savba.sk FAU - Gajdosik, A AU - Gajdosik A FAU - Gajdosikova, A AU - Gajdosikova A FAU - Krizanova, L AU - Krizanova L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Benzaldehydes) RN - 0 (Enzyme Inhibitors) RN - 0 (Glycation End Products, Advanced) RN - 0 (Guanidines) RN - 0 (Indicators and Reagents) RN - 0 (Pyrroles) RN - 9007-34-5 (Collagen) RN - EC 3.4.23.1 (Pepsin A) RN - SCQ4EZQ113 (pimagedine) RN - V7E88PR1YB (p-dimethylaminobenzaldehyde) SB - IM MH - Animals MH - *Benzaldehydes MH - Collagen/*chemistry/metabolism MH - Diabetes Mellitus, Experimental/blood/*metabolism MH - Disease Models, Animal MH - Enzyme Inhibitors/pharmacology MH - Glycation End Products, Advanced/*analysis MH - Guanidines/pharmacology MH - Indicators and Reagents MH - Male MH - Pepsin A MH - Pyrroles/chemistry MH - Rats MH - Rats, Wistar MH - Spectrophotometry MH - Stress, Mechanical MH - Tail MH - Tendons/*chemistry/metabolism MH - Time Factors EDAT- 2000/11/09 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/11/09 11:00 PHST- 2000/11/09 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/11/09 11:00 [entrez] AID - S0925-4439(00)00064-8 [pii] AID - 10.1016/s0925-4439(00)00064-8 [doi] PST - ppublish SO - Biochim Biophys Acta. 2000 Nov 15;1502(3):398-404. doi: 10.1016/s0925-4439(00)00064-8. PMID- 15829785 OWN - NLM STAT- MEDLINE DCOM- 20050526 LR - 20190917 IS - 0894-9115 (Print) IS - 0894-9115 (Linking) VI - 84 IP - 5 DP - 2005 May TI - Enthesitis of biceps brachii short head and coracobrachialis at the coracoid process: a generator of shoulder and neck pain. PG - 376-80 AB - This series describes the outcome of diagnostic block at the coracoid process's common origin of the biceps brachii short head and coracobrachialis for anterior shoulder pain and cervical myofascial pain syndrome in six patients. All showed significant tenderness over the tip of the coracoid process. All underwent diagnostic injection with Marcaine at the coracoid process, followed by therapeutic injection with Marcaine and DepoMedrol. All reported complete relief of pain after local injection. Enthesitis at the coracoid process needs to be considered as a causative or contributing factor in patients presenting with shoulder and neck symptoms. No study was found in the literature describing this association. Whether tendonitis of the common origin is a primary cause or result of chronic neck and shoulder dysfunction remains to be established. FAU - Karim, M Razul AU - Karim MR AD - University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. FAU - Fann, Alice V AU - Fann AV FAU - Gray, Richard P AU - Gray RP FAU - Neale, David F AU - Neale DF FAU - Escarda, Jose Dan AU - Escarda JD LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 0 (Anesthetics, Local) RN - 0 (Glucocorticoids) RN - X4W7ZR7023 (Methylprednisolone) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adult MH - Aged MH - Anesthetics, Local/*therapeutic use MH - Bupivacaine/*therapeutic use MH - Female MH - Glucocorticoids/*therapeutic use MH - Humans MH - Male MH - Methylprednisolone/*therapeutic use MH - Middle Aged MH - Muscle, Skeletal/physiopathology MH - Neck Pain/*drug therapy/physiopathology MH - Nerve Block MH - Range of Motion, Articular/physiology MH - Scapula/physiopathology MH - Shoulder Joint/physiopathology MH - Shoulder Pain/*drug therapy/physiopathology MH - Tendons/physiopathology EDAT- 2005/04/15 09:00 MHDA- 2005/05/27 09:00 CRDT- 2005/04/15 09:00 PHST- 2005/04/15 09:00 [pubmed] PHST- 2005/05/27 09:00 [medline] PHST- 2005/04/15 09:00 [entrez] AID - 00002060-200505000-00009 [pii] AID - 10.1097/01.phm.0000159973.97391.c9 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2005 May;84(5):376-80. doi: 10.1097/01.phm.0000159973.97391.c9. PMID- 8835246 OWN - NLM STAT- MEDLINE DCOM- 19961212 LR - 20170112 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 13 IP - 6 DP - 1995 Nov-Dec TI - Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up. PG - 733-6 AB - The persistence of enthesopathic changes was studied by ultrasound (US) in 23 patients with spondylarthropathy during a 6-month prospective trial with sulphasalazine (Salazopyrin). During the follow-up significant improvement was seen in the joint symptoms and in the laboratory variables. By US 78% of the patients had enthesopathy at entry and 74% after 6 months of follow-up. The plantar fascia was the enthesis most frequently affected. Treatment with sulphasalazine had no obvious influence on the persistence of enthesopathy. Enthesopathy is as a rule a constant phenomenon and is probably caused by chronic enthesitis. A parallel resolution of anatomic soft tissue changes and the clinical status was not seen on US. There was also no evidence of a favourable effect of sulphasalazine on enthesopathy in the 6-month follow-up. FAU - Lehtinen, A AU - Lehtinen A AD - Department of Radiology, Helsinki University Central Hospital, Finland. FAU - Leirisalo-Repo, M AU - Leirisalo-Repo M FAU - Taavitsainen, M AU - Taavitsainen M LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Antirheumatic Agents) RN - 3XC8GUZ6CB (Sulfasalazine) SB - IM MH - Adult MH - Antirheumatic Agents/therapeutic use MH - Calcaneus/diagnostic imaging/pathology MH - Double-Blind Method MH - Female MH - Follow-Up Studies MH - Humans MH - Inflammation/pathology MH - Joints/diagnostic imaging MH - Male MH - Middle Aged MH - Spondylitis, Ankylosing/*diagnostic imaging/drug therapy MH - Sulfasalazine/therapeutic use MH - Tendons/*diagnostic imaging MH - Ultrasonography EDAT- 1995/11/01 00:00 MHDA- 1995/11/01 00:01 CRDT- 1995/11/01 00:00 PHST- 1995/11/01 00:00 [pubmed] PHST- 1995/11/01 00:01 [medline] PHST- 1995/11/01 00:00 [entrez] PST - ppublish SO - Clin Exp Rheumatol. 1995 Nov-Dec;13(6):733-6. PMID- 7986937 OWN - NLM STAT- MEDLINE DCOM- 19950106 LR - 20190815 IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 15 IP - 10 DP - 1994 Aug TI - Xenografts for tendon and ligament repair. PG - 745-52 AB - Collagenous materials, usually of bovine or equine origin, have been popular starting points for the development of xenograft prostheses for tendon and ligament repair. Xenografts are highly attractive as they carry small risk of infectious disease, do not compromise the patient's remaining tissues and may have the 'correct' structure as the component being replaced. Animal studies, on dog, rabbit and chicken, have shown tremendous potential for this use of xenograft material as a tendon replacement. Why, therefore, have xenografts been almost universally a total failure in clinical application? The reasons would appear to be two-fold: the animal models have not been appropriate to the intended clinical use and the cross-linking of xenograft materials has not been optimized. Our work on xenograft, heterograft and autograft tissues indicates that both aspects deserve more attention. Quantitative histology indicates that the extent and type of response to xenograft materials differs widely with degree of cross-linking (glutaraldehyde). Attention must also be given to the join of the graft to the host. For both tendon and ligament the join is a site of particular fragility. Even with adequate strength in the mid-substance, tendon and ligament grafts can, and do, fail at the join. We have investigated a variety of mechanisms for joining tendon to tendon and ligaments to bone. The failures of these methods present some insight into the biology of the repair process involved and into how failure may be avoided in future. FAU - Milthorpe, B K AU - Milthorpe BK AD - Centre for Biomedical Engineering, University of New South Wales, Australia. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Cross-Linking Reagents) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Biomedical Engineering/methods MH - *Bioprosthesis MH - Cross-Linking Reagents/pharmacology MH - Glutaral/therapeutic use MH - Humans MH - Ligaments/*surgery MH - Models, Biological MH - Tendons/*surgery RF - 14 EDAT- 1994/08/01 00:00 MHDA- 1994/08/01 00:01 CRDT- 1994/08/01 00:00 PHST- 1994/08/01 00:00 [pubmed] PHST- 1994/08/01 00:01 [medline] PHST- 1994/08/01 00:00 [entrez] AID - 0142-9612(94)90027-2 [pii] AID - 10.1016/0142-9612(94)90027-2 [doi] PST - ppublish SO - Biomaterials. 1994 Aug;15(10):745-52. doi: 10.1016/0142-9612(94)90027-2. PMID- 7062282 OWN - NLM STAT- MEDLINE DCOM- 19820527 LR - 20141120 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 221 IP - 1 DP - 1982 Apr TI - Inotropic and electrophysiologic effects of amrinone in untreated and digitalized ventricular tissues. PG - 188-96 AB - The purposes of this study were to determine whether amrinone induces oscillatory afterpotentials (OAP) or aftercontractions (AC) in Purkinje tissue or myocardium, to determine whether a relationship exists between the production of OAP or AC and the inotropic effects of amrinone and to determine possible effects of amrinone on the oscillations and the positive inotropic effect produced by digitalis. Isolated canine papillary and trabecullar muscles, as well as false tendons, were exposed to 5.3 X 10(-4) M amrinone. Some of the preparations had been pretreated with acetylstrophanthidin (AS) in a dose just sufficient to induce OAP or AC. Standard electrophysiologic techniques were used to record transmembrane action potentials. Developed tension also was recorded. Amrinone by itself did not induce OAP or AC in myocardium or false tendons. This was true even when the resting membrane potential of the false tendons was reduced by means of focal current application. Amrinone increased the amplitude of AS-induced oscillations in both myocardium and false tendons. Amrinone increased strength of contraction of untreated myocardium at all basic cycle lengths and of AS-treated myocardium, especially at shorter basic cycle lengths. Amrinone decreased strength of contraction both of untreated and AS-treated false tendons at all basic cycle lengths. The results suggest that there may be important differences in the mechanisms of action of amrinone and digitalis. FAU - Rosenthal, J E AU - Rosenthal JE FAU - Ferrier, G R AU - Ferrier GR LA - eng GR - HL 19487/HL/NHLBI NIH HHS/United States GR - T32HL07254/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Aminopyridines) RN - 0 (Digitalis Glycosides) RN - JUT23379TN (Amrinone) SB - IM MH - Aminopyridines/*pharmacology MH - Amrinone MH - Animals MH - Digitalis Glycosides/*pharmacology MH - Dogs MH - Electric Stimulation MH - Electroencephalography MH - Female MH - Heart/*drug effects MH - In Vitro Techniques MH - Male MH - Myocardial Contraction/drug effects MH - Papillary Muscles/drug effects MH - Purkinje Fibers/drug effects EDAT- 1982/04/01 00:00 MHDA- 1982/04/01 00:01 CRDT- 1982/04/01 00:00 PHST- 1982/04/01 00:00 [pubmed] PHST- 1982/04/01 00:01 [medline] PHST- 1982/04/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1982 Apr;221(1):188-96. PMID- 23412444 OWN - NLM STAT- MEDLINE DCOM- 20140404 LR - 20211021 IS - 1432-1068 (Electronic) IS - 1633-8065 (Linking) VI - 23 IP - 2 DP - 2013 Feb TI - Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. PG - 145-8 LID - 10.1007/s00590-012-0944-9 [doi] AB - Celecoxib, a selective cox-2 inhibitor, has been shown to prevent the heterotopic ossification following total hip arthroplasty. However, the effects of celecoxib on heterotopic ossification at other locations remain unclear. This study aimed to investigate the effect of celecoxib on heterotopic ossification in the rat model with Achilles tenotomy. Forty male Sprague-Dawley rats, which were randomly divided into 2 groups (n = 20), underwent midpoint Achilles tenotomy on left legs through a posterior approach under aseptic condition. Experimental group was treated with the saline solution of celecoxib (10 mg/kg) per day, while control group was treated by normal saline (0.9%). At 3, 5 and 10 postoperative weeks, all animals were examined by X-ray to assess new bone formation in the Achilles tendon. At 10 weeks after surgery, all animals were killed and Achilles tendons were taken for hematoxylin-eosin (HE) and immunohistochemical staining. Heterotopic ossification developed in 3 rats (15%) in experimental group and 20 rats (100%) in control group by postoperative 10 weeks. The incidence of heterotopic ossification was significantly lower in experimental group than in control group (P < 0.05). Our findings suggest that celecoxib inhibits HO development in rat model with Achilles tenotomy. FAU - Zhang, Kairui AU - Zhang K AD - Department of Orthopedics and Traumatology, Nanfang Hospital, Southern Medical University, No. 1838 Guangzhou avenue north, Guangzhou, 510515, China. FAU - Wang, Liang AU - Wang L FAU - Zhang, Sheng AU - Zhang S FAU - Yu, Bin AU - Yu B FAU - Liu, Feng AU - Liu F FAU - Cui, Zhuang AU - Cui Z FAU - Jin, Dadi AU - Jin D FAU - Bai, Xiaochun AU - Bai X LA - eng PT - Journal Article DEP - 20120210 PL - France TA - Eur J Orthop Surg Traumatol JT - European journal of orthopaedic surgery & traumatology : orthopedie traumatologie JID - 9518037 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Achilles Tendon/drug effects/pathology/*surgery MH - Animals MH - Celecoxib MH - Cyclooxygenase 2 Inhibitors/*therapeutic use MH - Disease Models, Animal MH - Male MH - Ossification, Heterotopic/pathology/*prevention & control MH - Pyrazoles/*therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Sulfonamides/*therapeutic use MH - Tenotomy/*adverse effects/methods EDAT- 2013/02/16 06:00 MHDA- 2014/04/05 06:00 CRDT- 2013/02/16 06:00 PHST- 2011/07/16 00:00 [received] PHST- 2012/01/20 00:00 [accepted] PHST- 2013/02/16 06:00 [entrez] PHST- 2013/02/16 06:00 [pubmed] PHST- 2014/04/05 06:00 [medline] AID - 10.1007/s00590-012-0944-9 [doi] PST - ppublish SO - Eur J Orthop Surg Traumatol. 2013 Feb;23(2):145-8. doi: 10.1007/s00590-012-0944-9. Epub 2012 Feb 10. PMID- 17583829 OWN - NLM STAT- MEDLINE DCOM- 20070710 LR - 20131121 IS - 1439-4413 (Electronic) IS - 0012-0472 (Linking) VI - 132 IP - 27 DP - 2007 Jul 29 TI - [Cerebrotendinous xanthomatosis]. PG - 1463-6 AB - HISTORY AND CLINICAL FINDINGS: A 43-year-old woman had since childhood suffered from progressive dementia. Gait ataxia and mild polyneuropathy were noted in the neurological examination. She also had painful xanthomas of the achilles tendons. A bilateral cataract operation had been performed during adolescence. INVESTIGATIONS: An elevated concentration of cholestanol and a normal cholesterol level were found in the blood samples. The cerebral computed tomography revealed slight cerebral atrophy, predominantly affecting the cerebellum. Neurophysiological tests detected a sensory polyneuropathy in the legs. In addition the electroencephalogram showed a generalized slowing of electrical activity. DIAGNOSIS, TREATMENT AND COURSE: Clinical findings and laboratory values indicated the diagnosis of a cerebrotendinous xanthomatosis. After initiation of a drug therapy, based on a combination of an HMG-CoA-reductase inhibitor (simvastatin 20 mg/day) and a bile acid, chenodeoxycholic acid (15 mg/kg/day), further progression of the disease was prevented. CONCLUSION: The diagnosis of cerebrotendinous xanthomatosis is easily made in patients presenting all clinical symptoms expected in the disease. However, up to 30% of the patients do not show severe xanthomas. Especially in early stages of the disease the diagnosis may be difficult. Treatment can be efficacious and should be started as early as possible to prevent irreversible damage, particularly in the nervous system. FAU - Burghaus, L AU - Burghaus L AD - Klinik und Poliklinik für Neurologie, Universität zu Köln, Köln, Germany. lothar.burghaus@uk-koeln.de FAU - Liu, W AU - Liu W FAU - Haupt, W F AU - Haupt WF LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Zerebrotendinöse Xanthomatose. PL - Germany TA - Dtsch Med Wochenschr JT - Deutsche medizinische Wochenschrift (1946) JID - 0006723 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 8M308U816E (Cholestanol) RN - 97C5T2UQ7J (Cholesterol) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Adult MH - Brain/*pathology MH - Cataract/etiology MH - Chenodeoxycholic Acid/*therapeutic use MH - Cholestanol/*blood MH - Cholesterol/blood MH - Dementia/etiology/prevention & control MH - Diagnosis, Differential MH - Female MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use MH - Simvastatin/*therapeutic use MH - Treatment Outcome MH - Xanthomatosis, Cerebrotendinous/blood/complications/*diagnosis/drug therapy EDAT- 2007/06/23 09:00 MHDA- 2007/07/11 09:00 CRDT- 2007/06/23 09:00 PHST- 2007/06/23 09:00 [pubmed] PHST- 2007/07/11 09:00 [medline] PHST- 2007/06/23 09:00 [entrez] AID - 10.1055/s-2007-982053 [doi] PST - ppublish SO - Dtsch Med Wochenschr. 2007 Jul 29;132(27):1463-6. doi: 10.1055/s-2007-982053. PMID- 9187727 OWN - NLM STAT- MEDLINE DCOM- 19971015 LR - 20101118 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 210 IP - 12 DP - 1997 Jun 15 TI - Use of tenoscopy for management of septic tenosynovitis caused by a penetrating porcupine quill in the synovial sheath surrounding the digital flexor tendons of a horse. PG - 1768-70 AB - A 6-year-old Quarter Horse gelding with acute onset of a grade-4/5 lameness of the left forelimb 21 days after an encounter with a porcupine was examined. Quills had been removed by the referring veterinarian, and the horse had been treated with antibiotics and hydrotherapy for 14 days. The horse was pyretic and had effusion in the digital synovial sheath. Signs of pain were elicited on palpation of the area. A tentative diagnosis of septic tenosynovitis caused by a porcupine quill was made. Exploratory tenoscopy revealed large amounts of fibrin in the sheath and a 1.2-cm quill. Bacteriologic culture of synovial fluid yielded a pure growth of Staphylococcus aureus. The horse improved dramatically after tenoscopic removal of the quill, debridement of fibrin, and lavage to dilute inflammatory mediators and bacteria, debridement of fibrin, discovery and removal of a quill, and complete evaluation of the sheath for prognostic purposes. Tenoscopy can provide a means for direct observation and enhance the ability of clinicians to debride a septic synovial sheath in a minimally invasive manner. FAU - Magee, A A AU - Magee AA AD - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman 99164, USA. FAU - Ragle, C A AU - Ragle CA FAU - Howlett, M R AU - Howlett MR LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) RN - 0 (Penicillins) SB - IM MH - Animals MH - Anti-Bacterial Agents/therapeutic use MH - Arthroscopes MH - Arthroscopy/methods/*veterinary MH - Debridement/methods/veterinary MH - Foreign Bodies/complications/surgery/*veterinary MH - Gentamicins/therapeutic use MH - Horse Diseases/etiology/microbiology/*therapy MH - Horses MH - Male MH - Penicillins/therapeutic use MH - Rodentia MH - Staphylococcal Infections/drug therapy/etiology/veterinary MH - Staphylococcus aureus/isolation & purification MH - Synovial Membrane/*injuries/microbiology MH - Tendon Injuries/etiology/therapy/*veterinary MH - Tenosynovitis/etiology/therapy/*veterinary MH - Therapeutic Irrigation/methods/veterinary MH - Wounds, Penetrating/complications/microbiology/*veterinary EDAT- 1997/06/15 00:00 MHDA- 1997/06/15 00:01 CRDT- 1997/06/15 00:00 PHST- 1997/06/15 00:00 [pubmed] PHST- 1997/06/15 00:01 [medline] PHST- 1997/06/15 00:00 [entrez] PST - ppublish SO - J Am Vet Med Assoc. 1997 Jun 15;210(12):1768-70. PMID- 7214538 OWN - NLM STAT- MEDLINE DCOM- 19810623 LR - 20190720 IS - 0008-8749 (Print) IS - 0008-8749 (Linking) VI - 57 IP - 2 DP - 1981 Jan 15 TI - Effect of immunosuppressive agents on antigen retained in lymphoid follicles and collagenous tissue of immune mice. PG - 505-16 FAU - Phipps, R P AU - Phipps RP FAU - Mandel, T E AU - Mandel TE FAU - Tew, J G AU - Tew JG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Cell Immunol JT - Cellular immunology JID - 1246405 RN - 0 (Antigens) RN - 0 (Immunosuppressive Agents) RN - 8N3DW7272P (Cyclophosphamide) RN - 9007-34-5 (Collagen) RN - MRK240IY2L (Azathioprine) RN - V27W9254FZ (Cortisone) SB - IM MH - Animals MH - *Antigens MH - Azathioprine/pharmacology MH - Collagen MH - Cortisone/analogs & derivatives/pharmacology MH - Cyclophosphamide/pharmacology MH - Immunization MH - Immunosuppressive Agents/*pharmacology MH - Lymph Nodes/*immunology MH - Male MH - Mice MH - Mice, Inbred CBA MH - Spleen/*immunology MH - Tendons/*immunology MH - X-Rays EDAT- 1981/01/15 00:00 MHDA- 1981/01/15 00:01 CRDT- 1981/01/15 00:00 PHST- 1981/01/15 00:00 [pubmed] PHST- 1981/01/15 00:01 [medline] PHST- 1981/01/15 00:00 [entrez] AID - 0008-8749(81)90108-8 [pii] AID - 10.1016/0008-8749(81)90108-8 [doi] PST - ppublish SO - Cell Immunol. 1981 Jan 15;57(2):505-16. doi: 10.1016/0008-8749(81)90108-8. PMID- 199434 OWN - NLM STAT- MEDLINE DCOM- 19771229 LR - 20190620 IS - 0014-2956 (Print) IS - 0014-2956 (Linking) VI - 78 IP - 2 DP - 1977 Sep TI - Tetramers and monomers of prolyl hydroxylase in isolated chick-embryo tendon cells. The association of inactive monomers to active tetramers and a preliminary characterization of the intracellular monomer-size protein. PG - 547-56 FAU - Tuderman, L AU - Tuderman L FAU - Oikarinen, A AU - Oikarinen A FAU - Kivirikko, K I AU - Kivirikko KI LA - eng PT - Journal Article PL - England TA - Eur J Biochem JT - European journal of biochemistry JID - 0107600 RN - 0 (Macromolecular Substances) RN - 98600C0908 (Cycloheximide) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Cycloheximide/pharmacology MH - Dithiothreitol/pharmacology MH - Kinetics MH - Macromolecular Substances MH - Molecular Weight MH - Precipitin Tests MH - *Procollagen-Proline Dioxygenase/metabolism MH - Tendons/*enzymology EDAT- 1977/09/01 00:00 MHDA- 1977/09/01 00:01 CRDT- 1977/09/01 00:00 PHST- 1977/09/01 00:00 [pubmed] PHST- 1977/09/01 00:01 [medline] PHST- 1977/09/01 00:00 [entrez] AID - 10.1111/j.1432-1033.1977.tb11768.x [doi] PST - ppublish SO - Eur J Biochem. 1977 Sep;78(2):547-56. doi: 10.1111/j.1432-1033.1977.tb11768.x. PMID- 25544391 OWN - NLM STAT- MEDLINE DCOM- 20160101 LR - 20181202 IS - 1873-6351 (Electronic) IS - 0278-6915 (Linking) VI - 77 DP - 2015 Mar TI - Structural and biomechanical changes in the Achilles tendon after chronic treatment with statins. PG - 50-7 LID - S0278-6915(14)00523-7 [pii] LID - 10.1016/j.fct.2014.12.014 [doi] AB - Cases of tendinopathy and tendon ruptures have been reported as side effects associated with statin therapy. This work assessed possible changes in the structural and biomechanical properties of the tendons after chronic treatment with statins. Wistar rats were divided into the following groups: treated with atorvastatin (A-20 and A-80), simvastatin (S-20 and S-80) and the group that received no treatment (C). The doses of statins were calculated using allometric scaling, based on the doses of 80 mg/day and 20 mg/day recommended for humans. The morphological aspect of the tendons in A-20, S-20 and S-80 presented signals consistent with degeneration. Both the groups A-80 and S-80 showed a less pronounced metachromasia in the compression region of the tendons. Measurements of birefringence showed that A-20, A-80 and S-80 groups had a lower degree of organization of the collagen fibers. In all of the groups treated with statins, the thickness of the epitenon was thinner when compared to the C group. In the biomechanical tests the tendons of the groups A-20, A-80 and S-20 were less resistant to rupture. Therefore, statins affected the organization of the collagen fibers and decreased the biomechanical strength of the tendons, making them more predisposed to ruptures. CI - Copyright © 2014 Elsevier Ltd. All rights reserved. FAU - de Oliveira, L P AU - de Oliveira LP AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. Electronic address: leprado.farm@gmail.com. FAU - Vieira, C P AU - Vieira CP AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. FAU - Guerra, F D AU - Guerra FD AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. FAU - Almeida, M S AU - Almeida MS AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. FAU - Pimentel, E R AU - Pimentel ER AD - Department of Structural and Functional Biology, Institute of Biology, University of Campinas - UNICAMP, Campinas, SP, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141225 PL - England TA - Food Chem Toxicol JT - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association JID - 8207483 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 9007-34-5 (Collagen) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Achilles Tendon/anatomy & histology/*drug effects/*injuries MH - Animals MH - Atorvastatin/pharmacology MH - Collagen/*metabolism MH - Dose-Response Relationship, Drug MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Male MH - Rats MH - Rats, Wistar MH - Rupture MH - Simvastatin/pharmacology MH - Tendon Injuries/*pathology OTO - NOTNLM OT - Biomechanics OT - Birefringence OT - Collagen OT - Ruptures OT - Statins OT - Tendinopathy EDAT- 2014/12/30 06:00 MHDA- 2016/01/02 06:00 CRDT- 2014/12/30 06:00 PHST- 2014/06/06 00:00 [received] PHST- 2014/12/13 00:00 [revised] PHST- 2014/12/17 00:00 [accepted] PHST- 2014/12/30 06:00 [entrez] PHST- 2014/12/30 06:00 [pubmed] PHST- 2016/01/02 06:00 [medline] AID - S0278-6915(14)00523-7 [pii] AID - 10.1016/j.fct.2014.12.014 [doi] PST - ppublish SO - Food Chem Toxicol. 2015 Mar;77:50-7. doi: 10.1016/j.fct.2014.12.014. Epub 2014 Dec 25. PMID- 16026696 OWN - NLM STAT- MEDLINE DCOM- 20060110 LR - 20220321 IS - 0968-0160 (Print) IS - 0968-0160 (Linking) VI - 12 IP - 4 DP - 2005 Aug TI - Daystay hamstring ACL reconstruction performed under regional anaesthesia. PG - 271-3 AB - Daycase ACL reconstruction is commonly performed under general anaesthesia with a patella tendon graft. We report our experience with hamstring reconstruction under regional anaesthesia. Over a 14-month period, 104 daycase arthroscopic ACL reconstructions were performed by one surgeon and one anaesthetist. All operations were performed under spinal anaesthesia with a femoral nerve block. Patients were discharged with oral analgesia, brace and a cryocuff. One hundred and two patients were prospectively evaluated with a visual analogue pain score (0-10) and a patient satisfaction questionnaire. Of these 102 patients, 101 (99%) were happy to be discharged on the same day. One patient was admitted from the daycase unit, and one patient was re-admitted. Patients were very satisfied with the pain relief provided. The mean visual analogue pain score was 1.0 at discharge, 1.8 in the middle of the first night, and 2.1 on the first post-op day. Patients experienced significantly more pain the day after surgery than the evening of surgery (p=0.04). We conclude that hamstring ACL reconstruction under regional anaesthesia is well tolerated by patients as a daycase procedure. FAU - Shaw, A D AU - Shaw AD AD - Department of Orthopaedic Surgery, Victoria Infirmary, Langside Road, Glasgow G42, United Kingdom. hawkeye_shaw@yahoo.com FAU - DiBartolo, G AU - DiBartolo G FAU - Clatworthy, M AU - Clatworthy M LA - eng PT - Journal Article DEP - 20041121 PL - Netherlands TA - Knee JT - The Knee JID - 9430798 RN - 0 (Anesthetics, Local) RN - 0 (Vasoconstrictor Agents) RN - Y8335394RO (Bupivacaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - *Ambulatory Care MH - *Anesthesia, Spinal MH - Anesthetics, Local/*therapeutic use MH - Anterior Cruciate Ligament/*surgery MH - Anterior Cruciate Ligament Injuries MH - Arthroscopy MH - Bupivacaine/*therapeutic use MH - Epinephrine/therapeutic use MH - Humans MH - *Nerve Block MH - Pain Measurement MH - Patient Satisfaction MH - Prospective Studies MH - Tendons/transplantation MH - Treatment Outcome MH - Vasoconstrictor Agents/therapeutic use EDAT- 2005/07/20 09:00 MHDA- 2006/01/13 09:00 CRDT- 2005/07/20 09:00 PHST- 2004/03/15 00:00 [received] PHST- 2004/05/24 00:00 [accepted] PHST- 2005/07/20 09:00 [pubmed] PHST- 2006/01/13 09:00 [medline] PHST- 2005/07/20 09:00 [entrez] AID - S0968-0160(04)00192-9 [pii] AID - 10.1016/j.knee.2004.05.010 [doi] PST - ppublish SO - Knee. 2005 Aug;12(4):271-3. doi: 10.1016/j.knee.2004.05.010. Epub 2004 Nov 21. PMID- 10751002 OWN - NLM STAT- MEDLINE DCOM- 20000511 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 28 IP - 2 DP - 2000 Mar-Apr TI - The effects of chlorhexidine irrigation solution on contaminated bone-tendon allografts. PG - 241-4 AB - The purpose of this study was to determine an expedient and effective method for disinfecting contaminated human bone-tendon allografts. The first part of this study used beef muscle and cadaveric human tissues to determine the most effective solution and volume to decontaminate tissues inoculated with four different organisms: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Of the solutions tested (benzalkonium chloride, castile soap, castile soap followed by benzalkonium chloride, triple antibiotic, chlorhexidine gluconate, and chlorhexidine gluconate/triple antibiotic), only the 4% chlorhexidine power irrigation solution and 4% chlorhexidine/triple antibiotic bath completely disinfected all tissues. Work in part 2 revealed that a 2% chlorhexidine irrigation solution was equally effective as the 4% solutions. Part 3 of the study involved human Achilles tendon-calcaneus allografts. We found similar results: 3 liters of 2% chlorhexidine power irrigation solution thoroughly removed all microorganisms from the contaminated tissues. All control allografts irrigated with normal saline solution alone revealed positive bacterial growth for all four organisms after 72 hours' growth on sheep blood agar. Total decontamination time was 10 to 12 minutes. Two percent chlorhexidine irrigation solution may be an effective method for decontaminating human bone-tendon allografts challenged with a polymicrobial inoculum. This method of disinfecting bone-tendon allografts is at least five times more expeditious than methods in previously reported studies. FAU - Burd, T AU - Burd T AD - University of Missouri Hospital & Clinics, Department of Orthopaedic Surgery, Columbia 65212, USA. FAU - Conroy, B P AU - Conroy BP FAU - Meyer, S C AU - Meyer SC FAU - Allen, W C AU - Allen WC LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Disinfectants) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Animals MH - *Bone Transplantation MH - Cattle MH - Chlorhexidine/*therapeutic use MH - Disinfectants/*therapeutic use MH - Humans MH - Tendons/*transplantation MH - *Therapeutic Irrigation MH - Transplantation, Homologous EDAT- 2000/04/06 09:00 MHDA- 2000/05/16 09:00 CRDT- 2000/04/06 09:00 PHST- 2000/04/06 09:00 [pubmed] PHST- 2000/05/16 09:00 [medline] PHST- 2000/04/06 09:00 [entrez] AID - 10.1177/03635465000280021601 [doi] PST - ppublish SO - Am J Sports Med. 2000 Mar-Apr;28(2):241-4. doi: 10.1177/03635465000280021601. PMID- 634382 OWN - NLM STAT- MEDLINE DCOM- 19780517 LR - 20191210 IS - 0028-1298 (Print) IS - 0028-1298 (Linking) VI - 301 IP - 3 DP - 1978 Jan-Feb TI - Reversible decrease of collagen crosslinking by protein low diet and aminoacetonitrile--effect of D-penicillamine and prednisolone on the rise of crosslinks. PG - 241-4 AB - After ending a 4-week period of low-protein diet with or without aminoacetonitrile (AAN), the tail tendons of rats showed an increase of hydroxylysinonorleucine (HLNL) together with other unidentified reducible crosslinks. The binding of dihydroxylysinonorleucine type (DHLNL) was an exception: its content remained unchanged. It may be, assumed, therefore, that the procedures mentioned above act indiscriminately against all reducible crosslinks with the exception of DHLNL. The rise in crosslinks after the 4-week pretreatment was disturbed, when d-penicillamine was given, because it specifically inhibited the formation of HLNL. The content of other crosslink components was slightly increased above that of controls so that the absolute content of total isolated crosslinks increased in the presence of d-penicillamine. No statistically significant differences could be obtained under prednisolone. FAU - Ruiz-Torres, A AU - Ruiz-Torres A FAU - Wille, G AU - Wille G LA - eng PT - Journal Article PL - Germany TA - Naunyn Schmiedebergs Arch Pharmacol JT - Naunyn-Schmiedeberg's archives of pharmacology JID - 0326264 RN - 0 (Acetonitriles) RN - 0 (Dietary Proteins) RN - 0 (Dipeptides) RN - 12764-49-7 (5,5'-dihydroxylysylnorleucine) RN - 21895-67-0 (delta-hydroxylysylnorleucine) RN - 2GQB349IUB (Hydroxylysine) RN - 3739OQ10IJ (Aminoacetonitrile) RN - 832C8OV84S (Norleucine) RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Acetonitriles/*pharmacology MH - Aminoacetonitrile/*pharmacology MH - Animals MH - Collagen/*metabolism MH - Depression, Chemical MH - Dietary Proteins/*administration & dosage MH - Dipeptides/metabolism MH - Hydroxylysine/analogs & derivatives/metabolism MH - Male MH - Norleucine/analogs & derivatives/metabolism MH - Penicillamine/*pharmacology MH - Prednisolone/*pharmacology MH - Rats MH - Skin/metabolism MH - Tendons/metabolism EDAT- 1978/01/01 00:00 MHDA- 1978/01/01 00:01 CRDT- 1978/01/01 00:00 PHST- 1978/01/01 00:00 [pubmed] PHST- 1978/01/01 00:01 [medline] PHST- 1978/01/01 00:00 [entrez] AID - 10.1007/BF00507043 [doi] PST - ppublish SO - Naunyn Schmiedebergs Arch Pharmacol. 1978 Jan-Feb;301(3):241-4. doi: 10.1007/BF00507043. PMID- 5641891 OWN - NLM STAT- MEDLINE DCOM- 19680509 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 150 IP - 2 DP - 1968 Mar 1 TI - Alpha-aminoisobutyric acid uptake in vitro by the rat extensor digitorum longus muscle after denervation and tenotomy. PG - 226-36 FAU - Bombara, G AU - Bombara G FAU - Bergamini, E AU - Bergamini E LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Aminoisobutyric Acids) RN - 0 (Carbon Isotopes) RN - 0 (Nitrophenols) RN - 5ACL011P69 (Ouabain) SB - IM MH - Aminoisobutyric Acids/*metabolism MH - Animals MH - Biological Transport, Active MH - Carbon Isotopes MH - Cell Membrane Permeability MH - Depression, Chemical MH - Hypoxia MH - Manometry MH - Muscle Denervation MH - Muscles/*metabolism MH - Muscular Diseases/*metabolism MH - Nitrophenols/pharmacology MH - Ouabain/pharmacology MH - Oxygen Consumption MH - Rats MH - Tendons/surgery EDAT- 1968/03/01 00:00 MHDA- 1968/03/01 00:01 CRDT- 1968/03/01 00:00 PHST- 1968/03/01 00:00 [pubmed] PHST- 1968/03/01 00:01 [medline] PHST- 1968/03/01 00:00 [entrez] AID - 0005-2736(68)90166-1 [pii] AID - 10.1016/0005-2736(68)90166-1 [doi] PST - ppublish SO - Biochim Biophys Acta. 1968 Mar 1;150(2):226-36. doi: 10.1016/0005-2736(68)90166-1. PMID- 5395649 OWN - NLM STAT- MEDLINE DCOM- 19700324 LR - 20141120 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 19 IP - 11 DP - 1969 Nov TI - [Effect of hormones on physical and chemical properties of connective- and supportive tissue. 3]. PG - 1790-801 FAU - Vogel, G AU - Vogel G LA - ger PT - Journal Article TT - Zur Wirkung von Hormonen auf physikalische und chemische Eigenschaflen des Binde- und Stützgewebes. 3. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Acetates) RN - 0 (Hormones) RN - 06LU7C9H1V (Triiodothyronine) RN - 3XMK78S47O (Testosterone) RN - 4TI98Z838E (Estradiol) RN - 9PHQ9Y1OLM (Prednisolone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Acetates/*pharmacology MH - Animals MH - Bone Development MH - Bone and Bones/*drug effects MH - Chickens MH - Connective Tissue/*drug effects MH - Depression, Chemical MH - Epiphyses/drug effects MH - Estradiol/*pharmacology MH - Femur/drug effects MH - Guinea Pigs MH - Hormones/administration & dosage MH - Hydrocortisone/*pharmacology MH - In Vitro Techniques MH - Mice MH - Prednisolone/*pharmacology MH - Rabbits MH - Rats MH - *Species Specificity MH - Stimulation, Chemical MH - Tail MH - Temperature MH - Tendons/drug effects MH - Testosterone/*pharmacology MH - Tibia/drug effects MH - Triiodothyronine/*pharmacology EDAT- 1969/11/01 00:00 MHDA- 1969/11/01 00:01 CRDT- 1969/11/01 00:00 PHST- 1969/11/01 00:00 [pubmed] PHST- 1969/11/01 00:01 [medline] PHST- 1969/11/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1969 Nov;19(11):1790-801. PMID- 23338666 OWN - NLM STAT- MEDLINE DCOM- 20141027 LR - 20220321 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 22 IP - 2 DP - 2014 Feb TI - Local infiltration analgesia is comparable to femoral nerve block after anterior cruciate ligament reconstruction with hamstring tendon graft: a randomised controlled trial. PG - 317-23 LID - 10.1007/s00167-013-2399-x [doi] AB - PURPOSE: Arthroscopic anterior cruciate ligament (ACL) reconstruction is a painful procedure requiring intensive postoperative pain management. Femoral nerve block is widely used in ACL surgery. However, femoral nerve block does not cover the donor site of the hamstring tendons. Local infiltration analgesia is a simple technique that has proven effective in postoperative pain management after total knee arthroplasty. Further, local infiltration analgesia covers the donor site and is associated with few complications. It was hypothesised that local infiltration analgesia at the donor site and wounds would decrease pain and opioid consumption after ACL reconstruction with hamstring tendon graft. METHODS: Sixty patients undergoing primary ACL surgery with hamstring tendon graft were randomised to receive either local infiltration analgesia or femoral nerve block. Pain was scored on the numeric rating scale, and use of opioid, range of motion and adverse effects were assessed at the postoperative recovery unit (0 h), 3, 24 and 48 h, postoperatively. RESULTS: There were no significant differences between the groups in pain intensity or total opioid consumption at any of the follow-up points. Further, there were no differences between groups concerning side effects and range of motion. CONCLUSIONS: Local infiltration analgesia and femoral nerve block are similar in the management of postoperative pain after ACL reconstruction with hamstring tendon graft. Until randomised studies have investigated femoral nerve block combined with infiltration at the donor site, we recommend local infiltration analgesia in ACL reconstruction with hamstring tendon graft. FAU - Kristensen, Pia Kjær AU - Kristensen PK AD - Department of Orthopedic Surgery, Region Hospital Horsens, Sundvej 30, Horsens, Denmark, pia.kjar.kristensen@horsens.rm.dk. FAU - Pfeiffer-Jensen, Mogens AU - Pfeiffer-Jensen M FAU - Storm, Jens Ole AU - Storm JO FAU - Thillemann, Theis Muncholm AU - Thillemann TM LA - eng SI - ClinicalTrials.gov/NCT01260363 PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20130123 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 7IO5LYA57N (Ropivacaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Amides/therapeutic use MH - *Anesthesia, Local MH - Anesthetics, Local/therapeutic use MH - Anterior Cruciate Ligament/surgery MH - *Anterior Cruciate Ligament Injuries MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Arthroscopy MH - Epinephrine/therapeutic use MH - Female MH - Femoral Nerve MH - Follow-Up Studies MH - Humans MH - Knee Injuries/*surgery MH - Male MH - Middle Aged MH - Muscle, Skeletal MH - *Nerve Block MH - Pain Measurement MH - Pain, Postoperative/drug therapy/*prevention & control MH - Ropivacaine MH - Single-Blind Method MH - Tendons/*transplantation MH - Treatment Outcome EDAT- 2013/01/23 06:00 MHDA- 2014/10/28 06:00 CRDT- 2013/01/23 06:00 PHST- 2012/06/17 00:00 [received] PHST- 2013/01/14 00:00 [accepted] PHST- 2013/01/23 06:00 [entrez] PHST- 2013/01/23 06:00 [pubmed] PHST- 2014/10/28 06:00 [medline] AID - 10.1007/s00167-013-2399-x [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2014 Feb;22(2):317-23. doi: 10.1007/s00167-013-2399-x. Epub 2013 Jan 23. PMID- 4363502 OWN - NLM STAT- MEDLINE DCOM- 19740628 LR - 20190516 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 99 DP - 1974 Mar-Apr TI - Physical biochemistry of calcification. PG - 246-66 FAU - Wadkins, C L AU - Wadkins CL FAU - Luben, R AU - Luben R FAU - Thomas, M AU - Thomas M FAU - Humphreys, R AU - Humphreys R LA - eng PT - Comparative Study PT - Journal Article PT - Review PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Apatites) RN - 0 (Calcium Phosphates) RN - 0 (Diphosphates) RN - 0 (Diphosphoglyceric Acids) RN - 0 (Hydroxyapatites) RN - 0 (Minerals) RN - 0 (Phosphates) RN - 9007-34-5 (Collagen) RN - F8VB5M810T (Tetracycline) RN - Q80VPU408O (Fluorides) RN - SY7Q814VUP (Calcium) RN - YZS2RPE8LE (Strontium) SB - IM MH - Animals MH - Apatites/biosynthesis MH - Bone Matrix/drug effects/metabolism MH - Bone and Bones/metabolism MH - *Calcinosis MH - Calcium/metabolism MH - Calcium Phosphates/metabolism MH - Catalysis MH - Collagen/metabolism MH - Diphosphates/pharmacology MH - Diphosphoglyceric Acids/pharmacology MH - Fluorides/pharmacology MH - Hydrogen-Ion Concentration MH - Hydroxyapatites/metabolism MH - Minerals/metabolism MH - Phosphates/metabolism MH - Strontium/pharmacology MH - Tendons/metabolism MH - Tetracycline/pharmacology RF - 68 OID - NASA: 74154637 EDAT- 1974/03/01 00:00 MHDA- 1974/03/01 00:01 CRDT- 1974/03/01 00:00 PHST- 1974/03/01 00:00 [pubmed] PHST- 1974/03/01 00:01 [medline] PHST- 1974/03/01 00:00 [entrez] AID - 10.1097/00003086-197403000-00029 [doi] PST - ppublish SO - Clin Orthop Relat Res. 1974 Mar-Apr;(99):246-66. doi: 10.1097/00003086-197403000-00029. PMID- 4245018 OWN - NLM STAT- MEDLINE DCOM- 19700514 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 19 IP - 12 DP - 1969 Dec TI - [Effect of hormones on physical and chemical properties of connective and supportive tissue. 4]. PG - 1981-96 FAU - Vogel, H G AU - Vogel HG LA - ger PT - Comparative Study PT - Journal Article TT - Zur Wirkung von Hormonen auf physikalische und chemische Eigenschaften des Binde- und Stützgewebes. 4. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Acetates) RN - 0 (Glycosaminoglycans) RN - 0 (Hexosamines) RN - 0 (Hormones) RN - 06LU7C9H1V (Triiodothyronine) RN - 27YLU75U4W (Phosphorus) RN - 3XMK78S47O (Testosterone) RN - 4TI98Z838E (Estradiol) RN - 9007-34-5 (Collagen) RN - 9NEZ333N27 (Sodium) RN - 9PHQ9Y1OLM (Prednisolone) RN - RMB44WO89X (Hydroxyproline) RN - RWP5GA015D (Potassium) RN - SY7Q814VUP (Calcium) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Acetates/pharmacology MH - Animals MH - Calcium/analysis MH - Chickens MH - Collagen/*analysis MH - Connective Tissue/*drug effects MH - Depression, Chemical MH - Estradiol/pharmacology MH - Femur/analysis MH - Glycosaminoglycans/analysis MH - Hexosamines/analysis MH - Hormones/*pharmacology MH - Hydrocortisone/pharmacology MH - Hydroxyproline/analysis MH - Phosphorus/analysis MH - Potassium/analysis MH - Prednisolone/pharmacology MH - Rats MH - Skin/analysis MH - Sodium/analysis MH - Stimulation, Chemical MH - Tail MH - Tendons/*drug effects MH - Testosterone/pharmacology MH - Tibia/analysis MH - Time Factors MH - Triiodothyronine/pharmacology EDAT- 1969/12/01 00:00 MHDA- 1969/12/01 00:01 CRDT- 1969/12/01 00:00 PHST- 1969/12/01 00:00 [pubmed] PHST- 1969/12/01 00:01 [medline] PHST- 1969/12/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1969 Dec;19(12):1981-96. PMID- 26375530 OWN - NLM STAT- MEDLINE DCOM- 20160418 LR - 20220331 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 38 IP - 9 DP - 2015 Sep TI - Suture Technique Influences the Biomechanical Integrity of Pectoralis Major Repairs. PG - e746-52 LID - 10.3928/01477447-20150902-50 [doi] AB - Pectoralis major ruptures occur in large, muscular individuals, and repair constructs may experience significant tension. Four different suture techniques were evaluated biomechanically to determine the effect of suture technique on optimizing fixation strength. Forty fresh-frozen cadaveric shoulders were repaired using endosteal buttons. The control group was repaired with #2 polyblend suture in a modified Mason-Allen stitch configuration. The triple group was repaired using the same suture and configuration, but with the addition of triple-loaded buttons. The configuration group was repaired using the same suture in a Krackow/Bunnell configuration. The tape group was repaired using 2-mm polyethylene tape and #5 polyblend suture in the Krackow/Bunnell configuration. Under cyclic loading, there was no significant difference between groups. Under load-to-failure testing, the tape group withstood a significantly greater maximum load (726.0±90.0 N) than the control and triple groups (330.2±20.2 and 400.2±35.2 N, respectively; P<.005), and similar load to the configuration group (509.9±68.6 N; P=.16). The configuration group failed via suture breakage (9/10); the other groups failed via suture pullout, in which suture pulled through tendon (26/30). Pectoralis major repair in a running, locked configuration appears to improve biomechanical performance by preventing suture pullout. Use of a polyethylene tape construct demonstrates the potential for improved failure loads, but its role remains undefined. CI - Copyright 2015, SLACK Incorporated. FAU - Gregory, James M AU - Gregory JM FAU - Klosterman, Emma L AU - Klosterman EL FAU - Thomas, Jacqueline M AU - Thomas JM FAU - Hammond, James AU - Hammond J FAU - Shewman, Elizabeth F AU - Shewman EF FAU - Wang, Vincent M AU - Wang VM FAU - Verma, Nikhil N AU - Verma NN FAU - Romeo, Anthony A AU - Romeo AA LA - eng PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 9002-88-4 (Polyethylene) SB - IM MH - Biomechanical Phenomena/physiology MH - Cadaver MH - Case-Control Studies MH - Equipment Failure MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pectoralis Muscles/injuries/*surgery MH - Polyethylene/therapeutic use MH - Rupture/surgery MH - Surgical Tape MH - *Suture Techniques MH - Sutures/standards MH - Tendons/surgery MH - Wound Healing/physiology EDAT- 2015/09/17 06:00 MHDA- 2016/04/19 06:00 CRDT- 2015/09/17 06:00 PHST- 2014/07/04 00:00 [received] PHST- 2014/12/10 00:00 [accepted] PHST- 2015/09/17 06:00 [entrez] PHST- 2015/09/17 06:00 [pubmed] PHST- 2016/04/19 06:00 [medline] AID - 10.3928/01477447-20150902-50 [doi] PST - ppublish SO - Orthopedics. 2015 Sep;38(9):e746-52. doi: 10.3928/01477447-20150902-50. PMID- 18021580 OWN - NLM STAT- MEDLINE DCOM- 20080206 LR - 20171116 IS - 1071-1007 (Print) IS - 1071-1007 (Linking) VI - 28 IP - 11 DP - 2007 Nov TI - Comparison of MRI and local anesthetic tendon sheath injection in the diagnosis of posterior tibial tendon tenosynovitis. PG - 1124-7 AB - BACKGROUND: The modalities currently available to clinicians to confirm the clinical suspicion of posterior tibial tendinitis include MRI, CT, sonography, tenography, and local anesthetic tendon sheath injections. There are no reports in the literature comparing local anesthetic tendon sheath injection to MRI as tools for diagnosing posterior tibial tenosynovitis. METHODS: The authors reviewed the records of all patients with stage 1 posterior tibial tendon dysfunction between the dates of September 1, 2001, to November 21, 2004. Fifteen patients (17 ankles) had a local anesthetic injection into the posterior tibial tendon sheath and MRI for clinically suspected tenosynovitis of the posterior tibial tendon. RESULTS: Seventeen (100%) of 17 ankles had complete relief of symptoms after the local anesthetic tendon sheath injections. Fifteen (88%) of 17 ankles had abnormally increased fluid signal within the posterior tibial tendon sheath seen on MRI. Two of two ankles (100%), after having negative MRI findings, had complete relief with a local anesthetic tendon sheath injection. In addition, conservative treatment failed in these two patients, and they subsequently had tenosynovectomy with gross confirmation at surgery of inflammatory changes within the tendon sheath. These two patients had complete symptom relief after tenosynovectomy. CONCLUSIONS: Local tendon sheath injections and MRI are both reliable diagnostic tools. Injection of the posterior tibial tendon is an accurate, safe, and sensitive modality useful in patients in whom MRI studies are negative in the face of continued clinical suspicion. FAU - Cooper, Andrew J AU - Cooper AJ AD - Department of Orthopaedic Surgery, University of Miami, Miami, FL, USA. FAU - Mizel, Mark S AU - Mizel MS FAU - Patel, Preetesh D AU - Patel PD FAU - Steinmetz, Neil D AU - Steinmetz ND FAU - Clifford, Paul D AU - Clifford PD LA - eng PT - Journal Article PL - United States TA - Foot Ankle Int JT - Foot & ankle international JID - 9433869 RN - 0 (Anesthetics, Local) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - *Anesthetics, Local/therapeutic use MH - *Bupivacaine/therapeutic use MH - Female MH - Foot/pathology MH - Humans MH - Injections MH - *Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Pain Measurement MH - Synovectomy MH - Tendons/pathology MH - Tenosynovitis/*diagnosis/therapy MH - Treatment Outcome EDAT- 2007/11/21 09:00 MHDA- 2008/02/07 09:00 CRDT- 2007/11/21 09:00 PHST- 2007/11/21 09:00 [pubmed] PHST- 2008/02/07 09:00 [medline] PHST- 2007/11/21 09:00 [entrez] AID - 962849 [pii] AID - 10.3113/FAI.2007.1124 [doi] PST - ppublish SO - Foot Ankle Int. 2007 Nov;28(11):1124-7. doi: 10.3113/FAI.2007.1124. PMID- 10421198 OWN - NLM STAT- MEDLINE DCOM- 19990729 LR - 20190711 IS - 0022-5282 (Print) IS - 0022-5282 (Linking) VI - 47 IP - 1 DP - 1999 Jul TI - Inhibition of alpha-smooth muscle actin expression in an in vitro wound healing model by certain antibiotics. PG - 130-5 AB - OBJECTIVE: This study assesses the effects of antimicrobials on wound healing in an in vitro model of chicken flexor tendons in a collagen gel matrix. Two equidistant tendons were bathed in a culture medium for 28 days as fibroblasts (fb) grew from the tendon ends into the collagen gel and migrated toward each other until gap closure. Five groups of 10 paired tendons each included the control and the study groups, which received oxacillin (Ox), clindamycin (Cl), chloramphenicol (Chl), or tetracycline (Tet) in the culture medium to assess their effects on gap closure rate, fb migration, and myofibroblast alpha-smooth muscle (alpha-SM) actin expression. RESULTS: Gap closure, by day 27, was 98.5% in the controls compared with 97%, 92%, 89.5%, 21.75% in the Tet, Cl, Ox, and Chl groups. Chl retarded gap closure (p < 0.05). Fb migration was similar for all groups. In the control and Ox groups, myofibroblast expressed actin at day 5. By day 7, fb cells were clearly visible in the control, Ox, and Cl groups, whereas, only light actin was present in the Chl and Tet groups. Actin band densities for the Cl, Ox, Tet, and Chl groups were 78.4%, 62.5%, 61.7% and 26.1%, respectively, of the control group. CONCLUSION: These studies suggest that one reason certain antimicrobials impair wound healing, is due to myofibroblast inhibition of alpha-SM actin. FAU - Yu, P AU - Yu P AD - Department of Surgery at Wayne State University, Detroit, Michigan 48201, USA. FAU - Vlahos, A L AU - Vlahos AL FAU - Dombi, G W AU - Dombi GW FAU - Ledgerwood, A M AU - Ledgerwood AM FAU - Lucas, C E AU - Lucas CE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Trauma JT - The Journal of trauma JID - 0376373 RN - 0 (Actins) RN - 0 (Anti-Bacterial Agents) RN - 3U02EL437C (Clindamycin) RN - 66974FR9Q1 (Chloramphenicol) RN - F8VB5M810T (Tetracycline) RN - UH95VD7V76 (Oxacillin) SB - IM MH - Actins/drug effects/*metabolism MH - Animals MH - Anti-Bacterial Agents/*pharmacology MH - Blotting, Western MH - Cell Movement MH - Chickens MH - Chloramphenicol/pharmacology MH - Clindamycin/pharmacology MH - Culture Techniques MH - Fibroblasts/cytology/physiology MH - Fluorescent Antibody Technique MH - Muscle, Smooth/cytology/*metabolism MH - Oxacillin/pharmacology MH - Tendon Injuries/physiopathology MH - Tendons/cytology MH - Tetracycline/pharmacology MH - Wound Healing/drug effects/*physiology EDAT- 1999/07/27 00:00 MHDA- 1999/07/27 00:01 CRDT- 1999/07/27 00:00 PHST- 1999/07/27 00:00 [pubmed] PHST- 1999/07/27 00:01 [medline] PHST- 1999/07/27 00:00 [entrez] AID - 10.1097/00005373-199907000-00026 [doi] PST - ppublish SO - J Trauma. 1999 Jul;47(1):130-5. doi: 10.1097/00005373-199907000-00026. PMID- 22628605 OWN - NLM STAT- MEDLINE DCOM- 20120813 LR - 20220408 IS - 2044-5377 (Electronic) IS - 0301-620X (Linking) VI - 94 IP - 6 DP - 2012 Jun TI - A comparison of lidocaine, ropivacaine and dexamethasone toxicity on bovine tenocytes in culture. PG - 856-62 LID - 10.1302/0301-620X.94B6.29063 [doi] AB - Peri-tendinous injection of local anaesthetic, both alone and in combination with corticosteroids, is commonly performed in the treatment of tendinopathies. Previous studies have shown that local anaesthetics and corticosteroids are chondrotoxic, but their effect on tenocytes remains unknown. We compared the effects of lidocaine and ropivacaine, alone or combined with dexamethasone, on the viability of cultured bovine tenocytes. Tenocytes were exposed to ten different conditions: 1) normal saline; 2) 1% lidocaine; 3) 2% lidocaine; 4) 0.2% ropivacaine; 5) 0.5% ropivacaine; 6) dexamethasone (dex); 7) 1% lidocaine+dex; 8) 2% lidocaine+dex; 9) 0.2% ropivacaine+dex; and 10) 0.5% ropivacaine+dex, for 30 minutes. After a 24-hour recovery period, the viability of the tenocytes was quantified using the CellTiter-Glo viability assay and fluorescence-activated cell sorting (FACS) for live/dead cell counts. A 30-minute exposure to lidocaine alone was significantly toxic to the tenocytes in a dose-dependent manner, but a 30-minute exposure to ropivacaine or dexamethasone alone was not significantly toxic. Dexamethasone potentiated ropivacaine tenocyte toxicity at higher doses of ropivacaine, but did not potentiate lidocaine tenocyte toxicity. As seen in other cell types, lidocaine has a dose-dependent toxicity to tenocytes but ropivacaine is not significantly toxic. Although dexamethasone alone is not toxic, its combination with 0.5% ropivacaine significantly increased its toxicity to tenocytes. These findings might be relevant to clinical practice and warrant further investigation. FAU - Piper, S L AU - Piper SL AD - University of California, San Francisco, Department of Orthopaedic Surgery, 500 Parnassus Avenue, MUW 3rd Floor, San Francisco, California 94143, USA. FAU - Laron, D AU - Laron D FAU - Manzano, G AU - Manzano G FAU - Pattnaik, T AU - Pattnaik T FAU - Liu, X AU - Liu X FAU - Kim, H T AU - Kim HT FAU - Feeley, B T AU - Feeley BT LA - eng PT - Comparative Study PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 0 (Drug Combinations) RN - 0 (Glucocorticoids) RN - 7IO5LYA57N (Ropivacaine) RN - 7S5I7G3JQL (Dexamethasone) RN - 98PI200987 (Lidocaine) SB - IM MH - Amides/*toxicity MH - Anesthetics, Local/*toxicity MH - Animals MH - Cattle MH - Cell Survival/drug effects MH - Cells, Cultured MH - Dexamethasone/*toxicity MH - Dose-Response Relationship, Drug MH - Drug Combinations MH - Drug Synergism MH - Glucocorticoids/*toxicity MH - Lidocaine/*toxicity MH - Ropivacaine MH - Tendons/cytology/*drug effects EDAT- 2012/05/26 06:00 MHDA- 2012/08/14 06:00 CRDT- 2012/05/26 06:00 PHST- 2012/05/26 06:00 [entrez] PHST- 2012/05/26 06:00 [pubmed] PHST- 2012/08/14 06:00 [medline] AID - 94-B/6/856 [pii] AID - 10.1302/0301-620X.94B6.29063 [doi] PST - ppublish SO - J Bone Joint Surg Br. 2012 Jun;94(6):856-62. doi: 10.1302/0301-620X.94B6.29063. PMID- 331187 OWN - NLM STAT- MEDLINE DCOM- 19771028 LR - 20131121 IS - 0030-5898 (Print) IS - 0030-5898 (Linking) VI - 8 IP - 2 DP - 1977 Apr TI - Some biologic and technical considerations in the repair of long tendons. PG - 449-72 FAU - Peacock, E E Jr AU - Peacock EE Jr LA - eng PT - Journal Article PL - United States TA - Orthop Clin North Am JT - The Orthopedic clinics of North America JID - 0254463 RN - 0 (Silicone Elastomers) RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Aminopropionitrile/therapeutic use MH - Animals MH - Cadaver MH - Cicatrix/physiopathology MH - Collagen/biosynthesis/immunology MH - Connective Tissue/physiopathology MH - Dogs MH - Fingers/surgery MH - Foreign-Body Reaction/physiopathology MH - Graft Rejection MH - Hand/surgery MH - Humans MH - Hydroxyproline/therapeutic use MH - Microsurgery/methods MH - Movement MH - Silicone Elastomers/adverse effects MH - Skin Transplantation MH - Tendon Injuries/physiopathology/*surgery MH - Tendon Transfer/methods MH - Tissue Adhesions MH - Transplantation, Heterologous MH - Transplantation, Homologous MH - Wound Healing/drug effects EDAT- 1977/04/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1977/04/01 00:00 PHST- 1977/04/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1977/04/01 00:00 [entrez] PST - ppublish SO - Orthop Clin North Am. 1977 Apr;8(2):449-72. PMID- 4576164 OWN - NLM STAT- MEDLINE DCOM- 19730810 LR - 20191030 IS - 0029-6678 (Print) IS - 0029-6678 (Linking) VI - 15 IP - 1 DP - 1973 TI - Principles of drug therapy of hyperlipidemic xanthomatous diseases. PG - 144-50 FAU - Zöllner, N AU - Zöllner N LA - eng PT - Clinical Trial PT - Journal Article PL - Switzerland TA - Nutr Metab JT - Nutrition and metabolism JID - 0330472 RN - 0 (Dietary Fats) RN - 0 (Lipoproteins) RN - 0 (Pyridines) RN - 97C5T2UQ7J (Cholesterol) RN - Y4S76JWI15 (Methanol) SB - IM MH - Blood Protein Disorders/drug therapy MH - Cholesterol/blood MH - Clinical Trials as Topic MH - Coronary Disease/drug therapy/prevention & control MH - Diet Therapy MH - Dietary Fats/therapeutic use MH - Evaluation Studies as Topic MH - Humans MH - Hypercholesterolemia/*drug therapy/genetics/therapy MH - Hyperlipidemias/drug therapy MH - Lipoproteins/blood MH - Methanol/*therapeutic use MH - Pyridines/*therapeutic use MH - Skin MH - Tendons MH - Time Factors MH - Xanthomatosis/*drug therapy EDAT- 1973/01/01 00:00 MHDA- 1973/01/01 00:01 CRDT- 1973/01/01 00:00 PHST- 1973/01/01 00:00 [pubmed] PHST- 1973/01/01 00:01 [medline] PHST- 1973/01/01 00:00 [entrez] AID - 10.1159/000175433 [doi] PST - ppublish SO - Nutr Metab. 1973;15(1):144-50. doi: 10.1159/000175433. PMID- 5394522 OWN - NLM STAT- MEDLINE DCOM- 19691203 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 19 IP - 9 DP - 1969 Sep TI - [Effect of hormones on physical and chemical properties of connective- and supporting tissue. 1]. PG - 1495-503 FAU - Vogel, H G AU - Vogel HG LA - ger PT - Comparative Study PT - Journal Article TT - Zur Wirkung von Hormonen auf physikalische und chemische Eigenschaften des Binde- und Stützgewebes. 1. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Acetates) RN - 0 (Hormones) RN - 0 (Succinates) RN - 27O7W4T232 (Spironolactone) RN - 3XMK78S47O (Testosterone) RN - 40GP35YQ49 (Desoxycorticosterone) RN - 4964P6T9RB (Aldosterone) RN - 4G7DS2Q64Y (Progesterone) RN - 4TI98Z838E (Estradiol) RN - 9PHQ9Y1OLM (Prednisolone) RN - R5LM3H112R (Dihydrotachysterol) RN - W980KJ009P (Corticosterone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Acetates/pharmacology MH - Adrenalectomy MH - Age Factors MH - Aldosterone/pharmacology MH - Animals MH - Body Weight MH - Connective Tissue/*drug effects MH - Corticosterone/pharmacology MH - Depression, Chemical MH - Desoxycorticosterone/pharmacology MH - Dihydrotachysterol/pharmacology MH - Epiphyses/*drug effects MH - Estradiol/pharmacology MH - Female MH - Femur/drug effects MH - Guinea Pigs MH - Hormones/*pharmacology MH - Hydrocortisone/pharmacology MH - Male MH - Mice MH - Prednisolone/pharmacology MH - Progesterone/pharmacology MH - Rabbits MH - Rats MH - Sex Factors MH - Spironolactone/pharmacology MH - Stimulation, Chemical MH - Stress, Physiological MH - Succinates/pharmacology MH - Tail/drug effects MH - Tendons/*drug effects MH - Testosterone/pharmacology EDAT- 1969/09/01 00:00 MHDA- 1969/09/01 00:01 CRDT- 1969/09/01 00:00 PHST- 1969/09/01 00:00 [pubmed] PHST- 1969/09/01 00:01 [medline] PHST- 1969/09/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1969 Sep;19(9):1495-503. PMID- 21555843 OWN - NLM STAT- MEDLINE DCOM- 20111227 LR - 20151119 IS - 1748-605X (Electronic) IS - 1748-6041 (Linking) VI - 6 IP - 3 DP - 2011 Jun TI - Improved human tenocyte proliferation and differentiation in vitro by optimized silk degumming. PG - 035010 LID - 10.1088/1748-6041/6/3/035010 [doi] AB - Tendon disorders are common clinical conditions. Tendon tissue engineering provides a new approach for tendon repair by integrating engineered substitutes with their native counterparts. Silk is considered to be a promising candidate for tendon engineering because of its biological and mechanical properties. However, a major concern with using silk for biomedical applications is the immune responses generated by sericin, a glue-like protein that coats the silk fibres. This study improves the existing protocols for silk 'degumming' which removes sericin and enables preparation of silk that is suitable for tendon regeneration. Bombyx mori silks were treated by sequential treatments with different proteases. The efficiency of degumming was determined by measuring weight loss, picric acid and carmine staining and scanning electron microscopy. To evaluate the cellular responses after degumming, the growth and differentiation of human tenocytes on silks were examined. The results showed that sequential protease treatment effectively degummed raw silks. The sequentially degummed silks showed enhanced tenocyte proliferation and upregulated mRNA levels of tendon markers. Thick cell multilayers formed on the treated silks, with cells and collagen fibres penetrating into the spaces in individual silk filaments, resulting in a structure resembling human tendon. FAU - Wang, Xiao AU - Wang X AD - Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. FAU - Qiu, Yiwei AU - Qiu Y FAU - Carr, Andrew J AU - Carr AJ FAU - Triffitt, James T AU - Triffitt JT FAU - Sabokbar, Afsie AU - Sabokbar A FAU - Xia, Zhidao AU - Xia Z LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20110510 PL - England TA - Biomed Mater JT - Biomedical materials (Bristol, England) JID - 101285195 RN - 0 (Oxazines) RN - 0 (Picrates) RN - 0 (Silk) RN - 0 (Xanthenes) RN - 1FN9YD6968 (resazurin) RN - A49OS0F91S (picric acid) RN - CID8Z8N95N (Carmine) SB - IM MH - Animals MH - Bombyx MH - Carmine/pharmacology MH - Cell Differentiation MH - Cell Proliferation MH - *Gene Expression Regulation MH - Humans MH - Materials Testing MH - Microscopy, Electron, Scanning/methods MH - Oxazines/pharmacology MH - Picrates/pharmacology MH - Silk MH - Stress, Mechanical MH - Tendon Injuries/*therapy MH - Tendons/*cytology/*pathology MH - Tissue Engineering/methods MH - Xanthenes/pharmacology EDAT- 2011/05/11 06:00 MHDA- 2011/12/28 06:00 CRDT- 2011/05/11 06:00 PHST- 2011/05/11 06:00 [entrez] PHST- 2011/05/11 06:00 [pubmed] PHST- 2011/12/28 06:00 [medline] AID - S1748-6041(11)67983-7 [pii] AID - 10.1088/1748-6041/6/3/035010 [doi] PST - ppublish SO - Biomed Mater. 2011 Jun;6(3):035010. doi: 10.1088/1748-6041/6/3/035010. Epub 2011 May 10. PMID- 39544139 OWN - NLM STAT- MEDLINE DCOM- 20250426 LR - 20250516 IS - 2192-2659 (Electronic) IS - 2192-2640 (Print) IS - 2192-2640 (Linking) VI - 14 IP - 4 DP - 2025 Feb TI - Human Tendon-on-a-Chip for Modeling the Myofibroblast Microenvironment in Peritendinous Fibrosis. PG - e2403116 LID - 10.1002/adhm.202403116 [doi] LID - 2403116 AB - Understanding the myofibroblast microenvironment is critical to developing therapies for fibrotic diseases. Here the development of a novel human tendon-on-a-chip (hToC) is reported to model this crosstalk in peritendinous adhesions, which currently lacks biological therapies. The hToC facilitates cellular and paracrine interactions between a vascular component, which contains endothelial cells and monocytes, and a tissue hydrogel component that houses tendon cells and macrophages. It is found that the hToC replicates some aspects of in vivo inflammatory and fibrotic phenotypes in preclinical and clinical samples, including activated mTOR signaling, vascular inflammation, tissue contraction induced by myofibroblast activation, inflammatory cytokines secretion, and transendothelial migration of monocytes to the tissue hydrogel. Transcriptional analysis demonstrates significant overlap in enriched pathways in the hToC with human tenolysis samples, including the activation of mTOR signaling. Rapamycin suppresses the vascular inflammation and fibrotic phenotype in the hToC, which provides proof-of-concept of its utility as an in vitro tool for investigating multicellular crosstalk in fibrosis and testing therapeutics to mitigate it. CI - © 2024 The Author(s). Advanced Healthcare Materials published by Wiley‐VCH GmbH. FAU - Ajalik, Raquel E AU - Ajalik RE AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. FAU - Linares, Isabelle AU - Linares I AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. FAU - Alenchery, Rahul G AU - Alenchery RG AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. FAU - Zhang, Victor Z AU - Zhang VZ AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. FAU - Wright, Terry W AU - Wright TW AD - Department of Pediatrics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Microbiology and Immunology, University of Rochester, Rochester, NY, 14642, USA. FAU - Miller, Benjamin L AU - Miller BL AUID- ORCID: 0000-0001-9168-8047 AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Dermatology, University of Rochester, Rochester, NY, 14642, USA. AD - Institute of Optics, University of Rochester, Rochester, NY, 14627, USA. FAU - McGrath, James L AU - McGrath JL AUID- ORCID: 0000-0003-2017-8335 AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. FAU - Awad, Hani A AU - Awad HA AUID- ORCID: 0000-0003-2197-2610 AD - Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY, 14642, USA. AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, 14627, USA. LA - eng GR - (NIAMS)/ GR - T32GM007356/GM/NIGMS NIH HHS/United States GR - T32 GM007356/GM/NIGMS NIH HHS/United States GR - UG3 TR003281/TR/NCATS NIH HHS/United States GR - UH3 TR003281/TR/NCATS NIH HHS/United States GR - T32 AR076950/AR/NIAMS NIH HHS/United States GR - (NCATS)/ GR - UG3TR003281/AR/NIAMS NIH HHS/United States GR - UH3TR003281/AR/NIAMS NIH HHS/United States GR - UG3TR003281/TR/NCATS NIH HHS/United States GR - T32AR076950/AR/NIAMS NIH HHS/United States GR - U2CAG088071/TR/NCATS NIH HHS/United States GR - UH3TR003281/TR/NCATS NIH HHS/United States GR - U2CAG088071/National Institute of Aging (NIA)/ GR - U2C AG088071/AG/NIA NIH HHS/United States GR - National Science Foundation/ PT - Journal Article DEP - 20241115 PL - Germany TA - Adv Healthc Mater JT - Advanced healthcare materials JID - 101581613 RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM UOF - Res Sq. 2023 Dec 13:rs.3.rs-3722255. doi: 10.21203/rs.3.rs-3722255/v1. PMID: 38168335 MH - Humans MH - Fibrosis/metabolism MH - *Myofibroblasts/metabolism/pathology MH - *Lab-On-A-Chip Devices MH - *Tendons/pathology/metabolism MH - *Cellular Microenvironment MH - TOR Serine-Threonine Kinases/metabolism MH - Signal Transduction MH - Sirolimus/pharmacology PMC - PMC11804843 MID - NIHMS2035508 OTO - NOTNLM OT - TGF‐β1 OT - fibrosis OT - human microphysiological system OT - mTOR OT - myofibroblast microenvironment OT - peritendinous adhesions OT - tendon‐on‐a‐chip OT - vascular inflammation COIS- Co‐author, James L McGrath, JLM is a co‐founder of SiMPore Inc., the manufacturer of the ultrathin silicon‐based membranes used in this work. EDAT- 2024/11/15 06:24 MHDA- 2025/02/07 12:25 PMCR- 2025/02/07 CRDT- 2024/11/15 04:04 PHST- 2024/11/06 00:00 [revised] PHST- 2024/08/23 00:00 [received] PHST- 2025/02/07 12:25 [medline] PHST- 2024/11/15 06:24 [pubmed] PHST- 2024/11/15 04:04 [entrez] PHST- 2025/02/07 00:00 [pmc-release] AID - ADHM202403116 [pii] AID - 10.1002/adhm.202403116 [doi] PST - ppublish SO - Adv Healthc Mater. 2025 Feb;14(4):e2403116. doi: 10.1002/adhm.202403116. Epub 2024 Nov 15. PMID- 33897889 OWN - NLM STAT- MEDLINE DCOM- 20210730 LR - 20210730 IS - 1838-7640 (Electronic) IS - 1838-7640 (Linking) VI - 11 IP - 12 DP - 2021 TI - Synergistic enhancement of tendon-to-bone healing via anti-inflammatory and pro-differentiation effects caused by sustained release of Mg(2+)/curcumin from injectable self-healing hydrogels. PG - 5911-5925 LID - 10.7150/thno.56266 [doi] AB - Poor healing response after rotator cuff reconstruction is multifactorial, with the inflammatory microenvironment and deficiency of stem cell differentiation factors at the lesion site being most relevant. However, there is a lack of effective tissue engineering strategies that can simultaneously exert anti-inflammatory and pro-differentiation effects to promote rotator cuff healing. Methods: In this study, we synthesized and characterized a novel active drug delivery vector that successfully overcame the challenge of simultaneous high-efficiency loading and controlled release of Mg(2+) and curcumin. The anti-inflammatory and pro-differentiation effects of the composite hydrogel were evaluated in vitro and in vivo. Moreover, healing of the rotator cuff tendon-to-bone interface was studied by histology, immunofluorescence, and biomechanical tests. Results: The composite hydrogel exhibited excellent biocompatibility and injectability, good adhesiveness, and rapid self-healing. The released curcumin showed obvious anti-inflammatory and antioxidation effects, which protected stem cells and tendon matrix. Furthermore, released Mg(2+) promoted stem cell aggregation and chondrogenesis. Moreover, biomechanical tests and histological results of a rat rotator cuff tear model at 8 weeks after surgery indicated that the composite hydrogel significantly enhanced tendon-to-bone healing. Conclusions: The composite hydrogel mediated sustained in situ release of curcumin and Mg(2+) to effectively promote rotator cuff tendon-to-bone healing via anti-inflammatory and pro-differentiation effects. Therefore, this composite hydrogel offers significant promise for rotator cuff repair. CI - © The author(s). FAU - Chen, Baojun AU - Chen B AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Liang, Yongping AU - Liang Y AD - Frontier Institute of Science and Technology, and State Key Laboratory for Mechanical Behavior of Materials, and Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, 710049, China. FAU - Zhang, Jing AU - Zhang J AD - Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education. School of Medicine, Northwest University, 229 Taibai North Road, Xi'an 710069, China. FAU - Bai, Lang AU - Bai L AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Xu, Meiguang AU - Xu M AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Han, Qian AU - Han Q AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Han, Xuezhe AU - Han X AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Xiu, Jintao AU - Xiu J AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Li, Meng AU - Li M AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Zhou, Xiaoling AU - Zhou X AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. FAU - Guo, Baolin AU - Guo B AD - Frontier Institute of Science and Technology, and State Key Laboratory for Mechanical Behavior of Materials, and Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, 710049, China. FAU - Yin, Zhanhai AU - Yin Z AD - Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210403 PL - Australia TA - Theranostics JT - Theranostics JID - 101552395 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Delayed-Action Preparations) RN - 0 (Hydrogels) RN - I38ZP9992A (Magnesium) RN - IT942ZTH98 (Curcumin) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*pharmacology MH - Biomechanical Phenomena/drug effects MH - Bone and Bones/*drug effects MH - Cell Differentiation/*drug effects MH - Chondrogenesis/drug effects MH - Curcumin/*pharmacology MH - Delayed-Action Preparations/*pharmacology MH - Hydrogels/*pharmacology MH - Magnesium/*pharmacology MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/drug effects MH - Stem Cells/drug effects MH - Tendons/*drug effects MH - Wound Healing/drug effects PMC - PMC8058719 OTO - NOTNLM OT - anti-inflammation OT - hydrogels OT - pro-chondrogenesis OT - rotator cuff OT - synergistic effects OT - tendon-to-bone healing COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2021/04/27 06:00 MHDA- 2021/07/31 06:00 PMCR- 2021/01/01 CRDT- 2021/04/26 05:51 PHST- 2020/11/22 00:00 [received] PHST- 2021/03/18 00:00 [accepted] PHST- 2021/04/26 05:51 [entrez] PHST- 2021/04/27 06:00 [pubmed] PHST- 2021/07/31 06:00 [medline] PHST- 2021/01/01 00:00 [pmc-release] AID - thnov11p5911 [pii] AID - 10.7150/thno.56266 [doi] PST - epublish SO - Theranostics. 2021 Apr 3;11(12):5911-5925. doi: 10.7150/thno.56266. eCollection 2021. PMID- 20487623 OWN - NLM STAT- MEDLINE DCOM- 20100820 LR - 20151119 IS - 0393-974X (Print) IS - 0393-974X (Linking) VI - 24 IP - 2 DP - 2010 Apr-Jun TI - The effects of COX-2 anti-inflammatory drugs on soft tissue healing: a review of the literature. PG - 107-14 AB - COX-2 specific inhibitors (coxibs) have become a popular treatment for musculoskeletal disorders given that the incidence of gastrointestinal side effects is lower with these drugs than with traditional non-steroidal anti-inflammatory drugs. The aim of this review is to discuss the results of animal studies investigating the role of coxibs in the healing of soft tissues. MEDLINE was searched (years 2001-2009) for studies analyzing the effect of coxibs on the healing of soft tissues. There are relatively few data in the literature suggesting that coxibs can impair soft tissue healing and the data existing have the limitation of having been generated in animal studies. In fact, the method of administration and the doses used make it difficult to translate these results to the clinical setting. Short-term use of coxibs following lesions to ligaments or tendons remains a prudent choice. Traditional anti-inflammatory drugs are a safer treatment for patients with a high cardiovascular risk. These drugs should, however, be evaluated carefully with regards to gastrointestinal events and their still poorly defined effect on tissue healing. FAU - Randelli, Pietro AU - Randelli P FAU - Randelli, F AU - Randelli F FAU - Cabitza, P AU - Cabitza P FAU - Vaienti, L AU - Vaienti L LA - eng PT - Editorial PT - Review PL - Singapore TA - J Biol Regul Homeost Agents JT - Journal of biological regulators and homeostatic agents JID - 8809253 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*pharmacology MH - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*pharmacology/therapeutic use MH - Celecoxib MH - Cyclooxygenase 2 Inhibitors/adverse effects/*pharmacology/therapeutic use MH - Humans MH - Pyrazoles/therapeutic use MH - Safety MH - Sulfonamides/therapeutic use MH - Tendinopathy/drug therapy MH - Wound Healing/*drug effects RF - 51 EDAT- 2010/05/22 06:00 MHDA- 2010/08/21 06:00 CRDT- 2010/05/22 06:00 PHST- 2010/05/22 06:00 [entrez] PHST- 2010/05/22 06:00 [pubmed] PHST- 2010/08/21 06:00 [medline] AID - 1 [pii] PST - ppublish SO - J Biol Regul Homeost Agents. 2010 Apr-Jun;24(2):107-14. PMID- 7964884 OWN - NLM STAT- MEDLINE DCOM- 19941220 LR - 20190724 IS - 0022-510X (Print) IS - 0022-510X (Linking) VI - 125 IP - 1 DP - 1994 Aug TI - Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use. PG - 22-8 AB - Treatments by oral administration of chenodeoxycholic acid (CDCA) alone, 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitor (pravastatin) alone, and combination of the two drugs were attempted for 7 patients with cerebrotendinous xanthomatosis (CTX). CDCA treatment at a dose of 300 mg/day reduced serum cholestanol (67.3% reduction), lathosterol (50.8%), campesterol (61.7%) and sitosterol (12.7%). However, the sera of the patients changed to be "atherogenic"; total cholesterol, triglyceride and low-density lipoprotein (LDL)-cholesterol were increased, while high-density lipoprotein (HDL)-cholesterol was decreased. Contrarily, pravastatin at a dose of 10 mg/day improved the sera of the patients to be markedly "anti-atherogenic", but the reductions of cholestanol (30.4%), lathosterol (44.0%), campesterol (22.9%) and sitosterol (9.6%) were inadequate. Combined treatment with CDCA and pravastatin showed good overlapping of the effects of each drug alone. The sera of the patients were apparently more "anti-atherogenic" than those after CDCA treatment. Serum cholestanol concentration was still 2.7 times higher than in controls, but the serum lathosterol level was within the normal range, indicating that the enhancement of overall cholesterol synthesis in the patients was sufficiently suppressed. Plant sterol levels were also within the normal range. The combination of CDCA and pravastatin was a good treatment for CTX, based on the improvement of serum lipoprotein metabolism, the suppression of cholesterol synthesis, and reductions of cholestanol and plant sterol levels. In all of 7 patients, the progression of disease was arrested, but dramatic effects on clinical manifestations, xanthoma, and electrophysiological findings could not be found after the treatment of these drugs. FAU - Kuriyama, M AU - Kuriyama M AD - Third Department of Internal Medicine, Kagoshima University School of Medicine, Japan. FAU - Tokimura, Y AU - Tokimura Y FAU - Fujiyama, J AU - Fujiyama J FAU - Utatsu, Y AU - Utatsu Y FAU - Osame, M AU - Osame M LA - eng PT - Journal Article PL - Netherlands TA - J Neurol Sci JT - Journal of the neurological sciences JID - 0375403 RN - 0 (Apolipoproteins) RN - 0 (Lipids) RN - 0 (Lipoproteins) RN - 0 (Phytosterols) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 80-99-9 (lathosterol) RN - 8M308U816E (Cholestanol) RN - 97C5T2UQ7J (Cholesterol) RN - KXO2KT9N0G (Pravastatin) SB - IM MH - Adult MH - Apolipoproteins/blood MH - Brain Diseases/blood/*drug therapy/physiopathology MH - Chenodeoxycholic Acid/*therapeutic use MH - Cholestanol/blood MH - Cholesterol/blood MH - Drug Therapy, Combination MH - Electrophysiology MH - Humans MH - Lipids/blood MH - Lipoproteins/blood MH - Male MH - Middle Aged MH - Muscular Diseases/blood/drug therapy/physiopathology MH - Phytosterols/blood MH - Pravastatin/*therapeutic use MH - *Tendons MH - Xanthomatosis/blood/*drug therapy/physiopathology EDAT- 1994/08/01 00:00 MHDA- 1994/08/01 00:01 CRDT- 1994/08/01 00:00 PHST- 1994/08/01 00:00 [pubmed] PHST- 1994/08/01 00:01 [medline] PHST- 1994/08/01 00:00 [entrez] AID - 0022-510X(94)90237-2 [pii] AID - 10.1016/0022-510x(94)90237-2 [doi] PST - ppublish SO - J Neurol Sci. 1994 Aug;125(1):22-8. doi: 10.1016/0022-510x(94)90237-2. PMID- 40119667 OWN - NLM STAT- MEDLINE DCOM- 20250624 LR - 20250624 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 66 IP - 3 DP - 2025 May TI - The impact of N-acetylcysteine on early periods of tendon healing: histopathologic, immunohistochemical, and biomechanical analysis in a rat model. PG - 161-174 LID - 10.1080/03008207.2025.2479501 [doi] AB - PURPOSE: This study aimed to evaluate the early effects of N-acetylcysteine, which has antioxidant, inflame-modulatory, and cytoprotective properties, on tendon healing. MATERIALS AND METHODS: Thirty-five male Wistar Hannover rats were divided into five groups: first-week treatment (Group 1T), first-week control (Group 1C), third-week treatment (Group 3T), third-week control (Group 3C), and native tendons (Group N). Bilateral Achilles tenotomy was performed on all rats except Group N. After tenotomy, 150 mg/kg N-acetylcysteine was administered daily intraperitoneally to treatment groups, while isotonic saline was given to the control groups. Tendons were evaluated histopathologically, immunohistochemically, and biomechanically after sacrifice in the first and third weeks. RESULTS: No significant differences were observed in the first week (p > 0.05). Movin and Bonar scores (lower scores reflect improved histologic healing) were significantly lower in Group 3T than in Group 3C (p = 0.002). Collagen type-I/type-III ratios were higher in Group 3T compared to Group 3C (p = 0.001). Fmax (N) values were similar across Group 3T, Group 3C, and Group N (p = 0.772). However, cross-sectional areas (mm(2)) were significantly smaller in Group 3T than in Group 3C (p = 0.001), with the smallest areas observed in native tendons. Thus, tensile strength (MPa, load per unit area) and toughness (J/10(3) mm(3), energy absorbed per unit volume) were significantly higher in Group 3T than in Group 3C (p = 0.001). CONCLUSION: N-acetylcysteine supplied some improved results on early markers of tendon healing. Although our findings support the potential of NAC as a therapeutic adjunct in tendon injuries, further studies are needed to evaluate the long-term effects and underlying mechanisms. FAU - Büyükdoğan, Halil AU - Büyükdoğan H AUID- ORCID: 0000-0002-0202-444X AD - Istanbul Kanuni Sultan Süleyman Training and Research Hospital, Department of Orthopaedics and Traumatology, Health Sciences University, Istanbul, Turkey. FAU - Ertürk, Cemil AU - Ertürk C AD - Istanbul Kanuni Sultan Süleyman Training and Research Hospital, Department of Orthopaedics and Traumatology, Health Sciences University, Istanbul, Turkey. FAU - Eren, Erdal AU - Eren E AD - Gülhane Training and Research Hospital, Department of Orthopaedics and Traumatology, Health Sciences University, Ankara, Turkey. FAU - Öztürk, Çiğdem AU - Öztürk Ç AD - Department of Pathology, Recep Tayyip Erdoğan University Training and Research Hospital, Rize, Turkey. FAU - Yıldırım, Burak AU - Yıldırım B AD - Kırklareli Training and Research Hospital, Department of Orthopaedics and Traumatology, Kırklareli, Turkey. FAU - Sarıtaş, Tahir Burak AU - Sarıtaş TB AD - Tuzla State Hospital, Department of Orthopaedics and Traumatology, Istanbul, Turkey. FAU - Demirkol, Metehan AU - Demirkol M AD - Department of Mechanical Engineering, Yıldız Technical University, Istanbul, Turkey. AD - Department of Mechanical Engineering, YTU-AMRG (Advanced Materials Research Group), Yıldız Technical University, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20250322 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - Animals MH - *Acetylcysteine/pharmacology MH - Male MH - *Wound Healing/drug effects MH - Rats, Wistar MH - Rats MH - Biomechanical Phenomena/drug effects MH - *Achilles Tendon/pathology/drug effects/injuries MH - *Tendon Injuries/pathology/drug therapy/metabolism MH - Immunohistochemistry MH - Disease Models, Animal OTO - NOTNLM OT - Biomechanics OT - N-acetylcysteine;  OT - collagen OT - immunohistochemistry OT - tendon healing EDAT- 2025/03/22 20:45 MHDA- 2025/06/24 18:29 CRDT- 2025/03/22 05:22 PHST- 2025/06/24 18:29 [medline] PHST- 2025/03/22 20:45 [pubmed] PHST- 2025/03/22 05:22 [entrez] AID - 10.1080/03008207.2025.2479501 [doi] PST - ppublish SO - Connect Tissue Res. 2025 May;66(3):161-174. doi: 10.1080/03008207.2025.2479501. Epub 2025 Mar 22. PMID- 40495482 OWN - NLM STAT- MEDLINE DCOM- 20250627 LR - 20250716 IS - 1976-670X (Electronic) IS - 1976-6696 (Print) IS - 1976-6696 (Linking) VI - 58 IP - 6 DP - 2025 Jun TI - mTORC1 and STAT3 signaling are indispensable for in vitro TGFβ1-dependent three-dimensional (3D) tendon constructs. PG - 257-263 AB - Transforming Growth Factor-β1 (TGFβ1) is an established growth factor that regulates tenocyte differentiation, extracellular matrix production, and cell fate. We previously demonstrated its pivotal role in in vitro 3D tendon constructs formation; however, the downstream signaling mechanisms remain elusive. In this study, we explore the roles of mTORC1 (Mammalian Target of Rapamycin Complex 1) and STAT3 (Signal Transducer and Activator of Transcription 3) in mediating TGFβ1-induced 3D tendon formation using rapamycin (an mTORC1 inhibitor) and stattic (a STAT3 inhibitor). Inhibition of either pathway compromised TGFβ1-induced thickening of the tendon construct, cellular proliferation, and collagen fibrillogenesis. Molecular analyses revealed that mTORC1-STAT3 signaling partially mediates TGFβ1-induced Scx expression and tenocyte elongation in the peripheral layer of 3D tendon constructs. Moreover, TGFβ1 treatment augmented mTOR and STAT3 phosphorylation, while inhibition of mTORC1 signaling attenuated TGFβ1-induced STAT3 phosphorylation. These findings underscore the TGFb1-mTORC1-STAT3 signaling pathway as integral to 3D tendon constructs. Overall, our study identifies the mTORC1-STAT3 axis as a crucial mediator of TGFβ1-driven in vitro tendon formation, highlighting its importance in tendon maturation and extracellular matrix organization. [BMB Reports 2025; 58(6): 257-263]. FAU - Koo, Bon-Hyeock AU - Koo BH AD - McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6081, USA. FAU - Smith, Aiden AU - Smith A AD - McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6081, USA. FAU - Joeng, Kyu Sang AU - Joeng KS AD - McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6081, USA. LA - eng GR - P30 AR069619/AR/NIAMS NIH HHS/United States GR - R01 AR079486/AR/NIAMS NIH HHS/United States PT - Journal Article PL - Korea (South) TA - BMB Rep JT - BMB reports JID - 101465334 RN - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1) RN - W36ZG6FT64 (Sirolimus) RN - 0 (STAT3 Transcription Factor) RN - 0 (Transforming Growth Factor beta1) SB - IM MH - Animals MH - Cell Differentiation MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Extracellular Matrix/metabolism MH - *Mechanistic Target of Rapamycin Complex 1/metabolism MH - Phosphorylation MH - Signal Transduction/drug effects MH - Sirolimus/pharmacology MH - *STAT3 Transcription Factor/metabolism/antagonists & inhibitors MH - *Tendons/metabolism/cytology MH - Tenocytes/metabolism MH - *Transforming Growth Factor beta1/metabolism PMC - PMC12207444 COIS- CONFLICTS OF INTEREST The authors have no conflicting interests. EDAT- 2025/06/11 06:30 MHDA- 2025/06/27 06:27 PMCR- 2025/05/07 CRDT- 2025/06/11 02:52 PHST- 2024/12/21 00:00 [received] PHST- 2025/06/27 06:27 [medline] PHST- 2025/06/11 06:30 [pubmed] PHST- 2025/06/11 02:52 [entrez] PHST- 2025/05/07 00:00 [pmc-release] AID - 6414 [pii] AID - bmb-58-6-257 [pii] AID - 10.5483/BMBRep.2024-0198 [doi] PST - ppublish SO - BMB Rep. 2025 Jun;58(6):257-263. doi: 10.5483/BMBRep.2024-0198. PMID- 38219090 OWN - NLM STAT- MEDLINE DCOM- 20240226 LR - 20240226 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 40 IP - 3 DP - 2024 Mar TI - Editorial Commentary: Postoperative Zoledronic Acid Improves Tendon Healing but Does Not Affect Outcomes in Rotator Cuff Repair Patients With Postmenopausal Osteoporosis. PG - 723-725 LID - S0749-8063(23)00942-8 [pii] LID - 10.1016/j.arthro.2023.11.013 [doi] AB - Understanding the preoperative risk factors for successful rotator cuff repair (RCR) and ways to optimize these factors is an evolving area of study. The Rotator Cuff Healing Index and other proxy risk factors for failed rotator cuff healing have implicated significant fatty infiltration, muscular atrophy, advanced chronological age, tear size and retraction, and ultimately, osteoporosis. Although structural (or biological) augmentation and tendon transfer have been proposed as solutions for the alarmingly high rate of failure after primary RCR, other options may preferentially focus on the enthesis and underlying osseous footprint. Currently, bisphosphonates are frequently used in the treatment of osteoporosis and prevention of fragility fractures. However, burgeoning evidence suggests that postoperative zoledronic acid may have clinical utility after rotator cuff and other tendon repairs. In the cost-conscious world of evidence-based medicine, the added economic burden of additional medications and office visits may or may not improve patient outcomes-much less confer added value. Our advice to fellow shoulder surgeons: Wait for further information, but continue to holistically consider and optimize risk factors for poor soft-tissue healing. Although the addition of postoperative bisphosphonates may improve suture anchor fixation and promote a better foundation for healing, it will not immediately transform your RCR success rates. CI - Copyright © 2023 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Dean, Robert S AU - Dean RS AD - Royal Oak, Michigan (R.S.D.). FAU - Waterman, Brian R AU - Waterman BR AD - Royal Oak, Michigan (R.S.D.). LA - eng PT - Comment PT - Editorial DEP - 20240114 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 6XC1PAD3KF (Zoledronic Acid) SB - IM CON - Arthroscopy. 2024 Mar;40(3):714-722. doi: 10.1016/j.arthro.2023.09.033. PMID: 37832742 MH - Female MH - Humans MH - Rotator Cuff/surgery MH - Zoledronic Acid/therapeutic use MH - *Rotator Cuff Injuries/drug therapy/surgery MH - *Osteoporosis, Postmenopausal/drug therapy MH - Tendons/surgery MH - *Osteoporosis/complications/drug therapy MH - Treatment Outcome MH - Arthroscopy COIS- Disclosure The authors report the following potential conflicts of interest or sources of funding: R.S.D. reports a relationship with Beaumont Department of Orthopedic Surgery. B.R.W. reports relationships with American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, American Shoulder and Elbow Surgeons, and Arthroscopy Association of North America that include board membership; relationships with Arthrex, DePuy Orthopaedics, and FH ORTHO Group that include consulting or advisory services; relationships with Arthrex, Sparta, and Vericel that include paid expert testimony; relationships with Elsevier, Musculoskeletal Transplant Foundation, and Smith & Nephew that include funding grants; and relationships with Kaliber AI, Sparta, and Vivorte that include equity or stocks. Full ICMJE author disclosure forms are available for this article online, as supplementary material. EDAT- 2024/01/14 14:41 MHDA- 2024/02/26 06:43 CRDT- 2024/01/14 10:34 PHST- 2023/11/12 00:00 [received] PHST- 2023/11/17 00:00 [accepted] PHST- 2024/02/26 06:43 [medline] PHST- 2024/01/14 14:41 [pubmed] PHST- 2024/01/14 10:34 [entrez] AID - S0749-8063(23)00942-8 [pii] AID - 10.1016/j.arthro.2023.11.013 [doi] PST - ppublish SO - Arthroscopy. 2024 Mar;40(3):723-725. doi: 10.1016/j.arthro.2023.11.013. Epub 2024 Jan 14. PMID- 3790517 OWN - NLM STAT- MEDLINE DCOM- 19870210 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 25 IP - 20 DP - 1986 Oct 7 TI - Decreased synthesis and increased intracellular degradation of newly synthesized collagen in freshly isolated chick tendon cells incubated with monensin. PG - 6208-13 AB - The synthesis and secretion of procollagen in embryonic chick tendon fibroblasts in suspension culture were inhibited with the carboxylic ionophore monensin. The synthesis of procollagen was inhibited by 50% in a 2-h exposure to 0.1 microM monensin and was inhibited by 70% in a 6-h exposure to 0.1 microM monensin. Secretion of procollagen was inhibited by greater than 90% in the 0.1 microM monensin-treated cultures and was totally inhibited by higher doses of the reagent. A cellular pool of collagenase-digestible peptides was demonstrated in the control cells, the level of which was elevated 3-4 times in the monensin-treated cultures. In order to determine whether the secretory and synthesis block caused by monensin inhibited intracellular degradation of newly synthesized collagen, the hydroxy[14C]proline in degraded collagen fragments present in control and monensin-treated cultures was determined and compared to the total hydroxy[14C]proline synthesized in each culture. The intracellular degradation of newly synthesized, pulse-labeled collagen was shown to proceed at rates comparable to those seen in the control cultures. The monensin-treated cells degraded pulse-labeled newly synthesized collagen nearly twice as long as the controls, resulting in an overall increase in the fraction of newly synthesized collagen that was degraded. These findings suggest that force generation in the activated cross-bridge cycle may occur as a result of an actin-attached cross-bridge transition between these two orientations. FAU - Neblock, D S AU - Neblock DS FAU - Berg, R A AU - Berg RA LA - eng GR - AM 31839/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 9007-34-5 (Collagen) RN - 906O0YJ6ZP (Monensin) RN - 9DLQ4CIU6V (Proline) SB - IM MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Collagen/biosynthesis/*metabolism MH - Kinetics MH - Monensin/*pharmacology MH - Proline/metabolism MH - Tendons/drug effects/*metabolism EDAT- 1986/10/07 00:00 MHDA- 1986/10/07 00:01 CRDT- 1986/10/07 00:00 PHST- 1986/10/07 00:00 [pubmed] PHST- 1986/10/07 00:01 [medline] PHST- 1986/10/07 00:00 [entrez] AID - 10.1021/bi00368a056 [doi] PST - ppublish SO - Biochemistry. 1986 Oct 7;25(20):6208-13. doi: 10.1021/bi00368a056. PMID- 34445689 OWN - NLM STAT- MEDLINE DCOM- 20210929 LR - 20210929 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 22 IP - 16 DP - 2021 Aug 20 TI - Altered Differentiation of Tendon-Derived Stem Cells in Diabetic Conditions Mediated by Macrophage Migration Inhibitory Factor. LID - 10.3390/ijms22168983 [doi] LID - 8983 AB - The purpose of our study was to evaluate the role of macrophage migration inhibitory factor (MIF) in the differentiation of tendon-derived stem cells (TdSCs) under hyperglycemic conditions. In the in vivo experiment, rats were classified into diabetic (DM) and non-DM groups depending on the intraperitoneal streptozotocin (STZ) or saline injection. Twelve-week after STZ injection, the supraspinatus tendon was harvested and prepared for histological evaluation and real-time reverse transcription polymerase chain reaction for osteochondrogenic (aggrecan, BMP-2, and Sox9) and tenogenic (Egr1, Mkx, scleraxis, type 1 collagen, and Tnmd) markers. For the in vitro experiment, TdSCs were isolated from healthy rat Achilles tendons. Cultured TdSCs were treated with methylglyoxal and recombinant MIF or MIF gene knockdown to determine the effect of hyperglycemic conditions and MIF on the differentiation function of TdSCs. These conditions were classified into four groups: hyperglycemic-control group, hyperglycemic-recombinant-MIF group, hyperglycemic-knockdown-MIF group, and normal-control group. The mRNA expression of osteochondrogenic and tenogenic markers was compared among the groups. In the in vivo experiment, the mRNA expression of all osteochondrogenic and tenogenic differentiation markers in the DM group was significantly higher and lower than that in the non-DM group, respectively. Similarly, in the in vitro experiments, the expression of all osteochondrogenic and tenogenic differentiation markers was significantly upregulated and downregulated, respectively, in the hyperglycemic-control group compared to that in the normal-control group. The hyperglycemic-knockdown-MIF group demonstrated significantly decreased expression of all osteochondrogenic differentiation markers and increased expression of only some tenogenic differentiation markers compared with the hyperglycemic-control group. In contrast, the hyperglycemic-recombinant-MIF group showed significantly increased expression of all osteochondrogenic differentiation markers, but no significant difference in any tenogenic marker level, compared to the hyperglycemic-control group. These results suggest that tendon homeostasis could be affected by hyperglycemic conditions, and MIF appears to alter the differentiation of TdSCs via enhancement of the osteochondrogenic differentiation in hyperglycemic conditions. These are preliminary findings, and must be confirmed in a further study. FAU - Kim, Du-Hwan AU - Kim DH AUID- ORCID: 0000-0002-9980-8549 AD - Department of Physical Medicine and Rehabilitation, College of Medicine, Chung-Ang University, Seoul 06973, Korea. FAU - Noh, Sun-Up AU - Noh SU AUID- ORCID: 0000-0003-2091-8647 AD - Medical Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea. FAU - Chae, Seoung-Wan AU - Chae SW AD - Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea. FAU - Kim, Sang-Jun AU - Kim SJ AD - Seoul Jun Research Center, Seoul Jun Rehabilitation Clinic, Seoul 06737, Korea. FAU - Lee, Yong-Taek AU - Lee YT AUID- ORCID: 0000-0001-6611-0999 AD - Medical Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea. AD - Department of Physical and Rehabilitation Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea. LA - eng PT - Journal Article DEP - 20210820 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Collagen Type I) RN - 0 (Macrophage Migration-Inhibitory Factors) RN - 5W494URQ81 (Streptozocin) SB - IM MH - Animals MH - Cell Differentiation/drug effects MH - Cells, Cultured MH - Collagen Type I/metabolism MH - Diabetes Mellitus, Experimental/physiopathology MH - Gene Expression/genetics MH - Macrophage Migration-Inhibitory Factors/*metabolism/pharmacology/physiology MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cells/*metabolism MH - Streptozocin/pharmacology MH - Tendons/*metabolism/physiology PMC - PMC8396498 OTO - NOTNLM OT - diabetes OT - macrophage migration inhibitory factor OT - tendinopathy OT - tendon-derived stem cells COIS- All authors declare no conflict of interest. EDAT- 2021/08/28 06:00 MHDA- 2021/09/30 06:00 PMCR- 2021/08/20 CRDT- 2021/08/27 01:25 PHST- 2021/07/21 00:00 [received] PHST- 2021/08/14 00:00 [revised] PHST- 2021/08/16 00:00 [accepted] PHST- 2021/08/27 01:25 [entrez] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/30 06:00 [medline] PHST- 2021/08/20 00:00 [pmc-release] AID - ijms22168983 [pii] AID - ijms-22-08983 [pii] AID - 10.3390/ijms22168983 [doi] PST - epublish SO - Int J Mol Sci. 2021 Aug 20;22(16):8983. doi: 10.3390/ijms22168983. PMID- 28264197 OWN - NLM STAT- MEDLINE DCOM- 20170825 LR - 20190208 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 3 DP - 2017 TI - Simvastatin and atorvastatin reduce the mechanical properties of tendon constructs in vitro and introduce catabolic changes in the gene expression pattern. PG - e0172797 LID - 10.1371/journal.pone.0172797 [doi] LID - e0172797 AB - Treatment with lipid-lowering drugs, statins, is common all over the world. Lately, the occurrence of spontaneous tendon ruptures or tendinosis have suggested a negative influence of statins upon tendon tissue. But how statins might influence tendons is not clear. In the present study, we investigated the effect of statin treatment on mechanical strength, cell proliferation, collagen content and gene expression pattern in a tendon-like tissue made from human tenocytes in vitro. Human tendon fibroblasts were grown in a 3D tissue culture model (tendon constructs), and treated with either simvastatin or atorvastatin, low or high dose, respectively, for up to seven days. After seven days of treatment, mechanical testing of the constructs was performed. Collagen content and cell proliferation were also determined. mRNA levels of several target genes were measured after one or seven days. The maximum force and stiffness were reduced by both statins after 7 days (p<0.05), while the cross sectional area was unaffected. Further, the collagen content was reduced by atorvastatin (p = 0.01) and the cell proliferation rate was decreased by both types of statins (p<0.05). Statin treatment also introduced increased mRNA levels of MMP-1, MMP-3, MMP-13, TIMP-1 and decreased levels of collagen type 1 and 3. In conclusion, statin treatment appears to have a negative effect on tendon matrix quality as seen by a reduced strength of the tendon constructs. Further, activated catabolic changes in the gene expression pattern and a reduced collagen content indicated a disturbed balance in matrix production of tendon due to statin administration. FAU - Eliasson, Pernilla AU - Eliasson P AUID- ORCID: 0000-0001-6718-034X AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. AD - Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. FAU - Svensson, Rene B AU - Svensson RB AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Giannopoulos, Antonis AU - Giannopoulos A AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Eismark, Christian AU - Eismark C AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Kjær, Michael AU - Kjær M AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Schjerling, Peter AU - Schjerling P AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Heinemeier, Katja M AU - Heinemeier KM AD - Institute of Sports Medicine Copenhagen, Dept of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20170306 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 9007-34-5 (Collagen) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Adolescent MH - Adult MH - Atorvastatin/*pharmacology MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Collagen/genetics/metabolism MH - Energy Metabolism/*drug effects MH - Fibroblasts/drug effects/metabolism MH - Gene Expression Regulation/*drug effects MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Matrix Metalloproteinases/genetics/metabolism MH - Mechanical Phenomena/*drug effects MH - Simvastatin/*pharmacology MH - Tendon Injuries/genetics/metabolism/physiopathology MH - Tendons/*drug effects/*physiology MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Young Adult PMC - PMC5339395 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2017/03/07 06:00 MHDA- 2017/08/26 06:00 PMCR- 2017/03/06 CRDT- 2017/03/07 06:00 PHST- 2016/10/25 00:00 [received] PHST- 2017/02/09 00:00 [accepted] PHST- 2017/03/07 06:00 [entrez] PHST- 2017/03/07 06:00 [pubmed] PHST- 2017/08/26 06:00 [medline] PHST- 2017/03/06 00:00 [pmc-release] AID - PONE-D-16-42454 [pii] AID - 10.1371/journal.pone.0172797 [doi] PST - epublish SO - PLoS One. 2017 Mar 6;12(3):e0172797. doi: 10.1371/journal.pone.0172797. eCollection 2017. PMID- 8730343 OWN - NLM STAT- MEDLINE DCOM- 19961024 LR - 20190512 IS - 1460-2725 (Print) IS - 1460-2393 (Linking) VI - 89 IP - 1 DP - 1996 Jan TI - Cerebrotendinous xanthomatosis: a family study of sterol 27-hydroxylase mutations and pharmacotherapy. PG - 55-63 AB - We examined the phenotypic characteristics, molecular genetics and optimal pharmacological treatment of cerebrotendinous xanthomatosis (CTX) in an English family with combined hyperlipidaemia. The proband presented in adulthood with classical clinical characteristics of CTX, a greater than tenfold elevation in plasma cholestanol and combined hyperlipidaemia. His brother also had typical features of CTX without the presence of dyslipidaemia. Genotyping revealed that the two brothers were compound heterozygotes for a novel missense mutation in exon 2 (R94Q) and for a recently described nonsense mutation in exon 5, of the sterol 27-hydroxylase gene (CYP27). Analysis of all available family members revealed that hyperlipidaemia did not co-segregate with the presence of a CYP27 mutant allele. Trial of therapy showed that the lowest plasma sterol and triglyceride concentrations and cholestanol:cholesterol ratio were achieved with the combination of chenodeoxycholic acid (CDCA) 750 mg/day, a primary bile acid, and simvastatin 40 mg/day, an inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. CDCA alone and simvastatin alone significantly lowered plasma cholestanol concentration, but the decrease was greater with the former. After 1 year there was significant improvement in both cognitive and motor function with regression of tendon xanthomata on computerized tomography. We conclude that CTX in this English pedigree is probably due to compound mutant alleles in CYP27, that combined hyperlipidaemia in this family is unrelated to CTX, and that this complicated condition responds optimally to the combination of CDCA and simvastatin. FAU - Watts, G F AU - Watts GF AD - University Department of Medicine, University of Western Australia, Perth. FAU - Mitchell, W D AU - Mitchell WD FAU - Bending, J J AU - Bending JJ FAU - Reshef, A AU - Reshef A FAU - Leitersdorf, E AU - Leitersdorf E LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 RN - 0 (Anticholesteremic Agents) RN - 0 (Cholagogues and Choleretics) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 9035-51-2 (Cytochrome P-450 Enzyme System) RN - 9LHU78OQFD (Lovastatin) RN - AGG2FN16EV (Simvastatin) RN - EC 1.14.- (Steroid Hydroxylases) RN - EC 1.14.15.15 (CYP27A1 protein, human) RN - EC 1.14.15.15 (Cholestanetriol 26-Monooxygenase) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Anticholesteremic Agents/*therapeutic use MH - Chenodeoxycholic Acid/*therapeutic use MH - Child MH - Child, Preschool MH - Cholagogues and Choleretics/therapeutic use MH - Cholestanetriol 26-Monooxygenase MH - Cytochrome P-450 Enzyme System/genetics MH - England/epidemiology MH - Exons MH - Female MH - Humans MH - Hyperlipidemia, Familial Combined/complications MH - Lovastatin/*analogs & derivatives/therapeutic use MH - Male MH - Middle Aged MH - Musculoskeletal Diseases/blood/complications/*drug therapy/genetics MH - *Mutation MH - Pedigree MH - Simvastatin MH - Steroid Hydroxylases/genetics MH - Tendons MH - Xanthomatosis/blood/*drug therapy/genetics EDAT- 1996/01/01 00:00 MHDA- 1996/01/01 00:01 CRDT- 1996/01/01 00:00 PHST- 1996/01/01 00:00 [pubmed] PHST- 1996/01/01 00:01 [medline] PHST- 1996/01/01 00:00 [entrez] AID - 10.1093/oxfordjournals.qjmed.a030138 [doi] PST - ppublish SO - QJM. 1996 Jan;89(1):55-63. doi: 10.1093/oxfordjournals.qjmed.a030138. PMID- 4294771 OWN - NLM STAT- MEDLINE DCOM- 19680226 LR - 20141120 IS - 0003-9780 (Print) IS - 0003-9780 (Linking) VI - 170 IP - 2 DP - 1967 Dec TI - Influence of new guanidine derivatives on ganglionic and neuromuscular transmission. PG - 297-309 FAU - Kadzielawa, K AU - Kadzielawa K FAU - Gumulka, W AU - Gumulka W LA - eng PT - Comparative Study PT - Journal Article PL - Belgium TA - Arch Int Pharmacodyn Ther JT - Archives internationales de pharmacodynamie et de therapie JID - 0405353 RN - 0 (Guanidines) RN - 0 (Parasympatholytics) RN - 0 (Sympatholytics) RN - 3982TWQ96G (Neostigmine) RN - J2R869A8YF (Succinylcholine) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/pharmacology MH - Action Potentials/drug effects MH - Animals MH - Anura MH - Blood Pressure/drug effects MH - Cats MH - Columbidae MH - Diaphragm/innervation MH - Electric Stimulation MH - Ganglia, Autonomic/*drug effects MH - Guanidines/*pharmacology MH - Guinea Pigs MH - Ilium/drug effects MH - In Vitro Techniques MH - Muscle Contraction/drug effects MH - Muscles/drug effects MH - Neostigmine/pharmacology MH - Nerve Tissue/drug effects MH - Neuromuscular Junction/*drug effects MH - Nictitating Membrane/drug effects MH - Parasympatholytics/pharmacology MH - Phrenic Nerve/drug effects MH - Rats MH - Succinylcholine/pharmacology MH - Sympatholytics/*pharmacology MH - Synaptic Transmission/*drug effects MH - Tendons/innervation EDAT- 1967/12/01 00:00 MHDA- 1967/12/01 00:01 CRDT- 1967/12/01 00:00 PHST- 1967/12/01 00:00 [pubmed] PHST- 1967/12/01 00:01 [medline] PHST- 1967/12/01 00:00 [entrez] PST - ppublish SO - Arch Int Pharmacodyn Ther. 1967 Dec;170(2):297-309. PMID- 526306 OWN - NLM STAT- MEDLINE DCOM- 19800327 LR - 20191210 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 91 IP - 4 DP - 1979 Dec 28 TI - Effect of various aminoacid analogues on chick tendon procollagen synthesis and secretion: selective inhibition by S-2-aminoethyl cysteine. PG - 1330-6 FAU - Jimenez, S AU - Jimenez S FAU - Benditt, M AU - Benditt M FAU - Yankowski, R AU - Yankowski R FAU - Christner, P AU - Christner P LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Amino Acids) RN - 0 (Procollagen) RN - 2936-69-8 (S-2-aminoethyl cysteine) RN - K848JZ4886 (Cysteine) SB - IM MH - Amino Acids/*pharmacology MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Cysteine/*analogs & derivatives/pharmacology MH - Fibroblasts/metabolism MH - Kinetics MH - Procollagen/*biosynthesis/metabolism MH - Structure-Activity Relationship MH - Tendons/*metabolism EDAT- 1979/12/28 00:00 MHDA- 1979/12/28 00:01 CRDT- 1979/12/28 00:00 PHST- 1979/12/28 00:00 [pubmed] PHST- 1979/12/28 00:01 [medline] PHST- 1979/12/28 00:00 [entrez] AID - 0006-291X(79)91212-9 [pii] AID - 10.1016/0006-291x(79)91212-9 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1979 Dec 28;91(4):1330-6. doi: 10.1016/0006-291x(79)91212-9. PMID- 26863924 OWN - NLM STAT- MEDLINE DCOM- 20161219 LR - 20181202 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Feb 11 TI - Focal Adhesion Kinase Signaling Mediated the Enhancement of Osteogenesis of Human Mesenchymal Stem Cells Induced by Extracorporeal Shockwave. PG - 20875 LID - 10.1038/srep20875 [doi] LID - 20875 AB - Extracorporeal shockwave (ESW) has been shown of great potential in promoting the osteogenesis of bone marrow mesenchymal stem cells (BMSCs), but it is unknown whether this osteogenic promotion effect can also be achieved in other MSCs (i.e., tendon-derived stem cells (TDSCs) and adipose-derived stem cells (ADSCs)). In the current study, we aimed not only to compare the osteogenic effects of BMSCs induced by ESW to those of TDSCs and ADSCs; but also to investigate the underlying mechanisms. We show here that ESW (0.16 mj/mm(2)) significantly promoted the osteogenic differentiation in all the tested types of MSCs, accompanied with the downregulation of miR-138, but the activation of FAK, ERK1/2, and RUNX2. The enhancement of osteogenesis in these MSCs was consistently abolished when the cells were pretreated with one of the following conditions: overexpression of miR-138, FAK knockdown using specific siRNA, and U0126, implying that all of these elements are indispensable for mediating the effect of ESW. Moreover, our study provides converging genetic and molecular evidence that the miR-138-FAK-ERK1/2-RUNX2 machinery can be generally activated in ESW-preconditioned MSCs, suggesting that ESW may be a promising therapeutic strategy for the enhancement of osteogenesis of MSCs, regardless of their origins. FAU - Hu, Jun AU - Hu J AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Liao, Haojie AU - Liao H AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Ma, Zebin AU - Ma Z AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Chen, Hongjiang AU - Chen H AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Huang, Zhonglian AU - Huang Z AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Zhang, Yuantao AU - Zhang Y AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Yu, Menglei AU - Yu M AD - The Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen University, Guangdong Province, China. FAU - Chen, Youbin AU - Chen Y AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. FAU - Xu, Jiankun AU - Xu J AD - Department of Orthopaedics, the First Affiliated Hospital, Shantou University Medical College, Guangdong Province, China. AD - Department of Orthopaedics and Traumatology, Prince of Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160211 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Antigens, CD) RN - 0 (Butadienes) RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (MIRN138 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Nitriles) RN - 0 (RNA, Small Interfering) RN - 0 (RUNX2 protein, human) RN - 0 (U 0126) RN - EC 2.7.10.2 (Focal Adhesion Kinase 1) RN - EC 2.7.10.2 (PTK2 protein, human) RN - EC 2.7.11.24 (MAPK1 protein, human) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3) SB - IM MH - Adipose Tissue/cytology/metabolism/radiation effects MH - Adult MH - Animals MH - Antigens, CD/genetics/metabolism MH - Bone Marrow Cells/cytology/metabolism/radiation effects MH - Butadienes/pharmacology MH - Cell Differentiation/radiation effects MH - Core Binding Factor Alpha 1 Subunit/genetics/metabolism MH - Focal Adhesion Kinase 1/*genetics/metabolism MH - Gene Expression Regulation MH - High-Energy Shock Waves/*therapeutic use MH - Humans MH - Male MH - Mesenchymal Stem Cells/cytology/metabolism/*radiation effects MH - Mice MH - Mice, Nude MH - MicroRNAs/*genetics/metabolism MH - Mitogen-Activated Protein Kinase 1/genetics/metabolism MH - Mitogen-Activated Protein Kinase 3/genetics/metabolism MH - Nitriles/pharmacology MH - Osteogenesis/genetics/*radiation effects MH - Primary Cell Culture MH - RNA, Small Interfering/genetics/metabolism MH - Signal Transduction MH - Tendons/cytology/metabolism/radiation effects PMC - PMC4750003 EDAT- 2016/02/13 06:00 MHDA- 2016/12/20 06:00 PMCR- 2016/02/11 CRDT- 2016/02/12 06:00 PHST- 2015/06/15 00:00 [received] PHST- 2016/01/11 00:00 [accepted] PHST- 2016/02/12 06:00 [entrez] PHST- 2016/02/13 06:00 [pubmed] PHST- 2016/12/20 06:00 [medline] PHST- 2016/02/11 00:00 [pmc-release] AID - srep20875 [pii] AID - 10.1038/srep20875 [doi] PST - epublish SO - Sci Rep. 2016 Feb 11;6:20875. doi: 10.1038/srep20875. PMID- 25846724 OWN - NLM STAT- MEDLINE DCOM- 20150921 LR - 20250529 IS - 1097-4652 (Electronic) IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 230 IP - 10 DP - 2015 Oct TI - Lovastatin-Mediated Changes in Human Tendon Cells. PG - 2543-51 LID - 10.1002/jcp.25010 [doi] AB - Statins are among the most widely prescribed drugs worldwide. Numerous studies have shown their beneficial effects in prevention of cardiovascular disease through cholesterol-lowering and anti-atherosclerotic properties. Although some statin patients may experience muscle-related symptoms, severe side effects of statin therapy are rare, primarily due to extensive first-pass metabolism in the liver. Skeletal muscles appear to be the main site of side effects; however, recently some statin-related adverse effects have been described in tendon. The mechanism behind these side effects remains unknown. This is the first study that explores tendon-specific effects of statins in human primary tenocytes. The cells were cultured with different concentrations of lovastatin for up to 1 week. No changes in cell viability or morphology were observed in tenocytes incubated with therapeutic doses. Short-term exposure to lovastatin concentrations outside the therapeutic range had no effect on tenocyte viability; however, cell migration was reduced. Simvastatin and atorvastatin, two other drug family members, also reduced the migratory properties of the cells. Prolonged exposure to high concentrations of lovastatin induced changes in cytoskeleton leading to cell rounding and decreased levels of mRNA for matrix proteins, but increased BMP-2 expression. Gap junctional communication was impaired but due to cell shape change and separation rather than direct gap junction inhibition. These effects were accompanied by inhibition of prenylation of Rap1a small GTPase. Collectively, we showed that statins in a dose-dependent manner decrease migration of human tendon cells, alter their expression profile and impair the functional network, but do not inhibit gap junction function. CI - © 2015 The Authors. Journal of Cellular Physiology Published by Wiley Periodicals, Inc. FAU - Kuzma-Kuzniarska, Maria AU - Kuzma-Kuzniarska M AD - Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. FAU - Cornell, Hannah R AU - Cornell HR AD - Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. FAU - Moneke, Michael C AU - Moneke MC AD - Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. FAU - Carr, Andrew J AU - Carr AJ AD - Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. FAU - Hulley, Philippa A AU - Hulley PA AD - Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom. LA - eng GR - 19482/VAC_/Versus Arthritis/United Kingdom GR - ARUK19482/ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Heptanoic Acids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Pyrroles) RN - 97C5T2UQ7J (Cholesterol) RN - 9LHU78OQFD (Lovastatin) RN - A0JWA85V8F (Atorvastatin) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Atorvastatin MH - Cholesterol/metabolism MH - Cytoskeleton/*drug effects/metabolism MH - Gap Junctions/*drug effects MH - Heptanoic Acids/pharmacology MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Lovastatin/*pharmacology MH - Pyrroles/pharmacology MH - Simvastatin/pharmacology MH - Tendons/*drug effects/metabolism PMC - PMC4832302 EDAT- 2015/04/08 06:00 MHDA- 2015/09/22 06:00 PMCR- 2016/04/15 CRDT- 2015/04/08 06:00 PHST- 2014/09/10 00:00 [received] PHST- 2015/03/31 00:00 [accepted] PHST- 2015/04/08 06:00 [entrez] PHST- 2015/04/08 06:00 [pubmed] PHST- 2015/09/22 06:00 [medline] PHST- 2016/04/15 00:00 [pmc-release] AID - JCP25010 [pii] AID - 10.1002/jcp.25010 [doi] PST - ppublish SO - J Cell Physiol. 2015 Oct;230(10):2543-51. doi: 10.1002/jcp.25010. PMID- 26063979 OWN - NLM STAT- MEDLINE DCOM- 20160212 LR - 20220202 IS - 1466-1861 (Electronic) IS - 0962-9351 (Print) IS - 0962-9351 (Linking) VI - 2015 DP - 2015 TI - The Effect of Cyclooxygenase Inhibition on Tendon-Bone Healing in an In Vitro Coculture Model. PG - 926369 LID - 10.1155/2015/926369 [doi] LID - 926369 AB - The effects of cyclooxygenase (COX) inhibition following the reconstruction of the anterior cruciate ligament remain unclear. We examined the effects of selective COX-2 and nonselective COX inhibition on bone-tendon integration in an in vitro model. We measured the dose-dependent effects of ibuprofen and parecoxib on the viability of lipopolysaccharide- (LPS-) stimulated and unstimulated mouse MC3T3-E1 and 3T3 cells, the influence on gene expression at the osteoblast, interface, and fibroblast regions measured by quantitative PCR, and cellular outgrowth assessed on histological sections. Ibuprofen led to a dose-dependent suppression of MC3T3 cell viability, while parecoxib reduced the viability of 3T3 cultures. Exposure to ibuprofen significantly suppressed expression of Alpl (P < 0.01), Bglap (P < 0.001), and Runx2 (P < 0.01), and although parecoxib reduced expression of Alpl (P < 0.001), Fmod (P < 0.001), and Runx2 (P < 0.01), the expression of Bglap was increased (P < 0.01). Microscopic analysis showed a reduction in cellular outgrowth in LPS-stimulated cultures following exposure to ibuprofen and parecoxib. Nonselective COX inhibition and the specific inhibition of COX-2 led to region-specific reductions in markers of calcification and cell viability. We suggest further in vitro and in vivo studies examining the biologic and biomechanical effects of selective and nonselective COX inhibition. FAU - Schwarting, Tim AU - Schwarting T AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany. FAU - Pretzsch, Sebastian AU - Pretzsch S AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany. FAU - Debus, Florian AU - Debus F AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany. FAU - Ruchholtz, Steffen AU - Ruchholtz S AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany. FAU - Lechler, Philipp AU - Lechler P AD - Department of Trauma, Hand and Reconstructive Surgery, University Hospital Marburg, 35043 Marburg, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150506 PL - United States TA - Mediators Inflamm JT - Mediators of inflammation JID - 9209001 RN - 0 (Core Binding Factor Alpha 1 Subunit) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Isoxazoles) RN - 0 (Lipopolysaccharides) RN - 9TUW81Y3CE (parecoxib) RN - EC 3.1.3.1 (ALPL protein, mouse) RN - EC 3.1.3.1 (Alkaline Phosphatase) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Alkaline Phosphatase/metabolism MH - Animals MH - Cell Survival/drug effects MH - Coculture Techniques/methods MH - Core Binding Factor Alpha 1 Subunit/metabolism MH - Cyclooxygenase Inhibitors/*pharmacology MH - Ibuprofen/pharmacology MH - Isoxazoles/pharmacology MH - Lipopolysaccharides/*pharmacology MH - Mice MH - Osteoblasts/drug effects/metabolism MH - Tendons/drug effects/metabolism MH - Wound Healing/drug effects PMC - PMC4438175 EDAT- 2015/06/13 06:00 MHDA- 2016/02/13 06:00 PMCR- 2015/05/06 CRDT- 2015/06/12 06:00 PHST- 2014/12/24 00:00 [received] PHST- 2015/04/16 00:00 [accepted] PHST- 2015/06/12 06:00 [entrez] PHST- 2015/06/13 06:00 [pubmed] PHST- 2016/02/13 06:00 [medline] PHST- 2015/05/06 00:00 [pmc-release] AID - 10.1155/2015/926369 [doi] PST - ppublish SO - Mediators Inflamm. 2015;2015:926369. doi: 10.1155/2015/926369. Epub 2015 May 6. PMID- 30267787 OWN - NLM STAT- MEDLINE DCOM- 20181214 LR - 20181214 IS - 1879-0631 (Electronic) IS - 0024-3205 (Linking) VI - 212 DP - 2018 Nov 1 TI - Chronical treatment with sildenafil causes Achilles tendinopathy in rats. PG - 87-92 LID - S0024-3205(18)30600-3 [pii] LID - 10.1016/j.lfs.2018.09.048 [doi] AB - AIMS: The primary goal was to assess the effects of chronic sildenafil treatment over the Achilles tendons in rats. MAIN METHODS: Animals were divided into two groups, control and sildenafil administration (n = 5). After 60 days, the tendons were subject to biochemical and image analysis to compare tendons between the groups: collagen I and decorin content, polarisation microscopy and birefringence analysis, and tissue zymography. KEY FINDINGS: The animals exposed to sildenafil presented a much less organised tendon matrix, with reduced collagen I and non-collagenous protein content and a much higher decorin content. SIGNIFICANCE: The results observed in the animals can be characterised as tendinopathy, a condition not yet described as a sildenafil side effect. CI - Copyright © 2018 Elsevier Inc. All rights reserved. FAU - Marques, Petrus Pires AU - Marques PP AD - Department of Medicine, José do Rosário Vellano University - Unifenas, 37130-000 Alfenas, MG, Brazil. Electronic address: petrus.marques@unifenas.br. FAU - Vieira, Cristiano Pedrozo AU - Vieira CP AD - Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas - UNICAMP, 13083-970 Campinas, SP, Brazil. FAU - de Oliveira, Letícia Prado AU - de Oliveira LP AD - Department of Anatomy, Cell Biology and Physiology and Biophysics, Institute of Biology, CP 6109, University of Campinas - UNICAMP, 13083-970 Campinas, SP, Brazil. FAU - Pimentel, Edson Rosa AU - Pimentel ER AD - Department of Anatomy, Cell Biology and Physiology and Biophysics, Institute of Biology, CP 6109, University of Campinas - UNICAMP, 13083-970 Campinas, SP, Brazil. FAU - Guerra, Flávia Da Ré AU - Guerra FDR AD - Department of Anatomy, Institute of Biomedical Science, Federal University of Alfenas - UNIFAL-MG, 37130-000 Alfenas, MG, Brazil. LA - eng PT - Journal Article DEP - 20180926 PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Collagen Type I) RN - 0 (Vasodilator Agents) RN - BW9B0ZE037 (Sildenafil Citrate) SB - IM MH - Achilles Tendon/*drug effects MH - Animals MH - Collagen Type I/metabolism MH - *Disease Models, Animal MH - Male MH - Rats MH - Rats, Wistar MH - Sildenafil Citrate/*toxicity MH - Tendinopathy/*chemically induced/metabolism/pathology MH - Vasodilator Agents/*toxicity OTO - NOTNLM OT - Collagen OT - Decorin OT - Extracellular matrix OT - Sildenafil OT - Tendinopathy OT - Tendon EDAT- 2018/09/30 06:00 MHDA- 2018/12/15 06:00 CRDT- 2018/09/30 06:00 PHST- 2018/07/11 00:00 [received] PHST- 2018/09/10 00:00 [revised] PHST- 2018/09/25 00:00 [accepted] PHST- 2018/09/30 06:00 [pubmed] PHST- 2018/12/15 06:00 [medline] PHST- 2018/09/30 06:00 [entrez] AID - S0024-3205(18)30600-3 [pii] AID - 10.1016/j.lfs.2018.09.048 [doi] PST - ppublish SO - Life Sci. 2018 Nov 1;212:87-92. doi: 10.1016/j.lfs.2018.09.048. Epub 2018 Sep 26. PMID- 9435616 OWN - NLM STAT- MEDLINE DCOM- 19980209 LR - 20190513 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 273 IP - 6 DP - 1997 Dec TI - Interstitial exclusion of macromolecules studied by graded centrifugation of rat tail tendon. PG - H2794-803 LID - 10.1152/ajpheart.1997.273.6.H2794 [doi] AB - Mechanical compression of cartilage and tendon has been shown to expel fluid both from collagen fibrils and from the extrafibrillar space. As reported previously, albumin (Alb) concentration and colloid osmotic pressure in tendon fluid (TF) expelled by repeated centrifugations fell progressively at increasing centrifugation force (G = 600, 2,400, and 13,100), suggesting either molecular sieving in compressed tendon or mobilization of protein-free (excluded) fluid. The present experiments, including analysis of 51Cr-EDTA, aprotinin (Ap), Alb, immunoglobulin G (IgG), and hyaluronan (hyaluronic acid; HA) with molecular weight (MW) ranging from 341 to 5 x 10(6), strongly favored the exclusion hypothesis; the fraction of Alb, IgG, and HA-free fluid (excluded) was already 0.23-0.36 in the first centrifugate, increasing to 0.73-0.82 in the third. The corresponding numbers were, respectively, 0.11 and 0.43 for Ap (MW 6,500), and 0 and 0.08 for 51Cr-EDTA. These data, combined with calculated exclusion by collagen fibrils, proteoglycans, and HA, indicated that the first centrifugate was mainly derived from the extrafibrillar space, with increasing addition of macromolecular free intrafibrillar fluid in the second and third centrifugates, with each space contributing about equally to the total centrifugate volume. The calculations also indicated that Alb-, IgG-, and Ap-free fluid was mobilized from extrafibrillar space by increasing overlap of excluded territories. An excess of HA in tendon compared with that estimated from centrifugate concentrations suggests a large bound or immobilized HA fraction. FAU - Aukland, K AU - Aukland K AD - Department of Physiology, University of Bergen, Norway. FAU - Wiig, H AU - Wiig H FAU - Tenstad, O AU - Tenstad O FAU - Renkin, E M AU - Renkin EM LA - eng GR - HL-18010/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Chromium Radioisotopes) RN - 0 (Immunoglobulin G) RN - 0 (Iodine Radioisotopes) RN - 9004-61-9 (Hyaluronic Acid) RN - 9087-70-1 (Aprotinin) RN - 9G34HU7RV0 (Edetic Acid) SB - IM MH - Animals MH - Aprotinin/pharmacokinetics MH - Centrifugation MH - Chromium Radioisotopes/pharmacokinetics MH - Edetic Acid/pharmacokinetics MH - Extracellular Space/physiology MH - Female MH - Hyaluronic Acid/pharmacokinetics MH - Immunoglobulin G/metabolism MH - Iodine Radioisotopes/pharmacokinetics MH - Male MH - Rats MH - Rats, Wistar MH - Tail MH - Tendons/chemistry/*physiology EDAT- 1998/01/22 00:00 MHDA- 1998/01/22 00:01 CRDT- 1998/01/22 00:00 PHST- 1998/01/22 00:00 [pubmed] PHST- 1998/01/22 00:01 [medline] PHST- 1998/01/22 00:00 [entrez] AID - 10.1152/ajpheart.1997.273.6.H2794 [doi] PST - ppublish SO - Am J Physiol. 1997 Dec;273(6):H2794-803. doi: 10.1152/ajpheart.1997.273.6.H2794. PMID- 9346401 OWN - NLM STAT- MEDLINE DCOM- 19971119 LR - 20180214 IS - 0031-7012 (Print) IS - 0031-7012 (Linking) VI - 55 IP - 3 DP - 1997 Sep TI - Effects of aminoguanidine on adhesion molecule expression of human endothelial cells. PG - 126-35 AB - The effect of aminoguanidine (AG) on the expression of adhesion molecules on nonactivated human umbilical vein endothelial cells (HUVEC) was investigated in vitro. Nonactivated HUVEC cultivated on long-term glycated fibronectin (FN) as compared to native FN showed a significant upregulation of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1) and CD31 which could be further promoted by long-term glycated bovine serum albumin. AG, at a concentration of 0.01 mol/l, caused an upregulation of ICAM-1 of 48 +/- 17.4% in HUVEC cultivated on gelatin. In contrast, VCAM-1 and E-selectin remained unaffected. At this concentration, formation of advanced glycation end products (AGE) was inhibited by 57%, as determined immunologically, and by 50%, as verified by AGE-specific fluorescence. A hypothesis concerning the upregulation of ICAM-1 by AG as compared to VCAM-1 is proposed relating to its relative redox insensitivity. Our results demonstrate that the beneficial effect of AG in reducing the risk of accelerated development of atherosclerosis in diabetic patients by inhibiting formation of AGE on matrix proteins such as FN might be hampered by its tendency to upregulate ICAM-1 on endothelial cells. FAU - Menzel, E J AU - Menzel EJ AD - Institute of Immunology, University of Vienna, Austria. FAU - Neumüller, J AU - Neumüller J FAU - Sengoelge, G AU - Sengoelge G FAU - Reihsner, R AU - Reihsner R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - Pharmacology JT - Pharmacology JID - 0152016 RN - 0 (Glycation End Products, Advanced) RN - 0 (Guanidines) RN - 0 (Platelet Endothelial Cell Adhesion Molecule-1) RN - 0 (Vascular Cell Adhesion Molecule-1) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Cells, Cultured MH - Endothelium, Vascular/*drug effects/metabolism MH - Glycation End Products, Advanced/metabolism MH - Guanidines/*pharmacology MH - Humans MH - Intercellular Adhesion Molecule-1/*metabolism MH - Platelet Endothelial Cell Adhesion Molecule-1/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/drug effects/metabolism MH - Vascular Cell Adhesion Molecule-1/*metabolism EDAT- 1997/11/05 00:00 MHDA- 1997/11/05 00:01 CRDT- 1997/11/05 00:00 PHST- 1997/11/05 00:00 [pubmed] PHST- 1997/11/05 00:01 [medline] PHST- 1997/11/05 00:00 [entrez] AID - 10.1159/000139520 [doi] PST - ppublish SO - Pharmacology. 1997 Sep;55(3):126-35. doi: 10.1159/000139520. PMID- 26749008 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20161230 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 104 IP - 5 DP - 2016 May TI - Effect of carbodiimide-derivatized hyaluronic acid gelatin on preventing postsurgical intra-abdominal adhesion formation and promoting healing in a rat model. PG - 1175-81 LID - 10.1002/jbm.a.35653 [doi] AB - Adhesions often occur after abdominal surgery. It could cause chronic pelvic pain, intestinal obstruction, and infertility. A hydrogel biomaterial, carbodiimide-derivatized hyaluronic acid gelatin (cd-HA gelatin), has been successfully used to reduce adhesion formation after flexor tendon grafting. This study investigated the efficacy of cd-HA gelatin in preventing postsurgical peritoneal adhesions in a rat model. The surgical traumas were created on the underlying muscle of the abdominal wall and the serosal layer of the cecum. The wounds were covered with or without cd-HA gelatin. Animals were euthanized at day 14 after surgery. Adhesion formation was assessed with adhesion degree and adhesion breaking strength. The healing of abdominal wall was evaluated with biomechanical testing and histological analysis. The adhesions occurred in all rats (n = 12) without cd-HA gelatin treatment. The application of cd-HA gelatin significantly reduced the adhesion rate from 100% to 58%. The decrease of adhesion breaking strength also manifested that cd-HA gelatin could reduce postsurgical intra-abdominal adhesion formation. Moreover, it was found that cd-HA gelatin was a safe material and could promote tissue healing. The cd-HA gelatin hydrogel could reduce the formation of intra-abdominal adhesions without adversely effects on wound healing. CI - © 2016 Wiley Periodicals, Inc. FAU - Yuan, Fang AU - Yuan F AD - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. FAU - Lin, Long-Xiang AU - Lin LX AD - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. FAU - Zhang, Hui-Hui AU - Zhang HH AD - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. FAU - Huang, Dan AU - Huang D AD - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. FAU - Sun, Yu-Long AU - Sun YL AD - Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160202 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Biocompatible Materials) RN - 0 (Carbodiimides) RN - 0 (Hydrogels) RN - 9000-70-8 (Gelatin) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Abdominal Wall/*pathology/*surgery MH - Animals MH - Biocompatible Materials/chemistry/*therapeutic use MH - Carbodiimides/chemistry/therapeutic use MH - Female MH - Gelatin/chemistry/*therapeutic use MH - Hyaluronic Acid/analogs & derivatives/*therapeutic use MH - Hydrogels/chemistry/*therapeutic use MH - Rats, Sprague-Dawley MH - Tendons/transplantation MH - Tissue Adhesions/etiology/pathology/*prevention & control MH - Wound Healing/drug effects OTO - NOTNLM OT - healing OT - hyaluronic acid OT - hydrogel OT - postsurgical intra-abdominal adhesion EDAT- 2016/01/11 06:00 MHDA- 2016/12/15 06:00 CRDT- 2016/01/11 06:00 PHST- 2015/11/04 00:00 [received] PHST- 2015/12/22 00:00 [revised] PHST- 2016/01/08 00:00 [accepted] PHST- 2016/01/11 06:00 [entrez] PHST- 2016/01/11 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.1002/jbm.a.35653 [doi] PST - ppublish SO - J Biomed Mater Res A. 2016 May;104(5):1175-81. doi: 10.1002/jbm.a.35653. Epub 2016 Feb 2. PMID- 18512112 OWN - NLM STAT- MEDLINE DCOM- 20080807 LR - 20240322 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 466 IP - 8 DP - 2008 Aug TI - Mechanoactive scaffold induces tendon remodeling and expression of fibrocartilage markers. PG - 1938-48 LID - 10.1007/s11999-008-0310-8 [doi] AB - Biological fixation of soft tissue-based grafts for anterior cruciate ligament (ACL) reconstruction poses a major clinical challenge. The ACL integrates with subchondral bone through a fibrocartilage enthesis, which serves to minimize stress concentrations and enables load transfer between two distinct tissue types. Functional integration thus requires the reestablishment of this fibrocartilage interface on reconstructed ACL grafts. We designed and characterized a novel mechanoactive scaffold based on a composite of poly-alpha-hydroxyester nanofibers and sintered microspheres; we then used the scaffold to test the hypothesis that scaffold-induced compression of tendon grafts would result in matrix remodeling and the expression of fibrocartilage interface-related markers. Histology coupled with confocal microscopy and biochemical assays were used to evaluate the effects of scaffold-induced compression on tendon matrix collagen distribution, cellularity, proteoglycan content, and gene expression over a 2-week period. Scaffold contraction resulted in over 15% compression of the patellar tendon graft and upregulated the expression of fibrocartilage-related markers such as Type II collagen, aggrecan, and transforming growth factor-beta3 (TGF-beta3). Additionally, proteoglycan content was higher in the compressed tendon group after 1 day. The data suggest the potential of a mechanoactive scaffold to promote the formation of an anatomic fibrocartilage enthesis on tendon-based ACL reconstruction grafts. FAU - Spalazzi, Jeffrey P AU - Spalazzi JP AD - Department of Biomedical Engineering, Biomaterials and Interface Tissue Engineering Laboratory, Columbia University, 351 Engineering Terrace Building, MC 8904, 1210 Amsterdam Avenue, New York, NY 10027, USA. FAU - Vyner, Moira C AU - Vyner MC FAU - Jacobs, Matthew T AU - Jacobs MT FAU - Moffat, Kristen L AU - Moffat KL FAU - Lu, Helen H AU - Lu HH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080530 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Aggrecans) RN - 0 (Collagen Type II) RN - 0 (Glycosaminoglycans) RN - 0 (TGFB3 protein, human) RN - 0 (Transforming Growth Factor beta3) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Aggrecans/metabolism MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Injuries MH - Collagen Type II/metabolism MH - Compressive Strength MH - Fibrocartilage/*metabolism MH - Glycosaminoglycans/chemistry MH - Humans MH - Image Processing, Computer-Assisted MH - Lactic Acid/therapeutic use MH - Microscopy, Confocal MH - Nanotechnology MH - Polyglycolic Acid/therapeutic use MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - Stress, Mechanical MH - Tendons/*physiology MH - Tissue Engineering/*methods MH - *Tissue Scaffolds MH - Transforming Growth Factor beta3/metabolism PMC - PMC2584247 EDAT- 2008/05/31 09:00 MHDA- 2008/08/08 09:00 PMCR- 2009/08/01 CRDT- 2008/05/31 09:00 PHST- 2007/11/05 00:00 [received] PHST- 2008/05/05 00:00 [accepted] PHST- 2008/05/31 09:00 [pubmed] PHST- 2008/08/08 09:00 [medline] PHST- 2008/05/31 09:00 [entrez] PHST- 2009/08/01 00:00 [pmc-release] AID - 310 [pii] AID - 10.1007/s11999-008-0310-8 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2008 Aug;466(8):1938-48. doi: 10.1007/s11999-008-0310-8. Epub 2008 May 30. PMID- 15035543 OWN - NLM STAT- MEDLINE DCOM- 20040507 LR - 20150826 IS - 0370-629X (Print) IS - 0370-629X (Linking) VI - 59 IP - 1 DP - 2004 Jan TI - [Xanthomas]. PG - 46-50 AB - Xanthomas are cutaneous lesions due to a local accumulation of spumous cells in the dermal tissue or the tendons. Histologically, they are characterized by the presence of histiocytes, fibroblasts, macrophages and Touton cells full of lipids. Xanthomas may be found on any part of the body and are usually yellow-orange in color. They may or may not be associated to hyperlipoproteinemia which may be genetic or secondary. A blood test and a complete physical examination are necessary in case such a lesion is discovered. When there is no hyperlipemia some types of xanthomas may be associated to rare diseases. Xanthomas are classified according to their clinical features. FAU - de Schaetzen, V AU - de Schaetzen V AD - Université de Liège, Service de Dermatologie. FAU - Richert, B AU - Richert B FAU - de la Brassinne, M AU - de la Brassinne M LA - fre PT - English Abstract PT - Journal Article PT - Review TT - Les xanthomes. PL - Belgium TA - Rev Med Liege JT - Revue medicale de Liege JID - 0404317 RN - 0 (Caustics) RN - 5V2JDO056X (Trichloroacetic Acid) SB - IM MH - Biopsy MH - Causality MH - Caustics/therapeutic use MH - Diagnosis, Differential MH - Electrocoagulation MH - Humans MH - Hyperlipidemias/classification/complications/therapy MH - Hyperlipoproteinemias/classification/complications/therapy MH - Laser Therapy MH - Physical Examination MH - Trichloroacetic Acid/therapeutic use MH - *Xanthomatosis/classification/*diagnosis/*etiology/therapy RF - 16 EDAT- 2004/03/24 05:00 MHDA- 2004/05/08 05:00 CRDT- 2004/03/24 05:00 PHST- 2004/03/24 05:00 [pubmed] PHST- 2004/05/08 05:00 [medline] PHST- 2004/03/24 05:00 [entrez] PST - ppublish SO - Rev Med Liege. 2004 Jan;59(1):46-50. PMID- 31140381 OWN - NLM STAT- MEDLINE DCOM- 20200723 LR - 20201130 IS - 1937-3392 (Electronic) IS - 1937-3384 (Linking) VI - 25 IP - 7 DP - 2019 Jul TI - Induction of Tendon-Specific Markers in Adipose-Derived Stem Cells in Serum-Free Culture Conditions. PG - 389-400 LID - 10.1089/ten.TEC.2019.0080 [doi] AB - Herein, we describe the tenogenic effect of bone morphogenetic protein-12 and transforming growth factor-β1 in cultured adipose-derived stem cells (ADSCs) in serum-free conditions. This culture system provides an insight into serum-free culture conditions in stem cell differentiation protocols. A positive response of the ADSCs to the tenogenic induction was observed. In particular, the different growth factors used in this study displayed notable differences both on the gene and on the protein expression of the tendon-specific markers. The results underline the positive outcome of the serum removal in tenogenic differentiation protocols, contributing to the development of future cell-based therapies for tendon regeneration and repair. FAU - Falcon, Noelia D AU - Falcon ND AD - 1School of Pharmacy, University of East Anglia, Norwich, United Kingdom. FAU - Riley, Graham P AU - Riley GP AD - 2School of Biological Sciences, University of East Anglia, Norwich, United Kingdom. FAU - Saeed, Aram AU - Saeed A AD - 1School of Pharmacy, University of East Anglia, Norwich, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tissue Eng Part C Methods JT - Tissue engineering. Part C, Methods JID - 101466663 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Biomarkers) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Collagen Type I) RN - 0 (Culture Media, Serum-Free) RN - 0 (SCX protein, human) RN - 0 (Transforming Growth Factor beta1) RN - 0 (growth differentiation factor 7) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adipose Tissue/*cytology MH - Ascorbic Acid/pharmacology MH - Basic Helix-Loop-Helix Transcription Factors/metabolism MH - Biomarkers/*metabolism MH - Bone Morphogenetic Proteins/pharmacology MH - Cell Membrane Permeability/drug effects MH - Cell Survival/drug effects MH - Collagen Type I/metabolism MH - Culture Media, Serum-Free/*pharmacology MH - Humans MH - Osteogenesis/drug effects MH - Stem Cells/*cytology/drug effects MH - Tendons/*metabolism MH - Transforming Growth Factor beta1/pharmacology OTO - NOTNLM OT - BMP-12 OT - TGF-β1 OT - adipose-derived stem cells OT - tenogenic differentiation EDAT- 2019/05/30 06:00 MHDA- 2020/07/24 06:00 CRDT- 2019/05/30 06:00 PHST- 2019/05/30 06:00 [pubmed] PHST- 2020/07/24 06:00 [medline] PHST- 2019/05/30 06:00 [entrez] AID - 10.1089/ten.TEC.2019.0080 [doi] PST - ppublish SO - Tissue Eng Part C Methods. 2019 Jul;25(7):389-400. doi: 10.1089/ten.TEC.2019.0080. PMID- 6263355 OWN - NLM STAT- MEDLINE DCOM- 19810827 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 674 IP - 3 DP - 1981 May 18 TI - Differences between proline and lysine hydroxylations in their inhibition by zinc or by ascorbate deficiency during collagen synthesis in various cell types. PG - 336-44 AB - The addition of Zn2+ inhibited lysine hydroxylation markedly less effectively than it did proline hydroxylation in chick embryo tendon cells, 3T6 fibroblasts and lysyl hydroxylase-deficient Ehlers-Danlos Syndrome Type VI fibroblasts. With low Zn2+ concentrations, a similar difference was also seen in chick embryo cartilage cells, whereas with high concentrations both hydroxylations were affected to the same extent in this cell type. Ascorbate deficiency likewise had a much less effect on lysine than proline hydroxylation when studied with 3T6 fibroblasts. As these two effectors involve quite different mechanisms, it is suggested that relative insensitivity to inhibition may be a property of lysine hydroxylation seen in many cell types with a number of agents. Studies on the mechanism of the difference in the inhibition indicates that the phenomenon is probably not due to differences in the kinetic constants of Zn2+ and ascorbate for the two enzymes. Neither is it probably to any major extent due to delayed procollagen triple helix formation nor a difference in the location of the two hydroxylases within the cisternae of the rough endoplasmic reticulum. The difference similarly cannot be explained solely by an excess of lysyl hydroxylase in the cell. It may thus be due either to some other intracellular property or to the combined effect of several factors. FAU - Anttinen, H AU - Anttinen H FAU - Puistola, U AU - Puistola U FAU - Pihlajaniemi, T AU - Pihlajaniemi T FAU - Kivirikko, K I AU - Kivirikko KI LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 9007-34-5 (Collagen) RN - EC 1.- (Mixed Function Oxygenases) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - EC 1.14.11.4 (Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase) RN - J41CSQ7QDS (Zinc) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*pharmacology MH - Ascorbic Acid Deficiency/enzymology MH - Cartilage/enzymology MH - Cells, Cultured MH - Chick Embryo MH - Chickens MH - Collagen/*biosynthesis MH - Ehlers-Danlos Syndrome/enzymology MH - Fibroblasts/enzymology MH - Kinetics MH - Mice MH - Mixed Function Oxygenases/*metabolism MH - Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase/*metabolism MH - Procollagen-Proline Dioxygenase/*metabolism MH - Skin/enzymology MH - Tendons/enzymology MH - Zinc/*pharmacology EDAT- 1981/05/18 00:00 MHDA- 1981/05/18 00:01 CRDT- 1981/05/18 00:00 PHST- 1981/05/18 00:00 [pubmed] PHST- 1981/05/18 00:01 [medline] PHST- 1981/05/18 00:00 [entrez] AID - 0304-4165(81)90364-0 [pii] AID - 10.1016/0304-4165(81)90364-0 [doi] PST - ppublish SO - Biochim Biophys Acta. 1981 May 18;674(3):336-44. doi: 10.1016/0304-4165(81)90364-0. PMID- 35321025 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20220325 IS - 1178-2013 (Electronic) IS - 1176-9114 (Print) IS - 1176-9114 (Linking) VI - 17 DP - 2022 TI - Simvastatin-Loaded Nanofibrous Membrane Efficiency on the Repair of Achilles Tendons. PG - 1171-1184 LID - 10.2147/IJN.S353066 [doi] AB - INTRODUCTION: In this study, simvastatin-incorporated poly(D,L-lactide-co-glycolide) (PLGA) nanofibrous mats were fabricated via electrospinning, and their efficacy in the repair of the Achilles tendon was evaluated. METHODS: The morphology of spun nanofibers and the in vitro drug release kinetics were assessed, while the in vivo efficacy in tendon repair was tested using a rat model. RESULTS: Images obtained by scanning electron microscopy revealed that spun nanofibers exhibit a porous structure with a fiber diameter of approximately 350 nm. Fourier-transform infrared spectrometry and differential scanning calorimetry demonstrated successful incorporation of pharmaceutical agents into the PLGA nanofibers. The drug-loaded nanofibrous membranes sustainably discharged high concentrations of simvastatin for >28 days at the target site, and drug concentrations in blood were low. Tendons repaired using simvastatin-eluting nanofibers exhibited superior mechanical strength and animal activities to those repaired without nanofibers or with pure PLGA nanofibers. DISCUSSION: Simvastatin-loaded nanofibers demonstrated effectiveness and sustainable capability for the repair of Achilles tendons. Eventually biodegradable drug-eluting nanofibrous mats may be used in humans for the treatment of tendon ruptures. CI - © 2022 Weng et al. FAU - Weng, Chun-Jui AU - Weng CJ AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. AD - Department of Orthopaedics, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Liao, Chieh-Tun AU - Liao CT AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. FAU - Hsu, Ming-Yi AU - Hsu MY AUID- ORCID: 0000-0003-1000-9925 AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. AD - Department of Radiology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. FAU - Chang, Fu-Pang AU - Chang FP AD - Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. FAU - Liu, Shih-Jung AU - Liu SJ AUID- ORCID: 0000-0003-2083-4865 AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan, Taiwan. LA - eng PT - Journal Article DEP - 20220316 PL - New Zealand TA - Int J Nanomedicine JT - International journal of nanomedicine JID - 101263847 RN - AGG2FN16EV (Simvastatin) SB - IM MH - *Achilles Tendon MH - Animals MH - Drug Liberation MH - Membranes MH - *Nanofibers/chemistry MH - Rats MH - Simvastatin/pharmacology PMC - PMC8935736 OTO - NOTNLM OT - nanofibers OT - simvastatin OT - sustainable release OT - tendon repair COIS- The authors declare no conflicts of interest in this work. EDAT- 2022/03/25 06:00 MHDA- 2022/03/26 06:00 PMCR- 2022/03/16 CRDT- 2022/03/24 05:06 PHST- 2021/12/08 00:00 [received] PHST- 2022/03/10 00:00 [accepted] PHST- 2022/03/24 05:06 [entrez] PHST- 2022/03/25 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] PHST- 2022/03/16 00:00 [pmc-release] AID - 353066 [pii] AID - 10.2147/IJN.S353066 [doi] PST - epublish SO - Int J Nanomedicine. 2022 Mar 16;17:1171-1184. doi: 10.2147/IJN.S353066. eCollection 2022. PMID- 23162007 OWN - NLM STAT- MEDLINE DCOM- 20130521 LR - 20161125 IS - 1940-1574 (Electronic) IS - 0003-3197 (Linking) VI - 64 IP - 4 DP - 2013 May TI - First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene. PG - 287-92 LID - 10.1177/0003319712465171 [doi] AB - Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder. Mutations have been found in at least 3 genes: the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9). We report the first case of FH in an Omani family due to a novel mutation in the LDLR gene. A 9-year-old female was referred to our lipid clinic with eye xanthelasmata and thickening of both Achilles tendons. Evaluation of the lipid profile showed the off treatment total cholesterol of 896 mg/dL (23.2 mmol/L), low-density lipoprotein cholesterol (LDL-C) of 853 mg/dL (22.1 mmol/L), APOB of 4.5 g/L, triglyceride of 71 mg/dL (0.8 mmol/L), and high-density lipoprotein cholesterol of 0.74 mmol/L. Genetic analysis of the LDLR gene showed a homozygous frameshift deletion mutation (272delG) at exon 3. The female patient was treated with a combination of rosuvastatin/ezetimibe and LDL apheresis. FAU - Al-Hinai, Ali T AU - Al-Hinai AT AD - Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. FAU - Al-Abri, Abdulrahim AU - Al-Abri A FAU - Al-Dhuhli, Humoud AU - Al-Dhuhli H FAU - Al-Waili, Khalid AU - Al-Waili K FAU - Al-Sabti, Hilal AU - Al-Sabti H FAU - Al-Yaarubi, Saif AU - Al-Yaarubi S FAU - Al-Hashmi, Khamis AU - Al-Hashmi K FAU - Banerjee, Yajnavalka AU - Banerjee Y FAU - Al-Zakwani, Ibrahim AU - Al-Zakwani I FAU - Al-Rasadi, Khalid AU - Al-Rasadi K LA - eng PT - Case Reports PT - Journal Article DEP - 20121115 PL - United States TA - Angiology JT - Angiology JID - 0203706 RN - 0 (Anticholesteremic Agents) RN - 0 (Apolipoproteins B) RN - 0 (Azetidines) RN - 0 (Biomarkers) RN - 0 (Cholesterol, HDL) RN - 0 (Cholesterol, LDL) RN - 0 (Drug Combinations) RN - 0 (Fluorobenzenes) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (LDLR protein, human) RN - 0 (Pyrimidines) RN - 0 (Receptors, LDL) RN - 0 (Sulfonamides) RN - 0 (Triglycerides) RN - 83MVU38M7Q (Rosuvastatin Calcium) RN - 97C5T2UQ7J (Cholesterol) RN - EOR26LQQ24 (Ezetimibe) SB - IM MH - Achilles Tendon/diagnostic imaging MH - Anticholesteremic Agents/therapeutic use MH - Apolipoproteins B/blood MH - Azetidines/therapeutic use MH - Biomarkers/blood MH - Blood Component Removal MH - Carotid Artery Diseases/genetics MH - Carotid Intima-Media Thickness MH - Child MH - Cholesterol/blood MH - Cholesterol, HDL/blood MH - Cholesterol, LDL/blood MH - DNA Mutational Analysis MH - Drug Combinations MH - Exons MH - Eye Diseases/genetics MH - Ezetimibe MH - Female MH - Fluorobenzenes/therapeutic use MH - *Frameshift Mutation MH - Genetic Predisposition to Disease MH - Homozygote MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use MH - Hyperlipoproteinemia Type II/blood/diagnosis/*genetics/*therapy MH - Oman MH - Pedigree MH - Phenotype MH - Pyrimidines/therapeutic use MH - Receptors, LDL/*genetics MH - Rosuvastatin Calcium MH - *Sequence Deletion MH - Sulfonamides/therapeutic use MH - Treatment Outcome MH - Triglycerides/blood MH - Xanthomatosis/genetics EDAT- 2012/11/20 06:00 MHDA- 2013/05/23 06:00 CRDT- 2012/11/20 06:00 PHST- 2012/11/20 06:00 [entrez] PHST- 2012/11/20 06:00 [pubmed] PHST- 2013/05/23 06:00 [medline] AID - 0003319712465171 [pii] AID - 10.1177/0003319712465171 [doi] PST - ppublish SO - Angiology. 2013 May;64(4):287-92. doi: 10.1177/0003319712465171. Epub 2012 Nov 15. PMID- 1908036 OWN - NLM STAT- MEDLINE DCOM- 19910913 LR - 20190725 IS - 0026-0495 (Print) IS - 0026-0495 (Linking) VI - 40 IP - 7 DP - 1991 Jul TI - Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. PG - 741-6 AB - We studied the effect of chenodeoxycholic acid (CDCA) and a competitive HMG-CoA reductase inhibitor, pravastatin, on clinical symptoms and sterol metabolism in a 36-year-old Japanese man with cerebrotendinous xanthomatosis (CTX). He had marked tendon xanthomas and mild dementia, with obvious electroencephalographic (EEG) abnormalities. He was treated for 2 years with CDCA alone (0.6 g/d) and then for a further year with the combination of pravastatin (10 mg/d) and CDCA (0.6 g/d). For the following year, he was given pravastatin alone, and then was returned to combined treatment again. The plasma cholestanol level before treatment was 3.12 mg/dL, which was 20 times above the control level. After CDCA alone, the plasma cholestanol was reduced to 1.96 mg/dL, and this was further reduced to 0.92 mg/dL by combination therapy with CDCA and pravastatin. However, after the discontinuation of CDCA, his cholestanol levels returned to the pretreatment levels despite the continuing of pravastatin treatment. When the combination therapy was restarted, his cholestanol level was once again markedly reduced. His clinical symptoms showed a close association with the plasma cholestanol level; the xanthomas regressed remarkably and the mental retardation improved in association with normalization of EEG findings during treatment with CDCA alone or in combination with pravastatin. However, during treatment with pravastatin alone, his tendon xanthomas enlarged again and slow waves reappeared on the EEG. Because inhibition of cholesterol synthesis by treatment with the HMG-CoA reductase inhibitor alone was not effective in causing a reduction of cholestanol, the increase in plasma cholestanol levels in CTX may not have been solely due to increased cholesterol synthesis.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Nakamura, T AU - Nakamura T AD - Second Department of Internal Medicine, Osaka University Medical School, Japan. FAU - Matsuzawa, Y AU - Matsuzawa Y FAU - Takemura, K AU - Takemura K FAU - Kubo, M AU - Kubo M FAU - Miki, H AU - Miki H FAU - Tarui, S AU - Tarui S LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (Anticholesteremic Agents) RN - 0 (Bile Acids and Salts) RN - 0 (Heptanoic Acids) RN - 0 (Naphthalenes) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 8M308U816E (Cholestanol) RN - 97C5T2UQ7J (Cholesterol) RN - KXO2KT9N0G (Pravastatin) SB - IM MH - Adult MH - Anticholesteremic Agents/therapeutic use MH - Bile Acids and Salts/analysis MH - Brain Diseases/blood/*drug therapy/pathology MH - Chenodeoxycholic Acid/pharmacokinetics/*therapeutic use MH - Cholestanol/*blood MH - Cholesterol/blood MH - Chromatography, High Pressure Liquid MH - Drug Therapy, Combination MH - Heptanoic Acids/*therapeutic use MH - Humans MH - Male MH - Muscular Diseases/blood/drug therapy/pathology MH - Naphthalenes/*therapeutic use MH - Pravastatin MH - *Tendons MH - Xanthomatosis/blood/*drug therapy/pathology EDAT- 1991/07/01 00:00 MHDA- 1991/07/01 00:01 CRDT- 1991/07/01 00:00 PHST- 1991/07/01 00:00 [pubmed] PHST- 1991/07/01 00:01 [medline] PHST- 1991/07/01 00:00 [entrez] AID - 0026-0495(91)90094-D [pii] AID - 10.1016/0026-0495(91)90094-d [doi] PST - ppublish SO - Metabolism. 1991 Jul;40(7):741-6. doi: 10.1016/0026-0495(91)90094-d. PMID- 7385563 OWN - NLM STAT- MEDLINE DCOM- 19800825 LR - 20181130 IS - 0042-4625 (Print) IS - 0042-4625 (Linking) VI - 124 IP - 4 DP - 1980 Apr TI - [Characteristics of the regeneration of the knee joint ligaments after plastic substitution with lavsan]. PG - 74-8 AB - The observations were made in 125 patients of a department of trauma sequellae. It has been shown that plastic repair of the knee joint tendons with the help of lavsan is the method of choice especially in the treatment of young working people and sportsmen for whom the normal functioning of this joint is of special importance. FAU - Gurgenidze, N I AU - Gurgenidze NI FAU - Nakashidze, D K AU - Nakashidze DK FAU - Kalashnikova, M S AU - Kalashnikova MS FAU - Shakhbazov, E T AU - Shakhbazov ET LA - rus PT - Journal Article TT - Ob osobennostiakh regeneratsii sviazok kolennogo sustava posle plasticheskogo zameshcheniia lavsanom. PL - Russia (Federation) TA - Vestn Khir Im I I Grek JT - Vestnik khirurgii imeni I. I. Grekova JID - 0411377 RN - 0 (Phthalic Acids) RN - 0 (Polyethylene Terephthalates) RN - 25038-59-9 (Lavsan) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adult MH - Female MH - Follow-Up Studies MH - Humans MH - Knee Injuries/physiopathology/surgery MH - Knee Joint/*physiology/surgery MH - Ligaments, Articular/*physiology/surgery MH - Male MH - Middle Aged MH - Phthalic Acids/*therapeutic use MH - Polyethylene Glycols/*therapeutic use MH - *Polyethylene Terephthalates MH - Regeneration/*drug effects MH - Time Factors EDAT- 1980/04/01 00:00 MHDA- 1980/04/01 00:01 CRDT- 1980/04/01 00:00 PHST- 1980/04/01 00:00 [pubmed] PHST- 1980/04/01 00:01 [medline] PHST- 1980/04/01 00:00 [entrez] PST - ppublish SO - Vestn Khir Im I I Grek. 1980 Apr;124(4):74-8. PMID- 3732282 OWN - NLM STAT- MEDLINE DCOM- 19860925 LR - 20190620 IS - 0014-2956 (Print) IS - 0014-2956 (Linking) VI - 158 IP - 3 DP - 1986 Aug 1 TI - Intracellular transport and tyrosine sulfation of procollagens V. PG - 511-8 AB - Several tyrosine residues of the extracellular p-collagens V and collagens V are sulfated [Fessler, L. I., Brosh, S., Chapin, S. and Fessler, J. H. (1986) J. Biol. Chem. 261, 5034-5040]. Here, the sulfation of their intracellular precursors, the procollagens V, was studied. A Golgi-enriched subcellular fraction of chick embryo tendon catalyzed the sulfation of tyrosine residues in both endogenous and added, unsulfated procollagens V with the sulfate donor 3'-phosphoadenosine 5'-[35S]phosphosulfate. Intracellular tyrosine sulfation of procollagen V occurred at a point distal to the cis Golgi compartment as judged by change of the N-linked carbohydrate of procollagen V from being endoglycosidase-H-sensitive to being resistant. The time course of the intracellular modifications of procollagen V was determined by incubating tendons with 3H-labeled amino acids and with [35S]sulfate. The pro alpha(V) chains were synthesised in about 10 min and then assembled into unsulfated procollagen V molecules. Tyrosine sulfation occurred 50 min after completion of polypeptide synthesis and the molecules were successively sulfated in the order in which they had been synthesized. The antimicrotubular drug Nocodazole, which disrupts the spatial organization of the Golgi, decreased the time interval between synthesis of procollagens V and sulfation. The sulfated procollagens V were soon secreted and cut to sulfated p-collagens V. Sulfated pro alpha 1(V) chains were cleaved faster than sulfated pro alpha 1'(V) chains. The relationship of sequential protein modification to spatial cellular organization is discussed. FAU - Fessler, L I AU - Fessler LI FAU - Chapin, S AU - Chapin S FAU - Brosh, S AU - Brosh S FAU - Fessler, J H AU - Fessler JH LA - eng GR - AM13748/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Eur J Biochem JT - European journal of biochemistry JID - 0107600 RN - 0 (Benzimidazoles) RN - 0 (Procollagen) RN - 0 (Sulfates) RN - 0 (Sulfur Radioisotopes) RN - 42HK56048U (Tyrosine) RN - 8N3DW7272P (Cyclophosphamide) RN - SH1WY3R615 (Nocodazole) SB - IM MH - Animals MH - Benzimidazoles/pharmacology MH - Biological Transport MH - Chick Embryo MH - Cyclophosphamide/pharmacology MH - Nocodazole MH - Procollagen/*metabolism MH - Sulfates/*metabolism MH - Sulfur Radioisotopes MH - Tendons/metabolism MH - Tyrosine/*metabolism EDAT- 1986/08/01 00:00 MHDA- 1986/08/01 00:01 CRDT- 1986/08/01 00:00 PHST- 1986/08/01 00:00 [pubmed] PHST- 1986/08/01 00:01 [medline] PHST- 1986/08/01 00:00 [entrez] AID - 10.1111/j.1432-1033.1986.tb09784.x [doi] PST - ppublish SO - Eur J Biochem. 1986 Aug 1;158(3):511-8. doi: 10.1111/j.1432-1033.1986.tb09784.x. PMID- 11557548 OWN - NLM STAT- MEDLINE DCOM- 20011025 LR - 20200930 IS - 0363-6135 (Print) IS - 0363-6135 (Linking) VI - 281 IP - 4 DP - 2001 Oct TI - Distribution spaces for hyaluronan and albumin in rat tail tendons. PG - H1589-97 AB - A low concentration of hyaluronan (HA) in lymph compared with tissue suggests a large bound fraction. To investigate the distribution and mobility of HA and serum albumin (Alb), we eluted the rat tail tendon with a series of l5 successive centrifugations, each preceded by the addition of 0.15 M NaCl (15% of initial wet wt). The eluate concentration fell exponentially versus the accumulated eluate, allowing estimation of the maximal elutable amount (E(HA) and E(Alb)). Alb elution was practically complete from a space of approximately 28% of wet wt at all centrifugation rates. Twenty percent of HA was elutable at 500 rpm, apparently from the same space as Alb, increasing to 40% at >4,000 rpm. This pattern was not significantly influenced by using 2 M NaCl or by the addition of plasma or metabolic inhibitors. Without prehydration and centrifugation at high revolutions per minute, both Alb and HA concentrations fell rapidly toward zero, presumably in part reflecting mobilization of HA- and Alb-free fluid from the collagen intrafibrillar space (3). We conclude that with prehydration the fibrils swell, increasing the intramolecular spaces to become "penetrable" to HA and allowing removal of HA-containing fluid when the fibrils are compressed by the next centrifugation at high revolutions per minute, increasing E(HA) from 23 to 45%. Chemical binding presumably explains the unelutable 55% of tendon HA. Intrafibrillar HA may act to stabilize the fibrillar volume. FAU - Aukland, K AU - Aukland K AD - Department of Physiology, University of Bergen, N-5009 Bergen, Norway. knut.aukland@fys.uib.no FAU - Tenstad, O AU - Tenstad O FAU - Wiig, H AU - Wiig H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Enzyme Inhibitors) RN - 0 (Iodoacetates) RN - 0 (Serum Albumin) RN - 451W47IQ8X (Sodium Chloride) RN - 9004-61-9 (Hyaluronic Acid) RN - 968JJ8C9DV (Sodium Azide) SB - IM MH - Animals MH - Blood Physiological Phenomena MH - Centrifugation MH - Enzyme Inhibitors/pharmacology MH - Female MH - Hyaluronic Acid/antagonists & inhibitors/*metabolism MH - Iodoacetates/pharmacology MH - Male MH - Osmolar Concentration MH - Rats MH - Rats, Sprague-Dawley MH - Rats, Wistar MH - Serum Albumin/*metabolism MH - Sodium Azide/pharmacology MH - Sodium Chloride/pharmacology MH - Tail/*metabolism MH - Tendons/*metabolism MH - Tissue Distribution EDAT- 2001/09/15 10:00 MHDA- 2001/10/26 10:01 CRDT- 2001/09/15 10:00 PHST- 2001/09/15 10:00 [pubmed] PHST- 2001/10/26 10:01 [medline] PHST- 2001/09/15 10:00 [entrez] AID - 10.1152/ajpheart.2001.281.4.H1589 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2001 Oct;281(4):H1589-97. doi: 10.1152/ajpheart.2001.281.4.H1589. PMID- 1150643 OWN - NLM STAT- MEDLINE DCOM- 19751106 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 250 IP - 13 DP - 1975 Jul 10 TI - The metabolic requirements for transcellular movement and secretion of collagen. PG - 4841-7 AB - Cultures of chick tendon fibroblasts were capable of normal ATP production and protein synthetic activity even though the normally high rate of glycolysis was markedly reduced by substitution of pyruvate for glucose. Iodoacetate and 2-deoxyglucose reduced ATP levels and protein synthesis even in the presence of pyruvate. Under these conditions, both inhibitors were shown to have effects on the energy metabolism of cells which were apparently unrelated to an inhibition of glycolysis. Selective inhibition of either glycolysis, by incubation in glucose-free medium, or of oxidative phosphorylation, by incubation with an uncoupler, was shown to have little effect on cellular ATP levels or intracellular transport and secretion of collagen. However, inhibition of both glycolysis and oxidative phosphorylation resulted in decreased cellular ATP levels and an inhibition of collagen secretion. This effect was not due to a requirement for continued protein synthesis, since inhibition of protein synthesis with cycloheximide or puromycin had little effect on collagen secretion. The ATP requirement for intracellular transport and secretion is discussed in relation to the secretory pathway for collagen. FAU - Kruse, N J AU - Kruse NJ FAU - Bornstein, P AU - Bornstein P LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Iodoacetates) RN - 0 (Lactates) RN - 0 (Pyruvates) RN - 10028-17-8 (Tritium) RN - 4A6ZS6Q2CL (Puromycin) RN - 8DUH1N11BX (Tryptophan) RN - 8L70Q75FXE (Adenosine Triphosphate) RN - 9007-34-5 (Collagen) RN - 98600C0908 (Cycloheximide) RN - 9DLQ4CIU6V (Proline) RN - 9G2MP84A8W (Deoxyglucose) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Adenosine Triphosphate/metabolism MH - Animals MH - Biological Transport, Active MH - Cells, Cultured MH - Chick Embryo MH - Collagen/biosynthesis/*metabolism MH - Cycloheximide/pharmacology MH - Deoxyglucose/pharmacology MH - Energy Metabolism MH - Fibroblasts/drug effects/*metabolism MH - Glycolysis MH - Hydroxyproline/metabolism MH - Iodoacetates/pharmacology MH - Lactates/metabolism MH - Proline/metabolism MH - Puromycin/pharmacology MH - Pyruvates/metabolism MH - Tendons MH - Tritium MH - Tryptophan/metabolism EDAT- 1975/07/10 00:00 MHDA- 1975/07/10 00:01 CRDT- 1975/07/10 00:00 PHST- 1975/07/10 00:00 [pubmed] PHST- 1975/07/10 00:01 [medline] PHST- 1975/07/10 00:00 [entrez] AID - S0021-9258(19)41245-3 [pii] PST - ppublish SO - J Biol Chem. 1975 Jul 10;250(13):4841-7. PMID- 9111457 OWN - NLM STAT- MEDLINE DCOM- 19970508 LR - 20220408 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 78 IP - 4 DP - 1997 Apr TI - Acetic acid iontophoresis and ultrasound for the treatment of calcifying tendinitis of the shoulder: a randomized control trial. PG - 379-84 AB - OBJECTIVE: To assess the effects of acetic acid iontophoresis (AAI) and ultrasound on calcifying tendinitis of the shoulder, and to determine the relation between changes in the radiological measures of calcium deposit (CD) and shoulder function. DESIGN: Randomized control trial. SETTING: General community, private practice. PATIENTS: Twenty-two adults (7 men, 15 women) with a calcifying tendinitis of the shoulder, without associated conditions, stratified according to the type of lesions (X-ray: type I, fleecy appearance: type II, homogeneous), were randomly allocated to an experimental (EXP, n = 11) or to a control (CTL, n = 10) group. INTERVENTIONS: CTL group, no treatment; EXP group, nine treatments including AAI (5% acetic acid solution via the negative electrode, 5mA galvanic current, 20 minutes) followed by continuous ultrasound (0.8w/cm2, 1MHz, 5 minutes). MAIN OUTCOME MEASURES: Area and density of the CD, passive shoulder abduction (range of motion [ROM]), pain intensity. RESULTS: Significant reduction in the area and density of CD (ANCOVA, p = .01 and .03) over time in the EXP and CTL groups, but no significant difference between groups for any of the variables measured. The decrease in the area of CD in type I lesions (n = 5) was larger (Mann-Whitney U test, p < .01) than in type II (n = 16) lesions. The relation was stronger (rs = .90) between changes in area and density of CD than between ROM and pain (rs = -.67). Correlations were weak (rs = .21 to .41) between radiological and functional changes. CONCLUSION: The reduction in CD area and density likely results from a natural process rather than treatment (AAI and ultrasound); type I lesions (resorptive phase) are more likely to display resorption of the CD than type II lesions (formative phase). Reduction of the CD area does not necessary result in a functional improvement. FAU - Perron, M AU - Perron M AD - Clinique de Physiothérapie de Charny, Canada. FAU - Malouin, F AU - Malouin F LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - Q40Q9N063P (Acetic Acid) SB - IM MH - Acetic Acid/*therapeutic use MH - Adult MH - Calcinosis/*complications MH - Female MH - Humans MH - *Iontophoresis MH - Male MH - Middle Aged MH - *Shoulder Joint MH - Tendinopathy/etiology/pathology/*therapy MH - Tendons/pathology MH - Treatment Failure MH - *Ultrasonic Therapy EDAT- 1997/04/01 00:00 MHDA- 1997/04/01 00:01 CRDT- 1997/04/01 00:00 PHST- 1997/04/01 00:00 [pubmed] PHST- 1997/04/01 00:01 [medline] PHST- 1997/04/01 00:00 [entrez] AID - S0003-9993(97)90229-X [pii] AID - 10.1016/s0003-9993(97)90229-x [doi] PST - ppublish SO - Arch Phys Med Rehabil. 1997 Apr;78(4):379-84. doi: 10.1016/s0003-9993(97)90229-x. PMID- 21430512 OWN - NLM STAT- MEDLINE DCOM- 20110914 LR - 20220408 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 90 IP - 6 DP - 2011 Jun TI - The comparative effectiveness of tendon and nerve gliding exercises in patients with carpal tunnel syndrome: a randomized trial. PG - 435-42 LID - 10.1097/PHM.0b013e318214eaaf [doi] AB - OBJECTIVE: : The aim of this study was to investigate the effectiveness of tendon and nerve gliding exercises as a part of combined treatments for carpal tunnel syndrome. DESIGN: : Patients with carpal tunnel syndrome were randomized into three groups. All patients received conventional treatments (splint and paraffin therapy, as in group 3), but group 1 underwent additional tendon gliding exercises and group 2 underwent additional nerve gliding exercises. Each patient received a package of questionnaires and underwent physical examinations and nerve conduction study of the upper limbs before and after treatment for 2 mos. RESULTS: : Sixty patients were recruited, and 53 completed the study. There were significant improvements in symptom severity and pain scale scores in all groups. However, only group 1 showed significant improvements in their scores on functional status; the Disabilities of the Arm, Shoulder, and Hand questionnaire; and the physical domain of the World Health Organization Quality of Life Questionnaire Brief Version. After adjusting for baseline data, we found significant differences in the functional status scores among the groups. Post hoc analyses detected a significant difference in functional status scores between groups 1 and 2. CONCLUSIONS: : The combination of tendon gliding exercises with conventional treatments may be more effective than that of nerve gliding exercises with conventional treatments. FAU - Horng, Yi-Shiung AU - Horng YS AD - Department of Physical Medicine and Rehabilitation, Buddhist Tzu Chi General Hospital, Taipei, Taiwan. FAU - Hsieh, Shih-Fu AU - Hsieh SF FAU - Tu, Yu-Kang AU - Tu YK FAU - Lin, Ming-Chuan AU - Lin MC FAU - Horng, Yu-Shiow AU - Horng YS FAU - Wang, Jung-Der AU - Wang JD LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 0 (Oils) RN - 8002-74-2 (Paraffin) RN - 8012-95-1 (paraffin oils) SB - IM MH - Adult MH - Carpal Tunnel Syndrome/diagnosis/*rehabilitation MH - Combined Modality Therapy MH - Exercise Therapy/*methods MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Median Nerve/physiopathology MH - Middle Aged MH - Neural Conduction MH - Oils/*therapeutic use MH - Pain Measurement MH - Paraffin/*therapeutic use MH - Patient Satisfaction MH - Physical Therapy Modalities MH - Prospective Studies MH - Reference Values MH - Risk Assessment MH - Severity of Illness Index MH - Single-Blind Method MH - *Splints MH - Tendons/physiopathology EDAT- 2011/03/25 06:00 MHDA- 2011/09/15 06:00 CRDT- 2011/03/25 06:00 PHST- 2011/03/25 06:00 [entrez] PHST- 2011/03/25 06:00 [pubmed] PHST- 2011/09/15 06:00 [medline] AID - 10.1097/PHM.0b013e318214eaaf [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2011 Jun;90(6):435-42. doi: 10.1097/PHM.0b013e318214eaaf. PMID- 16177476 OWN - NLM STAT- MEDLINE DCOM- 20051223 LR - 20171116 IS - 0971-5916 (Print) IS - 0971-5916 (Linking) VI - 122 IP - 2 DP - 2005 Aug TI - Taurine prevents collagen abnormalities in high fructose-fed rats. PG - 171-7 AB - BACKGROUND & OBJECTIVE: Accumulation of collagen and changes in its physiochemical properties contribute to the development of secondary complications of diabetes. We undertook this study to see the effects of taurine on the content and characteristics of collagen from tail tendon of rats fed with high fructose diet. METHODS: The rats were divided into four groups of six each: control group (CON), taurine-supplemented control group (CON+TAU), taurine supplemented (FRU+TAU) and not supplemented fructose-fed group (FRU). The physico-chemical properties of collagen isolated from the tail tendon were studied. RESULTS: Fructose administration caused accumulation of collagen in tail tendon. Enhanced glycation and advanced glycation end products (AGE)-linked fluorescence together with alterations in aldehyde content, solubility pattern, susceptibility to denaturing agents and shrinkage temperature were observed in fructose-fed rats. Elevated b component of type I collagen was evidenced from the SDS gel pattern of collagen from the fructose-fed rats. Simultaneous administration of taurine alleviated these changes. INTERPRETATION & CONCLUSION: Taurine administration to fructose-rats had a positive influence on both quantitative and qualitative properties of collagen. The results of the present study suggested a role for the action of taurine in delaying diabetic complications and the possible use of taurine as an adjuvant therapeutic measure in the management of diabetes and its complications. FAU - Nandhini, A T Anitha AU - Nandhini AT AD - Department of Biochemistry, Faculty of Science, Annamalai University, Annamalai Nagar 608-002, India. FAU - Thirunavukkarasu, V AU - Thirunavukkarasu V FAU - Anuradha, C V AU - Anuradha CV LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 RN - 0 (Amino Acids) RN - 0 (Antioxidants) RN - 0 (Collagen Type I) RN - 0 (Glycation End Products, Advanced) RN - 0 (Salts) RN - 1EQV5MLY3D (Taurine) RN - 30237-26-4 (Fructose) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 9007-34-5 (Collagen) RN - EC 3.4.23.1 (Pepsin A) SB - IM MH - Amino Acids/chemistry MH - *Animal Nutritional Physiological Phenomena MH - Animals MH - Antioxidants/pharmacology MH - Collagen/chemistry/*metabolism MH - Collagen Type I/metabolism MH - Fructose/metabolism/*pharmacology MH - Glycation End Products, Advanced/metabolism MH - Lipid Peroxidation MH - Male MH - Models, Animal MH - Pepsin A/chemistry MH - Rats MH - Rats, Wistar MH - Salts/pharmacology MH - Sodium Dodecyl Sulfate/chemistry/metabolism MH - Solubility MH - Tail MH - Taurine/chemistry/metabolism/*pharmacology MH - Temperature MH - Tendons/*metabolism EDAT- 2005/09/24 09:00 MHDA- 2005/12/24 09:00 CRDT- 2005/09/24 09:00 PHST- 2005/09/24 09:00 [pubmed] PHST- 2005/12/24 09:00 [medline] PHST- 2005/09/24 09:00 [entrez] PST - ppublish SO - Indian J Med Res. 2005 Aug;122(2):171-7. PMID- 31757369 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20200219 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 28 IP - 12 DP - 2019 Dec TI - Celecoxib cannot inhibit the progression of initiated traumatic heterotopic ossification. PG - 2379-2385 LID - S1058-2746(19)30587-7 [pii] LID - 10.1016/j.jse.2019.08.013 [doi] AB - BACKGROUND AND HYPOTHESIS: Heterotopic ossification (HO) is a recognized sequela after trauma and arthroplasty. The purpose of this study was to evaluate the therapeutic effect of celecoxib on HO. We hypothesized that celecoxib may inhibit the progression of initiated HO. METHODS: We performed a retrospective review of 37 patients who underwent elbow joint surgery between January 2014 and June 2018. Seventeen patients were prescribed orally administered celecoxib (200 mg/dose, twice daily) for 2 months after the diagnosis of HO, whereas the remaining 20 patients were administered celecoxib for 1 month starting immediately after surgery. HO progression was evaluated by plain radiographs. By use of an Achilles tendon puncture-induced HO mouse model, the curative effect of celecoxib was illustrated at different HO progression stages. The mice were assigned to 1 of 4 groups: sham group, vehicle group, group receiving celecoxib on day 1, and group receiving celecoxib in week 6. Achilles tendons were analyzed by micro-computed tomography and histochemistry after 12 weeks. RESULTS: Celecoxib did not inhibit the progression of initiated HO in the patients in whom HO was diagnosed, whereas those who received celecoxib after surgery had lower morbidity. Achilles tendon puncture effectively induced typical HO in mice. The ectopic bone volume was significantly reduced in the day 1 celecoxib group compared with the vehicle group; however, the difference was not statistically significant in the week 6 celecoxib group. CONCLUSIONS: Administration of celecoxib starting immediately after surgery can significantly inhibit the formation of HO. Once HO is visible on plain radiographs or micro-computed tomography, celecoxib cannot effectively attenuate further progression of HO in humans and mice. CI - Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. FAU - Li, Fengfeng AU - Li F AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. FAU - Mao, Dong AU - Mao D AD - Research Institute of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. FAU - Pan, Xiaoyun AU - Pan X AD - Research Institute of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. FAU - Zhang, Xin AU - Zhang X AD - Research Institute of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. FAU - Mi, Jingyi AU - Mi J AD - Department of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. FAU - Rui, Yongjun AU - Rui Y AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, China. Electronic address: wxswkryj@163.com. LA - eng PT - Journal Article PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Achilles Tendon/diagnostic imaging/injuries/pathology MH - Adult MH - Aged MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Celecoxib/*therapeutic use MH - Disease Models, Animal MH - *Disease Progression MH - Elbow Joint/diagnostic imaging/surgery MH - Female MH - Humans MH - Male MH - Mice MH - Middle Aged MH - Ossification, Heterotopic/diagnostic imaging/*drug therapy/etiology/*prevention & control MH - Postoperative Complications/diagnostic imaging/*drug therapy/etiology MH - Retrospective Studies MH - X-Ray Microtomography MH - Young Adult OTO - NOTNLM OT - Heterotopic ossification OT - NSAID OT - celecoxib OT - elbow joint OT - prostaglandin E2 OT - trauma EDAT- 2019/11/24 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/11/24 06:00 PHST- 2019/02/03 00:00 [received] PHST- 2019/08/12 00:00 [revised] PHST- 2019/08/14 00:00 [accepted] PHST- 2019/11/24 06:00 [entrez] PHST- 2019/11/24 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] AID - S1058-2746(19)30587-7 [pii] AID - 10.1016/j.jse.2019.08.013 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2019 Dec;28(12):2379-2385. doi: 10.1016/j.jse.2019.08.013. PMID- 36177054 OWN - NLM STAT- MEDLINE DCOM- 20221104 LR - 20221104 IS - 2314-6141 (Electronic) IS - 2314-6133 (Print) VI - 2022 DP - 2022 TI - Tamoxifen Prevents Peritendinous Adhesions: A Preliminary Report. PG - 4250771 LID - 10.1155/2022/4250771 [doi] LID - 4250771 AB - BACKGROUND: Scarless healing comprises the ultimate goal after an injury. Since tendon healing results in a fibrotic scar, an injured tendon can never regain the mechanical potential and strength of its uninjured form. A wide variety of studies focus on the tendon healing with an absent or minimal peritendinous adhesions. However, no simple method has managed it at all. Possible complex actions and peritendinous environmental events take place during the tendon healing process. Tamoxifen (TAM), besides its breast cancer-related usage, is a potent antifibrotic drug. Here, we aimed to reduce the peritendinous adhesion with TAM administration. METHODS: Achilles tendons of 44 Wistar albino rats were randomly distributed in 4 groups. In group 1, bilateral lower extremities were used as control and sham. Groups 2 and 3 were comprised of low-dose (1 mg/kg) and high-dose (40 mg/kg) systemic administration of TAM, respectively. Group 4 included local administration (1 mg/kg) of TAM. Biomechanical, macroscopical, and histopathological analyses were done and compared statistically. Biomechanically, the maximum force that led to tendon rupture was determined, and tensile force data were recorded via tensile testing device. Macroscopical and histopathological analysis were composed of the quantity, quality, and grade of peritendinous adhesions. RESULTS: Macroscopic and histopathologic findings revealed that groups 2 and 3 had a variety of values ranging between slight to severe adhesions. In group 2, almost half of the animals had moderate adhesions, whereas in group 3, the majority of the animals had moderate adhesions. There were no animals with moderate or severe adhesions in group 4. Statistically significant values were calculated between sham and control groups. Biomechanically, group 2 showed the most significant result. The tendons in group 2 had the highest stiffness when maximal force was applied to rupture the tendons. Henceforth, all these consequences were proven statistically. CONCLUSION: We achieved less peritendinous adhesion with the local administration of TAM when compared to systemic administration of TAM. A better understanding of the peritendinous environmental process will reveal to develop new therapies in the prevention of peritendinous adhesions. CI - Copyright © 2022 Oguz Kayiran et al. FAU - Kayiran, Oguz AU - Kayiran O AUID- ORCID: 0000-0002-8179-5313 AD - Department of Plastic, Reconstructive and Aesthetic Surgery, Demiroglu Bilim University, Turkey. FAU - Tunc, Suphan AU - Tunc S AD - Private Practice in Plastic, Reconstructive and Aesthetic Surgery, Turkey. FAU - Ozcan, Guler Gamze Eren AU - Ozcan GGE AD - Private Practice in Plastic, Reconstructive and Aesthetic Surgery, Turkey. FAU - Kaya, Neslihan AU - Kaya N AD - Department of Pathology, Sultan Abdulhamid Han Training and Research Hospital, Turkey. FAU - Karabulut, Derya AU - Karabulut D AD - Department of Mechanical Engineering, Istanbul University, Turkey. LA - eng PT - Journal Article DEP - 20220920 PL - United States TA - Biomed Res Int JT - BioMed research international JID - 101600173 RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Animals MH - Rats MH - *Achilles Tendon/pathology MH - Biomechanical Phenomena MH - Rats, Wistar MH - Tamoxifen/pharmacology MH - *Tendon Injuries/drug therapy/pathology MH - Tissue Adhesions/drug therapy/pathology/prevention & control PMC - PMC9514950 COIS- The authors declare that they have no conflicts of interest. EDAT- 2022/10/01 06:00 MHDA- 2022/10/04 06:00 PMCR- 2022/09/20 CRDT- 2022/09/30 02:41 PHST- 2022/02/12 00:00 [received] PHST- 2022/08/16 00:00 [revised] PHST- 2022/08/24 00:00 [accepted] PHST- 2022/09/30 02:41 [entrez] PHST- 2022/10/01 06:00 [pubmed] PHST- 2022/10/04 06:00 [medline] PHST- 2022/09/20 00:00 [pmc-release] AID - 10.1155/2022/4250771 [doi] PST - epublish SO - Biomed Res Int. 2022 Sep 20;2022:4250771. doi: 10.1155/2022/4250771. eCollection 2022. PMID- 16210573 OWN - NLM STAT- MEDLINE DCOM- 20060721 LR - 20220410 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 34 IP - 3 DP - 2006 Mar TI - Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing. PG - 362-9 AB - BACKGROUND: Nonsteroidal anti-inflammatory drugs are commonly prescribed after rotator cuff repair. These agents can impair bone formation, but no studies have evaluated their impact on tendon-to-bone healing. HYPOTHESIS: Traditional nonselective nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs interfere with tendon-to-bone healing. STUDY DESIGN: Controlled laboratory study. METHODS: One hundred eighty Sprague-Dawley rats underwent acute rotator cuff repairs. Postoperatively, 60 rats received 14 days of celecoxib, a cyclooxygenase-2-specific nonsteroidal anti-inflammatory drug; 60 received indomethacin, a traditional nonselective nonsteroidal anti-inflammatory drug; and 60 received standard rat chow. Animals were sacrificed at 2, 4, and 8 weeks and evaluated by gross inspection, biomechanical testing, histologic analysis, and polarized light microscopy to quantify collagen formation and maturation. RESULTS: Five tendons completely failed to heal (4 celecoxib, 1 indomethacin). There were significantly lower failure loads in the celecoxib and indomethacin groups compared with the control groups at 2, 4, and 8 weeks (P < .001), with no significant difference between nonsteroidal anti-inflammatory drug groups. There were significant differences in collagen organization and maturation between the controls and both nonsteroidal anti-inflammatory drug groups at 4 and 8 weeks (P < .001). Controls demonstrated progressively increasing collagen organization during the course of the study (P < .001), whereas the nonsteroidal anti-inflammatory drug groups did not. CONCLUSION: Traditional and cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs significantly inhibited tendon-to-bone healing. This inhibition appears linked to cyclooxygenase-2. CLINICAL RELEVANCE: If the results of this study are verified in a larger animal model, the common practice of administering non-steroidal anti-inflammatory drugs after rotator cuff repair should be reconsidered. FAU - Cohen, David B AU - Cohen DB AD - Connecticut Orthopaedic Specialists, 2408 Whitney Avenue, Hamden, CT 06518, USA. dbcomd@aol.com FAU - Kawamura, Sumito AU - Kawamura S FAU - Ehteshami, John R AU - Ehteshami JR FAU - Rodeo, Scott A AU - Rodeo SA LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20051006 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Celecoxib MH - Indomethacin/*therapeutic use MH - Male MH - New York City MH - Pyrazoles/*therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*physiopathology MH - Sulfonamides/*therapeutic use MH - Tendon Injuries/*drug therapy/physiopathology MH - Treatment Outcome MH - Wound Healing/*drug effects EDAT- 2005/10/08 09:00 MHDA- 2006/07/22 09:00 CRDT- 2005/10/08 09:00 PHST- 2005/10/08 09:00 [pubmed] PHST- 2006/07/22 09:00 [medline] PHST- 2005/10/08 09:00 [entrez] AID - 0363546505280428 [pii] AID - 10.1177/0363546505280428 [doi] PST - ppublish SO - Am J Sports Med. 2006 Mar;34(3):362-9. doi: 10.1177/0363546505280428. Epub 2005 Oct 6. PMID- 8537946 OWN - NLM STAT- MEDLINE DCOM- 19960208 LR - 20200611 IS - 0141-0768 (Print) IS - 0141-0768 (Linking) VI - 88 IP - 10 DP - 1995 Oct TI - The skinache syndrome. PG - 565-9 AB - Chronic pain of unknown aetiology, and characterized by cutaneous trigger points, has been coined the skinache syndrome. The treatment of the skinache syndrome was evaluated in 94 patients by two independent methods 2 years after treatment. After one subcutaneous injection of lidocaine 68% of the patients were cured. The pain recurred in 27 patients having suffered for an average of 2 years. Surgical removal of the cutaneous trigger points cured 77% of the latter patients. The odds ratio of success of surgical treatment versus all other treatments combined was 101.3. The skinache syndrome requires a precise clinical investigation. Even when the origin of the pain in tendons, muscle and adipose tissue is excluded, the skinache syndrome remains a common, debilitating disorder. In contrast to fibromyalgia, the skinache syndrome has a simple and effective cure. FAU - Bassøe, C F AU - Bassøe CF AD - Promed Institute, Bergen, Norway. LA - eng PT - Journal Article PL - England TA - J R Soc Med JT - Journal of the Royal Society of Medicine JID - 7802879 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Aged MH - Anesthetics, Local/*therapeutic use MH - Chronic Disease MH - Female MH - Humans MH - Lidocaine/*therapeutic use MH - Male MH - Middle Aged MH - Pain Management MH - Skin Diseases/*therapy MH - Syndrome PMC - PMC1295357 EDAT- 1995/10/01 00:00 MHDA- 1995/10/01 00:01 PMCR- 1995/10/01 CRDT- 1995/10/01 00:00 PHST- 1995/10/01 00:00 [pubmed] PHST- 1995/10/01 00:01 [medline] PHST- 1995/10/01 00:00 [entrez] PHST- 1995/10/01 00:00 [pmc-release] PST - ppublish SO - J R Soc Med. 1995 Oct;88(10):565-9. PMID- 16435353 OWN - NLM STAT- MEDLINE DCOM- 20060323 LR - 20220227 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 24 IP - 2 DP - 2006 Feb TI - Nitric oxide enhances collagen synthesis in cultured human tendon cells. PG - 159-72 AB - Collagen deposition is an important process that occurs during wound healing. We and others have shown that nitric oxide (NO) is important in tendon healing. The mechanisms whereby healing is enhanced are, however, undetermined. The aim of this study was to investigate whether NO could enhance collagen synthesis in cultured human tendon cells via exogenous NO and via an adenovirus containing the gene for inducible nitric oxide synthase (Ad-iNOS). Tendon cells from the torn edge of the tendons of patients undergoing rotator cuff repair surgery were cultured following collagenase digestion, and stimulated with exogenous NO (SNAP), transfected with Ad-iNOS, and treated with the NOS inhibitor, L-NMMA. Total protein and collagen synthesis were evaluated by (3)H-proline and collagenase sensitive (3)H-proline incorporation in human tendon cells. High doses of exogenous NO (SNAP) inhibited collagen synthesis. Lower doses enhanced total protein and collagen synthesis of the tendon cells. Ad-iNOS successfully transfected active iNOS into human tendon cells in vitro and also enhanced total protein and collagen synthesis of the tendon cells. The NOS inhibitor, L-NMMA, inhibited the effects of iNOS on the cells. Our studies show for first time that nitric oxide can enhance collagen synthesis in human tendon cells in vitro. These results may explain, in part, at least, the beneficial effects of NO donors in animal models and during the treatment of tendonopathies in human clinical trials. . CI - (c) 2005 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res. FAU - Xia, Wei AU - Xia W AD - Orthopaedic Research Institute, St. George Hospital Campus, University of New South Wales, Kogarah, Sydney, New South Wales 2217, Australia. FAU - Szomor, Zoltan AU - Szomor Z FAU - Wang, Yao AU - Wang Y FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Enzyme Inhibitors) RN - 0 (Nitric Oxide Donors) RN - 27JT06E6GR (omega-N-Methylarginine) RN - 31C4KY9ESH (Nitric Oxide) RN - 79032-48-7 (S-Nitroso-N-Acetylpenicillamine) RN - 9007-34-5 (Collagen) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) SB - IM MH - Adenoviridae/genetics MH - Aged MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/*biosynthesis MH - Dose-Response Relationship, Drug MH - Enzyme Inhibitors/pharmacology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Nitric Oxide/*pharmacology MH - Nitric Oxide Donors/pharmacology MH - Nitric Oxide Synthase Type II/antagonists & inhibitors/genetics/metabolism MH - Rotator Cuff/cytology/*drug effects/enzymology MH - S-Nitroso-N-Acetylpenicillamine/pharmacology MH - Transfection MH - omega-N-Methylarginine/pharmacology EDAT- 2006/01/26 09:00 MHDA- 2006/03/24 09:00 CRDT- 2006/01/26 09:00 PHST- 2006/01/26 09:00 [pubmed] PHST- 2006/03/24 09:00 [medline] PHST- 2006/01/26 09:00 [entrez] AID - 10.1002/jor.20060 [doi] PST - ppublish SO - J Orthop Res. 2006 Feb;24(2):159-72. doi: 10.1002/jor.20060. PMID- 15099639 OWN - NLM STAT- MEDLINE DCOM- 20040602 LR - 20220408 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 22 IP - 3 DP - 2004 May TI - Ibuprofen inhibition of tendon cell proliferation and upregulation of the cyclin kinase inhibitor p21CIP1. PG - 586-91 AB - Sports-related tendon injuries are commonly treated with nonsteroidal antiinflammatory drugs. This study was designed to determine the in vitro effect of ibuprofen on the proliferation of tendon cells intrinsic to rat Achilles tendon. Furthermore, the existence of a correlation between this effect and the expression of the cyclin kinase inhibitor p21(CIP1) and retinoblastoma (Rb) protein was also examined. Using cultured tendon cells, cell viability was evaluated by MTT assay. To determine whether apoptosis was related to the effect of ibuprofen, terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) assay was used. The mitotic index (MI) was calculated from the number of cells in the mitotic phase as stained and identified by propidium iodide. The mRNA expression of p21(CIP1) was determined by reverse transcription-polymerase chain reaction (RT-PCR). Protein expressions of p21(CIP1) and Rb protein were determined by Western blot analysis. A dose-dependent decrease in the cellularity of tendon cells by ibuprofen was demonstrated by MTT assay (p<0.001). However, TUNEL assay revealed no evidence of apoptosis. Ibuprofen dose-dependently reduced the MI (p<0.001). Upregulation of p21(CIP1) both at the levels of mRNA expression and protein was revealed from RT-PCR and Western blot analyses. The inhibition of Rb protein phosphorylation was also noted in ibuprofen-treated cells. In conclusion, ibuprofen inhibits tendon cell proliferation in a process that is probably mediated by the upregulation of p21(CIP1) and reduced phosphorylation of Rb protein. FAU - Tsai, Wen-Chung AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Graduate Institute of Clinical Medical Sciences, Chang Gung Memorial Hospital, Chang Gung University, Building J, 12F, 5 Fu-Shing Street, Kweishan, Taoyuan 333, Taiwan. FAU - Tang, Fuk-Tan AU - Tang FT FAU - Hsu, Chih-Chin AU - Hsu CC FAU - Hsu, Yai-Hui AU - Hsu YH FAU - Pang, Jong-Hwei S AU - Pang JH FAU - Shiue, Chian-Chuan AU - Shiue CC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cdkn1a protein, rat) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 0 (Cyclins) RN - 0 (RNA, Messenger) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Blotting, Western MH - Cell Division/drug effects MH - Cyclin-Dependent Kinase Inhibitor p21 MH - Cyclins/*genetics MH - Gene Expression Regulation/*drug effects MH - Ibuprofen/*pharmacology MH - In Situ Nick-End Labeling MH - RNA, Messenger/analysis MH - Rats MH - Rats, Sprague-Dawley MH - Reverse Transcriptase Polymerase Chain Reaction MH - Tendons/cytology/*drug effects MH - Up-Regulation EDAT- 2004/04/22 05:00 MHDA- 2004/06/03 05:00 CRDT- 2004/04/22 05:00 PHST- 2003/10/13 00:00 [received] PHST- 2003/10/15 00:00 [accepted] PHST- 2004/04/22 05:00 [pubmed] PHST- 2004/06/03 05:00 [medline] PHST- 2004/04/22 05:00 [entrez] AID - S0736026603002626 [pii] AID - 10.1016/j.orthres.2003.10.014 [doi] PST - ppublish SO - J Orthop Res. 2004 May;22(3):586-91. doi: 10.1016/j.orthres.2003.10.014. PMID- 14586921 OWN - NLM STAT- MEDLINE DCOM- 20031118 LR - 20220408 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 84 IP - 10 DP - 2003 Oct TI - Treatment of calcifying tendinitis of the shoulder by acetic acid iontophoresis: a double-blind randomized controlled trial. PG - 1523-7 AB - OBJECTIVE: To assess the effects of acetic acid iontophoresis on the treatment of calcifying tendinitis of the shoulder. DESIGN: Double-blind randomized controlled trial. SETTING: Ambulatory academic hospital in Quebec, Canada. PARTICIPANTS: Thirty-six subjects with a calcifying tendinitis of the shoulder. INTERVENTIONS: Subjects were randomized into 1 of 2 groups: physiotherapy during 6 weeks (10 sessions) plus acetic acid iontophoresis for the treatment group (n=18) and sham acetic acid iontophoresis for the control group (n=18). MAIN OUTCOME MEASURES: The Shoulder Pain and Disability Index (SPADI), shoulder range of motion (ROM); and radiologic evaluation of shoulder calcifications. RESULTS: Nine patients dropped out, leaving 27 assessable subjects for analysis. Interim analysis showed that, in both groups, treatment led to improvement, as measured by the SPADI score (P=.004), ROM of the shoulder for abduction (P<.001), internal rotation (P=.001), external rotation (P<.001), and the mean number of calcifications per subject (P=.010). Although no formal significant intervention effects (P=.13) were found for the primary endpoint (SPADI), exploratory analyses suggest a greater improvement in the treatment group (P=.001) than in the control group (P=.33). CONCLUSIONS: Despite a trend toward greater improvement in the SPADI score in the treatment group, the use of acetic acid iontophoresis and physiotherapy for the treatment of calcifying tendinitis of the shoulder did not result in better clinical and radiologic effects than those observed in subjects treated by physiotherapyalone. FAU - Leduc, Bernard E AU - Leduc BE AD - Hôpital Hôtel-Dieu du Centre Hospitalier, Universitaire de Montréal, QC, Canada. bnleduc@citenet.net FAU - Caya, Jocelyne AU - Caya J FAU - Tremblay, Sylvie AU - Tremblay S FAU - Bureau, Nathalie J AU - Bureau NJ FAU - Dumont, Marc AU - Dumont M LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 0 (Indicators and Reagents) RN - Q40Q9N063P (Acetic Acid) SB - IM MH - Acetic Acid/*therapeutic use MH - Adult MH - Aged MH - Calcinosis/complications/*drug therapy/pathology MH - Double-Blind Method MH - Female MH - Humans MH - Indicators and Reagents/*therapeutic use MH - Iontophoresis/*methods MH - Joint Diseases/etiology/pathology/*therapy MH - Male MH - Middle Aged MH - Range of Motion, Articular/physiology MH - Severity of Illness Index MH - Shoulder Joint/pathology MH - Tendinopathy/*drug therapy/etiology/pathology MH - Tendons/pathology MH - Treatment Outcome EDAT- 2003/10/31 05:00 MHDA- 2003/12/03 05:00 CRDT- 2003/10/31 05:00 PHST- 2003/10/31 05:00 [pubmed] PHST- 2003/12/03 05:00 [medline] PHST- 2003/10/31 05:00 [entrez] AID - S0003-9993(03)00284-3 [pii] AID - 10.1016/s0003-9993(03)00284-3 [doi] PST - ppublish SO - Arch Phys Med Rehabil. 2003 Oct;84(10):1523-7. doi: 10.1016/s0003-9993(03)00284-3. PMID- 2558504 OWN - NLM STAT- MEDLINE DCOM- 19900214 LR - 20131121 IS - 0884-0431 (Print) IS - 0884-0431 (Linking) VI - 4 IP - 6 DP - 1989 Dec TI - WR-2721 reduces bone loss after hindlimb tenotomy in rats. PG - 885-90 AB - WR-2721 is a thiophosphate analog of cysteamine that produces hypocalcemia in vivo. Previous studies suggest that WR-2721 produces hypocalcemia by independent inhibitory effects on parathyroid hormone (PTH) secretion, osteoclastic bone resorption, and tubular reabsorption of calcium. We sought to determine if WR-2721 would decrease bone loss in an animal model of disuse osteoporosis produced by unilateral knee tenotomy in the rat. Tenotomy significantly increased osteoclast number in tibias on the side of the procedure compared with tibias on the opposite side which had not undergone the procedure at 3 and 14 days. Femoral weight of tenotomized limbs were also reduced significantly compared with the contralateral limb at 3 and 14 days. WR-2721 treatment (240 mg/kg daily) prevented 26% of the loss of femoral dry weight and 29% of the loss of femoral ashed weight produced 14 days after tenotomy. In addition, WR-2721 treated (240 mg/kg daily) animals had fewer osteoclasts in tenotomized tibias than control animals at 3 days (6.6 +/- 0.7/mm versus 10.3 +/- 0.9/mm, p less than 0.02) and at 14 days (5.8 +/- 0.3/mm versus 8.7 +/- 0.4/mm, p less than 0.02). These data suggest that WR-2721 decreases bone loss in this model by decreasing osteoclastic bone resorption. FAU - Shaker, J L AU - Shaker JL AD - Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104. FAU - Fallon, M D AU - Fallon MD FAU - Goldfarb, S AU - Goldfarb S FAU - Farber, J AU - Farber J FAU - Attie, M F AU - Attie MF LA - eng GR - 1-F32-AM07944/AM/NIADDK NIH HHS/United States GR - AR-39226/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - J Bone Miner Res JT - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JID - 8610640 RN - 0 (Organothiophosphorus Compounds) RN - M487QF2F4V (Amifostine) RN - SY7Q814VUP (Calcium) SB - IM MH - Amifostine/*therapeutic use MH - Animals MH - Bone Resorption/*drug therapy/pathology MH - Calcium/blood MH - Data Interpretation, Statistical MH - Disease Models, Animal MH - Femur/pathology MH - Hindlimb MH - Male MH - Organ Size MH - Organothiophosphorus Compounds/*therapeutic use MH - Rats MH - Rats, Inbred Strains MH - Tendons/surgery EDAT- 1989/12/01 00:00 MHDA- 1989/12/01 00:01 CRDT- 1989/12/01 00:00 PHST- 1989/12/01 00:00 [pubmed] PHST- 1989/12/01 00:01 [medline] PHST- 1989/12/01 00:00 [entrez] AID - 10.1002/jbmr.5650040613 [doi] PST - ppublish SO - J Bone Miner Res. 1989 Dec;4(6):885-90. doi: 10.1002/jbmr.5650040613. PMID- 16967202 OWN - NLM STAT- MEDLINE DCOM- 20070315 LR - 20220227 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 14 IP - 12 DP - 2006 Dec TI - Sclerosing polidocanol injections in mid-portion Achilles tendinosis: remaining good clinical results and decreased tendon thickness at 2-year follow-up. PG - 1327-32 AB - The short-term results after treatment with sclerosing polidocanol injections have been shown to be good in patients with chronic painful mid-portion Achilles tendinosis. This study aimed to evaluate the longer-term effects on tendon thickness, structure and vascularity, patient satisfaction with treatment, and pain during tendon loading activity. Ultrasonography (US) + colour Doppler (CD) was used for evaluation of the tendon, and the patients graded the amount of pain during tendon loading activity on a VAS. Forty-two patient's tendons (23 men and 19 women, mean age 53 years) with a long duration (mean 32 months) of pain symptoms from mid-portion Achilles tendinosis (US + CD showed a localised thickening, structural changes and neovascularisation), were at three (mean) occasions (6-8 weeks in between) treated with US and CD guided injections of the sclerosing substance polidocanol, targeting the area with neovessels ventral to the tendon. After treatment, 37 patients were satisfied with the results of the treatment and back to previous (before injury) activity level. At the 2-year follow-up (mean 23 months), 38 patients were satisfied with the results of the treatment, and there was a significant reduction in VAS (from 75 to 7; P < 0.05). US showed a significant reduction in the mean mid-portion tendon thickness (from 10 to 8 mm, P < 0.05) and a "more normal" structure. CD showed no, or a few, remaining neovessels in the majority of the successfully treated tendons. In conclusion, treatment with sclerosing polidocanol injections in patients with chronic painful mid-portion Achilles tendinosis showed remaining good clinical results at a 2-year follow-up. Decreased tendon thickness and improved structure after treatment, might indicate a remodelling potential? FAU - Lind, Bengt AU - Lind B AD - Department of Radiology, University of Umeå, 901 87 Umeå, Sweden. FAU - Ohberg, Lars AU - Ohberg L FAU - Alfredson, Håkan AU - Alfredson H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060912 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - *Achilles Tendon/diagnostic imaging/pathology MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pain Measurement MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Statistics, Nonparametric MH - Tendinopathy/diagnostic imaging/pathology/*therapy MH - Treatment Outcome MH - Ultrasonography, Doppler, Color EDAT- 2006/09/13 09:00 MHDA- 2007/03/16 09:00 CRDT- 2006/09/13 09:00 PHST- 2005/12/28 00:00 [received] PHST- 2006/04/20 00:00 [accepted] PHST- 2006/09/13 09:00 [pubmed] PHST- 2007/03/16 09:00 [medline] PHST- 2006/09/13 09:00 [entrez] AID - 10.1007/s00167-006-0161-3 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2006 Dec;14(12):1327-32. doi: 10.1007/s00167-006-0161-3. Epub 2006 Sep 12. PMID- 16832128 OWN - NLM STAT- MEDLINE DCOM- 20070109 LR - 20220331 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 34 IP - 11 DP - 2006 Nov TI - Ultrasound-guided sclerosis of neovessels in painful chronic patellar tendinopathy: a randomized controlled trial. PG - 1738-46 AB - BACKGROUND: Color Doppler ultrasound examination frequently reveals neovascularization in chronic painful Achilles and patellar tendinopathy. Sclerosing the area with vascular ingrowth using polidocanol has shown promising clinical results in patients with Achilles tendinopathy. PURPOSE: To investigate sclerosing treatment using polidocanol on a group of elite athletes with patellar tendinopathy. STUDY DESIGN: Randomized controlled trial/cross-over study; Level of evidence, 1. METHODS: The authors recruited 33 patients (42 tendons), mainly from the Norwegian elite divisions in basketball, team handball, and volleyball. Seventeen patients (23 knees) were randomized to the treatment group (polidocanol injections in the area of neovascularization) and 16 patients (20 knees) to the control group (similar injections with lidocaine/epinephrine). After 4 months of treatment, the control group was crossed over to active treatment. Pain and function were recorded using the Victorian Institute of Sport Assessment score before the start of treatment and 4, 8, and 12 months after the first injection. Victorian Institute of Sport Assessment scores between groups were compared using multivariate analysis of variance for repeated measures. RESULTS: The treatment group reported a significant improvement in Victorian Institute of Sport Assessment score from 51 to 62 after 4 months; there was no change for the control group (group by time interaction, P = .052). After 8 months, when the control group had also received active treatment with polidocanol, they had a greater improvement in Victorian Institute of Sport Assessment score (58-79) than did the treatment group (54-70; group by time interaction, P = .022; time effect, P < .0001). There was no further time or group effect in Victorian Institute of Sport Assessment score to the 12-month follow-up (treatment, 72; control, 85). CONCLUSION: Sclerosing injections with polidocanol resulted in a significant improvement in knee function and reduced pain in patients with patellar tendinopathy. FAU - Hoksrud, Aasne AU - Hoksrud A AD - Department of Sports Medicine, Oslo Sports Trauma Research Center, Norwegian School of Sport Sciences, PO Box 4014, Ullevaal Stadion, 0806 Oslo, Norway. FAU - Ohberg, Lars AU - Ohberg L FAU - Alfredson, Håkan AU - Alfredson H FAU - Bahr, Roald AU - Bahr R LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20060710 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM EIN - Am J Sports Med. 2011 Jul;39(7). doi:10.1177/0363546511415225 MH - Adolescent MH - Adult MH - Cross-Over Studies MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Neovascularization, Pathologic/*therapy MH - Pain Measurement MH - Patellar Ligament/blood supply/*diagnostic imaging MH - Patient Satisfaction MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Sports MH - Tendinopathy/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography, Doppler, Color EDAT- 2006/07/13 09:00 MHDA- 2007/01/11 09:00 CRDT- 2006/07/13 09:00 PHST- 2006/07/13 09:00 [pubmed] PHST- 2007/01/11 09:00 [medline] PHST- 2006/07/13 09:00 [entrez] AID - 0363546506289168 [pii] AID - 10.1177/0363546506289168 [doi] PST - ppublish SO - Am J Sports Med. 2006 Nov;34(11):1738-46. doi: 10.1177/0363546506289168. Epub 2006 Jul 10. PMID- 15688235 OWN - NLM STAT- MEDLINE DCOM- 20050913 LR - 20220330 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 13 IP - 4 DP - 2005 May TI - Sclerosing injections to areas of neo-vascularisation reduce pain in chronic Achilles tendinopathy: a double-blind randomised controlled trial. PG - 338-44 AB - Local injections of the sclerosing substance Polidocanol has been demonstrated to give good clinical results in a pilot study on patients with chronic Achilles tendinopathy. In this study, 20 consecutive patients (9 men and 11 women, mean age 50 years) with chronic painful mid-portion Achilles tendinopathy were randomised to injection treatment with either Polidocanol (5 mg/ml) (group A) or Lidocaine hydro-chloride (5 mg/ml) + Adrenaline (5 microg/ml) (group B). Both substances have a local anaesthetic effect, but Polidocanol also has a sclerosing effect. The patients and the treating physician were blinded to the substance injected. The short-term effects were evaluated after a maximum of two treatments, 3-6 weeks apart. Before treatment, all patients had structural tendon changes and neo-vascularisation demonstrated with US and colour doppler. Under US and colour doppler-guidance, the injections targeted the area of neo-vascularisation just outside the ventral part of the tendon. For evaluation, the patients recorded the severity of Achilles tendon pain during tendon loading activity, before and after treatment, on a VAS. Patient's satisfaction with treatment was also assessed. At follow-up (mean 3 months) after a maximum of two treatments, 5/10 patients in group A were satisfied with the treatment and had a significantly reduced level of tendon pain (p < 0.005). In group B, no patient was satisfied with treatment. In the pain-free tendons, but not in the painful tendons, neo-vascularisation was absent after treatment. After completion of the study, treatment with Polidocanol injections (Cross-over in group B and additional treatments in group A) resulted in 10/10 and 9/10 satisfied patients in group A and B, respectively. In summary, injections with the sclerosing substance Polidocanol have the potential to reduce tendon pain during activity in patients with chronic painful mid-portion Achilles tendinopathy. FAU - Alfredson, Håkan AU - Alfredson H AD - Department of Surgical and Perioperative Science Sports Medicine, Centre for Musculoskeletal Research, National Institute for Working Life, University of Umea, 90187, Umeå, Sweden. hakan.alfredson@idrott.umu.se FAU - Ohberg, Lars AU - Ohberg L LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial DEP - 20050202 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Anesthetics, Local) RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 98PI200987 (Lidocaine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Achilles Tendon/blood supply/*injuries MH - Anesthetics, Local/therapeutic use MH - Double-Blind Method MH - Epinephrine/therapeutic use MH - Female MH - Humans MH - Lidocaine/therapeutic use MH - Male MH - Middle Aged MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Sclerotherapy/*methods MH - Statistics, Nonparametric MH - Tendon Injuries/*therapy MH - Treatment Outcome EDAT- 2005/02/03 09:00 MHDA- 2005/09/15 09:00 CRDT- 2005/02/03 09:00 PHST- 2004/03/23 00:00 [received] PHST- 2004/08/27 00:00 [accepted] PHST- 2005/02/03 09:00 [pubmed] PHST- 2005/09/15 09:00 [medline] PHST- 2005/02/03 09:00 [entrez] AID - 10.1007/s00167-004-0585-6 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2005 May;13(4):338-44. doi: 10.1007/s00167-004-0585-6. Epub 2005 Feb 2. PMID- 30755039 OWN - NLM STAT- MEDLINE DCOM- 20200820 LR - 20200820 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 60 IP - 5 DP - 2019 Sep TI - N-acetylcysteine reduces glutamate-induced cytotoxicity to fibroblasts of rat supraspinatus tendons. PG - 431-443 LID - 10.1080/03008207.2019.1580702 [doi] AB - Purpose: Neuronal theory regarding rotator cuff degeneration has developed from the findings that glutamate, an amino acid and an excitatory neurotransmitter, is present in increased concentrations in tendon tissues with tendinopathy and that glutamate induces cell death in fibroblasts of origin in rat supraspinatus tendon. The purpose of the current study was to determine whether N-acetylcysteine (NAC) has cytoprotective effects against glutamate-induced fibroblast death. Materials and Methods: Primary cultured fibroblasts were obtained from rat supraspinatus tendons. Varying concentrations of glutamate (0.5, 1, 5, and 10 mM) and of NAC (0.5, 1, 2, and 5 mM) were used for evaluation of cytotoxicity. Cell viability, cell cycles, types of cell death, intracellular ROS production, expressions of caspase-3/7, and Ca(2+) influx were evaluated. Results: Glutamate significantly induced cell death, apoptosis, and Ca(2+) influx and significantly increased caspase-3/7 activity and intracellular ROS production (p < 0.001). NAC significantly reduced the glutamate-induced cell death, apoptosis, Ca(2+) influx, caspase-3/7 activity, and intracellular ROS production (p < 0.001). Conclusions: The glutamate-induced cytotoxic effects can be reduced by NAC, an antioxidant, through the reduction of intracellular oxidative stress and/or Ca(2+) influx. FAU - Kim, Ra Jeong AU - Kim RJ AD - a Department of Convergence Medical Science , Gyeongsang National University , Jinju , Korea. FAU - Hah, Young-Sool AU - Hah YS AD - b Clinical Research Institute , Gyeongsang National University Hospital , Jinju , Korea. FAU - Gwark, Ji-Yong AU - Gwark JY AD - c Department of Orthopaedic Surgery , Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea. FAU - Park, Hyung Bin AU - Park HB AD - d Department of Orthopaedic Surgery , School of Medicine and Gyeongsang National University Changwon Hospital , Changwon , Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190508 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Reactive Oxygen Species) RN - 3KX376GY7L (Glutamic Acid) RN - EC 3.4.22.- (Caspase 3) RN - SY7Q814VUP (Calcium) RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - Acetylcysteine/*pharmacology MH - Animals MH - Apoptosis/*drug effects MH - Calcium/metabolism MH - Caspase 3/metabolism MH - Fibroblasts/drug effects/metabolism/*pathology MH - Glutamic Acid/*toxicity MH - Intracellular Space/metabolism MH - Male MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism MH - Rotator Cuff/drug effects/*pathology OTO - NOTNLM OT - Tendinopathy OT - antioxidant OT - excitotoxicity OT - neurotransmitter OT - rotator cuff tendon EDAT- 2019/02/14 06:00 MHDA- 2020/08/21 06:00 CRDT- 2019/02/14 06:00 PHST- 2019/02/14 06:00 [pubmed] PHST- 2020/08/21 06:00 [medline] PHST- 2019/02/14 06:00 [entrez] AID - 10.1080/03008207.2019.1580702 [doi] PST - ppublish SO - Connect Tissue Res. 2019 Sep;60(5):431-443. doi: 10.1080/03008207.2019.1580702. Epub 2019 May 8. PMID- 6886686 OWN - NLM STAT- MEDLINE DCOM- 19831008 LR - 20190724 IS - 0022-3018 (Print) IS - 0022-3018 (Linking) VI - 171 IP - 9 DP - 1983 Sep TI - Depression in a patient with dementia secondary to cerebrotendinous xanthomatosis. PG - 568-71 AB - The occurrence of depression in a patient with pre-existing dementia, associated with a rare neurological disorder, is described. Cerebrotendinous xanthomatosis is a genetically transmitted disease that is associated with deposition of cholestanol in the central nervous system and Achilles tendons. A focus on the often unusual presentation of combined major depression and dementia is offered as well as the interaction of genetic disorders and psychiatric symptoms. The diagnostic and treatment approach to these patients is discussed in regard to this reported case. Also, there is a review of the importance of recognition of early signs and symptoms of both depression in demented patients and evidences of presenile dementia because the prospects of treatability and reversibility should be a prime consideration for these disorders. This case report illustrates the potential for effectiveness of psychiatric interventions for patients with neurological and genetic disorders. FAU - Shapiro, S AU - Shapiro S LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Nerv Ment Dis JT - The Journal of nervous and mental disease JID - 0375402 RN - 1668-19-5 (Doxepin) RN - J6292F8L3D (Haloperidol) SB - IM MH - Depressive Disorder/diagnosis/drug therapy/*etiology MH - Doxepin/therapeutic use MH - Haloperidol/therapeutic use MH - Humans MH - Lipidoses/*complications MH - Male MH - Middle Aged MH - Neurocognitive Disorders/complications/*etiology MH - Xanthomatosis/*complications EDAT- 1983/09/01 00:00 MHDA- 1983/09/01 00:01 CRDT- 1983/09/01 00:00 PHST- 1983/09/01 00:00 [pubmed] PHST- 1983/09/01 00:01 [medline] PHST- 1983/09/01 00:00 [entrez] AID - 10.1097/00005053-198309000-00008 [doi] PST - ppublish SO - J Nerv Ment Dis. 1983 Sep;171(9):568-71. doi: 10.1097/00005053-198309000-00008. PMID- 1128884 OWN - NLM STAT- MEDLINE DCOM- 19750720 LR - 20131121 IS - 0030-5898 (Print) IS - 0030-5898 (Linking) VI - 6 IP - 2 DP - 1975 Apr TI - The rheumatoid shoulder. PG - 593-6 AB - The rheumatoid shoulder is a frequent manifestation in the rheumatoid patient. Most of the symptoms are of a mild to moderate degree and can usually be ameliorated by heat, massage, and gently exercise. Local injection therapy may be of value in selected cases. Strenuous exercise or manipulation is contraindicated. Tendon ruptures and rotator cuff tears are not amenable to surgical reconstruction and are adequately treated with a conservative regimen. Prophylactic synovectomy is not performed as a routine, because the majority of patients do not develop disabling symptoms. This procedure is usually restricted to the few patients who exhibit uncontrollable proliferative synovitis. Prosthetic replacement is employed for intractable pain with full anticipation of limitied mobility. Various designs of a "total shoulder" are undergoing clinical evaluation, but their application has not been defined. FAU - Sbarbaro, J L Jr AU - Sbarbaro JL Jr LA - eng PT - Journal Article PL - United States TA - Orthop Clin North Am JT - The Orthopedic clinics of North America JID - 0254463 RN - 4Z8Y51M438 (Procaine) RN - V27W9254FZ (Cortisone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Adult MH - Arthritis, Rheumatoid/complications/diagnosis/therapy MH - Bursitis/drug therapy/etiology MH - Cortisone/therapeutic use MH - Hot Temperature/therapeutic use MH - Humans MH - Hydrocortisone/therapeutic use MH - Massage MH - Middle Aged MH - Procaine/therapeutic use MH - *Shoulder Joint MH - Tendinopathy/drug therapy/etiology MH - Tendons EDAT- 1975/04/11 19:15 MHDA- 2001/03/28 10:01 CRDT- 1975/04/11 19:15 PHST- 1975/04/11 19:15 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1975/04/11 19:15 [entrez] PST - ppublish SO - Orthop Clin North Am. 1975 Apr;6(2):593-6. PMID- 25362529 OWN - NLM STAT- MEDLINE DCOM- 20150423 LR - 20181202 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 134 IP - 12 DP - 2014 Dec TI - The effect of diclofenac on matrix metalloproteinase levels in the rotator cuff. PG - 1739-44 LID - 10.1007/s00402-014-2099-0 [doi] AB - INTRODUCTION: Matrix metalloproteinases (MMPs) are involved in physiological events such as restructuring of the tissue, morphogenesis, wound healing and normal developmental process. Use of diclofenac sodium following rotator cuff repair can disrupt healing of tendon through acting on MMPs. MATERIALS AND METHODS: Supraspinatus tendons of rats (n = 84) were detached from their insertion on humerus, and repaired to anatomic footprint. Rats were divided into study group (n = 42) and control group (n = 42). Study group received a dose of 1 mg/kg daily diclofenac sodium subcutaneously. The rats were killed at weeks 1, 3 and 6, and seven rats from each groups were included in biomechanical and immunohistological examinations. Immunohistological staining of MMP-2, MMP-3 and MMP13 were used. RESULTS: Maximum load was reduced in the study group at the end of week 1 (8.76 vs. 5.28 N) (p = 0.01). MMP-3 level was statistically significantly lower in the study group at the end of week 1. MMP-13 level and stiffness decreased towards week 6 in the study group while in the control group the level of MMP-2 decreased towards week 6. CONCLUSION: Diclofenac has an impact on the levels of MMP-2, MMP-3 and MMP-13, which are needed for normal healing process, and it can also lead to disruption of tendon healing. FAU - Cabuk, Haluk AU - Cabuk H AD - Department of Orthopedics and Traumatology, Okmeydanı and Research Hospital, Şişli, Turkey, halukcabuk@hotmail.com. FAU - Avci, Arzu AU - Avci A FAU - Durmaz, Hüseyin AU - Durmaz H FAU - Cabuk, Fatmagül Kuşku AU - Cabuk FK FAU - Ertem, Fatih AU - Ertem F FAU - Muhittin Şener, I AU - Muhittin Şener I LA - eng PT - Journal Article DEP - 20141102 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 144O8QL0L1 (Diclofenac) RN - 9B627AW319 (Nitrendipine) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Diclofenac/*pharmacology MH - Immunohistochemistry MH - Male MH - Matrix Metalloproteinase 13/metabolism MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 3/metabolism MH - Matrix Metalloproteinases/*metabolism MH - Nitrendipine MH - Rats, Wistar MH - Rotator Cuff/*enzymology/physiopathology/surgery MH - Tendons/surgery MH - Wound Healing/*drug effects/physiology EDAT- 2014/11/05 06:00 MHDA- 2015/04/24 06:00 CRDT- 2014/11/03 06:00 PHST- 2014/08/19 00:00 [received] PHST- 2014/11/03 06:00 [entrez] PHST- 2014/11/05 06:00 [pubmed] PHST- 2015/04/24 06:00 [medline] AID - 10.1007/s00402-014-2099-0 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2014 Dec;134(12):1739-44. doi: 10.1007/s00402-014-2099-0. Epub 2014 Nov 2. PMID- 20981466 OWN - NLM STAT- MEDLINE DCOM- 20110729 LR - 20161125 IS - 1439-7609 (Electronic) IS - 1439-7595 (Linking) VI - 21 IP - 2 DP - 2011 Apr TI - Achilles paratendonitis as the initial manifestation of rheumatoid arthritis. PG - 219-22 LID - 10.1007/s10165-010-0369-4 [doi] AB - We report a case of rheumatoid arthritis in which the earliest symptom was bilateral paratendonitis of the Achilles tendons, followed by paratendonitis of a finger extensor. A series of musculoskeletal ultrasonograms revealed a progression from paratendonitis of the extensor tendon to erosive synovitis of the adjacent metacarpophalangeal joint. High-resolution ultrasonography combined with power Doppler imaging seems to be a useful and convenient tool both for diagnosing paratendonitis early and for closely monitoring the progressing inflammation. FAU - Suzuki, Takeshi AU - Suzuki T AD - Division of Rheumatology, Mitsui Memorial Hospital, 1 Kandaizumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan. suzuki-rheum@mitsuihosp.or.jp FAU - Ishihara, Keiko AU - Ishihara K LA - eng PT - Case Reports PT - Journal Article DEP - 20101028 PL - England TA - Mod Rheumatol JT - Modern rheumatology JID - 100959226 RN - 0 (Antirheumatic Agents) RN - 3XC8GUZ6CB (Sulfasalazine) SB - IM MH - Achilles Tendon/diagnostic imaging/*pathology MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Rheumatoid/complications/*diagnosis/drug therapy MH - Diagnosis, Differential MH - Disease Progression MH - Female MH - Humans MH - Metacarpophalangeal Joint/diagnostic imaging/pathology MH - Middle Aged MH - Sulfasalazine/therapeutic use MH - Synovitis/complications/pathology MH - Tendinopathy/complications/*diagnosis/drug therapy MH - Treatment Outcome MH - Ultrasonography, Doppler/methods EDAT- 2010/10/29 06:00 MHDA- 2011/07/30 06:00 CRDT- 2010/10/29 06:00 PHST- 2010/06/15 00:00 [received] PHST- 2010/09/30 00:00 [accepted] PHST- 2010/10/29 06:00 [entrez] PHST- 2010/10/29 06:00 [pubmed] PHST- 2011/07/30 06:00 [medline] AID - 10.1007/s10165-010-0369-4 [doi] PST - ppublish SO - Mod Rheumatol. 2011 Apr;21(2):219-22. doi: 10.1007/s10165-010-0369-4. Epub 2010 Oct 28. PMID- 37261543 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20230922 IS - 1435-5604 (Electronic) IS - 0914-8779 (Linking) VI - 41 IP - 5 DP - 2023 Sep TI - TNFα-dependent mTOR activity is required for tenotomy-induced ectopic ossification in mice. PG - 583-591 LID - 10.1007/s00774-023-01437-8 [doi] AB - INTRODUCTION: Ectopic ossifications often occur in skeletal muscles or tendons following local trauma or internal hemorrhage, and occasionally cause severe pain that limits activities of daily living. However, mechanisms underlying their development remain unknown. MATERIALS AND METHODS: The right Achilles tendon in 8-week-old female or male mice was dissected. Some mice were injected intraperitoneally either with phosphate-buffered saline, dimethyl sulfoxide, cimetidine, rapamycin, celecoxib or loxoprofen for 10 weeks. One week after surgery, immunohistochemical analysis was performed for mTOR, TNFα or F4/80. Ten weeks after surgery, ectopic ossification at the tenotomy site was detected by 3D micro-CT. RESULTS: Ectopic ossification was seen at dissection sites in all wild-type mice by dissection of the Achilles tendon. mTOR activation was detected at dissection sites, and development of ectopic ossification was significantly inhibited by administration of rapamycin, an mTOR inhibitor, to wild-type mice. Moreover, administration of the histamine 2 blocker cimetidine, which reportedly inhibits ectopic ossification in tendons, was not effective in inhibiting ectopic ossification in our models. TNFα-expressing F4/80-positive macrophages accumulate at dissection sites and that ectopic ossification of the Achilles tendon dissection was significantly inhibited in TNFα-deficient mice in vivo. Ectopic ossification is significantly inhibited by administration of either celecoxib or loxoprofen, both anti-inflammatory agents, in wild-type mice. mTOR activation by Achilles tendon tenotomy is inhibited in TNFα-deficient mice. CONCLUSION: The TNFα-mTOR axis could be targeted therapeutically to prevent trauma-induced ectopic ossification in tendons. CI - © 2023. The Japanese Society Bone and Mineral Research. FAU - Kushima, Yu AU - Kushima Y AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. AD - Department of Orthopedic Surgery, National Defense Medical College, Namiki 3-2, Tokorozawa, Saitama, 359-8513, Japan. FAU - Sato, Yuiko AU - Sato Y AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. AD - Department of Musculoskeletal Reconstruction and Regeneration Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Kobayashi, Tami AU - Kobayashi T AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. AD - Department of Musculoskeletal Reconstruction and Regeneration Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Fukuma, Yuko AU - Fukuma Y AD - Department of Orthopedic Surgery, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. FAU - Matsumoto, Morio AU - Matsumoto M AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Nakamura, Masaya AU - Nakamura M AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. FAU - Iwamoto, Takuji AU - Iwamoto T AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. iwatakuji@gmail.com. FAU - Miyamoto, Takeshi AU - Miyamoto T AD - Department of Orthopedic Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. miyamoto.takeshi@kuh.kumamoto-u.ac.jp. AD - Department of Musculoskeletal Reconstruction and Regeneration Surgery, Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan. miyamoto.takeshi@kuh.kumamoto-u.ac.jp. AD - Department of Orthopedic Surgery, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. miyamoto.takeshi@kuh.kumamoto-u.ac.jp. LA - eng PT - Journal Article DEP - 20230601 PL - Japan TA - J Bone Miner Metab JT - Journal of bone and mineral metabolism JID - 9436705 RN - JCX84Q7J1L (Celecoxib) RN - 80061L1WGD (Cimetidine) RN - 3583H0GZAP (loxoprofen) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 0 (Tumor Necrosis Factor-alpha) RN - EC 2.7.1.1 (mTOR protein, mouse) SB - IM MH - Animals MH - Female MH - Humans MH - Male MH - Mice MH - *Achilles Tendon/surgery MH - Activities of Daily Living MH - Celecoxib/pharmacology MH - Cimetidine MH - *Ossification, Heterotopic/etiology/prevention & control MH - Tenotomy/adverse effects MH - TOR Serine-Threonine Kinases MH - Tumor Necrosis Factor-alpha OTO - NOTNLM OT - Ectopic ossification OT - TNFα OT - Tenotomy OT - mTOR EDAT- 2023/06/01 13:10 MHDA- 2023/09/20 06:42 CRDT- 2023/06/01 11:09 PHST- 2022/11/10 00:00 [received] PHST- 2023/04/27 00:00 [accepted] PHST- 2023/09/20 06:42 [medline] PHST- 2023/06/01 13:10 [pubmed] PHST- 2023/06/01 11:09 [entrez] AID - 10.1007/s00774-023-01437-8 [pii] AID - 10.1007/s00774-023-01437-8 [doi] PST - ppublish SO - J Bone Miner Metab. 2023 Sep;41(5):583-591. doi: 10.1007/s00774-023-01437-8. Epub 2023 Jun 1. PMID- 21209015 OWN - NLM STAT- MEDLINE DCOM- 20110225 LR - 20250529 IS - 1945-7170 (Electronic) IS - 0013-7227 (Linking) VI - 152 IP - 2 DP - 2011 Feb TI - Protection against glucocorticoid-induced damage in human tenocytes by modulation of ERK, Akt, and forkhead signaling. PG - 503-14 LID - 10.1210/en.2010-1087 [doi] AB - Antiinflammatory glucocorticoid (GC) injections are extensively used to treat painful tendons. However, GC cause severe tissue wasting in other collagen-producing tissues such as skin and bone. The objective of this study was to determine the effects of GC on tenocytes and to explore strategies to protect against unwanted side effects of GC treatment. Cell survival, collagen production, and the induction of signaling pathways in primary human tenocytes treated with dexamethasone (Dex) were assessed. Antioxidant and growth factor approaches to protection were tested. Dex treatment resulted in reduced viable cell number, cell proliferation, and collagen production. Dex induced reactive oxygen species generation in tenocytes and strongly up-regulated the stress-response transcription factors FOXO1 and FOXO3A. Phosphorylation of ERK and protein kinase B/Akt, which regulate cell proliferation and also inhibit forkhead activity, was decreased. Chemical inhibition of ERK or Akt activity significantly reduced tenocyte cell number. Ameliorating the Dex-induced reduction in ERK or Akt activity by cotreatment with vitamin C or insulin protected against the Dex-induced reduction in cell number. Silencing FOXO1 prevented the Dex-induced reduction in collagen 1α1 expression. Cotreatment with vitamin C or insulin protected against the Dex-induced increase in FOXO and the Dex-induced inhibition of collagen 1α1 expression. Reduced ERK and Akt activation and increased forkhead signaling contribute to the negative effects of GC on tenocytes. Cotreatment therapies that target these signaling pathways are protective. Vitamin C in particular may be a clinically useable co-therapy to reduce connective tissue side effects associated with GC therapy. FAU - Poulsen, Raewyn C AU - Poulsen RC AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom. raewyn.poulsen@ndorms.ox.ac.uk FAU - Carr, Andrew J AU - Carr AJ FAU - Hulley, Philippa A AU - Hulley PA LA - eng GR - 19482/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110105 PL - United States TA - Endocrinology JT - Endocrinology JID - 0375040 RN - 0 (Anti-Inflammatory Agents) RN - 0 (FOXO1 protein, human) RN - 0 (FOXO3 protein, human) RN - 0 (Forkhead Box Protein O1) RN - 0 (Forkhead Box Protein O3) RN - 0 (Forkhead Transcription Factors) RN - 0 (Glucocorticoids) RN - 0 (Glycosaminoglycans) RN - 0 (Insulin) RN - 0 (RNA, Small Interfering) RN - 0 (Reactive Oxygen Species) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adult MH - Anti-Inflammatory Agents/pharmacology MH - Apoptosis/genetics/physiology MH - Ascorbic Acid/pharmacology MH - Blotting, Western MH - Cell Proliferation/drug effects MH - Cell Survival/genetics/physiology MH - Cells, Cultured MH - Collagen/metabolism MH - Dexamethasone/pharmacology MH - Extracellular Signal-Regulated MAP Kinases/*metabolism MH - Female MH - Forkhead Box Protein O1 MH - Forkhead Box Protein O3 MH - Forkhead Transcription Factors/genetics/*metabolism MH - Glucocorticoids/*pharmacology MH - Glycosaminoglycans/metabolism MH - Humans MH - Immunohistochemistry MH - Insulin/pharmacology MH - Male MH - Middle Aged MH - Phosphorylation MH - Proto-Oncogene Proteins c-akt/*metabolism MH - RNA, Small Interfering MH - Reactive Oxygen Species/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Signal Transduction/drug effects/genetics EDAT- 2011/01/07 06:00 MHDA- 2011/02/26 06:00 CRDT- 2011/01/07 06:00 PHST- 2011/01/07 06:00 [entrez] PHST- 2011/01/07 06:00 [pubmed] PHST- 2011/02/26 06:00 [medline] AID - en.2010-1087 [pii] AID - 10.1210/en.2010-1087 [doi] PST - ppublish SO - Endocrinology. 2011 Feb;152(2):503-14. doi: 10.1210/en.2010-1087. Epub 2011 Jan 5. PMID- 112707 OWN - NLM STAT- MEDLINE DCOM- 19791017 LR - 20131121 IS - 0040-3709 (Print) IS - 0040-3709 (Linking) VI - 19 IP - 3 DP - 1979 Jun TI - Unusual muscle abnormalities associated with thalidomide treatment in a rhesus monkey: a case report. PG - 313-9 AB - Unusual musculotendinous abnormalities were observed in the forelimbs of a rhesus monkey treated prenatally with thalidomide (10 mg/kg maternal body weight, gestation days 33, 34, and 35). Although the hindlimbs exhibited malformations typical of thalidomide dysmelia, the forelimbs appeared relatively normal externally. However, dissection revealed totally anomalous insertions of preaxial muscles of both forearms. Extensor muscles inserted on flexor surfaces even though normal sites of insertion were present and unoccupied. Radiographs revealed only minor ossification deficiencies in the carpus and distal radius. These observations suggest that thalidomide, given at the appropriate time, can disrupt condensation and splitting of pre-muscle masses without greatly disturbing condensation of corresponding preskeletal elements. These types of musculoskeletal relationships are unusual findings in congenital malformations of the limbs and have not been widely associated with thalidomide teratogenesis. FAU - Theisen, C T AU - Theisen CT FAU - Bodin, J D AU - Bodin JD FAU - Svoboda, J A AU - Svoboda JA FAU - Pettinelli, M W AU - Pettinelli MW LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Teratology JT - Teratology JID - 0153257 RN - 4Z8R6ORS6L (Thalidomide) SB - IM MH - *Abnormalities, Drug-Induced MH - Animals MH - Female MH - Forearm/abnormalities MH - Haplorhini MH - Macaca mulatta MH - Muscles/*abnormalities MH - Pregnancy MH - Tendons/abnormalities MH - Thalidomide/*toxicity EDAT- 1979/06/01 00:00 MHDA- 1979/06/01 00:01 CRDT- 1979/06/01 00:00 PHST- 1979/06/01 00:00 [pubmed] PHST- 1979/06/01 00:01 [medline] PHST- 1979/06/01 00:00 [entrez] AID - 10.1002/tera.1420190306 [doi] PST - ppublish SO - Teratology. 1979 Jun;19(3):313-9. doi: 10.1002/tera.1420190306. PMID- 24584568 OWN - NLM STAT- MEDLINE DCOM- 20150105 LR - 20220318 IS - 1024-2708 (Print) IS - 1024-2708 (Linking) VI - 20 IP - 2 DP - 2014 Apr TI - Lateral epicondylalgia: midlife crisis of a tendon. PG - 145-51 LID - 10.12809/hkmj134110 [doi] AB - The pathogenesis and management of lateral epicondylalgia, or tennis elbow, a common ailment affecting middle-aged subjects of both genders continue to provoke controversy. Currently it is thought to be due to local tendon pathology, pain system changes, and motor system impairment. Its diagnosis is usually clinical, based on a classical history, as well as symptoms and signs. In selected cases, additional imaging (X-rays, ultrasound, and magnetic resonance imaging) can help to confirm the diagnosis. Different treatment modalities have been described, including the use of orthotics, non-steroidal anti-inflammatory drugs, steroid injections, topical glyceryl trinitrate, exercise therapy, manual therapy, ultrasound therapy, laser therapy, extracorporeal shockwave therapy, acupuncture, taping, platelet-rich plasma injections, hyaluronan gel injections, botulinum toxin injections, and surgery. Nevertheless, evidence to select the best treatment is lacking and the choice of therapy depends on the experience of the management team, availability of the equipment and expertise, and patient response. This article provides a snapshot of current medical practice for lateral epicondylalgia management. FAU - Luk, James K H AU - Luk JK AD - Department of Medicine and Geriatrics, Fung Yiu King Hospital, 9 Sandy Bay Road, Pokfulam, Hong Kong. FAU - Tsang, Raymond C C AU - Tsang RC AD - Physiotherapy Department, MacLehose Medical Rehabilitation Centre, 7 Sha Wan Drive, Pokfulam, Hong Kong. FAU - Leung, H B AU - Leung HB AD - Department of Orthopaedics and Traumatology, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong. LA - eng PT - Journal Article PT - Review DEP - 20140228 PL - China TA - Hong Kong Med J JT - Hong Kong medical journal = Xianggang yi xue za zhi JID - 9512509 RN - 0 (Glucocorticoids) RN - 0 (Neurotoxins) RN - 0 (Vasodilator Agents) RN - 0 (Viscosupplements) RN - 9004-61-9 (Hyaluronic Acid) RN - EC 3.4.24.69 (Botulinum Toxins) RN - G59M7S0WS3 (Nitroglycerin) SB - IM MH - Acupuncture Therapy MH - Administration, Topical MH - Athletic Tape MH - Botulinum Toxins/therapeutic use MH - Braces MH - Exercise Therapy MH - Glucocorticoids/therapeutic use MH - High-Energy Shock Waves MH - Humans MH - Hyaluronic Acid/therapeutic use MH - Injections, Intra-Articular MH - Laser Therapy MH - Massage MH - Muscle Strength/physiology MH - Neurotoxins/therapeutic use MH - Nitroglycerin/therapeutic use MH - Orthopedic Procedures MH - Pain Perception/physiology MH - Physical Examination/methods MH - Platelet-Rich Plasma MH - Tennis Elbow/diagnosis/physiopathology/*therapy MH - Ultrasonic Therapy MH - Vasodilator Agents/therapeutic use MH - Viscosupplements/therapeutic use OTO - NOTNLM OT - Middle aged OT - Tendons OT - Tennis elbow/rehabilitation EDAT- 2014/03/04 06:00 MHDA- 2015/01/06 06:00 CRDT- 2014/03/04 06:00 PHST- 2014/03/04 06:00 [entrez] PHST- 2014/03/04 06:00 [pubmed] PHST- 2015/01/06 06:00 [medline] AID - 10.12809/hkmj134110 [doi] PST - ppublish SO - Hong Kong Med J. 2014 Apr;20(2):145-51. doi: 10.12809/hkmj134110. Epub 2014 Feb 28. PMID- 30314704 OWN - NLM STAT- MEDLINE DCOM- 20190520 LR - 20190520 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 505 IP - 4 DP - 2018 Nov 10 TI - Von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1α. PG - 1063-1069 LID - S0006-291X(18)32111-9 [pii] LID - 10.1016/j.bbrc.2018.09.172 [doi] AB - Enthesis is the region where a tendon attaches to a bone. It is a relatively vulnerable position, and in most cases surgical treatment is required upon rupture. The reconstructed enthesis is usually weaker compared to the original, and is prone to rupture again. Hypoxia-inducible factor-1 α (HIF-1α) is known to be involved in extensive activities in cells. It is inhibited under normoxic conditions, and undergoes two essential processes, hydroxylation and ubiquitination, the latter of which has been largely unexplored. Herein, we measured the levels of HIF-1α and hydroxy-HIF-1α in VH298-treated rat tendon-derived stem cells (TDSCs) by immunoblotting. We also detected the proliferation of TDSCs using CCK-8 assay and the mRNA levels of related genes by quantitative RT-PCR. The TDSCs were observed to be induced and the chondrogenic differentiation related genes were found to be enhanced. We also simulated in-vitro wounding in a scratch test and reconstructed the enthesis in a rat model of Achilles tendon by classical surgery followed by administration of phosphate buffer saline (PBS) injection or VH298 injection. We observed that HIF-1α and hydroxy-HIF-1α levels were increased in VH298-treated TDSCs in a dose- and time-dependent manner. Thirty micromolar VH298 could significantly increase cell proliferation, migration, and expression of collagen-1α, collagen-3α, decorin, tenomodulin, tenascin C genes, and chondrogenic differentiation-related genes, collagen-2α, SRY-box9, aggrecan. VH298-treated enthesis could tolerate more load-to-failure, had a better healing pattern, and activation of HIF signaling pathway. VH298 can thus enhance the functional activities of TDSCs, enhance their chondrogenic differentiation potential, and accelerate enthesis healing by inhibiting the ubiquitination of hydroxy-HIF-1α. CI - Copyright © 2018 Elsevier Inc. All rights reserved. FAU - Qiu, Shuo AU - Qiu S AD - Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. FAU - Jia, Yachao AU - Jia Y AD - Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. FAU - Tang, Jin AU - Tang J AD - Department of Clinical Laboratory, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. FAU - Liu, Xuanzhe AU - Liu X AD - Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. FAU - Hu, Hai AU - Hu H AD - Biomechanics Laboratory, Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. FAU - Wu, Tianyi AU - Wu T AD - Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. Electronic address: xiaoxongwu@hotmail.com. FAU - Chai, Yimin AU - Chai Y AD - Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, PR China. Electronic address: ymchai@sjtu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181009 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Cyclopropanes) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Pyrrolidines) RN - 0 (Thiazoles) RN - 0 (VH298) SB - IM MH - Animals MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Cyclopropanes/*pharmacology MH - Dose-Response Relationship, Drug MH - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/metabolism MH - Male MH - Pyrrolidines/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cells/*drug effects/metabolism MH - Structure-Activity Relationship MH - Tendons/*drug effects/metabolism MH - Thiazoles/*pharmacology MH - Ubiquitination/*drug effects MH - Wound Healing/*drug effects OTO - NOTNLM OT - Enthesis healing OT - Tendon-derived stem cells OT - VH298 OT - VHL inhibition EDAT- 2018/10/14 06:00 MHDA- 2019/05/21 06:00 CRDT- 2018/10/14 06:00 PHST- 2018/09/18 00:00 [received] PHST- 2018/09/27 00:00 [accepted] PHST- 2018/10/14 06:00 [pubmed] PHST- 2019/05/21 06:00 [medline] PHST- 2018/10/14 06:00 [entrez] AID - S0006-291X(18)32111-9 [pii] AID - 10.1016/j.bbrc.2018.09.172 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2018 Nov 10;505(4):1063-1069. doi: 10.1016/j.bbrc.2018.09.172. Epub 2018 Oct 9. PMID- 5769449 OWN - NLM STAT- MEDLINE DCOM- 19690629 LR - 20190701 IS - 0024-3205 (Print) IS - 0024-3205 (Linking) VI - 8 IP - 7 DP - 1969 Apr 1 TI - Early development of acetylcholine receptors on fast and slow mammalian skeletal muscle. PG - 409-16 FAU - Albuquerque, E X AU - Albuquerque EX FAU - McIsaac, R J AU - McIsaac RJ LA - eng PT - Journal Article PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Receptors, Drug) RN - 70FP3JLY7N (Edrophonium) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Animals MH - Edrophonium/pharmacology MH - Male MH - Membrane Potentials MH - *Muscle Denervation MH - Muscles/*drug effects MH - Neuromuscular Junction/drug effects/physiology MH - Rats MH - *Receptors, Drug MH - Tendons MH - Time Factors EDAT- 1969/04/01 00:00 MHDA- 1969/04/01 00:01 CRDT- 1969/04/01 00:00 PHST- 1969/04/01 00:00 [pubmed] PHST- 1969/04/01 00:01 [medline] PHST- 1969/04/01 00:00 [entrez] AID - 0024-3205(69)90235-5 [pii] AID - 10.1016/0024-3205(69)90235-5 [doi] PST - ppublish SO - Life Sci. 1969 Apr 1;8(7):409-16. doi: 10.1016/0024-3205(69)90235-5. PMID- 40643508 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250713 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 14 IP - 13 DP - 2025 Jun 27 TI - Lidocaine Affects Collagen Breakdown Without Compromising Cell Viability in Cultured Human Tenocytes: An In Vitro Study. LID - 10.3390/cells14130988 [doi] LID - 988 AB - Local anesthetics (LAs) are frequently administered via peritendinous ultrasound-guided injections for diagnostic and therapeutic purposes. Since in vitro studies have demonstrated LAs' tenotoxic effects, raising concerns about their safety in infiltrative treatments, and since lidocaine (LD) emerged as one of the most cytotoxic LAs, we analyzed apoptosis, oxidative stress, and collagen turnover pathways in human tenocytes treated with LD, as well as the possible protection from LD-induced injury elicited by antioxidant ascorbic acid (AA). Tenocytes from gluteal tendons were treated with 0.2 and 1 mg/mL LD, or left untreated (CT), and treated with 50 μg/mL or 250 μg/mL AA. Nuclear morphology, cytochrome c expression, and caspase 3 activation were analyzed to study the effect of LD on apoptosis. Heme Oxygenase 1 (HO-1) mRNA and genes and proteins involved in collagen turnover were investigated using molecular approaches. Our results show that 0.2 and 1 mg/mL LD did not induce apoptosis and did not modify collagen synthesis and maturation. Conversely, increased collagen degradation was observed, and AA was not protective against oxidative stress induction in the presence of LD. Our findings suggest that LD does not affect the cell viability of tenocytes and that peritendinous LD injections are safe in this regard. LD-associated collagen degradation and the AA buffer effect are still debatable. Overall, our study contributes to clarifying the effect of LD on tenocytes' viability and ECM homeostasis and provides new additional information useful for the safe clinical application of this drug and for further analysis. FAU - Randelli, Filippo AU - Randelli F AUID- ORCID: 0000-0002-7643-0512 AD - Hip Department (CAD), Gaetano Pini-CTO Orthopedic Institute, University of Milan, P-za Cardinal Ferrari 1, 20122 Milano, Italy. FAU - Mazzoleni, Manuel G AU - Mazzoleni MG AUID- ORCID: 0000-0002-8802-7122 AD - Hip Department (CAD), Gaetano Pini-CTO Orthopedic Institute, University of Milan, P-za Cardinal Ferrari 1, 20122 Milano, Italy. FAU - Menon, Alessandra AU - Menon A AUID- ORCID: 0000-0003-2786-8099 AD - Laboratory of Applied Biomechanics, Department of Biomedical Sciences for Health, Università Degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy. AD - U.O.C. 1° Clinica Ortopedica, Gaetano Pini-CTO Orthopedic Institute, University of Milan, P-za Cardinal Ferrari 1, 20122 Milano, Italy. FAU - Fioruzzi, Alberto AU - Fioruzzi A AUID- ORCID: 0000-0002-4412-7375 AD - Hip Department (CAD), Gaetano Pini-CTO Orthopedic Institute, University of Milan, P-za Cardinal Ferrari 1, 20122 Milano, Italy. FAU - Henin, Dolaji AU - Henin D AD - Department of Biomedical, Surgical and Dental Sciences, Università Degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy. FAU - Sommariva, Michele AU - Sommariva M AUID- ORCID: 0000-0002-7622-0996 AD - Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy. FAU - Gagliano, Nicoletta AU - Gagliano N AUID- ORCID: 0000-0002-3393-3144 AD - Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy. LA - eng PT - Journal Article DEP - 20250627 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 9007-34-5 (Collagen) RN - 98PI200987 (Lidocaine) RN - PQ6CK8PD0R (Ascorbic Acid) RN - EC 3.4.22.- (Caspase 3) RN - EC 1.14.14.18 (Heme Oxygenase-1) RN - 0 (Anesthetics, Local) SB - IM MH - Humans MH - *Tenocytes/drug effects/metabolism/cytology MH - Cell Survival/drug effects MH - *Collagen/metabolism MH - *Lidocaine/pharmacology MH - Apoptosis/drug effects MH - Cells, Cultured MH - Oxidative Stress/drug effects MH - Ascorbic Acid/pharmacology MH - Caspase 3/metabolism MH - Heme Oxygenase-1/metabolism/genetics MH - *Anesthetics, Local/pharmacology MH - Tendons MH - Male PMC - PMC12248775 OTO - NOTNLM OT - apoptosis OT - collagen turnover OT - infiltration OT - lidocaine injection OT - tendinopathy OT - tendon OT - tenocytes COIS- The authors declare no conflicts of interest. EDAT- 2025/07/11 12:30 MHDA- 2025/07/11 12:31 PMCR- 2025/06/27 CRDT- 2025/07/11 10:44 PHST- 2025/05/13 00:00 [received] PHST- 2025/06/23 00:00 [revised] PHST- 2025/06/26 00:00 [accepted] PHST- 2025/07/11 12:31 [medline] PHST- 2025/07/11 12:30 [pubmed] PHST- 2025/07/11 10:44 [entrez] PHST- 2025/06/27 00:00 [pmc-release] AID - cells14130988 [pii] AID - cells-14-00988 [pii] AID - 10.3390/cells14130988 [doi] PST - epublish SO - Cells. 2025 Jun 27;14(13):988. doi: 10.3390/cells14130988. PMID- 23588255 OWN - NLM STAT- MEDLINE DCOM- 20140206 LR - 20220331 IS - 1439-6327 (Electronic) IS - 1439-6319 (Linking) VI - 113 IP - 8 DP - 2013 Aug TI - No inflammatory gene-expression response to acute exercise in human Achilles tendinopathy. PG - 2101-9 LID - 10.1007/s00421-013-2638-3 [doi] AB - Although histology data favour the view of a degenerative nature of tendinopathy, indirect support for inflammatory reactions to loading in affected tendons exists. The purpose of the present study was to elucidate whether inflammatory signalling responses after acute mechanical loading were more pronounced in tendinopathic versus healthy regions of human tendon and if treatment with non-steroidal anti-inflammatory medications (NSAID's) reduces this response. Twenty-seven tendinopathy patients (>6 months) were randomly assigned to a placebo (n = 14) or NSAID (Ibumetin NYCOMED GmbH Plant Oranienburg Germany (600 mg) × 3/day/1 week) group (n = 13) in a double-blinded-fashion. Tendon biopsies were taken from the painful and a healthy region of the same tendon 2 h after 1 h running. Gene-expression of several targets was analysed in the sampled Achilles tendon biopsies. The mRNA for TGF-β, collagen-I and collagen-III were significantly higher expressed, and decorin, CTGF, IL-6 and IL-10 were significantly lower expressed in the tendinopathic versus healthy tendon area. Only IL-10 was lower in expression in experiments with NSAID administration, while all other determined parameters were unaffected by NSAID. All ultrasonographic outcomes were unchanged in response to acute exercise and not influenced by NSAID. The signalling for collagen and TGF-beta was upregulated after acute loading in tendinopathic tendon. In contrast to the hypothesis, inflammatory signalling was not exaggerated in tendinopathic tendon 2 h after acute mechanical loading. FAU - Pingel, Jessica AU - Pingel J AD - Department of Orthopaedic Surgery M. Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health Sciences, Institute of Sports Medicine Copenhagen, University of Copenhagen, Bispebjerg Bakke 23, Copenhagen NV, Denmark. Jessica.pingel@gmx.de FAU - Fredberg, Ulrich AU - Fredberg U FAU - Mikkelsen, Lone Ramer AU - Mikkelsen LR FAU - Schjerling, Peter AU - Schjerling P FAU - Heinemeier, Katja Maria AU - Heinemeier KM FAU - Kjaer, Michael AU - Kjaer M FAU - Harisson, Adrian AU - Harisson A FAU - Langberg, Henning AU - Langberg H LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20130416 PL - Germany TA - Eur J Appl Physiol JT - European journal of applied physiology JID - 100954790 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (CCN2 protein, human) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (DCN protein, human) RN - 0 (Decorin) RN - 0 (IL10 protein, human) RN - 0 (IL6 protein, human) RN - 0 (Interleukin-6) RN - 0 (Transforming Growth Factor beta) RN - 130068-27-8 (Interleukin-10) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Achilles Tendon/diagnostic imaging/*metabolism MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Connective Tissue Growth Factor/genetics/metabolism MH - Decorin/genetics/metabolism MH - *Exercise MH - Female MH - Humans MH - Ibuprofen/therapeutic use MH - Inflammation/drug therapy/etiology/metabolism MH - Interleukin-10/genetics/metabolism MH - Interleukin-6/genetics/metabolism MH - Male MH - Middle Aged MH - Tendinopathy/drug therapy/etiology/*metabolism MH - *Transcription, Genetic MH - Transforming Growth Factor beta/genetics/metabolism MH - Ultrasonography EDAT- 2013/04/17 06:00 MHDA- 2014/02/07 06:00 CRDT- 2013/04/17 06:00 PHST- 2012/10/22 00:00 [received] PHST- 2013/03/30 00:00 [accepted] PHST- 2013/04/17 06:00 [entrez] PHST- 2013/04/17 06:00 [pubmed] PHST- 2014/02/07 06:00 [medline] AID - 10.1007/s00421-013-2638-3 [doi] PST - ppublish SO - Eur J Appl Physiol. 2013 Aug;113(8):2101-9. doi: 10.1007/s00421-013-2638-3. Epub 2013 Apr 16. PMID- 27281275 OWN - NLM STAT- MEDLINE DCOM- 20171023 LR - 20191008 IS - 1552-3365 (Electronic) IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 44 IP - 9 DP - 2016 Sep TI - Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. PG - 2237-45 LID - 10.1177/0363546516646377 [doi] AB - BACKGROUND: Previous studies have shown that ibuprofen is detrimental to tissue healing after acute injury; however, the effects of ibuprofen when combined with noninjurious exercise are debated. HYPOTHESIS: Administration of ibuprofen to rats undergoing a noninjurious treadmill exercise protocol will abolish the beneficial adaptations found with exercise but will have no effect on sedentary muscle and tendon properties. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 167 male Sprague-Dawley rats were divided into exercise or cage activity (sedentary) groups and acute (a single bout of exercise followed by 24 hours of rest) and chronic (2 or 8 weeks of repeated exercise) response times. Half of the rats were administered ibuprofen to investigate the effects of this drug over time when combined with different activity levels (exercise and sedentary). Supraspinatus tendons were used for mechanical testing and histologic assessment (organization, cell shape, cellularity), and supraspinatus muscles were used for morphologic (fiber cross-sectional area, centrally nucleated fibers) and fiber type analysis. RESULTS: Chronic intake of ibuprofen did not impair supraspinatus tendon organization or mechanical adaptations (stiffness, modulus, maximum load, maximum stress, dynamic modulus, or viscoelastic properties) to exercise. Tendon mechanical properties were not diminished and in some instances increased with ibuprofen. In contrast, total supraspinatus muscle fiber cross-sectional area decreased with ibuprofen at chronic response times, and some fiber type-specific changes were detected. CONCLUSION: Chronic administration of ibuprofen does not impair supraspinatus tendon mechanical properties in a rat model of exercise but does decrease supraspinatus muscle fiber cross-sectional area. This fundamental study adds to the growing literature on the effects of ibuprofen on musculoskeletal tissues and provides a solid foundation on which future work can build. CLINICAL RELEVANCE: The study findings suggest that ibuprofen does not detrimentally affect regulation of supraspinatus tendon adaptations to exercise but does decrease muscle growth. Individuals should be advised on the risk of decreased muscle hypertrophy when consuming ibuprofen. CI - © 2016 The Author(s). FAU - Rooney, Sarah Ilkhanipour AU - Rooney SI AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Baskin, Rachel AU - Baskin R AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Torino, Daniel J AU - Torino DJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Vafa, Rameen P AU - Vafa RP AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Khandekar, Pooja S AU - Khandekar PS AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Kuntz, Andrew F AU - Kuntz AF AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Soslowsky, Louis J AU - Soslowsky LJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA soslowsk@mail.med.upenn.edu. LA - eng GR - P30 AR050950/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20160608 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - WK2XYI10QM (Ibuprofen) SB - IM MH - *Adaptation, Physiological MH - Animals MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Ibuprofen/*toxicity MH - Male MH - Muscle Fibers, Skeletal MH - *Physical Conditioning, Animal MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*pathology MH - Tendons/pathology PMC - PMC5492953 MID - NIHMS869705 OTO - NOTNLM OT - *NSAID OT - *biomechanics of tendon OT - *muscle physiology OT - *rotator cuff OT - *shoulder EDAT- 2016/06/10 06:00 MHDA- 2017/10/24 06:00 PMCR- 2017/09/01 CRDT- 2016/06/10 06:00 PHST- 2016/06/10 06:00 [entrez] PHST- 2016/06/10 06:00 [pubmed] PHST- 2017/10/24 06:00 [medline] PHST- 2017/09/01 00:00 [pmc-release] AID - 0363546516646377 [pii] AID - 10.1177/0363546516646377 [doi] PST - ppublish SO - Am J Sports Med. 2016 Sep;44(9):2237-45. doi: 10.1177/0363546516646377. Epub 2016 Jun 8. PMID- 36045032 OWN - NLM STAT- MEDLINE DCOM- 20221024 LR - 20221024 IS - 1879-0267 (Electronic) IS - 0020-1383 (Linking) VI - 53 IP - 11 DP - 2022 Nov TI - Effect of angiotensin II pathway inhibitors on post-surgical adhesion band formation: a potential repurposing of old drugs. PG - 3642-3649 LID - S0020-1383(22)00608-8 [pii] LID - 10.1016/j.injury.2022.08.046 [doi] AB - BACKGROUND: In this study we investigated the therapeutic potential of angiotensin II pathway inhibitors in attenuating post-surgical adhesion band formation in tendon injury. METHOD: We assigned 30 Wistar albino rats to 5 groups, including negative control, positive control, sham, Telmisartan- and Enalapril-treated groups (n=6). Telmisartan and Enalapril at a dose of 10 mg/kg were administered intraperitoneally for 21 days. Hematoxylin-Eosin, and Masson's trichrome staining were used to measure the inflammatory cell accumulation and collagen deposition in the Achilles tendon tissue sections. Oxidative stress markers were analyzed in tissue samples by spectrophotometric methods. Properties of Achilles tendon adhesions were compared based on Tang and Ishiyama scoring systems in the presence and absence of angiotensin II pathway inhibitors. RESULTS: Telmisartan and Enalapril reduced severity, length, and density of surgical-induced tendon adhesion at site of injury (***p < 0.001). Our results showed that administration of angiotensin II pathway inhibitors decreased infiltration of inflammatory cells to the injured area (*p < 0.05) and suppressed inflammation by regulating oxidative stress markers including MDA (***p < 0.001), total thiol (***p < 0.001), CAT (***p < 0.001), and SOD (***p < 0.001), in post-operative Achilles tendon tissues. Significant lower collagen deposition and formation of fibrotic tissues was seen in Telmisartan- and Enalapril-treated groups as detected by Masson's trichrome staining which correlated with a decrease in quantity (**p < 0.01) and grading of fibrosis score (***p < 0.001), in adhesive tissues. Moreover, inhibition of angiotensin II pathway could also ameliorate mechanical properties including ultimate load (***p < 0.001), and ultimate stress (*p < 0.05) in injured Tendons. CONCLUSION: Our results showed that ssuppression of inflammation and fibrosis are two mechanisms by which Telmisartan and Enalapril elicit potent protective responses post Achilles tendon injuries. CI - Copyright © 2022 Elsevier Ltd. All rights reserved. FAU - Nazari, Seyedeh Elnaz AU - Nazari SE AD - Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Naimi, Hamideh AU - Naimi H AD - Department of Cellular and Molecular Biology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Sayyed-Hosseinian, Sayyed-Hadi AU - Sayyed-Hosseinian SH AD - Orthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Vahedi, Ehsan AU - Vahedi E AD - Orthopedic Research Center, Shahid Kamyab Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Daghiani, Maryam AU - Daghiani M AD - Department of Physiotherapy, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Asgharzadeh, Fereshteh AU - Asgharzadeh F AD - Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Askarnia-Faal, Mohammad-Mostafa AU - Askarnia-Faal MM AD - Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Avan, Amir AU - Avan A AD - Department of Human Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran. FAU - Khazaei, Majid AU - Khazaei M AD - Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: KhazaeiM@mums.ac.ir. FAU - Hassanian, Seyed Mahdi AU - Hassanian SM AD - Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hasanianmehrm@mums.ac.ir. LA - eng PT - Journal Article DEP - 20220821 PL - Netherlands TA - Injury JT - Injury JID - 0226040 RN - U5SYW473RQ (Telmisartan) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 11128-99-7 (Angiotensin II) RN - 0 (Benzimidazoles) RN - 0 (Pharmaceutical Preparations) RN - TDQ283MPCW (Eosine Yellowish-(YS)) RN - YKM8PY2Z55 (Hematoxylin) RN - 69PN84IO1A (Enalapril) RN - 0 (Sulfhydryl Compounds) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Animals MH - Rats MH - Telmisartan/pharmacology MH - *Angiotensin-Converting Enzyme Inhibitors/therapeutic use MH - Tissue Adhesions/drug therapy MH - *Angiotensin II/pharmacology MH - Benzimidazoles/pharmacology/therapeutic use MH - Pharmaceutical Preparations MH - Eosine Yellowish-(YS) MH - Hematoxylin MH - Drug Repositioning MH - Enalapril/pharmacology/therapeutic use MH - Fibrosis MH - Rats, Wistar MH - Inflammation/drug therapy MH - Sulfhydryl Compounds MH - Superoxide Dismutase OTO - NOTNLM OT - Angiotensin II pathway inhibitors OT - Enalapril OT - Telmisartan OT - Tendon injury OT - post-operative adhesion bands COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/09/01 06:00 MHDA- 2022/10/25 06:00 CRDT- 2022/08/31 22:03 PHST- 2022/03/29 00:00 [received] PHST- 2022/08/10 00:00 [revised] PHST- 2022/08/20 00:00 [accepted] PHST- 2022/09/01 06:00 [pubmed] PHST- 2022/10/25 06:00 [medline] PHST- 2022/08/31 22:03 [entrez] AID - S0020-1383(22)00608-8 [pii] AID - 10.1016/j.injury.2022.08.046 [doi] PST - ppublish SO - Injury. 2022 Nov;53(11):3642-3649. doi: 10.1016/j.injury.2022.08.046. Epub 2022 Aug 21. PMID- 2991688 OWN - NLM STAT- MEDLINE DCOM- 19850916 LR - 20190701 IS - 0024-3205 (Print) IS - 0024-3205 (Linking) VI - 37 IP - 6 DP - 1985 Aug 12 TI - A novel inhibitor of mammalian collagenase. PG - 575-8 AB - N-[[[(5-chloro-2-benzothiazolyl)thiolphenyllacetyll-L-cysteine (WY-45,368) is a potent inhibitor of human skin fibroblast collagenase. Kinetic data show that the inhibition is competitive, with a Ki of 3.5 microM. WY-45,368 inhibits neither of two other metalloproteinases, thermolysin and angiotensin converting enzyme, nor does it inhibit clostridial collagenase--thus indicating specificity for mammalian collagenase. FAU - Clark, D E AU - Clark DE FAU - Wei, P AU - Wei P FAU - Grant, N H AU - Grant NH LA - eng PT - Journal Article PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Benzothiazoles) RN - 0 (N-((((5-chloro-2-benzothiazolyl)thio)phenyl)acetyl)cysteine) RN - 0 (Protease Inhibitors) RN - EC 3.4.21.4 (Trypsin) RN - EC 3.4.24.27 (Thermolysin) RN - EC 3.4.24.3 (Microbial Collagenase) RN - K848JZ4886 (Cysteine) RN - WYQ7N0BPYC (Acetylcysteine) SB - IM MH - *Acetylcysteine/*analogs & derivatives MH - Angiotensin-Converting Enzyme Inhibitors MH - Animals MH - Benzothiazoles MH - Cell Line MH - Clostridium/enzymology MH - Cysteine/*analogs & derivatives/pharmacology MH - Fibroblasts/enzymology MH - Humans MH - Kinetics MH - Microbial Collagenase/*antagonists & inhibitors MH - Protease Inhibitors/*pharmacology MH - Rats MH - Skin/enzymology MH - Substrate Specificity MH - Tail MH - Tendons MH - Thermolysin/antagonists & inhibitors MH - Trypsin/metabolism EDAT- 1985/08/12 00:00 MHDA- 1985/08/12 00:01 CRDT- 1985/08/12 00:00 PHST- 1985/08/12 00:00 [pubmed] PHST- 1985/08/12 00:01 [medline] PHST- 1985/08/12 00:00 [entrez] AID - 0024-3205(85)90471-0 [pii] AID - 10.1016/0024-3205(85)90471-0 [doi] PST - ppublish SO - Life Sci. 1985 Aug 12;37(6):575-8. doi: 10.1016/0024-3205(85)90471-0. PMID- 26721400 OWN - NLM STAT- MEDLINE DCOM- 20160613 LR - 20241116 IS - 1091-6490 (Electronic) IS - 0027-8424 (Print) IS - 0027-8424 (Linking) VI - 113 IP - 3 DP - 2016 Jan 19 TI - Inhibition of Hif1α prevents both trauma-induced and genetic heterotopic ossification. PG - E338-47 LID - 10.1073/pnas.1515397113 [doi] AB - Pathologic extraskeletal bone formation, or heterotopic ossification (HO), occurs following mechanical trauma, burns, orthopedic operations, and in patients with hyperactivating mutations of the type I bone morphogenetic protein receptor ACVR1 (Activin type 1 receptor). Extraskeletal bone forms through an endochondral process with a cartilage intermediary prompting the hypothesis that hypoxic signaling present during cartilage formation drives HO development and that HO precursor cells derive from a mesenchymal lineage as defined by Paired related homeobox 1 (Prx). Here we demonstrate that Hypoxia inducible factor-1α (Hif1α), a key mediator of cellular adaptation to hypoxia, is highly expressed and active in three separate mouse models: trauma-induced, genetic, and a hybrid model of genetic and trauma-induced HO. In each of these models, Hif1α expression coincides with the expression of master transcription factor of cartilage, Sox9 [(sex determining region Y)-box 9]. Pharmacologic inhibition of Hif1α using PX-478 or rapamycin significantly decreased or inhibited extraskeletal bone formation. Importantly, de novo soft-tissue HO was eliminated or significantly diminished in treated mice. Lineage-tracing mice demonstrate that cells forming HO belong to the Prx lineage. Burn/tenotomy performed in lineage-specific Hif1α knockout mice (Prx-Cre/Hif1α(fl:fl)) resulted in substantially decreased HO, and again lack of de novo soft-tissue HO. Genetic loss of Hif1α in mesenchymal cells marked by Prx-cre prevents the formation of the mesenchymal condensations as shown by routine histology and immunostaining for Sox9 and PDGFRα. Pharmacologic inhibition of Hif1α had a similar effect on mesenchymal condensation development. Our findings indicate that Hif1α represents a promising target to prevent and treat pathologic extraskeletal bone. FAU - Agarwal, Shailesh AU - Agarwal S AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Loder, Shawn AU - Loder S AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Brownley, Cameron AU - Brownley C AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Cholok, David AU - Cholok D AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Mangiavini, Laura AU - Mangiavini L AD - Department of Orthopedic Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Li, John AU - Li J AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Breuler, Christopher AU - Breuler C AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Sung, Hsiao H AU - Sung HH AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Li, Shuli AU - Li S AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Ranganathan, Kavitha AU - Ranganathan K AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Peterson, Joshua AU - Peterson J AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; FAU - Tompkins, Ronald AU - Tompkins R AD - Department of Surgery, Massachusetts General Hospital, Boston, MA 02114; FAU - Herndon, David AU - Herndon D AD - Department of Surgery, Shriners Hospital for Children and University of Texas Medical Branch, Galveston, TX 77555; FAU - Xiao, Wenzhong AU - Xiao W AD - Department of Surgery, Genome Technology Center, Stanford University, Palo Alto, CA 94305; FAU - Jumlongras, Dolrudee AU - Jumlongras D AD - Department of Developmental Biology, Harvard Dental School, Boston, MA 02115; FAU - Olsen, Bjorn R AU - Olsen BR AD - Department of Developmental Biology, Harvard Dental School, Boston, MA 02115; FAU - Davis, Thomas A AU - Davis TA AD - Regenerative Medicine Department, Naval Medical Research Center, Silver Spring, MD 20910; FAU - Mishina, Yuji AU - Mishina Y AD - Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor, MI 48109. FAU - Schipani, Ernestina AU - Schipani E AD - Department of Orthopedic Surgery, University of Michigan, Ann Arbor, MI 48109; eschipan@med.umich.edu blevi@umich.edu. FAU - Levi, Benjamin AU - Levi B AD - Department of Surgery, University of Michigan, Ann Arbor, MI 48109; eschipan@med.umich.edu blevi@umich.edu. LA - eng GR - P30 CA046592/CA/NCI NIH HHS/United States GR - P50 GM021700/GM/NIGMS NIH HHS/United States GR - P01 AR048564/AR/NIAMS NIH HHS/United States GR - F32 AR068902/AR/NIAMS NIH HHS/United States GR - U54 GM062119/GM/NIGMS NIH HHS/United States GR - R01 AR036820/AR/NIAMS NIH HHS/United States GR - R01 DE020843/DE/NIDCR NIH HHS/United States GR - K08 GM109105/GM/NIGMS NIH HHS/United States GR - P30 AR069620/AR/NIAMS NIH HHS/United States GR - P30CA046592/CA/NCI NIH HHS/United States GR - HHMI/Howard Hughes Medical Institute/United States GR - U54GM062119/GM/NIGMS NIH HHS/United States GR - T35 HL007690/HL/NHLBI NIH HHS/United States GR - K08GM109105-0/GM/NIGMS NIH HHS/United States GR - R01AR065403-02/AR/NIAMS NIH HHS/United States GR - R01 AR065403/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20151231 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Mustard Compounds) RN - 0 (Phenylpropionates) RN - 0 (RNA, Messenger) RN - 0 (SOX9 Transcription Factor) RN - EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor alpha) RN - EC 2.7.11.30 (Activin Receptors, Type I) RN - EC 2.7.7.- (Cre recombinase) RN - EC 2.7.7.- (Integrases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Activin Receptors, Type I/metabolism MH - Adipose Tissue/drug effects/metabolism MH - Animals MH - Burns/complications/genetics MH - Chondrogenesis/drug effects/genetics MH - Disease Models, Animal MH - Gene Regulatory Networks/drug effects MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists & inhibitors/genetics/metabolism MH - Integrases/metabolism MH - Luminescent Measurements MH - Mesenchymal Stem Cells/drug effects MH - Mice, Knockout MH - Models, Biological MH - Mustard Compounds/pharmacology MH - Ossification, Heterotopic/diagnostic imaging/drug therapy/*genetics/*prevention & control MH - Phenylpropionates/pharmacology MH - RNA, Messenger/genetics/metabolism MH - Receptor, Platelet-Derived Growth Factor alpha/metabolism MH - SOX9 Transcription Factor/metabolism MH - Signal Transduction/drug effects MH - Sirolimus/pharmacology MH - Tendons/drug effects/pathology/surgery MH - Tenotomy MH - Up-Regulation/drug effects MH - Wound Healing/drug effects MH - Wounds and Injuries/*complications/pathology MH - X-Ray Microtomography PMC - PMC4725488 OTO - NOTNLM OT - HIF1α OT - Prx OT - cartilage OT - heterotopic ossification OT - mesenchymal condensation COIS- The authors declare no conflict of interest. EDAT- 2016/01/02 06:00 MHDA- 2016/06/14 06:00 PMCR- 2016/07/19 CRDT- 2016/01/02 06:00 PHST- 2016/01/02 06:00 [entrez] PHST- 2016/01/02 06:00 [pubmed] PHST- 2016/06/14 06:00 [medline] PHST- 2016/07/19 00:00 [pmc-release] AID - 1515397113 [pii] AID - 201515397 [pii] AID - 10.1073/pnas.1515397113 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E338-47. doi: 10.1073/pnas.1515397113. Epub 2015 Dec 31. PMID- 21478457 OWN - NLM STAT- MEDLINE DCOM- 20111209 LR - 20220311 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 39 IP - 7 DP - 2011 Jul TI - Biomechanical analysis of chlorhexidine power irrigation to disinfect contaminated anterior cruciate ligament grafts. PG - 1528-33 LID - 10.1177/0363546511401175 [doi] AB - BACKGROUND: Accidental graft contamination is a likely complication to occur in an orthopaedic sports medicine surgeon's career. There are no clinical outcome studies to direct management, and a recent survey showed that preferred management varied. Three liters of 2% chlorhexidine power irrigation has been shown to be an efficient and effective disinfection protocol; however, the biomechanical sequelae of this disinfection protocol to the graft are unknown. PURPOSE: The purpose of this study was to determine if 3 L of 2% chlorhexidine power irrigation used to disinfect contaminated anterior cruciate ligament (ACL) grafts significantly weakens the graft at time zero. STUDY DESIGN: Controlled laboratory study. METHODS: Eight fresh bovine superficial digital flexor tendons underwent disinfection protocol with 3 L of 2% chlorhexidine power irrigation. Contralateral tendons served as the control. Tendons were preconditioned and loaded to failure. RESULTS: The average ultimate failure load for the control tendons and disinfected tendons was 4081 ± 654.4 N and 4146 ± 723.2 N, respectively. The average ultimate failure stress for the control tendons and disinfected tendons was 97.10 ± 12.03 MPa and 95.18 ± 11.79 MPa, respectively. The average stiffness for the control tendons and disinfected tendons was 546.20 ± 28.16 N/mm and 539.2 ± 25.93 N/mm, respectively. The P values for ultimate failure load, ultimate failure stress, and stiffness showed no statistically significant difference between the chlorhexidine and control tendons. CONCLUSION: Disinfecting tendons with 3 L of 2% chlorhexidine power irrigation does not adversely weaken the tendon's tensile mechanical properties. CLINICAL RELEVANCE: Three liters of 2% chlorhexidine power irrigation can effectively disinfect a contaminated ACL graft without weakening the graft. FAU - Han, Yung AU - Han Y AD - Department of Orthopaedic Surgery, McGill University, Montreal, Quebec, Canada. han.md@hotmail.com FAU - Giannitsios, Demetri AU - Giannitsios D FAU - Duke, Kajsa AU - Duke K FAU - Steffen, Thomas AU - Steffen T FAU - Burman, Mark AU - Burman M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110408 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Disinfectants) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Animals MH - Anterior Cruciate Ligament MH - Biomechanical Phenomena MH - Cattle MH - Chlorhexidine/*pharmacology MH - Disinfectants/*pharmacology MH - Disinfection/methods MH - Elasticity/drug effects MH - Tendons/*drug effects/*physiology MH - Tensile Strength/drug effects EDAT- 2011/04/12 06:00 MHDA- 2011/12/14 06:00 CRDT- 2011/04/12 06:00 PHST- 2011/04/12 06:00 [entrez] PHST- 2011/04/12 06:00 [pubmed] PHST- 2011/12/14 06:00 [medline] AID - 0363546511401175 [pii] AID - 10.1177/0363546511401175 [doi] PST - ppublish SO - Am J Sports Med. 2011 Jul;39(7):1528-33. doi: 10.1177/0363546511401175. Epub 2011 Apr 8. PMID- 22674405 OWN - NLM STAT- MEDLINE DCOM- 20130114 LR - 20151119 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 30 IP - 12 DP - 2012 Dec TI - Low-level laser therapy in collagenase-induced Achilles tendinitis in rats: analyses of biochemical and biomechanical aspects. PG - 1945-51 LID - 10.1002/jor.22156 [doi] AB - NSAIDs are widely prescribed and used over the years to treat tendon injuries despite its well-known long-term side effects. In the last years several animal and human trials have shown that low-level laser therapy (LLLT) presents modulatory effects on inflammatory markers, however the mechanisms involved are not fully understood. The aim of this study was to evaluate the short-term effects of LLLT or sodium diclofenac treatments on biochemical markers and biomechanical properties of inflamed Achilles tendons. Wistar rats Achilles tendons (n = 6/group) were injected with saline (control) or collagenase at peritendinous area of Achilles tendons. After 1 h animals were treated with two different doses of LLLT (810 nm, 1 and 3 J) at the sites of the injections, or with intramuscular sodium diclofenac. Regarding biochemical analyses, LLLT significantly decreased (p < 0.05) COX-2, TNF-α, MMP-3, MMP-9, and MMP-13 gene expression, as well as prostaglandin E(2) (PGE(2) ) production when compared to collagenase group. Interestingly, diclofenac treatment only decreased PGE(2) levels. Biomechanical properties were preserved in the laser-treated groups when compared to collagenase and diclofenac groups. We conclude that LLLT was able to reduce tendon inflammation and to preserve tendon resistance and elasticity. CI - Copyright © 2012 Orthopaedic Research Society. FAU - Marcos, Rodrigo Labat AU - Marcos RL AD - Laboratory of Pharmacology and Experimental Therapeutics, Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, Butantan, São Paulo 05508-900, SP, Brazil. FAU - Leal-Junior, Ernesto Cesar Pinto AU - Leal-Junior EC FAU - Arnold, Gilles AU - Arnold G FAU - Magnenet, Vincent AU - Magnenet V FAU - Rahouadj, Rachid AU - Rahouadj R FAU - Wang, Xiong AU - Wang X FAU - Demeurie, Frank AU - Demeurie F FAU - Magdalou, Jacques AU - Magdalou J FAU - de Carvalho, Maria Helena Catelli AU - de Carvalho MH FAU - Lopes-Martins, Rodrigo Álvaro Brandão AU - Lopes-Martins RÁ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120605 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Tumor Necrosis Factor-alpha) RN - 144O8QL0L1 (Diclofenac) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Achilles Tendon/*pathology MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Biochemistry/methods MH - Biomechanical Phenomena MH - Collagenases/chemistry/*metabolism MH - Cyclooxygenase 2/metabolism MH - Diclofenac/pharmacology MH - Dinoprostone/metabolism MH - Inflammation MH - Low-Level Light Therapy/*methods MH - Male MH - Matrix Metalloproteinases/biosynthesis MH - Rats MH - Rats, Wistar MH - Tendinopathy/etiology/*radiotherapy MH - Tumor Necrosis Factor-alpha/biosynthesis EDAT- 2012/06/08 06:00 MHDA- 2013/01/15 06:00 CRDT- 2012/06/08 06:00 PHST- 2012/03/06 00:00 [received] PHST- 2012/05/07 00:00 [accepted] PHST- 2012/06/08 06:00 [entrez] PHST- 2012/06/08 06:00 [pubmed] PHST- 2013/01/15 06:00 [medline] AID - 10.1002/jor.22156 [doi] PST - ppublish SO - J Orthop Res. 2012 Dec;30(12):1945-51. doi: 10.1002/jor.22156. Epub 2012 Jun 5. PMID- 14521300 OWN - NLM STAT- MEDLINE DCOM- 20031017 LR - 20220408 IS - 0001-6470 (Print) IS - 0001-6470 (Linking) VI - 74 IP - 4 DP - 2003 Aug TI - Indomethacin and celecoxib improve tendon healing in rats. PG - 465-9 AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the formation of bone. However, they have been shown to increase tensile strength in healing tendons. Most NSAIDs inhibit two isoforms of cyclooxygenases called Cox-1 and Cox-2. Thanks to fewer side-effects, the recently introduced selective cyclooxygenase-2 (Cox-2) inhibitors will probably promote more widespread use of this kind of drug. To clarify the effects on tendon healing of a general Cox-inhibitor (indomethacin) as well as a selective Cox-2 inhibitor (celecoxib), we resected 3 mm of the Achilles tendon in rats and measured the strength of the tendon regenerate. Indomethacin given as daily injections in doses of 1.5, 3.0 and 5.0 mg/kg reduced the thickness (cross-sectional area) of the tendon regenerate at 14 days, as compared to controls, but there was no difference in the failure load or stiffness. In another series of measurements, indomethacin in a dose of 3.0 mg/kg reduced the cross-sectional area at 10, 14 and 18 days after transsection. Failure load was not affected, but tensile stress at failure was increased by indomethacin at 14 and 18 days. Indomethacin (3 mg/kg) was then compared to celecoxib (4.5 mg/kg) and controls 14 days after tendon transsection. No difference between the drugs was seen. Again, the transverse area was smaller in the treated tendons than in the controls. Failure load was unchanged and the tensile stress was higher in the treated tendons than in the controls. Because of the reduction in cross-sectional area without an effect on failure load, the use of Cox-inhibitors may be beneficial in clinical situations where thickening of a healing tendon is a problem--e.g., in the hand or shoulder. FAU - Forslund, Carina AU - Forslund C AD - Orthopedic Department, Lund University Hospital, Lund, Sweden. FAU - Bylander, Birger AU - Bylander B FAU - Aspenberg, Per AU - Aspenberg P LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Acta Orthop Scand JT - Acta orthopaedica Scandinavica JID - 0370352 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Sulfonamides) RN - JCX84Q7J1L (Celecoxib) RN - XXE1CET956 (Indomethacin) SB - IM MH - Analysis of Variance MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Celecoxib MH - Cross-Sectional Studies MH - Cyclooxygenase Inhibitors/pharmacology MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Female MH - Indomethacin/*pharmacology MH - Pyrazoles MH - Rats MH - Rats, Sprague-Dawley MH - Reference Values MH - Sensitivity and Specificity MH - Sulfonamides/*pharmacology MH - Tendon Injuries/*drug therapy MH - Wound Healing/drug effects/physiology EDAT- 2003/10/03 05:00 MHDA- 2003/10/18 05:00 CRDT- 2003/10/03 05:00 PHST- 2003/10/03 05:00 [pubmed] PHST- 2003/10/18 05:00 [medline] PHST- 2003/10/03 05:00 [entrez] AID - 10.1080/00016470310017802 [doi] PST - ppublish SO - Acta Orthop Scand. 2003 Aug;74(4):465-9. doi: 10.1080/00016470310017802. PMID- 32106592 OWN - NLM STAT- MEDLINE DCOM- 20201125 LR - 20201125 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 5 DP - 2020 Feb 25 TI - Effects of SCCO(2), Gamma Irradiation, and Sodium Dodecyl Sulfate Treatments on the Initial Properties of Tendon Allografts. LID - 10.3390/ijms21051565 [doi] LID - 1565 AB - Sterile and decellularized allograft tendons are viable biomaterials used in reconstructive surgeries for dense connective tissue injuries. Established allograft processing techniques including gamma irradiation and sodium dodecyl sulfate (SDS) can affect tissue integrity. Supercritical carbon dioxide (SCCO(2)) represents a novel alternative that has the potential to decellularize and sterilize tendons with minimized exposure to denaturants, shortened treatment time, lack of toxic residues, and superior tissue penetration, and thus efficacy. This study attempted to develop a single-step hybrid decellularization and sterilization protocol for tendons that involved SCCO(2) treatment with various chemical additives. The processed tendons were evaluated with mechanical testing, histology, scanning electron microscopy (SEM), and Fourier-transform infrared (FTIR) spectroscopy. Uniaxial mechanical testing showed that tendons treated with SCCO(2) and additive NovaKill(TM) Gen2 and 0.1% SDS had significantly higher (p < 0.05) ultimate tensile stress (UTS) and Young's modulus compared to gamma-irradiated and standard-SDS-treated tendons. This was corroborated by the ultrastructural intactness of SCCO(2)-treated tendons as examined by SEM and FTIR spectroscopy, which was not preserved in gamma-irradiated and standard SDS-treated tendons. However, complete decellularization was not achieved by the experimented SCCO(2)-SDS protocols used in this study. The present study therefore serves as a concrete starting point for development of an SCCO(2)-based combined sterilization and decellularization protocol for allograft tendons, where additive choice is to be optimized. FAU - Sun, Yikan AU - Sun Y AD - Surgical and Orthopedic Research Laboratories, Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Lovric, Vedran AU - Lovric V AD - Surgical and Orthopedic Research Laboratories, Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Wang, Tian AU - Wang T AD - Surgical and Orthopedic Research Laboratories, Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Oliver, Rema A AU - Oliver RA AD - Surgical and Orthopedic Research Laboratories, Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Walsh, William R AU - Walsh WR AD - Surgical and Orthopedic Research Laboratories, Prince of Wales Clinical School, Prince of Wales Hospital, University of New South Wales, Randwick, NSW 2031, Australia. LA - eng PT - Journal Article DEP - 20200225 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 142M471B3J (Carbon Dioxide) RN - 368GB5141J (Sodium Dodecyl Sulfate) SB - IM MH - Allografts/*drug effects/radiation effects/transplantation MH - Animals MH - Carbon Dioxide/pharmacology MH - Elastic Modulus MH - Gamma Rays MH - Sheep MH - Sodium Dodecyl Sulfate/pharmacology MH - Tendons/*drug effects/radiation effects/transplantation MH - Tensile Strength MH - Tissue Transplantation/*methods MH - Tissue and Organ Harvesting/*methods PMC - PMC7084268 OTO - NOTNLM OT - Allograft OT - decellularization OT - sterilization OT - supercritical carbon dioxide OT - supercritical fluid OT - tendon COIS- The authors declare no conflicts of interest. EDAT- 2020/02/29 06:00 MHDA- 2020/11/26 06:00 PMCR- 2020/03/01 CRDT- 2020/02/29 06:00 PHST- 2019/11/28 00:00 [received] PHST- 2020/02/07 00:00 [revised] PHST- 2020/02/15 00:00 [accepted] PHST- 2020/02/29 06:00 [entrez] PHST- 2020/02/29 06:00 [pubmed] PHST- 2020/11/26 06:00 [medline] PHST- 2020/03/01 00:00 [pmc-release] AID - ijms21051565 [pii] AID - ijms-21-01565 [pii] AID - 10.3390/ijms21051565 [doi] PST - epublish SO - Int J Mol Sci. 2020 Feb 25;21(5):1565. doi: 10.3390/ijms21051565. PMID- 35872167 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20220920 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 31 IP - 10 DP - 2022 Oct TI - Three weeks of indomethacin is not superior to 1 week of meloxicam as prophylaxis for heterotopic ossifications after distal biceps tendon repair with a single-incision technique. PG - 2157-2163 LID - S1058-2746(22)00566-3 [pii] LID - 10.1016/j.jse.2022.06.002 [doi] AB - BACKGROUND: The aim of this study was to assess the efficacy of 3 weeks of indomethacin, a nonselective nonsteroidal anti-inflammatory drug, in comparison to 1 week of meloxicam as prophylaxis for heterotopic ossifications (HOs) after distal biceps tendon repair. METHODS: A single-center retrospective study was performed on 78 patients undergoing distal biceps tendon repair between 2008 and 2019. From 2008 to 2016, patients received meloxicam 15 mg daily for the period of 1 week as usual care. From 2016 onward, the standard protocol was changed to indomethacin 25 mg 3 times daily for 3 weeks. All patients underwent a single-incision repair with a cortical button technique. The postoperative rehabilitation protocol was similar for all patients. The postoperative radiographs at 8-week follow-up were assessed blindly by 7 independent assessors. If HOs were present, it was classified according to the Ilahi-Gabel classification for size and according to the Gärtner-Heyer classification for density. Statistical analysis was performed to analyze the difference in HO between the patients who were treated with indomethacin and with meloxicam. RESULTS: Seventy-eight patients, with a mean age of 48.8 years (range 30-72) were included. The mean follow-up after surgery was 12 months (range 2-45). Indomethacin (21 days, 25 mg 3 times per day) was prescribed to 26 (33%) patients. The 52 other patients (67%) were prescribed meloxicam 15 mg daily for 7 days. HOs were seen in 19 patients 8 weeks postoperatively. Five of 26 patients treated with indomethacin developed HO, and 14 of 52 patients treated with meloxicam developed HO (P = .5). Two patients had symptomatic HO with minor restrictions in movement; neither patient was treated with indomethacin. Significantly more HOs were seen in patients with a longer time from injury to surgery (P = .01) The intraclass correlation score for reliability between assessors for HO scoring on postoperative radiographs was good to excellent for both classifications. CONCLUSION: In this study, HOs were seen in 24% of postoperative radiographs. Three weeks of indomethacin was not superior to meloxicam for 1 week for the prevention of HO after single-incision distal biceps tendon repair. CI - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Wörner, Elisabeth A AU - Wörner EA AD - Department of Orthopaedics and Sports Medicine, Erasmus University Medical Center, Rotterdam, Netherlands; Foundation for Orthopaedic Research, Care & Education (FORCE), Amphia Hospital, Breda, Netherlands. Electronic address: lisaworner@gmail.com. FAU - Kodde, Isaak F AU - Kodde IF AD - Department of Orthopaedic and Trauma Surgery, Deventer Ziekenhuis, Deventer, Netherlands. FAU - Spaans, Anne J AU - Spaans AJ AD - Department of Orthopaedic Surgery, Sint Maartenskliniek, Nijmegen/Boxmeer, Netherlands. FAU - Colic, Nicola AU - Colic N AD - Department of Orthopaedic Surgery, Institute for Orthopaedic Surgery, Banjica, Belgrade, Serbia. FAU - Hilgersom, Nick AU - Hilgersom N AD - Foundation for Orthopaedic Research, Care & Education (FORCE), Amphia Hospital, Breda, Netherlands. FAU - van Oost, Iris AU - van Oost I AD - Foundation for Orthopaedic Research, Care & Education (FORCE), Amphia Hospital, Breda, Netherlands. FAU - The, Bertram AU - The B AD - Foundation for Orthopaedic Research, Care & Education (FORCE), Amphia Hospital, Breda, Netherlands. FAU - Eygendaal, Denise AU - Eygendaal D AD - Department of Orthopaedics and Sports Medicine, Erasmus University Medical Center, Rotterdam, Netherlands; Foundation for Orthopaedic Research, Care & Education (FORCE), Amphia Hospital, Breda, Netherlands. LA - eng PT - Journal Article DEP - 20220722 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - VG2QF83CGL (Meloxicam) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Humans MH - Indomethacin/therapeutic use MH - Meloxicam/therapeutic use MH - Middle Aged MH - *Ossification, Heterotopic/drug therapy/etiology/prevention & control MH - Reproducibility of Results MH - Retrospective Studies MH - Rupture/surgery MH - *Tendon Injuries/surgery MH - Tendons OTO - NOTNLM OT - Heterotopic ossifications OT - distal biceps tendon OT - elbow OT - indomethacin OT - meloxicam OT - prophylaxis OT - repair OT - single incision EDAT- 2022/07/26 06:00 MHDA- 2022/09/21 06:00 CRDT- 2022/07/25 01:51 PHST- 2022/01/24 00:00 [received] PHST- 2022/05/22 00:00 [revised] PHST- 2022/06/05 00:00 [accepted] PHST- 2022/07/26 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/07/25 01:51 [entrez] AID - S1058-2746(22)00566-3 [pii] AID - 10.1016/j.jse.2022.06.002 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2022 Oct;31(10):2157-2163. doi: 10.1016/j.jse.2022.06.002. Epub 2022 Jul 22. PMID- 18198777 OWN - NLM STAT- MEDLINE DCOM- 20080221 LR - 20191029 IS - 0147-7447 (Print) IS - 0147-7447 (Linking) VI - 30 IP - 12 DP - 2007 Dec TI - Perioperative care of the patient with osteogenesis imperfecta. PG - 1043-9 LID - 10.3928/01477447-20071201-12 [doi] AB - Osteogenesis imperfecta is an inherited disorder of the connective tissue whose primary manifestation is an increased susceptibility to fractures. Severely affected patients often suffer multiple fractures after minimal or no trauma. In addition to its primary effect on the skeletal system, the alterations in connective tissue may affect several extraskeletal structures, such as the cardiovascular system, sclera, middle and inner ear, tendons/ligaments, central nervous system, and teeth. Patients with osteogenesis imperfecta also have a greater incidence of airway anomalies, thoracic anatomy abnormalities, coagulation dysfunction, hyperthyroidism, and an increased tendency to develop perioperative hyperthermia. Given the multisystem involvement of osteogenesis imperfecta, several issues exist that may impact the perioperative management of these patients. Of particular concern are the associated cardiovascular anomalies, increased incidence of perioperative bleeding, easily fractured bones and teeth, airway anomalies, the tendency to develop intraoperative hyperthermia, and hyperthyroidism. FAU - Stynowick, Gregory A AU - Stynowick GA AD - Department of Anesthesiology University of Missouri, 3W40H, One Hospital Dr, Columbia, MO 65212, USA. FAU - Tobias, Joseph D AU - Tobias JD LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Anti-Bacterial Agents) RN - 7C782967RD (Ampicillin) SB - IM MH - Adolescent MH - Ampicillin/therapeutic use MH - Anti-Bacterial Agents/therapeutic use MH - Child MH - Endocarditis, Bacterial/complications/*prevention & control MH - Female MH - Femur/*surgery MH - Humans MH - Male MH - Osteogenesis Imperfecta/complications/*surgery MH - Osteotomy/*methods MH - Perioperative Care/*methods MH - Tibia/*surgery EDAT- 2008/01/18 09:00 MHDA- 2008/02/22 09:00 CRDT- 2008/01/18 09:00 PHST- 2008/01/18 09:00 [pubmed] PHST- 2008/02/22 09:00 [medline] PHST- 2008/01/18 09:00 [entrez] AID - 10.3928/01477447-20071201-12 [doi] PST - ppublish SO - Orthopedics. 2007 Dec;30(12):1043-9. doi: 10.3928/01477447-20071201-12. PMID- 14443736 OWN - NLM STAT- MEDLINE DCOM- 19981101 LR - 20181201 IS - 0036-7672 (Print) IS - 0036-7672 (Linking) VI - 90 DP - 1960 Jul 16 TI - [The alcoholization of the tendons-a further possibility of therapy in spastic paralyses]. PG - 781-2 FAU - SCHULER, C AU - SCHULER C LA - ger PT - Journal Article PL - Switzerland TA - Schweiz Med Wochenschr JT - Schweizerische medizinische Wochenschrift JID - 0404401 RN - 3K9958V90M (Ethanol) SB - OM MH - Ethanol/*pharmacology MH - Humans MH - Muscle Spasticity/*therapy MH - Paralysis/*therapy MH - Tendons/*pharmacology OTO - NLM OT - *ALCOHOL, ETHYL/pharmacology OT - *PARALYSIS, SPASTIC/therapy OT - *TENDONS/pharmacology EDAT- 1960/07/16 00:00 MHDA- 1960/07/16 00:01 CRDT- 1960/07/16 00:00 PHST- 1960/07/16 00:00 [pubmed] PHST- 1960/07/16 00:01 [medline] PHST- 1960/07/16 00:00 [entrez] PST - ppublish SO - Schweiz Med Wochenschr. 1960 Jul 16;90:781-2. PMID- 3525029 OWN - NLM STAT- MEDLINE DCOM- 19860916 LR - 20171116 IS - 0009-4722 (Print) IS - 0009-4722 (Linking) VI - 57 IP - 5 DP - 1986 May TI - [Effectiveness of tetrachlorodecaoxide (TCDO) in the treatment of complicated disorders of wound healing. A controlled study: TCDO versus PVP-iodine complex]. PG - 334-9 AB - In a controlled study on the treatment of wound-healing impairments 29 patients underwent local treatment with TCDO (Oxoferin) while Beta-isodona was used in 31 cases. Regarding the criterion of reducing the wound area, i.e. epithelization, a highly significant superiority of Oxoferin could be demonstrated in the treatment of complicated wounds. The evaluation of the state of granulation, that was documented by a semiquantitative procedure, indicated that Oxoferin tends to be slightly superior. However, the following observations have to be emphasized: Oxoferin induces a development of granulation tissue on exposed tendons, bones, and fasciae and the granular tissue is of much better quality than after treatment with Betaisodona. Concerning its effect on the degree of contamination, Oxoferin proved to be at least as efficacious as the established and effective antiseptic Betaisodona. Both substances are tolerated well and the application is simple, they do not differ here. FAU - Zenker, W AU - Zenker W FAU - Thiede, A AU - Thiede A FAU - Dommes, M AU - Dommes M FAU - Ullmann, U AU - Ullmann U LA - ger PT - Clinical Trial PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article TT - Die Wirksamkeit von Tetrachlordecaoxid (TCDO) zur Behandlung komplizierter Wundheilungsstörungen. Eine kontrollierte Studie: TCDO versus PVP-Jod-Komplex. PL - Germany TA - Chirurg JT - Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen JID - 16140410R RN - 0 (Oxides) RN - 4R7X1O2820 (Chlorine) RN - 85H0HZU99M (Povidone-Iodine) RN - 92047-76-2 (tetrachlorodecaoxide) RN - FZ989GH94E (Povidone) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Chlorine/*therapeutic use MH - Clinical Trials as Topic MH - Epithelium/drug effects MH - Female MH - Granulation Tissue/drug effects MH - Humans MH - Male MH - Middle Aged MH - Oxides/*therapeutic use MH - Povidone/*analogs & derivatives MH - Povidone-Iodine/*therapeutic use MH - Random Allocation MH - Surgical Wound Infection/*drug therapy MH - Wound Healing/*drug effects MH - Wound Infection/*drug therapy EDAT- 1986/05/01 00:00 MHDA- 1986/05/01 00:01 CRDT- 1986/05/01 00:00 PHST- 1986/05/01 00:00 [pubmed] PHST- 1986/05/01 00:01 [medline] PHST- 1986/05/01 00:00 [entrez] PST - ppublish SO - Chirurg. 1986 May;57(5):334-9. PMID- 4744687 OWN - NLM STAT- MEDLINE DCOM- 19731215 LR - 20031114 IS - 0001-6217 (Print) IS - 0001-6217 (Linking) VI - 21 IP - 2 DP - 1973 TI - Submicroscopic investigation of homologous tendon grafts preserved by means of different methods. PG - 175-97 FAU - Salamon, G AU - Salamon G FAU - Deák, G AU - Deák G FAU - Hámori, J AU - Hámori J FAU - Mayer, F AU - Mayer F FAU - Temes, G AU - Temes G LA - eng PT - Journal Article PL - Hungary TA - Acta Morphol Acad Sci Hung JT - Acta morphologica Academiae Scientiarum Hungaricae JID - 0370334 RN - 0 (Anti-Infective Agents, Local) RN - 0 (Benzoates) RN - 0 (Ethylmercury Compounds) RN - 0 (Sulfides) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Anti-Infective Agents, Local/pharmacology MH - Benzoates/pharmacology MH - Collagen MH - Dogs MH - Ethylmercury Compounds/pharmacology MH - Fibroblasts MH - Freezing MH - Microscopy, Electron MH - Microscopy, Polarization MH - Radiation Effects MH - Sulfides/pharmacology MH - Tendons/drug effects/radiation effects/*transplantation MH - *Tissue Preservation MH - Transplantation, Homologous EDAT- 1973/01/01 00:00 MHDA- 1973/01/01 00:01 CRDT- 1973/01/01 00:00 PHST- 1973/01/01 00:00 [pubmed] PHST- 1973/01/01 00:01 [medline] PHST- 1973/01/01 00:00 [entrez] PST - ppublish SO - Acta Morphol Acad Sci Hung. 1973;21(2):175-97. PMID- 4270363 OWN - NLM STAT- MEDLINE DCOM- 19731214 LR - 20190623 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 20 IP - 7 DP - 1971 Jul TI - Effect of D-penicillamine on glycosaminoglycan changes during rabbit tendon regeneration. PG - 1493-500 FAU - Dorner, R W AU - Dorner RW FAU - Coleman, A N AU - Coleman AN FAU - Zuckner, J AU - Zuckner J LA - eng PT - Journal Article PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Chlorides) RN - 0 (Glycosaminoglycans) RN - 0 (Hexosamines) RN - 0 (Pyridinium Compounds) RN - 451W47IQ8X (Sodium Chloride) RN - 9007-27-6 (Chondroitin) RN - 9007-34-5 (Collagen) RN - 96F264O9SV (1-Propanol) RN - GNN1DV99GX (Penicillamine) RN - I38ZP9992A (Magnesium) RN - QTT17582CB (Hydrochloric Acid) RN - RMB44WO89X (Hydroxyproline) RN - Y4S76JWI15 (Methanol) SB - IM MH - 1-Propanol MH - Animals MH - Chlorides MH - Chondroitin/metabolism MH - Chromatography MH - Collagen/metabolism MH - Glycosaminoglycans/analysis/*metabolism MH - Hexosamines/metabolism MH - Hydrochloric Acid MH - Hydroxyproline/metabolism MH - In Vitro Techniques MH - Kinetics MH - Magnesium MH - Methanol MH - Penicillamine/*pharmacology MH - Pyridinium Compounds MH - Rabbits MH - Regeneration/*drug effects MH - Sodium Chloride MH - Solubility MH - Tendons/growth & development/*metabolism/surgery MH - Time Factors EDAT- 1971/07/01 00:00 MHDA- 1971/07/01 00:01 CRDT- 1971/07/01 00:00 PHST- 1971/07/01 00:00 [pubmed] PHST- 1971/07/01 00:01 [medline] PHST- 1971/07/01 00:00 [entrez] AID - 0006-2952(71)90277-2 [pii] AID - 10.1016/0006-2952(71)90277-2 [doi] PST - ppublish SO - Biochem Pharmacol. 1971 Jul;20(7):1493-500. doi: 10.1016/0006-2952(71)90277-2. PMID- 3919711 OWN - NLM STAT- MEDLINE DCOM- 19850419 LR - 20220318 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 225 IP - 3 DP - 1985 Feb 1 TI - Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. PG - 745-52 AB - Rabbit forelimb tendons incubated for 15 or 21 days at 35 degrees C in the presence of 8 or 24 mg of glucose/ml were shown to change their chemical, biochemical and mechanical characteristics. The tendons treated with glucose contained up to three times as much hexosyl-lysine and hexosylhydroxylysine as did control tendons as judged by assay of NaB3H4-reduced samples. Measurement of the force generated on thermal contraction showed significant increases in glycosylated tendons compared with controls, indicating the formation of new covalent stabilizing bonds. This conclusion was supported by the decreased solubility of intact tendons and re-formed fibres glycosylated in vitro, and by the evidence from peptide maps of CNBr-digested glucose-incubated tendons. The latter, when compared with peptide maps of control tendons, revealed the presence of additional high-Mr peptide material. These peptides appear to be cross-linked by a new type of covalent bond stable to mild thermal and chemical treatment. This system in vitro provides a readily controlled model for the study of the chemistry of changes brought about in collagen by non-enzymic glycosylation in diabetes. FAU - Kent, M J AU - Kent MJ FAU - Light, N D AU - Light ND FAU - Bailey, A J AU - Bailey AJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Peptide Fragments) RN - 9007-34-5 (Collagen) RN - IY9XDZ35W2 (Glucose) RN - OS382OHJ8P (Cyanogen Bromide) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Chemical Phenomena MH - Chemistry MH - Collagen/*metabolism MH - Cyanogen Bromide/pharmacology MH - Electrophoresis, Polyacrylamide Gel MH - Glucose/*pharmacology MH - Glutaral/pharmacology MH - In Vitro Techniques MH - Isometric Contraction MH - Peptide Fragments/analysis MH - Rabbits MH - Rats MH - Tendons/drug effects/*metabolism PMC - PMC1144652 EDAT- 1985/02/01 00:00 MHDA- 1985/02/01 00:01 PMCR- 1985/08/01 CRDT- 1985/02/01 00:00 PHST- 1985/02/01 00:00 [pubmed] PHST- 1985/02/01 00:01 [medline] PHST- 1985/02/01 00:00 [entrez] PHST- 1985/08/01 00:00 [pmc-release] AID - 10.1042/bj2250745 [doi] PST - ppublish SO - Biochem J. 1985 Feb 1;225(3):745-52. doi: 10.1042/bj2250745. PMID- 6478819 OWN - NLM STAT- MEDLINE DCOM- 19841101 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 12 IP - 3-4 DP - 1984 TI - Effect of monensin on secretion of basement membrane collagen by cultured rabbit corneal endothelial cells in comparison with rabbit tendon fibroblasts. PG - 179-90 AB - Monensin, a monovalent ionophore, affects differently the secretion of basement membrane collagen and interstitial procollagen. At 1 X 10(-8) M, monensin inhibited only slightly the secretion of procollagen synthesized by tendon cells while secretion of basement membrane collagen synthesized by endothelial cells was inhibited by 43% after 2 hours of labelling. At higher concentration (1 X 10(-6) M), the secretion of type I procollagen by tendon cells was inhibited after two h (36%) or 24 h (24%) of labelling. The pattern of basement membrane collagen secretion varied from inhibition to stimulation depending on the labeling time. No changes in the phenotypic expression of collagen were observed in either the monensin-treated tendon cultures or endothelial cells. Phase-contrast microscopy revealed differential responses of cells to monensin: tendon cells appeared spindle-shaped or rounded-up, in contrast to the enlarged shape displayed by endothelial cells. FAU - Kay, E P AU - Kay EP FAU - Jester, J V AU - Jester JV FAU - Smith, R E AU - Smith RE FAU - Nimni, M E AU - Nimni ME LA - eng GR - I RO1-01993/PHS HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Furans) RN - 0 (Procollagen) RN - 9007-34-5 (Collagen) RN - 906O0YJ6ZP (Monensin) SB - IM MH - Animals MH - Basement Membrane/*metabolism MH - Cells, Cultured MH - Collagen/*metabolism MH - Cornea/*metabolism MH - Endothelium/metabolism MH - Fibroblasts/metabolism MH - Furans/*pharmacology MH - Kinetics MH - Monensin/*pharmacology MH - Organ Specificity MH - Procollagen/biosynthesis/*metabolism MH - Rabbits MH - Tendons/*metabolism EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] AID - 10.3109/03008208409013680 [doi] PST - ppublish SO - Connect Tissue Res. 1984;12(3-4):179-90. doi: 10.3109/03008208409013680. PMID- 173570 OWN - NLM STAT- MEDLINE DCOM- 19760320 LR - 20190629 IS - 0014-4754 (Print) IS - 0014-4754 (Linking) VI - 31 IP - 10 DP - 1975 Oct 15 TI - Studies on ageing of collagen by perchlorate reactions. PG - 1183-6 FAU - Verzár, F AU - Verzár F FAU - Strittmatter-Ackerschott, E AU - Strittmatter-Ackerschott E LA - eng PT - Journal Article PL - Switzerland TA - Experientia JT - Experientia JID - 0376547 RN - 0 (Aldehydes) RN - 0 (Perchlorates) RN - 9007-34-5 (Collagen) RN - AE28F7PNPL (Methionine) SB - IM MH - *Aging MH - Aldehydes/pharmacology MH - Animals MH - *Collagen/analysis MH - Elasticity MH - Methionine/pharmacology MH - Perchlorates/pharmacology MH - Rats MH - Tendons/*analysis/drug effects EDAT- 1975/10/15 00:00 MHDA- 1975/10/15 00:01 CRDT- 1975/10/15 00:00 PHST- 1975/10/15 00:00 [pubmed] PHST- 1975/10/15 00:01 [medline] PHST- 1975/10/15 00:00 [entrez] AID - 10.1007/BF02326783 [doi] PST - ppublish SO - Experientia. 1975 Oct 15;31(10):1183-6. doi: 10.1007/BF02326783. PMID- 23681552 OWN - NLM STAT- MEDLINE DCOM- 20140625 LR - 20131125 IS - 1573-6814 (Electronic) IS - 1389-9333 (Linking) VI - 14 IP - 4 DP - 2013 Dec TI - Effect of hydrogen peroxide on human tendon allograft. PG - 667-71 LID - 10.1007/s10561-013-9377-x [doi] AB - Bacterial contamination of tendon allografts at the completion of processing has historically been about 2 %, with tendons that are found to be culture positive being discarded. Treatment of tendon allograft with hydrogen peroxide at the beginning of tissue processing may reduce bacterial contamination, however, the potential side effects of hydrogen peroxide treatment include hydrolysis of the collagen and this may alter the mechanical properties of the graft. Pairs of human tendons were used. One was washed in 3 % hydrogen peroxide for 5 min and the untreated tendon was used as a control. The ultimate tensile strength of the tendons was determined using a material testing machine. A freeze clamp technique was used to hold the tendons securely at the high loads required to cause tendon failure. There was no statistical difference in the ultimate tensile strength between the treated and untreated tendons. Mean strength ranged from Extensor Hallucis Longus at 588 Newtons to Tibialis Posterior at 2,366 Newtons. Hydrogen peroxide washing may reduce bacterial contamination of tendon allograft and does not affect the strength of the tendon. FAU - Gardner, E M H AU - Gardner EM AD - Perth Bone and Tissue Bank, Nedlands, WA, Australia, egardner@doctors.org.uk. FAU - VonderHeide, N AU - VonderHeide N FAU - Fisher, R AU - Fisher R FAU - Brooker, G AU - Brooker G FAU - Yates, P J AU - Yates PJ LA - eng PT - Journal Article DEP - 20130518 PL - Netherlands TA - Cell Tissue Bank JT - Cell and tissue banking JID - 100965121 RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Allografts/*drug effects/physiology MH - Humans MH - Hydrogen Peroxide/*pharmacology MH - Materials Testing MH - Stress, Mechanical MH - Tendons/*drug effects/physiology MH - Tensile Strength EDAT- 2013/05/18 06:00 MHDA- 2014/06/26 06:00 CRDT- 2013/05/18 06:00 PHST- 2013/01/19 00:00 [received] PHST- 2013/04/29 00:00 [accepted] PHST- 2013/05/18 06:00 [entrez] PHST- 2013/05/18 06:00 [pubmed] PHST- 2014/06/26 06:00 [medline] AID - 10.1007/s10561-013-9377-x [doi] PST - ppublish SO - Cell Tissue Bank. 2013 Dec;14(4):667-71. doi: 10.1007/s10561-013-9377-x. Epub 2013 May 18. PMID- 10672798 OWN - NLM STAT- MEDLINE DCOM- 20000225 LR - 20090608 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 24 IP - 6 DP - 1999 Dec TI - Cytotoxicity of cyanoacrylate adhesives to cultured tendon cells. PG - 658-61 AB - The in vitro cytotoxicity of four cyanoacrylate adhesives was tested using cultures of cells derived from human tendons. All four were found to be cytotoxic, even at concentrations as low as 1.7%, over the experimental period of up to 18 weeks. This study shows that such adhesives in their present state may not be suitable for re-joining cut tendons as their initial and long-term toxicity may hinder the slow healing process of tendons. FAU - Evans, C E AU - Evans CE AD - Department of Orthopaedic Surgery, University of Manchester, UK. cevans@fs1.ho.man.ac.uk FAU - Lees, G C AU - Lees GC FAU - Trail, I A AU - Trail IA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Cyanoacrylates) RN - 0 (Tissue Adhesives) SB - IM MH - Cells, Cultured MH - Cyanoacrylates/*toxicity MH - Humans MH - Tendons/cytology/*drug effects MH - Tissue Adhesives/*toxicity EDAT- 2000/02/15 09:00 MHDA- 2000/03/04 09:00 CRDT- 2000/02/15 09:00 PHST- 2000/02/15 09:00 [pubmed] PHST- 2000/03/04 09:00 [medline] PHST- 2000/02/15 09:00 [entrez] AID - S0266-7681(99)90279-6 [pii] AID - 10.1054/jhsb.1999.0279 [doi] PST - ppublish SO - J Hand Surg Br. 1999 Dec;24(6):658-61. doi: 10.1054/jhsb.1999.0279. PMID- 31262555 OWN - NLM STAT- MEDLINE DCOM- 20200312 LR - 20200312 IS - 1873-4030 (Electronic) IS - 1350-4533 (Linking) VI - 71 DP - 2019 Sep TI - Morphologically bioinspired hierarchical nylon 6,6 electrospun assembly recreating the structure and performance of tendons and ligaments. PG - 79-90 LID - S1350-4533(19)30113-4 [pii] LID - 10.1016/j.medengphy.2019.06.019 [doi] AB - Reconstructions of ruptured tendons and ligaments currently have dissatisfactory failure rate. Failures are mainly due to the mechanical mismatch of commercial implants with respect to the host tissue. In fact, it is crucial to replicate the morphology (hierarchical in nature) and mechanical response (highly-nonlinear) of natural tendons and ligaments. The aim of this study was to develop morphologically bioinspired hierarchical Nylon 6,6 electrospun assemblies recreating the structure and performance of tendons and ligaments. First, we built different electrospun bundles to find the optimal orientation of the nanofibers. A 2nd-level hierarchical assembly was fabricated with a dedicated process that allowed tightly joining the bundles one next to the other with an electrospun sheath, so as to improve the mechanical performance. Finally, a further hierarchical 3rd-level assembly was constructed by grouping several 2nd-level assemblies. The morphology of the different structures was assessed with scanning electron microscopy and high-resolution X-ray tomography, which allowed measuring the directionality of the nanofibers in the bundles and in the sheaths. The mechanical properties of the single bundles and of the 2nd-level assemblies were measured with tensile tests. The single bundles and the hierarchical assemblies showed morphology and directionality of the nanofibers similar to the tendons and ligaments. The strength and stiffness were comparable to that of tendons and ligaments. In conclusion, this work showed an innovative electrospinning production process to build nanofibrous Nylon 6,6 hierarchical assemblies which are suitable as future implantable devices and able to mimic the multiscale morphology and the biomechanical properties of tendons and ligaments. CI - Copyright © 2019 IPEM. All rights reserved. FAU - Sensini, Alberto AU - Sensini A AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy. FAU - Gotti, Carlo AU - Gotti C AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy. FAU - Belcari, Juri AU - Belcari J AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy. FAU - Zucchelli, Andrea AU - Zucchelli A AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy. FAU - Focarete, Maria Letizia AU - Focarete ML AD - Department of Chemistry 'G. Ciamician' and National Consortium of Materials Science and Technology (INSTM, Bologna RU), Alma Mater Studiorum-University of Bologna, I-40126 Bologna, Italy; Health Sciences and Technologies-Interdepartmental Center for Industrial Research (CIRI-HST), Alma Mater Studiorum-University of Bologna, I-40064 Ozzano dell'Emilia, Bologna, Italy. FAU - Gualandi, Chiara AU - Gualandi C AD - Department of Chemistry 'G. Ciamician' and National Consortium of Materials Science and Technology (INSTM, Bologna RU), Alma Mater Studiorum-University of Bologna, I-40126 Bologna, Italy; Advanced Mechanics and Materials - Interdepartmental Center for Industrial Research (CIRI-MAM), Alma Mater Studiorum-University of Bologna, I-40123 Bologna, Italy. FAU - Todaro, Ivan AU - Todaro I AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy. FAU - Kao, Alexander P AU - Kao AP AD - Zeiss Global Centre, School of Mechanical and Design Engineering, University of Portsmouth, Portsmouth PO1 3DJ, United Kingdom. FAU - Tozzi, Gianluca AU - Tozzi G AD - Zeiss Global Centre, School of Mechanical and Design Engineering, University of Portsmouth, Portsmouth PO1 3DJ, United Kingdom. FAU - Cristofolini, Luca AU - Cristofolini L AD - Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, I-40131 Bologna, Italy; Health Sciences and Technologies-Interdepartmental Center for Industrial Research (CIRI-HST), Alma Mater Studiorum-University of Bologna, I-40064 Ozzano dell'Emilia, Bologna, Italy. Electronic address: luca.cristofolini@unibo.it. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190629 PL - England TA - Med Eng Phys JT - Medical engineering & physics JID - 9422753 RN - 0 (Polymers) RN - 25038-54-4 (nylon 6) RN - 6879X594Z8 (Caprolactam) SB - IM MH - Biomechanical Phenomena/drug effects MH - Biomimetics/*methods MH - Caprolactam/*analogs & derivatives/chemistry/pharmacology MH - Ligaments/cytology/*drug effects/physiology MH - Materials Testing MH - Nanofibers/chemistry MH - Polymers/chemistry/*pharmacology MH - Tendons/cytology/*drug effects/physiology MH - Tissue Engineering MH - Tissue Scaffolds/chemistry OTO - NOTNLM OT - Bioinspired structures OT - Electrospinning OT - Hierarchical devices OT - Tendons and Ligaments EDAT- 2019/07/03 06:00 MHDA- 2020/03/13 06:00 CRDT- 2019/07/03 06:00 PHST- 2019/02/01 00:00 [received] PHST- 2019/05/17 00:00 [revised] PHST- 2019/06/19 00:00 [accepted] PHST- 2019/07/03 06:00 [pubmed] PHST- 2020/03/13 06:00 [medline] PHST- 2019/07/03 06:00 [entrez] AID - S1350-4533(19)30113-4 [pii] AID - 10.1016/j.medengphy.2019.06.019 [doi] PST - ppublish SO - Med Eng Phys. 2019 Sep;71:79-90. doi: 10.1016/j.medengphy.2019.06.019. Epub 2019 Jun 29. PMID- 645262 OWN - NLM STAT- MEDLINE DCOM- 19780612 LR - 20140725 IS - 0044-409X (Print) IS - 0044-409X (Linking) VI - 103 IP - 2 DP - 1978 TI - [Application of homologous tendons and ligaments (author's transl)]. PG - 98-107 AB - The report deals with the postoperative results of homologous cialit-preserved tendons and ligaments in 237 patients with 281 homologous cialit-preserved transplants. This material proved to be equally effective to the autologous and even superior to it when grafting flexor tendons of the finger. COMPLICATIONS: 4.7% disturbed woundhealing, 5.2% infections, 5.5% mechanical insufficiency. FAU - Ansorge, D AU - Ansorge D FAU - Franke, A AU - Franke A LA - ger PT - English Abstract PT - Journal Article TT - Anwendungsmöglichkeiten homologer cialitkonservierter Sehnen und Bänder. PL - Germany TA - Zentralbl Chir JT - Zentralblatt fur Chirurgie JID - 0413645 RN - 0 (Ethylmercury Compounds) RN - 16509-11-8 (Cialit) SB - IM MH - Cialit/*pharmacology MH - Ethylmercury Compounds/*pharmacology MH - Humans MH - Joints/surgery MH - Ligaments/*transplantation MH - Postoperative Complications MH - Tendons/*transplantation MH - Tissue Preservation/methods MH - Transplantation, Homologous EDAT- 1978/01/01 00:00 MHDA- 1978/01/01 00:01 CRDT- 1978/01/01 00:00 PHST- 1978/01/01 00:00 [pubmed] PHST- 1978/01/01 00:01 [medline] PHST- 1978/01/01 00:00 [entrez] PST - ppublish SO - Zentralbl Chir. 1978;103(2):98-107. PMID- 7326397 OWN - NLM STAT- MEDLINE DCOM- 19820412 LR - 20191023 IS - 0006-355X (Print) IS - 0006-355X (Linking) VI - 18 IP - 3-6 DP - 1981 TI - The order-disorder transitions in fibrillar proteins. Stress-temperature dependence of hydrothermal contraction of the native collagen fibers. PG - 601-18 FAU - Kukhareva, L V AU - Kukhareva LV FAU - Vorob'ev, V I AU - Vorob'ev VI LA - eng PT - Journal Article PL - United States TA - Biorheology JT - Biorheology JID - 0372526 RN - 0 (Benzoquinones) RN - 0 (Quinones) RN - 3T006GV98U (quinone) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - *Benzoquinones MH - *Collagen/physiology MH - Quinones/pharmacology MH - Rats MH - Stress, Mechanical MH - Tail MH - Temperature MH - Tendons/analysis/drug effects MH - Thermodynamics EDAT- 1981/01/01 00:00 MHDA- 1981/01/01 00:01 CRDT- 1981/01/01 00:00 PHST- 1981/01/01 00:00 [pubmed] PHST- 1981/01/01 00:01 [medline] PHST- 1981/01/01 00:00 [entrez] AID - 10.3233/bir-1981-183-623 [doi] PST - ppublish SO - Biorheology. 1981;18(3-6):601-18. doi: 10.3233/bir-1981-183-623. PMID- 35510525 OWN - NLM STAT- MEDLINE DCOM- 20221230 LR - 20230106 IS - 1742-481X (Electronic) IS - 1742-4801 (Print) IS - 1742-4801 (Linking) VI - 20 IP - 1 DP - 2023 Jan TI - Novel application of absorbable gelatine sponge combined with polyurethane film for dermal reconstruction of wounds with bone or tendon exposure. PG - 18-27 LID - 10.1111/iwj.13832 [doi] AB - Trauma, burns, and diabetes result in nonhealing wounds that can cause bone or tendon exposure, a significant health threat. The use of an artificial regeneration template combined with skin grafting as an alternative method to highly invasive flap surgery has been shown to be an effective way to cover full-thickness skin defects with bone or tendon exposure for both functional and aesthetic recovery. However, artificial regeneration templates, such as Pelnac, are overwhelmingly expensive, limiting their clinical use. Here, we demonstrate for the first time that polyurethane film combined with absorbable gelatine sponge, affordable materials widely used for haemostasis, are effective for dermal reconstruction in wounds with bone or tendon exposure. The absorbable gelatine sponge combined with polyurethane film was applied to eight patients, all resulting in adequate granulation that fully covered the exposed bone or tendon. The outcome of absorbable gelatine sponge combined with polyurethane film application indicates that this approach is a potential novel and cost-effective dermal reconstruction strategy for the treatment of severe wounds with bone or tendon exposure. CI - © 2022 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd. FAU - Yu, Pan AU - Yu P AD - Department of Burn and Plastic Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China. FAU - Hong, Nan AU - Hong N AD - Department of Burn and Plastic Surgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China. AD - Department of Dermatology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen, China. FAU - Chen, Min AU - Chen M AD - Department of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, China. FAU - Zou, Xianbiao AU - Zou X AD - Department of Dermatology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen, China. LA - eng GR - CLB20J022/Medical Technology Foundation/ PT - Journal Article DEP - 20220505 PL - England TA - Int Wound J JT - International wound journal JID - 101230907 RN - 0 (Polyurethanes) SB - IM MH - Humans MH - *Wound Healing MH - Polyurethanes/therapeutic use MH - Skin Transplantation/methods MH - Surgical Flaps MH - Tendons MH - *Skin, Artificial PMC - PMC9797930 OTO - NOTNLM OT - absorbable gelatine sponge OT - artificial dermis OT - full-thickness skin defect OT - polyurethane film OT - wound healing COIS- All authors hereby declare that they have no conflicts of interest. EDAT- 2022/05/06 06:00 MHDA- 2022/12/31 06:00 PMCR- 2022/05/05 CRDT- 2022/05/05 04:52 PHST- 2022/04/19 00:00 [revised] PHST- 2022/03/14 00:00 [received] PHST- 2022/04/21 00:00 [accepted] PHST- 2022/05/06 06:00 [pubmed] PHST- 2022/12/31 06:00 [medline] PHST- 2022/05/05 04:52 [entrez] PHST- 2022/05/05 00:00 [pmc-release] AID - IWJ13832 [pii] AID - 10.1111/iwj.13832 [doi] PST - ppublish SO - Int Wound J. 2023 Jan;20(1):18-27. doi: 10.1111/iwj.13832. Epub 2022 May 5. PMID- 17223585 OWN - NLM STAT- MEDLINE DCOM- 20070313 LR - 20070226 IS - 1528-395X (Electronic) IS - 1079-2104 (Linking) VI - 103 IP - 3 DP - 2007 Mar TI - Osteogenesis imperfecta. PG - 314-20 AB - Osteogenesis imperfecta is a relatively common hereditary connective tissue disorder characterized by bone fragility and fractures. Other frequently affected tissues include tendons, ligaments, skin, sclera, teeth, and middle and inner ear. Molecular studies have demonstrated that most cases result from mutations affecting the genes responsible for the formation of type 1 collagen. The phenotypic presentation varies from mild to lethal. Commonly observed dental abnormalities include dentinogenesis imperfecta and malocclusion. Medical therapies using bisphosphonates have resulted in reduced fracture risk and decreased bone pain. To date, no cases of bisphosphonate-associated osteonecrosis have been reported. With appropriate precautions, the patient with osteogenesis imperfecta can tolerate and benefit from the delivery of necessary dental care to control oral disease, improve function, and improve esthetics. FAU - Huber, Michaell A AU - Huber MA AD - Division of Oral Medicine, Department of Dental Diagnostic Science, University of Texas Health Science Center at San Antonio, Dental School, San Antonio, TX 78229, USA. huberm@uthscsa.edu LA - eng PT - Journal Article DEP - 20070112 PL - United States TA - Oral Surg Oral Med Oral Pathol Oral Radiol Endod JT - Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics JID - 9508562 RN - 0 (Bone Density Conservation Agents) RN - 0 (Collagen Type I) RN - 0 (Diphosphonates) SB - IM MH - Bone Density Conservation Agents/*therapeutic use MH - Collagen Type I/genetics MH - *Dental Care for Chronically Ill MH - Dentinogenesis Imperfecta/drug therapy/etiology/*pathology MH - Diphosphonates/*therapeutic use MH - Humans MH - Malocclusion/etiology/therapy MH - Osteogenesis Imperfecta/classification/complications/*drug therapy/genetics EDAT- 2007/01/16 09:00 MHDA- 2007/03/14 09:00 CRDT- 2007/01/16 09:00 PHST- 2006/03/24 00:00 [received] PHST- 2006/09/27 00:00 [revised] PHST- 2006/10/04 00:00 [accepted] PHST- 2007/01/16 09:00 [pubmed] PHST- 2007/03/14 09:00 [medline] PHST- 2007/01/16 09:00 [entrez] AID - S1079-2104(06)00803-1 [pii] AID - 10.1016/j.tripleo.2006.10.003 [doi] PST - ppublish SO - Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103(3):314-20. doi: 10.1016/j.tripleo.2006.10.003. Epub 2007 Jan 12. PMID- 4053393 OWN - NLM STAT- MEDLINE DCOM- 19851218 LR - 20190706 IS - 0009-8981 (Print) IS - 0009-8981 (Linking) VI - 152 IP - 1-2 DP - 1985 Oct 31 TI - Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis. PG - 115-22 AB - Patients suffering from cerebrotendinous xanthomatosis, an inborn error of metabolism in bile acid synthesis, were given oral treatment with chenodeoxycholic acid, ursodeoxycholic acid, cholic acid and taurocholic acid. The effectiveness of the different therapies was evaluated by measuring the urinary excretion of 5 beta-cholestane-3 alpha,7 alpha,12 alpha,23,25-pentol, which should decrease, when the administered bile acid is able to suppress endogenous bile acid synthesis. From the results it is concluded that chenodeoxycholic acid and cholic acid activate the bile acid negative feedback mechanism, contrary to ursodeoxycholic acid and taurine conjugated cholic acid. Either cholic acid or chenodeoxycholic acid are the therapies of choice for the treatment of cerebrotendinous xanthomatosis. For various reasons the use of cholic acid is especially recommended. FAU - Koopman, B J AU - Koopman BJ FAU - Wolthers, B G AU - Wolthers BG FAU - van der Molen, J C AU - van der Molen JC FAU - Waterreus, R J AU - Waterreus RJ LA - eng PT - Journal Article PL - Netherlands TA - Clin Chim Acta JT - Clinica chimica acta; international journal of clinical chemistry JID - 1302422 RN - 0 (Bile Acids and Salts) RN - 0 (Cholestanols) RN - 0 (Cholic Acids) RN - 0GEI24LG0J (Chenodeoxycholic Acid) RN - 5E090O0G3Z (Taurocholic Acid) RN - 6127-75-9 (5 beta-bufol) RN - 724L30Y2QR (Ursodeoxycholic Acid) RN - G1JO7801AE (Cholic Acid) SB - IM MH - Adult MH - Aged MH - Bile Acids and Salts/*therapeutic use MH - Brain Diseases/complications/drug therapy MH - Chenodeoxycholic Acid/therapeutic use MH - Cholestanols/urine MH - Cholic Acid MH - Cholic Acids/therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Taurocholic Acid/therapeutic use MH - Tendons MH - Ursodeoxycholic Acid/therapeutic use MH - Xanthomatosis/*drug therapy EDAT- 1985/10/31 00:00 MHDA- 1985/10/31 00:01 CRDT- 1985/10/31 00:00 PHST- 1985/10/31 00:00 [pubmed] PHST- 1985/10/31 00:01 [medline] PHST- 1985/10/31 00:00 [entrez] AID - 0009-8981(85)90182-2 [pii] AID - 10.1016/0009-8981(85)90182-2 [doi] PST - ppublish SO - Clin Chim Acta. 1985 Oct 31;152(1-2):115-22. doi: 10.1016/0009-8981(85)90182-2. PMID- 40203131 OWN - NLM STAT- MEDLINE DCOM- 20250409 LR - 20251022 IS - 2160-3251 (Electronic) IS - 2160-3251 (Linking) VI - 15 IP - 2 DP - 2025 Apr 1 TI - Diagnostic Challenges and Complex Surgical Management of an Atypical Mycoplasma Infection From a Cat Scratch: A Case Report. LID - 10.2106/JBJS.CC.25.00071 [doi] AB - CASE: A 58-year-old veterinarian presented with a dorsal-radial hand and wrist infection after a catch scratch. Despite multiple courses of broad-spectrum antibiotics, her symptoms progressed culminating in rupture of the first dorsal compartment tendons. An unspecified Mycoplasma species was identified through broad-range bacterial PCR testing. The patient was then started on oral doxycycline which, combined with serial debridement and eventual tenolysis, resulted in successful eradication of her infection and functional improvement. CONCLUSION: Our case highlights the power of clinical utility of broad-range bacterial PCR in detecting atypical infections; this modality should be considered in infections caused by cat scratches with otherwise negative cultures. CI - Copyright © 2025 by The Journal of Bone and Joint Surgery, Incorporated. FAU - Lauck, Bradley J AU - Lauck BJ AUID- ORCID: 0000-0001-6071-8944 AD - The University of North Carolina School of Medicine, Chapel Hill, North Carolina. FAU - Dicks, Kristen V AU - Dicks KV AUID- ORCID: 0009-0006-2045-9590 AD - Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. FAU - Pidgeon, Tyler AU - Pidgeon T AUID- ORCID: 0000-0002-0300-2883 AD - Department of Orthopaedic Surgery, Duke University Hospital, Durham, North Carolina. LA - eng PT - Case Reports PT - Journal Article DEP - 20250409 PL - United States TA - JBJS Case Connect JT - JBJS case connector JID - 101596828 RN - 0 (Anti-Bacterial Agents) RN - N12000U13O (Doxycycline) SB - IM MH - Humans MH - Middle Aged MH - Female MH - *Mycoplasma Infections/diagnosis/surgery/microbiology MH - Cats MH - Animals MH - Anti-Bacterial Agents/therapeutic use MH - *Cat-Scratch Disease/diagnosis MH - Doxycycline/therapeutic use MH - Debridement OTO - NOTNLM OT - cat scratch OT - diagnostic challenges OT - infectious tenosynovitis OT - mycoplasma infection COIS- Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSCC/C591). EDAT- 2025/04/09 18:26 MHDA- 2025/04/09 18:27 CRDT- 2025/04/09 14:12 PHST- 2025/04/09 18:27 [medline] PHST- 2025/04/09 18:26 [pubmed] PHST- 2025/04/09 14:12 [entrez] AID - 01709767-202506000-00009 [pii] AID - 10.2106/JBJS.CC.25.00071 [doi] PST - epublish SO - JBJS Case Connect. 2025 Apr 9;15(2). doi: 10.2106/JBJS.CC.25.00071. eCollection 2025 Apr 1. PMID- 13632710 OWN - NLM STAT- MEDLINE DCOM- 20000701 LR - 20190618 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 183 IP - 4657 DP - 1959 Jan 31 TI - Effect of cross-linking by formaldehyde on the contraction-relaxation of rat tail tendon. PG - 332-3 FAU - ELDEN, H R AU - ELDEN HR LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 1HG84L3525 (Formaldehyde) SB - OM MH - Animals MH - Formaldehyde/*pharmacology MH - Rats MH - Tendons/*drug effects OID - CLML: 5936:6541:213:525 OTO - NLM OT - *FORMALDEHYDE/effects OT - *TENDONS/effect of drugs on EDAT- 1959/01/31 00:00 MHDA- 1959/01/31 00:01 CRDT- 1959/01/31 00:00 PHST- 1959/01/31 00:00 [pubmed] PHST- 1959/01/31 00:01 [medline] PHST- 1959/01/31 00:00 [entrez] AID - 10.1038/183332a0 [doi] PST - ppublish SO - Nature. 1959 Jan 31;183(4657):332-3. doi: 10.1038/183332a0. PMID- 4762896 OWN - NLM STAT- MEDLINE DCOM- 19740212 LR - 20131121 IS - 0046-6794 (Print) IS - 0046-6794 (Linking) VI - 5 IP - 2 DP - 1973 Feb TI - [Management of adhesions of flexor tendon grafts]. PG - 85-7 FAU - Schmidt, A AU - Schmidt A FAU - Seiffert, K E AU - Seiffert KE LA - ger PT - Journal Article TT - Zur Beeinflussung der Verwachsungen von Beugesehnentransplantaten. PL - Germany TA - Handchirurgie JT - Handchirurgie JID - 1252612 RN - GNN1DV99GX (Penicillamine) SB - IM MH - Animals MH - Chickens MH - Penicillamine/*pharmacology MH - Postoperative Complications/*prevention & control MH - Tendon Transfer/*adverse effects MH - Tendons/drug effects/transplantation MH - Tissue Adhesions MH - Transplantation, Autologous EDAT- 1973/02/01 00:00 MHDA- 1973/02/01 00:01 CRDT- 1973/02/01 00:00 PHST- 1973/02/01 00:00 [pubmed] PHST- 1973/02/01 00:01 [medline] PHST- 1973/02/01 00:00 [entrez] PST - ppublish SO - Handchirurgie. 1973 Feb;5(2):85-7. PMID- 27832632 OWN - NLM STAT- MEDLINE DCOM- 20170206 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 39 IP - 6 DP - 2016 TI - Autophagy Prevents Oxidative Stress-Induced Loss of Self-Renewal Capacity and Stemness in Human Tendon Stem Cells by Reducing ROS Accumulation. PG - 2227-2238 AB - BACKGROUND/AIMS: Tendon stem cells (TSCs) exhibit a high self-renewal capacity, multi-differentiation potential, and low immunogenicity; thus, these cells might provide a new cell source for tendon repair and regeneration. TSCs are exposed to increased oxidative stress at tendon injury sites; however, how TSCs maintain their stemness under oxidative stress is not clear. METHODS AND RESULTS: In this study, we found that H2O2 treatment increased ROS accumulation in human TSCs (hTSCs) and resulted in loss of self-renewal capacity and stemness, as reflected in reduced colony formation and proliferation, decreased expression of the stemness markers Nanog, Oct-4, NS, and SSEA-4, and impaired differentiation capability. These H2O2-induced damages were prevented by pretreatment with starvation or rapamycin. Pretreatment with starvation or rapamycin prior to H2O2 exposure also led to decreased intracellular and mitochondrial ROS accumulation along with increased autophagic activity, as manifested in increased LC3 cleavage, Beclin-1 expression, and GFP-LC3-labeled autophagosome formation. Autophagy inhibition by 3-MA or CQ, or by shRNA silencing of Agt-7 or Beclin-1 reduced the protective effects of starvation and rapamycin on H2O2-treated hTSCs. CONCLUSION: Thus, the findings of this study suggest that autophagy prevents oxidative stress-induced loss of self-renewal capacity and stemness in hTSCs through suppression of ROS accumulation. CI - © 2016 The Author(s) Published by S. Karger AG, Basel. FAU - Chen, Hua AU - Chen H AD - Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Ge, Heng-An AU - Ge HA FAU - Wu, Gen-Bing AU - Wu GB FAU - Cheng, Biao AU - Cheng B FAU - Lu, Yong AU - Lu Y FAU - Jiang, Chaoyin AU - Jiang C LA - eng PT - Journal Article DEP - 20161107 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Protective Agents) RN - 0 (Reactive Oxygen Species) RN - BBX060AN9V (Hydrogen Peroxide) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Adult MH - *Autophagy/drug effects MH - Cell Differentiation/drug effects MH - *Cell Self Renewal/drug effects MH - Humans MH - Hydrogen Peroxide/pharmacology MH - *Oxidative Stress/drug effects MH - Protective Agents/pharmacology MH - Reactive Oxygen Species/*metabolism MH - Sirolimus/pharmacology MH - Stem Cells/drug effects/metabolism/*pathology MH - Tendons/*pathology EDAT- 2016/11/11 06:00 MHDA- 2017/02/07 06:00 CRDT- 2016/11/11 06:00 PHST- 2016/09/02 00:00 [accepted] PHST- 2016/11/11 06:00 [pubmed] PHST- 2017/02/07 06:00 [medline] PHST- 2016/11/11 06:00 [entrez] AID - 000447916 [pii] AID - 10.1159/000447916 [doi] PST - ppublish SO - Cell Physiol Biochem. 2016;39(6):2227-2238. doi: 10.1159/000447916. Epub 2016 Nov 7. PMID- 22822928 OWN - NLM STAT- MEDLINE DCOM- 20130806 LR - 20211021 IS - 1365-2125 (Electronic) IS - 0306-5251 (Print) IS - 0306-5251 (Linking) VI - 75 IP - 3 DP - 2013 Mar TI - Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration. PG - 799-804 LID - 10.1111/j.1365-2125.2012.04394.x [doi] AB - AIM: To compare tissue concentrations of flurbiprofen resulting from topical application and oral administration according to the regulatory approved dosing guidelines. METHOD: Sixteen patients were included in this study. Each patient was randomly assigned to the topical application or oral administration group. In each group, a pair of tapes or a tablet, containing a total of 40 mg flurbiprofen, was administered twice at 16 and 2 h before the surgery. RESULTS: The flurbiprofen concentration in the fat, tendon, muscle and periosteum tissues was significantly higher (P < 0.0330) after topical application (992 ng g⁻¹ [95% CI 482, 1503], 944 [95% CI 481, 1407], 492 [95% CI 248, 735], and 455 [95% CI 153, 756], respectively) than after oral administration (150 ng g⁻¹ [95% CI 84, 217], 186 [95% CI 118, 254], 82 [95% CI 49, 116],and 221 [95% CI, 135, 307], respectively). CONCLUSION: Topical application is an effective method to deliver flurbiprofen to the human body, particularly to soft tissues near the body surface. CI - © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. FAU - Kai, Shuken AU - Kai S AD - Department of Sports Medicine and Joint Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan. FAU - Kondo, Eiji AU - Kondo E FAU - Kawaguchi, Yasuyuki AU - Kawaguchi Y FAU - Kitamura, Nobuto AU - Kitamura N FAU - Yasuda, Kazunori AU - Yasuda K LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - England TA - Br J Clin Pharmacol JT - British journal of clinical pharmacology JID - 7503323 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 5GRO578KLP (Flurbiprofen) SB - IM MH - Adipose Tissue/*metabolism MH - Administration, Oral MH - Administration, Topical MH - Adolescent MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics MH - Biological Availability MH - Female MH - Flurbiprofen/*pharmacokinetics MH - Humans MH - Male MH - Muscles/*metabolism MH - Periosteum/*metabolism MH - Tendons/*metabolism MH - Tissue Distribution MH - Young Adult PMC - PMC3575946 EDAT- 2012/07/25 06:00 MHDA- 2013/08/07 06:00 PMCR- 2014/03/01 CRDT- 2012/07/25 06:00 PHST- 2012/01/13 00:00 [received] PHST- 2012/07/05 00:00 [accepted] PHST- 2012/07/25 06:00 [entrez] PHST- 2012/07/25 06:00 [pubmed] PHST- 2013/08/07 06:00 [medline] PHST- 2014/03/01 00:00 [pmc-release] AID - 10.1111/j.1365-2125.2012.04394.x [doi] PST - ppublish SO - Br J Clin Pharmacol. 2013 Mar;75(3):799-804. doi: 10.1111/j.1365-2125.2012.04394.x. PMID- 16979063 OWN - NLM STAT- MEDLINE DCOM- 20061003 LR - 20161124 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 15 IP - 5 DP - 2006 Sep-Oct TI - Biomechanical evaluation of a rotator cuff defect model augmented with a bioresorbable scaffold in goats. PG - 639-44 AB - A bioresorbable patch used for augmentation of rotator cuff repair was evaluated to determine if it would increase strength of cuff repairs associated with tendon defects and also show histologic incorporation over time. Forty goats underwent rotator cuff repairs of the infraspinatus tendon bilaterally. Tendons were detached and a defect was created prior to repair. One side was repaired and augmented with a 4 cm2 polylactic acid patch in each animal. On the other side, the same size defect was repaired in the same manner but without the patch to serve as a control. Animals were sacrificed at 3, 6, 12, and 24 weeks. Ultimate load to failure and histology were reported. No significant difference in load to failure was found between groups. A cellular fibrous tissue occupied the patch at 6 weeks, which over time matured into a dense, homogeneous fibrous tissue with alignment of collagen between the scaffold bundles. FAU - MacGillivray, John D AU - MacGillivray JD AD - Department of Sports Medicine & Shoulder Service, Hospital for Special Surgery, New York, NY, USA. Macgillivrayj@hss.edu FAU - Fealy, Stephen AU - Fealy S FAU - Terry, Michael A AU - Terry MA FAU - Koh, Jason L AU - Koh JL FAU - Nixon, Alan J AU - Nixon AJ FAU - Warren, Russell F AU - Warren RF LA - eng PT - Journal Article PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Biocompatible Materials) RN - 0 (Polyesters) RN - 0 (Polymers) RN - 33X04XA5AT (Lactic Acid) RN - 459TN2L5F5 (poly(lactide)) SB - IM MH - *Absorbable Implants MH - Animals MH - Biocompatible Materials/*therapeutic use MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Goats MH - Lactic Acid/*therapeutic use MH - Orthopedic Procedures/instrumentation MH - Polyesters MH - Polymers/*therapeutic use MH - Rotator Cuff/*surgery MH - Rotator Cuff Injuries MH - Tendon Injuries/*surgery MH - Wound Healing/physiology EDAT- 2006/09/19 09:00 MHDA- 2006/10/04 09:00 CRDT- 2006/09/19 09:00 PHST- 2005/08/30 00:00 [received] PHST- 2005/11/15 00:00 [accepted] PHST- 2006/09/19 09:00 [pubmed] PHST- 2006/10/04 09:00 [medline] PHST- 2006/09/19 09:00 [entrez] AID - S1058-2746(05)00387-3 [pii] AID - 10.1016/j.jse.2005.11.009 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2006 Sep-Oct;15(5):639-44. doi: 10.1016/j.jse.2005.11.009. PMID- 9351315 OWN - NLM STAT- MEDLINE DCOM- 19971126 LR - 20131121 IS - 8750-7315 (Print) IS - 1930-8264 (Linking) VI - 87 IP - 10 DP - 1997 Oct TI - 1997 William J. Stickel Silver Award. The anti-inflammatory action of locally injected ketorolac. PG - 460-5 AB - Locally injected steroids are used to treat inflammatory conditions, in spite of the complications associated with their use. Ketorolac tromethamine, an injectable nonsteroidal anti-inflammatory drug, has not previously been evaluated for treatment of musculoskeletal inflammatory conditions via local administration. Eighty Achilles tendons of rabbits were traumatized in a controlled fashion. At the time of trauma, a single dose of ketorolac (1, 3, or 5 mg/kg) or normal saline was administered peritendinously. Three days later, the tendons were harvested and examined histologically to evaluate the degree of inflammation present in the tissue. No statistically significant difference was found between the experimental and control groups. The authors conclude that locally injected ketorolac does not prevent the onset of an inflammatory process. FAU - Brook, J W AU - Brook JW AD - Department of Surgery, Mount Sinai Medical Center, Cleveland, OH 44106, USA. FAU - Boike, A AU - Boike A FAU - Zema, R L AU - Zema RL FAU - Weaver, M AU - Weaver M FAU - Postak, P AU - Postak P LA - eng PT - Historical Article PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Podiatr Med Assoc JT - Journal of the American Podiatric Medical Association JID - 8501423 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 023C2WHX2V (Tromethamine) RN - 4EVE5946BQ (Ketorolac Tromethamine) RN - D8K2JPN18B (Tolmetin) SB - IM CIN - J Am Podiatr Med Assoc. 1998 Feb;88(2):105-6. doi: 10.7547/87507315-88-2-105. PMID: 9503775 MH - Achilles Tendon/*injuries MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - *Awards and Prizes MH - Disease Models, Animal MH - History, 20th Century MH - Inflammation/*prevention & control MH - Injections, Intralesional MH - Ketorolac Tromethamine MH - *Podiatry/history MH - Rabbits MH - Tendon Injuries/drug therapy MH - Tolmetin/analogs & derivatives/pharmacology MH - Tromethamine/analogs & derivatives/pharmacology MH - United States EDAT- 1997/11/14 00:00 MHDA- 1997/11/14 00:01 CRDT- 1997/11/14 00:00 PHST- 1997/11/14 00:00 [pubmed] PHST- 1997/11/14 00:01 [medline] PHST- 1997/11/14 00:00 [entrez] AID - 10.7547/87507315-87-10-460 [doi] PST - ppublish SO - J Am Podiatr Med Assoc. 1997 Oct;87(10):460-5. doi: 10.7547/87507315-87-10-460. PMID- 39190750 OWN - NLM STAT- MEDLINE DCOM- 20240827 LR - 20240830 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 8 DP - 2024 TI - Evaluation of suitable reference genes for qPCR normalisation of gene expression in a Achilles tendon injury model. PG - e0306678 LID - 10.1371/journal.pone.0306678 [doi] LID - e0306678 AB - Tendons are one of the major load-bearing tissues in the body; subjected to enormous peak stresses, and thus vulnerable to injury. Cellular responses to tendon injury are complex, involving inflammatory and repair components, with the latter employing both resident and recruited exogenous cell populations. Gene expression analyses are valuable tools for investigating tendon injury, allowing assessment of repair processes and pathological responses such as fibrosis, and permitting evaluation of therapeutic pharmacological interventions. Quantitative polymerase chain reaction (qPCR) is a commonly used approach for such studies, but data obtained by this method must be normalised to reference genes: genes known to be stably expressed between the experimental conditions investigated. Establishing suitable tendon injury reference genes is thus essential. Accordingly we investigated mRNA expression stability in a rat model of tendon injury, comparing both injured and uninjured tendons, and the effects of rapamycin treatment, at 1 and 3 weeks post injury. We used 11 candidate genes (18S, ACTB, AP3D1, B2M, CSNK2A2, GAPDH, HPRT1, PAK1IP1, RPL13a, SDHA, UBC) and assessed stability via four complementary algorithms (Bestkeeper, deltaCt, geNorm, Normfinder). Our results suggests that ACTB, CSNK2A2, HPRT1 and PAK1IP1 are all stably expressed in tendon, regardless of injury or drug treatment: any three of these would serve as universally suitable reference gene panel for normalizing qPCR expression data in the rat tendon injury model. We also reveal 18S, UBC, GAPDH, and SDHA as consistently poor scoring candidates (with the latter two exhibiting rapamycin- and injury-associated changes, respectively): these genes should be avoided. CI - Copyright: © 2024 Marr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Marr, Neil AU - Marr N AUID- ORCID: 0000-0001-6312-8640 AD - Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom. FAU - Meeson, Richard AU - Meeson R AD - Clinical Sciences and Services, Royal Veterinary College, Hatfield, United Kingdom. FAU - Piercy, Richard J AU - Piercy RJ AD - Clinical Sciences and Services, Royal Veterinary College, Hatfield, United Kingdom. FAU - Hildyard, John C W AU - Hildyard JCW AD - Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom. FAU - Thorpe, Chavaunne T AU - Thorpe CT AUID- ORCID: 0000-0001-7051-3504 AD - Comparative Biomedical Sciences, Royal Veterinary College, London, United Kingdom. LA - eng PT - Journal Article DEP - 20240827 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (RNA, Messenger) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Animals MH - *Achilles Tendon/injuries/pathology/metabolism MH - Rats MH - *Tendon Injuries/genetics MH - *Reference Standards MH - Real-Time Polymerase Chain Reaction/methods/standards MH - Disease Models, Animal MH - Gene Expression Profiling/methods MH - Male MH - RNA, Messenger/genetics MH - Sirolimus/pharmacology MH - Rats, Sprague-Dawley PMC - PMC11349184 COIS- The authors have declared that no competing interests exist. EDAT- 2024/08/27 18:43 MHDA- 2024/08/27 18:44 PMCR- 2024/08/27 CRDT- 2024/08/27 14:23 PHST- 2024/06/21 00:00 [received] PHST- 2024/08/12 00:00 [accepted] PHST- 2024/08/27 18:44 [medline] PHST- 2024/08/27 18:43 [pubmed] PHST- 2024/08/27 14:23 [entrez] PHST- 2024/08/27 00:00 [pmc-release] AID - PONE-D-24-25318 [pii] AID - 10.1371/journal.pone.0306678 [doi] PST - epublish SO - PLoS One. 2024 Aug 27;19(8):e0306678. doi: 10.1371/journal.pone.0306678. eCollection 2024. PMID- 19845462 OWN - NLM STAT- MEDLINE DCOM- 20100602 LR - 20131121 IS - 1937-335X (Electronic) IS - 1937-3341 (Linking) VI - 16 IP - 3 DP - 2010 Mar TI - Tissue engineering of the anterior cruciate ligament-sodium dodecyl sulfate-acellularized and revitalized tendons are inferior to native tendons. PG - 1031-40 LID - 10.1089/ten.TEA.2009.0043 [doi] AB - The acellularization of tendons using detergents (sodium dodecyl sulfate, Triton-X, tri-nitro-butyl-phosphate) is a new source of scaffolds for tissue engineering in anterior cruciate ligament (ACL) repair. In vitro testing demonstrated that acellular tendon scaffolds are biocompatible and show good biomechanical properties, but in vivo confirmation of these results is not yet available. Therefore, the aim of this study was to see in vivo if an acellular allogenic construct colonized with autologous fibroblasts improves the quality of ACL reconstruction. ACL replacement was performed in 31 New Zealand White rabbits using a standardized model. Fifteen animals received autologous semitendinosus tendon, whereas 16 animals were treated with a tissue-engineered construct. This construct was made by acellularization of allogenic semitendinosus tendons using sodium dodecyl sulfate and subsequent in vitro colonization with autologous fibroblasts. Eight weeks postoperatively, macroscopic, biomechanical (ultimate load to failure, elongation, stiffness; n = 8/9), and histological (n = 5) examinations were performed. Biomechanical testing showed decreasing strength of the constructs at 8 weeks after implantation compared with the direct postsurgical strength. However, tissue-engineered constructs (F = 19.7 +/- 20.3 N) were significantly weaker than autologous tendons (F = 61.2 +/- 31.2 N). Histologically, the autologous tendons showed signs of partial necrosis and tissue remodeling. The tissue-engineered constructs exhibited an inflammatory reaction and showed both repopulated and acellular regions. In conclusion, in vivo results were much more unfavorable than in vitro results had suggested. Further studies have to be performed to test if modifications of the acellularization process yield better results in vivo. FAU - Tischer, Thomas AU - Tischer T AD - Department of Orthopaedic and Trauma Surgery, Technical University of Munich, Munich, Germany. thomas.tischer@gmx.net FAU - Aryee, Sebastian AU - Aryee S FAU - Wexel, Gabriele AU - Wexel G FAU - Steinhauser, Erwin AU - Steinhauser E FAU - Adamczyk, Christopher AU - Adamczyk C FAU - Eichhorn, Stefan AU - Eichhorn S FAU - Milz, Stefan AU - Milz S FAU - Martinek, Vladimir AU - Martinek V FAU - Gänsbacher, Bernd AU - Gänsbacher B FAU - Imhoff, Andreas B AU - Imhoff AB FAU - Vogt, Stephan AU - Vogt S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 368GB5141J (Sodium Dodecyl Sulfate) SB - IM MH - Animals MH - Anterior Cruciate Ligament/*drug effects/*pathology/surgery MH - Biomechanical Phenomena/drug effects MH - Female MH - Rabbits MH - Sodium Dodecyl Sulfate/*pharmacology MH - Tendons/*drug effects/*pathology/surgery MH - Tissue Engineering/*methods MH - Weight-Bearing/physiology EDAT- 2009/10/23 06:00 MHDA- 2010/06/03 06:00 CRDT- 2009/10/23 06:00 PHST- 2009/10/23 06:00 [entrez] PHST- 2009/10/23 06:00 [pubmed] PHST- 2010/06/03 06:00 [medline] AID - 10.1089/ten.TEA.2009.0043 [doi] PST - ppublish SO - Tissue Eng Part A. 2010 Mar;16(3):1031-40. doi: 10.1089/ten.TEA.2009.0043. PMID- 4985110 OWN - NLM STAT- MEDLINE DCOM- 19700504 LR - 20171213 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 218 IP - 4 DP - 1970 Apr TI - Zinc 65 distribution and movement in frog skeletal muscle and tendon. PG - 1239-48 FAU - Isaacson, A AU - Isaacson A FAU - Bianchi, C P AU - Bianchi CP FAU - Sandow, A AU - Sandow A LA - eng PT - Journal Article PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Calcium Isotopes) RN - 0 (Zinc Isotopes) RN - 9G34HU7RV0 (Edetic Acid) RN - J41CSQ7QDS (Zinc) RN - M4I0D6VV5M (Calcium Chloride) RN - SY7Q814VUP (Calcium) SB - IM MH - Achilles Tendon MH - Action Potentials MH - Animals MH - Calcium/metabolism MH - Calcium Chloride MH - Calcium Isotopes MH - Edetic Acid/pharmacology MH - In Vitro Techniques MH - Kinetics MH - Muscle Contraction MH - Muscles/analysis/*metabolism MH - Tendons/analysis/*metabolism MH - Zinc/analysis/*metabolism MH - Zinc Isotopes EDAT- 1970/04/01 00:00 MHDA- 1970/04/01 00:01 CRDT- 1970/04/01 00:00 PHST- 1970/04/01 00:00 [pubmed] PHST- 1970/04/01 00:01 [medline] PHST- 1970/04/01 00:00 [entrez] AID - 10.1152/ajplegacy.1970.218.4.1239 [doi] PST - ppublish SO - Am J Physiol. 1970 Apr;218(4):1239-48. doi: 10.1152/ajplegacy.1970.218.4.1239. PMID- 14465541 OWN - NLM STAT- MEDLINE DCOM- 19981101 LR - 20221207 IS - 0096-8501 (Print) IS - 0096-8501 (Linking) VI - 28 DP - 1961 Dec TI - The effect of an anthistamine (promethazine) on digital flexor tendon healing in the chicken. PG - 634-48 FAU - LINDSAY, W K AU - LINDSAY WK FAU - WALKER, F G AU - WALKER FG LA - eng PT - Journal Article PL - United States TA - Plast Reconstr Surg Transplant Bull JT - Plastic and reconstructive surgery and the transplantation bulletin JID - 101243645 RN - FF28EJQ494 (Promethazine) SB - OM MH - Animals MH - *Chickens MH - Humans MH - Promethazine/*pharmacology MH - *Plastic Surgery Procedures MH - Tendons/*surgery MH - Wound Healing/*pharmacology OTO - NLM OT - *PROMETHAZINE/pharmacology OT - *TENDONS/surgery OT - *WOUND HEALING/pharmacology EDAT- 1961/12/01 00:00 MHDA- 1961/12/01 00:01 CRDT- 1961/12/01 00:00 PHST- 1961/12/01 00:00 [pubmed] PHST- 1961/12/01 00:01 [medline] PHST- 1961/12/01 00:00 [entrez] AID - 10.1097/00006534-196112000-00003 [doi] PST - ppublish SO - Plast Reconstr Surg Transplant Bull. 1961 Dec;28:634-48. doi: 10.1097/00006534-196112000-00003. PMID- 4622313 OWN - NLM STAT- MEDLINE DCOM- 19720524 LR - 20190829 IS - 0022-5320 (Print) IS - 0022-5320 (Linking) VI - 38 IP - 5 DP - 1972 Mar TI - An electron microscopic study of the effect of crude bacterial -amylase and ethylenediaminetetraacetic acid on human tendon. PG - 466-72 FAU - Dixon, J S AU - Dixon JS FAU - Hunter, J A AU - Hunter JA FAU - Steven, F S AU - Steven FS LA - eng PT - Journal Article PL - United States TA - J Ultrastruct Res JT - Journal of ultrastructure research JID - 0376344 RN - 9007-34-5 (Collagen) RN - 9G34HU7RV0 (Edetic Acid) RN - EC 3.2.1.- (Amylases) SB - IM MH - Amylases/*pharmacology MH - Bacillus subtilis/enzymology MH - Collagen/isolation & purification MH - Edetic Acid/*pharmacology MH - Histocytochemistry MH - Humans MH - Male MH - Microscopy, Electron MH - Middle Aged MH - Tendons/cytology/*drug effects EDAT- 1972/03/01 00:00 MHDA- 1972/03/01 00:01 CRDT- 1972/03/01 00:00 PHST- 1972/03/01 00:00 [pubmed] PHST- 1972/03/01 00:01 [medline] PHST- 1972/03/01 00:00 [entrez] AID - 10.1016/0022-5320(72)90084-6 [doi] PST - ppublish SO - J Ultrastruct Res. 1972 Mar;38(5):466-72. doi: 10.1016/0022-5320(72)90084-6. PMID- 4586622 OWN - NLM STAT- MEDLINE DCOM- 19740207 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 55 IP - 3 DP - 1973 Dec 10 TI - Rate of helix formation by intracellular procollagen and protocollagen. Evidence for a role for disulfide bonds. PG - 904-11 FAU - Uitto, J AU - Uitto J FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Carbon Radioisotopes) RN - 0 (Disulfides) RN - 0 (Protein Precursors) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 3.4.23.1 (Pepsin A) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*metabolism MH - Disulfides/metabolism MH - Dithiothreitol/pharmacology MH - Hydroxylation MH - Kinetics MH - Pepsin A MH - Proline MH - Protein Conformation/drug effects MH - Protein Precursors MH - Temperature MH - Tendons/drug effects/metabolism MH - Time Factors EDAT- 1973/12/10 00:00 MHDA- 1973/12/10 00:01 CRDT- 1973/12/10 00:00 PHST- 1973/12/10 00:00 [pubmed] PHST- 1973/12/10 00:01 [medline] PHST- 1973/12/10 00:00 [entrez] AID - 0006-291X(73)91229-1 [pii] AID - 10.1016/0006-291x(73)91229-1 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1973 Dec 10;55(3):904-11. doi: 10.1016/0006-291x(73)91229-1. PMID- 4187641 OWN - NLM STAT- MEDLINE DCOM- 19700109 LR - 20031114 IS - 0001-5423 (Print) IS - 0001-5423 (Linking) VI - 11 IP - 3 DP - 1969 TI - Dynamics of morphological changes after homografts of tendons preserved in anticytolytic solutions. PG - 187-96 FAU - Beringer, U V AU - Beringer UV FAU - Darkshevich, U N AU - Darkshevich UN LA - eng PT - Journal Article PL - Czech Republic TA - Acta Chir Plast JT - Acta chirurgiae plasticae JID - 0370301 RN - 0 (Phenothiazines) RN - 0 (Solutions) SB - IM MH - Animals MH - Phenothiazines/*pharmacology MH - Rabbits MH - *Solutions MH - Sterilization MH - Tendons/*transplantation MH - *Tissue Preservation MH - Transplantation, Homologous EDAT- 1969/01/01 00:00 MHDA- 1969/01/01 00:01 CRDT- 1969/01/01 00:00 PHST- 1969/01/01 00:00 [pubmed] PHST- 1969/01/01 00:01 [medline] PHST- 1969/01/01 00:00 [entrez] PST - ppublish SO - Acta Chir Plast. 1969;11(3):187-96. PMID- 22523372 OWN - NLM STAT- MEDLINE DCOM- 20121108 LR - 20131121 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 40 IP - 7 DP - 2012 Jul TI - The effects of chlorhexidine graft decontamination on tendon graft collagen and cell viability. PG - 1646-53 LID - 10.1177/0363546512443808 [doi] AB - BACKGROUND: Chlorhexidine (CLX) has been reported as a popular and effective disinfectant of contaminated tendon grafts with no biomechanical sequelae; however, its biochemical effects on tendon collagen and fibroblasts remain unknown. PURPOSE: To determine whether CLX disinfection of contaminated tendon grafts has deleterious effects on tendon collagen or a toxic effect on fibroblast function. STUDY DESIGN: Controlled laboratory study. METHODS: Collagen fibrils prepared from purified bovine collagen type I were treated with various CLX concentrations (0.5%-4%) and incubation times (10-40 minutes), and the effects on fibril degradation and solubility were then examined using gel electrophoresis. Fresh bovine tendons were treated with sterile water or 2% CLX; then, fibroblast mobility and metabolic activity were evaluated using light microscopy and Alamar Blue assay, respectively. RESULTS: No effect on collagen fibrils was observed when they were exposed to 0%, 0.5%, or 2% CLX at any exposure time. However, 4% CLX dissolved the fibrils even after short incubation times. Fibroblasts migrated out from the control tendon explants but not from explants treated with 2% CLX, and a 5-fold reduction in metabolic activity was observed throughout the tendon in explants exposed to 2% CLX, suggesting that CLX penetrated and killed cells throughout the tissue. CONCLUSION: Four-percent CLX caused collagen fibrils to dissolve in vitro, and tendon graft disinfection with 2% CLX was cytotoxic to the cells. CLINICAL RELEVANCE: Because of its chemical effect on tendon collagen and cytotoxic effect on tendon fibroblasts, 4% CLX should not be used as a disinfectant. Two-percent CLX can be used to disinfect contaminated ACL grafts, but such treatment will drastically reduce the metabolic activity of the cells within the graft, making it similar to an acellular allograft tendon. FAU - Alomar, Abdulaziz Z AU - Alomar AZ AD - Orthopaedic Research Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada. dr_abdulaziz@yahoo.com FAU - Gawri, Rahul AU - Gawri R FAU - Roughley, Peter J AU - Roughley PJ FAU - Haglund, Lisbet AU - Haglund L FAU - Burman, Mark AU - Burman M LA - eng PT - Journal Article DEP - 20120420 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Disinfectants) RN - 9007-34-5 (Collagen) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Animals MH - Cattle MH - Cell Movement/drug effects MH - Cell Survival/*drug effects MH - Chlorhexidine/*pharmacology MH - Collagen/*metabolism MH - Disinfectants/*pharmacology MH - Fibroblasts/drug effects/physiology MH - Tendons/cytology/*drug effects/metabolism/transplantation EDAT- 2012/04/24 06:00 MHDA- 2012/11/09 06:00 CRDT- 2012/04/24 06:00 PHST- 2012/04/24 06:00 [entrez] PHST- 2012/04/24 06:00 [pubmed] PHST- 2012/11/09 06:00 [medline] AID - 0363546512443808 [pii] AID - 10.1177/0363546512443808 [doi] PST - ppublish SO - Am J Sports Med. 2012 Jul;40(7):1646-53. doi: 10.1177/0363546512443808. Epub 2012 Apr 20. PMID- 35955918 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20250728 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 23 IP - 15 DP - 2022 Aug 7 TI - Lidocaine Inhibited Tendon Cell Proliferation and Extracellular Matrix Production by Down Regulation of Cyclin A, CDK2, Type I and Type III Collagen Expression. LID - 10.3390/ijms23158787 [doi] LID - 8787 AB - Lidocaine injection is a common treatment for tendon injuries. However, the evidence suggests that lidocaine is toxic to tendon cells. This study investigated the effects of lidocaine on cultured tendon cells, focusing on the molecular mechanisms underlying cell proliferation and extracellular matrix (ECM) production. Tendon cells cultured from rat Achilles tendons were treated with 0.5, 1.0, or 1.5 mg/mL lidocaine for 24 h. Cell proliferation was evaluated by Cell Counting Kit 8 (CCK-8) assay and bromodeoxyuridine (BrdU) assay. Cell apoptosis was assessed by Annexin V and propidium iodide (PI) stain. Cell cycle progression and cell mitosis were assessed through flow cytometry and immunofluorescence staining, respectively. The expression of cyclin E, cyclin A, cyclin-dependent kinase 2 (CDK2), p21, p27, p53, matrix metalloproteinases-2 (MMP-2), matrix metalloproteinases-9 (MMP-9), type I collagen, and type III collagen were examined through Western blotting, and the enzymatic activity of MMP-9 was determined through gelatin zymography. Lidocaine reduced cell proliferation and reduced G1/S transition and cell mitosis. Lidocaine did not have a significant negative effect on cell apoptosis. Lidocaine significantly inhibited cyclin A and CDK2 expression but promoted p21, p27, and p53 expression. Furthermore, the expression of MMP-2 and MMP-9 increased, whereas that of type I and type III collagen decreased. Lidocaine also increased the enzymatic activity of MMP-9. Our findings support the premise that lidocaine inhibits tendon cell proliferation by changing the expression of cell-cycle-related proteins and reduces ECM production by altering levels of MMPs and collagens. FAU - Chen, Yen-Chia AU - Chen YC AUID- ORCID: 0000-0003-2826-8503 AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. FAU - Chang, Hsiang-Ning AU - Chang HN AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. FAU - Pang, Jong-Hwei Su AU - Pang JS AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 33302, Taiwan. FAU - Lin, Li-Ping AU - Lin LP AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 33302, Taiwan. FAU - Chen, Jing-Min AU - Chen JM AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. FAU - Yu, Tung-Yang AU - Yu TY AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. FAU - Tsai, Wen-Chung AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. AD - School of Medicine, Chang Gung University, Taoyuan City 33302, Taiwan. AD - Center of Comprehensive Sports Medicine, Chang Gung Memorial Hospital, Taoyuan City 33302, Taiwan. LA - eng GR - CMRPG3H1891/Linkou Chang Gung Memorial Hospital/ PT - Journal Article DEP - 20220807 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cell Cycle Proteins) RN - 0 (Collagen Type III) RN - 0 (Cyclin A) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 0 (Tumor Suppressor Protein p53) RN - 98PI200987 (Lidocaine) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 2) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Animals MH - Cell Cycle Proteins/metabolism MH - Cell Proliferation MH - *Collagen Type III/genetics MH - Cyclin A/metabolism MH - Cyclin-Dependent Kinase 2/metabolism MH - Cyclin-Dependent Kinase Inhibitor p21/metabolism MH - Down-Regulation MH - Extracellular Matrix/metabolism MH - Lidocaine/pharmacology MH - Matrix Metalloproteinase 2/metabolism MH - *Matrix Metalloproteinase 9/metabolism MH - Rats MH - Tendons/metabolism MH - Tumor Suppressor Protein p53/metabolism PMC - PMC9368801 OTO - NOTNLM OT - CDK 2 OT - MMP-9 OT - cell cycle OT - cell proliferation OT - cyclin A OT - lidocaine OT - p21 OT - tendon cells COIS- The authors declare no conflict of interest. EDAT- 2022/08/13 06:00 MHDA- 2022/08/16 06:00 PMCR- 2022/08/07 CRDT- 2022/08/12 01:14 PHST- 2022/07/26 00:00 [received] PHST- 2022/07/28 00:00 [revised] PHST- 2022/08/03 00:00 [accepted] PHST- 2022/08/12 01:14 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] PHST- 2022/08/07 00:00 [pmc-release] AID - ijms23158787 [pii] AID - ijms-23-08787 [pii] AID - 10.3390/ijms23158787 [doi] PST - epublish SO - Int J Mol Sci. 2022 Aug 7;23(15):8787. doi: 10.3390/ijms23158787. PMID- 4321095 OWN - NLM STAT- MEDLINE DCOM- 19710204 LR - 20220215 IS - 0021-9533 (Print) IS - 0021-9533 (Linking) VI - 7 IP - 2 DP - 1970 Sep TI - The effects of irradiation with high energy electrons on the structure and reactivity of native and cross-linked collagen fibres. PG - 387-405 FAU - Grant, R A AU - Grant RA FAU - Cox, R W AU - Cox RW FAU - Kent, C M AU - Kent CM LA - eng PT - Journal Article PL - England TA - J Cell Sci JT - Journal of cell science JID - 0052457 RN - 0 (Aldehydes) RN - 0 (Amino Acids) RN - 0 (Peptides) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.36 (Pancreatic Elastase) RN - EC 3.4.24.3 (Microbial Collagenase) SB - IM MH - Aldehydes/pharmacology MH - Amino Acids/analysis MH - Animals MH - Collagen/analysis/*radiation effects MH - *Electrons MH - Histocytochemistry MH - Microbial Collagenase MH - Microscopy, Electron MH - Pancreatic Elastase MH - Peptides/radiation effects MH - *Radiation Effects MH - Rats MH - Solubility MH - Tendons/drug effects/radiation effects EDAT- 1970/09/01 00:00 MHDA- 1970/09/01 00:01 CRDT- 1970/09/01 00:00 PHST- 1970/09/01 00:00 [pubmed] PHST- 1970/09/01 00:01 [medline] PHST- 1970/09/01 00:00 [entrez] AID - 10.1242/jcs.7.2.387 [doi] PST - ppublish SO - J Cell Sci. 1970 Sep;7(2):387-405. doi: 10.1242/jcs.7.2.387. PMID- 20736063 OWN - NLM STAT- MEDLINE DCOM- 20110721 LR - 20231106 IS - 1569-1802 (Electronic) IS - 0945-053X (Print) IS - 0945-053X (Linking) VI - 29 IP - 8 DP - 2010 Oct TI - An experimental model for studying the biomechanics of embryonic tendon: Evidence that the development of mechanical properties depends on the actinomyosin machinery. PG - 678-89 LID - 10.1016/j.matbio.2010.08.009 [doi] AB - Tendons attach muscles to bone and thereby transmit tensile forces during joint movement. However, a detailed understanding of the mechanisms that establish the mechanical properties of tendon has remained elusive because of the practical difficulties of studying tissue mechanics in vivo. Here we have performed a study of tendon-like constructs made by culturing embryonic tendon cells in fixed-length fibrin gels. The constructs display mechanical properties (toe-linear-fail stress-strain curve, stiffness, ultimate tensile strength, and failure strain) as well as collagen fibril volume fraction and extracellular matrix (ECM)/cell ratio that are statistically similar to those of embryonic chick metatarsal tendons. The development of mechanical properties during time in culture was abolished when the constructs were treated separately with Triton X-100 (to solubilise membranes), cytochalasin (to disassemble the actin cytoskeleton) and blebbistatin (a small molecule inhibitor of non-muscle myosin II). Importantly, these treatments had no effect on the mechanical properties of the constructs that existed prior to treatment. Live-cell imaging and (14)C-proline metabolic labeling showed that blebbistatin inhibited the contraction of the constructs without affecting cell viability, procollagen synthesis, or conversion of procollagen to collagen. In conclusion, the mechanical properties per se of the tendon constructs are attributable to the ECM generated by the cells but the improvement of mechanical properties during time in culture was dependent on non-muscle myosin II-derived forces. CI - Copyright © 2010 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved. FAU - Kalson, Nicholas S AU - Kalson NS AD - Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, UK. FAU - Holmes, David F AU - Holmes DF FAU - Kapacee, Zoher AU - Kapacee Z FAU - Otermin, Iker AU - Otermin I FAU - Lu, Yinhui AU - Lu Y FAU - Ennos, Roland A AU - Ennos RA FAU - Canty-Laird, Elizabeth G AU - Canty-Laird EG FAU - Kadler, Karl E AU - Kadler KE LA - eng GR - WT_/Wellcome Trust/United Kingdom GR - BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100822 PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Actins) RN - 0 (Fibrillar Collagens) RN - 0 (Heterocyclic Compounds, 4 or More Rings) RN - 0 (Procollagen) RN - 20WC4J7CQ6 (blebbistatin) RN - 3CHI920QS7 (Cytochalasin B) RN - 9002-93-1 (Octoxynol) RN - EC 3.6.1.- (Nonmuscle Myosin Type IIA) RN - EC 3.6.1.- (Nonmuscle Myosin Type IIB) RN - EC 3.6.4.1 (Myosins) SB - IM MH - Actin Cytoskeleton/*metabolism MH - Actins/antagonists & inhibitors MH - Animals MH - Biomechanical Phenomena MH - Cell Count MH - Cell Movement/drug effects/physiology MH - Cell Survival/physiology MH - Chick Embryo MH - Cytochalasin B/pharmacology MH - Elastic Modulus MH - Extracellular Matrix/ultrastructure MH - Fibrillar Collagens/ultrastructure MH - Heterocyclic Compounds, 4 or More Rings/pharmacology MH - Metatarsus/physiology MH - Myosins/antagonists & inhibitors/*metabolism MH - Nonmuscle Myosin Type IIA/antagonists & inhibitors/genetics MH - Nonmuscle Myosin Type IIB/antagonists & inhibitors/genetics/metabolism MH - Octoxynol/pharmacology MH - Procollagen/metabolism MH - Tendons/cytology/drug effects/*embryology/metabolism/*physiology/ultrastructure MH - Tensile Strength MH - Tissue Engineering PMC - PMC3611596 EDAT- 2010/08/26 06:00 MHDA- 2011/07/22 06:00 PMCR- 2010/10/01 CRDT- 2010/08/26 06:00 PHST- 2010/05/18 00:00 [received] PHST- 2010/07/27 00:00 [revised] PHST- 2010/08/17 00:00 [accepted] PHST- 2010/08/26 06:00 [entrez] PHST- 2010/08/26 06:00 [pubmed] PHST- 2011/07/22 06:00 [medline] PHST- 2010/10/01 00:00 [pmc-release] AID - S0945-053X(10)00134-4 [pii] AID - 10.1016/j.matbio.2010.08.009 [doi] PST - ppublish SO - Matrix Biol. 2010 Oct;29(8):678-89. doi: 10.1016/j.matbio.2010.08.009. Epub 2010 Aug 22. PMID- 17293464 OWN - NLM STAT- MEDLINE DCOM- 20070614 LR - 20171116 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 35 IP - 5 DP - 2007 May TI - Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study. PG - 763-9 AB - BACKGROUND: An increase in matrix metalloproteinases (MMPs) and the resulting degradation of the extracellular matrix have been implicated in the pathogenesis of tendinopathy. Studies have documented the beneficial effects of MMP inhibitors used to treat pathologic conditions in which MMP activity has had a negative effect on connective tissues. HYPOTHESIS: Matrix metalloproteinase inhibitors will prevent the decrease in material properties associated with tendon stress deprivation by inhibiting MMP activity. STUDY DESIGN: Controlled laboratory study. METHODS: Rat tail tendons were subjected to 7 days of in vitro stress deprivation with and without the addition of 1 of 2 broad-spectrum MMP inhibitors (doxycycline and ilomastat). The material properties (ultimate tensile stress, strain, and tensile modulus) of the tendons were compared with each other and with fresh control tendons. In addition, tendons from each group were evaluated for MMP-13 messenger RNA expression, MMP-13 protein synthesis, MMP-13 activity, and pericellular matrix morphology. RESULTS: Both MMP inhibitors resulted in a statistically significant reduction in MMP activity in 7 day stress-deprived tendons when compared with nontreated, stress-deprived tendons. Similarly, tendons treated with either ilomastat or doxycycline had significantly improved material properties. MMP-13 messenger RNA expression and protein synthesis were not significantly affected by either MMP inhibitor. Both MMP inhibitors were able to maintain the integrity of the pericellular matrix when compared with nontreated, stress-deprived tendons. CONCLUSION: Matrix metalloproteinase inhibitors prevented the activation of MMP-13 and significantly inhibited pericellular matrix degeneration and the loss of material properties associated with stress deprivation. CLINICAL RELEVANCE: Matrix metalloproteinase inhibitors may play a supportive role in the treatment of tendinopathy by limiting the MMP-mediated degradation of the extracellular matrix. FAU - Arnoczky, Steven P AU - Arnoczky SP AD - Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA. arnoczky@cvm.msu.edu FAU - Lavagnino, Michael AU - Lavagnino M FAU - Egerbacher, Monika AU - Egerbacher M FAU - Caballero, Oscar AU - Caballero O FAU - Gardner, Keri AU - Gardner K LA - eng PT - Journal Article DEP - 20070209 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Bacterial Agents) RN - 0 (Hydroxamic Acids) RN - 0 (Indoles) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - I0403ML141 (ilomastat) RN - N12000U13O (Doxycycline) SB - IM MH - Animals MH - Anti-Bacterial Agents/*pharmacology MH - Doxycycline/*pharmacology MH - Extracellular Matrix/*drug effects MH - Hydroxamic Acids MH - In Vitro Techniques MH - Indoles/*pharmacology MH - Matrix Metalloproteinase 13/drug effects MH - *Matrix Metalloproteinase Inhibitors MH - Rats MH - Rats, Sprague-Dawley MH - *Stress, Mechanical MH - Tendinopathy/*drug therapy MH - Tendons/*drug effects EDAT- 2007/02/13 09:00 MHDA- 2007/06/15 09:00 CRDT- 2007/02/13 09:00 PHST- 2007/02/13 09:00 [pubmed] PHST- 2007/06/15 09:00 [medline] PHST- 2007/02/13 09:00 [entrez] AID - 0363546506296043 [pii] AID - 10.1177/0363546506296043 [doi] PST - ppublish SO - Am J Sports Med. 2007 May;35(5):763-9. doi: 10.1177/0363546506296043. Epub 2007 Feb 9. PMID- 28449861 OWN - NLM STAT- MEDLINE DCOM- 20171031 LR - 20181202 IS - 1873-2380 (Electronic) IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 57 DP - 2017 May 24 TI - The effects of irradiation dose and storage time following treatment on the viscoelastic properties of decellularised porcine super flexor tendon. PG - 157-160 LID - S0021-9290(17)30203-8 [pii] LID - 10.1016/j.jbiomech.2017.04.005 [doi] AB - Decellularised porcine super flexor tendon (pSFT) offers a promising solution to the replacement of damaged anterior cruciate ligament. It is desirable to package and terminally sterilise the acellular grafts to eliminate any possible harmful pathogens. However, irradiation techniques can damage the collagen structure and consequently reduce the mechanical properties. The aims of this study were to investigate the effects of irradiation sterilisation of varying dosages on the viscoelastic properties of the decellularised pSFT. Decellularised pSFT tendons were subjected to irradiation sterilisation using either 30kGygamma, 55kGygamma, 34kGy E-beam, 15kGygamma, 15kGy E-beam and (15+15) kGy E-beam (fractionated dose). Specimens then underwent stress relaxation testing at 0 and 12months post sterilisation to determine whether any effect on the viscoelastic properties was progressive. Significant differences were found which demonstrated that all irradiation treatments had an effect on the time-independent and time-dependent viscoelastic properties of irradiated tendons compared to peracetic acid only treated controls. No significant differences were found between the irradiated groups and no significant differences were found between groups at 0 and 12months. These results indicate the decellularised pSFT graft has a stable shelf-life. CI - Copyright © 2017. Published by Elsevier Ltd. FAU - Herbert, Anthony AU - Herbert A AD - (IMBE) Institute of Medical and Biological Engineering, School of Mechanical Engineering, University of Leeds, Leeds, UK. Electronic address: A.Herbert@leeds.ac.uk. FAU - Edwards, Jennifer H AU - Edwards JH AD - IMBE, Faculty of Biomedical Sciences, University of Leeds, Leeds, UK. FAU - Jones, Gemma L AU - Jones GL AD - IMBE, Faculty of Biomedical Sciences, University of Leeds, Leeds, UK. FAU - Ingham, Eileen AU - Ingham E AD - IMBE, Faculty of Biomedical Sciences, University of Leeds, Leeds, UK. FAU - Fisher, John AU - Fisher J AD - (IMBE) Institute of Medical and Biological Engineering, School of Mechanical Engineering, University of Leeds, Leeds, UK. LA - eng GR - Wellcome Trust/United Kingdom PT - Journal Article DEP - 20170419 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - Animals MH - Elasticity MH - Female MH - Peracetic Acid/pharmacology MH - Radiation Dosage MH - Specimen Handling MH - Sterilization/*methods MH - Stress, Mechanical MH - Swine MH - *Tendons/drug effects/physiology/radiation effects MH - Viscosity PMC - PMC5754329 OTO - NOTNLM OT - Anterior cruciate ligament OT - Decellularised OT - Irradiation OT - Tendon OT - Tissue engineering EDAT- 2017/04/30 06:00 MHDA- 2017/11/01 06:00 PMCR- 2017/05/24 CRDT- 2017/04/29 06:00 PHST- 2016/12/06 00:00 [received] PHST- 2017/03/31 00:00 [revised] PHST- 2017/04/09 00:00 [accepted] PHST- 2017/04/30 06:00 [pubmed] PHST- 2017/11/01 06:00 [medline] PHST- 2017/04/29 06:00 [entrez] PHST- 2017/05/24 00:00 [pmc-release] AID - S0021-9290(17)30203-8 [pii] AID - 10.1016/j.jbiomech.2017.04.005 [doi] PST - ppublish SO - J Biomech. 2017 May 24;57:157-160. doi: 10.1016/j.jbiomech.2017.04.005. Epub 2017 Apr 19. PMID- 126137 OWN - NLM STAT- MEDLINE DCOM- 19751218 LR - 20190918 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 3 IP - 4 DP - 1975 TI - Collagen and mechanical strength in various organs of rats treated with D-penicillamine or amino-acetonitrile. PG - 237-44 AB - After oral treatment with D-penicillamine (D-Pc) or with aminoacetonitrile (AAn) for 10 days, mechanical and chemical parameters were studied simultaneously in various organs of Sprague Dawley rats. Tensile strength of skin strips and of tail tendons, breaking strength of femur bones and tensile strength of granuloma tissue (induced by implanted glass rods) were measured and calculated. In the same tissue the soluble collagen fractions and the insoluble collagen were determined. Total collagen and the ratio insoluble vs. soluble collagen were calculated. Tensile strength of skin, tendon and granuloma tissue were greatly reduced by D-Pc treatment but only minimally influenced by AAN treatment. On the other hand only AAN significantly reduced the breaking strength of bone. All these changes were closely correlated with the content of insoluble collagen in the respective tissues. The correlation coefficients to total collagen were similar but lower. The correlation coefficients between strength and the ratio insoluble vs. soluble collagen were generally still lower. Earlier findings in aged and corticoid treated rats, proving that insoluble collagen content determines mechanical strength of connnective and supporting tissue thus could be confirmed. FAU - Vogel, H G AU - Vogel HG LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Acetonitriles) RN - 3739OQ10IJ (Aminoacetonitrile) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Acetonitriles/*pharmacology MH - Aminoacetonitrile/*pharmacology MH - Animals MH - *Collagen/analysis MH - Connective Tissue/*drug effects MH - Femur/analysis/drug effects/physiology MH - Penicillamine/*pharmacology MH - Rats MH - Skin/analysis/drug effects MH - Skin Physiological Phenomena MH - Stress, Mechanical MH - Tendons/analysis/drug effects/physiology EDAT- 1975/01/01 00:00 MHDA- 1975/01/01 00:01 CRDT- 1975/01/01 00:00 PHST- 1975/01/01 00:00 [pubmed] PHST- 1975/01/01 00:01 [medline] PHST- 1975/01/01 00:00 [entrez] AID - 10.3109/03008207509152184 [doi] PST - ppublish SO - Connect Tissue Res. 1975;3(4):237-44. doi: 10.3109/03008207509152184. PMID- 23849733 OWN - NLM STAT- MEDLINE DCOM- 20140415 LR - 20211021 IS - 1531-6564 (Electronic) IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 38 IP - 9 DP - 2013 Sep TI - The effect of surface modification on gliding ability of decellularized flexor tendon in a canine model in vitro. PG - 1698-704 LID - S0363-5023(13)00703-X [pii] LID - 10.1016/j.jhsa.2013.05.023 [doi] AB - PURPOSE: To investigate the gliding ability and mechanical properties of decellularized intrasynovial tendons with and without surface modification designed to reduce gliding resistance. METHODS: We randomly assigned 33 canine flexor digitorum profundus tendons to 1 of 3 groups: untreated fresh tendons, to serve as a control; tendons decellularized with trypsin and Triton X-100; and tendons decellularized as in group 2 with surface modification using carbodiimide-derivatized hyaluronic acid and gelatin (cd-HA-gelatin). Tendons were subjected to cyclic friction testing for 1,000 cycles with subsequent tensile stiffness testing. We qualitatively evaluated the surface roughness after 1,000 cycles using scanning electron microscopy. RESULTS: The gliding resistance of the decellularized group was significantly higher than that of both the control and cd-HA-gelatin tendons (0.20, 0.09, and 0.11 N after the first cycle; and 0.41, 0.09, and 0.14 N after 1,000 cycles, respectively). Gliding resistance between the control and cd-HA-gelatin groups was not significantly different. The Young modulus was not significantly different between groups. The surfaces of the control and cd-HA-gelatin-treated tendons appeared smooth after 1,000 cycles, whereas those of the decellularized tendons appeared roughened under scanning electron microscopy observation. CONCLUSIONS: Decellularization with trypsin and Triton X-100 did not change tendon stiffness. However, although this treatment was effective in removing cells, it adversely altered the tendon surface in both appearance and gliding resistance. Surface modification with cd-HA-gelatin improved the tendon surface smoothness and significantly decreased the gliding resistance. CLINICAL RELEVANCE: The combination of decellularization and surface modification may improve the function of tendon allografts when used clinically. CI - Copyright © 2013 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Ozasa, Yasuhiro AU - Ozasa Y AD - Biomechanics and Tendon and Soft Tissue Laboratories, Division of Orthopedic Research, Mayo Clinic, Rochester, MN 55905, USA. FAU - Amadio, Peter C AU - Amadio PC FAU - Thoreson, Andrew R AU - Thoreson AR FAU - An, Kai-Nan AU - An KN FAU - Zhao, Chunfeng AU - Zhao C LA - eng GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - AR57745/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20130709 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Surface-Active Agents) RN - 9002-93-1 (Octoxynol) RN - EC 3.4.21.4 (Trypsin) SB - IM MH - Allografts MH - Animals MH - Biomechanical Phenomena MH - Dogs MH - Friction/*drug effects MH - Microscopy, Electron, Scanning MH - Models, Animal MH - Octoxynol/*pharmacology MH - Surface Properties/drug effects MH - Surface-Active Agents/*therapeutic use MH - Tendons/*physiopathology MH - Trypsin/*pharmacology PMC - PMC3782077 MID - NIHMS504162 OTO - NOTNLM OT - Allograft OT - decellularization OT - flexor tendon OT - gliding resistance EDAT- 2013/07/16 06:00 MHDA- 2014/04/16 06:00 PMCR- 2014/09/01 CRDT- 2013/07/16 06:00 PHST- 2013/01/22 00:00 [received] PHST- 2013/05/16 00:00 [revised] PHST- 2013/05/18 00:00 [accepted] PHST- 2013/07/16 06:00 [entrez] PHST- 2013/07/16 06:00 [pubmed] PHST- 2014/04/16 06:00 [medline] PHST- 2014/09/01 00:00 [pmc-release] AID - S0363-5023(13)00703-X [pii] AID - 10.1016/j.jhsa.2013.05.023 [doi] PST - ppublish SO - J Hand Surg Am. 2013 Sep;38(9):1698-704. doi: 10.1016/j.jhsa.2013.05.023. Epub 2013 Jul 9. PMID- 10208479 OWN - NLM STAT- MEDLINE DCOM- 19990528 LR - 20220318 IS - 0021-9150 (Print) IS - 0021-9150 (Linking) VI - 143 IP - 1 DP - 1999 Mar TI - The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. PG - 41-54 AB - In a genetically heterogeneous group of 109 patients with a clinical diagnosis of heterozygous familial hypercholesterolaemia (FH), the influence of gender, apolipoprotein (apo) E genotype and the type of molecular defect in the LDL-receptor (LDLR) gene on the reduction of plasma LDL-cholesterol levels to treatment with a HMG-CoA reductase inhibitor (simvastatin) were studied. Response was determined as the percentage fall in LDL-cholesterol from untreated levels and as the proportion of patients where levels fell below 4.9 or 4.1 mmol/l. Of the patients, 86 individuals had tendon xanthomata (TX+) and a diagnosis of 'definite' FH and these individuals presented with a significantly higher untreated LDL-cholesterol compared to the 23 individuals who did not have xanthomas (TX-) and a diagnosis of 'probable' FH (8.14+/-0.19 vs. 6.81+/-0.25, P= 0.001). Overall, HMG-CoA reductase inhibitor doses of 10, 20 or 40 mg/day resulted in a significant fall of LDL-cholesterol levels of 29, 39 and 49%, but at all doses those with TX had significantly higher levels than those without, and significantly fewer TX + patients achieved LDL-cholesterol levels below 4.9 or 4.1 mmol/l than the TX - group (P < 0.05 at each dose). In the TX+ group the response to treatment was of similar magnitude in men and women and in patients with different apoE genotype. In the 'probable' FH probands only three mutations were identified (detection rate 13%), one in the LDLR gene and two in the APOB gene, a detection rate significantly lower (P= 0.02) than in the 'definite' FH probands where 28 mutations were detected (detection rate 37%). In the TX + patients where no mutation was detected, treatment resulted in a greater proportion achieving LDL-cholesterol levels below 4.9 and 4.1 mmol/l compared to those with any LDLR mutation, this difference was close to statistical significance at the 4.9 mmol/l threshold at 10 mg/day (41 vs. 13%, P = 0.058). For the 14 patients with an LDLR mutation that was predicted to be 'severe', fewer achieved LDL-cholesterol levels below 4.9 or 4.1 mmol/l at each dosage compared to the 16 individuals with 'mild' mutations, and this difference was statistically significant at the maximal dosage of 40 mg/day (P = 0.018). Thus although characterisation of the molecular defect in FH patients may not be relevant to their immediate clinical management, those with a particular mutation may need more aggressive lipid-lowering treatment to reach LDL-cholesterol levels recommended to reduce the risk of coronary heart disease (CHD). FAU - Heath, K E AU - Heath KE AD - Centre for Genetics of Cardiovascular Disorders, Department of Medicine, The Rayne Institute, University College London Medical School, UK. kheath@hgmp.mrc.ac.uk FAU - Gudnason, V AU - Gudnason V FAU - Humphries, S E AU - Humphries SE FAU - Seed, M AU - Seed M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 RN - 0 (Apolipoproteins E) RN - 0 (Cholesterol, LDL) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Receptors, LDL) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Adult MH - Aged MH - Apolipoproteins E/genetics MH - Cholesterol, LDL/*blood MH - Dose-Response Relationship, Drug MH - Female MH - Genotype MH - Heterozygote MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use MH - Hyperlipoproteinemia Type II/blood/complications/*drug therapy/*genetics MH - Male MH - Middle Aged MH - Muscular Diseases/complications/genetics MH - *Mutation MH - Receptors, LDL/*genetics MH - Simvastatin/*therapeutic use MH - Tendons MH - Xanthomatosis/complications/genetics EDAT- 1999/04/20 00:00 MHDA- 1999/04/20 00:01 CRDT- 1999/04/20 00:00 PHST- 1999/04/20 00:00 [pubmed] PHST- 1999/04/20 00:01 [medline] PHST- 1999/04/20 00:00 [entrez] AID - S0021-9150(98)00274-3 [pii] AID - 10.1016/s0021-9150(98)00274-3 [doi] PST - ppublish SO - Atherosclerosis. 1999 Mar;143(1):41-54. doi: 10.1016/s0021-9150(98)00274-3. PMID- 7717815 OWN - NLM STAT- MEDLINE DCOM- 19950517 LR - 20190830 IS - 0003-9993 (Print) IS - 0003-9993 (Linking) VI - 76 IP - 3 DP - 1995 Mar TI - Shoulder complaints in patients with reflex sympathetic dystrophy of the upper extremity. PG - 239-42 AB - Five hundred forty-one patients with reflex sympathetic dystrophy (RSD) of the upper extremity were prospectively studied. One hundred fifteen patients complained of pain and/or limited range of motion in the shoulder. Shoulder complaints more often occurred in women (p = .01); age and etiology were not different from patients with RSD without shoulder complaints. Physical examination showed a tendinitis of one or both tendons of the biceps muscle in 109 patients. Seventy one patients were treated with local injection of bupivacaine followed by methylprednisolone. This resulted in permanent relief of complaints in 34 patients, temporary or moderate relief in 31, no difference in 3, increase of complaints in 1 patient, and in 2 patients results were not documented. We conclude that shoulder complaints in RSD occur in a minority of patients and more often in female patients. There are no predisposing factors. The pathophysiologic mechanism for developing shoulder complaints remains unknown. In most cases complaints can be attributed to a bicipital tendinitis for which local injection of bupivacaine followed by prednisolone are both diagnostic and therapeutic. FAU - Veldman, P H AU - Veldman PH AD - Department of Surgery, University Hospital Nijmegen, The Netherlands. FAU - Goris, R J AU - Goris RJ LA - eng PT - Journal Article PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - X4W7ZR7023 (Methylprednisolone) RN - Y8335394RO (Bupivacaine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Bupivacaine/therapeutic use MH - Child MH - Drug Therapy, Combination MH - Female MH - Humans MH - Male MH - Methylprednisolone/therapeutic use MH - Middle Aged MH - Pain/drug therapy/*etiology MH - Prospective Studies MH - Range of Motion, Articular MH - Reflex Sympathetic Dystrophy/*complications/physiopathology MH - *Shoulder/physiopathology MH - Tendinopathy/drug therapy/etiology MH - Treatment Outcome EDAT- 1995/03/01 00:00 MHDA- 1995/03/01 00:01 CRDT- 1995/03/01 00:00 PHST- 1995/03/01 00:00 [pubmed] PHST- 1995/03/01 00:01 [medline] PHST- 1995/03/01 00:00 [entrez] AID - S0003-9993(95)80608-3 [pii] AID - 10.1016/s0003-9993(95)80608-3 [doi] PST - ppublish SO - Arch Phys Med Rehabil. 1995 Mar;76(3):239-42. doi: 10.1016/s0003-9993(95)80608-3. PMID- 3349684 OWN - NLM STAT- MEDLINE DCOM- 19880512 LR - 20141120 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 229 DP - 1988 Apr TI - Isobutyl cyanoacrylate as a soft tissue adhesive. An in vitro study in the rabbit Achilles tendon. PG - 241-8 AB - Cyanoacrylates (CAs) are biodegradable, bacteriostatic, and hemostatic adhesives. CAs have been used in medical applications, but with adverse effects, including excessive inflammatory reaction and neural toxicity. Isobutyl CA (ICA) appears more biocompatible, with a long half-life that may be ideal for a soft tissue adhesive. The rabbit Achilles tendon was chosen to test (ICA), and a special muscle-freezing clamp to test this model was designed. The tendons were sharply cut 2 cm proximal to their insertion and repaired in four groups. They were tested to failure on an Instron machine. The breaking strength of the repairs was then noted. Also, the breaking strength of several suture materials was tested. Four Achilles tendon repair groups were evaluated: ICA alone 9.03 newtons (NTS); 4-0 silk Kessler stitch, mean 12.9 NTS; Kessler stitch plus three simple stitches, mean 23.0 NTS; and a combination of (a) and (c)--i.e., suture and adhesive, mean 40.2 NTS. The intact Achilles tendon was tested with an average breaking strength of 317 NTS. The muscle-freezing clamp facilitated reasonable testing of this tendon repair. ICA alone exhibits reasonable strength in vitro and in combination with suture provides a stronger initial repair than either suture or adhesive alone. FAU - Bonutti, P M AU - Bonutti PM AD - Department of Orthopaedics, Cleveland Clinic Foundation, Ohio. FAU - Weiker, G G AU - Weiker GG FAU - Andrish, J T AU - Andrish JT LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Cyanoacrylates) RN - 2HJV1F859Z (Bucrylate) SB - IM MH - Achilles Tendon/*drug effects/surgery MH - Animals MH - Bucrylate/*therapeutic use MH - Cyanoacrylates/*therapeutic use MH - Drug Evaluation, Preclinical MH - In Vitro Techniques MH - Materials Testing/methods MH - Rabbits MH - Stress, Mechanical MH - Sutures EDAT- 1988/04/01 00:00 MHDA- 1988/04/01 00:01 CRDT- 1988/04/01 00:00 PHST- 1988/04/01 00:00 [pubmed] PHST- 1988/04/01 00:01 [medline] PHST- 1988/04/01 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1988 Apr;(229):241-8. PMID- 4632628 OWN - NLM STAT- MEDLINE DCOM- 19730518 LR - 20190820 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 6 IP - 2 DP - 1973 Mar TI - The role of the fibrous components and ground substance in the mechanical properties of biological tissues: a preliminary investigation. PG - 153-65 FAU - Minns, R J AU - Minns RJ FAU - Soden, P D AU - Soden PD FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Muscle Proteins) RN - 9007-34-5 (Collagen) RN - 9007-58-3 (Elastin) RN - 9G34HU7RV0 (Edetic Acid) RN - EC 3.2.1.- (Amylases) SB - IM MH - Amylases/pharmacology MH - Animals MH - Aorta/drug effects/*physiology MH - Bacillus subtilis/enzymology MH - Biomechanical Phenomena MH - Cattle MH - Collagen/physiology MH - Edetic Acid/pharmacology MH - Elastin/physiology MH - Humans MH - Kinetics MH - Ligaments/*physiology MH - Mathematics MH - Muscle Proteins/physiology MH - Stress, Mechanical MH - Tendons/drug effects/*physiology MH - Viscosity OID - NASA: 73144630 EDAT- 1973/03/01 00:00 MHDA- 1973/03/01 00:01 CRDT- 1973/03/01 00:00 PHST- 1973/03/01 00:00 [pubmed] PHST- 1973/03/01 00:01 [medline] PHST- 1973/03/01 00:00 [entrez] AID - 0021-9290(73)90084-5 [pii] AID - 10.1016/0021-9290(73)90084-5 [doi] PST - ppublish SO - J Biomech. 1973 Mar;6(2):153-65. doi: 10.1016/0021-9290(73)90084-5. PMID- 16276022 OWN - NLM STAT- MEDLINE DCOM- 20060130 LR - 20191026 IS - 0914-9465 (Print) IS - 0914-9465 (Linking) VI - 68 IP - 3 DP - 2005 Sep TI - Functional ability of tendinocytes to take up Fe substances in an inflamed tendon. PG - 161-9 AB - The fate of iron (Fe) after bleeding has been analyzed in various connective tissues, but there have been only a few inconclusive studies on Fe in the tendon. In this study, energy dispersive X-ray microanalysis and an iron staining method were used to determine the localization of Fe in cells of the equine superficial digital flexor tendon. In inflamed tendons, Fe was detected in tendinocytes as well as macrophages. In contrast, negative or weak reactions were observed in many cells in the normal tendon. Although the accepted theory states that the reticuloendothelial system (macrophages and reticuloendothelial cells) is mainly responsible for the uptake and decomposition of erythrocytes, and tendon cells under conditions of inflammation show a functional ability to take up Fe substances. It has been reported that tendinocytes have multiple functions, including synthesis and secretion of collagen, cytokines, and matrix metalloproteinases. Taking these functions into consideration, indicates that the tendinocyte is not only an active cell but also a multi-functional cell. FAU - Hosaka, Yoshinao AU - Hosaka Y AD - Department of Veterinary Anatomy, School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Japan. hosap@rakuno.ac.jp FAU - Yamaguchi, Mamoru AU - Yamaguchi M FAU - Takehana, Kazushige AU - Takehana K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Japan TA - Arch Histol Cytol JT - Archives of histology and cytology JID - 8806082 RN - 9G34HU7RV0 (Edetic Acid) RN - E1UOL152H7 (Iron) SB - IM MH - Animals MH - Edetic Acid/metabolism/pharmacology MH - Female MH - Hemorrhage/metabolism MH - Horses MH - Inflammation/metabolism MH - Iron/*metabolism MH - Macrophages/cytology/metabolism MH - Male MH - Microscopy, Electron, Transmission MH - Microscopy, Polarization MH - Tendons/metabolism/*pathology/ultrastructure EDAT- 2005/11/09 09:00 MHDA- 2006/01/31 09:00 CRDT- 2005/11/09 09:00 PHST- 2005/11/09 09:00 [pubmed] PHST- 2006/01/31 09:00 [medline] PHST- 2005/11/09 09:00 [entrez] AID - JST.JSTAGE/aohc/68.161 [pii] AID - 10.1679/aohc.68.161 [doi] PST - ppublish SO - Arch Histol Cytol. 2005 Sep;68(3):161-9. doi: 10.1679/aohc.68.161. PMID- 21980023 OWN - NLM STAT- MEDLINE DCOM- 20111115 LR - 20191027 IS - 1067-151X (Print) IS - 1067-151X (Linking) VI - 19 IP - 10 DP - 2011 Oct TI - Biologic and pharmacologic augmentation of rotator cuff repairs. PG - 583-9 AB - As rotator cuff repair techniques have improved, failure of the tendon to heal to the proximal humerus is less likely to occur from weak tendon-to-bone fixation. More likely causes of failure include biologic factors such as intrinsic tendon degeneration, fatty atrophy, fatty infiltration of muscle, and lack of vascularity of the tendons. High failure rates have led to the investigation of biologic augmentation to potentially enhance the healing response. Histologic studies have shown that restoration of the rotator cuff footprint during repair can help reestablish the enthesis. In animal models, growth factors and their delivery scaffolds as well as tissue engineering have shown promise in decreasing scar tissue while maintaining biomechanical strength. Platelet-rich plasma may be a safe adjuvant to rotator cuff repair, but it has not been shown to improve healing or function. Many of these strategies need to be further defined to permit understanding of, and to optimize, the biologic environment; in addition, techniques need to be refined for clinical use. FAU - Edwards, Sara L AU - Edwards SL AD - Department of Orthopaedic Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. FAU - Lynch, T Sean AU - Lynch TS FAU - Saltzman, Matthew D AU - Saltzman MD FAU - Terry, Michael A AU - Terry MA FAU - Nuber, Gordon W AU - Nuber GW LA - eng PT - Journal Article PT - Review PL - United States TA - J Am Acad Orthop Surg JT - The Journal of the American Academy of Orthopaedic Surgeons JID - 9417468 RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Diphosphonates) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 62031-54-3 (Fibroblast Growth Factors) SB - IM MH - Animals MH - Bone Morphogenetic Proteins/therapeutic use MH - Diphosphonates/therapeutic use MH - Fibroblast Growth Factors/therapeutic use MH - Genetic Therapy/methods MH - Humans MH - Intercellular Signaling Peptides and Proteins/therapeutic use MH - Platelet-Rich Plasma/chemistry MH - *Rotator Cuff Injuries MH - Tendon Injuries/surgery/*therapy MH - Tissue Engineering MH - Tissue Scaffolds MH - Wound Healing/*physiology EDAT- 2011/10/08 06:00 MHDA- 2011/11/16 06:00 CRDT- 2011/10/08 06:00 PHST- 2011/10/08 06:00 [entrez] PHST- 2011/10/08 06:00 [pubmed] PHST- 2011/11/16 06:00 [medline] AID - 19/10/583 [pii] AID - 10.5435/00124635-201110000-00002 [doi] PST - ppublish SO - J Am Acad Orthop Surg. 2011 Oct;19(10):583-9. doi: 10.5435/00124635-201110000-00002. PMID- 16752399 OWN - NLM STAT- MEDLINE DCOM- 20070123 LR - 20250529 IS - 1549-3296 (Print) IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 79 IP - 3 DP - 2006 Dec 1 TI - Effect of curing time and concentration for a chemical treatment that improves surface gliding for extrasynovial tendon grafts in vitro. PG - 451-5 AB - The purpose of this study was to evaluate whether treatment time and concentration of these reagents have an effect on the resulting gliding resistance. Forty peroneus longus (PL) tendons were used, from 20 adult mongrel dogs, along with the A2 pulley obtained from the ipsilateral hind paw. After the baseline gliding resistance was measured, the PL tendons were treated with one of three concentrations of hyaluronic acid (HA) and 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) or N-hydroxysuccinimide (NHS) mixed with 10% gelatin for various times (5, 30, and 60 min). Tendon friction was measured over 1000 cycles of simulated flexion/extension motion. Gliding resistance of the untreated PL tendons had no significant difference among the groups. After surface treatment with low concentration of HA and EDC/NHS for 5-min cure, the gliding resistance was similar to that of the untreated PL tendon and significantly higher than its 30- and 60-min treatment. For the rest of high concentration of HA and EDC/NHS groups, the gliding resistance was lower than that of untreated PL tendon. However, there was no significant difference among the timing points. It is possible to optimize the effect of surface treatment on friction and durability by regulating cure time and concentration of reagents in a canine extrasynovial tendon in vitro. FAU - Tanaka, Toshikazu AU - Tanaka T AD - Orthopedic Biomechanics Laboratory, Division of Orthopedic Research, Mayo Clinic, Rochester, Minnesota, USA. FAU - Sun, Yu-Long AU - Sun YL FAU - Zhao, Chunfeng AU - Zhao C FAU - Zobitz, Mark E AU - Zobitz ME FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - R03 AR049407/AR/NIAMS NIH HHS/United States GR - AR49407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Succinimides) RN - 9004-61-9 (Hyaluronic Acid) RN - MJE3791M4T (N-hydroxysuccinimide) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) SB - IM MH - Animals MH - Dogs MH - Dose-Response Relationship, Drug MH - Ethyldimethylaminopropyl Carbodiimide/*pharmacology MH - Hyaluronic Acid/*pharmacology MH - In Vitro Techniques MH - Joint Capsule/*drug effects/pathology/*transplantation MH - Succinimides/*pharmacology MH - Tendons/*drug effects/pathology/*transplantation MH - Time Factors PMC - PMC3782254 MID - NIHMS371758 EDAT- 2006/06/06 09:00 MHDA- 2007/01/24 09:00 PMCR- 2013/09/24 CRDT- 2006/06/06 09:00 PHST- 2006/06/06 09:00 [pubmed] PHST- 2007/01/24 09:00 [medline] PHST- 2006/06/06 09:00 [entrez] PHST- 2013/09/24 00:00 [pmc-release] AID - 10.1002/jbm.a.30868 [doi] PST - ppublish SO - J Biomed Mater Res A. 2006 Dec 1;79(3):451-5. doi: 10.1002/jbm.a.30868. PMID- 35293974 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20230414 IS - 1573-4935 (Electronic) IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 42 IP - 3 DP - 2022 Mar 31 TI - High glucose represses the proliferation of tendon fibroblasts by inhibiting autophagy activation in tendon injury. LID - 10.1042/BSR20210640 [doi] LID - BSR20210640 AB - Diabetic foot ulcer (DFU) is a kind of common and disabling complication of Diabetes Mellitus (DM). Emerging studies have demonstrated that tendon fibroblasts play a crucial role in remodeling phase of wound healing. However, little is known about the mechanism underlying high glucose (HG)-induced decrease in tendon fibroblasts viability. In the present study, the rat models of DFU were established, and collagen deposition, autophagy activation and cell apoptosis in tendon tissues were assessed using Hematoxylin-Eosin (HE) staining, immunohistochemistry (IHC), and TdT-mediated dUTP Nick-End Labeling (TUNEL) assay, respectively. Tendon fibroblasts were isolated from Achilles tendon of the both limbs, and the effect of HG on autophagy activation in tendon fibroblasts was assessed using Western blot analysis, Cell Counting Kit-8 (CCK-8) assay, and flow cytometry. We found that cell apoptosis was increased significantly and autophagy activation was decreased in foot tendon tissues of DFU rats compared with normal tissues. The role of HG in regulating tendon fibroblasts viability was then investigated in vitro, and data showed that HG repressed cell viability and increased cell apoptosis. Furthermore, HG treatment reduced LC3-II expression and increased p62 expression, indicating that HG repressed autophagy activation of tendon fibroblasts. The autophagy activator rapamycin reversed the effect. More importantly, rapamycin alleviated the suppressive role of HG in tendon fibroblasts viability. Taken together, our data demonstrate that HG represses tendon fibroblasts proliferation by inhibiting autophagy activation in tendon injury. CI - © 2022 The Author(s). FAU - Song, Fu-Chen AU - Song FC AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Yuan, Jia-Qin AU - Yuan JQ AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Zhu, Mei-Dong AU - Zhu MD AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Li, Qi AU - Li Q AD - Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Liu, Sheng-Hua AU - Liu SH AD - Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Zhang, Lei AU - Zhang L AUID- ORCID: 0000-0003-2688-7300 AD - Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. FAU - Zhao, Cheng AU - Zhao C AD - Department of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - IY9XDZ35W2 (Glucose) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Animals MH - Apoptosis MH - Autophagy MH - Cell Proliferation MH - *Diabetic Foot/metabolism MH - Fibroblasts/metabolism MH - Glucose/metabolism MH - Rats MH - Sirolimus/pharmacology MH - *Tendon Injuries/metabolism MH - Tendons/metabolism PMC - PMC8935382 OTO - NOTNLM OT - Diabetic foot ulcer OT - Hyperglycemia OT - apoptosis OT - autophagy OT - tendon fibroblasts COIS- The authors declare that there are no competing interests associated with the manuscript. EDAT- 2022/03/17 06:00 MHDA- 2022/05/06 06:00 PMCR- 2022/03/16 CRDT- 2022/03/16 12:13 PHST- 2021/04/20 00:00 [received] PHST- 2021/07/28 00:00 [revised] PHST- 2021/08/09 00:00 [accepted] PHST- 2022/03/16 12:13 [entrez] PHST- 2022/03/17 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2022/03/16 00:00 [pmc-release] AID - 231043 [pii] AID - BSR20210640 [pii] AID - 10.1042/BSR20210640 [doi] PST - ppublish SO - Biosci Rep. 2022 Mar 31;42(3):BSR20210640. doi: 10.1042/BSR20210640. PMID- 35894650 OWN - NLM STAT- MEDLINE DCOM- 20220816 LR - 20250728 IS - 2042-650X (Electronic) IS - 2042-6496 (Linking) VI - 13 IP - 16 DP - 2022 Aug 15 TI - Structural characteristics and immunostimulatory activity of sea cucumber tendon polysaccharides in cyclophosphamide-induced Balb/c mice. PG - 8627-8642 LID - 10.1039/d2fo00942k [doi] AB - Sea cucumber tendon, one of the main parts of sea cucumber viscera, is widely accepted as a waste residue. In this study, a sea cucumber tendon polysaccharide (SCTPII) was purified from sea cucumber tendons and its primary structures and immunomodulatory activity were investigated. SCTPII is a triple-helix conformation homogeneous polysaccharide with a molecular weight of 3.97 × 10(6) Da that consists of glucose and fucose with molar ratios of 92.09% and 7.91% with high thermostability. In vivo tests on immunosuppressed Balb/c mice revealed that compared with the model group, the proliferation of T cells and B cells in splenic lymphocytes of mice in the high-dose group was significantly improved by 0.92 times and 5.14 times, respectively. Additionally, SCTPII could improve the proliferation ability and phagocytosis of macrophages, as well as promoting the expression of IL-6, TNF-α and IFN-γ and enhancing the intestinal physical barrier function by increasing the protein expression of claudin-1, occludin, ZO-1 and MUC2. Furthermore, the 16S rRNA sequencing of fecal samples was performed, and gene count and α-diversity analysis revealed that SCTPs could improve the microbial community richness. In particular, SCTPs could increase the relative abundance of Lactobacillus, Bacteroides and Akkermansia and reduce the relative abundance of Lachnospiraceae_NK4A136_group and Rikenellaceae_RC9_gut_group. These results demonstrate that SCPII possesses potential immunoregulatory activities in cyclophosphamide-induced mice by regulating intestinal microbiota diversity and improving immune organs, enhancing the proliferation ability of macrophages and splenocyte proliferation, and enhancing intestinal physical barrier function, which might provide important evidence for the development and utilization of the viscera of sea cucumber. FAU - Zhang, Zhuchi AU - Zhang Z AD - State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science & Technology, Tianjin 300457, China. zm0102@tust.edu.cn. FAU - Mwizerwa Muhindo, Esther AU - Mwizerwa Muhindo E AD - State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science & Technology, Tianjin 300457, China. zm0102@tust.edu.cn. FAU - Wang, Songjun AU - Wang S AD - State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science & Technology, Tianjin 300457, China. zm0102@tust.edu.cn. FAU - Yun, Liyuan AU - Yun L AUID- ORCID: 0000-0003-4030-1425 AD - China-Russia Agricultural Processing Joint Laboratory, Tianjin Agricultural University, Tianjin 300392, PR China. yunly1120@163.com. FAU - Zhang, Min AU - Zhang M AUID- ORCID: 0000-0002-8943-4002 AD - State Key Laboratory of Food Nutrition and Safety, Tianjin University of Science & Technology, Tianjin 300457, China. zm0102@tust.edu.cn. AD - China-Russia Agricultural Processing Joint Laboratory, Tianjin Agricultural University, Tianjin 300392, PR China. yunly1120@163.com. LA - eng PT - Journal Article DEP - 20220815 PL - England TA - Food Funct JT - Food & function JID - 101549033 RN - 0 (Polysaccharides) RN - 0 (RNA, Ribosomal, 16S) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Animals MH - Cyclophosphamide/pharmacology MH - Mice MH - Mice, Inbred BALB C MH - Polysaccharides/chemistry/pharmacology MH - RNA, Ribosomal, 16S/genetics MH - *Sea Cucumbers MH - Tendons EDAT- 2022/07/28 06:00 MHDA- 2022/08/17 06:00 CRDT- 2022/07/27 09:13 PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/08/17 06:00 [medline] PHST- 2022/07/27 09:13 [entrez] AID - 10.1039/d2fo00942k [doi] PST - epublish SO - Food Funct. 2022 Aug 15;13(16):8627-8642. doi: 10.1039/d2fo00942k. PMID- 5068851 OWN - NLM STAT- MEDLINE DCOM- 19721108 LR - 20191022 IS - 0008-0594 (Print) IS - 0008-0594 (Linking) VI - 9 IP - 4 DP - 1972 TI - Studies of the mechanism of biological calcification. 3. The interaction of strontium with a calcifiable matrix from beef tendon. PG - 310-24 FAU - Jethi, R K AU - Jethi RK FAU - Mackey, M G AU - Mackey MG FAU - Meredith, P D AU - Meredith PD FAU - Wadkins, C L AU - Wadkins CL LA - eng PT - Journal Article PL - Germany TA - Calcif Tissue Res JT - Calcified tissue research JID - 0114414 RN - 0 (Acetates) RN - 0 (Calcium Isotopes) RN - 0 (Phosphates) RN - 0 (Phosphorus Isotopes) RN - 0 (Strontium Isotopes) RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) RN - I38ZP9992A (Magnesium) RN - SY7Q814VUP (Calcium) RN - YZS2RPE8LE (Strontium) SB - IM MH - Acetates/pharmacology MH - Animals MH - *Calcification, Physiologic MH - Calcium/pharmacology MH - Calcium Isotopes/analysis MH - Cattle MH - Collagen/metabolism MH - Connective Tissue/metabolism MH - Culture Techniques MH - Magnesium/pharmacology MH - Methods MH - Phosphates/pharmacology MH - Phosphorus Isotopes/analysis MH - Spectrophotometry, Atomic MH - Strontium/antagonists & inhibitors/*metabolism MH - Strontium Isotopes/analysis MH - Tendons/analysis/*metabolism MH - Urea/pharmacology OID - NASA: 73000391 EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] AID - 10.1007/BF02061970 [doi] PST - ppublish SO - Calcif Tissue Res. 1972;9(4):310-24. doi: 10.1007/BF02061970. PMID- 36797536 OWN - NLM STAT- MEDLINE DCOM- 20240531 LR - 20240531 IS - 1573-6814 (Electronic) IS - 1389-9333 (Linking) VI - 25 IP - 2 DP - 2024 Jun TI - Repair of tendons treated with peracetic acid-ethanol and gamma irradiation by EDC combined with NHS: a morphological, biochemical and biomechanical study in vitro. PG - 427-442 LID - 10.1007/s10561-023-10080-6 [doi] AB - The purpose of this study was to investigate whether 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) combined with n-hydroxysuccinimide (NHS) can repair tendon damage caused by peracetic acid-ethanol and gamma irradiation sterilization. The semitendinosus tendons of 15 New Zealand white rabbits were selected as experimental materials, and the tendons were sterilized in a solution containing 1% (v/w) peracetic acid and 24% (v/w) ethanol. After 15 kGy gamma irradiation sterilization, the tendons were randomly divided into three groups (n = 10). The tendons were repaired with EDCs of 0, 2.5 and 5 mM combined with 5 mM NHS for 6 h, the tendons were temporarily stored at - 80 ± °C. The arrangement and spatial structure of collagen fibers were observed by light microscopy and scanning electron microscopy, the collagen type and collagen crimp period were observed under a polarizing microscope, and the collagen fibril diameter and its distribution were measured by transmission electron microscopy, from which the collagen fibril index and mass average diameter were calculated. The resistance of collagen to enzymolysis was detected by the free hydroxyproline test, and tensile fracture and cyclic loading tests of each group of tendons were carried out, from which the elastic modulus, maximum stress, maximum strain, strain energy density and cyclic creep strain were calculated. The obtained results showed that the gap between loose collagen fibers in the 0 mM control group was wider, the parallel arrangement of tendons in the 2.5 and 5 mM groups was more uniform and regular and the fiber space decreased, the crimp period in the 5 mM group was lower than that in the 0 mM group (P < 0.05), and the concentration of hydroxyproline in the 5 mM group (711.64 ± 77.95 μg/g) was better than that in the control group (1150.57 ± 158.75 μg/g). The elastic modulus of the 5 mM group (424.73 ± 150.96 MPa) was better than that of the 0 mM group (179.09 ± 37.14 MPa). Our results show that EDC combined with NHS can repair damaged tendons after peracetic acid-ethanol and gamma radiation treatment, and 5 mM EDC has better morphological performance, anti-enzymolysis ability and biomechanical properties than 2.5 mM EDC. CI - © 2023. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Ma, Rong-Xing AU - Ma RX AD - Department of Bone and Soft Tissue Oncology, Tianjin Hospital, 406 Jiefang Southern Road, Tianjin, 300211, China. AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Li, Rui-Feng AU - Li RF AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Deng, Xiao-Qiang AU - Deng XQ AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Qiao, Rui-Qi AU - Qiao RQ AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Li, Ji-Kai AU - Li JK AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Song, Kun-Xiu AU - Song KX AD - Department of Hand and Microsurgery, Binzhou Medical University Hospital, Binzhou, Shandong Province, China. FAU - Ji, Shao-Lin AU - Ji SL AD - Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong Province, China. FAU - Hu, Yong-Cheng AU - Hu YC AUID- ORCID: 0000-0001-9034-4269 AD - Department of Bone and Soft Tissue Oncology, Tianjin Hospital, 406 Jiefang Southern Road, Tianjin, 300211, China. huycdoctor@163.com. LA - eng PT - Journal Article DEP - 20230216 PL - Netherlands TA - Cell Tissue Bank JT - Cell and tissue banking JID - 100965121 RN - 3K9958V90M (Ethanol) RN - I6KPI2E1HD (Peracetic Acid) RN - 9007-34-5 (Collagen) RN - MJE3791M4T (N-hydroxysuccinimide) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) RN - 0 (Succinimides) SB - IM MH - Animals MH - Rabbits MH - *Gamma Rays MH - *Ethanol/pharmacology MH - *Tendons/drug effects/radiation effects MH - Biomechanical Phenomena/drug effects MH - *Peracetic Acid/pharmacology MH - *Collagen/metabolism MH - Ethyldimethylaminopropyl Carbodiimide/chemistry/pharmacology MH - Tensile Strength/drug effects MH - Tendon Injuries/therapy/pathology MH - Succinimides OTO - NOTNLM OT - 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide OT - Allografts OT - Collagen cross-linking OT - Peracetic acid OT - Tendon EDAT- 2023/02/17 06:00 MHDA- 2024/05/31 12:43 CRDT- 2023/02/16 23:29 PHST- 2022/11/23 00:00 [received] PHST- 2023/02/04 00:00 [accepted] PHST- 2024/05/31 12:43 [medline] PHST- 2023/02/17 06:00 [pubmed] PHST- 2023/02/16 23:29 [entrez] AID - 10.1007/s10561-023-10080-6 [pii] AID - 10.1007/s10561-023-10080-6 [doi] PST - ppublish SO - Cell Tissue Bank. 2024 Jun;25(2):427-442. doi: 10.1007/s10561-023-10080-6. Epub 2023 Feb 16. PMID- 35234523 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220719 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 50 IP - 5 DP - 2022 Apr TI - Promethazine Downregulates Wnt/β-Catenin Signaling and Increases the Biomechanical Forces of the Injured Achilles Tendon in the Early Stage of Healing. PG - 1317-1327 LID - 10.1177/03635465221077116 [doi] AB - BACKGROUND: Wnt/β-catenin signaling suppresses the differentiation of cultured tenocytes, but its roles in tendon repair remain mostly elusive. No chemical compounds are currently available to treat tendon injury. HYPOTHESIS: We hypothesized that the inhibition of Wnt/β-catenin signaling would accelerate tendon healing. STUDY DESIGN: Controlled laboratory study. METHODS: Tendon-derived cells (TDCs) were isolated from rat Achilles tendons. The right Achilles tendon was injured via a dermal punch, while the left tendon was sham operated. A Wnt/β-catenin inhibitor, IWR-1, and an antihistamine agent, promethazine (PH), were locally and intramuscularly injected, respectively, for 2 weeks after surgery. The healing tendons were histologically and biomechanically evaluated. RESULTS: The amount of β-catenin protein was increased in the injured tendons from postoperative weeks 0.5 to 2. Inhibition of Wnt/β-catenin signaling by IWR-1 in healing tendons improved the histological abnormalities and decreased β-catenin, but it compromised the biomechanical properties. As we previously reported that antihistamine agents suppressed Wnt/β-catenin signaling in human chondrosarcoma cells, we examined the effects of antihistamines on TDCs. We found that a first-generation antihistamine agent, PH, increased the expression of the tendon marker genes Mkx and Tnmd in TDCs. Intramuscular injection of PH did not improve histological abnormalities, but it decreased β-catenin in healing tendons and increased the peak force and stiffness of the healing tendons on postoperative week 2. On postoperative week 8, however, the biomechanical properties of vehicle-treated tendons became similar to those of PH-treated tendons. CONCLUSION: IWR-1 and PH suppressed Wnt/β-catenin signaling and improved the histological abnormalities of healing tendons. IWR-1, however, compromised the biomechanical properties of healing tendons, whereas PH improved them. CLINICAL RELEVANCE: PH is a candidate repositioned drug that potentially accelerates tendon repair. FAU - Sakaguchi, Takefumi AU - Sakaguchi T AD - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Ohkawara, Bisei AU - Ohkawara B AD - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Kishimoto, Yasuzumi AU - Kishimoto Y AD - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Miyamoto, Kentaro AU - Miyamoto K AD - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Ishizuka, Shinya AU - Ishizuka S AUID- ORCID: 0000-0003-1877-9502 AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Hiraiwa, Hideki AU - Hiraiwa H AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Ishiguro, Naoki AU - Ishiguro N AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Imagama, Shiro AU - Imagama S AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan. FAU - Ohno, Kinji AU - Ohno K AD - Division of Neurogenetics, Center for Neurological Diseases and Cancer, Graduate School of Medicine, Nagoya University, Nagoya, Japan. LA - eng PT - Journal Article DEP - 20220302 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (beta Catenin) RN - FF28EJQ494 (Promethazine) SB - IM MH - *Achilles Tendon/injuries MH - Animals MH - Biomechanical Phenomena MH - Humans MH - *Promethazine/metabolism/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Wnt Signaling Pathway MH - Wound Healing/physiology MH - beta Catenin/metabolism/pharmacology OTO - NOTNLM OT - Achilles tendon OT - biomechanics of the tendon OT - drug repositioning OT - promethazine OT - tendon healing EDAT- 2022/03/03 06:00 MHDA- 2022/04/19 06:00 CRDT- 2022/03/02 12:18 PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2022/03/02 12:18 [entrez] AID - 10.1177/03635465221077116 [doi] PST - ppublish SO - Am J Sports Med. 2022 Apr;50(5):1317-1327. doi: 10.1177/03635465221077116. Epub 2022 Mar 2. PMID- 28225101 OWN - NLM STAT- MEDLINE DCOM- 20180323 LR - 20180323 IS - 2047-4849 (Electronic) IS - 2047-4830 (Linking) VI - 5 IP - 8 DP - 2017 Jul 25 TI - Macrophage infiltration of electrospun polyester fibers. PG - 1579-1587 LID - 10.1039/c6bm00958a [doi] AB - Electrospun fibrous polylactide (PLA) membranes have been widely used for peritendinous anti-adhesion, but their degradation may lead to granuloma formation triggered by macrophages as the result of a foreign body reaction. To understand and solve this problem in peritendinous anti-adhesion, the effects of electrospun fibrous PLA membranes (PLA-M) and the mechanism by which macrophages elicit a foreign body reaction should be elaborated. Thus, the purpose of this study was to evaluate the ability of PLA-M and ibuprofen (IBU)-loaded fibrous PLA membranes (IBU/PLA-M) to prevent adhesion/granuloma formation around the tendon, and to understand the mechanism of macrophage infiltration. The results showed that PLA-M and IBU/PLA-M were porous and that IBU could be sustainably released from IBU/PLA-M. The adhesion and proliferation of RAW264.7 macrophages were worse on the surface of IBU/PLA-M than on PLA-M. After implantation around the tendon, IBU/PLA-M had higher anti-adhesion and tendon healing scores than PLA-M. Furthermore, PLA-M was able to promote macrophage infiltration, neovascularization, TNF-α expression and collagen III deposition to a greater extent than IBU/PLA-M. Consequently, these results show that macrophages can be triggered by PLA-M which subsequently leads to inflammation and granuloma formation, while IBU/PLA-M results in enhanced anti-inflammation and anti-adhesion effects when compared to PLA-M, by reducing macrophage infiltration. FAU - Liu, Shen AU - Liu S AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, People's Republic of China. wgcui80@hotmail.com xuyaozeng@163.com and Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, P.R. China. FAU - Chen, Hua AU - Chen H AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, People's Republic of China. wgcui80@hotmail.com xuyaozeng@163.com. FAU - Wu, Tianyi AU - Wu T AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, P.R. China. FAU - Pan, Guoqing AU - Pan G AUID- ORCID: 0000-0001-5187-796X AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, People's Republic of China. wgcui80@hotmail.com xuyaozeng@163.com. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, P.R. China. FAU - Xu, Yaozeng AU - Xu Y AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, People's Republic of China. wgcui80@hotmail.com xuyaozeng@163.com. FAU - Cui, Wenguo AU - Cui W AUID- ORCID: 0000-0002-6938-9582 AD - Department of Orthopedics, The First Affiliated Hospital of Soochow University, Orthopedic Institute, Soochow University, 708 Renmin Rd, Suzhou, Jiangsu 215006, People's Republic of China. wgcui80@hotmail.com xuyaozeng@163.com. LA - eng PT - Journal Article PL - England TA - Biomater Sci JT - Biomaterials science JID - 101593571 RN - 0 (Drug Carriers) RN - 0 (Membranes, Artificial) RN - 0 (Polyesters) RN - 459TN2L5F5 (poly(lactide)) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Animals MH - Cell Adhesion/drug effects MH - Cell Proliferation/drug effects MH - Drug Carriers/*chemistry MH - *Electricity MH - Granuloma/immunology/metabolism MH - Ibuprofen/chemistry/pharmacology MH - Macrophages/*cytology/*drug effects/immunology MH - Membranes, Artificial MH - Mice MH - Polyesters/*chemistry MH - RAW 264.7 Cells MH - Tendons/immunology EDAT- 2017/02/23 06:00 MHDA- 2018/03/24 06:00 CRDT- 2017/02/23 06:00 PHST- 2017/02/23 06:00 [pubmed] PHST- 2018/03/24 06:00 [medline] PHST- 2017/02/23 06:00 [entrez] AID - 10.1039/c6bm00958a [doi] PST - ppublish SO - Biomater Sci. 2017 Jul 25;5(8):1579-1587. doi: 10.1039/c6bm00958a. PMID- 6674504 OWN - NLM STAT- MEDLINE DCOM- 19840620 LR - 20190829 IS - 0022-5320 (Print) IS - 0022-5320 (Linking) VI - 85 IP - 2 DP - 1983 Nov TI - Light microscopy, electron microscopy, and X-ray diffraction analysis of glycerinated collagen fibers. PG - 228-37 AB - Light microscopy, transmission electron microscopy (freeze-fracture replicas and thin sections), and X-ray diffraction techniques were used to investigate the structure of rat tail tendon collagen fibers subjected to one of the following treatments: water, phosphate buffer, glutaraldehyde, glutaraldehyde followed by glycerol, glycerol, and glycerol followed by phosphate buffer. As seen by light microscopy, only treatment with glycerol induces a remarkable swelling of the native (untreated) collagen specimens. Replicas and thin sections show that this swelling is due to an expansion of the interfibrillar space, and to a dissociation of the collagen fibrils into microfibrils. X-Ray diffraction analysis reveals great disorder in the glycerol-swollen collagen fibers. However, this does not appreciably involve the microfibrillar and molecular structure. Light and electron microscopy as well as X-ray diffraction techniques show that the collagen fiber swelling induced by glycerol is an almost completely reversible process. FAU - Leonardi, L AU - Leonardi L FAU - Ruggeri, A AU - Ruggeri A FAU - Roveri, N AU - Roveri N FAU - Bigi, A AU - Bigi A FAU - Reale, E AU - Reale E LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Ultrastruct Res JT - Journal of ultrastructure research JID - 0376344 RN - PDC6A3C0OX (Glycerol) SB - IM MH - Animals MH - Freeze Fracturing MH - Glycerol/*pharmacology MH - Male MH - Microscopy, Electron MH - Rats MH - Rats, Inbred Strains MH - Tendons/anatomy & histology/drug effects/*ultrastructure MH - X-Ray Diffraction EDAT- 1983/11/01 00:00 MHDA- 1983/11/01 00:01 CRDT- 1983/11/01 00:00 PHST- 1983/11/01 00:00 [pubmed] PHST- 1983/11/01 00:01 [medline] PHST- 1983/11/01 00:00 [entrez] AID - 10.1016/s0022-5320(83)90109-0 [doi] PST - ppublish SO - J Ultrastruct Res. 1983 Nov;85(2):228-37. doi: 10.1016/s0022-5320(83)90109-0. PMID- 28538572 OWN - NLM STAT- MEDLINE DCOM- 20170901 LR - 20221207 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 139 IP - 6 DP - 2017 Jun TI - Intratendinous Injection of Hydrogel for Reseeding Decellularized Human Flexor Tendons. PG - 1305e-1314e LID - 10.1097/PRS.0000000000003359 [doi] AB - BACKGROUND: Decellularized cadaveric tendons are a potential source for reconstruction. Reseeding to enhance healing is ideal; however, cells placed on the tendon surface result in inadequate delivery. The authors used an injection technique to evaluate intratendinous cell delivery. METHODS: Decellularized tendons were reseeded with adipose-derived stem cells in culture, and injected with fetal bovine serum or hydrogel. PKH26-stained cells in cross-section were quantified. To evaluate cell viability, the authors delivered luciferase-labeled cells and performed bioluminescent imaging. To evaluate synthetic ability, the authors performed immunohistochemistry of procollagen. Adipose-derived stem cells' ability to attract tenocytes was assessed using transwell inserts. Cell-to-cell interaction was assessed by co-culturing, measuring proliferation and collagen production, and quantifying synergy. Finally, tensile strength was tested. RESULTS: Both fetal bovine serum (p < 0.001) and hydrogel (p < 0.001) injection led to more cells inside the tendon compared with culturing. Hydrogel injection initially demonstrated greater bioluminescence than culturing (p < 0.005) and fetal bovine serum injection (p < 0.05). Injection groups demonstrated intratendinous procollagen staining correlating with the cells' location. Co-culture led to greater tenocyte migration (p < 0.05). Interaction index of proliferation and collagen production assays were greater than 1 for all co-culture ratios, demonstrating synergistic proliferation and collagen production compared with controls (p < 0.05). There were no differences in tensile strength. CONCLUSIONS: Hydrogel injection demonstrated the greatest intratendinous seeding efficiency and consistency, without compromising tensile strength. Intratendinous cells demonstrated synthetic capabilities and can potentially attract tenocytes inside the tendon, where synergy would promote intrinsic tendon healing. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V. FAU - Long, Chao AU - Long C AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Galvez, Michael G AU - Galvez MG AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Legrand, Anais AU - Legrand A AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Joubert, Lydia-Marie AU - Joubert LM AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Wang, Zhen AU - Wang Z AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Chattopadhyay, Arhana AU - Chattopadhyay A AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Chang, James AU - Chang J AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Fox, Paige M AU - Fox PM AD - Stanford and Palo Alto, Calif. AD - From the Cell Sciences Imaging Facility, Stanford University School of Medicine; the Division of Plastic and Reconstructive Surgery, Stanford Health Care; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. LA - eng PT - Journal Article PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) SB - IM MH - Adipocytes/cytology MH - Animals MH - Cattle MH - Cell Survival MH - Coculture Techniques MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Injections, Intralesional MH - Rats MH - Plastic Surgery Procedures/methods MH - Sensitivity and Specificity MH - Stem Cells/cytology MH - Tendon Injuries/*surgery MH - Tendons/cytology/*drug effects/*transplantation MH - Tensile Strength MH - Tissue Engineering/*methods MH - Tissue Scaffolds EDAT- 2017/05/26 06:00 MHDA- 2017/09/02 06:00 CRDT- 2017/05/25 06:00 PHST- 2017/05/25 06:00 [entrez] PHST- 2017/05/26 06:00 [pubmed] PHST- 2017/09/02 06:00 [medline] AID - 00006534-201706000-00032 [pii] AID - 10.1097/PRS.0000000000003359 [doi] PST - ppublish SO - Plast Reconstr Surg. 2017 Jun;139(6):1305e-1314e. doi: 10.1097/PRS.0000000000003359. PMID- 18226666 OWN - NLM STAT- MEDLINE DCOM- 20080306 LR - 20220311 IS - 1532-821X (Electronic) IS - 0003-9993 (Linking) VI - 89 IP - 2 DP - 2008 Feb TI - High-resolution ultrasound and magnetic resonance imaging to document tissue repair after prolotherapy: a report of 3 cases. PG - 377-85 LID - 10.1016/j.apmr.2007.09.017 [doi] AB - High-resolution ultrasound imaging of musculoskeletal tissue is increasing in popularity because of patient tolerability, low cost, ability to visualize tissue in real-time motion, and superior resolution of highly organized tissue such as a tendon. Prolotherapy, defined as the injection of growth factors or growth factor production stimulants to grow normal cells or tissue, has been a controversial procedure for decades; it is currently gaining in popularity among physiatrists and other musculoskeletal physicians. This report describes imaging of tendons, ligaments, and medial meniscus disease (from trauma or degeneration). Although these tissues have been poorly responsive to nonsurgical treatment, it is proposed that tissue growth and repair after prolotherapy in these structures can be documented with ultrasound and confirmed with magnetic resonance imaging. Directions for future research application are discussed. FAU - Fullerton, Bradley D AU - Fullerton BD AD - Patient-Physician Partnership, Austin, TX, USA. drbdf@aol.com LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R RN - 0 (Anesthetics, Local) RN - 339NCG44TV (Phenol) RN - 98PI200987 (Lidocaine) RN - IY9XDZ35W2 (Glucose) RN - PDC6A3C0OX (Glycerol) SB - IM MH - Adolescent MH - Adult MH - Anesthetics, Local/*therapeutic use MH - Ankle Injuries/diagnosis/diagnostic imaging/*drug therapy MH - Athletic Injuries/diagnosis/diagnostic imaging/*drug therapy MH - Chronic Disease MH - Female MH - Glucose/*therapeutic use MH - Glycerol/therapeutic use MH - Humans MH - Injections MH - Knee Injuries/diagnosis/diagnostic imaging/*drug therapy MH - Lidocaine/*therapeutic use MH - Ligaments/injuries MH - *Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Phenol/therapeutic use MH - Tendon Injuries/diagnosis/diagnostic imaging/*drug therapy MH - Ultrasonography MH - Wound Healing/drug effects EDAT- 2008/01/30 09:00 MHDA- 2008/03/07 09:00 CRDT- 2008/01/30 09:00 PHST- 2008/01/30 09:00 [pubmed] PHST- 2008/03/07 09:00 [medline] PHST- 2008/01/30 09:00 [entrez] AID - S0003-9993(07)01594-8 [pii] AID - 10.1016/j.apmr.2007.09.017 [doi] PST - ppublish SO - Arch Phys Med Rehabil. 2008 Feb;89(2):377-85. doi: 10.1016/j.apmr.2007.09.017. PMID- 40464962 OWN - NLM STAT- MEDLINE DCOM- 20250604 LR - 20250929 IS - 1573-6814 (Electronic) IS - 1389-9333 (Linking) VI - 26 IP - 3 DP - 2025 Jun 4 TI - Effects of chemical and physical deimmunogenicity methods on the biological and biomechanical properties of allogeneic tendons. PG - 28 LID - 10.1007/s10561-025-10177-0 [doi] AB - To compare the differences in biological and biomechanical characteristics of cadaver tendon treated by deep freezing, 95wt.% ethanol, tributyl phosphate (TBP), and sodium dodecyl sulfate (SDS) respectively. A total of 50 fresh tendon specimens were randomly divided into five groups, and four groups were treated with deep freezing (- 80 °C), 95wt.% ethanol, 1% TBP, or 1% SDS, respectively. Hematoxylin-eosin (HE), toluidine blue (TB) and 4',6-diamidino-2-phenylindole (DAPI) staining, and transmission/scanning electron microscope observations were performed. Then, cyclic creep and tensile tests were conducted to investigate the biomechanical properties. The content of residual DNA was tested. The HE, TB and DAPI staining showed a significant decrease in tendon cells following treatments, compared with fresh specimens. SDS, TBP, alcohol can almost completely decellularize the tendon, and deep-frozen group remained a few number of tendon cells. The residual DNA content was significantly lowered, with an average percentage of 50.97%, 79.16%, 88.91% and 72.56%, for groups of deep freezing, alcohol, TBP and SDS, respectively. The arrangement of collagen fibers was significantly disrupted, and the gap between fibers was widened, following treatments by alcohol, TBP and SDS. However, the biomechanical properties were generally similar among the five groups, with significantly lowered cyclic creep for ethanol group and lowered Young's modulus for SDS group exclusively. The four treatments can effectively reduce the number of residual cells and DNA content. Among them, cryogenic treatment has almost no damage to tendon histology and biomechanics, while ethanol, SDS and TBP decellularization methods cause different degrees of damage. CI - © 2025. The Author(s), under exclusive licence to Springer Nature B.V. FAU - Yang, Xiong-Gang AU - Yang XG AD - Department of Orthopedic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - The Key Laboratory of Digital Orthopedics of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - Intelligent Orthopedic Medical Technology Research Center, Kunming University of Science and Technology, Kunming, China. FAU - Zhong, Hui AU - Zhong H AD - Department of Orthopedic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - The Key Laboratory of Digital Orthopedics of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - Intelligent Orthopedic Medical Technology Research Center, Kunming University of Science and Technology, Kunming, China. FAU - Zhang, Gui-Qian AU - Zhang GQ AD - Department of Orthopedic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - The Key Laboratory of Digital Orthopedics of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. FAU - Zhou, Jing-Cheng AU - Zhou JC AD - Department of Orthopedic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. AD - The Key Laboratory of Digital Orthopedics of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. FAU - Hu, Yong-Cheng AU - Hu YC AD - Department of Orthopedic Oncology, Tianjin Hospital, No. 406, Southern Jiefang Road, Hexi District, Tianjin, 300211, China. huyongchengtianjin@163.com. FAU - Lu, Sheng AU - Lu S AD - Department of Orthopedic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. drlusheng@163.com. AD - The Key Laboratory of Digital Orthopedics of Yunnan Province, No. 157 Jinbi Road, Xishan District, Kunming City, 650034, Yunnan Province, China. drlusheng@163.com. AD - Intelligent Orthopedic Medical Technology Research Center, Kunming University of Science and Technology, Kunming, China. drlusheng@163.com. LA - eng GR - KHBSH-2023-03/Postdoctoral Project of Yunnan First People's Hospital/ GR - 202501CF070009/Yunnan Fundamental Research Projects/ GR - 202403AC100003/Social Development Project of Science and Technology Department of Yunnan Province/ GR - 202102AA310068/Yunnan Orthopedics and Sports Rehabilitation Clinical Medical Research Center/ GR - ZX2022000101/Yunnan Spinal Cord Disease Clinical Medical Center/ GR - 202102AA310042/Major Science and Technology Project of Yunnan Province Science and Technology Plan/ GR - YNWR-MY-2019-058/Yunnan Province "Ten Thousand People Plan" Famous Medical Project/ GR - L-2019006/Yunnan Medical Leading Talents Project/ PT - Journal Article DEP - 20250604 PL - Netherlands TA - Cell Tissue Bank JT - Cell and tissue banking JID - 100965121 RN - 3K9958V90M (Ethanol) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 9007-49-2 (DNA) SB - IM MH - *Tendons/transplantation/physiology/drug effects/ultrastructure/cytology MH - Humans MH - Biomechanical Phenomena/drug effects MH - Ethanol/pharmacology MH - *Cryopreservation/methods MH - Sodium Dodecyl Sulfate/pharmacology MH - Male MH - DNA/analysis MH - Freezing MH - Transplantation, Homologous MH - Middle Aged MH - Tensile Strength MH - Female OTO - NOTNLM OT - Biological properties OT - Biomechanical properties OT - Decellularization OT - Tendon allograft COIS- Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical approval: This research was conducted in accordance with the Declaration of Helsinki, and upon attaining of the ethical approval from the Institutional Review Board of our Hospital. Informed consent: Not applicable. EDAT- 2025/06/04 12:29 MHDA- 2025/06/04 12:30 CRDT- 2025/06/04 11:14 PHST- 2022/08/17 00:00 [received] PHST- 2025/05/15 00:00 [accepted] PHST- 2025/06/04 12:30 [medline] PHST- 2025/06/04 12:29 [pubmed] PHST- 2025/06/04 11:14 [entrez] AID - 10.1007/s10561-025-10177-0 [pii] AID - 10.1007/s10561-025-10177-0 [doi] PST - epublish SO - Cell Tissue Bank. 2025 Jun 4;26(3):28. doi: 10.1007/s10561-025-10177-0. PMID- 2743769 OWN - NLM STAT- MEDLINE DCOM- 19890825 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 18 IP - 4 DP - 1989 TI - The contribution of labile crosslinks to the tensile behavior of tendons. PG - 293-305 AB - The tensile strength of rat tail tendons, measured by the load that ruptures the tendon, varies with the weight of the animal, the vertebra to which the tendon was attached, the pH of the tendon, and the chemical treatment. Reduction with sodium borohydride multiplies the tensile strength by a factor up to 4.5 (the factor diminishing with age) and reduces creep in the strained tendon. It is concluded that strain catalyzes the hydrolysis of aldimine intermolecular crosslinks that contribute significantly to the tensile strength under physiological conditions, and that the crosslinks are stabilized by reduction or with aging. It is postulated that creep is the result of slippage between polymeric assemblies of stably crosslinked molecules. This postulate leads to a plausible description of elongation of connective tissue fibrils in growing animals. FAU - Davison, P F AU - Davison PF AD - Boston Biomedical Research Institute, Boston, MA 02114. LA - eng GR - EY-4595/EY/NEI NIH HHS/United States GR - RR-5711/RR/NCRR NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Borohydrides) RN - 0 (Cross-Linking Reagents) RN - 0 (Imines) RN - 0 (Macromolecular Substances) RN - 87L0B9CPPA (sodium borohydride) RN - 9007-34-5 (Collagen) SB - IM MH - Aging MH - Animals MH - Body Weight MH - Borohydrides/pharmacology MH - Collagen/*metabolism MH - Cross-Linking Reagents MH - Female MH - Hydrogen-Ion Concentration MH - Hydrolysis MH - Imines MH - Kinetics MH - Macromolecular Substances MH - Male MH - Oxidation-Reduction MH - Rats MH - Tendons/anatomy & histology/*physiology MH - Tensile Strength/drug effects EDAT- 1989/01/01 00:00 MHDA- 1989/01/01 00:01 CRDT- 1989/01/01 00:00 PHST- 1989/01/01 00:00 [pubmed] PHST- 1989/01/01 00:01 [medline] PHST- 1989/01/01 00:00 [entrez] AID - 10.3109/03008208909019078 [doi] PST - ppublish SO - Connect Tissue Res. 1989;18(4):293-305. doi: 10.3109/03008208909019078. PMID- 21364414 OWN - NLM STAT- MEDLINE DCOM- 20110426 LR - 20210106 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 127 IP - 3 DP - 2011 Mar TI - Optimization of human tendon tissue engineering: peracetic acid oxidation for enhanced reseeding of acellularized intrasynovial tendon. PG - 1107-1117 LID - 10.1097/PRS.0b013e318205f298 [doi] AB - BACKGROUND: Tissue engineering of human flexor tendons combines tendon scaffolds with recipient cells to create complete cell-tendon constructs. Allogenic acellularized human flexor tendon has been shown to be a useful natural scaffold. However, there is difficulty repopulating acellularized tendon with recipient cells, as cell penetration is restricted by a tightly woven tendon matrix. The authors evaluated peracetic acid treatment in optimizing intratendinous cell penetration. METHODS: Cadaveric human flexor tendons were harvested, acellularized, and divided into experimental groups. These groups were treated with peracetic acid in varying concentrations (2%, 5%, and 10%) and for varying time periods (4 and 20 hours) to determine the optimal treatment protocol. Experimental tendons were analyzed for differences in tendon microarchitecture. Additional specimens were reseeded by incubation in a fibroblast cell suspension at 1 × 10(6) cells/ml. This group was then analyzed for reseeding efficacy. A final group underwent biomechanical studies for strength. RESULTS: The optimal treatment protocol comprising peracetic acid at 5% concentration for 4 hours produced increased scaffold porosity, improving cell penetration and migration. Treated scaffolds did not show reduced collagen or glycosaminoglycan content compared with controls (p = 0.37 and p = 0.65, respectively). Treated scaffolds were cytotoxic to neither attached cells nor the surrounding cell suspension. Treated scaffolds also did not show inferior ultimate tensile stress or elastic modulus compared with controls (p = 0.26 and p = 0.28, respectively). CONCLUSIONS: Peracetic acid treatment of acellularized tendon scaffolds increases matrix porosity, leading to greater reseeding. It may prove to be an important step in tissue engineering of human flexor tendon using natural scaffolds. FAU - Woon, Colin Y L AU - Woon CYL AD - Palo Alto, Calif. From the Division of Plastic and Reconstructive Surgery, Stanford University Medical Center, and the Section of Plastic Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Pridgen, Brian C AU - Pridgen BC FAU - Kraus, Armin AU - Kraus A FAU - Bari, Sina AU - Bari S FAU - Pham, Hung AU - Pham H FAU - Chang, James AU - Chang J LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Oxidants) RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - Biomechanical Phenomena MH - Cadaver MH - Cells, Cultured MH - Fibroblasts/drug effects/*metabolism/transplantation MH - Humans MH - Oxidants/*pharmacology MH - Oxidation-Reduction/*drug effects MH - Peracetic Acid/*pharmacokinetics MH - Tendons/cytology/metabolism/*transplantation MH - Tissue Engineering/*methods EDAT- 2011/03/03 06:00 MHDA- 2011/04/27 06:00 CRDT- 2011/03/03 06:00 PHST- 2011/03/03 06:00 [entrez] PHST- 2011/03/03 06:00 [pubmed] PHST- 2011/04/27 06:00 [medline] AID - 00006534-201103000-00011 [pii] AID - 10.1097/PRS.0b013e318205f298 [doi] PST - ppublish SO - Plast Reconstr Surg. 2011 Mar;127(3):1107-1117. doi: 10.1097/PRS.0b013e318205f298. PMID- 10559756 OWN - NLM STAT- MEDLINE DCOM- 20000121 LR - 20190910 IS - 0021-9304 (Print) IS - 0021-9304 (Linking) VI - 49 IP - 1 DP - 2000 Jan TI - Effect of chemical treatments on tendon cellularity and mechanical properties. PG - 134-40 AB - Removal of cells may decrease the antigenicity and risk of disease transmission associated with tendon allografts and xenografts. An ideal cell removal method would not compromise graft structure and mechanical properties. This study compared the effects of three extraction chemicals [t-octyl-phenoxypolyethoxyethanol (Triton X-100), tri(n-butyl)phosphate (TnBP), and sodium dodecyl sulfate (SDS)] on tendon cellularity, structure, nativity, and mechanical properties. Rat tail tendons were soaked in extraction solutions for various time periods (12-48 h) and concentrations (0.5-2%), then they were rinsed with distilled water and ethyl alcohol. Histological analysis and tensile tests were performed on control and chemically treated tendons. Changes in collagen nativity were estimated by mechanical testing following incubation in a trypsin solution. Treatment of tendons with 1% Triton X-100 for 24 h disrupted the collagen fiber structure and did not remove cells. Treatment with 1% SDS for 24 h or 1% TnBP for 48 h resulted in an acellular tendon matrix with retention of near normal structure and mechanical properties. Consistent with previous studies demonstrating cell removal from other tissue types using SDS and TnBP, our preliminary results suggest these treatments are potentially useful for removing cells from tendon allografts or xenografts without compromising the graft structure or mechanical properties. CI - Copyright 2000 John Wiley & Sons, Inc. FAU - Cartmell, J S AU - Cartmell JS AD - Orthopaedic Research Laboratory, Division of Orthopaedic Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA. FAU - Dunn, M G AU - Dunn MG LA - eng GR - R29-AR42230/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biomed Mater Res JT - Journal of biomedical materials research JID - 0112726 RN - 0 (Organophosphates) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 9002-93-1 (Octoxynol) RN - 9007-34-5 (Collagen) RN - 95UAS8YAF5 (tributyl phosphate) RN - EC 3.4.21.4 (Trypsin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/biosynthesis MH - Fibroblasts MH - Hydrolysis MH - In Vitro Techniques MH - Muscle, Smooth, Vascular/cytology/drug effects MH - Octoxynol/*pharmacology MH - Organophosphates/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Sodium Dodecyl Sulfate/*pharmacology MH - Tendons/*cytology/*drug effects/physiology MH - Trypsin EDAT- 1999/11/24 00:00 MHDA- 1999/11/24 00:01 CRDT- 1999/11/24 00:00 PHST- 1999/11/24 00:00 [pubmed] PHST- 1999/11/24 00:01 [medline] PHST- 1999/11/24 00:00 [entrez] AID - 10.1002/(SICI)1097-4636(200001)49:1<134::AID-JBM17>3.0.CO;2-D [pii] AID - 10.1002/(sici)1097-4636(200001)49:1<134::aid-jbm17>3.0.co;2-d [doi] PST - ppublish SO - J Biomed Mater Res. 2000 Jan;49(1):134-40. doi: 10.1002/(sici)1097-4636(200001)49:1<134::aid-jbm17>3.0.co;2-d. PMID- 6438934 OWN - NLM STAT- MEDLINE DCOM- 19841226 LR - 20201209 IS - 0232-7295 (Print) IS - 0232-7295 (Linking) VI - 17 IP - 5 DP - 1984 TI - [Experimental studies of the sterilization of transplantation material with peracetic acid]. PG - 254-8 AB - Experimental investigations for sterilization of prepared transplantation material without aseptic conditions were carried out with peracetic acid of different aqueous and alcoholic dilutions. This chemical germicide is qualified yet for the sterilization of tendinous tissue but not for bone tissue (spongiosa and compact substance). The different cellular structures of the test objects condition this behaviour likely. Peracetic acid is consequently no substitute for beta-propiolactone as germicide in a tissue bank which preserves various tissues (above all also bone) for transplantation. FAU - Starke, R AU - Starke R FAU - Hackensellner, H A AU - Hackensellner HA FAU - von Versen, R AU - von Versen R LA - ger PT - Journal Article TT - Experimentelle Untersuchungen zur Entkeimung von Transplantationsmaterial mit Peressigsäure. PL - Germany TA - Z Exp Chir Transplant Kunstliche Organe JT - Zeitschrift fur experimentelle Chirurgie, Transplantation, und kunstliche Organe : Organ der Sektion Experimentelle Chirurgie der Gesellschaft fur Chirurgie der DDR JID - 8302880 RN - 0 (Acetates) RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - *Acetates/pharmacology MH - Bacillus subtilis/drug effects MH - Bone Transplantation MH - *Bone and Bones/microbiology MH - Candida albicans/drug effects MH - Humans MH - *Peracetic Acid/pharmacology MH - Pseudomonas aeruginosa/drug effects MH - Staphylococcus aureus/drug effects MH - *Sterilization MH - *Tendons/microbiology/transplantation EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] PST - ppublish SO - Z Exp Chir Transplant Kunstliche Organe. 1984;17(5):254-8. PMID- 6272752 OWN - NLM STAT- MEDLINE DCOM- 19820120 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 196 IP - 1 DP - 1981 Apr 15 TI - Effect of prevention of procollagen triple-helix formation on proline 3-hydroxylation in freshly isolated chick-embryo tendon cells. PG - 203-6 AB - Inhibition of procollagen triple-helix formation by the addition of cis-hydroxyproline or azetidine-2-carboxylic acid increased the synthesis of 3-hydroxy[14C]proline 1.7-1.8-fold in pulse-chase experiments with freshly isolated chick-embryo tendon cells. The amount of 3-hydroxy[14C]proline, expressed as a percentage of the total 14C radioactivity in hydroxyproline, reached 8.4%. Control experiments indicated that the two analogues had no effect on the prolyl 3-hydroxylase activity of these cells. The data suggest that the time available before triple-helix formation in part regulates the extent of the 3-hydroxylation of proline in the biosynthesis of collagen in intact cells. FAU - Majamaa, K AU - Majamaa K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Azetines) RN - 0 (Procollagen) RN - 5GZ3E0L9ZU (Azetidinecarboxylic Acid) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Azetidinecarboxylic Acid/*pharmacology MH - Azetines/*pharmacology MH - Chick Embryo MH - Hydroxylation MH - Hydroxyproline/*biosynthesis/pharmacology MH - In Vitro Techniques MH - Procollagen/*biosynthesis MH - Procollagen-Proline Dioxygenase/metabolism MH - Protein Conformation/drug effects MH - Tendons/cytology/drug effects/*metabolism PMC - PMC1162983 EDAT- 1981/04/15 00:00 MHDA- 1981/04/15 00:01 PMCR- 1981/10/15 CRDT- 1981/04/15 00:00 PHST- 1981/04/15 00:00 [pubmed] PHST- 1981/04/15 00:01 [medline] PHST- 1981/04/15 00:00 [entrez] PHST- 1981/10/15 00:00 [pmc-release] AID - 10.1042/bj1960203 [doi] PST - ppublish SO - Biochem J. 1981 Apr 15;196(1):203-6. doi: 10.1042/bj1960203. PMID- 27641547 OWN - NLM STAT- MEDLINE DCOM- 20171002 LR - 20181202 IS - 1873-2380 (Electronic) IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 49 IP - 14 DP - 2016 Oct 3 TI - Embryonically inspired scaffolds regulate tenogenically differentiating cells. PG - 3281-3288 LID - S0021-9290(16)30886-7 [pii] LID - 10.1016/j.jbiomech.2016.08.011 [doi] AB - Tendon injuries heal as scar tissue with significant dysfunction and propensity to re-injure, motivating efforts to develop stem cell-based therapies for tendon regeneration. For these therapies to succeed, effective cues to guide tenogenesis are needed. Our aim is to identify these cues within the embryonic tendon microenvironment. We recently demonstrated embryonic tendon elastic modulus increases during development and is substantially lower than in adult. Here, we examined how these embryonic mechanical properties influence tenogenically differentiating cells, by culturing embryonic tendon progenitor cells (TPCs) within alginate gel scaffolds fabricated with embryonic tendon mechanical properties. We showed that nano- and microscale moduli of RGD-functionalized alginate gels can be tailored to that of embryonic tendons by adjusting polymer concentration and crosslink density. These gels differentially regulated morphology of encapsulated TPCs as a function of initial elastic modulus. Additionally, higher initial elastic moduli elicited higher mRNA levels of scleraxis and collagen type XII but lower levels of collagen type I, whereas late tendon markers tenomodulin and collagen type III were unaffected. Our results demonstrate the potential to engineer scaffolds with embryonic mechanical properties and to use these scaffolds to regulate the behavior of tenogenically differentiating cells. CI - Copyright © 2016 Elsevier Ltd. All rights reserved. FAU - Marturano, Joseph E AU - Marturano JE AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States. FAU - Schiele, Nathan R AU - Schiele NR AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States. FAU - Schiller, Zachary A AU - Schiller ZA AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States. FAU - Galassi, Thomas V AU - Galassi TV AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States. FAU - Stoppato, Matteo AU - Stoppato M AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States. FAU - Kuo, Catherine K AU - Kuo CK AD - Tufts University, Department of Biomedical Engineering, 4 Colby St, Medford, MA 02155, United States; University of Rochester, Department of Biomedical Engineering, Department of Orthopaedics, Center for Musculoskeletal Research, 215 Robert B. Goergen Hall, Rochester, NY 14627, United States. Electronic address: Catherine.K.Kuo@rochester.edu. LA - eng GR - K12 GM074869/GM/NIGMS NIH HHS/United States GR - R03 AR061036/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20160821 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Alginates) RN - 0 (Collagen Type XII) RN - 0 (Hexuronic Acids) RN - 0 (Membrane Proteins) RN - 8A5D83Q4RW (Glucuronic Acid) SB - IM MH - Alginates/pharmacology MH - Animals MH - *Cell Differentiation/drug effects MH - Chick Embryo MH - Collagen Type XII/metabolism MH - Elastic Modulus/drug effects MH - Embryonic Stem Cells/*cytology/drug effects/metabolism MH - Glucuronic Acid/pharmacology MH - Hexuronic Acids/pharmacology MH - Membrane Proteins/metabolism MH - Regeneration/drug effects MH - Tendons/*cytology/*embryology/physiology MH - Tissue Engineering MH - Tissue Scaffolds PMC - PMC6086339 MID - NIHMS817858 OTO - NOTNLM OT - Alginate gels OT - Elastic modulus OT - Embryonic OT - Tendon OT - Tissue Engineering COIS- 6. Conflict of Interest Statement The authors have no conflicts of interest to disclose. EDAT- 2016/10/22 06:00 MHDA- 2017/10/03 06:00 PMCR- 2018/08/10 CRDT- 2016/09/20 06:00 PHST- 2016/03/02 00:00 [received] PHST- 2016/07/14 00:00 [revised] PHST- 2016/08/09 00:00 [accepted] PHST- 2016/10/22 06:00 [pubmed] PHST- 2017/10/03 06:00 [medline] PHST- 2016/09/20 06:00 [entrez] PHST- 2018/08/10 00:00 [pmc-release] AID - S0021-9290(16)30886-7 [pii] AID - 10.1016/j.jbiomech.2016.08.011 [doi] PST - ppublish SO - J Biomech. 2016 Oct 3;49(14):3281-3288. doi: 10.1016/j.jbiomech.2016.08.011. Epub 2016 Aug 21. PMID- 25184246 OWN - NLM STAT- MEDLINE DCOM- 20150427 LR - 20181202 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 42 IP - 12 DP - 2014 Dec TI - Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study. PG - 2869-76 LID - 10.1177/0363546514545856 [doi] AB - BACKGROUND: Statins are lipid-lowering drugs with many beneficial pleiotropic effects. Cyclooxygenase (COX2) selective inhibitors that are commonly prescribed in orthopaedic patients may effect healing. Evidence indicates that statins stimulate COX2 activity. HYPOTHESIS: Atorvastatin (ATV) administration will enhance tendon healing by stimulating the acute inflammatory phase via increasing the production of prostaglandin E2 (PGE2). STUDY DESIGN: Controlled laboratory study. METHODS: After experimental rotator cuff (RC) tearing and suturing, 48 Wistar rats were randomly allocated into 4 groups: (1) ATV (20 mg/kg), (2) celecoxib (CEL; COX2 inhibitor) (10 mg/kg), (3) ATV + CEL (20 mg/kg + 10 mg/kg), and (4) saline alone. Animals were sacrificed 3 weeks after RC tears and repair, and tendon integrity was tested biomechanically in tension. To further evaluate the underlying mechanism of action, human and rat primary tenocytes were obtained from the supraspinatus tendon. Cultures were treated with a therapeutic dosage of 5 commonly used statins: CEL, ATV + CEL, PGE2, and a selective antagonist of PGE2 receptor 4 (EP4). Cell proliferation (thymidine incorporation), migration (wound healing assay), and adhesion (iCELLigence) were evaluated. The expression of all PGE2 receptors (EPs) was determined by quantitative reverse transcription polymerase chain reaction. RESULTS: Tension testing of healed tendons demonstrated significantly higher maximal loading and stiffness in the ATV group as compared with the saline (+30% and +20%, respectively; P < .001) and CEL groups (+33% and +50%, respectively; P < .005). Celecoxib alone did not affect tendon healing (P = .88). In line with these in vivo results, tenocytes treated with statins demonstrated significantly higher proliferation rates; CEL abrogated this effect, and PGE2 treatment stimulated tenocyte proliferation even in the presence of CEL. Also, ATV stimulated the migration (wound healing) and adhesion of tenocytes. Among all PGE2 receptors, tenocytes mainly express EP4, and an EP4 selective antagonist blocked the effect of ATV. CONCLUSION: Results indicate that ATV enhances tendon healing by stimulating tenocyte proliferation, migration, and adhesion via increased COX2 activity and autocrine/paracrine PGE2 signaling. Findings also demonstrate that this effect is mediated by EP4 signaling. CLINICAL RELEVANCE: Although chronic inflammation contributes to the development of tendinopathy, study results advocate for a positive role of PGE2 in tendon healing during the acute inflammatory phase that follows tendon surgical repair. It is therefore suggested that ATV should be further investigated as a possible modality to improve tendon healing. CI - © 2014 The Author(s). FAU - Dolkart, Oleg AU - Dolkart O AD - Shoulder Unit, Orthopedic Surgery Division, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Bone Research Laboratory, Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Liron, Tamar AU - Liron T AD - Bone Research Laboratory, Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Chechik, Ofir AU - Chechik O AD - Shoulder Unit, Orthopedic Surgery Division, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Somjen, Dalia AU - Somjen D AD - Shoulder Unit, Orthopedic Surgery Division, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Brosh, Tamar AU - Brosh T AD - Biomechanics Laboratory, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Maman, Eran AU - Maman E AD - Shoulder Unit, Orthopedic Surgery Division, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel dremaman@gmail.com. FAU - Gabet, Yankel AU - Gabet Y AD - Bone Research Laboratory, Department of Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20140902 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Heptanoic Acids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Pyrroles) RN - 0 (Receptors, Prostaglandin E, EP4 Subtype) RN - 0 (Sulfonamides) RN - A0JWA85V8F (Atorvastatin) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (Ptgs2 protein, rat) RN - JCX84Q7J1L (Celecoxib) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Animals MH - Atorvastatin MH - Biomechanical Phenomena MH - Celecoxib MH - Cell Adhesion/drug effects MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Cyclooxygenase 2/metabolism MH - Cyclooxygenase 2 Inhibitors/pharmacology MH - Dinoprostone/*metabolism MH - Heptanoic Acids/*pharmacology MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Models, Animal MH - Pyrazoles/pharmacology MH - Pyrroles/*pharmacology MH - Random Allocation MH - Rats, Wistar MH - Receptors, Prostaglandin E, EP4 Subtype/metabolism MH - Rotator Cuff/*surgery MH - Sulfonamides/pharmacology MH - Tendons/cytology MH - Wound Healing/*drug effects OTO - NOTNLM OT - COX2 OT - EP4 OT - PGE2 OT - acute inflammatory phase OT - rotator cuff OT - statins OT - tendon healing EDAT- 2014/09/04 06:00 MHDA- 2015/04/29 06:00 CRDT- 2014/09/04 06:00 PHST- 2014/09/04 06:00 [entrez] PHST- 2014/09/04 06:00 [pubmed] PHST- 2015/04/29 06:00 [medline] AID - 0363546514545856 [pii] AID - 10.1177/0363546514545856 [doi] PST - ppublish SO - Am J Sports Med. 2014 Dec;42(12):2869-76. doi: 10.1177/0363546514545856. Epub 2014 Sep 2. PMID- 6182917 OWN - NLM STAT- MEDLINE DCOM- 19830107 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 707 IP - 1 DP - 1982 Sep 22 TI - The effects of polymers on the shrinkage temperature of tendon. PG - 142-6 AB - The shrinkage temperature of tendon increases in the presence of a variety of polymers, both charged and uncharged. Using poly(ethylene glycol)s and carbohydrates of varying size, an effective radius of approx. 0.6 nm was found to be the minimum size required to achieve maximum stabilization. Above this minimum size, variations in solute size had little effect. Smaller solutes lowered the shrinkage temperature of tendon by disrupting the fibrillar structure. The study demonstrates that stabilization occurs when the solute is excluded from the fibrils and does not appear to require binding of the solute and collagen. FAU - Snowden, J M AU - Snowden JM LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Dextrans) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9007-27-6 (Chondroitin) RN - 9007-28-7 (Chondroitin Sulfates) SB - IM MH - Animals MH - Cartilage, Articular/*physiology MH - Cattle MH - Chondroitin/*analogs & derivatives MH - Chondroitin Sulfates/*pharmacology MH - Dextrans/*pharmacology MH - Femur Head MH - Kinetics MH - Polyethylene Glycols/*pharmacology MH - Rats MH - Tail MH - Temperature MH - Tendons/drug effects/*physiology EDAT- 1982/09/22 00:00 MHDA- 1982/09/22 00:01 CRDT- 1982/09/22 00:00 PHST- 1982/09/22 00:00 [pubmed] PHST- 1982/09/22 00:01 [medline] PHST- 1982/09/22 00:00 [entrez] AID - 0167-4838(82)90407-1 [pii] AID - 10.1016/0167-4838(82)90407-1 [doi] PST - ppublish SO - Biochim Biophys Acta. 1982 Sep 22;707(1):142-6. doi: 10.1016/0167-4838(82)90407-1. PMID- 6439142 OWN - NLM STAT- MEDLINE DCOM- 19850110 LR - 20131121 IS - 0003-9152 (Print) IS - 0003-9152 (Linking) VI - 53 IP - 2 DP - 1984 Mar 1 TI - Experimental study on tendon transplantation using allograft. PG - 273-86 FAU - Hirasawa, Y AU - Hirasawa Y FAU - Shikata, Y AU - Shikata Y FAU - Nakamura, T AU - Nakamura T FAU - Sakakida, K AU - Sakakida K LA - eng PT - Journal Article PL - Japan TA - Nihon Geka Hokan JT - Nihon geka hokan. Archiv fur japanische Chirurgie JID - 0421143 RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Freezing MH - Glutaral/pharmacology MH - Organ Preservation MH - Rabbits MH - Tendons/*transplantation MH - Transplantation, Homologous EDAT- 1984/03/01 00:00 MHDA- 1984/03/01 00:01 CRDT- 1984/03/01 00:00 PHST- 1984/03/01 00:00 [pubmed] PHST- 1984/03/01 00:01 [medline] PHST- 1984/03/01 00:00 [entrez] PST - ppublish SO - Nihon Geka Hokan. 1984 Mar 1;53(2):273-86. PMID- 24307236 OWN - NLM STAT- MEDLINE DCOM- 20140407 LR - 20220408 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 32 IP - 2 DP - 2014 Feb TI - Macrophage depletion reduces cell proliferation and extracellular matrix accumulation but increases the ultimate tensile strength of injured Achilles tendons. PG - 279-85 LID - 10.1002/jor.22504 [doi] AB - Macrophages are present in large numbers and display specific and distinct phenotypes during the various phases of tissue repair. However, their role following tendon injury and during repair has never been investigated. We injected C57BL/6 mice daily for 4 days with liposome-encapsulated clodronate to deplete circulating monocytes/macrophages. Placebo mice were injected with PBS. The left Achilles tendons of the mice were transversely sectioned and sutured using the 8-strand technique. Macrophage accumulation and cell proliferation were significantly lower in the tendons of clodronate-treated mice than in those of PBS-treated mice on days 3 and 7 post-injury. TGF-β1 staining was significantly more intense in the tendons of PBS-treated mice on day 7 post-injury. Edema and the dry mass of the Achilles tendons were also higher in the PBS-treated mice on days 7 and 14 post-injury. No differences in absolute strength and stiffness were observed, but Young's modulus and maximal stress were significantly greater for tendons from the clodronate-treated mice than those from PBS-treated mice after 14 days of tendon repair. Overall, our findings showed that macrophages promote cell proliferation and extracellular matrix accumulation but their presence leads to inferior ultimate tensile strength of the Achilles tendons. CI - © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - de la Durantaye, Mélissa AU - de la Durantaye M AD - Centre de Recherche du CHU de Québec-CHUL, Université Laval, 2705 boulevard Laurier, Quebec City, QC, Canada, G1V 4G2. FAU - Piette, Antoine Boulanger AU - Piette AB FAU - van Rooijen, Nico AU - van Rooijen N FAU - Frenette, Jérôme AU - Frenette J LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131025 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0813BZ6866 (Clodronic Acid) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Cell Proliferation/*drug effects MH - Clodronic Acid/pharmacology MH - Edema/etiology MH - Elastic Modulus/drug effects MH - Extracellular Matrix/*metabolism MH - Macrophages/drug effects/*physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Tensile Strength/*physiology MH - Wound Healing/*physiology OTO - NOTNLM OT - TGF-B1 OT - clodronate OT - macrophage depletion OT - mechanical properties OT - tendon repair EDAT- 2013/12/07 06:00 MHDA- 2014/04/08 06:00 CRDT- 2013/12/06 06:00 PHST- 2013/05/01 00:00 [received] PHST- 2013/09/24 00:00 [accepted] PHST- 2013/12/06 06:00 [entrez] PHST- 2013/12/07 06:00 [pubmed] PHST- 2014/04/08 06:00 [medline] AID - 10.1002/jor.22504 [doi] PST - ppublish SO - J Orthop Res. 2014 Feb;32(2):279-85. doi: 10.1002/jor.22504. Epub 2013 Oct 25. PMID- 27925641 OWN - NLM STAT- MEDLINE DCOM- 20170518 LR - 20181202 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 40 IP - 2 DP - 2017 Mar 1 TI - Simvastatin Exposure and Rotator Cuff Repair in a Rat Model. PG - e288-e292 LID - 10.3928/01477447-20161128-02 [doi] AB - Simvastatin is a common medication prescribed for hypercholesterolemia that accelerates local bone formation. It is unclear whether simvastatin can accelerate healing at the tendon-bone interface after rotator cuff repair. This study was conducted to investigate whether local and systemic administration of simvastatin increased tendon-bone healing of the rotator cuff as detected by maximum load to failure in a controlled animal-based model. Supraspinatus tendon repair was performed on 120 Sprague-Dawley rats. Sixty rats had a polylactic acid membrane overlying the repair site. Of these, 30 contained simvastatin and 30 did not contain medication. Sixty rats underwent repair without a polylactic acid membrane. Of these, 30 received oral simvastatin (25 mg/kg/d) and 30 received a regular diet. At 4 weeks, 5 rats from each group were killed for histologic analysis. At 8 weeks, 5 rats from each group were killed for histologic analysis and the remaining 20 rats were killed for biomechanical analysis. One rat that received oral simvastatin died of muscle necrosis. Average maximum load to failure was 35.2±6.2 N for those receiving oral simvastatin, 36.8±9.0 N for oral control subjects, 39.5±12.8 N for those receiving local simvastatin, and 39.1±9.3 N for control subjects with a polylactic acid membrane. No statistically significant differences were found between any of the 4 groups (P>.05). Qualitative histologic findings showed that all groups showed increased collagen formation and organization at 8 weeks compared with 4 weeks, with no differences between the 4 groups at each time point. The use of systemic and local simvastatin offered no benefit over control groups. [Orthopedics. 2017; 40(2):e288-e292.]. CI - Copyright 2016, SLACK Incorporated. FAU - Deren, Matthew E AU - Deren ME FAU - Ehteshami, John R AU - Ehteshami JR FAU - Dines, Joshua S AU - Dines JS FAU - Drakos, Mark C AU - Drakos MC FAU - Behrens, Steve B AU - Behrens SB FAU - Doty, Stephen AU - Doty S FAU - Coleman, Struan H AU - Coleman SH LA - eng PT - Journal Article DEP - 20161207 PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - AGG2FN16EV (Simvastatin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology MH - Male MH - Orthopedic Procedures MH - Osteogenesis/*drug effects MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/drug effects/*surgery MH - Rotator Cuff Injuries/*surgery MH - Simvastatin/*pharmacology MH - Tendons/pathology MH - Wound Healing/*drug effects/physiology EDAT- 2016/12/08 06:00 MHDA- 2017/05/19 06:00 CRDT- 2016/12/08 06:00 PHST- 2016/01/24 00:00 [received] PHST- 2016/10/10 00:00 [accepted] PHST- 2016/12/08 06:00 [pubmed] PHST- 2017/05/19 06:00 [medline] PHST- 2016/12/08 06:00 [entrez] AID - 10.3928/01477447-20161128-02 [doi] PST - ppublish SO - Orthopedics. 2017 Mar 1;40(2):e288-e292. doi: 10.3928/01477447-20161128-02. Epub 2016 Dec 7. PMID- 25433272 OWN - NLM STAT- MEDLINE DCOM- 20150629 LR - 20220318 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 20 DP - 2014 Nov 29 TI - Lidocaine potentiates the deleterious effects of triamcinolone acetonide on tenocytes. PG - 2478-83 LID - 10.12659/MSM.891116 [doi] AB - BACKGROUND: Local anesthetics are commonly used for the treatment of a variety of tendinopathies in combination with corticosteroids injection. The goal of this study was to evaluate the effects of lidocaine and triamcinolone acetonide (TA) on cultured rat tenocytes and to determine whether there is a synergistic effect. MATERIAL/METHODS: Rat patellar tendon-derived tenocytes were cultured with or without TA and lidocaine, and the culture without any additive served as the control. Cell morphology and cell viability were evaluated. Expressions of tenocyte-related genes were measured by qRT-PCR. RESULTS: TA, when exposed to tenocytes in vitro, significantly decreased cell viability. The cells cultured with TA had a flattened shape. Moreover, the expressions of tenocyte-related genes in tenocytes were markedly decreased in the TA-treated group. We found that 1% lidocaine synergistically increased the deleterious effects of TA. CONCLUSIONS: Our data provide evidence of the detrimental effects of these drugs on tendon tissues. Injection of TA in combination with 1% lidocaine should be used with caution. FAU - Yang, Shu-long AU - Yang SL AD - Department of Pediatric Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, China (mainland). FAU - Zhang, Yu-bo AU - Zhang YB AD - Department of Pediatric Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, China (mainland). FAU - Jiang, Zhi-tao AU - Jiang ZT AD - Department of Pediatric Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, China (mainland). FAU - Li, Zhao-zhu AU - Li ZZ AD - Department of Pediatric Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, China (mainland). FAU - Jiang, Da-peng AU - Jiang DP AD - Department of Pediatric Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin, China (mainland). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141129 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 98PI200987 (Lidocaine) RN - F446C597KA (Triamcinolone Acetonide) SB - IM MH - Animals MH - Cell Count MH - Cell Shape/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Drug Synergism MH - Gene Expression Regulation/drug effects MH - Lidocaine/*toxicity MH - Male MH - Rats, Sprague-Dawley MH - Tendons/drug effects/metabolism/*pathology MH - Triamcinolone Acetonide/*toxicity PMC - PMC4259563 EDAT- 2014/11/30 06:00 MHDA- 2015/06/30 06:00 PMCR- 2014/11/29 CRDT- 2014/11/30 06:00 PHST- 2014/11/30 06:00 [entrez] PHST- 2014/11/30 06:00 [pubmed] PHST- 2015/06/30 06:00 [medline] PHST- 2014/11/29 00:00 [pmc-release] AID - 891116 [pii] AID - 10.12659/MSM.891116 [doi] PST - epublish SO - Med Sci Monit. 2014 Nov 29;20:2478-83. doi: 10.12659/MSM.891116. PMID- 21846161 OWN - NLM STAT- MEDLINE DCOM- 20111227 LR - 20211020 IS - 1179-2035 (Electronic) IS - 0112-1642 (Linking) VI - 41 IP - 9 DP - 2011 Sep 1 TI - Skin conditions in figure skaters, ice-hockey players and speed skaters: part I - mechanical dermatoses. PG - 709-19 LID - 10.2165/11590540-000000000-00000 [doi] AB - Figure skaters, ice-hockey players and speed skaters experience a range of dermatologic conditions and tissue-related injuries on account of mechanical trauma, infectious pathogens, inflammatory processes and environmental factors related to these competitive pursuits. Sports medicine practitioners, family physicians, dermatologists and coaches should be familiar with these skin conditions to ensure timely and accurate diagnosis and management of affected athletes. This review is Part I of a subsequent companion review and provides a comprehensive review of mechanical dermatoses experienced by ice-skating athletes, including skater's nodules and its variants, pump bumps, piezogenic pedal papules, talon noir, skate/lace bite, friction bullae, corns and calluses, onychocryptosis, skater's toe and skate blade-induced lacerations. These injuries result from friction, shear forces, chronic pressure and collisions with surfaces that occur when athletes endure repetitive jump landings, accelerated starts and stops and other manoeuvres during rigorous training and competition. Ill-fitting skates, improper lacing techniques and insufficient lubrication or protective padding of the foot and ankle often contribute to the development of skin conditions that result from these physical and mechanical stresses. As we will explain, simple measures can frequently prevent the development of these conditions. The treatment of skater's nodules involves reduction in chronic stimulation of the malleoli, and the use of keratolytics and intralesional steroid injections; if malleolar bursitis develops, bursa aspirations may be required. Pump bumps, which result from repetitive friction posteriorly, can be prevented by wearing skates that fit correctly at the heel. Piezogenic pedal papules may be treated conservatively by using heel cups, compressive stockings and by reducing prolonged standing. Talon noir usually resolves without intervention within several weeks. The treatment of skate bite is centred on reducing compression by the skate tongue of the extensor tendons of the anterior ankle, which can be accomplished by use of proper lacing techniques, increasing pliability of the skate tongue and using protective padding, such as Bunga Pads™. Anti-inflammatory medications and cold compresses can also help reduce inflammation. Friction bullae are best managed by careful lancing of painful blisters and application of petrolatum or protective dressings to accelerate healing; preventative measures include the use of well fitting skates, proper lacing techniques and moisture-wicking socks. Corns and calluses are similarly best prevented by the use of well fitted skates and orthotic devices. Symptomatic, debridement reduces the irritant effect of the thick epidermis, and can be accomplished by soaking the area in warm water followed by paring. Application of creams with high concentrations of urea or salicylic acid can also soften callosities. Cases of onychocryptosis benefit from warm soaks, antibiotic ointments and topical steroids to reduce inflammation, but sometimes chemical or surgical matricectomies are required. Preventative measures of both onychocryptosis and skater's toe include cutting toenails straight across to allow for a more equal distribution of forces within the toe box. Finally, the prevention and treatment of lacerations, which constitute a potentially fatal type of mechanical injury, require special protective gear and acute surgical intervention with appropriate suturing. The subsequent companion review of skin conditions in ice skaters will discuss infectious, inflammatory and cold-induced dermatoses, with continued emphasis on clinical presentation, diagnosis, treatment and prevention. FAU - Tlougan, Brook E AU - Tlougan BE AD - Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA. brook.tlougan@gmail.com FAU - Mancini, Anthony J AU - Mancini AJ FAU - Mandell, Jenny A AU - Mandell JA FAU - Cohen, David E AU - Cohen DE FAU - Sanchez, Miguel R AU - Sanchez MR LA - eng PT - Journal Article PT - Review PL - New Zealand TA - Sports Med JT - Sports medicine (Auckland, N.Z.) JID - 8412297 SB - IM MH - Athletes MH - Callosities/diagnosis/etiology/therapy MH - Female MH - Hockey/*injuries MH - Humans MH - Lacerations/diagnosis/etiology/therapy MH - Male MH - Skating/*injuries MH - Skin Diseases/*diagnosis/etiology/*therapy MH - Stress, Mechanical EDAT- 2011/08/19 06:00 MHDA- 2011/12/28 06:00 CRDT- 2011/08/18 06:00 PHST- 2011/08/18 06:00 [entrez] PHST- 2011/08/19 06:00 [pubmed] PHST- 2011/12/28 06:00 [medline] AID - 2 [pii] AID - 10.2165/11590540-000000000-00000 [doi] PST - ppublish SO - Sports Med. 2011 Sep 1;41(9):709-19. doi: 10.2165/11590540-000000000-00000. PMID- 27020782 OWN - NLM STAT- MEDLINE DCOM- 20180419 LR - 20220409 IS - 1432-5195 (Electronic) IS - 0341-2695 (Linking) VI - 40 IP - 9 DP - 2016 Sep TI - Hamstring graft bacterial contamination during anterior cruciate ligament reconstruction: clinical and microbiological study. PG - 1899-903 LID - 10.1007/s00264-016-3168-5 [doi] AB - PURPOSE: Autograft preparation for anterior cruciate ligament (ACL) reconstruction has a potential for graft contamination. The purpose of this study was to evaluate the possibility of bacterial contamination of hamstring autograft during preparation and when dropped onto the operating room floor and methods of graft decontamination. METHODS: Sixty hamstring tendon autograft specimens were used as the test group. Excess tendon not used in the ACL procedure was divided into five segments. One segment, at the completion of preparation, was sent for culture as a control; the remaining four segments were dropped onto the floor adjacent to the surgical field for 15 seconds. One segment was cultured without undergoing any further treatment. Cultures were taken from each segment after immersion in 10 % povidone-iodine solution, 4 % chlorhexidine and bacitracin, respectively, for three minutes. Cultures of a skin swab and floor swab were taken at the same time and place that the ACL was dropped. RESULTS: Cultures of control graft tissue from ten patients (16.7 %) were positive for bacteria. No patient developed post-operative infection. Ninety organisms were identified, with Staphylococcus epidermidis being the most common isolate. Grafts rinsed in either bacitracin or 4 % chlorhexidine solutions were less likely to be culture positive. CONCLUSIONS: A high rate of contamination can be expected during autograft preparation for ACL reconstruction. Soaking the hamstring autograft in either bacitracin or 4 % chlorhexidine solution is effective for decontamination, particulary if graft is dropped on the floor. FAU - Badran, Mohamad Aboelnour AU - Badran MA AD - Department of Medical Microbiology and Immunology, Mansoura University, Mansoura, Egypt. maboelnour@gmail.com. AD - Faculty of Medicine, Mansoura University, Mansoura, Egypt. maboelnour@gmail.com. FAU - Moemen, Dalia Mohamed AU - Moemen DM AD - Department of Orthopedics and Traumatology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. AD - Faculty of Medicine, Mansoura University, Mansoura, Egypt. LA - eng PT - Journal Article DEP - 20160329 PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - 0 (Disinfectants) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Anterior Cruciate Ligament Injuries MH - Anterior Cruciate Ligament Reconstruction/*adverse effects MH - Bacteria/*isolation & purification MH - Chlorhexidine/*therapeutic use MH - Disinfectants/*therapeutic use MH - Hamstring Muscles/*microbiology MH - Humans MH - Tendons MH - Transplantation, Autologous OTO - NOTNLM OT - *ACL OT - *Autograft OT - *Contamination OT - *Hamstring OT - *Infection OT - *Sterilisation EDAT- 2016/03/30 06:00 MHDA- 2018/04/20 06:00 CRDT- 2016/03/30 06:00 PHST- 2015/12/05 00:00 [received] PHST- 2016/03/09 00:00 [accepted] PHST- 2016/03/30 06:00 [entrez] PHST- 2016/03/30 06:00 [pubmed] PHST- 2018/04/20 06:00 [medline] AID - 10.1007/s00264-016-3168-5 [pii] AID - 10.1007/s00264-016-3168-5 [doi] PST - ppublish SO - Int Orthop. 2016 Sep;40(9):1899-903. doi: 10.1007/s00264-016-3168-5. Epub 2016 Mar 29. PMID- 18544016 OWN - NLM STAT- MEDLINE DCOM- 20090810 LR - 20220331 IS - 1937-3376 (Electronic) IS - 1937-3368 (Linking) VI - 14 IP - 2 DP - 2008 Jun TI - Fibrin: a versatile scaffold for tissue engineering applications. PG - 199-215 LID - 10.1089/ten.teb.2007.0435 [doi] AB - Tissue engineering combines cell and molecular biology with materials and mechanical engineering to replace damaged or diseased organs and tissues. Fibrin is a critical blood component responsible for hemostasis, which has been used extensively as a biopolymer scaffold in tissue engineering. In this review we summarize the latest developments in organ and tissue regeneration using fibrin as the scaffold material. Commercially available fibrinogen and thrombin are combined to form a fibrin hydrogel. The incorporation of bioactive peptides and growth factors via a heparin-binding delivery system improves the functionality of fibrin as a scaffold. New technologies such as inkjet printing and magnetically influenced self-assembly can alter the geometry of the fibrin structure into appropriate and predictable forms. Fibrin can be prepared from autologous plasma, and is available as glue or as engineered microbeads. Fibrin alone or in combination with other materials has been used as a biological scaffold for stem or primary cells to regenerate adipose tissue, bone, cardiac tissue, cartilage, liver, nervous tissue, ocular tissue, skin, tendons, and ligaments. Thus, fibrin is a versatile biopolymer, which shows a great potential in tissue regeneration and wound healing. FAU - Ahmed, Tamer A E AU - Ahmed TA AD - Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada. FAU - Dare, Emma V AU - Dare EV FAU - Hincke, Max AU - Hincke M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - United States TA - Tissue Eng Part B Rev JT - Tissue engineering. Part B, Reviews JID - 101466660 RN - 0 (Fibrin Tissue Adhesive) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 9001-31-4 (Fibrin) SB - IM MH - Animals MH - Fibrin/chemistry/*therapeutic use MH - Fibrin Tissue Adhesive/therapeutic use MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry/therapeutic use MH - Microspheres MH - Models, Biological MH - Tissue Engineering/*methods MH - Tissue Scaffolds/*chemistry RF - 198 EDAT- 2008/06/12 09:00 MHDA- 2009/08/11 09:00 CRDT- 2008/06/12 09:00 PHST- 2008/06/12 09:00 [pubmed] PHST- 2009/08/11 09:00 [medline] PHST- 2008/06/12 09:00 [entrez] AID - 10.1089/ten.teb.2007.0435 [doi] PST - ppublish SO - Tissue Eng Part B Rev. 2008 Jun;14(2):199-215. doi: 10.1089/ten.teb.2007.0435. PMID- 16374097 OWN - NLM STAT- MEDLINE DCOM- 20060502 LR - 20220321 IS - 0148-7043 (Print) IS - 0148-7043 (Linking) VI - 56 IP - 1 DP - 2006 Jan TI - The use of a hydrogel sealant on flexor tendon repairs to prevent adhesion formation. PG - 54-8 AB - The prevention of peritendinous adhesions after zone II flexor tendon repair poses a significant challenge to hand surgeons. This study evaluates a hydrogel sealant (FocalSeal-L) as a barrier to peritendinous adhesion formation. The deep flexors of toes 2 through 4 were divided and repaired in 30 chickens. Chickens were randomized to tendon repair with (n = 15) or without (n = 15) FocalSeal-L. Each group was further randomized to have their tendons studied postoperatively at 3 (n = 10), 6 (n = 10), or 12 (n = 10) weeks. Histologic evaluation revealed decreased peritendinous adhesion formation in the FocalSeal-L group. Biomechanical analysis demonstrated a decrease in work of flexion in the FocalSeal-L group that was most pronounced at 6 weeks (P = 0.0020). There was no significant difference in breaking strength. Apparently, an effective barrier to peritendinous adhesion formation, this sealant system is easy to use, biocompatible, and bioresorbable. In addition, it is not bulky or restrictive to tendon glide. FAU - Ferguson, Robert E H AU - Ferguson RE AD - Division of Plastic Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA. dr.rob@uky.edu FAU - Rinker, Brian AU - Rinker B LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 RN - 0 (Fibrin Tissue Adhesive) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) SB - IM MH - Animals MH - Chickens MH - Fibrin Tissue Adhesive/*therapeutic use MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*therapeutic use MH - Postoperative Complications/*prevention & control MH - Random Allocation MH - Tendon Injuries/*surgery MH - Tissue Adhesions/prevention & control EDAT- 2005/12/24 09:00 MHDA- 2006/05/04 09:00 CRDT- 2005/12/24 09:00 PHST- 2005/12/24 09:00 [pubmed] PHST- 2006/05/04 09:00 [medline] PHST- 2005/12/24 09:00 [entrez] AID - 00000637-200601000-00011 [pii] AID - 10.1097/01.sap.0000181666.00492.0e [doi] PST - ppublish SO - Ann Plast Surg. 2006 Jan;56(1):54-8. doi: 10.1097/01.sap.0000181666.00492.0e. PMID- 12861039 OWN - NLM STAT- MEDLINE DCOM- 20030812 LR - 20230216 IS - 0023-6837 (Print) IS - 0023-6837 (Linking) VI - 83 IP - 7 DP - 2003 Jul TI - Nonsteroidal anti-inflammatory drug reduces neutrophil and macrophage accumulation but does not improve tendon regeneration. PG - 991-9 AB - Whether nonsteroidal anti-inflammatory drugs have a beneficial effect on tendon regeneration is still a matter of debate. Given that inflammatory cells are thought to induce nonspecific damage following an injury, we tested the hypothesis that a 3-day treatment with diclofenac would protect tendons from inflammatory cell injury and would promote healing. Neutrophil and ED1(+) macrophage concentrations were determined in the paratenon and the core of the rat Achilles tendon following collagenase-induced injury. Hydroxyproline content, edema, and mechanical properties were also evaluated at 1, 3, 7, 14, and 28 days post-trauma. Collagenase injections induced a 70% decrease in the ultimate rupture point at Day 3. Diclofenac treatments (1 mg/kg bid) selectively decreased the accumulation of neutrophils and ED1(+) macrophages by 59% and 35%, respectively, in the paratenon, where blood vessels are numerous, but did not reduce the accumulation of neutrophils and ED1(+) macrophages in the core of the tendon. Edema was significantly reduced on Day 3 but persisted during the remodeling phase in the diclofenac-treated group only. The inhibition of leukocyte accumulation by diclofenac did not translate into a reduction of tissue damage or a promotion of tissue healing, because the mechanical properties of injured Achilles tendons were identical in placebo and diclofenac-treated groups. These results indicate that diclofenac reduced both edema and the accumulation of inflammatory cells within the paratenon but provided no biochemical or functional benefits for the Achilles tendon. FAU - Marsolais, David AU - Marsolais D AD - Department of Rehabilitation, Faculty of Medicine, Université Laval, Quebec, Canada. FAU - Côté, Claude H AU - Côté CH FAU - Frenette, Jérôme AU - Frenette J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Lab Invest JT - Laboratory investigation; a journal of technical methods and pathology JID - 0376617 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 144O8QL0L1 (Diclofenac) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Achilles Tendon/*drug effects/pathology/physiopathology MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Diclofenac/*pharmacology MH - Edema/pathology MH - Female MH - Hindlimb MH - Hydroxyproline/metabolism MH - Immunohistochemistry MH - Macrophages/*drug effects/pathology MH - Neutrophil Infiltration/*drug effects MH - Neutrophils/*drug effects/pathology MH - Rats MH - Rats, Wistar MH - Recovery of Function MH - Stress, Mechanical MH - Tendon Injuries/metabolism/pathology/physiopathology MH - Wound Healing/*drug effects/physiology EDAT- 2003/07/16 05:00 MHDA- 2003/08/13 05:00 CRDT- 2003/07/16 05:00 PHST- 2003/07/16 05:00 [pubmed] PHST- 2003/08/13 05:00 [medline] PHST- 2003/07/16 05:00 [entrez] AID - S0023-6837(22)03498-5 [pii] AID - 10.1097/01.lab.0000078688.07696.ac [doi] PST - ppublish SO - Lab Invest. 2003 Jul;83(7):991-9. doi: 10.1097/01.lab.0000078688.07696.ac. PMID- 5967499 OWN - NLM STAT- MEDLINE DCOM- 19670814 LR - 20190617 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 211 IP - 5048 DP - 1966 Jul 30 TI - Effect of peroxides on the hydration elongation of rat tail tendon. PG - 536 FAU - Pospísilová, J AU - Pospísilová J LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 9007-34-5 (Collagen) RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Animals MH - Chemical Phenomena MH - Chemistry, Physical MH - *Collagen MH - Hydrogen Peroxide/*pharmacology MH - In Vitro Techniques MH - Rats MH - Tendons/*drug effects EDAT- 1966/07/30 00:00 MHDA- 1966/07/30 00:01 CRDT- 1966/07/30 00:00 PHST- 1966/07/30 00:00 [pubmed] PHST- 1966/07/30 00:01 [medline] PHST- 1966/07/30 00:00 [entrez] AID - 10.1038/211536a0 [doi] PST - ppublish SO - Nature. 1966 Jul 30;211(5048):536. doi: 10.1038/211536a0. PMID- 24445876 OWN - NLM STAT- MEDLINE DCOM- 20140626 LR - 20221207 IS - 1529-4242 (Electronic) IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 133 IP - 5 DP - 2014 May TI - The effects of biological lubricating molecules on flexor tendon reconstruction in a canine allograft model in vivo. PG - 628e-637e LID - 10.1097/PRS.0000000000000102 [doi] AB - BACKGROUND: Using allograft is an attractive alternative for flexor tendon reconstruction because of the lack of donor-site morbidity, and better matching to the intrasynovial environment. The purpose of this study was to use biological lubricant molecules to modify the graft surface to decrease adhesions and improve digit function. METHODS: Twenty-eight flexor digitorum profundus tendons from the second and fifth digits of 14 dogs were lacerated and repaired to create a model with repair failure and scar digit for tendon reconstruction. Six weeks after the initial operation, the tendons were reconstructed with flexor digitorum profundus allograft tendons obtained from canine cadavers. One graft tendon in each dog was treated with saline as a control and the other was treated with carbodiimide-derivatized hyaluronic acid and gelatin plus lubricin. Six weeks postoperatively, digit function, graft mechanics, and biology were analyzed. RESULTS: Allograft tendons treated with carbodiimide-derivatized hyaluronic acid-lubricin had decreased adhesions at the proximal tendon/graft repair and within the flexor sheath, improved digit function, and increased graft gliding ability. The treatment also reduced the strength at the distal tendon-to-bone repair, but the distal attachment rupture rate was similar for both graft types. Histologic evaluation showed that viable cells migrated to the allograft, but these were limited to the tendon surface. CONCLUSIONS: Carbodiimide-derivatized hyaluronic acid-lubricin treatment of tendon allograft improves digit functional outcomes after flexor tendon reconstruction. However, delayed bone-to-tendon healing should be a caution. Furthermore, the cell infiltration into the allograft tendon substance should be a target for future studies, to shorten the allograft self-regeneration period. FAU - Zhao, Chunfeng AU - Zhao C AD - Rochester, Minn.; and Providence, R.I. From the Biomechanics & Tendon and Soft Tissue Biology Laboratories, Mayo Clinic; and Brown University. FAU - Wei, Zhuang AU - Wei Z FAU - Reisdorf, Ramona L AU - Reisdorf RL FAU - Thoreson, Andrew R AU - Thoreson AR FAU - Jay, Gregory D AU - Jay GD FAU - Moran, Steven L AU - Moran SL FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - P20 GM104937/GM/NIGMS NIH HHS/United States GR - R01 AR044391/AR/NIAMS NIH HHS/United States GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - AR 57745/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Carbodiimides) RN - 0 (Glycoproteins) RN - 0 (lubricin) RN - 9000-70-8 (Gelatin) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Carbodiimides/pharmacology MH - Dogs MH - Forelimb/surgery MH - Gelatin/pharmacology MH - Glycoproteins/*pharmacology MH - Hyaluronic Acid/*pharmacology MH - Lacerations/surgery MH - Models, Animal MH - Plastic Surgery Procedures/*methods MH - Recovery of Function/drug effects MH - Tendon Injuries/*surgery MH - Tendons/surgery/*transplantation MH - Tissue Adhesions/pathology/*prevention & control MH - Transplantation, Homologous MH - Wound Healing/drug effects PMC - PMC4006300 MID - NIHMS559996 EDAT- 2014/01/22 06:00 MHDA- 2014/06/27 06:00 PMCR- 2015/05/01 CRDT- 2014/01/22 06:00 PHST- 2014/01/22 06:00 [entrez] PHST- 2014/01/22 06:00 [pubmed] PHST- 2014/06/27 06:00 [medline] PHST- 2015/05/01 00:00 [pmc-release] AID - 00006534-201405000-00010 [pii] AID - 10.1097/PRS.0000000000000102 [doi] PST - ppublish SO - Plast Reconstr Surg. 2014 May;133(5):628e-637e. doi: 10.1097/PRS.0000000000000102. PMID- 15201139 OWN - NLM STAT- MEDLINE DCOM- 20041028 LR - 20220227 IS - 0363-6143 (Print) IS - 0363-6143 (Linking) VI - 287 IP - 4 DP - 2004 Oct TI - Norepinephrine-induced calcium signaling and expression of adrenoceptors in avian tendon cells. PG - C912-8 AB - Sympathetic efferent nerves are present in tendons, but their function within tendon is unknown. alpha(1)-Adrenoceptors are expressed by a variety of cell types. In the presence of norepinephrine (NE), adrenoceptors activate G(q/11) signaling pathways that subsequently increase intracellular Ca(2+) concentration ([Ca(2+)](ic)). It was hypothesized that avian tendon cells express functional adrenoceptors that respond to NE by increasing [Ca(2+)](ic). Avian tendon cells were analyzed for mRNA expression of alpha(1)-adrenoceptors by RT-PCR. Avian tendons expressed the alpha(1A)- and alpha(1B)-adrenoceptor subtypes. Furthermore, both tendon surface epitenon cells and internal fibroblasts infused with a Ca(2+)-sensitive dye, fura 2, and stimulated with NE responded by increasing [Ca(2+)](ic). KMD-3213, an alpha(1A)-adrenoceptor antagonist, significantly reduced the Ca(2+) response. Other adrenoceptor antagonists had no effect on the Ca(2+) response. The absence of extracellular Ca(2+) also significantly reduced the response to NE, indicating that Ca(2+) influx contributed to the rise in [Ca(2+)](ic). This study provides the first evidence that tendon cells express adrenoceptors and that the NE-induced Ca(2+) response is coupled to the alpha(1A)-adrenoceptor subtype. FAU - Wall, Michelle E AU - Wall ME AD - Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7055, USA. FAU - Faber, James E AU - Faber JE FAU - Yang, Xi AU - Yang X FAU - Tsuzaki, Mari AU - Tsuzaki M FAU - Banes, Albert J AU - Banes AJ LA - eng GR - AR-38121/AR/NIAMS NIH HHS/United States GR - AR-62584/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20040616 PL - United States TA - Am J Physiol Cell Physiol JT - American journal of physiology. Cell physiology JID - 100901225 RN - 0 (Adrenergic Antagonists) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Adrenergic) RN - X4W3ENH1CV (Norepinephrine) SB - IM MH - Adrenergic Antagonists/pharmacology MH - Animals MH - Calcium Signaling/drug effects/*physiology MH - Cells, Cultured MH - Chickens MH - Connective Tissue/metabolism MH - Fibroblasts/metabolism MH - Norepinephrine/*pharmacology MH - RNA, Messenger/analysis MH - Receptors, Adrenergic/*biosynthesis/drug effects MH - Reverse Transcriptase Polymerase Chain Reaction MH - Tendons/cytology/*innervation/*metabolism EDAT- 2004/06/18 05:00 MHDA- 2004/10/29 09:00 CRDT- 2004/06/18 05:00 PHST- 2004/06/18 05:00 [pubmed] PHST- 2004/10/29 09:00 [medline] PHST- 2004/06/18 05:00 [entrez] AID - 00099.2004 [pii] AID - 10.1152/ajpcell.00099.2004 [doi] PST - ppublish SO - Am J Physiol Cell Physiol. 2004 Oct;287(4):C912-8. doi: 10.1152/ajpcell.00099.2004. Epub 2004 Jun 16. PMID- 16865710 OWN - NLM STAT- MEDLINE DCOM- 20061003 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 24 IP - 9 DP - 2006 Sep TI - Gene expression changes in SNAP-stimulated and iNOS-transfected tenocytes--expression of extracellular matrix genes and its implications for tendon-healing. PG - 1869-82 AB - Nitric oxide (NO) has a variety of physiological roles, including acting as a key mediator in various phases of tendon healing, but its importance as a modulator of gene expression during tendon healing has not been well studied. The current study used microarray analysis to elucidate global gene expression after transfection with inducible nitric oxide synthase (iNOS) in tenocytes isolated from the injured rotator cuff tendons of human patients. We show that the expression of a wide range of genes is affected by NO, with many activated genes having known roles in healing. Of particular significance is that NOS overexpression stimulates the transcription and translation of a range of extracellular matrix genes important to the structure of connective tissues such as tendons, including collagen Ialpha1, collagen IIIalpha1, collagen IValpha5, biglycan, decorin, laminin, and matrix metalloproteinase 10 (MMP10). These genes were also shown to respond to stimulation by the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) in a dose-dependent manner. We further show that varying levels of NO significantly affect cellular adhesion in tenocytes, a critical process during tendon repair. These findings will be of use when optimizing the dose of NO delivery in further work investigating NO as potential treatment of tendon injuries. FAU - Molloy, Timothy J AU - Molloy TJ AD - Orthopaedic Research Institute, St. George Hospital, University of New South Wales, Kogarah, Sydney, NSW 2217, Australia. FAU - de Bock, Charles E AU - de Bock CE FAU - Wang, Yao AU - Wang Y FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (BGN protein, human) RN - 0 (Biglycan) RN - 0 (DCN protein, human) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Laminin) RN - 0 (Nitric Oxide Donors) RN - 0 (Proteoglycans) RN - 0 (S-nitro-N-acetylpenicillamine) RN - 9007-34-5 (Collagen) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 3.4.24.- (Metalloendopeptidases) RN - EC 3.4.24.22 (Matrix Metalloproteinase 10) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Aged MH - Biglycan MH - Cell Adhesion/drug effects MH - Cells, Cultured MH - Collagen/genetics/metabolism MH - Decorin MH - Extracellular Matrix Proteins/*genetics/metabolism MH - Female MH - Gene Expression Regulation/*drug effects MH - Humans MH - Laminin/genetics/metabolism MH - Male MH - Matrix Metalloproteinase 10 MH - Metalloendopeptidases/genetics/metabolism MH - Middle Aged MH - Nitric Oxide Donors/*pharmacology MH - Nitric Oxide Synthase Type II/genetics/*metabolism MH - Oligonucleotide Array Sequence Analysis MH - Penicillamine/*analogs & derivatives/pharmacology MH - Proteoglycans/genetics/metabolism MH - Rotator Cuff/cytology MH - Tendon Injuries/metabolism/physiopathology MH - Tendons/cytology/drug effects/*metabolism MH - Transfection MH - Wound Healing/*genetics/physiology EDAT- 2006/07/26 09:00 MHDA- 2006/10/04 09:00 CRDT- 2006/07/26 09:00 PHST- 2006/07/26 09:00 [pubmed] PHST- 2006/10/04 09:00 [medline] PHST- 2006/07/26 09:00 [entrez] AID - 10.1002/jor.20237 [doi] PST - ppublish SO - J Orthop Res. 2006 Sep;24(9):1869-82. doi: 10.1002/jor.20237. PMID- 8192699 OWN - NLM STAT- MEDLINE DCOM- 19940620 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 44 IP - 3 DP - 1994 Mar TI - [Binding capacity of ibuprofen to muscle proteins]. PG - 341-3 AB - From former studies it is well known, that ibuprofen (CAS 15687-27-1) binds to muscular tissue in a higher degree than to tendons or ligaments. It is not known, however, what constituents of muscle tissue are responsible for this binding. Therefore the binding capacity of ibuprofen to different muscular proteins was studied. Actin, actomyosin, myosin, myoglobin, tropomyosin, lecithin, and native human collagen type I were incubated with 14C-ibuprofen and the specific binding was measured in relation to the total radioactivity. It could be shown that ibuprofen binds most markedly to actin. This binding could be inhibited by pre-incubation of ibuprofen with soluble actin. In comparison to the other proteins studied the specific binding of ibuprofen to actin was 4 to 5 times higher. As actin is a constituent of the cytoskeleton which plays an important role in generating oxygen radicals, its possible inhibition by ibuprofen could additionally explain the antiphlogistic effect of this compound. FAU - Menzel, E J AU - Menzel EJ AD - Institut für Immunologie, Universität Wien. FAU - Kolarz, G AU - Kolarz G LA - ger PT - English Abstract PT - Journal Article TT - Bindungsvermögen von Ibuprofen an Muskelproteine. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Actins) RN - 0 (Muscle Proteins) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Actins/metabolism MH - Humans MH - Ibuprofen/*pharmacokinetics MH - Muscle Proteins/*metabolism MH - Protein Binding EDAT- 1994/03/01 00:00 MHDA- 1994/03/01 00:01 CRDT- 1994/03/01 00:00 PHST- 1994/03/01 00:00 [pubmed] PHST- 1994/03/01 00:01 [medline] PHST- 1994/03/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1994 Mar;44(3):341-3. PMID- 5684859 OWN - NLM STAT- MEDLINE DCOM- 19681208 LR - 20190617 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 220 IP - 5164 DP - 1968 Oct 19 TI - Thermally labile cross-links in native collagen. PG - 280-1 FAU - Bailey, A J AU - Bailey AJ FAU - Lister, D AU - Lister D LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Amino Acids) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) RN - N9E3X5056Q (Boron) SB - IM MH - Amino Acids/analysis MH - Animals MH - Biophysical Phenomena MH - Biophysics MH - Boron MH - Chickens MH - *Collagen MH - *Hot Temperature MH - In Vitro Techniques MH - Penicillamine/pharmacology MH - *Protein Denaturation MH - Rats MH - Swine MH - Tendons/physiology EDAT- 1968/10/19 00:00 MHDA- 1968/10/19 00:01 CRDT- 1968/10/19 00:00 PHST- 1968/10/19 00:00 [pubmed] PHST- 1968/10/19 00:01 [medline] PHST- 1968/10/19 00:00 [entrez] AID - 10.1038/220280a0 [doi] PST - ppublish SO - Nature. 1968 Oct 19;220(5164):280-1. doi: 10.1038/220280a0. PMID- 4531190 OWN - NLM STAT- MEDLINE DCOM- 19750317 LR - 20150608 IS - 0365-5954 (Print) IS - 0365-5954 (Linking) VI - 319 DP - 1972 TI - Disappearance of 133Xe from the superficial flexor tendon in the horse. PG - 25-9 FAU - Strömberg, B AU - Strömberg B LA - eng PT - Journal Article PL - Sweden TA - Acta Radiol Suppl JT - Acta radiologica. Supplementum JID - 0370370 RN - 0 (Radioisotopes) RN - 3H3U766W84 (Xenon) RN - YKH834O4BH (Epinephrine) SB - IM MH - Animals MH - Blood Flow Velocity MH - *Capillaries MH - Epinephrine/pharmacology MH - *Horses MH - Mathematics MH - Physical Exertion MH - Radioisotopes MH - Regional Blood Flow/drug effects MH - Tendons/*blood supply MH - Xenon EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PST - ppublish SO - Acta Radiol Suppl. 1972;319:25-9. PMID- 25443884 OWN - NLM STAT- MEDLINE DCOM- 20150921 LR - 20250529 IS - 1873-2380 (Electronic) IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 48 IP - 1 DP - 2015 Jan 2 TI - A biomechanical characterisation of acellular porcine super flexor tendons for use in anterior cruciate ligament replacement: investigation into the effects of fat reduction and bioburden reduction bioprocesses. PG - 22-9 LID - S0021-9290(14)00601-0 [pii] LID - 10.1016/j.jbiomech.2014.11.013 [doi] AB - The decellularisation of xenogenic and allogeneic biological grafts offers a promising solution to replacement of the anterior cruciate ligament (ACL). The purpose of this investigation was to determine the biomechanical effects of additional fat reduction and bioburden reduction steps in the decellularisation of porcine super flexor tendon (pSFT). Study 1 investigated the use of acetone or chloroform-methanol as a fat reduction agent. The most effective of these was then carried forward into Study 2, which investigated the use of antibiotics or peracetic acid (PAA) as a bioburden reduction agent. Stress relaxation data was analysed using a Maxwell-Wiechert viscoelastic model and, in addition to classical material properties, the tangent modulus of the toe-region was determined from strength testing data. In both studies, the majority of decellularised groups demonstrated no statistical differences for material properties such as tensile strength and Young's modulus compared to native controls. Different trends were observed for many of the viscoelastic parameters, but also for the tangent modulus in the toe-region indicating a change in performance at low strains. The most severe deviations from the profile of the native tangent modulus were found to occur in Study 2 when PAA was used for bioburden reduction. Classic material properties (E, UTS etc.) are often used to compare the characteristics of native and decellularised tissues, however they may not highlight changes occurring in the tissues at low strains. In this study, this represented the physiological strains encountered by substitute acellular ACL grafts. Acetone was chosen as the fat reduction step whereas, antibiotics was preferable over PAA as a bioburden reduction step. CI - Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Herbert, Anthony AU - Herbert A AD - (IMBE) Institute of Medical and Biological Engineering, School of Mechanical Engineering University of Leeds, Leeds, UK. Electronic address: A.Herbert@leeds.ac.uk. FAU - Jones, Gemma L AU - Jones GL AD - IMBE, Faculty of Biomedical Sciences, University of Leeds, Leeds, UK. FAU - Ingham, Eileen AU - Ingham E AD - IMBE, Faculty of Biomedical Sciences, University of Leeds, Leeds, UK. FAU - Fisher, John AU - Fisher J AD - (IMBE) Institute of Medical and Biological Engineering, School of Mechanical Engineering University of Leeds, Leeds, UK. LA - eng GR - 267114/ERC_/European Research Council/International GR - WT088908/z/09/z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141118 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Anti-Bacterial Agents) RN - 1364PS73AF (Acetone) RN - 7V31YC746X (Chloroform) RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - Acetone/pharmacology MH - Animals MH - Anterior Cruciate Ligament/*surgery MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Anti-Bacterial Agents/pharmacology MH - Biomechanical Phenomena/physiology MH - Chloroform/pharmacology MH - Elastic Modulus/physiology MH - Female MH - Models, Animal MH - Models, Biological MH - Peracetic Acid/pharmacology MH - Swine MH - Tendons/drug effects/*physiology/*transplantation MH - Tensile Strength/physiology MH - *Tissue Scaffolds MH - Tissue Transplantation/*methods PMC - PMC4295818 OTO - NOTNLM OT - Acellular graft OT - Anterior cruciate ligament OT - Decellularisation OT - Knee reconstruction OT - Porcine EDAT- 2014/12/03 06:00 MHDA- 2015/09/22 06:00 PMCR- 2015/01/02 CRDT- 2014/12/03 06:00 PHST- 2014/08/04 00:00 [received] PHST- 2014/11/07 00:00 [revised] PHST- 2014/11/10 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2015/09/22 06:00 [medline] PHST- 2015/01/02 00:00 [pmc-release] AID - S0021-9290(14)00601-0 [pii] AID - 10.1016/j.jbiomech.2014.11.013 [doi] PST - ppublish SO - J Biomech. 2015 Jan 2;48(1):22-9. doi: 10.1016/j.jbiomech.2014.11.013. Epub 2014 Nov 18. PMID- 21371626 OWN - NLM STAT- MEDLINE DCOM- 20110726 LR - 20211020 IS - 1531-6564 (Electronic) IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 36 IP - 3 DP - 2011 Mar TI - Application of carbodiimide derivatized synovial fluid to enhance extrasynovial tendon gliding ability. PG - 456-63 LID - 10.1016/j.jhsa.2010.12.015 [doi] AB - PURPOSE: To investigate the effects of surface modification of extrasynovial tendon with a carbodiimide derivatized synovial fluid (SF) on the gliding ability of extrasynovial tendon for a possible tendon graft application. METHODS: We used 63 peroneus longus tendons from canine hind legs. We immediately assessed 3 tendons morphologically using a scanning electron microscope (SEM); these served as the normal tendon group. The other 60 tendons were randomly assigned to each of 6 experimental groups treated with (1) control (saline); (2) 1% 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) plus 1% N-hydroxysuccinimide (NHS) (cd only); (3) 1% EDC/NHS plus 10% gelatin (cd-G); (4) SF plus 1% EDC/NHS plus 10% gelatin (cd-SF-G); (5) SF only; or (6) SF plus 1% EDC/NHS (cd-SF). We measured the gliding resistance for 1,000 cycles of simulated flexion-extension motion. We also observed the tendon surface smoothness by SEM. RESULTS: Compared with the first cycle in each group, the gliding resistance after 1,000 cycles of tendon motion was significantly increased in the control, cd only, cd-gelatin, SF only, and cd-SF groups (p<.05). In contrast, we found no significant difference in gliding resistance between the first cycle and 1,000 cycles for the cd-SF-G-treated group. In addition, the gliding resistance in the cd-SF, cd-G, and cd-SF-G groups was significantly lower than the control group after 1,000 cycles of tendon motion (p<.05) and the gliding resistance of the cd-SF-G group was significantly lower than both the cd-G and cd-SF groups (p<.05). On SEM, the surface treated with cd-SF-G was smooth after 1,000 cycles, whereas the other surfaces were rough. CONCLUSIONS: Surface modification of extrasynovial tendon with cd-SF-G improves tendon gliding ability. This treatment may be useful clinically in improving the outcomes of tendon autografts. CI - Copyright © 2011 American Society for Surgery of the Hand. All rights reserved. FAU - Ikeda, Jun AU - Ikeda J AD - Orthopedic Biomechanics Laboratory, Division of Orthopedic Research, Mayo Clinic, Rochester, MN 55905, USA. FAU - Sun, Yu-Long AU - Sun YL FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC FAU - Zhao, Chunfeng AU - Zhao C LA - eng GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - R03 AR049407/AR/NIAMS NIH HHS/United States PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Succinimides) RN - MJE3791M4T (N-hydroxysuccinimide) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) SB - IM MH - Animals MH - Dogs MH - Ethyldimethylaminopropyl Carbodiimide/*pharmacology MH - Friction/*drug effects MH - *Hindlimb MH - In Vitro Techniques MH - Succinimides/pharmacology MH - Surface Properties/drug effects MH - Synovial Fluid/*physiology MH - Tendons/*drug effects/ultrastructure MH - Tensile Strength/drug effects MH - Weight-Bearing PMC - PMC3625936 MID - NIHMS371748 EDAT- 2011/03/05 06:00 MHDA- 2011/07/27 06:00 PMCR- 2013/04/15 CRDT- 2011/03/05 06:00 PHST- 2010/05/13 00:00 [received] PHST- 2010/12/10 00:00 [revised] PHST- 2010/12/11 00:00 [accepted] PHST- 2011/03/05 06:00 [entrez] PHST- 2011/03/05 06:00 [pubmed] PHST- 2011/07/27 06:00 [medline] PHST- 2013/04/15 00:00 [pmc-release] AID - S0363-5023(10)01558-3 [pii] AID - 10.1016/j.jhsa.2010.12.015 [doi] PST - ppublish SO - J Hand Surg Am. 2011 Mar;36(3):456-63. doi: 10.1016/j.jhsa.2010.12.015. PMID- 6486792 OWN - NLM STAT- MEDLINE DCOM- 19841101 LR - 20190629 IS - 0003-9861 (Print) IS - 0003-9861 (Linking) VI - 233 IP - 2 DP - 1984 Sep TI - The proteinase inhibitors leupeptin, pepstatin A, and TLCK cause reduced collagen production in freshly isolated embryonic chick fibroblasts in suspension culture. PG - 338-44 AB - The production of [14C]proline-labeled collagen by embryonic chick tendon cells in suspension culture is reduced when the cells are incubated in the presence of lysosomotropic agents NH4Cl or chloroquine. Since these agents have multiple effects on fibroblasts, including inhibition of collagen secretion, specific proteinase inhibitors were tested for their effect on collagen production. Here the proteinase inhibitors N-p-tosyl-L-lysine chloromethylketone (TLCK) and leupeptin, specific for certain cysteine and serine proteinases, and pepstatin A, specific for aspartic proteinases, were tested for their effects on both the production and secretion of collagen. When treated with the proteinase inhibitor TLCK, the percentage of protein synthesis devoted to collagen decreased from control levels of 19.0 +/- 1.4% to 10.5 +/- 2.4% with 10 microM TLCK. Collagen synthesis was further reduced to only 1.2% of total protein synthesis with 100 microM TLCK. The incorporation of [14C]proline into collagenase-digestible peptides was only slightly decreased in the samples treated separately with 50 micrograms/ml leupeptin or 60 micrograms/ml pepstatin A. However, the production of collagen was reduced to 10.9 +/- 1.4% of total protein synthesis in samples treated with leupeptin and pepstatin A together. The basal intracellular degradation of newly synthesized, [14C]proline-labeled collagen was not significantly altered by any of the reagents tested, and secretion of the collagen which was produced was not impaired except in samples treated with 100 microM TLCK. The data presented are consistent with the hypothesis that a proteolytic mechanism utilizing some combination of cysteine, serine, and aspartic proteinases is necessary for continued collagen synthesis in freshly isolated embryonic chick tendon fibroblasts, and suggests that a heretofore unknown regulatory system may be operative in controlling the synthesis of collagen in fibroblasts. FAU - Neblock, D S AU - Neblock DS FAU - Berg, R A AU - Berg RA LA - eng GR - AM 31839/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Arch Biochem Biophys JT - Archives of biochemistry and biophysics JID - 0372430 RN - 0 (Amino Acid Chloromethyl Ketones) RN - 0 (Leupeptins) RN - 0 (Oligopeptides) RN - 0 (Pepstatins) RN - 11076-29-2 (Streptomyces pepsin inhibitor) RN - 2104-86-1 (Tosyllysine Chloromethyl Ketone) RN - 9007-34-5 (Collagen) RN - J97339NR3V (leupeptin) RN - V6Y2T27Q1U (pepstatin) SB - IM MH - Amino Acid Chloromethyl Ketones/*pharmacology MH - Animals MH - Chick Embryo MH - Collagen/*biosynthesis MH - Fibroblasts/drug effects/metabolism MH - In Vitro Techniques MH - Leupeptins/*pharmacology MH - Oligopeptides/*pharmacology MH - Pepstatins/*pharmacology MH - Tendons/metabolism MH - Tosyllysine Chloromethyl Ketone/*pharmacology EDAT- 1984/09/01 00:00 MHDA- 1984/09/01 00:01 CRDT- 1984/09/01 00:00 PHST- 1984/09/01 00:00 [pubmed] PHST- 1984/09/01 00:01 [medline] PHST- 1984/09/01 00:00 [entrez] AID - 0003-9861(84)90454-5 [pii] AID - 10.1016/0003-9861(84)90454-5 [doi] PST - ppublish SO - Arch Biochem Biophys. 1984 Sep;233(2):338-44. doi: 10.1016/0003-9861(84)90454-5. PMID- 5958370 OWN - NLM STAT- MEDLINE DCOM- 19670411 LR - 20131121 IS - 0081-1386 (Print) IS - 0081-1386 (Linking) VI - 20 DP - 1966 TI - Basic patterns of plastic change in the mammalian nervous system. PG - 509-43 FAU - Kozak, W AU - Kozak W FAU - Westerman, R AU - Westerman R LA - eng PT - Journal Article PL - England TA - Symp Soc Exp Biol JT - Symposia of the Society for Experimental Biology JID - 0404517 RN - U42B7VYA4P (Chlorpromazine) SB - IM MH - Animals MH - Cats MH - Central Nervous System/*physiology MH - Chlorpromazine/pharmacology MH - *Conditioning, Classical MH - Dogs MH - Electric Stimulation MH - Movement/physiology MH - *Muscle Denervation MH - Reflex/drug effects MH - Skin/innervation MH - Tendons/*physiology EDAT- 1966/01/01 00:00 MHDA- 1966/01/01 00:01 CRDT- 1966/01/01 00:00 PHST- 1966/01/01 00:00 [pubmed] PHST- 1966/01/01 00:01 [medline] PHST- 1966/01/01 00:00 [entrez] PST - ppublish SO - Symp Soc Exp Biol. 1966;20:509-43. PMID- 30104932 OWN - NLM STAT- MEDLINE DCOM- 20181218 LR - 20181218 IS - 1555-1377 (Electronic) IS - 1541-5457 (Print) IS - 1541-5457 (Linking) VI - 38 DP - 2018 TI - In Vivo Toxicity of Local Anesthetics and Corticosteroids on Supraspinatus Tenocyte Cell Viability and Metabolism. PG - 107-112 AB - BACKGROUND: This study was conducted to evaluate the effects of commonly used injection medication combinations on supraspinatus tenocyte cell viability and tissue metabolism. METHODS: Twenty adult dogs underwent ultrasound guided injection of the canine equivalent of the subacromial space, based on random assignment to one of four treatment groups (n=5/group): normal saline, 1.0% lidocaine/methylprednisolone, 1.0% lidocaine/triamcinolone or 0.0625% bupivacaine/triamcinolone. Full-thickness sections of supraspinatus tendon were harvested under aseptic conditions and evaluated on days 1 and 7 post-harvest for cell viability and tissue metabolism. Data were analyzed for significant differences among groups. RESULTS: Tendons exposed to 1% lidocaine/ methylprednisolone had significantly lower cell viability at day 1 as compared to all other groups and control. All local anesthetic/ corticosteroid combination groups had decreased cell viability at day 7 when compared to the control group. CONCLUSIONS: This study demonstrated significant in vivo supraspinatus tenotoxicity following a single injection of combination local anesthetic/ corticosteroid when compared to saline controls. LEVEL OF EVIDENCE: Level II. FAU - Nuelle, Clayton W AU - Nuelle CW AD - Department of Orthopaedic Surgery, University of Missouri, Columbia. AD - The San Antonio Orthopaedic Group, San Antonio, TX. FAU - Cook, Cristi R AU - Cook CR AD - Department of Orthopaedic Surgery, University of Missouri, Columbia. AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia. FAU - Stoker, Aaron M AU - Stoker AM AD - Department of Orthopaedic Surgery, University of Missouri, Columbia. AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia. FAU - Cook, James L AU - Cook JL AD - Department of Orthopaedic Surgery, University of Missouri, Columbia. AD - Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia. FAU - Sherman, Seth L AU - Sherman SL AD - Department of Orthopaedic Surgery, University of Missouri, Columbia. LA - eng PT - Journal Article PL - United States TA - Iowa Orthop J JT - The Iowa orthopaedic journal JID - 8908272 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Adrenal Cortex Hormones/*toxicity MH - Anesthetics, Local/*toxicity MH - Animals MH - Cell Survival/*drug effects MH - Dogs MH - Lidocaine/toxicity MH - Methylprednisolone/toxicity MH - Tendons/*drug effects/metabolism MH - Tenocytes/*drug effects/metabolism PMC - PMC6047373 OTO - NOTNLM OT - corticosteroid OT - injections OT - local anesthetic OT - tendon OT - tenotoxicity EDAT- 2018/08/15 06:00 MHDA- 2018/12/19 06:00 PMCR- 2018/01/01 CRDT- 2018/08/15 06:00 PHST- 2018/08/15 06:00 [entrez] PHST- 2018/08/15 06:00 [pubmed] PHST- 2018/12/19 06:00 [medline] PHST- 2018/01/01 00:00 [pmc-release] PST - ppublish SO - Iowa Orthop J. 2018;38:107-112. PMID- 9245644 OWN - NLM STAT- MEDLINE DCOM- 19970922 LR - 20131121 IS - 0026-2862 (Print) IS - 0026-2862 (Linking) VI - 54 IP - 1 DP - 1997 Jul TI - Vessels supplying septa and tendons as functional shunts in perfused rat hindlimb. PG - 49-57 AB - An assessment was made of the relationship between vasoconstrictor-mediated changes in metabolism and the apparent flow in putative nonnutritive vessels of muscle located on tendon. Surgically isolated rat hindlimbs were perfused at constant flow while monitoring perfusion pressure and venous pO2. In addition exposed tibial tendon vessels of the biceps femoris muscle of the perfused leg were positioned either under a surface fluorometer probe to monitor signal strength when pulses of fluorescein isothiocyanate dextran were infused or over the objective lens of an inverted microscope for photography when pulses of India ink were infused. Measurements were conducted under steady state with vehicle, norepinephrine, or serotonin infused. Norepinephrine increased perfusion pressure and oxygen uptake (VO2), but decreased fluorescence signal from the tendon vessels. Photomicroscopy confirmed that the vessels had generally decreased in diameter. Serotonin also increased perfusion pressure but decreased VO2 and increased fluorescence signal from the tendon vessels. Photomicroscopy confirmed that serotonin infusion had led to a marked increase in diameter of the vessels. It is concluded that a reciprocal relationship exists between resting muscle metabolism as controlled by vasoconstrictors and flow-through muscle tendon vessels. FAU - Newman, J M AU - Newman JM AD - Medical School, University of Tasmania, Hobart, 7001, Australia. FAU - Steen, J T AU - Steen JT FAU - Clark, M G AU - Clark MG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Microvasc Res JT - Microvascular research JID - 0165035 RN - 0 (Vasoconstrictor Agents) RN - 0 (Vasodilator Agents) RN - 333DO1RDJY (Serotonin) RN - X4W3ENH1CV (Norepinephrine) SB - IM MH - Animals MH - Hindlimb/*blood supply/metabolism MH - Muscle, Skeletal/*blood supply/metabolism MH - Norepinephrine/pharmacology MH - Oxygen Consumption/drug effects MH - Photomicrography MH - Rats MH - Rats, Wistar MH - Serotonin/pharmacology MH - Tendons/*blood supply/metabolism MH - Vasoconstriction/drug effects MH - Vasoconstrictor Agents/pharmacology MH - Vasodilator Agents/pharmacology EDAT- 1997/07/01 00:00 MHDA- 1997/07/01 00:01 CRDT- 1997/07/01 00:00 PHST- 1997/07/01 00:00 [pubmed] PHST- 1997/07/01 00:01 [medline] PHST- 1997/07/01 00:00 [entrez] AID - S0026-2862(97)92021-5 [pii] AID - 10.1006/mvre.1997.2021 [doi] PST - ppublish SO - Microvasc Res. 1997 Jul;54(1):49-57. doi: 10.1006/mvre.1997.2021. PMID- 2120238 OWN - NLM STAT- MEDLINE DCOM- 19901109 LR - 20141120 IS - 0021-9304 (Print) IS - 0021-9304 (Linking) VI - 24 IP - 9 DP - 1990 Sep TI - Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. PG - 1185-201 AB - The reversibility of glutaraldehyde crosslinks has been suggested as a reason for failure of long-term bioprosthetic implants. The stability of such crosslinks was investigated in tendons and model compounds. Small but cytotoxic levels of glutaraldehyde were still released from crosslinked tendons even after these tendons were extensively rinsed for up to 6 months. The toxic effect was evidenced by the death of fibroblasts surrounding a midsection piece of rinsed crosslinked tendon, while the end section pieces did not show toxic effects. The formation and stability of glutaraldehyde modified [14C]-L-lysine derivatives were investigated. The polymerization of glutaraldehyde with amino compounds was initially fast but continued to proceed slowly for months. Degradation of high-molecular-weight soluble polymers was detected by gel filtration chromatography. Low-molecular-weight soluble materials were also released from insoluble products which were formed when high concentrations of glutaraldehyde and radioactive lysine were reacted. These chemical and biological studies suggest that local cytotoxicity of glutaraldehyde crosslinked bioprostheses may be due to unstable glutaraldehyde polymers that persist in the interstices of crosslinked tissues. FAU - Huang-Lee, L L AU - Huang-Lee LL AD - Department of Biochemistry, School of Medicine, University of Southern California, Los Angeles 90007. FAU - Cheung, D T AU - Cheung DT FAU - Nimni, M E AU - Nimni ME LA - eng GR - AR-10358/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biomed Mater Res JT - Journal of biomedical materials research JID - 0112726 RN - 0 (Cross-Linking Reagents) RN - K3Z4F929H6 (Lysine) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - *Bioprosthesis MH - Cattle MH - Cell Survival/*drug effects MH - Cells, Cultured MH - *Cross-Linking Reagents MH - Fibroblasts/cytology/drug effects MH - Glutaral/*metabolism/pharmacology MH - In Vitro Techniques MH - Lysine/metabolism MH - Materials Testing MH - Tendons/metabolism EDAT- 1990/09/01 00:00 MHDA- 1990/09/01 00:01 CRDT- 1990/09/01 00:00 PHST- 1990/09/01 00:00 [pubmed] PHST- 1990/09/01 00:01 [medline] PHST- 1990/09/01 00:00 [entrez] AID - 10.1002/jbm.820240905 [doi] PST - ppublish SO - J Biomed Mater Res. 1990 Sep;24(9):1185-201. doi: 10.1002/jbm.820240905. PMID- 4978620 OWN - NLM STAT- MEDLINE DCOM- 19690904 LR - 20151008 VI - 2 IP - 2 DP - 1969 TI - [Intermolecular processes of collagen. I. Influence of nonaequous lipids]. PG - 103-13 FAU - Nemetschek, T AU - Nemetschek T LA - ger PT - Journal Article TT - Intermolekulare Abläufe am Kollagen. I. Einfluss nichtwässriger Flüssigkeiten. PL - Germany TA - Virchows Arch B Cell Pathol JT - Virchows Archiv. B, Cell pathology JID - 0437105 RN - 0 (Alcohols) RN - 0 (Ethyl Ethers) RN - 0 (Plasma Substitutes) RN - 9007-34-5 (Collagen) SB - IM MH - Alcohols/*pharmacology MH - Animals MH - Chemistry, Organic MH - Collagen/*metabolism/pharmacology MH - Dogs MH - Ethyl Ethers/pharmacology MH - Humans MH - Microscopy, Electron MH - Organic Chemistry Phenomena MH - Plasma Substitutes/pharmacology MH - Rats MH - Tail MH - Tendons/metabolism EDAT- 1969/01/01 00:00 MHDA- 1969/01/01 00:01 CRDT- 1969/01/01 00:00 PHST- 1969/01/01 00:00 [pubmed] PHST- 1969/01/01 00:01 [medline] PHST- 1969/01/01 00:00 [entrez] PST - ppublish SO - Virchows Arch B Cell Pathol. 1969;2(2):103-13. PMID- 39600050 OWN - NLM STAT- MEDLINE DCOM- 20250102 LR - 20250102 IS - 2192-2659 (Electronic) IS - 2192-2640 (Linking) VI - 14 IP - 1 DP - 2025 Jan TI - Coaxial Electrospun Nanofibrous Membranes as Dual-Functional Biomimetic Tendon Sheath for Tendon Repair and Anti-Peritendinous Adhesion. PG - e2402074 LID - 10.1002/adhm.202402074 [doi] AB - Tendon injuries often exhibit limited healing capacity, frequently complicated by peritendinous adhesion, posing a substantial challenge in clinical tendon repair. Although present biomaterial-based membranes offer a promising strategy for tendon treatment, their clinical application is hindered by inflammation-induced adhesion. Herein, this study presents a dual-functional biomimetic tendon sheath based on a coaxial electrospun nanofibrous membrane for enhancing tendon repair and simultaneously preventing peritendinous adhesion. This nanofibrous membrane is fabricated using a coaxial electrospinning method, encapsulating celecoxib-loaded polycaprolactone (PCL) within gelatin methacryloyl (GelMA) shell. Both in vitro and in vivo analysis results demonstrated that such coaxial biomimetic tendon sheath enhanced tenogenic differentiation of tendon stem/progenitor cells (TSPCs) due to nanofibrous GelMA shell providing a suitable microenvironment surface. Simultaneously, the sustained release of celecoxib (CEL) from the core is able to significantly decrease the expression of inflammatory cytokines. Notably, in vivo assessments in animal models with patellar tendon defects revealed significant reductions in peritendinous adhesion, leading to further enhancement in tendon repair. These results underscore the potential of the coaxial nanofibrous membrane as a dual-functional biomimetic tendon sheath, offering a promising avenue for the long-term management of tendon injuries. CI - © 2024 Wiley‐VCH GmbH. FAU - Yang, Qiao AU - Yang Q AD - Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. FAU - Li, Jianfeng AU - Li J AD - Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. AD - The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China. FAU - Meng, Hongfang AU - Meng H AD - Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. FAU - Wang, Yongdi AU - Wang Y AD - The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China. FAU - Hu, Lanlan AU - Hu L AD - Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. AD - Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Su, Weiwei AU - Su W AD - Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. FAU - Xu, Jie AU - Xu J AD - Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. FAU - Hou, Juedong AU - Hou J AD - Division of Spine Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Zhao, Rui AU - Zhao R AD - Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. FAU - Wang, Zihan AU - Wang Z AD - Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. FAU - Zhang, Kairui AU - Zhang K AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. FAU - Wu, Yaobin AU - Wu Y AUID- ORCID: 0000-0003-2570-2837 AD - Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics, Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. FAU - Wang, Ling AU - Wang L AUID- ORCID: 0000-0001-6043-5661 AD - Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, China. LA - eng GR - 32271423/National Natural Science Foundation of China/ GR - 32000955/National Natural Science Foundation of China/ GR - 2024A1515013273/Guangdong Basic and Applied Basic Research Foundation/ GR - 2024A04J6372/Science and Technology Program of Guangzhou/ PT - Journal Article DEP - 20241126 PL - Germany TA - Adv Healthc Mater JT - Advanced healthcare materials JID - 101581613 RN - JCX84Q7J1L (Celecoxib) RN - 0 (Polyesters) RN - 9000-70-8 (Gelatin) RN - 24980-41-4 (polycaprolactone) RN - 0 (Membranes, Artificial) SB - IM MH - Animals MH - *Nanofibers/chemistry MH - *Tendon Injuries/therapy/pathology MH - *Celecoxib/chemistry/pharmacology MH - *Tendons/drug effects MH - *Polyesters/chemistry MH - Gelatin/chemistry MH - Biomimetic Materials/chemistry/pharmacology MH - Tissue Adhesions/prevention & control/metabolism MH - Cell Differentiation/drug effects MH - Membranes, Artificial MH - Male MH - Stem Cells/metabolism/cytology/drug effects MH - Rats MH - Rabbits OTO - NOTNLM OT - anti‐peritendinous adhesions OT - biomimetic tendon sheath OT - coaxial electrospinning OT - nanofibrous membrane OT - tendon repair EDAT- 2024/11/27 06:18 MHDA- 2025/01/02 06:19 CRDT- 2024/11/27 01:46 PHST- 2024/11/15 00:00 [revised] PHST- 2024/06/05 00:00 [received] PHST- 2025/01/02 06:19 [medline] PHST- 2024/11/27 06:18 [pubmed] PHST- 2024/11/27 01:46 [entrez] AID - 10.1002/adhm.202402074 [doi] PST - ppublish SO - Adv Healthc Mater. 2025 Jan;14(1):e2402074. doi: 10.1002/adhm.202402074. Epub 2024 Nov 26. PMID- 24038530 OWN - NLM STAT- MEDLINE DCOM- 20131217 LR - 20131023 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 31 IP - 12 DP - 2013 Dec TI - Cross-link stabilization does not affect the response of collagen molecules, fibrils, or tendons to tensile overload. PG - 1907-13 LID - 10.1002/jor.22460 [doi] AB - We investigated whether immature allysine-derived cross-links provide mechanically labile linkages by exploring the effects of immature cross-link stabilization at three levels of collagen hierarchy: damaged fibril morphology, whole tendon mechanics, and molecular stability. Tendons from the tails of young adult steers were either treated with sodium borohydride (NaBH₄) to stabilize labile cross-links, exposed only to the buffer used during stabilization treatment, or maintained as untreated controls. One-half of each tendon was then subjected to five cycles of subrupture overload. Morphologic changes to collagen fibrils resulting from overload were investigated using scanning electron microscopy, and changes in the hydrothermal stability of collagen molecules were assessed using hydrothermal isometric tension testing. NaBH4 cross-link stabilization did not affect the response of tendon collagen to tensile overload at any of the three levels of hierarchy studied. Cross-link stabilization did not prevent the characteristic overload-induced mode of fibril damage that we term discrete plasticity. Similarly, stabilization did not alter the mechanical response of whole tendons to overload, and did not prevent an overload-induced thermal destabilization of collagen molecules. Our results indicate that hydrothermally labile cross-links may not be as mechanically labile as was previously thought. CI - © 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Veres, Samuel P AU - Veres SP AD - Division of Engineering, Saint Mary's University, Halifax, Nova Scotia, Canada, B3H 3C3. FAU - Harrison, Julia M AU - Harrison JM FAU - Lee, J Michael AU - Lee JM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130822 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Borohydrides) RN - 0 (Fibrillar Collagens) RN - 87L0B9CPPA (sodium borohydride) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Borohydrides/pharmacology MH - Cattle MH - Collagen/*chemistry MH - Fibrillar Collagens/*chemistry MH - Male MH - Protein Stability MH - Stress, Mechanical MH - Tendons/*physiology MH - *Tensile Strength OTO - NOTNLM OT - collagen fibril OT - cross-links OT - discrete plasticity OT - mechanical overload OT - tendon damage EDAT- 2013/09/17 06:00 MHDA- 2013/12/18 06:00 CRDT- 2013/09/17 06:00 PHST- 2013/02/21 00:00 [received] PHST- 2013/07/15 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2013/12/18 06:00 [medline] AID - 10.1002/jor.22460 [doi] PST - ppublish SO - J Orthop Res. 2013 Dec;31(12):1907-13. doi: 10.1002/jor.22460. Epub 2013 Aug 22. PMID- 7463374 OWN - NLM STAT- MEDLINE DCOM- 19810421 LR - 20190512 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 306 DP - 1980 Sep TI - The effect of suxamethonium on the response to stretch of Golgi tendon organs in the cat. PG - 511-8 AB - 1. The effects of intra-arterial infusion of suxamethonium (succinylcholine, SCh) on the response to stretch of Golgi tendon organs in the soleus muscle of the cat have been studied. 2. SCh infusion produced a gradual facilitation of the discharge of tendon organs with low thresholds to passive muscle stretch, but had no detectable effect on tendon organs with high thresholds to stretch. 3. The time course of excitation and recovery of low-threshold tendon organs after SCh infusion was much longer than that of muscle spindle primary and secondary sensory endings. 4. Control experiments showed that there was no change in the passive tension of the soleus muscle during SCh infusion, thus excluding the possibility that the excitation of the low-threshold tendon organs is caused by an increase in passive muscle tension. 5. These findings complement recent observations that SCh can excite receptors other than those in muscle spindles, and indicate that SCh activation on its own may not be a sufficient criterion on the basis of which to identify muscle spindle afferent axons. FAU - Dutia, M B AU - Dutia MB FAU - Ferrell, W R AU - Ferrell WR LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - J2R869A8YF (Succinylcholine) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Axons/physiology MH - Cats MH - Mechanoreceptors/*drug effects/physiology MH - Muscle Contraction MH - Muscles/innervation MH - Neurons, Afferent/physiology MH - Succinylcholine/*pharmacology MH - Tendons/drug effects/*innervation PMC - PMC1283020 EDAT- 1980/09/01 00:00 MHDA- 1980/09/01 00:01 PMCR- 1980/09/01 CRDT- 1980/09/01 00:00 PHST- 1980/09/01 00:00 [pubmed] PHST- 1980/09/01 00:01 [medline] PHST- 1980/09/01 00:00 [entrez] PHST- 1980/09/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1980.sp013411 [doi] PST - ppublish SO - J Physiol. 1980 Sep;306:511-8. doi: 10.1113/jphysiol.1980.sp013411. PMID- 7281719 OWN - NLM STAT- MEDLINE DCOM- 19811118 LR - 20141010 IS - 0044-2224 (Print) IS - 0044-2224 (Linking) VI - 35 IP - 4 DP - 1980 TI - [On the influence of D-penicillamine on collage metabolism - investigations of the rupture of strength in tailfibre in rats of several ages (author's transl)]. PG - 297-301 AB - The tensile strength of rat tail tendons of animals wtih a different age is more influenced by D-Penicillamine (DPA) in younger rats than in elderly rats. DPA has the best effect in the regions with the highest collagen turnover. After the use of DPA the collagen of tails of the elderly rats resembles the collagen of the younger animals. The reason of this alteration is probably a lower degree of cross-links of the collagen after the use of DPA. FAU - Trzenschik, K AU - Trzenschik K FAU - Lindenhayn, K AU - Lindenhayn K FAU - Mühlbach, R AU - Mühlbach R FAU - Napieralski, P AU - Napieralski P FAU - Noack, K AU - Noack K LA - ger PT - English Abstract PT - Journal Article TT - Zum Einfluss von D-Penicillamin auf der Kollagenstoffwechsel - Reissfestikeitsuntersuchungen an Schwanzsehnen verschieden alter Ratten. PL - Germany TA - Z Alternsforsch JT - Zeitschrift fur Alternsforschung JID - 0414005 RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - *Aging MH - Animals MH - Collagen/*metabolism MH - Models, Biological MH - Penicillamine/*pharmacology MH - Rats MH - Tail MH - Tendons/drug effects MH - Tensile Strength/drug effects EDAT- 1980/01/01 00:00 MHDA- 1980/01/01 00:01 CRDT- 1980/01/01 00:00 PHST- 1980/01/01 00:00 [pubmed] PHST- 1980/01/01 00:01 [medline] PHST- 1980/01/01 00:00 [entrez] PST - ppublish SO - Z Alternsforsch. 1980;35(4):297-301. PMID- 24969500 OWN - NLM STAT- MEDLINE DCOM- 20150331 LR - 20140627 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 39 IP - 7 DP - 2014 Jul TI - A simple alternative to the looped suture for flexor tendon repair. PG - 1448 LID - S0363-5023(14)00343-8 [pii] LID - 10.1016/j.jhsa.2014.02.027 [doi] FAU - Raza, Muhammad Sheraz AU - Raza MS AD - Department of Hand and Reconstructive Microsurgery, National University Hospital, Singapore. LA - eng PT - Letter PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Polypropylenes) SB - IM MH - Hand/physiopathology/surgery MH - Humans MH - *Needles MH - Polypropylenes/pharmacology MH - *Suture Techniques MH - *Sutures MH - Tendon Injuries/diagnosis/*surgery MH - Tendons/surgery MH - Tensile Strength EDAT- 2014/06/28 06:00 MHDA- 2015/04/01 06:00 CRDT- 2014/06/28 06:00 PHST- 2014/02/11 00:00 [received] PHST- 2014/02/19 00:00 [revised] PHST- 2014/02/25 00:00 [accepted] PHST- 2014/06/28 06:00 [entrez] PHST- 2014/06/28 06:00 [pubmed] PHST- 2015/04/01 06:00 [medline] AID - S0363-5023(14)00343-8 [pii] AID - 10.1016/j.jhsa.2014.02.027 [doi] PST - ppublish SO - J Hand Surg Am. 2014 Jul;39(7):1448. doi: 10.1016/j.jhsa.2014.02.027. PMID- 6120783 OWN - NLM STAT- MEDLINE DCOM- 19820527 LR - 20190825 IS - 0300-9629 (Print) IS - 0300-9629 (Linking) VI - 71 IP - 3 DP - 1982 TI - Characterization of progesterone-independent avidin production of chicken tissues in culture. PG - 389-93 AB - 1. Primary cell cultures of chick oviduct, intestine, peritoneal membrane and lung, but not those of wing muscle or calcaneal tendon, produced avidin progesterone-independently through a 5-week culture. 2. Actinomycin D and cycloheximide, but not hydroxyurea, inhibited the avidin production. 3. The common feature of the cultures producing avidin was a fibroblast-like cell type. 4. Similarly, oviduct and lung, but not muscle or tendon, also produced avidin in hormone-free short-term organ cultures, where the avidin synthesis began during the first 8 h of culture. 5. Induction of the general protein synthesis does not explain the avidin production, since another egg-white protein, ovalbumin, was not induced by the culture procedure. FAU - Nordback, I AU - Nordback I FAU - Kulomaa, M AU - Kulomaa M FAU - Joensuu, T AU - Joensuu T FAU - Tuohimaa, P AU - Tuohimaa P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Comp Biochem Physiol A Comp Physiol JT - Comparative biochemistry and physiology. A, Comparative physiology JID - 1276312 RN - 1405-69-2 (Avidin) RN - 4G7DS2Q64Y (Progesterone) RN - 731DCA35BT (Diethylstilbestrol) RN - 9006-59-1 (Ovalbumin) SB - IM MH - Animals MH - Avidin/*biosynthesis MH - Chickens MH - Diethylstilbestrol/pharmacology MH - Lung/drug effects/metabolism MH - Muscles/drug effects/*metabolism MH - Organ Culture Techniques MH - Ovalbumin/*analogs & derivatives/biosynthesis MH - Oviducts/drug effects/metabolism MH - Progesterone/*pharmacology MH - Tendons/drug effects/*metabolism EDAT- 1982/01/01 00:00 MHDA- 1982/01/01 00:01 CRDT- 1982/01/01 00:00 PHST- 1982/01/01 00:00 [pubmed] PHST- 1982/01/01 00:01 [medline] PHST- 1982/01/01 00:00 [entrez] AID - 10.1016/0300-9629(82)90423-6 [doi] PST - ppublish SO - Comp Biochem Physiol A Comp Physiol. 1982;71(3):389-93. doi: 10.1016/0300-9629(82)90423-6. PMID- 4968873 OWN - NLM STAT- MEDLINE DCOM- 19680820 LR - 20141120 IS - 0065-1281 (Print) IS - 0065-1281 (Linking) VI - 23 IP - 5 DP - 1966 TI - The importance of hydrogen linkages playing a role in the fibre formation of acid-soluble collagen, investigated by urea. PG - 180-8 FAU - Neumark, T AU - Neumark T FAU - Marót, I AU - Marót I LA - eng PT - Journal Article PL - Germany TA - Acta Histochem JT - Acta histochemica JID - 0370320 RN - 0 (Sulfuric Acids) RN - 7YNJ3PO35Z (Hydrogen) RN - 8W8T17847W (Urea) RN - 9007-27-6 (Chondroitin) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Chemical Phenomena MH - Chemical Precipitation MH - Chemistry MH - Chondroitin/pharmacology MH - Collagen/*analysis MH - Hydrogen MH - In Vitro Techniques MH - Microscopy, Electron MH - Rats MH - Sulfuric Acids/pharmacology MH - Tendons/analysis MH - Urea/pharmacology EDAT- 1966/01/01 00:00 MHDA- 1966/01/01 00:01 CRDT- 1966/01/01 00:00 PHST- 1966/01/01 00:00 [pubmed] PHST- 1966/01/01 00:01 [medline] PHST- 1966/01/01 00:00 [entrez] PST - ppublish SO - Acta Histochem. 1966;23(5):180-8. PMID- 16732611 OWN - NLM STAT- MEDLINE DCOM- 20060918 LR - 20141120 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 24 IP - 7 DP - 2006 Jul TI - Optimization of surface modifications of extrasynovial tendon to improve its gliding ability in a canine model in vitro. PG - 1555-61 AB - Previous studies have shown that the carboxyl groups in hyaluronic acid (HA) could be activated by 1-ethy 1-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC)/N-hydroxysuccinimide (NHS) to form intermediate O-acylisoureas, which can chemically bind to exposed amino groups on the tendon surface, leading to improved gliding ability. However, the optimal ratio and concentrations of the components in this chemical mixture were not investigated. The purpose of this study was to optimize the constituents of this tissue engineering approach to tendon surface modification, to reduce friction and improve durability. Peroneus longus (PL) tendons (n=40) were harvested from adult mongrel dogs along with the A2 pulley obtained from the ipsilateral hind paw. After the gliding resistance of the normal PL tendon was measured, the tendons were treated under varying concentrations of HA (0.5, 1, and 2%) and EDC/NHS (0.05, 0.25, and 1%) mixed with a 10% gelatin. Tendon friction was measured for 1000 cycles of simulated flexion/extension motion. Following testing, the residual HA on the tendon surface was evaluated by immunohistochemisty. The gliding resistance of the untreated PL tendons had a mean value of 0.087+/-0.021 N. After surface treatment, there was no significant difference in friction due to HA concentration alone, but the concentration of EDC/NHS and the interaction between HA concentration and EDC/NHS concentration had a significant effect on friction. Regardless of HA concentration, the friction after 1000 cycles was significantly decreased in preparations which included a 1% concentration of EDC/NHS. The tendons with lower gliding resistance presented a smoother surface on light microscopy and maintained more residual HA on the tendon surface. By varying the relative concentrations of HA, EDC, and NHS it is possible to optimize the effect of surface treatment on friction and durability in a canine extrasynovial tendon in vitro. CI - Copyright (c) 2006 Orthopaedic Research Society. FAU - Tanaka, Toshikazu AU - Tanaka T AD - Biomechanics Laboratory, Division of Orthopedic Research, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905, USA. FAU - Sun, Yu-Long AU - Sun YL FAU - Zhao, Chunfeng AU - Zhao C FAU - Zobitz, Mark E AU - Zobitz ME FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - AR49407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Succinimides) RN - 9004-61-9 (Hyaluronic Acid) RN - MJE3791M4T (N-hydroxysuccinimide) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) SB - IM MH - Animals MH - Dogs MH - Drug Synergism MH - Ethyldimethylaminopropyl Carbodiimide/*pharmacology MH - Friction MH - Hyaluronic Acid/*pharmacology MH - In Vitro Techniques MH - Succinimides/*pharmacology MH - Tendons/*drug effects EDAT- 2006/05/30 09:00 MHDA- 2006/09/19 09:00 CRDT- 2006/05/30 09:00 PHST- 2006/05/30 09:00 [pubmed] PHST- 2006/09/19 09:00 [medline] PHST- 2006/05/30 09:00 [entrez] AID - 10.1002/jor.20205 [doi] PST - ppublish SO - J Orthop Res. 2006 Jul;24(7):1555-61. doi: 10.1002/jor.20205. PMID- 22584912 OWN - NLM STAT- MEDLINE DCOM- 20130619 LR - 20220409 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 21 IP - 3 DP - 2013 Mar TI - Evaluation of sterilization methods following contamination of hamstring autograft during anterior cruciate ligament reconstruction. PG - 696-701 LID - 10.1007/s00167-012-2049-8 [doi] AB - PURPOSE: Inadvertent contamination of the hamstring autograft during ACL reconstruction is infrequent, but can result in significant complications. The purpose of this study is to evaluate bacterial contamination of hamstring autografts dropped onto the operating room floor and methods of graft decontamination. METHODS: Hamstring tendons were harvested from patients. Excess tendon not used in the ACL procedure was divided into 6 segments. Segments were assigned to 6 groups (A through F, N = 30 in each group): group A: uncontaminated graft immediately postharvest (control), group B: graft dropped onto the floor (5 s), group C: graft dropped onto the floor (15 s). grafts in groups D to F were dropped onto floor for 15 s then rinsed with saline (group D), bacitracin solution (group E) or chlorhexidine 4 % solution (group F) for 3 min. All grafts were sent to the microbiology laboratory for anaerobic and aerobic cultures. RESULTS: Cultures were positive in 23 % of graft segments from group A (7/30), 33 % of grafts from group B (10/30), 23 % from group C (7/30), 30 % from group D (9/30) and 3 % from both group E (1/30) and group F (1/30). Sixteen unique organisms were identified, with Staphylococcus aureus as the most common isolate. Grafts rinsed in either bacitracin solution or 4 % chlorhexidine solutions were significantly less likely to be culture positive when compared to control graft segments (p < 0.05). However, there was no significant difference between uncontaminated grafts retrieved in <5 versus 15 s from the floor. CONCLUSION: This study supports the practice of decontaminating a dropped ACL hamstring autograft using either 4 % chlorhexidine or bacitracin solution. Specimens should be retrieved sterilely and washed for at least 3 min. This study also demonstrates no advantage in retrieval time of less than 5 s as compared to 15 s for uncontaminated graft. Hamstring harvest in ACL reconstruction may result in positive cultures, thus routine soaking of the hamstring autograft in either bacitracin or 4 % chlorhexidine solution is recommended. In addition, dropped hamstring autograft can be effectively sterilized with bacitracin or 4 % chlorhexidine solution. LEVEL OF EVIDENCE: II. FAU - Plante, Matthew J AU - Plante MJ AD - Division of Sports Medicine, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA, USA. FAU - Li, Xinning AU - Li X FAU - Scully, Gail AU - Scully G FAU - Brown, Michael A AU - Brown MA FAU - Busconi, Brian D AU - Busconi BD FAU - DeAngelis, Nicola A AU - DeAngelis NA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120515 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Anti-Infective Agents, Local) RN - 0 (Disinfectants) RN - 1405-87-4 (Bacitracin) RN - R4KO0DY52L (Chlorhexidine) SB - IM MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Anti-Infective Agents, Local/*pharmacology MH - Bacitracin/pharmacology MH - Chlorhexidine/pharmacology MH - Disinfectants/*pharmacology MH - Equipment Contamination MH - Humans MH - Sterilization/*methods MH - Tendons/drug effects/*microbiology/transplantation MH - Transplantation, Autologous EDAT- 2012/05/16 06:00 MHDA- 2013/06/20 06:00 CRDT- 2012/05/16 06:00 PHST- 2012/02/25 00:00 [received] PHST- 2012/05/02 00:00 [accepted] PHST- 2012/05/16 06:00 [entrez] PHST- 2012/05/16 06:00 [pubmed] PHST- 2013/06/20 06:00 [medline] AID - 10.1007/s00167-012-2049-8 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2013 Mar;21(3):696-701. doi: 10.1007/s00167-012-2049-8. Epub 2012 May 15. PMID- 11918318 OWN - NLM STAT- MEDLINE DCOM- 20020411 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 20 IP - 2 DP - 2002 Mar TI - Differential expression of neural cell adhesion molecule (NCAM) after tenotomy in rabbit skeletal muscle. PG - 364-9 AB - Tenotomy is a commonly encountered event in orthopaedic surgery. In 23 rabbit extensor digitorum longus (EDL) muscles, within 24 h after tenotomy, a marked drop in maximum force production occurred. This was not explainable based on architectural changes and histological examination using standard markers for muscle injury, i.e., haematoxylin and eosin morphology, developmental myosin heavy chain (MHC) immunolabeling, and quantitation of muscle fiber type percentage, area and distribution. The expression of neural cell adhesion molecule (NCAM), a glycoprotein expressed during muscle development was measured as a function of time in these muscles. NCAM expression was increased as early as one day after tenotomy with 2.2+/-1.2% of the fibers showing positive expression. This expression level increased significantly to 15.4+/-15.2% after 7 days and then subsided to 13.2+/-10.6% 21 days after tenotomy. Two-way analysis of variance demonstrated a significant effect of time and a significant time x tenotomy method interaction. These results suggest that tenotomy leads to possible changes in muscle-nerve connections and/or excitation-contraction (EC) coupling. FAU - Jamali, Amir A AU - Jamali AA AD - Department of Orthopaedics, UC San Diego School of Medicine, Veterans Affairs and University of California Medical Centers, 92161, USA. FAU - Afshar, Pouya AU - Afshar P FAU - Abrams, Reid A AU - Abrams RA FAU - Lieber, Richard L AU - Lieber RL LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Neural Cell Adhesion Molecules) RN - 0 (Protein Isoforms) RN - EC 3.6.4.1 (Myosin Heavy Chains) RN - Y8335394RO (Bupivacaine) SB - IM MH - Animals MH - Bupivacaine/toxicity MH - Immunohistochemistry MH - Injections, Intramuscular MH - Isometric Contraction/physiology MH - Male MH - Muscle, Skeletal/drug effects/*metabolism/pathology MH - Myosin Heavy Chains/analysis MH - Neural Cell Adhesion Molecules/*biosynthesis MH - Protein Isoforms/analysis MH - Rabbits MH - Tendon Injuries/*physiopathology/surgery MH - Tendons/drug effects/*physiology/surgery EDAT- 2002/03/29 10:00 MHDA- 2002/04/12 10:01 CRDT- 2002/03/29 10:00 PHST- 2002/03/29 10:00 [pubmed] PHST- 2002/04/12 10:01 [medline] PHST- 2002/03/29 10:00 [entrez] AID - 10.1016/S0736-0266(01)00095-X [doi] PST - ppublish SO - J Orthop Res. 2002 Mar;20(2):364-9. doi: 10.1016/S0736-0266(01)00095-X. PMID- 5141345 OWN - NLM STAT- MEDLINE DCOM- 19720516 LR - 20141010 IS - 0044-2224 (Print) IS - 0044-2224 (Linking) VI - 24 IP - 4 DP - 1971 TI - [Effect of penicillamine on thermic contraction of the tail tendon fibers in old rats]. PG - 355-7 FAU - Kalbe, I AU - Kalbe I FAU - Reitzig, P AU - Reitzig P FAU - Brüschke, G AU - Brüschke G FAU - Schmidt, U J AU - Schmidt UJ LA - ger PT - Journal Article TT - Uber die Wirkung von Penicillamin auf das Verhalten der thermischen Kontraktion von Schwanzsehnenfasern alter Ratten. PL - Germany TA - Z Alternsforsch JT - Zeitschrift fur Alternsforschung JID - 0414005 RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Aminopropionitrile/*pharmacology MH - Animals MH - Collagen MH - Connective Tissue/*drug effects MH - Male MH - Myography MH - Penicillamine/*pharmacology MH - Rats MH - Rats, Inbred Strains MH - Tail/drug effects MH - Tendons/drug effects EDAT- 1971/01/01 00:00 MHDA- 1971/01/01 00:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 1971/01/01 00:01 [medline] PHST- 1971/01/01 00:00 [entrez] PST - ppublish SO - Z Alternsforsch. 1971;24(4):355-7. PMID- 6028252 OWN - NLM STAT- MEDLINE DCOM- 19670903 LR - 20190511 IS - 0006-8950 (Print) IS - 0006-8950 (Linking) VI - 90 IP - 2 DP - 1967 Jun TI - Studies of spasticity in man. 2. Analysis of stretch reflexes in spasticity. PG - 333-58 FAU - Dimitrijevíc, M R AU - Dimitrijevíc MR FAU - Nathan, P W AU - Nathan PW LA - eng PT - Journal Article PL - England TA - Brain JT - Brain : a journal of neurology JID - 0372537 RN - 4Z8Y51M438 (Procaine) SB - IM MH - Ankle/physiopathology MH - Electromyography MH - Functional Laterality MH - Humans MH - Knee/physiopathology MH - Leg/physiopathology MH - Motor Neurons/physiopathology MH - Muscles/drug effects/*physiopathology MH - Muscular Diseases/*physiopathology MH - Procaine/pharmacology MH - Spinal Cord/physiopathology MH - Spinal Cord Diseases/*physiopathology MH - Tendons/physiopathology EDAT- 1967/06/01 00:00 MHDA- 1967/06/01 00:01 CRDT- 1967/06/01 00:00 PHST- 1967/06/01 00:00 [pubmed] PHST- 1967/06/01 00:01 [medline] PHST- 1967/06/01 00:00 [entrez] AID - 10.1093/brain/90.2.333 [doi] PST - ppublish SO - Brain. 1967 Jun;90(2):333-58. doi: 10.1093/brain/90.2.333. PMID- 21123612 OWN - NLM STAT- MEDLINE DCOM- 20110111 LR - 20250529 IS - 1535-1386 (Electronic) IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 92 IP - 17 DP - 2010 Dec 1 TI - Improvement of flexor tendon reconstruction with carbodiimide-derivatized hyaluronic acid and gelatin-modified intrasynovial allografts: study of a primary repair failure model. PG - 2817-28 LID - 10.2106/JBJS.I.01148 [doi] AB - BACKGROUND: Tendon grafts play an important role in flexor tendon reconstruction. This study was an investigation of the effects of surface modification of allograft intrasynovial tendons with carbodiimide-derivatized hyaluronic acid and gelatin in an in vivo canine model. To mimic the actual clinical situation, a novel and clinically relevant model of a failed primary flexor tendon repair was used to evaluate the flexor tendon grafts. METHODS: Twenty-eight flexor digitorum profundus tendons from the second and fifth digits of fourteen dogs were lacerated and repaired in zone II in a first-surgery phase. The dogs were allowed free active motion postoperatively. In a second phase, six weeks later, the tendons were reconstructed with use of a flexor digitorum profundus allograft. In each dog, one graft was treated with carbodiimide-derivatized hyaluronic acid and gelatin (the CHG group) and the other was treated with saline solution, as a control. The dogs were restricted from free active motion, but daily therapy was performed beginning on postoperative day 5 and continued until six weeks after the operation, when the animals were killed. The outcomes were evaluated on the basis of digit work of flexion, gliding resistance, healing at the distal attachment, graft cell viability, histological findings, and findings on scanning electron microscopy. RESULTS: In the first phase, all twenty-eight repaired tendons ruptured, with scar and adhesion formation in the repair site. Six weeks after allograft reconstruction, the mean work of flexion was 0.37 and 0.94 N-mm/degree in the CHG group and the saline-solution control group, respectively; these values were significantly different (p < 0.05). The gliding resistance in the CHG group was also significantly less than that in the saline-solution control group (0.18 versus 0.28 N) (p < 0.05), but no difference between groups was observed with regard to the distal tendon-bone pullout strength. Histological analysis showed that tenocytes in the host tendon proliferated and migrated toward the acellular allograft. CONCLUSIONS: This primary repair failure model was reproducible and reliable, with a uniform failure pattern, and provides an appropriate and clinically relevant animal model with which to study flexor tendon reconstruction. The surface modification of allografts with carbodiimide-derivatized hyaluronic acid and gelatin improved digital function and tendon gliding ability. FAU - Zhao, Chunfeng AU - Zhao C AD - Biomechanics Laboratory, Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA. zhaoc@mayo.edu FAU - Sun, Yu-Long AU - Sun YL FAU - Ikeda, Jun AU - Ikeda J FAU - Kirk, Ramona L AU - Kirk RL FAU - Thoreson, Andrew R AU - Thoreson AR FAU - Moran, Steven L AU - Moran SL FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - R03 AR049407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Biocompatible Materials) RN - 0 (Carbodiimides) RN - 9000-70-8 (Gelatin) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Biocompatible Materials MH - Carbodiimides/*pharmacology MH - Dogs MH - Gelatin/*pharmacology MH - Hyaluronic Acid/*pharmacology MH - Models, Animal MH - Orthopedic Procedures MH - Tendon Injuries/*surgery MH - Tendons/*surgery/transplantation MH - Transplantation, Homologous PMC - PMC7002081 EDAT- 2010/12/03 06:00 MHDA- 2011/01/12 06:00 PMCR- 2020/02/05 CRDT- 2010/12/03 06:00 PHST- 2010/12/03 06:00 [entrez] PHST- 2010/12/03 06:00 [pubmed] PHST- 2011/01/12 06:00 [medline] PHST- 2020/02/05 00:00 [pmc-release] AID - 92/17/2817 [pii] AID - I01148 [pii] AID - 10.2106/JBJS.I.01148 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2010 Dec 1;92(17):2817-28. doi: 10.2106/JBJS.I.01148. PMID- 17606070 OWN - NLM STAT- MEDLINE DCOM- 20070918 LR - 20131121 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 32 IP - 6 DP - 2007 Jul-Aug TI - The effect of carbodiimide-derivatized hyaluronic acid and gelatin surface modification on peroneus longus tendon graft in a short-term canine model in vivo. PG - 876-81 AB - PURPOSE: We have recently reported that application of carbodiimide-derivatized hyaluronic acid and gelatin (cd-HA gelatin) to a peroneus longus tendon graft increased tendon graft gliding ability and decreased work of flexion compared with untreated grafts in a canine model in vivo. In this study, we investigated the effect of this modification on adhesions, stiffness, strength of the distal attachment, and fibroblast count. METHODS: A total of 24 dogs were used for this study. The peroneus longus tendons of each hind leg were grafted into the 2nd and 5th digits of one forepaw in each dog. One peroneus longus tendon was treated with cd-HA gelatin prior to grafting, and the other one was immersed in 0.9% saline solution as a control. Animals were killed 1, 3, or 6 weeks postoperatively. RESULTS: The adhesion score of cd-HA gelatin-treated tendons was significantly less than that in the saline-treated tendons at all time points. There was no significant difference in the indentation stiffness between HA- and saline-treated grafts at any time point. For the ultimate force at the distal attachment, there was a significant difference among the time points, with a steady increase over time, but no significant difference between treated and control tendons at any time point. There was no significant difference in fibroblast count between treated and control tendons at any time point. CONCLUSIONS: Although gross adhesion formation was less, there was no significant difference in strength at the distal tendon-bone interface, cellularity, or tendon graft stiffness when comparing saline-treated and cd-HA gelatin-treated tendon grafts in vivo. FAU - Tanaka, Toshikazu AU - Tanaka T AD - Biomechanics Laboratory, Division of Orthopedic Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. FAU - Zhao, Chunfeng AU - Zhao C FAU - Sun, Yu-Long AU - Sun YL FAU - Zobitz, Mark E AU - Zobitz ME FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - AR49407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Adjuvants, Immunologic) RN - 9000-70-8 (Gelatin) RN - 9004-61-9 (Hyaluronic Acid) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) SB - IM MH - Adjuvants, Immunologic/*pharmacology MH - Animals MH - Cell Count MH - Dogs MH - Ethyldimethylaminopropyl Carbodiimide/*pharmacology MH - Fibroblasts/metabolism MH - Gelatin/*pharmacology MH - Hyaluronic Acid/*pharmacology MH - Models, Animal MH - Tendon Injuries/surgery MH - Tendons/*transplantation MH - Tensile Strength MH - Tissue Adhesions/pathology/prevention & control MH - Tissue Transplantation/methods EDAT- 2007/07/04 09:00 MHDA- 2007/09/19 09:00 CRDT- 2007/07/04 09:00 PHST- 2006/09/25 00:00 [received] PHST- 2007/03/05 00:00 [revised] PHST- 2007/03/06 00:00 [accepted] PHST- 2007/07/04 09:00 [pubmed] PHST- 2007/09/19 09:00 [medline] PHST- 2007/07/04 09:00 [entrez] AID - S0363-5023(07)00350-4 [pii] AID - 10.1016/j.jhsa.2007.03.007 [doi] PST - ppublish SO - J Hand Surg Am. 2007 Jul-Aug;32(6):876-81. doi: 10.1016/j.jhsa.2007.03.007. PMID- 4406366 OWN - NLM STAT- MEDLINE DCOM- 19740619 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 24 IP - 2 DP - 1974 Feb TI - Organ specificity of the effects of D-penicillamine and of lathyrogen (aminoacetonitrile) on mechanical properties of connective and supporting tissue. PG - 157-63 FAU - Vogel, H G AU - Vogel HG LA - eng PT - Journal Article PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Amines) RN - 0 (Nitriles) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Amines/pharmacology MH - Animals MH - Biomechanical Phenomena MH - Collagen MH - Connective Tissue/*drug effects MH - Elasticity MH - Epiphyses/drug effects MH - Femur/drug effects MH - Nitriles/*pharmacology MH - Penicillamine/*pharmacology MH - Rats MH - Tendons/drug effects MH - Tibia/drug effects EDAT- 1974/02/01 00:00 MHDA- 1974/02/01 00:01 CRDT- 1974/02/01 00:00 PHST- 1974/02/01 00:00 [pubmed] PHST- 1974/02/01 00:01 [medline] PHST- 1974/02/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1974 Feb;24(2):157-63. PMID- 5905214 OWN - NLM STAT- MEDLINE DCOM- 19660521 LR - 20131121 IS - 0363-0153 (Print) IS - 0363-0153 (Linking) VI - 81 IP - 4 DP - 1966 Apr TI - Effects of various blocking reagents upon local mechanism of calcification. PG - 325-42 FAU - Urist, M R AU - Urist MR FAU - Adams, J M Jr AU - Adams JM Jr LA - eng PT - Journal Article PL - United States TA - Arch Pathol JT - Archives of pathology JID - 7605251 RN - 0 (Amides) RN - 0 (Anhydrides) RN - 0 (Indicators and Reagents) RN - 0 (Nitrobenzenes) RN - 0 (Sulfhydryl Compounds) RN - M4I0D6VV5M (Calcium Chloride) SB - IM MH - Amides MH - Anhydrides MH - Animals MH - Anterior Chamber/*physiology MH - *Calcification, Physiologic MH - Calcium Chloride/pharmacology MH - Hypercalcemia MH - Indicators and Reagents/pharmacology MH - Nitrobenzenes MH - Rats MH - Sulfhydryl Compounds/pharmacology MH - Tendons/*transplantation OID - NASA: 66093476 EDAT- 1966/04/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1966/04/01 00:00 PHST- 1966/04/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1966/04/01 00:00 [entrez] PST - ppublish SO - Arch Pathol. 1966 Apr;81(4):325-42. PMID- 20135679 OWN - NLM STAT- MEDLINE DCOM- 20100719 LR - 20131121 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 28 IP - 8 DP - 2010 Aug TI - Transient neutropenia increases macrophage accumulation and cell proliferation but does not improve repair following intratendinous rupture of Achilles tendon. PG - 1084-91 LID - 10.1002/jor.21092 [doi] AB - Neutrophils are the first leukocytes to invade tendons after an acute injury. They could modulate both the inflammatory response and early repair processes through the release of reactive species, cytokines, growth factors, and proteinases. However, the exact role of these cells in damaged tendons remains unclear. We investigated their role by inducing a transient neutropenia in C57BL/6 male mice using an anti-Ly6C/Ly6G antibody. Placebo mice received only serum. The right Achilles tendon was sectioned and sutured using the 8-strand technique, which allowed immediate weight bearing. A significant increase in macrophage accumulation and cell proliferation was observed in tendons from neutropenic animals compared to the placebo group at days 3 and/or 7 postinjury. However, there was a reduction in cell proliferation in a group of mice depleted in macrophages, indicating that macrophages play a role in cell replication in injured tendons. Lastly, the tendons of neutropenic and placebo mice had similar collagen content and mechanical properties at days 7, 14, and/or 28 postinjury. Our findings demonstrate that neutropenia modulates macrophage accumulation and cell proliferation, but overall, a reduction in neutrophil number has no significant effect on tendon repair. CI - Copyright 2010 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Godbout, Charles AU - Godbout C AD - Centre de Recherche du CHUL (CHUQ), 2705 Boulevard Laurier, T-R-93, Quebec, Quebec, Canada G1V 4G2. FAU - Bilodeau, Rosalie AU - Bilodeau R FAU - Van Rooijen, Nico AU - Van Rooijen N FAU - Bouchard, Patrice AU - Bouchard P FAU - Frenette, Jérôme AU - Frenette J LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0813BZ6866 (Clodronic Acid) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Cell Proliferation MH - Clodronic Acid/pharmacology MH - Collagen/metabolism MH - Macrophages/drug effects/*physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Neutropenia/*physiopathology MH - Rupture MH - Tendon Injuries/metabolism/pathology/*physiopathology MH - Wound Healing/drug effects/*physiology EDAT- 2010/02/06 06:00 MHDA- 2010/07/20 06:00 CRDT- 2010/02/06 06:00 PHST- 2010/02/06 06:00 [entrez] PHST- 2010/02/06 06:00 [pubmed] PHST- 2010/07/20 06:00 [medline] AID - 10.1002/jor.21092 [doi] PST - ppublish SO - J Orthop Res. 2010 Aug;28(8):1084-91. doi: 10.1002/jor.21092. PMID- 34483334 OWN - NLM STAT- MEDLINE DCOM- 20220117 LR - 20220117 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 27 DP - 2021 Sep 6 TI - Effects of Cyanoacrylate in Rabbits with Induced Achilles Tendon Rupture. PG - e929709 LID - 10.12659/MSM.929709 [doi] AB - BACKGROUND In this study, we aimed to investigate the effects of N-butyl-2-cyanoacrylate (cyanoacrylate) on the biomechanical and histopathological aspects of tendon healing in a rabbit model of Achilles tendon injury. MATERIAL AND METHODS In total, 36 rabbits were randomized to experimental (cyanoacrylate) and control groups (n=36 tendons in each group). A simple suture was used in the control group and a simple suture plus cyanoacrylate was used in the experimental group. Nine rabbits from each group were euthanized at week 4 and week 6 after surgery for histopathological and biomechanical testing. RESULTS Granulation tissue formation was significantly greater in the experimental group in week 4 and week 6 than in the control group. Foreign body giant cell formation was significantly higher in the experimental group in week 4 and week 6. The maximum rupture force was significantly higher in the experimental group in week 4 and week 6 than in the control group. Elasticity and stiffness were comparable between groups in week 4; however, stiffness, but not elasticity, was significantly higher in the experimental group in week 6. CONCLUSIONS In the short term, cyanoacrylate enhanced tendon endurance in both a histopathological and biomechanical manner. We conclude that the early initiation of rehabilitation in patients may be safe in cases of cyanoacrylate use for surgical repair of tendon injury. FAU - Bala, Mehmet Murat AU - Bala MM AUID- ORCID: 0000-0002-7213-5647 AD - Department of Orthopaedics and Traumatology, Trabzon Kanuni Training and Research Hospital, University of Health Sciences, Trabzon, Turkey. FAU - Şahin, Abdullah Alper AU - Şahin AA AUID- ORCID: 0000-0002-8973-2050 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, University of Ordu, Ordu, Turkey. FAU - Boz, Mehmet AU - Boz M AUID- ORCID: 0000-0003-0710-6978 AD - Department of Orthopaedics and Traumatology, Malatya Training and Research Hospital, Malatya, Turkey. FAU - Durukan, Yasin AU - Durukan Y AUID- ORCID: 0000-0002-3363-8364 AD - Department of Orthopaedics and Traumatology, Sakarya Training and Research Hospital, University of Sakarya, Sakarya, Turkey. FAU - Fırat, Tülin AU - Fırat T AUID- ORCID: 0000-0002-8317-7092 AD - Department of Histology and Embryology, Faculty of Medicine, University of Bolu Abant Izzet Baysal, Bolu, Turkey. FAU - Pakdil, Murat AU - Pakdil M AUID- ORCID: 0000-0001-8058-1690 AD - Department of Mechanical Engineering, Faculty of Engineering, University of Bolu Abant Izzet Baysal, Bolu, Turkey. FAU - Özturan, Kutay Engin AU - Özturan KE AUID- ORCID: 0000-0001-9506-4370 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, University of Bolu Abant Izzet Baysal, Bolu, Turkey. LA - eng PT - Journal Article DEP - 20210906 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (Cyanoacrylates) RN - 0 (Tissue Adhesives) SB - IM MH - Achilles Tendon/*injuries/pathology MH - Animals MH - Biomechanical Phenomena MH - Cyanoacrylates/*therapeutic use MH - Male MH - Rabbits MH - Random Allocation MH - Rupture/pathology/*surgery MH - Tendon Injuries/pathology/*surgery MH - Tissue Adhesives/*therapeutic use PMC - PMC8434771 COIS- Conflict of Interest None. EDAT- 2021/09/07 06:00 MHDA- 2022/01/18 06:00 PMCR- 2021/09/06 CRDT- 2021/09/06 05:43 PHST- 2021/09/06 05:43 [entrez] PHST- 2021/09/07 06:00 [pubmed] PHST- 2022/01/18 06:00 [medline] PHST- 2021/09/06 00:00 [pmc-release] AID - 929709 [pii] AID - 10.12659/MSM.929709 [doi] PST - epublish SO - Med Sci Monit. 2021 Sep 6;27:e929709. doi: 10.12659/MSM.929709. PMID- 4962100 OWN - NLM STAT- MEDLINE DCOM- 19671005 LR - 20191021 VI - 264 IP - 4 DP - 1967 Jan 23 TI - [Potentiation by cholinesterase-inhibitors of the depolarizing effect of acetylcholine at the level of the musculo-tendinous junction]. PG - 628-31 FAU - Pécot-Dechavassine, M AU - Pécot-Dechavassine M LA - fre PT - Journal Article TT - Potentialisation par les anticholinestérasiques de l'effet dépolarisant de l'acétylcholine au niveau de la jonction musculo-tendineuse. PL - France TA - C R Acad Hebd Seances Acad Sci D JT - Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles JID - 7501107 RN - 0 (Cholinesterase Inhibitors) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Animals MH - Anura MH - Cholinesterase Inhibitors/*pharmacology MH - Muscles/*drug effects MH - Tendons/*drug effects EDAT- 1967/01/23 00:00 MHDA- 1967/01/23 00:01 CRDT- 1967/01/23 00:00 PHST- 1967/01/23 00:00 [pubmed] PHST- 1967/01/23 00:01 [medline] PHST- 1967/01/23 00:00 [entrez] PST - ppublish SO - C R Acad Hebd Seances Acad Sci D. 1967 Jan 23;264(4):628-31. PMID- 4835493 OWN - NLM STAT- MEDLINE DCOM- 19740906 LR - 20141120 IS - 0021-0005 (Print) IS - 0021-0005 (Linking) VI - 12 IP - 1 DP - 1974 Jul TI - Simple synthetic and natural urines have equivalent anticalcifying properties. PG - 79-81 FAU - Barker, L M AU - Barker LM FAU - Pallante, S L AU - Pallante SL FAU - Eisenberg, H AU - Eisenberg H FAU - Joule, J A AU - Joule JA FAU - Becker, G L AU - Becker GL FAU - Howard, J E AU - Howard JE LA - eng PT - Journal Article PL - United States TA - Invest Urol JT - Investigative urology JID - 0374747 RN - 0 (Citrates) RN - 0 (Solutions) RN - 27YLU75U4W (Phosphorus) RN - I38ZP9992A (Magnesium) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Biochemical Phenomena MH - Biochemistry MH - Calcinosis/*prevention & control MH - Calcium/pharmacology MH - Citrates/pharmacology MH - Humans MH - Hydrogen-Ion Concentration MH - In Vitro Techniques MH - Magnesium/pharmacology MH - Phosphorus/pharmacology MH - Solutions MH - Tendons/metabolism MH - Urine/*physiology EDAT- 1974/07/01 00:00 MHDA- 1974/07/01 00:01 CRDT- 1974/07/01 00:00 PHST- 1974/07/01 00:00 [pubmed] PHST- 1974/07/01 00:01 [medline] PHST- 1974/07/01 00:00 [entrez] PST - ppublish SO - Invest Urol. 1974 Jul;12(1):79-81. PMID- 21048180 OWN - NLM STAT- MEDLINE DCOM- 20101208 LR - 20220408 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 92 IP - 15 DP - 2010 Nov 3 TI - Novel approaches for the management of tendinopathy. PG - 2604-13 LID - 10.2106/JBJS.I.01744 [doi] AB - Tendinopathy is a failed healing response of the tendon. Despite an abundance of therapeutic options, very few randomized prospective, placebo-controlled trials have been carried out to assist physicians in choosing the best evidence-based management. Eccentric exercises have been proposed to promote collagen fiber cross-link formation within the tendon, thereby facilitating tendon remodeling. Overall results suggest a trend for a positive effect of eccentric exercises, with no reported adverse effects. Combining eccentric training and shock wave therapy produces higher success rates compared with eccentric loading alone or shock wave therapy alone. The use of injectable substances such as platelet-rich plasma, autologous blood, polidocanol, corticosteroids, and aprotinin in and around tendons is popular, but there is minimal clinical evidence to support their use. The aim of operative treatment is to excise fibrotic adhesions, remove areas of failed healing, and make multiple longitudinal incisions in the tendon to detect intratendinous lesions and to restore vascularity and possibly stimulate the remaining viable cells to initiate cell matrix response and healing. New operative procedures include endoscopy, electrocoagulation, and minimally invasive stripping. The aim of these techniques is to disrupt the abnormal neoinnervation to interfere with the pain sensation caused by tendinopathy. Randomized controlled trials are necessary to better clarify the best therapeutic options for the management of tendinopathy. FAU - Maffulli, Nicola AU - Maffulli N AD - Centre for Sports and Exercise Medicine, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Mile End Hospital, 275 Bancroft Road, London E1 4DG, England. n.maffulli@qmul.ac.uk FAU - Longo, Umile Giuseppe AU - Longo UG FAU - Denaro, Vincenzo AU - Denaro V LA - eng PT - Journal Article PT - Review PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Anesthetics, Local/therapeutic use MH - Blood Transfusion, Autologous MH - Electrocoagulation MH - Endoscopy MH - Exercise Therapy/methods MH - High-Energy Shock Waves/therapeutic use MH - Humans MH - Minimally Invasive Surgical Procedures MH - Platelet-Rich Plasma MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Randomized Controlled Trials as Topic MH - Sclerosing Solutions/therapeutic use MH - Tendinopathy/*therapy MH - Tissue Adhesions/therapy MH - Wound Healing/physiology EDAT- 2010/11/05 06:00 MHDA- 2010/12/14 06:00 CRDT- 2010/11/05 06:00 PHST- 2010/11/05 06:00 [entrez] PHST- 2010/11/05 06:00 [pubmed] PHST- 2010/12/14 06:00 [medline] AID - 92/15/2604 [pii] AID - 10.2106/JBJS.I.01744 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2010 Nov 3;92(15):2604-13. doi: 10.2106/JBJS.I.01744. PMID- 21248208 OWN - NLM STAT- MEDLINE DCOM- 20110223 LR - 20171116 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 93 IP - 2 DP - 2011 Jan 19 TI - Peritendinous adhesions that form after the repair of lacerated digital flexor tendons cause stiffness and functional impairment. PG - e7 LID - 10.2106/JBJS.J.01472 [doi] FAU - Gougoulias, Nikolaos AU - Gougoulias N AD - Foot & Ankle Orthopaedic Clinic, Thessaloniki, Greece. FAU - Maffulli, Nicola AU - Maffulli N LA - eng PT - Comment PT - Comparative Study PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Biocompatible Materials) RN - 0 (Methacrylates) RN - 0 (Polymers) RN - 107-73-3 (Phosphorylcholine) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 59RU860S8D (2-methacryloyloxyethyl phosphorylcholine) SB - IM CON - J Bone Joint Surg Am. 2011 Jan 19;93(2):142-9. doi: 10.2106/JBJS.I.01634. PMID: 21248211 MH - Achilles Tendon/injuries/*surgery MH - Animals MH - Biocompatible Materials/pharmacology MH - Disease Models, Animal MH - Hydrogel, Polyethylene Glycol Dimethacrylate/pharmacology MH - Injections, Intralesional MH - Intraoperative Care/methods MH - Lacerations/complications/*surgery MH - Methacrylates/*pharmacology MH - Orthopedic Procedures/adverse effects/methods MH - Phosphorylcholine/*analogs & derivatives/pharmacology MH - Polymers/pharmacology MH - Rabbits MH - Rats MH - Tendon Injuries/surgery MH - Tendons/surgery MH - Tissue Adhesions/*etiology/*prevention & control MH - Wound Healing/physiology EDAT- 2011/01/21 06:00 MHDA- 2011/02/24 06:00 CRDT- 2011/01/21 06:00 PHST- 2011/01/21 06:00 [entrez] PHST- 2011/01/21 06:00 [pubmed] PHST- 2011/02/24 06:00 [medline] AID - 93/2/e7 [pii] AID - 10.2106/JBJS.J.01472 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2011 Jan 19;93(2):e7. doi: 10.2106/JBJS.J.01472. PMID- 2549962 OWN - NLM STAT- MEDLINE DCOM- 19890927 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 261 IP - 1 DP - 1989 Jul 1 TI - Inhibition of collagen hydroxylation by 2,7,8-trihydroxyanthraquinone in embryonic-chick tendon cells. PG - 127-30 AB - Prolyl 4-hydroxylase (EC 1.14.11.2) is an essential enzyme in the post-translational modification of collagen. Inhibitors of this enzyme are of potential interest for the treatment of diseases involving excessive deposition of collagen. 2,7,8-Trihydroxyanthraquinone (THA) is an effective inhibitor of prolyl 4-hydroxylase by virtue of its ability to compete with the co-substrate 2-oxoglutarate (Ki = 40.3 microM). Using a simple and reproducible assay for collagen hydroxylation, we show that THA inhibits the hydroxylation of collagen in embryonic-chick tendon cells in short-term culture, with an IC50 value (concn. giving 50% inhibition) of 32 microM. In comparison, the ethyl ester of 3,4-dihydroxybenzoic acid has an IC50 value of 0.1 mM against collagen hydroxylation by chick tendon cells, whereas its Ki versus isolated prolyl 4-hydroxylase is 49 microM. FAU - Franklin, T J AU - Franklin TJ AD - ICI Pharmaceuticals, Macclesfield, Cheshire, U.K. FAU - Hitchen, M AU - Hitchen M LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Anthraquinones) RN - 0 (Hydroxybenzoates) RN - 4YGJ96WTBG (ethyl protocatechuate) RN - 82-29-1 (2,7,8-trihydroxyanthraquinone) RN - 9007-34-5 (Collagen) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) SB - IM MH - Animals MH - Anthraquinones/*pharmacology MH - Cells, Cultured MH - Chick Embryo MH - Collagen MH - Hydroxybenzoates/pharmacology MH - Hydroxylation MH - Procollagen-Proline Dioxygenase/*antagonists & inhibitors MH - Tendons/drug effects/*enzymology PMC - PMC1138791 EDAT- 1989/07/01 00:00 MHDA- 1989/07/01 00:01 PMCR- 1990/01/01 CRDT- 1989/07/01 00:00 PHST- 1989/07/01 00:00 [pubmed] PHST- 1989/07/01 00:01 [medline] PHST- 1989/07/01 00:00 [entrez] PHST- 1990/01/01 00:00 [pmc-release] AID - 10.1042/bj2610127 [doi] PST - ppublish SO - Biochem J. 1989 Jul 1;261(1):127-30. doi: 10.1042/bj2610127. PMID- 5056494 OWN - NLM STAT- MEDLINE DCOM- 19721025 LR - 20141010 IS - 0044-2224 (Print) IS - 0044-2224 (Linking) VI - 25 IP - 3 DP - 1972 TI - [Methods for studying the changes of physical properties of connective tissue in the aging process]. PG - 247-55 FAU - Banga, I AU - Banga I LA - ger PT - Journal Article TT - Methoden zur Untersuchung der Veränderungen der physikalischen Eigenschaften des Bindegewebes im Alternsgang. PL - Germany TA - Z Alternsforsch JT - Zeitschrift fur Alternsforschung JID - 0414005 RN - 0 (Salts) RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Aged MH - *Aging MH - Animals MH - Arteriosclerosis/physiopathology MH - Carotid Arteries/physiology/physiopathology MH - Collagen MH - Connective Tissue/drug effects/*physiology/physiopathology MH - Elasticity MH - Hot Temperature MH - Humans MH - Methods MH - Middle Aged MH - Rats MH - Salts/pharmacology MH - Tendons/physiology MH - Urea/pharmacology EDAT- 1972/01/01 00:00 MHDA- 1972/01/01 00:01 CRDT- 1972/01/01 00:00 PHST- 1972/01/01 00:00 [pubmed] PHST- 1972/01/01 00:01 [medline] PHST- 1972/01/01 00:00 [entrez] PST - ppublish SO - Z Alternsforsch. 1972;25(3):247-55. PMID- 42618 OWN - NLM STAT- MEDLINE DCOM- 19800317 LR - 20141120 IS - 0971-5916 (Print) IS - 0971-5916 (Linking) VI - 70 DP - 1979 Aug TI - Factors influencing the rate and extent of in vitro demineralization. PG - 313-21 FAU - Gupta, M AU - Gupta M FAU - Jethi, R K AU - Jethi RK LA - eng PT - Journal Article PL - United States TA - Indian J Med Res JT - The Indian journal of medical research JID - 0374701 RN - 0 (Citrates) RN - 9007-34-5 (Collagen) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Bone Matrix/metabolism MH - Calcium/*metabolism MH - Calcium Metabolism Disorders/*etiology MH - Citrates/pharmacology MH - Collagen/metabolism MH - Decalcification, Pathologic/*etiology MH - Humans MH - Hydrogen-Ion Concentration MH - In Vitro Techniques MH - Plasma/metabolism MH - Sheep MH - Stimulation, Chemical MH - Tendons/metabolism OID - NASA: 80093485 EDAT- 1979/08/01 00:00 MHDA- 1979/08/01 00:01 CRDT- 1979/08/01 00:00 PHST- 1979/08/01 00:00 [pubmed] PHST- 1979/08/01 00:01 [medline] PHST- 1979/08/01 00:00 [entrez] PST - ppublish SO - Indian J Med Res. 1979 Aug;70:313-21. PMID- 798154 OWN - NLM STAT- MEDLINE DCOM- 19770415 LR - 20131121 IS - 0030-5987 (Print) IS - 0030-5987 (Linking) IP - 6 DP - 1976 Jun TI - [Comparative characteristics of the experimental tissue reaction of the tendon and paratenon to suture material]. PG - 44-6 FAU - Shugarov, N A AU - Shugarov NA FAU - Lapin, V V AU - Lapin VV FAU - Vasin, V A AU - Vasin VA LA - rus PT - Comparative Study PT - English Abstract PT - Journal Article TT - Sravnitel'naia kharakteristika reaktsii tkani sukhozhiliia i paratenova v éksperimente na shovnyĭ material. PL - Ukraine TA - Ortop Travmatol Protez JT - Ortopediia travmatologiia i protezirovanie JID - 0376411 RN - 0 (Azepines) RN - 0 (Polymers) RN - 12597-68-1 (Stainless Steel) RN - 6879X594Z8 (Caprolactam) SB - IM MH - Achilles Tendon/*drug effects MH - Animals MH - Azepines/*pharmacology MH - Caprolactam/*pharmacology MH - Fascia/drug effects MH - *Foreign-Body Reaction MH - Polymers/pharmacology MH - Rats MH - Stainless Steel/pharmacology MH - *Sutures MH - Tendons/drug effects EDAT- 1976/06/01 00:00 MHDA- 1976/06/01 00:01 CRDT- 1976/06/01 00:00 PHST- 1976/06/01 00:00 [pubmed] PHST- 1976/06/01 00:01 [medline] PHST- 1976/06/01 00:00 [entrez] PST - ppublish SO - Ortop Travmatol Protez. 1976 Jun;(6):44-6. PMID- 18285337 OWN - NLM STAT- MEDLINE DCOM- 20080619 LR - 20210206 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 283 IP - 18 DP - 2008 May 2 TI - Active negative control of collagen fibrillogenesis in vivo. Intracellular cleavage of the type I procollagen propeptides in tendon fibroblasts without intracellular fibrils. PG - 12129-35 LID - 10.1074/jbc.M708198200 [doi] AB - It is established fact that type I collagen spontaneously self-assembles in vitro in the absence of cells or other macromolecules. Whether or not this is the situation in vivo was unknown. Recent evidence shows that intracellular cleavage of procollagen (the soluble precursor of collagen) to collagen can occur in embryonic tendon cells in vivo, and when this occurs, intracellular collagen fibrils are observed. A cause-and-effect relationship between intracellular collagen and intracellular fibrils was not established. Here we show that intracellular cleavage of procollagen to collagen occurs in postnatal murine tendon cells in situ. Pulse-chase analyses showed cleavage of procollagen to collagen via its two propeptide-retained intermediates. Furthermore, immunoelectron microscopy, using an antibody that recognizes the triple helical domain of collagen, shows collagen molecules in large-diameter transport compartments close to the plasma membrane. However, neither intracellular fibrils nor fibripositors (collagen fibril-containing plasma membrane protrusions) were observed. The results show that intracellular collagen occurs in murine tendon in the absence of intracellular fibrillogenesis and fibripositor formation. Furthermore, the results show that murine postnatal tendon cells have a high capacity to prevent intracellular collagen fibrillogenesis. FAU - Humphries, Sally M AU - Humphries SM AD - Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Faculty of Life Sciences, Michael Smith Building, Oxford Road, Manchester M13 9PT, United Kingdom. FAU - Lu, Yinhui AU - Lu Y FAU - Canty, Elizabeth G AU - Canty EG FAU - Kadler, Karl E AU - Kadler KE LA - eng GR - Biotechnology and Biological Sciences Research Council/United Kingdom GR - Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080219 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Collagen Type I) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fibrillar Collagens) RN - 0 (Peptides) RN - 0 (Protein Precursors) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9002-93-1 (Octoxynol) RN - 9036-19-5 (Nonidet P-40) RN - EC 3.4.21.4 (Trypsin) SB - IM MH - Animals MH - Animals, Newborn MH - Collagen Type I/*metabolism MH - Extracellular Matrix/drug effects/metabolism MH - Extracellular Matrix Proteins/isolation & purification/metabolism MH - Fibrillar Collagens/*metabolism MH - Fibroblasts/drug effects/*metabolism/ultrastructure MH - Intracellular Space/drug effects/*metabolism MH - Mice MH - Mice, Inbred C57BL MH - Octoxynol MH - Peptides/*metabolism MH - Polyethylene Glycols/pharmacology MH - Protein Precursors/*metabolism MH - Protein Processing, Post-Translational/drug effects MH - Species Specificity MH - Tail/drug effects/ultrastructure MH - Tendons/drug effects/*metabolism/ultrastructure MH - Trypsin/metabolism EDAT- 2008/02/21 09:00 MHDA- 2008/06/20 09:00 CRDT- 2008/02/21 09:00 PHST- 2008/02/21 09:00 [pubmed] PHST- 2008/06/20 09:00 [medline] PHST- 2008/02/21 09:00 [entrez] AID - S0021-9258(20)49315-9 [pii] AID - 10.1074/jbc.M708198200 [doi] PST - ppublish SO - J Biol Chem. 2008 May 2;283(18):12129-35. doi: 10.1074/jbc.M708198200. Epub 2008 Feb 19. PMID- 5098255 OWN - NLM STAT- MEDLINE DCOM- 19711212 LR - 20191022 IS - 0008-0594 (Print) IS - 0008-0594 (Linking) VI - 7 IP - 4 DP - 1971 TI - Studies of the mechanism of biological calcification. II. Evidence for a multi-step mechanism of calcification by tendon matrix. PG - 277-89 FAU - Jethi, R K AU - Jethi RK FAU - Wadkins, C L AU - Wadkins CL LA - eng PT - Journal Article PL - Germany TA - Calcif Tissue Res JT - Calcified tissue research JID - 0114414 RN - 0 (Acetates) RN - 0 (Calcium Isotopes) RN - 0 (Organophosphonates) RN - 0 (Phosphates) RN - 0 (Phosphorus Isotopes) RN - 284SYP0193 (Fluorine) RN - 9007-34-5 (Collagen) RN - I38ZP9992A (Magnesium) RN - SY7Q814VUP (Calcium) SB - IM MH - Acetates/pharmacology MH - Animals MH - Calcification, Physiologic/*drug effects MH - Calcium/metabolism MH - Calcium Isotopes MH - Catalysis MH - Collagen/*metabolism/pharmacology MH - Fluorine/pharmacology MH - Magnesium/pharmacology MH - Methylation MH - Organophosphonates/pharmacology MH - Phosphates/metabolism MH - Phosphorus Isotopes MH - Tendons/*metabolism OID - NASA: 72011795 EDAT- 1971/01/01 00:00 MHDA- 1971/01/01 00:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 1971/01/01 00:01 [medline] PHST- 1971/01/01 00:00 [entrez] AID - 10.1007/BF02062617 [doi] PST - ppublish SO - Calcif Tissue Res. 1971;7(4):277-89. doi: 10.1007/BF02062617. PMID- 41061321 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251211 IS - 2772-9508 (Electronic) IS - 2772-9508 (Linking) VI - 180 DP - 2026 Mar TI - A novel polyurethane nanofiber scaffold with mechanical adaptability and anti-adhesion properties promotes tendon regeneration. PG - 214536 LID - S2772-9508(25)00363-2 [pii] LID - 10.1016/j.bioadv.2025.214536 [doi] AB - The High-quality repair of tendon injuries continues to encounter two significant challenges: promoting tendon regeneration and preventing postoperative adhesion (PA). While traditional surgical methods can partially restore tendon function, issues such as postoperative adhesions and insufficient mechanical properties hinder clinical effectiveness. Recently, electrospun nanofiber membranes (ENMs) have emerged as a promising material for tackling these challenges, owing to their capability to mimic the structure and function of the natural extracellular matrix (ECM). This study presents a novel functionalized polyurethane (PU)-based nanofiber scaffold (NFS) using electrospinning technology, creating a multifunctional therapeutic platform characterized by excellent mechanical properties, bioactivity, and anti-adhesion capabilities. Initially, a new PU material was synthesized, incorporating rigid structures and active reactive sites within its backbone, thereby overcoming the limitations posed by traditional PU's chemical inertness for functional modification. The material's mechanical properties were tailored to match those of natural tendons through optimization of molecular design while preserving reactive sites for additional functionalization. The aligned PU nanofiber membrane fabricated via electrospinning successfully mimicked the topological structure of natural tendon sheaths, exhibiting remarkable degradation properties and biocompatibility. Furthermore, it significantly promoted the expression of tendon-related genes and enhanced the tenogenic differentiation potential of bone marrow-derived mesenchymal stem cells (BM-MSCs). Experimental results from a rat model with infected Achilles tendon defects demonstrated that the optimized PU NFS provided exceptional anti-adhesion effects and facilitated tendon repair. This innovative dynamic repair strategy provides an innovative solution for the clinical repair of tendons and other musculoskeletal tissue injuries. CI - Copyright © 2025 Elsevier B.V. All rights reserved. FAU - Yang, Qingxin AU - Yang Q AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China; Jin Feng Laboratory, Chongqing, 401329, China; School of Chemistry and Chemical Engineering, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Di, Tianxu AU - Di T AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Zhang, Guiping AU - Zhang G AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Luo, Xuanran AU - Luo X AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Zhu, Yuling AU - Zhu Y AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China; School of Chemistry and Chemical Engineering, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Wen, Yu AU - Wen Y AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China. FAU - Yang, Shuang AU - Yang S AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China. Electronic address: 2020003@cqust.edu.cn. FAU - Zhang, Maolan AU - Zhang M AD - Chongqing Engineering Laboratory for Nano-Micro Biomedical Testing Technology, Chongqing University of Science and Technology, Chongqing, 401331, China; Jin Feng Laboratory, Chongqing, 401329, China. Electronic address: 2019016@cqust.edu.cn. LA - eng PT - Journal Article DEP - 20251001 PL - Netherlands TA - Biomater Adv JT - Biomaterials advances JID - 9918383886206676 RN - 0 (Polyurethanes) RN - 0 (Biocompatible Materials) SB - IM MH - *Polyurethanes/chemistry/pharmacology MH - *Nanofibers/chemistry MH - Animals MH - *Tissue Scaffolds/chemistry MH - *Regeneration/drug effects MH - Tissue Adhesions/prevention & control MH - Mesenchymal Stem Cells/cytology MH - *Tendons/physiology/drug effects MH - Rats MH - *Tendon Injuries/therapy MH - Rats, Sprague-Dawley MH - Tissue Engineering MH - Biocompatible Materials/chemistry MH - Cell Differentiation/drug effects MH - Male OTO - NOTNLM OT - Anti-postoperative adhesion OT - PU NFS OT - Promoting tendon healing OT - Reactive PU COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/09 00:30 MHDA- 2025/12/11 07:43 CRDT- 2025/10/08 18:02 PHST- 2025/08/20 00:00 [received] PHST- 2025/09/29 00:00 [revised] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/12/11 07:43 [medline] PHST- 2025/10/09 00:30 [pubmed] PHST- 2025/10/08 18:02 [entrez] AID - S2772-9508(25)00363-2 [pii] AID - 10.1016/j.bioadv.2025.214536 [doi] PST - ppublish SO - Biomater Adv. 2026 Mar;180:214536. doi: 10.1016/j.bioadv.2025.214536. Epub 2025 Oct 1. PMID- 1220686 OWN - NLM STAT- MEDLINE DCOM- 19760520 LR - 20191210 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 152 IP - 2 DP - 1975 Nov TI - Studies on the glycosylation of hydroxylysine residues during collagen biosynthesis and the subcellular localization of collagen galactosyltransferase and collagen glucosyltransferase in tendon and cartilage cells. PG - 291-302 AB - 1. The glycosylation of hydroxylysine during the biosynthesis of procollagen by embryonic chick tendon and cartilage cells was examined. When free and membrane-bound ribosomes isolated from cells labelled for 4min with [(14)C]lysine were assayed for hydroxy[(14)C]lysine and hydroxy[(14)C]lysine glycosides, it was found that hydroxylation took place only on membrane-bound ribosomes and that some synthesis of galactosylhydroxy[(14)C]lysine and glucosylgalactosylhydroxy[(14)C]lysine had occurred on the nascent peptides. 2. Assays of subcellular fractions isolated from tendon and cartilage cells labelled for 2h with [(14)C]lysine demonstrated that the glycosylation of procollagen polypeptides began in the rough endoplasmic reticulum. (14)C-labelled polypeptides present in the smooth endoplasmic reticulum and Golgi fractions were glycosylated to extents almost identical with the respective secreted procollagens. 3. Assays specific for collagen galactosyltransferase and collagen glucosyltransferase are described, using as substrate chemically treated bovine anterior-lens-capsule collagen. 4. When homogenates were assayed for the collagen glycosyltransferase activities, addition of Triton X-100 (0.01%, w/v) was found to stimulate enzyme activities by up to 45%, suggesting that the enzymes were probably membrane-bound. 5. Assays of subcellular fractions obtained by differential centrifugation for collagen galactosyltransferase activity indicated the specific activity to be highest in the microsomal fractions. Similar results were obtained for collagen glucosyltransferase activity. 6. When submicrosomal fractions obtained by discontinuous-sucrose-density-gradient-centrifugation procedures were assayed for these enzymic activities, the collagen galactosyltransferase was found to be distributed in the approximate ratio 7:3 between rough and smooth endoplasmic reticulum of both cell types. Similar determinations of collagen glucosyltransferase indicated a distribution in the approximate ratio 3:2 between rough and smooth microsomal fractions. 7. Assays of subcellular fractions for the plasma-membrane marker 5'-nucleotidase revealed a distribution markedly different from the distributions obtained for the collagen glycosyltransferase. 8. The studies described here demonstrate that glycosylation occurs early in the intracellular processing of procollagen polypeptides rather than at the plasma membrane, as was previously suggested. FAU - Harwood, R AU - Harwood R FAU - Grant, M E AU - Grant ME FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Peptides) RN - 2GQB349IUB (Hydroxylysine) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9007-34-5 (Collagen) RN - EC 2.4.1.- (Galactosyltransferases) RN - EC 2.4.1.- (Glucosyltransferases) RN - EC 2.4.1.66 (UDP glucose-collagen glucosyltransferase) RN - EC 3.1.3.- (Nucleotidases) RN - K3Z4F929H6 (Lysine) SB - IM MH - Animals MH - Cartilage/drug effects/enzymology/*metabolism MH - Cell Membrane/metabolism MH - Chick Embryo MH - Collagen/*biosynthesis MH - Endoplasmic Reticulum/metabolism MH - Galactosyltransferases/*analysis MH - Glucosyltransferases/*analysis MH - Hydroxylysine/*metabolism MH - Lysine/metabolism MH - Nucleotidases/analysis MH - Peptides/analysis MH - Polyethylene Glycols/pharmacology MH - Ribosomes/metabolism MH - Subcellular Fractions/analysis/drug effects/enzymology MH - Tendons/drug effects/enzymology/*metabolism PMC - PMC1172471 EDAT- 1975/11/01 00:00 MHDA- 1975/11/01 00:01 PMCR- 1975/11/01 CRDT- 1975/11/01 00:00 PHST- 1975/11/01 00:00 [pubmed] PHST- 1975/11/01 00:01 [medline] PHST- 1975/11/01 00:00 [entrez] PHST- 1975/11/01 00:00 [pmc-release] AID - 10.1042/bj1520291 [doi] PST - ppublish SO - Biochem J. 1975 Nov;152(2):291-302. doi: 10.1042/bj1520291. PMID- 571106 OWN - NLM STAT- MEDLINE DCOM- 19790626 LR - 20190726 IS - 0031-6768 (Print) IS - 0031-6768 (Linking) VI - 379 IP - 1 DP - 1979 Feb 14 TI - Effects of motor nerve anesthesia and tenotomy on muscle membrane properties. PG - 89-93 AB - Motor nerves to soleus muscles of rats were kept anesthetized for up to 7 days by applying solutions of lidocaine base or marcaine HCl. The anesthetic solutions were delivered from a subcutaneously located ALZA-minipump and reached the nerves through silastic cuffs. The ACh supersensitivity of muscles inactivated by nerve anesthesia for 3--7 days was comparable to that of muscles denervated for the same length of time. gm/gk (the ratio of total membrane conductance to the membrane K conductance) decreased from a normal value of 5--10 to less than two in 6--7 days, in anesthetic-inactivated and denervated muscles. The results were variable after 3 days of anesthesia. gm/gk of muscles which were tenotomized for 3 weeks was unchanged. The voltage-current curve for muscles kept in a solution containing 50 mM K propionate, which is steep at +50 mV, was less steep in denervated and anesthetic-inactivated, but not in tenotomized muscles, although atrophy was marked in all non-normal muscles. FAU - Lorković, H AU - Lorković H LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - Germany TA - Pflugers Arch JT - Pflugers Archiv : European journal of physiology JID - 0154720 RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/pharmacology MH - *Anesthesia MH - Animals MH - Cell Membrane Permeability MH - Electric Conductivity MH - Female MH - Male MH - Motor Neurons/*physiology MH - Muscle Denervation MH - Rats MH - Restraint, Physical MH - Sarcolemma/drug effects/*physiology MH - Tendons/*physiology/surgery OID - NASA: 79157883 EDAT- 1979/02/14 00:00 MHDA- 1979/02/14 00:01 CRDT- 1979/02/14 00:00 PHST- 1979/02/14 00:00 [pubmed] PHST- 1979/02/14 00:01 [medline] PHST- 1979/02/14 00:00 [entrez] AID - 10.1007/BF00622909 [doi] PST - ppublish SO - Pflugers Arch. 1979 Feb 14;379(1):89-93. doi: 10.1007/BF00622909. PMID- 5413560 OWN - NLM STAT- MEDLINE DCOM- 19700322 LR - 20181113 IS - 0021-8782 (Print) IS - 1469-7580 (Electronic) IS - 0021-8782 (Linking) VI - 106 IP - Pt 1 DP - 1970 Jan TI - Anatomical basis for non-nutritive circulation in skeletal muscle exemplified by blood vessels of rat biceps femoris tendon. PG - 125-33 FAU - Grant, R T AU - Grant RT FAU - Wright, H P AU - Wright HP LA - eng PT - Journal Article PL - England TA - J Anat JT - Journal of anatomy JID - 0137162 RN - 820484N8I3 (Histamine) RN - N9YNS0M02X (Acetylcholine) RN - X4W3ENH1CV (Norepinephrine) RN - YKH834O4BH (Epinephrine) SB - IM MH - Acetylcholine/pharmacology MH - Animals MH - Arteriovenous Anastomosis MH - Blood Circulation MH - Blood Vessels/drug effects MH - Body Temperature MH - Capillaries MH - Constriction MH - Dilatation MH - Epinephrine/pharmacology MH - Histamine/pharmacology MH - Muscles/*blood supply MH - Norepinephrine/pharmacology MH - Rats MH - Temperature MH - Tendons/*blood supply PMC - PMC1233857 EDAT- 1970/01/01 00:00 MHDA- 1970/01/01 00:01 PMCR- 1970/01/01 CRDT- 1970/01/01 00:00 PHST- 1970/01/01 00:00 [pubmed] PHST- 1970/01/01 00:01 [medline] PHST- 1970/01/01 00:00 [entrez] PHST- 1970/01/01 00:00 [pmc-release] PST - ppublish SO - J Anat. 1970 Jan;106(Pt 1):125-33. PMID- 6312844 OWN - NLM STAT- MEDLINE DCOM- 19831123 LR - 20151119 IS - 0003-276X (Print) IS - 0003-276X (Linking) VI - 206 IP - 4 DP - 1983 Aug TI - Properties of soleus muscle Z-lines and induced Z-line analogs revealed by dissection with Ca2+-activated neutral protease. PG - 345-62 AB - Rat soleus muscle Z-lines and Z-line anomalies induced by neostigmine methyl sulfate (NMS) and cat soleus muscle Z-lines and Z-line anomalies induced by tenotomy were examined by electron microscopy before and after dissection of muscle fibers with Ca2+-activated neutral protease (CAF) to elucidate structural properties of Z-lines and related Z-line-type structures. In both normal and treated muscles, interdigitation of thin (6-7 nm) filaments, which were continuous with I-filaments (actin) from adjacent sarcomeres, was observed at the Z-line in longitudinal section. Both neostigmine methyl sulfate and tenotomy treatments induced muscle atrophy associated with Z-line degradation, streaming, and irregular distribution and accumulation of Z-line material and Z-rod formation. Tenotomized muscle also was characterized by the presence of N-line-like bands and I-Z-I brushes. CAF digestion removed the electron-dense covering material from Z-rods and revealed a backbone of actin filaments. The origin of Z-rods, their structural similarity to Z-lines in longitudinal and cross section, and their susceptibility to CAF indicate that Z-rods are directly related to native Z-lines and are probably lateral polymers of a basic Z-line unit. The regular square net alignment (22 nm) of I-filaments (actin) in cross sections of I-Z-I brushes which contain no N-lines suggests that the I-square net arrangement near the Z-line is determined by Z-filament-actin filament interaction rather than by the N-line or other factors. The results suggest that I-filaments (actin) penetrate the mammalian Z-line and are Z-line constituents and that the width of Z-lines and the length of Z-rods are determined by the amount of overlap of actin filaments. The perpendicular periodicity of Z-rods and the zigzag-oblique arrowheadlike appearance seen in longitudinal sections of Z-lines are attributed to alpha-actinin. FAU - Yamaguchi, M AU - Yamaguchi M FAU - Robson, R M AU - Robson RM FAU - Stromer, M H AU - Stromer MH FAU - Cholvin, N R AU - Cholvin NR FAU - Izumimoto, M AU - Izumimoto M LA - eng GR - HL-15679/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Anat Rec JT - The Anatomical record JID - 0370540 RN - 0 (Muscle Proteins) RN - 0 (Myosin Subfragments) RN - 3982TWQ96G (Neostigmine) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.22.- (Calpain) SB - IM MH - Animals MH - Calpain MH - Cats MH - *Endopeptidases MH - Hindlimb MH - Muscle Proteins/analysis MH - Muscles/drug effects/*ultrastructure MH - Muscular Atrophy/chemically induced/pathology MH - Myofibrils/analysis/ultrastructure MH - Myosin Subfragments MH - Neostigmine/pharmacology MH - Rats MH - Tendons/surgery EDAT- 1983/08/01 00:00 MHDA- 1983/08/01 00:01 CRDT- 1983/08/01 00:00 PHST- 1983/08/01 00:00 [pubmed] PHST- 1983/08/01 00:01 [medline] PHST- 1983/08/01 00:00 [entrez] AID - 10.1002/ar.1092060402 [doi] PST - ppublish SO - Anat Rec. 1983 Aug;206(4):345-62. doi: 10.1002/ar.1092060402. PMID- 4408087 OWN - NLM STAT- MEDLINE DCOM- 19741107 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 24 IP - 7 DP - 1974 Jul TI - [Pharmacokinetic and metabolism of D- and L-penicillamine. 2. Distribution of D- and L-penicillamine-14C in the rat organism after oral administration]. PG - 1043-6 FAU - Ruiz-Torres, A AU - Ruiz-Torres A LA - ger PT - English Abstract PT - Journal Article TT - Zur Pharmakokinetik und zum Stoffwechsel von D- und L-Penicillamin. 2. Verteilung von D- und L-Penicillamin-14C im Organismus der Ratte nach peroraler Verabfolgung. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Carbon Radioisotopes) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Administration, Oral MH - Animals MH - Binding Sites MH - Carbon Radioisotopes MH - Collagen/metabolism MH - Isomerism MH - Kidney/metabolism MH - Liver/metabolism MH - Male MH - Pancreas/metabolism MH - Penicillamine/*metabolism/pharmacology MH - Radionuclide Imaging MH - Rats MH - Skin/metabolism MH - Tendons/metabolism MH - Testis/metabolism EDAT- 1974/07/01 00:00 MHDA- 1974/07/01 00:01 CRDT- 1974/07/01 00:00 PHST- 1974/07/01 00:00 [pubmed] PHST- 1974/07/01 00:01 [medline] PHST- 1974/07/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1974 Jul;24(7):1043-6. PMID- 4706524 OWN - NLM STAT- MEDLINE DCOM- 19730723 LR - 20190908 IS - 0531-5565 (Print) IS - 0531-5565 (Linking) VI - 8 IP - 1 DP - 1973 Feb TI - Modelling of cross linking interactions in the terminal region of the collagen molecule. PG - 39-43 FAU - Rosmus, J AU - Rosmus J FAU - Vancíková, O AU - Vancíková O FAU - Deyl, Z AU - Deyl Z LA - eng PT - Journal Article PL - England TA - Exp Gerontol JT - Experimental gerontology JID - 0047061 RN - 0 (Amino Acids) RN - 0 (Coloring Agents) RN - 0 (Nitrophenols) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Pronase) RN - K3Z4F929H6 (Lysine) SB - IM MH - Amino Acids/analysis MH - Animals MH - Binding Sites MH - Cattle MH - Chemical Phenomena MH - Chemistry MH - Chromatography, Paper MH - Chromatography, Thin Layer MH - Collagen/*metabolism MH - Coloring Agents MH - Dialysis MH - Hydrogen-Ion Concentration MH - Lysine/metabolism MH - Molecular Weight MH - Nitrophenols/pharmacology MH - Peptide Biosynthesis MH - Pronase/metabolism MH - Rats MH - *Structure-Activity Relationship MH - Temperature MH - Tendons/metabolism EDAT- 1973/02/01 00:00 MHDA- 1973/02/01 00:01 CRDT- 1973/02/01 00:00 PHST- 1973/02/01 00:00 [pubmed] PHST- 1973/02/01 00:01 [medline] PHST- 1973/02/01 00:00 [entrez] AID - 10.1016/0531-5565(73)90049-1 [doi] PST - ppublish SO - Exp Gerontol. 1973 Feb;8(1):39-43. doi: 10.1016/0531-5565(73)90049-1. PMID- 4357901 OWN - NLM STAT- MEDLINE DCOM- 19740213 LR - 20191030 IS - 0016-898X (Print) IS - 0016-898X (Linking) VI - 19 IP - 3 DP - 1973 TI - Influences on the structural stability of collagen in relation to ageing. PG - 129-37 FAU - Verzár, F AU - Verzár F FAU - Ackerschott-Strittmatter AU - Ackerschott-Strittmatter FAU - Moser, P AU - Moser P LA - eng PT - Journal Article PL - Switzerland TA - Gerontologia JT - Gerontologia JID - 7601654 RN - 0 (Perchlorates) RN - 1HG84L3525 (Formaldehyde) RN - 451W47IQ8X (Sodium Chloride) RN - 9007-34-5 (Collagen) RN - AE28F7PNPL (Methionine) RN - GNN1DV99GX (Penicillamine) RN - K848JZ4886 (Cysteine) SB - IM MH - *Aging MH - Animals MH - Biomechanical Phenomena MH - *Collagen MH - Connective Tissue/drug effects/*physiology MH - Cysteine/pharmacology MH - Drug Interactions MH - Formaldehyde/pharmacology MH - Methionine/pharmacology MH - Muscle Contraction/drug effects MH - Penicillamine/pharmacology MH - Perchlorates/pharmacology MH - Rats MH - Sodium Chloride/antagonists & inhibitors/pharmacology MH - Tail MH - Tendons/*physiology EDAT- 1973/01/01 00:00 MHDA- 1973/01/01 00:01 CRDT- 1973/01/01 00:00 PHST- 1973/01/01 00:00 [pubmed] PHST- 1973/01/01 00:01 [medline] PHST- 1973/01/01 00:00 [entrez] AID - 10.1159/000211966 [doi] PST - ppublish SO - Gerontologia. 1973;19(3):129-37. doi: 10.1159/000211966. PMID- 12382958 OWN - NLM STAT- MEDLINE DCOM- 20021203 LR - 20220330 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 20 IP - 5 DP - 2002 Sep TI - Activation of stress-activated protein kinases (SAPK) in tendon cells following cyclic strain: the effects of strain frequency, strain magnitude, and cytosolic calcium. PG - 947-52 AB - Cyclic strain has been shown to benefit tendon health. However, repetitive loading has also been implicated in the etiology of tendon overuse injuries. Recent studies demonstrated that in several cell lines cyclic strain was associated with an activation of stress-activated protein kinases (SAPKs). These SAPKs, in turn, were shown to be important upstream regulators of a variety of cell processes including apoptosis. To examine the effect of repetitive loading on SAPK activation in tendon cells in vitro, canine patellar tendon cells were cyclically strained, and the cellular stress response evaluated by measuring c-Jun N-terminal kinase (JNK) activation. The effects of strain frequency and strain magnitude as well as the role of calcium signaling in this mechanotransduction mechanism were also examined. Cyclic strain resulted in an immediate activation of JNK, which peaked at 30 min and returned to resting levels by 2 h. This activation was regulated by a magnitude-dependent but not frequency-dependent response and appeared to be mediated through a calcium-dependent mechanotransduction pathway. While transient JNK activation is associated with normal cell processes. persistent JNK activation has been linked to the initiation of the apoptotic cascade. A similar mechanism could be responsible for initiating the pathological events (localized cell death) seen in tendon overuse injury. FAU - Arnoczky, Steven P AU - Arnoczky SP AD - Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing 48824, USA. arnoczky@cvm.msu.edu FAU - Tian, Tao AU - Tian T FAU - Lavagnino, Michael AU - Lavagnino M FAU - Gardner, Keri AU - Gardner K FAU - Schuler, Paul AU - Schuler P FAU - Morse, Patrick AU - Morse P LA - eng PT - Journal Article PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 139890-68-9 (1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester) RN - 37H9VM9WZL (Calcimycin) RN - 526U7A2651 (Egtazic Acid) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 8) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) SB - IM MH - Animals MH - Blotting, Western MH - Calcimycin/pharmacology MH - *Calcium Signaling MH - Cell Survival/drug effects MH - Cells, Cultured MH - Cytosol/metabolism MH - Dogs MH - Egtazic Acid/*analogs & derivatives/pharmacology MH - Fibroblasts/drug effects/*enzymology/physiology MH - Metabolism/drug effects MH - Mitogen-Activated Protein Kinase 8 MH - Mitogen-Activated Protein Kinases/*biosynthesis MH - Patella MH - Stress, Mechanical MH - Tendons/drug effects/*enzymology/physiology MH - Weight-Bearing MH - p38 Mitogen-Activated Protein Kinases EDAT- 2002/10/18 04:00 MHDA- 2002/12/04 04:00 CRDT- 2002/10/18 04:00 PHST- 2002/10/18 04:00 [pubmed] PHST- 2002/12/04 04:00 [medline] PHST- 2002/10/18 04:00 [entrez] AID - 10.1016/S0736-0266(02)00038-4 [doi] PST - ppublish SO - J Orthop Res. 2002 Sep;20(5):947-52. doi: 10.1016/S0736-0266(02)00038-4. PMID- 20513575 OWN - NLM STAT- MEDLINE DCOM- 20100921 LR - 20141120 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 35 IP - 6 DP - 2010 Jun TI - Effects of nonsteroidal anti-inflammatory drugs on flexor tendon adhesion. PG - 941-7 LID - 10.1016/j.jhsa.2010.02.033 [doi] AB - PURPOSE: Besides its anti-inflammatory effects, nonsteroidal anti-inflammatory drug therapy may affect tendon healing and the development of peritendinous adhesions. The purpose of this study was to compare the effect of nonselective (ibuprofen) and COX-2 selective (rofecoxib) nonsteroidal anti-inflammatory drugs on the adhesion formation after tendon repair. METHODS: We assigned 67 rabbits to one of 3 (placebo, ibuprofen, or rofecoxib) groups. The deep flexor tendon was transected, followed by a primary repair. Dosing of the medication began the day after surgery and continued for 27 days. The animals were immobilized in a cast for the first 14 days. Postoperatively, tendon adhesion formation was assessed histologically by calculating the total adhesion in serial axial tendon sections at 3 and 6 weeks and by range of motion measurements at 6 and 12 weeks. We measured range of motion by fixing the metacarpal, applying increasing weight to the free end of the flexor digitorum profundus, and measuring the flexion angle between the metacarpal and the proximal phalanx. Comparison was performed between the treatment groups, as well as to the unoperated forepaws. RESULTS: Based on histology, we found no difference between the treatment groups when determining the percentage of adhesion between the flexor tendon and its sheath. Control unoperated forepaws had a significantly greater range of metacarpophalangeal joint flexion than the surgically repaired groups. At 12 weeks, range of motion in the ibuprofen group was significantly better than the placebo (p=.009) and rofecoxib (p=.009) groups. CONCLUSIONS: Ibuprofen has a more important effect in limiting adhesion formation compared with rofecoxib after flexor tendon repair. Because ibuprofen inhibits both COX-1 and COX-2, whereas rofecoxib only inhibits COX-2, ibuprofen therapy appears to offer a greater beneficial effect on tendon repair by reducing formation of adhesions. CI - Copyright 2010. Published by Elsevier Inc. FAU - Tan, Virak AU - Tan V AD - Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School and Graduate School of Biomedical Sciences, Newark, NJ, USA. tanvi@umdnj.edu FAU - Nourbakhsh, Ali AU - Nourbakhsh A FAU - Capo, John AU - Capo J FAU - Cottrell, Jessica A AU - Cottrell JA FAU - Meyenhofer, Marcus AU - Meyenhofer M FAU - O'Connor, J Patrick AU - O'Connor JP LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Lactones) RN - 0 (Sulfones) RN - 0QTW8Z7MCR (rofecoxib) RN - WK2XYI10QM (Ibuprofen) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Cyclooxygenase 2 Inhibitors/*pharmacology MH - Forelimb MH - Ibuprofen/*pharmacology MH - Lactones/*pharmacology MH - Male MH - Rabbits MH - Sulfones/*pharmacology MH - Tendons/*surgery MH - Tissue Adhesions/prevention & control MH - Wound Healing/*drug effects EDAT- 2010/06/02 06:00 MHDA- 2010/09/23 06:00 CRDT- 2010/06/02 06:00 PHST- 2009/09/16 00:00 [received] PHST- 2010/02/23 00:00 [revised] PHST- 2010/02/26 00:00 [accepted] PHST- 2010/06/02 06:00 [entrez] PHST- 2010/06/02 06:00 [pubmed] PHST- 2010/09/23 06:00 [medline] AID - S0363-5023(10)00261-3 [pii] AID - 10.1016/j.jhsa.2010.02.033 [doi] PST - ppublish SO - J Hand Surg Am. 2010 Jun;35(6):941-7. doi: 10.1016/j.jhsa.2010.02.033. PMID- 26838844 OWN - NLM STAT- MEDLINE DCOM- 20161021 LR - 20220321 IS - 1873-0191 (Electronic) IS - 0928-4931 (Linking) VI - 61 DP - 2016 Apr 1 TI - Release of celecoxib from a bi-layer biomimetic tendon sheath to prevent tissue adhesion. PG - 220-6 LID - S0928-4931(15)30639-1 [pii] LID - 10.1016/j.msec.2015.12.028 [doi] AB - Posttraumatic tendon adhesion limits the motion of the limbs greatly. Biomimetic tendon sheaths have been developed to promote tendon healing and gliding. However, after introduction of these biomaterials, the associated inflammatory responses can decrease the anti-adhesion effect. Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that can decrease inflammation responses. We blended hyaluronic acid and poly(l-lactic acid)-polyethylene glycol (PELA) with microgel electrospinning technology to form an inner layer of a bi-layer biomimetic sheath using sequential electrospinning of an outer celecoxib-PELA layer. Electrospun bi-layer fibrous membranes were mechanically tested and characterized by morphology, surface wettability, and drug release. The tensile strength showed a decreased trend and water contact angles were 114.7 ± 3.9°, 103.6 ± 4.4°, 116.3 ± 5.1°, 122.8 ± 4.7°, and 126.5 ± 4.2° for the surface of PELA, hyaluronic acid-PELA, 2, 6, and 10% celecoxib-PELA electrospun fibrous membranes, respectively. In vitro drug release studies confirmed burst release and then sustained release from the fibrous membranes containing celecoxib for 20 days. In a chicken model of flexor digitorum profundus tendon surgery, the outer celecoxib/PELA layer offered advanced anti-adhesion roles compared to the outer PELA layer and the inner hyaluronic acid-loaded PELA layer still offered tendon healing and gliding. Thus, celecoxib-loaded anti-adhesive tendon sheaths can continuously offer bi-layer biomimetic tendon sheath effects with celecoxib release from the outer layer to prevent tendon adhesion. CI - Copyright © 2015 Elsevier B.V. All rights reserved. FAU - Li, Laifeng AU - Li L AD - Department of Orthopaedics, The Third Hospital of Jinan, No. 1 Industrial Road, Wangsheren North Street, Jinan City, Shandong 250132, PR China. FAU - Zheng, Xianyou AU - Zheng X AD - Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China. FAU - Fan, Dapeng AU - Fan D AD - Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China. FAU - Yu, Shiyang AU - Yu S AD - Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China. FAU - Wu, Di AU - Wu D AD - Department of Anesthesia, Shanghai Fire Corps Hospital, 26 Sanquan Road, Shanghai 200233, PR China. FAU - Fan, Cunyi AU - Fan C AD - Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China. FAU - Cui, Wenguo AU - Cui W AD - Orthopedic Institute, Soochow University, 708 Renmin Road, Suzhou, Jiangsu 215006, PR China. Electronic address: wgcui80@hotmail.com. FAU - Ruan, Hongjiang AU - Ruan H AD - Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai 200233, PR China. Electronic address: ruanhongjiang@yeah.net. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151217 PL - Netherlands TA - Mater Sci Eng C Mater Biol Appl JT - Materials science & engineering. C, Materials for biological applications JID - 101484109 RN - 0 (Lactates) RN - 113717-54-7 (polyethylene oxide-polylactic acid block copolymer) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Animals MH - *Biomimetic Materials/chemistry/pharmacology MH - *Celecoxib/chemistry/pharmacology MH - Chickens MH - *Lactates/chemistry/pharmacology MH - *Polyethylene Glycols/chemistry/pharmacology MH - Tendons/*pathology MH - Tissue Adhesions/pathology/*prevention & control OTO - NOTNLM OT - Adhesion prevention OT - Biomimetic tendon sheath OT - Celecoxib releasing OT - Electrospun fibrous membrane OT - Tendon sheath EDAT- 2016/02/04 06:00 MHDA- 2016/10/22 06:00 CRDT- 2016/02/04 06:00 PHST- 2015/02/27 00:00 [received] PHST- 2015/12/09 00:00 [revised] PHST- 2015/12/14 00:00 [accepted] PHST- 2016/02/04 06:00 [entrez] PHST- 2016/02/04 06:00 [pubmed] PHST- 2016/10/22 06:00 [medline] AID - S0928-4931(15)30639-1 [pii] AID - 10.1016/j.msec.2015.12.028 [doi] PST - ppublish SO - Mater Sci Eng C Mater Biol Appl. 2016 Apr 1;61:220-6. doi: 10.1016/j.msec.2015.12.028. Epub 2015 Dec 17. PMID- 25625433 OWN - NLM STAT- MEDLINE DCOM- 20160126 LR - 20180531 IS - 1937-335X (Electronic) IS - 1937-3341 (Linking) VI - 21 IP - 9-10 DP - 2015 May TI - Optimization of an injectable tendon hydrogel: the effects of platelet-rich plasma and adipose-derived stem cells on tendon healing in vivo. PG - 1579-86 LID - 10.1089/ten.TEA.2014.0490 [doi] AB - INTRODUCTION: Acute and chronic tendon injuries would benefit from stronger and more expeditious healing. We hypothesize that supplementation of a biocompatible tendon hydrogel with platelet-rich plasma (PRP) and adipose-derived stem cells (ASCs) would augment the tendon healing process. MATERIALS AND METHODS: Using 55 Wistar rats, a full-thickness defect was created within the midsubstance of each Achilles tendon with the addition of one of five experimental conditions: (i) saline control (50-μL), (ii) tendon hydrogel (50-μL), (iii) tendon hydrogel (45-μL)+PRP (5-μL), (iv) tendon hydrogel (45-μL)+2×10(6)-ASCs/mL in phosphate buffered saline (5-μL), and (v) tendon hydrogel (45-μL)+2×10(6)-ASCs/mL in PRP (5-μL). Hydrogel was developed from decellularized, human cadaveric tendons. Fresh rat PRP was obtained per Amable et al.'s technique, and green fluorescent protein/luciferase-positive rat ASCs were utilized. Rats were sacrificed at weeks 1, 2, 4, and 8 after injury. Real-time in vivo bioluminescence imaging of groups with ASCs was performed. Upon sacrifice, Achilles tendons underwent biomechanical and histological evaluation. Comparisons across groups were analyzed using the two-sample Z-test for proportions and the Student's t-test for independent samples. Significance was set at p<0.05. RESULTS: (i) Bioluminescence imaging demonstrated that total photon flux was significantly increased for hydrogel+PRP+ASCs, versus hydrogel+ASCs for each postoperative day imaged (p<0.03). (ii) Mean ultimate failure load (UFL) was increased for hydrogel augmented with PRP and/or ASCs versus hydrogel alone at week 2 (p<0.03). By week 4, hydrogel alone reached a similar mean UFL to hydrogel augmented with PRP and/or ASCs (p>0.3). However, at week 8, hydrogel with PRP and ASCs demonstrated increased strength over other groups (p<0.05), except for hydrogel with PRP (p=0.25). (iii) Upon histological analysis, Hematoxylin and Eosin staining showed increased extracellular matrix formation in groups containing PRP and increased cellularity in groups containing ASCs. Groups containing both PRP and ASCs demonstrated both of these characteristics. CONCLUSION: PRP and ASCs are easily accessible bioactive products that have potentiating effects on tendon hydrogel. Augmentation with these two factors encourages earlier mechanical strength and functional restoration. Thus, biochemically, tendon hydrogel augmented with PRP and/or ASCs, serves as a promising therapeutic modality for augmenting the tendon healing process after injury. FAU - Chiou, Grace Jane AU - Chiou GJ AD - 1 Division of Plastic and Reconstructive Surgery, Stanford University Medical Center , Stanford, California. FAU - Crowe, Christopher AU - Crowe C FAU - McGoldrick, Rory AU - McGoldrick R FAU - Hui, Kenneth AU - Hui K FAU - Pham, Hung AU - Pham H FAU - Chang, James AU - Chang J LA - eng GR - I01 RX001458/RX/RRD VA/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) SB - IM MH - Adipose Tissue/*cytology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Elastic Modulus/drug effects MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Imaging, Three-Dimensional MH - Injections MH - Luminescent Measurements MH - Platelet-Rich Plasma/*metabolism MH - Rats, Wistar MH - Staining and Labeling MH - *Stem Cell Transplantation MH - Stem Cells/*cytology/drug effects/metabolism MH - Tendon Injuries/pathology/physiopathology/therapy MH - Tendons/drug effects/*pathology/physiopathology MH - Weight-Bearing MH - Wound Healing/*drug effects EDAT- 2015/01/28 06:00 MHDA- 2016/01/27 06:00 CRDT- 2015/01/28 06:00 PHST- 2015/01/28 06:00 [entrez] PHST- 2015/01/28 06:00 [pubmed] PHST- 2016/01/27 06:00 [medline] AID - 10.1089/ten.TEA.2014.0490 [doi] PST - ppublish SO - Tissue Eng Part A. 2015 May;21(9-10):1579-86. doi: 10.1089/ten.TEA.2014.0490. PMID- 23021188 OWN - NLM STAT- MEDLINE DCOM- 20130415 LR - 20181202 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 37 IP - 10 DP - 2012 Oct TI - The effect of suture coated with mesenchymal stem cells and bioactive substrate on tendon repair strength in a rat model: a complementary mechanism. PG - 2203; author reply 2203-4 LID - S0363-5023(12)01193-8 [pii] LID - 10.1016/j.jhsa.2012.08.021 [doi] FAU - Namazi, Hamid AU - Namazi H LA - eng PT - Comment PT - Letter PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 25104-18-1 (Polylysine) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CON - J Hand Surg Am. 2012 Aug;37(8):1639-45. doi: 10.1016/j.jhsa.2012.04.038. PMID: 22727924 MH - Animals MH - Intercellular Adhesion Molecule-1/*pharmacology MH - Male MH - *Mesenchymal Stem Cells MH - Polyethylene Glycols/*pharmacology MH - Polylysine/*analogs & derivatives MH - *Sutures MH - Tendons/*surgery MH - Wound Healing/*physiology EDAT- 2012/10/02 06:00 MHDA- 2013/04/16 06:00 CRDT- 2012/10/02 06:00 PHST- 2012/08/02 00:00 [received] PHST- 2012/08/06 00:00 [accepted] PHST- 2012/10/02 06:00 [entrez] PHST- 2012/10/02 06:00 [pubmed] PHST- 2013/04/16 06:00 [medline] AID - S0363-5023(12)01193-8 [pii] AID - 10.1016/j.jhsa.2012.08.021 [doi] PST - ppublish SO - J Hand Surg Am. 2012 Oct;37(10):2203; author reply 2203-4. doi: 10.1016/j.jhsa.2012.08.021. PMID- 17323097 OWN - NLM STAT- MEDLINE DCOM- 20071018 LR - 20220716 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 15 IP - 7 DP - 2007 Jul TI - Colour doppler ultrasonography and sclerosing therapy in diagnosis and treatment of tendinopathy in horses-a research model for human medicine. PG - 935-9 AB - Sclerosing therapy has in recent studies showed promising results in patients with clinically and ultrasonographically diagnosed tendinosis in Achilles and patellar tendons. The aim of this investigation was to study the presence of intratendinous colour Doppler (CD) flow in horses with clinically diagnosed chronic tendinopathy and to test if experience from human studies could be extrapolated to horses. Special interest was focused on the treatment with sclerosing therapy and whether we could obtain the same successful peroperative findings as in humans. Four horses with clinically diagnosed unilateral chronic tendinosis in the forelimbs were examinated with both grey-scale ultrasonography (US) and CD. The horses were to be euthanised according to standard procedure is such cases. The US findings were used for guidance of sclerosing therapy. All horses showed abnormal findings on US, especially intratendinous neovascularisation in the affected limb but not in the contralateral limb. The CD findings had the same appearance as seen in human Achilles tendons with chronic tendinopathy. In all cases the intratendinous neovascularisation was successfully "shut down" peroperatively. The horses showed no signs of discomfort or worsening of symptoms during the short follow-up period after the procedure. The results indicate that the promising results from human medicine might be transferred to treatment of horses with chronic tendinopathy. In the future it will hopefully be possible to use the model from overused tendons in the horse to determine the best treatment of overuse injuries in humans as well. The animal model will allow experimental studies including substantial tissue sampling for mechanical and molecular biological analysis. FAU - Boesen, Morten Ilum AU - Boesen MI AD - Parker Institute, Frederiksberg Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark. parkerinst@fh.hosp.dk FAU - Nanni, Simone AU - Nanni S FAU - Langberg, Henning AU - Langberg H FAU - Boesen, Mikael AU - Boesen M FAU - Falk-Ronne, Jorgen AU - Falk-Ronne J FAU - Bliddal, Henning AU - Bliddal H FAU - Torp-Pedersen, Soren AU - Torp-Pedersen S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070224 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Animals MH - Disease Models, Animal MH - Horse Diseases/*diagnosis/*therapy MH - Horses MH - Humans MH - Polidocanol MH - Polyethylene Glycols/pharmacology MH - Sclerosing Solutions/pharmacology MH - Tendinopathy/*diagnosis/*therapy MH - Tendons/diagnostic imaging MH - Ultrasonography, Doppler, Color EDAT- 2007/02/27 09:00 MHDA- 2007/10/19 09:00 CRDT- 2007/02/27 09:00 PHST- 2006/10/31 00:00 [received] PHST- 2006/11/09 00:00 [accepted] PHST- 2007/02/27 09:00 [pubmed] PHST- 2007/10/19 09:00 [medline] PHST- 2007/02/27 09:00 [entrez] AID - 10.1007/s00167-006-0245-0 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2007 Jul;15(7):935-9. doi: 10.1007/s00167-006-0245-0. Epub 2007 Feb 24. PMID- 29526154 OWN - NLM STAT- MEDLINE DCOM- 20180807 LR - 20181202 IS - 1309-0313 (Electronic) VI - 29 IP - 1 DP - 2018 Apr TI - Effects of low molecular weight heparin and rivaroxaban on rat Achilles tendon healing. PG - 13-9 LID - ehc.2018.54577 [pii] LID - 10.5606/ehc.2018.54577 [doi] AB - OBJECTIVES: This study aims to compare the histopathological and biomechanical effects of low molecular weight heparin (LMWH) and rivaroxaban, which are frequently used in orthopedic surgery for thromboembolic prophylaxis, on rat Achilles tendon healing. MATERIALS AND METHODS: In the study, 36 adult, male Sprague Dawley rats weighing between 300 g and 400 g were used. Three groups were formed including 12 rats in each. Achilles tendons of all rats were cut and repaired. Nadroparin calcium was administered subcutaneously for 21 days at a dose of 170 IU AXa to the first group (LMWH group). Rivaroxaban was administered daily at a dose of 3 mg/kg for 21 days as gastric lavage to the second group (rivaroxaban group). The third group was identified as the control group and no medication was administered in this group. At the end of three weeks, tendons extracted from the groups were examined histopathologically and biomechanically. RESULTS: Bonar's and Movin's scores obtained as a result of histopathological examination were statistically significantly higher in the control group (p=0.003 and p=0.004, respectively) (high scores indicate that tendon healing is not sufficient). When type I and type III collagen ratios were examined, type I collagen ratio, which should be found at a higher ratio in mature tendon, was statistically significantly higher in rivaroxaban and LMWH groups compared with the control group (p=0.002). As a result of biomechanical examination, higher mean maximum force values were obtained from the rivaroxaban group compared with the LMWH group (p=0.31). Mean maximum force values obtained from the control group were higher than those obtained from the LMWH group (p=0.03) and the rivaroxaban group (p=0.18). CONCLUSION: Histopathological examination revealed that both LMWH and rivaroxaban have positive effects on tendon healing. However, the same positive effects were not detected in biomechanical examination. FAU - Eren, Yılmaz AU - Eren Y AD - Department of Orthopedics and Traumatology, Bağcılar Training and Research Hospital, 34100 Bağcılar, İstanbul, Turkey. FAU - Adanır, Oktay AU - Adanır O FAU - Dinçel, Yaşar Mahsut AU - Dinçel YM FAU - Genç, Erdinç AU - Genç E FAU - Arslan, Yunus Ziya AU - Arslan YZ FAU - Çağlar, Aysel AU - Çağlar A LA - eng PT - Journal Article PL - Turkey TA - Eklem Hastalik Cerrahisi JT - Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery JID - 101265191 RN - 0 (Anticoagulants) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Factor Xa Inhibitors) RN - 0 (Heparin, Low-Molecular-Weight) RN - 9NDF7JZ4M3 (Rivaroxaban) SB - IM MH - Achilles Tendon/metabolism/*physiopathology/surgery MH - Animals MH - Anticoagulants/*pharmacology MH - Biomechanical Phenomena/drug effects MH - Collagen Type I/metabolism MH - Collagen Type III/metabolism MH - Factor Xa Inhibitors/*pharmacology MH - Heparin, Low-Molecular-Weight/*pharmacology MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Rivaroxaban/*pharmacology MH - Tendon Injuries/surgery MH - Wound Healing/*drug effects EDAT- 2018/03/13 06:00 MHDA- 2018/08/08 06:00 CRDT- 2018/03/13 06:00 PHST- 2018/03/13 06:00 [entrez] PHST- 2018/03/13 06:00 [pubmed] PHST- 2018/08/08 06:00 [medline] AID - ehc.2018.54577 [pii] AID - 10.5606/ehc.2018.54577 [doi] PST - ppublish SO - Eklem Hastalik Cerrahisi. 2018 Apr;29(1):13-9. doi: 10.5606/ehc.2018.54577. PMID- 26085530 OWN - NLM STAT- MEDLINE DCOM- 20150827 LR - 20181113 IS - 1535-1386 (Electronic) IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 97 IP - 12 DP - 2015 Jun 17 TI - Surface Modification with Chemically Modified Synovial Fluid for Flexor Tendon Reconstruction in a Canine Model in Vivo. PG - 972-8 LID - 10.2106/JBJS.N.01100 [doi] AB - BACKGROUND: Functional restoration is the major concern after flexor tendon reconstruction in the hand. The purpose of the present study was to investigate the effects of modifying the surface of extrasynovial tendon autografts with carbodiimide-derivatized synovial fluid with gelatin (cd-SF-G) on functional outcomes of flexor tendon reconstruction using a canine model. METHODS: The second and fifth flexor digitorum profundus tendons from eleven dogs were transected and repaired in zone II. The dogs then had six weeks of free activity leading to tendon rupture and scar formation (the repair-failure phase). In the reconstruction phase, two autologous peroneus longus tendons from each dog were harvested; one tendon was coated with cd-SF-G and the other, with saline solution, as a control. A non-weight-bearing rehabilitation protocol was followed for six weeks after reconstruction. The digits were then harvested and evaluations of function, adhesion status, gliding resistance, attachment strength, cell viability, and histology were performed. RESULTS: The tendons coated with cd-SF-G demonstrated significantly lower values (mean and standard deviation) compared with the saline-solution group for work of flexion (0.63 ± 0.24 versus 1.34 ± 0.42 N-mm/deg), adhesion score (3.5 ± 1.6 versus 6.1 ± 1.3), proximal adhesion breaking force (8.6 ± 3.2 versus 20.2 ± 10.2 N), and gliding resistance (0.26 ± 0.08 versus 0.46 ± 0.22 N) (p < 0.05). There was no significant difference between the cd-SF-G and saline-solution groups (p > 0.05) in distal attachment-site strength (56.9 ± 28.4 versus 77.2 ± 36.2 N), stiffness (19 ± 7.5 versus 24.5 ± 14.5 N/mm), and compressive modulus from indentation testing (4.37 ± 1.26 versus 3.98 ± 1.24 N/mm). Histological analysis showed that tendons coated with cd-SF-G had smoother surfaces and demonstrated tendon-to-bone and tendon-to-tendon incorporation. No significant difference in viable cell count between the two groups was observed on tendon culture. CONCLUSIONS: Modification of the flexor tendon surface with cd-SF-G significantly improved digital function and reduced adhesion formation without affecting graft healing and stiffness. CLINICAL RELEVANCE: This study used native synovial fluid as a basic lubricating reagent to treat a tendon graft in vivo, a novel avenue for improving clinical outcomes of flexor tendon reconstruction. This methodology may also apply to other surgical procedures where postoperative adhesions impair function. CI - Copyright © 2015 by The Journal of Bone and Joint Surgery, Incorporated. FAU - Ji, Xiaoxi AU - Ji X AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Reisdorf, Ramona L AU - Reisdorf RL AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Thoreson, Andrew R AU - Thoreson AR AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Berglund, Lawrence R AU - Berglund LR AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Moran, Steven L AU - Moran SL AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Jay, Gregory D AU - Jay GD AD - Department of Emergency Medicine, Brown University, 593 Eddy Street, Claverick 100, Providence, RI 02903. FAU - An, Kai-Nan AU - An KN AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Amadio, Peter C AU - Amadio PC AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. FAU - Zhao, Chunfeng AU - Zhao C AD - Departments of Orthopedic Surgery (X.J., R.L.R., A.R.T., L.R.B., K-N.A., P.C.A., and C.Z.) and Plastic Surgery (S.L.M.), Mayo Clinic, 200 First Street S.W., Rochester, MN 55905. E-mail address for C. Zhao: zhao.chunfeng@mayo.edu. LA - eng GR - AR057745/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Carbodiimides) RN - 9000-70-8 (Gelatin) SB - IM MH - Animals MH - Carbodiimides/pharmacology MH - Dogs MH - Gelatin MH - Models, Animal MH - Orthopedic Procedures/methods MH - Surface Properties MH - *Synovial Fluid/drug effects MH - Tendons/*surgery/transplantation MH - Tissue Adhesions/prevention & control PMC - PMC4469787 EDAT- 2015/06/19 06:00 MHDA- 2015/08/28 06:00 PMCR- 2016/06/17 CRDT- 2015/06/19 06:00 PHST- 2015/06/19 06:00 [entrez] PHST- 2015/06/19 06:00 [pubmed] PHST- 2015/08/28 06:00 [medline] PHST- 2016/06/17 00:00 [pmc-release] AID - 97/12/972 [pii] AID - jbjsam.n01100 [pii] AID - 10.2106/JBJS.N.01100 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2015 Jun 17;97(12):972-8. doi: 10.2106/JBJS.N.01100. PMID- 16859807 OWN - NLM STAT- MEDLINE DCOM- 20070309 LR - 20231213 IS - 0171-9335 (Print) IS - 0171-9335 (Linking) VI - 85 IP - 11 DP - 2006 Nov TI - Connexin 32 and 43 gap junctions differentially modulate tenocyte response to cyclic mechanical load. PG - 1145-54 AB - Gap junctions allow rapid exchange of ions and small metabolites between cells. They can occur between connective tissue cells, and in tendons there are two prominent types, composed of connexin 32 or 43. These form distinct networks - tenocyte rows are linked by both longitudinally, but only by connexin 43 laterally. We hypothesised that the junctions had different roles in cell response to mechanical loading, and measured the effects of inhibitors of gap junction function on secretion of collagen by tenocyte cultures exposed to mechanical strain. Chicken tendon fibroblasts were exposed to cyclic tensile loading in the presence or absence of general gap junction inhibitors (halothane or the biomimetic peptide gap27), or antisense oligonucleotides to chicken connexin 32 or 43. Untreated cultures increased collagen secretion by around 25% under load. Halothane eliminated this response but caused cell damage. Gap27 peptide reduced secretion but maintained loading effects - strained cultures secreting more collagen than unstrained. Antisense downregulation showed major differences between connexins: antisense 32 reduced, and antisense 43 increased, collagen secretion. In both cases loading effects were maintained. This shows that (i) gap junctional integration of signals is important in load response of tenocyte populations - mechanotransduction occurs in individual cells but integration of signals markedly enhances it and (ii) communication via connexin 32 and 43 have differential effects on the load response, with connexin 32 being stimulatory and connexin 43 being inhibitory. Cells coordinate and control their response to mechanical signals at least in part by differential actions of these two types of gap junction. FAU - Waggett, Andrew D AU - Waggett AD AD - Connective Tissue Biology Laboratory, School of Biosciences, Cardiff University, Biomedical Sciences Building, Museum Avenue, PO Box 911, Cardiff CF10 3US, UK. FAU - Benjamin, Michael AU - Benjamin M FAU - Ralphs, James R AU - Ralphs JR LA - eng GR - Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060721 PL - Germany TA - Eur J Cell Biol JT - European journal of cell biology JID - 7906240 RN - 0 (Anesthetics, Inhalation) RN - 0 (Antisense Elements (Genetics)) RN - 0 (Connexin 43) RN - 0 (Connexins) RN - 0 (Isoquinolines) RN - 0 (Peptides) RN - 9007-34-5 (Collagen) RN - 9654F8OVKE (lucifer yellow) RN - UQT9G45D1P (Halothane) SB - IM MH - Anesthetics, Inhalation/pharmacology MH - Animals MH - Antisense Elements (Genetics)/pharmacology MH - *Cell Communication MH - Cells, Cultured MH - Chickens MH - Collagen/metabolism MH - Connexin 43/*physiology MH - Connexins/*physiology MH - Gap Junctions/*physiology MH - Halothane/pharmacology MH - Isoquinolines/metabolism MH - Peptides/pharmacology MH - Signal Transduction MH - Stress, Mechanical MH - Tendons/cytology/*physiology MH - Gap Junction beta-1 Protein EDAT- 2006/07/25 09:00 MHDA- 2007/03/10 09:00 CRDT- 2006/07/25 09:00 PHST- 2005/05/25 00:00 [received] PHST- 2006/06/07 00:00 [revised] PHST- 2006/06/12 00:00 [accepted] PHST- 2006/07/25 09:00 [pubmed] PHST- 2007/03/10 09:00 [medline] PHST- 2006/07/25 09:00 [entrez] AID - S0171-9335(06)00117-8 [pii] AID - 10.1016/j.ejcb.2006.06.002 [doi] PST - ppublish SO - Eur J Cell Biol. 2006 Nov;85(11):1145-54. doi: 10.1016/j.ejcb.2006.06.002. Epub 2006 Jul 21. PMID- 10149965 OWN - NLM STAT- MEDLINE DCOM- 19921029 LR - 20191103 IS - 0267-6605 (Print) IS - 0267-6605 (Linking) VI - 9 IP - 3-4 DP - 1992 TI - The effect of gamma irradiation on a xenograft tendon bioprosthesis. PG - 149-54 AB - Radiation sterilisation of xenograft prostheses has been shown to cause damage to the material. Such damage has been imputed to affect the mechanical and biological properties and may contribute to long-term failure. This study has examined the effect of 25 kGy (2.5 Mrad) of gamma radiation on the mechanical and physicochemical properties and the biological function of a xenograft tendon bioprosthesis derived from glutaraldehyde cross-linked kangaroo tail tendon. The ultimate tensile stress of nonirradiated glutaraldehyde cross-linked tendon was greater than that of fresh frozen tendon, but irradiated cross-linked tendon did not differ. Irradiation did not alter the response to prolonged collagenase exposure. There was a decrease in overall apparent cross-link density (as determined by thermal denaturation temperature). After 12 months implantation, there was a slightly more active cellular response around irradiated tendon and the very peripheral fibres were infiltrated, but the mechanical properties of the retrieved implants were the same for irradiated and nonirradiated material. Gamma irradiation would appear to be a satisfactory method of sterilisation for glutaraldehyde cross-linked tendon materials. However, as damage to the cross-linked structure was detected in this study, it may not be appropriate in other applications. FAU - Roe, S C AU - Roe SC AD - Centre for Biomedical Engineering, University of New South Wales, Kensington, Australia. FAU - Milthorpe, B K AU - Milthorpe BK FAU - True, K AU - True K FAU - Rogers, G J AU - Rogers GJ FAU - Schindhelm, K AU - Schindhelm K LA - eng PT - Journal Article PL - England TA - Clin Mater JT - Clinical materials JID - 8707278 RN - 0 (Cross-Linking Reagents) RN - 9007-34-5 (Collagen) RN - T3C89M417N (Glutaral) MH - Animals MH - *Bioprosthesis MH - Collagen/*radiation effects MH - Cross-Linking Reagents/pharmacology MH - Gamma Rays MH - Glutaral/pharmacology MH - Hot Temperature MH - Macropodidae MH - Male MH - Materials Testing MH - Prosthesis Design MH - Protein Denaturation MH - Sheep MH - Sterilization/methods MH - Tail MH - Tendons/drug effects/*radiation effects MH - Tensile Strength EDAT- 1991/12/10 00:00 MHDA- 1991/12/10 00:01 CRDT- 1991/12/10 00:00 PHST- 1991/12/10 00:00 [pubmed] PHST- 1991/12/10 00:01 [medline] PHST- 1991/12/10 00:00 [entrez] AID - 10.1016/0267-6605(92)90094-a [doi] PST - ppublish SO - Clin Mater. 1992;9(3-4):149-54. doi: 10.1016/0267-6605(92)90094-a. PMID- 608116 OWN - NLM STAT- MEDLINE DCOM- 19780517 LR - 20191210 IS - 0006-8950 (Print) IS - 0006-8950 (Linking) VI - 100 IP - 4 DP - 1977 Dec TI - A quantitative analysis of sensations of tension and of kinaesthesia in man. Evidence for a peripherally originating muscular sense and for a sense of effort. PG - 671-92 FAU - Roland, P E AU - Roland PE FAU - Ladegaard-Pedersen, H AU - Ladegaard-Pedersen H LA - eng PT - Journal Article PL - England TA - Brain JT - Brain : a journal of neurology JID - 0372537 RN - Q3254X40X2 (Gallamine Triethiodide) SB - IM MH - Afferent Pathways/physiology MH - Anesthesia, Local MH - Discrimination, Psychological/physiology MH - Female MH - Forearm/blood supply MH - Gallamine Triethiodide/pharmacology MH - Humans MH - Ischemia/complications MH - Kinesthesis/*physiology MH - Mechanoreceptors/physiology MH - *Muscle Contraction MH - Muscles/innervation/*physiology MH - *Physical Exertion MH - Sensory Receptor Cells/physiology MH - Tendons/physiology OID - NASA: 78125021 EDAT- 1977/12/01 00:00 MHDA- 1977/12/01 00:01 CRDT- 1977/12/01 00:00 PHST- 1977/12/01 00:00 [pubmed] PHST- 1977/12/01 00:01 [medline] PHST- 1977/12/01 00:00 [entrez] AID - 10.1093/brain/100.4.671 [doi] PST - ppublish SO - Brain. 1977 Dec;100(4):671-92. doi: 10.1093/brain/100.4.671. PMID- 16767738 OWN - NLM STAT- MEDLINE DCOM- 20070213 LR - 20200930 IS - 1552-4973 (Print) IS - 1552-4973 (Linking) VI - 80 IP - 1 DP - 2007 Jan TI - Modulation of peritendinous adhesion formation by alginate solution in a rabbit flexor tendon model. PG - 273-9 AB - To examine the antiadhesive effect of an alginate solution following tendon surgery, unilateral subtotal laceration of the flexor digitorum communis tendon was created in one hind limb while the other side was left intact in 32 Japanese white rabbits. The lesion was coated with alginate solution in 16 animals and not coated in the other 16. Degree of adhesion formation was assessed histologically and biomechanically by measuring the flexion angle of the first toe when the flexor digitorum tendon was pulled with a specified force at 4 weeks postoperatively. When compared with the control group, the alginate-treated group demonstrated significantly greater toe flexion, with less scar tissue formation at the repair site. Histologically, complete tendon healing with longitudinal remodeling of collagen fibers was observed in the alginate-treated group, while a random pattern of fibers was observed in the control group. Reduction in adhesion formation using alginate solution represents a novel strategy for the management of tendon injury and repair in the clinical setting. CI - 2006 Wiley Periodicals, Inc. FAU - Namba, Jiro AU - Namba J AD - Department of Orthopaedic Surgery, Minoh City Hospital, 5-7-1, Kayano, Minoh, Osaka 562-0014, Japan. yonamba@ybb.ne.jp FAU - Shimada, Kozo AU - Shimada K FAU - Saito, Masanobu AU - Saito M FAU - Murase, Tsuyoshi AU - Murase T FAU - Yamada, Hideaki AU - Yamada H FAU - Yoshikawa, Hideki AU - Yoshikawa H LA - eng PT - Journal Article PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 0 (Alginates) RN - 0 (Biocompatible Materials) RN - 0 (Hexuronic Acids) RN - 8A5D83Q4RW (Glucuronic Acid) SB - IM MH - Alginates/*pharmacology MH - Animals MH - Biocompatible Materials/*pharmacology MH - Cicatrix/*drug therapy MH - Disease Models, Animal MH - Glucuronic Acid/pharmacology MH - Hexuronic Acids/pharmacology MH - Rabbits MH - Tendon Injuries/*drug therapy/pathology/physiopathology MH - *Tendons/pathology/physiopathology MH - Wound Healing/*drug effects EDAT- 2006/06/13 09:00 MHDA- 2007/02/14 09:00 CRDT- 2006/06/13 09:00 PHST- 2006/06/13 09:00 [pubmed] PHST- 2007/02/14 09:00 [medline] PHST- 2006/06/13 09:00 [entrez] AID - 10.1002/jbm.b.30594 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2007 Jan;80(1):273-9. doi: 10.1002/jbm.b.30594. PMID- 24316363 OWN - NLM STAT- MEDLINE DCOM- 20150512 LR - 20211021 IS - 1878-7568 (Electronic) IS - 1742-7061 (Print) IS - 1742-7061 (Linking) VI - 10 IP - 3 DP - 2014 Mar TI - Lysyl oxidase-mediated collagen crosslinks may be assessed as markers of functional properties of tendon tissue formation. PG - 1370-9 LID - S1742-7061(13)00591-6 [pii] LID - 10.1016/j.actbio.2013.11.024 [doi] AB - Mechanical property elaboration of engineered tissues is often assumed on the basis of gene and protein characterizations, rather than mechanical testing. However, we recently demonstrated that mechanical properties are not consistently correlated with matrix content and organization during embryonic tissue development. Based on this, mechanical properties should be assessed independently during natural or engineered tissue formation. Unfortunately, mechanical testing is destructive, and thus alternative means of assessing these properties are desirable. In this study, we examined lysyl oxidase (LOX)-mediated crosslinks as markers for mechanical properties during embryonic tendon formation and the potential to detect them non-destructively. We used tandem mass spectrometry (LC-MS/MS) to quantify changes in hydroxylysyl pyridinoline (HP) and lysyl pyridinoline (LP) crosslink density in embryonic chick tendon as a function of developmental stage. In addition, we assessed a multiphoton imaging approach that exploits the natural fluorescence of HP and LP. With both techniques, we quantified crosslink density in normal and LOX-inhibited tendons, and correlated measurements with mechanical properties. HP and LP crosslink density varied as a function of developmental stage, with HP-to-dry mass ratio correlating highly to elastic modulus, even when enzymatic crosslink formation was inhibited. Multiphoton optical imaging corroborated LC-MS/MS data, identifying significant reductions in crosslink density from LOX inhibition. Taken together, crosslink density may be useful as a marker of tissue mechanical properties that could be assessed with imaging non-destructively and perhaps non-invasively. These outcomes could have significant scientific and clinical implications, enabling continuous and long-term monitoring of mechanical properties of collagen-crosslinked tissues or engineered constructs. CI - Copyright © 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Marturano, Joseph E AU - Marturano JE AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA. FAU - Xylas, Joanna F AU - Xylas JF AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA. FAU - Sridharan, Gautham V AU - Sridharan GV AD - Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155, USA. FAU - Georgakoudi, Irene AU - Georgakoudi I AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA. FAU - Kuo, Catherine K AU - Kuo CK AD - Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA; Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111, USA. Electronic address: catherinek.kuo@tufts.edu. LA - eng GR - P41 EB002520/EB/NIBIB NIH HHS/United States GR - R01 EB007542/EB/NIBIB NIH HHS/United States GR - R01EB007542/EB/NIBIB NIH HHS/United States GR - P41EB002520/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20131206 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Amino Acids) RN - 0 (Cross-Linking Reagents) RN - 151-18-8 (Aminopropionitrile) RN - 63800-01-1 (pyridinoline) RN - 90032-33-0 (deoxypyridinoline) RN - 9007-34-5 (Collagen) RN - EC 1.4.3.13 (Protein-Lysine 6-Oxidase) SB - IM MH - Amino Acids/pharmacology MH - Aminopropionitrile/pharmacology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Cattle MH - Chick Embryo MH - Chromatography, Liquid MH - Collagen/*metabolism MH - Cross-Linking Reagents/*pharmacology MH - Elastic Modulus/drug effects MH - Mass Spectrometry MH - Microscopy, Fluorescence, Multiphoton MH - Protein-Lysine 6-Oxidase/*metabolism MH - Reference Standards MH - Reproducibility of Results MH - Tendons/drug effects/embryology/*physiology MH - Tissue Engineering/*methods PMC - PMC4053294 MID - NIHMS547074 OTO - NOTNLM OT - Crosslinking OT - Mass spectrometry OT - Mechanical properties OT - Multiphoton microscopy OT - Tendon COIS- Disclosures: The authors declare no potential conflicts of interest. EDAT- 2013/12/10 06:00 MHDA- 2015/05/13 06:00 PMCR- 2015/03/01 CRDT- 2013/12/10 06:00 PHST- 2013/07/01 00:00 [received] PHST- 2013/11/22 00:00 [revised] PHST- 2013/11/26 00:00 [accepted] PHST- 2013/12/10 06:00 [entrez] PHST- 2013/12/10 06:00 [pubmed] PHST- 2015/05/13 06:00 [medline] PHST- 2015/03/01 00:00 [pmc-release] AID - S1742-7061(13)00591-6 [pii] AID - 10.1016/j.actbio.2013.11.024 [doi] PST - ppublish SO - Acta Biomater. 2014 Mar;10(3):1370-9. doi: 10.1016/j.actbio.2013.11.024. Epub 2013 Dec 6. PMID- 5755889 OWN - NLM STAT- MEDLINE DCOM- 19690401 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 18 IP - 5 DP - 1968 May TI - [On the mechanism of the penicillamine action on collagen metabolism]. PG - 594-7 FAU - Ruiz-Torres, A AU - Ruiz-Torres A LA - ger PT - Journal Article TT - Uber den Mechanismus der Penicillaminwirkung auf den Kollagenstoffwechsel. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 0 (Amino Acids) RN - 0 (Blood Proteins) RN - 0 (Carbon Isotopes) RN - 42HK56048U (Tyrosine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - GNN1DV99GX (Penicillamine) RN - TE7660XO1C (Glycine) SB - IM MH - Amino Acids/*metabolism MH - Animals MH - Blood Proteins/metabolism MH - Carbon Isotopes MH - Chromatography, Thin Layer MH - Collagen/*metabolism MH - Femur/metabolism MH - Glycine/metabolism MH - Liver/metabolism MH - Male MH - Penicillamine/*pharmacology MH - Proline/metabolism MH - Protein Binding/drug effects MH - Rats MH - Skin/metabolism MH - Tendons/metabolism MH - Tyrosine EDAT- 1968/05/01 00:00 MHDA- 1968/05/01 00:01 CRDT- 1968/05/01 00:00 PHST- 1968/05/01 00:00 [pubmed] PHST- 1968/05/01 00:01 [medline] PHST- 1968/05/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1968 May;18(5):594-7. PMID- 18162197 OWN - NLM STAT- MEDLINE DCOM- 20080411 LR - 20131121 IS - 1566-0702 (Print) IS - 1566-0702 (Linking) VI - 138 IP - 1-2 DP - 2008 Feb 29 TI - Muscle receptors close to the myotendinous junction play a role in eliciting exercise pressor reflex during contraction. PG - 99-107 AB - Although a muscle mechanosensitive reflex contributes to regulation of the cardiovascular responses during exercise, the precise location of muscle mechanoreceptors responding to contraction has not been identified yet. We have recently reported that mechanosensitive receptors located at or close to the myotendinous junction play a role in eliciting the cardiovascular responses to passive stretch of skeletal muscle. The mechanoreceptors located at or near the myotendinous junction are hypothesized to respond to static contraction as well. To test this hypothesis, we had two interventions for the reflex cardiovascular responses to static contraction of the triceps surae muscle with the same tension development in decerebrate or pentobarbital-anesthetized rats; cutting the Achilles tendon and local injection of lidocaine into the myotendinous junction. The cardiovascular responses were evoked by static contraction regardless of the achillotomy, suggesting that mechanoreceptors terminating in the more distal part of the cut Achilles tendon did not contribute to the reflex cardiovascular responses. Lidocaine (volume, 0.04-0.1 ml) injected into the myotendinous junction blunted the reflex cardiovascular responses, indicating that muscle afferent fibers terminating at or passing through the myotendinous junction contribute to the exercise pressor reflex. The achillotomy did not affect the cardiovascular responses to passive stretch with the same tension as static contraction, but the localized injection of lidocaine similarly blunted the responses to passive stretch as contraction. We conclude that the mechanosensitive receptors eliciting the reflex cardiovascular responses may at least partly locate close to the myotendinous junction, to monitor tension development during muscular activity. FAU - Nakamoto, Tomoko AU - Nakamoto T AD - Department of Physiology, Graduate School of Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, Japan. FAU - Matsukawa, Kanji AU - Matsukawa K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20071227 PL - Netherlands TA - Auton Neurosci JT - Autonomic neuroscience : basic & clinical JID - 100909359 RN - 0 (Anesthetics, Local) RN - 98PI200987 (Lidocaine) SB - IM MH - Afferent Pathways/drug effects/physiology MH - Anesthetics, Local/pharmacology MH - Animals MH - Blood Pressure/drug effects/*physiology MH - Cardiovascular Physiological Phenomena/drug effects MH - Lidocaine/pharmacology MH - Male MH - Mechanoreceptors/drug effects/*physiology MH - Muscle Contraction/drug effects/*physiology MH - Muscle Fibers, Skeletal/drug effects/physiology MH - Muscle, Skeletal/drug effects/*innervation/*physiology MH - Physical Conditioning, Animal/*physiology MH - Rats MH - Rats, Wistar MH - Reflex/drug effects/physiology MH - Sensory Receptor Cells/drug effects/physiology MH - Stress, Mechanical MH - Tendons/drug effects/innervation/physiology EDAT- 2007/12/29 09:00 MHDA- 2008/04/12 09:00 CRDT- 2007/12/29 09:00 PHST- 2007/10/10 00:00 [received] PHST- 2007/11/23 00:00 [accepted] PHST- 2007/12/29 09:00 [pubmed] PHST- 2008/04/12 09:00 [medline] PHST- 2007/12/29 09:00 [entrez] AID - S1566-0702(07)00542-5 [pii] AID - 10.1016/j.autneu.2007.11.005 [doi] PST - ppublish SO - Auton Neurosci. 2008 Feb 29;138(1-2):99-107. doi: 10.1016/j.autneu.2007.11.005. Epub 2007 Dec 27. PMID- 7213937 OWN - NLM STAT- MEDLINE DCOM- 19810613 LR - 20131121 IS - 0006-3525 (Print) IS - 0006-3525 (Linking) VI - 19 IP - 10 DP - 1980 Oct TI - Role of aldehydes in collagen fibrillogenesis in vitro. PG - 1861-73 FAU - Brennan, M AU - Brennan M FAU - Davison, P F AU - Davison PF LA - eng GR - EY002213/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biopolymers JT - Biopolymers JID - 0372525 RN - 0 (Aldehydes) RN - 9007-34-5 (Collagen) RN - GNN1DV99GX (Penicillamine) SB - IM MH - Aldehydes/*metabolism MH - Animals MH - Cattle MH - Collagen/*metabolism MH - Kinetics MH - Penicillamine/pharmacology MH - Tendons/metabolism EDAT- 1980/10/01 00:00 MHDA- 1980/10/01 00:01 CRDT- 1980/10/01 00:00 PHST- 1980/10/01 00:00 [pubmed] PHST- 1980/10/01 00:01 [medline] PHST- 1980/10/01 00:00 [entrez] AID - 10.1002/bip.1980.360191013 [doi] PST - ppublish SO - Biopolymers. 1980 Oct;19(10):1861-73. doi: 10.1002/bip.1980.360191013. PMID- 31957239 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20231113 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 24 IP - 3 DP - 2020 Feb TI - Pioglitazone attenuates advanced glycation end products-induced apoptosis and calcification by modulating autophagy in tendon-derived stem cells. PG - 2240-2251 LID - 10.1111/jcmm.14901 [doi] AB - Diabetes mellitus (DM) is one of the prominent risk factors for pathological development and progression of tendinopathy. One feature of DM-related changes in tendinopathy is accumulation of advanced glycation end products (AGEs) in affected tendons. Pioglitazone (Pio), a peroxisome proliferator-activated receptor γ agonist, performs a protective effect against AGEs. The present study aimed to investigate the pathogenetic role of AGEs on tendon-derived stem cells (TDSCs) and to determine the effect of Pio on AGEs-induced TDSC dysfunctions. Results indicated that AGEs induced TDSC apoptosis as well as compensatory activation of autophagy. Pharmacologic activation/inhibition of autophagy leaded to alleviate/exacerbate apoptosis induced by AGEs. We further confirmed the effect of Pio on autophagy, which ameliorated apoptosis and abnormal calcification caused by AGEs both in vitro and in vivo. Thus, we suggest that Pio ameliorates the dysfunctions of TDSCs against AGEs by promoting autophagy, and we also reveal that Pio is a potential pharmacological choice for tendinopathy. CI - © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Xu, Langhai AU - Xu L AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Xu, Kai AU - Xu K AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Wu, Zhipeng AU - Wu Z AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Chen, Zhonggai AU - Chen Z AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - He, Yuzhe AU - He Y AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Ma, Chiyuan AU - Ma C AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Moqbel, Safwat A A AU - Moqbel SAA AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Ran, Jisheng AU - Ran J AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Zhang, Caihua AU - Zhang C AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Wu, Lidong AU - Wu L AUID- ORCID: 0000-0002-2561-6069 AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. FAU - Xiong, Yan AU - Xiong Y AD - Department of Orthopedics Surgery, The 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200119 PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Glycation End Products, Advanced) RN - 0 (PPAR gamma) RN - 0 (Receptor for Advanced Glycation End Products) RN - X4OV71U42S (Pioglitazone) SB - IM MH - Animals MH - Apoptosis/*drug effects MH - Autophagy/*drug effects MH - Calcification, Physiologic/*drug effects MH - Glycation End Products, Advanced/*metabolism MH - Male MH - PPAR gamma/metabolism MH - Pioglitazone/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Receptor for Advanced Glycation End Products/metabolism MH - Stem Cells/*drug effects/metabolism MH - Tendons/*drug effects/metabolism PMC - PMC7011144 OTO - NOTNLM OT - advanced glycation end products OT - apoptosis OT - autophagy OT - pioglitazone OT - tendon-derived stem cells COIS- The authors declare no conflict of interest. EDAT- 2020/01/21 06:00 MHDA- 2021/04/28 06:00 PMCR- 2020/02/01 CRDT- 2020/01/21 06:00 PHST- 2019/07/31 00:00 [received] PHST- 2019/10/29 00:00 [revised] PHST- 2019/11/22 00:00 [accepted] PHST- 2020/01/21 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2020/01/21 06:00 [entrez] PHST- 2020/02/01 00:00 [pmc-release] AID - JCMM14901 [pii] AID - 10.1111/jcmm.14901 [doi] PST - ppublish SO - J Cell Mol Med. 2020 Feb;24(3):2240-2251. doi: 10.1111/jcmm.14901. Epub 2020 Jan 19. PMID- 19743506 OWN - NLM STAT- MEDLINE DCOM- 20100301 LR - 20181201 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 28 IP - 3 DP - 2010 Mar TI - Improving bone density at the rotator cuff footprint increases supraspinatus tendon failure stress in a rat model. PG - 308-14 LID - 10.1002/jor.20972 [doi] AB - The purpose of this study was to investigate whether supraspinatus tendon failure stress at the footprint can increase by improving the bone density at the rotator cuff footprint in a rat model. Bilateral ovariectomies were performed in twenty-four 4-month-old Sprague-Dawley rats. Half received bisphosphonate (zoledronic acid) and the other half received no treatment (OVX + ZOM and OVX, respectively). Twelve additional rats did not undergo ovariectomy or receive bisphosphonate treatment (CON). All rats were sacrificed at 7 months of age. Quantitative micro-computed tomography was used to assess bone density in the proximal humerus. A series of stress-relaxation tests were performed to assess stiffness and failure stress of the supraspinatus tendon. Bone density in OVX + ZOM was significantly higher at the rotator cuff footprint when compared to CON and OVX rats (p < 0.0001). The supraspinatus tendons in the OVX group were significantly stiffer when compared to the CON and OVX + ZOM groups (p < 0.05). The failure stress of the OVX + ZOM group was significantly greater than the CON and OVX groups (22.89 +/- 4.43 MPa vs. 18.36 +/- 3.16 and 17.70 +/- 4.92, respectively). In conclusion, improving the bone density at the rotator cuff footprint enhances failure stress of the suprapinatus tendon. FAU - Cadet, Edwin R AU - Cadet ER AD - Center of Shoulder, Elbow, and Sports Medicine, Department of Orthopaedic Surgery, Columbia University Medical Center, 622 West 168th Street, PH 11th Floor, New York, New York 10032, USA. ec2195@columbia.edu FAU - Vorys, George C AU - Vorys GC FAU - Rahman, Ra'Kerry AU - Rahman R FAU - Park, Sang-Hyun AU - Park SH FAU - Gardner, Thomas R AU - Gardner TR FAU - Lee, Francis Y AU - Lee FY FAU - Levine, William N AU - Levine WN FAU - Bigliani, Louis U AU - Bigliani LU FAU - Ahmad, Christopher S AU - Ahmad CS LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Bone Density Conservation Agents) RN - 0 (Diphosphonates) RN - 0 (Imidazoles) RN - 6XC1PAD3KF (Zoledronic Acid) SB - IM MH - Animals MH - Biomechanical Phenomena MH - *Bone Density/drug effects MH - Bone Density Conservation Agents/pharmacology MH - Diphosphonates/pharmacology MH - Female MH - Humerus/diagnostic imaging/*metabolism MH - Imidazoles/pharmacology MH - Organ Size MH - Ovariectomy MH - Rats MH - Rats, Sprague-Dawley MH - *Rotator Cuff MH - *Stress, Mechanical MH - Tendons/pathology/*physiopathology MH - Tomography, X-Ray Computed/methods MH - Uterus/pathology MH - Zoledronic Acid EDAT- 2009/09/11 06:00 MHDA- 2010/03/02 06:00 CRDT- 2009/09/11 06:00 PHST- 2009/09/11 06:00 [entrez] PHST- 2009/09/11 06:00 [pubmed] PHST- 2010/03/02 06:00 [medline] AID - 10.1002/jor.20972 [doi] PST - ppublish SO - J Orthop Res. 2010 Mar;28(3):308-14. doi: 10.1002/jor.20972. PMID- 16256125 OWN - NLM STAT- MEDLINE DCOM- 20060830 LR - 20131121 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 39 IP - 6 DP - 2006 TI - Cyclic strain increases fibroblast proliferation, matrix accumulation, and elastic modulus of fibroblast-seeded polyurethane constructs. PG - 1136-44 AB - Rapid induction of matrix production and mechanical strengthening is essential to the development of bio-artificial constructs for repair and replacement of load-bearing connective tissues. Toward this end, we describe the development of a mechanical bioreactor and its application to investigate the influence of cyclic strain on fibroblast proliferation, matrix accumulation, and the mechanical properties of fibroblast-seeded polyurethane constructs (FSPC). Human fibroblasts were cultured in 10% serum-containing conditions within three-dimensional, porous elastomeric substrates under static conditions and a model regime of cyclic strain (10% strain, 0.25 Hz, 8 h/day), with and without ascorbic acid supplementation. After one week, the combination of cyclic strain and ascorbic acid resulted in significantly increased construct elastic modulus (>110%) relative to either condition alone. In contrast, cyclic strain alone was sufficient to stimulate significant increases in fibroblast proliferation. Mechanical strengthening of FSPCs was accompanied by increased type I collagen and fibronectin matrix accumulation and distribution, and significantly increased gene expression for type I collagen, TGFbeta-1, and CTGF. These results suggest that strain-induced conditioning in vitro leads to mechanical strengthening of fibroblast/material constructs, most likely resulting from increased collagen matrix deposition, secondary to strain-induced increases in cytokine production. FAU - Webb, Ken AU - Webb K AD - Department of Bioengineering, The Keck Center for Tissue Engineering, University of Utah, Salt Lake City, UT 84112, USA. FAU - Hitchcock, Robert W AU - Hitchcock RW FAU - Smeal, Roy M AU - Smeal RM FAU - Li, Wenhua AU - Li W FAU - Gray, Steven D AU - Gray SD FAU - Tresco, Patrick A AU - Tresco PA LA - eng GR - R01 DC 04336/DC/NIDCD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20051026 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Polyurethanes) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Ascorbic Acid/pharmacology MH - *Bioreactors MH - Cell Culture Techniques MH - Cell Proliferation/*drug effects MH - Extracellular Matrix/drug effects/genetics MH - Fibroblasts/*drug effects MH - Humans MH - Ligaments MH - Molecular Sequence Data MH - Polyurethanes/*pharmacology MH - Stress, Mechanical MH - Tendons MH - Tissue Engineering/*methods MH - Transplantation, Autologous MH - Weight-Bearing/physiology EDAT- 2005/11/01 09:00 MHDA- 2006/08/31 09:00 CRDT- 2005/11/01 09:00 PHST- 2004/07/27 00:00 [received] PHST- 2004/08/02 00:00 [accepted] PHST- 2005/11/01 09:00 [pubmed] PHST- 2006/08/31 09:00 [medline] PHST- 2005/11/01 09:00 [entrez] AID - S0021-9290(05)00098-9 [pii] AID - 10.1016/j.jbiomech.2004.08.026 [doi] PST - ppublish SO - J Biomech. 2006;39(6):1136-44. doi: 10.1016/j.jbiomech.2004.08.026. Epub 2005 Oct 26. PMID- 2982627 OWN - NLM STAT- MEDLINE DCOM- 19850424 LR - 20190707 IS - 0014-4827 (Print) IS - 0014-4827 (Linking) VI - 157 IP - 1 DP - 1985 Mar TI - Prolyl hydroxylase production can be uncoupled from the regulation of procollagen synthesis. PG - 265-70 AB - Primary avian tendon (PAT) cells increase the production of procollagen from 10-12% to 40-50% of total protein synthesis in response to the addition of ascorbate and an increasing cell density. We now show that prolyl hydroxylase (PH) also increases its activity by greater than five-fold in response to increasing cell density; but unlike procollagen production, this is independent of the presence of ascorbate. The increased activity is a result of greater enzyme production and not a shift in the ratio of inactive to active forms which remains constant at about 10% of the total enzyme proteins. We present the possibility that at low cell density the levels of PH activity could limit production of collagen. FAU - Kao, W W AU - Kao WW FAU - Kao, C W AU - Kao CW FAU - Schwarz, R I AU - Schwarz RI LA - eng GR - CA 37958/CA/NCI NIH HHS/United States GR - EY-04641/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Procollagen) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/pharmacology MH - Cell Count MH - Cells, Cultured MH - Chick Embryo MH - Immunoelectrophoresis, Two-Dimensional MH - Kinetics MH - Procollagen/*biosynthesis MH - Procollagen-Proline Dioxygenase/*biosynthesis MH - Tendons EDAT- 1985/03/01 00:00 MHDA- 1985/03/01 00:01 CRDT- 1985/03/01 00:00 PHST- 1985/03/01 00:00 [pubmed] PHST- 1985/03/01 00:01 [medline] PHST- 1985/03/01 00:00 [entrez] AID - 10.1016/0014-4827(85)90168-5 [doi] PST - ppublish SO - Exp Cell Res. 1985 Mar;157(1):265-70. doi: 10.1016/0014-4827(85)90168-5. PMID- 6820342 OWN - NLM STAT- MEDLINE DCOM- 19830610 LR - 20190909 IS - 0531-5565 (Print) IS - 0531-5565 (Linking) VI - 17 IP - 5 DP - 1982 TI - Changes in the characteristics of collagen of young male garden lizards following centrophenoxine and lysine treatment. PG - 399-405 FAU - Brahma, K C AU - Brahma KC FAU - Patnaik, B K AU - Patnaik BK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Exp Gerontol JT - Experimental gerontology JID - 0047061 RN - 0 (Glycolates) RN - 9007-34-5 (Collagen) RN - C76QQ2I0RG (Meclofenoxate) RN - K3Z4F929H6 (Lysine) SB - IM MH - *Aging MH - Animals MH - Bone and Bones/drug effects MH - Collagen/*analysis MH - Glycolates/*pharmacology MH - Lizards/*physiology MH - Lysine/*pharmacology MH - Male MH - Meclofenoxate/*pharmacology MH - Skin/drug effects MH - Tendons/drug effects EDAT- 1982/01/01 00:00 MHDA- 1982/01/01 00:01 CRDT- 1982/01/01 00:00 PHST- 1982/01/01 00:00 [pubmed] PHST- 1982/01/01 00:01 [medline] PHST- 1982/01/01 00:00 [entrez] AID - 0531-5565(82)90040-7 [pii] AID - 10.1016/0531-5565(82)90040-7 [doi] PST - ppublish SO - Exp Gerontol. 1982;17(5):399-405. doi: 10.1016/0531-5565(82)90040-7. PMID- 26185974 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20161230 IS - 1943-2720 (Electronic) IS - 0889-5899 (Linking) VI - 61 IP - 7 DP - 2015 Jul TI - Management of a Dehisced Hand Wound Using Hydrogen Peroxide, Electrical Stimulation, Silver-containing Dressings, and Compression: A Case Study. PG - 32-7 AB - Wound dehiscence is the separation of a wound along surgical sutures. A 57-year-old, otherwise healthy mechanic presented with a large open wound of >1 month duration on his left hand. His wound had dehisced after treatment that involved cleansing, surgical sutures, and oral antibiotics. He presented with a 5.0 cmx0.7 cmx0.3 cm lesion through the palmar creases of the hand with edema around the fourth and fifth digits and a callous formation around the distal portion of the wound. The wound had scant serosanguinous drainage and some induration at the periwound area, as well as a moderate foul odor. Tendons were not affected, but function was limited, the hand was painful, and the patient had been unable to work. Treatment was initiated with twice-a-week immersion of the hand in hydrogen peroxide diluted with water subjected to high-voltage pulsed current electric stimulation (HVPC). The wound was dressed with silver-containing dressings secured with stretch gauze and a compression garment. The wound was completely closed after 9 visits (35 days). No functional limitations of the hand or fingers, no cosmetic defect, and no wound recurrence were noted 9 months after healing. Although uncommon, dehisced wounds, especially in certain anatomical locations such as the hand, can be difficult to heal and may cause long-term problems with functioning. The treatment combination facilitated expedient healing of this dehisced hand wound. Research is needed to help elucidate the observations from this case study. FAU - Zhou, Kehua AU - Zhou K AD - Department of Health Care Studies, Daemen CollegePlease address correspondence to: Kehua Zhou, MD, DPT, LAc, Daemen College, 4380 Main Street, Amherst, NY 14226; email: kzhou@daemen.edu. FAU - Krug, Kenneth AU - Krug K AD - Daemen College Physical Therapy Wound Care Clinic, Cheektowaga, NY. FAU - Brogan, Michael S AU - Brogan MS AD - Department of Physical Therapy, Daemen College. LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Ostomy Wound Manage JT - Ostomy/wound management JID - 8912029 RN - 0 (Acticoat) RN - 0 (Anti-Infective Agents, Local) RN - 0 (Polyesters) RN - 0 (Polyethylenes) RN - 0 (Polyurethanes) RN - 0 (allevyn) RN - BBX060AN9V (Hydrogen Peroxide) MH - Anti-Infective Agents, Local/*therapeutic use MH - Bandages MH - *Electric Stimulation Therapy MH - Hand Injuries/etiology/pathology/*therapy MH - Humans MH - Hydrogen Peroxide/*therapeutic use MH - Male MH - Middle Aged MH - *Polyesters MH - *Polyethylenes MH - Polyurethanes MH - Surgical Wound Dehiscence/etiology/pathology/*therapy EDAT- 2015/07/18 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/07/18 06:00 PHST- 2015/07/18 06:00 [entrez] PHST- 2015/07/18 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PST - ppublish SO - Ostomy Wound Manage. 2015 Jul;61(7):32-7. PMID- 23058811 OWN - NLM STAT- MEDLINE DCOM- 20130426 LR - 20220408 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 28 IP - 12 DP - 2012 Dec TI - Regeneration of rotator cuff tear using electrospun poly(d,l-Lactide-Co-Glycolide) scaffolds in a rabbit model. PG - 1790-9 LID - S0749-8063(12)01514-9 [pii] LID - 10.1016/j.arthro.2012.05.887 [doi] AB - PURPOSE: The purpose of this study was to evaluate an application of poly(d,l-lactide-co-glycolide) (PLG) scaffold created by electrospinning in a rabbit rotator cuff defect model. METHODS: Forty-two Japanese white rabbits were used in this study. Defects of the infraspinatus tendon were created, and the PLG scaffolds were implanted. Contralateral infraspinatus tendons were reattached without creating defects. Histologic analyses were performed 4, 8, and 16 weeks after the operation, and mechanical evaluations were performed 0, 4, 8, and 16 weeks after the operation. RESULTS: Scaffold fibers remained without dissolution and spindle-shaped cells were observed inside of the scaffold at 4 weeks postoperatively. At 8 weeks, the PLG scaffold had dissolved and bone formation was observed at the scaffold-bone interface. At 16 weeks, the scaffold-bone interface matured and expression of type II collagen was observed. A statistical difference in ultimate failure load was not seen between the scaffold group and reattachment group or normal tendon after 8 weeks postoperatively. The stiffness in the scaffold group was not significantly different from that in the reattachment group at each time point. However, it was significantly weaker than normal tendon at each time point. CONCLUSIONS: Transplantation of cell-free PLG scaffold showed cell migration and type II collagen and proteoglycan expression at the scaffold-bone junction by 16 weeks postoperatively with a sufficient ultimate failure load in a rabbit rotator cuff defect model. CLINICAL RELEVANCE: The PLG scaffold could be applied to bridge rotator cuff defects. The results showed that bridging with scaffold can be equivalent to reattachment. CI - Copyright © 2012 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Inui, Atsuyuki AU - Inui A AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. atsuyukii@yahoo.co.jp FAU - Kokubu, Takeshi AU - Kokubu T FAU - Mifune, Yutaka AU - Mifune Y FAU - Sakata, Ryosuke AU - Sakata R FAU - Nishimoto, Hanako AU - Nishimoto H FAU - Nishida, Kotaro AU - Nishida K FAU - Akisue, Toshihiro AU - Akisue T FAU - Kuroda, Ryosuke AU - Kuroda R FAU - Satake, Makoto AU - Satake M FAU - Kaneko, Hiroaki AU - Kaneko H FAU - Fujioka, Hiroyuki AU - Fujioka H LA - eng PT - Journal Article DEP - 20121009 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Collagen Type II) RN - 0 (Proteoglycans) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Animals MH - Cell Movement MH - Collagen Type II/metabolism MH - Female MH - Lactic Acid/*therapeutic use MH - Osteogenesis/physiology MH - Polyglycolic Acid/*therapeutic use MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - Proteoglycans/metabolism MH - Rabbits MH - Regeneration/*physiology MH - Replantation/methods MH - Rotator Cuff/*physiology MH - Rupture/pathology/surgery MH - Time Factors MH - *Tissue Scaffolds EDAT- 2012/10/13 06:00 MHDA- 2013/04/27 06:00 CRDT- 2012/10/13 06:00 PHST- 2011/09/09 00:00 [received] PHST- 2012/05/20 00:00 [revised] PHST- 2012/05/24 00:00 [accepted] PHST- 2012/10/13 06:00 [entrez] PHST- 2012/10/13 06:00 [pubmed] PHST- 2013/04/27 06:00 [medline] AID - S0749-8063(12)01514-9 [pii] AID - 10.1016/j.arthro.2012.05.887 [doi] PST - ppublish SO - Arthroscopy. 2012 Dec;28(12):1790-9. doi: 10.1016/j.arthro.2012.05.887. Epub 2012 Oct 9. PMID- 17028867 OWN - NLM STAT- MEDLINE DCOM- 20070315 LR - 20220331 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 14 IP - 12 DP - 2006 Dec TI - Sclerosing polidocanol injections to treat chronic painful shoulder impingement syndrome-results of a two-centre collaborative pilot study. PG - 1321-6 AB - The histological changes found in the supraspinatus tendon have similarities with the findings in Achilles-, patellar- and extensor carpi radialis brevis (ECRB)-tendinopathy. In recent studies, we have found a vasculo-neural ingrowth in chronic painful Achilles and patellar tendinopathy, and demonstrated good short-term clinical effects with injections of the sclerosing substance polidocanol. In this collaborative two-centre pilot study, 15 patients (10 males and 5 females, mean age 46 years) with a long duration of shoulder pain (mean 28 months), and given the diagnosis chronic painful shoulder impingement syndrome, were included. They had tried rest, traditional rehabilitation exercises and multiple subacromial corticosteroid injections, without effect. We found vascularity (neovessels) in chronic painful, but not in pain-free, supraspinatus tendons, and prospectively studied the clinical effects of ultrasound (US) and colour Doppler (CD)-guided injections of polidocanol, targeting the area with neovessels. The patients evaluated the amount of shoulder pain during horizontal shoulder activity on a visual analogue scale (VAS), and satisfaction with treatment. Two (median) (range 1-5) polidocanol treatments (with 4-8 weeks in between) were given. In four patients (considered treatment failure), cortisone was injected into an inflamed subacromial bursa at one separate occasion weeks after the last polidocanol injection. At follow-up, 8 (median) (range 4-17) months after the treatment, 14 patients were satisfied with the result. Using the visual analogue scale evaluation (VAS), the pain dropped from 79 before treatment to 21 at follow-up (P < 0.05). In the short-term perspective, sclerosing polidocanol injections targeting the neovessels in the supraspinatus tendon and/or bursa wall seems to have a potential to reduce the pain during shoulder loading activity. FAU - Alfredson, Håkan AU - Alfredson H AD - Department of Surgical and Perioperative Science, Sports Medicine Unit, University of Umeå, 901 87 Umea, Sweden. hakan.alfredson@idrott.umu.se FAU - Harstad, Herlof AU - Harstad H FAU - Haugen, Simen AU - Haugen S FAU - Ohberg, Lars AU - Ohberg L LA - eng PT - Journal Article PT - Multicenter Study DEP - 20061007 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Adult MH - Chronic Disease MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pain Measurement MH - Pilot Projects MH - Polidocanol MH - Polyethylene Glycols/*therapeutic use MH - Sclerosing Solutions/*therapeutic use MH - Shoulder Impingement Syndrome/diagnostic imaging/*therapy MH - Statistics, Nonparametric MH - Treatment Outcome MH - Ultrasonography EDAT- 2006/10/10 09:00 MHDA- 2007/03/16 09:00 CRDT- 2006/10/10 09:00 PHST- 2006/06/26 00:00 [received] PHST- 2006/08/28 00:00 [accepted] PHST- 2006/10/10 09:00 [pubmed] PHST- 2007/03/16 09:00 [medline] PHST- 2006/10/10 09:00 [entrez] AID - 10.1007/s00167-006-0205-8 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2006 Dec;14(12):1321-6. doi: 10.1007/s00167-006-0205-8. Epub 2006 Oct 7. PMID- 17946857 OWN - NLM STAT- MEDLINE DCOM- 20080319 LR - 20250529 IS - 1557-170X (Print) IS - 1557-170X (Linking) VI - 2006 DP - 2006 TI - Fibroblastic differentiation of human mesenchymal stem cells using connective tissue growth factor. PG - 775-8 AB - The present study was designed to explore an ex vivo culturing protocol for fibroblastic differentiation of human mesenchymal stem cells (hMSCs) using connective tissue growth factor (CTGF). Fibroblastic differentiation from stem cells is of widespread significance in the engineering of virtually all tissues including tendons, ligaments, periodontal ligament, cranial sutures and as interstitial filler of all organs. The treatment with 100 ng/ml of recombinant human CTGF and 50 mug/ml ascorbic acids on monolayer cultured hMSCs showed significant increases in type I collagen and tenascin-C (Tn-C) contents by 2 and 4 wks. In addition, CTGF-treated hMSCs failed to show osteogenic or chondrogenic differentiation. The present data show that CTGF is an effective induction factor for fibroblastic differentiation of hMSCs. These findings have implications for engineering fibrous tissue by providing the initial evidence of a reproducible protocol for fibroblastic differentiation of hMSCs. FAU - Lee, Chang H AU - Lee CH AD - Department of Orthodontics, University of Illinois, Chicago, IL 60612, USA. chl2109@columbia.edu FAU - Moioli, Eduardo K AU - Moioli EK FAU - Mao, Jeremy J AU - Mao JJ LA - eng GR - RC2 DE020767/DE/NIDCR NIH HHS/United States GR - R01 EB002332/EB/NIBIB NIH HHS/United States GR - EB 02332/EB/NIBIB NIH HHS/United States GR - DE 13964/DE/NIDCR NIH HHS/United States GR - DE 15391/DE/NIDCR NIH HHS/United States GR - R01 DE013964/DE/NIDCR NIH HHS/United States GR - R01 DE015391/DE/NIDCR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Conf Proc IEEE Eng Med Biol Soc JT - Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference JID - 101243413 RN - 0 (CCN2 protein, human) RN - 0 (Immediate-Early Proteins) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Adolescent MH - Adult MH - Ascorbic Acid/pharmacology MH - Cell Culture Techniques/*methods MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Connective Tissue Growth Factor MH - Female MH - Fibroblasts/*cytology/drug effects/*physiology MH - Humans MH - Immediate-Early Proteins/*pharmacology MH - Intercellular Signaling Peptides and Proteins/*pharmacology MH - Male MH - Mesenchymal Stem Cells/*cytology/drug effects/*physiology MH - Middle Aged MH - Tissue Engineering/*methods PMC - PMC4035038 MID - NIHMS232006 EDAT- 2007/10/20 09:00 MHDA- 2008/03/20 09:00 PMCR- 2014/05/27 CRDT- 2007/10/20 09:00 PHST- 2007/10/20 09:00 [pubmed] PHST- 2008/03/20 09:00 [medline] PHST- 2007/10/20 09:00 [entrez] PHST- 2014/05/27 00:00 [pmc-release] AID - 10.1109/IEMBS.2006.259866 [doi] PST - ppublish SO - Conf Proc IEEE Eng Med Biol Soc. 2006;2006:775-8. doi: 10.1109/IEMBS.2006.259866. PMID- 20478906 OWN - NLM STAT- MEDLINE DCOM- 20100914 LR - 20240516 IS - 1758-535X (Electronic) IS - 1079-5006 (Print) IS - 1079-5006 (Linking) VI - 65 IP - 9 DP - 2010 Sep TI - Does accumulation of advanced glycation end products contribute to the aging phenotype? PG - 963-75 LID - 10.1093/gerona/glq074 [doi] AB - BACKGROUND: Aging is a complex multifactorial process characterized by accumulation of deleterious changes in cells and tissues, progressive deterioration of structural integrity and physiological function across multiple organ systems, and increased risk of death. METHODS: We conducted a review of the scientific literature on the relationship of advanced glycation end products (AGEs) with aging. AGEs are a heterogeneous group of bioactive molecules that are formed by the nonenzymatic glycation of proteins, lipids, and nucleic acids. RESULTS: Humans are exposed to AGEs produced in the body, especially in individuals with abnormal glucose metabolism, and AGEs ingested in foods. AGEs cause widespread damage to tissues through upregulation of inflammation and cross-linking of collagen and other proteins. AGEs have been shown to adversely affect virtually all cells, tissues, and organ systems. Recent epidemiological studies demonstrate that elevated circulating AGEs are associated with increased risk of developing many chronic diseases that disproportionally affect older individuals. CONCLUSIONS: Based on these data, we propose that accumulation of AGEs accelerate the multisystem functional decline that occurs with aging, and therefore contribute to the aging phenotype. Exposure to AGEs can be reduced by restriction of dietary intake of AGEs and drug treatment with AGE inhibitors and AGE breakers. Modification of intake and circulating levels of AGEs may be a possible strategy to promote health in old age, especially because most Western foods are processed at high temperature and are rich in AGEs. FAU - Semba, Richard D AU - Semba RD AD - Department of Ophthalmology, Johns Hopkins University School of Medicine, Smith Building, M015, 400 North Broadway, Baltimore, MD 21287, USA. rdsemba@jhmi.edu FAU - Nicklett, Emily J AU - Nicklett EJ FAU - Ferrucci, Luigi AU - Ferrucci L LA - eng GR - R01 AG027012/AG/NIA NIH HHS/United States GR - R01 AG029148/AG/NIA NIH HHS/United States GR - ImNIH/Intramural NIH HHS/United States GR - R01 HL094507/HL/NHLBI NIH HHS/United States GR - R37 AG019905/AG/NIA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, N.I.H., Intramural PT - Review DEP - 20100517 PL - United States TA - J Gerontol A Biol Sci Med Sci JT - The journals of gerontology. Series A, Biological sciences and medical sciences JID - 9502837 RN - 0 (Enzyme Inhibitors) RN - 0 (Glycation End Products, Advanced) RN - 0 (Guanidines) RN - 0 (Receptor for Advanced Glycation End Products) RN - 0 (Receptors, Immunologic) RN - 0 (Thiazoles) RN - DGH49JXB1F (alagebrium) RN - SCQ4EZQ113 (pimagedine) SB - IM MH - Aging/*metabolism MH - Bone and Bones/metabolism MH - Brain/metabolism MH - Diet MH - Enzyme Inhibitors/pharmacology MH - Erythrocytes/metabolism MH - Eye/metabolism MH - Food Analysis MH - Glycation End Products, Advanced/antagonists & inhibitors/*metabolism MH - Guanidines/pharmacology MH - Humans MH - Inflammation/metabolism MH - Kidney/metabolism MH - Liver/metabolism MH - Longevity MH - Muscle, Skeletal/metabolism MH - Myocardium/metabolism MH - Oxidative Stress/physiology MH - Receptor for Advanced Glycation End Products MH - Receptors, Immunologic/metabolism MH - Tendons/metabolism MH - Thiazoles/pharmacology PMC - PMC2920582 EDAT- 2010/05/19 06:00 MHDA- 2010/09/16 06:00 PMCR- 2011/09/01 CRDT- 2010/05/19 06:00 PHST- 2010/05/19 06:00 [entrez] PHST- 2010/05/19 06:00 [pubmed] PHST- 2010/09/16 06:00 [medline] PHST- 2011/09/01 00:00 [pmc-release] AID - glq074 [pii] AID - 10.1093/gerona/glq074 [doi] PST - ppublish SO - J Gerontol A Biol Sci Med Sci. 2010 Sep;65(9):963-75. doi: 10.1093/gerona/glq074. Epub 2010 May 17. PMID- 28035909 OWN - NLM STAT- MEDLINE DCOM- 20171218 LR - 20220318 IS - 1878-6324 (Electronic) IS - 1053-8127 (Linking) VI - 30 IP - 3 DP - 2017 TI - Comparison of the efficacy of lidocaine and betamethasone dipropionate in carpal tunnel syndrome injection. PG - 435-440 LID - 10.3233/BMR-150477 [doi] AB - BACKGROUND: Carpal tunnel syndrome (CTS) is a commonly seen peripheral nerve mononeuropathy. Corticosteroid injection within the carpal tunnel is among the conservative treatment options. The exact mechanism of action of steroids is not fully clear; decreased inflammation surrounding nerves or tendons is thought to be the main effect. Lidocaine has been shown to have anti-inflammatory effects on certain cells (monocytes, macrophages, neutrophils etc.). The aim of this study is to evaulate the efficacy of lidocaine treatment as a alternative to corticosteroid treatment in carpal tunnel syndrome. METHODS: A total of 67 carpal tunnel syndrome patients who were diagnosed with physical examination and EMG were evaluated. Twenty-nine patients received a mixture of normal saline solution and lidocaine (0.5 cc of normal saline solution and 0.5 cc of lidocaine) while 38 patients were administered betamethasone dipropionate (1 cc). Quick DASH (Disabilities of the Arm, Shoulder and Hand) and Visual Analog Scale (VAS) scores were noted in 1st, 3rd and 6th month follow-ups. RESULTS: There were no significant difference between saline solution + Lidocaine group and betamethasone dipropionate groups; initial, 1st, 3rd and 6th month VAS scores and QDASH scores (p > 0.05). CONCLUSION: Considering the potential side effects of corticosteroid, lidocaine injection is a good alternative treatment of carpal tunnel syndrome instead of corticosteroids. FAU - Dernek, Bahar AU - Dernek B AD - Physical Therapy and Rehabilitation Clinic, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. FAU - Aydin, Tugba AU - Aydin T AD - Physical Therapy and Rehabilitation Clinic, Okmeydanı Training and Research Hospital, Istanbul, Turkey. FAU - Koseoglu, Pinar Kursuz AU - Koseoglu PK AD - Physical Therapy and Rehabilitation Clinic, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey. FAU - Kesiktas, Fatma Nur AU - Kesiktas FN AD - Istanbul Physical Medicine and Rehabilitation Training Hospital, Istanbul, Turkey. FAU - Yesilyurt, Tugba AU - Yesilyurt T AD - Istanbul Physical Medicine and Rehabilitation Training Hospital, Istanbul, Turkey. FAU - Diracoglu, Demirhan AU - Diracoglu D AD - Department of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. FAU - Aksoy, Cihan AU - Aksoy C AD - Department of Physical Medicine and Rehabilitation, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PL - United States TA - J Back Musculoskelet Rehabil JT - Journal of back and musculoskeletal rehabilitation JID - 9201340 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Steroids) RN - 826Y60901U (betamethasone-17,21-dipropionate) RN - 9842X06Q6M (Betamethasone) RN - 98PI200987 (Lidocaine) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Adult MH - Anesthetics, Local/*therapeutic use MH - Anti-Inflammatory Agents/*therapeutic use MH - Betamethasone/*analogs & derivatives/therapeutic use MH - Carpal Tunnel Syndrome/*drug therapy MH - Female MH - Humans MH - Lidocaine/*therapeutic use MH - Male MH - Middle Aged MH - Physical Examination MH - Steroids/therapeutic use OTO - NOTNLM OT - Carpal tunnel OT - lidocaine OT - pain EDAT- 2016/12/31 06:00 MHDA- 2017/12/19 06:00 CRDT- 2016/12/31 06:00 PHST- 2016/12/31 06:00 [pubmed] PHST- 2017/12/19 06:00 [medline] PHST- 2016/12/31 06:00 [entrez] AID - BMR150477 [pii] AID - 10.3233/BMR-150477 [doi] PST - ppublish SO - J Back Musculoskelet Rehabil. 2017;30(3):435-440. doi: 10.3233/BMR-150477. PMID- 18516593 OWN - NLM STAT- MEDLINE DCOM- 20081021 LR - 20211020 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 16 IP - 8 DP - 2008 Aug TI - Neovascularisation in de Quervain's disease of the wrist: novel combined therapy using sclerosing therapy with polidocanol and eccentric training of the forearms and wrists-a pilot report. PG - 803-5 LID - 10.1007/s00167-008-0555-5 [doi] AB - De Quervain's disease has been described as an entrapment of the extensor pollicis brevis and abductor pollicis tendons in the first dorsal compartment of the wrist is a common cause of wrist and hand pain. Currently, intrasheath corticosteroid injections have been reported to be successful as well as surgical release of the first dorsal compartment. We report on three female recreational athletes (median age 57 years, pain VAS 7/10) where we found significant neovascularisation of the extensor retinaculum using Power-Doppler sonography, which was not evident among subjects without de Quervain's disease of the wrist. Polidocanol sclerosing therapy (0.25% 1 ml) was performed with consecutive eccentric training (Thera-Band Flex-Bar, 6 x 15 repetitions of the forearm and wrist extensors and flexors daily). Four weeks later two patients had a resolution of their pain levels (DASH 61 vs. 27, p < 0.05) with resolution of the neovascularisation, while one patient underwent surgery despite pain reduction (6 to 2) 3 weeks following sclerosing therapy. Neovascularisation has been found in de Quervain's disease of the wrist using Power Doppler sonography. Combined treatment with Power Doppler controlled sclerosing therapy with consecutive eccentric training led to encouraging pilot results in terms of pain reduction and functional improvement within 1 month of therapy. A prospective randomized controlled trial is warranted to answer the question whether the sclerosing therapy, the eccentric training or the combination of both is beneficial in de Quervain's disease of the wrist. FAU - Knobloch, Karsten AU - Knobloch K AD - Plastic, Hand and Reconstructive Surgery, Hannover Medical School, Hannover, Germany. kknobi@yahoo.com FAU - Gohritz, Andreas AU - Gohritz A FAU - Spies, Marcus AU - Spies M FAU - Vogt, Peter M AU - Vogt PM LA - eng PT - Journal Article DEP - 20080531 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Sclerosing Solutions) RN - 0AWH8BFG9A (Polidocanol) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - De Quervain Disease/*therapy MH - Female MH - Humans MH - Middle Aged MH - *Neovascularization, Physiologic MH - Pain Measurement MH - Physical Therapy Modalities/instrumentation MH - Pilot Projects MH - Polidocanol MH - Polyethylene Glycols/therapeutic use MH - Sclerosing Solutions/therapeutic use MH - Ultrasonography, Interventional MH - Wrist/*blood supply EDAT- 2008/06/03 09:00 MHDA- 2008/10/22 09:00 CRDT- 2008/06/03 09:00 PHST- 2008/03/04 00:00 [received] PHST- 2008/04/14 00:00 [accepted] PHST- 2008/06/03 09:00 [pubmed] PHST- 2008/10/22 09:00 [medline] PHST- 2008/06/03 09:00 [entrez] AID - 10.1007/s00167-008-0555-5 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2008 Aug;16(8):803-5. doi: 10.1007/s00167-008-0555-5. Epub 2008 May 31. PMID- 560978 OWN - NLM STAT- MEDLINE DCOM- 19771014 LR - 20190629 IS - 0014-4754 (Print) IS - 0014-4754 (Linking) VI - 33 IP - 6 DP - 1977 Jun 15 TI - Effects of carmine and carminic acid on embryonic tissue cell cultures. PG - 755-6 AB - The biological reaction to carmine and carminic acid at cellular level on 'in vitro' cultures was tested and significant variables were controlled. Results suggested that proliferation and metabolism of these cultures were not affected by the 2 stains. FAU - Marzona, L AU - Marzona L FAU - Olivo, O M AU - Olivo OM FAU - Volpi, G AU - Volpi G FAU - Toni, G AU - Toni G LA - eng PT - Journal Article PL - Switzerland TA - Experientia JT - Experientia JID - 0376547 RN - 0 (Anthraquinones) RN - CID8Z8N95N (Carmine) SB - IM MH - Animals MH - Anthraquinones/*pharmacology MH - Carmine/analogs & derivatives/*pharmacology MH - Cell Movement/drug effects MH - Cells, Cultured/*drug effects MH - Chick Embryo MH - Heart/embryology MH - Mitosis/drug effects MH - Myocardial Contraction/drug effects MH - Tendons/embryology EDAT- 1977/06/15 00:00 MHDA- 1977/06/15 00:01 CRDT- 1977/06/15 00:00 PHST- 1977/06/15 00:00 [pubmed] PHST- 1977/06/15 00:01 [medline] PHST- 1977/06/15 00:00 [entrez] AID - 10.1007/BF01944173 [doi] PST - ppublish SO - Experientia. 1977 Jun 15;33(6):755-6. doi: 10.1007/BF01944173. PMID- 22818894 OWN - NLM STAT- MEDLINE DCOM- 20130617 LR - 20220317 IS - 1532-6500 (Electronic) IS - 1058-2746 (Print) IS - 1058-2746 (Linking) VI - 22 IP - 4 DP - 2013 Apr TI - Rotator cuff healing after continuous subacromial bupivacaine infusion: an in vivo rabbit study. PG - 489-99 LID - S1058-2746(12)00180-2 [pii] LID - 10.1016/j.jse.2012.04.014 [doi] AB - BACKGROUND: The objective of this study was to evaluate the effects of continuous subacromial bupivacaine infusion on supraspinatus muscle and rotator cuff tendon healing using gross, biomechanical, and histologic analyses. MATERIALS AND METHODS: Thirty-three New Zealand White rabbits underwent unilateral supraspinatus transection and rotator cuff repair (RCR). Rabbits were assigned to 1 of 3 groups: (1) RCR only, (2) RCR with continuous saline infusion for 48 hours, or (3) RCR with continuous 0.25% bupivacaine with epinephrine (1:200,000) infusion for 48 hours. Rabbits were euthanized postoperatively at 2 weeks (for histologic assessment) or 8 weeks (for biomechanical and histologic assessment). RESULTS: Tensile testing showed a significantly higher load to failure in intact tendons compared with repaired tendons (P < .01); however, no statistical differences were detected among RCR only, RCR saline, and RCR bupivacaine groups. Histologically, the enthesis of repaired tendons showed increased cellularity and disorganized collagen fibers compared with intact tendons, with no differences between treatment groups. Muscle histology demonstrated scattered degenerative muscle fibers at 2 weeks in RCR saline and RCR bupivacaine groups, but no degeneration was noted at 8 weeks. CONCLUSIONS: The healing supraspinatus tendons exposed to bupivacaine infusion showed similar histologic and biomechanical characteristics compared with untreated and saline-infused RCR groups. Muscle histology showed fiber damage at 2 weeks for the saline and bupivacaine-treated groups, with no apparent disruption at 8 weeks, suggesting a recovery process. Therefore, subacromial bupivacaine infusion in this rabbit rotator cuff model does not appear to impair muscle or tendon after acute injury and repair. CI - Published by Mosby, Inc. FAU - Friel, Nicole A AU - Friel NA AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL 60612, USA. FAU - Wang, Vincent M AU - Wang VM FAU - Slabaugh, Mark A AU - Slabaugh MA FAU - Wang, FanChia AU - Wang F FAU - Chubinskaya, Susan AU - Chubinskaya S FAU - Cole, Brian J AU - Cole BJ LA - eng GR - T32 AR052272/AR/NIAMS NIH HHS/United States GR - T32 AR-052272/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20120720 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anesthetics, Local) RN - Y8335394RO (Bupivacaine) SB - IM MH - Anesthetics, Local/*pharmacology MH - Animals MH - Bupivacaine/*pharmacology MH - Male MH - Muscle, Skeletal/*drug effects/surgery MH - Rabbits MH - Rotator Cuff/*drug effects/pathology/surgery MH - Wound Healing/*drug effects PMC - PMC3777805 MID - NIHMS511481 EDAT- 2012/07/24 06:00 MHDA- 2013/06/19 06:00 PMCR- 2013/09/19 CRDT- 2012/07/24 06:00 PHST- 2011/08/12 00:00 [received] PHST- 2012/04/12 00:00 [revised] PHST- 2012/04/21 00:00 [accepted] PHST- 2012/07/24 06:00 [entrez] PHST- 2012/07/24 06:00 [pubmed] PHST- 2013/06/19 06:00 [medline] PHST- 2013/09/19 00:00 [pmc-release] AID - S1058-2746(12)00180-2 [pii] AID - 10.1016/j.jse.2012.04.014 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2013 Apr;22(4):489-99. doi: 10.1016/j.jse.2012.04.014. Epub 2012 Jul 20. PMID- 21735243 OWN - NLM STAT- MEDLINE DCOM- 20120622 LR - 20250529 IS - 1617-7940 (Electronic) IS - 1617-7959 (Print) IS - 1617-7940 (Linking) VI - 11 IP - 3-4 DP - 2012 Mar TI - Tenocyte contraction induces crimp formation in tendon-like tissue. PG - 449-59 LID - 10.1007/s10237-011-0324-0 [doi] AB - Tendons are composed of longitudinally aligned collagen fibrils arranged in bundles with an undulating pattern, called crimp. The crimp structure is established during embryonic development and plays a vital role in the mechanical behaviour of tendon, acting as a shock-absorber during loading. However, the mechanism of crimp formation is unknown, partly because of the difficulties of studying tendon development in vivo. Here, we used a 3D cell culture system in which embryonic tendon fibroblasts synthesise a tendon-like construct comprised of collagen fibrils arranged in parallel bundles. Investigations using polarised light microscopy, scanning electron microscopy and fluorescence microscopy showed that tendon constructs contained a regular pattern of wavy collagen fibrils. Tensile testing indicated that this superstructure was a form of embryonic crimp producing a characteristic toe region in the stress-strain curves. Furthermore, contraction of tendon fibroblasts was the critical factor in the buckling of collagen fibrils during the formation of the crimp structure. Using these biological data, a finite element model was built that mimics the contraction of the tendon fibroblasts and monitors the response of the Extracellular matrix. The results show that the contraction of the fibroblasts is a sufficient mechanical impulse to build a planar wavy pattern. Furthermore, the value of crimp wavelength was determined by the mechanical properties of the collagen fibrils and inter-fibrillar matrix. Increasing fibril stiffness combined with constant matrix stiffness led to an increase in crimp wavelength. The data suggest a novel mechanism of crimp formation, and the finite element model indicates the minimum requirements to generate a crimp structure in embryonic tendon. FAU - Herchenhan, Andreas AU - Herchenhan A AD - Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT UK. FAU - Kalson, Nicholas S AU - Kalson NS AD - Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT UK. FAU - Holmes, David F AU - Holmes DF AD - Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT UK. FAU - Hill, Patrick AU - Hill P AD - School of Chemical Engineering and Analytical Science, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom. FAU - Kadler, Karl E AU - Kadler KE AD - Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, Michael Smith Building, University of Manchester, Oxford Road, Manchester M13 9PT UK. FAU - Margetts, Lee AU - Margetts L AD - High Performance Computing, Research Computing Services, University of Manchester, Devonshire House, Oxford Road, Manchester M13 9PL UK. LA - eng GR - 088785/WT_/Wellcome Trust/United Kingdom GR - 091840/WT_/Wellcome Trust/United Kingdom GR - BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110707 PL - Germany TA - Biomech Model Mechanobiol JT - Biomechanics and modeling in mechanobiology JID - 101135325 RN - 0 (Detergents) RN - 9002-93-1 (Octoxynol) RN - 9007-34-5 (Collagen) SB - IM MH - Biomechanical Phenomena MH - Cell Culture Techniques MH - Collagen/chemistry MH - Detergents/pharmacology MH - Extracellular Matrix/metabolism MH - Fibroblasts/metabolism MH - Finite Element Analysis MH - Humans MH - Imaging, Three-Dimensional/methods MH - Microscopy, Electron, Scanning/methods MH - Microscopy, Fluorescence/methods MH - Movement MH - Octoxynol/pharmacology MH - Pressure MH - Tendons/*cytology/*pathology MH - Tensile Strength PMC - PMC3822867 MID - EMS49483 OID - NLM: EMS49483 EDAT- 2011/07/08 06:00 MHDA- 2012/06/23 06:00 PMCR- 2013/11/11 CRDT- 2011/07/08 06:00 PHST- 2010/12/03 00:00 [received] PHST- 2011/06/17 00:00 [accepted] PHST- 2011/07/08 06:00 [entrez] PHST- 2011/07/08 06:00 [pubmed] PHST- 2012/06/23 06:00 [medline] PHST- 2013/11/11 00:00 [pmc-release] AID - 10.1007/s10237-011-0324-0 [doi] PST - ppublish SO - Biomech Model Mechanobiol. 2012 Mar;11(3-4):449-59. doi: 10.1007/s10237-011-0324-0. Epub 2011 Jul 7. PMID- 17205555 OWN - NLM STAT- MEDLINE DCOM- 20070504 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 25 IP - 4 DP - 2007 Apr TI - Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model. PG - 473-9 AB - Previously we showed a loss of bone and a concomitant decrease in mechanical properties in the first 21 days after flexor tendon insertion site injury and repair in a canine model. The goal of this short-term study was to suppress bone loss after insertion site repair using alendronate in an attempt to prevent the reduction in biomechanical properties. Flexor tendons of the second and fifth digits of the right forelimbs of canines were injured and repaired. Dogs received a daily oral dose of alendronate (2 mg/kg). One digit in each dog also received a local dose of alendronate in the bone tunnel at the time of surgery. The repair was evaluated for bone mineral density (BMD) and biomechanical properties and compared to data from a previous study in which no alendronate was used. Alendronate was effective in protecting the distal phalanx from resorption during tendon-to-bone healing (BMD was 94 and 104% of control for systemic alendronate and for systemic plus local alendronate, respectively). Alendronate treatment prevented much of the decrease in ultimate load that occurs in the first 21 days. Without treatment, ultimate load was 42% of control. With systemic alendronate treatment and systemic plus local alendronate treatment, ultimate load was 78 and 69% of control, respectively. Failure mode was significantly different when comparing alendronate treatment to repair alone. A lower incidence of suture pull through was found in alendronate treated dogs, suggesting less tendon degeneration. Ultimate load can be improved in association with preventing the bone loss that normally occurs during the early period following tendon-to-bone repair. These initial short-term data demonstrate the potential for a clinical treatment that could enhance tendon-to-bone healing. FAU - Thomopoulos, Stavros AU - Thomopoulos S AD - Department of Orthopaedic Surgery, Washington University, 1 Barnes-Jewish Hospital Plaza, Suite 11300, Campus Box 8233, St. Louis, Missouri 63110, USA. ThomopoulosS@wudosis.wustl.edu FAU - Matsuzaki, Hironori AU - Matsuzaki H FAU - Zaegel, Melissa AU - Zaegel M FAU - Gelberman, Richard H AU - Gelberman RH FAU - Silva, Matthew J AU - Silva MJ LA - eng GR - 5R01AR033097/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Bone Density Conservation Agents) RN - EC 3.4.- (Metalloproteases) RN - X1J18R4W8P (Alendronate) SB - IM MH - Alendronate/*pharmacology MH - Animals MH - Biomechanical Phenomena MH - Bone Density/drug effects/physiology MH - Bone Density Conservation Agents/*pharmacology MH - Bone Resorption/physiopathology/*prevention & control MH - Bone and Bones/drug effects/*physiology MH - Dogs MH - Dose-Response Relationship, Drug MH - Metalloproteases/metabolism MH - Models, Animal MH - Tendon Injuries/physiopathology MH - Tendons/drug effects/*physiology MH - Wound Healing/*drug effects/physiology EDAT- 2007/01/06 09:00 MHDA- 2007/05/05 09:00 CRDT- 2007/01/06 09:00 PHST- 2007/01/06 09:00 [pubmed] PHST- 2007/05/05 09:00 [medline] PHST- 2007/01/06 09:00 [entrez] AID - 10.1002/jor.20293 [doi] PST - ppublish SO - J Orthop Res. 2007 Apr;25(4):473-9. doi: 10.1002/jor.20293. PMID- 36054510 OWN - NLM STAT- MEDLINE DCOM- 20221005 LR - 20221012 IS - 1757-7861 (Electronic) IS - 1757-7853 (Print) IS - 1757-7853 (Linking) VI - 14 IP - 10 DP - 2022 Oct TI - Effects of Chemical Sterilization and Gamma Irradiation on the Biochemical and Biomechanical Properties of Human Tendon Allografts In Vitro Study. PG - 2657-2668 LID - 10.1111/os.13465 [doi] AB - OBJECTIVE: Pre-implantation sterilization procedures for tendons are important measures to reduce the risk of disease transmission, however these procedures may compromise tendon microarchitecture and biomechanical properties to varying degrees. We explore the effects of different sterilization procedures on the micro-histology, biomechanical strength and biochemical properties of human tendon allografts in vitro study. METHODS: The tendon allografts were harvested from cadaveric donors after the donors were serologically screened by antibody or nucleic acid testing of infectious agents. All samples were divided into five groups, which were fresh-frozen group (control group), 15 kGy gamma irradiation group, 25 kGy gamma irradiation group, 70% ethanol group, and peracetic acid-ethanol group. Each group included 10 tendons for testing. Histological staining and transmission electron microscopy were applied to observe the internal structure and arrangement of tendon collagen fibers, while the machine learning classifier was trained to distinguish the darker cross-sections of collagen fibers and brighter backgrounds of the electron micrograph to detect the distribution of diameters of tendon collagen fibers. The viscoelasticity, mechanical properties and material properties of tendon allografts were examined to detect the influence of different intervention factors on the biomechanical properties of tendons. RESULTS: Histological staining and transmission electron microscopy showed that the structure of fresh-frozen tendons was similar to the structures of other experimental groups, and no obvious fiber disorder or delamination was observed. In the uniaxial cyclic test, the cyclic creep of 25 kGy irradiation group (1.5%) and peracetic acid-ethanol group (1.5%) were significantly lower than that of the control group (3.6%, F = 1.52, P = 0.039) while in the load-to-failure test, the maximum elongation and maximum strain of the peracetic acid-ethanol group were significantly higher than those of the control group (F = 4.60, P = 0.010), and there was no significant difference in other biomechanical indicators. According to the experimental results of denatured collagen, it could be seen that no matter which disinfection procedure was used, the denaturation of the tendon sample would be promoted (F = 1.97, P = 0.186), and high-dose irradiation seemed to cause more damage to collagen fibers than the other two disinfection procedures (296.2 vs 171.1 vs 212.9 μg/g). CONCLUSION: Biomechanical experiments and collagen denaturation tests showed that 15 kGy gamma irradiation and 70% ethanol can preserve the biomechanical strength and biochemical properties of tendons to the greatest extent, and these two sterilization methods are worthy of further promotion. CI - © 2022 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd. FAU - Zhang, Hao-Ran AU - Zhang HR AUID- ORCID: 0000-0002-7929-9003 AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. FAU - Xu, Ming-You AU - Xu MY AUID- ORCID: 0000-0001-8957-6572 AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Zhang, Lei AU - Zhang L AD - Beijing Wonderful Medical Biomaterial Co. Ltd., Beijing, China. FAU - Zhang, Hao AU - Zhang H AUID- ORCID: 0000-0002-7377-0589 AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Yang, Li AU - Yang L AUID- ORCID: 0000-0002-0220-6200 AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Liu, Jie AU - Liu J AD - Graduate School, Tianjin Medical University, Tianjin, China. FAU - Zhang, Jing-Yu AU - Zhang JY AUID- ORCID: 0000-0003-4924-6418 AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. FAU - Hu, Yong-Cheng AU - Hu YC AUID- ORCID: 0000-0002-9846-6735 AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. LA - eng PT - Journal Article DEP - 20220824 PL - Australia TA - Orthop Surg JT - Orthopaedic surgery JID - 101501666 RN - 0 (Nucleic Acids) RN - 3K9958V90M (Ethanol) RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - Allografts MH - Biomechanical Phenomena MH - Ethanol MH - Gamma Rays MH - Humans MH - *Nucleic Acids MH - *Peracetic Acid/pharmacology MH - Sterilization/methods MH - Tendons PMC - PMC9531057 OTO - NOTNLM OT - Biochemistry OT - Biomechanical property OT - Gamma irradiation OT - Histology OT - Peracetic acid OT - Tendon allograft EDAT- 2022/09/03 06:00 MHDA- 2022/10/06 06:00 PMCR- 2022/08/24 CRDT- 2022/09/02 14:23 PHST- 2022/07/10 00:00 [revised] PHST- 2021/04/18 00:00 [received] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/09/03 06:00 [pubmed] PHST- 2022/10/06 06:00 [medline] PHST- 2022/09/02 14:23 [entrez] PHST- 2022/08/24 00:00 [pmc-release] AID - OS13465 [pii] AID - 10.1111/os.13465 [doi] PST - ppublish SO - Orthop Surg. 2022 Oct;14(10):2657-2668. doi: 10.1111/os.13465. Epub 2022 Aug 24. PMID- 9330151 OWN - NLM STAT- MEDLINE DCOM- 19971202 LR - 20151119 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 22 IP - 5 DP - 1997 Sep TI - Comparison of transthecal and subcutaneous single-injection digital block techniques in cadaver hands. PG - 897-900 AB - A controlled, randomized single-blinded study was performed on the thumbs and little fingers of 20 cadaver hands. The digits were randomly divided into 2 groups. In the transthecal group, 2 mL of 0.5% methylene blue was injected into the tendon sheath at the A1 pulley. In the subcutaneous group, the same amount of dye was injected into the subcutaneous tissue superficial to the A1 pulley. The injections were performed by 2 investigators. They exchanged specimens and performed dissections on the injected digits without knowledge of which technique had been used. The distributions of dye along the digit and the color intensity of the dye on the digital nerves were studied. There was no significant difference (p > .05) between results for the 2 techniques. It was expected that both techniques would result in similar anesthetic distribution in the clinical setting. In the transthecal group, intra-articular staining of the metacarpophalangeal joint was noted in 3 little fingers and 1 thumb. This complication did not occur in the subcutaneous group. This difference was significant (p < .05). FAU - Low, C K AU - Low CK AD - Department of Orthopaedic Surgery, University of California, San Francisco, USA. FAU - Vartany, A AU - Vartany A FAU - Diao, E AU - Diao E LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - T42P99266K (Methylene Blue) SB - IM MH - Cadaver MH - Fingers/*innervation MH - Humans MH - Injections MH - Injections, Subcutaneous MH - Methylene Blue/pharmacokinetics MH - Nerve Block/*methods MH - Single-Blind Method MH - Tendons MH - Thumb/innervation EDAT- 1997/10/23 00:00 MHDA- 1997/10/23 00:01 CRDT- 1997/10/23 00:00 PHST- 1997/10/23 00:00 [pubmed] PHST- 1997/10/23 00:01 [medline] PHST- 1997/10/23 00:00 [entrez] AID - S0363-5023(97)80087-1 [pii] AID - 10.1016/S0363-5023(97)80087-1 [doi] PST - ppublish SO - J Hand Surg Am. 1997 Sep;22(5):897-900. doi: 10.1016/S0363-5023(97)80087-1. PMID- 4265287 OWN - NLM STAT- MEDLINE DCOM- 19730323 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 248 IP - 3 DP - 1973 Feb 10 TI - Myosin adenosine triphosphatase activity during work-induced growth of slow and fast skeletal muscle in the normal rat. PG - 1056-62 FAU - Jablecki, C AU - Jablecki C FAU - Kaufman, S AU - Kaufman S LA - eng PT - Journal Article PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Chlorides) RN - 0 (Macromolecular Substances) RN - 0 (Peptides) RN - 9G34HU7RV0 (Edetic Acid) RN - EC 3.6.1.- (Adenosine Triphosphatases) RN - EC 3.6.4.1 (Myosins) RN - I38ZP9992A (Magnesium) RN - M4I0D6VV5M (Calcium Chloride) SB - IM MH - Adenosine Triphosphatases/*metabolism MH - Age Factors MH - Animals MH - Animals, Newborn MH - Calcium Chloride/pharmacology MH - Chlorides/pharmacology MH - Drug Stability MH - Edetic Acid/pharmacology MH - Electrophoresis, Polyacrylamide Gel MH - Hindlimb MH - Hydrogen-Ion Concentration MH - Hypertrophy/enzymology MH - Macromolecular Substances MH - Magnesium/pharmacology MH - Muscle Development MH - Muscles/anatomy & histology/*enzymology/physiology MH - Myosins/*metabolism MH - Organ Size MH - Peptides MH - Physical Exertion MH - Rats MH - Tendons/physiology OID - NASA: 73087042 EDAT- 1973/02/10 00:00 MHDA- 1973/02/10 00:01 CRDT- 1973/02/10 00:00 PHST- 1973/02/10 00:00 [pubmed] PHST- 1973/02/10 00:01 [medline] PHST- 1973/02/10 00:00 [entrez] AID - S0021-9258(19)44370-6 [pii] PST - ppublish SO - J Biol Chem. 1973 Feb 10;248(3):1056-62. PMID- 9192518 OWN - NLM STAT- MEDLINE DCOM- 19971002 LR - 20190831 IS - 0171-967X (Print) IS - 0171-967X (Linking) VI - 61 IP - 1 DP - 1997 Jul TI - Effect of sodium chloride solutions on mineralized and unmineralized turkey leg tendon. PG - 74-6 AB - Previous studies showed that the equatorial diffraction spacing of the collagen molecules in mineralized tissues decreases when the tissue is dried and that the spacing in totally dried tissue is about the same (1.1 nm) whether mineralized or not. Here we report that spacing decreases were observed in both mineralized and unmineralized turkey leg tendon after soaking in various sodium chloride solutions up to 4.0 M concentration. The effect was seen by X-ray diffraction as well as by neutron diffraction. No effect was seen in turkey leg tendon soaked in 3.0 M ethylene glycol solution. The spacing in unmineralized tissue decreased from 1.459 +/- 0.011 nm in 0.15 M saline to 1.403 +/- 0.025 nm in 1.5 M saline, a change of 0.056 +/- 0.03 nm or 3.84%. In mineralized turkey leg tendon the corresponding spacings were 1.387 +/- 0.012 and 1.321 +/- 0.019 nm, a change of 0.046 +/- 0.02 nm or 3.4%. No significant dimensional change was noted in the thickness even though the equatorial diffraction spacing decreased by 3.4%. Electron microscopy showed the collagen fibrils within the mineralized turkey leg tendon to be surrounded by highly mineralized material. Presumably the composition of the extrafibrillar material is different from the intrafibrillar and therefore the extrafibrillar material is a different kind of composite. If it is assumed that the extrafibrillar material does not change dimensions significantly, then the collagen molecules in the fibrils can be mobile within the dimensionally stable cage-like structure. FAU - Lees, S AU - Lees S AD - Forsyth Dental Center, 140 Fenway, Boston, Massachusetts 02115, USA. FAU - Capel, M AU - Capel M FAU - Hukins, D W AU - Hukins DW FAU - Mook, H A AU - Mook HA LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Calcif Tissue Int JT - Calcified tissue international JID - 7905481 RN - 0 (Ethylene Glycols) RN - 451W47IQ8X (Sodium Chloride) RN - 9007-34-5 (Collagen) RN - FC72KVT52F (Ethylene Glycol) SB - IM MH - Animals MH - Calcification, Physiologic/*drug effects MH - Collagen/*metabolism MH - Crystallography/methods MH - Dose-Response Relationship, Drug MH - Ethylene Glycol MH - Ethylene Glycols/*pharmacology MH - Extremities MH - Rats MH - Sodium Chloride/*pharmacology MH - Tail MH - Tendons/*drug effects/physiology MH - Turkeys MH - X-Ray Diffraction EDAT- 1997/07/01 00:00 MHDA- 1997/07/01 00:01 CRDT- 1997/07/01 00:00 PHST- 1997/07/01 00:00 [pubmed] PHST- 1997/07/01 00:01 [medline] PHST- 1997/07/01 00:00 [entrez] AID - 10.1007/s002239900298 [doi] PST - ppublish SO - Calcif Tissue Int. 1997 Jul;61(1):74-6. doi: 10.1007/s002239900298. PMID- 4429037 OWN - NLM STAT- MEDLINE DCOM- 19750201 LR - 20190622 IS - 0065-2598 (Print) IS - 0065-2598 (Linking) VI - 48 IP - 0 DP - 1974 TI - Copper and amine oxidases in connective tissue metabolism. PG - 267-84 FAU - Harris, E D AU - Harris ED FAU - O'Dell, B L AU - O'Dell BL LA - eng PT - Journal Article PL - United States TA - Adv Exp Med Biol JT - Advances in experimental medicine and biology JID - 0121103 RN - 0 (Amino Acids) RN - 0 (Benzyl Compounds) RN - 151-18-8 (Aminopropionitrile) RN - 789U1901C5 (Copper) RN - 9007-34-5 (Collagen) RN - 9007-58-3 (Elastin) RN - EC 1.5.- (Oxidoreductases Acting on CH-NH Group Donors) RN - K3Z4F929H6 (Lysine) SB - IM MH - Amino Acids/analysis MH - Aminopropionitrile/pharmacology MH - Animals MH - Aorta/enzymology/metabolism MH - Benzyl Compounds MH - Binding Sites MH - Cattle MH - Chickens MH - Chromatography, DEAE-Cellulose MH - Collagen/metabolism MH - Connective Tissue/*metabolism MH - Copper/deficiency/*metabolism MH - Diet MH - Elastin/metabolism MH - Electrophoresis, Disc MH - Lathyrism/metabolism MH - Lysine MH - Oxidoreductases Acting on CH-NH Group Donors/*metabolism MH - Protein Binding MH - Swine MH - Tendons/enzymology EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 10.1007/978-1-4684-0943-7_13 [doi] PST - ppublish SO - Adv Exp Med Biol. 1974;48(0):267-84. doi: 10.1007/978-1-4684-0943-7_13. PMID- 9688505 OWN - NLM STAT- MEDLINE DCOM- 19980911 LR - 20190512 IS - 0021-8782 (Print) IS - 1469-7580 (Electronic) IS - 0021-8782 (Linking) VI - 192 ( Pt 3) IP - Pt 3 DP - 1998 Apr TI - The structure of interfibrillar proteoglycan bridges (shape modules') in extracellular matrix of fibrous connective tissues and their stability in various chemical environments. PG - 391-405 AB - Collagen fibrils in extracellular matrices of connective tissues (tendon, cornea, etc.) are bridged and linked by the anionic glycosaminoglycans (AGAGs) of the small proteoglycans (decoron, etc.). It was proposed that these bridges and ties maintain the collagen fibril dispositions in relation to each other, helping to define tissue shape, and hence called shape modules. This investigation describes chemical and physicochemical conditions in which these structures are stable and what treatments cause their disruption. The effects on fixed and unfixed sections of tendon, cornea, lung and ear from rat, mouse and rabbit of pH, electrolyte concentration, EDTA, mercaptoethanol, hydrogen peroxide, free radicals, periodate, acetylation, urea, nonionic detergent and organic solvents were assessed by staining with Cupromeronic blue or Alcec blue in CEC techniques to localise AGAG bridges or their disintegration products. Ca2+ was not involved in the structures, oxidation/reduction had no effect and Triton X100, a nonionic detergent did not damage them. They were stable between pH 4.5 and 9.5. Periodate as a glycol-cleaving reagent did not affect them. High concentrations of urea (> 2.0 M) and MgCl2 (0.5 M) disrupted the tissues. The combination of Triton and urea at concentrations too low to cause damage separately was disruptive. Free radicals in periodate solutions were damaging. Organic solvents caused collapse and rearrangements of the AGAG filaments. Acetylation caused considerable disruption of shape modules. Dermochondan but not keratan sulphate AGAGs were removed by treatment with NaOH. After fixing with glutaraldehyde only free radical and NaOH treatments were severely disruptive of shape modules. The results are compatible with a previously proposed structure for the shape modules, stabilised by hydrophobic and hydrogen bonding. FAU - Scott, J E AU - Scott JE AD - Department of Chemical Morphology, Manchester University, UK. FAU - Thomlinson, A M AU - Thomlinson AM LA - eng PT - Journal Article PL - England TA - J Anat JT - Journal of anatomy JID - 0137162 RN - 0 (Caustics) RN - 0 (Coloring Agents) RN - 0 (Detergents) RN - 0 (Free Radicals) RN - 0 (Proteoglycans) RN - 10450-60-9 (Periodic Acid) RN - 55X04QC32I (Sodium Hydroxide) RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) RN - 9056-36-4 (Keratan Sulfate) RN - B45A1BUM4Q (metaperiodate) RN - T3C89M417N (Glutaral) SB - IM MH - Acetylation MH - Animals MH - Caustics/pharmacology MH - Collagen/*ultrastructure MH - Coloring Agents MH - Connective Tissue/chemistry/drug effects/*ultrastructure MH - Cornea/drug effects/ultrastructure MH - Detergents/pharmacology MH - Ear MH - Extracellular Matrix/chemistry/drug effects/*ultrastructure MH - Free Radicals/pharmacology MH - Glutaral MH - Hydrogen-Ion Concentration MH - Keratan Sulfate/analysis MH - Lung/drug effects/ultrastructure MH - Mice MH - Microscopy, Electron MH - Periodic Acid/pharmacology MH - Proteoglycans/*ultrastructure MH - Rabbits MH - Rats MH - Sodium Hydroxide/pharmacology MH - Tendons/drug effects/ultrastructure MH - Tissue Fixation MH - Urea/pharmacology PMC - PMC1467783 EDAT- 1998/08/04 00:00 MHDA- 1998/08/04 00:01 PMCR- 2000/04/01 CRDT- 1998/08/04 00:00 PHST- 1998/08/04 00:00 [pubmed] PHST- 1998/08/04 00:01 [medline] PHST- 1998/08/04 00:00 [entrez] PHST- 2000/04/01 00:00 [pmc-release] AID - 10.1046/j.1469-7580.1998.19230391.x [doi] PST - ppublish SO - J Anat. 1998 Apr;192 ( Pt 3)(Pt 3):391-405. doi: 10.1046/j.1469-7580.1998.19230391.x. PMID- 23348249 OWN - NLM STAT- MEDLINE DCOM- 20131112 LR - 20171116 IS - 1569-1802 (Electronic) IS - 0945-053X (Linking) VI - 32 IP - 3-4 DP - 2013 Apr 24 TI - Advanced glycation end-products diminish tendon collagen fiber sliding. PG - 169-77 LID - S0945-053X(13)00004-8 [pii] LID - 10.1016/j.matbio.2013.01.003 [doi] AB - Connective tissue aging and diabetes related comorbidity are associated with compromised tissue function, increased susceptibility to injury, and reduced healing capacity. This has been partly attributed to collagen cross-linking by advanced glycation end-products (AGEs) that accumulate with both age and disease. While such cross-links are believed to alter the physical properties of collagen structures and tissue behavior, existing data relating AGEs to tendon mechanics is contradictory. In this study, we utilized a rat tail tendon model to quantify the micro-mechanical repercussion of AGEs at the collagen fiber-level. Individual tendon fascicles were incubated with methylglyoxal (MGO), a naturally occurring metabolite known to form AGEs. After incubation in MGO solution or buffer only, tendons were stretched on the stage of a multiphoton confocal microscope and individual collagen fiber stretch and relative fiber sliding were quantified. Treatment by MGO yielded increased fluorescence and elevated denaturation temperatures as found in normally aged tissue, confirming formation of AGEs and related cross-links. No apparent ultrastructural changes were noted in transmission electron micrographs of cross-linked fibrils. MGO treatment strongly reduced tissue stress relaxation (p<0.01), with concomitantly increased tissue yield stress (p<0.01) and ultimate failure stress (p=0.036). MGO did not affect tangential modulus in the linear part of the stress-strain curve (p=0.46). Microscopic analysis of collagen fiber kinematics yielded striking results, with MGO treatment drastically reducing fiber-sliding (p<0.01) with a compensatory increase in fiber-stretch (p<0.01). We thus conclude that the main mechanical effect of AGEs is a loss of tissue viscoelasticity driven by matrix-level loss of fiber-fiber sliding. This has potentially important implications to tissue damage accumulation, mechanically regulated cell signaling, and matrix remodeling. It further highlights the importance of assessing viscoelasticity - not only elastic response - when considering age-related changes in the tendon matrix and connective tissue in general. CI - Copyright © 2013 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved. FAU - Li, Yufei AU - Li Y AD - Department of Orthopaedics, Balgrist Hospital, University of Zurich, Switzerland. FAU - Fessel, Gion AU - Fessel G FAU - Georgiadis, Marios AU - Georgiadis M FAU - Snedeker, Jess G AU - Snedeker JG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130121 PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Fibrillar Collagens) RN - 0 (Glycation End Products, Advanced) RN - 722KLD7415 (Pyruvaldehyde) SB - IM MH - Aging MH - Animals MH - Biomechanical Phenomena MH - Elastic Modulus MH - Extracellular Matrix/physiology/ultrastructure MH - Fibrillar Collagens/ultrastructure MH - Glycation End Products, Advanced/pharmacology/*physiology MH - In Vitro Techniques MH - Pyruvaldehyde/pharmacology MH - Rats MH - Stress, Physiological MH - Tendons/*physiology/ultrastructure MH - Transition Temperature MH - Viscosity EDAT- 2013/01/26 06:00 MHDA- 2013/11/13 06:00 CRDT- 2013/01/26 06:00 PHST- 2012/10/11 00:00 [received] PHST- 2013/01/07 00:00 [revised] PHST- 2013/01/07 00:00 [accepted] PHST- 2013/01/26 06:00 [entrez] PHST- 2013/01/26 06:00 [pubmed] PHST- 2013/11/13 06:00 [medline] AID - S0945-053X(13)00004-8 [pii] AID - 10.1016/j.matbio.2013.01.003 [doi] PST - ppublish SO - Matrix Biol. 2013 Apr 24;32(3-4):169-77. doi: 10.1016/j.matbio.2013.01.003. Epub 2013 Jan 21. PMID- 17412787 OWN - NLM STAT- MEDLINE DCOM- 20070920 LR - 20131121 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 103 IP - 2 DP - 2007 Aug TI - Unloaded rat Achilles tendons continue to grow, but lose viscoelasticity. PG - 459-63 AB - Tendons can function as springs and thereby preserve energy during cyclic loading. They might also have damping properties, which, hypothetically, could reduce risk of microinjuries due to fatigue at sites of local stress concentration within the tendon. At mechanical testing, damping will appear as hysteresis. How is damping influenced by training or disuse? Does training decrease hysteresis, thereby making the tendon a better spring, or increase hysteresis and thus improve damping? Seventy-eight female 10-wk-old Sprague-Dawley rats were randomized to three groups. Two groups had botulinum toxin injected into the calf muscles to unload the left Achilles tendon through muscle paralysis. One of these groups was given doxycycline, as a systemic matrix metalloproteinase inhibitor. The third group served as loaded controls. The Achilles tendons were harvested after 1 or 6 wk for biomechanical testing. An increase with time was seen in tendon dry weight, wet weight, water content, transverse area, length, stiffness, force at failure, and energy uptake in all three groups (P < 0.001 for each parameter). Disuse had no effect on these parameters. Creep was decreased with time in all groups. The only significant effect of disuse was on hysteresis (P = 0.004) and creep (P = 0.007), which both decreased with disuse compared with control, and on modulus, which was increased (P = 0.008). Normalized glycosaminoglycan content was unaffected by time and disuse. No effect of doxycycline was observed. The results suggest that in growing animals, the tendons continue to grow regardless of mechanical loading history, whereas maintenance of damping properties requires mechanical stimulation. FAU - Eliasson, Pernilla AU - Eliasson P AD - Division of Orthopaedics, Department of Neuroscience and Locomotion, Faculty of Health Sciences, Linköping University, Linköping, Sweden. FAU - Fahlgren, Anna AU - Fahlgren A FAU - Pasternak, Björn AU - Pasternak B FAU - Aspenberg, Per AU - Aspenberg P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070405 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Proteoglycans) RN - 9007-34-5 (Collagen) RN - EC 3.4.- (Metalloproteases) RN - N12000U13O (Doxycycline) SB - IM CIN - J Appl Physiol (1985). 2007 Aug;103(2):423-4. doi: 10.1152/japplphysiol.00426.2007. PMID: 17446408 MH - Achilles Tendon/drug effects/*growth & development/*physiology MH - Animals MH - Biomechanical Phenomena MH - Collagen/physiology MH - Doxycycline/pharmacology MH - Elasticity MH - Female MH - Hindlimb Suspension/*physiology MH - Metalloproteases/antagonists & inhibitors MH - Models, Animal MH - Proteoglycans/physiology MH - Rats MH - Rats, Sprague-Dawley MH - Weight-Bearing/physiology EDAT- 2007/04/07 09:00 MHDA- 2007/09/21 09:00 CRDT- 2007/04/07 09:00 PHST- 2007/04/07 09:00 [pubmed] PHST- 2007/09/21 09:00 [medline] PHST- 2007/04/07 09:00 [entrez] AID - 01333.2006 [pii] AID - 10.1152/japplphysiol.01333.2006 [doi] PST - ppublish SO - J Appl Physiol (1985). 2007 Aug;103(2):459-63. doi: 10.1152/japplphysiol.01333.2006. Epub 2007 Apr 5. PMID- 10885733 OWN - NLM STAT- MEDLINE DCOM- 20001013 LR - 20190815 IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 21 IP - 15 DP - 2000 Aug TI - Tendon cell contraction of collagen-GAG matrices in vitro: effect of cross-linking. PG - 1607-19 AB - The contraction of connective tissue cells can play important roles in wound healing and pathological contractures. The effects of this contractile behavior on cell-seeded constructs for tissue engineering have not yet been investigated. The goal of this work was to investigate in vitro tendon cell-mediated contraction of collagen-glycosaminoglycan (GAG) matrices cross-linked using selected methods. Highly porous collagen-GAG sponges were seeded with calf tendon cells and the projected area and DNA content of the sponges measured at 3, 7, 14, and 21 days post-seeding. Immunohistochemistry was performed to determine if alpha-smooth muscle actin (SMA) was associated with the cell contraction of the matrices. Dehydrothermal (DHT) treatment alone was not sufficient to resist contraction by the seeded tendon fibroblasts. Cross-linking of the collagen-GAG sponges to the extent that the modulus was three times that of sponges treated by DHT alone was necessary to resist contraction. SMA was seen in the cytoplasm of most cells in all sponges at all time periods. The results provide a rational basis for the determination of the mechanical properties of collagen matrices required for engineering certain connective tissues. FAU - Torres, D S AU - Torres DS AD - Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, USA. FAU - Freyman, T M AU - Freyman TM FAU - Yannas, I V AU - Yannas IV FAU - Spector, M AU - Spector M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Cross-Linking Reagents) RN - 0 (Glycosaminoglycans) RN - 0 (collagen-glycosaminoglycan copolymer) RN - 9007-34-5 (Collagen) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Cattle MH - Cell Division/drug effects/radiation effects MH - Cells, Cultured MH - *Collagen/chemistry MH - Cross-Linking Reagents MH - Extracellular Matrix MH - Fibroblasts/cytology/physiology MH - Glutaral/pharmacology MH - *Glycosaminoglycans/chemistry MH - Patella MH - Tendons/cytology/*physiology MH - Ultraviolet Rays MH - Wound Healing EDAT- 2000/07/08 11:00 MHDA- 2000/10/21 11:01 CRDT- 2000/07/08 11:00 PHST- 2000/07/08 11:00 [pubmed] PHST- 2000/10/21 11:01 [medline] PHST- 2000/07/08 11:00 [entrez] AID - S014296120000051X [pii] AID - 10.1016/s0142-9612(00)00051-x [doi] PST - ppublish SO - Biomaterials. 2000 Aug;21(15):1607-19. doi: 10.1016/s0142-9612(00)00051-x. PMID- 29352963 OWN - NLM STAT- MEDLINE DCOM- 20180405 LR - 20240330 IS - 1095-564X (Electronic) IS - 0012-1606 (Print) IS - 0012-1606 (Linking) VI - 435 IP - 2 DP - 2018 Mar 15 TI - Three-dimensional visualization of extracellular matrix networks during murine development. PG - 122-129 LID - S0012-1606(17)30543-2 [pii] LID - 10.1016/j.ydbio.2017.12.022 [doi] AB - The extracellular matrix (ECM) plays a crucial role in embryogenesis, serving both as a substrate to which cells attach and as an active regulator of cell behavior. However, little is known about the spatiotemporal expression patterns and 3D structure of ECM proteins during embryonic development. The lack of suitable methods to visualize the embryonic ECM is largely responsible for this gap, posing a major technical challenge for biologists and tissue engineers. Here, we describe a method of viewing the 3D organization of the ECM using a polyacrylamide-based hydrogel to provide a 3D framework within developing murine embryos. After removal of soluble proteins using sodium dodecyl sulfate, confocal microscopy was used to visualize the 3D distribution of independent ECM networks in multiple developing tissues, including the forelimb, eye, and spinal cord. Comparative analysis of E12.5 and E14.5 autopods revealed proteoglycan-rich fibrils maintain connections between the epidermis and the underlying tendon and cartilage, indicating a role for the ECM during musculoskeletal assembly and demonstrating that our method can be a powerful tool for defining the spatiotemporal distribution of the ECM during embryogenesis. CI - Copyright © 2018 Elsevier Inc. All rights reserved. FAU - Acuna, Andrea AU - Acuna A AD - Weldon School of Biomedical Engineering, Purdue University, 206 South Martin Jischke Drive, West Lafayette, IN 47907, USA. FAU - Drakopoulos, Michael A AU - Drakopoulos MA AD - Weldon School of Biomedical Engineering, Purdue University, 206 South Martin Jischke Drive, West Lafayette, IN 47907, USA. FAU - Leng, Yue AU - Leng Y AD - Weldon School of Biomedical Engineering, Purdue University, 206 South Martin Jischke Drive, West Lafayette, IN 47907, USA. FAU - Goergen, Craig J AU - Goergen CJ AD - Weldon School of Biomedical Engineering, Purdue University, 206 South Martin Jischke Drive, West Lafayette, IN 47907, USA. FAU - Calve, Sarah AU - Calve S AD - Weldon School of Biomedical Engineering, Purdue University, 206 South Martin Jischke Drive, West Lafayette, IN 47907, USA. Electronic address: scalve@purdue.edu. LA - eng GR - DP2 AT009833/AT/NCCIH NIH HHS/United States GR - R01 AR071359/AR/NIAMS NIH HHS/United States GR - R03 AR065201/AR/NIAMS NIH HHS/United States GR - R21 AR069248/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20180117 PL - United States TA - Dev Biol JT - Developmental biology JID - 0372762 RN - 0 (Acrylic Resins) RN - 0 (Detergents) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fluorescent Dyes) RN - 0 (Hydrogels) RN - 0 (Polymers) RN - 0 (Proteoglycans) RN - 1HG84L3525 (Formaldehyde) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 9003-05-8 (polyacrylamide) RN - Y19UC83H8E (paraform) SB - IM MH - Acrylic Resins MH - Animals MH - Detergents/pharmacology MH - *Embryonic Development MH - Epidermis/ultrastructure MH - Extracellular Matrix/*ultrastructure MH - Extracellular Matrix Proteins/drug effects/ultrastructure MH - Fluorescent Dyes MH - Forelimb/embryology/ultrastructure MH - Formaldehyde MH - Hydrogels MH - Mice MH - Mice, Inbred C57BL MH - Microscopy, Confocal/*methods MH - Morphogenesis MH - Polymers MH - Proteoglycans/analysis MH - Sodium Dodecyl Sulfate/pharmacology MH - Specimen Handling MH - Staining and Labeling/methods MH - Tendons/embryology/ultrastructure MH - Tissue Embedding/*methods MH - Tissue Fixation PMC - PMC6097807 MID - NIHMS936395 OTO - NOTNLM OT - Decellularization OT - Extracellular matrix OT - Morphogenesis OT - Mouse embryo COIS- Competing interests The authors declare no competing interests. EDAT- 2018/01/22 06:00 MHDA- 2018/04/06 06:00 PMCR- 2019/03/15 CRDT- 2018/01/22 06:00 PHST- 2017/08/10 00:00 [received] PHST- 2017/12/16 00:00 [revised] PHST- 2017/12/30 00:00 [accepted] PHST- 2018/01/22 06:00 [pubmed] PHST- 2018/04/06 06:00 [medline] PHST- 2018/01/22 06:00 [entrez] PHST- 2019/03/15 00:00 [pmc-release] AID - S0012-1606(17)30543-2 [pii] AID - 10.1016/j.ydbio.2017.12.022 [doi] PST - ppublish SO - Dev Biol. 2018 Mar 15;435(2):122-129. doi: 10.1016/j.ydbio.2017.12.022. Epub 2018 Jan 17. PMID- 19637057 OWN - NLM STAT- MEDLINE DCOM- 20091008 LR - 20220408 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 50 IP - 4 DP - 2009 TI - Glutaraldehyde cross-linking of tendon--mechanical effects at the level of the tendon fascicle and fibril. PG - 211-22 LID - 10.1080/03008200802610040 [doi] AB - Conclusive insight into the microscopic principles that govern the strength of tendon and related connective tissues is lacking and the importance of collagen cross-linking has not been firmly established. The combined application of whole-tissue mechanical testing and atomic force spectroscopy allowed for a detailed characterization of the effect of cross-linking in rat-tail tendon. The cross-link inducing agent glutaraldehyde augmented the tensile strength of tendon fascicles. Stress at failure increased from approximately 8 MPa to approximately 39 MPa. The mechanical effects of glutaraldehyde at the tendon fibril level were examined by atomic force microscopy. Peak forces increased from approximately 1379 to approximately 2622 pN while an extended Hertz fit of force-indentation data showed a approximately 24 fold increase in Young's modulus on indentation. The effect of glutaraldehyde cross-linking on the tensile properties of a single collagen fibril was investigated by a novel methodology based on atomic force spectroscopy. The Young's modulus of a secluded fibril increased from approximately 407 MPa to approximately 1.1 GPa with glutaraldehyde treatment. Collectively, the findings indicate that cross-linking at the level of the collagen fibril is of key importance for the mechanical strength of tendon tissue. However, when comparing the effects at the level of the tendon fascicle and fibril, respectively, further questions are prompted regarding the pathways of force through the tendon microstructure as fibril strength seems to surpass that of the tendon fascicle. FAU - Hansen, Philip AU - Hansen P AD - Institute of Sports Medicine Copenhagen, Bispebjerg Hospital & Centre for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Hassenkam, Tue AU - Hassenkam T FAU - Svensson, Rene Bruggebusch AU - Svensson RB FAU - Aagaard, Per AU - Aagaard P FAU - Trappe, Todd AU - Trappe T FAU - Haraldsson, Bjarki Thor AU - Haraldsson BT FAU - Kjaer, Michael AU - Kjaer M FAU - Magnusson, Peter AU - Magnusson P LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Cross-Linking Reagents) RN - 9007-34-5 (Collagen) RN - T3C89M417N (Glutaral) SB - IM MH - Animals MH - Collagen/*drug effects/physiology/ultrastructure MH - Cross-Linking Reagents/*pharmacology MH - Glutaral/*pharmacology MH - Male MH - Rats MH - Rats, Wistar MH - Spectrum Analysis/methods MH - Stress, Mechanical MH - Tendons/*drug effects/physiology MH - Tensile Strength/*drug effects/physiology EDAT- 2009/07/29 09:00 MHDA- 2009/10/09 06:00 CRDT- 2009/07/29 09:00 PHST- 2009/07/29 09:00 [entrez] PHST- 2009/07/29 09:00 [pubmed] PHST- 2009/10/09 06:00 [medline] AID - 913458330 [pii] AID - 10.1080/03008200802610040 [doi] PST - ppublish SO - Connect Tissue Res. 2009;50(4):211-22. doi: 10.1080/03008200802610040. PMID- 7077530 OWN - NLM STAT- MEDLINE DCOM- 19820722 LR - 20131121 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 221 IP - 2 DP - 1982 May TI - Effects of lidocaine on conduction through depolarized canine false tendons and on a model of reflected reentry. PG - 353-61 AB - Reflected reentry was produced in canine false tendons, mounted in a three-chamber bath, in which the central fiber segment was partially depolarized with an "ischemic" solution to provide an area of impaired conduction. Lidocaine (3-5 mg/l) added to the central chamber further impaired conduction; consequently, reflections were obtained at lower frequencies and over a wider range of stimulation cycle lengths. Complete block followed drug exposure in some preparations. At moderate stimulation rates, the drug-induced shift of the frequency-dependence of manifest reflected reentries was either arrhythmogenic or antiarrhythmic. The action of lidocaine can be explained on the basis of effects on depressed fast or slow response activity at the boundary regions of the ischemic gap. Under slow response conditions, in false tendons homogeneously exposed to a solution containing 20 mM K+ and 9 mM Ca++, lidocaine delayed propagation or induced complete block. In fibers mounted in a single sucrose gap, the drug increased the current required to reach threshold without significant changes in resting potential, threshold voltage or input resistance. The effect of lidocaine on threshold current was lost in Na+-deficient solutions. Thus, lidocaine impairs conduction through K+-depolarized false tendons, an effect that may be related to the Na+ background current. FAU - Lamanna, V AU - Lamanna V FAU - Antzelevitch, C AU - Antzelevitch C FAU - Moe, G K AU - Moe GK LA - eng GR - HL19487/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 98PI200987 (Lidocaine) RN - 9NEZ333N27 (Sodium) RN - RWP5GA015D (Potassium) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Calcium/pharmacology MH - Dogs MH - Female MH - Lidocaine/*pharmacology MH - Male MH - Membrane Potentials/drug effects MH - Models, Neurological MH - Neural Conduction/*drug effects MH - Potassium/pharmacology MH - Purkinje Fibers/drug effects/physiology MH - Sodium/physiology EDAT- 1982/05/01 00:00 MHDA- 1982/05/01 00:01 CRDT- 1982/05/01 00:00 PHST- 1982/05/01 00:00 [pubmed] PHST- 1982/05/01 00:01 [medline] PHST- 1982/05/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1982 May;221(2):353-61. PMID- 18309503 OWN - NLM STAT- MEDLINE DCOM- 20090420 LR - 20220331 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 129 IP - 2 DP - 2009 Feb TI - High-dose vitamin C supplementation accelerates the Achilles tendon healing in healthy rats. PG - 281-6 LID - 10.1007/s00402-008-0603-0 [doi] AB - INTRODUCTION: This experimental study was performed to assess, whether or not, vitamin C, required during the collagen synthesis, would influence the Achilles tendon healing in a healthy rat model. MATERIALS AND METHODS: The right Achilles tendons of 42 healthy female Wistar Albino rats were completely ruptured. The rats were randomly divided into the vitamin C and control groups and both groups included third, tenth and twenty-first day subgroups. One hundred and fifty milligrams (1.5 cc) of vitamin C and 1.5 cc % 0.9 NaCl were injected once for every 2 days for the vitamin C and control groups, respectively. Qualitative and quantitative microscopic comparisons of the repair tissues of both groups were made on the mentioned days. RESULTS: Angiogenesis was more evident on the third day in the vitamin C group. There was a significant difference between the control and vitamin C groups regarding the type I collagen production on the tenth day. The structure of the repair tissue was almost in the form of regular dense connective tissue at the end of twenty-first day in the vitamin C group. Mean collagen fiber diameter was considerably higher, and the number of active fibroblasts in the repair tissue was slightly elevated in the vitamin C group during the entire healing process. CONCLUSION: High-dose vitamin C supplementation once for every 2 days has stimulating effects on the Achilles tendon healing because of early angiogenesis and increased collagen synthesis in a healthy rat model. Further studies are needed to make clear the mentioned encouraging effects of the vitamin C on the Achilles tendon healing. FAU - Omeroğlu, Suna AU - Omeroğlu S AD - Department of Histology and Embryology, Faculty of Medicine, Gazi University, Ankara, Turkey. FAU - Peker, Tuncay AU - Peker T FAU - Türközkan, Nurten AU - Türközkan N FAU - Omeroğlu, Hakan AU - Omeroğlu H LA - eng PT - Evaluation Study PT - Journal Article DEP - 20080229 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 0 (Vitamins) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Achilles Tendon/*drug effects/injuries MH - Animals MH - Ascorbic Acid/*pharmacology MH - Collagen/biosynthesis MH - Disease Models, Animal MH - Female MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy/metabolism MH - Vitamins/*pharmacology MH - Wound Healing/*drug effects EDAT- 2008/03/01 09:00 MHDA- 2009/04/21 09:00 CRDT- 2008/03/01 09:00 PHST- 2008/01/02 00:00 [received] PHST- 2008/03/01 09:00 [pubmed] PHST- 2009/04/21 09:00 [medline] PHST- 2008/03/01 09:00 [entrez] AID - 10.1007/s00402-008-0603-0 [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2009 Feb;129(2):281-6. doi: 10.1007/s00402-008-0603-0. Epub 2008 Feb 29. PMID- 28690388 OWN - NLM STAT- MEDLINE DCOM- 20180418 LR - 20181202 IS - 2532-1900 (Electronic) IS - 1128-2460 (Print) IS - 1128-2460 (Linking) VI - 36 IP - 1 DP - 2017 Mar TI - (23)Na MRI and myometry to compare eplerenone vs. glucocorticoid treatment in Duchenne dystrophy. PG - 2-13 AB - In this pilot study we tested whether a low dose application of a mild diuretic substance such as eplerenone is beneficial in early stages of Duchenne muscular dystrophy using (23)Na und (1)H imaging, myometry, and clinical testing versus the glucocorticoid gold standard. Two 7-years old patients with DMD were examined on a 3T MRI system. (1)H MRI and (23)Na density-adapted 3-dimensional radial MRI sequences were performed both before and 1, 3 and 6 months after therapy with eplerenone respectively cortisone. We quantified fatty infiltration on T1-weighted images using subcutaneous fat as reference and fat fraction with a two-point DIXON sequence. Muscle oedema was quantified on STIR images and DIXON water maps with background noise as reference. We quantified Na(+) by a muscular tissue concentration sequence with a 51.3mM Na(+) with 5% agarose reference tube. A Na(+) IR-sequence was used for determination of mainly myoplasmic Na(+). Correspondingly myometry of muscles and tendons were assessed. Clinical tests (i.e. 4-steps-test) and blood counts (i.e. K(+)) were done by a pediatrician. Under eplerenone therapy we detected a reduction of muscular oedema, intracellular-weighted sodium IR signal and muscular sodium concentration. The oedema reduction in the DMD patient receiving eplerenone was more pronounced to the patient with cortisone. Myometric-measured tissue parameters such as muscle stiffness had a more pronounced effect in the child treated with eplerenone after a first increase in muscle stiffness both after eplerenone and cortisone treatment. Clinical abilities during both therapies were mostly constant. Eplerenone might be a possible new therapy option in DMD patients. FAU - Glemser, Philip A AU - Glemser PA AD - Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. AD - Institute of Forensic Medicine, University of Heidelberg, Heidelberg, Germany. FAU - Jaeger, Heike AU - Jaeger H AD - Division of Neurophysiology, Ulm University, Ulm, Germany. FAU - Nagel, Armin M AU - Nagel AM AD - Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. AD - Institute of Radiology, University Hospital Erlangen, Erlangen, Germany. FAU - Ziegler, Andreas E AU - Ziegler AE AD - Center for Child and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany. FAU - Simons, David AU - Simons D AD - Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Schlemmer, Heinz-Peter AU - Schlemmer HP AD - Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. FAU - Lehmann-Horn, Frank AU - Lehmann-Horn F AD - Division of Neurophysiology, Ulm University, Ulm, Germany. FAU - Jurkat-Rott, Karin AU - Jurkat-Rott K AD - Department of Neurosurgery, Ulm University, Ulm, Germany. FAU - Weber, Marc-André AU - Weber MA AD - Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany. LA - eng PT - Comparative Study PT - Journal Article PL - Italy TA - Acta Myol JT - Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology JID - 9811169 RN - 0 (Diuretics) RN - 0 (Glucocorticoids) RN - 0 (Pregnenediones) RN - 0 (Sodium Radioisotopes) RN - 27O7W4T232 (Spironolactone) RN - 6995V82D0B (Eplerenone) RN - 7YNJ3PO35Z (Hydrogen) RN - KR5YZ6AE4B (deflazacort) SB - IM MH - Adipose Tissue/diagnostic imaging MH - Child MH - Diuretics/*therapeutic use MH - Edema/diagnostic imaging MH - Elasticity MH - Eplerenone MH - Glucocorticoids/*therapeutic use MH - Humans MH - Hydrogen MH - Imaging, Three-Dimensional MH - *Magnetic Resonance Imaging MH - Male MH - Muscle, Skeletal/physiopathology MH - Muscular Dystrophy, Duchenne/*diagnostic imaging/*drug therapy MH - Pilot Projects MH - Pregnenediones/*therapeutic use MH - Sodium Radioisotopes MH - Spironolactone/*analogs & derivatives/therapeutic use PMC - PMC5479105 OTO - NOTNLM OT - 23Na MRI OT - Duchenne OT - eplerenone EDAT- 2017/07/12 06:00 MHDA- 2018/04/19 06:00 PMCR- 2017/03/01 CRDT- 2017/07/11 06:00 PHST- 2017/07/11 06:00 [entrez] PHST- 2017/07/12 06:00 [pubmed] PHST- 2018/04/19 06:00 [medline] PHST- 2017/03/01 00:00 [pmc-release] AID - Pacini [pii] PST - ppublish SO - Acta Myol. 2017 Mar;36(1):2-13. PMID- 30583679 OWN - NLM STAT- MEDLINE DCOM- 20190408 LR - 20200225 IS - 2476-762X (Electronic) IS - 1513-7368 (Print) IS - 1513-7368 (Linking) VI - 19 IP - 12 DP - 2018 Dec 25 TI - The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer. PG - 3525-3531 AB - Background: Around 50% of women receiving Aromatase Inhibitors (AIs) develop musculoskeletal symptoms which may become severe causing interruption of treatment. Patients with AI-induced arthralgia had higher rates of joint effusions and fluid in the tendons, so use of diuretics may be helpful. Methods: This prospective phase II study was conducted in department of clinical oncology and nuclear medicine, Menoufia University Hospital, Egypt, between Jan. to Dec. 2015. Fifty Women with stage I,II and III breast cancer receiving AIs as adjuvant hormonal treatment complaining of AIs related musculoskeletal symptoms received Lasilactone® 50 mg tablet; (an oral combination of Frusemide 20mg/Spironolactone 50 mg), every other day for 4 weeks. Patients were assessed by modified Western Ontario and McMaster Universities osteoarthritis (WOMAC) index for lower limb and the quick Disabilities of the Arm, Shoulder and Hand Score (DASH) scoring system for upper limbs, Arabic versions, at baseline and after 4 weeks of treatment. Results: The mean WOMAC pain score improved significantly (6.0 v 10; P < 0.001), the mean WOMAC stiffness score improved (2.3 v 3.9; P = 0.002), the mean WOMAC functional score improved (8.7 v 15; P < 0.001), the total WOMAC score improved (17 v 29; P < 0.001), also a significant difference was noticed for the quick DASH score; total score (16 v 25; P = 0.02) After use of diuretics for 4 weeks of treatment compared with baseline scores. Conclusions: The use of diuretics effectively reduces AI related musculoskeletal symptoms with good tolerance. CI - Creative Commons Attribution License FAU - Alhanafy, Alshimaa Mahmoud AU - Alhanafy AM AD - Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Menoufia University, Shebin El kom, Egypt. Email: Alshimaa_Alhanafy@yahoo.com FAU - Labeeb, Alaa AU - Labeeb A FAU - Khalil, Ashraf AU - Khalil A LA - eng PT - Clinical Trial, Phase II PT - Journal Article DEP - 20181225 PL - Thailand TA - Asian Pac J Cancer Prev JT - Asian Pacific journal of cancer prevention : APJCP JID - 101130625 RN - 0 (Aromatase Inhibitors) RN - 0 (Diuretics) RN - 27O7W4T232 (Spironolactone) RN - 7LXU5N7ZO5 (Furosemide) SB - IM MH - Aged MH - Aromatase Inhibitors/*adverse effects/*therapeutic use MH - Arthralgia/drug therapy MH - Breast Neoplasms/*drug therapy MH - Diuretics/*therapeutic use MH - Egypt MH - Female MH - Furosemide/therapeutic use MH - Humans MH - Middle Aged MH - Musculoskeletal Diseases/*chemically induced/*drug therapy MH - Pain/drug therapy MH - Prospective Studies MH - Spironolactone/therapeutic use PMC - PMC6428535 OTO - NOTNLM OT - *Diuretics OT - *aromatase inhibitors OT - *musculoskeletal symptoms EDAT- 2018/12/26 06:00 MHDA- 2019/04/09 06:00 PMCR- 2018/03/01 CRDT- 2018/12/26 06:00 PHST- 2018/12/26 06:00 [entrez] PHST- 2018/12/26 06:00 [pubmed] PHST- 2019/04/09 06:00 [medline] PHST- 2018/03/01 00:00 [pmc-release] AID - APJCP-19-3525 [pii] AID - 10.31557/APJCP.2018.19.12.3525 [doi] PST - epublish SO - Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3525-3531. doi: 10.31557/APJCP.2018.19.12.3525. PMID- 7226464 OWN - NLM STAT- MEDLINE DCOM- 19810720 LR - 20220309 IS - 0009-7330 (Print) IS - 0009-7330 (Linking) VI - 48 IP - 6 Pt 2 DP - 1981 Jun TI - Central projections from ergoreceptors (C fibers) in muscle involved in cardiopulmonary responses to static exercise. PG - I48-62 FAU - Kalia, M AU - Kalia M FAU - Mei, S S AU - Mei SS FAU - Kao, F F AU - Kao FF LA - eng GR - HL-00103/HL/NHLBI NIH HHS/United States GR - HL-04302/HL/NHLBI NIH HHS/United States GR - HL-17800/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 4Z8Y51M438 (Procaine) RN - EC 1.11.1.- (Horseradish Peroxidase) SB - IM MH - Animals MH - Cardiovascular System/*innervation MH - Cats MH - Dogs MH - Horseradish Peroxidase MH - Medulla Oblongata/metabolism MH - Muscles/*innervation MH - Nerve Fibers/*physiology MH - Neurons/metabolism MH - *Physical Exertion MH - Pressure MH - Procaine/pharmacology MH - Rats MH - Spinal Cord/metabolism MH - Tendons/physiology OID - NASA: 81186703 EDAT- 1981/06/01 00:00 MHDA- 1981/06/01 00:01 CRDT- 1981/06/01 00:00 PHST- 1981/06/01 00:00 [pubmed] PHST- 1981/06/01 00:01 [medline] PHST- 1981/06/01 00:00 [entrez] PST - ppublish SO - Circ Res. 1981 Jun;48(6 Pt 2):I48-62. PMID- 2443196 OWN - NLM STAT- MEDLINE DCOM- 19871106 LR - 20191210 IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 7 IP - 2 DP - 1987 Feb TI - The effect of the anabolic agent, clenbuterol, on overloaded rat skeletal muscle. PG - 143-9 AB - The dietary administration of clenbuterol to young male rats has been shown to produce a muscle specific hypertrophic growth response. This paper demonstrates that the combined effect of drug treatment and hypertrophic stimulus induced by tenotomy produced an additive effect on muscle growth. This effect was demonstrated in terms of both muscle composition (protein and RNA) and fibre size. FAU - Maltin, C A AU - Maltin CA AD - Rowett Research Institute, Bucksburn, Aberdeen. FAU - Delday, M I AU - Delday MI FAU - Hay, S M AU - Hay SM FAU - Smith, F G AU - Smith FG FAU - Lobley, G E AU - Lobley GE FAU - Reeds, P J AU - Reeds PJ LA - eng PT - Journal Article PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - 0 (Ethanolamines) RN - 0 (Muscle Proteins) RN - 63231-63-0 (RNA) RN - EC 7.2.2.10 (Calcium-Transporting ATPases) RN - XTZ6AXU7KN (Clenbuterol) SB - IM MH - Animals MH - Calcium-Transporting ATPases/metabolism MH - Clenbuterol/*pharmacology MH - Ethanolamines/*pharmacology MH - Hindlimb MH - Hypertrophy MH - Muscle Proteins/metabolism MH - Muscles/*drug effects/metabolism/pathology MH - RNA/metabolism MH - Rats MH - Stress, Mechanical MH - Tendons/surgery EDAT- 1987/02/01 00:00 MHDA- 1987/02/01 00:01 CRDT- 1987/02/01 00:00 PHST- 1987/02/01 00:00 [pubmed] PHST- 1987/02/01 00:01 [medline] PHST- 1987/02/01 00:00 [entrez] AID - 10.1007/BF01121878 [doi] PST - ppublish SO - Biosci Rep. 1987 Feb;7(2):143-9. doi: 10.1007/BF01121878. PMID- 14758225 OWN - NLM STAT- MEDLINE DCOM- 20040226 LR - 20150624 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 113 IP - 2 DP - 2004 Feb TI - Flexor tendon wound healing in vitro: lactate up-regulation of TGF-beta expression and functional activity. PG - 625-32 AB - Flexor tendon wound healing in zone II is complicated by adhesions to the surrounding fibro-osseous sheath. These adhesions can significantly alter tendon gliding and ultimately hand function. Lactate and transforming growth factor-beta (TGF-beta) are two important mediators of wound healing that have been demonstrated to independently increase collagen production by cells of the tendon sheath, epitenon, and endotenon. This study examined the effects of lactate on TGF-beta peptide and receptor production by flexor tendon cells. Tendon sheath fibroblasts, epitenon tenocytes, and endotenon tenocytes were isolated from rabbit flexor tendons and cultured separately. Cell cultures were supplemented with 50 mM lactate, and the expression of three TGF-beta peptide isoforms (beta1, beta2, and beta3) and three receptor isoforms (R1, R2, and R3) was quantified with enzyme-linked immunosorbent assays. TGF-beta functional activity was also assessed with the addition of tendon cell conditioned media to mink lung epithelial cells transfected with a luciferase reporter gene expression construct responsive to TGF-beta. Supplementation of the cell culture medium with lactate significantly (p < 0.05) increased the expression of all TGF-beta peptide and receptor isoforms in all three cell lines. Tendon sheath fibroblasts exhibited the greatest increases in beta1 and beta2 peptide isoform expression (30 and 23 percent, respectively), whereas endotenon tenocytes demonstrated the greatest increase in beta3 peptide expression (32 percent). Epitenon tenocytes exhibited the greatest increases in receptor isoform R1 and R2 expression (17 and 19 percent, respectively). All three tendon cell types demonstrated significant (p < 0.05) increases in TGF-beta functional activity when exposed to lactate. Epitenon tenocytes demonstrated the greatest increase in activity (>4 times control values), whereas tendon sheath fibroblasts demonstrated the highest overall levels of total TGF-beta functional activity. Lactate significantly increased TGF-beta peptide (beta1, beta2, and beta3) expression, receptor (R1, R2, and R3) expression, and functional activity, suggesting a common pathway regulating tendon cell collagen production. Modulation of lactate and TGF-beta levels may provide a means of modulating the effects of TGF-beta on adhesion formation in flexor tendon wound healing. FAU - Yalamanchi, Naveen AU - Yalamanchi N AD - Division of Plastic Surgery, Stanford University Medical Center, Calif. 94305, USA. FAU - Klein, Matthew B AU - Klein MB FAU - Pham, Hung M AU - Pham HM FAU - Longaker, Michael T AU - Longaker MT FAU - Chang, James AU - Chang J LA - eng PT - Journal Article PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Receptors, Transforming Growth Factor beta) RN - 0 (Transforming Growth Factor beta) RN - 33X04XA5AT (Lactic Acid) SB - IM MH - Animals MH - Biological Assay MH - Cell Line MH - Cells, Cultured MH - Enzyme-Linked Immunosorbent Assay MH - Forelimb MH - Lactic Acid/*pharmacology MH - Male MH - Rabbits MH - Receptors, Transforming Growth Factor beta/biosynthesis MH - Tendon Injuries/metabolism MH - Tendons/cytology/*metabolism MH - Transforming Growth Factor beta/*biosynthesis/pharmacology MH - Up-Regulation MH - *Wound Healing EDAT- 2004/02/06 05:00 MHDA- 2004/02/27 05:00 CRDT- 2004/02/06 05:00 PHST- 2004/02/06 05:00 [pubmed] PHST- 2004/02/27 05:00 [medline] PHST- 2004/02/06 05:00 [entrez] AID - 00006534-200402000-00023 [pii] AID - 10.1097/01.PRS.0000101529.47062.34 [doi] PST - ppublish SO - Plast Reconstr Surg. 2004 Feb;113(2):625-32. doi: 10.1097/01.PRS.0000101529.47062.34. PMID- 4371784 OWN - NLM STAT- MEDLINE DCOM- 19750106 LR - 20191030 IS - 0065-258X (Print) VI - 41 IP - 0 DP - 1974 TI - Prolyl hydroxylase. PG - 245-300 FAU - Cardinale, G J AU - Cardinale GJ FAU - Udenfriend, S AU - Udenfriend S LA - eng PT - Comparative Study PT - Journal Article PT - Review PL - United States TA - Adv Enzymol Relat Areas Mol Biol JT - Advances in enzymology and related areas of molecular biology JID - 0337243 RN - 0 (Amino Acids) RN - 0 (Ketoglutaric Acids) RN - 0 (Oxygen Isotopes) RN - EC 1.- (Mixed Function Oxygenases) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - K3Z4F929H6 (Lysine) RN - RMB44WO89X (Hydroxyproline) RN - S8TIM42R2W (Bradykinin) SB - IM MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Binding Sites MH - Bradykinin MH - Chromatography, Affinity MH - Chromatography, Gel MH - Enzyme Activation/drug effects MH - Hydrogen-Ion Concentration MH - Hydroxyproline/metabolism MH - Isoelectric Focusing MH - Ketoglutaric Acids/pharmacology MH - Kinetics MH - Lysine MH - Mixed Function Oxygenases/metabolism MH - Molecular Weight MH - Oxygen Isotopes MH - *Procollagen-Proline Dioxygenase/antagonists & inhibitors/isolation & purification/metabolism MH - Protein Binding MH - Protein Conformation MH - Skin/metabolism MH - Species Specificity MH - Structure-Activity Relationship MH - Tendons/metabolism MH - Ultracentrifugation RF - 236 EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 10.1002/9780470122860.ch6 [doi] PST - ppublish SO - Adv Enzymol Relat Areas Mol Biol. 1974;41(0):245-300. doi: 10.1002/9780470122860.ch6. PMID- 28761625 OWN - NLM STAT- MEDLINE DCOM- 20180417 LR - 20220330 IS - 1942-0994 (Electronic) IS - 1942-0900 (Print) IS - 1942-0994 (Linking) VI - 2017 DP - 2017 TI - Effects of Redox Modulation on Cell Proliferation, Viability, and Migration in Cultured Rat and Human Tendon Progenitor Cells. PG - 8785042 LID - 10.1155/2017/8785042 [doi] LID - 8785042 AB - Tendon healing is slow and usually results in inferior fibrotic tissue formation. Recently, application of tendon derived stem cells (TDSCs) improved tendon healing in animal studies. In a chicken model, local injection of antioxidants reduced tendon adhesion after tendon injury. An in vitro study demonstrated that supplementation of H(2)O(2) reduced tenogenic marker expression in TDSCs. These findings suggested that the possibility of TDSCs is involved in tendon healing and the cellular activities of TDSCs might be affected by oxidative stress of the local environment. After tendon injury, oxidative stress is increased. Redox modulation might affect healing outcomes via affecting cellular activities in TDSCs. To study the effect of oxidative stress on TDSCs, the cellular activities of rat/human TDSCs were measured under different dosages of vitamin C or H(2)O(2) in this study. Lower dose of vitamin C increased cell proliferation, viability and migration; H(2)O(2) affected colony formation and suppressed cell migration, cell viability, apoptosis, and proliferation. Consistent with previous studies, oxidative stresses (H(2)O(2)) affect both recruitment and survival of TDSCs, while the antioxidant vitamin C may exert beneficial effects at low doses. In conclusion, redox modulation affected cellular activities of TDSCs and might be a potential strategy for tendon healing treatment. FAU - Lee, Yuk Wa AU - Lee YW AUID- ORCID: 0000-0001-6095-7822 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Fu, Sai Chuen AU - Fu SC AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Yeung, Man Yi AU - Yeung MY AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Lau, Chun Man Lawrence AU - Lau CML AD - Department of Orthopaedics and Traumatology, Prince of Wales Hospital, Shatin, Hong Kong. FAU - Chan, Kai Ming AU - Chan KM AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. FAU - Hung, Leung Kim AU - Hung LK AUID- ORCID: 0000-0002-0979-5829 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong. LA - eng PT - Journal Article DEP - 20170702 PL - United States TA - Oxid Med Cell Longev JT - Oxidative medicine and cellular longevity JID - 101479826 RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Cell Movement/*drug effects MH - Cell Proliferation/*drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Humans MH - Hydrogen Peroxide/*pharmacology MH - Oxidative Stress/*drug effects MH - Rats MH - Stem Cells/*metabolism/pathology MH - Tendon Injuries/*metabolism/pathology MH - Tendons/*metabolism/pathology PMC - PMC5518521 EDAT- 2017/08/02 06:00 MHDA- 2018/04/18 06:00 PMCR- 2017/07/02 CRDT- 2017/08/02 06:00 PHST- 2017/01/12 00:00 [received] PHST- 2017/04/26 00:00 [revised] PHST- 2017/05/18 00:00 [accepted] PHST- 2017/08/02 06:00 [entrez] PHST- 2017/08/02 06:00 [pubmed] PHST- 2018/04/18 06:00 [medline] PHST- 2017/07/02 00:00 [pmc-release] AID - 10.1155/2017/8785042 [doi] PST - ppublish SO - Oxid Med Cell Longev. 2017;2017:8785042. doi: 10.1155/2017/8785042. Epub 2017 Jul 2. PMID- 2268305 OWN - NLM STAT- MEDLINE DCOM- 19910214 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 272 IP - 3 DP - 1990 Dec 15 TI - Increased association of ribosomes with myofibrils during the skeletal-muscle hypertrophy induced either by the beta-adrenoceptor agonist clenbuterol or by tenotomy. PG - 831-3 AB - Ribosome distribution in skeletal-muscle myofibres was investigated by immunohistochemistry and microdensitometry by using anti-(60 S ribosomal subunit) antibodies. Administration of the beta-adrenoceptor agonist clenbuterol caused an increase in the staining of the myofibrillar region with this antibody relative to that found in the subsarcolemmal cytoplasm. A similar effect was observed during hypertrophy of the plantaris muscle following severance of the tendon to the gastrocnemius. The results suggest that increased association of ribosomes with the myofibrils occurs during muscle hypertrophy. FAU - Horne, Z AU - Horne Z AD - Division of Biochemical Sciences, Rowett Research Institute, Bucksburn, Aberdeen, U.K. FAU - Hesketh, J AU - Hesketh J LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Antibodies) RN - XTZ6AXU7KN (Clenbuterol) SB - IM MH - Animals MH - Antibodies MH - Clenbuterol/*pharmacology MH - Hypertrophy MH - Male MH - Muscles/drug effects/pathology/*ultrastructure MH - Myofibrils/drug effects/*ultrastructure MH - Rats MH - Rats, Inbred Strains MH - Reference Values MH - Ribosomes/drug effects/*ultrastructure MH - Sarcolemma/drug effects/ultrastructure MH - Tendons/*physiology PMC - PMC1149783 EDAT- 1990/12/15 00:00 MHDA- 1990/12/15 00:01 PMCR- 1991/06/15 CRDT- 1990/12/15 00:00 PHST- 1990/12/15 00:00 [pubmed] PHST- 1990/12/15 00:01 [medline] PHST- 1990/12/15 00:00 [entrez] PHST- 1991/06/15 00:00 [pmc-release] AID - 10.1042/bj2720831 [doi] PST - ppublish SO - Biochem J. 1990 Dec 15;272(3):831-3. doi: 10.1042/bj2720831. PMID- 6722288 OWN - NLM STAT- MEDLINE DCOM- 19840709 LR - 20190606 IS - 0144-8463 (Print) IS - 0144-8463 (Linking) VI - 4 IP - 3 DP - 1984 Mar TI - Catalysis by protein disulphide-isomerase of the assembly of trimeric procollagen from procollagen polypeptide chains. PG - 223-9 AB - Type-I procollagen, 14C-biosynthetically labelled, was reduced under denaturing and non-denaturing conditions. Reoxidation to disulphide-linked trimers occurred with non-denatured chains in the presence of an oxidant system containing oxidized and reduced glutathione. Dimeric intermediates were not detected. This reoxidation was accelerated by homogeneous beef liver protein disulphide-isomerase. FAU - Forster, S J AU - Forster SJ FAU - Freedman, R B AU - Freedman RB LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biosci Rep JT - Bioscience reports JID - 8102797 RN - 0 (Carbon Radioisotopes) RN - 0 (Macromolecular Substances) RN - 0 (Procollagen) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - EC 5.- (Isomerases) RN - EC 5.3.4.1 (Protein Disulfide-Isomerases) RN - GAN16C9B8O (Glutathione) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Chick Embryo MH - Dithiothreitol/pharmacology MH - Glutathione/pharmacology MH - Isomerases/*metabolism MH - Kinetics MH - Macromolecular Substances MH - Molecular Weight MH - Procollagen/isolation & purification/*metabolism MH - Protein Disulfide-Isomerases MH - Sodium Dodecyl Sulfate/pharmacology MH - Tendons/metabolism EDAT- 1984/03/01 00:00 MHDA- 1984/03/01 00:01 CRDT- 1984/03/01 00:00 PHST- 1984/03/01 00:00 [pubmed] PHST- 1984/03/01 00:01 [medline] PHST- 1984/03/01 00:00 [entrez] AID - 10.1007/BF01119657 [doi] PST - ppublish SO - Biosci Rep. 1984 Mar;4(3):223-9. doi: 10.1007/BF01119657. PMID- 17400 OWN - NLM STAT- MEDLINE DCOM- 19770723 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 163 IP - 2 DP - 1977 May 1 TI - The chemistry of the collagen cross-links. Characterization of the products of reduction of skin, tendon and bone with sodium cyanoborohydride. PG - 339-46 AB - Reduction of tissues with sodium cyanoborohydride at pH7.4 gave results identical with those obtained by KBH4 treatment. On reduction with sodium cyanoborohydride at pH 4.4, however, a previously undetected basic compound was formed and was identified by mass spectrometry and chemical degradation techniques as dihydrohydroxymerodesmosine. Histidino-hydroxymerodesmosine was not present, and further analysis confirmed that reduced aldol, a mojor product of reduction with KBH4 at the lower pH, was also absent. These results, together with an analysis of the time course of the reduction, support previous assertions that histidino-hydroxymerodesmosine is an artifact [robins *Bailey (1973) Biochem. J. 135, 657-665] and suggests that the non-reduced form of hydroxymerodesmosine probably does not constitute a major intermolecular bond in vivo. FAU - Robins, S P AU - Robins SP FAU - Bailey, A J AU - Bailey AJ LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Borohydrides) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Binding Sites MH - Bone and Bones/drug effects MH - Borohydrides/pharmacology MH - *Collagen MH - Hydrogen-Ion Concentration MH - Kinetics MH - Mass Spectrometry MH - Rats MH - Skin/drug effects MH - Tendons/drug effects PMC - PMC1164702 EDAT- 1977/05/01 00:00 MHDA- 1977/05/01 00:01 PMCR- 1977/05/01 CRDT- 1977/05/01 00:00 PHST- 1977/05/01 00:00 [pubmed] PHST- 1977/05/01 00:01 [medline] PHST- 1977/05/01 00:00 [entrez] PHST- 1977/05/01 00:00 [pmc-release] AID - 10.1042/bj1630339 [doi] PST - ppublish SO - Biochem J. 1977 May 1;163(2):339-46. doi: 10.1042/bj1630339. PMID- 30217557 OWN - NLM STAT- MEDLINE DCOM- 20190605 LR - 20191026 IS - 1873-2380 (Electronic) IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 80 DP - 2018 Oct 26 TI - Doxycycline improves cage activity, but not exercised, supraspinatus tendon and muscle in a rat model. PG - 79-87 LID - S0021-9290(18)30709-7 [pii] LID - 10.1016/j.jbiomech.2018.08.027 [doi] AB - The objective of this study was to investigate the effects of doxycycline, a broad-spectrum MMP inhibitor, on cage activity and exercised supraspinatus tendon and muscle using a Sprague-Dawley rat model of non-injurious exercise. Because exercise may alter muscle and tendon MMP activity and matrix turnover, we hypothesized that doxycycline would abolish the beneficial adaptations found with exercise but have no effect on cage activity muscle and tendon properties. Rats were divided into acute or chronic exercise (EX) or cage activity (CA) groups, and half of the rats received doxycycline orally. Animals in acute EX groups were euthanized 24 h after a single bout of exercise (10 m/min, 1 h) on a flat treadmill. Animals in chronic EX groups walked on a flat treadmill and were euthanized at 2 or 8 week time points. Assays included supraspinatus tendon mechanics and histology and muscle fiber morphologic and type analysis. Doxycycline improved tendon mechanical properties and collagen organization in chronic cage activity groups, which was not consistently evident in exercised groups. Combined with exercise, doxycycline decreased average muscle fiber cross-sectional area. Results of this study suggest that administration of doxycycline at pharmaceutical doses induces beneficial supraspinatus tendon adaptations without negatively affecting the muscle in cage activity animals, supporting the use of doxycycline to combat degenerative processes associated with underuse; however, when combined with exercise, doxycycline does not consistently produce the same beneficial adaptations in rat supraspinatus tendons and reduces muscle fiber cross-sectional area, suggesting that doxycycline is not advantageous when combined with activity. CI - Copyright © 2018 Elsevier Ltd. All rights reserved. FAU - Rooney, Sarah Ilkhanipour AU - Rooney SI AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Torino, Daniel J AU - Torino DJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Baskin, Rachel AU - Baskin R AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Vafa, Rameen P AU - Vafa RP AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Khandekar, Pooja S AU - Khandekar PS AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Kuntz, Andrew F AU - Kuntz AF AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. FAU - Soslowsky, Louis J AU - Soslowsky LJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: soslowsk@upenn.edu. LA - eng GR - P30 AR050950/AR/NIAMS NIH HHS/United States GR - P30 AR069619/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20180905 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Anti-Bacterial Agents) RN - 9007-34-5 (Collagen) RN - N12000U13O (Doxycycline) SB - IM MH - Adaptation, Physiological MH - Animals MH - Anti-Bacterial Agents/*pharmacology MH - Biomechanical Phenomena MH - Collagen/physiology MH - Doxycycline/*pharmacology MH - Male MH - Muscle Fibers, Skeletal/*drug effects/physiology MH - Physical Conditioning, Animal/physiology MH - Rats, Sprague-Dawley MH - Rotator Cuff/drug effects/physiology MH - Tendons/*drug effects/physiology PMC - PMC6188802 MID - NIHMS1505927 OTO - NOTNLM OT - Doxycycline OT - Exercise OT - Matrix metalloproteinases OT - Rotator cuff OT - Tendon COIS- Conflict of Interest Statement The authors have no conflicts of interest with this work. EDAT- 2018/09/16 06:00 MHDA- 2019/06/06 06:00 PMCR- 2019/10/26 CRDT- 2018/09/16 06:00 PHST- 2018/03/29 00:00 [received] PHST- 2018/07/16 00:00 [revised] PHST- 2018/08/22 00:00 [accepted] PHST- 2018/09/16 06:00 [pubmed] PHST- 2019/06/06 06:00 [medline] PHST- 2018/09/16 06:00 [entrez] PHST- 2019/10/26 00:00 [pmc-release] AID - S0021-9290(18)30709-7 [pii] AID - 10.1016/j.jbiomech.2018.08.027 [doi] PST - ppublish SO - J Biomech. 2018 Oct 26;80:79-87. doi: 10.1016/j.jbiomech.2018.08.027. Epub 2018 Sep 5. PMID- 21248211 OWN - NLM STAT- MEDLINE DCOM- 20110223 LR - 20171116 IS - 1535-1386 (Electronic) IS - 0021-9355 (Linking) VI - 93 IP - 2 DP - 2011 Jan 19 TI - Reduction of Peritendinous adhesions by hydrogel containing biocompatible phospholipid polymer MPC for tendon repair. PG - 142-9 LID - 10.2106/JBJS.I.01634 [doi] AB - BACKGROUND: Peritendinous adhesions are serious complications after surgical repair of tendons. As an anti-adhesion material, we focused on 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer, our original biocompatible polymer, and prepared an aqueous solution of MPC-containing polymer called poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate-co-p-vinylphenylboronic acid) (PMBV), which can be formed into hydrogel properties by mixture with another aqueous polymer, poly(vinyl alcohol) (PVA). The objective of the present study was to examine the possible application of the MPC hydrogel for the reduction of peritendinous adhesions. METHODS: the effects of the hydrogel on peritendinous adhesions and tendon healing were examined by means of histological and mechanical analyses in a rat Achilles tendon model and a rabbit flexor digitorum profundus tendon model. Cell migration and viability were examined with use of fibroblastic NIH3T3 cells cultured in a double chamber dish. RESULTS: among the concentrations examined, 2.5% and 5.0% PMBV formed hydrogel properties immediately after mixing with 2.5% PVA and maintained a honeycomb microstructure with nanometer-scaled pores for three weeks after implantation. In animal models, the hydrogel formed from 5.0% PMBV remained at the sutured site during the critical period up to three weeks and disappeared by six weeks. The MPC hydrogel reduced the peritendinous adhesions histologically and mechanically by >25% at three weeks, without impairing tendon healing as determined with mechanical analyses. In the cell culture, cell migration was reduced by the MPC hydrogel, although cell viability was unaffected, indicating physical prevention, rather than cytotoxicity, to be the anti-adhesion mechanism. CONCLUSIONS: the MPC hydrogel that was formed by a local injection and mixture of two aqueous solutions, 5.0% PMBV and 2.5% PVA, reduced peritendinous adhesions without impairing tendon healing. This effect may be due to its excellent biocompatibility without a foreign-body reaction and the formation of a microstructure that physically prevents passage of cells but allows cytokines and growth factors to pass for healing. CLINICAL RELEVANCE: this nanotechnology could potentially improve the quality of surgical repair of tendon, especially the zone-II area of the digital flexor tendon. FAU - Ishiyama, Noriyuki AU - Ishiyama N AD - Sensory & Motor System Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. FAU - Moro, Toru AU - Moro T FAU - Ohe, Takashi AU - Ohe T FAU - Miura, Toshiki AU - Miura T FAU - Ishihara, Kazuhiko AU - Ishihara K FAU - Konno, Tomohiro AU - Konno T FAU - Ohyama, Tadashi AU - Ohyama T FAU - Kimura, Mizuna AU - Kimura M FAU - Kyomoto, Masayuki AU - Kyomoto M FAU - Saito, Taku AU - Saito T FAU - Nakamura, Kozo AU - Nakamura K FAU - Kawaguchi, Hiroshi AU - Kawaguchi H LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Biocompatible Materials) RN - 0 (Methacrylates) RN - 0 (Polymers) RN - 107-73-3 (Phosphorylcholine) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 59RU860S8D (2-methacryloyloxyethyl phosphorylcholine) SB - IM CIN - J Bone Joint Surg Am. 2011 Jan 19;93(2):e7. doi: 10.2106/JBJS.J.01472. PMID: 21248208 MH - Achilles Tendon/*drug effects/injuries/surgery MH - Animals MH - Biocompatible Materials MH - Disease Models, Animal MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Materials Testing MH - Methacrylates/*pharmacology MH - Phosphorylcholine/*analogs & derivatives/pharmacology MH - Polymers/pharmacology MH - Postoperative Complications/prevention & control MH - Rabbits MH - Random Allocation MH - Rats MH - Statistics, Nonparametric MH - Tendon Injuries/surgery MH - Tendons/*drug effects/surgery MH - Tensile Strength MH - Tissue Adhesions/prevention & control MH - Wound Healing/drug effects EDAT- 2011/01/21 06:00 MHDA- 2011/02/24 06:00 CRDT- 2011/01/21 06:00 PHST- 2011/01/21 06:00 [entrez] PHST- 2011/01/21 06:00 [pubmed] PHST- 2011/02/24 06:00 [medline] AID - 93/2/142 [pii] AID - 10.2106/JBJS.I.01634 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2011 Jan 19;93(2):142-9. doi: 10.2106/JBJS.I.01634. PMID- 7345878 OWN - NLM STAT- MEDLINE DCOM- 19820910 LR - 20190830 IS - 0001-6683 (Print) IS - 0001-6683 (Linking) VI - 49 IP - 5 DP - 1981 Nov TI - Effects of indomethacin, naproxen and paracetamol on regional blood flow in rabbits: a microsphere study. PG - 327-33 AB - Ulcerogenic side-effects and prostaglandin-synthesis-inhibiting capacity are well documented in indomethacin treatment. According to recent works, indomethacin reduces gastrointestinal blood-flow. Naproxen and paracetamol, claimed to be prostaglandin-synthesis-inhibitors, have few ulcerogenic side effects. In an attempt further to study the indomethacin effects and to reveal whether naproxen and paracetamol have similar effects, the labelled microsphere technique was used. The regional blood flow determinations were made before, and 12-15 min. after, the injection of the drugs. Indomethacin 3 mg/kg, reduced gastrointestinal blood flow and increased arterial blood flow to the liver. Naproxen, 10 mg/kg, and paracetamol, 25 mg/kg, had no effects except for a very small decrease in liver blood flow with paracetamol. The results strongly suggest that, at least under light general anaesthesia, prostaglandins influence resting blood flow in the gastrointestinal tract, the liver and parts of the brain. The results more raise doubts whether naproxen and paracetamol inhibit prostaglandin synthesis in these tissues. These data offer a plausible explanation as to why naproxen and paracetamol are usually well tolerated in the gastrointestinal tract. None of the drugs tested influenced resting blood flow in muscles, tendons, bones, joints or synovial membranes. FAU - Hierton, C AU - Hierton C LA - eng PT - Journal Article PL - Denmark TA - Acta Pharmacol Toxicol (Copenh) JT - Acta pharmacologica et toxicologica JID - 0370572 RN - 0 (Prostaglandin Antagonists) RN - 362O9ITL9D (Acetaminophen) RN - 57Y76R9ATQ (Naproxen) RN - XXE1CET956 (Indomethacin) SB - IM MH - Acetaminophen/*pharmacology MH - Animals MH - Female MH - Indomethacin/*pharmacology MH - Male MH - Microspheres MH - Naproxen/*pharmacology MH - Organ Specificity MH - Prostaglandin Antagonists/pharmacology MH - Rabbits MH - Regional Blood Flow/*drug effects EDAT- 1981/11/01 00:00 MHDA- 1981/11/01 00:01 CRDT- 1981/11/01 00:00 PHST- 1981/11/01 00:00 [pubmed] PHST- 1981/11/01 00:01 [medline] PHST- 1981/11/01 00:00 [entrez] AID - 10.1111/j.1600-0773.1981.tb00915.x [doi] PST - ppublish SO - Acta Pharmacol Toxicol (Copenh). 1981 Nov;49(5):327-33. doi: 10.1111/j.1600-0773.1981.tb00915.x. PMID- 28040578 OWN - NLM STAT- MEDLINE DCOM- 20171019 LR - 20181202 IS - 1877-0568 (Electronic) IS - 1877-0568 (Linking) VI - 103 IP - 2 DP - 2017 Apr TI - Analgesia after ACL reconstruction: Hamstring donor-site injection versus intra-articular local anaesthetic injection. PG - 235-238 LID - S1877-0568(16)30240-7 [pii] LID - 10.1016/j.otsr.2016.11.011 [doi] AB - BACKGROUND: The purpose of this study was to compare hamstring donor-site injection versus intra-articular injection of a local anaesthetic for analgesia after anterior cruciate ligament (ACL) reconstruction. HYPOTHESIS: The two methods provide similar pain relief. MATERIAL AND METHODS: 158 consecutive patients undergoing ACL hamstring tendon graft reconstruction (semi-tendinosus/gracilis [STG] or four-stranded semi-tendinosus [ST4]) during two periods in 2015 were included. Peripheral nerve block was not performed. At the end of surgery, 20mL of ropivacaine 7.5mg/mL was injected, intra-articularly during the early period (n=79) and into the hamstring donor site during the second period (n=79). Post-operative pain was evaluated subjectively by the patients using a visual analogue scale (VAS). We recorded patient demographics, concomitant surgical procedures, VAS pain scores, rescue analgesic use, time to discharge, and patient satisfaction. VAS pain score, side effects, and patient satisfaction were also recorded during a phone interview on the day after surgery (D1). RESULTS: Mean VAS pain scores were not significantly different between the two groups immediately after surgery (D0) or on D1 (D0: intra-articular, 2.08 and donor site, 1.88; Mann-Whitney P=0.6). Neither were the groups significantly different for rescue analgesic use, patient satisfaction, or quadriceps activation. CONCLUSION: The same local anaesthetic provides similar pain relief when injected intra-articularly or into the hamstring donor site after hamstring tendon ACL reconstruction (STG or ST4). LEVEL OF EVIDENCE: III, prospective case-control study. CI - Copyright © 2016 Elsevier Masson SAS. All rights reserved. FAU - Sonnery-Cottet, B AU - Sonnery-Cottet B AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. Electronic address: Sonnerycottet@aol.com. FAU - Saithna, A AU - Saithna A AD - Southport and Ormskirk Hospitals NHS Trust, Lancashire, United Kingdom. FAU - Azeem, A AU - Azeem A AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. FAU - Choudja, E AU - Choudja E AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. FAU - Pic, J B AU - Pic JB AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. FAU - Cabaton, J AU - Cabaton J AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. FAU - Thaunat, M AU - Thaunat M AD - Centre Orthopédique Santy, FIFA Medical Center of Excellence, Ramsay-Générale de Santé, Lyon, France. LA - eng PT - Comparative Study PT - Journal Article DEP - 20161228 PL - France TA - Orthop Traumatol Surg Res JT - Orthopaedics & traumatology, surgery & research : OTSR JID - 101494830 RN - 0 (Amides) RN - 0 (Anesthetics, Local) RN - 7IO5LYA57N (Ropivacaine) SB - IM MH - Adolescent MH - Adult MH - Amides/*therapeutic use MH - Anesthetics, Local/*therapeutic use MH - Anterior Cruciate Ligament Injuries/*surgery MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Case-Control Studies MH - Female MH - *Hamstring Muscles MH - Hamstring Tendons/*transplantation MH - Humans MH - Injections, Intra-Articular/*methods MH - Male MH - Pain Management MH - Pain Measurement MH - Pain, Postoperative/*drug therapy MH - Patient Satisfaction MH - Prospective Studies MH - Ropivacaine MH - Young Adult OTO - NOTNLM OT - Anterior cruciate ligament OT - Hamstring donor-site injection OT - Knee OT - Local anaesthesia EDAT- 2017/01/04 06:00 MHDA- 2017/10/20 06:00 CRDT- 2017/01/02 06:00 PHST- 2016/07/27 00:00 [received] PHST- 2016/11/07 00:00 [revised] PHST- 2016/11/24 00:00 [accepted] PHST- 2017/01/04 06:00 [pubmed] PHST- 2017/10/20 06:00 [medline] PHST- 2017/01/02 06:00 [entrez] AID - S1877-0568(16)30240-7 [pii] AID - 10.1016/j.otsr.2016.11.011 [doi] PST - ppublish SO - Orthop Traumatol Surg Res. 2017 Apr;103(2):235-238. doi: 10.1016/j.otsr.2016.11.011. Epub 2016 Dec 28. PMID- 24461939 OWN - NLM STAT- MEDLINE DCOM- 20140930 LR - 20211021 IS - 1878-5905 (Electronic) IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 35 IP - 11 DP - 2014 Apr TI - The behavior of neuronal cells on tendon-derived collagen sheets as potential substrates for nerve regeneration. PG - 3551-7 LID - S0142-9612(13)01578-0 [pii] LID - 10.1016/j.biomaterials.2013.12.082 [doi] AB - Peripheral nervous system injuries result in a decreased quality of life, and generally require surgical intervention for repair. Currently, the gold standard of nerve autografting, based on the use of host tissue such as sensory nerves is suboptimal as it results in donor-site loss of function and requires a secondary surgery. Nerve guidance conduits fabricated from natural polymers such as collagen are a common alternative to bridge nerve defects. In the present work, tendon sections derived through a process named bioskiving were studied for their potential for use as a substrate to fabricate nerve guidance conduits. We show that cells such as rat Schwann cells adhere, proliferate, and align along the fibrous tendon substrate which has been shown to result in a more mature phenotype. Additionally we demonstrate that chick dorsal root ganglia explants cultured on the tendon grow to similar lengths compared to dorsal root ganglia cultured on collagen gels, but also grow in a more oriented manner on the tendon sections. These results show that tendon sections produced through bioskiving can support directional nerve growth and may be of use as a substrate for the fabrication of nerve guidance conduits. CI - Copyright © 2014 Elsevier Ltd. All rights reserved. FAU - Alberti, Kyle A AU - Alberti KA AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA. Electronic address: kyle.alberti@tufts.edu. FAU - Hopkins, Amy M AU - Hopkins AM AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA. Electronic address: amy.hopkins@Tufts.edu. FAU - Tang-Schomer, Min D AU - Tang-Schomer MD AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA. Electronic address: min.tang-schomer@tufts.edu. FAU - Kaplan, David L AU - Kaplan DL AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA. Electronic address: david.kaplan@tufts.edu. FAU - Xu, Qiaobing AU - Xu Q AD - Department of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, MA 02155, USA. Electronic address: qiaobing.xu@tufts.edu. LA - eng GR - P41 EB002520/EB/NIBIB NIH HHS/United States GR - R03 EB017402/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140122 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Polystyrenes) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cattle MH - Cell Adhesion/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Chickens MH - Collagen/*pharmacology/ultrastructure MH - Ganglia, Spinal/cytology/drug effects/growth & development MH - Guided Tissue Regeneration MH - Nerve Regeneration/*drug effects MH - Neurons/*cytology/drug effects/metabolism MH - Polystyrenes/pharmacology MH - Rats MH - Tendons/drug effects/*metabolism MH - Tissue Scaffolds PMC - PMC3950350 MID - NIHMS554625 OTO - NOTNLM OT - Biomedical engineering OT - Biomimetic materials OT - Collagen OT - Peripheral nerve repair OT - Tendon OT - Tissue section COIS- Author Disclosure Statement: No competing financial interests exist EDAT- 2014/01/28 06:00 MHDA- 2014/10/01 06:00 PMCR- 2015/04/01 CRDT- 2014/01/28 06:00 PHST- 2013/10/17 00:00 [received] PHST- 2013/12/22 00:00 [accepted] PHST- 2014/01/28 06:00 [entrez] PHST- 2014/01/28 06:00 [pubmed] PHST- 2014/10/01 06:00 [medline] PHST- 2015/04/01 00:00 [pmc-release] AID - S0142-9612(13)01578-0 [pii] AID - 10.1016/j.biomaterials.2013.12.082 [doi] PST - ppublish SO - Biomaterials. 2014 Apr;35(11):3551-7. doi: 10.1016/j.biomaterials.2013.12.082. Epub 2014 Jan 22. PMID- 20149434 OWN - NLM STAT- MEDLINE DCOM- 20100621 LR - 20171116 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 31 IP - 14 DP - 2010 May TI - The prevention of peritendinous adhesions by a phospholipid polymer hydrogel formed in situ by spontaneous intermolecular interactions. PG - 4009-16 LID - 10.1016/j.biomaterials.2010.01.100 [doi] AB - Preventing peritendinous adhesions after surgical repair of tendon is difficult. In order to establish an ideal anti-adhesion material, we prepared a spontaneously forming hydrogel by mixing the aqueous solutions of two polymers, poly(MPC-co-methacrylic acid) (PMA) and amphiphilic poly(MPC-co-n-butyl methacrylate) (PMB), in the presence of Fe(3+). This PMA/PMB/Fe(3+) hydrogel (MPC polymer hydrogel) had a honeycomb microstructure with nanometer-scale pores, which resist cell invasion but allow the passage of cytokines and growth factors for tendon healing. The dissociation rate of the hydrogel could be controlled by changing Fe(3+) concentration, and by examining the viscoelasticity of the hydrogel, we determined the optimal Fe(3+) concentration to be 0.05 M. We then examined the effects of the in situ application of this MPC polymer hydrogel containing 0.05 M Fe(3+) by using two animal models: the rat Achilles tendon model and the chicken flexor digitorum profundus tendon model. In both models, macroscopic and histological observation revealed that peritendinous adhesions were significantly decreased by the hydrogel application. Mechanical analyses revealed that the hydrogel prevented peritendinous adhesions but did not affect the tendon healing. Because of its characteristic microstructure and excellent biocompatibility, we believe that the MPC polymer hydrogel will be ideal for preventing peritendinous adhesions. CI - Copyright 2010 Elsevier Ltd. All rights reserved. FAU - Ishiyama, Noriyuki AU - Ishiyama N AD - Sensory & Motor System Medicine, The University of Tokyo, Tokyo, Japan. FAU - Moro, Toru AU - Moro T FAU - Ishihara, Kazuhiko AU - Ishihara K FAU - Ohe, Takashi AU - Ohe T FAU - Miura, Toshiki AU - Miura T FAU - Konno, Tomohiro AU - Konno T FAU - Ohyama, Tadashi AU - Ohyama T FAU - Kimura, Mizuna AU - Kimura M FAU - Kyomoto, Masayuki AU - Kyomoto M FAU - Nakamura, Kozo AU - Nakamura K FAU - Kawaguchi, Hiroshi AU - Kawaguchi H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100210 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Methacrylates) RN - 0 (Polymers) RN - 107-73-3 (Phosphorylcholine) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 59RU860S8D (2-methacryloyloxyethyl phosphorylcholine) RN - E1UOL152H7 (Iron) SB - IM MH - Achilles Tendon/drug effects/pathology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Chickens MH - Disease Models, Animal MH - Elasticity/drug effects MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Iron/metabolism MH - Methacrylates/chemistry/*pharmacology MH - Microscopy, Electron, Scanning MH - Phosphorylcholine/*analogs & derivatives/chemistry/pharmacology MH - Polymers/*pharmacology MH - Rats MH - Staining and Labeling MH - Tendons/*drug effects/*pathology MH - Time Factors MH - Tissue Adhesions/pathology/prevention & control MH - Viscosity/drug effects MH - Wound Healing/drug effects EDAT- 2010/02/13 06:00 MHDA- 2010/06/22 06:00 CRDT- 2010/02/13 06:00 PHST- 2009/12/18 00:00 [received] PHST- 2010/01/15 00:00 [accepted] PHST- 2010/02/13 06:00 [entrez] PHST- 2010/02/13 06:00 [pubmed] PHST- 2010/06/22 06:00 [medline] AID - S0142-9612(10)00132-8 [pii] AID - 10.1016/j.biomaterials.2010.01.100 [doi] PST - ppublish SO - Biomaterials. 2010 May;31(14):4009-16. doi: 10.1016/j.biomaterials.2010.01.100. Epub 2010 Feb 10. PMID- 10954016 OWN - NLM STAT- MEDLINE DCOM- 20000830 LR - 20171116 IS - 0026-0495 (Print) IS - 0026-0495 (Linking) VI - 49 IP - 8 DP - 2000 Aug TI - Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. PG - 996-1000 AB - The accelerated formation of advanced glycation end-products (AGEs) due to elevated glycemia has repeatedly been reported as a central pathogenic factor in the development of diabetic microvascular complications. The effects of a novel inhibitor of AGE formation, NNC39-0028 (2,3-diaminophenazine), and a breaker of already formed AGE cross-links, N-phenacylthiazolium bromide (PTB), were investigated in streptozotocin-diabetic female Wistar rats. Diabetes for 24 weeks resulted in decreased tail collagen pepsin solubility, reflecting the formation of AGE cross-linking. Collagen solubility was significantly ameliorated by treatment with NNC39-0028, whereas PTB had no effect. Increased urinary albumin excretion (UAE) in diabetic rats was observed in serial measurements throughout the study period, and was not reduced by any treatment. Vascular dysfunction in the eye, measured as increased clearance of 125I-albumin, was induced by diabetes. NNC39-0028 did not affect this abnormality. This study demonstrated a pharmacological inhibition of collagen solubility alterations in diabetic rats without affecting diabetes-induced pathophysiology such as the increase in UAE or albumin clearance. Treatment with PTB, a specific breaker of AGE cross-links, had no effects in this study. FAU - Oturai, P S AU - Oturai PS AD - Novo Nordisk, Health Care Discovery, Bagsvaerd, Denmark. FAU - Christensen, M AU - Christensen M FAU - Rolin, B AU - Rolin B FAU - Pedersen, K E AU - Pedersen KE FAU - Mortensen, S B AU - Mortensen SB FAU - Boel, E AU - Boel E LA - eng PT - Journal Article PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (Glycation End Products, Advanced) RN - 0 (N-phenacylthiazolium bromide) RN - 0 (Phenazines) RN - 0 (Radiopharmaceuticals) RN - 0 (Serum Albumin) RN - 0 (Serum Albumin, Radio-Iodinated) RN - 0 (Thiazoles) RN - 0B20H27U1Y (2,3-diaminophenazine) RN - 9007-34-5 (Collagen) SB - IM MH - Albuminuria/urine MH - Animals MH - Collagen/metabolism MH - Diabetes Mellitus, Experimental/*drug therapy/*metabolism/physiopathology MH - Diabetic Angiopathies/blood MH - Drinking/drug effects MH - Eye/blood supply MH - Female MH - Glycation End Products, Advanced/*antagonists & inhibitors/biosynthesis MH - Kidney/anatomy & histology/drug effects MH - Organ Size/drug effects MH - Phenazines/*pharmacology MH - Radiopharmaceuticals MH - Rats MH - Rats, Wistar MH - Serum Albumin/metabolism MH - Serum Albumin, Radio-Iodinated MH - Solubility MH - Tail MH - Tendons/drug effects/metabolism MH - Thiazoles/*pharmacology MH - Weight Gain/drug effects EDAT- 2000/08/23 11:00 MHDA- 2000/09/02 11:01 CRDT- 2000/08/23 11:00 PHST- 2000/08/23 11:00 [pubmed] PHST- 2000/09/02 11:01 [medline] PHST- 2000/08/23 11:00 [entrez] AID - S0026-0495(00)13023-9 [pii] AID - 10.1053/meta.2000.7731 [doi] PST - ppublish SO - Metabolism. 2000 Aug;49(8):996-1000. doi: 10.1053/meta.2000.7731. PMID- 2556924 OWN - NLM STAT- MEDLINE DCOM- 19900123 LR - 20220330 IS - 0002-9440 (Print) IS - 1525-2191 (Electronic) IS - 0002-9440 (Linking) VI - 135 IP - 6 DP - 1989 Dec TI - Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints. PG - 1001-14 AB - Male, 10-week-old C57B1 10 mice received a single intraarticular injection in the knee joints with papain, iodoacetate, or collagenase. This led to osteoarthritic lesions, such as matrix depletion, chondrocyte proliferation, and osteophyte formation, in the injected knee joints within several weeks. After injection of iodoacetate and papain, the main osteoarthritic alterations were localized in the femoropatellar joint, whereas injection of collagenase led to marked osteoarthritic lesions in the femorotibial joint. The mechanism of induction of these alterations appears to differ for iodoacetate and papain on one site and collagenase on the other site. Data are presented that collagenase injection, by way of damaging ligaments and tendons, destabilizes the knee joint eventually leading to osteoarthritic alterations. In contrast, injection of papain or iodoacetate directly interferes with cartilage metabolism resulting in osteoarthritic changes. FAU - van der Kraan, P M AU - van der Kraan PM AD - Department of Rheumatology, Academic Hospital St. Radboud, Nijmegen, The Netherlands. FAU - Vitters, E L AU - Vitters EL FAU - van de Putte, L B AU - van de Putte LB FAU - van den Berg, W B AU - van den Berg WB LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Pathol JT - The American journal of pathology JID - 0370502 RN - 0 (Glycosaminoglycans) RN - 0 (Iodoacetates) RN - EC 3.4.22.2 (Papain) RN - EC 3.4.24.3 (Microbial Collagenase) RN - WF5188V710 (Iodoacetic Acid) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Glycosaminoglycans/antagonists & inhibitors/biosynthesis MH - Injections, Intra-Articular MH - Iodoacetates/pharmacology MH - Iodoacetic Acid MH - Knee Joint/*metabolism/pathology/physiopathology MH - Mice MH - Mice, Inbred C57BL MH - Microbial Collagenase/pharmacology MH - Osteoarthritis/chemically induced/*pathology/physiopathology MH - Papain/pharmacology MH - Time Factors PMC - PMC1880494 EDAT- 1989/12/01 00:00 MHDA- 1989/12/01 00:01 PMCR- 1990/06/01 CRDT- 1989/12/01 00:00 PHST- 1989/12/01 00:00 [pubmed] PHST- 1989/12/01 00:01 [medline] PHST- 1989/12/01 00:00 [entrez] PHST- 1990/06/01 00:00 [pmc-release] PST - ppublish SO - Am J Pathol. 1989 Dec;135(6):1001-14. PMID- 30527883 OWN - NLM STAT- MEDLINE DCOM- 20190508 LR - 20190508 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 28 IP - 4 DP - 2019 Apr TI - The effect of adipose-derived stem cells on enthesis healing after repair of acute and chronic massive rotator cuff tears in rats. PG - 654-664 LID - S1058-2746(18)30656-6 [pii] LID - 10.1016/j.jse.2018.08.044 [doi] AB - BACKGROUND: Chronic massive rotator cuff tears heal poorly and often retear. This study investigated the effect of adipose-derived stem cells (ADSCs) and transforming growth factor-β3 (TGF-β3) delivered in 1 of 2 hydrogels (fibrin or gelatin methacrylate [GelMA]) on enthesis healing after repair of acute or chronic massive rotator cuff tears in rats. METHODS: Adult male Lewis rats underwent bilateral transection of the supraspinatus and infraspinatus tendons with intramuscular injection of botulinum toxin A (n = 48 rats). After 8 weeks, animals received 1 of 8 interventions (n = 12 shoulders/group): (1) no repair, (2) repair only, or repair augmented with (3) fibrin, (4) GelMA, (5) fibrin + ADSCs, (6) GelMA + ADSCs, (7) fibrin + ADSCs + TGF-β3, or (8) GelMA + ADSCs + TGF-β3. An equal number of animals underwent acute tendon transection and immediate application of 1 of 8 interventions. Enthesis healing was evaluated 4 weeks after the repair by microcomputed tomography, histology, and mechanical testing. RESULTS: Increased bone loss and reduced structural properties were seen in chronic compared with acute tears. Bone mineral density of the proximal humerus was higher in repairs of chronic tears augmented with fibrin + ADSCs and GelMA + ADSCs than in unrepaired chronic tears. Similar improvement was not seen in acute tears. No intervention enhanced histologic appearance or structural properties in acute or chronic tears. CONCLUSIONS: Surgical repair augmented with ADSCs may provide more benefit in chronic tears compared with acute tears, although there was no added benefit to supplementing ADSCs with TGF-β3. CI - Copyright © 2018 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. FAU - Rothrauff, Benjamin B AU - Rothrauff BB AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Smith, Catherine A AU - Smith CA AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Ferrer, Gerald A AU - Ferrer GA AD - Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Novaretti, João V AU - Novaretti JV AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Pauyo, Thierry AU - Pauyo T AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Chao, Tom AU - Chao T AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Hirsch, David AU - Hirsch D AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Beaudry, Mason F AU - Beaudry MF AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Herbst, Elmar AU - Herbst E AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Tuan, Rocky S AU - Tuan RS AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Debski, Richard E AU - Debski RE AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Musahl, Volker AU - Musahl V AD - Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: musahlv@upmc.edu. LA - eng PT - Journal Article DEP - 20181204 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Hydrogels) RN - 0 (Methacrylates) RN - 0 (Tgfb3 protein, rat) RN - 0 (Transforming Growth Factor beta3) RN - 9001-31-4 (Fibrin) SB - IM MH - Acute Disease MH - Adipose Tissue/cytology MH - Animals MH - Bone Density MH - Chronic Disease MH - Fibrin/therapeutic use MH - Humerus/physiology MH - Hydrogels/therapeutic use MH - Male MH - Methacrylates/therapeutic use MH - Orthopedic Procedures MH - Rats MH - Rats, Inbred Lew MH - Rotator Cuff Injuries/diagnostic imaging/*physiopathology/*therapy MH - *Stem Cell Transplantation MH - Transforming Growth Factor beta3/*therapeutic use MH - *Wound Healing/drug effects MH - X-Ray Microtomography OTO - NOTNLM OT - Shoulder OT - augmented repair OT - chronicity OT - enthesis OT - mesenchymal stem cell OT - rat OT - rotator cuff EDAT- 2018/12/12 06:00 MHDA- 2019/05/09 06:00 CRDT- 2018/12/12 06:00 PHST- 2018/05/25 00:00 [received] PHST- 2018/08/26 00:00 [revised] PHST- 2018/08/29 00:00 [accepted] PHST- 2018/12/12 06:00 [pubmed] PHST- 2019/05/09 06:00 [medline] PHST- 2018/12/12 06:00 [entrez] AID - S1058-2746(18)30656-6 [pii] AID - 10.1016/j.jse.2018.08.044 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2019 Apr;28(4):654-664. doi: 10.1016/j.jse.2018.08.044. Epub 2018 Dec 4. PMID- 22238058 OWN - NLM STAT- MEDLINE DCOM- 20120716 LR - 20161125 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 40 IP - 3 DP - 2012 Mar TI - Ultrasound-guided sclerosis of neovessels in patellar tendinopathy: a prospective study of 101 patients. PG - 542-7 LID - 10.1177/0363546511433012 [doi] AB - BACKGROUND: A randomized controlled study has shown promising clinical results after treatment with sclerosing injections in a group of patients with patellar tendinopathy, but no study has investigated medium- or long-term outcome in a large and unselected group of patients. PURPOSE: To investigate if sclerosing treatment would affect the level of patellar tendon pain and knee function after 24 months in a large group of patients with patellar tendinopathy. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: This prospective study recruited patients with a clinical diagnosis of jumper's knee and visible neovascularization corresponding to the painful area on power Doppler ultrasound. They received up to a maximum of 5 ultrasound-guided sclerosing injections using polidocanol at 4- to 6-week intervals. Knee pain and function were recorded using the Victorian Institute of Sport Assessment-Patella (VISA-P) score before treatment and 6, 12, and 24 months after the first injection. RESULTS: In total, 101 patients (15 women and 86 men) with 120 tendons were included and given from 1 to 5 sclerosing injections (mean [SD], 2.5 [0.9]). The patients reported a significantly improved VISA-P score from baseline (mean, 39; 95% confidence interval [CI], 36-42) to the 24-month follow-up (mean, 65; 95% CI, 60-70) (range, 21-100; P < .001, paired t test). However, a VISA-P score of >95 points was reported in only 22 cases (20%), whereas 37 cases (36%) reported a VISA-P score of <50 at 24 months. CONCLUSION: Sclerosing treatment with polidocanol resulted in a moderate improvement in knee function and reduced pain in a heterogeneous group of patients with patellar tendinopathy. Nevertheless, few of the patients were cured, and the majority still had reduced function and substantial pain after 24 months of follow-up. FAU - Hoksrud, Aasne AU - Hoksrud A AD - Oslo Sports Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, PO Box 4014 Ullevaal Stadion, 0806 Oslo, Norway. aasne.hoksrud@nih.no FAU - Torgalsen, Thomas AU - Torgalsen T FAU - Harstad, Herlof AU - Harstad H FAU - Haugen, Simen AU - Haugen S FAU - Andersen, Thor Einar AU - Andersen TE FAU - Risberg, May Arna AU - Risberg MA FAU - Bahr, Roald AU - Bahr R LA - eng PT - Clinical Trial PT - Journal Article DEP - 20120111 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Fatty Alcohols) RN - 0 (Sclerosing Solutions) RN - 142583-61-7 (policosanol) SB - IM MH - Adolescent MH - Adult MH - Fatty Alcohols/therapeutic use MH - Female MH - Humans MH - Male MH - Middle Aged MH - Neovascularization, Pathologic/diagnostic imaging/*therapy MH - Pain/diagnostic imaging MH - Pain Management MH - Patellar Ligament/diagnostic imaging/*injuries MH - Sclerosing Solutions/therapeutic use MH - Sclerotherapy/*methods MH - Tendinopathy/diagnostic imaging/*therapy MH - Treatment Outcome MH - Ultrasonography MH - Young Adult EDAT- 2012/01/13 06:00 MHDA- 2012/07/17 06:00 CRDT- 2012/01/13 06:00 PHST- 2012/01/13 06:00 [entrez] PHST- 2012/01/13 06:00 [pubmed] PHST- 2012/07/17 06:00 [medline] AID - 0363546511433012 [pii] AID - 10.1177/0363546511433012 [doi] PST - ppublish SO - Am J Sports Med. 2012 Mar;40(3):542-7. doi: 10.1177/0363546511433012. Epub 2012 Jan 11. PMID- 9139171 OWN - NLM STAT- MEDLINE DCOM- 19970508 LR - 20220410 IS - 0195-9131 (Print) IS - 0195-9131 (Linking) VI - 29 IP - 3 DP - 1997 Mar TI - The effect of ultrasound on collagen synthesis and fibroblast proliferation in vitro. PG - 326-32 AB - Ultrasound has been applied therapeutically to accelerate connective tissue healing although there is little direct scientific evidence to support its use. This investigation was conducted to determine the effects of ultrasound on the rate of collagen synthesis and cell proliferation using cultured fibroblasts derived from Achilles tendons of neonatal rats. Ultrasound (intensity = 0.4 W.cm-2; frequency = 1 MHz) was applied to experimental cells growing as monolayers in culture flasks. Ultrasound had no effect on the rate of collagen synthesis by control fibroblasts over a period of 9 d. The addition of vitamin C to culture media stimulated collagen synthesis to the same extent in both control and ultrasound-treated cultures. Partial digestion of cell matrices with collagenase (used to simulate injury) resulted in an approximately 20% increase in the rate of collagen synthesis. Synthesis was further increased with ultrasound treatment (50-67%). For example, after a single ultrasound treatment, the rate of collagen synthesis was 3.0 +/- 0.4 pg.micrograms-1 DNA.h-1 in cultures treated with collagenase, compared with 1.8 +/- 0.3 pg.micrograms-1 DNA.h-1 in collagenase-treated cultures not treated with ultrasound and 1.4 +/- 0.3 pg.micrograms-1 DNA.h-1 in controls. Ultrasound applied to preconfluent cultures resulted in significant increases in the rate of thymidine incorporation and DNA content. Three daily ultrasound treatments caused a 100% increase in the rate of thymidine incorporation and a 28% increase in DNA content. The results indicate that ultrasound stimulates collagen synthesis in tendon fibroblasts in response to an injury of the connective tissue matrix and that ultrasound stimulates cell division during periods of rapid cell proliferation. FAU - Ramirez, A AU - Ramirez A AD - Department of Health and Kinesiology, University of Texas at Tyler 75799, USA. FAU - Schwane, J A AU - Schwane JA FAU - McFarland, C AU - McFarland C FAU - Starcher, B AU - Starcher B LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) RN - EC 3.4.24.- (Collagenases) RN - PQ6CK8PD0R (Ascorbic Acid) RN - VC2W18DGKR (Thymidine) SB - IM MH - Achilles Tendon/*cytology/drug effects/metabolism MH - Analysis of Variance MH - Animals MH - Animals, Newborn MH - Ascorbic Acid/pharmacology MH - Cell Division MH - Cells, Cultured MH - Collagen/*biosynthesis/drug effects MH - Collagenases/pharmacology MH - Connective Tissue Cells MH - DNA/analysis/biosynthesis MH - Fibroblasts/*cytology/drug effects/metabolism MH - Rats MH - Thymidine/analysis/metabolism MH - *Ultrasonics EDAT- 1997/03/01 00:00 MHDA- 1997/03/01 00:01 CRDT- 1997/03/01 00:00 PHST- 1997/03/01 00:00 [pubmed] PHST- 1997/03/01 00:01 [medline] PHST- 1997/03/01 00:00 [entrez] AID - 10.1097/00005768-199703000-00007 [doi] PST - ppublish SO - Med Sci Sports Exerc. 1997 Mar;29(3):326-32. doi: 10.1097/00005768-199703000-00007. PMID- 15455368 OWN - NLM STAT- MEDLINE DCOM- 20050420 LR - 20200930 IS - 1552-4973 (Print) IS - 1552-4973 (Linking) VI - 71 IP - 2 DP - 2004 Nov 15 TI - Tensile properties and biological response of poly(L-lactic acid) felt graft: an experimental trial for rotator-cuff reconstruction. PG - 252-9 AB - Poly(L-lactic acid) felt (PLLA felt) was prepared for reconstruction of the rotator cuff in animal models. Small changes were found in the tensile strength of both the cultured PLLA felt and the PLLA felt implanted on the paravertebral muscle of rabbits up to 16 postoperative weeks. The stiffness of the felt implanted on the muscle from 6 to 16 weeks showed a statistically significant increase. When the infraspinatus tendons of beagle dog were reconstructed with the PLLA felt, the ultimate strength of PLLA felt increased threefold, and the stiffness increased fivefold by 16 postoperative weeks compared to that of the initial PLLA felt. They were statistically significant (p < 0.01). All the implanted specimens ruptured at the junction between the bone and the PLLA felt. Histological examination demonstrated infiltration of fibrous tissue into the interstices of the PLLA felt fibers. Connection between the infraspinatus tendon and the PLLA felt was tight with the formed scar tissue, but the connective tissue between the bone and PLLA felt fibers was sparse even at 16 and 32 postoperative weeks. A few deteriorated PLLA felt fibers were observed at 32 postoperative weeks. It was concluded that the degradation rate of PLLA felt was low and the tensile recovery of the PLLA felt graft in beagle dogs was excellent. Thus, PLLA felt might be a useful bioabsorbable material for rotator-cuff reconstruction. CI - (c) 2004 Wiley Periodicals, Inc. FAU - Aoki, Mitsuhiro AU - Aoki M AD - Department of Physical Therapy, Sapporo Medical University School of Health Sciences, Chuo-ku, Japan. maoki@sapmed.ac.jp FAU - Miyamoto, Shigenori AU - Miyamoto S FAU - Okamura, Kenji AU - Okamura K FAU - Yamashita, Toshihiko AU - Yamashita T FAU - Ikada, Yoshito AU - Ikada Y FAU - Matsuda, Shojiro AU - Matsuda S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 0 (Biocompatible Materials) RN - 0 (Polyesters) RN - 0 (Polymers) RN - 33X04XA5AT (Lactic Acid) RN - 459TN2L5F5 (poly(lactide)) SB - IM MH - Animals MH - Biocompatible Materials/*pharmacology MH - Dogs MH - Female MH - Granulation Tissue/pathology MH - Hydrolysis MH - Lactic Acid/*pharmacology MH - Materials Testing MH - Molecular Weight MH - Polyesters MH - Polymers/*pharmacology MH - *Prostheses and Implants MH - Rabbits MH - Rotator Cuff/*surgery MH - Stress, Mechanical MH - Tendons/physiology MH - Tensile Strength EDAT- 2004/09/30 05:00 MHDA- 2005/04/21 09:00 CRDT- 2004/09/30 05:00 PHST- 2004/09/30 05:00 [pubmed] PHST- 2005/04/21 09:00 [medline] PHST- 2004/09/30 05:00 [entrez] AID - 10.1002/jbm.b.30084 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2004 Nov 15;71(2):252-9. doi: 10.1002/jbm.b.30084. PMID- 4374839 OWN - NLM STAT- MEDLINE DCOM- 19750423 LR - 20141120 IS - 0044-3220 (Print) IS - 0044-3220 (Linking) VI - 112 IP - 4 DP - 1974 Aug TI - [Proceedings: The effect of diphosphonate on crystal formation of calcium phosphates in vitro]. PG - 984-6 FAU - Reischauer, H C AU - Reischauer HC FAU - Münzenberg, J AU - Münzenberg J LA - ger PT - Journal Article TT - Die Auswirkung von Diphosphonat auf die Kristallbildung von Kalziumphosphaten in vitro. PL - Germany TA - Z Orthop Ihre Grenzgeb JT - Zeitschrift fur Orthopadie und ihre Grenzgebiete JID - 1256465 RN - 0 (Calcium Phosphates) RN - 0 (Diphosphates) RN - 0 (Organophosphonates) SB - IM MH - Animals MH - *Calcium Phosphates MH - Crystallization MH - Diphosphates/pharmacology MH - In Vitro Techniques MH - Organophosphonates/*pharmacology MH - Rats MH - Tail MH - Tendons EDAT- 1974/08/01 00:00 MHDA- 1974/08/01 00:01 CRDT- 1974/08/01 00:00 PHST- 1974/08/01 00:00 [pubmed] PHST- 1974/08/01 00:01 [medline] PHST- 1974/08/01 00:00 [entrez] PST - ppublish SO - Z Orthop Ihre Grenzgeb. 1974 Aug;112(4):984-6. PMID- 3582315 OWN - NLM STAT- MEDLINE DCOM- 19870715 LR - 20190903 IS - 0013-9351 (Print) IS - 0013-9351 (Linking) VI - 43 IP - 1 DP - 1987 Jun TI - Effects of methylmercury on the motor and sensory innervation of the rat extensor digitorum longus muscle. PG - 85-96 AB - This histochemical study examined the effects of chronic methylmercury (MeHg) intoxication on the motor and sensory innervation of extensor digitorum longus muscles. Light microscopic examination of silver-stained axons in the intramuscular nerve bundles of MeHg-treated rats showed Wallerian-like degeneration and a reduction in the number of nerve fibers. Disrupted axons were predominantly sensory because 22.2% of spindle afferents (Ia) and 90.0% of Golgi tendon organ (Ib) sensory fibers were completely degenerated whereas less than 1% of motor endings were totally destroyed. Partial disruption occurred in the cholinesterase and motor terminals of 13.7% of endplates. Our results demonstrated greater vulnerability of sensory nerves than of motor nerves to MeHg-induced degeneration. Thus, the abnormal reflexes, ataxia, and muscle weakness following MeHg poisoning appear related to reduction of proprioceptive feedback from muscles and tendons in addition to the documented lesions in the central nervous system. FAU - Yip, R K AU - Yip RK FAU - Riley, D A AU - Riley DA LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - Netherlands TA - Environ Res JT - Environmental research JID - 0147621 RN - 0 (Methylmercury Compounds) RN - RWZ4L3O1X0 (methylmercuric chloride) SB - IM MH - Animals MH - Axons/drug effects MH - Male MH - Mechanoreceptors/drug effects MH - Methylmercury Compounds/*toxicity MH - Motor Neurons/*drug effects MH - Muscles/*innervation MH - Nerve Fibers/drug effects MH - Nerve Fibers, Myelinated/drug effects MH - Neurons, Afferent/*drug effects MH - Rats MH - Rats, Inbred Strains MH - Tendons/innervation OID - NASA: 87218394 EDAT- 1987/06/01 00:00 MHDA- 1987/06/01 00:01 CRDT- 1987/06/01 00:00 PHST- 1987/06/01 00:00 [pubmed] PHST- 1987/06/01 00:01 [medline] PHST- 1987/06/01 00:00 [entrez] AID - S0013-9351(87)80060-9 [pii] AID - 10.1016/s0013-9351(87)80060-9 [doi] PST - ppublish SO - Environ Res. 1987 Jun;43(1):85-96. doi: 10.1016/s0013-9351(87)80060-9. PMID- 33180557 OWN - NLM STAT- MEDLINE DCOM- 20210921 LR - 20210921 IS - 1944-7876 (Electronic) IS - 1071-1007 (Print) IS - 1071-1007 (Linking) VI - 41 IP - 12 DP - 2020 Dec TI - Effect of Metformin on Development of Tendinopathy Due to Mechanical Overloading in an Animal Model. PG - 1455-1465 LID - 10.1177/1071100720966318 [doi] AB - BACKGROUND: Tendinopathy is a debilitating tendon disorder that affects millions of Americans and costs billions of health care dollars every year. High mobility group box 1 (HMGB1), a known tissue damage signaling molecule, has been identified as a mediator in the development of tendinopathy due to mechanical overloading of tendons in mice. Metformin (Met), a drug approved by the Food and Drug Administration used for the treatment of type 2 diabetes, specifically inhibits HMGB1. This study tested the hypothesis that Met would prevent mechanical overloading-induced tendinopathy in a mouse model of tendinopathy created by intensive treadmill running (ITR). METHODS: C57BL/6J mice (female, 3 months old) were equally separated into 4 groups and treated for 24 weeks as follows: group 1 had cage control activities, group 2 received a single intraperitoneal injection of Met (50 mg/kg body weight) daily, group 3 underwent ITR to induce tendinopathy, and group 4 received daily Met injection along with ITR to inhibit HMGB1. Tendinopathic changes were assessed in Achilles tendons of all mice using histology, immunohistochemistry, and enzyme-linked immunosorbent assays. RESULTS: ITR induced HMGB1 release into the tendon matrix and developed characteristics of tendinopathy as evidenced by the expression of macrophage marker CD68, proinflammatory molecules (COX-2, PGE(2)), cell morphological changes from normal elongated cells to round cells, high levels of expression of chondrogenic markers (SOX-9, collagen type II), and accumulation of proteoglycans in tendinopathic tendons. Daily injection of Met inhibited HMGB1 release and decreased these degenerative changes in ITR tendons. CONCLUSIONS: Inhibition of HMGB1 by injections of Met prevented tendinopathy development due to mechanical overloading in the Achilles tendon in mice. CLINICAL RELEVANCE: Met may be able to be repurposed as a therapeutic option for preventing the development of tendinopathy in high-risk patients. FAU - Zhang, Jianying AU - Zhang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Li, Feng AU - Li F AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Nie, Daibang AU - Nie D AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. AD - Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. FAU - Onishi, Kentaro AU - Onishi K AD - Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Hogan, MaCalus V AU - Hogan MV AUID- ORCID: 0000-0002-6598-1095 AD - Departments of Orthopaedic Surgery, Bioengineering, and Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA. FAU - Wang, James H-C AU - Wang JH AUID- ORCID: 0000-0001-7279-0679 AD - Departments of Orthopaedic Surgery, Bioengineering, and Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA. LA - eng GR - R01 AR061395/AR/NIAMS NIH HHS/United States GR - R01 AR065949/AR/NIAMS NIH HHS/United States GR - R21 AR070340/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20201112 PL - United States TA - Foot Ankle Int JT - Foot & ankle international JID - 9433869 RN - 0 (HMGB1 Protein) RN - 0 (Hypoglycemic Agents) RN - 9100L32L2N (Metformin) SB - IM MH - Achilles Tendon/*drug effects MH - Animals MH - Disease Models, Animal MH - Female MH - HMGB1 Protein/*drug effects MH - Hypoglycemic Agents/pharmacology MH - Metformin/*pharmacology MH - Mice MH - Mice, Inbred C57BL MH - Tendinopathy/*prevention & control PMC - PMC7736509 MID - NIHMS1632361 OTO - NOTNLM OT - HMGB1 OT - mechanical overloading OT - metformin OT - tendinopathy COIS- Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. ICMJE forms for all authors are available online. EDAT- 2020/11/13 06:00 MHDA- 2021/09/22 06:00 PMCR- 2020/12/15 CRDT- 2020/11/12 17:10 PHST- 2020/11/13 06:00 [pubmed] PHST- 2021/09/22 06:00 [medline] PHST- 2020/11/12 17:10 [entrez] PHST- 2020/12/15 00:00 [pmc-release] AID - 10.1177/1071100720966318 [doi] PST - ppublish SO - Foot Ankle Int. 2020 Dec;41(12):1455-1465. doi: 10.1177/1071100720966318. Epub 2020 Nov 12. PMID- 28127950 OWN - NLM STAT- MEDLINE DCOM- 20180723 LR - 20190123 IS - 1932-7005 (Electronic) IS - 1932-6254 (Linking) VI - 11 IP - 12 DP - 2017 Dec TI - Kartogenin with PRP promotes the formation of fibrocartilage zone in the tendon-bone interface. PG - 3445-3456 LID - 10.1002/term.2258 [doi] AB - Treatment of tendon-bone junction injuries is a challenge because tendon-bone interface often heals poorly and the fibrocartilage zone, which reduces stress concentration, at the interface is not formed. In this study, we used a compound called kartogenin (KGN) with platelet-rich plasma (PRP) to induce the formation of fibrocartilage zone in a rat tendon graft-bone tunnel model. The experimental rats received KGN-PRP or PRP injections in the tendon graft-bone tunnel interface. The control group received saline. After 4, 8 and 12 weeks, Safranin O staining of the tendon graft-bone tunnels revealed abundant proteoglycans in the KGN-PRP group indicating the formation of cartilage-like transition zone. Immunohistochemical and immuno-fluorescence staining revealed collagen types I (Col-I) and II (Col-II) in the newly formed fibrocartilage zone. Both fibrocartilage zone formation and maturation were healing time dependent. In contrast, the PRP and saline control groups had no cartilage-like tissues and minimal Col-I and Col-II staining. Some gaps were also present in the saline control group. Finally, pull-out strength in the KGN-PRP-treated group at 8 weeks was 1.4-fold higher than the PRP-treated group and 1.6-fold higher than the saline control group. These findings indicate that KGN, with PRP as a carrier, promotes the formation of fibrocartilage zone between the tendon graft and bone interface. Thus, KGN-PRP may be used as a convenient cell-free therapy in clinics to promote fibrocartilage zone formation in rotator calf repair and anterior cruciate ligament reconstruction, thereby enhancing the mechanical strength of the tendon-bone interface and hence the clinical outcome of these procedures. Copyright © 2017 John Wiley & Sons, Ltd. CI - Copyright © 2017 John Wiley & Sons, Ltd. FAU - Zhou, Yiqin AU - Zhou Y AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. AD - Joint Surgery and Sports Medicine Department, Shanghai Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu, Shanghai, 200003, China. FAU - Zhang, Jianying AU - Zhang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Yang, Jinsong AU - Yang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Narava, Manoj AU - Narava M AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Zhao, Guangyi AU - Zhao G AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Yuan, Ting AU - Yuan T AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Wu, Haishan AU - Wu H AD - Joint Surgery and Sports Medicine Department, Shanghai Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu, Shanghai, 200003, China. FAU - Zheng, Nigel AU - Zheng N AD - Department of Mechanical Engineering and Engineering Science, Center for Biomedical Engineering and Science, University of North Carolina at Charlotte, Charlotte, NC, USA. FAU - Hogan, MaCalus V AU - Hogan MV AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. FAU - Wang, James H-C AU - Wang JH AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20170127 PL - England TA - J Tissue Eng Regen Med JT - Journal of tissue engineering and regenerative medicine JID - 101308490 RN - 0 (Anilides) RN - 0 (Gels) RN - 0 (Phthalic Acids) RN - Q93BBN11CP (kartogenin) SB - IM MH - Anilides/*pharmacology MH - Animals MH - Bone and Bones/drug effects/*physiology MH - Female MH - Fibrocartilage/drug effects/*growth & development MH - Gels MH - Phthalic Acids/*pharmacology MH - Platelet-Rich Plasma/*metabolism MH - Rats, Sprague-Dawley MH - Tendons/drug effects/*physiology MH - Wound Healing/drug effects OTO - NOTNLM OT - Kartogenin OT - PRP OT - bone tunnel OT - fibrocartilage OT - interface OT - tendon graft EDAT- 2017/01/28 06:00 MHDA- 2018/07/24 06:00 CRDT- 2017/01/28 06:00 PHST- 2016/02/03 00:00 [received] PHST- 2016/04/11 00:00 [revised] PHST- 2016/07/03 00:00 [accepted] PHST- 2017/01/28 06:00 [pubmed] PHST- 2018/07/24 06:00 [medline] PHST- 2017/01/28 06:00 [entrez] AID - 10.1002/term.2258 [doi] PST - ppublish SO - J Tissue Eng Regen Med. 2017 Dec;11(12):3445-3456. doi: 10.1002/term.2258. Epub 2017 Jan 27. PMID- 15164149 OWN - NLM STAT- MEDLINE DCOM- 20050222 LR - 20131121 IS - 0171-967X (Print) IS - 0171-967X (Linking) VI - 75 IP - 3 DP - 2004 Sep TI - Mineralization of decalcified bone occurs under cell culture conditions and requires bovine serum but not cells. PG - 231-42 AB - The purpose of this study was to develop an in vitro model system for bone matrix mineralization in the absence of cells. For this model, we utilized EDTA-decalcified new-born rat tibias with the cartilaginous ends intact, allowing us to visually determine the specificity of mineralization within the bone. Our results show that supplementation of DMEM culture medium with 10mM beta-glycerophosphate and 15% fetal bovine serum (FBS) results in non-physiological mineral percipitation in the tibia because of the generation of supraphysiological (5mM) levels of inorganic phosphate in the medium. The same medium supplemented only with inorganic phosphate to a final concentration of 2mM failed to mineralize a decalcified tibia matrix. However, additional supplementation of this medium with as little as 5% FBS resulted in mineralization of those regions of the type I collagen where mineral was found prior to decalcification, with no evidence for mineralization in the cartilage at the bone ends or in the periosteum. Analysis of the mineral by Fourier-transform infrared spectroscopy and powder X-ray diffraction shows that tibias that have been decalcified and then remineralized contain an apatitic mineral that is strikingly similar to the mineral in normal bone. Tendon, a type I collagen matrix not normally mineralized in vivo, also mineralizes when incubated in DMEM containing 2mM Pi and as little as 1.5% FBS, but not when incubated in DMEM without serum. These data indicate that serum contains a nucleator of type I collagen matrix mineralization, and that mineralization of type I collagen under cell culture conditions requires serum but not living cells. FAU - Hamlin, N J AU - Hamlin NJ AD - Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093-0368, USA. FAU - Price, P A AU - Price PA LA - eng GR - AR25921/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Calcif Tissue Int JT - Calcified tissue international JID - 7905481 RN - 0 (Collagen Type I) RN - 0 (Glycerophosphates) RN - 0 (Phosphates) RN - SY7Q814VUP (Calcium) RN - WWH06G87W6 (beta-glycerophosphoric acid) SB - IM MH - Animals MH - Calcification, Physiologic/*physiology MH - Calcium/analysis/metabolism MH - Cattle MH - *Cell Culture Techniques MH - Cell-Free System/*physiology MH - Collagen Type I/metabolism MH - Glycerophosphates/metabolism/pharmacology MH - Male MH - Phosphates/analysis/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - *Serum MH - Spectroscopy, Fourier Transform Infrared MH - Tendons/chemistry/physiology MH - Tibia/chemistry/*physiology MH - X-Ray Diffraction EDAT- 2004/05/28 05:00 MHDA- 2005/02/23 09:00 CRDT- 2004/05/28 05:00 PHST- 2004/05/28 05:00 [pubmed] PHST- 2005/02/23 09:00 [medline] PHST- 2004/05/28 05:00 [entrez] AID - 10.1007/s00223-004-0190-1 [doi] PST - ppublish SO - Calcif Tissue Int. 2004 Sep;75(3):231-42. doi: 10.1007/s00223-004-0190-1. PMID- 12031595 OWN - NLM STAT- MEDLINE DCOM- 20020813 LR - 20190706 IS - 0009-8981 (Print) IS - 0009-8981 (Linking) VI - 321 IP - 1-2 DP - 2002 Jul TI - Glucose-mediated cross-linking of collagen in rat tendon and skin. PG - 69-76 AB - BACKGROUND: Cross-linking of macromolecules like collagen plays an important role in the development of complications in diabetes and ageing. One of the underlying mechanisms of this cross-linking is the formation of advanced glycation endproducts (AGEs). METHODS: In this study, we assessed the use of differential scanning calorimetry (DSC) for the determination of these cross-links and the effects of an AGE inhibitor and breaker. RESULTS: Treatment with N-phenacylthiazolium bromide (ALT-711) of diabetic rats with 2 months duration of diabetes normalized large artery stiffness, assessed by characteristic input impedance and systemic arterial compliance, but with the use of DSC, no statistical difference in cross-linking between control and treated animals could be measured. In addition, we performed in vitro incubation of collagen preparations with ribose and glucose to assess the DSC method as well as the influence of AGE breakers and inhibitors. Incubation of rat tail tendon (RTT) with 100 mmol/l glucose showed an increase in collagen cross-linking expressed as an increase in shrinkage temperature (T(s)). Addition of aminoguanidine (AG), an inhibitor of AGE formation, prior to glucose incubation showed a slower increase of the amount of glucose-derived cross-linking. Replacing glucose with ribose showed a quicker increase in cross-linking and less effect on cross-linking by adding aminoguanidine, demonstrating the higher reactivity of pentoses above hexoses. Similar experiments with rat skin samples (RSS) showed that RSS (type III collagen) are less susceptible to glucose-mediated cross-linking than RTT (type I collagen). We observed no effect of addition of ALT-711, a breaker of glucose-derived cross-links, on the extent of collagen cross-linking in both RTT and RSS. CONCLUSION: Overall, DSC is considered a useful method for assessing glucose-mediated cross-linking in vitro with nonphysiological glucose concentrations. The in vivo use in biological samples is limited due to the lack of sensitivity. However, DSC remains a quick and well-quantitated method in comparison with other methods, like enzymatic digestibility. FAU - Mentink, Cyriel J A L AU - Mentink CJ AD - Department of Endocrinology, Maastricht University Hospital, 6202 AZ, Maastricht, Netherlands. cmen@sint.azm.nl FAU - Hendriks, Marc AU - Hendriks M FAU - Levels, Anita A G AU - Levels AA FAU - Wolffenbuttel, Bruce H R AU - Wolffenbuttel BH LA - eng PT - Journal Article PL - Netherlands TA - Clin Chim Acta JT - Clinica chimica acta; international journal of clinical chemistry JID - 1302422 RN - 0 (Cross-Linking Reagents) RN - 0 (Thiazoles) RN - 9007-34-5 (Collagen) RN - DGH49JXB1F (alagebrium) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Calorimetry, Differential Scanning/*methods MH - Collagen/*chemistry/*metabolism MH - Cross-Linking Reagents/pharmacology MH - Glucose/*pharmacology MH - Male MH - Protein Structure, Secondary/drug effects MH - Rats MH - Rats, Wistar MH - Sensitivity and Specificity MH - Skin/*drug effects/metabolism MH - Tail MH - Tendons/*drug effects/metabolism MH - Thiazoles/pharmacology MH - Time Factors EDAT- 2002/05/29 10:00 MHDA- 2002/08/14 10:01 CRDT- 2002/05/29 10:00 PHST- 2002/05/29 10:00 [pubmed] PHST- 2002/08/14 10:01 [medline] PHST- 2002/05/29 10:00 [entrez] AID - S0009898102000979 [pii] AID - 10.1016/s0009-8981(02)00097-9 [doi] PST - ppublish SO - Clin Chim Acta. 2002 Jul;321(1-2):69-76. doi: 10.1016/s0009-8981(02)00097-9. PMID- 5686171 OWN - NLM STAT- MEDLINE DCOM- 19681209 LR - 20190617 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 220 IP - 5166 DP - 1968 Nov 2 TI - Neural control of acetylcholine-sensitivity in rat muscle fibers. PG - 497-8 FAU - Miledi, R AU - Miledi R FAU - Stefani, E AU - Stefani E FAU - Zelená, J AU - Zelená J LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Receptors, Drug) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/pharmacology/*physiology MH - Animals MH - Muscles/drug effects MH - Neuromuscular Junction/*physiology MH - Rats MH - Receptors, Drug MH - Tendons EDAT- 1968/11/02 00:00 MHDA- 1968/11/02 00:01 CRDT- 1968/11/02 00:00 PHST- 1968/11/02 00:00 [pubmed] PHST- 1968/11/02 00:01 [medline] PHST- 1968/11/02 00:00 [entrez] AID - 10.1038/220497a0 [doi] PST - ppublish SO - Nature. 1968 Nov 2;220(5166):497-8. doi: 10.1038/220497a0. PMID- 872157 OWN - NLM STAT- MEDLINE DCOM- 19770812 LR - 20190509 IS - 0008-6363 (Print) IS - 0008-6363 (Linking) VI - 11 IP - 3 DP - 1977 May TI - The effect on atrial and ventricular intracellular potentials, and other pharmacological actions of L9146, a non-halogenated benzo(b)thiophene related to amiodarone. PG - 187-97 AB - L9146 was synthesised in the hope of eliminating the unwanted side-effects of amiodarone which has been shown to be effective in the control of atrial fibrillation, flutter, and in pre-excitation syndromes such as Wolff-Parkinson-White syndrome. L9146 has pharmacological and electrophysiological effects similar to those of amiodarone. It is an antagonist of both alpha and beta adrenoceptor-mediated cardiovascular effects of a noncompetitive type. It lowers vascular resistance briefly, and causes a longer lasting bradycardia. It moderately reduces the maximum rate of depolarisation (MRD), conduction velocity, and totally suppresses ventricular pacemakers activated by high doses of isoprenaline. In addition, L9146 greatly prolongs action potential duration (APD) in atrial and ventricular muscle. In normal ventricular conducting tissue the action potential duration (APD) is shorter in the bundle of His than in the false tendons, and shorter still in the ventricular muscle. L9146 lengthened APD throughout, but particularly in the proximal portion, and even more in the muscle, so that APD became uniform. The decrement of conduction of premature action potentials was increased to the point at which slowly conducting premature AP's were eliminated altogether. FAU - Williams, E M AU - Williams EM FAU - Salako, L AU - Salako L FAU - Wittig, J H AU - Wittig JH LA - eng PT - Journal Article PL - England TA - Cardiovasc Res JT - Cardiovascular research JID - 0077427 RN - 0 (Propylamines) RN - 0 (Thiophenes) RN - N3RQ532IUT (Amiodarone) SB - IM MH - Action Potentials/drug effects MH - Amiodarone/pharmacology MH - Animals MH - Body Weight MH - Dogs MH - Female MH - Heart/anatomy & histology/*drug effects MH - Heart Conduction System/drug effects MH - Heart Rate/drug effects MH - In Vitro Techniques MH - Male MH - Myocardial Contraction/drug effects MH - Organ Size/drug effects MH - Propylamines/pharmacology MH - Rabbits MH - Thiophenes/*pharmacology EDAT- 1977/05/01 00:00 MHDA- 1977/05/01 00:01 CRDT- 1977/05/01 00:00 PHST- 1977/05/01 00:00 [pubmed] PHST- 1977/05/01 00:01 [medline] PHST- 1977/05/01 00:00 [entrez] AID - 10.1093/cvr/11.3.187 [doi] PST - ppublish SO - Cardiovasc Res. 1977 May;11(3):187-97. doi: 10.1093/cvr/11.3.187. PMID- 40488746 OWN - NLM STAT- MEDLINE DCOM- 20250609 LR - 20250609 IS - 1530-6860 (Electronic) IS - 0892-6638 (Linking) VI - 39 IP - 11 DP - 2025 Jun 15 TI - α-Asarone Promotes Tendon-Bone Healing Through Regulating Dmp1 Transcription via Targeting Transcription Factor PPARG in BMSCs. PG - e70701 LID - 10.1096/fj.202403274RR [doi] AB - The tendon-bone interface (TBI) is challenging to restore following injury, frequently resulting in unsatisfactory healing even after surgical reconstruction. α-Asarone (αASA), a bioactive ingredient derived from the Chinese medicinal plant Calamus, has shown benefits in the treatment of inflammatory conditions. However, its applications in musculoskeletal repair are rarely investigated. This was the first study to examine the therapeutic effects of αASA on TBI healing and elucidate the associated healing mechanisms. In a mouse model of TBI healing, αASA treatment significantly improved the biomechanical properties and osseointegration of tendon-bone samples over 10 weeks. The addition of αASA to in vitro cultures of bone marrow mesenchymal stem cells (BMSCs) greatly enhanced osteogenic differentiation. Using network pharmacology, 114 co-targeting genes were identified between αASA targets and TBI-related genes. RNA-seq analysis revealed that the top 20 differentially expressed genes (DEGs) were involved in tissue mineralization and ossification processes. A total of 207 transcription factors (TFs) were predicted for these DEGs, with 9 identified as core co-target genes. Surface plasmon resonance (SPR) confirmed the strong affinity of αASA for the PPARG TF, while luciferase assays demonstrated PPARG binding to the Dmp1 promoter to regulate transcription. Thus, αASA promotes osteogenic differentiation and improves TBI healing by selectively downregulating PPARG, hence reducing PPARG binding to the Dmp1 promoter. This enhances Dmp1 transcription, a critical factor in osteoblast maturation and mineralization, leading to improved tendon-bone integration. These findings provide new insights into the potential to apply αASA for enhancing TBI healing in the management of tendon-bone injuries. CI - © 2025 Federation of American Societies for Experimental Biology. FAU - Li, Tong AU - Li T AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Li, Guanzhi AU - Li G AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Deng, Xiao AU - Deng X AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhu, Tingrun AU - Zhu T AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Li, Jiao Jiao AU - Li JJ AD - School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia. FAU - Chen, Chao AU - Chen C AD - Department of Orthopaedics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China. FAU - Jia, Jishan AU - Jia J AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhang, Sheng AU - Zhang S AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhang, Kairui AU - Zhang K AD - Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. LA - eng GR - 82072430/National Natural Science Foundation of China/ GR - 2025A1515012457/GuangDong Basic and Applied Basic Research Foundation/ PT - Journal Article PL - United States TA - FASEB J JT - FASEB journal : official publication of the Federation of American Societies for Experimental Biology JID - 8804484 RN - 0 (Allylbenzene Derivatives) RN - 0 (PPAR gamma) RN - 0 (Anisoles) RN - 0 (asarone) RN - 0 (Pparg protein, mouse) RN - 0 (Extracellular Matrix Proteins) SB - IM MH - Animals MH - *Mesenchymal Stem Cells/metabolism/drug effects MH - Mice MH - *Allylbenzene Derivatives/pharmacology MH - *PPAR gamma/metabolism/genetics MH - *Anisoles/pharmacology MH - *Tendons/drug effects/metabolism MH - Osteogenesis/drug effects MH - Male MH - Cell Differentiation/drug effects MH - Mice, Inbred C57BL MH - *Wound Healing/drug effects MH - *Tendon Injuries/drug therapy/metabolism MH - *Extracellular Matrix Proteins/genetics/metabolism MH - *Bone and Bones/metabolism/drug effects MH - Cells, Cultured OTO - NOTNLM OT - RNA sequencing OT - network pharmacology OT - osseointegration OT - tendon–bone interface OT - α‐Asarone EDAT- 2025/06/09 12:30 MHDA- 2025/06/09 12:31 CRDT- 2025/06/09 10:53 PHST- 2025/05/16 00:00 [revised] PHST- 2024/12/17 00:00 [received] PHST- 2025/05/27 00:00 [accepted] PHST- 2025/06/09 12:31 [medline] PHST- 2025/06/09 12:30 [pubmed] PHST- 2025/06/09 10:53 [entrez] AID - 10.1096/fj.202403274RR [doi] PST - ppublish SO - FASEB J. 2025 Jun 15;39(11):e70701. doi: 10.1096/fj.202403274RR. PMID- 24370639 OWN - NLM STAT- MEDLINE DCOM- 20150512 LR - 20181203 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 10 IP - 3 DP - 2014 Mar TI - Porous membrane with reverse gradients of PDGF-BB and BMP-2 for tendon-to-bone repair: in vitro evaluation on adipose-derived stem cell differentiation. PG - 1272-9 LID - S1742-7061(13)00633-8 [pii] LID - 10.1016/j.actbio.2013.12.031 [doi] AB - Polycaprolactone (PCL)/Pluronic F127 membrane with reverse gradients of dual platelet-derived growth factor-β (PDGF-BB) and bone morphogenetic protein 2 (BMP-2) concentrations was fabricated using a diffusion method to investigate the effect of reverse gradients of dual growth factor concentrations on adipose-derived stem cell (ASC) differentiations, such as tenogenesis and osteogenesis. The PDGF-BB and BMP-2 were continuously released from the membrane for up to 35 days, with reversely increasing/decreasing growth factors along the membrane length. Human ASCs were seeded on the membrane with reverse PDGF-BB and BMP-2 gradients. The cells were confluent after 1 week of culture, regardless of growth factor types or concentrations on the membrane. Gene expression (real-time polymerase chain reaction), Western blot and immunohistological analyses after 1 and 2 weeks of ASC culture showed that the membrane sections with higher PDGF-BB and lower BMP-2 concentrations provided a better environment for ASC tenogenesis, while the membrane sections with higher BMP-2 and lower PDGF-BB concentrations were better for promoting osteogenesis. The results suggest that the membrane with reverse gradients of PDGF-BB and BMP-2 may be promising for tendon-to-bone repair, as most essential biological processes are mediated by gradients of biological molecules in the body. CI - Copyright © 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Min, Hyun Ki AU - Min HK AD - Department of Advanced Materials, Hannam University, Daejeon 305-811, Republic of Korea. FAU - Oh, Se Heang AU - Oh SH AD - Department of Nanobiomedical Science & WCU Center, Dankook University, Cheonan 330-714, Republic of Korea. FAU - Lee, Jong Min AU - Lee JM AD - Department of Orthopedics, Dongguk University International Hospital, Goyang 411-373, Republic of Korea. FAU - Im, Gun Il AU - Im GI AD - Department of Orthopedics, Dongguk University International Hospital, Goyang 411-373, Republic of Korea. FAU - Lee, Jin Ho AU - Lee JH AD - Department of Advanced Materials, Hannam University, Daejeon 305-811, Republic of Korea. Electronic address: jhlee@hnu.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20131225 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Membranes, Artificial) RN - 0 (Polyesters) RN - 0 (Proto-Oncogene Proteins c-sis) RN - 106392-12-5 (Poloxamer) RN - 1B56C968OA (Becaplermin) RN - 24980-41-4 (polycaprolactone) RN - 9007-49-2 (DNA) SB - IM MH - Adipose Tissue/cytology MH - Adult MH - Becaplermin MH - Blotting, Western MH - Bone Morphogenetic Protein 2/*pharmacology MH - Bone and Bones/drug effects/*pathology MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - DNA/metabolism MH - Densitometry MH - Female MH - Humans MH - Immunohistochemistry MH - *Membranes, Artificial MH - Osteogenesis/drug effects MH - Poloxamer/pharmacology MH - Polyesters/pharmacology MH - Porosity MH - Proto-Oncogene Proteins c-sis/*pharmacology MH - Stem Cells/*cytology MH - Tendons/drug effects/*pathology MH - Wound Healing/*drug effects OTO - NOTNLM OT - Adipose stem cell OT - Differentiation OT - Growth factor gradient OT - Membrane OT - Tendon-to-bone EDAT- 2013/12/29 06:00 MHDA- 2015/05/13 06:00 CRDT- 2013/12/28 06:00 PHST- 2013/08/14 00:00 [received] PHST- 2013/12/06 00:00 [revised] PHST- 2013/12/16 00:00 [accepted] PHST- 2013/12/28 06:00 [entrez] PHST- 2013/12/29 06:00 [pubmed] PHST- 2015/05/13 06:00 [medline] AID - S1742-7061(13)00633-8 [pii] AID - 10.1016/j.actbio.2013.12.031 [doi] PST - ppublish SO - Acta Biomater. 2014 Mar;10(3):1272-9. doi: 10.1016/j.actbio.2013.12.031. Epub 2013 Dec 25. PMID- 16293043 OWN - NLM STAT- MEDLINE DCOM- 20051214 LR - 20221207 IS - 1743-4440 (Print) IS - 1743-4440 (Linking) VI - 1 IP - 2 DP - 2004 Nov TI - Bioabsorbable fixation devices in trauma and bone surgery: current clinical standing. PG - 229-40 AB - Bioabsorbable fixation devices are increasingly used in trauma, orthopedic and craniomaxillofacial surgery. The devices are essentially made of polylactic acid and/or polyglycolic acid polymers. Ultra-high-strength implants are manufactured from such polymers using self-reinforcing techniques. Implants are available for stabilization of fractures, osteotomies, bone grafts and fusions, as well as for reattachment of ligaments, tendons, meniscal tears and other soft tissue structures. As these implants are completely absorbed, the need for a removal operation is overcome and long-term interference with tendons, nerves and the growing skeleton is avoided. The risk of implant-associated stress shielding, peri-implant osteoporosis and infections is reduced. Implants do not interfere with clinical imaging. Current clinical use of bioabsorbable devices is reviewed. FAU - Waris, Eero AU - Waris E AD - Peijas Hospital, Helsinki University Central Hospital, Finland and Biomedicum Helsinki, Institute of Biomedicine/Anatomy, PO Box 63, FIN-00014 University of Helsinki, Finland. eero.waris@helsinki.fi FAU - Konttinen, Y T AU - Konttinen YT FAU - Ashammakhi, Nureddin AU - Ashammakhi N FAU - Suuronen, Riitta AU - Suuronen R FAU - Santavirta, Seppo AU - Santavirta S LA - eng PT - Journal Article PT - Review PL - England TA - Expert Rev Med Devices JT - Expert review of medical devices JID - 101230445 RN - 0 (Biocompatible Materials) RN - 0 (Polyesters) RN - 0 (Polymers) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) RN - 459TN2L5F5 (poly(lactide)) SB - IM MH - *Absorbable Implants MH - Biocompatible Materials/pharmacokinetics MH - Bone and Bones/injuries/surgery MH - Humans MH - *Internal Fixators MH - Lactic Acid/pharmacokinetics MH - Polyesters MH - Polyglycolic Acid/pharmacokinetics MH - Polymers/pharmacokinetics MH - Plastic Surgery Procedures RF - 110 EDAT- 2005/11/19 09:00 MHDA- 2005/12/15 09:00 CRDT- 2005/11/19 09:00 PHST- 2005/11/19 09:00 [pubmed] PHST- 2005/12/15 09:00 [medline] PHST- 2005/11/19 09:00 [entrez] AID - 10.1586/17434440.1.2.229 [doi] PST - ppublish SO - Expert Rev Med Devices. 2004 Nov;1(2):229-40. doi: 10.1586/17434440.1.2.229. PMID- 36184261 OWN - NLM STAT- MEDLINE DCOM- 20230323 LR - 20230324 IS - 1742-481X (Electronic) IS - 1742-4801 (Print) IS - 1742-4801 (Linking) VI - 20 IP - 4 DP - 2023 Apr TI - Management of wounds with exposed bone structures using an induced-membrane followed by polymethyl methacrylate and second-stage skin grafting in the elderly with a 3-year follow-up. PG - 1020-1032 LID - 10.1111/iwj.13955 [doi] AB - The treatment of traumatic wounds with exposed bone or tendons is often challenging. An induced membrane (IM) is used to reconstruct bone defects, as it provides an effective and sufficient blood supply for bone and soft-tissue reconstruction. This study explored a novel two-stage strategy for wound management, consisting of initial wound coverage with polymethyl methacrylate (PMMA) and an autologous split-thickness skin graft under the IM. Fifty inpatients were enrolled from December 2016 to December 2019. Each patient underwent reconstruction according to a two-stage process. In the first stage, the defect area was thoroughly debrided, and the freshly treated wound was then covered using PMMA cement. After 4-6 weeks, during the second stage, the PMMA cement was removed to reveal an IM covering the exposed bone and tendon. An autologous split-thickness skin graft was then performed. Haematoxylin and eosin (H&E) staining and immunohistochemical analysis of vascular endothelial growth factor (VEGF), CD31 and CD34 were used to evaluate the IM and compare it with the normal periosteal membrane (PM). The psychological status and the Lower Extremity Function Scale (LEFS) as well as any complications were recorded at follow-up. We found that all skin grafts survived and evidenced no necrosis or infection. H&E staining revealed vascularised tissue in the IM, and immunohistochemistry showed a larger number of VEGF-, CD31- and CD34-positive cells in the IM than in the normal PM. The duration of healing in the group was 5.40 ± 1.32 months with a mean number of debridement procedures of 1.92 ± 0.60. There were two patients with reulceration in the group. The self-rating anxiety scale scores ranged from 35 to 60 (mean 48.02 ± 8.12). Postoperatively, the LEFS score was 50.10 ± 9.77. Finally, our strategy for the management of a non-healing wound in the lower extremities, consisting of an IM in combination with skin grafting, was effective, especially in cases in which bony structures were exposed in the elderly. The morbidity rate was low. CI - © 2022 The Authors. International Wound Journal published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd. FAU - Cai, Leyi AU - Cai L AUID- ORCID: 0000-0002-5475-0742 AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Hong, Zipu AU - Hong Z AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Zhang, Yingying AU - Zhang Y AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Xiang, Guangheng AU - Xiang G AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Luo, Peng AU - Luo P AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Gao, Weiyang AU - Gao W AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Li, Zhijie AU - Li Z AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. FAU - Zhou, Feiya AU - Zhou F AD - Department of Orthopaedics Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. LA - eng GR - Y20210046/Wenzhou Science and Technology Bureau Foundation/ PT - Journal Article DEP - 20221002 PL - England TA - Int Wound J JT - International wound journal JID - 101230907 RN - 9011-14-7 (Polymethyl Methacrylate) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Humans MH - Aged MH - *Skin Transplantation MH - *Polymethyl Methacrylate/therapeutic use MH - Vascular Endothelial Growth Factor A MH - Follow-Up Studies MH - Debridement PMC - PMC10031252 OTO - NOTNLM OT - VEGF OT - induced membrane OT - non-healing wound OT - skin grafting COIS- The authors declare no conflicts of interest. EDAT- 2022/10/03 06:00 MHDA- 2023/03/24 06:00 PMCR- 2022/10/02 CRDT- 2022/10/02 21:42 PHST- 2022/08/25 00:00 [revised] PHST- 2022/07/10 00:00 [received] PHST- 2022/08/26 00:00 [accepted] PHST- 2022/10/03 06:00 [pubmed] PHST- 2023/03/24 06:00 [medline] PHST- 2022/10/02 21:42 [entrez] PHST- 2022/10/02 00:00 [pmc-release] AID - IWJ13955 [pii] AID - 10.1111/iwj.13955 [doi] PST - ppublish SO - Int Wound J. 2023 Apr;20(4):1020-1032. doi: 10.1111/iwj.13955. Epub 2022 Oct 2. PMID- 19129355 OWN - NLM STAT- MEDLINE DCOM- 20090625 LR - 20161125 IS - 2043-6289 (Electronic) IS - 0266-7681 (Linking) VI - 34 IP - 1 DP - 2009 Feb TI - Single injection digital block: is a transthecal injection necessary? PG - 94-8 LID - 10.1177/1753193408097323 [doi] AB - Three different methods of injection to obtain digital block anaesthesia were performed on 15 healthy volunteers to evaluate the success and extent of anaesthesia. We found that the traditional transthecal injection technique was inaccurate and the injected agent mainly flowed into the subcutaneous space, and did not remain within the sheath. The deep transthecal single injection kept the anaesthetic agent within the flexor tendon sheath, as intended. The duration of anaesthesia and the area anaesthetised by the subcutaneous injection and the traditional transthecal injection was similar and satisfactory. However, the anaesthetic area after the deep transthecal injection was significantly smaller than that of the other two techniques (P<0.01). A transthecal digital block offers no advantage over a simple subcutaneous digital block. FAU - Sonohata, M AU - Sonohata M AD - Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Saga, Japan. epc9719@yahoo.co.jp FAU - Asami, A AU - Asami A FAU - Ogawa, K AU - Ogawa K FAU - Nagamine, S AU - Nagamine S FAU - Hotokebuchi, T AU - Hotokebuchi T LA - eng PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial DEP - 20090107 PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Anesthetics, Local) RN - 0 (Contrast Media) RN - 98PI200987 (Lidocaine) SB - IM MH - Adult MH - *Anesthetics, Local/pharmacokinetics MH - Contrast Media MH - Diffusion MH - Female MH - Fingers/diagnostic imaging/*innervation MH - Fluoroscopy MH - Humans MH - Injections, Subcutaneous MH - *Lidocaine/pharmacokinetics MH - Male MH - Nerve Block/*methods MH - Tendons/drug effects EDAT- 2009/01/09 09:00 MHDA- 2009/06/26 09:00 CRDT- 2009/01/09 09:00 PHST- 2009/01/09 09:00 [entrez] PHST- 2009/01/09 09:00 [pubmed] PHST- 2009/06/26 09:00 [medline] AID - 1753193408097323 [pii] AID - 10.1177/1753193408097323 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2009 Feb;34(1):94-8. doi: 10.1177/1753193408097323. Epub 2009 Jan 7. PMID- 39942697 OWN - NLM STAT- MEDLINE DCOM- 20250507 LR - 20250507 IS - 1420-3049 (Electronic) IS - 1420-3049 (Linking) VI - 30 IP - 3 DP - 2025 Jan 28 TI - In Vitro CO-Releasing and Antioxidant Properties of Sulfonamide-Based CAI-CORMs in a H(2)O(2)-Stimulated Human Achilles Tendon-Derived Cell Model. LID - 10.3390/molecules30030593 [doi] LID - 593 AB - Tendinopathy is often described as a complex and multifactorial condition which affects tendons. Tendon disorders are marked by a reduction in mechanical function, accompanied by pain and swelling. At the molecular level, tendinopathy leads to oxidative stress-driven inflammation, increased cell death, disruption of extracellular matrix balance, abnormal growth of capillaries and arteries, and degeneration of collagen formation. Here, we report an innovative approach to modulate oxidative stress during tendinopathy based on sulfonamide-based Carbonic Anhydrase Inhibitors-carbon monoxide releasing molecules (CAI-CORMs) hybrids endowed with dual carbon monoxide (CO) releasing activity and carbonic anhydrase (CA) inhibition. The synthesised compounds have been studied in a model of human Achilles tendon-derived cells stimulated by H(2)O(2). Among the library, compound 1c and, to a greater extent, compound 1a, showed to be extremely effective in terms of restoration of cell metabolic activity and cell proliferation due to their capacity to release CO and inhibit the CA isoforms involved in inflammatory processes in the nanomolar range. Moreover, 1a can restore collagen type 1 secretion under pro-oxidant conditions. FAU - Berrino, Emanuela AU - Berrino E AUID- ORCID: 0000-0002-4258-0678 AD - Department of Life Science, Health, and Health Professions, Link Campus University, Via del Casale di San Pio V, 44, 00165 Rome, Italy. AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Guglielmi, Paolo AU - Guglielmi P AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Carta, Fabrizio AU - Carta F AUID- ORCID: 0000-0002-1141-6146 AD - NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy. FAU - Carradori, Simone AU - Carradori S AUID- ORCID: 0000-0002-8698-9440 AD - Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy. FAU - Campestre, Cristina AU - Campestre C AUID- ORCID: 0000-0001-5870-7509 AD - Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy. FAU - Angeli, Andrea AU - Angeli A AUID- ORCID: 0000-0002-1470-7192 AD - NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy. FAU - Arrighi, Francesca AU - Arrighi F AUID- ORCID: 0009-0002-6449-265X AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Pontecorvi, Virginia AU - Pontecorvi V AUID- ORCID: 0000-0003-3976-2291 AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Chimenti, Paola AU - Chimenti P AUID- ORCID: 0000-0002-4395-8126 AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Secci, Daniela AU - Secci D AD - Department of Drug Chemistry and Technologies, Sapienza University of Rome, P.le A. Moro 5, 00185 Rome, Italy. FAU - Supuran, Claudiu T AU - Supuran CT AUID- ORCID: 0000-0003-4262-0323 AD - NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche, University of Florence, Sesto Fiorentino, 50019 Florence, Italy. FAU - Gallorini, Marialucia AU - Gallorini M AUID- ORCID: 0000-0002-2283-4159 AD - Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy. LA - eng PT - Journal Article DEP - 20250128 PL - Switzerland TA - Molecules JT - Molecules (Basel, Switzerland) JID - 100964009 RN - BBX060AN9V (Hydrogen Peroxide) RN - 0 (Antioxidants) RN - 0 (Sulfonamides) RN - 0 (Carbonic Anhydrase Inhibitors) RN - 7U1EE4V452 (Carbon Monoxide) RN - EC 4.2.1.1 (Carbonic Anhydrases) RN - 0 (Collagen Type I) SB - IM MH - Humans MH - *Achilles Tendon/cytology/drug effects/metabolism MH - *Hydrogen Peroxide/pharmacology MH - *Antioxidants/pharmacology/chemistry MH - *Sulfonamides/pharmacology/chemistry MH - *Carbonic Anhydrase Inhibitors/pharmacology/chemistry MH - *Carbon Monoxide/metabolism/chemistry MH - Oxidative Stress/drug effects MH - Cell Proliferation/drug effects MH - Carbonic Anhydrases/metabolism MH - Collagen Type I/metabolism PMC - PMC11819963 OTO - NOTNLM OT - CO release OT - CORMs OT - carbonic anhydrase inhibitors OT - molecular hybrids OT - myoglobin OT - spectrophotometric assay OT - tendinopathy COIS- The authors state no conflicts of interest. EDAT- 2025/02/13 11:00 MHDA- 2025/02/13 11:01 PMCR- 2025/01/28 CRDT- 2025/02/13 01:14 PHST- 2024/12/12 00:00 [received] PHST- 2025/01/23 00:00 [revised] PHST- 2025/01/24 00:00 [accepted] PHST- 2025/02/13 11:01 [medline] PHST- 2025/02/13 11:00 [pubmed] PHST- 2025/02/13 01:14 [entrez] PHST- 2025/01/28 00:00 [pmc-release] AID - molecules30030593 [pii] AID - molecules-30-00593 [pii] AID - 10.3390/molecules30030593 [doi] PST - epublish SO - Molecules. 2025 Jan 28;30(3):593. doi: 10.3390/molecules30030593. PMID- 24733182 OWN - NLM STAT- MEDLINE DCOM- 20151102 LR - 20220309 IS - 1436-2023 (Electronic) IS - 0949-2658 (Linking) VI - 19 IP - 4 DP - 2014 Jul TI - Tendon allograft sterilized by peracetic acid/ethanol combined with gamma irradiation. PG - 627-36 LID - 10.1007/s00776-014-0556-9 [doi] AB - BACKGROUND: Research and clinical applications have demonstrated that the effects of tendon allografts are comparable to those of autografts when reconstructing injured tendons or ligaments, but allograft safety remains problematic. Sterilisation could eliminate or decrease the possibility of disease transmission, but current methods seldom achieve satisfactory sterilisation without affecting the mechanical properties of the tendon. HYPOTHESIS: Peracetic acid-ethanol in combination with low-dose gamma irradiation (PE-R) would inactivate potential deleterious microorganisms without affecting mechanical and biocompatible properties of tendon allograft. STUDY DESIGN: Controlled laboratory design. METHODS: HIV, PPV, PRV and BVDV inactivation was evaluated. After verifying viral inactivation, the treated tendon allografts were characterised by optical microscopy, scanning electron microscopy and tensile testing, and the cytocompatibility was assessed with an MTT assay and by subcutaneous implantation. RESULTS: Effective and efficient inactivation of HIV, PPV, PRV and BVDV was observed. Histological structure and ultrastructure were unchanged in the treated tendon allograft, which also exhibited comparable biomechanical properties and good biocompatibility. CONCLUSION: The preliminary results confirmed our hypothesis and demonstrated that the PE-R tendon allograft has significant potential as an alternative to ligament/tendon reconstruction. CLINICAL RELEVANCE: Tendon allografts have been extensively used in ligament reconstruction and tendon repair. However, current sterilisation methods have various shortcomings, so PE-R has been proposed. This study suggests that PE-R tendon allograft has great potential as an alternative for ligament/tendon reconstruction. WHAT IS KNOWN ABOUT THIS SUBJECT: Sterilisation has been a great concern for tendon allografts. However, most sterilisation methods cannot inactivate viruses and bacteria without impairing the mechanical properties of the tendon allograft. WHAT THIS STUDY ADDS TO EXISTING KNOWLEDGE: Peracetic acid/ethanol with gamma irradiation can effectively inactivate viruses and bacteria. Meanwhile, tendon allografts sterilised by this method maintain their physiological tendon structure, biomechanical integrity and good compatibility. FAU - Zhou, Mo AU - Zhou M AD - Southern Medical University, Tonghe, Guangzhou, Guangdong, 510515, China, remembermz13@163.com. FAU - Zhang, Naili AU - Zhang N FAU - Liu, Xiaoming AU - Liu X FAU - Li, Youchen AU - Li Y FAU - Zhang, Yumin AU - Zhang Y FAU - Wang, Xusheng AU - Wang X FAU - Li, Baoming AU - Li B FAU - Li, Baoxing AU - Li B LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140415 PL - Japan TA - J Orthop Sci JT - Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association JID - 9604934 RN - 3K9958V90M (Ethanol) RN - I6KPI2E1HD (Peracetic Acid) SB - IM MH - *Allografts/drug effects/radiation effects MH - *Ethanol/pharmacology MH - *Gamma Rays MH - Humans MH - *Peracetic Acid/pharmacology MH - Sterilization/*methods MH - Tendons/*transplantation EDAT- 2014/04/16 06:00 MHDA- 2015/11/03 06:00 CRDT- 2014/04/16 06:00 PHST- 2013/08/22 00:00 [received] PHST- 2014/03/02 00:00 [accepted] PHST- 2014/04/16 06:00 [entrez] PHST- 2014/04/16 06:00 [pubmed] PHST- 2015/11/03 06:00 [medline] AID - S0949-2658(15)30239-6 [pii] AID - 10.1007/s00776-014-0556-9 [doi] PST - ppublish SO - J Orthop Sci. 2014 Jul;19(4):627-36. doi: 10.1007/s00776-014-0556-9. Epub 2014 Apr 15. PMID- 18512113 OWN - NLM STAT- MEDLINE DCOM- 20080807 LR - 20211020 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 466 IP - 8 DP - 2008 Aug TI - Radioprotection of tendon tissue via crosslinking and free radical scavenging. PG - 1788-95 LID - 10.1007/s11999-008-0301-9 [doi] AB - Ionizing radiation could supplement tissue bank screening to further reduce the probability of diseases transmitted by allografts if denaturation effects can be minimized. It is important, however, such sterilization procedures be nondetrimental to tissues. We compared crosslinking and free radical scavenging potential methods to accomplish this task in tendon tissue. In addition, two forms of ionizing irradiation, gamma and electron beam (e-beam), were also compared. Crosslinkers included 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and glucose, which were used to add exogenous crosslinks to collagen. Free radical scavengers included mannitol, ascorbate, and riboflavin. Radioprotective effects were assessed through tensile testing and collagenase resistance testing after irradiation at 25 kGy and 50 kGy. Gamma and e-beam irradiation produced similar degenerative effects. Crosslinkers had the highest strength at 50 kGy, EDC treated tendons had 54% and 49% higher strength than untreated, for gamma and e-beam irradiation respectively. Free radical scavengers showed protective effects up to 25 kGy, especially for ascorbate and riboflavin. Crosslinked samples had higher resistance to collagenase and over a wider dose range than scavenger-treated. Of the options studied, the data suggest EDC precrosslinking or glucose treatment provides the best maintenance of native tendon properties after exposure to ionizing irradiation. FAU - Seto, Aaron AU - Seto A AD - Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, UMDNJ-Robert Wood Johnson Medical School, 51 French Street, Orthopaedic Surgery, Room 424, PO Box 19, New Brunswick, NJ 08903, USA. FAU - Gatt, Charles J Jr AU - Gatt CJ Jr FAU - Dunn, Michael G AU - Dunn MG LA - eng PT - Comparative Study PT - Journal Article DEP - 20080530 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Cross-Linking Reagents) RN - 0 (Free Radical Scavengers) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Collagenases) RN - IY9XDZ35W2 (Glucose) RN - RJ5OZG6I4A (Ethyldimethylaminopropyl Carbodiimide) SB - IM MH - Animals MH - Collagen/drug effects/radiation effects MH - Collagenases/metabolism MH - Cross-Linking Reagents/*pharmacology MH - Dose-Response Relationship, Radiation MH - *Electrons MH - Ethyldimethylaminopropyl Carbodiimide/pharmacology MH - Female MH - Free Radical Scavengers/*pharmacology MH - Gamma Rays/adverse effects MH - Glucose/pharmacology MH - Male MH - Rabbits MH - Radiation Dosage MH - Radiation Protection/*methods MH - Radiation, Ionizing MH - Sterilization/*methods MH - Tendons/*radiation effects MH - Tensile Strength/drug effects/radiation effects MH - Transplantation, Homologous PMC - PMC2584246 EDAT- 2008/05/31 09:00 MHDA- 2008/08/08 09:00 PMCR- 2009/08/01 CRDT- 2008/05/31 09:00 PHST- 2007/11/01 00:00 [received] PHST- 2008/04/29 00:00 [accepted] PHST- 2008/05/31 09:00 [pubmed] PHST- 2008/08/08 09:00 [medline] PHST- 2008/05/31 09:00 [entrez] PHST- 2009/08/01 00:00 [pmc-release] AID - 301 [pii] AID - 10.1007/s11999-008-0301-9 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2008 Aug;466(8):1788-95. doi: 10.1007/s11999-008-0301-9. Epub 2008 May 30. PMID- 20557686 OWN - NLM STAT- MEDLINE DCOM- 20110401 LR - 20220311 IS - 1568-5624 (Electronic) IS - 0920-5063 (Linking) VI - 21 IP - 13 DP - 2010 TI - A poly(lactic-co-glycolic acid) knitted scaffold for tendon tissue engineering: an in vitro and in vivo study. PG - 1737-60 LID - 10.1163/092050609X12560455246676 [doi] AB - We have designed a composite scaffold for potential use in tendon or ligament tissue engineering. The composite scaffold was made of a cellularized alginate gel that encapsulated a knitted structure. Our hypothesis was that the alginate would act as a cell carrier and deliver cells to the injury site while the knitted structure would provide mechanical strength to the composite construct. The mechanical behaviour and the degradation profile of the poly(lactic-co-glycolic acid) knitted scaffolds were evaluated. We found that our scaffolds had an elastic modulus of 750 MPa and that they lost their physical integrity within 7 weeks of in vitro incubation. Autologous rabbit mesenchymal stem cell seeded composite scaffolds were implanted in a 1-cm-long defect created in the rabbit tendon, and the biomechanical properties and the morphology of the regenerated tissues were evaluated after 13 weeks. The regenerated tendons presented higher normalized elastic modulus of (60%) when compared with naturally healed tendons (40%). The histological study showed a higher cell density and vascularization in the regenerated tendons. FAU - Vaquette, Cédryck AU - Vaquette C AD - Group of Cell and Tissue Engineering, LEMTA, Nancy-Université, CNRS, Vandoeuvre, France. vaquettc@yahoo.fr FAU - Slimani, Saïd AU - Slimani S FAU - Kahn, Cyril J F AU - Kahn CJ FAU - Tran, Nguyen AU - Tran N FAU - Rahouadj, Rachid AU - Rahouadj R FAU - Wang, Xiong AU - Wang X LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100616 PL - England TA - J Biomater Sci Polym Ed JT - Journal of biomaterials science. Polymer edition JID - 9007393 RN - 0 (Alginates) RN - 0 (Hexuronic Acids) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) RN - 26009-03-0 (Polyglycolic Acid) RN - 33X04XA5AT (Lactic Acid) RN - 8A5D83Q4RW (Glucuronic Acid) SB - IM MH - Achilles Tendon/*cytology/*drug effects/metabolism/physiology MH - Alginates/chemistry MH - Animals MH - Biomechanical Phenomena/drug effects MH - Female MH - Glucuronic Acid/chemistry MH - Hexuronic Acids/chemistry MH - Hydrogen-Ion Concentration MH - Lactic Acid/*chemistry/*pharmacology MH - Polyglycolic Acid/*chemistry/*pharmacology MH - Polylactic Acid-Polyglycolic Acid Copolymer MH - Rabbits MH - Regeneration/drug effects MH - Tensile Strength/drug effects MH - Tissue Engineering/*methods MH - Tissue Scaffolds/*chemistry MH - Viscosity EDAT- 2010/06/19 06:00 MHDA- 2011/04/02 06:00 CRDT- 2010/06/19 06:00 PHST- 2010/06/19 06:00 [entrez] PHST- 2010/06/19 06:00 [pubmed] PHST- 2011/04/02 06:00 [medline] AID - jbs3076 [pii] AID - 10.1163/092050609X12560455246676 [doi] PST - ppublish SO - J Biomater Sci Polym Ed. 2010;21(13):1737-60. doi: 10.1163/092050609X12560455246676. Epub 2010 Jun 16. PMID- 19381661 OWN - NLM STAT- MEDLINE DCOM- 20100513 LR - 20131121 IS - 1434-3916 (Electronic) IS - 0936-8051 (Linking) VI - 129 IP - 12 DP - 2009 Dec TI - The effect of ethanol intake on tendon healing: a histological and biomechanical study in a rat model. PG - 1721-6 LID - 10.1007/s00402-009-0877-x [doi] AB - INTRODUCTION: Ethanol has a suppressive effect on inflammation and the immune system, but the effect of ethanol on tendon healing in vivo has not been studied. The purpose of this study was to investigate the histological and biomechanical effects of ethanol intake on tendon healing in a rat tendon injury model. MATERIALS AND METHODS: Forty-seven rats were randomly assigned to either ethanol or control groups. Progressively increasing concentrations of ethanol combined with glucose were administered to these rats in their drinking water. After 1 week, the Achilles tendon of each rat was injured proximal to its insertion on the calcaneus. All rats were euthanized at 4 weeks. The tendons were evaluated both histologically and biomechanically. The histologic examination of these tendons was done using a semi-quantitative 4-point scale to rate cell morphology, the degree of ground substance staining, collagen organization, and vascular changes. Load to failure (N) strength was obtained with biomechanical testing. RESULTS: Tendon failure loads were lower in the ethanol group (31.6 +/- 8.8 N) than in the control group (39.7 +/- 8.2 N) (P = 0.04). Histologic tenocyte scores were higher in the ethanol group (1.90 +/- 0.73) than the control group (0.9 +/- 0.73) (P = 0.01). CONCLUSION: Ethanol ingestion resulted in abnormal tenocyte morphology, disorganized collagen bundles with a tendency toward increased tenocyte number, and neovascularization 3 weeks after the tendon injury indicating delayed and abnormal healing. The healing tendons in the alcohol treated group failed at statistically lower loads than the control group. FAU - Hapa, Onur AU - Hapa O AD - Department of Orthopedics and Traumatology, Bolu Köroğlu State Hospital, Furkan apt No: 2/7, Gonca Sokak, Borazanlar Mah, Bolu, Turkey. onurhapa@gmail.com FAU - Cakici, Hüsamettin AU - Cakici H FAU - Gideroğlu, Kaan AU - Gideroğlu K FAU - Ozturan, Kutay AU - Ozturan K FAU - Kükner, Aysel AU - Kükner A FAU - Buğdayci, Güler AU - Buğdayci G LA - eng PT - Journal Article DEP - 20090421 PL - Germany TA - Arch Orthop Trauma Surg JT - Archives of orthopaedic and trauma surgery JID - 9011043 RN - 3K9958V90M (Ethanol) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/*injuries/pathology/physiopathology MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Ethanol/*pharmacology MH - Female MH - Rats MH - Rats, Wistar MH - Wound Healing/*drug effects EDAT- 2009/04/22 09:00 MHDA- 2010/05/14 06:00 CRDT- 2009/04/22 09:00 PHST- 2008/12/11 00:00 [received] PHST- 2009/04/22 09:00 [entrez] PHST- 2009/04/22 09:00 [pubmed] PHST- 2010/05/14 06:00 [medline] AID - 10.1007/s00402-009-0877-x [doi] PST - ppublish SO - Arch Orthop Trauma Surg. 2009 Dec;129(12):1721-6. doi: 10.1007/s00402-009-0877-x. Epub 2009 Apr 21. PMID- 11592319 OWN - NLM STAT- MEDLINE DCOM- 20020327 LR - 20190915 IS - 0002-9645 (Print) IS - 0002-9645 (Linking) VI - 62 IP - 10 DP - 2001 Oct TI - Effects of beta-aminopropionitrile on equine tendon metabolism in vitro and on effects of insulin-like growth factor-I on matrix production by equine tenocytes. PG - 1557-62 AB - OBJECTIVE: To investigate effects of beta-aminopropionitrile and a combination of insulin-like growth factor (IGF)-I and beta-aminopropionitrile on metabolism of equine tendon fibroblasts. SAMPLE POPULATION: Flexor tendon explants from 3 horses. PROCEDURE: Explants received 1 of 4 treatments (control, IGF-I, beta-aminopropionitrile, and IGF-I/beta-aminopropionitrile) for 10 days, and message expression for collagen types I and III was assessed by use of in situ hybridization. Histologic findings, new protein production, and quantitative determinations of glycosaminoglycan, DNA, and de novo collagen synthesis were made. RESULTS: Insulin-like growth factor-I stimulated an anabolic response in tendon. Collagen synthesis and glycosaminoglycan and DNA content of explants were all increased. Beta-aminopropionitrile significantly suppressed collagen synthesis, which was not ameliorated by concurrent IGF-I treatment. Beta-aminopropionitrile caused alterations in cell morphology characterized by large round cells with eccentric nuclei and decreased density of collagen fibers. Protein production and collagen type-III mRNA expression were reduced in these cells. CONCLUSIONS AND CLINICAL RELEVANCE: Treatment with beta-aminopropionitrile resulted in decreased production of protein and collagen synthesis, which could be expected to suppress tendon healing. The negative effects of beta-aminopropionitrile could not be abrogated by addition of IGF-I to the medium. Treatment resulted in alterations in cell morphology and matrix consistency, which could further delay tendon healing. Beta-aminopropionitrile may impair tendon healing at a cellular level by decreasing collagen production or increasing rate of degradation of existing matrix. Because of reduced crosslinking during beta-aminopropionitrile treatment, in combination with transiently decreased tensile strength, alterations in collagen content and structure may weaken the healing tendon. FAU - Dahlgren, L A AU - Dahlgren LA AD - Comparative Orthopaedics Laboratory, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA. FAU - Nixon, A J AU - Nixon AJ FAU - Brower-Toland, B D AU - Brower-Toland BD LA - eng GR - AR08587/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 151-18-8 (Aminopropionitrile) RN - 67763-96-6 (Insulin-Like Growth Factor I) SB - IM MH - Aminopropionitrile/*pharmacology MH - Animals MH - Collagen Type I/biosynthesis MH - Collagen Type III/biosynthesis MH - Extracellular Matrix/drug effects/*metabolism MH - Fibroblasts/drug effects/metabolism MH - Histocytochemistry/veterinary MH - Horse Diseases/metabolism MH - Horses/*metabolism MH - In Situ Hybridization/veterinary MH - Insulin-Like Growth Factor I/*pharmacology MH - Statistics, Nonparametric MH - Tendinopathy/drug therapy/metabolism/veterinary MH - Tendons/*drug effects/metabolism EDAT- 2001/10/11 10:00 MHDA- 2002/03/28 10:01 CRDT- 2001/10/11 10:00 PHST- 2001/10/11 10:00 [pubmed] PHST- 2002/03/28 10:01 [medline] PHST- 2001/10/11 10:00 [entrez] AID - 10.2460/ajvr.2001.62.1557 [doi] PST - ppublish SO - Am J Vet Res. 2001 Oct;62(10):1557-62. doi: 10.2460/ajvr.2001.62.1557. PMID- 1483965 OWN - NLM STAT- MEDLINE DCOM- 19930216 LR - 20191101 IS - 0883-8364 (Print) IS - 0883-8364 (Linking) VI - 28A IP - 11-12 DP - 1992 Nov-Dec TI - Evidence supporting the role of a proteinaceous, loosely bound extracellular molecule in the cell density signaling between tendon cells. PG - 745-54 AB - Normal cells in culture respond to cell density by altering their proliferation rates and their pattern of protein expression. Primary avian tendon (PAT) cells are a case in point where procollagen production increases approximately 10-fold at high cell density while proliferation almost ceases. In an earlier report focusing on the cell density regulation of procollagen expression, the signaling mechanism communicating the presence of other cells was shown to have the characteristics of a loosely bound component of the cell layer. Extending these studies to the cell density regulation of proliferation, the cell density signal (CDS) was again shown to be altered by medium agitation, stimulating cell division. Agitation, however, was only disruptive to cell signaling when there was a high ratio of medium to cells. When sufficient cells were present, agitation was less effective. Therefore, the CDS controlling procollagen production and the CDS controlling the inhibition of growth seemed to be linked because the signaling mechanism is disrupted in a parallel manner by agitation. However, the proliferative response of PAT cells is more complex in that there is also a positive influence at moderate cell density (> 2 x 10(4) cells/cm2) on the rate of cell division. As a consequence, PAT cells would not proliferate into an area of low cell density, but within the same dish would rapidly fill an area of moderate density. PAT cells were capable of filling a gap between high cell density areas if the gap was less than 2 mm. Medium agitation also affected cells at low cell density in a different manner. It was inhibitory if all the cells were at low cell density but it was stimulatory if the cells at low cell density were in close proximity to cells at high cell density. In addition, medium conditioned by agitation over cells at a high cell density would stimulate cells at low cell density to divide and grow out into low cell density regions. Using the growth-promoting activity of the conditioned medium as an assay, this component of the CDS was shown to have unique characteristics: heat, pH, dithiothreitol (DTT) stable; tris ion and protease sensitive. By gel exclusion chromatography it was larger than 100 kDa. But after DTT treatment its mobility shifted to < 30 kDa while retaining activity. FAU - Zayas, J R AU - Zayas JR AD - Cell and Molecular Biology Division, Lawrence Berkeley Laboratory, University of California, Berkeley 94720. FAU - Schwarz, R I AU - Schwarz RI LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - In Vitro Cell Dev Biol JT - In vitro cellular & developmental biology : journal of the Tissue Culture Association JID - 8506951 RN - 0 (Culture Media, Conditioned) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Procollagen) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Autoradiography MH - Cell Communication/physiology MH - Cell Count/drug effects MH - Cell Division/drug effects/physiology MH - Cells, Cultured MH - Chick Embryo MH - Chromatography, Gel MH - Culture Media, Conditioned/pharmacology MH - Dithiothreitol/pharmacology MH - Extracellular Matrix Proteins/*physiology MH - Hot Temperature MH - Hydrogen-Ion Concentration MH - Procollagen/metabolism MH - Signal Transduction/*physiology MH - Tendons/*cytology/metabolism EDAT- 1992/11/01 00:00 MHDA- 1992/11/01 00:01 CRDT- 1992/11/01 00:00 PHST- 1992/11/01 00:00 [pubmed] PHST- 1992/11/01 00:01 [medline] PHST- 1992/11/01 00:00 [entrez] AID - 10.1007/BF02631063 [doi] PST - ppublish SO - In Vitro Cell Dev Biol. 1992 Nov-Dec;28A(11-12):745-54. doi: 10.1007/BF02631063. PMID- 26017614 OWN - NLM STAT- MEDLINE DCOM- 20150805 LR - 20210106 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 135 IP - 6 DP - 2015 Jun TI - Tendon regeneration with a novel tendon hydrogel: in vitro effects of platelet-rich plasma on rat adipose-derived stem cells. PG - 981e-989e LID - 10.1097/PRS.0000000000001268 [doi] AB - BACKGROUND: Tendon hydrogel is a promising new injectable substance that has been shown to improve repair strength after tendon injury. This study assesses the capacity of platelet-rich plasma to stimulate proliferation and migration of rat adipose-derived stem cells in tendon hydrogel in vitro. METHODS: To assess proliferation, adipose-derived stem cells were exposed to plasma, plasma supplemented with growth factors, or platelet-rich plasma in culture medium and tendon hydrogel. To assess migration, adipose-derived stem cells were plated onto tendon hydrogel -coated wells and covered with medium containing plasma, plasma supplemented with growth factors, platelet-rich plasma, or bovine serum albumin. Migration from cell-seeded to cell-free zones was assessed at 12-hour intervals. RESULTS: Platelet-rich plasma augmented proliferation to a greater extent compared with plasma and plasma supplemented with growth factors (10%: optical density, 1.18 versus 0.75 versus 0.98, respectively). Platelet-rich plasma was superior to plasma in tendon hydrogel (10%: optical density, 1.19 versus 0.85) but did not augment proliferation to the extent that plasma supplemented with growth factors did (10%: optical density, 1.19 versus 1.56). Platelet-rich plasma enhanced the migration of adipose-derived stem cells compared with serum-free medium (bovine serum albumin) (36 hours: platelet-rich plasma, 1.88; plasma, 1.51; plasma plus growth factor, 1.80; bovine serum albumin, 1.43). CONCLUSIONS: Tendon healing is mediated by migration of cells to the injured area and cellular proliferation at that site. Tendon hydrogel supplemented with platelet-rich plasma stimulates these processes. Future studies will evaluate this combination's ability to stimulate healing in chronic tendon injuries in vivo. FAU - Crowe, Christopher S AU - Crowe CS AD - Stanford and Palo Alto, Calif. From the Division of Plastic and Reconstructive Surgery, Stanford University Medical Center; and the Division of Plastic and Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System. FAU - Chiou, Grace AU - Chiou G FAU - McGoldrick, Rory AU - McGoldrick R FAU - Hui, Kenneth AU - Hui K FAU - Pham, Hung AU - Pham H FAU - Chang, James AU - Chang J LA - eng GR - I01 RX001458/RX/RRD VA/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Culture Media) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) SB - IM MH - Adipocytes/*transplantation MH - Animals MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Culture Media MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - In Vitro Techniques MH - Models, Animal MH - *Platelet-Rich Plasma MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Reference Values MH - Regeneration/*physiology MH - Sensitivity and Specificity MH - Stem Cells/cytology/physiology MH - Tendons/*physiology/surgery EDAT- 2015/05/29 06:00 MHDA- 2015/08/06 06:00 CRDT- 2015/05/29 06:00 PHST- 2015/05/29 06:00 [entrez] PHST- 2015/05/29 06:00 [pubmed] PHST- 2015/08/06 06:00 [medline] AID - 00006534-201506000-00018 [pii] AID - 10.1097/PRS.0000000000001268 [doi] PST - ppublish SO - Plast Reconstr Surg. 2015 Jun;135(6):981e-989e. doi: 10.1097/PRS.0000000000001268. PMID- 5709842 OWN - NLM STAT- MEDLINE DCOM- 19690401 LR - 20190501 IS - 0022-3050 (Print) IS - 1468-330X (Electronic) IS - 0022-3050 (Linking) VI - 31 IP - 6 DP - 1968 Dec TI - Recruitment order of motor units on voluntary contraction: changes induced by proprioceptive afferent activity. PG - 565-73 FAU - Grimby, L AU - Grimby L FAU - Hannerz, J AU - Hannerz J LA - eng PT - Journal Article PL - England TA - J Neurol Neurosurg Psychiatry JT - Journal of neurology, neurosurgery, and psychiatry JID - 2985191R RN - 98PI200987 (Lidocaine) SB - IM MH - Action Potentials MH - Humans MH - Leg MH - Lidocaine/pharmacology MH - Motor Neurons/*physiology MH - *Muscle Contraction MH - Neural Conduction/drug effects MH - Oscillometry MH - Reflex MH - Sensory Receptor Cells/physiology MH - Tendons MH - Vibration PMC - PMC496424 EDAT- 1968/12/01 00:00 MHDA- 1968/12/01 00:01 PMCR- 1968/12/01 CRDT- 1968/12/01 00:00 PHST- 1968/12/01 00:00 [pubmed] PHST- 1968/12/01 00:01 [medline] PHST- 1968/12/01 00:00 [entrez] PHST- 1968/12/01 00:00 [pmc-release] AID - 10.1136/jnnp.31.6.565 [doi] PST - ppublish SO - J Neurol Neurosurg Psychiatry. 1968 Dec;31(6):565-73. doi: 10.1136/jnnp.31.6.565. PMID- 5718414 OWN - NLM STAT- MEDLINE DCOM- 19690520 LR - 20131121 IS - 0071-8041 (Print) IS - 0071-8041 (Linking) VI - 19 DP - 1968 TI - Effect of controlled lathyrism following repair of flexor tendons in man. PG - 60-2 FAU - Madden, J W AU - Madden JW FAU - Peacock, E E Jr AU - Peacock EE Jr LA - eng PT - Journal Article PL - United States TA - Surg Forum JT - Surgical forum JID - 0337723 RN - 0 (Nitriles) RN - 151-18-8 (Aminopropionitrile) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Aminopropionitrile MH - Collagen/metabolism MH - Humans MH - Hydroxyproline/analysis/urine MH - Lathyrism/chemically induced/*physiopathology MH - Nitriles/*pharmacology MH - Tendon Injuries/metabolism/*therapy EDAT- 1968/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1968/01/01 00:00 PHST- 1968/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1968/01/01 00:00 [entrez] PST - ppublish SO - Surg Forum. 1968;19:60-2. PMID- 13018875 OWN - NLM STAT- MEDLINE DCOM- 20030501 LR - 20181201 IS - 0037-8771 (Print) IS - 0037-8771 (Linking) VI - 28 IP - 8-10 DP - 1952 Aug-Oct TI - [Shortening and mechanical work of fibrous proteins due to chemical-physical modifications of the external environment; velocity of shortening of tendon treated with lactic acid]. PG - 1591-3 FAU - MESCHIA, G AU - MESCHIA G FAU - SETNIKAR, I AU - SETNIKAR I LA - und PT - Journal Article TT - Accorciamento e lavoro meccanico di una proteina fibrosa per modificazioni chimico-fisiche dell'ambiente esterno. III. Velocita' di accorciamento di un tendine trattato con acido lattico. PL - Italy TA - Boll Soc Ital Biol Sper JT - Bollettino della Societa italiana di biologia sperimentale JID - 7506962 RN - 0 (Scleroproteins) RN - 33X04XA5AT (Lactic Acid) SB - OM MH - Lactic Acid/*pharmacology MH - *Muscles MH - *Scleroproteins MH - *Tendons OID - CLML: 5323:43778:297:351 OTO - NLM OT - *LACTIC ACID/effects OT - *MUSCLES EDAT- 1952/08/01 00:00 MHDA- 1952/08/01 00:01 CRDT- 1952/08/01 00:00 PHST- 1952/08/01 00:00 [pubmed] PHST- 1952/08/01 00:01 [medline] PHST- 1952/08/01 00:00 [entrez] PST - ppublish SO - Boll Soc Ital Biol Sper. 1952 Aug-Oct;28(8-10):1591-3. PMID- 6086895 OWN - NLM STAT- MEDLINE DCOM- 19840824 LR - 20190511 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 350 DP - 1984 May TI - Characteristics of membrane channels induced by acetylcholine at frog muscle-tendon junctions. PG - 269-77 AB - The membrane at the tendinous ends of frog muscle fibres has acetylcholine (ACh) receptors that are blocked by alpha-bungarotoxin. The properties of ACh-activated channels in the myotendinous region were investigated by noise analysis. These channels displayed the same characteristics in normal, denervated and reinnervated muscles. The mean lifetime and conductance of ACh-induced channels at the myotendinous junction resembled those of channels at the normal neuromuscular junction. Both channels opened with a lifetime shorter than that of extrajunctional receptors. Channels of short lifetime could be detected at distances of several hundred micrometres from the tendon junction. The similarity of ACh-activated channels at neuromuscular and myotendon junctions was found both in the fast, 'singly' innervated sartorius and cutaneous pectoris muscle and in the intermediate, multiply innervated submaxillaris muscle. FAU - Miledi, R AU - Miledi R FAU - Reiser, G AU - Reiser G FAU - Uchitel, O D AU - Uchitel OD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (Bungarotoxins) RN - 0 (Ion Channels) RN - 0 (Receptors, Cholinergic) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Action Potentials MH - Animals MH - Bungarotoxins/pharmacology MH - Electric Conductivity MH - Ion Channels/*drug effects/physiology MH - Membrane Potentials MH - Muscle Denervation MH - Muscles/*physiology MH - Nerve Regeneration MH - Rana temporaria MH - Receptors, Cholinergic/drug effects MH - Tendons/*physiology PMC - PMC1199268 OID - NASA: 84267413 EDAT- 1984/05/01 00:00 MHDA- 1984/05/01 00:01 PMCR- 1984/05/01 CRDT- 1984/05/01 00:00 PHST- 1984/05/01 00:00 [pubmed] PHST- 1984/05/01 00:01 [medline] PHST- 1984/05/01 00:00 [entrez] PHST- 1984/05/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1984.sp015200 [doi] PST - ppublish SO - J Physiol. 1984 May;350:269-77. doi: 10.1113/jphysiol.1984.sp015200. PMID- 38427791 OWN - NLM STAT- MEDLINE DCOM- 20240529 LR - 20250602 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 482 IP - 6 DP - 2024 Jun 1 TI - Can the Sterilization Protocol Be Improved to Enhance the Healing of Allograft Tendons? An In Vivo Study in Rabbit Tendons. PG - 1074-1086 LID - 10.1097/CORR.0000000000003017 [doi] AB - BACKGROUND: Peracetic acid and irradiation are common sterilization methods for allograft tendons; however, under some conditions, both methods adversely affect the fiber arrangement and ultimate load of the tendon. An in vitro study showed that low-dose peracetic acid combined with irradiation may be less detrimental to allograft tendon structure and properties, possibly because the breakdown of peracetic acid can lead to an enlargement of the interstitial spaces and an increase in porosity. QUESTIONS/PURPOSES: Using a rabbit Achilles tendon model, we asked: What is the effect of peracetic acid-ethanol combined irradiation on (1) the histopathology and fiber diameter of the allograft tendon, (2) tensile creep and load-to-failure biomechanical properties of allograft tendons, and (3) healing of the treated tendon in vivo compared with fresh-frozen allograft and peracetic acid-ethanol sterilization at 4 and 8 weeks? METHODS: The Achilles tendons used in this study were sourced from euthanized 10-week-old male New Zealand White rabbits previously used for ophthalmic experiments. All allografts were divided into three groups: fresh-frozen group (control group, n = 20), peracetic acid-ethanol sterilization group (n =20), and peracetic acid-ethanol combined irradiation group (n = 20). The sterilization protocols were performed per a predetermined plan. In the peracetic acid-ethanol sterilization group, the tendon tissues were covered with the peracetic acid-ethanol sterilization solution (1% peracetic acid for 30 minutes). In the peracetic acid-ethanol combined irradiation group, the tendon tissues were covered with the peracetic acid-ethanol sterilization solution (0.2% peracetic acid for 30 minutes) and were subjected to 15 kGy gamma irradiation. Thirty 10-week-old male New Zealand White rabbits received bilateral Achilles tendon allografts surgically. Tendon samples from each group were harvested at 4 weeks (n = 30) and 8 weeks (n = 30) postoperatively. For each timepoint, eight tissues were used for histologic staining and electron microscopy, 15 tissues were used for biomechanical testing, and seven tissues were used for hydroxyproline assay and quantitative polymerase chain reaction. Histopathology was determined qualitatively by hematoxylin and eosin and Masson staining, while fiber diameter was measured quantitatively by transmission electron microscopy. Biomechanical properties were measured using cyclic loading tests and load-to-failure tests. The healing outcome was quantitatively judged through healing-related genes and proteins. RESULTS: At 4 weeks and 8 weeks postoperatively, the peracetic acid-ethanol combined irradiation group visually demonstrated the best continuity and minimal peripheral adhesions. Histologic staining showed that tendon fibers in the peracetic acid-ethanol combined irradiation group maintained consistent alignment without notable disruptions or discontinuities, and there was a qualitatively observed increase in the number of infiltrating cells compared with the control group at the 4-week timepoint (444 ± 49 /mm 2 versus 256 ± 43 /mm 2 , mean difference 188 /mm 2 [95% confidence interval 96 to 281]; p < 0.001). At 8 weeks postoperatively, the tendon fiber diameter in the peracetic acid-ethanol combined irradiation groups was similar to that of the control group (0.23 ± 0.04 µm versus 0.21 ± 0.03 µm, mean difference 0.02 µm [95% CI -0.04 to 0.08]; p = 0.56). At 8 weeks postoperatively, the peracetic acid-ethanol combined irradiation group exhibited better properties in terms of both ultimate load (129 ± 15 N versus 89 ± 20 N, mean difference 40 N [95% CI 7 to 73]; p = 0.02) and energy absorption density (17 ± 6 kJ/m 2 versus 8 ± 4 kJ/m 2 , mean difference 8 kJ/m 2 [95% CI 0.7 to 16]; p = 0.004) compared with the control group. Gene expression analysis revealed higher expression levels of COL1A1 (2.1 ± 0.8 versus 1.0 ± 0, mean difference 1.1 [95% CI 0.1 to 2.1]; p = 0.003) and MMP13 (2.0 ± 0.8 versus 1.0 ± 0, mean difference 1.0 [95% CI 0.4 to 1.6]; p = 0.03) in the peracetic acid-ethanol combined irradiation group than in the control group. There was a higher amount of collagen Type I in tendons treated with peracetic acid-ethanol combined irradiation than in the control group (0.36 ± 0.03 versus 0.31 ± 0.04, mean difference 0.05 [95% CI 0.01 to 0.09]; p = 0.02). CONCLUSION: Treatment with peracetic acid-ethanol combined irradiation did not have any discernible adverse effect on the histology, fiber diameter, enzymatic resistance, collagen content, or biomechanical strength of the allograft tendons compared with the control group. Peracetic acid-ethanol combined irradiation treatment had a positive impact on remodeling of the extracellular matrix and realignment of collagen fibers. CLINICAL RELEVANCE: This sterilization method could be helpful to expand the scope and frequency with which allogeneic materials are applied. The long-term healing effect and strength of allograft tendons must be tested before clinical use, and it is necessary to conduct comparative studies on autografts and synthetic materials that are currently widely used clinically. CI - Copyright © 2024 by the Association of Bone and Joint Surgeons. FAU - Zhang, Haoran AU - Zhang H AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. FAU - Xu, Mingyou AU - Xu M AD - Department of Orthopedics, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. FAU - Zhao, Yiwei AU - Zhao Y AD - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Li, Zhiyi AU - Li Z AD - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Han, Bingtai AU - Han B AD - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Shengru AU - Wang S AD - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Zhang, Jingyu AU - Zhang J AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. FAU - Zhang, Jianguo AU - Zhang J AD - Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. FAU - Hu, Yongcheng AU - Hu Y AUID- ORCID: 0000-0002-9846-6735 AD - Department of Bone Tumor, Tianjin Hospital, Tianjin, China. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240301 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - I6KPI2E1HD (Peracetic Acid) RN - 3K9958V90M (Ethanol) SB - IM MH - Animals MH - Rabbits MH - Male MH - *Wound Healing/radiation effects/drug effects MH - *Peracetic Acid/pharmacology MH - *Allografts MH - *Ethanol/pharmacology MH - *Sterilization/methods MH - *Achilles Tendon/surgery/radiation effects/pathology MH - Tensile Strength MH - Biomechanical Phenomena MH - Time Factors MH - Tendon Injuries/surgery PMC - PMC11124595 COIS- Each author certifies that there are no funding or commercial associations (consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article related to the author or any immediate family members. All ICMJE Conflict of Interest Forms for authors and Clinical Orthopaedics and Related Research ® editors and board members are on file with the publication and can be viewed on request. EDAT- 2024/03/01 18:43 MHDA- 2024/05/29 18:43 PMCR- 2025/06/01 CRDT- 2024/03/01 14:53 PHST- 2023/09/07 00:00 [received] PHST- 2024/01/31 00:00 [accepted] PHST- 2024/05/29 18:43 [medline] PHST- 2024/03/01 18:43 [pubmed] PHST- 2024/03/01 14:53 [entrez] PHST- 2025/06/01 00:00 [pmc-release] AID - 00003086-202406000-00030 [pii] AID - CORR-D-23-01058 [pii] AID - 10.1097/CORR.0000000000003017 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2024 Jun 1;482(6):1074-1086. doi: 10.1097/CORR.0000000000003017. Epub 2024 Mar 1. PMID- 5897910 OWN - NLM STAT- MEDLINE DCOM- 19660209 LR - 20131121 IS - 0001-5598 (Print) IS - 0001-5598 (Linking) VI - 50 IP - 4 DP - 1965 Dec TI - [Intensity and duration of the effect of 6-methylprednisolone and its esters in rats]. PG - 621-42 FAU - Vogel, H G AU - Vogel HG LA - ger PT - Journal Article TT - Intensität und Dauer der Wirkung von 6-alpha-Methylprednisolon und seinen Estern an der Ratte. PL - Denmark TA - Acta Endocrinol (Copenh) JT - Acta endocrinologica JID - 0370312 RN - 0 (Acetates) RN - 0 (Liver Glycogen) RN - 0 (Propionates) RN - W980KJ009P (Corticosterone) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Acetates/*pharmacology MH - Animals MH - Blood MH - Connective Tissue/drug effects MH - Corticosterone MH - Femur MH - Granuloma MH - Liver Glycogen MH - Methylprednisolone/*pharmacology MH - Propionates/*pharmacology MH - Rats MH - Tendons MH - Time EDAT- 1965/12/01 00:00 MHDA- 1965/12/01 00:01 CRDT- 1965/12/01 00:00 PHST- 1965/12/01 00:00 [pubmed] PHST- 1965/12/01 00:01 [medline] PHST- 1965/12/01 00:00 [entrez] PST - ppublish SO - Acta Endocrinol (Copenh). 1965 Dec;50(4):621-42. PMID- 13406737 OWN - NLM STAT- MEDLINE DCOM- 20020501 LR - 20190513 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 135 IP - 2 DP - 1957 Feb 15 TI - The selective effect of proCaine on the stretch reflex and tendon jerk of soleus muscle when applied to its nerve. PG - 245-62 FAU - MATTHEWS, P B AU - MATTHEWS PB FAU - RUSHWORTH, G AU - RUSHWORTH G LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 4Z8Y51M438 (Procaine) SB - OM MH - Humans MH - *Muscle, Skeletal MH - Procaine/*pharmacology MH - Reflex/*drug effects MH - *Reflex, Stretch MH - *Tendons PMC - PMC1358831 OID - CLML: 5732:4576 OTO - NLM OT - *PROCAINE/effects OT - *REFLEX/effect of drugs on EDAT- 1957/02/15 00:00 MHDA- 1957/02/15 00:01 PMCR- 1958/02/15 CRDT- 1957/02/15 00:00 PHST- 1957/02/15 00:00 [pubmed] PHST- 1957/02/15 00:01 [medline] PHST- 1957/02/15 00:00 [entrez] PHST- 1958/02/15 00:00 [pmc-release] AID - 10.1113/jphysiol.1957.sp005707 [doi] PST - ppublish SO - J Physiol. 1957 Feb 15;135(2):245-62. doi: 10.1113/jphysiol.1957.sp005707. PMID- 37681499 OWN - NLM STAT- MEDLINE DCOM- 20231030 LR - 20231112 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 51 IP - 12 DP - 2023 Oct TI - The Effect of Combining Hyaluronic Acid and Human Dermal Fibroblasts on Tendon Healing. PG - 3243-3250 LID - 10.1177/03635465231191779 [doi] AB - BACKGROUND: The incidence of rotator cuff tears is rapidly increasing, and operative techniques for rotator cuff repair have been developed. However, the rates of postoperative retear remain high. PURPOSE/HYPOTHESIS: The purpose was to determine the effects of human dermal fibroblasts (HDFs) with hyaluronic acid (HA) on tendon-to-bone healing in a rabbit model of chronic rotator cuff tear injury. It was hypothesized that HA would enhance HDF proliferation and that a combination of HA and HDFs would produce a synergistic effect on the healing of repaired rotator cuff tendons of rabbits. STUDY DESIGN: Controlled laboratory study. METHODS: For in vitro study, HDFs were plated on a 24-well plate. After 1 day, 2 wells were designated as the test group and treated with 0.75% HA in phenol red-free Dulbecco's modified Eagle medium (DMEM). An other 2 wells served as control groups and were treated with the same volume of phenol red-free DMEM without HA. Each group was duplicated, resulting in a total of 4 wells, with 2 wells in each group for replication purposes. The cells were incubated for 24 hours, followed by 72-hour cultivation. Absorbance ratios at 96 and 24 hours were compared to evaluate cell proliferation. For the in vivo study, a total of 24 rabbits were randomly allocated to groups A, B, and C (n = 8 each). Supraspinatus tendons were detached bilaterally and left for 6 weeks to establish a chronic rotator tear model. Torn tendons were subsequently repaired using the following injections: group A, 0.5 × 10(6) HDFs with HA; group B, HA only; and group C, saline only. At 12 weeks after repair, biomechanical tests and histological evaluation were performed. RESULTS: In vitro study showed that HDF proliferation significantly increased with HA (HDFs with HA vs HDFs without HA; 3.96 ± 0.09 vs 2.53 ± 0.15; P < .01). In vivo, group A showed significantly higher load-to-failure values than the other groups (53.8 ± 6.9 N/kg for group A, 30.6 ± 6.4 N/kg for group B, and 24.3 ± 7.6 N/kg for group C; P < .001). Histological evaluation confirmed that group A showed higher collagen fiber density and better collagen fiber continuity, tendon-to-bone interface maturation, and nuclear shape than the other groups (all P < .05). CONCLUSION: This controlled laboratory study verified the potential of the combination of HDFs and HA in enhancing healing in a chronic rotator cuff tear rabbit model. CLINICAL RELEVANCE: A potential synergistic effect on rotator cuff tendon healing may be expected from a combination of HDFs and HA. FAU - Rhee, Sung-Min AU - Rhee SM AD - Shoulder & Elbow Clinic, Department of Orthopaedic Surgery, College of Medicine, Kyung Hee University, Seoul, Republic of Korea. FAU - Jeon, Saewha AU - Jeon S AD - Cutigen Research Institute, Tego Science Inc, Seoul, Republic of Korea. FAU - Han, Jikhyon AU - Han J AD - Cutigen Research Institute, Tego Science Inc, Seoul, Republic of Korea. FAU - Kim, Yun Hee AU - Kim YH AD - Cutigen Research Institute, Tego Science Inc, Seoul, Republic of Korea. FAU - Jeong, Hyeon Jang AU - Jeong HJ AD - Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea. FAU - Park, Joo Hyun AU - Park JH AD - Department of Orthopaedic Surgery, College of Medicine, Dongguk University Hospital, Goyang-si, Republic of Korea. FAU - Oh, Joo Han AU - Oh JH AD - Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230908 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 9004-61-9 (Hyaluronic Acid) RN - 9007-34-5 (Collagen) RN - 0 (Phenols) SB - IM MH - Animals MH - Humans MH - Rabbits MH - *Rotator Cuff Injuries/surgery/pathology MH - Hyaluronic Acid/pharmacology/therapeutic use MH - Wound Healing MH - Disease Models, Animal MH - Tendons/surgery MH - Rupture/surgery MH - Fibroblasts MH - Collagen/pharmacology MH - Phenols/pharmacology MH - Biomechanical Phenomena OTO - NOTNLM OT - chronic rotator cuff tear OT - healing OT - human dermal fibroblast OT - hyaluronic acid OT - rotator cuff tendon COIS- One or more of the authors has declared the following potential conflict of interest or source of funding: This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant No. HI20C0645). AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. EDAT- 2023/09/08 12:42 MHDA- 2023/10/30 06:47 CRDT- 2023/09/08 06:53 PHST- 2023/10/30 06:47 [medline] PHST- 2023/09/08 12:42 [pubmed] PHST- 2023/09/08 06:53 [entrez] AID - 10.1177/03635465231191779 [doi] PST - ppublish SO - Am J Sports Med. 2023 Oct;51(12):3243-3250. doi: 10.1177/03635465231191779. Epub 2023 Sep 8. PMID- 21720603 OWN - NLM STAT- MEDLINE DCOM- 20111025 LR - 20220321 IS - 1934-3418 (Electronic) IS - 1078-4519 (Linking) VI - 40 IP - 3 DP - 2011 Mar TI - The effect of butyric acid on normal tendons: a potential stimulus for extracellular matrix expression. PG - 142-7 AB - We propose comparing angiogenic effects of butyric acid (BA)-impregnated suture vs control suture on an aged tendon model. Twenty-four 3-year-old rabbits underwent bilateral Achilles tendon exposure. BA-impregnated orthopedic suture was sutured into one side, and a control orthopedic suture into the contralateral side similarly. The rabbits were sacrificed at 7, 30, and 45 days and the tendons harvested for gross, histologic, and biochemical study. Histologically, there was increased vascularity/cell migration at all time points in the BA-treated tendons; proteoglycan expression (ie, safranin O staining) increased at 30 and 45 days. DNA concentration was significantly (P = .05) higher in the BA-treated tendon group relative to the control group at 7 days but was unchanged at 30 and 45 days. Similarly, messenger RNA (mRNA) expression of vascular endothelial growth factor (VEGF) was significantly (P = .05) higher in the BA-treated tendon at 7 days. A trend (P = .12) for higher expression in the BA group also was found at 30 days. FAU - Tracy, Sean C AU - Tracy SC AD - San Diego Arthroscopy and Sports Medicine Center, San Diego, California, USA. FAU - Tasto, James P AU - Tasto JP FAU - Oshima, Yasushi AU - Oshima Y FAU - Murata, Ryo AU - Murata R FAU - Garcia, Jason AU - Garcia J FAU - Amiel, David AU - Amiel D LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Orthop (Belle Mead NJ) JT - American journal of orthopedics (Belle Mead, N.J.) JID - 9502918 RN - 0 (Histamine Antagonists) RN - 0 (RNA, Messenger) RN - 0 (Vascular Endothelial Growth Factor A) RN - 107-92-6 (Butyric Acid) RN - 9007-49-2 (DNA) SB - IM MH - Achilles Tendon/blood supply/*drug effects/metabolism/pathology MH - Animals MH - Butyric Acid/*pharmacology MH - Cell Movement/drug effects MH - DNA/biosynthesis MH - Extracellular Matrix/*drug effects/metabolism/pathology MH - Gene Expression/drug effects MH - Histamine Antagonists/*pharmacology MH - Neovascularization, Physiologic/drug effects MH - RNA, Messenger/metabolism MH - Rabbits MH - Vascular Endothelial Growth Factor A/genetics/metabolism EDAT- 2011/07/02 06:00 MHDA- 2011/10/26 06:00 CRDT- 2011/07/02 06:00 PHST- 2011/07/02 06:00 [entrez] PHST- 2011/07/02 06:00 [pubmed] PHST- 2011/10/26 06:00 [medline] PST - ppublish SO - Am J Orthop (Belle Mead NJ). 2011 Mar;40(3):142-7. PMID- 36700268 OWN - NLM STAT- MEDLINE DCOM- 20230130 LR - 20230215 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 34 IP - 1 DP - 2023 TI - Effects of L-carnitine on healing of Achilles tendon in rats. PG - 84-91 LID - jdrs.2023.853 [pii] LID - 10.52312/jdrs.2023.853 [doi] AB - OBJECTIVES: In this experimental study, we aimed to analyze the effects of levocarnitine (L-carnitine) on tendon healing after surgical repair of Achilles tendon rupture in a rat model. MATERIALS AND METHODS: The study included 40 Wistar Albino rats divided into four groups: Group 1, neither surgical intervention nor substance applications were performed for the Achilles tendons. In the other groups, the right Achilles tendons were cut using a scalpel and repaired with a modified Kessler-type technique with 3/0 monofilament polydioxanone suture. In Group 2, the rats did not receive any additional treatment, except for surgical repair. In Group 3, the same volume similar to Group 4 of saline solution was administered intraperitoneally for seven days. In Group 4, each rat received 300 mg/kg of L-carnitine intraperitoneally for seven days. At Week 6, all rats were sacrificed. All right Achilles tendons were used for biomechanical tests and histopathological evaluations. Biochemical analysis of the matrix metalloproteinase was also performed using the blood specimens. RESULTS: There were no significant differences among the groups in terms of the histopathological parameters. Although the mean matrix metalloproteinase level was low in the L-carnitine group, it did not reach statistical significance. A significant increase in maximum force, tensile strength, and strength to 2-mm gap was observed in the L-carnitine group. CONCLUSION: The significant effects of L-carnitine on biomechanical parameters may indicate favorable effects on Achilles tendon healing in rats by reducing matrix metalloproteinase 2 and 9. To improve Achilles tendon healing, further investigation for these markers is needed. Since the effects of L-carnitine on the Achilles tendon cannot be clearly distinguished histopathologically, further studies involving L-carnitine-induced effects are warranted. FAU - Kuşcu, Burak AU - Kuşcu B AD - Kahramanmaraş Pazarcık Devlet Hastanesi Ortopedi ve Travmatoloji Kliniği, 46700 Pazarcık, Kahramanmaraş, Türkiye. dr.burakkuscu@hotmail.com. FAU - Bilal, Ökkeş AU - Bilal Ö FAU - Doğar, Fatih AU - Doğar F FAU - Topak, Duran AU - Topak D FAU - Gürbüz, Kaan AU - Gürbüz K FAU - Dere, Kadir İsmail AU - Dere Kİ FAU - Telek, Mikail AU - Telek M FAU - Karadeniz, Ali Aydın AU - Karadeniz AA FAU - Seyithanoğlu, Muhammed AU - Seyithanoğlu M FAU - Koçaslan, Sezen AU - Koçaslan S LA - eng PT - Journal Article DEP - 20221227 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - S7UI8SM58A (Carnitine) SB - IM MH - Animals MH - Rats MH - *Achilles Tendon/drug effects/surgery MH - Matrix Metalloproteinase 2 MH - Rats, Wistar MH - Rupture MH - *Wound Healing/drug effects MH - *Carnitine/pharmacology PMC - PMC9903123 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2023/01/27 06:00 MHDA- 2023/01/28 06:00 PMCR- 2022/12/27 CRDT- 2023/01/26 02:56 PHST- 2022/09/17 00:00 [received] PHST- 2022/11/15 00:00 [accepted] PHST- 2023/01/26 02:56 [entrez] PHST- 2023/01/27 06:00 [pubmed] PHST- 2023/01/28 06:00 [medline] PHST- 2022/12/27 00:00 [pmc-release] AID - jdrs.2023.853 [pii] AID - 10.52312/jdrs.2023.853 [doi] PST - ppublish SO - Jt Dis Relat Surg. 2023;34(1):84-91. doi: 10.52312/jdrs.2023.853. Epub 2022 Dec 27. PMID- 16902184 OWN - NLM STAT- MEDLINE DCOM- 20070208 LR - 20200930 IS - 0363-6119 (Print) IS - 0363-6119 (Linking) VI - 292 IP - 1 DP - 2007 Jan TI - Pifithrin-alpha, an inhibitor of p53 transactivation, alters the inflammatory process and delays tendon healing following acute injury. PG - R321-7 AB - Transcription factor p53, which was initially associated with cancer, has now emerged as an important regulator of inflammation and extracellular matrix homeostasis, two processes highly relevant to tendon repair. The goal of this study was to evaluate the effect of a p53 transactivation inhibitor, namely, pifithrin-alpha, on the pathophysiological sequence following collagenase-induced tendon injury. Administration of pifithrin-alpha during the inflammatory phase reduced the accumulation of neutrophils and macrophages by 30 and 40%, respectively, on day 3 postinjury. Pifithrin-alpha failed to reduce the percentage of apoptotic cells following collagenase injection but delayed functional recovery. In uninjured Achilles tendons, pifithrin-alpha increased metalloprotease activity 2.4-fold. Accordingly, pifithrin-alpha reduced the collagen content in intact tendons as well as in injured tendons 7 days posttrauma compared with placebo. The effect of pifithrin-alpha on load to failure and stiffness was also evaluated. The administration of pifithrin-alpha during the inflammatory phase did not significantly decrease the functional deficit 3 days posttrauma. More importantly, load to failure and stiffness were significantly decreased in the pifithrin-alpha group from day 7 to day 28 compared with placebo. Overall, our results suggest that administration of pifithrin-alpha alters the inflammatory process and delays tendon healing. The present findings also support the concept that p53 can regulate extracellular matrix homeostasis in vivo. FAU - Marsolais, David AU - Marsolais D AD - CRML, CHUL Research Center, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada. FAU - Côté, Claude H AU - Côté CH FAU - Frenette, Jérôme AU - Frenette J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060810 PL - United States TA - Am J Physiol Regul Integr Comp Physiol JT - American journal of physiology. Regulatory, integrative and comparative physiology JID - 100901230 RN - 0 (Benzothiazoles) RN - 3FPU23BG52 (Toluene) RN - 9000-70-8 (Gelatin) RN - 9007-34-5 (Collagen) RN - D213B92S1Y (pifithrin) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.24.- (Collagenases) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Achilles Tendon/injuries MH - Animals MH - Apoptosis/drug effects MH - Benzothiazoles/*pharmacology MH - Biomechanical Phenomena MH - Caspase 3/physiology MH - Collagen/metabolism MH - Collagenases/metabolism MH - Female MH - Gelatin/metabolism MH - Genes, p53/*drug effects MH - Homeostasis/physiology MH - Hydroxyproline/metabolism MH - Inflammation/metabolism/*pathology MH - Leukocytes/drug effects MH - Rats MH - Rats, Wistar MH - Tendon Injuries/metabolism/*pathology MH - Toluene/*analogs & derivatives/pharmacology MH - Transcriptional Activation/*drug effects MH - Wound Healing/*drug effects EDAT- 2006/08/12 09:00 MHDA- 2007/02/09 09:00 CRDT- 2006/08/12 09:00 PHST- 2006/08/12 09:00 [pubmed] PHST- 2007/02/09 09:00 [medline] PHST- 2006/08/12 09:00 [entrez] AID - 00411.2005 [pii] AID - 10.1152/ajpregu.00411.2005 [doi] PST - ppublish SO - Am J Physiol Regul Integr Comp Physiol. 2007 Jan;292(1):R321-7. doi: 10.1152/ajpregu.00411.2005. Epub 2006 Aug 10. PMID- 36604630 OWN - NLM STAT- MEDLINE DCOM- 20230109 LR - 20230111 IS - 2661-8850 (Electronic) IS - 2661-8850 (Linking) VI - 24 IP - 1 DP - 2023 Jan 5 TI - N-Acetyl-L-cysteine facilitates tendon repair and promotes the tenogenic differentiation of tendon stem/progenitor cells by enhancing the integrin α5/β1/PI3K/AKT signaling. PG - 1 LID - 10.1186/s12860-022-00463-0 [doi] LID - 1 AB - BACKGROUND: Tendon injury is associated with oxidative stress, leading to reactive oxygen species (ROS) production and inflammation. N-acetyl-L-cysteine (NAC) is a potent antioxidant. However, how NAC affects the biological functions of tendon stem/progenitor cells (TSPCs) and tendon repair has not been clarified.  METHOD: The impacts of NAC on the viability, ROS production, and differentiation of TSPCs were determined with the cell counting kit-8, fluorescence staining, Western blotting, and immunofluorescence. The effect of NAC on gene transcription in TSPCs was analyzed by transcriptomes and bioinformatics and validated by Western blotting. The potential therapeutic effect of NAC on tendon repair was tested in a rat model of Achilles tendon injury. RESULTS: Compared with the untreated control, treatment with 500 µM NAC greatly promoted the proliferation of TSPCs and significantly mitigated hydrogen peroxide-induced ROS production and cytotoxicity in vitro. NAC treatment significantly increased the relative protein expression of collagen type 1 alpha 1 (COL1A1), tenascin C (TNC), scleraxis (SCX), and tenomodulin (TNMD) in TPSCs. Bioinformatics analyses revealed that NAC modulated transcriptomes, particularly in the integrin-related phosphoinositide 3-kinase (PI3K)/AKT signaling, and Western blotting revealed that NAC enhanced integrin α5β1 expression and PI3K/AKT activation in TSPCs. Finally, NAC treatment mitigated the tendon injury, but enhanced the protein expression of SCX, TNC, TNMD, and COLIA1 in the injured tissue regions of the rats. CONCLUSION: NAC treatment promoted the survival and differentiation of TSPCs to facilitate tendon repair after tendon injury in rats. Thus, NAC may be valuable for the treatment of tendon injury. CI - © 2023. The Author(s). FAU - Lu, Kang AU - Lu K AD - Department of Orthopedics-Spine Surgery Center, the Second Affiliated Hospital, Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, China. FAU - Zhou, Mei AU - Zhou M AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - Wang, Liyuan AU - Wang L AD - Department of Orthopedics-Spine Surgery Center, the Second Affiliated Hospital, Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, China. FAU - Wang, Yang AU - Wang Y AD - Department of Orthopedics-Spine Surgery Center, the Second Affiliated Hospital, Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, China. FAU - Tang, Hong AU - Tang H AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - He, Gang AU - He G AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - Wang, Huan AU - Wang H AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - Tang, Chuyue AU - Tang C AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - He, Jie AU - He J AD - Department of Orthopedics-Spine Surgery Center, the Second Affiliated Hospital, Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, China. FAU - Wang, Wei AU - Wang W AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. tangkanglai@hotmail.com. FAU - Wang, Yunjiao AU - Wang Y AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Army Medical University, Third Military Medical University, No. 29, Yanzheng Street, Gaotan, Shapingba District, Chongqing, China. wangyunjiao@tmmu.edu.cn. FAU - Deng, Zhongliang AU - Deng Z AD - Department of Orthopedics-Spine Surgery Center, the Second Affiliated Hospital, Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, China. dengzl@cqmu.edu.cn. LA - eng GR - CQYC2021059825/Chongqing talents funding/ GR - CQYC2021059825/Chongqing talents funding/ GR - CQYC2021059825/Chongqing talents funding/ GR - 4174DH/National Key Research of China/ GR - 4174DH/National Key Research of China/ GR - 4174DH/National Key Research of China/ GR - 82002306/National Science Foundation for Young Scientists of China/ GR - 82002306/National Science Foundation for Young Scientists of China/ GR - 82002306/National Science Foundation for Young Scientists of China/ GR - cstc2021jcyj-msxmX0137/Chongqing Science & Technology Commission/ GR - cstc2021jcyj-msxmX0137/Chongqing Science & Technology Commission/ GR - cstc2021jcyj-msxmX0137/Chongqing Science & Technology Commission/ GR - cstc2020jcyj-cxttX0004/Sports Injury Repair and Reconstruction Research Innovation Group/ GR - cstc2020jcyj-cxttX0004/Sports Injury Repair and Reconstruction Research Innovation Group/ GR - cstc2020jcyj-cxttX0004/Sports Injury Repair and Reconstruction Research Innovation Group/ PT - Journal Article DEP - 20230105 PL - England TA - BMC Mol Cell Biol JT - BMC molecular and cell biology JID - 101741148 RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 0 (Integrin alpha5beta1) RN - WYQ7N0BPYC (Acetylcysteine) RN - 0 (Integrin alpha5) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) RN - 0 (Reactive Oxygen Species) SB - IM MH - Rats MH - Animals MH - *Phosphatidylinositol 3-Kinases/metabolism MH - Integrin alpha5beta1/metabolism MH - Acetylcysteine/pharmacology/metabolism MH - Integrin alpha5/metabolism/pharmacology MH - Proto-Oncogene Proteins c-akt/metabolism MH - Phosphatidylinositol 3-Kinase/metabolism/pharmacology MH - Reactive Oxygen Species/metabolism MH - Tendons MH - Cell Differentiation/genetics MH - Stem Cells MH - *Tendon Injuries/drug therapy/metabolism PMC - PMC9814204 OTO - NOTNLM OT - Differentiation OT - NAC OT - Rats OT - TSPCs OT - Tendon injury COIS- The authors declare that they have no conflict of interest. EDAT- 2023/01/06 06:00 MHDA- 2023/01/10 06:00 PMCR- 2023/01/05 CRDT- 2023/01/05 23:36 PHST- 2022/09/07 00:00 [received] PHST- 2022/12/26 00:00 [accepted] PHST- 2023/01/05 23:36 [entrez] PHST- 2023/01/06 06:00 [pubmed] PHST- 2023/01/10 06:00 [medline] PHST- 2023/01/05 00:00 [pmc-release] AID - 10.1186/s12860-022-00463-0 [pii] AID - 463 [pii] AID - 10.1186/s12860-022-00463-0 [doi] PST - epublish SO - BMC Mol Cell Biol. 2023 Jan 5;24(1):1. doi: 10.1186/s12860-022-00463-0. PMID- 11561237 OWN - NLM STAT- MEDLINE DCOM- 20011018 LR - 20131121 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 26 IP - 5 DP - 2001 Sep TI - Flexor tendon wound healing in vitro: the effect of lactate on tendon cell proliferation and collagen production. PG - 847-54 AB - Flexor tendon repair in zone II is complicated by adhesions to the surrounding fibro-osseous sheath. Lactate is an early mediator of wound healing known to play an important role in stimulation of collagen production after cellular injury. Little attention has been paid to the role of lactate in flexor tendon wound healing. In this study tendon and tendon sheath were excised from rabbit forepaws. We examined proliferation of tendon sheath fibroblasts, epitenon tenocytes, and endotenon tenocytes; collagen production by each of these 3 cell types; and effects of lactate on cell proliferation and collagen production. Three cell lines, tendon sheath, epitenon, and endotenon, were isolated and cultured. Tendon sheath fibroblasts showed the greatest proliferation. All 3 cell lines produced collagen I, II, and III. Lactate significantly increased collagen production by all 3 cell lines. We show that cells of the tendon sheath, epitenon, and endotenon produce collagen in vitro. Modulation of lactate levels may provide a means to modulate collagen production. FAU - Klein, M B AU - Klein MB AD - Division of Plastic Surgery, Stanford University Medical Center, Stanford, CA 94305, USA. FAU - Pham, H AU - Pham H FAU - Yalamanchi, N AU - Yalamanchi N FAU - Chang, J AU - Chang J LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Culture Media) RN - 33X04XA5AT (Lactic Acid) RN - 9007-34-5 (Collagen) SB - IM EIN - J Hand Surg [Am] 2002 Jul;27(4):740 MH - Animals MH - Cell Division/physiology MH - Cells, Cultured MH - Collagen/*biosynthesis MH - Culture Media MH - Enzyme-Linked Immunosorbent Assay MH - Lactic Acid/*pharmacology MH - Male MH - Rabbits MH - *Tendon Injuries/*physiopathology MH - Tendons/cytology MH - Tissue Adhesions/physiopathology MH - Wound Healing/*physiology EDAT- 2001/09/19 10:00 MHDA- 2001/10/19 10:01 CRDT- 2001/09/19 10:00 PHST- 2001/09/19 10:00 [pubmed] PHST- 2001/10/19 10:01 [medline] PHST- 2001/09/19 10:00 [entrez] AID - S0363-5023(01)22297-7 [pii] AID - 10.1053/jhsu.2001.26185 [doi] PST - ppublish SO - J Hand Surg Am. 2001 Sep;26(5):847-54. doi: 10.1053/jhsu.2001.26185. PMID- 2453073 OWN - NLM STAT- MEDLINE DCOM- 19880623 LR - 20190824 IS - 0090-6980 (Print) IS - 0090-6980 (Linking) VI - 34 IP - 6 DP - 1987 Dec TI - Changes in protein turnover in hypertrophying plantaris muscles of rats: effect of fenbufen--an inhibitor of prostaglandin synthesis. PG - 841-52 AB - Plantaris muscle of the right hind limb of rats was subjected to hypertrophic stimulus by section of the tendons of the right gastrocnemius muscle. The RNA and protein content and the fractional rate of protein synthesis were elevated both 3 and 7 days after operation compared both with the unoperated left limb and with sham-operated control rats. The rate of protein degradation, calculated from the difference between the fractional rates of protein synthesis and protein gain of the muscles, was elevated in the plantaris 3-7 days after tenotomy. Dietary administration of the drug fenbufen reduced the RNA content and the ratio of RNA:protein in muscles from control animals. In one group of tenotomised rats administration of fenbufen commenced 3 days before tenotomy and resulted in a reduction in the ratio RNA:protein of the muscles of the left limb 3 days after the operation. Four days later, i.e. 7 days after tenotomy, both the ratio RNA:protein and the fractional rate of protein synthesis were significantly reduced in the fenbufen treated rats. In spite of these effects, fenbufen did not impair the ability of the plantaris to hypertrophy since the drug also reduced the rate of protein degradation. FAU - McMillan, D N AU - McMillan DN AD - Division of Biochemistry, Rowett Research Institute, Bucksburn, Aberdeen, Scotland. FAU - Reeds, P J AU - Reeds PJ FAU - Lobley, G E AU - Lobley GE FAU - Palmer, R M AU - Palmer RM LA - eng PT - Journal Article PL - United States TA - Prostaglandins JT - Prostaglandins JID - 0320271 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Phenylbutyrates) RN - 0 (Prostaglandins E) RN - 0 (Proteins) RN - 63231-63-0 (RNA) RN - 9815R1WR9B (fenbufen) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Dinoprostone MH - Female MH - Hindlimb MH - Hypertrophy/metabolism MH - Muscles/drug effects/*metabolism/pathology MH - Phenylbutyrates/*pharmacology MH - Prostaglandins E/urine MH - Proteins/*metabolism MH - RNA/metabolism MH - Rats MH - Rats, Inbred Strains EDAT- 1987/12/01 00:00 MHDA- 1987/12/01 00:01 CRDT- 1987/12/01 00:00 PHST- 1987/12/01 00:00 [pubmed] PHST- 1987/12/01 00:01 [medline] PHST- 1987/12/01 00:00 [entrez] AID - 0090-6980(87)90065-7 [pii] AID - 10.1016/0090-6980(87)90065-7 [doi] PST - ppublish SO - Prostaglandins. 1987 Dec;34(6):841-52. doi: 10.1016/0090-6980(87)90065-7. PMID- 12628822 OWN - NLM STAT- MEDLINE DCOM- 20031215 LR - 20191210 IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 24 IP - 12 DP - 2003 May TI - The chitosan prepared from crab tendon I: the characterization and the mechanical properties. PG - 2031-6 AB - Crystalline chitosan was prepared from crab tendon consisting mainly of chitin, including various proteins and calcium phosphates. The crab tendon has high mechanical properties due to its aligned molecular structure. Crab tendon components, i.e. proteins and calcium phosphates, were removed by deacetyl treatment using 50wt% NaOH aqueous solution at 100 degrees C, and a subsequent ethanol treatment. As judged from microscopic observations using an optical polarizer, the treated chitosan remained intact regarding its aligned molecular structure, and had a high tensile strength of 67.9+/-11.4MPa. The tensile strength was further enhanced to 235+/-30MPa by a thermal treatment at 120 degrees C, corresponding to the formation of the intermolecular hydrogen bonds. FAU - Yamaguchi, Isamu AU - Yamaguchi I AD - National Institute for Materials Science, Advanced Materials Laboratory, Namiki 1-1, Tsukuba, 305-0044, Ibaraki, Japan. i_yamaguchi@takichem.co.jp FAU - Itoh, Soichiro AU - Itoh S FAU - Suzuki, Masumi AU - Suzuki M FAU - Sakane, Masataka AU - Sakane M FAU - Osaka, Akiyoshi AU - Osaka A FAU - Tanaka, Junzo AU - Tanaka J LA - eng PT - Journal Article PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Biocompatible Materials) RN - 0 (Calcium Phosphates) RN - 0 (alpha-tricalcium phosphate) RN - 0 (tetracalcium phosphate) RN - 1398-61-4 (Chitin) RN - 3K9958V90M (Ethanol) RN - 55X04QC32I (Sodium Hydroxide) RN - 701EKV9RMN (calcium phosphate, monobasic, anhydrous) RN - 9012-76-4 (Chitosan) RN - 97Z1WI3NDX (calcium phosphate) RN - L11K75P92J (calcium phosphate, dibasic, anhydrous) SB - IM MH - Animals MH - Biocompatible Materials/chemistry MH - Calcium Phosphates/chemistry MH - Chitin/*analogs & derivatives/*analysis/*chemistry MH - Chitosan MH - Crystallography, X-Ray MH - Decapoda MH - Ethanol/pharmacology MH - Hot Temperature MH - Hydrogen Bonding MH - Sodium Hydroxide/pharmacology MH - Spectroscopy, Fourier Transform Infrared MH - Temperature MH - Tendons/*metabolism MH - Tensile Strength EDAT- 2003/03/12 04:00 MHDA- 2003/12/16 05:00 CRDT- 2003/03/12 04:00 PHST- 2003/03/12 04:00 [pubmed] PHST- 2003/12/16 05:00 [medline] PHST- 2003/03/12 04:00 [entrez] AID - S0142961202006336 [pii] AID - 10.1016/s0142-9612(02)00633-6 [doi] PST - ppublish SO - Biomaterials. 2003 May;24(12):2031-6. doi: 10.1016/s0142-9612(02)00633-6. PMID- 7986277 OWN - NLM STAT- MEDLINE DCOM- 19950112 LR - 20131121 IS - 0735-0414 (Print) IS - 0735-0414 (Linking) VI - 29 IP - 4 DP - 1994 Jul TI - The in vitro binding of acetaldehyde to collagen studied by neutron diffraction. PG - 403-9 AB - The location of acetaldehyde binding sites in the axial unit cell of tendon collagen was investigated by neutron diffraction. Acetaldehyde forms spontaneous cross-links with specific residues in collagen. The use of deuterated acetaldehyde increased the neutron scattering length of these groups. The introduction of deuterated acetaldehyde at specific locations allowed the acetaldehyde-reacted collagen to be treated as multiple isomorphous derivatives for neutron fibre diffraction. The low resolution axially projected structure was determined using amplitudes of the first eight meridional reflections (d = 67 nm). Results indicate that the process of acetaldehyde labelling takes place at different rates at different sites within the collagen fibril. The position of acetaldehyde attachment correlates well with the position of lysine and hydroxylysine residues especially in the regions of the molecular termini. This information is relevant to the process of cirrhosis and fibrosis of the liver since adduction of collagen by acetaldehyde may interfere with normal Schiff base cross-link formation at the C- and N-termini. This may result in subsequent alterations in the intra- and inter-molecular cross-linking pattern of collagen molecules. FAU - Wess, T J AU - Wess TJ AD - Department of Biochemistry, University of Edinburgh Medical School, U.K. FAU - Wess, L AU - Wess L FAU - Miller, A AU - Miller A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Alcohol Alcohol JT - Alcohol and alcoholism (Oxford, Oxfordshire) JID - 8310684 RN - 9007-34-5 (Collagen) RN - GO1N1ZPR3B (Acetaldehyde) SB - IM MH - Acetaldehyde/*pharmacokinetics MH - Animals MH - Binding Sites MH - Collagen/*metabolism MH - Neutrons MH - Rats MH - Rats, Wistar MH - Tendons/metabolism MH - X-Ray Diffraction EDAT- 1994/07/01 00:00 MHDA- 1994/07/01 00:01 CRDT- 1994/07/01 00:00 PHST- 1994/07/01 00:00 [pubmed] PHST- 1994/07/01 00:01 [medline] PHST- 1994/07/01 00:00 [entrez] PST - ppublish SO - Alcohol Alcohol. 1994 Jul;29(4):403-9. PMID- 5592925 OWN - NLM STAT- MEDLINE DCOM- 19680913 LR - 20171116 IS - 0007-2680 (Print) IS - 0007-2680 (Linking) VI - 215 IP - 1 DP - 1967 Aug TI - [Animal experimental studies of the gliding problem of injured tendons]. PG - 111-25 FAU - Zeumer, G AU - Zeumer G LA - ger PT - Journal Article TT - Tierexperimentelle Untersuchungen zum Gleitproblem verletzter Sehnen. PL - Germany TA - Bruns Beitr Klin Chir (1971) JT - Bruns' Beitrage fur klinische Chirurgie JID - 7611943 RN - 0 (Dextrans) RN - 0 (Fats) RN - FZ989GH94E (Povidone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Animals MH - Cicatrix/drug effects MH - Connective Tissue/*drug effects MH - Dextrans/*pharmacology MH - Fats/*pharmacology MH - Hydrocortisone/*pharmacology MH - Povidone/*pharmacology MH - Rabbits MH - Rats MH - Tendon Injuries/*drug therapy/physiopathology MH - Wound Healing/drug effects EDAT- 1967/08/01 00:00 MHDA- 1967/08/01 00:01 CRDT- 1967/08/01 00:00 PHST- 1967/08/01 00:00 [pubmed] PHST- 1967/08/01 00:01 [medline] PHST- 1967/08/01 00:00 [entrez] PST - ppublish SO - Bruns Beitr Klin Chir (1971). 1967 Aug;215(1):111-25. PMID- 31631887 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20200218 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 25 DP - 2019 Oct 21 TI - Tamoxifen Inhibits the Progression of Trauma-Induced Heterotopic Ossification in Mice. PG - 7872-7881 LID - 10.12659/MSM.916733 [doi] AB - BACKGROUND Heterotopic ossification (HO) is a kind of abnormal mineralized bone which usually occurs in muscle, tendon, or ligament. There are currently no effective drugs for the treatment and prevention of HO. Developing effective drugs that can inhibit HO is of profound significance and would provide new strategies for clinical treatment of this disease. The present investigation evaluated the inhibitory effect of tamoxifen against HO. MATERIAL AND METHODS Using an Achilles tendon trauma-induced HO female mice model, we screened different doses of tamoxifen (1, 3, and 9 mg/kg) in mice to determine the optimal dosage on the inhibition of the HO formation. The curative effect of tamoxifen was also illustrated at different HO progression stages including inflammation, chondrogenesis, osteogenesis, and HO maturation. RESULTS Heterotopic bone was formed with typical endochondral ossification in Achilles tendons 6 weeks after surgery and continued to enlarge up to 12 weeks. The formation of HO was significantly inhibited with the treatment of tamoxifen at the dosage of 9 mg/kg, whereas 1 mg/kg and 3 mg/kg did not reduce HO bone volume remarkably. The progression of HO was both attenuated by tamoxifen from Day 1 and Week 4 post-surgery, whereas no inhibitory effect was shown at the osteogenesis and maturation stages treated with tamoxifen. CONCLUSIONS Tamoxifen exerts an inhibitory effect on the heterotopic bone progression at inflammation and chondrogenesis stages, with the TGF-ß signaling pathway suppressed following the increase in estrogen receptor alpha activity. FAU - Mao, Dong AU - Mao D AD - Research Institute of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China (mainland). FAU - Mi, Jingyi AU - Mi J AD - Department of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China (mainland). FAU - Pan, Xiaoyun AU - Pan X AD - Research Institute of Hand Surgery, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China (mainland). FAU - Li, Fengfeng AU - Li F AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China (mainland). FAU - Rui, Yongjun AU - Rui Y AD - Department of Orthopedics, Wuxi 9th People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China (mainland). LA - eng PT - Journal Article DEP - 20191021 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Achilles Tendon/*drug effects MH - Animals MH - Bone and Bones/metabolism MH - China MH - Chondrogenesis/drug effects MH - Disease Models, Animal MH - Disease Progression MH - Female MH - Mice MH - Mice, Inbred C57BL MH - Muscles/metabolism MH - Ossification, Heterotopic/*drug therapy/metabolism MH - Osteogenesis/drug effects MH - Signal Transduction/drug effects MH - Tamoxifen/metabolism/*pharmacology MH - Tendon Injuries/drug therapy PMC - PMC6820362 COIS- Conflict of interests None. EDAT- 2019/10/22 06:00 MHDA- 2020/02/19 06:00 PMCR- 2019/10/21 CRDT- 2019/10/22 06:00 PHST- 2019/10/22 06:00 [entrez] PHST- 2019/10/22 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2019/10/21 00:00 [pmc-release] AID - 916733 [pii] AID - 10.12659/MSM.916733 [doi] PST - epublish SO - Med Sci Monit. 2019 Oct 21;25:7872-7881. doi: 10.12659/MSM.916733. PMID- 23661215 OWN - NLM STAT- MEDLINE DCOM- 20131209 LR - 20130604 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 41 IP - 6 DP - 2013 Jun TI - Bupivacaine induces short-term alterations and impairment in rat tendons. PG - 1411-8 LID - 10.1177/0363546513485406 [doi] AB - BACKGROUND: Toxicity of the local anesthetic bupivacaine (BV) has been a matter of debate across medical fields. Numerous in vitro studies demonstrate considerable toxicity of BV on various cell types. PURPOSE: This study addresses the question of how tendon tissue responds to BV in vivo and in vitro. STUDY DESIGN: Controlled laboratory study. METHODS: In vitro studies on cultured rat Achilles tendon-derived cells were performed with cell viability assays and cleaved caspase 3 immunocytochemistry. Quantitative reverse transcription-polymerase chain reaction, Western blotting, gelatin zymography, and a biomechanical testing routine were applied on rat Achilles tendons at 1 and 4 weeks after a single unilateral peritendinous injection of 0.5% BV. The BV-mediated cell death in tendons was estimated with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and immunohistochemical detection of cleaved caspase 3. RESULTS: Treatment of rat tendon-derived cells with 0.5% bupivacaine for 10 minutes had detrimental effects on cell viability, which can be reduced by N-acetyl-L-cysteine or reduction of extracellular calcium. In vivo, single peritendinous injections of BV caused apoptosis in endotenon cells and an increase of pro-matrix metalloproteinase-9 after 6 hours. The collagen ratio shifted toward collagen type III after 6 hours and 2 days; scleraxis messenger RNA (mRNA) expression was reduced by 87%. Maximum tensile load was reduced by 17.6% after 1 week. CONCLUSION: Bupivacaine exerts a severe, reactive oxygen species-mediated effect on tendon cell viability in vitro in a time- and dose-dependent manner, depending on extracellular calcium concentration. Culture conditions need to be taken into account when in vitro data are translated into the in vivo situation. In vivo, administration of BV elicits a marked but temporary functional damage. CLINICAL RELEVANCE: Local anesthetics cause short-term alterations in rat tendons, which, if occurring in humans to a similar extent, may be relevant regarding decreased biomechanical properties and increased vulnerability to tendon overload or injury. FAU - Lehner, Christine AU - Lehner C AD - Paracelsus Medical University, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Institute of Tendon and Bone Regeneration, Salzburg, Austria. FAU - Gehwolf, Renate AU - Gehwolf R FAU - Hirzinger, Corinna AU - Hirzinger C FAU - Stephan, Daniel AU - Stephan D FAU - Augat, Peter AU - Augat P FAU - Tauber, Mark AU - Tauber M FAU - Resch, Herbert AU - Resch H FAU - Bauer, Hans-Christian AU - Bauer HC FAU - Bauer, Hannelore AU - Bauer H FAU - Tempfer, Herbert AU - Tempfer H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130509 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anesthetics, Local) RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (RNA, Messenger) RN - 0 (Scx protein, rat) RN - 9007-34-5 (Collagen) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - Y8335394RO (Bupivacaine) SB - IM MH - Achilles Tendon/cytology/*drug effects/pathology MH - Anesthetics, Local/*toxicity MH - Animals MH - Apoptosis/*drug effects MH - Basic Helix-Loop-Helix Transcription Factors/genetics MH - Biomechanical Phenomena MH - Bupivacaine/*toxicity MH - Caspase 3/metabolism MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/metabolism MH - Dose-Response Relationship, Drug MH - Female MH - Gene Expression MH - Matrix Metalloproteinase 9/metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Inbred Lew MH - Rupture/chemically induced MH - Tensile Strength MH - Time Factors OTO - NOTNLM OT - biomechanics OT - bupivacaine toxicity OT - extracellular calcium OT - local anesthetics OT - tendon EDAT- 2013/05/11 06:00 MHDA- 2013/12/16 06:00 CRDT- 2013/05/11 06:00 PHST- 2013/05/11 06:00 [entrez] PHST- 2013/05/11 06:00 [pubmed] PHST- 2013/12/16 06:00 [medline] AID - 0363546513485406 [pii] AID - 10.1177/0363546513485406 [doi] PST - ppublish SO - Am J Sports Med. 2013 Jun;41(6):1411-8. doi: 10.1177/0363546513485406. Epub 2013 May 9. PMID- 22727924 OWN - NLM STAT- MEDLINE DCOM- 20130412 LR - 20181201 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 37 IP - 8 DP - 2012 Aug TI - The effect of suture coated with mesenchymal stem cells and bioactive substrate on tendon repair strength in a rat model. PG - 1639-45 LID - 10.1016/j.jhsa.2012.04.038 [doi] AB - PURPOSE: Exogenously administered mesenchymal stem cells and bioactive molecules are known to enhance tendon healing. Biomolecules have been successfully delivered using sutures that elute growth factors over time. We sought to evaluate the histologic and biomechanical effect of delivering both cells and bioactive substrates on a suture delivery vehicle in comparison with sutures coated with bioactive substrates alone. METHODS: Bone marrow-derived stem cells were harvested from Sprague-Dawley rat femurs. Experimental cell and substrate-coated, coated suture (CS) group sutures were precoated with intercellular cell adhesion molecule 1 and poly-L-lysine and seeded with labeled bone marrow-derived stem cells. Control (substrate-only [SO] coated) group sutures were coated with intercellular cell adhesion molecule 1 and poly-L-lysine only. Using a matched-paired design, bilateral Sprague-Dawley rat Achilles tendons (n = 105 rats) were transected and randomized to CS or SO repairs. Tendons were harvested at 4, 7, 10, 14, and 28 days and subjected to histologic and mechanical assessment. RESULTS: Labeled cells were present at repair sites at all time points. The CS suture repairs displayed statistically greater strength compared to SO repairs at 7 days (12.6 ± 5.0 N vs 8.6 ± 3.7 N, respectively) and 10 days (21.2 ± 4.9 N vs 16.4 ± 4.8 N, respectively). There was no significant difference between the strength of CS suture repairs compared with SO repairs at 4 days (8.1 ± 5.1 N vs 6.6 ± 2.3 N, respectively), 14 days (22.8 ± 7.3 N vs 25.1 ± 9.7 N, respectively), and 28 days (40.9 ± 12.4 N vs 34.6 ± 15.0 N, respectively). CONCLUSIONS: Bioactive CS sutures enhanced repair strength at 7 to 10 days. There was no significant effect at later stages. CLINICAL RELEVANCE: The strength nadir of a tendon repair occurs in the first 2 weeks after surgery. Bioactive suture repair might provide a clinical advantage by jump-starting the repair process during this strength nadir. Improved early strength might, in turn allow earlier unprotected mobilization. CI - Copyright © 2012 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Yao, Jeffrey AU - Yao J AD - Department of Orthopaedic Surgery, Stanford University Medical Center, Palo Alto, CA, USA. jyao@stanford.edu FAU - Woon, Colin Yi-Loong AU - Woon CY FAU - Behn, Anthony AU - Behn A FAU - Korotkova, Tatiana AU - Korotkova T FAU - Park, Don-Young AU - Park DY FAU - Gajendran, Varun AU - Gajendran V FAU - Smith, R Lane AU - Smith RL LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120623 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Coated Materials, Biocompatible) RN - 0 (polylysine-graft-(poly(ethylene glycol))) RN - 126547-89-5 (Intercellular Adhesion Molecule-1) RN - 25104-18-1 (Polylysine) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM CIN - J Hand Surg Am. 2012 Oct;37(10):2203; author reply 2203-4. doi: 10.1016/j.jhsa.2012.08.021. PMID: 23021188 MH - Animals MH - Chi-Square Distribution MH - Coated Materials, Biocompatible MH - Disease Models, Animal MH - Intercellular Adhesion Molecule-1/*pharmacology MH - Male MH - *Mesenchymal Stem Cells MH - Polyethylene Glycols/*pharmacology MH - Polylysine/*analogs & derivatives/pharmacology MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - *Sutures MH - Tendons/*surgery MH - Wound Healing/*physiology EDAT- 2012/06/26 06:00 MHDA- 2013/04/13 06:00 CRDT- 2012/06/26 06:00 PHST- 2011/11/07 00:00 [received] PHST- 2012/04/26 00:00 [revised] PHST- 2012/04/27 00:00 [accepted] PHST- 2012/06/26 06:00 [entrez] PHST- 2012/06/26 06:00 [pubmed] PHST- 2013/04/13 06:00 [medline] AID - S0363-5023(12)00594-1 [pii] AID - 10.1016/j.jhsa.2012.04.038 [doi] PST - ppublish SO - J Hand Surg Am. 2012 Aug;37(8):1639-45. doi: 10.1016/j.jhsa.2012.04.038. Epub 2012 Jun 23. PMID- 26945631 OWN - NLM STAT- MEDLINE DCOM- 20161226 LR - 20221115 IS - 1878-7568 (Electronic) IS - 1742-7061 (Print) IS - 1742-7061 (Linking) VI - 35 DP - 2016 Apr 15 TI - Multilayered polycaprolactone/gelatin fiber-hydrogel composite for tendon tissue engineering. PG - 68-76 LID - S1742-7061(16)30088-5 [pii] LID - 10.1016/j.actbio.2016.03.004 [doi] AB - Regeneration of injured tendon and ligament (T&L) remains a clinical challenge due to their poor intrinsic healing capacity. Tissue engineering provides a promising alternative treatment approach to facilitate T&L healing and regeneration. Successful tendon tissue engineering requires the use of three-dimensional (3D) biomimetic scaffolds that possess the physical and biochemical features of native tendon tissue. We report here the development and characterization of a novel composite scaffold fabricated by co-electrospinning of poly-ε-caprolactone (PCL) and methacrylated gelatin (mGLT). We found that photocrosslinking retained mGLT, resulted in a uniform distribution of mGLT throughout the depth of scaffold and also preserved scaffold mechanical strength. Moreover, photocrosslinking was able to integrate stacked scaffold sheets to form multilayered constructs that mimic the structure of native tendon tissues. Importantly, cells impregnated into the constructs remained responsive to topographical cues and exogenous tenogenic factors, such as TGF-β3. The excellent biocompatibility and highly integrated structure of the scaffold developed in this study will allow the creation of a more advanced tendon graft that possesses the architecture and cell phenotype of native tendon tissues. STATEMENT OF SIGNIFICANCE: The clinical challenges in tendon repair have spurred the development of tendon tissue engineering approaches to create functional tissue replacements. In this study, we have developed a novel composite scaffold as a tendon graft consisting of aligned poly-ε-caprolactone (PCL) microfibers and methacrylated gelatin (mGLT). Cell seeding and photocrosslinking between scaffold layers can be performed simultaneously to create cell impregnated multilayered constructs. This cell-scaffold construct combines the advantages of PCL nanofibrous scaffolds and photocrosslinked gelatin hydrogels to mimic the structure, mechanical anisotropy, and cell phenotype of native tendon tissue. The scaffold engineered here as a building block for multilayer constructs should have applications beyond tendon tissue engineering in the fabrication of tissue grafts that consist of both fibrous and hydrogel components. CI - Copyright © 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Yang, Guang AU - Yang G AD - Center for Cellular and Molecular Engineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, PA 15219, USA. Electronic address: guy9@pitt.edu. FAU - Lin, Hang AU - Lin H AD - Center for Cellular and Molecular Engineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA. Electronic address: hal46@pitt.edu. FAU - Rothrauff, Benjamin B AU - Rothrauff BB AD - Center for Cellular and Molecular Engineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA. Electronic address: bbr4@pitt.edu. FAU - Yu, Shuting AU - Yu S AD - Center for Cellular and Molecular Engineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; School of Medicine, Tsinghua University, Beijing 100083, China. Electronic address: shy39@pitt.edu. FAU - Tuan, Rocky S AU - Tuan RS AD - Center for Cellular and Molecular Engineering, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; Department of Bioengineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh, PA 15219, USA. Electronic address: rst13@pitt.edu. LA - eng GR - R01 AR062947/AR/NIAMS NIH HHS/United States GR - T32 EB001026/EB/NIBIB NIH HHS/United States GR - 5R01 AR062947/AR/NIAMS NIH HHS/United States GR - T32EB001026/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20160302 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Cross-Linking Reagents) RN - 0 (Polyesters) RN - 24980-41-4 (polycaprolactone) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 9000-70-8 (Gelatin) SB - IM MH - Adipose Tissue/cytology MH - Adult MH - Cross-Linking Reagents/pharmacology MH - Female MH - Gelatin/*pharmacology MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Light MH - Male MH - Polyesters/*pharmacology MH - Stem Cells/cytology/drug effects MH - Tendons/drug effects/*physiology MH - Tissue Engineering/*methods MH - Tissue Scaffolds/chemistry PMC - PMC5408748 MID - NIHMS767193 OTO - NOTNLM OT - Adipose stem cells OT - Aligned fibrous scaffold OT - Photocrosslinked hydrogel OT - Tendon regeneration COIS- Disclosure Statement No competing financial interests exist. EDAT- 2016/03/08 06:00 MHDA- 2016/12/27 06:00 PMCR- 2017/04/28 CRDT- 2016/03/07 06:00 PHST- 2015/11/24 00:00 [received] PHST- 2016/02/26 00:00 [revised] PHST- 2016/03/01 00:00 [accepted] PHST- 2016/03/07 06:00 [entrez] PHST- 2016/03/08 06:00 [pubmed] PHST- 2016/12/27 06:00 [medline] PHST- 2017/04/28 00:00 [pmc-release] AID - S1742-7061(16)30088-5 [pii] AID - 10.1016/j.actbio.2016.03.004 [doi] PST - ppublish SO - Acta Biomater. 2016 Apr 15;35:68-76. doi: 10.1016/j.actbio.2016.03.004. Epub 2016 Mar 2. PMID- 5718754 OWN - NLM STAT- MEDLINE DCOM- 19690521 LR - 20141120 IS - 0014-4878 (Print) IS - 0014-4878 (Linking) VI - 26 IP - 1-2 DP - 1968 TI - The effect of various cartilage and tendon extracts, oxidized gold thiosulphate and trichloroacetic acid on the formation of fibrils from collagen solutions. PG - 3-8 FAU - Ryback, R AU - Ryback R LA - eng PT - Journal Article PL - United States TA - Exp Med Surg JT - Experimental medicine and surgery JID - 0435437 RN - 0 (Thiosulfates) RN - 0 (Tissue Extracts) RN - 5V2JDO056X (Trichloroacetic Acid) RN - 7440-57-5 (Gold) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - *Bone Marrow MH - Cattle MH - Chemical Precipitation MH - *Collagen MH - Gold MH - Humans MH - In Vitro Techniques MH - Marfan Syndrome/prevention & control MH - *Tendons MH - Thiosulfates/*pharmacology/therapeutic use MH - Tissue Extracts/*pharmacology MH - Trichloroacetic Acid/*pharmacology EDAT- 1968/01/01 00:00 MHDA- 1968/01/01 00:01 CRDT- 1968/01/01 00:00 PHST- 1968/01/01 00:00 [pubmed] PHST- 1968/01/01 00:01 [medline] PHST- 1968/01/01 00:00 [entrez] PST - ppublish SO - Exp Med Surg. 1968;26(1-2):3-8. PMID- 41196436 OWN - NLM STAT- MEDLINE DCOM- 20251106 LR - 20251109 IS - 1573-4978 (Electronic) IS - 0301-4851 (Print) IS - 0301-4851 (Linking) VI - 53 IP - 1 DP - 2025 Nov 6 TI - Inhibition of interleukin-1 receptor-associated kinase (IRAK)-4 provides partial rescue of interleukin-1 beta induced functional and gene expression changes in equine tenocytes. PG - 54 LID - 10.1007/s11033-025-11219-2 [doi] LID - 54 AB - BACKGROUND: Interleukin 1 beta (IL-1β) is upregulated following a tendon injury and in vitro studies have shown that it leads to numerous negative effects on tendon cell function and gene expression. IL-1β activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and we hypothesised that inhibiting NF-κB activation would mediate the negative effects of IL-1β on equine tendon cells in 3-dimensional (3D) cultures. METHODS AND RESULTS: Here, we tested three inhibitors of NF-κB signalling (Bortezomib, BAY11-7082 and Wedelolactone) along withTJ-M2010-5, an inhibitor of MyD88, which is a critical adaptor protein for mediating IL-1β signalling. None of these inhibitors were able to rescue gel contraction by equine tenocytes exposed to IL-1β in 3D culture. However, the daily application of the interleukin-1 receptor-associated kinase (IRAK)-4 inhibitor PF-06650833 resulted in a partial rescue of collagen contraction and interleukin-6 (IL-6) production by equine tenocytes in 3D culture. Global gene expression using RNA sequencing also revealed a partial rescue, although this was not as complete as that achieved using interleukin-1 receptor antagonist protein (IL1Ra), with many inflammatory pathways remaining upregulated. ENPP2 expression was significantly increased by IL-1β and rescued by both IL1Ra and PF-06650833 suggesting ENPP2 may be involved in collagen contraction. However, direct ENPP2 inhibition does not rescue IL-1β mediated inhibition of contraction and ENPP2 inhibition alone reduces collagen contraction. CONCLUSIONS: Together, this data demonstrates that IL-1β has a broad mechanism of action on tendon cells which cannot be fully mediated by targeting specific parts of the signalling pathway. CI - © 2025. The Author(s). FAU - Beaumont, Ross Eric AU - Beaumont RE AD - Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK. FAU - Flood, Caroline AU - Flood C AD - Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK. FAU - Guest, Deborah Jane AU - Guest DJ AUID- ORCID: 0000-0002-0034-3332 AD - Centre for Vaccinology and Regenerative Medicine, Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, UK. djguest@rvc.ac.uk. LA - eng GR - S22-1151-1190/Petplan Charitable Trust/ GR - S22-1151-1190/Petplan Charitable Trust/ PT - Journal Article DEP - 20251106 PL - Netherlands TA - Mol Biol Rep JT - Molecular biology reports JID - 0403234 RN - 0 (Interleukin-1beta) RN - EC 2.7.11.1 (Interleukin-1 Receptor-Associated Kinases) RN - 0 (NF-kappa B) RN - 0 (Sulfones) RN - 0 (Nitriles) RN - 0 (3-(4-methylphenylsulfonyl)-2-propenenitrile) SB - IM MH - Animals MH - Horses MH - *Interleukin-1beta/metabolism/pharmacology MH - *Tenocytes/metabolism/drug effects MH - *Interleukin-1 Receptor-Associated Kinases/antagonists & inhibitors/metabolism/genetics MH - Signal Transduction/drug effects MH - NF-kappa B/metabolism MH - Sulfones/pharmacology MH - Tendons/metabolism/cytology MH - Nitriles/pharmacology MH - Gene Expression Regulation/drug effects MH - Cells, Cultured PMC - PMC12592280 OTO - NOTNLM OT - Horse OT - Inflammation OT - Interleukin-1 Receptor-Associated kinases OT - Interleukin-1beta OT - Nuclear factor kappa-light-chain-enhancer of activated B cells OT - Tendon COIS- Declarations. Competing interests: The authors declare no competing interests. Ethics approval: The cells used in this study were collected and used with the approval of the Royal Veterinary College Clinical Research Ethical Review Board (URN 2020 2017-2). EDAT- 2025/11/06 12:32 MHDA- 2025/11/06 12:33 PMCR- 2025/11/06 CRDT- 2025/11/06 11:16 PHST- 2025/08/04 00:00 [received] PHST- 2025/10/27 00:00 [accepted] PHST- 2025/11/06 12:33 [medline] PHST- 2025/11/06 12:32 [pubmed] PHST- 2025/11/06 11:16 [entrez] PHST- 2025/11/06 00:00 [pmc-release] AID - 10.1007/s11033-025-11219-2 [pii] AID - 11219 [pii] AID - 10.1007/s11033-025-11219-2 [doi] PST - epublish SO - Mol Biol Rep. 2025 Nov 6;53(1):54. doi: 10.1007/s11033-025-11219-2. PMID- 26485650 OWN - NLM STAT- MEDLINE DCOM- 20160617 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 10 DP - 2015 TI - Long-Term Effects of Botulinum Toxin Complex Type A Injection on Mechano- and Metabo-Sensitive Afferent Fibers Originating from Gastrocnemius Muscle. PG - e0140439 LID - 10.1371/journal.pone.0140439 [doi] LID - e0140439 AB - The aim of the present study was to investigate long term effects of motor denervation by botulinum toxin complex type A (BoNT/A) from Clostridium Botulinum, on the afferent fibers originating from the gastrocnemius muscle of rats. Animals were divided in 2 experimental groups: 1) untreated animals acting as control and 2) treated animals in which the toxin was injected in the left muscle, the latter being itself divided into 3 subgroups according to their locomotor recovery with the help of a test based on footprint measurements of walking rats: i) no recovery (B0), ii) 50% recovery (B50) and iii) full recovery (B100). Then, muscle properties, metabosensitive afferent fiber responses to potassium chloride (KCl) and lactic acid injections and Electrically-Induced Fatigue (EIF), and mechanosensitive responses to tendon vibrations were measured. At the end of the experiment, rats were killed and the toxin injected muscles were weighted. After toxin injection, we observed a complete paralysis associated to a loss of force to muscle stimulation and a significant muscle atrophy, and a return to baseline when the animals recover. The response to fatigue was only decreased in the B0 group. The responses to KCl injections were only altered in the B100 groups while responses to lactic acid were altered in the 3 injected groups. Finally, our results indicated that neurotoxin altered the biphasic pattern of response of the mechanosensitive fiber to tendon vibrations in the B0 and B50 groups. These results indicated that neurotoxin injection induces muscle afferent activity alterations that persist and even worsen when the muscle has recovered his motor activity. FAU - Caron, Guillaume AU - Caron G AD - Aix-Marseille Université (AMU) and Centre National de la Recherche Scientifique (CNRS), UMR 7287, Institut des Sciences du Mouvement: Etienne-Jules MAREY (ISM-EJM), Equipe, Plasticité des Systèmes Nerveux et Musculaire, Parc Scientifique et Technologique de Luminy, Faculté des Sciences du Sport de Marseille, CC910 - 163 Avenue de Luminy, F-13288, Marseille, cedex 09, France. FAU - Marqueste, Tanguy AU - Marqueste T AD - Aix-Marseille Université (AMU) and Centre National de la Recherche Scientifique (CNRS), UMR 7287, Institut des Sciences du Mouvement: Etienne-Jules MAREY (ISM-EJM), Equipe, Plasticité des Systèmes Nerveux et Musculaire, Parc Scientifique et Technologique de Luminy, Faculté des Sciences du Sport de Marseille, CC910 - 163 Avenue de Luminy, F-13288, Marseille, cedex 09, France. FAU - Decherchi, Patrick AU - Decherchi P AD - Aix-Marseille Université (AMU) and Centre National de la Recherche Scientifique (CNRS), UMR 7287, Institut des Sciences du Mouvement: Etienne-Jules MAREY (ISM-EJM), Equipe, Plasticité des Systèmes Nerveux et Musculaire, Parc Scientifique et Technologique de Luminy, Faculté des Sciences du Sport de Marseille, CC910 - 163 Avenue de Luminy, F-13288, Marseille, cedex 09, France. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151020 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Neurotoxins) RN - 33X04XA5AT (Lactic Acid) RN - 660YQ98I10 (Potassium Chloride) RN - EC 3.4.24.69 (Botulinum Toxins, Type A) SB - IM MH - Afferent Pathways/drug effects MH - Animals MH - Botulinum Toxins, Type A/administration & dosage/*pharmacology MH - Electric Stimulation MH - Electrophysiological Phenomena/drug effects MH - Hindlimb/drug effects/physiology MH - Injections, Intramuscular MH - Lactic Acid/pharmacology MH - Male MH - Motor Activity/*drug effects MH - Muscle Contraction/drug effects MH - Muscle Fatigue/drug effects MH - Muscle, Skeletal/*drug effects/innervation/physiology MH - Neurons, Afferent/*drug effects/physiology MH - Neurotoxins/administration & dosage/pharmacology MH - Potassium Chloride/pharmacology MH - Rats, Sprague-Dawley MH - Recovery of Function/drug effects MH - Tendons/drug effects/physiology MH - Time Factors PMC - PMC4617719 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/10/21 06:00 MHDA- 2016/06/18 06:00 PMCR- 2015/10/20 CRDT- 2015/10/21 06:00 PHST- 2015/04/20 00:00 [received] PHST- 2015/09/25 00:00 [accepted] PHST- 2015/10/21 06:00 [entrez] PHST- 2015/10/21 06:00 [pubmed] PHST- 2016/06/18 06:00 [medline] PHST- 2015/10/20 00:00 [pmc-release] AID - PONE-D-15-17170 [pii] AID - 10.1371/journal.pone.0140439 [doi] PST - epublish SO - PLoS One. 2015 Oct 20;10(10):e0140439. doi: 10.1371/journal.pone.0140439. eCollection 2015. PMID- 26848746 OWN - NLM STAT- MEDLINE DCOM- 20160802 LR - 20190222 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 11 IP - 2 DP - 2016 TI - Creating an Animal Model of Tendinopathy by Inducing Chondrogenic Differentiation with Kartogenin. PG - e0148557 LID - 10.1371/journal.pone.0148557 [doi] LID - e0148557 AB - Previous animal studies have shown that long term rat treadmill running induces over-use tendinopathy, which manifests as proteoglycan accumulation and chondrocytes-like cells within the affected tendons. Creating this animal model of tendinopathy by long term treadmill running is however time-consuming, costly and may vary among animals. In this study, we used a new approach to develop an animal model of tendinopathy using kartogenin (KGN), a bio-compound that can stimulate endogenous stem/progenitor cells to differentiate into chondrocytes. KGN-beads were fabricated and implanted into rat Achilles tendons. Five weeks after implantation, chondrocytes and proteoglycan accumulation were found at the KGN implanted site. Vascularity as well as disorganization in collagen fibers were also present in the same site along with increased expression of the chondrocyte specific marker, collagen type II (Col. II). In vitro studies confirmed that KGN was released continuously from KGN-alginate in vivo beads and induced chondrogenic differentiation of tendon stem/progenitor cells (TSCs) suggesting that chondrogenesis after KGN-bead implantation into the rat tendons is likely due to the aberrant differentiation of TSCs into chondrocytes. Taken together, our results showed that KGN-alginate beads can be used to create a rat model of tendinopathy, which, at least in part, reproduces the features of over-use tendinopathy model created by long term treadmill running. This model is mechanistic (stem cell differentiation), highly reproducible and precise in creating localized tendinopathic lesions. It is expected that this model will be useful to evaluate the effects of various topical treatments such as NSAIDs and platelet-rich plasma (PRP) for the treatment of tendinopathy. FAU - Yuan, Ting AU - Yuan T AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. AD - Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. FAU - Zhang, Jianying AU - Zhang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. FAU - Zhao, Guangyi AU - Zhao G AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. FAU - Zhou, Yiqin AU - Zhou Y AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. FAU - Zhang, Chang-Qing AU - Zhang CQ AD - Department of Orthopaedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. FAU - Wang, James H-C AU - Wang JH AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. LA - eng GR - AR06092/AR/NIAMS NIH HHS/United States GR - R01 AR065949/AR/NIAMS NIH HHS/United States GR - AR061395/AR/NIAMS NIH HHS/United States GR - R01 AR061395/AR/NIAMS NIH HHS/United States GR - AR065949/AR/NIAMS NIH HHS/United States GR - R21 AR060920/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20160205 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Anilides) RN - 0 (Phthalic Acids) RN - Q93BBN11CP (kartogenin) SB - IM MH - Achilles Tendon/drug effects/pathology MH - Anilides/*pharmacology MH - Animals MH - Cell Differentiation/drug effects MH - Chondrocytes/*drug effects MH - *Disease Models, Animal MH - Female MH - Phthalic Acids/*pharmacology MH - Rats MH - *Rats, Sprague-Dawley MH - Tendinopathy/chemically induced/*pathology PMC - PMC4744046 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2016/02/06 06:00 MHDA- 2016/08/03 06:00 PMCR- 2016/02/05 CRDT- 2016/02/06 06:00 PHST- 2015/12/13 00:00 [received] PHST- 2016/01/20 00:00 [accepted] PHST- 2016/02/06 06:00 [entrez] PHST- 2016/02/06 06:00 [pubmed] PHST- 2016/08/03 06:00 [medline] PHST- 2016/02/05 00:00 [pmc-release] AID - PONE-D-15-53853 [pii] AID - 10.1371/journal.pone.0148557 [doi] PST - epublish SO - PLoS One. 2016 Feb 5;11(2):e0148557. doi: 10.1371/journal.pone.0148557. eCollection 2016. PMID- 11218843 OWN - NLM STAT- MEDLINE DCOM- 20010322 LR - 20190915 IS - 0287-4547 (Print) IS - 0287-4547 (Linking) VI - 19 IP - 3 DP - 2000 Sep TI - The effects of alcoholic compounds on the stability of type I collagen studied by differential scanning calorimetry. PG - 221-8 AB - The interaction between bovine tendon collagen and a series of homologous alcohols were investigated using a differential scanning calorimetry. For all alcoholic substances, as well as 2-hydroxyethyl methacrylate (HEMA), the concentration dependence of the denaturation temperature of collagen was observed, which showed a minimum at 30%. Clearly there are two opposing actions on the stabilization of the collagen structure; destabilization dominates over stabilization at lower concentrations, and vice versa at higher concentrations. The concentration dependence became greater for longer chain alcohols, while it was suppressed by the increased number of OH groups. The chain length-dependent surface tension may be related, which controls the permeation of the additives through the collagen fibers. Overall hydrophobicity, indicated by the hydrophile-lipophile balance (HLB) numbers, suggests the importance of the hydrophobic effect in the interaction of collagen and alcoholic substances, including adhesive monomers such as HEMA. FAU - Fukuda, K AU - Fukuda K AD - Faculty of Dentistry, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. FAU - Nezu, T AU - Nezu T FAU - Terada, Y AU - Terada Y LA - eng PT - Journal Article PL - Japan TA - Dent Mater J JT - Dental materials journal JID - 8309299 RN - 0 (Alcohols) RN - 0 (Dentin-Bonding Agents) RN - 0 (Methacrylates) RN - 0 (Resin Cements) RN - 059QF0KO0R (Water) RN - 3352-57-6 (Hydroxyl Radical) RN - 6E1I4IV47V (hydroxyethyl methacrylate) RN - 9007-34-5 (Collagen) MH - Alcohols/chemistry/*pharmacology MH - Animals MH - Calorimetry, Differential Scanning MH - Cattle MH - Collagen/chemistry/*drug effects MH - Dentin/chemistry MH - Dentin Permeability MH - Dentin-Bonding Agents/*chemistry/pharmacology MH - Hydroxyl Radical MH - Methacrylates/chemistry/pharmacology MH - Protein Denaturation MH - Protein Structure, Secondary/drug effects MH - Quantitative Structure-Activity Relationship MH - Resin Cements/*chemistry/pharmacology MH - Tendons/chemistry MH - Water/chemistry EDAT- 2001/02/24 12:00 MHDA- 2001/03/27 10:01 CRDT- 2001/02/24 12:00 PHST- 2001/02/24 12:00 [pubmed] PHST- 2001/03/27 10:01 [medline] PHST- 2001/02/24 12:00 [entrez] AID - 10.4012/dmj.19.221 [doi] PST - ppublish SO - Dent Mater J. 2000 Sep;19(3):221-8. doi: 10.4012/dmj.19.221. PMID- 18075814 OWN - NLM STAT- MEDLINE DCOM- 20080206 LR - 20131121 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 48 IP - 6 DP - 2007 TI - Calcific tendonitis : a model. PG - 286-91 AB - Calcific tendonitis is a common clinical condition associated with high rates of tendon rupture, prolonged symptoms, and poor response to therapy. Little is known about the pathogenesis of calcifications in tendons and consequently few effective therapies are available. We hypothesized that tendon calcification, like pathologic calcification in other sites, was generated by extracellular organelles known as matrix vesicles and that isolated matrix vesicles would constitute the basis for a useful model of this process. Tendon matrix vesicles were isolated from adult porcine patellar tendons using enzymatic digestion and differential centrifugation. Vesicle morphology was examined with electron microscopy. Levels of calcium, phosphate, pyrophosphate, ATP, and mineralization-associated enzymes were measured and compared with articular cartilage vesicles from porcine articular cartilage. Vesicles were embedded in agarose gels with or without type I collagen or dermatan sulfate and incubated in calcifying salt solution trace labeled with (45)calcium. (45)Calcium in the vesicle fraction was measured after 5-7 days. The type of mineral formed was determined by micro-x-ray diffraction. Matrix vesicles isolated from adult porcine tendon were similar morphologically to those obtained from articular cartilage. They contained mineralization-related enzymes and formed hydroxyapatite mineral in vitro. Mineralization was suppressed by levamisole and modulated by extracellular matrix components. Matrix vesicles isolated from tendons mineralize in vitro. This model may aid in the study of the pathogenesis of calcific tendonitis as well as serve as a means to identify effective therapies for this common disorder. FAU - Gohr, Claudia M AU - Gohr CM AD - Medical College of Wisconsin and Zablocki VA Medical Center, Milwaukee, Wisconsin, USA. FAU - Fahey, Mark AU - Fahey M FAU - Rosenthal, Ann K AU - Rosenthal AK LA - eng GR - AG015337/AG/NIA NIH HHS/United States GR - AR052615/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Collagen Type I) RN - 0 (Glycerophosphates) RN - 24967-94-0 (Dermatan Sulfate) RN - 2880D3468G (Levamisole) RN - WWH06G87W6 (beta-glycerophosphoric acid) SB - IM MH - Animals MH - Calcinosis/*pathology MH - Cartilage, Articular/ultrastructure MH - Collagen Type I/pharmacology MH - Dermatan Sulfate/pharmacology MH - Disease Models, Animal MH - Extracellular Matrix/drug effects/physiology MH - Glycerophosphates/pharmacology MH - Levamisole/pharmacology MH - Microscopy, Electron MH - Patellar Ligament/drug effects/pathology/ultrastructure MH - Sus scrofa MH - Tendinopathy/*pathology EDAT- 2007/12/14 09:00 MHDA- 2008/02/07 09:00 CRDT- 2007/12/14 09:00 PHST- 2007/12/14 09:00 [pubmed] PHST- 2008/02/07 09:00 [medline] PHST- 2007/12/14 09:00 [entrez] AID - 788420637 [pii] AID - 10.1080/03008200701692362 [doi] PST - ppublish SO - Connect Tissue Res. 2007;48(6):286-91. doi: 10.1080/03008200701692362. PMID- 35862638 OWN - NLM STAT- MEDLINE DCOM- 20220803 LR - 20250728 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 50 IP - 10 DP - 2022 Aug TI - Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model. PG - 2805-2816 LID - 10.1177/03635465221107943 [doi] AB - BACKGROUND: Studies in our laboratory have demonstrated mitochondrial dysfunction in human and animal models of supraspinatus tendinopathy. SS-31 (elamipretide) has been reported to improve mitochondrial function and to be effective in clinical trials for several diseases. The potential of SS-31 in treating tendinopathy has not been explored. HYPOTHESIS: SS-31 would improve mitochondrial function in human tenocytes sampled from patients with tendinopathy. STUDY DESIGN: Controlled laboratory study. METHODS: Healthy tenocytes were obtained from normal hamstring tendon biopsy specimens in 9 patients undergoing anterior cruciate ligament reconstruction, and tenocytes were collected from degenerative supraspinatus tendon biopsy specimens in 9 patients undergoing rotator cuff repair. Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours. The outcomes included measurements of mitochondrial potential, mitochondrial morphology by transmission electron microscopy imaging, reactive oxygen species and superoxidative dismutase activity, gene expression, and cell viability. RESULTS: An increase in the cell fraction with depolarized mitochondria was found in degenerative tenocytes (P = .014), followed by a decrease after SS-31 treatment (P = .018). Transmission electron microscopy images demonstrated morphological changes with a decreased number and size of mitochondria per cell in the degenerative tenocytes (P = .018) and with improvement after SS-31 treatment. There was no significant difference in the level of reactive oxygen species between healthy and degenerative tenocytes in culture, but superoxidative dismutase activity was significantly decreased in the degenerative group (P = .006), which then increased after SS-31 treatment (P = .012). These findings suggested that mitochondrial dysfunction may be reversed by SS-31 treatment. The gene expression of matrix metalloproteinase-1 (matrix remodeling, P = .029) and fatty acid-binding protein 4 (fatty infiltration, P = .046) was significantly upregulated in the degenerative tenocytes and reduced by SS-31 treatment (P = .048; P = .007). Gene expression for hypoxia-inducible factor1 α and the proapoptotic regulator Bcl-2-associated X protein was increased in the degenerative tenocytes. There was a significant decrease in cell viability in degenerative tenocytes as compared with the healthy tenocytes, with small improvement after treatment with SS-31. CONCLUSION: There are changes in mitochondrial structure and function in tenocytes derived from degenerative tendons, and SS-31, as a mitochondrial protectant, could improve mitochondrial function and promote the healing of tendinopathy. CLINICAL RELEVANCE: Mitochondrial dysfunction appears to play a role in the development of tendinopathy, and SS-31, as a mitochondrial protective agent, may be a therapeutic agent in the treatment of tendinopathy. FAU - Zhang, Xueying AU - Zhang X AUID- ORCID: 0000-0001-7674-0273 AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. AD - Department of Sports Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. FAU - Zhang, Ying AU - Zhang Y AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. FAU - Zhang, Meng AU - Zhang M AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. FAU - Nakagawa, Yusuke AU - Nakagawa Y AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. FAU - Caballo, Camila B AU - Caballo CB AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. FAU - Szeto, Hazel H AU - Szeto HH AD - Social Profit Network Research Lab, Menlo Park, California, USA. FAU - Deng, Xiang-Hua AU - Deng XH AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. FAU - Rodeo, Scott A AU - Rodeo SA AD - Orthopedic Soft Tissue Research Program, Hospital for Special Surgery, New York, New York, USA. LA - eng PT - Journal Article DEP - 20220721 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Reactive Oxygen Species) SB - IM MH - Animals MH - Humans MH - Reactive Oxygen Species/metabolism/therapeutic use MH - Rotator Cuff/surgery MH - *Rotator Cuff Injuries/pathology MH - *Tendinopathy/therapy MH - Tenocytes/metabolism OTO - NOTNLM OT - SS-31 peptide OT - human tenocytes OT - mitochondria OT - tendinopathy EDAT- 2022/07/22 06:00 MHDA- 2022/08/04 06:00 CRDT- 2022/07/21 14:42 PHST- 2022/07/22 06:00 [pubmed] PHST- 2022/08/04 06:00 [medline] PHST- 2022/07/21 14:42 [entrez] AID - 10.1177/03635465221107943 [doi] PST - ppublish SO - Am J Sports Med. 2022 Aug;50(10):2805-2816. doi: 10.1177/03635465221107943. Epub 2022 Jul 21. PMID- 39866153 OWN - NLM STAT- MEDLINE DCOM- 20250503 LR - 20250524 IS - 2047-4849 (Electronic) IS - 2047-4830 (Linking) VI - 13 IP - 5 DP - 2025 Feb 25 TI - Fabrication of a micropatterned shape-memory polymer patch with L-DOPA for tendon regeneration. PG - 1243-1260 LID - 10.1039/d4bm00298a [doi] AB - A scaffold design for tendon regeneration has been proposed, which mimics the microstructural features of tendons and provides appropriate mechanical properties. We synthesized a temperature-triggered shape-memory polymer (SMP) using the ring-opening polymerization of polycaprolactone (PCL) with polyethylene glycol (PEG) as a macroinitiator. We fabricated a micropatterned patch using SMP via capillary force lithography, which mimicked a native tendon, for providing physical cues and guiding effects. The SMP patches (the SMP-flat patch is referred to as SMP-F, and the SMP-patterned patch is referred to as SMP-P) were surface-modified with 3,4-dihydroxy-L-phenylalanine (L-DOPA, referred to as D) for improving cell adhesion. We hypothesized that SMP patches could be applied in minimally invasive surgery and the micropatterned structure would improve tendon regeneration by providing geometrical cues. The SMP patches exhibited excellent shape-memory properties, mechanical performance, and biocompatibility in vitro and in vivo. Especially, SMP-DP demonstrated enhanced cell behaviors in vitro, including cell orientation, elongation, migration, and tenogenic differentiation potential. The in vivo data showed notable biomechanical functionality and histological morphometric findings in various analyses of SMP-DP in the ruptured Achilles tendon model. FAU - Son, Yucheol AU - Son Y AD - Department of Nanobiomedical Science & BK21 FOUR micropatterned shape-memory NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of Korea. hsyang@dankook.ac.kr. FAU - Lee, Min Suk AU - Lee MS AD - Department of Nanobiomedical Science & BK21 FOUR micropatterned shape-memory NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of Korea. hsyang@dankook.ac.kr. AD - Medical Laser Research Center, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea. AD - Richard and Loan Hill Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60612, USA. FAU - Hwang, Dong Jun AU - Hwang DJ AUID- ORCID: 0000-0003-2819-8410 AD - Materials Architecturing Research Center, Korea Institute of Science and Technology, Hwarang-ro 14-gil 5, Seongbuk Gu, Seoul 02972, Republic of Korea. AD - Department of Chemistry, Research Institute for Natural Sciences, Korea University, Seoul 02841, Republic of Korea. FAU - Lee, Sun Hong AU - Lee SH AD - Department of Nanobiomedical Science & BK21 FOUR micropatterned shape-memory NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of Korea. hsyang@dankook.ac.kr. FAU - Lee, Albert S AU - Lee AS AUID- ORCID: 0000-0002-1396-1244 AD - Materials Architecturing Research Center, Korea Institute of Science and Technology, Hwarang-ro 14-gil 5, Seongbuk Gu, Seoul 02972, Republic of Korea. FAU - Hwang, Seung Sang AU - Hwang SS AD - Materials Architecturing Research Center, Korea Institute of Science and Technology, Hwarang-ro 14-gil 5, Seongbuk Gu, Seoul 02972, Republic of Korea. FAU - Choi, Dong Hoon AU - Choi DH AUID- ORCID: 0000-0002-3165-0597 AD - Department of Chemistry, Research Institute for Natural Sciences, Korea University, Seoul 02841, Republic of Korea. FAU - Jo, Chris Hyunchul AU - Jo CH AD - Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea. FAU - Yang, Hee Seok AU - Yang HS AUID- ORCID: 0000-0001-8707-523X AD - Department of Nanobiomedical Science & BK21 FOUR micropatterned shape-memory NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Republic of Korea. hsyang@dankook.ac.kr. AD - School of Biomedical Sciences & Biosystems, College of Bio-convergence, Dankook University, Cheonan, 31116, Republic of Korea. AD - Center for Bio-Medical Engineering Core-Facility, Dankook University, Cheonan 31116, Republic of Korea. LA - eng PT - Journal Article DEP - 20250225 PL - England TA - Biomater Sci JT - Biomaterials science JID - 101593571 RN - 0 (Polyesters) RN - 46627O600J (Levodopa) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 24980-41-4 (polycaprolactone) RN - 0 (Biocompatible Materials) RN - 0 (Smart Materials) SB - IM MH - Animals MH - *Regeneration/drug effects MH - Polyesters/chemistry MH - *Levodopa/chemistry/pharmacology MH - Polyethylene Glycols/chemistry MH - *Tendons/physiology MH - *Tissue Scaffolds/chemistry MH - *Biocompatible Materials/chemistry MH - Cell Adhesion/drug effects MH - Mice MH - *Smart Materials/chemistry MH - Tissue Engineering MH - Cell Differentiation/drug effects EDAT- 2025/01/27 06:20 MHDA- 2025/02/25 12:25 CRDT- 2025/01/27 05:33 PHST- 2025/02/25 12:25 [medline] PHST- 2025/01/27 06:20 [pubmed] PHST- 2025/01/27 05:33 [entrez] AID - 10.1039/d4bm00298a [doi] PST - epublish SO - Biomater Sci. 2025 Feb 25;13(5):1243-1260. doi: 10.1039/d4bm00298a. PMID- 4376955 OWN - NLM STAT- MEDLINE DCOM- 19750903 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 144 IP - 1 DP - 1974 Oct TI - Collagen biosynthesis. Characterization of subcellular fractions from embyonic chick fibroblasts and the intracellular localization of protocollagen prolyl and protocollagen lysyl hydroxylases. PG - 123-30 AB - 1. Subcellular fractions of freshly isolated matrix-free embryonic chick tendon and sternal cartilage cells have been characterized by chemical analysis, electron microscopy and the location of specific marker enzymes. These data indicate the fractions to be of a high degree of purity comparable with those obtained from other tissues, e.g. liver and kidney. 2. When homogenates were assayed for protocollagen prolyl hydroxylase and protocollagen lysyl hydroxylase activities, addition of Triton X-100 (0.1%, w/v) was found to stimulate enzyme activities by up to 60% suggesting that the enzymes were probably membrane-bound. 3. Assay of subcellular fractions obtained by differential centrifugation for protocollagen prolyl hydroxylase activity indicated the specific activity to be highest in the microsomal fraction. Similar results were obtained for protocollagen lysyl hydroxylase activity. 4. Submicrosomal fractions obtained by discontinuous sucrose-gradient centrifugation were assayed for the two enzymes and protocollagen prolyl hydroxylase and protocollagen lysyl hydroxylase were found to be associated almost exclusively with the rough endoplasmic reticulum fraction in both tendon and cartilage cells. FAU - Harwood, R AU - Harwood R FAU - Grant, M E AU - Grant ME FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9007-34-5 (Collagen) RN - EC 1.- (Mixed Function Oxygenases) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - K3Z4F929H6 (Lysine) SB - IM MH - Animals MH - Centrifugation, Density Gradient MH - Chick Embryo MH - Collagen/*biosynthesis MH - Endoplasmic Reticulum MH - Enzyme Activation MH - Fibroblasts/analysis/*enzymology/ultrastructure MH - Lysine MH - Membranes MH - Microscopy, Electron MH - Mixed Function Oxygenases/*analysis MH - Polyethylene Glycols/pharmacology MH - Procollagen-Proline Dioxygenase/*analysis MH - Subcellular Fractions MH - Tendons/cytology PMC - PMC1168472 EDAT- 1974/10/01 00:00 MHDA- 1974/10/01 00:01 PMCR- 1975/04/01 CRDT- 1974/10/01 00:00 PHST- 1974/10/01 00:00 [pubmed] PHST- 1974/10/01 00:01 [medline] PHST- 1974/10/01 00:00 [entrez] PHST- 1975/04/01 00:00 [pmc-release] AID - 10.1042/bj1440123 [doi] PST - ppublish SO - Biochem J. 1974 Oct;144(1):123-30. doi: 10.1042/bj1440123. PMID- 5114981 OWN - NLM STAT- MEDLINE DCOM- 19720108 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 10 IP - 12 DP - 1971 Jun 8 TI - Studies of the relationship of proton production and calcification of tendon matrix in vitro. PG - 2183-9 FAU - Luben, R A AU - Luben RA FAU - Wadkins, C L AU - Wadkins CL LA - eng PT - Journal Article PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Chlorides) RN - 0 (Hydroxyapatites) RN - 0 (Organophosphonates) RN - 0 (Phosphates) RN - 0 (Protons) RN - I38ZP9992A (Magnesium) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - *Calcification, Physiologic/drug effects MH - Calcium/metabolism MH - Cattle MH - Chlorides/pharmacology MH - Connective Tissue/*metabolism MH - Depression, Chemical MH - Hydrogen-Ion Concentration MH - Hydroxyapatites/biosynthesis MH - In Vitro Techniques MH - Magnesium/pharmacology MH - Organophosphonates/pharmacology MH - Phosphates/metabolism MH - *Protons MH - *Tendons OID - NASA: 72029446 EDAT- 1971/06/08 00:00 MHDA- 1971/06/08 00:01 CRDT- 1971/06/08 00:00 PHST- 1971/06/08 00:00 [pubmed] PHST- 1971/06/08 00:01 [medline] PHST- 1971/06/08 00:00 [entrez] AID - 10.1021/bi00788a001 [doi] PST - ppublish SO - Biochemistry. 1971 Jun 8;10(12):2183-9. doi: 10.1021/bi00788a001. PMID- 31904561 OWN - NLM STAT- MEDLINE DCOM- 20210127 LR - 20210127 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 104 DP - 2020 Mar 1 TI - Thiolated bone and tendon tissue particles covalently bound in hydrogels for in vivo calvarial bone regeneration. PG - 66-75 LID - S1742-7061(19)30878-5 [pii] LID - 10.1016/j.actbio.2019.12.035 [doi] AB - Bone regeneration of large cranial defects, potentially including traumatic brain injury (TBI) treatment, presents a major problem with non-crosslinking, clinically available products due to material migration outside the defect. Commercial products such as bone cements are permanent and thus not conducive to bone regeneration, and typical commercial bioactive materials for bone regeneration do not crosslink. Our previous work demonstrated that non-crosslinking materials may be prone to material migration following surgical placement, and the current study attempted to address these problems by introducing a new hydrogel system where tissue particles are themselves the crosslinker. Specifically, a pentenoate-modified hyaluronic acid (PHA) polymer was covalently linked to thiolated tissue particles of demineralized bone matrix (TDBM) or devitalized tendon (TDVT), thereby forming an interconnected hydrogel matrix for calvarial bone regeneration. All hydrogel precursor solutions exhibited sufficient yield stress for surgical placement and an adequate compressive modulus post-crosslinking. Critical-size calvarial defects were filled with a 4% PHA hydrogel containing 10 or 20% TDBM or TDVT, with the clinical product DBX(Ⓡ) being employed as the standard of care control for the in vivo study. At 12 weeks, micro-computed tomography analysis demonstrated similar bone regeneration among the experimental groups, TDBM and TDVT, and the standard of care control DBX(Ⓡ). The group with 10% TDBM was therefore identified as an attractive material for potential calvarial defect repair, as it additionally exhibited a sufficient initial recovery after shearing (i.e., > 80% recovery). Future studies will focus on applying a hydrogel in a rat model for treatment of TBI. STATEMENT OF SIGNIFICANCE: Non-crosslinking materials may be prone to material migration from a calvarial bone defect following surgical placement, which is problematic for materials intended for bone regeneration. Unfortunately, typical crosslinking materials such as bone cements are permanent and thus not conducive to bone regeneration, and typical bioactive materials for bone regeneration such as tissue matrix are not crosslinked in commercial products. The current study addressed these problems by introducing a new biomaterial where tissue particles are themselves the crosslinker in a hydrogel system. The current study successfully demonstrated a new material based on pentenoate-modified hyaluronic acid with thiolated demineralized bone matrix that is capable of rapid crosslinking, with desirable paste-like rheology of the precursor material for surgical placement, and with bone regeneration comparable to a commercially available standard-of-care product. Such a material may hold promise for a single-surgery treatment of severe traumatic brain injury (TBI) following hemicraniectomy. CI - Copyright © 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Townsend, Jakob M AU - Townsend JM AD - Stephenson School of Biomedical Engineering, University of Oklahoma, OK, United States. FAU - Sali, Goksel AU - Sali G AD - Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. FAU - Homburg, Hannah B AU - Homburg HB AD - Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. FAU - Cassidy, Nina T AU - Cassidy NT AD - Stephenson School of Biomedical Engineering, University of Oklahoma, OK, United States. FAU - Sanders, Megan E AU - Sanders ME AD - Stephenson School of Biomedical Engineering, University of Oklahoma, OK, United States. FAU - Fung, Kar-Ming AU - Fung KM AD - Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. FAU - Andrews, Brian T AU - Andrews BT AD - Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, KS, United States. FAU - Nudo, Randolph J AU - Nudo RJ AD - Department of Rehabilitation Medicine, University of Kansas Medical Center, Kansas City, KS, United States. FAU - Bohnstedt, Bradley N AU - Bohnstedt BN AD - Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. FAU - Detamore, Michael S AU - Detamore MS AD - Stephenson School of Biomedical Engineering, University of Oklahoma, OK, United States. Electronic address: detamore@ou.edu. LA - eng GR - R03 DE025906/DE/NIDCR NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200103 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Cross-Linking Reagents) RN - 0 (Hydrogels) RN - 0 (Sulfhydryl Compounds) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Aged MH - Animals MH - Bone Regeneration/*drug effects MH - Bone and Bones/drug effects/*physiology MH - Cross-Linking Reagents/chemistry MH - Humans MH - Hyaluronic Acid/*pharmacology MH - Hydrogels/*pharmacology MH - Male MH - Middle Aged MH - Rats, Sprague-Dawley MH - Rheology MH - Skull/*physiology MH - Sulfhydryl Compounds/*pharmacology MH - Tendons/drug effects/*physiology OTO - NOTNLM OT - Calvarial bone OT - Hyaluronic acid OT - Hydrogel OT - Thiolated bone OT - Thiolated tendon COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2020/01/07 06:00 MHDA- 2021/01/28 06:00 CRDT- 2020/01/07 06:00 PHST- 2019/09/10 00:00 [received] PHST- 2019/12/17 00:00 [revised] PHST- 2019/12/30 00:00 [accepted] PHST- 2020/01/07 06:00 [pubmed] PHST- 2021/01/28 06:00 [medline] PHST- 2020/01/07 06:00 [entrez] AID - S1742-7061(19)30878-5 [pii] AID - 10.1016/j.actbio.2019.12.035 [doi] PST - ppublish SO - Acta Biomater. 2020 Mar 1;104:66-75. doi: 10.1016/j.actbio.2019.12.035. Epub 2020 Jan 3. PMID- 29164815 OWN - NLM STAT- MEDLINE DCOM- 20190815 LR - 20190815 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 106 IP - 4 DP - 2018 Apr TI - Application of kartogenin for musculoskeletal regeneration. PG - 1141-1148 LID - 10.1002/jbm.a.36300 [doi] AB - Kartogenin (KGN) is a recently characterized small molecule that promotes the selective differentiation of mesenchymal stem cells into chondrocytes, and thus, KGN stimulates cartilage regeneration. KGN also possess chondro-protective effect. Furthermore, because it is a highly stable small molecule, KGN can be stored and transported at room temperature. These obvious superiorities over peptide growth factors make KGN a desirable chondrogenic agent for cartilage regeneration. Since its discovery, KGN has drawn much attention as a new chondrogenic drug for intraarticular (IA) treatment. Although it was originally developed with a focus on OA, it has been used to treat other conditions and to promote disc and bone-tendon junction regeneration. Our group has also developed several formulations for IA delivery of KGN including KGN-conjugated chitosan nano/microparticles, thermo-responsive polymeric nanospheres based on chitosan oligosaccharide conjugated pluronic F127, and hyluronate hydrogels containing polyethylene glycol (PEG/KGN) micelles. This review was undertaken to summarize current research on the action mechanism of KGN and the various formulations described in the literature that induce musculoskeletal regeneration. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1141-1148, 2018. CI - © 2017 Wiley Periodicals, Inc. FAU - Im, Gun-Il AU - Im GI AD - Department of Orthopaedics, Dongguk University Ilsan Hospital, Goyang, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20171210 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Anilides) RN - 0 (Phthalic Acids) RN - Q93BBN11CP (kartogenin) MH - Anilides/*pharmacology MH - Animals MH - Bone and Bones/pathology MH - Humans MH - Musculoskeletal System/*drug effects MH - Phthalic Acids/*pharmacology MH - Regeneration/*drug effects MH - Tendons/pathology MH - Wound Healing OTO - NOTNLM OT - chondrogenesis OT - kartogenin OT - musculoskeletal regeneration OT - osteoarthritis EDAT- 2017/11/23 06:00 MHDA- 2019/08/16 06:00 CRDT- 2017/11/23 06:00 PHST- 2017/07/07 00:00 [received] PHST- 2017/10/07 00:00 [revised] PHST- 2017/11/03 00:00 [accepted] PHST- 2017/11/23 06:00 [pubmed] PHST- 2019/08/16 06:00 [medline] PHST- 2017/11/23 06:00 [entrez] AID - 10.1002/jbm.a.36300 [doi] PST - ppublish SO - J Biomed Mater Res A. 2018 Apr;106(4):1141-1148. doi: 10.1002/jbm.a.36300. Epub 2017 Dec 10. PMID- 194596 OWN - NLM STAT- MEDLINE DCOM- 19770723 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 76 IP - 2 DP - 1976 May 23 TI - Separation of prolyl 3-hydroxylase and 4-hydroxylase activities and the 4-hydroxyproline requirement for synthesis of 3-hydroxyproline. PG - 275-81 FAU - Tryggvason, K AU - Tryggvason K FAU - Risteli, J AU - Risteli J FAU - Kivirikko, K I AU - Kivirikko KI LA - eng PT - Journal Article PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Procollagen) RN - 9DLQ4CIU6V (Proline) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - RMB44WO89X (Hydroxyproline) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Chick Embryo MH - Dithiothreitol/pharmacology MH - Hydroxyproline/*metabolism MH - Kidney Cortex/enzymology MH - Procollagen/metabolism MH - Procollagen-Proline Dioxygenase/isolation & purification/*metabolism MH - Proline/metabolism MH - Rats MH - Stereoisomerism MH - Tendons EDAT- 1976/05/23 00:00 MHDA- 1976/05/23 00:01 CRDT- 1976/05/23 00:00 PHST- 1976/05/23 00:00 [pubmed] PHST- 1976/05/23 00:01 [medline] PHST- 1976/05/23 00:00 [entrez] AID - 0006-291X(77)90722-7 [pii] AID - 10.1016/0006-291x(77)90722-7 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1976 May 23;76(2):275-81. doi: 10.1016/0006-291x(77)90722-7. PMID- 597231 OWN - NLM STAT- MEDLINE DCOM- 19780218 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 166 IP - 3 DP - 1977 Sep 15 TI - Further studies on the effect of the collagen triple-helix formation on the hydroxylation of lysine and the glycosylations of hydroxylysine in chick-embryo tendon and cartilage cells. PG - 357-62 AB - The hydroxylation of lysine and glycosylations of hydroxylysine were studied in isolated chick-embryo tendon and cartilage cells under conditions in which collagen triple-helix formation was either inhibited or accelerated. The former situation was obtained by incubating the tendon cells with 0.6mm-dithiothreitol, thus decreasing their proline hydroxylase activity by about 99%. After labelling with [(14)C]proline, the formation of hydroxy[(14)C]proline was found to have declined by about 95%. Since the hydroxylation of a relatively large number of proline residues is required for triple-helix formation at 37 degrees C, the pro-alpha-chains synthesized under these conditions apparently cannot form triple-helical molecules. Labelling experiments with [(14)C]lysine indicated that the degree of hydroxylation of the lysine residues in the collagen synthesized was slightly increased and the degree of the glycosylations of the hydroxylysine residues more than doubled, the largest increase being in the content of glucosylgalactosylhydroxylysine. Recovery of chick-embryo cartilage cells from temporary anoxia was used to obtain accelerated triple-helix formation. A marked decrease was found in the extent of hydroxylation of the lysine residues in the collagen synthesized under these conditions, and an even larger decrease occurred in the glycosylations of the hydroxylysine residues. The results support the previous suggestion that the triple-helix formation of the pro-alpha-chains prevents further hydroxylation of lysine residues and glycosylations of hydroxylysine residues during collagen biosynthesis. FAU - Oikarinen, A AU - Oikarinen A FAU - Anttinen, H AU - Anttinen H FAU - Kivirikko, K I AU - Kivirikko KI LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 2GQB349IUB (Hydroxylysine) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - K3Z4F929H6 (Lysine) RN - RMB44WO89X (Hydroxyproline) RN - T8ID5YZU6Y (Dithiothreitol) SB - IM MH - Animals MH - Cartilage/*metabolism MH - Chick Embryo MH - Collagen/*metabolism MH - Dithiothreitol/pharmacology MH - Hydroxylation MH - Hydroxylysine/*metabolism MH - Hydroxyproline/metabolism MH - Hypoxia MH - Lysine/*metabolism MH - Proline/metabolism MH - Tendons/*metabolism PMC - PMC1165017 EDAT- 1977/09/15 00:00 MHDA- 1977/09/15 00:01 PMCR- 1978/03/15 CRDT- 1977/09/15 00:00 PHST- 1977/09/15 00:00 [pubmed] PHST- 1977/09/15 00:01 [medline] PHST- 1977/09/15 00:00 [entrez] PHST- 1978/03/15 00:00 [pmc-release] AID - 10.1042/bj1660357 [doi] PST - ppublish SO - Biochem J. 1977 Sep 15;166(3):357-62. doi: 10.1042/bj1660357. PMID- 4281373 OWN - NLM STAT- MEDLINE DCOM- 19750612 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 2 IP - 4 DP - 1974 TI - The degradation of human dentine collagen by trypsin. PG - 299-307 FAU - Scott, P G AU - Scott PG FAU - Leaver, A G AU - Leaver AG LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Amino Acids) RN - 0 (Hexosamines) RN - 0 (Hexoses) RN - 27YLU75U4W (Phosphorus) RN - 9007-34-5 (Collagen) RN - 9G34HU7RV0 (Edetic Acid) RN - EC 3.4.21.4 (Trypsin) RN - N762921K75 (Nitrogen) RN - QTT17582CB (Hydrochloric Acid) RN - RMB44WO89X (Hydroxyproline) RN - SY7Q814VUP (Calcium) SB - IM MH - Amino Acids/analysis MH - Animals MH - Calcium/pharmacology MH - Cattle MH - Collagen/analysis/*metabolism MH - Decalcification Technique MH - Dentin/*metabolism MH - Edetic Acid/pharmacology MH - Hexosamines/analysis MH - Hexoses/analysis MH - Humans MH - Hydrochloric Acid/pharmacology MH - Hydroxyproline/analysis MH - Nitrogen/analysis MH - Peptide Biosynthesis MH - Phosphorus/analysis MH - Solubility MH - Temperature MH - Tendons MH - Tooth Root MH - Trypsin/*metabolism EDAT- 1974/01/01 00:00 MHDA- 1974/01/01 00:01 CRDT- 1974/01/01 00:00 PHST- 1974/01/01 00:00 [pubmed] PHST- 1974/01/01 00:01 [medline] PHST- 1974/01/01 00:00 [entrez] AID - 10.3109/03008207409152259 [doi] PST - ppublish SO - Connect Tissue Res. 1974;2(4):299-307. doi: 10.3109/03008207409152259. PMID- 9748585 OWN - NLM STAT- MEDLINE DCOM- 19981019 LR - 20190610 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1407 IP - 3 DP - 1998 Sep 30 TI - Advanced glycation end products induce crosslinking of collagen in vitro. PG - 215-24 AB - We have investigated the effect of advanced glycation end products (AGEs) on the crosslinking of collagen. The potential pathological significance of AGEs and the altered metabolism of ascorbic acid (ASA) in diabetes have prompted us to investigate the role of ASA in the crosslinking and advanced glycation of collagen. Rat tail tendons were incubated with ASA and dehydroascorbic acid (DHA) under physiological conditions of temperature and pH, and the crosslinking and the level of AGEs were analyzed. Analysis of crosslinking was conducted by pepsin solubility and cyanogen bromide digestion. Level of AGEs was estimated by enzyme-linked immunosorbent assay (ELISA) using antibodies raised against AGE-ribonuclease. It was noted that ASA and DHA induced crosslinking of collagen and stimulated the formation of AGEs. It was also noted that these pathways were dependent on oxidative conditions. Similarly incubation of collagen with AGEs, prepared by the in vitro incubation of bovine serum albumin (BSA) with glucose, also resulted in increased crosslinking. The extent of crosslinking was dependent on the duration of incubation. The novel finding of this study, which is in contrast to the earlier reports on glucose-induced crosslinking of collagen, was that AGEs-induced crosslinking of collagen was not inhibited by radical scavengers and the metal chelator. EDTA, whereas glucose-induced crosslinking of collagen was almost completely prevented by free radical scavengers. The increased fluorescence intensity observed in collagen incubated with AGEs was also not prevented by radical scavengers. Estimation of AGEs by ELISA revealed an increased accumulation of AGEs in collagen incubated with AGE-BSA. The inhibitory effect of aminoguanidine and aspirin on AGEs-induced modification of collagen, strongly suggests that the amino-carbonyl interaction between AGEs and collagen may play a key role in the crosslinking process. The results obtained in this study indicate that soluble AGEs can directly induce crosslinking of collagen and this process is independent of oxidative conditions. From these results it may be hypothesized that glucose, under oxidative conditions, reacts with proteins to form potentially reactive end products called AGEs. These AGEs, once formed, could induce crosslinking of collagen even in the absence of both glucose and oxygen. FAU - Sajithlal, G B AU - Sajithlal GB AD - Department of Biochemistry, Central Leather Research Institute, Adyar, Chennai, India. FAU - Chithra, P AU - Chithra P FAU - Chandrakasan, G AU - Chandrakasan G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Cross-Linking Reagents) RN - 0 (Free Radical Scavengers) RN - 0 (Glycation End Products, Advanced) RN - 9007-34-5 (Collagen) RN - EC 3.4.23.1 (Pepsin A) RN - IY9XDZ35W2 (Glucose) RN - OS382OHJ8P (Cyanogen Bromide) RN - Y2Z3ZTP9UM (Dehydroascorbic Acid) SB - IM MH - Animals MH - Collagen/*chemistry/metabolism MH - Cross-Linking Reagents/*chemistry MH - Cyanogen Bromide MH - Dehydroascorbic Acid/chemistry/pharmacology MH - Diabetes Mellitus/metabolism MH - Free Radical Scavengers MH - Glucose/chemistry/pharmacology MH - Glycation End Products, Advanced/*chemistry/metabolism MH - Pepsin A MH - Peptide Mapping MH - Rats MH - Tendons/metabolism EDAT- 1998/09/28 00:00 MHDA- 1998/09/28 00:01 CRDT- 1998/09/28 00:00 PHST- 1998/09/28 00:00 [pubmed] PHST- 1998/09/28 00:01 [medline] PHST- 1998/09/28 00:00 [entrez] AID - S0925-4439(98)00043-X [pii] AID - 10.1016/s0925-4439(98)00043-x [doi] PST - ppublish SO - Biochim Biophys Acta. 1998 Sep 30;1407(3):215-24. doi: 10.1016/s0925-4439(98)00043-x. PMID- 21601852 OWN - NLM STAT- MEDLINE DCOM- 20130408 LR - 20151119 IS - 1879-0267 (Electronic) IS - 0020-1383 (Linking) VI - 43 IP - 9 DP - 2012 Sep TI - Prophylactic antibiotics for simple hand lacerations: time for a clinical trial? PG - 1497-501 LID - 10.1016/j.injury.2011.05.001 [doi] AB - BACKGROUND: Simple hand lacerations (not involving bones, tendons, nerves, or vessels) are a common emergency department (ED) complaint. Whilst the practices of irrigation, debridement, foreign body removal, and suture repair are well accepted, the use of prophylactic antibiotics is not. Without evidenced-based guidelines, practice is left to physician preference. OBJECTIVES: The aim of this study was to assess the need for, and the feasibility to perform, a randomised controlled trial to evaluate the role of prophylactic antibiotics in simple hand lacerations. METHODS: The study was done in three phases: (1) estimation of the national ED burden of simple hand lacerations and the use of antibiotic prophylaxis; (2) assessment of indications for antibiotic prophylaxis and (3) investigation of patient willingness to enrol in a randomised controlled trial and their preferred outcomes from simple hand lacerations. For Phase 1, we analysed the 2007 National Hospital Ambulatory Medical Care Survey. For Phase 2, we surveyed ED physicians in three urban teaching institutions (two in Brooklyn, NY and one in Washington, DC). For Phase 3, we surveyed ED patients at the same three institutions. RESULTS: Phase 1: out of 116.8 million ED visits nationally in 2007, 1.8 million (1.6%) were due to simple hand lacerations, of which 1.3 million (71%) required repair. Of those repaired, 27% (95% CI, 19-35%) were prescribed prophylactic antibiotics, most commonly cephalexin (73%). Phase 2: out of 108 providers surveyed, 69 (64%) responded. 16% (95% CI, 9-27%) reported prescribing prophylactic antibiotics routinely, most commonly cephalexin (84%, 95% CI, 67-93%). The degree of contamination was the most important factor (91%, 95% CI, 82-96%) in the physicians' decision to prescribe antibiotics. Phase 3: of the 490 patients surveyed, 64% (95% CI, 60-68%) expressed interest in participating in a study to evaluate the use of prophylactic antibiotics. Their primary concern was prevention of infection (77%, 95% CI, 73-81%). CONCLUSION: Simple hand lacerations represent a substantial number of ED visits in the United States. Absence of clear guidelines, disparity in physician practice, and patient interest in infection prevention all support performing a prospective randomised controlled trial to establish the role of antibiotic prophylaxis in simple hand lacerations. CI - Copyright © 2011 Elsevier Ltd. All rights reserved. FAU - Zehtabchi, Shahriar AU - Zehtabchi S AD - Department of Emergency Medicine, State University of New York, Downstate Medical Center, NY 11203 , USA. Shahriar.zehtabchi@downstate.edu FAU - Yadav, Kabir AU - Yadav K FAU - Brothers, Elizabeth AU - Brothers E FAU - Khan, Feras AU - Khan F FAU - Singh, Savitri AU - Singh S FAU - Wilcoxson, R Daniel AU - Wilcoxson RD FAU - Malhotra, Shweta AU - Malhotra S LA - eng PT - Journal Article PT - Multicenter Study DEP - 20110524 PL - Netherlands TA - Injury JT - Injury JID - 0226040 RN - 0 (Anti-Bacterial Agents) RN - OBN7UDS42Y (Cephalexin) SB - IM MH - Adolescent MH - Adult MH - Anti-Bacterial Agents/*therapeutic use MH - *Antibiotic Prophylaxis MH - Cephalexin/*therapeutic use MH - Child MH - District of Columbia/epidemiology MH - Emergency Service, Hospital/statistics & numerical data MH - Female MH - Hand Injuries/*complications/epidemiology MH - Health Care Surveys MH - Hospitals, Urban/statistics & numerical data MH - Humans MH - Incidence MH - Lacerations/*complications/epidemiology MH - Male MH - Middle Aged MH - New York/epidemiology MH - Practice Patterns, Physicians'/*statistics & numerical data MH - Surveys and Questionnaires MH - Wound Healing MH - Wound Infection/*drug therapy/epidemiology/etiology/prevention & control MH - Young Adult EDAT- 2011/05/24 06:00 MHDA- 2013/04/09 06:00 CRDT- 2011/05/24 06:00 PHST- 2011/02/26 00:00 [received] PHST- 2011/04/14 00:00 [revised] PHST- 2011/05/03 00:00 [accepted] PHST- 2011/05/24 06:00 [entrez] PHST- 2011/05/24 06:00 [pubmed] PHST- 2013/04/09 06:00 [medline] AID - S0020-1383(11)00181-1 [pii] AID - 10.1016/j.injury.2011.05.001 [doi] PST - ppublish SO - Injury. 2012 Sep;43(9):1497-501. doi: 10.1016/j.injury.2011.05.001. Epub 2011 May 24. PMID- 23212463 OWN - NLM STAT- MEDLINE DCOM- 20130807 LR - 20250529 IS - 1432-0878 (Electronic) IS - 0302-766X (Print) IS - 0302-766X (Linking) VI - 351 IP - 3 DP - 2013 Mar TI - Human tenocytes are stimulated to proliferate by acetylcholine through an EGFR signalling pathway. PG - 465-75 LID - 10.1007/s00441-012-1530-5 [doi] AB - Studies of human patellar and Achilles tendons have shown that primary tendon fibroblasts (tenocytes) not only have the capacity to produce acetylcholine (ACh) but also express muscarinic ACh receptors (mAChRs) through which ACh can exert its effects. In patients with tendinopathy (chronic tendon pain) with tendinosis, the tendon tissue is characterised by hypercellularity and angiogenesis, both of which might be influenced by ACh. In this study, we have tested the hypothesis that ACh increases the proliferation rate of tenocytes through mAChR stimulation and have examined whether this mechanism operates via the extracellular activation of the epidermal growth factor receptor (EGFR), as shown in other fibroblastic cells. By use of primary human tendon cell cultures, we identified cells expressing vimentin, tenomodulin and scleraxis and found that these cells also contained enzymes related to ACh synthesis and release (choline acetyltransferase and vesicular acetylcholine transporter). The cells furthermore expressed mAChRs of several subtypes. Exogenously administered ACh stimulated proliferation and increased the viability of tenocytes in vitro. When the cells were exposed to atropine (an mAChR antagonist) or the EGFR inhibitor AG1478, the proliferative effect of ACh decreased. Western blot revealed increased phosphorylation, after ACh stimulation, for both EGFR and the extracellular-signal-regulated kinases 1 and 2. Given that tenocytes have been shown to produce ACh and express mAChRs, this study provides evidence of a possible autocrine loop that might contribute to the hypercellularity seen in tendinosis tendon tissue. FAU - Fong, Gloria AU - Fong G AD - Department of Integrative Medical Biology, Anatomy, Umeå University, SE-901 87, Umeå, Sweden. FAU - Backman, Ludvig J AU - Backman LJ FAU - Andersson, Gustav AU - Andersson G FAU - Scott, Alexander AU - Scott A FAU - Danielson, Patrik AU - Danielson P LA - eng GR - 126604-1/CAPMC/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121205 PL - Germany TA - Cell Tissue Res JT - Cell and tissue research JID - 0417625 RN - 0 (Receptors, Muscarinic) RN - 0 (Vesicular Acetylcholine Transport Proteins) RN - EC 2.3.1.6 (Choline O-Acetyltransferase) RN - EC 2.7.10.1 (ErbB Receptors) RN - G34N38R2N1 (Bromodeoxyuridine) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Achilles Tendon/*cytology MH - Blotting, Western MH - Bromodeoxyuridine/metabolism MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Choline O-Acetyltransferase/metabolism MH - ErbB Receptors/*metabolism MH - Humans MH - Immunohistochemistry MH - Models, Biological MH - Phenotype MH - Phosphorylation/drug effects MH - Polymerase Chain Reaction MH - Receptors, Muscarinic/metabolism MH - Signal Transduction/*drug effects MH - Vesicular Acetylcholine Transport Proteins/metabolism PMC - PMC3582816 EDAT- 2012/12/06 06:00 MHDA- 2013/08/08 06:00 PMCR- 2012/12/05 CRDT- 2012/12/06 06:00 PHST- 2012/07/05 00:00 [received] PHST- 2012/11/07 00:00 [accepted] PHST- 2012/12/06 06:00 [entrez] PHST- 2012/12/06 06:00 [pubmed] PHST- 2013/08/08 06:00 [medline] PHST- 2012/12/05 00:00 [pmc-release] AID - 1530 [pii] AID - 10.1007/s00441-012-1530-5 [doi] PST - ppublish SO - Cell Tissue Res. 2013 Mar;351(3):465-75. doi: 10.1007/s00441-012-1530-5. Epub 2012 Dec 5. PMID- 18991487 OWN - NLM STAT- MEDLINE DCOM- 20090910 LR - 20181201 IS - 1937-335X (Electronic) IS - 1937-3341 (Linking) VI - 15 IP - 6 DP - 2009 Jun TI - Engineering the bone-ligament interface using polyethylene glycol diacrylate incorporated with hydroxyapatite. PG - 1201-9 LID - 10.1089/ten.tea.2008.0105 [doi] AB - Ligaments and tendons have previously been tissue engineered. However, without the bone attachment, implantation of a tissue-engineered ligament would require it to be sutured to the remnant of the injured native tissue. Due to slow repair and remodeling, this would result in a chronically weak tissue that may never return to preinjury function. In contrast, orthopaedic autograft reconstruction of the ligament often uses a bone-to-bone technique for optimal repair. Since bone-to-bone repairs heal better than other methods, implantation of an artificial ligament should also occur from bone-to-bone. The aim of this study was to investigate the use of a poly(ethylene glycol) diacrylate (PEGDA) hydrogel incorporated with hydroxyapatite (HA) and the cell-adhesion peptide RGD (Arg-Gly-Asp) as a material for creating an in vitro tissue interface to engineer intact ligaments (i.e., bone-ligament-bone). Incorporation of HA into PEG hydrogels reduced the swelling ratio but increased mechanical strength and stiffness of the hydrogels. Further, HA addition increased the capacity for cell growth and interface formation. RGD incorporation increased the swelling ratio but decreased mechanical strength and stiffness of the material. Optimum levels of cell attachment were met using a combination of both HA and RGD, but this material had no better mechanical properties than PEG alone. Although adherence of the hydrogels containing HA was achieved, failure occurs at about 4 days with 5% HA. Increasing the proportion of HA improved interface formation; however, with high levels of HA, the PEG HA composite became brittle. This data suggests that HA, by itself or with other materials, might be well suited for engineering the ligament-bone interface. FAU - Paxton, Jennifer Z AU - Paxton JZ AD - Division of Molecular Physiology, University of Dundee, Dundee, United Kingdom. FAU - Donnelly, Kenneth AU - Donnelly K FAU - Keatch, Robert P AU - Keatch RP FAU - Baar, Keith AU - Baar K LA - eng GR - BB/F002084/1/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 0 (Hydrogels) RN - 0 (Oligopeptides) RN - 0 (poly(ethylene glycol)diacrylate) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 91D9GV0Z28 (Durapatite) SB - IM MH - Animals MH - Bone and Bones/*drug effects/*physiology MH - Cell Adhesion/drug effects MH - Durapatite/*pharmacology MH - Fibroblasts/cytology/drug effects MH - Hydrogels/chemistry MH - Ligaments/*drug effects/*physiology MH - Mechanical Phenomena/drug effects MH - Oligopeptides/pharmacology MH - Polyethylene Glycols/*pharmacology MH - Rats MH - *Tissue Engineering EDAT- 2008/11/11 09:00 MHDA- 2009/09/11 06:00 CRDT- 2008/11/11 09:00 PHST- 2008/11/11 09:00 [pubmed] PHST- 2009/09/11 06:00 [medline] PHST- 2008/11/11 09:00 [entrez] AID - 10.1089/ten.tea.2008.0105 [doi] PST - ppublish SO - Tissue Eng Part A. 2009 Jun;15(6):1201-9. doi: 10.1089/ten.tea.2008.0105. PMID- 12813143 OWN - NLM STAT- MEDLINE DCOM- 20040429 LR - 20181113 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 551 IP - Pt 2 DP - 2003 Sep 1 TI - Cyclo-oxygenase-2 mediated prostaglandin release regulates blood flow in connective tissue during mechanical loading in humans. PG - 683-9 AB - Mechanical loading is known to increase connective tissue blood flow of human tendons and to cause local release of vasodilatory substances. The present study investigated the importance of prostaglandins (PG) formed by cyclo-oxygenase isoforms (COX-1 and 2) for the exercise-related increase in blood flow in connective tissue. Healthy individuals (n = 24, age: 23-31 years) underwent 30 min of intermittent, isometric, plantarflexion with both calf muscles either without (n = 6, Control, C) or with blockade of PG formation, either COX-2 specific (n = 10, Celecoxib 2 x 100 mg day-1 for 3 days prior to the experiment) or COX unspecific (n = 8, indomethacin 100 mg (12 and 1 h pre-experiment) and acetyl salicylic acid 500 mg day-1 for 3 days pre-experiment). Prostaglandin E2 (PGE2) concentration was determined by microdialysis and blood flow by 133Xe washout. In C, interstitial PGE2 rose from (0.8 +/- 0.2 (rest) to 1.4 +/- 0.5 ng ml-1 (exercise), P < 0.05), whereas during unspecific COX inhibition, tissue PGE2 was completely inhibited at rest and during exercise. COX-2 specific blockade did not inhibit tissue PGE2 at rest, but totally abolished the exercise induced increase. Blood flow was similar in the three groups at rest (P > 0.05), whereas the increase in flow with exercise was reduced by 35 and 43 % with COX-2 specific blockade (3.2 +/- 0.7 to 6.1 +/- 1.5 ml (100 g tissue)-1 min-1 or COX unspecific blockade (3.0 +/- 0.8 to 7.6 +/- 1.6), respectively, compared to C (2.7 +/- 0.8 to 10.2 +/- 2.0)(P < 0.05). The findings indicate that COX-2 specific mechanisms are responsible for the exercise-induced increase in prostaglandin synthesis, and that increase in tissue prostaglandin plays an important role for blood flow in peritendinous connective tissue during physical loading in vivo. FAU - Langberg, H AU - Langberg H AD - Sports Medicine Research Unit, Department of Rheumatology, Copenhagen University Hospital at Bispebjerg, DK-2400 Copenhagen NV, Denmark. hl02@bbh.hosp.dk FAU - Boushel, R AU - Boushel R FAU - Skovgaard, D AU - Skovgaard D FAU - Risum, N AU - Risum N FAU - Kjaer, M AU - Kjaer M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20030617 PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (Cyclooxygenase 2 Inhibitors) RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Isoenzymes) RN - 0 (Membrane Proteins) RN - 0 (Prostaglandins) RN - 3H3U766W84 (Xenon) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 1.14.99.1 (PTGS2 protein, human) RN - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Achilles Tendon/metabolism MH - Adult MH - Calibration MH - Connective Tissue/*blood supply/*physiology MH - Cyclooxygenase 2 MH - Cyclooxygenase 2 Inhibitors MH - Cyclooxygenase Inhibitors/pharmacology MH - Dinoprostone/metabolism MH - Exercise/physiology MH - Humans MH - Immunohistochemistry MH - Isoenzymes/*physiology MH - Leg/blood supply/physiology MH - Membrane Proteins MH - Microdialysis MH - Prostaglandin-Endoperoxide Synthases/*physiology MH - Prostaglandins/*metabolism MH - Regional Blood Flow/physiology MH - Rest/physiology MH - Xenon PMC - PMC2343237 EDAT- 2003/06/19 05:00 MHDA- 2004/04/30 05:00 PMCR- 2004/09/01 CRDT- 2003/06/19 05:00 PHST- 2003/06/19 05:00 [pubmed] PHST- 2004/04/30 05:00 [medline] PHST- 2003/06/19 05:00 [entrez] PHST- 2004/09/01 00:00 [pmc-release] AID - jphysiol.2003.046094 [pii] AID - 10.1113/jphysiol.2003.046094 [doi] PST - ppublish SO - J Physiol. 2003 Sep 1;551(Pt 2):683-9. doi: 10.1113/jphysiol.2003.046094. Epub 2003 Jun 17. PMID- 2414449 OWN - NLM STAT- MEDLINE DCOM- 19851203 LR - 20190710 IS - 0022-2836 (Print) IS - 0022-2836 (Linking) VI - 185 IP - 2 DP - 1985 Sep 20 TI - Glutaraldehyde-induced changes in the axially projected fine structure of collagen fibrils. PG - 359-70 AB - The fine structure of the collagen fibril, as seen in axial projection, is changed by treatment with glutaraldehyde. The changes are detectable in electron-optical staining patterns and in the intensities of the low-angle meridional X-ray diffraction maxima. Current knowledge of the amino acid sequence of collagen and of the axial arrangement of molecules in fibrils permits interpretation in terms of specific alterations to the axial distribution of electron density along the fibril. Analysis of fibril staining patterns from glutaraldehyde-treated calf skin collagen shows that uptake of staining ions in positive staining patterns is inhibited at residues known to interact with glutaraldehyde (lysyl, hydroxylysyl and probably histidyl side-chains) and on other charged residues in the immediate neighbourhood of the glutaraldehyde-reactive residues. This can be seen as a "stain-exclusion effect" due to the presence of bulky polymeric complexes of glutaraldehyde molecules at cross-linking sites. Such stain exclusion accounts for the drastic changes in the negative staining pattern following treatment with glutaraldehyde. The intensity changes observed in the low-angle meridional X-ray reflections from rat tail tendon, similarly treated, also can be explained by the presence of these bulky complexes. Existing data have been used to predict a model of the altered electron density profile indicating the axial distribution of glutaraldehyde along a D-period of moist tendon collagen. FAU - Meek, K M AU - Meek KM FAU - Chapman, J A AU - Chapman JA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - J Mol Biol JT - Journal of molecular biology JID - 2985088R RN - 0 (Aldehydes) RN - 2GQB349IUB (Hydroxylysine) RN - 9007-34-5 (Collagen) RN - K3Z4F929H6 (Lysine) RN - T3C89M417N (Glutaral) SB - IM MH - Aldehydes/*pharmacology MH - Amino Acid Sequence MH - Animals MH - Cattle MH - *Collagen MH - Densitometry MH - Glutaral/*pharmacology MH - Hydroxylysine/metabolism MH - Lysine/metabolism MH - Protein Conformation MH - Rats MH - Staining and Labeling MH - Tendons/analysis MH - X-Ray Diffraction EDAT- 1985/09/20 00:00 MHDA- 1985/09/20 00:01 CRDT- 1985/09/20 00:00 PHST- 1985/09/20 00:00 [pubmed] PHST- 1985/09/20 00:01 [medline] PHST- 1985/09/20 00:00 [entrez] AID - 0022-2836(85)90409-7 [pii] AID - 10.1016/0022-2836(85)90409-7 [doi] PST - ppublish SO - J Mol Biol. 1985 Sep 20;185(2):359-70. doi: 10.1016/0022-2836(85)90409-7. PMID- 40189016 OWN - NLM STAT- MEDLINE DCOM- 20251116 LR - 20251116 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 34 IP - 12 DP - 2025 Dec TI - The toxicity of chlorhexidine and povidone-iodine to rotator cuff tendon. PG - 2727-2734 LID - S1058-2746(25)00276-9 [pii] LID - 10.1016/j.jse.2025.02.054 [doi] AB - BACKGROUND: Antimicrobial wound lavages containing chlorhexidine gluconate (CHG) or povidone-iodine (PI) are commonly used for infection prophylaxis in arthroplasty surgery, including shoulder arthroplasty. However, the potential toxicity of these solutions to the surrounding native tissue, including rotator cuff tendons, is not well understood. The purpose of this study was to investigate the ex vivo effects of a 1-minute 0.05% CHG exposure and a 3-minute 0.35% PI exposure on the viability and biochemical content of rotator cuff tendon explants. METHODS: Infraspinatus tendons (n = 6 per group) were isolated from the shoulders of Nubian goats. Tendons were submerged in 0.05% CHG in sterile water for 1 minute or 0.35% PI for 3 minutes per manufacturer guidelines, followed by phosphate-buffered saline (PBS) wash and culture in tissue medium. Control tendon specimens were bathed in PBS solution for 1 minute, followed by PBS wash and culture in tissue medium. Seven days after exposure, isolates from both the tendinous and enthesis portions were analyzed for tenocyte viability, biochemical content (collagen and glycosaminoglycan [GAG]), and matrix histology. RESULTS: Within the tendinous portion of the tendon, CHG and PI exposure led to reduced mean tenocyte viability compared to controls (4.35% ± 4.64% viability in the CHG group, P = .045; 14.4% ± 20.3% viability for the PI group, P = .097; vs. 35.4% ± 28.4% viability in the control group). Within the enthesis, CHG and PI exposure led to smaller and nonsignificant decreased mean tenocyte viability compared to controls (29.5% ± 22.9%, P = .336 for CHG; 37.5% ± 29.4%, P = .327 for PI). There were no significant differences in mean collagen content/wet weight or GAG/wet weight among groups within the tendinous and enthesis isolates, nor were there any appreciable differences on histology in collagen and GAG distribution among groups. CONCLUSION: Brief 0.05% CHG and 0.35% PI exposures to rotator cuff tendon may lead to reduced tenocyte viability, with the tendinous portion seemingly more susceptible than the enthesis. Additionally, at these concentrations tested, CHG appears to be more toxic than PI. These findings raise concern for the potential cytotoxic effects of low-dose CHG and PI on native tendon tissue, even after brief exposures commonly used for antimicrobial prophylaxis in shoulder arthroplasty. CI - Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Moslehyazdi, Maziar AU - Moslehyazdi M AD - Department of Orthopaedic Surgery, University of California Irvine, Irvine, CA, USA; Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA. FAU - Pasko, Kory B Dylan AU - Pasko KBD AD - Department of Orthopaedic Surgery, University of California Irvine, Irvine, CA, USA; Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA; Georgetown University School of Medicine, Washington, DC, USA. FAU - Bielajew, Benjamin AU - Bielajew B AD - Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA. FAU - Johnston, Tyler R AU - Johnston TR AD - Department of Orthopaedic Surgery, University of California Irvine, Irvine, CA, USA. FAU - Hu, Jerry C AU - Hu JC AD - Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA. FAU - Athanasiou, Kyriacos A AU - Athanasiou KA AD - Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA. FAU - Wang, Dean AU - Wang D AD - Department of Orthopaedic Surgery, University of California Irvine, Irvine, CA, USA; Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, USA. Electronic address: DeanWangMD@gmail.com. LA - eng PT - Journal Article DEP - 20250404 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - R4KO0DY52L (Chlorhexidine) RN - 85H0HZU99M (Povidone-Iodine) RN - 0 (Anti-Infective Agents, Local) RN - MOR84MUD8E (chlorhexidine gluconate) SB - IM MH - Animals MH - *Chlorhexidine/toxicity/analogs & derivatives MH - *Povidone-Iodine/toxicity MH - *Rotator Cuff/drug effects/pathology MH - *Anti-Infective Agents, Local/toxicity MH - Goats MH - Tenocytes/drug effects OTO - NOTNLM OT - Shoulder replacement OT - chlorhexidine OT - infection OT - periprosthetic joint infection OT - povidone-iodine OT - rotator cuff OT - tendon EDAT- 2025/04/07 02:02 MHDA- 2025/11/17 00:28 CRDT- 2025/04/06 19:34 PHST- 2024/12/24 00:00 [received] PHST- 2025/02/19 00:00 [revised] PHST- 2025/02/22 00:00 [accepted] PHST- 2025/11/17 00:28 [medline] PHST- 2025/04/07 02:02 [pubmed] PHST- 2025/04/06 19:34 [entrez] AID - S1058-2746(25)00276-9 [pii] AID - 10.1016/j.jse.2025.02.054 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2025 Dec;34(12):2727-2734. doi: 10.1016/j.jse.2025.02.054. Epub 2025 Apr 4. PMID- 21210498 OWN - NLM STAT- MEDLINE DCOM- 20110513 LR - 20200930 IS - 1552-4981 (Electronic) IS - 1552-4973 (Linking) VI - 96 IP - 2 DP - 2011 Feb TI - Method of preparing a decellularized porcine tendon using tributyl phosphate. PG - 199-206 LID - 10.1002/jbm.b.31753 [doi] AB - Extracellular matrix (ECM) materials are currently utilized for soft tissue repair applications such as vascular grafts, tendon reconstruction, and hernia repair. These materials are derived from tissues such as human dermis and porcine small intestine submucosa, which must be rendered acellular to prevent disease transmission and decrease the risk of an immune response. The ideal decellularization technique removes cells and cellular remnants, but leaves the original collagen architecture intact. The tissue utilized in this study was the central tendon of the porcine diaphragm, which had not been previously investigated for soft tissue repair. Several treatments were investigated during this study including peracetic acid, TritonX-100, sodium dodecyl sulfate, and tri(n-butyl) phosphate (TnBP). Of the decellularization treatments investigated, only 1% TnBP was effective in removing cell nuclei while leaving the structure and composition of the tissue intact. Overall, the resulting acellular tissue scaffold retained the ECM composition, strength, resistance to enzymatic degradation, and biocompatibility of the original tissue, making 1% TnBP an acceptable decellularization treatment for porcine diaphragm tendon. CI - Copyright © 2010 Wiley Periodicals, Inc. FAU - Deeken, C R AU - Deeken CR AD - Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - White, A K AU - White AK FAU - Bachman, S L AU - Bachman SL FAU - Ramshaw, B J AU - Ramshaw BJ FAU - Cleveland, D S AU - Cleveland DS FAU - Loy, T S AU - Loy TS FAU - Grant, S A AU - Grant SA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20101117 PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 0 (Organophosphates) RN - 95UAS8YAF5 (tributyl phosphate) SB - IM MH - Animals MH - Guided Tissue Regeneration/*methods MH - Methods MH - Organophosphates/*pharmacology MH - Sus scrofa MH - Tendons/*drug effects MH - *Tissue Scaffolds EDAT- 2011/01/07 06:00 MHDA- 2011/05/14 06:00 CRDT- 2011/01/07 06:00 PHST- 2010/04/20 00:00 [received] PHST- 2010/08/16 00:00 [revised] PHST- 2010/08/25 00:00 [accepted] PHST- 2011/01/07 06:00 [entrez] PHST- 2011/01/07 06:00 [pubmed] PHST- 2011/05/14 06:00 [medline] AID - 10.1002/jbm.b.31753 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2011 Feb;96(2):199-206. doi: 10.1002/jbm.b.31753. Epub 2010 Nov 17. PMID- 1731749 OWN - NLM STAT- MEDLINE DCOM- 19920218 LR - 20190501 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 281 ( Pt 1) IP - Pt 1 DP - 1992 Jan 1 TI - Expression of c-myc and c-fos in rat skeletal muscle. Evidence for increased levels of c-myc mRNA during hypertrophy. PG - 143-7 AB - The levels of c-myc and c-fos mRNA were investigated in rat skeletal muscle by Northern hybridization. During post-natal development in the rat, c-myc mRNA levels were similar at birth and at 7 and 21 days of age, but then declined at 90 days and were barely detectable at 1 year. c-fos mRNA levels followed this pattern of expression until 90 days, but showed a large increase at 1 year. Hypertrophy of soleus and plantaris muscles was induced either by severance of the tendon to the synergistic gastrocnemius (tenotomy) or by administration of the beta-adrenoceptor agonist clenbuterol. In both cases hypertrophy was associated with a rapid increase in c-myc mRNA levels. Following tenotomy the increase was both greater (8-fold) and more rapid (3 h) in soleus than in plantaris (2-3 fold, 12 h). Similar effects were observed during clenbuterol administration. Neither treatment caused any alteration in c-fos mRNA levels in the plantaris muscle. The results show that increased c-myc mRNA levels are an early event in the response of skeletal muscle to hypertrophic stimuli; it is argued that this occurs within the differentiated skeletal muscle fibres. FAU - Whitelaw, P F AU - Whitelaw PF AD - Division of Biochemical Sciences, Rowett Research Institute, Bucksburn, Aberdeen, U.K. FAU - Hesketh, J E AU - Hesketh JE LA - eng PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (RNA, Messenger) RN - 0 (RNA, Ribosomal, 18S) RN - XTZ6AXU7KN (Clenbuterol) SB - IM GS - c-fos GS - c-myc MH - Aging MH - Animals MH - Blotting, Northern MH - Clenbuterol/pharmacology MH - Female MH - Gene Expression MH - *Genes, fos MH - *Genes, myc/drug effects MH - Hypertrophy MH - *Muscle Development MH - Muscles/drug effects/*pathology MH - RNA, Messenger/*metabolism MH - RNA, Ribosomal, 18S/metabolism MH - Rats MH - Rats, Inbred Strains MH - Tendons/physiology PMC - PMC1130652 EDAT- 1992/01/01 00:00 MHDA- 1992/01/01 00:01 PMCR- 1992/01/01 CRDT- 1992/01/01 00:00 PHST- 1992/01/01 00:00 [pubmed] PHST- 1992/01/01 00:01 [medline] PHST- 1992/01/01 00:00 [entrez] PHST- 1992/01/01 00:00 [pmc-release] AID - 10.1042/bj2810143 [doi] PST - ppublish SO - Biochem J. 1992 Jan 1;281 ( Pt 1)(Pt 1):143-7. doi: 10.1042/bj2810143. PMID- 38081952 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20231226 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Dec 11 TI - Novel CO(2)-encapsulated Pluronic F127 hydrogel for the treatment of Achilles tendon injury. PG - 21895 LID - 10.1038/s41598-023-49339-z [doi] LID - 21895 AB - Nonsurgical treatment and surgical repairment of injured Achilles tendons seldom restore the wounded tendon to its original elasticity and stiffness. Therefore, we hypothesized that the surgically repaired Achilles tendon can achieve satisfactory regeneration by applying multi-drug encapsulated hydrogels. In this study, a novel bupivacaine-eluting carbon dioxide-encapsulated Pluronic F127 hydrogel (BC-hydrogel) was developed for the treatment of Achilles tendon injuries. The rheological properties of BC-hydrogel were measured. A high-performance liquid chromatography assay was used to assess the release characteristics of bupivacaine in both in vitro and in vivo settings. Furthermore, the effectiveness of BC-hydrogel in treating torn tendons was examined in a rat model, and histological analyses were conducted. Evidently, the degradable hydrogels continuously eluted bupivacaine for more than 14 days. The animal study results revealed that the BC-hydrogel improved the post-surgery mobility of the animals compared with pristine hydrogels. Histological assay results demonstrated a significant reaction to high vascular endothelial growth factor in the surrounding tissues and expression of collagen I within the repaired tendon. This demonstrates the potential of this novel BC-hydrogel as an effective treatment method for Achilles tendon injuries. CI - © 2023. The Author(s). FAU - Yu, Yi-Hsun AU - Yu YH AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, 33305, Taiwan. FAU - Lee, Chen-Hung AU - Lee CH AD - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Medicine, Tao-Yuan, 33305, Taiwan. FAU - Hsu, Yung-Heng AU - Hsu YH AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, 33305, Taiwan. FAU - Chou, Ying-Chao AU - Chou YC AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, 33305, Taiwan. FAU - Hong, Bo-Kui AU - Hong BK AD - Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, 33302, Taiwan. FAU - Huang, Chao-Tsai AU - Huang CT AD - Department of Chemical and Materials Engineering, Tamkang University, New Taipei City, 251301, Taiwan. FAU - Liu, Shih-Jung AU - Liu SJ AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital at Linkou, Tao-Yuan, 33305, Taiwan. shihjung@mail.cgu.edu.tw. AD - Department of Mechanical Engineering, Chang Gung University, Tao-Yuan, 33302, Taiwan. shihjung@mail.cgu.edu.tw. AD - Biomaterials Lab, Mechanical Engineering, Chang Gung University, 259, Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan, 33302, Taiwan. shihjung@mail.cgu.edu.tw. LA - eng PT - Journal Article DEP - 20231211 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Hydrogels) RN - 142M471B3J (Carbon Dioxide) RN - 106392-12-5 (Poloxamer) RN - 0 (Vascular Endothelial Growth Factor A) RN - Y8335394RO (Bupivacaine) SB - IM MH - Rats MH - Animals MH - Hydrogels/pharmacology MH - *Achilles Tendon/pathology MH - Carbon Dioxide/metabolism MH - Poloxamer/pharmacology MH - Vascular Endothelial Growth Factor A/metabolism MH - *Tendon Injuries/pathology MH - Bupivacaine/pharmacology PMC - PMC10713641 COIS- The authors declare no competing interests. EDAT- 2023/12/12 00:42 MHDA- 2023/12/17 09:46 PMCR- 2023/12/11 CRDT- 2023/12/11 23:36 PHST- 2023/10/16 00:00 [received] PHST- 2023/12/07 00:00 [accepted] PHST- 2023/12/17 09:46 [medline] PHST- 2023/12/12 00:42 [pubmed] PHST- 2023/12/11 23:36 [entrez] PHST- 2023/12/11 00:00 [pmc-release] AID - 10.1038/s41598-023-49339-z [pii] AID - 49339 [pii] AID - 10.1038/s41598-023-49339-z [doi] PST - epublish SO - Sci Rep. 2023 Dec 11;13(1):21895. doi: 10.1038/s41598-023-49339-z. PMID- 6477673 OWN - NLM STAT- MEDLINE DCOM- 19841005 LR - 20190718 IS - 0021-9150 (Print) IS - 0021-9150 (Linking) VI - 52 IP - 2 DP - 1984 Aug TI - Effect of D-penicillamine on the mechanical properties of aorta, muscle tendon and skin in rats. PG - 243-52 AB - The biomechanical properties of rat aorta, muscle tendon and skin were studied after daily D-penicillamine treatment (500 mg/kg) for 5, 10 and 42 days. D-Penicillamine treatment for 5 days resulted in increased aortic extensibility. After long-term treatment the aorta exhibited a shift towards decreased extensibility and increased stiffness at small 'stress' values. Simultaneously the dry weight and diameter of the aortic samples were increased after D-penicillamine treatment for 42 days. After correction of the mechanical parameters for the increased amount of tissue of the samples, the stiffness at small 'stress' values was still increased and the mechanical stability at high 'stress' values retained. This is in contrast to the marked reduction in the strength of muscle tendon and skin of the same animals after D-penicillamine treatment for 42 days. This study demonstrates that a primary increase in the extensibility of aorta may elicit a reactive formation of vascular connective tissue. It is proposed that aortic smooth muscle cells are activated by an increased pulsatile distension of the vessel wall secondary to the early effect of D-penicillamine on collagen and elastin. The resulting excess deposition of collagen and elastin leads to increased stiffness, which may in turn increase the susceptibility of the aortic wall to hemodynamic injury. Consequently D-penicillamine may not as proposed counteract the development of atherosclerosis. FAU - Oxlund, H AU - Oxlund H FAU - Andreassen, T T AU - Andreassen TT FAU - Junker, P AU - Junker P FAU - Jensen, B A AU - Jensen BA FAU - Lorenzen, I AU - Lorenzen I LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Ireland TA - Atherosclerosis JT - Atherosclerosis JID - 0242543 RN - GNN1DV99GX (Penicillamine) SB - IM MH - Animals MH - Aorta, Thoracic/drug effects MH - Biomechanical Phenomena MH - Elasticity MH - Male MH - Muscle, Smooth, Vascular/*drug effects MH - Penicillamine/*pharmacology MH - Rats MH - Rats, Inbred Strains MH - Skin/*drug effects MH - Tendons/*drug effects EDAT- 1984/08/01 00:00 MHDA- 1984/08/01 00:01 CRDT- 1984/08/01 00:00 PHST- 1984/08/01 00:00 [pubmed] PHST- 1984/08/01 00:01 [medline] PHST- 1984/08/01 00:00 [entrez] AID - 0021-9150(84)90122-9 [pii] AID - 10.1016/0021-9150(84)90122-9 [doi] PST - ppublish SO - Atherosclerosis. 1984 Aug;52(2):243-52. doi: 10.1016/0021-9150(84)90122-9. PMID- 39188199 OWN - NLM STAT- MEDLINE DCOM- 20241217 LR - 20250104 IS - 2192-2659 (Electronic) IS - 2192-2640 (Print) IS - 2192-2640 (Linking) VI - 13 IP - 31 DP - 2024 Dec TI - Enthesitis on Chip - A Model for Studying Acute and Chronic Inflammation of the Enthesis and its Pharmacological Treatment. PG - e2401815 LID - 10.1002/adhm.202401815 [doi] LID - 2401815 AB - Enthesitis, the inflammation of the enthesis, which is the point of attachment of tendons and ligaments to bones, is a common musculoskeletal disease. The inflammation often originates from the fibrocartilage region of the enthesis as a consequence of mechanical overuse or -load and consequently tissue damage. During enthesitis, waves of inflammatory cytokines propagate in(to) the fibrocartilage, resulting in detrimental, heterotopic bone formation. Understanding of human enthesitis and its treatment options is limited, also because of lacking in vitro model systems that can closely mimic the pathophysiology of the enthesis and can be used to develop therapies. In this study, an enthes(it)is-on-chip model is developed. On opposite sides of a porous culture membrane separating the chip's two microfluidic compartments, human mesenchymal stromal cells are selectively differentiated into tenocytes and fibrochondrocytes. By introducing an inflammatory cytokine cocktail into the fibrochondrocyte compartment, key aspects of acute and chronic enthesitis, measured as increased expression of inflammatory markers, can be recapitulated. Upon inducing chronic inflammatory conditions, hydroxyapatite deposition, enhanced osteogenic marker expression and reduced secretion of tissue-related extracellular matrix components are observed. Adding the anti-inflammatory drug celecoxib to the fibrochondrocyte compartment mitigates the inflammatory state, demonstrating the potential of the enthesitis-on-chip model for drug testing. CI - © 2024 The Author(s). Advanced Healthcare Materials published by Wiley‐VCH GmbH. FAU - Giacomini, Francesca AU - Giacomini F AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Rho, Hoon Suk AU - Rho HS AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Eischen-Loges, Maria AU - Eischen-Loges M AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. AD - Department of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Tahmasebi Birgani, Zeinab AU - Tahmasebi Birgani Z AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - van Blitterswijk, Clemens AU - van Blitterswijk C AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. AD - Department of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - van Griensven, Martijn AU - van Griensven M AD - Department of Cell Biology-Inspired Tissue Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Giselbrecht, Stefan AU - Giselbrecht S AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Habibović, Pamela AU - Habibović P AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. FAU - Truckenmüller, Roman AU - Truckenmüller R AUID- ORCID: 0000-0001-7541-525X AD - Department of Instructive Biomaterials Engineering, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, Maastricht, 6229 ER, The Netherlands. LA - eng GR - SAS-2014-00837/Limburg INvesteert in haar Kenniseconomie/ GR - SAS-2018-02477/Limburg INvesteert in haar Kenniseconomie/ GR - 0433/Interreg Vlaanderen-Nederland/ GR - 024.003.013/Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ GR - 15604/Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ GR - 18748/Nederlandse Organisatie voor Wetenschappelijk Onderzoek/ PT - Journal Article DEP - 20240827 PL - Germany TA - Adv Healthc Mater JT - Advanced healthcare materials JID - 101581613 RN - JCX84Q7J1L (Celecoxib) RN - 0 (Cytokines) SB - IM MH - Humans MH - *Lab-On-A-Chip Devices MH - *Mesenchymal Stem Cells/metabolism/drug effects MH - *Inflammation/pathology/metabolism/drug therapy MH - Celecoxib/pharmacology MH - Enthesopathy/metabolism/pathology MH - Cytokines/metabolism MH - Cell Differentiation/drug effects MH - Chronic Disease MH - Chondrocytes/metabolism/drug effects MH - Tenocytes/metabolism/drug effects PMC - PMC11650547 OTO - NOTNLM OT - drug testing OT - enthesis OT - enthesitis OT - inflammation OT - organ on chip COIS- The authors declare no conflict of interest. EDAT- 2024/08/27 09:49 MHDA- 2024/12/17 12:31 PMCR- 2024/12/17 CRDT- 2024/08/27 03:43 PHST- 2024/08/14 00:00 [revised] PHST- 2024/06/12 00:00 [received] PHST- 2024/12/17 12:31 [medline] PHST- 2024/08/27 09:49 [pubmed] PHST- 2024/08/27 03:43 [entrez] PHST- 2024/12/17 00:00 [pmc-release] AID - ADHM202401815 [pii] AID - 10.1002/adhm.202401815 [doi] PST - ppublish SO - Adv Healthc Mater. 2024 Dec;13(31):e2401815. doi: 10.1002/adhm.202401815. Epub 2024 Aug 27. PMID- 34419763 OWN - NLM STAT- MEDLINE DCOM- 20211118 LR - 20211204 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 573 DP - 2021 Oct 8 TI - Rapamycin prevents heterotopic ossification by inhibiting the mTOR pathway and oxidative stress. PG - 171-178 LID - S0006-291X(21)01097-4 [pii] LID - 10.1016/j.bbrc.2021.07.060 [doi] AB - Rapamycin (RAPA), which was first described as an anti-fungal agent, is a potent immunosuppressant that suppresses tumors and inhibits the mTOR signaling pathway. Heterotopic ossification (HO) is abnormal bone formation outside the skeletal system (e.g., in muscles, tendons, articular capsules and other soft tissues), often due to trauma or injury. There are currently no drugs available to treat traumatic HO, largely due to limited understanding of the disease. In this study, we focused on the role of oxidative stress (OS) in the early stage of traumatic HO, and explored the underlying mechanism of traumatic HO by using RAPA to specifically inhibit the mTOR pathway, which is known to play a role in the pathogenesis of HO. To assess the effects of RAPA in traumatic HO, we used an NSE-BMP4 transgenic mouse model that develops ossification in response to traumatic injury and intramuscular injection of cardiotoxin to initiate injury. These mice were then treated with RAPA or vehicle intraperitoneally every other day for 2 weeks. Our results demonstrate that RAPA can inhibit HO through a number of different mechanisms. We show that OS and a strong inflammatory response contribute to the hypoxia associated with the early stages of HO, and that RAPA inhibits these responses. Furthermore, RAPA reduces the vascularization triggered by mTOR signaling that leads to HO formation. Therefore, we believe that RAPA could be an effective treatment for the early stages of HO. CI - Copyright © 2021 Elsevier Inc. All rights reserved. FAU - Hu, Yangyang AU - Hu Y AD - Department of Pathology, Anhui Provincial Hospital, The First Affiliated Hospital of the University of Science and Technology of China, 230002, Hefei, Anhui, China. Electronic address: YYanghu2021@163.com. FAU - Wang, Zhe AU - Wang Z AD - Department of Pathology, Anhui Provincial Hospital, The First Affiliated Hospital of the University of Science and Technology of China, 230002, Hefei, Anhui, China. Electronic address: zhwang@fmmu.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210820 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Immunosuppressive Agents) RN - EC 2.7.1.1 (mTOR protein, mouse) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Animals MH - Disease Models, Animal MH - Immunosuppressive Agents/*pharmacology MH - Mice MH - Mice, Transgenic MH - Ossification, Heterotopic/*drug therapy/metabolism/pathology MH - Oxidative Stress/drug effects MH - Sirolimus/*pharmacology MH - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/08/23 06:00 MHDA- 2021/11/19 06:00 CRDT- 2021/08/22 20:53 PHST- 2021/05/29 00:00 [received] PHST- 2021/07/13 00:00 [revised] PHST- 2021/07/18 00:00 [accepted] PHST- 2021/08/23 06:00 [pubmed] PHST- 2021/11/19 06:00 [medline] PHST- 2021/08/22 20:53 [entrez] AID - S0006-291X(21)01097-4 [pii] AID - 10.1016/j.bbrc.2021.07.060 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2021 Oct 8;573:171-178. doi: 10.1016/j.bbrc.2021.07.060. Epub 2021 Aug 20. PMID- 32494667 OWN - NLM STAT- MEDLINE DCOM- 20220408 LR - 20220408 IS - 2375-2548 (Electronic) IS - 2375-2548 (Linking) VI - 6 IP - 18 DP - 2020 May TI - Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification. PG - eaay9526 LID - 10.1126/sciadv.aay9526 [doi] LID - eaay9526 AB - Heterotopic ossification (HO) in connective tissues like tendons and ligaments severely damages tissue structure. The pathogenesis of HO remains unclear but may involve mTOR. The results presented here indicate that tendon stem/progenitor cells do not undergo osteochondrogenic differentiation when mTOR signaling is inactivated by gene knockout or rapamycin (RAPA) treatment. Meanwhile, it is necessary to deliver RAPA to the injured sites and avoid disturbing the normal tendon. A RAPA delivery system, developed using collagen hybrid peptide (CHP) to modify the surface of poly(lactic-co-glycolic acid) (PLGA) nanoparticles, targeted RAPA specifically to pathological tendon collagen. The CHP-PLGA-RAPA nanoparticles showed excellent pathological collagen affinity, sustained-release ability, and bioactivity. In a mouse model of tendon HO, CHP-PLGA-RAPA nanoparticles specifically bound to pathological tendon and strongly suppressed HO progression. The mTOR signaling pathway appears to be a viable therapeutic target for tendon HO, and CHP-PLGA nanoparticles may be valuable for the treatment of tendon-related diseases. CI - Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). FAU - Chen, Yangwu AU - Chen Y AUID- ORCID: 0000-0003-4917-678X AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Shen, Weiliang AU - Shen W AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Tang, Chenqi AU - Tang C AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Huang, Jiayun AU - Huang J AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Fan, Chunmei AU - Fan C AUID- ORCID: 0000-0003-0829-6187 AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Yin, Zi AU - Yin Z AUID- ORCID: 0000-0003-2892-8962 AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Hu, Yejun AU - Hu Y AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Chen, Weishan AU - Chen W AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Ouyang, Hongwei AU - Ouyang H AUID- ORCID: 0000-0003-2892-8962 AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. FAU - Zhou, Yiting AU - Zhou Y AUID- ORCID: 0000-0003-4543-3099 AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Biochemistry and Molecular Biology, School of Medicine, Zhejiang University, 866 Yu Hang Tang Road, Hangzhou, Zhejiang 310058, China. FAU - Mao, Zhengwei AU - Mao Z AUID- ORCID: 0000-0001-7990-2856 AD - MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China. FAU - Chen, Xiao AU - Chen X AUID- ORCID: 0000-0002-4438-5286 AD - Dr. Li Dak Sum-Yip Yio Chin Center for Stem Cells and Regenerative Medicine and Department of Orthopedic Surgery of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. AD - Department of Sports Medicine, Zhejiang University School of Medicine, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200429 PL - United States TA - Sci Adv JT - Science advances JID - 101653440 RN - 0 (Delayed-Action Preparations) RN - 9007-34-5 (Collagen) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Animals MH - Collagen MH - Delayed-Action Preparations/pharmacology MH - Mice MH - *Ossification, Heterotopic/drug therapy/prevention & control MH - *Sirolimus/pharmacology MH - TOR Serine-Threonine Kinases/metabolism PMC - PMC7239699 EDAT- 2020/06/05 06:00 MHDA- 2022/04/09 06:00 PMCR- 2020/04/29 CRDT- 2020/06/05 06:00 PHST- 2019/07/31 00:00 [received] PHST- 2020/02/07 00:00 [accepted] PHST- 2020/06/05 06:00 [entrez] PHST- 2020/06/05 06:00 [pubmed] PHST- 2022/04/09 06:00 [medline] PHST- 2020/04/29 00:00 [pmc-release] AID - aay9526 [pii] AID - 10.1126/sciadv.aay9526 [doi] PST - epublish SO - Sci Adv. 2020 Apr 29;6(18):eaay9526. doi: 10.1126/sciadv.aay9526. eCollection 2020 May. PMID- 16606655 OWN - NLM STAT- MEDLINE DCOM- 20061214 LR - 20131121 IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 45 IP - 11 DP - 2006 Nov TI - Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. PG - 1389-94 AB - OBJECTIVE: To determine the extent to which treatment of patients with symptomatic knee osteoarthritis (OA) with non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (ACET) reduces total effusion volume and synovial tissue volume, as quantified by magnetic resonance imaging (MRI). METHODS: Sequential pilot studies used subjects whose knee OA was treated with NSAIDs (n=10) or with ACET or=15 of 25 on the Western Ontario and McMaster Universities' pain scale underwent l.5T MRI. Effusion was quantified in axial short tau inversion recovery images; to measure synovial tissue volume, fat-suppressed T1-weighted axial images were obtained 3 min after i.v. injection of gadolinium contrast. After the initial MRI examination, patients resumed their customary pain medications until the severity of knee pain returned to baseline, when pain was again measured and the MRI was repeated. RESULTS: Pain severity after washout was similar in subjects taking ACET and NSAIDs. Reinstitution of ACET resulted in a 50% decrease in the mean of pain scores (P=1.7 x 10(-12)) that was comparable with that seen after the reinstitution of NSAID (49%, P=6.0 x 10(-7)). The mean total effusion volume measured during the flare of knee pain induced by the withdrawal of the two drugs was comparable (ACET 16.9 ml, NSAID 16.2 ml; P=0.884). Significant decreases in mean total effusion volume were observed after reinstitution of both ACET (-4.5 ml, P=0.009) and NSAID (-3.3 ml, P=0.013); the difference between drugs was not significant. Analyses of synovial volume yielded similar results. CONCLUSION: While uncontrolled and derived from small samples, these data suggest that ACET may have a significant anti-inflammatory effect in patients with knee OA, comparable with that achieved with NSAIDs, possibly through an effect on neurogenic inflammation. Joint pain is the clinical feature of OA that most often leads the affected individual to seek medical attention. Because many patients with OA improve symptomatically with the use of NSAIDs, it has been widely assumed that the pain of OA is due to synovial inflammation. However, the origins of OA pain are numerous and may vary from patient to patient and, within the same subject, from visit to visit. Although the articular cartilage is usually the site of the most obvious pathological changes in this disease, it is aneural and, therefore, is not the source of joint pain. However, in addition to the synovium, the subchondral bone, joint capsule, osteophytes, menisci, ligaments, periarticular tendons, entheses and bursae all contain nociceptive nerve endings, stimulation of which by chemical or physical mediators may be a basis for OA pain. FAU - Brandt, Kenneth D AU - Brandt KD AD - Department of Medicine, Rheumatology Division, Indiana University School of Medicine, Indianapolis, IN 46202-5100, USA. FAU - Mazzuca, Steven A AU - Mazzuca SA FAU - Buckwalter, Kenneth A AU - Buckwalter KA LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060410 PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Analgesics, Non-Narcotic) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 362O9ITL9D (Acetaminophen) SB - IM MH - Acetaminophen/*therapeutic use MH - Aged MH - Analgesics, Non-Narcotic/*therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Female MH - Humans MH - Image Processing, Computer-Assisted/methods MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Osteoarthritis, Knee/complications/*drug therapy/pathology MH - Pain/drug therapy/etiology MH - Pain Measurement/methods MH - Pilot Projects MH - Synovitis/*drug therapy/etiology/pathology MH - Treatment Outcome EDAT- 2006/04/12 09:00 MHDA- 2006/12/15 09:00 CRDT- 2006/04/12 09:00 PHST- 2006/04/12 09:00 [pubmed] PHST- 2006/12/15 09:00 [medline] PHST- 2006/04/12 09:00 [entrez] AID - kel100 [pii] AID - 10.1093/rheumatology/kel100 [doi] PST - ppublish SO - Rheumatology (Oxford). 2006 Nov;45(11):1389-94. doi: 10.1093/rheumatology/kel100. Epub 2006 Apr 10. PMID- 25911389 OWN - NLM STAT- MEDLINE DCOM- 20160303 LR - 20181202 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 31 IP - 8 DP - 2015 Aug TI - Local Application of Gelatin Hydrogel Sheets Impregnated With Platelet-Derived Growth Factor BB Promotes Tendon-to-Bone Healing After Rotator Cuff Repair in Rats. PG - 1482-91 LID - S0749-8063(15)00195-4 [pii] LID - 10.1016/j.arthro.2015.03.008 [doi] AB - PURPOSE: To determine whether the local application of platelet-derived growth factor BB (PDGF-BB) in hydrogel sheets would promote healing and improve histologic characteristics and biomechanical strength after rotator cuff (RC) repair in rats. METHODS: To assess the effect of PDGF-BB on tendon-to-bone healing we divided 36 adult male Sprague-Dawley rats treated with bilateral surgery to repair the supraspinatus tendon at its insertion site into 3 groups: group 1 = suture-only group; group 2 = suture and gelatin hydrogel sheets impregnated with phosphate-buffered saline (PBS); and group 3 = suture and gelatin hydrogel sheets impregnated with PDGF-BB (0.5 μg). Semiquantitative histologic evaluation was carried out 2, 6, and 12 weeks later; cell proliferation was assessed 2 and 6 weeks postoperatively by immunostaining for proliferating cell nuclear antigen (PCNA), and biomechanical testing, including ultimate load to failure, stiffness, and ultimate stress to failure, was performed 12 weeks after the operation. RESULTS: At 2 weeks, the average percentage of PCNA-positive cells at the insertion site was significantly higher in group 3 (40.5% ± 2.4%) than in group 1 (32.1% ± 6.9%; P = .03) and group 2 (31.9% ± 3.7%; P = .02). At 2 and 6 weeks, the histologic scores were similar among the 3 groups. At 12 weeks, the histologic score was significantly higher in group 3 (10.3 ± 0.8) than in group 1 (8.5 ± 0.5; P = .002) or group 2 (8.8 ± 0.8; P = .009), whereas ultimate load to failure, stiffness, and ultimate load to stress (normal control population, 44.73 ± 9.75 N, 27.59 ± 4.32 N/mm, and 21.33 ± 4.65 N/mm(2), respectively) were significantly higher in group 3 (28.28 ± 6.28 N, 11.05 ± 2.37 N/mm, and 7.99 ± 2.13 N/mm(2), respectively) than in group 1 (10.44 ± 1.98 N, 4.74 ± 1.31 N/mm, and 3.28 ± 1.27 N/mm(2), respectively; all P < .001) or group 2 (11.85 ± 2.89 N, 5.86 ± 1.75 N/mm, and 3.31 ± 0.80 N/mm(2), respectively; all P < .001). CONCLUSIONS: The placement of a PDGF-BB-impregnated hydrogel sheet just lateral to a transected and acutely reattached supraspinatus tendon produced significantly more PCNA-positive cells at 2 weeks and greater collagen fiber orientation, ultimate failure loads, stiffness, and stress to failure at 12 weeks than did a PBS-impregnated hydrogel sheet. No differences in vascularity or cellularity were observed. CLINICAL RELEVANCE: The local application of PDGF-BB-impregnated gelatin hydrogel may help to promote tendon-to-bone healing after RC repair in humans. CI - Copyright © 2015 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Tokunaga, Takuya AU - Tokunaga T AD - Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Electronic address: ttokunaga@fc.kuh.kumamoto-u.ac.jp. FAU - Ide, Junji AU - Ide J AD - Department of Advanced Joint Reconstructive Surgery, Kumamoto University Hospital, Kumamoto University, Kumamoto, Japan. FAU - Arimura, Hitoshi AU - Arimura H AD - Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. FAU - Nakamura, Takayuki AU - Nakamura T AD - Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. FAU - Uehara, Yusuke AU - Uehara Y AD - Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. FAU - Sakamoto, Hidetoshi AU - Sakamoto H AD - Department of Mechanical System Engineering, Graduate School of Science and Technology, Kumamoto University, Kumamoto, Japan. FAU - Mizuta, Hiroshi AU - Mizuta H AD - Department of Orthopaedic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. LA - eng PT - Journal Article DEP - 20150422 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Angiogenesis Inducing Agents) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 0 (Proto-Oncogene Proteins c-sis) RN - 1B56C968OA (Becaplermin) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 9000-70-8 (Gelatin) SB - IM MH - Angiogenesis Inducing Agents/*pharmacology MH - Animals MH - Arthroplasty MH - Becaplermin MH - Biomechanical Phenomena/drug effects MH - Bone and Bones/*drug effects/surgery MH - Cell Proliferation/drug effects MH - Gelatin/pharmacology MH - Hydrogel, Polyethylene Glycol Dimethacrylate/pharmacology MH - Male MH - Orthopedic Procedures MH - Proliferating Cell Nuclear Antigen/drug effects/metabolism MH - Proto-Oncogene Proteins c-sis/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*drug effects/surgery MH - Tendons/*drug effects/surgery MH - Wound Healing/*drug effects EDAT- 2015/04/26 06:00 MHDA- 2016/03/05 06:00 CRDT- 2015/04/26 06:00 PHST- 2014/09/02 00:00 [received] PHST- 2015/02/12 00:00 [revised] PHST- 2015/03/06 00:00 [accepted] PHST- 2015/04/26 06:00 [entrez] PHST- 2015/04/26 06:00 [pubmed] PHST- 2016/03/05 06:00 [medline] AID - S0749-8063(15)00195-4 [pii] AID - 10.1016/j.arthro.2015.03.008 [doi] PST - ppublish SO - Arthroscopy. 2015 Aug;31(8):1482-91. doi: 10.1016/j.arthro.2015.03.008. Epub 2015 Apr 22. PMID- 36382449 OWN - NLM STAT- MEDLINE DCOM- 20221118 LR - 20221124 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 36 IP - 11 DP - 2022 Nov 15 TI - [Short-term safety and effectiveness of domestic polyether-ether-ketone suture anchors for rotator cuff repair: A multicenter, randomized, single-blind, parallel-controlled noninferiority study]. PG - 1335-1342 LID - 10.7507/1002-1892.202207131 [doi] AB - OBJECTIVE: A multicenter, randomized, single-blind, parallel-controlled noninferiority study was used to evaluate the short-term safety and effectiveness of domestic polyether-ether-ketone (PEEK) suture anchor for rotator cuff repair by comparing with the imported PEEK suture anchor commonly used in clinical practice. METHODS: A total of 59 patients with rotator cuff tears who were admitted between May 2019 and October 2019 were selected as the research objects. Among them, 3 patients were excluded because they did not meet the selection criteria, and 1 patient withdrew from the study because of serious adverse events. A total of 55 patients were included in the study. They were randomly divided into trial group ( n=27) and control group ( n=28). The trial group used PEEK suture anchors produced from REJOIN Company, and the control group used PEEK suture anchors from American Arthrex Company. Two patients in control group were lost to follow-up. Twenty-seven patients in trial group and 26 patients in control group were included in the final quantitative analysis. There was no significant difference ( P>0.05) in gender, age, disease duration, side and sizes of rotator cuff tears, composition ratio of patients with type 2 diabetes, and preoperative American Shoulder and Elbow Surgeons (ASES) score, Constant-Murley score, University of California at Los Angeles (UCLA) score, and visual analogue scale (VAS) score. The patients were followed up regularly after operation. The postoperative follow-up included safety evaluation (complications, anchor position, and anchor bone reaction) and effectiveness evaluation (shoulder joint function and pain scores, rotator cuff integrity based on Sugaya classification criteria). RESULTS: The operations in both groups were successfully completed, and there was no complication related to the operation and suture anchor. All incisions healed by first intention. There was no significant difference in follow-up time between trial group [(5.85±0.77) months] and control group [(5.96±0.72) months] ( t=0.535, P=0.595). MRI examination indicated that the repaired tendons were fixed and the anchors did not get loose or torn. At 1 day, 3 months, and 6 months after operation, there was no patient with grade 3-4 anchor bone reaction in the two groups, and there was no significant difference in the bone reaction grading between groups ( P>0.05). After operation, the VAS scores of the two groups gradually decreased, and the ASES scores, Constant-Murley scores, and UCLA scores gradually increased, and there were significant differences between groups at each time point ( P<0.05). There was no significant difference between groups at different time points ( P>0.05). There was no significant difference in Sugaya classification of rotator cuff integrity at 1 day, 3 months, and 6 months after operation between groups ( P>0.05). CONCLUSION: The short-term safety and effectiveness of domestic PEEK suture anchors in rotator cuff tear repair are not significant different from those of imported PEEK suture anchors commonly used in clinical practice. FAU - Li, Yinghao AU - Li Y AD - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China. FAU - Xu, Yang AU - Xu Y AD - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China. FAU - Xu, Longwei AU - Xu L AD - Department of Orthopedics, Lishui People's Hospital, Lishui Yunnan, 323000, P. R. China. FAU - Li, Tao AU - Li T AD - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China. FAU - Li, Ran AU - Li R AD - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China. FAU - Tang, Xin AU - Tang X AD - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, P. R. China. LA - chi PT - English Abstract PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - 31694-16-3 (polyetheretherketone) RN - 0 (Ketones) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 0 (Ethers) SB - IM MH - Humans MH - Suture Anchors MH - *Rotator Cuff Injuries/surgery MH - Rotator Cuff/surgery MH - Arthroscopy MH - Single-Blind Method MH - *Diabetes Mellitus, Type 2 MH - Range of Motion, Articular MH - Ketones/therapeutic use MH - Polyethylene Glycols/therapeutic use MH - Magnetic Resonance Imaging MH - Ethers MH - Treatment Outcome PMC - PMC9681596 OTO - NOTNLM OT - Rotator cuff tear OT - effectiveness OT - polyether-ether-ketone suture anchor OT - safety COIS- 利益冲突　在课题研究和文章撰写过程中不存在利益冲突；本项目接受杭州锐健马斯汀医疗器材有限公司资助，经费支持没有影响文章观点和对研究数据客观结果的统计分析及其报道 EDAT- 2022/11/17 06:00 MHDA- 2022/11/19 06:00 PMCR- 2022/11/01 CRDT- 2022/11/16 03:43 PHST- 2022/11/16 03:43 [entrez] PHST- 2022/11/17 06:00 [pubmed] PHST- 2022/11/19 06:00 [medline] PHST- 2022/11/01 00:00 [pmc-release] AID - zgxfcjwkzz-36-11-1335 [pii] AID - 10.7507/1002-1892.202207131 [doi] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022 Nov 15;36(11):1335-1342. doi: 10.7507/1002-1892.202207131. PMID- 11179049 OWN - NLM STAT- MEDLINE DCOM- 20010329 LR - 20200930 IS - 0363-6135 (Print) IS - 0363-6135 (Linking) VI - 280 IP - 3 DP - 2001 Mar TI - Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. PG - H1075-80 AB - Although cardiac Purkinje cells (PCs) are believed to be the source of early afterdepolarizations generating ventricular tachyarrhythmias in long Q-T syndromes (LQTS), the ionic determinants of PC repolarization are incompletely known. To evaluate the role of the slow delayed rectifier current (I(Ks)) in PC repolarization, we studied PCs from canine ventricular false tendons with whole cell patch clamp (37 degrees C). Typical I(Ks) voltage- and time-dependent properties were noted. Isoproterenol enhanced I(Ks) in a concentration-dependent fashion (EC(50) approximately 30 nM), negatively shifted I(Ks) activation voltage dependence, and accelerated I(Ks) activation. Block of I(Ks) with 293B did not alter PC action potential duration (APD) in the absence of isoproterenol; however, in the presence of isoproterenol, 293B significantly prolonged APD. We conclude that, without beta-adrenergic stimulation, I(Ks) contributes little to PC repolarization; however, beta-adrenergic stimulation increases the contribution of I(Ks) by increasing current amplitude, accelerating I(Ks) activation, and shifting activation voltage toward the PC plateau voltage range. I(Ks) may therefore provide an important "braking" function to limit PC APD prolongation in the presence of beta-adrenergic stimulation. FAU - Han, W AU - Han W AD - Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec H3G 1Y6, Canada. FAU - Wang, Z AU - Wang Z FAU - Nattel, S AU - Nattel S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Acetamides) RN - 0 (Adrenergic beta-Agonists) RN - 0 (Anti-Arrhythmia Agents) RN - 0 (Benzodiazepinones) RN - 0 (Delayed Rectifier Potassium Channels) RN - 0 (L 768673) RN - 0 (Potassium Channels) RN - 0 (Potassium Channels, Voltage-Gated) RN - L628TT009W (Isoproterenol) SB - IM MH - Acetamides/pharmacology MH - Action Potentials/drug effects/physiology MH - Adrenergic beta-Agonists/pharmacology MH - Animals MH - Anti-Arrhythmia Agents/pharmacology MH - Benzodiazepinones/pharmacology MH - Delayed Rectifier Potassium Channels MH - Dogs MH - Isoproterenol/pharmacology MH - Long QT Syndrome/*physiopathology MH - Patch-Clamp Techniques/standards MH - Potassium Channels/*physiology MH - *Potassium Channels, Voltage-Gated MH - Purkinje Fibers/*physiology MH - Reproducibility of Results MH - Tachycardia, Ventricular/*physiopathology MH - Tendons EDAT- 2001/02/17 11:00 MHDA- 2001/04/03 10:01 CRDT- 2001/02/17 11:00 PHST- 2001/02/17 11:00 [pubmed] PHST- 2001/04/03 10:01 [medline] PHST- 2001/02/17 11:00 [entrez] AID - 10.1152/ajpheart.2001.280.3.H1075 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1075-80. doi: 10.1152/ajpheart.2001.280.3.H1075. PMID- 10937627 OWN - NLM STAT- MEDLINE DCOM- 20000817 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 18 IP - 3 DP - 2000 May TI - Mechanical modulation of tenascin-C and collagen-XII expression during avian synovial joint formation. PG - 406-15 AB - The objective of this study was to investigate how temporal and spatial patterns of characteristic extracellular matrix molecules are altered in the absence of normal functional skeletal muscle contractions during avian synovial joint development. By using in situ detection of protein and mRNA expression in developing avian feet and femorotibial joints from a wide range of developmental stages, we demonstrate that the morphological abnormalities that result from embryonic immobilization are associated with altered patterns of tenascin-C and collagen-XII expression within developing joint structures. As the joints fuse in immobilized embryos, the cells of the presumptive articular surface differentiate from flattened fibroblasts to more rounded chondrocytes and collagens XII and I are no longer detected at sites of complete joint fusion. Although the expression of collagen XII persists at normal levels elsewhere within the immobilized joint, tenascin-C expression is diminished within the chondroepiphysis, synovium, and tendons, as well as within the remains of the fibrous articular surface. This effect is most notable for the shortest tenascin variant (Tn190) within the chondroepiphysis and the largest variant (Tn230) within tendons, synovium, and the fibrous surface layer of the joint. This study thus provides in vivo support of previous in vitro work that suggests that tenascin expression is sensitive to external changes in mechanical loading environment. However, these data do not support a similar conclusion for collagen XII during early development. FAU - Mikic, B AU - Mikic B AD - Department of Orthopaedics, University of Virginia, Charlottesville 22908, USA. bm6j@virginia.edu FAU - Wong, M AU - Wong M FAU - Chiquet, M AU - Chiquet M FAU - Hunziker, E B AU - Hunziker EB LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Antibodies, Monoclonal) RN - 0 (Decamethonium Compounds) RN - 0 (Tenascin) RN - 9007-34-5 (Collagen) RN - C1CG1S3T2W (decamethonium) SB - IM MH - Animals MH - Antibodies, Monoclonal/immunology MH - Biomechanical Phenomena MH - Chick Embryo MH - Collagen/*analysis MH - Decamethonium Compounds/pharmacology MH - Immobilization MH - Immunohistochemistry MH - Muscle, Skeletal/pathology MH - Synovial Membrane/*embryology MH - Tenascin/*analysis EDAT- 2000/08/11 11:00 MHDA- 2000/08/19 11:00 CRDT- 2000/08/11 11:00 PHST- 2000/08/11 11:00 [pubmed] PHST- 2000/08/19 11:00 [medline] PHST- 2000/08/11 11:00 [entrez] AID - 10.1002/jor.1100180312 [doi] PST - ppublish SO - J Orthop Res. 2000 May;18(3):406-15. doi: 10.1002/jor.1100180312. PMID- 3184562 OWN - NLM STAT- MEDLINE DCOM- 19881130 LR - 20190828 IS - 0021-521X (Print) IS - 0021-521X (Linking) VI - 38 IP - 3 DP - 1988 TI - The functional characteristics of tendon blood circulation in the rabbit hindlimbs. PG - 361-74 AB - Neurohormonal, mechanical, and muscle exercise effects on tendon blood flow were studied in thirty-five rabbits. After anesthesia by urethane, experiments were performed on in situ preparation of the hindlimb under stable state in systemic blood pressure. Tendon and muscle blood flow were measured simultaneously by the hydrogen gas clearance method, and their temperature and PO2 were continuously observed by thermocouple and oxygen sensor, respectively. The resting blood flow in the denervated tendon tibialis anterior, gastrocnemius, and soleus (ml/(100 g.min] was 39.0 +/- 4.0, 34.5 +/- 8.2, and 30.2 +/- 4.3, respectively, whereas in their muscles it was 17.8 +/- 1.5, 17.1 +/- 2.1, and 12.6 +/- 1.1, respectively. The tendon tissue temperature and PO2 increased gradually until 15-20 min after cutting the sciatic nerve, and the increasing rate depended upon the initial control level before denervation. Intravenous injection of noradrenaline in the dose of 1-9.9 micrograms/kg produced a marked decrease in the tendon tissue temperature of the tibialis anterior, but a mild one in the muscle. The longitudinal tension force produced a decrease in the tendon tissue temperature of the tibialis anterior, but no change in the muscle. During muscle exercise, tendon blood flow and temperature tended to decrease, whereas the muscle blood flow and temperature increased markedly from the beginning of muscle exercise. There was no evidence to demonstrate the existence of exercise hyperemia in the tendon tissue. These data suggest that tendon blood circulation can be modified by many factors, and that mechanical and exercise effects may play a role in regulation of tendon blood flow channels and fluid transfer for the lubrication of tendon fiber movements. FAU - Takemiya, T AU - Takemiya T AD - Division of Physiology, University of Tsukuba, Japan. FAU - Maeda, J AU - Maeda J LA - eng PT - Journal Article PL - Japan TA - Jpn J Physiol JT - The Japanese journal of physiology JID - 2985184R RN - S88TT14065 (Oxygen) RN - X4W3ENH1CV (Norepinephrine) SB - IM MH - Animals MH - Female MH - Hindlimb MH - Male MH - Muscles/blood supply MH - Norepinephrine/pharmacology MH - Oxygen MH - Partial Pressure MH - Rabbits MH - Regional Blood Flow MH - Rest MH - Sciatic Nerve/physiology MH - Temperature MH - Tendons/*blood supply EDAT- 1988/01/01 00:00 MHDA- 1988/01/01 00:01 CRDT- 1988/01/01 00:00 PHST- 1988/01/01 00:00 [pubmed] PHST- 1988/01/01 00:01 [medline] PHST- 1988/01/01 00:00 [entrez] AID - 10.2170/jjphysiol.38.361 [doi] PST - ppublish SO - Jpn J Physiol. 1988;38(3):361-74. doi: 10.2170/jjphysiol.38.361. PMID- 26969960 OWN - NLM STAT- MEDLINE DCOM- 20161228 LR - 20181023 IS - 2589-1294 (Electronic) IS - 1017-995X (Linking) VI - 50 IP - 2 DP - 2016 TI - Role of anti-adhesive barriers following rotator cuff repair surgery: an experimental study. PG - 227-33 LID - 10.3944/AOTT.2015.15.0134 [doi] AB - OBJECTIVE: This experimental study investigates the effectiveness of expanded polytetrafluoroethylene (Dualmesh®, Gore Medical, Flagstaff, AZ, USA), sodium hyaluronate-carboxymethyl cellulose (Seprafilm®, Genzyme, Cambridge, MA, USA), and polysiloxane (silicone) as anti-adhesive barriers for inhibition of fibrosis in the subacromial area following rotator cuff repair. METHODS: Rabbit rotator cuff tenotomy and repair was conducted on 24 rabbits in 4 groups: control (Group A), Dualmesh® (Group B), Seprafilm® (Group C), and silicone (Group D). Anti-adhesive barrier materials were sutured over the repaired rotator cuff. Macroscopic and histological evaluations were made at the end of the sixth postoperative week. RESULTS: Macroscopic evaluation revealed that minimal adhesion occurred in the control and silicone groups, while the Seprafilm® and Dualmesh® groups showed evidence of fibrosis. Microscopic evaluation revealed diffuse fibrosis and collagen accumulation in the Dualmesh® and Seprafilm® groups, whereas minimal collagen deposition and inflammatory cell reaction was found among the silicone and control groups. Significant differences were found between the silicone and Dualmesh® (p=0.001) and silicone and Seprafilm® groups (p=0.002), as well as between the control and Dualmesh® (p=0.002) and control and Seprafilm® groups (p=0.002). CONCLUSION: Expanded polytetrafluoroethylene (ePTFE/Dualmesh®) and sodium hyaluronate carboxymethyl cellulose (SH-CMC/Seprafilm®) did not prevent or attenuate postoperative subacromial fibrosis following cuff tear repair. Nor did silicone prevent or attenuate fibrosis. More detailed research is needed for development of an effective anti-adhesive barrier for use after rotator cuff tear surgery. FAU - Kalem, Mahmut AU - Kalem M AD - Ankara University Faculty of Medicine, Department of Orthopaedics and Traumatology, Ankara, Turkey. FAU - Şahin, Ercan AU - Şahin E AD - Bülent Ecevit University Faculty of Medicine, Department of Orthopedics and Traumatology, Zonguldak, Turkey. FAU - Songür, Murat AU - Songür M AD - Bülent Ecevit University Faculty of Medicine, Department of Orthopedics and Traumatology, Zonguldak, Turkey. FAU - Zehir, Sinan AU - Zehir S AD - Hitit University Faculty of Medicine, Department of Orthopedics and Traumatology, Çorum, Turkey. FAU - Armangil, Mehmet AU - Armangil M AD - Ankara University Faculty of Medicine, Department of Orthopaedics and Traumatology, Ankara, Turkey. FAU - Demirtaş, Mehmet A AU - Demirtaş MA AD - Memorial Hospital, Department of Orthopedics and Traumatology, Ankara, Turkey. LA - eng PT - Journal Article PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Seprafilm) RN - 0 (Silicones) RN - 9002-84-0 (Polytetrafluoroethylene) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Disease Models, Animal MH - Fibrosis/prevention & control MH - Hyaluronic Acid/*pharmacology MH - Polytetrafluoroethylene/*pharmacology MH - Postoperative Complications/*prevention & control MH - Rabbits MH - Rotator Cuff Injuries/*surgery MH - Silicones/*pharmacology MH - Tendons/pathology MH - Tenotomy/*adverse effects MH - Tissue Adhesions/*prevention & control EDAT- 2016/03/13 06:00 MHDA- 2016/12/29 06:00 CRDT- 2016/03/13 06:00 PHST- 2016/03/13 06:00 [entrez] PHST- 2016/03/13 06:00 [pubmed] PHST- 2016/12/29 06:00 [medline] AID - 10.3944/AOTT.2015.15.0134 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2016;50(2):227-33. doi: 10.3944/AOTT.2015.15.0134. PMID- 25589157 OWN - NLM STAT- MEDLINE DCOM- 20160829 LR - 20220316 IS - 2280-8000 (Electronic) IS - 2280-8000 (Linking) VI - 13 IP - 2 DP - 2015 Jul 4 TI - Nano/micro hybrid scaffold of PCL or P3HB nanofibers combined with silk fibroin for tendon and ligament tissue engineering. PG - e156-68 LID - 7D656DEB-3E4D-48E3-AB2D-00B954AE057A [pii] LID - 10.5301/jabfm.5000216 [doi] AB - A novel biodegradable nano/micro hybrid structure was obtained by electrospinning P3HB or PCL nanofibers onto a twisted silk fibroin (SF) structure, with the aim of fabricating a suitable scaffold for tendon and ligament tissue engineering. The electrospinning (ES) processing parameters for P3HB and PCL were optimized on 2D samples, and applied to produce two different nano/micro hybrid constructs (SF/ES-PCL and SF/ES-P3HB).Morphological, chemico-physical and mechanical properties of the novel hybrid scaffolds were evaluated by SEM, ATR FT-IR, DSC, tensile and thermodynamic mechanical tests. The results demonstrated that the nanofibers were tightly wrapped around the silk filaments, and the crystallinity of the SF twisted yarns was not influenced by the presence of the electrospun polymers. The slightly higher mechanical properties of the hybrid constructs confirmed an increase of internal forces due to the interaction between nano and micro components. Cell culture tests with L929 fibroblasts, in the presence of the sample eluates or in direct contact with the hybrid structures, showed no cytotoxic effects and a good level of cytocompatibility of the nano/micro hybrid structures in term of cell viability, particularly at day 1. Cell viability onto the nano/micro hybrid structures decreased from the first to the third day of culture when compared with the control culture plastic, but appeared to be higher when compared with the uncoated SF yarns. Although additional in vitro and in vivo tests are needed, the original fabrication method here described appears promising for scaffolds suitable for tendon and ligament tissue engineering. FAU - Naghashzargar, Elham AU - Naghashzargar E AD - Department of Textile Engineering, Isfahan University of Technology, Isfahan - Iran. AD - BioMatLab, Department of Chemistry, Materials and Chemical Engineering G. Natta, Politecnico di Milano, Milan - Italy. FAU - Farè, Silvia AU - Farè S AD - BioMatLab, Department of Chemistry, Materials and Chemical Engineering G. Natta, Politecnico di Milano, Milan - Italy. AD - Local Unit Politecnico di Milano, INSTM, Milan - Italy. FAU - Catto, Valentina AU - Catto V AD - BioMatLab, Department of Chemistry, Materials and Chemical Engineering G. Natta, Politecnico di Milano, Milan - Italy. AD - Local Unit Politecnico di Milano, INSTM, Milan - Italy. FAU - Bertoldi, Serena AU - Bertoldi S AD - BioMatLab, Department of Chemistry, Materials and Chemical Engineering G. Natta, Politecnico di Milano, Milan - Italy. AD - Local Unit Politecnico di Milano, INSTM, Milan - Italy. FAU - Semnani, Dariush AU - Semnani D AD - Department of Textile Engineering, Isfahan University of Technology, Isfahan - Iran. FAU - Karbasi, Saeed AU - Karbasi S AD - Department of Medical Physics and Biomedical Engineering, School of Medicine, Isfahan University of Medical Sciences, Isfahan - Iran. FAU - Tanzi, Maria Cristina AU - Tanzi MC AD - BioMatLab, Department of Chemistry, Materials and Chemical Engineering G. Natta, Politecnico di Milano, Milan - Italy. AD - Local Unit Politecnico di Milano, INSTM, Milan - Italy. LA - eng PT - Journal Article DEP - 20150704 PL - United States TA - J Appl Biomater Funct Mater JT - Journal of applied biomaterials & functional materials JID - 101586617 RN - 0 (Biocompatible Materials) RN - 0 (Hydroxybutyrates) RN - 0 (Polyesters) RN - 24980-41-4 (polycaprolactone) RN - 26063-00-3 (poly-beta-hydroxybutyrate) RN - 9007-76-5 (Fibroins) SB - IM MH - Animals MH - Biocompatible Materials MH - Cell Line MH - Cell Survival/drug effects MH - Fibroins/*chemistry/toxicity MH - Hydroxybutyrates/chemistry/toxicity MH - Ligaments/*cytology MH - Materials Testing MH - Mice MH - Nanofibers/*chemistry/toxicity/ultrastructure MH - Polyesters/chemistry/toxicity MH - Tendons/*cytology MH - Tissue Engineering/*methods MH - Tissue Scaffolds/*chemistry EDAT- 2015/01/16 06:00 MHDA- 2016/08/30 06:00 CRDT- 2015/01/16 06:00 PHST- 2014/06/11 00:00 [accepted] PHST- 2015/01/16 06:00 [entrez] PHST- 2015/01/16 06:00 [pubmed] PHST- 2016/08/30 06:00 [medline] AID - 7D656DEB-3E4D-48E3-AB2D-00B954AE057A [pii] AID - 10.5301/jabfm.5000216 [doi] PST - epublish SO - J Appl Biomater Funct Mater. 2015 Jul 4;13(2):e156-68. doi: 10.5301/jabfm.5000216. PMID- 12788227 OWN - NLM STAT- MEDLINE DCOM- 20030715 LR - 20190610 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1641 IP - 1 DP - 2003 Jun 17 TI - Involvement of cytochrome c release and caspase-3 activation in the oxidative stress-induced apoptosis in human tendon fibroblasts. PG - 35-41 AB - Our previous studies have demonstrated that oxidative stress and apoptosis are involved in human tendon degeneration. The objectives of our current study were to investigate the effect of oxidative stress on human tendon cell apoptosis, and to explore pathways by which tendon cell apoptosis was induced. In vitro oxidative stress was created by exposure of cultured human rotator cuff tendon cells to H(2)O(2). Apoptotic cells were assessed by Annexin V-FITC staining and necrotic cells by propidium iodide (PI) staining using flow cytometry. Cytochrome c and caspase-3 protein expression were detected by Western blotting. A mini-dialysis unit was employed to increase the protein concentration of the cytosolic fraction. Caspase-3 activity was determined by a colorimetric assay. Tendon cell apoptosis induced by H(2)O(2) was both dose and time dependent. Addition of H(2)O(2) resulted in the release of cytochrome c to the cytosol, and an increase of caspase-3 activity and the expression of caspase-3 subunit. The data suggest that oxidative stress-induced apoptosis in human tendon fibroblasts is mediated via pathway(s) that includes release of cytochrome c from mitochondria to the cytosol and activation of caspase-3. FAU - Yuan, Jun AU - Yuan J AD - Orthopaedic Research Institute, St. George Hospital Campus, University of New South Wales, 4-10 South Street, Sydney, NSW 2217, Australia. FAU - Murrell, George A C AU - Murrell GA FAU - Trickett, Annette AU - Trickett A FAU - Wang, Min-Xia AU - Wang MX LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Cytochrome c Group) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 3.4.22.- (Caspases) SB - IM MH - Apoptosis/*drug effects MH - Caspases/*metabolism MH - Cells, Cultured MH - Cytochrome c Group/*metabolism MH - Cytosol/metabolism MH - Dose-Response Relationship, Drug MH - Enzyme Activation MH - Fibroblasts/cytology/drug effects/*metabolism MH - Humans MH - Hydrogen Peroxide/pharmacology MH - Mitochondria/enzymology MH - *Oxidative Stress MH - Tendons/cytology MH - Time Factors EDAT- 2003/06/06 05:00 MHDA- 2003/07/16 05:00 CRDT- 2003/06/06 05:00 PHST- 2003/06/06 05:00 [pubmed] PHST- 2003/07/16 05:00 [medline] PHST- 2003/06/06 05:00 [entrez] AID - S0167488903000478 [pii] AID - 10.1016/s0167-4889(03)00047-8 [doi] PST - ppublish SO - Biochim Biophys Acta. 2003 Jun 17;1641(1):35-41. doi: 10.1016/s0167-4889(03)00047-8. PMID- 22592911 OWN - NLM STAT- MEDLINE DCOM- 20130114 LR - 20141120 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 30 IP - 12 DP - 2012 Dec TI - Famotidine suppresses osteogenic differentiation of tendon cells in vitro and pathological calcification of tendon in vivo. PG - 1958-62 LID - 10.1002/jor.22146 [doi] AB - Heterotopic ossification or calcification follows any type of musculoskeletal trauma and is known to occur after arthroplasties of hip, knee, shoulder, or elbow; fractures; joint dislocations; or tendon ruptures. Histamine receptor H2 (Hrh2) has been shown to be effective for reducing pain and decreasing calcification in patients with calcifying tendinitis, which suggested that H2 blockers were effective for the treatment of tendon ossification or calcification. However, the detailed mechanisms of its action on tendon remain to be clarified. We investigated the mechanisms underlying H2 blocker-mediated suppression of tendon calcification, with a focus on the direct action of the drug on tendon cells. Famotidine treatment suppressed the mRNA expressions of Col10a1 and osteocalcin, ossification markers, in a tendon-derived cell line TT-D6, as well as a preosteoblastic one MC3T3-E1. Both of the cell lines expressed Hrh2; histamine treatment induced osteocalcin expression in these cells. Famotidine administration suppressed calcification in the Achilles tendon of ttw mice, a mouse model of ectopic ossification. These data suggest that famotidine inhibits osteogenic differentiation of tendon cells in vitro, and this inhibition may underlie the anti-calcification effects of the drug in vivo. This study points to the use of H2 blockers as a promising strategy for treating heterotopic ossification or calcification in tendon, and provides evidence in support of the clinical use of famotidine. CI - Copyright © 2012 Orthopaedic Research Society. FAU - Yamamoto, Kenichi AU - Yamamoto K AD - Center for Disease Biology and Integrative Medicine, Division of Clinical Biotechnology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. FAU - Hojo, Hironori AU - Hojo H FAU - Koshima, Isao AU - Koshima I FAU - Chung, Ung-il AU - Chung UI FAU - Ohba, Shinsuke AU - Ohba S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120516 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Histamine H2 Antagonists) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Histamine H2) RN - 5QZO15J2Z8 (Famotidine) SB - IM MH - 3T3 Cells MH - Administration, Oral MH - Animals MH - *Calcinosis MH - Cell Differentiation MH - Cell Line MH - Famotidine/*pharmacology MH - Histamine H2 Antagonists/pharmacology MH - In Vitro Techniques MH - Male MH - Mice MH - Osteoblasts/metabolism MH - Osteogenesis/*drug effects MH - RNA, Messenger/metabolism MH - Receptors, Histamine H2/metabolism MH - Signal Transduction MH - Tendons/*pathology EDAT- 2012/05/18 06:00 MHDA- 2013/01/15 06:00 CRDT- 2012/05/18 06:00 PHST- 2011/10/28 00:00 [received] PHST- 2012/04/26 00:00 [accepted] PHST- 2012/05/18 06:00 [entrez] PHST- 2012/05/18 06:00 [pubmed] PHST- 2013/01/15 06:00 [medline] AID - 10.1002/jor.22146 [doi] PST - ppublish SO - J Orthop Res. 2012 Dec;30(12):1958-62. doi: 10.1002/jor.22146. Epub 2012 May 16. PMID- 19706016 OWN - NLM STAT- MEDLINE DCOM- 20110302 LR - 20131121 IS - 1755-3768 (Electronic) IS - 1755-375X (Linking) VI - 88 IP - 8 DP - 2010 Dec TI - Succinylcholine activation of human horizontal eye muscles. PG - 872-6 LID - 10.1111/j.1755-3768.2009.01597.x [doi] AB - PURPOSE: Succinylcholine (Sch) can induce contracture in slow, multiply innervated muscle fibres of the extraocular muscles in animals of different species. Slow muscle fibres also exist in human eye muscle but their physiological properties have not been studied. METHODS: Isometric tension development was recorded in the lateral and medial rectus muscles in 12 patients operated under general anaesthesia. A strain gauge probe was attached with 5-0 silk sutures to the muscle tendon. Recordings were made in 12 eye muscles with the tendon attached to the globe and in four muscles detached from the globe. Muscle activation was produced by i.v. injection of Sch at a dose of 0.2-0.3 mg/kg bodyweight. RESULTS:   A single injection of Sch induced slow contractures lasting for several minutes. In the muscles attached to the globe, mean maximal isometric tension was 12.2 g in the lateral rectus and 12.8 g in the medial rectus. Similar tension was shown in the muscles detached from the globe. CONCLUSIONS: The contracture of eye muscles in response to Sch showed characteristics typical of slow muscle fibre activation in amphibian and avian muscle and confirmed the participation of slow fibre systems in ocular motor control. CI - © 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol. FAU - Lennerstrand, Gunnar AU - Lennerstrand G AD - Department of Ophthalmology, Karolinska Institutet, Stockholm, Sweden. Gunnar.Lennerstrand@ste.ki.se FAU - Bolzani, Roberto AU - Bolzani R FAU - Tian, Suna AU - Tian S FAU - Benassi, Mariagrazia AU - Benassi M FAU - Fusari, Maurizio AU - Fusari M FAU - Campos, Emilio AU - Campos E FAU - Schiavi, Costantino AU - Schiavi C LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Acta Ophthalmol JT - Acta ophthalmologica JID - 101468102 RN - 0 (Neuromuscular Depolarizing Agents) RN - J2R869A8YF (Succinylcholine) SB - IM MH - Adolescent MH - Adult MH - Anesthesia, General MH - Eye Movements/physiology MH - Humans MH - Injections, Intravenous MH - Isometric Contraction/drug effects/*physiology MH - Middle Aged MH - Muscle Fibers, Slow-Twitch/*physiology MH - Neuromuscular Depolarizing Agents/*pharmacology MH - Oculomotor Muscles/drug effects/*physiology MH - Strabismus/physiopathology/surgery MH - Succinylcholine/*pharmacology MH - Tendons/innervation EDAT- 2009/08/27 09:00 MHDA- 2011/03/03 06:00 CRDT- 2009/08/27 09:00 PHST- 2009/08/27 09:00 [entrez] PHST- 2009/08/27 09:00 [pubmed] PHST- 2011/03/03 06:00 [medline] AID - AOS1597 [pii] AID - 10.1111/j.1755-3768.2009.01597.x [doi] PST - ppublish SO - Acta Ophthalmol. 2010 Dec;88(8):872-6. doi: 10.1111/j.1755-3768.2009.01597.x. PMID- 37694883 OWN - NLM STAT- MEDLINE DCOM- 20231205 LR - 20240415 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 112 IP - 2 DP - 2024 Feb TI - Kartogenin-loaded polyvinyl alcohol/nano-hydroxyapatite composite hydrogel promotes tendon-bone healing in rabbits after anterior cruciate ligament reconstruction. PG - 180-192 LID - 10.1002/jbm.a.37605 [doi] AB - Accumulating evidence supports the role of cartilage tissue engineering in cartilage defect repair, but the biological function has yet to be fully explained. In this work, kartogenin (KGN), an emerging chondroinductive nonprotein small molecule, was incorporated into a composite hydrogel of polyvinyl alcohol/nano-hydroxyapatite (PVA/n-HA) to fabricate an appropriate microenvironment for tendon-bone healing after anterior cruciate ligament (ACL) reconstruction. KGN/PVA/n-HA composite hydrogel scaffolds were prepared by in situ synthesis and physical adsorption, followed by characterization under a scanning electron microscope. The scaffolds were transplanted into healthy New Zealand White (NZW) rabbits. It was confirmed that KGN/PVA/n-HA scaffolds were successfully prepared and exhibited good supporting properties and excellent biocompatibility. Unilateral ACL reconstruction was constructed with tendon autograft in NZW rabbits, and the morphology and diameter of collagen fiber were analyzed. The scaffolds were shown to promote ACL growth and collagen fiber formation. Furthermore, microcomputerized tomography analysis and bone formation histology were performed to detect new bone formation. KGN/PVA/n-HA scaffolds effectively alleviated cartilage damage and prevented the occurrence of osteoarthritis. Meanwhile, ligament-bone healing and bone formation were observed in the presence of KGN/PVA/n-HA scaffolds. In conclusion, these results suggest that the KGN/PVA/n-HA scaffolds can facilitate tendon-bone healing after ACL reconstruction and might be considered novel hydrogel biomaterials in cartilage tissue engineering. CI - © 2023 Wiley Periodicals LLC. FAU - Lv, Hao AU - Lv H AD - Jinan Central Hospital, Jinan, People's Republic of China. FAU - Liu, Yaobo AU - Liu Y AD - Jinan Central Hospital, Jinan, People's Republic of China. FAU - Lu, Duyi AU - Lu D AD - Jinan Central Hospital, Jinan, People's Republic of China. FAU - Wang, Yuanrui AU - Wang Y AUID- ORCID: 0000-0001-8580-1824 AD - Jinan Central Hospital, Jinan, People's Republic of China. LA - eng GR - 2021 Jinan Science and Technology Innovation Fund project/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230911 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 91D9GV0Z28 (Durapatite) RN - Q93BBN11CP (kartogenin) RN - 0 (polyvinyl alcohol hydrogel) RN - 9002-89-5 (Polyvinyl Alcohol) RN - 9007-34-5 (Collagen) RN - 0 (Hydrogels) SB - IM MH - Rabbits MH - Animals MH - *Durapatite/pharmacology MH - Polyvinyl Alcohol/pharmacology MH - Collagen MH - *Anterior Cruciate Ligament Reconstruction/methods MH - Tendons/surgery MH - Hydrogels/pharmacology OTO - NOTNLM OT - anterior cruciate ligament reconstruction OT - composite hydrogel scaffolds OT - kartogenin OT - ligament-bone healing OT - nano-hydroxyapatite OT - polyvinyl alcohol EDAT- 2023/09/11 12:43 MHDA- 2023/12/05 12:43 CRDT- 2023/09/11 07:44 PHST- 2023/06/20 00:00 [revised] PHST- 2021/08/04 00:00 [received] PHST- 2023/08/22 00:00 [accepted] PHST- 2023/12/05 12:43 [medline] PHST- 2023/09/11 12:43 [pubmed] PHST- 2023/09/11 07:44 [entrez] AID - 10.1002/jbm.a.37605 [doi] PST - ppublish SO - J Biomed Mater Res A. 2024 Feb;112(2):180-192. doi: 10.1002/jbm.a.37605. Epub 2023 Sep 11. PMID- 38900641 OWN - NLM STAT- MEDLINE DCOM- 20240727 LR - 20250117 IS - 2211-1247 (Electronic) VI - 43 IP - 7 DP - 2024 Jul 23 TI - Spatial proteomics of skeletal muscle using thin cryosections reveals metabolic adaptation at the muscle-tendon transition zone. PG - 114374 LID - S2211-1247(24)00702-2 [pii] LID - 10.1016/j.celrep.2024.114374 [doi] AB - Morphological studies of skeletal muscle tissue provide insights into the architecture of muscle fibers, the surrounding cells, and the extracellular matrix (ECM). However, a spatial proteomics analysis of the skeletal muscle including the muscle-tendon transition zone is lacking. Here, we prepare cryotome muscle sections of the mouse soleus muscle and measure each slice using short liquid chromatography-mass spectrometry (LC-MS) gradients. We generate 3,000 high-resolution protein profiles that serve as the basis for a network analysis to reveal the complex architecture of the muscle-tendon junction. Among the protein profiles that increase from muscle to tendon, we find proteins related to neuronal activity, fatty acid biosynthesis, and the renin-angiotensin system (RAS). Blocking the RAS in cultured mouse tenocytes using losartan reduces the ECM synthesis. Overall, our analysis of thin cryotome sections provides a spatial proteome of skeletal muscle and reveals that the RAS acts as an additional regulator of the matrix within muscle-tendon junctions. CI - Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Schmidt, Luisa AU - Schmidt L AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. FAU - Saynisch, Michael AU - Saynisch M AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. FAU - Hoegsbjerg, Christian AU - Hoegsbjerg C AD - Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark; Part of IOC Research Center Copenhagen and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Schmidt, Andreas AU - Schmidt A AD - Bruker Daltonics GmbH & Co. KG, Bremen, Germany. FAU - Mackey, Abigail AU - Mackey A AD - Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark; Part of IOC Research Center Copenhagen and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Lackmann, Jan-Wilm AU - Lackmann JW AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. FAU - Müller, Stefan AU - Müller S AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. FAU - Koch, Manuel AU - Koch M AD - Institute for Dental Research and Oral Musculoskeletal Biology, Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany. FAU - Brachvogel, Bent AU - Brachvogel B AD - Department of Pediatrics and Adolescent Medicine, Experimental Neonatology, Medical Faculty, University of Cologne, Cologne, Germany; Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany. FAU - Kjaer, Michael AU - Kjaer M AD - Institute of Sports Medicine Copenhagen, Department of Orthopaedic Surgery, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark; Part of IOC Research Center Copenhagen and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. FAU - Antczak, Philipp AU - Antczak P AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Center for Molecular Medicine (CMMC), University of Cologne, 50931 Cologne, Germany. Electronic address: pantczak@uni-koeln.de. FAU - Krüger, Marcus AU - Krüger M AD - Institute for Genetics, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Center for Molecular Medicine (CMMC), University of Cologne, 50931 Cologne, Germany. Electronic address: marcus.krueger@uni-koeln.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240619 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (Proteome) RN - JMS50MPO89 (Losartan) SB - IM MH - Animals MH - *Proteomics/methods MH - *Muscle, Skeletal/metabolism MH - *Tendons/metabolism MH - Mice MH - Extracellular Matrix/metabolism MH - Male MH - Mice, Inbred C57BL MH - Renin-Angiotensin System/physiology MH - Adaptation, Physiological MH - Proteome/metabolism MH - Losartan/pharmacology OTO - NOTNLM OT - CP: Metabolism OT - distance-based network OT - myotendinous junction OT - skeletal muscle OT - spatial proteomics COIS- Declaration of interests The authors declare no competing interests. EDAT- 2024/06/20 18:42 MHDA- 2024/07/28 14:48 CRDT- 2024/06/20 12:37 PHST- 2023/12/07 00:00 [received] PHST- 2024/04/05 00:00 [revised] PHST- 2024/05/31 00:00 [accepted] PHST- 2024/07/28 14:48 [medline] PHST- 2024/06/20 18:42 [pubmed] PHST- 2024/06/20 12:37 [entrez] AID - S2211-1247(24)00702-2 [pii] AID - 10.1016/j.celrep.2024.114374 [doi] PST - ppublish SO - Cell Rep. 2024 Jul 23;43(7):114374. doi: 10.1016/j.celrep.2024.114374. Epub 2024 Jun 19. PMID- 27694930 OWN - NLM STAT- MEDLINE DCOM- 20180620 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Oct 3 TI - Low Concentration of Sodium Butyrate from Ultrabraid+NaBu suture, Promotes Angiogenesis and Tissue Remodelling in Tendon-bones Injury. PG - 34649 LID - 10.1038/srep34649 [doi] LID - 34649 AB - Sodium butyrate (NaBu), a form of short-chain fatty acid (SCFA), acts classically as a potent anti-angiogenic agent in tumour angiogenesis models, some authors demonstrated that low concentrations of NaBu may contribute to healing of tendon-bone injury in part at least through promotion of tissue remodelling. Here, we investigated the effects of low-range concentrations of NaBu using in vitro and in vivo assays using angiogenesis as the primary outcome measure and the mechanisms through which it acts. We demonstrated that NaBu, alone or perfused from the UltraBraid+NaBu suture was pro-angiogenic at very low-range doses promoting migration, tube formation and cell invasion in bovine aortic endothelial cells (BAECs). Furthermore, cell exposure to low NaBu concentrations increased expression of proteins involved in angiogenic cell signalling, including p-PKCβ1, p-FAK, p-ERK1/2, p-NFκβ, p-PLCγ1 and p-VEGFR2. In addition, inhibitors of both VEGFR2 and PKCβ1 blocked the angiogenic response. In in vivo assays, low concentrations of NaBu induced neovascularization in sponge implants in mice, evidenced by increased numbers of vessels and haemoglobin content in these implants. The findings in this study indicate that low concentrations of NaBu could be an important compound to stimulate angiogenesis at a site where vasculature is deficient and healing is compromised. FAU - Liu, Donghui AU - Liu D AD - School of Healthcare Science, GMBC, Manchester Metropolitan University, Manchester, United Kingdom. FAU - Andrade, Silvia Passos AU - Andrade SP AD - Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. FAU - Castro, Pollyana Ribeiro AU - Castro PR AD - Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil. FAU - Treacy, John AU - Treacy J AD - Smith &Nephew Research Centre, York Science, Park Heslington, York, UK. FAU - Ashworth, Jason AU - Ashworth J AD - School of Healthcare Science, GMBC, Manchester Metropolitan University, Manchester, United Kingdom. FAU - Slevin, Mark AU - Slevin M AD - School of Healthcare Science, GMBC, Manchester Metropolitan University, Manchester, United Kingdom. AD - University of Medicine and Pharmacy, Tirgu Mures, Romania. LA - eng PT - Journal Article DEP - 20161003 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 107-92-6 (Butyric Acid) RN - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2) RN - EC 2.7.11.13 (Protein Kinase C beta) SB - IM MH - Animals MH - Bone and Bones/*blood supply/injuries MH - Butyric Acid/chemistry/*pharmacology MH - Cattle MH - Cell Movement/drug effects MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - Endothelial Cells/drug effects/metabolism/physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Neovascularization, Physiologic/*drug effects MH - Protein Kinase C beta/metabolism MH - *Sutures MH - Tendon Injuries/physiopathology MH - Tendons/*blood supply MH - Vascular Endothelial Growth Factor Receptor-2/metabolism PMC - PMC5046145 EDAT- 2016/10/04 06:00 MHDA- 2018/06/21 06:00 PMCR- 2016/10/03 CRDT- 2016/10/04 06:00 PHST- 2016/04/28 00:00 [received] PHST- 2016/09/16 00:00 [accepted] PHST- 2016/10/04 06:00 [entrez] PHST- 2016/10/04 06:00 [pubmed] PHST- 2018/06/21 06:00 [medline] PHST- 2016/10/03 00:00 [pmc-release] AID - srep34649 [pii] AID - 10.1038/srep34649 [doi] PST - epublish SO - Sci Rep. 2016 Oct 3;6:34649. doi: 10.1038/srep34649. PMID- 4515003 OWN - NLM STAT- MEDLINE DCOM- 19730904 LR - 20190501 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 70 IP - 3 DP - 1973 Mar TI - Coagulation of blood plasma of guinea pig by the bone matrix. PG - 929-33 AB - Optimal amounts of demineralized bone matrix possess the ability to coagulate platelet-free heparinized, citrated, and oxalated blood plasmas of guinea pigs. Clotting constituents become denatured in contact with the insoluble coagulant proteins. Quantities in excess of optimal modify plasma so that it does not gel when thrombin is added. The newly described coagulant effects are not restricted to the bone matrix, but are present also in the demineralized matrices of tooth and ivory, and in denatured tendon as well. They are regulated properties that were not demonstrated in mineralized bone or native tendon. The coagulant attributes of bone matrix are consistent with those of electropositive polymers of a specific sort. FAU - Huggins, C B AU - Huggins CB FAU - Reddi, A H AU - Reddi AH LA - eng PT - Journal Article PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Amines) RN - 0 (Sulfur Isotopes) RN - 9001-32-5 (Fibrinogen) RN - 9005-49-6 (Heparin) RN - EC 3.4.21.5 (Thrombin) SB - IM MH - Amines/pharmacology MH - Animals MH - *Blood Coagulation/drug effects MH - *Bone Matrix/metabolism MH - Fibrinogen MH - Guinea Pigs MH - Heparin/metabolism MH - *Plasma MH - Rats MH - Sulfur Isotopes MH - Tendons MH - Thrombin MH - Time Factors PMC - PMC433390 OID - NASA: 73209613 EDAT- 1973/03/01 00:00 MHDA- 1973/03/01 00:01 PMCR- 1973/09/01 CRDT- 1973/03/01 00:00 PHST- 1973/03/01 00:00 [pubmed] PHST- 1973/03/01 00:01 [medline] PHST- 1973/03/01 00:00 [entrez] PHST- 1973/09/01 00:00 [pmc-release] AID - 10.1073/pnas.70.3.929 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 1973 Mar;70(3):929-33. doi: 10.1073/pnas.70.3.929. PMID- 26115533 OWN - NLM STAT- MEDLINE DCOM- 20160517 LR - 20220321 IS - 1873-4367 (Electronic) IS - 0927-7765 (Linking) VI - 133 DP - 2015 Sep 1 TI - Prevention of peritendinous adhesions with electrospun polyethylene glycol/polycaprolactone nanofibrous membranes. PG - 221-30 LID - S0927-7765(15)00385-9 [pii] LID - 10.1016/j.colsurfb.2015.06.012 [doi] AB - Postoperative adhesion formation is the major complication that could occur after acute tendon surgery. The application of an anti-adhesive membrane at the post-surgical site is deemed as a potential way to solve this problem by preventing adhesive fibrotic tissue development. In this study, we fabricated electrospun composite poly(ethylene glycol) (PEG)/poly(caprolactone) (PCL) nanofibrous membrane (NFM) to prevent peritendinous adhesions, which could act as a barrier between the tendon and surrounding tissues, without interrupting mass transfer and normal tendon gliding. PCL/PEG NFMs of 0% PEG (PCL), 25% PEG (25PECL), 50% PEG (50PECL) and 75% PEG (75PECL) were prepared and characterized for physico-chemical properties. The PCL NFM shows the lowest protein permeability while 25PECL NFM exhibited the largest fiber diameter, smallest pore size and the largest ultimate stress and strain. The 75PECL NFM had the lowest water contact angle and the highest Young's modulus. In vitro cell adhesion and migration experiments with fibroblasts indicate that all NFMs could prevent cell penetration, with 75PECL NFM having the least cell attachment. In vivo application of 75PECL NFM on the repaired site of rabbit flexor tendon rupture model demonstrated improved efficacy compared with the PCL NFM and a commercial anti-adhesion barrier (Seprafilm™), from gross observation, histological analysis and functional assays. We concluded that 75PECL NFM could function as an effective anti-adhesion membrane after tendon surgery in a clinical setting. CI - Copyright © 2015 Elsevier B.V. All rights reserved. FAU - Chen, Chih-Hao AU - Chen CH AD - Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 333, Taiwan, ROC; Craniofacial Research Center, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kwei-San, Taoyuan 333, Taiwan, ROC. FAU - Chen, Shih-Hsien AU - Chen SH AD - Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 333, Taiwan, ROC. FAU - Shalumon, K T AU - Shalumon KT AD - Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 333, Taiwan, ROC. FAU - Chen, Jyh-Ping AU - Chen JP AD - Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 333, Taiwan, ROC; Research Center for Industry of Human Ecology, Chang Gung University of Science and Technology, Kwei-San, Taoyuan 333, Taiwan, ROC. Electronic address: jpchen@mail.cgu.edu.tw. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Validation Study DEP - 20150611 PL - Netherlands TA - Colloids Surf B Biointerfaces JT - Colloids and surfaces. B, Biointerfaces JID - 9315133 RN - 0 (Membranes, Artificial) RN - 0 (Polyesters) RN - 24980-41-4 (polycaprolactone) RN - 3WJQ0SDW1A (Polyethylene Glycols) SB - IM MH - Animals MH - Cells, Cultured MH - Humans MH - *Membranes, Artificial MH - *Nanofibers MH - Polyesters/chemistry/*pharmacology MH - Polyethylene Glycols/chemistry/*pharmacology MH - Rabbits MH - Tendons/*pathology MH - Tissue Adhesions/*prevention & control OTO - NOTNLM OT - Anti-adhesion OT - Nanofibrous membranes OT - Polycaprolactone OT - Polyethylene glycol EDAT- 2015/06/27 06:00 MHDA- 2016/05/18 06:00 CRDT- 2015/06/27 06:00 PHST- 2014/11/17 00:00 [received] PHST- 2015/06/03 00:00 [revised] PHST- 2015/06/04 00:00 [accepted] PHST- 2015/06/27 06:00 [entrez] PHST- 2015/06/27 06:00 [pubmed] PHST- 2016/05/18 06:00 [medline] AID - S0927-7765(15)00385-9 [pii] AID - 10.1016/j.colsurfb.2015.06.012 [doi] PST - ppublish SO - Colloids Surf B Biointerfaces. 2015 Sep 1;133:221-30. doi: 10.1016/j.colsurfb.2015.06.012. Epub 2015 Jun 11. PMID- 10591685 OWN - NLM STAT- MEDLINE DCOM- 19991227 LR - 20190831 IS - 1079-5642 (Print) IS - 1079-5642 (Linking) VI - 19 IP - 12 DP - 1999 Dec TI - Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. PG - 3033-43 AB - The molecular differences between native-type collagen type I fibrils (NC) and their pepsinated monomers (PC) were used to uncover receptors involved in platelet-collagen interaction along the adhesion-activation axis. The platelet-depositing capacity of NC and PC under blood flow and their adhesive properties and respective morphologies, aggregation, procoagulant capacity, and tyrosine phosphorylation were compared under different cationic milieus, including or excluding the glycoprotein (GP) Ia/IIa. NC was consistently a more preferable and activating substrate than PC during flow (5 minutes) and in platelet aggregation. In PPACK-treated blood, both NC (3.3-fold) and PC (2.7-fold) increased platelet attachment on elevation of the shear rate from 500 to 1640 s(-1), whereas in citrated blood, adhesion and thrombus growth on PC were negligible under the high shear rate, unlike on NC (1.9-fold increase). The complete lack of platelet deposition on PC in citrated blood could be overcome by restoring physiological Mg(2+) concentration, and in contrast to NC, platelets interacting with PC were highly dependent on Mg(2+) during adhesion, aggregation, and procoagulant response. Monoclonal antibody (mAb 131.7) against GP IV inhibited platelet deposition to NC in citrated blood (2 minutes) by 49%, which was not further increased by coincubation with mAb against GP Ia (6F1). These results stress the importance of GP Ia/IIa in shear-resistant platelet deposition on collagen monomers. In native fibers, however, the preserved quaternary structure with telopeptides activates additional platelet receptors capable of substituting GP Ia/IIa and GP IV. FAU - Siljander, P AU - Siljander P AD - Wihuri Research Institute, University of Helsinki, Helsinki, Finland. FAU - Lassila, R AU - Lassila R LA - eng PT - Journal Article PL - United States TA - Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology JID - 9505803 RN - 0 (Anticoagulants) RN - 0 (Cations, Divalent) RN - 0 (Citrates) RN - 0 (Hemostatics) RN - 0 (Integrins) RN - 0 (Receptors, Collagen) RN - 1Q73Q2JULR (Sodium Citrate) RN - 42HK56048U (Tyrosine) RN - 9007-34-5 (Collagen) RN - 9035-58-9 (Thromboplastin) RN - EC 3.4.21.5 (Thrombin) RN - I38ZP9992A (Magnesium) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Anticoagulants/pharmacology MH - Blood Flow Velocity MH - Blood Platelets/chemistry/physiology/ultrastructure MH - Calcium/pharmacology MH - Cations, Divalent/pharmacology MH - Cattle MH - Citrates/pharmacology MH - Collagen/chemistry/*metabolism/pharmacology MH - Hemostasis/drug effects/*physiology MH - Hemostatics/pharmacology MH - Humans MH - Integrins/*physiology MH - Magnesium/pharmacology MH - Microscopy, Electron, Scanning MH - Phosphorylation MH - Platelet Adhesiveness/drug effects/*physiology MH - Platelet Aggregation/drug effects/physiology MH - Protein Structure, Quaternary MH - Receptors, Collagen MH - Sodium Citrate MH - Stress, Mechanical MH - Tendons/chemistry MH - Thrombin/metabolism MH - Thromboplastin/pharmacology MH - Tyrosine/metabolism EDAT- 1999/12/11 00:00 MHDA- 1999/12/11 00:01 CRDT- 1999/12/11 00:00 PHST- 1999/12/11 00:00 [pubmed] PHST- 1999/12/11 00:01 [medline] PHST- 1999/12/11 00:00 [entrez] AID - 10.1161/01.atv.19.12.3033 [doi] PST - ppublish SO - Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):3033-43. doi: 10.1161/01.atv.19.12.3033. PMID- 16221456 OWN - NLM STAT- MEDLINE DCOM- 20060213 LR - 20220309 IS - 1071-1007 (Print) IS - 1071-1007 (Linking) VI - 26 IP - 10 DP - 2005 Oct TI - Exogenously administered substance P and neutral endopeptidase inhibitors stimulate fibroblast proliferation, angiogenesis and collagen organization during Achilles tendon healing. PG - 832-9 AB - BACKGROUND: In the last few years much research has been conducted in methods to promote tendon healing. The aim of this study was to determine if the healing process after operative repair of rat Achilles tendons could be stimulated by the paratendinous injection of a sensory peptide, substance P (SP). METHODS: Ninety-six male Sprague-Dawley rats were randomly allocated to four groups: (I) control buffer injections, (II) injections of SP 10(-6) mol/kg body weight combined with a carrier, (III) injections of SP 10(-8) mol/kg BW with the carrier, and (IV) injections with the carrier only (thiorphan 1 micromol/kg BW and captopril 30 micromol/kg BW, both neutral endopeptidase inhibitors). The influence on tissue repair was determined from the histologic measurement of fibroblast proliferation, angiogenesis, and collagen organization. On days 7, 14, 28 and 42, animals were sacrificed and histologic evaluations were performed on the injured Achilles tendon constructs. RESULTS: The two groups subjected to SP injections showed a significant initial fibroblast proliferation on day 7 (p < 0.05), which rapidly declined by day 14 to the level of cellular proliferation observed with the use of thiorphan and captopril. Capillary proliferation showed a similar evolution, except that in the second week angiogenesis in the treated groups was below the level of the control group. Strikingly, collagen orientation increased faster in the groups injected with SP. This was obvious from the second week already and the difference remained until the completion of the study. CONCLUSION: This is the first study to demonstrate that paratendinous injections of SP after operative repair of the Achilles tendon in rats appears to provide a boost to the initial stages of healing and significantly accelerate the reparative phase of the healing process. FAU - Burssens, Peter AU - Burssens P AD - Gent University Hospital, Orthopaedic Surgery, De Pintelaan 185, Gent, Oost-Vlaanderen B 9000, Belgium. Peter.Burssens@skynet.be FAU - Steyaert, Adelheid AU - Steyaert A FAU - Forsyth, Ramses AU - Forsyth R FAU - van Ovost, Edwin Johan AU - van Ovost EJ FAU - Depaepe, Yves AU - Depaepe Y FAU - Verdonk, Rene AU - Verdonk R LA - eng PT - Journal Article PL - United States TA - Foot Ankle Int JT - Foot & ankle international JID - 9433869 RN - 0 (Drug Combinations) RN - 0 (Protease Inhibitors) RN - 33507-63-0 (Substance P) RN - 9007-34-5 (Collagen) RN - 9G64RSX1XD (Captopril) RN - B79L7B5X3Z (Thiorphan) RN - EC 3.4.24.11 (Neprilysin) SB - IM EIN - Foot Ankle Int. 2007 Oct;28(10):table of contents. De Paepe, Yves [corrected to Depaepe, Yves] MH - Achilles Tendon/blood supply/*injuries/physiopathology MH - Animals MH - Captopril/pharmacology MH - Cell Proliferation/drug effects MH - Collagen/physiology MH - Disease Models, Animal MH - Drug Combinations MH - Fibroblasts/drug effects/physiology MH - Male MH - Neovascularization, Physiologic/drug effects MH - Neprilysin/*antagonists & inhibitors MH - Protease Inhibitors/pharmacology MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Rupture MH - Substance P/*pharmacology MH - Tendon Injuries/*drug therapy/physiopathology MH - Thiorphan/pharmacology MH - Treatment Outcome MH - Wound Healing/*drug effects/physiology EDAT- 2005/10/14 09:00 MHDA- 2006/02/14 09:00 CRDT- 2005/10/14 09:00 PHST- 2005/10/14 09:00 [pubmed] PHST- 2006/02/14 09:00 [medline] PHST- 2005/10/14 09:00 [entrez] AID - 901887 [pii] AID - 10.1177/107110070502601008 [doi] PST - ppublish SO - Foot Ankle Int. 2005 Oct;26(10):832-9. doi: 10.1177/107110070502601008. PMID- 27934929 OWN - NLM STAT- MEDLINE DCOM- 20180606 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Dec 9 TI - Use of polyvinylpyrrolidone-iodine solution for sterilisation and preservation improves mechanical properties and osteogenesis of allografts. PG - 38669 LID - 10.1038/srep38669 [doi] LID - 38669 AB - Allografts eliminate the disadvantages associated with autografts and synthetic scaffolds but are associated with a disease-transmission risk. Therefore, allograft sterilisation is crucial. We aimed to determine whether polyvinylpyrrolidone-iodine (PVP-I) can be used for sterilisation and as a new wet-preservation method. PVP-I-sterilised and preserved allografts demonstrated improved mechanical property, osteogenesis, and excellent microbial inhibition. A thigh muscle pouch model of nude mice showed that PVP-I-preserved allografts demonstrated better ectopic formation than Co(60)-sterilised allografts (control) in vivo (P < 0.05). Furthermore, the PVP-I-preserved group showed no difference between 24 h and 12 weeks of allograft preservation (P > 0.05). PVP-I-preserved allografts showed more hydrophilic surfaces and PVP-I-sterilised tendons showed higher mechanical strength than Co(60)-sterilised tendons (P < 0.05). The level of residual PVP-I was higher without washing and with prolonged preservation (P < 0.05). In vitro cellular tests showed that appropriate PVP-I concentration was nontoxic to preosteoblast cells, and cellular differentiation measured by alkaline phosphatase activity and osteogenic gene markers was enhanced (P < 0.05). Therefore, the improved biological performance of implanted allografts may be attributable to better surface properties and residual PVP-I, and PVP-I immersion can be a simple, easy method for allograft sterilisation and preservation. FAU - Zhao, Yantao AU - Zhao Y AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Hu, Xiantong AU - Hu X AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Li, Zhonghai AU - Li Z AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Wang, Fuli AU - Wang F AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Xia, Yang AU - Xia Y AD - Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing 210029, P. R. China. AD - State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory of Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China. FAU - Hou, Shuxun AU - Hou S AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Zhong, Hongbin AU - Zhong H AD - Beijing Engineering Research Center of Orthopaedic Implants, First Affiliated Hospital of CPLA General Hospital, Beijing 100048, P. R. China. FAU - Zhang, Feimin AU - Zhang F AD - Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing 210029, P. R. China. AD - Suzhou Institute &Collaborative Innovation Center of Suzhou Nano Science and Technology, Southeast University, Suzhou 215000, P. R. China. FAU - Gu, Ning AU - Gu N AD - State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory of Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China. AD - Suzhou Institute &Collaborative Innovation Center of Suzhou Nano Science and Technology, Southeast University, Suzhou 215000, P. R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20161209 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Biomarkers) RN - 0 (Organ Preservation Solutions) RN - 85H0HZU99M (Povidone-Iodine) SB - IM MH - Animals MH - Biomarkers MH - *Bone Transplantation MH - Bone and Bones/diagnostic imaging/*drug effects/*physiology/ultrastructure MH - Immunohistochemistry MH - Male MH - Mechanical Phenomena/drug effects MH - Mice MH - Organ Preservation Solutions/*pharmacology MH - Osteogenesis/*drug effects MH - Povidone-Iodine/*pharmacology MH - *Preservation, Biological MH - *Sterilization MH - Transplantation, Homologous PMC - PMC5146663 EDAT- 2016/12/10 06:00 MHDA- 2018/06/07 06:00 PMCR- 2016/12/09 CRDT- 2016/12/10 06:00 PHST- 2016/07/25 00:00 [received] PHST- 2016/11/11 00:00 [accepted] PHST- 2016/12/10 06:00 [entrez] PHST- 2016/12/10 06:00 [pubmed] PHST- 2018/06/07 06:00 [medline] PHST- 2016/12/09 00:00 [pmc-release] AID - srep38669 [pii] AID - 10.1038/srep38669 [doi] PST - epublish SO - Sci Rep. 2016 Dec 9;6:38669. doi: 10.1038/srep38669. PMID- 3019385 OWN - NLM STAT- MEDLINE DCOM- 19861107 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 25 IP - 15 DP - 1986 Jul 29 TI - Iron-containing metallocenes as active site directed inhibitors of the proteinase that cleaves the NH2-terminal propeptides from type I procollagen. PG - 4302-9 AB - Derivatives of ferrocene (dicyclopentadienyliron) (Fc) were examined as active site directed inhibitors of type I procollagen N-proteinase, the enzyme that cleaves the NH2-terminal propeptides from type I procollagen. The compounds were shown here to be reversible, competitive inhibitors of the enzyme. The effectiveness of the Fc inhibitors varied with modification of the cyclopentadienyl (cp) rings. The monocarboxylic acid (I) and the 1,1'-dicarboxylic acid (II) derivatives of Fc inhibited 50% of the enzymic activity (I50) at concentrations of 1.0 and 0.5 mM, respectively. The Ki values were 0.3 mM for both I and II. Derivatization of the carbonyl alpha to the cp ring of compound I (FcCOCH2CH2COOH, III) increased the inhibitory activity (I50 = 0.100 mM; Ki = 0.065 mM). Removal of the carbonyl alpha to the cp ring of III did not improve inhibitory activity: FcCH2CH2COOH, I50 = 2 mM; FcCH = CHCOOH, I50 = 1.5 mM. The active inhibitory species apparently contained iron in the 3+ valence state since two ferrocenium derivatives were very effective inhibitors: ferrocenium tetrachloroferrate, IV (I50 = 0.030 mM; Ki = 0.004 mM), and carboxyferrocenium hexafluorophosphate, V (I50 less than 0.1 mM; Ki less than 0.05 mM). In addition, reduction of III with ascorbic acid abolished its inhibitory activity. Compounds I and III stabilized the enzyme to heat denaturation in the absence of exogenous calcium; compound IV did not stabilize the enzyme. Further observations indicated that Fc derivatives were specific inhibitors of procollagen N-proteinase.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Dombrowski, K E AU - Dombrowski KE FAU - Sheats, J E AU - Sheats JE FAU - Prockop, D J AU - Prockop DJ LA - eng GR - AM-16516/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Ferrous Compounds) RN - 0 (Indicators and Reagents) RN - 0 (Metallocenes) RN - 0 (Organometallic Compounds) RN - 0 (Procollagen) RN - 0 (Protease Inhibitors) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.24.14 (Procollagen N-Endopeptidase) RN - EC 3.4.24.3 (Microbial Collagenase) RN - U96PKG90JQ (ferrocene) SB - IM MH - Animals MH - Chickens MH - Endopeptidases MH - Ferrous Compounds/chemical synthesis/*pharmacology MH - Fibroblasts/enzymology MH - Indicators and Reagents MH - Kinetics MH - Metallocenes MH - Microbial Collagenase/isolation & purification/metabolism MH - Organometallic Compounds/chemical synthesis/*pharmacology MH - Procollagen/*metabolism MH - Procollagen N-Endopeptidase MH - *Protease Inhibitors/*pharmacology MH - Rabbits MH - Synovial Fluid/enzymology MH - Tendons/enzymology EDAT- 1986/07/29 00:00 MHDA- 1986/07/29 00:01 CRDT- 1986/07/29 00:00 PHST- 1986/07/29 00:00 [pubmed] PHST- 1986/07/29 00:01 [medline] PHST- 1986/07/29 00:00 [entrez] AID - 10.1021/bi00363a019 [doi] PST - ppublish SO - Biochemistry. 1986 Jul 29;25(15):4302-9. doi: 10.1021/bi00363a019. PMID- 18599594 OWN - NLM STAT- MEDLINE DCOM- 20081016 LR - 20211020 IS - 0363-6135 (Print) IS - 1522-1539 (Electronic) IS - 0363-6135 (Linking) VI - 295 IP - 3 DP - 2008 Sep TI - Acid-sensing ion and epithelial sodium channels do not contribute to the mechanoreceptor component of the exercise pressor reflex. PG - H1017-H1024 LID - 10.1152/ajpheart.00450.2008 [doi] AB - Amiloride, injected into the popliteal artery, has been reported to attenuate the reflex pressor response to static contraction of the triceps surae muscles. Both mechanical and metabolic stimuli arising in contracting skeletal muscle are believed to evoke this effect, which has been named the exercise pressor reflex. Amiloride blocks both acid-sensing ion channels, as well as epithelial sodium channels. Nevertheless, amiloride is thought to block the metabolic stimulus to the reflex, because this agent has been shown to attenuate the reflex pressor response to injection of lactic acid into the arterial supply of skeletal muscle. The possibility exists, however, that amiloride may also block mechanical stimuli evoking the exercise pressor reflex. The mechanical component of the reflex can be assessed by measuring renal sympathetic nerve activity during the first 2-5 s of contraction. During this period of time, the sudden tension developed by contraction onset briskly discharges mechanoreceptors, whereas it has little effect on the discharge of metaboreceptors. We, therefore, examined the effect of amiloride (0.5 microg/kg) injected into the popliteal artery on the renal sympathetic and pressor responses to static contraction of the triceps surae muscles in decerebrated cats. We found that amiloride significantly attenuated the pressor and renal sympathetic responses to contraction; for the latter variable, the attenuation started 10 s after the onset of contraction. Our findings lead us to conclude that acid-sensing ion channels and epithelial sodium channels play little, if any, role in evoking the mechanical component of the exercise pressor reflex. FAU - McCord, Jennifer L AU - McCord JL AD - Penn State Heart and Vascular Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA. jmccord@hmc.psu.edu FAU - Hayes, Shawn G AU - Hayes SG FAU - Kaufman, Marc P AU - Kaufman MP LA - eng GR - AR 051503/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20080703 PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Acid Sensing Ion Channels) RN - 0 (Diuretics) RN - 0 (Epithelial Sodium Channels) RN - 0 (Nerve Tissue Proteins) RN - 0 (Sodium Channels) RN - 33X04XA5AT (Lactic Acid) RN - 7DZO8EB0Z3 (Amiloride) SB - IM MH - Acid Sensing Ion Channels MH - Amiloride/pharmacology MH - Animals MH - Blood Pressure/drug effects/*physiology MH - Cats MH - Decerebrate State/physiopathology MH - Diuretics/pharmacology MH - Epithelial Cells/drug effects/*physiology MH - Epithelial Sodium Channels/*physiology MH - Female MH - Heart Rate/drug effects/physiology MH - Kidney/innervation/physiology MH - Lactic Acid/pharmacology MH - Male MH - Mechanoreceptors/drug effects/*physiology MH - Muscle Contraction/physiology MH - Nerve Tissue Proteins/*physiology MH - Physical Exertion/*physiology MH - Sodium Channels/*physiology MH - Tendons/physiology PMC - PMC2544505 EDAT- 2008/07/05 09:00 MHDA- 2008/10/17 09:00 PMCR- 2009/09/01 CRDT- 2008/07/05 09:00 PHST- 2008/07/05 09:00 [pubmed] PHST- 2008/10/17 09:00 [medline] PHST- 2008/07/05 09:00 [entrez] PHST- 2009/09/01 00:00 [pmc-release] AID - 00450.2008 [pii] AID - H-00450-2008 [pii] AID - 10.1152/ajpheart.00450.2008 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H1017-H1024. doi: 10.1152/ajpheart.00450.2008. Epub 2008 Jul 3. PMID- 31295489 OWN - NLM STAT- MEDLINE DCOM- 20200127 LR - 20200127 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 138 DP - 2019 Oct 1 TI - The application of BMP-12-overexpressing mesenchymal stem cells loaded 3D-printed PLGA scaffolds in rabbit rotator cuff repair. PG - 79-88 LID - S0141-8130(19)31768-4 [pii] LID - 10.1016/j.ijbiomac.2019.07.041 [doi] AB - This study investigates if the application of bone marrow-derived mesenchymal stem cells (BM-MSCs) loaded 3D-printed scaffolds could improve rotator cuff repair. The polylactic-co-glycolic acid (PLGA) scaffolds were fabricated by 3D print technology. Rabbit BM-MSCs were transfected with a recombinant adenovirus encoding bone morphogenic protein 12 (BMP-12). The effect of BM-MSCs loaded PLGA scaffolds on tendon-bone healing was assessed by biomechanical testing and histological analysis in a rabbit rotator cuff repair model. We found that the PLGA scaffolds had good biocompatible and biodegradable property. Overexpression of BMP-12 increased the mRNA and protein expression of tenogenic genes in BM-MSCs cultured with DMEM medium and seeded in PLGA scaffolds. When BMP-12-overexpressing BM-MSCs-loaded PLGA scaffolds were implanted into the injured rabbit supraspinatus tendon-bone junctions, the tendon-bone healing was improved. Our results suggest that application of BMP-12 overexpressing BM-MSCs loaded 3D-printed PLGA scaffolds promote the healing of tendon-bone interface, improve collagen organization and increase fibrocartilage in the rabbit rotor cuff repair. Rotator cuff regeneration achieved by BMP-12-overexpressing BM-MSCs-loaded PLGA scaffolds may represent a novel approach for the management of rotator cuff defect. CI - Copyright © 2019 Elsevier B.V. All rights reserved. FAU - Chen, Peng AU - Chen P AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. FAU - Cui, Lei AU - Cui L AD - First Clinical Medical College of Anhui Medical University, 230000 Hefei, China. FAU - Chen, Guofei AU - Chen G AD - Department of Orthopedics, Shenzhen Guangming New District People's Hospital, 518000 Shenzhen, China. FAU - You, Tian AU - You T AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. FAU - Li, Wei AU - Li W AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. FAU - Zuo, Jianwei AU - Zuo J AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. FAU - Wang, Chen AU - Wang C AD - First Clinical Medical College of Anhui Medical University, 230000 Hefei, China. FAU - Zhang, Wentao AU - Zhang W AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. FAU - Jiang, Changqing AU - Jiang C AD - Department of Sports Medicine, Peking University Shenzhen Hospital, 518000 Shenzhen, China. Electronic address: Jiangchangqing2019@126.com. LA - eng PT - Journal Article DEP - 20190708 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (Biomarkers) RN - 0 (Bone Morphogenetic Proteins) RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) SB - IM MH - Animals MH - Biomarkers/metabolism MH - Bone Morphogenetic Proteins/*genetics MH - Cell Adhesion/drug effects MH - Cell Proliferation/drug effects MH - Gene Expression MH - Mesenchymal Stem Cells/chemistry/cytology/drug effects/*metabolism MH - Polylactic Acid-Polyglycolic Acid Copolymer/*chemistry/pharmacology MH - *Printing, Three-Dimensional MH - Rabbits MH - Regeneration MH - Rotator Cuff/*physiology MH - Tendons/physiology MH - Tissue Scaffolds/*chemistry OTO - NOTNLM OT - 3D print OT - BM-MSCs OT - PLGA scaffolds OT - Rotator cuff repair EDAT- 2019/07/12 06:00 MHDA- 2020/01/28 06:00 CRDT- 2019/07/12 06:00 PHST- 2019/03/08 00:00 [received] PHST- 2019/07/04 00:00 [revised] PHST- 2019/07/06 00:00 [accepted] PHST- 2019/07/12 06:00 [pubmed] PHST- 2020/01/28 06:00 [medline] PHST- 2019/07/12 06:00 [entrez] AID - S0141-8130(19)31768-4 [pii] AID - 10.1016/j.ijbiomac.2019.07.041 [doi] PST - ppublish SO - Int J Biol Macromol. 2019 Oct 1;138:79-88. doi: 10.1016/j.ijbiomac.2019.07.041. Epub 2019 Jul 8. PMID- 39358851 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20250106 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 43 IP - 2 DP - 2025 Feb TI - Suramin enhances proliferation, migration, and tendon gene expression of human supraspinatus tenocytes. PG - 252-263 LID - 10.1002/jor.25990 [doi] AB - Rotator cuff tendinopathy is a common musculoskeletal disorder with limited pharmacological treatment strategies. This study aimed to investigate tenocytes' functional in vitro response from a ruptured supraspinatus tendon to suramin administration and to elucidate whether suramin can enhance tendon repair and modulate the inflammatory response to injury. Tenocytes were obtained from human supraspinatus tendons (n = 6). We investigated the effect of suramin on LPS-induced inflammatory responses and the underlying molecular mechanisms in THP-1 macrophages. Suramin enhanced the proliferation, cell viability, and migration of tenocytes. It also increased the protein expression of PCNA and Ki-67. Suramin-treated tenocytes exhibited increased expression of COL1A1, COL3A1, TNC, SCX, and VEGF. Suramin significantly reduced LPS-induced iNOS, COX2 synthesis, inflammatory cytokine TNF-α production, and inflammatory signaling by influencing the NF-κB pathways in THP-1 cells. Our results suggest that suramin holds great promise as a therapeutic option for treating rotator cuff tendinopathy. CI - © 2024 Orthopaedic Research Society. FAU - Huang, Shih-Hao AU - Huang SH AUID- ORCID: 0000-0002-4687-9183 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Wang, Chih-Chien AU - Wang CC AD - Department of Anesthesiology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. FAU - Shen, Po-Chih AU - Shen PC AUID- ORCID: 0000-0001-5185-5584 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - School of Post-Baccalaureate Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Orthopaedic Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. FAU - Liu, Zi-Miao AU - Liu ZM AUID- ORCID: 0000-0002-8827-3243 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Chen, Shu-Jung AU - Chen SJ AUID- ORCID: 0000-0001-5015-2932 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Tien, Yin-Chun AU - Tien YC AUID- ORCID: 0000-0001-5497-1118 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. FAU - Lu, Cheng-Chang AU - Lu CC AUID- ORCID: 0000-0002-7194-9147 AD - Department of Orthopaedic Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. AD - School of Post-Baccalaureate Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Orthopaedic Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan. AD - Department of Orthopaedic Surgery, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan. AD - School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. LA - eng GR - 111-2314-B-037-118/Ministry of Science and Technology Taipei, Taiwan/ GR - MOST 108-2314-B-037-060/Ministry of Science and Technology Taipei, Taiwan/ GR - 103-3M35/Kaohsiung Medical University Chung-Ho Memorial Hospital/ GR - 112-2-R52/Kaohsiung Medical University Chung-Ho Memorial Hospital/ GR - S-112-11/Kaohsiung Municipal Siaogang Hospital/ PT - Journal Article DEP - 20241002 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 6032D45BEM (Suramin) RN - 0 (SCX protein, human) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (NF-kappa B) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - 0 (Collagen Type I) RN - 0 (Vascular Endothelial Growth Factor A) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - 0 (Collagen Type III) RN - 0 (Basic Helix-Loop-Helix Transcription Factors) SB - IM MH - Humans MH - *Suramin/pharmacology MH - *Tenocytes/metabolism/drug effects MH - *Cell Proliferation/drug effects MH - *Cell Movement/drug effects MH - *Rotator Cuff/drug effects MH - Tumor Necrosis Factor-alpha/metabolism MH - NF-kappa B/metabolism MH - THP-1 Cells MH - Rotator Cuff Injuries/metabolism MH - Cyclooxygenase 2/metabolism MH - Collagen Type I/metabolism MH - Male MH - Vascular Endothelial Growth Factor A/metabolism MH - Nitric Oxide Synthase Type II/metabolism MH - Collagen Type III/metabolism/genetics MH - Middle Aged MH - Tendinopathy/metabolism MH - Gene Expression/drug effects MH - Female MH - Basic Helix-Loop-Helix Transcription Factors OTO - NOTNLM OT - inflammation OT - macrophage polarization OT - rotator cuff tendinopathy OT - suramin EDAT- 2024/10/03 06:58 MHDA- 2025/01/07 00:21 CRDT- 2024/10/03 00:23 PHST- 2024/08/23 00:00 [revised] PHST- 2024/04/24 00:00 [received] PHST- 2024/09/06 00:00 [accepted] PHST- 2025/01/07 00:21 [medline] PHST- 2024/10/03 06:58 [pubmed] PHST- 2024/10/03 00:23 [entrez] AID - 10.1002/jor.25990 [doi] PST - ppublish SO - J Orthop Res. 2025 Feb;43(2):252-263. doi: 10.1002/jor.25990. Epub 2024 Oct 2. PMID- 25935481 OWN - NLM STAT- MEDLINE DCOM- 20150811 LR - 20230201 IS - 1090-2104 (Electronic) IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 462 IP - 1 DP - 2015 Jun 19 TI - Cell proliferation is a key determinant of the outcome of FOXO3a activation. PG - 78-84 LID - S0006-291X(15)00832-3 [pii] LID - 10.1016/j.bbrc.2015.04.112 [doi] AB - The FOXO family of forkhead transcription factors have a pivotal role in determining cell fate in response to oxidative stress. FOXO activity can either promote cell survival or induce cell death. Increased FOXO-mediated cell death has been implicated in the pathogenesis of degenerative diseases affecting musculoskeletal tissues. The aim of this study was to determine the conditions under which one member of the FOXO family, FOXO3a, promotes cell survival as opposed to cell death. Treatment of primary human tenocytes with 1 pM hydrogen peroxide for 18 h resulted in increased protein levels of FOXO3a. In peroxide-treated cells cultured in low serum media, FOXO3a inhibited cell proliferation and protected against apoptosis. However in peroxide treated cells cultured in high serum media, cell proliferation was unchanged but level of apoptosis significantly increased. Similarly, in tenocytes transduced to over-express FOXO3a, cell proliferation was inhibited and level of apoptosis unchanged in cells cultured in low serum. However there was a robust increase in cell death in FOXO3a-expressing cells cultured in high serum. Inhibition of cell proliferation in either peroxide-treated or FOXO3a-expressing cells cultured in high serum protected against apoptosis induction. Conversely, addition of a Chk2 inhibitor to peroxide-treated or FOXO3a-expressing cells overrode the inhibitory effect of FOXO3a on cell proliferation and led to increased apoptosis in cells cultured in low serum. This study demonstrates that proliferating cells may be particularly susceptible to the apoptosis-inducing actions of FOXO3a. Inhibition of cell proliferation by FOXO3a may be a critical event in allowing the pro-survival rather than the pro-apoptotic activity of FOXO3a to prevail. CI - Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Poulsen, Raewyn C AU - Poulsen RC AD - Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK. Electronic address: raewyn.poulsen@gmail.com. FAU - Carr, Andrew J AU - Carr AJ AD - Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK. FAU - Hulley, Philippa A AU - Hulley PA AD - Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK. LA - eng GR - 19482/ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150430 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Culture Media) RN - 0 (FOXO3 protein, human) RN - 0 (Forkhead Box Protein O3) RN - 0 (Forkhead Transcription Factors) RN - 0 (Oxidants) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.22.- (Caspase 7) SB - IM MH - Apoptosis/drug effects/*genetics MH - Blotting, Western MH - Caspase 3/metabolism MH - Caspase 7/metabolism MH - Cell Proliferation/drug effects/*genetics MH - Cell Survival/drug effects/genetics MH - Cells, Cultured MH - Culture Media/chemistry/pharmacology MH - Forkhead Box Protein O3 MH - Forkhead Transcription Factors/*genetics/metabolism MH - Humans MH - Hydrogen Peroxide/pharmacology MH - MCF-7 Cells MH - Oxidants/pharmacology MH - RNA Interference MH - Serum/metabolism MH - Tendons/*cytology PMC - PMC4449364 OTO - NOTNLM OT - Apoptosis OT - Cell death OT - Cell survival OT - Forkhead transcription factors OT - Oxidative stress EDAT- 2015/05/04 06:00 MHDA- 2015/08/12 06:00 PMCR- 2015/06/19 CRDT- 2015/05/04 06:00 PHST- 2015/04/15 00:00 [received] PHST- 2015/04/22 00:00 [accepted] PHST- 2015/05/04 06:00 [entrez] PHST- 2015/05/04 06:00 [pubmed] PHST- 2015/08/12 06:00 [medline] PHST- 2015/06/19 00:00 [pmc-release] AID - S0006-291X(15)00832-3 [pii] AID - 10.1016/j.bbrc.2015.04.112 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2015 Jun 19;462(1):78-84. doi: 10.1016/j.bbrc.2015.04.112. Epub 2015 Apr 30. PMID- 24580752 OWN - NLM STAT- MEDLINE DCOM- 20141027 LR - 20211021 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 9 IP - 1 DP - 2014 Mar 1 TI - Effect of Poloxamer 407 as a carrier vehicle on rotator cuff healing in a rat model. PG - 12 LID - 10.1186/1749-799X-9-12 [doi] AB - BACKGROUND: In vivo studies showing the effects of biologic healing-promoting factors on tendon-to-bone healing after rotator cuff repair have focused only on biologic healing-promoting factors and have not taken into consideration the effect of the carrier vehicle. Moreover, most studies have evaluated the healing process using different carrier vehicles, each of which may have specific effects on tendon healing. This may explain the large variability seen in outcomes in research studies. In this study, we investigated the effects of Poloxamer 407 as a carrier vehicle on rotator cuff healing at the repair site and compared it with those of a collagen sponge, which is a commonly used carrier vehicle. METHODS: Fifty-seven adult male Sprague-Dawley rats underwent detachment and immediate repair of the bilateral supraspinatus tendons. Rats were randomly assigned to three groups: repair only, repair with collagen sponge, and repair with Poloxamer 407. The repairs were evaluated at 1, 2, 4, and 8 weeks after surgery with histological analysis and biomechanical testing. RESULTS: At 4 weeks, more cellular organization, a greater number of collagen fibers, and increased maturity of collagen fibers were observed in the repair with Poloxamer 407 group than in the other groups. The repair with collagen sponge group had delayed development and collagen fiber maturation. Significant differences in the biomechanical properties were found between groups at 4 weeks. Stiffness in the case of the repair with Poloxamer 407 group was significantly higher than that in the repair with collagen sponge group. The modulus was significantly lower in the repair with collagen sponge group than in the repair only group. However, the use of Poloxamer 407 versus the collagen sponge did not significantly affect the biomechanical properties of the repaired tendons at 8 weeks. CONCLUSIONS: Carrier vehicles may have differing effects at the early stages of rotator cuff healing. The use of Poloxamer 407 as a carrier vehicle may be useful for promoting the early stages of healing and for maintaining the initial biomechanical properties of the repaired rotator cuff tendon. FAU - Kim, Soung-Yon AU - Kim SY AD - Department of Orthopaedic Surgery, Hallym University Kangnam Sacred Heart Hospital, 948-1, Daerim-1 Dong, Yeongdeungpo-gu, Seoul 150-950, South Korea. singsingkr@yahoo.co.kr. FAU - Chae, Soo-Won AU - Chae SW FAU - Lee, Juneyoung AU - Lee J LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20140301 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Excipients) RN - 106392-12-5 (Poloxamer) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Collagen/pharmacology MH - Disease Models, Animal MH - Excipients/*pharmacology MH - Male MH - Poloxamer/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*drug effects MH - Rotator Cuff Injuries MH - Tendon Injuries/*drug therapy MH - Wound Healing/*drug effects PMC - PMC3942324 EDAT- 2014/03/04 06:00 MHDA- 2014/10/28 06:00 PMCR- 2014/03/01 CRDT- 2014/03/04 06:00 PHST- 2013/09/06 00:00 [received] PHST- 2014/02/20 00:00 [accepted] PHST- 2014/03/04 06:00 [entrez] PHST- 2014/03/04 06:00 [pubmed] PHST- 2014/10/28 06:00 [medline] PHST- 2014/03/01 00:00 [pmc-release] AID - 1749-799X-9-12 [pii] AID - 10.1186/1749-799X-9-12 [doi] PST - epublish SO - J Orthop Surg Res. 2014 Mar 1;9(1):12. doi: 10.1186/1749-799X-9-12. PMID- 40224957 OWN - NLM STAT- MEDLINE DCOM- 20250414 LR - 20250723 IS - 1932-7005 (Electronic) IS - 1932-6254 (Print) IS - 1932-6254 (Linking) VI - 2025 DP - 2025 TI - Application of Tendon-Derived Matrix and Carbodiimide Crosslinking Matures the Engineered Tendon-Like Proteome on Meltblown Scaffolds. PG - 2184723 LID - 10.1155/term/2184723 [doi] LID - 2184723 AB - Background: Tendon injuries are increasingly common and heal by fibrosis rather than scar-less regeneration. Tissue engineering seeks to improve repair using synthetic polymer scaffolds with biomimetic factors to enhance the regenerative potential. Methods: In this study, we compared three groups, namely, poly(lactic acid) (PLA) meltblown scaffolds, PLA meltblown scaffolds coated with tendon-derived matrix (TDM), and PLA meltblown scaffolds with carbodiimide crosslinked TDM (2.5:1:1 EDC:NHS:COOH ratio) (EDC-TDM) and determined their potential for engineered tendon development. We cultured human adipose stem cells (hASCs) for 28 days on meltblown scaffolds (n = 4-6/group) and measured tensile mechanical function, matrix synthesis, and matrix composition using biochemical assays and proteomics. Results: Coating PLA meltblown scaffolds with TDM improved yield stretch and stress at 28 days compared with PLA. Matrix synthesis rates for TDM or EDC-TDM were similar to PLA. Proteomic analysis revealed that hASCs produced a collagen-rich extracellular matrix, with many tendon-related matrix proteins. Coating scaffolds with TDM led to an increase in collagen type I whereas EDC-TDM scaffolds had an increase in glycoproteins and ECM regulators compared with other groups, consistent with increased maturity of the newly deposited matrix. Conclusions: TDM coating and crosslinking of meltblown scaffolds demonstrated matricellular benefits for the proteome of engineered tendon development but provided fewer clear benefits toward mechanical, biochemical, and rate of matrix accumulation than expected, and that previous work with electrospun scaffolds would suggest. However, electrospun scaffolds have different fiber structure and microarchitecture than meltblown, suggesting that further consideration of these differences and refinement of TDM application methods to meltblown scaffolds is required. CI - Copyright © 2025 Thomas Lee Jenkins et al. Journal of Tissue Engineering and Regenerative Medicine published by John Wiley & Sons Ltd. FAU - Jenkins, Thomas Lee AU - Jenkins TL AUID- ORCID: 0000-0001-8462-7510 AD - Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA. FAU - Venkataraman, Sadhana AU - Venkataraman S AUID- ORCID: 0000-0002-0094-6731 AD - Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA. FAU - Saleh, Aya AU - Saleh A AUID- ORCID: 0009-0007-1746-0838 AD - Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA. FAU - Calve, Sarah AU - Calve S AUID- ORCID: 0000-0002-7887-6307 AD - Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA. AD - Department of Mechanical Engineering, University of Colorado-Boulder, Boulder, Colorado, USA. FAU - Pourdeyhimi, Behnam AU - Pourdeyhimi B AUID- ORCID: 0000-0002-8787-7221 AD - The Nonwovens Institute, North Carolina State University, Raleigh, North Carolina, USA. FAU - Little, Dianne AU - Little D AUID- ORCID: 0000-0002-1869-7083 AD - Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA. AD - Department of Basic Medical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA. LA - eng GR - F31 AR079844/AR/NIAMS NIH HHS/United States GR - K08 AR059784/AR/NIAMS NIH HHS/United States GR - R01 AR073882/AR/NIAMS NIH HHS/United States GR - R03 AR065764/AR/NIAMS NIH HHS/United States PT - Journal Article DEP - 20250226 PL - England TA - J Tissue Eng Regen Med JT - Journal of tissue engineering and regenerative medicine JID - 101308490 RN - 0 (Carbodiimides) RN - 0 (Cross-Linking Reagents) RN - 0 (Proteome) RN - 0 (Polyesters) RN - 459TN2L5F5 (poly(lactide)) SB - IM MH - Humans MH - *Tissue Scaffolds/chemistry MH - *Tendons/metabolism MH - *Tissue Engineering/methods MH - *Carbodiimides/chemistry/pharmacology MH - *Cross-Linking Reagents/chemistry/pharmacology MH - *Proteome/metabolism MH - *Extracellular Matrix/metabolism/chemistry MH - Polyesters/chemistry MH - Stem Cells/cytology/metabolism MH - Adipose Tissue/cytology PMC - PMC11985250 OTO - NOTNLM OT - biomaterials OT - collagen OT - extracellular matrix OT - human adipose stem cells OT - mesenchymal stem cell COIS- The authors declare no conflicts of interest. EDAT- 2025/04/14 17:27 MHDA- 2025/04/14 17:28 PMCR- 2025/02/26 CRDT- 2025/04/14 07:05 PHST- 2024/07/23 00:00 [received] PHST- 2025/01/20 00:00 [accepted] PHST- 2025/04/14 17:28 [medline] PHST- 2025/04/14 17:27 [pubmed] PHST- 2025/04/14 07:05 [entrez] PHST- 2025/02/26 00:00 [pmc-release] AID - 10.1155/term/2184723 [doi] PST - epublish SO - J Tissue Eng Regen Med. 2025 Feb 26;2025:2184723. doi: 10.1155/term/2184723. eCollection 2025. PMID- 19770194 OWN - NLM STAT- MEDLINE DCOM- 20100726 LR - 20211020 IS - 1469-7793 (Electronic) IS - 0022-3751 (Print) IS - 0022-3751 (Linking) VI - 587 IP - Pt 22 DP - 2009 Nov 15 TI - Involvement of Na+/Ca2+ exchanger in migration and contraction of rat cultured tendon fibroblasts. PG - 5345-59 LID - 10.1113/jphysiol.2009.172080 [doi] AB - In response to injury and inflammation of tendons, tendon fibroblasts are activated, migrate to the wound, and eventually induce contraction of the extracellular matrices to repair the tissue. Under such conditions, Ca(2+) signalling is involved in motility and contractility of tendon fibroblasts. Using cultured tendon fibroblasts isolated from rat Achilles tendons, we investigated functional expression of Na(+)/Ca(2+) exchangers (NCX). The fluorometric study showed that the intracellular Ca(2+) concentration ([Ca(2+)](i)) was increased by reducing extracellular Na(+) concentration ([Na(+)](o)) in tendon fibroblasts. Selective NCX inhibitors, KB-R7943 and SEA0400, both attenuated [Na(+)](o)-dependent [Ca(2+)](i) elevation and the resting [Ca(2+)](i) in tendon fibroblasts. RT-PCR, Western blots and sequence analyses revealed that NCX1.3 and NCX1.7 were expressed in cultured tendon fibroblasts. NCX2 mRNA was undetected. NCX3 expression was negligibly low. Immunofluorescence microscopy indicated that NCX1 protein localized in the plasma membrane especially at the microspikes of tendon fibroblasts. In the wound-healing scratch assay, the cells migrated toward the space created by a scratch and almost completely filled the space within 48 h. This phenomenon was significantly suppressed by KB-R7943 and SEA0400. Furthermore, the NCX inhibitors abrogated the tendon fibroblast-mediated collagen-matrix contractions. Two types of siRNAs for NCX1 also suppressed the migration and contraction of tendon fibroblasts. We conclude that NCX is expressed and mediates Ca(2+) influx in cultured tendon fibroblasts. Since the pharmacological inhibitors and siRNA for NCX1 suppressed motility and contractility of tendon fibroblasts, NCX may play an important role in the function of tendon fibroblasts in the wound healing. FAU - Sakamoto, Kazuho AU - Sakamoto K AD - Department of Pharmacology, Fukushima Medical University, School of Medicine, Hikarigaoka, Fukushima, Japan. kazuho@fmu.ac.jp FAU - Owada, Yuki AU - Owada Y FAU - Shikama, Yayoi AU - Shikama Y FAU - Wada, Ikuo AU - Wada I FAU - Waguri, Satoshi AU - Waguri S FAU - Iwamoto, Takahiro AU - Iwamoto T FAU - Kimura, Junko AU - Kimura J LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090921 PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate) RN - 0 (Sodium-Calcium Exchanger) RN - GYV9AM2QAG (Thiourea) SB - IM MH - Achilles Tendon/cytology/drug effects/*physiology MH - Animals MH - Cell Movement/drug effects/*physiology MH - Cells, Cultured MH - Fibroblasts/drug effects/*physiology MH - Male MH - Membrane Potentials/drug effects/physiology MH - Muscle Contraction/drug effects/*physiology MH - Rats MH - Rats, Wistar MH - Sodium-Calcium Exchanger/antagonists & inhibitors/*physiology MH - Thiourea/analogs & derivatives/pharmacology MH - Wound Healing/drug effects/physiology PMC - PMC2793869 EDAT- 2009/09/23 06:00 MHDA- 2010/07/27 06:00 PMCR- 2010/11/15 CRDT- 2009/09/23 06:00 PHST- 2009/09/23 06:00 [entrez] PHST- 2009/09/23 06:00 [pubmed] PHST- 2010/07/27 06:00 [medline] PHST- 2010/11/15 00:00 [pmc-release] AID - jphysiol.2009.172080 [pii] AID - 10.1113/jphysiol.2009.172080 [doi] PST - ppublish SO - J Physiol. 2009 Nov 15;587(Pt 22):5345-59. doi: 10.1113/jphysiol.2009.172080. Epub 2009 Sep 21. PMID- 12127084 OWN - NLM STAT- MEDLINE DCOM- 20020926 LR - 20190712 IS - 0306-4522 (Print) IS - 0306-4522 (Linking) VI - 113 IP - 2 DP - 2002 TI - Effect of muscle electrostimulation on afferent activities from tibialis anterior muscle after nerve repair by self-anastomosis. PG - 257-71 AB - Numerous previous studies were devoted to the regeneration of motoneurons toward a denervated muscle after nerve repair by self-anastomosis but, to date, few investigations have evaluated the regeneration of sensory muscle endings. In a previous electrophysiological study (Decherchi et al., 2001) we showed that the functional characteristics of tibialis anterior muscle afferents are affected after self-anastomosis of the peroneal nerve even when the neuromuscular preparation was not chronically stimulated. The present study examines the regeneration of groups I-II (mechanosensitive) and groups III-IV (metabosensitive) muscle afferents by evaluating the recovery of their response to different test agents after self-anastomosis combined or not with chronic muscle stimulation for a 10-weeks period. We compared five groups of rats: C, control; L, nerve lesion without suture; LS, nerve lesion with suture; LSE(m): nerve lesion plus chronic muscle stimulation with a monophasic rectangular current; and LSE(b): nerve lesion plus chronic stimulation with a biphasic current with modulations of pulse duration and frequency, eliciting a pattern of activity resembling that delivered by the nerve to the muscle. Compared to the control group, (1) muscle kept only its original weight in the LSE(b) group, (2) in the LS group the response curve to tendon vibration was shifted toward the highest mechanical frequencies and the response of groups III-IV afferents after fatiguing muscle stimulation lowered, (3) in the LSE(m) group, the pattern of activation of mechanoreceptors by tendon vibrations was altered as in the LS group, and the response of metabosensitive afferents to KCl injections was markedly reduced, (4) in the LSE(b) group, the response to tendon vibration was not modified and the activation of metabosensitive units by increased extracellular potassium chloride concentration was conserved. Both LSE(b) and LSE(m) conditions were ineffective to maintain the post muscle stimulation activation of metabosensitive units as well as their activation by injected lactic acid solutions. Our data indicate that chronic muscle electrostimulation partially favors the recovery of mechano- and metabosensitivity in a denervated muscle and that biphasic modulated currents seem to provide better results. CI - Copyright 2002 IBRO FAU - Marqueste, T AU - Marqueste T AD - Institut Fédératif de Recherche Jean ROCHE (IFR11), Faculté de Médecine Nord, Université de la Méditerranée (Aix-Marseille II), Boulevard Pierre Dramard, 13916 Marseille Cedex 20, France. FAU - Decherchi, P AU - Decherchi P FAU - Dousset, E AU - Dousset E FAU - Berthelin, F AU - Berthelin F FAU - Jammes, Y AU - Jammes Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 33X04XA5AT (Lactic Acid) RN - 660YQ98I10 (Potassium Chloride) SB - IM MH - Action Potentials/physiology MH - Afferent Pathways/physiology MH - Animals MH - Electric Stimulation MH - Female MH - Lactic Acid/pharmacology MH - Muscle Denervation MH - Muscle, Skeletal/*innervation/*physiology MH - Nerve Regeneration/*physiology MH - Neurons, Afferent/physiology MH - Potassium Chloride/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/physiology MH - Vibration EDAT- 2002/07/20 10:00 MHDA- 2002/09/27 06:00 CRDT- 2002/07/20 10:00 PHST- 2002/07/20 10:00 [pubmed] PHST- 2002/09/27 06:00 [medline] PHST- 2002/07/20 10:00 [entrez] AID - S0306452202001872 [pii] AID - 10.1016/s0306-4522(02)00187-2 [doi] PST - ppublish SO - Neuroscience. 2002;113(2):257-71. doi: 10.1016/s0306-4522(02)00187-2. PMID- 33592162 OWN - NLM STAT- MEDLINE DCOM- 20210427 LR - 20210427 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 49 IP - 4 DP - 2021 Mar TI - The Enhancement Effect of Acetylcholine and Pyridostigmine on Bone-Tendon Interface Healing in a Murine Rotator Cuff Model. PG - 909-917 LID - 10.1177/0363546520988680 [doi] AB - BACKGROUND: How to improve rotator cuff healing remains a challenge. Little is known about the effect of the parasympathetic transmitter acetylcholine (ACh) and the acetylcholinesterase inhibitor pyridostigmine (PYR), both of which have anti-inflammatory properties, in the healing process of rotator cuff injury. HYPOTHESIS: ACh and PYR could enhance bone-tendon interface healing in a murine model of rotator cuff repair. STUDY DESIGN: Controlled laboratory study. METHODS: A total of 160 C57BL/6 mice underwent unilateral rotator cuff repair surgery. Fibrin gel (FG) was used as a drug carrier. The mice were randomly assigned to 4 groups with 40 mice per group: FG group (received FG alone), 10(-5) M ACh group (received FG containing 10(-5) M ACh), 10(-6) M ACh group (received FG containing 10(-6) M ACh), and PYR group (received FG containing 25 µg of PYR). Ten mice in each group were euthanized at 2, 4, 8, and 12 weeks postoperatively. Histologic, immunohistochemical, and biomechanical evaluations were performed for analysis. RESULTS: Histologically, fibrocartilage-like tissue was shown at the repaired site. The proteoglycan content of the 10(-5) M ACh group was significantly increased compared with the FG group at 4 weeks. M2 macrophages were identified at the repaired site for all groups at 2 and 4 weeks. At 8 weeks, M2 macrophages withdrew back to the tendon in the FG group, but a number of M2 macrophages were retained at the repaired sites in the ACh and PYR groups. Biomechanically, failure load and stiffness of the ACh and PYR groups were significantly higher than those of the FG group at 4 weeks. The stiffness of the ACh and PYR groups was significantly increased compared with the FG group at 8 weeks (P < .001 for all). At 12 weeks, most of the healing properties of the ACh and PYR groups were not significantly different compared with the FG group. CONCLUSION: ACh and PYR enhanced the early stage of bone-tendon insertion healing after rotator cuff repair. CLINICAL RELEVANCE: These findings imply that ACh and PYR could serve as potential therapeutic strategies for rotator cuff healing. FAU - Wang, Zhanwen AU - Wang Z AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Chen, Yang AU - Chen Y AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Xiao, Han AU - Xiao H AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Li, Shengcan AU - Li S AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Zhang, Tao AU - Zhang T AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Hu, Jianzhong AU - Hu J AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. AD - Department of Spine Surgery, Xiangya Hospital, Central South University, Changsha, China. FAU - Lu, Hongbin AU - Lu H AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. FAU - Xie, Hui AU - Xie H AD - Department of Sports Medicine, Xiangya Hospital, Central South University, Changsha, China. AD - Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, China. AD - Movement System Injury and Repair Research Center, Xiangya Hospital, Central South University, Changsha, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210216 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - KVI301NA53 (Pyridostigmine Bromide) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/pharmacology MH - Animals MH - Biomechanical Phenomena MH - Mice MH - Mice, Inbred C57BL MH - Pyridostigmine Bromide/pharmacology MH - *Rotator Cuff/surgery MH - *Rotator Cuff Injuries/drug therapy/surgery MH - Tendons OTO - NOTNLM OT - acetylcholine OT - bone-tendon healing OT - murine model OT - pyridostigmine OT - rotator cuff EDAT- 2021/02/17 06:00 MHDA- 2021/04/28 06:00 CRDT- 2021/02/16 20:08 PHST- 2021/02/17 06:00 [pubmed] PHST- 2021/04/28 06:00 [medline] PHST- 2021/02/16 20:08 [entrez] AID - 10.1177/0363546520988680 [doi] PST - ppublish SO - Am J Sports Med. 2021 Mar;49(4):909-917. doi: 10.1177/0363546520988680. Epub 2021 Feb 16. PMID- 25931129 OWN - NLM STAT- MEDLINE DCOM- 20170428 LR - 20181202 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 24 IP - 12 DP - 2016 Dec TI - Effects of boric acid on the healing of Achilles tendons of rats. PG - 3738-3744 AB - PURPOSE: Tendinous lesions are among the most frequent pathologies encountered in sportsmen. The objectives of new treatments are to improve the healing process and reduce the recovery time. Boron plays an important role in the wound repair process by increasing components of extracellular matrix and angiogenesis. This animal study aimed to investigate the effect of boric acid on healing of the Achilles tendon. METHODS: The right Achilles tendons of 40 rats were completely sectioned, and the rats were randomly divided into five groups. Each group consisted of eight rats. Groups 1 and 2 were oral boric acid groups with the doses of 4 and 8 mg/kg/day boric acid, respectively. Group 3 was the local boric acid group (8 mg/kg boric acid intratendinous injection). Group 4 was administered both oral and local boric acid (8 mg/kg/day orally and 8 mg/kg boric acid intratendinous injection), and group 5 was the control group with no boric acid application. At the end of the fourth week, all the rats were killed and histopathological examination of the Achilles tendon repair site was made. RESULTS: Histopathological examination of the tissue sections revealed more properly oriented collagen fibres, more normal cellular distribution of tenocytes and more properly organized vascular bundles in group 1 and group 2, which were the groups administered oral boric acid. Pathological sum scores of groups 1 and 2 were less than those of the other groups, and the differences between the oral boric acid groups (group 1 and group 2) and the other three groups (groups 3, 4 and 5) were statistically significant (p = 0.001). CONCLUSION: As boric acid is safe and toxicity even after very high doses is unusual, oral boric acid may be used as an agent to improve the healing process of tendon injuries. However, biomechanical tests should also be performed to show the effect of boric acid on strength and endurance of the tendon before it can be used in clinical practice. FAU - Kaymaz, Burak AU - Kaymaz B AD - Department of Orthopaedics and Traumatology, Medical School, Çanakkale Onsekiz Mart University, Kepez, Çanakkale, Turkey. kaymaz23@yahoo.com. FAU - Gölge, Umut Hatay AU - Gölge UH AD - Department of Orthopaedics and Traumatology, Medical School, Çanakkale Onsekiz Mart University, Kepez, Çanakkale, Turkey. FAU - Ozyalvaclı, Gulzade AU - Ozyalvaclı G AD - Department of Pathology, Medical School, Bolu Abant Izzet Baysal University, Bolu, Turkey. FAU - Kömürcü, Erkam AU - Kömürcü E AD - Department of Orthopaedics and Traumatology, Medical School, Çanakkale Onsekiz Mart University, Kepez, Çanakkale, Turkey. FAU - Goksel, Ferdi AU - Goksel F AD - Department of Orthopaedics and Traumatology, Medical School, Çanakkale Onsekiz Mart University, Kepez, Çanakkale, Turkey. FAU - Mermerkaya, Musa Ugur AU - Mermerkaya MU AD - Department of Orthopaedics and Traumatology, Medical School, Bozok University, Yozgat, Turkey. FAU - Doral, Mahmut Nedim AU - Doral MN AD - Department of Orthopaedics and Traumatology, Medical School, Hacettepe University, Ankara, Turkey. LA - eng PT - Journal Article DEP - 20150501 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Boric Acids) RN - 9007-34-5 (Collagen) RN - R57ZHV85D4 (boric acid) SB - IM MH - Achilles Tendon/*drug effects/injuries/pathology MH - Administration, Oral MH - Animals MH - Boric Acids/*pharmacology MH - Collagen/drug effects MH - Injections, Intralesional MH - Male MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/*pathology MH - Tenocytes/*drug effects/pathology MH - Wound Healing/*drug effects OTO - NOTNLM OT - Achilles tendon OT - Angiogenesis OT - Boric acid OT - Collagen fibres OT - Rats OT - Tendon healing EDAT- 2015/05/02 06:00 MHDA- 2017/04/30 06:00 CRDT- 2015/05/02 06:00 PHST- 2014/11/10 00:00 [received] PHST- 2015/04/22 00:00 [accepted] PHST- 2015/05/02 06:00 [pubmed] PHST- 2017/04/30 06:00 [medline] PHST- 2015/05/02 06:00 [entrez] AID - 10.1007/s00167-015-3617-5 [pii] AID - 10.1007/s00167-015-3617-5 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2016 Dec;24(12):3738-3744. doi: 10.1007/s00167-015-3617-5. Epub 2015 May 1. PMID- 10970127 OWN - NLM STAT- MEDLINE DCOM- 20000914 LR - 20220309 IS - 1085-9489 (Print) IS - 1085-9489 (Linking) VI - 3 IP - 4 DP - 1998 TI - Modifications of afferent activities from Tibialis anterior muscle in rat by tendon vibrations, increase of interstitial potassium or lactate concentration and electrically-induced fatigue. PG - 267-76 AB - Although previous experiments with a partially similar objective have been described in dogs, cats and rabbits, the purpose of this study was to identify and characterize mechanosensitive and chemosensitive muscle afferents in the anaesthetized rat since it is a widely used laboratory animal. The peroneal nerve innervating the tibialis anterior muscle was studied. Measurement of conduction velocities from compound action nerve potentials evoked by peripheral nerve stimulation allowed identification of group I-II (10.79+/-1.02 m/s), group III (2.96+/-0.58 m/s) and group IV (0.46+/-0.07 m/s) afferent fibers. Computation of the different compound potential areas showed that afferents I and II arising from spindles and tendon organs represented 9.65+/-2.2%, whereas afferents III and IV arising from free nerve endings in muscle represented 90.35+/-2.2% (III, 46.66+/-2.71% and IV, 43.69+/-2.52%). Action potentials were recorded from teased nerve filaments. Mechanical tendon vibrations (10 to 90 Hz) were used to activate mechanoreceptors. Peak increase in afferent discharge (fimpulses) was measured at 50 Hz (n = 12/19 units) or 70 Hz (n = 7/19 units). Intra-arterial bolus injections of different concentrations of potassium chloride (KCl: 1 to 20 mM) or lactic acid (LA: 0.5 to 3 mM) elicited marked activation of III and IV afferents (n = 124). Enhancement of fimpulses was not proportional to the increase in [KCl] or [LA]. Activation of afferents plateaued when [KCl] was equal or greater than 5 mM while fimpulses peaked, then decreased, when [LA] was 1 mM. Muscle fatigue induced by direct electrical muscle stimulation (EIF) markedly activated group III-IV (n = 17/18) afferents (176.9+/-29.7% of control) which persisted for the 3 minutes of recovery from fatigue. Maximal fimpulses increases in response to LA (+67%) and KCl (+46.9%) injections and to EIF (+76.9%) were similar. This procedure for characterizing the functional properties of sensory nerve endings in a skeletal muscle may be used to assess further changes in sensory muscle paths in experimental rodent pathophysiological systems. FAU - Decherchi, P AU - Decherchi P AD - Laboratoire de Physiopathologie Respiratoire Intégrée et Cellulaire (EA 2201), Institut Jean Roche, Faculté de Médecine, Université de la Méditerranée, Marseille, France. FAU - Darques, J L AU - Darques JL FAU - Jammes, Y AU - Jammes Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Peripher Nerv Syst JT - Journal of the peripheral nervous system : JPNS JID - 9704532 RN - 33X04XA5AT (Lactic Acid) RN - 660YQ98I10 (Potassium Chloride) RN - RWP5GA015D (Potassium) SB - IM MH - Afferent Pathways/drug effects/physiology MH - Animals MH - Electric Stimulation MH - Extracellular Space/*metabolism MH - Female MH - Hindlimb MH - Lactic Acid/*metabolism/pharmacology MH - Muscle Fatigue/*physiology MH - Muscle, Skeletal/*innervation MH - Osmolar Concentration MH - Potassium/*metabolism MH - Potassium Chloride/pharmacology MH - Rats MH - Tendons/*physiology MH - Vibration EDAT- 2000/09/02 11:00 MHDA- 2000/09/19 11:01 CRDT- 2000/09/02 11:00 PHST- 2000/09/02 11:00 [pubmed] PHST- 2000/09/19 11:01 [medline] PHST- 2000/09/02 11:00 [entrez] PST - ppublish SO - J Peripher Nerv Syst. 1998;3(4):267-76. PMID- 39295227 OWN - NLM STAT- MEDLINE DCOM- 20241225 LR - 20250806 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 113 IP - 1 DP - 2025 Jan TI - Electrospun poly(ε-caprolactone)/poly(glycerol sebacate) aligned fibers fabricated with benign solvents for tendon tissue engineering. PG - e37794 LID - 10.1002/jbm.a.37794 [doi] AB - The electrospinning technique is a commonly employed approach to fabricate fibers intended for various tissue engineering applications. The aim of this study is to develop a novel strategy for tendon repair through the use of aligned poly(ε-caprolactone) (PCL) and poly(glycerol sebacate) (PGS) fibers fabricated in benign solvents, and further explore the potential application of PGS in tendon tissue engineering (TTE). The fibers were characterized for their morphological and physicochemical properties; amniotic epithelial stem cells (AECs) were used to assess the fibers teno-inductive and immunomodulatory potential due to their ability to teno-differentiate undergoing first a stepwise epithelial to mesenchymal transition, and due to their documented therapeutic role in tendon regeneration. The addition of PGS to PCL improved the spinnability of the polymer solution, as well as the uniformity and directionality of the so-obtained fibers. The mechanical properties were in the range of most TTE applications, specifically in the case of PCL/PGS 4:1 and 2:1 ratios. Compared to PCL alone, the same ratios also allowed a better AECs infiltration and growth over 7 days of culture, and triggered the activation of tendon-related genes (SCX, COL1, TNMD) and the expression of tenomodulin (TNMD) at the protein level. Concerning the immunomodulatory properties, both PCL and PCL/PGS fibers negatively affected the immunomodulatory profile of AECs, up-regulating both anti-inflammatory (IL-10) and pro-inflammatory (IL-12) cytokines over 7 days of culture. Overall, PCL/PGS 2:1 fibers fabricated with benign solvents proved to be the most suitable composition for TTE application based on their topographical cues, mechanical properties, biocompatibility, and teno-inductive properties. CI - © 2024 The Author(s). Journal of Biomedical Materials Research Part A published by Wiley Periodicals LLC. FAU - Iorio, Francesco AU - Iorio F AUID- ORCID: 0000-0003-1982-7377 AD - Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Erlangen, Germany. AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - El Khatib, Mohammad AU - El Khatib M AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Wöltinger, Natalie AU - Wöltinger N AD - Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Erlangen, Germany. FAU - Turriani, Maura AU - Turriani M AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Di Giacinto, Oriana AU - Di Giacinto O AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Mauro, Annunziata AU - Mauro A AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Russo, Valentina AU - Russo V AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Barboni, Barbara AU - Barboni B AD - Department of Bioscience and Agro-Food and Environmental Technology, Unit of Basic and Applied Biosciences, University of Teramo, Teramo, Italy. FAU - Boccaccini, Aldo R AU - Boccaccini AR AUID- ORCID: 0000-0002-7377-2955 AD - Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Erlangen, Germany. LA - eng GR - 955685/H2020 Marie Skłodowska-Curie Actions/ GR - European Union's Horizon 2020 research and innovation programme/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240918 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Polyesters) RN - 0 (poly(glycerol-sebacate)) RN - 0 (Decanoates) RN - PDC6A3C0OX (Glycerol) RN - 24980-41-4 (polycaprolactone) RN - 0 (Polymers) RN - 0 (Solvents) SB - IM MH - *Polyesters/chemistry MH - *Decanoates/chemistry MH - *Glycerol/analogs & derivatives/chemistry/pharmacology MH - *Tissue Engineering/methods MH - *Polymers/chemistry MH - *Tendons/cytology MH - *Solvents/chemistry MH - Humans MH - Tissue Scaffolds/chemistry MH - Stem Cells/cytology/drug effects/metabolism MH - Animals MH - Cells, Cultured OTO - NOTNLM OT - amniotic epithelial stem cells OT - electrospinning OT - poly(glycerol sebacate) OT - poly(ε‐caprolactone) OT - scaffolds OT - tendon tissue engineering EDAT- 2024/09/19 06:43 MHDA- 2024/12/25 06:20 CRDT- 2024/09/19 02:33 PHST- 2024/07/02 00:00 [revised] PHST- 2024/04/16 00:00 [received] PHST- 2024/08/31 00:00 [accepted] PHST- 2024/12/25 06:20 [medline] PHST- 2024/09/19 06:43 [pubmed] PHST- 2024/09/19 02:33 [entrez] AID - 10.1002/jbm.a.37794 [doi] PST - ppublish SO - J Biomed Mater Res A. 2025 Jan;113(1):e37794. doi: 10.1002/jbm.a.37794. Epub 2024 Sep 18. PMID- 21820736 OWN - NLM STAT- MEDLINE DCOM- 20111227 LR - 20220317 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 32 IP - 32 DP - 2011 Nov TI - Bioprinting of growth factors onto aligned sub-micron fibrous scaffolds for simultaneous control of cell differentiation and alignment. PG - 8097-107 LID - 10.1016/j.biomaterials.2011.07.025 [doi] AB - The capability to spatially control stem cell orientation and differentiation simultaneously using a combination of geometric cues that mimic structural aspects of native extracellular matrix (ECM) and biochemical cues such as ECM-bound growth factors (GFs) is important for understanding the organization and function of musculoskeletal tissues. Herein, oriented sub-micron fibers, which are morphologically similar to musculoskeletal ECM, were spatially patterned with GFs using an inkjet-based bioprinter to create geometric and biochemical cues that direct musculoskeletal cell alignment and differentiation in vitro in registration with fiber orientation and printed patterns, respectively. Sub-micron polystyrene fibers (diameter ~ 655 nm) were fabricated using a Spinneret-based Tunable Engineered Parameters (STEP) technique and coated with serum or fibrin. The fibers were subsequently patterned with tendon-promoting fibroblast growth factor-2 (FGF-2) or bone-promoting bone morphogenetic protein-2 (BMP-2) prior to seeding with mouse C2C12 myoblasts or C3H10T1/2 mesenchymal fibroblasts. Unprinted regions of STEP fibers showed myocyte differentiation while printed FGF-2 and BMP-2 patterns promoted tenocyte and osteoblast fates, respectively, and inhibited myocyte differentiation. Additionally, cells aligned along the fiber length. Functionalizing oriented sub-micron fibers with printed GFs provides instructive cues to spatially control cell fate and alignment to mimic native tissue organization and may have applications in regenerative medicine. CI - Copyright © 2011. Published by Elsevier Ltd. FAU - Ker, Elmer D F AU - Ker ED AD - Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA. FAU - Nain, Amrinder S AU - Nain AS FAU - Weiss, Lee E AU - Weiss LE FAU - Wang, Ji AU - Wang J FAU - Suhan, Joseph AU - Suhan J FAU - Amon, Cristina H AU - Amon CH FAU - Campbell, Phil G AU - Campbell PG LA - eng GR - R01EB004343/EB/NIBIB NIH HHS/United States GR - R01EB007369/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20110805 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Polystyrenes) RN - 0 (Scx protein, mouse) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Alkaline Phosphatase/metabolism MH - Animals MH - Basic Helix-Loop-Helix Transcription Factors/metabolism MH - Bone Morphogenetic Protein 2/pharmacology MH - Cell Differentiation/*drug effects MH - Cell Line MH - Fibroblast Growth Factor 2/pharmacology MH - Intercellular Signaling Peptides and Proteins/*pharmacology MH - Mice MH - Muscle Fibers, Skeletal/cytology/drug effects/enzymology MH - Osteoblasts/cytology/drug effects/metabolism MH - *Particle Size MH - Polystyrenes/pharmacology MH - Serum/metabolism MH - Tendons/cytology MH - Tissue Engineering/*methods MH - Tissue Scaffolds/*chemistry EDAT- 2011/08/09 06:00 MHDA- 2011/12/28 06:00 CRDT- 2011/08/09 06:00 PHST- 2011/05/31 00:00 [received] PHST- 2011/07/08 00:00 [accepted] PHST- 2011/08/09 06:00 [entrez] PHST- 2011/08/09 06:00 [pubmed] PHST- 2011/12/28 06:00 [medline] AID - S0142-9612(11)00796-4 [pii] AID - 10.1016/j.biomaterials.2011.07.025 [doi] PST - ppublish SO - Biomaterials. 2011 Nov;32(32):8097-107. doi: 10.1016/j.biomaterials.2011.07.025. Epub 2011 Aug 5. PMID- 32012741 OWN - NLM STAT- MEDLINE DCOM- 20210210 LR - 20231113 IS - 2073-4409 (Electronic) IS - 2073-4409 (Linking) VI - 9 IP - 2 DP - 2020 Jan 27 TI - Tendon Biomimetic Electrospun PLGA Fleeces Induce an Early Epithelial-Mesenchymal Transition and Tenogenic Differentiation on Amniotic Epithelial Stem Cells. LID - 10.3390/cells9020303 [doi] LID - 303 AB - Background. The design of tendon biomimetic electrospun fleece with Amniotic Epithelial Stem Cells (AECs) that have shown a high tenogenic attitude may represent an alternative strategy to overcome the unsatisfactory results of conventional treatments in tendon regeneration. Methods. In this study, we evaluated AEC-engineered electrospun poly(lactide-co-glycolide) (PLGA) fleeces with highly aligned fibers (ha-PLGA) that mimic tendon extracellular matrix, their biocompatibility, and differentiation towards the tenogenic lineage. PLGA fleeces with randomly distributed fibers (rd-PLGA) were generated as control. Results. Optimal cell infiltration and biocompatibility with both PLGA fleeces were shown. However, only ha-PLGA fleeces committed AECs towards an Epithelial-Mesenchymal Transition (EMT) after 48 h culture, inducing their cellular elongation along the fibers' axis and the upregulation of mesenchymal markers. AECs further differentiated towards tenogenic lineage as confirmed by the up-regulation of tendon-related genes and Collagen Type 1 (COL1) protein expression that, after 28 days culture, appeared extracellularly distributed along the direction of ha-PLGA fibers. Moreover, long-term co-cultures of AEC-ha-PLGA bio-hybrids with fetal tendon explants significantly accelerated of half time AEC tenogenic differentiation compared to ha-PLGA fleeces cultured only with AECs. Conclusions. The fabricated tendon biomimetic ha-PLGA fleeces induce AEC tenogenesis through an early EMT, providing a potential tendon substitute for tendon engineering research. FAU - Russo, Valentina AU - Russo V AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. FAU - El Khatib, Mohammad AU - El Khatib M AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. FAU - di Marcantonio, Lisa AU - di Marcantonio L AD - Laboratory of Bacteriology, Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "Giuseppe Caporale", 64100 Teramo, Italy. FAU - Ancora, Massimo AU - Ancora M AD - Laboratory of Molecular Biology and Genomic, Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "Giuseppe Caporale, 64100 Teramo, Italy. FAU - Wyrwa, Ralf AU - Wyrwa R AD - Department of Biomaterials, INNOVENT e. V, J-07749 Jena, Germany. FAU - Mauro, Annunziata AU - Mauro A AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. FAU - Walter, Torsten AU - Walter T AD - Department of Biomaterials, INNOVENT e. V, J-07749 Jena, Germany. FAU - Weisser, Jürgen AU - Weisser J AD - Department of Biomaterials, INNOVENT e. V, J-07749 Jena, Germany. FAU - Citeroni, Maria Rita AU - Citeroni MR AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. FAU - Lazzaro, Francesco AU - Lazzaro F AD - Research & Development Department, Assut Europe S.p.A., 67062 Magliano dei Marsi, L'Aquila, Italy. FAU - Di Federico, Marta AU - Di Federico M AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. AD - Laboratory of Molecular Biology and Genomic, Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "Giuseppe Caporale, 64100 Teramo, Italy. FAU - Berardinelli, Paolo AU - Berardinelli P AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. FAU - Cammà, Cesare AU - Cammà C AD - Laboratory of Molecular Biology and Genomic, Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "Giuseppe Caporale, 64100 Teramo, Italy. FAU - Schnabelrauch, Matthias AU - Schnabelrauch M AD - Department of Biomaterials, INNOVENT e. V, J-07749 Jena, Germany. FAU - Barboni, Barbara AU - Barboni B AD - Unit of Basic and Applied Biosciences, Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, 64100 Teramo, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200127 PL - Switzerland TA - Cells JT - Cells JID - 101600052 RN - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer) SB - IM MH - Amnion/*cytology MH - Animals MH - Biomimetic Materials/*pharmacology MH - Cell Differentiation/*drug effects MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Epithelial Cells/*cytology/drug effects/metabolism MH - Epithelial-Mesenchymal Transition/*drug effects/genetics MH - Gene Expression Regulation/drug effects MH - Polylactic Acid-Polyglycolic Acid Copolymer/*pharmacology MH - Sheep MH - Stem Cells/*cytology/drug effects/metabolism MH - Tendons/*cytology MH - *Tissue Engineering PMC - PMC7072418 OTO - NOTNLM OT - PLGA OT - aligned fibers OT - amniotic epithelial stem cells OT - biomimetic scaffold OT - electrospinning OT - epithelial-mesenchymal transition OT - tendon tissue engineering OT - tenogenic differentiation COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2020/02/06 06:00 MHDA- 2021/02/11 06:00 PMCR- 2020/02/01 CRDT- 2020/02/05 06:00 PHST- 2020/01/10 00:00 [received] PHST- 2020/01/24 00:00 [revised] PHST- 2020/01/25 00:00 [accepted] PHST- 2020/02/05 06:00 [entrez] PHST- 2020/02/06 06:00 [pubmed] PHST- 2021/02/11 06:00 [medline] PHST- 2020/02/01 00:00 [pmc-release] AID - cells9020303 [pii] AID - cells-09-00303 [pii] AID - 10.3390/cells9020303 [doi] PST - epublish SO - Cells. 2020 Jan 27;9(2):303. doi: 10.3390/cells9020303. PMID- 8864904 OWN - NLM STAT- MEDLINE DCOM- 19961226 LR - 20131121 IS - 0884-0431 (Print) IS - 0884-0431 (Linking) VI - 11 IP - 9 DP - 1996 Sep TI - Mineral anisotropy in mineralized tissues is similar among species and mineral growth occurs independently of collagen orientation in rats: results from acoustic velocity measurements. PG - 1292-301 AB - It has been reported that the mineral crystals in long bones have their c-axis aligned with the bone axis, presumably because collagen fibrils in bone also align with the bone axis. However, the predominant collagen orientation in bone often does not appear to be aligned with the mineral crystals, especially in rat primary bone. We hypothesized that mineral orientation in bone is not necessarily related to collagen orientation. An acoustic microscope was used to measure elastic constants of mineralized tissues from rat, cow, monkey, and human bone, and mineralized turkey leg tendon (MTLT). Measurements were made before and after demineralization with 10% ethylenediaminetetraacetic acid (EDTA) or decollagenization with 7% sodium hypochlorite. The elastic anisotropy ratio (AR) was defined as the ratio of the elastic coefficient in the longitudinal direction to the elastic coefficient in the transverse direction. Anisotropy ratios of mineralized tissues were not affected by formalin fixation or plastic embedding. An evaluation of tissues from the different species showed that the AR after decollagenization was not significantly different (p > 0.4, analysis of variance) among the groups, while AR after demineralization varied from 1.04 (rat bone) to 1.51 (MTLT). There was no correlation between AR after demineralization and AR after decollagenization (r = 0.13, p = 0.5). This showed that the elastic anisotropy of collagen is more variable than mineral anisotropy in bone and MTLT. Another experiment showed that mineralization of turkey leg tendon changes the elasticity of the collagen matrix, making it less anisotropic. A final, prospective experiment was performed in which tibiae of rats were subjected to mechanical loading for 16 weeks. After 12 days, new periosteal woven bone was observed on the tibiae and, after 16 weeks, this new bone was consolidated and mineralized. Mineral in the newly formed woven bone was virtually isotropic (AR = 1.07) after 12 days of loading, then became more anisotropic (AR = 1.52) after 16 weeks of mechanical loading, as the mineral density of the new bone increased. This increase in anisotropy of bone mineral occurred even though the collagen matrix was woven and had no measureable fibril orientation. We conclude that (1) collagen anisotropy and mineral anisotropy are not necessarily correlated in mineralized tissues, (2) mineralization can affect the collagen matrix elasticity of mineralized tissues, and (3) an organized mineral structure can form in the absence of an organized collagen matrix. FAU - Takano, Y AU - Takano Y AD - Department of Anatomy, Indiana University Medical Center, Indianapolis, USA. FAU - Turner, C H AU - Turner CH FAU - Burr, D B AU - Burr DB LA - eng GR - AR39708/AR/NIAMS NIH HHS/United States GR - AR40688/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - J Bone Miner Res JT - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JID - 8610640 RN - 9G34HU7RV0 (Edetic Acid) RN - DY38VHM5OD (Sodium Hypochlorite) SB - IM MH - Acoustics MH - Analysis of Variance MH - Animals MH - Anisotropy MH - Bone Density/*physiology MH - Calcification, Physiologic/physiology MH - Cattle MH - Edetic Acid/toxicity MH - Elasticity MH - Femur/*physiology MH - Humans MH - Macaca fascicularis MH - Microscopy MH - Myofibrils MH - Rats MH - Sodium Hypochlorite/toxicity MH - Sound Localization MH - Species Specificity MH - Tendons/physiology MH - Tibia/*physiology MH - Tissue Fixation MH - Weight-Bearing EDAT- 1996/09/01 00:00 MHDA- 1996/09/01 00:01 CRDT- 1996/09/01 00:00 PHST- 1996/09/01 00:00 [pubmed] PHST- 1996/09/01 00:01 [medline] PHST- 1996/09/01 00:00 [entrez] AID - 10.1002/jbmr.5650110914 [doi] PST - ppublish SO - J Bone Miner Res. 1996 Sep;11(9):1292-301. doi: 10.1002/jbmr.5650110914. PMID- 35906661 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20250728 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 13 IP - 1 DP - 2022 Jul 29 TI - Tenogenic induction of human adipose-derived stem cells by soluble tendon extracellular matrix: composition and transcriptomic analyses. PG - 380 LID - 10.1186/s13287-022-03038-0 [doi] LID - 380 AB - BACKGROUND: Tendon healing is clinically challenging largely due to its inferior regenerative capacity. We have previously prepared a soluble, DNA-free, urea-extracted bovine tendon-derived extracellular matrix (tECM) that exhibits strong pro-tenogenic bioactivity on human adipose-derived stem cells (hASCs). In this study, we aimed to elucidate the mechanism of tECM bioactivity via characterization of tECM protein composition and comparison of transcriptomic profiles of hASC cultures treated with tECM versus collagen type I (Col1) as a control ECM component. METHODS: The protein composition of tECM was characterized by SDS-PAGE, hydroxyproline assay, and proteomics analysis. To investigate tECM pro-tenogenic bioactivity and mechanism of action, differentiation of tECM-treated hASC cultures was compared to serum control medium or Col1-treated groups, as assessed via immunofluorescence for tenogenic markers and RNA Sequencing (RNA-Seq). RESULTS: Urea-extracted tECM yielded consistent protein composition, including collagens (20% w/w) and at least 17 non-collagenous proteins (< 100 kDa) based on MS analysis. Compared to current literature, tECM included key tendon ECM components that are functionally involved in tendon regeneration, as well as those that are involved in similar principal Gene Ontology (GO) functions (ECM-receptor interaction and collagen formation) and signaling pathways (ECM-receptor interaction and focal adhesion). When used as a cell culture supplement, tECM enhanced hASC proliferation and tenogenic differentiation compared to the Col1 and FBS treatment groups based on immunostaining of tenogenesis-associated markers. Furthermore, RNA-Seq analysis revealed a total of 584 genes differentially expressed among the three culture groups. Specifically, Col1-treated hASCs predominantly exhibited expression of genes and pathways related to ECM-associated processes, while tECM-treated hASCs expressed a mixture of ECM- and cell activity-associated processes, which may explain in part the enhanced proliferation and tenogenic differentiation of tECM-treated hASCs. CONCLUSIONS: Our findings showed that urea-extracted tECM contained 20% w/w collagens and is significantly enriched with other non-collagenous tendon ECM components. Compared to Col1 treatment, tECM supplementation enhanced hASC proliferation and tenogenic differentiation as well as induced distinct gene expression profiles. These findings provide insights into the potential mechanism of the pro-tenogenic bioactivity of tECM and support the development of future tECM-based approaches for tendon repair. CI - © 2022. The Author(s). FAU - Rao, Ying AU - Rao Y AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. FAU - Zhu, Chenxian AU - Zhu C AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. FAU - Suen, Hoi Ching AU - Suen HC AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. FAU - Huang, Shuting AU - Huang S AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. FAU - Liao, Jinyue AU - Liao J AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. FAU - Ker, Dai Fei Elmer AU - Ker DFE AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - Ministry of Education Key Laboratory for Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. AD - Center for Neuromusculoskeletal Restorative Medicine, Hong Kong Science Park, Sha Tin, Hong Kong, SAR, China. FAU - Tuan, Rocky S AU - Tuan RS AUID- ORCID: 0000-0001-6067-6705 AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. tuanr@cuhk.edu.hk. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. tuanr@cuhk.edu.hk. AD - Center for Neuromusculoskeletal Restorative Medicine, Hong Kong Science Park, Sha Tin, Hong Kong, SAR, China. tuanr@cuhk.edu.hk. FAU - Wang, Dan AU - Wang D AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. wangmd@cuhk.edu.hk. AD - School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. wangmd@cuhk.edu.hk. AD - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. wangmd@cuhk.edu.hk. AD - Ministry of Education Key Laboratory for Regenerative Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong, SAR, China. wangmd@cuhk.edu.hk. AD - Center for Neuromusculoskeletal Restorative Medicine, Hong Kong Science Park, Sha Tin, Hong Kong, SAR, China. wangmd@cuhk.edu.hk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220729 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - 8W8T17847W (Urea) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cattle MH - Cell Differentiation MH - Collagen/metabolism MH - Extracellular Matrix/metabolism MH - Humans MH - *Stem Cells/metabolism MH - Tendons/metabolism MH - Tissue Engineering MH - *Transcriptome MH - Urea/metabolism/pharmacology PMC - PMC9338462 OTO - NOTNLM OT - Adipose-derived stem cells OT - Bioinformatics OT - Extracellular matrix OT - Mass spectrometry OT - RNA sequencing OT - Tendon COIS- The authors declare that they have no competing interests regarding the current manuscript. EDAT- 2022/07/30 06:00 MHDA- 2022/08/03 06:00 PMCR- 2022/07/29 CRDT- 2022/07/29 23:48 PHST- 2022/01/28 00:00 [received] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/29 23:48 [entrez] PHST- 2022/07/30 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/07/29 00:00 [pmc-release] AID - 10.1186/s13287-022-03038-0 [pii] AID - 3038 [pii] AID - 10.1186/s13287-022-03038-0 [doi] PST - epublish SO - Stem Cell Res Ther. 2022 Jul 29;13(1):380. doi: 10.1186/s13287-022-03038-0. PMID- 24776566 OWN - NLM STAT- MEDLINE DCOM- 20140626 LR - 20210106 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 133 IP - 5 DP - 2014 May TI - Augmentation of tendon healing with an injectable tendon hydrogel in a rat Achilles tendon model. PG - 645e-653e LID - 10.1097/PRS.0000000000000106 [doi] AB - BACKGROUND: Many unsolved problems in plastic and hand surgery are related to poor healing of acute and chronic tendon injuries. The authors hypothesized that tendon healing could be augmented by the addition of a tendon-derived, extracellular matrix hydrogel that would guide tissue regeneration. METHODS: Both Achilles tendons of 36 Wistar rats were given full-thickness injuries approximately 5 mm long and 0.5 mm wide from the tendon insertion at the calcaneus to the midsubstance. The hydrogel was injected into the injury site of one leg and compared with control saline in the other. The ultimate failure load, ultimate tensile stress, and stiffness were evaluated at 2, 4, and 8 weeks. Tendon cross-sections underwent histologic analysis (hematoxylin and eosin and picrosirius red) after the animals were killed. Statistical analysis of biomechanical data was performed using a paired t test. RESULTS: There was no significant difference in strength between gel and saline injections in ultimate failure load (p = 0.15), ultimate tensile stress (p = 0.42), or stiffness (p = 0.76) at 2 weeks. However, there was a significant difference in ultimate failure load (74.8 ± 11.6 N versus 58.4 ± 14.2 N; p = 0.02) at 4 weeks. The difference in ultimate tensile stress (p = 0.63) and stiffness (p = 0.08) remained insignificant. By 8 weeks, there was no significant difference in strength in ultimate failure load (p = 0.15), ultimate tensile stress (p = 0.39), or stiffness (p = 0.75). CONCLUSIONS: Treatment with the tendon hydrogel significantly increases the ultimate failure load of tendons at the critical 4-week time point, and is a promising method for augmentation of tendon healing. FAU - Kim, Maxwell Y AU - Kim MY AD - Stanford and Palo Alto, Calif. From the Division of Plastic and Reconstructive Surgery, Stanford University Medical Center; and the Section of Plastic Surgery, VA Palo Alto Health Care System. FAU - Farnebo, Simon AU - Farnebo S FAU - Woon, Colin Y L AU - Woon CYL FAU - Schmitt, Taliah AU - Schmitt T FAU - Pham, Hung AU - Pham H FAU - Chang, James AU - Chang J LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) SB - IM MH - Achilles Tendon/*drug effects/*physiology MH - Animals MH - Biomechanical Phenomena/drug effects MH - Cadaver MH - Calcaneus/physiology MH - Disease Models, Animal MH - Extracellular Matrix MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy/*physiopathology MH - Tensile Strength/drug effects/physiology MH - Weight-Bearing/physiology MH - Wound Healing/*drug effects EDAT- 2014/04/30 06:00 MHDA- 2014/06/27 06:00 CRDT- 2014/04/30 06:00 PHST- 2014/04/30 06:00 [entrez] PHST- 2014/04/30 06:00 [pubmed] PHST- 2014/06/27 06:00 [medline] AID - 00006534-201405000-00014 [pii] AID - 10.1097/PRS.0000000000000106 [doi] PST - ppublish SO - Plast Reconstr Surg. 2014 May;133(5):645e-653e. doi: 10.1097/PRS.0000000000000106. PMID- 30066401 OWN - NLM STAT- MEDLINE DCOM- 20190517 LR - 20190517 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 36 IP - 12 DP - 2018 Dec TI - Hydrogen peroxide induced tendinopathic changes in a rat model of patellar tendon injury. PG - 3268-3274 LID - 10.1002/jor.24119 [doi] AB - Tendinopathy includes cases with chronic tendon pain and spontaneous tendon ruptures, which is putatively resulted from failed tendon healing. Overuse is a major risk factor of tendinopathy, which can impose mechanical and oxidative stress to tendons. Previous studies investigated the influences of mechanical stress, but the direct impact of oxidative stress on tendon healing remains unclear. We hypothesized that imposed oxidative stress can impair tendon healing and lead to tendinopathic changes. Thirty-nine rats were operated for patellar tendon window injury. From weeks 3-5 post-operation, the rats received three weekly subcutaneous injections of saline, 50 or 500 μM H(2) O(2) (n = 13) over patellar tendon. Gait analysis for pain assessment and 3D ultrasound imaging for detection of tendinopathic changes were performed at pre-injury and 6-week post-operation. At week 6, knee specimens were harvested for histology or tensile mechanical test. Elastic modulus of the healing patellar tendons was significantly lower in 50 μM but not 500 μM H(2) O(2) group, while ultimate mechanical stress was not significantly different across groups. Similarly, only the 50 μM H(2) O(2) group exhibited pain-associated gait asymmetry. Significant tendon swelling with increased tendon volume was observed in the 50 μM H(2) O(2) group. There were hypoechogenic changes in the tendon wound, but there was no significant difference in percentage vascularity. H(2) O(2) impaired tendon healing and elicited tendinopathic changes, with respect to pain and structural abnormalities. Oxidative stress plays a role in the failed tendon healing of tendinopathies, and H(2) O(2) -induced failed tendon healing may serve as a good animal model to study tendinopathy. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:3268-3274, 2018. CI - © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Fu, Sai-Chuen AU - Fu SC AUID- ORCID: 0000-0001-5865-6801 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Yeung, Man-Yi AU - Yeung MY AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Rolf, Christer G AU - Rolf CG AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Department of Orthopaedic Surgery, Huddinge University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden. FAU - Yung, Patrick Shu-Hang AU - Yung PS AUID- ORCID: 0000-0002-7214-5503 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Chan, Kai-Ming AU - Chan KM AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Hung, Leung-Kim AU - Hung LK AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China. AD - Lui Che Woo Institute of Innovative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. LA - eng GR - 464912/Research Grants Council, University Grants Committee (Hong Kong SAR)/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180822 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Gait Analysis MH - Hydrogen Peroxide/*pharmacology MH - Imaging, Three-Dimensional MH - Male MH - Oxidative Stress MH - Patella/*injuries MH - Rats MH - Rats, Sprague-Dawley MH - Tendinopathy/*etiology/pathology/physiopathology MH - Tendon Injuries/pathology/*physiopathology MH - Ultrasonography MH - Wound Healing OTO - NOTNLM OT - animal model OT - hydrogen peroxide OT - oxidative stress OT - tendinopathy OT - tendon healing EDAT- 2018/08/02 06:00 MHDA- 2019/05/18 06:00 CRDT- 2018/08/02 06:00 PHST- 2018/01/10 00:00 [received] PHST- 2018/07/26 00:00 [accepted] PHST- 2018/08/02 06:00 [pubmed] PHST- 2019/05/18 06:00 [medline] PHST- 2018/08/02 06:00 [entrez] AID - 10.1002/jor.24119 [doi] PST - ppublish SO - J Orthop Res. 2018 Dec;36(12):3268-3274. doi: 10.1002/jor.24119. Epub 2018 Aug 22. PMID- 2127590 OWN - NLM STAT- MEDLINE DCOM- 19910425 LR - 20190515 IS - 0341-2695 (Print) IS - 0341-2695 (Linking) VI - 14 IP - 4 DP - 1990 TI - [Effect of a calcium inhibitor, verapamil, on the development of heterotopic ossifications. An experimental study in rats]. PG - 415-21 AB - After division of the tendo achilles in rats heterotopic bone forms in the muscle and in the tendon stumps. Tenotomy was performed in 26 male rats. Thirteen received Verapamil (36 mm/Kg) for six days per week for five months, and the remainder were not given this drug. The onset of heterotopic ossification was monitored by monthly x-rays. After five months the animals were killed and the sectioned tendons examined microscopically. The radiographs had shown that the amount of ossification was less in rats treated with Verapamil. This was confirmed at microscopy, but examination of the sections under polarised light showed that the ratio of lamellar to woven bone was the same in the two groups. Verapamil appeared to reduce the amount of heterotopic bone formation but did not influence the substitution of woven by lamellar bone. FAU - Duriez, J AU - Duriez J AD - Institut de Recherche sur les Maladies du Squelette, Institut Calot, Berck sur Mer, France. FAU - Flautre, B AU - Flautre B FAU - Blary, M C AU - Blary MC FAU - Duriez, R AU - Duriez R LA - fre PT - Journal Article TT - Effet d'un inhibiteur calcique, le vérapamil, sur le développement des ossifications hétérotopiques. Etude expérimentale chez le rat. PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - CJ0O37KU29 (Verapamil) SB - IM MH - Achilles Tendon/diagnostic imaging/drug effects/*surgery MH - Animals MH - Hindlimb/diagnostic imaging MH - Male MH - Microscopy, Polarization MH - Ossification, Heterotopic/diagnostic imaging/*prevention & control MH - Radiography MH - Rats MH - Rats, Inbred Strains MH - Verapamil/*pharmacology EDAT- 1990/01/01 00:00 MHDA- 1990/01/01 00:01 CRDT- 1990/01/01 00:00 PHST- 1990/01/01 00:00 [pubmed] PHST- 1990/01/01 00:01 [medline] PHST- 1990/01/01 00:00 [entrez] AID - 10.1007/BF00182655 [doi] PST - ppublish SO - Int Orthop. 1990;14(4):415-21. doi: 10.1007/BF00182655. PMID- 6425113 OWN - NLM STAT- MEDLINE DCOM- 19840606 LR - 20190814 IS - 0016-6480 (Print) IS - 0016-6480 (Linking) VI - 53 IP - 1 DP - 1984 Jan TI - Changes in morphometric parameters and the characteristics of collagen following thyroxine and thiourea treatments in young male garden lizards. PG - 100-6 AB - Administration of both thyroxine (1 microgram/g body wt) and thiourea (0.5 mg/10 g body wt) to young male garden lizards for a period of 2 weeks led to changes in morphometric/biochemical parameters. Percentages of increase in body weight and snout-to-vent length of thyroxine-treated lizards during this period were significantly lower than the percentages of increase observed in control lizards. Thiourea-induced inhibition of increase in body weight was marginal but not significant statistically. The total collagen content of tendons decreased upon thyroxine treatment and increased following thiourea administration. Thyroxine treatment led to an increase in salt solubility of bone and skin collagens and thiourea showed a reverse effect. On the other hand, the acid solubility of tendon collagen increased after thyroxine administration and decreased following thiourea treatment. FAU - Brahma, K C AU - Brahma KC FAU - Patnaik, B K AU - Patnaik BK LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Gen Comp Endocrinol JT - General and comparative endocrinology JID - 0370735 RN - 9007-34-5 (Collagen) RN - GYV9AM2QAG (Thiourea) RN - Q51BO43MG4 (Thyroxine) SB - IM MH - Aging/drug effects MH - Animals MH - Body Weight/drug effects MH - Collagen/analysis/*metabolism MH - Lizards/*growth & development MH - Male MH - Solubility MH - Thiourea/*pharmacology MH - Thyroxine/*pharmacology/physiology EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] AID - 0016-6480(84)90229-6 [pii] AID - 10.1016/0016-6480(84)90229-6 [doi] PST - ppublish SO - Gen Comp Endocrinol. 1984 Jan;53(1):100-6. doi: 10.1016/0016-6480(84)90229-6. PMID- 6308512 OWN - NLM STAT- MEDLINE DCOM- 19830923 LR - 20190712 IS - 0306-4522 (Print) IS - 0306-4522 (Linking) VI - 9 IP - 2 DP - 1983 Jun TI - Changes in the distribution of the extrajunctional acetylcholine sensitivity along muscle fibers during development and following cordotomy in the rat. PG - 437-43 AB - Acetylcholine sensitivity along the entire length of muscle fibers was studied during postnatal development and following transection of the spinal cord in the rat. During postnatal development, the acetylcholine sensitivity in the soleus and extensor digitorum longus muscles decreased faster at the juxtajunctional region than near the tendons. Thus, the adult pattern of low acetylcholine sensitivity at the extrajunctional membrane was achieved through the uneven change of acetylcholine sensitivity during normal development. This uneven pattern of the sensitivity was found to appear in both muscles in older rats after cordotomy, and is in striking contrast to the uniform pattern in denervated muscles. The uneven appearance of the sensitivity could not be explained by changes in input resistance or resting membrane potential. In the soleus muscle whose nerve was implanted at an ectopic site, the lowest sensitivity also appeared at the ectopic juxtajunctional region after cordotomy. These results indicate that the motor nerve exerts regionally different effects along a fiber with respect to the appearance of acetylcholine receptors. FAU - Yoshioka, K AU - Yoshioka K FAU - Miyata, Y AU - Miyata Y LA - eng PT - Journal Article PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 0 (Ion Channels) RN - 0 (Receptors, Cholinergic) RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Age Factors MH - Animals MH - Female MH - Ion Channels/drug effects MH - Male MH - Membrane Potentials/drug effects MH - Motor Endplate/drug effects MH - Muscles/*innervation MH - Nerve Regeneration/drug effects MH - Neuromuscular Junction/*drug effects MH - Rats MH - Rats, Inbred Strains MH - Receptors, Cholinergic/drug effects MH - Spinal Cord/*drug effects EDAT- 1983/06/01 00:00 MHDA- 1983/06/01 00:01 CRDT- 1983/06/01 00:00 PHST- 1983/06/01 00:00 [pubmed] PHST- 1983/06/01 00:01 [medline] PHST- 1983/06/01 00:00 [entrez] AID - 0306-4522(83)90306-8 [pii] AID - 10.1016/0306-4522(83)90306-8 [doi] PST - ppublish SO - Neuroscience. 1983 Jun;9(2):437-43. doi: 10.1016/0306-4522(83)90306-8. PMID- 25151131 OWN - NLM STAT- MEDLINE DCOM- 20151223 LR - 20181202 IS - 1878-1632 (Electronic) IS - 1529-9430 (Linking) VI - 15 IP - 6 DP - 2015 Jun 1 TI - Baclofen or nNOS inhibitor affect molecular and behavioral alterations evoked by traumatic spinal cord injury in rat spinal cord. PG - 1366-78 LID - S1529-9430(14)00845-6 [pii] LID - 10.1016/j.spinee.2014.08.013 [doi] AB - BACKGROUND CONTEXT: The loss of descending control after spinal cord injury (SCI) and incessant stimulation of Ia monosynaptic pathway, carrying proprioceptive impulses from the muscles and tendons into the spinal cord, evoke exaggerated α-motoneuron activity leading to increased reflex response. Previous results from our laboratory have shown that Ia monosynaptic pathway is nitrergic. PURPOSE: The aim of this study was to find out whether nitric oxide produced by neuronal nitric oxide synthase (nNOS) plays a role in setting the excitability of α-motoneurons after thoracic spinal cord transection. STUDY DESIGN: We tested the hypothesis that the inhibition of nNOS in α-motoneurons after SCI could have a neuroprotective effect on reflex response. METHODS: Rats underwent spinal cord transection at Th10 level followed by 7, 10, and 14 days of survival. The animals were treated with Baclofen (a gamma aminobutyric acid B receptor agonist, 3 μg/two times per day/intrathecally) applied for 3 days from the seventh day after transection; N-nitro-l-arginine (NNLA) (nNOS blocator) applied for the first 3 days after injury (20 mg/kg per day, intramuscularly); NNLA and Baclofen; or NNLA (60 mg/kg/day, single dose) applied on the 10th day after transection. We detected the changes in the level of nNOS protein, nNOS messenger RNA, and nNOS immunoreactivity. To investigate the reflex response to heat-induced stimulus, tail-flick test was monitored in treated animals up to 16 days after SCI. RESULTS: Our data indicate that Baclofen therapy is more effective than the combined treatment with NNLA and Baclofen therapy. The single dose of NNLA (60 mg/kg) applied on the 10th day after SCI or Baclofen therapy reduced nNOS expression in α-motoneurons and suppressed symptoms of increased reflex activity. CONCLUSIONS: The results clearly show that increased nNOS expression in α-motoneurons after SCI may be pharmacologically modifiable with Baclofen or bolus dose of nNOS blocker. CI - Copyright © 2015. Published by Elsevier Inc. FAU - Kisucká, Alexandra AU - Kisucká A AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia. FAU - Hricová, Ľudmila AU - Hricová Ľ AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia. FAU - Pavel, Jaroslav AU - Pavel J AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia. FAU - Strosznajder, Joanna B AU - Strosznajder JB AD - Department of Cellular Signaling, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego Street, 02-106 Warsaw, Poland. FAU - Chalimoniuk, Malgorzata AU - Chalimoniuk M AD - Department of Cellular Signaling, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego Street, 02-106 Warsaw, Poland. FAU - Langfort, Jozef AU - Langfort J AD - Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego Street, 02-106 Warsaw, Poland. FAU - Gálik, Ján AU - Gálik J AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia. FAU - Maršala, Martin AU - Maršala M AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia; Anesthesiology Research Laboratory, University of California-San Diego, La Jolla, CA, USA. FAU - Radoňak, Jozef AU - Radoňak J AD - First Department of Surgery, University Hospital and Safarik University, SNP Street 1, Košice, Slovakia. FAU - Lukáčová, Nadežda AU - Lukáčová N AD - Department of Neurodegeneration, Plasticity and Repair, Institute of Neurobiology, Slovak Academy of Sciences, Šoltésovej 4, Košice 040 01, Slovakia. Electronic address: lukacova@saske.sk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140820 PL - United States TA - Spine J JT - The spine journal : official journal of the North American Spine Society JID - 101130732 RN - 0 (Enzyme Inhibitors) RN - 0 (GABA-B Receptor Agonists) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type I) RN - H789N3FKE8 (Baclofen) SB - IM MH - Animals MH - Baclofen/*pharmacology MH - Enzyme Inhibitors/*pharmacology MH - GABA-B Receptor Agonists/*pharmacology MH - Hot Temperature MH - Male MH - Motor Neurons/*drug effects/metabolism MH - Nitric Oxide Synthase Type I/*antagonists & inhibitors/metabolism MH - Pain Perception/*drug effects/physiology MH - Rats MH - Rats, Wistar MH - Reaction Time/drug effects/physiology MH - Reflex/drug effects/physiology MH - Spinal Cord Injuries/*metabolism/physiopathology OTO - NOTNLM OT - Baclofen OT - NNLA OT - Neuronal nitric oxide synthase OT - Rat OT - Reflex response OT - Spinal cord injury OT - Tail-flick text OT - α-Motoneurons EDAT- 2014/08/26 06:00 MHDA- 2015/12/24 06:00 CRDT- 2014/08/25 06:00 PHST- 2013/10/28 00:00 [received] PHST- 2014/08/01 00:00 [revised] PHST- 2014/08/13 00:00 [accepted] PHST- 2014/08/25 06:00 [entrez] PHST- 2014/08/26 06:00 [pubmed] PHST- 2015/12/24 06:00 [medline] AID - S1529-9430(14)00845-6 [pii] AID - 10.1016/j.spinee.2014.08.013 [doi] PST - ppublish SO - Spine J. 2015 Jun 1;15(6):1366-78. doi: 10.1016/j.spinee.2014.08.013. Epub 2014 Aug 20. PMID- 22703182 OWN - NLM STAT- MEDLINE DCOM- 20130416 LR - 20211021 IS - 1937-335X (Electronic) IS - 1937-3341 (Print) IS - 1937-3341 (Linking) VI - 18 IP - 21-22 DP - 2012 Nov TI - Modulation of mesenchymal stem cell shape in enzyme-sensitive hydrogels is decoupled from upregulation of fibroblast markers under cyclic tension. PG - 2365-75 LID - 10.1089/ten.TEA.2011.0727 [doi] AB - Our laboratory has developed a tensile culture bioreactor as a system for understanding mesenchymal stem cell (MSC) differentiation toward a tendon/ligament fibroblast phenotype in response to cyclic tensile strain. In this study, we investigated whether increased degradability of the biomaterial carrier would induce changes in MSC morphology and subsequent upregulation of tendon/fibroblast markers under tensile strain. Degradability of a synthetic poly(ethylene glycol) hydrogel was introduced by incorporating either fast- or slow-degrading matrix metalloproteinase (MMP)-sensitive peptide sequences into the polymer backbone. Although a decline in cellularity was observed over culture in all sample groups, at 14 days, MSCs were significantly more spread in fast-cleaving gels (84%±8%) compared with slow-cleaving gels (59%±4%). Cyclic tensile strain upregulated tendon/ligament fibroblast-related genes, such as collagen III (3.8-fold vs. 2.1-fold in fast-degrading gels) and tenascin-C (2.5-fold vs. 1.7-fold in fast-degrading gels). However, few differences were observed in gene expression between different gel types. Immunostaining demonstrated increased collagen III deposition in dynamically strained gels at day 14, as well as increased collagen I and tenascin-C deposition at day 14 in all groups. Results suggest that cell spreading may not be a major factor controlling MSC response to cyclic strain in this system over 14 days. However, these findings provide key parameters for the design of future biomaterial carriers and strain regimens to prime stem cells to a tendon/ligament phenotype prior to release and use in vivo. FAU - Yang, Peter J AU - Yang PJ AD - Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech/Emory University, Atlanta, Georgia 30332, USA. FAU - Levenston, Marc E AU - Levenston ME FAU - Temenoff, Johnna S AU - Temenoff JS LA - eng GR - P40RR017447/RR/NCRR NIH HHS/United States GR - R21 EB8918/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20120725 PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 0 (Biomarkers) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9007-49-2 (DNA) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Biomarkers/metabolism MH - Cell Count MH - Cell Differentiation/drug effects/genetics MH - Cell Shape/*drug effects MH - DNA/metabolism MH - Fibroblasts/cytology/drug effects/*metabolism MH - Gene Expression Regulation/drug effects MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry/*pharmacology MH - Imaging, Three-Dimensional MH - Matrix Metalloproteinases/*pharmacology MH - Mesenchymal Stem Cells/*cytology/metabolism MH - Microscopy, Confocal MH - Polyethylene Glycols/chemical synthesis MH - *Stress, Mechanical MH - Tendons/cytology MH - Up-Regulation/*drug effects PMC - PMC3482850 EDAT- 2012/06/19 06:00 MHDA- 2013/04/17 06:00 PMCR- 2013/11/01 CRDT- 2012/06/19 06:00 PHST- 2012/06/19 06:00 [entrez] PHST- 2012/06/19 06:00 [pubmed] PHST- 2013/04/17 06:00 [medline] PHST- 2013/11/01 00:00 [pmc-release] AID - 10.1089/ten.tea.2011.0727 [pii] AID - 10.1089/ten.TEA.2011.0727 [doi] PST - ppublish SO - Tissue Eng Part A. 2012 Nov;18(21-22):2365-75. doi: 10.1089/ten.TEA.2011.0727. Epub 2012 Jul 25. PMID- 20633279 OWN - NLM STAT- MEDLINE DCOM- 20100923 LR - 20211020 IS - 1744-8069 (Electronic) IS - 1744-8069 (Linking) VI - 6 DP - 2010 Jul 15 TI - Long lasting pain hypersensitivity following ligation of the tendon of the masseter muscle in rats: a model of myogenic orofacial pain. PG - 40 LID - 10.1186/1744-8069-6-40 [doi] AB - BACKGROUND: A major subgroup of patients with temporomandibular joint (TMJ) disorders have masticatory muscle hypersensitivity. To study myofacial temporomandibular pain, a number of preclinical models have been developed to induce myogenic pain of the masseter muscle, one of the four muscles involved in mastication. The currently used models, however, generate pain that decreases over time and only lasts from hours to weeks and hence are not suitable for studying chronicity of the myogenic pain in TMJ disorders. Here we report a model of constant myogenic orofacial pain that lasts for months. RESULTS: The model involves unilateral ligation of the tendon of the anterior superficial part of the rat masseter muscle (TASM). The ligation of the TASM was achieved with two chromic gut (4.0) ligatures via an intraoral approach. Nocifensive behavior of the rat was assessed by probing the skin site above the TASM with a series of von Frey filaments. The response frequencies were determined and an EF50 value, defined as the von Frey filament force that produces a 50% response frequency, was derived and used as a measure of mechanical sensitivity. Following TASM ligation, the EF50 of the injured side was significantly reduced and maintained throughout the 8-week observation period, suggesting the presence of mechanical hyperalgesia/allodynia. In sham-operated rats, the EF50 of the injured side was transiently reduced for about a week, likely due to injury produced by the surgery. Somatotopically relevant Fos protein expression was indentified in the subnucleus caudalis of the spinal trigeminal sensory complex. In the same region, persistent upregulation of NMDA receptor NR1 phosphorylation and protein expression and increased expression of glial markers glial fibrillary acidic protein (astroglia) and CD11b (microglia) were found. Morphine (0.4-8 mg/kg, s.c.) and duloxetine (0.4-20 mg/kg, i.p.), a selective serotonin-norepinephrine reuptake inhibitor, produced dose-dependent attenuation of hyperalgesia. CONCLUSIONS: Ligation injury of the TASM in rats led to long-lasting and constant mechanical hypersensitivity of myogenic origin. The model will be particularly useful in studying the chronicity of myogenic pain TMJ disorders. The model can also be adapted to other regions of the body for studying pathology of painful tendinopathy seen in sports injury, muscle overuse, and rheumatoid arthritis. FAU - Guo, Wei AU - Guo W AD - Department of Neural and Pain Sciences, Dental School & Program in Neuroscience, University of Maryland, Baltimore, MD 21201, USA. FAU - Wang, Hu AU - Wang H FAU - Zou, Shiping AU - Zou S FAU - Wei, Feng AU - Wei F FAU - Dubner, Ronald AU - Dubner R FAU - Ren, Ke AU - Ren K LA - eng GR - NS059028/NS/NINDS NIH HHS/United States GR - T32 DE007309/DE/NIDCR NIH HHS/United States GR - R01 DE011964/DE/NIDCR NIH HHS/United States GR - DE018573/DE/NIDCR NIH HHS/United States GR - DE11964/DE/NIDCR NIH HHS/United States GR - NS060735/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20100715 PL - United States TA - Mol Pain JT - Molecular pain JID - 101242662 RN - 0 (Adrenergic Uptake Inhibitors) RN - 0 (Analgesics) RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 0 (Thiophenes) RN - 9044SC542W (Duloxetine Hydrochloride) SB - IM MH - Adrenergic Uptake Inhibitors/pharmacology MH - Analgesics/pharmacology MH - Animals MH - Disease Models, Animal MH - Duloxetine Hydrochloride MH - Facial Pain/etiology/*physiopathology MH - Hyperalgesia/etiology/*physiopathology MH - Ligation MH - Male MH - Masseter Muscle/*physiopathology MH - Neuroglia/physiology MH - Rats MH - Rats, Sprague-Dawley MH - Receptors, N-Methyl-D-Aspartate/agonists MH - Tendons/*physiopathology MH - Thiophenes/pharmacology MH - Trigeminal Nucleus, Spinal/physiopathology PMC - PMC2914030 EDAT- 2010/07/17 06:00 MHDA- 2010/09/24 06:00 PMCR- 2010/07/15 CRDT- 2010/07/17 06:00 PHST- 2010/05/06 00:00 [received] PHST- 2010/07/15 00:00 [accepted] PHST- 2010/07/17 06:00 [entrez] PHST- 2010/07/17 06:00 [pubmed] PHST- 2010/09/24 06:00 [medline] PHST- 2010/07/15 00:00 [pmc-release] AID - 1744-8069-6-40 [pii] AID - 10.1186/1744-8069-6-40 [doi] PST - epublish SO - Mol Pain. 2010 Jul 15;6:40. doi: 10.1186/1744-8069-6-40. PMID- 11901389 OWN - NLM STAT- MEDLINE DCOM- 20020912 LR - 20190901 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 27 IP - 2 DP - 2002 Mar TI - Chondroitin sulfate-coated polyhydroxyethyl methacrylate membrane prevents adhesion in full-thickness tendon tears of rabbits. PG - 293-306 AB - Polyhydroxyethyl methacrylate (pHEMA) membranes coated on one side with chondroitin sulfate (CS) were used to block adhesion physically and to reduce friction between healing flexor tendons and the surrounding tissue in rabbit forepaws after surgical repair. Digits with pHEMA-only, standard tendon sheath repair, and with no sheath repair were the controls. Over 12 weeks the CS-coated membranes were evaluated for joint flexion, adhesion limitation, and tendon healing progress. The membranes initially allowed for better flexion (ie, for 6 weeks), but their relative superior effectiveness faded afterward. Histology showed that adhesions were less severe and healing was better in the CS-pHEMA membranes at 3 and 6 weeks. If further studies determine precise amounts or thicknesses of CS coats that will maximize its healing properties, CS-pHEMA should prove useful in clinical settings in which restoration of tendon sheath integrity with a minimum of adhesions is not possible. FAU - Güdemez, Eftal AU - Güdemez E AD - Department of Orthopaedic Surgery and Traumatology, Kirikkale University School of Medicine, Kirikkale, Turkey. FAU - Ekşioğlu, Fatih AU - Ekşioğlu F FAU - Korkusuz, Petek AU - Korkusuz P FAU - Aşan, Esin AU - Aşan E FAU - Gürsel, Ihsan AU - Gürsel I FAU - Hasirci, Vasif AU - Hasirci V LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Biocompatible Materials) RN - 0 (Drug Combinations) RN - 25249-16-5 (Polyhydroxyethyl Methacrylate) RN - 9007-28-7 (Chondroitin Sulfates) SB - IM MH - Animals MH - Biocompatible Materials/pharmacology MH - Chondroitin Sulfates/*pharmacology MH - Disease Models, Animal MH - Drug Combinations MH - Polyhydroxyethyl Methacrylate/*pharmacology MH - Rabbits MH - Range of Motion, Articular MH - Tendon Injuries/*pathology/physiopathology/*surgery MH - Time Factors MH - Tissue Adhesions/etiology/prevention & control MH - Wound Healing/*drug effects EDAT- 2002/03/20 10:00 MHDA- 2002/09/13 10:01 CRDT- 2002/03/20 10:00 PHST- 2002/03/20 10:00 [pubmed] PHST- 2002/09/13 10:01 [medline] PHST- 2002/03/20 10:00 [entrez] AID - S0363502302990441 [pii] AID - 10.1053/jhsu.2002.31161 [doi] PST - ppublish SO - J Hand Surg Am. 2002 Mar;27(2):293-306. doi: 10.1053/jhsu.2002.31161. PMID- 1206569 OWN - NLM STAT- MEDLINE DCOM- 19760320 LR - 20220309 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 252 IP - 3 DP - 1975 Nov TI - Further studies on the control of ACh sensitivity by muscle activity in the rat. PG - 603-26 AB - 1. Denervated rat soleus muscles were stimulated directly through chronically implanted electrodes and the influence of different amounts and patterns of stimuli on the acetylcholine (ACh) sensitivity of the muscle was studied. The number of stimuli was varied by giving similar trains of stimuli (10 Hz for 10 sec) at different intervals (0 to 12 hr). The pattern of stimulation was varied by giving different trains of stimuli (100 Hz for 1 sec, 10 Hz for 10 sec and 1 Hz continuously) as the same average frequency of stimulation (1 Hz). 2. Stimulation usually started 5 days after the denervation when ACh hypersensitivity was fully developed. Most stimulation procedures reduced extrajunctional ACh sensitivity to normal or below normal values within 5-21 days, and these levels were maintained on prolonged stimulation. 3. The rate at which ACh hypersensitivity disappeared increased with increasing amount and frequency of stimulation. However, as few as 100 stimuli given every 5-5 hr for 3 weeks caused a tenfold reduction of sensitivity. 4. The stimulation had little or no effect on the ACh sensitivity at the end plate. Along the rest of the fibre the sensitivity was reduced at approximately the same rate except near the tendons where it appeared to fall more slowly in some fibres. 5. The stimulation restored the resting membrane potential of the denervated fibres to normal. FAU - Lomo, T AU - Lomo T FAU - Westgaard, R H AU - Westgaard RH LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Animals MH - Dose-Response Relationship, Drug MH - Electric Stimulation MH - Male MH - Membrane Potentials MH - *Muscle Contraction MH - Muscle Denervation MH - Muscles/*drug effects/physiology MH - Neuromuscular Junction/physiology MH - Rats MH - Time Factors PMC - PMC1348486 OID - NASA: 76097222 EDAT- 1975/11/01 00:00 MHDA- 1975/11/01 00:01 PMCR- 1976/11/01 CRDT- 1975/11/01 00:00 PHST- 1975/11/01 00:00 [pubmed] PHST- 1975/11/01 00:01 [medline] PHST- 1975/11/01 00:00 [entrez] PHST- 1976/11/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1975.sp011161 [doi] PST - ppublish SO - J Physiol. 1975 Nov;252(3):603-26. doi: 10.1113/jphysiol.1975.sp011161. PMID- 4336524 OWN - NLM STAT- MEDLINE DCOM- 19720628 LR - 20220316 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 221 IP - 2 DP - 1972 Mar TI - Control of ACh sensitivity by muscle activity in the rat. PG - 493-513 AB - 1. Rat soleus and extensor digitorum longus (EDL) muscles were examined following complete blockade of sciatic nerve impulses with anaesthetics or diphtheria toxin for periods up to 14 days.2. Muscles showed atrophy equivalent to that seen after similar periods of denervation.3. Nerve blockade appeared to have little or no effect on neuromuscular transmission when tested by stimulation beyond the block. Normal spontaneous miniature end-plate potentials were present.4. Nerve impulse blockade caused the entire muscle membrane to become sensitive to iontophoretically applied acetylcholine.5. The increase in sensitivity in soleus could be prevented by chronic nerve stimulation distal to the region of block.6. Tenotomy, of 5-12 days duration, which produced atrophy, had no effect on the sensitivity of soleus to acetylcholine.7. Chronic direct stimulation of denervated soleus or EDL muscles could prevent the usual denervation supersensitivity, or cause it to decline towards normal once it had appeared. However, the sensitivity of the end-plate region remained normal. FAU - Lomo, T AU - Lomo T FAU - Rosenthal, J AU - Rosenthal J LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - N9YNS0M02X (Acetylcholine) SB - IM MH - Acetylcholine/*pharmacology MH - Action Potentials MH - Animals MH - Axons/anatomy & histology MH - Biometry MH - Cell Membrane/drug effects MH - Electric Stimulation MH - Membrane Potentials MH - Microscopy, Electron MH - Muscle Contraction MH - *Muscle Denervation MH - Muscles/anatomy & histology/drug effects/innervation/*physiology MH - Muscular Atrophy/pathology MH - Nerve Fibers, Myelinated/anatomy & histology MH - Rats MH - Synapses/physiology MH - Synaptic Transmission MH - Tendons PMC - PMC1331346 OID - NASA: 72166248 EDAT- 1972/03/01 00:00 MHDA- 1972/03/01 00:01 PMCR- 1973/03/01 CRDT- 1972/03/01 00:00 PHST- 1972/03/01 00:00 [pubmed] PHST- 1972/03/01 00:01 [medline] PHST- 1972/03/01 00:00 [entrez] PHST- 1973/03/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1972.sp009764 [doi] PST - ppublish SO - J Physiol. 1972 Mar;221(2):493-513. doi: 10.1113/jphysiol.1972.sp009764. PMID- 25898827 OWN - NLM STAT- MEDLINE DCOM- 20160828 LR - 20181113 IS - 1543-706X (Electronic) IS - 1071-2690 (Linking) VI - 51 IP - 9 DP - 2015 Oct TI - FAK activity is required for HGF to suppress TGF-β1-induced cellular proliferation. PG - 941-9 LID - 10.1007/s11626-015-9914-y [doi] AB - Due to the complex nature of the tendon architecture, the regeneration of these tissues results in the formation of scars. As a direct result of scar formation, the ability of the tendon tissues to function is impaired and often results in further damage that has been afflicted to the tendon architecture. The growth and proliferation of tendon fibroblasts involve a complex network of signalling molecules. To understand and aid in the proper repair of this complex tissue network, a more in-depth understanding is required in the events that induce the growth of tendon cells. Several studies have shown the apoptotic mechanisms induced by the mitogen, hepatocyte growth factor, in multiple biological and pathological systems. In our recent research, we have described a mechanism where hepatocyte growth factor (HGF) is able to inhibit the proliferative effects of transforming growth factor-β1 (TGF-β1) and induce apoptosis in rat tendon fibroblasts. Transforming growth factor-β1 is able to induce the proliferation of fibroblast cells by increasing both the gene expression and protein levels of α-smooth muscle actin (α-SMA) and c-MET. We have also shown that inhibition of extracellular signal-regulated kinase 1/2 does not block hepatocyte growth factor-induced growth arrest. However, we have shown that blocking the activity of focal adhesion kinase can prevent the growth inhibition ability of hepatocyte growth factor in tendon fibroblasts. Collectively, our studies show growth inhibitory pathway in tendon fibroblasts induced by hepatocyte growth factor and mediated focal adhesion kinase. FAU - Zhao, Zheng AU - Zhao Z AD - Pediatric Orthopedics Unit, First Affiliated Hospital of Harbin Medical University, 23 Youzheng Street, Harbin, 150001, China. FAU - Sun, Yu AU - Sun Y AD - Pediatric Orthopedics Unit, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. FAU - Yang, Sulong AU - Yang S AD - Pediatric Orthopedics Unit, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. FAU - Cui, Qingbo AU - Cui Q AD - Pediatric Orthopedics Unit, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. FAU - Li, Zhaozhu AU - Li Z AD - Pediatric Orthopedics Unit, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China. zhaozhu247@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150422 PL - Germany TA - In Vitro Cell Dev Biol Anim JT - In vitro cellular & developmental biology. Animal JID - 9418515 RN - 0 (6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one) RN - 0 (Actins) RN - 0 (Quinolones) RN - 0 (Sulfones) RN - 0 (Transforming Growth Factor beta1) RN - 0 (smooth muscle actin, rat) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) RN - EC 2.7.10.2 (Focal Adhesion Kinase 1) RN - EC 2.7.10.2 (Ptk2 protein, rat) SB - IM MH - Actins/genetics MH - Animals MH - Apoptosis/drug effects/physiology MH - Cell Cycle Checkpoints/drug effects MH - Cell Proliferation/drug effects/physiology MH - Cells, Cultured MH - Fibroblasts/cytology/drug effects/metabolism MH - Focal Adhesion Kinase 1/antagonists & inhibitors/*metabolism MH - Hepatocyte Growth Factor/metabolism/*pharmacology MH - MAP Kinase Signaling System/drug effects MH - Male MH - Proto-Oncogene Proteins c-met/genetics MH - Quinolones/pharmacology MH - Rats, Sprague-Dawley MH - Sulfones/pharmacology MH - Tendons/cytology MH - Transforming Growth Factor beta1/metabolism/*pharmacology OTO - NOTNLM OT - FAK OT - Hepatocyte growth factor OT - Tendon fibroblast OT - Transforming growth factor-β1 EDAT- 2015/04/23 06:00 MHDA- 2016/08/29 06:00 CRDT- 2015/04/23 06:00 PHST- 2014/11/05 00:00 [received] PHST- 2015/04/08 00:00 [accepted] PHST- 2015/04/23 06:00 [entrez] PHST- 2015/04/23 06:00 [pubmed] PHST- 2016/08/29 06:00 [medline] AID - 10.1007/s11626-015-9914-y [pii] AID - 10.1007/s11626-015-9914-y [doi] PST - ppublish SO - In Vitro Cell Dev Biol Anim. 2015 Oct;51(9):941-9. doi: 10.1007/s11626-015-9914-y. Epub 2015 Apr 22. PMID- 29055701 OWN - NLM STAT- MEDLINE DCOM- 20180726 LR - 20180726 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 107 IP - Pt B DP - 2018 Feb TI - Self-healing and tough hydrogels with physically cross-linked triple networks based on Agar/PVA/Graphene. PG - 2291-2297 LID - S0141-8130(17)32786-1 [pii] LID - 10.1016/j.ijbiomac.2017.10.104 [doi] AB - The aim of this work was to prepare polyvinyl alcohol (PVA)/Agar/Graphene nanocomposite hydrogels through a one-pot and green solution mixing method using water as solvent. Herein a novel strategy for designing stiff, tough and self-healing triple network (TN) hydrogels was proposed. The prepared TN hydrogels composed of strong Agar polysaccharide as the first network, tough PVA biopolymer gel as the second network, and graphene nanoplatelets as the third network. Interestingly, similar to natural biomaterials, all of the networks of the nanocomposite hydrogel were physically cross-linked via dynamic hydrogen bonding associations, i.e. Agar helix bundles, PVA crystallites and polymer chain physisorption on graphene. Therefore, the prepared hydrogels demonstrated simultaneous high strength, toughness, and autonomous self-healing within a short time of 10min, which is rare in the literature. The developed hydrogels can be a promising material in many biomedical applications, such as scaffolds, cartilages, tendons and muscles. CI - Copyright © 2017 Elsevier B.V. All rights reserved. FAU - Samadi, Navid AU - Samadi N AD - Department of Chemical Engineering, Faculty of Engineering, University of Maragheh, Maragheh 55181-83111, Iran. FAU - Sabzi, Mohammad AU - Sabzi M AD - Department of Chemical Engineering, Faculty of Engineering, University of Maragheh, Maragheh 55181-83111, Iran. Electronic address: m.sabzi@maragheh.ac.ir. FAU - Babaahmadi, Masoud AU - Babaahmadi M AD - Department of Chemical Engineering, Faculty of Engineering, University of Maragheh, Maragheh 55181-83111, Iran. LA - eng PT - Journal Article DEP - 20171018 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (Cross-Linking Reagents) RN - 059QF0KO0R (Water) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 7782-42-5 (Graphite) RN - 9002-18-0 (Agar) RN - 9002-89-5 (Polyvinyl Alcohol) SB - IM MH - Agar/*chemistry MH - Cross-Linking Reagents/chemistry MH - Graphite/*chemistry MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry/pharmacology MH - Hydrogen Bonding MH - Nanocomposites/chemistry MH - Polyvinyl Alcohol/*chemistry MH - Tensile Strength MH - Tissue Engineering MH - Tissue Scaffolds/chemistry MH - Water/chemistry OTO - NOTNLM OT - Agar polysaccharide OT - Nano graphene OT - Physically cross-linking OT - Polyvinyl alcohol OT - Self-healing hydrogel OT - Triple network EDAT- 2017/10/23 06:00 MHDA- 2018/07/27 06:00 CRDT- 2017/10/23 06:00 PHST- 2017/07/29 00:00 [received] PHST- 2017/10/04 00:00 [revised] PHST- 2017/10/16 00:00 [accepted] PHST- 2017/10/23 06:00 [pubmed] PHST- 2018/07/27 06:00 [medline] PHST- 2017/10/23 06:00 [entrez] AID - S0141-8130(17)32786-1 [pii] AID - 10.1016/j.ijbiomac.2017.10.104 [doi] PST - ppublish SO - Int J Biol Macromol. 2018 Feb;107(Pt B):2291-2297. doi: 10.1016/j.ijbiomac.2017.10.104. Epub 2017 Oct 18. PMID- 10893225 OWN - NLM STAT- MEDLINE DCOM- 20001120 LR - 20210209 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 275 IP - 42 DP - 2000 Oct 20 TI - Identification of an intermediate state in the helix-coil degradation of collagen by ultraviolet light. PG - 33014-20 AB - Differential scanning calorimetry has revealed the presence of a new denaturation endotherm at 32 degrees C following UV irradiation of collagen, compared with 39 degrees C for the native triple helix. Kinetic analyses showed that the new peak was a previously unknown intermediate state in the collagen helix-coil transition induced by UV light, and at least 80% of the total collagen was transformed to random chains via this state. Its rate of formation was increased by hydrogen peroxide and inhibited by free radical scavengers. SDS-polyacrylamide gels showed evidence of competing reactions of cross-linking and random primary chain scission. The cross-linking was evident from initial gelling of the collagen solution, but there was no evidence for a dityrosine cross-link. Primary chain scission was confirmed by end group analysis using fluorescamine. Electron microscopy showed that the segment long spacing crystallites formed from the intermediate state were identical to the native molecules. Clearly, collagen can undergo quite extensive damage by cleavage of peptide bonds without disorganizing the triple helical structure. This leads to the formation of a damaged intermediate state prior to degradation of the molecules to short random chains. FAU - Miles, C A AU - Miles CA AD - University of Bristol, Collagen Research Group, School of Veterinary Science, Langford, Bristol BS40 5DU, United Kingdom. chris.miles@bristol.ac.uk FAU - Sionkowska, A AU - Sionkowska A FAU - Hulin, S L AU - Hulin SL FAU - Sims, T J AU - Sims TJ FAU - Avery, N C AU - Avery NC FAU - Bailey, A J AU - Bailey AJ LA - eng PT - Journal Article PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Free Radical Scavengers) RN - 3352-57-6 (Hydroxyl Radical) RN - 9007-34-5 (Collagen) RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Animals MH - Calorimetry, Differential Scanning/methods MH - Collagen/*chemistry/*radiation effects/ultrastructure MH - Crystallization MH - Free Radical Scavengers/pharmacology MH - Hydrogen Peroxide/pharmacology MH - Hydroxyl Radical/pharmacology MH - Kinetics MH - Microscopy, Electron MH - Protein Structure, Secondary/*radiation effects MH - Rats MH - Tail MH - Tendons MH - Thermodynamics MH - *Ultraviolet Rays EDAT- 2000/07/13 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/07/13 11:00 PHST- 2000/07/13 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/07/13 11:00 [entrez] AID - S0021-9258(20)89194-7 [pii] AID - 10.1074/jbc.M002346200 [doi] PST - ppublish SO - J Biol Chem. 2000 Oct 20;275(42):33014-20. doi: 10.1074/jbc.M002346200. PMID- 6156827 OWN - NLM STAT- MEDLINE DCOM- 19801024 LR - 20190620 IS - 0014-2956 (Print) IS - 0014-2956 (Linking) VI - 106 IP - 2 DP - 1980 May TI - Extraction and translation of collagen mRNA from fetal calf skin. PG - 593-601 AB - RNA was extracted from fetal calf skin by two different procedures, using phenol or guanidine hydrochloride. Poly(A)-rich RNA was separated by oligo(dT)-cellulose affinity chromatography and was further fractionated by sucrose density gradient centrifugation. When translated in an optimized wheat germ extract cell-free system, unfractionated guanidine-hydrochloride-extracted poly(A)-rich RNA directed the synthesis of two collagenase-sensitive protein bands, while phenol-extracted poly(A)-rich RNA with a sedimentation coefficient higher than 25 S was the only fraction to direct the same synthesis. On the basis of their electrophoretic mobility on a sodium dodecylsulfate/urea/polyacrylamide gel, these proteins were identified with procollagen alpha 1(I) and procollagen alpha 2. Inhibition of translation by phenol-extracted poly(A)-rich RNA with a sedimentation coefficient lower than 25 S was also observed. Guanidine-hydrochloride-extracted poly(A)-rich RNA from fetal skin directed the synthesis of three distinct collagenase-sensitive proteins in the micrococcal-nuclease-digested rabbit reticulocyte cell-free system; these seemed to correspond to procollagen alpha 1(I), procollagen alpha 2 and procollagen alpha 1 (III). FAU - Kaufmann, R AU - Kaufmann R FAU - Belayew, A AU - Belayew A FAU - Nusgens, B AU - Nusgens B FAU - Lapière, C M AU - Lapière CM FAU - Gielen, J E AU - Gielen JE LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Eur J Biochem JT - European journal of biochemistry JID - 0107600 RN - 0 (Guanidines) RN - 0 (Phenols) RN - 0 (Proteins) RN - 0 (RNA, Messenger) RN - 24937-83-5 (Poly A) RN - 63231-63-0 (RNA) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cattle MH - Cell-Free System MH - Collagen/*biosynthesis MH - Guanidines/pharmacology MH - Phenols/pharmacology MH - Poly A/metabolism MH - Protein Biosynthesis MH - Proteins/analysis MH - RNA/metabolism MH - RNA, Messenger/*isolation & purification MH - Reticulocytes/metabolism MH - Skin/analysis MH - Tendons EDAT- 1980/05/01 00:00 MHDA- 1980/05/01 00:01 CRDT- 1980/05/01 00:00 PHST- 1980/05/01 00:00 [pubmed] PHST- 1980/05/01 00:01 [medline] PHST- 1980/05/01 00:00 [entrez] AID - 10.1111/j.1432-1033.1980.tb04607.x [doi] PST - ppublish SO - Eur J Biochem. 1980 May;106(2):593-601. doi: 10.1111/j.1432-1033.1980.tb04607.x. PMID- 25589402 OWN - NLM STAT- MEDLINE DCOM- 20151203 LR - 20181113 IS - 1520-6017 (Electronic) IS - 0022-3549 (Print) IS - 0022-3549 (Linking) VI - 104 IP - 4 DP - 2015 Apr TI - Effect of silicone on the collagen fibrillogenesis and stability. PG - 1275-81 LID - 10.1002/jps.24351 [doi] AB - Collagen, the most abundant protein in mammals, is able to form fibrils, which have central role in tissue repair, fibrosis, and tumor invasion. As a component of skin, tendons, and cartilages, this protein contacts with any implanted materials. An inherent problem associated with implanted prostheses is their propensity to be coated with host proteins shortly after implantation. Also, silicone implants undergoing relatively long periods of contact with blood can lead to formation of thrombi and emboli. In this paper, we demonstrate the existence of interactions between siloxanes and collagen. Low-molecular-weight cyclic siloxane (hexamethylcyclotrisiloxane-D3) and polydimethylsiloxanes (PDMS) forming linear chains, ranging in viscosity from 20 to 12,000 cSt, were analyzed. We show that D3 as well as short-chain PDMS interact with collagen, resulting in a decrease in fibrillogenesis. However, loss of collagen native structure does not occur because of these interactions. Rather, collagen seems to be sequestered in its native form in an interlayer formed by collagen-siloxane complexes. On the other hand, silicone molecules with longer chains (i.e., PDMS with viscosity of 1000 and 12,000 cSt, the highest viscosity analyzed here) demonstrate little interaction with this protein and do not seem to affect collagen activity. CI - © 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association. FAU - Kadziński, Leszek AU - Kadziński L AD - Department of Molecular and Cellular Biology, Intercollegiate Faculty of Biotechnology of the University of Gdansk and Medical University of Gdansk, Gdansk, Poland. FAU - Prokopowicz, Magdalena AU - Prokopowicz M FAU - Jakóbkiewicz-Banecka, Joanna AU - Jakóbkiewicz-Banecka J FAU - Gabig-Cimińska, Magdalena AU - Gabig-Cimińska M FAU - Łukasiak, Jerzy AU - Łukasiak J FAU - Banecki, Bogdan AU - Banecki B LA - eng PT - Journal Article DEP - 20150114 PL - United States TA - J Pharm Sci JT - Journal of pharmaceutical sciences JID - 2985195R RN - 0 (Collagen Type I) RN - 0 (Dimethylpolysiloxanes) RN - 0 (Protein Aggregates) RN - 0 (Siloxanes) RN - 63148-62-9 (baysilon) RN - EPV75L8O0R (hexamethylcyclotrisiloxane) SB - IM MH - Collagen Type I/*chemistry MH - Dimethylpolysiloxanes/*chemistry/toxicity MH - Molecular Structure MH - Molecular Weight MH - *Prostheses and Implants/adverse effects MH - Prosthesis Design MH - Protein Aggregates MH - Protein Denaturation MH - Protein Stability MH - Protein Structure, Secondary MH - Siloxanes/*chemistry/toxicity MH - Structure-Activity Relationship MH - Time Factors MH - Viscosity PMC - PMC4418381 OTO - NOTNLM OT - FTIR OT - biocompatibility OT - emulsion OT - interaction OT - light-scattering OT - micelle OT - polymers OT - protein aggregation OT - silica EDAT- 2015/01/16 06:00 MHDA- 2015/12/15 06:00 PMCR- 2015/05/04 CRDT- 2015/01/16 06:00 PHST- 2014/06/24 00:00 [received] PHST- 2014/12/18 00:00 [revised] PHST- 2014/12/19 00:00 [accepted] PHST- 2015/01/16 06:00 [entrez] PHST- 2015/01/16 06:00 [pubmed] PHST- 2015/12/15 06:00 [medline] PHST- 2015/05/04 00:00 [pmc-release] AID - S0022-3549(15)30151-9 [pii] AID - 10.1002/jps.24351 [doi] PST - ppublish SO - J Pharm Sci. 2015 Apr;104(4):1275-81. doi: 10.1002/jps.24351. Epub 2015 Jan 14. PMID- 31078765 OWN - NLM STAT- MEDLINE DCOM- 20200701 LR - 20200701 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 92 DP - 2019 Jul 1 TI - Substrate stiffness- and topography-dependent differentiation of annulus fibrosus-derived stem cells is regulated by Yes-associated protein. PG - 254-264 LID - S1742-7061(19)30328-9 [pii] LID - 10.1016/j.actbio.2019.05.013 [doi] AB - Annulus fibrosus (AF) tissue engineering has attracted increasing attention as a promising therapy for degenerative disc disease (DDD). However, regeneration of AF still faces many challenges due to the tremendous complexity of this tissue and lack of in-depth understanding of the structure-function relationship at cellular level within AF is highly required. In light of the fact that AF is composed of various types of cells and has gradient mechanical, topographical and biochemical features along the radial direction. In this study, we aimed to achieve directed differentiation of AF-derived stem cells (AFSCs) by mimicking the mechanical and topographical features of native AF tissue. AFSCs were cultured on four types of electrospun poly(ether carbonate urethane)urea (PECUU) scaffolds with various stiffness and fiber size (soft, small size; stiff, small size; soft, large size and stiff, large size). The results show that with constant fiber size, the expression level of the outer AF (oAF) phenotypic marker genes in AFSCs increased with the scaffold stiffness, while that of inner AF (iAF) phenotypic marker genes showed an opposite trend. When scaffold stiffness was fixed, the expression of oAF phenotypic marker genes in AFSCs increased with fiber size. While the expression of iAF phenotypic marker genes decreased. Such substrate stiffness- and topography-dependent changes of AFSCs was in accordance with the genetic and biochemical distribution of AF tissue from the inner to outer regions. Further, we found that the Yes-associated protein (YAP) was translocated to the nucleus in AFSCs cultured with increasing stiffness and fiber size of scaffolds, yet it remained mostly phosphorylated and cytosolic in cells on soft scaffolds with small fiber size. Inhibition of YAP down-regulated the expression of tendon/ligament-related genes, whereas expression of the cartilage-related genes was upregulated. The results illustrate that matrix stiffness is a potent regulator of AFSC differentiation. Moreover, we reveal that fiber size of scaffolds induced changes in cell adhesions and determined cell shape, spreading area, and extracellular matrix expression. In all, both mechanical property and topography features of scaffolds regulate AFSC differentiation, possibly through a YAP-dependent mechanotransduction mechanism. STATEMENT OF SIGNIFICANCE: Physical cues such as mechanical properties, topographical and geometrical features were shown to profoundly impact the growth and differentiation of cultured stem cells. Previously, we have found that the differentiation of annulus fibrosus-derived stem cells (AFSCs) could be regulated by the stiffness of scaffold. In this study, we fabricated four types of poly(ether carbonate urethane)urea (PECUU) scaffolds with controlled stiffness and fiber size to explore the potential of induced differentiation of AFSCs. We found that AFSCs are able to present different gene expression patterns simply as a result of the stiffness and fiber size of scaffold material. This work has, for the first time, demonstrated that larger-sized and higher-stiffness substrates increase the amount of vinculin assembly and activate YAP signaling in pre-differentiated AFSCs. The present study affords an in-depth comprehension of materiobiology, and be helpful for explain the mechanism of YAP mechanosensing in AF in response to biophysical effects of materials. CI - Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. FAU - Chu, Genglei AU - Chu G AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Yuan, Zhangqin AU - Yuan Z AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Zhu, Caihong AU - Zhu C AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Zhou, Pinghui AU - Zhou P AD - Department of Orthopaedic Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China. FAU - Wang, Huan AU - Wang H AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Zhang, Weidong AU - Zhang W AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Cai, Yan AU - Cai Y AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Zhu, Xuesong AU - Zhu X AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Yang, Huilin AU - Yang H AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. FAU - Li, Bin AU - Li B AD - Department of Orthopaedic Surgery, Orthopaedic Institute, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; China Orthopaedic Regenerative Medicine Group (CORMed), Hangzhou, Zhejiang, China. Electronic address: binli@suda.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190509 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Cell Cycle Proteins) RN - 0 (Polyurethanes) RN - 0 (poly(carbonate urea) urethane) SB - IM MH - Animals MH - Annulus Fibrosus/*cytology MH - Cell Cycle Proteins/*metabolism MH - *Cell Differentiation/drug effects MH - Cell Nucleus/drug effects/metabolism MH - Cell Proliferation/drug effects MH - Cell Shape/drug effects MH - Cells, Cultured MH - Focal Adhesions/drug effects/metabolism MH - Gene Expression Regulation/drug effects MH - Ligaments/metabolism MH - Phenotype MH - Polyurethanes/*pharmacology MH - Rabbits MH - Stem Cells/*cytology/drug effects MH - Tendons/metabolism MH - Tissue Scaffolds/chemistry OTO - NOTNLM OT - Annulus fibrosus OT - Annulus fibrosus-derived stem cells OT - Differentiation OT - Poly(ether carbonate urethane)urea OT - Stiffness OT - Topography OT - YAP EDAT- 2019/05/13 06:00 MHDA- 2020/07/02 06:00 CRDT- 2019/05/13 06:00 PHST- 2018/12/20 00:00 [received] PHST- 2019/04/24 00:00 [revised] PHST- 2019/05/06 00:00 [accepted] PHST- 2019/05/13 06:00 [pubmed] PHST- 2020/07/02 06:00 [medline] PHST- 2019/05/13 06:00 [entrez] AID - S1742-7061(19)30328-9 [pii] AID - 10.1016/j.actbio.2019.05.013 [doi] PST - ppublish SO - Acta Biomater. 2019 Jul 1;92:254-264. doi: 10.1016/j.actbio.2019.05.013. Epub 2019 May 9. PMID- 23142862 OWN - NLM STAT- MEDLINE DCOM- 20130625 LR - 20220309 IS - 1432-5195 (Electronic) IS - 0341-2695 (Print) IS - 0341-2695 (Linking) VI - 37 IP - 2 DP - 2013 Feb TI - SPECT/CT tracer uptake is influenced by tunnel orientation and position of the femoral and tibial ACL graft insertion site. PG - 301-9 LID - 10.1007/s00264-012-1704-5 [doi] AB - PURPOSE: SPECT/CT is a hybrid imaging modality, which combines a 3D scintigraphy (SPECT) and a conventional computerised tomography (CT). SPECT/CT allows accurate anatomical localisation of metabolic tracer activity. It allows the correlation of surgical factors such as tunnel position and orientation with mechanical alignment, clinical outcome and biological factors. The purpose of this study was to investigate whether the SPECT/CT tracer uptake (intensity and distribution) correlates with the stability and laxity of the knee joint and the position and orientation of the tibial and femoral tunnels in patients after anterior cruciate ligament (ACL) reconstruction. METHODS: A consecutive series of knees (n=66), with symptoms of pain and/or instability after ACL reconstruction were prospectively evaluated using clinical examination and 99mTc-HDP-SPECT/CT. Clinical laxity testing was performed using the Rolimeter (Ormed, Freiburg, Germany) including Lachman testing (0-2 mm, 3-5 mm, 6-10 mm, >10 mm), anterior drawer test (0-2 mm, 3-5 mm, 6-10 mm, >10 mm), pivot shift test (positive versus negative) and patient-based subjective instability (yes versus no). For analysis of SPECT/CT tracer uptake a previously validated SPECT/CT localisation scheme consisting of 17 tibial, nine femoral and four patellar regions on standardised axial, coronal, and sagittal slices was used. The tracer activity on SPECT/CT was localised and recorded using a 3D volumetric and quantitative analysis software. Mean, standard deviation, minimum and maximum of grading for each area of the localisation scheme were recorded. The position and orientation of the tibial and femoral tunnel was assessed using a previously published method on 3D-CT. RESULTS: Correlation of instability, pivot shift as well as clinical laxity testing with 99mTc-HDP-SPECT/CT tracer uptake intensity and distribution showed no significant correlation. 99mTc-HDP-SPECT/CT tracer uptake correlated significantly with the position and orientation of the ACL graft. A more horizontal femoral graft position showed significantly increased tracer uptake within the superior and posterior femoral regions. A more posteriorly-placed femoral insertion site showed significantly more tracer uptake within the femoral and tibial tunnel regions. A more vertical or a less medial tibial tunnel orientation showed significant increased uptake within the tibial and femoral tunnel regions. A more anterior tibial tunnel position showed significantly more tracer uptake in the femoral and tibial tunnel regions as well as the entire tibiofemoral joint. CONCLUSIONS: SPECT/CT tracer uptake intensity and distribution showed a significant correlation with the femoral and tibial tunnel position and orientation in patients with symptomatic knees after ACL reconstruction. No correlation was found with stability or clinical laxity. SPECT/CT tracer uptake distribution has the potential to give us important information on joint homeostasis and remodelling after ACL reconstruction. It might help to predict ACL graft failure and improve our surgical ACL reconstruction technique in finding the optimal tunnel and graft position and orientation. FAU - Hirschmann, Michael T AU - Hirschmann MT AD - Department of Orthopaedic Surgery and Traumatology, Kantonsspital Bruderholz, 4101, Bruderholz, Switzerland. Michael.Hirschmann@unibas.ch FAU - Mathis, Dominic AU - Mathis D FAU - Rasch, Helmut AU - Rasch H FAU - Amsler, Felix AU - Amsler F FAU - Friederich, Niklaus F AU - Friederich NF FAU - Arnold, Markus P AU - Arnold MP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121111 PL - Germany TA - Int Orthop JT - International orthopaedics JID - 7705431 RN - 0 (Radiopharmaceuticals) RN - 72945-61-0 (technetium Tc 99m hydroxymethylene diphosphonate) RN - X89XV46R07 (Technetium Tc 99m Medronate) SB - IM MH - Adolescent MH - Adult MH - Anterior Cruciate Ligament/surgery MH - Anterior Cruciate Ligament Injuries MH - Anterior Cruciate Ligament Reconstruction/adverse effects/*methods MH - Female MH - Femur/*surgery MH - Humans MH - Joint Instability/*diagnosis/etiology MH - Knee Injuries/surgery MH - Knee Joint/surgery MH - Male MH - *Multimodal Imaging MH - Patella/surgery MH - *Positron-Emission Tomography MH - Radiopharmaceuticals/*pharmacokinetics MH - Technetium Tc 99m Medronate/*analogs & derivatives/pharmacokinetics MH - Tendons/transplantation MH - Tibia/*surgery MH - *Tomography, X-Ray Computed MH - Young Adult PMC - PMC3560910 EDAT- 2012/11/13 06:00 MHDA- 2013/06/26 06:00 PMCR- 2014/02/01 CRDT- 2012/11/13 06:00 PHST- 2012/10/12 00:00 [received] PHST- 2012/10/21 00:00 [accepted] PHST- 2012/11/13 06:00 [entrez] PHST- 2012/11/13 06:00 [pubmed] PHST- 2013/06/26 06:00 [medline] PHST- 2014/02/01 00:00 [pmc-release] AID - 1704 [pii] AID - 10.1007/s00264-012-1704-5 [doi] PST - ppublish SO - Int Orthop. 2013 Feb;37(2):301-9. doi: 10.1007/s00264-012-1704-5. Epub 2012 Nov 11. PMID- 37391109 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 1873-3476 (Electronic) IS - 0378-5173 (Linking) VI - 642 DP - 2023 Jul 25 TI - Metformin suppressed tendon injury-induced adhesion via hydrogel-nanoparticle sustained-release system. PG - 123190 LID - S0378-5173(23)00610-5 [pii] LID - 10.1016/j.ijpharm.2023.123190 [doi] AB - Tendon adhesion is one of the sequelae of tendon injury and can lead to disability in severe cases. Metformin is a commonly used antidiabetic drug. Some studies had shown that metformin could reduce tendon adhesion as well. Considering the characteristic of low absorption rate and short half-life, we established a sustained-release system, i.e., hydrogel-nanoparticle system to deliver metformin. In vitro, metformin could effectively suppress TGF-β1-induced cell proliferation and accelerate cell apoptosis, according to cell counting kit-8, flow cytometry, and 5-ethynyl-2'-deoxyuridine (EdU) staining studies. In vivo, hydrogel-nanoparticle/metformin system could significantly lower adhesion scores and improve the gliding function of repaired flexor tendons, as well as decrease the expression of fibrotic proteins Col1a1, Col3a1, and α-smooth muscle actin (α-SMA). Histological staining revealed that the inflammation had subsided and that the gap between the tendon and the surrounding tissue was wider in the hydrogel-nanoparticle/metformin treatment group. Finally, we speculated that effect of metformin on reducing tendon adhesion might be achieved by regulating both Smad and MAPK-TGF-β1 signaling pathways. In conclusion, metformin delivered through hydrogel-nanoparticle sustained-release system may be a promising strategy for coping with tendon adhesion. CI - Copyright © 2023. Published by Elsevier B.V. FAU - Jie Li, Zhi AU - Jie Li Z AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. FAU - Bing Luo, Chun AU - Bing Luo C AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. FAU - Liang Wang, Hao AU - Liang Wang H AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. FAU - Sun, Jie AU - Sun J AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. FAU - Qian Yang, Qian AU - Qian Yang Q AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. FAU - Lang Zhou, You AU - Lang Zhou Y AD - Hand Surgery Research Center, Research Central of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China. Electronic address: youlangzhou@163.com. LA - eng PT - Journal Article DEP - 20230629 PL - Netherlands TA - Int J Pharm JT - International journal of pharmaceutics JID - 7804127 RN - 0 (Transforming Growth Factor beta1) RN - 9100L32L2N (Metformin) RN - 0 (Hydrogels) RN - 0 (Delayed-Action Preparations) SB - IM MH - Humans MH - Transforming Growth Factor beta1 MH - *Metformin/pharmacology MH - Hydrogels MH - Delayed-Action Preparations MH - *Tendon Injuries/drug therapy MH - Tissue Adhesions MH - *Nanoparticles OTO - NOTNLM OT - Adhesion OT - Hydrogel OT - Metformin OT - Nanoparticle OT - TGF-β1 OT - Tendon COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/07/01 11:41 MHDA- 2023/10/23 00:44 CRDT- 2023/06/30 19:17 PHST- 2022/12/20 00:00 [received] PHST- 2023/06/21 00:00 [revised] PHST- 2023/06/28 00:00 [accepted] PHST- 2023/10/23 00:44 [medline] PHST- 2023/07/01 11:41 [pubmed] PHST- 2023/06/30 19:17 [entrez] AID - S0378-5173(23)00610-5 [pii] AID - 10.1016/j.ijpharm.2023.123190 [doi] PST - ppublish SO - Int J Pharm. 2023 Jul 25;642:123190. doi: 10.1016/j.ijpharm.2023.123190. Epub 2023 Jun 29. PMID- 4046649 OWN - NLM STAT- MEDLINE DCOM- 19851101 LR - 20161123 IS - 0252-1156 (Print) IS - 0252-1156 (Linking) VI - 4 IP - 2-3 DP - 1985 TI - Preservation of resting potential by magnesium in hypoxic canine cardiac cells. PG - 96-101 AB - This study was designed to test the hypothesis that Mg++ prevents the electrophysiologic changes caused by hypoxia in cardiac cells. Canine right ventricular false tendons (32 hearts) were pinned to the floor of a tissue bath and suffused with physiologic solution. Microelectrodes recorded the spontaneous action potentials. The isolated tissue was exposed to a hypoxic solution (PO2 less than 50 mm Hg) containing either normal [Mg++] (0.85 mmol/l) or high [Mg++] (3.4 mmol/l). Hypoxia with normal [Mg++] caused increased firing rate (+40%), depolarization of the resting (maximum diastolic) potential (from-72 to -55 mV), and reduction in amplitude (from 88 to 76 mV). The depolarization, reduction in amplitude, and most of the increased firing rate were completely blocked when [Mg++] was elevated to 3.4 mmol/l; propranolol (10 mg/l) blocked the residual increase in firing rate. FAU - Woods, W T Jr AU - Woods WT Jr FAU - Chapman, G D AU - Chapman GD LA - eng GR - HL 30486/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - Switzerland TA - Magnesium JT - Magnesium JID - 8219687 RN - 9Y8NXQ24VQ (Propranolol) RN - I38ZP9992A (Magnesium) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Dogs MH - Female MH - Heart/*physiopathology MH - Heart Ventricles/physiopathology MH - Hypoxia/*physiopathology MH - Kinetics MH - Magnesium/*pharmacology MH - Male MH - Propranolol/pharmacology MH - Purkinje Fibers/physiopathology EDAT- 1985/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1985/01/01 00:00 PHST- 1985/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1985/01/01 00:00 [entrez] PST - ppublish SO - Magnesium. 1985;4(2-3):96-101. PMID- 17151859 OWN - NLM STAT- MEDLINE DCOM- 20070913 LR - 20220321 IS - 0938-7994 (Print) IS - 0938-7994 (Linking) VI - 17 IP - 6 DP - 2007 Jun TI - Material differentiation by dual energy CT: initial experience. PG - 1510-7 AB - The aim of this study was to assess the feasibility of a differentiation of iodine from other materials and of different body tissues using dual energy CT. Ten patients were scanned on a SOMATOM Definition Dual Source CT (DSCT; Siemens, Forchheim, Germany) system in dual energy mode at tube voltages of 140 and 80 kVp and a ratio of 1:3 between tube currents. Weighted CT Dose Index ranged between 7 and 8 mGy, remaining markedly below reference dose values for the respective body regions. Image post-processing with three-material decomposition was applied to differentiate iodine or collagen from other tissue. The results showed that a differentiation and depiction of contrast material distribution is possible in the brain, the lung, the liver and the kidneys with or without the underlying tissue of the organ. In angiographies, bone structures can be removed from the dataset to ease the evaluation of the vessels. The differentiation of collagen makes it possible to depict tendons and ligaments. Dual energy CT offers a more specific tissue characterization in CT and can improve the assessment of vascular disease. Further studies are required to draw conclusions on the diagnostic value of the individual applications. FAU - Johnson, Thorsten R C AU - Johnson TR AD - Department of Clinical Radiology, University of Munich-Grosshadern Campus, Marchioninistrasse 15, 81377 Munich, Germany. thorsten.johnson@med.uni-muenchen.de FAU - Krauss, Bernhard AU - Krauss B FAU - Sedlmair, Martin AU - Sedlmair M FAU - Grasruck, Michael AU - Grasruck M FAU - Bruder, Herbert AU - Bruder H FAU - Morhard, Dominik AU - Morhard D FAU - Fink, Christian AU - Fink C FAU - Weckbach, Sabine AU - Weckbach S FAU - Lenhard, Miriam AU - Lenhard M FAU - Schmidt, Bernhard AU - Schmidt B FAU - Flohr, Thomas AU - Flohr T FAU - Reiser, Maximilian F AU - Reiser MF FAU - Becker, Christoph R AU - Becker CR LA - eng PT - Journal Article DEP - 20061207 PL - Germany TA - Eur Radiol JT - European radiology JID - 9114774 RN - 0 (Contrast Media) RN - 4419T9MX03 (Iohexol) RN - 712BAC33MZ (iopromide) SB - IM MH - Algorithms MH - Contrast Media/*pharmacokinetics MH - Diagnosis, Differential MH - Feasibility Studies MH - Female MH - Humans MH - Imaging, Three-Dimensional MH - Iohexol/*analogs & derivatives/pharmacokinetics MH - Male MH - Radiographic Image Interpretation, Computer-Assisted/*methods MH - Tomography, X-Ray Computed/*methods EDAT- 2006/12/08 09:00 MHDA- 2007/09/14 09:00 CRDT- 2006/12/08 09:00 PHST- 2006/05/31 00:00 [received] PHST- 2006/10/20 00:00 [accepted] PHST- 2006/10/19 00:00 [revised] PHST- 2006/12/08 09:00 [pubmed] PHST- 2007/09/14 09:00 [medline] PHST- 2006/12/08 09:00 [entrez] AID - 10.1007/s00330-006-0517-6 [doi] PST - ppublish SO - Eur Radiol. 2007 Jun;17(6):1510-7. doi: 10.1007/s00330-006-0517-6. Epub 2006 Dec 7. PMID- 135841 OWN - NLM STAT- MEDLINE DCOM- 19770103 LR - 20220408 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 261 IP - 3 DP - 1976 Oct TI - The responses of human muscle spindle endings to vibration during isometric contraction. PG - 695-711 AB - 1. An human subjects, vibration of amplitude 1-5 mm and frequency 20-220 Hz was applied to the tendons of muscles in the leg to examine the effects on the discharge of primary and secondary endings during manoeuvres designed to alter the level of fusimotor drive. 2. In four experiments, the peroneal nerve was completely blocked with lidocaine proximal to the recording site in order to de-efferent spindle endings temporarily. The responses to muscle stretch and vibration, as seen in multi-unit recordings and in single unit recordings, were similar during the block as in the relaxed state prior to the block. Thus, these experiments provided no evidence for a functionally effective resting fusimotor drive. 3. The responses to vibration of nine primary endings and four secondary endings were examined during isometric voluntary contractions of the receptor-bearing muscles. Providing that the endings were responding submaximally in the relaxed state, voluntary contraction enhanced the response to vibration, suggesting co-activation of the fusimotor system sufficient to compensate for mechanical unloading. Unloading effects were observed during contractions of neighbouring synergistic muscles, indicating a close spatial relationship between the co-activated skeletomotor and fusimotor outflows. 4. Recordings were obtained from ten primary endings and seven secondary endings during isometric reflex contractions resulting from the vibratory stimulus (TVR contractions). For twelve endings, the appearance of the tonic vibration reflex in the receptor-bearing muscle resulted in a significant decrease in the response to vibration, suggesting that the endings were unloaded by the extrafusal contraction. On voluntary suppression of the reflex contraction spindle responses reverted to their previous levels. 5. These results suggest that the tonic vibration reflex, like the tendon jerk reflex, operates predominantly or exclusively on alpha motoneurones and that it does not utilize the same cortically originating efferent pathways as are used in the performance of voluntary contractions. FAU - Burke, D AU - Burke D FAU - Hagbarth, K E AU - Hagbarth KE FAU - Löfstedt, L AU - Löfstedt L FAU - Wallin, B G AU - Wallin BG LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 98PI200987 (Lidocaine) SB - IM MH - Action Potentials MH - Adolescent MH - Adult MH - Humans MH - Lidocaine/pharmacology MH - Mechanoreceptors/physiology MH - Middle Aged MH - *Muscle Contraction MH - Muscle Spindles/drug effects/*physiology MH - Nerve Block MH - Reflex, Stretch MH - *Vibration PMC - PMC1309167 EDAT- 1976/10/01 00:00 MHDA- 1976/10/01 00:01 PMCR- 1976/10/01 CRDT- 1976/10/01 00:00 PHST- 1976/10/01 00:00 [pubmed] PHST- 1976/10/01 00:01 [medline] PHST- 1976/10/01 00:00 [entrez] PHST- 1976/10/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1976.sp011581 [doi] PST - ppublish SO - J Physiol. 1976 Oct;261(3):695-711. doi: 10.1113/jphysiol.1976.sp011581. PMID- 3572789 OWN - NLM STAT- MEDLINE DCOM- 19870522 LR - 20131121 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 241 IP - 1 DP - 1987 Apr TI - Interval-dependent effects of lidocaine on conduction in canine cardiac Purkinje fibers: experimental observations and theoretical analysis. PG - 275-81 AB - Whereas the interval-dependence of antiarrhythmic drug effects on Vmax is known, the corresponding time-dependence of drug-induced changes in cardiac conduction is not established. The purpose of these experiments was to study the relationship between the time-dependence of lidocaine-induced changes in Vmax and in conduction time. Standard microelectrode techniques were used to monitor conduction and action potential characteristics of Purkinje fibers within free-running canine false tendons. Lidocaine-induced alterations in conduction and Vmax were related to drug concentration and to the preceding diastolic recovery time. At concentrations of 18 to 74 microM, changes in both Vmax and conduction time were an exponential function of diastolic interval, with recovery time constants averaging 123 to 150 msec for conduction time and 138 to 150 msec for Vmax. With higher lidocaine concentrations, changes in Vmax continued to be an exponential function of recovery interval, whereas changes in conduction time consistently deviated from the terminal exponential relationship at short diastolic intervals. These observations are consistent with the predictions of a model based on linear cable theory. Calculations using this model suggest that recovery from moderate drug-induced conduction slowing should proceed with a time course similar to changes in Vmax, whereas recovery from more severe conduction slowing should occur more rapidly than changes in Vmax. These observations suggest that the time dependence of drug effects on conduction in vivo can be analyzed quantitatively in relationship to observations on Vmax in vitro. FAU - Nattel, S AU - Nattel S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 98PI200987 (Lidocaine) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Dogs MH - Dose-Response Relationship, Drug MH - Electric Conductivity MH - Electrophysiology MH - Heart Conduction System/*drug effects MH - Kinetics MH - Lidocaine/*pharmacology MH - Mathematics MH - Microelectrodes MH - Purkinje Fibers/*drug effects/physiology EDAT- 1987/04/01 00:00 MHDA- 1987/04/01 00:01 CRDT- 1987/04/01 00:00 PHST- 1987/04/01 00:00 [pubmed] PHST- 1987/04/01 00:01 [medline] PHST- 1987/04/01 00:00 [entrez] PST - ppublish SO - J Pharmacol Exp Ther. 1987 Apr;241(1):275-81. PMID- 20068147 OWN - NLM STAT- MEDLINE DCOM- 20100309 LR - 20250529 IS - 1538-7445 (Electronic) IS - 0008-5472 (Print) IS - 0008-5472 (Linking) VI - 70 IP - 2 DP - 2010 Jan 15 TI - Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. PG - 639-45 LID - 10.1158/0008-5472.CAN-09-1121 [doi] AB - Clear cell sarcoma (CCS), a childhood tumor of the tendons and aponeuroses, is uniformly fatal once it has metastasized because of its profound therapeutic resistance. CCS is characterized by production of a chimeric transcription factor, EWS-ATF1, which is formed as the result of a disease-specific chromosomal translocation. EWS-ATF1 activates the melanocyte transcription factor MITF, which in turn activates transcription of c-Met, an oncogenic receptor tyrosine kinase recently shown to be activated in CCS. Based on this connection, we hypothesized that c-Met inhibition may offer a strategy to treat CCS, as an indirect tactic to defeat a transforming pathway downstream of EWS-ATF1. Here, we show that primary CCS and CCS-derived cell lines express c-Met, which is activated in an autocrine fashion by its ligand hepatocyte growth factor (HGF)/scatter factor in some CCS cell lines. c-Met expression is critical for CCS invasion, chemotaxis, and survival. Blocking c-Met activity with a small-molecule inhibitor (SU11274) or a neutralizing antibody to its ligand HGF (AMG 102) significantly reduced CCS cell growth in culture. Similarly, AMG 102 significantly suppressed in vivo tumor growth in an autocrine xenograft model of CCS. Collectively, these findings suggest the HGF:c-Met signaling axis as a candidate therapeutic target to improve clinical management of CCS. FAU - Davis, Ian J AU - Davis IJ AD - Department of Pediatric Oncology, Ludwig Center for Cancer Research, Dana-Farber Cancer Institute, Children's Hospital Boston, Boston, Massachusetts, USA. dfisher3@partners.org FAU - McFadden, Andrew W AU - McFadden AW FAU - Zhang, Yixiang AU - Zhang Y FAU - Coxon, Angela AU - Coxon A FAU - Burgess, Teresa L AU - Burgess TL FAU - Wagner, Andrew J AU - Wagner AJ FAU - Fisher, David E AU - Fisher DE LA - eng GR - K08CA100400/CA/NCI NIH HHS/United States GR - R01 AR043369/AR/NIAMS NIH HHS/United States GR - R01CA102309/CA/NCI NIH HHS/United States GR - K08 CA100400/CA/NCI NIH HHS/United States GR - R01 CA102309/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20100112 PL - United States TA - Cancer Res JT - Cancer research JID - 2984705R RN - 0 (((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)) RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antibodies, Neutralizing) RN - 0 (EWS-ATF1 fusion protein, human) RN - 0 (Indoles) RN - 0 (Oncogene Proteins, Fusion) RN - 0 (Piperazines) RN - 0 (Sulfonamides) RN - 0 (Transcription Factors) RN - 51WEW898IJ (rilotumumab) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) SB - IM MH - Animals MH - Antibodies, Monoclonal/*pharmacology MH - Antibodies, Monoclonal, Humanized MH - Antibodies, Neutralizing/immunology/pharmacology MH - Cell Line, Tumor MH - Drug Delivery Systems MH - Hepatocyte Growth Factor/antagonists & inhibitors/immunology/*metabolism MH - Humans MH - Indoles/*pharmacology MH - Male MH - Mice MH - Mice, Nude MH - Oncogene Proteins, Fusion/biosynthesis MH - Piperazines/*pharmacology MH - Proto-Oncogene Proteins c-met/antagonists & inhibitors/biosynthesis/*metabolism MH - Sarcoma, Clear Cell/*drug therapy/*metabolism MH - Signal Transduction MH - Sulfonamides/*pharmacology MH - Transcription Factors/biosynthesis MH - Xenograft Model Antitumor Assays PMC - PMC2807989 MID - NIHMS160301 EDAT- 2010/01/14 06:00 MHDA- 2010/03/10 06:00 PMCR- 2011/01/15 CRDT- 2010/01/14 06:00 PHST- 2010/01/14 06:00 [entrez] PHST- 2010/01/14 06:00 [pubmed] PHST- 2010/03/10 06:00 [medline] PHST- 2011/01/15 00:00 [pmc-release] AID - 0008-5472.CAN-09-1121 [pii] AID - 10.1158/0008-5472.CAN-09-1121 [doi] PST - ppublish SO - Cancer Res. 2010 Jan 15;70(2):639-45. doi: 10.1158/0008-5472.CAN-09-1121. Epub 2010 Jan 12. PMID- 38726944 OWN - NLM STAT- MEDLINE DCOM- 20241213 LR - 20241213 IS - 1473-7760 (Electronic) IS - 1052-0295 (Linking) VI - 99 IP - 4 DP - 2024 May TI - Comparison of three techniques for decellularization of porcine bone-tendon-bone grafts. PG - 190-196 LID - 10.1080/10520295.2024.2350030 [doi] AB - Anterior cruciate ligament injuries are frequent afflictions related to sports or physical trauma. Autograft reconstruction strategies cause secondary injury to the patient. One alternative, supported by clinical evidence, is porcine xenografts. For clinical use, xenografts must be conditioned to avoid immune rejection. The most widely accepted procedure is tissue decellularization. We analyzed three decellularization strategies: the application of the anionic detergent sodium dodecyl sulfate (SDS), sonication, and freezing and thawing cycles. The treated tissues were evaluated histologically using H&E, Masson's trichrome, Verhoeff-van Gieson staining, and DAPI for fluorescent staining of nuclei. Finally, collagen fiber preservation was evaluated by quantifying this protein by colorimetry. The most efficient decellularization techniques were sonication and SDS. Collagen fibers were preserved in all experimental conditions. FAU - Sepúlveda-García, Jorge Arturo AU - Sepúlveda-García JA AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Martínez-Puente, David Hernán AU - Martínez-Puente DH AUID- ORCID: 0000-0001-7534-2556 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Ballesteros-Elizondo, Raquel Guadalupe AU - Ballesteros-Elizondo RG AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Rodríguez-Rocha, Humberto AU - Rodríguez-Rocha H AUID- ORCID: 0000-0003-0486-7448 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - García-García, Aracely AU - García-García A AUID- ORCID: 0000-0002-1699-9678 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Soto-Domínguez, Adolfo AU - Soto-Domínguez A AUID- ORCID: 0000-0002-4144-5474 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Saucedo-Cárdenas, Odila AU - Saucedo-Cárdenas O AUID- ORCID: 0000-0003-3922-2615 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Vilchez-Cavazos, José Félix AU - Vilchez-Cavazos JF AUID- ORCID: 0000-0001-9540-3379 AD - Servicio de Ortopedia y Traumatología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Montes de Oca-Luna, Roberto AU - Montes de Oca-Luna R AUID- ORCID: 0000-0001-8253-680X AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. FAU - Loera-Arias, María de Jesús AU - Loera-Arias MJ AUID- ORCID: 0000-0001-9561-3624 AD - Departamento de Histología, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, México. LA - eng PT - Comparative Study PT - Journal Article DEP - 20240510 PL - England TA - Biotech Histochem JT - Biotechnic & histochemistry : official publication of the Biological Stain Commission JID - 9107378 RN - 368GB5141J (Sodium Dodecyl Sulfate) SB - IM MH - Animals MH - Swine MH - *Tendons MH - Sodium Dodecyl Sulfate/pharmacology MH - Bone Transplantation/methods MH - Bone and Bones OTO - NOTNLM OT - Allografts OT - collagen OT - decellularization OT - elastin OT - porcine xenografts OT - tendon EDAT- 2024/05/10 12:44 MHDA- 2024/12/13 20:06 CRDT- 2024/05/10 06:53 PHST- 2024/12/13 20:06 [medline] PHST- 2024/05/10 12:44 [pubmed] PHST- 2024/05/10 06:53 [entrez] AID - 10.1080/10520295.2024.2350030 [doi] PST - ppublish SO - Biotech Histochem. 2024 May;99(4):190-196. doi: 10.1080/10520295.2024.2350030. Epub 2024 May 10. PMID- 30716140 OWN - NLM STAT- MEDLINE DCOM- 20191112 LR - 20240714 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 14 IP - 2 DP - 2019 TI - Effect of photobiomodulation and exercise on early remodeling of the Achilles tendon in streptozotocin-induced diabetic rats. PG - e0211643 LID - 10.1371/journal.pone.0211643 [doi] LID - e0211643 AB - The aim of this study was to compare the treatment effects of laser photobiomodulation (LPBM) therapy and aerobic exercise on the biomechanical properties, tissue morphology and the expression of tendon matrix molecules during early remodeling of Achilles tendon (AT) injury in diabetic rats. Animals were randomly assigned to five groups: injured non diabetic (I, n = 15), injured diabetic (ID, n = 15), injured diabetic plus LPBM (IDL, n = 16), injured diabetic plus aerobic exercise (IDE, n = 16) and injured diabetic plus aerobic exercise and LPBM (IDEAL, n = 17). Type 1 diabetes was induced via a single intravenous injection of Streptozotocin at a dose of 40 mg/kg. A partial tenotomy was performed in the right AT. LPBM was performed with an indium-gallium-aluminum-phosphide 660 nm 10 mW laser device (spot size 0.04 cm2, power density 250 mW/cm2, irradiation duration 16 s, energy 0.16 J, energy density 4 J/cm2) on alternate days for a total of 9 sessions over 3 weeks (total energy 1.44 J), using a stationary contact technique to a single point over the dorsal aspect of the AT. Moderate aerobic exercise was performed on a motorized treadmill (velocity 9 m/min for 60 minutes). At 3 weeks post-injury, biomechanical analyzes as well as assessment of fibroblast number and orientation were performed. Collagen 1 (Col1) and 3 (Col3) and matrix metalloproteinases (MMPs) -3 and 13 protein distributions were studied by immunohistochemistry; while Col1 and Col3 and MMP-2 and 9 gene expression were assessed by quantitative RT-PCR (qRT-PCR). IDEAL exhibited significant increases in several biomechanical parameters in comparison to the other groups. Moreover, IDEAL presented stronger Col1 immunoreactivity when compared to ID, and weaker Col3 immunoreactivity than IDE. Both IDL and IDEAL demonstrated weaker expression of MMP-3 in comparison to I, while IDL presented no expression of MMP-13 when compared to ID. ID, IDL and IDE showed an increased number of fibroblasts in comparison to I, while IDEAL decreased the number of these cells in comparison to ID and IDE. IDL and IDEAL groups exhibited decreased angular dispersion among the fibroblasts when compared to I. The gene expression results showed that IDE demonstrated a downregulation in Col1 mRNA expression in comparison to I and ID. IDEAL demonstrated upregulation of Col1 mRNA expression when compared to IDL or IDE alone and increased MMP-2 expression when compared to IDL and IDE. MMP-9 expression was upregulated in IDEAL when compared to I, IDL and IDE. Our results suggest a beneficial interaction of combining both treatment strategies i.e., aerobic exercise and LPBM, on the biomechanical properties, tissue morphology and the expression of matrix molecules in diabetic tendons. FAU - de Oliveira, Anderson Rodrigues AU - de Oliveira AR AD - Department of Physical Therapy, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - da Silva, Flávio Santos AU - da Silva FS AD - Department of Health Sciences, Federal University of the Semiarid Region, Mossoró, Brazil. FAU - Bortolin, Raul Hernandes AU - Bortolin RH AD - Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Marques, Dáfiny Emanuele da Silva AU - Marques DEDS AD - Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Ramos, Gracielle Vieira AU - Ramos GV AD - Universidade Paulista (UNIP), Brasília, Brazil. FAU - Marqueti, Rita C AU - Marqueti RC AD - University of Brasília (UnB), Brasília, Brazil. FAU - da Silva, Naisandra Bezerra AU - da Silva NB AD - Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Medeiros, Karina Carla de Paula AU - Medeiros KCP AD - Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Corrêa, Márcio Assolin AU - Corrêa MA AUID- ORCID: 0000-0002-8904-4151 AD - Department of Physics, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Lima, João Paulo Matos Santos AU - Lima JPMS AD - Department of Biochemistry, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - de Rezende, Adriana Augusto AU - de Rezende AA AD - Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - Ackermann, Paul W AU - Ackermann PW AD - Department of Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. FAU - Abreu, Bento J AU - Abreu BJ AUID- ORCID: 0000-0001-8010-806X AD - Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil. FAU - de Brito Vieira, Wouber Hérickson AU - de Brito Vieira WH AUID- ORCID: 0000-0003-3588-5577 AD - Department of Physical Therapy, Federal University of Rio Grande do Norte, Natal, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190204 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (RNA, Messenger) RN - 5W494URQ81 (Streptozocin) RN - EC 3.4.24.- (Metalloendopeptidases) SB - IM MH - Achilles Tendon/metabolism/*physiopathology MH - Animals MH - Collagen Type I/metabolism MH - Collagen Type III/metabolism MH - Diabetes Mellitus, Experimental/chemically induced/etiology/metabolism/*physiopathology MH - Diabetes Mellitus, Type 1/chemically induced/complications/metabolism/*physiopathology MH - Fibroblasts/metabolism MH - Low-Level Light Therapy/methods MH - Male MH - Metalloendopeptidases/metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Wistar MH - Streptozocin/pharmacology MH - Tendon Injuries/etiology/metabolism/physiopathology/*therapy MH - Up-Regulation/physiology MH - Wound Healing/physiology PMC - PMC6361457 COIS- The authors have declared that no competing interests exist. EDAT- 2019/02/05 06:00 MHDA- 2019/11/13 06:00 PMCR- 2019/02/04 CRDT- 2019/02/05 06:00 PHST- 2018/10/09 00:00 [received] PHST- 2019/01/17 00:00 [accepted] PHST- 2019/02/05 06:00 [entrez] PHST- 2019/02/05 06:00 [pubmed] PHST- 2019/11/13 06:00 [medline] PHST- 2019/02/04 00:00 [pmc-release] AID - PONE-D-18-29338 [pii] AID - 10.1371/journal.pone.0211643 [doi] PST - epublish SO - PLoS One. 2019 Feb 4;14(2):e0211643. doi: 10.1371/journal.pone.0211643. eCollection 2019. PMID- 36917311 OWN - NLM STAT- MEDLINE DCOM- 20230725 LR - 20230725 IS - 2629-3277 (Electronic) IS - 2629-3277 (Linking) VI - 19 IP - 5 DP - 2023 Jul TI - The Regulation of the AMPK/mTOR Axis Mitigates Tendon Stem/Progenitor Cell Senescence and Delays Tendon Aging. PG - 1492-1506 LID - 10.1007/s12015-023-10526-0 [doi] AB - Age-related tendon disorders are closely linked with tendon stem/progenitor cell (TSPC) senescence. However, the underlying mechanisms of TSPC senescence and promising therapeutic strategies for rejuvenation of TSPC senescence remain unclear. In this study, the senescent state of TSPCs increased with age. It was also verified that the AMPK inhibition/mTOR activation is correlated with the senescent state of TSPCs. Furthermore, a low dose of metformin mitigated TSPC senescence and restored senescence-related functions, including proliferation, colony-forming ability, migration ability and tenogenic differentiation ability at the early stage of aging. The protective effects of metformin on TSPCs were regulated through the AMPK/mTOR axis. An in vivo study showed that metformin treatment postpones tendon aging and enhances AMPK phosphorylation but reduces mTOR phosphorylation in a natural aging rat model. Our study revealed new insight and mechanistic exploration of TSPC senescence and proposed a novel therapeutic treatment for age-related tendon disorders by targeting the AMPK/mTOR axis at the early stage of aging. CI - © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dai, Guangchun AU - Dai G AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Li, Yingjuan AU - Li Y AD - Department of Geriatrics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, Nanjing, PR China. FAU - Zhang, Ming AU - Zhang M AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Lu, Panpan AU - Lu P AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Zhang, Yuanwei AU - Zhang Y AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Wang, Hao AU - Wang H AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Shi, Liu AU - Shi L AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Cao, Mumin AU - Cao M AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Shen, Renwang AU - Shen R AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. AD - School of Medicine, Southeast University, N0.87 Ding Jia Qiao, 210009, Nanjing, PR China. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. FAU - Rui, Yunfeng AU - Rui Y AUID- ORCID: 0000-0001-9019-5531 AD - Department of Orthopaedics, School of Medicine, Zhongda Hospital, Southeast University, NO.87 Ding Jia Qiao, 210009, Nanjing, Jiangsu, PR China. ruiyunfeng@126.com. AD - Trauma Center, Zhongda Hospital, Southeast University, 210009, Nanjing, Jiangsu, PR China. ruiyunfeng@126.com. AD - Orthopaedic Trauma Institute (OTI), Southeast University, 210009, Nanjing, Jiangsu, PR China. ruiyunfeng@126.com. AD - China Orthopedic Regenerative Medicine Group, 310000, Hangzhou, Zhejiang, PR China. ruiyunfeng@126.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230314 PL - United States TA - Stem Cell Rev Rep JT - Stem cell reviews and reports JID - 101752767 RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - 9100L32L2N (Metformin) RN - EC 2.7.1.1 (mTOR protein, rat) SB - IM MH - Rats MH - Animals MH - *AMP-Activated Protein Kinases/pharmacology MH - Cellular Senescence/physiology MH - Aging MH - Stem Cells MH - Tendons MH - TOR Serine-Threonine Kinases MH - *Metformin/pharmacology OTO - NOTNLM OT - AMPK/mTOR axis OT - Age-related tendon disorders OT - Delay aging OT - Metformin OT - Natural aging OT - Tendon stem/progenitor cells EDAT- 2023/03/15 06:00 MHDA- 2023/07/25 06:43 CRDT- 2023/03/14 12:16 PHST- 2023/03/03 00:00 [accepted] PHST- 2023/07/25 06:43 [medline] PHST- 2023/03/15 06:00 [pubmed] PHST- 2023/03/14 12:16 [entrez] AID - 10.1007/s12015-023-10526-0 [pii] AID - 10.1007/s12015-023-10526-0 [doi] PST - ppublish SO - Stem Cell Rev Rep. 2023 Jul;19(5):1492-1506. doi: 10.1007/s12015-023-10526-0. Epub 2023 Mar 14. PMID- 22729622 OWN - NLM STAT- MEDLINE DCOM- 20121217 LR - 20220321 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 40 IP - 8 DP - 2012 Aug TI - Augmentation of tendon healing with butyric acid-impregnated sutures: biomechanical evaluation in a rabbit model. PG - 1762-71 LID - 10.1177/0363546512450691 [doi] AB - BACKGROUND: Butyric acid (BA) has been shown to be angiogenic and to enhance transcriptional activity in tissue. These properties of BA have the potential to augment biological healing of a repaired tendon. PURPOSE: To evaluate this possibility both biomechanically and histologically in an animal tendon repair model. STUDY DESIGN: Controlled laboratory study. METHODS: A rabbit Achilles tendon healing model was used to evaluate the biomechanical strength and histological properties at 6 and 12 weeks after repair. Unilateral tendon defects were created in the middle bundle of the Achilles tendon of each rabbit, which were repaired equivalently with either Ultrabraid BA-impregnated sutures or control Ultrabraid sutures. RESULTS: After 6 weeks, BA-impregnated suture repairs had a significantly increased (P < .0001) Young's modulus and ultimate tensile strength relative to the control suture repairs. At 12 weeks, no statistical difference was observed between these measures. The histological data at 6 weeks demonstrated significantly increased (P < .005) vessel density within 0.25 mm of the repair suture in the BA-impregnated group. There was also an associated 42% increase in the local number of myofibroblasts in the BA samples relative to the controls at this time. By 12 weeks, these differences were not observed. CONCLUSION: Tendons repaired with BA-impregnated sutures demonstrated improved biomechanical properties at 6 weeks relative to control sutures, suggesting a neoangiogenic mechanism of enhanced healing through an increased myofibroblast presence. CLINICAL RELEVANCE: These findings demonstrate that a relatively simple alteration of suture material may augment early tendon healing to create a stronger repair construct during this time. FAU - Leek, Bryan T AU - Leek BT AD - San Diego Sports Medicine and Orthopaedic Center, San Diego, California, USA. FAU - Tasto, James P AU - Tasto JP FAU - Tibor, Lisa M AU - Tibor LM FAU - Healey, Robert M AU - Healey RM FAU - Freemont, Anthony AU - Freemont A FAU - Linn, Michael S AU - Linn MS FAU - Chase, Derek E AU - Chase DE FAU - Amiel, David AU - Amiel D LA - eng PT - Journal Article DEP - 20120622 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Coated Materials, Biocompatible) RN - 107-92-6 (Butyric Acid) SB - IM MH - Achilles Tendon/*drug effects/physiology MH - Animals MH - Biomechanical Phenomena MH - Butyric Acid/*pharmacology MH - *Coated Materials, Biocompatible MH - Models, Animal MH - Neovascularization, Physiologic/*drug effects MH - Rabbits MH - *Sutures MH - Wound Healing/*drug effects/physiology EDAT- 2012/06/26 06:00 MHDA- 2012/12/18 06:00 CRDT- 2012/06/26 06:00 PHST- 2012/06/26 06:00 [entrez] PHST- 2012/06/26 06:00 [pubmed] PHST- 2012/12/18 06:00 [medline] AID - 0363546512450691 [pii] AID - 10.1177/0363546512450691 [doi] PST - ppublish SO - Am J Sports Med. 2012 Aug;40(8):1762-71. doi: 10.1177/0363546512450691. Epub 2012 Jun 22. PMID- 10924043 OWN - NLM STAT- MEDLINE DCOM- 20000912 LR - 20200930 IS - 0363-6135 (Print) IS - 0363-6135 (Linking) VI - 279 IP - 2 DP - 2000 Aug TI - A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. PG - H466-74 AB - Although abnormalities in Purkinje cell (PC) repolarization are important causes of cardiac arrhythmias, the detailed properties of repolarizing currents in PCs are incompletely understood. We compared transient outward K(+) current (I(to)) in single PCs from canine false tendons with midmyocardial ventricular myocytes (VMs). I(to) reactivation was biexponential, with a similar rapid-phase time constant (30 +/- 5 and 35 +/- 4 ms for VM and PC, respectively) but a large, slow component in PCs with a much greater time constant than VM (1,427 +/- 70 vs. 181 +/- 24 ms, P < 0.001). Tetraethylammonium had no effect on VM I(to) but reversibly inhibited PC I(to) (IC(50) = 2.4 +/- 0.4 mM). PC I(to) was also more sensitive to 4-aminopyridine (IC(50) = 50 +/- 7 vs. 526 +/- 49 microM in VM, P < 0.0001). H(2)O(2) slowed I(to) inactivation in PCs but did not affect VM I(to). We conclude that PC I(to) shows significant differences from VM I(to), with some features, such as tetraethylammonium sensitivity, that have been reported in neither cardiac I(to) of atrial or ventricular myocytes nor cloned K(+) channel subunits (Kv1.4, Kv4.2, or Kv4.3) known to participate in cardiac I(to). FAU - Han, W AU - Han W AD - Department of Medicine and Research Center, Montreal Heart Institute, Montreal, Quebec H1T 1C8. FAU - Wang, Z AU - Wang Z FAU - Nattel, S AU - Nattel S LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Elapid Venoms) RN - 0 (Potassium Channels) RN - 66-40-0 (Tetraethylammonium) RN - 74811-93-1 (dendrotoxin) RN - BBX060AN9V (Hydrogen Peroxide) RN - BH3B64OKL9 (4-Aminopyridine) SB - IM MH - 4-Aminopyridine/pharmacology MH - Action Potentials/drug effects/physiology MH - Animals MH - Dogs MH - Elapid Venoms/pharmacology MH - Electric Stimulation MH - Heart/*physiology MH - Heart Atria MH - Heart Ventricles MH - Hydrogen Peroxide/pharmacology MH - Myocardium/cytology MH - Patch-Clamp Techniques MH - Potassium Channels/drug effects/*physiology MH - Purkinje Cells/cytology/*physiology MH - Tetraethylammonium/pharmacology EDAT- 2000/08/03 11:00 MHDA- 2000/09/19 11:01 CRDT- 2000/08/03 11:00 PHST- 2000/08/03 11:00 [pubmed] PHST- 2000/09/19 11:01 [medline] PHST- 2000/08/03 11:00 [entrez] AID - 10.1152/ajpheart.2000.279.2.H466 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2000 Aug;279(2):H466-74. doi: 10.1152/ajpheart.2000.279.2.H466. PMID- 10051031 OWN - NLM STAT- MEDLINE DCOM- 19990428 LR - 20200313 IS - 0032-5791 (Print) IS - 0032-5791 (Linking) VI - 78 IP - 2 DP - 1999 Feb TI - Effects of dietary roxarsone supplementation, lighting program, and season on the incidence of leg abnormalities in broiler chickens. PG - 197-203 AB - Two 4 x 2 factorial experiments were designed to test the effects of four diets, differing in anticoccidial programs and roxarsone (3-nitro-4-hydroxyphenylarsonic acid) content, and two lighting programs on the incidence of leg abnormalities in 56-d-old male and female broiler chickens. The four diets were: A) basal diet + salinomycin (60.0 g/ton); B) basal diet + salinomycin (60.0 g/ton) + roxarsone (45.4 g/ton); C) basal diet + roxarsone (45.4 g/ton) + live coccidial vaccine; and D) basal diet + live coccidial vaccine. The light treatments were: 1) restricted (R) [18 h light (L): 6 h dark (D)] and 2) standard (S) [23L:1D]. The respective experiments were conducted during winter (Experiment 1, November to January) and summer (Experiment 2, June to August) growing conditions in the southeastern U.S. Light treatment had no significant (P > 0.10) effect on the incidence of leg abnormalities in either experiment. However, in Experiment 1, there was a light treatment by sex interaction; leg abnormalities were greater for males on Treatment R than Treatment S. In Experiment 2, females had a higher incidence of leg abnormalities than males (8.29 vs 4.73%). There was a diet by sex interaction for the incidence of leg abnormalities in Experiment 2; females had a greater incidence of leg abnormalities than males on Treatment A. In both experiments, the incidence was greater with dietary treatments containing roxarsone (P < 0.10). The percentage of leg abnormalities was greater in Experiment 2 than Experiment 1. Leg abnormalities were primarily due to fibrosis of the gastrocnemius tendons and tendon sheaths. FAU - Laster, C P AU - Laster CP AD - Department of Pathobiology, Auburn University, Alabama 36849, USA. FAU - Hoerr, F J AU - Hoerr FJ FAU - Bilgili, S F AU - Bilgili SF FAU - Kincaid, S A AU - Kincaid SA LA - eng PT - Journal Article PL - England TA - Poult Sci JT - Poultry science JID - 0401150 RN - 0 (Anti-Bacterial Agents) RN - H5GU9YQL7L (Roxarsone) SB - IM MH - *Animal Feed MH - Animals MH - Anti-Bacterial Agents/*pharmacology MH - Chickens/growth & development/*physiology MH - Female MH - Hindlimb/*abnormalities MH - Light MH - Male MH - Roxarsone/*pharmacology MH - Seasons EDAT- 1999/03/02 00:00 MHDA- 1999/03/02 00:01 CRDT- 1999/03/02 00:00 PHST- 1999/03/02 00:00 [pubmed] PHST- 1999/03/02 00:01 [medline] PHST- 1999/03/02 00:00 [entrez] AID - S0032-5791(19)41281-9 [pii] AID - 10.1093/ps/78.2.197 [doi] PST - ppublish SO - Poult Sci. 1999 Feb;78(2):197-203. doi: 10.1093/ps/78.2.197. PMID- 2036712 OWN - NLM STAT- MEDLINE DCOM- 19910628 LR - 20190706 IS - 0009-7330 (Print) IS - 0009-7330 (Linking) VI - 68 IP - 6 DP - 1991 Jun TI - Rapid and complete recovery of responsiveness to adenosine and norepinephrine by regenerating arterioles of the tibialis anterior muscle of the hamster after in situ autografting. PG - 1600-9 AB - Intravital microscopy studies of small bundles of fibers of the extensor digitorum longus muscle grafted onto the hamster cheek pouch revealed a persistent reduction in the responsiveness of regenerated arterioles to vasoactive agents. We tested the hypothesis that the recovery of responsiveness to vasoactive agents by regenerating arterioles within whole, in situ autografted tibialis anterior muscles occurs earlier and more completely than that reported for regenerating arterioles within bundles of fibers of the extensor digitorum longus muscle grafted ectopically to the hamster cheek pouch. The tibialis anterior muscles of Syrian golden hamsters were excised and soaked in bupivacaine (0.75%) for 10 minutes to ensure uniform degeneration of muscle fibers. The tendons were resutured, and the graft became revascularized spontaneously. Fluorescent intravital microscopy was used to measure the responsiveness of 10-40-microns arterioles to topically applied adenosine and norepinephrine at 7, 14, and 30 days after grafting. Nine to 25 arterioles were studied at each time period. Both intravital and light microscopy were used at each time period to characterize the structural development of the microcirculation. We found that the responsiveness of regenerated arterioles returned to control values for topically applied norepinephrine by 14 days and for adenosine by 30 days. Light microscopy showed regenerated blood vessels in the center of the grafts early in the second week after grafting. The structure of the microcirculation at 7 days was characterized by a plexiform microvascular pattern, long spiderlike capillaries, and arterioles and venules that had irregular walls and an irregular branching pattern. Rhodamine-labeled albumin extravasated spontaneously. The 14-day grafts had a more linear capillary pattern, and the arterioles and venules often contained loops that had circular flow patterns. By 30 days, a parallel capillary structure had developed, no vascular loops were present, and the arteriolar-venular pattern was nearly normal.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Messina, L M AU - Messina LM AD - Department of Surgery, University of Michigan Medical Center, Ann Arbor. FAU - Carlson, B M AU - Carlson BM LA - eng GR - DE-07687/DE/NIDCR NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - K72T3FS567 (Adenosine) RN - X4W3ENH1CV (Norepinephrine) SB - IM MH - Adenosine/*pharmacology MH - Animals MH - Arterioles/anatomy & histology/drug effects/*physiology MH - Cricetinae MH - Hindlimb MH - Mesocricetus MH - Muscles/anatomy & histology/blood supply/*transplantation MH - Norepinephrine/*pharmacology MH - *Regeneration MH - Transplantation, Autologous EDAT- 1991/06/01 00:00 MHDA- 1991/06/01 00:01 CRDT- 1991/06/01 00:00 PHST- 1991/06/01 00:00 [pubmed] PHST- 1991/06/01 00:01 [medline] PHST- 1991/06/01 00:00 [entrez] AID - 10.1161/01.res.68.6.1600 [doi] PST - ppublish SO - Circ Res. 1991 Jun;68(6):1600-9. doi: 10.1161/01.res.68.6.1600. PMID- 11397098 OWN - NLM STAT- MEDLINE DCOM- 20010705 LR - 20131121 IS - 0022-2836 (Print) IS - 0022-2836 (Linking) VI - 309 IP - 3 DP - 2001 Jun 8 TI - Osteogenesis imperfecta murine: interaction between type I collagen homotrimers. PG - 807-15 AB - Types I, II, and III collagens are believed to have evolved from the same homotrimer ancestor and they have substantial sequence homology, but type I molecules are alpha1(I)(2)alpha2(I) heterotrimers, unlike homotrimeric types II and III. It is believed that the alpha2(I) chain first appeared in lower vertebrates and that it plays a particularly important role in bone formation. For instance, spontaneous mutations resulting in non- functional alpha2 chains and formation of type I homotrimers cause severe bone pathology (osteogenesis imperfecta) in humans and in animals. However, the exact role of the alpha2 chain is not known. Here, we report measurements of intermolecular forces between collagen helices in native and reconstituted fibers composed of type I homotrimers, heterotrimers and their mix. For comparison, we report forces between type II homotrimers in reconstituted fibers. In agreement with previous studies, we find that the absence of the alpha2 chain reduces temperature-favored attraction between collagen helices, either because of the difference in amino acid sequence of the alpha1 and alpha2 chains or because of more extensive post-translational modification of homotrimers. We find that forces between helices in fibers from type I (as well as type II) homotrimers are not sensitive to pH between pH 6 and 7.5, in contrast to type I heterotrimers. Apparently, the effect of pH is related to extra histidine residues present on alpha2 chains but not on alpha1 chains. Finally, our measurements indicate that the alpha2 chain is responsible for binding some soluble compound(s), possibly glycosaminoglycans, whose displacement results, e.g., in the loss of tendon crystallinity. The ability of the alpha2 chain to bind non-collagen matrix components may be particularly important for bone matrix formation and mineralization. CI - Copyright 2001 Academic Press. FAU - Kuznetsova, N AU - Kuznetsova N AD - Laboratory of Physical and Structural Biology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA. FAU - McBride, D J Jr AU - McBride DJ Jr FAU - Leikin, S AU - Leikin S LA - eng PT - Journal Article PL - Netherlands TA - J Mol Biol JT - Journal of molecular biology JID - 2985088R RN - 0 (Biopolymers) RN - 059QF0KO0R (Water) RN - 4QD397987E (Histidine) RN - 9007-34-5 (Collagen) RN - PDC6A3C0OX (Glycerol) SB - IM MH - Animals MH - Biopolymers/chemistry/metabolism MH - Collagen/*chemistry/genetics/*metabolism MH - Glycerol/pharmacology MH - Histidine/metabolism MH - Hydrogen-Ion Concentration MH - Mice MH - Osmotic Pressure MH - Osteogenesis Imperfecta/genetics/*metabolism MH - Protein Binding/drug effects MH - Protein Denaturation/drug effects MH - Protein Folding MH - Protein Structure, Quaternary/drug effects MH - Tail MH - Temperature MH - Tendons MH - Water/metabolism EDAT- 2001/06/09 10:00 MHDA- 2001/07/06 10:01 CRDT- 2001/06/09 10:00 PHST- 2001/06/09 10:00 [pubmed] PHST- 2001/07/06 10:01 [medline] PHST- 2001/06/09 10:00 [entrez] AID - S0022283601946820 [pii] AID - 10.1006/jmbi.2001.4682 [doi] PST - ppublish SO - J Mol Biol. 2001 Jun 8;309(3):807-15. doi: 10.1006/jmbi.2001.4682. PMID- 15820258 OWN - NLM STAT- MEDLINE DCOM- 20050524 LR - 20131121 IS - 0022-4804 (Print) IS - 0022-4804 (Linking) VI - 124 IP - 2 DP - 2005 Apr TI - Photochemical repair of Achilles tendon rupture in a rat model. PG - 274-9 AB - BACKGROUND: Photochemical tissue bonding (PTB) is an emerging technique for bonding or sealing tissue surfaces that requires light and a photoactive dye for its effect. The potential of PTB for tendon repair was assessed in a rat model. MATERIALS AND METHODS: The optical properties of bovine tendon were determined ex vivo to gauge the depth of light penetration as a function of wavelength and dosimetry parameters were established for PTB repair of ruptured tendon. PTB was then tested in vivo to repair transected tendons in Sprague-Dawley rats. Repair strengths were measured using a strain gauge up to 14 days post treatment. RESULTS: The effective penetration depth in tendon was estimated to be 0.68 mm at 514 nm. Following PTB treatment of mechanically ruptured tendon, significant bonding was dependent on the presence of both light and dye and attained a plateau strength at a fluence of 125 J/cm2. In a subsequent in vivo study to investigate PTB for repair of transected rat Achilles tendon, the ultimate stress required to break the repaired tendon was measured immediately after irradiation and at 7 and 14 days post-repair. Results showed that the difference in the ultimate stress between control and PTB treatment groups was statistically significant immediately after treatment and at 7 days (p = 0.04) but not 14 days (p = 0.75) post-repair. CONCLUSIONS: PTB provides a benefit to tendon repair at early stages in repair and is worthy of further investigation as a potential surgical adjunct for tendon repair in orthopedic surgeries. FAU - Chan, Barbara P AU - Chan BP AD - Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. FAU - Amann, Christopher AU - Amann C FAU - Yaroslavsky, Anna N AU - Yaroslavsky AN FAU - Title, Craig AU - Title C FAU - Smink, David AU - Smink D FAU - Zarins, Bertram AU - Zarins B FAU - Kochevar, Irene E AU - Kochevar IE FAU - Redmond, Robert W AU - Redmond RW LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Surg Res JT - The Journal of surgical research JID - 0376340 RN - 0 (Fluorescent Dyes) RN - 1ZPG1ELY14 (Rose Bengal) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Disease Models, Animal MH - Fluorescent Dyes/pharmacology MH - *Lasers MH - Male MH - Photochemotherapy/*methods MH - Rats MH - Rats, Sprague-Dawley MH - Rose Bengal/pharmacology MH - Rupture MH - Tendon Injuries/*drug therapy MH - Tensile Strength EDAT- 2005/04/12 09:00 MHDA- 2005/05/25 09:00 CRDT- 2005/04/12 09:00 PHST- 2004/08/03 00:00 [received] PHST- 2005/04/12 09:00 [pubmed] PHST- 2005/05/25 09:00 [medline] PHST- 2005/04/12 09:00 [entrez] AID - S0022-4804(04)00616-X [pii] AID - 10.1016/j.jss.2004.09.019 [doi] PST - ppublish SO - J Surg Res. 2005 Apr;124(2):274-9. doi: 10.1016/j.jss.2004.09.019. PMID- 6465335 OWN - NLM STAT- MEDLINE DCOM- 19840917 LR - 20171213 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 247 IP - 2 Pt 2 DP - 1984 Aug TI - H+-induced membrane depolarization in canine cardiac Purkinje fibers. PG - H312-21 AB - The H+-induced membrane depolarization in canine cardiac Purkinje cells in false tendons was studied. In some electrically paced Purkinje cells ("sensitive" cells), exposure to a pH 6.0 superfusate produced a large membrane depolarization [44.5 +/- 6.7 (SD) mV], whereas other Purkinje cells ("resistant" cells) developed only a small depolarization (9.8 +/- 5.6 mV) even after 60 min of exposure to the low-pH superfusate. Cs+, Ba2+, tetraethylammonium, 9-aminoacridine, verapamil, or exposure to Ca2+- or K+-deficient or hypertonic solutions were capable of converting resistant cells to sensitive cells. Increasing extracellular K+ concentration [( K+]) or rapid electrical pacing failed to convert resistant cells to sensitive cells. Membrane depolarizations of approximately equal magnitude produced in Purkinje cells by either increasing [K+] to 18.2 mM, decreasing [K+] to 0.5 mM, reducing extracellular pH to 4.1, or ouabain administration were associated with membrane resistances of approximately 45, 377, 386, or 45%, respectively, of the membrane resistances in the control solution. The results suggest that the H+-induced membrane depolarization in sensitive Purkinje cells is caused by a mechanism similar to that responsible for a low [K+]-induced depolarization. FAU - Lauer, M R AU - Lauer MR FAU - Rusy, B F AU - Rusy BF FAU - Davis, L D AU - Davis LD LA - eng GR - HL-13375/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Saline Solution, Hypertonic) RN - 0 (Tetraethylammonium Compounds) RN - 1KSV9V4Y4I (Cesium) RN - 24GP945V5T (Barium) RN - 78OY3Z0P7Z (Aminacrine) RN - CJ0O37KU29 (Verapamil) RN - RWP5GA015D (Potassium) RN - SY7Q814VUP (Calcium) SB - IM MH - Aminacrine/pharmacology MH - Animals MH - Barium/pharmacology MH - Calcium/physiology MH - Cesium/pharmacology MH - Dogs MH - Heart Conduction System/*physiology MH - *Hydrogen-Ion Concentration MH - Membrane Potentials MH - Potassium/pharmacology MH - Purkinje Fibers/*physiology MH - Saline Solution, Hypertonic MH - Tetraethylammonium Compounds/pharmacology MH - Verapamil/pharmacology EDAT- 1984/08/01 00:00 MHDA- 1984/08/01 00:01 CRDT- 1984/08/01 00:00 PHST- 1984/08/01 00:00 [pubmed] PHST- 1984/08/01 00:01 [medline] PHST- 1984/08/01 00:00 [entrez] AID - 10.1152/ajpheart.1984.247.2.H312 [doi] PST - ppublish SO - Am J Physiol. 1984 Aug;247(2 Pt 2):H312-21. doi: 10.1152/ajpheart.1984.247.2.H312. PMID- 37864473 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20240627 IS - 2192-2659 (Electronic) IS - 2192-2640 (Linking) VI - 13 IP - 4 DP - 2024 Feb TI - Decellularization-Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair. PG - e2302660 LID - 10.1002/adhm.202302660 [doi] AB - Xenografts have emerged as a promising option for severe tendon defects treatment. However, despite undergoing decellularization, concerns still remain regarding the immunogenicity of xenografts. Because certain components within the extracellular matrix also possess immunogenicity. In this study, a novel strategy of post-decellularization modification aimed at preserving the endogenous capacity of cells on collagen synthesis to mask antigenic epitopes in extracellular matrix is proposed. To implement this strategy, a human-derived rosiglitazone-loaded decellularized extracellular matrix (R-dECM) is developed. R-dECM can release rosiglitazone for over 7 days in vitro. By suppressing M1 macrophage polarization, R-dECM protects the migration and collagen synthesis abilities of tendon-derived stem cells (TDSCs), while also stabilizing the phenotype of M2 macrophages in vitro. RNA sequencing reveals R-dECM can mitigate the detrimental crosstalk between TDSCs and inflammatory cells. When applied to a rat patellar tendon defect model, R-dECM effectively inhibits early inflammation, preventing chronic inflammation. Its duration of function far exceeds the release time of rosiglitazone, implying the establishment of immune evasion, confirming the effectiveness of the proposed strategy. And R-dECM demonstrates superior tendon repair outcomes compared to dECM. Thus, this study provides a novel bioactive scaffold with the potential to enhance the long-term clinical outcomes of xenogeneic tendon grafts. CI - © 2023 Wiley-VCH GmbH. FAU - Jin, Haocheng AU - Jin H AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Kang, Yuhao AU - Kang Y AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Gao, Haihan AU - Gao H AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Lin, Zhiqi AU - Lin Z AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Huang, Dongcheng AU - Huang D AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Zheng, Zhi AU - Zheng Z AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Zhao, Jinzhong AU - Zhao J AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Wang, Liren AU - Wang L AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. FAU - Jiang, Jia AU - Jiang J AUID- ORCID: 0009-0002-7616-2498 AD - Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yishan Rd, Shanghai, 200233, P. R. China. LA - eng GR - 81871753/National Natural Science Foundation of China/ GR - 31972923/National Natural Science Foundation of China/ GR - 82272570/National Natural Science Foundation of China/ GR - 2021057/Shanghai Talent Development Fund/ GR - 2021JCPTO2/Shanghai Jiao Tong University Science and Technology Innovation Special Fund/ GR - 22dz1204700/Shanghai Science and Technology Committee/ GR - SUITM-2023005/Foundation of National Center for Translational Medicine (Shanghai) SHU Branch/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231123 PL - Germany TA - Adv Healthc Mater JT - Advanced healthcare materials JID - 101581613 RN - 05V02F2KDG (Rosiglitazone) RN - 9007-34-5 (Collagen) SB - IM MH - Humans MH - Rats MH - Animals MH - Heterografts MH - Rosiglitazone/pharmacology MH - *Extracellular Matrix MH - *Inflammation MH - Collagen MH - Tendons MH - Tissue Engineering MH - Tissue Scaffolds OTO - NOTNLM OT - immunogenicity OT - rosiglitazone OT - tendon defects OT - xenografts EDAT- 2023/10/21 10:42 MHDA- 2024/02/07 06:42 CRDT- 2023/10/21 05:53 PHST- 2023/10/09 00:00 [revised] PHST- 2023/08/13 00:00 [received] PHST- 2024/02/07 06:42 [medline] PHST- 2023/10/21 10:42 [pubmed] PHST- 2023/10/21 05:53 [entrez] AID - 10.1002/adhm.202302660 [doi] PST - ppublish SO - Adv Healthc Mater. 2024 Feb;13(4):e2302660. doi: 10.1002/adhm.202302660. Epub 2023 Nov 23. PMID- 38044475 OWN - NLM STAT- MEDLINE DCOM- 20240415 LR - 20250305 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 42 IP - 5 DP - 2024 May TI - Lidocaine inhibits migration of tenocytes by downregulating focal adhesion kinase and paxillin phosphorylation. PG - 985-992 LID - 10.1002/jor.25762 [doi] AB - Lidocaine is the most frequently applied local infiltration anesthetic agent for treating tendinopathies. However, studies have discovered lidocaine to negatively affect tendon healing. In the current study, the molecular mechanisms and effects of lidocaine on tenocyte migration were evaluated. We treated tenocytes intrinsic to the Achilles tendons of Sprague-Dawley rats with lidocaine. The migration ability of cells was analyzed using electric cell-substrate impedance sensing (ECIS) and scratch wound assay. We then used a microscope to evaluate the cell spread. We assessed filamentous actin (F-actin) cytoskeleton formation through immunofluorescence staining. In addition, we used Western blot analysis to analyze the expression of phospho-focal adhesion kinase (FAK), FAK, phospho-paxillin, paxillin, and F-actin. We discovered that lidocaine had an inhibitory effect on the migration of tenocytes in the scratch wound assay and on the ECIS chip. Lidocaine treatment suppressed cell spreading and changed the cell morphology and F-actin distribution. Lidocaine reduced F-actin formation in the tenocyte during cell spreading; furthermore, it inhibited phospho-FAK, F-actin, and phospho-paxillin expression in the tenocytes. Our study revealed that lidocaine inhibits the spread and migration of tenocytes. The molecular mechanism potentially underlying this effect is downregulation of F-actin, phospho-FAK, and phospho-paxillin expression when cells are treated with lidocaine. CI - © 2023 Orthopaedic Research Society. FAU - Chang, Hsiang-Ning AU - Chang HN AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. FAU - Chen, Chih-Kuang AU - Chen CK AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Taoyuan, Taoyuan City, Taiwan. FAU - Yu, Tung-Yang AU - Yu TY AUID- ORCID: 0000-0003-3320-9866 AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. FAU - Pang, Jong-Hwei S AU - Pang JS AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City, Taiwan. FAU - Hsu, Chih-Chin AU - Hsu CC AUID- ORCID: 0000-0002-5558-3456 AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Keelung, Keelung City, Taiwan. FAU - Lin, Li-Ping AU - Lin LP AUID- ORCID: 0000-0001-6208-0075 AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Taoyuan, Taoyuan City, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City, Taiwan. FAU - Tsai, Wen-Chung AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Taoyuan, Taoyuan City, Taiwan. AD - School of Medicine, Chang Gung University, Taoyuan City, Taiwan. AD - Center of Comprehensive Sports Medicine, Chang Gung Memorial Hospital at Taoyuan, Taoyuan City, Taiwan. LA - eng GR - CMRPG3H1891/Chang Gung Memorial Hospital, Linkou, Taiwan/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231213 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Actins) RN - EC 2.7.10.2 (Focal Adhesion Protein-Tyrosine Kinases) RN - 98PI200987 (Lidocaine) RN - 0 (Paxillin) SB - IM MH - Animals MH - Rats MH - *Achilles Tendon/drug effects/metabolism MH - *Actins/drug effects/metabolism MH - Cell Adhesion MH - Cell Movement MH - Focal Adhesion Protein-Tyrosine Kinases/drug effects/metabolism MH - *Lidocaine/pharmacology MH - Paxillin/drug effects/metabolism MH - Phosphorylation MH - Rats, Sprague-Dawley MH - *Tenocytes/drug effects/metabolism OTO - NOTNLM OT - cell migration OT - focal adhesion kinase OT - lidocaine OT - paxillin OT - tenocyte EDAT- 2023/12/04 00:42 MHDA- 2024/04/15 06:44 CRDT- 2023/12/03 23:33 PHST- 2023/11/27 00:00 [revised] PHST- 2023/08/13 00:00 [received] PHST- 2023/11/29 00:00 [accepted] PHST- 2024/04/15 06:44 [medline] PHST- 2023/12/04 00:42 [pubmed] PHST- 2023/12/03 23:33 [entrez] AID - 10.1002/jor.25762 [doi] PST - ppublish SO - J Orthop Res. 2024 May;42(5):985-992. doi: 10.1002/jor.25762. Epub 2023 Dec 13. PMID- 15363164 OWN - NLM STAT- MEDLINE DCOM- 20050324 LR - 20191210 IS - 1076-3279 (Print) IS - 1076-3279 (Linking) VI - 10 IP - 7-8 DP - 2004 Jul-Aug TI - Development of cell-seeded patellar tendon allografts for anterior cruciate ligament reconstruction. PG - 1065-75 AB - Patellar tendon (PT) allografts for anterior cruciate ligament (ACL) reconstruction are potentially immunogenic and incorporate slowly compared with autografts. Our tissue-engineering approach to improve allograft efficacy is to (1) remove intrinsic cells from the graft to reduce antigenicity and then (2) seed the graft with extrinsic cells to improve ligamentization. To remove cells, tendons were soaked in 1% extraction solutions of tri(n-butyl)phosphate (TBP) or sodium dodecyl sulfate (SDS) for various time periods (24-72 h) and rinsed exhaustively. After treatment, we measured tendon cellularity, crimp structure, and mechanical properties. Treatment with either SDS or TBP removed approximately 70-90% of the intrinsic PT cells. Mechanical properties of treated PTs were similar to those of controls, despite changes in appearance. TBP- and SDS-treated PTs were then seeded with fibroblasts and cultured for up to 2 weeks in vitro. Fibroblast proliferation was retarded on SDS-treated PTs; in contrast, TBP-treated PTs supported cell proliferation similar to that of untreated controls. Extrinsic fibroblasts were successfully cultured on the TBP-treated PTs in vitro, creating viable tissue-engineered grafts potentially useful for ACL reconstruction. These modified allografts have the potential to be developed into mechanically functional delivery vehicles for cells, gene therapy vectors, or other biological agents. FAU - Cartmell, Jeffrey S AU - Cartmell JS AD - Orthopedic Research Laboratories, Department of Orthopedic Surgery, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA. FAU - Dunn, Michael G AU - Dunn MG LA - eng GR - R29-AR42230/AR/NIAMS NIH HHS/United States PT - Comparative Study PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Tissue Eng JT - Tissue engineering JID - 9505538 RN - 0 (Organophosphates) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 95UAS8YAF5 (tributyl phosphate) SB - IM MH - Animals MH - Anterior Cruciate Ligament/*pathology/*surgery MH - Anterior Cruciate Ligament Injuries MH - Cell Culture Techniques/methods MH - Cell Proliferation MH - Cell Survival MH - Cells, Cultured MH - Elasticity MH - Fibroblasts/cytology/drug effects/*physiology/*transplantation MH - Humans MH - Organophosphates/pharmacology MH - Patellar Ligament/cytology/drug effects/*physiology/*transplantation MH - Rabbits MH - Sodium Dodecyl Sulfate/pharmacology MH - Tensile Strength MH - Tissue Engineering/*methods MH - Transplantation, Homologous/methods EDAT- 2004/09/15 05:00 MHDA- 2005/03/25 09:00 CRDT- 2004/09/15 05:00 PHST- 2004/09/15 05:00 [pubmed] PHST- 2005/03/25 09:00 [medline] PHST- 2004/09/15 05:00 [entrez] AID - 10.1089/ten.2004.10.1065 [doi] PST - ppublish SO - Tissue Eng. 2004 Jul-Aug;10(7-8):1065-75. doi: 10.1089/ten.2004.10.1065. PMID- 15077693 OWN - NLM STAT- MEDLINE DCOM- 20040702 LR - 20190917 IS - 0002-9645 (Print) IS - 0002-9645 (Linking) VI - 65 IP - 4 DP - 2004 Apr TI - In vitro effects of oxytetracycline on matrix metalloproteinase-1 mRNA expression and on collagen gel contraction by cultured myofibroblasts obtained from the accessory ligament of foals. PG - 491-6 AB - OBJECTIVE: To determine the effects of oxytetracycline on matrix metalloproteinase-1 (MMP-1) mRNA expression and collagen gel contraction by equine myofibroblasts in an effort to explain the mechanistic basis for the pharmacologic treatment of flexural deformities in foals. SAMPLE POPULATION: Cultured myofibroblasts from the accessory ligament (distal check ligament) of 6 foals. PROCEDURE: Collagen gel scaffolds seeded with equine myofibroblasts were cultured in individual culture dishes containing complete media (Dulbecco's modified Eagle medium with 10% fetal bovine serum) and oxytetracycline (0, 12.5, 25, or 75 microg/mL) for 48 hours. After 24 hours, the gels were released from the bottom of the culture plate and allowed to contract. Photographs were taken at 0, 1, 2, 4, 6, 8, and 24 hours after release to assess the degree of collagen gel contraction. Additional gels were harvested at 2 hours after release for RNA isolation and reverse transcriptase-polymerase chain reaction assessment of the degree of MMP-1 mRNA expression. RESULTS: Oxytetracycline induced a dose-dependent inhibition of collagen gel contraction by equine myofibroblasts. Oxytetracycline also induced a dose-dependent decrease in MMP-1 mRNA expression by equine myofibroblasts. CONCLUSIONS AND CLINICAL RELEVANCE: Results of this study indicate that oxytetracycline inhibits tractional structuring of collagen fibrils by equine myofibroblasts through an MMP-1 mediated mechanism. In young foals, oxytetracycline administration may make the developing ligaments and tendons more susceptible to elongation during normal weight-bearing. Inhibition of normal collagen organization may provide the mechanistic explanation for the results seen following the pharmacologic treatment of flexural deformities in foals by oxytetracycline administration. FAU - Arnoczky, Steven P AU - Arnoczky SP AD - Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA. FAU - Lavagnino, Michael AU - Lavagnino M FAU - Gardner, Keri L AU - Gardner KL FAU - Tian, Tao AU - Tian T FAU - Vaupel, Zachary M AU - Vaupel ZM FAU - Stick, John A AU - Stick JA LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Vet Res JT - American journal of veterinary research JID - 0375011 RN - 0 (Gels) RN - 0 (RNA, Messenger) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) RN - X20I9EN955 (Oxytetracycline) SB - IM MH - Analysis of Variance MH - Animals MH - Collagen/*drug effects/metabolism MH - Gels/metabolism MH - Gene Expression/*drug effects MH - Horses MH - In Vitro Techniques MH - Matrix Metalloproteinase 1/genetics/*metabolism MH - Oxytetracycline/*pharmacology MH - RNA, Messenger/genetics/*metabolism MH - Tumor Cells, Cultured EDAT- 2004/04/14 05:00 MHDA- 2004/07/03 05:00 CRDT- 2004/04/14 05:00 PHST- 2004/04/14 05:00 [pubmed] PHST- 2004/07/03 05:00 [medline] PHST- 2004/04/14 05:00 [entrez] AID - 10.2460/ajvr.2004.65.491 [doi] PST - ppublish SO - Am J Vet Res. 2004 Apr;65(4):491-6. doi: 10.2460/ajvr.2004.65.491. PMID- 8391227 OWN - NLM STAT- MEDLINE DCOM- 19930727 LR - 20190704 IS - 0003-2999 (Print) IS - 0003-2999 (Linking) VI - 77 IP - 1 DP - 1993 Jul TI - The effects of halothane and isoflurane on slowly inactivating sodium current in canine cardiac Purkinje cells. PG - 32-7 AB - The effects of halothane (0.45 and 0.9 mM, equivalent to 0.7 and 1.5 vol%, respectively) and isoflurane (0.56 and 1.23 mM, equivalent to 0.9 and 2.0 vol%) on slowly inactivating Na+ current were examined by whole-cell voltage-clamp techniques. This approach allows evaluation of the role of anesthetic inhibition of inward Na+ current on the action potentials of canine Purkinje fibers isolated from the false tendons. Cells were superfused with Tyrode's solution containing nifedipine and Ni2+ to block Ca2+ channel currents and internally dialyzed with Cs+ to block outward K+ currents. Veratridine (0.5 microM) was used throughout the experiments to enhance the slow Na+ current. Na+ current was elicited by depolarizing pulses from a holding potential of -100 mV to stepwise (10 mV increments) more positive membrane potentials and measured at 200 ms after initiation of the voltage pulse before, during, and after exposure to anesthetics. Slowly inactivating Na+ current showed threshold activation at -80 mV and peak activation around -55 to -40 mV. This current was abolished by 5 microM tetrodotoxin, showing the characteristic feature of Na+ channel current. Halothane and isoflurane depressed the amplitude of slowly inactivating Na+ current in a concentration-dependent manner and did not shift the current-voltage relationship for slow Na+ current activation. There was no significant difference between the sensitivities of slow Na+ current to halothane or isoflurane at equianesthetic concentrations. Inhibition of slow inward Na+ current may contribute to the marked decrease of action potential duration produced by volatile anesthetics in false tendon Purkinje fibers but does not account for the larger decreases of duration produced by isoflurane than halothane.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Eskinder, H AU - Eskinder H AD - Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226. FAU - Supan, F D AU - Supan FD FAU - Turner, L A AU - Turner LA FAU - Kampine, J P AU - Kampine JP FAU - Bosnjak, Z J AU - Bosnjak ZJ LA - eng GR - GM 08377/GM/NIGMS NIH HHS/United States GR - HL 01901/HL/NHLBI NIH HHS/United States GR - HL 39776/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Anesth Analg JT - Anesthesia and analgesia JID - 1310650 RN - 0 (Sodium Channels) RN - CYS9AKD70P (Isoflurane) RN - RWP5GA015D (Potassium) RN - UQT9G45D1P (Halothane) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Dogs MH - Halothane/*pharmacology MH - Heart/*drug effects MH - Isoflurane/*pharmacology MH - Potassium/metabolism MH - Purkinje Fibers/drug effects MH - Sodium Channels/*drug effects EDAT- 1993/07/01 00:00 MHDA- 1993/07/01 00:01 CRDT- 1993/07/01 00:00 PHST- 1993/07/01 00:00 [pubmed] PHST- 1993/07/01 00:01 [medline] PHST- 1993/07/01 00:00 [entrez] AID - 10.1213/00000539-199307000-00007 [doi] PST - ppublish SO - Anesth Analg. 1993 Jul;77(1):32-7. doi: 10.1213/00000539-199307000-00007. PMID- 7139882 OWN - NLM STAT- MEDLINE DCOM- 19830107 LR - 20190706 IS - 0009-7330 (Print) IS - 0009-7330 (Linking) VI - 51 IP - 5 DP - 1982 Nov TI - Effects of extracellular calcium ions, verapamil, and lanthanum on active and passive properties of canine cardiac purkinje fibers. PG - 637-51 AB - The effects of alteration of extracellular calcium ion concentration ([Ca++]o) were studied in isolated false tendons using microelectrode techniques. Several determinants of cellular excitability and conduction velocity were affected by extracellular calcium. Increasing [Ca++]o from 2 to 8 mM resulted in: (1) a progressive decrease in interelectrode conduction velocity (2) a 7-mV shift of the maximum upstroke velocity-membrane potential relation toward less negative potential, (3) an increase in rheobasic current, (4) a 14-mV shift of the voltage threshold for all-or-none depolarization to less negative potentials, (5) a 52% increase in internal longitudinal resistance per unit length, and (6) a 27% decrease in the capacitance filled by the foot of the action potential from 4.90 to 3.56 microF/cm2. Blockade of the slow inward current by Mn++ or verapamil did not alter the [Ca++]o-induced effects on the maximum upstroke velocity-membrane potential relation. Cable properties were determined during alteration of [Ca++]o in the presence of verapamil (3 X 10(-6) and 1 X 10(-5) M) or in the presence of La+++ (0.2 mM). Verapamil increased membrane resistance X unit length but did not affect internal longitudinal resistance per unit length. La+++ had no effects on either membrane resistance X unit length or internal longitudinal resistance per unit length. Verapamil did not block the increase in ri induced by elevation of [Ca++]o. However, no change in ri occurred during an increase of [Ca++]o when La+++ was present. The results suggest that [Ca++]o-induced changes in internal longitudinal resistance may occur by the influx of calcium ions through the Na+/Ca++ exchange mechanism. FAU - Pressler, M L AU - Pressler ML FAU - Elharrar, V AU - Elharrar V FAU - Bailey, J C AU - Bailey JC LA - eng GR - HL06242/HL/NHLBI NIH HHS/United States GR - HL06308/HL/NHLBI NIH HHS/United States GR - HL07182/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 0 (Buffers) RN - 0 (Calcium Channel Blockers) RN - 6I3K30563S (Lanthanum) RN - CJ0O37KU29 (Verapamil) RN - SY7Q814VUP (Calcium) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Biological Transport, Active/drug effects MH - Buffers MH - Calcium/*metabolism/pharmacology MH - Calcium Channel Blockers/pharmacology MH - Dogs MH - Extracellular Space/metabolism MH - Heart Conduction System/*metabolism MH - Lanthanum/*pharmacology MH - Purkinje Fibers/drug effects/*metabolism MH - Verapamil/*pharmacology EDAT- 1982/11/01 00:00 MHDA- 1982/11/01 00:01 CRDT- 1982/11/01 00:00 PHST- 1982/11/01 00:00 [pubmed] PHST- 1982/11/01 00:01 [medline] PHST- 1982/11/01 00:00 [entrez] AID - 10.1161/01.res.51.5.637 [doi] PST - ppublish SO - Circ Res. 1982 Nov;51(5):637-51. doi: 10.1161/01.res.51.5.637. PMID- 37700364 OWN - NLM STAT- MEDLINE DCOM- 20230914 LR - 20231120 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 18 IP - 1 DP - 2023 Sep 12 TI - Metformin increases the expression of proinflammatory cytokines and inhibits supraspinatus fatty infiltration. PG - 674 LID - 10.1186/s13018-023-04163-z [doi] LID - 674 AB - BACKGROUND: After a rotator cuff (RC) tendon tear, the supraspinatus (SS) inflammatory response induces fatty infiltration (FI). Metformin has the effect of regulating the initial inflammatory response of atrophic muscles. Therefore, this study aimed to investigate the effect of metformin use on modulating the expression of proinflammatory cytokines and SS FI in an acute RC tear rat model. METHODS: This study used 26 male Sprague-Dawley rats. Animals were randomly divided into two groups: The metformin group received metformin for 5 days after cutting the RC tendon, and the control group was administered only with saline after cutting the tendon. Metformin 50 mg/kg was intraperitoneally injected for 5 days. Three rats in each group were sacrificed 5 days after SS tendon rupture surgery, and 10 rats in each group were sacrificed 14 days after surgery. The SS was sampled 5 days after SS tendon tear surgery, and the expression of proinflammatory cytokines was measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). On day 14 after sampling, histological analysis of the SS was performed using hematoxylin and eosin, Masson's trichrome, and picrosirius red staining. RESULTS: On day 5 of surgery, the expression values of interferon gamma (increased 7.2-fold, P < .01), tumor necrosis factor alpha (increased 13-fold, P < .05), interleukin-1β (increased 4.7-fold, P < .001), and interleukin-6 (increased 4.6-fold, P < .01) increased significantly in the metformin group compared with those in the control group. As a result of Oil Red O staining, SS FI was significantly suppressed in the metformin group compared with that in the control group (metformin group, 305 ± 50.3 µm(2), P < .001; control group, 3136 ± 662.8 µm(2), P < .001). In addition, the SS volume of the metformin group was not reduced compared with those of the control group, and the morphology and structure of the SS were better preserved. CONCLUSIONS: The results of this study revealed that metformin can increase the expression of proinflammatory cytokines and suppress SS fat infiltration in delayed sutures. CI - © 2023. BioMed Central Ltd., part of Springer Nature. FAU - Yoon, Jong Pil AU - Yoon JP AD - Department of Orthopaedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Park, Sung-Jin AU - Park SJ AD - Department of Orthopaedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. knuhos_sh2@naver.com. FAU - Kim, Dong-Hyun AU - Kim DH AD - Department of Orthopaedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Chung, Seok Won AU - Chung SW AD - Department of Orthopaedic Surgery, School of Medicine, Konkuk University Medical Center, Seoul, Korea. LA - eng PT - Journal Article DEP - 20230912 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Cytokines) RN - 9100L32L2N (Metformin) SB - IM MH - Male MH - Animals MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff MH - Cytokines MH - Tendons MH - *Rotator Cuff Injuries/drug therapy/surgery MH - *Metformin/pharmacology PMC - PMC10496168 OTO - NOTNLM OT - Fatty infiltration OT - Histology OT - Inflammatory response OT - Metformin OT - Rotator cuff tear OT - Supraspinatus atrophy COIS- All authors declare that they have no competing interests. EDAT- 2023/09/13 00:42 MHDA- 2023/09/14 06:42 PMCR- 2023/09/12 CRDT- 2023/09/12 23:49 PHST- 2023/07/12 00:00 [received] PHST- 2023/09/04 00:00 [accepted] PHST- 2023/09/14 06:42 [medline] PHST- 2023/09/13 00:42 [pubmed] PHST- 2023/09/12 23:49 [entrez] PHST- 2023/09/12 00:00 [pmc-release] AID - 10.1186/s13018-023-04163-z [pii] AID - 4163 [pii] AID - 10.1186/s13018-023-04163-z [doi] PST - epublish SO - J Orthop Surg Res. 2023 Sep 12;18(1):674. doi: 10.1186/s13018-023-04163-z. PMID- 23574488 OWN - NLM STAT- MEDLINE DCOM- 20140526 LR - 20161125 IS - 2042-3306 (Electronic) IS - 0425-1644 (Linking) VI - 45 IP - 6 DP - 2013 Nov TI - Distribution and persistence of technetium-99 hexamethyl propylene amine oxime-labelled bone marrow-derived mesenchymal stem cells in experimentally induced tendon lesions after intratendinous injection and regional perfusion of the equine distal limb. PG - 726-31 LID - 10.1111/evj.12063 [doi] AB - REASONS FOR PERFORMING STUDY: Intralesional (i.l.) injection is currently the most commonly used technique for stem cell therapy in equine tendon injury. A comparison of different techniques of injection of mesenchymal stem cells for the treatment of tendon lesions is required. OBJECTIVES: We hypothesised that vascular perfusion of the equine distal limb with mesenchymal stem cells (MSCs) would result in preferential distribution of MSCs to acute tendon injuries. STUDY DESIGN: In vivo experimental study. METHODS: Lesions were surgically induced in forelimb superficial digital flexor tendons of 8 horses. Three or 10 days after lesion induction, technetium-99 hexamethyl propylene amine oxime-labelled MSCs were injected via i.v. or intra-arterial (i.a.) regional limb perfusion (RLP) at the level of the distal antebrachium and compared to i.l. injection. Mesenchymal stem cell persistence and distribution within the forelimb and tendon lesions was assessed with scintigraphy for 24 h. RESULTS: Lesion uptake was higher with i.l. injection than with RLP, but MSC persistence decreased similarly over time in all 3 techniques. Intra-arterial RLP resulted in a better distribution of MSCs and a higher uptake at the lesion site than i.v. RLP. Limbs perfused i.a. on Day 10 showed greater accumulation of MSCs in the lesion than limbs perfused on Day 3. Arterial thrombosis occurred in 50% of the i.v. RLP limbs and in 100% of the i.a. RLP limbs, which led to clinical complications in one horse. CONCLUSIONS AND POTENTIAL RELEVANCE: Compared with i.l. injection, RLP results in lower uptake but similar persistence of MSCs at the site of tendon lesions. A time dependent accumulation of MSCs was identified with i.a. RLP. The i.a. RLP appears more advantageous than the i.v. RLP in terms of distribution and uptake. However, the described i.a. technique produced arterial thrombosis and thus cannot currently be recommended for clinical use. CI - © 2013 EVJ Ltd. FAU - Sole, A AU - Sole A AD - Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, USA. FAU - Spriet, M AU - Spriet M FAU - Padgett, K A AU - Padgett KA FAU - Vaughan, B AU - Vaughan B FAU - Galuppo, L D AU - Galuppo LD FAU - Borjesson, D L AU - Borjesson DL FAU - Wisner, E R AU - Wisner ER FAU - Vidal, M A AU - Vidal MA LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130409 PL - United States TA - Equine Vet J JT - Equine veterinary journal JID - 0173320 RN - 3B744AG22N (Technetium Tc 99m Exametazime) SB - IM MH - Animals MH - Female MH - Forelimb MH - Horse Diseases/diagnostic imaging/*therapy MH - Horses MH - Macrophages/*metabolism MH - Male MH - Mesenchymal Stem Cell Transplantation/*veterinary MH - Radionuclide Imaging/veterinary MH - Technetium Tc 99m Exametazime/*pharmacology MH - Tendon Injuries/diagnostic imaging/*therapy MH - Ultrasonography OTO - NOTNLM OT - HMPAO OT - experimental injury OT - horse OT - mesenchymal stem cell OT - regional limb perfusion OT - scintigraphy OT - superficial digital flexor tendon EDAT- 2013/04/12 06:00 MHDA- 2014/05/27 06:00 CRDT- 2013/04/12 06:00 PHST- 2012/09/02 00:00 [received] PHST- 2013/01/27 00:00 [accepted] PHST- 2013/04/12 06:00 [entrez] PHST- 2013/04/12 06:00 [pubmed] PHST- 2014/05/27 06:00 [medline] AID - 10.1111/evj.12063 [doi] PST - ppublish SO - Equine Vet J. 2013 Nov;45(6):726-31. doi: 10.1111/evj.12063. Epub 2013 Apr 9. PMID- 37977426 OWN - NLM STAT- MEDLINE DCOM- 20231206 LR - 20231216 IS - 1872-7573 (Electronic) IS - 0378-8741 (Linking) VI - 320 DP - 2024 Feb 10 TI - Insights into the inhibition of stomach cancer MKN45 cell growth by Poria cocos ethanol-soluble extract based on MAPK/PI3K signaling pathways and components cell fishing. PG - 117417 LID - S0378-8741(23)01287-4 [pii] LID - 10.1016/j.jep.2023.117417 [doi] AB - ETHNOPHARMACOLOGICAL RELEVANCE: Poria cocos F.A. Wolf is an edible fungus with forming sclerotia, which has the effects of promoting diuresis, exuding dampness, invigorating the spleen, and regulating the stomach. P. cocos has a high application in the clinic of traditional Chinese medicine, and some studies have indicated that P. cocos has a good effect on tumor diseases. According to ancient records and modern studies, P. cocos wine offers beneficial effects in terms of strengthening tendons and bones and anti-tumor effects. AIM OF THE STUDY: To understand the substance composition of P. cocos ethanol-soluble extract (PESE) and then further study the effect and potential mechanism of PESE components on gastric cancer. MATERIALS AND METHODS: In vitro and in vivo experiments were performed to detect the cell activity and apoptotic condition. Differential expression analysis and pathway enrichment were performed based on transcriptomics and were verified by real-time polymerase chain reaction and western blotting. The mice of the stomach cancer tumor model were randomly categorized into three groups. The weight and tumor volume of the mice were measured, and the pathological characteristics of tumor tissue and immunohistochemical changes were determined. Then, the main active components of PESE were detected by MKN45 cell fishing. RESULTS: In vitro experiments showed that PESE inhibited the proliferation of MKN45 cells, but it did not induce apoptosis. Based on the transcriptome and western blotting results, the inhibition of MKN45 proliferation by PESE may be influenced by mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase-protein kinase B (PI3K-Akt) signaling pathways. In vivo experiments showed that PESE inhibited tumor growth in mice and caused partial necrosis of tumor cells but had no toxic effect on mice. Cell fishing identified nine triterpenoids of P. cocos as the major active components of PESE. CONCLUSIONS: The results indicated that PESE has a significant inhibitory effect on stomach cancer, and its mechanism probably commonly affects the MAPK and PI3K-Akt signaling pathways, which could be due to the triterpenoid components. CI - Copyright © 2023 Elsevier B.V. All rights reserved. FAU - Xie, Zhenni AU - Xie Z AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China; Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, 410036, China. FAU - Zeng, Hongliang AU - Zeng H AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China; Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, 410036, China. FAU - He, Dan AU - He D AD - Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, 410036, China. FAU - Luo, Ji AU - Luo J AD - The Affiliated Hospital of Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China. FAU - Liu, Tingting AU - Liu T AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China. FAU - Shen, Bingbing AU - Shen B AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China. FAU - Qin, You AU - Qin Y AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China. FAU - Zhang, Shuihan AU - Zhang S AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China; Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan, 410036, China. FAU - Jin, Jian AU - Jin J AD - Institute of Chinese Medicine Resources, Hunan Academy of Chinese Medicine, Changsha, Hunan, 410013, China. Electronic address: jinjian2016@163.com. LA - eng PT - Journal Article DEP - 20231117 PL - Ireland TA - J Ethnopharmacol JT - Journal of ethnopharmacology JID - 7903310 RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.1.- (Phosphatidylinositol 3-Kinases) RN - 3K9958V90M (Ethanol) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinases) SB - IM MH - Mice MH - Animals MH - Proto-Oncogene Proteins c-akt MH - *Wolfiporia/chemistry MH - Phosphatidylinositol 3-Kinases MH - *Stomach Neoplasms/drug therapy MH - Ethanol/pharmacology MH - Signal Transduction MH - Mitogen-Activated Protein Kinases MH - *Poria/chemistry OTO - NOTNLM OT - Anti-proliferation OT - MAPK3 OT - PIK3R3 OT - Poria cocos triterpenoids component fraction OT - Stomach cancer COIS- Declaration of competing interest All authors have read and approved the submitted manuscript. And the author declared no conflict of interests. EDAT- 2023/11/18 11:42 MHDA- 2023/12/06 06:42 CRDT- 2023/11/17 19:38 PHST- 2023/10/07 00:00 [received] PHST- 2023/11/02 00:00 [revised] PHST- 2023/11/09 00:00 [accepted] PHST- 2023/12/06 06:42 [medline] PHST- 2023/11/18 11:42 [pubmed] PHST- 2023/11/17 19:38 [entrez] AID - S0378-8741(23)01287-4 [pii] AID - 10.1016/j.jep.2023.117417 [doi] PST - ppublish SO - J Ethnopharmacol. 2024 Feb 10;320:117417. doi: 10.1016/j.jep.2023.117417. Epub 2023 Nov 17. PMID- 29806433 OWN - NLM STAT- MEDLINE DCOM- 20180723 LR - 20210930 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 31 IP - 8 DP - 2017 Aug 15 TI - [Effect of silk fibroin/poly ( L-lactic acid-co-e-caprolactone) nanofibrous scaffold on tendon-bone healing of rabbits]. PG - 957-962 LID - 10.7507/1002-1892.201704077 [doi] AB - OBJECTIVE: To explore the effect of silk fibroin/poly( L-lactic acid-co-e-caprolactone) [SF/P(LLA-CL)] nanofibrous scaffold on tendon-bone healing of rabbits. METHODS: SF/P(LLA-CL) nanofibrous scaffold was fabricated by electrospinning methods. The morphology of the scaffold was observed by scanning electron microscope (SEM). Pre-osteoblasts MC3T3-E1 cells were seeded on the scaffold and cultured for 1, 3, and 5 days. Cell adhesion and proliferation were also observed by SEM. Meanwhile, twenty-four New Zealand white rabbits were randomly divided into the autogenous tendon group (control group) and the autogenous tendon wrapped with SF/P(LLA-CL) scaffold group (experimental group), with twelve rabbits in each group. An extra-articular model was established, the effect was evaluated by histological examination and mechanical testing. RESULTS: The morphology of SF/P(LLA-CL) nanofibrous scaffold was random, with a diameter of (219.4±66.5) nm. SEM showed that the MC3T3-E1 cells seeded on the scaffold were in the normal shape, growing well, and proliferating with time course. The results of histological examination showed that inflammatory cells infltrated into the graft-host bone interface at 6 weeks after operation in both groups. Besides, the width of interface showed no significant difference between groups. At 12 weeks after operation, protruding new bone tissue could be observed at the interface in the experimental group, while scar tissue but no new bone tissue could be seen at the interface in the control group. Mechanical testing showed that there was no significant difference in the failure load and the stiffness between groups at 6 weeks after operation ( P>0.05). The failure load and the stiffness in the experimental group were significantly higher than those in the control group at 12 weeks after operation ( P<0.05). CONCLUSION: The SF/P(LLA-CL) nanofibrous scaffold has good cell biocompatibility and can effectively promote tendon-bone healing, thus providing new method for modifying graft for ACL reconstruction in the clinical practice. FAU - Cai, Jiangyu AU - Cai J AD - Department of Sports Medicine and Arthroscopic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P.R.China. FAU - Jiang, Jia AU - Jiang J AD - Department of Sports Medicine and Arthroscopic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P.R.China. FAU - Mo, Xiumei AU - Mo X AD - Biomaterials and Tissue Engineering Laboratory, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, P.R.China. FAU - Chen, Shiyi AU - Chen S AD - Department of Sports Medicine and Arthroscopic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P.R.China.cshiyi@163.com. LA - chi PT - Journal Article PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - 0 (Caproates) RN - 0 (Lactones) RN - 0 (Silk) RN - 33X04XA5AT (Lactic Acid) RN - 56RE988L1R (caprolactone) RN - 9007-76-5 (Fibroins) SB - IM MH - Animals MH - Anterior Cruciate Ligament Reconstruction/*methods MH - Caproates/*pharmacology MH - *Cell Proliferation MH - Fibroins/*pharmacology MH - Lactic Acid MH - Lactones/*pharmacology MH - *Nanofibers MH - Rabbits MH - Random Allocation MH - Silk MH - Tendons MH - *Tissue Scaffolds PMC - PMC8458587 OTO - NOTNLM OT - Anterior cruciate ligament OT - nanofibrous scaffold OT - poly(L-lactic acid-co-e-caprolactone) OT - rabbit OT - silk fibroin OT - tendon-bone healing EDAT- 2018/05/29 06:00 MHDA- 2018/07/24 06:00 PMCR- 2017/08/01 CRDT- 2018/05/29 06:00 PHST- 2018/05/29 06:00 [entrez] PHST- 2018/05/29 06:00 [pubmed] PHST- 2018/07/24 06:00 [medline] PHST- 2017/08/01 00:00 [pmc-release] AID - zgxfcjwkzz-31-8-957 [pii] AID - 10.7507/1002-1892.201704077 [doi] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2017 Aug 15;31(8):957-962. doi: 10.7507/1002-1892.201704077. PMID- 8909874 OWN - NLM STAT- MEDLINE DCOM- 19970529 LR - 20190920 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 34 IP - 2 DP - 1996 TI - Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery. PG - 97-103 AB - To test in vivo the effect of previously observed inhibition of collagen type I transcription by the plant alkaloid Halofuginone, deep flexor tendons of 12 chickens were severed and sutured, and Halofuginone was applied topically at the site of surgery. Intact tendons, and severed but untreated tendons served as controls. The effect of the treatment was assessed by histological, biochemical, and biomechanical examinations of the operated and intact tendons three weeks after surgery. The results indicated an almost complete absence of fibrous peritendinous adhesions in the histologic sections of the Halofuginone treated tendons. There was a statistically significant decrease in collagen contents of and in both force and energy required to pull out the Halofuginone treated tendons from their sheath, relative to the untreated controls. Halofuginone had no effect on the cellularity of the healing tissue. We conclude that Halofuginone is a potent inhibitor of fibrous peritendinous adhesions with potentially important clinical applications. FAU - Nyska, M AU - Nyska M AD - Department of Orthopaedic Surgery, Hadassah University Hospital, Jerusalem, Israel. FAU - Nyska, A AU - Nyska A FAU - Rivlin, E AU - Rivlin E FAU - Porat, S AU - Porat S FAU - Pines, M AU - Pines M FAU - Shoshan, S AU - Shoshan S FAU - Nagler, A AU - Nagler A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Piperidines) RN - 0 (Protein Synthesis Inhibitors) RN - 0 (Quinazolines) RN - 0 (Quinazolinones) RN - 9007-34-5 (Collagen) RN - L31MM1385E (halofuginone) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Chickens MH - Collagen/*metabolism MH - Gene Expression Regulation MH - Hydroxyproline/metabolism MH - Inflammation/drug therapy MH - Piperidines MH - Protein Synthesis Inhibitors/*therapeutic use MH - Quinazolines/*therapeutic use MH - Quinazolinones MH - Statistics, Nonparametric MH - Tendon Injuries/*drug therapy/pathology/surgery MH - Tissue Adhesions/pathology/*prevention & control EDAT- 1996/01/01 00:00 MHDA- 1996/01/01 00:01 CRDT- 1996/01/01 00:00 PHST- 1996/01/01 00:00 [pubmed] PHST- 1996/01/01 00:01 [medline] PHST- 1996/01/01 00:00 [entrez] AID - 10.3109/03008209609021495 [doi] PST - ppublish SO - Connect Tissue Res. 1996;34(2):97-103. doi: 10.3109/03008209609021495. PMID- 26866452 OWN - NLM STAT- MEDLINE DCOM- 20171127 LR - 20181202 IS - 1878-0180 (Electronic) IS - 1878-0180 (Linking) VI - 61 DP - 2016 Aug TI - A preliminary technical study on sodium dodecyl sulfate-induced changes of the nano-structural and macro-mechanical properties in human iliotibial tract specimens. PG - 164-173 LID - S1751-6161(16)00021-7 [pii] LID - 10.1016/j.jmbbm.2016.01.018 [doi] AB - INTRODUCTION: Acellular scaffolds are frequently used for the surgical repair of ligaments and tendons. Even though data on the macro-mechanical properties related to the acellularization process exist, corresponding data on the nano-structural properties are still lacking. Such data would help identify target proteins of the formed extracellular matrix that are chemically altered by the acellularization. In this study we examined the altered structure by comparing molecular properties of collagens from native and acellular iliotibial tract samples to the macroscopic stress-strain behavior of tract samples. MATERIAL AND METHODS: Matched pairs of five human iliotibial tract samples were obtained from five donors (mean age 28.2±4.7 years). One of each pair was acellularized using 1vol% sodium dodecyl sulfate (SDS) for 7 days. (13)C magic angle spinning nuclear magnetic resonance spectroscopy ((13)C CP MAS NMR) was utilized to compare the collagen overall secondary structure and internal dynamics of collagen-typical amino acid proteins. The resulting data was compared to age-matched stress-strain data of tract samples obtained in an uniaxial tensile setup and histologically. RESULTS: Typical and nearly identical collagen (13)C CP MAS NMR spectra were found in the tract samples before and after acellularization with SDS. The characteristic collagen backbone remained intact in the native and acellular samples. Collagen molecular composition was largely unaltered in both conditions. Furthermore, a similar dynamic behavior was found for the amino acids Hyp γ, Pro α/Hyp α, Ala α, Gly α and Ala β. These minute alterations in the collagens' molecular properties related to acellularization with SDS were in line with the similarly minute changes in the macro-mechanical tensile behavior, such as the elastic modulus and ultimate stress. Histology showed intact type I collagens, minute amounts of elastins before and after acellularization and evidence for acellularization-induced reductions of proteoglycans. DISCUSSION: Nano-structural properties of collagens are minutely affected by SDS treatment for acellularization, indicated by the molecular composition and dynamics. The lacking acellularization-related changes in the molecular structure properties of collagens in iliotibial tract samples are in line with the small alterations in their macro-mechanical tensile behavior. Though the given setup approaches soft tissue mechanics from both scaling extremes of mechanical testing, further structural analyzes are needed in a larger sample size to substantiate these findings. CI - Copyright © 2016 Elsevier Ltd. All rights reserved. FAU - Hammer, Niels AU - Hammer N AD - Department of Anatomy, University of Otago, 270 Great King Street, Dunedin 9054, New Zealand. Electronic address: nlshammer@googlemail.com. FAU - Huster, Daniel AU - Huster D AD - Institute of Medical Physics and Biophysics, University of Leipzig, Faculty of Medicine, Leipzig, Germany. FAU - Boldt, Andreas AU - Boldt A AD - Institute of Clinical Immunology, University of Leipzig, Faculty of Medicine, Leipzig, Germany; Translational Centre for Regenerative Medicine, University of Leipzig, Faculty of Medicine, Leipzig, Germany. FAU - Hädrich, Carsten AU - Hädrich C AD - Institute of Forensic Medicine, University of Leipzig, Faculty of Medicine, Leipzig, Germany. FAU - Koch, Holger AU - Koch H AD - Translational Centre for Regenerative Medicine, University of Leipzig, Faculty of Medicine, Leipzig, Germany. FAU - Möbius, Robert AU - Möbius R AD - Institute of Anatomy, University of Leipzig, Faculty of Medicine, Leipzig, Germany. FAU - Schulze-Tanzil, Gundula AU - Schulze-Tanzil G AD - Department of Anatomy, Nuremberg Hospital Medical School, Paracelsus Medical University, Nuremburg, Germany and Salzburg, Austria. FAU - Scheidt, Holger A AU - Scheidt HA AD - Institute of Medical Physics and Biophysics, University of Leipzig, Faculty of Medicine, Leipzig, Germany. LA - eng PT - Journal Article DEP - 20160126 PL - Netherlands TA - J Mech Behav Biomed Mater JT - Journal of the mechanical behavior of biomedical materials JID - 101322406 RN - 0 (Amino Acids) RN - 368GB5141J (Sodium Dodecyl Sulfate) RN - 9007-34-5 (Collagen) SB - IM MH - Adult MH - Amino Acids/chemistry MH - Collagen/chemistry MH - Extracellular Matrix/chemistry MH - Fascia Lata/drug effects/*ultrastructure MH - Humans MH - Protein Structure, Secondary MH - Sodium Dodecyl Sulfate/*pharmacology MH - *Tissue Scaffolds MH - Young Adult OTO - NOTNLM OT - (13)C CP MAS NMR OT - Acellularization OT - Collagen OT - Elastic modulus OT - Human iliotibial tract scaffold OT - Sodium dodecyl sulfate EDAT- 2016/02/13 06:00 MHDA- 2017/11/29 06:00 CRDT- 2016/02/12 06:00 PHST- 2015/09/03 00:00 [received] PHST- 2016/01/12 00:00 [revised] PHST- 2016/01/20 00:00 [accepted] PHST- 2016/02/12 06:00 [entrez] PHST- 2016/02/13 06:00 [pubmed] PHST- 2017/11/29 06:00 [medline] AID - S1751-6161(16)00021-7 [pii] AID - 10.1016/j.jmbbm.2016.01.018 [doi] PST - ppublish SO - J Mech Behav Biomed Mater. 2016 Aug;61:164-173. doi: 10.1016/j.jmbbm.2016.01.018. Epub 2016 Jan 26. PMID- 36272687 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20221221 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 154 DP - 2022 Dec TI - Growth and differentiation factor-7 immobilized, mechanically strong quadrol-hexamethylene diisocyanate-methacrylic anhydride polyurethane polymer for tendon repair and regeneration. PG - 108-122 LID - S1742-7061(22)00685-7 [pii] LID - 10.1016/j.actbio.2022.10.029 [doi] AB - Biological and mechanical cues are both vital for biomaterial aided tendon repair and regeneration. Here, we fabricated mechanically tendon-like (0 s UV) QHM polyurethane scaffolds (Q: Quadrol, H: Hexamethylene diisocyanate; M: Methacrylic anhydride) and immobilized them with Growth and differentiation factor-7 (GDF-7) to produce mechanically strong and tenogenic scaffolds. In this study, we assessed QHM polymer cytocompatibility, amenability to fibrin-coating, immobilization and persistence of GDF-7, and capability to support GDF-7-mediated tendon differentiation in vitro as well as in vivo in mouse subcutaneous and acute rat rotator cuff tendon resection models. Cytocompatibility studies showed that QHM facilitated cell attachment, proliferation, and viability. Fibrin-coating and GDF-7 retention studies showed that mechanically tendon-like 0 s UV QHM polymer could be immobilized with GDF-7 and retained the growth factor (GF) for at least 1-week ex vivo. In vitro differentiation studies showed that GDF-7 mediated bone marrow-derived human mesenchymal stem cell (hMSC) tendon-like differentiation on 0 s UV QHM. Subcutaneous implantation of GDF-7-immobilized, fibrin-coated, QHM polymer in mice for 2 weeks demonstrated de novo formation of tendon-like tissue while implantation of GDF-7-immobilized, fibrin-coated, QHM polymer in a rat acute rotator cuff resection injury model indicated tendon-like tissue formation in situ and the absence of heterotopic ossification. Together, our work demonstrates a promising synthetic scaffold with human tendon-like biomechanical attributes as well as immobilized tenogenic GDF-7 for tendon repair and regeneration. STATEMENT OF SIGNIFICANCE: Biological activity and mechanical robustness are key features required for tendon-promoting biomaterials. While synthetic biomaterials can be mechanically robust, they often lack bioactivity. To biologically augment synthetic biomaterials, numerous drug and GF delivery strategies exist but the large tissue space within the shoulder is constantly flushed with saline during arthroscopic surgery, hindering efficacious controlled release of therapeutic molecules. Here, we coated QHM polymer (which exhibits human tendon-to-bone-like biomechanical attributes) with fibrin for GF binding. Unlike conventional drug delivery strategies, our approach utilizes immobilized GFs as opposed to released GFs for sustained, localized tissue regeneration. Our data demonstrated that GF immobilization can be broadly applied to synthetic biomaterials for enhancing bioactivity, and GDF-7-immobilized QHM exhibit high clinical translational potential for tendon repair. CI - Copyright © 2022. Published by Elsevier Ltd. FAU - Wang, Dan AU - Wang D AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA; Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Ministry of Education Key Laboratory for Regenerative Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Center for Neuromuscular Restorative Medicine, Hong Kong Science Park, Hong Kong SAR, China. FAU - Zhang, Xu AU - Zhang X AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Ng, Ka Wai AU - Ng KW AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Rao, Ying AU - Rao Y AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Wang, Chenyang AU - Wang C AD - Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Gharaibeh, Burhan AU - Gharaibeh B AD - Department of Biological Sciences, University of Pittsburgh, 4249 Fifth Avenue, Pittsburgh, PA 15260, USA. FAU - Lin, Sien AU - Lin S AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA; Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Abrams, Geoffrey AU - Abrams G AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA. FAU - Safran, Marc AU - Safran M AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA. FAU - Cheung, Emilie AU - Cheung E AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA. FAU - Campbell, Phil AU - Campbell P AD - Engineering Research Accelerator, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA; Department of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA; Robotics Institute, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA. FAU - Weiss, Lee AU - Weiss L AD - Robotics Institute, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA; Engineering Research Accelerator, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA; Department of Biomedical Engineering, Carnegie Mellon University, 5000 Forbes Avenue, Pittsburgh, PA 15213, USA. FAU - Ker, Dai Fei Elmer AU - Ker DFE AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA; Institute for Tissue Engineering and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China; Ministry of Education Key Laboratory for Regenerative Medicine, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; Center for Neuromuscular Restorative Medicine, Hong Kong Science Park, Hong Kong SAR, China. Electronic address: elmerker@cuhk.edu.hk. FAU - Yang, Yunzhi Peter AU - Yang YP AD - Department of Orthopaedic Surgery, Stanford University, 240 Pasteur Drive, Stanford, CA 94304, USA; Department of Material Science and Engineering, Stanford University, 496 Lomita Mall, Stanford, CA 94305, USA; Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, CA 94305, USA. Electronic address: ypyang@stanford.edu. LA - eng PT - Journal Article DEP - 20221019 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Polymers) RN - 0 (Polyurethanes) RN - 0 (Anhydrides) RN - 0 (Biocompatible Materials) SB - IM MH - Rats MH - Mice MH - Humans MH - Animals MH - *Polymers MH - Polyurethanes/pharmacology MH - Anhydrides MH - Tendons MH - Cell Differentiation MH - Biocompatible Materials MH - *Rotator Cuff Injuries/surgery MH - Tissue Scaffolds/chemistry OTO - NOTNLM OT - Extracellular matrix OT - GDF-7 immobilization OT - Growth factor OT - Polyurethane OT - Rotator cuff repair OT - Tendon tissue engineering COIS- Declaration of Competing Interest The authors declare no conflict of interest. EDAT- 2022/10/23 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/10/22 19:35 PHST- 2022/01/18 00:00 [received] PHST- 2022/10/13 00:00 [revised] PHST- 2022/10/13 00:00 [accepted] PHST- 2022/10/23 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/22 19:35 [entrez] AID - S1742-7061(22)00685-7 [pii] AID - 10.1016/j.actbio.2022.10.029 [doi] PST - ppublish SO - Acta Biomater. 2022 Dec;154:108-122. doi: 10.1016/j.actbio.2022.10.029. Epub 2022 Oct 19. PMID- 25819324 OWN - NLM STAT- MEDLINE DCOM- 20160404 LR - 20181113 IS - 1937-335X (Electronic) IS - 1937-3341 (Print) IS - 1937-3341 (Linking) VI - 21 IP - 13-14 DP - 2015 Jul TI - Stimulation of Rotator Cuff Repair by Sustained Release of Bone Morphogenetic Protein-7 Using a Gelatin Hydrogel Sheet. PG - 2025-33 LID - 10.1089/ten.TEA.2014.0541 [doi] AB - Bone morphogenetic protein-7 (BMP-7) promotes not only osteogenesis but also matrix production in chondrocytes and tenocytes. However, because of its short half-life, maintaining local concentrations of BMP-7 is difficult. We examined the use of a gelatin hydrogel sheet (GHS) for the sustained release of BMP-7 in stimulating rotator cuff repair at the tendon-to-bone insertion. Twelve-week-old male Sprague-Dawley rats were used. Radiolabeled BMP-7 ((125)I-BMP-7) was injected into the subacromial bursa in the (125)I-BMP-7 group, whereas a GHS impregnated with (125)I-BMP-7 was implanted on the tendon attached to the tendon-to-bone insertion in the (125)I-BMP-7+GHS group. Levels of (125)I-BMP-7 in the tendon-to-bone insertion were assessed at 1, 3, 7, 14, and 21 postoperative days. The BMP-7 concentrations were significantly higher in the (125)I-BMP-7+GHS group than in the (125)I-BMP-7 group. Next, the bilateral supraspinatus tendons were resected and sutured to the greater tuberosity of the humerus using the Mason-Allen technique. Treatment groups were created as follows: either phosphate-buffered saline (PBS) or BMP-7 was injected into the subacromial bursa in the PBS and BMP-7 groups, whereas a GHS impregnated with either PBS or BMP-7 was implanted on the repaired tendon attached to the tendon-to-bone insertion in the PBS+GHS and BMP-7+GHS groups. The resected specimens were stained at 2, 4, and 8 postoperative weeks with hematoxylin and eosin as well as Safranin O, and tissue repair was evaluated histologically by using the tendon-to-bone maturing score. Tissue repair was assessed biomechanically at 4 and 8 postoperative weeks. The BMP-7+GHS group at 8 postoperative weeks demonstrated a favorable cartilage matrix production and tendon orientation; moreover, the tendon-to-bone maturing score and the ultimate force-to-failure were the highest in this group. The ability of GHS to provide controlled release of various growth factors has been previously reported. We confirmed that the GHS releases BMP-7 in a sustained manner in the rat shoulder joint. At 8 postoperative weeks, the repaired tissue was mostly restored, both histologically and biomechanically, in the BMP-7+GHS group. We therefore conclude that the sustained release of BMP-7 from a GHS can stimulate rotator cuff repair. FAU - Kabuto, Yukichi AU - Kabuto Y AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Morihara, Toru AU - Morihara T AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Sukenari, Tsuyoshi AU - Sukenari T AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Kida, Yoshikazu AU - Kida Y AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Oda, Ryo AU - Oda R AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Arai, Yuji AU - Arai Y AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Sawada, Koshiro AU - Sawada K AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Matsuda, Ken-Ichi AU - Matsuda K AD - 2 Department of Anatomy and Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Kawata, Mitsuhiro AU - Kawata M AD - 2 Department of Anatomy and Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Tabata, Yasuhiko AU - Tabata Y AD - 3 Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University , Kyoto, Japan . FAU - Fujiwara, Hiroyoshi AU - Fujiwara H AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . FAU - Kubo, Toshikazu AU - Kubo T AD - 1 Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto, Japan . LA - eng PT - Journal Article DEP - 20150512 PL - United States TA - Tissue Eng Part A JT - Tissue engineering. Part A JID - 101466659 RN - 0 (Bone Morphogenetic Protein 7) RN - 0 (Delayed-Action Preparations) RN - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate) RN - 9000-70-8 (Gelatin) SB - IM MH - Animals MH - Biomechanical Phenomena/drug effects MH - Bone Morphogenetic Protein 7/*pharmacology MH - Bone and Bones/drug effects MH - Delayed-Action Preparations MH - Gelatin/*pharmacology MH - Humans MH - Hydrogel, Polyethylene Glycol Dimethacrylate/*pharmacology MH - Male MH - Rats, Sprague-Dawley MH - Rotator Cuff/diagnostic imaging/drug effects/*pathology/surgery MH - Wound Healing/*drug effects MH - X-Ray Microtomography PMC - PMC4507128 EDAT- 2015/03/31 06:00 MHDA- 2016/04/05 06:00 PMCR- 2016/07/01 CRDT- 2015/03/31 06:00 PHST- 2015/03/31 06:00 [entrez] PHST- 2015/03/31 06:00 [pubmed] PHST- 2016/04/05 06:00 [medline] PHST- 2016/07/01 00:00 [pmc-release] AID - 10.1089/ten.tea.2014.0541 [pii] AID - 10.1089/ten.TEA.2014.0541 [doi] PST - ppublish SO - Tissue Eng Part A. 2015 Jul;21(13-14):2025-33. doi: 10.1089/ten.TEA.2014.0541. Epub 2015 May 12. PMID- 8641050 OWN - NLM STAT- MEDLINE DCOM- 19960716 LR - 20171116 IS - 0192-253X (Print) IS - 0192-253X (Linking) VI - 17 IP - 4 DP - 1995 TI - Cloning and developmental expression of the ecdysone receptor gene from the spruce budworm, Choristoneura fumiferana. PG - 319-30 AB - Degenerate oligonucleotides were designed on the basis of conserved amino acid sequences in the DNA and ligand-binding regions of the members of the steroid hormone receptor superfamily. Using these oligonucleotides in RNA-PCR, a cDNA fragment was isolated from the spruce budworm, Choristoneura fumiferana. Comparison of the deduced amino acid sequence of this cDNA fragment with the members of the steroid hormone receptor superfamily suggested that this PCR fragment is a region of the ecdysone receptor from C. fumiferana. Using this cDNA fragment as a probe, 10 clones were isolated from a cDNA library that was constructed using the RNA from 4- and 5-day old embryos of C. fumiferana. Two cDNA clones (1.3 and 3 kb) that overlap and show amino acid identity with Drosophila melanogaster ecdysone receptor B-1 isoform (DmEcR) were characterized and sequenced. The longest open reading frame had 539 codons and covered the complete EcR coding region. The deduced amino acid sequence of this open reading frame had all five of the regions typical for a steroid hormone nuclear receptor. The C domain or DNA binding region showed the highest identity wit EcR proteins from D. melanogaster, Chironomus tendons, Aedes aegypti, Manduca sexta, and Bombyx mori. The A/B region, D domain or hinge region, E domain, or ligand binding region also showed significant amino acid similarity with the EcR proteins from the five insects mentioned above. The C. fumiferana ecdysteroid receptor (CfEcR) cDNA probe detected a 6.0-kb mRNA that was present throughout the development of C. fumiferana. The CfEcR mRNA increases in abundance at the time of the ecdysteroid peak during the molting phase in the embryonic, larval and pupal stages but remains low during the intermolt period. In the 6th instar larvae, the 6-kb CfEcR mRNA was detected in the epidermis, fat body, and midgut and maximum expression was observed during the prepupal peak of ecdysteroids in the hemolymph. CfEcR mRNA was induced in ecdysone treated CF-203 cells as well in the epidermis and midgut of larvae that were fed the nonsteroidal ecdysteroid agonist, RH-5992. The induction occurred within an hour and reached maximum levels around 3 hr, after which it decreased to the basal level by 6 hr. In vitro transcription and translation of the CfEcR cDNA yielded a 67-Kda protein that bound to the ecdysone response element (EcRE) as a heterodimer, along with the ultraspiracle protein. FAU - Kothapalli, R AU - Kothapalli R AD - Canadian Forest Service--Saulte St. Marie, Ontario, Canada. FAU - Palli, S R AU - Palli SR FAU - Ladd, T R AU - Ladd TR FAU - Sohi, S S AU - Sohi SS FAU - Cress, D AU - Cress D FAU - Dhadialla, T S AU - Dhadialla TS FAU - Tzertzinis, G AU - Tzertzinis G FAU - Retnakaran, A AU - Retnakaran A LA - eng SI - GENBANK/U29531 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Dev Genet JT - Developmental genetics JID - 7909963 RN - 0 (DNA, Complementary) RN - 0 (Hydrazines) RN - 0 (Receptors, Steroid) RN - 0 (ecdysone receptor) RN - 5289-74-7 (Ecdysterone) RN - TNN5MI5EKF (tebufenozide) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Cell Line MH - Cloning, Molecular MH - DNA, Complementary MH - Ecdysterone/pharmacology MH - Gene Expression MH - Hydrazines/pharmacology MH - Molecular Sequence Data MH - Moths/drug effects/*genetics MH - Receptors, Steroid/*genetics/metabolism MH - Sequence Homology, Amino Acid EDAT- 1995/01/01 00:00 MHDA- 1995/01/01 00:01 CRDT- 1995/01/01 00:00 PHST- 1995/01/01 00:00 [pubmed] PHST- 1995/01/01 00:01 [medline] PHST- 1995/01/01 00:00 [entrez] AID - 10.1002/dvg.1020170405 [doi] PST - ppublish SO - Dev Genet. 1995;17(4):319-30. doi: 10.1002/dvg.1020170405. PMID- 25238962 OWN - NLM STAT- MEDLINE DCOM- 20150126 LR - 20240322 IS - 1095-564X (Electronic) IS - 0012-1606 (Print) IS - 0012-1606 (Linking) VI - 395 IP - 2 DP - 2014 Nov 15 TI - Mouse limb skeletal growth and synovial joint development are coordinately enhanced by Kartogenin. PG - 255-67 LID - S0012-1606(14)00468-0 [pii] LID - 10.1016/j.ydbio.2014.09.011 [doi] AB - Limb development requires the coordinated growth of several tissues and structures including long bones, joints and tendons, but the underlying mechanisms are not wholly clear. Recently, we identified a small drug-like molecule - we named Kartogenin (KGN) - that greatly stimulates chondrogenesis in marrow-derived mesenchymal stem cells (MSCs) and enhances cartilage repair in mouse osteoarthritis (OA) models. To determine whether limb developmental processes are regulated by KGN, we tested its activity on committed preskeletal mesenchymal cells from mouse embryo limb buds and whole limb explants. KGN did stimulate cartilage nodule formation and more strikingly, boosted digit cartilaginous anlaga elongation, synovial joint formation and interzone compaction, tendon maturation as monitored by ScxGFP, and interdigit invagination. To identify mechanisms, we carried out gene expression analyses and found that several genes, including those encoding key signaling proteins, were up-regulated by KGN. Amongst highly up-regulated genes were those encoding hedgehog and TGFβ superfamily members, particularly TFGβ1. The former response was verified by increases in Gli1-LacZ activity and Gli1 mRNA expression. Exogenous TGFβ1 stimulated cartilage nodule formation to levels similar to KGN, and KGN and TGFβ1 both greatly enhanced expression of lubricin/Prg4 in articular superficial zone cells. KGN also strongly increased the cellular levels of phospho-Smads that mediate canonical TGFβ and BMP signaling. Thus, limb development is potently and harmoniously stimulated by KGN. The growth effects of KGN appear to result from its ability to boost several key signaling pathways and in particular TGFβ signaling, working in addition to and/or in concert with the filamin A/CBFβ/RUNX1 pathway we identified previously to orchestrate overall limb development. KGN may thus represent a very powerful tool not only for OA therapy, but also limb regeneration and tissue repair strategies. CI - Copyright © 2014 Elsevier Inc. All rights reserved. FAU - Decker, Rebekah S AU - Decker RS AD - Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children׳s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address: DeckerR@email.chop.edu. FAU - Koyama, Eiki AU - Koyama E AD - Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children׳s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA. FAU - Enomoto-Iwamoto, Motomi AU - Enomoto-Iwamoto M AD - Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children׳s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA. FAU - Maye, Peter AU - Maye P AD - Department of Reconstructive Sciences, University of Connecticut Health Center School of, Dental Medicine, 263 Farmington Ave, Farmington, CT 06030, USA. FAU - Rowe, David AU - Rowe D AD - Department of Reconstructive Sciences, University of Connecticut Health Center School of, Dental Medicine, 263 Farmington Ave, Farmington, CT 06030, USA. FAU - Zhu, Shoutian AU - Zhu S AD - California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, CA 92037, USA. FAU - Schultz, Peter G AU - Schultz PG AD - The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. FAU - Pacifici, Maurizio AU - Pacifici M AD - Translational Research Program in Pediatric Orthopaedics, Division of Orthopaedic Surgery, The Children׳s Hospital of Philadelphia, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA. LA - eng GR - 1F32AR064071/AR/NIAMS NIH HHS/United States GR - AR062908/AR/NIAMS NIH HHS/United States GR - R01 AR062908/AR/NIAMS NIH HHS/United States GR - F32 AR064071/AR/NIAMS NIH HHS/United States GR - R01 AR046000/AR/NIAMS NIH HHS/United States GR - AR046000/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140918 PL - United States TA - Dev Biol JT - Developmental biology JID - 0372762 RN - 0 (Anilides) RN - 0 (DNA Primers) RN - 0 (Gli1 protein, mouse) RN - 0 (Kruppel-Like Transcription Factors) RN - 0 (Luminescent Proteins) RN - 0 (Phthalic Acids) RN - 0 (Prg4 protein, mouse) RN - 0 (Proteoglycans) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Zinc Finger Protein GLI1) RN - Q93BBN11CP (kartogenin) SB - IM MH - Anilides/*pharmacology MH - Animals MH - Chondrogenesis/*drug effects MH - DNA Primers/genetics MH - Extremities/*embryology MH - Gene Expression Regulation, Developmental/*drug effects MH - Image Processing, Computer-Assisted MH - Immunoblotting MH - In Situ Hybridization MH - Joint Capsule/drug effects/*embryology MH - Kruppel-Like Transcription Factors/metabolism MH - Luminescent Proteins/metabolism MH - Mesoderm/*drug effects MH - Mice MH - Microscopy, Confocal MH - Phthalic Acids/*pharmacology MH - Proteoglycans/metabolism MH - Regeneration/physiology MH - Reverse Transcriptase Polymerase Chain Reaction MH - Signal Transduction MH - Transforming Growth Factor beta1/metabolism MH - Zinc Finger Protein GLI1 MH - Red Fluorescent Protein PMC - PMC4253021 MID - NIHMS629080 OTO - NOTNLM OT - BMP and hedgehog signaling OT - Joint interzone OT - Kartogenin OT - Limb development OT - Lubricin OT - Skeletogenesis OT - Synovial joint formation OT - TGFB EDAT- 2014/09/23 06:00 MHDA- 2015/01/27 06:00 PMCR- 2015/11/15 CRDT- 2014/09/21 06:00 PHST- 2014/04/10 00:00 [received] PHST- 2014/07/31 00:00 [revised] PHST- 2014/09/09 00:00 [accepted] PHST- 2014/09/21 06:00 [entrez] PHST- 2014/09/23 06:00 [pubmed] PHST- 2015/01/27 06:00 [medline] PHST- 2015/11/15 00:00 [pmc-release] AID - S0012-1606(14)00468-0 [pii] AID - 10.1016/j.ydbio.2014.09.011 [doi] PST - ppublish SO - Dev Biol. 2014 Nov 15;395(2):255-67. doi: 10.1016/j.ydbio.2014.09.011. Epub 2014 Sep 18. PMID- 7793657 OWN - NLM STAT- MEDLINE DCOM- 19950721 LR - 20190628 IS - 0003-3022 (Print) IS - 0003-3022 (Linking) VI - 82 IP - 6 DP - 1995 Jun TI - A subtype of alpha 1 adrenoceptor mediates depression of conduction in Purkinje fibers exposed to halothane. PG - 1438-46 AB - BACKGROUND: An action of epinephrine at alpha adrenoceptors has been reported to slow conduction in Purkinje fibers exposed to halothane. In Purkinje fibers one pharmacologically distinguishable alpha 1-adrenoceptor subtype (alpha 1B) sensitive to the noncompetitive antagonist chloroethylcholinidine mediates decreases in automaticity. Another alpha 1 subtype (alpha 1A), sensitive to the competitive antagonist WB4101, increases spontaneous rate and action potential duration by a mechanism thought to involve hydrolysis of membrane phosphoinositides by phospholipase C. This study examined the dose-response relation and receptor-effector mechanisms underlying depression of conduction in canine Purkinje fibers by epinephrine with halothane. METHODS: Conduction velocity was determined in vitro by measuring the conduction time between action potentials recorded from two Purkinje fibers located about 6 mm apart along the length of free running portions of the ventricular conduction system, the false tendons. Velocity was evaluated at 1-min intervals during trials of rapid exposure to different agonists in groups of 6-12 preparations. RESULTS: Epinephrine (0.2-5.0 microM) transiently decreased Purkinje conduction velocity in a dose-related manner by as much as 33% (at 5 microM epinephrine with 0.86 mM (2.8%) halothane). Velocity decreased by 5% (P < or = 0.01) at an epinephrine concentration similar to "just-threshold" dysrhythmogenic plasma epinephrine concentrations (0.2 microM epinephrine with 0.46 mM halothane) reported in halothane-anesthetized dogs. The decreases of conduction velocity were blocked by prazosin but not by metoprolol, were produced by phenylephrine but not by clonidine, and were antagonized by equimolar (0.5 microM) concentrations of WB4101 more so (P < or = 0.01) than by chloroethylclonidine. WB4101 (0.1 microM) produced 87% inhibition of the response to 0.2 microM epinephrine after chloroethylclonidine pretreatment, indicating mediation by the alpha 1A subtype. Other agonists linked to cardiac phospholipase C activation, including endothelin 1 (40 nM) and the muscarinic agonist carbamylcholine (1 mM), also decreased conduction velocity in fibers exposed to halothane. CONCLUSIONS: Clinically relevant concentrations of epinephrine transiently depress conduction in Purkinje fibers exposed to halothane by activating cardiac alpha 1 adrenoceptors, largely but not exclusively the WB4101-sensitive alpha 1A subtype, reportedly coupled to stimulation of phospholipase C and generation of the second messengers diacylglycerol and inositol trisphosphate. Anesthetic potentiation of cardiac alpha 1-adrenoceptor effects may contribute to the generation of halothane-epinephrine dysrhythmias by abnormally slowing conduction and facilitating reentry. FAU - Turner, L A AU - Turner LA AD - Department of Anesthesiology, Medical College of Wisconsin, Milwaukee 53226, USA. FAU - Vodanovic, S AU - Vodanovic S FAU - Hoffmann, R G AU - Hoffmann RG FAU - Kampine, J P AU - Kampine JP FAU - Bosnjak, Z J AU - Bosnjak ZJ LA - eng GR - GM08377/GM/NIGMS NIH HHS/United States GR - HL39776/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Anesthesiology JT - Anesthesiology JID - 1300217 RN - 0 (Dioxanes) RN - 0 (Receptors, Adrenergic, alpha-1) RN - E9H51OIT2B ((2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane) RN - EC 3.1.4.- (Type C Phospholipases) RN - UQT9G45D1P (Halothane) RN - YKH834O4BH (Epinephrine) SB - IM MH - Animals MH - Depression, Chemical MH - Dioxanes/pharmacology MH - Dogs MH - Dose-Response Relationship, Drug MH - Epinephrine/pharmacology MH - Halothane/*pharmacology MH - In Vitro Techniques MH - Purkinje Fibers/*drug effects/physiology MH - Receptors, Adrenergic, alpha-1/*drug effects/physiology MH - Type C Phospholipases/physiology EDAT- 1995/06/01 00:00 MHDA- 1995/06/01 00:01 CRDT- 1995/06/01 00:00 PHST- 1995/06/01 00:00 [pubmed] PHST- 1995/06/01 00:01 [medline] PHST- 1995/06/01 00:00 [entrez] AID - 10.1097/00000542-199506000-00015 [doi] PST - ppublish SO - Anesthesiology. 1995 Jun;82(6):1438-46. doi: 10.1097/00000542-199506000-00015. PMID- 344168 OWN - NLM STAT- MEDLINE DCOM- 19780508 LR - 20061115 IS - 0046-6794 (Print) IS - 0046-6794 (Linking) VI - 9 IP - 3 DP - 1977 TI - [Tendon suture in the tendinous sheath--experimental study]. PG - 113-8 AB - Tendon sutures were carried out in the flexor digitorum longus tendon 54 rabbits within the osteofibrous canal at the level of the ankle joint. The suture technique of BUNNELL, LENGEMANN and KESSLER were compared. The adhesions and the vascular pattern in the suture are were observed by means of idian ink injection, microdissection and in thin sections cleared with methyl salicylate. Tendon healing with only minimal adhesions seems to be possible provided that the gap between the tendon stumps is rather small. It originates from the vascularised epitenon of the tendon stumps. In tendon sutures after KESSLER the gap averaged only 2,5 mm whereas the average after BUNNELL suture was 6,7 mm, after LENGEMANN suture 9,8 mm. Early mobilisation of the tendons without tension according to the technique of KLEINERT seems to be suitable to minimise adhesions in the suture area. FAU - Greulich, M AU - Greulich M FAU - Lanz, U AU - Lanz U FAU - Glöckner, J AU - Glöckner J LA - ger PT - English Abstract PT - Journal Article TT - Sehnennaht im Bereich der Sehnenscheide--Experimentelle Untersuchungen. PL - Germany TA - Handchirurgie JT - Handchirurgie JID - 1252612 SB - IM MH - Animals MH - Hindlimb MH - Methods MH - Rabbits MH - *Suture Techniques MH - Tendons/*surgery EDAT- 1977/01/01 00:00 MHDA- 1977/01/01 00:01 CRDT- 1977/01/01 00:00 PHST- 1977/01/01 00:00 [pubmed] PHST- 1977/01/01 00:01 [medline] PHST- 1977/01/01 00:00 [entrez] PST - ppublish SO - Handchirurgie. 1977;9(3):113-8. PMID- 38593721 OWN - NLM STAT- MEDLINE DCOM- 20240422 LR - 20240422 IS - 1873-2380 (Electronic) IS - 0021-9290 (Linking) VI - 167 DP - 2024 Apr TI - Regional shear wave speeds track regional axial stress in nonuniformly loaded fibrous soft tissues. PG - 112071 LID - S0021-9290(24)00148-9 [pii] LID - 10.1016/j.jbiomech.2024.112071 [doi] AB - Ligaments and tendons undergo nonuniform deformation during movement. While deformations can be imaged, it remains challenging to use such information to infer regional tissue loading. Shear wave tensiometry is a promising noninvasive technique to gauge axial stress and is premised on a tensioned beam model. However, it is unknown whether tensiometry can predict regional stress in a nonuniformly loaded structure. The objectives of this study were to (1) determine whether regional shear wave speed tracks regional axial stress in nonuniformly loaded fibrous soft tissues, and (2) determine the sensitivity of regional axial stress and shear wave speed to nonuniform load distribution and fiber alignment. We created a representative set of 12,000 dynamic finite element models of a fibrous soft tissue with probabilistic variations in fiber alignment, stiffness, and aspect ratio. In each model, we applied a randomly selected nonuniform load distribution, and then excited a shear wave and tracked its regional propagation. We found that regional shear wave speed was an excellent predictor of the regional axial stress (RMSE = 0.57 MPa) and that the nature of the regional shear wave speed-stress relationship was consistent with a tensioned beam model (R(2) = 0.99). Variations in nonuniform load distribution and fiber alignment did not substantially alter the wave speed-stress relationship, particularly at higher loads. Thus, these findings suggests that shear wave tensiometry could provide a quantitative estimate of regional tissue stress in ligaments and tendons. CI - Copyright © 2024 Elsevier Ltd. All rights reserved. FAU - Blank, Jonathon L AU - Blank JL AD - Department of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI, USA. FAU - Thelen, Darryl G AU - Thelen DG AD - Department of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA. FAU - Roth, Joshua D AU - Roth JD AD - Department of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI, USA; Department of Orthopedics and Rehabilitation, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: roth@ortho.wisc.edu. LA - eng PT - Journal Article DEP - 20240331 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - U68WG3173Y (Carmustine) RN - 6PLQ3CP4P3 (Etoposide) SB - IM MH - *Tendons MH - Movement MH - Ligaments MH - Stress, Mechanical MH - Carmustine MH - Etoposide MH - *Elasticity Imaging Techniques OTO - NOTNLM OT - Fiber alignment OT - Finite element model OT - Ligament OT - Regional material properties OT - Shear wave propagation OT - Tendon COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/04/10 00:43 MHDA- 2024/04/22 06:45 CRDT- 2024/04/09 18:14 PHST- 2023/09/22 00:00 [received] PHST- 2024/02/19 00:00 [revised] PHST- 2024/03/30 00:00 [accepted] PHST- 2024/04/22 06:45 [medline] PHST- 2024/04/10 00:43 [pubmed] PHST- 2024/04/09 18:14 [entrez] AID - S0021-9290(24)00148-9 [pii] AID - 10.1016/j.jbiomech.2024.112071 [doi] PST - ppublish SO - J Biomech. 2024 Apr;167:112071. doi: 10.1016/j.jbiomech.2024.112071. Epub 2024 Mar 31. PMID- 8961227 OWN - NLM STAT- MEDLINE DCOM- 19970306 LR - 20191101 IS - 0942-2056 (Print) IS - 0942-2056 (Linking) VI - 4 IP - 3 DP - 1996 TI - Anterior cruciate ligament reconstruction with fresh-frozen patellar tendon allografts: sixty cases with 2 years' minimum follow-up. PG - 137-42 AB - A prospective study was performed on 101 patients who underwent an arthroscopic anterior cruciate ligament (ACL) reconstruction with fresh-frozen patellar tendon allograft (bone-patellar tendon-bone). We present the results of the first 60 patients with a minimum follow-up of 2 years. Thirty-four were men and 26 women with a mean age of 23. In 45 patients, a postoperative arthroscopy was performed, and tissue biopsies of the reconstructed ACL were obtained. Patients were evaluated according to the International Knee Documentation Committee evaluation form. After a mean follow-up of 47 months, the overall results were normal or nearly normal in 85%. Under postoperative arthroscopy, the macroscopic appearance of the implant was similar to that of a normal ligament. The ACL allograft was covered with a normal, well-vascularized synovium. There were no cases of infection, disease transmission or tissue rejection. We conclude that the use of fresh-frozen patellar tendon allografts is a good method of ACL reconstruction. FAU - Nín, J R AU - Nín JR AD - Department of Orthopedic Surgery, University Clinic of Navarra, Pamplona, Spain. FAU - Leyes, M AU - Leyes M FAU - Schweitzer, D AU - Schweitzer D LA - eng PT - Journal Article PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 SB - IM MH - Activities of Daily Living MH - Adolescent MH - Adult MH - Anterior Cruciate Ligament/*surgery MH - *Anterior Cruciate Ligament Injuries MH - Arthroscopy MH - Cryopreservation MH - Endoscopy MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Patella/*transplantation MH - Range of Motion, Articular MH - Tendons/*transplantation MH - Transplantation, Homologous MH - Treatment Outcome EDAT- 1996/01/01 00:00 MHDA- 1996/01/01 00:01 CRDT- 1996/01/01 00:00 PHST- 1996/01/01 00:00 [pubmed] PHST- 1996/01/01 00:01 [medline] PHST- 1996/01/01 00:00 [entrez] AID - 10.1007/BF01577405 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 1996;4(3):137-42. doi: 10.1007/BF01577405. PMID- 37782988 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20241025 IS - 1878-0180 (Electronic) IS - 1751-6161 (Print) IS - 1878-0180 (Linking) VI - 147 DP - 2023 Nov TI - Adjacent tissues modulate shear wave propagation in axially loaded tendons. PG - 106138 LID - S1751-6161(23)00491-5 [pii] LID - 10.1016/j.jmbbm.2023.106138 [doi] AB - Shear wave tensiometry is a noninvasive approach for gauging tendon loads based on shear wave speed. Transient shear waves are induced and tracked via sensors secured to the skin overlying a superficial tendon. Wave speeds measured in vivo via tensiometry modulate with tendon load but are lower than that predicted by a tensioned beam model of an isolated tendon, which may be due to the added inertia of adjacent tissues. The objective of this study was to investigate the effects of adjacent fat tissue on shear wave propagation measurements in axially loaded tendons. We created a layered, dynamic finite element model of an elliptical tendon surrounded by subcutaneous fat. Transient shear waves were generated via an impulsive excitation delivered across the tendon or through the subcutaneous fat. The layered models demonstrated dispersive behavior with phase velocity increasing with frequency. Group shear wave speed could be ascertained via dispersion analysis or time-to-peak measures at sequential spatial locations. Simulated wave speeds in the tendon and adjacent fat were similar and modulated with tendon loading. However, wave speed magnitudes were consistently lower in the layered models than in an isolated tendon. For all models, the wave speed-stress relationship was well described by a tensioned beam model after accounting for the added inertia of the adjacent tissues. These results support the premise that externally excited shear waves are measurable in subcutaneous fat and modulate with axial loading in the underlying tendon. The model suggests that adjacent tissues add inertia to the system, which in turn lowers shear wave speeds. This information must be considered when using tensiometry as a clinical or research tool to infer absolute tendon loading. CI - Copyright © 2023. Published by Elsevier Ltd. FAU - Blank, Jonathon L AU - Blank JL AD - Department of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: jlblank@wisc.edu. FAU - Thelen, Darryl G AU - Thelen DG AD - Department of Mechanical Engineering, University of Wisconsin-Madison, Madison, WI, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: dgthelen@wisc.edu. LA - eng GR - R01 HD092697/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20230928 PL - Netherlands TA - J Mech Behav Biomed Mater JT - Journal of the mechanical behavior of biomedical materials JID - 101322406 RN - U68WG3173Y (Carmustine) RN - 6PLQ3CP4P3 (Etoposide) SB - IM MH - *Tendons MH - Weight-Bearing MH - Adipose Tissue MH - Carmustine MH - Etoposide MH - *Elasticity Imaging Techniques/methods PMC - PMC11498333 MID - NIHMS2027998 OTO - NOTNLM OT - Finite element model OT - Multi-layered model OT - Shear wave dispersion OT - Shear wave propagation OT - Subcutaneous fat OT - Tendon COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/10/02 18:41 MHDA- 2023/10/23 01:18 PMCR- 2024/10/23 CRDT- 2023/10/02 18:00 PHST- 2023/03/11 00:00 [received] PHST- 2023/04/27 00:00 [revised] PHST- 2023/09/20 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/02 18:41 [pubmed] PHST- 2023/10/02 18:00 [entrez] PHST- 2024/10/23 00:00 [pmc-release] AID - S1751-6161(23)00491-5 [pii] AID - 10.1016/j.jmbbm.2023.106138 [doi] PST - ppublish SO - J Mech Behav Biomed Mater. 2023 Nov;147:106138. doi: 10.1016/j.jmbbm.2023.106138. Epub 2023 Sep 28. PMID- 1375420 OWN - NLM STAT- MEDLINE DCOM- 19920622 LR - 20141120 IS - 0001-5423 (Print) IS - 0001-5423 (Linking) VI - 34 IP - 1 DP - 1992 TI - Experimental substantiation of allogenic tendon tissue transplantation. PG - 10-9 AB - Substantiation of transplantation of tendon allografts treated with a new solution showing both sterilizing and preservatory effects was provided in experiments on 84 dogs. The solution prepared on the basis of 0.1% formaldehyde with the addition of dimethyl sulphoxide, monomycin and prednisolone (FDMP) shows a high antimicrobial activity, preserves the structure of the tendons and their elasticity. In their duration, the processes of reconstruction of allografts preserved in FDMP are very similar to autotransplants. Clinical application of preserved tendons on repairing defects in 418 patients proved the method to be highly effective. FAU - Plotnikova, V A AU - Plotnikova VA AD - Sverdlovsk Branch, All-Union Kurgan Scientific Centre for Reconstructive Traumatology and Orthopedics, Ministry of Health, Yekaterinoburg, Russia. FAU - Stakheyev, I A AU - Stakheyev IA FAU - Shtin, V P AU - Shtin VP LA - eng PT - Journal Article PL - Czech Republic TA - Acta Chir Plast JT - Acta chirurgiae plasticae JID - 0370301 RN - 0 (Solutions) RN - 1014KSJ86F (Erythromycin Ethylsuccinate) RN - 1HG84L3525 (Formaldehyde) RN - 9PHQ9Y1OLM (Prednisolone) RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Animals MH - Dimethyl Sulfoxide MH - Dogs MH - Erythromycin Ethylsuccinate MH - Formaldehyde MH - Humans MH - In Vitro Techniques MH - Prednisolone MH - Solutions MH - Tendons/*transplantation MH - *Tissue Preservation EDAT- 1992/01/01 00:00 MHDA- 1992/01/01 00:01 CRDT- 1992/01/01 00:00 PHST- 1992/01/01 00:00 [pubmed] PHST- 1992/01/01 00:01 [medline] PHST- 1992/01/01 00:00 [entrez] PST - ppublish SO - Acta Chir Plast. 1992;34(1):10-9. PMID- 7834818 OWN - NLM STAT- MEDLINE DCOM- 19950227 LR - 20220409 IS - 0263-6484 (Print) IS - 0263-6484 (Linking) VI - 12 IP - 4 DP - 1994 Dec TI - Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH.) radicals is dependent on hyaluronan molecular mass. PG - 281-8 AB - Hyaluronan (HA) protected tendon fibroblasts against cell damage mediated by hydroxyl radicals (OH.) as demonstrated by release of 51Cr from labelled cells. Protection afforded by high molecular mass (M(r)) HA (1218 kDa) was much more effective than that provided by lower (176 kDa and 668 kDa) M(r) HA. OH. was generated by coupling H2O2 produced by glucose oxidase:glucose to [Fe(2+)-EDTA] chelate in a Fenton-type system. The flux of OH. was measured by a spectrofluorimetric assay of salicylate produced by the reaction of benzoate with OH.. Cell damage caused by the OH. generating system was prevented in the presence of catalase, which destroyed H2O2. Damage caused in a standard incubation time increased with increased amounts of glucose oxidase. Protection against OH.-mediated cell damage increased with increasing concentration of HA. The presence of HA did not interfere with the enzyme-Fenton system, as monitored by production of gluconate. On the other hand, HA scavenged OH. produced by the enzyme-Fenton system, as shown by competition with benzoate, which produced less salicylate in the spectrofluorimetric assay in the presence of HA. The reaction of OH. with HA was measured directly by a pulse radiolysis technique in which a hydrated electron (eaq-) produced OH. by the reaction with nitrous oxide. Second order rate constants obtained in distilled H2O or in phosphate buffer showed no dependence on HA M(r). Similarly, fluorimetric assay of the flux of in the enzyme-Fenton system confirmed that HA competed with benzoate, thus lowering salicylate production, and the flux was also independent of the molecular mass of HA.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Presti, D AU - Presti D AD - Fidia Research Laboratories, Abano Terme, Italy. FAU - Scott, J E AU - Scott JE LA - eng PT - Journal Article PL - England TA - Cell Biochem Funct JT - Cell biochemistry and function JID - 8305874 RN - 0 (Chromium Radioisotopes) RN - 3352-57-6 (Hydroxyl Radical) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Cell Membrane/*chemistry MH - Cell Survival/drug effects MH - Cells, Cultured MH - Chick Embryo MH - Chromium Radioisotopes MH - Hyaluronic Acid/chemistry/*pharmacology MH - Hydroxyl Radical/*chemistry MH - Molecular Weight MH - Tendons EDAT- 1994/12/01 00:00 MHDA- 1994/12/01 00:01 CRDT- 1994/12/01 00:00 PHST- 1994/12/01 00:00 [pubmed] PHST- 1994/12/01 00:01 [medline] PHST- 1994/12/01 00:00 [entrez] AID - 10.1002/cbf.290120409 [doi] PST - ppublish SO - Cell Biochem Funct. 1994 Dec;12(4):281-8. doi: 10.1002/cbf.290120409. PMID- 39975674 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250222 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 12 DP - 2025 TI - Does quercetin affect tendon healing? An experimental study in a rat model of Achilles tendon injury. PG - 1522517 LID - 10.3389/fmed.2025.1522517 [doi] LID - 1522517 AB - PURPOSE: The objective of this study was to investigate the impact of quercetin, a potent antioxidant, on tendon healing utilizing a rat Achilles tendon injury model. MATERIALS AND METHODS: The study involved 32 male Wistar-Albino rats, randomly split into experimental (quercetin) and control groups, each with 16 rats. A bilateral Achilles tenotomy model was applied, with the experimental group receiving quercetin and the control group receiving corn oil via oral gavage from surgery until sacrifice. One Achilles tendon per rat underwent histopathological and immunohistochemical evaluations, while the other underwent biomechanical analysis. RESULTS: Tendons were evaluated histopathologically in terms of tenocyte, ground substance, collagen, and vascularity, and quercetin was observed to significantly increase tendon healing in the experimental group (p-values = 0.0232, 0.0128, 0.0272, 0.0307, respectively). In the immunohistochemical analysis, type I collagen, type III collagen, alpha smooth muscle actin (SMA), and Galectin-3 were evaluated, and it was observed that quercetin increased tendon healing (p-values = 0.0166, 0.0036, 0.0323, 0.0295, respectively). In the biomechanical analysis, the rupture strength was evaluated with six parameters (failure load, maximum energy, displacement, stiffness, ultimate stress, and strain), and it was observed that quercetin significantly increased the rupture strength (p-values = 0.032, 0.014, 0.026, 0.025, 0.045, 0.012, respectively). CONCLUSION: Quercetin significantly enhanced tendon healing both biomechanically and immunohistochemically. However, further clinical studies are needed to understand its effects on human tendon healing, as this is the first study of its kind. CI - Copyright © 2025 Yurteri, Mercan, Çelik, Yaykaşlı and Yıldırım. FAU - Yurteri, Ahmet AU - Yurteri A AD - Department of Orthopedics and Traumatology, Konya City Hospital, Konya, Türkiye. FAU - Mercan, Numan AU - Mercan N AD - Department of Orthopedics and Traumatology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Türkiye. FAU - Çelik, Zeliha Esin AU - Çelik ZE AD - Department of Medical Pathology, Selçuk University, Konya, Türkiye. FAU - Yaykaşlı, Hakan AU - Yaykaşlı H AD - Department of Electronics, Kahramanmaraş İstiklal University, Kahramanmaraş, Türkiye. FAU - Yıldırım, Ahmet AU - Yıldırım A AD - Department of Orthopedics and Traumatology, Konya City Hospital, Konya, Türkiye. LA - eng PT - Journal Article DEP - 20250205 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC11835819 OTO - NOTNLM OT - biomechanical OT - histopathological OT - immunohistochemical OT - polyphenols OT - quercetin COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/02/20 06:22 MHDA- 2025/02/20 06:23 PMCR- 2025/02/05 CRDT- 2025/02/20 05:42 PHST- 2024/11/04 00:00 [received] PHST- 2025/01/24 00:00 [accepted] PHST- 2025/02/20 06:23 [medline] PHST- 2025/02/20 06:22 [pubmed] PHST- 2025/02/20 05:42 [entrez] PHST- 2025/02/05 00:00 [pmc-release] AID - 10.3389/fmed.2025.1522517 [doi] PST - epublish SO - Front Med (Lausanne). 2025 Feb 5;12:1522517. doi: 10.3389/fmed.2025.1522517. eCollection 2025. PMID- 10637963 OWN - NLM STAT- MEDLINE DCOM- 20000525 LR - 20061115 IS - 0043-5341 (Print) IS - 0043-5341 (Linking) VI - 149 IP - 19-20 DP - 1999 TI - [Use of topical non-steroidal anti-inflammatory drugs in aggravated and decompensated arthroses]. PG - 546-7 AB - Pain in osteoarthritis of the big weight bearing joints is either derived from periarticular ligaments, tendons, fascias, muscles, bursae--periarthropathy as sign of decompensation or from the reactive synovitis with or without effusion. NSAIDs (ibuprofen, diclofenac, indometacin, some salicylates, etofenamate and piroxicam) have demonstrated relevant advantages of the percutaneous route over the systemic one in soft tissue rheumatism. NSAIDs, mentioned above, locally administered as cream, gel or spray, quickly penetrate through the corneal layer of the skin and the site of application, reach highly effective concentrations in subcutis, fascias, tendons, ligaments and muscles, less in joint-capsule and -fluid indicating direct penetration. The blood levels of topical NSAIDs are extremely low with no systemic side effects, especially no gastric toxicity; however, local skin irritation is observed (1 to 2%). In contrast to this, systemic (oral) NSAIDs lead primarily via high blood levels to a lower concentration--only one tenth--in periarticular soft tissues with a high incidence of side effects. In conclusion the percutaneous application of certain NSAIDs has become a well established therapeutic regimen in painful osteoarthritis and in all other inflammatory degenerative and posttraumatic alterations of soft tissue structure. FAU - Chlud, K AU - Chlud K AD - Medizinisch-Pharmazeutischen Interessengemeinschaft Wien. LA - ger PT - English Abstract PT - Journal Article TT - Zur Anwendung von NSAR-Topika bei irritierten und dekompensierten Arthrosen. PL - Austria TA - Wien Med Wochenschr JT - Wiener medizinische Wochenschrift (1946) JID - 8708475 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) SB - IM MH - Administration, Topical MH - Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects MH - Humans MH - Osteoarthritis/*drug therapy/etiology MH - Periarthritis/drug therapy/etiology MH - Synovitis/drug therapy/etiology MH - Treatment Outcome EDAT- 2000/01/19 09:00 MHDA- 2000/06/08 09:00 CRDT- 2000/01/19 09:00 PHST- 2000/01/19 09:00 [pubmed] PHST- 2000/06/08 09:00 [medline] PHST- 2000/01/19 09:00 [entrez] PST - ppublish SO - Wien Med Wochenschr. 1999;149(19-20):546-7. PMID- 11834816 OWN - NLM STAT- MEDLINE DCOM- 20020312 LR - 20220309 IS - 1095-9203 (Electronic) IS - 0036-8075 (Linking) VI - 295 IP - 5557 DP - 2002 Feb 8 TI - Tending tender tendons. PG - 1011 FAU - Pennisi, Elizabeth AU - Pennisi E LA - eng PT - News PL - United States TA - Science JT - Science (New York, N.Y.) JID - 0404511 RN - 0 (Biocompatible Materials) RN - 0 (Biopolymers) RN - 0 (Cross-Linking Reagents) RN - 0 (Polyesters) RN - 7BO8G1BYQU (Masoprocol) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - *Biocompatible Materials MH - Biopolymers MH - *Collagen MH - Cross-Linking Reagents MH - Humans MH - *Masoprocol MH - Ovum MH - Polyesters MH - Skates, Fish MH - *Tendons/anatomy & histology/cytology MH - Tensile Strength MH - *Tissue Engineering EDAT- 2002/02/09 10:00 MHDA- 2002/03/13 10:01 CRDT- 2002/02/09 10:00 PHST- 2002/02/09 10:00 [pubmed] PHST- 2002/03/13 10:01 [medline] PHST- 2002/02/09 10:00 [entrez] AID - 295/5557/1011 [pii] AID - 10.1126/science.295.5557.1011 [doi] PST - ppublish SO - Science. 2002 Feb 8;295(5557):1011. doi: 10.1126/science.295.5557.1011. PMID- 2011838 OWN - NLM STAT- MEDLINE DCOM- 19910509 LR - 20080212 IS - 0040-5930 (Print) IS - 0040-5930 (Linking) VI - 48 IP - 1 DP - 1991 Jan TI - [Percutaneous therapy of painful arthritis]. PG - 42-5 AB - Pain in osteoarthrosis of the big weight bearing joints is either derived from periarticular ligaments, tendons, fasciae, muscles, bursae--peri-arthropathy as sign of decompensation--or from the reactive synovitis with or without effusion. NSAIDs systemically administered have been so far considered as first choice medication together with physical therapy. New pharmacokinetic data on the topical, percutaneous application of NSAIDs (ibuprofen, diclofenac, indomethacin, some salicylates and to a lesser degree for etofenamate and piroxicam) have demonstrated relevant advantages of the percutaneous route over the systemic one in soft tissue rheumatism. NSAIDs, mentioned above, locally administered as cream, gel or spray, quickly penetrate through the corneal layer of the skin at the site of application, reach high effective concentrations in subcutis, fasciae, tendons, ligaments and muscles, lesser in joint-capsule and -fluid indicating direct penetration. The blood levels of topical NSAIDs are extremely low with no systemic side effects, especially no gastric toxicity; however, local skin irritation is observed (1 to 2%). In contrast to this, systemic (oral) NSAIDs lead primarily via high blood levels to a much lesser concentration--only one tenth--in particular soft tissues with a high incidence of side effects. In conclusion the percutaneous application of certain NSAIDs has become a well established therapeutic regimen in painful osteoarthrosis and in all other inflammatory degenerative and posttraumatic alterations of soft tissue structures. FAU - Chlud, K AU - Chlud K AD - 2. Medizinische Abteilung mit Rheumatologie und Osteologie, Kaiser-Franz-Josef-Spital der Stadt Wien. LA - ger PT - English Abstract PT - Journal Article TT - Perkutane Therapie der schmerzhaften Arthrose. PL - Switzerland TA - Ther Umsch JT - Therapeutische Umschau. Revue therapeutique JID - 0407224 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) SB - IM MH - Administration, Topical MH - Anti-Inflammatory Agents/*therapeutic use MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use MH - Humans MH - Osteoarthritis/*drug therapy/physiopathology MH - Pain/drug therapy EDAT- 1991/01/01 00:00 MHDA- 1991/01/01 00:01 CRDT- 1991/01/01 00:00 PHST- 1991/01/01 00:00 [pubmed] PHST- 1991/01/01 00:01 [medline] PHST- 1991/01/01 00:00 [entrez] PST - ppublish SO - Ther Umsch. 1991 Jan;48(1):42-5. PMID- 14216663 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20190711 IS - 0022-5282 (Print) IS - 0022-5282 (Linking) VI - 4 DP - 1964 Sep TI - SOME STUDIES OF WOUND HEALING: EXPERIMENTAL METHODS, EFFECT OF ASCORBIC ACID AND EFFECT OF DEUTERIUM OXIDE. PG - 543-66 FAU - LEVENSON, S M AU - LEVENSON SM FAU - CROWLEY, L V AU - CROWLEY LV FAU - GEEVER, E F AU - GEEVER EF FAU - ROSEN, H AU - ROSEN H FAU - BERARD, C W AU - BERARD CW LA - eng PT - Journal Article PL - United States TA - J Trauma JT - The Journal of trauma JID - 0376373 RN - 0 (Polyvinyls) RN - 0 (Proteins) RN - 9007-34-5 (Collagen) RN - AR09D82C7G (Deuterium) RN - J65BV539M3 (Deuterium Oxide) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - OM MH - Animals MH - *Ascorbic Acid MH - *Biochemical Phenomena MH - *Biochemistry MH - *Biomedical Technology MH - *Biophysical Phenomena MH - *Biophysics MH - *Chromatography MH - *Collagen MH - *Deuterium MH - *Deuterium Oxide MH - *Equipment and Supplies MH - Guinea Pigs MH - *Histology MH - *Hydroxyproline MH - *Medical Laboratory Science MH - *Pathology MH - *Pharmacology MH - *Polyvinyls MH - Proteins/*metabolism MH - Rats MH - *Research MH - *Scurvy MH - *Skin MH - *Tendons MH - *Wound Healing OTO - NLM OT - *ASCORBIC ACID OT - *BIOCHEMISTRY OT - *BIOPHYSICS OT - *CHROMATOGRAPHY OT - *COLLAGEN OT - *DEUTERIUM OT - *EQUIPMENT AND SUPPLIES OT - *EXPERIMENTAL LAB STUDY OT - *GUINEA PIGS OT - *HISTOLOGY OT - *HYDROXYPROLINE OT - *PATHOLOGY OT - *PHARMACOLOGY OT - *POLYVINYLS OT - *PROTEIN METABOLISM OT - *RATS OT - *SCURVY OT - *SKIN OT - *TECHNOLOGY, MEDICAL OT - *TENDONS OT - *WOUND HEALING EDAT- 1964/09/01 00:00 MHDA- 1964/09/01 00:01 CRDT- 1964/09/01 00:00 PHST- 1964/09/01 00:00 [pubmed] PHST- 1964/09/01 00:01 [medline] PHST- 1964/09/01 00:00 [entrez] AID - 10.1097/00005373-196409000-00001 [doi] PST - ppublish SO - J Trauma. 1964 Sep;4:543-66. doi: 10.1097/00005373-196409000-00001. PMID- 8662699 OWN - NLM STAT- MEDLINE DCOM- 19960815 LR - 20210210 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 271 IP - 22 DP - 1996 May 31 TI - Involvement of hydrogen peroxide in collagen cross-linking by high glucose in vitro and in vivo. PG - 12964-71 AB - The Maillard reaction has been implicated in cross-linking and fluorescence formation of collagen exposed to high glucose in vitro. However, several pharmacologic agents, whose action seems unrelated to pathways of nonenzymatic glycation, have been demonstrated to prevent cross-linking in diabetes. To clarify this discrepancy, kinetic changes in glycation, glycoxidation (carboxymethyllysine, CML), and cross-linking (measured as tendon breaking time, TBT) were evaluated in rat tail tendons incubated in 5 and 30 mM glucose in vitro and in tendons implanted in vivo into diabetic rat peritoneal cavity. In vitro, rates were found to be both O2- and glucose-dependent. Tendon preglycation and presence of added 2 mM glycosylamine and Amadori compounds (Amadori product of glucose and propylamine) catalyzed these changes in a primarily O2-dependent manner. In the presence of Amadori compounds, kinetic changes were dramatically increased and were preventable by addition of catalase to the medium. Tendons implanted into diabetic rat peritoneum became more rapidly glycoxidized and cross-linked when implanted at day 30 from diabetes onset (high tissue glycation) compared to day 3 (low tissue glycation) in spite of similar glycation kinetics, suggesting a mechanistic dissociation between glycation, glycoxidation, and cross-linking in diabetes. Indeed, intraperitoneal injection of catalase and other antioxidants dramatically suppressed cross-linking, fluorescence formation, and, to some extent, glycoxidation, without affecting glycation. This study confirms the role of oxidative stress in protein cross-linking by the Maillard reaction in vitro and provides the first evidence for a role of H2O2 in cross-linking in diabetes. Whereas Amadori products are a potent source of H2O2 formation in vitro, their precise contribution to H2O2 generation and the actual role of Maillard reaction products in collagen cross-linking in diabetes requires further investigation. FAU - Elgawish, A AU - Elgawish A AD - Institute of Pathology and Department of Medicine, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44102, USA. FAU - Glomb, M AU - Glomb M FAU - Friedlander, M AU - Friedlander M FAU - Monnier, V M AU - Monnier VM LA - eng GR - AG 05601/AG/NIA NIH HHS/United States GR - EY 07099/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Antioxidants) RN - 0 (Cross-Linking Reagents) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) RN - BBX060AN9V (Hydrogen Peroxide) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Antioxidants/chemistry MH - Collagen/*chemistry MH - Cross-Linking Reagents/*chemistry MH - Diabetes Mellitus, Experimental/chemically induced/metabolism MH - Female MH - Glucose/*chemistry/metabolism MH - Hydrogen Peroxide/*chemistry MH - In Vitro Techniques MH - Kinetics MH - Maillard Reaction MH - Oxidative Stress MH - Rats MH - Rats, Sprague-Dawley MH - Streptozocin MH - Tendons/chemistry/transplantation EDAT- 1996/05/31 00:00 MHDA- 1996/05/31 00:01 CRDT- 1996/05/31 00:00 PHST- 1996/05/31 00:00 [pubmed] PHST- 1996/05/31 00:01 [medline] PHST- 1996/05/31 00:00 [entrez] AID - S0021-9258(18)41458-5 [pii] AID - 10.1074/jbc.271.22.12964 [doi] PST - ppublish SO - J Biol Chem. 1996 May 31;271(22):12964-71. doi: 10.1074/jbc.271.22.12964. PMID- 9289004 OWN - NLM STAT- MEDLINE DCOM- 19970911 LR - 20191102 IS - 1153-2424 (Print) IS - 1153-2424 (Linking) VI - 16 IP - 2 DP - 1997 TI - [Repeated rupture of the extensor tendons of the hand due to fluoroquinolones. Apropos of a case]. PG - 130-3 AB - Fluoroquinolone toxicity on cartilages and tendons has been well known since 1983. Tendon inflammation or rupture has been described. Achilles tendon rupture is the most frequent complication but many other sites of tendon injuries have been reported. This article presents a case of rupture of extensor tendons of the hand in an elderly woman treated by fluoroquinolones. As far as we know, this site of tendon lesion has never been previously described. Histological examination of tendon injuries was possible after surgical treatment. Histological structures were similar to the classical description but had specific features. Like other authors, we think that the mechanism of the disease involves vascular disorders as well as direct toxicity. The histological lesions seem to be different in chronic and acute forms. FAU - Levadoux, M AU - Levadoux M AD - Service de chirurgie Orthopédique, Hôpital d'Instruction des Armées, Sainte-Anne, Toulon, Naval. FAU - Carli, P AU - Carli P FAU - Gadea, J F AU - Gadea JF FAU - De Mauleon De Bruyere, P AU - De Mauleon De Bruyere P FAU - Perre, C AU - Perre C LA - fre PT - Case Reports PT - English Abstract PT - Journal Article TT - Rupture itérative des tendons extenseurs de la main sous fluoroquinolones. A propos d'un cas. PL - France TA - Ann Chir Main Memb Super JT - Annales de chirurgie de la main et du membre superieur : organe officiel des societes de chirurgie de la main = Annals of hand and upper limb surgery JID - 9011039 RN - 0 (Anti-Infective Agents) RN - 2H52Z9F2Q5 (Pefloxacin) RN - N0F8P22L1P (Norfloxacin) SB - IM MH - Acute Disease MH - Aged MH - Anti-Infective Agents/*adverse effects MH - Blood Vessels/drug effects MH - Chronic Disease MH - Female MH - *Hand/blood supply/pathology MH - Hemosiderosis/chemically induced/pathology MH - Humans MH - Lymphocytes/pathology MH - Muscular Diseases/chemically induced/pathology MH - Neovascularization, Pathologic/chemically induced/pathology MH - Norfloxacin/*adverse effects MH - Pefloxacin/*adverse effects MH - Recurrence MH - Rupture, Spontaneous MH - Tendinopathy/chemically induced/pathology MH - Tendons/*drug effects/pathology MH - Urinary Tract Infections/drug therapy EDAT- 1997/01/01 00:00 MHDA- 1997/01/01 00:01 CRDT- 1997/01/01 00:00 PHST- 1997/01/01 00:00 [pubmed] PHST- 1997/01/01 00:01 [medline] PHST- 1997/01/01 00:00 [entrez] AID - 10.1016/s0753-9053(97)80033-6 [doi] PST - ppublish SO - Ann Chir Main Memb Super. 1997;16(2):130-3. doi: 10.1016/s0753-9053(97)80033-6. PMID- 4364842 OWN - NLM STAT- MEDLINE DCOM- 19740730 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 342 IP - 2 DP - 1974 Apr 11 TI - Effect of neuraminidase on the synthesis of collagen and other proteins. PG - 247-53 FAU - Aalto, M AU - Aalto M FAU - Rönnemaa, T AU - Rönnemaa T FAU - Kulonen, E AU - Kulonen E LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 10028-17-8 (Tritium) RN - 1CC1JFE158 (Dactinomycin) RN - 9004-34-6 (Cellulose) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - E0399OZS9N (Cyclic AMP) RN - EC 3.2.1.18 (Neuraminidase) SB - IM MH - Animals MH - Cellulose MH - Chick Embryo MH - Collagen/*biosynthesis MH - Cyclic AMP/pharmacology MH - Dactinomycin/pharmacology MH - Electrophoresis, Polyacrylamide Gel MH - Fibroblasts/drug effects/metabolism MH - Granulation Tissue/drug effects/*metabolism MH - Hydrogen-Ion Concentration MH - Kinetics MH - Male MH - Neuraminidase/*pharmacology MH - Proline MH - Protein Biosynthesis MH - Rats MH - Tendons/drug effects/*metabolism MH - Time Factors MH - Tritium MH - Vibrio cholerae/enzymology EDAT- 1974/04/11 00:00 MHDA- 1974/04/11 00:01 CRDT- 1974/04/11 00:00 PHST- 1974/04/11 00:00 [pubmed] PHST- 1974/04/11 00:01 [medline] PHST- 1974/04/11 00:00 [entrez] AID - 0005-2795(74)90079-8 [pii] AID - 10.1016/0005-2795(74)90079-8 [doi] PST - ppublish SO - Biochim Biophys Acta. 1974 Apr 11;342(2):247-53. doi: 10.1016/0005-2795(74)90079-8. PMID- 10961538 OWN - NLM STAT- MEDLINE DCOM- 20001228 LR - 20190831 IS - 0300-8126 (Print) IS - 0300-8126 (Linking) VI - 28 IP - 4 DP - 2000 Jul-Aug TI - Fluoroquinolone-induced tendinopathy: also occurring with levofloxacin. PG - 256-7 FAU - Fleisch, F AU - Fleisch F FAU - Hartmann, K AU - Hartmann K FAU - Kuhn, M AU - Kuhn M LA - eng PT - Letter PL - Germany TA - Infection JT - Infection JID - 0365307 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Infective Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Adrenal Cortex Hormones/therapeutic use MH - Adult MH - Adverse Drug Reaction Reporting Systems MH - Aged MH - Anti-Infective Agents/*adverse effects/therapeutic use MH - Asthma/drug therapy MH - Female MH - Humans MH - *Levofloxacin MH - Lung Diseases, Obstructive/drug therapy MH - Male MH - Middle Aged MH - Ofloxacin/*adverse effects/therapeutic use MH - Tendinopathy/*chemically induced/pathology MH - Tendons/drug effects/pathology EDAT- 2000/08/29 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/08/29 11:00 PHST- 2000/08/29 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/08/29 11:00 [entrez] AID - 10.1007/s150100070050 [doi] PST - ppublish SO - Infection. 2000 Jul-Aug;28(4):256-7. doi: 10.1007/s150100070050. PMID- 4859449 OWN - NLM STAT- MEDLINE DCOM- 19741031 LR - 20190621 IS - 0014-5793 (Print) IS - 0014-5793 (Linking) VI - 41 IP - 1 DP - 1974 Apr 15 TI - Presumptive mRNA for procollagen: occurrence in membrane bound ribosomes of embryonic chick tendon fibroblasts. PG - 85-8 FAU - Harwood, R AU - Harwood R FAU - Connolly, A D AU - Connolly AD FAU - Grant, M E AU - Grant ME FAU - Jackson, D S AU - Jackson DS LA - eng PT - Journal Article PL - England TA - FEBS Lett JT - FEBS letters JID - 0155157 RN - 0 (Carbon Radioisotopes) RN - 0 (RNA, Messenger) RN - 10028-17-8 (Tritium) RN - 1CC1JFE158 (Dactinomycin) RN - 9004-34-6 (Cellulose) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - RMB44WO89X (Hydroxyproline) RN - WHI7HQ7H85 (Uridine) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Cellulose MH - Centrifugation, Density Gradient MH - Chick Embryo MH - Chromatography MH - Collagen/*biosynthesis MH - Dactinomycin/pharmacology MH - Electrophoresis, Polyacrylamide Gel MH - Fibroblasts/cytology/metabolism MH - Hydroxyproline/metabolism MH - Membranes/drug effects/metabolism MH - Molecular Weight MH - Polyribosomes/metabolism MH - Proline/metabolism MH - *Protein Biosynthesis MH - RNA, Messenger/*metabolism MH - Ribosomes/drug effects/*metabolism MH - Spectrophotometry, Ultraviolet MH - Tendons/cytology/*metabolism MH - Tritium MH - Uridine/metabolism EDAT- 1974/04/15 00:00 MHDA- 1974/04/15 00:01 CRDT- 1974/04/15 00:00 PHST- 1974/04/15 00:00 [pubmed] PHST- 1974/04/15 00:01 [medline] PHST- 1974/04/15 00:00 [entrez] AID - 0014-5793(74)80960-9 [pii] AID - 10.1016/0014-5793(74)80960-9 [doi] PST - ppublish SO - FEBS Lett. 1974 Apr 15;41(1):85-8. doi: 10.1016/0014-5793(74)80960-9. PMID- 26283157 OWN - NLM STAT- MEDLINE DCOM- 20160607 LR - 20220311 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 69 DP - 2015 Nov TI - Use of biomimetic microtissue spheroids and specific growth factor supplementation to improve tenocyte differentiation and adaptation to a collagen-based scaffold in vitro. PG - 99-109 LID - S0142-9612(15)00671-7 [pii] LID - 10.1016/j.biomaterials.2015.08.013 [doi] AB - Tenocytes represent a valuable source of cells for the purposes of tendon tissue engineering and regenerative medicine and as such, should possess a high degree of tenogenic differentiation prior to their use in vivo in order to achieve maximal efficacy. In the current report, we identify an efficient means by which to maintain differentiated tenocytes in vitro by employing the hanging drop technique in combination with defined growth media supplements. Equine tenocytes retained a more differentiated state when cultured as scaffold-free microtissue spheroids in low serum-containing medium supplemented with L-ascorbic acid 2-phosphate, insulin and transforming growth factor (TGF)-β1. This was made evident by significant increases in the expression levels of pro-tenogenic markers collagen type I (COL1A2), collagen type III (COL3A1), scleraxis (SCX) and tenomodulin (TNMD), as well as by enhanced levels of collagen type I and tenomodulin protein. Furthermore, tenocytes cultured under these conditions demonstrated a typical spindle-like morphology and when embedded in collagen gels, became highly aligned with respect to the orientation of the collagen structure following their migration out from the microtissue spheroids. Our findings therefore provide evidence to support the use of a biomimetic microtissue approach to culturing tenocytes and that in combination with the defined growth media described, can improve their differentiation status and functional repopulation of collagen matrix. CI - Copyright © 2015 Elsevier Ltd. All rights reserved. FAU - Theiss, Felix AU - Theiss F AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Equine Department, Vetsuisse-Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland. FAU - Mirsaidi, Ali AU - Mirsaidi A AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland. FAU - Mhanna, Rami AU - Mhanna R AD - Cartilage Engineering and Regeneration, ETH Zurich, 8093 Zurich, Switzerland; American University of Beirut, Faculty of Engineering and Architecture, Riad El Solh, 1107 2020 Beirut, Lebanon. FAU - Kümmerle, Jan AU - Kümmerle J AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Equine Department, Vetsuisse-Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland. FAU - Glanz, Stephan AU - Glanz S AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland. FAU - Bahrenberg, Gregor AU - Bahrenberg G AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland. FAU - Tiaden, André N AU - Tiaden AN AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. FAU - Richards, Peter J AU - Richards PJ AD - Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland. Electronic address: peter.richards@cabmm.uzh.ch. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150810 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Culture Media) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Transforming Growth Factor beta1) RN - 23313-12-4 (ascorbate-2-phosphate) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/analogs & derivatives/metabolism MH - Biomimetics MH - Cell Differentiation MH - Cells, Cultured MH - Collagen/*chemistry MH - Culture Media/*metabolism MH - Horses MH - Intercellular Signaling Peptides and Proteins/*metabolism MH - Regeneration MH - Spheroids, Cellular MH - Tendons/*cytology/physiology MH - Tissue Engineering/*methods MH - Tissue Scaffolds/*chemistry MH - Transforming Growth Factor beta1/metabolism OTO - NOTNLM OT - Growth factors OT - In vitro test OT - Microsphere OT - TGF (transforming growth factor) OT - Tendon EDAT- 2015/08/19 06:00 MHDA- 2016/06/09 06:00 CRDT- 2015/08/19 06:00 PHST- 2015/04/16 00:00 [received] PHST- 2015/08/06 00:00 [revised] PHST- 2015/08/07 00:00 [accepted] PHST- 2015/08/19 06:00 [entrez] PHST- 2015/08/19 06:00 [pubmed] PHST- 2016/06/09 06:00 [medline] AID - S0142-9612(15)00671-7 [pii] AID - 10.1016/j.biomaterials.2015.08.013 [doi] PST - ppublish SO - Biomaterials. 2015 Nov;69:99-109. doi: 10.1016/j.biomaterials.2015.08.013. Epub 2015 Aug 10. PMID- 20808174 OWN - NLM STAT- MEDLINE DCOM- 20101216 LR - 20250529 IS - 1536-7355 (Electronic) IS - 1076-1608 (Print) IS - 1076-1608 (Linking) VI - 16 IP - 6 DP - 2010 Sep TI - Diffuse palpable tendon friction rubs in a patient with seronegative erosive polyarthritis. PG - 300-1 LID - 10.1097/RHU.0b013e3181ef6ee1 [doi] FAU - Rose, Shawn AU - Rose S AD - Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. s-rose@md.northwestern.edu FAU - Varga, John AU - Varga J LA - eng GR - R01 AR042309/AR/NIAMS NIH HHS/United States GR - R56 AR042309/AR/NIAMS NIH HHS/United States GR - AR-42309/AR/NIAMS NIH HHS/United States PT - Case Reports PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Clin Rheumatol JT - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases JID - 9518034 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antirheumatic Agents) RN - FYS6T7F842 (Adalimumab) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adalimumab MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Humanized MH - Antirheumatic Agents/therapeutic use MH - Arthritis/*complications/drug therapy/*physiopathology MH - Drug Therapy, Combination MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Methotrexate/therapeutic use MH - Middle Aged MH - Tendons/pathology/*physiopathology MH - Treatment Outcome PMC - PMC2935273 MID - NIHMS229484 EDAT- 2010/09/03 06:00 MHDA- 2010/12/17 06:00 PMCR- 2011/09/01 CRDT- 2010/09/03 06:00 PHST- 2010/09/03 06:00 [entrez] PHST- 2010/09/03 06:00 [pubmed] PHST- 2010/12/17 06:00 [medline] PHST- 2011/09/01 00:00 [pmc-release] AID - 00124743-201009000-00012 [pii] AID - 10.1097/RHU.0b013e3181ef6ee1 [doi] PST - ppublish SO - J Clin Rheumatol. 2010 Sep;16(6):300-1. doi: 10.1097/RHU.0b013e3181ef6ee1. PMID- 15045551 OWN - NLM STAT- MEDLINE DCOM- 20040817 LR - 20131121 IS - 0949-2658 (Print) IS - 0949-2658 (Linking) VI - 9 IP - 2 DP - 2004 TI - Levofloxacin-induced bilateral Achilles tendon rupture: a case report and review of the literature. PG - 186-90 AB - We present a rare case of spontaneous bilateral Achilles tendon rupture induced by levofloxacin, one of the fluoroquinolone antibiotics. A 76-year-old man was diagnosed with acute appendicitis and was commenced on oral levofloxacin 300 mg/day for 2 weeks. Seven days afterward he developed pain in both Achilles tendons, and at 14 days he developed swelling in the tendons. Four days later he felt a sharp, painful snap in both Achilles tendons while changing trousers. Both Achilles tendons ruptured completely at the mid-portion. There was no obvious underlying disease or pathophysiological factor causing fragility of his Achilles tendons. Despite the relatively large volume of case-based evidence, the pathophysiology of fluoroquinolone-induced tendinitis and tendon rupture is unclear. When tendinitis develops during fluoroquinolone therapy, the physician should consider the possible association between the fluoroquinolone and tendon rupture. FAU - Kowatari, Kenji AU - Kowatari K AD - Department of Orthopaedic Surgery, Aomori Rosai Hospital, 1 Minamigaoka, Shirogane-machi, Hachinohe 031-8551, Japan. FAU - Nakashima, Kikuo AU - Nakashima K FAU - Ono, Atsushi AU - Ono A FAU - Yoshihara, Masakazu AU - Yoshihara M FAU - Amano, Masafumi AU - Amano M FAU - Toh, Satoshi AU - Toh S LA - eng PT - Case Reports PT - Journal Article PT - Review PL - Japan TA - J Orthop Sci JT - Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association JID - 9604934 RN - 0 (Anti-Infective Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/*injuries/surgery MH - Aged MH - Anti-Infective Agents/*adverse effects MH - Appendicitis/drug therapy MH - Humans MH - *Levofloxacin MH - Male MH - Ofloxacin/*adverse effects MH - Rupture/chemically induced RF - 26 EDAT- 2004/03/27 05:00 MHDA- 2004/08/18 05:00 CRDT- 2004/03/27 05:00 PHST- 2003/09/05 00:00 [received] PHST- 2003/12/22 00:00 [accepted] PHST- 2004/03/27 05:00 [pubmed] PHST- 2004/08/18 05:00 [medline] PHST- 2004/03/27 05:00 [entrez] AID - S0949-2658(15)32903-1 [pii] AID - 10.1007/s00776-003-0761-4 [doi] PST - ppublish SO - J Orthop Sci. 2004;9(2):186-90. doi: 10.1007/s00776-003-0761-4. PMID- 15148565 OWN - NLM STAT- MEDLINE DCOM- 20050329 LR - 20220408 IS - 0340-5761 (Print) IS - 0340-5761 (Linking) VI - 78 IP - 10 DP - 2004 Oct TI - The effects of enrofloxacin on decorin and glycosaminoglycans in avian tendon cell cultures. PG - 599-608 AB - Tendonitis and tendon rupture have been reported to occur during or following therapy with fluoroquinolone antibiotics. Though the pathogenesis is unknown, several studies suggest that fluoroquinolone antibiotics alter proteoglycan content in soft tissues, including tendons, and thereby alter collagen fibrillogenesis. To better understand the mechanism of action of fluoroquinolones, we studied the effects of enrofloxacin, a widely used fluoroquinolone in veterinary medicine, on avian tendon cell cultures established from gastrocnemius tendons from 18-day-old chicken embryos. We found that cell proliferation was progressively inhibited with increasing concentrations of enrofloxacin. This was accompanied by changes in morphology, extracellular matrix content and collagen fibril formation as detected by electron microscopy. We also observed a 35% decrease in the content of total monosaccharides in enrofloxacin-treated cells. The ratio of individual monosaccharides was also altered in enrofloxacin-treated cells. Enrofloxacin also induced the synthesis of small amounts of keratan sulfate in tendon cells. Moreover we observed enrofloxacin-induced changes in glycosylation of decorin, the most abundant tendon proteoglycan, resulting in the emergence of multiple lower molecular bands that were identifiable as decorin after chondroitinase ABC and N-glycanase treatment of extracts from enrofloxacin-treated cells. Medium conditioned by enrofloxacin-treated cells contained less decorin than did medium conditioned by control cells. We hypothesize that enrofloxacin induces either changes in the number of N-linked oligosaccharides attached to the core protein of decorin or changes in decorin degradation process. In conclusion, our data suggest that enrofloxacin affects cell proliferation and extracellular matrix through changes in glycosylation. FAU - Yoon, Jung Hae AU - Yoon JH AD - Department of Pathology, College of Veterinary Medicine, The University of Georgia, Athens, GA 30602, USA. FAU - Brooks, Randolph L Jr AU - Brooks RL Jr FAU - Zhao, Jian Zeng AU - Zhao JZ FAU - Isaacs, David AU - Isaacs D FAU - Halper, Jaroslava AU - Halper J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20040518 PL - Germany TA - Arch Toxicol JT - Archives of toxicology JID - 0417615 RN - 0 (Antineoplastic Agents) RN - 0 (Culture Media, Conditioned) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fluoroquinolones) RN - 0 (Glycosaminoglycans) RN - 0 (Proteoglycans) RN - 0 (Quinolones) RN - 0 (Reticulin) RN - 3DX3XEK1BN (Enrofloxacin) RN - 9056-36-4 (Keratan Sulfate) SB - IM MH - Animals MH - Antineoplastic Agents/*toxicity MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Chick Embryo MH - Culture Media, Conditioned/chemistry/metabolism MH - Decorin MH - Dose-Response Relationship, Drug MH - Enrofloxacin MH - Extracellular Matrix/drug effects/metabolism MH - Extracellular Matrix Proteins MH - Fluoroquinolones/*toxicity MH - Gas Chromatography-Mass Spectrometry MH - Glycosaminoglycans/*metabolism MH - Keratan Sulfate/biosynthesis MH - Muscle, Skeletal MH - Proteoglycans/analysis/*metabolism MH - Quinolones/*toxicity MH - Reticulin/drug effects/ultrastructure MH - Tendons/*drug effects/metabolism/ultrastructure EDAT- 2004/05/19 05:00 MHDA- 2005/03/30 09:00 CRDT- 2004/05/19 05:00 PHST- 2004/01/12 00:00 [received] PHST- 2004/03/16 00:00 [accepted] PHST- 2004/05/19 05:00 [pubmed] PHST- 2005/03/30 09:00 [medline] PHST- 2004/05/19 05:00 [entrez] AID - 10.1007/s00204-004-0574-z [doi] PST - ppublish SO - Arch Toxicol. 2004 Oct;78(10):599-608. doi: 10.1007/s00204-004-0574-z. Epub 2004 May 18. PMID- 19506908 OWN - NLM STAT- MEDLINE DCOM- 20091008 LR - 20131121 IS - 1432-0878 (Electronic) IS - 0302-766X (Linking) VI - 337 IP - 2 DP - 2009 Aug TI - Organization of collagen bundles during tendon healing in rats treated with L-NAME. PG - 235-42 LID - 10.1007/s00441-009-0819-5 [doi] AB - The Achilles tendon can support high tension forces and may experience lesions. The damaged tissue does not regenerate completely, with the organization and mechanical properties of the repaired tendon being inferior to those of a healthy tendon. Nitric oxide (NO) plays an important role in wound repair. We have examined the structural reorganization and repair in Achilles tendon after injury in rats treated with the NO synthase inhibitor L-NAME. The right Achilles tendon of male Wistar rats was partially transected. One group of rats was treated with L-NAME (~300 mg/kg per day, given in drinking water) for 4 days prior to tendon sectioning and throughout the post-operative period. Control rats received water without L-NAME. The tendons were excised at 7, 14, and 21 days post-injury and used to quantify hydroxyproline and for mechanical tests. Tendons were also processed for histomorphological analysis by polarized light microscopy, which showed that the collagen fibers were disorganized by day 7 in non-treated and L-NAME-treated rats. In non-treated rats, the organization of the extracellular matrix was more homogeneous by days 14 and 21 compared with day 7, although this homogeneity was less than that in normal tendon. In contrast, in injured tendons from L-NAME-treated rats, the collagen fibers were still disorganized on day 21. Tendons from treated rats had more hydroxyproline but lower mechanical properties compared with those from non-treated rats. Thus, NO modulates tendon healing, with a reduction in NO biosynthesis delaying reorganization of the extracellular matrix, especially collagen. FAU - Tomiosso, Tatiana Carla AU - Tomiosso TC AD - Department of Anatomy, Cell Biology, Physiology and Biophysics, Institute of Biology, State University of Campinas, UNICAMP, SP, Brazil. FAU - Nakagaki, Wilson Romero AU - Nakagaki WR FAU - Gomes, Laurecir AU - Gomes L FAU - Hyslop, Stephen AU - Hyslop S FAU - Pimentel, Edson Rosa AU - Pimentel ER LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090609 PL - Germany TA - Cell Tissue Res JT - Cell and tissue research JID - 0417625 RN - 0 (Enzyme Inhibitors) RN - 31C4KY9ESH (Nitric Oxide) RN - 9007-34-5 (Collagen) RN - EC 1.14.13.39 (Nitric Oxide Synthase) RN - RMB44WO89X (Hydroxyproline) RN - V55S2QJN2X (NG-Nitroarginine Methyl Ester) SB - IM MH - Achilles Tendon/drug effects/*physiology/ultrastructure MH - Animals MH - Biomechanical Phenomena MH - Collagen/drug effects/physiology/*ultrastructure MH - Enzyme Inhibitors/pharmacology MH - Hydroxyproline/metabolism MH - Male MH - NG-Nitroarginine Methyl Ester/pharmacology MH - Nitric Oxide/*physiology MH - Nitric Oxide Synthase/antagonists & inhibitors/metabolism MH - Rats MH - Rats, Wistar MH - *Regeneration/drug effects MH - Tendon Injuries/*metabolism MH - Wound Healing/drug effects/*physiology EDAT- 2009/06/10 09:00 MHDA- 2009/10/09 06:00 CRDT- 2009/06/10 09:00 PHST- 2008/11/11 00:00 [received] PHST- 2009/05/08 00:00 [accepted] PHST- 2009/06/10 09:00 [entrez] PHST- 2009/06/10 09:00 [pubmed] PHST- 2009/10/09 06:00 [medline] AID - 10.1007/s00441-009-0819-5 [doi] PST - ppublish SO - Cell Tissue Res. 2009 Aug;337(2):235-42. doi: 10.1007/s00441-009-0819-5. Epub 2009 Jun 9. PMID- 23047144 OWN - NLM STAT- MEDLINE DCOM- 20130625 LR - 20211021 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 7 DP - 2012 Oct 9 TI - Biomechanical effects of steroid injections used to treat pyogenic flexor tenosynovitis. PG - 34 LID - 10.1186/1749-799X-7-34 [doi] AB - BACKGROUND: A recent study from our laboratory has demonstrated improved range of motion in the toes of broiler chickens afflicted with pyogenic flexor tenosynovitis when treated with local antibiotic and corticosteroid injections, without surgical drainage. However, the use of corticosteroids as an adjunct treatment raised peer concern, as steroids are thought to have deleterious effects on tendon strength. The purpose of this study was to compare the tensile strength of the aforementioned steroid treated tendons, to a group of tendons administered with the current standard treatment: systemic antibiotics, surgical drainage and no corticosteroids. METHODS: Twenty-three tendons' structural and material properties were investigated (fifteen receiving the standard treatment, eight receiving the steroid treatment). The measurements from each group were interpreted via Student's unpaired t-test and a post-hoc power analysis. RESULTS: The steroid treated tendons did demonstrate a trend toward decreased mechanical properties when compared with the standard treatment group, but the results were not statistically significant. CONCLUSIONS: Treatment of septic tenosynovitis with local corticosteroid and local antibiotic injections resulted in better digital motion, without a significant loss of tendon strength, over a twenty-eight day recovery period. FAU - Turvey, Blake R AU - Turvey BR AD - University of North Carolina, School of Medicine, Department of Orthopaedics, Campus Box #7055, Bioinformatics Building, Chapel Hill, NC 27599-7055, USA. FAU - Weinhold, Paul S AU - Weinhold PS FAU - Draeger, Reid W AU - Draeger RW FAU - Bynum, Donald K AU - Bynum DK FAU - Dahners, Laurence E AU - Dahners LE LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20121009 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Animals MH - Anti-Bacterial Agents/administration & dosage MH - Biomechanical Phenomena MH - Chickens MH - Dexamethasone/*administration & dosage MH - Female MH - Gentamicins/administration & dosage MH - Glucocorticoids/*administration & dosage MH - Injections MH - Tendons/*drug effects MH - Tenosynovitis/*drug therapy PMC - PMC3554501 EDAT- 2012/10/11 06:00 MHDA- 2013/06/26 06:00 PMCR- 2012/10/09 CRDT- 2012/10/11 06:00 PHST- 2012/03/06 00:00 [received] PHST- 2012/10/05 00:00 [accepted] PHST- 2012/10/11 06:00 [entrez] PHST- 2012/10/11 06:00 [pubmed] PHST- 2013/06/26 06:00 [medline] PHST- 2012/10/09 00:00 [pmc-release] AID - 1749-799X-7-34 [pii] AID - 10.1186/1749-799X-7-34 [doi] PST - epublish SO - J Orthop Surg Res. 2012 Oct 9;7:34. doi: 10.1186/1749-799X-7-34. PMID- 12602391 OWN - HSR STAT- MEDLINE DCOM- 20030321 LR - 20131121 IS - 1167-7422 (Print) IS - 1167-7422 (Linking) VI - 12 IP - 63 DP - 2003 Feb TI - Tendon abnormalities and hypersensitivity of levofloxacin. PG - 20 LA - eng PT - Journal Article PL - France TA - Prescrire Int JT - Prescrire international JID - 9439295 RN - 0 (Anti-Infective Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) MH - Anti-Infective Agents/adverse effects MH - Humans MH - Hypersensitivity/*etiology MH - *Levofloxacin MH - Ofloxacin/*adverse effects MH - Rupture/*chemically induced MH - Tendons/*drug effects EDAT- 2003/02/27 04:00 MHDA- 2003/03/22 04:00 CRDT- 2003/02/27 04:00 PHST- 2003/02/27 04:00 [pubmed] PHST- 2003/03/22 04:00 [medline] PHST- 2003/02/27 04:00 [entrez] PST - ppublish SO - Prescrire Int. 2003 Feb;12(63):20. PMID- 19404974 OWN - NLM STAT- MEDLINE DCOM- 20090630 LR - 20131121 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 60 IP - 5 DP - 2009 May TI - Effect of ciprofloxacin-mediated inhibition on cell proliferation in rat tendon cells: comment on the article by Tsai et al. PG - 1564; author reply 1564 LID - 10.1002/art.24527 [doi] FAU - Medhi, Bikash AU - Medhi B FAU - Kaur, Harjot AU - Kaur H FAU - Prakash, Ajay AU - Prakash A LA - eng PT - Comment PT - Letter PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM CON - Arthritis Rheum. 2008 Jun;58(6):1657-63. doi: 10.1002/art.23518. PMID: 18512786 MH - Animals MH - Cell Proliferation/*drug effects MH - Ciprofloxacin/*pharmacology MH - Rats MH - Tendons/*cytology EDAT- 2009/05/01 09:00 MHDA- 2009/07/01 09:00 CRDT- 2009/05/01 09:00 PHST- 2009/05/01 09:00 [entrez] PHST- 2009/05/01 09:00 [pubmed] PHST- 2009/07/01 09:00 [medline] AID - 10.1002/art.24527 [doi] PST - ppublish SO - Arthritis Rheum. 2009 May;60(5):1564; author reply 1564. doi: 10.1002/art.24527. PMID- 9435847 OWN - NLM STAT- MEDLINE DCOM- 19980127 LR - 20161209 IS - 0755-4982 (Print) IS - 0755-4982 (Linking) VI - 26 IP - 31 DP - 1997 Oct 18 TI - [Tendon disease caused by ciprofloxacin, an atypical site]. PG - 1489 FAU - Peyrade, F AU - Peyrade F FAU - Taillan, B AU - Taillan B FAU - Chichmanian, R M AU - Chichmanian RM FAU - Lebrun, C AU - Lebrun C FAU - Dujardin, P AU - Dujardin P LA - fre PT - Case Reports PT - Letter TT - Tendinopathie à ciprofloxacine, une localisation atypique. PL - France TA - Presse Med JT - Presse medicale (Paris, France : 1983) JID - 8302490 RN - 0 (Anti-Infective Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Adult MH - Anti-Infective Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Humans MH - Male MH - Muscular Diseases/*chemically induced MH - Tendons/*drug effects EDAT- 1998/01/22 00:00 MHDA- 1998/01/22 00:01 CRDT- 1998/01/22 00:00 PHST- 1998/01/22 00:00 [pubmed] PHST- 1998/01/22 00:01 [medline] PHST- 1998/01/22 00:00 [entrez] PST - ppublish SO - Presse Med. 1997 Oct 18;26(31):1489. PMID- 25073614 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20211021 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 35 IP - 2 DP - 2016 Feb TI - Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate. PG - 363-70 LID - 10.1007/s10067-014-2753-5 [doi] AB - The objective of the study was to combine ultrasonographic (US) with clinical findings for comparing the effect of adalimumab (ADA) to methotrexate (MTX) on the thickness of tendons and enthesis in psoriatic arthritis (PsA) patients. Forty-three consecutive PsA patients were examined at baseline and after 6 and 12 weeks of treatment with ADA or MTX. The US assessment included thickness measurement of the extensor (ET) and flexor tendons (FT) of the second and third finger of both hands, plantar aponeurosis (PA) and the Achilles tendon (AT) bilaterally. Disease activity (DA) was assessed by the number of tender (TJ) and swollen joints (SJ), the number of inflamed enthesis (IE), pain assessment (PAI), and patient (PDAI) and physician (PHDAI) disease activity evaluations by visual activity score (VAS). Nineteen patients received MTX and 24 patients received ADA. All DA parameters improved in both groups. A decrease in thickness of tendons and enthesis was observed only in the ADA group, reaching a level of significance for the left AT (p = 0.01), left PA (p = 0.007), the second left FT (p = 0.04) and the third ET (p = 0.04). ADA patients showed a trend towards a better response to treatment compared to MTX patients that reach significance at week 6 of treatment for the thickness of left AT (p = 0.04), left PA (p = 0.03), the number of TJ (p = 0.0136), PAI (p = 0.0028), and PDAI (p = 0.029). ADA treatment for PsA compared to MTX significantly improved signs of DA and several US parameters. US assessment of enthesis can be an additional useful tool in the monitoring of psoriatic enthesopathy. FAU - Litinsky, Irena AU - Litinsky I AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. litinskyira@yahoo.com. FAU - Balbir-Gurman, Alexandra AU - Balbir-Gurman A AD - Department of Rheumatology, Rambam Health Care Campus, Rappaport School of Medicine, The Technion, Haifa, Israel. FAU - Wollman, Jonathan AU - Wollman J AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Arad, Uri AU - Arad U AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Paran, Daphna AU - Paran D AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Caspi, Dan AU - Caspi D AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Elkayam, Ori AU - Elkayam O AD - Department of Rheumatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Comparative Study PT - Journal Article DEP - 20140731 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Antirheumatic Agents) RN - FYS6T7F842 (Adalimumab) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adalimumab/pharmacology/*therapeutic use MH - Adult MH - Antirheumatic Agents/pharmacology/*therapeutic use MH - Arthritis, Psoriatic/diagnostic imaging/*drug therapy MH - Female MH - Humans MH - Joints/diagnostic imaging/*drug effects MH - Male MH - Methotrexate/pharmacology/*therapeutic use MH - Middle Aged MH - Tendons/diagnostic imaging/drug effects MH - Ultrasonography OTO - NOTNLM OT - Adalimumab OT - Methotrexate OT - Psoriatic arthritis OT - Ultrasound EDAT- 2014/07/31 06:00 MHDA- 2016/12/15 06:00 CRDT- 2014/07/31 06:00 PHST- 2014/03/12 00:00 [received] PHST- 2014/07/18 00:00 [accepted] PHST- 2014/05/19 00:00 [revised] PHST- 2014/07/31 06:00 [entrez] PHST- 2014/07/31 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.1007/s10067-014-2753-5 [pii] AID - 10.1007/s10067-014-2753-5 [doi] PST - ppublish SO - Clin Rheumatol. 2016 Feb;35(2):363-70. doi: 10.1007/s10067-014-2753-5. Epub 2014 Jul 31. PMID- 11292056 OWN - NLM STAT- MEDLINE DCOM- 20010726 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 29 IP - 2 DP - 2001 Mar-Apr TI - The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. PG - 262-3 FAU - Riley, G AU - Riley G FAU - Fenwick, S AU - Fenwick S FAU - Hazleman, B AU - Hazleman B LA - eng PT - Comment PT - Letter PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Infective Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM CON - Am J Sports Med. 2000 May-Jun;28(3):364-9. doi: 10.1177/03635465000280031401. PMID: 10843129 MH - Anti-Infective Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Humans MH - Muscular Diseases/*chemically induced MH - Tendons/*drug effects EDAT- 2001/04/09 10:00 MHDA- 2001/07/28 10:01 CRDT- 2001/04/09 10:00 PHST- 2001/04/09 10:00 [pubmed] PHST- 2001/07/28 10:01 [medline] PHST- 2001/04/09 10:00 [entrez] AID - 10.1177/03635465010290022701 [doi] PST - ppublish SO - Am J Sports Med. 2001 Mar-Apr;29(2):262-3. doi: 10.1177/03635465010290022701. PMID- 31009093 OWN - NLM STAT- MEDLINE DCOM- 20200106 LR - 20220411 IS - 2042-3306 (Electronic) IS - 0425-1644 (Linking) VI - 52 IP - 1 DP - 2020 Jan TI - Administration of enrofloxacin during late pregnancy failed to induce lesions in the resulting newborn foals. PG - 136-143 LID - 10.1111/evj.13131 [doi] AB - BACKGROUND: A recent study demonstrated that enrofloxacin and ciprofloxacin cross the equine placenta without causing gross cartilage or tendon lesions in the 9-month fetus; however, long-term effects of in utero fluoroquinolone exposure remain unknown. OBJECTIVES: To assess effects of fetal exposure to enrofloxacin on the resulting foal's cartilage and tendon strength. STUDY DESIGN AND METHODS: Healthy mares at 280 days' gestation were allocated into four groups: untreated (n = 5), therapeutic treatment (7.5 mg/kg enrofloxacin, PO × 14 days, n = 6), supratherapeutic treatment (15 mg/kg, PO × 14 days, n = 6) and no mare treatment with treatment of the foals post-partum (n = 2). Mares were allowed to carry pregnancy to term, and foals were maintained on pasture for 5 weeks. After that foals were euthanized, and their articular cartilage and extensor and flexor tendons were examined macroscopically and histologically for lesions. Tendon strength was tested by loading until failure. RESULTS: Administration of enrofloxacin at recommended doses in late gestation did not result in cartilaginous lesions or clinical lameness in any foal by 5 weeks old. Tensile strength was greater in hind tendons than front tendons, but no difference was found between foals born from treated and control mares. Expectedly, osteochondral changes were present both in foals born from enrofloxacin-treated mares and in negative control foals with no apparent association with fluoroquinolone treatment during pregnancy. MAIN LIMITATIONS: Only one time point in gestation was evaluated, and mares treated in the study were healthy at time of treatment. Additionally, it is possible that the assessments performed herein were not sensitive enough to detect subtle or functional changes in the articular cartilage. Further studies are needed to determine if enrofloxacin administration during late pregnancy potentiates osteochondral alterations in the first year of life. CONCLUSIONS: While this study did not assess other stages of gestation or long-term foal outcomes, short-term administration of enrofloxacin to late gestation mares did not result in macroscopic or microscopic lesions in the resulting foals by 5 weeks of age. CI - © 2019 EVJ Ltd. FAU - Ellerbrock, R E AU - Ellerbrock RE AD - Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. AD - Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. FAU - Canisso, I F AU - Canisso IF AUID- ORCID: 0000-0003-3799-6641 AD - Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. AD - Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. FAU - Roady, P J AU - Roady PJ AD - Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. AD - Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. FAU - Litsky, A AU - Litsky A AD - Department of Orthopaedics, College of Medicine, Ohio State University, Columbus, Ohio, USA. AD - Department of Biomedical Engineering, College of Engineering, Ohio State University, Columbus, Ohio, USA. FAU - Durgam, S AU - Durgam S AD - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus, Ohio, USA. FAU - Podico, G AU - Podico G AD - Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. FAU - Li, Z AU - Li Z AD - Roy J. Carver Biotechnology Center, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. FAU - Lima, F S AU - Lima FS AD - Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. AD - Department of Comparative Biosciences, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. LA - eng GR - USDA Hatch/ GR - Department of Veterinary Clinical Medicine Koteska Fellowship, University of Illinois/ PT - Journal Article PT - Randomized Controlled Trial, Veterinary DEP - 20190530 PL - United States TA - Equine Vet J JT - Equine veterinary journal JID - 0173320 RN - 0 (Anti-Bacterial Agents) RN - 3DX3XEK1BN (Enrofloxacin) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Animals MH - Animals, Newborn MH - Anti-Bacterial Agents/administration & dosage/adverse effects MH - Biomechanical Phenomena MH - Ciprofloxacin/adverse effects/metabolism MH - Dose-Response Relationship, Drug MH - Enrofloxacin/administration & dosage/*adverse effects MH - Female MH - Horse Diseases/*etiology MH - Horses MH - Pregnancy MH - Pregnancy Complications/chemically induced/*veterinary MH - *Pregnancy, Animal MH - Prenatal Exposure Delayed Effects MH - Tendons/drug effects/pathology OTO - NOTNLM OT - ciprofloxacin OT - fetal toxicity OT - fluoroquinolone OT - horse OT - pregnancy EDAT- 2019/04/23 06:00 MHDA- 2020/01/07 06:00 CRDT- 2019/04/23 06:00 PHST- 2018/10/10 00:00 [received] PHST- 2019/04/12 00:00 [accepted] PHST- 2019/04/23 06:00 [pubmed] PHST- 2020/01/07 06:00 [medline] PHST- 2019/04/23 06:00 [entrez] AID - 10.1111/evj.13131 [doi] PST - ppublish SO - Equine Vet J. 2020 Jan;52(1):136-143. doi: 10.1111/evj.13131. Epub 2019 May 30. PMID- 25047394 OWN - NLM STAT- MEDLINE DCOM- 20150615 LR - 20220321 IS - 1525-1497 (Electronic) IS - 0884-8734 (Print) IS - 0884-8734 (Linking) VI - 29 IP - 11 DP - 2014 Nov TI - Ciprofloxacin-induced tendinopathy of the gluteal tendons. PG - 1559-62 LID - 10.1007/s11606-014-2960-4 [doi] AB - Fluoroquinolone-induced tendinopathy most commonly affects the Achilles tendon; however, involvement of several other tendons has been described. This is a case report of ciprofloxacin-induced tendinopathy of the gluteal tendons with MRI findings. An obese 25-year-old woman with no significant past medical history was diagnosed with acute pyelonephritis and was treated with intravenous ciprofloxacin. Shortly after her first dose of ciprofloxacin, she developed severe left hip pain and decreased range of motion. MRI of the hips showed bilateral tendinopathy of the gluteal muscle insertion. A diagnosis of ciprofloxacin-induced tendinopathy was made based on her MRI and a Naranjo score of 7. Ciprofloxacin was stopped and her pain quickly resolved. Fluoroquinolones cause tendinopathy in 0.14 % to 0.4 % of patients using these agents. Fluoroquinolone-associated tendinopathy is a serious adverse reaction that can affect many tendons and should be considered in any patient presenting with new musculoskeletal complaints and in whom there is a history of fluoroquinolone use within the preceding 6 months. FAU - Shimatsu, Kaumakaokalani AU - Shimatsu K AD - Department of Internal Medicine, University of California at Davis Internal Medicine Residency Program, 3100 PSSB 4150 V St., Sacramento, CA, 95817, USA. FAU - Subramaniam, Somasundaram AU - Subramaniam S FAU - Sim, Helen AU - Sim H FAU - Aronowitz, Paul AU - Aronowitz P LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Gen Intern Med JT - Journal of general internal medicine JID - 8605834 RN - 0 (Anti-Bacterial Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Acute Disease MH - Adult MH - Anti-Bacterial Agents/*adverse effects/therapeutic use MH - Buttocks MH - Ciprofloxacin/*adverse effects/therapeutic use MH - Female MH - Humans MH - Magnetic Resonance Imaging MH - Pyelonephritis/drug therapy MH - Tendinopathy/*chemically induced/diagnosis PMC - PMC4238198 EDAT- 2014/07/23 06:00 MHDA- 2015/06/16 06:00 PMCR- 2015/11/01 CRDT- 2014/07/23 06:00 PHST- 2014/07/23 06:00 [entrez] PHST- 2014/07/23 06:00 [pubmed] PHST- 2015/06/16 06:00 [medline] PHST- 2015/11/01 00:00 [pmc-release] AID - 2960 [pii] AID - 10.1007/s11606-014-2960-4 [doi] PST - ppublish SO - J Gen Intern Med. 2014 Nov;29(11):1559-62. doi: 10.1007/s11606-014-2960-4. PMID- 25143490 OWN - NLM STAT- MEDLINE DCOM- 20150427 LR - 20200914 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 42 IP - 12 DP - 2014 Dec TI - Fluoroquinolones impair tendon healing in a rat rotator cuff repair model: a preliminary study. PG - 2851-9 LID - 10.1177/0363546514545858 [doi] AB - BACKGROUND: Recent studies suggest that fluoroquinolone antibiotics predispose tendons to tendinopathy and/or rupture. However, no investigations on the reparative capacity of tendons exposed to fluoroquinolones have been conducted. HYPOTHESIS: Fluoroquinolone-treated animals will have inferior biochemical, histological, and biomechanical properties at the healing tendon-bone enthesis compared with controls. STUDY DESIGN: Controlled laboratory study. METHODS: Ninety-two rats underwent rotator cuff repair and were randomly assigned to 1 of 4 groups: (1) preoperative (Preop), whereby animals received fleroxacin for 1 week preoperatively; (2) pre- and postoperative (Pre/Postop), whereby animals received fleroxacin for 1 week preoperatively and for 2 weeks postoperatively; (3) postoperative (Postop), whereby animals received fleroxacin for 2 weeks postoperatively; and (4) control, whereby animals received vehicle for 1 week preoperatively and for 2 weeks postoperatively. Rats were euthanized at 2 weeks postoperatively for biochemical, histological, and biomechanical analysis. All data were expressed as mean ± standard error of the mean (SEM). Statistical comparisons were performed using either 1-way or 2-way ANOVA, with P < .05 considered significant. RESULTS: Reverse transcriptase quantitative polymerase chain reaction (RTqPCR) analysis revealed a 30-fold increase in expression of matrix metalloproteinase (MMP)-3, a 7-fold increase in MMP-13, and a 4-fold increase in tissue inhibitor of metalloproteinases (TIMP)-1 in the Pre/Postop group compared with the other groups. The appearance of the healing enthesis in all treated animals was qualitatively different than that in controls. The tendons were friable and atrophic. All 3 treated groups showed significantly less fibrocartilage and poorly organized collagen at the healing enthesis compared with control animals. There was a significant difference in the mode of failure, with treated animals demonstrating an intrasubstance failure of the supraspinatus tendon during testing. In contrast, only 1 of 10 control samples failed within the tendon substance. The healing enthesis of the Pre/Postop group displayed significantly reduced ultimate load to failure compared with the Preop, Postop, and control groups. There was no significant difference in load to failure in the Preop group compared with the Postop group. Pre/Postop animals demonstrated significantly reduced cross-sectional area compared with the Postop and control groups. There was also a significant reduction in area between the Preop and control groups. CONCLUSION: In this preliminary study, fluoroquinolone treatment negatively influenced tendon healing. CLINICAL RELEVANCE: These findings indicate that there was an active but inadequate repair response that has potential clinical implications for patients who are exposed to fluoroquinolones before tendon repair surgery. CI - © 2014 The Author(s). FAU - Fox, Alice J S AU - Fox AJ AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA foxa@hss.edu ajsfox27@hotmail.com. FAU - Schär, Michael O AU - Schär MO AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Wanivenhaus, Florian AU - Wanivenhaus F AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Chen, Tony AU - Chen T AD - Laboratory for Soft Tissue Research, Department of Biomechanics, Hospital for Special Surgery, New York, New York, USA. FAU - Attia, Erik AU - Attia E AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Binder, Nikolaus B AU - Binder NB AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Otero, Miguel AU - Otero M AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Gilbert, Susannah L AU - Gilbert SL AD - Department of Biomechanics, Hospital for Special Surgery, New York, New York, USA. FAU - Nguyen, Joseph T AU - Nguyen JT AD - Healthcare Research Institute, Hospital for Special Surgery, New York, New York, USA. FAU - Chaudhury, Salma AU - Chaudhury S AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Warren, Russell F AU - Warren RF AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. FAU - Rodeo, Scott A AU - Rodeo SA AD - Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, New York, USA. LA - eng PT - Journal Article DEP - 20140820 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Infective Agents) RN - 0 (RNA, Messenger) RN - 0 (TIMP1 protein, rat) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.- (Mmp13 protein, rat) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - N804LDH51K (Fleroxacin) SB - IM MH - Animals MH - Anti-Infective Agents/administration & dosage/*adverse effects MH - Fibrocartilage/pathology MH - Fleroxacin/administration & dosage/*adverse effects MH - Male MH - Matrix Metalloproteinase 13/genetics/metabolism MH - Matrix Metalloproteinase 3/genetics/metabolism MH - Microscopy MH - Models, Animal MH - RNA, Messenger/metabolism MH - Random Allocation MH - Rats, Sprague-Dawley MH - Reverse Transcriptase Polymerase Chain Reaction MH - Rotator Cuff/pathology/physiopathology/*surgery MH - Stress, Mechanical MH - Tendons/pathology/physiopathology/*surgery MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Wound Healing/*drug effects OTO - NOTNLM OT - fleroxacin OT - fluoroquinolone OT - rotator cuff repair OT - tendinopathy OT - tendon healing EDAT- 2014/08/22 06:00 MHDA- 2015/04/29 06:00 CRDT- 2014/08/22 06:00 PHST- 2014/08/22 06:00 [entrez] PHST- 2014/08/22 06:00 [pubmed] PHST- 2015/04/29 06:00 [medline] AID - 0363546514545858 [pii] AID - 10.1177/0363546514545858 [doi] PST - ppublish SO - Am J Sports Med. 2014 Dec;42(12):2851-9. doi: 10.1177/0363546514545858. Epub 2014 Aug 20. PMID- 26712373 OWN - NLM STAT- MEDLINE DCOM- 20170110 LR - 20181113 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 36 IP - 3 DP - 2016 Mar TI - Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission? PG - 387-96 LID - 10.1007/s00296-015-3409-8 [doi] AB - The aim of the study was to investigate the predictive value of different reduced joint ultrasound (US) assessments of synovitis and tenosynovitis in relation to unstable remission in a cohort of rheumatoid arthritis (RA) patients on methotrexate therapy. Forty-seven RA patients (38 women, 9 men), being treated with methotrexate (MTX), in clinical remission as judged by their consultant rheumatologist were evaluated for disease activity according to the Disease Activity Score (DAS) 28 at baseline and 6 months. Sustained remission and unstable remission were defined according to the baseline and 6-month DAS28 and changes in RA therapy during the follow-up. Each patient underwent at baseline a B-mode and power Doppler (PD) assessment of 44 joints and 20 tendons/tendon compartments by a rheumatologist blinded to the clinical and laboratory data. B-mode synovial hypertrophy (SH), synovial PD signal, B-mode tenosynovitis, and Doppler tenosynovitis were scored 0-3. The presence and index of synovial PD signal in 44 joints [odds ratio (OR) 8.21 (p = 0.016) and OR 2.20 (p = 0.049), respectively] and in 12 joints [OR 5.82 (p = 0.041) and OR 4.19 (p = 0.020), respectively], the presence of SH in wrist and MCP joints [OR 4.79 (p = 0.045)], and the presence of synovial PD signal in wrist-MCP-ankle-MTP joints [OR 4.62 (p = 0.046)] were predictors of unstable remission. The 12-joint or wrist-hand-ankle-MTP US assessments can predict unstable remission in RA patients in apparent clinical remission being treated with MTX. FAU - Janta, Iustina AU - Janta I AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. iustinajanta@yahoo.com. FAU - Valor, Lara AU - Valor L AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - De la Torre, Inmaculada AU - De la Torre I AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Martínez-Estupiñán, Lina AU - Martínez-Estupiñán L AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Nieto, Juan Carlos AU - Nieto JC AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Ovalles-Bonilla, Juan Gabriel AU - Ovalles-Bonilla JG AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Martínez-Barrio, Julia AU - Martínez-Barrio J AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Bello, Natalia AU - Bello N AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Hinojosa, Michelle AU - Hinojosa M AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Montoro, María AU - Montoro M AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - González, Carlos Manuel AU - González CM AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - López-Longo, Javier AU - López-Longo J AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Monteagudo, Indalecio AU - Monteagudo I AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Carreño, Luis AU - Carreño L AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. FAU - Naredo, Esperanza AU - Naredo E AD - Department of Rheumatology, Faculty of Medicine, Hospital General Universitario Gregorio Marañón, Complutense University, Doctor Esquerdo 46, 28007, Madrid, Spain. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151228 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 0 (Antirheumatic Agents) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antirheumatic Agents/*therapeutic use MH - Arthritis, Rheumatoid/*diagnostic imaging/*drug therapy MH - Chi-Square Distribution MH - Disability Evaluation MH - Female MH - Humans MH - Joints/*diagnostic imaging/*drug effects MH - Logistic Models MH - Male MH - Methotrexate/*therapeutic use MH - Middle Aged MH - Multivariate Analysis MH - Odds Ratio MH - Predictive Value of Tests MH - Prospective Studies MH - Recurrence MH - Remission Induction MH - Synovitis/diagnostic imaging/drug therapy MH - Tendons/*diagnostic imaging/*drug effects MH - Tenosynovitis/diagnosis/diagnostic imaging MH - Time Factors MH - Treatment Outcome MH - *Ultrasonography, Doppler OTO - NOTNLM OT - Doppler OT - Remission OT - Rheumatoid arthritis OT - Synovitis OT - Tenosynovitis OT - Ultrasound EDAT- 2015/12/30 06:00 MHDA- 2017/01/11 06:00 CRDT- 2015/12/30 06:00 PHST- 2015/08/31 00:00 [received] PHST- 2015/12/12 00:00 [accepted] PHST- 2015/12/30 06:00 [entrez] PHST- 2015/12/30 06:00 [pubmed] PHST- 2017/01/11 06:00 [medline] AID - 10.1007/s00296-015-3409-8 [pii] AID - 10.1007/s00296-015-3409-8 [doi] PST - ppublish SO - Rheumatol Int. 2016 Mar;36(3):387-96. doi: 10.1007/s00296-015-3409-8. Epub 2015 Dec 28. PMID- 10424209 OWN - NLM STAT- MEDLINE DCOM- 19990908 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 27 IP - 4 DP - 1999 Jul-Aug TI - The effects of aging, antiinflammatory drugs, and ultrasound on the in vitro response of tendon tissue. PG - 417-21 AB - We investigated the effects of aging and various treatments on rat patellar tendon using an in vitro model. In the first part of the study, the 3H-thymidine and 3H-proline incorporation rates at 12 and 24 hours were determined in transected patellar tendon explants from young (21 days), intermediate age (8 to 10 weeks), and older (4 to 6 months) rats. In the second part, the same incorporation rates were measured in the older tendon explants in response to treatment with control medium, medium with a high and low concentration of indomethacin, and medium with a high and low concentration of dexamethasone. Finally, the effects of ultrasound treatment were measured and compared with a sham ultrasound treatment. The results indicated an age-dependent response of the tendon. The youngest specimens consistently showed the highest incorporation rates. The addition of a high concentration of dexamethasone resulted in a small negative effect on the 3H-thymidine incorporation. Ultrasound and indomethacin had no significant effects. This study indicates that aging is associated with a lower metabolic activity of tendon. In this model, currently used treatment methods failed to result in direct positive effects on tendon tissue, and a high concentration of dexamethasone appeared to have a small negative effect. FAU - Almekinders, L C AU - Almekinders LC AD - Department of Orthopaedic Surgery, University of North Carolina School of Medicine, Chapel Hill, USA. FAU - Deol, G AU - Deol G LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Aging/*physiology MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Dexamethasone/pharmacology MH - Glucocorticoids/pharmacology MH - In Vitro Techniques MH - Indomethacin/pharmacology MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Tendinopathy/drug therapy/physiopathology/therapy MH - Tendons/drug effects/*metabolism MH - Ultrasonic Therapy EDAT- 1999/07/29 00:00 MHDA- 1999/07/29 00:01 CRDT- 1999/07/29 00:00 PHST- 1999/07/29 00:00 [pubmed] PHST- 1999/07/29 00:01 [medline] PHST- 1999/07/29 00:00 [entrez] AID - 10.1177/03635465990270040301 [doi] PST - ppublish SO - Am J Sports Med. 1999 Jul-Aug;27(4):417-21. doi: 10.1177/03635465990270040301. PMID- 12515937 OWN - NLM STAT- MEDLINE DCOM- 20030211 LR - 20131121 IS - 0181-5512 (Print) IS - 0181-5512 (Linking) VI - 25 IP - 9 DP - 2002 Nov TI - [Tenotoxic potential of fluoroquinolones in the choice of surgical antibiotic prophylaxis in ophthalmology]. PG - 921-6 AB - PURPOSE: Fluoroquinolones are mainly used in ophthalmic antibiotic prophylaxis because of their broad spectrum activity and good ocular diffusion. But a single oral dose of fluoroquinolones can result in a serious source of tendinopathy and tendon rupture, especially in patients 60 years and older. It seems very important to investigate tendon toxicity of fluoroquinolones to improve the risk-benefit ratio in ophthalmologic antibiotic prophylaxis. MATERIAL: and methods: The intrinsic tenotoxic potential of four fluoroquinolones (pefloxacin, ofloxacin, ciprofloxacin, levofloxacin) was directly evaluated on living adherent tendon cells in microplates. Cell viability and reactive oxygen species production was evaluated using neutral red, alamar blue, and dichlorofluorescin diacetate tests. RESULTS: Results showed a loss of viability associated with free radical production depending on fluoroquinolone molecules. Pefloxacin appeared more tenotoxic but no study has confirmed its efficacy in surgical antibiotic prophylaxis and its use in the patient who is 60 years and older could be disputed. Ciprofloxacin is highly toxic with a low ocular diffusion and seems to be inappropriate for antibiotic prophylaxis. Ofloxacin and levofloxacin are less cytotoxic, associated with good ocular diffusion and a broad antibacterial spectrum. CONCLUSION: Ofloxacin and levofloxacin seem to be good alternatives for improving the risk-benefit ratio in surgical antibiotic prophylaxis in patients 60 years and older. FAU - Pouzaud, F AU - Pouzaud F AD - Unité de Pharmaco-Toxicologie Cellulaire, CHNO des XV-XX, 28, rue de Charenton, 75571 Paris cedex 12, France. FAU - Rat, P AU - Rat P FAU - Cambourieu, C AU - Cambourieu C FAU - Nourry, H AU - Nourry H FAU - Warnet, J M AU - Warnet JM LA - fre PT - Comparative Study PT - English Abstract PT - Journal Article TT - Prise en compte du potentiel ténotoxique des fluoroquinolones dans le choix d'une antibioprophylaxie chirurgicale en ophtalmologie. PL - France TA - J Fr Ophtalmol JT - Journal francais d'ophtalmologie JID - 7804128 RN - 0 (Fluoroquinolones) RN - 0 (Free Radicals) RN - 2H52Z9F2Q5 (Pefloxacin) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/injuries MH - Aged MH - Animals MH - *Antibiotic Prophylaxis MH - Cells, Cultured/drug effects MH - Ciprofloxacin/toxicity MH - Data Interpretation, Statistical MH - Fluoroquinolones/*toxicity MH - Free Radicals MH - Humans MH - Levofloxacin MH - Middle Aged MH - Ofloxacin/toxicity MH - *Ophthalmologic Surgical Procedures MH - Pefloxacin/toxicity MH - Rabbits MH - Rupture MH - Tendons/cytology/*drug effects MH - Time Factors EDAT- 2003/01/08 04:00 MHDA- 2003/02/13 04:00 CRDT- 2003/01/08 04:00 PHST- 2003/01/08 04:00 [pubmed] PHST- 2003/02/13 04:00 [medline] PHST- 2003/01/08 04:00 [entrez] AID - MDOI-JFO-11-2002-25-9-0181-5512-101019-ART7 [pii] PST - ppublish SO - J Fr Ophtalmol. 2002 Nov;25(9):921-6. PMID- 11354912 OWN - NLM STAT- MEDLINE DCOM- 20010927 LR - 20190906 IS - 0340-5761 (Print) IS - 0340-5761 (Linking) VI - 75 IP - 2 DP - 2001 Apr TI - Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. PG - 97-102 AB - Quinolone therapy can be associated with tendon disorders (tendinitis, ruptures), but little is known about possible ultrastructural changes in tendons after exposure to these antimicrobials. We studied the Achilles tendons from fleroxacin-treated adult rats by electron microscopy. Wistar rats were treated orally with single oral doses of 0, 30, 100, 300 or 600 mg fleroxacin/kg body weight (n = 6 per group). The animals were killed 4 weeks after treatment. Achilles tendon samples were collected and tangential sections were made from the distal part of the tendon. Subsequently, tendons were cut crosswise for preparation of ultrathin sections. Samples were fixed by using glutaraldehyde, osmium tetroxide, tannic acid and finally contrasted with uranyl acetate/lead citrate before they were examined by transmission electron microscopy. The rats did not show any general effects such as behavioural changes or body weight changes which could be attributed to the treatment. However, we were able to detect pathological changes even at the lowest dose level (30 mg/kg), which increased in incidence and severity with increasing doses. Tenocytes exhibited degenerative changes such as multiple vacuoles and large vesicles in the cytoplasm that resulted from swelling and dilatation of cell organelles (mitochondria, endoplasmic reticulum). The nucleus became dense and the chromatin had clumped to form rough plaques. The cells detached from the extracellular matrix. Other important findings were a general decrease of the fibril diameter and an increase in the distance between the collagenous fibrils. The finding that these rather low single dose of a fluoroquinolone induce ultrastructural changes in Achilles tendons from rats, which were not associated with clinical symptoms and which were still present 4 weeks after treatment, is of concern. Further toxicological as well as clinical studies are needed to characterize the conditions under which quinolone-induced tendon lesions develop. FAU - Shakibaei, M AU - Shakibaei M AD - Institute for Anatomy, Benjamin Franklin Medical Center, Freie Universität Berlin, Königin-Luise-Strasse 15, 14195 Berlin, Germany. FAU - Stahlmann, R AU - Stahlmann R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Arch Toxicol JT - Archives of toxicology JID - 0417615 RN - 0 (Anti-Infective Agents) RN - N804LDH51K (Fleroxacin) SB - IM MH - Achilles Tendon/*drug effects/ultrastructure MH - Animals MH - Anti-Infective Agents/*toxicity MH - Dose-Response Relationship, Drug MH - Female MH - Fleroxacin/*toxicity MH - Microscopy, Electron MH - Rats MH - Rats, Wistar EDAT- 2001/05/17 10:00 MHDA- 2001/09/28 10:01 CRDT- 2001/05/17 10:00 PHST- 2001/05/17 10:00 [pubmed] PHST- 2001/09/28 10:01 [medline] PHST- 2001/05/17 10:00 [entrez] AID - 10.1007/s002040000203 [doi] PST - ppublish SO - Arch Toxicol. 2001 Apr;75(2):97-102. doi: 10.1007/s002040000203. PMID- 31839190 OWN - NLM STAT- MEDLINE DCOM- 20200102 LR - 20200108 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 394 IP - 10215 DP - 2019 Dec 14 TI - Gouty tophus in the quadriceps tendon: exclude malignancy. PG - 2197 LID - S0140-6736(19)32950-2 [pii] LID - 10.1016/S0140-6736(19)32950-2 [doi] FAU - Goebel, Lars AU - Goebel L AD - Department of Orthopaedic Surgery, Saarland University Medical Center, Kirrberger Straße, Homburg, Germany. Electronic address: lars.goebel@uks.eu. FAU - Schneider, Günther AU - Schneider G AD - Department of Radiology, Saarland University Medical Center, Kirrberger Straße, Homburg, Germany. FAU - Bohle, Rainer AU - Bohle R AD - Department of Pathology, Saarland University Medical Center, Kirrberger Straße, Homburg, Germany. FAU - Veith, Christian AU - Veith C AD - Department of Pathology, Saarland University Medical Center, Kirrberger Straße, Homburg, Germany. FAU - Orth, Patrick AU - Orth P AD - Department of Orthopaedic Surgery, Saarland University Medical Center, Kirrberger Straße, Homburg, Germany. LA - eng PT - Case Reports PT - Journal Article PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (Gout Suppressants) RN - 63CZ7GJN5I (Allopurinol) SB - IM MH - Aged MH - Allopurinol/therapeutic use MH - Combined Modality Therapy MH - Cryotherapy MH - Diagnosis, Differential MH - Gout/*diagnostic imaging/therapy MH - Gout Suppressants/therapeutic use MH - Humans MH - Image-Guided Biopsy MH - Iontophoresis MH - *Knee Joint MH - *Magnetic Resonance Imaging MH - Male MH - Physical Therapy Modalities MH - *Tendons EDAT- 2019/12/17 06:00 MHDA- 2020/01/03 06:00 CRDT- 2019/12/17 06:00 PHST- 2019/09/06 00:00 [received] PHST- 2019/09/27 00:00 [revised] PHST- 2019/11/07 00:00 [accepted] PHST- 2019/12/17 06:00 [entrez] PHST- 2019/12/17 06:00 [pubmed] PHST- 2020/01/03 06:00 [medline] AID - S0140-6736(19)32950-2 [pii] AID - 10.1016/S0140-6736(19)32950-2 [doi] PST - ppublish SO - Lancet. 2019 Dec 14;394(10215):2197. doi: 10.1016/S0140-6736(19)32950-2. PMID- 7578737 OWN - NLM STAT- MEDLINE DCOM- 19951130 LR - 20190512 IS - 1058-4838 (Print) IS - 1058-4838 (Linking) VI - 21 IP - 1 DP - 1995 Jul TI - Granulomatous tophaceous gout mimicking tuberculous tenosynovitis: report of two cases. PG - 217-9 AB - Granulomatous inflammation in a tissue specimen raises concern about infection with Mycobacterium tuberculosis, atypical mycobacteria, certain fungi, Brucella species, and other infectious agents. Inflammatory disorders, such as sarcoidosis, crystal-associated arthritis, or foreign body reactions also are considered when granulomatous changes are seen on histological examination of a tissue specimen. We describe two cases of granulomatous tenosynovitis due to tophaceous deposits in patients with gout. In one case, tuberculous synovitis was considered the primary diagnosis until the diagnosis of gout was confirmed by examination of a tissue specimen with polarized light. In the second case, gout and tuberculosis were found in the patient's wrist joint. After antituberculous therapy was discontinued, he continued to have wrist synovitis and chronic drainage due to granulomatous tophaceous gout. The findings in this report suggest that gouty tenosynovitis can mimic tuberculous tenosynovitis and that gout should be considered in the differential diagnosis of granulomatous tenosynovitis, especially when acid-fast stains and cultures are negative for mycobacteria. FAU - Kostman, J R AU - Kostman JR AD - Department of Medicine, Cooper Hospital/University Medical Center, Robert Wood Johnson Medical School, Camden, New Jersey, USA. FAU - Rush, P AU - Rush P FAU - Reginato, A J AU - Reginato AJ LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Antitubercular Agents) RN - 0 (Gout Suppressants) RN - 63CZ7GJN5I (Allopurinol) SB - IM MH - Adult MH - Allopurinol/therapeutic use MH - Antitubercular Agents/therapeutic use MH - Diagnosis, Differential MH - Finger Joint/*pathology MH - Gout/complications/*diagnosis/drug therapy MH - Gout Suppressants/therapeutic use MH - Granuloma/*diagnosis/drug therapy/etiology MH - Humans MH - Male MH - Middle Aged MH - Synovitis/diagnosis MH - Tendons/pathology MH - Tenosynovitis/*diagnosis/drug therapy/etiology MH - Tuberculosis, Osteoarticular/*diagnosis/drug therapy MH - Wrist Joint/*pathology EDAT- 1995/07/01 00:00 MHDA- 1995/07/01 00:01 CRDT- 1995/07/01 00:00 PHST- 1995/07/01 00:00 [pubmed] PHST- 1995/07/01 00:01 [medline] PHST- 1995/07/01 00:00 [entrez] AID - 10.1093/clinids/21.1.217 [doi] PST - ppublish SO - Clin Infect Dis. 1995 Jul;21(1):217-9. doi: 10.1093/clinids/21.1.217. PMID- 39189576 OWN - NLM STAT- MEDLINE DCOM- 20240827 LR - 20240921 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 35 IP - 3 DP - 2024 Aug 14 TI - The fluoroquinolones may positively affect tendon healing after surgical repair. PG - 654-661 LID - jdrs.2024.1832 [pii] LID - 10.52312/jdrs.2024.1832 [doi] AB - OBJECTIVES: This study aimed to evaluate the biomechanical and histological effects of fluoroquinolones on surgically repaired tendon healing. MATERIALS AND METHODS: The Achilles tendons of 40 Wistar rats (mean weight: 213.5 g; range 201 to 242 g) were bilaterally surgically cut and repaired. The rats were randomly divided into four groups: the first and third groups were designated as control groups and did not receive drug therapy, whereas the second and fourth groups received 300 mg/kg ciprofloxacin for a week after the surgical procedure. The first and second groups had both tendons dissected at the end of the first week, while the third and fourth groups were dissected at the end of the third week. The left tendons were examined biomechanically, while the right tendons were examined histologically. RESULTS: Statistical analysis revealed that the mean maximum tensile forces of tendons in the first and second groups were 5.2±1.84 N (range, 2.9 to 8.5 N) and 11.1±2.65 N (range, 7.3 to 13.9 N), respectively, which was found to be statistically significant (p< 0.05). At the end of the third week, mean maximum tensile forces of the third and fourth groups were determined to be 20.7±5.0 N (range, 22.1 to 29.8 N) and 28.7±4.6 N (range, 22.1 to 36.8 N), respectively, which was also statistically significant (p< 0.05). Histologically, our results were compatible. CONCLUSION: This study demonstrated that ciprofloxacin did not exhibit the expected adverse effects on surgically repaired tendon healing in the early stages but likely contributed to healing in the short term by affecting the inflammatory phase. FAU - Demir, Tugcan AU - Demir T AD - Giresun Üniversitesi Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, 28200 Giresun, Türkiye. tugcandem@hotmail.com. FAU - Sener, Ertugrul AU - Sener E FAU - Öztürk, Akif Muhtar AU - Öztürk AM FAU - Bekmezci, Taner AU - Bekmezci T FAU - Esen, Erdinç AU - Esen E FAU - Take Kaplanoglu, Gülnur AU - Take Kaplanoglu G LA - eng PT - Journal Article DEP - 20240814 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - 5E8K9I0O4U (Ciprofloxacin) RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Animals MH - *Rats, Wistar MH - *Wound Healing/drug effects MH - *Achilles Tendon/surgery/injuries/drug effects/pathology MH - Rats MH - *Ciprofloxacin/adverse effects/pharmacology MH - *Tensile Strength/drug effects MH - *Tendon Injuries/surgery/drug therapy/pathology MH - Anti-Bacterial Agents/pharmacology/adverse effects MH - Biomechanical Phenomena/drug effects MH - Male MH - Fluoroquinolones/pharmacology/adverse effects PMC - PMC11411887 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2024/08/27 12:46 MHDA- 2024/08/27 12:47 PMCR- 2024/08/14 CRDT- 2024/08/27 07:43 PHST- 2024/07/04 00:00 [received] PHST- 2024/07/21 00:00 [accepted] PHST- 2024/08/27 12:47 [medline] PHST- 2024/08/27 12:46 [pubmed] PHST- 2024/08/27 07:43 [entrez] PHST- 2024/08/14 00:00 [pmc-release] AID - jdrs.2024.1832 [pii] AID - 10.52312/jdrs.2024.1832 [doi] PST - ppublish SO - Jt Dis Relat Surg. 2024 Aug 14;35(3):654-661. doi: 10.52312/jdrs.2024.1832. Epub 2024 Aug 14. PMID- 21632978 OWN - NLM STAT- MEDLINE DCOM- 20120117 LR - 20250529 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 39 IP - 9 DP - 2011 Sep TI - Platelet-rich plasma protects tenocytes from adverse side effects of dexamethasone and ciprofloxacin. PG - 1929-35 LID - 10.1177/0363546511407283 [doi] AB - BACKGROUND: Ruptured tendons heal very slowly and complete recovery from injury is uncertain. Platelet-rich plasma (PRP), a rich source of growth factors, is currently being widely tested as a soft tissue healing agent and may accelerate tendon repair. The authors assessed the ability of PRP to prevent in vitro adverse effects of 2 drugs commonly linked to tendon rupture and tendinopathy, glucocorticoids and fluoroquinolone antibiotics. HYPOTHESIS: The pro-healing response induced by PRP protects human tenocytes against the cytotoxic effects of dexamethasone and ciprofloxacin. STUDY DESIGN: Controlled laboratory study. METHODS: Human primary hamstring tenocytes were exposed to different doses of ciprofloxacin and dexamethasone with and without PRP. AlamarBlue, β-galactosidase assay, and live/dead stain were used to measure, respectively, viability, senescence, and death in tenocyte culture. RESULTS: The viability of cells exposed to high doses of ciprofloxacin was significantly decreased compared with controls, with no induced senescence but increased cell death. Dexamethasone reduced viable cell number without inducing overt cell death, but the number of senescent cells increased considerably. After co-treatment with 10% PRP, viable cell number increased significantly in both conditions and the number of dead cells decreased in ciprofloxacin-treated cultures. Moreover, dexamethasone-induced senescence was markedly reduced by co-treatment with 10% PRP. CONCLUSION: This study demonstrates that ciprofloxacin and dexamethasone have differing adverse effects on human tenocytes, with ciprofloxacin inducing cell death while dexamethasone primarily induces senescence. The authors showed that PRP can protect cultured human tenocytes against cell death or senescence induced by these drugs. CLINICAL RELEVANCE: Both ciprofloxacin and dexamethasone are highly effective in treatment of inflammatory and infectious conditions, therefore new strategies to minimize their adverse effects are of strong interest. These findings suggest the potential for local administration of PRP to enhance tendon healing in patients undergoing glucocorticoid or fluoroquinolone treatment. FAU - Zargar Baboldashti, Nasim AU - Zargar Baboldashti N AD - Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK. nasim.zargarbaboldashti@eng.ox.ac.uk FAU - Poulsen, Raewyn C AU - Poulsen RC FAU - Franklin, Sarah L AU - Franklin SL FAU - Thompson, Mark S AU - Thompson MS FAU - Hulley, Philippa A AU - Hulley PA LA - eng GR - 19482/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110601 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Infective Agents) RN - 0 (Glucocorticoids) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Adult MH - Anti-Infective Agents/*adverse effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Cellular Senescence/drug effects MH - Ciprofloxacin/*adverse effects MH - Dexamethasone/*adverse effects MH - Glucocorticoids/*adverse effects MH - Humans MH - Middle Aged MH - *Platelet Transfusion MH - *Platelet-Rich Plasma MH - Rupture/chemically induced/prevention & control MH - Tendinopathy/therapy MH - Tendon Injuries/*chemically induced/*prevention & control MH - Tendons/cytology/*drug effects MH - Wound Healing/drug effects MH - Young Adult EDAT- 2011/06/03 06:00 MHDA- 2012/01/18 06:00 CRDT- 2011/06/03 06:00 PHST- 2011/06/03 06:00 [entrez] PHST- 2011/06/03 06:00 [pubmed] PHST- 2012/01/18 06:00 [medline] AID - 0363546511407283 [pii] AID - 10.1177/0363546511407283 [doi] PST - ppublish SO - Am J Sports Med. 2011 Sep;39(9):1929-35. doi: 10.1177/0363546511407283. Epub 2011 Jun 1. PMID- 6125308 OWN - NLM STAT- MEDLINE DCOM- 19821029 LR - 20190825 IS - 0300-9629 (Print) IS - 0300-9629 (Linking) VI - 72 IP - 2 DP - 1982 TI - Collagen levels in tissues from selenium deficient ducks. PG - 383-9 AB - 1. Nutritional myopathy was produced in ducks by feeding the birds selenium deficient diets. The myopathy increased in severity the longer the ducks were fed the selenium deficient diet. 2. There was less total collagen and lesser amounts of soluble collagen found in the tendons of ducks fed the selenium-deficient diet. Likewise, the collagen fibrils were of decreased diameter in those birds. 3. The fibroblasts present in the tendons of the deficient ducks were degenerate. It appears the selenium deficiency produced damaged fibroblast membranes which resulted in decreased collagen synthesis. The resultant loss of collagen structure could have produced a functional tendotomy which caused myodegeneration. FAU - Brown, R G AU - Brown RG FAU - Sweeny, P R AU - Sweeny PR FAU - Moran, E T Jr AU - Moran ET Jr LA - eng PT - Journal Article PL - England TA - Comp Biochem Physiol A Comp Physiol JT - Comparative biochemistry and physiology. A, Comparative physiology JID - 1276312 RN - 9007-34-5 (Collagen) RN - H6241UJ22B (Selenium) SB - IM MH - Animals MH - Animals, Newborn/metabolism MH - Collagen/*analysis/biosynthesis MH - Ducks/*metabolism MH - Fibroblasts/pathology/ultrastructure MH - Muscular Dystrophy, Animal/*metabolism/pathology MH - Myofibrils/ultrastructure MH - Poultry Diseases/*metabolism/pathology MH - Selenium/*deficiency MH - Tendons/analysis/pathology/ultrastructure EDAT- 1982/01/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1982/01/01 00:00 PHST- 1982/01/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1982/01/01 00:00 [entrez] AID - 10.1016/0300-9629(82)90235-3 [doi] PST - ppublish SO - Comp Biochem Physiol A Comp Physiol. 1982;72(2):383-9. doi: 10.1016/0300-9629(82)90235-3. PMID- 23727633 OWN - NLM STAT- MEDLINE DCOM- 20140818 LR - 20250529 IS - 1468-2060 (Electronic) IS - 0003-4967 (Print) IS - 0003-4967 (Linking) VI - 73 IP - 7 DP - 2014 Jul TI - Glucocorticoids induce senescence in primary human tenocytes by inhibition of sirtuin 1 and activation of the p53/p21 pathway: in vivo and in vitro evidence. PG - 1405-13 LID - 10.1136/annrheumdis-2012-203146 [doi] AB - Cellular senescence is an irreversible side effect of some pharmaceuticals which can contribute to tissue degeneration. OBJECTIVE: To determine whether pharmaceutical glucocorticoids induce senescence in tenocytes. METHODS: Features of senescence (β-galactosidase activity at pH 6 (SA-β-gal) and active mammalian/mechanistic target of rapamycin (mTOR) in cell cycle arrest) as well as the activity of the two main pathways leading to cell senescence were examined in glucocorticoid-treated primary human tenocytes. Evidence of senescence-inducing pathway induction in vivo was obtained using immunohistochemistry on tendon biopsy specimens taken before and 7 weeks after subacromial Depo-Medrone injection. RESULTS: Dexamethasone treatment of tenocytes resulted in an increased percentage of SA-βgal-positive cells. Levels of phosphorylated p70S6K did not decrease with glucocorticoid treatment indicating mTOR remained active. Increased levels of acetylated p53 as well as increased RNA levels of its pro-senescence effector p21 were evident in dexamethasone-treated tenocytes. Levels of the p53 deacetylase sirtuin 1 were lower in dexamethasone-treated cells compared with controls. Knockdown of p53 or inhibition of p53 activity prevented dexamethasone-induced senescence. Activation of sirtuin 1 either by exogenous overexpression or by treatment with resveratrol or low glucose prevented dexamethasone-induced senescence. Immunohistochemical analysis of tendon biopsies taken before and after glucocorticoid injection revealed a significant increase in the percentage of p53-positive cells (p=0.03). The percentage of p21-positive cells also tended to be higher post-injection (p=0.06) suggesting glucocorticoids activate the p53/p21 senescence-inducing pathway in vivo as well as in vitro. CONCLUSION: As cell senescence is irreversible in vivo, glucocorticoid-induced senescence may result in long-term degenerative changes in tendon tissue. CI - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. FAU - Poulsen, Raewyn C AU - Poulsen RC AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. FAU - Watts, Anna C AU - Watts AC AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. FAU - Murphy, Richard J AU - Murphy RJ AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. FAU - Snelling, Sarah J AU - Snelling SJ AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. FAU - Carr, Andrew J AU - Carr AJ AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. FAU - Hulley, Philippa A AU - Hulley PA AD - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. LA - eng GR - 19222/VAC_/Versus Arthritis/United Kingdom GR - 19482/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom GR - 20087/ARC_/Arthritis Research UK/United Kingdom GR - 19482/ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130601 PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (CDKN1A protein, human) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 0 (Glucocorticoids) RN - 0 (Tumor Suppressor Protein p53) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) RN - EC 3.2.1.23 (beta-Galactosidase) RN - EC 3.5.1.- (SIRT1 protein, human) RN - EC 3.5.1.- (Sirtuin 1) SB - IM MH - Adult MH - Aged MH - Cell Cycle/drug effects MH - Cells, Cultured MH - Cellular Senescence/*drug effects MH - Cyclin-Dependent Kinase Inhibitor p21/*drug effects/metabolism MH - Dexamethasone/*pharmacology/therapeutic use MH - Female MH - Gene Knockdown Techniques MH - Glucocorticoids/*pharmacology/therapeutic use MH - Humans MH - In Vitro Techniques MH - Male MH - Middle Aged MH - Rotator Cuff MH - Signal Transduction/*drug effects MH - Sirtuin 1/*drug effects/metabolism MH - TOR Serine-Threonine Kinases/*drug effects/metabolism MH - Tendinopathy/drug therapy MH - Tendons/cytology/*drug effects/metabolism MH - Tumor Suppressor Protein p53/*drug effects/genetics/metabolism MH - beta-Galactosidase/drug effects/metabolism PMC - PMC4078757 OTO - NOTNLM OT - Chondrocytes OT - Corticosteroids OT - Fibroblasts OT - Inflammation OT - Tendinitis EDAT- 2013/06/04 06:00 MHDA- 2014/08/19 06:00 CRDT- 2013/06/04 06:00 PHST- 2013/06/04 06:00 [entrez] PHST- 2013/06/04 06:00 [pubmed] PHST- 2014/08/19 06:00 [medline] AID - S0003-4967(24)14869-8 [pii] AID - annrheumdis-2012-203146 [pii] AID - 10.1136/annrheumdis-2012-203146 [doi] PST - ppublish SO - Ann Rheum Dis. 2014 Jul;73(7):1405-13. doi: 10.1136/annrheumdis-2012-203146. Epub 2013 Jun 1. PMID- 22806927 OWN - NLM STAT- MEDLINE DCOM- 20130405 LR - 20250626 IS - 1096-9098 (Electronic) IS - 0022-4790 (Linking) VI - 107 IP - 4 DP - 2013 Mar TI - A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal. PG - 433-45 LID - 10.1002/jso.23220 [doi] AB - Giant cell tumors deriving from synovium are classified into a localized (GCT of tendon sheath; GCT-TS) and diffuse form (diffuse-type GCT, Dt-GCT). We propose a multidisciplinary management based upon a systematic review and authors' opinion. Open excision for GCT-TS and open synovectomy (plus excision) for Dt-GCT is advised to reduce the relatively high recurrence risk. External beam radiotherapy should be considered in severe cases, as Dt-GCT commonly extends extra-articular. CI - Copyright © 2012 Wiley Periodicals, Inc. FAU - van der Heijden, Lizz AU - van der Heijden L AD - Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, The Netherlands. l.van_der_heijden@lumc.nl FAU - Gibbons, C L Max H AU - Gibbons CL FAU - Hassan, A Bass AU - Hassan AB FAU - Kroep, Judith R AU - Kroep JR FAU - Gelderblom, Hans AU - Gelderblom H FAU - van Rijswijk, Carla S P AU - van Rijswijk CS FAU - Nout, Remi A AU - Nout RA FAU - Bradley, Kevin M AU - Bradley KM FAU - Athanasou, Nick A AU - Athanasou NA FAU - Dijkstra, P D Sander AU - Dijkstra PD FAU - Hogendoorn, Pancras C W AU - Hogendoorn PC FAU - van de Sande, Michiel A J AU - van de Sande MA LA - eng PT - Journal Article PT - Systematic Review DEP - 20120717 PL - United States TA - J Surg Oncol JT - Journal of surgical oncology JID - 0222643 RN - 0 (Antineoplastic Agents) RN - 0 (Benzamides) RN - 0 (Indoles) RN - 0 (Piperazines) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyrimidines) RN - 0 (Pyrroles) RN - 0 (Radioisotopes) RN - 8A1O1M485B (Imatinib Mesylate) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - F41401512X (nilotinib) RN - V99T50803M (Sunitinib) SB - IM MH - Adult MH - Antineoplastic Agents/*therapeutic use MH - Arthroplasty MH - Arthroscopy MH - Benzamides MH - Chemotherapy, Adjuvant MH - Female MH - Giant Cell Tumors/complications/*diagnosis/pathology/radiotherapy/surgery/*therapy MH - Humans MH - Imatinib Mesylate MH - Indoles/therapeutic use MH - *Interdisciplinary Communication MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - *Molecular Targeted Therapy/methods MH - Neoplasm Recurrence, Local/diagnosis/prevention & control MH - Piperazines/therapeutic use MH - Protein Kinase Inhibitors/therapeutic use MH - Protein-Tyrosine Kinases/antagonists & inhibitors MH - Pyrimidines/therapeutic use MH - Pyrroles/therapeutic use MH - Radioisotopes/therapeutic use MH - Radiotherapy, Adjuvant MH - Sunitinib MH - Synovectomy MH - *Synovial Membrane/pathology MH - *Tendons/pathology/surgery MH - Tenosynovitis/etiology EDAT- 2012/07/19 06:00 MHDA- 2013/04/06 06:00 CRDT- 2012/07/19 06:00 PHST- 2012/01/26 00:00 [received] PHST- 2012/06/19 00:00 [accepted] PHST- 2012/07/19 06:00 [entrez] PHST- 2012/07/19 06:00 [pubmed] PHST- 2013/04/06 06:00 [medline] AID - 10.1002/jso.23220 [doi] PST - ppublish SO - J Surg Oncol. 2013 Mar;107(4):433-45. doi: 10.1002/jso.23220. Epub 2012 Jul 17. PMID- 10221832 OWN - NLM STAT- MEDLINE DCOM- 19990517 LR - 20161124 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 17 IP - 2 DP - 1999 Mar TI - Cytokine-induced tendinitis: a preliminary study in rabbits. PG - 168-77 AB - This study was designed to determine the effects of a single injection of a species-specific preparation of cytokines into rabbit patellar tendons and to compare the results with a known model of tendinitis, the collagenase-injection model. New Zealand White rabbits were divided into two groups and two time periods (4 and 16 weeks) and injected in the midsubstance of the right patellar tendon with either cytokines or collagenase under ultrasound guidance to confirm intratendinous needle placement. The left patellar tendon was injected with 0.025 ml of saline solution and served as a control. The rabbits were returned to cage activity after injection. At death, two rabbits in each group underwent histological analysis; the remaining eight animals in each time frame were evaluated biomechanically and then biochemically with use of the patella/whole patellar tendon/tibia complex. Histologic results at 4 weeks in the tendons injected with cytokines demonstrated increased cellularity, which was resolving by 16 weeks. The matrix appeared unchanged. The tendons injected with collagenase demonstrated increased angiogenesis of the matrix, hypercellularity, and fibrosis around the tendon at 4 weeks. At 16 weeks, myxoid changes, focal fibrosis, and collagen-bundle disarray with persistent increase in cellularity were noted. Biomechanically, a significant decrease in ultimate load at 16 weeks was seen in the tendons injected with cytokines but no change was seen in cross-sectional area. The tendons injected with collagenase demonstrated a significant increase in cross-sectional area at 4 and 16 weeks compared with those injected with cytokines. Biochemically, there was no significant difference in collagen content between the two groups at 4 or 16 weeks but the tendons injected with collagenase demonstrated a significant increase in crosslinking at 16 weeks. Our conclusion is that the tendons injected with the cytokine preparation represent a model of mild, seemingly reversible tendon injury. The cytokine preparation produces no matrix damage or evidence of collagen degradation and is species specific. FAU - Stone, D AU - Stone D AD - Musculoskeletal Research Center, University of Pittsburgh Medical Center, Pennsylvania 15213, USA. dstone@uoi.upmc.edu FAU - Green, C AU - Green C FAU - Rao, U AU - Rao U FAU - Aizawa, H AU - Aizawa H FAU - Yamaji, T AU - Yamaji T FAU - Niyibizi, C AU - Niyibizi C FAU - Carlin, G AU - Carlin G FAU - Woo, S L AU - Woo SL LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Cross-Linking Reagents) RN - 0 (Cytokines) RN - 0 (Pyridines) RN - 4KBE4P5B6S (3-hydroxypyridine) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Animals MH - Collagen/analysis MH - Collagenases/administration & dosage/pharmacology MH - Cross-Linking Reagents/analysis MH - Cytokines/*adverse effects MH - Disease Models, Animal MH - Hindlimb MH - Injections MH - Knee Joint/diagnostic imaging/drug effects MH - *Patella/diagnostic imaging MH - Pyridines/analysis MH - Rabbits MH - Species Specificity MH - Tendinopathy/*chemically induced/pathology MH - Tendon Injuries/chemically induced/pathology MH - Tendons/chemistry/diagnostic imaging/*drug effects/pathology MH - Ultrasonography EDAT- 1999/04/30 00:00 MHDA- 1999/04/30 00:01 CRDT- 1999/04/30 00:00 PHST- 1999/04/30 00:00 [pubmed] PHST- 1999/04/30 00:01 [medline] PHST- 1999/04/30 00:00 [entrez] AID - 10.1002/jor.1100170204 [doi] PST - ppublish SO - J Orthop Res. 1999 Mar;17(2):168-77. doi: 10.1002/jor.1100170204. PMID- 28857901 OWN - NLM STAT- MEDLINE DCOM- 20190215 LR - 20190215 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 97 IP - 5 DP - 2018 May TI - Two Unique Cases of Ciprofloxacin-Associated Avulsion of Ligament and Tendon. PG - e33-e36 LID - 10.1097/PHM.0000000000000816 [doi] AB - Ciprofloxacin is recognized to have a deleterious relationship with tendons, particularly Achilles tendinopathy, which makes up most case reports. Tendinopathy seems to occur because of induction of collagen-degrading enzymes causing damage and ischemia of the poorly vascularized regions preventing repair. The focus on the relationship of ciprofloxacin and the Achilles tendon leaves patients on fluoroquinolones with non-Achilles tendinopathy symptoms at risk of misdiagnosis. There have not been any documented instances of ligament damage with ciprofloxacin administration in the literature, although ligament and tendon compositions are similar and should have similar susceptibility. This report includes two cases, one presenting with right lateral thumb pain and a medical history of gastroenteritis treated with ciprofloxacin. Physical examination showed swelling of the right metacarpophalangeal joint and ultrasound confirmed disruption of the radial collateral ligament at insertion on first metacarpal; the second case is of a woman presenting with right hip pain in setting of chronic recurrent diverticulitis treated with ciprofloxacin. She received work-up for lumbar disc disease and spondylosis. After standard therapy with pharmacotherapy and physical therapy for radiculopathy failed, magnetic resonance imaging was performed showing near complete avulsion of the right hamstring tendons from the ischial tuberosity. FAU - Smith, Jeffrey David AU - Smith JD AD - From the University of Miami Miller School of Medicine, Miami, Florida (JDS); and Department of Physical Medicine and Rehabilitation, University of Miami, Miami, Florida (RWI, ETW). FAU - Irwin, Robert W AU - Irwin RW FAU - Wolff, Erin T AU - Wolff ET LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Ciprofloxacin/*adverse effects MH - Collateral Ligaments/*drug effects MH - Diverticulitis/drug therapy MH - Female MH - Gastroenteritis/drug therapy MH - Hamstring Tendons/*drug effects MH - Humans MH - Male MH - Metacarpophalangeal Joint/*drug effects MH - Middle Aged MH - Tendinopathy/*chemically induced EDAT- 2017/09/01 06:00 MHDA- 2019/02/16 06:00 CRDT- 2017/09/01 06:00 PHST- 2017/09/01 06:00 [pubmed] PHST- 2019/02/16 06:00 [medline] PHST- 2017/09/01 06:00 [entrez] AID - 10.1097/PHM.0000000000000816 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2018 May;97(5):e33-e36. doi: 10.1097/PHM.0000000000000816. PMID- 16773852 OWN - NLM STAT- MEDLINE DCOM- 20060721 LR - 20181201 IS - 0017-8594 (Print) IS - 0017-8594 (Linking) VI - 65 IP - 4 DP - 2006 Apr TI - Serial sonographic evaluation of Achilles tendons in patients taking fluoroquinolone antibiotics. PG - 112-4 AB - We performed a prospective study to determine if subclinical tendinopathy occurs in asymptomatic adults treated with fluoroquinolone antibiotics. Thirty-eight adults were enrolled. Serial ultrasounds of the Achilles tendons were performed. A board certified musculoskeletal radiologist interpreted the images in a blinded fashion. No changes were identified. Subclinical tendinopathy does not appear to exist in asymptomatic adults treated with fluoroquinolone antibiotics. FAU - Roberts, Jefferson R AU - Roberts JR AD - Tripler Army Medical Center Honolulu, HI 96859, USA. FAU - Hudson, Jay A AU - Hudson JA FAU - Lindell, Kenneth K AU - Lindell KK FAU - Finger, David R AU - Finger DR LA - eng PT - Journal Article PL - United States TA - Hawaii Med J JT - Hawaii medical journal JID - 2984209R RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) RN - L4618BD7KJ (Gatifloxacin) SB - IM MH - Achilles Tendon/*diagnostic imaging/*drug effects MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Bacterial Agents/*adverse effects/pharmacology MH - Female MH - Fluoroquinolones/*adverse effects/pharmacology MH - Gatifloxacin MH - Hawaii MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Tendinopathy/*chemically induced MH - Ultrasonography EDAT- 2006/06/16 09:00 MHDA- 2006/07/22 09:00 CRDT- 2006/06/16 09:00 PHST- 2006/06/16 09:00 [pubmed] PHST- 2006/07/22 09:00 [medline] PHST- 2006/06/16 09:00 [entrez] PST - ppublish SO - Hawaii Med J. 2006 Apr;65(4):112-4. PMID- 39614310 OWN - NLM STAT- MEDLINE DCOM- 20241130 LR - 20241202 IS - 1752-1947 (Electronic) IS - 1752-1947 (Linking) VI - 18 IP - 1 DP - 2024 Nov 29 TI - Post-traumatic intraosseous sheath development of the extensor carpi radials brevis tendon: a case report. PG - 585 LID - 10.1186/s13256-024-04932-2 [doi] LID - 585 AB - BACKGROUND: Complications from closed treatment in children are rare but can include growth disturbances and deformities. This case report presents a unique, post-traumatic growth deformity in the distal radius, where the extensor carpi radialis brevis tendon developed an interosseous course. CASE PRESENTATION: A 49-year-old Caucasian male presented with chronic, dull pain in the radiodorsal aspect of the right wrist, worsened by weightbearing and terminal flexion and extension. The patient had a history of a distal radius fracture from a motor vehicle accident in adolescence, which was treated nonsurgically. Current X-rays showed a lucent process along the distal lateral radius without aggressive features. Magnetic resonance imaging revealed the extensor carpi radialis brevis tendon in an interosseous position within the distal dorsal lateral radius, with a longitudinal tear of the tendon. A noncontrast computed tomography scan confirmed a complete bone bridge along the tendon's interosseous component, limiting potential surgical access. The patient, found to have a positive Antinuclear Antibody (ANA), was treated with prednisone and later with methotrexate and folic acid, which alleviated symptoms. CONCLUSIONS: This case highlights a rare post-traumatic deformity following a distal radius fracture, where the extensor carpi radialis brevis tendon formed an intraosseous sheath. It underscores the importance of considering unique anatomical changes when planning surgical interventions. This is the first reported case of an interosseous tendon sheath development around a tendon postdistal radius fracture, expanding the spectrum of known complications. CI - © 2024. The Author(s). FAU - Hinrichs, Seela AU - Hinrichs S AD - Northwestern University, 811 Emerson St., #622, Evanston, IL, 60201, USA. Seelahinrichs@yahoo.com. FAU - Snellings, Rich AU - Snellings R AD - ImageCare Radiology, LLC, 57 Route 47, Suite 212, Hackettsown, NJ, 07840, USA. FAU - Scholte, Ryan AU - Scholte R AD - Emory University, 52 Mountainside Rd, Mendham, NJ, 07945, USA. LA - eng PT - Case Reports PT - Journal Article DEP - 20241129 PL - England TA - J Med Case Rep JT - Journal of medical case reports JID - 101293382 RN - YL5FZ2Y5U1 (Methotrexate) RN - 935E97BOY8 (Folic Acid) RN - VB0R961HZT (Prednisone) SB - IM MH - Humans MH - Male MH - Middle Aged MH - *Radius Fractures/diagnostic imaging/complications MH - *Tendon Injuries/diagnostic imaging/etiology MH - *Magnetic Resonance Imaging MH - Methotrexate/therapeutic use/administration & dosage MH - Tomography, X-Ray Computed MH - Folic Acid/therapeutic use/administration & dosage MH - Radius/diagnostic imaging MH - Tendons/diagnostic imaging MH - Prednisone/therapeutic use PMC - PMC11607930 OTO - NOTNLM OT - Distal radius fracture OT - Extensor carpi radialis brevis tendon OT - Inflammatory disorders OT - Interosseous tendon course OT - Post-traumatic growth deformity COIS- Declarations. Ethics approval and consent to participate: There is ethics approval and consent of the Ethics Committee of ImageCare, LLC. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: There are no financial or non-financial competing interests. EDAT- 2024/11/30 11:17 MHDA- 2024/11/30 12:41 PMCR- 2024/11/29 CRDT- 2024/11/29 23:52 PHST- 2024/07/04 00:00 [received] PHST- 2024/11/01 00:00 [accepted] PHST- 2024/11/30 12:41 [medline] PHST- 2024/11/30 11:17 [pubmed] PHST- 2024/11/29 23:52 [entrez] PHST- 2024/11/29 00:00 [pmc-release] AID - 10.1186/s13256-024-04932-2 [pii] AID - 4932 [pii] AID - 10.1186/s13256-024-04932-2 [doi] PST - epublish SO - J Med Case Rep. 2024 Nov 29;18(1):585. doi: 10.1186/s13256-024-04932-2. PMID- 22021103 OWN - NLM STAT- MEDLINE DCOM- 20120501 LR - 20131121 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 30 IP - 5 DP - 2012 May TI - The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin. PG - 764-8 LID - 10.1002/jor.21576 [doi] AB - Quinolone-induced tendinopathy or tendon rupture tends to be age-related. However, the synergistic effects of quinolone and aging on tenocytes remained to be explored. Tenocytes intrinsic to rat Achilles tendon from two age groups (young: 2 months; and near senescent (old): 24 months) were treated with ciprofloxacin. Tenocyte migration and proliferation were assessed by transwell filter migration assay and MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay, respectively. Messenger RNA and protein expressions of types I and III collagen were determined by reverse transcription-polymerase chain reaction (RT/PCR) and Western blot analysis, respectively. Transwell filter migration assay revealed that ciprofloxacin inhibited tenocytes migration, which became more significant in old tenocytes (p < 0.05). The results of MTT assay revealed that tenocytes proliferation decreased after ciprofloxacin treatment (p < 0.05), which also became more significant in old tenocytes. The results of RT-PCR and Western blot analysis revealed that mRNA and protein expressions of type I collagen remained unchanged in either young or old tenocytes with ciprofloxacin treatment, whereas the expressions of type III collagen were down-regulated by ciprofloxacin, which was more significant in old tenocytes. In conclusion, aging potentiated the ciprofloxacin-mediated inhibition of migration, proliferation, and expression of type III collagen of tenocytes. CI - Copyright © 2011 Orthopaedic Research Society. FAU - Chang, Hsiang-Ning AU - Chang HN AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, Taiwan. FAU - Pang, Jong-Hwei S AU - Pang JH FAU - Chen, Carl P C AU - Chen CP FAU - Ko, Pei-Chih AU - Ko PC FAU - Lin, Miao-Sui AU - Lin MS FAU - Tsai, Wen-Chung AU - Tsai WC FAU - Yang, Yun-Ming AU - Yang YM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20111021 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Anti-Infective Agents) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - *Aging/metabolism MH - Animals MH - Anti-Infective Agents/*adverse effects MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Ciprofloxacin/*adverse effects MH - Collagen Type I/metabolism MH - Collagen Type III/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Tendinopathy/*chemically induced/metabolism MH - Tendons/*cytology/metabolism EDAT- 2011/10/25 06:00 MHDA- 2012/05/02 06:00 CRDT- 2011/10/25 06:00 PHST- 2011/07/06 00:00 [received] PHST- 2011/10/06 00:00 [accepted] PHST- 2011/10/25 06:00 [entrez] PHST- 2011/10/25 06:00 [pubmed] PHST- 2012/05/02 06:00 [medline] AID - 10.1002/jor.21576 [doi] PST - ppublish SO - J Orthop Res. 2012 May;30(5):764-8. doi: 10.1002/jor.21576. Epub 2011 Oct 21. PMID- 39987523 OWN - NLM STAT- MEDLINE DCOM- 20250223 LR - 20250509 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 240 IP - 2 DP - 2025 Feb TI - Comparative Single-Cell Analysis Reveals Tendon Progenitor Dysfunction by Age-Associated Oxidative Stress and Its Restoration by Antioxidant Treatments. PG - e70016 LID - 10.1002/jcp.70016 [doi] AB - Impaired healing of adult tendons with fibrosis remains clinical challenges while neonatal tendons have full functional restoration. However, age-associated cellular and molecular changes in tendon cells and tendon stem/progenitor cells (TSPCs) remain unknown. Here, comparative single cell transcriptomics of early postnatal (2 weeks old) and adult (20 weeks old) mouse tendons revealed that adult tendons have reduced number of TSPCs, decreased gene expression in tendon and cartilage development, and a greater population of fibro-tenogenic cells. Notably, adult TSPCs and tenocytes exhibit increased expression of immune-response and oxidative-stress genes with higher EGFR but decreased IGF signaling. Adult tendon cells show increased levels of intracellular reactive oxygen species (ROS) in vivo. In contrast, antioxidant treatment of adult tendons significantly reduces intracellular ROS of TSPCs and improves tendon strength in vivo. Hence, these findings suggest that increased inflammation and ROS during tendon aging deteriorates tendon function and regeneration that can be mitigated by antioxidant treatment. CI - © 2025 Wiley Periodicals LLC. FAU - Jeong, Youngjae AU - Jeong Y AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. FAU - Yang, Dongwook AU - Yang D AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. FAU - Solidum, Jea Giezl AU - Solidum JG AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. AD - Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines, Manila, Philippines. FAU - Ortinau, Laura AU - Ortinau L AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. FAU - Park, Dongsu AU - Park D AUID- ORCID: 0000-0002-2570-3250 AD - Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. AD - Center for Skeletal Biology, Baylor College of Medicine, Houston, Texas, USA. LA - eng GR - Work performed in this study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and National Institute of Dental and Craniofacial Research of the National Institutes of Health under award numbers 1R01AR072018, R01DE31288, R01DE031162 (to DP), and T32DK060445 (to YJ)./ PT - Comparative Study PT - Journal Article PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) SB - IM MH - Animals MH - *Oxidative Stress/drug effects MH - *Antioxidants/pharmacology MH - *Tendons/drug effects/metabolism/pathology MH - *Stem Cells/drug effects/metabolism/pathology MH - Mice MH - Reactive Oxygen Species/metabolism MH - *Aging/pathology MH - Single-Cell Analysis/methods MH - Regeneration/drug effects MH - Mice, Inbred C57BL MH - Tenocytes/drug effects/metabolism/pathology MH - Male MH - Transcriptome OTO - NOTNLM OT - antioxidant restoration OT - oxidative stress OT - single‐cell analysis OT - tendon progenitor dysfunction EDAT- 2025/02/24 02:05 MHDA- 2025/02/24 02:06 CRDT- 2025/02/23 10:42 PHST- 2025/01/23 00:00 [revised] PHST- 2024/07/19 00:00 [received] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/02/24 02:06 [medline] PHST- 2025/02/24 02:05 [pubmed] PHST- 2025/02/23 10:42 [entrez] AID - 10.1002/jcp.70016 [doi] PST - ppublish SO - J Cell Physiol. 2025 Feb;240(2):e70016. doi: 10.1002/jcp.70016. PMID- 11233695 OWN - NLM STAT- MEDLINE DCOM- 20010503 LR - 20191027 IS - 1217-8950 (Print) IS - 1217-8950 (Linking) VI - 48 IP - 1 DP - 2001 TI - Fleroxacin uptake in ischaemic limb tissue. PG - 11-5 AB - Antibiotic application to patients with ischaemia of lower limbs may be indicated to avoid or treat infection of soft tissues. Fleroxacin, a fluoroquinolone, active against various Gram-negative and Gram-positive organisms may be used for this purpose. We evaluated the diffusion of fleroxacin into bone, subcutaneous fat, muscle and tendon tissues of lower limb tissue after a 400 mg i.v. dose. Concentrations in ischaemic tissues were similar to those found in non-ischaemic sites. Since the maximum antibiotic levels found were lower than the MICs of various pathogens relevant for infection, we suggest to increase the dose used for this peri-operative prophylaxis to 800 mg. FAU - Miglioli, P A AU - Miglioli PA AD - Department of Pharmacology, University of Padua, L.go E. Meneghetti, 2., 35131 Padova, Italy. FAU - Kafka, R AU - Kafka R FAU - Bonatti, H AU - Bonatti H FAU - Fraedrich, G AU - Fraedrich G FAU - Allerberger, F AU - Allerberger F FAU - Schoeffel, U AU - Schoeffel U LA - eng PT - Journal Article PL - Hungary TA - Acta Microbiol Immunol Hung JT - Acta microbiologica et immunologica Hungarica JID - 9434021 RN - 0 (Anti-Infective Agents) RN - N804LDH51K (Fleroxacin) SB - IM MH - Adipose Tissue/metabolism MH - Animals MH - Anti-Infective Agents/blood/*pharmacokinetics MH - Bone and Bones/metabolism MH - Diffusion MH - Extremities MH - Female MH - Fleroxacin/*pharmacokinetics MH - Ischemia/*metabolism MH - Male MH - Muscle, Skeletal/metabolism MH - Sheep MH - Tendons/metabolism EDAT- 2001/03/10 10:00 MHDA- 2001/05/05 10:01 CRDT- 2001/03/10 10:00 PHST- 2001/03/10 10:00 [pubmed] PHST- 2001/05/05 10:01 [medline] PHST- 2001/03/10 10:00 [entrez] AID - 10.1556/amicr.48.2001.1.2 [doi] PST - ppublish SO - Acta Microbiol Immunol Hung. 2001;48(1):11-5. doi: 10.1556/amicr.48.2001.1.2. PMID- 27220702 OWN - NLM STAT- MEDLINE DCOM- 20171106 LR - 20180821 IS - 1468-2834 (Electronic) IS - 0002-0729 (Linking) VI - 45 IP - 5 DP - 2016 Sep TI - Ciprofloxacin-associated bilateral iliopsoas tendon rupture: a case report. PG - 737-8 LID - 10.1093/ageing/afw092 [doi] AB - Fluoroquinolone use is associated with the development of tendinopathy, most commonly affecting the Achilles tendon. Here we present the first reported case of bilateral iliopsoas tendon rupture associated with prolonged ciprofloxacin use. This older woman presented with non-traumatic, sudden onset hip pain which was diagnosed as a right iliopsoas rupture on MRI. Despite stopping ciprofloxacin, she went on to develop rupture of the contralateral iliopsoas tendon. This case highlights the time lag between fluoroquinolone use and susceptibility to this rare but important complication. CI - © The Author 2016. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Smith, Natalie AU - Smith N AD - Royal United Hospital Bath NHS Trust, Bath BA1 3NG, UK. FAU - Fackrell, Robin AU - Fackrell R AD - Royal United Hospital Bath NHS Trust, Bath BA1 3NG, UK. FAU - Henderson, Emily AU - Henderson E AD - Royal United Hospital Bath NHS Trust, Bath BA1 3NG, UK School of Social and Community Medicine, University of Bristol, Bristol, UK. LA - eng PT - Case Reports PT - Journal Article DEP - 20160523 PL - England TA - Age Ageing JT - Age and ageing JID - 0375655 RN - 0 (Anti-Bacterial Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Aged MH - Anti-Bacterial Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Female MH - Hip/diagnostic imaging MH - Humans MH - Magnetic Resonance Imaging MH - Rupture, Spontaneous MH - Tendinopathy/*chemically induced/diagnostic imaging MH - Tendons/diagnostic imaging OTO - NOTNLM OT - ciprofloxacin OT - fluoroquinolone OT - iliopsoas rupture OT - older people OT - tendinopathy EDAT- 2016/05/26 06:00 MHDA- 2017/11/07 06:00 CRDT- 2016/05/26 06:00 PHST- 2015/12/22 00:00 [received] PHST- 2016/04/13 00:00 [accepted] PHST- 2016/05/26 06:00 [entrez] PHST- 2016/05/26 06:00 [pubmed] PHST- 2017/11/07 06:00 [medline] AID - afw092 [pii] AID - 10.1093/ageing/afw092 [doi] PST - ppublish SO - Age Ageing. 2016 Sep;45(5):737-8. doi: 10.1093/ageing/afw092. Epub 2016 May 23. PMID- 37710328 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231121 IS - 1226-4601 (Print) IS - 2055-7124 (Electronic) IS - 1226-4601 (Linking) VI - 27 IP - 1 DP - 2023 Sep 14 TI - Silver nanoparticles-decorated extracellular matrix graft: fabrication and tendon reconstruction performance. PG - 85 LID - 10.1186/s40824-023-00428-0 [doi] LID - 85 AB - BACKGROUND: The reconstruction of tendons with large defects requires grafts with high mechanical strength and is often hindered by complications such as infection and adhesion. Hence, grafts combining the advantages of mechanical resilience and antibacterial/antiadhesion activity are highly sought after. METHODS: The silver nanoparticles (GA-Ag NPs) synthesized from gallic acid and silver nitrate were attached to a decellularized extracellular matrix (Decellularized Tendon crosslinking GA-AgNPs, DT-Ag). We examined the histological structure, mechanical property, morphology, Zeta potential, cytotoxicity, antibacterial properties, antioxidant and anti-inflammatory properties, and ability of the DT-Ag to treat tendon defects in animals. RESULTS: Approximately 108.57 ± 0.94 μg GA-Ag NPs loaded per 50 mg DT, the cross-linked part of GA-Ag NPs was 65.47 ± 0.57%, which provided DT-Ag with long-lasting antibacterial activity. Meanwhile, GA endowed DT-Ag with good antioxidant and anti-inflammatory activities. Additionally, The DT-Ag facilitated M2 macrophage polarization, and suppressed fibrin deposition by hindering fibroblast adhesion. Mormore, the main advantages of DT-Ag, namely its long-lasting antibacterial activity (tested using Escherichia coli and Staphylococcus aureus as models) and the ability to prevent tissue adhesion were confirmed in vivo. CONCLUSION: The fabricated multifunctional tendon graft was highly hydrophilic, biocompatible, and mechanically resilient, and concluded to be well suited for dealing with the main complications of surgical tendon reconstruction and has bright application prospects. CI - © 2023. The Korean Society for Biomaterials. FAU - Chen, Sunfang AU - Chen S AD - Department of Orthopedics, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310000, China. AD - Department of Orthopedics, the Central Hospital Affiliated to Shaoxing University, Shaoxing, 312030, China. FAU - Cai, Dan AU - Cai D AD - Department of Orthopedics, the First People's Hospital of Huzhou, First Affiliated Hospital of Huzhou University, Huzhou, 313000, China. FAU - Dong, Qi AU - Dong Q AD - Department of Orthopedics, Honghui Hospital, Xi'an Jiao Tong University, Xi'an City, 710054, China. FAU - Ma, Gaoxiang AU - Ma G AD - Department of Orthopedics, the Central Hospital Affiliated to Shaoxing University, Shaoxing, 312030, China. FAU - Xu, Chennan AU - Xu C AD - Department of Orthopedics, the Central Hospital Affiliated to Shaoxing University, Shaoxing, 312030, China. FAU - Bao, Xiaogang AU - Bao X AD - Department of Orthopedics, The Spine Surgical Center, Second Affiliated Hospital of Naval Medical University, Shanghai, 200003, China. FAU - Yuan, Wei AU - Yuan W AD - Department of Orthopedics, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China. wei95960@126.com. FAU - Wu, Bing AU - Wu B AD - Department of Orthopedics, the Central Hospital Affiliated to Shaoxing University, Shaoxing, 312030, China. wubing@usx.edu.cn. FAU - Fang, Bin AU - Fang B AD - Department of Orthopedics, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310000, China. 20233006@zcmu.edu.cn. AD - Department of Orthopedics, the Central Hospital Affiliated to Shaoxing University, Shaoxing, 312030, China. 20233006@zcmu.edu.cn. LA - eng GR - grant No. LBY22H180007/Natural Science Foundation of Zhejiang Province/ GR - grant No. LBY22H270004/Natural Science Foundation of Zhejiang Province/ GR - grant No. 2022KY416/Medical and Health Science and Technology Plan Project of Zhejiang Province/ GR - grant No. 2023KY374/Medical and Health Science and Technology Plan Project of Zhejiang Province/ GR - grant No. 202040317/Shanghai Municipal Health Commission/ GR - Grant No. 21YF1458200/Shanghai Sailing Program/ PT - Journal Article DEP - 20230914 PL - United States TA - Biomater Res JT - Biomaterials research JID - 101650636 PMC - PMC10503197 OTO - NOTNLM OT - Extracellular matrix OT - Infection OT - Inflammation OT - Silver nanoparticles OT - Tendon graft COIS- The authors declare that they have no competing interests. EDAT- 2023/09/15 00:42 MHDA- 2023/09/15 00:43 PMCR- 2023/09/14 CRDT- 2023/09/14 23:50 PHST- 2023/06/07 00:00 [received] PHST- 2023/09/03 00:00 [accepted] PHST- 2023/09/15 00:43 [medline] PHST- 2023/09/15 00:42 [pubmed] PHST- 2023/09/14 23:50 [entrez] PHST- 2023/09/14 00:00 [pmc-release] AID - 10.1186/s40824-023-00428-0 [pii] AID - 428 [pii] AID - 10.1186/s40824-023-00428-0 [doi] PST - epublish SO - Biomater Res. 2023 Sep 14;27(1):85. doi: 10.1186/s40824-023-00428-0. PMID- 5414418 OWN - NLM STAT- MEDLINE DCOM- 19700327 LR - 20180330 IS - 0022-3166 (Print) IS - 0022-3166 (Linking) VI - 100 IP - 2 DP - 1970 Feb TI - Biochemical and histological study of guinea pig fetal and uterine tissue in ascorbic acid deficiency. PG - 217-27 FAU - Rivers, J M AU - Rivers JM FAU - Krook, L AU - Krook L FAU - Cormier, A AU - Cormier A LA - eng PT - Journal Article PL - United States TA - J Nutr JT - The Journal of nutrition JID - 0404243 RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Adrenal Glands/metabolism MH - Animals MH - Ascorbic Acid/metabolism MH - Ascorbic Acid Deficiency/*metabolism/pathology MH - Bone and Bones/embryology/pathology MH - Collagen/*metabolism MH - Connective Tissue/metabolism MH - Diet MH - Female MH - Fetus/cytology/*metabolism MH - Guinea Pigs MH - Hydroxyproline/metabolism MH - Organ Size MH - Pregnancy MH - Proline/metabolism MH - Tendons/embryology/pathology MH - Tibia MH - Umbilical Cord/pathology MH - Uterus/anatomy & histology/*metabolism/pathology EDAT- 1970/02/01 00:00 MHDA- 1970/02/01 00:01 CRDT- 1970/02/01 00:00 PHST- 1970/02/01 00:00 [pubmed] PHST- 1970/02/01 00:01 [medline] PHST- 1970/02/01 00:00 [entrez] AID - 10.1093/jn/100.2.217 [doi] PST - ppublish SO - J Nutr. 1970 Feb;100(2):217-27. doi: 10.1093/jn/100.2.217. PMID- 1432657 OWN - NLM STAT- MEDLINE DCOM- 19921215 LR - 20131121 IS - 8750-7315 (Print) IS - 1930-8264 (Linking) VI - 82 IP - 7 DP - 1992 Jul TI - Ciprofloxacin in the treatment of Mycobacterium fortuitum infection of the peroneal tendons. A case report. PG - 382-5 AB - In the case reported, M. fortuitum was sensitive in vitro to amikacin, erythromycin, tobramycin, and ciprofloxacin. Because the patient did not respond to long-term therapy with amikacin and erythromycin, an experimental antibiotic, ciprofloxacin, was tried. Only after extensive surgical debridement and 2 1/2 months of oral ciprofloxacin therapy was the infection eradicated and wound healing obtained. The authors conclude that a wound that has reopened, but remains indolent, exudes a clear, serous drainage and responds poorly to antibiotics should suggest a possible mycobacterial infection. Combination antibiotic therapy is recommended because of the high rate of relapse and development of resistance to drugs. Extensive surgical debridement of all infected tissue remains the primary treatment. The therapeutic value of ciprofloxacin and other newer antibiotics in the treatment of mycobacterial infection is promising. FAU - Binning, T A AU - Binning TA AD - Department of Podiatric Surgery, Kaiser Permanente Medical Center, Oakland, CA 94611-5693. FAU - Karlin, J M AU - Karlin JM FAU - Klein, D AU - Klein D FAU - Scurran, B L AU - Scurran BL FAU - Cooke, R A AU - Cooke RA LA - eng PT - Case Reports PT - Journal Article PL - United States TA - J Am Podiatr Med Assoc JT - Journal of the American Podiatric Medical Association JID - 8501423 RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Adult MH - Ciprofloxacin/*therapeutic use MH - Female MH - Humans MH - *Leg MH - Muscular Diseases/drug therapy MH - Mycobacterium Infections, Nontuberculous/*drug therapy MH - *Tendons EDAT- 1992/07/01 00:00 MHDA- 1992/07/01 00:01 CRDT- 1992/07/01 00:00 PHST- 1992/07/01 00:00 [pubmed] PHST- 1992/07/01 00:01 [medline] PHST- 1992/07/01 00:00 [entrez] AID - 10.7547/87507315-82-7-382 [doi] PST - ppublish SO - J Am Podiatr Med Assoc. 1992 Jul;82(7):382-5. doi: 10.7547/87507315-82-7-382. PMID- 10639347 OWN - NLM STAT- MEDLINE DCOM- 20000323 LR - 20210526 IS - 0066-4804 (Print) IS - 1098-6596 (Electronic) IS - 0066-4804 (Linking) VI - 44 IP - 2 DP - 2000 Feb TI - Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. PG - 261-6 AB - Fluoroquinolones can cause tendinitis and tendon rupture. However, toxicological as well as clinical information on quinolone-induced tendopathy is scarce. We performed extensive electron microscopic studies with Achilles tendon specimens from ofloxacin-treated rats. The drug was given at a dose of 1,200 mg/kg (body weight) orally. Juvenile Wistar rats received one or three oral doses each of 1,200 mg of ofloxacin/kg (body weight)/day. Three days after treatment, the tenocytes of their Achilles tendons showed degenerative alterations, such as multiple vacuoles and vesicles in the cytoplasm that had developed due to swellings and dilatations of cell organelles. Other indications of cell degradation were the occurrence of cell debris and cell detachment from the extracellular matrix accompanied by a loss of cell-matrix interaction. The tenocytes of juvenile Wistar rats that had been treated at day 36 with a single oral dose of 1,200 mg of ofloxacin/kg (body weight) and sacrificed either 3 or 6 months later exhibited similar degenerative alterations. The number of degenerative alterations of tenocytes after ofloxacin treatment was considerably higher in rats that had received a magnesium-deficient diet than in rats with normal magnesium status. Of the adult rats that had been treated once, 5 times, and 10 times with ofloxacin and killed 1 day later, only those with the 10-times treatment showed a significantly increased number of degeneratively altered tenocytes. In summary, effects observed in tendons show similar pathological features as described earlier in cartilage, indicating that quinolone-induced arthropathy and quinolone-induced tendopathy probably are different clinical manifestations of the same toxic effect on cellular components of connective tissue structures. FAU - Shakibaei, M AU - Shakibaei M AD - Institute of Anatomy, Benjamin Franklin Medical Center, Freie Universit]at Berlin, 14195 Berlin, Germany. FAU - Pfister, K AU - Pfister K FAU - Schwabe, R AU - Schwabe R FAU - Vormann, J AU - Vormann J FAU - Stahlmann, R AU - Stahlmann R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Antimicrob Agents Chemother JT - Antimicrobial agents and chemotherapy JID - 0315061 RN - 0 (Anti-Infective Agents) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/*drug effects/pathology/ultrastructure MH - Aging MH - Animals MH - Anti-Infective Agents/*toxicity MH - Diet MH - *Magnesium Deficiency/pathology MH - Ofloxacin/*toxicity MH - Rats MH - Rats, Wistar PMC - PMC89668 EDAT- 2000/01/20 09:00 MHDA- 2000/03/25 09:00 PMCR- 2000/02/01 CRDT- 2000/01/20 09:00 PHST- 2000/01/20 09:00 [pubmed] PHST- 2000/03/25 09:00 [medline] PHST- 2000/01/20 09:00 [entrez] PHST- 2000/02/01 00:00 [pmc-release] AID - 1025 [pii] AID - 10.1128/AAC.44.2.261-266.2000 [doi] PST - ppublish SO - Antimicrob Agents Chemother. 2000 Feb;44(2):261-6. doi: 10.1128/AAC.44.2.261-266.2000. PMID- 36419049 OWN - NLM STAT- MEDLINE DCOM- 20221125 LR - 20221213 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 23 IP - 1 DP - 2022 Nov 22 TI - Spontaneous tendon rupture in a patient with systemic sclerosis: a case report. PG - 1001 LID - 10.1186/s12891-022-05967-6 [doi] LID - 1001 AB - BACKGROUND: Systemic sclerosis (SSc) is an incurable autoimmune disease characterized by progressive skin fibrosis and organ failure. Tenosynovitis is a common musculoskeletal manifestation, but tendon rupture has seldom reported in SSc. CASE PRESENTATION: We present a rare case of a 49-year-old female with SSc who has suffered from bilateral tendon rupture of the fourth and fifth digits with positive antinuclear antibody (ANA) and anti-centromere B antibody, but negative rheumatoid factor in serum. In the extensor tendons of the patient's hands, inflammation, edema, hypertrophy and tendon interruption were detected with ultrasound and magnetic resonance imaging(MRI). Tendon transfer repair surgery was performed and 10 mg/week methotrexate was then used in this patient. Her hand function was improved well with methotrexate and rehabilitation treatment postoperatively. CONCLUSIONS: Early detection of tenosynovitis is necessary to prevent tendon rupture in SSc patients. Ultrasound and Magnetic Resonance Imaging appear to be useful examinations for evaluating tendon pathology for early detection. CI - © 2022. The Author(s). FAU - Lin, Cong AU - Lin C AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. FAU - Shen, Jun AU - Shen J AD - Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, China. FAU - Jiang, Zhixing AU - Jiang Z AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. FAU - Cheng, Yi AU - Cheng Y AD - Department of Ultrasound in Medicine, Huashan Hospital, Fudan University, Shanghai, China. FAU - Shen, Yundong AU - Shen Y AD - Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, China. FAU - Ren, Guoqiang AU - Ren G AD - Department of Pathology, Huashan Hospital North, Fudan University, Shanghai, China. FAU - Xu, Wendong AU - Xu W AD - Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, China. FAU - Wan, Weiguo AU - Wan W AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. FAU - Cao, Ling AU - Cao L AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. FAU - Zou, Hejian AU - Zou H AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. FAU - Zhu, Xiaoxia AU - Zhu X AUID- ORCID: 0000-0002-3580-1997 AD - Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. 15901811889@163.com. AD - Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. 15901811889@163.com. LA - eng GR - 82161138022/National Natural Science Foundation of China/ GR - SPROG2106/Shanghai Pujiang Young Rheumatologists Training Program/ PT - Case Reports PT - Journal Article DEP - 20221122 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Humans MH - Female MH - Middle Aged MH - *Tenosynovitis/diagnostic imaging/etiology/surgery MH - Methotrexate MH - *Tendon Injuries/complications/diagnostic imaging MH - Rupture, Spontaneous MH - *Scleroderma, Systemic/complications/diagnostic imaging MH - Tendons/pathology PMC - PMC9682771 OTO - NOTNLM OT - Case report OT - Rheumatic disease OT - Rupture OT - Systemic sclerosis(SSc) OT - Tendon COIS- Written informed consent for publication of this Case Report was obtained from the patient. Competing interests. The authors declare there are no competing financial interests. All authors certify that they have no competing interests to declare that are relevant to the content of this article. EDAT- 2022/11/25 06:00 MHDA- 2022/11/26 06:00 PMCR- 2022/11/22 CRDT- 2022/11/24 00:11 PHST- 2022/04/15 00:00 [received] PHST- 2022/11/08 00:00 [accepted] PHST- 2022/11/24 00:11 [entrez] PHST- 2022/11/25 06:00 [pubmed] PHST- 2022/11/26 06:00 [medline] PHST- 2022/11/22 00:00 [pmc-release] AID - 10.1186/s12891-022-05967-6 [pii] AID - 5967 [pii] AID - 10.1186/s12891-022-05967-6 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2022 Nov 22;23(1):1001. doi: 10.1186/s12891-022-05967-6. PMID- 15119847 OWN - NLM STAT- MEDLINE DCOM- 20041108 LR - 20220408 IS - 0742-2091 (Print) IS - 0742-2091 (Linking) VI - 20 IP - 1 DP - 2004 Feb TI - The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells. PG - 41-54 AB - Fluoroquinolone antibiotics have been used widely in humans and domestic animals, including horses, because of their broad-spectrum bactericidal activity, and relative safety. The use of fluoroquinolones, however, is not without risk. Tendonitis and spontaneous tendon rupture have been reported in people during or following therapy with fluoroquinolones. We have studied the effects of enrofloxacin, a fluoroquinolone antibiotic used commonly in domestic animals, on tendon cell cultures established from equine superficial digital flexor tendons. Effects on cell proliferation and morphology were studied using cell counting and scanning electron microscopy. Monosaccharide content and composition was determined by gas chromatography-mass spectrometry analysis. Western and Northern blot analyses were utilized to evaluate the synthesis and expression of two proteoglycans, biglycan and decorin. Our data demonstrate that enrofloxacin inhibits cell proliferation, induces morphological changes, decreases total monosacharide content and alters small proteoglycan synthesis at the glycosylation level in equine tendon cell cultures. These effects are more pronounced in juvenile tendon cells than in adult equine tendon cells. We hypothesize that morphological changes and inhibition of cell proliferation are a result of impaired production of biglycan and decorin, proteoglycans involved in fibrillogenesis of collagen, the most important structural component of the tendon of enrofloxacin-treated tendon cells. Our findings suggest that fluoroquinolones should be used with caution in horses, especially in foals. FAU - Yoon, J H AU - Yoon JH AD - The Soft Tissue Center, Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388, USA. FAU - Brooks, R L Jr AU - Brooks RL Jr FAU - Khan, A AU - Khan A FAU - Pan, H AU - Pan H FAU - Bryan, J AU - Bryan J FAU - Zhang, J AU - Zhang J FAU - Budsberg, S C AU - Budsberg SC FAU - Mueller, P O E AU - Mueller PO FAU - Halper, J AU - Halper J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - Cell Biol Toxicol JT - Cell biology and toxicology JID - 8506639 RN - 0 (Antineoplastic Agents) RN - 0 (BGN protein, human) RN - 0 (Biglycan) RN - 0 (Carbohydrates) RN - 0 (DCN protein, human) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fluoroquinolones) RN - 0 (Proteoglycans) RN - 0 (Quinolones) RN - 3DX3XEK1BN (Enrofloxacin) RN - 63231-63-0 (RNA) SB - IM MH - Animals MH - Antineoplastic Agents/*toxicity MH - Apoptosis MH - Biglycan MH - Blotting, Northern MH - Blotting, Western MH - Carbohydrates/chemistry MH - Cell Division/drug effects MH - Chromatography, Gas MH - Decorin MH - Electrophoresis, Polyacrylamide Gel MH - Enrofloxacin MH - Extracellular Matrix Proteins MH - Fluoroquinolones/*toxicity MH - Horses MH - Mass Spectrometry MH - Microscopy, Electron, Scanning MH - Proteoglycans/chemistry/metabolism MH - Quinolones/*toxicity MH - RNA/chemistry MH - Tendons/*drug effects MH - Time Factors EDAT- 2004/05/04 05:00 MHDA- 2004/11/09 09:00 CRDT- 2004/05/04 05:00 PHST- 2004/05/04 05:00 [pubmed] PHST- 2004/11/09 09:00 [medline] PHST- 2004/05/04 05:00 [entrez] AID - 10.1023/b:cbto.0000021154.01035.f9 [doi] PST - ppublish SO - Cell Biol Toxicol. 2004 Feb;20(1):41-54. doi: 10.1023/b:cbto.0000021154.01035.f9. PMID- 11570695 OWN - NLM STAT- MEDLINE DCOM- 20020403 LR - 20190906 IS - 0340-5761 (Print) IS - 0340-5761 (Linking) VI - 75 IP - 6 DP - 2001 Aug TI - Biochemical changes in Achilles tendon from juvenile dogs after treatment with ciprofloxacin or feeding a magnesium-deficient diet. PG - 369-74 AB - Quinolones are antibacterial agents that have the potential to induce Achilles tendon disorders - such as tendinitis or even ruptures - in patients treated with these drugs. We studied the effects of ciprofloxacin on several proteins of Achilles tendons from immature dogs, 10- to 11-weeks-old. The dogs were treated orally for 5 days with 30 or 200 mg ciprofloxacin/kg body weight or with the vehicle alone. Since quinolone-like alterations in joint cartilage were observed in magnesium-deficient animals, another group was fed a magnesium-deficient diet for 6 weeks. At necropsy, tendons (n=3 from each group) were frozen and stored until analysis when they were homogenized in a lysis buffer to release a soluble fraction of the tendon proteins. Densitometric analysis of the immunoblots with anticollagen type I, anti-elastin, anti-fibronectin, and antiintegrin antibodies showed a significant reduction of all proteins. For example, collagen type I concentrations (mean +/-SD, arbitrary densitometric units) were 3190+/-217 (controls), 1890+/-468 (30mg/kg), 1695+/-135 (200mg/kg) and 2053+/-491 in the magnesium-deficient dogs. The differences between concentrations in controls and all treated groups were statistically significant (P<0.01, t-test). Similarly, compared with control samples, relative concentrations of other proteins in tendons from ciprofloxacin-treated dogs (30 mg/kg) decreased by 73% (elastin), 88% (fibronectin), and 96% (beta1 integrin) (data from low-dose group only). A very similar pattern of protein alterations was detected in samples from magnesium-deficient dogs. In conclusion, rather low doses of a fluoroquinolone or a diet-induced magnesium deficiency caused similar biochemical alterations in the soluble fraction of proteins from canine tendons. These findings support our hypothesis that quinolone-induced toxic effects on connective tissue structures are due to the magnesium-antagonistic effects of these antibacterial agents. They also indicate that patients with a latent magnesium deficiency could be at an increased risk of quinolone-induced tendon disorders. FAU - Shakibaei, M AU - Shakibaei M AD - Institute of Anatomy, Freie Universität Berlin, Germany. mehshaki@zedat.fu-berlin.de FAU - de Souza, P AU - de Souza P FAU - van Sickle, D AU - van Sickle D FAU - Stahlmann, R AU - Stahlmann R LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Arch Toxicol JT - Archives of toxicology JID - 0417615 RN - 0 (Anti-Infective Agents) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Proteins) RN - 5E8K9I0O4U (Ciprofloxacin) RN - I38ZP9992A (Magnesium) SB - IM MH - Achilles Tendon/chemistry/*drug effects/ultrastructure MH - Administration, Oral MH - Animal Feed/analysis MH - Animals MH - Anti-Infective Agents/administration & dosage/*pharmacology MH - Blotting, Western MH - Ciprofloxacin/administration & dosage/*pharmacology MH - Densitometry MH - Dogs MH - Extracellular Matrix Proteins/analysis MH - Magnesium/metabolism MH - Magnesium Deficiency/etiology/*metabolism/pathology MH - Musculoskeletal Diseases/etiology/*metabolism/pathology MH - Proteins/*analysis MH - Time Factors EDAT- 2001/09/26 10:00 MHDA- 2002/04/04 10:01 CRDT- 2001/09/26 10:00 PHST- 2001/09/26 10:00 [pubmed] PHST- 2002/04/04 10:01 [medline] PHST- 2001/09/26 10:00 [entrez] AID - 10.1007/s002040100243 [doi] PST - ppublish SO - Arch Toxicol. 2001 Aug;75(6):369-74. doi: 10.1007/s002040100243. PMID- 8763095 OWN - NLM STAT- MEDLINE DCOM- 19961024 LR - 20131121 IS - 0003-410X (Print) IS - 0003-410X (Linking) VI - 147 IP - 1 DP - 1996 TI - [Rupture of the long biceps tendon following ingestion of fluoroquinolone]. PG - 69 FAU - Guérin, B AU - Guérin B FAU - Grateau, G AU - Grateau G FAU - Quartier, G AU - Quartier G FAU - Durand, H AU - Durand H LA - fre PT - Case Reports PT - Letter TT - Rupture du tendon du long biceps faisant suite à la prise de fluoroquinolone. PL - France TA - Ann Med Interne (Paris) JT - Annales de medecine interne JID - 0171744 RN - 0 (Anti-Infective Agents) RN - N0F8P22L1P (Norfloxacin) SB - IM MH - Anti-Infective Agents/*adverse effects MH - Humans MH - Male MH - Middle Aged MH - Norfloxacin/*adverse effects MH - Rupture, Spontaneous MH - *Tendons EDAT- 1996/01/01 00:00 MHDA- 1996/01/01 00:01 CRDT- 1996/01/01 00:00 PHST- 1996/01/01 00:00 [pubmed] PHST- 1996/01/01 00:01 [medline] PHST- 1996/01/01 00:00 [entrez] PST - ppublish SO - Ann Med Interne (Paris). 1996;147(1):69. PMID- 14243399 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20190618 IS - 0028-0836 (Print) IS - 0028-0836 (Linking) VI - 204 DP - 1964 Dec 12 TI - HISTOTOPOCHEMISTRY OF ASCORBIC ACID IN TENDON FIBRES. PG - 1104 FAU - BARTOS, F AU - BARTOS F LA - eng PT - Journal Article PL - England TA - Nature JT - Nature JID - 0410462 RN - 0 (Coloring Agents) RN - 0 (Proteins) RN - 3M4G523W1G (Silver) RN - 9007-34-5 (Collagen) RN - 95IT3W8JZE (Silver Nitrate) RN - 9DLQ4CIU6V (Proline) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - OM MH - *Ascorbic Acid MH - *Collagen MH - *Coloring Agents MH - *Cytoplasm MH - *Hydroxyproline MH - *Proline MH - Proteins/*metabolism MH - Rats MH - *Research MH - *Silver MH - *Silver Nitrate MH - *Staining and Labeling MH - *Tendons OTO - NLM OT - *ASCORBIC ACID OT - *COLLAGEN OT - *CYTOPLASM OT - *EXPERIMENTAL LAB STUDY OT - *HYDROXYPROLINE OT - *PROLINE OT - *PROTEIN METABOLISM OT - *RATS OT - *SILVER OT - *SILVER NITRATE OT - *STAINS AND STAINING OT - *TENDONS EDAT- 1964/12/12 00:00 MHDA- 1964/12/12 00:01 CRDT- 1964/12/12 00:00 PHST- 1964/12/12 00:00 [pubmed] PHST- 1964/12/12 00:01 [medline] PHST- 1964/12/12 00:00 [entrez] AID - 10.1038/2041104a0 [doi] PST - ppublish SO - Nature. 1964 Dec 12;204:1104. doi: 10.1038/2041104a0. PMID- 7234963 OWN - NLM STAT- MEDLINE DCOM- 19810720 LR - 20181113 IS - 0002-9440 (Print) IS - 1525-2191 (Electronic) IS - 0002-9440 (Linking) VI - 103 IP - 2 DP - 1981 May TI - Ultrastructural studies on the gastrocnemius tendon of selenium-deficient ducklings. PG - 201-9 AB - This paper presents an ultrastructural study of the changes occurring in the gastrocnemius tendon of normal and selenium-deficient ducklings from 1 to 12 days of age. The study revealed that the normal 1--8-day-old duckling tendon contained 2 morphologically distinct cell types and a third occurring at Days 8--12. The location of these cells within the endotendineum and fiber bundles and their morphologic characteristics are presented. Most cells showed cytologic alterations as early as 4 days on the deficient diet with progressive deterioration to Day 12. The various cell types showed a differential response to the deficiency. Changes included altered endoplasmic reticulum and Golgi apparatus and eventual cell rupture. The significance of these observations and their possible relationship to the etiology of selenium-deficiency-induced dystrophy is discussed. FAU - Sweeny, P R AU - Sweeny PR FAU - Brown, R G AU - Brown RG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Pathol JT - The American journal of pathology JID - 0370502 RN - H6241UJ22B (Selenium) SB - IM MH - Animals MH - Ducks/*metabolism MH - Hindlimb MH - Selenium/*deficiency MH - Tendons/pathology/*ultrastructure PMC - PMC1903831 EDAT- 1981/05/01 00:00 MHDA- 1981/05/01 00:01 PMCR- 1981/11/01 CRDT- 1981/05/01 00:00 PHST- 1981/05/01 00:00 [pubmed] PHST- 1981/05/01 00:01 [medline] PHST- 1981/05/01 00:00 [entrez] PHST- 1981/11/01 00:00 [pmc-release] PST - ppublish SO - Am J Pathol. 1981 May;103(2):201-9. PMID- 7406022 OWN - NLM STAT- MEDLINE DCOM- 19801024 LR - 20181113 IS - 0002-9440 (Print) IS - 1525-2191 (Electronic) IS - 0002-9440 (Linking) VI - 100 IP - 2 DP - 1980 Aug TI - Ultrastructural studies of the myotendonous junction of selenium-deficient ducklings. PG - 481-96 AB - An ultrastructural study was made of the changes occurring within the gastrocnemius insertion of normal and selenium-deficient ducklings from 1 to 12 days of age. The cytologic characteristics of the fibroblasts, vessels, collagen, and muscle cells are described. Those exposed to the selenium deficiency showed major alterations of all components. The fibroblasts showed changes ranging from collapsed cisternae and degenerating mitochondria to rupture. The capillary endothelium was abnormal, as was the smooth muscle of arteriolar walls. The collagen sizes were altered, and the muscle cell termini showed major pathologic changes. The above alterations occurred within 4 days of exposure of the deficiency. The muscle cells of the body portion of the gastrocnemius showed no alterations until Day 8. The observations present evidence that indicates that connective-tissue-vascular abnormalities precede myopathic changes in nutritionally induced dystrophy. The significance of these findings is discussed with respect to the etiology of nutritionally induced dystrophy. FAU - Sweeny, P R AU - Sweeny PR FAU - Brown, R G AU - Brown RG LA - eng PT - Journal Article PL - United States TA - Am J Pathol JT - The American journal of pathology JID - 0370502 RN - 9007-34-5 (Collagen) RN - H6241UJ22B (Selenium) SB - IM MH - Animals MH - Blood Vessels/ultrastructure MH - Collagen/biosynthesis MH - Diet MH - Ducks MH - Fibroblasts/ultrastructure MH - Muscle Development MH - Muscle, Smooth, Vascular/ultrastructure MH - Muscles/*ultrastructure MH - Muscular Dystrophy, Animal/etiology/pathology MH - Selenium/*deficiency MH - Tendons/growth & development/*ultrastructure MH - Time Factors PMC - PMC1903542 EDAT- 1980/08/01 00:00 MHDA- 1980/08/01 00:01 PMCR- 1981/02/01 CRDT- 1980/08/01 00:00 PHST- 1980/08/01 00:00 [pubmed] PHST- 1980/08/01 00:01 [medline] PHST- 1980/08/01 00:00 [entrez] PHST- 1981/02/01 00:00 [pmc-release] PST - ppublish SO - Am J Pathol. 1980 Aug;100(2):481-96. PMID- 21476078 OWN - NLM STAT- MEDLINE DCOM- 20120206 LR - 20220317 IS - 1432-119X (Electronic) IS - 0948-6143 (Linking) VI - 135 IP - 5 DP - 2011 May TI - Platelet-released growth factors can accelerate tenocyte proliferation and activate the anti-oxidant response element. PG - 453-60 LID - 10.1007/s00418-011-0808-0 [doi] AB - Little is know about the pathophysiology of acute and degenerative tendon injuries. Although most lesions are uncomplicated, treatment is long and unsatisfactory in a considerable number of cases. Besides the common growth factors that were shown to be relevant for tendon integrity more recently protection against oxidative stress was shown to promote tendon healing. To improve tendon regeneration, many have advocated the use of platelet-rich plasma (PRP), a thrombocyte concentrate that can serve as an autologous source of growth factors. In this study, we investigated the effect of platelet-released growth factors (PRGF) on tenocytes. Tenocytes were isolated from the Achilles tendon of postnatal rats. Tenocyte cell cultures were stimulated with PRGF. We used a CyQuant assay and WST assay to analyse tendon cell growth and viability in different concentrations of PRGF. Migration and proliferation of cells grown in PRGF were assessed by a scratch test. A dual-luciferase assay was used to demonstrate the activation of the anti-oxidant response element (ARE) in tenocytes. A positive effect of PRGF could be shown on tendon cell growth and migratory capacity. PRGF activated the Nrf2-ARE pathway in a dose-dependent manner. Here, we provide evidence of a biological effect of PRGF on tenocytes by the promotion of tenocyte growth and activation of the Nrf2-ARE pathway. This is a novel aspect of the action of platelet concentrates on tendon growth. FAU - Tohidnezhad, M AU - Tohidnezhad M AD - Department of Anatomy and Cell Biology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany. FAU - Varoga, D AU - Varoga D FAU - Wruck, C J AU - Wruck CJ FAU - Brandenburg, L O AU - Brandenburg LO FAU - Seekamp, A AU - Seekamp A FAU - Shakibaei, M AU - Shakibaei M FAU - Sönmez, T T AU - Sönmez TT FAU - Pufe, Thomas AU - Pufe T FAU - Lippross, S AU - Lippross S LA - eng PT - Journal Article DEP - 20110408 PL - Germany TA - Histochem Cell Biol JT - Histochemistry and cell biology JID - 9506663 RN - 0 (Antioxidants) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (NF-E2-Related Factor 2) RN - 0 (Nfe2l2 protein, rat) SB - IM MH - Animals MH - Antioxidants/*metabolism MH - Blood Platelets/*metabolism MH - Cell Movement/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Female MH - Gene Expression Regulation/drug effects/genetics MH - Intercellular Signaling Peptides and Proteins/*metabolism/*pharmacology MH - Male MH - NF-E2-Related Factor 2/metabolism MH - Phenotype MH - Rats MH - Rats, Wistar MH - Response Elements/*genetics MH - Tendons/*cytology/*drug effects/metabolism EDAT- 2011/04/09 06:00 MHDA- 2012/02/07 06:00 CRDT- 2011/04/09 06:00 PHST- 2011/03/21 00:00 [accepted] PHST- 2011/04/09 06:00 [entrez] PHST- 2011/04/09 06:00 [pubmed] PHST- 2012/02/07 06:00 [medline] AID - 10.1007/s00418-011-0808-0 [doi] PST - ppublish SO - Histochem Cell Biol. 2011 May;135(5):453-60. doi: 10.1007/s00418-011-0808-0. Epub 2011 Apr 8. PMID- 19273194 OWN - NLM STAT- MEDLINE DCOM- 20090407 LR - 20250529 IS - 2768-6698 (Electronic) IS - 2768-6698 (Linking) VI - 14 IP - 6 DP - 2009 Jan 1 TI - Neuropeptides in tendinopathy. PG - 2203-11 LID - 10.2741/3372 [doi] AB - Overuse tendinopathy remains a major clinical burden for sports medicine and general practitioners. Recent studies have highlighted the role of sensory and autonomic nerves in generating or perpetuating the symptoms and tissue abnormalities associated with tendinopathy. We outline the neuroanatomy and potential roles of nerves and associated neuropeptides in tendinopathy. In addition, intriguing new data is reviewed which suggests that there may be a substantial intrinsic source of neuropeptides within tendons - namely, the tenocytes themselves. The potential roles of Substance P and mast cells are highlighted in particular. We discuss the implications for conservative management including sclerosing injections and exercise training. FAU - Scott, Alexander AU - Scott A AD - Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, Canada. ascott@interchange.ubc.ca FAU - Bahr, Roald AU - Bahr R LA - eng GR - 84986-1/CAPMC/CIHR/Canada PT - Journal Article PT - Review DEP - 20090101 PL - Singapore TA - Front Biosci (Landmark Ed) JT - Frontiers in bioscience (Landmark edition) JID - 101612996 RN - 0 (Neuropeptides) RN - 0 (Opioid Peptides) RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Exercise MH - Humans MH - Mast Cells/cytology MH - Neuropeptides/*metabolism MH - Nitric Oxide/metabolism MH - Opioid Peptides/metabolism MH - Signal Transduction MH - Tendon Injuries/*metabolism MH - Tendons/innervation PMC - PMC4000254 MID - CAMS4220 OID - NLM: CAMS4220 EDAT- 2009/03/11 09:00 MHDA- 2009/04/08 09:00 PMCR- 2014/04/25 CRDT- 2009/03/11 09:00 PHST- 2009/03/11 09:00 [entrez] PHST- 2009/03/11 09:00 [pubmed] PHST- 2009/04/08 09:00 [medline] PHST- 2014/04/25 00:00 [pmc-release] AID - 3372 [pii] AID - 10.2741/3372 [doi] PST - epublish SO - Front Biosci (Landmark Ed). 2009 Jan 1;14(6):2203-11. doi: 10.2741/3372. PMID- 432880 OWN - NLM STAT- MEDLINE DCOM- 19790626 LR - 20131121 IS - 0040-7453 (Print) IS - 0040-7453 (Linking) VI - 104 IP - 8 DP - 1979 Apr 15 TI - Contribution to the aetiology of synovitis in chickens, with special reference to non-infective factors. IV. PG - suppl 90-6 AB - The comparative study reported in the present paper was undertaken to collect data on the collagen content and collagen quality of tendons showing high (low) tensile strength levels and a compact (loose) histological structure. It was shown that tendon tissues of these two groups do not differ in this regard. The effect of administering a number of mutrients (known to be essential in collagenesis) was tested during this study. Administration of these mutrients did not prevent synovitis and did not increase tensile strength. FAU - van Walsum, J AU - van Walsum J LA - eng PT - Journal Article PL - Netherlands TA - Tijdschr Diergeneeskd JT - Tijdschrift voor diergeneeskunde JID - 0031550 RN - 0 (Glycosaminoglycans) RN - 0 (Mucoproteins) RN - 1406-18-4 (Vitamin E) RN - 789U1901C5 (Copper) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) RN - TE7660XO1C (Glycine) SB - IM MH - Animals MH - Ascorbic Acid/metabolism MH - *Chickens MH - Collagen/biosynthesis MH - Copper/metabolism MH - Female MH - Glycine/metabolism MH - Glycosaminoglycans/metabolism MH - Male MH - Mucoproteins/metabolism MH - Poultry Diseases/*etiology MH - Stress, Physiological MH - Synovitis/etiology/*veterinary MH - Tendons/metabolism MH - Vitamin E/metabolism EDAT- 1979/04/15 00:00 MHDA- 1979/04/15 00:01 CRDT- 1979/04/15 00:00 PHST- 1979/04/15 00:00 [pubmed] PHST- 1979/04/15 00:01 [medline] PHST- 1979/04/15 00:00 [entrez] PST - ppublish SO - Tijdschr Diergeneeskd. 1979 Apr 15;104(8):suppl 90-6. PMID- 27535270 OWN - NLM STAT- MEDLINE DCOM- 20171205 LR - 20171205 IS - 0065-2598 (Print) IS - 0065-2598 (Linking) VI - 920 DP - 2016 TI - Do Dietary Factors Influence Tendon Metabolism? PG - 283-9 LID - 10.1007/978-3-319-33943-6_27 [doi] AB - There is very little direct research to conclusively prove the relevance of diet in primary tendinopathies, however it seems prudent to ask whether our current knowledge about the impact of nutrition on collagen metabolism could be useful in assessing, preventing, or treating tendinopathy. The objective of this chapter is to discuss the potential impact (negative or positive) that nutrition may have on the metabolism of tendons by summarizing the related research. The chapter briefly discusses the roles that specific vitamins, amino acids, lipids, and antioxidants have in various processes of the body that may be directly or indirectly related to tenocyte metabolism. FAU - Scott, Alex AU - Scott A AD - Department of Physical Therapy, Centre for Hip Health and Mobility, University of British Columbia, Vancouver, BC, Canada. ascott@mail.ubc.ca. FAU - Nordin, Cara AU - Nordin C AD - Department of Physical Therapy, Centre for Hip Health and Mobility, University of British Columbia, Vancouver, BC, Canada. LA - eng PT - Journal Article PT - Review PL - United States TA - Adv Exp Med Biol JT - Advances in experimental medicine and biology JID - 0121103 RN - 0 (Antioxidants) RN - 0 (Vitamins) SB - IM MH - Animals MH - Antioxidants/*therapeutic use MH - *Dietary Supplements MH - Humans MH - Tendinopathy/*diet therapy/metabolism MH - Tendons/*metabolism MH - Vitamins/*therapeutic use OTO - NOTNLM OT - Amino acid OT - Antioxidant OT - Diet OT - Lipid OT - Nutrition OT - Tendinopathy OT - Tendon OT - Vitamin EDAT- 2016/08/19 06:00 MHDA- 2017/12/06 06:00 CRDT- 2016/08/19 06:00 PHST- 2016/08/19 06:00 [entrez] PHST- 2016/08/19 06:00 [pubmed] PHST- 2017/12/06 06:00 [medline] AID - 10.1007/978-3-319-33943-6_27 [doi] PST - ppublish SO - Adv Exp Med Biol. 2016;920:283-9. doi: 10.1007/978-3-319-33943-6_27. PMID- 7206820 OWN - NLM STAT- MEDLINE DCOM- 19810513 LR - 20190830 IS - 0047-6374 (Print) IS - 0047-6374 (Linking) VI - 14 IP - 3-4 DP - 1980 Nov-Dec TI - The action of vitamin E on the ageing of connective tissues in the mouse. PG - 305-16 AB - In an attempt to determine the relevance of the free radical theory of ageing to age changes discernible in connective tissue parameters, a small colony of C3H/He and LAF1 mice was set up, with sample culled at intervals throughout the lifespan to provide experimental samples. To half of the stock a dietary supplement of vitamin E, a naturally occurring antioxidant, was given at a level of 2500 mg/kg of diet. Tests were carried out on culled samples to provide data on the total collagen levels of bone and skin, on thermal shrinkage temperature and maximal degree of shrinkage of tendon fibres, and on the recovery of skin from stress. Vitamin E was found to have no effect on any of the parameters measured on C3H/He mice but to exert an influence on the parameters of LAF1 mice around the age of 10 months. This influence, however, is not regarded as being relevant to the ageing of the tissues and thus no evidence can be derived for a free-radical mechanism playing a role in the ageing of connective tissues. FAU - Blackett, A D AU - Blackett AD FAU - Hall, D A AU - Hall DA LA - eng PT - Comparative Study PT - Journal Article PL - Ireland TA - Mech Ageing Dev JT - Mechanisms of ageing and development JID - 0347227 RN - 1406-18-4 (Vitamin E) SB - IM MH - Aging MH - Animals MH - Connective Tissue/drug effects/*physiology MH - Growth MH - Mice MH - Mice, Inbred Strains MH - Skin/drug effects/growth & development MH - Species Specificity MH - Stress, Mechanical MH - Tendons/drug effects/growth & development MH - Vitamin E/*pharmacology EDAT- 1980/11/01 00:00 MHDA- 1980/11/01 00:01 CRDT- 1980/11/01 00:00 PHST- 1980/11/01 00:00 [pubmed] PHST- 1980/11/01 00:01 [medline] PHST- 1980/11/01 00:00 [entrez] AID - 0047-6374(80)90004-4 [pii] AID - 10.1016/0047-6374(80)90004-4 [doi] PST - ppublish SO - Mech Ageing Dev. 1980 Nov-Dec;14(3-4):305-16. doi: 10.1016/0047-6374(80)90004-4. PMID- 24063715 OWN - NLM STAT- MEDLINE DCOM- 20160411 LR - 20220331 IS - 1603-6824 (Electronic) IS - 0041-5782 (Linking) VI - 175 IP - 39 DP - 2013 Sep 23 TI - [Bilateral rupture of the Achilles tendons after treatment with ciprofloxacin]. PG - 2264-5 AB - We report a case of spontaneous non-traumatic bilateral rupture of the Achilles tendons following ciprofloxacin treatment. A 54-year-old man presented with spontaneous Achilles tendon rupture on the left side, tendinitis and partial tear on the right side following few days of treatment with ciprofloxacin 500 mg twice daily and long-term treatment with prednisolon 10 mg once daily. This rare side effect caused by concurrent treatment with steroids and ciprofloxacin should be kept in mind. Any signs of tendinitis following this treatment should arouse the physicians' suspicion towards ciprofloxacin. FAU - Attarzadeh, Amir Pasha AU - Attarzadeh AP AD - Ortopædkirurgisk Afdeling, Herlev Hospital. pasha.attarzadeh@gmail.com FAU - Ryge, Camilla AU - Ryge C LA - dan PT - Case Reports PT - Journal Article TT - Bilateral akillesseneruptur efter behandling med ciprofloxacin. PL - Denmark TA - Ugeskr Laeger JT - Ugeskrift for laeger JID - 0141730 RN - 0 (Anti-Infective Agents) RN - 0 (Glucocorticoids) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Achilles Tendon/diagnostic imaging/*injuries MH - Anti-Infective Agents/administration & dosage/*adverse effects/therapeutic use MH - Ciprofloxacin/administration & dosage/*adverse effects/therapeutic use MH - Drug Therapy, Combination/*adverse effects MH - Glucocorticoids/administration & dosage/adverse effects/therapeutic use MH - Humans MH - Male MH - Middle Aged MH - Prednisolone/administration & dosage/adverse effects/therapeutic use MH - Rupture/*chemically induced/diagnostic imaging/therapy MH - Tendinopathy/chemically induced/diagnostic imaging/therapy MH - Treatment Outcome MH - Ultrasonography EDAT- 2013/09/26 06:00 MHDA- 2016/04/12 06:00 CRDT- 2013/09/26 06:00 PHST- 2013/09/26 06:00 [entrez] PHST- 2013/09/26 06:00 [pubmed] PHST- 2016/04/12 06:00 [medline] AID - VP08120501 [pii] PST - ppublish SO - Ugeskr Laeger. 2013 Sep 23;175(39):2264-5. PMID- 2003780 OWN - NLM STAT- MEDLINE DCOM- 19910415 LR - 20190704 IS - 0003-9950 (Print) IS - 0003-9950 (Linking) VI - 109 IP - 3 DP - 1991 Mar TI - Ascorbic acid is cytotoxic to dividing human tenon's capsule fibroblasts: a possible contributing factor in glaucoma filtration surgery success. PG - 318-9 FAU - Shin, D H AU - Shin DH FAU - Juzych, M S AU - Juzych MS FAU - Oh, Y H AU - Oh YH FAU - Ramocki, J M AU - Ramocki JM LA - eng PT - Comment PT - Letter PL - United States TA - Arch Ophthalmol JT - Archives of ophthalmology (Chicago, Ill. : 1960) JID - 7706534 RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM CON - Arch Ophthalmol. 1990 Sep;108(9):1323-5. doi: 10.1001/archopht.1990.01070110139038. PMID: 2095758 MH - Ascorbic Acid/*metabolism MH - Cell Division MH - Fibroblasts/cytology MH - Glaucoma/metabolism/*surgery MH - Humans MH - Prognosis MH - Tendons/*metabolism MH - *Trabeculectomy EDAT- 1991/03/01 00:00 MHDA- 1991/03/01 00:01 CRDT- 1991/03/01 00:00 PHST- 1991/03/01 00:00 [pubmed] PHST- 1991/03/01 00:01 [medline] PHST- 1991/03/01 00:00 [entrez] AID - 10.1001/archopht.1991.01080030020012 [doi] PST - ppublish SO - Arch Ophthalmol. 1991 Mar;109(3):318-9. doi: 10.1001/archopht.1991.01080030020012. PMID- 19127169 OWN - NLM STAT- MEDLINE DCOM- 20090319 LR - 20211020 IS - 1081-5589 (Print) IS - 1708-8267 (Electronic) IS - 1081-5589 (Linking) VI - 57 IP - 2 DP - 2009 Feb TI - Advanced glycation end products increase transglutaminase activity in primary porcine tenocytes. PG - 460-6 LID - 10.2310/JIM.0b013e3181954ac6 [doi] AB - OBJECTIVES: Tendon abnormalities, such as increased stiffness, thickness, and excess calcification, occur commonly in patients with diabetes mellitus and cause considerable disability. These changes are frequently attributed to increased cross-linking of extracellular matrix components by advanced glycation end-products (AGEs). However, cellular effects of AGEs, such as increased activity of the cross-linking transglutaminase (Tgase) enzymes, could also contribute to altered tissue biomechanics and calcification in diabetic tendons. We determined the effect of AGE-modified protein on tenocyte Tgase activity. RESEARCH DESIGN AND METHODS: Primary porcine tenocytes were exposed to N- carboxymethyl-lysine (CML)-modified type I collagen in high or normal glucose media. Protein and mRNA levels of the Tgase enzymes and Tgase activity levels were measured, as were markers of apoptosis. We also determined the effect of antioxidants on CML-collagen mediated Tgase activity. RESULTS: Carboxymethyl-lysine-collagen increased Tgase activity in tenocytes 2.3- to 5.6-fold over unmodified collagen controls in both normal and high glucose media, without altering enzyme protein levels. Anti-oxidant treatment reduced the effect of CML-collagen on Tgase activity. Deoxyribonucleic acid laddering and annexin V protein levels were not altered by CML-collagen exposure. CONCLUSIONS: Carboxymethyl-lysine-collagen increased Tgase activity in tenocytes, likely posttranslationally. Increased levels of Tgase-mediated cross-links may contribute to the excess calcification and biomechanical pathology seen in diabetic tendons. FAU - Rosenthal, Ann K AU - Rosenthal AK AD - Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, USA. akrose@mcw.edu FAU - Gohr, Claudia M AU - Gohr CM FAU - Mitton, Elizabeth AU - Mitton E FAU - Monnier, Vincent AU - Monnier V FAU - Burner, Todd AU - Burner T LA - eng GR - R01 AG015337/AG/NIA NIH HHS/United States PT - Journal Article PL - England TA - J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research JID - 9501229 RN - 0 (Antioxidants) RN - 0 (Glycation End Products, Advanced) RN - 0 (RNA, Messenger) RN - 0 (Tetrazolium Salts) RN - 0 (Thiazoles) RN - 70YDX3Z2O7 (N(6)-carboxymethyllysine) RN - EC 2.3.2.13 (Transglutaminases) RN - EUY85H477I (thiazolyl blue) RN - K3Z4F929H6 (Lysine) SB - IM MH - Animals MH - Antioxidants/pharmacology MH - Apoptosis/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - Gene Expression Regulation, Enzymologic/drug effects MH - Glycation End Products, Advanced/*metabolism MH - Lysine/analogs & derivatives/pharmacology MH - RNA, Messenger/metabolism MH - Stifle/metabolism MH - Swine MH - Tendons/drug effects/*enzymology MH - Tetrazolium Salts/metabolism MH - Thiazoles/metabolism MH - Transglutaminases/genetics/*metabolism PMC - PMC6240446 MID - NIHMS995607 EDAT- 2009/01/08 09:00 MHDA- 2009/03/20 09:00 PMCR- 2018/11/18 CRDT- 2009/01/08 09:00 PHST- 2009/01/08 09:00 [entrez] PHST- 2009/01/08 09:00 [pubmed] PHST- 2009/03/20 09:00 [medline] PHST- 2018/11/18 00:00 [pmc-release] AID - 10.2310/JIM.0b013e3181954ac6 [doi] PST - ppublish SO - J Investig Med. 2009 Feb;57(2):460-6. doi: 10.2310/JIM.0b013e3181954ac6. PMID- 5552831 OWN - NLM STAT- MEDLINE DCOM- 19710604 LR - 20190829 IS - 0008-4018 (Print) IS - 0008-4018 (Linking) VI - 49 IP - 4 DP - 1971 Apr TI - Comparative uptake of selenium by low cystine and high cystine proteins. PG - 468-72 FAU - Jenkins, K J AU - Jenkins KJ FAU - Hidiroglou, M AU - Hidiroglou M LA - eng PT - Journal Article PL - Canada TA - Can J Biochem JT - Canadian journal of biochemistry JID - 0421034 RN - 0 (Albumins) RN - 0 (Caseins) RN - 0 (Histones) RN - 0 (Lactoglobulins) RN - 0 (Radioisotopes) RN - 0 (Sulfides) RN - 48TCX9A1VT (Cystine) RN - 68238-35-7 (Keratins) RN - 9000-70-8 (Gelatin) RN - 9007-34-5 (Collagen) RN - H6241UJ22B (Selenium) RN - K848JZ4886 (Cysteine) SB - IM MH - Albumins/metabolism MH - Animals MH - Caseins/metabolism MH - Cattle MH - Chickens MH - Collagen/*metabolism MH - Cysteine/metabolism MH - Cystine/*metabolism MH - Feathers/metabolism MH - Female MH - Gelatin/*metabolism MH - Guinea Pigs MH - Hair/metabolism MH - Histones/*metabolism MH - Keratins/metabolism MH - Lactoglobulins/metabolism MH - Male MH - Radioisotopes MH - Selenium/*metabolism MH - Sheep MH - Skin/metabolism MH - Sulfides/biosynthesis MH - Tendons/metabolism MH - Thymus Gland/metabolism EDAT- 1971/04/01 00:00 MHDA- 1971/04/01 00:01 CRDT- 1971/04/01 00:00 PHST- 1971/04/01 00:00 [pubmed] PHST- 1971/04/01 00:01 [medline] PHST- 1971/04/01 00:00 [entrez] AID - 10.1139/o71-069 [doi] PST - ppublish SO - Can J Biochem. 1971 Apr;49(4):468-72. doi: 10.1139/o71-069. PMID- 6627794 OWN - NLM STAT- MEDLINE DCOM- 19831217 LR - 20131121 IS - 0009-921X (Print) IS - 0009-921X (Linking) IP - 180 DP - 1983 Nov TI - Mechanical and functional properties of implanted freeze-dried flexor tendons. PG - 301-9 AB - Tendons harvested from donor dogs were freeze-dried and implanted as free allografts in the paws of recipient experimental animals; the tendons were subsequently tested for mechanical properties, clinical function, and histologic appearance. Free tendon autografts, normal tendons in the operated experimental paw, and normal tendons in the unoperated paw were used as controls and compared with the allografts. Mechanically, the free tendon allografts and autografts were similar. The ultimate strength of the two grafts was statistically the same but significantly less, about one-third, than that of normal tendons. The implanted allografts appeared to be tolerated well by the host and to allow flexor tendon function similar to that allowed by autografts. The histologic appearance of the allograft and autograft tendons was similar at three and six months. Freeze-dried flexor tendon allografting is a satisfactory alternative to free tendon autografting. FAU - Webster, D A AU - Webster DA FAU - Werner, F W AU - Werner FW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Gentamicins) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Dogs MH - Freeze Drying MH - Gentamicins/pharmacology MH - Movement MH - Tendons/anatomy & histology/physiology/*transplantation MH - Tissue Preservation/*methods EDAT- 1983/11/01 00:00 MHDA- 1983/11/01 00:01 CRDT- 1983/11/01 00:00 PHST- 1983/11/01 00:00 [pubmed] PHST- 1983/11/01 00:01 [medline] PHST- 1983/11/01 00:00 [entrez] PST - ppublish SO - Clin Orthop Relat Res. 1983 Nov;(180):301-9. PMID- 36553476 OWN - NLM STAT- MEDLINE DCOM- 20221226 LR - 20230110 IS - 2073-4425 (Electronic) IS - 2073-4425 (Linking) VI - 13 IP - 12 DP - 2022 Nov 25 TI - Short-Term Exposure to Ciprofloxacin Reduces Proteoglycan Loss in Tendon Explants. LID - 10.3390/genes13122210 [doi] LID - 2210 AB - Fluoroquinolone antibiotics are associated with increased risk of tendinopathy and tendon rupture, which can occur well after cessation of treatment. We have previously reported that the fluoroquinolone ciprofloxacin (CPX) reduced proteoglycan synthesis in equine tendon explants. This study aimed to determine the effects of CPX on proteoglycan catabolism and whether any observed effects are reversible. Equine superficial digital flexor tendon explant cultures were treated for 4 days with 1, 10, 100 or 300 µg/mL CPX followed by 8 days without CPX. The loss of [(35)S]-labelled proteoglycans and chemical pool of aggrecan and versican was studied as well as the gene expression levels of matrix-degrading enzymes responsible for proteoglycan catabolism. CPX suppressed [(35)S]-labelled proteoglycan and total aggrecan loss from the explants, although not in a dose-dependent manner, which coincided with downregulation of mRNA expression of MMP-9, -13, ADAMTS-4, -5. The suppressed loss of proteoglycans was reversed upon removal of the fluoroquinolone with concurrent recovery of MMP and ADAMTS mRNA expression, and downregulated TIMP-2 and upregulated TIMP-1 expression. No changes in MMP-3 expression by CPX was observed at any stage. These findings suggest that CPX suppresses proteoglycan catabolism in tendon, and this is partially attributable to downregulation of matrix-degrading enzymes. FAU - James, Stuart AU - James S AUID- ORCID: 0000-0001-7320-1856 AD - Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University, Melbourne, VIC 3086, Australia. FAU - Daffy, John AU - Daffy J AD - Department of Infectious Diseases, St Vincent's Hospital, Melbourne, VIC 3065, Australia. FAU - Cook, Jill AU - Cook J AD - Sports and Exercise Medicine Research Centre, La Trobe University, Melbourne, VIC 3086, Australia. FAU - Samiric, Tom AU - Samiric T AD - Department of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University, Melbourne, VIC 3086, Australia. LA - eng PT - Journal Article DEP - 20221125 PL - Switzerland TA - Genes (Basel) JT - Genes JID - 101551097 RN - 0 (Aggrecans) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 0 (Fluoroquinolones) RN - 126968-45-4 (Versicans) RN - 0 (RNA, Messenger) SB - IM MH - Animals MH - Horses MH - Aggrecans/metabolism MH - *Ciprofloxacin/pharmacology MH - *Tendons/metabolism MH - Fluoroquinolones MH - Versicans/metabolism MH - RNA, Messenger/metabolism PMC - PMC9777606 OTO - NOTNLM OT - ciprofloxacin OT - equine OT - fluoroquinolones OT - proteoglycans OT - recovery OT - tendinopathy COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/27 06:00 PMCR- 2022/11/25 CRDT- 2022/12/23 01:21 PHST- 2022/10/03 00:00 [received] PHST- 2022/11/22 00:00 [revised] PHST- 2022/11/24 00:00 [accepted] PHST- 2022/12/23 01:21 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/27 06:00 [medline] PHST- 2022/11/25 00:00 [pmc-release] AID - genes13122210 [pii] AID - genes-13-02210 [pii] AID - 10.3390/genes13122210 [doi] PST - epublish SO - Genes (Basel). 2022 Nov 25;13(12):2210. doi: 10.3390/genes13122210. PMID- 26537954 OWN - NLM STAT- MEDLINE DCOM- 20170125 LR - 20170125 IS - 1460-2393 (Electronic) IS - 1460-2393 (Linking) VI - 109 IP - 4 DP - 2016 Apr TI - Achilles is not alone!!! Ciprofloxacin induced tendinopathy of gluteal tendons. PG - 275-6 LID - 10.1093/qjmed/hcv203 [doi] FAU - Goyal, H AU - Goyal H AD - From the Mercer University School of Medicine, 707, Pine St, Macon, GA 31201, USA doc.hemant@yahoo.com. FAU - Dennehy, J AU - Dennehy J AD - From the Mercer University School of Medicine, 707, Pine St, Macon, GA 31201, USA. FAU - Barker, J AU - Barker J AD - From the Mercer University School of Medicine, 707, Pine St, Macon, GA 31201, USA. FAU - Singla, U AU - Singla U AD - From the Mercer University School of Medicine, 707, Pine St, Macon, GA 31201, USA. LA - eng PT - Case Reports PT - Journal Article DEP - 20151104 PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 RN - 0 (Anti-Bacterial Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Aged MH - Anti-Bacterial Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Diabetes Mellitus, Type 2 MH - Hip/physiopathology MH - Humans MH - Kidney Failure, Chronic MH - Magnetic Resonance Imaging MH - Male MH - Tendinopathy/*chemically induced/*diagnostic imaging EDAT- 2015/11/06 06:00 MHDA- 2017/01/26 06:00 CRDT- 2015/11/06 06:00 PHST- 2015/11/06 06:00 [entrez] PHST- 2015/11/06 06:00 [pubmed] PHST- 2017/01/26 06:00 [medline] AID - hcv203 [pii] AID - 10.1093/qjmed/hcv203 [doi] PST - ppublish SO - QJM. 2016 Apr;109(4):275-6. doi: 10.1093/qjmed/hcv203. Epub 2015 Nov 4. PMID- 7150716 OWN - NLM STAT- MEDLINE DCOM- 19830311 LR - 20191023 IS - 0006-355X (Print) IS - 0006-355X (Linking) VI - 19 IP - 5 DP - 1982 TI - The biochemical properties of tendon and skin as influenced by long term glucocorticoid treatment and food restriction. PG - 631-46 AB - The influence of long term systemic glucocorticoid treatment and food restriction on the mechanical properties of muscle tendons and skin was investigated. A group of male, albino rabbits received prednisolone intramuscularly for 63 days. Another group was food restricted to achieve the same weight loss as the prednisolone treated group. The untreated control group had free access to food and water. Peroneus tertius and longus tendons and strip specimens of lumbal skin were tested in a materials testing machine. Long term prednisolone treatment reduced the dry weights of the muscle tendons, with no change in collagen content and "stress"-strain parameters. The elastic stiffness measured after exhaustion of the viscosity in the tendons was found to be increased. The collagen content of skin was reduced, which resulted in a weakening of the skin as such. However, the extensibility of the skin strips was reduced and the maximum "stress" value, i.e. load value normalized to collagen content, was increased. The food restriction did not change the mechanical properties of muscle tendons. For skin the collagen content was reduced and so were the maximum load and "stress" values after food restriction. It is concluded that both long term glucocorticoid treatment and food restriction reduce the amount of collagen and strength of skin, consistent with clinical experiences. However, in long term glucocorticoid treatment the remaining collagen has increased stability, probably caused by a changed cross-linking pattern, in contrast to a reduced stability of skin collagen in food restriction. Skin is thus influenced more easily than muscle tendon. FAU - Oxlund, H AU - Oxlund H FAU - Manthorpe, R AU - Manthorpe R LA - eng PT - Journal Article PL - United States TA - Biorheology JT - Biorheology JID - 0372526 RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/analysis MH - Elasticity MH - Food Deprivation/*physiology MH - Male MH - Prednisolone/*pharmacology MH - Rabbits MH - Skin/analysis/drug effects MH - *Skin Physiological Phenomena MH - Stress, Mechanical MH - Tendons/analysis/drug effects/*physiology EDAT- 1982/01/01 00:00 MHDA- 1982/01/01 00:01 CRDT- 1982/01/01 00:00 PHST- 1982/01/01 00:00 [pubmed] PHST- 1982/01/01 00:01 [medline] PHST- 1982/01/01 00:00 [entrez] AID - 10.3233/bir-1982-19505 [doi] PST - ppublish SO - Biorheology. 1982;19(5):631-46. doi: 10.3233/bir-1982-19505. PMID- 5511206 OWN - NLM STAT- MEDLINE DCOM- 19710615 LR - 20131121 IS - 0005-8149 (Print) IS - 0005-8149 (Linking) VI - 17 IP - 1 DP - 1970 Jan TI - [The effect of prednisolone on the physical behavior of tendon tissue]. PG - 60-2 FAU - Jaster, D AU - Jaster D LA - ger PT - Journal Article TT - Der Einfluss von Prednisolon auf das physikalische Verhalten von Sehnengewebe. PL - Germany TA - Beitr Orthop Traumatol JT - Beitrage zur Orthopadie und Traumatologie JID - 0372503 RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Animals MH - *Elasticity MH - Injections, Intramuscular MH - Prednisolone/administration & dosage/*pharmacology MH - Rabbits MH - Tendon Injuries/drug therapy MH - Tendons/*drug effects/physiology EDAT- 1970/01/01 00:00 MHDA- 1970/01/01 00:01 CRDT- 1970/01/01 00:00 PHST- 1970/01/01 00:00 [pubmed] PHST- 1970/01/01 00:01 [medline] PHST- 1970/01/01 00:00 [entrez] PST - ppublish SO - Beitr Orthop Traumatol. 1970 Jan;17(1):60-2. PMID- 13598058 OWN - NLM STAT- MEDLINE DCOM- 20000701 LR - 20191107 IS - 0016-898X (Print) IS - 0016-898X (Linking) VI - 2 IP - 2 DP - 1958 TI - Thermic-contraction of single tendon fibres from animals of different age after treatment with formaldehyde, urethane, glycerol, acetic acid and other substances. PG - 81-103 FAU - VERZAR, F AU - VERZAR F FAU - HUBER, K AU - HUBER K LA - eng PT - Journal Article PL - Switzerland TA - Gerontologia JT - Gerontologia JID - 7601654 RN - 0 (Acetates) RN - 0 (Laxatives) RN - 1HG84L3525 (Formaldehyde) RN - 3IN71E75Z5 (Urethane) RN - PDC6A3C0OX (Glycerol) RN - Q40Q9N063P (Acetic Acid) SB - OM MH - *Acetates MH - *Acetic Acid MH - Animals MH - *Formaldehyde MH - *Glycerol MH - *Hot Temperature MH - *Laxatives MH - Tendons/*physiology MH - *Urethane OID - CLML: 5935:27566:575 OTO - NLM OT - *TENDONS/physiology EDAT- 1958/01/01 00:00 MHDA- 1958/01/01 00:01 CRDT- 1958/01/01 00:00 PHST- 1958/01/01 00:00 [pubmed] PHST- 1958/01/01 00:01 [medline] PHST- 1958/01/01 00:00 [entrez] AID - 10.1159/000210728 [doi] PST - ppublish SO - Gerontologia. 1958;2(2):81-103. doi: 10.1159/000210728. PMID- 10843129 OWN - NLM STAT- MEDLINE DCOM- 20001005 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 28 IP - 3 DP - 2000 May-Jun TI - The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. PG - 364-9 AB - The pathologic mechanisms underlying fluoroquinolone-induced tendinopathy are poorly understood. The observed incidence of tendinitis and tendon rupture in patients treated with ciprofloxacin hydrochloride suggests that the fluoroquinolone antibiotics alter tendon fibroblast metabolism. The purpose of this study was to examine the effect of ciprofloxacin on fibroblast metabolism in vitro. Canine Achilles tendon, paratenon, and shoulder capsule specimens were maintained in culture with ciprofloxacin (5, 10, or 50 microg/ml). Fibroblast proliferation, collagen synthesis, proteoglycan synthesis, and matrix-degrading activity were analyzed. Incubation of Achilles tendon, Achilles paratenon, and shoulder capsule fibroblasts with ciprofloxacin resulted in a statistically significant 66% to 68% decrease in cell proliferation compared with control cells at day 3 in culture. Ciprofloxacin caused a statistically significant 36% to 48% decrease in collagen synthesis compared with controls in all fibroblast cultures. Ciprofloxacin caused a statistically significant 14% to 60% decrease in proteoglycan synthesis in all fibroblast cell lines. Compared with unstimulated control fibroblasts, culture media from Achilles tendon, paratenon, and shoulder capsule cells that were exposed to ciprofloxacin demonstrated statistically significant increases in matrix-degrading proteolytic activity after 72 hours in culture. This study demonstrates that ciprofloxacin stimulates matrix-degrading protease activity from fibroblasts and that it exerts an inhibitory effect on fibroblast metabolism. The increase in protease activity and the inhibition of both cell proliferation and the synthesis of matrix ground substance may contribute to the clinically described tendinopathies associated with ciprofloxacin therapy. FAU - Williams, R J 3rd AU - Williams RJ 3rd AD - Laboratory for Soft Tissue Research, Sports Medicine & Shoulder Service, Hospital for Special Surgery, New York, New York, USA. FAU - Attia, E AU - Attia E FAU - Wickiewicz, T L AU - Wickiewicz TL FAU - Hannafin, J A AU - Hannafin JA LA - eng PT - Journal Article PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Infective Agents) RN - 0 (Proteoglycans) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 9007-34-5 (Collagen) SB - IM CIN - Am J Sports Med. 2001 Mar-Apr;29(2):262-3. doi: 10.1177/03635465010290022701. PMID: 11292056 MH - Achilles Tendon/metabolism MH - Animals MH - Anti-Infective Agents/*pharmacology/toxicity MH - Cell Culture Techniques MH - Ciprofloxacin/*pharmacology/toxicity MH - Collagen/metabolism MH - Dogs MH - Extracellular Matrix/metabolism MH - Fibroblasts/drug effects/*metabolism MH - Proteoglycans/metabolism MH - Tendons/*metabolism EDAT- 2000/06/08 09:00 MHDA- 2000/10/07 11:01 CRDT- 2000/06/08 09:00 PHST- 2000/06/08 09:00 [pubmed] PHST- 2000/10/07 11:01 [medline] PHST- 2000/06/08 09:00 [entrez] AID - 10.1177/03635465000280031401 [doi] PST - ppublish SO - Am J Sports Med. 2000 May-Jun;28(3):364-9. doi: 10.1177/03635465000280031401. PMID- 26063369 OWN - NLM STAT- MEDLINE DCOM- 20160315 LR - 20181113 IS - 2542-5641 (Electronic) IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 128 IP - 12 DP - 2015 Jun 20 TI - Biomechanical and Macroscopic Evaluations of the Effects of 5-Fluorouracil on Partially Divided Flexor Tendon Injuries in Rabbits. PG - 1655-61 LID - 10.4103/0366-6999.158367 [doi] AB - BACKGROUND: The main goals of flexor tendon surgery are to restore digital motion by providing tendon healing and to preserve tendon gliding. Our purpose was to investigate the effects of 5-fluorouracil (5-FU) on tendon adhesions in partially divided profundus flexor tendons (flexor digitorum profundus [FDPs]) following surgical repair and in partially divided FDPs without surgical repair, and to compare the results of the repair versus the nonrepair of zone two injuries via macroscopic and biomechanical evaluations of tendon adhesions. METHODS: We used 32 adult male European rabbits (Oryctolagus cunniculus) weighing from 2.5 to 3.5 kg. The study was performed on the deep flexor tendons of the second and third digits of the right hind paws of the rabbits; thus, a total of 64 tendons were examined in this study. RESULTS: Based on the results achieved in our experimental study, the load (N) significantly increased in subgroup 1a in which the tendons were surgically repaired and were not treated with 5-FU compared with subgroup 2a in which tendons were surgically repaired and treated with 5-FU. CONCLUSIONS: The load (N) significantly increased in subgroup 1a in which the tendons were surgically repaired and were not treated with 5-FU compared to subgroup 2a in which the tendons were surgically repaired and treated with 5-FU. Therefore, these results revealed a decrease in adhesion formation in the subgroup that was treated with 5-FU due to increased resistance to tendon adhesions during their excursion through the tendon sheath, which in this case required greater traction force. FAU - Duci, Shkelzen B AU - Duci SB FAU - Arifi, Hysni M AU - Arifi HM FAU - Ahmeti, Hasan R AU - Ahmeti HR AD - Department of Pediatric Surgery, University Clinical Center of Kosovo, Prishtina 10000, Kosovo. FAU - Manxhuka-Kerliu, Suzana AU - Manxhuka-Kerliu S FAU - Neziri, Burim AU - Neziri B FAU - Mekaj, Agon Y AU - Mekaj AY FAU - Lajqi, Shpetim AU - Lajqi S FAU - Shahini, Labinot AU - Shahini L LA - eng PT - Journal Article PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Fluorouracil/*therapeutic use MH - Male MH - Rabbits MH - Tendon Injuries/*drug therapy/physiopathology MH - Tendons/drug effects/pathology MH - Tissue Adhesions/drug therapy/physiopathology MH - Wound Healing/drug effects PMC - PMC4733738 COIS- Conflict of Interest: None declared. EDAT- 2015/06/13 06:00 MHDA- 2016/03/16 06:00 PMCR- 2015/06/20 CRDT- 2015/06/12 06:00 PHST- 2015/06/12 06:00 [entrez] PHST- 2015/06/13 06:00 [pubmed] PHST- 2016/03/16 06:00 [medline] PHST- 2015/06/20 00:00 [pmc-release] AID - ChinMedJ_2015_128_12_1655_158367 [pii] AID - CMJ-128-1655 [pii] AID - 10.4103/0366-6999.158367 [doi] PST - ppublish SO - Chin Med J (Engl). 2015 Jun 20;128(12):1655-61. doi: 10.4103/0366-6999.158367. PMID- 14872227 OWN - NLM STAT- MEDLINE DCOM- 20040505 LR - 20191108 IS - 0048-7449 (Print) IS - 0048-7449 (Linking) VI - 55 IP - 4 DP - 2003 Oct-Dec TI - [Levofloxacin-induced bilateral rupture of the Achilles tendon: clinical and sonographic findings]. PG - 267-9 AB - The fluoroquinolones are antibiotics widely used in the clinical practice. The concomitant use of corticosteroids and fluoroquinolones in elderly patients is recognised as a risk factor for developing clinically relevant tendon lesions. Fluoroquinolone-induced tendinopathy is underreported in the literature. A 67-year-old man, came to our observation complaining of 5 days history of bilateral heel pain. The patient had a medical history of sarcoidosis and was treated with a daily dose of 5 mg of prednisone. He was initially given oral levofloxacin (500 mg/die) for 10 days, because of an acute respiratory infection. Two days before the end of the antibiotic therapy, he developed bilateral heel pain. He denied any history of trauma. Physical examination revealed swelling and marked tenderness with mild palpation of the Achilles tendons at the calcaneal insertion. The ultrasound evaluation of the Achilles tendons revealed the following main abnormalities: diffuse thickening, loss of the "fibrillar" echotexture, blurred margins, and bilateral partial tendon tears. Bilateral Achilles tendon pain and rupture has been described as a rare adverse effect of fluoroquinolone treatment. Most of the fluoroquinolone-induced tendinopathies of the Achilles tendon are due to ciprofloxacin. To the best of our knowledge, this is the first description of bilateral Achilles tendon rupture due to levofloxacin. The risk/benefit ratio of the fluoroquinolones should be carefully considered and these drugs should be prescribed cautiously in elderly patients treated with corticosteroids. This case can be regarded as a representative example of the potential clinical efficacy of sonography in daily rheumatological practise. FAU - Filippucci, E AU - Filippucci E AD - Clinica Reumatologica--Università Politecnica delle Marche, Italia. emilio_filippucci@yahoo.it FAU - Farina, A AU - Farina A FAU - Bartolucci, F AU - Bartolucci F FAU - Spallacci, C AU - Spallacci C FAU - Busilacchi, P AU - Busilacchi P FAU - Grassi, W AU - Grassi W LA - ita PT - Case Reports PT - Journal Article TT - Tendinopatia dell'achilleo da levofloxacina: dalle immagini alla diagnosi. PL - Italy TA - Reumatismo JT - Reumatismo JID - 0401302 RN - 0 (Anti-Infective Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/diagnostic imaging/*injuries MH - Aged MH - Anti-Infective Agents/*adverse effects MH - Humans MH - *Levofloxacin MH - Male MH - Ofloxacin/*adverse effects MH - Rupture/chemically induced MH - Ultrasonography EDAT- 2004/02/12 05:00 MHDA- 2004/05/07 05:00 CRDT- 2004/02/12 05:00 PHST- 2004/02/12 05:00 [pubmed] PHST- 2004/05/07 05:00 [medline] PHST- 2004/02/12 05:00 [entrez] AID - 10.4081/reumatismo.2003.267 [doi] PST - ppublish SO - Reumatismo. 2003 Oct-Dec;55(4):267-9. doi: 10.4081/reumatismo.2003.267. PMID- 9733283 OWN - NLM STAT- MEDLINE DCOM- 19990119 LR - 20191102 IS - 0742-2091 (Print) IS - 0742-2091 (Linking) VI - 14 IP - 4 DP - 1998 Aug TI - In vitro study of cytotoxicity of quinolones on rabbit tenocytes. PG - 283-92 AB - Tendinitis and tendon rupture complicating fluoroquinolone therapy have been reported recently, especially affecting men over 60 years. These new quinolones are more potent antimicrobial agents than older nonfluorinated compounds like nalidixic acid. We compared the effects of one quinolone (nalidixic acid) and two fluoroquinolones (norfloxacin and pefloxacin) on cultured rabbit Achilles tendon cells. First, we examined their effects on cell viability, mitochondrial succinate dehydrogenase and global activity, mitochondrial activity using microtitration methods. Pefloxacin and norfloxacin were more cytotoxic than nalidixic acid according to IC50 values. These results confirm that mitochondria represent a biological target of fluoroquinolones. Moreover, the extracellular matrix was studied by molecular hybridization. After a 72 h treatment, the level of type I collagen transcripts was not modified with any of the three antimicrobial agents, whereas mRNA encoding decorin was decreased with 10(-4) mol/L pefloxacin only. The decrease of transcripts encoding decorin suggests that this matrix component is another target of pefloxacin and modification of decorin seems to be an early event (before mitochondrion alteration) which may contribute to the explanation of tendon rupture. FAU - Bernard-Beaubois, K AU - Bernard-Beaubois K AD - Laboratoire de Pharmacologie Cellulaire de l'Ecole Pratique des Hautes Etudes, Centre de Recherches Biomédicales des Cordeliers, Paris, France. FAU - Hecquet, C AU - Hecquet C FAU - Hayem, G AU - Hayem G FAU - Rat, P AU - Rat P FAU - Adolphe, M AU - Adolphe M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - Cell Biol Toxicol JT - Cell biology and toxicology JID - 8506639 RN - 0 (Anti-Infective Agents) RN - 0 (Dcn protein, rat) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Proteoglycans) RN - 2H52Z9F2Q5 (Pefloxacin) RN - 3B91HWA56M (Nalidixic Acid) RN - 9007-34-5 (Collagen) RN - EC 1.3.99.1 (Succinate Dehydrogenase) RN - N0F8P22L1P (Norfloxacin) SB - IM MH - Animals MH - Anti-Infective Agents/*pharmacology MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/biosynthesis/genetics MH - Decorin MH - Extracellular Matrix Proteins MH - Mitochondria/drug effects MH - Nalidixic Acid/*pharmacology MH - Norfloxacin/*pharmacology MH - Pefloxacin/*pharmacology MH - Proteoglycans/biosynthesis/genetics MH - Rabbits MH - Succinate Dehydrogenase/drug effects MH - Tendons/cytology EDAT- 1998/09/11 00:00 MHDA- 1998/09/11 00:01 CRDT- 1998/09/11 00:00 PHST- 1998/09/11 00:00 [pubmed] PHST- 1998/09/11 00:01 [medline] PHST- 1998/09/11 00:00 [entrez] AID - 10.1023/a:1007435025616 [doi] PST - ppublish SO - Cell Biol Toxicol. 1998 Aug;14(4):283-92. doi: 10.1023/a:1007435025616. PMID- 4751782 OWN - NLM STAT- MEDLINE DCOM- 19740115 LR - 20250214 IS - 0003-4967 (Print) IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 32 IP - 5 DP - 1973 Sep TI - Rupture of the extensor tendons of the hand in lupus erythematosus disseminatus. PG - 457-9 FAU - Lotem, M AU - Lotem M FAU - Maor, P AU - Maor P FAU - Levi, M AU - Levi M LA - eng PT - Journal Article PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - VB0R961HZT (Prednisone) SB - IM MH - Hand MH - Humans MH - Lupus Erythematosus, Systemic/*complications/drug therapy MH - Male MH - Middle Aged MH - Prednisone/therapeutic use MH - Rupture, Spontaneous/complications/pathology/surgery MH - Synovial Membrane/pathology MH - *Tendons/pathology/surgery PMC - PMC1006145 EDAT- 1973/09/01 00:00 MHDA- 1973/09/01 00:01 PMCR- 1976/09/01 CRDT- 1973/09/01 00:00 PHST- 1973/09/01 00:00 [pubmed] PHST- 1973/09/01 00:01 [medline] PHST- 1973/09/01 00:00 [entrez] PHST- 1976/09/01 00:00 [pmc-release] AID - S0003-4967(24)41314-9 [pii] AID - 10.1136/ard.32.5.457 [doi] PST - ppublish SO - Ann Rheum Dis. 1973 Sep;32(5):457-9. doi: 10.1136/ard.32.5.457. PMID- 4220986 OWN - NLM STAT- MEDLINE DCOM- 19660115 LR - 20141120 IS - 0065-1281 (Print) IS - 0065-1281 (Linking) VI - 20 IP - 1 DP - 1965 Mar 31 TI - [Studies on collagen fibers. V. On changes due to aging in connective tissue. (Comparative chemical and morphological studies]. PG - 65-81 FAU - Németh-Csóka, M AU - Németh-Csóka M LA - ger PT - Journal Article TT - Untersuchungen über die Kollagenfasern. V. Uber die durch das Alternbedingten Veränderungen im Bindegewebe. (Vergleichende chemisch-morphologischeUntersuchungen). PL - Germany TA - Acta Histochem JT - Acta histochemica JID - 0370320 RN - 0 (Glycosaminoglycans) RN - 0 (Hexosamines) RN - 0 (Hexoses) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Achilles Tendon/anatomy & histology MH - Adolescent MH - Adult MH - Aged MH - *Aging MH - Aorta/anatomy & histology MH - *Ascorbic Acid MH - Cartilage/anatomy & histology MH - Chemical Phenomena MH - Chemistry MH - Child MH - Child, Preschool MH - *Collagen MH - Connective Tissue/*anatomy & histology MH - *Glycosaminoglycans MH - *Hexosamines MH - *Hexoses MH - Humans MH - *Hydroxyproline MH - In Vitro Techniques MH - Infant MH - Infant, Newborn MH - Middle Aged MH - Skin/anatomy & histology MH - Tendons/anatomy & histology EDAT- 1965/03/31 00:00 MHDA- 1965/03/31 00:01 CRDT- 1965/03/31 00:00 PHST- 1965/03/31 00:00 [pubmed] PHST- 1965/03/31 00:01 [medline] PHST- 1965/03/31 00:00 [entrez] PST - ppublish SO - Acta Histochem. 1965 Mar 31;20(1):65-81. PMID- 16532832 OWN - NLM STAT- MEDLINE DCOM- 20090428 LR - 20131121 IS - 1001-5515 (Print) IS - 1001-5515 (Linking) VI - 23 IP - 1 DP - 2006 Feb TI - [Experimental study on cryopreservation of seeding cells of tissue engineered tendons]. PG - 159-65 AB - This study sought to find out a good way for the cryopreservation of tendon seeding cells so as to facilitate the preparation of tissue engineering tendons as products. The related questions are how different factors affect cell survival rate at the procedure of preservation and whether cryopreservation affects seeding cells' biological characters as well as collagen secretive function. The results of experiment indicate that DMSO is a more effective cryoprotectant in cryopreservation of tissue engineered tendon seeding cells. Blood serum nourishment is very important in cell culture, preservation and treatment. The same sustenance after cryopreservation increases cell survival rate. In the process of cryopreservation, the concentration of cells is important to cell survival rate; cell survival rate will decrease when it is less than 1.0 x 10(6)/ml. In the process of cryopreservation, the cooling speed is also important to cell survival rate, slow cooling method achieves higher cell survival rate than does the rapid cooling method. Cryopreservation by use of 10%DMSO+15%FCS+75%DMEM does not affect seeding cells' collagen secretive function greatly and does not affect seeding cells' growth curve, cell cycle and chromosome mode obviously. The prescription of 10%DMSO +15%FCS+75%DMEM is suited for the cryopreservation of tendon seeding cells. FAU - Zhu, Xiaoqi AU - Zhu X AD - Division of Stem Cell and Tissue Engineering, Key Laboratory of Biotherapy of Human Diseases, Educational Ministry P.R. China. FAU - Yang, Zhiming AU - Yang Z FAU - Xie, Huiqi AU - Xie H FAU - Qin, Tingwu AU - Qin T LA - chi PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi JT - Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi JID - 9426398 RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Cell Count MH - Cell Survival MH - Cryopreservation/*methods MH - Dimethyl Sulfoxide MH - Humans MH - Muscle, Skeletal/cytology MH - Tendons/*cytology MH - *Tissue Engineering MH - Tissue Preservation/methods EDAT- 2006/03/15 09:00 MHDA- 2009/04/29 09:00 CRDT- 2006/03/15 09:00 PHST- 2006/03/15 09:00 [pubmed] PHST- 2009/04/29 09:00 [medline] PHST- 2006/03/15 09:00 [entrez] PST - ppublish SO - Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2006 Feb;23(1):159-65. PMID- 9915176 OWN - NLM STAT- MEDLINE DCOM- 19990203 LR - 20190713 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 103 IP - 1 DP - 1999 Jan TI - Decrease in adhesion formation by a single application of 5-fluorouracil after flexor tendon injury. PG - 151-8 AB - Using an animal model, the effect of a single intraoperative application of 5-fluorouracil on digital flexor tendon adhesions was assessed. After a standard partial division of the tendon and immobilization with a stitch, the synovial sheath in 30 rabbit tendons was treated with 5-fluorouracil solution (50 mg/ml)-soaked sponge pledgets for 5 minutes. Buffered saline was substituted for 5-fluorouracil in 30 control tendons. The tendons were harvested 1 week postoperatively, and histologic sections were assessed with a light microscope. There was a significant reduction in synovial sheath thickening (p < 0.001), cell counts (p < 0.001) and proportional length of adhesions (p < 0.001) in the treated tendons. The reduction in synovial reaction and adhesion formation using this "one touch" technique presents a novel strategy for the management of the clinical problem of postoperative adhesions complicating tendon injury and repair. FAU - Akali, A AU - Akali A AD - Division of Plastic and Reconstructive Surgery, University College, London, England. FAU - Khan, U AU - Khan U FAU - Khaw, P T AU - Khaw PT FAU - McGrouther, A D AU - McGrouther AD LA - eng PT - Journal Article PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Antimetabolites) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Antimetabolites/*administration & dosage MH - Fluorouracil/*administration & dosage MH - Foot MH - Hindlimb MH - Male MH - Postoperative Complications/prevention & control MH - Rabbits MH - Tendon Injuries/surgery MH - Tendons/pathology/*surgery MH - Tissue Adhesions/etiology/prevention & control EDAT- 1999/01/23 00:00 MHDA- 1999/01/23 00:01 CRDT- 1999/01/23 00:00 PHST- 1999/01/23 00:00 [pubmed] PHST- 1999/01/23 00:01 [medline] PHST- 1999/01/23 00:00 [entrez] AID - 10.1097/00006534-199901000-00024 [doi] PST - ppublish SO - Plast Reconstr Surg. 1999 Jan;103(1):151-8. doi: 10.1097/00006534-199901000-00024. PMID- 2471413 OWN - NLM STAT- MEDLINE DCOM- 19890705 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 17 IP - 3 DP - 1989 May-Jun TI - Effects of fibrin sealant on incorporation of autograft and xenograft tendons within bone tunnels. A preliminary study. PG - 318-24 AB - The anterior and posterior tibialis tendons in both hindlimbs of six adult dogs were rerouted through extraarticular bone holes created in the distal tibial metaphysis. Xenograft tendons of comparable dimensions were used in an additional six dogs. Fibrin Sealant System (FSS) was applied to the bone tendon interface in the right legs, whereas the left legs were used as controls. The animals were sacrificed at 5, 9, and 28 days. Coronal sections of the distal tibias were studied histologically and microangiographically. The autogenous tendons appeared to incorporate by means of fibrous ingrowth, whereas spicules of new bone in direct opposition to the xenografts were observed at 28 days. FSS promoted organization and maturation of fibrous connective tissue surrounding both implants at early sacrifice but did not appreciably alter incorporation at 28 days. FAU - Shoemaker, S C AU - Shoemaker SC AD - Division of Orthopaedic Surgery, University of California, Los Angeles. FAU - Rechl, H AU - Rechl H FAU - Campbell, P AU - Campbell P FAU - Kram, H B AU - Kram HB FAU - Sanchez, M AU - Sanchez M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Drug Combinations) RN - 0 (Fibrin Tissue Adhesive) RN - 9001-32-5 (Fibrinogen) RN - 9013-56-3 (Factor XIII) RN - 9087-70-1 (Aprotinin) RN - EC 3.4.21.5 (Thrombin) SB - IM MH - Animals MH - Aprotinin/*pharmacology MH - Bone and Bones/*surgery MH - Dogs MH - Drug Combinations/pharmacology MH - Factor XIII/*pharmacology MH - Fibrin Tissue Adhesive MH - Fibrinogen/*pharmacology MH - Tendons/drug effects/pathology/*transplantation MH - Thrombin/*pharmacology MH - Transplantation, Autologous MH - Transplantation, Heterologous EDAT- 1989/05/01 00:00 MHDA- 1989/05/01 00:01 CRDT- 1989/05/01 00:00 PHST- 1989/05/01 00:00 [pubmed] PHST- 1989/05/01 00:01 [medline] PHST- 1989/05/01 00:00 [entrez] AID - 10.1177/036354658901700302 [doi] PST - ppublish SO - Am J Sports Med. 1989 May-Jun;17(3):318-24. doi: 10.1177/036354658901700302. PMID- 15589446 OWN - NLM STAT- MEDLINE DCOM- 20050304 LR - 20220331 IS - 1297-319X (Print) IS - 1297-319X (Linking) VI - 71 IP - 6 DP - 2004 Nov TI - Rupture of multiple tendons after levofloxacin therapy. PG - 586-7 AB - An 80-year-old man treated by levofloxacin developed multiple tendon ruptures. His symptoms resolved over 9 months after levofloxacin discontinuation. Nasal corticosteroid therapy, aging and chronic respiratory insufficiency were probably predisposing factors in this patient. FAU - Braun, Denis AU - Braun D AD - Pneumology Department, Maillot Hospital, 54150 Briey, France. FAU - Petitpain, Nadine AU - Petitpain N FAU - Cosserat, Françoise AU - Cosserat F FAU - Loeuille, Damien AU - Loeuille D FAU - Bitar, Suleiman AU - Bitar S FAU - Gillet, Pierre AU - Gillet P FAU - Trechot, Philippe AU - Trechot P LA - eng PT - Case Reports PT - Journal Article PL - France TA - Joint Bone Spine JT - Joint bone spine JID - 100938016 RN - 0 (Anti-Bacterial Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Aged MH - Aged, 80 and over MH - Anti-Bacterial Agents/*adverse effects MH - Humans MH - *Levofloxacin MH - Male MH - Ofloxacin/*adverse effects MH - Risk Factors MH - Rupture MH - Tendon Injuries/*chemically induced/epidemiology EDAT- 2004/12/14 09:00 MHDA- 2005/03/05 09:00 CRDT- 2004/12/14 09:00 PHST- 2003/06/10 00:00 [received] PHST- 2003/10/15 00:00 [accepted] PHST- 2004/12/14 09:00 [pubmed] PHST- 2005/03/05 09:00 [medline] PHST- 2004/12/14 09:00 [entrez] AID - S1297319X03002392 [pii] AID - 10.1016/j.jbspin.2003.10.016 [doi] PST - ppublish SO - Joint Bone Spine. 2004 Nov;71(6):586-7. doi: 10.1016/j.jbspin.2003.10.016. PMID- 7531742 OWN - NLM STAT- MEDLINE DCOM- 19950315 LR - 20131121 IS - 0021-5325 (Print) IS - 0021-5325 (Linking) VI - 68 IP - 11 DP - 1994 Nov TI - A study on cell proliferation in cultured human tendons--time dependence, and labeling of 5-bromodeoxyuridine. PG - 961-9 AB - Cells which proliferated on cultured human tendon were studied using scanning and transmission electron microscopy, and by immunohistochemical staining. Cell proliferation was continuously observed after 3, 6, 9 and 14 days in culture. Electron microscopy revealed the proliferation and differentiation of fibroblasts and macrophages on the cut surface of the tendon. Immunohistochemical staining by 5-bromodeoxyuridine demonstrated increased cellular activity of the proliferation in the epitenon and endotenon, and also in some mature tenocytes. This activity reached a peak on the 9th day of incubation. FAU - Matsuda, S AU - Matsuda S AD - Department of Orthopaedic Surgery, Shinshu University School of Medicine, Nagano, Japan. LA - eng PT - Journal Article PL - Japan TA - Nihon Seikeigeka Gakkai Zasshi JT - Nihon Seikeigeka Gakkai zasshi JID - 0413716 RN - 0 (Culture Media) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Bromodeoxyuridine MH - Cell Division/physiology MH - Cells, Cultured MH - Child MH - Culture Media MH - Humans MH - Immunohistochemistry MH - Microscopy, Electron MH - Middle Aged MH - S Phase MH - Staining and Labeling MH - Tendons/*cytology/ultrastructure MH - Time Factors EDAT- 1994/11/01 00:00 MHDA- 1994/11/01 00:01 CRDT- 1994/11/01 00:00 PHST- 1994/11/01 00:00 [pubmed] PHST- 1994/11/01 00:01 [medline] PHST- 1994/11/01 00:00 [entrez] PST - ppublish SO - Nihon Seikeigeka Gakkai Zasshi. 1994 Nov;68(11):961-9. PMID- 3894315 OWN - NLM STAT- MEDLINE DCOM- 19850829 LR - 20191101 IS - 0883-8364 (Print) IS - 0883-8364 (Linking) VI - 21 IP - 5 DP - 1985 May TI - A low-serum medium for tendon cells: effects of growth factors on tendon cell growth and collagen production. PG - 291-6 AB - Primary avian tendon cells maintain a higher percentage of net collagen synthesis when cultured in low serum concentrations than in high. However, under these conditions the cells grow slowly and can only be subcultured one or two times. We therefore examined various growth factors for their effects on tendon cell multiplication in order to develop a new medium for these cells. Of the growth factors tested, epidermal growth factor, insulin, transferrin, and selenium each stimulated tendon cell division. We also investigated how these factors affected collagen synthesis, and found that they all increased both collagen and noncollagen protein synthesis equally, thus leaving the percentage of protein synthesis devoted to collagen the same. When combined with 0.2% fetal bovine serum in Ham's F12 medium, epidermal growth factor and insulin together stimulated cell multiplication to a level comparable to that of cells grown in Ham's F12 plus 10% serum. Cells could also be successfully subcultured in this medium. Thus, by using selected growth factors we have reduced significantly the serum requirements of cultured tendon cells without affecting population doubling time or subculture capability. This low-serum medium should prove useful for the study of the regulation of collagen biosynthesis. FAU - Gauger, A AU - Gauger A FAU - Robertson, C AU - Robertson C FAU - Greenlee, T K Jr AU - Greenlee TK Jr FAU - Riederer-Henderson, M A AU - Riederer-Henderson MA LA - eng GR - AM 25749/AM/NIADDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - In Vitro Cell Dev Biol JT - In vitro cellular & developmental biology : journal of the Tissue Culture Association JID - 8506951 RN - 0 (Culture Media) RN - 0 (Growth Substances) RN - 0 (Insulin) RN - 0 (Transferrin) RN - 62229-50-9 (Epidermal Growth Factor) RN - 9007-34-5 (Collagen) RN - H6241UJ22B (Selenium) SB - IM MH - Animals MH - Blood MH - Cell Division/drug effects MH - Chick Embryo MH - Collagen/*biosynthesis MH - Culture Media MH - Dose-Response Relationship, Drug MH - Epidermal Growth Factor/pharmacology MH - Fibroblasts/cytology/metabolism MH - Growth Substances/*pharmacology MH - Insulin/pharmacology MH - Selenium/pharmacology MH - Tendons/*cytology/metabolism MH - Transferrin/pharmacology EDAT- 1985/05/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1985/05/01 00:00 PHST- 1985/05/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1985/05/01 00:00 [entrez] AID - 10.1007/BF02620945 [doi] PST - ppublish SO - In Vitro Cell Dev Biol. 1985 May;21(5):291-6. doi: 10.1007/BF02620945. PMID- 3786804 OWN - NLM STAT- MEDLINE DCOM- 19870107 LR - 20190824 IS - 0090-6980 (Print) IS - 0090-6980 (Linking) VI - 32 IP - 3 DP - 1986 Sep TI - The influence of indomethacin on collagen synthesis during tendon healing in the rabbit. PG - 353-8 AB - The influence of indomethacin on collagen synthesis in intact and healing plantaris longus tendons in the rabbit was investigated. Forty-four male New Zealand White rabbits were subjected to a standardized trauma (tenetomy + repair) on the left hindlimb. Half of the animals were subsequently treated with indomethacin, 10 mg/kg per day orally, and the other half with placebo. After 2 and 4 weeks the rabbits were injected intravenously with 3H-proline and killed 18 h later. Indomethacin affected the collagen metabolism differently depending on whether the tendons were involved in wound healing or not. In intact tendons the drug caused a small general inhibition of collagen synthesis. In the healing tendon there was a shift towards the synthesis of more insoluble collagen with little effect on the total synthesis. After 4 weeks there was also a slight but significant decrease in the amount of hydroxyproline in the most soluble collagen fraction from the tenotomized, indomethacin treated tendons. FAU - Carlstedt, C A AU - Carlstedt CA FAU - Madsen, K AU - Madsen K FAU - Wredmark, T AU - Wredmark T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Prostaglandins JT - Prostaglandins JID - 0320271 RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - RMB44WO89X (Hydroxyproline) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Collagen/*biosynthesis MH - Hydroxyproline/analysis MH - Indomethacin/*pharmacology MH - Male MH - Proline/metabolism MH - Rabbits MH - Tendons/metabolism/*pathology MH - Wound Healing EDAT- 1986/09/01 00:00 MHDA- 1986/09/01 00:01 CRDT- 1986/09/01 00:00 PHST- 1986/09/01 00:00 [pubmed] PHST- 1986/09/01 00:01 [medline] PHST- 1986/09/01 00:00 [entrez] AID - 0090-6980(86)90004-3 [pii] AID - 10.1016/0090-6980(86)90004-3 [doi] PST - ppublish SO - Prostaglandins. 1986 Sep;32(3):353-8. doi: 10.1016/0090-6980(86)90004-3. PMID- 2971920 OWN - NLM STAT- MEDLINE DCOM- 19881122 LR - 20181130 IS - 0031-2983 (Print) IS - 0031-2983 (Linking) VI - 79 IP - 1063 DP - 1987 Sep-Oct TI - [Diverse actions of pure crystalline progesterone, 17-alpha-hydroxyprogesterone capronate and medroxyprogesterone acetate (MPA), on the biosynthesis of collagen in the tail of the rat (ovariectomized females)]. PG - 581-6 FAU - Gambella, G R AU - Gambella GR FAU - Vascotto, E AU - Vascotto E FAU - Novelli, A AU - Novelli A FAU - Burlando, F AU - Burlando F FAU - Buffrini, L AU - Buffrini L FAU - Bianchi, V AU - Bianchi V LA - ita PT - Journal Article TT - Diversa azione del progesterone puro cristallino, del 17-alpha-idrossiprogesterone capronato e medrossiprogesterone acetato (MPA), sulla biosintesi del collagene nella coda di ratto (femmina ovariectomizzata). PL - Italy TA - Pathologica JT - Pathologica JID - 0401123 RN - 0 (Hydroxyprogesterones) RN - 276F2O42F5 (17 alpha-Hydroxyprogesterone Caproate) RN - 4G7DS2Q64Y (Progesterone) RN - 9007-34-5 (Collagen) RN - C2QI4IOI2G (Medroxyprogesterone Acetate) RN - HSU1C9YRES (Medroxyprogesterone) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - 17 alpha-Hydroxyprogesterone Caproate MH - Animals MH - Collagen/*biosynthesis MH - Crystallization MH - Female MH - Hydroxyprogesterones/*pharmacology MH - Hydroxyproline/analysis MH - Medroxyprogesterone/*analogs & derivatives/pharmacology MH - Medroxyprogesterone Acetate MH - Ovariectomy MH - Progesterone/*pharmacology MH - Rats MH - Tendons/drug effects/metabolism EDAT- 1987/09/01 00:00 MHDA- 1987/09/01 00:01 CRDT- 1987/09/01 00:00 PHST- 1987/09/01 00:00 [pubmed] PHST- 1987/09/01 00:01 [medline] PHST- 1987/09/01 00:00 [entrez] PST - ppublish SO - Pathologica. 1987 Sep-Oct;79(1063):581-6. PMID- 26984348 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20181202 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 31 IP - 4 DP - 2016 May TI - Low-level laser therapy modulates pro-inflammatory cytokines after partial tenotomy. PG - 759-66 LID - 10.1007/s10103-016-1918-7 [doi] AB - Tendon injuries give rise to substantial morbidity, and current understanding of the mechanisms involved in tendon injury and repair is limited. This lesion remains a clinical issue because the injury site becomes a region with a high incidence of recurrent rupture and has drawn the attention of researchers. We already demonstrated that low-level laser therapy (LLLT) stimulates the synthesis and organization of collagen I, MMP-9, and MMP-2 and improved the gait recovery of the treated animals. The aim of this study was to evaluate the effects of LLLT in the nitric oxide and cytokines profile during the inflammatory and remodeling phases. Adult male rats were divided into the following groups: G1--intact, G2-- injured, G3--injured + LLLT (4 J/cm(2) continuous), G4--injured + LLLT (4 J/cm(2)-20 Hz--pulsed laser). According to the analysis, the animals were euthanized on different dates (1, 4, 8, or 15 days after injury). ELISA assay of TNF-α, IL-1β, IL-10, and TGF-β was performed. Western blotting of isoform of nitric oxide synthase (i-NOS) and nitric oxide dosage experiments was conducted. Our results showed that the pulsed LLLT seems to exert an anti-inflammatory effect over injured tendons, with reduction of the release of proinflammatory cytokines, such as TNF-α and the decrease in the i-NOS activity. Thanks to the pain reduction and the facilitation of movement, there was a stimulation in the TGF-β and IL-1β release. In conclusion, we believe that pulsed LLLT worked effectively as a therapy to reestablish the tendon integrity after rupture. FAU - Da Ré Guerra, Flávia AU - Da Ré Guerra F AD - Department of Anatomy, Institute of Biomedical Science, Federal University of Alfenas - UNIFAL-MG, 37130-000, Alfenas, MG, Brazil. dgflavia@yahoo.com.br. FAU - Vieira, Cristiano Pedrozo AU - Vieira CP AD - Department of Structural and Functional Biology, Institute of Biology, CP 6109, University of Campinas - UNICAMP, 13083-970, Campinas, SP, Brazil. FAU - Oliveira, Letícia Prado AU - Oliveira LP AD - Department of Structural and Functional Biology, Institute of Biology, CP 6109, University of Campinas - UNICAMP, 13083-970, Campinas, SP, Brazil. FAU - Marques, Petrus Pires AU - Marques PP AD - Department of Biochemistry, Institute of Biomedical Science, Federal University of Alfenas - UNIFAL-MG, 37130-000, Alfenas, MG, Brazil. FAU - dos Santos Almeida, Marcos AU - dos Santos Almeida M AD - Department of Anatomy, Institute of Biomedical Science, Federal University of Alfenas - UNIFAL-MG, 37130-000, Alfenas, MG, Brazil. FAU - Pimentel, Edson Rosa AU - Pimentel ER AD - Department of Structural and Functional Biology, Institute of Biology, CP 6109, University of Campinas - UNICAMP, 13083-970, Campinas, SP, Brazil. LA - eng PT - Journal Article DEP - 20160316 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 RN - 0 (Collagen Type I) RN - 0 (Cytokines) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.13.39 (Nos2 protein, rat) SB - IM MH - Animals MH - Collagen Type I/metabolism MH - Cytokines/*blood MH - Lasers, Semiconductor/*therapeutic use MH - Low-Level Light Therapy/methods MH - Male MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase Type II/metabolism MH - Rats MH - Rats, Wistar MH - Tendon Injuries/blood/*radiotherapy MH - Tendons/metabolism/radiation effects MH - Tenotomy MH - Treatment Outcome MH - Wound Healing/radiation effects OTO - NOTNLM OT - IL-1β OT - Inflammatory OT - TGF-β OT - TNF-α OT - i-NOS EDAT- 2016/03/18 06:00 MHDA- 2016/12/15 06:00 CRDT- 2016/03/18 06:00 PHST- 2015/05/04 00:00 [received] PHST- 2016/03/01 00:00 [accepted] PHST- 2016/03/18 06:00 [entrez] PHST- 2016/03/18 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - 10.1007/s10103-016-1918-7 [pii] AID - 10.1007/s10103-016-1918-7 [doi] PST - ppublish SO - Lasers Med Sci. 2016 May;31(4):759-66. doi: 10.1007/s10103-016-1918-7. Epub 2016 Mar 16. PMID- 35667996 OWN - NLM STAT- MEDLINE DCOM- 20220616 LR - 20220616 IS - 1532-2653 (Electronic) IS - 0967-5868 (Linking) VI - 101 DP - 2022 Jul TI - The involvement of tendons in IgG4-related diffuse orbital myositis. PG - 278-279 LID - S0967-5868(22)00244-2 [pii] LID - 10.1016/j.jocn.2022.05.030 [doi] FAU - Zhang, Ying AU - Zhang Y AD - Ophthalmology Department, West China Hospital, Sichuan University, Chengdu, China. FAU - Zhang, Yanan AU - Zhang Y AD - Neurology Department, West China Hospital, Sichuan University, Chengdu, China. Electronic address: dr.yananzhang@163.com. LA - eng PT - Journal Article DEP - 20220603 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (Immunoglobulin G) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Humans MH - Immunoglobulin G MH - *Myositis/complications/diagnostic imaging MH - *Orbital Diseases MH - *Orbital Myositis/complications/diagnostic imaging MH - Rituximab MH - Tendons MH - Tomography, X-Ray Computed OTO - NOTNLM OT - Compressive optic neuropathy OT - Diffuse orbital myositis OT - IgG4-related disease OT - Muscle tendons EDAT- 2022/06/07 06:00 MHDA- 2022/06/18 06:00 CRDT- 2022/06/06 22:07 PHST- 2022/05/05 00:00 [received] PHST- 2022/05/23 00:00 [revised] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/06/07 06:00 [pubmed] PHST- 2022/06/18 06:00 [medline] PHST- 2022/06/06 22:07 [entrez] AID - S0967-5868(22)00244-2 [pii] AID - 10.1016/j.jocn.2022.05.030 [doi] PST - ppublish SO - J Clin Neurosci. 2022 Jul;101:278-279. doi: 10.1016/j.jocn.2022.05.030. Epub 2022 Jun 3. PMID- 15185511 OWN - NLM STAT- MEDLINE DCOM- 20041028 LR - 20131121 IS - 0012-7183 (Print) IS - 0012-7183 (Linking) VI - 120 IP - 8 DP - 2004 TI - [The rupture of both Achilles tendons as a complication from fluoroquinolone treatment]. PG - 975-9 FAU - Pohjola-Sintonen, Sinikka AU - Pohjola-Sintonen S AD - HYKS, Peijaksen sairaala Sairaalakatu 1 01400 Vantaa. sinikka.pohjola-sintonen@hus.fi FAU - Kannisto, Mikko AU - Kannisto M LA - fin PT - Case Reports PT - Journal Article TT - Molempien akillesjänteiden repeämä fluorokinolonin komplikaationa. PL - Finland TA - Duodecim JT - Duodecim; laaketieteellinen aikakauskirja JID - 0373207 RN - 0 (Fluoroquinolones) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/drug effects/*injuries MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Finland MH - Fluoroquinolones/*adverse effects/therapeutic use MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Ofloxacin/*adverse effects/therapeutic use MH - Pneumonia, Bacterial/diagnosis/drug therapy MH - Risk Assessment MH - Rupture/chemically induced MH - Treatment Outcome EDAT- 2004/06/10 05:00 MHDA- 2004/10/29 09:00 CRDT- 2004/06/10 05:00 PHST- 2004/06/10 05:00 [pubmed] PHST- 2004/10/29 09:00 [medline] PHST- 2004/06/10 05:00 [entrez] PST - ppublish SO - Duodecim. 2004;120(8):975-9. PMID- 5317074 OWN - NLM STAT- MEDLINE DCOM- 19720803 LR - 20081121 IS - 0046-6794 (Print) IS - 0046-6794 (Linking) VI - 3 IP - 4 DP - 1971 TI - [Animal experiment studies on the prevention of postoperative adhesions in flexor tendon transplantation]. PG - 143-9 FAU - Geldmacher, J AU - Geldmacher J FAU - König, D U AU - König DU LA - ger PT - Journal Article TT - Tierexperimentelle Untersuchungen zur Prophylaxe postoperativer Adhäsionen bei freien Beugesehnentransplantationen. PL - Germany TA - Handchirurgie JT - Handchirurgie JID - 1252612 RN - 9087-70-1 (Aprotinin) SB - IM MH - Animals MH - Aprotinin/pharmacology MH - Granulation Tissue/pathology MH - Postoperative Complications/*prevention & control MH - Rabbits MH - Tendons/pathology/*transplantation MH - Tissue Adhesions/*prevention & control MH - Transplantation, Autologous MH - Wound Healing/drug effects EDAT- 1971/01/01 00:00 MHDA- 1971/01/01 00:01 CRDT- 1971/01/01 00:00 PHST- 1971/01/01 00:00 [pubmed] PHST- 1971/01/01 00:01 [medline] PHST- 1971/01/01 00:00 [entrez] PST - ppublish SO - Handchirurgie. 1971;3(4):143-9. PMID- 11357195 OWN - NLM STAT- MEDLINE DCOM- 20010830 LR - 20191210 IS - 1058-8388 (Print) IS - 1058-8388 (Linking) VI - 221 IP - 1 DP - 2001 May TI - A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I. PG - 72-80 AB - Chondromodulin-I (CHM1) was identified recently as an angiogenesis inhibitor in cartilage. It is highly expressed in the avascular zones of cartilage but is absent in the late hypertrophic region, which is invaded by blood vessels during enchondral ossification. Blast searches with the C-terminal part of CHM1 in available databases led to the identification of human and mouse cDNAs encoding a new protein, Tendin, that shares high homology with CHM1. Based on computer predictions, Tendin is a type II transmembrane protein containing a putative proteinase cleavage and two glycosylation sites. Northern assays with mouse RNAs demonstrated strong expression of a 1.5-kb tendin transcript in the diaphragm, skeletal muscle, and the eye and low levels of expression in all other tissues investigated. In 17.5-day-old mouse embryos, in situ hybridization revealed high levels of tendin transcript in tendons and ligaments. Additional signals were detected in brain and spinal cord, liver, lung, bowels, thymus, and eye. Cartilage, where CHM1 is found, revealed low levels of tendin m-RNA. In adult mice, tendin is expressed in neurons of all brain regions and the spinal cord. The tendin gene is localized in the human Xq22 region, to which several human diseases have been mapped. CI - Copyright 2001 Wiley-Liss, Inc. FAU - Brandau, O AU - Brandau O AD - Department of Experimental Pathology, Lund University, Lund, Sweden. FAU - Meindl, A AU - Meindl A FAU - Fässler, R AU - Fässler R FAU - Aszódi, A AU - Aszódi A LA - eng SI - GENBANK/AF291655 SI - GENBANK/AL035608 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Dev Dyn JT - Developmental dynamics : an official publication of the American Association of Anatomists JID - 9201927 RN - 0 (Cnmd protein, mouse) RN - 0 (DNA, Complementary) RN - 0 (Growth Substances) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Membrane Proteins) RN - 0 (RNA, Messenger) RN - 136362-10-2 (CNMD protein, human) SB - IM MH - Animals MH - Base Sequence MH - DNA, Complementary MH - *Gene Expression Regulation, Developmental MH - Growth Substances/*genetics MH - Humans MH - In Situ Hybridization MH - *Intercellular Signaling Peptides and Proteins MH - Ligaments/chemistry/embryology/*physiology MH - Membrane Proteins/*genetics MH - Mice MH - Molecular Sequence Data MH - RNA, Messenger/analysis MH - Sequence Homology, Amino Acid MH - Tendons/chemistry/embryology/*physiology EDAT- 2001/05/18 10:00 MHDA- 2001/08/31 10:01 CRDT- 2001/05/18 10:00 PHST- 2001/05/18 10:00 [pubmed] PHST- 2001/08/31 10:01 [medline] PHST- 2001/05/18 10:00 [entrez] AID - 10.1002/dvdy.1126 [pii] AID - 10.1002/dvdy.1126 [doi] PST - ppublish SO - Dev Dyn. 2001 May;221(1):72-80. doi: 10.1002/dvdy.1126. PMID- 16916923 OWN - NLM STAT- MEDLINE DCOM- 20070313 LR - 20131121 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 102 IP - 1 DP - 2007 Jan TI - Inflammatory cells do not decrease the ultimate tensile strength of intact tendons in vivo and in vitro: protective role of mechanical loading. PG - 11-7 AB - Although inflammatory cells and their products are involved in various pathological processes, a possible role in tendon dysfunction has never been convincingly confirmed and extensively investigated. The goal of this study was to determine whether or not an acute inflammatory process deprived of mechanical trauma can induce nonspecific damages to intact collagen fibers. To induce leukocyte accumulation, carrageenan was injected into rat Achilles tendons. We first tested the effect of leukocyte recruitment on the concentrations or activities of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases. Second, we analyzed at the biochemical, histological, and biomechanical levels the impact of leukocyte invasion on tendons. Finally, collagen bundles isolated from rat-tail tendons were exposed in vitro to mechanical stress and/or inflammatory cells to determine if mechanical loading could protect tendons from the leukocyte proteolytic activity. Carrageenan-induced leukocyte accumulation was associated with an increased matrix metalloproteinase activity and a decreased content of tissue inhibitors of matrix metalloproteinases. However, hydroxyproline content and load to failure did not change significantly in these tendons. Interestingly, mechanical stress, when applied in vitro, protected collagen bundles from inflammatory cell-induced deterioration. Together, our results suggest that acute inflammation does not induce damages to intact and mechanically stressed collagen fibers. This protective effect would not rely on increased tissue inhibitors of matrix metalloproteinases content but would rather be conferred to the intrinsic resistance of mechanically loaded collagen fibers to proteolytic degradation. FAU - Marsolais, David AU - Marsolais D AD - Centre de Recherche du Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada. FAU - Duchesne, Elise AU - Duchesne E FAU - Côté, Claude H AU - Côté CH FAU - Frenette, Jérôme AU - Frenette J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060817 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - 9000-07-1 (Carrageenan) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - RMB44WO89X (Hydroxyproline) SB - IM CIN - J Appl Physiol (1985). 2007 Jan;102(1):3-4. doi: 10.1152/japplphysiol.00916.2006. PMID: 16931557 MH - Animals MH - Biomechanical Phenomena MH - Carrageenan MH - Collagen/*metabolism MH - Female MH - Hydroxyproline/metabolism MH - Inflammation/chemically induced/*pathology/physiopathology MH - Leukocytes/metabolism/pathology MH - Matrix Metalloproteinases/metabolism MH - Rats MH - Rats, Wistar MH - Stress, Mechanical MH - Tendinopathy/chemically induced/*pathology/physiopathology MH - Tendon Injuries/etiology/pathology/physiopathology MH - Tendons/metabolism/*pathology/*physiopathology MH - Tensile Strength/*physiology MH - Tissue Inhibitor of Metalloproteinase-1/metabolism MH - Tissue Inhibitor of Metalloproteinase-2/metabolism MH - Weight-Bearing EDAT- 2006/08/19 09:00 MHDA- 2007/03/14 09:00 CRDT- 2006/08/19 09:00 PHST- 2006/08/19 09:00 [pubmed] PHST- 2007/03/14 09:00 [medline] PHST- 2006/08/19 09:00 [entrez] AID - 00162.2006 [pii] AID - 10.1152/japplphysiol.00162.2006 [doi] PST - ppublish SO - J Appl Physiol (1985). 2007 Jan;102(1):11-7. doi: 10.1152/japplphysiol.00162.2006. Epub 2006 Aug 17. PMID- 19421908 OWN - NLM STAT- MEDLINE DCOM- 20100119 LR - 20220331 IS - 1745-3674 (Print) IS - 1745-3682 (Electronic) IS - 1745-3674 (Linking) VI - 80 IP - 3 DP - 2009 Jun TI - The effect of glucocorticoids on tendon cell viability in human tendon explants. PG - 363-7 LID - 10.3109/17453670902988386 [doi] AB - BACKGROUND AND PURPOSE: Previous studies on the culture of human tenocytes have shown that dexamethasone and triamcinolone reduce cell viability, suppress cell proliferation, and reduce collagen synthesis. However, such cell cultures lack the extracellular matrix and three-dimensional structure of normal tendons, which affects their response to stimuli. We established a human tendon explant culture system and tested the effects of dexamethasone and triamcinolone on cell viability. METHODS: Primary human tendon explant cultures were prepared from healthy hamstring tendons. Tendon strips were harvested from hamstring tendons and cultured in 24-well plates in Dulbecco's modification of Eagle's Medium (DMEM) supplemented with 2% fetal calf serum. The tendon explants were treated with 0 microM (control), 10 microM, or 100 microM dexamethasone sodium phosphate or 0 microM (control), 10 microM, or 100 microM triamcinolone acetonide in DMEM for 96 h. Cell viability was measured by Alamar blue assay before and after glucocorticoid treatment. RESULTS: Incubation with 10 microM and 100 microM dexamethasone reduced cell viability in human tendon explants by 35% and 45%, respectively, as compared to a 6% increase in the controls (p = 0.01, mixed-effects ANOVA). Triamcinolone at 10 microM and 100 microM reduced cell viability by 33% and 36%, respectively, as compared to a 9% increase in the controls (p = 0.07, mixed-effects ANOVA). INTERPRETATION: Human tendon explant cultures can be used to study the effects of glucocorticoids on human tendon. Dexamethasone and triamcinolone suppress the cell viability of human tendon in its natural 3-dimensional environment with matrix anchorage. Human tendon explant cultures provide a species-specific model for further investigation of the effects of glucocorticoids on the metabolism of the extracellular matrix of human tendon, and on its mechanical properties. FAU - Wong, Margaret Wan Nar AU - Wong MW AD - Department of Orthopaedics and Traumatology, Chinese University of Hong Kong, Shatin, Hong Kong. mwnwong@cuhk.edu.hk FAU - Lui, Wai Ting AU - Lui WT FAU - Fu, Sai Chuen AU - Fu SC FAU - Lee, Kwong Man AU - Lee KM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Sweden TA - Acta Orthop JT - Acta orthopaedica JID - 101231512 RN - 0 (Glucocorticoids) RN - 1ZK20VI6TY (Triamcinolone) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Cell Survival/*drug effects MH - Cells, Cultured MH - Dexamethasone/pharmacology MH - Glucocorticoids/*pharmacology MH - Humans MH - Tendons/cytology/*drug effects/metabolism MH - Triamcinolone/pharmacology PMC - PMC2823211 EDAT- 2009/05/08 09:00 MHDA- 2010/01/20 06:00 PMCR- 2009/06/05 CRDT- 2009/05/08 09:00 PHST- 2009/05/08 09:00 [entrez] PHST- 2009/05/08 09:00 [pubmed] PHST- 2010/01/20 06:00 [medline] PHST- 2009/06/05 00:00 [pmc-release] AID - 910986930 [pii] AID - SORT_A_399010_O [pii] AID - 10.3109/17453670902988386 [doi] PST - ppublish SO - Acta Orthop. 2009 Jun;80(3):363-7. doi: 10.3109/17453670902988386. PMID- 40625234 OWN - NLM STAT- MEDLINE DCOM- 20250805 LR - 20250805 IS - 2047-4849 (Electronic) IS - 2047-4830 (Linking) VI - 13 IP - 16 DP - 2025 Aug 5 TI - Nano-enzymatic functionalized dual network hydrogel promotes tendon repair by modulating the inflammatory cycle and cellular behavior. PG - 4502-4523 LID - 10.1039/d5bm00441a [doi] AB - Tendon injuries are prone to adhesions after repair, which in turn lead to limb dysfunction, which remains a major challenge in clinical treatment. Current research suggests that tendon injuries are affected by the accumulation of reactive oxygen species (ROS), inflammatory responses, and type III collagen deposition. These factors lead to an imbalance between extrinsic and intrinsic tendon healing and are the main reasons for the occurrence of peritendinous adhesions. In this study, we constructed a carrier using a polyvinyl alcohol/polyethylene glycol (PVA/PEG) dual network hydrogel and loaded it with zeolite imidazolium ester framework-8@CeO(2) nano-enzymes (ZIF-8@CeO(2)) to form a nano-enzyme-functionalized hydrogel (PVA/PEG/ZIF-8@CeO(2)) therapeutic system. The surface of PVA/PEG/ZIF-8@CeO(2) is rich in hydrophilic hydroxyl groups that form hydrogen bonds with water molecules, creating a hydrated layer that inhibits fibrin adsorption and fibroblast adhesion, reduces the impact of exogenous healing, and reduces the formation of adhesions. Similarly, the loaded ZIF-8@CeO(2) has catalase (CAT) and superoxide dismutase (SOD) activities, which can effectively remove the excessive ROS in the injured tendon, down-regulate the inflammatory response, enhance the tendon differentiation of tendon stem cells, promote intrinsic healing, and ultimately promote the repair of injured tendons. Furthermore, the system can accelerate the transition from inflammation to repair and remodeling in the tendon healing process. The PVA/PEG/ZIF-8@CeO(2) treatment system is a novel approach for reducing peritendinous adhesions and effectively promoting the repair of injured tendons. FAU - Yin, Heng AU - Yin H AUID- ORCID: 0009-0002-5344-3254 AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Zhang, Zhuo AU - Zhang Z AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Wang, Yi AU - Wang Y AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Song, Weiyong AU - Song W AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Pu, Chaoyu AU - Pu C AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Wang, Yong AU - Wang Y AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. FAU - Jiang, Ke AU - Jiang K AUID- ORCID: 0009-0000-3604-6041 AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, 637000, Nanchong, China. jiangke2010@nsmc.edu.cn. LA - eng PT - Journal Article DEP - 20250805 PL - England TA - Biomater Sci JT - Biomaterials science JID - 101593571 RN - 0 (Hydrogels) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 9002-89-5 (Polyvinyl Alcohol) RN - 30K4522N6T (Cerium) RN - 1318-02-1 (Zeolites) RN - 619G5K328Y (ceric oxide) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.11.1.6 (Catalase) RN - 0 (Reactive Oxygen Species) SB - IM MH - Animals MH - *Hydrogels/chemistry/pharmacology MH - Polyethylene Glycols/chemistry MH - Polyvinyl Alcohol/chemistry MH - Cerium/chemistry MH - Zeolites/chemistry MH - *Tendon Injuries/drug therapy/pathology/metabolism MH - Wound Healing/drug effects MH - Superoxide Dismutase/metabolism/chemistry MH - Catalase/chemistry/metabolism MH - Inflammation/drug therapy MH - Tendons/drug effects MH - Reactive Oxygen Species/metabolism MH - Rats EDAT- 2025/07/08 06:26 MHDA- 2025/08/05 18:28 CRDT- 2025/07/08 05:12 PHST- 2025/08/05 18:28 [medline] PHST- 2025/07/08 06:26 [pubmed] PHST- 2025/07/08 05:12 [entrez] AID - 10.1039/d5bm00441a [doi] PST - epublish SO - Biomater Sci. 2025 Aug 5;13(16):4502-4523. doi: 10.1039/d5bm00441a. PMID- 15513608 OWN - NLM STAT- MEDLINE DCOM- 20050310 LR - 20221207 IS - 0284-4311 (Print) IS - 0284-4311 (Linking) VI - 38 IP - 5 DP - 2004 TI - Osseous destruction and rupture of the extensor tendon caused by sarcoidosis of the finger. PG - 317-9 AB - We describe a woman with osseous destruction and rupture of the extensor tendon as a result of sarcoidosis in the left third finger with no evidence of systemic involvement. The tendon was repaired and she was successfully treated with prednisone. FAU - Terzioglu, Ahmet AU - Terzioglu A AD - Department of Plastic and Reconstructive Surgery, Ankara Training Research Hospital, Turkey. FAU - Bingul, Ferruh AU - Bingul F FAU - Tuncali, Doğan AU - Tuncali D FAU - Sahin, Firdevs AU - Sahin F FAU - Aslan, Gürcan AU - Aslan G LA - eng PT - Case Reports PT - Journal Article PL - England TA - Scand J Plast Reconstr Surg Hand Surg JT - Scandinavian journal of plastic and reconstructive surgery and hand surgery JID - 8707869 RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Adult MH - Biopsy, Needle MH - Combined Modality Therapy MH - Female MH - Fingers/*pathology/surgery MH - Follow-Up Studies MH - Humans MH - Immunohistochemistry MH - Prednisolone/therapeutic use MH - Plastic Surgery Procedures/methods MH - Risk Assessment MH - Rupture/etiology/surgery MH - Sarcoidosis/*complications/drug therapy/*pathology MH - Tendon Injuries/*etiology/pathology/*surgery MH - Tendons/*pathology/surgery MH - Treatment Outcome EDAT- 2004/10/30 09:00 MHDA- 2005/03/11 09:00 CRDT- 2004/10/30 09:00 PHST- 2004/10/30 09:00 [pubmed] PHST- 2005/03/11 09:00 [medline] PHST- 2004/10/30 09:00 [entrez] AID - AKVLY2GXXFJUDY4L [pii] AID - 10.1080/02844310410027248 [doi] PST - ppublish SO - Scand J Plast Reconstr Surg Hand Surg. 2004;38(5):317-9. doi: 10.1080/02844310410027248. PMID- 4365178 OWN - NLM STAT- MEDLINE DCOM- 19740823 LR - 20190620 IS - 0014-2956 (Print) IS - 0014-2956 (Linking) VI - 43 IP - 2 DP - 1974 Apr 1 TI - Intracellular hydroxylation of non-helical protocollagen to form triple-helical procollagen and subsequent secretion of the molecule. PG - 221-30 FAU - Uitto, J AU - Uitto J FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Journal Article PL - England TA - Eur J Biochem JT - European journal of biochemistry JID - 0107600 RN - 0 (Carbon Radioisotopes) RN - 0 (Protein Precursors) RN - 0 (Pyridines) RN - 9007-34-5 (Collagen) RN - 98600C0908 (Cycloheximide) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) RN - EC 3.4.21.1 (Chymotrypsin) RN - EC 3.4.23.1 (Pepsin A) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Anaerobiosis MH - Animals MH - Carbon Radioisotopes MH - Chick Embryo MH - Chromatography, Gel MH - Chymotrypsin MH - Collagen/biosynthesis/*metabolism MH - Cycloheximide/pharmacology MH - Electrophoresis, Polyacrylamide Gel MH - Hydroxyproline/biosynthesis MH - Pepsin A MH - Procollagen-Proline Dioxygenase/metabolism MH - Protein Conformation MH - Protein Precursors MH - Pyridines/pharmacology MH - Temperature MH - Tendons/drug effects/metabolism MH - Time Factors EDAT- 1974/04/01 00:00 MHDA- 1974/04/01 00:01 CRDT- 1974/04/01 00:00 PHST- 1974/04/01 00:00 [pubmed] PHST- 1974/04/01 00:01 [medline] PHST- 1974/04/01 00:00 [entrez] AID - 10.1111/j.1432-1033.1974.tb03403.x [doi] PST - ppublish SO - Eur J Biochem. 1974 Apr 1;43(2):221-30. doi: 10.1111/j.1432-1033.1974.tb03403.x. PMID- 19005915 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20081113 IS - 0963-8288 (Print) IS - 0963-8288 (Linking) VI - 30 IP - 20-22 DP - 2008 TI - Novel methods for tendon investigations. PG - 1514-22 LID - 10.1080/09638280701785403 [doi] AB - PURPOSE: Tendon structures have been studied for decades, but over the last decade, methodological development and renewed interest for metabolic, circulatory and tissue protein turnover in tendon tissue has resulted in a rising amount of investigations. METHOD: This paper will detail the various modern investigative techniques available to study tendons. RESULTS: There are a variety of investigative methods available to study the correlations between mechanics and biology in tendons. CONCLUSION: The available methodologies not only allow for potential insight into physiological and pathophysiological mechanisms in tendon tissue, but also, to some extent, allow for more elaborate studies of the intact human tendon. FAU - Kjaer, M AU - Kjaer M AD - Institute of Sports Medicine, Department of Rheumatology, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark. m.kjaer@mfi.ku.dk FAU - Langberg, H AU - Langberg H FAU - Bojsen-Møller, J AU - Bojsen-Møller J FAU - Koskinen, S O AU - Koskinen SO FAU - Mackey, A AU - Mackey A FAU - Heinemeier, K AU - Heinemeier K FAU - Holm, L AU - Holm L FAU - Skovgaard, D AU - Skovgaard D FAU - Døssing, S AU - Døssing S FAU - Hansen, M AU - Hansen M FAU - Hansen, P AU - Hansen P FAU - Haraldsson, B AU - Haraldsson B FAU - Carøe, I AU - Carøe I FAU - Magnusson, S P AU - Magnusson SP LA - eng PT - Journal Article PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Biopsy MH - Collagen/metabolism MH - Humans MH - Intercellular Signaling Peptides and Proteins/metabolism MH - Matrix Metalloproteinases/metabolism MH - Microdialysis MH - Microscopy, Atomic Force MH - Positron-Emission Tomography MH - RNA, Messenger/metabolism MH - Stem Cells MH - Stress, Mechanical MH - Tendons/pathology/*physiology MH - Tensile Strength MH - Tissue Inhibitor of Metalloproteinases/metabolism EDAT- 2008/11/14 09:00 MHDA- 2009/02/12 09:00 CRDT- 2008/11/14 09:00 PHST- 2008/11/14 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] PHST- 2008/11/14 09:00 [entrez] AID - 905460353 [pii] AID - 10.1080/09638280701785403 [doi] PST - ppublish SO - Disabil Rehabil. 2008;30(20-22):1514-22. doi: 10.1080/09638280701785403. PMID- 4472803 OWN - NLM STAT- MEDLINE DCOM- 19750110 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 60 IP - 1 DP - 1974 Sep 9 TI - Synthesis and secretion of under-hydroxylated procollagen at various temperatures by cells subject to temporary anoxia. PG - 414-23 FAU - Uitto, J AU - Uitto J FAU - Prockop, D J AU - Prockop DJ LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Carbon Radioisotopes) RN - 0 (Protein Precursors) RN - 2GQB349IUB (Hydroxylysine) RN - 9007-34-5 (Collagen) RN - 98600C0908 (Cycloheximide) RN - 9DLQ4CIU6V (Proline) RN - EC 1.- (Mixed Function Oxygenases) RN - K3Z4F929H6 (Lysine) RN - N762921K75 (Nitrogen) SB - IM MH - Animals MH - Carbon Radioisotopes MH - Cells, Cultured MH - Chick Embryo MH - Chromatography, Gel MH - Collagen/*biosynthesis/metabolism MH - Cycloheximide MH - Electrophoresis, Polyacrylamide Gel MH - Hydroxylysine/metabolism MH - Hypoxia/*metabolism MH - Isotope Labeling MH - Lysine/metabolism MH - Mixed Function Oxygenases/metabolism MH - Nitrogen MH - Proline/metabolism MH - Protein Conformation MH - Protein Precursors/*biosynthesis/metabolism MH - Temperature MH - Tendons/enzymology/*metabolism MH - Time Factors EDAT- 1974/09/09 00:00 MHDA- 1974/09/09 00:01 CRDT- 1974/09/09 00:00 PHST- 1974/09/09 00:00 [pubmed] PHST- 1974/09/09 00:01 [medline] PHST- 1974/09/09 00:00 [entrez] AID - 0006-291X(74)90220-4 [pii] AID - 10.1016/0006-291x(74)90220-4 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1974 Sep 9;60(1):414-23. doi: 10.1016/0006-291x(74)90220-4. PMID- 15402382 OWN - NLM STAT- MEDLINE DCOM- 20040930 LR - 20190729 IS - 0002-9955 (Print) IS - 0002-9955 (Linking) VI - 142 IP - 6 DP - 1950 Feb 11 TI - Streptomycin in the treatment of tuberculous tenosynovitis. PG - 408 FAU - MILLER, J M AU - MILLER JM FAU - LIPIN, R J AU - LIPIN RJ FAU - GINSBERG, M AU - GINSBERG M LA - eng PT - Journal Article PL - United States TA - J Am Med Assoc JT - Journal of the American Medical Association JID - 7507176 RN - Y45QSO73OB (Streptomycin) SB - OM MH - Humans MH - *Streptomycin MH - *Tendons MH - *Tenosynovitis MH - *Tuberculosis MH - *Tuberculosis, Osteoarticular OID - CLML: 5018:667a:12:13 OTO - NLM OT - *STREPTOMYCIN OT - *TENDONS OT - *TUBERCULOSIS EDAT- 1950/02/11 00:00 MHDA- 1950/02/11 00:01 CRDT- 1950/02/11 00:00 PHST- 1950/02/11 00:00 [pubmed] PHST- 1950/02/11 00:01 [medline] PHST- 1950/02/11 00:00 [entrez] AID - 10.1001/jama.1950.72910240001006 [doi] PST - ppublish SO - J Am Med Assoc. 1950 Feb 11;142(6):408. doi: 10.1001/jama.1950.72910240001006. PMID- 19609527 OWN - NLM STAT- MEDLINE DCOM- 20101028 LR - 20211020 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 30 IP - 10 DP - 2010 Aug TI - Two cases of distal extremity swelling with pitting oedema in psoriatic arthritis: the different pathological mechanisms. PG - 1367-70 LID - 10.1007/s00296-009-1060-y [doi] AB - In psoriatic arthritis, swelling and pitting oedema may be caused by different pathogenic mechanisms: on one hand, the involvement of tenosynovial structures; on the other hand, the involvement of lymphatic vessels, which may be rarely implicated by the inflammatory process. This different involvement is responsible for a different response to therapy and a different clinical outcome. In fact, patients with inflammation of the tenosynovial structures and normal lymphatic drainage have a more favourable clinical outcome and response to pharmacologic treatment, whilst patients affected by psoriatic arthritis with chronic lymphatic vascular damage are characterized usually by resistance of oedema to therapy. In this study, we report two cases of psoriatic arthritis with distal extremity swelling and pitting oedema. In the first patient, the swelling and pitting oedema were associated with lymphatic obstruction, as detected by lymphoscintigraphy. In the second, the predominant involvement of the tenosynovial structures, as shown by magnetic resonance, with normal lymphatic flow, may have been the cause of arthritis with oedema. These different pathogenetic mechanisms were associated with different response to therapy. Nevertheless, oedema was resistant to therapy in both patients probably because of other unknown factors, which influence therapy and clinical outcome. FAU - Quarta, L AU - Quarta L AD - Department of Rheumatology, University of Foggia Medical School, Foggia, Italy. FAU - Corrado, A AU - Corrado A FAU - d'Onofrio, F AU - d'Onofrio F FAU - Maruotti, N AU - Maruotti N FAU - Cantatore, Francesco Paolo AU - Cantatore FP LA - eng PT - Case Reports PT - Journal Article DEP - 20090716 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Antirheumatic Agents) RN - 0 (Immunoglobulin G) RN - 0 (Receptors, Tumor Necrosis Factor) RN - OP401G7OJC (Etanercept) RN - X4W7ZR7023 (Methylprednisolone) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Psoriatic/complications/drug therapy/*pathology MH - Drug Therapy, Combination MH - Etanercept MH - Extremities MH - Female MH - Humans MH - Immunoglobulin G/therapeutic use MH - Lymphatic Vessels/pathology MH - Lymphedema/complications/drug therapy/*pathology MH - Male MH - Methotrexate/therapeutic use MH - Methylprednisolone/therapeutic use MH - Middle Aged MH - Receptors, Tumor Necrosis Factor/therapeutic use MH - Synovial Membrane/pathology MH - Tendons/pathology MH - Tenosynovitis/complications/pathology MH - Treatment Failure EDAT- 2009/07/18 09:00 MHDA- 2010/10/29 06:00 CRDT- 2009/07/18 09:00 PHST- 2009/05/21 00:00 [received] PHST- 2009/06/28 00:00 [accepted] PHST- 2009/07/18 09:00 [entrez] PHST- 2009/07/18 09:00 [pubmed] PHST- 2010/10/29 06:00 [medline] AID - 10.1007/s00296-009-1060-y [doi] PST - ppublish SO - Rheumatol Int. 2010 Aug;30(10):1367-70. doi: 10.1007/s00296-009-1060-y. Epub 2009 Jul 16. PMID- 3314319 OWN - NLM STAT- MEDLINE DCOM- 19871127 LR - 20191029 IS - 0300-8827 (Print) IS - 0300-8827 (Linking) VI - 224 DP - 1987 TI - Mechanical and chemical factors in tendon healing. Effects of indomethacin and surgery in the rabbit. PG - 1-75 FAU - Carlstedt, C A AU - Carlstedt CA AD - Karolinska Institute Department of Orthopedics at Huddinge, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Sweden TA - Acta Orthop Scand Suppl JT - Acta orthopaedica Scandinavica. Supplementum JID - 0370353 RN - 9007-34-5 (Collagen) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Humans MH - Indomethacin/therapeutic use MH - Ligaments/physiology MH - Male MH - Models, Biological MH - Rabbits MH - Tendon Injuries/drug therapy/*physiopathology MH - Tendons/*physiology/surgery MH - *Wound Healing/drug effects RF - 262 EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] AID - 10.3109/17453678709154163 [doi] PST - ppublish SO - Acta Orthop Scand Suppl. 1987;224:1-75. doi: 10.3109/17453678709154163. PMID- 10722815 OWN - NLM STAT- MEDLINE DCOM- 20000419 LR - 20131121 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 25 IP - 2 DP - 2000 Mar TI - Effects of 5-fluorouracil on flexor tendon repair. PG - 242-51 AB - This study was performed to assess the effects of a single 5-minute exposure of 5-fluorouracil (5-FU) applied topically at the time of flexor tendon repair in an attempt to reduce postoperative adhesions. The flexor digitorum profundus tendon to the long and fourth toe of Leghorn chickens was lacerated and primarily repaired using a 2-strand technique. The repair site was then exposed to a single 5-minute application of 5-FU in concentrations of 5, 25, or 50 mg/mL. Legs were casted for 3 weeks. After death the tendon was examined for the work of flexion using a tensile testing machine and examined with light microscopy, scanning electron microscopy, and transmission electron microscopy for morphologic and histologic differences in adhesion formation. Forty-seven chickens were examined. Average work of flexion values were 0.12 J for normal tendon, 0.31 J for operative controls, 0.34 J for the 5 mg/mL group, 0.15 J for the 25 mg/mL group, and 0.19 J for the 50 mg/mL group. The work of flexion was significantly reduced in the 25 and 50 mg/mL groups compared with the operative controls (p =.008 and p =.03, respectively). Histologic sections as graded by a blinded pathologist revealed decreased adhesion formation in all the 5-FU-treated animals (p <.008). Histologic examination showed that the highest concentration of 5-FU was not as effective at reducing adhesions as the 25 mg/mL dose. This appeared to be due to increasing inflammatory changes seen around and within the tendons of the 50 mg/mL group. Overall, a single intraoperative application of 5-FU at concentrations of 25 mg/mL appears to be an effective mechanism for reducing postoperative flexor tendon adhesions. CI - Copyright 2000 by the American Society for Surgery of the Hand. FAU - Moran, S L AU - Moran SL AD - Division of Plastic Surgery, University of Rochester School of Medicine, Rochester, NY, USA. FAU - Ryan, C K AU - Ryan CK FAU - Orlando, G S AU - Orlando GS FAU - Pratt, C E AU - Pratt CE FAU - Michalko, K B AU - Michalko KB LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Antimetabolites, Antineoplastic) RN - 9007-34-5 (Collagen) RN - U3P01618RT (Fluorouracil) SB - IM MH - Administration, Topical MH - Analysis of Variance MH - Animals MH - Antimetabolites, Antineoplastic/*administration & dosage MH - Biomechanical Phenomena MH - Chickens MH - Collagen/ultrastructure MH - Disease Models, Animal MH - Fluorouracil/*administration & dosage MH - Postoperative Complications/*prevention & control MH - Random Allocation MH - Range of Motion, Articular MH - Reference Values MH - Tendon Injuries/physiopathology/surgery MH - Tendons/drug effects/pathology/physiopathology/*surgery MH - Tissue Adhesions/*prevention & control MH - Treatment Outcome MH - Wound Healing/drug effects EDAT- 2000/03/21 09:00 MHDA- 2000/05/29 09:00 CRDT- 2000/03/21 09:00 PHST- 2000/03/21 09:00 [pubmed] PHST- 2000/05/29 09:00 [medline] PHST- 2000/03/21 09:00 [entrez] AID - S0363-5023(00)97161-2 [pii] AID - 10.1053/jhsu.2000.jhsu25a0242 [doi] PST - ppublish SO - J Hand Surg Am. 2000 Mar;25(2):242-51. doi: 10.1053/jhsu.2000.jhsu25a0242. PMID- 20379786 OWN - NLM STAT- MEDLINE DCOM- 20110224 LR - 20211020 IS - 1860-2002 (Electronic) IS - 1536-1632 (Linking) VI - 12 IP - 6 DP - 2010 Dec TI - Increased cellular proliferation in rat skeletal muscle and tendon in response to exercise: use of FLT and PET/CT. PG - 626-34 LID - 10.1007/s11307-010-0316-y [doi] AB - PURPOSE: The purpose of this study is to investigate exercise-induced cellular proliferation in rat skeletal muscle/tendon with the use of 3'-[F-18]fluoro-3'deoxythymidine (FLT) and to quantitatively study concomitant changes in the proliferation-associated factor, Ki67. PROCEDURES: Wistar rats (n = 13) performed 3 days of treadmill running. Cellular proliferation was investigated 3 days before and 48 h after the running exercise with the use of FLT and positron emission tomography/computed tomography (PET/CT). Results were compared to a sedentary control group (n = 10). Image-derived standardized uptake values were calculated for Achilles tendons and calf muscles and compared to gene expression and immunohistochemical evaluations of Ki67. RESULTS: Treadmill running induced increased uptake of FLT uptake in calf muscles (30%; p < 0.001) and in Achilles tendon (21%, p < 0.001). The image-derived results were supported by a correlation in calf muscle to Ki67 (protein and mRNA level), while this coherence was not found in tendon. CONCLUSION: FLT-PET seems to be a promising tool for imaging of exercise-induced cellular proliferation in musculo-tendinous tissue. FAU - Skovgaard, Dorthe AU - Skovgaard D AD - Institute of Sports Medicine Copenhagen, Bispebjerg Hospital and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. dskovgaard@dadlnet.dk FAU - Bayer, Monika L AU - Bayer ML FAU - Mackey, Abigail L AU - Mackey AL FAU - Madsen, Jacob AU - Madsen J FAU - Kjaer, Michael AU - Kjaer M FAU - Kjaer, Andreas AU - Kjaer A LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Mol Imaging Biol JT - Molecular imaging and biology JID - 101125610 RN - 0 (Dideoxynucleosides) RN - 0 (Ki-67 Antigen) RN - PG53R0DWDQ (alovudine) SB - IM MH - Animals MH - *Cell Proliferation MH - *Dideoxynucleosides MH - Exercise Test MH - Hyperplasia/diagnosis MH - Ki-67 Antigen/genetics/metabolism MH - Male MH - Muscle, Skeletal/metabolism/pathology/*physiology MH - Physical Conditioning, Animal/*physiology MH - Positron-Emission Tomography/*methods MH - Rats MH - Rats, Wistar MH - Running/physiology MH - Tendons/cytology/metabolism/pathology/*physiology MH - Tomography, Emission-Computed/methods MH - Up-Regulation EDAT- 2010/04/10 06:00 MHDA- 2011/02/25 06:00 CRDT- 2010/04/10 06:00 PHST- 2010/04/10 06:00 [entrez] PHST- 2010/04/10 06:00 [pubmed] PHST- 2011/02/25 06:00 [medline] AID - 10.1007/s11307-010-0316-y [doi] PST - ppublish SO - Mol Imaging Biol. 2010 Dec;12(6):626-34. doi: 10.1007/s11307-010-0316-y. PMID- 22169737 OWN - NLM STAT- MEDLINE DCOM- 20120730 LR - 20191210 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 28 IP - 3 DP - 2012 Mar TI - Biologic enhancement of a common arthroscopic suture. PG - 390-6 LID - 10.1016/j.arthro.2011.08.306 [doi] AB - PURPOSE: The purpose of this study was to investigate the in vitro effects of an arginine-glycine-aspartic acid (RGD) coating on a high-strength nonabsorbable polyester/polyethylene (PE/PEE) suture material commonly used in orthopaedic procedures. METHODS: Human bone and tendon specimens were isolated and cultured. The cells were then plated in known densities in the presence of RGD-coated and uncoated PE/PEE suture and allowed to adhere for predetermined time periods. The RGD-coated and uncoated control sutures were then removed and assayed for cell osteoblast and tenocyte adhesion and proliferation. RESULTS: The RGD-modified suture showed a statistically significant increase in both adhesion and proliferation of human tenocytes when compared with uncoated controls (P < .05). CONCLUSIONS: The RGD peptide sequence can be effectively coupled with commercially available PE/PEE suture. RGD-coated suture is able to stimulate the adhesion and proliferation of human tenocyte cells in vitro, as well as withstand standard sterilization and storage conditions. Furthermore, the acid hydrolysis process did not affect the strength of the suture material. CLINICAL RELEVANCE: RGD-modified suture materials have the potential to create favorable biologic responses when used in common orthopaedic procedures. CI - Copyright © 2012 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Mazzocca, Augustus D AU - Mazzocca AD AD - Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut 06034, USA. admazzocca@yahoo.com FAU - Trainer, Gabriel AU - Trainer G FAU - McCarthy, Mary Beth AU - McCarthy MB FAU - Obopilwe, Elifho AU - Obopilwe E FAU - Arciero, Robert A AU - Arciero RA LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20111209 PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Oligopeptides) RN - 0 (Polyesters) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 9002-88-4 (Polyethylene) SB - IM MH - Arthroscopy/*instrumentation MH - Biomechanical Phenomena MH - Cell Adhesion/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Humans MH - Oligopeptides/administration & dosage/*pharmacology MH - Osteoblasts/*drug effects/physiology MH - Polyesters MH - Polyethylene MH - *Sutures MH - Tendons/cytology/*drug effects/physiology EDAT- 2011/12/16 06:00 MHDA- 2012/07/31 06:00 CRDT- 2011/12/16 06:00 PHST- 2010/05/07 00:00 [received] PHST- 2011/05/25 00:00 [revised] PHST- 2011/08/24 00:00 [accepted] PHST- 2011/12/16 06:00 [entrez] PHST- 2011/12/16 06:00 [pubmed] PHST- 2012/07/31 06:00 [medline] AID - S0749-8063(11)01051-6 [pii] AID - 10.1016/j.arthro.2011.08.306 [doi] PST - ppublish SO - Arthroscopy. 2012 Mar;28(3):390-6. doi: 10.1016/j.arthro.2011.08.306. Epub 2011 Dec 9. PMID- 3004598 OWN - NLM STAT- MEDLINE DCOM- 19860415 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 881 IP - 1 DP - 1986 Mar 19 TI - The action of pulsed magnetic fields on cyclic AMP levels in cultured fibroblasts. PG - 46-53 AB - Pulsed magnetic fields, similar to those used clinically to promote bone repair, have been applied to cultured fibroblasts obtained from chick embryo tendons and rabbit bone marrow. Cyclic adenosine monophosphate (cAMP) levels were found to be lower in field-treated cultures in response to hormones such as prostaglandin E2 and isoproterenol, and the fibroblasts appear less sensitive to environmental perturbation prior to hormone incubation. We propose that the adenylate cyclase complex is temporarily inactivated by prolonged exposure to pulsed magnetic fields, and that this effect might be analogous to desensitisation phenomena. FAU - Farndale, R W AU - Farndale RW FAU - Murray, J C AU - Murray JC LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Prostaglandins E) RN - E0399OZS9N (Cyclic AMP) RN - K7Q1JQR04M (Dinoprostone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Bone Marrow/drug effects MH - Bone Marrow Cells MH - Cells, Cultured MH - Chickens MH - Cyclic AMP/*analysis MH - Dinoprostone MH - Fibroblasts/*analysis/drug effects MH - Indomethacin/pharmacology MH - *Magnetics MH - Prostaglandins E/pharmacology MH - Rabbits MH - Tendons/cytology/drug effects EDAT- 1986/03/19 00:00 MHDA- 1986/03/19 00:01 CRDT- 1986/03/19 00:00 PHST- 1986/03/19 00:00 [pubmed] PHST- 1986/03/19 00:01 [medline] PHST- 1986/03/19 00:00 [entrez] AID - 0304-4165(86)90095-4 [pii] AID - 10.1016/0304-4165(86)90095-4 [doi] PST - ppublish SO - Biochim Biophys Acta. 1986 Mar 19;881(1):46-53. doi: 10.1016/0304-4165(86)90095-4. PMID- 21855540 OWN - NLM STAT- MEDLINE DCOM- 20120123 LR - 20250529 IS - 1096-0945 (Electronic) IS - 0014-4800 (Print) IS - 0014-4800 (Linking) VI - 91 IP - 3 DP - 2011 Dec TI - Demonstrating collagen tendon fibril segments involvement in intrinsic tendon repair. PG - 660-3 LID - 10.1016/j.yexmp.2011.08.002 [doi] AB - Severed tendons can undergo regenerative healing, intrinsic tendon repair. Fibrillogenesis of chick tendon involves "collagen fibril segments" (CFS), which are the building blocks of collagen fibers that make up tendon fascicles. The CFS are 10.5 micron in length, composed of tropocollagen monomers arranged in parallel arrays. Rather than incorporating single tropocollagen molecules into growing collagen fibers, incorporating large CFS units is the mechanism for generating collagen fibers. Is intrinsic tendon repair through the reestablishment of tendon embryogenesis? Gentamicin treated 10-day-old chick embryo tendons released CFS were fluorescently tagged with Rhodamine (Rh). Organ cultured severed 14-day-old embryo tendon explants received Rh tagged CFS. At day 4 auto fluorescent tagged CFS were identified at the severed tendon ends by fluorescent microscopy. Accumulation of fluorescent tagged CFS was exclusively localized to the severed ends of tendon explants. Parallels between collagen fiber growth during embryonic fibrillogenesis and tendon repair reveal CFS incorporation is responsible for collagen fibers growth. CFS incorporation into frayed collagen fibers from severed tendons is the proposed mechanism for intrinsic tendon repair, which is an example of regenerative repair. CI - Copyright © 2011 Elsevier Inc. All rights reserved. FAU - Hazard, Sprague W AU - Hazard SW AD - Wound Healing Laboratory, Division of Plastic Surgery, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States. FAU - Myers, Roland L AU - Myers RL FAU - Ehrlich, H Paul AU - Ehrlich HP LA - eng GR - R01 GM056851/GM/NIGMS NIH HHS/United States PT - Journal Article DEP - 20110807 PL - Netherlands TA - Exp Mol Pathol JT - Experimental and molecular pathology JID - 0370711 RN - 0 (Fibrillar Collagens) RN - 0 (Gentamicins) RN - 0 (Protein Synthesis Inhibitors) RN - 0 (Rhodamines) RN - 0 (Tropocollagen) SB - IM MH - Animals MH - Chick Embryo MH - *Fibrillar Collagens/metabolism/ultrastructure MH - Gentamicins/toxicity MH - Microscopy, Electron MH - Microscopy, Fluorescence MH - Organ Culture Techniques MH - Protein Synthesis Inhibitors/toxicity MH - *Regeneration MH - Rhodamines MH - Tendon Injuries/chemically induced/pathology/*physiopathology MH - Tendons/embryology/*physiopathology MH - Tropocollagen/metabolism/ultrastructure PMC - PMC3220756 MID - NIHMS331570 COIS- Conflict of Interest Statement The authors declare that there are no conflicts of interest. EDAT- 2011/08/23 06:00 MHDA- 2012/01/24 06:00 PMCR- 2012/12/01 CRDT- 2011/08/23 06:00 PHST- 2011/08/01 00:00 [received] PHST- 2011/08/02 00:00 [accepted] PHST- 2011/08/23 06:00 [entrez] PHST- 2011/08/23 06:00 [pubmed] PHST- 2012/01/24 06:00 [medline] PHST- 2012/12/01 00:00 [pmc-release] AID - S0014-4800(11)00107-9 [pii] AID - 10.1016/j.yexmp.2011.08.002 [doi] PST - ppublish SO - Exp Mol Pathol. 2011 Dec;91(3):660-3. doi: 10.1016/j.yexmp.2011.08.002. Epub 2011 Aug 7. PMID- 9330140 OWN - NLM STAT- MEDLINE DCOM- 19971202 LR - 20131121 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 22 IP - 5 DP - 1997 Sep TI - Reduction of restrictive adhesions by local aprotinin application and primary sheath repair in surgically traumatized flexor tendons of the rabbit. PG - 826-32 AB - The effects of microsurgical and medical treatments on reduction of adhesions in surgically traumatized flexor tendons of rabbits are quantified in this study. The effects of the mentioned techniques were investigated for the following 4 groups: (1) neither primary sheath repair nor aprotinin application was done, (2) primary sheath repair was done but no aprotinin was used, (3) primary sheath repair was not done but local aprotinin (15,000 IU/kg) was applied, and (4) primary sheath repair was done and local aprotinin was applied. At the sixth and twelfth postoperative weeks, the flexor digitorum profundus tendons of the second and the third digits were subjected to biomechanical tests. Only the third digit was used in macroscopic and histopathologic evaluations. There were 6 digits included in each subgroup of biomechanical tests and 4 digits per subgroups in macroscopic and histopathologic evaluations. Work of flexion (WOF) values were obtained by calculating the area under the load-displacement curve. Percent resistive work of flexion (PRWOF) was obtained by calculating the difference between the WOF value for the repaired right digit and the WOF value for the contralateral corresponding nonrepaired digit. Combined primary sheath repair and medical treatment yielded the best results in reducing the restrictive adhesions in injured tendons. The differences between the PRWOF values of group 4 were 33.7% +/- 8.2% and 15.8% +/- 7.7% for the sixth and twelfth postoperative weeks, respectively. The corresponding values for group 1 were 95.7% +/- 13.8% and 51.75% +/- 10.25%. FAU - Komurcu, M AU - Komurcu M AD - Gulhane Military Medical Academy and Medical Faculty, Department of Orthopaedics and Traumatology, Ankara, Turkey. FAU - Akkus, O AU - Akkus O FAU - Basbozkurt, M AU - Basbozkurt M FAU - Gur, E AU - Gur E FAU - Akkas, N AU - Akkas N LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Serine Proteinase Inhibitors) RN - 9087-70-1 (Aprotinin) SB - IM MH - Animals MH - Aprotinin/*pharmacology MH - Biomechanical Phenomena MH - Male MH - Rabbits MH - Range of Motion, Articular/drug effects MH - Serine Proteinase Inhibitors/*pharmacology MH - Tendon Injuries/*pathology MH - Tendons/drug effects/pathology MH - Tissue Adhesions/pathology MH - Wound Healing/*drug effects EDAT- 1997/10/23 00:00 MHDA- 1997/10/23 00:01 CRDT- 1997/10/23 00:00 PHST- 1997/10/23 00:00 [pubmed] PHST- 1997/10/23 00:01 [medline] PHST- 1997/10/23 00:00 [entrez] AID - S0363-5023(97)80076-7 [pii] AID - 10.1016/S0363-5023(97)80076-7 [doi] PST - ppublish SO - J Hand Surg Am. 1997 Sep;22(5):826-32. doi: 10.1016/S0363-5023(97)80076-7. PMID- 11386771 OWN - NLM STAT- MEDLINE DCOM- 20010809 LR - 20131121 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 26 IP - 3 DP - 2001 Jun TI - Early breaking strength of repaired flexor tendon treated with 5-fluorouracil. PG - 220-3 AB - This study investigated the effect of a single intraoperative application of 5-fluorouracil, which may diminish peritendinous adhesion formation, on the tensile strength of repaired digital flexor tendons after 7, 14 and 21 days of healing. Twenty-seven deep flexor tendons from 14 rabbits were exposed to 5-fluorouracil (50 mg/ml) for 5 minutes immediately after repair whereas matched control tendons were exposed to normal saline. Tensile testing at 7, 14 and 21 days revealed no significant differences in the gap or ultimate strengths of the 5-fluorouracil treated and control tendons. CI - Copyright 2001 The British Society for Surgery of the Hand. FAU - Cerovac, S AU - Cerovac S AD - Department of Plastic and Reconstructive Surgery, University College London, London, UK. scerovac@aol.com FAU - Afoke, A AU - Afoke A FAU - Akali, A AU - Akali A FAU - McGROUTHER, D A AU - McGROUTHER DA LA - eng PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Fluorouracil/*pharmacology MH - Male MH - Rabbits MH - Sutures MH - Tendon Injuries/physiopathology/*surgery MH - Tensile Strength MH - Tissue Adhesions/physiopathology MH - Wound Healing/*drug effects EDAT- 2001/06/02 10:00 MHDA- 2001/08/10 10:01 CRDT- 2001/06/02 10:00 PHST- 2001/06/02 10:00 [pubmed] PHST- 2001/08/10 10:01 [medline] PHST- 2001/06/02 10:00 [entrez] AID - S0266-7681(00)90537-0 [pii] AID - 10.1054/jhsb.2000.0537 [doi] PST - ppublish SO - J Hand Surg Br. 2001 Jun;26(3):220-3. doi: 10.1054/jhsb.2000.0537. PMID- 986819 OWN - NLM STAT- MEDLINE DCOM- 19761020 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 71 IP - 1 DP - 1976 Jul 12 TI - Removal of amino-terminal and carboxy-terminal extension peptides from procollagen during synthesis of chick embryo tendon collagen. PG - 60-7 FAU - Uitto, J AU - Uitto J FAU - Lichtenstein, J R AU - Lichtenstein JR LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Amino Acids) RN - 0 (Protein Precursors) RN - 9007-34-5 (Collagen) RN - 98600C0908 (Cycloheximide) RN - 9DLQ4CIU6V (Proline) SB - IM MH - Amino Acids/analysis MH - Animals MH - Chick Embryo MH - Collagen/*biosynthesis MH - Cycloheximide/pharmacology MH - Kinetics MH - Proline/metabolism MH - Protein Precursors/*metabolism MH - Tendons/drug effects/*metabolism EDAT- 1976/07/12 00:00 MHDA- 1976/07/12 00:01 CRDT- 1976/07/12 00:00 PHST- 1976/07/12 00:00 [pubmed] PHST- 1976/07/12 00:01 [medline] PHST- 1976/07/12 00:00 [entrez] AID - 0006-291X(76)90249-7 [pii] AID - 10.1016/0006-291x(76)90249-7 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1976 Jul 12;71(1):60-7. doi: 10.1016/0006-291x(76)90249-7. PMID- 16435354 OWN - NLM STAT- MEDLINE DCOM- 20060323 LR - 20220331 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 24 IP - 2 DP - 2006 Feb TI - Glucocorticoids inhibit tenocyte proliferation and Tendon progenitor cell recruitment. PG - 173-82 AB - Corticosteroid injection is commonly used to treat tendon injuries but is often associated with tendon rupture and impaired tendon healing. The effects of dexamethasone on tenocytes have been studied in vitro but only using high concentrations of dexamethasone in monolayer cultures of tenocytes over short periods of time. We have therefore investigated the effects of physiological and pharmacological concentrations of dexamethasone on monolayer cultures of tenocytes over extended time periods. We have also used fibroblastic-colony forming unit cultures to examine the effects of dexamethasone on a progenitor cell population located in tendons. Culturing tenocytes in the presence of dexamethasone for a period of 24 days resulted in a concentration-related decrease in cell number and collagen synthesis as compared to control cultures. This effect was time dependent with cell number in both dexamethasone-treated and control cultures leveling off after 14 days with the control cultures reaching higher cell densities. In contrast in control cultures, collagen accumulation continued to increase until week 4, whereas in the presence of dexamethasone, this tended to level off after 14 days. To study the role of progenitor cell recruitment, the effects of dexamethasone were investigated using the fibroblastic-colony forming unit assay. Treatment with dexamethasone at concentrations of 0.1 nM to 10 microM leads to a progressive reduction in mean colony size as compared to control cultures. Colony number remained constant at concentrations below 10 nM but fell progressively at concentrations above this. In conclusion, dexamethasone reduces both cell number and collagen synthesis in tenocyte cultures in a concentration-dependent manner by both direct effects on tenocyte proliferation and collagen accumulation, and also by modulating the recruitment of tendon progenitor cells. CI - (c) 2005 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res. FAU - Scutt, Nanette AU - Scutt N AD - Sheffield Centre for Sports Medicine, Division of Clinical Sciences South, University of Sheffield Medical School, Sheffield, United Kingdom. FAU - Rolf, Christer G AU - Rolf CG FAU - Scutt, Andrew AU - Scutt A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Cell Count MH - Cell Proliferation/*drug effects MH - Cells, Cultured MH - Collagen/metabolism MH - Colony-Forming Units Assay MH - Dexamethasone/*pharmacology MH - Dose-Response Relationship, Drug MH - Fibroblasts/drug effects/pathology/physiology MH - Glucocorticoids/*pharmacology MH - Male MH - Rats MH - Rats, Wistar MH - Stem Cells/*drug effects/pathology/physiology MH - Tail MH - Tendons/*drug effects/metabolism/pathology EDAT- 2006/01/26 09:00 MHDA- 2006/03/24 09:00 CRDT- 2006/01/26 09:00 PHST- 2006/01/26 09:00 [pubmed] PHST- 2006/03/24 09:00 [medline] PHST- 2006/01/26 09:00 [entrez] AID - 10.1002/jor.20030 [doi] PST - ppublish SO - J Orthop Res. 2006 Feb;24(2):173-82. doi: 10.1002/jor.20030. PMID- 9338923 OWN - NLM STAT- MEDLINE DCOM- 19971121 LR - 20071115 IS - 1169-8446 (Print) IS - 1169-8446 (Linking) VI - 64 IP - 7-9 DP - 1997 Jul-Sep TI - Tendons and fluoroquinolones. Unresolved issues. PG - 437-9 FAU - Kahn, M F AU - Kahn MF FAU - Hayem, G AU - Hayem G LA - eng PT - Editorial PT - Review PL - France TA - Rev Rhum Engl Ed JT - Revue du rhumatisme (English ed.) JID - 9313916 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Adult MH - Age Distribution MH - Anti-Infective Agents/*adverse effects/therapeutic use MH - Child MH - Clinical Trials as Topic MH - Fluoroquinolones MH - France/epidemiology MH - Humans MH - Incidence MH - Middle Aged MH - Risk Factors MH - Tendinopathy/*chemically induced/epidemiology MH - Tendons/drug effects RF - 26 EDAT- 1997/07/01 00:00 MHDA- 1997/10/27 00:01 CRDT- 1997/07/01 00:00 PHST- 1997/07/01 00:00 [pubmed] PHST- 1997/10/27 00:01 [medline] PHST- 1997/07/01 00:00 [entrez] PST - ppublish SO - Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):437-9. PMID- 15439648 OWN - NLM STAT- MEDLINE DCOM- 20040930 LR - 20221207 IS - 0028-7628 (Print) IS - 0028-7628 (Linking) VI - 50 IP - 17:1 DP - 1950 Sep 1 TI - Immediate tendon repair with fascia lata transference in a compound fracture treated with aureomycin. PG - 2074 FAU - COLE, F R AU - COLE FR LA - eng PT - Journal Article PL - United States TA - N Y State J Med JT - New York state journal of medicine JID - 0401064 RN - WCK1KIQ23Q (Chlortetracycline) SB - OM MH - *Chlortetracycline MH - *Fascia Lata MH - *Fractures, Bone MH - *Fractures, Open MH - Humans MH - *Plastic Surgery Procedures MH - *Tendons OID - CLML: 5019:30354:18:89:241 OTO - NLM OT - *AUREOMYCIN OT - *FRACTURES OT - *TENDONS EDAT- 1950/09/01 00:00 MHDA- 1950/09/01 00:01 CRDT- 1950/09/01 00:00 PHST- 1950/09/01 00:00 [pubmed] PHST- 1950/09/01 00:01 [medline] PHST- 1950/09/01 00:00 [entrez] PST - ppublish SO - N Y State J Med. 1950 Sep 1;50(17:1):2074. PMID- 5014835 OWN - NLM STAT- MEDLINE DCOM- 19720603 LR - 20190516 IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 83 DP - 1972 Mar-Apr TI - Stenosing tenovaginitis of the wrist and fingers. PG - 87-90 FAU - Lapidus, P W AU - Lapidus PW FAU - Guidotti, F P AU - Guidotti FP LA - eng PT - Journal Article PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Aged MH - Child MH - Female MH - *Fingers/surgery MH - Humans MH - Male MH - Postoperative Complications MH - Prednisolone/*therapeutic use MH - Recurrence MH - Tendons/surgery MH - Tenosynovitis/*drug therapy/surgery MH - *Wrist/surgery EDAT- 1972/03/01 00:00 MHDA- 1972/03/01 00:01 CRDT- 1972/03/01 00:00 PHST- 1972/03/01 00:00 [pubmed] PHST- 1972/03/01 00:01 [medline] PHST- 1972/03/01 00:00 [entrez] AID - 10.1097/00003086-197203000-00015 [doi] PST - ppublish SO - Clin Orthop Relat Res. 1972 Mar-Apr;83:87-90. doi: 10.1097/00003086-197203000-00015. PMID- 12798059 OWN - NLM STAT- MEDLINE DCOM- 20030814 LR - 20091103 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 21 IP - 4 DP - 2003 Jul TI - Mechanical factors influence the expression of endostatin--an inhibitor of angiogenesis--in tendons. PG - 610-6 AB - Avascular zones of tendons are predisposed for degenerative changes and spontaneous rupture. Therefore, we analyzed the expression of the endogenous angiogenesis inhibiting factor endostatin in human fetal and adult tendons by immunohistochemical and biochemical methods. Moreover, to elucidate factors involved in the regulation of vascularity, we exposed primary cultures of rat tendon cells to intermittent hydrostatic pressure (0.2 MPa, 0.1 Hz for 24 h), and measured the endostatin content by ELISA and the effect of the conditioned medium to the proliferation of human umbilical vein endothelial cells (HUVEC). In fetal tendons high endostatin levels could be quantified by ELISA whereas low levels were found in adult tissue. In fetal tendons endostatin could also be immunostained in endothelial cells but mainly in fibroblasts. In adult Achilles tendons endostatin immunostaining was restricted to endothelial cells. In the tibialis posterior tendon--as an example for "wrap around"--endostatin immunostaining remained positive in the fibrocartilage adjacent to the medial malleolus. Fibrochondrocytes of the type II collagen positive fibrocartilage were intensively stained with the endostatin antibody. Factor VIII immunostaining showed that this region was largely avascular. Monolayer cultures of tendon cells released measurable amounts of endostatin into their culture supernatants. Application of intermittent hydrostatic pressure increased endostatin expression significantly. The conditioned media of tendon fibroblasts cultivated under intermittent hydrostatic pressure inhibited the proliferation of HUVEC in a dose dependent way. The spatial expression of endostatin in adult gliding tendons suggests that mechanical factors are involved in the regulation of this anti-angiogenic factor. In accordance, tendon cells exposed to intermittent hydrostatic pressure inhibit endothelial cell proliferation via humoral factors and produce endostatin. These findings support the view that the development and maintenance of avascular zones in tendons might be caused by a mechanically induced upregulation of anti-angiogenic factors. FAU - Pufe, Thomas AU - Pufe T AD - Department of Anatomy, Christian Albrechts University, Michaelisstrasse 1, D-24105, Kiel, Germany. FAU - Petersen, Wolf AU - Petersen W FAU - Kurz, Bodo AU - Kurz B FAU - Tsokos, Michael AU - Tsokos M FAU - Tillmann, Bernhard AU - Tillmann B FAU - Mentlein, Rolf AU - Mentlein R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Collagen Type XVIII) RN - 0 (Culture Media, Conditioned) RN - 0 (Endostatins) RN - 0 (Peptide Fragments) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/*blood supply/embryology/*metabolism MH - Adult MH - Age Factors MH - Aged MH - Cell Division/drug effects/physiology MH - Cells, Cultured MH - Collagen/*biosynthesis MH - Collagen Type XVIII MH - Culture Media, Conditioned/pharmacology MH - Endostatins MH - Endothelium, Vascular/cytology MH - Female MH - Fetus/metabolism MH - Humans MH - Hydrostatic Pressure MH - Male MH - Middle Aged MH - Neovascularization, Physiologic/*physiology MH - Peptide Fragments/*biosynthesis MH - Stress, Mechanical MH - Umbilical Veins/cytology MH - Up-Regulation/physiology EDAT- 2003/06/12 05:00 MHDA- 2003/08/15 05:00 CRDT- 2003/06/12 05:00 PHST- 2003/06/12 05:00 [pubmed] PHST- 2003/08/15 05:00 [medline] PHST- 2003/06/12 05:00 [entrez] AID - S0736026602002620 [pii] AID - 10.1016/S0736-0266(02)00262-0 [doi] PST - ppublish SO - J Orthop Res. 2003 Jul;21(4):610-6. doi: 10.1016/S0736-0266(02)00262-0. PMID- 21617553 OWN - NLM STAT- MEDLINE DCOM- 20111215 LR - 20131121 IS - 1536-7355 (Electronic) IS - 1076-1608 (Linking) VI - 17 IP - 4 DP - 2011 Jun TI - Rapid development of sarcoid tenosynovitis. PG - 201-3 LID - 10.1097/RHU.0b013e31821c0a17 [doi] AB - We report a case of acute tenosynovitis from sarcoidosis and review previously reported cases of this entity. A woman with known pulmonary sarcoidosis rapidly developed painless nodules in the tendon sheaths of the dorsum of both hands and wrists. Sarcoid tenosynovitis is almost exclusively found in the upper extremity. The flexor and extensor tendons are equally affected. The condition may respond to medical therapy including corticosteroids and other immunomodulating medications. Surgical debulking and tendon sheathectomy have also been curative. The disease has also been reported to spontaneously resolve. Our patient dramatically improved while on methotrexate. FAU - Lambert, Lara AU - Lambert L AD - Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. FAU - Riemer, Ellen C AU - Riemer EC FAU - Judson, Marc A AU - Judson MA LA - eng PT - Case Reports PT - Journal Article PT - Review PL - United States TA - J Clin Rheumatol JT - Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases JID - 9518034 RN - 0 (Antirheumatic Agents) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Acute Disease MH - Antirheumatic Agents/therapeutic use MH - Female MH - Humans MH - Methotrexate/therapeutic use MH - Middle Aged MH - Sarcoidosis, Pulmonary/*complications MH - Tenosynovitis/*diagnosis/drug therapy/*etiology MH - Treatment Outcome EDAT- 2011/05/28 06:00 MHDA- 2011/12/16 06:00 CRDT- 2011/05/28 06:00 PHST- 2011/05/28 06:00 [entrez] PHST- 2011/05/28 06:00 [pubmed] PHST- 2011/12/16 06:00 [medline] AID - 10.1097/RHU.0b013e31821c0a17 [doi] PST - ppublish SO - J Clin Rheumatol. 2011 Jun;17(4):201-3. doi: 10.1097/RHU.0b013e31821c0a17. PMID- 10832946 OWN - NLM STAT- MEDLINE DCOM- 20000614 LR - 20131121 IS - 0038-4348 (Print) IS - 0038-4348 (Linking) VI - 93 IP - 5 DP - 2000 May TI - Quinolones and tendon ruptures. PG - 488-91 AB - We report two cases of tendon rupture associated with ciprofloxacin. One patient had a complete rupture of an Achilles tendon 6 months after taking the medication. The other case involved a partial rupture of the subscapularis tendon. Both ruptures occurred with minimal mechanical stress on the tendons, suggesting that the fluoroquinolone increased the susceptibility to rupture. We also review the literature describing the association between fluoroquinolones and tendon rupture and discuss the mechanisms explaining the heightened risk of tendon rupture associated with these drugs. FAU - Casparian, J M AU - Casparian JM AD - Department of Medicine, University of Kansas Medical Center, Kansas City 66160-7319, USA. FAU - Luchi, M AU - Luchi M FAU - Moffat, R E AU - Moffat RE FAU - Hinthorn, D AU - Hinthorn D LA - eng PT - Case Reports PT - Journal Article PT - Review PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 RN - 0 (Anti-Infective Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM CIN - South Med J. 2000 May;93(5):525-6. doi: 10.1097/00007611-200005000-00019. PMID: 10832957 MH - Achilles Tendon/*drug effects MH - Adult MH - Anti-Infective Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Disease Susceptibility MH - Humans MH - Male MH - Middle Aged MH - Muscular Diseases/*chemically induced MH - Rotator Cuff/*drug effects MH - Rupture, Spontaneous/chemically induced MH - Stress, Mechanical RF - 15 EDAT- 2000/06/01 09:00 MHDA- 2000/06/17 09:00 CRDT- 2000/06/01 09:00 PHST- 2000/06/01 09:00 [pubmed] PHST- 2000/06/17 09:00 [medline] PHST- 2000/06/01 09:00 [entrez] PST - ppublish SO - South Med J. 2000 May;93(5):488-91. PMID- 22772553 OWN - NLM STAT- MEDLINE DCOM- 20120919 LR - 20211021 IS - 1546-170X (Electronic) IS - 1078-8956 (Linking) VI - 18 IP - 7 DP - 2012 Jul 6 TI - Primed for inflammation: enthesis-resident T cells. PG - 1018-9 LID - 10.1038/nm.2854 [doi] FAU - Lories, Rik J AU - Lories RJ FAU - McInnes, Iain B AU - McInnes IB LA - eng PT - Comment PT - News DEP - 20120706 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 RN - 0 (Interleukin-23) SB - IM CON - Nat Med. 2012 Jul 01;18(7):1069-76. doi: 10.1038/nm.2817. PMID: 22772566 MH - Animals MH - Humans MH - Interleukin-23/*immunology MH - Spondylarthropathies/*immunology MH - T-Lymphocytes/*immunology MH - Tendons/*immunology EDAT- 2012/07/10 06:00 MHDA- 2012/09/20 06:00 CRDT- 2012/07/10 06:00 PHST- 2012/07/10 06:00 [entrez] PHST- 2012/07/10 06:00 [pubmed] PHST- 2012/09/20 06:00 [medline] AID - nm.2854 [pii] AID - 10.1038/nm.2854 [doi] PST - epublish SO - Nat Med. 2012 Jul 6;18(7):1018-9. doi: 10.1038/nm.2854. PMID- 15013092 OWN - NLM STAT- MEDLINE DCOM- 20040324 LR - 20211008 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 22 IP - 2 DP - 2004 Mar TI - Ex vivo static tensile loading inhibits MMP-1 expression in rat tail tendon cells through a cytoskeletally based mechanotransduction mechanism. PG - 328-33 AB - To determine the effect of various degrees of ex vivo static tensile loading on the expression of collagenase (MMP-1) in tendon cells, rat tail tendons were statically loaded in tension at 0.16, 0.77, 1.38 or 2.6 MPa for 24 h. Northern blot analysis was used to assay for mRNA expression of MMP-1 in freshly harvested, 24 h load deprived, and 24 h statically loaded tendons. Western blot analysis was used to assay for pro-MMP-1 and MMP-1 protein expression in fresh and 24 h load deprived tendons. Freshly harvested rat tail tendons demonstrated no evidence of MMP-1 mRNA expression and no evidence of the pro-MMP-1 or MMP-1 protein. Ex vivo load deprivation for 24 h resulted in a marked increase in the mRNA expression of MMP-1 which coincided with a marked increase of both pro-MMP-1 and MMP-1 protein expression. When tendons were subjected to ex vivo static tensile loading during the 24 h culture period, a significant inhibition of this upregulation of MMP-1 mRNA expression was found with increasing load (p<0.05). A strong (r2=0.78) and significant (p<0.001) inverse correlation existed between the level of static tensile load and the expression of MMP-1. Disruption of the actin cytoskeleton with cytochalasin D abolished the inhibitory effect of ex vivo static tensile loading on MMP-1 expression. The results of this study suggest that up-regulation of MMP-1 expression in tendon cells ex vivo can be inhibited by static tensile loading, presumably through a cytoskeletally based mechanotransduction pathway. FAU - Arnoczky, Steven P AU - Arnoczky SP AD - Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA. arnoczky@cvm.msu.edu FAU - Tian, Tao AU - Tian T FAU - Lavagnino, Michael AU - Lavagnino M FAU - Gardner, Keri AU - Gardner K LA - eng PT - Journal Article PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (RNA, Messenger) RN - 22144-77-0 (Cytochalasin D) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Animals MH - Blotting, Northern MH - Blotting, Western MH - Cytochalasin D/pharmacology MH - Cytoskeleton/drug effects MH - Gene Expression MH - Matrix Metalloproteinase 1/genetics/*metabolism MH - Mechanotransduction, Cellular/*physiology MH - Microscopy, Confocal MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Tail MH - Tendons/cytology/*metabolism MH - *Tensile Strength MH - Weight-Bearing/*physiology EDAT- 2004/03/12 05:00 MHDA- 2004/03/25 05:00 CRDT- 2004/03/12 05:00 PHST- 2003/07/21 00:00 [accepted] PHST- 2004/03/12 05:00 [pubmed] PHST- 2004/03/25 05:00 [medline] PHST- 2004/03/12 05:00 [entrez] AID - S0736026603001852 [pii] AID - 10.1016/S0736-0266(03)00185-2 [doi] PST - ppublish SO - J Orthop Res. 2004 Mar;22(2):328-33. doi: 10.1016/S0736-0266(03)00185-2. PMID- 19587082 OWN - NLM STAT- MEDLINE DCOM- 20100406 LR - 20211020 IS - 2043-6289 (Electronic) IS - 1753-1934 (Print) IS - 0266-7681 (Linking) VI - 34 IP - 5 DP - 2009 Oct TI - The effect of tissue culture on suture holding strength and degradation in canine tendon. PG - 643-50 LID - 10.1177/1753193409104564 [doi] AB - The purpose of this study was to assess tendon metabolism and suture pull-out strength after simple tendon suture in a tissue culture model. One hundred and twelve flexor digitorum profundus tendons from 28 dogs were cultured for 7, 14, or 21 days with or without a static tensile load. In both groups increased levels of matrix metalloproteinase (MMP) mRNA was noted. Suture pull-out strength did not decrease during tissue culture. While the presence of a static load had no effect on the pull-out strength, it did affect MMP mRNA expression. This tissue culture model could be useful in studying the effect of factors on the tendon-suture interface. FAU - Omae, H AU - Omae H AD - Orthopedic Biomechanics Laboratory, Mayo Clinic Rochester, MN 55905, USA. FAU - Zhao, C AU - Zhao C FAU - Sun, Y-L AU - Sun YL FAU - Zobitz, M E AU - Zobitz ME FAU - Moran, S L AU - Moran SL FAU - Amadio, P C AU - Amadio PC LA - eng GR - R01 AR044391/AR/NIAMS NIH HHS/United States GR - R01 AR057745/AR/NIAMS NIH HHS/United States GR - R03 AR049407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090708 PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Dogs MH - *Forelimb MH - Matrix Metalloproteinases/genetics/metabolism MH - RNA, Messenger/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - *Sutures MH - Tendons/*metabolism/*physiopathology/surgery MH - Tensile Strength MH - Tissue Culture Techniques MH - Tissue Inhibitor of Metalloproteinases/genetics/metabolism MH - Weight-Bearing PMC - PMC3694784 MID - NIHMS371753 EDAT- 2009/07/10 09:00 MHDA- 2010/04/07 06:00 PMCR- 2013/06/27 CRDT- 2009/07/10 09:00 PHST- 2009/07/10 09:00 [entrez] PHST- 2009/07/10 09:00 [pubmed] PHST- 2010/04/07 06:00 [medline] PHST- 2013/06/27 00:00 [pmc-release] AID - 1753193409104564 [pii] AID - 10.1177/1753193409104564 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2009 Oct;34(5):643-50. doi: 10.1177/1753193409104564. Epub 2009 Jul 8. PMID- 17538473 OWN - NLM STAT- MEDLINE DCOM- 20070713 LR - 20141009 IS - 0744-6020 (Print) IS - 0744-6020 (Linking) VI - 26 IP - 3 DP - 2007 May-Jun TI - Pathogenesis of tendon rupture secondary to fluoroquinolone therapy. PG - 175-82; quiz 183-4 AB - Tendon rupture related to trauma and corticosteroid injection, in and about tendon insertion sites, is well documented in the literature. Rupture of tendon after fluoroquinolone therapy has been identified in the recent past. Both short- and long-term courses of antibiotic treatment with fluoroquinolone may precipitate alteration in tendon matrix leading to tendinopathy with subsequent rupture. The pathogenesis of tendon rupture secondary to fluoroquinolone therapy is presented. FAU - Childs, Sharon G AU - Childs SG AD - Adult/Acute Care Nurse Practitioner, Baltimore, MD, USA. LA - eng PT - Journal Article PT - Review PL - United States TA - Orthop Nurs JT - Orthopedic nursing JID - 8409486 RN - 0 (Fluoroquinolones) MH - Fluoroquinolones/*adverse effects MH - Humans MH - Risk Factors MH - Rupture, Spontaneous/chemically induced/physiopathology MH - Tendinopathy/*chemically induced/*physiopathology MH - Tendons/anatomy & histology/physiology RF - 44 EDAT- 2007/06/01 09:00 MHDA- 2007/07/14 09:00 CRDT- 2007/06/01 09:00 PHST- 2007/06/01 09:00 [pubmed] PHST- 2007/07/14 09:00 [medline] PHST- 2007/06/01 09:00 [entrez] AID - 00006416-200705000-00009 [pii] AID - 10.1097/01.NOR.0000276969.09808.2c [doi] PST - ppublish SO - Orthop Nurs. 2007 May-Jun;26(3):175-82; quiz 183-4. doi: 10.1097/01.NOR.0000276969.09808.2c. PMID- 15890441 OWN - NLM STAT- MEDLINE DCOM- 20050825 LR - 20220408 IS - 0300-483X (Print) IS - 0300-483X (Linking) VI - 212 IP - 1 DP - 2005 Aug 15 TI - Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. PG - 24-36 AB - Antimicrobial therapy with fluoroquinolones can be associated with tendinitis and other tendon disorders as an adverse reaction associated with this class of antimicrobials. Here we investigated aspects of the mechanism of quinolone-induced tendotoxicity in human tenocytes focussing mainly on the question whether fluoroquinolones may induce apoptosis. Monolayers of human tenocytes were incubated with ciprofloxacin or levofloxacin at different concentrations (0, 3, 10, 30 and 100mg/L medium) for up to 4 days. Ultrastructural changes were studied by electron microscopy, and alterations in synthesis of specific proteins were determined using immunoblotting. At concentrations, which are achievable during quinolone therapy, 3mg ciprofloxacin/L medium significantly decreased type I collagen; similar changes were observed with 3mg ciprofloxacin or 10mg levofloxacin/L medium for the beta(1)- integrin receptors. Effects were intensified at higher concentrations and longer incubation periods. Cytoskeletal and signalling proteins, such as activated shc or erk 1/2, were significantly reduced by both fluoroquinolones already at 3mg/L. Furthermore, time- and concentration-dependent increases of matrix metalloproteinases as well as of the apoptosis marker activated caspase-3 were found. Apoptotic changes were confirmed by electron microscopy: both fluoroquinolones caused typical alterations like condensed material in the nucleus, swollen cell organelles, apoptotic bodies and bleb formation at the cell membrane. Our results provide evidence that besides changes in receptor and signalling proteins apoptosis has to be considered as a final event in the pathogenesis of fluoroquinolone-induced tendopathies. FAU - Sendzik, Judith AU - Sendzik J AD - Institute of Clinical Pharmacology and Toxicology, Department of Toxicology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Garystr. 5, 14195 Berlin, Germany. FAU - Shakibaei, Mehdi AU - Shakibaei M FAU - Schäfer-Korting, Monika AU - Schäfer-Korting M FAU - Stahlmann, Ralf AU - Stahlmann R LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Ireland TA - Toxicology JT - Toxicology JID - 0361055 RN - 0 (Fluoroquinolones) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - EC 3.4.- (Metalloproteases) RN - EC 3.4.22.- (CASP3 protein, human) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.22.- (Caspases) SB - IM MH - Apoptosis/drug effects/physiology MH - Caspase 3 MH - Caspases/*metabolism MH - Cells, Cultured MH - Extracellular Matrix/*drug effects/metabolism/pathology MH - Fluoroquinolones/*toxicity MH - Humans MH - Intracellular Signaling Peptides and Proteins/*metabolism MH - Male MH - Metalloproteases/*metabolism MH - Middle Aged MH - Tendons/*drug effects/metabolism/pathology/ultrastructure EDAT- 2005/05/14 09:00 MHDA- 2005/08/27 09:00 CRDT- 2005/05/14 09:00 PHST- 2005/01/05 00:00 [received] PHST- 2005/03/10 00:00 [revised] PHST- 2005/04/02 00:00 [accepted] PHST- 2005/05/14 09:00 [pubmed] PHST- 2005/08/27 09:00 [medline] PHST- 2005/05/14 09:00 [entrez] AID - S0300-483X(05)00175-7 [pii] AID - 10.1016/j.tox.2005.04.002 [doi] PST - ppublish SO - Toxicology. 2005 Aug 15;212(1):24-36. doi: 10.1016/j.tox.2005.04.002. PMID- 28671883 OWN - NLM STAT- MEDLINE DCOM- 20181119 LR - 20191210 IS - 1536-3708 (Electronic) IS - 0148-7043 (Linking) VI - 80 IP - 2 DP - 2018 Feb TI - Prevention of Peritendinous Adhesion Formation After the Flexor Tendon Surgery in Rabbits: A Comparative Study Between Use of Local Interferon-α, Interferon-β, and 5-Fluorouracil. PG - 171-175 LID - 10.1097/SAP.0000000000001169 [doi] AB - BACKGROUND: Peritendinous adhesion is the most common complication after tendon surgery, particularly in zone II of the hand. Prevention of inflammation around the tendon, which develops after trauma and surgery, can decrease the tendon adhesion formation. This study compares the effect of some anti-inflammatory cytokines with 5-fluorouracil (5-FU) on the tensile strength and in prevention of peritendinous adhesion formation. METHODS: Sixteen rabbits were allocated equally into 4 groups. Tendons of the index and ring fingers in zone II of the right hind paw were cut in all animals and then repaired. Interferon (IFN)-α in group 1, 5-FU in group 2, normal saline in group 3, and IFN-β in group 4 were locally applied to the repaired sites. Three weeks later, tensometric and histopathologic evaluations were performed. RESULTS: The force required for removing the tendon from the sheath was not different between the groups (P = 0.130), but the time required for removal was significantly shorter in 5-FU group (P = 0.049). The strength of repair was not different between the groups in terms of force and time needed for rupture (P = 0.11 and 0.67, respectively). In histopathologic examination, normal architecture of the tendon and peritendon environment was less disturbed in the IFN groups, especially in IFN-β specimens. CONCLUSIONS: Local application of 5-FU significantly reduced peritendinous adhesion. Local IFN-α and IFN-β had no significant effect on the prevention of peritendinous adhesion formation. The strength of the repair was not affected by these cytokines and 5-FU. FAU - Fatemi, Mohammad Javad AU - Fatemi MJ FAU - Shirani, Shahram AU - Shirani S FAU - Sobhani, Roohollah AU - Sobhani R FAU - Lebaschi, Amir Hossein AU - Lebaschi AH FAU - Gharegozlou, Mohammad Javad AU - Gharegozlou MJ FAU - Bagheri, Tooran AU - Bagheri T FAU - Pedram, Mirsepehr AU - Pedram M FAU - Saberi, Mohsen AU - Saberi M FAU - Araghi, Shirin AU - Araghi S FAU - Fatemi, Mohammad Ali AU - Fatemi MA LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PL - United States TA - Ann Plast Surg JT - Annals of plastic surgery JID - 7805336 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Interferon-alpha) RN - 77238-31-4 (Interferon-beta) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology/*therapeutic use MH - Biomechanical Phenomena MH - Fluorouracil/pharmacology/*therapeutic use MH - Interferon-alpha/pharmacology/*therapeutic use MH - Interferon-beta/pharmacology/*therapeutic use MH - Postoperative Complications/*prevention & control MH - Rabbits MH - Tendon Injuries/*surgery MH - Tendons/drug effects/physiopathology/surgery MH - Tensile Strength/drug effects MH - Tissue Adhesions/etiology/*prevention & control MH - Treatment Outcome EDAT- 2017/07/04 06:00 MHDA- 2018/11/20 06:00 CRDT- 2017/07/04 06:00 PHST- 2017/07/04 06:00 [pubmed] PHST- 2018/11/20 06:00 [medline] PHST- 2017/07/04 06:00 [entrez] AID - 10.1097/SAP.0000000000001169 [doi] PST - ppublish SO - Ann Plast Surg. 2018 Feb;80(2):171-175. doi: 10.1097/SAP.0000000000001169. PMID- 7240273 OWN - NLM STAT- MEDLINE DCOM- 19810820 LR - 20190821 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 14 IP - 3 DP - 1981 TI - The biochemical properties of connective tissue in rabbits as influenced by short-term glucocorticoid treatment. PG - 129-33 FAU - Oxlund, H AU - Oxlund H FAU - Manthorpe, R AU - Manthorpe R FAU - Viidik, A AU - Viidik A LA - eng PT - Journal Article PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Glucocorticoids) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Connective Tissue/*drug effects MH - Elasticity MH - Glucocorticoids/*pharmacology MH - Male MH - Muscles/drug effects MH - Prednisolone/pharmacology MH - Rabbits MH - Tendons/drug effects MH - Tensile Strength MH - Viscosity EDAT- 1981/01/01 00:00 MHDA- 1981/01/01 00:01 CRDT- 1981/01/01 00:00 PHST- 1981/01/01 00:00 [pubmed] PHST- 1981/01/01 00:01 [medline] PHST- 1981/01/01 00:00 [entrez] AID - 0021-9290(81)90018-X [pii] AID - 10.1016/0021-9290(81)90018-x [doi] PST - ppublish SO - J Biomech. 1981;14(3):129-33. doi: 10.1016/0021-9290(81)90018-x. PMID- 2025646 OWN - NLM STAT- MEDLINE DCOM- 19910612 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1089 IP - 1 DP - 1991 May 2 TI - Comparison on collagen gene expression in the developing chick embryo tendon and heart. Tissue and development time-dependent action of dexamethasone. PG - 40-6 AB - Glucocorticoids modulate various cellular functions such as proliferation, energy metabolism and the synthesis of proteins. In the present study, the response of collagen genes to dexamethasone in different stages of chick embryo development was studied in tendon and heart using Northern blot analysis and specific cDNA probes. The changes in collagen gene expression were compared to alterations in two reference mRNAs: actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The levels of specific mRNAs measured per ribosomal RNA in tendon and heart varied markedly during normal development. In tendon the relative levels of alpha 1(I), alpha 2(I) and alpha 1(III) collagen mRNAs were highest between days 14-16 when also the synthesis of matrix proteins is most active. In heart the levels of these mRNAs peaked at day 12. In addition, qualitative differences were observed in the expression of actin genes between tendon and heart. Dexamethasone in high dose decreased collagen mRNA levels in tendons, while in heart a stimulatory effect was noted. Dexamethasone also decreased GAPDH mRNA levels in tendons. The alterations in gene expression after dexamethasone treatment in tendon and heart did not correlate with the level of specific glucocorticoid receptors, which varied markedly during the development of chick embryos. The cDNA for pro alpha 1(I) collagen hybridized to two transcripts corresponding to 6.2 and 5.1 kb in tendon and heart. During normal development of chick embryos the ratio of 6.2/5.1 kb mRNAs decreased markedly in heart, but no such change was observed in tendons. Dexamethasone, however, decreased the ratio of 6.2/5.1 kb transcripts in tendons. There was a significant correlation between the ratio 6.2/5.1 kb transcripts and total alpha 1(I) mRNA both in tendon and heart, suggesting that the 6.2 kb transcript may be associated with the rate of synthesis of type I collagen. FAU - Oikarinen, A AU - Oikarinen A AD - Department of Dermatology, University of Oulu, Finland. FAU - Mäkelä, J AU - Mäkelä J FAU - Vuorio, T AU - Vuorio T FAU - Vuorio, E AU - Vuorio E LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Actins) RN - 0 (RNA, Messenger) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) RN - EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases) SB - IM MH - Actins/genetics MH - Animals MH - Blotting, Northern MH - Chick Embryo MH - Collagen/*genetics MH - Dexamethasone/*pharmacology MH - Gene Expression Regulation/drug effects MH - Glyceraldehyde-3-Phosphate Dehydrogenases/genetics MH - Heart/embryology MH - Myocardium/*metabolism MH - Organ Specificity MH - RNA, Messenger/metabolism MH - Tendons/embryology/*metabolism MH - Time Factors MH - Transcription, Genetic EDAT- 1991/05/02 00:00 MHDA- 1991/05/02 00:01 CRDT- 1991/05/02 00:00 PHST- 1991/05/02 00:00 [pubmed] PHST- 1991/05/02 00:01 [medline] PHST- 1991/05/02 00:00 [entrez] AID - 0167-4781(91)90082-W [pii] AID - 10.1016/0167-4781(91)90082-w [doi] PST - ppublish SO - Biochim Biophys Acta. 1991 May 2;1089(1):40-6. doi: 10.1016/0167-4781(91)90082-w. PMID- 15922918 OWN - NLM STAT- MEDLINE DCOM- 20051017 LR - 20050530 IS - 1083-7515 (Print) IS - 1083-7515 (Linking) VI - 10 IP - 2 DP - 2005 Jun TI - Molecular events in tendinopathy: a role for metalloproteases. PG - 267-77 AB - Disorganized, haphazard ineffective healing is a constant feature of chronic tendinopathy. Normal tendon is composed mostly of type I collagen. Tendinopathic tendons, conversely, have a greater proportion of type III collagen, which is associated with tendon rupture. Matrix metalloproteinases (MMPs) are involved in remodelling of the extracellular matrix (ECM) of tendons, because they are either up- or down-regulated in tendinopathy. A balance between MMPs and tissue inhibitors of metalloproteinases is required to maintain tendon homeostasis. The mechanism of activation of MMPs is poorly understood, and their precise role in tendinopathy is unclear. FAU - Magra, Merzesh AU - Magra M AD - Department of Trauma and Orthopaedic Surgery, Keele University School of Medicine, Thornburrow Drive, Hartshill, Stoke-on-Trent, ST4 7QB Staffordshire, UK. FAU - Maffulli, Nicola AU - Maffulli N LA - eng PT - Journal Article PT - Review PL - United States TA - Foot Ankle Clin JT - Foot and ankle clinics JID - 9615073 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Connective Tissue Diseases/enzymology/etiology/physiopathology MH - Humans MH - Matrix Metalloproteinases/*physiology MH - Tendons/*enzymology MH - Tissue Inhibitor of Metalloproteinases/*physiology RF - 78 EDAT- 2005/06/01 09:00 MHDA- 2005/10/18 09:00 CRDT- 2005/06/01 09:00 PHST- 2005/06/01 09:00 [pubmed] PHST- 2005/10/18 09:00 [medline] PHST- 2005/06/01 09:00 [entrez] AID - S1083-7515(05)00013-6 [pii] AID - 10.1016/j.fcl.2005.01.012 [doi] PST - ppublish SO - Foot Ankle Clin. 2005 Jun;10(2):267-77. doi: 10.1016/j.fcl.2005.01.012. PMID- 19296084 OWN - NLM STAT- MEDLINE DCOM- 20091208 LR - 20220311 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 17 IP - 7 DP - 2009 Jul TI - Negative effects of parecoxib and indomethacin on tendon healing: an experimental study in rats. PG - 835-9 LID - 10.1007/s00167-009-0763-7 [doi] AB - Conventional non-steroidal anti-inflammatory drugs (NSAIDs) and newer specific cyclooxygenase-2 (cox-2) inhibitors are commonly used in muscular skeletal trauma and in relation to orthopedic surgery to reduce the inflammatory response and pain. Studies have indicated that these drugs can have a negative effect on tendon healing in the early proliferative phase, but might be beneficial in the remodeling phase when inflammation might impede healing. Our study was designed to investigate if short-term administration of cox inhibitors after injury or postoperatively might have negative effects on the tendon healing. The right Achilles tendon of 60 rats was cut transversely, a 3 mm long segment of the tendon was removed and left unrepaired. The animals were then given parecoxib, indomethacin or saline intraperitoneally twice daily for 7 days. After 14 days, the animals were euthanized. The transverse and sagittal diameters in the healing area were measured and mechanical testing of the tensile strength of the tendons was performed. We found a significantly lower tensile strength in rats given both parecoxib and indomethacin compared to the control group. Stiffness in the healing tendons was significantly lower in the parecoxib group compared to both the placebo and the indomethacin groups. The transverse and sagittal diameters of the tendons were reduced in both the parecoxib and indomethacin groups. Both parecoxib and indomethacin impaired tendon healing; the negative effect was most pronounced with parecoxib. FAU - Dimmen, Sigbjorn AU - Dimmen S AD - Faculty of Medicine, Orthopaedic Centre, Ullevaal University Hospital, University of Oslo, Kirkeveien 166, 0407, Oslo, Norway. sidimmen@online.no FAU - Engebretsen, Lars AU - Engebretsen L FAU - Nordsletten, Lars AU - Nordsletten L FAU - Madsen, Jan Erik AU - Madsen JE LA - eng PT - Journal Article DEP - 20090319 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Isoxazoles) RN - 9TUW81Y3CE (parecoxib) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Cyclooxygenase Inhibitors/administration & dosage/*adverse effects MH - Female MH - Indomethacin/administration & dosage/*adverse effects MH - Isoxazoles/administration & dosage/*adverse effects MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Recovery of Function/drug effects/physiology MH - Tendons/*drug effects/physiopathology MH - Tensile Strength/drug effects/physiology MH - Treatment Outcome MH - Wound Healing/*drug effects EDAT- 2009/03/20 09:00 MHDA- 2009/12/16 06:00 CRDT- 2009/03/20 09:00 PHST- 2008/09/24 00:00 [received] PHST- 2009/02/18 00:00 [accepted] PHST- 2009/03/20 09:00 [entrez] PHST- 2009/03/20 09:00 [pubmed] PHST- 2009/12/16 06:00 [medline] AID - 10.1007/s00167-009-0763-7 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2009 Jul;17(7):835-9. doi: 10.1007/s00167-009-0763-7. Epub 2009 Mar 19. PMID- 34257376 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20211214 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 11 IP - 1 DP - 2021 Jul 13 TI - A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders. PG - 14375 LID - 10.1038/s41598-021-93763-y [doi] LID - 14375 AB - Recent drug safety concerns described fluoroquinolone (FQ)-induced serious musculoskeletal reactions. The objective of this study was to characterize reports with FQ-associated disabling musculoskeletal disorders, from VigiBase. The analysis included all FQ-induced musculoskeletal and connective tissue disorders adverse drug reaction (ADR) reports (up to July-2019), (disabling/incapacitating, or recovered/resolved with sequelae or fatal). We described aspects like reporter, suspected FQs, ADRs, associated corticosteroid therapy. We also looked into the disproportionality data in terms of proportional reporting ratio (PRR) and information component (IC) values. A total of 5355 reports with 13,563 ADRs and 5558 FQs were reported. The majority of reports were for patients aged 18-64 (62.67%), and the female gender prevailed (61.76%). Consumers reported almost half (45.99%), with a peak in reporting rates in 2017. Top reported ADRs were arthralgia (16.34%), tendonitis (11.04%), pain in extremity (9.98%), tendon pain (7.63%), and myalgia (7.17%). Top suspected FQs were levofloxacin (50.04%), ciprofloxacin (38.41%), moxifloxacin (5.16%), ofloxacin (3.17%) and norfloxacin (1.01%). For these, FQs-ADR association was supported by the disproportionality analysis. Corticosteroids were associated with about 7% of tendon related reports. The results augment the existing data on FQs safety concerns, specifically their potential effect on the musculoskeletal system. CI - © 2021. The Author(s). FAU - Huruba, Madalina AU - Huruba M AD - Department of Pharmacology, Physiology and Physiopathology, Faculty of Pharmacy, Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Farcas, Andreea AU - Farcas A AUID- ORCID: 0000-0003-2109-8409 AD - Drug Information Research Center, "Iuliu Hatieganu" University of Medicine and Pharmacy, Pasteur Street no 6A, Cluj-Napoca, Romania. afarcas@umfcluj.ro. FAU - Leucuta, Daniel Corneliu AU - Leucuta DC AD - Department of Medical Informatics and Biostatistics, Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Bucsa, Camelia AU - Bucsa C AD - Drug Information Research Center, "Iuliu Hatieganu" University of Medicine and Pharmacy, Pasteur Street no 6A, Cluj-Napoca, Romania. FAU - Sipos, Mariana AU - Sipos M AD - Department of Pharmacology, Physiology and Physiopathology, Faculty of Pharmacy, Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Mogosan, Cristina AU - Mogosan C AD - Department of Pharmacology, Physiology and Physiopathology, Faculty of Pharmacy, Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. AD - Drug Information Research Center, "Iuliu Hatieganu" University of Medicine and Pharmacy, Pasteur Street no 6A, Cluj-Napoca, Romania. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210713 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Fluoroquinolones) RN - 5E8K9I0O4U (Ciprofloxacin) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) RN - N0F8P22L1P (Norfloxacin) RN - U188XYD42P (Moxifloxacin) SB - IM MH - Adolescent MH - Adrenal Cortex Hormones/adverse effects MH - Adult MH - Adverse Drug Reaction Reporting Systems MH - Arthralgia/chemically induced MH - Ciprofloxacin/adverse effects MH - Connective Tissue Diseases/*drug therapy MH - Databases, Factual MH - *Drug-Related Side Effects and Adverse Reactions MH - Female MH - Fluoroquinolones/*pharmacology MH - Humans MH - Levofloxacin/adverse effects MH - Male MH - Middle Aged MH - Moxifloxacin/adverse effects MH - Musculoskeletal Diseases/*drug therapy MH - Myalgia/chemically induced MH - Norfloxacin/administration & dosage MH - Ofloxacin/administration & dosage MH - Pain/chemically induced/drug therapy MH - Risk Factors MH - Tendinopathy/chemically induced MH - Tendons/pathology MH - Young Adult PMC - PMC8277836 COIS- The authors declare no competing interests. EDAT- 2021/07/15 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/07/13 CRDT- 2021/07/14 06:49 PHST- 2020/12/22 00:00 [received] PHST- 2021/06/14 00:00 [accepted] PHST- 2021/07/14 06:49 [entrez] PHST- 2021/07/15 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/07/13 00:00 [pmc-release] AID - 10.1038/s41598-021-93763-y [pii] AID - 93763 [pii] AID - 10.1038/s41598-021-93763-y [doi] PST - epublish SO - Sci Rep. 2021 Jul 13;11(1):14375. doi: 10.1038/s41598-021-93763-y. PMID- 29203823 OWN - NLM STAT- MEDLINE DCOM- 20190708 LR - 20190708 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 7 IP - 1 DP - 2017 Dec 4 TI - Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology. PG - 16887 LID - 10.1038/s41598-017-17177-5 [doi] LID - 16887 AB - Organotypic co-cultures bridge the gap between standard two-dimensional culture and mouse models. Such assays increase the fidelity of pre-clinical studies, to better inform lead compound development and address the increasing attrition rates of lead compounds within the pharmaceutical industry, which are often a result of screening in less faithful two-dimensional models. Using large-scale acid-extraction techniques, we demonstrate a step-by-step process to isolate collagen I from commercially available animal byproducts. Using the well-established rat tail tendon collagen as a benchmark, we apply our novel kangaroo tail tendon collagen as an alternative collagen source for our screening-ready three-dimensional organotypic co-culture platform. Both collagen sources showed equal applicability for invasive, proliferative or survival assessment of well-established cancer models and clinically relevant patient-derived cancer cell lines. Additional readouts were also demonstrated when comparing these alternative collagen sources for stromal contributions to stiffness, organization and ultrastructure via atomic force microscopy, second harmonic generation imaging and scanning electron microscopy, among other vital biological readouts, where only minor differences were found between the preparations. Organotypic co-cultures represent an easy, affordable and scalable model to investigate drug responses within a physiologically relevant 3D platform. FAU - Conway, James R W AU - Conway JRW AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Vennin, Claire AU - Vennin C AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Cazet, Aurélie S AU - Cazet AS AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Herrmann, David AU - Herrmann D AUID- ORCID: 0000-0002-9514-7501 AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Murphy, Kendelle J AU - Murphy KJ AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Warren, Sean C AU - Warren SC AUID- ORCID: 0000-0002-5253-7147 AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Wullkopf, Lena AU - Wullkopf L AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Boulghourjian, Alice AU - Boulghourjian A AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Zaratzian, Anaiis AU - Zaratzian A AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Da Silva, Andrew M AU - Da Silva AM AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Pajic, Marina AU - Pajic M AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. FAU - Morton, Jennifer P AU - Morton JP AD - Beatson Institute of Cancer Research, Switchback Road, Bearsden, Glasgow, G61 1BD, UK. AD - Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK. FAU - Cox, Thomas R AU - Cox TR AUID- ORCID: 0000-0001-9294-1745 AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. t.cox@garvan.org.au. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. t.cox@garvan.org.au. FAU - Timpson, Paul AU - Timpson P AD - Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Cancer Division, Sydney, NSW 2010, Australia. p.timpson@garvan.org.au. AD - St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, NSW 2010, Australia. p.timpson@garvan.org.au. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20171204 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 9007-34-5 (Collagen) RN - S65743JHBS (Gefitinib) SB - IM MH - Animals MH - Cell Culture Techniques/*methods MH - Cell Line MH - Cell Proliferation/drug effects MH - Cell Survival/drug effects MH - Coculture Techniques MH - Collagen/*chemistry/isolation & purification MH - Extracellular Matrix/metabolism MH - Gefitinib/pharmacology MH - Humans MH - Macropodidae/metabolism MH - Mice MH - Microscopy, Atomic Force MH - Rats MH - Tendons/metabolism PMC - PMC5715059 COIS- The authors declare that they have no competing interests. EDAT- 2017/12/06 06:00 MHDA- 2019/07/10 06:00 PMCR- 2017/12/04 CRDT- 2017/12/06 06:00 PHST- 2017/05/31 00:00 [received] PHST- 2017/11/22 00:00 [accepted] PHST- 2017/12/06 06:00 [entrez] PHST- 2017/12/06 06:00 [pubmed] PHST- 2019/07/10 06:00 [medline] PHST- 2017/12/04 00:00 [pmc-release] AID - 10.1038/s41598-017-17177-5 [pii] AID - 17177 [pii] AID - 10.1038/s41598-017-17177-5 [doi] PST - epublish SO - Sci Rep. 2017 Dec 4;7(1):16887. doi: 10.1038/s41598-017-17177-5. PMID- 5271302 OWN - NLM STAT- MEDLINE DCOM- 19701008 LR - 20191030 IS - 0300-8827 (Print) IS - 0300-8827 (Linking) DP - 1970 TI - An experimental study of the effects of growth on the relationship of tendons and ligaments to bone at the site of diaphyseal insertion. PG - 1-22 FAU - Videman, T AU - Videman T LA - eng PT - Journal Article PL - Sweden TA - Acta Orthop Scand Suppl JT - Acta orthopaedica Scandinavica. Supplementum JID - 0370353 RN - 0 (Metals) RN - 0 (Sulfur Isotopes) RN - 10028-17-8 (Tritium) RN - F8VB5M810T (Tetracycline) RN - VC2W18DGKR (Thymidine) SB - IM MH - Animals MH - Autoradiography MH - *Bone Development MH - Femur/*growth & development MH - Ligaments/growth & development MH - Ligaments, Articular/*growth & development MH - Metals MH - Rabbits MH - Sulfur Isotopes MH - Tendons/*growth & development MH - Tetracycline/metabolism MH - Thymidine/metabolism MH - Tibia/*growth & development MH - Tritium EDAT- 1970/01/01 00:00 MHDA- 1970/01/01 00:01 CRDT- 1970/01/01 00:00 PHST- 1970/01/01 00:00 [pubmed] PHST- 1970/01/01 00:01 [medline] PHST- 1970/01/01 00:00 [entrez] AID - 10.3109/ort.1970.41.suppl-131.01 [doi] PST - ppublish SO - Acta Orthop Scand Suppl. 1970:1-22. doi: 10.3109/ort.1970.41.suppl-131.01. PMID- 16320826 OWN - NLM STAT- MEDLINE DCOM- 20060123 LR - 20131121 IS - 0940-9602 (Print) IS - 0940-9602 (Linking) VI - 187 IP - 5-6 DP - 2005 Nov TI - The influence of biomechanical parameters on the expression of VEGF and endostatin in the bone and joint system. PG - 461-72 AB - Many degenerative processes in the skeletal system are induced by mechanical overload. Osteoarthritis and spontaneous tendon ruptures are two examples of mechanically influenced diseases. Incubator-housed compression apparatuses and cyclic strain chambers are adequate models to investigate the cellular processes. Recent studies have shown that growth factors are involved in the transduction pathways of mechanical overload leading to tissue degradation. Vascular endothelial growth factor (VEGF) is a dimerized, 45 kDa peptide that normally attracts endothelial cells in wound healing. VEGF can be detected in the superficial zone of the tibial plateau in osteoarthritic (OA) patients with degenerative changes but not in healthy articular cartilage. Blood vessels are only rarely observed in OA cartilage suggesting that there are other roles for VEGF in cartilage. VEGF is also detectable in ruptured but not in normal tendons. The mechanically induced expression of VEGF in avascular tissues like articular cartilage or fibrocartilage of contact areas from gliding tendons initiates degenerative processes. Chondrocytes from OA cartilage also express the VEGF receptor 2. In vitro assays have shown that VEGF binds the VEGFR-2 leading to a phosphorylation of MAP kinases (ERK1/2) with subsequent transcription factor accumulation (activator protein 1 = AP-1). One of the antagonists of VEGF is endostatin. Endostatin, a fragment of collagen type XVIII, is expressed in avascular tissues and has the potency to decrease VEGF induced effects (ERK1/2 phosphorylation). The increase in matrix metalloproteinase (MMP) production and the decrease in tissue inhibitor metalloproteinase (TIMP) synthesis is a result of the signal transduction cascade activation. MMPs participate in the degradation processes of osteoarthritis whereas TIMPs are inhibitors of the MMPs. Taken together mechanically induced VEGF is involved in the destruction and endostatin in the maintenance of avascular tissues of the bone and joint system. FAU - Pufe, Thomas AU - Pufe T AD - Department of Anatomy, Christian-Albrechts University, Olshausenstrasse 40, 24098 Kiel, Germany. t.pufe@anat.uni-kiel.de FAU - Kurz, Bodo AU - Kurz B FAU - Petersen, Wolf AU - Petersen W FAU - Varoga, Deike AU - Varoga D FAU - Mentlein, Rolf AU - Mentlein R FAU - Kulow, Svea AU - Kulow S FAU - Lemke, Angelika AU - Lemke A FAU - Tillmann, Bernhard AU - Tillmann B LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Germany TA - Ann Anat JT - Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft JID - 100963897 RN - 0 (Endostatins) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Biomechanical Phenomena MH - Bone and Bones/*physiology MH - Cartilage/*physiology MH - Chondrocytes/physiology MH - Endostatins/*metabolism MH - Humans MH - Joints/*physiology MH - Osteoarthritis/physiopathology MH - Tendons/pathology/physiology MH - Vascular Endothelial Growth Factor A/*metabolism MH - Wound Healing RF - 66 EDAT- 2005/12/03 09:00 MHDA- 2006/01/24 09:00 CRDT- 2005/12/03 09:00 PHST- 2005/12/03 09:00 [pubmed] PHST- 2006/01/24 09:00 [medline] PHST- 2005/12/03 09:00 [entrez] AID - S0940-9602(05)00088-9 [pii] AID - 10.1016/j.aanat.2005.06.008 [doi] PST - ppublish SO - Ann Anat. 2005 Nov;187(5-6):461-72. doi: 10.1016/j.aanat.2005.06.008. PMID- 19884442 OWN - NLM STAT- MEDLINE DCOM- 20091125 LR - 20211020 IS - 1535-1386 (Electronic) IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 91 IP - 11 DP - 2009 Nov TI - Surface treatment with 5-fluorouracil after flexor tendon repair in a canine in vivo model. PG - 2673-82 LID - 10.2106/JBJS.H.01695 [doi] AB - BACKGROUND: Topical 5-fluorouracil has been reported to reduce adhesions in animal models of tenolysis. The purpose of this study was to investigate the effects of topical 5-fluorouracil on adhesion formation after tendon repairs were subjected to immediate postoperative rehabilitation in a canine model in vivo. METHODS: Sixty dogs were randomly assigned to either a 5-fluorouracil treatment (thirty dogs) or a control group (thirty dogs). Each treatment group was then divided into three survival time points: ten days, twenty-one days, and forty-two days. The second and fifth flexor digitorum profundus tendons from each dog were fully lacerated at the zone-II area and then were repaired. Passive motion therapy started at day 5 postoperatively and continued until the dogs were killed. The repaired tendons were evaluated for normalized work of flexion, gliding resistance, repair strength, gene expression for type-I and type-III collagen and transforming growth factor-beta1, and histological appearance. RESULTS: The normalized work of flexion of the repaired tendons treated with 5-fluorouracil was significantly lower than that of the repaired tendons without 5-fluorouracil treatment at ten days. However, there was no significant difference between treated and untreated tendons at twenty-one and forty-two days. There was also no significant difference in gliding resistance, repair failure strength, or stiffness between treated and untreated tendons at any time point, or in the gross or histological appearance of adhesions at the time of killing. The expression of types-I and III collagen and transforming growth factor-beta1 of the repaired tendon with 5-fluorouracil treatment was significantly lower than that of the tendons without treatment at ten days postoperatively, but not at twenty-one or forty-two days. CONCLUSIONS: Although 5-fluorouracil treatment can reduce adhesions in in vivo models of tenolysis, this treatment had only a transient effect in an in vivo model of tendon repair that included passive motion. FAU - Zhao, Chunfeng AU - Zhao C AD - Department of Orthopedic Surgery, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA. FAU - Zobitz, Mark E AU - Zobitz ME FAU - Sun, Yu-Long AU - Sun YL FAU - Predmore, Kelly S AU - Predmore KS FAU - Amadio, Peter C AU - Amadio PC FAU - An, Kai-Nan AU - An KN FAU - Moran, Steven L AU - Moran SL LA - eng GR - R01 AR044391/AR/NIAMS NIH HHS/United States GR - AR44391/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Antimetabolites) RN - U3P01618RT (Fluorouracil) SB - IM MH - Administration, Topical MH - Animals MH - Antimetabolites/*administration & dosage MH - Dogs MH - Fluorouracil/*administration & dosage MH - Musculoskeletal Diseases/*prevention & control MH - Tendon Injuries/*surgery MH - Tissue Adhesions/prevention & control PMC - PMC2767124 EDAT- 2009/11/04 06:00 MHDA- 2009/12/16 06:00 PMCR- 2010/11/01 CRDT- 2009/11/04 06:00 PHST- 2009/11/04 06:00 [entrez] PHST- 2009/11/04 06:00 [pubmed] PHST- 2009/12/16 06:00 [medline] PHST- 2010/11/01 00:00 [pmc-release] AID - 91/11/2673 [pii] AID - 01695 [pii] AID - 10.2106/JBJS.H.01695 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2009 Nov;91(11):2673-82. doi: 10.2106/JBJS.H.01695. PMID- 12165684 OWN - NLM STAT- MEDLINE DCOM- 20021004 LR - 20190901 IS - 0195-9131 (Print) IS - 0195-9131 (Linking) VI - 34 IP - 8 DP - 2002 Aug TI - Effects of iontophoretic versus injection administration of dexamethasone. PG - 1294-301 AB - PURPOSE: Sixty-eight skeletally mature New Zealand white rabbits were used to study the effects of iontophoresis- and injection-delivered sodium phosphate dexamethasone (DX) on the morphologic, histologic, microscopic, and biomechanical properties of uninjured rabbit patellar tendons over an initial 14-d period. METHODS: Three control (untreated, placebo iontophoresis, and placebo injection) groups and two treatment (iontophoresis and injection) groups underwent serum, ELISA tendon, histology, electron microscopy, and biomechanical analysis. RESULTS: Serum DX levels were detectable and quantifiable in both treatment groups at 1 h but were significantly greater (P < 0.05) in the injected group (11.29 ng.mL-1) compared with the iontophoresis group (6.34 ng.mL-1). The most significant histologic finding was a lack of a cellular inflammatory response in the DX-treated groups at 24 h. Ultrastructural analysis produced no significant differences between size or size ratio of collagen fibrils among any groups. Morphologic examination revealed only injection puncture marks seen in appropriate tendons. Biomechanical testing produced disruption at the patellar insertion in 81% of the specimens. No injected tendon failed at the injection site. Normalized biomechanical properties included: 1) Stiffness increased in control and iontophoresis groups from 1 to 24 h, then gradually declined; the DX-injected specimens showed a similar but delayed effect. 2) Peak load at failure for iontophoresis and control groups was greatest at 24 h. The DX-injected group again showed a delayed response. 3) In general, total energy to failure revealed no significant differences between groups at any time period. CONCLUSION: It appears that iontophoresis or injection-delivered DX may produce anti-inflammatory effects without significantly altering ultrastructural or biomechanical characteristics of the rabbit patellar tendon within an initial 14-d period. FAU - Nowicki, Kevin D AU - Nowicki K AD - Central Florida Orthopedics & Sports Medicine, Orlando, FL, USA. FAU - Hummer, Charles D 3rd AU - Hummer CD 3rd FAU - Heidt, Robert S Jr AU - Heidt RS Jr FAU - Colosimo, Angelo J AU - Colosimo AJ LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Analysis of Variance MH - Animals MH - Biomechanical Phenomena MH - Dexamethasone/*metabolism/*pharmacology MH - Disease Models, Animal MH - Enzyme-Linked Immunosorbent Assay MH - Injections, Intra-Articular MH - Iontophoresis/*methods MH - Male MH - Microscopy, Electron MH - Patella MH - Pilot Projects MH - Probability MH - Rabbits MH - Random Allocation MH - Sensitivity and Specificity MH - Tendon Injuries/drug therapy MH - Tendons/*drug effects/pathology EDAT- 2002/08/08 10:00 MHDA- 2002/10/09 04:00 CRDT- 2002/08/08 10:00 PHST- 2002/08/08 10:00 [pubmed] PHST- 2002/10/09 04:00 [medline] PHST- 2002/08/08 10:00 [entrez] AID - 10.1097/00005768-200208000-00010 [doi] PST - ppublish SO - Med Sci Sports Exerc. 2002 Aug;34(8):1294-301. doi: 10.1097/00005768-200208000-00010. PMID- 11041601 OWN - NLM STAT- MEDLINE DCOM- 20001113 LR - 20190915 IS - 0301-620X (Print) IS - 0301-620X (Linking) VI - 82 IP - 7 DP - 2000 Sep TI - Modulation of the formation of adhesions during the healing of injured tendons. PG - 1054-8 AB - The formation of restrictive adhesions around the musculotendinous unit after injury is one of the most vexing processes faced by the surgeon. In flexor tendons it has been shown that the synovial tissue is the source of aggressive fibroblasts which contribute to this process. Using a rabbit model, we have examined the effects of treating the synovial sheath with the antimetabolite 5-fluorouracil (5-FU) for five minutes. Inflammatory, proliferative and molecular markers were compared in the response of the treated and control tendons to injury. Compared with a control group we found that the proliferative and inflammatory responses were significantly reduced (p < 0.001) in the treated tendons. Not only was there a reduction in the cellular and cytokine response, but there also was a significant (p < 0.001) reduction in the level of activity of the known pro-scarring agent, transforming growth factor beta 1 (TGF-beta1). These pilot studies indicate that the formation of restrictive adhesions may be modulated using a simple single-touch technique in the hope of producing a better return of function. FAU - Khan, U AU - Khan U AD - Department of Plastic and Reconstructive Surgery, University College, Grafton Way, London, UK. FAU - Kakar, S AU - Kakar S FAU - Akali, A AU - Akali A FAU - Bentley, G AU - Bentley G FAU - McGrouther, D A AU - McGrouther DA LA - eng PT - Comparative Study PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Immunosuppressive Agents) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 0 (Transforming Growth Factor beta) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Vascular Cell Adhesion Molecule-1) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Cell Count MH - Disease Models, Animal MH - Fibroblasts/drug effects/physiology MH - Fluorouracil/therapeutic use MH - Hindlimb MH - Immunosuppressive Agents/therapeutic use MH - Macrophages/drug effects/pathology MH - Male MH - Microscopy, Electron MH - Muscular Diseases/*prevention & control MH - Pilot Projects MH - Proliferating Cell Nuclear Antigen/analysis MH - Rabbits MH - Random Allocation MH - Statistics, Nonparametric MH - Synovial Membrane/drug effects/physiology MH - Tendon Injuries/*complications/physiopathology MH - Tendons/drug effects MH - Tissue Adhesions/prevention & control MH - Transforming Growth Factor beta/drug effects MH - Transforming Growth Factor beta1 MH - Vascular Cell Adhesion Molecule-1/analysis MH - Wound Healing EDAT- 2000/10/21 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/10/21 11:00 PHST- 2000/10/21 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/10/21 11:00 [entrez] AID - 10.1302/0301-620x.82b7.9892 [doi] PST - ppublish SO - J Bone Joint Surg Br. 2000 Sep;82(7):1054-8. doi: 10.1302/0301-620x.82b7.9892. PMID- 26058332 OWN - NLM STAT- MEDLINE DCOM- 20170331 LR - 20250529 IS - 1600-0838 (Electronic) IS - 0905-7188 (Linking) VI - 26 IP - 6 DP - 2016 Jun TI - Ageing does not result in a decline in cell synthetic activity in an injury prone tendon. PG - 684-93 LID - 10.1111/sms.12500 [doi] AB - Advancing age is a well-known risk factor for tendon disease. Energy-storing tendons [e.g., human Achilles, equine superficial digital flexor tendon (SDFT)] are particularly vulnerable and it is thought that injury occurs following an accumulation of micro-damage in the extracellular matrix (ECM). Several authors suggest that age-related micro-damage accumulates due to a failure of the aging cell population to maintain the ECM or an imbalance between anabolic and catabolic pathways. We hypothesized that ageing results in a decreased ability of tendon cells to synthesize matrix components and matrix-degrading enzymes, resulting in a reduced turnover of the ECM and a decreased ability to repair micro-damage. The SDFT was collected from horses aged 3-30 years with no signs of tendon injury. Cell synthetic and degradative ability was assessed at the mRNA and protein levels. Telomere length was measured as an additional marker of cell ageing. There was no decrease in cellularity or relative telomere length with increasing age, and no decline in mRNA or protein levels for matrix proteins or degradative enzymes. The results suggest that the mechanism for age-related tendon deterioration is not due to reduced cellularity or a loss of synthetic functionality and that alternative mechanisms should be considered. CI - © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Thorpe, C T AU - Thorpe CT AD - Institute of Orthopaedics and Musculoskeletal Science, Royal National Orthopaedic Hospital, University College London, Stanmore, UK. FAU - McDermott, B T AU - McDermott BT AD - Department of Musculoskeletal Biology, University of Liverpool, Cheshire, UK. FAU - Goodship, A E AU - Goodship AE AD - Institute of Orthopaedics and Musculoskeletal Science, Royal National Orthopaedic Hospital, University College London, Stanmore, UK. FAU - Clegg, P D AU - Clegg PD AD - Department of Musculoskeletal Biology, University of Liverpool, Cheshire, UK. FAU - Birch, H L AU - Birch HL AD - Institute of Orthopaedics and Musculoskeletal Science, Royal National Orthopaedic Hospital, University College London, Stanmore, UK. LA - eng GR - MR/K006312/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article DEP - 20150609 PL - Denmark TA - Scand J Med Sci Sports JT - Scandinavian journal of medicine & science in sports JID - 9111504 RN - 0 (Peptide Fragments) RN - 0 (Procollagen) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 0 (procollagen Type I N-terminal peptide) RN - 9007-49-2 (DNA) RN - EC 3.4.24.- (ADAM12 Protein) RN - EC 3.4.24.- (ADAMTS Proteins) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - EC 3.4.24.86 (ADAM17 Protein) SB - IM MH - ADAM12 Protein/genetics MH - ADAM17 Protein/genetics MH - ADAMTS Proteins/genetics MH - Aging/*metabolism/pathology MH - Animals MH - DNA/metabolism MH - Extracellular Matrix/*physiology MH - Horses MH - Matrix Metalloproteinases/genetics/*metabolism MH - Peptide Fragments/*biosynthesis MH - Procollagen/*biosynthesis MH - RNA, Messenger/metabolism MH - Telomere Shortening MH - Tendons/*cytology/enzymology/*metabolism MH - Tissue Inhibitor of Metalloproteinase-3/genetics MH - Tissue Inhibitor of Metalloproteinases/genetics MH - Tissue Inhibitor of Metalloproteinase-4 OTO - NOTNLM OT - Tendon OT - ageing OT - degeneration OT - metabolism OT - telomere OT - tenocyte EDAT- 2015/06/11 06:00 MHDA- 2017/04/01 06:00 CRDT- 2015/06/11 06:00 PHST- 2015/05/05 00:00 [accepted] PHST- 2015/06/11 06:00 [entrez] PHST- 2015/06/11 06:00 [pubmed] PHST- 2017/04/01 06:00 [medline] AID - 10.1111/sms.12500 [doi] PST - ppublish SO - Scand J Med Sci Sports. 2016 Jun;26(6):684-93. doi: 10.1111/sms.12500. Epub 2015 Jun 9. PMID- 10526383 OWN - NLM STAT- MEDLINE DCOM- 19991124 LR - 20131121 IS - 1169-8446 (Print) IS - 1169-8446 (Linking) VI - 66 IP - 7-9 DP - 1999 Jul-Sep TI - Suspected role of ofloxacin in a case of arthalgia, myalgia, and multiple tendinopathy. PG - 419-21 AB - A 53-year-old woman on ofloxacin developed myalgia, arthralgia, and tendinopathy. Her symptoms resolved after ofloxacin discontinuation. Although tendinopathy is a well-documented complication of quinolone therapy, there have been few reports of muscle symptoms. Concomitant involvement of the tendons, muscles, and joints has been exceedingly rare. Inhaled glucocorticoid therapy and moderate hypothyroidism were probably precipitating factors in our patient. FAU - Schwald, N AU - Schwald N AD - Geriatrics Department, Hôtel-Dieu, Paris, France. FAU - Debray-Meignan, S AU - Debray-Meignan S LA - eng PT - Case Reports PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - France TA - Rev Rhum Engl Ed JT - Revue du rhumatisme (English ed.) JID - 9313916 RN - 0 (Anti-Infective Agents) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Anti-Infective Agents/*adverse effects MH - Arthralgia/*chemically induced MH - Female MH - Humans MH - Middle Aged MH - Muscular Diseases/*chemically induced MH - Ofloxacin/*adverse effects MH - Tendinopathy/*chemically induced EDAT- 1999/10/20 00:00 MHDA- 1999/10/20 00:01 CRDT- 1999/10/20 00:00 PHST- 1999/10/20 00:00 [pubmed] PHST- 1999/10/20 00:01 [medline] PHST- 1999/10/20 00:00 [entrez] PST - ppublish SO - Rev Rhum Engl Ed. 1999 Jul-Sep;66(7-9):419-21. PMID- 12553513 OWN - NLM STAT- MEDLINE DCOM- 20030212 LR - 20211008 IS - 0001-6470 (Print) IS - 0001-6470 (Linking) VI - 73 IP - 6 DP - 2002 Dec TI - Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis. PG - 658-62 AB - We studied the expression of procollagen type I, matrix metalloproteinase 1 (MMP1) and tissue inhibitor of metalloproteinase 1 (TIMP-1) by immunohistochemistry in human patellar tendinosis tissues and healthy patellar tendons. In situ gelatin zymography was used to detect collagenolytic activities. The productions of MMP1, TIMP1 and gelatinolytic activities were compared in cell cultures from tendinosis samples and controls. Tendinosis tissues and cultures showed an increase in the expression level of MMP1 and a decrease in that of TIMP1, a condition favoring collagen degradation. Gelatinolytic activities in tendinosis tissues and cultures were elevated. Collagenolysis is a striking feature in patellar tendinosis. FAU - Fu, Sai C AU - Fu SC AD - Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Shatin, NT, Hong Kong. FAU - Chan, Barbara P AU - Chan BP FAU - Wang, Wen AU - Wang W FAU - Pau, Hon M AU - Pau HM FAU - Chan, Kai M AU - Chan KM FAU - Rolf, Christer G AU - Rolf CG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Acta Orthop Scand JT - Acta orthopaedica Scandinavica JID - 0370352 RN - 0 (Collagen Type I) RN - 0 (Protease Inhibitors) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Adolescent MH - Adult MH - Collagen Type I/analysis MH - Female MH - Humans MH - Male MH - Matrix Metalloproteinase 1/*analysis MH - Patella/*pathology/physiopathology MH - Protease Inhibitors/analysis MH - Tendinopathy/*pathology/physiopathology MH - Tendons/*pathology/physiopathology MH - Tissue Inhibitor of Metalloproteinase-1/analysis EDAT- 2003/01/30 04:00 MHDA- 2003/02/14 04:00 CRDT- 2003/01/30 04:00 PHST- 2003/01/30 04:00 [pubmed] PHST- 2003/02/14 04:00 [medline] PHST- 2003/01/30 04:00 [entrez] AID - 10.1080/000164702321039624 [doi] PST - ppublish SO - Acta Orthop Scand. 2002 Dec;73(6):658-62. doi: 10.1080/000164702321039624. PMID- 3813844 OWN - NLM STAT- MEDLINE DCOM- 19870310 LR - 20220311 IS - 0344-8444 (Print) IS - 0344-8444 (Linking) VI - 105 IP - 6 DP - 1986 TI - The influence of indomethacin on tendon healing. A biomechanical and biochemical study. PG - 332-6 AB - The influence of indomethacin on the biomechanical and biochemical properties of tendons during their healing was investigated. In 68 New Zealand White rabbits a transverse tenotomy followed by repair with a criss-cross suture was performed in the plantaris longus tendon of the left hind limb. The leg was immobilized for 4 weeks postoperatively in a long-leg plastic splint. Half of the animals were treated with indomethacin, 10 mg/kg/day orally, and the other half with placebo. After 4, 8, and 16 weeks of treatment the animals were killed and biomechanical and biochemical parameters were measured. After 16 weeks there was a significant increase in tensile strength in the indomethacin group. There were only small biochemical differences between the groups. However, there was a slight but significant decrease in the amount of soluble collagen in the indomethacin group. This may indicate a higher degree of cross-linkage following indomethacin treatment, which might explain the increased tensile strength. FAU - Carlstedt, C A AU - Carlstedt CA FAU - Madsén, K AU - Madsén K FAU - Wredmark, T AU - Wredmark T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Arch Orthop Trauma Surg (1978) JT - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie JID - 7803037 RN - 9007-34-5 (Collagen) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Indomethacin/*pharmacology/therapeutic use MH - Male MH - Rabbits MH - Tendon Injuries/drug therapy MH - Tendons/*drug effects/metabolism MH - Tensile Strength/drug effects MH - Time Factors MH - Wound Healing/*drug effects EDAT- 1986/01/01 00:00 MHDA- 1986/01/01 00:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 1986/01/01 00:01 [medline] PHST- 1986/01/01 00:00 [entrez] AID - 10.1007/BF00449937 [doi] PST - ppublish SO - Arch Orthop Trauma Surg (1978). 1986;105(6):332-6. doi: 10.1007/BF00449937. PMID- 4280824 OWN - NLM STAT- MEDLINE DCOM- 19750411 LR - 20081121 IS - 0044-3220 (Print) IS - 0044-3220 (Linking) VI - 112 IP - 5 DP - 1974 Oct TI - [Animal experiments on influencing post-operative adhesions in the surgery of tendons (author's transl)]. PG - 1029-35 FAU - Gay, B AU - Gay B LA - ger PT - English Abstract PT - Journal Article TT - Tierexperimentelle Untersuchungen zur Beeinflussung postoperativer Adhäsionen in der Sehnenchirurgie. PL - Germany TA - Z Orthop Ihre Grenzgeb JT - Zeitschrift fur Orthopadie und ihre Grenzgebiete JID - 1256465 RN - 9087-70-1 (Aprotinin) SB - IM MH - Achilles Tendon/pathology/surgery MH - Administration, Topical MH - Animals MH - Aprotinin/administration & dosage/adverse effects/*therapeutic use MH - Dose-Response Relationship, Drug MH - Drainage MH - Female MH - Male MH - Necrosis MH - Postoperative Complications/*prevention & control MH - Rabbits MH - Tendons/*surgery MH - Tissue Adhesions/*prevention & control MH - Wound Healing/drug effects EDAT- 1974/10/01 00:00 MHDA- 1974/10/01 00:01 CRDT- 1974/10/01 00:00 PHST- 1974/10/01 00:00 [pubmed] PHST- 1974/10/01 00:01 [medline] PHST- 1974/10/01 00:00 [entrez] PST - ppublish SO - Z Orthop Ihre Grenzgeb. 1974 Oct;112(5):1029-35. PMID- 14428746 OWN - NLM STAT- MEDLINE DCOM- 19981101 LR - 20181201 IS - 0071-8041 (Print) IS - 0071-8041 (Linking) VI - 10 DP - 1960 TI - Prophylactic penicillin and streptomycin in elective operations on bones, joints and tendons. PG - 818-9 FAU - OLIX, M L AU - OLIX ML FAU - KLUG, T J AU - KLUG TJ FAU - COLEMAN, C R AU - COLEMAN CR FAU - SMITH, W S AU - SMITH WS LA - eng PT - Journal Article PL - United States TA - Surg Forum JT - Surgical forum JID - 0337723 RN - 0 (Penicillins) RN - Y45QSO73OB (Streptomycin) SB - OM MH - *Bone and Bones MH - *Joints MH - *Orthopedic Procedures MH - Orthopedics/*surgery MH - *Penicillins MH - Streptomycin/*toxicity MH - *Tendons OTO - NLM OT - *ORTHOPEDICS/surgery OT - *STREPTOMYCIN/toxicology EDAT- 1960/01/01 00:00 MHDA- 1960/01/01 00:01 CRDT- 1960/01/01 00:00 PHST- 1960/01/01 00:00 [pubmed] PHST- 1960/01/01 00:01 [medline] PHST- 1960/01/01 00:00 [entrez] PST - ppublish SO - Surg Forum. 1960;10:818-9. PMID- 25768932 OWN - NLM STAT- MEDLINE DCOM- 20160129 LR - 20220408 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 10 IP - 3 DP - 2015 TI - p38 MAPK signaling in postnatal tendon growth and remodeling. PG - e0120044 LID - 10.1371/journal.pone.0120044 [doi] LID - e0120044 AB - Tendon is a dynamic tissue whose structure and function is influenced by mechanical loading, but little is known about the fundamental mechanisms that regulate tendon growth and remodeling in vivo. Data from cultured tendon fibroblasts indicated that the p38 MAPK pathway plays an important role in tendon fibroblast proliferation and collagen synthesis in vitro. To gain greater insight into the mechanisms of tendon growth, and explore the role of p38 MAPK signaling in this process, we tested the hypotheses that inducing plantaris tendon growth through the ablation of the synergist Achilles tendon would result in rapid expansion of a neotendon matrix surrounding the original tendon, and that treatment with the p38 MAPK inhibitor SB203580 would prevent this growth. Rats were treated with vehicle or SB203580, and subjected to synergist ablation by bilateral tenectomy of the Achilles tendon. Changes in histological and biochemical properties of plantaris tendons were analyzed 3, 7, or 28 days after overload, and comparisons were made to non-overloaded animals. By 28 days after overload, tendon mass had increased by 30% compared to non-overloaded samples, and cross-sectional area (CSA) increased by around 50%, with most of the change occurring in the neotendon. The expansion in CSA initially occurred through the synthesis of a hyaluronic acid rich matrix that was progressively replaced with mature collagen. Pericytes were present in areas of active tendon growth, but never in the original tendon ECM. Inhibition of p38 MAPK resulted in a profound decrease in IL6 expression, and had a modest effect on the expression of other ECM and cell proliferation genes, but had a negligible impact on overall tendon growth. The combined results from this study provided novel insights into tendon mechanobiology, and suggest that p38 MAPK signaling does not appear to be necessary for tendon growth in vivo. FAU - Schwartz, Andrew J AU - Schwartz AJ AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. FAU - Sarver, Dylan C AU - Sarver DC AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. FAU - Sugg, Kristoffer B AU - Sugg KB AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Surgery, Section of Plastic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. FAU - Dzierzawski, Justin T AU - Dzierzawski JT AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. FAU - Gumucio, Jonathan P AU - Gumucio JP AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. FAU - Mendias, Christopher L AU - Mendias CL AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America. LA - eng GR - R01-AR063649/AR/NIAMS NIH HHS/United States GR - F32 AR067086/AR/NIAMS NIH HHS/United States GR - R01 AR063649/AR/NIAMS NIH HHS/United States GR - F31-AR065931/AR/NIAMS NIH HHS/United States GR - F31 AR065931/AR/NIAMS NIH HHS/United States GR - F32-AR067086/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20150313 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Imidazoles) RN - 0 (Interleukin-6) RN - 0 (Pyridines) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) RN - OU13V1EYWQ (SB 203580) SB - IM MH - Animals MH - Cell Proliferation/drug effects MH - Extracellular Matrix/drug effects/metabolism MH - Gene Expression Regulation, Enzymologic/drug effects MH - Imidazoles/pharmacology MH - Interleukin-6/metabolism MH - *MAP Kinase Signaling System/drug effects MH - Macrophages/drug effects MH - Male MH - Neutrophils/drug effects MH - Pyridines/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/*cytology/*growth & development/immunology/physiology MH - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism PMC - PMC4359143 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2015/03/15 06:00 MHDA- 2016/01/30 06:00 PMCR- 2015/03/13 CRDT- 2015/03/14 06:00 PHST- 2014/10/19 00:00 [received] PHST- 2015/02/03 00:00 [accepted] PHST- 2015/03/14 06:00 [entrez] PHST- 2015/03/15 06:00 [pubmed] PHST- 2016/01/30 06:00 [medline] PHST- 2015/03/13 00:00 [pmc-release] AID - PONE-D-14-46984 [pii] AID - 10.1371/journal.pone.0120044 [doi] PST - epublish SO - PLoS One. 2015 Mar 13;10(3):e0120044. doi: 10.1371/journal.pone.0120044. eCollection 2015. PMID- 14563798 OWN - NLM STAT- MEDLINE DCOM- 20031120 LR - 20190605 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 85 IP - 10 DP - 2003 Oct TI - Effect of dexamethasone on cultured human tenocytes and its reversibility by platelet-derived growth factor. PG - 1914-20 AB - BACKGROUND: Many cases of tendon rupture after glucocorticoid injections have been reported in the literature. Despite previous studies on the histological and biomechanical changes in tendons after glucocorticoid injections, the role of glucocorticoid in causing tendon rupture still remains controversial. The objective of this study was to determine whether glucocorticoid has deleterious effects on the cellular metabolism and collagen production of cultured human tenocytes and the reversibility of these effects by platelet-derived growth factor-BB (PDGFBB). METHODS: Primary cultures of human tenocytes obtained from explants of healthy patellar tendon, harvested during anterior cruciate ligament reconstructions, were performed. The effects on cell viability, cell proliferation, and induction of apoptosis were measured by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, 5-bromo-deoxyuridine incorporation, and DNA fragmentation assay, respectively. The effect on collagen synthesis was measured by (3) H-proline incorporation assay. RESULTS: The number of viable cells was decreased, in a dose-dependent manner, by the administration of 10 (-9) to 10 (-4) -M dexamethasone. This dose range also suppressed cell proliferation. No apoptotic effect was detected. Treatment with 10 (-6) -M dexamethasone significantly reduced the amount of collagen synthesis. Co-incubation with 10 ng/mL of PDGFBB significantly reversed the effects caused by 10 (-6) -M dexamethasone. CONCLUSIONS: Dexamethasone significantly decreased cell viability, suppressed cell proliferation, and reduced collagen synthesis in cultured human tenocytes. The effects were reversed by the simultaneous administration of PDGFBB. FAU - Wong, Margaret Wan Nar AU - Wong MW AD - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin. mwnwong@cuhk.edu.hk FAU - Tang, Yvonne Yin Nei AU - Tang YY FAU - Lee, Simon Kwong Man AU - Lee SK FAU - Fu, Bruma Sai Chuen AU - Fu BS FAU - Chan, Barbara Pui AU - Chan BP FAU - Chan, Cavor Kai Ming AU - Chan CK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Anticoagulants) RN - 0 (Platelet-Derived Growth Factor) RN - 0 (Proto-Oncogene Proteins c-sis) RN - 1B56C968OA (Becaplermin) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) SB - IM MH - Anti-Inflammatory Agents/*pharmacology MH - Anticoagulants/*pharmacology MH - Apoptosis/drug effects MH - Becaplermin MH - Cell Division/drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/biosynthesis/drug effects MH - Dexamethasone/*pharmacology MH - Dose-Response Relationship, Drug MH - Humans MH - In Vitro Techniques MH - Platelet-Derived Growth Factor/*pharmacology MH - Proto-Oncogene Proteins c-sis MH - Tendons/*cytology/*drug effects/metabolism MH - Time Factors EDAT- 2003/10/18 05:00 MHDA- 2003/12/03 05:00 CRDT- 2003/10/18 05:00 PHST- 2003/10/18 05:00 [pubmed] PHST- 2003/12/03 05:00 [medline] PHST- 2003/10/18 05:00 [entrez] AID - 10.2106/00004623-200310000-00008 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2003 Oct;85(10):1914-20. doi: 10.2106/00004623-200310000-00008. PMID- 9369955 OWN - NLM STAT- MEDLINE DCOM- 19971204 LR - 20161124 IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 173 IP - 3 DP - 1997 Dec TI - Cell behavior and cell-matrix interactions of human palmar aponeurotic cells in vitro. PG - 415-22 AB - The present investigation has been performed to better characterize, in vitro, normal aponeurotic cells in comparison with dermal fibroblasts and with cells derived from Dupuytren's affected aponeuroses. Cells were cultured in monolayer and/or into three-dimensional collagen gels. Cell structure, adhesion, and spreading capability on different substrates, as well as integrin expression were investigated by light and electron microscopy and by flow cytometry. Cell-matrix interactions were also analyzed by gel retraction experiments in the presence, or absence, of RGD peptides and anti-integrin antibodies. Normal aponeurotic cells, compared with dermal fibroblasts, exhibited in vitro peculiar structural features, which were substantially maintained in Dupuytren's aponeurotic cells, irrespective of the substrate they were grown on. By contrast, the aponeurotic cell behavior was different in normal and diseased cells, these latter approaching that of dermal fibroblasts. Normal aponeurotic cells, in fact, were characterized by low efficiency in retracting the collagen gel, low alpha 2, alpha 1, and alpha 5 integrin subunit expression and low adhesion properties onto collagen and fibronectin, whereas cells isolated from the aponeuroses of Dupuytren's patients exhibited higher capability of retracting the collagen gel, increased adhesion properties toward collagen and fibronectin, and higher levels of integrin expression. No differences were observed between dermal fibroblasts from Dupuytren's patients or from normal subjects. These in vitro results are consistent with those previously obtained in situ, suggesting that palmar aponeurotic cells have a peculiar phenotype and that changes in cell-matrix interactions occur in Dupuytren's contracture. Moreover, by comparing data obtained from the retracted fibrotic cords and the still clinically unaffected aponeuroses of the same patients, it may be noted that Dupuytren's disease is not only confined to the clinically involved branches, but includes the whole aponeurosis of the affected hand. FAU - Quaglino, D AU - Quaglino D AD - Department of Biomedical Sciences, University of Modena, Italy. micro@unimo.it FAU - Bergamini, G AU - Bergamini G FAU - Croce, A AU - Croce A FAU - Boraldi, F AU - Boraldi F FAU - Barbieri, D AU - Barbieri D FAU - Caroli, A AU - Caroli A FAU - Marcuzzi, A AU - Marcuzzi A FAU - Tiozzo, R AU - Tiozzo R FAU - Ronchetti, I P AU - Ronchetti IP LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Integrins) RN - 0 (Oligopeptides) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 9007-34-5 (Collagen) SB - IM MH - Cell Adhesion/drug effects MH - Cells, Cultured MH - Collagen MH - Dupuytren Contracture/pathology/*physiopathology MH - Extracellular Matrix/pathology/physiology/ultrastructure MH - Fibroblasts/cytology/drug effects/physiology MH - Flow Cytometry MH - Hand MH - Humans MH - Integrins/analysis/*physiology MH - Kinetics MH - Oligopeptides/pharmacology MH - Skin/*cytology/drug effects MH - Tendons/*cytology/drug effects/*physiology MH - Wounds and Injuries/pathology/*physiopathology EDAT- 1997/11/25 02:42 MHDA- 2000/06/20 09:00 CRDT- 1997/11/25 02:42 PHST- 1997/11/25 02:42 [pubmed] PHST- 2000/06/20 09:00 [medline] PHST- 1997/11/25 02:42 [entrez] AID - 10.1002/(SICI)1097-4652(199712)173:3<415::AID-JCP14>3.0.CO;2-A [pii] AID - 10.1002/(SICI)1097-4652(199712)173:3<415::AID-JCP14>3.0.CO;2-A [doi] PST - ppublish SO - J Cell Physiol. 1997 Dec;173(3):415-22. doi: 10.1002/(SICI)1097-4652(199712)173:3<415::AID-JCP14>3.0.CO;2-A. PMID- 15519344 OWN - NLM STAT- MEDLINE DCOM- 20050215 LR - 20131121 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 38 IP - 1 DP - 2005 Jan TI - Tendon properties in interleukin-4 and interleukin-6 knockout mice. PG - 99-105 AB - Cytokines are known to play an important role in normal tendon development, function, and maintenance through interactions with fibroblasts and extracellular matrix proteins. However, the role of interleukins on normal tendon activity remains poorly understood. Previous studies that have researched the role of specific cytokines by exogenously applying them have often reported conflicting results. Therefore, a knockout mouse model was used to investigate the role of interleukins 4 and 6 on normal tendon organizational and biomechanical properties. It was hypothesized that interleukin-6 knockout (IL6 -/-) mice will display more organized collagen orientation and greater cross-sectional area and mechanical properties when compared to that of control mice. In addition, interleukin-4 knockout (IL4 -/-) mice will display the most disorganized collagen orientation and lowest cross-sectional area and mechanical properties. As hypothesized, IL6 -/- mice show a trend towards lower angular deviation (more organized) (p<0.1) when compared to IL4 -/- mice. In addition, the IL6 -/- mice show a trend towards a higher percent relaxation (p<0.1) and a significantly higher modulus (p<0.01) when compared to CTL and IL4 -/- mice. Unexpectedly, the IL6 -/- mice exhibited no significant differences in collagen fiber distribution and maximum stress from the other groups and actually had a smaller cross-sectional area than CTL mice (p<0.1). This study supports transgenic mice as an animal model for investigating how cytokines affect normal tendon properties. In addition, this study demonstrates that interleukins may play an important role in tendon development, function, and maintenance. FAU - Lin, Tony W AU - Lin TW AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, 424 Stemmler Hall, 36th and Hamilton walk, Philadelphia, PA 19104-6081, USA. FAU - Cardenas, Luis AU - Cardenas L FAU - Soslowsky, Louis J AU - Soslowsky LJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Interleukin-6) RN - 207137-56-2 (Interleukin-4) RN - 9007-34-5 (Collagen) SB - IM MH - Anatomy, Cross-Sectional MH - Animals MH - Biomechanical Phenomena MH - Collagen/ultrastructure MH - Interleukin-4/deficiency/*physiology MH - Interleukin-6/deficiency/*physiology MH - Knee Joint MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Tendons/anatomy & histology/*physiology/ultrastructure EDAT- 2004/11/03 09:00 MHDA- 2005/02/16 09:00 CRDT- 2004/11/03 09:00 PHST- 2004/03/16 00:00 [accepted] PHST- 2004/11/03 09:00 [pubmed] PHST- 2005/02/16 09:00 [medline] PHST- 2004/11/03 09:00 [entrez] AID - S002192900400140X [pii] AID - 10.1016/j.jbiomech.2004.03.008 [doi] PST - ppublish SO - J Biomech. 2005 Jan;38(1):99-105. doi: 10.1016/j.jbiomech.2004.03.008. PMID- 17059091 OWN - NLM STAT- MEDLINE DCOM- 20061127 LR - 20131121 IS - 0028-2162 (Print) IS - 0028-2162 (Linking) VI - 150 IP - 39 DP - 2006 Sep 30 TI - [Spontaneous bilateral rupture of the Achilles tendon in an elderly woman undergoing prednisone pulse therapy with a history of polymyalgia rheumatica]. PG - 2155-8 AB - An 83-year-old woman presented at the neurology out-patient clinic with acute bilateral weakness of the calf muscles that had lasted for a few weeks. Ultrasound and MRI evaluation of the Achilles tendons revealed bilateral ruptures. Possible predisposing factors included treatment with prednisone pulse therapy for obstructive pulmonary disease and prior polymyalgia rheumatica. Surgical reconstruction of the tendons resulted in a major clinical improvement. Rupture of the Achilles tendons can occur spontaneously, and sometimes bilaterally. A predisposing factor is present in nearly every case of spontaneous bilateral rupture of the Achilles tendons. As in spontaneous unilateral ruptures, the most frequently described predisposing factor is the use of corticosteroids or quinolones. FAU - de Wolf, M M AU - de Wolf MM AD - Universitair Medisch Centrum Utrecht, Postbus 85.500, 3508 GA Utrecht. FAU - van der Krans, A AU - van der Krans A FAU - Frijns, C J M AU - Frijns CJ LA - dut PT - Case Reports PT - English Abstract PT - Journal Article TT - Spontane bilaterale achillespeesruptuur bij een oudere vrouw met prednisonstootkuren en in de voorgeschiedenis polymyalgia rheumatica. PL - Netherlands TA - Ned Tijdschr Geneeskd JT - Nederlands tijdschrift voor geneeskunde JID - 0400770 RN - 0 (Glucocorticoids) RN - VB0R961HZT (Prednisone) SB - IM MH - Achilles Tendon/*injuries/surgery MH - Aged, 80 and over MH - Female MH - Glucocorticoids/*adverse effects/therapeutic use MH - Humans MH - Polymyalgia Rheumatica/drug therapy MH - Prednisone/*adverse effects/therapeutic use MH - Pulmonary Disease, Chronic Obstructive/drug therapy MH - Rupture, Spontaneous MH - Treatment Outcome EDAT- 2006/10/25 09:00 MHDA- 2006/12/09 09:00 CRDT- 2006/10/25 09:00 PHST- 2006/10/25 09:00 [pubmed] PHST- 2006/12/09 09:00 [medline] PHST- 2006/10/25 09:00 [entrez] PST - ppublish SO - Ned Tijdschr Geneeskd. 2006 Sep 30;150(39):2155-8. PMID- 6481508 OWN - NLM STAT- MEDLINE DCOM- 19841121 LR - 20131121 IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 1 IP - 3 DP - 1984 TI - Intrinsic tendon fibroplasia: documentation by in vitro studies. PG - 251-6 AB - There has been considerable controversy concerning the capacity of tendons to heal intrinsically without adhesion formation. To help clarify this issue, a tissue culture model was developed to study the potential of tendon fibroblasts to proliferate and migrate. Avian flexor tendons, isolated free of sheath and all synovial components, were maintained in sterile culture plates with Dulbecco's Modified Eagle Medium. After 5 days in culture, the 2 mm tendon biopsies were analyzed for DNA synthesis [( 125I])iododeoxyuridine incorporation) and migration of fibroblasts out of the explant (planimeter analysis). DNA synthesis was maximal on day 5 in culture, and tendon fibroblasts were observed migrating from the biopsy within 48 h. Addition of cells from plasma resulted in a significant increase in fibroblast migration, and the presence of fibrin in the plasma clot was an absolute requirement for the migratory process. These findings further support the hypothesis that injured tendons can heal by an intrinsic healing process in addition to healing by adhesion formation. FAU - Graham, M F AU - Graham MF FAU - Becker, H AU - Becker H FAU - Cohen, I K AU - Cohen IK FAU - Merritt, W AU - Merritt W FAU - Diegelmann, R F AU - Diegelmann RF LA - eng GR - GM-20298/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Blood Proteins) RN - 9007-49-2 (DNA) RN - LGP81V5245 (Idoxuridine) SB - IM MH - Animals MH - Blood Cells/physiology MH - Blood Proteins/physiology MH - Cell Division MH - Cell Movement MH - Chickens MH - Culture Techniques MH - DNA/biosynthesis MH - Female MH - Fibroblasts/physiology MH - Idoxuridine/metabolism MH - Tendon Injuries/physiopathology MH - Tendons/*physiology MH - Wound Healing EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] AID - 10.1002/jor.1100010304 [doi] PST - ppublish SO - J Orthop Res. 1984;1(3):251-6. doi: 10.1002/jor.1100010304. PMID- 34019595 OWN - NLM STAT- MEDLINE DCOM- 20211026 LR - 20211026 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 5 DP - 2021 TI - Associations of ultrasound-based inflammation patterns with peripheral innate lymphoid cell populations, serum cytokines/chemokines, and treatment response to methotrexate in rheumatoid arthritis and spondyloarthritis. PG - e0252116 LID - 10.1371/journal.pone.0252116 [doi] LID - e0252116 AB - OBJECTIVES: We aimed to explore the associations of musculoskeletal inflammation patterns with peripheral blood innate lymphoid cell (ILC) populations, serum cytokines/chemokines, and treatment response to methotrexate in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). METHODS: We enrolled 100 patients with either RA or SpA and performed ultrasound to evaluate power Doppler signals for synovitis (52 joint regions), tenosynovitis (20 tendons), and enthesitis (44 sites). We performed clustering analysis using unsupervised random forest based on the multi-axis ultrasound information and classified the patients into groups. We identified and counted ILC1-3 populations in the peripheral blood by flow cytometry and also measured the serum levels of 20 cytokines/chemokines. We also determined ACR20 response at 3 months in 38 patients who began treatment with methotrexate after study assessment. RESULTS: Synovitis was more prevalent and severe in RA than in SpA, whereas tenosynovitis and enthesitis were comparable between RA and SpA. Patients were classified into two groups which represented synovitis-dominant and synovitis-nondominant inflammation patterns. While peripheral ILC counts were not significantly different between RA and SpA, they were significantly higher in the synovitis-nondominant group than in the synovitis-dominant group (ILC1-3: p = 0.0007, p = 0.0061, and p = 0.0002, respectively). On the other hand, clustering of patients based on serum cytokines/chemokines did not clearly correspond either to clinical diagnoses or to synovitis-dominant/nondominant patterns. The synovitis-dominant pattern was the most significant factor that predicted clinical response to methotrexate (p = 0.0065). CONCLUSIONS: Musculoskeletal inflammation patterns determined by ultrasound are associated with peripheral ILC counts and could predict treatment response to methotrexate. FAU - Kato, Manami AU - Kato M AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Ikeda, Kei AU - Ikeda K AUID- ORCID: 0000-0003-0574-9611 AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Sugiyama, Takahiro AU - Sugiyama T AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Tanaka, Shigeru AU - Tanaka S AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Iida, Kazuma AU - Iida K AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Suga, Kensuke AU - Suga K AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Nishimura, Nozomi AU - Nishimura N AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Mimura, Norihiro AU - Mimura N AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Kasuya, Tadamichi AU - Kasuya T AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Kumagai, Takashi AU - Kumagai T AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Furuya, Hiroki AU - Furuya H AUID- ORCID: 0000-0002-2288-923X AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Iwamoto, Taro AU - Iwamoto T AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Iwata, Arifumi AU - Iwata A AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Furuta, Shunsuke AU - Furuta S AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Suto, Akira AU - Suto A AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Suzuki, Kotaro AU - Suzuki K AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. FAU - Kawakami, Eiryo AU - Kawakami E AD - Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. AD - Medical Sciences Innovation Hub Program, RIKEN, Wako, Saitama, Japan. FAU - Nakajima, Hiroshi AU - Nakajima H AD - Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210521 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Chemokines) RN - 0 (Cytokines) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Arthritis, Rheumatoid/*blood/*drug therapy/immunology MH - Chemokines/*blood MH - Cluster Analysis MH - Cytokines/*blood MH - Humans MH - Inflammation/*blood/*drug therapy/immunology MH - Lymphocytes/drug effects/*metabolism MH - Methotrexate/*therapeutic use MH - Middle Aged MH - Spondylarthritis/*blood/*drug therapy/immunology PMC - PMC8139502 COIS- The authors declare that they have no competing interests as regards this work. EDAT- 2021/05/22 06:00 MHDA- 2021/10/27 06:00 PMCR- 2021/05/21 CRDT- 2021/05/21 17:19 PHST- 2021/03/08 00:00 [received] PHST- 2021/05/10 00:00 [accepted] PHST- 2021/05/21 17:19 [entrez] PHST- 2021/05/22 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/05/21 00:00 [pmc-release] AID - PONE-D-21-07558 [pii] AID - 10.1371/journal.pone.0252116 [doi] PST - epublish SO - PLoS One. 2021 May 21;16(5):e0252116. doi: 10.1371/journal.pone.0252116. eCollection 2021. PMID- 12428247 OWN - NLM STAT- MEDLINE DCOM- 20021218 LR - 20220408 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 46 IP - 11 DP - 2002 Nov TI - Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. PG - 3034-40 AB - OBJECTIVE: To determine whether the fluoroquinolone antibiotic ciprofloxacin, which can cause tendon pain and rupture in a proportion of treated patients, affects the expression of matrix metalloproteinases (MMPs) in human tendon-derived cells in culture. METHODS: Cell cultures were derived from 6 separate tendon explants, and were incubated in 6-well culture plates for 2 periods of 48 hours each, with ciprofloxacin (or DMSO in controls) and interleukin-1beta (IL-1beta), alone and in combination. Samples of supernatant medium from the second 48-hour incubation were assayed for MMPs 1, 2, and 3 by Western blotting. RNA was extracted from the cells and assayed for MMP messenger RNA (mRNA) by semiquantitative reverse transcription-polymerase chain reaction, with normalization for GAPDH mRNA. RESULTS: Unstimulated tendon cells expressed low or undetectable levels of MMP-1 and MMP-3, and substantial levels of MMP-2. IL-1beta induced a substantial output of both MMP-1 and MMP-3 into cell supernatants, reflecting increases (typically 100-fold) in MMP mRNA, but had only minor effects on MMP-2 expression. Ciprofloxacin had no detectable effect on MMP output in unstimulated cells. Preincubation with ciprofloxacin potentiated IL-1beta-stimulated MMP-3 output, reflecting a similar effect on MMP-3 mRNA expression. Ciprofloxacin also potentiated IL-1beta-stimulated MMP-1 mRNA expression, but did not potentiate the output of MMP-1, and had no significant effects on MMP-2 mRNA expression or output. CONCLUSION: Ciprofloxacin can selectively enhance MMP expression in tendon-derived cells. Such effects might compromise tendon microstructure and integrity. FAU - Corps, Anthony N AU - Corps AN AD - Addenbrooke's Hospital, Cambridge, UK. Rheumatology Research Unit, Box 194, Unit E6, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. anc@mole.bio.cam.ac.uk FAU - Harrall, Rebecca L AU - Harrall RL FAU - Curry, Valerie A AU - Curry VA FAU - Fenwick, Steven A AU - Fenwick SA FAU - Hazleman, Brian L AU - Hazleman BL FAU - Riley, Graham P AU - Riley GP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Anti-Infective Agents) RN - 0 (Interleukin-1) RN - 0 (RNA, Messenger) RN - 5E8K9I0O4U (Ciprofloxacin) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Anti-Infective Agents/adverse effects MH - Cells, Cultured MH - Ciprofloxacin/adverse effects/*pharmacology MH - Humans MH - Interleukin-1/*physiology MH - Matrix Metalloproteinase 1/biosynthesis MH - Matrix Metalloproteinase 2/biosynthesis MH - Matrix Metalloproteinase 3/*biosynthesis MH - Musculoskeletal Diseases/chemically induced MH - RNA, Messenger/analysis MH - Reverse Transcriptase Polymerase Chain Reaction MH - Tendons/*cytology EDAT- 2002/11/13 04:00 MHDA- 2002/12/19 04:00 CRDT- 2002/11/13 04:00 PHST- 2002/11/13 04:00 [pubmed] PHST- 2002/12/19 04:00 [medline] PHST- 2002/11/13 04:00 [entrez] AID - 10.1002/art.10617 [doi] PST - ppublish SO - Arthritis Rheum. 2002 Nov;46(11):3034-40. doi: 10.1002/art.10617. PMID- 4987299 OWN - NLM STAT- MEDLINE DCOM- 19700810 LR - 20131121 IS - 0013-7227 (Print) IS - 0013-7227 (Linking) VI - 87 IP - 1 DP - 1970 Jul TI - Failure of calcitonin to prevent disuse osteopenia: An experimental study in rabbits. PG - 183-6 FAU - Singh, M AU - Singh M FAU - Jowsey, J AU - Jowsey J LA - eng PT - Journal Article PL - United States TA - Endocrinology JT - Endocrinology JID - 0375040 RN - 9007-12-9 (Calcitonin) RN - F8VB5M810T (Tetracycline) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Bone Diseases/*drug therapy MH - *Bone Resorption MH - Calcitonin/*therapeutic use MH - Calcium/blood MH - Female MH - Fibula MH - Hindlimb MH - Immobilization MH - Microradiography MH - Organ Size MH - Ossification, Heterotopic MH - Rabbits MH - Swine MH - Tendons/surgery MH - Tetracycline MH - Tibia OID - NASA: 70213973 EDAT- 1970/07/01 00:00 MHDA- 1970/07/01 00:01 CRDT- 1970/07/01 00:00 PHST- 1970/07/01 00:00 [pubmed] PHST- 1970/07/01 00:01 [medline] PHST- 1970/07/01 00:00 [entrez] AID - 10.1210/endo-87-1-183 [doi] PST - ppublish SO - Endocrinology. 1970 Jul;87(1):183-6. doi: 10.1210/endo-87-1-183. PMID- 2533553 OWN - NLM STAT- MEDLINE DCOM- 19900320 LR - 20131121 IS - 0013-7200 (Print) IS - 0013-7200 (Linking) VI - 23 IP - 4 DP - 1989 Dec TI - Glycosaminoglycans in urine, articular and periarticular tissues in streptozotocin diabetes in rats. PG - 295-304 AB - Experimental data support the hypothesis that insulin deficiency increases the degradation of glycosaminoglycans (GAGs) and decreases their synthesis. The purpose of this study was to investigate the effect of streptozotocin-induced experimental diabetes on mucopolysaccharide content of the articular and periarticular tissues as well as on the urine GAGs excretion. In two groups (A and B) of ten white Wistar rats, experimental diabetes was induced after administration of streptozotocin in a dose of 65 and 45 mg/kg of body weight, respectively. The animals of group A (short term diabetes) and B (long term diabetes) were sacrificed on the 8th and 87th day of the experimental procedure respectively. GAGs were determined in urine specimens collected before and on the 8th day in group A and before and on 3rd, 8th, 16th, 23rd, 36th, 52nd, 71st and the 87th day in group B. At the end of the experiment articular and periarticular tissue specimens were examined for changes in their mucopolysaccharides content and compared to a group of five animals of the same age and dietary conditions (control group, C). We found a marked increase (P less than 0.001) of urine GAGs excretion during streptozotocin-induced diabetes as compared to the respective values before the experiment in both groups, while in group B a positive relationship (P less than 0.001) between 24 hour urine GASGs excretion, and the duration of diabetes was observed. The histochemistry of the articular and periarticular tissues revealed marked decrease in GAGs content, as well as hardening of the tendons. FAU - Mavrikakis, M E AU - Mavrikakis ME AD - University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra General Hospital, Greece. FAU - Kontoyannis, D AU - Kontoyannis D FAU - Karli, J AU - Karli J FAU - Kittas, C AU - Kittas C FAU - Giagiakou, E AU - Giagiakou E FAU - Moulopoulou, A AU - Moulopoulou A FAU - Koutras, D A AU - Koutras DA LA - eng PT - Journal Article PL - Slovakia TA - Endocrinol Exp JT - Endocrinologia experimentalis JID - 0125712 RN - 0 (Blood Glucose) RN - 0 (Glycosaminoglycans) RN - 5W494URQ81 (Streptozocin) SB - IM MH - Animals MH - Blood Glucose/analysis MH - Diabetes Mellitus, Experimental/chemically induced/*metabolism MH - Glycosaminoglycans/*metabolism/urine MH - Joints/*metabolism MH - Rats MH - Rats, Inbred Strains MH - Streptozocin MH - Tendons/metabolism/pathology EDAT- 1989/12/01 00:00 MHDA- 1989/12/01 00:01 CRDT- 1989/12/01 00:00 PHST- 1989/12/01 00:00 [pubmed] PHST- 1989/12/01 00:01 [medline] PHST- 1989/12/01 00:00 [entrez] PST - ppublish SO - Endocrinol Exp. 1989 Dec;23(4):295-304. PMID- 20533294 OWN - NLM STAT- MEDLINE DCOM- 20101123 LR - 20220316 IS - 1529-0131 (Electronic) IS - 0004-3591 (Linking) VI - 62 IP - 10 DP - 2010 Oct TI - Change in proteoglycan metabolism is a characteristic of human patellar tendinopathy. PG - 3028-35 LID - 10.1002/art.27587 [doi] AB - OBJECTIVE: To determine differences in the metabolism of proteoglycans and the gene expression of proteinases and their inhibitors between patellar tendons exhibiting chronic overuse tendinopathy and normal patellar tendons in humans. METHODS: Rates of loss and synthesis of proteoglycans were determined. Radiolabeled and total proteoglycans retained in and lost from the tissue were analyzed by fluorography and Western blotting. Levels of messenger RNA for matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, MMP-13, ADAMTS-1, ADAMTS-4, ADAMTS-5, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2, TIMP-3, and TIMP-4 were determined in fresh tissue. RESULTS: The rate of loss of (35)S-labeled proteoglycans was greater in abnormal tendons, as was the rate of synthesis of proteoglycans. Fluorography and Western blotting revealed the presence of greater amounts of large proteoglycans (aggrecan and versican) in abnormal tendons, and these proteoglycans were rapidly lost from the matrix of abnormal tendons. There was no significant difference in the expression of ADAMTS-1, ADAMTS-4, ADAMTS-5, MMP-1, MMP-2, MMP-3, MMP-13, TIMP-2, TIMP-3, or TIMP-4. There was a significant increase in the expression of MMP-9 and TIMP-1 in abnormal tendons. CONCLUSION: Our findings suggest that a change in the proteoglycan content of the extracellular matrix in abnormal tendons results from the altered metabolism of the cells, reflected in the enhanced synthesis of the large proteoglycans aggrecan and versican, and does not appear to result from changes at the level of gene expression. FAU - Parkinson, John AU - Parkinson J AD - La Trobe University, Melbourne, Victoria, Australia. FAU - Samiric, Tom AU - Samiric T FAU - Ilic, Mirna Z AU - Ilic MZ FAU - Cook, Jill AU - Cook J FAU - Feller, Julian A AU - Feller JA FAU - Handley, Christopher J AU - Handley CJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Aggrecans) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 126968-45-4 (Versicans) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Aggrecans/*metabolism MH - Case-Control Studies MH - Gene Expression Profiling MH - Humans MH - Matrix Metalloproteinase 9/genetics/*metabolism MH - Patellar Ligament/*enzymology MH - RNA, Messenger/metabolism MH - Tendinopathy/*metabolism MH - Tissue Culture Techniques MH - Tissue Inhibitor of Metalloproteinase-1/genetics/*metabolism MH - Versicans/*metabolism EDAT- 2010/06/10 06:00 MHDA- 2010/12/14 06:00 CRDT- 2010/06/10 06:00 PHST- 2010/06/10 06:00 [entrez] PHST- 2010/06/10 06:00 [pubmed] PHST- 2010/12/14 06:00 [medline] AID - 10.1002/art.27587 [doi] PST - ppublish SO - Arthritis Rheum. 2010 Oct;62(10):3028-35. doi: 10.1002/art.27587. PMID- 20947711 OWN - NLM STAT- MEDLINE DCOM- 20110325 LR - 20211020 IS - 1522-1601 (Electronic) IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 109 IP - 6 DP - 2010 Dec TI - Temporal response of canine flexor tendon to limb suspension. PG - 1762-8 LID - 10.1152/japplphysiol.00051.2010 [doi] AB - Tendon disuse, or stress deprivation, frequently accompanies clinical disorders and treatments, yet the metabolism of tendons subject to stress deprivation has rarely been investigated systematically. The effects of stress deprivation on canine flexor tendon were investigated in this study. One adult canine forepaw was suspended for 21 or 42 days. Control forepaws were collected from dogs that had no intervention on their limbs and paws. The expression of collagen I and III was not significantly altered in the tendons disused for 21 days but was significantly decreased at 42 days (P < 0.03). The expression of collagen II, aggrecan, decorin, and fibronectin was significantly decreased in the tendons in the suspended limbs at 21 days (P < 0.002) and further reduced at 42 days. With stress deprivation, the expression of matrix metalloproteinase 2 (MMP2) was significantly increased (P < 0.004) at 21 and 42 days. The expression of MMP3 was significantly decreased at 21 and 42 days (P < 0.03). The expression of MMP13 was not altered with stress deprivation at 21 and 42 days. The expression of MMP14 was significantly increased at 21 days (P = 0.0015) and returned to the control level at 42 days. Tissue inhibitor of metalloproteinase 1 (TIMP1) expression was decreased after the limbs were suspended for 42 days (P = 0.0043), but not 21 days. However, TIMP2 expression was not significantly different from control at 21 or 42 days. Furthermore, the cross-sectional area of the stress-deprived tendons at 42 days was decreased compared with the control group (P < 0.01). The intervention method in this study did not result in any alteration of stiffness of the tendon. Our study demonstrated that stress deprivation decreases the anabolic process and increases the catabolic process of extracellular matrix in flexor tendon. FAU - Sun, Yu-Long AU - Sun YL AD - Biomechanics Laboratory, Mayo Clinic, 200 First St., Rochester, MN 55905, USA. sun.yulong@mayo.edu FAU - Thoreson, Andrew R AU - Thoreson AR FAU - Cha, Stephen S AU - Cha SS FAU - Zhao, Chunfeng AU - Zhao C FAU - An, Kai-Nan AU - An KN FAU - Amadio, Peter C AU - Amadio PC LA - eng GR - R01 AR044391/AR/NIAMS NIH HHS/United States GR - AR-44391/AR/NIAMS NIH HHS/United States GR - AR-049407/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20101014 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Aggrecans) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fibronectins) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Aggrecans/metabolism MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Decorin/metabolism MH - Dogs MH - Extracellular Matrix Proteins/genetics/*metabolism MH - Fibronectins/metabolism MH - *Hindlimb Suspension MH - Matrix Metalloproteinases/metabolism MH - RNA, Messenger/metabolism MH - Stress, Mechanical MH - Tendons/*metabolism/pathology MH - Time Factors MH - Tissue Inhibitor of Metalloproteinases/metabolism PMC - PMC3006401 EDAT- 2010/10/16 06:00 MHDA- 2011/03/26 06:00 PMCR- 2011/12/01 CRDT- 2010/10/16 06:00 PHST- 2010/10/16 06:00 [entrez] PHST- 2010/10/16 06:00 [pubmed] PHST- 2011/03/26 06:00 [medline] PHST- 2011/12/01 00:00 [pmc-release] AID - japplphysiol.00051.2010 [pii] AID - JAPPL-00051-2010 [pii] AID - 10.1152/japplphysiol.00051.2010 [doi] PST - ppublish SO - J Appl Physiol (1985). 2010 Dec;109(6):1762-8. doi: 10.1152/japplphysiol.00051.2010. Epub 2010 Oct 14. PMID- 4322955 OWN - NLM STAT- MEDLINE DCOM- 19710415 LR - 20221207 IS - 0035-1040 (Print) IS - 0035-1040 (Linking) VI - 56 IP - 6 DP - 1970 Sep TI - [Clear-cell sarcoma of the tendons and aponeurosis. Diagnostic and therapeutic problems. Apropos of a case]. PG - 553-62 FAU - Jung, A AU - Jung A FAU - Kehr, P AU - Kehr P FAU - Arama, M AU - Arama M FAU - Vuillard, N AU - Vuillard N LA - fre PT - Case Reports PT - Journal Article TT - Le sarcome à cellules claires des tendons et des aponévroses. Problèmes diagnostique et thérapeutique. A propos d'un cas. PL - France TA - Rev Chir Orthop Reparatrice Appar Mot JT - Revue de chirurgie orthopedique et reparatrice de l'appareil moteur JID - 1272427 RN - 0 (Antineoplastic Agents) SB - IM MH - Amputation, Surgical MH - Antineoplastic Agents/therapeutic use MH - Bone Resorption/etiology MH - Diagnosis, Differential MH - Fingers/*pathology MH - Humans MH - Male MH - Middle Aged MH - Neoplasm Metastasis MH - Prognosis MH - *Sarcoma, Synovial/diagnosis/drug therapy/pathology/radiotherapy/surgery MH - Synovial Membrane/*pathology MH - *Tendons EDAT- 1970/09/01 00:00 MHDA- 1970/09/01 00:01 CRDT- 1970/09/01 00:00 PHST- 1970/09/01 00:00 [pubmed] PHST- 1970/09/01 00:01 [medline] PHST- 1970/09/01 00:00 [entrez] PST - ppublish SO - Rev Chir Orthop Reparatrice Appar Mot. 1970 Sep;56(6):553-62. PMID- 14218624 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20181201 IS - 0096-1736 (Print) IS - 0096-1736 (Linking) VI - 6 DP - 1964 Nov TI - THE ROLE OF PARATENON IN HEALING OF EXPERIMENTAL TENDON TRANSPLANTS. PG - 429-36 FAU - SCHNEEWIND, J H AU - SCHNEEWIND JH FAU - KLINE, I K AU - KLINE IK FAU - MONSOUR, C W AU - MONSOUR CW LA - eng PT - Journal Article PL - United States TA - J Occup Med JT - Journal of occupational medicine. : official publication of the Industrial Medical Association JID - 7502807 RN - 61G466064D (Parathion) SB - OM MH - *Adipose Tissue MH - Animals MH - Dogs MH - *Histology MH - *Parathion MH - *Research MH - Tendons/*transplantation MH - *Transplantation, Autologous MH - *Wound Healing OTO - NLM OT - *ADIPOSE TISSUE OT - *DOGS OT - *EXPERIMENTAL LAB STUDY OT - *HISTOLOGY OT - *PARATHION OT - *TENDON TRANSPLANTATION OT - *TRANSPLANTATION, AUTOLOGOUS OT - *WOUND HEALING EDAT- 1964/11/01 00:00 MHDA- 1964/11/01 00:01 CRDT- 1964/11/01 00:00 PHST- 1964/11/01 00:00 [pubmed] PHST- 1964/11/01 00:01 [medline] PHST- 1964/11/01 00:00 [entrez] PST - ppublish SO - J Occup Med. 1964 Nov;6:429-36. PMID- 9336638 OWN - NLM STAT- MEDLINE DCOM- 19971118 LR - 20191102 IS - 0753-9053 (Print) IS - 0753-9053 (Linking) VI - 2 IP - 3 DP - 1983 TI - The forearm fascia flap. PG - 197-201 AB - A new subcutaneous flap technic, derived from the chinese forearm flap has been demonstrated. It has been used to cover large cutaneous defects of the hand, especially when the extensor tendons were exposed. An excellent functional repair has been obtained in a single procedure avoiding large scar formation usually seen on the forearm after classical chinese fasciocutaneous flap. FAU - Schoofs, M AU - Schoofs M AD - Unité de Chirurgie Plastique, U.C.L., Cliniques St-Luc, Bruxelles, Belgique. FAU - Bienfait, B AU - Bienfait B FAU - Calteux, N AU - Calteux N FAU - Dachy, C AU - Dachy C FAU - Vandermaeren, C AU - Vandermaeren C FAU - De Coninck, A AU - De Coninck A LA - eng LA - fre PT - Case Reports PT - Journal Article PL - France TA - Ann Chir Main JT - Annales de chirurgie de la main : organe officiel des societes de chirurgie de la main JID - 8411230 RN - 0 (Antineoplastic Agents) SB - IM MH - Adult MH - Antineoplastic Agents/adverse effects MH - Burns/surgery MH - Cicatrix/prevention & control MH - Dermatologic Surgical Procedures MH - Extravasation of Diagnostic and Therapeutic Materials MH - Fascia/transplantation MH - Female MH - Follow-Up Studies MH - Forearm MH - Hand Deformities, Acquired/*surgery MH - Hand Injuries/surgery MH - Humans MH - Male MH - Radial Artery/surgery MH - Saphenous Vein/transplantation MH - Skin Transplantation/adverse effects MH - Skin Ulcer/surgery MH - *Surgical Flaps/blood supply/pathology MH - Tendons/surgery EDAT- 1983/01/01 00:00 MHDA- 1997/10/23 00:01 CRDT- 1983/01/01 00:00 PHST- 1983/01/01 00:00 [pubmed] PHST- 1997/10/23 00:01 [medline] PHST- 1983/01/01 00:00 [entrez] AID - 10.1016/s0753-9053(83)80001-5 [doi] PST - ppublish SO - Ann Chir Main. 1983;2(3):197-201. doi: 10.1016/s0753-9053(83)80001-5. PMID- 3606355 OWN - NLM STAT- MEDLINE DCOM- 19870813 LR - 20191022 IS - 0344-8444 (Print) IS - 0344-8444 (Linking) VI - 106 IP - 3 DP - 1987 TI - The influence of indomethacin on biomechanical and biochemical properties of the plantaris longus tendon in the rabbit. PG - 157-60 AB - It has previously been reported that indomethacin inhibits fracture healing and heterotopic bone formation. Stimulated by these reports, we undertook the present investigation to study the influence of indomethacin on biomechanical and biochemical properties of the plantaris longus tendon in the rabbit. Sixty-eight New Zealand White rabbits were used for the experiment. Half of them were treated with indomethacin, 10 mg/kg orally a day, and the other half with placebo. After 4, 8, and 16 weeks of treatment biomechanical and biochemical variables were determined and compared between the two groups. After 16 weeks there was a significant increase in tensile strength in the group treated with indomethacin. There was no certain concomitant change in the total collagen content, the amounts of soluble and insoluble collagen, or the water content. Further investigations concerning the influence of indomethacin on tendon healing are indicated. FAU - Carlstedt, C A AU - Carlstedt CA FAU - Madsen, K AU - Madsen K FAU - Wredmark, T AU - Wredmark T LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Germany TA - Arch Orthop Trauma Surg (1978) JT - Archives of orthopaedic and traumatic surgery. Archiv fur orthopadische und Unfall-Chirurgie JID - 7803037 RN - 9007-34-5 (Collagen) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Indomethacin/*pharmacology MH - Male MH - Rabbits MH - Tendons/*drug effects/physiology MH - Tensile Strength EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] AID - 10.1007/BF00452202 [doi] PST - ppublish SO - Arch Orthop Trauma Surg (1978). 1987;106(3):157-60. doi: 10.1007/BF00452202. PMID- 15540698 OWN - NLM STAT- MEDLINE DCOM- 20050202 LR - 20181113 IS - 0008-428X (Print) IS - 1488-2310 (Electronic) IS - 0008-428X (Linking) VI - 47 IP - 5 DP - 2004 Oct TI - Patellar tendon laxity in systemic lupus erythematosus. PG - 385-6 FAU - Al-Ahaideb, Abdulaziz AU - Al-Ahaideb A AD - Division of Orthopedic Surgery, University of Alberta, Edmonton, Alta. ahaideb@hotmail.com FAU - Lavoie, Guy AU - Lavoie G FAU - Secretan, Charles AU - Secretan C LA - eng PT - Case Reports PT - Journal Article PL - Canada TA - Can J Surg JT - Canadian journal of surgery. Journal canadien de chirurgie JID - 0372715 RN - 0 (Adrenal Cortex Hormones) RN - VB0R961HZT (Prednisone) SB - IM MH - Adrenal Cortex Hormones/*adverse effects MH - Humans MH - Joint Instability/*chemically induced MH - Lupus Erythematosus, Systemic/*drug therapy MH - Male MH - Middle Aged MH - Patella MH - Prednisone/*adverse effects MH - Tendons/drug effects PMC - PMC3211952 EDAT- 2004/11/16 09:00 MHDA- 2005/02/03 09:00 PMCR- 2004/10/01 CRDT- 2004/11/16 09:00 PHST- 2004/11/16 09:00 [pubmed] PHST- 2005/02/03 09:00 [medline] PHST- 2004/11/16 09:00 [entrez] PHST- 2004/10/01 00:00 [pmc-release] AID - 0002789-200410000-00018 [pii] PST - ppublish SO - Can J Surg. 2004 Oct;47(5):385-6. PMID- 22918883 OWN - NLM STAT- MEDLINE DCOM- 20140226 LR - 20130619 IS - 2043-6289 (Electronic) IS - 0266-7681 (Linking) VI - 38 IP - 6 DP - 2013 Jul TI - The effects of 5-fluorouracil on flexor tendon healing by using a biodegradable gelatin, slow releasing system: experimental study in a hen model. PG - 651-7 LID - 10.1177/1753193412458646 [doi] AB - This study investigated the effects of 5-fluorouracil in a slow-release biodegradable gelatin system on tendon healing. Gelatin blocks prepared in a size of 10 × 20 × 1 mm were loaded with 10, 20, and 30 mg of 5-fluorouracil, and 30 adult white Leghorn chickens were used. The tendons to the third and fourth toes were severed and repaired. The extremities were casted for three weeks. After sacrifice, the tendons were examined histologically and biomechanically for adhesion formation. The 10 mg-loaded gelatin group showed a decrease in adhesion formation when compared with the operative control group; the 20 and 30 mg groups showed signs of severe inflammation. Low doses of 5-fluorouracil applied via a slow-release gelatin system reduced adhesion formation in flexor tendon healing. FAU - Karaaltin, M V AU - Karaaltin MV AD - Department of Plastic, Reconstructive, and Aesthetic Surgery, Bezmi Alem Vakif University, Fatih-Istanbul, Turkey. mkerkuk@yahoo.com FAU - Ozalp, B AU - Ozalp B FAU - Dadaci, M AU - Dadaci M FAU - Kayikcioglu, A AU - Kayikcioglu A FAU - Kecik, A AU - Kecik A FAU - Oner, F AU - Oner F LA - eng PT - Journal Article DEP - 20120823 PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Delayed-Action Preparations) RN - 9000-70-8 (Gelatin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Absorbable Implants MH - Animals MH - Antimetabolites, Antineoplastic/*administration & dosage MH - Casts, Surgical MH - Chickens MH - Delayed-Action Preparations MH - Dose-Response Relationship, Drug MH - Fluorouracil/*administration & dosage MH - Gelatin MH - Inflammation/chemically induced/pathology MH - Microscopy, Electron MH - Models, Animal MH - Tendon Injuries/*therapy MH - Tendons/pathology MH - Tissue Adhesions/*prevention & control MH - Wound Healing/*drug effects OTO - NOTNLM OT - 5-fluorouracil OT - adhesions OT - gelatin OT - slow releasing OT - tendon EDAT- 2012/08/25 06:00 MHDA- 2014/02/27 06:00 CRDT- 2012/08/25 06:00 PHST- 2012/08/25 06:00 [entrez] PHST- 2012/08/25 06:00 [pubmed] PHST- 2014/02/27 06:00 [medline] AID - 1753193412458646 [pii] AID - 10.1177/1753193412458646 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2013 Jul;38(6):651-7. doi: 10.1177/1753193412458646. Epub 2012 Aug 23. PMID- 9626149 OWN - NLM STAT- MEDLINE DCOM- 19980702 LR - 20161124 IS - 0021-972X (Print) IS - 0021-972X (Linking) VI - 83 IP - 6 DP - 1998 Jun TI - Reversibility of joint thickening in acromegalic patients: an ultrasonography study. PG - 2121-5 AB - Axial and peripheral arthropathy affects the majority of patients with acromegaly, being a leading cause of morbidity and functional disability. Treatment with octreotide (OCT) improves symptoms and signs of acromegalic arthropathy, but objective detection of structural changes in bone and cartilage has not been reported to date. This open prospective study was designed to evaluate the effect of a long term treatment with OCT on acromegalic arthropathy assessed by ultrasonography examination. Articular cartilage thicknesses of shoulder, wrist, and knee as well as sizes of heel tendons were measured in 30 acromegalic patients (18 with active and 12 with inactive disease) and 18 sex-, age-, and body mass index-matched healthy subjects. The thicknesses of shoulder, wrists and knees articular cartilages and that of heel tendons were significantly increased in patients with active acromegaly compared to those in healthy subjects (P < 0.01). With the exception of shoulder cartilage, significant increases in wrist and knee cartilages (P < 0.01) and right and left heel tendon sizes (P < 0.05) were found in patients with active compared to those with inactive disease. After 6 months of OCT treatment, a significant decrease in shoulder, wrist, and left knee articular cartilage was found (P < 0.001). No significant change was recorded in right knee cartilage or heel tendon size. The decrease in thickness of shoulder and wrist cartilages was more pronounced than that measured at the level of left knee (26.3 +/- 3.3% and 27.2 +/- 4.2% vs. 14.2 +/- 4.2%, respectively; P < 0.05). Ultrasonography is able to reveal articular involvement in acromegalic patients and may be useful to monitor the effect of treatment. FAU - Colao, A AU - Colao A AD - Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy. FAU - Marzullo, P AU - Marzullo P FAU - Vallone, G AU - Vallone G FAU - Marinò, V AU - Marinò V FAU - Annecchino, M AU - Annecchino M FAU - Ferone, D AU - Ferone D FAU - De Brasi, D AU - De Brasi D FAU - Scarpa, R AU - Scarpa R FAU - Oriente, P AU - Oriente P FAU - Lombardi, G AU - Lombardi G LA - eng PT - Journal Article PL - United States TA - J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism JID - 0375362 RN - 12629-01-5 (Human Growth Hormone) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - RWM8CCW8GP (Octreotide) SB - IM MH - Acromegaly/*complications/diagnostic imaging MH - Adult MH - Aged MH - Cartilage, Articular/diagnostic imaging/pathology MH - Female MH - Heel MH - Human Growth Hormone/blood MH - Humans MH - Insulin-Like Growth Factor I/metabolism MH - Joint Diseases/*diagnostic imaging/*drug therapy/etiology MH - Joints/*diagnostic imaging/pathology MH - Knee Joint/diagnostic imaging/pathology MH - Male MH - Middle Aged MH - Octreotide/*therapeutic use MH - Shoulder Joint/diagnostic imaging/pathology MH - Tendons/diagnostic imaging/pathology MH - Ultrasonography MH - Wrist Joint/diagnostic imaging/pathology EDAT- 1998/06/17 00:00 MHDA- 1998/06/17 00:01 CRDT- 1998/06/17 00:00 PHST- 1998/06/17 00:00 [pubmed] PHST- 1998/06/17 00:01 [medline] PHST- 1998/06/17 00:00 [entrez] AID - 10.1210/jcem.83.6.4865 [doi] PST - ppublish SO - J Clin Endocrinol Metab. 1998 Jun;83(6):2121-5. doi: 10.1210/jcem.83.6.4865. PMID- 23251524 OWN - NLM STAT- MEDLINE DCOM- 20130603 LR - 20220311 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 12 DP - 2012 TI - Gene expression analysis of the pleiotropic effects of TGF-β1 in an in vitro model of flexor tendon healing. PG - e51411 LID - 10.1371/journal.pone.0051411 [doi] LID - e51411 AB - Flexor tendon injuries are among the most challenging problems for hand surgeons and tissue engineers alike. Not only do flexor tendon injuries heal with poor mechanical strength, they can also form debilitating adhesions that may permanently impair hand function. While TGF-β1 is a necessary factor for regaining tendon strength, it is associated with scar and adhesion formation in the flexor tendons and other tissues as well as fibrotic diseases. The pleiotropic effects of TGF-β1 on tendon cells and tissue have not been characterized in detail. The goal of the present study was to identify the targets through which the effects of TGF-β1 on tendon healing could be altered. To accomplish this, we treated flexor tendon tenocytes cultured in pinned collagen gels with 1, 10 or 100 ng/mL of TGF-β1 and measured gel contraction and gene expression using RT-PCR up to 48 hours after treatment. Specifically, we studied the effects of TGF-β1 on the expression of collagens, fibronectin, proteoglycans, MMPs, MMP inhibitors, and the neotendon transcription factors, Scleraxis and Mohawk. Area contraction of the gels was not dose-dependent with the TGF-β1 concentrations tested. We observed dose-dependent downregulation of MMP-16 (MT3-MMP) and decorin, and upregulation of biglycan, collagen V, collagen XII, PAI-1, Scleraxis, and Mohawk by TGF-β1. Inter-gene analyses were also performed to further characterize the expression of ECM and MMP genes in the tenocyte-seeded collagen gels. These analyses illustrate that TGF-β1 tilts the balance of gene expression in favor of ECM synthesis rather than the matrix-remodeling MMPs, a possible means by which TGF-β1 promotes adhesion formation. FAU - Farhat, Youssef M AU - Farhat YM AD - Department of Biomedical Engineering, University of Rochester, Rochester, New York, USA. FAU - Al-Maliki, Alaa A AU - Al-Maliki AA FAU - Chen, Tony AU - Chen T FAU - Juneja, Subhash C AU - Juneja SC FAU - Schwarz, Edward M AU - Schwarz EM FAU - O'Keefe, Regis J AU - O'Keefe RJ FAU - Awad, Hani A AU - Awad HA LA - eng GR - T32 GM07356/GM/NIGMS NIH HHS/United States GR - R01AR056696/AR/NIAMS NIH HHS/United States GR - T32 AR053459/AR/NIAMS NIH HHS/United States GR - T32 GM007356/GM/NIGMS NIH HHS/United States GR - R01 AR056696/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20121210 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Biglycan) RN - 0 (Decorin) RN - 0 (Fibronectins) RN - 0 (Gels) RN - 0 (Homeodomain Proteins) RN - 0 (Metallothionein 3) RN - 0 (Mt3 protein, mouse) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (Scx protein, mouse) RN - 0 (Transforming Growth Factor beta1) RN - 0 (mohawk protein, mouse) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Basic Helix-Loop-Helix Transcription Factors/genetics/metabolism MH - Biglycan/metabolism MH - Collagen/genetics/metabolism MH - Decorin/genetics/metabolism MH - Extracellular Matrix/genetics/metabolism MH - Fibronectins/genetics/metabolism MH - Gels/chemistry MH - *Gene Expression Profiling MH - Genetic Pleiotropy/*drug effects MH - Homeodomain Proteins/genetics/metabolism MH - Matrix Metalloproteinases/genetics/metabolism MH - Metallothionein 3 MH - Mice MH - Mice, Inbred C57BL MH - *Models, Biological MH - Plasminogen Activator Inhibitor 1/metabolism MH - Tendons/drug effects/growth & development/*metabolism/*pathology MH - Tissue Inhibitor of Metalloproteinase-2/metabolism MH - Transforming Growth Factor beta1/*pharmacology MH - Up-Regulation/drug effects/genetics MH - Wound Healing/drug effects/*genetics PMC - PMC3519680 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2012/12/20 06:00 MHDA- 2013/06/05 06:00 PMCR- 2012/12/10 CRDT- 2012/12/20 06:00 PHST- 2012/07/17 00:00 [received] PHST- 2012/10/31 00:00 [accepted] PHST- 2012/12/20 06:00 [entrez] PHST- 2012/12/20 06:00 [pubmed] PHST- 2013/06/05 06:00 [medline] PHST- 2012/12/10 00:00 [pmc-release] AID - PONE-D-12-20886 [pii] AID - 10.1371/journal.pone.0051411 [doi] PST - ppublish SO - PLoS One. 2012;7(12):e51411. doi: 10.1371/journal.pone.0051411. Epub 2012 Dec 10. PMID- 19444761 OWN - NLM STAT- MEDLINE DCOM- 20090717 LR - 20181201 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 50 IP - 3 DP - 2009 TI - Expression profiling of genes involved in collagen turnover in tendons from cerebral palsy patients. PG - 203-8 LID - 10.1080/03008200802613630 [doi] AB - Cerebral palsy (CP) is a nonprogressive central nervous system lesion clinically characterized by impairment of voluntary movement related to spasticity, time of activation, and strength of skeletal muscle. Altered muscular control may act on tendon structure and influence extracellular matrix homeostasis, in particular, collagen. The effect of spasticity on collagen turnover in CP patients' tendons has not been described previously. We studied collagen turnover related genes in the gracilis and semitendinosus tendons of diplegic (n = 6) and quadriplegic (n = 15) patients, compared to normal subjects (n = 7). In particular, using real time RT-PCR, we analyzed the mRNA levels of the major extracellular matrix (ECM) components collagen type I (COL-I, alpha 2 chain COL1A2), the matrix metalloproteinase-1 (MMP-1) and the tissue inhibitor of MMP (TIMP-1), the enzyme responsible for collagen maturation lysyl hydroxylase 2b (LH2b), of the matricellular protein involved ECM remodelling (secreted protein acidic and rich in cysteine, SPARC), and the transforming growth factor-beta1 (TGF-beta1), a multipotent cytokine involved in collagen turnover. Our results show that gene expression profiles are quite different in CP samples compared to normal ones. In fact, spasticity induces relevant modifications of tendons at the molecular level, which modify their phenotypes to respond to the higher mechanical loading and increased functional demands. Interestingly, hypertonic quadriplegic subjects displayed the highest mRNA levels of COL1A2, LH2b, TGF-beta1, and SPARC, suggesting that their tendons undergo higher mechanical loading stimulation. FAU - Gagliano, Nicoletta AU - Gagliano N AD - Department of Human Morphology, Extracellular Matrix Laboratory, University of Milan School of Medicine, Milan, Italy. nicoletta.gagliano@unimi.it FAU - Pelillo, Francesco AU - Pelillo F FAU - Chiriva-Internati, Maurizio AU - Chiriva-Internati M FAU - Picciolini, Odoardo AU - Picciolini O FAU - Costa, Francesco AU - Costa F FAU - Schutt, Robert C Jr AU - Schutt RC Jr FAU - Gioia, Magda AU - Gioia M FAU - Portinaro, Nicola AU - Portinaro N LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Collagen Type I) RN - 0 (Osteonectin) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Transforming Growth Factor beta1) RN - 9007-34-5 (Collagen) RN - EC 1.14.11.4 (Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Adolescent MH - Cerebral Palsy/*genetics MH - Collagen/genetics MH - Collagen Type I MH - Extracellular Matrix/*genetics MH - Female MH - *Gene Expression Profiling MH - Humans MH - Male MH - Matrix Metalloproteinase 1/genetics MH - Osteonectin/genetics MH - Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase/genetics MH - RNA, Messenger/biosynthesis MH - Tendons/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/genetics MH - Transforming Growth Factor beta1/genetics EDAT- 2009/05/16 09:00 MHDA- 2009/07/18 09:00 CRDT- 2009/05/16 09:00 PHST- 2009/05/16 09:00 [entrez] PHST- 2009/05/16 09:00 [pubmed] PHST- 2009/07/18 09:00 [medline] AID - 911211747 [pii] AID - 10.1080/03008200802613630 [doi] PST - ppublish SO - Connect Tissue Res. 2009;50(3):203-8. doi: 10.1080/03008200802613630. PMID- 24035455 OWN - NLM STAT- MEDLINE DCOM- 20140619 LR - 20161125 IS - 1872-7727 (Electronic) IS - 0720-048X (Linking) VI - 82 IP - 12 DP - 2013 Dec TI - Acceleration of tendon healing using US guided intratendinous injection of bevacizumab: first pre-clinical study on a murine model. PG - e823-8 LID - S0720-048X(13)00329-X [pii] LID - 10.1016/j.ejrad.2013.06.012 [doi] AB - PURPOSE: Tendinopathy shows early disorganized collagen fibers with neo-angiogenesis on histology. Peri-tendinous injection of corticosteroid is the commonly accepted strategy despite the abscence of inflammation in tendinosis. The aim of our study was to assess the potential of intratendinous injection of an anti-angiogenic drug (bevacizumab, AA) to treat tendinopathy in a murine model of patellar and Achilles tendinopathy, and to evaluate its local toxicity. MATERIALS AND METHOD: Forty rats (160 patellar and Achilles tendons) were used for this study. We induced tendinosis (T+) in 80 tendons by injecting under ultrasonography (US) guidance Collagenase 1(®) (day 0 = D0, patellar = 40 and Achilles = 40). Clinical examination and tendon US were performed at D3, immediately followed by either AA (AAT+, n = 40) or physiological serum (PST+, n = 40, control) US-guided intratendinous injection. Follow-up at D6 and D13 using clinical, US and histology, and comparison between the 2 groups were performed. To study AA toxicity we compared the 80 remaining normal tendons (T-) after injecting AA in 40 (AAT-). RESULTS: All AAT+ showed a better joint mobilization compared to PST+ at D6 (p = 0.004) with thinner US tendon diameters (p<0.004), and less disorganized collagen fibers and neovessels on histology (p<0.05). There was no difference at D13 regarding clinical status, US tendon diameter and histology (p>0.05). Comparison between AAT- and T- showed no AA toxicity on tendon (p = 0.18). CONCLUSION: Our study suggests that high dose mono-injection of AA in tendinosis, early after the beginning of the disease, accelerates tendon's healing, with no local toxicity. CI - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. FAU - Dallaudière, Benjamin AU - Dallaudière B AD - Service de Radiologie, Hôpital universitaire Bichat, Paris, France; Inserm U698, Hôpital universitaire Bichat, Paris, France; Université de Médecine Paris Diderot, France. Electronic address: bendallau64@hotmail.fr. FAU - Lempicki, Marta AU - Lempicki M FAU - Pesquer, Lionel AU - Pesquer L FAU - Louedec, Liliane AU - Louedec L FAU - Preux, Pierre Marie AU - Preux PM FAU - Meyer, Philippe AU - Meyer P FAU - Hess, Agathe AU - Hess A FAU - Durieux, Marie Hèlène Moreau AU - Durieux MH FAU - Hummel, Vincent AU - Hummel V FAU - Larbi, Ahmed AU - Larbi A FAU - Deschamps, Lydia AU - Deschamps L FAU - Benayoun, Yohan AU - Benayoun Y FAU - Journe, Clement AU - Journe C FAU - Perozziello, Anne AU - Perozziello A FAU - Schouman-Claeys, Elisabeth AU - Schouman-Claeys E FAU - Michel, Jean Baptiste AU - Michel JB FAU - Serfaty, Jean Michel AU - Serfaty JM LA - eng PT - Comparative Study PT - Journal Article DEP - 20130912 PL - Ireland TA - Eur J Radiol JT - European journal of radiology JID - 8106411 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 2S9ZZM9Q9V (Bevacizumab) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Angiogenesis Inhibitors/administration & dosage MH - Animals MH - Antibodies, Monoclonal, Humanized/*administration & dosage MH - Bevacizumab MH - Collagenases MH - *Disease Models, Animal MH - Humans MH - Injections, Intralesional MH - Male MH - Pilot Projects MH - Rats MH - Rats, Sprague-Dawley MH - Recovery of Function/drug effects MH - Tendinopathy/chemically induced/*diagnostic imaging/*drug therapy MH - Treatment Outcome MH - Ultrasonography, Interventional/*methods MH - Wound Healing/*drug effects OTO - NOTNLM OT - Anti-angiogenic OT - Rat OT - Tendinosis OT - Tendon OT - US EDAT- 2013/09/17 06:00 MHDA- 2014/06/20 06:00 CRDT- 2013/09/17 06:00 PHST- 2013/01/22 00:00 [received] PHST- 2013/05/12 00:00 [revised] PHST- 2013/06/26 00:00 [accepted] PHST- 2013/09/17 06:00 [entrez] PHST- 2013/09/17 06:00 [pubmed] PHST- 2014/06/20 06:00 [medline] AID - S0720-048X(13)00329-X [pii] AID - 10.1016/j.ejrad.2013.06.012 [doi] PST - ppublish SO - Eur J Radiol. 2013 Dec;82(12):e823-8. doi: 10.1016/j.ejrad.2013.06.012. Epub 2013 Sep 12. PMID- 31782241 OWN - NLM STAT- MEDLINE DCOM- 20200817 LR - 20231020 IS - 2051-817X (Electronic) IS - 2051-817X (Linking) VI - 7 IP - 22 DP - 2019 Nov TI - Prostaglandin D(2) signaling is not involved in the recovery of rat hind limb tendons from injury. PG - e14289 LID - 10.14814/phy2.14289 [doi] LID - e14289 AB - Injured tendons heal through the formation of a fibrovascular scar that has inferior mechanical properties compared to native tendon tissue. Reducing inflammation that occurs as a result of the injury could limit scar formation and improve functional recovery of tendons. Prostaglandin D(2) (PGD(2) ) plays an important role in promoting inflammation in some injury responses and chronic disease processes, and the inhibition of PGD(2) has improved healing and reduced disease burden in animal models and early clinical trials. Based on these findings, we sought to determine the role of PGD(2) signaling in the healing of injured tendon tissue. We tested the hypothesis that a potent and specific inhibitor of hematopoietic PGD synthase (HPGDS), GSK2894631A, would improve the recovery of tendons of adult male rats following an acute tenotomy and repair. To test this hypothesis, we performed a full-thickness plantaris tendon tenotomy followed by immediate repair and treated rats twice daily with either 0, 2, or 6 mg/kg of GSK2894631A. Tendons were collected either 7 or 21 days after surgical repair, and mechanical properties of tendons were assessed along with RNA sequencing and histology. While there were some differences in gene expression across groups, the targeted inhibition of HPGDS did not impact the functional repair of tendons after injury, as HPGDS expression was surprisingly low in injured tendons. These results indicate that PGD(2) signaling does not appear to be important in modulating the repair of injured tendon tissue. CI - © 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society. FAU - Sarver, Dylan C AU - Sarver DC AD - Department of Orthopaedic Surgery, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Sugg, Kristoffer B AU - Sugg KB AUID- ORCID: 0000-0002-0301-4083 AD - Department of Orthopaedic Surgery, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Department of Molecular & Integrative Physiology, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Department of Surgery, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. FAU - Talarek, Jeffrey R AU - Talarek JR AD - Department of Orthopaedic Surgery, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Department of Molecular & Integrative Physiology, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Hospital for Special Surgery, New York, NY, USA. FAU - Swanson, Jacob B AU - Swanson JB AUID- ORCID: 0000-0003-4658-2037 AD - Hospital for Special Surgery, New York, NY, USA. FAU - Oliver, David J AU - Oliver DJ AD - Hospital for Special Surgery, New York, NY, USA. FAU - Hinken, Aaron C AU - Hinken AC AD - Muscle Metabolism DPU, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA. FAU - Kramer, Henning F AU - Kramer HF AD - Muscle Metabolism DPU, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA. FAU - Mendias, Christopher L AU - Mendias CL AUID- ORCID: 0000-0002-2384-0171 AD - Department of Orthopaedic Surgery, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Department of Molecular & Integrative Physiology, Section of Plastic & Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, MI, USA. AD - Hospital for Special Surgery, New York, NY, USA. AD - Department of Physiology & Biophysics, Weill Cornell Medical College, New York, NY, USA. LA - eng GR - F32 AR067086/AR/NIAMS NIH HHS/United States GR - F32-AR067086/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Physiol Rep JT - Physiological reports JID - 101607800 RN - 0 (Enzyme Inhibitors) RN - RXY07S6CZ2 (Prostaglandin D2) SB - IM MH - Achilles Tendon/drug effects/*injuries/*metabolism MH - Animals MH - Biomechanical Phenomena/drug effects/physiology MH - Enzyme Inhibitors/pharmacology MH - Hindlimb/drug effects/injuries/metabolism MH - Male MH - Prostaglandin D2/antagonists & inhibitors/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Recovery of Function/drug effects/*physiology MH - Signal Transduction/drug effects/*physiology MH - Tendon Injuries/metabolism PMC - PMC6882956 OTO - NOTNLM OT - GSK2894631A OT - HPGDS OT - RNA sequencing OT - tendon mechanics OT - tenotomy COIS- HFK and ACH are employees of GlaxoSmithKline, which holds a patent for the GSK2894631A compound evaluated in this study. CLM has received compensation as a consultant for GlaxoSmithKline. The authors otherwise have no disclosures to report. EDAT- 2019/11/30 06:00 MHDA- 2020/08/18 06:00 PMCR- 2019/11/28 CRDT- 2019/11/30 06:00 PHST- 2019/09/20 00:00 [received] PHST- 2019/10/24 00:00 [revised] PHST- 2019/10/25 00:00 [accepted] PHST- 2019/11/30 06:00 [entrez] PHST- 2019/11/30 06:00 [pubmed] PHST- 2020/08/18 06:00 [medline] PHST- 2019/11/28 00:00 [pmc-release] AID - PHY214289 [pii] AID - 10.14814/phy2.14289 [doi] PST - ppublish SO - Physiol Rep. 2019 Nov;7(22):e14289. doi: 10.14814/phy2.14289. PMID- 6085682 OWN - NLM STAT- MEDLINE DCOM- 19851002 LR - 20101118 IS - 0009-4749 (Print) IS - 0009-4749 (Linking) VI - 69 IP - 4 DP - 1984 Oct-Dec TI - [Surgical mobilization of subtotal rigidity of the knee. Technics and results. Postoperative hydropneumoarthrotherapy]. PG - 329-34 FAU - Zanasi, R AU - Zanasi R FAU - Fioretta, G AU - Fioretta G LA - ita PT - English Abstract PT - Journal Article TT - Mobilizzazioni chirurgiche nelle rigidità subtotali di ginocchio. Tecniche e risultati. Idropneumoartroterapia postoperatoria. PL - Italy TA - Chir Organi Mov JT - La Chirurgia degli organi di movimento JID - 0372573 RN - 9087-70-1 (Aprotinin) SB - IM MH - Adolescent MH - Adult MH - Aprotinin/administration & dosage MH - Child MH - Humans MH - *Knee Joint MH - Middle Aged MH - Movement Disorders/*surgery MH - Muscle Rigidity/*surgery MH - Tendons/surgery MH - Therapeutic Irrigation/*methods MH - Wound Healing/drug effects EDAT- 1984/10/01 00:00 MHDA- 1984/10/01 00:01 CRDT- 1984/10/01 00:00 PHST- 1984/10/01 00:00 [pubmed] PHST- 1984/10/01 00:01 [medline] PHST- 1984/10/01 00:00 [entrez] PST - ppublish SO - Chir Organi Mov. 1984 Oct-Dec;69(4):329-34. PMID- 19221802 OWN - NLM STAT- MEDLINE DCOM- 20091103 LR - 20250529 IS - 1432-0878 (Electronic) IS - 0302-766X (Print) IS - 0302-766X (Linking) VI - 336 IP - 1 DP - 2009 Apr TI - Collagen fibril growth during chicken tendon development: matrix metalloproteinase-2 and its activation. PG - 79-89 LID - 10.1007/s00441-009-0755-4 [doi] AB - The role of matrix metalloproteinases (MMPs) in collagen fibrillogenesis during development has been studied in the well-characterized chicken metatarsal tendon. Collagen fibrils are initially assembled as intermediates, and the mature fibrils assemble by linear and lateral growth from these intermediates. We hypothesize that this involves the turnover of fibril-associated molecules mediated by the expression and activation of matrix metalloproteinase-2 (MMP-2). We demonstrate changes in the ratio of full-length to truncated MMP-2 during tendon development, consistent with enzyme activation. The level of full-length proMMP-2 remains relatively unchanged, although the truncated form of MMP-2 is highest prior to and during fibril growth. Membrane-type matrix metalloproteinase-3 (MT3-MMP, MMP-16) is fibroblast-associated and involved in the regulation of MMP-2 and in direct matrix turnover. The ratio of full-length proMT3-MMP/truncated (active) MT3-MMP has a pattern similar to that of full-length proMMP-2/truncated (active) MMP-2 during tendon development. Regulation of proMMP-2 activation involves complex formation with active MT3-MMP and TIMP-2. The constantly low TIMP-2 expression seen in tendon development is consistent with this role. Isolation of collagen fibrils from pre-fibril growth tendons (14 day) in the presence of activated MMP-2 is associated with premature fibril growth observed as increased fibril diameters compared with controls. These data implicate MMP-2/MT3-MMP in the initiation and progression of fibril growth, matrix assembly, and tendon development. This may involve the turnover of fibril-associated molecules involved in regulating linear and lateral growth, such as small leucine-rich proteoglycans and fibril-associated collagens. Activation of proMMP-2 dependent on MT3-MMP would allow the focal control of turnover. FAU - Jung, Jae-Chang AU - Jung JC AD - Department of Biology, College of Natural Sciences, Kyungpook National University, Daegu, South Korea. FAU - Wang, Paul X AU - Wang PX FAU - Zhang, Guiyun AU - Zhang G FAU - Ezura, Yoichi AU - Ezura Y FAU - Fini, M Elizabeth AU - Fini ME FAU - Birk, David E AU - Birk DE LA - eng GR - P30 EY014801/EY/NEI NIH HHS/United States GR - AR44745/AR/NIAMS NIH HHS/United States GR - R01 EY012651/EY/NEI NIH HHS/United States GR - R01 AR044745/AR/NIAMS NIH HHS/United States GR - EY14801/EY/NEI NIH HHS/United States GR - EY12651/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20090217 PL - Germany TA - Cell Tissue Res JT - Cell and tissue research JID - 0417625 RN - 0 (Fibrillar Collagens) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Matrix Metalloproteinase 16) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Animals MH - Chick Embryo MH - Enzyme Activation MH - Extracellular Matrix/metabolism MH - Fibrillar Collagens/*metabolism/physiology MH - Matrix Metalloproteinase 16/metabolism/physiology MH - Matrix Metalloproteinase 2/*metabolism/*physiology MH - Protein Multimerization MH - Tendons/*embryology/growth & development/metabolism MH - Tissue Distribution MH - Tissue Inhibitor of Metalloproteinases/metabolism PMC - PMC2746393 MID - NIHMS127908 EDAT- 2009/02/18 09:00 MHDA- 2009/11/05 06:00 PMCR- 2010/04/01 CRDT- 2009/02/18 09:00 PHST- 2008/08/04 00:00 [received] PHST- 2009/01/09 00:00 [accepted] PHST- 2009/02/18 09:00 [entrez] PHST- 2009/02/18 09:00 [pubmed] PHST- 2009/11/05 06:00 [medline] PHST- 2010/04/01 00:00 [pmc-release] AID - 10.1007/s00441-009-0755-4 [doi] PST - ppublish SO - Cell Tissue Res. 2009 Apr;336(1):79-89. doi: 10.1007/s00441-009-0755-4. Epub 2009 Feb 17. PMID- 10372859 OWN - NLM STAT- MEDLINE DCOM- 19990629 LR - 20190702 IS - 0038-4348 (Print) IS - 0038-4348 (Linking) VI - 92 IP - 6 DP - 1999 Jun TI - Fluoroquinolone-induced tendinopathy: what do we know? PG - 622-5 AB - Fluoroquinolones are relatively safe, effective antibiotics. As their use becomes more frequent, so will the adverse side effects. I highlight a rare but debilitating adverse reaction-fluoroquinolone-induced tendinopathy. Case reports and letters from 1987 to 1998 were identified by using Grateful Med and PubMed Internet accesses to the National Library of Medicine. Articles were reviewed for clinical practicality. There are few articles on fluoroquinolone-induced tendinopathy in the US literature targeting primary care physicians. This entity has been described in many case reports, but little has been done to isolate the causative agents. Incidence of this side effect is difficult to estimate, since no prospective studies are available for review or calculation of risk. Fluoroquinolone-induced tendinopathy appears more commonly in tendons under high stress. The cause is probably multifactorial. Risk factors for the development of fluoroquinolone-induced tendinopathy are age, renal failure, corticosteroid use, and previous tendinopathy from fluoroquinolones. FAU - Harrell, R M AU - Harrell RM AD - Department of Emergency Medicine, Louisiana State University School of Medicine, Shreveport, USA. LA - eng PT - Case Reports PT - Journal Article PT - Review PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 RN - 0 (Anti-Infective Agents) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Achilles Tendon MH - Adult MH - Anti-Infective Agents/*adverse effects MH - Ciprofloxacin/*adverse effects MH - Female MH - Humans MH - Tendinopathy/*chemically induced/diagnosis/therapy RF - 26 EDAT- 1999/06/18 00:00 MHDA- 1999/06/18 00:01 CRDT- 1999/06/18 00:00 PHST- 1999/06/18 00:00 [pubmed] PHST- 1999/06/18 00:01 [medline] PHST- 1999/06/18 00:00 [entrez] AID - 10.1097/00007611-199906000-00014 [doi] PST - ppublish SO - South Med J. 1999 Jun;92(6):622-5. doi: 10.1097/00007611-199906000-00014. PMID- 18801769 OWN - NLM STAT- MEDLINE DCOM- 20110729 LR - 20220331 IS - 1473-0480 (Electronic) IS - 0306-3674 (Linking) VI - 44 IP - 10 DP - 2010 Aug TI - Changes in mechanical loading lead to tendonspecific alterations in MMP and TIMP expression: influence of stress deprivation and intermittent cyclic hydrostatic compression on rat supraspinatus and Achilles tendons. PG - 698-703 LID - 10.1136/bjsm.2008.050575 [doi] AB - BACKGROUND: Tendinopathy commonly occurs in tendons with large in vivo loading demands like the Achilles tendon (AT) and supraspinatus tendon (SST). In addition to differences in their local anatomic environment, these tendons are designed for different loading requirements because of the muscles to which they attach, with the AT experiencing higher loads than the SST. One possible factor in the progression of tendinopathy is the interplay between mechanical loading and the regulation of enzymes that degrade the extracellular matrix (matrix metalloproteinases (MMPs)) and their inhibitors (tissue inhibitor of metalloprotienases (TIMPs)). Thus, overuse injuries may have different biological consequences in tendons designed for different in vivo loading demands. AIM: In this study, the tendon-specific regulation of MMP-13, MMP-3 and TIMP-2 expression in rat AT and SST exposed to two different mechanical environments was investigated. METHODS: Rat AT and SST were exposed to stress deprivation (ie, detached from attachments) and intermittent cyclic hydrostatic compression (with attachments intact). Levels of MMP-13, MMP-3 and TIMP-2 mRNA were evaluated in time-zero control, attached, stressdeprived and "compressed" tendons. RESULTS: Stress deprivation led to elevated expression of MMP-13, MMP-3 and TIMP-2 in both tendons, although the magnitude of the increase was greater for the SST than the AT. Intermittent cyclic hydrostatic compression of attached tendons increased expression of MMP-13 in the SST, but not the AT. CONCLUSIONS: The results of this study suggest that stress deprivation may be one contributor to the progression of tendinopathy in AT and SST, where the tendon designed for the lower in vivo loading demand (SST) was the most affected by a change in mechanical loading. The unique upregulation of MMP-13 with hydrostatic compression supports the impingement injury theory for rotator cuff tears. FAU - Thornton, G M AU - Thornton GM AD - Department of Surgery, University of Calgary, 451A Heritage Medical Research Building, 3330 Hospital Dr NW, Calgary, Alberta T2N4N1, Canada. gail.thornton@ucalgary.ca FAU - Shao, X AU - Shao X FAU - Chung, M AU - Chung M FAU - Sciore, P AU - Sciore P FAU - Boorman, R S AU - Boorman RS FAU - Hart, D A AU - Hart DA FAU - Lo, I K Y AU - Lo IK LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080918 PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Achilles Tendon/*metabolism/physiopathology MH - Animals MH - Biomechanical Phenomena/physiology MH - In Situ Hybridization MH - Male MH - Matrix Metalloproteinase 13/*metabolism MH - Matrix Metalloproteinase 3/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Reverse Transcriptase Polymerase Chain Reaction MH - Rotator Cuff/*metabolism MH - Stress, Mechanical MH - Tendinopathy/etiology/*metabolism/physiopathology MH - Tissue Inhibitor of Metalloproteinase-2/*metabolism MH - Up-Regulation/physiology EDAT- 2008/09/20 09:00 MHDA- 2011/07/30 06:00 CRDT- 2008/09/20 09:00 PHST- 2008/09/20 09:00 [pubmed] PHST- 2011/07/30 06:00 [medline] PHST- 2008/09/20 09:00 [entrez] AID - bjsm.2008.050575 [pii] AID - 10.1136/bjsm.2008.050575 [doi] PST - ppublish SO - Br J Sports Med. 2010 Aug;44(10):698-703. doi: 10.1136/bjsm.2008.050575. Epub 2008 Sep 18. PMID- 33811434 OWN - NLM STAT- MEDLINE DCOM- 20220307 LR - 20240226 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 109 IP - 10 DP - 2021 Oct TI - Preparation and biological characteristics of a bovine acellular tendon fiber material. PG - 1931-1941 LID - 10.1002/jbm.a.37185 [doi] AB - Acellular tendon matrix is an ideal substitute for constructing tissue engineering ligaments, but using detergents causes damage to collagen and fibrin during the process of decellularization. In this study, fresh tendons were lyophilized and separated into fresh tendon fiber (FTF) bundles, and then the cellular components in FTF were removed to prepare acellular tendon fiber (ATF) without adding chemical detergent. H&E staining and DAPI fluorescence microscopy showed no nucleus and DNA residue. Compared with FTFs, the DNA content of ATFs was significantly lower without the collagen content change before and after decellularization. The microstructure of collagen fibrils in ATFs was intact under scanning electron microscopy (SEM), and the maximum tensile load and elastic modulus between FTFs and ATFs were not statistically different. The ATF bundles were cultured with SD rat tenocytes for 72 hr and cells attachment to fiber surfaces were observed under SEM. ATF bundles were then implanted into paraspinal muscles, and histological analysis showed fibroblast-like cells within the ATFs and was similar to the control group (fresh tendon autograft) in morphology. H&E staining showed that the number of lymphocytes and plasma cells in ATF was less than that in fresh tendon autograft. ATF bundles were twisted into linear fiber materials by hand, of which the maximum breaking strength was similar to silk with same diameter. These findings demonstrated that ATFs retain their original fibril structure and mechanical properties after decellularization by trypsin and pancreatic deoxyribonuclease without detergent. Lyophilized ATFs linear fiber material provides the possibility of preparing personalized ligament and other tissue engineering scaffolds. CI - © 2021 Wiley Periodicals LLC. FAU - Zhou, Shengyuan AU - Zhou S AD - Spine Center, Department of Orthopedic Surgery, Chang Zheng Hospital, Naval Medical Univeristy (Second Military Medical University), Shanghai, China. FAU - Yuan, Bo AU - Yuan B AD - Spine Center, Department of Orthopedic Surgery, Chang Zheng Hospital, Naval Medical Univeristy (Second Military Medical University), Shanghai, China. FAU - Huang, Wenmao AU - Huang W AD - Spine Center, Department of Orthopedic Surgery, Chang Zheng Hospital, Naval Medical Univeristy (Second Military Medical University), Shanghai, China. FAU - Tang, Yifan AU - Tang Y AD - Spine Center, Department of Orthopedic Surgery, Chang Zheng Hospital, Naval Medical Univeristy (Second Military Medical University), Shanghai, China. FAU - Chen, Xiongsheng AU - Chen X AD - Spine Center, Department of Orthopedic Surgery, Chang Zheng Hospital, Naval Medical Univeristy (Second Military Medical University), Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210402 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Indoles) RN - 47165-04-8 (DAPI) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) SB - IM MH - Animals MH - Cattle MH - Cell Proliferation MH - Collagen/metabolism MH - DNA/metabolism MH - Fibroblasts/cytology MH - Indoles/metabolism MH - Inflammation/pathology MH - Intracellular Membranes/ultrastructure MH - Male MH - Materials Testing MH - Rats, Sprague-Dawley MH - Tendons/*cytology/ultrastructure MH - Rats OTO - NOTNLM OT - decellularization OT - fiber separation OT - lyophilization OT - tendon fiber OT - tissue engineering EDAT- 2021/04/04 06:00 MHDA- 2022/03/08 06:00 CRDT- 2021/04/03 06:00 PHST- 2021/03/14 00:00 [revised] PHST- 2020/07/05 00:00 [received] PHST- 2021/03/24 00:00 [accepted] PHST- 2021/04/04 06:00 [pubmed] PHST- 2022/03/08 06:00 [medline] PHST- 2021/04/03 06:00 [entrez] AID - 10.1002/jbm.a.37185 [doi] PST - ppublish SO - J Biomed Mater Res A. 2021 Oct;109(10):1931-1941. doi: 10.1002/jbm.a.37185. Epub 2021 Apr 2. PMID- 14504039 OWN - NLM STAT- MEDLINE DCOM- 20040720 LR - 20220331 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 44 IP - 3-4 DP - 2003 TI - Effect of amplitude and frequency of cyclic tensile strain on the inhibition of MMP-1 mRNA expression in tendon cells: an in vitro study. PG - 181-7 AB - To determine the effect of cyclic strain amplitude and frequency on MMP-1 (interstitial collagenase) expression in tendon cells, rat tail tendons (RTT) were immobilized or cyclically displaced to various amplitudes (1, 3, or 6% strain at 0.017 Hz) or frequencies (1% strain at 0.017, 0.17, or 1.0 Hz) for 24 hr. Stress-deprivation for 24 hr resulted in a marked upregulation in MMP-1 expression. Cyclic tensile loading at 0.017 Hz was found to significantly inhibit, but not completely eliminate, MMP-1 expression at 1% strain. MMP-1 expression was completely eliminated at 3 and 6% strain. Increasing the frequency of application of the 1% strain to 0.17 or 1.0 Hz completely eliminated MMP-1 expression. Disruption of the actin cytoskeleton with cytochalasin D abolished all inhibitory effects of cyclic strain on MMP-1 expression. The results of our study demonstrate that MMP-1 expression in tendon cells can be modulated by varying amplitudes and frequencies of cyclic tensile strain, presumably through a cytoskeletally based mechanotransduction pathway. FAU - Lavagnino, Michael AU - Lavagnino M AD - Laboratory for Comparative Orthopaedic Research, Michigan State University, East Lansing, Michigan 48824, USA. FAU - Arnoczky, Steven P AU - Arnoczky SP FAU - Tian, Tao AU - Tian T FAU - Vaupel, Zachary AU - Vaupel Z LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Actins) RN - 0 (RNA, Messenger) RN - 22144-77-0 (Cytochalasin D) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Actin Cytoskeleton/drug effects/metabolism MH - Actins/antagonists & inhibitors/metabolism MH - Animals MH - Cytochalasin D/pharmacology MH - Gene Expression Regulation/*genetics MH - Matrix Metalloproteinase 1/*genetics MH - Mechanotransduction, Cellular/genetics MH - Periodicity MH - RNA, Messenger/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Stress, Mechanical MH - Tendons/cytology/*enzymology MH - Tensile Strength/physiology MH - Up-Regulation/genetics MH - Weight-Bearing/physiology EDAT- 2003/09/25 05:00 MHDA- 2004/07/21 05:00 CRDT- 2003/09/25 05:00 PHST- 2003/09/25 05:00 [pubmed] PHST- 2004/07/21 05:00 [medline] PHST- 2003/09/25 05:00 [entrez] AID - A87H3VGU33YHW0U2 [pii] AID - 10.1080/03008200390215881 [doi] PST - ppublish SO - Connect Tissue Res. 2003;44(3-4):181-7. doi: 10.1080/03008200390215881. PMID- 8076449 OWN - NLM STAT- MEDLINE DCOM- 19941003 LR - 20191027 VI - 109 IP - 1 DP - 1994 Sep TI - Energy metabolism in isolated chick (Gallus domesticus) gastrocnemius and tilapia (Tilapia mossambica) epaxial muscle at various temperatures in vitro. PG - 139-50 AB - Muscle respiration experiments on inhibitor dosage (experiment 1), muscle preparation (tendons removed vs. unstretched vs. stretched muscles; chick muscle only; experiment 2) and media temperature (26.5, 32, 37, 42 degrees C; experiment 3) were conducted on chick (Gallus domesticus) gastrocnemius and tilapia (Tilapia mossambica) epaxial muscle in vitro. Experiment 1: The dosage of cycloheximide and ouabain required for maximum inhibition of protein synthesis and Na+,K+ ATPase, respectively, in chick and tilapia muscle was approximately 6 x 10(-5) M. Experiment 2: Removing the tendons of chick muscle decreased (% inhibition, P = 0.05) cycloheximide-sensitive respiration compared to stretched and unstretched muscles (tendons intact). However, muscle preparation had little influence on ouabain-sensitive respiration. Experiment 3: Cycloheximide-sensitive respiration tended to increase (microliter O2/mg DNA.hr, P = 0.054) with media temperature in tilapia muscle. Chick muscle was less responsive in this respect. Ouabain-sensitive respiration increased at lower temperature in chick muscle (% inhibition, cubic relationship, P = 0.001) and at higher temperature in tilapia muscle (% inhibition, quadratic relationship, P = 0.0002). FAU - Suzuki, E Y AU - Suzuki EY AD - Department of Animal Science, University of Hawaii at Manoa, Honolulu 96822. FAU - Early, R J AU - Early RJ FAU - Patterson, P H AU - Patterson PH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Comp Biochem Physiol Physiol JT - Comparative biochemistry and physiology. Physiology JID - 9441448 RN - 0 (Proteins) RN - 5ACL011P69 (Ouabain) RN - 98600C0908 (Cycloheximide) SB - IM MH - Animals MH - Animals, Newborn MH - Chickens/*metabolism MH - Culture Techniques MH - Cycloheximide/pharmacology MH - Dose-Response Relationship, Drug MH - *Energy Metabolism MH - Muscles/*metabolism MH - Ouabain/pharmacology MH - Oxygen Consumption/drug effects MH - Proteins/antagonists & inhibitors MH - *Temperature MH - Tilapia/*metabolism EDAT- 1994/09/01 00:00 MHDA- 1994/09/01 00:01 CRDT- 1994/09/01 00:00 PHST- 1994/09/01 00:00 [pubmed] PHST- 1994/09/01 00:01 [medline] PHST- 1994/09/01 00:00 [entrez] AID - 10.1016/0300-9629(94)90320-4 [doi] PST - ppublish SO - Comp Biochem Physiol Physiol. 1994 Sep;109(1):139-50. doi: 10.1016/0300-9629(94)90320-4. PMID- 10832957 OWN - NLM STAT- MEDLINE DCOM- 20000614 LR - 20190702 IS - 0038-4348 (Print) IS - 0038-4348 (Linking) VI - 93 IP - 5 DP - 2000 May TI - Fluoroquinolones. PG - 525-6 FAU - Litt, J Z AU - Litt JZ LA - eng PT - Comment PT - Editorial PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM CON - South Med J. 2000 May;93(5):488-91. PMID: 10832946 MH - Anti-Infective Agents/*adverse effects/classification MH - Fluoroquinolones MH - Humans MH - Muscular Diseases/*chemically induced MH - Rupture, Spontaneous/chemically induced MH - Tendons/*drug effects EDAT- 2000/06/01 09:00 MHDA- 2000/06/17 09:00 CRDT- 2000/06/01 09:00 PHST- 2000/06/01 09:00 [pubmed] PHST- 2000/06/17 09:00 [medline] PHST- 2000/06/01 09:00 [entrez] AID - 10.1097/00007611-200005000-00019 [doi] PST - ppublish SO - South Med J. 2000 May;93(5):525-6. doi: 10.1097/00007611-200005000-00019. PMID- 22456290 OWN - NLM STAT- MEDLINE DCOM- 20120507 LR - 20131121 IS - 1876-8784 (Electronic) IS - 0028-2162 (Linking) VI - 156 IP - 13 DP - 2012 TI - [Bilateral Achilles tendon rupture following levofloxacin and glucocorticoid use]. PG - A4192 AB - The combination of fluorquinolones and glucocorticoids leads to a high risk of tendon rupture. Especially the Achilles tendon is at risk. We present a report of a 65-year-old woman with a bilateral Achilles tendon rupture following use of levofloxacin and corticosteroids for pneumonia. Symptoms of the tendons in patients using glucocorticoids and fluorquinolones should be evaluated. The physician should be aware of the high risk of an Achilles tendon rupture, particularly in older patients using this combination. FAU - Kok, Laura M AU - Kok LM AD - Leids Universitair Medisch Centrum, afd. Orthopedie, Leiden, The Netherlands. laura.m.kok@gmail.com FAU - Bénard, Menno R AU - Bénard MR FAU - van Arkel, Ewoud R A AU - van Arkel ER LA - dut PT - Case Reports PT - English Abstract PT - Journal Article TT - Bilaterale achillespeesruptuur bij gebruik van levofloxacine en glucocorticoïden. PL - Netherlands TA - Ned Tijdschr Geneeskd JT - Nederlands tijdschrift voor geneeskunde JID - 0400770 RN - 0 (Anti-Infective Agents) RN - 0 (Glucocorticoids) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Achilles Tendon/*injuries MH - Aged MH - Anti-Infective Agents/adverse effects/therapeutic use MH - Casts, Surgical MH - Female MH - Glucocorticoids/*adverse effects/therapeutic use MH - Humans MH - *Levofloxacin MH - Ofloxacin/*adverse effects/therapeutic use MH - Pneumonia/drug therapy MH - Rupture/chemically induced EDAT- 2012/03/30 06:00 MHDA- 2012/05/09 06:00 CRDT- 2012/03/30 06:00 PHST- 2012/03/30 06:00 [entrez] PHST- 2012/03/30 06:00 [pubmed] PHST- 2012/05/09 06:00 [medline] PST - ppublish SO - Ned Tijdschr Geneeskd. 2012;156(13):A4192. PMID- 21333952 OWN - NLM STAT- MEDLINE DCOM- 20110421 LR - 20220331 IS - 1934-1482 (Print) IS - 1934-1482 (Linking) VI - 3 IP - 2 DP - 2011 Feb TI - Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PG - 132-42 LID - 10.1016/j.pmrj.2010.10.003 [doi] AB - Fluoroquinolone antibiotics are associated with a wide spectrum of musculoskeletal complications that involve not only tendon but also cartilage, bone, and muscle. Insights into the pathoetiology of fluoroquinolone toxicity on musculoskeletal tissues have been evolving over recent years. Although the pathoetiology is certainly multifactorial, alterations in cell signaling proteins and direct toxic effects on musculoskeletal tissues have been strongly implicated. Increasing age and concomitant systemic corticosteroid use appear to significantly increase the risk of adverse events. The purpose of this article is to review the musculoskeletal complications associated with use of fluoroquinolone antibiotics by adults; identify risk factors associated with fluoroquinolone toxicity; explore the possible pathoetiology of fluoroquinolone toxicity on tendon, cartilage, bone, and muscle; and offer recommendations regarding evaluation and treatment of fluoroquinolone-associated musculoskeletal complications. In addition, this review will provide recommendations regarding fluoroquinolone use in athletes and return to play after fluoroquinolone exposure. CI - Copyright © 2011 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved. FAU - Hall, Mederic M AU - Hall MM AD - Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Mayo Clinic Sports Medicine Center, Rochester, MN 55905, USA. FAU - Finnoff, Jonathan T AU - Finnoff JT FAU - Smith, Jay AU - Smith J LA - eng PT - Journal Article PT - Review PL - United States TA - PM R JT - PM & R : the journal of injury, function, and rehabilitation JID - 101491319 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Anti-Bacterial Agents/*adverse effects MH - Bone and Bones/drug effects MH - Cartilage/drug effects/physiology MH - Fluoroquinolones/*adverse effects MH - Humans MH - Muscle, Skeletal/drug effects MH - Musculoskeletal System/*drug effects MH - Tendinopathy/chemically induced MH - Tendons/drug effects/physiology EDAT- 2011/02/22 06:00 MHDA- 2011/04/22 06:00 CRDT- 2011/02/22 06:00 PHST- 2010/07/01 00:00 [received] PHST- 2010/09/29 00:00 [revised] PHST- 2010/10/04 00:00 [accepted] PHST- 2011/02/22 06:00 [entrez] PHST- 2011/02/22 06:00 [pubmed] PHST- 2011/04/22 06:00 [medline] AID - S1934-1482(10)01195-0 [pii] AID - 10.1016/j.pmrj.2010.10.003 [doi] PST - ppublish SO - PM R. 2011 Feb;3(2):132-42. doi: 10.1016/j.pmrj.2010.10.003. PMID- 10594522 OWN - NLM STAT- MEDLINE DCOM- 20000411 LR - 20190813 IS - 0300-0664 (Print) IS - 0300-0664 (Linking) VI - 51 IP - 5 DP - 1999 Nov TI - Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. PG - 611-8 AB - BACKGROUND: A major cause of morbidity and functional disability in acromegaly is represented by axial and peripheral arthropathy. OBJECTIVE: The effect of a 12-month treatment with lanreotide (LAN) on arthropathy in 12 untreated acromegalic patients has been evaluated. Twelve healthy subjects served as controls. STUDY DESIGN: Open prospective. STUDY PROTOCOL: Articular cartilage thickness of shoulder, wrist and knee, as well as the size of the heel tendons, was measured by ultrasonic (USG) examination before, monthly for the first 3 months and quarterly thereafter, during treatment with 60-90 mg/month of LAN. The achievement of safe GH and IGF-I levels was considered when fasting GH was below 5 mU/l and IGF-I levels were normalized for age. RESULTS: Before treatment, thickening of shoulder, wrist and knee cartilages, and of heel tendons, was found in all patients compared with controls (P < 0.01). During the first 3 months of LAN treatment, a significant decrease in circulating GH (from 86.8 +/- 19.8 to 25.6 +/- 9.8 mU/l) and IGF-I levels (from 624 +/- 47.8 to 412.2 +/- 44.5 microg/l) was observed. Overall, a slight decrease was noted in all the articular sites examined, but it reached statistical significance only at the right shoulder (P < 0. 001). However, a notable improvement of joint pain and active and passive articular mobility were recorded in all patients, as well as of weakness, soft tissue swelling, hyperhydrosis and headache. After 6 months of LAN treatment, a further significant decrease was observed at the level of the right shoulder (P < 0.01) and the right knee (P < 0.01). Eight patients achieved safe GH and IGF-I levels. After 12 months of LAN treatment, a significant decrease was observed at the level of all the articular sites examined (P < 0.01), as well as at the level of both heel tendons (P < 0.01). Safe GH and IGF-I levels were achieved in all but one of the patients who, similarly, had a significant decrease in shoulder, wrist and both heel tendon thicknesses. The thickness reduction of right shoulder cartilage, a non-weight-bearing joint, was significantly greater than that observed at the level of the right and left knee cartilages and heel tendons (37.4 +/- 4.4% vs. 18 +/- 6.1%, 19.3 +/- 4.4%, 16.5 +/- 4.2%, and 13.7 +/- 5.5%, respectively, P < 0.01). No difference was found in thickness decrease of all sites examined between the eight patients achieving safe GH levels after 3-6 months, and the remaining four patients, or between patients with estimated disease duration below (n = 6) or above 10 years (n = 6). CONCLUSIONS: Improvement in articular and periarticular soft tissue hypertrophy of the shoulder and wrist, two non-weight-bearing joints, but also of the knees, two weight-bearing joints, and heel tendons, was obtained by suppressing GH and IGF-I levels for 12 months with LAN treatment, although complete reversal of joint thickening was not achieved. Since no difference in the response to treatment, in terms of joint size decrease, was found between patients with short or long disease duration, treatment longer than 12 months may be needed to reverse the acromegalic arthropathy completely. FAU - Colao, A AU - Colao A AD - Molecular and Clinical Endocrinology and Oncology,'Federico II' University of Naples, Italy. colao@unina.it FAU - Marzullo, P AU - Marzullo P FAU - Vallone, G AU - Vallone G FAU - Giaccio, A AU - Giaccio A FAU - Ferone, D AU - Ferone D FAU - Rossi, E AU - Rossi E FAU - Scarpa, R AU - Scarpa R FAU - Smaltino, F AU - Smaltino F FAU - Lombardi, G AU - Lombardi G LA - eng PT - Journal Article PL - England TA - Clin Endocrinol (Oxf) JT - Clinical endocrinology JID - 0346653 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Peptides, Cyclic) RN - 0G3DE8943Y (lanreotide) RN - 51110-01-1 (Somatostatin) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 9002-72-6 (Growth Hormone) SB - IM MH - Acromegaly/diagnostic imaging/*drug therapy MH - Adult MH - Aged MH - Analysis of Variance MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Cartilage, Articular/diagnostic imaging/*drug effects MH - Female MH - Growth Hormone/blood MH - Heel MH - Humans MH - Insulin-Like Growth Factor I/analysis MH - Joint Diseases/diagnostic imaging/*drug therapy MH - Knee Joint MH - Male MH - Middle Aged MH - Peptides, Cyclic/*therapeutic use MH - Prospective Studies MH - Shoulder Joint MH - Somatostatin/*analogs & derivatives/therapeutic use MH - Tendons/diagnostic imaging/drug effects MH - Ultrasonography MH - Wrist Joint EDAT- 1999/12/14 09:00 MHDA- 2000/04/15 09:00 CRDT- 1999/12/14 09:00 PHST- 1999/12/14 09:00 [pubmed] PHST- 2000/04/15 09:00 [medline] PHST- 1999/12/14 09:00 [entrez] AID - cen851 [pii] AID - 10.1046/j.1365-2265.1999.00851.x [doi] PST - ppublish SO - Clin Endocrinol (Oxf). 1999 Nov;51(5):611-8. doi: 10.1046/j.1365-2265.1999.00851.x. PMID- 17882881 OWN - NLM STAT- MEDLINE DCOM- 20090605 LR - 20131121 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 21 IP - 8 DP - 2007 Aug TI - [An effect of 5-fluorouracil on tendon adhesion formation after flexor tendon repair in chickens]. PG - 842-6 AB - OBJECTIVE: To assess an effect of 5-fluorouracil (5-FU) applied topically on the tendon adhesion and the healing process after the flexor tendon repair in Leghorn chickens. METHODS: Thirty-two white Leghorn chickens, aged 4 months and weighing 1.5-1.7 kg, were randomly divided into 2 groups: Group A and Group B, with 16 chickens in each group. The flexor digitorum profundus tendons of the 2nd, 3rd and 4th toes were transected and repaired. The repair site in Group A was given 5-FU in a concentration of 25 mg/ml with a soaked sponge that was cut into pieces 7 mm X 20 mm x 1 mm in size, and the synovial sheath of the repair site was wrapped with the 5-FU-soaked sponge for 1 min for 4 times. The repair site in Group B was served as a control, with no 5-FU but with the sterile normal saline. At 3 and 6 weeks postoperatively, the repaired tendons and the tendon adhesion formation were examined macroscopically and histologically, and the repaired tendons were tested biomechanically. The tissue blocks from the tendon repair site were examined under the transmission electron microscope. RESULTS: At 3 and 6 weeks postoperatively, the macroscopic and histological observation showed that the peritendinous adhesions in Group A were looser when compared with those in Group B. The length of the tendon gliding and the extent of yieldance to exercise were found to be 4.85+/-1.31 mm, 0.67+/-0.42 mm and 5.74+/-1.61 mm, 1.55+/-0.35 mm respectively at 3 and 6 weeks after operation in Group A,but 2. 99+/-0.51 mm,0.24+/-0.14 mm and 3.65+/-0.54 mm, 1.22+/-0.16 mm in Group B. Group A was significantly greater in the above-mentioned parameters than Group B (P<0.05). At 3 weeks after operation, the ultimate breaking strength was 20.28 +/- 4.92 N in Group A and 21.29 +/- 4.88 N in Group B, with no statistically significant difference found between the two groups (P>0.05). At 6 weeks, the ultimate breaking strength was 47.12+/-6.76 N in Group A but 39. 31 +/- 7.20 N in Group B, with a significant difference between the two groups (P < 0.05). CONCLUSION: 5-fuorouracil, when applied topically, can reduce the tendon adhesion, with no inhibition of the intrinsic healing mechanism. It is an ideal treatment strategy to prevent peritendinous adhesion. FAU - Guo, Mingke AU - Guo M AD - Department of Orthopedics, 260th Hospital of PLA, Shijiazhuang Hebei, China. guomk@tom.com FAU - Zhang, Jingqi AU - Zhang J FAU - Tian, Dehu AU - Tian D LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - U3P01618RT (Fluorouracil) SB - IM MH - Administration, Topical MH - Animals MH - Biomechanical Phenomena MH - Chickens MH - Fluorouracil/administration & dosage/*therapeutic use MH - Male MH - Postoperative Complications/prevention & control MH - Random Allocation MH - Tendon Injuries/pathology/*surgery MH - Tendons/pathology/*surgery MH - Tissue Adhesions/*prevention & control MH - Toes/*injuries/surgery MH - Treatment Outcome MH - Wound Healing EDAT- 2007/09/22 09:00 MHDA- 2009/06/06 09:00 CRDT- 2007/09/22 09:00 PHST- 2007/09/22 09:00 [pubmed] PHST- 2009/06/06 09:00 [medline] PHST- 2007/09/22 09:00 [entrez] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007 Aug;21(8):842-6. PMID- 5171815 OWN - NLM STAT- MEDLINE DCOM- 19720406 LR - 20131121 IS - 0004-4172 (Print) IS - 0004-4172 (Linking) VI - 21 IP - 11 DP - 1971 Nov TI - [Experimental studies on influencing wound healing]. PG - 1840-1 FAU - Struck, H AU - Struck H FAU - Hernández-Richter, J AU - Hernández-Richter J LA - ger PT - Journal Article TT - Experimentelle Untersuchungen zur Beeinflussung der Wundheilung. PL - Germany TA - Arzneimittelforschung JT - Arzneimittel-Forschung JID - 0372660 RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen/metabolism MH - Hydroxyproline/urine MH - Indomethacin/pharmacology/*therapeutic use MH - Rabbits MH - Rats MH - Stimulation, Chemical MH - Tendons/drug effects MH - Wound Healing/*drug effects MH - Wounds and Injuries/drug therapy EDAT- 1971/11/01 00:00 MHDA- 1971/11/01 00:01 CRDT- 1971/11/01 00:00 PHST- 1971/11/01 00:00 [pubmed] PHST- 1971/11/01 00:01 [medline] PHST- 1971/11/01 00:00 [entrez] PST - ppublish SO - Arzneimittelforschung. 1971 Nov;21(11):1840-1. PMID- 16271588 OWN - NLM STAT- MEDLINE DCOM- 20060217 LR - 20131121 IS - 0021-9290 (Print) IS - 0021-9290 (Linking) VI - 39 IP - 1 DP - 2006 TI - Tendon healing in interleukin-4 and interleukin-6 knockout mice. PG - 61-9 AB - Cytokines have been shown to play an important role in tendon and ligament healing by regulating cellular differentiation and activity. The majority of studies that have investigated the role of cytokines in tendon and ligament healing have added them to injured tissue and assessed their effect. Because the efficacy of exogenously applying cytokines is dependent upon many factors such as the correct dosage, timing, and frequency, conflicting results are often reported. To avoid these factors, this study used transgenic mice with knockouts of interleukin-4 (IL4 -/-) and interleukin-6 (IL6 -/-) to investigate their role in tendon healing. Because of the reported roles of both of these cytokines in inflammation and fibroplasia, it was hypothesized that the order of organizational, geometric, and mechanical properties would be (greatest to least) injured IL6 -/-, injured control, and injured IL4 -/- mice. In addition, it was hypothesized that specific cytokines would be upregulated in each knockout group, but not compensate for the lack of IL-4 or IL-6. Mechanical and organizational properties of injured tendons from IL6 -/- mice were inferior to that of control and IL4 -/- mice despite the upregulation of the pro-inflammatory cytokine TNF-alpha. Temporal levels of IL-10 and IL-13 in the IL4 -/- mice resulted in comparable and even superior properties when compared to CTL mice. This study shows that IL-6 could not be compensated for and plays an important role in tendon healing. This study also supports the use of this animal model to further investigate tendon healing. FAU - Lin, Tony W AU - Lin TW AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, 424 Stemmler Hall, 36th and Hamilton Walk, Philadelphia, PA 19104-6081, USA. FAU - Cardenas, Luis AU - Cardenas L FAU - Glaser, David L AU - Glaser DL FAU - Soslowsky, Louis J AU - Soslowsky LJ LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20050107 PL - United States TA - J Biomech JT - Journal of biomechanics JID - 0157375 RN - 0 (Interleukin-1) RN - 0 (Interleukin-13) RN - 0 (Interleukin-5) RN - 0 (Interleukin-6) RN - 0 (Tumor Necrosis Factor-alpha) RN - 130068-27-8 (Interleukin-10) RN - 207137-56-2 (Interleukin-4) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Interleukin-1/biosynthesis MH - Interleukin-10/biosynthesis MH - Interleukin-13/biosynthesis MH - Interleukin-4/genetics/*physiology MH - Interleukin-5/biosynthesis MH - Interleukin-6/genetics/*physiology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Patella MH - Tendons/metabolism/*physiology MH - Tumor Necrosis Factor-alpha/biosynthesis MH - Up-Regulation MH - Wound Healing/*physiology EDAT- 2005/11/08 09:00 MHDA- 2006/02/18 09:00 CRDT- 2005/11/08 09:00 PHST- 2004/07/02 00:00 [received] PHST- 2004/11/04 00:00 [accepted] PHST- 2005/11/08 09:00 [pubmed] PHST- 2006/02/18 09:00 [medline] PHST- 2005/11/08 09:00 [entrez] AID - S0021-9290(04)00549-4 [pii] AID - 10.1016/j.jbiomech.2004.11.009 [doi] PST - ppublish SO - J Biomech. 2006;39(1):61-9. doi: 10.1016/j.jbiomech.2004.11.009. Epub 2005 Jan 7. PMID- 29283422 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20181113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 19 IP - 1 DP - 2017 Dec 28 TI - Hyperglycemia Augments the Adipogenic Transdifferentiation Potential of Tenocytes and Is Alleviated by Cyclic Mechanical Stretch. LID - 10.3390/ijms19010090 [doi] LID - 90 AB - Diabetes mellitus is associated with damage to tendons, which may result from cellular dysfunction in response to a hyperglycemic environment. Tenocytes express diminished levels of tendon-associated genes under hyperglycemic conditions. In contrast, mechanical stretch enhances tenogenic differentiation. However, whether hyperglycemia increases the non-tenogenic differentiation potential of tenocytes and whether this can be mitigated by mechanical stretch remains elusive. We explored the in vitro effects of high glucose and mechanical stretch on rat primary tenocytes. Specifically, non-tenogenic gene expression, adipogenic potential, cell migration rate, filamentous actin expression, and the activation of signaling pathways were analyzed in tenocytes treated with high glucose, followed by the presence or absence of mechanical stretch. We analyzed tenocyte phenotype in vivo by immunohistochemistry using an STZ (streptozotocin)-induced long-term diabetic mouse model. High glucose-treated tenocytes expressed higher levels of the adipogenic transcription factors PPARγ and C/EBPs. PPARγ was also highly expressed in diabetic tendons. In addition, increased adipogenic differentiation and decreased cell migration induced by high glucose implicated a fibroblast-to-adipocyte phenotypic change. By applying mechanical stretch to tenocytes in high-glucose conditions, adipogenic differentiation was repressed, while cell motility was enhanced, and fibroblastic morphology and gene expression profiles were strengthened. In part, these effects resulted from a stretch-induced activation of ERK (extracellular signal-regulated kinases) and a concomitant inactivation of Akt. Our results show that mechanical stretch alleviates the augmented adipogenic transdifferentiation potential of high glucose-treated tenocytes and helps maintain their fibroblastic characteristics. The alterations induced by high glucose highlight possible pathological mechanisms for diabetic tendinopathy. Furthermore, the beneficial effects of mechanical stretch on tenocytes suggest that an appropriate physical load possesses therapeutic potential for diabetic tendinopathy. FAU - Wu, Yu-Fu AU - Wu YF AD - School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei 10055, Taiwan. Jay5300@gmail.com. AD - Department of Kinesiology and Community Health, College of Applied Health Science, University of Illinois Urbana-Champaign, Champaign, IL 61801, USA. Jay5300@gmail.com. FAU - Huang, Yu-Ting AU - Huang YT AD - School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei 10055, Taiwan. r05428002@ntu.edu.tw. FAU - Wang, Hsing-Kuo AU - Wang HK AD - School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei 10055, Taiwan. hkwang@ntu.edu.tw. FAU - Yao, Chung-Chen Jane AU - Yao CJ AD - Graduate Institute of Clinical Dentistry and Department of Dentistry, School of Dentistry, National Taiwan University, Taipei 10048, Taiwan. janeyao@ntu.edu.tw. AD - Dental Department, National Taiwan University Hospital, Taipei 10048, Taiwan. janeyao@ntu.edu.tw. FAU - Sun, Jui-Sheng AU - Sun JS AD - Department of Orthopedic Surgery, College of Medicine, National Taiwan University, Taipei 10051, Taiwan. drjssun@ntuh.gov.tw. AD - Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei 10002, Taiwan. drjssun@ntuh.gov.tw. FAU - Chao, Yuan-Hung AU - Chao YH AD - School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei 10055, Taiwan. yuanhungchao@ntu.edu.tw. AD - Center of Physical Therapy, National Taiwan University Hospital, Taipei 10048, Taiwan. yuanhungchao@ntu.edu.tw. AD - Rehabilitation Center, National Taiwan University Hospital Chu-Tung Branch, Hsinchu County 31064, Taiwan. yuanhungchao@ntu.edu.tw. LA - eng PT - Journal Article DEP - 20171228 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (CCAAT-Enhancer-Binding Protein-beta) RN - 0 (Cebpb protein, rat) RN - 0 (PPAR gamma) RN - 5W494URQ81 (Streptozocin) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Adipocytes/*drug effects/metabolism/pathology MH - Adipogenesis/drug effects/genetics MH - Animals MH - Biomechanical Phenomena MH - CCAAT-Enhancer-Binding Protein-beta/genetics/metabolism MH - Cell Transdifferentiation/drug effects MH - Diabetes Mellitus, Experimental/chemically induced/genetics/pathology/*therapy MH - Gene Expression Regulation MH - Glucose/*pharmacology MH - Male MH - Mechanotransduction, Cellular/*genetics MH - Mice MH - Mitogen-Activated Protein Kinase 1/genetics/metabolism MH - Mitogen-Activated Protein Kinase 3/genetics/metabolism MH - PPAR gamma/genetics/metabolism MH - Primary Cell Culture MH - Proto-Oncogene Proteins c-akt/genetics/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Streptozocin MH - *Stress, Mechanical MH - Tendons/drug effects/metabolism/pathology MH - Tenocytes/*drug effects/metabolism/pathology PMC - PMC5796040 OTO - NOTNLM OT - PPARγ OT - diabetes OT - differentiation OT - glucose OT - mechanical stretch OT - tendon COIS- The authors declare no conflict of interest. EDAT- 2017/12/29 06:00 MHDA- 2018/07/25 06:00 PMCR- 2018/01/01 CRDT- 2017/12/29 06:00 PHST- 2017/12/13 00:00 [received] PHST- 2017/12/25 00:00 [revised] PHST- 2017/12/26 00:00 [accepted] PHST- 2017/12/29 06:00 [entrez] PHST- 2017/12/29 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - ijms19010090 [pii] AID - ijms-19-00090 [pii] AID - 10.3390/ijms19010090 [doi] PST - epublish SO - Int J Mol Sci. 2017 Dec 28;19(1):90. doi: 10.3390/ijms19010090. PMID- 35175165 OWN - NLM STAT- MEDLINE DCOM- 20220929 LR - 20221118 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 63 IP - 6 DP - 2022 Nov TI - The inhibitory effect of tocilizumab on systemic bone loss and tendon inflammation in a juvenile Collagen-Induced arthritis rat model. PG - 577-589 LID - 10.1080/03008207.2022.2042275 [doi] AB - PURPOSE OF THE STUDY: Reduced Bone Mineral Density (BMD) is a prevalent comorbidity in Juvenile Idiopathic Arthritis (JIA). Enthesitis and other tendon abnormalities, such as tenosynovitis, tendinitis and tendon ruptures are, also, common extra-articular manifestations of the disease. The aim of the present study was to investigate the effect of tocilizumab, an antibody that binds the Interleukin-6 (IL-6) Receptor, on inflammation-related bone loss and tendon inflammation in an animal model of JIA. MATERIALS AND METHODS: The Collagen-Induced Arthritis (CIA) model was induced in male rats followed by intraperitoneal administration of tocilizumab for 8 weeks. Methotrexate, the most widely used Disease-Modifying Antirheumatic Drug in the management of JIA, was, also, administered, either as a monotherapy or as an add-on therapy to tocilizumab. BMD was evaluated with Micro-Computed Tomography (Micro-CT) and histopathological examination. Tendon damage was, also, assessed histologically. Finally, two pro-inflammatory cytokines, Tumor Necrosis Factor-alpha (TNF-a) and Interleukin-23 (IL-23) were quantified in tendon tissues by ELISA analysis. RESULTS: Tocilizumab-treated animals exhibited a significantly improved trabecular microarchitecture on micro-CT analysis and histological examination. Tendon morphology was also improved. Anti-IL-6 treatment led to a significant decrease in TNF-a and IL-23 expression in tendon tissue. CONCLUSIONS: The results of the present study provide evidence that tocilizumab reduces inflammation-related bone loss and suppresses tendon inflammation in a juvenile CIA rat model. These findings offer perspectives for the management of osteoporosis and enthesitis in JIA. FAU - Poutoglidou, Frideriki AU - Poutoglidou F AUID- ORCID: 0000-0003-4840-9748 AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. FAU - Pourzitaki, Chryssa AU - Pourzitaki C AUID- ORCID: 0000-0002-3781-9680 AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. FAU - Manthou, Maria Eleni AU - Manthou ME AD - Laboratory of Histology and Embryology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. FAU - Samoladas, Efthimios AU - Samoladas E AD - Orthopaedics Division, "Genimatas" Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Saitis, Athanasios AU - Saitis A AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. FAU - Malliou, Foteini AU - Malliou F AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. FAU - Kouvelas, Dimitrios AU - Kouvelas D AD - Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220217 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Antirheumatic Agents) RN - 0 (Cytokines) RN - 0 (Interleukin-23) RN - 0 (Interleukin-6) RN - 0 (Tumor Necrosis Factor-alpha) RN - I031V2H011 (tocilizumab) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Animals MH - Antibodies, Monoclonal, Humanized MH - *Antirheumatic Agents/therapeutic use MH - *Arthritis, Experimental/drug therapy/pathology MH - *Arthritis, Juvenile/drug therapy MH - Cytokines MH - Inflammation/drug therapy MH - Interleukin-23/therapeutic use MH - Interleukin-6 MH - Male MH - Methotrexate/therapeutic use MH - Rats MH - Tendons/pathology MH - Tumor Necrosis Factor-alpha MH - X-Ray Microtomography OTO - NOTNLM OT - Collagen-Induced arthritis OT - Juvenile idiopathic arthritis OT - animal model OT - bone mineral density OT - enthesitis OT - tocilizumab EDAT- 2022/02/18 06:00 MHDA- 2022/09/30 06:00 CRDT- 2022/02/17 12:19 PHST- 2022/02/18 06:00 [pubmed] PHST- 2022/09/30 06:00 [medline] PHST- 2022/02/17 12:19 [entrez] AID - 10.1080/03008207.2022.2042275 [doi] PST - ppublish SO - Connect Tissue Res. 2022 Nov;63(6):577-589. doi: 10.1080/03008207.2022.2042275. Epub 2022 Feb 17. PMID- 21246620 OWN - NLM STAT- MEDLINE DCOM- 20110707 LR - 20110426 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 29 IP - 6 DP - 2011 Jun TI - Growth factor and protease expression during different phases of healing after rabbit deep flexor tendon repair. PG - 886-92 LID - 10.1002/jor.21330 [doi] AB - The purpose of the study was to contribute to the mapping of molecular events during flexor tendon healing, in particular the growth factors insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF) and nerve growth factor (NGF), matrix metalloproteinases (MMP-3 and MMP-13) and their inhibitors (tissue inhibitors of metalloproteinases, TIMP-1 and TIMP-3, and the protease cathepsin K. In a rabbit model of flexor tendon injury, the mRNA expression for the growth factors, MMPs and TIMPs were measured in tendon and tendon sheath tissue at several time points (3, 6, 21, and 42 days) representing different phases of the healing process. We found that MMP-13 remained increased during the study period, whereas MMP-3 returned to normal levels within the first week after injury. TIMP-3 was down-regulated in the tendon sheaths. Cathepsin K was up-regulated in tendons and sheaths after injury. NGF was present in both tendons and sheaths, but unaltered. IGF-1 exhibited a late increase in the tendons, while VEGF was down-regulated at the later time points. In conclusion, we have demonstrated the presence of NGF in flexor tendons. MMP-13 expression appears to play a more protracted role in flexor tendon healing than MMP-3. The relatively low levels of endogenous IGF-1 and VEGF mRNA following injury support their potential beneficial role as exogenous modulators to optimize tendon healing and strength without increasing adhesion formation. CI - Copyright © 2011 Orthopaedic Research Society. FAU - Berglund, M E AU - Berglund ME AD - Department of Hand Surgery, Uppsala University, Uppsala, Sweden. maria.e.berglund@gmail.com FAU - Hart, D A AU - Hart DA FAU - Reno, C AU - Reno C FAU - Wiig, M AU - Wiig M LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110118 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - EC 3.4.22.38 (Cathepsin K) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Animals MH - Cathepsin K/metabolism MH - Female MH - Intercellular Signaling Peptides and Proteins/*metabolism MH - Matrix Metalloproteinase 13/metabolism MH - Matrix Metalloproteinase 3/metabolism MH - Rabbits MH - Tendon Injuries/*metabolism MH - Tendons/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/metabolism MH - Tissue Inhibitor of Metalloproteinase-3/metabolism MH - *Wound Healing EDAT- 2011/01/20 06:00 MHDA- 2011/07/08 06:00 CRDT- 2011/01/20 06:00 PHST- 2010/04/27 00:00 [received] PHST- 2010/11/11 00:00 [accepted] PHST- 2011/01/20 06:00 [entrez] PHST- 2011/01/20 06:00 [pubmed] PHST- 2011/07/08 06:00 [medline] AID - 10.1002/jor.21330 [doi] PST - ppublish SO - J Orthop Res. 2011 Jun;29(6):886-92. doi: 10.1002/jor.21330. Epub 2011 Jan 18. PMID- 21577109 OWN - NLM STAT- MEDLINE DCOM- 20110927 LR - 20220331 IS - 1531-703X (Electronic) IS - 1040-8746 (Linking) VI - 23 IP - 4 DP - 2011 Jul TI - Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. PG - 361-6 LID - 10.1097/CCO.0b013e328347e1e3 [doi] AB - PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor (TGCT) or pigmented villonodular synovitis (PVNS) and its therapeutic implications. RECENT FINDINGS: TGCT or PVNS is a benign clonal neoplastic proliferation arising from the synovium characterized by a minor population of intratumoral cells that harbor a recurrent translocation. These cells overexpress CSF1, resulting in recruitment of CSF1R-bearing macrophages that are polyclonal and make up the bulk of the tumor. Inhibition of CSF1R using small molecule inhibitors such as imatinib, nilotinib or sunitinib can result in clinical, radiological and functional improvement in the affected joint. SUMMARY: Currently, surgery remains the treatment of choice for patients with TGCT/PVNS. Localized TGCT/PVNS is managed by marginal excision. Recurrences occur in 8-20% of patients and are easily managed by re-excision. Diffuse TGCT/PVNS tends to recur more often (33-50%) and has a much more aggressive clinical course. Patients are often symptomatic and require multiple surgical procedures during their lifetime. For patients with unresectable disease or multiple recurrences, systemic therapy using CSF1R inhibitors may help delay or avoid surgical procedures and improve functional outcomes. FAU - Ravi, Vinod AU - Ravi V AD - Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, Houston, Texas 77030, USA. vravi@mdanderson.org FAU - Wang, Wei-Lien AU - Wang WL FAU - Lewis, Valerae O AU - Lewis VO LA - eng PT - Journal Article PT - Review PL - United States TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 RN - 0 (Antineoplastic Agents) RN - 0 (Benzamides) RN - 0 (Indoles) RN - 0 (Piperazines) RN - 0 (Pyrimidines) RN - 0 (Pyrroles) RN - 81627-83-0 (Macrophage Colony-Stimulating Factor) RN - 8A1O1M485B (Imatinib Mesylate) RN - EC 2.7.10.1 (Receptor, Macrophage Colony-Stimulating Factor) RN - F41401512X (nilotinib) RN - V99T50803M (Sunitinib) SB - IM MH - Antineoplastic Agents/pharmacology/*therapeutic use MH - Benzamides MH - Giant Cell Tumors/drug therapy/pathology/surgery/*therapy MH - Humans MH - Imatinib Mesylate MH - Indoles/pharmacology/therapeutic use MH - Macrophage Colony-Stimulating Factor/biosynthesis MH - Macrophages/metabolism MH - Piperazines/pharmacology/therapeutic use MH - Pyrimidines/pharmacology/therapeutic use MH - Pyrroles/pharmacology/therapeutic use MH - Receptor, Macrophage Colony-Stimulating Factor/antagonists & inhibitors/metabolism MH - Soft Tissue Neoplasms/drug therapy/pathology/surgery/*therapy MH - Sunitinib MH - Synovial Membrane/pathology MH - Synovitis, Pigmented Villonodular/drug therapy/pathology/surgery/*therapy MH - Tendons/pathology EDAT- 2011/05/18 06:00 MHDA- 2011/09/29 06:00 CRDT- 2011/05/18 06:00 PHST- 2011/05/18 06:00 [entrez] PHST- 2011/05/18 06:00 [pubmed] PHST- 2011/09/29 06:00 [medline] AID - 10.1097/CCO.0b013e328347e1e3 [doi] PST - ppublish SO - Curr Opin Oncol. 2011 Jul;23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3. PMID- 22882155 OWN - NLM STAT- MEDLINE DCOM- 20141114 LR - 20211203 IS - 1600-0838 (Electronic) IS - 0905-7188 (Linking) VI - 24 IP - 2 DP - 2014 Apr TI - Trigger finger, tendinosis, and intratendinous gene expression. PG - 363-8 LID - 10.1111/j.1600-0838.2012.01514.x [doi] AB - The pathogenesis of trigger finger has generally been ascribed to primary changes in the first annular ligament. In contrast, we recently found histological changes in the tendons, similar to the findings in Achilles tendinosis or tendinopathy. We therefore hypothesized that trigger finger tendons would show differences in gene expression in comparison to normal tendons in a pattern similar to what is published for Achilles tendinosis. We performed quantitative real-time polymerase chain reaction on biopsies from finger flexor tendons, 13 trigger fingers and 13 apparently healthy control tendons, to assess the expression of 10 genes which have been described to be differently expressed in tendinosis (collagen type 1a1, collagen 3a1, MMP-2, MMP-3, ADAMTS-5, TIMP-3, aggrecan, biglycan, decorin, and versican). In trigger finger tendons, collagen types 1a1 and 3a1, aggrecan and biglycan were all up-regulated, and MMP-3and TIMP-3 were down-regulated. These changes were statistically significant and have been previously described for Achilles tendinosis. The remaining four genes were not significantly altered. The changes in gene expression support the hypothesis that trigger finger is a form of tendinosis. Because trigger finger is a common condition, often treated surgically, it could provide opportunities for clinical research on tendinosis. CI - © 2012 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Lundin, A-C AU - Lundin AC AD - Department of Hand Surgery, Plastic Surgery and Burns, Linkoping University Hospital, Linkoping, Sweden. FAU - Aspenberg, P AU - Aspenberg P FAU - Eliasson, P AU - Eliasson P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120812 PL - Denmark TA - Scand J Med Sci Sports JT - Scandinavian journal of medicine & science in sports JID - 9111504 RN - 0 (Aggrecans) RN - 0 (Biglycan) RN - 0 (COL3A1 protein, human) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Collagen Type III) RN - 0 (Decorin) RN - 0 (TIMP3 protein, human) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 126968-45-4 (Versicans) RN - EC 3.4.24.- (ADAM Proteins) RN - EC 3.4.24.- (ADAMTS5 Protein) RN - EC 3.4.24.- (ADAMTS5 protein, human) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - ADAM Proteins/genetics MH - ADAMTS5 Protein MH - Achilles Tendon MH - Adult MH - Aged MH - Aged, 80 and over MH - Aggrecans/genetics MH - Biglycan/genetics MH - Case-Control Studies MH - Collagen Type I/genetics MH - Collagen Type I, alpha 1 Chain MH - Collagen Type III/genetics MH - Decorin/genetics MH - Down-Regulation MH - Female MH - *Gene Expression MH - Humans MH - Male MH - Matrix Metalloproteinase 2/genetics MH - Matrix Metalloproteinase 3/genetics MH - Middle Aged MH - Prospective Studies MH - Tendinopathy/genetics MH - Tissue Inhibitor of Metalloproteinase-3/genetics MH - Trigger Finger Disorder/*genetics MH - Up-Regulation MH - Versicans/genetics MH - Young Adult OTO - NOTNLM OT - qPCR OT - quantitative real-time PCR OT - stenosing tendovaginitis OT - tendinopathy OT - tendinosis OT - tendovaginitis stenosans EDAT- 2012/08/14 06:00 MHDA- 2014/11/15 06:00 CRDT- 2012/08/14 06:00 PHST- 2012/06/29 00:00 [accepted] PHST- 2012/08/14 06:00 [entrez] PHST- 2012/08/14 06:00 [pubmed] PHST- 2014/11/15 06:00 [medline] AID - 10.1111/j.1600-0838.2012.01514.x [doi] PST - ppublish SO - Scand J Med Sci Sports. 2014 Apr;24(2):363-8. doi: 10.1111/j.1600-0838.2012.01514.x. Epub 2012 Aug 12. PMID- 6086241 OWN - NLM STAT- MEDLINE DCOM- 19840906 LR - 20131121 IS - 0907-8916 (Print) IS - 0907-8916 (Linking) VI - 31 IP - 3 DP - 1984 Jun TI - Changes in connective tissues during corticotrophin and corticosteroid treatment. Biomechanical and biochemical studies on muscle tendon, skin and aorta in experimental animals. PG - 187-206 FAU - Oxlund, H AU - Oxlund H LA - eng PT - Journal Article PL - Denmark TA - Dan Med Bull JT - Danish medical bulletin JID - 0066040 RN - 9002-60-2 (Adrenocorticotropic Hormone) RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Adrenocorticotropic Hormone/*pharmacology MH - Animals MH - Aorta, Thoracic/drug effects MH - Collagen/physiology MH - Connective Tissue/anatomy & histology/*drug effects MH - Hydrocortisone/*pharmacology MH - Ligaments/drug effects MH - Male MH - Prednisolone/*pharmacology MH - Rabbits MH - Rats MH - Rats, Inbred Strains MH - Skin/drug effects MH - Stress, Mechanical MH - Tendons/drug effects EDAT- 1984/06/01 00:00 MHDA- 1984/06/01 00:01 CRDT- 1984/06/01 00:00 PHST- 1984/06/01 00:00 [pubmed] PHST- 1984/06/01 00:01 [medline] PHST- 1984/06/01 00:00 [entrez] PST - ppublish SO - Dan Med Bull. 1984 Jun;31(3):187-206. PMID- 21706231 OWN - NLM STAT- MEDLINE DCOM- 20120622 LR - 20120221 IS - 1617-7940 (Electronic) IS - 1617-7940 (Linking) VI - 11 IP - 3-4 DP - 2012 Mar TI - Gap junction permeability between tenocytes within tendon fascicles is suppressed by tensile loading. PG - 439-47 LID - 10.1007/s10237-011-0323-1 [doi] AB - Gap junction communication is an essential component in the mechanosensitive response of tenocytes. However, little is known about direct mechanoregulation of gap junction turnover and permeability. The present study tests the hypothesis that mechanical loading alters gap junction communication between tenocyte within tendon fascicles. Viable tenocytes within rat tail tendon fasicles were labelled with calcein-AM and subjected to a fluorescent loss induced by photobleaching (FLIP) protocol. A designated target cell within a row of tenocytes was continuously photobleached at 100% laser power whilst recording the fluorescent intensity of neighbouring cells. A mathematical compartment model was developed to estimate the intercellular communication between tenocytes based upon the experimental FLIP data. This produced a permeability parameter, k, which quantifies the degree of functioning gap functions between cells as confirmed by the complete inhibition of FLIP by the inhibitor 18α-glycyrrhentic acid. The application of 1N static tensile load for 10 min had no effect on gap junction communication. However, when loading was increased to 1 h, there was a statistically significant reduction in gap junction permeability. This coincided with suppression of connexin 43 protein expression in loaded samples as determined by confocal immunofluorescence. However, there was an upregulation of connexin 43 mRNA. These findings demonstrate that tenocytes remodel their gap junctions in response to alterations in mechanical loading with a complex mechanosensitive mechanism of breakdown and remodelling. This is therefore the first study to show that tenocyte gap junctions are not only important in transmitting mechanically activated signals but that mechanical loading directly regulates gap junction permeability. FAU - Maeda, Eijiro AU - Maeda E AD - School of Engineering and Materials Science, Queen Mary, University of London, Mile End Road, London, E1 4NS, UK. FAU - Ye, Shangjun AU - Ye S FAU - Wang, Wen AU - Wang W FAU - Bader, Dan L AU - Bader DL FAU - Knight, Martin M AU - Knight MM FAU - Lee, David A AU - Lee DA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110625 PL - Germany TA - Biomech Model Mechanobiol JT - Biomechanics and modeling in mechanobiology JID - 101135325 RN - 0 (Connexin 43) RN - 0 (Fluoresceins) RN - 0 (RNA, Messenger) RN - 148504-34-1 (calcein AM) SB - IM MH - Animals MH - Cell Communication MH - Connexin 43/metabolism MH - Fluoresceins/metabolism MH - Gap Junctions/*physiology MH - Lasers MH - Light MH - Male MH - Models, Theoretical MH - Permeability MH - Photobleaching MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Wistar MH - Stress, Mechanical MH - Tendons/*cytology/*pathology MH - Tensile Strength EDAT- 2011/06/28 06:00 MHDA- 2012/06/23 06:00 CRDT- 2011/06/28 06:00 PHST- 2011/01/04 00:00 [received] PHST- 2011/06/09 00:00 [accepted] PHST- 2011/06/28 06:00 [entrez] PHST- 2011/06/28 06:00 [pubmed] PHST- 2012/06/23 06:00 [medline] AID - 10.1007/s10237-011-0323-1 [doi] PST - ppublish SO - Biomech Model Mechanobiol. 2012 Mar;11(3-4):439-47. doi: 10.1007/s10237-011-0323-1. Epub 2011 Jun 25. PMID- 8665625 OWN - NLM STAT- MEDLINE DCOM- 19960805 LR - 20051117 IS - 0037-9247 (Print) IS - 0037-9247 (Linking) VI - 132 IP - 3 DP - 1995 TI - [Tendinopathies and fluoroquinolones: a public health problem? Value of drug monitoring studies]. PG - 39-40 FAU - Pierfitte, C AU - Pierfitte C AD - Centre de Pharmacovigilance de Lorraine, Nancy. LA - fre PT - Journal Article TT - Tendinopathies et fluoroquinolones: un probleme de santé publique? De l'intétêt des enquetes de pharmacogvigilance. PL - Luxembourg TA - Bull Soc Sci Med Grand Duche Luxemb JT - Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg JID - 7503402 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Adverse Drug Reaction Reporting Systems MH - Anti-Infective Agents/*adverse effects MH - Drug Monitoring MH - Fluoroquinolones MH - France MH - Humans MH - Rupture, Spontaneous MH - Tendinopathy/*chemically induced MH - Tendons/*drug effects EDAT- 1995/01/01 00:00 MHDA- 1995/01/01 00:01 CRDT- 1995/01/01 00:00 PHST- 1995/01/01 00:00 [pubmed] PHST- 1995/01/01 00:01 [medline] PHST- 1995/01/01 00:00 [entrez] PST - ppublish SO - Bull Soc Sci Med Grand Duche Luxemb. 1995;132(3):39-40. PMID- 16826121 OWN - NLM STAT- MEDLINE DCOM- 20060810 LR - 20161124 IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 448 DP - 2006 Jul TI - RGD-tethered silk substrate stimulates the differentiation of human tendon cells. PG - 234-9 AB - Tendon reconstruction surgery often requires healing of the tendon to bone. The development of a more rapid and strong interaction at the tendon to bone interface would be invaluable to patients having orthopaedic surgery. Therefore, our rationale was to modify sutures so that they would be anabolic for tendon to bone healing. It has been shown that silk stimulates bone formation in osteoblast cultures. In the current study, we tested the ability of silk and silk-RGD (arginine-glycine-aspartic acid) to stimulate human tenocyte adhesion, proliferation, and differentiation. A 1.3-fold increase in tenocyte adhesion was found on silk-RGD compared with tissue culture plastic. By 72 hours, proliferation had increased on all substrates but was particularly enhanced on silk-RGD compared with the control. At 6 weeks, Northern blot analysis of decorin and Type I collagen mRNA levels showed a 2-3-fold increase in message levels on silk-RGD and silk compared with tissue culture plastic. The data suggest cultured human tenocytes adhere, proliferate, and differentiate on silk and silk-RGD substrates. A suture material, such as silk, decorated with RGD, may have the potential to facilitate tendon-bone healing with widespread applications in tendon reconstruction surgery. FAU - Kardestuncer, T AU - Kardestuncer T AD - Department of Orthopaedics, University of Connecticut Health Center, Farmington, USA. tkardes@gmail.com FAU - McCarthy, M B AU - McCarthy MB FAU - Karageorgiou, V AU - Karageorgiou V FAU - Kaplan, D AU - Kaplan D FAU - Gronowicz, G AU - Gronowicz G LA - eng GR - DE13405/DE/NIDCR NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Oligopeptides) RN - 0 (Silk) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) SB - IM MH - Amino Acid Sequence MH - Cell Adhesion/drug effects MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - *Coated Materials, Biocompatible MH - Follow-Up Studies MH - Humans MH - In Vitro Techniques MH - Oligopeptides/*pharmacology MH - *Silk MH - Suture Techniques/*instrumentation MH - *Sutures MH - Tendons/*cytology/drug effects EDAT- 2006/07/11 09:00 MHDA- 2006/08/11 09:00 CRDT- 2006/07/11 09:00 PHST- 2006/07/11 09:00 [pubmed] PHST- 2006/08/11 09:00 [medline] PHST- 2006/07/11 09:00 [entrez] AID - 00003086-200607000-00034 [pii] AID - 10.1097/01.blo.0000205879.50834.fe [doi] PST - ppublish SO - Clin Orthop Relat Res. 2006 Jul;448:234-9. doi: 10.1097/01.blo.0000205879.50834.fe. PMID- 10432350 OWN - NLM STAT- MEDLINE DCOM- 19991018 LR - 20190513 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 519 Pt 1 IP - Pt 1 DP - 1999 Aug 15 TI - The myotubal origin of rat muscle fibres affects the extent of tenotomy-induced atrophy. PG - 197-202 AB - 1. Immature muscle fibres (myotubes) can be divided into primary and secondary generations, which differ from each other in their time of formation, growth rates and myosin isoform expression. It is unclear whether the intrinsic differences between primary and secondary myotubes are totally extinguished once they mature and extrinsic factors, such as load, become important. 2. Four pregnant rats were injected with 5-bromo-2'-deoxyuridine (BrdU) on the 14th and 15th days of gestation. This selectively and permanently labels primary myotubes. Ten rats from four litters were killed when 8 months old, with three males (365-430 g) from a single litter being used for the quantitative study and the remainder being examined qualitatively. The extensor digitorum longus muscle (EDL) in each rat was tenotomized for 14 days. The sizes of fibres in the EDL were then correlated with their fibre type and whether they contained BrdU-labelled nuclei. 3. We reported that (i) II A and II B fibres derived from primary myotubes atrophied significantly less after tenotomy than II A and II B fibres derived from secondary myotubes and (ii) BrdU-labelled myonuclei were retained in the tenotomized muscle, even though tenotomy resulted in a substantial loss of myonuclei from the EDL. 4. We conclude that the origin of a fibre is a determinant of its response to the external forces which control its size, and hence force generation. FAU - Zhang, M AU - Zhang M AD - Department of Anatomy and Structural Biology, University of Otago, Dunedin, New Zealand. FAU - McLennan, I S AU - McLennan IS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - EC 3.6.1.- (Adenosine Triphosphatases) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Adenosine Triphosphatases/analysis MH - Animals MH - Atrophy MH - Bromodeoxyuridine MH - Female MH - Male MH - Muscle Fibers, Skeletal/pathology/*physiology MH - Muscle, Skeletal/*embryology/pathology/*physiology MH - Pregnancy MH - Rats MH - Tendons/*physiology/surgery PMC - PMC2269490 EDAT- 1999/08/05 00:00 MHDA- 1999/08/05 00:01 PMCR- 2000/08/15 CRDT- 1999/08/05 00:00 PHST- 1999/08/05 00:00 [pubmed] PHST- 1999/08/05 00:01 [medline] PHST- 1999/08/05 00:00 [entrez] PHST- 2000/08/15 00:00 [pmc-release] AID - PHY_9432 [pii] AID - 10.1111/j.1469-7793.1999.0197o.x [doi] PST - ppublish SO - J Physiol. 1999 Aug 15;519 Pt 1(Pt 1):197-202. doi: 10.1111/j.1469-7793.1999.0197o.x. PMID- 1780680 OWN - NLM STAT- MEDLINE DCOM- 19920312 LR - 20131121 IS - 0035-2659 (Print) IS - 0035-2659 (Linking) VI - 58 IP - 12 DP - 1991 Dec TI - [Achilles tendon rupture in 2 adults treated with pefloxacin, one of the cases with bilateral involvement]. PG - 904 FAU - Franck, J L AU - Franck JL FAU - Bouteiller, G AU - Bouteiller G FAU - Chagnaud, P AU - Chagnaud P FAU - Sapene, M AU - Sapene M FAU - Gautier, D AU - Gautier D LA - fre PT - Case Reports PT - Letter TT - Rupture des tendons d'achille chez deux adultes traités par péfloxacine dont un cas bilatéral. PL - France TA - Rev Rhum Mal Osteoartic JT - Revue du rhumatisme et des maladies osteo-articulaires JID - 0407211 RN - 2H52Z9F2Q5 (Pefloxacin) SB - IM MH - Achilles Tendon/*injuries MH - Aged MH - Humans MH - Male MH - Middle Aged MH - Pefloxacin/*adverse effects MH - Rupture, Spontaneous EDAT- 1991/12/01 00:00 MHDA- 1991/12/01 00:01 CRDT- 1991/12/01 00:00 PHST- 1991/12/01 00:00 [pubmed] PHST- 1991/12/01 00:01 [medline] PHST- 1991/12/01 00:00 [entrez] PST - ppublish SO - Rev Rhum Mal Osteoartic. 1991 Dec;58(12):904. PMID- 16429255 OWN - NLM STAT- MEDLINE DCOM- 20061205 LR - 20131121 IS - 1023-3830 (Print) IS - 1023-3830 (Linking) VI - 55 IP - 1 DP - 2006 Jan TI - Spontaneous recovery of injured Achilles tendon in inducible nitric oxide synthase gene knockout mice. PG - 40-5 AB - OBJECTIVE AND DESIGN: To determine if inducible nitric oxide synthase (iNOS) gene could affect Achilles tendon healing using iNOS gene knockout mice. METHODS: 21 iNOS knockout (iNOS(-/-)) mice and 8 of the wild type (iNOS(+/+)) mice were utilized in this study. Group 1: iNOS(+/+) mice (n = 8), group 2: iNOS(-/-) mice (n = 11) and group 3: iNOS(-/-) with a NOS inhibitor, (aminoguanidine, 500 mg/kg/day, via an intraperitoneal mini-osmotic pump for 7 days, n = 10). The right Achilles tendon was transected in all mice and harvested on day 7 for cross-sectional area and biomechanical properties. Serum nitrate concentration of the mice was measured by gas chromatography mass spectrometry (GC/MS). RESULTS: A significant reduction in cross-sectional area of the healing Achilles tendon was observed in group 3 mice compared to group 2 mice (p < 0.01). The serum nitrate concentration in both group 2 and group 3 mice was lower than that in group 1 mice (p < 0.01) iNOS gene deletion and inhibition of NOS did not affect the biomechanical properties of the healing tendons. CONCLUSIONS: iNOS gene is not solely responsible for the beneficial effects of nitric oxide (NO) on tendon healing. FAU - Xia, W AU - Xia W AD - Orthopaedic Research Institute, St. George Hospital Campus, University of New South Wales, Kogarah, Sydney, NSW 2217, Australia. admin@ori.org.au FAU - Wang, Y AU - Wang Y FAU - Appleyard, R C AU - Appleyard RC FAU - Smythe, G A AU - Smythe GA FAU - Murrell, G A C AU - Murrell GA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Switzerland TA - Inflamm Res JT - Inflammation research : official journal of the European Histamine Research Society ... [et al.] JID - 9508160 RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) SB - IM MH - Achilles Tendon/*injuries/pathology MH - Animals MH - Biomechanical Phenomena MH - Gas Chromatography-Mass Spectrometry MH - Genotype MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase Type II/biosynthesis/*genetics/*physiology MH - Polymerase Chain Reaction MH - Tendons/pathology MH - Wound Healing EDAT- 2006/01/24 09:00 MHDA- 2006/12/09 09:00 CRDT- 2006/01/24 09:00 PHST- 2006/01/24 09:00 [pubmed] PHST- 2006/12/09 09:00 [medline] PHST- 2006/01/24 09:00 [entrez] AID - 10.1007/s00011-005-0006-4 [doi] PST - ppublish SO - Inflamm Res. 2006 Jan;55(1):40-5. doi: 10.1007/s00011-005-0006-4. PMID- 570970 OWN - NLM STAT- MEDLINE DCOM- 19790626 LR - 20210212 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 254 IP - 7 DP - 1979 Apr 10 TI - Kinetics for the secretion of nonhelical procollagen by freshly isolated tendon cells. PG - 2234-43 AB - Fibroblasts isolated by enzymic digestion of chick embryo tendons have previously been used to examine the kinetics for the secretion of procollagen (Kao, W. W.-Y., Berg, R. A., and Prockop, D. J. (1977) J. Biol. Chem. 252, 8391-8397). The results indicated that the kinetics approximated the sum of two first order processes with half-times of 14 and 115 min. Here, the same fibroblasts were incubated in the presence of 1.53 mM cis-4-hydroxyproline, an analogue of proline, or in the presence of 0.3 mM alpha,alpha'-dipyridyl, an inhibitor of prolyl hydroxylase, so that the cells synthesized procollagen which could not assume a triple helical conformation characteristic of procollagen. Measurements of the secretion of nonhelical procollagen indicated that the kinetics for secretion differed from the kinetics for the secretion of procollagen and approximated a single first order process with a half-time of approximately 130 min. The nonhelical procollagen synthesized and secreted in the presence of either cis-4-hydroxyproline or alpha,alpha'-dipyridyl consisted of disulfide-bonded pro gamma chains of type I procollagen. The results suggested that the intracellular nonhelical procollagen was present in a single metabolic pool and secretion from this pool occurred with a different rate-limiting step than for helical procollagen. Further results indicated that nonhelical procollagen had a high affinity for prolyl hydroxylase and the affinity for the enzyme was greatly reduced if the procollagen was allowed to assume the triple helical conformation characteristic of normal procollagen. The results are consistent with the hypothesis that the secretion of procollagen is influenced by its conformation-dependent interaction with prolyl hydroxylase or other post-translational enzymes. FAU - Kao, W W AU - Kao WW FAU - Prockop, D J AU - Prockop DJ FAU - Berg, R A AU - Berg RA LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Procollagen) RN - 551W113ZEP (2,2'-Dipyridyl) RN - 98600C0908 (Cycloheximide) SB - IM MH - 2,2'-Dipyridyl/pharmacology MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Cycloheximide/pharmacology MH - Fibroblasts/metabolism MH - Kinetics MH - Procollagen/biosynthesis/*metabolism MH - Protein Conformation MH - Tendons/drug effects/*metabolism EDAT- 1979/04/10 00:00 MHDA- 1979/04/10 00:01 CRDT- 1979/04/10 00:00 PHST- 1979/04/10 00:00 [pubmed] PHST- 1979/04/10 00:01 [medline] PHST- 1979/04/10 00:00 [entrez] AID - S0021-9258(17)30212-0 [pii] PST - ppublish SO - J Biol Chem. 1979 Apr 10;254(7):2234-43. PMID- 23815595 OWN - NLM STAT- MEDLINE DCOM- 20140702 LR - 20220409 IS - 1557-8534 (Electronic) IS - 1547-3287 (Print) IS - 1547-3287 (Linking) VI - 22 IP - 23 DP - 2013 Dec 1 TI - In vivo identity of tendon stem cells and the roles of stem cells in tendon healing. PG - 3128-40 LID - 10.1089/scd.2013.0073 [doi] AB - We investigated the spatial distribution of stem cells in tendons and the roles of stem cells in early tendon repair. The relationship between tendon-derived stem cells (TDSCs) isolated in vitro and tendon stem cells in vivo was also explored. Iododeoxyuridine (IdU) label-retaining method was used for labeling stem cells in rat patellar tendons with and without injury. Co-localization of label-retaining cells (LRCs) with different markers was done by immunofluorescent staining. TDSCs were isolated from patellar tendon mid-substance after IdU pulsing, and the expression of different markers in fresh and expanded cells was done by immunofluorescent staining. More LRCs were found at the peritenon and tendon-bone junction compared with the mid-substance. Some LRCs at the peritenon were located at the perivascular niche. The LRC number and the expression of proliferative, tendon-related, pluripotency, and pericyte-related markers in LRCs in the window wound increased. Most of the freshly isolated TDSCs expressed IdU, and some TDSCs expressed pericyte-related markers, which were lost during expansion. Both freshly isolated and subcultured TDSCs expressed pluripotency markers, which were absent in LRCs in intact tendons. In conclusion, we identified LRCs at the peritenon, mid-substance, and tendon-bone junction. There were both vascular and non-vascular sources of LRCs at the peritenon, while the source of LRCs at the mid-substance was non-vascular. LRCs participated in tendon repair via migration, proliferation, activation for tenogenesis, and increased pluripotency. Some LRCs in the window wound were pericyte like. Most of the mid-substance TDSCs were LRCs. The pluripotency markers and pericyte-related marker in LRCs might be important for function after injury. FAU - Tan, Qi AU - Tan Q AD - 1 Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong , Hong Kong SAR, China . FAU - Lui, Pauline Po Yee AU - Lui PP FAU - Lee, Yuk Wa AU - Lee YW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130803 PL - United States TA - Stem Cells Dev JT - Stem cells and development JID - 101197107 RN - 0 (Antigens, Ly) RN - 0 (Biomarkers) RN - 0 (Hyaluronan Receptors) RN - LGP81V5245 (Idoxuridine) SB - IM MH - Animals MH - Antigens, Ly/metabolism MH - Biomarkers/metabolism MH - Cell Proliferation MH - Hyaluronan Receptors/metabolism MH - Idoxuridine/metabolism MH - Male MH - Pericytes/metabolism MH - Pluripotent Stem Cells/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Staining and Labeling MH - Stem Cells/*cytology MH - Tendons/*pathology MH - Time Factors MH - *Wound Healing PMC - PMC3857013 EDAT- 2013/07/03 06:00 MHDA- 2014/07/06 06:00 PMCR- 2014/12/01 CRDT- 2013/07/03 06:00 PHST- 2013/07/03 06:00 [entrez] PHST- 2013/07/03 06:00 [pubmed] PHST- 2014/07/06 06:00 [medline] PHST- 2014/12/01 00:00 [pmc-release] AID - 10.1089/scd.2013.0073 [pii] AID - 10.1089/scd.2013.0073 [doi] PST - ppublish SO - Stem Cells Dev. 2013 Dec 1;22(23):3128-40. doi: 10.1089/scd.2013.0073. Epub 2013 Aug 3. PMID- 17300926 OWN - NLM STAT- MEDLINE DCOM- 20070718 LR - 20070827 IS - 0945-053X (Print) IS - 0945-053X (Linking) VI - 26 IP - 4 DP - 2007 May TI - Inhibition of aggrecan turnover in short-term explant cultures of bovine tendon. PG - 280-90 AB - The large aggregating proteoglycan, aggrecan, better known for its physiological role in articular cartilage where it serves to facilitate resistance of compressive forces during joint articulation, is also present within the distinct functional regions of tendon (i.e., compressed/fibrocartilaginous and tensional). Previous studies demonstrate that an increased turnover of aggrecan occurs in tendon, which is mediated principally by the 'aggrecanases' and, as such, these proteinases may play an important role in the normal functioning of the tissue. In the present study, utilising bovine tendon explant culture systems, we demonstrated that aggrecanase-mediated tendon aggrecan turnover may be modulated by generic metalloproteinase inhibitors (i.e., the aggrecanase inhibitor, actinonin and the broad-spectrum MMP inhibitor, marimistat). As expected, no MMP-generated aggrecan catabolites were detected in the culture system, suggesting that tendon aggrecanases may be inhibited by marimistat. Furthermore, immunohistochemical analyses revealed that aggrecan metabolites are present in the endotenon, surrounding the collagen fibre bundles, suggesting that aggrecan may provide functions of water imbibement and resistance of reversible and repeated compressive loads manifest between the collagen fibres; these functions, in turn, may be associated with increased aggrecan turnover in this tissue. Thus, inhibition of tendon aggrecanases and consequently aggrecan turnover in this tissue, may be related to some of the deleterious effects observed in the tendons of patients undergoing drug therapy with broad-spectrum MMP inhibitors for cancer and arthritis. FAU - Rees, Sarah G AU - Rees SG AD - School of Medicine, Swansea University, Singleton Park, Swansea, SA2 8PP, UK. s.g.rees@swansea.ac.uk FAU - Waggett, Andrew D AU - Waggett AD FAU - Dent, Colin M AU - Dent CM FAU - Caterson, Bruce AU - Caterson B LA - eng SI - GENBANK/AF192771 SI - GENBANK/AF516915 SI - GENBANK/J03209 SI - GENBANK/S48568 SI - GENBANK/S68252 SI - GENBANK/U02571 SI - GENBANK/X01677 SI - RefSeq/NM_002427 PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070119 PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Aggrecans) RN - 0 (Culture Media) RN - 0 (Enzyme Inhibitors) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Proteoglycans) RN - 9007-34-5 (Collagen) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - EC 3.4.99.- (aggrecanase) SB - IM MH - Aggrecans/*metabolism MH - Animals MH - Cartilage/metabolism MH - Cattle MH - Cell Culture Techniques/methods MH - Collagen/metabolism MH - Culture Media/metabolism MH - Endopeptidases/metabolism MH - Enzyme Inhibitors/pharmacology MH - Extracellular Matrix Proteins/metabolism MH - Matrix Metalloproteinases/*metabolism MH - Molecular Sequence Data MH - Proteoglycans/metabolism MH - Tendons/cytology/*metabolism EDAT- 2007/02/16 09:00 MHDA- 2007/07/19 09:00 CRDT- 2007/02/16 09:00 PHST- 2006/12/15 00:00 [received] PHST- 2007/01/08 00:00 [accepted] PHST- 2007/02/16 09:00 [pubmed] PHST- 2007/07/19 09:00 [medline] PHST- 2007/02/16 09:00 [entrez] AID - S0945-053X(07)00002-9 [pii] AID - 10.1016/j.matbio.2007.01.003 [doi] PST - ppublish SO - Matrix Biol. 2007 May;26(4):280-90. doi: 10.1016/j.matbio.2007.01.003. Epub 2007 Jan 19. PMID- 5071801 OWN - NLM STAT- MEDLINE DCOM- 19721116 LR - 20190624 IS - 0014-2999 (Print) IS - 0014-2999 (Linking) VI - 19 IP - 2 DP - 1972 Aug TI - Singular effects of a new short acting cardiac glycoside in purkinje cells. PG - 291-3 FAU - Pastelin, G AU - Pastelin G FAU - Mendez, R AU - Mendez R LA - eng PT - Journal Article PL - Netherlands TA - Eur J Pharmacol JT - European journal of pharmacology JID - 1254354 RN - 0 (Cardiac Glycosides) RN - 0 (Neuromuscular Depolarizing Agents) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Cardiac Glycosides/administration & dosage/adverse effects/*pharmacology MH - Dogs MH - In Vitro Techniques MH - Neuromuscular Depolarizing Agents/pharmacology MH - Purkinje Cells/*drug effects MH - Tendons/drug effects EDAT- 1972/08/01 00:00 MHDA- 1972/08/01 00:01 CRDT- 1972/08/01 00:00 PHST- 1972/08/01 00:00 [pubmed] PHST- 1972/08/01 00:01 [medline] PHST- 1972/08/01 00:00 [entrez] AID - 0014-2999(72)90024-6 [pii] AID - 10.1016/0014-2999(72)90024-6 [doi] PST - ppublish SO - Eur J Pharmacol. 1972 Aug;19(2):291-3. doi: 10.1016/0014-2999(72)90024-6. PMID- 6065449 OWN - NLM STAT- MEDLINE DCOM- 19680213 LR - 20160512 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 49 IP - 8 DP - 1967 Dec TI - Infection of synovial tissues by mycobacteria other than Mycobacterium tuberculosis. PG - 1521-30 FAU - Kelly, P J AU - Kelly PJ FAU - Karlson, A G AU - Karlson AG FAU - Weed, L A AU - Weed LA FAU - Lipscomb, P R AU - Lipscomb PR LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - OAY8ORS3CQ (Ethionamide) RN - Y45QSO73OB (Streptomycin) SB - IM MH - Adult MH - Aged MH - Bursitis MH - Ethionamide/therapeutic use MH - Female MH - Finger Joint/microbiology MH - Humans MH - Joint Diseases/*microbiology MH - Male MH - Middle Aged MH - *Mycobacterium Infections/drug therapy/surgery MH - Streptomycin/therapeutic use MH - Synovitis/drug therapy/*microbiology/surgery MH - Tendinopathy MH - Tendons/microbiology MH - Tuberculin Test MH - Wrist Joint/microbiology EDAT- 1967/12/01 00:00 MHDA- 1967/12/01 00:01 CRDT- 1967/12/01 00:00 PHST- 1967/12/01 00:00 [pubmed] PHST- 1967/12/01 00:01 [medline] PHST- 1967/12/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Am. 1967 Dec;49(8):1521-30. PMID- 16264114 OWN - NLM STAT- MEDLINE DCOM- 20051213 LR - 20220311 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 87 IP - 11 DP - 2005 Nov TI - Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. PG - 2401-10 AB - BACKGROUND: The use of soft-tissue grafts for anterior cruciate ligament reconstruction delays the healing process. This delay may be due to biochemical and/or biomechanical insults. We hypothesized that the blocking effect of alpha2-macroglobulin on synovial matrix metalloproteinase activity may enhance the healing of tendon graft in a bone tunnel. METHODS: The study was performed on twenty-eight healthy, skeletally mature New Zealand White rabbits. Each rabbit underwent bilateral anterior cruciate ligament reconstruction with use of the ipsilateral semitendinosus tendon. Alpha-2-macroglobulin (alpha2-macroglobulin) was injected into the knee joint in one limb, and the contralateral limb served as a control. The rabbits were killed two weeks (fourteen rabbits) or five weeks (fourteen rabbits) after the operative procedures. The presence of matrix metalloproteinases in synovial fluid, and the blocking effect of alpha2-macroglobulin on them, were determined with enzymatic assays. Healing between the tendon and the bone tunnel was assessed morphologically by determining the presence of fibrovascular tissue and collagen fibers. Healing also was assessed quantitatively by measuring the ultimate load to failure of the reconstructed complex. RESULTS: There was an increase in matrix metalloproteinases in the control group; in contrast, there was a decrease in the study group (p < 0.05). In the control specimens, the fibrovascular tissue at the bone-tendon interface had developed into dense connective tissue with poor vascularization. In the treated specimens, the bone tunnel had more areas of denser connective-tissue ingrowth. The interface tissue was more mature and contained numerous perpendicular collagen bundles (Sharpey fibers). The ultimate load to failure was significantly greater in the alpha2-macroglobulin-treated specimens than in the untreated controls at both two and five weeks. CONCLUSIONS: The present study demonstrated that alpha2-macroglobulin blockade of matrix metalloproteinases can enhance bone-tendon healing. This effect of alpha2-macroglobulin could occur through its effect solely on collagenase or on a subset of matrix metalloproteinases that are present at the healing interface. FAU - Demirag, Burak AU - Demirag B AD - Department of Orthopaedic Surgery, Uludag University Medical School, 16059, Görükle, Bursa, Turkey. burakdemirag@hotmail.com FAU - Sarisozen, Bartu AU - Sarisozen B FAU - Ozer, Ozgur AU - Ozer O FAU - Kaplan, Tolga AU - Kaplan T FAU - Ozturk, Cagatay AU - Ozturk C LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Enzyme Inhibitors) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (alpha-Macroglobulins) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Anterior Cruciate Ligament/physiopathology/surgery MH - *Anterior Cruciate Ligament Injuries MH - Bone and Bones/drug effects/physiopathology MH - Enzyme Inhibitors/*administration & dosage MH - Injections, Intra-Articular MH - *Matrix Metalloproteinase Inhibitors MH - Matrix Metalloproteinases/analysis MH - Models, Animal MH - Orthopedic Procedures/methods MH - Rabbits MH - Synovial Fluid/chemistry MH - Tendons/drug effects/physiopathology/transplantation MH - Transplantation, Autologous MH - Wound Healing/*drug effects/physiology MH - alpha-Macroglobulins/*administration & dosage EDAT- 2005/11/03 09:00 MHDA- 2005/12/15 09:00 CRDT- 2005/11/03 09:00 PHST- 2005/11/03 09:00 [pubmed] PHST- 2005/12/15 09:00 [medline] PHST- 2005/11/03 09:00 [entrez] AID - 87/11/2401 [pii] AID - 10.2106/JBJS.D.01952 [doi] PST - ppublish SO - J Bone Joint Surg Am. 2005 Nov;87(11):2401-10. doi: 10.2106/JBJS.D.01952. PMID- 29053586 OWN - NLM STAT- MEDLINE DCOM- 20180606 LR - 20211204 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 18 IP - 10 DP - 2017 Oct 20 TI - Time-Dependent Alterations of MMPs, TIMPs and Tendon Structure in Human Achilles Tendons after Acute Rupture. LID - 10.3390/ijms18102199 [doi] LID - 2199 AB - A balance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) is required to maintain tendon homeostasis. Variation in this balance over time might impact on the success of tendon healing. This study aimed to analyze structural changes and the expression profile of MMPs and TIMPs in human Achilles tendons at different time-points after rupture. Biopsies from 37 patients with acute Achilles tendon rupture were taken at surgery and grouped according to time after rupture: early (2-4 days), middle (5-6 days), and late (≥7 days), and intact Achilles tendons served as control. The histological score increased from the early to the late time-point after rupture, indicating the progression towards a more degenerative status. In comparison to intact tendons, qRT-PCR analysis revealed a significantly increased expression of MMP-1, -2, -13, TIMP-1, COL1A1, and COL3A1 in ruptured tendons, whereas TIMP-3 decreased. Comparing the changes over time post rupture, the expression of MMP-9, -13, and COL1A1 significantly increased, whereas MMP-3 and -10 expression decreased. TIMP expression was not significantly altered over time. MMP staining by immunohistochemistry was positive in the ruptured tendons exemplarily analyzed from early and late time-points. The study demonstrates a pivotal contribution of all investigated MMPs and TIMP-1, but a minor role of TIMP-2, -3, and -4, in the early human tendon healing process. FAU - Minkwitz, Susann AU - Minkwitz S AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Susann.Minkwitz@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Susann.Minkwitz@charite.de. FAU - Schmock, Aysha AU - Schmock A AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Aysha.Schmock@charite.de. FAU - Kurtoglu, Alper AU - Kurtoglu A AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Alper.Kurtoglu@charite.de. FAU - Tsitsilonis, Serafeim AU - Tsitsilonis S AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Serafeim.Tsitsilonis@charite.de. FAU - Manegold, Sebastian AU - Manegold S AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Sebastian.Manegold@charite.de. FAU - Wildemann, Britt AU - Wildemann B AUID- ORCID: 0000-0002-8365-1188 AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Britt.Wildemann@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Britt.Wildemann@charite.de. FAU - Klatte-Schulz, Franka AU - Klatte-Schulz F AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Franka.Klatte@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 13353 Berlin, Germany. Franka.Klatte@charite.de. LA - eng PT - Journal Article DEP - 20171020 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (COL3A1 protein, human) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Collagen Type III) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Achilles Tendon/*injuries/metabolism/surgery MH - Adult MH - Biopsy MH - Collagen Type I/genetics MH - Collagen Type I, alpha 1 Chain MH - Collagen Type III/genetics MH - Female MH - Gene Expression Profiling MH - Gene Expression Regulation MH - Humans MH - Male MH - Matrix Metalloproteinases/*genetics/metabolism MH - Middle Aged MH - Rupture/genetics/*pathology/surgery MH - Tendon Injuries/genetics/*pathology/surgery MH - Time Factors MH - Tissue Inhibitor of Metalloproteinases/*genetics MH - Young Adult PMC - PMC5666880 OTO - NOTNLM OT - ECM composition OT - human OT - matrix metalloproteinases OT - tendon healing OT - tissue inhibitors of metalloproteinases COIS- The authors declare no conflict of interest. EDAT- 2017/10/21 06:00 MHDA- 2018/06/07 06:00 PMCR- 2017/10/01 CRDT- 2017/10/21 06:00 PHST- 2017/09/20 00:00 [received] PHST- 2017/10/10 00:00 [revised] PHST- 2017/10/17 00:00 [accepted] PHST- 2017/10/21 06:00 [entrez] PHST- 2017/10/21 06:00 [pubmed] PHST- 2018/06/07 06:00 [medline] PHST- 2017/10/01 00:00 [pmc-release] AID - ijms18102199 [pii] AID - ijms-18-02199 [pii] AID - 10.3390/ijms18102199 [doi] PST - epublish SO - Int J Mol Sci. 2017 Oct 20;18(10):2199. doi: 10.3390/ijms18102199. PMID- 32467241 OWN - NLM STAT- MEDLINE DCOM- 20210205 LR - 20220816 IS - 1477-9129 (Electronic) IS - 0950-1991 (Print) IS - 0950-1991 (Linking) VI - 147 IP - 12 DP - 2020 Jun 24 TI - The mevalonate pathway is a crucial regulator of tendon cell specification. LID - 10.1242/dev.185389 [doi] LID - dev185389 AB - Tendons and ligaments are crucial components of the musculoskeletal system, yet the pathways specifying these fates remain poorly defined. Through a screen of known bioactive chemicals in zebrafish, we identified a new pathway regulating tendon cell induction. We established that statin, through inhibition of the mevalonate pathway, causes an expansion of the tendon progenitor population. Co-expression and live imaging studies indicate that the expansion does not involve an increase in cell proliferation, but rather results from re-specification of cells from the neural crest-derived sox9a(+)/sox10(+) skeletal lineage. The effect on tendon cell expansion is specific to the geranylgeranylation branch of the mevalonate pathway and is mediated by inhibition of Rac activity. This work establishes a novel role for the mevalonate pathway and Rac activity in regulating specification of the tendon lineage. CI - © 2020. Published by The Company of Biologists Ltd. FAU - Chen, Jessica W AU - Chen JW AUID- ORCID: 0000-0003-4425-6369 AD - Center for Regenerative Medicine, Harvard Stem Cell Institute, Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA. AD - Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. FAU - Niu, Xubo AU - Niu X AD - Center for Regenerative Medicine, Harvard Stem Cell Institute, Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA. FAU - King, Matthew J AU - King MJ AD - Center for Regenerative Medicine, Harvard Stem Cell Institute, Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA. FAU - Noedl, Marie-Therese AU - Noedl MT AD - Center for Regenerative Medicine, Harvard Stem Cell Institute, Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA. FAU - Tabin, Clifford J AU - Tabin CJ AD - Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. FAU - Galloway, Jenna L AU - Galloway JL AUID- ORCID: 0000-0003-3792-3290 AD - Center for Regenerative Medicine, Harvard Stem Cell Institute, Department of Orthopedic Surgery, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA jenna_galloway@hms.harvard.edu. LA - eng GR - R03 DE024771/DE/NIDCR NIH HHS/United States GR - R00 HD069533/HD/NICHD NIH HHS/United States GR - R01 AR074541/AR/NIAMS NIH HHS/United States GR - R01 HD032443/HD/NICHD NIH HHS/United States GR - K99 HD069533/HD/NICHD NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20200624 PL - England TA - Development JT - Development (Cambridge, England) JID - 8701744 RN - 0 (Morpholinos) RN - 0 (SOX9 Transcription Factor) RN - 0 (SOXE Transcription Factors) RN - 0 (Sox9a protein, zebrafish) RN - 0 (Zebrafish Proteins) RN - 0 (sox10 protein, zebrafish) RN - A0JWA85V8F (Atorvastatin) RN - EC 2.5.- (Alkyl and Aryl Transferases) RN - EC 2.5.1.- (geranylgeranyltransferase type-I) RN - EC 2.5.1.29 (Farnesyltranstransferase) RN - EC 3.6.5.2 (rac GTP-Binding Proteins) RN - S5UOB36OCZ (Mevalonic Acid) SB - IM MH - Alkyl and Aryl Transferases/antagonists & inhibitors/genetics/metabolism MH - Animals MH - Animals, Genetically Modified/metabolism MH - Atorvastatin/pharmacology MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Farnesyltranstransferase/antagonists & inhibitors/genetics/metabolism MH - Mevalonic Acid/*metabolism MH - Morpholinos/metabolism MH - Neural Crest/metabolism MH - SOX9 Transcription Factor/genetics/metabolism MH - SOXE Transcription Factors/genetics/metabolism MH - Signal Transduction MH - Stem Cells/cytology/metabolism MH - Tendons/cytology/*metabolism/pathology MH - Zebrafish/metabolism MH - Zebrafish Proteins/antagonists & inhibitors/genetics/metabolism MH - rac GTP-Binding Proteins/antagonists & inhibitors/metabolism PMC - PMC7328158 OTO - NOTNLM OT - Chemical screen OT - Scleraxis OT - Statin OT - Tendon OT - Zebrafish COIS- Competing interestsJ.W.C. is currently a full-time employee at Genentech and holds stocks in Roche. EDAT- 2020/05/30 06:00 MHDA- 2021/02/07 06:00 PMCR- 2021/06/24 CRDT- 2020/05/30 06:00 PHST- 2019/10/04 00:00 [received] PHST- 2020/05/04 00:00 [accepted] PHST- 2020/05/30 06:00 [pubmed] PHST- 2021/02/07 06:00 [medline] PHST- 2020/05/30 06:00 [entrez] PHST- 2021/06/24 00:00 [pmc-release] AID - dev.185389 [pii] AID - DEV185389 [pii] AID - 10.1242/dev.185389 [doi] PST - epublish SO - Development. 2020 Jun 24;147(12):dev185389. doi: 10.1242/dev.185389. PMID- 23640595 OWN - NLM STAT- MEDLINE DCOM- 20140602 LR - 20220408 IS - 1522-1601 (Electronic) IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 115 IP - 6 DP - 2013 Sep TI - MMP inhibition as a potential method to augment the healing of skeletal muscle and tendon extracellular matrix. PG - 884-91 LID - 10.1152/japplphysiol.00137.2013 [doi] AB - The extracellular matrix (ECM) of skeletal muscle and tendon is composed of different types of collagen molecules that play important roles in the transmission of forces throughout the body, and in the repair and regeneration of injured tissues. Fibroblasts are the primary cells in muscle and tendon that maintain, repair, and modify the ECM in response to mechanical loading, injury, and inactivity. Matrix metalloproteinases (MMPs) are enzymes that digest collagen and other structural molecules, which are synthesized and excreted by fibroblasts. MMPs are required for baseline ECM homeostasis, but disruption of MMP regulation due to injury or disease can alter the normal ECM architecture and prevent proper force transmission. Chronic injuries and diseases of muscles and tendons can be severely debilitating, and current therapeutic modalities to enhance healing are quite limited. This review will discuss the mechanobiology of MMPs, and the potential use of MMP inhibitors to improve the treatment of injured and diseased skeletal muscle and tendon tissue. FAU - Davis, Max E AU - Davis ME AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan; FAU - Gumucio, Jonathan P AU - Gumucio JP FAU - Sugg, Kristoffer B AU - Sugg KB FAU - Bedi, Asheesh AU - Bedi A FAU - Mendias, Christopher L AU - Mendias CL LA - eng GR - T32 GM008322/GM/NIGMS NIH HHS/United States GR - GM-008322/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20130502 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Collagen/metabolism MH - Extracellular Matrix/drug effects/enzymology MH - Humans MH - Matrix Metalloproteinase Inhibitors/*pharmacology MH - Matrix Metalloproteinases/metabolism MH - Muscle, Skeletal/*drug effects/*enzymology/injuries MH - Regeneration/drug effects/physiology MH - Tendon Injuries/drug therapy/enzymology MH - Tendons/*drug effects/*enzymology MH - Tissue Inhibitor of Metalloproteinases/metabolism MH - Wound Healing/drug effects/physiology PMC - PMC3764625 OTO - NOTNLM OT - MMP OT - TIMP OT - collagen OT - extracellular matrix OT - muscle injury OT - tendinopathy EDAT- 2013/05/04 06:00 MHDA- 2014/06/03 06:00 PMCR- 2014/09/15 CRDT- 2013/05/04 06:00 PHST- 2013/05/04 06:00 [entrez] PHST- 2013/05/04 06:00 [pubmed] PHST- 2014/06/03 06:00 [medline] PHST- 2014/09/15 00:00 [pmc-release] AID - japplphysiol.00137.2013 [pii] AID - JAPPL-00137-2013 [pii] AID - 10.1152/japplphysiol.00137.2013 [doi] PST - ppublish SO - J Appl Physiol (1985). 2013 Sep;115(6):884-91. doi: 10.1152/japplphysiol.00137.2013. Epub 2013 May 2. PMID- 12710717 OWN - NLM STAT- MEDLINE DCOM- 20031229 LR - 20131121 IS - 0940-2993 (Print) IS - 0940-2993 (Linking) VI - 54 IP - 4 DP - 2003 Mar TI - Cyclic mechanical strain induces NO production in human patellar tendon fibroblasts--a possible role for remodelling and pathological transformation. PG - 335-8 AB - The mechanism by which tendon fibroblasts can detect strain forces and respond to them is fairly unknown. Nitric oxide (NO) is a messenger molecule that among others can respond to shear stress in endothelial cells. Therefore, it was investigated whether cyclic mechanical strain induces NO in vitro in human patellar tendon fibroblasts. Human patellar tendon fibroblasts were cultured from remnants of patellar tendon transplants after reconstructive surgery. Fibroblasts were cultured on elastic silicone dishes. The cells were longitudinally strained (5%, 1 Hz) for 15' or 60'. As a control, no strain was applied. The experiments were finished after 0', 5', 15', and 30'. NO was determined using the Griess reaction. 15' strain showed at 0' and 5' 200% activation, which thereafter at 15' and 30' returned to normal levels. 60' strain showed a biphasic pattern. At 5' and 30', NO levels were increased to 175%. At 15', NO measurement displayed 120% increased levels. Mechanical strain induces NO production by tendon fibroblasts. Therefore, NO produced by tendon fibroblasts, as a response to alteration in their mechanical microenvironment, could modulate fibroblast function. The results of our study suggests that strain-related adaptive changes may, at least in part, be controlled by a process in which strain-related NO production from the fibroblast network may play a pivotal role. Moreover, these are basic findings that are important for further unravelling pathophysiology of tendon diseases. FAU - van Griensven, Martijn AU - van Griensven M AD - Department of Trauma Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. Griensven.Martijn.van@MH-Hannover.de FAU - Zeichen, Johannes AU - Zeichen J FAU - Skutek, Michael AU - Skutek M FAU - Barkhausen, Tanja AU - Barkhausen T FAU - Krettek, Christian AU - Krettek C FAU - Bosch, Ulrich AU - Bosch U LA - eng PT - Journal Article PL - Germany TA - Exp Toxicol Pathol JT - Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie JID - 9208920 RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Adaptation, Biological MH - Cells, Cultured MH - Enzyme Induction MH - Fibroblasts/*physiology MH - Humans MH - *Knee MH - Nitric Oxide/*metabolism MH - Stress, Mechanical MH - Tendons/*metabolism MH - Time Factors EDAT- 2003/04/25 05:00 MHDA- 2003/12/31 05:00 CRDT- 2003/04/25 05:00 PHST- 2003/04/25 05:00 [pubmed] PHST- 2003/12/31 05:00 [medline] PHST- 2003/04/25 05:00 [entrez] AID - S0940-2993(04)70113-X [pii] AID - 10.1078/0940-2993-00268 [doi] PST - ppublish SO - Exp Toxicol Pathol. 2003 Mar;54(4):335-8. doi: 10.1078/0940-2993-00268. PMID- 16470453 OWN - NLM STAT- MEDLINE DCOM- 20060221 LR - 20220331 IS - 1745-3674 (Print) IS - 1745-3674 (Linking) VI - 76 IP - 6 DP - 2005 Dec TI - Glucocorticoids suppress proteoglycan production by human tenocytes. PG - 927-31 AB - BACKGROUND: The role of glucocortiocid injection therapy in spontaneous tendon rupture is controversial. We hypothesized that glucocorticoids suppress proteoglycan production in tendon and studied the in vitro effects of dexamethasone and triamcinolone on proteoglycan production by cultured human tenocytes. MATERIAL AND METHODS: We obtained primary cultures of human tenocytes from explants of healthy human patellar tendon. The human tenocytes were treated with 1 microM dexamethasone or 1 microM triamcinolone. The amount of proteoglycan production was measured by 35S-sulfate incorporation assay and compared with control cultures. The reversibility of the effect of dexamethasone by co-incubation with 10 ng platelet-derived growth factor (PDGFBB) was also tested. RESULTS: Treatment with 1 microM triamcinolone reduced the amount of 35S-sulfate incorporation to 80% of control cultures (p = 0.007), whereas 1 microM dexamethasone reduced it to 72% (p = 0.01). Co-incubation of 10 ng/mL PDGFBB with 1 microM dexamethasone returned the 35S-sulfate incorporation to a level that was significantly higher than for dexamethasone treatment alone (108%; p = 0.01). INTERPRETATION: Glucocorticoids suppressed proteoglycan production in cultured human tenocytes. The suppression by dexamethasone was reversed by simultaneous addition of PDGFBB. Suppressed proteoglycan production may affect the viscoelastic properties of tendon and increase the risk of spontaneous rupture. FAU - Wong, Margaret Wan Nar AU - Wong MW AD - Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, Hong Kong. mwnwong@cuhk.edu.hk FAU - Tang, Yvonne Yin Nei AU - Tang YY FAU - Lee, Simon Kwong Man AU - Lee SK FAU - Fu, Bruma Sai Chuen AU - Fu BS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Sweden TA - Acta Orthop JT - Acta orthopaedica JID - 101231512 RN - 0 (Glucocorticoids) RN - 0 (Proteoglycans) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Cells, Cultured MH - Dexamethasone/adverse effects/pharmacology MH - Glucocorticoids/adverse effects/*pharmacology MH - Humans MH - Patella MH - Proteoglycans/*biosynthesis MH - Tendon Injuries/chemically induced MH - Tendons/cytology/*drug effects EDAT- 2006/02/14 09:00 MHDA- 2006/02/24 09:00 CRDT- 2006/02/14 09:00 PHST- 2006/02/14 09:00 [pubmed] PHST- 2006/02/24 09:00 [medline] PHST- 2006/02/14 09:00 [entrez] AID - 732224755 [pii] AID - 10.1080/17453670610046118 [doi] PST - ppublish SO - Acta Orthop. 2005 Dec;76(6):927-31. doi: 10.1080/17453670610046118. PMID- 9315365 OWN - NLM STAT- MEDLINE DCOM- 19971119 LR - 20190826 IS - 0305-1870 (Print) IS - 0305-1870 (Linking) VI - 24 IP - 9-10 DP - 1997 Sep-Oct TI - Levels of fructosyllysine in collagen are low compared with the loss of lysine in diabetic rats: involvement of oxidation in increased cross-linking. PG - 657-60 AB - 1. It is thought that early glycation products on lysine residues of collagen are re-arranged to form collagen cross-links (advanced glycation end-products), which are increased in hyperglycaemia. We have previously reported that 4 week vitamin E supplementation in diabetic rats protected against the development of increased collagen cross-linking. In the present study we analysed early glycation products as fructosyllysine and amino acid content of tail tendon collagen in rats. 2. The amount of lysine residues in early collagen glycation products in diabetic rats was estimated to be less than 0.2 mol/mol type I collagen, whereas in the diabetic rats the loss of lysine residues was estimated to be 2.5 mol/mol. However, vitamin E supplementation protected against the loss of lysine residues without affecting early glycation products. 3. Thus, it is demonstrated that the amount of early collagen glycation products is quite small compared with the loss of lysine residues in diabetic rats and we suggest that the oxidative modification of lysine residues may be involved in the increased cross-linking observed in hyperglycaemia. FAU - Aoki, Y AU - Aoki Y AD - Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan. FAU - Karasawa, Y AU - Karasawa Y FAU - Yazaki, K AU - Yazaki K FAU - Shirotori, K AU - Shirotori K FAU - Kawa, S AU - Kawa S FAU - Kiyosawa, K AU - Kiyosawa K LA - eng PT - Journal Article PL - Australia TA - Clin Exp Pharmacol Physiol JT - Clinical and experimental pharmacology & physiology JID - 0425076 RN - 0 (Amino Acids) RN - 0 (Cross-Linking Reagents) RN - 1406-18-4 (Vitamin E) RN - 21291-40-7 (fructosyl-lysine) RN - 9007-34-5 (Collagen) RN - K3Z4F929H6 (Lysine) SB - IM MH - Amino Acids/metabolism MH - Animals MH - Collagen/*metabolism MH - Cross-Linking Reagents MH - Diabetes Mellitus, Experimental/*metabolism MH - Lysine/*analogs & derivatives/*metabolism MH - Oxidation-Reduction MH - Rats MH - Tail/metabolism MH - Tendons/metabolism MH - Vitamin E/metabolism EDAT- 1997/10/07 00:00 MHDA- 1997/10/07 00:01 CRDT- 1997/10/07 00:00 PHST- 1997/10/07 00:00 [pubmed] PHST- 1997/10/07 00:01 [medline] PHST- 1997/10/07 00:00 [entrez] AID - 10.1111/j.1440-1681.1997.tb02108.x [doi] PST - ppublish SO - Clin Exp Pharmacol Physiol. 1997 Sep-Oct;24(9-10):657-60. doi: 10.1111/j.1440-1681.1997.tb02108.x. PMID- 23641740 OWN - NLM STAT- MEDLINE DCOM- 20131022 LR - 20151119 IS - 1735-3947 (Electronic) IS - 1029-2977 (Linking) VI - 16 IP - 5 DP - 2013 May TI - The short- and long- term effects of estrogen deficiency on apoptosis in musculoskeletal tissues: an experimental animal model study. PG - 271-6 AB - BACKGROUND: Estrogen is the major sex steroid affecting the growth, remodeling, and homeostasis of the female skeleton. Estrogen loss in postmenopausal women leads to osteoporosis. The aim of this study was to evaluate the early and long- term effects of estrogen loss on bones, tendons, muscles, and menisci in ovariectomized rats.  METHODS: Fifteen rats were randomized into three groups of five animals each. The first group was the control group with no additional surgical procedure, but the rest (groups 2 and 3) were bilaterally ovariectomized . All animals in the group 2 were sacrificed at 14th week to evaluate the short- term effect, and all of other animals in the groups 1 and 3 were sacrificed at 28th week to analyze the long- term effect of estrogen loss in the ovariectomized group and to control with the group 1. Quadriceps muscles, Achilles tendons, menisci, and femur cortical bones from both lower extremities were taken. The amount of apoptosis was measured. RESULTS: There was a significant increase in cell apoptosis in bones, muscles, and tendons with insignificant increase in cell apoptosis in menisci at early and late periods in rats with ovariectomies than the control.  CONCLUSION: The results indicated that estrogen loss after ovariectomy does not only affect bones; it may also increase cell apoptosis in different tissues such as muscles, tendons, and menisci. FAU - Aydin, Adem AU - Aydin A AD - Department of Orthopedics and Traumatology, Izmit Seka State Hospital, Kocaeli, Turkey. drhalilatmaca@hotmail.com. FAU - Kenar, Halime AU - Kenar H FAU - Atmaca, Halil AU - Atmaca H FAU - Alici, Tuğrul AU - Alici T FAU - Gacar, Gülçin AU - Gacar G FAU - Müezzinoğlu, Ümit Sefa AU - Müezzinoğlu ÜS FAU - Karaöz, Erdal AU - Karaöz E LA - eng PT - Journal Article TA - Arch Iran Med JT - Archives of Iranian medicine JID - 100889644 RN - 0 (Annexin A5) RN - 0 (Estrogens) SB - IM MH - Animals MH - Annexin A5 MH - Apoptosis/*physiology MH - Estrogens/*deficiency MH - Female MH - Flow Cytometry MH - Musculoskeletal Development/*physiology MH - Ovariectomy/*adverse effects MH - Rats MH - Rats, Wistar EDAT- 2013/05/07 06:00 MHDA- 2013/10/23 06:00 CRDT- 2013/05/07 06:00 PHST- 2013/05/07 06:00 [entrez] PHST- 2013/05/07 06:00 [pubmed] PHST- 2013/10/23 06:00 [medline] AID - 006 [pii] PST - ppublish SO - Arch Iran Med. 2013 May;16(5):271-6. PMID- 26260402 OWN - NLM STAT- MEDLINE DCOM- 20160513 LR - 20160113 IS - 1938-2707 (Electronic) IS - 0009-9228 (Linking) VI - 55 IP - 2 DP - 2016 Feb TI - The Risk of Musculoskeletal Adverse Events With Fluoroquinolones in Children: What Is the Verdict Now? PG - 107-10 LID - 10.1177/0009922815599959 [doi] FAU - Binz, Jonathan AU - Binz J AD - Moses H. Cone Memorial Hospital, Greensboro, NC, USA. FAU - Adler, Christina K AU - Adler CK AD - University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA. FAU - So, Tsz-Yin AU - So TY AD - Moses H. Cone Memorial Hospital, Greensboro, NC, USA Tsz-Yin.So@conehealth.com. LA - eng PT - Journal Article PT - Review DEP - 20150809 PL - United States TA - Clin Pediatr (Phila) JT - Clinical pediatrics JID - 0372606 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Animals MH - Anti-Bacterial Agents/*adverse effects MH - Child MH - Fluoroquinolones/*adverse effects MH - Humans MH - Joint Diseases/chemically induced MH - Musculoskeletal Diseases/*chemically induced MH - Tendons/drug effects EDAT- 2015/08/12 06:00 MHDA- 2016/05/14 06:00 CRDT- 2015/08/12 06:00 PHST- 2015/08/12 06:00 [entrez] PHST- 2015/08/12 06:00 [pubmed] PHST- 2016/05/14 06:00 [medline] AID - 0009922815599959 [pii] AID - 10.1177/0009922815599959 [doi] PST - ppublish SO - Clin Pediatr (Phila). 2016 Feb;55(2):107-10. doi: 10.1177/0009922815599959. Epub 2015 Aug 9. PMID- 19669958 OWN - NLM STAT- MEDLINE DCOM- 20091002 LR - 20131121 IS - 1306-696X (Print) IS - 1306-696X (Linking) VI - 15 IP - 4 DP - 2009 Jul TI - The effects of long-term low-dose cyclosporin A treatment on muscles and tendons: an experimental study. PG - 317-23 AB - BACKGROUND: Limited studies report that patients receiving immunosuppressive therapy, including cyclosporin A (CsA), face muscle and/or tendon pathologies. The current study aimed (i) to investigate if CsA cause changes in the microscopic structure of striated muscle tissues and tendons after long-term low-dose therapy and (ii) to examine if the vehicle of CsA, Cremophor EL, or steroid administration might cause additional effects. METHODS: Twenty-four adult female Sprague-Dawley rats weighing 230-300 g were divided at random into four groups. Group 1 served as the control. Groups 2-4 received CsA intraperitoneally for 2.5 months: Group 2 received the oral form of CsA, Group 3 received the intravenous form of CsA, which contains Cremophor EL, and Group 4 received the intravenous form of CsA and prednisolone. Samples from the Achilles tendons and triceps surae muscles were examined at light microscope level. RESULTS: Focal necrotic areas, enlargement of connective tissue and increase in mononuclear cells were clear on muscles in the experimental groups. No morphologic effects were observed on tendons. CONCLUSION: Long-term low-dose CsA therapy causes focal microscopic changes in muscles but not in tendons. No additional effects were demonstrated with Cremophor EL or steroids. It should be noted that muscle tissue damage after trauma or surgeries in patients receiving CsA might be more dramatic due to the pathologic changes already caused by CsA, as supported by several case reports. FAU - Aktaş, Ranan Gülhan AU - Aktaş RG AD - Department of ART, Zeynep Kamil Hospital, Istanbul, Turkey. ranagulhan@yahoo.com FAU - Aktaş, Seref AU - Aktaş S FAU - Yazgan, Omer AU - Yazgan O FAU - Altaner, Semsi AU - Altaner S LA - eng PT - Journal Article PL - Turkey TA - Ulus Travma Acil Cerrahi Derg JT - Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES JID - 101274231 RN - 0 (Immunosuppressive Agents) RN - 83HN0GTJ6D (Cyclosporine) SB - IM MH - Achilles Tendon/*drug effects/ultrastructure MH - Animals MH - Cyclosporine/*administration & dosage/therapeutic use MH - Dose-Response Relationship, Drug MH - Drug Administration Routes MH - Drug Administration Schedule MH - Female MH - Humans MH - Immunosuppressive Agents/*administration & dosage/therapeutic use MH - Muscle, Skeletal/*drug effects/ultrastructure MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley EDAT- 2009/08/12 09:00 MHDA- 2009/10/03 06:00 CRDT- 2009/08/12 09:00 PHST- 2009/08/12 09:00 [entrez] PHST- 2009/08/12 09:00 [pubmed] PHST- 2009/10/03 06:00 [medline] PST - ppublish SO - Ulus Travma Acil Cerrahi Derg. 2009 Jul;15(4):317-23. PMID- 4747232 OWN - NLM STAT- MEDLINE DCOM- 19731219 LR - 20190511 IS - 0022-3751 (Print) IS - 1469-7793 (Electronic) IS - 0022-3751 (Linking) VI - 233 IP - 2 DP - 1973 Sep TI - Rubidium influx into rat skeletal muscles in relation to electrical activity. PG - 363-74 AB - 1. Rates of (86)Rb influx were compared in vivo over 2, 4 and 6 hr periods in various tonic and phasic muscles of rat following its I.P. injection. During the 2 hr period its influx rate into soleus was about 4 times that of the vastus with the EDL muscles at an intermediate rate. Uptake by diaphragm was fastest reaching equilibrium within 2 hr.2. Unilateral section of the sciatic nerve 48 hr before (86)Rb injection reduced isotope uptake into soleus to about 50% of its contralateral control muscle over a 4 hr period. In EDL muscles on the other hand nerve section increased influx by about 75% of control in conscious rats and more than doubled influx in anaesthetized rats.3. Tenotomy of soleus reduced (86)Rb influx to 40% of control, but tenotomy in EDL was without effect in influx.4. Uptake of urea into muscles within 5 min of its I.V. injection was used to determine the possibility of muscle blood flow determining (86)Rb influx. Accumulation of urea was not significantly different in control and denervated EDL muscles nor between soleus and vastus muscles in anaesthetized rats, so it seems unlikely that blood flow is important here.5. Membrane depolarization in response to addition of 30 mM rubidium to external bathing fluid was greater in the case of denervated than in control EDL muscles which was in keeping with the greater (86)Rb influx seen in the former muscles. The ouabain sensitivity of rubidium-induced depolarization in the denervated EDL muscles would suggest, however, that rubidium enters the fibres actively. FAU - Kernan, R P AU - Kernan RP FAU - McDermott, M AU - McDermott M LA - eng PT - Journal Article PL - England TA - J Physiol JT - The Journal of physiology JID - 0266262 RN - 0 (Radioisotopes) RN - 5ACL011P69 (Ouabain) RN - 8W8T17847W (Urea) RN - MLT4718TJW (Rubidium) SB - IM MH - Animals MH - Cell Membrane Permeability MH - Diaphragm/metabolism MH - Membrane Potentials MH - Muscle Denervation MH - Muscle Tonus MH - Muscles/blood supply/*metabolism MH - Ouabain/pharmacology MH - Radioisotopes MH - Rats MH - Rubidium/*metabolism MH - Sciatic Nerve/physiology MH - Tendons/physiology/surgery MH - Urea/metabolism PMC - PMC1350571 EDAT- 1973/09/01 00:00 MHDA- 1973/09/01 00:01 PMCR- 1974/09/01 CRDT- 1973/09/01 00:00 PHST- 1973/09/01 00:00 [pubmed] PHST- 1973/09/01 00:01 [medline] PHST- 1973/09/01 00:00 [entrez] PHST- 1974/09/01 00:00 [pmc-release] AID - 10.1113/jphysiol.1973.sp010312 [doi] PST - ppublish SO - J Physiol. 1973 Sep;233(2):363-74. doi: 10.1113/jphysiol.1973.sp010312. PMID- 32100720 OWN - NLM STAT- MEDLINE DCOM- 20200921 LR - 20200921 IS - 2084-4336 (Electronic) IS - 1509-3492 (Linking) VI - 21 IP - 6 DP - 2019 Dec 31 TI - The Effect of Pentoxifylline and Hyperbaric Oxygen on Achilles Osteotendinous Junction İnjury: An experimental animal model study. PG - 437-446 LID - 10.5604/01.3001.0013.7401 [doi] AB - BACKGROUND: To investigate the effects of hyperbaric oxygen (HBO) and pentoxifylline (PTX) treatment on osteotendinous junction healing of Achilles tendon in an animal model. MATERIALS AND METHODS: Thirty-six adult female Wistar-albino rats were randomly divided into three groups as control, PTX and HBO groups with a total of 12 rats per group. Under general anesthesia, the Achilles tendons were cut at the level of the osteotendinous junction and repaired. After the surgery, no treatment was given to the control group. Fifty mg/kg intraperitoneal PTX was administered to the PTX group daily for 1 week. The HBO group was exposed to 2,5 atmospheric pressure, 100% oxygen for 2 hours daily for 1 week. All animals were sacrificed at the end of sixth week. Biomechanical tests and histological examinations were performed. RESULTS: Energy absorption was significantly higher in the PTX group than that in the control group after biomechanical tests (p=0.010). Histopathological evaluation results revealed no difference between the groups: however, hyalinization level was relatively better in the HBO group than that in the control group (p=0.026). CONCLUSIONS: 1. We concluded that PTX has a positive effect on the treatment of osteotendinous junction injuries based on our results. 2. Although HBO therapy did not provide statistically significant differences, it might have some positive effects on these injuries. 3. Further experimental studies and clinical trials should be conducted. FAU - Palabıyık, Mehmet Taner AU - Palabıyık MT AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Orthopedics and Traumatology, Bursa, Turkey. FAU - Akalın, Yavuz AU - Akalın Y AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Orthopedics and Traumatology, Bursa, Turkey. FAU - Yalçın, Ömer AU - Yalçın Ö AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Pathology, Bursa, Turkey. FAU - Şahin, İsmail Gökhan AU - Şahin İG AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Orthopedics and Traumatology, Bursa, Turkey. FAU - Çevik, Nazan AU - Çevik N AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Orthopedics and Traumatology, Bursa, Turkey. FAU - Öztürk, Alpaslan AU - Öztürk A AD - University of Health Sciences, Health Application and Research Center,Yüksek İhtisas Training and Research Hospital, Department of Orthopedics and Traumatology, Bursa, Turkey. LA - eng PT - Journal Article PL - Poland TA - Ortop Traumatol Rehabil JT - Ortopedia, traumatologia, rehabilitacja JID - 101240146 RN - 0 (Phosphodiesterase Inhibitors) RN - SD6QCT3TSU (Pentoxifylline) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Female MH - Humans MH - Hyperbaric Oxygenation/*methods MH - Models, Animal MH - Pentoxifylline/*therapeutic use MH - Phosphodiesterase Inhibitors/*therapeutic use MH - Rats MH - Rats, Wistar MH - Tendon Injuries/*drug therapy MH - Wound Healing/*drug effects OTO - NOTNLM OT - Achilles tendon OT - experiment OT - healing OT - hyperbaric oxygen OT - osteotendinous junction OT - pentoxifylline EDAT- 2020/02/27 06:00 MHDA- 2020/09/22 06:00 CRDT- 2020/02/27 06:00 PHST- 2020/02/27 06:00 [entrez] PHST- 2020/02/27 06:00 [pubmed] PHST- 2020/09/22 06:00 [medline] AID - 01.3001.0013.7401 [pii] AID - 10.5604/01.3001.0013.7401 [doi] PST - ppublish SO - Ortop Traumatol Rehabil. 2019 Dec 31;21(6):437-446. doi: 10.5604/01.3001.0013.7401. PMID- 4570894 OWN - NLM STAT- MEDLINE DCOM- 19730508 LR - 20181130 IS - 0021-9355 (Print) IS - 0021-9355 (Linking) VI - 55 IP - 1 DP - 1973 Jan TI - Allograft replacement of all or part of the end of a long bone following excision of a tumor. PG - 1-22 FAU - Parrish, F F AU - Parrish FF LA - eng PT - Journal Article PL - United States TA - J Bone Joint Surg Am JT - The Journal of bone and joint surgery. American volume JID - 0014030 RN - 0 (Strontium Isotopes) RN - 1405-87-4 (Bacitracin) RN - I16QD7X297 (Neomycin) SB - IM MH - Adolescent MH - Adult MH - Bacitracin/therapeutic use MH - Bone Neoplasms/*surgery MH - Bone Transplantation MH - Cadaver MH - Chondrosarcoma/*surgery MH - Femoral Neoplasms/*surgery MH - Fibrosarcoma/*surgery MH - Giant Cell Tumors/*surgery MH - Graft Rejection MH - Humans MH - Humerus/*surgery MH - Ligaments, Articular/surgery MH - Methods MH - Middle Aged MH - Neomycin/therapeutic use MH - Osteosarcoma/*surgery MH - Postoperative Complications MH - Strontium Isotopes MH - Tendons/surgery MH - Tibia/*surgery MH - Transplantation, Homologous EDAT- 1973/01/01 00:00 MHDA- 1973/01/01 00:01 CRDT- 1973/01/01 00:00 PHST- 1973/01/01 00:00 [pubmed] PHST- 1973/01/01 00:01 [medline] PHST- 1973/01/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Am. 1973 Jan;55(1):1-22. PMID- 38961188 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20240706 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Jul 3 TI - Dexamethasone treatment influences tendon healing through altered resolution and a direct effect on tendon cells. PG - 15304 LID - 10.1038/s41598-024-66038-5 [doi] LID - 15304 AB - Inflammation, corticosteroids, and loading all affect tendon healing, with an interaction between them. However, underlying mechanisms behind the effect of corticosteroids and the interaction with loading remain unclear. The aim of this study was to investigate the role of dexamethasone during tendon healing, including specific effects on tendon cells. Rats (n = 36) were randomized to heavy loading or mild loading, the Achilles tendon was transected, and animals were treated with dexamethasone or saline. Gene and protein analyses of the healing tendon were performed for extracellular matrix-, inflammation-, and tendon cell markers. We further tested specific effects of dexamethasone on tendon cells in vitro. Dexamethasone increased mRNA levels of S100A4 and decreased levels of ACTA2/α-SMA, irrespective of load level. Heavy loading + dexamethasone reduced mRNA levels of FN1 and TenC (p < 0.05), while resolution-related genes were unaltered (p > 0.05). In contrast, mild loading + dexamethasone increased mRNA levels of resolution-related genes ANXA1, MRC1, PDPN, and PTGES (p < 0.03). Altered protein levels were confirmed in tendons with mild loading. Dexamethasone treatment in vitro prevented tendon construct formation, increased mRNA levels of S100A4 and decreased levels of SCX and collagens. Dexamethasone during tendon healing appears to act through immunomodulation by promoting resolution, but also through an effect on tendon cells. CI - © 2024. The Author(s). FAU - Dietrich-Zagonel, Franciele AU - Dietrich-Zagonel F AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, 581 83, Linköping, Sweden. FAU - Alim, Md Abdul AU - Alim MA AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, 581 83, Linköping, Sweden. AD - Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK. FAU - Beckman, Leo Bon AU - Beckman LB AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, 581 83, Linköping, Sweden. FAU - Eliasson, Pernilla AU - Eliasson P AUID- ORCID: 0000-0001-6718-034X AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, 581 83, Linköping, Sweden. pernilla.eliasson@vgregion.se. AD - Department of Orthopaedics, Sahlgrenska University Hospital, Länsmansgatan 28, 431 80, Mölndal, Sweden. pernilla.eliasson@vgregion.se. LA - eng GR - FO2020-0178/Stiftelsen Lars Hiertas Minne/ GR - VR2017-00990/Vetenskapsrådet/ GR - M20-0021/Åke Wiberg Stiftelse/ GR - 2019-03211/Magnus Bergvalls Stiftelse/ GR - 2022-0094/Centrum för idrottsforskning/ PT - Journal Article DEP - 20240703 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 7S5I7G3JQL (Dexamethasone) RN - 0 (S100 Calcium-Binding Protein A4) RN - 0 (Scx protein, rat) RN - 0 (Annexin A1) RN - 0 (Actins) RN - 0 (Acta2 protein, rat) RN - 9007-34-5 (Collagen) RN - 0 (RNA, Messenger) RN - 0 (Basic Helix-Loop-Helix Transcription Factors) SB - IM MH - *Dexamethasone/pharmacology MH - Animals MH - Rats MH - *Wound Healing/drug effects MH - *Tendon Injuries/drug therapy/metabolism MH - *Achilles Tendon/drug effects/metabolism/injuries/pathology MH - S100 Calcium-Binding Protein A4/metabolism/genetics MH - Male MH - Annexin A1/metabolism/genetics MH - Actins/metabolism/genetics MH - Collagen/metabolism MH - Rats, Sprague-Dawley MH - Tendons/drug effects/metabolism MH - Extracellular Matrix/metabolism/drug effects MH - RNA, Messenger/metabolism/genetics MH - Basic Helix-Loop-Helix Transcription Factors PMC - PMC11222440 OTO - NOTNLM OT - Achilles tendon OT - Corticosteroids OT - In vitro OT - Injury OT - Loading OT - Resolution COIS- The authors declare no competing interests. EDAT- 2024/07/04 00:43 MHDA- 2024/07/04 00:44 PMCR- 2024/07/03 CRDT- 2024/07/03 23:32 PHST- 2023/12/15 00:00 [received] PHST- 2024/06/26 00:00 [accepted] PHST- 2024/07/04 00:44 [medline] PHST- 2024/07/04 00:43 [pubmed] PHST- 2024/07/03 23:32 [entrez] PHST- 2024/07/03 00:00 [pmc-release] AID - 10.1038/s41598-024-66038-5 [pii] AID - 66038 [pii] AID - 10.1038/s41598-024-66038-5 [doi] PST - epublish SO - Sci Rep. 2024 Jul 3;14(1):15304. doi: 10.1038/s41598-024-66038-5. PMID- 24631378 OWN - NLM STAT- MEDLINE DCOM- 20150106 LR - 20220310 IS - 1879-291X (Electronic) IS - 0301-5629 (Linking) VI - 40 IP - 6 DP - 2014 Jun TI - Soft-focused extracorporeal shock waves increase the expression of tendon-specific markers and the release of anti-inflammatory cytokines in an adherent culture model of primary human tendon cells. PG - 1204-15 LID - S0301-5629(13)01230-1 [pii] LID - 10.1016/j.ultrasmedbio.2013.12.003 [doi] AB - Focused extracorporeal shock waves have been found to upregulate the expression of collagen and to initiate cell proliferation in healthy tenocytes and to positively affect the metabolism of tendons, promoting the healing process. Recently, soft-focused extracorporeal shock waves have also been found to have a significant effect on tissue regeneration. However, very few in vitro reports have dealt with the application of this type of shock wave to cells, and in particular, no previous studies have investigated the response of tendon cells to this impulse. We devised an original model to investigate the in vitro effects of soft-focused shock waves on a heterogeneous population of human resident tendon cells in adherent monolayer culture. Our results indicate that soft-focused extracorporeal shock wave treatment (0.17 mJ/mm(2)) is able to induce positive modulation of cell viability, proliferation and tendon-specific marker expression, as well as release of anti-inflammatory cytokines. This could prefigure a new rationale for routine employment of soft-focused shock waves to treat the failed healing status that distinguishes tendinopathies. CI - Copyright © 2014 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved. FAU - de Girolamo, Laura AU - de Girolamo L AD - Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. Electronic address: laura.degirolamo@grupposandonato.it. FAU - Stanco, Deborah AU - Stanco D AD - Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. FAU - Galliera, Emanuela AU - Galliera E AD - Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Milan, Italy; IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. FAU - Viganò, Marco AU - Viganò M AD - Orthopaedic Biotechnology Laboratory, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. FAU - Lovati, Arianna Barbara AU - Lovati AB AD - Cell and Tissue Engineering Laboratory, Gruppo Ospedaliero San Donato Foundation, Milan, Italy. FAU - Marazzi, Monica Gioia AU - Marazzi MG AD - Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy. FAU - Romeo, Pietro AU - Romeo P AD - Orthopaedic Department, Istituto Ortopedico Galeazzi, Milan, Italy. FAU - Sansone, Valerio AU - Sansone V AD - Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy; Orthopaedic Department, Istituto Ortopedico Galeazzi, Milan, Italy. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20140314 PL - England TA - Ultrasound Med Biol JT - Ultrasound in medicine & biology JID - 0410553 RN - 0 (Biomarkers) RN - 0 (Collagen Type I) RN - 0 (Cytokines) RN - 0 (Transforming Growth Factor beta) RN - 0 (Vascular Endothelial Growth Factor A) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Adult MH - Apoptosis MH - Biomarkers/*metabolism MH - Cell Proliferation MH - Cells, Cultured MH - Collagen Type I/metabolism MH - Cytokines/metabolism MH - Flow Cytometry MH - *High-Energy Shock Waves MH - Humans MH - In Vitro Techniques MH - Matrix Metalloproteinases/metabolism MH - Nitric Oxide/metabolism MH - Tendinopathy/pathology/*therapy MH - Tendons/*cytology MH - Transforming Growth Factor beta/metabolism MH - Vascular Endothelial Growth Factor A/metabolism OTO - NOTNLM OT - Cell proliferation OT - Cytokines OT - Soft-focused extracorporeal shock waves OT - Tendinopathy OT - Tendon cells OT - Tendon-specific markers OT - Transforming growth factor β OT - Vascular endothelial growth factor EDAT- 2014/03/19 06:00 MHDA- 2015/01/07 06:00 CRDT- 2014/03/18 06:00 PHST- 2013/06/17 00:00 [received] PHST- 2013/09/26 00:00 [revised] PHST- 2013/12/05 00:00 [accepted] PHST- 2014/03/18 06:00 [entrez] PHST- 2014/03/19 06:00 [pubmed] PHST- 2015/01/07 06:00 [medline] AID - S0301-5629(13)01230-1 [pii] AID - 10.1016/j.ultrasmedbio.2013.12.003 [doi] PST - ppublish SO - Ultrasound Med Biol. 2014 Jun;40(6):1204-15. doi: 10.1016/j.ultrasmedbio.2013.12.003. Epub 2014 Mar 14. PMID- 12616702 OWN - NLM STAT- MEDLINE DCOM- 20030529 LR - 20131121 IS - 0379-0355 (Print) IS - 0379-0355 (Linking) VI - 24 IP - 9 DP - 2002 Nov TI - The pyridoindole antioxidant stobadine attenuates albuminuria, enzymuria, kidney lipid peroxidation and matrix collagen cross-linking in streptozotocin-induced diabetic rats. PG - 565-71 AB - The aim of the present study was to investigate the effect of dietary supplementation with the pyridoindole antioxidant stobadine on kidney status and function in streptozotocin-induced diabetic rats. Diabetic male Wistar rats were fed a standard diet for 32 weeks or a diet supplemented with stobadine (0.05% w/w). The diabetic state was characterized by significantly elevated plasma levels of glucose, HbA1c and urea, severe reduction of total body weight and relatively enlarged kidneys. Elevated levels of conjugated dienes were recorded in the diabetic kidney confirming the presence of oxidative stress in diabetic animals. All diabetic rats showed marked proteinuria and albuminuria along with elevated excretion of the enzyme N-acetyl-beta-D-glucosaminidase. Long-term treatment of diabetic animals with stobadine significantly reduced total proteinuria, albuminuria and enzymuria, yet left the overall physical and glycemic status unaffected. It reduced oxidative damage of kidney tissue as shown by decreased conjugated diene level, and decreased matrix collagen cross-linking, as indicated by decreased breaking time values of rat tail tendons. These beneficial effects of stobadine, supported also by histological findings, may be brought about by virtue of the combination of its antioxidant potential with other effects, e.g., the postulated cholesterol-lowering ability or its ability to alter vascular reactivity and reduce the vascular tone. FAU - Stefek, M AU - Stefek M AD - Institute of Experimental Pharmacology, Comenius University, Bratislava, Slovakia. exfastfk@savba.sk FAU - Gajdosik, A AU - Gajdosik A FAU - Tribulova, N AU - Tribulova N FAU - Navarova, J AU - Navarova J FAU - Volkovova, K AU - Volkovova K FAU - Weismann, P AU - Weismann P FAU - Gajdosikova, A AU - Gajdosikova A FAU - Drimal, J AU - Drimal J FAU - Mihalova, D AU - Mihalova D LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Spain TA - Methods Find Exp Clin Pharmacol JT - Methods and findings in experimental and clinical pharmacology JID - 7909595 RN - 0 (Antioxidants) RN - 0 (Blood Glucose) RN - 0 (Carbolines) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) RN - EC 3.2.1.52 (Acetylglucosaminidase) RN - Y0EA50IJ3V (dicarbine) SB - IM MH - Acetylglucosaminidase/urine MH - Albuminuria/*drug therapy MH - Animals MH - Antioxidants/*pharmacology MH - Blood Glucose/analysis MH - Carbolines/*pharmacology/therapeutic use MH - Collagen/*chemistry MH - Diabetes Mellitus, Experimental/*drug therapy MH - Diabetic Nephropathies/*drug therapy MH - Kidney/*drug effects/metabolism/pathology MH - Lipid Peroxidation/*drug effects MH - Male MH - Organ Size/drug effects MH - Rats MH - Rats, Wistar MH - Streptozocin EDAT- 2003/03/06 04:00 MHDA- 2003/05/30 05:00 CRDT- 2003/03/06 04:00 PHST- 2003/03/06 04:00 [pubmed] PHST- 2003/05/30 05:00 [medline] PHST- 2003/03/06 04:00 [entrez] AID - 802308 [pii] PST - ppublish SO - Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):565-71. PMID- 8388071 OWN - NLM STAT- MEDLINE DCOM- 19930617 LR - 20141120 IS - 0195-9131 (Print) IS - 0195-9131 (Linking) VI - 25 IP - 5 DP - 1993 May TI - Effects of repetitive motion on human fibroblasts. PG - 603-7 AB - Repetitive motion injuries such as tendonitis are common sports injuries. However, few scientific studies are available on the effects of repetitive motion on mesenchymal cells and the presumed inflammatory response. This study used a new in vitro model to study the effects of repetitive motion. Human tendon fibroblasts were subcultured and plated on culture wells with flexible bottoms. The cells were repetitively stretched using a micro-processor-controlled pressure unit that causes a cyclic deformation of the flexible bottom. The wells were divided in the following groups: group I controls without repetitive motion, group IIA repetitive motion with 0.25 strain at 0.17 Hz (10 cycles.min-1), group IIB repetitive motion with 0.25 strain and 0.17 Hz in presence of 25 microM indomethacin, and group III repetitive motion with 0.25 strain at 1 Hz (60 cycles.min-1). After 3 h of stimulation the supernatant fluids were harvested and evaluated for prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and lactate dehydrogenase (LDH). The results showed significantly (P < 0.001) increased levels of PGE2 in groups IIA (46.9 +/- 4.7 pg.0.1 ml-1) and III (65.7 +/- 8.0 pg.0.1 ml-1). This represents a 1.3- and 1.8-fold increase, respectively, compared with the control group I (36.4 +/- 5.9 pg.0.1 ml-1). LTB4 was significantly (P < 0.001) elevated in the indomethacin-treated group IIB (45.0 +/- 11.0 pg.0.1 ml-1) compared with very low levels in all other groups. LDH was not significantly different in any of the experimental groups compared with the control group I. The results indicate that repetitive motion induces production of PGE2.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Almekinders, L C AU - Almekinders LC AD - Division of Orthopaedic Surgery, University of North Carolina, Chapel Hill 27599-7055. FAU - Banes, A J AU - Banes AJ FAU - Ballenger, C A AU - Ballenger CA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 1HGW4DR56D (Leukotriene B4) RN - EC 1.1.1.27 (L-Lactate Dehydrogenase) RN - K7Q1JQR04M (Dinoprostone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Analysis of Variance MH - Cells, Cultured MH - Cumulative Trauma Disorders/*metabolism/pathology MH - Dinoprostone/antagonists & inhibitors/*biosynthesis MH - Fibroblasts/drug effects/*metabolism/pathology MH - Humans MH - In Vitro Techniques MH - Indomethacin/pharmacology MH - Inflammation/physiopathology MH - L-Lactate Dehydrogenase/metabolism MH - Leukotriene B4/*biosynthesis MH - Tendons/metabolism/pathology/physiopathology EDAT- 1993/05/01 00:00 MHDA- 1993/05/01 00:01 CRDT- 1993/05/01 00:00 PHST- 1993/05/01 00:00 [pubmed] PHST- 1993/05/01 00:01 [medline] PHST- 1993/05/01 00:00 [entrez] PST - ppublish SO - Med Sci Sports Exerc. 1993 May;25(5):603-7. PMID- 19190065 OWN - NLM STAT- MEDLINE DCOM- 20090313 LR - 20131121 IS - 2044-5377 (Electronic) IS - 0301-620X (Linking) VI - 91 IP - 2 DP - 2009 Feb TI - The effect of parecoxib and indometacin on tendon-to-bone healing in a bone tunnel: an experimental study in rats. PG - 259-63 LID - 10.1302/0301-620X.91B2.21471 [doi] AB - Conventional non-steroidal anti-inflammatory drugs (NSAIDs) and newer specific cyclo-oxygenase-2 (cox-2) inhibitors are commonly used in musculoskeletal trauma and orthopaedic surgery to reduce the inflammatory response and pain. These drugs have been reported to impair bone metabolism. In reconstruction of the anterior cruciate ligament the hamstring tendons are mainly used as the graft of choice, and a prerequisite for good results is healing of the tendons in the bone tunnel. Many of these patients are routinely given NSAIDs or cox-2 inhibitors, although no studies have elucidated the effects of these drugs on tendon healing in the bone tunnel. In our study 60 female Wistar rats were randomly allocated into three groups of 20. One received parecoxib, one indometacin and one acted as a control. In all the rats the tendo-Achillis was released proximally from the calf muscles. It was then pulled through a drill hole in the distal tibia and sutured anteriorly. The rats were given parecoxib, indometacin or saline intraperitoneally twice daily for seven days. After 14 days the tendon/bone-tunnel interface was subjected to mechanical testing. Significantly lower maximum pull-out strength (p < 0.001), energy absorption (p < 0.001) and stiffness (p = 0.035) were found in rats given parecoxib and indometacin compared with the control group, most pronounced with parecoxib. FAU - Dimmen, S AU - Dimmen S AD - Orthopaedic Centre, Ullevaal University Hospital and Faculty of Medicine, University of Oslo, N-0407 Oslo, Norway. sidimmen@online.no FAU - Nordsletten, L AU - Nordsletten L FAU - Engebretsen, L AU - Engebretsen L FAU - Steen, H AU - Steen H FAU - Madsen, J E AU - Madsen JE LA - eng PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (Isoxazoles) RN - 9TUW81Y3CE (parecoxib) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Anterior Cruciate Ligament/*drug effects/surgery MH - Biomechanical Phenomena MH - Bone Density/*drug effects MH - Cyclooxygenase Inhibitors MH - Female MH - Indomethacin/*pharmacology MH - Isoxazoles/*pharmacology MH - Random Allocation MH - Rats MH - Rats, Wistar MH - Stress, Mechanical MH - Tendons/*drug effects MH - Wound Healing/*drug effects EDAT- 2009/02/05 09:00 MHDA- 2009/03/14 09:00 CRDT- 2009/02/05 09:00 PHST- 2009/02/05 09:00 [entrez] PHST- 2009/02/05 09:00 [pubmed] PHST- 2009/03/14 09:00 [medline] AID - 91-B/2/259 [pii] AID - 10.1302/0301-620X.91B2.21471 [doi] PST - ppublish SO - J Bone Joint Surg Br. 2009 Feb;91(2):259-63. doi: 10.1302/0301-620X.91B2.21471. PMID- 22799114 OWN - NLM STAT- MEDLINE DCOM- 20120807 LR - 20181201 IS - 0004-5772 (Print) IS - 0004-5772 (Linking) VI - 60 DP - 2012 Mar TI - Tendinous xanthoma. PG - 46 FAU - Kumar, K V S Hari AU - Kumar KV AD - Command Hospital, Lucknow--226002. FAU - Ghosh, A K AU - Ghosh AK FAU - Kumar, K Kiran AU - Kumar KK FAU - Prusty, P AU - Prusty P LA - eng PT - Case Reports PT - Journal Article PL - India TA - J Assoc Physicians India JT - The Journal of the Association of Physicians of India JID - 7505585 RN - 0 (Anticholesteremic Agents) RN - 0 (Heptanoic Acids) RN - 0 (Pyrroles) RN - 97C5T2UQ7J (Cholesterol) RN - A0JWA85V8F (Atorvastatin) SB - IM MH - Anticholesteremic Agents/administration & dosage MH - Atorvastatin MH - Cholesterol/*blood MH - Coronary Angiography MH - Coronary Stenosis/diagnostic imaging/therapy MH - Echocardiography MH - Female MH - Heptanoic Acids/administration & dosage MH - Humans MH - Hypercholesterolemia/*diagnosis/drug therapy/genetics MH - Middle Aged MH - Pyrroles/administration & dosage MH - Stents MH - Tendons/*pathology MH - Treatment Outcome MH - Xanthomatosis/*diagnosis/therapy EDAT- 2012/07/18 06:00 MHDA- 2012/08/08 06:00 CRDT- 2012/07/18 06:00 PHST- 2012/07/18 06:00 [entrez] PHST- 2012/07/18 06:00 [pubmed] PHST- 2012/08/08 06:00 [medline] PST - ppublish SO - J Assoc Physicians India. 2012 Mar;60:46. PMID- 38003425 OWN - NLM STAT- MEDLINE DCOM- 20231127 LR - 20231127 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 22 DP - 2023 Nov 12 TI - Anti-Adhesive Resorbable Indomethacin/Bupivacaine-Eluting Nanofibers for Tendon Rupture Repair: In Vitro and In Vivo Studies. LID - 10.3390/ijms242216235 [doi] LID - 16235 AB - The treatment and surgical repair of torn Achilles tendons seldom return the wounded tendon to its original elasticity and stiffness. This study explored the in vitro and in vivo simultaneous release of indomethacin and bupivacaine from electrospun polylactide-polyglycolide composite membranes for their capacity to repair torn Achilles tendons. These membranes were fabricated by mixing polylactide-polyglycolide/indomethacin, polylactide-polyglycolide/collagen, and polylactide-polyglycolide/bupivacaine with 1,1,1,3,3,3-hexafluoro-2-propanol into sandwich-structured composites. Subsequently, the in vitro pharmaceutic release rates over 30 days were determined, and the in vivo release behavior and effectiveness of the loaded drugs were assessed using an animal surgical model. High concentrations of indomethacin and bupivacaine were released for over four weeks. The released pharmaceutics resulted in complete recovery of rat tendons, and the nanofibrous composite membranes exhibited exceptional mechanical strength. Additionally, the anti-adhesion capacity of the developed membrane was confirmed. Using the electrospinning technique developed in this study, we plan on manufacturing degradable composite membranes for tendon healing, which can deliver sustained pharmaceutical release and provide a collagenous habitat. FAU - Yu, Yi-Hsun AU - Yu YH AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan 33305, Taiwan. FAU - Lee, Chen-Hung AU - Lee CH AUID- ORCID: 0000-0002-8392-8423 AD - Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou, Chang Gung University College of Medicine, Taoyuan 33305, Taiwan. FAU - Hsu, Yung-Heng AU - Hsu YH AUID- ORCID: 0000-0001-7391-3212 AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan 33305, Taiwan. FAU - Chou, Ying-Chao AU - Chou YC AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan 33305, Taiwan. FAU - Yu, Ping-Chun AU - Yu PC AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan 33302, Taiwan. FAU - Huang, Chao-Tsai AU - Huang CT AD - Department of Chemical and Materials Engineering, Tamkang University, New Taipei City 25137, Taiwan. FAU - Liu, Shih-Jung AU - Liu SJ AUID- ORCID: 0000-0003-2083-4865 AD - Department of Orthopedic Surgery, Bone and Joint Research Center, Chang Gung Memorial Hospital-Linkou, Taoyuan 33305, Taiwan. AD - Department of Mechanical Engineering, Chang Gung University, Taoyuan 33302, Taiwan. LA - eng PT - Journal Article DEP - 20231112 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - XXE1CET956 (Indomethacin) RN - Y8335394RO (Bupivacaine) RN - 0 (Adhesives) RN - 26009-03-0 (Polyglycolic Acid) SB - IM MH - Rats MH - Animals MH - *Nanofibers MH - Indomethacin MH - Bupivacaine MH - Adhesives MH - *Tendon Injuries/drug therapy/surgery MH - Polyglycolic Acid MH - Tendons PMC - PMC10671766 OTO - NOTNLM OT - anti-adhesion OT - drug-eluting nanofibers OT - sustained release OT - tendon repair COIS- The authors declare no conflict of interest. EDAT- 2023/11/25 12:47 MHDA- 2023/11/27 12:44 PMCR- 2023/11/12 CRDT- 2023/11/25 01:16 PHST- 2023/10/20 00:00 [received] PHST- 2023/11/08 00:00 [revised] PHST- 2023/11/09 00:00 [accepted] PHST- 2023/11/27 12:44 [medline] PHST- 2023/11/25 12:47 [pubmed] PHST- 2023/11/25 01:16 [entrez] PHST- 2023/11/12 00:00 [pmc-release] AID - ijms242216235 [pii] AID - ijms-24-16235 [pii] AID - 10.3390/ijms242216235 [doi] PST - epublish SO - Int J Mol Sci. 2023 Nov 12;24(22):16235. doi: 10.3390/ijms242216235. PMID- 1375257 OWN - NLM STAT- MEDLINE DCOM- 19920622 LR - 20190902 IS - 0266-7681 (Print) IS - 0266-7681 (Linking) VI - 17 IP - 2 DP - 1992 Apr TI - The contents of macromolecule solutes in flexor tendon sheath fluid and their relation to synovial fluid. A quantitative analysis. PG - 167-71 AB - The importance of synovial environment for minimal adhesion formation in flexor tendon healing has recently gained attention. Various techniques have been used to restore an injured synovial tendon sheath. Therefore a quantitative analysis of flexor tendon sheath fluid is of interest to increase our knowledge about the specific synovial milieu and to evaluate the success of different types of sheath reconstructions from a biochemical point of view. Samples of tendon sheath fluid from trigger digits and tendon sheaths containing ganglions have been assayed for contents of hyaluronic acid and proteins of different molecular weights. The results show concentrations of hyaluronate and several proteins similar to those in normal joint fluid. These results indicate that flexor tendon sheath fluid has a character similar to synovial fluid of joints and apparently has specific functions such as soft tissue lubrication and nutrition of avascular tendon tissue. FAU - Hagberg, L AU - Hagberg L AD - Department of Hand Surgery, Malmö Allmänna Sjukhus, Sweden. FAU - Heinegård, D AU - Heinegård D FAU - Ohlsson, K AU - Ohlsson K LA - eng PT - Comparative Study PT - Journal Article PL - Scotland TA - J Hand Surg Br JT - Journal of hand surgery (Edinburgh, Scotland) JID - 8403839 RN - 0 (Albumins) RN - 0 (Blood Proteins) RN - 0 (Immunoglobulin G) RN - 0 (Macromolecular Substances) RN - 0 (Proteinase Inhibitory Proteins, Secretory) RN - 0 (Proteins) RN - 0 (Serine Proteinase Inhibitors) RN - 0 (Serum Albumin) RN - 0 (alpha 1-Antichymotrypsin) RN - 0 (alpha 1-Antitrypsin) RN - 0 (alpha-Macroglobulins) RN - 9004-61-9 (Hyaluronic Acid) RN - EC 3.4.21.36 (Pancreatic Elastase) RN - EC 3.4.21.37 (Leukocyte Elastase) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Albumins/analysis MH - Blood Proteins/analysis MH - Extracellular Space/*chemistry MH - Female MH - Ganglia/metabolism MH - Humans MH - Hyaluronic Acid/*analysis/blood MH - Immunoglobulin G/analysis MH - Leukocyte Elastase MH - Leukocytes/enzymology MH - Macromolecular Substances MH - Male MH - Middle Aged MH - Pancreatic Elastase/analysis/blood MH - Proteinase Inhibitory Proteins, Secretory MH - Proteins/*analysis MH - Serine Proteinase Inhibitors/analysis/blood MH - Serum Albumin/analysis MH - Synovial Fluid/*chemistry MH - Tendons/innervation/*metabolism MH - alpha 1-Antichymotrypsin/analysis/blood MH - alpha 1-Antitrypsin/analysis MH - alpha-Macroglobulins/analysis EDAT- 1992/04/01 00:00 MHDA- 1992/04/01 00:01 CRDT- 1992/04/01 00:00 PHST- 1992/04/01 00:00 [pubmed] PHST- 1992/04/01 00:01 [medline] PHST- 1992/04/01 00:00 [entrez] AID - 10.1016/0266-7681(92)90081-c [doi] PST - ppublish SO - J Hand Surg Br. 1992 Apr;17(2):167-71. doi: 10.1016/0266-7681(92)90081-c. PMID- 7706350 OWN - NLM STAT- MEDLINE DCOM- 19950511 LR - 20231213 IS - 0301-620X (Print) IS - 0301-620X (Linking) VI - 77 IP - 2 DP - 1995 Mar TI - Epicondylitis after treatment with fluoroquinolone antibiotics. PG - 293-5 AB - We report two cases of epicondylitis of the elbow occurring after treatment with fluoroquinolone antibiotics. Both patients had intense pain which appeared very shortly after the first dose of the drug and was not relieved by conservative treatment. Ultrasonography revealed extensive inflammatory lesions with pseudonecrotic areas. MRI confirmed the lesions and also showed a subclinical abnormality of the adjoining tendons. The persistent nature of the pain was the indication for surgical release of the extensor mechanism. After operation pain disappeared completely and the patients were able to return to their normal activities. Lesions of the tendo Achillis are a well-known side-effect of treatment with fluoroquinolone. Our two cases show that such lesions may occur elsewhere. They also indicate the need for caution when prescribing these antibiotics to patients at risk of tendon lesions, such as top-level sportsmen or patients on dialysis or steroid treatment. FAU - Le Huec, J C AU - Le Huec JC AD - University of Bordeaux II, Hôpital Pellegrin, France. FAU - Schaeverbeke, T AU - Schaeverbeke T FAU - Chauveaux, D AU - Chauveaux D FAU - Rivel, J AU - Rivel J FAU - Dehais, J AU - Dehais J FAU - Le Rebeller, A AU - Le Rebeller A LA - eng PT - Case Reports PT - Journal Article PL - England TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (4-Quinolones) RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) RN - 0 (Quinolones) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - *4-Quinolones MH - Anti-Infective Agents/*adverse effects MH - Ciprofloxacin/*adverse effects/therapeutic use MH - *Fluoroquinolones MH - Humans MH - Male MH - Middle Aged MH - Orchitis/drug therapy MH - Quinolones/*adverse effects/therapeutic use MH - Respiratory Tract Infections/drug therapy MH - Tennis Elbow/*chemically induced/pathology/surgery MH - Pefloxacin EDAT- 1995/03/01 00:00 MHDA- 1995/03/01 00:01 CRDT- 1995/03/01 00:00 PHST- 1995/03/01 00:00 [pubmed] PHST- 1995/03/01 00:01 [medline] PHST- 1995/03/01 00:00 [entrez] PST - ppublish SO - J Bone Joint Surg Br. 1995 Mar;77(2):293-5. PMID- 16508964 OWN - NLM STAT- MEDLINE DCOM- 20060413 LR - 20250529 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 54 IP - 3 DP - 2006 Mar TI - Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon. PG - 832-42 AB - OBJECTIVE: To profile the messenger RNA (mRNA) expression for the 23 known genes of matrix metalloproteinases (MMPs), 19 genes of ADAMTS, 4 genes of tissue inhibitors of metalloproteinases (TIMPs), and ADAM genes 8, 10, 12, and 17 in normal, painful, and ruptured Achilles tendons. METHODS: Tendon samples were obtained from cadavers or from patients undergoing surgical procedures to treat chronic painful tendinopathy or ruptured tendon. Total RNA was extracted and mRNA expression was analyzed by quantitative real-time reverse transcription-polymerase chain reaction, normalized to 18S ribosomal RNA. RESULTS: In comparing expression of all genes, the normal, painful, and ruptured Achilles tendon groups each had a distinct mRNA expression signature. Three mRNA were not detected and 14 showed no significant difference in expression levels between the groups. Statistically significant (P < 0.05) differences in mRNA expression, when adjusted for age, included lower levels of MMPs 3 and 10 and TIMP-3 and higher levels of ADAM-12 and MMP-23 in painful compared with normal tendons, and lower levels of MMPs 3 and 7 and TIMPs 2, 3, and 4 and higher levels of ADAMs 8 and 12, MMPs 1, 9, 19, and 25, and TIMP-1 in ruptured compared with normal tendons. CONCLUSION: The distinct mRNA profile of each tendon group suggests differences in extracellular proteolytic activity, which would affect the production and remodeling of the tendon extracellular matrix. Some proteolytic activities are implicated in the maintenance of normal tendon, while chronically painful tendons and ruptured tendons are shown to be distinct groups. These data will provide a foundation for further study of the role and activity of many of these enzymes that underlie the pathologic processes in the tendon. FAU - Jones, Gavin C AU - Jones GC AD - Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK. gjj23@cam.ac.uk FAU - Corps, Anthony N AU - Corps AN FAU - Pennington, Caroline J AU - Pennington CJ FAU - Clark, Ian M AU - Clark IM FAU - Edwards, Dylan R AU - Edwards DR FAU - Bradley, Michelle M AU - Bradley MM FAU - Hazleman, Brian L AU - Hazleman BL FAU - Riley, Graham P AU - Riley GP LA - eng GR - G0100250/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.- (Metalloproteases) RN - EC 3.4.24.- (ADAM Proteins) SB - IM MH - ADAM Proteins/analysis MH - Achilles Tendon/*enzymology/injuries MH - Adult MH - Aged MH - Humans MH - Metalloproteases/*analysis MH - Middle Aged MH - RNA, Messenger/analysis MH - Rupture MH - Tissue Inhibitor of Metalloproteinases/*analysis EDAT- 2006/03/02 09:00 MHDA- 2006/04/14 09:00 CRDT- 2006/03/02 09:00 PHST- 2006/03/02 09:00 [pubmed] PHST- 2006/04/14 09:00 [medline] PHST- 2006/03/02 09:00 [entrez] AID - 10.1002/art.21672 [doi] PST - ppublish SO - Arthritis Rheum. 2006 Mar;54(3):832-42. doi: 10.1002/art.21672. PMID- 15375579 OWN - NLM STAT- MEDLINE DCOM- 20050328 LR - 20091119 IS - 1107-3756 (Print) IS - 1107-3756 (Linking) VI - 14 IP - 4 DP - 2004 Oct TI - Stress deprivation enhances manganese superoxide dismutase expression in the rat patellar tendon. PG - 537-43 AB - Manganese superoxide dismutase (Mn-SOD) is a key antioxidant enzyme that prevents reactive oxygen species (ROS) damage to biological tissues. Although Mn-SOD has been investigated for a variety of cells, little is known about its expression in the tendon, particularly in the stress-deprived condition. The present study demonstrated that Mn-SOD is excessively expressed in the cultured fibroblasts derived from the stress-deprived patellar tendon in the rat using subtractive hybridization analysis. In addition, we confirmed that the expression of Mn-SOD is up-regulated in the stress-deprived patellar tendon in vivo at both the mRNA and protein levels. These results suggest that Mn-SOD may play a role in regulating ROS and matrix degradation involving mechanical deterioration of the stress-deprived tendon tissue. FAU - Kitamura, Nobuto AU - Kitamura N AD - Department of Sports Medicine and Joint Reconstruction Surgery, Hokkaido University School of Medicine, Kita-ku, Kita-15 Nishi 7, Sapporo 060-8638, Japan. FAU - Tohyama, Harukazu AU - Tohyama H FAU - Nishihira, Jun AU - Nishihira J FAU - Hatano, Motoko AU - Hatano M FAU - Suzuki, Masaki AU - Suzuki M FAU - Yasuda, Kazunori AU - Yasuda K LA - eng PT - Journal Article PL - Greece TA - Int J Mol Med JT - International journal of molecular medicine JID - 9810955 RN - 0 (DNA, Complementary) RN - 0 (RNA, Messenger) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 2.7.10.1 (Receptors, Platelet-Derived Growth Factor) SB - IM MH - Animals MH - Cells, Cultured MH - DNA, Complementary/genetics MH - *Gene Expression Regulation, Enzymologic MH - Immunoblotting MH - Immunohistochemistry MH - Male MH - Patella/*enzymology MH - RNA, Messenger/genetics/metabolism MH - Rats MH - Rats, Wistar MH - Receptors, Platelet-Derived Growth Factor/metabolism MH - Stress, Physiological/*enzymology/genetics MH - Superoxide Dismutase/genetics/*metabolism MH - Tendons/*enzymology EDAT- 2004/09/18 05:00 MHDA- 2005/03/29 09:00 CRDT- 2004/09/18 05:00 PHST- 2004/09/18 05:00 [pubmed] PHST- 2005/03/29 09:00 [medline] PHST- 2004/09/18 05:00 [entrez] PST - ppublish SO - Int J Mol Med. 2004 Oct;14(4):537-43. PMID- 5090038 OWN - NLM STAT- MEDLINE DCOM- 19710813 LR - 20210323 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 246 IP - 13 DP - 1971 Jul 10 TI - In vitro enzymatic hydroxylation of prolyl residues in the alpha 1-CB2 fragment of rat collagen. PG - 4138-42 FAU - Rhoads, R E AU - Rhoads RE FAU - Udenfriend, S AU - Udenfriend S FAU - Bornstein, P AU - Bornstein P LA - eng PT - Journal Article PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Amino Acids) RN - 0 (Carbon Isotopes) RN - 0 (Cyanides) RN - 0 (Ketoglutaric Acids) RN - 0 (Peptides) RN - 142M471B3J (Carbon Dioxide) RN - 9007-34-5 (Collagen) RN - 9DLQ4CIU6V (Proline) RN - EC 1.- (Mixed Function Oxygenases) RN - EC 1.11.1.6 (Catalase) RN - EC 3.4.21.1 (Chymotrypsin) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Air Sacs MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Carbon Dioxide/analysis MH - Carbon Isotopes MH - Catalase MH - Cattle MH - Chemical Phenomena MH - Chemistry MH - Chickens MH - Chromatography, Ion Exchange MH - Chymotrypsin MH - *Collagen MH - Connective Tissue MH - Cyanides MH - Cyprinidae MH - Guinea Pigs MH - *Hydroxyproline/analysis MH - Ketoglutaric Acids MH - *Mixed Function Oxygenases MH - Peptides MH - *Proline MH - Protein Denaturation MH - Rats MH - Sharks MH - Skin MH - Tendons EDAT- 1971/07/10 00:00 MHDA- 1971/07/10 00:01 CRDT- 1971/07/10 00:00 PHST- 1971/07/10 00:00 [pubmed] PHST- 1971/07/10 00:01 [medline] PHST- 1971/07/10 00:00 [entrez] AID - S0021-9258(18)62064-2 [pii] PST - ppublish SO - J Biol Chem. 1971 Jul 10;246(13):4138-42. PMID- 18448879 OWN - NLM STAT- MEDLINE DCOM- 20080916 LR - 20161124 IS - 0190-6011 (Print) IS - 0190-6011 (Linking) VI - 38 IP - 5 DP - 2008 May TI - The effect of skin thickness and time in the absorption of dexamethasone in human tendons using iontophoresis. PG - 238-45 LID - 10.2519/jospt.2008.2648 [doi] AB - STUDY DESIGN: Experimental laboratory study. OBJECTIVES: To measure the transmission of dexamethasone sodium phosphate (DEX-P) using iontophoresis as a function of skinfold tissue thickness and time elapsed between treatment and tissue extraction. BACKGROUND: Iontophoresis is a modality used in physical therapy with the intent to drive medications through the skin to underlying tissues using a direct electrical current. DEX-P is the most commonly used medication with iontophoresis and is used to treat a variety of connective tissue conditions. METHODS AND MEASURES: Sixteen adults undergoing anterior cruciate ligament reconstructive surgery using the semitendinosis/gracilis autograft received a 40-mA-min dose of iontophoresis with 0.4% DEX-P superficial to a slip of the distal semitendinosis tendon prior to surgery. The tendon slip was extracted within 4 hours. Time between treatment and tissue extraction and skinfold thickness were measured. Analysis was performed on the slip of the semitendinosis using high-performance liquid chromatography mass spectrum. RESULTS: Of the 16 subjects (10 female, 6 male; mean age, 33 years), 7 had measurable amounts of DEX-P in the tendon slip (4 female, 3 male; mean age, 34 years). The average concentration in the 16 subjects was 2.9 ng/g of tendon tissue. There was no correlation between DEX-P absorbed and skinfold thickness (r = -0.08, P = .79) or time elapsed (r = 0.25, P = .38). In a subset of the 7 individuals that showed measurable levels of DEX-P absorbed, the average concentration of DEX-P was 6.6 ng/g of tendon tissue, and there was a relationship between DEX-P concentrations and time elapsed that did not reach statistical significance (r = 0.71, P = .11). CONCLUSIONS: Iontophoresis appears to facilitate the transmission of dexamethasone to connective tissues in humans with skinfold thickness up to at least 30 mm. The absorption of the dexamethasone seemed to continue to occur for up to 4 hours after delivery. It is not clear why DEX-P was measured in only 7 of the 16 subjects. LEVEL OF EVIDENCE: Therapy, level 5. FAU - Gurney, Burke AU - Gurney B AD - University of New Mexico, Physical Therapy Program, Albuquerque, NM 87131-0001, USA. BGurney@salud.unm.edu FAU - Wascher, Daniel AU - Wascher D FAU - Eaton, Leslie AU - Eaton L FAU - Benesh, Errin AU - Benesh E FAU - Lucak, Joseph AU - Lucak J LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080122 PL - United States TA - J Orthop Sports Phys Ther JT - The Journal of orthopaedic and sports physical therapy JID - 7908150 RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Adult MH - Anterior Cruciate Ligament/surgery MH - *Anterior Cruciate Ligament Injuries MH - Chromatography, High Pressure Liquid MH - Dexamethasone/administration & dosage/*pharmacokinetics MH - Female MH - Glucocorticoids/administration & dosage/pharmacokinetics MH - Humans MH - Iontophoresis/*methods MH - Knee Injuries/metabolism/*therapy MH - Male MH - Preoperative Care/methods MH - Skin/*anatomy & histology MH - Skin Absorption/*physiology MH - Tendons/*metabolism/transplantation MH - Time Factors EDAT- 2008/05/02 09:00 MHDA- 2008/09/17 09:00 CRDT- 2008/05/02 09:00 PHST- 2008/05/02 09:00 [pubmed] PHST- 2008/09/17 09:00 [medline] PHST- 2008/05/02 09:00 [entrez] AID - 1383 [pii] AID - 10.2519/jospt.2008.2648 [doi] PST - ppublish SO - J Orthop Sports Phys Ther. 2008 May;38(5):238-45. doi: 10.2519/jospt.2008.2648. Epub 2008 Jan 22. PMID- 8941560 OWN - NLM STAT- MEDLINE DCOM- 19970313 LR - 20171213 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 81 IP - 5 DP - 1996 Nov TI - Infrared spectroscopy of dystrophic mdx mouse muscle tissue distinguishes among treatment groups. PG - 2328-35 AB - Four groups of mdx mice (deflazacort, high dose of 1.5 mg/kg and low dose of 0.75 mg/kg; prednisone, 1.0 mg/kg; and a placebo) were examined in a double-blind protocol. The experiments tested the hypothesis that infrared spectroscopy can distinguish among gastrocnemius muscle tissues derived from dystrophic animals (n = 22) from different treatment groups and from control muscle tissue (n = 23). Results showed that muscle, inflamed muscle, and tendon can be distinguished on the basis of their infrared absorption patterns. Distinctions among the spectra of the four treatment groups were sought with automated pattern-recognition methods. These classification methods, based either on spectral regions (900-1,500 cm-1) or on principal-component analysis, were in close agreement, assigning 15 or 16, respectively, of 22 mdx spectra to the correct treatment group. Both trials cleanly separated the high-dose deflazacort from the placebo group of muscles, whereas the prednisone and low-dose deflazacort groups were persistently confused in these classifications. Changes in the histology of muscle inflammation paralleled the spectral-classification results. Thus the proposed method, combining infrared spectroscopy with pattern-recognition algorithms, can distinguish treatment effects on muscle tissue. Specific spectral features characteristic of tissue type, disease progression, and treatment effects are not yet elucidated. FAU - Shaw, R A AU - Shaw RA AD - Institute for Biodiagnostics, National Research Council of Canada, Winnipeg, Canada. FAU - Mantsch, H H AU - Mantsch HH FAU - Anderson, J E AU - Anderson JE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Pregnenediones) RN - KR5YZ6AE4B (deflazacort) RN - VB0R961HZT (Prednisone) SB - IM MH - Algorithms MH - Animals MH - Anti-Inflammatory Agents/therapeutic use MH - Inflammation/metabolism/pathology MH - Mice MH - Mice, Inbred mdx MH - Muscle, Skeletal/*chemistry/pathology MH - Muscular Dystrophy, Animal/genetics/*metabolism/pathology MH - Prednisone/therapeutic use MH - Pregnenediones/therapeutic use MH - Reproducibility of Results MH - Spectrophotometry, Infrared MH - Tendons/chemistry/pathology EDAT- 1996/11/01 00:00 MHDA- 1996/11/01 00:01 CRDT- 1996/11/01 00:00 PHST- 1996/11/01 00:00 [pubmed] PHST- 1996/11/01 00:01 [medline] PHST- 1996/11/01 00:00 [entrez] AID - 10.1152/jappl.1996.81.5.2328 [doi] PST - ppublish SO - J Appl Physiol (1985). 1996 Nov;81(5):2328-35. doi: 10.1152/jappl.1996.81.5.2328. PMID- 22403643 OWN - NLM STAT- MEDLINE DCOM- 20120709 LR - 20211021 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 7 IP - 3 DP - 2012 TI - WNT5 interacts with the Ryk receptors doughnut and derailed to mediate muscle attachment site selection in Drosophila melanogaster. PG - e32297 LID - 10.1371/journal.pone.0032297 [doi] LID - e32297 AB - In recent years a number of the genes that regulate muscle formation and maintenance in higher organisms have been identified. Studies employing invertebrate and vertebrate model organisms have revealed that many of the genes required for early mesoderm specification are highly conserved throughout evolution. Less is known about the molecules that mediate the steps subsequent to myogenesis, e. g. myotube guidance and attachment to tendon cells. We use the stereotypic pattern of the Drosophila embryonic body wall musculature in genetic approaches to identify novel factors required for muscle attachment site selection. Here, we show that Wnt5 is needed in this process. The lateral transverse muscles frequently overshoot their target attachment sites and stably attach at novel epidermal sites in Wnt5 mutant embryos. Restoration of WNT5 expression in either the muscle or the tendon cell rescues the mutant phenotype. Surprisingly, the novel attachment sites in Wnt5 mutants frequently do not express the Stripe (SR) protein which has been shown to be required for terminal tendon cell differentiation. A muscle bypass phenotype was previously reported for embryos lacking the WNT5 receptor Derailed (DRL). drl and Wnt5 mutant embryos also exhibit axon path finding errors. DRL belongs to the conserved Ryk receptor tyrosine kinase family which includes two other Drosophila orthologs, the Doughnut on 2 (DNT) and Derailed-2 (DRL-2) proteins. We generated a mutant allele of dnt and find that dnt, but not Drl-2, mutant embryos also show a muscle bypass phenotype. Genetic interaction experiments indicate that drl and dnt act together, likely as WNT5 receptors, to control muscle attachment site selection. These results extend previous findings that at least some of the molecular pathways that guide axons towards their targets are also employed for guidance of muscle fibers to their appropriate attachment sites. FAU - Lahaye, Liza L AU - Lahaye LL AD - Laboratory of Developmental Neurobiology, Department of Molecular and Cell Biology, Leiden University Medical Center, Leiden, The Netherlands. FAU - Wouda, Rene R AU - Wouda RR FAU - de Jong, Anja W M AU - de Jong AW FAU - Fradkin, Lee G AU - Fradkin LG FAU - Noordermeer, Jasprina N AU - Noordermeer JN LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120305 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (DNA-Binding Proteins) RN - 0 (Drosophila Proteins) RN - 0 (Elapid Venoms) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Transcription Factors) RN - 0 (Wnt Proteins) RN - 0 (Wnt5 protein, Drosophila) RN - 0 (sr protein, Drosophila) RN - 86697-68-9 (fasciculin) RN - EC 2.7.1.- (dnt protein, Drosophila) RN - EC 2.7.10.1 (DRL protein, Drosophila) RN - EC 2.7.10.1 (Protein-Tyrosine Kinases) RN - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) SB - IM MH - Animals MH - DNA-Binding Proteins/metabolism MH - Drosophila Proteins/deficiency/genetics/*metabolism MH - Drosophila melanogaster/cytology/embryology/*metabolism MH - Elapid Venoms/metabolism MH - Embryo, Nonmammalian/cytology/metabolism MH - Female MH - Gene Expression Regulation, Developmental MH - Larva/cytology/metabolism MH - Male MH - Muscle Fibers, Skeletal/metabolism MH - Muscles/cytology/embryology/*metabolism MH - Mutation MH - Phenotype MH - Protein Binding MH - Protein-Tyrosine Kinases/genetics/*metabolism MH - Proto-Oncogene Proteins/deficiency/genetics/*metabolism MH - Receptor Protein-Tyrosine Kinases/genetics/*metabolism MH - Tendons/cytology/embryology/metabolism MH - Transcription Factors/metabolism MH - Wnt Proteins/deficiency/genetics/*metabolism PMC - PMC3293800 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2012/03/10 06:00 MHDA- 2012/07/10 06:00 PMCR- 2012/03/05 CRDT- 2012/03/10 06:00 PHST- 2011/09/08 00:00 [received] PHST- 2012/01/24 00:00 [accepted] PHST- 2012/03/10 06:00 [entrez] PHST- 2012/03/10 06:00 [pubmed] PHST- 2012/07/10 06:00 [medline] PHST- 2012/03/05 00:00 [pmc-release] AID - PONE-D-11-17691 [pii] AID - 10.1371/journal.pone.0032297 [doi] PST - ppublish SO - PLoS One. 2012;7(3):e32297. doi: 10.1371/journal.pone.0032297. Epub 2012 Mar 5. PMID- 23000921 OWN - NLM STAT- MEDLINE DCOM- 20140326 LR - 20211021 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 21 IP - 8 DP - 2013 Aug TI - Increased matrix metalloprotease-3 gene expression in ruptured rotator cuff tendons is associated with postoperative tendon retear. PG - 1807-12 LID - 10.1007/s00167-012-2209-x [doi] AB - PURPOSE: The role of matrix metalloproteases (MMPs) in ruptured rotator cuff tendons remains unknown. This study aimed to investigate the gene expression of MMPs in ruptured rotator cuff tendons and to compare their expression levels between patients with and without postoperative tendon retear. METHODS: Twenty-four patients (a median age of 61 years: interquartile range, 55-66 years) with full-thickness rotator cuff tears were examined in this study. The marginal site of the ruptured tendon was harvested during surgery. The mRNA expression levels of collagen types I and III, MMP-1, MMP-3, MMP-7, MMP-9, MMP-13, tissue inhibitor of MMP (TIMP)-1, and TIMP-2 were analysed by real-time reverse transcription polymerase chain reaction. Postoperative retear was evaluated by magnetic resonance imaging at a minimum of 1 year following surgery. RESULTS: The mRNA expression levels of MMP-3 and TIMP-1 in ruptured rotator cuff tendons were significantly increased in patients with postoperative retear (n = 6), compared with patients without retear (n = 18) (P = 0.04). For collagens, MMP-1, MMP-7, MMP-9, MMP-13, and TIMP-2, there were no significant differences in the mRNA expression levels in ruptured tendons between patients with and without retear. CONCLUSIONS: These results suggest that, in addition to up-regulation of TIMP-1 gene expression, increased MMP-3 gene expression in ruptured rotator cuff tendons is associated with postoperative tendon retear. Thus, drug therapy specifically targeting MMP-3 after rotator cuff repair should be considered in the future. FAU - Gotoh, Masafumi AU - Gotoh M AD - Department of Orthopedic Surgery, Kurume University Medical Center, 155 Kokubu-machi, Kurume, Fukuoka, 839-0863, Japan. gomasa@med.kurume-u.ac.jp FAU - Mitsui, Yasuhiro AU - Mitsui Y FAU - Shibata, Hideaki AU - Shibata H FAU - Yamada, Tetsu AU - Yamada T FAU - Shirachi, Isao AU - Shirachi I FAU - Nakama, Kenjiro AU - Nakama K FAU - Okawa, Takahiro AU - Okawa T FAU - Higuchi, Fujio AU - Higuchi F FAU - Nagata, Kensei AU - Nagata K LA - eng PT - Journal Article DEP - 20120922 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (RNA, Messenger) RN - 0 (TIMP2 protein, human) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.- (Matrix Metalloproteinases, Secreted) SB - IM MH - Aged MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Humans MH - Magnetic Resonance Imaging MH - Matrix Metalloproteinases, Secreted/*genetics/metabolism MH - Middle Aged MH - Postoperative Complications MH - RNA, Messenger/*metabolism MH - Real-Time Polymerase Chain Reaction MH - Recurrence MH - Rotator Cuff/*metabolism/pathology/surgery MH - *Rotator Cuff Injuries MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Tissue Inhibitor of Metalloproteinase-2/genetics/metabolism MH - Up-Regulation EDAT- 2012/09/25 06:00 MHDA- 2014/03/29 06:00 CRDT- 2012/09/25 06:00 PHST- 2012/02/28 00:00 [received] PHST- 2012/09/10 00:00 [accepted] PHST- 2012/09/25 06:00 [entrez] PHST- 2012/09/25 06:00 [pubmed] PHST- 2014/03/29 06:00 [medline] AID - 10.1007/s00167-012-2209-x [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2013 Aug;21(8):1807-12. doi: 10.1007/s00167-012-2209-x. Epub 2012 Sep 22. PMID- 1827307 OWN - NLM STAT- MEDLINE DCOM- 19910612 LR - 20190718 IS - 0959-8049 (Print) IS - 0959-8049 (Linking) VI - 27 IP - 3 DP - 1991 TI - Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses. PG - 254-6 AB - Clear cell sarcoma of tendons and aponeuroses is a rare disorder which originates from migrated neural crest cells. It tends to local recurrences and dissemination and the prognosis has to be considered as poor. Based on a small series of patients, a wide surgical excision of the primary tumour or amputation are the therapies of choice. Radiotherapy might be of some value as an adjuvant treatment but radiotherapy and chemotherapy are of little value in the treatment of the advanced disease. Because of the lack of treatment alternatives we treated a 40-year-old female patient with disseminated clear cell sarcoma with interferon-alpha 2b (IFN-alpha 2b) perilesionally after several courses of systemic chemotherapy and radiotherapy had failed. After 4 months of therapy the patient came into a complete pathological remission which lasted for 17 months. A relapse of round cell sarcoma on both tumour sites was then noted. This outcome shows that IFN-alpha 2b was able to induce a complete remission in clear cell sarcoma and might have altered the natural course of the disease. IFN-alpha should be studied as adjuvant therapy after surgery of primary clear cell sarcoma and as a first-line palliative treatment in disseminated disease. FAU - Steger, G G AU - Steger GG AD - Department of Chemotherapy, University of Vienna, Austria. FAU - Wrba, F AU - Wrba F FAU - Mader, R AU - Mader R FAU - Schlappack, O AU - Schlappack O FAU - Dittrich, C AU - Dittrich C FAU - Rainer, H AU - Rainer H LA - eng PT - Case Reports PT - Journal Article PL - England TA - Eur J Cancer JT - European journal of cancer (Oxford, England : 1990) JID - 9005373 RN - 0 (Interferon alpha-2) RN - 0 (Interferon-alpha) RN - 0 (Recombinant Proteins) SB - IM CIN - Eur J Cancer. 1991;27(9):1187. doi: 10.1016/0277-5379(91)90329-c. PMID: 1835638 MH - Adult MH - Female MH - Humans MH - Interferon alpha-2 MH - Interferon-alpha/*therapeutic use MH - Lymph Nodes/pathology MH - Lymphatic Metastasis MH - Neoplasm Recurrence, Local/drug therapy MH - Recombinant Proteins MH - Sarcoma/*drug therapy/pathology MH - *Tendons EDAT- 1991/01/01 00:00 MHDA- 1991/01/01 00:01 CRDT- 1991/01/01 00:00 PHST- 1991/01/01 00:00 [pubmed] PHST- 1991/01/01 00:01 [medline] PHST- 1991/01/01 00:00 [entrez] AID - 10.1016/0277-5379(91)90509-c [doi] PST - ppublish SO - Eur J Cancer. 1991;27(3):254-6. doi: 10.1016/0277-5379(91)90509-c. PMID- 10372854 OWN - NLM STAT- MEDLINE DCOM- 19990629 LR - 20190702 IS - 0038-4348 (Print) IS - 0038-4348 (Linking) VI - 92 IP - 6 DP - 1999 Jun TI - Effect of injected versus iontophoretic corticosteroid on the rabbit tendon. PG - 600-8 AB - BACKGROUND: The etiologic role of corticosteroid therapy in tendon rupture is controversial. This study compared the effects of injected versus iontophoretically delivered corticosteroid on the normal rabbit Achilles tendon. METHODS: Rabbits were divided into three treatment groups: (1) corticosteroid injections, (2) iontophoretically delivered corticosteroid, and (3) no treatment. One tendon of each rabbit in the treatment groups was treated with either drug injection or iontophoresis; the tendon of the other leg served as a control. Some tendons were used for testing elastic modulus, ultimate load, and ultimate stress, while the remaining tendons were evaluated histologically. RESULTS: Injections of either corticosteroid or saline into the tendon sheath resulted in short-term changes in tendon biomechanical characteristics and somewhat higher histologic severity scores; however, iontophoretic delivery of corticosteroid or saline did not affect either significantly. CONCLUSIONS: Iontophoresis using sterile water or corticosteroid resulted in minimal or no biochemical and histologic changes in the tendon compared with injection of either substance. The method of corticosteroid delivery may be as important as the actual drug effects on the biomechanical and histologic properties of tendons. FAU - Martin, D F AU - Martin DF AD - Department of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1070, USA. FAU - Carlson, C S AU - Carlson CS FAU - Berry, J AU - Berry J FAU - Reboussin, B A AU - Reboussin BA FAU - Gordon, E S AU - Gordon ES FAU - Smith, B P AU - Smith BP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - South Med J JT - Southern medical journal JID - 0404522 RN - 0 (Anti-Inflammatory Agents) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Achilles Tendon/*drug effects/pathology/physiopathology MH - Animals MH - Anti-Inflammatory Agents/*administration & dosage/toxicity MH - Biomechanical Phenomena MH - Dexamethasone/*administration & dosage/toxicity MH - Injections, Intramuscular MH - *Iontophoresis MH - Male MH - Rabbits EDAT- 1999/06/18 00:00 MHDA- 1999/06/18 00:01 CRDT- 1999/06/18 00:00 PHST- 1999/06/18 00:00 [pubmed] PHST- 1999/06/18 00:01 [medline] PHST- 1999/06/18 00:00 [entrez] AID - 10.1097/00007611-199906000-00009 [doi] PST - ppublish SO - South Med J. 1999 Jun;92(6):600-8. doi: 10.1097/00007611-199906000-00009. PMID- 8003526 OWN - NLM STAT- MEDLINE DCOM- 19940721 LR - 20190610 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1206 IP - 2 DP - 1994 Jun 12 TI - Methylene blue sensitized photo-oxidation of collagen fibrils. PG - 225-30 AB - Isometric tension measurements on rat tail tendons showed that visible light in the presence of Methylene blue led to an increase in the thermal stability of the collagen. Analysis of CNBr fragments by SDS-polyacrylamide gel electrophoresis showed a decrease in the amounts of low molecular weight fragments and an increase in the formation higher molecular components with irradiation time. Amino-acid analysis data indicated that the relative yields of only tyrosine, methionine and histidine were reduced by the irradiation, with the loss of histidine being the greatest. The loss of methionine was not sufficient to completely account for the increases in the CNBr fragment sizes. Comparable results were also obtained with ultra-violet light. These thermal and chemical data were interpreted as being due to the formation of new intermolecular cross-links in the tendon collagen. X-ray fibre diffraction showed that the irradiation and the induced cross-linking did not lead to a substantial change or disorder in the molecular packing arrangement within the native collagen fibril. FAU - Ramshaw, J A AU - Ramshaw JA AD - CSIRO Division of Biomolecular Engineering, Parkville, Vic., Australia. FAU - Stephens, L J AU - Stephens LJ FAU - Tulloch, P A AU - Tulloch PA LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 9007-34-5 (Collagen) RN - T42P99266K (Methylene Blue) SB - IM MH - Animals MH - Collagen/*chemistry/ultrastructure MH - Hot Temperature MH - Light MH - Methylene Blue/*chemistry MH - Molecular Structure MH - Oxidation-Reduction MH - Photochemistry MH - Rats MH - Tendons/chemistry MH - Ultraviolet Rays MH - X-Ray Diffraction EDAT- 1994/06/12 00:00 MHDA- 1994/06/12 00:01 CRDT- 1994/06/12 00:00 PHST- 1994/06/12 00:00 [pubmed] PHST- 1994/06/12 00:01 [medline] PHST- 1994/06/12 00:00 [entrez] AID - 0167-4838(94)90212-7 [pii] AID - 10.1016/0167-4838(94)90212-7 [doi] PST - ppublish SO - Biochim Biophys Acta. 1994 Jun 12;1206(2):225-30. doi: 10.1016/0167-4838(94)90212-7. PMID- 20656345 OWN - NLM STAT- MEDLINE DCOM- 20110112 LR - 20191210 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 31 IP - 30 DP - 2010 Oct TI - Biochemical and biomechanical gradients for directed bone marrow stromal cell differentiation toward tendon and bone. PG - 7695-704 LID - 10.1016/j.biomaterials.2010.06.046 [doi] AB - Substrates with mechanical property gradients and various extracellular matrix ligand loadings were evaluated for their ability to direct bone marrow stromal cell differentiation along osteogenic and tenogenic lineages. After verifying reproducible mechanical compliance characteristics of commercial hydrogel gradient substrates, substrates were functionalized with whole length fibronectin or collagen, both of which are found in skeletal structures and are relevant to cell-matrix signalling. Bone marrow stromal cells were seeded onto the substrates in growth media and cultured first to examine cell attachment and morphology, indicating higher levels of attachment on collagen substrates after 1h, and increased spreading and organization trends after 24h. Differentiation studies showed an increase in osteoblast differentiation on fibronectin substrates while collagen substrates lacked osteogenic differentiation. Osteogenic differentiation decreased on substrates of lower stiffness and lower ligand density. Molecular investigations revealed an increase in relevant signalling molecules for osteoblasts that were consistent with differentiation studies, but detected the presence of tenoblast markers on collagen substrates within a narrow range of stiffness. Our results indicate that mechanovariant substrates do hold promise as a culture platform for directed differentiation to tendon and bone by altering gene level expression of relevant signalling molecules. This study aids in understanding the molecular mechanisms that drive differentiation from substrate based cues, and could aid the design of therapeutic biomaterials at the transition from tendon to bone. CI - Copyright 2010 Elsevier Ltd. All rights reserved. FAU - Sharma, Ram I AU - Sharma RI AD - Department of Orthopedics, University of Zurich, Zurich, Switzerland. FAU - Snedeker, Jess G AU - Snedeker JG LA - eng PT - Evaluation Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100724 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Enzyme Inhibitors) RN - 0 (Fibronectins) RN - 0 (Hydrogels) RN - 9007-34-5 (Collagen) SB - IM MH - Bone Marrow Cells/cytology/*physiology MH - Bone and Bones/cytology/*physiology MH - Cell Culture Techniques MH - Cell Differentiation/*physiology MH - Cells, Cultured MH - Collagen/chemistry/metabolism MH - Elasticity MH - Enzyme Inhibitors/metabolism MH - Extracellular Matrix/chemistry/metabolism MH - Fibronectins/chemistry/metabolism MH - Humans MH - Hydrogels/chemistry MH - Materials Testing MH - Osteogenesis/physiology MH - Signal Transduction/physiology MH - Stromal Cells/cytology/*physiology MH - Tendons/cytology/*physiology EDAT- 2010/07/27 06:00 MHDA- 2011/01/13 06:00 CRDT- 2010/07/27 06:00 PHST- 2010/04/10 00:00 [received] PHST- 2010/06/28 00:00 [accepted] PHST- 2010/07/27 06:00 [entrez] PHST- 2010/07/27 06:00 [pubmed] PHST- 2011/01/13 06:00 [medline] AID - S0142-9612(10)00826-4 [pii] AID - 10.1016/j.biomaterials.2010.06.046 [doi] PST - ppublish SO - Biomaterials. 2010 Oct;31(30):7695-704. doi: 10.1016/j.biomaterials.2010.06.046. Epub 2010 Jul 24. PMID- 7726341 OWN - NLM STAT- MEDLINE DCOM- 19950525 LR - 20220316 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 23 IP - 1 DP - 1995 Jan-Feb TI - An in vitro investigation into the effects of repetitive motion and nonsteroidal antiinflammatory medication on human tendon fibroblasts. PG - 119-23 AB - Soft tissue injuries due to repetitive motion are common sports injuries and are often treated with antiinflammatory therapies. We investigated the in vitro effects of repetitive motion and nonsteroidal antiinflammatory medication on human tendon fibroblasts. In addition, we studied the effects related to the presence of inflammatory cells. Repetitive motion was associated with an increased release of prostaglandin E2 and increased deoxyribonucleic acid (DNA) and protein synthesis. The presence of nonsteroidal antiinflammatory medication decreased prostaglandin E2 release and DNA synthesis but increased protein synthesis. Contact with macrophages caused a marked additional increase in prostaglandin E2 and a concomitant increase in DNA synthesis. Release of interleukin-6 by the macrophages also suggested that this cytokine plays a role in the response to repetitive motion. Our results can aid in the search for a more scientific approach to the treatment of soft tissue injuries associated with repetitive motion. They suggest that nonsteroidal antiinflammatory medication may have potentially negative effects during the proliferative phase of a healing since it was associated with decreased DNA synthesis. However, it may be beneficial in the maturation and remodeling phase since it stimulated protein synthesis. FAU - Almekinders, L C AU - Almekinders LC AD - Division of Orthopaedic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7055. FAU - Baynes, A J AU - Baynes AJ FAU - Bracey, L W AU - Bracey LW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Prostaglandins E) RN - XXE1CET956 (Indomethacin) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Cells, Cultured MH - Cumulative Trauma Disorders/complications/*physiopathology MH - Fibroblasts/*drug effects/metabolism MH - Humans MH - Indomethacin/pharmacology MH - Macrophages/metabolism MH - Prostaglandins E/metabolism MH - Soft Tissue Injuries/physiopathology MH - Tendons/cytology/*drug effects EDAT- 1995/01/01 00:00 MHDA- 1995/01/01 00:01 CRDT- 1995/01/01 00:00 PHST- 1995/01/01 00:00 [pubmed] PHST- 1995/01/01 00:01 [medline] PHST- 1995/01/01 00:00 [entrez] AID - 10.1177/036354659502300120 [doi] PST - ppublish SO - Am J Sports Med. 1995 Jan-Feb;23(1):119-23. doi: 10.1177/036354659502300120. PMID- 5031483 OWN - NLM STAT- MEDLINE DCOM- 19720807 LR - 20170214 IS - 0036-9330 (Print) IS - 0036-9330 (Linking) VI - 17 IP - 5 DP - 1972 May TI - Local steroid therapy in painful orthopaedic conditions. PG - 176-86 FAU - Goldie, I AU - Goldie I LA - eng PT - Journal Article PL - Scotland TA - Scott Med J JT - Scottish medical journal JID - 2983335R RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Steroids) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Adrenal Cortex Hormones/adverse effects/pharmacology/*therapeutic use MH - Animals MH - Anti-Inflammatory Agents/therapeutic use MH - Arthritis, Rheumatoid/drug therapy MH - Blood Vessels/drug effects MH - Bone Diseases/*drug therapy/etiology MH - Bone and Bones/drug effects MH - Bursitis/drug therapy MH - Cartilage/drug effects MH - Connective Tissue/drug effects MH - Cricetinae MH - Humans MH - Joint Diseases/*drug therapy MH - Joints/drug effects MH - Muscular Diseases/*drug therapy MH - Osteoarthritis/drug therapy MH - Prednisolone/therapeutic use MH - Skin/drug effects MH - Steroids/*therapeutic use MH - Synovitis/etiology MH - Tendons/drug effects EDAT- 1972/05/01 00:00 MHDA- 1972/05/01 00:01 CRDT- 1972/05/01 00:00 PHST- 1972/05/01 00:00 [pubmed] PHST- 1972/05/01 00:01 [medline] PHST- 1972/05/01 00:00 [entrez] AID - 10.1177/003693307201700504 [doi] PST - ppublish SO - Scott Med J. 1972 May;17(5):176-86. doi: 10.1177/003693307201700504. PMID- 20839322 OWN - NLM STAT- MEDLINE DCOM- 20101007 LR - 20211020 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 28 IP - 10 DP - 2010 Oct TI - Cycle-dependent matrix remodeling gene expression response in fatigue-loaded rat patellar tendons. PG - 1380-6 LID - 10.1002/jor.21132 [doi] AB - Expression profiling of selected matrix remodeling genes was conducted to evaluate differences in molecular response to low-cycle (100) and high-cycle (7,200) sub-failure-fatigue loading of patellar tendons. Using our previously developed in vivo patellar tendon model, tendons were loaded for 100 or 7,200 cycles and expression of selected metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), and collagens were quantified by real-time RT-PCR at 1- and 7-day post-loading. Expression profiles were also obtained from lacerated tendons as an acute injury model. The high-cycle group showed upregulation of TIMP-1, -2, Col3a1, and Col5a1, and downregulation TIMP-4 at both time points, upregulation of MMP-2 at 7-day post-loading and downregulation of MMP-13 and -14 at 1-day post-loading, suggesting overall repair/remodeling. In contrast, the low-cycle loaded group showed upregulation of MMP-2, -3, -13, and Col12a1 at both time points, upregulation of TIMP-1, -2, -3, Col3a1, and integrin β1 and downregulation of integrin α11 at 1-day post-loading and upregulation of Col1a1 at 7-day post-loading, consistent with a hypertrophic (adaptive) pattern. Lacerated tendons showed a typical acute wound response with upregulation of all examined remodeling genes. Differences found in tendon response to high- and low-cycle loading are suggestive of the underlying mechanisms associated with a healthy or damaging response. CI - Published by Wiley Periodicals, Inc. J Orthop Res 28:1380-1386, 2010. FAU - Sun, Hui B AU - Sun HB AD - Leni and Peter W. May Department of Orthopaedics, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1188, New York, New York 10029, USA. FAU - Andarawis-Puri, Nelly AU - Andarawis-Puri N FAU - Li, Yonghui AU - Li Y FAU - Fung, David T AU - Fung DT FAU - Lee, Jonathan Y AU - Lee JY FAU - Wang, Vincent M AU - Wang VM FAU - Basta-Pljakic, Jelena AU - Basta-Pljakic J FAU - Leong, Daniel J AU - Leong DJ FAU - Sereysky, Jedd B AU - Sereysky JB FAU - Ros, Stephen J AU - Ros SJ FAU - Klug, Raymond A AU - Klug RA FAU - Braman, Jonathan AU - Braman J FAU - Schaffler, Mitch B AU - Schaffler MB FAU - Jepsen, Karl J AU - Jepsen KJ FAU - Flatow, Evan L AU - Flatow EL LA - eng GR - R01 AR052743/AR/NIAMS NIH HHS/United States GR - AR052743/AR/NIAMS NIH HHS/United States GR - AR050968/AR/NIAMS NIH HHS/United States GR - AR04768/AR/NIAMS NIH HHS/United States GR - R01 AR041210/AR/NIAMS NIH HHS/United States GR - R01 AR050968/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Bone Matrix/metabolism/*physiopathology MH - Bone Remodeling/*physiology MH - Collagen/metabolism MH - Fatigue/metabolism/*physiopathology MH - Female MH - Gene Expression Regulation/*physiology MH - Matrix Metalloproteinases/metabolism MH - Models, Animal MH - Patellar Ligament/metabolism/*physiopathology MH - Rats MH - Rats, Sprague-Dawley MH - Tissue Inhibitor of Metalloproteinases/metabolism MH - Weight-Bearing/physiology PMC - PMC4408775 MID - NIHMS680240 EDAT- 2010/09/15 06:00 MHDA- 2010/10/12 06:00 PMCR- 2015/04/24 CRDT- 2010/09/15 06:00 PHST- 2010/09/15 06:00 [entrez] PHST- 2010/09/15 06:00 [pubmed] PHST- 2010/10/12 06:00 [medline] PHST- 2015/04/24 00:00 [pmc-release] AID - 10.1002/jor.21132 [doi] PST - ppublish SO - J Orthop Res. 2010 Oct;28(10):1380-6. doi: 10.1002/jor.21132. PMID- 14569066 OWN - NLM STAT- MEDLINE DCOM- 20040211 LR - 20250306 IS - 0022-3565 (Print) IS - 0022-3565 (Linking) VI - 308 IP - 1 DP - 2004 Jan TI - In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. PG - 394-402 AB - Tendinopathy are classic side effects observed with fluoroquinolones antibiotics. A previously validated model based on a spontaneously immortalized rabbit tendon cell line (Teno cell line) was used to evaluate cellular responses to the fluoroquinolones pefloxacin (PEF), ofloxacin (OFX), levofloxacin (LVX), and ciprofloxacin (CIP), in various concentrations. Cell viability, redox status changes, reduced glutathione content, and reactive oxygen species production were assessed using neutral red, Alamar blue, monobromobimane and 2,7-dichlorofluorescindiacetate fluorescent probes, respectively. Living adherent tenocytes were analyzed using a cold light cytofluorometer adapted to 96-well microplates. All fluoroquinolones showed moderate cytotoxicity after 24 h and more severe, significant toxicity after 72 h on tendon cells. Moreover, two groups of fluoroquinolones may be differentiated: intrinsic toxicity for tendon cells was high with ciprofloxacin and pefloxacin [redox status decrease was 80 and 62% (*p < 0.05) for PEF and CIP at 1 mM for 72 h, respectively], but moderate with ofloxacin and levofloxacin LVX [redox status decrease was 30 and 22% (*p < 0.05) for OFX and LVX at 1 mM during 72 h, respectively]. Our model supports a role for early oxidative stress in the development of fluoroquinolone-induced tendinopathy. Moreover, our study indicates that intrinsic toxicity to tendon cells varies across fluoroquinolones. The Teno cell line may be a useful model for detecting and evaluating tendon toxicity of new fluoroquinolones and other drugs associated with tendinopathy. FAU - Pouzaud, F AU - Pouzaud F AD - Laboratoire de Toxicologie, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris, Paris, France. FAU - Bernard-Beaubois, K AU - Bernard-Beaubois K FAU - Thevenin, M AU - Thevenin M FAU - Warnet, J-M AU - Warnet JM FAU - Hayem, G AU - Hayem G FAU - Rat, P AU - Rat P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20031020 PL - Netherlands TA - J Pharmacol Exp Ther JT - The Journal of pharmacology and experimental therapeutics JID - 0376362 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) RN - 0 (Reactive Oxygen Species) RN - GAN16C9B8O (Glutathione) SB - IM MH - Animals MH - Anti-Infective Agents/toxicity MH - Cell Survival/drug effects MH - Cells, Cultured MH - Fluoroquinolones/*toxicity MH - Glutathione/metabolism MH - Oxidative Stress/drug effects MH - Rabbits MH - Reactive Oxygen Species/metabolism MH - Tendons/cytology/*drug effects EDAT- 2003/10/22 05:00 MHDA- 2004/02/12 05:00 CRDT- 2003/10/22 05:00 PHST- 2003/10/22 05:00 [pubmed] PHST- 2004/02/12 05:00 [medline] PHST- 2003/10/22 05:00 [entrez] AID - S0022-3565(24)31134-6 [pii] AID - 10.1124/jpet.103.057984 [doi] PST - ppublish SO - J Pharmacol Exp Ther. 2004 Jan;308(1):394-402. doi: 10.1124/jpet.103.057984. Epub 2003 Oct 20. PMID- 32093733 OWN - NLM STAT- MEDLINE DCOM- 20201207 LR - 20201214 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 15 IP - 1 DP - 2020 Feb 24 TI - Downregulation of type I collagen expression in the Achilles tendon by dexamethasone: a controlled laboratory study. PG - 70 LID - 10.1186/s13018-020-01602-z [doi] LID - 70 AB - BACKGROUND: Spontaneous Achilles tendon rupture associated with long-term dexamethasone (Dex) use has been reported. However, few studies have investigated the potential mechanism. The aim of this study was to evaluate the effects of oral Dex on type I collagen in humans and rats and its association with tendon rupture. METHODS: First, six Achilles tendons from patients who received long-term Dex treatment, and another six normal tendons were harvested for histological evaluation. Secondly, 8-week-old rats (n = 72) were randomly assigned to a Dex group or a control group. Type I collagen was studied at the mechanical, histological, and molecular levels after 3 and 5 weeks. Tenocytes isolated from normal human and rat tendon were used to investigate the effect of Dex on cellular scale. RESULTS: Histological analysis of human and rat tendon tissue revealed an irregular, disordered arrangement of type I collagen in the Dex group compared with the control group. In addition, In the Dex+ group, type I collagen expression decreased in comparison with the Dex- group in both human and rat tenocytes. The mechanical strength of tendons was significantly reduced in the Dex group (68.87 ± 11.07 N) in comparison with the control group (81.46 ± 7.62 N, P = 0.013) after 5 weeks. Tendons in the Dex group were shorter with smaller cross-sectional areas (10.71 ± 0.34 mm(2), 1.44 ± 0.22 mm(2), respectively) after 5 weeks than those in the control group (11.13 ± 0.50 mm(2), P = 0.050, 2.74 ± 0.34 mm(2), P < 0.001, respectively). CONCLUSIONS: This finding suggests long-term use of Dex that decreases the expression of type I collagen at molecular and tissue levels both in human and rat Achilles tendons. Furthermore, Dex decreases the mechanical strength of the tendon, thereby increasing the risk of Achilles tendon rupture. FAU - Ge, Zilu AU - Ge Z AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Tang, Hong AU - Tang H AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Chen, Wan AU - Chen W AUID- ORCID: 0000-0001-5734-3432 AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. chenwanfred@foxmail.com. FAU - Wang, Yunjiao AU - Wang Y AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Yuan, Chengsong AU - Yuan C AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Tao, Xu AU - Tao X AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Zhou, Binghua AU - Zhou B AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopedics/Sports Medicine Center, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University (Army Medical University), Gaotanyan Street. 30, Shapingba District, Chongqing, 400038, China. LA - eng GR - 81601943/National Science Foundation for Young Scientists of China/ PT - Journal Article DEP - 20200224 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Collagen Type I) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Achilles Tendon/drug effects/*metabolism/pathology MH - Adult MH - Animals MH - Anti-Inflammatory Agents/*adverse effects MH - Cells, Cultured MH - Collagen Type I/antagonists & inhibitors/*biosynthesis/genetics MH - Dexamethasone/*adverse effects MH - Down-Regulation/drug effects/*physiology MH - Female MH - Humans MH - Male MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley PMC - PMC7038574 OTO - NOTNLM OT - Achilles tendon OT - Dexamethasone OT - Human OT - Rats OT - Type I collagen COIS- The authors declare that they have no competing interests. EDAT- 2020/02/26 06:00 MHDA- 2020/12/15 06:00 PMCR- 2020/02/24 CRDT- 2020/02/26 06:00 PHST- 2019/10/19 00:00 [received] PHST- 2020/02/17 00:00 [accepted] PHST- 2020/02/26 06:00 [entrez] PHST- 2020/02/26 06:00 [pubmed] PHST- 2020/12/15 06:00 [medline] PHST- 2020/02/24 00:00 [pmc-release] AID - 10.1186/s13018-020-01602-z [pii] AID - 1602 [pii] AID - 10.1186/s13018-020-01602-z [doi] PST - epublish SO - J Orthop Surg Res. 2020 Feb 24;15(1):70. doi: 10.1186/s13018-020-01602-z. PMID- 38467838 OWN - NLM STAT- MEDLINE DCOM- 20240430 LR - 20240503 IS - 1432-0827 (Electronic) IS - 0171-967X (Linking) VI - 114 IP - 5 DP - 2024 May TI - Roles of Plasminogen Activator Inhibitor-1 in Heterotopic Ossification Induced by Achilles Tenotomy in Thermal Injured Mice. PG - 535-549 LID - 10.1007/s00223-024-01193-5 [doi] AB - Heterotopic ossification (HO) is the process by which ectopic bone forms at an extraskeletal site. Inflammatory conditions induce plasminogen activator inhibitor 1 (PAI-1), an inhibitor of fibrinolysis, which regulates osteogenesis. In the present study, we investigated the roles of PAI-1 in the pathophysiology of HO induced by trauma/burn treatment using PAI-1-deficient mice. PAI-1 deficiency significantly promoted HO and increased the number of alkaline phosphatase (ALP)-positive cells in Achilles tendons after trauma/burn treatment. The mRNA levels of inflammation markers were elevated in Achilles tendons of both wild-type and PAI-1-deficient mice after trauma/burn treatment and PAI-1 mRNA levels were elevated in Achilles tendons of wild-type mice. PAI-1 deficiency significantly up-regulated the expression of Runx2, Osterix, and type 1 collagen in Achilles tendons 9 weeks after trauma/burn treatment in mice. In in vitro experiments, PAI-1 deficiency significantly increased ALP activity and mineralization in mouse osteoblasts. Moreover, PAI-1 deficiency significantly increased ALP activity and up-regulated osteocalcin expression during osteoblastic differentiation from mouse adipose-tissue-derived stem cells, but suppressed the chondrogenic differentiation of these cells. In conclusion, the present study showed that PAI-1 deficiency promoted HO in Achilles tendons after trauma/burn treatment partly by enhancing osteoblast differentiation and ALP activity in mice. Endogenous PAI-1 may play protective roles against HO after injury and inflammation. CI - © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Mizukami, Yuya AU - Mizukami Y AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Kawao, Naoyuki AU - Kawao N AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Ohira, Takashi AU - Ohira T AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Hashimoto, Daiki AU - Hashimoto D AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Okada, Kiyotaka AU - Okada K AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Matsuo, Osamu AU - Matsuo O AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. FAU - Kaji, Hiroshi AU - Kaji H AUID- ORCID: 0000-0001-7433-5135 AD - Department of Physiology and Regenerative Medicine, Faculty of Medicine, Kindai University, 377-2 Ohnohigashi, Osakasayama, 589-8511, Japan. hkaji@med.kindai.ac.jp. LA - eng GR - 22K16755/Japan Society for the Promotion of Science/ GR - C:20K09514/Japan Society for the Promotion of Science/ GR - C:KK230021/Japan Society for the Promotion of Science/ GR - 22C1/Salt Science Research Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240311 PL - United States TA - Calcif Tissue Int JT - Calcified tissue international JID - 7905481 RN - 0 (Plasminogen Activator Inhibitor 1) RN - Plasminogen Activator Inhibitor-1 Deficiency SB - IM MH - Animals MH - *Ossification, Heterotopic/metabolism/etiology MH - *Achilles Tendon/metabolism/injuries/pathology MH - Mice MH - *Plasminogen Activator Inhibitor 1/metabolism/*deficiency MH - *Tenotomy/methods MH - Osteogenesis/physiology MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Male MH - Osteoblasts/metabolism MH - Cell Differentiation MH - Disease Models, Animal MH - *Hemorrhagic Disorders OTO - NOTNLM OT - Heterotopic ossification OT - Inflammation OT - Osteoblast OT - Plasminogen activator inhibitor EDAT- 2024/03/12 06:43 MHDA- 2024/05/01 01:49 CRDT- 2024/03/12 00:29 PHST- 2023/11/16 00:00 [received] PHST- 2024/02/02 00:00 [accepted] PHST- 2024/05/01 01:49 [medline] PHST- 2024/03/12 06:43 [pubmed] PHST- 2024/03/12 00:29 [entrez] AID - 10.1007/s00223-024-01193-5 [pii] AID - 10.1007/s00223-024-01193-5 [doi] PST - ppublish SO - Calcif Tissue Int. 2024 May;114(5):535-549. doi: 10.1007/s00223-024-01193-5. Epub 2024 Mar 11. PMID- 13899058 OWN - NLM STAT- MEDLINE DCOM- 19981101 LR - 20181201 IS - 0029-2001 (Print) IS - 0029-2001 (Linking) VI - 82 DP - 1962 Jan 1 TI - [Bilateral rupture of the Achilles tendons in steroid treatment]. PG - 16-7 FAU - GJONE, E AU - GJONE E LA - nor PT - Journal Article PL - Norway TA - Tidsskr Nor Laegeforen JT - Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke JID - 0413423 RN - 9PHQ9Y1OLM (Prednisolone) SB - OM MH - *Achilles Tendon MH - *Disease MH - *Heel MH - Humans MH - Prednisolone/*toxicity MH - Rupture OTO - NLM OT - *HEEL/diseases OT - *PREDNISOLONE/toxicology EDAT- 1962/01/01 00:00 MHDA- 1962/01/01 00:01 CRDT- 1962/01/01 00:00 PHST- 1962/01/01 00:00 [pubmed] PHST- 1962/01/01 00:01 [medline] PHST- 1962/01/01 00:00 [entrez] PST - ppublish SO - Tidsskr Nor Laegeforen. 1962 Jan 1;82:16-7. PMID- 7860672 OWN - NLM STAT- MEDLINE DCOM- 19950323 LR - 20161123 IS - 0021-7697 (Print) IS - 0021-7697 (Linking) VI - 131 IP - 10 DP - 1994 Oct TI - [Epicondylitis induced by fluoroquinolones in athletes. Apropos of 2 cases]. PG - 408-12 AB - Epicondylitis occurred in two leisure athletes who were taking fluoroquinolones. No similar cases have been reported in the literature. In both cases, pain occurred early after initiating drug therapy. Pain was intense and was not controlled by usual care. Echography demonstrated major inflammatory lesions with pseudo-necrosis. Magnetic resonance imaging confirmed the lesions and gave evidence of infraclinical lesions of the adjacent tendons. Surgical disinsertion of the epicondyles with biopsy was indicated due to the persistent pain. Histological examination revealed unspecific lesions of hyalin degeneration and a few giant cells in one case. Pain disappeared after surgery and the patients were able to return to their work, but neither was able to continue his sports activity. Lesions of the Achilles tendon have been observed in patients taking fluoroquinolone and the two cases reported here confirm the possibility of other localizations. Care must therefore be taken when prescribing these antibiotics in patients at risk (dialysis patients, those on corticosteroids, high-performance athletes). FAU - Le Huec, J C AU - Le Huec JC AD - Service de Rhumatologie, CHU Pellegrin, Université de Bordeaux II. FAU - Schaeverbeke, T AU - Schaeverbeke T FAU - Chauveaux, D AU - Chauveaux D FAU - Moinard, M AU - Moinard M FAU - Rivel, J AU - Rivel J FAU - Le Rebeller, A AU - Le Rebeller A LA - fre PT - Case Reports PT - Journal Article TT - Epicondylites induites par les fluoroquinolones chez le sportif. A propos de 2 cas. PL - France TA - J Chir (Paris) JT - Journal de chirurgie JID - 0374754 RN - 2H52Z9F2Q5 (Pefloxacin) RN - 5E8K9I0O4U (Ciprofloxacin) SB - IM MH - Ciprofloxacin/*adverse effects/therapeutic use MH - Humans MH - Lung Diseases/drug therapy/microbiology MH - Magnetic Resonance Spectroscopy MH - Male MH - Middle Aged MH - Orchitis/drug therapy MH - Pefloxacin/*adverse effects/therapeutic use MH - Sports MH - Tennis Elbow/*chemically induced/diagnosis/diagnostic imaging/pathology MH - Ultrasonography EDAT- 1994/10/01 00:00 MHDA- 1994/10/01 00:01 CRDT- 1994/10/01 00:00 PHST- 1994/10/01 00:00 [pubmed] PHST- 1994/10/01 00:01 [medline] PHST- 1994/10/01 00:00 [entrez] PST - ppublish SO - J Chir (Paris). 1994 Oct;131(10):408-12. PMID- 5661359 OWN - NLM STAT- MEDLINE DCOM- 19680830 LR - 20190623 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 17 IP - 6 DP - 1968 Jun TI - Effect of nitrogen mustard on soluble collagen. PG - 975-82 FAU - Dorner, R W AU - Dorner RW FAU - Uddin, J AU - Uddin J LA - eng PT - Journal Article PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 50D9XSG0VR (Mechlorethamine) RN - 9007-34-5 (Collagen) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Chemical Phenomena MH - Chemistry MH - *Collagen MH - Densitometry MH - Dialysis MH - Hydrogen-Ion Concentration MH - Hydroxyproline MH - *Mechlorethamine MH - Rabbits MH - Rats MH - Skin MH - Solubility MH - Tendons MH - Viscosity EDAT- 1968/06/01 00:00 MHDA- 1968/06/01 00:01 CRDT- 1968/06/01 00:00 PHST- 1968/06/01 00:00 [pubmed] PHST- 1968/06/01 00:01 [medline] PHST- 1968/06/01 00:00 [entrez] AID - 0006-2952(68)90356-0 [pii] AID - 10.1016/0006-2952(68)90356-0 [doi] PST - ppublish SO - Biochem Pharmacol. 1968 Jun;17(6):975-82. doi: 10.1016/0006-2952(68)90356-0. PMID- 31887804 OWN - NLM STAT- MEDLINE DCOM- 20200316 LR - 20200316 IS - 1976-2437 (Electronic) IS - 0513-5796 (Print) IS - 0513-5796 (Linking) VI - 61 IP - 1 DP - 2020 Jan TI - Follistatin Mitigates Myofibroblast Differentiation and Collagen Synthesis of Fibroblasts from Scar Tissue around Injured Flexor Tendons. PG - 85-93 LID - 10.3349/ymj.2020.61.1.85 [doi] AB - PURPOSE: The aim of this study was to investigate the effect of FST gene on the inhibition of fibrosis in fibroblastic cells from scar tissue around repaired zone II flexor tendons. MATERIALS AND METHODS: Immunohistochemistry was conducted on fibroblast cells transfected with adenovirus-LacZ (Ad-LacZ) as a marker gene (control), or with adenovirus-FST (Ad-FST) as a therapeutic gene. Fibroblast cultures without adenoviral exposure served as controls. RESULTS: Fibroblastic cells transfected with Ad-FST demonstrated significant decrease in collagen type I, MMP-1, MMP2, and α-SMA mRNA expressions compared to those transfected with Ad-LacZ. In addition, fibroblastic cells transfected with Ad-FST exhibited significant decrease in MMP-1, TIMP-1, fibronectin, PAI-1, TRPV4, α-SMA, desmin, and PAX7 protein expressions. CONCLUSION: Based on these findings, we conclude that FST may be a novel therapeutic strategy for preventing scar adhesions around repaired tendons by inhibiting fibroblasts from differentiating into myofibroblasts, in addition to producing type I collagen and regulating extracellular matrix turnover via the downregulation of MMP-1 and TIMP-1. FST may also decrease contracture of the scar by inhibiting Ca2+-dependent cell contraction. CI - © Copyright: Yonsei University College of Medicine 2020. FAU - Kang, Young Mi AU - Kang YM AUID- ORCID: 0000-0002-7686-6316 AD - BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. AD - BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. FAU - Lee, Su Keon AU - Lee SK AUID- ORCID: 0000-0003-3524-6345 AD - BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. FAU - Chun, Yong Min AU - Chun YM AUID- ORCID: 0000-0002-8147-6136 AD - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea. FAU - Choi, Yun Rak AU - Choi YR AUID- ORCID: 0000-0001-5197-3716 AD - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea. YRCHOI@yuhs.ac. FAU - Moon, Seong Hwan AU - Moon SH AUID- ORCID: 0000-0003-1121-2730 AD - BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. AD - BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea. FAU - Lee, Hwan Mo AU - Lee HM AUID- ORCID: 0000-0002-5405-3832 AD - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea. FAU - Kang, Ho Jung AU - Kang HJ AUID- ORCID: 0000-0003-0273-1264 AD - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea. LA - eng PT - Journal Article PL - Korea (South) TA - Yonsei Med J JT - Yonsei medical journal JID - 0414003 RN - 0 (ACTA2 protein, human) RN - 0 (Actins) RN - 0 (Collagen Type I) RN - 0 (Desmin) RN - 0 (FN1 protein, human) RN - 0 (Fibronectins) RN - 0 (Follistatin) RN - 0 (PAX7 Transcription Factor) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (RNA, Messenger) RN - 0 (SERPINE1 protein, human) RN - 0 (TRPV Cation Channels) RN - 0 (TRPV4 protein, human) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Actins/metabolism MH - Animals MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - Cicatrix/*metabolism/*pathology MH - Collagen Type I/*biosynthesis MH - Desmin/metabolism MH - Female MH - Fibroblasts/*metabolism MH - Fibronectins/genetics/metabolism MH - Fibrosis MH - Follistatin/*metabolism MH - Gene Expression Regulation MH - Humans MH - Matrix Metalloproteinase 1/genetics/metabolism MH - Matrix Metalloproteinase 2/genetics/metabolism MH - Myofibroblasts/*pathology MH - PAX7 Transcription Factor/genetics/metabolism MH - Plasminogen Activator Inhibitor 1/genetics/metabolism MH - RNA, Messenger/genetics/metabolism MH - TRPV Cation Channels/genetics/metabolism MH - Tendon Injuries/*pathology MH - Tendons/pathology PMC - PMC6938778 OTO - NOTNLM OT - Follistatin OT - fibrosis OT - gene therapy OT - tendon adhesion OT - tendon injuries COIS- The authors have no potential conflicts of interest to disclose. EDAT- 2019/12/31 06:00 MHDA- 2020/03/17 06:00 PMCR- 2020/01/01 CRDT- 2019/12/31 06:00 PHST- 2019/08/14 00:00 [received] PHST- 2019/10/03 00:00 [revised] PHST- 2019/10/07 00:00 [accepted] PHST- 2019/12/31 06:00 [entrez] PHST- 2019/12/31 06:00 [pubmed] PHST- 2020/03/17 06:00 [medline] PHST- 2020/01/01 00:00 [pmc-release] AID - 61.85 [pii] AID - 10.3349/ymj.2020.61.1.85 [doi] PST - ppublish SO - Yonsei Med J. 2020 Jan;61(1):85-93. doi: 10.3349/ymj.2020.61.1.85. PMID- 18681276 OWN - NLM STAT- MEDLINE DCOM- 20090612 LR - 20221207 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 22 IP - 7 DP - 2008 Jul TI - [Effects of 5-fluorouracil on tendon adhesion formation after flexor tendon repair]. PG - 794-6 AB - OBJECTIVE: To evaluate the effect of 5-fluorouracil (5-FU) applied topically on preventing adhesion and promoting functional recovery after tendon repair. METHODS: From August 2003 to June 2007, 48 patients with flexor tendon rupture of the fingers by sharp instrument were treated and randomly divided into two groups. In 5-FU group, 39 fingers of 26 patients included 17 males and 9 females, aged (29.3 +/- 9.8) years; the locations were zone I in 19 fingers and zone II in 20 fingers; single finger was involved in 12 cases and more than 2 fingers were involved in 14 cases; and the time from injury to operation was (2.4 +/- 1.6) hours. In control group, 36 fingers of 22 patients included 14 males and 8 females; aged (26.1 +/- 8.7) years; the locations were zone I in 16 fingers and zone II in 20 fingers; single finger was involved in 10 cases and more than 2 fingers were involved in 12 cases; and the time from injury to operation was (2.1 +/- 1.8) hours. No statistically significant difference was found in constituent ratio of age, gender, injured fingers and their zones, between two groups (P > 0.05). The repair site in 5-FU group was given 5-FU at a concentration of 25 mg/mL with a soaked sponge, and the synovial sheath of the repaired site was wrapped with the 5-FU-soaked sponge for 1 minute for 4 times after the tendons were repaired; normal saline was used in the control group. RESULTS: Wound healed by first intention and no infection and tendon rupture occurred in two groups. The patients were followed up for 3-8 months (mean 4.1 months) and 3-8 months (mean 3.9 months) in 5-FU group and in control group respectively. The functional recovery degrees of the fingers were evaluated with total active movement (TAM) evaluation system. In 5-FU group, the results were excellent in 22 fingers, good in 13 fingers, fair in 3 fingers and poor in 1 finger; the excellent and good rate was 89.7%. In control group, the results were excellent in 11 fingers, good in 15 fingers, fair in 9 fingers and poor in 1 finger; the excellent and good rate was 72.2%. There was statistically significant difference in the functional recovery degrees of fingers between two groups (P < 0.05). The 2 fingers which had a poor result in 5-FU group and control group were served with tenolysis was performed in 2 cases having poor results after 6 months of operation and had an excellent result at last. CONCLUSION: 5-FU applied topically can reduce tendon adhesions after the ruptured tendon repair. FAU - Guo, Mingke AU - Guo M AD - Department of Orthopedics, the 260th Hospital of PLA, Shijiazhuang Hebei, 050041, PR China. FAU - Zhang, Jingqi AU - Zhang J FAU - Tian, Dehu AU - Tian D FAU - Zhang, Yingze AU - Zhang Y FAU - Peng, Xiuqing AU - Peng X FAU - Wang, Zhou AU - Wang Z FAU - Wu, Jun AU - Wu J FAU - Duan, Yafei AU - Duan Y FAU - Dou, Zhip AU - Dou Z FAU - Wang, Cuihua AU - Wang C LA - chi PT - English Abstract PT - Journal Article PT - Randomized Controlled Trial PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - U3P01618RT (Fluorouracil) SB - IM MH - Adult MH - Female MH - Finger Injuries/*surgery MH - Fluorouracil/*therapeutic use MH - Humans MH - Male MH - Plastic Surgery Procedures/methods MH - Tendon Injuries/*surgery MH - Tendons/pathology/surgery MH - Tissue Adhesions/*prevention & control MH - Wound Healing EDAT- 2008/08/07 09:00 MHDA- 2009/06/13 09:00 CRDT- 2008/08/07 09:00 PHST- 2008/08/07 09:00 [pubmed] PHST- 2009/06/13 09:00 [medline] PHST- 2008/08/07 09:00 [entrez] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008 Jul;22(7):794-6. PMID- 15585229 OWN - NLM STAT- MEDLINE DCOM- 20050607 LR - 20191210 IS - 0142-9612 (Print) IS - 0142-9612 (Linking) VI - 26 IP - 15 DP - 2005 May TI - Immobilization of laminin peptide in molecularly aligned chitosan by covalent bonding. PG - 2273-9 AB - We developed a new biomaterial effective for nerve regeneration consisting of molecularly aligned chitosan with laminin peptides bonded covalently. Molecularly aligned chitosan was prepared from crab (Macrocheira kaempferi) tendons by ethanol treatment and 4 wt%-NaOH aqueous solutions to remove proteins and calcium phosphate, followed by deacetyl treatment using a 50 wt%-NaOH aqueous solution at 100 degrees C. Molecularly aligned tendon chitosan was chemically thiolated by reacting 4-thiobutyrolactone with the chitosan amino group. The introduction of thiol groups and their distribution to tendon chitosan and chitosan cast film were confirmed using ATR FT-IR, (1)H-NMR, and EDS. The 1.24 micromol/g of thiol groups introduced on the surface of tendon chitosan and the chitosan cast film was confirmed using ultraviolet (UV) spectra. Thiol groups of cysteine located at the end of synthetic laminin peptides were then reacted chemically with thiolated chitosan to form chitosan-S-S-laminin peptide. YIGSR estimated at 0.92 micromol/g and IKVAV estimated at 0.28 micromol/g on thiolated tendon chitosan were confirmed using UV spectra. YIGSR was estimated at 0.85 micromol/g and IKVAV was estimated at 0.34 micromol/g on the thiolated chitosan cast film. FAU - Matsuda, Atsushi AU - Matsuda A AD - Biomaterials Research Center, National Institute for Materials Science, 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan. matsuda.atsushi@nims.go.jp FAU - Kobayashi, Hisatoshi AU - Kobayashi H FAU - Itoh, Soichiro AU - Itoh S FAU - Kataoka, Kazunori AU - Kataoka K FAU - Tanaka, Junzo AU - Tanaka J LA - eng PT - Comparative Study PT - Evaluation Study PT - Journal Article PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Laminin) RN - 0 (Oligopeptides) RN - 0 (Peptide Fragments) RN - 110590-64-2 (tyrosyl-isoleucyl-glycyl-seryl-arginine) RN - 131167-89-0 (isoleucyl-lysyl-valyl-alanyl-valine) RN - 9012-76-4 (Chitosan) SB - IM MH - Animals MH - Binding Sites MH - Brachyura MH - Chitosan/analysis/*chemistry MH - Coated Materials, Biocompatible/analysis/*chemistry MH - Laminin/*chemistry MH - Molecular Conformation MH - Oligopeptides/*chemistry MH - Peptide Fragments/*chemistry MH - Protein Binding MH - Surface Properties MH - Tendons/*chemistry EDAT- 2004/12/09 09:00 MHDA- 2005/06/09 09:00 CRDT- 2004/12/09 09:00 PHST- 2004/04/19 00:00 [received] PHST- 2004/07/20 00:00 [accepted] PHST- 2004/12/09 09:00 [pubmed] PHST- 2005/06/09 09:00 [medline] PHST- 2004/12/09 09:00 [entrez] AID - S0142-9612(04)00684-2 [pii] AID - 10.1016/j.biomaterials.2004.07.032 [doi] PST - ppublish SO - Biomaterials. 2005 May;26(15):2273-9. doi: 10.1016/j.biomaterials.2004.07.032. PMID- 28902861 OWN - NLM STAT- MEDLINE DCOM- 20171031 LR - 20181113 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 12 IP - 9 DP - 2017 TI - Epigenetic regulation of metalloproteinases and their inhibitors in rotator cuff tears. PG - e0184141 LID - 10.1371/journal.pone.0184141 [doi] LID - e0184141 AB - Rotator cuff tear is a common orthopedic condition. Metalloproteinases (MMP) and their inhibitors (TIMP) seem to play a role in the development of joint injuries and in the failure of tissue healing. However, the mechanisms of regulation of gene expression in tendons are still unknown. Epigenetic mechanisms, such as DNA methylation and microRNAs regulation, are involved in the dynamic control of gene expression. Here, the mRNA expression and DNA methylation status of MMPs (MMP1, MMP2, MMP3, MMP9, MMP13, and MMP14) and TIMPs (TIMP1-3) and the expression of miR-29 family members in ruptured supraspinatus tendons were compared with non-injured tendons of individuals without this lesion. Additionally, the gene expression and methylation status at the edge of the ruptured tendon were compared with macroscopically non-injured rotator cuff tendon samples from the anterior and posterior regions of patients with tendon tears. Moreover, the possible associations between the molecular alterations and the clinical and histologic characteristics were investigated. Dysregulated expression and DNA methylation of MMP and TIMP genes were found across the rotator cuff tendon samples of patients with supraspinatus tears. These alterations were influenced at least in part by age at surgery, sex, smoking habit, tear size, and duration of symptoms. Alterations in the studied MMP and TIMP genes may contribute to the presence of microcysts, fissures, necrosis, and neovascularization in tendons and may thus be involved in the tendon healing process. In conclusion, MMPs and their inhibitors are regulated by epigenetic modifications and may play a role in rotator cuff tears. FAU - Leal, Mariana Ferreira AU - Leal MF AUID- ORCID: 0000-0002-5949-1911 AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. AD - Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Caires Dos Santos, Leonardo AU - Caires Dos Santos L AD - Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Martins de Oliveira, Adrielle AU - Martins de Oliveira A AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. AD - Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Santoro Belangero, Paulo AU - Santoro Belangero P AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Antônio Figueiredo, Eduardo AU - Antônio Figueiredo E AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Cohen, Carina AU - Cohen C AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - de Seixas Alves, Felipe AU - de Seixas Alves F AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. AD - Departamento de Patologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Hiromi Yanaguizawa, Wânia AU - Hiromi Yanaguizawa W AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. AD - Departamento de Patologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Vicente Andreoli, Carlos AU - Vicente Andreoli C AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - de Castro Pochini, Alberto AU - de Castro Pochini A AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Ejnisman, Benno AU - Ejnisman B AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Cardoso Smith, Marília AU - Cardoso Smith M AD - Disciplina de Genética, Departamento de Morfologia e Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - de Seixas Alves, Maria Teresa AU - de Seixas Alves MT AD - Departamento de Patologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. FAU - Cohen, Moises AU - Cohen M AD - Departamento de Ortopedia e Traumatologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. LA - eng PT - Journal Article DEP - 20170913 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.- (Metalloproteases) SB - IM MH - Adult MH - Aged MH - Case-Control Studies MH - DNA Methylation MH - *Epigenesis, Genetic MH - Female MH - Gene Expression Regulation, Enzymologic MH - *Genes, Regulator MH - Humans MH - Male MH - Metalloproteases/*genetics MH - Middle Aged MH - Rotator Cuff Injuries/*genetics MH - Tissue Inhibitor of Metalloproteinases/*genetics PMC - PMC5597200 COIS- Competing Interests: The authors have declared that no competing interests exist. EDAT- 2017/09/14 06:00 MHDA- 2017/11/01 06:00 PMCR- 2017/09/13 CRDT- 2017/09/14 06:00 PHST- 2017/05/24 00:00 [received] PHST- 2017/08/18 00:00 [accepted] PHST- 2017/09/14 06:00 [entrez] PHST- 2017/09/14 06:00 [pubmed] PHST- 2017/11/01 06:00 [medline] PHST- 2017/09/13 00:00 [pmc-release] AID - PONE-D-17-19989 [pii] AID - 10.1371/journal.pone.0184141 [doi] PST - epublish SO - PLoS One. 2017 Sep 13;12(9):e0184141. doi: 10.1371/journal.pone.0184141. eCollection 2017. PMID- 24762232 OWN - NLM STAT- MEDLINE DCOM- 20150915 LR - 20250728 IS - 1938-162X (Electronic) IS - 1062-6050 (Print) IS - 1062-6050 (Linking) VI - 49 IP - 3 DP - 2014 May-Jun TI - Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. PG - 422-7 LID - 10.4085/1062-6050-49.2.09 [doi] AB - CONTEXT: Fluoroquinolone antibiotics have been used for several decades and are effective antimicrobials. Despite their usefulness as antibiotics, a growing body of evidence has accumulated in the peer-reviewed literature that shows fluoroquinolones can cause pathologic lesions in tendon tissue (tendinopathy). These adverse effects can occur within hours of commencing treatment and months after discontinuing the use of these drugs. In some cases, fluoroquinolone usage can lead to complete rupture of the tendon and substantial subsequent disability. OBJECTIVE: To discuss the cause, pharmacology, symptoms, and epidemiology of fluoroquinolone-associated tendinopathy and to discuss the clinical implications with respect to athletes and their subsequent physiotherapy. DATA SOURCES: We searched MEDLINE, Cumulative Index to Nursing and Allied Health (CINAHL), Allied and Complementary Medicine Database (AMED), and SPORTDiscus databases for available reports of fluoroquinolone-related tendinopathy (tendinitis, tendon pain, or rupture) published from 1966 to 2012. Search terms were fluoroquinolones or quinolones and tendinopathy, adverse effects, and tendon rupture. Included studies were written in or translated into English. Non-English-language and non-English translations of abstracts from reports were not included (n = 1). STUDY SELECTION: Eligible studies were any available reports of fluoroquinolone-related tendinopathy (tendinitis, tendon pain, or rupture). Both animal and human histologic studies were included. Any papers not focusing on the tendon-related side effects of fluoroquinolones were excluded (n = 71). DATA EXTRACTION: Data collected included any cases of fluoroquinolone-related tendinopathy, the particular tendon affected, type of fluoroquinolone, dosage, and concomitant risk factors. Any data outlining the adverse histologic effects of fluoroquinolones also were collected. DATA SYNTHESIS: A total of 175 papers, including 89 case reports and 8 literature reviews, were identified. CONCLUSIONS: Fluoroquinolone tendinopathy may not respond well to the current popular eccentric training regimes and may require an alternative, staged treatment approach. Clinicians, athletes, athletic trainers, and their medical support teams should be aware of the need to discuss and possibly discontinue these antibiotics if adverse effects arise. FAU - Lewis, Trevor AU - Lewis T AD - Physiotherapy Department, Aintree University Hospital National Health Service Foundation Trust, University Hospital Aintree, Liverpool, United Kingdom. FAU - Cook, Jill AU - Cook J LA - eng PT - Journal Article PT - Systematic Review DEP - 20140424 PL - United States TA - J Athl Train JT - Journal of athletic training JID - 9301647 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Animals MH - Anti-Bacterial Agents/*adverse effects MH - Athletic Injuries/*chemically induced/diagnosis/*epidemiology/rehabilitation MH - Fluoroquinolones/*adverse effects MH - Humans MH - Risk Factors MH - Tendinopathy/*chemically induced/diagnosis/*epidemiology/rehabilitation MH - Tendons/drug effects/physiopathology MH - Weight-Bearing PMC - PMC4080593 OTO - NOTNLM OT - adverse effects OT - tendinitis OT - tendon rupture EDAT- 2014/04/26 06:00 MHDA- 2015/09/16 06:00 PMCR- 2015/05/01 CRDT- 2014/04/26 06:00 PHST- 2014/04/26 06:00 [entrez] PHST- 2014/04/26 06:00 [pubmed] PHST- 2015/09/16 06:00 [medline] PHST- 2015/05/01 00:00 [pmc-release] AID - 10.4085/1062-6050-49.2.09 [doi] PST - ppublish SO - J Athl Train. 2014 May-Jun;49(3):422-7. doi: 10.4085/1062-6050-49.2.09. Epub 2014 Apr 24. PMID- 27383874 OWN - NLM STAT- MEDLINE DCOM- 20170103 LR - 20200103 IS - 0204-8043 (Print) IS - 0204-8043 (Linking) VI - 58 IP - 1 DP - 2016 Mar 1 TI - A Prospectus of Tenomodulin. PG - 19-27 LID - /j/folmed.2016.58.issue-1/folmed-2016-0003/folmed-2016-0003.xml [pii] LID - 10.1515/folmed-2016-0003 [doi] AB - Tenomodulin is a type II transmembrane glycoprotein that can regulate growth of tendon. The human tenomodulin encoding gene is mapped to Х chromosome and encodes a polypeptide consisting of 317 alpha amino acids. The protein is located on the cell surface as N-glycosylated or non-N-glycosylated polypeptide with molecular mass of 45 and 40 kDa, respectively. The molecule consists of three domains and a short cytoplasmic tail at N-terminus. Tenomodulin is predominantly expressed in dense connective hypovascularized tissues such as tendons, skeletal muscle epimysium, and ligaments. Furthermore, tenomodulin is an efficient marker of tenocyte differentiation and plays an important role in the regulation of tenocyte proliferation, tendon development, and angiogenesis inhibition. A number of tenomodulin gene polymorphisms have been recently associated with a risk of obesity, diabetes, systemic immune mediators, cholesterol levels, Alzheimer disease, and age-related macular degeneration. Tenomodulin is involved in cell adhesion, determination of cell morphology, cell aging and bone mineral density. It is expected to play an important role in tendon recovery, tendon tissue engineering, anti-tumor therapy, treatment of chordal disruption, and remodeling of extracellular matrix. FAU - Alexandrov, Vesselin P AU - Alexandrov VP AD - Department of Medical Biology, Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria FAU - Naimov, Samir I AU - Naimov SI AD - Department of Plant Physiology and Molecular Biology, Paisii Hilendaski University, Plovdiv, Bulgaria LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - Bulgaria TA - Folia Med (Plovdiv) JT - Folia medica JID - 2984761R RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Membrane Proteins) RN - 0 (TNMD protein, human) RN - 136362-10-2 (CNMD protein, human) SB - IM MH - Alzheimer Disease/genetics MH - Cell Adhesion/*physiology MH - Cellular Senescence/*physiology MH - Diabetes Mellitus/genetics MH - Dyslipidemias/genetics MH - Humans MH - Intercellular Signaling Peptides and Proteins MH - Ligaments/metabolism MH - Macular Degeneration/genetics MH - Membrane Proteins/genetics/metabolism/*physiology MH - Muscle, Skeletal/metabolism MH - Obesity/genetics MH - Tendons/metabolism EDAT- 2016/07/08 06:00 MHDA- 2017/01/04 06:00 CRDT- 2016/07/08 06:00 PHST- 2015/07/21 00:00 [received] PHST- 2016/04/15 00:00 [accepted] PHST- 2016/07/08 06:00 [entrez] PHST- 2016/07/08 06:00 [pubmed] PHST- 2017/01/04 06:00 [medline] AID - /j/folmed.2016.58.issue-1/folmed-2016-0003/folmed-2016-0003.xml [pii] AID - 10.1515/folmed-2016-0003 [doi] PST - ppublish SO - Folia Med (Plovdiv). 2016 Mar 1;58(1):19-27. doi: 10.1515/folmed-2016-0003. PMID- 21967573 OWN - NLM STAT- MEDLINE DCOM- 20120214 LR - 20211020 IS - 1470-8728 (Electronic) IS - 0264-6021 (Print) IS - 0264-6021 (Linking) VI - 441 IP - 2 DP - 2012 Jan 15 TI - Stepwise proteolytic activation of type I procollagen to collagen within the secretory pathway of tendon fibroblasts in situ. PG - 707-17 LID - 10.1042/BJ20111379 [doi] AB - Proteolytic cleavage of procollagen I to collagen I is essential for the formation of collagen fibrils in the extracellular matrix of vertebrate tissues. Procollagen is cleaved by the procollagen N- and C-proteinases, which remove the respective N- and C-propeptides from procollagen. Procollagen processing is initiated within the secretory pathway in tendon fibroblasts, which are adept in assembling an ordered extracellular matrix of collagen fibrils in vivo. It was thought that intracellular processing was restricted to the TGN (trans-Golgi network). In the present study, brefeldin A treatment of tendon explant cultures showed that N-proteinase activity is present in the resulting fused ER (endoplasmic reticulum)-Golgi compartment, but that C-proteinase activity is restricted to the TGN in embryonic chick tendon fibroblasts. In late embryonic and postnatal rat tail and postnatal mouse tail tendon, C-proteinase activity was detected in TGN and pre-TGN compartments. Preventing activation of the procollagen N- and C-proteinases with the furin inhibitor Dec-RVKR-CMK (decanoyl-Arg-Val-Lys-Arg-chloromethylketone) indicated that only a fraction of intracellular procollagen cleavage was mediated by newly activated proteinases. In conclusion, the N-propeptides are removed earlier in the secretory pathway than the C-propeptides. The removal of the C-propeptides in post-Golgi compartments most probably indicates preparation of collagen molecules for fibril formation at the cell-matrix interface. FAU - Canty-Laird, Elizabeth G AU - Canty-Laird EG AD - Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, University of Liverpool, Leahurst Campus, Chester High Road, Neston CH64 7TE, UK. FAU - Lu, Yinhui AU - Lu Y FAU - Kadler, Karl E AU - Kadler KE LA - eng GR - Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Amino Acid Chloromethyl Ketones) RN - 0 (Collagen Type I) RN - 0 (decanoylRVKRchloromethylketone) RN - 20350-15-6 (Brefeldin A) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.14 (Procollagen N-Endopeptidase) RN - EC 3.4.24.19 (Bmp1 protein, mouse) RN - EC 3.4.24.19 (Bone Morphogenetic Protein 1) SB - IM MH - Amino Acid Chloromethyl Ketones/pharmacology MH - Animals MH - Bone Morphogenetic Protein 1/*metabolism MH - Brefeldin A MH - Chick Embryo MH - Collagen/*biosynthesis MH - Collagen Type I/*metabolism MH - Enzyme Activation/drug effects MH - Fibroblasts/enzymology MH - Mice MH - Procollagen N-Endopeptidase/*metabolism MH - Rats MH - Secretory Pathway/*physiology MH - Tendons/drug effects/embryology MH - trans-Golgi Network/enzymology PMC - PMC3430002 EDAT- 2011/10/05 06:00 MHDA- 2012/02/15 06:00 PMCR- 2011/12/21 CRDT- 2011/10/05 06:00 PHST- 2011/10/05 06:00 [entrez] PHST- 2011/10/05 06:00 [pubmed] PHST- 2012/02/15 06:00 [medline] PHST- 2011/12/21 00:00 [pmc-release] AID - BJ20111379 [pii] AID - 10.1042/BJ20111379 [doi] PST - ppublish SO - Biochem J. 2012 Jan 15;441(2):707-17. doi: 10.1042/BJ20111379. PMID- 18665569 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20220330 IS - 0963-8288 (Print) IS - 0963-8288 (Linking) VI - 30 IP - 20-22 DP - 2008 TI - The effect of stress-deprivation and cyclic loading on the TIMP/MMP ratio in tendon cells: an in vitro experimental study. PG - 1523-9 LID - 10.1080/09638280701785395 [doi] AB - PURPOSE: To determine the effect of stress deprivation and cyclic loading on TIMP-1/MMP-13 mRNA expression ratio in rat tail tendon (RTT) cells. METHOD: Adult RTTs were stress-deprived for 0, 24, 48, or 72 hours in the presence or absence of a MMP inhibitor (ilomastat), or subjected to 1%, 3%, or 6% strain for 24 h under tissue culture conditions. TIMP-1 and MMP-13 (rat interstitial collagenase) mRNA expression were measured using quantitative PCR and TIMP/MMP ratios were calculated for each group. RESULTS: The ratio of TIMP-1 to MMP-13 in control RTTs was 3.73:1 +/- 0.73. Stress deprivation for 24 h significantly decreased the TIMP-1/MMP-13 ratio (0.25:1 +/- 0.04) and MMP-13 expression continued to increase significantly with time of stress deprivation. Inhibition of MMP-13 mRNA expression with ilomastat in stress-deprived samples did not alter TIMP-1 expression when compared to normal controls. Cyclic loading significantly increased TIMP-1/MMP-13 expression at all strain levels examined. CONCLUSIONS: RTTs normally have a positive TIMP-1/MMP-13 expression ratio. While cyclic loading increased the TIMP-1/MMP-13 ratio, loss of cellular homeostatic tension inversed this ratio through a significant increase in MMP-13 mRNA expression rather than a decrease in TIMP expression. A negative TIMP/MMP ratio has been implicated in the pathogenesis of tendinopathy. Increasing the TIMP/MMP ratios in these patients through exercise may be beneficial in the management of tendinopathy. FAU - Gardner, Keri AU - Gardner K AD - The Laboratory for Comparative Orthopaedic Research, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. FAU - Arnoczky, Steven P AU - Arnoczky SP FAU - Caballero, Oscar AU - Caballero O FAU - Lavagnino, Michael AU - Lavagnino M LA - eng PT - Journal Article PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 RN - 0 (Hydroxamic Acids) RN - 0 (Indoles) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - I0403ML141 (ilomastat) SB - IM MH - Animals MH - Hydroxamic Acids MH - In Vitro Techniques MH - Indoles/pharmacology MH - Matrix Metalloproteinase 13/*metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - *Stress, Physiological MH - Tendons/cytology/*metabolism MH - Time Factors MH - Tissue Inhibitor of Metalloproteinase-1/*metabolism MH - *Weight-Bearing EDAT- 2008/07/31 09:00 MHDA- 2009/02/12 09:00 CRDT- 2008/07/31 09:00 PHST- 2008/07/31 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] PHST- 2008/07/31 09:00 [entrez] AID - 795396214 [pii] AID - 10.1080/09638280701785395 [doi] PST - ppublish SO - Disabil Rehabil. 2008;30(20-22):1523-9. doi: 10.1080/09638280701785395. PMID- 12160227 OWN - NLM STAT- MEDLINE DCOM- 20020830 LR - 20151119 IS - 1342-8810 (Print) IS - 1342-8810 (Linking) VI - 49 IP - 1 DP - 2002 Mar TI - Gene expression of bone matrix proteins in a calcified tissue appeared in subcutaneously transplanted rat dental pulp. PG - 57-66 AB - Dental pulp self-mineralizes or induces calcified tissue formation, when it is subcutaneously transplanted. This study aims to clarify the nature and process of this tissue calcification by using histochemical techniques and in situ hybridization methods. The dental pulps of incisors from Sprague-Dawley strain rats were homogeneously transplanted into the subcutaneous tissue of the head of another rat. On the 1st day of transplantation, the mRNAs of type I collagen (COL I) and bone sialoprotein (BSP) were expressed in the transplant. On the 5th to 7th days after transplantation, von Kossa-positive, calcified tissues appeared in the transplanted tissues. The mRNAs of COL I, BSP and osteopontin (OPN) were expressed with the same distributions as those of the von Kossa-positive areas, but those of type II collagen (COL II) and bone morphogenic protein 2 (BMP-2) were not expressed in the transplant. When the cellular incorporation of BrdU was examined after its subcutaneous injection into the animals, positive cells were present in the von Kossa-positive calcified foci as well as in their surrounding areas. These results indicate that the transplanted dental pulp possesses the ability to induce cell proliferation resulting in the synthesis of several bone matrix proteins and the formation of calcified tissue. This may give us an insight into the nature and processes of pulp obliteration, which occurs in a human tooth following an episode of trauma. FAU - Yamazoe, Tomohiro AU - Yamazoe T AD - Department of Orofacial Development and Function, Graduate School, Tokyo Medical and Dental University, Japan. FAU - Aoki, Kazuhiro AU - Aoki K FAU - Simokawa, Hitoyata AU - Simokawa H FAU - Ohya, Keiichi AU - Ohya K FAU - Takagi, Yuzo AU - Takagi Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Japan TA - J Med Dent Sci JT - Journal of medical and dental sciences JID - 9717112 RN - 0 (Antimetabolites) RN - 0 (BMP2 protein, human) RN - 0 (Bmp2 protein, rat) RN - 0 (Bone Morphogenetic Protein 2) RN - 0 (Bone Morphogenetic Proteins) RN - 0 (Collagen Type I) RN - 0 (Collagen Type II) RN - 0 (IBSP protein, human) RN - 0 (Ibsp protein, rat) RN - 0 (Integrin-Binding Sialoprotein) RN - 0 (Phosphoproteins) RN - 0 (RNA, Messenger) RN - 0 (SPP1 protein, human) RN - 0 (Sialoglycoproteins) RN - 0 (Spp1 protein, rat) RN - 0 (Transforming Growth Factor beta) RN - 106441-73-0 (Osteopontin) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Animals MH - Antimetabolites MH - Aorta/metabolism/transplantation MH - Bone Morphogenetic Protein 2 MH - Bone Morphogenetic Proteins/analysis/genetics MH - Bromodeoxyuridine MH - Cell Division MH - Collagen Type I/*analysis/genetics MH - Collagen Type II/analysis/genetics MH - Dental Pulp/metabolism/*transplantation MH - Dental Pulp Calcification/*metabolism MH - Dermatologic Surgical Procedures MH - Gene Expression MH - Histocytochemistry MH - In Situ Hybridization MH - Integrin-Binding Sialoprotein MH - Mouth Mucosa/metabolism/transplantation MH - Osteopontin MH - Phosphoproteins/*analysis/genetics MH - RNA, Messenger/analysis/genetics MH - Rats MH - Rats, Sprague-Dawley MH - Sialoglycoproteins/*analysis/genetics MH - Silver Staining MH - Tendons/metabolism/transplantation MH - Transforming Growth Factor beta/analysis/genetics EDAT- 2002/08/06 10:00 MHDA- 2002/08/31 10:01 CRDT- 2002/08/06 10:00 PHST- 2002/08/06 10:00 [pubmed] PHST- 2002/08/31 10:01 [medline] PHST- 2002/08/06 10:00 [entrez] PST - ppublish SO - J Med Dent Sci. 2002 Mar;49(1):57-66. PMID- 37462644 OWN - NLM STAT- MEDLINE DCOM- 20230721 LR - 20230727 IS - 2687-4792 (Electronic) IS - 2687-4784 (Print) IS - 2687-4792 (Linking) VI - 34 IP - 2 DP - 2023 May 12 TI - Can pirfenidone prevent tendon adhesions? An experimental study in rats. PG - 396-404 LID - jdrs.2023.1012 [pii] LID - 10.52312/jdrs.2023.1012 [doi] AB - OBJECTIVES: In this experimental study, we aimed to investigate the effectiveness of oral pirfenidone (PFD) treatment on preventing tendon adhesion and tendon healing in rats. MATERIALS AND METHODS: A total of 21 rats were assigned into three groups including seven rats in each group. In Group 1 (sham group), no surgical procedure was performed. In Group 2 (control group), tendon repair was performed following right achillotomy. In Group 3 (treatment group), the rats also underwent tendon repair after right achillotomy. Additionally, 30 mg/kg of oral PFD was initiated from the postoperative Day 1 and administered via gavage for 28 days. At the end of the study, tendon healing and fibrosis levels in the tendon repair site were compared macroscopically, histopathologically, and immunohistochemically among the groups. RESULTS: Macroscopically, moderate and severe adhesions were observed in four and three rats, respectively in the control group, while no adhesion was found in four rats and filmy adhesions were observed in three rats in the treatment group (p<0.01). Microscopically, there was moderate adhesions in three rats and severe adhesions in four rats in the control group, while three rats had no adhesions and four rats had slight adhesions in the treatment group (p<0.01). Microscopically, tendon healing was good in six rats and fair in one rat in the control group, while five rats showed excellent tendon healing and two rats showed good tendon healing in the treatment group (p<0.01). Immunohistochemically, expressions of collagen I (p<0.01), collagen III (p<0.001), vascular endothelial growth factor (VEGF) (p<0.001), and proliferating cell nuclear antigen (PCNA) (p<0.001) significantly decreased in the treatment group compared to the control group. CONCLUSION: Our study results indicated that PFD decreased collagen synthesis and prevented the formation of peritendinous adhesion in rats; however, it did not impair tendon healing. FAU - Türközü, Tülin AU - Türközü T AD - Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi, Ortopedi ve Travmatoloji Anabilim Dalı, 65080 Van, Türkiye. dktrtulin@gmail.com. FAU - Güven, Necip AU - Güven N FAU - Altindağ, Fikret AU - Altindağ F FAU - Tokyay, Abbas AU - Tokyay A FAU - Gökalp, M Ata AU - Gökalp MA FAU - Ismailov, Ulan AU - Ismailov U FAU - Uyumaz, M Ali AU - Uyumaz MA FAU - Akkol, Suna AU - Akkol S LA - eng PT - Journal Article DEP - 20230512 PL - Turkey TA - Jt Dis Relat Surg JT - Joint diseases and related surgery JID - 101764223 RN - D7NLD2JX7U (pirfenidone) RN - 0 (Vascular Endothelial Growth Factor A) RN - 9007-34-5 (Collagen) SB - IM MH - Rats MH - Animals MH - *Tendon Injuries/drug therapy/surgery MH - Vascular Endothelial Growth Factor A MH - Tendons/surgery/pathology MH - Collagen MH - Tissue Adhesions/prevention & control PMC - PMC10367178 COIS- Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. EDAT- 2023/07/18 13:10 MHDA- 2023/07/21 06:43 PMCR- 2023/05/12 CRDT- 2023/07/18 10:53 PHST- 2023/07/21 06:43 [medline] PHST- 2023/07/18 13:10 [pubmed] PHST- 2023/07/18 10:53 [entrez] PHST- 2023/05/12 00:00 [pmc-release] AID - jdrs.2023.1012 [pii] AID - 10.52312/jdrs.2023.1012 [doi] PST - epublish SO - Jt Dis Relat Surg. 2023 May 12;34(2):396-404. doi: 10.52312/jdrs.2023.1012. PMID- 26748903 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20240610 IS - 1552-4965 (Electronic) IS - 1549-3296 (Print) IS - 1549-3296 (Linking) VI - 104 IP - 5 DP - 2016 May TI - Tuning microenvironment modulus and biochemical composition promotes human mesenchymal stem cell tenogenic differentiation. PG - 1162-74 LID - 10.1002/jbm.a.35650 [doi] AB - Mesenchymal stem cells (MSCs) are promising for the regeneration of tendon and ligament tissues. Toward realizing this potential, microenvironment conditions are needed for promoting robust lineage-specific differentiation into tenocytes/ligament fibroblasts. Here, we utilized a statistical design of experiments approach to examine combinations of matrix modulus, composition, and soluble factors in human MSC tenogenic/ligamentogenic differentiation. Specifically, well-defined poly(ethylene glycol)-based hydrogels were synthesized using thiol-ene chemistry providing a bioinert base for probing cell response to extracellular matrix cues. Monomer concentrations were varied to achieve a range of matrix moduli (E ∼ 10-90 kPa), and different ratios of integrin-binding peptides were incorporated (GFOGER and RGDS for collagen and fibronectin, respectively), mimicking aspects of developing tendon/ligament tissue. A face-centered central composite response surface design was utilized to understand the contributions of these cues to human MSC differentiation in the presence of soluble factors identified to promote tenogenesis/ligamentogenesis (BMP-13 and ascorbic acid). Increasing modulus and collagen mimetic peptide content increased relevant gene expression and protein production or retention (scleraxis, collagen I, tenascin-C). These findings could inform the design of materials for tendon/ligament regeneration. More broadly, the design of experiments enabled efficient data acquisition and analysis, requiring fewer replicates than if each factor had been varied one at a time. This approach can be combined with other stimuli (for example, mechanical stimulation) toward a better mechanistic understanding of differentiation down these challenging lineages. CI - © 2016 Wiley Periodicals, Inc. FAU - Rehmann, Matthew S AU - Rehmann MS AD - Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716. FAU - Luna, Jesus I AU - Luna JI AD - Department of Dermatology, School of Medicine, University of California, Davis, California, 95816. FAU - Maverakis, Emanual AU - Maverakis E AD - Department of Dermatology, School of Medicine, University of California, Davis, California, 95816. FAU - Kloxin, April M AU - Kloxin AM AD - Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716. AD - Department of Materials Science and Engineering, University of Delaware, Newark, Delaware, 19716. LA - eng GR - T32 GM008550/GM/NIGMS NIH HHS/United States GR - T32GM008550/GM/NIGMS NIH HHS/United States GR - P20 GM103541/GM/NIGMS NIH HHS/United States GR - P20 GM104316/GM/NIGMS NIH HHS/United States GR - P20 RR016458/RR/NCRR NIH HHS/United States GR - P30 GM110758/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20160202 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Biocompatible Materials) RN - 0 (Hydrogels) RN - 0 (Oligopeptides) RN - 3WJQ0SDW1A (Polyethylene Glycols) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 9007-34-5 (Collagen) SB - IM MH - Adult MH - Biocompatible Materials/*chemistry MH - Biomimetic Materials/*chemistry MH - *Cell Differentiation MH - Cells, Cultured MH - Collagen/chemistry MH - Elastic Modulus MH - Female MH - Gene Expression MH - Humans MH - Hydrogels/*chemistry MH - Mesenchymal Stem Cells/*cytology/metabolism MH - Oligopeptides/chemistry MH - Polyethylene Glycols/chemistry MH - Regeneration MH - Tendons/*cytology/physiology MH - Tissue Engineering PMC - PMC5510610 MID - NIHMS774746 OTO - NOTNLM OT - cell microenvironment OT - design of experiments OT - hydrogel OT - mesenchymal stem cell OT - tendon EDAT- 2016/01/11 06:00 MHDA- 2016/12/15 06:00 PMCR- 2017/07/14 CRDT- 2016/01/11 06:00 PHST- 2015/09/21 00:00 [received] PHST- 2015/12/19 00:00 [revised] PHST- 2016/01/08 00:00 [accepted] PHST- 2016/01/11 06:00 [entrez] PHST- 2016/01/11 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] PHST- 2017/07/14 00:00 [pmc-release] AID - 10.1002/jbm.a.35650 [doi] PST - ppublish SO - J Biomed Mater Res A. 2016 May;104(5):1162-74. doi: 10.1002/jbm.a.35650. Epub 2016 Feb 2. PMID- 22370620 OWN - NLM STAT- MEDLINE DCOM- 20131210 LR - 20220318 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 28 IP - 2 DP - 2013 Feb TI - Effect of low-level laser therapy on healing of tenotomized Achilles tendon in streptozotocin-induced diabetic rats. PG - 399-405 LID - 10.1007/s10103-012-1074-7 [doi] AB - Diabetes mellitus (DM) is associated with musculoskeletal damage. Investigations have indicated that healing of the surgically tenotomized Achilles tendon was considerably augmented following low-level laser therapy (LLLT) in non-diabetic, healthy animals. The aim of the present study was to evaluate the effect of LLLT on the Achilles tendon healing in streptozotocin-induced diabetic (STZ-D) rats via a biomechanical evaluating method. Thirty-three rats were divided into non-diabetic (n = 18) and diabetic (n = 15) groups. DM was induced in the rats by injections of STZ. The right Achilles tendons of all rats were tenotomized 1 month after STZ injections. The two experimental groups (n = 6 for each group) of non-diabetic rats were irradiated with a helium-neon (He-Ne) laser at 2.9 and 11.5 J/cm(2) for ten consecutive days. The two experimental groups of diabetic rats (n = 5 for each group) were irradiated with a He-Ne laser at 2.9 and 4.3 J/cm(2) for ten consecutive days. The tendons were submitted to a tensiometric test. Significant improvements in the maximum stress (MS) values (Newton per square millimeter) were found following LLLT at 2.9 J/cm(2) in both the non-diabetic (p = 0.031) and diabetic (p = 0.019) experimental groups when compared with their control groups. LLLT at 2.9 J/cm(2) to the tenotomized Achilles tendons in the non-diabetic and diabetic rats significantly increased the strength and MS of repairing Achilles tendons in our study. FAU - Nouruzian, Mohsen AU - Nouruzian M AD - Department of Anatomical sciences and Biology, Medical Faculty, Shahid Beheshti University, MC, PO Box 19395/4719, Tehran, 1985717443, Iran. hamidrr2003@yahoo.com FAU - Alidoust, Morteza AU - Alidoust M FAU - Bayat, Mohammad AU - Bayat M FAU - Bayat, Mehernoush AU - Bayat M FAU - Akbari, Mohammad AU - Akbari M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120228 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 RN - 5W494URQ81 (Streptozocin) SB - IM MH - Achilles Tendon/injuries/physiology/*radiation effects/surgery MH - Animals MH - Biomechanical Phenomena MH - Diabetes Complications/physiopathology MH - Diabetes Mellitus, Experimental/*complications MH - Diabetes Mellitus, Type 1/complications MH - Lasers, Gas MH - Low-Level Light Therapy/instrumentation/*methods MH - Male MH - Rats MH - Rats, Wistar MH - Streptozocin MH - Tenotomy MH - Wound Healing/*radiation effects EDAT- 2012/03/01 06:00 MHDA- 2013/12/16 06:00 CRDT- 2012/02/29 06:00 PHST- 2011/10/13 00:00 [received] PHST- 2012/02/15 00:00 [accepted] PHST- 2012/02/29 06:00 [entrez] PHST- 2012/03/01 06:00 [pubmed] PHST- 2013/12/16 06:00 [medline] AID - 10.1007/s10103-012-1074-7 [doi] PST - ppublish SO - Lasers Med Sci. 2013 Feb;28(2):399-405. doi: 10.1007/s10103-012-1074-7. Epub 2012 Feb 28. PMID- 11195319 OWN - NLM STAT- MEDLINE DCOM- 20010329 LR - 20200205 IS - 1297-319X (Print) IS - 1297-319X (Linking) VI - 67 IP - 6 DP - 2000 TI - Remitting asymmetrical pitting oedema in systemic lupus erythematosus: two cases studied with magnetic resonance imaging. PG - 544-9 AB - To our knowledge, only three cases of remitting symmetrical pitting oedema in systemic lupus erythematosus have been reported so far. This is the first report of two patients with asymmetrical pitting oedema and systemic lupus erythematosus. The first patient presented two consecutive episodes of unilateral oedema. The first episode involved the distal part of the right lower extremity and remitted spontaneously while the second involved the volar region of the left wrist and distal half of the forearm and promptly responded to steroids. Magnetic resonance imaging of the left wrist and forearm showed tenosynovitis of the flexor tendons and subcutaneous oedema. The second patient instead developed a single episode of pitting oedema of the distal part of the right lower extremity that resolved spontaneously. Magnetic resonance imaging of the right ankle and foot showed subcutaneous oedema without involvement of the tendon sheaths or osteoarticular and ligamental structures. These two cases suggest that pitting oedema in systemic lupus erythematosus may occasionally be asymmetric and associated or not with tenosynovitis. FAU - Pittau, E AU - Pittau E AD - Department of Medical Sciences, University of Cagliari, Italy. FAU - Passiu, G AU - Passiu G FAU - Mathieu, A AU - Mathieu A LA - eng PT - Case Reports PT - Journal Article PL - France TA - Joint Bone Spine JT - Joint bone spine JID - 100938016 RN - 83HN0GTJ6D (Cyclosporine) RN - VB0R961HZT (Prednisone) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Ankle/pathology/physiopathology MH - Cyclosporine/administration & dosage MH - Disease Progression MH - Drug Therapy, Combination MH - Edema/drug therapy/*etiology/*pathology MH - Female MH - Functional Laterality/physiology MH - Humans MH - Lupus Erythematosus, Systemic/*complications MH - Magnetic Resonance Imaging MH - Methotrexate/administration & dosage MH - Prednisone/administration & dosage MH - Remission, Spontaneous MH - Treatment Outcome MH - Wrist/pathology/physiopathology EDAT- 2001/02/24 12:00 MHDA- 2001/04/03 10:01 CRDT- 2001/02/24 12:00 PHST- 2001/02/24 12:00 [pubmed] PHST- 2001/04/03 10:01 [medline] PHST- 2001/02/24 12:00 [entrez] AID - S1297-319X(00)00217-7 [pii] AID - 10.1016/s1297-319x(00)00217-7 [doi] PST - ppublish SO - Joint Bone Spine. 2000;67(6):544-9. doi: 10.1016/s1297-319x(00)00217-7. PMID- 6884855 OWN - NLM STAT- MEDLINE DCOM- 19831021 LR - 20191031 IS - 0072-968X (Print) IS - 0072-968X (Linking) VI - 15 IP - 2 DP - 1983 Jun TI - The fate of injected trigger fingers. PG - 218-20 AB - Patients who were scheduled for surgical release of their trigger fingers underwent an injection of the involved tendon sheath prior to surgery. In thirty-six patients the injection of methylene blue was undertaken in a proximal-distal direction and in forty-three the direction of the injection was reversed. The success rate of the injections was 61 per cent. in the proximal distal group and 37 per cent in the second group. There was no significant statistical difference with regard to age, but duration of the disorder and mode of injection regarding the different fingers did have statistical significance. FAU - Kamhin, M AU - Kamhin M FAU - Engel, J AU - Engel J FAU - Heim, M AU - Heim M LA - eng PT - Journal Article PL - England TA - Hand JT - The Hand JID - 0231601 RN - 0 (Adrenal Cortex Hormones) RN - T42P99266K (Methylene Blue) SB - IM MH - Adolescent MH - Adrenal Cortex Hormones/administration & dosage MH - Adult MH - Aged MH - Child MH - Child, Preschool MH - Fingers/*metabolism MH - Humans MH - Injections MH - *Methylene Blue MH - Middle Aged MH - Muscular Diseases/*drug therapy/metabolism MH - Tendons/*metabolism EDAT- 1983/06/01 00:00 MHDA- 1983/06/01 00:01 CRDT- 1983/06/01 00:00 PHST- 1983/06/01 00:00 [pubmed] PHST- 1983/06/01 00:01 [medline] PHST- 1983/06/01 00:00 [entrez] AID - 10.1016/s0072-968x(83)80018-7 [doi] PST - ppublish SO - Hand. 1983 Jun;15(2):218-20. doi: 10.1016/s0072-968x(83)80018-7. PMID- 24231477 OWN - NLM STAT- MEDLINE DCOM- 20140116 LR - 20220409 IS - 1319-2442 (Print) IS - 1319-2442 (Linking) VI - 24 IP - 6 DP - 2013 Nov TI - The relationship between the antioxidant system, oxidative stress and dialysis-related amyloidosis in hemodialysis patients. PG - 1157-64 LID - 10.4103/1319-2442.121272 [doi] AB - End-stage renal disease (ESRD) is associated with several complications that are partly due to excess amounts of reactive oxygen species and/or decreased antioxidant activity. Dialysis-related amyloidosis (DRA) has also been linked to increased oxidative stress. The aim of this study was to investigate the relationships between the antioxidant system, including superoxide dismutase (SOD), malonyldialdehyde (MDA), various biochemical parameters and shoulder amyloidosis, in hemodialysis patients. We studied 107 non-diabetic chronic dialysis patients. The SOD levels correlated with right and left biceps tendon thickness (r = -0.219, P = 0.048 and r = -0.236, P = 0.031, respectively), MDA (r = -0.429, P = 0.000) and albumin levels (r = -0.319, P = 0.001). MDA levels correlated with right and left biceps thickness (r = 0.291, P = 0.006 and r = 0.337, P = 0.001, respectively) and β2 microglobulin levels (r = 0.455, P = 0.000). We also identified the statistically significant relationships between MDA levels and supraspinatus tendon thickening (greater than 7 mm) and right and left biceps tendon thickness (P = 0.022, P = 0.040 and P = 0.005, respectively). Our data suggest the complex relationship between antioxidants and oxidative stress and further support the roles of oxidative stress and antioxidants in DRA. FAU - Celik, Gulperi AU - Celik G AD - Department of Internal Medicine, Division of Nephrology, Selcuk University, Selcuklu School of Medicine, Konya, Turkey. FAU - Capraz, Irfan AU - Capraz I FAU - Yontem, Mustafa AU - Yontem M FAU - Bilge, Murat AU - Bilge M FAU - Unaldi, Mustafa AU - Unaldi M FAU - Mehmetoglu, Idris AU - Mehmetoglu I LA - eng PT - Journal Article PL - Saudi Arabia TA - Saudi J Kidney Dis Transpl JT - Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia JID - 9436968 RN - 0 (Antioxidants) RN - 0 (beta 2-Microglobulin) RN - 4Y8F71G49Q (Malondialdehyde) RN - EC 1.15.1.1 (Superoxide Dismutase) SB - IM MH - Aged MH - Amyloidosis/etiology/*metabolism MH - Antioxidants/*metabolism MH - Female MH - Humans MH - Male MH - Malondialdehyde/metabolism MH - Middle Aged MH - Oxidative Stress/*physiology MH - *Renal Dialysis/adverse effects MH - Superoxide Dismutase/metabolism MH - Tendons/pathology MH - beta 2-Microglobulin/metabolism EDAT- 2013/11/16 06:00 MHDA- 2014/01/17 06:00 CRDT- 2013/11/16 06:00 PHST- 2013/11/16 06:00 [entrez] PHST- 2013/11/16 06:00 [pubmed] PHST- 2014/01/17 06:00 [medline] AID - SaudiJKidneyDisTranspl_2013_24_6_1157_121272 [pii] AID - 10.4103/1319-2442.121272 [doi] PST - ppublish SO - Saudi J Kidney Dis Transpl. 2013 Nov;24(6):1157-64. doi: 10.4103/1319-2442.121272. PMID- 7603089 OWN - NLM STAT- MEDLINE DCOM- 19950810 LR - 20190830 IS - 0047-6374 (Print) IS - 0047-6374 (Linking) VI - 78 IP - 1 DP - 1995 Jan 31 TI - The effect of neonatal pinealectomy on the inhibitory actions of food restriction on vaginal opening and collagen aging in the rat. PG - 39-45 AB - Long-term food restriction is known to inhibit development and aging in the rat. These actions may be mediated by the pineal hormone, melatonin, whose secretion is increased by food restriction. This mechanism was investigated by studying the effects of pinealectomy in ad libitum fed and food restricted rats of both sexes living under normal conditions of temperature (23 degrees C) and lighting 12 h light:12 h dark cycle) over a period of 400 days. Pinealectomies were performed at the age of 5 days. Pinealectomy did not affect the amount of food eaten per day. Vaginal opening occurred at age 35 days in ad libitum fed female rats and was delayed to 49 days (P < 0.001) in rats whose food intake was restricted by 35%, but only to 41 days (P < 0.001) if food restricted (FR) rats were pinealectomized (Px). The inhibitory effect of food restriction on body growth and tail tendon collagen fibre aging was the same in both intact and pinealectomized rats. At the conclusion of the study in middle age at 400 days, plasma melatonin levels 4 h into the dark cycle were higher in food restricted than in ad libitum fed rats (P = 0.015). This study provides evidence for a role of the pineal in mediating the inhibitory action of food restriction on vaginal opening, but not on body growth or collagen aging in tail tendon up to middle age. FAU - Everitt, A V AU - Everitt AV AD - School of Biological Sciences, Macquarie University, Sydney, NSW, Australia. FAU - Destefanis, P AU - Destefanis P FAU - Parkes, A A AU - Parkes AA FAU - Cairncross, K D AU - Cairncross KD FAU - Eyland, A AU - Eyland A LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Ireland TA - Mech Ageing Dev JT - Mechanisms of ageing and development JID - 0347227 RN - 9007-34-5 (Collagen) RN - JL5DK93RCL (Melatonin) SB - IM MH - Aging/*physiology MH - Analysis of Variance MH - Animals MH - Collagen/*physiology MH - Female MH - Food Deprivation/*physiology MH - Male MH - Melatonin/blood MH - Pineal Gland/*surgery MH - Rats MH - Rats, Wistar MH - Tail/physiology MH - Tendons/physiology MH - Vagina/*physiology EDAT- 1995/01/31 00:00 MHDA- 1995/01/31 00:01 CRDT- 1995/01/31 00:00 PHST- 1995/01/31 00:00 [pubmed] PHST- 1995/01/31 00:01 [medline] PHST- 1995/01/31 00:00 [entrez] AID - 004763749401514M [pii] AID - 10.1016/0047-6374(94)01514-m [doi] PST - ppublish SO - Mech Ageing Dev. 1995 Jan 31;78(1):39-45. doi: 10.1016/0047-6374(94)01514-m. PMID- 26242118 OWN - NLM STAT- MEDLINE DCOM- 20160426 LR - 20181202 IS - 1003-5370 (Print) IS - 1003-5370 (Linking) VI - 35 IP - 6 DP - 2015 Jun TI - [Treatment of Knee Osteoarthritis by Tendons of Minimally Invasive Therapy Combined Drug Ther- apy: a Clinical Observation of Sixty Cases]. PG - 678-81 AB - OBJECTIVE: To assess the efficacy of tendons of minimally invasive therapy (TMIT) combined drug therapy by comparing it with treatment by drug therapy alone on patients with knee osteoarthritis (KOA). METHODS: Totally 60 KOA patients were assigned to the treatment group and the control group according to random digit table, 30 in each group. Patients in the control group took Hydrochloric Acid Glucosamine Capsule and Celecoxib Capsule. Patients in the treatment group additionally received TMIT. The treatment course for all was 4 weeks. Scores for visual analogue scale (VAS) and the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index were observed and recorded at week 1 and 4 after treatment by acupotomology mirror. RESULTS: Compared with before treatment, improvement was shown in VAS score, pain and stiffness degrees, activities and functions, and WOMAC scores at week 1 and 4 after treatment in all patients with statistical difference (P < 0.05). Besides, better effect was shown in the treatment group (P < 0.05). CONCLUSIONS: TMIT combined drug therapy could relieve KOA patients' pain, stiffness and joint activities, elevate the overall efficacy. TMIT was easily operated with less injury. FAU - Hou, Chun-fu AU - Hou CF FAU - Wei, Song AU - Wei S FAU - Chen, Zhi-huang AU - Chen ZH FAU - Li, Xiao-hao AU - Li XH FAU - Wang, Shu-ting AU - Wang ST FAU - Guo, Jing AU - Guo J LA - chi PT - Clinical Study PT - Journal Article PT - Observational Study PL - China TA - Zhongguo Zhong Xi Yi Jie He Za Zhi JT - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine JID - 9211576 RN - JCX84Q7J1L (Celecoxib) SB - IM MH - Celecoxib MH - Drug Therapy, Combination/*methods MH - Humans MH - Knee Joint MH - Osteoarthritis, Knee/*drug therapy MH - Pain MH - Pain Measurement MH - Tendons MH - Treatment Outcome EDAT- 2015/08/06 06:00 MHDA- 2016/04/27 06:00 CRDT- 2015/08/06 06:00 PHST- 2015/08/06 06:00 [entrez] PHST- 2015/08/06 06:00 [pubmed] PHST- 2016/04/27 06:00 [medline] PST - ppublish SO - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Jun;35(6):678-81. PMID- 23463583 OWN - NLM STAT- MEDLINE DCOM- 20140211 LR - 20250529 IS - 1699-5848 (Electronic) IS - 0213-3911 (Linking) VI - 28 IP - 8 DP - 2013 Aug TI - Is tendinitis an inflammatory disease initiated and driven by pro-inflammatory cytokines such as interleukin 1β? PG - 955-64 LID - 10.14670/HH-28.955 [doi] AB - Tendonitis and tendinitis are terms used to describe an inflamed and painful tendon. Tendinopathy, is a descriptive term for describing clinical conditions arising from tendon injury and overuse both within and around tendons. The aim of this mini-review is to explore the role of pro-inflammatory cytokines, particularly interleukin-1β (IL-1β) in tendon disorders. A number of investigators including our group have proposed that pro-inflammatory cytokines such as IL-1β are initiators of tendinopathies, stimulating inflammation, apoptosis and extracellular matrix (ECM) degradation. This is one of the reasons why IL-1β is frequently used in culture models of tendon inflammation to study the inflammatory and catabolic responses of tenocytes. However, some researchers oppose this view and suggest that although IL-1β may play a role in rheumatoid arthritis (RA) and osteoarthritis (OA), the involvement of IL-1β in the development of tendinopathy is questionable. This mini-review discusses the relevant papers published in this area and summarises the evidence for and against the involvement of pro-inflammatory cytokines such as IL-1β in tendonitis. Reaching a consensus will be important for the development and refinement of biomimetic models of tendon inflammation and the formulation of new therapeutic strategies for the treatment of tendon injuries. FAU - Mobasheri, A AU - Mobasheri A AD - Medical Research Council-Arthritis Research UK Centre for Musculoskeletal Ageing Research, Arthritis Research UK Pain Centre, Arthritis Research UK Centre for Sport, Exercise, and Osteoarthritis, Faculty of Medicine and Health Sciences, University of Nottingham, Sutton Bonington Campus, Leicestershire, United Kingdom. ali.mobasheri@nottingham.ac.uk FAU - Shakibaei, M AU - Shakibaei M LA - eng GR - MR/K00414X/1/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Review DEP - 20130306 PL - Spain TA - Histol Histopathol JT - Histology and histopathology JID - 8609357 RN - 0 (Cytokines) RN - 0 (Fluoroquinolones) RN - 0 (Interleukin-1beta) RN - 9007-34-5 (Collagen) SB - IM MH - Achilles Tendon/pathology/ultrastructure MH - Animals MH - Apoptosis MH - Collagen/chemistry MH - Cytokines/*metabolism MH - Extracellular Matrix/metabolism MH - Fluoroquinolones/chemistry MH - Humans MH - Inflammation/*metabolism/physiopathology MH - Interleukin-1beta/*metabolism MH - Rats MH - Tendinopathy/*metabolism MH - Tendons/pathology EDAT- 2013/03/07 06:00 MHDA- 2014/02/12 06:00 CRDT- 2013/03/07 06:00 PHST- 2013/03/07 06:00 [entrez] PHST- 2013/03/07 06:00 [pubmed] PHST- 2014/02/12 06:00 [medline] AID - HH-11-305 [pii] AID - 10.14670/HH-28.955 [doi] PST - ppublish SO - Histol Histopathol. 2013 Aug;28(8):955-64. doi: 10.14670/HH-28.955. Epub 2013 Mar 6. PMID- 6712309 OWN - NLM STAT- MEDLINE DCOM- 19840504 LR - 20250214 IS - 0003-4967 (Print) IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 43 IP - 2 DP - 1984 Apr TI - Multiple tendon rupture in systemic lupus erythematosus: case report and review of the literature. PG - 347-9 AB - Tendon rupture in systemic lupus erythematosus (SLE) is a rare complication that appears to occur in patients receiving corticosteroid therapy. A case is presented with sequential bilateral rupture of Achilles tendon and unilateral rupture of a patellar tendon. Six more published cases are reviewed. Tendon rupture in SLE has affected both males and females between the ages of 24 and 63 years. It occurred exclusively in the weight-bearing tendons: in 6 instances the patellar tendon was severed, in 2 the Achilles, and in one the quadriceps. All 7 patients were on corticosteroid therapy at or just before the time of injury. The deleterious effect of this treatment in loosening connective tissue is discussed. FAU - Potasman, I AU - Potasman I FAU - Bassan, H M AU - Bassan HM LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - VB0R961HZT (Prednisone) SB - IM MH - *Achilles Tendon MH - Adult MH - Female MH - Humans MH - Knee MH - Lupus Erythematosus, Systemic/*complications/drug therapy MH - Muscular Diseases/etiology MH - Prednisone/adverse effects MH - Rupture, Spontaneous MH - *Tendons PMC - PMC1001497 EDAT- 1984/04/01 00:00 MHDA- 1984/04/01 00:01 PMCR- 1987/04/01 CRDT- 1984/04/01 00:00 PHST- 1984/04/01 00:00 [pubmed] PHST- 1984/04/01 00:01 [medline] PHST- 1984/04/01 00:00 [entrez] PHST- 1987/04/01 00:00 [pmc-release] AID - S0003-4967(24)13341-9 [pii] AID - 10.1136/ard.43.2.347 [doi] PST - ppublish SO - Ann Rheum Dis. 1984 Apr;43(2):347-9. doi: 10.1136/ard.43.2.347. PMID- 5259405 OWN - NLM STAT- MEDLINE DCOM- 19691202 LR - 20170214 IS - 0022-0345 (Print) IS - 0022-0345 (Linking) VI - 48 IP - 5 DP - 1969 Sep-Oct TI - The connective tissue fiber-water interface: physiological and pathological implications. PG - 676-9 FAU - Smith, D J AU - Smith DJ LA - eng PT - Journal Article PL - United States TA - J Dent Res JT - Journal of dental research JID - 0354343 RN - 059QF0KO0R (Water) RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - WI4X0X7BPJ (Hydrocortisone) SB - IM MH - Aging MH - Animals MH - Cell Membrane Permeability/drug effects MH - Chick Embryo MH - *Collagen MH - *Connective Tissue MH - Culture Techniques MH - Hydrocortisone/pharmacology MH - Prednisolone/pharmacology MH - Rats MH - Tendons MH - *Water EDAT- 1969/09/01 00:00 MHDA- 1969/09/01 00:01 CRDT- 1969/09/01 00:00 PHST- 1969/09/01 00:00 [pubmed] PHST- 1969/09/01 00:01 [medline] PHST- 1969/09/01 00:00 [entrez] AID - 10.1177/00220345690480051101 [doi] PST - ppublish SO - J Dent Res. 1969 Sep-Oct;48(5):676-9. doi: 10.1177/00220345690480051101. PMID- 546173 OWN - NLM STAT- MEDLINE DCOM- 19800712 LR - 20190823 IS - 0065-4299 (Print) IS - 0065-4299 (Linking) VI - 9 IP - 5-6 DP - 1979 Dec TI - Influence of prednisolone and L-thyroxine on the changes in collagen metabolism in rats with adjuvant-induced arthritis. PG - 502-9 AB - In rats with adjuvant-induced arthritis the effects of prednisolone and L-thyroxine on the changes in collagen metabolism were investigated both in the skin and tendon during the acute and chronic phase of the arthritis. In untreated animals with adjuvant-induced arthritis, a decrease in the collagen synthesis accompanied by an increase in the catabolism of collagen and a retardation in the conversion of soluble to insoluble collagen were noted both in the skin and tendon during the course of the disease. Prednisolone was found to accelerate the conversion of soluble to insoluble collagen and to inhibit the enhanced catabolism of collagen in rats with adjuvant-induced arthritis. L-Thyroxine accelerated the conversion of soluble to insoluble collagen in adjuvant-induced arthritic rats more effectively than prednisolone but was less effective with regard to the inhibition of enhanced catabolism of collagen. However, the synthesis of collagen in adjuvant-induced arthritis was improved by both prednisolone and L-thyroxine. FAU - Kuberasampath, T AU - Kuberasampath T FAU - Bose, S M AU - Bose SM LA - eng PT - Journal Article PL - Switzerland TA - Agents Actions JT - Agents and actions JID - 0213341 RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - Q51BO43MG4 (Thyroxine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Acute Disease MH - Animals MH - Arthritis/*metabolism MH - Arthritis, Experimental/*metabolism MH - Chronic Disease MH - Collagen/*metabolism MH - Hydroxyproline/metabolism MH - Male MH - Prednisolone/*pharmacology MH - Rats MH - Skin/metabolism MH - Solubility MH - Tendons/metabolism MH - Thyroxine/*pharmacology EDAT- 1979/12/01 00:00 MHDA- 1979/12/01 00:01 CRDT- 1979/12/01 00:00 PHST- 1979/12/01 00:00 [pubmed] PHST- 1979/12/01 00:01 [medline] PHST- 1979/12/01 00:00 [entrez] AID - 10.1007/BF01968119 [doi] PST - ppublish SO - Agents Actions. 1979 Dec;9(5-6):502-9. doi: 10.1007/BF01968119. PMID- 22365712 OWN - NLM STAT- MEDLINE DCOM- 20120920 LR - 20141120 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 37 IP - 5 DP - 2012 May TI - Surface markers for locating the pulleys and flexor tendon anatomy in the palm and fingers with reference to minimally invasive incisions. PG - 913-8 LID - 10.1016/j.jhsa.2011.12.036 [doi] AB - PURPOSE: Palm and finger pulley anatomy has been well described in relation to osseous structures. The goal of this study was to describe skin surface markers that locate the underlying flexor tendon and pulley system. We describe the anatomic detail of these structures and provide a guide for the surgeon for making small incisions. Using this approach, extensile exposure can be avoided, and the integrity of the complex pulley system is maintained. METHODS: We dissected 12 palms and 48 fingers in 12 cadaver hands. We marked the palm and finger creases with methylene blue before dissection. We removed palm skin, finger skin, and subcutaneous tissue over the flexor tendon sheath and retained a 2-mm strip of each skin crease in its native position. We divided the palm and palmar surface of the fingers into 4 distinct zones and measured the location of the proximal and distal extent of each pulley and the tendon anatomy relative to the proximal and distal skin crease. RESULTS: We documented the location of the proximal and distal extent of the annular and cruciate pulleys as well as the decussation of the flexor digitorum superficialis (FDS) tendon and Camper chiasm. The results allow us to establish a relationship between the skin creases and underlying anatomy by dividing the palm and finger into 4 zones. In zone A, in the palm, the A2 pulley is located in the distal third and the FDS decussation is at the proximal extent of the A2 pulley. Zone B is in the proximal phalanx and A2 lies in the proximal third of this zone, whereas the Camper chiasm lies in the middle third. Zone C is in the middle phalanx and A4 and the insertion of FDS lie in the middle third of this zone. Zone D lies in the distal phalanx and the flexor digitorum profundus tendon inserts into the middle third of this zone. CONCLUSIONS: Skin creases can be used as surface markers to accurately locate the underlying pulley and tendon system and plan for limited incisions. CLINICAL RELEVANCE: These anatomic descriptions can aid surgeons in preoperative planning and may also help minimize the required exposure for flexor tendon repair and other surgery in the fingers and palm. CI - Copyright © 2012. Published by Elsevier Inc. FAU - Gordon, Joshua A AU - Gordon JA AD - Departments of Anatomy and Orthopaedic Surgery, University of California, San Francisco, CA, USA. FAU - Stone, Lindsay AU - Stone L FAU - Gordon, Leonard AU - Gordon L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120224 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - T42P99266K (Methylene Blue) SB - IM MH - Cadaver MH - Dissection MH - Fingers/*anatomy & histology/surgery MH - Hand/*anatomy & histology/surgery MH - Humans MH - Methylene Blue MH - Minimally Invasive Surgical Procedures MH - Tendons/*anatomy & histology/surgery EDAT- 2012/03/01 06:00 MHDA- 2012/09/21 06:00 CRDT- 2012/02/28 06:00 PHST- 2011/09/27 00:00 [received] PHST- 2011/12/19 00:00 [revised] PHST- 2011/12/20 00:00 [accepted] PHST- 2012/02/28 06:00 [entrez] PHST- 2012/03/01 06:00 [pubmed] PHST- 2012/09/21 06:00 [medline] AID - S0363-5023(11)01647-9 [pii] AID - 10.1016/j.jhsa.2011.12.036 [doi] PST - ppublish SO - J Hand Surg Am. 2012 May;37(5):913-8. doi: 10.1016/j.jhsa.2011.12.036. Epub 2012 Feb 24. PMID- 19800260 OWN - NLM STAT- MEDLINE DCOM- 20100603 LR - 20220311 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 19 IP - 3 DP - 2010 Apr TI - The effect of matrix metalloproteinase inhibition on tendon-to-bone healing in a rotator cuff repair model. PG - 384-91 LID - 10.1016/j.jse.2009.07.010 [doi] AB - HYPOTHESIS: Recent studies have demonstrated a potentially critical role of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in the pathophysiology of rotator cuff tears. We hypothesize that local delivery of a MMP inhibitor after surgical repair of the rotator cuff will improve healing at the tendon-to-bone surface interface. MATERIALS AND METHODS: Sixty-two male Sprague-Dawley rats underwent acute supraspinatus detachment and repair. In the control group (n=31), the supraspinatus was repaired to its anatomic footprint. In the experimental group (n=31), recombinant alpha-2-macroglobulin (A2M) protein, a universal MMP inhibitor, was applied at the tendon-bone interface with an identical surgical repair. Animals were sacrificed at 2 and 4 weeks for histomorphometry, immunohistochemistry, and biomechanical testing. Statistical comparisons were performed using unpaired t tests. Significance was set at P < .05. RESULTS: Significantly greater fibrocartilage was seen at the healing enthesis in the A2M-treated specimens compared with controls at 2 weeks (P < .05). Significantly greater collagen organization was observed in the A2M-treated animals compared with controls at 4 weeks (P < .01). A significant reduction in collagen degradation was observed at both 2 and 4 weeks in the experimental group (P < .05). Biomechanical testing revealed no significant differences in stiffness or ultimate load-to-failure. CONCLUSION: Local delivery of an MMP inhibitor is associated with distinct histologic differences at the tendon-to-bone interface after rotator cuff repair. Modulation of MMP activity after rotator cuff repair may offer a novel biologic pathway to augment tendon-to-bone healing after rotator cuff repair. CI - 2010 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Mosby, Inc. All rights reserved. FAU - Bedi, Asheesh AU - Bedi A AD - Sports Medicine and Shoulder Surgery, Laboratory for Soft Tissue Research, Hospital for Special Surgery, New York, NY 10021, USA. FAU - Kovacevic, David AU - Kovacevic D FAU - Hettrich, Carolyn AU - Hettrich C FAU - Gulotta, Lawrence V AU - Gulotta LV FAU - Ehteshami, John R AU - Ehteshami JR FAU - Warren, Russell F AU - Warren RF FAU - Rodeo, Scott A AU - Rodeo SA LA - eng PT - Journal Article DEP - 20091002 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Enzyme Inhibitors) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (alpha-Macroglobulins) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Bone and Bones/*drug effects/physiopathology MH - Collagen/biosynthesis MH - Disease Models, Animal MH - Enzyme Inhibitors/pharmacology MH - Fibrocartilage/physiology MH - Male MH - *Matrix Metalloproteinase Inhibitors MH - Rats MH - Rats, Sprague-Dawley MH - Rotator Cuff/*physiopathology/surgery MH - Tendons/*drug effects/physiopathology MH - Wound Healing/*drug effects MH - alpha-Macroglobulins/pharmacology EDAT- 2009/10/06 06:00 MHDA- 2010/06/04 06:00 CRDT- 2009/10/06 06:00 PHST- 2009/04/25 00:00 [received] PHST- 2009/07/06 00:00 [revised] PHST- 2009/07/13 00:00 [accepted] PHST- 2009/10/06 06:00 [entrez] PHST- 2009/10/06 06:00 [pubmed] PHST- 2010/06/04 06:00 [medline] AID - S1058-2746(09)00300-0 [pii] AID - 10.1016/j.jse.2009.07.010 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2010 Apr;19(3):384-91. doi: 10.1016/j.jse.2009.07.010. Epub 2009 Oct 2. PMID- 11355979 OWN - NLM STAT- MEDLINE DCOM- 20010705 LR - 20131121 IS - 0007-1226 (Print) IS - 0007-1226 (Linking) VI - 54 IP - 4 DP - 2001 Jun TI - Reduction in matrix metalloproteinase production by tendon and synovial fibroblasts after a single exposure to 5-fluorouracil. PG - 283-7 AB - This study investigated the effect of treatment with 5min exposures to 5-fluorouracil (5-FU) on the production of matrix metalloproteinases (MMPs) by endotenon and synovial fibroblasts. Fibroblasts were grown from the flexor tendons of New Zealand White rabbits and were then exposed to varying concentrations (ranging from 0.25 mg x ml(-1)to 25 mg x ml(-1)of 5-FU for 5 min. The treated fibroblasts were suspended in a three-dimensional collagen lattice. The conditioned media from these collagen lattices were then analysed for MMP production using gelatin zymography on days 1, 3 and 7 after treatment. In the majority of cases this treatment produced a dose- and time-dependent reduction in total MMP production by both cell lines, specifically in the production of MMPs 2 and 9. This reduction was significant for most concentrations (P< or =0.01-P< or =0.05) when compared to phosphate-buffered-saline-treated controls. We conclude that 5-FU may reduce adhesions by limiting the migratory capacity of synovial fibroblasts (extrinsic healing). CI - Copyright 2001 The British Association of Plastic Surgeons. FAU - Ragoowansi, R AU - Ragoowansi R AD - Phoenix Tissue Repair Unit, Department of Plastic and Reconstructive Surgery, University College London, London, UK. FAU - Khan, U AU - Khan U FAU - Brown, R A AU - Brown RA FAU - McGrouther, D A AU - McGrouther DA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Br J Plast Surg JT - British journal of plastic surgery JID - 2984714R RN - 0 (Antimetabolites) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Antimetabolites/*pharmacology MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - Electrophoresis, Polyacrylamide Gel MH - Fibroblasts/*drug effects/metabolism MH - Fluorouracil/*pharmacology MH - Matrix Metalloproteinase 2/biosynthesis/*drug effects MH - Matrix Metalloproteinase 9/biosynthesis/*drug effects MH - Rabbits MH - Synovial Membrane/cytology MH - Tendons/cytology MH - Time Factors EDAT- 2001/05/18 10:00 MHDA- 2001/07/06 10:01 CRDT- 2001/05/18 10:00 PHST- 2001/05/18 10:00 [pubmed] PHST- 2001/07/06 10:01 [medline] PHST- 2001/05/18 10:00 [entrez] AID - S0007-1226(00)93580-X [pii] AID - 10.1054/bjps.2000.3580 [doi] PST - ppublish SO - Br J Plast Surg. 2001 Jun;54(4):283-7. doi: 10.1054/bjps.2000.3580. PMID- 30655220 OWN - NLM STAT- MEDLINE DCOM- 20200211 LR - 20200211 IS - 2468-1210 (Electronic) IS - 2468-1210 (Linking) VI - 38 IP - 2 DP - 2019 Apr TI - Designing a minimally-invasive, ultrasound-guided, percutaneous flexor tendon sheath lavage technique: a cadaver study. PG - 87-90 LID - S2468-1229(18)30435-3 [pii] LID - 10.1016/j.hansur.2018.12.001 [doi] AB - The goal of this study was to develop a minimally-invasive, ultrasound-guided percutaneous flexor tendon sheath lavage technique on cadaver model. Two catheters were inserted using ultrasound guidance at the proximal and distal ends of the tendon sheath in 20 fingers from cadaveric forearms. Percutaneous injection of a saline solution colored with methylene blue resulted in anterograde lavage of the flexor tendon sheath. The technique was successful in 13 out of 20 cases. The proximal catheter was in the correct position in 17 cases and the distal catheter was correctly positioned in 15 cases. The flexor tendons were continuous in all cases and had puncture wounds in 9 cases. Based on our study, this minimally-invasive, ultrasound-guided percutaneous lavage of the flexor tendon sheath was effective in 65% of cases and safe in 100% of cases in the index, middle and ring fingers. If this percutaneous lavage fails, it is always possible to switch to a conventional open technique. CI - Copyright © 2018 SFCM. Published by Elsevier Masson SAS. All rights reserved. FAU - Boyer, E AU - Boyer E AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. FAU - Igeta, Y AU - Igeta Y AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France; Department of Orthopedic Surgery, Juntendo Nerima Hospital, 3-1-10, Takanedai, Nerima-ku, Tokyo, 177-8521, Japan. FAU - Jiang, S AU - Jiang S AD - Department of Hand Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, 138 Yixueyuan Road, Shanghai, 200040, China; Department of Hand and Upper Extremity Surgery, Jing'an District Central Hospital, No.12 Wulumuqi Middle Road, 200040, Shanghai, Popular Republic of China. FAU - Arianni, M AU - Arianni M AD - Hand Clinic, Ramsay Premier Bintaro Hospital, Jl. MH Thamrin no.1, Bintaro Jaya sector Tangerang Selatan, 15224, Banten, Indonesia. FAU - Goldammer, F AU - Goldammer F AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. FAU - Prunières, G AU - Prunières G AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. FAU - Paun, A AU - Paun A AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. FAU - Vernet, P AU - Vernet P AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. FAU - Liverneaux, P AU - Liverneaux P AD - Department of Hand Surgery, SOS main, CCOM, University Hospital of Strasbourg, FMTS, University of Strasbourg, Icube CNRS 7357, 10 avenue Baumann, 67400 Illkirch, France. Electronic address: Philippe.liverneaux@chru-strasbourg.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190114 PL - France TA - Hand Surg Rehabil JT - Hand surgery & rehabilitation JID - 101681801 RN - T42P99266K (Methylene Blue) SB - IM MH - Cadaver MH - Catheters MH - Humans MH - Methylene Blue MH - Tendons/*diagnostic imaging MH - Therapeutic Irrigation/*methods MH - Ultrasonography, Interventional OTO - NOTNLM OT - Flexor tendon sheath OT - Gaine des fléchisseurs des doigts OT - Lavage percutané OT - Mini-invasif OT - Minimally invasive OT - Percutaneous washout EDAT- 2019/01/19 06:00 MHDA- 2020/02/12 06:00 CRDT- 2019/01/19 06:00 PHST- 2018/07/23 00:00 [received] PHST- 2018/09/25 00:00 [revised] PHST- 2018/12/14 00:00 [accepted] PHST- 2019/01/19 06:00 [pubmed] PHST- 2020/02/12 06:00 [medline] PHST- 2019/01/19 06:00 [entrez] AID - S2468-1229(18)30435-3 [pii] AID - 10.1016/j.hansur.2018.12.001 [doi] PST - ppublish SO - Hand Surg Rehabil. 2019 Apr;38(2):87-90. doi: 10.1016/j.hansur.2018.12.001. Epub 2019 Jan 14. PMID- 18498123 OWN - NLM STAT- MEDLINE DCOM- 20080819 LR - 20211020 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 217 IP - 1 DP - 2008 Oct TI - Influence of vanadate on migrating fibroblast orientation within a fibrin matrix. PG - 72-6 LID - 10.1002/jcp.21475 [doi] AB - Treating rats with vanadate, a nonspecific inhibitor of protein tyrosine phosphatases, optimizes the uniform packing of collagen fiber bundles in wound granulation tissue and doubles wound breaking strength in rat incisional wounds. The speculation is vanadate optimizes the packing of collagen fiber bundles through the orientation of newly arrived wound fibroblasts in the fibrin clot filling the defect. Segments of 14 day chick embryo tendons were placed on fibrin clots and maintained in organ culture with and without 30 microM vanadate. On day 7 explants were examined histologically and biochemically. Tendon fibroblast outgrowth from untreated explants migrated in a random fashion, while fibroblasts from vanadate-treated explants migrated out in linear arrays. Fibroblasts were elongated by 20% form vanadate treated explant compared to controls. Myosin ATPase, required for optimal cell motility, is optimized by the phosphorylation of its myosin light chain (MLC). Western blot analysis of lysates from the fibroblasts that migrated into the fibrin showed vanadate increased MLC-P levles. These findings support the notion that vanadate promotes the deposition of regular, parallel collagen fiber bundles by advancing the orientation of fibroblasts in parallel linear arrays early in the wound repair process. CI - (c) 2008 Wiley-Liss, Inc. FAU - Lee, Michael Y AU - Lee MY AD - Division of Plastic Surgery, Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA. FAU - Ehrlich, H Paul AU - Ehrlich HP LA - eng GR - R01 GM056851/GM/NIGMS NIH HHS/United States GR - GM 056851/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Enzyme Inhibitors) RN - 0 (Myosin Light Chains) RN - 3WHH0066W5 (Vanadates) RN - 9001-31-4 (Fibrin) SB - IM MH - Animals MH - Blotting, Western MH - Cell Movement/*drug effects MH - Chick Embryo MH - Enzyme Inhibitors/*pharmacology MH - Extracellular Matrix/chemistry MH - Fibrin/*metabolism MH - Fibroblasts/cytology/*drug effects MH - Humans MH - Microscopy, Fluorescence MH - Myosin Light Chains/drug effects MH - Organ Culture Techniques MH - Phosphorylation MH - Tendons/cytology MH - Vanadates/*pharmacology MH - Wound Healing/*drug effects/physiology EDAT- 2008/05/24 09:00 MHDA- 2008/08/20 09:00 CRDT- 2008/05/24 09:00 PHST- 2008/05/24 09:00 [pubmed] PHST- 2008/08/20 09:00 [medline] PHST- 2008/05/24 09:00 [entrez] AID - 10.1002/jcp.21475 [doi] PST - ppublish SO - J Cell Physiol. 2008 Oct;217(1):72-6. doi: 10.1002/jcp.21475. PMID- 18819088 OWN - NLM STAT- MEDLINE DCOM- 20081017 LR - 20161021 IS - 1934-2616 (Electronic) IS - 1934-2616 (Linking) VI - Chapter 10 DP - 2008 Sep TI - Matrix metalloproteinases. PG - Unit 10.8 LID - 10.1002/0471143030.cb1008s40 [doi] AB - Matrix metalloproteinases are a class of enzymes that play an important role in the remodeling of the extracellular matrix in development and cancer metastasis. This unit describes a set of methods--cell-mediated dissolution of type-1 collagen fibrils, direct and reverse zymography, enzyme capture based on alpha2-macroglobulin and TIMP-1 and -2, and demonstration of cryptic thiol groups in metalloproteinase precursors--that are used to characterize the functions of matrix metalloproteinases and their inhibitors. CI - Copyright 2008 by John Wiley & Sons, Inc. FAU - Birkedal-Hansen, Henning AU - Birkedal-Hansen H AD - National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland, USA. FAU - Yamada, Susan AU - Yamada S FAU - Windsor, Jack AU - Windsor J FAU - Pollard, Anne Havernose AU - Pollard AH FAU - Lyons, Guy AU - Lyons G FAU - Stetler-Stevenson, William AU - Stetler-Stevenson W FAU - Birkedal-Hansen, Bente AU - Birkedal-Hansen B LA - eng PT - Journal Article PL - United States TA - Curr Protoc Cell Biol JT - Current protocols in cell biology JID - 101287856 RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 0 (alpha-Macroglobulins) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Biochemistry/*methods MH - Collagen/metabolism MH - Gene Expression MH - Humans MH - Matrix Metalloproteinase Inhibitors MH - Matrix Metalloproteinases/genetics/*metabolism MH - Rats MH - Staining and Labeling MH - Tendons/metabolism MH - Tissue Inhibitor of Metalloproteinases/metabolism MH - alpha-Macroglobulins/metabolism EDAT- 2008/09/27 09:00 MHDA- 2008/10/18 09:00 CRDT- 2008/09/27 09:00 PHST- 2008/09/27 09:00 [pubmed] PHST- 2008/10/18 09:00 [medline] PHST- 2008/09/27 09:00 [entrez] AID - 10.1002/0471143030.cb1008s40 [doi] PST - ppublish SO - Curr Protoc Cell Biol. 2008 Sep;Chapter 10:Unit 10.8. doi: 10.1002/0471143030.cb1008s40. PMID- 29643421 OWN - NLM STAT- MEDLINE DCOM- 20191007 LR - 20191007 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 8 IP - 1 DP - 2018 Apr 11 TI - Serpine1 Knockdown Enhances MMP Activity after Flexor Tendon Injury in Mice: Implications for Adhesions Therapy. PG - 5810 LID - 10.1038/s41598-018-24144-1 [doi] LID - 5810 AB - Injuries to flexor tendons can be complicated by fibrotic adhesions, which severely impair the function of the hand. Adhesions have been associated with TGF-β1, which causes upregulation of PAI-1, a master suppressor of protease activity, including matrix metalloproteinases (MMP). In the present study, the effects of inhibiting PAI-1 in murine zone II flexor tendon injury were evaluated utilizing knockout (KO) mice and local nanoparticle-mediated siRNA delivery. In the PAI-1 KO murine model, reduced adherence of injured tendon to surrounding subcutaneous tissue and accelerated recovery of normal biomechanical properties compared to wild type controls were observed. Furthermore, MMP activity was significantly increased in the injured tendons of the PAI-1 KO mice, which could explain their reduced adhesions and accelerated remodeling. These data demonstrate that PAI-1 mediates fibrotic adhesions in injured flexor tendons by suppressing MMP activity. In vitro siRNA delivery to silence Serpine1 expression after treatment with TGF-β1 increased MMP activity. Nanoparticle-mediated delivery of siRNA targeting Serpine1 in injured flexor tendons significantly reduced target gene expression and subsequently increased MMP activity. Collectively, the data demonstrate that PAI-1 can be a druggable target for treating adhesions and accelerating the remodeling of flexor tendon injuries. FAU - Freeberg, Margaret A T AU - Freeberg MAT AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Farhat, Youssef M AU - Farhat YM AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Easa, Anas AU - Easa A AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Kallenbach, Jacob G AU - Kallenbach JG AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Malcolm, Dominic W AU - Malcolm DW AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Buckley, Mark R AU - Buckley MR AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. FAU - Benoit, Danielle S W AU - Benoit DSW AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. AD - Department of Orthopedics, University of Rochester Medical Center, Rochester, NY, USA. FAU - Awad, Hani A AU - Awad HA AD - Department of Biomedical Engineering, University of Rochester, Rochester, NY, USA. hani_awad@urmc.rochester.edu. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. hani_awad@urmc.rochester.edu. AD - Department of Orthopedics, University of Rochester Medical Center, Rochester, NY, USA. hani_awad@urmc.rochester.edu. LA - eng GR - P30 AR069655/AR/NIAMS NIH HHS/United States GR - R01 AR056696/AR/NIAMS NIH HHS/United States GR - T32 AR053459/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20180411 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (Serine Proteinase Inhibitors) RN - 0 (Serpin E2) RN - 0 (Serpine2 protein, mouse) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Disease Models, Animal MH - Fibrosis/pathology MH - Gene Knockdown Techniques MH - Matrix Metalloproteinases/*metabolism MH - Mice MH - Mice, Knockout MH - Plasminogen Activator Inhibitor 1/*metabolism MH - Serine Proteinase Inhibitors/*metabolism MH - Serpin E2/deficiency MH - Tendon Injuries/*pathology PMC - PMC5895578 COIS- The authors declare no competing interests. EDAT- 2018/04/13 06:00 MHDA- 2019/10/08 06:00 PMCR- 2018/04/11 CRDT- 2018/04/13 06:00 PHST- 2017/12/20 00:00 [received] PHST- 2018/03/27 00:00 [accepted] PHST- 2018/04/13 06:00 [entrez] PHST- 2018/04/13 06:00 [pubmed] PHST- 2019/10/08 06:00 [medline] PHST- 2018/04/11 00:00 [pmc-release] AID - 10.1038/s41598-018-24144-1 [pii] AID - 24144 [pii] AID - 10.1038/s41598-018-24144-1 [doi] PST - epublish SO - Sci Rep. 2018 Apr 11;8(1):5810. doi: 10.1038/s41598-018-24144-1. PMID- 25450393 OWN - NLM STAT- MEDLINE DCOM- 20150204 LR - 20220408 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 454 IP - 2 DP - 2014 Nov 14 TI - Effect of indomethacin and lactoferrin on human tenocyte proliferation and collagen formation in vitro. PG - 301-7 LID - S0006-291X(14)01859-2 [pii] LID - 10.1016/j.bbrc.2014.10.061 [doi] AB - Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in patients with injuries and inflammation of tendon and ligament, and as post-surgical analgesics. The aim of this study is to investigate the effect of indomethacin, a classic NSAID and its combinational effect with an anabolic agent of skeletal tissue, lactoferrin, on the proliferation and collagen formation of human tenocytes in vitro. A factorial experimental design was employed to study the dose-dependent effect of the combination of indomethacin and lactoferrin. The results showed that indomethacin at high concentration (100 μM) inhibited human tenocyte proliferation in culture medium with 1-10% fetal bovine serum (FBS) in vitro. Also, high dose of indomethacin inhibited the collagen formation of human tenocytes in 1% FBS culture medium. Lactoferrin at 50-100 μg/ml promoted human tenocyte survival in serum-free culture medium and enhanced proliferation and collagen synthesis of human tenocytes in 1% FBS culture medium. When 50-100 μg/ml lactoferrin was used in combination with 100-200 μM indomethacin, it partially rescued the inhibitory effects of indomethacin on human tenocyte proliferation, viability and collagen formation. To our knowledge, it is the first evidence that lactoferrin is anabolic to human tenocytes in vitro and reverses potential inhibitory effects of NSAIDs on human tenocytes. CI - Copyright © 2014 Elsevier Inc. All rights reserved. FAU - Zhang, Yaonan AU - Zhang Y AD - Centre for Nanohealth, College of Medicine, Swansea University, Singleton Park, Swansea, UK SA2 8PP; Department of Orthopaedic, Beijing Hospital of Ministry of Public Health, Beijing, China 100730. FAU - Wang, Xiao AU - Wang X AD - Centre for Nanohealth, College of Medicine, Swansea University, Singleton Park, Swansea, UK SA2 8PP. FAU - Qiu, Yiwei AU - Qiu Y AD - Centre for Nanohealth, College of Medicine, Swansea University, Singleton Park, Swansea, UK SA2 8PP. FAU - Cornish, Jillian AU - Cornish J AD - Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand. FAU - Carr, Andrew J AU - Carr AJ AD - Centre for Nanohealth, College of Medicine, Swansea University, Singleton Park, Swansea, UK SA2 8PP. FAU - Xia, Zhidao AU - Xia Z AD - Centre for Nanohealth, College of Medicine, Swansea University, Singleton Park, Swansea, UK SA2 8PP. Electronic address: z.xia@swansea.ac.uk. LA - eng PT - Journal Article DEP - 20141018 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Anti-Infective Agents) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Drug Combinations) RN - 9007-34-5 (Collagen) RN - EC 3.4.21.- (Lactoferrin) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Animals MH - Anti-Infective Agents/administration & dosage/*pharmacology MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacology MH - Cattle MH - Cell Proliferation/*drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Collagen/*metabolism MH - Drug Combinations MH - Humans MH - Indomethacin/administration & dosage/*pharmacology MH - Lactoferrin/administration & dosage/*pharmacology MH - Male MH - Tendons/*cytology/drug effects OTO - NOTNLM OT - Anabolic OT - Human tenocyte OT - Indomethacin OT - Lactoferrin OT - Non-steroidal anti-inflammatory drugs (NSAIDs) EDAT- 2014/12/03 06:00 MHDA- 2015/02/05 06:00 CRDT- 2014/12/03 06:00 PHST- 2014/10/06 00:00 [received] PHST- 2014/10/13 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2015/02/05 06:00 [medline] AID - S0006-291X(14)01859-2 [pii] AID - 10.1016/j.bbrc.2014.10.061 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2014 Nov 14;454(2):301-7. doi: 10.1016/j.bbrc.2014.10.061. Epub 2014 Oct 18. PMID- 24962629 OWN - NLM STAT- MEDLINE DCOM- 20151023 LR - 20211021 IS - 1097-4652 (Electronic) IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 230 IP - 2 DP - 2015 Feb TI - TGF-β1 Suppresses Plasmin and MMP Activity in Flexor Tendon Cells via PAI-1: Implications for Scarless Flexor Tendon Repair. PG - 318-26 LID - 10.1002/jcp.24707 [doi] AB - Flexor tendon injuries caused by deep lacerations to the hands are a challenging problem as they often result in debilitating adhesions that prevent the movement of the afflicted fingers. Evidence exists that tendon adhesions as well as scarring throughout the body are largely precipitated by the pleiotropic growth factor, Transforming Growth Factor Beta 1(TGF-β1), but the effects of TGF-β1 are poorly understood in tendon healing. Using an in vitro model of tendon healing, we previously found that TGF-β1 causes gene expression changes in tenocytes that are consistent with scar tissue and adhesion formation, including upregulation of the anti-fibrinolytic protein, PAI-1. Therefore, we hypothesized that TGF-β1 contributes to scarring and adhesions by reducing the activity of proteases responsible for ECM degradation and remodeling, such as plasmin and MMPs, via upregulation of PAI-1. To test our hypothesis, we examined the effects of TGF-β1 on the protease activity of tendon cells. We found that flexor tendon tenocytes treated with TGF-β1 had significantly reduced levels of active MMP-2 and plasmin. Interestingly, the effects of TGF-β1 on protease activity were completely abolished in tendon cells from homozygous plasminogen activator inhibitor 1 (PAI-1) knockout (KO) mice, which are unable to express PAI-1. Our findings support the hypothesis that TGF-β1 induces PAI-1, which suppresses plasmin and plasmin-mediated MMP activity, and provide evidence that PAI-1 may be a novel therapeutic target for preventing adhesions and promoting a scarless, regenerative repair of flexor tendon injuries. CI - © 2014 Wiley Periodicals, Inc. FAU - Farhat, Youssef M AU - Farhat YM AD - Department of Biomedical Engineering, 601 Elmwood Ave, Rochester, New York. AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. FAU - Al-Maliki, Alaa A AU - Al-Maliki AA AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. FAU - Easa, Anas AU - Easa A AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. FAU - O'Keefe, Regis J AU - O'Keefe RJ AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. AD - Department of Orthopaedics University of Rochester, 601 Elmwood Ave, Rochester, New York. FAU - Schwarz, Edward M AU - Schwarz EM AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. AD - Department of Orthopaedics University of Rochester, 601 Elmwood Ave, Rochester, New York. FAU - Awad, Hani A AU - Awad HA AD - Department of Biomedical Engineering, 601 Elmwood Ave, Rochester, New York. AD - The Center for Musculoskeletal Research, 601 Elmwood Ave, Rochester, New York. AD - Department of Orthopaedics University of Rochester, 601 Elmwood Ave, Rochester, New York. LA - eng GR - T32 GM07356/GM/NIGMS NIH HHS/United States GR - R01AR056696/AR/NIAMS NIH HHS/United States GR - T32 AR053459/AR/NIAMS NIH HHS/United States GR - T32 GM007356/GM/NIGMS NIH HHS/United States GR - R01 AR056696/AR/NIAMS NIH HHS/United States GR - P30 AR061307/AR/NIAMS NIH HHS/United States GR - P30AR061307/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Fibronectins) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (Serpin E2) RN - 0 (Serpine2 protein, mouse) RN - 0 (Transforming Growth Factor beta1) RN - EC 3.4.21.7 (Fibrinolysin) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Animals MH - Cells, Cultured MH - Fibrinolysin/*metabolism MH - Fibronectins/metabolism MH - Matrix Metalloproteinases/*metabolism MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Plasminogen Activator Inhibitor 1/*metabolism MH - Serpin E2/*metabolism MH - Tendons/cytology/*metabolism MH - Transforming Growth Factor beta1/*metabolism MH - Wound Healing/*physiology PMC - PMC4276543 MID - NIHMS609065 EDAT- 2014/06/26 06:00 MHDA- 2015/10/24 06:00 PMCR- 2016/02/01 CRDT- 2014/06/26 06:00 PHST- 2014/06/04 00:00 [received] PHST- 2014/06/20 00:00 [accepted] PHST- 2014/06/26 06:00 [entrez] PHST- 2014/06/26 06:00 [pubmed] PHST- 2015/10/24 06:00 [medline] PHST- 2016/02/01 00:00 [pmc-release] AID - 10.1002/jcp.24707 [doi] PST - ppublish SO - J Cell Physiol. 2015 Feb;230(2):318-26. doi: 10.1002/jcp.24707. PMID- 4813765 OWN - NLM STAT- MEDLINE DCOM- 19740417 LR - 20151119 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 53 IP - 3 DP - 1974 Mar TI - Mucous cysts: the dorsal distal interphalangeal joint ganglion. PG - 313-5 FAU - Newmeyer, W L AU - Newmeyer WL FAU - Kilgore, E S Jr AU - Kilgore ES Jr FAU - Graham, W P 3rd AU - Graham WP 3rd LA - eng PT - Journal Article PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - T42P99266K (Methylene Blue) SB - IM MH - Finger Joint/*surgery MH - Humans MH - Methods MH - Methylene Blue MH - Synovial Cyst/*surgery MH - Tendons EDAT- 1974/03/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1974/03/01 00:00 PHST- 1974/03/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1974/03/01 00:00 [entrez] PST - ppublish SO - Plast Reconstr Surg. 1974 Mar;53(3):313-5. PMID- 26909661 OWN - NLM STAT- MEDLINE DCOM- 20170828 LR - 20171201 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 34 IP - 11 DP - 2016 Nov TI - Influence of repetitive mechanical loading on MMP2 activity in tendon fibroblasts. PG - 1991-2000 LID - 10.1002/jor.23207 [doi] AB - Matrix metalloproteinase2 has been implicated in tendon pathology caused by repetitive movements. However, its activity in the early stages of the tendon's response to overuse, and its presence in the circulation as a possible indicator of tendon degradation, remain unknown. Human tendon cells were repetitively stretched for 5 days, and the rabbit Achilles tendon complex underwent repetitive motion 3× per week for 2 weeks. Quantitative polymer chain reaction analysis was performed to detect matrix metalloproteinase2/14 and tissue inhibitor of matrix metalloproteinase2 messenger ribonucleic acid of cells and rabbit tissue, and matrix metalloproteinase2 protein levels were determined with an enzyme linked immunoassay. Matrix metalloproteinase2 activity was examined using zymography of the conditioned media, tendon and serum. Immunohistochemistry was used to localize matrix metalloproteinase2 in tendon tissue, and the density of fibrillar collagen in tendons was examined using second harmonic generation microscopy. Tendon cells stretched with high strain or high frequency demonstrated increased matrix metalloproteinase2 messenger ribonucleic acid and protein levels. Matrix metalloproteinase2 activity was increased in the rabbit Achilles tendon tissue at weeks 1 and 2; however, serum activity was only increased at week 1. After 2 weeks of exercise, the collagen density was lower in specific regions of the exercised rabbit Achilles tendon complex. Matrix metalloproteinase2 expression in exercised rabbit Achilles tendons was detected surrounding tendon fibroblasts. Repetitive mechanical stimulation of tendon cells results in a small increase in matrix metalloproteinase2 levels, but it appears unlikely that serum matrix metalloproteinase2 will be a useful indicator of tendon overuse injury. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1991-2000, 2016. CI - © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Huisman, Elise AU - Huisman E AD - Department of Physical Therapy, University of British Columbia, Vancouver, Canada. AD - Centre for Hip Health and Mobility, Vancouver Coastal Health and Research Institute, Vancouver, Canada. FAU - Lu, Alex AU - Lu A AD - Department of Physical Therapy, University of British Columbia, Vancouver, Canada. AD - Centre for Hip Health and Mobility, Vancouver Coastal Health and Research Institute, Vancouver, Canada. FAU - Jamil, Sarwat AU - Jamil S AD - Centre for Hip Health and Mobility, Vancouver Coastal Health and Research Institute, Vancouver, Canada. FAU - Mousavizadeh, Rouhollah AU - Mousavizadeh R AD - Centre for Hip Health and Mobility, Vancouver Coastal Health and Research Institute, Vancouver, Canada. FAU - McCormack, Robert AU - McCormack R AD - Department of Orthopaedic Surgery, University of British Columbia, Vancouver, Canada. FAU - Roberts, Clive AU - Roberts C AD - Department of Dentistry, University of British Columbia, Vancouver, Canada. FAU - Scott, Alex AU - Scott A AD - Department of Physical Therapy, University of British Columbia, Vancouver, Canada. AD - Centre for Hip Health and Mobility, Vancouver Coastal Health and Research Institute, Vancouver, Canada. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160407 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Biomarkers) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.80 (Matrix Metalloproteinase 14) SB - IM MH - Achilles Tendon/enzymology/pathology MH - Animals MH - Biomarkers/blood MH - Cells, Cultured MH - Cumulative Trauma Disorders/blood/*enzymology/pathology MH - Humans MH - Male MH - Matrix Metalloproteinase 14/metabolism MH - Matrix Metalloproteinase 2/*blood MH - Rabbits MH - *Stress, Mechanical MH - Tendinopathy/blood/*enzymology/pathology MH - Tenocytes/*enzymology MH - Tissue Inhibitor of Metalloproteinase-2/metabolism MH - Weight-Bearing OTO - NOTNLM OT - matrix metalloproteinase OT - mechanical stimulation OT - overuse OT - tendon EDAT- 2016/02/26 06:00 MHDA- 2017/08/29 06:00 CRDT- 2016/02/25 06:00 PHST- 2015/10/17 00:00 [received] PHST- 2016/02/18 00:00 [accepted] PHST- 2016/02/26 06:00 [pubmed] PHST- 2017/08/29 06:00 [medline] PHST- 2016/02/25 06:00 [entrez] AID - 10.1002/jor.23207 [doi] PST - ppublish SO - J Orthop Res. 2016 Nov;34(11):1991-2000. doi: 10.1002/jor.23207. Epub 2016 Apr 7. PMID- 35807843 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20250130 IS - 2072-6643 (Electronic) IS - 2072-6643 (Linking) VI - 14 IP - 13 DP - 2022 Jun 27 TI - Effect of Vitamin C on Tendinopathy Recovery: A Scoping Review. LID - 10.3390/nu14132663 [doi] LID - 2663 AB - Tendinopathies represent 30-50% of all sports injuries. The tendon response is influenced by the load (volume, intensity, and frequency) that the tendon support, resulting in irritability and pain, among others. The main molecular component of tendons is collagen I (60-85%). The rest consist of glycosaminoglycans-proteoglycans, glycoproteins, and other collagen subtypes. This study's aim was to critically evaluate the efficacy of vitamin C supplementation in the treatment of tendinopathies. At the same time, the study aims to determine the optimal conditions (dose and time) for vitamin C supplementation. A structured search was carried out in the SCOPUS, Medline (PubMed), and Web of Science (WOS) databases. The inclusion criteria took into account studies describing optimal tendon recovery when using vitamin C alone or in combination with other compounds. The study design was considered, including randomized, double-blind controlled, and parallel designs in animal models or humans. The main outcome is that vitamin C supplementation is potentially useful as a therapeutic approach for tendinopathy recovery. Vitamin C supplementation, alone or in combination with other products, increases collagen synthesis with a consequent improvement in the patient's condition. On the other hand, vitamin C deficiency is mainly associated with a decrease in procollagen synthesis and reduced hydroxylation of proline and lysine residues, hindering the tendon repair process. FAU - Noriega-González, David C AU - Noriega-González DC AD - Department of Surgery, Ophthalmology, Otorhinolaryngology and Physiotherapy, Faculty of Medicine, Hospital Clínico Universitario de Valladolid, 47002 Valladolid, Spain. FAU - Drobnic, Franchek AU - Drobnic F AD - Medical Services Shanghai Shenhua FC, Shanghai 201315, China. FAU - Caballero-García, Alberto AU - Caballero-García A AUID- ORCID: 0000-0002-9131-0615 AD - Department of Anatomy and Radiology, Faculty of Health Sciences, GIR Physical Exercise and Aging, Campus Los Pajaritos, University of Valladolid, 42004 Soria, Spain. FAU - Roche, Enrique AU - Roche E AUID- ORCID: 0000-0001-5128-1672 AD - Department of Applied Biology-Nutrition, Institute of Bioengineering, University Miguel Hernández, 03202 Elche, Spain. AD - Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain. AD - CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain. FAU - Perez-Valdecantos, Daniel AU - Perez-Valdecantos D AUID- ORCID: 0000-0002-6916-608X AD - Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, GIR Physical Exercise and Aging, Campus Duques de Soria, University of Valladolid, 42004 Soria, Spain. FAU - Córdova, Alfredo AU - Córdova A AUID- ORCID: 0000-0003-0236-2817 AD - Department of Biochemistry, Molecular Biology and Physiology, Faculty of Health Sciences, GIR Physical Exercise and Aging, Campus Duques de Soria, University of Valladolid, 42004 Soria, Spain. LA - eng GR - Caja Rural de Soria/ PT - Journal Article PT - Scoping Review DEP - 20220627 PL - Switzerland TA - Nutrients JT - Nutrients JID - 101521595 RN - 0 (Vitamins) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - *Ascorbic Acid MH - Collagen MH - Randomized Controlled Trials as Topic MH - *Tendinopathy/drug therapy MH - Tendons MH - Vitamins PMC - PMC9267994 OTO - NOTNLM OT - ascorbic acid OT - collagen OT - oxidative stress OT - tendinopathy OT - vitamin C COIS- The authors declare no conflict of interest. EDAT- 2022/07/10 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/06/27 CRDT- 2022/07/09 01:21 PHST- 2022/05/25 00:00 [received] PHST- 2022/06/22 00:00 [revised] PHST- 2022/06/24 00:00 [accepted] PHST- 2022/07/09 01:21 [entrez] PHST- 2022/07/10 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/27 00:00 [pmc-release] AID - nu14132663 [pii] AID - nutrients-14-02663 [pii] AID - 10.3390/nu14132663 [doi] PST - epublish SO - Nutrients. 2022 Jun 27;14(13):2663. doi: 10.3390/nu14132663. PMID- 16198031 OWN - NLM STAT- MEDLINE DCOM- 20060201 LR - 20141120 IS - 0268-0033 (Print) IS - 0268-0033 (Linking) VI - 21 IP - 1 DP - 2006 Jan TI - Cyclic loading alters biomechanical properties and secretion of PGE2 and NO from tendon explants. PG - 99-106 AB - BACKGROUND: Tendon overuse injuries are a common occurrence; accounting for a large proportion of occupational and athletic injuries. The concept examined in this study is the role of load-induced intrinsic inflammation to the mechanism of these injuries. This study examined the influence of cyclical loading on the mechanical properties, cell viability, and inflammatory mediators of cultured tendon explants. METHODS: Chicken digital flexor tendon explants were isolated and separated into no-load (24 h rest), moderate load (0.25-3.0 MPa, 1 Hz, 4 h, 20 h rest), and aggressive load (0.25-12.0 MPa, 1 Hz, 24 h) treatment groups. Tissue loading was carried out with a pneumatic device under load-control. The loading regimens for each explant treatment group started at a uniform time point (day 3 from isolation, t = 0 h). Medium was collected at t = 24 and t = 48 h and analyzed for the inflammatory mediators prostaglandin E(2) and nitric oxide. Viability was evaluated at t = 48 h. FINDINGS: Biomechanical data revealed a significantly (P < 0.05) lower strength in the aggressively loaded specimens compared to the moderately loaded samples. Prostaglandin E(2) concentrations of aggressively loaded samples showed significantly higher values compared to moderately loaded samples at t = 48 h. Nitric oxide concentrations were greater in the moderately loaded samples relative to the no-load group at t = 24 h. Viability was not found to differ among the groups. INTERPRETATION: Alterations in cyclical loading of tendon may cause a change in fibroblast-mediated inflammatory mediator production in tendon. This response is of clinical significance as it may have a role in the pathology of tendon overuse injuries. FAU - Flick, Jason AU - Flick J AD - Department of Biomedical Engineering, University of North Carolina, Chapel Hill, 27599, USA. FAU - Devkota, Aaditya AU - Devkota A FAU - Tsuzaki, Mari AU - Tsuzaki M FAU - Almekinders, Louis AU - Almekinders L FAU - Weinhold, Paul AU - Weinhold P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20050927 PL - England TA - Clin Biomech (Bristol) JT - Clinical biomechanics (Bristol, Avon) JID - 8611877 RN - 31C4KY9ESH (Nitric Oxide) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Adaptation, Physiological MH - Animals MH - Biomechanical Phenomena MH - Cell Survival MH - Cells, Cultured MH - Chickens MH - Compressive Strength MH - Cumulative Trauma Disorders/*physiopathology MH - Dinoprostone/*metabolism MH - Elasticity MH - In Vitro Techniques MH - Nitric Oxide/*metabolism MH - Periodicity MH - Stress, Mechanical MH - Tendon Injuries/*physiopathology MH - Tendons/*physiopathology MH - *Weight-Bearing EDAT- 2005/10/04 09:00 MHDA- 2006/02/02 09:00 CRDT- 2005/10/04 09:00 PHST- 2005/01/12 00:00 [received] PHST- 2005/07/29 00:00 [revised] PHST- 2005/08/11 00:00 [accepted] PHST- 2005/10/04 09:00 [pubmed] PHST- 2006/02/02 09:00 [medline] PHST- 2005/10/04 09:00 [entrez] AID - S0268-0033(05)00188-9 [pii] AID - 10.1016/j.clinbiomech.2005.08.008 [doi] PST - ppublish SO - Clin Biomech (Bristol). 2006 Jan;21(1):99-106. doi: 10.1016/j.clinbiomech.2005.08.008. Epub 2005 Sep 27. PMID- 30340149 OWN - NLM STAT- MEDLINE DCOM- 20191113 LR - 20191113 IS - 1879-1271 (Electronic) IS - 0268-0033 (Linking) VI - 60 DP - 2018 Dec TI - Irradiation at 11 kGy conserves the biomechanical properties of fascia lata better than irradiation at 25 kGy. PG - 100-107 LID - S0268-0033(18)30340-1 [pii] LID - 10.1016/j.clinbiomech.2018.10.016 [doi] AB - The objective of this study was to determine the biomechanical properties of the fascia lata and the effects of three preservation methods: freezing, cryopreservation with dimethylsulfoxide solution and lyophilization; and to compare the effects of low-dose (11 kGy) and normal-dose (25 kGy) gamma-ray sterilization versus no irradiation. 248 samples from 14 fasciae latae were collected. Freezing samples were frozen at -80 °C. Cryopreservation with dimethylsulfoxide solution samples were frozen with 10 cl dimethylsulfoxide solution at -80 °C. Lyophilization samples were frozen at -22 °C and lyophilized. Each preservation group were then randomly divided into 3 irradiation groups. The cryopreservation with dimethylsulfoxide solution samples had significantly worse results in all 3 irradiation conditions. Young's modulus was lower for the freezing samples (p < 0.001) and lyophilization samples groups (p < 0.001). Tear deformation was lower for the freezing samples (p = 0.001) and lyophilization samples groups (p = 0.003), as was stress at break (p < 0.001 and p < 0.001). Taking all preservation methods together, samples irradiated at 25 kGy had worse results than the 0 kGy and 11 kGy groups in terms of Young's modulus (p = 0.007 and p = 0.13) and of stress at break (p = 0.006 and p = 0.06). The biomechanical properties of fascia lata allografts were significantly worse under dimethylsulfoxide cryopreservation. The deleterious effects of irradiation were dose-dependent. CI - Copyright © 2018 Elsevier Ltd. All rights reserved. FAU - Erivan, Roger AU - Erivan R AD - Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: rerivan@chu-clermontferrand.fr. FAU - Aubret, Sylvain AU - Aubret S AD - Université Clermont Auvergne, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France. FAU - Villatte, Guillaume AU - Villatte G AD - Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont-Ferrand, France. FAU - Cueff, Régis AU - Cueff R AD - Université Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont-Ferrand, France. FAU - Mulliez, Aurélien AU - Mulliez A AD - Délégation à la Recherche Clinique et aux Innovations (DRCI), CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France. FAU - Descamps, Stéphane AU - Descamps S AD - Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont-Ferrand, France. FAU - Boisgard, Stéphane AU - Boisgard S AD - Université Clermont Auvergne, CHU Clermont-Ferrand, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont-Ferrand, France. LA - eng PT - Comparative Study PT - Journal Article DEP - 20181012 PL - England TA - Clin Biomech (Bristol) JT - Clinical biomechanics (Bristol, Avon) JID - 8611877 RN - YOW8V9698H (Dimethyl Sulfoxide) SB - IM MH - Adult MH - Aged MH - Allografts MH - Biomechanical Phenomena MH - Cadaver MH - Cryopreservation/*methods MH - Dimethyl Sulfoxide/chemistry MH - Elastic Modulus MH - Fascia Lata/*physiopathology/*radiation effects/*transplantation MH - Female MH - Freeze Drying MH - Freezing MH - *Gamma Rays MH - Humans MH - Male MH - Middle Aged MH - Rupture MH - Specimen Handling/methods MH - Sterilization/methods MH - Tendons/transplantation MH - Transplantation, Homologous MH - Young Adult OTO - NOTNLM OT - Cryopreservation OT - Dimethylsulfoxide OT - Fascia lata OT - Irradiation OT - Knee ligament OT - Lyophilization OT - Tendon allograft OT - Tendon biomechanics EDAT- 2018/10/20 06:00 MHDA- 2019/11/14 06:00 CRDT- 2018/10/20 06:00 PHST- 2018/04/17 00:00 [received] PHST- 2018/08/24 00:00 [revised] PHST- 2018/10/11 00:00 [accepted] PHST- 2018/10/20 06:00 [pubmed] PHST- 2019/11/14 06:00 [medline] PHST- 2018/10/20 06:00 [entrez] AID - S0268-0033(18)30340-1 [pii] AID - 10.1016/j.clinbiomech.2018.10.016 [doi] PST - ppublish SO - Clin Biomech (Bristol). 2018 Dec;60:100-107. doi: 10.1016/j.clinbiomech.2018.10.016. Epub 2018 Oct 12. PMID- 34081845 OWN - NLM STAT- MEDLINE DCOM- 20220118 LR - 20250530 IS - 2326-5205 (Electronic) IS - 2326-5191 (Linking) VI - 73 IP - 12 DP - 2021 Dec TI - Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation. PG - 2271-2281 LID - 10.1002/art.41882 [doi] AB - OBJECTIVE: To assess the involvement of the CCR6/CCL20 axis in psoriatic arthritis (PsA) and psoriasis (PsO) and to evaluate its potential as a therapeutic target. METHODS: First, we quantified CCL20 levels in peripheral blood and synovial fluid from PsA patients and examined the presence of CCR6+ cells in synovial and tendon tissue. Utilizing an interleukin-23 minicircle DNA (IL-23 MC) mouse model exhibiting key features of both PsO and PsA, we investigated CCR6 and CCL20 expression as well as the preventive and therapeutic effect of CCL20 blockade. Healthy tendon stromal cells were stimulated in vitro with IL-1β to assess the production of CCL20 by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay. The effect of conditioned media from stimulated tenocytes in inducing T cell migration was interrogated using a Transwell system. RESULTS: We observed an up-regulation of both CCR6 and CCL20 in the enthesis of IL-23 MC-treated mice, which was confirmed in human biopsy specimens. Specific targeting of the CCR6/CCL20 axis with a CCL20 locked dimer (CCL20LD) blocked entheseal inflammation, leading to profound reductions in clinical and proinflammatory markers in the joints and skin of IL-23 MC-treated mice. The stromal compartment in the tendon was the main source of CCL20 in this model and, accordingly, in vitro activated human tendon cells were able to produce this chemokine and to induce CCR6+ T cell migration, the latter of which could be blocked by CCL20LD. CONCLUSION: Our study highlights the pathogenic role of the CCR6/CCL20 axis in enthesitis and introduces the prospect of a novel therapeutic approach for treating patients with PsO and PsA. CI - © 2021, American College of Rheumatology. FAU - Shi, Zhenrui AU - Shi Z AUID- ORCID: 0000-0001-9416-1152 AD - University of California, Davis, Sacramento, and Sun Yat-sen Memorial Hospital and Sun Yat-sen University, Guangzhou, China. FAU - Garcia-Melchor, Emma AU - Garcia-Melchor E AD - University of Glasgow, Glasgow, UK. FAU - Wu, Xuesong AU - Wu X AD - University of California, Davis, Sacramento. FAU - Getschman, Anthony E AU - Getschman AE AUID- ORCID: 0000-0002-0143-1561 AD - Medical College of Wisconsin, Milwaukee. FAU - Nguyen, Mimi AU - Nguyen M AD - University of California, Davis, Sacramento. FAU - Rowland, Douglas J AU - Rowland DJ AD - University of California, Davis, Sacramento. FAU - Wilson, Machelle AU - Wilson M AD - University of California, Davis, Sacramento. FAU - Sunzini, Flavia AU - Sunzini F AD - University of Glasgow, Glasgow, UK. FAU - Akbar, Moeed AU - Akbar M AD - University of Glasgow, Glasgow, UK. FAU - Huynh, Mindy AU - Huynh M AD - University of California, Davis, Sacramento. FAU - Law, Timothy AU - Law T AUID- ORCID: 0000-0002-6434-5687 AD - University of California, Davis, Sacramento. FAU - Raychaudhuri, Smriti K AU - Raychaudhuri SK AD - University of California, Davis. FAU - Raychaudhuri, Siba P AU - Raychaudhuri SP AD - University of California, Davis. FAU - Volkman, Brian F AU - Volkman BF AD - Medical College of Wisconsin, Milwaukee. FAU - Millar, Neal L AU - Millar NL AUID- ORCID: 0000-0001-9251-9907 AD - University of Glasgow, Glasgow, UK. FAU - Hwang, Sam T AU - Hwang ST AD - University of California, Davis, Sacramento. LA - eng GR - 1R43AR074363-01/Small Business Innovation Research/ GR - R43 AR074363/AR/NIAMS NIH HHS/United States GR - R44 AR074363/AR/NIAMS NIH HHS/United States GR - UL1 TR001860/TR/NCATS NIH HHS/United States GR - NPF/National Psoriasis Foundation/United States GR - MR/R020515/1/MRC_/Medical Research Council/United Kingdom GR - WI238753/Pfizer/ GR - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/ GR - ROI_AR063091_01A1/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211101 PL - United States TA - Arthritis Rheumatol JT - Arthritis & rheumatology (Hoboken, N.J.) JID - 101623795 RN - 0 (Chemokine CCL20) RN - 0 (Interleukin-1beta) RN - 0 (Interleukin-23) SB - IM CIN - Nat Rev Rheumatol. 2021 Aug;17(8):441. doi: 10.1038/s41584-021-00663-6. PMID: 34226726 MH - Animals MH - Arthritis, Psoriatic/blood/*metabolism MH - Chemokine CCL20/*blood MH - Humans MH - Inflammation/blood/*metabolism MH - Interleukin-1beta/pharmacology MH - Interleukin-23/pharmacology MH - Mice MH - Skin/metabolism MH - Stromal Cells/drug effects/metabolism MH - Synovial Fluid/*metabolism MH - Synovial Membrane/metabolism MH - Tendons/drug effects/metabolism EDAT- 2021/06/04 06:00 MHDA- 2022/01/19 06:00 CRDT- 2021/06/03 17:26 PHST- 2020/07/29 00:00 [received] PHST- 2021/05/18 00:00 [accepted] PHST- 2021/06/04 06:00 [pubmed] PHST- 2022/01/19 06:00 [medline] PHST- 2021/06/03 17:26 [entrez] AID - 10.1002/art.41882 [doi] PST - ppublish SO - Arthritis Rheumatol. 2021 Dec;73(12):2271-2281. doi: 10.1002/art.41882. Epub 2021 Nov 1. PMID- 21842416 OWN - NLM STAT- MEDLINE DCOM- 20120629 LR - 20211203 IS - 1439-6327 (Electronic) IS - 1439-6319 (Linking) VI - 112 IP - 4 DP - 2012 Apr TI - Gene expression in distinct regions of rat tendons in response to jump training combined with anabolic androgenic steroid administration. PG - 1505-15 LID - 10.1007/s00421-011-2114-x [doi] AB - The aim of this study was to evaluate the expression of key genes responsible for tendon remodeling of the proximal and distal regions of calcaneal tendon (CT), intermediate and distal region of superficial flexor tendon (SFT) and proximal, intermediate and distal region of deep flexor tendon (DFT) submitted to 7 weeks of jumping water load exercise in combination with AAS administration. Wistar male rats were grouped as follows: sedentary (S), trained (jumping water load exercise) (T), sedentary animals treated with AAS (5 mg/kg, twice a week) and animals treated with AAS and trained (AAST). mRNA levels of COL1A1, COL3A1, TIMP-1, TIMP-2, MMP-2, IGF-IEa, GAPDH, CTGF and TGF-β-1 were evaluated by quantitative PCR. Our main results indicated that mRNA levels alter in different regions in each tendon of sedentary animals. The training did not alter the expression of COL1A1, COL3A, IGF-IEa and MMP-2 genes, while AAS administration or its combination with training reduced their expression. This study indicated that exercise did not alter the expression of collagen and related growth factors in different regions of rat tendon. Moreover, the pattern of gene expression was distinct in the different tendon regions of sedentary animals. Although, the RNA yield levels of CT, SFT and DFT were not distinct in each region, these regions possess not only the structural and biochemical difference, but also divergence in the expression of key genes involved in tendon adaptation. FAU - Marqueti, Rita Cássia AU - Marqueti RC AD - Department of Physiological Sciences, Federal University of São Carlos, São Carlos, SP, Brazil. marqueti@gmail.com FAU - Heinemeier, Katja Maria AU - Heinemeier KM FAU - Durigan, João Luiz Quaglioti AU - Durigan JL FAU - de Andrade Perez, Sérgio Eduardo AU - de Andrade Perez SE FAU - Schjerling, Peter AU - Schjerling P FAU - Kjaer, Michael AU - Kjaer M FAU - Carvalho, Hernandes Faustino AU - Carvalho HF FAU - Selistre-de-Araujo, Heloisa Sobreiro AU - Selistre-de-Araujo HS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110814 PL - Germany TA - Eur J Appl Physiol JT - European journal of applied physiology JID - 100954790 RN - 0 (Anabolic Agents) RN - 0 (Androgens) RN - 0 (CCN2 protein, rat) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Collagen Type III) RN - 0 (RNA, Messenger) RN - 0 (Tgfb1 protein, rat) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Transforming Growth Factor beta1) RN - 0 (insulin-like growth factor-1, rat) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 6PG9VR430D (Nandrolone) RN - EC 1.2.1.- (Glyceraldehyde-3-Phosphate Dehydrogenases) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.24 (Mmp2 protein, rat) RN - H45187T098 (Nandrolone Decanoate) SB - IM EIN - Eur J Appl Physiol. 2012 Apr;112(4):1517. Marqueti, Rita de Cássia [corrected to Marqueti, Rita Cássia] MH - Adaptation, Physiological MH - Anabolic Agents/*administration & dosage MH - Androgens/*administration & dosage MH - Animals MH - Collagen Type I/genetics MH - Collagen Type I, alpha 1 Chain MH - Collagen Type III/genetics MH - Connective Tissue Growth Factor/genetics MH - Gene Expression Regulation/drug effects MH - Glyceraldehyde-3-Phosphate Dehydrogenases/genetics MH - Insulin-Like Growth Factor I/genetics MH - Male MH - Matrix Metalloproteinase 2/genetics MH - Nandrolone/administration & dosage/*analogs & derivatives MH - Nandrolone Decanoate MH - *Physical Exertion MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Wistar MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Sedentary Behavior MH - Tendons/*drug effects/metabolism MH - Time Factors MH - Tissue Inhibitor of Metalloproteinase-1/genetics MH - Tissue Inhibitor of Metalloproteinase-2/genetics MH - Transforming Growth Factor beta1/genetics EDAT- 2011/08/16 06:00 MHDA- 2012/06/30 06:00 CRDT- 2011/08/16 06:00 PHST- 2011/04/30 00:00 [received] PHST- 2011/07/29 00:00 [accepted] PHST- 2011/08/16 06:00 [entrez] PHST- 2011/08/16 06:00 [pubmed] PHST- 2012/06/30 06:00 [medline] AID - 10.1007/s00421-011-2114-x [doi] PST - ppublish SO - Eur J Appl Physiol. 2012 Apr;112(4):1505-15. doi: 10.1007/s00421-011-2114-x. Epub 2011 Aug 14. PMID- 38657023 OWN - NLM STAT- MEDLINE DCOM- 20240424 LR - 20250522 IS - 1946-6242 (Electronic) IS - 1946-6234 (Print) IS - 1946-6234 (Linking) VI - 16 IP - 744 DP - 2024 Apr 24 TI - The subacromial bursa modulates tendon healing after rotator cuff injury in rats. PG - eadd8273 LID - 10.1126/scitranslmed.add8273 [doi] AB - Rotator cuff injuries result in more than 500,000 surgeries annually in the United States, many of which fail. These surgeries typically involve repair of the injured tendon and removal of the subacromial bursa, a synovial-like tissue that sits between the rotator cuff and the acromion. The subacromial bursa has been implicated in rotator cuff pathogenesis and healing. Using proteomic profiling of bursa samples from nine patients with rotator cuff injury, we show that the bursa responds to injury in the underlying tendon. In a rat model of supraspinatus tenotomy, we evaluated the bursa's effect on the injured supraspinatus tendon, the uninjured infraspinatus tendon, and the underlying humeral head. The bursa protected the intact infraspinatus tendon adjacent to the injured supraspinatus tendon by maintaining its mechanical properties and protected the underlying humeral head by maintaining bone morphometry. The bursa promoted an inflammatory response in injured rat tendon, initiating expression of genes associated with wound healing, including Cox2 and Il6. These results were confirmed in rat bursa organ cultures. To evaluate the potential of the bursa as a therapeutic target, polymer microspheres loaded with dexamethasone were delivered to the intact bursae of rats after tenotomy. Dexamethasone released from the bursa reduced Il1b expression in injured rat supraspinatus tendon, suggesting that the bursa could be used for drug delivery to reduce inflammation in the healing tendon. Our findings indicate that the subacromial bursa contributes to healing in underlying tissues of the shoulder joint, suggesting that its removal during rotator cuff surgery should be reconsidered. FAU - Marshall, Brittany P AU - Marshall BP AUID- ORCID: 0000-0001-5544-9938 AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Ashinsky, Beth G AU - Ashinsky BG AUID- ORCID: 0000-0001-8934-8801 AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Ferrer, Xavier E AU - Ferrer XE AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Kunes, Jennifer A AU - Kunes JA AUID- ORCID: 0000-0002-6820-4769 AD - Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. FAU - Innis, Astia C AU - Innis AC AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Luzzi, Andrew J AU - Luzzi AJ AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Forrester, Lynn Ann AU - Forrester LA AUID- ORCID: 0000-0002-8795-6173 AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Burt, Kevin G AU - Burt KG AUID- ORCID: 0000-0001-8504-7980 AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Lee, Andy J AU - Lee AJ AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. FAU - Song, Lee AU - Song L AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Lisiewski, Lauren E AU - Lisiewski LE AUID- ORCID: 0000-0001-9655-7839 AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Soni, Rajesh K AU - Soni RK AUID- ORCID: 0000-0002-4556-4358 AD - Proteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA. FAU - Hung, Clark T AU - Hung CT AUID- ORCID: 0000-0002-7189-9477 AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Levine, William N AU - Levine WN AUID- ORCID: 0000-0002-2826-1179 AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. FAU - Kovacevic, David AU - Kovacevic D AUID- ORCID: 0000-0002-1900-5181 AD - New York Metropolitan Orthopaedics and Spine, New York, NY 10001, USA. FAU - Thomopoulos, Stavros AU - Thomopoulos S AUID- ORCID: 0000-0003-1531-4849 AD - Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA. AD - Department of Orthopedic Surgery, Columbia University, New York, NY 10032, USA. LA - eng GR - K08 AR072092/AR/NIAMS NIH HHS/United States GR - R01 AR057836/AR/NIAMS NIH HHS/United States GR - R56 AR057836/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20240424 PL - United States TA - Sci Transl Med JT - Science translational medicine JID - 101505086 RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Animals MH - *Rotator Cuff Injuries/pathology/metabolism/surgery MH - *Wound Healing MH - Humans MH - *Rats, Sprague-Dawley MH - *Bursa, Synovial/pathology/metabolism MH - *Tendons/pathology/metabolism MH - Male MH - *Rotator Cuff/pathology MH - Rats MH - Dexamethasone/pharmacology/therapeutic use MH - Female PMC - PMC11646107 MID - NIHMS2038164 COIS- Competing interests: The authors declare that they have no competing interests. EDAT- 2024/04/24 19:04 MHDA- 2024/04/24 19:05 PMCR- 2025/04/24 CRDT- 2024/04/24 14:02 PHST- 2024/04/24 19:05 [medline] PHST- 2024/04/24 19:04 [pubmed] PHST- 2024/04/24 14:02 [entrez] PHST- 2025/04/24 00:00 [pmc-release] AID - 10.1126/scitranslmed.add8273 [doi] PST - ppublish SO - Sci Transl Med. 2024 Apr 24;16(744):eadd8273. doi: 10.1126/scitranslmed.add8273. Epub 2024 Apr 24. PMID- 21822103 OWN - NLM STAT- MEDLINE DCOM- 20111219 LR - 20180110 IS - 1538-1951 (Electronic) IS - 1062-8592 (Linking) VI - 19 IP - 3 DP - 2011 Sep TI - Role of metalloproteinases in rotator cuff tear. PG - 207-12 LID - 10.1097/JSA.0b013e318227b07b [doi] AB - The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPS) in the pathophysiology of rotator cuff tears has not been established yet. Recent advances empathize about the role of MMPs and TIMPS in extracellular matrix (ECM) remodeling and degradation in rotator cuff tears pathogenesis and healing after surgical repair. An increase in MMPs synthesis and the resulting MMPs mediated alterations in the ECM of tendons have been implicated in the etiopathogenesis of tendinopathy, and there is an increase in the expression of MMPs and a decrease in TIMP messenger ribonucleic acid expression in tenocytes from degenerative or ruptured tendons. Importantly, MMPs are amenable to inhibition by cheap, safe, and widely available drugs such as the tetracycline antibiotics and bisphosphonates. A better understanding of relationship and activity of these molecules could provide better strategies to optimize outcomes of rotator cuff therapy. FAU - Garofalo, Raffaele AU - Garofalo R AD - Department of Orthopedic and Traumatology, F Miulli Hospital, Acquaviva delle fonti, Bari, Italy. raffaelegarofalo@gmail.com FAU - Cesari, Eugenio AU - Cesari E FAU - Vinci, Enzo AU - Vinci E FAU - Castagna, Alessandro AU - Castagna A LA - eng PT - Journal Article PT - Review PL - United States TA - Sports Med Arthrosc Rev JT - Sports medicine and arthroscopy review JID - 9315689 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.- (Metalloproteases) SB - IM MH - Humans MH - Metalloproteases/antagonists & inhibitors/*metabolism MH - Rotator Cuff/*enzymology/physiopathology MH - *Rotator Cuff Injuries MH - Tendon Injuries/drug therapy/enzymology MH - Tissue Inhibitor of Metalloproteinases/*metabolism EDAT- 2011/08/09 06:00 MHDA- 2011/12/20 06:00 CRDT- 2011/08/09 06:00 PHST- 2011/08/09 06:00 [entrez] PHST- 2011/08/09 06:00 [pubmed] PHST- 2011/12/20 06:00 [medline] AID - 00132585-201109000-00005 [pii] AID - 10.1097/JSA.0b013e318227b07b [doi] PST - ppublish SO - Sports Med Arthrosc Rev. 2011 Sep;19(3):207-12. doi: 10.1097/JSA.0b013e318227b07b. PMID- 20692234 OWN - NLM STAT- MEDLINE DCOM- 20101007 LR - 20161125 IS - 1090-2104 (Electronic) IS - 0006-291X (Linking) VI - 399 IP - 4 DP - 2010 Sep 3 TI - Hypoxia induces adipogenic differentitation of myoblastic cell lines. PG - 721-6 LID - 10.1016/j.bbrc.2010.08.007 [doi] AB - Muscle atrophy usually accompanies fat accumulation in the muscle. In such atrophic conditions as back muscles of kyphotic spine and the rotator cuff muscles with torn tendons, blood flow might be diminished. It is known that hypoxia causes trans-differentiation of mesenchymal stem cells derived from bone marrow into adipocytes. However, it has not been elucidated yet if hypoxia turned myoblasts into adipocytes. We investigated adipogenesis in C2C12 and G8 murine myogenic cell line treated by hypoxia. Cells were also treated with the cocktail of insulin, dexamethasone and IBMX (MDI), which has been known to inhibit Wnt signaling and promote adipogenesis. Adipogenic differentiation was seen in both hypoxia and MDI. Adipogenic marker gene expression was assessed in C2C12. CCAAT/enhancer-binding protein (C/EBP) beta, alpha and peroxisome proliferator activating receptor (PPAR) gamma were increased by both hypoxia and MDI. The expression profile of Wnt10b was different between hypoxia and MDI. The mechanism for adipogenesis of myoblasts in hypoxia might be regulated by different mechanism than the modification of Wnt signaling. CI - Copyright 2010 Elsevier Inc. All rights reserved. FAU - Itoigawa, Yoshiaki AU - Itoigawa Y AD - Tohoku University School of Medicine, Sendai, Japan. FAU - Kishimoto, Koshi N AU - Kishimoto KN FAU - Okuno, Hiroshi AU - Okuno H FAU - Sano, Hirotaka AU - Sano H FAU - Kaneko, Kazuo AU - Kaneko K FAU - Itoi, Eiji AU - Itoi E LA - eng PT - Journal Article DEP - 20100806 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (CCAAT-Enhancer-Binding Protein-alpha) RN - 0 (CCAAT-Enhancer-Binding Protein-beta) RN - 0 (Insulin) RN - 0 (Nerve Tissue Proteins) RN - 0 (PPAR gamma) RN - 0 (Wnt Proteins) RN - 0 (Wnt10a protein, mouse) RN - 7S5I7G3JQL (Dexamethasone) RN - TBT296U68M (1-Methyl-3-isobutylxanthine) SB - IM MH - 1-Methyl-3-isobutylxanthine/pharmacology MH - Adipocytes/metabolism/*pathology MH - *Adipogenesis MH - Animals MH - CCAAT-Enhancer-Binding Protein-alpha/metabolism MH - CCAAT-Enhancer-Binding Protein-beta/metabolism MH - Cell Line MH - Dexamethasone/pharmacology MH - Gene Expression Regulation MH - Hypoxia/metabolism/*pathology MH - Insulin/pharmacology MH - Mice MH - Muscular Atrophy/metabolism/*pathology MH - Myoblasts/drug effects/metabolism/*pathology MH - Nerve Tissue Proteins/genetics MH - PPAR gamma/metabolism MH - Wnt Proteins/genetics EDAT- 2010/08/10 06:00 MHDA- 2010/10/12 06:00 CRDT- 2010/08/10 06:00 PHST- 2010/07/07 00:00 [received] PHST- 2010/08/03 00:00 [accepted] PHST- 2010/08/10 06:00 [entrez] PHST- 2010/08/10 06:00 [pubmed] PHST- 2010/10/12 06:00 [medline] AID - S0006-291X(10)01484-1 [pii] AID - 10.1016/j.bbrc.2010.08.007 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2010 Sep 3;399(4):721-6. doi: 10.1016/j.bbrc.2010.08.007. Epub 2010 Aug 6. PMID- 38564283 OWN - NLM STAT- MEDLINE DCOM- 20240801 LR - 20250625 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 42 IP - 9 DP - 2024 Sep TI - Investigation of the effects of pentoxifylline and alpha tocopherol treatment on recovery in rats with Achilles tendon rupture. PG - 1907-1915 LID - 10.1002/jor.25844 [doi] AB - Although the Achilles tendon is the largest and strongest tendon in the body, healing of the Achilles tendon is the most common injury, and this process is difficult due to poor tendon circulation; moreover, the underlying mechanism has not been fully elucidated. In our study, we aimed to investigate the effects of pentoxifylline and alpha-tocopherol administered separately or in combination on rats with Achilles tendon injury. Forty-eight male Wistar rats weighing 230 ± 30 g were used in the study. The rats were randomly divided into eight groups of six animals each. Tendons were evaluated histopathologically and biomechanically. According to the statistical analysis, the vascularity density in the pentoxifylline group on day 14 was significantly greater than that in the other groups (p < 0.05). The collagen arrangement in the pentoxifylline and alpha-tocopherol groups on day 14 was found to be firmer and smoother than that in the control group (p < 0.05). The collagen arrangement in the pentoxifylline group on day 28 was greater than that in the other groups (p < 0.05). The biomechanical results were significantly greater in all groups (p < 0.05). Pentoxifylline contributed to tendon healing both through neovascularization in the early period and by improving collagen orientation in the late period, while alpha-tocopherol had a positive effect on collagen orientation in the early period. No beneficial effects were observed when pentoxifylline and alpha-tocopherol were used together. We believe that further research is needed to understand the effects of this combination therapy on tendon healing. CI - © 2024 The Authors. Journal of Orthopaedic Research® published by Wiley Periodicals LLC on behalf of Orthopaedic Research Society. FAU - Toker, Mustafa AU - Toker M AUID- ORCID: 0000-0002-0697-9497 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Karaduman, Zekeriya Okan AU - Karaduman ZO AUID- ORCID: 0000-0002-6719-3666 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Arıcan, Mehmet AU - Arıcan M AUID- ORCID: 0000-0002-0649-2339 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Turhan, Yalçın AU - Turhan Y AUID- ORCID: 0000-0002-1440-9566 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Coşkun, Sinem Kantarcıoğlu AU - Coşkun SK AUID- ORCID: 0000-0002-8133-8665 AD - Department of Pathology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Dalaslan, Raşit Emin AU - Dalaslan RE AUID- ORCID: 0000-0001-5068-8024 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Çelik, Mücahit AU - Çelik M AUID- ORCID: 0009-0004-0187-8525 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. FAU - Uludağ, Veysel AU - Uludağ V AUID- ORCID: 0000-0002-9911-5961 AD - Department of Orthopedics and Traumatology, Medical Faculty, Duzce University, Düzce, Turkey. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240402 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - SD6QCT3TSU (Pentoxifylline) RN - H4N855PNZ1 (alpha-Tocopherol) RN - 0 (Antioxidants) RN - 9007-34-5 (Collagen) SB - IM MH - *Pentoxifylline/therapeutic use/pharmacology MH - Animals MH - *Achilles Tendon/injuries/drug effects MH - *alpha-Tocopherol/therapeutic use/pharmacology MH - Male MH - *Rats, Wistar MH - Rats MH - *Tendon Injuries/drug therapy MH - Rupture/drug therapy MH - Wound Healing/drug effects MH - Biomechanical Phenomena MH - Antioxidants/therapeutic use/pharmacology MH - Collagen/metabolism MH - Drug Therapy, Combination OTO - NOTNLM OT - alpha‐tocopherol OT - inflammation OT - pentoxifylline OT - tendon healing OT - vasculature EDAT- 2024/04/02 12:48 MHDA- 2024/08/01 12:42 CRDT- 2024/04/02 12:03 PHST- 2024/02/16 00:00 [revised] PHST- 2023/08/09 00:00 [received] PHST- 2024/03/20 00:00 [accepted] PHST- 2024/08/01 12:42 [medline] PHST- 2024/04/02 12:48 [pubmed] PHST- 2024/04/02 12:03 [entrez] AID - 10.1002/jor.25844 [doi] PST - ppublish SO - J Orthop Res. 2024 Sep;42(9):1907-1915. doi: 10.1002/jor.25844. Epub 2024 Apr 2. PMID- 10218530 OWN - NLM STAT- MEDLINE DCOM- 19990520 LR - 20220321 IS - 0140-6736 (Print) IS - 0140-6736 (Linking) VI - 353 IP - 9161 DP - 1999 Apr 17 TI - Human hand allograft: report on first 6 months. PG - 1315-20 AB - BACKGROUND: Long-term survival of animal limb allografts with new immunosuppressant combinations and encouraging results of autologous limb replantations led us to believe that clinical application of hand transplantation in human beings was viable. METHODS: On Sept 23, 1998, we transplanted the right distal forearm and hand of a brain-dead man aged 41 years on to a man aged 48 years who had had traumatic amputation of the distal third of his right forearm. The donor's arm was irrigated with UW organ preservation solution at 4 degrees C, amputated 5 cm above the elbow, and transported in a cool container. We dissected the donor limb and the recipient's arm simultaneously to identify anatomical structures. Appropriate lengths of viable structures were matched. Transplantation involved bone fixation, arterial and venous anastomoses (ischaemic time 12.5 h), nerve sutures, joining of muscles and tendons, and skin closure. Immunosuppression included antithymocyte globulins, tacrolimus, mycophenolic acid, and prednisone. Maintenance therapy included tacrolimus, mycophenolic acid, and prednisone. Follow-up included routine post-transplant laboratory tests, skin biopsies, intensive physiotherapy, and psychological support. FINDINGS: The initial postoperative course was uneventful. No surgical complications were seen. Immunosuppression was well tolerated. Mild clinical and histological signs of cutaneous rejection were seen at weeks 8-9 after surgery. These signs disappeared after prednisone dose was increased (from 20 mg/day to 40 mg/day) and topical application of immunosuppressive creams (tacrolimus, clobetasol). Intensive physiotherapy led to satisfactory progress of motor function. Sensory progress (Tinel's sign) was excellent and reached the wrist crease (20 cm) on day 100 for the median and ulnar nerves, and at least 24 cm to the palm by 6 months when deep pressure, but not light touch sensation, could be felt at the mid palm. INTERPRETATION: Hand allotransplantation is technically feasible. Currently available immunosuppression seems to prevent acute rejection. If no further episode of rejection occurs, the functional prognosis of this graft should be similar to if not better than that reported in large series of autoreconstruction. FAU - Dubernard, J M AU - Dubernard JM AD - Service de Chirugie de la Transplantation et d'Urologie, Hôpital Edouard Herriot, Lyon, France. jean-michel.dubernard@chu-lyon.fr FAU - Owen, E AU - Owen E FAU - Herzberg, G AU - Herzberg G FAU - Lanzetta, M AU - Lanzetta M FAU - Martin, X AU - Martin X FAU - Kapila, H AU - Kapila H FAU - Dawahra, M AU - Dawahra M FAU - Hakim, N S AU - Hakim NS LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Lancet JT - Lancet (London, England) JID - 2985213R RN - 0 (Immunosuppressive Agents) RN - 0 (Insulin) RN - 0 (Organ Preservation Solutions) RN - 0 (University of Wisconsin-lactobionate solution) RN - 63CZ7GJN5I (Allopurinol) RN - GAN16C9B8O (Glutathione) RN - K72T3FS567 (Adenosine) RN - N5O3QU595M (Raffinose) SB - IM CIN - Lancet. 1999 Apr 17;353(9161):1286-7. doi: 10.1016/S0140-6736(99)00112-9. PMID: 10218520 CIN - Lancet. 1999 Nov 20;354(9192):1820-1. doi: 10.1016/s0140-6736(05)70589-4. PMID: 10577667 MH - Adenosine MH - Allopurinol MH - Amputation, Traumatic/surgery MH - Feasibility Studies MH - Follow-Up Studies MH - Forearm/surgery MH - Glutathione MH - Graft Rejection/prevention & control MH - *Hand Transplantation MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Insulin MH - Male MH - Microsurgery MH - Middle Aged MH - Organ Preservation MH - Organ Preservation Solutions MH - Organ Transplantation/rehabilitation MH - Physical Therapy Modalities MH - Raffinose MH - Time Factors MH - Transplantation, Homologous EDAT- 1999/04/28 02:03 MHDA- 2000/02/19 09:00 CRDT- 1999/04/28 02:03 PHST- 1999/04/28 02:03 [pubmed] PHST- 2000/02/19 09:00 [medline] PHST- 1999/04/28 02:03 [entrez] AID - S0140-6736(99)02062-0 [pii] AID - 10.1016/S0140-6736(99)02062-0 [doi] PST - ppublish SO - Lancet. 1999 Apr 17;353(9161):1315-20. doi: 10.1016/S0140-6736(99)02062-0. PMID- 40641112 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250730 IS - 1791-244X (Electronic) IS - 1107-3756 (Print) IS - 1107-3756 (Linking) VI - 56 IP - 3 DP - 2025 Sep TI - TNF‑α induces premature senescence in tendon stem cells via the NF‑κB and p53/p21/cyclin E/CDK2 signaling pathways. LID - 140 [pii] LID - 10.3892/ijmm.2025.5581 [doi] AB - Achilles tendinitis (AT) is a complex disorder that affects tendon tissue and often responds poorly to non‑steroidal anti‑inflammatory drugs. Tumor necrosis factor‑α (TNF‑α), a proinflammatory cytokine involved in cell death and immune regulation, serves a central role in AT progression. The present study investigated the effects of TNF‑α on tendon stem cells (TSCs) and evaluated potential therapeutic strategies for AT. TNF‑α‑induced changes in TSCs were determined by investigating markers of cellular senescence, reactive oxygen species (ROS) activity, DNA damage and the expression of key transcription factors, including NF‑κB (phosphorylated‑p65, p65), p53, p21, cyclin E and CDK2. To determine whether TNF‑α‑induced senescence could be reversed, TSCs were treated with etanercept, a TNF‑α‑specific inhibitor. TNF‑α stimulation induced significant senescence in TSCs, as evidenced by increased ROS production, DNA damage and altered expression of senescence‑associated transcription factors. TNF‑α activated the NF‑κB and p53/p21/cyclin E/CDK2 signaling pathways, promoting TSC senescence. Etanercept treatment effectively reversed these effects, decreasing TSC senescence, suppressing inflammatory cell infiltration, decreasing TNF‑α protein expression and mitigating collagen fiber degradation. TNF‑α promotes TSCs senescence through specific signaling pathways and etanercept can counteract these deleterious effects. These results provide insights into the pathogenesis of AT and highlight TNF‑α inhibition as a promising therapeutic approach. Targeting TNF‑α may offer a novel treatment strategy for individuals with AT. FAU - Guo, Hua AU - Guo H AD - Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China. FAU - Cao, Haixia AU - Cao H AD - Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China. FAU - Lu, Qian AU - Lu Q AD - Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China. FAU - Gu, Zhifeng AU - Gu Z AD - Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China. FAU - Feng, Guijuan AU - Feng G AD - Department of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China. LA - eng PT - Journal Article DEP - 20250711 PL - Greece TA - Int J Mol Med JT - International journal of molecular medicine JID - 9810955 RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (NF-kappa B) RN - 0 (Tumor Suppressor Protein p53) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 2) RN - 0 (Cyclin E) RN - 0 (Cyclin-Dependent Kinase Inhibitor p21) RN - 0 (Reactive Oxygen Species) SB - IM MH - *Tumor Necrosis Factor-alpha/pharmacology/metabolism MH - *Cellular Senescence/drug effects MH - *Signal Transduction/drug effects MH - *NF-kappa B/metabolism MH - *Stem Cells/metabolism/drug effects/cytology MH - Tumor Suppressor Protein p53/metabolism MH - Cyclin-Dependent Kinase 2/metabolism MH - Cyclin E/metabolism MH - Animals MH - Cyclin-Dependent Kinase Inhibitor p21/metabolism MH - *Tendons/cytology/metabolism MH - Reactive Oxygen Species/metabolism MH - DNA Damage MH - Male MH - Humans MH - Rats PMC - PMC12270418 OTO - NOTNLM OT - Achilles tendinitis OT - DNA damage OT - senescence OT - tendon stem cell OT - tumor necrosis factor‑α COIS- The authors declare that they have no competing interests. EDAT- 2025/07/11 06:27 MHDA- 2025/07/11 06:28 PMCR- 2025/07/10 CRDT- 2025/07/11 01:53 PHST- 2024/09/24 00:00 [received] PHST- 2025/05/23 00:00 [accepted] PHST- 2025/07/11 06:28 [medline] PHST- 2025/07/11 06:27 [pubmed] PHST- 2025/07/11 01:53 [entrez] PHST- 2025/07/10 00:00 [pmc-release] AID - 140 [pii] AID - ijmm-56-03-05581 [pii] AID - 10.3892/ijmm.2025.5581 [doi] PST - ppublish SO - Int J Mol Med. 2025 Sep;56(3):140. doi: 10.3892/ijmm.2025.5581. Epub 2025 Jul 11. PMID- 14977670 OWN - NLM STAT- MEDLINE DCOM- 20040527 LR - 20170214 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 32 IP - 2 DP - 2004 Mar TI - Inflammatory response of human tendon fibroblasts to cyclic mechanical stretching. PG - 435-40 AB - BACKGROUND: The cellular and molecular mechanisms for the development of tendinopathy are not clear, but inflammatory mediators produced by tendon fibroblasts in response to repetitive mechanical loading may be an important factor. HYPOTHESES: (1) Cyclic stretching of tendon fibroblasts affects the production of leukotriene B(4) and the expression of 5-lipoxygenase; and (2) the production level of leukotriene B(4) is inversely related to that of prostaglandin E(2). STUDY DESIGN: Controlled laboratory study. METHODS: Human patellar tendon fibroblasts were uniaxially stretched in the presence of indomethacin (25 micro M) or MK-886 (10 micro M). After stretching for 4 hours, followed by 4 hours rest, levels of prostaglandin E(2), leukotriene B(4), and expression of 5-lipoxygenase were measured. RESULTS: Stretched tendon fibroblasts increased the levels of leukotriene B(4) but did not appreciably change the expression of 5-lipoxygenase. Indomethacin decreased the cellular production of prostaglandin E(2) but caused increased leukotriene B(4) levels. MK-886 caused decreased production of leukotriene B(4) but increased production of prostaglandin E(2). CONCLUSIONS: Cyclic stretching of human tendon fibroblasts increases the production of prostaglandin E(2) and leukotriene B(4). Blocking prostaglandin E(2) production leads to increased leukotriene B(4) levels and vice versa. CLINICAL RELEVANCE: The use of nonsteroidal anti-inflammatory drugs for the treatment of tendon inflammation might increase the levels of leukotriene B(4) within the tendon, potentially contributing to the development of tendinopathy. FAU - Li, Zhaozhu AU - Li Z AD - Musculoskeletal Research Center, Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. FAU - Yang, Guoguang AU - Yang G FAU - Khan, Mustafa AU - Khan M FAU - Stone, David AU - Stone D FAU - Woo, Savio L Y AU - Woo SL FAU - Wang, James H C AU - Wang JH LA - eng GR - AR049921/AR/NIAMS NIH HHS/United States GR - AR47372/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 0 (Indoles) RN - 0 (Lipoxygenase Inhibitors) RN - 080626SQ8C (MK-886) RN - 1HGW4DR56D (Leukotriene B4) RN - EC 1.13.11.34 (Arachidonate 5-Lipoxygenase) RN - K7Q1JQR04M (Dinoprostone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/pharmacology MH - Arachidonate 5-Lipoxygenase/biosynthesis MH - Bicycling/*physiology MH - Cell Culture Techniques MH - Dinoprostone/biosynthesis MH - Fibroblasts/*immunology MH - Humans MH - Indoles/pharmacology MH - Indomethacin/pharmacology MH - *Inflammation MH - Leukotriene B4/biosynthesis MH - Lipoxygenase Inhibitors/pharmacology MH - Tendons/*immunology/*pathology MH - Tensile Strength EDAT- 2004/02/24 05:00 MHDA- 2004/05/28 05:00 CRDT- 2004/02/24 05:00 PHST- 2004/02/24 05:00 [pubmed] PHST- 2004/05/28 05:00 [medline] PHST- 2004/02/24 05:00 [entrez] AID - 10.1177/0095399703258680 [doi] PST - ppublish SO - Am J Sports Med. 2004 Mar;32(2):435-40. doi: 10.1177/0095399703258680. PMID- 22772566 OWN - NLM STAT- MEDLINE DCOM- 20120919 LR - 20250529 IS - 1546-170X (Electronic) IS - 1078-8956 (Linking) VI - 18 IP - 7 DP - 2012 Jul 1 TI - IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. PG - 1069-76 LID - 10.1038/nm.2817 [doi] AB - The spondyloarthropathies are a group of rheumatic diseases that are associated with inflammation at anatomically distal sites, particularly the tendon-bone attachments (entheses) and the aortic root. Serum concentrations of interleukin-23 (IL-23) are elevated and polymorphisms in the IL-23 receptor are associated with ankyosing spondylitis, however, it remains unclear whether IL-23 acts locally at the enthesis or distally on circulating cell populations. We show here that IL-23 is essential in enthesitis and acts on previously unidentified IL-23 receptor (IL-23R)(+), RAR-related orphan receptor γt (ROR-γt)(+)CD3(+)CD4(-)CD8(-), stem cell antigen 1 (Sca1)(+) entheseal resident T cells. These cells allow entheses to respond to IL-23 in vitro-in the absence of further cellular recruitment--and to elaborate inflammatory mediators including IL-6, IL-17, IL-22 and chemokine (C-X-C motif) ligand 1 (CXCL1). Notably, the in vivo expression of IL-23 is sufficient to phenocopy the human disease, with the specific and characteristic development of enthesitis and entheseal new bone formation in the initial complete absence of synovitis. As in the human condition, inflammation also develops in vivo at the aortic root and valve, which are structurally similar to entheses. The presence of these entheseal resident cells and their production of IL-22, which activates signal transducer and activator of transcription 3 (STAT3)-dependent osteoblast-mediated bone remodeling, explains why dysregulation of IL-23 results in inflammation at this precise anatomical site. FAU - Sherlock, Jonathan P AU - Sherlock JP AD - Merck Research Laboratories, Palo Alto, California, USA. FAU - Joyce-Shaikh, Barbara AU - Joyce-Shaikh B FAU - Turner, Scott P AU - Turner SP FAU - Chao, Cheng-Chi AU - Chao CC FAU - Sathe, Manjiri AU - Sathe M FAU - Grein, Jeff AU - Grein J FAU - Gorman, Daniel M AU - Gorman DM FAU - Bowman, Edward P AU - Bowman EP FAU - McClanahan, Terrill K AU - McClanahan TK FAU - Yearley, Jennifer H AU - Yearley JH FAU - Eberl, Gérard AU - Eberl G FAU - Buckley, Christopher D AU - Buckley CD FAU - Kastelein, Robert A AU - Kastelein RA FAU - Pierce, Robert H AU - Pierce RH FAU - Laface, Drake M AU - Laface DM FAU - Cua, Daniel J AU - Cua DJ LA - eng GR - 19791/ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120701 PL - United States TA - Nat Med JT - Nature medicine JID - 9502015 RN - 0 (Antigens, CD) RN - 0 (CD3 Complex) RN - 0 (CD4 Antigens) RN - 0 (CD8 Antigens) RN - 0 (Interleukin-17) RN - 0 (Interleukin-23) RN - 0 (Interleukins) RN - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3) RN - 0 (Receptors, Interleukin) RN - 0 (interleukin-23 receptor, mouse) SB - IM CIN - Nat Med. 2012 Jul 06;18(7):1018-9. doi: 10.1038/nm.2854. PMID: 22772553 CIN - Nat Rev Rheumatol. 2012 Aug;8(8):439. doi: 10.1038/nrrheum.2012.117. PMID: 22801984 CIN - Nat Rev Immunol. 2012 Jul 25;12(8):552-3. doi: 10.1038/nri3269. PMID: 22828907 MH - Animals MH - Antigens, CD/metabolism MH - Aorta/pathology MH - Arthritis, Experimental/complications/immunology/pathology MH - Bone Remodeling MH - CD3 Complex/metabolism MH - CD4 Antigens/metabolism MH - CD8 Antigens/metabolism MH - Disease Models, Animal MH - Extremities/pathology MH - Flow Cytometry MH - Humans MH - Immunization, Passive MH - Inflammation/complications/immunology/pathology MH - Interleukin-17 MH - Interleukin-23/*immunology MH - Interleukins MH - Mice MH - Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism MH - Osteogenesis/immunology MH - Periosteum/growth & development MH - Receptors, Interleukin/metabolism MH - Spondylarthropathies/complications/*immunology/pathology MH - T-Lymphocytes/*immunology MH - Tendons/*immunology/pathology MH - Th17 Cells MH - Interleukin-22 EDAT- 2012/07/10 06:00 MHDA- 2012/09/20 06:00 CRDT- 2012/07/10 06:00 PHST- 2011/11/14 00:00 [received] PHST- 2012/04/27 00:00 [accepted] PHST- 2012/07/10 06:00 [entrez] PHST- 2012/07/10 06:00 [pubmed] PHST- 2012/09/20 06:00 [medline] AID - nm.2817 [pii] AID - 10.1038/nm.2817 [doi] PST - epublish SO - Nat Med. 2012 Jul 1;18(7):1069-76. doi: 10.1038/nm.2817. PMID- 6466930 OWN - NLM STAT- MEDLINE DCOM- 19841010 LR - 20220331 IS - 0306-3674 (Print) IS - 1473-0480 (Electronic) IS - 0306-3674 (Linking) VI - 18 IP - 2 DP - 1984 Jun TI - Bilateral spontaneous rupture of the Achilles tendons in a patient on long-term systemic steroid therapy. PG - 128-9 FAU - Baruah, D R AU - Baruah DR LA - eng PT - Case Reports PT - Journal Article PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - *Achilles Tendon/pathology MH - Aged MH - Arthritis, Rheumatoid/drug therapy MH - Asthma/drug therapy MH - Female MH - Humans MH - Male MH - Middle Aged MH - Necrosis MH - Prednisolone/*adverse effects MH - Rupture, Spontaneous PMC - PMC1859205 EDAT- 1984/06/01 00:00 MHDA- 1984/06/01 00:01 PMCR- 1984/06/01 CRDT- 1984/06/01 00:00 PHST- 1984/06/01 00:00 [pubmed] PHST- 1984/06/01 00:01 [medline] PHST- 1984/06/01 00:00 [entrez] PHST- 1984/06/01 00:00 [pmc-release] AID - 10.1136/bjsm.18.2.128 [doi] PST - ppublish SO - Br J Sports Med. 1984 Jun;18(2):128-9. doi: 10.1136/bjsm.18.2.128. PMID- 18478310 OWN - NLM STAT- MEDLINE DCOM- 20080626 LR - 20220408 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 466 IP - 7 DP - 2008 Jul TI - The basic science of tendinopathy. PG - 1528-38 LID - 10.1007/s11999-008-0286-4 [doi] AB - Tendinopathy is a common clinical problem with athletes and in many occupational settings. Tendinopathy can occur in any tendon, often near its insertion or enthesis where there is an area of stress concentration, and is directly related to the volume of repetitive load to which the tendon is exposed. Recent studies indicate tendinopathy is more likely to occur in situations that increase the "dose" of load to the tendon enthesis - including increased activity, weight, advancing age, and genetic factors. The cells in tendinopathic tendon are rounder, more numerous, and show evidence of oxidative damage and more apoptosis. These cells also produce a matrix that is thicker and weaker with more water, more immature and cartilage-like matrix proteins, and less organization. There is now evidence of a population of regenerating stem cells within tendon. These studies suggest prevention of tendinopathy should be directed at reducing the volume of repetitive loads to below that which induces oxidative-induced apoptosis and cartilage-like genes. The management strategies might involve agents or cells that induce tendon stem cell proliferation, repair and restoration of matrix integrity. FAU - Xu, Yinghua AU - Xu Y AD - Orthopaedic Research Institute, The St. George Hospital, University of New South Wales, Level 2, 4-10 South Street, Kogarah, Sydney, NSW, 2217, Australia. FAU - Murrell, George A C AU - Murrell GA LA - eng PT - Journal Article PT - Review DEP - 20080514 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.- (Metalloproteases) SB - IM MH - Animals MH - Apoptosis MH - Extracellular Matrix/physiology MH - Female MH - Humans MH - Male MH - Metalloproteases/metabolism MH - Tendinopathy/*diagnosis/genetics/*physiopathology MH - Tendons/cytology MH - Tissue Inhibitor of Metalloproteinases/metabolism PMC - PMC2505234 EDAT- 2008/05/15 09:00 MHDA- 2008/06/27 09:00 PMCR- 2009/07/01 CRDT- 2008/05/15 09:00 PHST- 2007/12/18 00:00 [received] PHST- 2008/04/22 00:00 [accepted] PHST- 2008/05/15 09:00 [pubmed] PHST- 2008/06/27 09:00 [medline] PHST- 2008/05/15 09:00 [entrez] PHST- 2009/07/01 00:00 [pmc-release] AID - 286 [pii] AID - 10.1007/s11999-008-0286-4 [doi] PST - ppublish SO - Clin Orthop Relat Res. 2008 Jul;466(7):1528-38. doi: 10.1007/s11999-008-0286-4. Epub 2008 May 14. PMID- 9530781 OWN - NLM STAT- MEDLINE DCOM- 19980507 LR - 20190727 IS - 0362-2436 (Print) IS - 0362-2436 (Linking) VI - 23 IP - 5 DP - 1998 Mar 1 TI - In vivo Bcl-2 oncogene neuronal expression in the rat spinal cord. PG - 517-23 AB - STUDY DESIGN: An acute mechanical rat spinal cord injury model was used to investigate in vivo Bcl-2 oncogene overexpression in neuronal tissue. OBJECTIVES: To introduce the Bcl-2 oncogene in vivo by a recombinant adenovirus vector into rat spinal cord tissue, and to investigate any potential protective effect on neural tissue in the zone of injury in a rat spinal cord model. SUMMARY OF BACKGROUND DATA: The Bcl-2 oncogene inhibits apoptotic and necrotic neural cell death in vitro by regulating an antioxidant pathway at sites of free radical generation. Thus, overexpression of the Bcl-2 oncogene may have a role in limiting the secondary injury cascade of spinal cord injury through its regulation of antioxidants. METHODS: After confirmation of Bcl-2 gene expression in vitro and in vivo in the rat spinal cord, a weight-drop spinal cord injury model was performed on seven rats with prior Bcl-2 inoculation, and on seven rats with prior B-gal inoculation (controls). RESULTS: In vivo Bcl-2 expression was documented by immunostaining. After spinal cord harvest, quantification of percentage preserved tissue at the spinal cord injury site suggested that Bcl-2 overexpression confers neuroprotection. CONCLUSIONS: In vivo Bcl-2 oncogene overexpression was successfully induced in neuronal tissue. After Bcl-2 oncogene expression in the rat spinal cord, the zone of microscopic injury was diminished. Further investigation of the Bcl-2 oncogene for potentially enhancing neuronal survival after spinal cord injury appears indicated. FAU - Lou, J AU - Lou J AD - Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. FAU - Lenke, L G AU - Lenke LG FAU - Xu, F AU - Xu F FAU - O'Brien, M AU - O'Brien M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Spine (Phila Pa 1976) JT - Spine JID - 7610646 RN - 0 (Antioxidants) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Recombinant Proteins) SB - IM MH - *Adenoviridae MH - Animals MH - Antioxidants/metabolism MH - Cell Death/physiology MH - Cell Survival/physiology MH - Chickens MH - Disease Models, Animal MH - Gene Expression MH - *Gene Transfer Techniques MH - Humans MH - Motor Neurons/*physiology MH - Proto-Oncogene Proteins c-bcl-2/*genetics MH - Rats MH - Rats, Sprague-Dawley MH - Recombinant Proteins/genetics MH - Spinal Cord/*cytology MH - Spinal Cord Injuries/metabolism/physiopathology MH - Tendons/cytology EDAT- 1998/04/08 00:00 MHDA- 1998/04/08 00:01 CRDT- 1998/04/08 00:00 PHST- 1998/04/08 00:00 [pubmed] PHST- 1998/04/08 00:01 [medline] PHST- 1998/04/08 00:00 [entrez] AID - 10.1097/00007632-199803010-00001 [doi] PST - ppublish SO - Spine (Phila Pa 1976). 1998 Mar 1;23(5):517-23. doi: 10.1097/00007632-199803010-00001. PMID- 35171523 OWN - NLM STAT- MEDLINE DCOM- 20221014 LR - 20231102 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 40 IP - 11 DP - 2022 Nov TI - Biglycan has a major role in maintenance of mature tendon mechanics. PG - 2546-2556 LID - 10.1002/jor.25299 [doi] AB - Decorin and biglycan are two small leucine-rich proteoglycans (SLRPs) that regulate collagen fibrillogenesis and extracellular matrix assembly in tendon. The objective of this study was to determine the individual roles of these molecules in maintaining the structural and mechanical properties of tendon during homeostasis in mature mice. We hypothesized that knockdown of decorin in mature tendons would result in detrimental changes to tendon structure and mechanics while knockdown of biglycan would have a minor effect on these parameters. To achieve this objective, we created tamoxifen-inducible mouse knockdown models targeting decorin or biglycan inactivation. This enables the evaluation of the roles of these SLRPs in mature tendon without the abnormal tendon development caused by conventional knockout models. Contrary to our hypothesis, knockdown of decorin resulted in minor alterations to tendon structure and no changes to mechanics while knockdown of biglycan resulted in broad changes to tendon structure and mechanics. Specifically, knockdown of biglycan resulted in reduced insertion modulus, maximum stress, dynamic modulus, stress relaxation, and increased collagen fiber realignment during loading. Knockdown of decorin and biglycan produced similar changes to tendon microstructure by increasing the collagen fibril diameter relative to wild-type controls. Biglycan knockdown also decreased the cell nuclear aspect ratio, indicating a more spindle-like nuclear shape. Overall, the extensive changes to tendon structure and mechanics after knockdown of biglycan, but not decorin, provides evidence that biglycan plays a major role in the maintenance of tendon structure and mechanics in mature mice during homeostasis. CI - © 2022 Orthopaedic Research Society. Published by Wiley Periodicals LLC. FAU - Beach, Zakary M AU - Beach ZM AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Bonilla, Kelsey A AU - Bonilla KA AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Dekhne, Mihir S AU - Dekhne MS AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Sun, Mei AU - Sun M AD - Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. FAU - Adams, Thomas H AU - Adams TH AD - Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. FAU - Adams, Sheila M AU - Adams SM AD - Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. FAU - Weiss, Stephanie N AU - Weiss SN AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Rodriguez, Ashley B AU - Rodriguez AB AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Shetye, Snehal S AU - Shetye SS AUID- ORCID: 0000-0001-7469-3039 AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. FAU - Birk, David E AU - Birk DE AD - Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. FAU - Soslowsky, Louis J AU - Soslowsky LJ AUID- ORCID: 0000-0001-9325-7662 AD - Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania, USA. LA - eng GR - P30 AR069619/AR/NIAMS NIH HHS/United States GR - R01AR068057/NH/NIH HHS/United States GR - P30AR069619/NH/NIH HHS/United States GR - R01 AR068057/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20220225 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Biglycan) RN - 0 (Extracellular Matrix Proteins) RN - 094ZI81Y45 (Tamoxifen) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Biglycan/analysis MH - *Collagen/chemistry MH - Disease Models, Animal MH - Extracellular Matrix/chemistry MH - Extracellular Matrix Proteins MH - Mice MH - Tamoxifen MH - *Tendons/physiology PMC - PMC9378794 MID - NIHMS1800057 OTO - NOTNLM OT - biglycan OT - biomechanics OT - decorin OT - proteoglycan OT - tendon EDAT- 2022/02/17 06:00 MHDA- 2022/10/15 06:00 PMCR- 2023/11/01 CRDT- 2022/02/16 12:17 PHST- 2022/02/03 00:00 [revised] PHST- 2021/09/01 00:00 [received] PHST- 2022/02/13 00:00 [accepted] PHST- 2022/02/17 06:00 [pubmed] PHST- 2022/10/15 06:00 [medline] PHST- 2022/02/16 12:17 [entrez] PHST- 2023/11/01 00:00 [pmc-release] AID - 10.1002/jor.25299 [doi] PST - ppublish SO - J Orthop Res. 2022 Nov;40(11):2546-2556. doi: 10.1002/jor.25299. Epub 2022 Feb 25. PMID- 2313381 OWN - NLM STAT- MEDLINE DCOM- 19900420 LR - 20180330 IS - 0022-3166 (Print) IS - 0022-3166 (Linking) VI - 120 IP - 2 DP - 1990 Feb TI - Effectiveness of isoascorbate versus ascorbate as an inducer of collagen synthesis in primary avian tendon cells. PG - 185-9 AB - In contrast to most biologically active molecules, the isomeric form of ascorbate retains significant biological activity. Moreover, in studies in vitro the isomer was found to be an equally effective cofactor in the enzymatic proline hydroxylation reaction. This raises questions about whether the lower biological activity in vivo results from selective transport into the cell, greater instability of the molecule, or stereospecificity by certain enzyme complexes. Distinguishing these possibilities can be accomplished most directly using a cell culture model. In this study primary avian tendon (PAT) cells were used. With PAT cells isoascorbate was shown to be three- to fivefold less active at inducing procollagen production than ascorbate. Isoascorbate was also internalized by the cell at about one-fifth the ascorbate level. In addition, isoascorbate was degraded in the medium at a slightly higher rate (half-life of 1.6 h) than ascorbate (2.1 h). The data are consistent with a model that postulates that once inside the cell isoascorbate is equally effective at inducing procollagen production but selectivity at the transport step restricts the percentage that is actually internalized. In addition, both ascorbate and isoascorbate were found to degrade very quickly inside the cell in the highly oxygenated environment of cell culture (approximately 2 h half-life). When ascorbate was added to the medium (100 micrograms/mL) the level inside the cell quickly reached a maximum (less than 2 h) and declined rapidly.(ABSTRACT TRUNCATED AT 250 WORDS) FAU - Kipp, D E AU - Kipp DE AD - Department of Dietetics and Nutrition, University of Kansas Medical Center, Kansas City 66103. FAU - Schwarz, R I AU - Schwarz RI LA - eng GR - R01 GM 34274/GM/NIGMS NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Nutr JT - The Journal of nutrition JID - 0404243 RN - 0 (Procollagen) RN - 311332OII1 (isoascorbic acid) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/*metabolism MH - Cells, Cultured MH - Chick Embryo MH - Collagen/*biosynthesis MH - Drug Stability MH - Procollagen/biosynthesis MH - Regression Analysis MH - Stereoisomerism MH - Tendons/cytology EDAT- 1990/02/01 00:00 MHDA- 1990/02/01 00:01 CRDT- 1990/02/01 00:00 PHST- 1990/02/01 00:00 [pubmed] PHST- 1990/02/01 00:01 [medline] PHST- 1990/02/01 00:00 [entrez] AID - 10.1093/jn/120.2.185 [doi] PST - ppublish SO - J Nutr. 1990 Feb;120(2):185-9. doi: 10.1093/jn/120.2.185. PMID- 33326689 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220405 IS - 1934-1563 (Electronic) IS - 1934-1482 (Linking) VI - 14 IP - 1 DP - 2022 Jan TI - Multifocal Tendon Ruptures during Nivolumab and Ipilimumab Therapy for Metastatic Melanoma: A Case Report. PG - 151-153 LID - 10.1002/pmrj.12536 [doi] FAU - Fricke, Brian AU - Fricke B AUID- ORCID: 0000-0002-2257-4895 AD - Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Ng, Amy AU - Ng A AUID- ORCID: 0000-0001-7555-1745 AD - Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. FAU - Bruera, Eduardo AU - Bruera E AD - Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LA - eng PT - Case Reports PT - Letter DEP - 20210120 PL - United States TA - PM R JT - PM & R : the journal of injury, function, and rehabilitation JID - 101491319 RN - 0 (Ipilimumab) RN - 31YO63LBSN (Nivolumab) SB - IM MH - Humans MH - Ipilimumab/adverse effects MH - *Melanoma/drug therapy/secondary MH - *Nivolumab/adverse effects MH - Tendons EDAT- 2020/12/17 06:00 MHDA- 2022/04/05 06:00 CRDT- 2020/12/16 17:17 PHST- 2020/11/18 00:00 [revised] PHST- 2020/07/06 00:00 [received] PHST- 2020/12/04 00:00 [accepted] PHST- 2020/12/17 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2020/12/16 17:17 [entrez] AID - 10.1002/pmrj.12536 [doi] PST - ppublish SO - PM R. 2022 Jan;14(1):151-153. doi: 10.1002/pmrj.12536. Epub 2021 Jan 20. PMID- 14160513 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20190701 IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 189 DP - 1964 Aug 3 TI - TENDON RUPTURE IN SYSTEMIC LUPUS ERYTHEMATOSUS. PG - 377-8 FAU - TWINING, R H AU - TWINING RH FAU - MARCUS, W Y AU - MARCUS WY FAU - GAREY, J L AU - GAREY JL LA - eng PT - Journal Article PL - United States TA - JAMA JT - JAMA JID - 7501160 RN - 0 (Penicillins) RN - V27W9254FZ (Cortisone) RN - VB0R961HZT (Prednisone) RN - WI4X0X7BPJ (Hydrocortisone) RN - X4W3ENH1CV (Norepinephrine) SB - OM MH - *Albuminuria MH - *Collagen Diseases MH - *Cortisone MH - Humans MH - *Hydrocortisone MH - *Lupus Erythematosus, Systemic MH - *Neutrophils MH - *Norepinephrine MH - *Patella MH - *Pathology MH - *Penicillins MH - *Pneumonia MH - *Prednisone MH - *Surgical Procedures, Operative MH - *Tendon Injuries MH - *Tendons MH - *Toxicology OTO - NLM OT - *ALBUMINURIA OT - *COLLAGEN DISEASES OT - *CORTISONE OT - *HYDROCORTISONE OT - *LE CELLS OT - *LUPUS ERYTHEMATOSUS, SYSTEMIC OT - *NOREPINEPHRINE OT - *PATELLA OT - *PATHOLOGY OT - *PENICILLIN OT - *PNEUMONIA OT - *PREDNISONE OT - *SURGERY, OPERATIVE OT - *TENDON INJURY OT - *TOXICOLOGIC REPORT EDAT- 1964/08/03 00:00 MHDA- 1964/08/03 00:01 CRDT- 1964/08/03 00:00 PHST- 1964/08/03 00:00 [pubmed] PHST- 1964/08/03 00:01 [medline] PHST- 1964/08/03 00:00 [entrez] AID - 10.1001/jama.1964.03070050043017 [doi] PST - ppublish SO - JAMA. 1964 Aug 3;189:377-8. doi: 10.1001/jama.1964.03070050043017. PMID- 11508425 OWN - NLM STAT- MEDLINE DCOM- 20010920 LR - 20220410 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 44 IP - 8 DP - 2001 Aug TI - Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. PG - 1754-60 AB - OBJECTIVE: To investigate the role of proinflammatory cytokines, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), and tissue inhibitor of metalloproteinases 1 (TIMP-1) in the destruction of tendons by tenosynovium in rheumatoid arthritis (RA). METHODS: Synovial specimens were obtained from encapsulating tenosynovium (n = 17), invasive tenosynovium (n = 13), and wrist joints (n = 17) in 18 RA patients undergoing wrist extensor tenosynovectomy. Synovial membrane cells were dissociated from connective tissue by enzyme digestion and cultured in vitro for 48 hours, and harvested supernatants were assayed for the cytokines tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6), VEGF, MMPs 1, 2, 3, and 13, and TIMP-1 by enzyme-linked immunosorbent assay. Gelatin zymography was performed to demonstrate enzyme activity. Statistical analysis was performed using Student's paired 2-tailed t-tests for parametric data and the Wilcoxon signed rank test for nonparametric data. RESULTS: MMP-1 and MMP-13 levels were approximately 2.5-fold higher in invasive tenosynovium compared with encapsulating tenosynovium. Levels of MMP-2 were approximately 1.5-fold higher in invasive tenosynovium compared with both encapsulating tenosynovium and wrist joint synovium. MMP-13 (P = 0.009) and IL-6 (P = 0.03) levels were significantly lower in encapsulating tenosynovium compared with wrist joint synovium. Levels of VEGF, TIMP-1, TNFalpha, and MMP-3 were similar in all synovial sample groups. Zymography demonstrated enzyme activity in all synovium samples from all 9 patients assessed. CONCLUSION: Tenosynovium produces proinflammatory cytokines and proteolytic enzymes that are important in the tissue degradation seen in RA. Increased production of the enzymes MMP-1, MMP-2, and MMP-13 by invasive tenosynovium suggests a possible explanation for the worse prognosis and increased rupture rate associated with invasive tenosynovitis in RA. Production of VEGF by tenosynovium suggests that angiogenesis may have a role in tenosynovial proliferation and invasion of tendons. FAU - Jain, A AU - Jain A AD - Imperial College School of Medicine, London, UK. FAU - Nanchahal, J AU - Nanchahal J FAU - Troeberg, L AU - Troeberg L FAU - Green, P AU - Green P FAU - Brennan, F AU - Brennan F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Cytokines) RN - 0 (Endothelial Growth Factors) RN - 0 (Lymphokines) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Vascular Endothelial Growth Factor A) RN - 0 (Vascular Endothelial Growth Factors) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Adult MH - Aged MH - Arthritis, Rheumatoid/etiology/*metabolism MH - Cells, Cultured MH - Cytokines/*biosynthesis MH - Endothelial Growth Factors/*biosynthesis MH - Female MH - Humans MH - Lymphokines/*biosynthesis MH - Male MH - Matrix Metalloproteinases/*biosynthesis MH - Middle Aged MH - Synovial Membrane/metabolism MH - Tendons/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/*biosynthesis MH - Vascular Endothelial Growth Factor A MH - Vascular Endothelial Growth Factors MH - Wrist Joint/metabolism EDAT- 2001/08/18 10:00 MHDA- 2001/09/21 10:01 CRDT- 2001/08/18 10:00 PHST- 2001/08/18 10:00 [pubmed] PHST- 2001/09/21 10:01 [medline] PHST- 2001/08/18 10:00 [entrez] AID - 10.1002/1529-0131(200108)44:8<1754::AID-ART310>3.0.CO;2-8 [doi] PST - ppublish SO - Arthritis Rheum. 2001 Aug;44(8):1754-60. doi: 10.1002/1529-0131(200108)44:8<1754::AID-ART310>3.0.CO;2-8. PMID- 19455992 OWN - NLM STAT- MEDLINE DCOM- 20090609 LR - 20090521 IS - 1781-782X (Print) IS - 1781-782X (Linking) VI - 5 IP - 1 DP - 2009 TI - Tenotomy of the tensor tympani and stapedius tendons in Ménière's disease. PG - 1-6 AB - Tenotomy of the tensor tympani and stapedius tendons in Ménière's disease. OBJECTIVE: In Ménière's disease (MD), when patients have incapacitating vertigo that is resistant to drug treatment, an intratympanic gentamicin application (ITG) is often proposed. Recently, some authors suggested that tenotomy, sectioning of the tensor tympani and stapedius tendons, could be a promising treatment. We examined whether tenotomy (ST) has additional benefit, compared to ITG alone, with respect to tinnitus, vertigo, and quality of life. METHODOLOGY: We conducted a retrospective survey of the charts of 24 patients with MD who underwent ITG, or ITG plus ST. Baseline data and follow-up assessments were obtained, using the Ménière's Disease Outcomes Questionnaire (MDOQ), the Dizziness Handicap Inventory (DHI), vertigo frequency per month, tinnitus visual analogue scale, and functional level. Failure was determined by the need for an additional procedure. RESULTS: ITG was performed on 15 patients, and 9 patients underwent ITG plus ST. The procedure was sufficient in 53% of the ITG group and in 22% of the ITG plus ST group. No significant difference was found between the two groups concerning MDOQ scores, DHI, functional level, vertigo frequency, and tinnitus. In the ITG group, we found a significant improvement in number of vertigo attacks and the tinnitus visual analogue scale. In the ITG plus ST group, there was a significant reduction in vertigo attacks, but not in tinnitus. CONCLUSION: This preliminary study suggests no additional benefit of stapedius and tensor tympani tenotomy in the treatment of Ménière's disease patients. FAU - De Valck, C F J AU - De Valck CF AD - Antwerp University Research centre for Equilibrium and Aerospace, Univ. Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital. paul.van.de.heyning@uza.be FAU - Van Rompaey, V AU - Van Rompaey V FAU - Wuyts, E L AU - Wuyts EL FAU - Van de Heyning, P H AU - Van de Heyning PH LA - eng PT - Journal Article PL - Belgium TA - B-ENT JT - B-ENT JID - 101247842 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Anti-Bacterial Agents/administration & dosage MH - Dizziness/etiology MH - Ear, Middle MH - Female MH - Gentamicins/administration & dosage MH - Humans MH - Male MH - Meniere Disease/complications/drug therapy/physiopathology/*surgery MH - Middle Aged MH - Quality of Life MH - Stapedius/*surgery MH - Tensor Tympani/*surgery MH - Vertigo/etiology MH - Young Adult EDAT- 2009/05/22 09:00 MHDA- 2009/06/10 09:00 CRDT- 2009/05/22 09:00 PHST- 2009/05/22 09:00 [entrez] PHST- 2009/05/22 09:00 [pubmed] PHST- 2009/06/10 09:00 [medline] PST - ppublish SO - B-ENT. 2009;5(1):1-6. PMID- 33302906 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 21 IP - 1 DP - 2020 Dec 10 TI - Parecoxib alleviates the inflammatory effect of leukocyte-rich platelet-rich plasma in normal rabbit tendons. PG - 831 LID - 10.1186/s12891-020-03793-2 [doi] LID - 831 AB - BACKGROUND: Platelet-rich plasma (PRP) is widely used to treat tendon injuries. Its therapeutic effect varies depending on the different cell components, and white blood cells (WBCs) may play an important role in this phenomenon. The purpose of this study was to evaluate how PRP with different concentrations of WBCs affect normal rabbit tendon and assess whether non-steroidal anti-inflammatory drugs (NSAIDs) can suppress the catabolic effects of WBCs. METHODS: Sixteen adult New Zealand White rabbits were used. Blood samples were collected from each rabbit, and PRP was extracted following two different protocols to obtain leukocyte-poor PRP (LP-PRP) and leukocyte-rich PRP (LR-PRP). LP-PRP or LR-PRP was injected into the patellar tendon of each rabbit, while normal saline (NS) was injected as control. In LR-PRP + NSAID group, Parecoxib was administered after LR-PRP injection. For each group, 2 rabbits were euthanatized at day 5 and 14. The patellar tendons were collected and stained with hematoxylin and eosin. A semi-quantitative approach was used to assess the inflammatory response and tendon destruction based on the evaluation of the WBCs, vascularization, fiber structure, and fibrosis. RESULTS: The LR-PRP group exhibited a higher total tendon score than the LP-PRP group at day 5 after PRP injection, but there was no significant difference between the two groups at day 14. For the NSAID group, the tendon score was lower than that of the LR-PRP group both at day 5 and 14. CONCLUSION: LR-PRP can promote a higher inflammatory response than LP-PRP in the normal rabbit patellar tendon, and this effect can be suppressed by NSAIDs. FAU - Zhou, Ming AU - Zhou M AD - Department of Rehabilitation Medicine, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China. FAU - Wang, Ning AU - Wang N AUID- ORCID: 0000-0003-3337-137X AD - Department of Rehabilitation Medicine, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China. wangning@plagh.cn. FAU - Wang, Gang AU - Wang G AD - Department of Rehabilitation Medicine, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China. FAU - Jia, Zishan AU - Jia Z AD - Department of Rehabilitation Medicine, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China. FAU - Qi, Xiaolei AU - Qi X AD - Department of Rehabilitation Medicine, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, People's Republic of China. LA - eng GR - 81401808/National Natural Science Foundation of China/ PT - Journal Article DEP - 20201210 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Isoxazoles) RN - 9TUW81Y3CE (parecoxib) SB - IM MH - Animals MH - Isoxazoles MH - Leukocytes MH - *Platelet-Rich Plasma MH - Rabbits MH - *Tendinopathy MH - Tendons PMC - PMC7731558 OTO - NOTNLM OT - Nonsteroidal anti-inflammatory drugs OT - Parecoxib OT - Platelet-rich plasma OT - Tendinopathy COIS- The authors declare that they have no competing interests. EDAT- 2020/12/12 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/12/10 CRDT- 2020/12/11 05:35 PHST- 2020/05/25 00:00 [received] PHST- 2020/11/12 00:00 [accepted] PHST- 2020/12/11 05:35 [entrez] PHST- 2020/12/12 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/12/10 00:00 [pmc-release] AID - 10.1186/s12891-020-03793-2 [pii] AID - 3793 [pii] AID - 10.1186/s12891-020-03793-2 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2020 Dec 10;21(1):831. doi: 10.1186/s12891-020-03793-2. PMID- 29514342 OWN - NLM STAT- MEDLINE DCOM- 20190401 LR - 20221207 IS - 1930-613X (Electronic) IS - 0026-4075 (Linking) VI - 183 IP - 3-4 DP - 2018 Mar 1 TI - A Case of Non-simultaneous Bilateral Partial Triceps Tendon Repair. PG - e229-e232 LID - 10.1093/milmed/usx075 [doi] AB - A partial triceps tendon tear is an uncommon injury. Even rarer is a bilateral partial triceps tendon tear in which there has been one documented case. This case report illustrates a 37-yr-old African-American male who sustained non-simultaneous bilateral partial triceps tendon avulsions. He sustained a traumatic right partial triceps tendon avulsion after a fall onto an outstretched right arm that required operative repair after failure of conservative treatment. Five months later, he sustained a similar injury after falling on an outstretched left arm that was repaired 9 d later. His post-operative courses were uncomplicated. He returned to full duty at his 6 mo and remained symptom free at 12 mo. The case demonstrates that operative treatment of partial triceps tendon avulsions using bone tunnels yields good outcomes in high-demand patients who have failed conservative treatment and who have had an operative repair of the contralateral extremity. FAU - Goodrich, Eric AU - Goodrich E AD - Training Air Wing Six, 390 San Carlos Rd. Suite C, Pensacola, FL 32508. FAU - Goodrich, Richard P AU - Goodrich RP AD - Naval Health Clinic New England, 43 Smith Road, Newport, RI 02840. LA - eng PT - Case Reports PT - Journal Article PL - England TA - Mil Med JT - Military medicine JID - 2984771R RN - 0 (Fluoroquinolones) SB - IM MH - Adult MH - Arm/*physiopathology/surgery MH - Fluoroquinolones/adverse effects/therapeutic use MH - Humans MH - Magnetic Resonance Imaging/methods MH - Male MH - Radiography/methods MH - Plastic Surgery Procedures/methods MH - Rupture/*surgery MH - Tendon Injuries/*surgery MH - Tendons/surgery EDAT- 2018/03/08 06:00 MHDA- 2019/04/02 06:00 CRDT- 2018/03/08 06:00 PHST- 2017/06/12 00:00 [received] PHST- 2017/10/30 00:00 [accepted] PHST- 2018/03/08 06:00 [entrez] PHST- 2018/03/08 06:00 [pubmed] PHST- 2019/04/02 06:00 [medline] AID - 4780213 [pii] AID - 10.1093/milmed/usx075 [doi] PST - ppublish SO - Mil Med. 2018 Mar 1;183(3-4):e229-e232. doi: 10.1093/milmed/usx075. PMID- 7594293 OWN - NLM STAT- MEDLINE DCOM- 19951128 LR - 20131121 IS - 0363-5023 (Print) IS - 0363-5023 (Linking) VI - 20 IP - 4 DP - 1995 Jul TI - The flexor synovial sheath anatomy of the little finger: a macroscopic study. PG - 636-41 AB - Anatomy texts describe the flexor synovial sheath of the little finger as extending proximally into the palm to join with the ulnar bursa in 80% of cases. Based on this, one would expect frequent extension of little finger flexor synovial sheath infections into the forearm. Methylene blue injection followed by open tenogram was used to define the anatomy of the flexor synovial sheath of the little finger in 60 cadaver hands. In 27 hands, the flexor synovial sheath extended proximally from the bony profundus tendon insertion to terminate at the palmar aponeurosis pulley. A stricture of varying length separated the flexor synovial sheath from the more proximal ulnar bursa. In 19 hands, the flexor synovial sheath was continuous with the ulnar bursa, conforming to the conventional textbook description. In 14 hands, the flexor synovial sheath stopped at the proximal border of the A1 pulley. An inconsistent defect from 1 to 10 mm was noted. The clinical implications of these findings suggest that many little finger flexor synovial sheath infections, when caught early and after careful physical examination, need only be managed by drainage at the distal palmar level. FAU - Phillips, C S AU - Phillips CS AD - University of Chicago Hospital, Department of Surgery, IL 60637-1470, USA. FAU - Falender, R AU - Falender R FAU - Mass, D P AU - Mass DP LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - T42P99266K (Methylene Blue) SB - IM MH - Cadaver MH - Fingers/*anatomy & histology MH - Humans MH - Methylene Blue MH - Staining and Labeling MH - Synovial Membrane/*anatomy & histology MH - Tendons/*anatomy & histology EDAT- 1995/07/01 00:00 MHDA- 1995/07/01 00:01 CRDT- 1995/07/01 00:00 PHST- 1995/07/01 00:00 [pubmed] PHST- 1995/07/01 00:01 [medline] PHST- 1995/07/01 00:00 [entrez] AID - S0363-5023(05)80282-5 [pii] AID - 10.1016/S0363-5023(05)80282-5 [doi] PST - ppublish SO - J Hand Surg Am. 1995 Jul;20(4):636-41. doi: 10.1016/S0363-5023(05)80282-5. PMID- 3223355 OWN - NLM STAT- MEDLINE DCOM- 19890316 LR - 20131121 IS - 0884-0431 (Print) IS - 0884-0431 (Linking) VI - 3 IP - 4 DP - 1988 Aug TI - Indomethacin inhibition of tenotomy-induced bone resorption in rats. PG - 409-14 AB - Loss of biomechanical function results in rapid bone loss. This study assesses the role of arachidonic acid metabolites in immobilization-related osteopenia. A hind limb of the rat was immobilized by knee tenotomy and bone resorption and formation parameters were quantitated by histological methods in indomethacin-treated (0.5 mg/kg per day) and vehicle-treated animals. Control animals sacrificed 30, 72, and 240 hr post-tenotomy revealed a significant increase in osteoclast number (30 hr) and resorption surfaces (72 hr) and a decrease in trabecular bone volume (240 hr) in the tenotomized tibiae. In the indomethacin-treated tibial metaphysis, no significant differences were noted for these parameters by comparison to the nontenotomized leg. Bone formation parameters remained reduced in the tenotomized legs of both the indomethacin and vehicle-treated groups compared to the control legs. Indomethacin inhibited bone resorption, but did not prevent the decrease in bone formation produced by immobilization over the 10 days of these experiments. FAU - Thompson, D D AU - Thompson DD AD - Department of Bone Biology/Osteoporosis, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486. FAU - Rodan, G A AU - Rodan GA LA - eng PT - Journal Article PL - England TA - J Bone Miner Res JT - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JID - 8610640 RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Bone Resorption/*drug effects MH - Femur/drug effects/physiology MH - Indomethacin/*pharmacology MH - Male MH - Osteoclasts/cytology/drug effects MH - Rats MH - Rats, Inbred Strains MH - Reference Values MH - Tendons/*physiology MH - Tibia/cytology/drug effects/physiology EDAT- 1988/08/01 00:00 MHDA- 1988/08/01 00:01 CRDT- 1988/08/01 00:00 PHST- 1988/08/01 00:00 [pubmed] PHST- 1988/08/01 00:01 [medline] PHST- 1988/08/01 00:00 [entrez] AID - 10.1002/jbmr.5650030407 [doi] PST - ppublish SO - J Bone Miner Res. 1988 Aug;3(4):409-14. doi: 10.1002/jbmr.5650030407. PMID- 4992324 OWN - NLM STAT- MEDLINE DCOM- 19710209 LR - 20190609 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 214 IP - 1 DP - 1970 Jul 27 TI - Action of crude bacterial alpha-amylase on tropocollagen. PG - 238-41 FAU - Bailey, A J AU - Bailey AJ FAU - Etherington, D J AU - Etherington DJ LA - eng PT - Journal Article PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Caseins) RN - 0 (Hemoglobins) RN - 12UHW9R67N (Isoflurophate) RN - 9000-70-8 (Gelatin) RN - 9007-34-5 (Collagen) RN - EC 3.2.1.- (Amylases) RN - EC 3.4.- (Peptide Hydrolases) RN - K3Z4F929H6 (Lysine) SB - IM MH - *Amylases MH - Animals MH - Bacillus subtilis/enzymology MH - Caseins MH - Cattle MH - *Collagen MH - Electrophoresis, Disc MH - Gelatin MH - Hemoglobins MH - Hot Temperature MH - Isoflurophate MH - Lysine MH - Peptide Hydrolases MH - Rats MH - Tendons MH - Ultracentrifugation EDAT- 1970/07/27 00:00 MHDA- 1970/07/27 00:01 CRDT- 1970/07/27 00:00 PHST- 1970/07/27 00:00 [pubmed] PHST- 1970/07/27 00:01 [medline] PHST- 1970/07/27 00:00 [entrez] AID - 0005-2795(70)90093-0 [pii] AID - 10.1016/0005-2795(70)90093-0 [doi] PST - ppublish SO - Biochim Biophys Acta. 1970 Jul 27;214(1):238-41. doi: 10.1016/0005-2795(70)90093-0. PMID- 11051026 OWN - NLM STAT- MEDLINE DCOM- 20001205 LR - 20221207 IS - 0044-3220 (Print) IS - 0044-3220 (Linking) VI - 137 IP - 4 DP - 1999 Jul-Aug TI - [Pathological rupture of the distal biceps tendon after long-term androgen substitution]. PG - 368-70 AB - QUESTION: Is the long-standing use of androgenes able to cause tendon lesions with pathological tendon ruptures? METHOD: In a case of a rupture of the distal biceps tendon after long-standing testosterone-substitution it is tried to show the connection between the use of androgenes and pathological tendon rupture by the help of the patients treatment documents, the X-rays and sonograms, the histological findings and the results of the clinical examination. RESULTS: For the first time a case with a rupture of the distal biceps tendon after long-standing testosterone-substitution for the support of a genital transformation is described. Since other tendon damaging factors could be excluded the suspicion of tendon alteration caused by androgenes is obvious. CONCLUSION: Looking at tendon ruptures of professionals and even amateur sportsmen the possible connection between long-standing use of androgenes and tendon damage has to be considered. FAU - Morgenthaler, M AU - Morgenthaler M AD - Orthopädische Abteilung, Chirurgischen Universitätsklinik Freiburg. FAU - Weber, M AU - Weber M LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Eine pathologische Ruptur der distalen Bizepssehne nach langjähriger Androgen-Substitution. PL - Germany TA - Z Orthop Ihre Grenzgeb JT - Zeitschrift fur Orthopadie und ihre Grenzgebiete JID - 1256465 RN - 0 (Testosterone Congeners) RN - V9EFU16ZIF (Methyltestosterone) SB - IM MH - Adult MH - Diagnosis, Differential MH - Elbow/pathology/surgery MH - Expert Testimony/legislation & jurisprudence MH - Female MH - Humans MH - Insurance, Accident/legislation & jurisprudence MH - Methyltestosterone/administration & dosage/*adverse effects MH - Tendon Injuries/*chemically induced/pathology/surgery MH - Tendons/pathology MH - Testosterone Congeners/administration & dosage/*adverse effects MH - Transsexualism/drug therapy MH - *Elbow Injuries EDAT- 2000/10/29 11:00 MHDA- 2001/02/28 10:01 CRDT- 2000/10/29 11:00 PHST- 2000/10/29 11:00 [pubmed] PHST- 2001/02/28 10:01 [medline] PHST- 2000/10/29 11:00 [entrez] AID - 10.1055/s-2008-1039728 [doi] PST - ppublish SO - Z Orthop Ihre Grenzgeb. 1999 Jul-Aug;137(4):368-70. doi: 10.1055/s-2008-1039728. PMID- 22868612 OWN - NLM STAT- MEDLINE DCOM- 20121213 LR - 20120807 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 35 IP - 8 DP - 2012 Aug 1 TI - Effects of interleukin-1 receptor antagonist on collagen and matrix metalloproteinases in stress-shielded achilles tendons of rats. PG - e1238-44 LID - 10.3928/01477447-20120725-26 [doi] AB - Based on previous studies showing that interleukin-1 (IL-1) significantly increased after stress shielding, this article reports further research into the possible therapeutic applications of IL-1 receptor antagonist (IL-1Ra). Forty rats whose left Achilles tendons were denervated and completely stress shielded were divided into 5 groups: 2-week phosphate-buffered saline (PBS); 4-week PBS; 2-week IL-1Ra; 4-week IL-1Ra; and normal control. The Achilles tendons were tested morphologically, and the changes in collagen I and III, matrix metalloproteinases (MMP)-1 and -3, and tissue inhibitors of metalloproteinase (TIMP)-1 were determined. The collagen fibrils in the IL-1Ra groups were morphologically more similar to those in the control group than to those in the PBS groups. The collagen I levels increased in the 2-week groups. Significant differences existed between the PBS and IL-1Ra groups at 4 weeks. The MMP-1 level increased dramatically after stress shielding and increased less in the 2-week IL-1Ra group than in the 2-week PBS group. The degree of decrease of MMP-3 in the IL-1Ra groups was significantly less than that in the PBS groups. The collagen III and TIMP-1 levels continued to increase, and no difference was found between the PBS and IL-1Ra groups. Interleukin-1 receptor antagonist prevented morphological deterioration and collagen metabolism of the denervated Achilles tendons after stress shielding, likely by inhibiting the decline of MMP-3 and increasing MMP-1 levels at an early stage. CI - Copyright 2012, SLACK Incorporated. FAU - Ma, Yanhong AU - Ma Y AD - Department of Rehabilitation Medicine, the Affiliated Sixth People’s Hospital of Shanghai Jiaotong University, Shanghai, China. myhmyh2006@126.com FAU - Yan, Xiaoyan AU - Yan X FAU - Zhao, Huakun AU - Zhao H FAU - Wang, Wei AU - Wang W LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Interleukin 1 Receptor Antagonist Protein) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Achilles Tendon/drug effects/innervation/*metabolism/ultrastructure MH - Animals MH - Collagen/analysis/*metabolism MH - Collagen Type I/analysis/metabolism MH - Collagen Type III/analysis/metabolism MH - Extracellular Matrix/metabolism MH - Injections MH - Interleukin 1 Receptor Antagonist Protein/administration & dosage/metabolism/*physiology MH - Male MH - Matrix Metalloproteinase 1/analysis/metabolism MH - Matrix Metalloproteinase 3/analysis/metabolism MH - Matrix Metalloproteinases/analysis/*metabolism MH - Microscopy, Electron, Transmission MH - Models, Animal MH - Rats MH - Rats, Sprague-Dawley MH - Tissue Inhibitor of Metalloproteinase-1/analysis/metabolism EDAT- 2012/08/08 06:00 MHDA- 2012/12/14 06:00 CRDT- 2012/08/08 06:00 PHST- 2012/08/08 06:00 [entrez] PHST- 2012/08/08 06:00 [pubmed] PHST- 2012/12/14 06:00 [medline] AID - 10.3928/01477447-20120725-26 [doi] PST - ppublish SO - Orthopedics. 2012 Aug 1;35(8):e1238-44. doi: 10.3928/01477447-20120725-26. PMID- 26935007 OWN - NLM STAT- MEDLINE DCOM- 20161228 LR - 20161230 IS - 1791-3004 (Electronic) IS - 1791-2997 (Linking) VI - 13 IP - 4 DP - 2016 Apr TI - Effect of transforming growth factor-β3 on the expression of Smad3 and Smad7 in tenocytes. PG - 3567-73 LID - 10.3892/mmr.2016.4944 [doi] AB - Tendon adhesion is a common problem in the healing of injured tendons. The molecular mechanisms of the TGF-β/Smad signaling pathway have been determined, and the role of TGF-β has been well characterized in wound healing. However, the intracellular mechanism or downstream signals by which TGF-β3 modulates its effects on tendon healing have not been well elucidated. The aim of this study was to determine the effect of TGF‑β3 on the TGF-β/Smad signaling pathway in tenocytes. Quantitative polymerase chain reaction and western blot analysis were used to analyze the effect of TGF‑β3 on the regulation of the expression of Smad proteins in tenocytes. The results demonstrated that TGF‑β3 has no significant effect on the proliferation of tendon cells. The addition of TGF‑β3 to tenocytes can significantly downregulate the expression of Smad3 and upregulate the expression of Smad7 at the gene and protein levels. The results demonstrate that TGF‑β3 may regulate Smad3 and Smad7 proteins through the TGF-β/Smad signaling pathway to minimize extrinsic scarring. Thus, it may provide a novel approach to decrease tendon adhesion and promote tendon healing. FAU - Jiang, Ke AU - Jiang K AD - Department of Orthopedics, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China. FAU - Chun, Guo AU - Chun G AD - Department of Medicine, Luohe Medical College, Luohe, Henan 462002, P.R. China. FAU - Wang, Ziming AU - Wang Z AD - Department of Orthopedics, Daping Hospital, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Du, Quanyin AU - Du Q AD - Department of Orthopedics, Daping Hospital, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Wang, Aimin AU - Wang A AD - Department of Orthopedics, Daping Hospital, The Third Military Medical University, Chongqing 400042, P.R. China. FAU - Xiong, Yan AU - Xiong Y AD - Department of Orthopedics, Daping Hospital, The Third Military Medical University, Chongqing 400042, P.R. China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160229 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Smad3 Protein) RN - 0 (Smad7 Protein) RN - 0 (Transforming Growth Factor beta3) RN - 1CC1JFE158 (Dactinomycin) RN - 98600C0908 (Cycloheximide) SB - IM MH - Animals MH - Blotting, Western MH - Cells, Cultured MH - Cycloheximide/pharmacology MH - Dactinomycin/pharmacology MH - Down-Regulation/*drug effects MH - Microscopy, Fluorescence MH - Rabbits MH - Real-Time Polymerase Chain Reaction MH - Smad3 Protein/genetics/*metabolism MH - Smad7 Protein/genetics/*metabolism MH - Tenocytes/cytology/metabolism MH - Transforming Growth Factor beta3/*pharmacology EDAT- 2016/03/05 06:00 MHDA- 2016/12/29 06:00 CRDT- 2016/03/04 06:00 PHST- 2015/03/07 00:00 [received] PHST- 2016/01/05 00:00 [accepted] PHST- 2016/03/04 06:00 [entrez] PHST- 2016/03/05 06:00 [pubmed] PHST- 2016/12/29 06:00 [medline] AID - 10.3892/mmr.2016.4944 [doi] PST - ppublish SO - Mol Med Rep. 2016 Apr;13(4):3567-73. doi: 10.3892/mmr.2016.4944. Epub 2016 Feb 29. PMID- 16623866 OWN - NLM STAT- MEDLINE DCOM- 20061026 LR - 20181201 IS - 1742-7835 (Print) IS - 1742-7835 (Linking) VI - 98 IP - 4 DP - 2006 Apr TI - Ultrastructural changes of the gemifloxacin on Achilles tendon in immature rats: comparison with those of ciproxacin and ofloxacin. PG - 406-10 AB - Gemifloxacin is a synthetic fluoroquinolone antimicrobial agent that exhibits potent activity against most Gram-negative and Gram-positive organisms, and has a comparatively low chondrotoxic potential in immature animals. This study examined the effects of gemifloxacin on the Achilles tendons in immature Sprague-Dawley rats treated by oral intubation once daily for 5 consecutive days from postnatal week 4 onward at doses of 0 (vehicle), and 600 mg/kg body weight. Ofloxacin or ciprofloxacin were used for comparison. The Achilles tendon specimens were examined by electron microscopy. In comparison with the vehicle-treated controls, there were ultrastructural changes in all samples from the gemifloxacin-, ofloxacin-, and ciprofloxacin-treated rats. Degenerative changes were observed in the tenocytes, and the cells that detached from the extracellular matrix were recognizable. The degree of degenerative changes and the number of degenerated cells in the Achilles tendon were significantly higher in the treated group than in the control group. Moreover, among the quinolone-treated groups, these findings were most significant in the ofloxacin-treated group, and least significant in the gemifloxacin-treated group. It is unclear what these findings mean with respect to the possible risk in juvenile patients treated with gemifloxacin or other quinolones. However, these results show that gemifloxacin causes less changes in the connective tissue structures. FAU - Bae, Chun-Sik AU - Bae CS AD - College of Veterinary Medicine, Biotechnology Research Institute, Chonnam National University, Gwangju 500-757, Korea. FAU - Oh, Dong-Min AU - Oh DM FAU - Bae, Jin-Gyu AU - Bae JG FAU - Kim, Jong-Choon AU - Kim JC FAU - Kim, Sung-Ho AU - Kim SH FAU - Kim, Su-Gwan AU - Kim SG FAU - Jeong, Moon-Jin AU - Jeong MJ FAU - Kim, Youn-Shin AU - Kim YS FAU - Lim, Sung-Chul AU - Lim SC LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Basic Clin Pharmacol Toxicol JT - Basic & clinical pharmacology & toxicology JID - 101208422 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) RN - 0 (Naphthyridines) RN - 5E8K9I0O4U (Ciprofloxacin) RN - A4P49JAZ9H (Ofloxacin) RN - OKR68Y0E4T (Gemifloxacin) SB - IM MH - Achilles Tendon/*drug effects/pathology/ultrastructure MH - Animals MH - Anti-Bacterial Agents/*toxicity MH - Ciprofloxacin/toxicity MH - Fluoroquinolones/*toxicity MH - Gemifloxacin MH - Male MH - Microscopy, Electron, Transmission MH - Naphthyridines/*toxicity MH - Ofloxacin/toxicity MH - Rats MH - Rats, Sprague-Dawley EDAT- 2006/04/21 09:00 MHDA- 2006/10/27 09:00 CRDT- 2006/04/21 09:00 PHST- 2006/04/21 09:00 [pubmed] PHST- 2006/10/27 09:00 [medline] PHST- 2006/04/21 09:00 [entrez] AID - PTOpto_326 [pii] AID - 10.1111/j.1742-7843.2006.pto_326.x [doi] PST - ppublish SO - Basic Clin Pharmacol Toxicol. 2006 Apr;98(4):406-10. doi: 10.1111/j.1742-7843.2006.pto_326.x. PMID- 33962783 OWN - NLM STAT- MEDLINE DCOM- 20211123 LR - 20211123 IS - 1768-3181 (Electronic) IS - 0003-3928 (Linking) VI - 70 IP - 3 DP - 2021 Jun TI - Pheochromocytoma presenting as an authentic small vessel vasculitis and complicated with pulmonary embolism: An original presentation. PG - 168-170 LID - S0003-3928(21)00048-2 [pii] LID - 10.1016/j.ancard.2021.04.006 [doi] AB - Diagnosis of pheochromocytoma can be simple when classic manifestations are present. It can also be challenging and complicated in some cases because of its wide array of faces and presentations. We present a case of a 30-year-old female patient who came with acute respiratory distress, chest pain, hemoptysis, asthenia, anorexia, weight loss of 20kg, and paresthesia in her lower limbs. Clinical examination found high blood pressure, accelerated heart and respiratory rates, signs of acute right heart failure with jugular venous distention and ankle edema, reticularis livedo in the four limbs, ulcers in both knees and in the 3rd metacarpo-phalangeal articulations and necrotic lesions in both calcaneal tendons and in the right toes. Further investigations concluded on myocarditis associated with alveolar hemorrhage, pericardic and pleuritic effusions and a segmental pulmonary embolism of the right inferior lobe. Neuro-muscular biopsy was suggestive of myositis. Cutaneous biopsy found nonspecific chronic dermatitis. ANCA antibodies were tested twice and were negative. Cryoglobulinemia was also negative. Thoraco-abdomino-pelvic scan was performed showing a large right adrenal mass suggestive of pheochromocytoma. Diagnosis of right adrenal pheochromocytoma was confirmed by MIBG-I123 hyperfixation findings and urinary normetanephrin levels. The patient was treated surgically. Postoperative outcomes were remarkably favorable with a complete regression of the cutaneous lesions and normalization of the blood pressure. Paresthesia significantly decreased. Control echocardiography at 3 months showed an improved heart function with a persistent apical and septal akinesis. CI - Copyright © 2021 Elsevier Masson SAS. All rights reserved. FAU - Toujani, S AU - Toujani S AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. Electronic address: sanatoujani1@gmail.com. FAU - Abida, R AU - Abida R AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - El Ouni, A AU - El Ouni A AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Belhassen, A AU - Belhassen A AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Abdelkefi, C AU - Abdelkefi C AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Meddeb, Z AU - Meddeb Z AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Larbi, T AU - Larbi T AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Hamzaoui, S AU - Hamzaoui S AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. FAU - Bouslama, K AU - Bouslama K AD - Service de médecine interne, Hôpital Mongi Slim La Marsa, Tunis, Tunisia. LA - eng PT - Case Reports PT - Journal Article DEP - 20210504 PL - France TA - Ann Cardiol Angeiol (Paris) JT - Annales de cardiologie et d'angeiologie JID - 0142167 RN - 0 (Iodine Radioisotopes) RN - 0 (Radiopharmaceuticals) RN - 35MRW7B4AD (3-Iodobenzylguanidine) RN - 8YWR746RPQ (Iodine-123) SB - IM MH - 3-Iodobenzylguanidine MH - Adrenal Gland Neoplasms/complications/*diagnosis MH - Adult MH - Diagnosis, Differential MH - Female MH - Hemorrhage/diagnosis MH - Humans MH - Iodine Radioisotopes MH - Myocarditis/complications/diagnosis MH - Myositis/diagnosis MH - Pheochromocytoma/complications/*diagnosis MH - Pulmonary Alveoli MH - Pulmonary Embolism/*complications MH - Radiopharmaceuticals MH - Tomography, X-Ray Computed MH - Vasculitis/*diagnosis OTO - NOTNLM OT - Embolie pulmonire OT - Myocardite OT - Myocarditis OT - Myosite OT - Myositis OT - Pheochromocytoma OT - Phéochromocytome OT - Pulmonary embolism OT - Vascularite OT - Vasculitis EDAT- 2021/05/09 06:00 MHDA- 2021/11/24 06:00 CRDT- 2021/05/08 06:16 PHST- 2020/09/04 00:00 [received] PHST- 2021/04/05 00:00 [accepted] PHST- 2021/05/09 06:00 [pubmed] PHST- 2021/11/24 06:00 [medline] PHST- 2021/05/08 06:16 [entrez] AID - S0003-3928(21)00048-2 [pii] AID - 10.1016/j.ancard.2021.04.006 [doi] PST - ppublish SO - Ann Cardiol Angeiol (Paris). 2021 Jun;70(3):168-170. doi: 10.1016/j.ancard.2021.04.006. Epub 2021 May 4. PMID- 12811465 OWN - NLM STAT- MEDLINE DCOM- 20040630 LR - 20131121 IS - 0340-5761 (Print) IS - 0340-5761 (Linking) VI - 77 IP - 9 DP - 2003 Sep TI - Ultrastructural changes induced by the des-F(6)-quinolone garenoxacin (BMS-284756) and two fluoroquinolones in Achilles tendon from immature rats. PG - 521-6 AB - Garenoxacin is a des-(6)-fluoroquinolone exhibiting a comparatively low chondrotoxic potential in juvenile animals. We studied the effects of the drug on Achilles tendons in immature Wistar rats treated by oral intubation once daily (1) for 5 consecutive days from postnatal week 4 onward at doses of 0 (vehicle), 200 and 600 mg/kg body weight (b wt), and (2) for 21 consecutive days from postnatal day 4 onward at doses of 0 (vehicle), 80, 240 or 300 mg/kg b wt; ofloxacin or ciprofloxacin were used as comparators. Achilles tendon specimens were studied by electron microscopy. In comparison with vehicle-treated controls, ultrastructural changes were detectable in all samples from the garenoxacin-, ofloxacin-, or ciprofloxacin-treated rats (one animal per group). We found degenerative changes such as multiple vacuoles and large vesicles in the cytoplasm of tenocytes that resulted from swelling and dilatation of cell organelles (mitochondria, endoplasmic reticulum), densified nuclei and clumped chromatin; furthermore, cells that detached from the extracellular matrix, a general decrease of the fibril diameter and an increase in the distance between the collagenous fibrils were recognizable. The degree of changes increased with increasing doses. It remains unclear what these findings mean with respect to a possible risk in juvenile patients treated with garenoxacin or the other quinolones, but our results underline the fact that, in principle, this des-(6)-fluoroquinolone also has the potential to cause changes in connective tissue structures. FAU - Shakibaei, Mehdi AU - Shakibaei M AD - Institute of Anatomy, Benjamin Franklin Medical Center, Freie Universität Berlin, 14195 Berlin, Germany. FAU - Stahlmann, Ralf AU - Stahlmann R LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20030617 PL - Germany TA - Arch Toxicol JT - Archives of toxicology JID - 0417615 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) RN - 5E8K9I0O4U (Ciprofloxacin) RN - A4P49JAZ9H (Ofloxacin) RN - V72H9867WB (garenoxacin) SB - IM MH - Achilles Tendon/*drug effects/pathology/*ultrastructure MH - Administration, Oral MH - Animals MH - Anti-Bacterial Agents/*toxicity MH - Ciprofloxacin/toxicity MH - Female MH - Fluoroquinolones/*toxicity MH - Male MH - Microscopy, Electron MH - Ofloxacin/toxicity MH - Rats MH - Rats, Wistar EDAT- 2003/06/18 05:00 MHDA- 2004/07/01 05:00 CRDT- 2003/06/18 05:00 PHST- 2003/01/03 00:00 [received] PHST- 2003/04/14 00:00 [accepted] PHST- 2003/06/18 05:00 [pubmed] PHST- 2004/07/01 05:00 [medline] PHST- 2003/06/18 05:00 [entrez] AID - 10.1007/s00204-003-0478-3 [doi] PST - ppublish SO - Arch Toxicol. 2003 Sep;77(9):521-6. doi: 10.1007/s00204-003-0478-3. Epub 2003 Jun 17. PMID- 29099894 OWN - NLM STAT- MEDLINE DCOM- 20180622 LR - 20180622 IS - 1934-3418 (Electronic) IS - 1078-4519 (Linking) VI - 46 IP - 5 DP - 2017 Sep/Oct TI - Effects of Platelet-Rich Plasma and Indomethacin on Biomechanics of Rotator Cuff Repair. PG - E336-E343 AB - We conducted a study to determine if platelet-rich plasma (PRP) enhances the strength of rotator cuff repair (RCR) and if concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) affects PRP efficacy. We also wanted to determine the optimal centrifugation protocol for making PRP from rats. This study used 48 rats, 14 in a centrifugation protocol and 34 in an operative protocol. Six syngeneic rats from the operative group were used as PRP blood donors; the other 28 operative rats underwent bilateral RCRs. The Autologous Conditioned Plasma system (Arthrex) was used to prepare leukocyte-poor PRP. One shoulder was randomized to an intratendinous PRP injection, and the other received normal saline. Each rat was also randomly placed on a postoperative diet, either a regular diet or an indomethacin-enhanced diet. After rats were euthanized at 3 weeks, specimens were dissected to isolate the supraspinatus tendon at its humeral attachment, which was subjected to biomechanical testing. PRP prepared with a protocol of 5 minutes × 1300 revolutions per minute had the highest platelet index. Mean (SD) energy to failure was significantly higher (P = .03) in tendons treated with PRP, 11.7 (7.3) N-mm, than in tendons treated with saline, 8.7 (4.6) N-mm. Both groups (PRP, saline) showed no significant differences between tendons treated with NSAIDs and those not treated with NSAIDs. Intraoperative application of PRP enhances energy to failure after RCR in rats. There were no differences in biomechanical strength with NSAID use and no interactions between PRP and NSAID use. FAU - Meadows, Molly C AU - Meadows MC AD - Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL. molly.meadows@gmail.com. FAU - Levy, David M AU - Levy DM FAU - Ferry, Christopher M AU - Ferry CM FAU - Gardner, Thomas R AU - Gardner TR FAU - Teratani, Takeshi AU - Teratani T FAU - Ahmad, Christopher S AU - Ahmad CS LA - eng PT - Journal Article PL - United States TA - Am J Orthop (Belle Mead NJ) JT - American journal of orthopedics (Belle Mead, N.J.) JID - 9502918 RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Biomechanical Phenomena/drug effects/physiology MH - Indomethacin/pharmacology/*therapeutic use MH - *Platelet-Rich Plasma MH - Range of Motion, Articular/drug effects/*physiology MH - Rats MH - Rotator Cuff/drug effects/physiopathology/*surgery MH - Rotator Cuff Injuries/drug therapy/physiopathology/surgery/*therapy MH - Wound Healing COIS- Authors’ Disclosure Statement: Dr. Ahmad reports that he is a consultant to Arthrex, which manufactures products used in the study described in this article. The other authors report no actual or potential conflict of interest in relation to this article. EDAT- 2017/11/04 06:00 MHDA- 2018/06/23 06:00 CRDT- 2017/11/04 06:00 PHST- 2017/11/04 06:00 [entrez] PHST- 2017/11/04 06:00 [pubmed] PHST- 2018/06/23 06:00 [medline] PST - ppublish SO - Am J Orthop (Belle Mead NJ). 2017 Sep/Oct;46(5):E336-E343. PMID- 29723756 OWN - NLM STAT- MEDLINE DCOM- 20191126 LR - 20191126 IS - 1878-5905 (Electronic) IS - 0142-9612 (Linking) VI - 172 DP - 2018 Jul TI - Histone deacetylase inhibitor treated cell sheet from mouse tendon stem/progenitor cells promotes tendon repair. PG - 66-82 LID - S0142-9612(18)30223-0 [pii] LID - 10.1016/j.biomaterials.2018.03.043 [doi] AB - Tendon stem/progenitor cells (TSPCs) have been identified as a rare population in tendons. In vitro propagation is indispensable to obtain sufficient quantities of TSPCs for therapies. However, culture-expanded TSPCs are prone to lose their phenotype, resulting in an inferior repaired capability. And little is known about the underlying mechanism. Here, we found that altered gene expression was associated with increased histone deacetylase (HDAC) activity and expression of HDAC subtypes. Therefore, we exposed ScxGFP mice-derived TSPCs to HDAC inhibitor (HDACi) trichostatin A (TSA) or valproic acid (VPA), and observed significant expansion of ScxGFP(+) cells without altering phenotypic properties. TSA upregulated Scx expression by inhibiting HDAC1 and -3, and increasing the H3K27Ac level of Tgfb1 and -2 genome region. Additionally, cell sheets formed from TSA-pretreated mTSPCs retained the ability to accelerate tendon repair in vivo. Thus, our results uncovered an unrecognized role of HDACi in phenotypic and functional mTSPCs expansion to enhance their therapeutic potential. CI - Copyright © 2018 Elsevier Ltd. All rights reserved. FAU - Zhang, Can AU - Zhang C AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China; Institute of Biomedical Engineering, College of Biology, Hunan University, Changsha 410082, China. FAU - Zhang, Erchen AU - Zhang E AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Yang, Long AU - Yang L AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Tu, Wenjing AU - Tu W AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Lin, Junxin AU - Lin J AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Yuan, Chunhui AU - Yuan C AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Bunpetch, Varisara AU - Bunpetch V AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. FAU - Chen, Xiao AU - Chen X AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China. Electronic address: chenxiao-610@zju.edu.cn. FAU - Ouyang, Hongwei AU - Ouyang H AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Tissue Engineering, Zhejiang University, Hangzhou 310058, China; Zhejiang Provincial Key Laboratory of Tissue Engineering and Regenerative Medicine, Hangzhou 310058, China; Department of Sports Medicine, School of Medicine, Zhejiang University, Hangzhou 310058, China; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. Electronic address: hwoy@zju.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180326 PL - Netherlands TA - Biomaterials JT - Biomaterials JID - 8100316 RN - 0 (Histone Deacetylase Inhibitors) RN - 0 (Hydroxamic Acids) RN - 3X2S926L3Z (trichostatin A) RN - 614OI1Z5WI (Valproic Acid) RN - EC 3.5.1.98 (Histone Deacetylases) SB - IM MH - Animals MH - Cell Culture Techniques MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Female MH - Gene Expression Regulation/drug effects MH - Histone Deacetylase Inhibitors/*metabolism MH - Histone Deacetylases/metabolism MH - Hydroxamic Acids/*metabolism MH - Mice MH - Mice, Transgenic MH - Rats, Sprague-Dawley MH - Signal Transduction MH - Stem Cells/*metabolism MH - Tendon Injuries/*therapy MH - Tendons/cytology MH - Valproic Acid/metabolism OTO - NOTNLM OT - Cell sheet OT - Histone deacetylase inhibitor OT - Histone deacetylation OT - Scleraxis OT - Stem cell phenotype OT - Tendon stem/progenitor cells EDAT- 2018/05/04 06:00 MHDA- 2019/11/27 06:00 CRDT- 2018/05/04 06:00 PHST- 2017/12/25 00:00 [received] PHST- 2018/03/17 00:00 [revised] PHST- 2018/03/25 00:00 [accepted] PHST- 2018/05/04 06:00 [pubmed] PHST- 2019/11/27 06:00 [medline] PHST- 2018/05/04 06:00 [entrez] AID - S0142-9612(18)30223-0 [pii] AID - 10.1016/j.biomaterials.2018.03.043 [doi] PST - ppublish SO - Biomaterials. 2018 Jul;172:66-82. doi: 10.1016/j.biomaterials.2018.03.043. Epub 2018 Mar 26. PMID- 22227881 OWN - NLM STAT- MEDLINE DCOM- 20120905 LR - 20211021 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 30 IP - 8 DP - 2012 Aug TI - Molecular response of the patellar tendon to fatigue loading explained in the context of the initial induced damage and number of fatigue loading cycles. PG - 1327-34 LID - 10.1002/jor.22059 [doi] AB - Accumulation of sub-rupture fatigue damage has been implicated in the development of tendinopathy. We previously developed an in vivo model of damage accumulation using the rat patellar tendon. Our model allows us to control the input loading parameters to induce fatigue damage in the tendon. Despite this precise control, the resulting induced damage could vary among animals because of differences in size or strength among their patellar tendons. In this study, we used number of applied cycles and initial (day-0) parameters that are indicative of induced damage to assess the molecular response 7 days after fatigue loading. We hypothesized that day-0 hysteresis, elongation, and stiffness of the loading and unloading load-displacement curves would be predictive of the 7-day molecular response. Results showed correlations between the 7-day molecular response and both day-0 elongation and unloading stiffness. Additionally, loading resulted in upregulation of several extracellular matrix genes that suggest adaptation; however, several of these genes (Col-I, -XII, MMP 2, and TIMP 3) shut down after a high level of damage was induced. We showed that evaluating the 7-day molecular profile in light of day-0 elongation provides important insight that is lost from comparing number of fatigue loading cycles only. Our data showed that loading generally results in an adaptive response. However, the tendon's ability to effectively respond deteriorates as greater damage is induced. CI - Copyright © 2012 Orthopaedic Research Society. FAU - Andarawis-Puri, Nelly AU - Andarawis-Puri N AD - Leni and Peter W. May Department of Orthopaedics, Mount Sinai School of Medicine, Mount Sinai School of Medicine, 5 East 98th Street, New York, New York 10029, USA. FAU - Sereysky, Jedd B AU - Sereysky JB FAU - Sun, Hui B AU - Sun HB FAU - Jepsen, Karl J AU - Jepsen KJ FAU - Flatow, Evan L AU - Flatow EL LA - eng GR - F32 AR058123/AR/NIAMS NIH HHS/United States GR - R01 AR052743/AR/NIAMS NIH HHS/United States GR - AR058123/AR/NIAMS NIH HHS/United States GR - AR52743/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20120106 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Collagen Type I) RN - 0 (Collagen Type V) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) RN - EC 3.4.24.35 (Mmp9 protein, rat) RN - EC 3.4.24.80 (Matrix Metalloproteinase 14) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Collagen Type I/biosynthesis MH - Collagen Type V/biosynthesis MH - Disease Models, Animal MH - Fatigue/*physiopathology MH - Female MH - Matrix Metalloproteinase 14 MH - Matrix Metalloproteinase 9/biosynthesis MH - Patellar Ligament/*physiopathology MH - Rats MH - Tendinopathy/*physiopathology MH - Tissue Inhibitor of Metalloproteinase-1/biosynthesis MH - Tissue Inhibitor of Metalloproteinase-2/biosynthesis MH - Up-Regulation PMC - PMC3763927 MID - NIHMS344955 EDAT- 2012/01/10 06:00 MHDA- 2012/09/06 06:00 PMCR- 2013/09/05 CRDT- 2012/01/10 06:00 PHST- 2011/06/18 00:00 [received] PHST- 2011/12/12 00:00 [accepted] PHST- 2012/01/10 06:00 [entrez] PHST- 2012/01/10 06:00 [pubmed] PHST- 2012/09/06 06:00 [medline] PHST- 2013/09/05 00:00 [pmc-release] AID - 10.1002/jor.22059 [doi] PST - ppublish SO - J Orthop Res. 2012 Aug;30(8):1327-34. doi: 10.1002/jor.22059. Epub 2012 Jan 6. PMID- 15794721 OWN - NLM STAT- MEDLINE DCOM- 20051219 LR - 20220318 IS - 1744-764X (Electronic) IS - 1474-0338 (Linking) VI - 4 IP - 2 DP - 2005 Mar TI - Fluoroquinolones and tendon disorders. PG - 299-309 AB - Fluoroquinolones are the most potent oral antibiotics in clinical use today. Increasingly, these drugs are being prescribed for relatively benign infections and for new categories of patients, including paediatric patients. As their use becomes more frequent, so will the adverse events. This review focuses on a rare but debilitating adverse reaction, the fluoroquinolone-associated tendinopathy. Despite many published case reports and approximately 3500 cases reported to the World Health Organization Collaborating Centre for Drug Monitoring, little is known about the mechanisms behind this fluoroquinolone-specific toxicity. Data on chemical properties, mode of action, pharmacokinetic features, clinical presentation and risk factors in relation to tendon toxicity are discussed and the literature reviewed. As long as the musculoskeletal toxicity cannot be predicted by in vitro or in vivo models and this class of antibiotics is one of the most commonly linked to selection of resistant bacteria, a more prudent use of fluoroquinolones is warranted. FAU - Melhus, Asa AU - Melhus A AD - Lund University, Department of Medical Microbiology, Malmö University Hospital, S-205 02 Malmö, Sweden. asa.melhus@mikrobiol.mas.lu.se LA - eng PT - Journal Article PT - Review PL - England TA - Expert Opin Drug Saf JT - Expert opinion on drug safety JID - 101163027 RN - 0 (Fluoroquinolones) SB - IM MH - Achilles Tendon/drug effects MH - Adult MH - Aged MH - Animals MH - Child MH - Disease Models, Animal MH - Drug Resistance, Bacterial MH - Female MH - Fluoroquinolones/*adverse effects/pharmacokinetics MH - Humans MH - Incidence MH - Male MH - Middle Aged MH - Musculoskeletal Diseases/*chemically induced/epidemiology MH - Risk Factors MH - Rupture, Spontaneous MH - Sweden/epidemiology MH - Tendinopathy/chemically induced/epidemiology MH - Tendons/*drug effects RF - 88 EDAT- 2005/03/30 09:00 MHDA- 2005/12/20 09:00 CRDT- 2005/03/30 09:00 PHST- 2005/03/30 09:00 [pubmed] PHST- 2005/12/20 09:00 [medline] PHST- 2005/03/30 09:00 [entrez] AID - EDS040213 [pii] AID - 10.1517/14740338.4.2.299 [doi] PST - ppublish SO - Expert Opin Drug Saf. 2005 Mar;4(2):299-309. doi: 10.1517/14740338.4.2.299. PMID- 3539309 OWN - NLM STAT- MEDLINE DCOM- 19870206 LR - 20190619 IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 59 IP - 1 DP - 1987 Jan 1 TI - Muramidase, alpha-1 antitrypsin, alpha-1 antichymotrypsin, and S-100 protein immunoreactivity in giant cell lesions. PG - 64-8 AB - A spectrum of giant cell lesions was evaluated for muramidase, alpha-1 antitrypsin, alpha-1 antichymotrypsin, and S-100 protein immunoreactivity using an avidin-biotin-complex immunoperoxidase method. Peripheral giant cell granuloma, central giant cell granuloma, giant cell tumor, osteitis fibrosa cystica, cherubism, and giant cell tumor of tendon sheath showed similar patterns of reactivity. Granulomatous inflammatory lesions stained more intensely for muramidase than did noninflammatory lesions. Alpha-1-antichymotrypsin was a slightly better marker of giant cell lesions than was alpha-1-antitrypsin. Positive S-100 protein staining in half the lesions was thought to be due to the presence of Langerhans cells. The results supported the belief that giant cell lesions of bone and tendon sheath are differentiated toward cells of the mononuclear-phagocyte system and that multinucleated giant cells are derived from macrophages. FAU - Regezi, J A AU - Regezi JA FAU - Zarbo, R J AU - Zarbo RJ FAU - Lloyd, R V AU - Lloyd RV LA - eng PT - Journal Article PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (S100 Proteins) RN - 0 (alpha 1-Antichymotrypsin) RN - 0 (alpha 1-Antitrypsin) RN - EC 3.2.1.17 (Muramidase) SB - IM MH - Cherubism/metabolism MH - Giant Cell Tumors/*metabolism MH - Granuloma, Giant Cell/metabolism MH - Histocytochemistry MH - Humans MH - Immunoenzyme Techniques MH - Macrophages/metabolism MH - Muramidase/*analysis MH - Osteitis Fibrosa Cystica/metabolism MH - S100 Proteins/*analysis MH - Tendons/metabolism MH - alpha 1-Antichymotrypsin/*analysis MH - alpha 1-Antitrypsin/*analysis EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] AID - 10.1002/1097-0142(19870101)59:1<64::aid-cncr2820590116>3.0.co;2-q [doi] PST - ppublish SO - Cancer. 1987 Jan 1;59(1):64-8. doi: 10.1002/1097-0142(19870101)59:1<64::aid-cncr2820590116>3.0.co;2-q. PMID- 4286149 OWN - NLM STAT- MEDLINE DCOM- 19660615 LR - 20191030 IS - 0016-898X (Print) IS - 0016-898X (Linking) VI - 11 IP - 3 DP - 1965 TI - The influence of hormone changes during pregnancy on the velocity of collagen aging. PG - 188-97 FAU - Arvay, A AU - Arvay A FAU - Takács, J AU - Takács J LA - eng PT - Journal Article PL - Switzerland TA - Gerontologia JT - Gerontologia JID - 7601654 RN - 0 (Chorionic Gonadotropin) RN - 3XMK78S47O (Testosterone) RN - 4G7DS2Q64Y (Progesterone) RN - 4TI98Z838E (Estradiol) RN - 9002-60-2 (Adrenocorticotropic Hormone) RN - 9007-34-5 (Collagen) RN - WI4X0X7BPJ (Hydrocortisone) RN - ZS9KD92H6V (Metyrapone) SB - IM MH - Adrenocorticotropic Hormone/*pharmacology MH - *Aging MH - Animals MH - Castration MH - Chorionic Gonadotropin/*pharmacology MH - Collagen MH - Estradiol/*pharmacology MH - Female MH - Hydrocortisone/*pharmacology MH - Male MH - Metyrapone/*pharmacology MH - Pregnancy MH - Pregnancy, Animal/*drug effects MH - Progesterone/*pharmacology MH - Rats MH - Tendons MH - Testosterone/*pharmacology EDAT- 1965/01/01 00:00 MHDA- 1965/01/01 00:01 CRDT- 1965/01/01 00:00 PHST- 1965/01/01 00:00 [pubmed] PHST- 1965/01/01 00:01 [medline] PHST- 1965/01/01 00:00 [entrez] AID - 10.1159/000211492 [doi] PST - ppublish SO - Gerontologia. 1965;11(3):188-97. doi: 10.1159/000211492. PMID- 6197420 OWN - NLM STAT- MEDLINE DCOM- 19840214 LR - 20091119 IS - 0021-9541 (Print) IS - 0021-9541 (Linking) VI - 117 IP - 3 DP - 1983 Dec TI - Abnormal behavior of cultured fibroblasts from nodule and nonaffected aponeurosis of Dupuytren's disease. PG - 353-61 AB - Vimentin-positive, desmin-negative cells were established in culture from the nodule and from apparently normal palmar aponeurosis of a patient with Dupuytren's disease and compared with normal human embryonic and adult fibroblasts or sarcomatous cells. Cells from the nodule display in vitro biological properties that are intermediate between those expressed by normal fibroblasts and sarcoma cells or cells from the nodule transformed with SV40 virus. Thus, they represent an interesting in vitro model of partially transformed human cells. This behavior is not evolutive and justifies the classification of Dupuytren's disease among the benign mesenchymal tumors. The production of high level of plasminogen activator probably explains the local reactive pathology, and could act as a mitogenic stimulus for the proliferation of the nodule itself. Cultures derived from the apparently normal palmar aponeurosis show some but not all the abnormal growth properties of cells from nodules; this may help to explain the onset of local recurrences. Our results suggest that Dupuytren's disease is not strictly local and limited to the nodules, but affects, at least partially, the whole aponeurosis. Dupuytren's nodules could be considered as a model of tumor progression in a benign situation. FAU - Azzarone, B AU - Azzarone B FAU - Failly-Crepin, C AU - Failly-Crepin C FAU - Daya-Grosjean, L AU - Daya-Grosjean L FAU - Chaponnier, C AU - Chaponnier C FAU - Gabbiani, G AU - Gabbiani G LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Fibronectins) RN - 9008-11-1 (Interferons) RN - EC 3.4.21.- (Plasminogen Activators) SB - IM MH - Blood MH - Cell Aggregation MH - Cell Count MH - Cell Division MH - Cell Line MH - Cell Transformation, Viral MH - Cells, Cultured MH - Clone Cells/cytology MH - Clot Retraction MH - Dupuytren Contracture/*pathology MH - Fibronectins/analysis MH - Humans MH - Interferons/pharmacology MH - Karyotyping MH - Kinetics MH - Plasminogen Activators/biosynthesis MH - Sarcoma MH - Simian virus 40 MH - Tendons/*pathology EDAT- 1983/12/01 00:00 MHDA- 1983/12/01 00:01 CRDT- 1983/12/01 00:00 PHST- 1983/12/01 00:00 [pubmed] PHST- 1983/12/01 00:01 [medline] PHST- 1983/12/01 00:00 [entrez] AID - 10.1002/jcp.1041170310 [doi] PST - ppublish SO - J Cell Physiol. 1983 Dec;117(3):353-61. doi: 10.1002/jcp.1041170310. PMID- 38052258 OWN - NLM STAT- MEDLINE DCOM- 20231222 LR - 20240103 IS - 1879-0720 (Electronic) IS - 0928-0987 (Linking) VI - 192 DP - 2024 Jan 1 TI - Gellan gum-based bi-polymeric hydrogel scaffolds loaded with Rosuvastatin calcium: A useful tool for tendon tissue regeneration. PG - 106659 LID - S0928-0987(23)00288-9 [pii] LID - 10.1016/j.ejps.2023.106659 [doi] AB - Statins have been long used in tissue engineering, besides their marketed hypolipidemic benefits. The aim of this research was to sustain the release of rosuvastatin calcium from bi-polymeric hydrogel scaffolds. A bi-polymer blend technique was used to enhance the mechanical properties of the fabricated hydrogels. Briefly, hydrogels were prepared via crosslinking gellan gum as the main polymer together with a secondary polymer in the presence of Ca(2+). The fabricated hydrogels were assessed in terms of % swelling capacity, hydrolytic degradation and % drug released to determine the most efficient carrier system. The selected hydrogel exhibited a swelling capacity of 131.45±1.49 % following 3 weeks in an aqueous environment with a % weight loss of 15.73±1.86 % after 4 weeks post-equilibrium in aqueous medium. The results ensure a proper window for adequate drug diffusion and nutrient exchange. Sustained release was attained where 94.61±2.77 % of rosuvastatin was released at the 4-week mark. Later, FT-IR and DSC, were carried out and suggested the successful crosslinking and formation of new matrix. SEM images demonstrated the porous surface of the hydrogel while a Young's modulus of 888.558±73.549 kPa indicated the suitability of the hydrogel for soft tissue engineering. In-vivo testing involved implanting the selected hydrogel at precisely surgical cuts in the Achilles tendon of male Wistar Albino rats. Upon visual and microscopic evaluation, enhanced rates of fibrous tissue formation, vascularization and collagen expression were clearly noticed in the treatment group. CI - Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Adel, Islam M AU - Adel IM AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. Electronic address: islam.hashim@pharma.cu.edu.eg. FAU - ElMeligy, Mohamed F AU - ElMeligy MF AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. FAU - Amer, Mohammed S AU - Amer MS AD - Department of Surgery, Anaesthesiology and Radiology, Faculty of Veterinary Medicine, Cairo University, Cairo 12211, Egypt. FAU - Elkasabgy, Nermeen A AU - Elkasabgy NA AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. LA - eng PT - Journal Article DEP - 20231203 PL - Netherlands TA - Eur J Pharm Sci JT - European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences JID - 9317982 RN - 0 (Hydrogels) RN - 83MVU38M7Q (Rosuvastatin Calcium) RN - 7593U09I4D (gellan gum) RN - 0 (Polysaccharides, Bacterial) RN - 9007-34-5 (Collagen) SB - IM MH - Rats MH - Animals MH - Male MH - *Hydrogels MH - Rosuvastatin Calcium MH - Spectroscopy, Fourier Transform Infrared MH - *Polysaccharides, Bacterial MH - Tendons MH - Rats, Wistar MH - Collagen MH - Tissue Scaffolds OTO - NOTNLM OT - Gellan gum OT - Hydrogel scaffolds OT - Rosuvastatin OT - Tendons repair OT - Tissue engineering COIS- Declaration of Competing Interest The authors of this work confirm that there is no conflict of interest. EDAT- 2023/12/06 03:43 MHDA- 2023/12/22 06:43 CRDT- 2023/12/05 19:19 PHST- 2023/10/04 00:00 [received] PHST- 2023/11/22 00:00 [revised] PHST- 2023/11/30 00:00 [accepted] PHST- 2023/12/22 06:43 [medline] PHST- 2023/12/06 03:43 [pubmed] PHST- 2023/12/05 19:19 [entrez] AID - S0928-0987(23)00288-9 [pii] AID - 10.1016/j.ejps.2023.106659 [doi] PST - ppublish SO - Eur J Pharm Sci. 2024 Jan 1;192:106659. doi: 10.1016/j.ejps.2023.106659. Epub 2023 Dec 3. PMID- 26310937 OWN - NLM STAT- MEDLINE DCOM- 20160208 LR - 20220318 IS - 1522-1490 (Electronic) IS - 0363-6119 (Linking) VI - 309 IP - 9 DP - 2015 Nov 1 TI - Influence of acute and chronic streptozotocin-induced diabetes on the rat tendon extracellular matrix and mechanical properties. PG - R1135-43 LID - 10.1152/ajpregu.00189.2015 [doi] AB - Diabetes is a major risk factor for tendinopathy, and tendon abnormalities are common in diabetic patients. The purpose of the present study was to evaluate the effect of streptozotocin (60 mg/kg)-induced diabetes and insulin therapy on tendon mechanical and cellular properties. Sprague-Dawley rats (n = 40) were divided into the following four groups: nondiabetic (control), 1 wk of diabetes (acute), 10 wk of diabetes (chronic), and 10 wk of diabetes with insulin treatment (insulin). After 10 wk, Achilles tendon and tail fascicle mechanical properties were similar between groups (P > 0.05). Cell density in the Achilles tendon was greater in the chronic group compared with the control and acute groups (control group: 7.8 ± 0.5 cells/100 μm(2), acute group: 8.3 ± 0.4 cells/100 μm(2), chronic group: 10.9 ± 0.9 cells/100 μm(2), and insulin group: 9.2 ± 0.8 cells/100 μm(2), P < 0.05). The density of proliferating cells in the Achilles tendon was greater in the chronic group compared with all other groups (control group: 0.025 ± 0.009 cells/100 μm(2), acute group: 0.019 ± 0.005 cells/100 μm(2), chronic group: 0.067 ± 0.015, and insulin group: 0.004 ± 0.004 cells/100 μm(2), P < 0.05). Patellar tendon collagen content was ∼32% greater in the chronic and acute groups compared with the control or insulin groups (control group: 681 ± 63 μg collagen/mg dry wt, acute group: 938 ± 21 μg collagen/mg dry wt, chronic: 951 ± 52 μg collagen/mg dry wt, and insulin group: 596 ± 84 μg collagen/mg dry wt, P < 0.05). In contrast, patellar tendon hydroxylysyl pyridinoline cross linking and collagen fibril organization were unchanged by diabetes or insulin (P > 0.05). Our findings suggest that 10 wk of streptozotocin-induced diabetes does not alter rat tendon mechanical properties even with an increase in collagen content. Future studies could attempt to further address the mechanisms contributing to the increase in tendon problems noted in diabetic patients, especially since our data suggest that hyperglycemia per se does not alter tendon mechanical properties. CI - Copyright © 2015 the American Physiological Society. FAU - Volper, Brent D AU - Volper BD AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, Arizona. FAU - Huynh, Richard T AU - Huynh RT AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, Arizona. FAU - Arthur, Kathryn A AU - Arthur KA AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; FAU - Noone, Joshua AU - Noone J AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina; FAU - Gordon, Benjamin D AU - Gordon BD AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina; FAU - Zacherle, Emily W AU - Zacherle EW AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina; FAU - Munoz, Eduardo AU - Munoz E AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina; FAU - Sørensen, Mikkel A AU - Sørensen MA AD - Musculoskeletal Rehabilitation Research Unit and Institute of Sports Medicine, Copenhagen Bispebjerg Hospital Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; and. FAU - Svensson, René B AU - Svensson RB AD - Musculoskeletal Rehabilitation Research Unit and Institute of Sports Medicine, Copenhagen Bispebjerg Hospital Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; and. FAU - Broderick, Tom L AU - Broderick TL AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; FAU - Magnusson, S Peter AU - Magnusson SP AD - Musculoskeletal Rehabilitation Research Unit and Institute of Sports Medicine, Copenhagen Bispebjerg Hospital Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark; and. FAU - Howden, Reuben AU - Howden R AD - Laboratory of Systems Physiology, Department of Kinesiology, University of North Carolina at Charlotte, Charlotte, North Carolina; FAU - Hale, Taben M AU - Hale TM AD - Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, Arizona. FAU - Carroll, Chad C AU - Carroll CC AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; ccarro@midwestern.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150826 PL - United States TA - Am J Physiol Regul Integr Comp Physiol JT - American journal of physiology. Regulatory, integrative and comparative physiology JID - 100901230 RN - 0 (Extracellular Matrix Proteins) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) SB - IM MH - Acute Disease MH - Animals MH - Chronic Disease MH - Collagen/metabolism MH - Diabetes Mellitus, Experimental/chemically induced/*pathology/*physiopathology MH - Elastic Modulus MH - Extracellular Matrix/*metabolism/pathology MH - Extracellular Matrix Proteins/*metabolism MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Streptozocin MH - Stress, Mechanical MH - Tendons/*pathology/*physiopathology MH - Tensile Strength OTO - NOTNLM OT - collagen OT - cross linking OT - diabetes OT - mechanical strength OT - tendinopathy OT - tendon OT - tenocytes EDAT- 2015/08/28 06:00 MHDA- 2016/02/09 06:00 CRDT- 2015/08/28 06:00 PHST- 2015/05/04 00:00 [received] PHST- 2015/08/24 00:00 [accepted] PHST- 2015/08/28 06:00 [entrez] PHST- 2015/08/28 06:00 [pubmed] PHST- 2016/02/09 06:00 [medline] AID - ajpregu.00189.2015 [pii] AID - 10.1152/ajpregu.00189.2015 [doi] PST - ppublish SO - Am J Physiol Regul Integr Comp Physiol. 2015 Nov 1;309(9):R1135-43. doi: 10.1152/ajpregu.00189.2015. Epub 2015 Aug 26. PMID- 31424116 OWN - NLM STAT- MEDLINE DCOM- 20200221 LR - 20200718 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 38 IP - 1 DP - 2020 Jan TI - Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI-1/Serpine1) Null Mice. PG - 43-58 LID - 10.1002/jor.24448 [doi] AB - Injuries to flexor tendons can be complicated by fibrotic adhesions, which severely impair the function of the hand. Plasminogen activator inhibitor 1 (PAI-1/SERPINE1), a master suppressor of fibrinolysis and protease activity, is associated with adhesions. Here, we used next-generation RNA sequencing (RNA-Seq) to assess genome-wide differences in messenger RNA expression due to PAI-1 deficiency after zone II flexor tendon injury. We used the ingenuity pathway analysis to characterize molecular pathways and biological drivers associated with differentially expressed genes (DEG). Analysis of hundreds of overlapping and DEG in PAI-1 knockout (KO) and wild-type mice (C57Bl/6J) during tendon healing revealed common and distinct biological processes. Pathway analysis identified cell proliferation, survival, and senescence, as well as chronic inflammation as potential drivers of fibrotic healing and adhesions in injured tendons. Importantly, we identified the activation of PTEN signaling and the inhibition of FOXO1-associated biological processes as unique transcriptional signatures of the healing tendon in the PAI-1/Serpine1 KO mice. Further, transcriptomic differences due to the genetic deletion of PAI-1 were mechanistically linked to PI3K/Akt/mTOR, PKC, and MAPK signaling cascades. These transcriptional observations provide novel insights into the biological roles of PAI-1 in tendon healing and could identify therapeutic targets to achieve scar-free regenerative healing of tendons. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:43-58, 2020. CI - © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Freeberg, Margaret A T AU - Freeberg MAT AD - Department of Biomedical Engineering, University of Rochester, Rochester, New York. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Easa, Anas AU - Easa A AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - Lillis, Jacquelyn A AU - Lillis JA AD - Genomics Research Center, University of Rochester Medical Center, Rochester, New York. FAU - Benoit, Danielle S W AU - Benoit DSW AD - Department of Biomedical Engineering, University of Rochester, Rochester, New York. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. FAU - van Wijnen, Andre J AU - van Wijnen AJ AD - Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota. FAU - Awad, Hani A AU - Awad HA AUID- ORCID: 0000-0003-2197-2610 AD - Department of Biomedical Engineering, University of Rochester, Rochester, New York. AD - Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York. AD - Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, New York. LA - eng GR - R01AR056696/RG/CSR NIH HHS/United States GR - P30 AR069655/AR/NIAMS NIH HHS/United States GR - T32AR053459/RG/CSR NIH HHS/United States GR - R01AR049069/RG/CSR NIH HHS/United States GR - R01 AR056696/AR/NIAMS NIH HHS/United States GR - R01 AR049069/AR/NIAMS NIH HHS/United States GR - R01 AR070613/AR/NIAMS NIH HHS/United States GR - T32 AR053459/AR/NIAMS NIH HHS/United States GR - P30AR069655/RG/CSR NIH HHS/United States GR - R01AR070613/RG/CSR NIH HHS/United States GR - DMR-1206219/Division of Materials Research/International GR - NYSTEM IDEA-N11G-035/New York State Stem Cell Science Program/International PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20190901 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Forkhead Box Protein O1) RN - 0 (Foxo1 protein, mouse) RN - 0 (Plasminogen Activator Inhibitor 1) RN - EC 2.7.11.13 (Protein Kinase C) RN - EC 3.1.3.67 (PTEN Phosphohydrolase) RN - EC 3.1.3.67 (Pten protein, mouse) SB - IM MH - Animals MH - Forkhead Box Protein O1/physiology MH - High-Throughput Nucleotide Sequencing MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - PTEN Phosphohydrolase/physiology MH - Plasminogen Activator Inhibitor 1/*physiology MH - Protein Kinase C/physiology MH - Tendon Injuries/*physiopathology MH - *Transcriptome MH - *Wound Healing PMC - PMC7364818 MID - NIHMS1062094 OTO - NOTNLM OT - FOXO1 OT - PAI-1 OT - PTEN OT - RNA sequencing OT - adhesions OT - fibrosis OT - ingenuity pathway analysis OT - tendon COIS- Competing financial interests The authors declare no competing financial interests. EDAT- 2019/08/20 06:00 MHDA- 2020/02/23 06:00 PMCR- 2020/07/16 CRDT- 2019/08/20 06:00 PHST- 2019/01/22 00:00 [received] PHST- 2019/08/07 00:00 [accepted] PHST- 2019/08/20 06:00 [pubmed] PHST- 2020/02/23 06:00 [medline] PHST- 2019/08/20 06:00 [entrez] PHST- 2020/07/16 00:00 [pmc-release] AID - 10.1002/jor.24448 [doi] PST - ppublish SO - J Orthop Res. 2020 Jan;38(1):43-58. doi: 10.1002/jor.24448. Epub 2019 Sep 1. PMID- 36594083 OWN - NLM STAT- MEDLINE DCOM- 20230104 LR - 20230522 IS - 1449-2288 (Electronic) IS - 1449-2288 (Linking) VI - 19 IP - 1 DP - 2023 TI - Tendon Cells Root Into (Instead of Attach to) Humeral Bone Head via Fibrocartilage-Enthesis. PG - 183-203 LID - 10.7150/ijbs.79007 [doi] AB - Large joints are composed of two closely linked cartilages: articular cartilage (AC; rich in type II collagen, a well-studied tissue) and fibrocartilaginous enthesis (FE; rich in type I collagen, common disorder sites of enthesopathy and sporting injuries, although receiving little attention). For many years, both cartilages were thought to be formed by chondrocytes, whereas tendon, which attaches to the humeral bone head, is primarily considered as a completely different connective tissue. In this study, we raised an unconventional hypothesis: tendon cells directly form FE via cell transdifferentiation. To test this hypothesis, we first qualitatively and quantitatively demonstrated distinct differences between AC and FE in cell morphology and cell distribution, mineralization status, extracellular matrix (ECM) contents, and critical ECM protein expression profiles using comprehensive approaches. Next, we traced the cell fate of tendon cells using Scx(Lin) (a tendon specific Cre Scx(CreERT2); R26R-tdTomato line) with one-time tamoxifen induction at early (P3) or young adult (P28) stages and harvested mice at different development ages, respectively. Our early tracing data revealed different growth events in tendon and FE: an initial increase but gradual decrease in the Scx(Lin) tendon cells and a continuous expansion in the Scx(Lin) FE cells. The young adult tracing data demonstrated continuous recruitment of Scx(Lin) cells into FE expansion during P28 and P56. A separate tracing line, 3.2 Col 1(Lin) (a so-called "bone-specific" line), further confirmed the direct contribution of tendon cells for FE cell formation, which occurred in days but FE ECM maturation (including high levels of SOST, a potent Wnt signaling inhibitor) took weeks. Finally, loss of function data using diphtheria toxin fragment A (DTA) in Scx(Lin) cells demonstrated a significant reduction of Scx(Lin) cells in both tendons and FE cells, whereas the gain of function study (by stabilizing β-catenin in Scx(Lin) tendon cells via one-time injection of tamoxifen at P3 and harvesting at P60) displayed great expansion of both Scx(Lin) tendon and FE mass. Together, our studies demonstrated that fibrocartilage is an invaded enthesis likely originating from the tendon via a quick cell transdifferentiation mechanism with a lengthy ECM maturation process. The postnatally formed fibrocartilage roots into existing cartilage and firmly connects tendon and bone instead of acting as a simple attachment site as widely believed. We believe that this study will stimulate more intense exploring in this understudied area, especially for patients with enthesopathy and sporting injuries. CI - © The author(s). FAU - Wang, Zheng AU - Wang Z AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Ma, Chi AU - Ma C AD - Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 75219, USA. FAU - Chen, Diane AU - Chen D AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Haslett, Caitlin AU - Haslett C AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Xu, Chunmei AU - Xu C AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Dong, Changchun AU - Dong C AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Wang, Xiaofang AU - Wang X AD - Department of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, Texas 75246, USA. FAU - Zheng, Minghao AU - Zheng M AD - Centre for Orthopaedic Research, Medical School, The University of Western Australia, Nedlands, WA, Australia. FAU - Jing, Yan AU - Jing Y AD - Department of Orthodontics, Texas A&M University College of Dentistry, Dallas, TX, 75246, USA. FAU - Feng, Jian Q AU - Feng JQ AD - Dental School and Oral Health Centre, The University of Western Australia, Nedlands, 6009 Australia. LA - eng GR - K08 DE028593/DE/NIDCR NIH HHS/United States GR - R01 DE028547/DE/NIDCR NIH HHS/United States GR - R03 DE029541/DE/NIDCR NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20230101 PL - Australia TA - Int J Biol Sci JT - International journal of biological sciences JID - 101235568 RN - 094ZI81Y45 (Tamoxifen) SB - IM MH - Mice MH - Animals MH - *Enthesopathy/metabolism MH - Tendons/metabolism MH - Fibrocartilage MH - Humerus MH - Tamoxifen PMC - PMC9760439 OTO - NOTNLM OT - Cell lineage tracing OT - Fibrocartilaginous enthesis OT - Scx OT - Tendon cell COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2023/01/04 06:00 MHDA- 2023/01/05 06:00 PMCR- 2023/01/01 CRDT- 2023/01/03 02:00 PHST- 2022/09/07 00:00 [received] PHST- 2022/09/24 00:00 [accepted] PHST- 2023/01/03 02:00 [entrez] PHST- 2023/01/04 06:00 [pubmed] PHST- 2023/01/05 06:00 [medline] PHST- 2023/01/01 00:00 [pmc-release] AID - ijbsv19p0183 [pii] AID - 10.7150/ijbs.79007 [doi] PST - epublish SO - Int J Biol Sci. 2023 Jan 1;19(1):183-203. doi: 10.7150/ijbs.79007. eCollection 2023. PMID- 34741033 OWN - NLM STAT- MEDLINE DCOM- 20220202 LR - 20240226 IS - 2041-4889 (Electronic) VI - 12 IP - 11 DP - 2021 Nov 5 TI - Tenomodulin knockout mice exhibit worse late healing outcomes with augmented trauma-induced heterotopic ossification of Achilles tendon. PG - 1049 LID - 10.1038/s41419-021-04298-z [doi] LID - 1049 AB - Heterotopic ossification (HO) represents a common problem after tendon injury with no effective treatment yet being developed. Tenomodulin (Tnmd), the best-known mature marker for tendon lineage cells, has important effects in tendon tissue aging and function. We have reported that loss of Tnmd leads to inferior early tendon repair characterized by fibrovascular scaring and therefore hypothesized that its lack will persistently cause deficient repair during later stages. Tnmd knockout (Tnmd(-/-)) and wild-type (WT) animals were subjected to complete Achilles tendon surgical transection followed by end-to-end suture. Lineage tracing revealed a reduction in tendon-lineage cells marked by ScleraxisGFP, but an increase in alpha smooth muscle actin myofibroblasts in Tnmd(-)(/-) tendon scars. At the proliferative stage, more pro-inflammatory M1 macrophages and larger collagen II cartilaginous template were detected in this group. At the remodeling stage, histological scoring revealed lower repair quality in the injured Tnmd(-/-) tendons, which was coupled with higher HO quantified by micro-CT. Tendon biomechanical properties were compromised in both groups upon injury, however we identified an abnormal stiffening of non-injured Tnmd(-/)(-) tendons, which possessed higher static and dynamic E-moduli. Pathologically thicker and abnormally shaped collagen fibrils were observed by TEM in Tnmd(-/-) tendons and this, together with augmented HO, resulted in diminished running capacity of Tnmd(-/-) mice. These novel findings demonstrate that Tnmd plays a protecting role against trauma-induced endochondral HO and can inspire the generation of novel therapeutics to accelerate repair. CI - © 2021. The Author(s). FAU - Delgado Caceres, Manuel AU - Delgado Caceres M AD - Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. FAU - Angerpointner, Katharina AU - Angerpointner K AD - Hand, Elbow and Plastic Surgery Department, Schön Klinik München Harlaching, Munich, Germany. FAU - Galler, Michael AU - Galler M AD - Department of Trauma Surgery, Caritas Hospital St. Josef, Regensburg, Germany. FAU - Lin, Dasheng AU - Lin D AD - Orthopaedic Center of People's Liberation Army, The Affiliated Southeast Hospital of Xiamen University, Zhangzhou, China. FAU - Michel, Philipp A AU - Michel PA AD - Department of Trauma-, Hand-, and Reconstructive Surgery, University Hospital Münster, Münster, Germany. FAU - Brochhausen, Christoph AU - Brochhausen C AD - Institute of Pathology, University of Regensburg, Regensburg, Germany. FAU - Lu, Xin AU - Lu X AD - Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany. FAU - Varadarajan, Adithi R AU - Varadarajan AR AD - Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany. FAU - Warfsmann, Jens AU - Warfsmann J AD - Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany. FAU - Stange, Richard AU - Stange R AD - Department of Regenerative Musculoskeletal Medicine, Institute for Musculoskeletal Medicine, University Hospital Münster, Westfälische Wilhelms-University, Münster, Germany. FAU - Alt, Volker AU - Alt V AD - Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. AD - Clinic and Policlinic for Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. FAU - Pfeifer, Christian G AU - Pfeifer CG AD - Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. AD - Clinic and Policlinic for Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. FAU - Docheva, Denitsa AU - Docheva D AUID- ORCID: 0000-0002-7588-1290 AD - Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany. denitsa.docheva@ukr.de. AD - Department of Musculoskeletal Tissue Regeneration, Orthopaedic Hospital König-Ludwig-Haus, University of Würzburg, Würzburg, Germany. denitsa.docheva@ukr.de. LA - eng GR - DO1414/3-1/Deutsche Forschungsgemeinschaft (German Research Foundation)/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211105 PL - England TA - Cell Death Dis JT - Cell death & disease JID - 101524092 RN - 0 (Acta2 protein, mouse) RN - 0 (Actins) RN - 0 (Fibrillar Collagens) RN - 0 (Membrane Proteins) RN - 0 (Tnmd protein, mouse) RN - 147336-22-9 (Green Fluorescent Proteins) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Achilles Tendon/*pathology/ultrastructure MH - Actins/metabolism MH - Animals MH - Bromodeoxyuridine/metabolism MH - Cell Count MH - Chondrogenesis MH - Cicatrix/pathology MH - Elastic Modulus MH - Elasticity MH - Extracellular Matrix/metabolism MH - Fibrillar Collagens/metabolism/ultrastructure MH - Genotype MH - Green Fluorescent Proteins/metabolism MH - Inflammation/pathology MH - Macrophages/pathology MH - Membrane Proteins/*deficiency/metabolism MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Ossification, Heterotopic/*etiology/*pathology MH - Viscosity MH - *Wound Healing MH - Wounds and Injuries/*complications MH - Mice PMC - PMC8571417 COIS- The authors declare no competing interests. EDAT- 2021/11/07 06:00 MHDA- 2022/02/03 06:00 PMCR- 2021/11/05 CRDT- 2021/11/06 05:42 PHST- 2021/07/08 00:00 [received] PHST- 2021/10/07 00:00 [accepted] PHST- 2021/10/05 00:00 [revised] PHST- 2021/11/06 05:42 [entrez] PHST- 2021/11/07 06:00 [pubmed] PHST- 2022/02/03 06:00 [medline] PHST- 2021/11/05 00:00 [pmc-release] AID - 10.1038/s41419-021-04298-z [pii] AID - 4298 [pii] AID - 10.1038/s41419-021-04298-z [doi] PST - epublish SO - Cell Death Dis. 2021 Nov 5;12(11):1049. doi: 10.1038/s41419-021-04298-z. PMID- 31089972 OWN - NLM STAT- MEDLINE DCOM- 20191111 LR - 20200309 IS - 1179-1918 (Electronic) IS - 1173-2563 (Linking) VI - 39 IP - 6 DP - 2019 Jun TI - Addendum to: Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case-Control Study. PG - 591-594 LID - 10.1007/s40261-019-00792-7 [doi] FAU - Morales, Daniel R AU - Morales DR AUID- ORCID: 0000-0002-0063-8069 AD - Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK. d.r.z.morales@dundee.ac.uk. FAU - Flynn, Rob AU - Flynn R AD - Department of Pharmacovigilance and Epidemiology, European Medicines Agency, Amsterdam, Netherlands. FAU - Kurz, Xavier AU - Kurz X AD - Department of Pharmacovigilance and Epidemiology, European Medicines Agency, Amsterdam, Netherlands. LA - eng PT - Comment PT - Letter PL - New Zealand TA - Clin Drug Investig JT - Clinical drug investigation JID - 9504817 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Fluoroquinolones) SB - IM CON - Clin Drug Investig. 2019 Feb;39(2):205-213. doi: 10.1007/s40261-018-0729-y. PMID: 30465300 MH - Adrenal Cortex Hormones MH - Case-Control Studies MH - *Fluoroquinolones MH - Humans MH - *Tendon Injuries MH - Tendons EDAT- 2019/05/16 06:00 MHDA- 2019/11/12 06:00 CRDT- 2019/05/16 06:00 PHST- 2019/05/16 06:00 [pubmed] PHST- 2019/11/12 06:00 [medline] PHST- 2019/05/16 06:00 [entrez] AID - 10.1007/s40261-019-00792-7 [pii] AID - 10.1007/s40261-019-00792-7 [doi] PST - ppublish SO - Clin Drug Investig. 2019 Jun;39(6):591-594. doi: 10.1007/s40261-019-00792-7. PMID- 7644621 OWN - NLM STAT- MEDLINE DCOM- 19950921 LR - 20151119 IS - 0033-8419 (Print) IS - 0033-8419 (Linking) VI - 196 IP - 3 DP - 1995 Sep TI - Plantar compartments of the foot: MR appearance in cadavers and diabetic patients. PG - 623-30 AB - PURPOSE: To demonstrate the plantar compartments of the foot on magnetic resonance (MR) images. MATERIALS AND METHODS: The plantar compartments of four cadaveric feet underwent MR imaging and were sectioned. Fifteen MR studies in 11 patients with compartmental fluid were evaluated. The epicenter of infection was determined from review of the history, radiographs, and MR images. RESULTS: In the cadaveric feet, distribution of contrast material conformed to the compartmental anatomic features. MR findings in the specimen correlated exactly with gross findings. All seven feet with infection centered at the second through fourth metatarsal heads demonstrated only central compartment fluid. In seven of eight feet with a more medial or lateral epicenter of infection, fluid was seen in the lateral or medial compartment and in the central compartment. In one foot with a lateral epicenter of infection, fluid was confined to the lateral compartment. CONCLUSION: MR imaging accurately depicts the compartmental anatomic features of the foot. FAU - Goodwin, D W AU - Goodwin DW AD - Veterans Administration Medical Center, San Diego, CA 92161, USA. FAU - Salonen, D C AU - Salonen DC FAU - Yu, J S AU - Yu JS FAU - Brossmann, J AU - Brossmann J FAU - Trudell, D J AU - Trudell DJ FAU - Resnick, D L AU - Resnick DL LA - eng PT - Journal Article PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - 0 (Contrast Media) RN - 0 (Drug Combinations) RN - 0 (Organometallic Compounds) RN - 6HG8UB2MUY (Meglumine) RN - 789U1901C5 (Copper) RN - 7A314HQM0I (Pentetic Acid) RN - 9000-70-8 (Gelatin) RN - AU0V1LM3JT (Gadolinium) RN - K2I13DR72L (Gadolinium DTPA) RN - LRX7AJ16DT (Copper Sulfate) RN - T42P99266K (Methylene Blue) RN - XUW72GOP7W (Iothalamate Meglumine) SB - IM MH - Cadaver MH - Contrast Media MH - Copper MH - Copper Sulfate MH - Diabetic Foot/*pathology MH - Drug Combinations MH - Exudates and Transudates MH - Fascia/pathology MH - Foot/*anatomy & histology/pathology MH - Gadolinium MH - Gadolinium DTPA MH - Gelatin MH - Humans MH - Iothalamate Meglumine MH - *Magnetic Resonance Imaging MH - Meglumine MH - Metatarsophalangeal Joint/pathology MH - Metatarsus/pathology MH - Methylene Blue MH - Muscle, Skeletal/pathology MH - Organometallic Compounds MH - Pentetic Acid/analogs & derivatives MH - Soft Tissue Infections/pathology MH - Tendons/pathology EDAT- 1995/09/01 00:00 MHDA- 1995/09/01 00:01 CRDT- 1995/09/01 00:00 PHST- 1995/09/01 00:00 [pubmed] PHST- 1995/09/01 00:01 [medline] PHST- 1995/09/01 00:00 [entrez] AID - 10.1148/radiology.196.3.7644621 [doi] PST - ppublish SO - Radiology. 1995 Sep;196(3):623-30. doi: 10.1148/radiology.196.3.7644621. PMID- 1449470 OWN - NLM STAT- MEDLINE DCOM- 19921230 LR - 20190612 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 189 IP - 1 DP - 1992 Nov 30 TI - The interaction of decorin core protein fragments with type I collagen. PG - 165-72 AB - To further define the molecular interaction between decorin and type I collagen we generated a 20 kD fragment containing the N-terminal half of the core protein by Endoproteinase Arg C digestion and a 40 kD fragment including all leucine-rich repeats in the central part of decorin core by cleavage with 2-nitro-5-thiocyanobenzoate. The fragments did not influence collagen fibril formation, even at high concentration, and radioactive fragments showed little binding to collagen fibrils. Our observations suggest that neither the N-terminal half nor the central leucine-rich repeats of the decorin core protein can, by itself, interact fully with fibrillar collagen. FAU - Pogány, G AU - Pogány G AD - Department of Biology, University of New Mexico, Albuquerque 87131. FAU - Vogel, K G AU - Vogel KG LA - eng GR - AR36110/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Peptide Fragments) RN - 0 (Proteoglycans) RN - 0 (Thiocyanates) RN - 9007-34-5 (Collagen) RN - EC 3.4.- (submandibular proteinase A) RN - EC 3.4.21.- (Serine Endopeptidases) RN - O5VCA1GS5O (2-nitro-5-thiocyanobenzoic acid) SB - IM MH - Animals MH - Cattle MH - Cells, Cultured MH - Chromatography, Ion Exchange MH - Collagen/chemistry/*metabolism MH - Decorin MH - Extracellular Matrix Proteins MH - Fibroblasts/metabolism MH - Hydrolysis MH - Molecular Weight MH - Peptide Fragments/chemistry/*metabolism MH - Protein Binding MH - Proteoglycans/chemistry/isolation & purification/*metabolism MH - Serine Endopeptidases/*metabolism MH - Tendons/metabolism MH - Thiocyanates EDAT- 1992/11/30 00:00 MHDA- 1992/11/30 00:01 CRDT- 1992/11/30 00:00 PHST- 1992/11/30 00:00 [pubmed] PHST- 1992/11/30 00:01 [medline] PHST- 1992/11/30 00:00 [entrez] AID - 0006-291X(92)91539-3 [pii] AID - 10.1016/0006-291x(92)91539-3 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1992 Nov 30;189(1):165-72. doi: 10.1016/0006-291x(92)91539-3. PMID- 14325334 OWN - NLM STAT- MEDLINE DCOM- 19961201 LR - 20190513 IS - 0366-0826 (Print) IS - 0366-0826 (Linking) VI - 24 IP - 2 DP - 1965 Apr TI - THE ACTION OF PRONETHALOL ON SPINAL REFLEXES. PG - 319-31 FAU - MORALES AGUILERA, A AU - MORALES AGUILERA A FAU - VAUGHANWILLIAMS, E M AU - VAUGHANWILLIAMS EM LA - eng PT - Journal Article PL - England TA - Br J Pharmacol Chemother JT - British journal of pharmacology and chemotherapy JID - 0154627 RN - 0 (Anesthetics) RN - 0 (Anesthetics, Local) RN - 0 (Ethanolamines) RN - 0 (Sympatholytics) RN - 98PI200987 (Lidocaine) RN - AL805O9OG9 (Orphenadrine) RN - I4744080IR (Pentobarbital) RN - XBP4RT1IMQ (pronethalol) SB - OM MH - *Anesthetics MH - *Anesthetics, Local MH - *Blood Pressure MH - *Electrophysiology MH - *Electroshock MH - *Ethanolamines MH - Guinea Pigs MH - *Hypotension MH - *Lidocaine MH - *Neural Conduction MH - *Orphenadrine MH - *Pentobarbital MH - *Peripheral Nerves MH - *Pharmacology MH - Rabbits MH - *Reflex MH - *Reflex, Stretch MH - *Research MH - *Sciatic Nerve MH - *Seizures MH - *Spinal Nerves MH - *Sympatholytics MH - *Tendons PMC - PMC1704112 OTO - NLM OT - *ANESTHETICS, LOCAL OT - *BLOOD PRESSURE OT - *CONVULSIONS OT - *ELECTROPHYSIOLOGY OT - *ELECTROSHOCK OT - *EXPERIMENTAL LAB STUDY OT - *GUINEA PIGS OT - *HYPOTENSION OT - *LIDOCAINE OT - *NEURAL CONDUCTION OT - *ORPHENADRINE OT - *PENTOBARBITAL OT - *PERIPHERAL NERVES OT - *PHARMACOLOGY OT - *PRONETHALOL OT - *RABBITS OT - *REFLEX OT - *REFLEX, TENDON OT - *SCIATIC NERVE OT - *SPINAL NERVES OT - *SYMPATHOLYTICS EDAT- 1965/04/01 00:00 MHDA- 1965/04/01 00:01 PMCR- 1965/04/01 CRDT- 1965/04/01 00:00 PHST- 1965/04/01 00:00 [pubmed] PHST- 1965/04/01 00:01 [medline] PHST- 1965/04/01 00:00 [entrez] PHST- 1965/04/01 00:00 [pmc-release] AID - 10.1111/j.1476-5381.1965.tb01718.x [doi] PST - ppublish SO - Br J Pharmacol Chemother. 1965 Apr;24(2):319-31. doi: 10.1111/j.1476-5381.1965.tb01718.x. PMID- 4323854 OWN - NLM STAT- MEDLINE DCOM- 19710526 LR - 20190613 IS - 0006-2960 (Print) IS - 0006-2960 (Linking) VI - 10 IP - 6 DP - 1971 Mar 16 TI - Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. PG - 988-94 FAU - Peterkofsky, B AU - Peterkofsky B FAU - Diegelmann, R AU - Diegelmann R LA - eng PT - Journal Article PL - United States TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Carbon Isotopes) RN - 0 (Protease Inhibitors) RN - 0 (Proteins) RN - 0 (Sulfhydryl Compounds) RN - 10028-17-8 (Tritium) RN - 5V2JDO056X (Trichloroacetic Acid) RN - 8DUH1N11BX (Tryptophan) RN - 9007-34-5 (Collagen) RN - 9014-25-9 (RNA, Transfer) RN - 9DLQ4CIU6V (Proline) RN - EC 3.1.- (Ribonucleases) RN - EC 3.4.24.3 (Microbial Collagenase) RN - O3C74ACM9V (Ethylmaleimide) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Age Factors MH - Animals MH - Bacteria/enzymology MH - Carbon Isotopes MH - Chemical Precipitation MH - Chick Embryo MH - Chromatography, Gel MH - Collagen/*analysis MH - Ethylmaleimide MH - Hydrogen-Ion Concentration MH - Hydrolysis MH - Hydroxyproline/analysis MH - Kinetics MH - Methods MH - *Microbial Collagenase MH - Proline/analysis MH - Protease Inhibitors MH - Proteins MH - RNA, Transfer MH - Ribonucleases MH - Solubility MH - Sulfhydryl Compounds MH - Tendons MH - Trichloroacetic Acid MH - Tritium MH - Tryptophan EDAT- 1971/03/16 00:00 MHDA- 1971/03/16 00:01 CRDT- 1971/03/16 00:00 PHST- 1971/03/16 00:00 [pubmed] PHST- 1971/03/16 00:01 [medline] PHST- 1971/03/16 00:00 [entrez] AID - 10.1021/bi00782a009 [doi] PST - ppublish SO - Biochemistry. 1971 Mar 16;10(6):988-94. doi: 10.1021/bi00782a009. PMID- 22544145 OWN - NLM STAT- MEDLINE DCOM- 20120625 LR - 20210106 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 129 IP - 5 DP - 2012 May TI - Rupture of both the abductor pollicis longus and extensor pollicis brevis tendons after steroid injection for de quervain tenosynovitis. PG - 883e-886e LID - 10.1097/PRS.0b013e31824aa06d [doi] FAU - Nguyen, Michael Ly AU - Nguyen ML AD - Department of Orthopaedic Surgery (Nguyen) Department of Orthopaedic Surgery and, Division of Plastic and Reconstructive Surgery, University of California-Irvine Medical Center, Orange, Calif. (Jones). FAU - Jones, Neil F AU - Jones NF LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Glucocorticoids) RN - 1ZK20VI6TY (Triamcinolone) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - De Quervain Disease/*drug therapy MH - Dexamethasone/*administration & dosage MH - Female MH - Glucocorticoids/*administration & dosage MH - Humans MH - Middle Aged MH - Recurrence MH - Rupture, Spontaneous MH - Tendon Injuries/*chemically induced MH - Triamcinolone/*administration & dosage EDAT- 2012/05/01 06:00 MHDA- 2012/06/26 06:00 CRDT- 2012/05/01 06:00 PHST- 2012/05/01 06:00 [entrez] PHST- 2012/05/01 06:00 [pubmed] PHST- 2012/06/26 06:00 [medline] AID - 00006534-201205000-00069 [pii] AID - 10.1097/PRS.0b013e31824aa06d [doi] PST - ppublish SO - Plast Reconstr Surg. 2012 May;129(5):883e-886e. doi: 10.1097/PRS.0b013e31824aa06d. PMID- 33952274 OWN - NLM STAT- MEDLINE DCOM- 20211021 LR - 20240226 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 16 IP - 1 DP - 2021 May 5 TI - Dynamic exacerbation in inflammation and oxidative stress during the formation of peritendinous adhesion resulted from acute tendon injury. PG - 293 LID - 10.1186/s13018-021-02445-y [doi] LID - 293 AB - BACKGROUND: Peritendinous adhesion is among the common complications after tendon injury. Numerous studies have been carried out to prevent its formation, including modifications of surgical procedures, postoperative cares, application of medicines, etc. This study dynamically monitored fluctuations of inflammation, state of oxidative stress, and histopathologic changes around injured tendon to provide theoretical basis for further exploration in mechanisms of peritendinous adhesion formation. METHODS: Eighteen mature Sprague-Dawley male rats were randomly allocated into 6 equal groups. Compared with control and sham group, every rat's right hind Achilles tendon in experimental groups was cut and repaired by the modified Kessler technique. Besides control and sham group, samples of tendon margin and serum were collected at different time points after the surgery. Content of TNF-α, IL-1β, and TGF-β were assayed in harvested serum. Reactive oxygen species (ROS) were detected, expression levels of related genes (IL-1β, IL-6, SOD1, SOD2, COL1, HIF1A) were quantified by qPCR, and various histopathological evaluations were performed. RESULTS: Indicators (TNF-α, IL-1β, TGF-β1, ROS) were noticed to have a similar trend of significant rising 24 h after the surgery except TGF-β which was rising 72 h later. So were the expression trends of IL-1β, IL-6, SOD1, SOD2, and COL1. HIF1A, inversely correlated with SOD2, showed the progressive relief of regional tissue hypoxia. Histological evaluation showed the same tendency that fibrosis and inflammation were getting serious 48 h later after the surgery. CONCLUSIONS: Inflammation, oxidative stress in injured tendon resulted from acute trauma, would be getting intense in 24 h. Peritendinous adhesion emerges and aggravates after 48 h. Thus, prompt efficient measures are advised to be taken after the injury as soon as possible. FAU - Li, Pengfei AU - Li P AD - Department of Plastic and Aesthetic Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. FAU - Zhou, Haiying AU - Zhou H AD - Department of Orthopedics, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. FAU - Tu, Tian AU - Tu T AD - Department of Plastic and Aesthetic Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. FAU - Lu, Hui AU - Lu H AUID- ORCID: 0000-0002-5921-1043 AD - Department of Orthopedics, The First Affiliated Hospital, College of Medicine, Zhejiang University, #79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. huilu@zju.edu.cn. LA - eng GR - 81702135/National Natural Science Foundation of China/ GR - LY20H060007/Zhejiang Provincial Natural Science Foundation/ GR - 2016ZA124, 2017ZB057/Zhejiang Traditional Chinese Medicine Research Program/ GR - 2016KYB101, 2015KYA100/Zhejiang Medicine and Hygiene Research Program/ PT - Journal Article DEP - 20210505 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 0 (Inflammation Mediators) RN - 0 (Interleukin-1beta) RN - 0 (Reactive Oxygen Species) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Tumor Necrosis Factor-alpha) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.15.1.1 (superoxide dismutase 2) SB - IM MH - Achilles Tendon/*injuries/metabolism/*pathology/surgery MH - Animals MH - *Disease Progression MH - Inflammation/*etiology/metabolism MH - Inflammation Mediators/metabolism MH - Interleukin-1beta/metabolism MH - Male MH - *Oxidative Stress MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism MH - Superoxide Dismutase/metabolism MH - Tendon Injuries/*complications/metabolism/pathology/surgery MH - Tendons/*pathology MH - Time Factors MH - Tissue Adhesions/*etiology/metabolism/*pathology/prevention & control MH - Transforming Growth Factor beta1/metabolism MH - Tumor Necrosis Factor-alpha/metabolism MH - Rats PMC - PMC8097959 OTO - NOTNLM OT - Acute tendon injury OT - Dynamic exacerbation OT - Inflammation OT - Peritendinous adhesion OT - Reactive oxygen species OT - Tendon surgery COIS- The authors declare that they have no competing interests. EDAT- 2021/05/07 06:00 MHDA- 2023/02/25 06:00 PMCR- 2021/05/05 CRDT- 2021/05/06 05:45 PHST- 2020/05/13 00:00 [received] PHST- 2021/04/22 00:00 [accepted] PHST- 2021/05/06 05:45 [entrez] PHST- 2021/05/07 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2021/05/05 00:00 [pmc-release] AID - 10.1186/s13018-021-02445-y [pii] AID - 2445 [pii] AID - 10.1186/s13018-021-02445-y [doi] PST - epublish SO - J Orthop Surg Res. 2021 May 5;16(1):293. doi: 10.1186/s13018-021-02445-y. PMID- 19258148 OWN - NLM STAT- MEDLINE DCOM- 20090618 LR - 20090304 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 34 IP - 3 DP - 2009 Mar TI - In vitro flexor tendon cell response to TGF-beta1: a gene expression study. PG - 495-503 LID - 10.1016/j.jhsa.2008.10.032 [doi] AB - PURPOSE: Adhesion formation around zone II flexor tendon repairs remains an important clinical challenge. Tendon healing is complex, and when uncontrolled it may lead to adhesion formation. Transforming growth factor-beta1 (TGF-beta1) is a multipotent growth factor known to be involved in wound healing and scar formation. It has also been shown to have a role in both tendon healing and adhesion formation. METHODS: Uninjured rabbit flexor tendons were divided into endotenon, epitenon, and sheath cells and cultured separately. The in vitro effect of TGF-beta1 gene expression was determined on quiescent tendon cells using real-time polymerase chain reaction for collagen type 1, collagen type 3, fibronectin, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA). RESULTS: Endotenon-derived cells showed a statistically significant down-regulation of collagen type I gene expression in response to TGF-beta1 compared with untreated endotenon cells and with both epitenon and sheath cells at a number of time points. However, endotenon cells showed an increase in collagen type 3 gene expression compared with untreated cells and epitenon cells. All cells showed a statistically significant increase in fibronectin in the later time points compared with the untreated cells. Endotenon-derived cells showed an early increase in PAI-1, whereas sheath cells showed a later increase. CONCLUSIONS: We have shown that cells cultured from 3 separate parts of the flexor tendon-sheath complex respond in different ways when stimulated with TGF-beta1. The down-regulation of collagen types 1 and 3 in endotenon cells may give further insight into the effects of TGF-beta1 in tendon healing. Also, the upregulation of fibronectin and PAI-1, combined with a down-regulation of tissue plasminogen activator, could explain the association of TGF-beta1 with tendon adhesion formation. Treatments aimed at improving tendon healing and the prevention of adhesions may arise from modification of the effects of TGF-beta1. FAU - Klass, B R AU - Klass BR AD - Department of Plastic and Reconstructive Surgery, Royal Free Hospital, London, UK. ben.klass@gmail.com FAU - Rolfe, K J AU - Rolfe KJ FAU - Grobbelaar, A O AU - Grobbelaar AO LA - eng PT - Journal Article PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Fibronectins) RN - 0 (Plasminogen Activator Inhibitor 1) RN - 0 (Transforming Growth Factor beta1) RN - 63231-63-0 (RNA) RN - EC 3.4.21.68 (Tissue Plasminogen Activator) SB - IM MH - Animals MH - Cells, Cultured MH - Collagen Type I/genetics MH - Collagen Type III/genetics MH - Down-Regulation MH - Fibronectins/genetics MH - *Gene Expression MH - Plasminogen Activator Inhibitor 1/genetics MH - Polymerase Chain Reaction MH - RNA/isolation & purification MH - Rabbits MH - Tendons/*cytology MH - Tissue Plasminogen Activator/genetics MH - Transforming Growth Factor beta1/*pharmacology MH - Up-Regulation MH - Wound Healing EDAT- 2009/03/05 09:00 MHDA- 2009/06/19 09:00 CRDT- 2009/03/05 09:00 PHST- 2008/03/20 00:00 [received] PHST- 2008/10/26 00:00 [revised] PHST- 2008/10/29 00:00 [accepted] PHST- 2009/03/05 09:00 [entrez] PHST- 2009/03/05 09:00 [pubmed] PHST- 2009/06/19 09:00 [medline] AID - S0363-5023(08)00969-6 [pii] AID - 10.1016/j.jhsa.2008.10.032 [doi] PST - ppublish SO - J Hand Surg Am. 2009 Mar;34(3):495-503. doi: 10.1016/j.jhsa.2008.10.032. PMID- 21903125 OWN - NLM STAT- MEDLINE DCOM- 20120113 LR - 20141120 IS - 1096-0333 (Electronic) IS - 0041-008X (Linking) VI - 257 IP - 1 DP - 2011 Nov 15 TI - The effects of levofloxacin on rabbit anterior cruciate ligament cells in vitro. PG - 67-73 LID - 10.1016/j.taap.2011.08.019 [doi] AB - Articular cartilage, epiphyseal growth plate and tendons have been recognized as targets of fluoroquinolone-induced connective tissue toxicity. The effects of fluoroquinolones on ligament tissues are still unknown. The aim of this study was to investigate the effects of levofloxacin, a typical fluoroquinolone antibiotic drug, on rabbit anterior cruciate ligament (ACL) cells in vitro. Rabbit ACL cells were treated with levofloxacin at different concentrations (0, 14, 28, 56, 112 and 224 μM) and were assessed to determine the possible cytotoxic effects of levofloxacin on ACL cells. Levofloxacin, with concentrations ranging from 28 to 224 μM, induced dose-dependent ACL cell apoptosis. Characteristic markers of programmed cell death and degenerative changes were identified by electron microscopy in the ACL cells treated with 28 μM of levofloxacin. Moreover, levofloxacin significantly increased the mRNA expression of matrix metalloproteinase 3 (MMP-3) and MMP-13 and decreased the expression of tissue inhibitors of metalloproteinase 1 (TIMP-1) in a concentration-dependent manner; TIMP-3 and collagen type I alpha 1 (Col1A1) mRNA expression was not affected. Immunocytochemical analysis indicated that levofloxacin markedly increased the expression of active caspase-3 within a concentration range of 28 to 224 μM, whereas a clear-cut decrease in Col1A1 expression was found with levofloxacin treatment concentrations of 112 and 224 μM, compared to controls. Our data suggest that levofloxacin has cytotoxic effects on ACL cells characterized by enhanced apoptosis and decreased extracellular matrix, which suggest a potential adverse effect of fluoroquinolones. CI - Copyright © 2011 Elsevier Inc. All rights reserved. FAU - Deng, Yu AU - Deng Y AD - Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. FAU - Chen, Biao AU - Chen B FAU - Qi, Yongjian AU - Qi Y FAU - Magdalou, Jacques AU - Magdalou J FAU - Wang, Hui AU - Wang H FAU - Chen, Liaobin AU - Chen L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110827 PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Anti-Bacterial Agents) RN - 6GNT3Y5LMF (Levofloxacin) RN - A4P49JAZ9H (Ofloxacin) SB - IM MH - Animals MH - Anterior Cruciate Ligament/cytology/*drug effects/ultrastructure MH - Anti-Bacterial Agents/*pharmacology MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - In Vitro Techniques MH - *Levofloxacin MH - Microscopy, Electron, Transmission MH - Ofloxacin/*pharmacology MH - Rabbits MH - Reverse Transcriptase Polymerase Chain Reaction EDAT- 2011/09/10 06:00 MHDA- 2012/01/14 06:00 CRDT- 2011/09/10 06:00 PHST- 2011/07/17 00:00 [received] PHST- 2011/08/15 00:00 [revised] PHST- 2011/08/19 00:00 [accepted] PHST- 2011/09/10 06:00 [entrez] PHST- 2011/09/10 06:00 [pubmed] PHST- 2012/01/14 06:00 [medline] AID - S0041-008X(11)00333-4 [pii] AID - 10.1016/j.taap.2011.08.019 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2011 Nov 15;257(1):67-73. doi: 10.1016/j.taap.2011.08.019. Epub 2011 Aug 27. PMID- 21628961 OWN - NLM STAT- MEDLINE DCOM- 20110920 LR - 20220318 IS - 1880-3989 (Electronic) IS - 0388-1350 (Linking) VI - 36 IP - 3 DP - 2011 Jun TI - Oral toxicity of pefloxacin, norfloxacin, ofloxacin and ciprofloxacin: comparison of biomechanical and histopathological effects on Achilles tendon in rats. PG - 339-45 AB - Four fluoroquinolones (pefloxacin, norfloxacin, ofloxacin and ciprofloxacin) were compared according to their biomechanical and histopathological effects on rat Achilles tendon. Wistar rats were divided into one untreated control and four treatment groups in parallel. Pefloxacin mesylate dihydrate (40 mg/kg), norfloxacin (40 mg/kg), ofloxacin (20 mg/kg) and ciprofloxacin (50 mg/kg) were administered by gavage twice daily for three consecutive weeks. 6 weeks after treatment, the test animals were euthanised and Achilles tendon specimens were collected. A computer monitored tensile testing machine was utilised for biomechanical testing. The mean elastic modulus of the control group was significantly higher than that of the norfloxacin and pefloxacin groups (p<0.05 and p<0.01, respectively). The mean yield force (YF) of the control group was significantly higher than those of ciprofloxacin, norfloxacin and pefloxacin groups (p<0.001, p<0.05 and p<0.01, respectively). The mean ultimate tensile force (UTF) of the control group was significantly higher than of the ciprofloxacin, norfloxacin, and pefloxacin groups (p<0.001, p<0.05 and p<0.01, respectively). Hyaline degeneration and fibre disarrangement were observed in the tendons of the ciprofloxacin, pefloxacin, and ofloxacin treated-groups, whereas myxomatous degeneration was observed only in the ciprofloxacin and pefloxacin groups. In conclusion, these findings in our rat model reveal significant deterioration of biomechanical parameters following fluoroquinolone exposure, and indicate significantly higher biomechanical toxicity for ciprofloxacin and pefloxacin. FAU - Olcay, Ercan AU - Olcay E AD - Vatan Cad., EmlakBank Evleri, Al, No:4, Faith 34090, Istanbul, Turkey. FAU - Beytemur, Ozan AU - Beytemur O FAU - Kaleagasioglu, Ferda AU - Kaleagasioglu F FAU - Gulmez, Turgut AU - Gulmez T FAU - Mutlu, Zihni AU - Mutlu Z FAU - Olgac, Vakur AU - Olgac V LA - eng PT - Comparative Study PT - Journal Article PL - Japan TA - J Toxicol Sci JT - The Journal of toxicological sciences JID - 7805798 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) RN - 2H52Z9F2Q5 (Pefloxacin) RN - 5E8K9I0O4U (Ciprofloxacin) RN - A4P49JAZ9H (Ofloxacin) RN - N0F8P22L1P (Norfloxacin) SB - IM MH - Achilles Tendon/*drug effects/metabolism/pathology MH - Administration, Oral MH - Animals MH - Anti-Bacterial Agents/administration & dosage/*toxicity MH - Ciprofloxacin/toxicity MH - Elastic Modulus/drug effects MH - Elasticity/drug effects MH - Fluoroquinolones/administration & dosage/*toxicity MH - Male MH - Norfloxacin/toxicity MH - Ofloxacin/toxicity MH - Pefloxacin/toxicity MH - Rats MH - Rats, Wistar MH - Tensile Strength/drug effects EDAT- 2011/06/02 06:00 MHDA- 2011/09/21 06:00 CRDT- 2011/06/02 06:00 PHST- 2011/06/02 06:00 [entrez] PHST- 2011/06/02 06:00 [pubmed] PHST- 2011/09/21 06:00 [medline] AID - JST.JSTAGE/jts/36.339 [pii] AID - 10.2131/jts.36.339 [doi] PST - ppublish SO - J Toxicol Sci. 2011 Jun;36(3):339-45. doi: 10.2131/jts.36.339. PMID- 18077498 OWN - NLM STAT- MEDLINE DCOM- 20080110 LR - 20131121 IS - 1462-0332 (Electronic) IS - 1462-0324 (Linking) VI - 47 IP - 1 DP - 2008 Jan TI - MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. PG - 92-5 AB - OBJECTIVES: To quantify the extent of inflammation in psoriatic dactylitis and to examine the relationship between clinical and magnetic resonance imaging (MRI) data in both tender and non-tender dactylitis. METHODS: Seventeen patients with psoriatic dactylitis underwent clinical assessment for 6 months after change of treatment, usually to methotrexate. Measures of dactylitis included the Leeds Dactylitis Index, the assessment tool used in the Infliximab in Psoriatic Arthritis Clinical Trial (IMPACT), a simple count of tender dactlylitic digits and a count of all dactylitic digits, both tender and non-tender. MRI scans of the affected hand or foot were performed before and after treatment using a 1.5T Siemen's scanner pre- and post-contrast. RESULTS: All patients improved clinically, as did their respective dactylitis scores and MRI images. The findings on MRI in both dactylitic and non-dactylitic digits were profound and widespread. The difference between tender and non-tender dactylitis was quantitative rather than qualitative. Synovitis and soft-tissue oedema were the most frequent abnormalities being present in 69% of tender dactylitic digits but bone oedema and flexor tenosynovitis were also frequently seen. Soft-tissue oedema was circumferential and enhancing and not limited to association with the flexor or extensor tendons. None of the clinical indices of dactylitis showed a close relationship to the extent of MRI abnormalities. CONCLUSIONS: MRI images demonstrate widespread abnormalities in digits of people with psoriatic arthritis. Tender dactylitic digits have more abnormalities than other digits but the relationship between clinical and MRI scores is not strong. FAU - Healy, P J AU - Healy PJ AD - Academic Unit of Musculoskeletal Medicine, University of Leeds, 36 Clarendon Road, Leeds LS2 9NZ, UK. FAU - Groves, C AU - Groves C FAU - Chandramohan, M AU - Chandramohan M FAU - Helliwell, P S AU - Helliwell PS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Antirheumatic Agents) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM CIN - Rheumatology (Oxford). 2008 May;47(5):561-2. doi: 10.1093/rheumatology/ken032. PMID: 18316336 MH - Adult MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Psoriatic/complications/drug therapy/*pathology MH - Edema/complications/drug therapy/*pathology MH - Female MH - Finger Joint/*pathology MH - Humans MH - Hyperalgesia/pathology/physiopathology MH - *Magnetic Resonance Imaging MH - Male MH - Methotrexate/therapeutic use MH - Pain/pathology/physiopathology MH - Severity of Illness Index MH - Synovitis/complications/drug therapy/*pathology MH - Toe Joint/*pathology MH - Treatment Outcome EDAT- 2007/12/14 09:00 MHDA- 2008/01/11 09:00 CRDT- 2007/12/14 09:00 PHST- 2007/12/14 09:00 [pubmed] PHST- 2008/01/11 09:00 [medline] PHST- 2007/12/14 09:00 [entrez] AID - 47/1/92 [pii] AID - 10.1093/rheumatology/kem315 [doi] PST - ppublish SO - Rheumatology (Oxford). 2008 Jan;47(1):92-5. doi: 10.1093/rheumatology/kem315. PMID- 1936895 OWN - NLM STAT- MEDLINE DCOM- 19911206 LR - 20221207 IS - 0306-3623 (Print) IS - 0306-3623 (Linking) VI - 22 IP - 4 DP - 1991 TI - Alpha-glucosidase inhibition prevents increased collagen fluorescence in experimental diabetes. PG - 607-10 AB - 1. The effect of the alpha-glucosidase inhibitor Acarbose on collagen fluorescence reflecting formation of advanced glycation end products was examined in streptozotocin-diabetic rats. 2. Treatment with Acarbose for eight weeks after induction of diabetes prevented the increased fluorescence in skin and tail tendon collagen associated with untreated diabetes. 3. Acarbose improves integrated glycemic control and beneficially influences the consequences of excess glycation in long-lived connective tissue proteins. FAU - Cohen, M P AU - Cohen MP AD - University City Science Center, Philadelphia, PA 19104. FAU - Klepser, H AU - Klepser H LA - eng GR - DK38308/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Gen Pharmacol JT - General pharmacology JID - 7602417 RN - 0 (Blood Glucose) RN - 0 (Glycated Hemoglobin A) RN - 0 (Glycoside Hydrolase Inhibitors) RN - 0 (Trisaccharides) RN - 9007-34-5 (Collagen) RN - T58MSI464G (Acarbose) SB - IM MH - Acarbose MH - Animals MH - Blood Glucose/metabolism MH - Collagen/*metabolism MH - Diabetes Mellitus, Experimental/blood/drug therapy/*metabolism MH - Glycated Hemoglobin/metabolism MH - *Glycoside Hydrolase Inhibitors MH - Glycosylation MH - Male MH - Rats MH - Skin/metabolism MH - Spectrometry, Fluorescence MH - Tendons/metabolism MH - Trisaccharides/therapeutic use EDAT- 1991/01/01 00:00 MHDA- 1991/01/01 00:01 CRDT- 1991/01/01 00:00 PHST- 1991/01/01 00:00 [pubmed] PHST- 1991/01/01 00:01 [medline] PHST- 1991/01/01 00:00 [entrez] AID - 0306-3623(91)90064-D [pii] AID - 10.1016/0306-3623(91)90064-d [doi] PST - ppublish SO - Gen Pharmacol. 1991;22(4):607-10. doi: 10.1016/0306-3623(91)90064-d. PMID- 2539078 OWN - NLM STAT- MEDLINE DCOM- 19890511 LR - 20211203 IS - 0005-2086 (Print) IS - 0005-2086 (Linking) VI - 33 IP - 1 DP - 1989 Jan-Mar TI - Effects of cyclosporine A on reovirus-infected broilers. PG - 86-92 AB - The effect of cyclosporine A on reovirus-infected male broiler chickens was studied. Beginning at 1 or 10 days of age, 3 groups of 15 broilers were injected in the pectoral muscle with 50 mg of cyclosporine A (CSA) in oil per kg body weight every 3 days until 28 days. Controls were injected with olive oil. Two CSA-injected groups and one untreated group were orally infected with 1000 TCID50 of reovirus at 1 day of age. Cell-mediated immunity was evaluated at 17 and 24 days by a delayed-wattle-response test to injected phytohemagglutinin (PHA-M). Cyclosporine A and reovirus significantly (P less than 0.001) depressed the wattle response following the first injection of PHA-M but not the second. At necropsy 28 days postinoculation (PI), no gross lesions were apparent. Histologic lesions in birds infected with reovirus were lymphocytic pericarditis and tenosynovitis; synovial cells were hyperplastic, and heterophils and fibrin were in synovial spaces. Thymic medullary diameters were significantly (P less than 0.001) smaller in all CSA-treated birds. Although CSA suppressed cell-mediated immunity somewhat, there were no apparent differences in severity of microscopic lesions among reovirus-infected groups. FAU - Hill, J E AU - Hill JE AD - Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens 30602. FAU - Rowland, G N AU - Rowland GN FAU - Latimer, K S AU - Latimer KS FAU - Brown, J AU - Brown J LA - eng PT - Journal Article PL - United States TA - Avian Dis JT - Avian diseases JID - 0370617 RN - 0 (Cyclosporins) SB - IM MH - Animals MH - Body Weight MH - *Chickens MH - Cyclosporins/*pharmacology MH - Immunity, Cellular/drug effects MH - Immunosuppression Therapy/*veterinary MH - Pericarditis/immunology/pathology/veterinary MH - Poultry Diseases/*immunology/pathology MH - Reoviridae Infections/immunology/pathology/*veterinary MH - Tendons/pathology MH - Tenosynovitis/immunology/pathology/veterinary MH - Thymus Gland/pathology EDAT- 1989/01/01 00:00 MHDA- 1989/01/01 00:01 CRDT- 1989/01/01 00:00 PHST- 1989/01/01 00:00 [pubmed] PHST- 1989/01/01 00:01 [medline] PHST- 1989/01/01 00:00 [entrez] PST - ppublish SO - Avian Dis. 1989 Jan-Mar;33(1):86-92. PMID- 27477928 OWN - NLM STAT- MEDLINE DCOM- 20170517 LR - 20250623 IS - 1472-8206 (Electronic) IS - 0767-3981 (Linking) VI - 31 IP - 1 DP - 2017 Feb TI - What tendon pathology is seen on imaging in people who have taken fluoroquinolones? A systematic review. PG - 4-16 LID - 10.1111/fcp.12228 [doi] AB - Fluoroquinolones (FQs) are highly effective broad-spectrum antibiotics. Clinical data reveal an increased incidence of tendon pain and rupture in those taking FQs, yet little is known about tendon structural changes. This review synthesises published data on tendon structural changes in people who have taken FQs. Eight databases were searched for potentially relevant articles (Medline, CINAHL, Biological Abstracts, AMED, Web of Knowledge, SCOPUS, SportDiscus and EMBASE) using MeSH and free-text searches. Inclusion and exclusion criteria determined which articles were used for this review. Twenty-six papers met the eligibility criteria. The Achilles tendon was most commonly affected, and ciprofloxacin and levofloxacin were the most commonly implicated FQs. Mean time to onset of symptoms was 16 days following first FQ dose. Imaging modalities used included magnetic resonance imaging (MRI), B-mode ultrasound (US) and computed tomography (CT). Tendon measurements were rarely reported, and intratendinous imaging findings were not reported in a consistent manner. Few studies imaged tendons bilaterally, and only two studies were longitudinal in design. Future studies should report imaging measures such as thickness and cross-sectional area and use consistent descriptions of intratendinous changes during and post-FQ treatment. CI - © 2016 Société Française de Pharmacologie et de Thérapeutique. FAU - Lang, Tina R AU - Lang TR AD - School of Primary Health Care, Monash University, PO Box 527, Frankston, Melbourne, 3199, Vic., Australia. FAU - Cook, Jill AU - Cook J AD - La Trobe Centre for Sports and Exercise Medicine Research, La Trobe University, Kingsbury Drive, Bundoora, Melbourne, 3086, Vic., Australia. AD - Australian Collaboration for Research into Injury in Sport and its Prevention, Australia. FAU - Rio, Ebonie AU - Rio E AD - La Trobe Centre for Sports and Exercise Medicine Research, La Trobe University, Kingsbury Drive, Bundoora, Melbourne, 3086, Vic., Australia. AD - Australian Collaboration for Research into Injury in Sport and its Prevention, Australia. FAU - Gaida, James E AU - Gaida JE AD - University of Canberra Research Institute for Sport and Exercise (UCRISE), University Drive, Bruce, ACT, 2617, Australia. AD - Discipline of Physiotherapy, University of Canberra, University Drive, Bruce, ACT, 2617, Australia. LA - eng PT - Journal Article PT - Systematic Review DEP - 20161005 PL - England TA - Fundam Clin Pharmacol JT - Fundamental & clinical pharmacology JID - 8710411 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Achilles Tendon/*drug effects/*pathology MH - Anti-Bacterial Agents/administration & dosage/*adverse effects MH - Fluoroquinolones/administration & dosage/*adverse effects MH - Humans MH - Magnetic Resonance Imaging MH - Rupture/chemically induced/*pathology MH - Tendon Injuries/chemically induced/*pathology MH - Tomography, X-Ray Computed MH - Ultrasonography OTO - NOTNLM OT - fluoroquinolones OT - imaging OT - tendinopathy OT - tendons EDAT- 2016/08/02 06:00 MHDA- 2017/05/18 06:00 CRDT- 2016/08/02 06:00 PHST- 2016/03/30 00:00 [received] PHST- 2016/06/15 00:00 [revised] PHST- 2016/07/28 00:00 [accepted] PHST- 2016/08/02 06:00 [pubmed] PHST- 2017/05/18 06:00 [medline] PHST- 2016/08/02 06:00 [entrez] AID - 10.1111/fcp.12228 [doi] PST - ppublish SO - Fundam Clin Pharmacol. 2017 Feb;31(1):4-16. doi: 10.1111/fcp.12228. Epub 2016 Oct 5. PMID- 28461643 OWN - NLM STAT- MEDLINE DCOM- 20180622 LR - 20250530 IS - 1499-2752 (Electronic) IS - 0315-162X (Linking) VI - 44 IP - 11 DP - 2017 Nov TI - Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise. PG - 1688-1693 LID - 10.3899/jrheum.161097 [doi] AB - OBJECTIVE: To develop and validate a magnetic resonance imaging (MRI) tenosynovitis (TS) score for tendons at the wrist and metacarpophalangeal (MCP) joint levels in patients with rheumatoid arthritis (RA). METHODS: Axial T1-weighted precontrast and postcontrast fat-saturated MR image sets of the hands of 43 patients with RA initiating rituximab therapy were obtained at baseline and after 14, 26, 38, or 52 weeks. The MR images were scored twice by 4 readers. Nine tendon compartments of the wrist and 4 flexor tendon compartments at the MCP joints were assessed. Tenosynovitis was scored as follows: 0: No; 1: < 1.5 mm; 2: ≥ 1.5 mm but < 3 mm; 3: ≥ 3 mm peritendinous effusion and/or postcontrast enhancement. Intrareader and interreader intraclass correlation coefficients (ICC), smallest detectable change (SDC), percentage of exact and close agreement (PEA/PCA), and standardized response mean (SRM) were calculated. RESULTS: Intrareader and interreader ICC for status and change scores were very good (≥ 0.80) for total scores for all readers. Intrareader SDC was ≤ 3.0 and interreader SDC was < 2.0. The overall PEA/PCA intrareader and interreader agreements for change scores in all tendons were 73.8%/97.6% and 47.9%/85.0%, respectively. Average SRM was moderate for total scores and 60.5% of the patients had a tenosynovitis change score ≥ SDC. CONCLUSION: The TS score showed high intrareader and interreader agreement for wrist and finger tendons, with moderate responsiveness, and the majority of the patients showed a change above the SDC. This scoring system may be included as a component of the RAMRIS. FAU - Glinatsi, Daniel AU - Glinatsi D AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. daniel.glinatsi@gmail.com. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. daniel.glinatsi@gmail.com. FAU - Bird, Paul AU - Bird P AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Gandjbakhch, Frédérique AU - Gandjbakhch F AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Haavardsholm, Espen A AU - Haavardsholm EA AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Peterfy, Charles G AU - Peterfy CG AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Vital, Edward M AU - Vital EM AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Emery, Paul AU - Emery P AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Conaghan, Philip G AU - Conaghan PG AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. FAU - Østergaard, Mikkel AU - Østergaard M AD - From the Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit; Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, UK; University of New South Wales (NSW), Sydney, Australia; Hôpital Pitié-Salpétrière, APHP, Université Paris VI, Paris, France; Diakonhjemmet Hospital, Oslo, Norway; Spire Sciences Inc., Boca Raton, Florida, USA. AD - D. Glinatsi, MD, research fellow, COPECARE, Center for Rheumatology and Spine Diseases; P. Bird, BMed (Hons), FRACP, PhD, Grad Dip MRI, Associate Professor, University of NSW; F. Gandjbakhch, MD, Practicing Rheumatologist, Hôpital Pitié-Salpétrière, APHP, Université Paris VI; E.A. Haavardsholm, MD, PhD, Postdoctoral Researcher, Department of Rheumatology, Diakonhjemmet Hospital; C.G. Peterfy, MD, PhD, FRCP, Chief Executive Officer, Spire Sciences Inc.; E.M. Vital, MRCP, PhD, Associate Professor and Honorary Consultant, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P. Emery, MA, MD, FRCP, ARC Professor in Rheumatology, Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; P.G. Conaghan, MB, BS, PhD, FRACP, FRCP, Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Musculoskeletal Biomedical Research Unit; M. Østergaard, MD, PhD, DMSc, Professor, COPECARE, Center for Rheumatology and Spine Diseases, Rigshospitalet, and the Department of Clinical Medicine, University of Copenhagen. LA - eng GR - 18475/VAC_/Versus Arthritis/United Kingdom GR - 20639/VAC_/Versus Arthritis/United Kingdom GR - CS-2013-13-032/DH_/Department of Health/United Kingdom GR - RC-PG-0407-10054/DH_/Department of Health/United Kingdom PT - Journal Article PT - Validation Study DEP - 20170501 PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Antirheumatic Agents) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Rheumatoid/*diagnostic imaging/drug therapy MH - Female MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Metacarpophalangeal Joint/*diagnostic imaging MH - Middle Aged MH - Reproducibility of Results MH - Rituximab/therapeutic use MH - Severity of Illness Index MH - Tenosynovitis/*diagnostic imaging MH - Wrist Joint/*diagnostic imaging OTO - NOTNLM OT - MAGNETIC RESONANCE IMAGING OT - OMERACT OT - RHEUMATOID ARTHRITIS OT - TENOSYNOVITIS EDAT- 2017/05/04 06:00 MHDA- 2018/06/23 06:00 CRDT- 2017/05/03 06:00 PHST- 2017/03/23 00:00 [accepted] PHST- 2017/05/04 06:00 [pubmed] PHST- 2018/06/23 06:00 [medline] PHST- 2017/05/03 06:00 [entrez] AID - jrheum.161097 [pii] AID - 10.3899/jrheum.161097 [doi] PST - ppublish SO - J Rheumatol. 2017 Nov;44(11):1688-1693. doi: 10.3899/jrheum.161097. Epub 2017 May 1. PMID- 21266557 OWN - NLM STAT- MEDLINE DCOM- 20110428 LR - 20190725 IS - 1550-9613 (Electronic) IS - 0278-4297 (Linking) VI - 30 IP - 2 DP - 2011 Feb TI - Sonographically guided tendon sheath injections are more accurate than blind injections: implications for trigger finger treatment. PG - 197-203 AB - OBJECTIVES: Trigger finger is frequently treated with tendon sheath injections. This cadaveric study evaluated the accuracy and safety of blind and sonographically guided tendon sheath injections. To our knowledge, a study that precisely mapped the locations of material injected into the tendon sheath has not been reported previously. METHODS: A total of 40 fingers (excluding thumbs) of 5 fresh cadavers were used. Methylene blue dye was injected into the flexor tendon sheath using either a blind or sonographically guided injection technique (20 fingers for each technique). The location of the dye was then determined via dissection. RESULTS: Dye was observed only in the tendon sheath (ie, optimal outcome) in 70% of sonographically guided injections and 15% of blind injections (P = .001). Dye was observed in the tendon proper (ie, unsafe outcome) in 30% of blind injections and 0% of sonographically guided injections (P = .02). CONCLUSIONS: We found that sonographically guided tendon sheath injections were more accurate and may be potentially safer than blind injections. These findings suggest that sonographically guided injections should be considered over blind injections when treating trigger finger. FAU - Lee, Dae-Hee AU - Lee DH AD - Department of Orthopedic Surgery, Korea University College of Medicine, Seoul, Korea. FAU - Han, Seung-Beom AU - Han SB FAU - Park, Jong-Woong AU - Park JW FAU - Lee, Soon-Hyuck AU - Lee SH FAU - Kim, Kwan-Woo AU - Kim KW FAU - Jeong, Woong-Kyo AU - Jeong WK LA - eng PT - Journal Article PL - England TA - J Ultrasound Med JT - Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine JID - 8211547 RN - 0 (Glucocorticoids) RN - T42P99266K (Methylene Blue) SB - IM MH - Aged MH - Cadaver MH - *Fingers MH - Glucocorticoids/*administration & dosage/adverse effects MH - Humans MH - In Vitro Techniques MH - *Injections/adverse effects/methods MH - Male MH - Methylene Blue MH - Middle Aged MH - Tendons/*diagnostic imaging MH - Trigger Finger Disorder/diagnostic imaging/*drug therapy MH - *Ultrasonography, Interventional EDAT- 2011/01/27 06:00 MHDA- 2011/04/29 06:00 CRDT- 2011/01/27 06:00 PHST- 2011/01/27 06:00 [entrez] PHST- 2011/01/27 06:00 [pubmed] PHST- 2011/04/29 06:00 [medline] AID - 30/2/197 [pii] AID - 10.7863/jum.2011.30.2.197 [doi] PST - ppublish SO - J Ultrasound Med. 2011 Feb;30(2):197-203. doi: 10.7863/jum.2011.30.2.197. PMID- 30241051 OWN - NLM STAT- MEDLINE DCOM- 20190228 LR - 20190228 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 108 DP - 2018 Dec TI - Equine suspensory ligament and tendon explants cultured with platelet-rich gel supernatants release different anti-inflammatory and anabolic mediators. PG - 476-485 LID - S0753-3322(18)34250-1 [pii] LID - 10.1016/j.biopha.2018.09.065 [doi] AB - The aim of this study was to evaluate the release of pro- and anti-inflammatory as well as anabolic mediators stimulated by a leukocyte-reduced platelet-rich gel supernatant (Lr-PRGS) and a leukocyte-reduced plasma supernatant (Lr-PL) at two concentrations (25 and 50%) on normal equine suspensory ligament explants (SLEs) and tendon explants (TEs). SLEs and TEs from six horses were independently incubated for 48 h with Lr-PRGS and Lr-PL at concentrations of 25 and 50%, respectively. Samples were collected from the incubated tissues at 1 h and 48 h, which were employed for ELISA determination of interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α),  IL-4, IL-1 receptor antagonist (IL-1ra), platelet-derived growth factor isoform BB (PDGF-BB), transforming growth factor beta-1 (TGF-β(1), and hyaluronic acid (HA). Overall, 50% Lr-PRGS induced significantly less IL-1β release than the other hemoderivatives in both tissues. At 48 h, both Lr-PRGS and 25% Lr-PL induced significantly higher TNF-α concentrations in SLEs when compared to TEs, whereas both Lr-PRGS concentrations induced significantly higher IL-4 concentrations in SLEs in comparison to TEs. IL-1ra release was not different between tissues. However, this cytokine was significantly higher in tissue explants cultured with both Lr-PRGS concentrations. HA concentration was lower in tissue explants cultured with all hemoderivatives at two concentrations when compared to the control group. The positive effects observed for ligaments and tendons treated with Lr-PRGS may be mediated by the inhibition of IL-1β release of and increased release of IL-4 and IL-1ra. Furthermore, PDGF-BB could be a polypeptide responsible for mediating the release of anti-inflammatory cytokines in SLEs and TEs incubated with Lr-PRGS. CI - Copyright © 2018 Elsevier Masson SAS. All rights reserved. FAU - Bonilla-Gutiérrez, Andrés F AU - Bonilla-Gutiérrez AF AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia. Electronic address: afbonillag@gmail.com. FAU - Castillo-Franz, Cristian AU - Castillo-Franz C AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia; Grupo de Investigación en Medicina Veterinaria GIVET, Corporación Universitaria Lasallista, Caldas, Colombia; Programa de Doctorado en Ciencias Veterinarias, Escuela de Graduados, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Becario Doctorado Nacional CONICYT, Valdivia, Chile. Electronic address: cricastillo@lasallistadocentes.edu.co. FAU - López, Catalina AU - López C AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia. Electronic address: catalina.lopez@ucaldas.edu.co. FAU - Álvarez, María E AU - Álvarez ME AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia. Electronic address: maria.alvarez_l@ucaldas.edu.c. FAU - Giraldo, Carlos E AU - Giraldo CE AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia. Electronic address: cgiraldo@ucaldas.edu.co. FAU - Carmona, Jorge U AU - Carmona JU AD - Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia. Electronic address: carmona@ucaldas.edu.co. LA - eng PT - Journal Article DEP - 20180919 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Gels) RN - 0 (Interleukin 1 Receptor Antagonist Protein) RN - 0 (Interleukin-1beta) RN - 0 (Transforming Growth Factor beta1) RN - 207137-56-2 (Interleukin-4) RN - 9004-61-9 (Hyaluronic Acid) SB - IM MH - Animals MH - Anti-Inflammatory Agents/*metabolism MH - Blood Platelets/*metabolism MH - Gels/*metabolism MH - Horses MH - Hyaluronic Acid/metabolism MH - Interleukin 1 Receptor Antagonist Protein/metabolism MH - Interleukin-1beta/metabolism MH - Interleukin-4/metabolism MH - Leukocytes/metabolism MH - Ligaments/*metabolism MH - Tendons/*metabolism MH - Transforming Growth Factor beta1/metabolism OTO - NOTNLM OT - Cytokines OT - Desmopathy OT - Growth factors OT - Horse OT - Platelet-rich plasma OT - Tendinopathy EDAT- 2018/09/22 06:00 MHDA- 2019/03/01 06:00 CRDT- 2018/09/22 06:00 PHST- 2018/06/23 00:00 [received] PHST- 2018/09/08 00:00 [revised] PHST- 2018/09/11 00:00 [accepted] PHST- 2018/09/22 06:00 [pubmed] PHST- 2019/03/01 06:00 [medline] PHST- 2018/09/22 06:00 [entrez] AID - S0753-3322(18)34250-1 [pii] AID - 10.1016/j.biopha.2018.09.065 [doi] PST - ppublish SO - Biomed Pharmacother. 2018 Dec;108:476-485. doi: 10.1016/j.biopha.2018.09.065. Epub 2018 Sep 19. PMID- 24622817 OWN - NLM STAT- MEDLINE DCOM- 20151216 LR - 20211021 IS - 1435-604X (Electronic) IS - 0268-8921 (Linking) VI - 29 IP - 4 DP - 2014 Jul TI - Evaluating the effect of low-level laser therapy on healing of tentomized Achilles tendon in streptozotocin-induced diabetic rats by light microscopical and gene expression examinations. PG - 1495-503 LID - 10.1007/s10103-014-1561-0 [doi] AB - Tendon healing is impaired in individuals diagnosed with diabetes mellitus (DM). According to research, there is considerable improvement in the healing of surgically tenotomized Achilles tendons following low-level laser therapy (LLLT) in non-diabetic, healthy animals. This study uses light microscopic (LM) and semi-quantitative reverse transcription PCR (RT-PCR) analyses to evaluate the ability of LLLT in healing Achilles tendons from streptozotocin-induced diabetic (STZ-D) rats. A total of 88 rats were randomly divided into two groups, non-diabetic and diabetic. DM was induced in the rats by injections of STZ. The right Achilles tendons of all rats were tenotomized 1 month after administration of STZ. Laser-treated rats were treated with a helium-neon (He-Ne) laser that had a 632.8-nm wavelength and 7.2-mW average power. Experimental group rats received a daily dose of 0.014 J (energy density, 2.9 J/cm(2)). Control rats did not receive LLLT. Animals were sacrificed on days 5, 10, and 15 post-operatively for semi-quantitative LM and semi-quantitative RT-PCR examinations of transforming growth factor-beta1 (TGF-β1) gene expression. The chi-square test showed that LLLT significantly reduced inflammation in non-diabetic rats compared with their non-diabetic controls (p = 0.02). LLLT significantly decreased inflammation in diabetic rats on days 5 (p = 0.03) and 10 (p = 0.02) compared to the corresponding control diabetic rats. According to the student's t test, LLLT significantly increased TGF-β1 gene expression in healthy (p = 0.000) and diabetic (p = 0.000) rats compared to their relevant controls. The He-Ne laser was effective in altering the inflammatory reaction and increasing TGF-β1 gene production. FAU - Aliodoust, Morteza AU - Aliodoust M AD - Department of Anatomical Sciences and Biology, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Bayat, Mohammad AU - Bayat M FAU - Jalili, Mohammad Reza AU - Jalili MR FAU - Sharifian, Zainalabedin AU - Sharifian Z FAU - Dadpay, Masoomeh AU - Dadpay M FAU - Akbari, Mohammad AU - Akbari M FAU - Bayat, Mehrnoush AU - Bayat M FAU - Khoshvaghti, Amir AU - Khoshvaghti A FAU - Bayat, Homa AU - Bayat H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140313 PL - England TA - Lasers Med Sci JT - Lasers in medical science JID - 8611515 RN - 5W494URQ81 (Streptozocin) SB - IM MH - Achilles Tendon/pathology/physiopathology/radiation effects MH - Animals MH - Diabetes Mellitus, Experimental/*metabolism/physiopathology MH - Gene Expression MH - Lasers, Gas/*therapeutic use MH - *Low-Level Light Therapy MH - Male MH - Rats MH - Streptozocin MH - Transcriptome MH - Wound Healing/*radiation effects EDAT- 2014/03/14 06:00 MHDA- 2015/12/19 06:00 CRDT- 2014/03/14 06:00 PHST- 2013/07/26 00:00 [received] PHST- 2014/03/03 00:00 [accepted] PHST- 2014/03/14 06:00 [entrez] PHST- 2014/03/14 06:00 [pubmed] PHST- 2015/12/19 06:00 [medline] AID - 10.1007/s10103-014-1561-0 [doi] PST - ppublish SO - Lasers Med Sci. 2014 Jul;29(4):1495-503. doi: 10.1007/s10103-014-1561-0. Epub 2014 Mar 13. PMID- 4211258 OWN - NLM STAT- MEDLINE DCOM- 19741005 LR - 20131121 IS - 0341-3098 (Print) IS - 0341-3098 (Linking) VI - 116 IP - 20 DP - 1974 May 17 TI - [Local corticosteroid therapy of degenerative diseases of joints and tendons (author's transl)]. PG - 1049-52 FAU - Luther, R AU - Luther R FAU - Mebs, G AU - Mebs G LA - ger PT - Journal Article TT - Lokale Kortikoidbehandlung degenerativer Gelenk- und Sehnenerkrankungen. PL - Germany TA - MMW Munch Med Wochenschr JT - MMW, Munchener medizinische Wochenschrift JID - 7801805 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anti-Inflammatory Agents) RN - 9PHQ9Y1OLM (Prednisolone) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Administration, Topical MH - Adrenal Cortex Hormones/adverse effects/*therapeutic use MH - Anti-Inflammatory Agents/therapeutic use MH - Calcaneus MH - Finger Joint MH - Hip Joint MH - Humans MH - Injections, Intra-Articular MH - Joint Diseases/*drug therapy MH - Knee Joint MH - Ligaments MH - Methylprednisolone/therapeutic use MH - Osteoarthritis/drug therapy MH - Patella MH - Prednisolone MH - Sacroiliac Joint MH - Shoulder Joint MH - Tendinopathy/*drug therapy MH - Wrist Joint EDAT- 1974/05/17 00:00 MHDA- 1974/05/17 00:01 CRDT- 1974/05/17 00:00 PHST- 1974/05/17 00:00 [pubmed] PHST- 1974/05/17 00:01 [medline] PHST- 1974/05/17 00:00 [entrez] PST - ppublish SO - MMW Munch Med Wochenschr. 1974 May 17;116(20):1049-52. PMID- 11859676 OWN - NLM STAT- MEDLINE DCOM- 20020904 LR - 20061115 IS - 1166-7087 (Print) IS - 1166-7087 (Linking) VI - 11 IP - 6 DP - 2001 Dec TI - [Tendinopathy associated with fluoroquinolones: individuals at risk, incriminated physiopathologic mechanisms, therapeutic management]. PG - 1331-4 AB - The use of fluoroquinolones in urology has grown considerably over recent years. Unfortunately, although these molecules are not associated with severe life-threatening complications, they have nevertheless been associated with tendon lesions responsible for functional disability. The frequency of these complications is probably underestimated. There is a variable lag-time (3 to 5 days) between introduction of the antibacterial and onset of pain. The symptom most frequently reported is pain over the tendon affected and the tendons most frequently affected are those submitted to high constraints. Bilateral lesions are present in 66% of cases. Although Pefloxacin is associated with the highest frequency of tendon complications (2.7% versus 0.2-0.3% for other fluoroquinolones), the duration of treatment appears to be important in every case, with a peak frequency after a fortnight of treatment. Although these complications were considered for a long time to be associated with patients presenting certain risk factors (age, steroid therapy, renal failure), they can also occur suddenly, in young adult sportsmen or non-sportsmen, with no known tendon disease. Several hypotheses have been proposed to explain the development of these cases of tendinopathy: immuno-allergic mechanisms, direct toxicity of the molecule on collagen fibres, cell-mediated oxidative aggression, or tendon necrosis due to vascular mechanisms. The outcome remains favourable in 75% of cases of tendinitis and in 49% of cases for tendon rupture. Contraindications must therefore be identified and the duration of treatment must be adapted, as the functional handicap can be long and particularly severe. FAU - Saint, F AU - Saint F AD - Service d'Urologie, Hôpital Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, 94010 Créteil. saintf@wanadoo.fr FAU - Salomon, L AU - Salomon L FAU - Cicco, A AU - Cicco A FAU - de la Taille, A AU - de la Taille A FAU - Chopin, D AU - Chopin D FAU - Abbou, C C AU - Abbou CC LA - fre PT - English Abstract PT - Journal Article PT - Review TT - Les tendinopathies liées aux fluoroquinolones: les sujets à risque, les mécanismes physiopathologiques incriminés, la prise en charge thérapeutique. PL - France TA - Prog Urol JT - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JID - 9307844 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Anti-Infective Agents/*adverse effects MH - Fluoroquinolones MH - Humans MH - Muscular Diseases/complications/physiopathology/therapy MH - Risk Factors MH - Rupture, Spontaneous/chemically induced MH - *Tendons MH - Urinary Tract Infections/drug therapy RF - 15 EDAT- 2002/02/28 10:00 MHDA- 2002/09/06 10:01 CRDT- 2002/02/28 10:00 PHST- 2002/02/28 10:00 [pubmed] PHST- 2002/09/06 10:01 [medline] PHST- 2002/02/28 10:00 [entrez] PST - ppublish SO - Prog Urol. 2001 Dec;11(6):1331-4. PMID- 29672303 OWN - NLM STAT- MEDLINE DCOM- 20180705 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 46 IP - 3 DP - 2018 TI - Bevacizumab Improves Achilles Tendon Repair in a Rat Model. PG - 1148-1158 LID - 10.1159/000489057 [doi] AB - BACKGROUND/AIMS: Effective wound-healing generally requires efficient re-vascularization after injury, ensuring sufficient supply with oxygen, nutrients, and various cell populations. While this applies to most tissues, tendons are mostly avascular in nature and harbor relatively few cells, probably contributing to their poor regenerative capacity. Considering the minimal vascularization of healthy tendons, we hypothesize that controlling angiogenesis in early tendon healing is beneficial for repair tissue quality and function. METHODS: To address this hypothesis, Bevacizumab, a monoclonal antibody blocking VEGF-A signaling, was locally injected into the defect area of a complete tenotomy in rat Achilles tendon. At 28 days post-surgery, the defect region was investigated using immunohistochemistry against vascular and lymphatic epitopes. Polarization microscopy and biomechanical testing was used to determine tendon integrity and gait analysis for functional testing in treated vs non-treated animals. RESULTS: Angiogenesis was found to be significantly reduced in the Bevacizumab treated repair tissue, accompanied by significantly reduced cross sectional area, improved matrix organization, increased stiffness and Young's modulus, maximum load and stress. Further, we observed an improved gait pattern when compared to the vehicle injected control group. CONCLUSION: Based on the results of this study we propose that reducing angiogenesis after tendon injury can improve tendon repair, potentially representing a novel treatment-option. CI - © 2018 The Author(s). Published by S. Karger AG, Basel. FAU - Tempfer, Herbert AU - Tempfer H AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Kaser-Eichberger, Alexandra AU - Kaser-Eichberger A AD - Dept. Ophthalmology/ Optometry, Research Program Experimental Ophthalmology, Paracelsus Medical University Salzburg, Salzburg, Austria. FAU - Lehner, Christine AU - Lehner C AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Gehwolf, Renate AU - Gehwolf R AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Korntner, Stefanie AU - Korntner S AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Kunkel, Nadja AU - Kunkel N AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Wagner, Andrea AU - Wagner A AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Gruetz, Moritz AU - Gruetz M AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. FAU - Heindl, Ludwig M AU - Heindl LM AD - Department of Ophthalmology, University of Cologne, Cologne, Germany. FAU - Schroedl, Falk AU - Schroedl F AD - Dept. Ophthalmology/ Optometry, Research Program Experimental Ophthalmology, Paracelsus Medical University Salzburg, Salzburg, Austria. AD - Department of Anatomy, Paracelsus Medical University Salzburg, Salzburg, Austria. FAU - Traweger, Andreas AU - Traweger A AD - Institute for Tendon and Bone Regeneration, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria. AD - Austrian Cluster for Tissue Regeneration, Vienna, Austria. LA - eng PT - Journal Article DEP - 20180416 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 2S9ZZM9Q9V (Bevacizumab) SB - IM MH - Achilles Tendon/pathology MH - Animals MH - Bevacizumab/pharmacology/*therapeutic use MH - Disease Models, Animal MH - Elastic Modulus MH - Female MH - Gait/physiology MH - Neovascularization, Physiologic/drug effects MH - Rats MH - Rats, Inbred Lew MH - Tendon Injuries/*drug therapy/pathology MH - Tensile Strength MH - Wound Healing/drug effects OTO - NOTNLM OT - Antiangiogenic treatment OT - Biomechanics OT - Rat tendon defect model OT - Tendon regeneration OT - VEGF-A EDAT- 2018/04/20 06:00 MHDA- 2018/07/06 06:00 CRDT- 2018/04/20 06:00 PHST- 2017/10/11 00:00 [received] PHST- 2018/02/12 00:00 [accepted] PHST- 2018/04/20 06:00 [pubmed] PHST- 2018/07/06 06:00 [medline] PHST- 2018/04/20 06:00 [entrez] AID - 000489057 [pii] AID - 10.1159/000489057 [doi] PST - ppublish SO - Cell Physiol Biochem. 2018;46(3):1148-1158. doi: 10.1159/000489057. Epub 2018 Apr 16. PMID- 21453063 OWN - NLM STAT- MEDLINE DCOM- 20120105 LR - 20151119 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 52 IP - 5 DP - 2011 Oct TI - Tensile force transmission in human patellar tendon fascicles is not mediated by glycosaminoglycans. PG - 415-21 LID - 10.3109/03008207.2010.551569 [doi] AB - Correct mechanical function of tendons is essential to human physiology and therefore the mechanical properties of tendon have been a subject of research for many decades now. However, one of the most fundamental questions remains unanswered: How is load transmitted through the tendon? It has been suggested that the proteoglycan-associated glycosaminoglycans (GAGs) found on the surface of the collagen fibrils may be an important transmitter of load, but existing results are ambiguous and have not investigated human tendons. We have used a small-scale mechanical testing system to measure the mechanical properties of fascicles from human patellar tendon at two different deformation rates before and after removal of GAGs by treatment with chondroitinase ABC. Efficiency of enzyme treatment was quantified using dimethylmethylene blue assay. Removal of at least 79% of the GAGs did not significantly change the tendon modulus, relative energy dissipation, peak stress, or peak strain. The effect of deformation rate was not modulated by the treatment either, indicating no effect on viscosity. These results suggest that GAGs cannot be considered mediators of tensile force transmission in the human patellar tendon, and as such, force transmission must either take place through other matrix components or the fibrils must be mechanically continuous at least to the tested length of 7 mm. FAU - Svensson, René B AU - Svensson RB AD - Institute of Sports Medicine Copenhagen, Bispebjerg Hospital and Center for Healthy Aging, University of Copenhagen, Denmark. FAU - Hassenkam, Tue AU - Hassenkam T FAU - Hansen, Philip AU - Hansen P FAU - Kjaer, Michael AU - Kjaer M FAU - Magnusson, Stig P AU - Magnusson SP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20110331 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Glycosaminoglycans) RN - 0 (dimethylmethylene blue) RN - EC 4.2.2.20 (Chondroitin ABC Lyase) RN - T42P99266K (Methylene Blue) SB - IM MH - Biomechanical Phenomena MH - Chondroitin ABC Lyase/metabolism MH - Glycosaminoglycans/*metabolism MH - Humans MH - Male MH - Methylene Blue/analogs & derivatives MH - Patellar Ligament/*physiology MH - Stress, Mechanical MH - Viscosity EDAT- 2011/04/02 06:00 MHDA- 2012/01/06 06:00 CRDT- 2011/04/02 06:00 PHST- 2011/04/02 06:00 [entrez] PHST- 2011/04/02 06:00 [pubmed] PHST- 2012/01/06 06:00 [medline] AID - 10.3109/03008207.2010.551569 [doi] PST - ppublish SO - Connect Tissue Res. 2011 Oct;52(5):415-21. doi: 10.3109/03008207.2010.551569. Epub 2011 Mar 31. PMID- 6453694 OWN - NLM STAT- MEDLINE DCOM- 19810810 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 8 IP - 2 DP - 1981 TI - Effect of adjuvant induced arthritis on the mechanical properties and thermal behavior of skin and tendon. PG - 93-100 AB - In rats with adjuvant induced arthritis, the mechanical properties and thermal behavior of the skin and tendon were studied during the acute and chronic phase of the disease. Among the mechanical properties, the tensile strength and elastic modulus were found to decrease markedly both in the skin and tendon of arthritic rats while the extensibility did not show any significant change during the course of the disease. The thermal behavior, namely, shrinkage temperature, denaturation temperature, isometric tension and the temperature at isometric tension were decreased appreciably both in the skin and tendon of arthritic rats, the decrease being prominent during the chronic phase of arthritis. Both the mechanical properties and thermal behavior were correlated with biochemical parameters such as total collagen content and the ratio of the total activity of 14C-hydroxyproline of soluble collagens to insoluble collagen. The results support the concept of impaired collagen crosslinking in adjuvant induced arthritis. Prednisolone and L-thyroxine were administered to arthritic rats and the changes in the mechanical properties and thermal behavior of the skin and tendon of arthritic rats were studied. Both prednisolone and L-thyroxine increased the decreased values of tensile strength and elastic modulus of the skin and tendon in adjuvant induced arthritis. Similarly the decreased values in the thermal behavior of arthritic rats were found to be increased by treatment with prednisolone and L-thyroxine. Results indicated correlations with the beneficial action of prednisolone and L-thyroxine on the impaired collagen crosslinking in adjuvant induced arthritis. FAU - Kuberasampath, T AU - Kuberasampath T FAU - Bose, S M AU - Bose SM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - Q51BO43MG4 (Thyroxine) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Animals MH - Arthritis/*physiopathology MH - Arthritis, Experimental/drug therapy/*physiopathology MH - Collagen/analysis MH - Elasticity MH - Hydroxyproline/metabolism MH - Male MH - Prednisolone/therapeutic use MH - Rats MH - Skin/*physiopathology MH - Temperature MH - Tendons/*physiopathology MH - Tensile Strength/drug effects MH - Thyroxine/therapeutic use EDAT- 1981/01/01 00:00 MHDA- 1981/01/01 00:01 CRDT- 1981/01/01 00:00 PHST- 1981/01/01 00:00 [pubmed] PHST- 1981/01/01 00:01 [medline] PHST- 1981/01/01 00:00 [entrez] AID - 10.3109/03008208109152129 [doi] PST - ppublish SO - Connect Tissue Res. 1981;8(2):93-100. doi: 10.3109/03008208109152129. PMID- 26221854 OWN - NLM STAT- MEDLINE DCOM- 20160412 LR - 20181202 IS - 1536-3732 (Electronic) IS - 1049-2275 (Linking) VI - 26 IP - 6 DP - 2015 Sep TI - Concomitant Idiopathic Orbital Inflammatory Pseudotumor and Thyroid-Associated Ophthalmopathy. PG - e479-81 LID - 10.1097/SCS.0000000000001963 [doi] AB - PURPOSE: Coexistence of idiopathic orbital inflammatory pseudotumor (IOIP) and thyroid-associated ophthalmopathy (TAO) is extremely rare. The purpose of this article is to analyze the clinical features, image findings, and therapeutic outcomes of concomitant IOIP and TAO in China. MATERIALS AND METHODS: Detailed clinical records of 3 Chinese patients with concomitant IOIP and TAO were reviewed, including their clinical history, symptoms and signs, ultrasonography, computed tomography (CT), and steroid therapy. RESULTS: Among the 3 patients, were 2 men and 1 woman, aged 42, 49, and 48 years, respectively. The right orbit was involved in 1 patient and both orbits in 2 patients. In addition to showing the typical features of TAO, such as hyperthyroidism, upper eyelid retraction, and enlarged extraocular muscles with tendon sparing, all 3 patients showed ambiguous soft tissue masses in one or both orbits. Pathologic examination after biopsy of the mass in 1 patient confirmed the diagnosis of lymphatic IOIP. All the patients responded extremely well to steroid treatment. CONCLUSIONS: Although rare, a simultaneous coexistence of IOIP and TAO can occur. Therefore, it is important for clinicians to be aware of the potential for concomitant IOIP and TAO. FAU - Shen, Tao AU - Shen T AD - The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People's Republic of China. FAU - Chen, Jingchang AU - Chen J FAU - Lin, Jing AU - Lin J FAU - Liu, Rongjiao AU - Liu R FAU - Yan, Jianhua AU - Yan J LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Craniofac Surg JT - The Journal of craniofacial surgery JID - 9010410 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) RN - VB0R961HZT (Prednisone) RN - X4W7ZR7023 (Methylprednisolone) MH - Adult MH - Anti-Inflammatory Agents/therapeutic use MH - Blepharoptosis/complications MH - Dexamethasone/therapeutic use MH - Female MH - Follow-Up Studies MH - Glucocorticoids/therapeutic use MH - Graves Ophthalmopathy/*complications/diagnostic imaging MH - Humans MH - Male MH - Methylprednisolone/therapeutic use MH - Middle Aged MH - Ocular Motility Disorders/complications MH - Orbit/pathology MH - Orbital Pseudotumor/*complications/diagnostic imaging MH - Prednisone/therapeutic use MH - Tendons/pathology MH - Tomography, X-Ray Computed MH - Treatment Outcome MH - Ultrasonography EDAT- 2015/07/30 06:00 MHDA- 2016/04/14 06:00 CRDT- 2015/07/30 06:00 PHST- 2015/07/30 06:00 [entrez] PHST- 2015/07/30 06:00 [pubmed] PHST- 2016/04/14 06:00 [medline] AID - 10.1097/SCS.0000000000001963 [doi] PST - ppublish SO - J Craniofac Surg. 2015 Sep;26(6):e479-81. doi: 10.1097/SCS.0000000000001963. PMID- 25103706 OWN - NLM STAT- MEDLINE DCOM- 20150511 LR - 20140808 IS - 1460-9584 (Electronic) IS - 1268-7731 (Linking) VI - 20 IP - 3 DP - 2014 Sep TI - Histological and biomechanical analysis of the effects of streptozotocin-induced type one diabetes mellitus on healing of tenotomised Achilles tendons in rats. PG - 186-91 LID - S1268-7731(14)00045-9 [pii] LID - 10.1016/j.fas.2014.04.003 [doi] AB - BACKGROUND: Tendon healing is impaired in patient with diabetes mellitus. The effects of streptozotocin-induced type 1 diabetes (STZ-D) on the healing of the transected Achilles tendon in rats was studied. METHODS: In the experimental group, type one diabetes was induced via administration of STZ. The right Achilles tendon of all the rats was transected 30 days after the STZ administration. The Achilles tendons were examined for biomechanical and histological examinations. RESULTS: The statistical analysis showed that Young's modulus of elasticity and stress tensile load of the control group were significantly higher than those of the experimental group, and inflammation in the experimental group was significantly higher than that in the control group. At the same time, fibrosis in the experimental group was significantly lower than that of the control group. CONCLUSION: Induction of type 1 diabetes by STZ significantly delayed the healing of the transected Achilles tendon in rats. CI - Copyright © 2014 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved. FAU - Mohsenifar, Zhaleh AU - Mohsenifar Z AD - Pathology Department, Ayatallah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran. FAU - Feridoni, Mohammad Javad AU - Feridoni MJ AD - Anatomy and Biology Department, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran. FAU - Bayat, Mohammad AU - Bayat M AD - Anatomy and Biology Department, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran. Electronic address: bayat_m@yahoo.com. FAU - Masteri Farahani, Reza AU - Masteri Farahani R AD - Anatomy and Biology Department, Medical Faculty, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran. FAU - Bayat, Shiva AU - Bayat S AD - Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Khoshvaghti, Amir AU - Khoshvaghti A AD - AJA University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140604 PL - France TA - Foot Ankle Surg JT - Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons JID - 9609647 RN - 5W494URQ81 (Streptozocin) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Diabetes Mellitus, Experimental/etiology/pathology/*physiopathology MH - Disease Models, Animal MH - Elastic Modulus MH - Male MH - Rats MH - Rats, Wistar MH - Recovery of Function MH - Streptozocin MH - Tendon Injuries/*pathology/*physiopathology/surgery MH - Tensile Strength MH - Time Factors MH - Weight-Bearing MH - Wound Healing/*physiology OTO - NOTNLM OT - Biomechanical examination OT - Histological examination OT - Rat OT - Tendon OT - Tendon healing OT - Type 1 diabetes mellitus EDAT- 2014/08/12 06:00 MHDA- 2015/05/12 06:00 CRDT- 2014/08/09 06:00 PHST- 2014/01/17 00:00 [received] PHST- 2014/03/29 00:00 [revised] PHST- 2014/04/01 00:00 [accepted] PHST- 2014/08/09 06:00 [entrez] PHST- 2014/08/12 06:00 [pubmed] PHST- 2015/05/12 06:00 [medline] AID - S1268-7731(14)00045-9 [pii] AID - 10.1016/j.fas.2014.04.003 [doi] PST - ppublish SO - Foot Ankle Surg. 2014 Sep;20(3):186-91. doi: 10.1016/j.fas.2014.04.003. Epub 2014 Jun 4. PMID- 18799239 OWN - NLM STAT- MEDLINE DCOM- 20090324 LR - 20090130 IS - 0195-6701 (Print) IS - 0195-6701 (Linking) VI - 70 IP - 3 DP - 2008 Nov TI - Bacteriostasis testing on allograft tissue inoculated in Wilkins-Chalgren broth. PG - 278-83 LID - 10.1016/j.jhin.2008.07.020 [doi] AB - Tissue banks culture tissue specimens to confirm the absence of viable micro-organisms after decontamination with antibiotics. It is possible that antibiotic residues attached to decontaminated tissue are introduced into enrichment culture media. These could have an inhibitory effect on the culture results and generate false-negative results. Our aim was to detect bacteriostasis in Wilkins-Chalgren broth inoculated with bone and tendon remnants. These remnants had been soaked in a solution containing gentamicin as part of the tissue-processing procedure. We used the United States Pharmacopeia method for bacteriostasis testing with gentamicin-susceptible Pseudomonas aeruginosa American Type Culture Collection (ATCC) 15442, Staphylococcus aureus ATCC 6538, Bacillus subtilis ATCC 6633 as test strains, and gentamicin-resistant Candida albicans ATCC 90029 as control. The residual gentamicin concentration in the broths was determined and gentamicin-soaked tissue was placed on Mueller-Hinton agar inoculated with a staphylococcal suspension. Bacteriostasis was present in 53-75% of the reference test strains. Tendon remnants had a significantly higher rate of bacteriostasis (85%) than bone remnants (28%). Broths inoculated with tendon remnants had the highest residual gentamicin concentrations. FAU - Saegeman, V AU - Saegeman V AD - Department of Microbiology, UH-KU Leuven, Leuven, Belgium. FAU - Ectors, N AU - Ectors N FAU - Lismont, D AU - Lismont D FAU - Verduyckt, B AU - Verduyckt B FAU - Verhaegen, J AU - Verhaegen J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Hosp Infect JT - The Journal of hospital infection JID - 8007166 RN - 0 (Anti-Bacterial Agents) RN - 0 (Culture Media) RN - 0 (Gentamicins) SB - IM MH - Anti-Bacterial Agents/*administration & dosage MH - Bacillus subtilis/*drug effects MH - Bone and Bones/microbiology MH - Candida albicans/*drug effects/growth & development MH - Culture Media MH - Decontamination/methods MH - Gentamicins/*administration & dosage MH - Humans MH - Pseudomonas aeruginosa/*drug effects MH - Staphylococcus aureus/*drug effects MH - Tendons/microbiology MH - Transplantation, Homologous EDAT- 2008/09/19 09:00 MHDA- 2009/03/25 09:00 CRDT- 2008/09/19 09:00 PHST- 2007/09/20 00:00 [received] PHST- 2008/07/31 00:00 [accepted] PHST- 2008/09/19 09:00 [pubmed] PHST- 2009/03/25 09:00 [medline] PHST- 2008/09/19 09:00 [entrez] AID - S0195-6701(08)00320-4 [pii] AID - 10.1016/j.jhin.2008.07.020 [doi] PST - ppublish SO - J Hosp Infect. 2008 Nov;70(3):278-83. doi: 10.1016/j.jhin.2008.07.020. PMID- 11896031 OWN - NLM STAT- MEDLINE DCOM- 20020708 LR - 20181130 IS - 8750-7587 (Print) IS - 0161-7567 (Linking) VI - 92 IP - 4 DP - 2002 Apr TI - Estrogen attenuates the cardiovascular and ventilatory responses to central command in cats. PG - 1635-41 AB - Static exercise is well known to increase heart rate, arterial blood pressure, and ventilation. These increases appear to be less in women than in men, a difference that has been attributed to an effect of estrogen on neuronal function. In decerebrate male cats, we examined the effect of estrogen (17beta-estradiol; 0.001, 0.01, 0.1, and 1.0 microg/kg iv) on the cardiovascular and ventilatory responses to central command and the exercise pressor reflex, the two neural mechanisms responsible for evoking the autonomic and ventilatory responses to exercise. We found that 17beta-estradiol, in each of the three doses tested, attenuated the pressor, cardioaccelerator, and phrenic nerve responses to electrical stimulation of the mesencephalic locomotor region (i.e., central command). In contrast, none of the doses of 17beta-estradiol had any effect on the pressor, cardioaccelerator, and ventilatory responses to static contraction or stretch of the triceps surae muscles. We conclude that, in decerebrate male cats, estrogen injected intravenously attenuates cardiovascular and ventilatory responses to central command but has no effect on responses to the exercise pressor reflex. FAU - Hayes, Shawn G AU - Hayes SG AD - Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, California 95616, USA. sghayes@ucdavis.edu FAU - Moya Del Pino, Nicolas B AU - Moya Del Pino NB FAU - Kaufman, Marc P AU - Kaufman MP LA - eng GR - HL-30710/HL/NHLBI NIH HHS/United States GR - HL-64125/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Estrogen Antagonists) RN - 22X328QOC4 (Fulvestrant) RN - 4TI98Z838E (Estradiol) SB - IM MH - Animals MH - Blood Pressure/*drug effects MH - Cats MH - Decerebrate State MH - Dose-Response Relationship, Drug MH - Estradiol/*analogs & derivatives/*pharmacology MH - Estrogen Antagonists/pharmacology MH - Fulvestrant MH - Heart Rate/*drug effects MH - Male MH - Muscle, Skeletal/physiology MH - Phrenic Nerve/drug effects/physiology MH - Physical Exertion/physiology MH - Reflex/*drug effects MH - Respiratory Mechanics/*drug effects MH - Tendons/physiology EDAT- 2002/03/16 10:00 MHDA- 2002/07/09 10:01 CRDT- 2002/03/16 10:00 PHST- 2002/03/16 10:00 [pubmed] PHST- 2002/07/09 10:01 [medline] PHST- 2002/03/16 10:00 [entrez] AID - 10.1152/japplphysiol.00981.2001 [doi] PST - ppublish SO - J Appl Physiol (1985). 2002 Apr;92(4):1635-41. doi: 10.1152/japplphysiol.00981.2001. PMID- 24681394 OWN - NLM STAT- MEDLINE DCOM- 20141215 LR - 20140430 IS - 1873-4367 (Electronic) IS - 0927-7765 (Linking) VI - 117 DP - 2014 May 1 TI - Effect of ionic liquids on the different hierarchical order of type I collagen. PG - 376-82 LID - S0927-7765(14)00134-9 [pii] LID - 10.1016/j.colsurfb.2014.03.014 [doi] AB - The effect of ionic liquids (ILs) on proteins has been gaining huge interest due to easy tunability of cation and anion for generating the desired effect. This study explores the effect of alkyl imidazolium chloride ILs on collagen at molecular, inter-fibrillar and skin matrix level. Circular dichroic studies reveal that at the molecular level, the secondary structure of collagen was not affected by imidazolium ILs and there was no change in thermal stability as well. However, collagen at the inter-fibrillar level behaved differently. With increase in concentration of ILs, remarkable decrease in thermal stability of rat tail tendon (RTT) collagen fibers with marginal swelling effect was seen. SEM micrographs of skin matrix treated with IL show opening up of pores. This kind of exquisite behavior of ILs at different hierarchal order of collagen indicates that ILs are endowed with potential lyotropic action, which can be judiciously employed for biomedical applications. CI - Copyright © 2014 Elsevier B.V. All rights reserved. FAU - Mehta, Ami AU - Mehta A AD - Chemical Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India. FAU - Rao, J Raghava AU - Rao JR AD - Chemical Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India. FAU - Fathima, Nishter Nishad AU - Fathima NN AD - Chemical Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India. Electronic address: nishad@clri.res.in. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140314 PL - Netherlands TA - Colloids Surf B Biointerfaces JT - Colloids and surfaces. B, Biointerfaces JID - 9315133 RN - 0 (Collagen Type I) RN - 0 (Imidazoles) RN - 0 (Ionic Liquids) RN - 7GBN705NH1 (imidazole) SB - IM MH - Animals MH - Collagen Type I/*chemistry/*drug effects MH - Goats MH - Imidazoles/pharmacology MH - Ionic Liquids/*pharmacology MH - Porosity MH - Protein Stability/drug effects MH - Protein Structure, Secondary MH - Rats MH - Skin/drug effects/ultrastructure MH - Spectroscopy, Fourier Transform Infrared MH - Tail MH - Temperature MH - Tendons/chemistry OTO - NOTNLM OT - Circular dichroism (CD) OT - Collagen OT - Imidazolium chloride OT - Lyotropic action OT - Room temperature ionic liquids OT - Scanning electron microscopy (SEM) EDAT- 2014/04/01 06:00 MHDA- 2014/12/17 06:00 CRDT- 2014/04/01 06:00 PHST- 2013/12/21 00:00 [received] PHST- 2014/02/25 00:00 [revised] PHST- 2014/03/04 00:00 [accepted] PHST- 2014/04/01 06:00 [entrez] PHST- 2014/04/01 06:00 [pubmed] PHST- 2014/12/17 06:00 [medline] AID - S0927-7765(14)00134-9 [pii] AID - 10.1016/j.colsurfb.2014.03.014 [doi] PST - ppublish SO - Colloids Surf B Biointerfaces. 2014 May 1;117:376-82. doi: 10.1016/j.colsurfb.2014.03.014. Epub 2014 Mar 14. PMID- 22431094 OWN - NLM STAT- MEDLINE DCOM- 20120501 LR - 20161125 IS - 1097-4598 (Electronic) IS - 0148-639X (Linking) VI - 45 IP - 4 DP - 2012 Apr TI - 7-Nitroindazole potentiates c-fos expression induced by muscle tendon vibration in the spinal cord. PG - 597-602 LID - 10.1002/mus.23230 [doi] AB - INTRODUCTION: Expression of c-fos initiated by muscle proprioceptive signaling was studied in rats after inhibition of neuronal nitric oxide synthase (nNOS) with administration of 7-nitroindazole (7-NI). METHODS: Fos-immunoreactive (Fos-ir) neurons were visualized immunohistochemically in the lumbar cord after vibration of the Achilles tendon and/or 7-NI systemic injections. RESULTS: The total number of Fos-ir interneurons and motoneurons (per slice) was significantly greater in the 7-NI-pretreated and tendon-vibrated (7-NI + Tv) group than in the isolated tendon vibration group (Tv group). The greatest increases in the number of Fos-ir neurons were found in the L4 (+100%) and L5 (+105%) segments (P < 0.05). CONCLUSIONS: Suppression of NO release after introduction of 7-NI was associated with potentiation of Fos immunoreactivity induced by muscle proprioceptive signaling within distinctive regions of the spinal cord. CI - Copyright © 2012 Wiley Periodicals, Inc. FAU - Pilyavskii, Alexander I AU - Pilyavskii AI AD - Department of Movement Physiology, Bogomoletz Institute of Physiology, National Academy of Sciences, Bogomoletz Str. 4, Kiev 01024, Ukraine. pil@biph.kiev.ua FAU - Maisky, Vladimir A AU - Maisky VA FAU - Maznychenko, Andrey V AU - Maznychenko AV FAU - Kostyukov, Alexander I AU - Kostyukov AI LA - eng PT - Journal Article PL - United States TA - Muscle Nerve JT - Muscle & nerve JID - 7803146 RN - 0 (Enzyme Inhibitors) RN - 0 (Indazoles) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type I) RN - UX0N37CMVH (7-nitroindazole) SB - IM MH - Achilles Tendon/physiology MH - Animals MH - Cell Count MH - Enzyme Inhibitors/*pharmacology MH - Gene Expression/*drug effects/*physiology MH - Genes, fos/*drug effects MH - Immunohistochemistry MH - Indazoles/*pharmacology MH - Injections, Intraperitoneal MH - Interneurons/physiology MH - Male MH - Motor Neurons/physiology MH - Muscle, Skeletal/physiology MH - Neurons, Afferent/metabolism/physiology MH - Nitric Oxide Synthase Type I/*antagonists & inhibitors MH - Proprioception/physiology MH - Rats MH - Rats, Wistar MH - Spinal Cord/*physiology MH - Tendons/*physiology MH - Vibration EDAT- 2012/03/21 06:00 MHDA- 2012/05/02 06:00 CRDT- 2012/03/21 06:00 PHST- 2012/03/21 06:00 [entrez] PHST- 2012/03/21 06:00 [pubmed] PHST- 2012/05/02 06:00 [medline] AID - 10.1002/mus.23230 [doi] PST - ppublish SO - Muscle Nerve. 2012 Apr;45(4):597-602. doi: 10.1002/mus.23230. PMID- 26851078 OWN - NLM STAT- MEDLINE DCOM- 20170110 LR - 20201130 IS - 1549-4918 (Electronic) IS - 1066-5099 (Linking) VI - 34 IP - 4 DP - 2016 Apr TI - Pharmacological Regulation of In Situ Tissue Stem Cells Differentiation for Soft Tissue Calcification Treatment. PG - 1083-96 LID - 10.1002/stem.2306 [doi] AB - Calcification of soft tissues, such as heart valves and tendons, is a common clinical problem with limited therapeutics. Tissue specific stem/progenitor cells proliferate to repopulate injured tissues. But some of them become divergent to the direction of ossification in the local pathological microenvironment, thereby representing a cellular target for pharmacological approach. We observed that HIF-2alpha (encoded by EPAS1 inclined form) signaling is markedly activated within stem/progenitor cells recruited at calcified sites of diseased human tendons and heart valves. Proinflammatory microenvironment, rather than hypoxia, is correlated with HIF-2alpha activation and promoted osteochondrogenic differentiation of tendon stem/progenitor cells (TSPCs). Abnormal upregulation of HIF-2alpha served as a key switch to direct TSPCs differentiation into osteochondral-lineage rather than teno-lineage. Notably, Scleraxis (Scx), an essential tendon specific transcription factor, was suppressed on constitutive activation of HIF-2alpha and mediated the effect of HIF-2alpha on TSPCs fate decision. Moreover, pharmacological inhibition of HIF-2alpha with digoxin, which is a widely utilized drug, can efficiently inhibit calcification and enhance tenogenesis in vitro and in the Achilles's tendinopathy model. Taken together, these findings reveal the significant role of the tissue stem/progenitor cells fate decision and suggest that pharmacological regulation of HIF-2alpha function is a promising approach for soft tissue calcification treatment. CI - © 2016 AlphaMed Press. FAU - Hu, Jia-Jie AU - Hu JJ AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Yin, Zi AU - Yin Z AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Shen, Wei-Liang AU - Shen WL AD - Department of Orthopedic Surgery, 2nd Affiliated Hospital , School of Medicine Zhejiang University, Zhejiang, 310009, China. FAU - Xie, Yu-Bin AU - Xie YB AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Zhu, Ting AU - Zhu T AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Lu, Ping AU - Lu P AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Cai, You-Zhi AU - Cai YZ AD - Department of Orthopedic Surgery, 1st Affiliated Hospital, School of Medicine Zhejiang University, Zhejiang, 310009, China. FAU - Kong, Min-Jian AU - Kong MJ AD - Department of Orthopedic Surgery, 2nd Affiliated Hospital , School of Medicine Zhejiang University, Zhejiang, 310009, China. FAU - Heng, Boon Chin AU - Heng BC AD - Faculty of Dentistry, The University of Hong Kong, Hong Kong, China. FAU - Zhou, Yi-Ting AU - Zhou YT AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Department of Biochemistry and Molecular Biology, Zhejiang University, Hangzhou, Zhejiang, 310000, China. FAU - Chen, Wei-Shan AU - Chen WS AD - Department of Orthopedic Surgery, 2nd Affiliated Hospital , School of Medicine Zhejiang University, Zhejiang, 310009, China. FAU - Chen, Xiao AU - Chen X AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. FAU - Ouyang, Hong-Wei AU - Ouyang HW AD - Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Key Laboratory of Tissue Engineering and Regenerative Medicine of Zhejiang Province, School of Medicine, Zhejiang University, Zhejiang, 310009, China. AD - Department of Sports Medicine, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China. AD - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, China. AD - China Orthopedic Regenerative Medicine Group (CORMed). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Stem Cells JT - Stem cells (Dayton, Ohio) JID - 9304532 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (SCX protein, human) RN - 1B37H0967P (endothelial PAS domain-containing protein 1) RN - 73K4184T59 (Digoxin) SB - IM MH - Achilles Tendon/*drug effects/growth & development/pathology MH - Aged MH - Animals MH - Basic Helix-Loop-Helix Transcription Factors/antagonists & inhibitors/*biosynthesis/genetics MH - Calcinosis/*drug therapy/genetics/pathology MH - Cell Differentiation/genetics MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Cellular Microenvironment/drug effects MH - Chondrogenesis/genetics MH - Digoxin/administration & dosage MH - Humans MH - Male MH - Middle Aged MH - Rats MH - Rheumatic Heart Disease/genetics/pathology MH - Stem Cells/drug effects/pathology MH - *Therapy, Soft Tissue OTO - NOTNLM OT - Calcification OT - Digoxin OT - HIF-2 alpha OT - Heart valves OT - Stem cells OT - Tendons EDAT- 2016/02/07 06:00 MHDA- 2017/01/11 06:00 CRDT- 2016/02/07 06:00 PHST- 2015/05/18 00:00 [received] PHST- 2015/10/25 00:00 [revised] PHST- 2015/11/29 00:00 [accepted] PHST- 2016/02/07 06:00 [entrez] PHST- 2016/02/07 06:00 [pubmed] PHST- 2017/01/11 06:00 [medline] AID - 10.1002/stem.2306 [doi] PST - ppublish SO - Stem Cells. 2016 Apr;34(4):1083-96. doi: 10.1002/stem.2306. PMID- 25380657 OWN - NLM STAT- MEDLINE DCOM- 20150629 LR - 20240510 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 20 DP - 2014 Nov 8 TI - Toxic effects of levofloxacin on rat annulus fibrosus cells: an in-vitro study. PG - 2205-12 LID - 10.12659/MSM.892610 [doi] AB - BACKGROUND: Fluoroquinolones are in wide clinical use as safe and effective antibiotics. Articular cartilage, tendons, and epiphyseal growth plates have been recognized as targets of fluoroquinolone-induced connective tissue toxicity. However, the effects of fluoroquinolones on annulus fibrosus (AF) cells are still unknown. MATERIAL/METHODS: The main objective of this study was to investigate the effects of levofloxacin, a typical fluoroquinolone antibiotic drug, on rat AF cells in vitro. Rat annulus fibrosus (RAF) cells were treated with levofloxacin at different concentrations (0, 10, 20, 30, 40, 60, 80, and 90 μg/ml) and were assessed to determine the possible cytotoxic effects of levofloxacin. Inverted phase-contrast microscopy was used to accomplish the morphological observation of apoptosis of treated cells. Western blot and real-time quantitative RT-PCR (qPCR) was used to explore the expression of active caspase-3 and MMP-3. Flow cytometry was used to measure the apoptotic incidences. RESULTS: Our study showed that levofloxacin, with concentrations at 30, 60, and 90 μg/ml, induced dose-dependent RAF cell apoptosis and higher expression of caspase-3 and MMP-3. More apoptotic cells were observed by inverted phase-contrast microscopy. Moreover, levofloxacin increased the activity of caspase-3, and it also reduced cell viability with different concentrations ranging from 10 to 80 μg/ml. CONCLUSIONS: Our study results suggest that levofloxacin has cytotoxic effects on RAF cells, characterized by enhancing apoptosis and reducing cell viability, and indicate a potential toxic effect of fluoroquinolones on RAF cells. FAU - Bai, Zhi-Long AU - Bai ZL AD - Department of Spine Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Chen, Qian AU - Chen Q AD - Department of Spine Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Yang, Si-Dong AU - Yang SD AD - Department of Spine Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Zhang, Feng AU - Zhang F AD - Department of Rehabilitation Medicine, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Wang, Hai-Ying AU - Wang HY AD - Department of Spine Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Yang, Da-Long AU - Yang DL AD - Department of Spine Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). FAU - Ding, Wen-Yuan AU - Ding WY AD - Department of Spinal Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (mainland). LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20141108 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (Annexin A5) RN - 36015-30-2 (Propidium) RN - 6GNT3Y5LMF (Levofloxacin) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - I223NX31W9 (Fluorescein-5-isothiocyanate) SB - IM MH - Animals MH - Annexin A5/metabolism MH - Blotting, Western MH - Caspase 3/metabolism MH - Cell Shape/drug effects MH - Cell Survival/drug effects MH - Fluorescein-5-isothiocyanate/metabolism MH - Intervertebral Disc/*drug effects/enzymology/*pathology MH - Levofloxacin/*toxicity MH - Matrix Metalloproteinase 3/metabolism MH - Polymerase Chain Reaction MH - Propidium/metabolism MH - Rats, Sprague-Dawley PMC - PMC4237079 EDAT- 2014/11/09 06:00 MHDA- 2015/06/30 06:00 PMCR- 2014/11/08 CRDT- 2014/11/09 06:00 PHST- 2014/11/09 06:00 [entrez] PHST- 2014/11/09 06:00 [pubmed] PHST- 2015/06/30 06:00 [medline] PHST- 2014/11/08 00:00 [pmc-release] AID - 892610 [pii] AID - 10.12659/MSM.892610 [doi] PST - epublish SO - Med Sci Monit. 2014 Nov 8;20:2205-12. doi: 10.12659/MSM.892610. PMID- 26313244 OWN - NLM STAT- MEDLINE DCOM- 20160711 LR - 20161126 IS - 1502-7732 (Electronic) IS - 0300-9742 (Linking) VI - 45 IP - 2 DP - 2016 TI - MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis. PG - 99-102 LID - 10.3109/03009742.2015.1070902 [doi] AB - OBJECTIVES: To determine the value of magnetic resonance imaging (MRI) of bones and joints in patients with recent-onset rheumatoid arthritis (RA) treated for 2 years from diagnosis with disease-modifying anti-rheumatic drugs (DMARDs) and glucocorticoids. METHOD: Thirteen patients with early RA were treated according to clinical practice and followed with MRI, radiographs, and Disease Activity Score calculated on 28 joints (DAS28) at inclusion (baseline) and after 1, 4, 7, 13, and 25 months. MRI of the dominant wrist and metacarpophalangeal (MCP) joints were assessed for synovitis, bone oedema, and erosions using the RA MRI Score (RAMRIS) and for tenosynovitis by an MRI tenosynovitis scoring method. Radiographs were assessed by the van der Heijde modified Sharp score (SHS). Clinical remission was defined by a DAS28 < 2.6. RESULTS: MRI at baseline detected inflammation in joints and tendons in all patients as well as erosions in 10 out of 13 patients. Over time, the erosion score increased while the synovitis and tenosynovitis scores remained almost unchanged. Bone oedema strongly correlated with synovitis. Synovitis and tenosynovitis correlated well with the erosion score at baseline but not thereafter. The MRI changes showed that joint damage started early and continued in the presence of persistent synovial and tenosynovial inflammation. CONCLUSIONS: The observations made in this small study suggest that the treatment goal of 'clinical remission' should be supplemented by a 'joint remission' goal. To this end, MRI is an appropriate tool. Further studies are needed to evaluate the optimal use of MRI in early RA. FAU - Forslind, K AU - Forslind K AD - a Department of Clinical Sciences, Section of Rheumatology , Lund University , Helsingborg , Sweden. AD - b Department of Medicine, Section of Rheumatology , Helsingborgs Lasarett , Helsingborg , Sweden. FAU - Svensson, B AU - Svensson B AD - c Department of Clinical Sciences, Section of Rheumatology , Lund University , Lund , Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150831 PL - England TA - Scand J Rheumatol JT - Scandinavian journal of rheumatology JID - 0321213 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antirheumatic Agents) RN - 0 (Glucocorticoids) RN - 91X1KLU43E (golimumab) RN - 9PHQ9Y1OLM (Prednisolone) RN - OP401G7OJC (Etanercept) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Aged MH - Antibodies, Monoclonal/therapeutic use MH - Antirheumatic Agents/therapeutic use MH - Arthritis, Rheumatoid/drug therapy/*pathology MH - Disease Progression MH - Edema/*pathology MH - Etanercept/therapeutic use MH - Female MH - Glucocorticoids/therapeutic use MH - Hand Bones/*pathology MH - Humans MH - Inflammation/*pathology MH - Magnetic Resonance Imaging MH - Male MH - Metacarpophalangeal Joint/*pathology MH - Methotrexate/therapeutic use MH - Middle Aged MH - Prednisolone/therapeutic use MH - Prognosis MH - Remission Induction MH - Severity of Illness Index MH - Synovitis/*pathology MH - Tenosynovitis/*pathology MH - Wrist Joint EDAT- 2015/08/28 06:00 MHDA- 2016/07/12 06:00 CRDT- 2015/08/28 06:00 PHST- 2015/08/28 06:00 [entrez] PHST- 2015/08/28 06:00 [pubmed] PHST- 2016/07/12 06:00 [medline] AID - 10.3109/03009742.2015.1070902 [doi] PST - ppublish SO - Scand J Rheumatol. 2016;45(2):99-102. doi: 10.3109/03009742.2015.1070902. Epub 2015 Aug 31. PMID- 30873946 OWN - NLM STAT- MEDLINE DCOM- 20190729 LR - 20190729 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 37 IP - 4 DP - 2019 Jul-Aug TI - Can ultrasound-detected subclinical synovitis be an indicator of flare recurrence in juvenile idiopathic arthritis remission patients on tapered TNFi? PG - 705-712 AB - OBJECTIVES: Subclinical synovitis is often detected by musculoskeletal ultrasound (MSUS) in juvenile idiopathic arthritis (JIA) patients in clinical remission. The main objective of this prospective, observational, longitudinal, multicentre study was to evaluate the predictive value of MSUS-detected subclinical synovitis in relation to flares at 12 months following TNFi tapering in a JIA population in stable clinical remission. METHODS: We included 56 JIA patients in stable remission undergoing TNFi therapy tapered at baseline and in some cases at 6 months. We performed baseline and 6-month MSUS assessment on B-mode (BM) and power Doppler (PD) mode of 22 joints and 8 tendons. RESULTS: Eighteen patients (32.1%) experienced a flare during the 12-month study period. BM synovitis was frequent (83.9%) but PD synovitis was scarcely found (8.9%). There were no significant differences in MSUS findings between patients who experienced a flare and those who remained in remission. Only 5 patients had positive for PD synovitis, in joints with BM synovitis grades 2 or 3, and none experienced a flare. Concomitant methotrexate (MTX) was more frequent in patients who were successfully tapered (71.1% vs. 27.8%; p=0.002) and patients older than 12 experienced a greater number of flares and earlier onset. CONCLUSIONS: Subclinical synovitis, as detected by MSUS, proved not to be a predictor of flares. Those patients on a TNFi-tapered concomitant methotrexate regimen experienced the fewest flares although flare risk increased with age. FAU - Nieto-González, Juan Carlos AU - Nieto-González JC AD - Hospital General Universitario Gregorio Marañón, Madrid, Spain. juancarlos.nietog@gmail.com. FAU - Rodríguez, Ana AU - Rodríguez A AD - Hospital Universitario Ramón y Cajal, Madrid, Spain. FAU - Gámir-Gámir, María Luz AU - Gámir-Gámir ML AD - Hospital Universitario Ramón y Cajal, Madrid, Spain. FAU - Boteanu, Alina AU - Boteanu A AD - Hospital Universitario Ramón y Cajal, Madrid, Spain. FAU - López-Robledillo, Juan Carlos AU - López-Robledillo JC AD - Hospital Universitario Infantil Niño Jesús, Madrid, Spain. FAU - Garulo, Daniel Clemente AU - Garulo DC AD - Hospital Universitario Infantil Niño Jesús, Madrid, Spain. FAU - Collado, Paz AU - Collado P AD - Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain. FAU - Calvo, Cristina AU - Calvo C AD - Hospital Universitario La Paz, Madrid, Spain. FAU - Garrido, Jesús AU - Garrido J AD - Departamento de Psicología Social y Metodología, Facultad de Psicología, Universidad Autónoma de Madrid, Spain. FAU - Monteagudo Sáez, Indalecio AU - Monteagudo Sáez I AD - Hospital General Universitario Gregorio Marañón, Madrid, Spain. FAU - Naredo, Esperanza AU - Naredo E AD - Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. LA - eng PT - Journal Article DEP - 20190307 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - 0 (Biological Products) RN - 0 (Tumor Necrosis Factor-alpha) RN - YL5FZ2Y5U1 (Methotrexate) MH - Arthritis, Juvenile/*diagnostic imaging/drug therapy/pathology MH - Biological Products/therapeutic use MH - Disease Progression MH - Humans MH - Methotrexate MH - Prospective Studies MH - Recurrence MH - Remission Induction MH - Synovial Membrane/diagnostic imaging MH - Synovitis/*diagnostic imaging MH - Tumor Necrosis Factor-alpha/antagonists & inhibitors MH - Ultrasonography/*methods EDAT- 2019/03/16 06:00 MHDA- 2019/07/30 06:00 CRDT- 2019/03/16 06:00 PHST- 2018/06/18 00:00 [received] PHST- 2018/11/13 00:00 [accepted] PHST- 2019/03/16 06:00 [pubmed] PHST- 2019/07/30 06:00 [medline] PHST- 2019/03/16 06:00 [entrez] AID - 13072 [pii] PST - ppublish SO - Clin Exp Rheumatol. 2019 Jul-Aug;37(4):705-712. Epub 2019 Mar 7. PMID- 34905481 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20220923 IS - 0392-856X (Print) IS - 0392-856X (Linking) VI - 40 IP - 9 DP - 2022 Sep TI - An ultrasonographic insight into musculoskeletal manifestation in 100 systemic lupus erythematosus patients. PG - 1686-1692 LID - 10.55563/clinexprheumatol/am4oj4 [doi] AB - OBJECTIVES: We aimed to investigate the prevalence of US findings in the hand joints and related tendons and explore clinical and laboratory associations in SLE patients of the typical lupus clinic. METHODS: One hundred consecutive SLE patients were enrolled in the study. Using B-mode and Doppler US, bilateral wrist, metacarpophalangeal and proximal interphalangeal joints were examined for synovitis and erosions, as well as for signs of hand tenosynovitis. RESULTS: US detected synovitis (grade 1-3) in 75% and erosive changes in 25% of the cohort. We found that clinical examination underestimated grade ≥2 synovitis by 13%, while US detected SH grade ≥2 in 10% of asymptomatic patients. The overall inflammatory burden, reflected by the US score, was associated with disease activity (respectively with CPR, SELENA-2K, MS-BILAG, and hypocomplementemia), as well as the presence of bone erosions. Rhupus patients had higher inflammatory markers, significantly more synovial hypertrophy, more erosions, more grade 3 tenosynovitis, and were more likely to receive methotrexate (p<0.001) than patients with SLE arthritis, while patients with Jaccoud's arthropathy were more likely to accumulate damage. The dominant hand exhibited more inflammatory changes (respectively synovial hypertrophy grade ≥2) at both the wrist and MCP joints; however, handedness was not associated with structural damage. CONCLUSIONS: In conclusion: 1. joint involvement in SLE is frequent and underacknowledged; 2. the overall inflammatory burden is associated with systemic disease activity and joint damage; (3) destructive arthritis is more likely to occur in the context of concomitant RA or within an "RA-like" subtype of SLE arthropathy; 4. hand dominance is associated with synovitis, but not structural changes; 5. US assessment may help tailor the management of joint involvement, thus preventing joint damage and disability in SLE patients. FAU - Popov, Ioan Horatiu AU - Popov IH AD - County Emergency Clinical Hospital Sălaj, Zalău, and Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Pamfil, Cristina AU - Pamfil C AD - Iuliu Hațieganu University of Medicine and Pharmacy, and County Emergency Clinical Hospital Cluj, ERN ReCONNET Center, Cluj-Napoca, Romania. cristinapamfil.umfcluj@gmail.com. FAU - Tămaș, Maria Magdalena AU - Tămaș MM AD - Iuliu Hațieganu University of Medicine and Pharmacy, and County Emergency Clinical Hospital Cluj, ERN ReCONNET Center, Cluj-Napoca, Romania. FAU - Onea, Teodor Nicolae AU - Onea TN AD - Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. FAU - Felea, Ioana AU - Felea I AD - County Emergency Clinical Hospital Cluj, ERN ReCONNET Center, Cluj-Napoca, Romania. FAU - Hălbac, Anca AU - Hălbac A AD - County Emergency Clinical Hospital Cluj, ERN ReCONNET Center, Cluj-Napoca, Romania. FAU - Rednic, Nicolae AU - Rednic N AD - Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, and Department of Internal Medicine, CF University Hospital Cluj, Cluj-Napoca, Romania. FAU - Rednic, Simona AU - Rednic S AD - Iuliu Hațieganu University of Medicine and Pharmacy, and County Emergency Clinical Hospital Cluj, ERN ReCONNET Center, Cluj-Napoca, Romania. LA - eng PT - Journal Article DEP - 20211210 PL - Italy TA - Clin Exp Rheumatol JT - Clinical and experimental rheumatology JID - 8308521 RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - *Arthritis/diagnostic imaging/epidemiology/etiology MH - Humans MH - *Joint Diseases MH - *Lupus Erythematosus, Systemic/complications/diagnostic imaging/epidemiology MH - Methotrexate MH - *Synovitis/diagnostic imaging/epidemiology/etiology MH - *Tenosynovitis/diagnostic imaging/epidemiology/etiology EDAT- 2021/12/15 06:00 MHDA- 2022/09/24 06:00 CRDT- 2021/12/14 17:14 PHST- 2021/06/29 00:00 [received] PHST- 2021/10/11 00:00 [accepted] PHST- 2021/12/15 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2021/12/14 17:14 [entrez] AID - 17610 [pii] AID - 10.55563/clinexprheumatol/am4oj4 [doi] PST - ppublish SO - Clin Exp Rheumatol. 2022 Sep;40(9):1686-1692. doi: 10.55563/clinexprheumatol/am4oj4. Epub 2021 Dec 10. PMID- 25833144 OWN - NLM STAT- MEDLINE DCOM- 20160510 LR - 20181113 IS - 1434-9949 (Electronic) IS - 0770-3198 (Linking) VI - 34 IP - 8 DP - 2015 Aug TI - Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort. PG - 1367-74 LID - 10.1007/s10067-015-2926-x [doi] AB - We analyzed the longitudinal changes in gray-scale ultrasonography (GSUS) and power Doppler ultrasonography (PDUS) parameters and correlated them with clinical, functional, and radiologic outcomes in patients with newly diagnosed rheumatoid arthritis (RA). GSUS and PDUS examinations, 44-joint disease activity score (DAS44) calculations, measurements of erythrocyte sedimentation rate, and C-reactive protein levels were performed in 68 RA patients at baseline and after 1, 3, 6, 9, and 12 months. Metacarpophalangeal joints, wrist, elbow, knee, ankle, metatarsophalangeal joints, and wrist and ankle tendons were examined by GSUS and PDUS. The laboratory and clinical findings began to decrease significantly at 1 month (P < 0.05). Improvement of the ultrasonography (US) variables began at 3 months. After 6 months, all of the joint synovitis scores, except those of the knee, elbow, and ankle joints, showed a statistically significant reduction compared to baseline scores (P < 0.001). DAS44 scores were lower in the very early RA group at 12 months compared to those whose symptom duration was greater than 3 months of RA (respectively, 1.53 ± 0.34; 1.80 ± 0.38; z = -2501, P = 0.012). The total modified Sharp scores at 12 months correlated with total PDUS synovitis scores at 12 months (r = 0.354, P = 0.003). Regression of US synovitis at large joints such as the knee, elbow, and ankle tended to be delayed compared to that at small joints. PD synovitis that is persistent despite disease-modifying anti-rheumatic drug therapy may cause radiographic bone erosions. FAU - Harman, Halil AU - Harman H AD - Department of Physical Medicine and Rehabilitation, Rheumatology, Faculty of Medicine, Sakarya University, Sakarya, Turkey, drhharman@yahoo.com. FAU - Tekeoğlu, İbrahim AU - Tekeoğlu İ FAU - Takçı, Sibel AU - Takçı S FAU - Kamanlı, Ayhan AU - Kamanlı A FAU - Nas, Kemal AU - Nas K FAU - Harman, Sibel AU - Harman S LA - eng PT - Journal Article DEP - 20150402 PL - Germany TA - Clin Rheumatol JT - Clinical rheumatology JID - 8211469 RN - 0 (Antirheumatic Agents) RN - 9PHQ9Y1OLM (Prednisolone) RN - X4W7ZR7023 (Methylprednisolone) RN - YL5FZ2Y5U1 (Methotrexate) SB - IM MH - Adult MH - Aged MH - Antirheumatic Agents/*therapeutic use MH - Arthritis, Rheumatoid/complications/*diagnostic imaging/drug therapy MH - Drug Therapy, Combination MH - Female MH - Follow-Up Studies MH - Humans MH - Joints/*diagnostic imaging MH - Male MH - Methotrexate/*therapeutic use MH - Methylprednisolone/*therapeutic use MH - Middle Aged MH - Prednisolone/*therapeutic use MH - Severity of Illness Index MH - Synovitis/complications/*diagnostic imaging/drug therapy MH - Treatment Outcome MH - Ultrasonography, Doppler EDAT- 2015/04/03 06:00 MHDA- 2016/05/11 06:00 CRDT- 2015/04/03 06:00 PHST- 2014/12/30 00:00 [received] PHST- 2015/03/20 00:00 [accepted] PHST- 2015/03/10 00:00 [revised] PHST- 2015/04/03 06:00 [entrez] PHST- 2015/04/03 06:00 [pubmed] PHST- 2016/05/11 06:00 [medline] AID - 10.1007/s10067-015-2926-x [doi] PST - ppublish SO - Clin Rheumatol. 2015 Aug;34(8):1367-74. doi: 10.1007/s10067-015-2926-x. Epub 2015 Apr 2. PMID- 30606221 OWN - NLM STAT- MEDLINE DCOM- 20200407 LR - 20200408 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 10 IP - 1 DP - 2019 Jan 3 TI - PEDF-derived peptide promotes tendon regeneration through its mitogenic effect on tendon stem/progenitor cells. PG - 2 LID - 10.1186/s13287-018-1110-z [doi] LID - 2 AB - BACKGROUND: Tendon stem/progenitor cells (TSPC) exhibit a low proliferative response to heal tendon injury, leading to limited regeneration outcomes. Exogenous growth factors that activate TSPC proliferation have emerged as a promising approach for treatment. Here, we evaluated the pigment epithelial-derived factor (PEDF)-derived short peptide (PSP; 29-mer) for treating acute tendon injury and to determine the timing and anatomical features of CD146- and necleostemin-positive TSPC in the tendon healing process. METHODS: Tendon cells were isolated from rabbit Achilles tendons, stimulated by the 29-mer and analyzed for colony-forming capacity. The expression of the TSPC markers CD146, Oct4, and nestin, induced by the 29-mer, was examined by immunostaining and western blotting. Tendo-Achilles injury was induced in rats by full-thickness insertion of an 18-G needle and immediately treated topically with an alginate gel, loaded with 29-mer. The distribution of TSPC in the injured tendon and their proliferation were monitored using immunohistochemistry with antibodies to CD146 and nucleostemin and by BrdU labeling. RESULTS: TSPC markers were enriched among the primary tendon cells when stimulated by the 29-mer. The 29-mer also induced the clonogenicity of CD146(+) TSPC, implying TSPC stemness was retained during TSPC expansion in culture. Correspondingly, the expanded TSPC differentiated readily into tenocyte-like cells after removal of the 29-mer from culture. 29-mer/alginate gel treatment caused extensive expansion of CD146(+) TSPC in their niche on postoperative day 2, followed by infiltration of CD146(+)/BrdU(-) TSPC into the injured tendon on day 7. The nucleostemin(+) TSPC were located predominantly in the healing region of the injured tendon in the later phase (day 7) and exhibited proliferative capacity. By 3 weeks, 29-mer-treated tendons showed more organized collagen fiber regeneration and higher tensile strength than control tendons. In culture, the mitogenic effect of the 29-mer was found to be mediated by the phosphorylation of ERK2 and STAT3 in nucleostemin(+) TSPC. CONCLUSIONS: The anatomical analysis of TSPC populations in the wound healing process supports the hypothesis that substantial expansion of resident TSPC by exogenous growth factor is beneficial for tendon healing. The study suggests that synthetic 29-mer peptide may be an innovative therapy for acute tendon rupture. FAU - Ho, Tsung-Chuan AU - Ho TC AD - Department of Medical Research, Mackay Memorial Hospital, No. 45, Minsheng Rd., Tamsui District, New Taipei City, 25160, Taiwan. FAU - Tsai, Shawn H AU - Tsai SH AD - Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Sec. 2, Chung Shan North Road, Taipei, 10449, Taiwan. AD - Department of Optometry, Chung Shan Medical University, Taichung, 40201, Taiwan. FAU - Yeh, Shu-I AU - Yeh SI AD - Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Sec. 2, Chung Shan North Road, Taipei, 10449, Taiwan. FAU - Chen, Show-Li AU - Chen SL AD - Department of Microbiology, School of Medicine, National Taiwan University, No. 1 Jen Ai road, section 1, Taipei, 100, Taiwan. FAU - Tung, Kwang-Yi AU - Tung KY AD - Department of Plastic Surgery, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Taipei, 10449, Taiwan. FAU - Chien, Hsin-Yu AU - Chien HY AD - Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Sec. 2, Chung Shan North Road, Taipei, 10449, Taiwan. FAU - Lu, Yung-Chang AU - Lu YC AD - Departments of Biomechanics Laboratory, and Orthopaedic Surgery, Mackay Memorial Hospital, No. 45, Minsheng Rd., Tamsui District, New Taipei City, 25160, Taiwan. FAU - Huang, Chang-Hung AU - Huang CH AD - Departments of Biomechanics Laboratory, and Orthopaedic Surgery, Mackay Memorial Hospital, No. 45, Minsheng Rd., Tamsui District, New Taipei City, 25160, Taiwan. AD - Department of Dentistry, National Yang-Ming University, Taipei, Taiwan. FAU - Tsao, Yeou-Ping AU - Tsao YP AD - Department of Medical Research, Mackay Memorial Hospital, No. 45, Minsheng Rd., Tamsui District, New Taipei City, 25160, Taiwan. yptsao@yahoo.com. AD - Department of Ophthalmology, Mackay Memorial Hospital, No. 92, Sec. 2, Chung Shan North Road, Taipei, 10449, Taiwan. yptsao@yahoo.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190103 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - 0 (Eye Proteins) RN - 0 (Nerve Growth Factors) RN - 0 (Peptides) RN - 0 (Serpins) RN - 0 (pigment epithelium-derived factor) SB - IM MH - Achilles Tendon/*physiopathology MH - Animals MH - Eye Proteins/*metabolism MH - Humans MH - Nerve Growth Factors/*metabolism MH - Peptides/*metabolism MH - Rabbits MH - Rats MH - Regeneration/*genetics MH - Serpins/*metabolism MH - Stem Cells/cytology/*metabolism MH - Tendon Injuries/*therapy PMC - PMC6318926 OTO - NOTNLM OT - PEDF OT - Peptide OT - Signaling OT - Tendon stem/progenitor cell COIS- ETHICS APPROVAL: Experimental procedures were approved by the Mackay Memorial Hospital Review Board (MMH-A-S-103-38 and MMH-A-S-106-47) (New Taipei City, Taiwan), which was in accordance with MOST Guide for the Care and Use of Laboratory Animals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2019/01/05 06:00 MHDA- 2020/04/09 06:00 PMCR- 2019/01/03 CRDT- 2019/01/05 06:00 PHST- 2018/08/21 00:00 [received] PHST- 2018/12/13 00:00 [accepted] PHST- 2018/12/04 00:00 [revised] PHST- 2019/01/05 06:00 [entrez] PHST- 2019/01/05 06:00 [pubmed] PHST- 2020/04/09 06:00 [medline] PHST- 2019/01/03 00:00 [pmc-release] AID - 10.1186/s13287-018-1110-z [pii] AID - 1110 [pii] AID - 10.1186/s13287-018-1110-z [doi] PST - epublish SO - Stem Cell Res Ther. 2019 Jan 3;10(1):2. doi: 10.1186/s13287-018-1110-z. PMID- 28533328 OWN - NLM STAT- MEDLINE DCOM- 20171013 LR - 20220113 IS - 1530-6860 (Electronic) IS - 0892-6638 (Print) IS - 0892-6638 (Linking) VI - 31 IP - 9 DP - 2017 Sep TI - Tendon stem/progenitor cells regulate inflammation in tendon healing via JNK and STAT3 signaling. PG - 3991-3998 LID - 10.1096/fj.201700071R [doi] AB - Tendon stem/progenitor cells (TSCs) have been found in different anatomic locations and showed a promising regenerative potential. We identified a role of TSCs in the regulation of inflammation during healing of acute tendon injuries. Delivery of connective tissue growth factor (CTGF) into full-transected rat patellar tendons significantly increased the number of CD146(+) TSCs, leading to enhanced healing. In parallel, CTGF delivery significantly reduced the number of iNOS(+) M1 macrophages and increased the expression of anti-inflammatory IL-10 at 2 d after surgery, with over 85% CD146(+) TSCs expressing IL-10. By 1 wk, the elevated IL-10 expression remained, and IL-6 expression was significantly attenuated in CTGF-delivered tendon healing. Matrix metalloproteinase (MMP)-3 expression in CTGF-delivered tendon was organized along with the reorienting collagen fibers by 1 wk after surgery, in comparison with the control group showing the abundant MMP-3 expression localized at healing junction. Tissue inhibitor of metalloprotease (TIMP)-3 was expressed in CD146(+) TSCs at 1 wk with CTGF, in contrast to control with no TIMP-3 expression. In vitro, IL-10 expression was detected only when tendon cells were stimulated with IL-1β, and CTGF and significantly higher in CD146(+) TSCs than CD146(-) tendon cells. Similarly, TIMP-3 expression was detected only when treated with CTGF or CTGF and IL-1β that is significantly higher in CD146(+) TSCs compared to CD146(-) tendon cells. Signaling study with specific inhibitors and Western blot analysis demonstrated that CTGF-induced expression of IL-10 and TIMP-3 in CD146(+) TSCs are regulated by JNK/signal transducer and activator of transcription 3 signaling. Taken together, these findings suggest anti-inflammatory roles of CTGF-stimulated TSCs that are likely associated with improved tendon healing.-Tarafder, S., Chen, E., Jun, Y., Kao, K., Sim, K. H., Back, J., Lee, F. Y., Lee, C. H. Tendon stem/progenitor cells regulate inflammation in tendon healing via JNK and STAT3 signaling. CI - © FASEB. FAU - Tarafder, Solaiman AU - Tarafder S AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA. FAU - Chen, Esther AU - Chen E AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA. FAU - Jun, Yena AU - Jun Y AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA. FAU - Kao, Kristy AU - Kao K AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA. FAU - Sim, Kun Hee AU - Sim KH AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA. FAU - Back, Jungho AU - Back J AD - Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut, USA. FAU - Lee, Francis Y AU - Lee FY AD - Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut, USA. FAU - Lee, Chang H AU - Lee CH AD - Regenerative Engineering Laboratory, Columbia University Irving Medical Center, New York, New York, USA; chl2109@cumc.columbia.edu. LA - eng GR - R03 DE026794/DE/NIDCR NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20170522 PL - United States TA - FASEB J JT - FASEB journal : official publication of the Federation of American Societies for Experimental Biology JID - 8804484 RN - 0 (CCN2 protein, rat) RN - 0 (Cytokines) RN - 0 (STAT3 Transcription Factor) RN - 0 (Stat3 protein, rat) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - EC 2.7.12.2 (MAP Kinase Kinase 4) SB - IM MH - Animals MH - Connective Tissue Growth Factor/genetics/metabolism MH - Cytokines/genetics/metabolism MH - Gene Expression Regulation/physiology MH - Inflammation/*metabolism MH - MAP Kinase Kinase 4/genetics/*metabolism MH - Rats MH - Rats, Sprague-Dawley MH - STAT3 Transcription Factor/genetics/*metabolism MH - Signal Transduction MH - Stem Cells MH - Tendon Injuries MH - Tendons/*cytology MH - Tissue Inhibitor of Metalloproteinase-3/genetics/metabolism PMC - PMC5572690 OTO - NOTNLM OT - CD146 OT - CTGF OT - TSC EDAT- 2017/05/24 06:00 MHDA- 2017/10/14 06:00 PMCR- 2018/09/01 CRDT- 2017/05/24 06:00 PHST- 2017/01/26 00:00 [received] PHST- 2017/05/01 00:00 [accepted] PHST- 2017/05/24 06:00 [pubmed] PHST- 2017/10/14 06:00 [medline] PHST- 2017/05/24 06:00 [entrez] PHST- 2018/09/01 00:00 [pmc-release] AID - fj.201700071R [pii] AID - FJ_201700071R [pii] AID - 10.1096/fj.201700071R [doi] PST - ppublish SO - FASEB J. 2017 Sep;31(9):3991-3998. doi: 10.1096/fj.201700071R. Epub 2017 May 22. PMID- 12162426 OWN - NLM STAT- MEDLINE DCOM- 20030214 LR - 20221207 IS - 0300-8177 (Print) IS - 0300-8177 (Linking) VI - 234-235 IP - 1-2 DP - 2002 May-Jun TI - Interactions of copper with glycated proteins: possible involvement in the etiology of diabetic neuropathy. PG - 135-42 AB - Humans and animals with diabetes frequently develop peripheral vascular dysfunction and peripheral neuropathies. There is accumulating evidence that impaired peripheral nerve function may derive from diminished endoneural blood flow. The decrements in nerve blood flow may, in turn, be due to diminished endothelium-dependent vasodilation. Although a number of possible causes of this defective vasodilation have been suggested, none has been definitely proven. Regardless of the precise cause, the impaired vasodilatory activity may reflect diminished availability of endothelium-derived relaxing factor (EDRF), variously thought to be nitric oxide or thiol adducts of nitric oxide. Other investigators have reported that administration of transition metal chelators to diabetic rats corrects EDRF-mediated arterial relaxation and restores both neural blood flow and nerve conduction velocity, suggesting the involvement of transition metals. Our investigations center about the hypothesis that glycated proteins bind transition metals such as copper and iron, and that such 'glycochelates' accumulate within the vasculature in diabetes and catalytically inactivate EDRF. In partial support of this hypothesis: (1) Glycated albumin binds approximately 3-fold greater amounts of both copper and iron. (2) Copper bound to glycated albumin remains redox active (e.g. capable of supporting the oxidation of ascorbic acid). (3) Copper and copper-containing glycochelates cause the rapid decomposition of one putative form of EDRF, nitrosocysteine. (4) The amount of exchangeable (i.e. chelatable) copper in the plasma of diabetic rats is approximately twice that in normal rat plasma. (5) Similarly, tail tendons of diabetic animals have about twice as much bound copper as do tendons of normal rats. (6) Implants bearing adsorbed glycated albumin placed in the peritonea of normal mice for 48 h accumulate approximately 5 times as much bound copper as do implants coated with control albumin. Overall, these observations support--but do not conclusively prove - the hypothesis that transition metals such as copper, bound to glycated proteins, may blunt normal EDRF-dependent relaxation of diabetic arteries and provide a rationale for the use of transition metal chelators in the therapy of diabetic vasculopathy and neuropathy. FAU - Eaton, John W AU - Eaton JW AD - Department of Medicine and James Graham Brown Cancer Center, University of Louisville, KY 40202, USA. EatonRedox@aol.com FAU - Qian, Mingwei AU - Qian M LA - eng GR - R01 DK 58882/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - Netherlands TA - Mol Cell Biochem JT - Molecular and cellular biochemistry JID - 0364456 RN - 0 (Chelating Agents) RN - 0 (Glycation End Products, Advanced) RN - 0 (Serum Albumin) RN - 27432CM55Q (Serum Albumin, Bovine) RN - 31C4KY9ESH (Nitric Oxide) RN - 789U1901C5 (Copper) RN - 0 (Glycated Serum Albumin) SB - IM MH - Animals MH - Cattle MH - Chelating Agents/therapeutic use MH - Copper/analysis/blood/*metabolism MH - Diabetes Mellitus, Experimental/blood/metabolism MH - Diabetic Neuropathies/blood/drug therapy/*etiology/*metabolism MH - Glycation End Products, Advanced MH - Glycosylation MH - Male MH - Nitric Oxide/metabolism MH - Protein Binding MH - Rats MH - Rats, Sprague-Dawley MH - Serum Albumin/*metabolism MH - Serum Albumin, Bovine/metabolism MH - Time Factors MH - Glycated Serum Albumin EDAT- 2002/08/07 10:00 MHDA- 2003/02/15 04:00 CRDT- 2002/08/07 10:00 PHST- 2002/08/07 10:00 [pubmed] PHST- 2003/02/15 04:00 [medline] PHST- 2002/08/07 10:00 [entrez] PST - ppublish SO - Mol Cell Biochem. 2002 May-Jun;234-235(1-2):135-42. PMID- 18807189 OWN - NLM STAT- MEDLINE DCOM- 20090106 LR - 20130530 IS - 1573-9686 (Electronic) IS - 0090-6964 (Linking) VI - 36 IP - 12 DP - 2008 Dec TI - Changes in gene expression of matrix constituents with respect to passage of ligament and tendon fibroblasts. PG - 1927-33 LID - 10.1007/s10439-008-9565-1 [doi] AB - Trauma to the knee joint often results in injury to one or more supporting soft tissue structures, such as the medial collateral (MCL) and anterior cruciate (ACL) ligaments. Also, a portion of the patellar tendon (PT) is frequently used as a replacement graft for the ACL, resulting in a PT defect. The healing responses of these tissues are dramatically different and range from spontaneous healing to little or no healing. Studies have suggested that native cell behavior could be responsible for differences in healing potential. However, it is difficult to make comparisons as the reported results are based on different cellular passages which could have a dramatic effect on their potential to form healing tissues. Therefore, the objective of this study was to quantify the gene expression of collagen and other matrix constituents of fibroblasts from the MCL, ACL, and PT to document how they change with cell passage. We hypothesized that MCL fibroblasts would possess higher potential for matrix production through passages than ACL and PT cells because the MCL mounts a robust healing response unlike the ACL and PT. These differences in matrix expression would be dependent on passage because at earlier passages all cells would mostly be proliferating while at later passages they would tend to become senescent. Cells were isolated from the MCL, ACL, and PT of three rats and passaged a total of five times (Passage 1 to Passage 5). Using real time RT-PCR, expression of all genes of interest (Collagen Type I (ligament/tendon's main matrix constituent), Collagen Type III, Fibronectin, Metalloprotease-13 [MMP-13], and Tissue Inhibitor of Metallopreotease-1 [TIMP-1]) were quantitatively assessed. It was found that cell number for all three fibroblast types remained high from Passage 1 to Passage 5. There was a statistically significant increase in Collagen Type I of rat MCL fibroblasts throughout passage (p < 0.05). This was evident in the higher relative abundance (to GAPDH) at Passages 3 and 4 (14.5 +/- 2.2 fold and 15.3 +/- 6.9 fold, respectively) than at Passage 1 (3.3 +/- 2.6 fold) (p < 0.05). On the other hand, Collagen Type I expression for ACL and PT fibroblasts were lower than that of MCL fibroblasts and remained at 2.5 +/- 2.0 fold and 1.7 +/- 0.8 fold, respectively. Interestingly, the gene expressions of Collagen Type III, Fibronectin, MMP-13, and TIMP-1 for MCL, ACL, and PT fibroblasts were all relatively constant throughout passage and were not significantly different from one another. The findings of this study indicate that passage does affect the Collagen Type I gene expression of rat MCL fibroblasts and further show that for in vitro ligament tissue engineering efforts, MCL fibroblasts have a more robust potential for ligament remodeling and repair due to the increase in collagen gene expression. FAU - Almarza, Alejandro J AU - Almarza AJ AD - Musculoskeletal Research Center, 405 Center for Bioengineering, Department of Bioengineering, University of Pittsburgh, 300 Technology Drive, Pittsburgh, PA 15219, USA. FAU - Augustine, Serena M AU - Augustine SM FAU - Woo, Savio L-Y AU - Woo SL LA - eng GR - AR41820/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20080919 PL - United States TA - Ann Biomed Eng JT - Annals of biomedical engineering JID - 0361512 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fibronectins) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) SB - IM MH - Animals MH - Cells, Cultured MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Extracellular Matrix/*genetics/metabolism MH - Extracellular Matrix Proteins/*genetics/metabolism MH - Female MH - Fibroblasts/*metabolism MH - Fibronectins/genetics/metabolism MH - *Gene Expression MH - Ligaments/*metabolism MH - Matrix Metalloproteinase 13/genetics/metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Rats, Long-Evans MH - Tendons/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism EDAT- 2008/09/23 09:00 MHDA- 2009/01/07 09:00 CRDT- 2008/09/23 09:00 PHST- 2008/04/28 00:00 [received] PHST- 2008/09/05 00:00 [accepted] PHST- 2008/09/23 09:00 [pubmed] PHST- 2009/01/07 09:00 [medline] PHST- 2008/09/23 09:00 [entrez] AID - 10.1007/s10439-008-9565-1 [doi] PST - ppublish SO - Ann Biomed Eng. 2008 Dec;36(12):1927-33. doi: 10.1007/s10439-008-9565-1. Epub 2008 Sep 19. PMID- 25150176 OWN - NLM STAT- MEDLINE DCOM- 20150326 LR - 20211021 IS - 1462-0332 (Electronic) IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 54 IP - 2 DP - 2015 Feb TI - Dexamethasone decreases substance P expression in human tendon cells: an in vitro study. PG - 318-23 LID - 10.1093/rheumatology/keu315 [doi] AB - OBJECTIVE: Glucocorticoid injections are used by rheumatologists to treat chronic tendinopathy. Surprisingly, the mechanisms by which corticosteroids induce pain relief in this condition have not been investigated. Previous studies have shown local substance P (SP) levels to be correlated with tendon pain and tissue pathology. The objective of this study was to determine whether SP production in human tenocytes is modulated by exposure to dexamethasone. METHODS: Human tendon fibroblasts were cultured in the presence or absence of dexamethasone (1-400 nM), an inhibitor of the glucocorticoid receptor, RU486, recombinant TGF-β (2.5 or 5.0 ng/ml) or an inhibitor of the TGF-β receptor (A83.01), recombinant human IL-1β and IL-6. Expression levels of the genes encoding for SP (TAC1) and its preferred receptor (NK1R), IL-1α, IL-1β and IL-6 were determined with quantitative PCR and protein levels of SP were examined by EIA and western blot. RESULTS: Exposure of human tendon cells to dexamethasone resulted in a time-dependent reduction of mRNA for SP in both hamstrings and Achilles tenocytes, whereas NK1R was unaffected. The reduction of SP mRNA was dependent on signalling through the glucocorticoid receptor. SP protein was substantially decreased by dexamethasone. Dexamethasone also prevented induction of SP by IL-1β and by cyclic mechanical loading. CONCLUSION: This study demonstrates that dexamethasone treatment of human tendon fibroblasts reduces the expression of SP through a glucocorticoid receptor-dependent pathway. Drugs interfering with SP signalling could be a future target in the treatment of tendinopathy. CI - © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. FAU - Mousavizadeh, Rouhollah AU - Mousavizadeh R AD - Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Umeå University, Institute for Integrative Medical Biology, Section for Anatomy, Umeå, Sweden, Department of Orthopedic Surgery and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada. FAU - Backman, Ludvig AU - Backman L AD - Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Umeå University, Institute for Integrative Medical Biology, Section for Anatomy, Umeå, Sweden, Department of Orthopedic Surgery and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada. FAU - McCormack, Robert G AU - McCormack RG AD - Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Umeå University, Institute for Integrative Medical Biology, Section for Anatomy, Umeå, Sweden, Department of Orthopedic Surgery and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada. FAU - Scott, Alex AU - Scott A AD - Department of Medicine, University of British Columbia, Vancouver, BC, Canada, Umeå University, Institute for Integrative Medical Biology, Section for Anatomy, Umeå, Sweden, Department of Orthopedic Surgery and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada. ascott@interchange.ubc.ca. LA - eng GR - Canadian Institutes of Health Research/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140822 PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Glucocorticoids) RN - 0 (Receptors, Neurokinin-1) RN - 33507-63-0 (Substance P) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Achilles Tendon/metabolism MH - Adult MH - Cells, Cultured MH - Dexamethasone/*pharmacology MH - Down-Regulation MH - Female MH - Fibroblasts/metabolism MH - Gene Expression MH - Glucocorticoids/*pharmacology MH - Healthy Volunteers MH - Humans MH - In Vitro Techniques MH - Male MH - Receptors, Neurokinin-1/metabolism MH - Substance P/*metabolism MH - Tendons/*metabolism MH - Young Adult PMC - PMC4301709 OTO - NOTNLM OT - corticosteroids OT - inflammation OT - soft tissue rheumatology OT - tendinopathy EDAT- 2014/08/26 06:00 MHDA- 2015/03/27 06:00 PMCR- 2016/02/01 CRDT- 2014/08/24 06:00 PHST- 2014/08/24 06:00 [entrez] PHST- 2014/08/26 06:00 [pubmed] PHST- 2015/03/27 06:00 [medline] PHST- 2016/02/01 00:00 [pmc-release] AID - keu315 [pii] AID - 10.1093/rheumatology/keu315 [doi] PST - ppublish SO - Rheumatology (Oxford). 2015 Feb;54(2):318-23. doi: 10.1093/rheumatology/keu315. Epub 2014 Aug 22. PMID- 23404516 OWN - NLM STAT- MEDLINE DCOM- 20140220 LR - 20211021 IS - 1433-7347 (Electronic) IS - 0942-2056 (Linking) VI - 21 IP - 7 DP - 2013 Jul TI - Detection of slow-cycling and stem/progenitor cells in different regions of rat Achilles tendon: response to treadmill exercise. PG - 1694-703 LID - 10.1007/s00167-013-2446-7 [doi] AB - PURPOSE: Tendons generally exhibit poor healing capacity, probably due to slow cell regeneration potential and low vascularization. The potential to regenerate may partly be due to activation of stem/progenitor cells localized in the tendon or its vicinity. In the present study, we attempted to determine where in the rat Achilles tendon stem/progenitor cells reside and to investigate the effect of exercise on cell proliferation in the in vivo situation. METHOD: We used bromodeoxyuridine (BrdU) labelling to investigate proliferation and label-retaining cells (i.e. slow-cycling cells) in non-exercised and exercised rats, in combination with immunostaining of the stem cell marker nucleostemin. Rat Achilles tendons were harvested 14, 28, 56 and 105 days after BrdU administration. RESULTS: We found the proportion of stem/progenitor cells to be twice as high in the distal tendon (DT) compared with the mid/proximal tendon (MPT) and that paratenon/endotenon regions appear to host a pool of existing stem/progenitor cells. Exercise increased the BrdU-stained cell population after 14 days only (DT region p = 0.032, MPT p = 0.065), indicating effect mainly on more differentiated cells, since the nucleostemin-positive cells (i.e. stem/progenitor cells) remained unaffected in the intact Achilles tendon. CONCLUSION: Stem/progenitor cells exist in several areas of the rat Achilles tendon which implies a possible stem cell regeneration pool of different origins. The distal region has twice the amount of stem/progenitor cells compared with the mid/proximal region, indicating a potentially higher stem cell activity in this tissue. Daily moderate exercise (treadmill running) mainly improves in vivo cell proliferation in rapidly proliferating cells, whereas the stem/progenitor pool remains constant. FAU - Runesson, Eva AU - Runesson E AD - Department of Orthopaedics, Institute of Clinical Sciences, University of Göteborg, Göteborg, Sweden. eva.runesson@gu.se FAU - Ackermann, Paul AU - Ackermann P FAU - Brisby, Helena AU - Brisby H FAU - Karlsson, Jón AU - Karlsson J FAU - Eriksson, Bengt I AU - Eriksson BI LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130212 PL - Germany TA - Knee Surg Sports Traumatol Arthrosc JT - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JID - 9314730 RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Achilles Tendon/*cytology/*physiology MH - Animals MH - Bromodeoxyuridine MH - Cell Proliferation MH - Exercise Test MH - Female MH - Immunohistochemistry MH - Rats MH - Rats, Sprague-Dawley MH - Staining and Labeling MH - Stem Cells/*cytology/*physiology EDAT- 2013/02/14 06:00 MHDA- 2014/02/22 06:00 CRDT- 2013/02/14 06:00 PHST- 2012/11/22 00:00 [received] PHST- 2013/01/29 00:00 [accepted] PHST- 2013/02/14 06:00 [entrez] PHST- 2013/02/14 06:00 [pubmed] PHST- 2014/02/22 06:00 [medline] AID - 10.1007/s00167-013-2446-7 [doi] PST - ppublish SO - Knee Surg Sports Traumatol Arthrosc. 2013 Jul;21(7):1694-703. doi: 10.1007/s00167-013-2446-7. Epub 2013 Feb 12. PMID- 21437947 OWN - NLM STAT- MEDLINE DCOM- 20110526 LR - 20250529 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 29 IP - 5 DP - 2011 May TI - Sodium cromolyn reduces expression of CTGF, ADAMTS1, and TIMP3 and modulates post-injury patellar tendon morphology. PG - 678-83 LID - 10.1002/jor.21291 [doi] AB - The purpose of this study was to determine whether administration of a mast cell inhibitor (sodium cromolyn, SC) would influence tendon repair and extracellular matrix gene expression following acute injury. CD1 mouse patellar tendons were unilaterally injured and mast cell prevalence was determined. The effect of SC injection on tendon hypercellularity, cross-sectional area, collagen organization, and expression of extracellular matrix-related genes was examined. Mast cell prevalence was markedly increased in injured patellar tendons (p = 0.009), especially at 8 weeks post-injury (p = 0.025). SC injection increased collagen organization compared to uninjected animals at 4 weeks and attenuated the development of tendon hypercellularity and tendon thickening post-injury. Expression of CTGF, ADAMTS1, and TIMP3 in injured tendon was reduced in the SC group. SC injections moderated the structural alterations of healing tendon in association with downregulation of several genes associated with tendon fibrosis. This work corroborates previous findings pointing to a role of mast cells in tendon repair. CI - Copyright © 2010 Orthopaedic Research Society. FAU - Sharma, Aishwariya AU - Sharma A AD - Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, British Columbia, Canada. FAU - Abraham, Thomas AU - Abraham T FAU - Sampaio, Arthur AU - Sampaio A FAU - Cowan, Matthew AU - Cowan M FAU - Underhill, Michael AU - Underhill M FAU - Scott, Alexander AU - Scott A LA - eng GR - 84986-1/CAPMC/CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20101203 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (CCN2 protein, mouse) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - EC 3.4.24.- (ADAM Proteins) RN - EC 3.4.24.- (ADAMTS1 Protein) RN - EC 3.4.24.- (Adamts1 protein, mouse) RN - Q2WXR1I0PK (Cromolyn Sodium) SB - IM MH - ADAM Proteins/*biosynthesis MH - ADAMTS1 Protein MH - Animals MH - Connective Tissue Growth Factor/*biosynthesis MH - Cromolyn Sodium/*pharmacology MH - Mast Cells/physiology MH - Mice MH - Patellar Ligament/cytology/drug effects/injuries/*metabolism MH - Tissue Inhibitor of Metalloproteinase-3/*biosynthesis MH - Wound Healing/physiology PMC - PMC3951484 MID - CAMS4201 OID - NLM: CAMS4201 EDAT- 2011/03/26 06:00 MHDA- 2011/05/27 06:00 PMCR- 2014/03/13 CRDT- 2011/03/26 06:00 PHST- 2010/08/12 00:00 [received] PHST- 2010/10/04 00:00 [accepted] PHST- 2011/03/26 06:00 [entrez] PHST- 2011/03/26 06:00 [pubmed] PHST- 2011/05/27 06:00 [medline] PHST- 2014/03/13 00:00 [pmc-release] AID - 10.1002/jor.21291 [doi] PST - ppublish SO - J Orthop Res. 2011 May;29(5):678-83. doi: 10.1002/jor.21291. Epub 2010 Dec 3. PMID- 12462640 OWN - NLM STAT- MEDLINE DCOM- 20040120 LR - 20190818 IS - 0031-8655 (Print) IS - 0031-8655 (Linking) VI - 76 IP - 5 DP - 2002 Nov TI - Photoactivated coumaryl-diazopyruvate fluorescent label for amine functional groups of tissues containing type-I collagen. PG - 473-9 AB - The design, synthesis and application of a new fluorescent-labeling reagent for collagen has been developed as a prerequisite for the design of a photoactivated collagen-crosslinking compound for surgical wound closure. The amine groups in collagen are the targets of a rational design for a new fluorophore because natural collagen crosslinks are formed between primary (1(o)) amine groups of lysine and hydroxylysine. The availability of 1(o) amines for crosslinking in native collagenous tissues was evaluated by reacting tendon and corneal samples with o-phthalaldehyde and dansyl chloride, fluorophores commonly used for the detection of 1(o) and 2(o) amines. The resulting fluorescent collagen fibrils indicated the presence of amines in native tissue. Subsequently, a photoactivated fluorescent label for 1(o) and 2(o) amines, coumaryl gamma-amino-butyric acid diazopyruvate (CGDP), was designed and synthesized. CGDP was first used to photolabel poly-L-lysine, forming a fluorescent, covalent bond to the 1(o) amine. CGDP was then photoreacted with corneal and tendon tissue samples to produce CGDP fluorescent-labeled samples that were statistically significantly more fluorescent than were the controls. These experiments support the postulate that 1(o) or 2(o) (or both) amines in native collagenous tissues are available to serve as targets for photoactivated collagen crosslinkers for wound closure. FAU - Timberlake, George T AU - Timberlake GT AD - Department of Ophthalmology, University of Kansas Medical Center, Kansas City, KS 66160-7379, USA. gtimberl@kumc.edu FAU - Reddy, G Kesava AU - Reddy GK FAU - Stehno-Bittel, Lisa AU - Stehno-Bittel L FAU - Weber, Jörg F AU - Weber JF FAU - Amslinger, Sabine AU - Amslinger S FAU - Givens, Richard S AU - Givens RS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Photochem Photobiol JT - Photochemistry and photobiology JID - 0376425 RN - 0 (Amines) RN - 0 (Aminobutyrates) RN - 0 (Collagen Type I) RN - 0 (Coumarins) RN - 0 (Dansyl Compounds) RN - 0 (Fluorescent Dyes) RN - 0 (Pyruvates) RN - 0 (coumaryl gamma-amino-butyric acid diazopyruvate) RN - 25104-18-1 (Polylysine) RN - 643-79-8 (o-Phthalaldehyde) RN - QMU9166TJ4 (dansyl chloride) SB - IM MH - Amines/*chemistry MH - Aminobutyrates/chemistry MH - Animals MH - Chromatography, High Pressure Liquid MH - Collagen Type I/*chemistry MH - Cornea/*chemistry MH - Coumarins/chemistry MH - Dansyl Compounds/chemistry MH - Fluorescent Dyes/chemical synthesis/*chemistry MH - Male MH - Polylysine/chemistry MH - Pyruvates/chemistry MH - Rabbits MH - Tendons/*chemistry MH - o-Phthalaldehyde/chemistry EDAT- 2002/12/05 04:00 MHDA- 2004/01/21 05:00 CRDT- 2002/12/05 04:00 PHST- 2002/12/05 04:00 [pubmed] PHST- 2004/01/21 05:00 [medline] PHST- 2002/12/05 04:00 [entrez] AID - 10.1562/0031-8655(2002)076<0473:pcdflf>2.0.co;2 [doi] PST - ppublish SO - Photochem Photobiol. 2002 Nov;76(5):473-9. doi: 10.1562/0031-8655(2002)076<0473:pcdflf>2.0.co;2. PMID- 11301348 OWN - NLM STAT- MEDLINE DCOM- 20010607 LR - 20091119 IS - 0893-3952 (Print) IS - 0893-3952 (Linking) VI - 14 IP - 4 DP - 2001 Apr TI - Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath. PG - 318-24 AB - The expression of cysteine proteinases cathepsins B and K and of the endogenous inhibitor of cysteine proteinases, cystatin C, was investigated in tissue specimens of patients with giant cell tumor of tendon sheath (GCTTS). Expression of both enzymes was examined by immunohistochemistry in tissue specimens of 14 patients with GCTTS. Applying double-labeling techniques, the coexpression of cathepsin B and its major endogenous inhibitor cystatin C was additionally studied. Cells expressing the respective proteins were further characterized with the macrophage markers HAM56 and anti-CD68 (clone PG-M1). Cathepsin B could be detected in numerous HAM56-positive mononuclear cells (MC), but only in very few giant cells (GC). In contrast, cathepsin K was predominantly identified in GC that were also strongly immunoreactive for cystatin C and CD68. Coexpression of cathepsin B and cystatin C occurred only in a few MC. The strong expression of both cathepsin B and K suggests that in GCTTS, bone erosion might be mediated not only by pressure of the proliferative tissue, but also by matrix-degrading cysteine proteinases. Because previous studies showed that osteoclasts express high levels of CD68, cathepsin K, and cystatin C but not of cathepsin B, our study contributes to the view that GC of GCTTS and osteoclasts are closely associated. FAU - Hansen, T AU - Hansen T AD - Institute of Pathology, Johannes Gutenberg-University, Mainz, Germany. FAU - Petrow, P K AU - Petrow PK FAU - Gaumann, A AU - Gaumann A FAU - Keyszer, G M AU - Keyszer GM FAU - Otto, M AU - Otto M FAU - Kirkpatrick, C J AU - Kirkpatrick CJ FAU - Kriegsmann, J AU - Kriegsmann J LA - eng PT - Journal Article PL - United States TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, Myelomonocytic) RN - 0 (CD68 antigen, human) RN - 0 (CST3 protein, human) RN - 0 (Cystatin C) RN - 0 (Cystatins) RN - 0 (Cysteine Proteinase Inhibitors) RN - 0 (HAM-56 antibody) RN - EC 3.4.- (Cathepsins) RN - EC 3.4.22.1 (Cathepsin B) RN - EC 3.4.22.38 (CTSK protein, human) RN - EC 3.4.22.38 (Cathepsin K) SB - IM MH - Adult MH - Aged MH - Antibodies, Monoclonal/metabolism MH - Antigens, CD/metabolism MH - Antigens, Differentiation, Myelomonocytic/metabolism MH - Cathepsin B/*metabolism MH - Cathepsin K MH - Cathepsins/*metabolism MH - Cell Count MH - Cystatin C MH - Cystatins/*metabolism MH - Cysteine Proteinase Inhibitors/*metabolism MH - Female MH - Giant Cell Tumors/*enzymology/pathology MH - Giant Cells/enzymology/pathology MH - Humans MH - Immunoenzyme Techniques MH - Leukocytes, Mononuclear/enzymology/pathology MH - Male MH - Middle Aged MH - Muscle Neoplasms/*enzymology/pathology MH - Tendons/*pathology EDAT- 2001/04/13 10:00 MHDA- 2001/06/08 10:01 CRDT- 2001/04/13 10:00 PHST- 2001/04/13 10:00 [pubmed] PHST- 2001/06/08 10:01 [medline] PHST- 2001/04/13 10:00 [entrez] AID - 10.1038/modpathol.3880309 [doi] PST - ppublish SO - Mod Pathol. 2001 Apr;14(4):318-24. doi: 10.1038/modpathol.3880309. PMID- 1448499 OWN - NLM STAT- MEDLINE DCOM- 19921229 LR - 20190712 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 90 IP - 6 DP - 1992 Dec TI - The peripheral nerve allograft in the primate immunosuppressed with Cyclosporin A: II. Functional evaluation of reinnervated muscle. PG - 1047-52 AB - Isometric contractile function was evaluated in primates receiving peripheral nerve allografts and autografts. Twelve adult male cynomolgus monkeys received both sural nerve allografts and autografts to the ulnar nerve in opposite forearms. Half the animals received Cyclosporin A (CsA) immunosuppression (25 mg/kg per day); the remaining animals received placebo. One year following nerve engraftment, isometric contractile muscle function was evaluated in reinnervated abductor digiti quinti and intact abductor pollicis brevis muscles. Maximal twitch tension (Pt), tetanic tension (P(o)), time to peak tension (tpt), rate of rise of twitch tension (DP/dt), and muscle fatigue were evaluated at optimal muscle length (L(o)). All reinnervated muscles distal to nerve autografts and allografts in both Cyclosporin A-immunosuppressed and placebo-treated animals generated equivalent maximal twitch tension, tetanic tension, and time to peak tension, with no significant difference between groups (p > 0.05 by ANOVA). There was a tendency toward increased muscle fatiguability in Cyclosporin A-treated animals (p > 0.05). However, the rate of rise of twitch tension was significantly faster in the reinnervated and intact muscles of Cyclosporin A-treated primates (p < 0.05). Evidence of excellent functional reinnervation across nerve allografts and autografts similar to that seen in histologic and electrophysiologic studies was noted. Cyclosporin A immunosuppression did not significantly enhance recovery of muscle function distal to nerve allografts in this model. FAU - Fish, J S AU - Fish JS AD - Department of Surgery, University of Toronto, Ont., Canada. FAU - Bain, J R AU - Bain JR FAU - McKee, N AU - McKee N FAU - Mackinnon, S E AU - Mackinnon SE LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Placebos) RN - 83HN0GTJ6D (Cyclosporine) SB - IM MH - Animals MH - Cyclosporine/administration & dosage/*therapeutic use MH - Electromyography MH - Fatigue/physiopathology MH - Hand/*innervation/*physiology MH - *Immunocompromised Host MH - Isometric Contraction/*physiology MH - Macaca fascicularis MH - Male MH - Muscles/*innervation/*physiology MH - Placebos MH - Random Allocation MH - Reaction Time/physiology MH - Sural Nerve/physiopathology/*transplantation MH - Tendons/physiology MH - Transplantation, Autologous MH - Transplantation, Homologous EDAT- 1992/12/01 00:00 MHDA- 1992/12/01 00:01 CRDT- 1992/12/01 00:00 PHST- 1992/12/01 00:00 [pubmed] PHST- 1992/12/01 00:01 [medline] PHST- 1992/12/01 00:00 [entrez] AID - 10.1097/00006534-199212000-00016 [doi] PST - ppublish SO - Plast Reconstr Surg. 1992 Dec;90(6):1047-52. doi: 10.1097/00006534-199212000-00016. PMID- 20034766 OWN - NLM STAT- MEDLINE DCOM- 20100505 LR - 20171116 IS - 1872-7913 (Electronic) IS - 0924-8579 (Linking) VI - 35 IP - 4 DP - 2010 Apr TI - Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. PG - 366-74 LID - 10.1016/j.ijantimicag.2009.10.009 [doi] AB - Quinolones and glucocorticoids are frequently used drugs that may cause tendinopathy as a rare adverse effect. We exposed human tenocyte cultures to the steroid dexamethasone alone or in combination with either ciprofloxacin or levofloxacin at concentrations of 3mg/L and 10mg/L. At concentrations corresponding to peak levels in plasma and tissues during therapy (ca. 3-10mg/L), ciprofloxacin caused a significant decrease in collagen type I and the beta(1)-integrin receptor. In contrast, no corresponding effect was induced by 3mg/L levofloxacin. With both quinolones at 3mg/L and 10mg/L, the amount of matrix metalloproteinase-1 (MMP-1) and MMP-13 was increased. In addition, 3mg/L ciprofloxacin and 10mg/L levofloxacin activated caspase-3. Apoptotic changes were confirmed by electron microscopy. Incubation of human tenocytes with dexamethasone decreased the main matrix protein collagen type I, the transmembrane beta(1)-integrin receptor and the cytoskeleton protein vinculin, but only at the high concentrations tested (0.1 microM or 10 microM). Concentrations of 0.1 microM and 10 microM dexamethasone increased the amount of MMPs and activated caspase-3 as an indicator of apoptosis. Combined exposure to quinolones and dexamethasone led to more pronounced effects in tenocyte cultures at most of the analysed endpoints. The clinical observations of an increased risk of quinolone-induced tendinopathy by glucocorticoids are supported by these in vitro data. CI - (c) 2009. Published by Elsevier B.V. FAU - Sendzik, Judith AU - Sendzik J AD - Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Garystr. 5, 14195 Berlin, Germany. FAU - Shakibaei, Mehdi AU - Shakibaei M FAU - Schäfer-Korting, Monika AU - Schäfer-Korting M FAU - Lode, Hartmut AU - Lode H FAU - Stahlmann, Ralf AU - Stahlmann R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100119 PL - Netherlands TA - Int J Antimicrob Agents JT - International journal of antimicrobial agents JID - 9111860 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Collagen Type I) RN - 0 (Integrin beta1) RN - 0 (Quinolones) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Anti-Bacterial Agents/adverse effects/*toxicity MH - Anti-Inflammatory Agents/adverse effects/*toxicity MH - Apoptosis MH - Cell Line MH - Collagen Type I/biosynthesis MH - Dexamethasone/*toxicity MH - Down-Regulation MH - Humans MH - Integrin beta1/biosynthesis MH - Matrix Metalloproteinase 1/biosynthesis MH - Matrix Metalloproteinase 13/biosynthesis MH - Quinolones/*toxicity MH - Tendons/*drug effects MH - Up-Regulation EDAT- 2009/12/26 06:00 MHDA- 2010/05/06 06:00 CRDT- 2009/12/26 06:00 PHST- 2009/07/28 00:00 [received] PHST- 2009/09/21 00:00 [revised] PHST- 2009/10/06 00:00 [accepted] PHST- 2009/12/26 06:00 [entrez] PHST- 2009/12/26 06:00 [pubmed] PHST- 2010/05/06 06:00 [medline] AID - S0924-8579(09)00483-X [pii] AID - 10.1016/j.ijantimicag.2009.10.009 [doi] PST - ppublish SO - Int J Antimicrob Agents. 2010 Apr;35(4):366-74. doi: 10.1016/j.ijantimicag.2009.10.009. Epub 2010 Jan 19. PMID- 17055235 OWN - NLM STAT- MEDLINE DCOM- 20070531 LR - 20070115 IS - 0945-053X (Print) IS - 0945-053X (Linking) VI - 26 IP - 1 DP - 2007 Jan TI - The role of osteopontin in tendon tissue remodeling after denervation-induced mechanical stress deprivation. PG - 42-53 AB - It has been shown that musculoskeletal tissues undergo dynamic tissue remodeling by a process that is quite sensitive to the mechanical environment. However, the detailed molecular mechanism underlying this process remains unclear. We demonstrate here that after denervation-induced mechanical stress deprivation, tendons undergo dynamic tissue remodeling as evidenced by a significant reduction of the collagen fibril diameter. Importantly, the transient up-regulation of osteopontin (OPN) expression was characteristic during the early phase of tendon tissue remodeling. Following this dynamic change of OPN expression, matrix metalloproteinase (MMP)-13 expression was induced, which presumably accounts for the morphological changes of tendon by degrading tendon collagen fibrils. The modulation of MMP-13 expression by OPN was specific, since the expression of MMP-2, which is also known to be involved in tissue remodeling, did not alter in the tendons under the absence or presence of OPN. We also demonstrate that the modulation of MMP-13 expression by OPN is due to the signaling through cell surface receptors for OPN. Thus, we conclude that OPN plays a crucial role in conveying the effect of denervation-induced mechanical stress deprivation to the tendon fibroblasts to degrade the extracellular matrices by regulating MMP-13 expression in tendon fibroblasts. FAU - Mori, Noriaki AU - Mori N AD - Department of Orthopaedic Surgery, Hokkaido University School of Medicine, Sapporo, Japan. FAU - Majima, Tokifumi AU - Majima T FAU - Iwasaki, Norimasa AU - Iwasaki N FAU - Kon, Shigeyuki AU - Kon S FAU - Miyakawa, Kiyoshi AU - Miyakawa K FAU - Kimura, Chiemi AU - Kimura C FAU - Tanaka, Kunio AU - Tanaka K FAU - Denhardt, David T AU - Denhardt DT FAU - Rittling, Susan AU - Rittling S FAU - Minami, Akio AU - Minami A FAU - Uede, Toshimitsu AU - Uede T LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060915 PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Antibodies) RN - 0 (Integrin alphaVbeta3) RN - 0 (Oligopeptides) RN - 0 (glycyl-arginyl-glycyl-glutamyl-serine) RN - 106441-73-0 (Osteopontin) RN - 9007-34-5 (Collagen) RN - 96426-21-0 (glycyl-arginyl-glycyl-aspartyl-serine) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) SB - IM MH - Animals MH - Antibodies/pharmacology MH - Apoptosis/drug effects MH - Cells, Cultured MH - Collagen/*metabolism MH - Denervation MH - Extracellular Matrix/*metabolism MH - Femoral Nerve/surgery MH - Fibroblasts/cytology/drug effects/metabolism MH - Gene Expression/drug effects MH - Integrin alphaVbeta3/immunology MH - Kinetics MH - Male MH - Matrix Metalloproteinase 13/genetics MH - Mice MH - Mice, Inbred C57BL MH - Mice, Inbred Strains MH - Mice, Knockout MH - Oligopeptides/pharmacology MH - Osteopontin/genetics/pharmacology/*physiology MH - Patellar Ligament/innervation/*metabolism MH - Stress, Mechanical EDAT- 2006/10/24 09:00 MHDA- 2007/06/01 09:00 CRDT- 2006/10/24 09:00 PHST- 2006/04/07 00:00 [received] PHST- 2006/08/28 00:00 [revised] PHST- 2006/09/06 00:00 [accepted] PHST- 2006/10/24 09:00 [pubmed] PHST- 2007/06/01 09:00 [medline] PHST- 2006/10/24 09:00 [entrez] AID - S0945-053X(06)00371-4 [pii] AID - 10.1016/j.matbio.2006.09.002 [doi] PST - ppublish SO - Matrix Biol. 2007 Jan;26(1):42-53. doi: 10.1016/j.matbio.2006.09.002. Epub 2006 Sep 15. PMID- 11139398 OWN - NLM STAT- MEDLINE DCOM- 20010322 LR - 20211124 IS - 0264-6021 (Print) IS - 1470-8728 (Electronic) IS - 0264-6021 (Linking) VI - 353 IP - Pt 2 DP - 2001 Jan 15 TI - Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones. PG - 333-8 AB - Examples of a novel series of phenanthrolinones are shown to be potent competitive inhibitors of avian prolyl 4-hydroxylase, and of collagen hydroxylation, in embryonic chick tendon cells and human foreskin fibroblasts in vitro and in the oestradiol-stimulated rat uterus in vivo. Two compounds, Compound 1 (1,4-dihydrophenanthrolin-4-one-3-carboxylic acid) and Compound 5 [8-(N-butyl-N-ethylcarbamoyl)-1,4-dihydrophenathrolin-4-one-3-carboxylic acid], with comparable potencies in vivo, were chosen to investigate the effect of the inhibition of the hydroxylation of newly synthesized uterine collagen on the turnover of this protein in vivo. Inhibition of hydroxylation by more than 50% for approx. 8 h following single oral doses of the compounds was associated with significant losses of radiolabelled proline and 4-hydroxyproline from collagen during this period. Progressive hydroxylation of collagen over 48 h, as the inhibitory action of the compounds declined, was accompanied by a decreased loss of radiolabel from the uterine collagen. Earlier reports indicated that underhydroxylated collagen, accumulating within the endoplasmic reticulum in cells where prolyl 4-hydroxylase is inactivated, is slowly degraded, but is then rapidly hydroxylated and secreted when the activity of prolyl 4-hydroxylase is restored. Taken with the present results, this suggests that the potential use of inhibitors of prolyl 4-hydroxylase to control excessive collagen deposition in pathological fibrosis may be limited by the need to maintain continuous inhibition of collagen hydroxylation so as to facilitate intracellular degradation of the accumulated protein. FAU - Franklin, T J AU - Franklin TJ AD - Research Department, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K. trevorfranklin@compuserve.com FAU - Morris, W P AU - Morris WP FAU - Edwards, P N AU - Edwards PN FAU - Large, M S AU - Large MS FAU - Stephenson, R AU - Stephenson R LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Biochem J JT - The Biochemical journal JID - 2984726R RN - 0 (Enzyme Inhibitors) RN - 0 (Phenanthrolines) RN - 0 (Procollagen) RN - 9007-34-5 (Collagen) RN - EC 1.14.11.2 (Procollagen-Proline Dioxygenase) SB - IM MH - Animals MH - Cells, Cultured MH - Chick Embryo MH - Collagen/metabolism MH - Dose-Response Relationship, Drug MH - Enzyme Inhibitors/pharmacology MH - Female MH - Fibroblasts MH - Hydroxylation/drug effects MH - Molecular Structure MH - Phenanthrolines/*pharmacology MH - Procollagen/metabolism MH - Procollagen-Proline Dioxygenase/*antagonists & inhibitors MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/embryology MH - Time Factors MH - Uterus/drug effects/metabolism PMC - PMC1221576 EDAT- 2001/01/05 11:00 MHDA- 2001/03/27 10:01 PMCR- 2001/07/15 CRDT- 2001/01/05 11:00 PHST- 2001/01/05 11:00 [pubmed] PHST- 2001/03/27 10:01 [medline] PHST- 2001/01/05 11:00 [entrez] PHST- 2001/07/15 00:00 [pmc-release] AID - 10.1042/0264-6021:3530333 [doi] PST - ppublish SO - Biochem J. 2001 Jan 15;353(Pt 2):333-8. doi: 10.1042/0264-6021:3530333. PMID- 18192495 OWN - NLM STAT- MEDLINE DCOM- 20080522 LR - 20161124 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 36 IP - 4 DP - 2008 Apr TI - Absorption of dexamethasone sodium phosphate in human connective tissue using iontophoresis. PG - 753-9 LID - 10.1177/0363546507311597 [doi] AB - BACKGROUND: Iontophoresis ostensibly facilitates the delivery of medications through the skin to underlying tissues using a direct electrical current. Dexamethasone is the most commonly used medication with iontophoresis to treat a variety of connective tissue disorders. HYPOTHESIS: Iontophoresis will facilitate the absorption of dexamethasone into connective tissue compared with diffusion. STUDY DESIGN: Controlled laboratory study. METHODS: Twenty-nine adults undergoing anterior cruciate ligament reconstructive surgery using the semitendinosus/gracilis autograft were randomly assigned to either a true iontophoresis (TI) or sham iontophoresis (SI). In the TI group, a 40-mA/min dose of iontophoresis using a 0.4% (4 mg/mL) solution of dexamethasone was used targeting the semitendinosus tendon just before surgery. The SI group underwent the same treatment, but the machine was not turned on. Tissue was extracted within 4 hours of treatment and analyzed for dexamethasone. In addition, 2 control samples were sent to the laboratory for analysis. RESULTS: There was a statistically significant difference in dexamethasone concentrations between the groups (P = .0216). Of the 16 samples in the TI group, 8 had measurable amounts of dexamethasone, with an average concentration of 2.906 ng/g of tendon tissue. In the SI group, 1 of the 13 samples had measurable amounts of dexamethasone with an average concentration of 0.205 ng/g of tendon tissue. The control samples contained no dexamethasone. CONCLUSION: Iontophoresis facilitates the transmission of dexamethasone to connective tissues in humans. CLINICAL RELEVANCE: Iontophoresis can deliver dexamethasone to connective tissues in humans. FAU - Gurney, A Burke AU - Gurney AB AD - University of New Mexico School of Medicine, Department of Orthopaedics and Rehabilitation, Albuquerque, New Mexico, USA. bgurney@salud.unm.edu FAU - Wascher, Daniel C AU - Wascher DC LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20080111 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents) RN - 2BP70L44PR (dexamethasone 21-phosphate) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Adult MH - Anterior Cruciate Ligament/surgery MH - Anti-Inflammatory Agents/*administration & dosage/metabolism MH - Connective Tissue/*physiology MH - Dexamethasone/administration & dosage/*analogs & derivatives/metabolism MH - Humans MH - *Iontophoresis/instrumentation MH - New Mexico MH - *Skin Absorption MH - Tendons/transplantation EDAT- 2008/01/15 09:00 MHDA- 2008/05/23 09:00 CRDT- 2008/01/15 09:00 PHST- 2008/01/15 09:00 [pubmed] PHST- 2008/05/23 09:00 [medline] PHST- 2008/01/15 09:00 [entrez] AID - 0363546507311597 [pii] AID - 10.1177/0363546507311597 [doi] PST - ppublish SO - Am J Sports Med. 2008 Apr;36(4):753-9. doi: 10.1177/0363546507311597. Epub 2008 Jan 11. PMID- 9778217 OWN - NLM STAT- MEDLINE DCOM- 19981103 LR - 20061115 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 41 IP - 10 DP - 1998 Oct TI - The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. PG - 1760-71 AB - OBJECTIVE: To study the interaction of interleukin-1alpha (IL-1alpha) and oncostatin M (OSM) in promoting cartilage collagen destruction. METHODS: Bovine, porcine, and human cartilage and human chondrocytes were studied in culture. The levels of collagenase (matrix metalloproteinase 1 [MMP-1]) and tissue inhibitor of metalloproteinases 1 (TIMP-1) were measured by bioassay and enzyme-linked immunosorbent assay (ELISA). The levels of OSM in rheumatoid synovial fluid were measured by ELISA. RESULTS: When combined with OSM, IL-1alpha, IL-1beta, and tumor necrosis factor alpha released proteoglycan and collagen from cartilage. OSM was the only member of the IL-6 family to have this effect. Human tendon also responded to IL-1alpha and OSM. OSM increased the production of MMP-1 and TIMP-1 but when combined with IL-1alpha, synergistically promoted MMP-1 production in human chondrocytes and synovial fibroblasts. High levels of OSM were found in human rheumatoid synovial fluids, and confocal microscopy showed that OSM was produced by macrophages in rheumatoid synovial tissue. CONCLUSION: These results highlight an important new mechanism by which there is irreversible loss of collagen from cartilage. FAU - Cawston, T E AU - Cawston TE AD - University of Newcastle, Newcastle Upon Tyne, UK. FAU - Curry, V A AU - Curry VA FAU - Summers, C A AU - Summers CA FAU - Clark, I M AU - Clark IM FAU - Riley, G P AU - Riley GP FAU - Life, P F AU - Life PF FAU - Spaull, J R AU - Spaull JR FAU - Goldring, M B AU - Goldring MB FAU - Koshy, P J AU - Koshy PJ FAU - Rowan, A D AU - Rowan AD FAU - Shingleton, W D AU - Shingleton WD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Cytokines) RN - 0 (Growth Inhibitors) RN - 0 (Interleukin-1) RN - 0 (Interleukin-6) RN - 0 (OSM protein, human) RN - 0 (Peptides) RN - 106956-32-5 (Oncostatin M) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Animals MH - Arthritis, Rheumatoid/*metabolism MH - Blotting, Northern MH - Blotting, Western MH - Cartilage, Articular/drug effects/enzymology/metabolism MH - Cattle MH - Chondrocytes/drug effects MH - Collagen/*metabolism MH - Collagenases/metabolism MH - Connective Tissue/*chemistry MH - Cytokines/metabolism MH - Growth Inhibitors/*physiology MH - Humans MH - Interleukin-1/pharmacology MH - Interleukin-6/pharmacology MH - Knee Joint/chemistry MH - Microscopy, Confocal MH - Oncostatin M MH - Osteoarthritis/metabolism MH - Peptides/*physiology MH - Phenotype MH - Swine MH - Synovial Fluid/chemistry MH - Synovial Membrane/chemistry/metabolism MH - Tendons/drug effects EDAT- 1998/10/20 00:00 MHDA- 1998/10/20 00:01 CRDT- 1998/10/20 00:00 PHST- 1998/10/20 00:00 [pubmed] PHST- 1998/10/20 00:01 [medline] PHST- 1998/10/20 00:00 [entrez] AID - 10.1002/1529-0131(199810)41:10<1760::AID-ART8>3.0.CO;2-M [doi] PST - ppublish SO - Arthritis Rheum. 1998 Oct;41(10):1760-71. doi: 10.1002/1529-0131(199810)41:10<1760::AID-ART8>3.0.CO;2-M. PMID- 14620536 OWN - NLM STAT- MEDLINE DCOM- 20040621 LR - 20061115 IS - 0940-2993 (Print) IS - 0940-2993 (Linking) VI - 55 IP - 2-3 DP - 2003 Sep TI - Modulation of cell functions of human tendon fibroblasts by different repetitive cyclic mechanical stress patterns. PG - 153-8 AB - Mechanical stress is a factor that is thought to play an essential role in tissue generation and reparation processes. The aim of the present study was to investigate the influence of different repetitive cyclic longitudinal stress patterns on proliferation, apoptosis and expression of heat shock protein (HSP) 72. To perform this study, human tendon fibroblasts were seeded on flexible silicone dishes. After adherence to the dish, cells were longitudinally stressed with three different repetitive stress patterns having a frequency of 1 Hz and an amplitude of 5%. The proliferation and apoptosis rates were investigated 0, 6, 12 and 24 hours after application of cyclic mechanical longitudinal strain. Expression of HSP 72 was tested after 0, 2, 4 and 8 hours. Control cells were also grown on silicone dishes, but did not receive any stress. Stress patterns applied during one day resulted in a significant increase in proliferation and a slight increase in apoptosis. HSP 72 expression was rather unchanged. A stress pattern applied during two days resulted in a reduced proliferation and apoptosis rate whereas the expression of HSP 72 showed a significant increase. This study shows that different stress patterns result in different cellular reactions dependent on the strength of applied stress. Repetitive stress applied during one day stimulated proliferation and apoptosis in contrast to an extended stress duration. The latter induced an inhibition of proliferation and apoptosis probably through an increased HSP 72 activity. This may be related to an excess of applied stress. Our results may implicate future modulation techniques for tissue reparation and tissue engineering. FAU - Barkhausen, Tanja AU - Barkhausen T AD - Department of Trauma Surgery, Hannover Medical School, Hannover, Germany. Barkhausen.Tanja@MH-Hannover.de FAU - van Griensven, Martijn AU - van Griensven M FAU - Zeichen, Johannes AU - Zeichen J FAU - Bosch, Ulrich AU - Bosch U LA - eng PT - Journal Article PL - Germany TA - Exp Toxicol Pathol JT - Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie JID - 9208920 RN - 0 (Annexin A5) RN - 0 (HSP72 Heat-Shock Proteins) RN - 0 (Heat-Shock Proteins) SB - IM MH - Annexin A5/analysis MH - Apoptosis/*physiology MH - Blotting, Western MH - Cell Division/physiology MH - Cells, Cultured MH - Fibroblasts/cytology/*physiology MH - HSP72 Heat-Shock Proteins MH - Heat-Shock Proteins/*metabolism MH - Humans MH - Patella MH - Stress, Mechanical MH - Tendons/*cytology EDAT- 2003/11/19 05:00 MHDA- 2004/06/23 05:00 CRDT- 2003/11/19 05:00 PHST- 2003/11/19 05:00 [pubmed] PHST- 2004/06/23 05:00 [medline] PHST- 2003/11/19 05:00 [entrez] AID - S0940-2993(04)70154-2 [pii] AID - 10.1078/0940-2993-00302 [doi] PST - ppublish SO - Exp Toxicol Pathol. 2003 Sep;55(2-3):153-8. doi: 10.1078/0940-2993-00302. PMID- 24176264 OWN - NLM STAT- MEDLINE DCOM- 20140723 LR - 20221207 IS - 1532-2963 (Electronic) IS - 0958-2592 (Linking) VI - 23 IP - 4 DP - 2013 Dec TI - Calcanectomy: avoiding major amputation in the presence of calcaneal osteomyelitis-A case series. PG - 130-5 LID - S0958-2592(13)00033-3 [pii] LID - 10.1016/j.foot.2013.09.002 [doi] AB - BACKGROUND: Calcaneal osteomyelitis is a surgical diagnosis that may be treated by local, resection or major amputation. OBJECTIVE: To determine the effectiveness of calcanectomy for treating calcaneal osteomyelitis. METHOD: We conducted a retrospective review of patients receiving calcanectomy between 1st April 2005 and 1st October 2011 for calcaneal osteomyelitis. We reviewed these cases to determine healing, rate, microbiological analysis, length of stay, limb salvage rate and survival rate. RESULTS: There were 10 patients included in this review. There were 7 with diabetes and 3 without. Mean age of group with diabetes was 64 years, of this group 5/7 healed at a mean of 64 days. Mean length of stay for this group was 49.3 ± 39.4 days. 2 patients required a transtibial amputation. Mean age of group without diabetes was 77 years, healing at a mean of 19 days. Mean length of stay for this group was 14 ± 16.8 days and all survived over 3 years. Microbiological analysis of suspected osteomyelitic bone typically isolated >4 organisms. CONCLUSIONS: Calcanectomy is a useful procedure for limb salvage. It may reduce morbidity rates for people with calcaneal osteomyelitis, those with diabetes can expect prolonged wound healing and longer length of stay. CI - Copyright © 2013 Elsevier Ltd. All rights reserved. FAU - Walsh, Tom P AU - Walsh TP AD - Department of Trauma and Orthopaedics, Great Western Hospitals, NHS Foundation Trust, Great Western Hospital, Marlborough Road, Swindon, United Kingdom. Electronic address: tom.walsh@health.sa.gov.au. FAU - Yates, Ben J AU - Yates BJ LA - eng PT - Journal Article DEP - 20131010 PL - Scotland TA - Foot (Edinb) JT - Foot (Edinburgh, Scotland) JID - 9109564 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) RN - 0 (Hemostatics) RN - VZ8RRZ51VK (Tobramycin) RN - WAT0DDB505 (Calcium Sulfate) SB - IM MH - Aged MH - Aged, 80 and over MH - Amputation, Surgical/statistics & numerical data MH - Anti-Bacterial Agents/therapeutic use MH - Calcaneus/microbiology/*surgery MH - Calcium Sulfate MH - Debridement MH - Diabetic Foot/surgery MH - Gentamicins/therapeutic use MH - Hemostatics/therapeutic use MH - Humans MH - Length of Stay/statistics & numerical data MH - Limb Salvage/*methods MH - Middle Aged MH - Osteomyelitis/drug therapy/microbiology/*surgery MH - Retrospective Studies MH - Tendons/surgery MH - Tobramycin/therapeutic use MH - Wound Healing OTO - NOTNLM OT - Calcanectomy OT - Calcaneus OT - Diabetes OT - Osteomyelitis OT - Ulceration EDAT- 2013/11/02 06:00 MHDA- 2014/07/24 06:00 CRDT- 2013/11/02 06:00 PHST- 2013/07/09 00:00 [received] PHST- 2013/09/10 00:00 [revised] PHST- 2013/09/29 00:00 [accepted] PHST- 2013/11/02 06:00 [entrez] PHST- 2013/11/02 06:00 [pubmed] PHST- 2014/07/24 06:00 [medline] AID - S0958-2592(13)00033-3 [pii] AID - 10.1016/j.foot.2013.09.002 [doi] PST - ppublish SO - Foot (Edinb). 2013 Dec;23(4):130-5. doi: 10.1016/j.foot.2013.09.002. Epub 2013 Oct 10. PMID- 17950228 OWN - NLM STAT- MEDLINE DCOM- 20080122 LR - 20171116 IS - 1753-1934 (Print) IS - 0266-7681 (Linking) VI - 32 IP - 5 DP - 2007 Oct TI - The inflammatory response and hyaluronan synthases in the rabbit flexor tendon and tendon sheath following injury. PG - 581-7 AB - Using a rabbit model of flexor tendon injury, mRNA levels for a subset of relevant molecules involved in inflammatory and fibrotic processes were assessed by reverse transcriptase-polymerase chain reaction 3, 6, 12 and 24 days after injury. Increased levels of COX-2, IL-1beta, MMP-13 and TIMP-1 mRNA were detected in both tendon and tendon sheath following injury, with each molecule exhibiting tissue and time-dependent changes. MMP-13 and TIMP-1 mRNA levels were markedly upregulated in both tissues, whereas COX-2 and IL-1beta predominantly increased in tendon. Both hyaluronan synthase (HAS) 2 and 3 exhibited increases in mRNA levels in tendon tissue after injury, HAS 2 being more pronounced. These findings support the concept that healing in the flexor tendon and the sheath involve different molecular events and that each tissue may require unique modifications if healing is to be enhanced and adhesions reduced. FAU - Berglund, M AU - Berglund M AD - Department of Hand Surgery, Uppsala University Hospital, Uppsala, Sweden. FAU - Hart, D A AU - Hart DA FAU - Wiig, M AU - Wiig M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070806 PL - England TA - J Hand Surg Eur Vol JT - The Journal of hand surgery, European volume JID - 101315820 RN - 0 (Inflammation Mediators) RN - 0 (Interleukin-1beta) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 0 (Tumor Necrosis Factor-alpha) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.99.1 (Cyclooxygenase 2) RN - EC 2.4.1.17 (Glucuronosyltransferase) RN - EC 2.4.1.212 (Hyaluronan Synthases) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) SB - IM MH - Animals MH - Cyclooxygenase 2/genetics MH - Female MH - Gene Expression/physiology MH - Glucuronosyltransferase/*genetics MH - Hyaluronan Synthases MH - Inflammation Mediators/*metabolism MH - Interleukin-1beta/genetics MH - Matrix Metalloproteinase 13/genetics MH - Nitric Oxide Synthase Type II/genetics MH - RNA, Messenger/genetics MH - Rabbits MH - Reverse Transcriptase Polymerase Chain Reaction MH - Tendon Injuries/*genetics MH - Tendons/metabolism MH - Tissue Inhibitor of Metalloproteinases/genetics MH - Tumor Necrosis Factor-alpha/genetics EDAT- 2007/10/24 09:00 MHDA- 2008/01/23 09:00 CRDT- 2007/10/24 09:00 PHST- 2006/06/26 00:00 [received] PHST- 2007/05/16 00:00 [revised] PHST- 2007/05/30 00:00 [accepted] PHST- 2007/10/24 09:00 [pubmed] PHST- 2008/01/23 09:00 [medline] PHST- 2007/10/24 09:00 [entrez] AID - S1753-1934(07)00417-7 [pii] AID - 10.1016/J.JHSE.2007.05.017 [doi] PST - ppublish SO - J Hand Surg Eur Vol. 2007 Oct;32(5):581-7. doi: 10.1016/J.JHSE.2007.05.017. Epub 2007 Aug 6. PMID- 8652078 OWN - NLM STAT- MEDLINE DCOM- 19960730 LR - 20181113 IS - 0114-5916 (Print) IS - 0114-5916 (Linking) VI - 13 IP - 6 DP - 1995 Dec TI - A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects. PG - 338-42 AB - The experience of the rheumatological adverse effects of fluoroquinolones should be helpful for both toxicologists and epidemiologists. In the case of fluoroquinolone-related arthropathy, the paediatric clinical experience seems to support the possible use of newer derivatives like ciprofloxacin in children who really need it. This therapeutic attitude is still contradictory to the labelling of fluoroquinolones. Inversely, there has been an important time-lag between the first reports of fluoroquinolone-related tendinopathies and the official recognition of this unusual toxic phenomenon. This delay, along with the widespread use of fluoroquinolones, makes it difficult to return to more reasonable prescribing guidelines for these very useful and effective anti-microbial compounds. The reasons why potentially serious adverse effects of fluoroquinolones were not anticipated before their commercialisation may be related to the lack of adequate in vitro and in vivo models, and the unexpectedness of the events. When it occurs, fluoroquinolone-induced arthropathy is most frequently benign, and heals without sequelae. The prognosis is not so favourable in the case of fluoroquinolone-related tendinopathy, which carries an important risk of immediate or secondary tendon rupture. Increasingly, fluoroquinolones are being prescribed for benign infections of the urinary or bronchopulmonary tracts. Sometimes, they are even used for antimicrobial prophylaxis before surgical or endoscopic procedures. We believe that for any prescription, the risk/benefit ratio of the fluoroquinolones should be carefully considered, since better tolerated, less expensive drugs can usually be prescribed. Clear information dedicated both to physicians and patients regarding the cautions for use and possible adverse effects of fluoroquinolones would help reduce the risk and severity of adverse reactions. This is especially important for phototoxicity, tendinopathy and cardiovascular adverse effects. As underlined by Ball and Tillotson in this issue, the future clinical use of the fluoroquinolones will be determined by the balance between the antibacterial efficacy and adverse effects of these agents. The adverse reactions affecting the musculoskeletal system provide a good example of this dilemma. Given the absence of an adequate model of tendinopathy and the poor predictivity of animal manifestations in arthropathy and cartilage lesions in humans, careful monitoring of patients during phase II and III trials and, more importantly, long term pharmacovigilance during the postmarketing period, are still strongly warranted. FAU - Hayem, G AU - Hayem G AD - Clinique de Rhumatologie, CHU Bichat-Claude Bernard, Paris, France. FAU - Carbon, C AU - Carbon C LA - eng PT - Journal Article PL - New Zealand TA - Drug Saf JT - Drug safety JID - 9002928 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Age Factors MH - Anti-Infective Agents/*adverse effects MH - Arthropathy, Neurogenic/*chemically induced MH - Fluoroquinolones MH - Muscular Diseases/classification MH - Tendons/drug effects EDAT- 1995/12/01 00:00 MHDA- 1995/12/01 00:01 CRDT- 1995/12/01 00:00 PHST- 1995/12/01 00:00 [pubmed] PHST- 1995/12/01 00:01 [medline] PHST- 1995/12/01 00:00 [entrez] AID - 10.2165/00002018-199513060-00003 [doi] PST - ppublish SO - Drug Saf. 1995 Dec;13(6):338-42. doi: 10.2165/00002018-199513060-00003. PMID- 19005916 OWN - NLM STAT- MEDLINE DCOM- 20090210 LR - 20090909 IS - 0963-8288 (Print) IS - 0963-8288 (Linking) VI - 30 IP - 20-22 DP - 2008 TI - Oxygen species and overuse tendinopathy in athletes. PG - 1563-71 LID - 10.1080/09638280701785643 [doi] AB - PURPOSE: To review the current concepts on tendon damage and reactive oxygen species (ROS). We suggest that tendons are subject to reactive oxygen generated both within the vicinity of the tendon and from the tenocytes themselves. METHOD: A literature search was conducted to trace relevant literature on tendon damage and ROS. RESULTS: Tendinopathies have a complex aetiology. Tendon physiology and structure may preclude ROS involvement in various aspects of the predisposition to and participation in a failed healing response process and subsequent response to injury. However, given the ubiquitous nature of ROS production and their now accepted involvement in signal transduction, such highly active chemicals may influence signal transduction in the tendon. Therefore, the tendon is continually exposed to ROS during normal and athletic exercise which, in combination with lifestyle and possibly hereditary factors, may influence tendon integrity and orchestrate tendon repair. CONCLUSIONS: The production of ROS by tenocytes may be a response to hyperthermia and to repetitive ischaemia/reperfusion, and may influence the development of tendinopathies. FAU - Longo, Umile Giuseppe AU - Longo UG AD - Department of Orthopaedic and Trauma Surgery, Campus Biomedico University, Via Longoni, Rome, Italy. FAU - Oliva, Francesco AU - Oliva F FAU - Denaro, Vincenzo AU - Denaro V FAU - Maffulli, Nicola AU - Maffulli N LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Disabil Rehabil JT - Disability and rehabilitation JID - 9207179 RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) SB - IM EIN - Disabil Rehabil. 2009;31(9):772. Olivia, Francesco [corrected to Oliva, Francesco] MH - Adaptation, Physiological MH - Antioxidants/physiology MH - Athletic Injuries/*metabolism/*physiopathology MH - Connective Tissue/metabolism MH - Humans MH - Oxidative Stress/physiology MH - Reactive Oxygen Species/*metabolism MH - Tendinopathy/*metabolism/*physiopathology MH - Tendon Injuries/metabolism/physiopathology MH - Wound Healing/physiology RF - 103 EDAT- 2008/11/14 09:00 MHDA- 2009/02/12 09:00 CRDT- 2008/11/14 09:00 PHST- 2008/11/14 09:00 [pubmed] PHST- 2009/02/12 09:00 [medline] PHST- 2008/11/14 09:00 [entrez] AID - 905458193 [pii] AID - 10.1080/09638280701785643 [doi] PST - ppublish SO - Disabil Rehabil. 2008;30(20-22):1563-71. doi: 10.1080/09638280701785643. PMID- 36201096 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230805 IS - 1970-9366 (Electronic) IS - 1828-0447 (Print) IS - 1828-0447 (Linking) VI - 18 IP - 1 DP - 2023 Jan TI - Short-term evolocumab-induced tendon xanthomas regression in an elderly patient with homozygous familial hypercholesterolemia. PG - 307-310 LID - 10.1007/s11739-022-03106-6 [doi] FAU - Cicero, Arrigo F G AU - Cicero AFG AD - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. arrigo.cicero@unibo.it. AD - Hypertension and Cardiovascular Risk Factors Research Center, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi University Hospital, 40138, Bologna, Italy. arrigo.cicero@unibo.it. AD - Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy. arrigo.cicero@unibo.it. FAU - Fogacci, Federica AU - Fogacci F AUID- ORCID: 0000-0001-7853-0042 AD - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Hypertension and Cardiovascular Risk Factors Research Center, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi University Hospital, 40138, Bologna, Italy. AD - Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Bragagni, Alessio AU - Bragagni A AD - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy. FAU - Borghi, Claudio AU - Borghi C AD - IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. AD - Hypertension and Cardiovascular Risk Factors Research Center, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi University Hospital, 40138, Bologna, Italy. AD - Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy. LA - eng PT - Journal Article DEP - 20221006 PL - Italy TA - Intern Emerg Med JT - Internal and emergency medicine JID - 101263418 RN - LKC0U3A8NJ (evolocumab) RN - 0 (Antibodies, Monoclonal, Humanized) SB - IM MH - Humans MH - Aged MH - *Homozygous Familial Hypercholesterolemia MH - Antibodies, Monoclonal, Humanized/adverse effects MH - *Xanthomatosis/drug therapy/etiology MH - Tendons PMC - PMC9883366 COIS- The authors declare that they have no conflict of interest. EDAT- 2022/10/07 06:00 MHDA- 2023/02/01 06:00 PMCR- 2022/10/06 CRDT- 2022/10/06 11:16 PHST- 2022/08/24 00:00 [received] PHST- 2022/09/15 00:00 [accepted] PHST- 2022/10/07 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2022/10/06 11:16 [entrez] PHST- 2022/10/06 00:00 [pmc-release] AID - 10.1007/s11739-022-03106-6 [pii] AID - 3106 [pii] AID - 10.1007/s11739-022-03106-6 [doi] PST - ppublish SO - Intern Emerg Med. 2023 Jan;18(1):307-310. doi: 10.1007/s11739-022-03106-6. Epub 2022 Oct 6. PMID- 23809450 OWN - NLM STAT- MEDLINE DCOM- 20131223 LR - 20220318 IS - 1526-3231 (Electronic) IS - 0749-8063 (Linking) VI - 29 IP - 7 DP - 2013 Jul TI - The effect of ketorolac tromethamine, methylprednisolone, and platelet-rich plasma on human chondrocyte and tenocyte viability. PG - 1164-74 LID - S0749-8063(13)00347-2 [pii] LID - 10.1016/j.arthro.2013.04.006 [doi] AB - PURPOSE: The purpose of this study was to evaluate the effect on cell viability of the isolated and combined use of allogeneic platelet-rich plasma (PRP) and ketorolac tromethamine on human chondrocytes and tenocytes in a highly controlled in vitro environment. METHODS: PRP was produced from 8 subjects. Human chondrocytes (Lonza, Hopkinton, MA) and tenocytes isolated from samples of the long head of the biceps tendons were treated in culture with PRP, ketorolac tromethamine, and methylprednisolone, both alone and in combination. Control samples were treated in media containing 2% or 10% fetal bovine serum (FBS). Cells were exposed for 1 hour. Luminescence assays were obtained to examine cell viability after 24 hours and long-term effects on cell viability after 120 hours. Radioactive thymidine assay was used to measure proliferation after 120 hours. RESULTS: For chondrocytes, cell viability (120 hours) increased significantly with the treatment of PRP alone (43,949 ± 28,104 cells; P < .001) and with the combination of ketorolac tromethamine and PRP (43,276 ± 31,208; P < .001), compared with the 2% FBS group (7,397 ± 470). Cell viability decreased significantly after exposure to methylprednisolone (1,323 ± 776; P < .001) and its combination with PRP (4,381 ± 5,116; p < .001). For tenocytes, cell viability (120 hours) was significantly higher with the treatment of PRP (61,287 ± 23,273; P < .001) and the combined treatment of ketorolac tromethamine and PRP (52,025 ± 17,307; P < .001), compared with the 2% FBS group (23,042 ± 2,973). Cell viability decreased significantly after exposure to methylprednisolone (3,934 ± 1,791; P = .001) and its combination with PRP (5,201 ± 2,834; P = .003), compared with 2% FBS. CONCLUSIONS: Tendon and cartilage cells showed increased cell viability after an exposure to allogeneic PRP and ketorolac tromethamine. Exposure to methylprednisolone alone decreased cell viability, and addition of PRP could partially reverse this negative effect. CLINICAL RELEVANCE: Intra-articular injections of pain-modifying or anti-inflammatory drugs are routinely given in orthopaedic practice. Among the many agents available for intra-articular injection, corticosteroids and local anesthetics are the most common in clinical practice. Potential detrimental side effects of intra-articular injections of corticosteroids and local anesthetics have prompted investigation into alternative treatment options such as combinations of PRP and ketorolac tromethamine. In vitro evaluation of their effect on cell viability might build a basis for further translational research and clinical application. CI - Copyright © 2013 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved. FAU - Beitzel, Knut AU - Beitzel K AD - Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT 06034, USA. FAU - McCarthy, Mary Beth AU - McCarthy MB FAU - Cote, Mark P AU - Cote MP FAU - Apostolakos, John AU - Apostolakos J FAU - Russell, Ryan P AU - Russell RP FAU - Bradley, James AU - Bradley J FAU - ElAttrache, Neal S AU - ElAttrache NS FAU - Romeo, Antony A AU - Romeo AA FAU - Arciero, Robert A AU - Arciero RA FAU - Mazzocca, Augustus D AU - Mazzocca AD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthroscopy JT - Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association JID - 8506498 RN - 0 (Adrenal Cortex Hormones) RN - 0 (Anesthetics, Local) RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 4EVE5946BQ (Ketorolac Tromethamine) RN - X4W7ZR7023 (Methylprednisolone) SB - IM MH - Adrenal Cortex Hormones/*pharmacology MH - Adult MH - Anesthetics, Local/pharmacology MH - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology MH - Cell Survival/drug effects MH - Cells, Cultured MH - Chondrocytes/*drug effects/physiology MH - Female MH - Humans MH - Ketorolac Tromethamine/*pharmacology MH - Male MH - Methylprednisolone/*pharmacology MH - *Platelet-Rich Plasma MH - Tendons/*cytology MH - Time Factors EDAT- 2013/07/03 06:00 MHDA- 2013/12/24 06:00 CRDT- 2013/07/02 06:00 PHST- 2011/10/07 00:00 [received] PHST- 2013/04/04 00:00 [revised] PHST- 2013/04/12 00:00 [accepted] PHST- 2013/07/02 06:00 [entrez] PHST- 2013/07/03 06:00 [pubmed] PHST- 2013/12/24 06:00 [medline] AID - S0749-8063(13)00347-2 [pii] AID - 10.1016/j.arthro.2013.04.006 [doi] PST - ppublish SO - Arthroscopy. 2013 Jul;29(7):1164-74. doi: 10.1016/j.arthro.2013.04.006. PMID- 24451112 OWN - NLM STAT- MEDLINE DCOM- 20140926 LR - 20181202 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 42 IP - 3 DP - 2014 Mar TI - Application of tendon-derived stem cell sheet for the promotion of graft healing in anterior cruciate ligament reconstruction. PG - 681-9 LID - 10.1177/0363546513517539 [doi] AB - BACKGROUND: Both osteointegration and remodeling of graft midsubstance (collectively called graft healing) are slow processes after anterior cruciate ligament (ACL) reconstruction. Tendon-derived stem cells (TDSCs) form a cell sheet after treatment with connective tissue growth factor (CTGF) and ascorbic acid, which exhibits higher tenogenic and maintains high chondro-osteogenic gene expression of TDSCs. No external scaffold is required for cell delivery. HYPOTHESIS: Wrapping the TDSC sheet around the ACL graft would promote early graft healing in a rat model. STUDY DESIGN: Controlled laboratory study. METHODS: Green fluorescent protein (GFP) rat TDSCs were treated with connective tissue growth factor and ascorbic acid to promote cell sheet formation. Rats undergoing unilateral ACL reconstruction were divided into a control group and a TDSC group. The tendon graft was wrapped with the GFP-TDSC sheet before graft insertion in the TDSC group. At weeks 2, 6, and 12 after reconstruction, the samples were harvested for computed tomography imaging and histologic or biomechanical testing. The fate of the transplanted cell sheet was examined by immunohistochemical staining of GFP. RESULTS: There were significantly higher tunnel bone mineral density (BMD) (42.3% increase, P = .047) and bone volume/total volume (BV/TV) (625% increase, P = .009) at the metaphyseal region of the tibial tunnel at week 2 and at the femoral tunnel at week 6 (BMD: 30.8% increase, P = .014; BV/TV: 100% increase, P = .014) in the TDSC group compared with the control group. Only the TDSC group showed a time-dependent increase in tunnel BMD (overall P = .038) and BV/TV (overall P = .015) at the epiphyseal region of the tibial tunnel. Semiquantitative image analysis showed better graft osteointegration and higher intra-articular graft integrity with lower cellularity and vascularity, better cell alignment, and higher collagen birefringence in the TDSC group. The ultimate load at week 2 (52.5% increase, P = .027) and stiffness at week 6 (62% increase, P = .008) were significantly higher in the TDSC group. Cells positive for GFP were observed in all samples in the TDSC group at week 2 but became reduced with time after reconstruction. CONCLUSION: The TDSC sheet improved early graft healing after ACL reconstruction in the rat model. CLINICAL RELEVANCE: The TDSC sheet could potentially be used for the promotion of graft healing in ACL reconstruction. FAU - Lui, Pauline Po Yee AU - Lui PP AD - Pauline Po Yee Lui, Headquarters, Hospital Authority, 9/F, Rumsey Street Multi-Storey Carpark Building, 2 Rumsey Street, Sheung Wan, Hong Kong SAR, China. paulinelui00@gmail.com. FAU - Wong, On Tik AU - Wong OT FAU - Lee, Yuk Wa AU - Lee YW LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20140122 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Luminescent Agents) RN - 139568-91-5 (Connective Tissue Growth Factor) RN - 147336-22-9 (Green Fluorescent Proteins) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - *Anterior Cruciate Ligament Reconstruction MH - Ascorbic Acid MH - Bone Density MH - Cells, Cultured MH - Connective Tissue Growth Factor MH - Femur/diagnostic imaging/pathology MH - Green Fluorescent Proteins MH - Immunohistochemistry MH - Luminescent Agents MH - Male MH - Models, Animal MH - *Osseointegration MH - Photomicrography MH - Rats MH - Rats, Sprague-Dawley MH - *Stem Cell Transplantation MH - Stem Cells/cytology MH - Tendons/*cytology MH - Tensile Strength MH - Tibia/diagnostic imaging/pathology MH - *Tissue Engineering MH - Tomography, X-Ray Computed MH - Weight-Bearing OTO - NOTNLM OT - anterior cruciate ligament reconstruction OT - cell sheet OT - tendon graft remodeling OT - tendon graft to bone tunnel healing OT - tendon stem/progenitor cells EDAT- 2014/01/24 06:00 MHDA- 2014/09/27 06:00 CRDT- 2014/01/24 06:00 PHST- 2014/01/24 06:00 [entrez] PHST- 2014/01/24 06:00 [pubmed] PHST- 2014/09/27 06:00 [medline] AID - 0363546513517539 [pii] AID - 10.1177/0363546513517539 [doi] PST - ppublish SO - Am J Sports Med. 2014 Mar;42(3):681-9. doi: 10.1177/0363546513517539. Epub 2014 Jan 22. PMID- 11828677 OWN - NLM STAT- MEDLINE DCOM- 20020305 LR - 20131121 IS - 0043-3284 (Print) IS - 0043-3284 (Linking) VI - 97 IP - 6 DP - 2001 Nov-Dec TI - The clinical entity of remitting seronegative synovitis with pitting edema (RS3PE syndrome). PG - 302-4 AB - Remitting seronegative symmetrical synovitis with pitting edema is a clinical entity distinct from polymyalgia rheumatica arthritis appearing in elderly patients. Distal pitting edema and tenosynovitis of the digitorum tendons are characteristically seen in this disorder. In contrast to polymyalgia rheumatica and rheumatoid arthritis, treatment with low-dose glucocorticoids usually produces a prompt and enduring remission after several months. Follow-up evaluations are necessary not only to assure this diagnosis is posterior, but also to observe for the possible occurrence of associated neoplasms. FAU - Triplett, L M AU - Triplett LM AD - Department of Internal Medicine, West Virginia University School of Medicine, Charleston Division, USA. FAU - Pfister, A K AU - Pfister AK LA - eng PT - Case Reports PT - Journal Article PL - United States TA - W V Med J JT - The West Virginia medical journal JID - 0413777 RN - 0 (Anti-Inflammatory Agents) RN - VB0R961HZT (Prednisone) SB - IM MH - Aged MH - Aged, 80 and over MH - Anti-Inflammatory Agents/therapeutic use MH - Edema/*diagnosis/drug therapy MH - Female MH - Humans MH - Prednisone/therapeutic use MH - Syndrome MH - Tenosynovitis/*diagnosis/drug therapy EDAT- 2002/02/07 10:00 MHDA- 2002/03/07 10:01 CRDT- 2002/02/07 10:00 PHST- 2002/02/07 10:00 [pubmed] PHST- 2002/03/07 10:01 [medline] PHST- 2002/02/07 10:00 [entrez] PST - ppublish SO - W V Med J. 2001 Nov-Dec;97(6):302-4. PMID- 2180165 OWN - NLM STAT- MEDLINE DCOM- 19900426 LR - 20220331 IS - 0340-2649 (Print) IS - 0340-2649 (Linking) VI - 16 IP - 1 DP - 1990 Feb TI - [Simultaneous bilateral Achilles tendon rupture following minor trauma on steroid treatment--a case report]. PG - 50-4 AB - The case of a bilateral simultaneous achilles tendon rupture under steroid therapy is reported in a 69 years old patient. The diagnosis includes clinical investigation, MRI, ultrasound and histological investigation. The steroid therapy was indicated because of a rheumatoid disease and pain in the shoulder. The cause of the influence of the steroid therapy as well as the literature supporting to this cases is discussed. Both achilles tendons were reconstructed in one operation. FAU - Weinstabl, R AU - Weinstabl R AD - I. Universitätsklinik für Unfallchirurgie, Wien. FAU - Hertz, H AU - Hertz H LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Gleichzeitige beidseitige Achillessehnenruptur nach Bagatelltrauma bei Steroidtherapie--Fallbericht. PL - Germany TA - Unfallchirurgie JT - Unfallchirurgie JID - 7909168 RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Achilles Tendon/drug effects/*injuries/surgery MH - Aged MH - Arthritis, Rheumatoid/*drug therapy MH - Drug Therapy, Combination MH - Humans MH - Male MH - Prednisolone/*adverse effects MH - Prostheses and Implants MH - Rupture MH - Suture Techniques EDAT- 1990/02/01 00:00 MHDA- 1990/02/01 00:01 CRDT- 1990/02/01 00:00 PHST- 1990/02/01 00:00 [pubmed] PHST- 1990/02/01 00:01 [medline] PHST- 1990/02/01 00:00 [entrez] AID - 10.1007/BF02587997 [doi] PST - ppublish SO - Unfallchirurgie. 1990 Feb;16(1):50-4. doi: 10.1007/BF02587997. PMID- 2946549 OWN - NLM STAT- MEDLINE DCOM- 19870114 LR - 20190919 IS - 0300-8207 (Print) IS - 0300-8207 (Linking) VI - 15 IP - 4 DP - 1986 TI - Collagen fibril formation in the presence of dexamethasone disodium phosphate. PG - 257-68 AB - Dexamethasone disodium phosphate was found to inhibit in vitro fibrillogenesis in a buffered collagen solution that otherwise formed in vivo like fibrils. A nonlinear relationship was observed between the steroid salt concentration and the kinetic parameter half transition time. Full fibril inhibition occurred at dexamethasone phosphate concentrations above 15 mM. At lower concentrations, sample buffers that also contained inorganic phosphate were not different from the control in activation energy of 224.3 +/- 29.3 kJ/mol (53.6 +/- 7.0 kcal/mol). The idea is advanced that the soluble steroid salt associates directly to the collagen and prevents the formation of lateral, hydrophobic interactions between adjacent collagen aggregates. FAU - Dombi, G W AU - Dombi GW FAU - Halsall, H B AU - Halsall HB LA - eng PT - Journal Article PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - 0 (Macromolecular Substances) RN - 0 (Phosphates) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) RN - SE337SVY37 (sodium phosphate) SB - IM EIN - Connect Tissue Res 1987;16(3):following 279 MH - Animals MH - Collagen/*metabolism MH - Dexamethasone/*pharmacology MH - Kinetics MH - Macromolecular Substances MH - Microscopy, Electron MH - Phosphates/*pharmacology MH - Rats MH - Tendons EDAT- 1986/01/01 00:00 MHDA- 1986/01/01 00:01 CRDT- 1986/01/01 00:00 PHST- 1986/01/01 00:00 [pubmed] PHST- 1986/01/01 00:01 [medline] PHST- 1986/01/01 00:00 [entrez] AID - 10.3109/03008208609001984 [doi] PST - ppublish SO - Connect Tissue Res. 1986;15(4):257-68. doi: 10.3109/03008208609001984. PMID- 25245131 OWN - NLM STAT- MEDLINE DCOM- 20150427 LR - 20220408 IS - 1552-3365 (Electronic) IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 42 IP - 12 DP - 2014 Dec TI - Inhibition of 5-LOX, COX-1, and COX-2 increases tendon healing and reduces muscle fibrosis and lipid accumulation after rotator cuff repair. PG - 2860-8 LID - 10.1177/0363546514549943 [doi] AB - BACKGROUND: The repair and restoration of function after chronic rotator cuff tears are often complicated by muscle atrophy, fibrosis, and fatty degeneration of the diseased muscle. The inflammatory response has been implicated in the development of fatty degeneration after cuff injuries. Licofelone is a novel anti-inflammatory drug that inhibits 5-lipoxygenase (5-LOX), as well as cyclooxygenase (COX)-1 and COX-2 enzymes, which play important roles in inducing inflammation after injuries. While previous studies have demonstrated that nonsteroidal anti-inflammatory drugs and selective inhibitors of COX-2 (coxibs) may prevent the proper healing of muscles and tendons, studies about bone and cartilage have demonstrated that drugs that inhibit 5-LOX concurrently with COX-1 and COX-2 may enhance tissue regeneration. HYPOTHESIS: After the repair of a chronic rotator cuff tear in rats, licofelone would increase the load to failure of repaired tendons and increase the force production of muscle fibers. STUDY DESIGN: Controlled laboratory study. METHODS: Rats underwent supraspinatus release followed by repair 28 days later. After repair, rats began a treatment regimen of either licofelone or a vehicle for 14 days, at which time animals were euthanized. Supraspinatus muscles and tendons were then subjected to contractile, mechanical, histological, and biochemical analyses. RESULTS: Compared with controls, licofelone-treated rats had a grossly apparent decrease in inflammation and increased fibrocartilage formation at the enthesis, along with a 62% increase in the maximum load to failure and a 51% increase in peak stress to failure. Licofelone resulted in a marked reduction in fibrosis and lipid content in supraspinatus muscles as well as reduced expression of several genes involved in fatty infiltration. Despite the decline in fibrosis and fat accumulation, muscle fiber specific force production was reduced by 23%. CONCLUSION: The postoperative treatment of cuff repair with licofelone may reduce fatty degeneration and enhance the development of a stable bone-tendon interface, although decreases in muscle fiber specific force production were observed, and force production in fact declined. CLINICAL RELEVANCE: This study demonstrates that the inhibition of 5-LOX, COX-1, and COX-2 modulates the healing process of repaired rotator cuff tendons. Although further studies are necessary, the treatment of patients with licofelone after cuff repair may improve the development of a stable enthesis and enhance postoperative outcomes. CI - © 2014 The Author(s). FAU - Oak, Nikhil R AU - Oak NR AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Gumucio, Jonathan P AU - Gumucio JP AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Flood, Michael D AU - Flood MD AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Saripalli, Anjali L AU - Saripalli AL AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Davis, Max E AU - Davis ME AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Harning, Julie A AU - Harning JA AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Lynch, Evan B AU - Lynch EB AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Roche, Stuart M AU - Roche SM AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Bedi, Asheesh AU - Bedi A AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. FAU - Mendias, Christopher L AU - Mendias CL AD - Department of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA cmendias@umich.edu. LA - eng GR - R01-AR063649/AR/NIAMS NIH HHS/United States GR - T32-GM008322/GM/NIGMS NIH HHS/United States GR - F31 AR065931/AR/NIAMS NIH HHS/United States GR - R01 AR063649/AR/NIAMS NIH HHS/United States GR - T32 GM008322/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20140922 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Apoptosis Regulatory Proteins) RN - 0 (Atg5 protein, rat) RN - 0 (Autophagy-Related Protein 5) RN - 0 (Beclin-1) RN - 0 (Becn1 protein, rat) RN - 0 (Carrier Proteins) RN - 0 (Cidec protein, rat) RN - 0 (Enzyme Inhibitors) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Muscle Proteins) RN - 0 (PPAR gamma) RN - 0 (Perilipin-1) RN - 0 (Phosphoproteins) RN - 0 (Proteins) RN - 0 (Pyrroles) RN - 0 (RNA, Messenger) RN - 0 (Vesicular Transport Proteins) RN - 0 (lipid storage droplet protein 5, mouse) RN - 130068-27-8 (Interleukin-10) RN - EC 2.3.1.20 (Dgat1 protein, rat) RN - EC 2.3.1.20 (Diacylglycerol O-Acyltransferase) RN - EC 2.3.1.9 (Acat1 protein, mouse) RN - EC 2.3.1.9 (Acetyl-CoA C-Acetyltransferase) RN - EC 3.6.1.- (Atg16L1 protein, rat) RN - P5T6BYS22Y (licofelone) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Acetyl-CoA C-Acetyltransferase/genetics/metabolism MH - Animals MH - Apoptosis Regulatory Proteins/genetics/metabolism MH - Autophagy-Related Protein 5 MH - Beclin-1 MH - Biomechanical Phenomena MH - Carrier Proteins/genetics/metabolism MH - Diacylglycerol O-Acyltransferase/genetics/metabolism MH - Enzyme Inhibitors/*pharmacology MH - Fibrocartilage/pathology MH - Fibrosis MH - Hydroxyproline/metabolism MH - Interleukin-10/genetics/metabolism MH - Intracellular Signaling Peptides and Proteins/genetics/metabolism MH - Lipid Metabolism/*drug effects MH - Male MH - Muscle Contraction/drug effects MH - Muscle Fibers, Fast-Twitch/drug effects MH - Muscle Proteins/genetics/metabolism MH - Muscle, Skeletal/metabolism/*pathology MH - PPAR gamma/genetics/metabolism MH - Perilipin-1 MH - Phosphoproteins/genetics/metabolism MH - Proteins/genetics/metabolism MH - Pyrroles/*pharmacology MH - RNA, Messenger/metabolism MH - Rats, Sprague-Dawley MH - Rotator Cuff/pathology/*surgery MH - Vesicular Transport Proteins/genetics/metabolism MH - Wound Healing/*drug effects/physiology PMC - PMC4246014 MID - NIHMS633712 OTO - NOTNLM OT - fatty degeneration OT - licofelone OT - myosteatosis OT - rotator cuff EDAT- 2014/09/24 06:00 MHDA- 2015/04/29 06:00 PMCR- 2015/12/01 CRDT- 2014/09/24 06:00 PHST- 2014/09/24 06:00 [entrez] PHST- 2014/09/24 06:00 [pubmed] PHST- 2015/04/29 06:00 [medline] PHST- 2015/12/01 00:00 [pmc-release] AID - 0363546514549943 [pii] AID - 10.1177/0363546514549943 [doi] PST - ppublish SO - Am J Sports Med. 2014 Dec;42(12):2860-8. doi: 10.1177/0363546514549943. Epub 2014 Sep 22. PMID- 28412025 OWN - NLM STAT- MEDLINE DCOM- 20180315 LR - 20211204 IS - 1096-0023 (Electronic) IS - 1043-4666 (Linking) VI - 93 DP - 2017 May TI - The influence of chronic IL-6 exposure, in vivo, on rat Achilles tendon extracellular matrix. PG - 10-14 LID - S1043-4666(17)30096-0 [pii] LID - 10.1016/j.cyto.2017.04.011 [doi] AB - When compared to placebo, acetaminophen (APAP) reduces tendon stiffness and collagen cross-linking. APAP also enhances the exercise-induced increase in peritendinous levels of IL-6. Elevated levels of IL-6 are associated with tendinopathy, thus we hypothesized that chronic, elevated peritendinous IL-6 would alter tendon extracellular matrix (ECM). IL-6 (∼3000pgml(-1)) was injected (3dwk(-1) for 8-wks) into the Achilles peritendinous region of male Wistar rats (n=16) with the opposite leg serving as a sham. Fractional synthesis rates (FSR) were determined using deuterium oxide. Collagen (hydroxyproline) and hydroxylysl pyridinoline (HP) cross-linking were analyzed by HPLC. ECM and IL-6 related genes were evaluated using qRT-PCR. Relative to sham, collagen (Col) 1a1 but not Col3a1 expression was suppressed (47%) in tendons exposed to IL-6 (p<0.05). Lysyl oxidase (LOX) and MMP-1 expression were also reduced (37%) in IL-6 treated tendons (p<0.05). Relative to sham the expression of MMP-2, -3, -9, and TIMP-1 were not altered by IL-6 treatment (p>0.05). Interleukin-6 receptor subunit beta precursor (IL6st) was lower (16%) in IL-6 treated tendons when compared to sham (p<0.05). Suppressor of cytokine signaling 3 (Socs3), signal transducer and activator of transcription 3 (STAT3), and protein inhibitor of activated STAT 1 (Pias1) were not altered by IL-6 exposure (p>0.05). Neither collagen nor cross-linking content were altered by IL-6 (p>0.05). Additionally, IL-6 treatment did not alter tendon FSR. Chronic treatment with physiologically relevant levels of IL-6 suppresses expression of Col1a1 and LOX while also altering expression of select MMPs but does not alter Achilles tendon collagen synthesis. CI - Copyright © 2017 Elsevier Ltd. All rights reserved. FAU - Katsma, Mark S AU - Katsma MS AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA. FAU - Patel, Shivam H AU - Patel SH AD - Department of Health and Kinesiology, Purdue University, West Lafayette, IN, USA. FAU - Eldon, Erica AU - Eldon E AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA. FAU - Corbell, Kathryn A AU - Corbell KA AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA. FAU - Shimkus, Kevin L AU - Shimkus KL AD - Texas A&M University, College Station, TX, USA. FAU - Fluckey, James D AU - Fluckey JD AD - Texas A&M University, College Station, TX, USA. FAU - Carroll, Chad C AU - Carroll CC AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA; Department of Health and Kinesiology, Purdue University, West Lafayette, IN, USA. Electronic address: carrol71@purdue.edu. LA - eng PT - Journal Article DEP - 20170413 PL - England TA - Cytokine JT - Cytokine JID - 9005353 RN - 0 (COL3A1 protein, rat) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Collagen Type III) RN - 0 (Il6st protein, rat) RN - 0 (Interleukin-6) RN - 0 (Protein Inhibitors of Activated STAT) RN - 0 (STAT3 Transcription Factor) RN - 0 (Socs3 protein, rat) RN - 0 (Stat3 protein, rat) RN - 0 (Suppressor of Cytokine Signaling 3 Protein) RN - 0 (TIMP1 protein, rat) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 133483-10-0 (Cytokine Receptor gp130) RN - EC 1.4.3.13 (Protein-Lysine 6-Oxidase) SB - IM MH - Achilles Tendon/*metabolism/pathology MH - Animals MH - Collagen Type I/biosynthesis MH - Collagen Type I, alpha 1 Chain MH - Collagen Type III/biosynthesis MH - Cytokine Receptor gp130/biosynthesis MH - Extracellular Matrix/*metabolism/pathology MH - Gene Expression Regulation/drug effects MH - Interleukin-6/*pharmacology MH - Male MH - Protein Inhibitors of Activated STAT/biosynthesis MH - Protein-Lysine 6-Oxidase/metabolism MH - Rats MH - Rats, Wistar MH - STAT3 Transcription Factor/biosynthesis MH - Suppressor of Cytokine Signaling 3 Protein/biosynthesis MH - Tissue Inhibitor of Metalloproteinase-1/biosynthesis OTO - NOTNLM OT - Acetaminophen OT - Achilles OT - Collagen OT - IL-6 OT - Tendon EDAT- 2017/04/17 06:00 MHDA- 2018/03/16 06:00 CRDT- 2017/04/17 06:00 PHST- 2017/02/28 00:00 [received] PHST- 2017/04/04 00:00 [revised] PHST- 2017/04/05 00:00 [accepted] PHST- 2017/04/17 06:00 [pubmed] PHST- 2018/03/16 06:00 [medline] PHST- 2017/04/17 06:00 [entrez] AID - S1043-4666(17)30096-0 [pii] AID - 10.1016/j.cyto.2017.04.011 [doi] PST - ppublish SO - Cytokine. 2017 May;93:10-14. doi: 10.1016/j.cyto.2017.04.011. Epub 2017 Apr 13. PMID- 39014435 OWN - NLM STAT- MEDLINE DCOM- 20240717 LR - 20240719 IS - 1749-799X (Electronic) IS - 1749-799X (Linking) VI - 19 IP - 1 DP - 2024 Jul 16 TI - Oncostatin M promotes osteogenic differentiation of tendon-derived stem cells through the JAK2/STAT3 signalling pathway. PG - 407 LID - 10.1186/s13018-024-04915-5 [doi] LID - 407 AB - PURPOSE: Oncostatin M (OSM) is involved in the regulation of osteogenic differentiation and has a major role in the development of heterotopic ossification. The role of OSM in osteogenic differentiation of tendon-derived stem cells (TDSCs) and its mechanism have not been reported. This study aim to investigate the role of OSM in osteogenic differentiation of TDSCs and study the mechanism. METHODS: TDSCs were differentiated in osteogenic differentiation medium for 7 days. Recombinant OSM was added to the osteogenic differentiation medium for 7 and 14 days. The effect of Janus kinase 2 (JAK2) inhibitor AZD1480 and signal transducer and activator of transcription 3 (STAT3) inhibitor stattic in the presence of recombinant OSM on osteogenic differentiation of TDSCs was examined after differentiation for 7 and 14 days. Alkaline phosphatase and alizarin red staining were used to assess the effects on early and mid-stage osteogenic differentiation, respectively. Western blotting and qPCR were used to assess the expression of receptor and signalling pathway-related proteins and osteogenic marker genes, respectively. RESULTS: TDSCs were successfully induced to differentiate into osteoblasts. Recombinant OSM promoted osteogenic differentiation of TDSCs to early and mid-stages. After addition of AZD1480 or stattic, decreased alkaline phosphatase and alizarin red staining were observed in the early and mid-stages of osteogenic differentiation. Additionally, decreased expression of receptor and pathway-related proteins, and osteogenic genes was found by western blotting and qPCR, respectively. CONCLUSION: OSM promotes osteogenic differentiation of TDSCs and the JAK2/STAT3 signalling pathway plays an important role. CI - © 2024. The Author(s). FAU - Yang, Jun AU - Yang J AUID- ORCID: 0000-0001-9645-1997 AD - Department of Orthopaedics, First Affiliated Hospital of Dalian Medical University, Dalian, PR China. FAU - Chen, Xiaolin AU - Chen X AD - Department of Orthopedic Surgery, The Second Affiliated Hospital of Chongqing Medical University, No. 76, Linjiang Road, Chongqing, 400010, Yuzhong District, PR China. FAU - Wu, Yueshu AU - Wu Y AD - Department of Orthopaedics, First Affiliated Hospital of Dalian Medical University, Dalian, PR China. FAU - Xu, Gang AU - Xu G AD - Department of Orthopaedics, First Affiliated Hospital of Dalian Medical University, Dalian, PR China. FAU - Qu, Xiaochen AU - Qu X AD - Department of Orthopaedics, First Affiliated Hospital of Dalian Medical University, Dalian, PR China. xiaochen13@hotmail.com. LA - eng PT - Journal Article DEP - 20240716 PL - England TA - J Orthop Surg Res JT - Journal of orthopaedic surgery and research JID - 101265112 RN - 106956-32-5 (Oncostatin M) RN - 0 (STAT3 Transcription Factor) RN - EC 2.7.10.2 (Janus Kinase 2) RN - 0 (STAT3 protein, human) SB - IM MH - *Oncostatin M/pharmacology MH - *STAT3 Transcription Factor/metabolism MH - *Janus Kinase 2/metabolism MH - *Osteogenesis/drug effects/physiology MH - *Cell Differentiation/drug effects/physiology MH - *Signal Transduction/drug effects/physiology MH - *Tendons/cytology MH - *Stem Cells/drug effects MH - Humans MH - Cells, Cultured MH - Animals PMC - PMC11253339 OTO - NOTNLM OT - JAK2/STAT3 signalling OT - Oncostatin M OT - Osteogenic differentiation OT - Tendon-derived stem cells COIS- The authors declare no competing interests. The authors declare no conflict of interest. EDAT- 2024/07/17 00:41 MHDA- 2024/07/17 06:43 PMCR- 2024/07/16 CRDT- 2024/07/16 23:47 PHST- 2024/05/04 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/07/17 06:43 [medline] PHST- 2024/07/17 00:41 [pubmed] PHST- 2024/07/16 23:47 [entrez] PHST- 2024/07/16 00:00 [pmc-release] AID - 10.1186/s13018-024-04915-5 [pii] AID - 4915 [pii] AID - 10.1186/s13018-024-04915-5 [doi] PST - epublish SO - J Orthop Surg Res. 2024 Jul 16;19(1):407. doi: 10.1186/s13018-024-04915-5. PMID- 31234474 OWN - NLM STAT- MEDLINE DCOM- 20200218 LR - 20240718 IS - 2218-273X (Electronic) IS - 2218-273X (Linking) VI - 9 IP - 6 DP - 2019 Jun 22 TI - Important Metabolites in Maintaining Folate Cycle, Homocysteine, and Polyamine Metabolism Associated with Ranibizumab Treatment in Cultured Human Tenon's Fibroblasts. LID - 10.3390/biom9060243 [doi] LID - 243 AB - The anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to vascular endothelial growth factor (VEGF), ranibizumab works by binding and neutralizing all active VEGF-A, thus limiting progressive cell growth and proliferation. Ranibizumab application in ocular diseases has shown remarkable desired effects; however, to date, its antifibrotic mechanism is not well understood. In this study, we identified metabolic changes in ranibizumab-treated human Tenon's fibroblasts (HTFs). Cultured HTFs were treated for 48 h with 0.5 mg/mL of ranibizumab and 0.5 mg/mL control IgG antibody which serves as a negative control. Samples from each group were injected into Agilent 6520 Q-TOF liquid chromatography/mass spectrometer (LC/MS) system to establish the metabolite expression in both ranibizumab treated cells and control group. Data obtained was analyzed using Agilent Mass Hunter Qualitative Analysis software to identify the most regulated metabolite following ranibizumab treatment. At p-value < 0.01 with the cut off value of two-fold change, 31 identified metabolites were found to be significantly upregulated in ranibizumab-treated group, with six of the mostly upregulated having insignificant role in fibroblast cell cycle and wound healing regulations. Meanwhile, 121 identified metabolites that were downregulated, and seven of the mostly downregulated are significantly involved in cell cycle and proliferation. Our findings suggest that ranibizumab abrogates the tissue scarring and wound healing process by regulating the expression of metabolites associated with fibrotic activity. In particular, we found that vitamin Bs are important in maintaining normal folate cycle, nucleotide synthesis, and homocysteine and spermidine metabolism. This study provides an insight into ranibizumab's mechanism of action in HTFs from the perspective of metabolomics. FAU - Munirah Md Noh, Siti AU - Munirah Md Noh S AD - Faculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, Malaysia. sitimunirah.umcic@um.edu.my. AD - University of Malaya Centre for Innovation and Commercialization (UMCIC), University of Malaya, Kuala Lumpur 50603, Malaysia. sitimunirah.umcic@um.edu.my. FAU - Hamimah Sheikh Abdul Kadir, Siti AU - Hamimah Sheikh Abdul Kadir S AUID- ORCID: 0000-0002-1671-4839 AD - Faculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, Malaysia. sitih587@salam.uitm.edu.my. AD - Institute of Medical Molecular Biotechnology, Faculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, Malaysia. sitih587@salam.uitm.edu.my. FAU - Vasudevan, Sushil AU - Vasudevan S AD - Faculty of Medicine, Universiti Teknologi MARA (UiTM), Cawangan Sungai Buloh, Selangor 47000, Malaysia. skvasudevan80@gmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190622 PL - Switzerland TA - Biomolecules JT - Biomolecules JID - 101596414 RN - 0 (Polyamines) RN - 0LVT1QZ0BA (Homocysteine) RN - 935E97BOY8 (Folic Acid) RN - ZL1R02VT79 (Ranibizumab) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Cells, Cultured MH - Female MH - Fibroblasts/cytology/drug effects/*metabolism MH - Folic Acid/*metabolism MH - Homocysteine/*metabolism MH - Humans MH - Male MH - *Metabolomics MH - Middle Aged MH - Polyamines/*metabolism MH - Ranibizumab/*pharmacology MH - Tendons/*cytology MH - Young Adult PMC - PMC6627437 OTO - NOTNLM OT - anti-VEGF OT - ranibizumab OT - trabeculectomy COIS- The authors declare no conflict of interest. EDAT- 2019/06/27 06:00 MHDA- 2020/02/19 06:00 PMCR- 2019/06/01 CRDT- 2019/06/26 06:00 PHST- 2019/05/12 00:00 [received] PHST- 2019/06/13 00:00 [revised] PHST- 2019/06/18 00:00 [accepted] PHST- 2019/06/26 06:00 [entrez] PHST- 2019/06/27 06:00 [pubmed] PHST- 2020/02/19 06:00 [medline] PHST- 2019/06/01 00:00 [pmc-release] AID - biom9060243 [pii] AID - biomolecules-09-00243 [pii] AID - 10.3390/biom9060243 [doi] PST - epublish SO - Biomolecules. 2019 Jun 22;9(6):243. doi: 10.3390/biom9060243. PMID- 25070655 OWN - NLM STAT- MEDLINE DCOM- 20141117 LR - 20211021 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 32 IP - 11 DP - 2014 Nov TI - Effect of isolated hyperglycemia on native mechanical and biologic shoulder joint properties in a rat model. PG - 1464-70 LID - 10.1002/jor.22695 [doi] AB - Recently, diabetes has been linked to rotator cuff disease and adhesive capsulitis, conditions with increased stiffness and inflammation. Unfortunately, limited research exists examining how hyperglycemia affects the native shoulder (tendon and capsule) properties. Therefore, the objectives of this study were to compare shoulder joint mechanics, tendon properties (mechanics and immunohistochemistry), and capsule of healthy control and hyperglycemic rats 8 weeks following induction of hyperglycemia with a submaximal dose of streptozotocin (STZ). Eighteen rats were injected with STZ to induce hyperglycemia or citrate buffer (control) and underwent normal cage activity for 8 weeks. Passive joint mechanics demonstrated significantly less external rotation in the hyperglycemic group compared to controls, with no other group differences. Tendon mechanical properties (stiffness and modulus) were not significantly different between groups at both the insertion site and mid-substance. Immunohistochemistry staining of the tendon and capsule demonstrated significantly increased interleukin 1-beta (IL1-β) and advanced glycated end-products (AGE) staining localized to the insertion and mid-substance of the tendon but not the capsule. In addition, tumor necrosis factor alpha (TNF-α) staining was significantly increased in the superior capsule but not the supraspinatus tendon. This study demonstrates that isolated hypergylcemia does not diminish shoulder mechanical properties but does induce a chronic inflammatory response. CI - © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Thomas, Stephen J AU - Thomas SJ AD - McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania. FAU - Sarver, Joseph J AU - Sarver JJ FAU - Yannascoli, Sarah M AU - Yannascoli SM FAU - Tucker, Jennica J AU - Tucker JJ FAU - Kelly, John D 4th AU - Kelly JD 4th FAU - Ahima, Rexford S AU - Ahima RS FAU - Barbe, Mary F AU - Barbe MF FAU - Soslowsky, Louis J AU - Soslowsky LJ LA - eng GR - F32 AR061959/AR/NIAMS NIH HHS/United States GR - P30 AR050950/AR/NIAMS NIH HHS/United States GR - P30AR050950/AR/NIAMS NIH HHS/United States GR - P30-DK-19525/DK/NIDDK NIH HHS/United States GR - P30 DK019525/DK/NIDDK NIH HHS/United States GR - 1F32AR061959-02/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20140728 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Glycation End Products, Advanced) RN - 0 (Interleukin-1beta) RN - 0 (Tumor Necrosis Factor-alpha) RN - 5W494URQ81 (Streptozocin) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Glycation End Products, Advanced/metabolism MH - Hyperglycemia/*physiopathology MH - Immunohistochemistry MH - Interleukin-1beta/metabolism MH - Male MH - Rats MH - Rotator Cuff MH - Shoulder Joint/*physiopathology MH - Streptozocin MH - Stress, Mechanical MH - Tendon Injuries/physiopathology MH - Tendons/physiopathology MH - Tumor Necrosis Factor-alpha/metabolism MH - Wound Healing/physiology PMC - PMC4406419 MID - NIHMS681119 OTO - NOTNLM OT - capsule OT - hyperglycemia OT - rat model OT - rotator cuff OT - tendon EDAT- 2014/07/30 06:00 MHDA- 2014/11/18 06:00 PMCR- 2015/11/01 CRDT- 2014/07/30 06:00 PHST- 2014/01/25 00:00 [received] PHST- 2014/06/23 00:00 [accepted] PHST- 2014/07/30 06:00 [entrez] PHST- 2014/07/30 06:00 [pubmed] PHST- 2014/11/18 06:00 [medline] PHST- 2015/11/01 00:00 [pmc-release] AID - 10.1002/jor.22695 [doi] PST - ppublish SO - J Orthop Res. 2014 Nov;32(11):1464-70. doi: 10.1002/jor.22695. Epub 2014 Jul 28. PMID- 35234541 OWN - NLM STAT- MEDLINE DCOM- 20220418 LR - 20220716 IS - 1552-3365 (Electronic) IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 50 IP - 5 DP - 2022 Apr TI - Dexamethasone Enhances Achilles Tendon Healing in an Animal Injury Model, and the Effects Are Dependent on Dose, Administration Time, and Mechanical Loading Stimulation. PG - 1306-1316 LID - 10.1177/03635465221077101 [doi] AB - BACKGROUND: Corticosteroid treatments such as dexamethasone are commonly used to treat tendinopathy but with mixed outcomes. Although this treatment can cause tendon rupture, it can also stimulate the tendon to heal. However, the mechanisms behind corticosteroid treatment during tendon healing are yet to be understood. PURPOSE: To comprehend when and how dexamethasone treatment can ameliorate injured tendons by using a rat model of Achilles tendon healing. STUDY DESIGN: Controlled laboratory study. METHODS: An overall 320 rats were used for a sequence of 6 experiments. We investigated whether the drug effect was time-, dose-, and load-dependent. Additionally, morphological data and drug administration routes were examined. Healing tendons were tested mechanically or used for histological examination 12 days after transection. Blood was collected for flow cytometry analysis in 1 experiment. RESULTS: We found that the circadian rhythm and drug injection timing influenced the treatment outcome. Dexamethasone treatment at the right time point (days 7-11) and dose (0.1 mg/kg) significantly improved the material properties of the healing tendon, while the adverse effects were reduced. Local dexamethasone treatment did not lead to increased peak stress, but it triggered systemic granulocytosis and lymphopenia. Mechanical loading (full or moderate) is essential for the positive effects of dexamethasone, as complete unloading leads to the absence of improvements. CONCLUSION: We conclude that dexamethasone treatment to improve Achilles tendon healing is dose- and time-dependent, and positive effects are perceived even in a partly unloaded condition. CLINICAL RELEVANCE: These findings are promising from a clinical perspective, as the positive effect of this drug was seen even when given at lower doses and in a moderate loading condition, which better mimics the load level in patients with tendon ruptures. FAU - Dietrich-Zagonel, Franciele AU - Dietrich-Zagonel F AUID- ORCID: 0000-0003-4871-8268 AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, Linköping, Sweden. FAU - Aspenberg, Per AU - Aspenberg P AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, Linköping, Sweden. FAU - Eliasson, Pernilla AU - Eliasson P AUID- ORCID: 0000-0001-6718-034X AD - Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Science, Linköping University, Linköping, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220302 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - *Achilles Tendon/injuries MH - Animals MH - Biomechanical Phenomena MH - Dexamethasone/pharmacology MH - Disease Models, Animal MH - Humans MH - Rats MH - *Tendon Injuries/therapy MH - Wound Healing PMC - PMC9014685 OTO - NOTNLM OT - biomechanics OT - calcaneal tendon OT - corticosteroids OT - rat OT - repair OT - resolution COIS- One or more of the authors has declared the following potential conflict of interest or source of funding: the Swedish Research Council (VR2017-00990), the Swedish National Centre for Research in Sports (F2018-0009), and Stiftelsen Lars Hiertas Minne (FO2020-0178) provided funding for this study. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto. EDAT- 2022/03/03 06:00 MHDA- 2022/04/19 06:00 PMCR- 2022/04/18 CRDT- 2022/03/02 12:18 PHST- 2022/03/03 06:00 [pubmed] PHST- 2022/04/19 06:00 [medline] PHST- 2022/03/02 12:18 [entrez] PHST- 2022/04/18 00:00 [pmc-release] AID - 10.1177_03635465221077101 [pii] AID - 10.1177/03635465221077101 [doi] PST - ppublish SO - Am J Sports Med. 2022 Apr;50(5):1306-1316. doi: 10.1177/03635465221077101. Epub 2022 Mar 2. PMID- 34368976 OWN - NLM STAT- MEDLINE DCOM- 20220504 LR - 20220504 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 237 IP - 1 DP - 2022 Jan TI - The impact of cryopreservation in signature markers and immunomodulatory profile of tendon and ligament derived cells. PG - 675-686 LID - 10.1002/jcp.30540 [doi] AB - Tendon and ligament (T/L) engineering strategies towards clinical practice have been challenged by a paucity of understanding in the identification and still poorly described characterization of cellular niches. Prospecting how resident cell populations behave in vitro, and how cryopreservation may influence T/ L-promoting factors, can provide insights into T/ L-cellular profiles for novel regenerative solutions. Therefore, we studied human T/ L-derived cells isolated from patellar tendons and cruciate ligaments as suitable cellular models to anticipate tendon and ligament niches responses for advanced strategies with predictive tenogenic and ligamentogenic value. Our results show that the crude populations isolated from tendon and ligament tissues hold a stem cell subset and share a similar behavior in terms of tenogenic/ligamentogenic commitment. Both T/ L-derived cells successfully undergo cryopreservation/thawing maintaining the tenogenic/ligamentogenic profiles. The major differences between cryopreserved and fresh populations were observed at the gene expression of MKX, SCX, and TNMD as well as at the protein levels of collagen type I and III, in which cells from tendon origin (hTDCs) evidence increased values in comparison to the ones from ligament (hLDCs, p < 0.05). In addition, low-temperature storage was shown to potentiate an immunomodulatory profile of cells, especially in hTDCs leading to an increase in the gene expression of the anti-inflammatory factors IL-4 and IL-10 (p < 0.05), as well as in the protein secretion of IL-10 (p < 0.01) and IL-4 (p < 0.001). Overall, the outcomes highlight the relevance of the cryopreserved T/ L-derived cells and their promising immunomodulatory cues as in vitro models for investigating cell-mediated mechanisms driving tissue healing and regeneration. CI - © 2021 Wiley Periodicals LLC. FAU - Gonçalves, Ana I AU - Gonçalves AI AUID- ORCID: 0000-0002-0466-9292 AD - 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark - Zona Industrial da Gandra, Barco, Guimarães, Portugal. AD - ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. FAU - Vinhas, Adriana AU - Vinhas A AUID- ORCID: 0000-0003-4682-0920 AD - 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark - Zona Industrial da Gandra, Barco, Guimarães, Portugal. AD - ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. FAU - Rodrigues, Márcia T AU - Rodrigues MT AUID- ORCID: 0000-0002-4483-5689 AD - 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark - Zona Industrial da Gandra, Barco, Guimarães, Portugal. AD - ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. FAU - Gomes, Manuela E AU - Gomes ME AUID- ORCID: 0000-0002-2036-6291 AD - 3B's Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Avepark - Zona Industrial da Gandra, Barco, Guimarães, Portugal. AD - ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210808 PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 130068-27-8 (Interleukin-10) RN - 207137-56-2 (Interleukin-4) SB - IM MH - Cell Differentiation MH - Cryopreservation MH - Humans MH - *Interleukin-10 MH - *Interleukin-4 MH - Ligaments MH - Tendons OTO - NOTNLM OT - cryopreservation OT - immunomodulatory cues/properties OT - ligament OT - tendon EDAT- 2021/08/10 06:00 MHDA- 2022/05/06 06:00 CRDT- 2021/08/09 07:01 PHST- 2021/06/09 00:00 [revised] PHST- 2021/01/29 00:00 [received] PHST- 2021/07/10 00:00 [accepted] PHST- 2021/08/10 06:00 [pubmed] PHST- 2022/05/06 06:00 [medline] PHST- 2021/08/09 07:01 [entrez] AID - 10.1002/jcp.30540 [doi] PST - ppublish SO - J Cell Physiol. 2022 Jan;237(1):675-686. doi: 10.1002/jcp.30540. Epub 2021 Aug 8. PMID- 24674614 OWN - NLM STAT- MEDLINE DCOM- 20150109 LR - 20140527 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 39 IP - 6 DP - 2014 Jun TI - Dorsal surgical approaches to the proximal interphalangeal joint: a comparative anatomic study. PG - 1082-7 LID - S0363-5023(14)00212-3 [pii] LID - 10.1016/j.jhsa.2014.02.004 [doi] AB - PURPOSE: Adequate exposure of the articular surface of the head of the proximal phalanx is essential for reduction of intra-articular fractures of the proximal interphalangeal (PIP) joint. We compared the articular exposure obtained by a dorsal extensor-tendon splitting (Swanson), an extensor tendon-reflecting (Chamay), and an extensor mechanism-sparing approach. METHODS: The PIP joints of 24 digits from 6 fresh-frozen cadaveric specimens were randomly assigned to 1 of 3 dorsal surgical exposures: an extensor tendon-splitting, extensor tendon-reflecting, or extensor mechanism-sparing approach. The exposed surface was painted with methylene blue and the PIP joints were disarticulated to reveal the distal articular surface of the proximal phalanx. Using 3-dimensional digital mapping, we calculated the percentage of the exposed dyed surface area to the total surface area and compared the 3 approaches. RESULTS: The mean percent exposed joint surface area for the extensor tendon-splitting, extensor tendon-reflecting, and extensor mechanism-sparing approaches were 41%, 52%, and 16%, respectively. Each approach provided a significantly different percentage of articular PIP joint surface area from the other 2. CONCLUSIONS: The amount of articular surface visualized using 3 dorsal approaches to the PIP joint must be weighed against the amount of extensor mechanism violated. Exposure of the articular surface by the extensor mechanism-sparing approach to the PIP joint allowed nearly a third of the exposure gained by the extensor tendon-reflecting exposure. Although the extensor tendon-reflecting technique revealed the greatest amount of surface, nearly 50% of the proximal phalanx articular surface remained inaccessible as long as the collateral ligaments were intact. CLINICAL RELEVANCE: Understanding the limitations inherent in dorsal exposure of the PIP joint may help guide the surgical approach for the individual patient. CI - Copyright © 2014 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Wei, David H AU - Wei DH AD - Department of Orthopaedic Surgery, Columbia University Medical Center, New York, NY. FAU - Strauch, Robert J AU - Strauch RJ AD - Department of Orthopaedic Surgery, Columbia University Medical Center, New York, NY. Electronic address: robertjstrauch@hotmail.com. LA - eng PT - Comparative Study PT - Journal Article DEP - 20140325 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - T42P99266K (Methylene Blue) SB - IM MH - Arthroplasty/*methods MH - Cadaver MH - Finger Injuries/*surgery MH - Finger Joint/*surgery MH - Fracture Fixation, Internal/*methods MH - Fractures, Bone/*surgery MH - Humans MH - Methylene Blue MH - Tendons/*surgery OTO - NOTNLM OT - Proximal interphalangeal joint OT - articular exposure OT - surgical approach EDAT- 2014/03/29 06:00 MHDA- 2015/01/13 06:00 CRDT- 2014/03/29 06:00 PHST- 2013/10/07 00:00 [received] PHST- 2014/02/02 00:00 [revised] PHST- 2014/02/04 00:00 [accepted] PHST- 2014/03/29 06:00 [entrez] PHST- 2014/03/29 06:00 [pubmed] PHST- 2015/01/13 06:00 [medline] AID - S0363-5023(14)00212-3 [pii] AID - 10.1016/j.jhsa.2014.02.004 [doi] PST - ppublish SO - J Hand Surg Am. 2014 Jun;39(6):1082-7. doi: 10.1016/j.jhsa.2014.02.004. Epub 2014 Mar 25. PMID- 20806777 OWN - NLM STAT- MEDLINE DCOM- 20110317 LR - 20181201 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 33 IP - 6 DP - 2010 Jun 9 TI - The influence of atorvastatin on tendon healing: an experimental study on rabbits. PG - 398 LID - 10.3928/01477447-20100429-06 [doi] AB - Hyperlipidemia is a major risk factor for coronary heart disease. The most commonly used antihyperlipidemic drugs are 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (statins), of which atorvastatin is one of the most widely used. Little is known about the relationship between tendinopathy and HMG CoA reductase inhibitors (statins) or the effects of atorvastatin use on tendon healing following surgical repair of tendon rupture. We hypothesized that atorvastatin negatively affects this healing process. The Achilles tendons of 16 New Zealand rabbits were ruptured surgically and repaired with sutures. Eight of the rabbits were given oral atorvastatin. The other 8 served as a surgical control group. Six weeks postoperatively, all the rabbits were sacrificed, and the repaired tendons were removed. After standard histological preparation, fibroblastic activity, re-vascularization, collagenization, collagen construction, and inflammatory-cell infiltration were evaluated. On comparing the atorvastatin and surgical control groups, we observed no difference in fibroblastic activity. Although it did not reach statistical significance in our study, a difference was noted in revascularization, collagenization, and inflammatory cell infiltration; and a statistical difference was observed in collagen construction. Doubt remains about the adverse effect of atorvastatin use during tendon healing. Further investigations in animal and human models are needed on the effects of tendon healing when atorvastatin is administered for a longer time frame prior to the injury. CI - Copyright 2010, SLACK Incorporated. FAU - Esenkaya, Irfan AU - Esenkaya I AD - Goztepe Research and Training Hospital, Istanbul. Turkey. iesenkaya@hotmail.com FAU - Sakarya, Bulent AU - Sakarya B FAU - Unay, Koray AU - Unay K FAU - Elmali, Nurzat AU - Elmali N FAU - Aydin, Nasuhi Engin AU - Aydin NE LA - eng PT - Comparative Study PT - Journal Article DEP - 20100609 PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Heptanoic Acids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Pyrroles) RN - A0JWA85V8F (Atorvastatin) SB - IM MH - Achilles Tendon/drug effects/*injuries/pathology MH - Administration, Oral MH - Animals MH - Atorvastatin MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Heptanoic Acids/administration & dosage/*therapeutic use MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*therapeutic use MH - Male MH - Orthopedic Procedures/methods MH - Pyrroles/administration & dosage/*therapeutic use MH - Rabbits MH - Tendon Injuries/pathology/*therapy MH - Treatment Outcome MH - Wound Healing/*drug effects EDAT- 2010/09/02 06:00 MHDA- 2011/03/18 06:00 CRDT- 2010/09/02 06:00 PHST- 2010/09/02 06:00 [entrez] PHST- 2010/09/02 06:00 [pubmed] PHST- 2011/03/18 06:00 [medline] AID - 10.3928/01477447-20100429-06 [doi] PST - epublish SO - Orthopedics. 2010 Jun 9;33(6):398. doi: 10.3928/01477447-20100429-06. PMID- 15276323 OWN - NLM STAT- MEDLINE DCOM- 20040921 LR - 20161126 IS - 0006-3002 (Print) IS - 0006-3002 (Linking) VI - 1693 IP - 1 DP - 2004 Jul 23 TI - Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. PG - 37-45 AB - Oxidative stress and apoptosis are implicated in tendon degeneration. Peroxiredoxin 5 (PRDX5) is a novel thioredoxin peroxidase recently identified in mammals, participating directly in eliminating hydrogen peroxide (H(2)O(2)) and neutralizing other reactive oxygen species (ROS). We have previously reported that PRDX5 is upregulated in degenerative human tendon. However, the effects of this upregulation on human tendon cell function remain unknown, in particular, with regards to oxidative stress conditions. Here we report that exposure of human tendon cells to 50 microM H(2)O(2) for 24 h (in vitro oxidative stress) caused a significant increase in the percentage of apoptotic cells (P<0.05) as assessed by flow cytometric analysis of Annexin V binding, accompanied by increased PRXD5 mRNA and protein expression. Overexpression of PRDX5 in human tendon cells via transfection inhibited H(2)O(2)-induced tendon cell apoptosis by 46% (P<0.05), and prevented the decrease in tendon cell collagen synthesis which occurs under H(2)O(2) challenge, although the decrease in collagen synthesis was small. Results from our study indicate that the antioxidant enzyme PRDX5 plays a protective role in human tendon cells against oxidative stress by reducing apoptosis and maintaining collagen synthesis. FAU - Yuan, Jun AU - Yuan J AD - Orthopaedic Research Institute, St. George Hospital Campus, 4-10 South Street, University of New South Wales, Sydney, NSW 2217, Australia. FAU - Murrell, George A C AU - Murrell GA FAU - Trickett, Annette AU - Trickett A FAU - Landtmeters, Marie AU - Landtmeters M FAU - Knoops, Bernard AU - Knoops B FAU - Wang, Min-Xia AU - Wang MX LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Biochim Biophys Acta JT - Biochimica et biophysica acta JID - 0217513 RN - 0 (Annexin A5) RN - 0 (DNA Primers) RN - 0 (RNA, Messenger) RN - 9007-34-5 (Collagen) RN - EC 1.11.1.- (Peroxidases) RN - EC 1.11.1.15 (PRDX5 protein, human) RN - EC 1.11.1.15 (Peroxiredoxins) SB - IM MH - Annexin A5/metabolism MH - Apoptosis/*physiology MH - Base Sequence MH - Collagen/biosynthesis MH - DNA Primers MH - Flow Cytometry MH - Humans MH - *Oxidative Stress MH - Peroxidases/genetics/metabolism/*physiology MH - Peroxiredoxins MH - RNA, Messenger/genetics/metabolism MH - Tendons/*cytology EDAT- 2004/07/28 05:00 MHDA- 2004/09/24 05:00 CRDT- 2004/07/28 05:00 PHST- 2003/10/22 00:00 [received] PHST- 2004/03/22 00:00 [revised] PHST- 2004/04/21 00:00 [accepted] PHST- 2004/07/28 05:00 [pubmed] PHST- 2004/09/24 05:00 [medline] PHST- 2004/07/28 05:00 [entrez] AID - S016748890400076X [pii] AID - 10.1016/j.bbamcr.2004.04.006 [doi] PST - ppublish SO - Biochim Biophys Acta. 2004 Jul 23;1693(1):37-45. doi: 10.1016/j.bbamcr.2004.04.006. PMID- 11593104 OWN - NLM STAT- MEDLINE DCOM- 20011207 LR - 20190822 IS - 0263-6352 (Print) IS - 0263-6352 (Linking) VI - 19 IP - 10 DP - 2001 Oct TI - Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. PG - 1835-9 AB - OBJECTIVE AND DESIGN: Angiotensin converting enzyme inhibitors are reported to inhibit the collagen accumulation involved in left ventricular hypertrophy. We tested the effect of captopril and enalapril on the conversion of procollagen to collagen in short-term tissue cultures in order to study the possible mechanisms by which the antifibrotic effect of this group of inhibitors takes place. METHODS: We employed short-term cartilage and tendon tissue cultures to monitor the conversion of procollagen to collagen. After pulse-labelling with [14C]-proline, the cultures were incubated further with the test compounds in different concentrations for a 180 min chase period. The reaction was stopped and radioactive collagenous peptides were analysed by gel electrophoresis. The amounts of collagenous proalpha and alpha chains were estimated, and the inhibition of procollagen to collagen conversion was calculated relative to 0 min control (100% inhibition) and 180 min control (0% inhibition) samples. RESULTS: Inhibition (50%) was obtained with 7 mmol/l captopril and 22 mmol/l enalapril in the cartilage cultures. Both compounds seemed to inhibit the conversion in clearly lower concentrations in tendon cultures, 4 mmol/l and 7 mmol/l, respectively, were sufficient for 50% inhibition. Angiotensin I, II, saralasin and bradykinin did not have any effect on conversion at 3.5, 9, 2 and 4 mmol/l concentrations, respectively. CONCLUSION: The peptidase inhibitors captopril and enalapril are able to inhibit the conversion of procollagen to collagen, which is a proteolytic process, possibly by inhibiting the specific procollagen proteases. Whether this phenomenon is involved in the antifibrotic property of angiotensin converting enzyme inhibitors warrants further study, as does the question of whether new antifibrotic agents could be developed on this basis. FAU - Männistö, T K AU - Männistö TK AD - Department of Medical Biochemistry, University of Oulu, Oulu, Finland. FAU - Karvonen, K E AU - Karvonen KE FAU - Kerola, T V AU - Kerola TV FAU - Ryhänen, L J AU - Ryhänen LJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - J Hypertens JT - Journal of hypertension JID - 8306882 RN - 0 (Angiotensin-Converting Enzyme Inhibitors) RN - 0 (Peptide Fragments) RN - 0 (Procollagen) RN - 0 (procollagen type I carboxy terminal peptide) RN - 0 (procollagen type II carboxy-terminal peptide) RN - 69PN84IO1A (Enalapril) RN - 9007-34-5 (Collagen) RN - 9G64RSX1XD (Captopril) SB - IM MH - Angiotensin-Converting Enzyme Inhibitors/*pharmacology MH - Animals MH - Captopril/*pharmacology MH - Cartilage/metabolism MH - Chick Embryo MH - Collagen/*biosynthesis MH - Culture Techniques MH - Enalapril/*pharmacology MH - Peptide Fragments/antagonists & inhibitors MH - Procollagen/antagonists & inhibitors/*metabolism MH - Tendons/metabolism EDAT- 2001/10/11 10:00 MHDA- 2002/01/05 10:01 CRDT- 2001/10/11 10:00 PHST- 2001/10/11 10:00 [pubmed] PHST- 2002/01/05 10:01 [medline] PHST- 2001/10/11 10:00 [entrez] AID - 10.1097/00004872-200110000-00018 [doi] PST - ppublish SO - J Hypertens. 2001 Oct;19(10):1835-9. doi: 10.1097/00004872-200110000-00018. PMID- 11580904 OWN - NLM STAT- MEDLINE DCOM- 20020219 LR - 20190706 IS - 0009-8981 (Print) IS - 0009-8981 (Linking) VI - 312 IP - 1-2 DP - 2001 Oct TI - Minerals, trace elements and related biological variables in athletes and during physical activity. PG - 1-11 AB - This review concerns various minerals (sodium, potassium, calcium, magnesium, phosphorus), trace elements (zinc, manganese, selenium, copper, iron, cobalt, iodine, chromium, fluorine, lead, cadmium) and other biological variables (nitric oxide, L-carnitine, glutamine, serum transferrin receptor, biopyrrins) in relation to hemorheologic effects, stress, immune response and infections during physical and sports activities. In athletes, macroelements in the ionized form contribute to heart and muscle contractions, oxidative phosphorylation and the synthesis and activation of enzymatic systems. Zinc (Zn) protects against the effects of increased free reactive oxygen species such as copper (Cu) and manganese (Mn) (Cu-Zn superoxide dismutases; Mn superoxide dismutase). Selenium in glutathione peroxidase protects the cardiovascular system and the muscles, and helps combat allergic and inflammatory diseases. Copper and iron are involved in many aspects of energy metabolism and are important components in the synthesis of hemoglobin, myoglobin and cytochromes. Fluorine and Cu protect the ligaments and tendons. Physical activity appears to be beneficial to urban residents who are exposed to metal pollution (lead, cadmium). The data cited in this review are often contradictory and incomplete. It is still unclear in many cases how minerals are involved in physiological changes, and much work remains. FAU - Speich, M AU - Speich M AD - Département de Santé Publique et de Pharmacie Clinique, Faculté de Pharmacie, Université de Nantes, l, rue Gaston Veil, B.P. 53508, F-44035 Cedex 1, Nantes, France. fball@sante.univ-nantes.fr FAU - Pineau, A AU - Pineau A FAU - Ballereau, F AU - Ballereau F LA - eng PT - Journal Article PT - Review PL - Netherlands TA - Clin Chim Acta JT - Clinica chimica acta; international journal of clinical chemistry JID - 1302422 RN - 0 (Biomarkers) RN - 0 (Minerals) RN - 0 (Receptors, Transferrin) RN - 0 (Trace Elements) RN - 31C4KY9ESH (Nitric Oxide) RN - RFM9X3LJ49 (Bilirubin) SB - IM MH - Bilirubin/metabolism MH - Biomarkers/*blood MH - Exercise/*physiology MH - Hemorheology MH - Humans MH - Immune System/physiology MH - Minerals/*metabolism MH - Nitric Oxide/metabolism MH - Oxidative Stress MH - Receptors, Transferrin/blood MH - Sports MH - Sports Medicine MH - Trace Elements/*metabolism RF - 62 EDAT- 2001/10/03 10:00 MHDA- 2002/02/20 10:01 CRDT- 2001/10/03 10:00 PHST- 2001/10/03 10:00 [pubmed] PHST- 2002/02/20 10:01 [medline] PHST- 2001/10/03 10:00 [entrez] AID - S0009898101005988 [pii] AID - 10.1016/s0009-8981(01)00598-8 [doi] PST - ppublish SO - Clin Chim Acta. 2001 Oct;312(1-2):1-11. doi: 10.1016/s0009-8981(01)00598-8. PMID- 32387689 OWN - NLM STAT- MEDLINE DCOM- 20210914 LR - 20210914 IS - 2468-1210 (Electronic) IS - 2468-1210 (Linking) VI - 39 IP - 4 DP - 2020 Sep TI - Molten metal high pressure injection injury of the hand. PG - 328-331 LID - S2468-1229(20)30100-6 [pii] LID - 10.1016/j.hansur.2020.03.007 [doi] AB - The second case of high temperature molten metal, high-pressure injection injury of the hand is reported here. Like in the previous case, there was an innocent-looking entry point with deep thermal injury to the flexor tendons and the digital nerves that appeared a few days after the injury and lead to finger amputation. LEVEL OF EVIDENCE: 5. CI - Copyright © 2020 SFCM. Published by Elsevier Masson SAS. All rights reserved. FAU - Feldman, G AU - Feldman G AD - Orthopedic Department, HaEmek Medical Center, Yitshak Rabin Boulevard 21, 1834111 Afula, Israel. FAU - Hitti, S AU - Hitti S AD - Orthopedic Department, HaEmek Medical Center, Yitshak Rabin Boulevard 21, 1834111 Afula, Israel. FAU - Rozen, N AU - Rozen N AD - Orthopedic Department, HaEmek Medical Center, Yitshak Rabin Boulevard 21, 1834111 Afula, Israel; Faculty of Medicine, Technion, 3200003 Haifa, Israel. FAU - Rubin, G AU - Rubin G AD - Orthopedic Department, HaEmek Medical Center, Yitshak Rabin Boulevard 21, 1834111 Afula, Israel; Faculty of Medicine, Technion, 3200003 Haifa, Israel. Electronic address: guytalr@bezeqint.net. LA - eng PT - Case Reports PT - Journal Article DEP - 20200507 PL - France TA - Hand Surg Rehabil JT - Hand surgery & rehabilitation JID - 101681801 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) RN - 0 (Metals) SB - IM MH - Adult MH - Anti-Bacterial Agents/therapeutic use MH - Burns/etiology/*surgery MH - Debridement MH - Gentamicins/therapeutic use MH - Hand Injuries/etiology/*surgery MH - Hot Temperature/adverse effects MH - Humans MH - Male MH - Metals/*adverse effects MH - Occupational Injuries/*surgery MH - *Pressure OTO - NOTNLM OT - Brûlures OT - Burn OT - Injection injury OT - Lésions par injection OT - Metal OT - Métal EDAT- 2020/05/11 06:00 MHDA- 2021/09/15 06:00 CRDT- 2020/05/11 06:00 PHST- 2020/01/31 00:00 [received] PHST- 2020/03/13 00:00 [revised] PHST- 2020/03/13 00:00 [accepted] PHST- 2020/05/11 06:00 [pubmed] PHST- 2021/09/15 06:00 [medline] PHST- 2020/05/11 06:00 [entrez] AID - S2468-1229(20)30100-6 [pii] AID - 10.1016/j.hansur.2020.03.007 [doi] PST - ppublish SO - Hand Surg Rehabil. 2020 Sep;39(4):328-331. doi: 10.1016/j.hansur.2020.03.007. Epub 2020 May 7. PMID- 2437734 OWN - NLM STAT- MEDLINE DCOM- 19870605 LR - 20061115 IS - 0044-409X (Print) IS - 0044-409X (Linking) VI - 112 IP - 2 DP - 1987 TI - [Gluing of the Achilles tendon with a fibrin adhesive]. PG - 99-104 AB - Reported in this paper are clinical findings and results obtained from follow-up checks, using computed tomography, in the wake of fibrin adhesive treatment of Achilles tendon ruptures. Complaints had almost completely disappeared from 27 in 35 patients who had undergone the above operations, between 1981 and 1985. These findings were confirmed by functional follow-up examinations. Investigations of Achilles tendons, using computed tomography, revealed increase in both tendon cross-section and density, within two to eight weeks from fibrin-adhesive surgery. FAU - Haas, F AU - Haas F FAU - Haiböck, H AU - Haiböck H FAU - Reindl, P AU - Reindl P LA - ger PT - English Abstract PT - Journal Article TT - Achillessehnenklebung mit Fibrinkleber. PL - Germany TA - Zentralbl Chir JT - Zentralblatt fur Chirurgie JID - 0413645 RN - 0 (Drug Combinations) RN - 0 (Fibrin Tissue Adhesive) RN - 9001-32-5 (Fibrinogen) RN - 9013-56-3 (Factor XIII) RN - 9087-70-1 (Aprotinin) RN - EC 3.4.21.5 (Thrombin) SB - IM MH - Achilles Tendon/*injuries/surgery MH - Adult MH - Aprotinin/*therapeutic use MH - Drug Combinations/therapeutic use MH - Factor XIII/*therapeutic use MH - Female MH - Fibrin Tissue Adhesive MH - Fibrinogen/*therapeutic use MH - Humans MH - Male MH - Postoperative Complications/etiology MH - Rupture MH - Thrombin/*therapeutic use MH - Wound Healing/drug effects EDAT- 1987/01/01 00:00 MHDA- 1987/01/01 00:01 CRDT- 1987/01/01 00:00 PHST- 1987/01/01 00:00 [pubmed] PHST- 1987/01/01 00:01 [medline] PHST- 1987/01/01 00:00 [entrez] PST - ppublish SO - Zentralbl Chir. 1987;112(2):99-104. PMID- 16259590 OWN - NLM STAT- MEDLINE DCOM- 20051222 LR - 20131121 IS - 1076-3279 (Print) IS - 1076-3279 (Linking) VI - 11 IP - 9-10 DP - 2005 Sep-Oct TI - Proliferation and differentiation of rat bone marrow stromal cells on poly(glycolic acid)-collagen sponge. PG - 1346-55 AB - We studied the effects of dexamethasone (Dex) and basic fibroblast growth factor (bFGF) on proliferation and differentiation of rat bone marrow stromal cells (RBMSCs), using three scaffolds: collagen sponge, poly(glycolic acid) (PGA)-collagen sponge, and PGA-collagen (UV) sponge. RBMSCs were seeded into the sponges, and cultured in primary medium, primary medium with Dex, and primary medium with bFGF and Dex. Three weeks after cultivation, we examined alkaline phosphatase (ALP) activity and cell number in the sponges, and also performed macroscopic, light microscopic, and scanning electron microscopic (SEM) observations. Collagen sponge shrank considerably, but PGA-collagen and PGA-collagen (UV) sponges maintained most of their original shape. PGA-collagen (UV) sponge supplemented with bFGF and Dex together had the highest ALP activity and cell number, followed by PGA-collagen sponge. Although collagen sponge showed cell proliferation only on the surface, the other two sponges showed cell proliferation in the interior. SEM showed the best cell attachment to PGA-collagen (UV) sponge in the presence of bFGF and Dex, followed by PGA-collagen sponge. In conclusion, PGA-collagen (UV) and PGA-collagen sponges proved to be much more useful as scaffolding for bone regeneration when combined with bFGF and Dex. FAU - Fujita, Motoki AU - Fujita M AD - Department of Pathology, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan. FAU - Kinoshita, Yukihiko AU - Kinoshita Y FAU - Sato, Emiko AU - Sato E FAU - Maeda, Hatsuhiko AU - Maeda H FAU - Ozono, Satoshi AU - Ozono S FAU - Negishi, Hideyuki AU - Negishi H FAU - Kawase, Toshio AU - Kawase T FAU - Hiraoka, Yosuke AU - Hiraoka Y FAU - Takamoto, Tomoaki AU - Takamoto T FAU - Tabata, Yasuhiko AU - Tabata Y FAU - Kameyama, Yoichiro AU - Kameyama Y LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Tissue Eng JT - Tissue engineering JID - 9505538 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Coated Materials, Biocompatible) RN - 0 (Collagen Type I) RN - 0 (Drug Combinations) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - 26009-03-0 (Polyglycolic Acid) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Alkaline Phosphatase/metabolism MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Bone Marrow Cells/cytology MH - Bone Regeneration MH - Cell Adhesion MH - Cell Count MH - Cell Culture Techniques MH - *Cell Differentiation MH - *Cell Proliferation MH - Cells, Cultured MH - Coated Materials, Biocompatible/chemistry/radiation effects MH - Collagen Type I/chemistry/radiation effects/ultrastructure MH - Dexamethasone/pharmacology MH - Drug Combinations MH - Fibroblast Growth Factor 2/pharmacology MH - Male MH - Microscopy, Electron, Scanning MH - Polyglycolic Acid/*chemistry/radiation effects MH - Rats MH - Rats, Inbred F344 MH - Stromal Cells/*cytology/drug effects/enzymology/metabolism/*physiology/ultrastructure MH - Swine MH - Tendons/chemistry MH - Tissue Engineering/*methods MH - Ultraviolet Rays EDAT- 2005/11/02 09:00 MHDA- 2005/12/24 09:00 CRDT- 2005/11/02 09:00 PHST- 2005/11/02 09:00 [pubmed] PHST- 2005/12/24 09:00 [medline] PHST- 2005/11/02 09:00 [entrez] AID - 10.1089/ten.2005.11.1346 [doi] PST - ppublish SO - Tissue Eng. 2005 Sep-Oct;11(9-10):1346-55. doi: 10.1089/ten.2005.11.1346. PMID- 25906952 OWN - NLM STAT- MEDLINE DCOM- 20151006 LR - 20150713 IS - 1879-1220 (Electronic) IS - 0960-0760 (Linking) VI - 152 DP - 2015 Aug TI - Dexamethasone inhibits the differentiation of rat tendon stem cells into tenocytes by targeting the scleraxis gene. PG - 16-24 LID - S0960-0760(15)00107-7 [pii] LID - 10.1016/j.jsbmb.2015.04.010 [doi] AB - Glucocorticoid-induced tendon rupture is very common in clinical practice, and the overall outcome of surgical suture repair is rather poor. The mechanism remains unclear, and effective treatments are still lacking. In the present study, we investigated the effect of dexamethasone on the differentiation of rat tendon stem cells (TSCs) to tenocytes and the underlying molecular mechanisms and found that dexamethasone inhibits the differentiation of TSCs to tenocytes by analyzing the development of long, spindle-shaped cells and detecting the expression of tenocyte markers type I collagen and tenomodulin (TNMD) at both the mRNA and protein levels. We also discovered that after treatment with dexamethasone, the scleraxis expression level is downregulated in vitro and in human specimen. Chromatin immunoprecipitation (ChIP)-PCR showed that dexamethasone promotes glucocorticoid receptor interacted with the TGGAAGCC sequence located between -734 and -726 base pairs (bp) upstream of the start codon of the scleraxis gene. Furthermore, TSCs were transfected with scleraxis knockdown or overexpression plasmids, and the results indicated that scleraxis plays a pivotal role in the differentiation of TSCs to tenocytes. In conclusion, dexamethasone inhibits the differentiation of TSCs to tenocytes by inhibiting the scleraxis gene. CI - Copyright © 2015 Elsevier Ltd. All rights reserved. FAU - Chen, Wan AU - Chen W AD - Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. FAU - Tang, Hong AU - Tang H AD - Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. FAU - Zhou, Mei AU - Zhou M AD - Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. FAU - Hu, Chao AU - Hu C AD - Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. FAU - Zhang, Jiqiang AU - Zhang J AD - Department of Neurology, Third Military Medical University, Chongqing 400038, China. Electronic address: zhangjqtmmu@yahoo.com. FAU - Tang, Kanglai AU - Tang K AD - Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. Electronic address: tangkanglai@hotmail.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150420 PL - England TA - J Steroid Biochem Mol Biol JT - The Journal of steroid biochemistry and molecular biology JID - 9015483 RN - 0 (Basic Helix-Loop-Helix Transcription Factors) RN - 0 (Collagen Type I) RN - 0 (Glucocorticoids) RN - 0 (Membrane Proteins) RN - 0 (RNA, Messenger) RN - 0 (RNA, Small Interfering) RN - 0 (Scx protein, rat) RN - 0 (Tnmd protein, rat) RN - 320T6RNW1F (Mifepristone) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Animals MH - Basic Helix-Loop-Helix Transcription Factors/*antagonists & inhibitors/biosynthesis/genetics MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Chromatin Immunoprecipitation MH - Collagen Type I/biosynthesis MH - Dexamethasone/adverse effects/*pharmacology MH - Glucocorticoids/adverse effects MH - Membrane Proteins/biosynthesis MH - Mifepristone/pharmacology MH - RNA Interference MH - RNA, Messenger/biosynthesis MH - RNA, Small Interfering MH - Rats MH - Rats, Sprague-Dawley MH - Stem Cells/cytology MH - Tendon Injuries/chemically induced/*surgery MH - Tendons/*cytology MH - Wound Healing/*drug effects OTO - NOTNLM OT - Dexamethasone OT - Differentiation OT - Scleraxis OT - Tendon stem cells EDAT- 2015/04/25 06:00 MHDA- 2015/10/07 06:00 CRDT- 2015/04/25 06:00 PHST- 2015/01/06 00:00 [received] PHST- 2015/03/24 00:00 [revised] PHST- 2015/04/08 00:00 [accepted] PHST- 2015/04/25 06:00 [entrez] PHST- 2015/04/25 06:00 [pubmed] PHST- 2015/10/07 06:00 [medline] AID - S0960-0760(15)00107-7 [pii] AID - 10.1016/j.jsbmb.2015.04.010 [doi] PST - ppublish SO - J Steroid Biochem Mol Biol. 2015 Aug;152:16-24. doi: 10.1016/j.jsbmb.2015.04.010. Epub 2015 Apr 20. PMID- 25857430 OWN - NLM STAT- MEDLINE DCOM- 20160208 LR - 20181202 IS - 1740-8261 (Electronic) IS - 1058-8183 (Linking) VI - 56 IP - 4 DP - 2015 Jul-Aug TI - SALINE ARTHROGRAPHY OF THE DISTAL INTERPHALANGEAL JOINT FOR LOW-FIELD MAGNETIC RESONANCE IMAGING OF THE EQUINE PODOTROCHLEAR BURSA: FEASIBILITY STUDY. PG - 417-24 LID - 10.1111/vru.12255 [doi] AB - Abnormalities of the deep digital flexor tendon, navicular bone, and collateral sesamoidean ligament can be difficult to visualize using magnetic resonance imaging (MRI) if bursal fluid is absent. The use of saline podotrochlear bursography improves podotrochlear apparatus evaluation, however, the technique has disadvantages. The objective of this prospective feasibility study was to describe saline arthrography of the distal interphalangeal joint as an alternative technique for improving MRI visualization of the deep digital flexor tendon, navicular bone, collateral sesamoidean ligament, and podotrochlear bursa, and to compare this technique with saline podotrochlear bursography. Eight paired cadaver forelimbs were sampled. Saline podotrochlear bursography or saline arthrography techniques were randomly assigned to one limb, with the alternate technique performed on the contralateral limb. For precontrast and postcontrast studies using each technique, independent observers scored visualization of the dorsal aspect of the deep digital flexor tendon, palmar aspect of the navicular bone, collateral sesamoidean ligament, and podotrochlear bursa. Both contrast techniques improved visualization of structures over precontrast MR images and visualization scores for both techniques were similar. Findings from this study demonstrated that saline arthrography is feasible and comparable to saline podotrochlear bursography for producing podotrochlear bursa distension and separation of the structures of the podotrochlear apparatus on nonweight bearing limbs evaluated with low-field MRI. Clinical evaluation of saline arthrography on live animals is needed to determine if this technique is safe and effective as an alternative to saline podotrochlear bursography in horses with suspected pathology of the podotrochlear apparatus. CI - © 2015 American College of Veterinary Radiology. FAU - McGill, Shannon L AU - McGill SL AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. FAU - Gutierrez-Nibeyro, Santiago D AU - Gutierrez-Nibeyro SD AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. FAU - Schaeffer, David J AU - Schaeffer DJ AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. FAU - Hartman, Susan K AU - Hartman SK AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. FAU - O'Brien, Robert T AU - O'Brien RT AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. FAU - Joslyn, Stephen K AU - Joslyn SK AUID- ORCID: 0000-0001-8049-6322 AD - Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150406 PL - England TA - Vet Radiol Ultrasound JT - Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association JID - 9209635 RN - 0 (Contrast Media) RN - 451W47IQ8X (Sodium Chloride) RN - T42P99266K (Methylene Blue) SB - IM MH - Animals MH - Arthrography/*veterinary MH - Bursa, Synovial/diagnostic imaging MH - Cadaver MH - Collateral Ligaments/diagnostic imaging MH - Contrast Media MH - Feasibility Studies MH - Foot/*diagnostic imaging MH - Forelimb/*diagnostic imaging MH - Horse Diseases/*diagnostic imaging MH - Horses MH - Magnetic Resonance Imaging/veterinary MH - Methylene Blue MH - Prospective Studies MH - Random Allocation MH - Sodium Chloride MH - Tendons/diagnostic imaging OTO - NOTNLM OT - MRI OT - arthrography OT - bursography OT - horse OT - podotrochlear apparatus EDAT- 2015/04/11 06:00 MHDA- 2016/02/09 06:00 CRDT- 2015/04/11 06:00 PHST- 2014/08/15 00:00 [received] PHST- 2015/01/14 00:00 [accepted] PHST- 2015/04/11 06:00 [entrez] PHST- 2015/04/11 06:00 [pubmed] PHST- 2016/02/09 06:00 [medline] AID - 10.1111/vru.12255 [doi] PST - ppublish SO - Vet Radiol Ultrasound. 2015 Jul-Aug;56(4):417-24. doi: 10.1111/vru.12255. Epub 2015 Apr 6. PMID- 18156656 OWN - NLM STAT- MEDLINE DCOM- 20080729 LR - 20080307 IS - 1460-2423 (Electronic) IS - 0959-6658 (Linking) VI - 18 IP - 3 DP - 2008 Mar TI - Antithrombin activity and disaccharide composition of dermatan sulfate from different bovine tissues. PG - 225-34 AB - Dermatan sulfate is a glycosaminoglycan that selectively inhibits the action of thrombin through interaction with heparin cofactor II. Unlike heparin it does not interact with other coagulation factors and is able to inhibit thrombin associated with clots. This property has made dermatan sulfate an attractive candidate as an antithrombotic drug. Previous studies have showed that dermatan sulfate derived from porcine/bovine intestinal mucosa/skin or marine invertebrates is capable of stimulating heparin cofactor II-mediated thrombin inhibition in vitro. This biological activity is reported for the first time in this study using dermatan sulfate derived from mammalian tissues other than intestinal mucosa or skin. Ten different bovine tissues including the aorta, diaphragm, eyes, large and small intestine, esophagus, skin, tendon, tongue, and tongue skin were used to prepare dermatan sulfate-enriched fractions by anion exchange chromatography and acetone precipitation. Heparin cofactor II/dermatan sulfate-mediated thrombin inhibition measured in vitro revealed activity comparable to or higher than the commercial standard with 2-fold differences observed between some tissues. Analysis of the extracted dermatan sulfate using fluorophore-assisted carbohydrate electrophoresis revealed significant differences in the relative percentage of all the mono-sulfated disaccharides, in particular the predominant mammalian disaccharide uronic acid-->N-acetyl-D-galactosamine-4-O-sulfate, confirming previous reports regarding variations in sulfation in dermatan sulfate from different tissues. Overall, these findings demonstrate that dermatan sulfate extracted from a range of bovine tissues exhibits in vitro antithrombin activity equivalent to or higher than that observed for porcine intestinal mucosa, identifying additional sources of dermatan sulfate as potential antithrombotic agents. FAU - Osborne, Simone A AU - Osborne SA AD - CSIRO, Livestock Industries, Queensland Bioscience Precinct, 306 Carmody Road, St Lucia, Queensland 4067, Australia. Simone.Osborne@csiro.au FAU - Daniel, Robyn A AU - Daniel RA FAU - Desilva, Kirthi AU - Desilva K FAU - Seymour, Robert B AU - Seymour RB LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20071222 PL - England TA - Glycobiology JT - Glycobiology JID - 9104124 RN - 0 (Antithrombins) RN - 0 (Disaccharides) RN - 24967-94-0 (Dermatan Sulfate) RN - 81604-65-1 (Heparin Cofactor II) SB - IM MH - Animals MH - Antithrombins/*chemistry/isolation & purification MH - Aorta/chemistry MH - Cattle MH - Dermatan Sulfate/*chemistry/isolation & purification MH - Diaphragm/chemistry MH - Disaccharides/*analysis MH - Electrophoresis, Agar Gel MH - Esophagus/chemistry MH - Eye/chemistry MH - Fractional Precipitation MH - Heparin Cofactor II/chemistry MH - Intestine, Large/chemistry MH - Intestine, Small/chemistry MH - Organ Specificity MH - Skin/chemistry MH - Tendons/chemistry MH - Tongue/chemistry EDAT- 2007/12/25 09:00 MHDA- 2008/07/30 09:00 CRDT- 2007/12/25 09:00 PHST- 2007/12/25 09:00 [pubmed] PHST- 2008/07/30 09:00 [medline] PHST- 2007/12/25 09:00 [entrez] AID - cwm136 [pii] AID - 10.1093/glycob/cwm136 [doi] PST - ppublish SO - Glycobiology. 2008 Mar;18(3):225-34. doi: 10.1093/glycob/cwm136. Epub 2007 Dec 22. PMID- 37984013 OWN - NLM STAT- MEDLINE DCOM- 20240129 LR - 20240129 IS - 1879-0267 (Electronic) IS - 0020-1383 (Linking) VI - 55 IP - 2 DP - 2024 Feb TI - Platelet-rich plasma-derived exosomes promote rotator cuff tendon-bone healing. PG - 111212 LID - S0020-1383(23)00929-4 [pii] LID - 10.1016/j.injury.2023.111212 [doi] AB - BACKGROUND: Rotator cuff tear (RCT) is the most common type of shoulder joint injury, platelet-rich plasma-derived exosomes (PRP-exos) are highly promising in tissue repair and regeneration. The purpose of this study was to determine the function of PRP-exos in rotator cuff tendon-bone healing. METHODS: PRP-exos were isolated from the rabbit whole blood by differential ultracentrifugation and characterized through transmission electron microscopy assay, nanoparticle tracking analysis, and western blotting. Alkaline phosphatase and Von Kossa staining were used to show tendon-derived stem cell (TDSC) differentiation. RT-qPCR and western blotting were performed to detect COL II, SOX-9, and TIMP-1. To determine the therapeutic effects of PRP-exos in vivo. Thirty New Zealand white rabbits were divided into control, model, and PRP-exos groups. The RCT animal model was constructed. The changes in tendon-bone tissue were determined by HE staining. Contents of COL-II, SOX-9, and TIMP-1 were determined by immunohistochemistry staining. RESULTS: PRP-exos were successfully isolated from rabbit blood. PRP-exos promoted TDSC proliferation and differentiation and also induced tendon-specific markers COL II, SOX-9, and TIMP-1 production. In vivo study revealed that PRP-exos promoted early healing of injured tendons. Rabbits treated with PRP-exos had better tissue arrangement in the tear site. Additionally, the contents of COL II, SOX-9, and TIMP-1 were also increased in the RCT rabbit model after PRP-exos treatment. CONCLUSIONS: PRP-exos enhanced tendon-bone healing by promoting TDSC proliferation and differentiation. This finding indicates that PRP-exos can serve as a promising strategy to treat rotator cuff tendon-bone healing. CI - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Han, Lei AU - Han L AD - Department of Orthopedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine), Hangzhou, 321000, China. FAU - Hu, Ningrui AU - Hu N AD - School of Clinical Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China. FAU - Wang, Canfeng AU - Wang C AD - Department of Orthopedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine), Hangzhou, 321000, China. FAU - Ye, Zhengcong AU - Ye Z AD - Department of Orthopedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine), Hangzhou, 321000, China. FAU - Wang, Tuo AU - Wang T AD - Department of Orthopedics, Jiangnan Hospital Affiliated to Zhejiang Chinese Medical University (Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine), Hangzhou, 321000, China. FAU - Lan, Fang AU - Lan F AD - Department of Orthopedics, Lishui TCM Hospital Affiliated to Zhejiang Chinese Medical University (Lishui Hospital of Traditional Chinese Medicine), No.800, Zhongshan Street, Lishui, 323000, China. Electronic address: lanfang866@126.com. LA - eng PT - Journal Article DEP - 20231114 PL - Netherlands TA - Injury JT - Injury JID - 0226040 RN - 0 (Tissue Inhibitor of Metalloproteinase-1) SB - IM MH - Rabbits MH - Animals MH - Rotator Cuff MH - Tissue Inhibitor of Metalloproteinase-1/analysis MH - *Exosomes MH - Tendons MH - *Rotator Cuff Injuries/therapy MH - *Shoulder Injuries MH - *Platelet-Rich Plasma OTO - NOTNLM OT - Exosomes OT - Platelet-rich plasma OT - Rotator cuff tear OT - Tendon stem cell OT - Tendon-bone healing COIS- Declaration of Competing Interest The authors report no conflict of interest. EDAT- 2023/11/20 18:43 MHDA- 2024/01/29 06:44 CRDT- 2023/11/20 18:00 PHST- 2023/09/21 00:00 [received] PHST- 2023/11/13 00:00 [accepted] PHST- 2024/01/29 06:44 [medline] PHST- 2023/11/20 18:43 [pubmed] PHST- 2023/11/20 18:00 [entrez] AID - S0020-1383(23)00929-4 [pii] AID - 10.1016/j.injury.2023.111212 [doi] PST - ppublish SO - Injury. 2024 Feb;55(2):111212. doi: 10.1016/j.injury.2023.111212. Epub 2023 Nov 14. PMID- 40141417 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20250514 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 26 IP - 6 DP - 2025 Mar 19 TI - Collagen Hydrolysates from Animal By-Products in Topical Cosmetic Formulations. LID - 10.3390/ijms26062776 [doi] LID - 2776 AB - The circular economy of animal by-products rich in collagen focuses on converting collagen into peptides with a defined molecular weight. Collagen hydrolysates prepared by biotechnological methods from chicken gizzards, deer tendons, and Cyprinus carpio skeletons can be an alternative source of collagen for cosmetic products that traditionally use bovine or porcine collagen hydrolysates. Collagen hydrolysates were characterized by antioxidant activity, surface tension, solution contact angle, and other parameters (dry weight, ash content, and solution clarity). Furthermore, the vibrational characterization of functional groups and their molecular weight was performed using the GPC-RID method. Subsequently, emulsion and gel cosmetic matrices were prepared with 0.5% and 1.5% collagen hydrolysates. Microbiological stability, organoleptic properties, and viscosity were investigated. Verification of the biophysical parameters of the topical formulations was performed in vivo on a group of volunteers by measuring skin hydration and pH and determining trans-epidermal water loss. Fish collagen hydrolysate was the most suitable for cosmetic applications in the parameters investigated. Moreover, it also effectively reduces wrinkles in the periorbital region when used in a gel matrix. FAU - Egner, Pavlína AU - Egner P AUID- ORCID: 0000-0001-5612-2996 AD - Department of Fat, Surfactant and Cosmetics Technology, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. FAU - Pavlačková, Jana AU - Pavlačková J AUID- ORCID: 0000-0002-4680-0930 AD - Department of Fat, Surfactant and Cosmetics Technology, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. FAU - Sedlaříková, Jana AU - Sedlaříková J AD - Department of Fat, Surfactant and Cosmetics Technology, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. FAU - Matošková, Lucie AU - Matošková L AD - Department of Fat, Surfactant and Cosmetics Technology, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. AD - Department of Polymer Engineering, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. FAU - Mokrejš, Pavel AU - Mokrejš P AUID- ORCID: 0000-0002-3168-413X AD - Department of Polymer Engineering, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. FAU - Janalíková, Magda AU - Janalíková M AUID- ORCID: 0000-0001-9669-1499 AD - Department of Environmental Protection Engineering, Faculty of Technology, Tomas Bata University in Zlín, Vavrečkova 5669, 760 01 Zlín, Czech Republic. LA - eng GR - IGA/FT/2025/006/Internal Grant Agency of the Faculty of Technology, Tomas Bata University in Zlín/ PT - Journal Article DEP - 20250319 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Cosmetics) RN - 9007-34-5 (Collagen) RN - 0 (Protein Hydrolysates) RN - 0 (Antioxidants) RN - 0 (Emulsions) SB - IM MH - Animals MH - *Cosmetics/chemistry/pharmacology MH - *Collagen/chemistry/pharmacology MH - *Protein Hydrolysates/chemistry/pharmacology MH - Humans MH - Antioxidants/chemistry/pharmacology MH - Skin/drug effects MH - Chickens MH - Cattle MH - Administration, Topical MH - Skin Aging/drug effects MH - Carps MH - Swine MH - Emulsions/chemistry PMC - PMC11942810 OTO - NOTNLM OT - animal by-products OT - antimicrobial effect OT - bioengineering methods OT - collagen hydrolysate OT - topical formulation OT - wrinkles COIS- The authors declare that they have no conflict of interest. EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 06:30 PMCR- 2025/03/19 CRDT- 2025/03/27 01:07 PHST- 2025/02/01 00:00 [received] PHST- 2025/03/16 00:00 [revised] PHST- 2025/03/17 00:00 [accepted] PHST- 2025/03/27 06:30 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 01:07 [entrez] PHST- 2025/03/19 00:00 [pmc-release] AID - ijms26062776 [pii] AID - ijms-26-02776 [pii] AID - 10.3390/ijms26062776 [doi] PST - epublish SO - Int J Mol Sci. 2025 Mar 19;26(6):2776. doi: 10.3390/ijms26062776. PMID- 36053307 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20221014 IS - 1437-160X (Electronic) IS - 0172-8172 (Linking) VI - 42 IP - 12 DP - 2022 Dec TI - Ochronotic arthropathy in the context of spondyloarthritis differential diagnosis: a case-based review. PG - 2277-2282 LID - 10.1007/s00296-022-05191-4 [doi] AB - Alkaptonuria is a disease often forgotten because of its rarity. Its pathogenic mechanism is the deficiency of one of the enzymes of the tyrosine degradation pathway-homogentisate-1, 2-dioxygenase, which sequelae is accumulation and deposition of its metabolite homogentisic acid in connective tissues and urine. Alkaptonuria presents as a clinical triad-darkening urine upon prolonged exposure to air, pigmentation of connective tissues and debilitating arthropathy. We present a case report of a 67-year old patient with alkaptonuria who presented with the clinical triad, but was mistakenly diagnosed as having ankylosing spondylitis in the past. Currently there is no treatment for the disease hence the management strategy was focused on symptoms control with analgesics, physical therapy, dietary modification, vitamin C supplementation, and joint arthroplasty. Alkaptonuria's clinical features are extensively described in the literature and despite the fact that it is a rare disease, due to the similar radiographic changes with spondyloarthropathies, it should be included in the differential diagnosis in young patients presenting with severe joint involvement. Early recognition of the disease is necessary since its natural evolution is joint destruction leading to significant reduction in the quality of life. Alkaptonuria's articular features in the spine and peripheral tissues are well described using the classical imaging techniques. Musculoskeletal ultrasonography shows a characteristic set of findings in the soft tissues, including synovium, cartilage, tendons and entheses. CI - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kostova, Tsvetelina AU - Kostova T AUID- ORCID: 0000-0003-0576-8345 AD - Department of Propaedeutics of Internal Medicine, Medical University-Plovdiv, Plovdiv, Bulgaria. tsvtkst@gmail.com. FAU - Batalov, Zguro AU - Batalov Z AUID- ORCID: 0000-0003-1233-5775 AD - Department of Propaedeutics of Internal Medicine, Medical University-Plovdiv, Plovdiv, Bulgaria. FAU - Karalilova, Rositsa AU - Karalilova R AUID- ORCID: 0000-0001-8030-0529 AD - Department of Propaedeutics of Internal Medicine, Medical University-Plovdiv, Plovdiv, Bulgaria. FAU - Batalov, Anastas AU - Batalov A AUID- ORCID: 0000-0001-8857-0574 AD - Department of Propaedeutics of Internal Medicine, Medical University-Plovdiv, Plovdiv, Bulgaria. LA - eng PT - Case Reports PT - Journal Article PT - Review DEP - 20220902 PL - Germany TA - Rheumatol Int JT - Rheumatology international JID - 8206885 RN - 42HK56048U (Tyrosine) RN - EC 1.13.11.- (Dioxygenases) RN - NP8UE6VF08 (Homogentisic Acid) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Aged MH - *Alkaptonuria/complications/diagnosis/metabolism MH - Ascorbic Acid MH - *Cartilage Diseases MH - *Dioxygenases MH - Homogentisic Acid/metabolism MH - Humans MH - *Joint Diseases MH - *Ochronosis/complications/diagnosis MH - *Osteoarthritis/complications MH - Quality of Life MH - *Spondylarthropathies/complications MH - Tyrosine OTO - NOTNLM OT - Alkaptonuria OT - Ochronosis OT - Ochronotic arthropathy OT - Spondyloarthritis EDAT- 2022/09/03 06:00 MHDA- 2022/10/12 06:00 CRDT- 2022/09/02 11:13 PHST- 2022/07/22 00:00 [received] PHST- 2022/08/16 00:00 [accepted] PHST- 2022/09/03 06:00 [pubmed] PHST- 2022/10/12 06:00 [medline] PHST- 2022/09/02 11:13 [entrez] AID - 10.1007/s00296-022-05191-4 [pii] AID - 10.1007/s00296-022-05191-4 [doi] PST - ppublish SO - Rheumatol Int. 2022 Dec;42(12):2277-2282. doi: 10.1007/s00296-022-05191-4. Epub 2022 Sep 2. PMID- 16932921 OWN - NLM STAT- MEDLINE DCOM- 20071105 LR - 20181113 IS - 0301-0449 (Print) IS - 0301-0449 (Linking) VI - 36 IP - 10 DP - 2006 Oct TI - Pre- and post-therapy MR imaging in fibrodysplasia ossificans progressiva. PG - 1108-11 AB - Fibrodysplasia ossificans progressiva, also known as myositis ossificans progressiva, is characterized by congenital skeletal malformations and progressive ectopic bone formation in connective tissues. The disorder presents as rapidly growing masses usually in the neck or paraspinal region with stiffness in the adjoining joints. The preosseous lesions involve the fascia, ligaments, tendons, and skeletal muscle. These lesions occasionally resolve but more often progress to form ectopic ossification. We present a boy who had a characteristic clinical presentation. Magnetic resonance (MR) imaging conducted in the preosseous stage of the lesion revealed the pathology, resulting in early therapy and resolution of the preosseous lesion without progression to ossification. To the best of our knowledge, post-therapy follow-up MR imaging in such a case has not been reported. FAU - Merchant, Rashid AU - Merchant R AD - Department of Pediatrics, Dr. Balabhai Nanavati Hospital and Research Centre, Mumbai, India. FAU - Sainani, Nisha I AU - Sainani NI FAU - Lawande, Malini A AU - Lawande MA FAU - Pungavkar, Sona A AU - Pungavkar SA FAU - Patkar, Deepak P AU - Patkar DP FAU - Walawalkar, Avinash AU - Walawalkar A LA - eng PT - Comparative Study PT - Journal Article DEP - 20060825 PL - Germany TA - Pediatr Radiol JT - Pediatric radiology JID - 0365332 RN - 0 (Glucocorticoids) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Child MH - Glucocorticoids/therapeutic use MH - Humans MH - *Magnetic Resonance Imaging MH - Male MH - Myositis Ossificans/drug therapy/*pathology MH - Prednisolone/therapeutic use EDAT- 2006/08/26 09:00 MHDA- 2007/11/06 09:00 CRDT- 2006/08/26 09:00 PHST- 2006/04/15 00:00 [received] PHST- 2006/06/09 00:00 [accepted] PHST- 2006/06/04 00:00 [revised] PHST- 2006/08/26 09:00 [pubmed] PHST- 2007/11/06 09:00 [medline] PHST- 2006/08/26 09:00 [entrez] AID - 10.1007/s00247-006-0270-7 [doi] PST - ppublish SO - Pediatr Radiol. 2006 Oct;36(10):1108-11. doi: 10.1007/s00247-006-0270-7. Epub 2006 Aug 25. PMID- 8810857 OWN - NLM STAT- MEDLINE DCOM- 19961211 LR - 20131121 IS - 0009-918X (Print) IS - 0009-918X (Linking) VI - 36 IP - 4 DP - 1996 Apr TI - [A case of diffuse fasciitis and its MRI findings]. PG - 594-7 AB - A 36-year-old woman with diffuse fasciitis and her MRI findings are reported. The patient developed pain and swelling in the calves, right forearm, and left arm, predominantly in the right calf muscle. Her body temperature was 38.4 degrees C, the ESR 104 mm/2 hours and white blood cell count 8,000/microliter without eosinophilia. The fascia and muscle were biopsied from her right calf. The light microscopy showed that the fascia was thickened and infiltrated with mononuclear cells with no eosinophils, mostly in perivascular areas. The muscle fibers were spared. MRI of legs revealed marked hyperintensities on T2 and mild hyperintensities on T1-weighted images in the fascia, superficial flexor muscles, especially soleus muscle, and Achilles tendons. Moderate dose of prednisolone was very effective and the abnormal signals on MRI almost disappeared within a month. T2 weighted MRI was very useful to detect the lesions and to evaluate the course of diffuse fasciitis. FAU - Fukuda, H AU - Fukuda H AD - Department of Neurology, Masuda Red Cross Hospital. FAU - Kitani, M AU - Kitani M LA - jpn PT - Case Reports PT - English Abstract PT - Journal Article PL - Japan TA - Rinsho Shinkeigaku JT - Rinsho shinkeigaku = Clinical neurology JID - 0417466 RN - 0 (Anti-Inflammatory Agents) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM CIN - Rinsho Shinkeigaku. 1997 Jan;37(1):70-1. PMID: 9146081 MH - Adult MH - Anti-Inflammatory Agents/administration & dosage MH - Fasciitis/*diagnosis/drug therapy/*pathology MH - Female MH - Humans MH - *Magnetic Resonance Imaging MH - Muscles/*pathology MH - Prednisolone/administration & dosage EDAT- 1996/04/01 00:00 MHDA- 1996/04/01 00:01 CRDT- 1996/04/01 00:00 PHST- 1996/04/01 00:00 [pubmed] PHST- 1996/04/01 00:01 [medline] PHST- 1996/04/01 00:00 [entrez] PST - ppublish SO - Rinsho Shinkeigaku. 1996 Apr;36(4):594-7. PMID- 27490216 OWN - NLM STAT- MEDLINE DCOM- 20180912 LR - 20210824 IS - 2329-9185 (Electronic) IS - 2329-9185 (Linking) VI - 4 IP - 5 DP - 2016 May 17 TI - Tendinopathy and Tendon Rupture Associated with Statins. LID - e4 [pii] LID - 10.2106/JBJS.RVW.15.00072 [doi] AB - Use of statins may be associated with certain tendinopathies and tendon ruptures, especially of the Achilles, quadriceps, and distal biceps tendons. Tendinopathy usually occurs within the first year of statin use and improves after the drug therapy is stopped. Systemic conditions with a higher risk of tendon rupture include diabetes, gout, rheumatoid arthritis, and chronic kidney disease. Certain drugs, such as corticosteroids and fluoroquinolones, have also been implicated in tendon ruptures. Patients with these systemic conditions who are taking statins in combination with other drugs that increase the risk of tendon injury should be educated about this risk and alternative treatments, including diet and exercise. FAU - Deren, Matthew E AU - Deren ME AD - Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island. FAU - Klinge, Stephen A AU - Klinge SA AD - Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island. FAU - Mukand, Nita H AU - Mukand NH AD - Wesleyan University, Middletown, Connecticut. AD - Southern New England Rehabilitation Center, North Providence, Rhode Island. FAU - Mukand, Jon A AU - Mukand JA AD - Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island. AD - Southern New England Rehabilitation Center, North Providence, Rhode Island. AD - Tufts University School of Medicine, Medford, Massachusetts. LA - eng PT - Journal Article PL - United States TA - JBJS Rev JT - JBJS reviews JID - 101674872 RN - 0 (Fluoroquinolones) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Achilles Tendon MH - Fluoroquinolones MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects MH - Rupture MH - Tendinopathy/*chemically induced MH - Tendon Injuries/*chemically induced EDAT- 2016/08/05 06:00 MHDA- 2018/09/13 06:00 CRDT- 2016/08/05 06:00 PHST- 2016/08/05 06:00 [entrez] PHST- 2016/08/05 06:00 [pubmed] PHST- 2018/09/13 06:00 [medline] AID - 01874474-201605000-00004 [pii] AID - 10.2106/JBJS.RVW.15.00072 [doi] PST - ppublish SO - JBJS Rev. 2016 May 17;4(5):e4. doi: 10.2106/JBJS.RVW.15.00072. PMID- 31726959 OWN - NLM STAT- MEDLINE DCOM- 20200605 LR - 20200605 IS - 1746-076X (Electronic) IS - 1746-0751 (Linking) VI - 14 IP - 11 DP - 2019 Nov TI - Regenerative effects of mesenchymal stem cells by dosage in a chronic rotator cuff tendon tear in a rabbit model. PG - 1001-1012 LID - 10.2217/rme-2018-0125 [doi] AB - Aim: We investigated the therapeutic effects and optimal dose of human umbilical cord blood (UCB)-derived mesenchymal stem cell (MSC) injection in a chronic full-thickness rotator cuff tendon tear. Methods: Rabbits (n = 30) were allocated into three groups (normal saline, G1-Sal; 1 × 10(6) cells UCB-MSC, G2-Low; 2 × 10(6) cells UCB-MSC, G3-High). Injections were done into the chronic full-thickness rotator cuff tendon tear 6 weeks after a full-thickness tendon tear of the subscapularis was created. Gross & histologic evaluation and motion analysis was done at pre and 4 weeks post-injection. Results: There were no significant differences in tear size and motion analysis parameters 4 weeks after injection between G2-Low and G3-High. Conclusion: The benefits of UCB-MSCs are not dose-dependent in a rabbit model. FAU - Kwon, Dong Rak AU - Kwon DR AD - Department of Rehabilitation Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea. FAU - Park, Gi-Young AU - Park GY AD - Department of Rehabilitation Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea. FAU - Lee, Sang Chul AU - Lee SC AD - Department & Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, South Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20191115 PL - England TA - Regen Med JT - Regenerative medicine JID - 101278116 RN - 0 (Proliferating Cell Nuclear Antigen) RN - G34N38R2N1 (Bromodeoxyuridine) SB - IM MH - Animals MH - Bromodeoxyuridine/metabolism MH - Chronic Disease MH - Disease Models, Animal MH - Fetal Blood/cytology MH - Humans MH - Injections MH - Male MH - *Mesenchymal Stem Cell Transplantation MH - Mesenchymal Stem Cells/*cytology MH - Proliferating Cell Nuclear Antigen/metabolism MH - Rabbits MH - *Regeneration MH - Rotator Cuff/*pathology MH - Rotator Cuff Injuries/pathology/*therapy OTO - NOTNLM OT - dose-response relationship OT - injections OT - mesenchymal stem cells OT - rabbits OT - regeneration OT - rotator cuff OT - shoulder OT - tendons OT - ultrasonography OT - umblical cord EDAT- 2019/11/16 06:00 MHDA- 2020/06/06 06:00 CRDT- 2019/11/16 06:00 PHST- 2019/11/16 06:00 [pubmed] PHST- 2020/06/06 06:00 [medline] PHST- 2019/11/16 06:00 [entrez] AID - 10.2217/rme-2018-0125 [doi] PST - ppublish SO - Regen Med. 2019 Nov;14(11):1001-1012. doi: 10.2217/rme-2018-0125. Epub 2019 Nov 15. PMID- 15988270 OWN - NLM STAT- MEDLINE DCOM- 20060120 LR - 20190713 IS - 1529-4242 (Electronic) IS - 0032-1052 (Linking) VI - 116 IP - 1 DP - 2005 Jul TI - 5-fluorouracil selectively inhibits collagen synthesis. PG - 209-21; discussion 222-3 AB - BACKGROUND: Fibroproliferative disorders, such as Dupuytren's contracture of the hand, are characterized by excessive production of collagen. 5-Fluorouracil has been used to treat fibroproliferative disorders of the eye and skin and is thought to inhibit thymidylate synthetase blocking DNA replication. 5-Fluorouracil has been shown to down-regulate fibroblast proliferation and differentiation in vitro. METHODS: This study investigated the dose-dependent effect of 5-fluorouracil on fibroblast extracellular matrix production. Fibroblasts were derived from tendon and primary Dupuytren's disease of the hand, a fibroproliferative disorder of the palmar aponeurosis (n = 4 patients). Total collagen synthesis was determined by means of the incorporation of radiolabeled proline. Fibroblast secretion of the profibrotic factor transforming growth factor-beta1 (TGF-beta1) was measured by a sandwich enzyme-linked immunosorbent assay. Gene expression of collagen types I and III and TGF-beta1 were quantified by means of reverse-transcriptase polymerase chain reaction assays. RESULTS: The authors found that 5-fluorouracil caused a dose-dependent, selective, and specific decrease in collagen production by Dupuytren's fibroblasts compared with noncollagenous protein synthesis. By contrast, procollagen types I and III mRNA were unaffected by 5-fluorouracil treatment. These changes did not appear to be mediated by alterations in the endogenous secretion of TGF-beta1 or its autocrine effect on collagen metabolism. CONCLUSIONS: The clinical implication is that 5-fluorouracil could possibly reduce extracellular matrix production and therefore reduce recurrence of Dupuytren's disease of the hand. FAU - Bulstrode, Neil W AU - Bulstrode NW AD - RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Middlesex, United Kingdom. FAU - Mudera, Vivek AU - Mudera V FAU - McGrouther, D Angus AU - McGrouther DA FAU - Grobbelaar, Adriaan O AU - Grobbelaar AO FAU - Cambrey, Alison D AU - Cambrey AD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Antimetabolites) RN - 0 (Extracellular Matrix Proteins) RN - 0 (TGFB1 protein, human) RN - 0 (Transforming Growth Factor beta) RN - 0 (Transforming Growth Factor beta1) RN - 9007-34-5 (Collagen) RN - U3P01618RT (Fluorouracil) SB - IM MH - Antimetabolites/administration & dosage/*pharmacology/therapeutic use MH - Cells, Cultured MH - Collagen/*biosynthesis MH - Dose-Response Relationship, Drug MH - Down-Regulation/physiology MH - Dupuytren Contracture/drug therapy/*metabolism MH - Extracellular Matrix Proteins/biosynthesis MH - Fibroblasts/*drug effects MH - Fluorouracil/administration & dosage/*pharmacology/therapeutic use MH - Gene Expression/drug effects MH - Granulation Tissue/cytology MH - Humans MH - Reverse Transcriptase Polymerase Chain Reaction MH - Tendons/metabolism MH - Transcription, Genetic/drug effects MH - Transforming Growth Factor beta/metabolism MH - Transforming Growth Factor beta1 EDAT- 2005/07/01 09:00 MHDA- 2006/01/21 09:00 CRDT- 2005/07/01 09:00 PHST- 2005/07/01 09:00 [pubmed] PHST- 2006/01/21 09:00 [medline] PHST- 2005/07/01 09:00 [entrez] AID - 00006534-200507000-00031 [pii] AID - 10.1097/01.prs.0000169701.16509.d6 [doi] PST - ppublish SO - Plast Reconstr Surg. 2005 Jul;116(1):209-21; discussion 222-3. doi: 10.1097/01.prs.0000169701.16509.d6. PMID- 11685105 OWN - NLM STAT- MEDLINE DCOM- 20011204 LR - 20190713 IS - 0041-1337 (Print) IS - 0041-1337 (Linking) VI - 72 IP - 8 DP - 2001 Oct 27 TI - Advanced glycation end product levels in eye lenses, aorta, and tail tendon in transplanted diabetic inbred Lewis rats. PG - 1370-5 AB - BACKGROUND: Pancreatic islet transplantation in diabetes, by restoring euglycemia, should in time correct the abnormal accumulation of advanced glycation end products (AGEs) over target tissues, thus delaying the development of late diabetic complications. METHODS: Homologous islet transplantation was performed in inbred Lewis rats 15 days (TA), 4 months (TB), and 8 months (TC) after streptozotocin diabetes. Group TA was studied for 12 months and groups TB and TC were studied for 4 months after transplantation. Normal (N) and diabetic (D) rats formed the control groups. Metabolic control in the transplant (T) groups was evaluated by oral glucose tolerance test. Blood glucose, glycated hemoglobin, and body weight were determined in all groups. AGE levels were determined by spectrofluorometry in eye lens proteins and by ELISA in aortic and tail tendon collagen. RESULTS: T groups showed normal oral glucose tolerance tests and metabolic parameters. The latter were altered in all D groups (P<0.005 to P<0.0001 versus N and T groups). AGEs were increased in the D groups (P<0.05 to P<0.001) versus the N groups. AGEs in the TA and TB groups were not different from those of the N groups but were significantly reduced (P<0.05 to P<0.001) when compared with those of the D groups. In the TC group, eye lens AGEs were significantly elevated (P<0.001) or significantly reduced (P<0.01) when compared with those of the N or D groups, respectively. Aortic collagen AGEs were elevated (P<0.01) by comparison with those of the N groups and not statistically different from those of the D groups. Tail tendon collagen AGE levels lay between those of the N and D groups, without reaching a statistical significance. CONCLUSIONS: These results indicate that primary and early secondary (groups TA and TB) but not late secondary (group TC) islet transplantations are capable of blocking or reducing an abnormal accumulation of AGEs, thus confirming the importance of preventive transplantation therapies. FAU - Sensi, M AU - Sensi M AD - Department of Clinical Sciences, University of Rome La Sapienza, Italy. maurizio.sensi@uniroma1.it FAU - Morano, S AU - Morano S FAU - Sagratella, E AU - Sagratella E FAU - Castaldo, P AU - Castaldo P FAU - Morelli, S AU - Morelli S FAU - Vetri, M AU - Vetri M FAU - Caltabiano, V AU - Caltabiano V FAU - Purrello, F AU - Purrello F FAU - Andreani, D AU - Andreani D FAU - Vecci, E AU - Vecci E FAU - Di Mario, U AU - Di Mario U LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Transplantation JT - Transplantation JID - 0132144 RN - 0 (Glycation End Products, Advanced) RN - 5W494URQ81 (Streptozocin) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Aorta/*chemistry MH - Collagen/analysis MH - Diabetes Mellitus, Experimental/metabolism/*therapy MH - Glycation End Products, Advanced/*analysis MH - *Islets of Langerhans Transplantation MH - Lens, Crystalline/*chemistry MH - Male MH - Rats MH - Rats, Inbred Lew MH - Streptozocin MH - Tail MH - Tendons/*chemistry EDAT- 2001/10/31 10:00 MHDA- 2002/01/05 10:01 CRDT- 2001/10/31 10:00 PHST- 2001/10/31 10:00 [pubmed] PHST- 2002/01/05 10:01 [medline] PHST- 2001/10/31 10:00 [entrez] AID - 10.1097/00007890-200110270-00006 [doi] PST - ppublish SO - Transplantation. 2001 Oct 27;72(8):1370-5. doi: 10.1097/00007890-200110270-00006. PMID- 25440131 OWN - NLM STAT- MEDLINE DCOM- 20150407 LR - 20181202 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 23 IP - 12 DP - 2014 Dec TI - Is resection of the tendon edge necessary to enhance the healing process? An evaluation of the expression of collagen type I, IL-1β, IFN-γ, IL-4, and IL-13 in the distal 1 cm of a torn supraspinatus tendon: part II. PG - 1779-1785 LID - S1058-2746(14)00496-0 [pii] LID - 10.1016/j.jse.2014.08.023 [doi] AB - BACKGROUND: Type I collagen proin pro-in expression in a damaged supraspinatus tendon is thought to be dependent on the distance from the edge of the tear and the local expression of pro-inflammatory, anti-proliferative, and pro-proliferative cytokines. The study evaluates the expression of type I collagen, pro-inflammatory interleukin (IL) 1β, anti-proliferative interferon-γ (IFN-γ), and pro-proliferative IL-4 and IL-13 cytokines along a 1-cm section taken from the edge of a torn supraspinatus tendon. Three sections were taken: 3 mm distal to the tear, 3 mm proximal to the tear, and the 4-mm middle section between them. METHODS: Nine patients (average age, 58 years) were included in the study. All fulfilled strict inclusion criteria regarding tear morphology and reconstruction technique. Samples were taken from the ruptured supraspinatus tendon at the time of arthroscopic repair. Quantitative real-time polymerase chain reaction assay was used for analysis. RESULTS: The expression of type I collagen, IL-4, and IL-13 significantly increased and that of IL-1β and IFN-γ decreased from the distal to the proximal parts of the tendon edge (P < .05). CONCLUSIONS: The expression of type I collagen is dependent on the distance from the edge of the torn supraspinatus tendon, the balance between anti-proliferative IFN-γ and pro-proliferative IL-4 and IL-13, and the expression of pro-inflammatory IL-1β. Hence, whereas resection of the distal 3 mm of the torn supraspinatus tendon edge eliminates its least valuable part, resection between 4 and 7 mm may enhance the healing process by reaching a reasonable compromise between the mechanical features of the tendon characterized by collagen type I expression and the technical abilities of reconstruction. CI - Copyright © 2014 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. FAU - Fabiś, Jaroslaw AU - Fabiś J AD - Department of Arthroscopy, Minimally Invasive Surgery and Sports Traumatology, Medical University of Łódź, Poland; FMC Private Medical Centre Łódź, Poland. Electronic address: fabis@onet.eu. FAU - Szemraj, Janusz AU - Szemraj J AD - Department of Medical Biochemistry, Medical University of Łódź, Poland. FAU - Strek, Małgorzata AU - Strek M AD - Department of Nucleic Acids Biochemistry, Medical University of Łódź, Poland. FAU - Fabiś, Anna AU - Fabiś A AD - Polish Mother's Memorial Research Institute, Łódź, Poland; FMC Private Medical Centre Łódź, Poland. FAU - Dutkiewicz, Zbigniew AU - Dutkiewicz Z AD - Department of Hand Surgery, Medical University of Łódź, Poland. FAU - Zwierzchowski, Tomasz Jacek AU - Zwierzchowski TJ AD - Department of Arthroscopy, Minimally Invasive Surgery and Sports Traumatology, Medical University of Łódź, Poland. LA - eng PT - Journal Article DEP - 20141108 PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Collagen Type I) RN - 0 (Cytokines) RN - 0 (Interleukin-13) RN - 0 (Interleukin-1beta) RN - 207137-56-2 (Interleukin-4) RN - 82115-62-6 (Interferon-gamma) SB - IM MH - Aged MH - Arthroscopy MH - Collagen Type I/biosynthesis MH - Cytokines/biosynthesis MH - Female MH - Humans MH - Interferon-gamma/biosynthesis MH - Interleukin-13/biosynthesis MH - Interleukin-1beta/biosynthesis MH - Interleukin-4/biosynthesis MH - Male MH - Middle Aged MH - Rotator Cuff/*metabolism/surgery MH - Rotator Cuff Injuries MH - Tendon Injuries/*metabolism/physiopathology MH - Tendons/*metabolism MH - Wound Healing/*physiology OTO - NOTNLM OT - Collagen type I OT - cytokines OT - supraspinatus tendon resection EDAT- 2014/12/03 06:00 MHDA- 2015/04/08 06:00 CRDT- 2014/12/03 06:00 PHST- 2014/05/01 00:00 [received] PHST- 2014/08/14 00:00 [revised] PHST- 2014/08/25 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2015/04/08 06:00 [medline] AID - S1058-2746(14)00496-0 [pii] AID - 10.1016/j.jse.2014.08.023 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2014 Dec;23(12):1779-1785. doi: 10.1016/j.jse.2014.08.023. Epub 2014 Nov 8. PMID- 33847460 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20220316 IS - 1552-4981 (Electronic) IS - 1552-4973 (Linking) VI - 109 IP - 11 DP - 2021 Nov TI - Inhibited effect of an RGD peptide hydrogel on the expression of β1-integrin, FAK, and Akt in Tenon's capsule fibroblasts. PG - 1857-1865 LID - 10.1002/jbm.b.34847 [doi] AB - Tenon's capsule fibroblasts are the main cellular components of filtration tract scar that limit the success rate of glaucoma filtration surgery. Scar formation results from infiltration and proliferation of fibroblasts into damaged areas, meanwhile synthesis of extracellular matrix glycoproteins. Integrins are cell surface receptors for extracellular molecules that mediate cell adhesion, spreading, migration, and invasion. They bind their ligands often through recognition of short amino-acid sequences-arginine-glycine-aspartic acid (RGD). Peptides that contain RGD sequence can compete with RGD containing insoluble matrix proteins for binding to the integrin receptor and thus prevent the downstream signaling pathway. Increasing evidence supports that β1-integrin/focal adhesion kinase (FAK)/Akt signal pathway plays an important role in fibrogenesis and scar formation in different tissues. In consideration of advantages of peptide hydrogel, that is well biocompatibility, gel state, degradability, good drug loading, we designed and fabricated an RGD peptide hydrogel, and hypothesized that it could inhibit the expression of β1-integrin, FAK, and Akt in Tenon's capsule fibroblasts. Rheology results showed that 1% wt Fmoc-FFGGRGD peptide solution could self-assemble into hydrogel. Western blot analysis revealed that there were statistical differences between control group and 1% wt group in β1-integrin/β-actin, FAK/β-actin, Akt/β-actin respectively (*p < .05). The relative mRNA expression of β1-integrin, FAK, Akt in control group and 1% wt group were also statistically different respectively (*p < .05). We proved that 1% wt Fmoc-FFGGRGD self-assembly peptide hydrogel could inhibit the expression of β1-integrin, FAK and Akt in Tenon's capsule fibroblasts. It is a promising way to solve scar formation of glaucoma filter channel. CI - © 2021 Wiley Periodicals LLC. FAU - Chen, Baoji AU - Chen B AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - Wu, Ping AU - Wu P AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - Liang, Liang AU - Liang L AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - Zhao, Chenchen AU - Zhao C AD - Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China. FAU - Wang, Zheng AU - Wang Z AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - He, Liye AU - He L AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - Zhang, Ran AU - Zhang R AD - Department of Ophthalmology, Yichang Central People's Hospital, The first college of Clinical Medical Science, China Three Gorges University, Yichang, China. FAU - Xu, Na AU - Xu N AD - Institute of Biology and Medicine, College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210413 PL - United States TA - J Biomed Mater Res B Appl Biomater JT - Journal of biomedical materials research. Part B, Applied biomaterials JID - 101234238 RN - 0 (Hydrogels) RN - 0 (Integrin beta1) RN - 0 (Oligopeptides) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - EC 2.7.10.2 (Focal Adhesion Kinase 1) RN - EC 2.7.10.2 (Ptk2 protein, rat) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) SB - IM MH - Animals MH - Fibroblasts/*metabolism MH - Focal Adhesion Kinase 1/*biosynthesis MH - Gene Expression Regulation/*drug effects MH - *Hydrogels/chemistry/pharmacology MH - Integrin beta1/*biosynthesis MH - *Oligopeptides/chemistry/pharmacology MH - Proto-Oncogene Proteins c-akt/*biosynthesis MH - Rats MH - Rats, Sprague-Dawley MH - Tendons/*metabolism OTO - NOTNLM OT - FAK/Akt OT - RGD OT - Tenon's capsule fibroblasts OT - integrin OT - peptide hydrogel EDAT- 2021/04/14 06:00 MHDA- 2022/03/17 06:00 CRDT- 2021/04/13 08:58 PHST- 2021/03/28 00:00 [revised] PHST- 2020/08/22 00:00 [received] PHST- 2021/03/31 00:00 [accepted] PHST- 2021/04/14 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/04/13 08:58 [entrez] AID - 10.1002/jbm.b.34847 [doi] PST - ppublish SO - J Biomed Mater Res B Appl Biomater. 2021 Nov;109(11):1857-1865. doi: 10.1002/jbm.b.34847. Epub 2021 Apr 13. PMID- 26518454 OWN - NLM STAT- MEDLINE DCOM- 20160829 LR - 20181113 IS - 1471-213X (Electronic) IS - 1471-213X (Linking) VI - 15 DP - 2015 Oct 30 TI - Stable and bicistronic expression of two genes in somite- and lateral plate-derived tissues to study chick limb development. PG - 39 LID - 10.1186/s12861-015-0088-3 [doi] LID - 39 AB - BACKGROUND: Components of the limb musculoskeletal system have distinct mesoderm origins. Limb skeletal muscles originate from somites, while the skeleton and attachments (tendons and connective tissues) derive from limb lateral plate. Despite distinct mesoderm origins, the development of muscle, skeleton and attachments is highly coordinated both spatially and temporally to ensure complete function of the musculoskeletal system. A system to study molecular interactions between somitic-derived tissues (muscles) and lateral-plate-derived tissues (skeletal components and attachments) during limb development is missing. RESULTS: We designed a gene delivery system in chick embryos with the ultimate aim to study the interactions between the components of the musculoskeletal system during limb development. We combined the Tol2 genomic integration system with the viral T2A system and developed new vectors that lead to stable and bicistronic expression of two proteins at comparable levels in chick cells. Combined with limb somite and lateral plate electroporation techniques, two fluorescent reporter proteins were co-expressed in stoichiometric proportion in the muscle lineage (somitic-derived) or in skeleton and their attachments (lateral-plate-derived). In addition, we designed three vectors with different promoters to target muscle cells at different steps of the differentiation process. CONCLUSION: Limb somite electroporation technique using vectors containing these different promoters allowed us to target all myogenic cells, myoblasts or differentiated muscle cells. These stable and promoter-specific vectors lead to bicistronic expression either in somitic-derived myogenic cells or lateral plate-derived cells, depending on the electroporation sites and open new avenues to study the interactions between myogenic cells and tendon or connective tissue cells during limb development. FAU - Bourgeois, Adeline AU - Bourgeois A AD - CNRS UMR 7622, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. la_logique@hotmail.com. AD - Sorbonne Universités, UPMC Univ Paris 06, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. la_logique@hotmail.com. AD - Inserm U1156, F-75005, Paris, France. la_logique@hotmail.com. FAU - Esteves de Lima, Joana AU - Esteves de Lima J AD - CNRS UMR 7622, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. joana.lima@upmc.fr. AD - Sorbonne Universités, UPMC Univ Paris 06, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. joana.lima@upmc.fr. AD - Inserm U1156, F-75005, Paris, France. joana.lima@upmc.fr. FAU - Charvet, Benjamin AU - Charvet B AD - CNRS UMR 7622, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. charvet.benjamin@voila.fr. AD - Sorbonne Universités, UPMC Univ Paris 06, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. charvet.benjamin@voila.fr. FAU - Kawakami, Koichi AU - Kawakami K AD - Division of Molecular and Developmental Biology, National Institute of Genetics, and Department of Genetics, SOKENDAI (The Graduate University for Advanced Studies), Mishima, Shizuoka, Japan. kokawaka@nig.ac.jp. FAU - Stricker, Sigmar AU - Stricker S AD - Institue for Chemistry and Biochemistry, Freie Universitaet Berlin, 14195, Berlin, Germany. sigmar.stricker@fu-berlin.de. FAU - Duprez, Delphine AU - Duprez D AD - CNRS UMR 7622, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. delphine.duprez@upmc.fr. AD - Sorbonne Universités, UPMC Univ Paris 06, IBPS-Developmental Biology Laboratory, F-75005, Paris, France. delphine.duprez@upmc.fr. AD - Inserm U1156, F-75005, Paris, France. delphine.duprez@upmc.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151030 PL - England TA - BMC Dev Biol JT - BMC developmental biology JID - 100966973 RN - 0 (Actins) RN - 0 (Cyclin-Dependent Kinase Inhibitor p57) RN - 0 (Myosin Light Chains) RN - 0 (enhanced green fluorescent protein) RN - 147336-22-9 (Green Fluorescent Proteins) SB - IM MH - Actins/genetics MH - Animals MH - Bone and Bones/*embryology MH - Chick Embryo MH - Cyclin-Dependent Kinase Inhibitor p57/genetics MH - Electroporation MH - Extremities/*embryology MH - Genetic Vectors/genetics MH - Green Fluorescent Proteins/genetics MH - Limb Buds/*embryology MH - Muscle Development/physiology MH - Muscle, Skeletal/*embryology MH - Myosin Light Chains/genetics MH - Organogenesis/genetics/physiology MH - Promoter Regions, Genetic/genetics MH - Somites/*embryology PMC - PMC4628273 EDAT- 2015/11/01 06:00 MHDA- 2016/08/30 06:00 PMCR- 2015/10/30 CRDT- 2015/11/01 06:00 PHST- 2015/06/19 00:00 [received] PHST- 2015/10/22 00:00 [accepted] PHST- 2015/11/01 06:00 [entrez] PHST- 2015/11/01 06:00 [pubmed] PHST- 2016/08/30 06:00 [medline] PHST- 2015/10/30 00:00 [pmc-release] AID - 10.1186/s12861-015-0088-3 [pii] AID - 88 [pii] AID - 10.1186/s12861-015-0088-3 [doi] PST - epublish SO - BMC Dev Biol. 2015 Oct 30;15:39. doi: 10.1186/s12861-015-0088-3. PMID- 19023016 OWN - NLM STAT- MEDLINE DCOM- 20090312 LR - 20211020 IS - 8750-7587 (Print) IS - 1522-1601 (Electronic) IS - 0161-7567 (Linking) VI - 106 IP - 2 DP - 2009 Feb TI - Effect of acute resistance exercise and sex on human patellar tendon structural and regulatory mRNA expression. PG - 468-75 LID - 10.1152/japplphysiol.91341.2008 [doi] AB - Tendon is mainly composed of collagen and an aqueous matrix of proteoglycans that are regulated by enzymes called matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Although it is known that resistance exercise (RE) and sex influence tendon metabolism and mechanical properties, it is uncertain what structural and regulatory components contribute to these responses. We measured the mRNA expression of tendon's main fibrillar collagens (type I and type III) and the main proteoglycans (decorin, biglycan, fibromodulin, and versican) and the regulatory enzymes MMP-2, MMP-9, MMP-3, and TIMP-1 at rest and after RE. Patellar tendon biopsy samples were taken from six individuals (3 men and 3 women) before and 4 h after a bout of RE and from a another six individuals (3 men and 3 women) before and 24 h after RE. Resting mRNA expression was used for sex comparisons (6 men and 6 women). Collagen type I, collagen type III, and MMP-2 were downregulated (P < 0.05) 4 h after RE but were unchanged (P > 0.05) 24 h after RE. All other genes remained unchanged (P > 0.05) after RE. Women had higher resting mRNA expression (P < 0.05) of collagen type III and a trend (P = 0.08) toward lower resting expression of MMP-3 than men. All other genes were not influenced (P > 0.05) by sex. Acute RE appears to stimulate a change in collagen type I, collagen type III, and MMP-2 gene regulation in the human patellar tendon. Sex influences the structural and regulatory mRNA expression of tendon. FAU - Sullivan, Bridget E AU - Sullivan BE AD - Human Performance Laboratory, Ball State University, Muncie, IN 47306, USA. FAU - Carroll, Chad C AU - Carroll CC FAU - Jemiolo, Bozena AU - Jemiolo B FAU - Trappe, Scott W AU - Trappe SW FAU - Magnusson, S Peter AU - Magnusson SP FAU - Døssing, Simon AU - Døssing S FAU - Kjaer, Michael AU - Kjaer M FAU - Trappe, Todd A AU - Trappe TA LA - eng GR - R01 AG-020532/AG/NIA NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20081120 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Fibrillar Collagens) RN - 0 (Proteoglycans) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.- (Matrix Metalloproteinases, Secreted) SB - IM MH - Adaptation, Physiological MH - Adult MH - Female MH - Fibrillar Collagens/*genetics MH - Gene Expression Regulation MH - Humans MH - Male MH - Matrix Metalloproteinases, Secreted/*genetics MH - Patellar Ligament/*metabolism MH - Proteoglycans/*genetics MH - RNA, Messenger/*metabolism MH - *Resistance Training MH - Sex Factors MH - Time Factors MH - Tissue Inhibitor of Metalloproteinase-1/*genetics MH - Young Adult PMC - PMC2644254 EDAT- 2008/11/22 09:00 MHDA- 2009/03/13 09:00 PMCR- 2010/02/01 CRDT- 2008/11/22 09:00 PHST- 2008/11/22 09:00 [pubmed] PHST- 2009/03/13 09:00 [medline] PHST- 2008/11/22 09:00 [entrez] PHST- 2010/02/01 00:00 [pmc-release] AID - 91341.2008 [pii] AID - JAPPL-91341-2008 [pii] AID - 10.1152/japplphysiol.91341.2008 [doi] PST - ppublish SO - J Appl Physiol (1985). 2009 Feb;106(2):468-75. doi: 10.1152/japplphysiol.91341.2008. Epub 2008 Nov 20. PMID- 15262646 OWN - NLM STAT- MEDLINE DCOM- 20050118 LR - 20220321 IS - 0363-5465 (Print) IS - 0363-5465 (Linking) VI - 32 IP - 5 DP - 2004 Jul-Aug TI - Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. PG - 1223-9 AB - BACKGROUND: Rotator cuff tears are a cause of pain and disability in the shoulder. The molecular changes associated with rotator cuff tearing are unclear. A subset of matrix metalloproteinases and tissue inhibitors of metalloproteinase, which are involved in extracellular matrix remodeling and degradation, were evaluated. HYPOTHESIS: There would be an increase in the mRNA level of specific matrix metalloproteinase and a decrease in the mRNA level of specific tissue inhibitors of metalloproteinase in rotator cuff tendon tissue obtained from patients with rotator cuff tears. STUDY DESIGN: Controlled laboratory study. METHODS: Tissue was obtained from 10 patients undergoing rotator cuff repair for full-thickness rotator cuff tears. Also, tissue was obtained from cadaveric specimens with no gross evidence of rotator cuff tearing. Reverse transcription polymerase chain reaction was performed for the collagenases (MMP-1, MMP-8, MMP-13), the stromelysins (MMP-3, MMP-10, MMP-11), and the tissue inhibitors of metalloproteinase (TIMP-1, TIMP-2, TIMP-3, TIMP-4). Western blotting was performed to confirm the mRNA changes demonstrated in collagenase-3 (MMP-13). RESULTS: There was a significant increase in collagenase-3 (MMP-13) mRNA levels, a decrease in stromelysin-1 (MMP-3) mRNA levels, and a decrease in tissue inhibitor of metalloproteinase-2, -3, and -4 mRNA levels. Western blotting demonstrated an increase in the active form of collagenase-3 (MMP-13) in rotator cuff tendon tears. CONCLUSIONS: The mRNA levels of specific matrix metalloproteinases and tissue inhibitors of metalloproteinase are altered in torn rotator cuff tendons. CLINICAL RELEVANCE: With the known action of the matrix metalloproteinases and tissue inhibitors of metalloproteinase in extra-cellular matrix remodeling, these findings suggest that their roles in remodeling of rotator cuff tears should be further investigated. CI - Copyright 2004 American Orthopaedic Society for Sports Medicine FAU - Lo, Ian K Y AU - Lo IK AD - University of Calgary, Alberta, Canada. ikylo@ucalgary.ca FAU - Marchuk, Linda L AU - Marchuk LL FAU - Hollinshead, Robert AU - Hollinshead R FAU - Hart, David A AU - Hart DA FAU - Frank, Cyril B AU - Frank CB LA - eng PT - Journal Article DEP - 20040518 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.- (MMP13 protein, human) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Aged MH - Blotting, Western MH - Cadaver MH - Case-Control Studies MH - Collagenases/*metabolism MH - Female MH - Humans MH - Male MH - Matrix Metalloproteinase 13 MH - Matrix Metalloproteinase 3/*metabolism MH - Middle Aged MH - RNA, Messenger/*metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Rotator Cuff/*metabolism MH - *Rotator Cuff Injuries MH - Tissue Inhibitor of Metalloproteinases/*metabolism EDAT- 2004/07/21 05:00 MHDA- 2005/01/19 09:00 CRDT- 2004/07/21 05:00 PHST- 2004/07/21 05:00 [pubmed] PHST- 2005/01/19 09:00 [medline] PHST- 2004/07/21 05:00 [entrez] AID - 0363546503262200 [pii] AID - 10.1177/0363546503262200 [doi] PST - ppublish SO - Am J Sports Med. 2004 Jul-Aug;32(5):1223-9. doi: 10.1177/0363546503262200. Epub 2004 May 18. PMID- 38722149 OWN - NLM STAT- MEDLINE DCOM- 20240530 LR - 20240530 IS - 1607-8438 (Electronic) IS - 0300-8207 (Linking) VI - 65 IP - 3 DP - 2024 May TI - Effect of cilostazol on healing of achilles tendon ruptures: an experimental study on rats. PG - 226-236 LID - 10.1080/03008207.2024.2349817 [doi] AB - PURPOSE: This study aimed to evaluate whether cilostazol (phosphodiesterase III inhibitor) could enhance the healing of Achilles tendon ruptures in rats. MATERIALS AND METHODS: The Achilles tendons of 24 healthy male adult rats were incised and repaired. The rats were randomly allocated to cilostazol and control groups. The cilostazol group received daily intragastric administration of 50 mg/kg cilostazol for 28 days, while the control group did not receive any medication. The rats were sacrificed on the 30th day, and the Achilles tendon was evaluated for biomechanical properties, histopathological characteristics, and immunohistochemical analysis. RESULTS: All rats completed the experiment. The Movin sum score of the control group was significantly higher (p = 0.008) than that of the cilostazol group, with means of 11 ± 0.63 and 7.50 ± 1.15, respectively. Similarly, the mean Bonar score was significantly higher (p = 0.026) in the control group compared to the cilostazol group (8.33 ± 1.50 vs. 5.5 ± 0.54, respectively). Moreover, the Type I/Type III Collagen ratio was notably higher (p = 0.016) in the cilostazol group (52.2 ± 8.4) than in the control group (34.6 ± 10.2). The load to failure was substantially higher in the cilostazol group than in the control group (p = 0.034), suggesting that the tendons in the cilostazol group were stronger and exhibited greater resistance to failure. CONCLUSIONS: The results of this study suggest that cilostazol treatment significantly improves the biomechanical and histopathological parameters of the healing Achilles tendon in rats. Cilostazol might be a valuable supplementary therapy in treating Achilles tendon ruptures in humans. Additional clinical studies are, however, required to verify these outcomes. FAU - Yılmaz, Baris AU - Yılmaz B AUID- ORCID: 0000-0003-2023-267X AD - Fatih Sultan Mehmet Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Istanbul, Turkey. FAU - Kose, Ozkan AU - Kose O AUID- ORCID: 0000-0002-7679-9635 AD - Antalya Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Antalya, Turkey. FAU - Karahan, Nazım AU - Karahan N AUID- ORCID: 0000-0003-0322-5515 AD - Fatih Sultan Mehmet Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Istanbul, Turkey. FAU - Tumentemur, Gamze AU - Tumentemur G AUID- ORCID: 0000-0002-3114-634X AD - Vocational School of Health Services, Department of Pedology, Acibadem University, Istanbul, Turkey. FAU - Ertan, Mehmet Barıs AU - Ertan MB AUID- ORCID: 0000-0002-3783-7109 AD - Antalya Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Antalya, Turkey. FAU - Ozdemir, Guzelali AU - Ozdemir G AUID- ORCID: 0000-0003-4279-0955 AD - Ankara Bilkent City Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Ankara, Turkey. FAU - Sirin, Evrim AU - Sirin E AUID- ORCID: 0000-0002-4752-2725 AD - Medical Faculty, Department of Orthopedics and Traumatology, Marmara University, Istanbul, Turkey. LA - eng PT - Journal Article DEP - 20240509 PL - England TA - Connect Tissue Res JT - Connective tissue research JID - 0365263 RN - N7Z035406B (Cilostazol) RN - 0 (Tetrazoles) SB - IM MH - Animals MH - *Cilostazol/pharmacology MH - *Achilles Tendon/pathology/injuries/drug effects MH - Male MH - *Wound Healing/drug effects MH - Rupture/drug therapy/pathology MH - Rats MH - Tendon Injuries/drug therapy/pathology MH - Rats, Sprague-Dawley MH - Biomechanical Phenomena/drug effects MH - Tetrazoles/pharmacology OTO - NOTNLM OT - Achilles tendon OT - Bonar score OT - Movin score OT - cilostazol OT - phosphodiesterase III inhibitor EDAT- 2024/05/09 14:25 MHDA- 2024/05/30 12:43 CRDT- 2024/05/09 08:53 PHST- 2024/05/30 12:43 [medline] PHST- 2024/05/09 14:25 [pubmed] PHST- 2024/05/09 08:53 [entrez] AID - 10.1080/03008207.2024.2349817 [doi] PST - ppublish SO - Connect Tissue Res. 2024 May;65(3):226-236. doi: 10.1080/03008207.2024.2349817. Epub 2024 May 9. PMID- 35012661 OWN - NLM STAT- MEDLINE DCOM- 20220323 LR - 20220323 IS - 1757-6512 (Electronic) IS - 1757-6512 (Linking) VI - 13 IP - 1 DP - 2022 Jan 10 TI - Nonwoven-based gelatin/polycaprolactone membrane loaded with ERK inhibitor U0126 for treatment of tendon defects. PG - 5 LID - 10.1186/s13287-021-02679-x [doi] LID - 5 AB - BACKGROUND: Tendon is a major component of musculoskeletal system connecting the muscles to the bone. Tendon injuries are very common orthopedics problems leading to impeded motion. Up to now, there still lacks effective treatments for tendon diseases. METHODS: Tendon stem/progenitor cells (TSPCs) were isolated from the patellar tendons of SD rats. The expression levels of genes were evaluated by quantitative RT-PCR. Immunohistochemistry staining was performed to confirm the presence of tendon markers in tendon tissues. Bioinformatics analysis of data acquired by RNA-seq was used to find out the differentially expressed genes. Rat patellar tendon injury model was used to evaluate the effect of U0126 on tendon injury healing. Biomechanical testing was applied to evaluate the mechanical properties of newly formed tendon tissues. RESULTS: In this study, we have shown that ERK inhibitor U0126 rather PD98059 could effectively increase the expression of tendon-related genes and promote the tenogenesis of TSPCs in vitro. To explore the underlying mechanisms, RNA sequencing was performed to identify the molecular difference between U0126-treated and control TSPCs. The result showed that GDF6 was significantly increased by U0126, which is an important factor of the TGFβ superfamily regulating tendon development and tenogenesis. In addition, NBM (nonwoven-based gelatin/polycaprolactone membrane) which mimics the native microenvironment of the tendon tissue was used as an acellular scaffold to carry U0126. The results demonstrated that when NBM was used in combination with U0126, tendon healing was significantly promoted with better histological staining outcomes and mechanical properties. CONCLUSION: Taken together, we have found U0126 promoted tenogenesis in TSPCs through activating GDF6, and NBM loaded with U0126 significantly promoted tendon defect healing, which provides a new treatment for tendon injury. CI - © 2021. The Author(s). FAU - Hou, Yonghui AU - Hou Y AD - Key Laboratory of Orthopaedics & Traumatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Zhou, Bingyu AU - Zhou B AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Ni, Ming AU - Ni M AD - Department of Orthopedics, the First Medical Center, the Fourth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, People's Republic of China. FAU - Wang, Min AU - Wang M AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Ding, Lingli AU - Ding L AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Li, Ying AU - Li Y AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. FAU - Liu, Yamei AU - Liu Y AD - Departments of Diagnostics of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Guangzhou, People's Republic of China. FAU - Zhang, Wencai AU - Zhang W AD - Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd., Suzhou, People's Republic of China. FAU - Li, Gang AU - Li G AD - Department of Orthopaedics & Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, People's Republic of China. gangli@cuhk.edu.hk. AD - Stem Cells and Regenerative Medicine Laboratory, Lui Che Woo Institute of Innovative Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Room 904, 9/F, Shatin, Hong Kong, SAR, People's Republic of China. gangli@cuhk.edu.hk. FAU - Wang, Jiali AU - Wang J AD - Biomedical Engineering School, Sun Yat-Sen University, Guangzhou, People's Republic of China. wangjli8@mail.sysu.edu.cn. FAU - Xu, Liangliang AU - Xu L AUID- ORCID: 0000-0002-5249-7480 AD - Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. xull-2016@gzucm.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220110 PL - England TA - Stem Cell Res Ther JT - Stem cell research & therapy JID - 101527581 RN - 0 (Butadienes) RN - 0 (Nitriles) RN - 0 (Polyesters) RN - 0 (U 0126) RN - 24980-41-4 (polycaprolactone) RN - 9000-70-8 (Gelatin) SB - IM MH - Animals MH - Butadienes MH - Cell Differentiation MH - *Gelatin/pharmacology MH - Nitriles MH - Polyesters MH - Rats MH - Rats, Sprague-Dawley MH - *Tendons PMC - PMC8744263 OTO - NOTNLM OT - GDF6 OT - Nonwoven-based gelatin OT - Polycaprolactone membrane OT - TSPCs OT - Tendon OT - U0126 COIS- The authors declare that they have no conflicts of interest with the contents of this article. EDAT- 2022/01/12 06:00 MHDA- 2022/03/24 06:00 PMCR- 2022/01/10 CRDT- 2022/01/11 05:57 PHST- 2021/05/28 00:00 [received] PHST- 2021/12/08 00:00 [accepted] PHST- 2022/01/11 05:57 [entrez] PHST- 2022/01/12 06:00 [pubmed] PHST- 2022/03/24 06:00 [medline] PHST- 2022/01/10 00:00 [pmc-release] AID - 10.1186/s13287-021-02679-x [pii] AID - 2679 [pii] AID - 10.1186/s13287-021-02679-x [doi] PST - epublish SO - Stem Cell Res Ther. 2022 Jan 10;13(1):5. doi: 10.1186/s13287-021-02679-x. PMID- 29694681 OWN - NLM STAT- MEDLINE DCOM- 20191024 LR - 20191024 IS - 1523-4681 (Electronic) IS - 0884-0431 (Linking) VI - 33 IP - 8 DP - 2018 Aug TI - Annexin A5 Involvement in Bone Overgrowth at the Enthesis. PG - 1532-1543 LID - 10.1002/jbmr.3453 [doi] AB - Little is known about the molecular mechanisms of enthesis formation in mature animals. Here, we report that annexin A5 (Anxa5) plays a critical role in the regulation of bone ridge outgrowth at the entheses. We found that Anxa5 is highly expressed in the entheses of postnatal and adult mice. In Anxa5-deficient (Anxa5(-/-) ) mice, the sizes of bone ridge outgrowths at the entheses of the tibias and femur were increased after age 7 weeks. Bone overgrowth was not observed at the fibrous enthesis where the fibrocartilage layer does not exist. More ALP-expressing cells were observed in the fibrocartilage layer in Anxa5(-/-) mice than in wild-type (WT) mice. Calcein and Alizarin Red double labeling revealed more mineralized areas in Anxa5(-/-) mice than WT mice. To examine the effects of mechanical forces, we performed tenotomy in which transmission of contractile forces by the tibial muscle was impaired by surgical muscle release. In tenotomized mice, bone overgrowth at the enthesis in Anxa5(-/-) mice was decreased to a level comparable to that in WT mice at 8 weeks after the operation. The tail-suspended mice also showed a decrease in bone overgrowth to similar levels in Anxa5(-/-) and WT mice at 8 weeks after hindlimb unloading. These results suggest that bone overgrowth at the enthesis requires mechanical forces. We further examined effects of Anxa5 gene knockdown (KD) in primary cultures of osteoblasts, chondrocytes, and tenocytes in vitro. Anxa5 KD increased ALP expression in tenocytes and chondrocytes but not in osteoblasts, suggesting that increased ALP activity in the fibrocartilaginous tissue in Anxa5(-/-) mice is directly caused by Anxa5 deletion in tenocytes or fibrocartilage cells. These data indicate that Anxa5 prevents bone overgrowth at the enthesis, whose formation is mediated through mechanical forces and modulating expression of mineralization regulators. © 2018 American Society for Bone and Mineral Research. CI - © 2018 American Society for Bone and Mineral Research. FAU - Shimada, Akemi AU - Shimada A AD - Department of Pharmacology, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Ideno, Hisashi AU - Ideno H AD - Department of Pharmacology, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Arai, Yoshinori AU - Arai Y AD - Nihon University, School of Dentistry, Chiyoda-ku, Tokyo, Japan. FAU - Komatsu, Koichiro AU - Komatsu K AD - Department of Pharmacology, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Wada, Satoshi AU - Wada S AD - Department of Orthodontics, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Yamashita, Teruhito AU - Yamashita T AD - Division of Hard Tissue Research, Institute for Oral Science, Matsumoto Dental University, Shiojiri, Japan. FAU - Amizuka, Norio AU - Amizuka N AD - Department of Developmental Biology of Hard Tissue, Division of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan. FAU - Pöschl, Ernst AU - Pöschl E AD - School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, UK. FAU - Brachvogel, Bent AU - Brachvogel B AD - Experimental Neonatology, Department of Pediatrics and Adolescent Medicine, Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany. FAU - Nakamura, Yoshiki AU - Nakamura Y AD - Department of Orthodontics, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Nakashima, Kazuhisa AU - Nakashima K AD - Department of Pharmacology, Tsurumi University School of Dental Medicine, Yokohama, Japan. FAU - Mizukami, Hiroaki AU - Mizukami H AD - Division of Genetics Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan. FAU - Ezura, Yoichi AU - Ezura Y AD - Department of Molecular Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan. FAU - Nifuji, Akira AU - Nifuji A AD - Department of Pharmacology, Tsurumi University School of Dental Medicine, Yokohama, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Bone Miner Res JT - Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research JID - 8610640 RN - 0 (Annexin A5) RN - EC 3.1.3.1 (Alkaline Phosphatase) SB - IM MH - Alkaline Phosphatase/metabolism MH - Animals MH - Annexin A5/deficiency/*metabolism MH - *Bone Development MH - Bone and Bones/*metabolism MH - Cartilage/growth & development MH - Cell Differentiation MH - Chondrocytes/metabolism MH - Femur/growth & development/metabolism MH - Hindlimb/metabolism MH - Mice, Knockout MH - Osteoblasts/metabolism MH - Tendons/growth & development MH - Tenocytes/metabolism MH - Tibia/growth & development/metabolism MH - Weight-Bearing OTO - NOTNLM OT - ANNEXIN A5 OT - BONE MORPHOGENESIS OT - ENTHESIS OT - LACZ KNOCK-IN MOUSE OT - TENDON/LIGAMENT EDAT- 2018/04/26 06:00 MHDA- 2019/10/28 06:00 CRDT- 2018/04/26 06:00 PHST- 2017/08/24 00:00 [received] PHST- 2018/04/08 00:00 [revised] PHST- 2018/08/12 00:00 [accepted] PHST- 2018/04/26 06:00 [pubmed] PHST- 2019/10/28 06:00 [medline] PHST- 2018/04/26 06:00 [entrez] AID - 10.1002/jbmr.3453 [doi] PST - ppublish SO - J Bone Miner Res. 2018 Aug;33(8):1532-1543. doi: 10.1002/jbmr.3453. PMID- 23371911 OWN - NLM STAT- MEDLINE DCOM- 20131030 LR - 20250227 IS - 1880-6562 (Electronic) IS - 1880-6546 (Print) IS - 1880-6546 (Linking) VI - 63 IP - 3 DP - 2013 May TI - Hepatocyte growth factor inhibits TGF-β1-induced myofibroblast differentiation in tendon fibroblasts: role of AMPK signaling pathway. PG - 163-70 LID - 10.1007/s12576-013-0251-1 [doi] AB - The transforming growth factor-β1 (TGF-β1)-induced myofibroblastic differentiation in tendon fibroblasts was thought to be one of the most important features of scar fibrosis formation, which is associated with occurrence of re-rupture. Previously, we reported that hepatocyte growth factor (HGF) inhibited TGF-β1-induced myofibroblast differentiation and extracellular matrix deposition in the Achilles tendon of rats. Here, we investigated the potential molecular mechanisms underlying the inhibitory effect of HGF on TGF-β1-induced myofibroblast differentiation. We found that treatment with HGF (10, 20, and 40 ng/ml) increased phosphorylation of adenosine monophosphate kinase (AMPK) and acetyl-CoA carboxylase (ACC) in tendon fibroblasts. Pharmacological inhibition of the AMPK signaling pathway using compound C, a specific blocker of AMPK signaling, remarkably attenuated the inhibitory effect of HGF on TGF-β1-induced myofibroblastic differentiation in tendon fibroblasts. Moreover, small interfering RNA (siRNA)-mediated knockdown of AMPKα1 subunit decreased the inhibitory effect of HGF on TGF-β1-induced myofibroblastic differentiation in tendon fibroblasts. Finally, overexpression of constitutively active AMPKα1, which led to constitutive activation of the AMPK signaling pathway in tendon fibroblasts, mimicked the inhibitory effect of HGF on the TGF-β1-induced myofibroblastic differentiation. Our study therefore suggests that HGF inhibits TGF-β1-induced myofibroblastic differentiation via an AMPK signaling pathway-dependent manner in tendon fibroblasts. FAU - Cui, Qingbo AU - Cui Q AD - Pediatric Orthopedics Unit, Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150081, China. FAU - Fu, Songbin AU - Fu S FAU - Li, Zhaozhu AU - Li Z LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130201 PL - United States TA - J Physiol Sci JT - The journal of physiological sciences : JPS JID - 101262417 RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 0 (Transforming Growth Factor beta1) RN - 10K52CIC1Z (dorsomorphin) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - EC 2.7.11.31 (AMP-Activated Protein Kinases) RN - EC 2.7.11.31 (Prkaa1 protein, rat) RN - EC 2.7.4.3 (Adenylate Kinase) RN - EC 6.4.1.2 (Acetyl-CoA Carboxylase) SB - IM EIN - J Physiol Sci. 2020 Oct 26;70(1):51. doi: 10.1186/s12576-020-00778-7. PMID: 33106156 MH - AMP-Activated Protein Kinases/biosynthesis/genetics MH - Acetyl-CoA Carboxylase/metabolism MH - Adenylate Kinase/antagonists & inhibitors/physiology MH - Animals MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - Fibroblasts/cytology/drug effects MH - Gene Knockdown Techniques MH - Hepatocyte Growth Factor/*pharmacology MH - Male MH - Myofibroblasts/*cytology MH - Phosphorylation/drug effects MH - Pyrazoles/pharmacology MH - Pyrimidines/pharmacology MH - Rats MH - Signal Transduction/drug effects/physiology MH - Tendons/cytology MH - Transforming Growth Factor beta1/*antagonists & inhibitors PMC - PMC10718008 COIS- All the authors declared no conflict of interests. EDAT- 2013/02/02 06:00 MHDA- 2013/10/31 06:00 PMCR- 2013/02/01 CRDT- 2013/02/02 06:00 PHST- 2012/10/24 00:00 [received] PHST- 2013/01/13 00:00 [accepted] PHST- 2013/02/02 06:00 [entrez] PHST- 2013/02/02 06:00 [pubmed] PHST- 2013/10/31 06:00 [medline] PHST- 2013/02/01 00:00 [pmc-release] AID - S1880-6546(24)00926-0 [pii] AID - 251 [pii] AID - 10.1007/s12576-013-0251-1 [doi] PST - ppublish SO - J Physiol Sci. 2013 May;63(3):163-70. doi: 10.1007/s12576-013-0251-1. Epub 2013 Feb 1. PMID- 29309458 OWN - NLM STAT- MEDLINE DCOM- 20180803 LR - 20180803 IS - 1934-3418 (Electronic) IS - 1078-4519 (Linking) VI - 46 IP - 6 DP - 2017 Nov/Dec TI - Peroneus Quartus Muscle. PG - E419-E422 AB - The peroneus quartus (PQ) muscle is a rare but sometimes missed potential etiology of ankle pain and tendon subluxation. We report the case of a 16-year-old boy who presented with lateral right ankle pain and subluxation of peroneal tendons. He had a history of non-Hodgkin lymphoma and palpable distal fibular osteochondroma. Seven months after excision of the exostosis and repair of the peroneal tendon retinaculum, the pain recurred. Imaging showed a split peroneus brevis (PB) tendon. During surgery, a PQ muscle was found and excised, and the PB tendon was repaired. One year after surgery, the patient's symptoms were resolved. FAU - Habashy, Alexander AU - Habashy A AD - Department of Orthopedics, Ochsner Clinic Foundation, New Orleans, LA. alexander.habashy@ochsner.org. FAU - Cook, Brandon AU - Cook B FAU - Sumarriva, Gonzalo AU - Sumarriva G FAU - Treuting, Robert AU - Treuting R LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Am J Orthop (Belle Mead NJ) JT - American journal of orthopedics (Belle Mead, N.J.) JID - 9502918 RN - 981Y8SX18M (Bendamustine Hydrochloride) SB - IM MH - Adolescent MH - Bendamustine Hydrochloride MH - Bone Neoplasms/complications/diagnostic imaging/*surgery MH - Fibula/diagnostic imaging/*surgery MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Muscle, Skeletal/*surgery MH - Orthopedic Procedures/*methods MH - Osteochondroma/complications/diagnostic imaging/*surgery MH - Tendon Injuries/complications/diagnostic imaging/*surgery COIS- Authors’ Disclosure Statement: The authors report no actual or potential conflict of interest in relation to this article. EDAT- 2018/01/09 06:00 MHDA- 2018/08/04 06:00 CRDT- 2018/01/09 06:00 PHST- 2018/01/09 06:00 [entrez] PHST- 2018/01/09 06:00 [pubmed] PHST- 2018/08/04 06:00 [medline] PST - ppublish SO - Am J Orthop (Belle Mead NJ). 2017 Nov/Dec;46(6):E419-E422. PMID- 38515411 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20240325 IS - 1003-0034 (Print) IS - 1003-0034 (Linking) VI - 37 IP - 3 DP - 2024 Mar 25 TI - [A multicenter clinical study on the treatment of lateral epicondylitis of humerus by manipulation]. PG - 251-7 LID - 10.12200/j.issn.1003-0034.20230252 [doi] AB - OBJECTIVE: To investigate clinical effect of tendons pulling,poking and kneading for the treatment of external humeral epicondylitis. METHODS: From January 2018 to December 2021,a multicenter randomized controlled study was performed to collect 192 patients with external humeral epicondylitis in Wangjing Hospital,Beijing Dianli Hospital,and Beijing Fengsheng Osteotraumatology Hospital,respectively,and they were divided into treatment group and control group by random number table method. There were 96 patients in treatment group,including 36 males and 60 females,aged from 28 to 60 years old with an average of (41.20±5.50) years old;the course of disease ranged from 1 to 14 days with an average of (5.24±1.35) days;they were treated once every other day for 2 weeks. There were 96 patients in control group ,including 33 males and 63 females,aged from 26 to 60 years old with an average of (43.35±7.75) years old;the course of disease ranged from 1 to 14 days with an average of (5.86±1.48) days;they were treated with topical voltaalin combined with elbow joint fixation for 2 weeks. Visual analogue scale (VAS) and Hospital for Surgery Scoring System (HSS) elbow pronation and supination angles,wrist metacarpal flexion and dorsal extension angles,elbow tenderness between two groups were compared before treatment and at 1,3,5,7,11 and 13 days after treatment;Hospital for Surgery Scoring System 2 (HSS2) was compared before treatment and the final treatment. RESULTS: All patients were followed up for 10 to 14 days with an average of (12±1.6) days. VAS between treatment group and control group before treatment were 6.83±1.36 and 6.79±1.58,respectively,and decreased to 1.49±1.09 and 2.11±1.81 after the final treatment. VAS of treatment group were significantly lower than those of control group at 1,3,5,7,9,11 and 13 days after treatment (P<0.05). HSS between two groups were 61.73±11.00 and 36.47±12.45 before treatment,respectively,and increased to 94.42±5.9 and 91.44±9.11 at the final treatment. HSS of treatment group were significantly higher than those of control group at 1,3,5,7,9,11 and 13 days after treatment (P<0.05). On the 5th day after treatment,the external and internal rotation angles of elbow in treatment group were (66.41±12.69) ° and (66.35±13.54) °,while those in control group were (62.08±16.03) ° and (61.77±16.35) °. On the 7th day after treatment,the external and internal rotation angles of elbow were (69.79±12.64) ° and (70.02±13.55) ° in treatment group,and (65.28±15.86) ° and (65.09±16.67) ° in control group. Elbow joint motion in treatment group was higher than that in control group (P<0.05). On the 5th day after treatment,angles of wrist dorsiflexion and palm flexion were (39.43±15.94) ° and (46.68±11.10) ° in treatment group,and (38.51±18.49) ° and (44.27±13.58) ° in control group. On the 7th day after treatment,angles of wrist dorsiflexion and palm flexion were (42.52±16.50) ° and (49.23±10.96) ° in treatment group,and (41.18±20.09) ° and (46.64±14.63) ° in control group. The motion of wrist joint in treatment group was higher than that in control group (P<0.05). On the 13th day after treatment,HSS2 in treatment group 93.61±6.32 were higher than those in control group 92.06±7.94(P<0.05). There was no significant difference in elbow tenderness between two groups at each time point (P>0.05). CONCLUSION: Voltaren external treatment combined with elbow fixation and tendons pulling,poking and kneading could effectively improve symptoms of external humeral epicondylitis. Compared with voltaren external treatment,tendons pulling,poking and kneading has advantages of longer analgesic time and better elbow function recovery. FAU - Hou, Xiao-Zhou AU - Hou XZ AD - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China. FAU - Yin, Jing AU - Yin J AD - Beijing Electric Power Hospital, Beijing 100055, China. FAU - Wang, Hai-Yang AU - Wang HY AD - Beijing Fengsheng TCM Bone Trauma Hospital, Beijing 100033, China. FAU - Gu, Jin-Yu AU - Gu JY AD - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China. FAU - Wan, Tian-Hao AU - Wan TH AD - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China. FAU - Yang, Man-Hong AU - Yang MH AD - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China. FAU - Xia, Di AU - Xia D AD - 1. Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China; 2. Beijing Electric Power Hospital, Beijing 100055, China; 3. Beijing Fengsheng TCM Bone Trauma Hospital, Beijing 100033, China. FAU - Zhang, Qing AU - Zhang Q AD - Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100102, China. LA - chi PT - English Abstract PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - China TA - Zhongguo Gu Shang JT - Zhongguo gu shang = China journal of orthopaedics and traumatology JID - 9815790 RN - 144O8QL0L1 (Diclofenac) SB - IM MH - Male MH - Female MH - Humans MH - Adult MH - Middle Aged MH - *Tennis Elbow/therapy MH - Diclofenac MH - Treatment Outcome MH - Humerus/surgery MH - Elbow MH - *Elbow Joint/surgery MH - Range of Motion, Articular MH - Retrospective Studies OTO - NOTNLM OT - Manipulation OT - Case-control study OT - Lateral epicondylitis EDAT- 2024/03/22 06:44 MHDA- 2024/03/25 06:43 CRDT- 2024/03/22 03:52 PHST- 2024/03/25 06:43 [medline] PHST- 2024/03/22 06:44 [pubmed] PHST- 2024/03/22 03:52 [entrez] AID - 10.12200/j.issn.1003-0034.20230252 [doi] PST - ppublish SO - Zhongguo Gu Shang. 2024 Mar 25;37(3):251-7. doi: 10.12200/j.issn.1003-0034.20230252. PMID- 17600990 OWN - NLM STAT- MEDLINE DCOM- 20070827 LR - 20131121 IS - 0300-5283 (Print) IS - 0300-5283 (Linking) VI - 61 Suppl B DP - 2006 Dec TI - Use of gentamicin impregnated POP discs for antibiotic pouch dressing. PG - 32-6 AB - Antibiotic pouch technique is commonly used due to the high local antibiotic concentration and moist environment for wound healing. We used locally made gentamicin impregnated Plaster of Paris discs in treating wounds with exposed deep structures like tendons and bones. Out of 22 patients treated with this method, 19 completed treatment. Granulation tissue formed quickly and effectively covered the exposed structures. All wounds either healed by secondary intention or became suitable for split skin grafting. Gentamicin impregnated Plaster of Paris disc pouch dressing is safe, cost saving, and effective for management of deep open wounds. FAU - Lau, C P AU - Lau CP AD - Department of Orthopaedics and Trauma, Hospital Tengku Ampuan Rahimah, Klang. FAU - Chee, E K AU - Chee EK FAU - Thirumal, M AU - Thirumal M LA - eng PT - Journal Article PL - Malaysia TA - Med J Malaysia JT - The Medical journal of Malaysia JID - 0361547 RN - 0 (Anti-Bacterial Agents) RN - 0 (Coated Materials, Biocompatible) RN - 0 (Gentamicins) RN - WAT0DDB505 (Calcium Sulfate) SB - IM MH - Administration, Topical MH - Adolescent MH - Adult MH - Aged MH - Anti-Bacterial Agents/administration & dosage/*therapeutic use MH - *Bandages MH - *Calcium Sulfate MH - *Coated Materials, Biocompatible MH - Female MH - Follow-Up Studies MH - Gentamicins/administration & dosage/*therapeutic use MH - Humans MH - Male MH - Middle Aged MH - Retrospective Studies MH - Treatment Outcome MH - Wound Healing/drug effects MH - Wound Infection/*therapy MH - Wounds and Injuries/therapy EDAT- 2007/07/03 09:00 MHDA- 2007/08/28 09:00 CRDT- 2007/07/03 09:00 PHST- 2007/07/03 09:00 [pubmed] PHST- 2007/08/28 09:00 [medline] PHST- 2007/07/03 09:00 [entrez] PST - ppublish SO - Med J Malaysia. 2006 Dec;61 Suppl B:32-6. PMID- 8832995 OWN - NLM STAT- MEDLINE DCOM- 19970512 LR - 20220316 IS - 0315-162X (Print) IS - 0315-162X (Linking) VI - 23 IP - 3 DP - 1996 Mar TI - Fluoroquinolone induced tendinopathy: report of 6 cases. PG - 516-20 AB - We describe 6 cases of fluoroquinolone induced Achilles tendinitis in 4 women and 2 men, mean age 68.6 years. Patients presented with pain and swelling of sudden onset, which was most often bilateral. Tendon rupture was frequent, accompanied by nodules and ecchymoses. The diagnosis was clinical, occasionally ultrasonography was helpful; the role of magnetic resonance imaging has yet to be defined. Certain risk factors were found, particularly association with longterm steroid therapy, and close surveillance of high risk subjects is mandatory. Although proper dosage and duration of treatment were respected, the principal fluoroquinolones were clearly incriminated. We found no correlation between treatment duration and the degree of involvement. Nevertheless, immediate discontinuation of the antibiotic and placement of both Achilles tendons at rest is essential. Early and appropriate management did not prevent prolonged recovery times and there was always a risk of functional sequelae. This side effect is class related and rare. Its physiopathologic mechanism is poorly understood. FAU - Zabraniecki, L AU - Zabraniecki L AD - CHRU Dupuytren, Department of Rheumatology, Limoges, France. FAU - Negrier, I AU - Negrier I FAU - Vergne, P AU - Vergne P FAU - Arnaud, M AU - Arnaud M FAU - Bonnet, C AU - Bonnet C FAU - Bertin, P AU - Bertin P FAU - Treves, R AU - Treves R LA - eng PT - Case Reports PT - Journal Article PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Infective Agents/*adverse effects MH - Contraindications MH - Female MH - Fluoroquinolones MH - Humans MH - Male MH - Tendinopathy/*chemically induced/diagnosis/therapy MH - Treatment Outcome EDAT- 1996/03/01 00:00 MHDA- 1996/03/01 00:01 CRDT- 1996/03/01 00:00 PHST- 1996/03/01 00:00 [pubmed] PHST- 1996/03/01 00:01 [medline] PHST- 1996/03/01 00:00 [entrez] PST - ppublish SO - J Rheumatol. 1996 Mar;23(3):516-20. PMID- 6578713 OWN - NLM STAT- MEDLINE DCOM- 19831123 LR - 20191023 IS - 0171-9750 (Print) IS - 0171-9750 (Linking) VI - 6 DP - 1983 TI - Disposition of phencyclidine after intramuscular administration. PG - 132-6 AB - The disposition of radioactive phencyclidine (PCP) in various rat tissues, after single or repeated intramuscular injections for 23 days, have been investigated. Peak levels of radioactivity appeared 45-90 min after a single administration. The pancreas, salivary glands and mesenteric fat contained 4 to 6-fold higher radioactivity than brain, muscles, tendons, and bones. After repeated 3H-PCP injections, radioactivity levels showed a similar pattern as to that of the peak levels after a single administration, but at notably higher values. On the other hand, the percentage of depletion, within 48 h after the final injection, was the highest in the pancreas, salivary glands and mesenteric fat. It is possible that despite the low retention capacity of PCP radioactivity per unit weight of muscle, tendon and bone, they may be considered important reservoirs for either PCP, or its metabolites or both because of their large relative mass in the body. FAU - Chari-Bitron, A AU - Chari-Bitron A FAU - Edery, H AU - Edery H FAU - Chen, R AU - Chen R FAU - Motola, L AU - Motola L LA - eng PT - Journal Article PL - Germany TA - Arch Toxicol Suppl JT - Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement JID - 7802567 RN - J1DOI7UV76 (Phencyclidine) SB - IM MH - Animals MH - Ataxia/chemically induced MH - Injections, Intramuscular MH - Male MH - Phencyclidine/administration & dosage/*metabolism MH - Rats MH - Rats, Inbred Strains MH - Time Factors MH - Tissue Distribution EDAT- 1983/01/01 00:00 MHDA- 1983/01/01 00:01 CRDT- 1983/01/01 00:00 PHST- 1983/01/01 00:00 [pubmed] PHST- 1983/01/01 00:01 [medline] PHST- 1983/01/01 00:00 [entrez] AID - 10.1007/978-3-642-69083-9_22 [doi] PST - ppublish SO - Arch Toxicol Suppl. 1983;6:132-6. doi: 10.1007/978-3-642-69083-9_22. PMID- 7543508 OWN - NLM STAT- MEDLINE DCOM- 19950914 LR - 20190913 IS - 0022-149X (Print) IS - 0022-149X (Linking) VI - 69 IP - 2 DP - 1995 Jun TI - Trichrome staining of Gyrodactylus sclerites and soft tissues following fixation in ammonium picrate-glycerin, including an improved rendition of the haptoral bars of G. turnbulli. PG - 149-54 AB - A simple technique using modified Mallory stain in the transferral of Gyrodactylus specimens from ammonium picrate-glycerin to a permanent mountant is described. Hamuli, their connecting bars and the penis sclerites are well defined by the technique as are muscles and tendons, cell nuclei, tegument and gland cells. As well as being useful in the study of general anatomy, the technique enhances the observation of the taxonomically important ventral and dorsal bars. In order to show this, improved illustrations of the dorsal and ventral bars of G. turnbulli are given along with explicit demonstrations of differences in morphology of the ventral bars of G. bullatarudis and G. rasini-two easily confused species. FAU - Richards, G R AU - Richards GR AD - Department of Environmental and Evolutionary Biology, University of Liverpool, UK. FAU - Chubb, J C AU - Chubb JC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - J Helminthol JT - Journal of helminthology JID - 2985115R RN - 0 (Azo Compounds) RN - 0 (Picrates) RN - 0 (trichrome stain) RN - 82-94-0 (Methyl Green) RN - A49OS0F91S (picric acid) RN - PDC6A3C0OX (Glycerol) RN - TDQ283MPCW (Eosine Yellowish-(YS)) SB - IM MH - Animals MH - *Azo Compounds MH - Cestoda/*cytology MH - *Eosine Yellowish-(YS) MH - Glycerol MH - *Methyl Green MH - Picrates MH - Staining and Labeling MH - Tissue Fixation/*methods EDAT- 1995/06/01 00:00 MHDA- 1995/06/01 00:01 CRDT- 1995/06/01 00:00 PHST- 1995/06/01 00:00 [pubmed] PHST- 1995/06/01 00:01 [medline] PHST- 1995/06/01 00:00 [entrez] AID - 10.1017/s0022149x00014036 [doi] PST - ppublish SO - J Helminthol. 1995 Jun;69(2):149-54. doi: 10.1017/s0022149x00014036. PMID- 7768488 OWN - NLM STAT- MEDLINE DCOM- 19950630 LR - 20191023 IS - 0767-3981 (Print) IS - 0767-3981 (Linking) VI - 9 IP - 1 DP - 1995 TI - Magnetic resonance imaging may be an asset to diagnose and classify fluoroquinolone-associated Achilles tendinitis. PG - 52-6 AB - The aim of this study was to document the accuracy of magnetic resonance imaging (MRI) during fluoroquinolone-associated Achilles tendinitis. Fourteen Achilles tendons were examined by MRI (T1 and T2 or T2*-weighted sequences) in nine patients with typical tendinopathy (13 cases of tendinitis and 1 rupture) during fluoroquinolone therapy. Tendinous involvement was classified according to the prominence of intra- or peritendinous changes. The most typical feature was the presence of intratendinous changes, longitudinal or transversal, detected on T1 or T2-weighted sequences. Peritendinitis was most visible in two cases and nodular involvement in three cases. It was concluded that MRI appears a helpful and accurate method in identifying and classifying such iatrogenic tendinitis. In addition, MRI indicates orthopedic management when detecting risk of rupture. FAU - Gillet, P AU - Gillet P AD - Department of Pharmacology, URA CNRS, Vandoeuvre-lès-Nancy, France. FAU - Blum, A AU - Blum A FAU - Hestin, D AU - Hestin D FAU - Pourel, J AU - Pourel J FAU - Pierfitte, C AU - Pierfitte C FAU - Mainard, D AU - Mainard D FAU - Kessler, M AU - Kessler M FAU - Netter, P AU - Netter P LA - eng PT - Journal Article PL - England TA - Fundam Clin Pharmacol JT - Fundamental & clinical pharmacology JID - 8710411 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Achilles Tendon/*drug effects MH - Adult MH - Aged MH - Anti-Infective Agents/*adverse effects MH - Female MH - Fluoroquinolones MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Tendinopathy/chemically induced/classification/*diagnosis EDAT- 1995/01/01 00:00 MHDA- 1995/01/01 00:01 CRDT- 1995/01/01 00:00 PHST- 1995/01/01 00:00 [pubmed] PHST- 1995/01/01 00:01 [medline] PHST- 1995/01/01 00:00 [entrez] AID - 10.1111/j.1472-8206.1995.tb00265.x [doi] PST - ppublish SO - Fundam Clin Pharmacol. 1995;9(1):52-6. doi: 10.1111/j.1472-8206.1995.tb00265.x. PMID- 38529805 OWN - NLM STAT- MEDLINE DCOM- 20240405 LR - 20250103 IS - 1944-8252 (Electronic) IS - 1944-8244 (Linking) VI - 16 IP - 13 DP - 2024 Apr 3 TI - Tannic Acid-Modified Decellularized Tendon Scaffold with Antioxidant and Anti-Inflammatory Activities for Tendon Regeneration. PG - 15879-15892 LID - 10.1021/acsami.3c19019 [doi] AB - Tendon regeneration is greatly influenced by the oxidant and the inflammatory microenvironment. Persistent inflammation during the tendon repair can cause matrix degradation, tendon adhesion, and excessive accumulation of reactive oxygen species (ROS), while excessive ROS affect extracellular matrix remodeling and tendon integration. Herein, we used tannic acid (TA) to modify a decellularized tendon slice (DTS) to fabricate a functional scaffold (DTS-TA) with antioxidant and anti-inflammatory properties for tendon repair. The characterizations and cytocompatibility of the scaffolds were examined in vitro. The antioxidant and anti-inflammatory activities of the scaffold were evaluated in vitro and further studied in vivo using a subcutaneous implantation model. It was found that the modified DTS combined with TA via hydrogen bonds and covalent bonds, and the hydrophilicity, thermal stability, biodegradability, and mechanical characteristics of the scaffold were significantly improved. Afterward, the results demonstrated that DTS-TA could effectively reduce inflammation by increasing the M2/M1 macrophage ratio and interleukin-4 (IL-4) expression, decreasing the secretion of interleukin-6 (IL-6) and interleukin-1β (IL-1β), as well as scavenging excessive ROS in vitro and in vivo. In summary, DTS modified with TA provides a potential versatile scaffold for tendon regeneration. FAU - Zhao, Lei-Lei AU - Zhao LL AUID- ORCID: 0009-0006-7876-2189 AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Luo, Jia-Jiao AU - Luo JJ AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Cui, Jing AU - Cui J AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Li, Xuan AU - Li X AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Hu, Ruo-Nan AU - Hu RN AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Xie, Xin-Yue AU - Xie XY AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Zhang, Yan-Jing AU - Zhang YJ AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Ding, Wei AU - Ding W AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Ning, Liang-Ju AU - Ning LJ AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Luo, Jing-Cong AU - Luo JC AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. FAU - Qin, Ting-Wu AU - Qin TW AUID- ORCID: 0000-0003-1063-857X AD - Department of Orthopedic Surgery and Orthopedic Research Institute, Laboratory of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. LA - eng PT - Journal Article DEP - 20240326 PL - United States TA - ACS Appl Mater Interfaces JT - ACS applied materials & interfaces JID - 101504991 RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) RN - 0 (tannic acid) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Polyphenols) SB - IM MH - Humans MH - *Tissue Scaffolds/chemistry MH - *Antioxidants/pharmacology MH - Reactive Oxygen Species MH - Tendons MH - Anti-Inflammatory Agents/pharmacology MH - Inflammation/drug therapy MH - Regeneration MH - *Polyphenols OTO - NOTNLM OT - anti-inflammatory OT - antioxidant OT - decellularized tendon slice OT - tannic acid OT - tendon regeneration EDAT- 2024/03/26 12:44 MHDA- 2024/04/05 06:44 CRDT- 2024/03/26 06:43 PHST- 2024/04/05 06:44 [medline] PHST- 2024/03/26 12:44 [pubmed] PHST- 2024/03/26 06:43 [entrez] AID - 10.1021/acsami.3c19019 [doi] PST - ppublish SO - ACS Appl Mater Interfaces. 2024 Apr 3;16(13):15879-15892. doi: 10.1021/acsami.3c19019. Epub 2024 Mar 26. PMID- 35287653 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20220606 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 23 IP - 1 DP - 2022 Mar 14 TI - Antioxidant effect of nicotinamide mononucleotide in tendinopathy. PG - 249 LID - 10.1186/s12891-022-05205-z [doi] LID - 249 AB - BACKGROUND: A link between tendinopathy and oxidative stress has been recently reported. Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide, which plays an important role in cell redox homeostasis. The aim of this study was to evaluate the antioxidant effect of NMN on tendinopathy in vitro and in vivo. METHODS: Tenocytes from healthy Sprague-Dawley rats were cultured in regular glucose (RG) and high-glucose (HG) conditions with or without NMN, and were divided into four groups: RG NMN(-), RG NMN(+), HG NMN(-), and HG NMN(+). Cell viability, reactive oxygen species (ROS) accumulation, apoptotic rate, and mRNA expression of nicotinamide adenine dinucleotide phosphate oxidase (NOX)1, NOX4, interleukin (IL)6, sirtuin (SIRT)1, and SIRT6 were investigated. In addition, rats with collagenase-induced tendinopathy were treated with or without NMN. Immunostaining of NOX1 and NOX4; mRNA expression of SIRT1, SIRT6, and IL6; and superoxide dismutase (SOD) activity measurements in the Achilles tendon were performed. RESULTS: NMN increased the expression of SIRT1 and SIRT6 in rat tenocytes, but decreased the levels of NOX1, NOX4, IL6, ROS, and apoptosis. In Achilles tendons with collagenase-induced tendinopathy, NMN increased the mRNA expression of SIRT1 and SIRT6, as well as SOD activity; while suppressing protein expression of NOX1 and NOX4, and mRNA expression of IL6. CONCLUSION: The in vitro and in vivo results of this study show that NMN exerts an antioxidant effect on tendinopathy by promoting the expression of SIRT while inhibiting that of NOX. CI - © 2022. The Author(s). FAU - Yamaura, Kohei AU - Yamaura K AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Mifune, Yutaka AU - Mifune Y AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. m-ship@kf7.so-net.ne.jp. FAU - Inui, Atsuyuki AU - Inui A AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Nishimoto, Hanako AU - Nishimoto H AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Kurosawa, Takashi AU - Kurosawa T AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Mukohara, Shintaro AU - Mukohara S AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Hoshino, Yuichi AU - Hoshino Y AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Niikura, Takahiro AU - Niikura T AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. FAU - Kuroda, Ryosuke AU - Kuroda R AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. LA - eng PT - Journal Article DEP - 20220314 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) RN - 1094-61-7 (Nicotinamide Mononucleotide) SB - IM EIN - BMC Musculoskelet Disord. 2022 Jun 6;23(1):541. doi: 10.1186/s12891-022-05424-4. PMID: 35668405 MH - Animals MH - Antioxidants/pharmacology MH - *Nicotinamide Mononucleotide/metabolism/pharmacology/therapeutic use MH - Rats MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism MH - *Tendinopathy/chemically induced/drug therapy PMC - PMC8922828 OTO - NOTNLM OT - Nicotinamide mononucleotide OT - Oxidative stress OT - SIRT OT - Tendinopathy COIS- The authors declare that they have no competing interests. EDAT- 2022/03/16 06:00 MHDA- 2022/03/17 06:00 PMCR- 2022/03/14 CRDT- 2022/03/15 05:36 PHST- 2021/12/25 00:00 [received] PHST- 2022/03/09 00:00 [accepted] PHST- 2022/03/15 05:36 [entrez] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2022/03/14 00:00 [pmc-release] AID - 10.1186/s12891-022-05205-z [pii] AID - 5205 [pii] AID - 10.1186/s12891-022-05205-z [doi] PST - epublish SO - BMC Musculoskelet Disord. 2022 Mar 14;23(1):249. doi: 10.1186/s12891-022-05205-z. PMID- 32250949 OWN - NLM STAT- MEDLINE DCOM- 20210426 LR - 20210426 IS - 1878-0180 (Electronic) IS - 1878-0180 (Linking) VI - 106 DP - 2020 Jun TI - Mechanical behavior of ropes based on polypropylene (PP) and poly(ethylene terephthalate) (PET) multifilament yarns for Achilles tendon partial substitution. PG - 103734 LID - S1751-6161(20)30288-5 [pii] LID - 10.1016/j.jmbbm.2020.103734 [doi] AB - In some clinical cases, attending to the type and extension of the Achilles tendon injury, a partial replacement of the tissue may be needed. Driven by this, the authors developed different structures based on polypropylene (PP) or poly (ethylene terephthalate) (PET) multifilament yarns, using a textile technology-based technique, in order to mimic the fibrous structure of tendons. Those structures are based on a core/shell system, being the core composed by several sub-components (braids) and the shell based on braided yarns enclosing the core. It was observed that the load at failure of ropes is mainly defined by the number of yarns that compose it, but the strain level is mostly influenced by the production take-up rate of the core braids and consequently by the braid angle. The ropes stiffness level results from a combination of the yarns number and braid angle of the core braids. The structure based on PET yarns revealed a non-linear force-strain curve similar to a typical curve of a natural Achilles tendon (AT), presenting a load at failure, strain to failure and stiffness levels very promising for AT replacement. Moreover, the PET rope also revealed a very promising fatigue and appropriate creep resistance for the final application, being in accordance with what has been reported for native AT. CI - Copyright © 2020 Elsevier Ltd. All rights reserved. FAU - Morais, D S AU - Morais DS AD - REQUIMTE-LAQV, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia, Universidade Do Porto, Rua Dr.Roberto Frias, 4200-465, Porto, Portugal; INEGI-Instituto de Engenharia Mecânica e Gestão Industrial, Faculdade de Engenharia, Universidade Do Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal. FAU - Cruz, J AU - Cruz J AD - Centre for Textile Science and Technology, University of Minho, Portugal. FAU - Fangueiro, R AU - Fangueiro R AD - Centre for Textile Science and Technology, University of Minho, Portugal. FAU - Lopes, H AU - Lopes H AD - DEM, ISEP, Instituto Politécnico Do Porto, Portugal. FAU - Guedes, R M AU - Guedes RM AD - INEGI-Instituto de Engenharia Mecânica e Gestão Industrial, Faculdade de Engenharia, Universidade Do Porto, Rua Dr. Roberto Frias, 4200-465, Porto, Portugal; Departamento de Engenharia Mecânica Faculdade de Engenharia, Universidade Do Porto, Rua Dr.Roberto Frias, 4200-465, Porto, Portugal. FAU - Lopes, M A AU - Lopes MA AD - REQUIMTE-LAQV, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia, Universidade Do Porto, Rua Dr.Roberto Frias, 4200-465, Porto, Portugal. Electronic address: malopes@fe.up.pt. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200323 PL - Netherlands TA - J Mech Behav Biomed Mater JT - Journal of the mechanical behavior of biomedical materials JID - 101322406 RN - 0 (Ethylenes) RN - 0 (Phthalic Acids) RN - 0 (Polyethylene Terephthalates) RN - 0 (Polypropylenes) RN - 6S7NKZ40BQ (terephthalic acid) SB - IM MH - *Achilles Tendon MH - Biomechanical Phenomena MH - Ethylenes MH - Phthalic Acids MH - Polyethylene Terephthalates MH - *Polypropylenes OTO - NOTNLM OT - Achilles tendon OT - Braid OT - PET OT - PP OT - Polypropylene OT - Rope OT - poly(ethylene terephthalate) COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2020/04/07 06:00 MHDA- 2021/04/27 06:00 CRDT- 2020/04/07 06:00 PHST- 2019/10/13 00:00 [received] PHST- 2020/02/04 00:00 [revised] PHST- 2020/03/10 00:00 [accepted] PHST- 2020/04/07 06:00 [pubmed] PHST- 2021/04/27 06:00 [medline] PHST- 2020/04/07 06:00 [entrez] AID - S1751-6161(20)30288-5 [pii] AID - 10.1016/j.jmbbm.2020.103734 [doi] PST - ppublish SO - J Mech Behav Biomed Mater. 2020 Jun;106:103734. doi: 10.1016/j.jmbbm.2020.103734. Epub 2020 Mar 23. PMID- 19601786 OWN - NLM STAT- MEDLINE DCOM- 20091106 LR - 20220409 IS - 1875-533X (Electronic) IS - 0929-8673 (Linking) VI - 16 IP - 19 DP - 2009 TI - Extracorporeal shock wave therapy in inflammatory diseases: molecular mechanism that triggers anti-inflammatory action. PG - 2366-72 AB - Shock waves (SW), defined as a sequence of single sonic pulses characterised by high peak pressure (100 MPa), a fast rise in pressure (< 10 ns) and a short lifecycle (10 micros), are conveyed by an appropriate generator to a specific target area at an energy density ranging from 0.03 to 0.11 mJ/mm(2). Extracorporeal SW (ESW) therapy was first used on patients in 1980 to break up kidney stones. During the last ten years, this technique has been successfully employed in orthopaedic diseases such as pseudoarthosis, tendinitis, calcarea of the shoulder, epicondylitis, plantar fasciitis and several inflammatory tendon diseases. In particular, treatment of the tendon and muscle tissues was found to induce a long-time tissue regeneration effect in addition to having a more immediate anthalgic and anti-inflammatory outcome. In keeping with this, an increase in neoangiogenesis in the tendons of dogs was observed after 4-8 weeks of ESW treatment. Furthermore, clinical observations indicate an immediate increase in blood flow around the treated area. Nevertheless, the biochemical mechanisms underlying these effects have yet to be fully elucidated. In the present review, we briefly detail the physical properties of ESW and clinical cases treated with this therapy. We then go on to describe the possible molecular mechanism that triggers the anti-inflammatory action of ESW, focusing on the possibility that ESW may modulate endogenous nitric oxide (NO) production either under normal or inflammatory conditions. Data on the rapid enhancement of endothelial NO synthase (eNOS) activity in ESW-treated cells suggest that increased NO levels and the subsequent suppression of NF-kappaB activation may account, at least in part, for the clinically beneficial action on tissue inflammation. FAU - Mariotto, Sofia AU - Mariotto S AD - Department of Morphological and Biomedical Sciences, Biochemistry Section, University of Verona, Verona, Italy. sofia.mariotto@univr.it FAU - de Prati, Alessandra Carcereri AU - de Prati AC FAU - Cavalieri, Elisabetta AU - Cavalieri E FAU - Amelio, Ernesto AU - Amelio E FAU - Marlinghaus, Ernst AU - Marlinghaus E FAU - Suzuki, Hisanori AU - Suzuki H LA - eng PT - Journal Article PT - Review PL - United Arab Emirates TA - Curr Med Chem JT - Current medicinal chemistry JID - 9440157 RN - 0 (Anti-Inflammatory Agents) RN - 0 (NF-kappa B) RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (Nitric Oxide Synthase) SB - IM MH - Anti-Inflammatory Agents/pharmacology MH - High-Energy Shock Waves/*therapeutic use MH - Humans MH - Inflammation/*therapy MH - *Lithotripsy MH - NF-kappa B/metabolism MH - Nitric Oxide/metabolism MH - Nitric Oxide Synthase/metabolism RF - 55 EDAT- 2009/07/16 09:00 MHDA- 2009/11/07 06:00 CRDT- 2009/07/16 09:00 PHST- 2009/07/16 09:00 [entrez] PHST- 2009/07/16 09:00 [pubmed] PHST- 2009/11/07 06:00 [medline] AID - 10.2174/092986709788682119 [doi] PST - ppublish SO - Curr Med Chem. 2009;16(19):2366-72. doi: 10.2174/092986709788682119. PMID- 31077091 OWN - NLM STAT- MEDLINE DCOM- 20200403 LR - 20250312 IS - 1179-1942 (Electronic) IS - 0114-5916 (Linking) VI - 42 IP - 9 DP - 2019 Sep TI - Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis. PG - 1025-1033 LID - 10.1007/s40264-019-00828-z [doi] AB - INTRODUCTION: It has been suggested that fluoroquinolone antibiotics increase the risk of developing collagen-associated adverse events such as aortic dissection and aortic aneurysm. These are life-threatening emergencies that need to be prevented. OBJECTIVES: We performed this systematic review to clarify the association between fluoroquinolones and three collagen-associated adverse events: aortic aneurysm or aortic dissection, retinal detachment, and tendon disorders. METHODS: We searched PubMed, Embase, and Scopus for observational studies up to January 2019. Cohort and case-control studies were included if they reported data on the risk of collagen-related adverse events associated with fluoroquinolone exposure versus no exposure. We assessed the quality of the included studies using the Newcastle-Ottawa Scale. Effect statistics were pooled using random-effects models. Sensitivity and subgroup analyses were performed to identify any source of heterogeneity. RESULTS: After screening 2729 citations, we included 22 observational studies (12 cohort studies and ten case-control studies) with 19,207,552 participants. Current use of fluoroquinolones was significantly associated with aortic aneurysm and aortic dissection (odds ratio [OR] 2.20; 95% confidence interval [CI] 1.92-2.52), tendon disorders (OR 1.89; 95% CI 1.53-2.33), and retinal detachment (sensitivity analysis, OR 1.25; 95% CI 1.01-1.53). Past fluoroquinolone use (> 30 and ≤ 365 days) was associated with retinal detachment (OR 1.27; 95% CI 1.09-1.47). CONCLUSIONS: Fluoroquinolone use incurs a risk of developing three collagen-associated diseases (aortic aneurysm or aortic dissection, retinal detachment, and tendon disorders). Patients at an increased risk of collagen-associated diseases should not use fluoroquinolones unless no other options are available. FAU - Yu, Xinyu AU - Yu X AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Jiang, Ding-Sheng AU - Jiang DS AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. AD - Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China. AD - NHC Key Laboratory of Organ Transplantation, Wuhan, China. AD - Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China. FAU - Wang, Jing AU - Wang J AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Wang, Rui AU - Wang R AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Chen, Taiqiang AU - Chen T AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Wang, Kan AU - Wang K AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. FAU - Cao, Shiyi AU - Cao S AUID- ORCID: 0000-0002-6338-9696 AD - School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. caoshiyi@hust.edu.cn. FAU - Wei, Xiang AU - Wei X AD - Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. xiangwei@tjh.tjmu.edu.cn. AD - Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China. xiangwei@tjh.tjmu.edu.cn. AD - NHC Key Laboratory of Organ Transplantation, Wuhan, China. xiangwei@tjh.tjmu.edu.cn. AD - Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China. xiangwei@tjh.tjmu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review PL - New Zealand TA - Drug Saf JT - Drug safety JID - 9002928 RN - 0 (Anti-Bacterial Agents) RN - 9007-34-5 (Collagen) RN - 0 (Fluoroquinolones) SB - IM MH - Humans MH - *Anti-Bacterial Agents/adverse effects MH - Aortic Aneurysm/chemically induced MH - Aortic Dissection/chemically induced MH - *Collagen/metabolism MH - *Fluoroquinolones/adverse effects MH - Retinal Detachment/chemically induced MH - Tendons/pathology MH - Observational Studies as Topic EDAT- 2019/05/12 06:00 MHDA- 2020/04/04 06:00 CRDT- 2019/05/12 06:00 PHST- 2019/05/12 06:00 [pubmed] PHST- 2020/04/04 06:00 [medline] PHST- 2019/05/12 06:00 [entrez] AID - 10.1007/s40264-019-00828-z [pii] AID - 10.1007/s40264-019-00828-z [doi] PST - ppublish SO - Drug Saf. 2019 Sep;42(9):1025-1033. doi: 10.1007/s40264-019-00828-z. PMID- 28104092 OWN - NLM STAT- MEDLINE DCOM- 20170404 LR - 20220410 IS - 1532-6500 (Electronic) IS - 1058-2746 (Linking) VI - 26 IP - 2 DP - 2017 Feb TI - The use of indomethacin in the prevention of postoperative radioulnar synostosis after distal biceps repair. PG - 295-298 LID - S1058-2746(16)30584-5 [pii] LID - 10.1016/j.jse.2016.11.011 [doi] AB - BACKGROUND: This study evaluated the incidence of symptomatic radioulnar synostosis/heterotopic ossification after distal biceps tendon repair in patients receiving indomethacin prophylaxis. We hypothesized that indomethacin use postoperatively would decrease the occurrence of symptomatic synostosis. METHODS: A single-center retrospective record review identified 124 patients undergoing distal biceps repair between 2011 and 2014. Patients were analyzed for administration of indomethacin, contraindications to administration, age, time to surgery, fixation method, medical comorbidities, and development of symptomatic synostosis. Oral indomethacin (75 mg, once daily) was prescribed postoperatively for 10 to 42 days per each attendings' protocol. RESULTS: After analysis, 112 patients met the inclusion criteria, with 7 undergoing a 1-incision distal biceps repair and 105 undergoing a 2-incision repair. Of those, 104 received indomethacin postoperatively, with a synostosis rate of 0.96% compared with 37.50% for the untreated group (P < .001). No statistically significant difference was found between fixation methods and synostosis. One patient with synostosis was a single-incision repair, and 3 were 2-incision suture bridge repairs. Three patients with synostosis had relative contraindications to administration of indomethacin, including concomitant warfarin use, clopidogrel use, and ulcerative colitis. CONCLUSION: Indomethacin use after distal biceps repair was associated with a statistically significant reduction in the rate of symptomatic radioulnar synostosis and did not have any associated adverse effects, including gastrointestinal bleeding or rerupture, despite prolonged use of up to 6 weeks. This study represents the largest study to report the outcomes of patients undergoing distal biceps repair with concomitant synostosis prophylaxis using indomethacin. CI - Copyright © 2017 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. FAU - Costopoulos, Callista L AU - Costopoulos CL AD - Department of Orthopedics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA. Electronic address: callista.costopoulos@gmail.com. FAU - Abboud, Joseph A AU - Abboud JA AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Ramsey, Matthew L AU - Ramsey ML AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Getz, Charles L AU - Getz CL AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Sholder, Daniel S AU - Sholder DS AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Taras, John P AU - Taras JP AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Huttman, Daniel AU - Huttman D AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. FAU - Lazarus, Mark D AU - Lazarus MD AD - Department of Orthopedics, The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA. LA - eng PT - Journal Article PL - United States TA - J Shoulder Elbow Surg JT - Journal of shoulder and elbow surgery JID - 9206499 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - XXE1CET956 (Indomethacin) RN - Radioulnar Synostosis SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use MH - Arm Injuries/*surgery MH - Cohort Studies MH - Female MH - Hamstring Tendons/*injuries/surgery MH - Humans MH - Indomethacin/administration & dosage/*therapeutic use MH - Male MH - Middle Aged MH - Postoperative Complications/prevention & control MH - Radius/*abnormalities MH - Retrospective Studies MH - Synostosis/*prevention & control MH - Tendon Injuries/*surgery MH - Treatment Outcome MH - Ulna/*abnormalities OTO - NOTNLM OT - 2-incision suture bridge repairs OT - Indomethacin prophylaxis OT - distal biceps tendon repair OT - heterotopic ossification OT - radioulnar synostosis OT - single incision repair EDAT- 2017/01/21 06:00 MHDA- 2017/04/05 06:00 CRDT- 2017/01/21 06:00 PHST- 2016/09/26 00:00 [received] PHST- 2016/11/03 00:00 [revised] PHST- 2016/11/11 00:00 [accepted] PHST- 2017/01/21 06:00 [entrez] PHST- 2017/01/21 06:00 [pubmed] PHST- 2017/04/05 06:00 [medline] AID - S1058-2746(16)30584-5 [pii] AID - 10.1016/j.jse.2016.11.011 [doi] PST - ppublish SO - J Shoulder Elbow Surg. 2017 Feb;26(2):295-298. doi: 10.1016/j.jse.2016.11.011. PMID- 15573880 OWN - NLM STAT- MEDLINE DCOM- 20050127 LR - 20191109 IS - 1297-3203 (Print) IS - 1297-3203 (Linking) VI - 23 IP - 5 DP - 2004 Oct TI - [Spontaneous rupture of extensor pollicis longus in systemic lupus erythematosus]. PG - 254-6 AB - We report a case of spontaneous rupture of extensor pollicis longus of the left hand. This 63 year-old woman was treated with oral corticosteroids for 23 years because of systemic lupus erythematosus. Her hands had no deformity. This rupture was spontaneous and caused pain for 15 days. The treatment was surgical and consisted of an extensor indicis proprius transposition. There was no macroscopic tenosynovitis. The follow-up of one year showed a good result. Less than 40 spontaneous ruptures in systemic lupus erythematosus have been described in the literature; only seven cases were ruptures of hand tendons and only extensors. As far as we know, the spontaneous rupture of extensor pollicis longus has never been described in systemic lupus erythematosus. The role of corticosteroids is discussed. FAU - Apard, T AU - Apard T AD - Service de chirurgie orthopédique et traumatologique, SOS main, centre hospitalier du Mans, 194, avenue Rubillard, 72037 Le Mans, France. thomasapard@yahoo.fr FAU - Moui, Y AU - Moui Y LA - fre PT - English Abstract PT - Journal Article PT - Review TT - Rupture spontanée du long extenseur du pouce dans le cadre du lupus érythémateux disséminé. Cas clinique et revue de la littérature. PL - France TA - Chir Main JT - Chirurgie de la main JID - 100937750 RN - 0 (Glucocorticoids) RN - VB0R961HZT (Prednisone) SB - IM MH - Female MH - Glucocorticoids/therapeutic use MH - Humans MH - Lupus Erythematosus, Systemic/*complications/drug therapy MH - Middle Aged MH - Prednisone/therapeutic use MH - Rupture, Spontaneous/etiology/surgery MH - Tendon Injuries/*etiology/surgery MH - Tendon Transfer/methods RF - 11 EDAT- 2004/12/03 09:00 MHDA- 2005/01/28 09:00 CRDT- 2004/12/03 09:00 PHST- 2004/12/03 09:00 [pubmed] PHST- 2005/01/28 09:00 [medline] PHST- 2004/12/03 09:00 [entrez] AID - S1297-3203(04)00084-8 [pii] AID - 10.1016/j.main.2004.08.004 [doi] PST - ppublish SO - Chir Main. 2004 Oct;23(5):254-6. doi: 10.1016/j.main.2004.08.004. PMID- 23813946 OWN - NLM STAT- MEDLINE DCOM- 20150226 LR - 20140626 IS - 1099-1263 (Electronic) IS - 0260-437X (Linking) VI - 34 IP - 8 DP - 2014 Aug TI - Cytotoxic effects of the quinolone levofloxacin on rabbit meniscus cells. PG - 870-7 LID - 10.1002/jat.2903 [doi] AB - Quinolones have been reported to induce adverse effects on articular cartilage, tendons and ligaments. However, the effects of quinolones on menisci have not been revealed. The present study was to test the effects of levofloxacin on meniscus cells in vitro. Rabbit meniscus cells were administrated with different concentrations of levofloxacin (0, 14, 28, 56, 112 and 224 µm) for 24 or 48 h, and cell viability and apoptosis were measured. The mRNA expression levels of matrix metalloproteinase (MMP)-1, MMP-3, MMP-13, tissue inhibitors of metalloproteinase (TIMP)-1, TIMP-3, Col1a1, Bcl-2, caspase-3 and inducible nitric oxide were analyzed by real-time polymerase chain reaction. Active caspase-3 was detected by immunocytochemical assay, while protein expression levels of MMP-3 and MMP-13 were measured by Western blotting assay. After treatment with levofloxacin for 48 h, cell viability was decreased from dose of 28 to 224 µm in a concentration-dependent manner. An increase of apoptotic cells was observed by flow cytometry. Active caspase-3 protein expression level was also increased. The mRNA level of Bcl-2 was decreased and levels of MMP-1, MMP-3 and MMP-13 in experimental groups were higher than those of controls. The protein levels of MMP-3 and MMP-13 were increased. Moreover, the mRNA levels of TIMP-3 and col1a1 were decreased. A dose-dependent increase of inducible nitric oxide mRNA expression level was also observed. Our results suggested the cytotoxic effects of levofloxacin on meniscus cells through induction of apoptosis and unbalanced MMPs/TIMPs expression. These side effects might result in meniscus extracellular matrix degradation and meniscal lesion. Thus, quinolones should be used cautiously on patients who perform athletic activities or undergo surgical meniscus repair. CI - Copyright © 2013 John Wiley & Sons, Ltd. FAU - Wang, Linlong AU - Wang L AD - Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. FAU - Wu, Yunpeng AU - Wu Y FAU - Tan, Yang AU - Tan Y FAU - Fei, Xi AU - Fei X FAU - Deng, Yu AU - Deng Y FAU - Cao, Hong AU - Cao H FAU - Chen, Biao AU - Chen B FAU - Wang, Hui AU - Wang H FAU - Magdalou, Jacques AU - Magdalou J FAU - Chen, Liaobin AU - Chen L LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130701 PL - England TA - J Appl Toxicol JT - Journal of applied toxicology : JAT JID - 8109495 RN - 0 (Collagen Type I) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) RN - 0 (bcl-2-Associated X Protein) RN - 6GNT3Y5LMF (Levofloxacin) RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Animals MH - Apoptosis/drug effects MH - Cartilage MH - Cell Survival/drug effects MH - Collagen Type I/genetics/metabolism MH - Gene Expression Regulation MH - Levofloxacin/*pharmacology MH - Matrix Metalloproteinase 1/genetics/metabolism MH - Matrix Metalloproteinase 13/genetics/metabolism MH - Matrix Metalloproteinase 3/genetics/metabolism MH - Menisci, Tibial/*cytology/*drug effects/metabolism MH - RNA, Messenger/genetics/metabolism MH - Rabbits MH - Real-Time Polymerase Chain Reaction MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Tissue Inhibitor of Metalloproteinase-3/genetics/metabolism MH - bcl-2-Associated X Protein/genetics/metabolism OTO - NOTNLM OT - apoptosis OT - extracellular matrix degradation OT - levofloxacin OT - matrix metalloproteinases OT - meniscus cell EDAT- 2013/07/03 06:00 MHDA- 2015/02/27 06:00 CRDT- 2013/07/02 06:00 PHST- 2013/03/04 00:00 [received] PHST- 2013/05/11 00:00 [revised] PHST- 2013/05/11 00:00 [accepted] PHST- 2013/07/02 06:00 [entrez] PHST- 2013/07/03 06:00 [pubmed] PHST- 2015/02/27 06:00 [medline] AID - 10.1002/jat.2903 [doi] PST - ppublish SO - J Appl Toxicol. 2014 Aug;34(8):870-7. doi: 10.1002/jat.2903. Epub 2013 Jul 1. PMID- 30421285 OWN - NLM STAT- MEDLINE DCOM- 20190916 LR - 20200225 IS - 1613-7671 (Electronic) IS - 0043-5325 (Linking) VI - 131 IP - 3-4 DP - 2019 Feb TI - Tenotomy of the middle ear muscles : An unknown surgical approach in Meniere's disease. PG - 87-91 LID - 10.1007/s00508-018-1405-1 [doi] AB - Tenotomy of the tendon of the stapedius and tensor tympani muscles is a relatively unknown therapeutic procedure in Menière's disease. Widespread approaches include medicinal treatment with betahistine or diuretics as well as interventional procedures, such as intratympanic gentamicin or glucocorticoid injection, vestibular neurectomy, labyrinthectomy or endolymphatic sac surgery. The exact pathomechanism of this approach is not fully known. It is assumed that by cutting the tendons of both middle ear muscles in cases of endolymphatic hydrops the stapes is not additionally actively pushed against the oval window but can deviate laterally and thereby does not augment the inner ear pressure even further. Studies have shown that this method does not only improve vestibular symptoms but also, in contrast to most other strategies, increases the hearing level. The formation of scar tissue and the resulting reduction of ossicular chain mobility, especially due to postoperative infections, may limit the success of tenotomy and should be considered as a possible factor in cases of limited postoperative vertigo control. FAU - Reichmayr, Caroline AU - Reichmayr C AD - Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Teaching Hospital, Juchgasse 25, 1030, Vienna, Austria. FAU - Sterrer, Elisabeth AU - Sterrer E AD - Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Teaching Hospital, Juchgasse 25, 1030, Vienna, Austria. FAU - Bachtiar, Arian AU - Bachtiar A AD - Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Teaching Hospital, Juchgasse 25, 1030, Vienna, Austria. FAU - Layr, Matthias AU - Layr M AD - Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Teaching Hospital, Juchgasse 25, 1030, Vienna, Austria. FAU - Loader, Benjamin AU - Loader B AUID- ORCID: 0000-0003-4387-5993 AD - Department of Otorhinolaryngology, Head and Neck Surgery, Rudolfstiftung Teaching Hospital, Juchgasse 25, 1030, Vienna, Austria. benjamin.loader@wienkav.at. LA - eng PT - Case Reports PT - Journal Article DEP - 20181112 PL - Austria TA - Wien Klin Wochenschr JT - Wiener klinische Wochenschrift JID - 21620870R RN - 0 (Gentamicins) SB - IM MH - Adult MH - Ear, Middle MH - Female MH - Gentamicins MH - Humans MH - *Meniere Disease/surgery MH - *Tenotomy/methods MH - Treatment Outcome MH - Vertigo OTO - NOTNLM OT - Aural fullness OT - Dizziness OT - Meniere’s disease OT - Stapedius OT - Tenotomy OT - Tinnitus OT - Tympanotomy OT - Vertigo EDAT- 2018/11/14 06:00 MHDA- 2019/09/17 06:00 CRDT- 2018/11/14 06:00 PHST- 2018/01/22 00:00 [received] PHST- 2018/10/20 00:00 [accepted] PHST- 2018/11/14 06:00 [pubmed] PHST- 2019/09/17 06:00 [medline] PHST- 2018/11/14 06:00 [entrez] AID - 10.1007/s00508-018-1405-1 [pii] AID - 10.1007/s00508-018-1405-1 [doi] PST - ppublish SO - Wien Klin Wochenschr. 2019 Feb;131(3-4):87-91. doi: 10.1007/s00508-018-1405-1. Epub 2018 Nov 12. PMID- 27903576 OWN - NLM STAT- MEDLINE DCOM- 20170308 LR - 20190202 IS - 1757-790X (Electronic) IS - 1757-790X (Linking) VI - 2016 DP - 2016 Nov 30 TI - First reported case of peroneal tenosynovitis caused by Coccidioides immitis successfully treated with fluconazole. LID - 10.1136/bcr-2016-216804 [doi] LID - bcr2016216804 AB - Coccidioidomycosis is an insidious infection caused by Coccidioides spp (C. immitis and C. posadasii). Disseminated disease occasionally involves tendon sheaths and synovium of the joints leading to tenosynovitis. Here, we describe the case of a 72-year-old woman from southern Arizona, who presented with right ankle pain, redness and swelling for 2 months. Her serum IgG was positive for C. immitis on complement fixation, and her MRI of the right ankle joint showed extensive tenosynovitis of the right peroneal tendons, and subtalar joint effusions with associated synovitis. The purpose of this case is to report an extremely rare manifestation of disseminated C. immitis, that is, peroneal tenosynovitis and challenges involved with diagnosis and treatment. We also document that azole therapy is an effective treatment option for peroneal tenosynovitis caused by C. immitis, and we had to double the dose for slow symptom resolution with 4-week trial with usual 400 mg oral dose of fluconazole. CI - 2016 BMJ Publishing Group Ltd. FAU - Majeed, Aneela AU - Majeed A AD - Infectious Disease Division, Department of Medicine, University of Arizona, Tucson, Arizona, USA. FAU - Ullah, Waqas AU - Ullah W AD - Department of Medicine, University of Arizona, Tucson, Arizona, USA. FAU - Hamadani, Auon Abbas AU - Hamadani AA AD - Department of Medicine, University of Arizona, Tucson, Arizona, USA. FAU - Georgescu, Anca AU - Georgescu A AD - Infectious Disease Division, Department of Medicine, University of Arizona, Tucson, Arizona, USA. LA - eng PT - Case Reports PT - Journal Article DEP - 20161130 PL - England TA - BMJ Case Rep JT - BMJ case reports JID - 101526291 RN - 0 (Antifungal Agents) RN - 8VZV102JFY (Fluconazole) SB - IM MH - Aged MH - Ankle Joint/microbiology MH - Antifungal Agents/*therapeutic use MH - *Coccidioides MH - Coccidioidomycosis/*drug therapy/microbiology MH - Female MH - Fluconazole/*therapeutic use MH - Humans MH - Peroneal Neuropathies/*drug therapy/microbiology MH - Tenosynovitis/*drug therapy/microbiology PMC - PMC5174760 COIS- Conflicts of Interest: None declared. EDAT- 2016/12/03 06:00 MHDA- 2017/03/09 06:00 PMCR- 2018/11/30 CRDT- 2016/12/02 06:00 PHST- 2016/12/02 06:00 [entrez] PHST- 2016/12/03 06:00 [pubmed] PHST- 2017/03/09 06:00 [medline] PHST- 2018/11/30 00:00 [pmc-release] AID - bcr-2016-216804 [pii] AID - 10.1136/bcr-2016-216804 [doi] PST - epublish SO - BMJ Case Rep. 2016 Nov 30;2016:bcr2016216804. doi: 10.1136/bcr-2016-216804. PMID- 25978115 OWN - NLM STAT- MEDLINE DCOM- 20150917 LR - 20250529 IS - 1473-2262 (Electronic) IS - 1473-2262 (Linking) VI - 29 DP - 2015 May 15 TI - In vivo biological response to extracorporeal shockwave therapy in human tendinopathy. PG - 268-80; discussion 280 AB - Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment for chronic tendinopathies, however little is known about the in-vivo biological mechanisms of ESWT. Using microdialysis, we examined the real-time biological response of healthy and pathological tendons to ESWT. A single session of ESWT was administered to the mid-portion of the Achilles tendon in thirteen healthy individuals (aged 25.7 ± 7.0 years) and patellar or Achilles tendon of six patients with tendinopathies (aged 39.0 ± 14.9 years). Dialysate samples from the surrounding peri-tendon were collected before and immediately after ESWT. Interleukins (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-17A, vascular endothelial growth factor and interferon-γ were quantified using a cytometric bead array while gelatinase activity (MMP-2 and -9) was examined using zymography. There were no statistical differences between the biological tissue response to ESWT in healthy and pathological tendons. IL-1β, IL-2, IL-6 and IL-8 were the cytokines predominantly detected in the tendon dialysate. IL-1β and IL-2 did not change significantly with ESWT. IL-6 and IL-8 concentrations were elevated immediately after ESWT and remained significantly elevated for four hours post-ESWT (p < 0.001). Pro-forms of MMP-2 and -9 also increased after ESWT (p < 0.003), whereas there were no significant changes in active MMP forms. In addition, the biological response to ESWT treatment could be differentiated between possible responders and non-responders based on a minimum 5-fold increase in any inflammatory marker or MMP from pre- to post-ESWT. Our findings provide novel evidence of the biological mechanisms underpinning ESWT in humans in vivo. They suggest that the mechanical stimulus provided by ESWT might aid tendon remodelling in tendinopathy by promoting the inflammatory and catabolic processes that are associated with removing damaged matrix constituents. The non-response of some individuals may help to explain why ESWT does not improve symptoms in all patients and provides a potential focus for future research. FAU - Waugh, C M AU - Waugh CM AD - School of Engineering & Materials Science, Queen Mary, University of London, Mile End Road, London, E1 4NS, UK.h.r.c.screen@qmul.ac.uk. FAU - Morrissey, D AU - Morrissey D FAU - Jones, E AU - Jones E FAU - Riley, G P AU - Riley GP FAU - Langberg, H AU - Langberg H FAU - Screen, H R C AU - Screen HR LA - eng GR - CAT SCL-2013-04-003/DH_/Department of Health/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150515 PL - United States TA - Eur Cell Mater JT - European cells & materials JID - 100973416 RN - 0 (Cytokines) RN - 0 (Dialysis Solutions) RN - 0 (Inflammation Mediators) RN - 0 (Interleukin-1beta) RN - 0 (Interleukin-2) RN - 0 (Interleukin-6) RN - 0 (Interleukin-8) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Achilles Tendon/metabolism/pathology MH - Adolescent MH - Adult MH - Cytokines/metabolism MH - Dialysis Solutions/metabolism MH - Female MH - High-Energy Shock Waves/*therapeutic use MH - Humans MH - Inflammation Mediators/metabolism MH - Interleukin-1beta/metabolism MH - Interleukin-2/metabolism MH - Interleukin-6/metabolism MH - Interleukin-8/metabolism MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Microdialysis/methods MH - Middle Aged MH - Tendinopathy/*therapy MH - Time Factors MH - Treatment Outcome MH - Young Adult EDAT- 2015/05/16 06:00 MHDA- 2015/09/18 06:00 CRDT- 2015/05/16 06:00 PHST- 2015/05/16 06:00 [entrez] PHST- 2015/05/16 06:00 [pubmed] PHST- 2015/09/18 06:00 [medline] AID - vol029a20 [pii] AID - 10.22203/ecm.v029a20 [doi] PST - epublish SO - Eur Cell Mater. 2015 May 15;29:268-80; discussion 280. doi: 10.22203/ecm.v029a20. PMID- 21076028 OWN - NLM STAT- MEDLINE DCOM- 20110315 LR - 20211020 IS - 1522-1539 (Electronic) IS - 0363-6135 (Print) IS - 0363-6135 (Linking) VI - 300 IP - 2 DP - 2011 Feb TI - Dorsal root tetrodotoxin-resistant sodium channels do not contribute to the augmented exercise pressor reflex in rats with chronic femoral artery occlusion. PG - H652-63 LID - 10.1152/ajpheart.00859.2010 [doi] AB - We investigated the contribution of tetrodotoxin (TTX)-resistant sodium channels to the augmented exercise pressor reflex observed in decerebrated rats with femoral artery ligation. The pressor responses to static contraction, to tendon stretch, and to electrical stimulation of the tibial nerve were compared before and after blocking TTX-sensitive sodium channels on the L3-L6 dorsal roots of rats whose hindlimbs were freely perfused and rats whose femoral arteries were ligated 72 h before the start of the experiment. In the freely perfused group (n=9), pressor (Δ22±4 mmHg) and cardioaccelerator (Δ32±6 beats/min) responses to contraction were attenuated by 1 μM TTX (Δ4±1 mmHg, P<0.05 and Δ17±4 beats/min, P<0.05, respectively). In the 72 h ligated group (n=9), the augmented pressor response to contraction (32±4 mmHg) was also attenuated by 1 μM TTX (Δ8±2 mmHg, P<0.05). The cardioaccelerator response to contraction was not significantly attenuated in these rats. In addition, TTX suppressed the pressor response to tendon stretch in both groups of rats. Electrical stimulation of the tibial nerve evoked similar pressor responses between the two groups (freely perfused: Δ74±9 mmHg and 72 h ligated: Δ78±5 mmHg). TTX attenuated the pressor response to the tibial nerve stimulation by about one-half in both groups. Application of the TTX-resistant sodium channel blocker A-803467 (1 μM) with TTX (1 μM) did not block the pressor response to tibial nerve stimulation to any greater extent than did application of TTX (1 μM) alone. Although the contribution of TTX-resistant sodium channels to the augmented exercise pressor reflex may be slightly increased in rats with chronic femoral artery ligation, TTX-resistant sodium channels on dorsal roots do not play a major role in the augmented exercise pressor reflex. FAU - Tsuchimochi, Hirotsugu AU - Tsuchimochi H AD - Pennsylvania State Heart and Vascular Institute, Pennsylvania State University College of Medicine, 500 Univ. Dr., Mail Code H047, Hershey Medical Center, Hershey, PA 17033, USA. FAU - McCord, Jennifer L AU - McCord JL FAU - Leal, Anna K AU - Leal AK FAU - Kaufman, Marc P AU - Kaufman MP LA - eng GR - P01 HL096570/HL/NHLBI NIH HHS/United States GR - P0 1 HL-096570/HL/NHLBI NIH HHS/United States GR - R01 AR-059397/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20101112 PL - United States TA - Am J Physiol Heart Circ Physiol JT - American journal of physiology. Heart and circulatory physiology JID - 100901228 RN - 0 (Sodium Channel Blockers) RN - 0 (Sodium Channels) RN - 4368-28-9 (Tetrodotoxin) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Blood Pressure/*physiology MH - Decerebrate State/physiopathology MH - Dexamethasone/pharmacology MH - Electric Stimulation MH - Femoral Artery/*physiology MH - Heart Rate/drug effects/physiology MH - Hindlimb/blood supply/drug effects/physiology MH - Ligation MH - Male MH - Muscle Contraction/drug effects MH - Physical Conditioning, Animal/*physiology MH - Physical Stimulation MH - Rats MH - Rats, Sprague-Dawley MH - Regional Blood Flow/drug effects MH - Sodium Channel Blockers/*pharmacology MH - Sodium Channels/*drug effects MH - Spinal Nerve Roots/drug effects/*metabolism MH - Tendons/physiology MH - Tetrodotoxin/*pharmacology MH - Tibial Nerve/physiology PMC - PMC3044047 EDAT- 2010/11/16 06:00 MHDA- 2011/03/16 06:00 PMCR- 2012/02/01 CRDT- 2010/11/16 06:00 PHST- 2010/11/16 06:00 [entrez] PHST- 2010/11/16 06:00 [pubmed] PHST- 2011/03/16 06:00 [medline] PHST- 2012/02/01 00:00 [pmc-release] AID - ajpheart.00859.2010 [pii] AID - H-00859-2010 [pii] AID - 10.1152/ajpheart.00859.2010 [doi] PST - ppublish SO - Am J Physiol Heart Circ Physiol. 2011 Feb;300(2):H652-63. doi: 10.1152/ajpheart.00859.2010. Epub 2010 Nov 12. PMID- 29215729 OWN - NLM STAT- MEDLINE DCOM- 20190514 LR - 20211204 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 233 IP - 7 DP - 2018 Jul TI - Crosstalk between adipose stem cells and tendon cells reveals a temporal regulation of tenogenesis by matrix deposition and remodeling. PG - 5383-5395 LID - 10.1002/jcp.26363 [doi] AB - Tendon injuries constitute an unmet clinical challenge owing to the limited intrinsic regenerative ability of this tissue. Cell-based therapies aim at improving tendon healing through the delicate orchestration of tissue rebuilding and regain of function. Hence, human adipose-derived stem cells (hASCs) have been proposed as a promising cell source for boosting tendon regeneration. In this work, we investigated the influence of hASCs on native human tendon-derived cells (hTDCs) through the establishment of a direct contact co-culture system. Results demonstrated that direct interactions between these cell types resulted in controlled proliferation and spontaneous cell elongation. ECM-related genes, particularly COL1A1 and TNC, and genes involved in ECM remodeling, such as MMP1, MMP2, MMP3, and TIMP1, were expressed in co-culture in a temporally regulated manner. In addition, deposition of collagen type I was accelerated in co-culture systems and favored over the production of collagen type III, resulting in an enhanced COL1/COL3 ratio as soon as 7 days. In conclusion, hASCs seem to be good candidates in modulating the behavior of native tendon cells, particularly through a balanced process of ECM synthesis and degradation. CI - © 2017 Wiley Periodicals, Inc. FAU - Costa-Almeida, Raquel AU - Costa-Almeida R AUID- ORCID: 0000-0001-7188-645X AD - 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark-Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco GMR, Guimarães, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. FAU - Calejo, Isabel AU - Calejo I AUID- ORCID: 0000-0002-6015-0655 AD - 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark-Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco GMR, Guimarães, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. FAU - Reis, Rui L AU - Reis RL AUID- ORCID: 0000-0002-4295-6129 AD - 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark-Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco GMR, Guimarães, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. AD - The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, Barco, Guimarães, Portugal. FAU - Gomes, Manuela E AU - Gomes ME AUID- ORCID: 0000-0002-2036-6291 AD - 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark-Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco GMR, Guimarães, Portugal. AD - ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal. AD - The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, Barco, Guimarães, Portugal. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180125 PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (COL3A1 protein, human) RN - 0 (Collagen Type I) RN - 0 (Collagen Type I, alpha 1 Chain) RN - 0 (Collagen Type III) RN - 0 (TIMP1 protein, human) RN - 0 (TNC protein, human) RN - 0 (Tenascin) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 3.4.24.7 (MMP1 protein, human) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Adipocytes/cytology/metabolism MH - Adipose Tissue/cytology MH - Cell Differentiation/*genetics MH - Cell Proliferation/genetics MH - Cell Survival/genetics MH - Collagen Type I/genetics MH - Collagen Type I, alpha 1 Chain MH - Collagen Type III/genetics MH - Extracellular Matrix/*genetics MH - Gene Expression Regulation, Neoplastic/genetics MH - Humans MH - Matrix Metalloproteinase 1/genetics MH - Stem Cells/*cytology MH - Tenascin/genetics MH - Tendons/*growth & development MH - Tissue Engineering MH - Tissue Inhibitor of Metalloproteinase-1/genetics OTO - NOTNLM OT - adipose-derived stem cells OT - co-culture OT - extracellular matrix OT - matrix metalloproteinases OT - temporal gene regulation OT - tendon regeneration EDAT- 2017/12/08 06:00 MHDA- 2019/05/15 06:00 CRDT- 2017/12/08 06:00 PHST- 2017/09/23 00:00 [received] PHST- 2017/12/02 00:00 [accepted] PHST- 2017/12/08 06:00 [pubmed] PHST- 2019/05/15 06:00 [medline] PHST- 2017/12/08 06:00 [entrez] AID - 10.1002/jcp.26363 [doi] PST - ppublish SO - J Cell Physiol. 2018 Jul;233(7):5383-5395. doi: 10.1002/jcp.26363. Epub 2018 Jan 25. PMID- 26009842 OWN - NLM STAT- MEDLINE DCOM- 20150923 LR - 20220321 IS - 1365-2184 (Electronic) IS - 0960-7722 (Print) IS - 0960-7722 (Linking) VI - 48 IP - 4 DP - 2015 Aug TI - Platelet-rich plasma increases proliferation of tendon cells by modulating Stat3 and p27 to up-regulate expression of cyclins and cyclin-dependent kinases. PG - 413-20 LID - 10.1111/cpr.12189 [doi] AB - OBJECTIVES: To investigate effects of platelet-rich plasma on tendon cell proliferation and the underlying molecular mechanisms. MATERIALS AND METHODS: Platelet-rich plasma was prepared manually by two-step centrifugation. Proliferation was evaluated in cultured rat tendon cells by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. Cell cycle progression was assessed by flow cytometry. Messenger RNA expression of proliferating cell nuclear antigen (PCNA), cyclin E1, A2 and B1, and cyclin-dependent kinases (Cdks) 1 and 2 was assessed by real-time polymerase chain reaction. Protein expression of the above cyclins and Cdks and of signal transducer and activator of transcription (Stat) 3 and p27 was evaluated by western blotting. RESULTS: Platelet-rich plasma used in the present study had concentrations of platelets, TGF-β1 and PDGF over 3-fold higher than normal whole blood. Platelet-rich plasma enhanced tendon cell proliferation (P = 0.008) by promoting G1 /S phase transition in the cell cycle, and increased expression of PCNA, cyclin E1, A2 and B1, Cdks1 and 2, and phosphorylated Stat3, while inhibiting p27 expression. CONCLUSIONS: Platelet-rich plasma contains high concentrations of TGF-β1 and PDGF that increase tendon cell proliferation by modulating Stat3/p27(Kip1), which enhances expression of cyclin-Cdk complexes that promote cell cycle progression. These results provide molecular evidence for positive effects of platelet-rich plasma on tendon cell proliferation, which can be useful in clinical applications of tendon injury. CI - © 2015 John Wiley & Sons Ltd. FAU - Yu, T-Y AU - Yu TY AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, 333, Taiwan. AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, 333, Taiwan. FAU - Pang, J-H S AU - Pang JH AUID- ORCID: 0000-0003-3432-0208 AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, 333, Taiwan. FAU - Wu, K P-H AU - Wu KP AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, 333, Taiwan. FAU - Lin, L-P AU - Lin LP AD - Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, 333, Taiwan. FAU - Tseng, W-C AU - Tseng WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, 333, Taiwan. FAU - Tsai, W-C AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Linkou, 333, Taiwan. AD - College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150525 PL - England TA - Cell Prolif JT - Cell proliferation JID - 9105195 RN - 0 (Cdkn1b protein, rat) RN - 0 (Cyclins) RN - 0 (Platelet-Derived Growth Factor) RN - 0 (RNA, Messenger) RN - 0 (STAT3 Transcription Factor) RN - 0 (Transforming Growth Factor beta) RN - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27) RN - EC 2.7.11.22 (CDC2 Protein Kinase) RN - EC 2.7.11.22 (Cdk1 protein, rat) RN - EC 2.7.11.22 (Cyclin-Dependent Kinase 2) RN - EC 2.7.11.22 (Cyclin-Dependent Kinases) SB - IM MH - Animals MH - CDC2 Protein Kinase MH - *Cell Proliferation MH - Cyclin-Dependent Kinase 2/genetics MH - Cyclin-Dependent Kinase Inhibitor p27/*metabolism MH - Cyclin-Dependent Kinases/*genetics MH - Cyclins/*genetics MH - Platelet-Derived Growth Factor/metabolism MH - Platelet-Rich Plasma/*metabolism MH - RNA, Messenger/genetics MH - Rats MH - STAT3 Transcription Factor/*metabolism MH - Tendons/*cytology MH - Transforming Growth Factor beta/metabolism MH - Up-Regulation PMC - PMC6496527 EDAT- 2015/05/27 06:00 MHDA- 2015/09/24 06:00 PMCR- 2015/05/25 CRDT- 2015/05/27 06:00 PHST- 2014/12/10 00:00 [received] PHST- 2015/02/05 00:00 [accepted] PHST- 2015/05/27 06:00 [entrez] PHST- 2015/05/27 06:00 [pubmed] PHST- 2015/09/24 06:00 [medline] PHST- 2015/05/25 00:00 [pmc-release] AID - CPR12189 [pii] AID - 10.1111/cpr.12189 [doi] PST - ppublish SO - Cell Prolif. 2015 Aug;48(4):413-20. doi: 10.1111/cpr.12189. Epub 2015 May 25. PMID- 7556451 OWN - NLM STAT- MEDLINE DCOM- 19951106 LR - 20081121 IS - 0014-4827 (Print) IS - 0014-4827 (Linking) VI - 220 IP - 2 DP - 1995 Oct TI - Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. PG - 415-23 AB - Cultured keratinocytes resemble migrating keratinocytes under conditions of reepithelialization during wound healing. Such keratinocytes express urokinase-type plasminogen activator (uPA) and its specific receptor (uPA receptor). Receptor-bound uPA activates plasminogen, thus providing plasmin for pericellular proteolysis. uPA is regulated by the plasminogen activator inhibitors PAI-1 and PAI-2. As indicated by immunohistology, neither uPA nor uPA receptor is expressed in normal epidermis. Thus, the down-regulation of uPA and uPA-receptor expression in keratinocytes appears to be an important event in epidermal healing and restoration of a normal epidermal tissue architecture. We have addressed this matter by using a culture and differentiation system for keratinocytes in vitro. Keratinocytes were grown in organotypic cocultures for 4, 7, and 14 days. Frozen sections were analyzed with indirect immunofluorescence staining and overlay zymography, the latter detecting activity of plasminogen activators. While tPA and PAI-1 stainings were consistently negative over the entire observation period, uPA and uPA receptor were expressed by basal keratinocytes at Days 4 and 7, but not at Day 14. Accordingly, overlay zymography revealed uPA activity at Days 4 and 7. PAI-2 was found throughout the entire observation period, but with varying distribution: at Days 4 and 7 all suprabasal keratinocytes stained positive for PAI-2. At Day 14, PAI-2-specific stainings were confined to the uppermost cells of the stratum spinosum. Our data demonstrate that uPA and uPA receptor, which are up-regulated in cultured keratinocytes, are down-regulated upon restoration of an epidermis-like structure. The distribution of PAI-2 varied over the observation period and at Day 14 resembled the distribution of PAI-2 in normal epidermis. Taken together, keratinocytes in organotypic coculture behave like keratinocytes in healing wounds in vivo with respect to the expression of the plasminogen activator system. FAU - Schaefer, B M AU - Schaefer BM AD - Institut für Immunologie der Universität, Laboratorium für Immunpathologie, Heidelberg, Germany. FAU - Stark, H J AU - Stark HJ FAU - Fusenig, N E AU - Fusenig NE FAU - Todd, R F 3rd AU - Todd RF 3rd FAU - Kramer, M D AU - Kramer MD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Antibodies) RN - 0 (Antibodies, Monoclonal) RN - 0 (PLAUR protein, human) RN - 0 (Plasminogen Activator Inhibitor 2) RN - 0 (Plaur protein, mouse) RN - 0 (Plaur protein, rat) RN - 0 (Receptors, Cell Surface) RN - 0 (Receptors, Urokinase Plasminogen Activator) RN - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator) SB - IM MH - Animals MH - Antibodies MH - Antibodies, Monoclonal MH - *Cell Differentiation MH - Cells, Cultured MH - Coculture Techniques MH - Culture Techniques/methods MH - Fibrosarcoma MH - Fluorescent Antibody Technique MH - *Gene Expression MH - Humans MH - Immunohistochemistry MH - Keratinocytes/*cytology/*metabolism MH - Mice/immunology MH - Organ Culture Techniques MH - Plasminogen Activator Inhibitor 2/analysis/*biosynthesis MH - Rats MH - Receptors, Cell Surface/analysis/*biosynthesis MH - Receptors, Urokinase Plasminogen Activator MH - Skin/cytology/metabolism MH - Staining and Labeling/methods MH - Tendons/*cytology MH - Tumor Cells, Cultured MH - Urokinase-Type Plasminogen Activator/analysis/*biosynthesis EDAT- 1995/10/01 00:00 MHDA- 2001/03/28 10:01 CRDT- 1995/10/01 00:00 PHST- 1995/10/01 00:00 [pubmed] PHST- 2001/03/28 10:01 [medline] PHST- 1995/10/01 00:00 [entrez] AID - S0014-4827(85)71333-X [pii] AID - 10.1006/excr.1995.1333 [doi] PST - ppublish SO - Exp Cell Res. 1995 Oct;220(2):415-23. doi: 10.1006/excr.1995.1333. PMID- 34086409 OWN - NLM STAT- MEDLINE DCOM- 20220131 LR - 20240402 IS - 2052-1707 (Electronic) IS - 2052-1707 (Linking) VI - 9 IP - 3 DP - 2021 May TI - Health service use and costs associated with fluoroquinolone-related tendon injuries. PG - e00796 LID - 10.1002/prp2.796 [doi] LID - e00796 AB - The aim of this study was to assess costs and health service use associated with tendon injuries after the use of fluoroquinolone antimicrobials in Finland during 2002-2012. This retrospective observational study included data from the Finnish Pharmaceutical Insurance Pool's pharmaceutical injury claims. In total, 145 compensated claimants aged ≥18 years presenting tendon injuries after the use of fluoroquinolones (FQs) were included in the study. Outcomes of interest were the number of outpatient visits to primary, secondary, tertiary, and private healthcare services, hospital days, rehabilitation and their costs. Regression models were used to analyze the impact of patient characteristics on hospital days, as well as the relationship between patient characteristics and tendon ruptures. Direct costs of a tendon injury averaged 14,800€ and indirect costs were estimated to be 9,077€ for employed claimants. Fifty-one percent of the claimants were hospitalized, with an average duration of 21 days. Hospitalization was the costliest form of health service use with an average of 9,915€ per hospital episode. Hospital days and direct costs increased with the severity of the injury. Tendon ruptures, in particular bilateral ruptures, required substantially more hospital days and their direct costs were significantly higher than those of uncomplicated tendinitis. Concurrent use of oral corticosteroids and increasing age were associated with a higher likelihood of tendon ruptures. Although rare, FQ-related tendon injuries can result in considerable costs and health service use. Medical staff should remain vigilant when prescribing FQs, especially in groups at increased risk for tendon injuries. CI - © 2021 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. FAU - Kuula, Laura S M AU - Kuula LSM AUID- ORCID: 0000-0001-8153-3033 AD - Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. FAU - Backman, Janne T AU - Backman JT AD - Individualized Drug Therapy Research Program, Faculty of Medicine, Department of Clinical Pharmacology, University of Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Blom, Marja L AU - Blom ML AD - Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. LA - eng PT - Journal Article PT - Observational Study PL - United States TA - Pharmacol Res Perspect JT - Pharmacology research & perspectives JID - 101626369 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM CIN - Pharmacol Res Perspect. 2021 Aug;9(4):e00821. doi: 10.1002/prp2.821. PMID: 34245659 MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Bacterial Agents/*adverse effects MH - Female MH - Finland MH - Fluoroquinolones/*adverse effects MH - Health Care Costs MH - Health Expenditures MH - Hospitalization/economics MH - Humans MH - Male MH - Middle Aged MH - Patient Acceptance of Health Care MH - Retrospective Studies MH - Tendon Injuries/*chemically induced/*economics MH - Young Adult PMC - PMC8177061 OTO - NOTNLM OT - adverse drug reactions OT - antibiotics OT - costs OT - tendons COIS- The authors of this manuscript have no conflicts of interest to declare. EDAT- 2021/06/05 06:00 MHDA- 2022/02/01 06:00 PMCR- 2021/06/04 CRDT- 2021/06/04 12:33 PHST- 2021/01/20 00:00 [received] PHST- 2021/04/27 00:00 [accepted] PHST- 2021/06/04 12:33 [entrez] PHST- 2021/06/05 06:00 [pubmed] PHST- 2022/02/01 06:00 [medline] PHST- 2021/06/04 00:00 [pmc-release] AID - PRP2796 [pii] AID - 10.1002/prp2.796 [doi] PST - ppublish SO - Pharmacol Res Perspect. 2021 May;9(3):e00796. doi: 10.1002/prp2.796. PMID- 38953556 OWN - NLM STAT- MEDLINE DCOM- 20240702 LR - 20240704 IS - 1582-4934 (Electronic) IS - 1582-1838 (Print) IS - 1582-1838 (Linking) VI - 28 IP - 13 DP - 2024 Jul TI - Role of oxidative stress in the concurrent development of osteoporosis and tendinopathy: Emerging challenges and prospects for treatment modalities. PG - e18508 LID - 10.1111/jcmm.18508 [doi] LID - e18508 AB - Both osteoporosis and tendinopathy are widely prevalent disorders, encountered in diverse medical contexts. Whilst each condition has distinct pathophysiological characteristics, they share several risk factors and underlying causes. Notably, oxidative stress emerges as a crucial intersecting factor, playing a pivotal role in the onset and progression of both diseases. This imbalance arises from a dysregulation in generating and neutralising reactive oxygen species (ROS), leading to an abnormal oxidative environment. Elevated levels of ROS can induce multiple cellular disruptions, such as cytotoxicity, apoptosis activation and reduced cell function, contributing to tissue deterioration and weakening the structural integrity of bones and tendons. Antioxidants are substances that can prevent or slow down the oxidation process, including Vitamin C, melatonin, resveratrol, anthocyanins and so on, demonstrating potential in treating these overlapping disorders. This comprehensive review aims to elucidate the complex role of oxidative stress within the interlinked pathways of these comorbid conditions. By integrating contemporary research and empirical findings, our objective is to outline new conceptual models and innovative treatment strategies for effectively managing these prevalent diseases. This review underscores the importance of further in-depth research to validate the efficacy of antioxidants and traditional Chinese medicine in treatment plans, as well as to explore targeted interventions focused on oxidative stress as promising areas for future medical advancements. CI - © 2024 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. FAU - Xia, Xianting AU - Xia X AD - Department of Orthopaedics, Kunshan Sixth People's Hospital, Kunshan, Jiangsu, China. FAU - Fang, Zhengyuan AU - Fang Z AD - The First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, Liaoning, China. FAU - Qian, Yinhua AU - Qian Y AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. FAU - Zhou, Yu AU - Zhou Y AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. FAU - Huang, Haoqiang AU - Huang H AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. FAU - Xu, Feng AU - Xu F AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. FAU - Luo, Zhiwen AU - Luo Z AUID- ORCID: 0000-0002-0524-9951 AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. AD - Department of Sports Medicine, Huashan Hospital, Fudan Universtiy, Shanghai, China. FAU - Wang, Qing AU - Wang Q AD - Department of Orthopaedics, Kunshan Hospital of Chinese Medicine, Kunshan, Jiangsu, China. LA - eng GR - [2019]No.6/Kunshan High-level Medical Talent Program Project/ GR - 03rczc25/Kunshan Hospital of Traditional Chinese Medicine Golden Apricot Superior Talent Project/ GR - KZYY2202/Kunshan Chinese Medicine Science and Technology Development Special Project/ GR - LCZX202127/Suzhou Clinical Key Disease Diagnosis and Treatment Technology Special Project/ PT - Journal Article PT - Review PL - England TA - J Cell Mol Med JT - Journal of cellular and molecular medicine JID - 101083777 RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) SB - IM MH - Humans MH - *Oxidative Stress MH - *Osteoporosis/metabolism/therapy/drug therapy MH - *Antioxidants/therapeutic use MH - *Tendinopathy/metabolism/therapy/pathology MH - *Reactive Oxygen Species/metabolism MH - Animals PMC - PMC11217991 OTO - NOTNLM OT - antioxidants OT - comorbidity OT - osteoporosis OT - oxidative stress OT - reactive oxygen species (ROS) OT - tendinopathy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/07/02 14:43 MHDA- 2024/07/02 14:44 PMCR- 2024/07/02 CRDT- 2024/07/02 08:23 PHST- 2024/06/12 00:00 [revised] PHST- 2024/05/05 00:00 [received] PHST- 2024/06/18 00:00 [accepted] PHST- 2024/07/02 14:44 [medline] PHST- 2024/07/02 14:43 [pubmed] PHST- 2024/07/02 08:23 [entrez] PHST- 2024/07/02 00:00 [pmc-release] AID - JCMM18508 [pii] AID - 10.1111/jcmm.18508 [doi] PST - ppublish SO - J Cell Mol Med. 2024 Jul;28(13):e18508. doi: 10.1111/jcmm.18508. PMID- 38413194 OWN - NLM STAT- MEDLINE DCOM- 20240601 LR - 20240628 IS - 2192-2659 (Electronic) IS - 2192-2640 (Linking) VI - 13 IP - 14 DP - 2024 Jun TI - Accurate Spatio-Temporal Delivery of Nitric Oxide Facilitates the Programmable Repair of Avascular Dense Connective Tissues Injury. PG - e2303740 LID - 10.1002/adhm.202303740 [doi] AB - Avascular dense connective tissues (e.g., the annulus fibrosus (AF) rupture, the meniscus tear, and tendons and ligaments injury) repair remains a challenge due to the "biological barrier" that hinders traditional drug permeation and limits self-healing of the injured tissue. Here, accurate delivery of nitric oxide (NO) to penetrate the "AF biological barrier" is achieved thereby enabling programmable AF repair. NO-loaded BioMOFs are synthesized and mixed in a modified polyvinyl alcohol and PCL-composited electrospun fiber membrane with excellent reactive oxygen species-responsive capability (LN@PM). The results show that LN@PM could respond to the high oxidative stress environment at the injured tissue and realize continuous and substantial NO release. Based on low molecular weight and lipophilicity, NO could penetrate through the "biological barrier" for accurate AF drug delivery. Moreover, the dynamic characteristics of the LN@PM reaction can be matched with the pathological microenvironment to initiate programmable tissue repair including sequential remodeling microenvironment, reprogramming the immune environment, and finally promoting tissue regeneration. This tailored programmable treatment strategy that matches the pathological repair process significantly repairs AF, ultimately alleviating intervertebral disc degeneration. This study highlights a promising approach for avascular dense connective tissue treatment through intelligent NO release, effectively overcoming "AF biological barriers" and programmable treatment. CI - © 2024 Wiley‐VCH GmbH. FAU - Feng, Yubo AU - Feng Y AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Su, Lefeng AU - Su L AD - College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200234, P. R. China. FAU - Liu, Lei AU - Liu L AD - College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200234, P. R. China. FAU - Chen, Zhanyi AU - Chen Z AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Ji, Yucheng AU - Ji Y AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Hu, Yuwei AU - Hu Y AD - College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200234, P. R. China. FAU - Zheng, Dandan AU - Zheng D AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Chen, Zhi AU - Chen Z AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Lei, Changbin AU - Lei C AD - Department of Orthopedics, Affiliated Hospital of Xiangnan University, Chenzhou, 423000, P. R. China. FAU - Xu, He AU - Xu H AUID- ORCID: 0000-0002-8345-7203 AD - College of Chemistry and Materials Science, Shanghai Normal University, Shanghai, 200234, P. R. China. FAU - Han, Yingchao AU - Han Y AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. FAU - Shen, Hongxing AU - Shen H AD - Department of Spine Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, P. R. China. LA - eng GR - 82072418/National Natural Science Foundation of China/ GR - 82272476/National Natural Science Foundation of China/ GR - 81902236/National Natural Science Foundation of China/ GR - 19ZR1437800/Natural Science Foundation of Shanghai Municipality/ GR - 18PJD027/Shanghai Pujiang Program/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240227 PL - Germany TA - Adv Healthc Mater JT - Advanced healthcare materials JID - 101581613 RN - 31C4KY9ESH (Nitric Oxide) RN - 0 (Reactive Oxygen Species) RN - 9002-89-5 (Polyvinyl Alcohol) SB - IM MH - *Nitric Oxide/metabolism MH - Animals MH - Annulus Fibrosus/drug effects MH - Drug Delivery Systems/methods MH - Connective Tissue MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/metabolism MH - Polyvinyl Alcohol/chemistry MH - Intervertebral Disc Degeneration/metabolism MH - Male MH - Rats MH - Mice MH - Rabbits OTO - NOTNLM OT - avascular dense connective tissue OT - bioMOFs OT - biological barrier OT - nitric oxidate OT - programmable treatment EDAT- 2024/02/28 00:43 MHDA- 2024/06/01 20:43 CRDT- 2024/02/27 21:23 PHST- 2023/12/21 00:00 [revised] PHST- 2023/10/27 00:00 [received] PHST- 2024/06/01 20:43 [medline] PHST- 2024/02/28 00:43 [pubmed] PHST- 2024/02/27 21:23 [entrez] AID - 10.1002/adhm.202303740 [doi] PST - ppublish SO - Adv Healthc Mater. 2024 Jun;13(14):e2303740. doi: 10.1002/adhm.202303740. Epub 2024 Feb 27. PMID- 657454 OWN - NLM STAT- MEDLINE DCOM- 19780828 LR - 20190706 IS - 0009-7330 (Print) IS - 0009-7330 (Linking) VI - 43 IP - 1 DP - 1978 Jul TI - The relationship of excitability to conduction velocity in canine Purkinje tissue. PG - 125-35 AB - The relationship between interelectrode conduction time and "take-off" potential (TOP) was studied with microelectrode techniques in isolated canine false tendons. Conduction of regular or test beats initiated during phase 4 dopolarization or late phase 3 repolarization speeded as TOP decreased. Similarly, beats initiated during digitalis-induced oscillatory after potentials demonstrated more rapid conduction at lower TOP. Because of the frequency-coupled nature of the oscillations, conduction times became rate dependent. Phenytoin antagonized digitalis oscillations and reversed speeding of conduction attributable to the oscillations. No uniform relationship between speed of conduction and maximum upstroke velocity of the action potential could be demonstrated in the above experiments or when speed of conduction was varied by changes in concentration of K+ or Ca2+. However speed of conduction could be demonstrated to vary directly with changes in excitability as measured by intracellular current injection. FAU - Peon, J AU - Peon J FAU - Ferrier, G R AU - Ferrier GR FAU - Moe, G K AU - Moe GK LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 0 (Digitalis Glycosides) RN - 6158TKW0C5 (Phenytoin) RN - RWP5GA015D (Potassium) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Calcium/pharmacology MH - Digitalis Glycosides/pharmacology MH - Dogs MH - Heart Conduction System/*physiology MH - *Membrane Potentials/drug effects MH - Microelectrodes MH - Phenytoin/pharmacology MH - Potassium/pharmacology MH - Purkinje Fibers/*physiology MH - Time Factors EDAT- 1978/07/01 00:00 MHDA- 1978/07/01 00:01 CRDT- 1978/07/01 00:00 PHST- 1978/07/01 00:00 [pubmed] PHST- 1978/07/01 00:01 [medline] PHST- 1978/07/01 00:00 [entrez] AID - 10.1161/01.res.43.1.125 [doi] PST - ppublish SO - Circ Res. 1978 Jul;43(1):125-35. doi: 10.1161/01.res.43.1.125. PMID- 26544628 OWN - NLM STAT- MEDLINE DCOM- 20160831 LR - 20191231 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 37 IP - 5 DP - 2015 TI - Dickkopf1 Up-Regulation Induced by a High Concentration of Dexamethasone Promotes Rat Tendon Stem Cells to Differentiate Into Adipocytes. PG - 1738-49 LID - 10.1159/000438538 [doi] AB - BACKGROUND/AIMS: Dexamethasone (Dex)-induced spontaneous tendon rupture and decreased self-repair capability is very common in clinical practice. The metaplasia of adipose tissue in the ruptured tendon indicates that Dex may induce tendon stem cells (TSCs) to differentiate into adipocytes, but the mechanism remains unclear. In the present study, we used in vitro methods to investigate the effects of Dex on rat TSC differentiation and the molecular mechanisms underlying this process. METHODS: First, we used qPCR and Western blotting to detect the expression of the adipogenic differentiation markers aP2 and C/EBPα after treating the TSCs with Dex. Oil red staining was used to confirm that high concentration Dex promoted adipogenic differentiation of rat TSCs. Next, we used qPCR and Western blotting to detect the effect of a high concentration of dexamethasone on molecules related to the canonical WNT/β-catenin pathway in TSCs. RESULTS: Treating rat TSCs with Dex promoted the synthesis of the inhibitory molecule dickkopf1 (DKK1) at the mRNA and protein levels. Western blotting results further showed that Dex downregulated the cellular signaling molecule phosphorylated glycogen synthase kinase-3β (P-GSK-3 β (ser9)), upregulated P-GSK-3β (tyr216), and downregulated the pivotal signaling molecule β-catenin. Furthermore, DKK1 knockdown attenuated Dex-induced inhibition of the canonical WNT/β-catenin pathway and of the adipogenic differentiation of TSCs. Lithium chloride (LiCl, a GSK-3β inhibitor) reduced Dex-induced inhibition of the classical WNT/β-catenin pathway in TSCs and of the differentiation of TSCs to adipocytes. CONCLUSION: In conclusion, by upregulating DKK1 expression, reducing the level of P-GSK-3β (ser9), and increasing the level of P-GSK-3β (tyr216), Dex causes the degradation of β-catenin, the central molecule of the classical WNT pathway, thereby inducing rat TSCs to differentiate into adipocytes. CI - © 2015 S. Karger AG, Basel. FAU - Chen, Wan AU - Chen W FAU - Tang, Hong AU - Tang H FAU - Liu, Xiangzhou AU - Liu X FAU - Zhou, Mei AU - Zhou M FAU - Zhang, Jiqiang AU - Zhang J FAU - Tang, Kanglai AU - Tang K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20151109 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Anti-Inflammatory Agents) RN - 0 (CCAAT-Enhancer-Binding Proteins) RN - 0 (Dkk1 protein, rat) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (RNA, Messenger) RN - 0 (RNA, Small Interfering) RN - 0 (beta Catenin) RN - 7S5I7G3JQL (Dexamethasone) RN - EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta) RN - EC 2.7.11.1 (Gsk3b protein, rat) RN - EC 2.7.11.26 (Glycogen Synthase Kinase 3) RN - G4962QA067 (Lithium Chloride) SB - IM MH - Adipocytes/cytology/metabolism MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - CCAAT-Enhancer-Binding Proteins/genetics/metabolism MH - Cell Differentiation/*drug effects MH - Cells, Cultured MH - Dexamethasone/*pharmacology MH - Glycogen Synthase Kinase 3/genetics/metabolism MH - Glycogen Synthase Kinase 3 beta MH - Intercellular Signaling Peptides and Proteins/chemistry/genetics/*metabolism MH - Lithium Chloride/pharmacology MH - Phosphorylation/drug effects MH - RNA Interference MH - RNA, Messenger/metabolism MH - RNA, Small Interfering/metabolism MH - Rats MH - Stem Cells/*cytology/metabolism MH - Tendons/*cytology MH - Up-Regulation/*drug effects MH - Wnt Signaling Pathway/drug effects MH - beta Catenin/genetics/metabolism EDAT- 2015/11/07 06:00 MHDA- 2016/09/01 06:00 CRDT- 2015/11/07 06:00 PHST- 2015/10/01 00:00 [accepted] PHST- 2015/11/07 06:00 [entrez] PHST- 2015/11/07 06:00 [pubmed] PHST- 2016/09/01 06:00 [medline] AID - 000438538 [pii] AID - 10.1159/000438538 [doi] PST - ppublish SO - Cell Physiol Biochem. 2015;37(5):1738-49. doi: 10.1159/000438538. Epub 2015 Nov 9. PMID- 15288357 OWN - NLM STAT- MEDLINE DCOM- 20050210 LR - 20151119 IS - 0306-9877 (Print) IS - 0306-9877 (Linking) VI - 63 IP - 3 DP - 2004 TI - Consideration of Rituximab for fibrodysplasia ossificans progressiva. PG - 407-8 AB - Fibrodysplasia ossificans progressiva (FOP) is a severe, progressive disease of the musculoskeletal system. Muscles, tendons and other connective tissues ossify after minor trauma, and patients often become encased in a second immobile skeleton. There is no known cure or treatment for FOP. It has been found that lymphocytes from FOP patients elaborate excess levels of bone morphogenic protein-4 (BMP-4). Given this, it has been suggested that allogenic bone marrow transplantation (BMT) possibly could be a cure for FOP, and drawn attention to a previously unappreciated case of an FOP patient who had successful BMT for aplastic anemia with apparent short- and medium-term arresting of the FOP disease process. However, BMT has non-trivial associated morbidity and mortality. Here, it is noted that if B cells are found to be the lymphocytes responsible for excess BMP-4 production in FOP, use of Rituximab, a monoclonal anti-CD20 antibody which effectively targets B cells, could be a less permanent and less risky treatment alternative for FOP. CI - Copyright 2004 Elsevier Ltd. FAU - Altschuler, Eric Lewin AU - Altschuler EL AD - Rehabitilation Medicine, Mt. Sinai School of Medicine, 1425 Madison Avenue, P.O. Box 1240, NY 10029, USA. eric.altschuler@mssm.edu LA - eng PT - Journal Article PL - United States TA - Med Hypotheses JT - Medical hypotheses JID - 7505668 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Murine-Derived) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Antibodies, Monoclonal/*administration & dosage MH - Antibodies, Monoclonal, Murine-Derived MH - B-Lymphocytes/*drug effects/*immunology MH - Bone Marrow Transplantation/methods MH - Clinical Trials as Topic MH - Evidence-Based Medicine MH - Humans MH - Myositis Ossificans/*drug therapy/*immunology/surgery MH - Rituximab MH - Treatment Outcome EDAT- 2004/08/04 05:00 MHDA- 2005/02/11 09:00 CRDT- 2004/08/04 05:00 PHST- 2004/03/21 00:00 [received] PHST- 2004/04/05 00:00 [accepted] PHST- 2004/08/04 05:00 [pubmed] PHST- 2005/02/11 09:00 [medline] PHST- 2004/08/04 05:00 [entrez] AID - S0306987704003329 [pii] AID - 10.1016/j.mehy.2004.04.024 [doi] PST - ppublish SO - Med Hypotheses. 2004;63(3):407-8. doi: 10.1016/j.mehy.2004.04.024. PMID- 32899140 OWN - NLM STAT- MEDLINE DCOM- 20210325 LR - 20240329 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 21 IP - 17 DP - 2020 Sep 3 TI - The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. LID - 10.3390/ijms21176401 [doi] LID - 6401 AB - Spondyloarthritis (SpA) is a subset of seronegative rheumatic-related autoimmune diseases that consist of ankylosing spondylitis (AS), psoriatic spondylitis (PsA), reactive spondylitis (re-SpA), inflammatory bowel disease (IBD)-associated spondylitis, and unclassifiable spondylitis. These subsets share clinical phenotypes such as joint inflammation and extra-articular manifestations (uveitis, IBD, and psoriasis [Ps]). Inflammation at the enthesis, where ligaments and tendons attach to bones, characterizes and distinguishes SpA from other types of arthritis. Over the past several years, genetic, experimental, and clinical studies have accumulated evidence showing that the IL-23/IL-17 axis plays a critical role in the pathogenesis of SpA. These discoveries include genetic association and the identification of IL-23- and IL-17-producing cells in the tissue of mouse models and human patients. In this review, we summarize the current knowledge of the pathomechanism by focusing on the IL-23/IL-17 pathway and examine the recent clinical studies of biological agents targeting IL-23 and IL-17 in the treatment of SpA. FAU - Tsukazaki, Hiroyuki AU - Tsukazaki H AUID- ORCID: 0000-0001-6759-1210 AD - Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. FAU - Kaito, Takashi AU - Kaito T AUID- ORCID: 0000-0003-4882-2997 AD - Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. LA - eng PT - Journal Article PT - Review DEP - 20200903 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Interleukin-17) RN - 0 (Interleukin-23) SB - IM MH - Animals MH - Humans MH - Interleukin-17/*metabolism MH - Interleukin-23/*metabolism MH - Spondylarthritis/metabolism/*pathology PMC - PMC7504446 OTO - NOTNLM OT - Spondyloarthritis OT - ankylosing arthritis OT - interleukin-17 OT - interleukin-23 OT - psoriatic arthritis COIS- The authors declare no conflict of interest. EDAT- 2020/09/10 06:00 MHDA- 2021/03/26 06:00 PMCR- 2020/09/01 CRDT- 2020/09/09 01:02 PHST- 2020/08/04 00:00 [received] PHST- 2020/08/30 00:00 [revised] PHST- 2020/09/02 00:00 [accepted] PHST- 2020/09/09 01:02 [entrez] PHST- 2020/09/10 06:00 [pubmed] PHST- 2021/03/26 06:00 [medline] PHST- 2020/09/01 00:00 [pmc-release] AID - ijms21176401 [pii] AID - ijms-21-06401 [pii] AID - 10.3390/ijms21176401 [doi] PST - epublish SO - Int J Mol Sci. 2020 Sep 3;21(17):6401. doi: 10.3390/ijms21176401. PMID- 16505089 OWN - NLM STAT- MEDLINE DCOM- 20060522 LR - 20240322 IS - 1473-0480 (Electronic) IS - 0306-3674 (Print) IS - 0306-3674 (Linking) VI - 40 IP - 3 DP - 2006 Mar TI - Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. PG - 275-9 AB - BACKGROUND: Achilles tendinopathy is a common condition, which can become chronic and interfere with athletic performance. The proteinase inhibitor aprotinin (as injection) has been found to improve recovery in patellar tendinopathy (evidence level 1b) and Achilles tendinopathy. Internationally this therapy is being used based on this limited knowledge base. AIM: To evaluate whether aprotinin injections decrease time to recovery in Achilles tendinopathy. METHOD: A prospective, randomised, double blind, placebo controlled trial was performed comparing saline (0.9%) plus local anaesthetic injections and eccentric exercises with aprotinin (30,000 kIU) plus local anaesthetic injection and eccentric exercise. Three injections were given, each a week apart. In total, 26 patients, with 33 affected tendons, were enrolled for this study. RESULTS: At no follow up point (2, 4, 12, or 52 weeks) was there any statistically significant difference between the treatment group and placebo. This included VISA-A scores and secondary outcome measures. However, a trend for improvement over placebo was noted. CONCLUSION: In this study on Achilles tendinopathy, aprotinin was not shown to offer any statistically significant benefit over placebo. Larger multicentre trials are needed to evaluate the efficacy of aprotinin in Achilles tendinopathy. FAU - Brown, R AU - Brown R AD - South Sydney Sports Medicine Centre, Sydney, NSW, Australia. rabrown4@lycos.com FAU - Orchard, J AU - Orchard J FAU - Kinchington, M AU - Kinchington M FAU - Hooper, A AU - Hooper A FAU - Nalder, G AU - Nalder G LA - eng PT - Journal Article PT - Randomized Controlled Trial PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - 0 (Protease Inhibitors) RN - 9087-70-1 (Aprotinin) SB - IM MH - *Achilles Tendon MH - Adult MH - Aged MH - Aprotinin/*therapeutic use MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Prospective Studies MH - Protease Inhibitors/*therapeutic use MH - *Sports MH - Tendinopathy/*drug therapy MH - Treatment Outcome PMC - PMC2491994 COIS- Competing interests: none EDAT- 2006/03/01 09:00 MHDA- 2006/05/23 09:00 PMCR- 2009/03/01 CRDT- 2006/03/01 09:00 PHST- 2006/03/01 09:00 [pubmed] PHST- 2006/05/23 09:00 [medline] PHST- 2006/03/01 09:00 [entrez] PHST- 2009/03/01 00:00 [pmc-release] AID - 40/3/275 [pii] AID - sm21931 [pii] AID - 10.1136/bjsm.2005.021931 [doi] PST - ppublish SO - Br J Sports Med. 2006 Mar;40(3):275-9. doi: 10.1136/bjsm.2005.021931. PMID- 37789395 OWN - NLM STAT- MEDLINE DCOM- 20231005 LR - 20231121 IS - 1477-3155 (Electronic) IS - 1477-3155 (Linking) VI - 21 IP - 1 DP - 2023 Oct 3 TI - Cerium oxide nanoparticles-carrying human umbilical cord mesenchymal stem cells counteract oxidative damage and facilitate tendon regeneration. PG - 359 LID - 10.1186/s12951-023-02125-5 [doi] LID - 359 AB - BACKGROUND: Tendon injuries have a high incidence and limited treatment options. Stem cell transplantation is essential for several medical conditions like tendon injuries. However, high local concentrations of reactive oxygen species (ROS) inhibit the activity of transplanted stem cells and hinder tendon repair. Cerium oxide nanoparticles (CeONPs) have emerged as antioxidant agents with reproducible reducibility. RESULTS: In this study, we synthesized polyethylene glycol-packed CeONPs (PEG-CeONPs), which were loaded into the human umbilical cord mesenchymal stem cells (hUCMSCs) to counteract oxidative damage. H(2)O(2) treatment was performed to evaluate the ROS scavenging ability of PEG-CeONPs in hUCMSCs. A rat model of patellar tendon defect was established to assess the effect of PEG-CeONPs-carrying hUCMSCs in vivo. The results showed that PEG-CeONPs exhibited excellent antioxidant activity both inside and outside the hUCMSCs. PEG-CeONPs protect hUCMSCs from senescence and apoptosis under excessive oxidative stress. Transplantation of hUCMSCs loaded with PEG-CeONPs reduced ROS levels in the tendon injury area and facilitated tendon healing. Mechanistically, NFκB activator tumor necrosis factor α and MAPK activator dehydrocrenatine, reversed the therapeutic effect of PEG-CeONPs in hUCMSCs, indicating that PEG-CeONPs act by inhibiting the NFκB and MAPK signaling pathways. CONCLUSIONS: The carriage of the metal antioxidant oxidase PEG-CeONPs maintained the ability of hUCMSCs in the injured area, reduced the ROS levels in the microenvironment, and facilitated tendon regeneration. The data presented herein provide a novel therapeutic strategy for tendon healing and new insights into the use of stem cells for disease treatment. CI - © 2023. BioMed Central Ltd., part of Springer Nature. FAU - Ren, Xunshan AU - Ren X AD - Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China. FAU - Zhuang, Huangming AU - Zhuang H AD - Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China. FAU - Zhang, Yuelong AU - Zhang Y AD - Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China. FAU - Zhou, Panghu AU - Zhou P AD - Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China. zhoupanghu@whu.edu.cn. LA - eng GR - 2021BCA147/the Hubei Provincial key research and development program/ GR - JCRCFZ-2022-019/Cross-Innovation Talent Program of Renmin Hospital of Wuhan University/ GR - 2042023kf0224/Fundamental Research Funds for Central Universities of the Central South University/ PT - Journal Article DEP - 20231003 PL - England TA - J Nanobiotechnology JT - Journal of nanobiotechnology JID - 101152208 RN - 619G5K328Y (ceric oxide) RN - 0 (Antioxidants) RN - 0 (Reactive Oxygen Species) RN - BBX060AN9V (Hydrogen Peroxide) SB - IM MH - Humans MH - Rats MH - Animals MH - Antioxidants/pharmacology MH - Reactive Oxygen Species MH - Hydrogen Peroxide MH - Oxidative Stress MH - *Mesenchymal Stem Cells MH - Regeneration MH - *Nanoparticles/therapeutic use MH - Tendons MH - *Tendon Injuries/therapy MH - Umbilical Cord PMC - PMC10546722 OTO - NOTNLM OT - Cerium oxide OT - Human umbilical cord mesenchymal stem cell OT - Reactive oxygen species OT - Tendon COIS- The authors declare no competing interests. EDAT- 2023/10/04 00:42 MHDA- 2023/10/05 06:43 PMCR- 2023/10/03 CRDT- 2023/10/03 23:52 PHST- 2023/06/27 00:00 [received] PHST- 2023/09/21 00:00 [accepted] PHST- 2023/10/05 06:43 [medline] PHST- 2023/10/04 00:42 [pubmed] PHST- 2023/10/03 23:52 [entrez] PHST- 2023/10/03 00:00 [pmc-release] AID - 10.1186/s12951-023-02125-5 [pii] AID - 2125 [pii] AID - 10.1186/s12951-023-02125-5 [doi] PST - epublish SO - J Nanobiotechnology. 2023 Oct 3;21(1):359. doi: 10.1186/s12951-023-02125-5. PMID- 19741110 OWN - NLM STAT- MEDLINE DCOM- 20100323 LR - 20131121 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 37 IP - 12 DP - 2009 Dec TI - Is apoptosis the cause of noninsertional achilles tendinopathy? PG - 2440-4 LID - 10.1177/0363546509340264 [doi] AB - BACKGROUND: The pathogenesis of chronic tendinopathy is unclear but it does not appear to be an inflammatory process. Apoptosis may lead to degenerate tissue through a nitric oxide-mediated pathway. Increased levels of nitric oxide have been demonstrated in Achilles tendinopathy. HYPOTHESIS: Nitric oxide-mediated apoptosis is an important mechanism in the development of Achilles tendinopathy. STUDY DESIGN: Controlled laboratory study. METHODS: Samples were obtained from the Achilles tendons of 14 patients with noninsertional Achilles tendinopathy. Control samples were taken from macroscopically normal tendon correlating with areas of normal tissue on magnetic resonance imaging. Immunohistochemical techniques identified the expression of inducible and endothelial nitric oxide synthase as markers of nitric oxide production. Apoptotic cells were identified using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and the demonstration of caspase-3 activation. RESULTS: Significant differences were found between the diseased tendon and the controls for all parameters. The mean caspase-3 cell count for diseased tendon was 51.9 versus 28.3 for the controls (P < .001). The mean TUNEL cell count for diseased tendon was 24.1 compared with 14.8 (P < .001). Inducible nitric oxide synthase (iNOS) densitometry revealed a mean of 26.1 for the diseased tissue versus 15.0 for the controls (P < .001) and the values for endothelial nitric oxide synthase (eNOS) were 48.3 and 23.7, respectively (P = .015). CONCLUSION: Apoptosis may play a role in the development of noninsertional Achilles tendinopathy and appears to be related to the presence of raised eNOS and iNOS levels. CLINICAL RELEVANCE: A clearer understanding of the tendinopathic process may lead to new treatment strategies aimed at modulating apoptosis. FAU - Pearce, Christopher J AU - Pearce CJ AD - Department of Trauma and Orthopaedic Surgery, Basingstoke and North Hampshire Hospitals, NHS Foundation Trust, Basingstoke, United Kingdom. chris.pearce@doctors.org.uk FAU - Ismail, Muhammad AU - Ismail M FAU - Calder, James D AU - Calder JD LA - eng PT - Journal Article DEP - 20090909 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 31C4KY9ESH (Nitric Oxide) RN - EC 1.14.13.39 (NOS2 protein, human) RN - EC 1.14.13.39 (NOS3 protein, human) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type III) SB - IM MH - Achilles Tendon/*pathology MH - Adult MH - Apoptosis/*physiology MH - Humans MH - Middle Aged MH - Nitric Oxide/biosynthesis/*physiology MH - Nitric Oxide Synthase Type II/metabolism MH - Nitric Oxide Synthase Type III/metabolism MH - Tendinopathy/etiology/*metabolism MH - Young Adult EDAT- 2009/09/11 06:00 MHDA- 2010/03/24 06:00 CRDT- 2009/09/11 06:00 PHST- 2009/09/11 06:00 [entrez] PHST- 2009/09/11 06:00 [pubmed] PHST- 2010/03/24 06:00 [medline] AID - 0363546509340264 [pii] AID - 10.1177/0363546509340264 [doi] PST - ppublish SO - Am J Sports Med. 2009 Dec;37(12):2440-4. doi: 10.1177/0363546509340264. Epub 2009 Sep 9. PMID- 8168645 OWN - NLM STAT- MEDLINE DCOM- 19940602 LR - 20220330 IS - 0012-1797 (Print) IS - 0012-1797 (Linking) VI - 43 IP - 5 DP - 1994 May TI - Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. PG - 676-83 AB - The Maillard or browning reaction between sugar and protein contributes to the increased chemical modification and cross-linking of long-lived tissue proteins in diabetes. To evaluate the role of glycation and oxidation in these reactions, we have studied the effects of oxidative and antioxidative conditions and various types of inhibitors on the reaction of glucose with rat tail tendon collagen in phosphate buffer at physiological pH and temperature. The chemical modifications of collagen that were measured included fructoselysine, the glycoxidation products N epsilon-(carboxymethyl)lysine and pentosidine and fluorescence. Collagen cross-linking was evaluated by analysis of cyanogen bromide peptides using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by changes in collagen solubilization on treatment with pepsin or sodium dodecylsulfate. Although glycation was unaffected, formation of glycoxidation products and cross-linking of collagen were inhibited by antioxidative conditions. The kinetics of formation of glycoxidation products proceeded with a short lag phase and were independent of the amount of Amadori adduct on the protein, suggesting that autoxidative degradation of glucose was a major contributor to glycoxidation and cross-linking reactions. Chelators, sulfhydryl compounds, antioxidants, and aminoguanidine also inhibited formation of glycoxidation products, generation of fluorescence, and cross-linking of collagen without significant effect on the extent of glycation of the protein. We conclude that autoxidation of glucose or Amadori compounds on protein plays a major role in the formation of glycoxidation products and cross-liking of collagen by glucose in vitro and that chelators, sulfhydryl compounds, antioxidants, and aminoguanidine act as uncouplers of glycation from subsequent glycoxidation and cross-linking reactions. FAU - Fu, M X AU - Fu MX AD - Department of Chemistry and Biochemistry, University of South Carolina, Columbia 29208. FAU - Wells-Knecht, K J AU - Wells-Knecht KJ FAU - Blackledge, J A AU - Blackledge JA FAU - Lyons, T J AU - Lyons TJ FAU - Thorpe, S R AU - Thorpe SR FAU - Baynes, J W AU - Baynes JW LA - eng GR - DK-19971/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Diabetes JT - Diabetes JID - 0372763 RN - 0 (Antioxidants) RN - 0 (Chelating Agents) RN - 0 (Cross-Linking Reagents) RN - 70YDX3Z2O7 (N(6)-carboxymethyllysine) RN - 7A314HQM0I (Pentetic Acid) RN - 9007-34-5 (Collagen) RN - 94ZLA3W45F (Arginine) RN - BJ4I2X2CQJ (pentosidine) RN - IY9XDZ35W2 (Glucose) RN - K3Z4F929H6 (Lysine) SB - IM MH - Animals MH - Antioxidants MH - Arginine/analogs & derivatives/analysis MH - Chelating Agents MH - Chromatography, High Pressure Liquid MH - Collagen/*chemistry/isolation & purification MH - Cross-Linking Reagents MH - Electrophoresis, Polyacrylamide Gel MH - Female MH - *Glucose MH - Glycosylation MH - Kinetics MH - Lysine/analogs & derivatives/analysis MH - Maillard Reaction MH - Oxidation-Reduction MH - Pentetic Acid MH - Rats MH - Rats, Sprague-Dawley MH - Spectrometry, Fluorescence MH - Tendons EDAT- 1994/05/01 00:00 MHDA- 1994/05/01 00:01 CRDT- 1994/05/01 00:00 PHST- 1994/05/01 00:00 [pubmed] PHST- 1994/05/01 00:01 [medline] PHST- 1994/05/01 00:00 [entrez] AID - 10.2337/diab.43.5.676 [doi] PST - ppublish SO - Diabetes. 1994 May;43(5):676-83. doi: 10.2337/diab.43.5.676. PMID- 36592017 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230201 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 51 IP - 1 DP - 2023 Jan TI - Bioactive Decellularized Tendon-Derived Stem Cell Sheet for Promoting Graft Healing After Anterior Cruciate Ligament Reconstruction. PG - 66-80 LID - 10.1177/03635465221135770 [doi] AB - BACKGROUND: Stem cell sheets provide a scaffold-free option for the promotion of graft healing after anterior cruciate ligament reconstruction (ACLR). However, cell viability, stability, and potential uncontrolled actions create challenges for clinical translation. The decellularization of cell sheets may overcome these problems as studies have shown that the natural extracellular matrix of stem cells is bioactive and can promote tissue repair. HYPOTHESIS: The decellularized tendon-derived stem cell (dTDSC) sheet can promote graft healing after ACLR. STUDY DESIGN: Controlled laboratory study. METHODS: An optimized decellularization protocol was developed to decellularize the TDSC sheets. A total of 64 Sprague-Dawley rats underwent ACLR with or without the dTDSC sheet wrapping the tendon graft (n = 32/group). At 2 and 6 weeks after surgery, graft healing was assessed by micro-computed tomography, histology, and biomechanical testing. The accumulation of iNOS(+) and CD206(+) cells and the expression of metalloproteinase 1 (MMP-1), MMP-13, and tissue inhibitor of metalloprotease 1 (TIMP-1) were assessed by immunohistochemistry. RESULTS: The decellularization was successful, with the removal of 98.4% nucleic acid while preserving the collagenous proteins and bioactive factors. The expression of bone morphogenetic protein 2 (BMP-2) and VEGF in the dTDSC sheet was comparable with the TDSC sheet (P > .05). Micro-computed tomography showed significantly more tunnel bone formation in the dTDSC sheet group. The dTDSC sheet group demonstrated better graft osteointegration and higher integrity of graft midsubstance with significantly higher ultimate failure load (16.58 ± 7.24 vs 8.93 ± 2.45 N; P = .002) and stiffness (11.97 ± 5.21 vs 6.73 ± 2.20 N/mm; P = .027). Significantly fewer iNOS(+) cells but more CD206(+) cells, as well as lower MMP-1 and MMP-13 but higher TIMP-1 expression, were detected at the tendon-bone interface and graft midsubstance in the dTDSC sheet group. CONCLUSION: An optimized decellularization protocol for producing bioactive dTDSC sheets was developed. Wrapping tendon graft with a dTDSC sheet promoted graft healing after ACLR, likely via enhancing bone formation and angiogenesis by BMP-2 and VEGF, modulating macrophage polarization and MMP/TIMP expression, and physically protecting the tendon graft. CLINICAL RELEVANCE: dTDSC sheets alleviate the quality control and safety concerns of cell transplantation and can be used as a cell-free alternative for the promotion of graft healing in ACLR. FAU - Yao, Shiyi AU - Yao S AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Liang, Zuru AU - Liang Z AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lee, Yuk Wa AU - Lee YW AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Yung, Patrick Shu Hang AU - Yung PSH AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lui, Pauline Po Yee AU - Lui PPY AUID- ORCID: 0000-0003-2446-6203 AD - Department of Orthopaedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - EC 3.4.24.- (Matrix Metalloproteinase 13) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Rats MH - Animals MH - *Anterior Cruciate Ligament/surgery MH - Matrix Metalloproteinase 13 MH - Rats, Sprague-Dawley MH - X-Ray Microtomography MH - Matrix Metalloproteinase 1 MH - Tissue Inhibitor of Metalloproteinase-1 MH - Vascular Endothelial Growth Factor A MH - Tendons/surgery MH - Stem Cells MH - *Anterior Cruciate Ligament Reconstruction/methods OTO - NOTNLM OT - anterior cruciate ligament reconstruction (ACLR) OT - cell sheet OT - decellularization OT - tendon-derived stem cells (TDSCs) EDAT- 2023/01/03 06:00 MHDA- 2023/01/04 06:00 CRDT- 2023/01/02 08:14 PHST- 2023/01/02 08:14 [entrez] PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] AID - 10.1177/03635465221135770 [doi] PST - ppublish SO - Am J Sports Med. 2023 Jan;51(1):66-80. doi: 10.1177/03635465221135770. PMID- 18548360 OWN - NLM STAT- MEDLINE DCOM- 20081020 LR - 20121115 IS - 0722-1819 (Print) IS - 0722-1819 (Linking) VI - 40 IP - 3 DP - 2008 Jun TI - [Successful correction of an adherent scar on the dorsal hand with Matriderm]. PG - 197-200 LID - 10.1055/s-2008-1038473 [doi] AB - Adherent scars on the hand often lead to a major functional impairment and an aesthetic deformity. The rate of recurrence after scar correction is usually very high. A 57-year-old woman with an adherent scar on the back of her hand and major functional impairment was successfully treated with Matriderm. Using Matriderm as an additional layer between the atrophic skin and the tendons adherency of the scar could be prevented. One year after surgery the patient is free of pain. There is normal mobility between the skin and the underlying tissue. Complete wrist flexion and extension could be achieved. To the best of our knowledge this is the first case reported of using Matriderm for the correction of a scar that was caused by the paravasal injection of cytostatic drugs. FAU - Keck, M AU - Keck M AD - Abteilung für Plastische und Asthetische Chirurgie, Asklepios Klinik Birkenwerder, Birkenwerder. maike.keck@gmx.de FAU - Ueberreiter, K AU - Ueberreiter K LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Erfolgreiche Korrektur einer adhärenten Narbe im Bereich des Handrückens mit Matriderm. DEP - 20080611 PL - Germany TA - Handchir Mikrochir Plast Chir JT - Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... JID - 8302815 RN - 0 (Antineoplastic Agents) RN - 0 (matriderm) RN - 9007-34-5 (Collagen) RN - 9007-58-3 (Elastin) SB - IM MH - *Absorbable Implants MH - Antineoplastic Agents/administration & dosage/toxicity MH - Breast Neoplasms/drug therapy MH - Cicatrix/chemically induced/*surgery MH - *Collagen MH - Dermatologic Surgical Procedures MH - Drug Eruptions/etiology/*surgery MH - *Elastin MH - Extravasation of Diagnostic and Therapeutic Materials/complications MH - Female MH - Hand/surgery MH - Hand Deformities, Acquired/chemically induced/*surgery MH - Humans MH - Infusions, Intravenous MH - Middle Aged MH - Postoperative Complications/surgery MH - Reoperation MH - Skin/drug effects MH - *Skin, Artificial MH - Suture Techniques MH - Tissue Adhesions/surgery EDAT- 2008/06/13 09:00 MHDA- 2008/10/22 09:00 CRDT- 2008/06/13 09:00 PHST- 2008/06/13 09:00 [pubmed] PHST- 2008/10/22 09:00 [medline] PHST- 2008/06/13 09:00 [entrez] AID - 10.1055/s-2008-1038473 [doi] PST - ppublish SO - Handchir Mikrochir Plast Chir. 2008 Jun;40(3):197-200. doi: 10.1055/s-2008-1038473. Epub 2008 Jun 11. PMID- 3584168 OWN - NLM STAT- MEDLINE DCOM- 19870710 LR - 20131121 IS - 0021-9304 (Print) IS - 0021-9304 (Linking) VI - 21 IP - 5 DP - 1987 May TI - In vitro and in vivo characterization of synthetic polymer/biopolymer composites. PG - 643-55 AB - Collagen, extracted from rat tail tendons using dilute acetic acid, was fabricated into films for subsequent characterization and biocompatibility testing. The reconstituted collagen was characterized with infrared spectroscopy, solution viscosity, contact angle, and tensile testing techniques and was found to be pure with molecular and physical properties consistent with findings of previous researchers. Composites composed of collagen coated on urethane and Silastic Rubber films were fabricated to give improved tear resistance. The biocompatibility of the composites and individual polymers was evaluated by discs implanted in the paravertebral muscle of rabbits. After four weeks none of the materials induced any gross changes in the muscle. Histopathological evaluation revealed a fibrous capsule around all of the materials. Collagen and collagen composites exhibited a stronger reaction as evidenced by a larger fibroblast layer and a variety of inflammatory cells, lymphocytes, eosinophils, and macrophages. The urethane was rated with a response index of 1.5 versus 3.25 for the urethane/collagen composite; Silastic Rubber rated a response index of 1.67 versus 3.12 for the Silastic Rubber/collagen composite; collagen rated a response index of 3.3. The polyester sutures also induced a reaction with a larger fibrous capsule but fewer inflammatory cells as compared to collagen and collagen composites. FAU - Gilbert, D L AU - Gilbert DL FAU - Lyman, D J AU - Lyman DJ LA - eng GR - GM 24487-06/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biomed Mater Res JT - Journal of biomedical materials research JID - 0112726 RN - 0 (Biocompatible Materials) RN - 0 (Biopolymers) RN - 0 (Macromolecular Substances) RN - 0 (Silicone Elastomers) RN - 3IN71E75Z5 (Urethane) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - *Biocompatible Materials MH - *Biopolymers MH - *Collagen MH - *Macromolecular Substances MH - Prostheses and Implants MH - Rabbits MH - Rats MH - Silicone Elastomers MH - Surface Tension MH - Tensile Strength MH - Urethane EDAT- 1987/05/01 00:00 MHDA- 1987/05/01 00:01 CRDT- 1987/05/01 00:00 PHST- 1987/05/01 00:00 [pubmed] PHST- 1987/05/01 00:01 [medline] PHST- 1987/05/01 00:00 [entrez] AID - 10.1002/jbm.820210509 [doi] PST - ppublish SO - J Biomed Mater Res. 1987 May;21(5):643-55. doi: 10.1002/jbm.820210509. PMID- 24439148 OWN - NLM STAT- MEDLINE DCOM- 20140930 LR - 20220331 IS - 1934-1563 (Electronic) IS - 1934-1482 (Linking) VI - 6 IP - 1 DP - 2014 Jan TI - Mesenchymal stem cell therapies in the treatment of musculoskeletal diseases. PG - 61-9 LID - S1934-1482(13)00280-3 [pii] LID - 10.1016/j.pmrj.2013.05.007 [doi] AB - The application of regenerative strategies to musculoskeletal ailments offers extraordinary promise to transform management of the conditions of numerous patients. The use of cell-based therapies and adjunct strategies is under active investigation for injuries and illnesses affecting bones, joints, tendons, and skeletal muscle. Of particular interest to the field is the mesenchymal stem cell, an adult stem cell found in bone marrow and adipose tissue. This cell type can be expanded ex vivo, has allogeneic application, and has the capacity for engraftment and differentiation into mesodermal lineages. Also of major interest in the field is the use of platelet-rich plasma, a strategy to concentrate endogenous cytokines and growth factors with reparative potential. Here we review the biological basis, clinical studies, safety, and current state of mesenchymal stem cell and platelet-rich plasma therapies in the treatment of musculoskeletal disease. CI - Copyright © 2014 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved. FAU - Bashir, Jamil AU - Bashir J AD - Department of Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, FL(∗). FAU - Sherman, Andrew AU - Sherman A AD - Department of Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, FL(†). FAU - Lee, Henry AU - Lee H AD - Department of Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, FL(‡). FAU - Kaplan, Lee AU - Kaplan L AD - Department of Orthopedics, University of Miami Miller School of Medicine, Miami, FL(§). FAU - Hare, Joshua M AU - Hare JM AD - Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, FL 33136(¶). Electronic address: jhare@med.miami.edu. LA - eng PT - Journal Article PT - Review PL - United States TA - PM R JT - PM & R : the journal of injury, function, and rehabilitation JID - 101491319 RN - 0 (Tissue Inhibitor of Metalloproteinase-1) SB - IM MH - Animals MH - Cartilage Diseases/therapy MH - Cell Differentiation MH - Cell Proliferation MH - Dendritic Cells/cytology/immunology MH - Guidelines as Topic MH - Humans MH - Immunomodulation MH - *Mesenchymal Stem Cell Transplantation MH - Mesenchymal Stem Cells/physiology MH - Osteoarthritis/*therapy MH - *Platelet-Rich Plasma MH - Regeneration MH - T-Lymphocytes/cytology/immunology MH - Tendon Injuries/*therapy MH - Tissue Inhibitor of Metalloproteinase-1/metabolism MH - Tissue Scaffolds EDAT- 2014/01/21 06:00 MHDA- 2014/10/01 06:00 CRDT- 2014/01/21 06:00 PHST- 2012/10/02 00:00 [received] PHST- 2013/05/01 00:00 [revised] PHST- 2013/05/03 00:00 [accepted] PHST- 2014/01/21 06:00 [entrez] PHST- 2014/01/21 06:00 [pubmed] PHST- 2014/10/01 06:00 [medline] AID - S1934-1482(13)00280-3 [pii] AID - 10.1016/j.pmrj.2013.05.007 [doi] PST - ppublish SO - PM R. 2014 Jan;6(1):61-9. doi: 10.1016/j.pmrj.2013.05.007. PMID- 3526843 OWN - NLM STAT- MEDLINE DCOM- 19860917 LR - 20161123 IS - 0361-803X (Print) IS - 0361-803X (Linking) VI - 147 IP - 3 DP - 1986 Sep TI - The shoulder impingement syndrome: prevalence of radiographic findings and correlation with response to therapy. PG - 557-61 AB - The shoulder impingement syndrome is believed to be caused by compression of the rotator cuff tendons and subacromial bursa between the humeral head and structures that make up the coracoacromial arch. Plain film findings were tabulated for 36 patients, 22-81 years old, who had signs and symptoms of an acute impingement syndrome. The most common radiographic abnormalities were subacromial bony proliferation in 68%, degenerative changes in the greater tuberosity of the humerus in 66%, and degenerative joint disease in the acromioclavicular joint in 66%. There was evidence of calcium deposition in the rotator cuff in 37%, inferiorly oriented acromioclavicular osteophytes in 32%, and degenerative changes of the lesser humeral tuberosity in 29%. The acromiohumeral space was narrowed in only 21%. The radiographic findings were scored blindly and compared to the treatment outcome of 6 weeks of medical therapy. There was no statistically significant correlation between any of the radiographic findings and the response to medical therapy. The results suggest that radiographic findings are extremely common in patients with the acute impingement syndrome, but that they are not useful as prognostic indicators of the short-term response to medical treatment. FAU - Hardy, D C AU - Hardy DC FAU - Vogler, J B 3rd AU - Vogler JB 3rd FAU - White, R H AU - White RH LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 RN - F446C597KA (Triamcinolone Acetonide) RN - XXE1CET956 (Indomethacin) SB - IM MH - Acute Disease MH - Adult MH - Aged MH - Clinical Trials as Topic MH - Double-Blind Method MH - Female MH - Humans MH - Indomethacin/therapeutic use MH - Joint Diseases/diagnostic imaging/drug therapy MH - Male MH - Middle Aged MH - Prospective Studies MH - Radiography MH - *Shoulder Joint/diagnostic imaging MH - Syndrome MH - Triamcinolone Acetonide/therapeutic use OID - NASA: 86292632 EDAT- 1986/09/01 00:00 MHDA- 1986/09/01 00:01 CRDT- 1986/09/01 00:00 PHST- 1986/09/01 00:00 [pubmed] PHST- 1986/09/01 00:01 [medline] PHST- 1986/09/01 00:00 [entrez] AID - 10.2214/ajr.147.3.557 [doi] PST - ppublish SO - AJR Am J Roentgenol. 1986 Sep;147(3):557-61. doi: 10.2214/ajr.147.3.557. PMID- 6482510 OWN - NLM STAT- MEDLINE DCOM- 19841119 LR - 20131121 IS - 0252-1156 (Print) IS - 0252-1156 (Linking) VI - 3 IP - 1 DP - 1984 TI - On the therapeutic mechanism of Mg2+ in digitoxic arrhythmias and the role of cardiac glycosides in Mg depletion. PG - 8-20 AB - In 9 (of 17 attempted) experiments (8 aborted due to premature tissue death), transmembrane electrical activity was recorded from canine false tendons superfused with Mg-free Tyrode's solution to simulate hypomagnesemia. Oscillatory after-potentials (OAP) developed similar to those seen after exposure to 2 X 10(-7) M ouabain, a short-lasting (0.5-1 time the duration of an action potential) OAP that often reached threshold superimposed on a long-lasting (3-4 times as long as the short) OAP. Both forms of OAP were shown to be Ca2+-dependent, as both were prevented by 10(-7) M nifedipine, but only the short OAP were abolished by nifedipine once they had appeared, while high (5 mM = 10 times normal) Mg2+ both prevented and terminated short and long OAP in digitoxic preparations. Results suggest that cardiac glycosides may deplete Mg from the myocardium. The mechanism of the therapeutic action of Mg2+ in digitalis intoxication is discussed in light of its involvement in Ca2+ sequestration by the sarcoplasmic reticulum. FAU - Moe, B H AU - Moe BH LA - eng PT - Journal Article PL - Switzerland TA - Magnesium JT - Magnesium JID - 8219687 RN - 0 (Cardiac Glycosides) RN - E90NZP2L9U (Digitoxin) RN - I38ZP9992A (Magnesium) RN - I9ZF7L6G2L (Nifedipine) RN - SY7Q814VUP (Calcium) SB - IM MH - Animals MH - Arrhythmias, Cardiac/chemically induced/*drug therapy MH - Calcium/therapeutic use MH - Cardiac Glycosides/*adverse effects MH - Digitoxin/*adverse effects MH - Dogs MH - Female MH - Heart/drug effects MH - Magnesium/*therapeutic use MH - Magnesium Deficiency/*chemically induced MH - Male MH - Nifedipine/therapeutic use MH - Purkinje Fibers/drug effects EDAT- 1984/01/01 00:00 MHDA- 1984/01/01 00:01 CRDT- 1984/01/01 00:00 PHST- 1984/01/01 00:00 [pubmed] PHST- 1984/01/01 00:01 [medline] PHST- 1984/01/01 00:00 [entrez] PST - ppublish SO - Magnesium. 1984;3(1):8-20. PMID- 28553748 OWN - NLM STAT- MEDLINE DCOM- 20180724 LR - 20180808 IS - 1533-1601 (Electronic) IS - 0192-6233 (Linking) VI - 45 IP - 7 DP - 2017 Oct TI - Mini-Review: Toxic Tendinopathy. PG - 834-837 LID - 10.1177/0192623317711614 [doi] AB - Toxic tendinopathy is a rare but reproducible complication in humans, given agents of four drug classes: aromatase inhibitors, fluoroquinolone antibiotics, glucocorticoids (long-term regimens), and statins. Toxic tendinopathy in humans has been linked less consistently to treatment with anabolic steroids, antiretroviral agents (mainly protease inhibitors), metalloproteinase inhibitors (MMPI), and isotretinoin. Classic drug-induced tendinopathies appear as "tendinosis" (i.e., progressive tendon degeneration without inflammation), although cases associated with aromatase inhibitors exhibit mainly tenosynovitis. Any tendon may be affected, but fluoroquinolones, glucocorticoids, and statins most frequently affect large load-bearing tendons in the lower limb, especially the calcaneal ("Achilles") tendon-which ruptures in approximately 30 to 40% of cases. The time to symptom onset ranges from days (fluoroquinolones) to weeks, months, or even years. The pathogenesis is incompletely understood, but proposed mechanisms include apoptosis of tenoblasts and tenocytes, deficient tenocyte function (leading to abnormal extracellular matrix maintenance and repair as well as disrupted intercellular signaling), and structural disintegration (via a combination of increased expression of lytic enzymes, lessened cholesterol content in cell membranes, and neoangiogenesis within highly ordered tendon tissue). Nonclinical safety assessment of therapeutic candidates in these drug classes should incorporate tendon routinely as a protocol-specified tissue for pathology evaluation. FAU - Bolon, Brad AU - Bolon B AD - 1 GEMpath, Inc., Longmont, Colorado, USA. LA - eng PT - Journal Article PT - Review DEP - 20170528 PL - United States TA - Toxicol Pathol JT - Toxicologic pathology JID - 7905907 RN - 0 (Aromatase Inhibitors) RN - 0 (Fluoroquinolones) RN - 0 (Glucocorticoids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) SB - IM MH - Achilles Tendon/drug effects MH - Animals MH - Aromatase Inhibitors/adverse effects MH - Disease Models, Animal MH - Drug-Related Side Effects and Adverse Reactions/diagnosis MH - Fluoroquinolones/adverse effects MH - Glucocorticoids/adverse effects MH - Humans MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects MH - Tendinopathy/*chemically induced/*diagnosis OTO - NOTNLM OT - review OT - tendinopathy OT - tendinosis OT - tendon OT - toxic tendinopathy OT - toxicity EDAT- 2017/05/30 06:00 MHDA- 2018/07/25 06:00 CRDT- 2017/05/30 06:00 PHST- 2017/05/30 06:00 [pubmed] PHST- 2018/07/25 06:00 [medline] PHST- 2017/05/30 06:00 [entrez] AID - 10.1177/0192623317711614 [doi] PST - ppublish SO - Toxicol Pathol. 2017 Oct;45(7):834-837. doi: 10.1177/0192623317711614. Epub 2017 May 28. PMID- 17692684 OWN - NLM STAT- MEDLINE DCOM- 20071012 LR - 20161124 IS - 0041-1345 (Print) IS - 0041-1345 (Linking) VI - 39 IP - 6 DP - 2007 Jul-Aug TI - Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report. PG - 2033-5 AB - Scedosporium apiospermum, the asexual form of Pseudallescheria boydii, is a ubiquitous fungus that represents an unfrequent complication of immune suppression. It accounts for 20% of all non-Aspergillus mold infections in organ transplant recipients. The infection can be localized or disseminated in multiple organs, including lungs, brain, joints, tendons, and skin, and is difficult to treat, due to resistance of S apiospermum to amphotericin B and other antifungal agents. The mortality rate is about 50%. To our knowledge, there are no prospective studies or registries of transplant recipients to guide diagnosis and there are no evidence-based recommendations for the optimal management of this infection. We report a case of S apiospermum infection in a woman with renal transplantation. The first occurrence of infection was a solitary nodule on the forearm, which was surgically excised. Two following relapses were disseminated to the knee, the Achilles tendon, and the skin of the left leg. The infection was successfully treated with voriconazole, but due to the severe iatrogenic immune suppression, a strong reduction in immunosuppressant drugs was needed. FAU - Rogasi, P G AU - Rogasi PG AD - Malattie Infettive, Azienda Ospedaliero Universitaria Careggi, Florence, Italy. rogasipg@aou-careggi.toscana.it FAU - Zanazzi, M AU - Zanazzi M FAU - Nocentini, J AU - Nocentini J FAU - Fantoni, E AU - Fantoni E FAU - Trotta, M AU - Trotta M FAU - Faggi, E AU - Faggi E FAU - Fontanelli, A AU - Fontanelli A FAU - Bertoni, E AU - Bertoni E FAU - Salvadori, M AU - Salvadori M FAU - Leoncini, F AU - Leoncini F LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 RN - 0 (Antifungal Agents) RN - 0 (Pyrimidines) RN - 0 (Triazoles) RN - JFU09I87TR (Voriconazole) SB - IM MH - Antifungal Agents/*therapeutic use MH - Female MH - Humans MH - Kidney Transplantation/*adverse effects MH - Middle Aged MH - Mycetoma/diagnostic imaging/*drug therapy/*etiology MH - Postoperative Complications/diagnostic imaging/drug therapy/*microbiology MH - Pyrimidines/*therapeutic use MH - *Scedosporium MH - Triazoles/*therapeutic use MH - Ultrasonography MH - Voriconazole EDAT- 2007/08/19 09:00 MHDA- 2007/10/13 09:00 CRDT- 2007/08/19 09:00 PHST- 2007/08/19 09:00 [pubmed] PHST- 2007/10/13 09:00 [medline] PHST- 2007/08/19 09:00 [entrez] AID - S0041-1345(07)00623-9 [pii] AID - 10.1016/j.transproceed.2007.05.044 [doi] PST - ppublish SO - Transplant Proc. 2007 Jul-Aug;39(6):2033-5. doi: 10.1016/j.transproceed.2007.05.044. PMID- 39068140 OWN - NLM STAT- MEDLINE DCOM- 20240817 LR - 20240817 IS - 1879-0305 (Electronic) IS - 1359-6101 (Linking) VI - 78 DP - 2024 Aug TI - Targeting cytokines in psoriatic arthritis. PG - 1-13 LID - S1359-6101(24)00042-X [pii] LID - 10.1016/j.cytogfr.2024.06.001 [doi] AB - Psoriatic arthritis (PsA) is part of the psoriatic disease spectrum and is characterized by a chronic inflammatory process that affects entheses, tendons and joints. Cytokines produced by immune and non-immune cells play a central role in the pathogenesis of PsA by orchestrating key aspects of the inflammatory response. Pro-inflammatory cytokines such as TNF, IL-23 and IL-17 have been shown to regulate the initiation and progression of PsA, ultimately leading to the destruction of the architecture of the local tissues such as soft tissue, cartilage and bone. The important role of cytokines in PsA has been underscored by the clinical success of antibodies that neutralize their function. In addition to biologic agents targeting individual pro-inflammatory cytokines, signaling inhibitors that block multiple cytokines simultaneously such as JAK inhibitors have been approved for PsA therapy. In this review, we will focus on our current understanding of the role of cytokines in the disease process of PsA and discuss potential new treatment options based on modulation of cytokine function. CI - Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Neurath, Laura AU - Neurath L AD - Department of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. FAU - Sticherling, Michael AU - Sticherling M AD - Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Department of Dermatology, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. FAU - Schett, Georg AU - Schett G AD - Department of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. FAU - Fagni, Filippo AU - Fagni F AD - Department of Internal Medicine 3, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie DZI, Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. Electronic address: filippo.fagni@uk-erlangen.de. LA - eng PT - Journal Article PT - Review DEP - 20240723 PL - England TA - Cytokine Growth Factor Rev JT - Cytokine & growth factor reviews JID - 9612306 RN - 0 (Cytokines) RN - 0 (Interleukin-17) RN - 0 (Interleukin-23) RN - 0 (Tumor Necrosis Factor-alpha) RN - 0 (Janus Kinase Inhibitors) SB - IM MH - *Arthritis, Psoriatic/drug therapy/immunology MH - Humans MH - *Cytokines/immunology MH - Animals MH - Interleukin-17/antagonists & inhibitors/immunology MH - Interleukin-23/immunology/antagonists & inhibitors MH - Signal Transduction MH - Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology MH - Janus Kinase Inhibitors/therapeutic use OTO - NOTNLM OT - Biological therapy OT - Cytokines OT - DMARD OT - Psoriasis OT - Psoriatic arthritis COIS- Declaration of Competing Interest None. EDAT- 2024/07/28 14:51 MHDA- 2024/08/18 04:43 CRDT- 2024/07/27 21:55 PHST- 2024/06/10 00:00 [received] PHST- 2024/06/26 00:00 [revised] PHST- 2024/06/27 00:00 [accepted] PHST- 2024/08/18 04:43 [medline] PHST- 2024/07/28 14:51 [pubmed] PHST- 2024/07/27 21:55 [entrez] AID - S1359-6101(24)00042-X [pii] AID - 10.1016/j.cytogfr.2024.06.001 [doi] PST - ppublish SO - Cytokine Growth Factor Rev. 2024 Aug;78:1-13. doi: 10.1016/j.cytogfr.2024.06.001. Epub 2024 Jul 23. PMID- 35672204 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20250728 IS - 1873-2364 (Electronic) IS - 0960-8966 (Linking) VI - 32 IP - 7 DP - 2022 Jul TI - Application of ultrasound in a case of eosinophilic fasciitis mimicking stiff-person syndrome. PG - 590-593 LID - S0960-8966(22)00146-8 [pii] LID - 10.1016/j.nmd.2022.05.009 [doi] AB - Eosinophilic fasciitis (EF) is a rare disorder characterized by muscle stiffness mimicking other neuromuscular diseases. The diagnosis of EF is made on the basis of typical skin lesions. We report a case of a 36-year-old male patient with suspected stiff-person syndrome (SPS), who presented with progressive limb muscle stiffness and limited mobility of both wrists without obvious skin changes. Ultrasound revealed fascial thickening of bilateral upper and lower limb muscles and enlargement of hypoechoic tissues around the flexor digitorum tendons of the wrist. Skin and fascia biopsy confirmed the diagnosis of EF. Prednisolone therapy resulted in the improvement of muscle stiffness and tightness. Our findings suggest the need to consider connective tissue diseases such as EF in a patient with atypical features of SPS. Ultrasound is helpful for visualizing the causes of muscle stiffness and joint contractures in EF patients. CI - Copyright © 2022 Elsevier B.V. All rights reserved. FAU - Yamazaki, Hiroki AU - Yamazaki H AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. Electronic address: yamazaki-hiroki@tokushima-u.ac.jp. FAU - Matsui, Naoko AU - Matsui N AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. FAU - Takamatsu, Naoko AU - Takamatsu N AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. FAU - Yoshida, Takeshi AU - Yoshida T AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan; Department of Rheumatology, Chikamori Hospital, Kochi, Japan. FAU - Fukushima, Koji AU - Fukushima K AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. FAU - Takata, Tadayuki AU - Takata T AD - Department of Supportive and Promotive Medicine of the Municipal Hospital, Kagawa University Faculty of Medicine, Kagawa, Japan. FAU - Osaki, Yusuke AU - Osaki Y AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. FAU - Tanaka, Keiko AU - Tanaka K AD - Department of Animal Model Development, Brain Research Institute, Niigata University, Niigata, Japan. FAU - Kubo, Yoshiaki AU - Kubo Y AD - Department of Dermatology, Tokushima University Hospital, Tokushima, Japan. FAU - Izumi, Yuishin AU - Izumi Y AD - Department of Neurology, Tokushima University Hospital, Tokushima, Japan. LA - eng PT - Case Reports PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220517 PL - England TA - Neuromuscul Disord JT - Neuromuscular disorders : NMD JID - 9111470 RN - 9PHQ9Y1OLM (Prednisolone) RN - Eosinophilic Fasciitis SB - IM MH - Adult MH - *Eosinophilia/diagnostic imaging/pathology MH - *Fasciitis/diagnostic imaging/pathology MH - Humans MH - Male MH - Prednisolone MH - *Stiff-Person Syndrome/diagnostic imaging OTO - NOTNLM OT - Eosinophilic fasciitis OT - Joint contracture OT - Muscle stiffness OT - Stiff-person syndrome OT - Ultrasound EDAT- 2022/06/08 06:00 MHDA- 2022/07/14 06:00 CRDT- 2022/06/07 22:04 PHST- 2021/09/29 00:00 [received] PHST- 2022/04/21 00:00 [revised] PHST- 2022/05/16 00:00 [accepted] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/07 22:04 [entrez] AID - S0960-8966(22)00146-8 [pii] AID - 10.1016/j.nmd.2022.05.009 [doi] PST - ppublish SO - Neuromuscul Disord. 2022 Jul;32(7):590-593. doi: 10.1016/j.nmd.2022.05.009. Epub 2022 May 17. PMID- 9737820 OWN - NLM STAT- MEDLINE DCOM- 19981119 LR - 20191024 IS - 0142-2782 (Print) IS - 0142-2782 (Linking) VI - 19 IP - 6 DP - 1998 Sep TI - Uptake of verteporfin by articular tissues following systemic and intra-articular administration. PG - 395-400 AB - Photodynamic therapy (PDT) using the photosensitizer BPD-Verteporfin (liposomal benzoporphyrin derivative-monoacid ring A) has been shown in previous studies to be effective in the amelioration of inflammatory arthritis in both the MRL-lpr mouse and the New Zealand White (NZW) rabbit models, and could potentially offer alleviation of certain inflammation-related symptoms of rheumatoid arthritis. Time and dose dependency of BPD-MA tissue uptake was carried out in the inflamed synovium and other articular and peri-articular tissues following intravenous and intra-articular administration in the NZW rabbit model. As some articular and peri-articular tissues are difficult to extract, this study uses a rapid fluorimetric sampling of tissues following dissolution in Soluene 350. Our results showed that i.v. injected BPD-MA preferentially distributed in the inflamed synovium, and in tissues with a high degree of vascularization. Little or no association was found with avascular tissues such as cartilage and tendons. Clearance from the synovium was rapid, supporting earlier rather than late light treatment. Much higher association of BPD-MA with the synovium was achieved using intra-articular injection, and BPD-MA concentrations were maintained at relatively steady levels for several hours. These observations support the possibility that PDT could offer a safe, highly versatile clinical option for the management of inflamed joints in autoimmune disorders. FAU - Chowdhary, R K AU - Chowdhary RK AD - Department of Microbiology, University of British Columbia, Vancouver, Canada. rchowdha@qlt-pdt.com FAU - Ratkay, L G AU - Ratkay LG FAU - Canaan, A J AU - Canaan AJ FAU - Waterfield, J D AU - Waterfield JD FAU - Richter, A M AU - Richter AM FAU - Levy, J G AU - Levy JG LA - eng PT - Comparative Study PT - Journal Article PL - England TA - Biopharm Drug Dispos JT - Biopharmaceutics & drug disposition JID - 7911226 RN - 0 (Antineoplastic Agents) RN - 0 (Liposomes) RN - 0 (Photosensitizing Agents) RN - 0 (Porphyrins) RN - 0X9PA28K43 (Verteporfin) RN - 9006-59-1 (Ovalbumin) SB - IM MH - Animals MH - Antineoplastic Agents/administration & dosage/*pharmacokinetics MH - Arthritis/chemically induced/metabolism MH - Injections, Intra-Articular MH - Injections, Intravenous MH - Liposomes MH - Ovalbumin MH - Photochemotherapy MH - Photosensitizing Agents/administration & dosage/*pharmacokinetics MH - Porphyrins/administration & dosage/*pharmacokinetics MH - Rabbits MH - Synovial Fluid/*metabolism MH - Tissue Distribution MH - Verteporfin EDAT- 1998/09/16 02:05 MHDA- 2000/06/20 09:00 CRDT- 1998/09/16 02:05 PHST- 1998/09/16 02:05 [pubmed] PHST- 2000/06/20 09:00 [medline] PHST- 1998/09/16 02:05 [entrez] AID - 10.1002/(SICI)1099-081X(199809)19:6<395::AID-BDD117>3.0.CO;2-9 [pii] AID - 10.1002/(sici)1099-081x(199809)19:6<395::aid-bdd117>3.0.co;2-9 [doi] PST - ppublish SO - Biopharm Drug Dispos. 1998 Sep;19(6):395-400. doi: 10.1002/(sici)1099-081x(199809)19:6<395::aid-bdd117>3.0.co;2-9. PMID- 24053860 OWN - NLM STAT- MEDLINE DCOM- 20140605 LR - 20161125 IS - 1872-6283 (Electronic) IS - 0379-0738 (Linking) VI - 232 IP - 1-3 DP - 2013 Oct 10 TI - Heat stress and sudden infant death syndrome--stress gene expression after exposure to moderate heat stress. PG - 16-24 LID - S0379-0738(13)00325-3 [pii] LID - 10.1016/j.forsciint.2013.06.003 [doi] AB - The aim of the present study was to investigate stress gene expression in cultured primary fibroblasts established from Achilles tendons collected during autopsies from sudden infant death syndrome (SIDS) cases, and age-matched controls (infants dying in a traumatic event). Expression of 4 stress responsive genes, HSPA1B, HSPD1, HMOX1, and SOD2, was studied by quantitative reverse transcriptase PCR analysis of RNA purified from cells cultured under standard or various thermal stress conditions. The expression of all 4 genes was highly influenced by thermal stress in both SIDS and control cells. High interpersonal variance found in the SIDS group indicated that they represented a more heterogeneous group than controls. The SIDS group responded to thermal stress with a higher expression of the HSPA1B and HSPD1 genes compared to the control group, whereas no significant difference was observed in the expression of SOD2 and HMOX1 between the two groups. The differences were related to the heat shock treatment as none of the genes were expressed significantly different in SIDS at base levels at 37 °C. SOD2 and HMOX1 were up regulated in both groups, for SOD2 though the expression was lower in SIDS at all time points measured, and may be less related to heat stress. Being found dead in the prone position (a known risk factor for SIDS) was related to a lower HSPA1B up-regulation in SIDS compared to SIDS found on their side or back. The study demonstrates the potential usefulness of gene expression studies using cultured fibroblasts established from deceased individuals as a tool for molecular and pathological investigations in forensic and biomedical sciences. CI - Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. FAU - Rohde, Marianne Cathrine AU - Rohde MC AD - Institute of Forensic Medicine, Department of Forensic Pathology, Aarhus University, Denmark. Electronic address: mcr@forensic.au.dk. FAU - Corydon, Thomas Juhl AU - Corydon TJ FAU - Hansen, Jakob AU - Hansen J FAU - Pedersen, Christina Bak AU - Pedersen CB FAU - Schmidt, Stinne P AU - Schmidt SP FAU - Gregersen, Niels AU - Gregersen N FAU - Banner, Jytte AU - Banner J LA - eng PT - Journal Article DEP - 20130727 PL - Ireland TA - Forensic Sci Int JT - Forensic science international JID - 7902034 RN - 0 (Chaperonin 60) RN - 0 (HSP70 Heat-Shock Proteins) RN - 0 (HSPA1B protein, human) RN - 0 (HSPD1 protein, human) RN - 0 (Mitochondrial Proteins) RN - 0 (RNA, Messenger) RN - EC 1.14.14.18 (HMOX1 protein, human) RN - EC 1.14.14.18 (Heme Oxygenase-1) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.15.1.1 (superoxide dismutase 2) SB - IM MH - Achilles Tendon/cytology MH - Case-Control Studies MH - Cells, Cultured MH - Chaperonin 60/*genetics MH - Fibroblasts/metabolism/pathology MH - Forensic Genetics MH - Forensic Pathology MH - HSP70 Heat-Shock Proteins/*genetics MH - Heat Stress Disorders/*genetics MH - Heme Oxygenase-1/*genetics MH - Hot Temperature MH - Humans MH - Infant MH - Infant, Newborn MH - Mitochondrial Proteins/*genetics MH - Prone Position MH - RNA, Messenger/metabolism MH - Real-Time Polymerase Chain Reaction MH - Reverse Transcriptase Polymerase Chain Reaction MH - Sudden Infant Death/*genetics MH - Superoxide Dismutase/*genetics MH - Time Factors MH - Up-Regulation OTO - NOTNLM OT - Fibroblast culture OT - Heat stress OT - Infant death OT - QRT-PCR OT - SIDS EDAT- 2013/09/24 06:00 MHDA- 2014/06/06 06:00 CRDT- 2013/09/24 06:00 PHST- 2012/10/08 00:00 [received] PHST- 2013/04/21 00:00 [revised] PHST- 2013/06/03 00:00 [accepted] PHST- 2013/09/24 06:00 [entrez] PHST- 2013/09/24 06:00 [pubmed] PHST- 2014/06/06 06:00 [medline] AID - S0379-0738(13)00325-3 [pii] AID - 10.1016/j.forsciint.2013.06.003 [doi] PST - ppublish SO - Forensic Sci Int. 2013 Oct 10;232(1-3):16-24. doi: 10.1016/j.forsciint.2013.06.003. Epub 2013 Jul 27. PMID- 28744328 OWN - NLM STAT- MEDLINE DCOM- 20180326 LR - 20231112 IS - 1838-7640 (Electronic) IS - 1838-7640 (Linking) VI - 7 IP - 9 DP - 2017 TI - Ultrasonographic Imaging and Anti-inflammatory Therapy of Muscle and Tendon Injuries Using Polymer Nanoparticles. PG - 2463-2476 LID - 10.7150/thno.18922 [doi] AB - Ultrasonography is a reliable diagnostic modality for muscle and tendon injuries, but it has been challenging to find right diagnosis of minor musculoskeletal injuries by conventional ultrasonographic imaging. A large amount of hydrogen peroxide (H(2)O(2)) are known to be generated during tissue damages such as mechanical injury and therefore H(2)O(2) holds great potential as a diagnostic and therapeutic marker for mechanical injuries in the musculoskeletal system. We previously developed poly(vanillyl alcohol-co-oxalate) (PVAX), which rapidly scavenges H(2)O(2) and exerts antioxidant and anti-inflammatory activity in H(2)O(2)-associated diseases. Based on the notion that PVAX nanoparticles generate CO(2) bubbles through H(2)O(2)-triggered hydrolysis, we postulated that PVAX nanoparticles could serve as ultrasonographic contrast agents and therapeutic agents for musculoskeletal injuries associated with overproduction of H(2)O(2). In the agarose gel phantom study, PVAX nanoparticles continuously generated CO(2) bubbles to enhance ultrasonographic echogenicity significantly. Contusion injury significantly elevated the level of H(2)O(2) in skeletal muscles and Achilles tendons. Upon intramuscular injection, PVAX nanoparticles significantly elevated the ultrasound contrast and suppressed inflammation and apoptosis in the contusion injury of musculoskeletal systems. We anticipate that PVAX nanoparticles hold great translational potential as theranostic agents for musculoskeletal injuries. FAU - Kim, Gi-Wook AU - Kim GW AD - Department of Physical Medicine and Rehabilitation, Chonbuk National University Medical School, Chonbuk, 561-756, Republic of Korea. AD - Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. AD - Translational Research & Clinical Trial Center for Medical Device, Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. FAU - Kang, Changsun AU - Kang C AD - Department of BIN Convergence Technology, Chonbuk National University, Chonbuk, 561-756, Republic of Korea. FAU - Oh, Young-Bin AU - Oh YB AD - Department of Physical Medicine and Rehabilitation, Chonbuk National University Medical School, Chonbuk, 561-756, Republic of Korea. AD - Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. FAU - Ko, Myoung-Hwan AU - Ko MH AD - Department of Physical Medicine and Rehabilitation, Chonbuk National University Medical School, Chonbuk, 561-756, Republic of Korea. AD - Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. AD - Translational Research & Clinical Trial Center for Medical Device, Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. FAU - Seo, Jeong-Hwan AU - Seo JH AD - Department of Physical Medicine and Rehabilitation, Chonbuk National University Medical School, Chonbuk, 561-756, Republic of Korea. AD - Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. AD - Translational Research & Clinical Trial Center for Medical Device, Chonbuk National University Hospital, Chonbuk, 561-756, Republic of Korea. FAU - Lee, Dongwon AU - Lee D AD - Department of BIN Convergence Technology, Chonbuk National University, Chonbuk, 561-756, Republic of Korea. AD - Department of Polymer•Nano Science and Technology, Chonbuk National University, Chonbuk, 561-756, Republic of Korea. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170624 PL - Australia TA - Theranostics JT - Theranostics JID - 101552395 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Antioxidants) RN - 0 (Contrast Media) SB - IM MH - Achilles Tendon/diagnostic imaging/*injuries MH - Animals MH - Anti-Inflammatory Agents/*administration & dosage MH - Antioxidants/administration & dosage MH - Contrast Media/administration & dosage MH - Disease Models, Animal MH - Injections, Intramuscular MH - Male MH - Muscles/diagnostic imaging/*injuries MH - Musculoskeletal Diseases/*diagnostic imaging/*drug therapy MH - Nanoparticles/*administration & dosage MH - Rats, Sprague-Dawley MH - *Ultrasonography PMC - PMC5525750 OTO - NOTNLM OT - CO2 Bubbles. OT - Hydrogen peroxide OT - Musculoskeletal injury OT - Polymer nanoparticles OT - Ultrasonography COIS- Competing Interests: The authors have declared that no competing interest exists. EDAT- 2017/07/27 06:00 MHDA- 2018/03/27 06:00 PMCR- 2017/01/01 CRDT- 2017/07/27 06:00 PHST- 2016/12/26 00:00 [received] PHST- 2017/04/17 00:00 [accepted] PHST- 2017/07/27 06:00 [entrez] PHST- 2017/07/27 06:00 [pubmed] PHST- 2018/03/27 06:00 [medline] PHST- 2017/01/01 00:00 [pmc-release] AID - thnov07p2463 [pii] AID - 10.7150/thno.18922 [doi] PST - epublish SO - Theranostics. 2017 Jun 24;7(9):2463-2476. doi: 10.7150/thno.18922. eCollection 2017. PMID- 10403771 OWN - NLM STAT- MEDLINE DCOM- 19990805 LR - 20171116 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 260 IP - 2 DP - 1999 Jul 5 TI - Protein aging by carboxymethylation of lysines generates sites for divalent metal and redox active copper binding: relevance to diseases of glycoxidative stress. PG - 332-8 AB - Aging and age-related diseases are associated with the production of reactive oxygen species which modify lipids, proteins and DNA. Here we hypothesized the glyco- and lipoxidation product N(epsilon)-(carboxymethyl)lysine (CML) in proteins should bind divalent and redox active transition metal binding. CML-rich poly-L-lysine and bovine serum albumin (BSA) were chemically prepared and found to bind non-dialyzable Cu(2+), Zn(2+) and Ca(2+). CML-BSA-copper complexes oxidized ascorbate and depolymerized protein in the presence of H(2)O(2). CML-rich tail tendons implanted for 25 days into the peritoneal cavity of diabetic rats had a 150% increase in copper content and oxidized ascorbate three times faster than controls. CML-rich proteins immunoprecipitated from serum of uremic patients oxidized four times more ascorbate than control and generated spin adducts of DMPO in the presence of H(2)O(2). The chelator DTPA suppressed ascorbate oxidation thereby implicating transition metals in the process. In aging and disease, CML accumulation may result in a deleterious vicious cycle since CML formation itself is catalyzed by lipoxidation and glycoxidation. CI - Copyright 1999 Academic Press. FAU - Saxena, A K AU - Saxena AK AD - Case Western Reserve University School of Medicine, Cleveland, Ohio, 44106, USA. FAU - Saxena, P AU - Saxena P FAU - Wu, X AU - Wu X FAU - Obrenovich, M AU - Obrenovich M FAU - Weiss, M F AU - Weiss MF FAU - Monnier, V M AU - Monnier VM LA - eng GR - AG05601/AG/NIA NIH HHS/United States GR - DK45619/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Biopolymers) RN - 0 (Cations, Divalent) RN - 0 (Free Radicals) RN - 0 (Glycation End Products, Advanced) RN - 452VLY9402 (Serine) RN - 70YDX3Z2O7 (N(6)-carboxymethyllysine) RN - 789U1901C5 (Copper) RN - 9007-34-5 (Collagen) RN - BBX060AN9V (Hydrogen Peroxide) RN - EC 1.11.1.7 (Peroxidase) RN - K3Z4F929H6 (Lysine) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Animals MH - Ascorbic Acid/metabolism MH - Binding Sites MH - Biopolymers MH - Catalysis MH - Cations, Divalent MH - Collagen/metabolism MH - Copper/*metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Free Radicals MH - *Glycation End Products, Advanced MH - Humans MH - Hydrogen Peroxide/metabolism MH - Kidney Failure, Chronic/*metabolism MH - Lysine/*analogs & derivatives/metabolism MH - Methylation MH - Oxidation-Reduction MH - Oxidative Stress MH - Peroxidase/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Serine/metabolism EDAT- 1999/07/15 00:00 MHDA- 1999/07/15 00:01 CRDT- 1999/07/15 00:00 PHST- 1999/07/15 00:00 [pubmed] PHST- 1999/07/15 00:01 [medline] PHST- 1999/07/15 00:00 [entrez] AID - S0006-291X(99)90898-7 [pii] AID - 10.1006/bbrc.1999.0898 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1999 Jul 5;260(2):332-8. doi: 10.1006/bbrc.1999.0898. PMID- 16538926 OWN - NLM STAT- MEDLINE DCOM- 20060413 LR - 20151119 IS - 1526-744X (Print) IS - 1526-744X (Linking) VI - 33 IP - 1 DP - 2006 Jan-Feb TI - Amyloidosis and its impact on patients with ESRD. PG - 31-3; quiz 34-5 AB - Patients, like those with ESRD, who have lost the ability to filter excess proteins from their bodies are at risk to develop beta-2-microglobin amyloidosis, also known as dialysis-related amyloidosis (DRA). When the kidneys do not work efficiently, a protein called beta-2-microglobulin can build up in the blood. Eventually, these molecules can form large deposits and potentially damage surrounding tissues. Currently, dialyzer membranes do not effectively remove these large molecules and, as the blood levels become elevated, deposits begin forming in bone, joints, and tendons resulting in pain and/or stiffness. Unfortunately, there is no known cure for DRA, although attempts are being made to develop dialyzer membranes that can more efficiently remove beta-2-microglobulin from the blood. Implications for practice include early diagnosis, patient teaching, optimal pain management and fall risk management. FAU - Copeland, Sandra D AU - Copeland SD AD - Renal Care Services, Medical Center of Central Georgia, Macon, USA. LA - eng PT - Journal Article PL - United States TA - Nephrol Nurs J JT - Nephrology nursing journal : journal of the American Nephrology Nurses' Association JID - 100909377 RN - 0 (CST3 protein, human) RN - 0 (Cystatin C) RN - 0 (Cystatins) RN - 0 (Membranes, Artificial) RN - 0 (beta 2-Microglobulin) MH - Accidental Falls/prevention & control MH - Amyloidosis/blood/diagnosis/epidemiology/*etiology/prevention & control MH - Biopsy MH - Cystatin C MH - Cystatins MH - Early Diagnosis MH - Equipment Design MH - Glomerular Filtration Rate MH - Humans MH - Incidence MH - Information Services MH - Internet MH - *Kidney Failure, Chronic/complications/therapy MH - Membranes, Artificial MH - Nurse's Role MH - Pain/etiology/prevention & control MH - Patient Education as Topic MH - Prognosis MH - Renal Dialysis/*adverse effects/instrumentation MH - Risk Factors MH - Risk Management MH - Survival Rate MH - Time Factors MH - United States/epidemiology MH - beta 2-Microglobulin/*metabolism EDAT- 2006/03/17 09:00 MHDA- 2006/04/14 09:00 CRDT- 2006/03/17 09:00 PHST- 2006/03/17 09:00 [pubmed] PHST- 2006/04/14 09:00 [medline] PHST- 2006/03/17 09:00 [entrez] PST - ppublish SO - Nephrol Nurs J. 2006 Jan-Feb;33(1):31-3; quiz 34-5. PMID- 22049953 OWN - NLM STAT- MEDLINE DCOM- 20120228 LR - 20220410 IS - 1938-2367 (Electronic) IS - 0147-7447 (Linking) VI - 34 IP - 11 DP - 2011 Nov 9 TI - Outcomes of modified 2-incision technique with use of indomethicin in treatment of distal biceps tendon rupture. PG - e724-9 LID - 10.3928/01477447-20110922-10 [doi] AB - Multiple surgical techniques for distal biceps tendon ruptures exist. Heterotopic ossification is an associated omplication of the 2-incision technique. The purpose of this study was to review the results of distal biceps tendon repairs via the modified 2-incision technique using indomethacin chemoprophylaxis. A retrospective review of 34 2-incision repairs of the distal biceps tendon was performed. All patients received 6 weeks of indomethacin treatment postoperatively to prophylax against heterotopic ossification. Outcome measures included disabilities of the arm, shoulder, and hand (DASH) scoring, incidence of heterotopic ossification, and forearm range of motion. Of the 34 elbows, 2 had minor complications that resolved within 6 weeks of presentation. The average DASH score at final follow-up was 3.8. No cases of heterotopic ossification, nerve palsies, reruptures, or radioulnar synostoses were observed. At final follow-up, no significant difference was noted in range of motion between the injured and uninjured extremity in all planes. The Morrey modification of the 2-incision technique can be safe and provide full functional recovery in patients with ruptured distal biceps tendons when performed in conjunction with indomethacin prophylaxis. CI - Copyright 2011, SLACK Incorporated. FAU - Anakwenze, Oke A AU - Anakwenze OA AD - Department of Orthopaedic Surgery, School of Medicine, University of Pennsylvania, Pa, USA. FAU - Kancherla, Vamsi K AU - Kancherla VK FAU - Warrender, William AU - Warrender W FAU - Abboud, Joseph A AU - Abboud JA LA - eng PT - Journal Article DEP - 20111109 PL - United States TA - Orthopedics JT - Orthopedics JID - 7806107 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Aged MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Arm Injuries/physiopathology/*surgery MH - Disability Evaluation MH - Elbow Joint/physiopathology/surgery MH - Humans MH - Indomethacin/*therapeutic use MH - Male MH - Middle Aged MH - Postoperative Complications MH - Retrospective Studies MH - Rupture MH - Tendon Injuries/*surgery MH - Tendon Transfer/adverse effects/*methods MH - Treatment Outcome EDAT- 2011/11/05 06:00 MHDA- 2012/03/01 06:00 CRDT- 2011/11/05 06:00 PHST- 2011/11/05 06:00 [entrez] PHST- 2011/11/05 06:00 [pubmed] PHST- 2012/03/01 06:00 [medline] AID - 10.3928/01477447-20110922-10 [doi] PST - epublish SO - Orthopedics. 2011 Nov 9;34(11):e724-9. doi: 10.3928/01477447-20110922-10. PMID- 9751097 OWN - NLM STAT- MEDLINE DCOM- 19981008 LR - 20161124 IS - 0004-3591 (Print) IS - 0004-3591 (Linking) VI - 41 IP - 9 DP - 1998 Sep TI - Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. PG - 1639-44 AB - OBJECTIVE: To determine the efficacy of a selective inhibitor of collagenases in an animal model of osteoarthritis (OA). METHODS: Ro 32-3555, an orally active collagenase selective inhibitor, was administered to STR/ORT mice. Microfocal x-ray-generated images of the hind limbs were visually scored for joint space narrowing, osteophyte formation, and calcification of tendons. Histologic sections of the knees were scored for cartilage changes including loss of surface matrix, fibrillation, and eburnation. RESULTS: Significant inhibition of joint space narrowing and osteophyte formation was achieved in groups of animals treated with 10-50 mg/kg(-1) of Ro 32-3555. These effects were confirmed histologically in the same groups of animals: histologic analysis revealed that Ro 32-3555 protected cartilage from degradative changes. CONCLUSION: Ro 32-3555, a collagenase selective inhibitor, inhibits both the cartilage and bone changes in this mouse model of OA, and thus shows great potential as a treatment of OA in humans. FAU - Brewster, M AU - Brewster M AD - Roche Discovery Welwyn, Welwyn Garden City, Hertfordshire, UK. FAU - Lewis, E J AU - Lewis EJ FAU - Wilson, K L AU - Wilson KL FAU - Greenham, A K AU - Greenham AK FAU - Bottomley, K M AU - Bottomley KM LA - eng PT - Journal Article PL - United States TA - Arthritis Rheum JT - Arthritis and rheumatism JID - 0370605 RN - 0 (Imidazoles) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (Protease Inhibitors) RN - 0 (Ro 32-3555) SB - IM MH - Animals MH - Cartilage, Articular/diagnostic imaging/*drug effects/pathology MH - Disease Models, Animal MH - Imidazoles/*pharmacology MH - Knee Joint/diagnostic imaging/*drug effects/pathology MH - Male MH - *Matrix Metalloproteinase Inhibitors MH - Mice MH - Mice, Inbred BALB C MH - Microradiography MH - Osteoarthritis/diagnostic imaging/pathology/*prevention & control MH - Protease Inhibitors/*pharmacology EDAT- 1998/09/29 00:00 MHDA- 1998/09/29 00:01 CRDT- 1998/09/29 00:00 PHST- 1998/09/29 00:00 [pubmed] PHST- 1998/09/29 00:01 [medline] PHST- 1998/09/29 00:00 [entrez] AID - 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0 [doi] PST - ppublish SO - Arthritis Rheum. 1998 Sep;41(9):1639-44. doi: 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0. PMID- 6728838 OWN - NLM STAT- MEDLINE DCOM- 19840720 LR - 20200930 IS - 0037-9727 (Print) IS - 0037-9727 (Linking) VI - 176 IP - 3 DP - 1984 Jul TI - An in vitro model of fibroplasia: simultaneous quantification of fibroblast proliferation, migration, and collagen synthesis. PG - 302-8 AB - Previous studies of fibroblast proliferation, migration, and collagen synthesis have been limited in their ability to define the interrelationship among these events in response to various inflammatory mediators. We have now defined an in vitro tissue culture model for the synchronous quantification of these parameters of fibroplasia. Biopsies (2 mm) of chicken flexor tendons are embedded in a fibrin matrix and exposed to various factors for 5 days in tissue culture. The availability of the fibrin matrix surrounding the tendon biopsy satisfies the need for a solid support medium for fibroblast migration. Multiple measurements of tendon fibroblast proliferation, migration into the fibrin matrix, and relative collagen synthesis are then made on these preparations. Fetal calf serum stimulated tendon fibroblast proliferation and migration in a dose responsive fashion, whereas the selective expression of collagen synthesis was decreased. Platelet lysate stimulated fibroblast proliferation at low concentration, but migration only at high concentration and was without effect on relative collagen synthesis. This model now provides a means of more clearly defining the influence of various inflammatory factors on the events of fibroplasia. FAU - Graham, M F AU - Graham MF FAU - Diegelmann, R F AU - Diegelmann RF FAU - Cohen, I K AU - Cohen IK LA - eng GR - GM-20298/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Proc Soc Exp Biol Med JT - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) JID - 7505892 RN - 9007-34-5 (Collagen) RN - LGP81V5245 (Idoxuridine) SB - IM MH - Animals MH - Blood MH - Blood Platelets/physiology MH - Cell Division MH - Cell Movement MH - Chickens MH - Collagen/*biosynthesis MH - Culture Techniques MH - Extracellular Matrix/physiology MH - Female MH - Fibroblasts/*cytology/metabolism MH - Idoxuridine/metabolism MH - *Models, Biological MH - Wound Healing EDAT- 1984/07/01 00:00 MHDA- 1984/07/01 00:01 CRDT- 1984/07/01 00:00 PHST- 1984/07/01 00:00 [pubmed] PHST- 1984/07/01 00:01 [medline] PHST- 1984/07/01 00:00 [entrez] AID - 10.3181/00379727-176-41875 [doi] PST - ppublish SO - Proc Soc Exp Biol Med. 1984 Jul;176(3):302-8. doi: 10.3181/00379727-176-41875. PMID- 29374418 OWN - NLM STAT- MEDLINE DCOM- 20180518 LR - 20180518 IS - 1426-9686 (Print) IS - 1426-9686 (Linking) VI - 44 IP - 259 DP - 2018 Jan 23 TI - Fast apixaban-related resolution of left ventricular thrombi in a patient with dilated cardiomyopathy. PG - 19-22 AB - Left ventricular thrombi (LVTs) develop most often in patients with post-myocardial left ventricular dysfunction and in cardiomyopathies, particularly in dilated cardiomyopathy (DCM). They constitute a danger of systemic embolization. So far, direct-acting oral anticoagulants (DOACs), including apixaban - a selective inhibitor of active Factor X, have not been systematically investigated in patients with LVTs; study comparing the efficacy of apixaban and warfarin has been undertaken only recently. A few case reports or case series presenting patients with LVTs treated with DOACs are available in the literature. The authors described a case of a 53-year-old male with DCM, hospitalized due to heart failure exacerbation. In echocardiography, apart from typical features of DCM, three apical LVTs connected with false tendons were revealed. Treatment with apixaban was introduced, initially in a dose of 2.5 mg twice daily, as creatinine concentration was 2.0 mg/dl, and after 2 days - when creatinine concentration dropped, the dose was augmented to 5 mg twice a day. Gradual resolution of LVTs was observed from day 3; they disappeared completely after one week. There were no symptoms of systemic embolization. The patient was discharged with advice to take apixaban permanently. To the best of the authors knowledge, the case presented is the fastest resolution of LVTs during therapy with apixaban reported in the literature and the first description of DOAC use for multiple LVTs. FAU - Elikowski, Waldemar AU - Elikowski W AD - Department of Internal Medicine, Józef Struś Hospital, Poznań, Poland. FAU - Małek-Elikowska, Magorzata AU - Małek-Elikowska M AD - 2nd Department of Cardiology, Poznań University of Medical Sciences, Poland. FAU - Fertała, Natalia AU - Fertała N AD - Department of Internal Medicine, Józef Struś Hospital, Poznań, Poland. FAU - Zawodna, Magdalena AU - Zawodna M AD - Department of Internal Medicine, Józef Struś Hospital, Poznań, Poland. FAU - Kruzel, Kamila AU - Kruzel K AD - Department of Internal Medicine, Józef Struś Hospital, Poznań, Poland. LA - eng PT - Case Reports PT - Journal Article PL - Poland TA - Pol Merkur Lekarski JT - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego JID - 9705469 RN - 0 (Factor Xa Inhibitors) RN - 0 (Pyrazoles) RN - 0 (Pyridones) RN - 3Z9Y7UWC1J (apixaban) SB - IM MH - Cardiomyopathy, Dilated/*complications MH - Echocardiography MH - Factor Xa Inhibitors/therapeutic use MH - Heart Failure/complications MH - Heart Ventricles/diagnostic imaging MH - Humans MH - Male MH - Middle Aged MH - Pyrazoles/*therapeutic use MH - Pyridones/*therapeutic use MH - Thrombosis/complications/diagnostic imaging/*drug therapy MH - Treatment Outcome OTO - NOTNLM OT - Apixaban OT - dilated cardiomyopathy OT - heart failure OT - left ventricular thrombus EDAT- 2018/01/28 06:00 MHDA- 2018/05/19 06:00 CRDT- 2018/01/28 06:00 PHST- 2018/01/28 06:00 [entrez] PHST- 2018/01/28 06:00 [pubmed] PHST- 2018/05/19 06:00 [medline] AID - PML259-019 [pii] PST - ppublish SO - Pol Merkur Lekarski. 2018 Jan 23;44(259):19-22. PMID- 7315990 OWN - NLM STAT- MEDLINE DCOM- 19820212 LR - 20171213 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 241 IP - 4 DP - 1981 Oct TI - Voltage dependence of digitalis afterpotentials, aftercontractions, and inotropy. PG - H646-53 AB - The effects of membrane potential on digitalis-induced oscillatory afterpotentials (OAP) and aftercontractions (AC) were investigated in isolated canine false tendons and canine and feline papillary muscles. Transmembrane potential and contractions were measured simultaneously. Membrane potential was varied by current applied through an extracellular pipet. The amplitudes of OAP and AC induced by acetylstrophanthidin (0.5-1.0 X 10(-7) g/ml) or actodigin (0.5-1.0 X 10(-6) g/ml) were increased by depolarization and decreased or abolished by hyperpolarization in all tissues. Prior to the appearance of OAP and AC in preparations exposed to the drugs, depolarization caused both phenomena to appear. As in muscle, the strength of beats superimposed on the ascending limb of AC was potentiated, and the strength of beats superimposed on the relaxation phase was depotentiated. When the amplitude of AC was decreased by hyperpolarization, both potentiation and depotentiation were diminished. This effect was accompanied by a partial reversal of the changes induced by acetylstrophanthidin in the course of restitution of contractility and the configuration of the force-frequency relation. FAU - Wasserstrom, J A AU - Wasserstrom JA FAU - Ferrier, G R AU - Ferrier GR LA - eng GR - HI-19487/HI/NHLBI NIH HHS/United States GR - T32 HL-07254/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Cardenolides) RN - 0 (Cardiac Glycosides) RN - 0 (Digitalis Glycosides) RN - 66-28-4 (Strophanthidin) RN - 9E4KL95FK9 (actodigin) RN - JG33H36364 (acetylstrophanthidin) SB - IM MH - Animals MH - Cardenolides/pharmacology MH - Cardiac Glycosides/pharmacology MH - Digitalis Glycosides/*pharmacology MH - Dogs MH - Female MH - Heart/*physiology MH - Male MH - Membrane Potentials/*drug effects MH - Myocardial Contraction/*drug effects MH - Strophanthidin/analogs & derivatives/pharmacology EDAT- 1981/10/01 00:00 MHDA- 1981/10/01 00:01 CRDT- 1981/10/01 00:00 PHST- 1981/10/01 00:00 [pubmed] PHST- 1981/10/01 00:01 [medline] PHST- 1981/10/01 00:00 [entrez] AID - 10.1152/ajpheart.1981.241.4.H646 [doi] PST - ppublish SO - Am J Physiol. 1981 Oct;241(4):H646-53. doi: 10.1152/ajpheart.1981.241.4.H646. PMID- 35288352 OWN - NLM STAT- MEDLINE DCOM- 20220523 LR - 20220629 IS - 2468-1210 (Electronic) IS - 2468-1210 (Linking) VI - 41 IP - 3 DP - 2022 Jun TI - Role of antibiotic treatment after surgical debridement of superficial hand infections in 180 patients. PG - 384-390 LID - S2468-1229(22)00080-9 [pii] LID - 10.1016/j.hansur.2022.02.010 [doi] AB - Considering the rising prevalence of antimicrobial resistance and the lack of recommendations on antibiotic treatment, the present study evaluated the necessity of local and systemic antibiotic therapy in addition to surgical debridement in superficial hand infections. Superficial hand infections were defined as not involving tendons, joints or bone. Data were analyzed for 180 patients, assigned to three study groups according to postoperative antimicrobial treatment. Patients in group I were treated with both systemic and local antibiotics; in group II antimicrobial therapy was limited to local antibiotics in the form of subcutaneous gentamicin bead chains; group III did not receive any antibiotic treatment after surgical debridement. Patients were followed up at two weeks and at three months. Immobilization time and length of stay were longer in group I, but there were no significant differences between the groups in terms of revision rate or recovery of hand function assessed by measurement of finger mobility, grip strength and the Disabilities of the Arm, Shoulder and Hand score at follow-up. Antibiotic treatment of hand infections should be considered carefully and reserved for specific indications: e.g., severe infections and selected patients such as those with diabetes or immunocompromising diseases. CI - Copyright © 2022 SFCM. Published by Elsevier Masson SAS. All rights reserved. FAU - Ederer, I A AU - Ederer IA AD - Department of Hand, Plastic and Reconstructive Surgery, BG Trauma Center, Eberhard-Karls University Tuebingen, Schnarrenbergstraße 95, 72076 Tuebingen, Germany; Department of Plastic and Aesthetic, Reconstructive and Hand Surgery, AGAPLESION Markus Hospital, Wilhelm-Epstein-Straße 4, 60431 Frankfurt am Main, Germany. Electronic address: ines.ederer@hotmail.com. FAU - Schreiner, J AU - Schreiner J AD - Department of Hand, Plastic and Reconstructive Surgery, BG Trauma Center, Eberhard-Karls University Tuebingen, Schnarrenbergstraße 95, 72076 Tuebingen, Germany. FAU - Stahl, S AU - Stahl S AD - Department of Hand, Plastic and Reconstructive Surgery, BG Trauma Center, Eberhard-Karls University Tuebingen, Schnarrenbergstraße 95, 72076 Tuebingen, Germany. FAU - Daigeler, A AU - Daigeler A AD - Department of Hand, Plastic and Reconstructive Surgery, BG Trauma Center, Eberhard-Karls University Tuebingen, Schnarrenbergstraße 95, 72076 Tuebingen, Germany. FAU - Wahler, T AU - Wahler T AD - Department of Hand, Plastic and Reconstructive Surgery, BG Trauma Center, Eberhard-Karls University Tuebingen, Schnarrenbergstraße 95, 72076 Tuebingen, Germany; Department of Hand, Plastic and Aesthetic Surgery, Medius Hospital Nuertingen, Auf dem Saeer 1, 72622 Nuertingen, Germany. LA - eng PT - Journal Article DEP - 20220311 PL - France TA - Hand Surg Rehabil JT - Hand surgery & rehabilitation JID - 101681801 RN - 0 (Anti-Bacterial Agents) RN - 0 (Gentamicins) SB - IM MH - *Anti-Bacterial Agents MH - Debridement MH - *Gentamicins/therapeutic use MH - Hand/surgery MH - Humans MH - Retrospective Studies OTO - NOTNLM OT - Antibiotics OT - Antibiotiques OT - Chirurgie de la main OT - Débridement chirurgical OT - Hand infection OT - Hand surgery OT - Infection de la main OT - Revision rate OT - Surgical debridement OT - Taux de révision EDAT- 2022/03/16 06:00 MHDA- 2022/05/24 06:00 CRDT- 2022/03/15 05:42 PHST- 2021/12/15 00:00 [received] PHST- 2022/02/09 00:00 [revised] PHST- 2022/02/12 00:00 [accepted] PHST- 2022/03/16 06:00 [pubmed] PHST- 2022/05/24 06:00 [medline] PHST- 2022/03/15 05:42 [entrez] AID - S2468-1229(22)00080-9 [pii] AID - 10.1016/j.hansur.2022.02.010 [doi] PST - ppublish SO - Hand Surg Rehabil. 2022 Jun;41(3):384-390. doi: 10.1016/j.hansur.2022.02.010. Epub 2022 Mar 11. PMID- 11956939 OWN - NLM STAT- MEDLINE DCOM- 20030212 LR - 20191210 IS - 0001-6268 (Print) IS - 0001-6268 (Linking) VI - 144 IP - 3 DP - 2002 Mar TI - A clinical study of a fibrinogen-based collagen fleece for dural repair in neurosurgery. PG - 265-9; discussion 269 AB - BACKGROUND: There is frequently a need for dural grafts to cover defects resulting from retraction, shrinkage, or excision following neurosurgical procedures. Many substances have been tried as possible dural substitution, and different tissues and materials have been evaluated for use in dural repair. METHOD: The authors performed a retrospective review of 288 consecutive neurosurgical procedures using a fibrinogen based collagen fleece (TachoComb), a resorbable mesh of collagen from horse tendons, coated with human fibrinogen, bovine thrombin, bovine aprotinin and riboflavin (for marking the coated side), for dural substitution. The fibrinogen and thrombin imitate the last step of the coagulation cascade. On contact with bleeding wounds or other body fluids the coagulation factors dissolve and a link is formed between the collagen carrier and the wound surface. Thrombin converts fibrinogen into fibrin by splitting off peptides. Aprotinin prevents premature lysis of the fibrin clot by plasmin. FINDINGS: Neither superficial or deep wound infections nor aseptic meningitis were noted. We found good fibrous incorporation of TachoComb into the surrounding normal dura. Postoperative cerebrospinal-fluid (CSF) leaks developed in only five cases, who had to be re-operated, upon as well as one patient with a rebleeding. In another four cases, there was notable subcutaneous cerebrospinal-fluid accumulation without CSF-leak. They required a lumbar cerebrospinal-fluid drainage. INTERPRETATION: We conclude that TachoComb is a valuable alternative to the patients fibrous tissues for dural repair in cases in which autogenous tissues are either unavailable or insufficient for proper reconstruction. FAU - Reddy, M AU - Reddy M AD - Department of Neurosurgery, University Clinic of Vienna, Austria. FAU - Schöggl, A AU - Schöggl A FAU - Reddy, B AU - Reddy B FAU - Saringer, W AU - Saringer W FAU - Weigel, G AU - Weigel G FAU - Matula, C AU - Matula C LA - eng PT - Evaluation Study PT - Journal Article PL - Austria TA - Acta Neurochir (Wien) JT - Acta neurochirurgica JID - 0151000 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Drug Combinations) RN - 0 (tachocomb) RN - 9001-32-5 (Fibrinogen) RN - 9007-34-5 (Collagen) RN - 9087-70-1 (Aprotinin) RN - EC 3.4.21.5 (Thrombin) SB - IM MH - *Aprotinin MH - Brain Diseases/surgery MH - Brain Neoplasms/surgery MH - *Coated Materials, Biocompatible MH - *Collagen MH - Craniotomy/*methods MH - *Drug Combinations MH - Dura Mater/*surgery MH - *Fibrinogen MH - Follow-Up Studies MH - *Hemostasis, Surgical MH - Humans MH - Postoperative Complications/etiology/surgery MH - Prosthesis Design MH - *Prosthesis Implantation MH - Reoperation MH - Retrospective Studies MH - Spinal Diseases/surgery MH - Spinal Neoplasms/surgery MH - *Thrombin MH - Treatment Outcome EDAT- 2002/04/17 10:00 MHDA- 2003/02/14 04:00 CRDT- 2002/04/17 10:00 PHST- 2002/04/17 10:00 [pubmed] PHST- 2003/02/14 04:00 [medline] PHST- 2002/04/17 10:00 [entrez] AID - 10.1007/s007010200034 [doi] PST - ppublish SO - Acta Neurochir (Wien). 2002 Mar;144(3):265-9; discussion 269. doi: 10.1007/s007010200034. PMID- 30811525 OWN - NLM STAT- MEDLINE DCOM- 20200224 LR - 20200224 IS - 1471-8391 (Electronic) IS - 0007-1420 (Linking) VI - 130 IP - 1 DP - 2019 Jun 19 TI - Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. PG - 39-49 LID - 10.1093/bmb/ldz006 [doi] AB - INTRODUCTION: The present systematic review investigates the biological and chemical mechanisms that affect the health and structure of tendons following the use of fluoroquinolones (FQs). SOURCES OF DATA: A total of 12 articles were included, organized, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. AREAS OF AGREEMENT: Five mechanisms were identified: arrest of proliferation through a decreased activity of cyclin B, CDK-1, CHK-1, and increased PK-1; decrease tenocytes migration through decreased phosphorylation of FAK; decrease type I collagen metabolism through increased MMP-2; chelate effect on ions that influence epigenetics and several enzymes; fluoroquinolones-induced ROS (radical oxygen species) production in mitochondria. AREAS OF CONTROVERSY: There is no definite structure-damage relationship. The dose-effect relationship is unclear. GROWING POINTS: Knowing and defining the damage exerted by FQs plays a role in clinical practice, replacing FQs with other antibacterial drugs or using antioxidants to attenuate their pathological effects. AREAS TIMELY FOR DEVELOPING RESEARCH: Clinical and basic sciences studies for each FQs are necessary. CI - © The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Bisaccia, Domenico Rocco AU - Bisaccia DR AD - Department of Pharmacology, School of Medicine and Surgery, University of Salerno, Salerno, Italy. FAU - Aicale, Rocco AU - Aicale R AD - Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Salerno, Italy. FAU - Tarantino, Domiziano AU - Tarantino D AD - Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Salerno, Italy. FAU - Peretti, Giuseppe M AU - Peretti GM AD - IRCCS Istituto Ortopedico Galeazzi, Milan, Italy. AD - Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. FAU - Maffulli, Nicola AU - Maffulli N AD - Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Salerno, Italy. AD - Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Mile End Hospital, 275 Bancroft Road, London, England. AD - Institute of Science and Technology in Medicine, Keele University School of Medicine, Thornburrow Drive, Stoke on Trent, England. LA - eng PT - Journal Article PT - Systematic Review PL - England TA - Br Med Bull JT - British medical bulletin JID - 0376542 RN - 0 (Anti-Bacterial Agents) RN - 0 (Cyclin B) RN - 0 (Fluoroquinolones) RN - 0 (Reactive Oxygen Species) SB - IM MH - Anti-Bacterial Agents/adverse effects/*pharmacology MH - Cyclin B MH - Dose-Response Relationship, Drug MH - Fluoroquinolones/adverse effects/*pharmacology MH - Humans MH - Phosphorylation/drug effects MH - Reactive Oxygen Species MH - Tendinopathy/*chemically induced/physiopathology OTO - NOTNLM OT - achilles OT - fluoroquinolone OT - tendinopathy OT - tendon OT - tendon rupture EDAT- 2019/02/28 06:00 MHDA- 2020/02/25 06:00 CRDT- 2019/02/28 06:00 PHST- 2018/08/01 00:00 [received] PHST- 2019/01/04 00:00 [revised] PHST- 2019/02/10 00:00 [accepted] PHST- 2019/02/28 06:00 [pubmed] PHST- 2020/02/25 06:00 [medline] PHST- 2019/02/28 06:00 [entrez] AID - 5366272 [pii] AID - 10.1093/bmb/ldz006 [doi] PST - ppublish SO - Br Med Bull. 2019 Jun 19;130(1):39-49. doi: 10.1093/bmb/ldz006. PMID- 18058671 OWN - NLM STAT- MEDLINE DCOM- 20080409 LR - 20071206 IS - 0722-1819 (Print) IS - 0722-1819 (Linking) VI - 39 IP - 6 DP - 2007 Dec TI - [Soft-tissue defects on the dorsum of the hand by extravasation of the cytostatic agents: surgical options of treatment]. PG - 409-13 AB - Systemic treatment with chemotherapeutic agents is often applied by infusions over peripheral vein cannulae located on the hands and lower arms. Dislocation of the cannulae or vein perforation causes an extravasation of the cytostatic agent. This complication occurs in approximately 0.1 - 6 % of intravenous treatments and is rarely noticed before administration of greater volumes. Depending on the tissue toxicity of the administered substances, the extravasation results in tissue damage of different extents. In a few cases, only conservative therapy is required. The majority of patients, however, needs immediate surgical therapy. The reason for this is the severe tissue damage caused by the chemotherapeutic agent that accumulates in the subcutaneous fat where it destroys the connective and fat tissue, nerves, vessels, tendons and muscles, impairing the functionality of the entire hand and arm. In very severe cases, partial or complete amputation of the extremity is the only treatment. The application of antidotes has been discussed controversially and is not a standard procedure. In the past 11 years, 18 patients with extravasations of chemotherapeutics on the dorsum of the hand were admitted to our department. After radical debridement no primary closure of the resulting defect was advisable in the first operation. In all cases we could later perform a stable wound closure. In our opinion, this two-step procedure with primary radical debridement, temporary wound coverage and later wound closure should be performed regularly. FAU - Damert, H-G AU - Damert HG AD - Klinik für Plastische, Wiederherstellungs- und Handchirurgie, Otto-von-Guericke-Universität Magdeburg, Germany. hans-georg.damert@medizin.uni-magdeburg.de FAU - Lenz-Scharf, O AU - Lenz-Scharf O FAU - Altmann, S AU - Altmann S FAU - Schneider, W AU - Schneider W LA - ger PT - English Abstract PT - Journal Article TT - Weichteildefekte an der Streckseite der Hand durch Paravasate im Rahmen systemischer Chemotherapien - chirurgische Therapieoptionen. PL - Germany TA - Handchir Mikrochir Plast Chir JT - Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V... JID - 8302815 RN - 0 (Antineoplastic Agents) SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/administration & dosage/*toxicity MH - Biological Dressings MH - Debridement/methods MH - Extravasation of Diagnostic and Therapeutic Materials/*complications/surgery MH - Female MH - Hand Injuries/*chemically induced/surgery MH - Humans MH - Infusions, Intravenous MH - Male MH - Middle Aged MH - Necrosis MH - Reoperation MH - Skin Transplantation MH - Soft Tissue Injuries/*chemically induced/surgery MH - Surgical Flaps MH - Wound Healing/physiology EDAT- 2007/12/07 09:00 MHDA- 2008/04/10 09:00 CRDT- 2007/12/07 09:00 PHST- 2007/12/07 09:00 [pubmed] PHST- 2008/04/10 09:00 [medline] PHST- 2007/12/07 09:00 [entrez] AID - 10.1055/s-2007-965231 [doi] PST - ppublish SO - Handchir Mikrochir Plast Chir. 2007 Dec;39(6):409-13. doi: 10.1055/s-2007-965231. PMID- 15292721 OWN - NLM STAT- MEDLINE DCOM- 20040923 LR - 20191108 IS - 0162-220X (Print) IS - 0162-220X (Linking) VI - 27 IP - 4 DP - 2004 Jul-Aug TI - Effect of acupressure on nausea and vomiting during chemotherapy cycle for Korean postoperative stomach cancer patients. PG - 267-74 AB - Despite the development of effective antiemetic drugs, nausea and vomiting remain the main side effects associated with cancer chemotherapy. The purpose of this study was to examine the effect of acupressure on emesis control in postoperative gastric cancer patients undergoing chemotherapy. Forty postoperative gastric cancer patients receiving the first cycle of chemotherapy with cisplatin and 5-Fluorouracil were divided into control and intervention groups (n = 20 each). Both groups received regular antiemesis medication; however, the intervention group received acupressure training and was instructed to perform the finger acupressure maneuver for 5 minutes on P6 (Nei-Guan) point located at 3-finger widths up from the first palmar crease, between palmaris longus and flexor carpi radialis tendons point, at least 3 times a day before chemotherapy and mealtimes or based on their needs. Both groups received equally frequent nursing visits and consultations, and reported nausea and vomiting using Rhode's Index of Nausea, Vomiting and Retching. We found significant differences between intervention and control groups in the severity of nausea and vomiting, the duration of nausea, and frequency of vomiting. This study suggests that acupressure on P6 point appears to be an effective adjunct maneuver in the course of emesis control. FAU - Shin, Yeong Hee AU - Shin YH AD - Keimyung University, Dongsan-dong, Jung-gu, Daegu, Korea. FAU - Kim, Tae Im AU - Kim TI FAU - Shin, Mi Sook AU - Shin MS FAU - Juon, Hee-Soon AU - Juon HS LA - eng PT - Clinical Trial PT - Controlled Clinical Trial PT - Journal Article PT - Multicenter Study PL - United States TA - Cancer Nurs JT - Cancer nursing JID - 7805358 RN - 0 (Antiemetics) RN - Q20Q21Q62J (Cisplatin) RN - U3P01618RT (Fluorouracil) SB - IM MH - Acupressure/*methods MH - Aged MH - Analysis of Variance MH - Antiemetics/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/*adverse effects MH - Chemotherapy, Adjuvant MH - Cisplatin/administration & dosage MH - Female MH - Fluorouracil/administration & dosage MH - Gastrectomy/adverse effects MH - Humans MH - Korea MH - Male MH - Middle Aged MH - Patient Education as Topic MH - Postoperative Care/methods MH - Postoperative Nausea and Vomiting/etiology/*therapy MH - Self Care MH - Severity of Illness Index MH - *Stomach Neoplasms/drug therapy/surgery MH - Time Factors MH - Treatment Outcome EDAT- 2004/08/05 05:00 MHDA- 2004/09/24 05:00 CRDT- 2004/08/05 05:00 PHST- 2004/08/05 05:00 [pubmed] PHST- 2004/09/24 05:00 [medline] PHST- 2004/08/05 05:00 [entrez] AID - 00002820-200407000-00002 [pii] AID - 10.1097/00002820-200407000-00002 [doi] PST - ppublish SO - Cancer Nurs. 2004 Jul-Aug;27(4):267-74. doi: 10.1097/00002820-200407000-00002. PMID- 41137318 OWN - NLM STAT- MEDLINE DCOM- 20251025 LR - 20251203 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 104 IP - 43 DP - 2025 Oct 24 TI - Bilateral Achilles tendinopathy of unknown origin responsive to corticosteroids: Case report. PG - e45436 LID - 10.1097/MD.0000000000045436 [doi] LID - e45436 AB - RATIONALE: This case presents a rare instance of bilateral acute Achilles tendinopathy with an unidentified etiology, unreported in previous literature. Documented cases of bilateral Achilles tendon pathologies have typically been associated with specific medications, chronic enthesitis, or slowly progressing xanthomas. PATIENT CONCERNS: A 55-year-old male presented with fever and bilateral Achilles tendon swelling and pain. Laboratory tests showed significantly elevated inflammatory markers (C-reactive protein 96.6 mg/L, erythrocyte sedimentation rate 69.0 mm/h) and elevated immunoglobulin A (4.44 g/L). Imaging revealed fusiform swelling with inflammatory changes in both Achilles tendons. The patient had a medical history of radical prostatectomy, chronic hepatitis B virus carrier status, and familial hypercholesterolemia. DIAGNOSES: Bilateral acute Achilles tendinopathy of unknown etiology. Its sensitivity to corticosteroid therapy, coupled with elevated serum immunoglobulin A, suggests a possible immune-mediated mechanism. INTERVENTIONS: The core treatment was systemic corticosteroid therapy (methylprednisolone, dexamethasone). Empirical antibiotics were initially administered but were subsequently discontinued due to lack of evidence for infection and the marked efficacy of corticosteroid therapy. Concurrent medications included atorvastatin for hypercholesterolemia and entecavir for hepatitis B. OUTCOMES: Symptoms resolved rapidly, with no recurrence during the 6-month follow-up period. LESSONS: This case suggests a possible pathogenic role of immunoglobulin A-related immune mechanisms, though the lack of histopathological biopsy and genetic testing limited further etiological investigation. It offers a diagnostic and therapeutic reference for this rare bilateral acute Achilles tendinopathy, highlighting the potential role of immune factors in atypical tendinopathies. CI - Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Huang, Jinqi AU - Huang J AD - Department of Interventional Vascular Surgery, The First Hospital of Putian City, Putian, Fujian Province, P.R. China. FAU - Chen, Qihong AU - Chen Q AUID- ORCID: 0009-0006-2235-3757 LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 7S5I7G3JQL (Dexamethasone) RN - X4W7ZR7023 (Methylprednisolone) RN - 0 (Glucocorticoids) RN - 0 (Adrenal Cortex Hormones) SB - IM MH - Humans MH - Male MH - *Achilles Tendon/pathology MH - Middle Aged MH - *Tendinopathy/drug therapy/etiology/diagnosis MH - Dexamethasone/therapeutic use MH - Methylprednisolone/therapeutic use MH - *Glucocorticoids/therapeutic use MH - *Adrenal Cortex Hormones/therapeutic use PMC - PMC12558304 OTO - NOTNLM OT - Achilles tendinopathy OT - acute OT - bilateral OT - glucocorticoid-responsive OT - idiopathic COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2025/10/25 06:29 MHDA- 2025/10/25 06:30 PMCR- 2025/10/24 CRDT- 2025/10/25 01:02 PHST- 2025/06/23 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/10/25 06:30 [medline] PHST- 2025/10/25 06:29 [pubmed] PHST- 2025/10/25 01:02 [entrez] PHST- 2025/10/24 00:00 [pmc-release] AID - 00005792-202510240-00105 [pii] AID - MD-D-25-07611 [pii] AID - 10.1097/MD.0000000000045436 [doi] PST - ppublish SO - Medicine (Baltimore). 2025 Oct 24;104(43):e45436. doi: 10.1097/MD.0000000000045436. PMID- 27253849 OWN - NLM STAT- MEDLINE DCOM- 20170510 LR - 20170510 IS - 1744-8328 (Electronic) IS - 1473-7140 (Linking) VI - 16 IP - 8 DP - 2016 Aug TI - Biology and management of clear cell sarcoma: state of the art and future perspectives. PG - 839-45 LID - 10.1080/14737140.2016.1197122 [doi] AB - INTRODUCTION: Clear cell sarcoma (CCS) is an aggressive tumor, typically developing in tendons or aponeuroses. The outcome of this orphan disease is poor, with 5-year and 10-year survival rates of localized CCS around 60-70% and 40-50%. Once the disease has metastasized, it is usually fatal due to its chemotherapy-resistant nature. Systemic treatment options are poorly standardized and the use of chemotherapy is based on weak scientific evidence. AREAS COVERED: In this review, we systematically discuss the current scientific evidence for the systemic treatment of CCS, including tyrosine kinase inhibitors, immunotherapy and MET inhibitors. Expert commentary: Recent insights in the biology of CCS have identified new potential therapeutic targets, which should be tested in prospective clinical trials. Whenever possible, patients with metastatic CCS should be included in clinical trials with good biological rationale. Innovative trial methodology and new regulatory mechanisms are required to provide patients with uncommon cancers with active drugs. FAU - Cornillie, Jasmien AU - Cornillie J AD - a Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology , University Hospitals Leuven, Leuven Cancer Institute , Leuven , Belgium. FAU - van Cann, Thomas AU - van Cann T AD - a Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology , University Hospitals Leuven, Leuven Cancer Institute , Leuven , Belgium. FAU - Wozniak, Agnieszka AU - Wozniak A AD - a Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology , University Hospitals Leuven, Leuven Cancer Institute , Leuven , Belgium. FAU - Hompes, Daphne AU - Hompes D AD - b Department of Surgical Oncology , KU Leuven and University Hospitals Leuven , Leuven , Belgium. FAU - Schöffski, Patrick AU - Schöffski P AD - a Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology , University Hospitals Leuven, Leuven Cancer Institute , Leuven , Belgium. LA - eng PT - Journal Article PT - Review DEP - 20160620 PL - England TA - Expert Rev Anticancer Ther JT - Expert review of anticancer therapy JID - 101123358 RN - 0 (Antineoplastic Agents) RN - 0 (Protein Kinase Inhibitors) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-met) SB - IM MH - Antineoplastic Agents/pharmacology/*therapeutic use MH - Drug Resistance, Neoplasm MH - Humans MH - Immunotherapy/*methods MH - Neoplasm Metastasis MH - Protein Kinase Inhibitors/pharmacology/therapeutic use MH - Proto-Oncogene Proteins c-met/antagonists & inhibitors MH - Sarcoma, Clear Cell/pathology/*therapy MH - Survival Rate OTO - NOTNLM OT - Clear cell sarcoma OT - EWSR1-ATF1 fusion protein OT - MET OT - chemotherapy resistance OT - immunotherapy OT - malignant melanoma of soft parts OT - molecular targets EDAT- 2016/06/03 06:00 MHDA- 2017/05/11 06:00 CRDT- 2016/06/03 06:00 PHST- 2016/06/03 06:00 [entrez] PHST- 2016/06/03 06:00 [pubmed] PHST- 2017/05/11 06:00 [medline] AID - 10.1080/14737140.2016.1197122 [doi] PST - ppublish SO - Expert Rev Anticancer Ther. 2016 Aug;16(8):839-45. doi: 10.1080/14737140.2016.1197122. Epub 2016 Jun 20. PMID- 9030156 OWN - NLM STAT- MEDLINE DCOM- 19970324 LR - 20190713 IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 99 IP - 2 DP - 1997 Feb TI - Single exposures to 5-fluorouracil: a possible mode of targeted therapy to reduce contractile scarring in the injured tendon. PG - 465-71 AB - After injury, adhesions may develop between the digital flexor tendons and their sheaths. Fibroblasts are key cells in this fibrotic adhesive process, and two possible sources for these cells are the synovial sheath and the endotenon tissue (tendon core). Fibroblasts seeded into a collagen lattice will contract the collagen. This fibroblast-populated collagen lattice contraction was used to investigate the ability of the fibroblasts from the synovial sheath and endotenon to reorganize collagen (an important function in the formation of adhesions). Endotenon and synovial fibroblasts isolated from 30 animals were used in the study. Synovial fibroblasts produced significantly greater collagen lattice contraction compared with endotenon fibroblasts (p < 0.05). The possibility of preventing collagen lattice contraction with a single, nontoxic 5-minute treatment of the fibroblast-populated collagen lattices with the antimetabolite 5-fluorouracil was investigated. Compared with controls the degree of fibroblast-populated collagen lattice contraction was significantly inhibited (p < 0.05) with the use of 5-fluorouracil for endotenon and synovial cells. These results demonstrate the potential for locally targeted therapy in tendon healing. Because of the different contractile properties of the two cell lines, a change in the balance between intrinsic and extrinsic healing might be achieved with this method of therapy; in turn, this might lead to better functional results following surgery. FAU - Khan, U AU - Khan U AD - Department of Plastic and Reconstructive Surgery, University College, London, England. FAU - Occleston, N L AU - Occleston NL FAU - Khaw, P T AU - Khaw PT FAU - McGrouther, D A AU - McGrouther DA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Antimetabolites) RN - 9007-34-5 (Collagen) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Antimetabolites/*administration & dosage MH - Cells, Cultured MH - Cicatrix/etiology/*prevention & control MH - Collagen/*drug effects/*physiology MH - Cytoskeleton/drug effects MH - Fibroblasts/*drug effects/physiology MH - Fluorouracil/*administration & dosage MH - Rabbits MH - Tendon Injuries/*complications/pathology EDAT- 1997/02/01 00:00 MHDA- 1997/02/01 00:01 CRDT- 1997/02/01 00:00 PHST- 1997/02/01 00:00 [pubmed] PHST- 1997/02/01 00:01 [medline] PHST- 1997/02/01 00:00 [entrez] AID - 10.1097/00006534-199702000-00023 [doi] PST - ppublish SO - Plast Reconstr Surg. 1997 Feb;99(2):465-71. doi: 10.1097/00006534-199702000-00023. PMID- 19256337 OWN - NLM STAT- MEDLINE DCOM- 20090924 LR - 20161124 IS - 1000-3061 (Print) IS - 1000-3061 (Linking) VI - 24 IP - 11 DP - 2008 Nov TI - [Preparation and characterization of an extracellular matrix of artificial tendon tissue from natural macromolecules]. PG - 1907-11 AB - Collagen and chitosan are well natrual polymers to be used as extracellular matrix on tissue engineering because of their biocompatibility, certain mechanical strength and biodegradability. But there are some disadvantages when they are used to construct extracellular matrix respectively. This experiment utilized their complementary performances to prepare a composite extracellular matrix of artificial tendon tissue that had adequacy mechanics strength and good biocompatibility, cell affinity, biodegradability. Collagen and chitosan were covalently crosslinked using EDC and NHS to obtain a porous scaffold material that the porous was oriented under an external force. Then RGD peptide was covalently attached to scaffold material surface to improve its affinity with cells. The microstructure of scaffold material was observed under microscope and scanning electron microscope. Simultaneously, the physical performance, hydrophilicity, ecto-degradation rate and cell compatibility of scaffold material were measured in the experiments. The results showed that this scaffold material was soft and stretchy. Its tensile strength was 15.0 MPa, corresponding shape extension was 7.33%, and its porosity was 79.4%. Its water absorption rate and water retention rate were 772% and 206% respectively. Its degradation rate in RPM 1640 culture mediun with 10% fetal bovine serum and in human serum were 4.13% and 37.2% respectively after three weeks. These degradation rates are suitable for the rehab course of injured tendon. Moreover the degradation rates can be controlled by adjusting technological conditions and degree of cross linking. Significantly higher affinity with 3T3-Ll cell was detected on the scaffold material modified by RGD peptide. The various physical performances of this complex scaffold material are appropriate for constructing extracellular matrix of artificial tendon tissue or artificial skin. Moreover, it could be used as soft tissue slurry for plastic surgery. FAU - Xiong, Yanfei AU - Xiong Y AD - Department of Biological Science and Technology, Wuhan University of Technology, Wuhan 430070, China. kennemy@126.com FAU - Wan, Li AU - Wan L LA - chi PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - China TA - Sheng Wu Gong Cheng Xue Bao JT - Sheng wu gong cheng xue bao = Chinese journal of biotechnology JID - 9426463 RN - 0 (Biocompatible Materials) RN - 0 (Collagen Type I) RN - 0 (Cross-Linking Reagents) RN - 0 (Oligopeptides) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 9012-76-4 (Chitosan) SB - IM MH - 3T3-L1 Cells MH - Animals MH - Biocompatible Materials/chemistry MH - Chitosan/*chemistry MH - Collagen Type I/*chemistry MH - Cross-Linking Reagents MH - Extracellular Matrix/*chemistry MH - Humans MH - Mice MH - Oligopeptides/chemistry MH - Porosity MH - *Tendons MH - Tensile Strength MH - Tissue Engineering/*methods MH - Tissue Scaffolds/chemistry EDAT- 2009/03/05 09:00 MHDA- 2009/09/25 06:00 CRDT- 2009/03/05 09:00 PHST- 2009/03/05 09:00 [entrez] PHST- 2009/03/05 09:00 [pubmed] PHST- 2009/09/25 06:00 [medline] PST - ppublish SO - Sheng Wu Gong Cheng Xue Bao. 2008 Nov;24(11):1907-11. PMID- 12415599 OWN - NLM STAT- MEDLINE DCOM- 20030425 LR - 20131121 IS - 0315-162X (Print) IS - 0315-162X (Linking) VI - 29 IP - 11 DP - 2002 Nov TI - Decreased expression of proliferating cell nuclear antigen is associated with dexamethasone inhibition of the proliferation of rat tendon fibroblasts. PG - 2397-402 AB - OBJECTIVE: To investigate the effects of dexamethasone (Dex) on the proliferation of cultured rat Achilles tendon fibroblasts at concentrations typically used for local injection treatment. METHODS: Fibroblasts cultured from rat Achilles tendons were treated with Dex at concentrations of 0, 10-4, 3 10-4, and 10-3 M. [3H]thymidine incorporation was used to measure the rate of cell proliferation. mRNA expression of proliferating cell nuclear antigen (PCNA) and cyclin kinase inhibitor p21CIP1 was determined by reverse transcription-polymerase chain reaction (RT-PCR). The protein levels of PCNA and p21CIP1 were investigated by Western blot analysis. RESULTS: An initial inhibitory effect on tendon fibroblast proliferation was observed at a concentration of 10-4 M. Further, a significant decline in [3H]thymidine incorporation as a function of Dex concentration was noted (p = 0.019). RT-PCR results revealed that PCNA mRNA expression was inhibited after Dex treatment. Western blot analysis of PCNA protein also revealed Dex downregulation. Gradual declines in the levels of PCNA mRNA expression and PCNA protein as a function of Dex concentration were noted. The expression of p21CIP1 both at mRNA and the protein levels remained constant. CONCLUSION: These results suggest that Dex inhibition of the proliferation of rat tendon fibroblasts is associated with a p21CIP1 independent decrease of the PCNA gene expression. FAU - Tsai, Wen-Chung AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital, Taoyuan, Taiwan. FAU - Tang, Fuk-Tan AU - Tang FT FAU - Wong, May-Kuen AU - Wong MK FAU - Yen, Hsiao-Cheng AU - Yen HC FAU - Pang, Jong-Hwei S AU - Pang JH LA - eng PT - Journal Article PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 RN - 0 (Glucocorticoids) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Achilles Tendon/*cytology MH - Animals MH - Cell Division/drug effects MH - Cells, Cultured MH - Dexamethasone/*pharmacology MH - Fibroblasts/cytology/*drug effects/metabolism MH - Gene Expression/drug effects MH - Glucocorticoids/*pharmacology MH - Proliferating Cell Nuclear Antigen/*genetics/metabolism MH - Rats MH - Rats, Sprague-Dawley EDAT- 2002/11/05 04:00 MHDA- 2003/04/26 05:00 CRDT- 2002/11/05 04:00 PHST- 2002/11/05 04:00 [pubmed] PHST- 2003/04/26 05:00 [medline] PHST- 2002/11/05 04:00 [entrez] AID - 0315162X-29-2397 [pii] PST - ppublish SO - J Rheumatol. 2002 Nov;29(11):2397-402. PMID- 40412506 OWN - NLM STAT- MEDLINE DCOM- 20250710 LR - 20250710 IS - 1878-7568 (Electronic) IS - 1742-7061 (Linking) VI - 201 DP - 2025 Jul 1 TI - Programmed drug delivering Janus hydrogel adapted to the spatio-temporal therapeutic window for Achilles tendon repair. PG - 139-155 LID - S1742-7061(25)00378-2 [pii] LID - 10.1016/j.actbio.2025.05.052 [doi] AB - Peritendinous adhesion formation and tendon re-rupture are prevalent clinical complications following tendon repair surgery. The key to reducing adhesions and enhancing the biomechanical strength of injured tendons lies in suppressing inflammation and extrinsic fibroblast activation while promoting intrinsic tenocyte proliferation. However, as tenocytes are inherently a type of fibroblast, it remains challenging for a single drug to reduce adhesion and improve tendon strength simultaneously. To address this challenge, a Janus hydrogel was designed for spatiotemporal programmed drug delivery specifically tailored to Achilles tendon repair. The outer layer of the Janus hydrogel rapidly releases melatonin (MT) via poly(N-acryloyl alaninamide) (PNAAA), effectively suppressing inflammation and extrinsic fibroblast activation. The inner layer gel, formed by thiol-modified gelatin (GelSH) and norbornene-modified hyaluronic acid (HANB), incorporates protein-binding AAc-NHS and gradually releases platelet-derived growth factor-BB (PDGF-BB), thereby promoting tenocyte proliferation. In the rat Achilles tendon injury model, the spatiotemporal programmed drug delivery Janus hydrogel successfully reduced adhesion while enhancing tendon healing strength. This work promoted Achilles tendon repair by meeting the distinct spatiotemporal therapeutic needs. STATEMENT OF SIGNIFICANCE: Melatonin may inhibit fibroblast proliferation and differentiation via the PI3K/AKT pathway, whereas PDGF-BB promotes tenocyte proliferation and differentiation through the same pathway. Consequently, the effects of these two drugs on fibroblasts and tenocytes may be conflicting. In this study, the programmed drug delivery Janus hydrogel was designed to match the different stages of tendon repair and achieved staggered release of melatonin and PDGF-BB. Melatonin@PNAAA primarily targets the extrinsic healing pathway, focusing on inflammatory cells during the inflammatory phase and fibroblasts during the proliferative phase. PDGF-BB@SHNB mainly targets intrinsic healing pathway, focusing on tenocytes during the proliferative phase and collagen synthesis during the remodeling phase. This spatiotemporal delivery system alleviates adhesion while promoting tendon healing. CI - Copyright © 2025. Published by Elsevier Inc. FAU - Zhou, Zekun AU - Zhou Z AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: zhouzk21@mails.jlu.edu.cn. FAU - Tang, Xiaoduo AU - Tang X AD - Joint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, The First Hospital of Jilin University, Changchun 130021, PR China; State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, PR China; Jilin Provincial Key Laboratory of Tooth Development and Bone Remodeling, Hospital of Stomatology, Jilin University, Changchun 130021, PR China. Electronic address: xdtang@jlu.edu.cn. FAU - Huang, Dongxu AU - Huang D AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: huangdongxu@jlu.edu.cn. FAU - Chen, Miao AU - Chen M AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. FAU - Wei, Xin AU - Wei X AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: weix23@mails.jlu.edu.cn. FAU - Zhan, Yongxin AU - Zhan Y AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: zhanyx2023@jlu.edu.cn. FAU - Jiang, Meijun AU - Jiang M AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. FAU - Chen, Xiang AU - Chen X AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. FAU - Cui, Xingyao AU - Cui X AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. FAU - Zhang, Junhu AU - Zhang J AD - Joint Laboratory of Opto-Functional Theranostics in Medicine and Chemistry, The First Hospital of Jilin University, Changchun 130021, PR China; State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, PR China. Electronic address: zjh@jlu.edu.cn. FAU - Gong, Xu AU - Gong X AD - Department of Hand and Foot Surgery, Orthopedics Center, The First Hospital of Jilin University, Changchun 130021, PR China; Jilin Province Key Laboratory on Tissue Repair, Reconstruction and Regeneration, The First Hospital of Jilin University, Changchun 130021, PR China. Electronic address: gongxu@jlu.edu.cn. LA - eng PT - Journal Article DEP - 20250522 PL - England TA - Acta Biomater JT - Acta biomaterialia JID - 101233144 RN - 0 (Hydrogels) RN - JL5DK93RCL (Melatonin) RN - 1B56C968OA (Becaplermin) SB - IM MH - *Achilles Tendon/pathology/injuries/metabolism/drug effects MH - Animals MH - *Hydrogels/chemistry/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - *Melatonin/pharmacology/chemistry/pharmacokinetics MH - *Becaplermin/pharmacology/chemistry/pharmacokinetics MH - *Tendon Injuries/pathology/drug therapy/metabolism MH - *Drug Delivery Systems MH - *Wound Healing/drug effects MH - Fibroblasts/metabolism/pathology MH - Cell Proliferation/drug effects MH - Male MH - Tenocytes/pathology/metabolism/drug effects OTO - NOTNLM OT - Achilles tendon repair OT - Janus hydrogel OT - Melatonin OT - PDGF-BB OT - Programmed drug delivery COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/05/25 20:36 MHDA- 2025/07/11 00:26 CRDT- 2025/05/24 19:34 PHST- 2025/01/12 00:00 [received] PHST- 2025/04/24 00:00 [revised] PHST- 2025/05/21 00:00 [accepted] PHST- 2025/07/11 00:26 [medline] PHST- 2025/05/25 20:36 [pubmed] PHST- 2025/05/24 19:34 [entrez] AID - S1742-7061(25)00378-2 [pii] AID - 10.1016/j.actbio.2025.05.052 [doi] PST - ppublish SO - Acta Biomater. 2025 Jul 1;201:139-155. doi: 10.1016/j.actbio.2025.05.052. Epub 2025 May 22. PMID- 39089344 OWN - NLM STAT- MEDLINE DCOM- 20240831 LR - 20240831 IS - 1873-3476 (Electronic) IS - 0378-5173 (Linking) VI - 663 DP - 2024 Sep 30 TI - Enhancing cellular affinity for skin disorders: Electrospun polyurethane/collagen nanofiber mats coated with phytoceramides. PG - 124541 LID - S0378-5173(24)00775-0 [pii] LID - 10.1016/j.ijpharm.2024.124541 [doi] AB - Although the use of thermoplastic polyurethane (Tpu) nanofiber mats as wound dressings is of great interest due to their mechanical properties, they are hindered by their poor wettability and bioavailability. In this study, we aimed to improve the cellular affinity of Tpu nanofiber mats for skin disorders by incorporating extracted collagen (Col) from tendons and physically mixed with a layer of phytoceramides (Phyto) to produce TpuCol@X-Phyto mats in which the weight % of Phyto relatively to the weight of the solution was X = 0.5, 1.0, or 1.5 wt% via facile electrospinning approach. The collective observations strongly indicate the successful incorporation and retention of Phyto within the TpuCol architecture. An increase in the Phyto concentration decreased the water contact angle from 69.4° ± 3.47° to 57.9° ± 2.89°, demonstrating improvement in the hydrophilicity of Tpu and binary blend TpuCol nanofiber mats. The mechanical property of 1.0 wt% Phyto aligns with practical requirements owing to the presence of two hydroxyl groups and the amide linkage likely contributing to various hydrogen bonds, providing mechanical strength to the channel structure and a degree of rigidity essential for transmitting mechanical stress. The proliferation of human skin fibroblast (HSF) peaked significantly 100 % with TpuCol@X-Phyto mats coated for X =1.0 and 1.5 wt% of Phyto. Electrospun scaffolds with the highest Phyto content have shown the lowest degree of hemolysis, demonstrating the high level of compatibility between them and blood. The TpuCol@1.5Phyto mat also demonstrated higher efficacy in antibacterial and antioxidant activities, achieving a rate of DPPH radical scavenging of 83.3 % for this latter property. The most notable wound closure among all tested formulations was attributed to higher Phyto. Thus, the developed TpuCol@1.5Phyto nanofiber formula exhibited enhanced healing in an in vitro epidermal model. CI - Copyright © 2024. Published by Elsevier B.V. FAU - Ewedah, Tassneim M AU - Ewedah TM AD - Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Egyptian Russian University, Egypt. FAU - Abdalla, Ahmed AU - Abdalla A AD - Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Egyptian Russian University, Egypt. Electronic address: ahmed-mohamedefat@eru.edu.eg. FAU - Hagag, Radwa Samir AU - Hagag RS AD - Lecturer at Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt. FAU - Elhabal, Sammar Fathy AU - Elhabal SF AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Modern University for Technology and Information (MTI), Mokattam, Cairo 11571, Egypt. Electronic address: Sammar.Fathy@pharm.mti.edu.eg. FAU - Teaima, Mahmoud H AU - Teaima MH AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: Mahmoud.teaima@pharma.cu.edu.eg. FAU - El-Nabarawi, Mohamed A AU - El-Nabarawi MA AD - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. FAU - Schlatter, Guy AU - Schlatter G AD - ICPEES, Institut de Chimie et Procédé pour l'Energie, l'Environnement et la Santé, CNRS, UMR 7515, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg Cedex 2, France. Electronic address: guy.schlatter@unistra.fr. FAU - Shoueir, Kamel R AU - Shoueir KR AD - ICPEES, Institut de Chimie et Procédé pour l'Energie, l'Environnement et la Santé, CNRS, UMR 7515, Université de Strasbourg, 25 rue Becquerel, 67087 Strasbourg Cedex 2, France; Institute of Nanoscience & Nanotechnology, Kafrelsheikh University, 33516 Kafrelsheikh, Egypt. Electronic address: rezkshoueir@unistra.fr. LA - eng PT - Journal Article DEP - 20240730 PL - Netherlands TA - Int J Pharm JT - International journal of pharmaceutics JID - 7804127 RN - 0 (Polyurethanes) RN - 9007-34-5 (Collagen) RN - 0 (Antioxidants) RN - 0 (Anti-Bacterial Agents) SB - IM MH - *Nanofibers/chemistry MH - *Polyurethanes/chemistry MH - Humans MH - *Collagen/chemistry MH - Skin Diseases/drug therapy MH - Cell Proliferation/drug effects MH - Antioxidants/chemistry/pharmacology/administration & dosage MH - Fibroblasts/drug effects MH - Anti-Bacterial Agents/chemistry/administration & dosage/pharmacology MH - Bandages MH - Wound Healing/drug effects MH - Skin/metabolism/drug effects MH - Hydrophobic and Hydrophilic Interactions OTO - NOTNLM OT - Biocomposites OT - Biomedical applications OT - Electrospinning process OT - Extracted collagen OT - Phytoceramides COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/08/02 00:46 MHDA- 2024/09/01 16:18 CRDT- 2024/08/01 19:12 PHST- 2024/04/02 00:00 [received] PHST- 2024/07/24 00:00 [revised] PHST- 2024/07/28 00:00 [accepted] PHST- 2024/09/01 16:18 [medline] PHST- 2024/08/02 00:46 [pubmed] PHST- 2024/08/01 19:12 [entrez] AID - S0378-5173(24)00775-0 [pii] AID - 10.1016/j.ijpharm.2024.124541 [doi] PST - ppublish SO - Int J Pharm. 2024 Sep 30;663:124541. doi: 10.1016/j.ijpharm.2024.124541. Epub 2024 Jul 30. PMID- 30245052 OWN - NLM STAT- MEDLINE DCOM- 20190225 LR - 20200225 IS - 2589-1294 (Electronic) IS - 1017-995X (Print) IS - 1017-995X (Linking) VI - 52 IP - 6 DP - 2018 Nov TI - Role of a combination dietary supplement containing mucopolysaccharides, vitamin C, and collagen on tendon healing in rats. PG - 452-458 LID - S1017-995X(17)30421-2 [pii] LID - 10.1016/j.aott.2018.06.012 [doi] AB - OBJECTIVE: The aim of this study was to investigate the effect of mucopolysaccharide, vitamin C, and collagen supplementation on the healing of Achilles tendon in rats. METHODS: Sixteen rats were separated into 2 groups. Both Achilles tendons of all rats were transected 5 mm above the insertion and repaired using a Kessler suture. After the surgical repair, the study group received the daily recommended amount of the supplement by gastric gavage, while the control group received a placebo. At the end of the third week, the animals were sacrificed. The biomechanical properties of the groups were compared with ultimate tensile strength and stiffness tests. The biological properties of the 2 groups were assessed with a histomorphometric comparison to determine the amount of collagen type I (COL1), proliferating cell nuclear antigen (PCNA), and transforming growth factor β1 (TGF-β1) expression in 3 different tissue subgroups (collagen matrix, tenocytes, and endotenon fibroblasts). RESULTS: Analysis of histomorphometric results revealed that the rats receiving dietary supplements demonstrated a significant increase in PCNA (mean value of 86 in the control group and 168.85 in the trial group; p < 0.05) and TGF-β1 (mean value of 87.57 in the control group and 161.85 in the trial group; p < 0.05) in the endotenon fibroblasts of the repair site. However, there was no difference between the groups in PCNA or TGF-β1 when the collagen matrix and the tenocytes of the repair site were examined. Furthermore, no significant difference could be found between groups in COL1 in any of the 3 tissue subgroups (collagen matrix, tenocytes, and endotenon fibroblasts). The statistical analysis also indicated that the rats receiving supplements did not demonstrate a significant increase in the ultimate tendon tensile strength or stiffness. CONCLUSION: The results of this study revealed no advantage to the oral administration of the trial supplement in collagen synthesis or biomechanical properties in rats after 3 weeks using the presented study design. However, the increased expression of PCNA and TGFβ1 seen in the endotenon fibroblasts of the repair site might play a role in the continuum of tendon healing. CI - Copyright © 2018 Turkish Association of Orthopaedics and Traumatology. Production and hosting by Elsevier B.V. All rights reserved. FAU - Gemalmaz, Halil Can AU - Gemalmaz HC AD - Acıbadem University School of Medicine, Istanbul, Turkey. Electronic address: cgemalmaz@gmail.com. FAU - Sarıyılmaz, Kerim AU - Sarıyılmaz K AD - Acıbadem University School of Medicine, Istanbul, Turkey. Electronic address: ksariyilmaz@gmail.com. FAU - Ozkunt, Okan AU - Ozkunt O AD - Acıbadem University School of Medicine, Istanbul, Turkey. Electronic address: drdeto@gmail.com. FAU - Gurgen, Seren Gulsen AU - Gurgen SG AD - Celal Bayar University School of Vocational Health Services, Department of Histology and Embryology, Manisa, Turkey. Electronic address: serengurgen@gmail.com. FAU - Silay, Sena AU - Silay S AD - Acıbadem University School of Medicine, Istanbul, Turkey. Electronic address: senasly@gmail.com. LA - eng PT - Journal Article DEP - 20180921 PL - Turkey TA - Acta Orthop Traumatol Turc JT - Acta orthopaedica et traumatologica turcica JID - 9424806 RN - 0 (Drug Combinations) RN - 0 (Glycosaminoglycans) RN - 0 (Proliferating Cell Nuclear Antigen) RN - 0 (Transforming Growth Factor beta1) RN - 9007-34-5 (Collagen) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - Achilles Tendon/*metabolism/physiopathology MH - Animals MH - Ascorbic Acid/*metabolism MH - Collagen/*metabolism MH - Dietary Supplements MH - Drug Combinations MH - Glycosaminoglycans/*metabolism MH - Male MH - Proliferating Cell Nuclear Antigen/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Regeneration/*physiology MH - *Tendon Injuries/diet therapy/surgery MH - Tensile Strength/physiology MH - Transforming Growth Factor beta1/metabolism MH - Treatment Outcome PMC - PMC6318503 OTO - NOTNLM OT - Collagen OT - Dietary supplement OT - Mucopolysaccharides OT - Tendon healing OT - Vitamin C EDAT- 2018/09/25 06:00 MHDA- 2019/02/26 06:00 PMCR- 2018/09/21 CRDT- 2018/09/25 06:00 PHST- 2017/07/30 00:00 [received] PHST- 2018/05/14 00:00 [revised] PHST- 2018/06/27 00:00 [accepted] PHST- 2018/09/25 06:00 [pubmed] PHST- 2019/02/26 06:00 [medline] PHST- 2018/09/25 06:00 [entrez] PHST- 2018/09/21 00:00 [pmc-release] AID - S1017-995X(17)30421-2 [pii] AID - 10.1016/j.aott.2018.06.012 [doi] PST - ppublish SO - Acta Orthop Traumatol Turc. 2018 Nov;52(6):452-458. doi: 10.1016/j.aott.2018.06.012. Epub 2018 Sep 21. PMID- 21735786 OWN - NLM STAT- MEDLINE DCOM- 20120508 LR - 20131121 IS - 1002-1892 (Print) IS - 1002-1892 (Linking) VI - 25 IP - 6 DP - 2011 Jun TI - [Effect of local basic fibroblast growth factor and 5-fluorouracil on accelerating healing and preventing tendon adhesion after flexor tendon repair]. PG - 711-7 AB - OBJECTIVE: To assess the effect of basic fibroblast growth factor (bFGF) and 5-fluorouracil (5-FU) applied topically on the tendon adhesion and the healing process after the flexor tendon repair in Leghorn chickens. METHODS: Ninety male Leghorn chickens (weighing 3.0-3.5 kg) were randomly divided into 3 groups, with 30 chickens in each group. The flexor digitorum profundus tendons of the third right toes were transected and sutured directly. The repair site in group A was given 0.6 microL fibrin sealant (FS). In group B, the repair site was given 0.6 microL FS containing 500 ng bFGF. In group C, before the tendons were transected, they had been soaked in 5-FU solution, and then the same treatment as group B was given. Six specimens of the third toe were harvested to perform the macroscopical and histological examinations at 1, 2, 4, and 8 weeks, respectively, and to perform the biomechanical test at 8 weeks. RESULTS: All animals survived until the experiment was completed. All incisions healed smoothly. No rupture occurred in the repaired tendon. At 8 weeks, the adhesion degree was lighter in group C than in group B (P < 0.05), but there was no significant difference in the adhesion degree between group A and groups B, C (P > 0.05). At 1, 2, and 4 weeks after operation, the number of fibroblast cells of group A was significantly less than that of group B (P < 0.05), and the number of fibroblast cells of group C was significantly less than that of group A and group B in the tendon sheath and epitenon (P < 0.05); however, it was significantly more than that of group A in the tendon parenchyma (P < 0.05), and no significant difference was observed when compared with that of group B (P > 0.05). At 8 weeks, no difference was found among 3 groups (P > 0.05). The collagen fiber content of group A was significantly less than that of group B at 4 and 8 weeks (P < 0.05). In the sheath and epitenon, the collagen fiber content of group A was significantly more than that of group C at 4 weeks (P < 0.05); however, no significant difference was found between 2 groups at 8 weeks (P > 0.05). The collagen fiber content of group A was significantly less than that of group C in the parenchyma at 4 and 8 weeks (P < 0.05). At all time points, the collagen fiber content of group B was significantly more than that of group C in the sheath and epitenon (P < 0.05), but no significant difference in the parenchyma was observed between 2 groups (P > 0.05). The biomechanical tests showed that the gliding excursion of the tendon in groups A, B, and C was (3.51 +/- 0.56), (2.84 +/- 0.42), and (4.56 +/- 0.59) mm, respectively; the work of flexion was (14.08 +/- 1.85), (20.62 +/- 3.52), and (10.91 +/- 1.53) N x mm, respectively; and the ultimate tensile strength of the tendon was (11.26 +/- 1.83), (15.02 +/-2.20), and (14.40 +/- 1.57) N, respectively. There were significant differences in the gliding excursion of the tendon and the work of flexion among 3 groups (P < 0.05) and in the ultimate tensile strength of the tendon between group A and groups B, C (P < 0.05), but there was no significant difference in the ultimate tensile strength of the tendon between group B and group C (P > 0.05). CONCLUSION: Local single-use bFGF and 5-FU can not only effectively promote the healing of flexor tendon, but also significantly reduce tendon adhesion. FAU - Sheng, Jiagen AU - Sheng J AD - Department of Orthopedics, Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, PR China. FAU - Zeng, Bingfang AU - Zeng B FAU - Jiang, Peizhu AU - Jiang P FAU - Fan, Cunyi AU - Fan C LA - chi PT - English Abstract PT - Journal Article PL - China TA - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi JT - Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery JID - 9425194 RN - 0 (Fibrin Tissue Adhesive) RN - 103107-01-3 (Fibroblast Growth Factor 2) RN - U3P01618RT (Fluorouracil) SB - IM MH - Animals MH - Biomechanical Phenomena MH - Chickens MH - Fibrin Tissue Adhesive MH - Fibroblast Growth Factor 2/administration & dosage/*pharmacology MH - Fluorouracil/administration & dosage/*pharmacology MH - Male MH - Sutures MH - Tendon Injuries/*surgery MH - Tissue Adhesions/prevention & control MH - Wound Healing/*drug effects EDAT- 2011/07/09 06:00 MHDA- 2012/05/09 06:00 CRDT- 2011/07/09 06:00 PHST- 2011/07/09 06:00 [entrez] PHST- 2011/07/09 06:00 [pubmed] PHST- 2012/05/09 06:00 [medline] PST - ppublish SO - Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011 Jun;25(6):711-7. PMID- 3608127 OWN - NLM STAT- MEDLINE DCOM- 19870909 LR - 20190623 IS - 0009-7322 (Print) IS - 0009-7322 (Linking) VI - 76 IP - 2 DP - 1987 Aug TI - Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity. PG - 442-9 AB - The purpose of these experiments was to determine the frequency dependence of the effects of amiodarone and its active desethyl metabolite on slow-channel tissues. Intravenous amiodarone and desethylamiodarone (10 or 25 mg/kg) increased atrioventricular conduction time (AVCT) and refractory period (AVERP) in open-chest, chloralose-anesthetized dogs. Drug effects on AVCT and AVERP were greatly augmented by increasing atrial stimulation frequency. The frequency dependence of drug effects was quantified by studying the response of atrioventricular (AV) conduction to changes in coupling interval. Under control conditions, premature atrial stimulation increased AVCT with a time constant of 70 msec. In the presence of amiodarone and desethylamiodarone, a biexponential relationship between AVCT and coupling interval was observed. One component had a time constant similar to control, and a slower component with a time constant of about 1 sec appeared. Slow-channel action potentials produced in canine cardiac false tendons by elevated potassium (25 mM) and isoproterenol in vitro showed interval-dependent changes in Vmax with a time constant averaging 74 msec in the absence of amiodarone. In the presence of amiodarone, a slower recovery phase of Vmax with a time constant averaging 0.94 sec was observed. These results indicate that amiodarone and its metabolite produce heart rate-dependent changes in AV nodal function in vivo and suggest use-dependent calcium-channel blockade as a mechanism of this action. Amiodarone's rate-related effects on slow-channel properties should produce selective depression of supraventricular tachyarrhythmias involving rapid activation of the AV node. FAU - Nattel, S AU - Nattel S FAU - Talajic, M AU - Talajic M FAU - Quantz, M AU - Quantz M FAU - DeRoode, M AU - DeRoode M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Calcium Channel Blockers) RN - M31FU99E3Y (desethylamiodarone) RN - N3RQ532IUT (Amiodarone) SB - IM MH - Action Potentials/*drug effects MH - Amiodarone/analogs & derivatives/*pharmacology MH - Animals MH - Atrioventricular Node/*drug effects/physiology MH - Calcium Channel Blockers/*pharmacology MH - Dogs MH - Female MH - Heart Conduction System/*drug effects MH - Male EDAT- 1987/08/01 00:00 MHDA- 1987/08/01 00:01 CRDT- 1987/08/01 00:00 PHST- 1987/08/01 00:00 [pubmed] PHST- 1987/08/01 00:01 [medline] PHST- 1987/08/01 00:00 [entrez] AID - 10.1161/01.cir.76.2.442 [doi] PST - ppublish SO - Circulation. 1987 Aug;76(2):442-9. doi: 10.1161/01.cir.76.2.442. PMID- 6705158 OWN - NLM STAT- MEDLINE DCOM- 19840516 LR - 20190623 IS - 0009-7322 (Print) IS - 0009-7322 (Linking) VI - 69 IP - 5 DP - 1984 May TI - The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers. PG - 1026-35 AB - Milrinone is a newly developed analogue of amrinone possessing potent positive inotropic action. Electrophysiologic actions of the drug have not been reported. In this study microelectrode techniques were used to assess the electrophysiologic effects of milrinone in canine false tendons homogeneously superfused with either normal or high-K Tyrode's solution and in Purkinje fibers mounted in a three-compartment chamber in which the central segment was depressed with an "ischemic" solution. Milrinone (0.2 to 20 micrograms/ml) caused no major changes in the action potential characteristics, refractoriness, or conduction velocity in fibers exposed to normal Tyrode's solution, but markedly improved conduction and abbreviated or eliminated postrepolarization refractoriness in the ischemic gap preparations. The drug also exerted important effects on reflected reentry generated in these preparations. Depending on the initial level of block, milrinone (1) suppressed the arrhythmia, (2) shifted its frequency dependence, or (3) created the conditions that allowed reflection to occur. Similar results were obtained in homogeneously depressed fibers. At similar concentrations, milrinone caused a relatively small enhancement of automaticity. Thus, in addition to its inotropic actions, milrinone produces important electrophysiologic effects. By restoring or improving conduction through areas of depressed conductivity, the drug may exert either antiarrhythmic or arrhythmogenic effects. FAU - Davidenko, J M AU - Davidenko JM FAU - Antzelevitch, C AU - Antzelevitch C LA - eng GR - HL 19487/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circulation JT - Circulation JID - 0147763 RN - 0 (Cardiotonic Agents) RN - 0 (Pyridones) RN - JU9YAX04C7 (Milrinone) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Arrhythmias, Cardiac/drug therapy MH - Cardiotonic Agents/*pharmacology MH - Dogs MH - Heart Conduction System/*drug effects MH - Milrinone MH - Myocardial Contraction/drug effects MH - Purkinje Fibers/*drug effects/physiopathology MH - Pyridones/*pharmacology EDAT- 1984/05/01 00:00 MHDA- 1984/05/01 00:01 CRDT- 1984/05/01 00:00 PHST- 1984/05/01 00:00 [pubmed] PHST- 1984/05/01 00:01 [medline] PHST- 1984/05/01 00:00 [entrez] AID - 10.1161/01.cir.69.5.1026 [doi] PST - ppublish SO - Circulation. 1984 May;69(5):1026-35. doi: 10.1161/01.cir.69.5.1026. PMID- 23605080 OWN - NLM STAT- MEDLINE DCOM- 20140404 LR - 20211021 IS - 2035-5114 (Electronic) IS - 2035-5114 (Linking) VI - 97 Suppl 1 DP - 2013 Jun TI - Metalloproteases and their inhibitors are altered in both torn and intact rotator cuff tendons. PG - 39-47 LID - 10.1007/s12306-013-0264-1 [doi] AB - BACKGROUND: We evaluated the role of matrix metalloproteases (MMPs) and their inhibitors which are involved in extracellular matrix remodeling and degradation, in the pathogenesis of chronic rotator cuff tears. MATERIALS AND METHODS: Tendon samples were harvested from 13 patients who underwent arthroscopic repair of a rotator cuff tear. Supraspinatus biopsy specimens were harvested en bloc from the arthroscopically intact middle portion of the tendon more than 1 cm from the torn edge, from the lateral edge of the tear, and from the superior one third of the macroscopically intact subscapularis tendon used as control. Histological analysis and an evaluation of the activity of specific metalloproteases and the tissue inhibitors of metalloprotease (TIMP-1, TIMP-2) was done blindly by multiplex sandwich ELISA (Search-Light technology) in each specimen RESULTS: Histological evidence of tendinopathy was present in all patients with a tear of the rotator cuff, and not in the macroscopically intact subscapularis tendon. There was a significant increase in MMP 1, MMP 2, MMP 3 and in TIMP-1, TIMP-2 levels in all specimens examined, including the macroscopically intact portion of the supraspinatus tendon and in the control specimens CONCLUSIONS: The tissue in the ruptured area of the supraspinatus tendon undergoes marked rearrangement at molecular levels. This involves the activity of MMP 1, 2 and 3, and supports the critical role of MMPs in the tendon physiology. Seemingly intact parts of the injured supraspinatus tendon can present tendinopathic features, with altered cellular metabolism. FAU - Castagna, A AU - Castagna A AD - Unitá Chirurgia Spalla e gomito, IRCCS Istituto Humanitas, Milan, Italy. FAU - Cesari, E AU - Cesari E FAU - Gigante, A AU - Gigante A FAU - Conti, M AU - Conti M FAU - Garofalo, R AU - Garofalo R LA - eng PT - Journal Article DEP - 20130421 PL - Italy TA - Musculoskelet Surg JT - Musculoskeletal surgery JID - 101498346 RN - 0 (TIMP1 protein, human) RN - 0 (TIMP2 protein, human) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.- (Metalloproteases) SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Metalloproteases/*metabolism MH - Middle Aged MH - Prospective Studies MH - Rotator Cuff/anatomy & histology/*enzymology/pathology MH - *Rotator Cuff Injuries MH - Tissue Inhibitor of Metalloproteinase-1/*metabolism MH - Tissue Inhibitor of Metalloproteinase-2/*metabolism EDAT- 2013/04/23 06:00 MHDA- 2014/04/05 06:00 CRDT- 2013/04/23 06:00 PHST- 2013/02/12 00:00 [received] PHST- 2013/03/15 00:00 [accepted] PHST- 2013/04/23 06:00 [entrez] PHST- 2013/04/23 06:00 [pubmed] PHST- 2014/04/05 06:00 [medline] AID - 10.1007/s12306-013-0264-1 [doi] PST - ppublish SO - Musculoskelet Surg. 2013 Jun;97 Suppl 1:39-47. doi: 10.1007/s12306-013-0264-1. Epub 2013 Apr 21. PMID- 20450026 OWN - NLM STAT- MEDLINE DCOM- 20100603 LR - 20191111 IS - 0189-2657 (Print) IS - 0189-2657 (Linking) VI - 20 IP - 1 DP - 2010 Jan-Mar TI - The effects of varied intensities of intrasound therapy with indomethacin on the morphology of the healing tendon. PG - 19-23 AB - BACKGROUND: Patients undergoing intrasound therapy are often concurrently on NSAIDs. The effect of varied intensities of intrasound therapy with NSAIDs on tendon healing is yet to be determined. OBJECTIVE: The study investigated the effects of a concurrent admistration of low and high intensity intrasound therapy (LIRT&HIRT) with indomethacin (Indocid) on the morphology of the tendon in the early stage of healing. METHODS: Thirty five male rats were divided randomly into seven groups; groups 2-6 underwent an induced crush injury. Group 1, nil injury and nil treatment. Group 2: injury but nil treatment. Group 3: Indomethacin only. Group 4: LIRT only, Group 5: Indocidand LIRT, Group 6: HIRT, Group 7: Indocid and HIRT. Intrasound therapy (IRT) commenced 24 hours post-injury and was given alternate days for the first 10 days post injury. Indocid was given at a dosage of 0.4 mg/kg body weight daily. On the 11 day post injury, the animals were sacrificed and the tendons excised and processed for histological study. RESULTS: Indocid significantly (p < 0.05) reduced the tenocyte population when combined with LIRT but marginally increased it when combined with HIRT (p > 0.05). There was significant difference in the tenocyte population between the combined Indocid and LIRT and the combined Indocid and HIRT groups (p < 0.05). CONCLUSION: High intensity intrasound given concurrently with oral indomethacin resulted in tenoblast proliferation and promoted healing in the injured tendon. FAU - Aiyegbusi, A I AU - Aiyegbusi AI AD - Department of Anatomy, College of Medicine, University of Lagos, Lagos, Nigeria. bogphysio@yahoo.com FAU - Akinbo, S R A AU - Akinbo SR FAU - Noronha, C C AU - Noronha CC FAU - Okanlawon, A O AU - Okanlawon AO LA - eng PT - Journal Article PL - Nigeria TA - Nig Q J Hosp Med JT - Nigerian quarterly journal of hospital medicine JID - 9713944 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - XXE1CET956 (Indomethacin) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use MH - Indomethacin/*therapeutic use MH - Male MH - Rats MH - Rats, Sprague-Dawley MH - Tendon Injuries/*therapy MH - *Ultrasonic Therapy EDAT- 2010/05/11 06:00 MHDA- 2010/06/04 06:00 CRDT- 2010/05/11 06:00 PHST- 2010/05/11 06:00 [entrez] PHST- 2010/05/11 06:00 [pubmed] PHST- 2010/06/04 06:00 [medline] AID - 10.4314/nqjhm.v20i1.57986 [doi] PST - ppublish SO - Nig Q J Hosp Med. 2010 Jan-Mar;20(1):19-23. doi: 10.4314/nqjhm.v20i1.57986. PMID- 7013505 OWN - NLM STAT- MEDLINE DCOM- 19810625 LR - 20171213 IS - 0002-9513 (Print) IS - 0002-9513 (Linking) VI - 240 IP - 4 DP - 1981 Apr TI - Electrophysiological effects of insulin on normal and depressed cardiac tissues. PG - H636-44 AB - The electrophysiological effects of insulin were studied in canine false tendons (FT) and papillary muscles from kittens and rats. Insulin caused hyperpolarization (2-8 mV) and an increase in action potential (AP) amplitude. However, the rate of rise and duration of the AP, the slope of phase 4 depolarization and conduction velocity were unchanged in the normal tissues. In preparations depressed spontaneously or by stretch or low pH (6.7), hyperpolarization was larger than observed in normal tissues. Insulin partially normalized electrophysiological parameters under these conditions but not in the presence of anoxia (95% N2). The membrane resistances of normal canine FT and kitten papillary muscles were not changed by insulin. Blockade of K channels by CsCl doubled hyperpolarization induced by the hormone. Insulin effects were abolished by cold (21 degrees C), ouabain (3-9 X 10(-7) M), or acetylstrophanthidin (0.5-3 X 10(-6) M). Overdrive hyperpolarization was enhanced by insulin. These experiments suggest that insulin-induced hyperpolarization is mediated by activation of the electrogenic Na pump and not by a change in membrane conductance. FAU - LaManna, V R AU - LaManna VR FAU - Ferrier, G R AU - Ferrier GR LA - eng GR - HL-19487/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Chlorides) RN - 0 (Insulin) RN - 1KSV9V4Y4I (Cesium) RN - 5ACL011P69 (Ouabain) RN - 66-28-4 (Strophanthidin) RN - GNR9HML8BA (cesium chloride) RN - JG33H36364 (acetylstrophanthidin) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Cats MH - Cesium/pharmacology MH - *Chlorides MH - Cold Temperature MH - Dogs MH - Dose-Response Relationship, Drug MH - Electric Conductivity MH - Female MH - Hypoxia/physiopathology MH - In Vitro Techniques MH - Insulin/*pharmacology MH - Male MH - Membrane Potentials/*drug effects MH - Ouabain/pharmacology MH - Papillary Muscles/*physiology MH - Purkinje Fibers/physiology MH - Rats MH - Strophanthidin/analogs & derivatives/pharmacology EDAT- 1981/04/01 00:00 MHDA- 1981/04/01 00:01 CRDT- 1981/04/01 00:00 PHST- 1981/04/01 00:00 [pubmed] PHST- 1981/04/01 00:01 [medline] PHST- 1981/04/01 00:00 [entrez] AID - 10.1152/ajpheart.1981.240.4.H636 [doi] PST - ppublish SO - Am J Physiol. 1981 Apr;240(4):H636-44. doi: 10.1152/ajpheart.1981.240.4.H636. PMID- 21452304 OWN - NLM STAT- MEDLINE DCOM- 20111010 LR - 20110804 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 29 IP - 10 DP - 2011 Oct TI - Decreased proliferation of aging tenocytes is associated with down-regulation of cellular senescence-inhibited gene and up-regulation of p27. PG - 1598-603 LID - 10.1002/jor.21418 [doi] AB - Symptomatic tendinopathy tends to be age-related. However, the molecular mechanisms of ageing and its effects on tenocyte proliferation and cell cycle progression are unknown. We examined tenocytes from Achilles tendons in rats from three age groups (young, 2 months; middle-aged, 12 months, and near senescence, 24 months). Tenocyte proliferation was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. Senescence-associated β-galactosidase (SA β-gal) staining was performed in all groups of tenocytes. mRNA and protein expression of cellular senescence-inhibited gene (CSIG) and p27 was measured by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot, respectively. The results of MTT assay revealed that tenocyte proliferation decreased with age (p < 0.05). Cell cycle progression was arrested at G0/G1 phase in senescent tenocytes. More senescent tenocytes expressed SA β-gal than young tenocytes did. By RT-PCR and Western blot analysis, the gene and protein expression of CSIG was found to be down-regulated, whereas that of p27 was up-regulated with age. In conclusion, the proliferation of tenocytes declines with age and is associated with the down-regulation of CSIG and up-regulation of p27. CI - Copyright © 2011 Orthopaedic Research Society. FAU - Tsai, Wen-Chung AU - Tsai WC AD - Department of Physical Medicine and Rehabilitation, Chang Gung Memorial Hospital at Linkou, Taiwan. FAU - Chang, Hsiang-Ning AU - Chang HN FAU - Yu, Tung-Yang AU - Yu TY FAU - Chien, Cheng-Hsiu AU - Chien CH FAU - Fu, Li-Fen AU - Fu LF FAU - Liang, Fang-Chen AU - Liang FC FAU - Pang, Jong-Hwei S AU - Pang JH LA - eng PT - Journal Article DEP - 20110330 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27) RN - EC 3.2.1.23 (beta-Galactosidase) SB - IM MH - Achilles Tendon/*cytology/metabolism MH - Aging/*metabolism MH - Animals MH - *Cell Proliferation MH - Cells, Cultured MH - Cyclin-Dependent Kinase Inhibitor p27/*metabolism MH - Flow Cytometry MH - Gene Expression Regulation MH - Rats MH - Rats, Sprague-Dawley MH - beta-Galactosidase/metabolism EDAT- 2011/04/01 06:00 MHDA- 2011/10/11 06:00 CRDT- 2011/04/01 06:00 PHST- 2010/10/15 00:00 [received] PHST- 2011/02/28 00:00 [accepted] PHST- 2011/04/01 06:00 [entrez] PHST- 2011/04/01 06:00 [pubmed] PHST- 2011/10/11 06:00 [medline] AID - 10.1002/jor.21418 [doi] PST - ppublish SO - J Orthop Res. 2011 Oct;29(10):1598-603. doi: 10.1002/jor.21418. Epub 2011 Mar 30. PMID- 36026559 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20230301 IS - 1029-2292 (Electronic) IS - 0897-7194 (Linking) VI - 40 IP - 5-6 DP - 2022 Nov TI - Platelet lysate and tendon healing: comparative analysis of autologous frozen-thawed PRP and ketorolac tromethamine in the treatment of patients with rotator cuff tendinopathy. PG - 163-174 LID - 10.1080/08977194.2022.2093198 [doi] AB - Platelet-rich blood derivatives are being nowadays increasingly used in the treatment of tendon-related pathologies as a rich source of growth factors. We sought to ascertain if local application of platelet lysate (PL) to augment rotator cuff repair ameliorates patient outcomes compared to ketorolac tromethamine treated group. A total of forty patients, with clinical diagnosis of Rotator Cuff Tendinopathy were randomized to receive sub acromial injections of PL every week for a total of 3 injections and two injection of ketorolac tromethamine once every two weeks. Subjective assessments included VAS, SPADI and shoulder range of motion were assessed at baseline and at 1 and 6 months after injection. Taking both control and PL groups, it was vividly seen that the outcomes were identical at the initial state, as well as the short-term one; whereas, when considering the 6-month period, there is a seemingly remarkable superiority in PL group in all parameters. FAU - Markazi, Raha AU - Markazi R AD - Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Soltani-Zangbar, Mohammad Sadegh AU - Soltani-Zangbar MS AUID- ORCID: 0000-0003-3960-5712 AD - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Zamani, Majid AU - Zamani M AD - Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran. FAU - Eghbal-Fard, Shadi AU - Eghbal-Fard S AD - Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Motavalli, Roza AU - Motavalli R AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Kamrani, Amin AU - Kamrani A AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Dolati, Sanam AU - Dolati S AUID- ORCID: 0000-0002-6257-5411 AD - Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Ahmadi, Majid AU - Ahmadi M AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Aghebati-Maleki, Leili AU - Aghebati-Maleki L AUID- ORCID: 0000-0002-0044-5961 AD - Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Mehdizadeh, Amir AU - Mehdizadeh A AD - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Eslamian, Fariba AU - Eslamian F AD - Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Pishgahi, Alireza AU - Pishgahi A AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Yousefi, Mehdi AU - Yousefi M AD - Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng SI - IRCT/IRCT20160422027520N17 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220826 PL - England TA - Growth Factors JT - Growth factors (Chur, Switzerland) JID - 9000468 RN - 4EVE5946BQ (Ketorolac Tromethamine) SB - IM MH - Humans MH - Rotator Cuff MH - Ketorolac Tromethamine/therapeutic use MH - *Rotator Cuff Injuries/drug therapy MH - *Platelet-Rich Plasma MH - *Tendinopathy/drug therapy MH - Tendons MH - Treatment Outcome OTO - NOTNLM OT - Platelet lysate OT - platelet-rich plasma OT - rotator cuff tendinopathy OT - tendon healing EDAT- 2022/08/27 06:00 MHDA- 2022/11/30 06:00 CRDT- 2022/08/26 14:51 PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/08/26 14:51 [entrez] AID - 10.1080/08977194.2022.2093198 [doi] PST - ppublish SO - Growth Factors. 2022 Nov;40(5-6):163-174. doi: 10.1080/08977194.2022.2093198. Epub 2022 Aug 26. PMID- 26068238 OWN - NLM STAT- MEDLINE DCOM- 20160314 LR - 20181113 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 16 IP - 6 DP - 2015 Jun 9 TI - Do Matrix Metalloproteases and Tissue Inhibitors of Metalloproteases in Tenocytes of the Rotator Cuff Differ with Varying Donor Characteristics? PG - 13141-57 LID - 10.3390/ijms160613141 [doi] AB - An imbalance between matrix metalloproteases (MMPs) and the tissue inhibitors of metalloproteases (TIMPs) may have a negative impact on the healing of rotator cuff tears. The aim of the project was to assess a possible relationship between clinical and radiographic characteristics of patients such as the age, sex, as well as the degenerative status of the tendon and the MMPs and TIMPs in their tenocyte-like cells (TLCs). TLCs were isolated from ruptured supraspinatus tendons and quantitative Real-Time PCR and ELISA was performed to analyze the expression and secretion of MMPs and TIMPs. In the present study, MMPs, mostly gelatinases and collagenases such as MMP-2, -9 and -13 showed an increased expression and protein secretion in TLCs of donors with higher age or degenerative status of the tendon. Furthermore, the expression and secretion of TIMP-1, -2 and -3 was enhanced with age, muscle fatty infiltration and tear size. The interaction between MMPs and TIMPs is a complex process, since TIMPs are not only inhibitors, but also activators of MMPs. This study shows that MMPs and TIMPs might play an important role in degenerative tendon pathologies. FAU - Klatte-Schulz, Franka AU - Klatte-Schulz F AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. franka.klatte@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. franka.klatte@charite.de. FAU - Aleyt, Thomas AU - Aleyt T AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. aleyt.thomas@gmx.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. aleyt.thomas@gmx.de. FAU - Pauly, Stephan AU - Pauly S AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. stephan.pauly@charite.de. FAU - Geißler, Sven AU - Geißler S AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. sven.geissler@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. sven.geissler@charite.de. FAU - Gerhardt, Christian AU - Gerhardt C AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. christian.gerhardt@charite.de. FAU - Scheibel, Markus AU - Scheibel M AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. markus.scheibel@charite.de. FAU - Wildemann, Britt AU - Wildemann B AD - Julius Wolff Institute, Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. britt.wildemann@charite.de. AD - Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin Berlin, 13353 Berlin, Germany. britt.wildemann@charite.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150609 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Adult MH - Age Factors MH - Aged MH - Cells, Cultured MH - Female MH - Humans MH - Male MH - Matrix Metalloproteinases/genetics/*metabolism MH - Middle Aged MH - Rotator Cuff/cytology/growth & development/*metabolism/pathology MH - Tissue Inhibitor of Metalloproteinases/genetics/*metabolism PMC - PMC4490489 OTO - NOTNLM OT - MMPs OT - TIMPs OT - age OT - degeneration OT - rotator cuff OT - tenocytes EDAT- 2015/06/13 06:00 MHDA- 2016/03/15 06:00 PMCR- 2015/06/01 CRDT- 2015/06/13 06:00 PHST- 2015/03/09 00:00 [received] PHST- 2015/05/28 00:00 [accepted] PHST- 2015/06/13 06:00 [entrez] PHST- 2015/06/13 06:00 [pubmed] PHST- 2016/03/15 06:00 [medline] PHST- 2015/06/01 00:00 [pmc-release] AID - ijms160613141 [pii] AID - ijms-16-13141 [pii] AID - 10.3390/ijms160613141 [doi] PST - epublish SO - Int J Mol Sci. 2015 Jun 9;16(6):13141-57. doi: 10.3390/ijms160613141. PMID- 26439405 OWN - NLM STAT- MEDLINE DCOM- 20160613 LR - 20250529 IS - 1759-4804 (Electronic) IS - 1759-4790 (Linking) VI - 12 IP - 2 DP - 2016 Feb TI - Genetics of ankylosing spondylitis--insights into pathogenesis. PG - 81-91 LID - 10.1038/nrrheum.2015.133 [doi] AB - Ankylosing spondylitis (AS), an immune-mediated arthritis, is the prototypic member of a group of conditions known as spondyloarthropathies that also includes reactive arthritis, psoriatic arthritis and enteropathic arthritis. Patients with these conditions share a clinical predisposition for spinal and pelvic joint dysfunction, as well as genetic associations, notably with HLA-B(*)27. Spondyloarthropathies are characterized by histopathological inflammation in entheses (regions of high mechanical stress where tendons and ligaments insert into bone) and in the subchondral bone marrow, and by abnormal osteoproliferation at involved sites. The association of AS with HLA-B(*)27, first described >40 years ago, led to hope that the cause of the disease would be rapidly established. However, even though many theories have been advanced to explain how HLA-B(*)27 is involved in AS, no consensus about the answers to this question has been reached, and no successful treatments have yet been developed that target HLA-B27 or its functional pathways. Over the past decade, rapid progress has been made in discovering further genetic associations with AS that have shed new light on the aetiopathogenesis of the disease. Some of these discoveries have driven translational ideas, such as the repurposing of therapeutics targeting the cytokines IL-12 and IL-23 and other factors downstream of this pathway. AS provides an excellent example of how hypothesis-free research can lead to major advances in understanding pathogenesis and to the development of innovative therapeutic strategies. FAU - Brown, Matthew A AU - Brown MA AD - University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia. FAU - Kenna, Tony AU - Kenna T AD - University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia. FAU - Wordsworth, B Paul AU - Wordsworth BP AD - NIHR Oxford Musculoskeletal Biomedical Research Unit and Comprehensive Biomedical Research Centre, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7LD, UK. LA - eng GR - 20402/ARC_/Arthritis Research UK/United Kingdom GR - 20796/ARC_/Arthritis Research UK/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20151006 PL - United States TA - Nat Rev Rheumatol JT - Nature reviews. Rheumatology JID - 101500080 RN - 0 (Biomarkers) RN - 0 (HLA-B27 Antigen) RN - 0 (Interleukin-23) RN - 187348-17-0 (Interleukin-12) SB - IM MH - Alleles MH - Biomarkers/blood MH - Evidence-Based Medicine MH - *Genetic Predisposition to Disease MH - HLA-B27 Antigen/*genetics MH - Humans MH - Interleukin-12/genetics MH - Interleukin-23/genetics MH - Polymorphism, Single Nucleotide/genetics MH - Predictive Value of Tests MH - Risk Factors MH - Sensitivity and Specificity MH - Spondylitis, Ankylosing/*genetics/pathology EDAT- 2015/10/07 06:00 MHDA- 2016/06/14 06:00 CRDT- 2015/10/07 06:00 PHST- 2015/10/07 06:00 [entrez] PHST- 2015/10/07 06:00 [pubmed] PHST- 2016/06/14 06:00 [medline] AID - nrrheum.2015.133 [pii] AID - 10.1038/nrrheum.2015.133 [doi] PST - ppublish SO - Nat Rev Rheumatol. 2016 Feb;12(2):81-91. doi: 10.1038/nrrheum.2015.133. Epub 2015 Oct 6. PMID- 37906574 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20231102 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 10 DP - 2023 TI - Bevacizumab promotes tenogenic differentiation and maturation of rat tendon-derived cells in vitro. PG - e0293463 LID - 10.1371/journal.pone.0293463 [doi] LID - e0293463 AB - Previous work suggested that tenogenic differentiation of tendon stem/progenitor cells (TSPCs) was suppressed by upregulated expression of the angiogenic marker vascular endothelial growth factor (VEGF). The purpose of this study was to test the hypothesis that anti-VEGF antibody, bevacizumab, promotes in vitro tenogenic differentiation and maturation of two distinct types of TSPCs, tendon proper-derived cells (TDCs), and paratenon-derived cells (PDCs) originating from rat Achilles tendon. TDCs and PDCs were isolated from the tendon proper and the paratenon of rat Achilles tendons. TDCs and PDCs were cultured for 3 days on plates with or without VEGF. TDCs and PDCs were also cultured in collagen gel matrix, and the blocking effect of VEGF was examined by the addition of 100 ng/mL of bevacizumab. Effects of bevacizumab on tenogenic differentiation were assessed using real-time PCR, immunofluorescent staining, and western blotting. VEGF significantly attenuated expression of the Tnmd gene in both PDCs and TDCs (P<0.05). Expressions of the Scx, Tnmd, and Col1a1 genes were significantly upregulated by the addition of bevacizumab (P<0.05). Immunofluorescent staining showed that the percentage of tenomodulin-positive PDCs and TDCs was significantly higher with bevacizumab treatment than in control cultures (P<0.05). Western blotting showed that bevacizumab suppressed pVEGFR-2 protein expression in both PDCs and TDCs. Bevacizumab promoted the in vitro tenogenic differentiation and maturation of two distinct TSPCs derived from rat Achilles tendon. Since the previous studies demonstrated that TSPCs have a potential to contribute to tendon repair, attenuating VEGF levels in TSPCs by administration of bevacizumab is a novel candidate therapeutic option for promoting tendon repair. CI - Copyright: © 2023 Kusaba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Kusaba, Yohei AU - Kusaba Y AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. FAU - Kumagai, Ken AU - Kumagai K AUID- ORCID: 0000-0002-7529-0343 AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. FAU - Ishikawa, Kimi AU - Ishikawa K AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. FAU - Choe, Hyonmin AU - Choe H AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. FAU - Ike, Hiroyuki AU - Ike H AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. FAU - Kobayashi, Naomi AU - Kobayashi N AD - Department of Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan. FAU - Inaba, Yutaka AU - Inaba Y AUID- ORCID: 0000-0002-6676-1190 AD - Department of Orthopaedic Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231031 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Vascular Endothelial Growth Factor A) RN - 2S9ZZM9Q9V (Bevacizumab) SB - IM MH - Rats MH - Animals MH - *Vascular Endothelial Growth Factor A/metabolism MH - Bevacizumab/pharmacology/metabolism MH - Cell Differentiation MH - *Achilles Tendon MH - Stem Cells PMC - PMC10617717 COIS- The authors have declared that no competing interests exist. EDAT- 2023/10/31 18:43 MHDA- 2023/11/02 12:45 PMCR- 2023/10/31 CRDT- 2023/10/31 13:35 PHST- 2023/04/30 00:00 [received] PHST- 2023/10/12 00:00 [accepted] PHST- 2023/11/02 12:45 [medline] PHST- 2023/10/31 18:43 [pubmed] PHST- 2023/10/31 13:35 [entrez] PHST- 2023/10/31 00:00 [pmc-release] AID - PONE-D-23-13097 [pii] AID - 10.1371/journal.pone.0293463 [doi] PST - epublish SO - PLoS One. 2023 Oct 31;18(10):e0293463. doi: 10.1371/journal.pone.0293463. eCollection 2023. PMID- 34063113 OWN - NLM STAT- MEDLINE DCOM- 20210924 LR - 20210924 IS - 1718-7729 (Electronic) IS - 1198-0052 (Print) IS - 1198-0052 (Linking) VI - 28 IP - 3 DP - 2021 May 5 TI - Malignant Skin Cancer Excision in Combined Therapy with Electro-Chemotherapy and Dermal Substitute. PG - 1718-1727 LID - 10.3390/curroncol28030160 [doi] AB - Squamous cell carcinoma (SCC) is the second most common malignancy skin cancer. It is characterized by abnormal, accelerated growth of squamous cells (SCs). SCC occurs when DNA damage from exposure to ultraviolet radiation or other damaging agents trigger abnormal changes in the SCs, presenting as painless lesions on areas of high sun exposure, such as the dorsum of the hand and upper extremity. For most skin SCC, the surgical excision alone is standard practice. However, recent efforts in new treatment strategies have involved around adjuvant or concomitant electrochemotherapy (ECT). ECT is a non-thermal tumor ablation modality, safe and effective on any type of solid tumor. An 87-year-old patient affected by hand SCC with invasion of deep structures including tendons was treated with neoadjuvant intra-tumoral ECT sessions followed by a selective surgical removal and reconstruction of the substance loss with collagen dermal template (CDT). Two neoadjuvant intra-tumoral ECT procedures, at distance of 3 months, with the aim to reduce the tumor size before a selective surgery, were performed. This study shows that combined surgical selective excision with ECT and CDT is a valid technique for the extended-deep dorsal hand tumor lesions reconstruction. FAU - De Angelis, Barbara AU - De Angelis B AUID- ORCID: 0000-0003-1712-6702 AD - Surgical Science Department, Medical School, University "Tor Vergata", 00133 Rome, Italy. AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - Balzani, Alberto AU - Balzani A AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - Pagnotta, Alessia AU - Pagnotta A AD - Hand and Microsurgery Unit, Jewish Hospital, 00148 Rome, Italy. FAU - Tati, Eleonora AU - Tati E AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - Orlandi, Fabrizio AU - Orlandi F AUID- ORCID: 0000-0001-8241-1812 AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - D'Autilio, Margarida Fernandes Lopes Morais AU - D'Autilio MFLM AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - Cervelli, Valerio AU - Cervelli V AD - Surgical Science Department, Medical School, University "Tor Vergata", 00133 Rome, Italy. AD - Plastic and Reconstructive Surgery, Complex Operative Unit, "Policlinico Casilino", 00169 Rome, Italy. FAU - Gentile, Pietro AU - Gentile P AUID- ORCID: 0000-0003-3123-3977 AD - Surgical Science Department, Medical School, University "Tor Vergata", 00133 Rome, Italy. LA - eng PT - Case Reports PT - Journal Article DEP - 20210505 PL - Switzerland TA - Curr Oncol JT - Current oncology (Toronto, Ont.) JID - 9502503 RN - 11056-06-7 (Bleomycin) SB - IM MH - Aged, 80 and over MH - Bleomycin/therapeutic use MH - *Carcinoma, Squamous Cell/drug therapy/surgery MH - *Electrochemotherapy MH - Humans MH - *Skin Neoplasms/drug therapy MH - Ultraviolet Rays PMC - PMC8161833 OTO - NOTNLM OT - dermal substitute OT - electrochemotherapy OT - malignant skin tumor treatment OT - skin cancer treatment OT - squamous cell carcinoma COIS- The authors declare no conflict of interest. EDAT- 2021/06/03 06:00 MHDA- 2021/09/25 06:00 PMCR- 2021/05/05 CRDT- 2021/06/02 01:05 PHST- 2021/03/30 00:00 [received] PHST- 2021/04/24 00:00 [revised] PHST- 2021/05/03 00:00 [accepted] PHST- 2021/06/02 01:05 [entrez] PHST- 2021/06/03 06:00 [pubmed] PHST- 2021/09/25 06:00 [medline] PHST- 2021/05/05 00:00 [pmc-release] AID - curroncol28030160 [pii] AID - curroncol-28-00160 [pii] AID - 10.3390/curroncol28030160 [doi] PST - epublish SO - Curr Oncol. 2021 May 5;28(3):1718-1727. doi: 10.3390/curroncol28030160. PMID- 24985902 OWN - NLM STAT- MEDLINE DCOM- 20141007 LR - 20140815 IS - 1554-527X (Electronic) IS - 0736-0266 (Linking) VI - 32 IP - 10 DP - 2014 Oct TI - Temporary inductions of matrix metalloprotease-3 (MMP-3) expression and cell apoptosis are associated with tendon degeneration or rupture after corticosteroid injection. PG - 1297-304 LID - 10.1002/jor.22681 [doi] AB - Corticosteroid injections are widely used to treat enthesopathy and tendinitis, but are also associated with possible side effects, such as tendon degeneration or rupture. However, the mechanism of tendon degeneration or rupture after corticosteroid injection remains controversial. The purpose of this study was to reveal the mechanism of tendon degeneration or rupture after injection of triamcinolone acetonide (TA) or prednisolone (PSL). Forty-two rats were divided into 3 groups: A normal saline injection group (control group), a TA injection group, and a PSL injection group; the normal saline or corticosteroid was injected around the Achilles tendon. One or 3 weeks after injection, the tendons were subjected to biomechanical testing and histological analysis. At 1 week, the biomechanical strength was significantly lower in the corticosteroid groups. Histological analysis, at 1-week post-injection, showed collagen attenuation, increased expression of MMP-3 and apoptotic cells in the corticosteroid groups. The histological changes and biomechanical weaknesses of the tendon were not seen at 3 weeks. These alterations appeared to be involved in tendon degeneration or rupture after corticosteroid injection. CI - © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. FAU - Muto, Tomoyuki AU - Muto T AD - Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan. FAU - Kokubu, Takeshi AU - Kokubu T FAU - Mifune, Yutaka AU - Mifune Y FAU - Inui, Atsuyuki AU - Inui A FAU - Harada, Yoshifumi AU - Harada Y FAU - Yoshifumi AU - Yoshifumi FAU - Takase, Fumiaki AU - Takase F FAU - Kuroda, Ryosuke AU - Kuroda R FAU - Kurosaka, Masahiro AU - Kurosaka M LA - eng PT - Journal Article DEP - 20140702 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Glucocorticoids) RN - 1ZK20VI6TY (Triamcinolone) RN - 9PHQ9Y1OLM (Prednisolone) RN - EC 3.4.24.17 (Matrix Metalloproteinase 3) SB - IM MH - Achilles Tendon/drug effects/pathology MH - Animals MH - Apoptosis/*drug effects/genetics MH - Biomechanical Phenomena MH - Glucocorticoids/administration & dosage/*adverse effects MH - Injections, Intra-Articular/adverse effects MH - Male MH - Matrix Metalloproteinase 3/biosynthesis/*genetics MH - Prednisolone/administration & dosage/adverse effects MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley MH - Rupture, Spontaneous/chemically induced/enzymology MH - Tendon Injuries/*chemically induced/enzymology MH - Triamcinolone/administration & dosage/adverse effects OTO - NOTNLM OT - Achilles tendon OT - MMP-3 OT - apoptosis OT - prednisolone OT - triamcinolone acetonide EDAT- 2014/07/06 06:00 MHDA- 2014/10/08 06:00 CRDT- 2014/07/03 06:00 PHST- 2014/02/11 00:00 [received] PHST- 2014/06/10 00:00 [accepted] PHST- 2014/07/03 06:00 [entrez] PHST- 2014/07/06 06:00 [pubmed] PHST- 2014/10/08 06:00 [medline] AID - 10.1002/jor.22681 [doi] PST - ppublish SO - J Orthop Res. 2014 Oct;32(10):1297-304. doi: 10.1002/jor.22681. Epub 2014 Jul 2. PMID- 21598203 OWN - NLM STAT- MEDLINE DCOM- 20141028 LR - 20140303 IS - 1438-9592 (Electronic) IS - 0044-409X (Linking) VI - 139 IP - 1 DP - 2014 Feb TI - [Clinical manifestation of extravasation caused by infusion and its therapeutic management]. PG - 83-8 LID - 10.1055/s-0031-1271432 [doi] AB - INTRODUCTION: Extravasal application of chemo-therapeutic agents may cause necrosis of surrounding tissue. Often tendons, nerves and muscles are destroyed. In some cases a surgical excision with an additional coverage is indicated. PATIENTS AND METHODS: In the last ten years we have treated 44  patients with necrosis after extravasation. The defects were mostly localised at the hand or distal forearm, but the cubital fossa and the thorax were affected, too. Excision of the infiltrated tissue was performed and the defect covered with local or free flaps, split skin graft or primary closure. RESULTS: In nearly all cases a stable coverage was achieved. An amputation of the hand was never necessary. Patients with immunosuppression or comorbidity sometimes had wound-healing difficulties that in some cases necessitated further operations. Serious complications were in one case a flap necrosis and another patient died 2  days after the operation because of his nephrotic syndrome. CONCLUSION: Chemotherapy extravasation is an important oncological complication that may cause permanent functional disability of the anatomic region. A variety of free and local flaps with tolerable donor site morbidity can be used for -coverage. We prefer a two-step procedure with radical resection of the area and conditioning of the wound with vacuum therapy or temporary wound coverage and in the next step the definitive wound closure. Conservative treatment is -often followed by a high rate of complications. Early radical debridement and coverage with an adequate flap offers a cure with good functional results. CI - Georg Thieme Verlag KG Stuttgart · New York. FAU - Altmann, S AU - Altmann S AD - Otto-von-Guericke-Universität, Klinik für Plastische, Ästhetische und Handchirurgie, Magdeburg, Deutschland. FAU - Damert, H-G AU - Damert HG AD - Otto-von-Guericke-Universität, Klinik für Plastische, Ästhetische und Handchirurgie, Magdeburg, Deutschland. FAU - Schneider, W AU - Schneider W AD - Otto-von-Guericke-Universität, Klinik für Plastische, Ästhetische und Handchirurgie, Magdeburg, Deutschland. LA - ger PT - English Abstract PT - Journal Article TT - Klinische Manifestationen infusionsbedingter Extravasate und ihr therapeutisches Management. DEP - 20110519 PL - Germany TA - Zentralbl Chir JT - Zentralblatt fur Chirurgie JID - 0413645 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antineoplastic Agents) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anti-Bacterial Agents/administration & dosage/*adverse effects MH - Antineoplastic Agents/*administration & dosage/*adverse effects MH - Child MH - Child, Preschool MH - Extravasation of Diagnostic and Therapeutic Materials/diagnosis/*surgery MH - Female MH - Humans MH - Infant MH - Male MH - Microsurgery MH - Middle Aged MH - Necrosis MH - Negative-Pressure Wound Therapy MH - Neoplasms/*drug therapy MH - Postoperative Complications/surgery MH - Reoperation MH - Skin/*drug effects/*pathology MH - Skin Transplantation MH - Surgical Flaps/surgery MH - Young Adult EDAT- 2011/05/21 06:00 MHDA- 2014/10/29 06:00 CRDT- 2011/05/21 06:00 PHST- 2011/05/21 06:00 [entrez] PHST- 2011/05/21 06:00 [pubmed] PHST- 2014/10/29 06:00 [medline] AID - 10.1055/s-0031-1271432 [doi] PST - ppublish SO - Zentralbl Chir. 2014 Feb;139(1):83-8. doi: 10.1055/s-0031-1271432. Epub 2011 May 19. PMID- 24274261 OWN - NLM STAT- MEDLINE DCOM- 20140904 LR - 20220309 IS - 1746-1596 (Electronic) IS - 1746-1596 (Linking) VI - 8 DP - 2013 Nov 25 TI - Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. PG - 192 LID - 10.1186/1746-1596-8-192 [doi] AB - Clear cell sarcoma is a rare cancer primarily of tendons, fascia, and aponeuroses that can be difficult to discern from primary cutaneous malignant melanoma. The two cancers share several histological markers, with most cases of both cancers staining positively for S-100, HMB-45, and melanin. Primary therapy of both cancers involves wide local excision, but while systemic therapy has proven benefit for malignant melanoma, it has not been established for clear cell sarcoma.We report the case of a 58 year old woman with a large, ulcerated, fungating mass on her left lower leg. Frozen section of the mass showed a malignant epithelioid and spindle cell tumor confined to the subcutaneous tissue. A provisional diagnosis of soft-tissue sarcoma was made. Through in-depth study of initial biopsy with immunohistochemistry for S-100, HMB-45, MART-1, and MITF, along with karyotyping and FISH analysis for EWS gene rearrangement, the diagnosis of amelanotic malignant melanoma was confirmed. The patient then underwent systemic treatment with ipilimumab upon recurrence with good response. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1989338475107348. FAU - Wagner, Barrett Parker AU - Wagner BP AD - University of Wisconsin School of Medicine and Public Health, 750 Highland Ave, Madison, WI, USA. bwagner1@wisc.edu. FAU - Epperla, Narendranath AU - Epperla N FAU - Medina-Flores, Rafael AU - Medina-Flores R LA - eng PT - Case Reports PT - Journal Article DEP - 20131125 PL - England TA - Diagn Pathol JT - Diagnostic pathology JID - 101251558 RN - 0 (Antibodies, Monoclonal) RN - 0 (Biomarkers, Tumor) RN - 0 (Ipilimumab) RN - 0 (MART-1 Antigen) RN - 0 (Microphthalmia-Associated Transcription Factor) RN - EC 2.7.11.1 (BRAF protein, human) RN - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) SB - IM MH - Antibodies, Monoclonal/therapeutic use MH - Biomarkers, Tumor/metabolism MH - Diagnosis, Differential MH - Female MH - Humans MH - Ipilimumab MH - MART-1 Antigen/metabolism MH - Melanoma/*diagnosis/drug therapy/metabolism MH - Microphthalmia-Associated Transcription Factor/metabolism MH - Middle Aged MH - *Proto-Oncogene Proteins B-raf MH - Sarcoma, Clear Cell/*diagnosis/metabolism MH - Skin Neoplasms/*diagnosis/drug therapy/metabolism MH - Soft Tissue Neoplasms/*diagnosis/metabolism MH - Treatment Outcome PMC - PMC4222667 EDAT- 2013/11/28 06:00 MHDA- 2014/09/05 06:00 PMCR- 2013/11/25 CRDT- 2013/11/27 06:00 PHST- 2013/09/06 00:00 [received] PHST- 2013/11/18 00:00 [accepted] PHST- 2013/11/27 06:00 [entrez] PHST- 2013/11/28 06:00 [pubmed] PHST- 2014/09/05 06:00 [medline] PHST- 2013/11/25 00:00 [pmc-release] AID - 1746-1596-8-192 [pii] AID - 10.1186/1746-1596-8-192 [doi] PST - epublish SO - Diagn Pathol. 2013 Nov 25;8:192. doi: 10.1186/1746-1596-8-192. PMID- 31793464 OWN - NLM STAT- MEDLINE DCOM- 20191212 LR - 20200108 IS - 0304-4920 (Print) IS - 0304-4920 (Linking) VI - 62 IP - 6 DP - 2019 Nov-Dec TI - The impact of high-intensity laser therapy on oxidative stress, lysosomal enzymes, and protease inhibitor in athletes. PG - 273-278 LID - 10.4103/CJP.CJP_40_19 [doi] AB - The aim of the study was to assess the effect of one session of high-intensity laser therapy (HILT) on the levels of selected oxidative stress parameters, lysosomal hydrolases, and anti-inflammatory serine protease inhibitor in the peripheral blood of amateur athletes with torn or pulled tendons of the ankle or the knee joint. The group of injured athletes comprised 16 males and females aged 16.3 ± 1.3 years, while the control group of 14 healthy, noninjured amateur athletes of both sexes (controls; age 17.4 ± 4.6 years). Material for the study was peripheral blood taken at three study time points: Immediately before, 30 min after, and 24 h after HILT intervention. In plasma and erythrocytes, thiobarbituric acid reactive substances (TBARSpl and TBARSer, respectively) were determined. In erythrocytes, the activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) were measured. In serum, the activity of acid phosphatase (AcP), arylsulfatase (ASA), cathepsin D (CTS D), and α1-antitrypsin (AAT) were determined. Among oxidative stress parameters, only the CAT activity significantly decreased 24 h after HILT compared to measurement 30 min after the treatment in the injured individuals (P < 0.01), while the GPx activity in that group was meaningfully higher 30 min after HILT compared to controls (P < 0.05). Thirty min after the intervention, the activities of AcP and ASA were lower in the injured participants compared to the uninjured ones (P < 0.01 and P < 0.05, respectively). The CTS D activity was lower 30 min and 24 h after HILT in both groups (P < 0.001) and did not differ significantly between them (P > 0.05). Moreover, the study showed statistically significant linear relationships between the TBARSer concentration and the SOD activity before HILT in the healthy participants (r = -0.6, P = 0.021) and 24 h after HILT in the injured ones (r = 0.6, P = 0.025). In the noninjured athletes before HILT, the CTS D activity linearly correlated with the AAT activity (r = -0.70, P = 0.005), and 30 min after the treatment, with the AcP activity (r = 0.5, P = 0.041). 24 h after the HILT intervention, the CTS D and AcP activities were also correlated in the injured athletes (r = 0.8, P = 0.002). The study suggests that one HILT intervention does not significantly influence the redox equilibrium but stabilizes lysosomal membranes. FAU - Sielski, Łukasz AU - Sielski Ł AD - Department of Pathophysiology of Hearing and Balance, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun; Rehabilitation Center Multidisciplinary City Hospital, Bydgoszcz, Poland. FAU - Sutkowy, Paweł AU - Sutkowy P AD - Department of Medical Biology and Biochemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. FAU - Katarzyna, Pawlak-Osińska AU - Katarzyna PO AD - Department of Pathophysiology of Hearing and Balance, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. FAU - Woźniak, Alina AU - Woźniak A AD - Department of Medical Biology and Biochemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. FAU - Skopkowska, Agnieszka AU - Skopkowska A AD - Rehabilitation Center Multidisciplinary City Hospital, Bydgoszcz; Department of Laser Therapy and Physiotherapy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland. FAU - Woźniak, Bartosz AU - Woźniak B AD - Department of Neurosurgery, Stanislaw Staszic Specialist Hospital, Pila, Poland. FAU - Czuczejko, Jolanta AU - Czuczejko J AD - Department of Psychiatry, Ludwik Rydygier Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland. LA - eng PT - Journal Article PL - India TA - Chin J Physiol JT - The Chinese journal of physiology JID - 7804502 RN - 0 (Antioxidants) RN - 0 (Protease Inhibitors) RN - EC 1.11.1.6 (Catalase) RN - EC 1.11.1.9 (Glutathione Peroxidase) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 3.- (Hydrolases) SB - IM MH - Adolescent MH - Antioxidants MH - Athletes MH - Catalase MH - Female MH - Glutathione Peroxidase MH - Humans MH - Hydrolases MH - *Laser Therapy MH - Lysosomes MH - Male MH - *Oxidative Stress MH - Protease Inhibitors MH - Superoxide Dismutase OTO - NOTNLM OT - High-intensity laser therapy OT - lysosomal hydrolases OT - oxidative stress OT - α1-antitrypsin COIS- None EDAT- 2019/12/04 06:00 MHDA- 2019/12/18 06:00 CRDT- 2019/12/04 06:00 PHST- 2019/12/04 06:00 [entrez] PHST- 2019/12/04 06:00 [pubmed] PHST- 2019/12/18 06:00 [medline] AID - ChinJPhysiol_2019_62_6_273_272023 [pii] AID - 10.4103/CJP.CJP_40_19 [doi] PST - ppublish SO - Chin J Physiol. 2019 Nov-Dec;62(6):273-278. doi: 10.4103/CJP.CJP_40_19. PMID- 30825206 OWN - NLM STAT- MEDLINE DCOM- 20200526 LR - 20200526 IS - 1097-4652 (Electronic) IS - 0021-9541 (Linking) VI - 234 IP - 10 DP - 2019 Aug TI - High cholesterol inhibits tendon-related gene expressions in tendon-derived stem cells through reactive oxygen species-activated nuclear factor-κB signaling. PG - 18017-18028 LID - 10.1002/jcp.28433 [doi] AB - Clinical studies have indicated that increased serum cholesterol levels raised the risk of tendinopathy in hypercholesterolemia, but the effect of cholesterol on tendon-derived stem cells (TDSCs) and its underlying mechanism have not been studied. The purpose of this study is to investigate the association between cholesterol and tendinopathy in vitro and in vivo, and its underlying molecular mechanism as well. In TDSCs, the effect of cholesterol was assessed by quantitative polymerase chain reaction, western blot analysis, and immunofluorescence staining. Intracellular levels of reactive oxygen species (ROS) was detected, using flow cytometry. The link between nuclear factor (NF)-κB signaling and the effect of cholesterol was evaluated using a representative IκB kinase (IKK) inhibitor, BAY 11-7082. In addition, Achilles tendons from apolipoprotein E mice fed with a high-fat diet were histologically assessed using hematoxylin and eosin staining and immunohistochemistry. We found that high cholesterol apparently lowered the expression of tendon cell markers (collagen 1, scleraxis, tenomodulin), and elevated ROS levels via the NF-κB pathway both in vitro and in vivo. The ROS scavenger N-acetylcysteine (NAC) and BAY 11-7082 reversed the inhibiting effect of cholesterol on the tendon-related gene expressions of TDSCs. Moreover, NAC blocked cholesterol-induced phosphorylation of IκBα and p65. Significant histological alternation in vivo was shown in Achilles tendon in the hypercholesterolemic group. These results indicated that high cholesterol may inhibit the tendon-related gene expressions in TDSCs via ROS-activated NF-кB signaling, implying pathogenesis of tendinopathy in hypercholesterolemia and suggesting a new mechanism underlying hypercholesterolemia-induced tendinopathy. CI - © 2019 Wiley Periodicals, Inc. FAU - Li, Kaiqun AU - Li K AUID- ORCID: 0000-0003-3322-4345 AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Deng, Ganming AU - Deng G AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. AD - Department of Bone and Joint Surgery, Baoan District People's Hospital of Shenzhen, Shenzhen, China. FAU - Deng, Ye AU - Deng Y AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Chen, Siwei AU - Chen S AD - Department of Orthopaedics and Traumatology, Changhai Hospital of Shanghai, The Second Military Medical University, Shanghai, China. FAU - Wu, Hangtian AU - Wu H AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Cheng, Caiyu AU - Cheng C AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhang, Xianrong AU - Zhang X AUID- ORCID: 0000-0002-0992-5013 AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Yu, Bin AU - Yu B AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. AD - Guangdong Provincial Key Laboratory of Bone and Cartilage Regenerative Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. FAU - Zhang, Kairui AU - Zhang K AD - Department of Orthopaedics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190301 PL - United States TA - J Cell Physiol JT - Journal of cellular physiology JID - 0050222 RN - 0 (Antioxidants) RN - 0 (NF-kappa B) RN - 0 (Reactive Oxygen Species) RN - 97C5T2UQ7J (Cholesterol) SB - IM MH - Achilles Tendon/drug effects/*metabolism/pathology MH - Animals MH - Antioxidants/pharmacology MH - Cells, Cultured MH - Cholesterol/*metabolism MH - Disease Models, Animal MH - Female MH - Gene Expression Regulation MH - Hypercholesterolemia/drug therapy/genetics/*metabolism/pathology MH - Male MH - Mice, Knockout, ApoE MH - NF-kappa B/*metabolism MH - *Oxidative Stress/drug effects MH - Rats, Sprague-Dawley MH - Reactive Oxygen Species/*metabolism MH - Signal Transduction MH - Stem Cells/drug effects/*metabolism/pathology MH - Tendinopathy/genetics/*metabolism/pathology/prevention & control OTO - NOTNLM OT - NF-κB pathway OT - ROS OT - cholesterol OT - tendinopathy OT - tendon-derived stem cells EDAT- 2019/03/03 06:00 MHDA- 2020/05/27 06:00 CRDT- 2019/03/03 06:00 PHST- 2019/01/03 00:00 [received] PHST- 2019/02/02 00:00 [revised] PHST- 2019/02/14 00:00 [accepted] PHST- 2019/03/03 06:00 [pubmed] PHST- 2020/05/27 06:00 [medline] PHST- 2019/03/03 06:00 [entrez] AID - 10.1002/jcp.28433 [doi] PST - ppublish SO - J Cell Physiol. 2019 Aug;234(10):18017-18028. doi: 10.1002/jcp.28433. Epub 2019 Mar 1. PMID- 17602244 OWN - NLM STAT- MEDLINE DCOM- 20080211 LR - 20070919 IS - 0302-766X (Print) IS - 0302-766X (Linking) VI - 330 IP - 1 DP - 2007 Oct TI - Association of TIMP-2 with extracellular matrix exposed to mechanical stress and its co-distribution with periostin during mouse mandible development. PG - 133-45 AB - Matrix remodeling is regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Periostin, originally identified in a mouse osteoblastic library, plays a role in cell adhesion and migration and in mechanical stress-induced matrix remodeling. In this study, we analyzed and compared the distribution patterns of TIMP-2 and periostin during mouse mandible development. Immunohistochemical staining for TIMP-2 and periostin was carried out on serial cryosections obtained from mice at embryonic days 13-16, postnatal day 2 (P2), P35, and 12 weeks of age. TIMP-2 and periostin exhibited a strikingly similar protein distribution during mandible development. From bud to early bell stages of molars, TIMP-2 and periostin were highly expressed on the lingual and anterior sides of the basement membrane and on the adjacent jaw mesenchyme. In pre- and postnatal incisors, the basement membrane of the apical loop and dental follicle was immunostained for TIMP-2 and periostin. At postnatal stages, TIMP-2 and periostin were prominently confined to the extracellular matrix (ECM) of gingival tissues, periodontal ligaments, and tendons (all recipients of mechanical strain). However, periostin was solely detected in the lower portion of the inner root sheath of hair follicles. Gingiva of P2 cultured in anti-TIMP-2 antibody-conditioned medium showed markedly reduced staining of periostin. We suggest that TIMP-2 and periostin are co-distributed on ECM exposed to mechanical forces and coordinately function as ECM modulators. FAU - Yoshiba, Nagako AU - Yoshiba N AD - Division of Cariology, Operative Dentistry and Endodontics, Department of Oral Health Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. nagako@dent.niigata-u.ac.jp FAU - Yoshiba, Kunihiko AU - Yoshiba K FAU - Hosoya, Akihiro AU - Hosoya A FAU - Saito, Masahiro AU - Saito M FAU - Yokoi, Takamasa AU - Yokoi T FAU - Okiji, Takashi AU - Okiji T FAU - Amizuka, Norio AU - Amizuka N FAU - Ozawa, Hidehiro AU - Ozawa H LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070630 PL - Germany TA - Cell Tissue Res JT - Cell and tissue research JID - 0417625 RN - 0 (Cell Adhesion Molecules) RN - 0 (Postn protein, mouse) RN - 0 (Tissue Inhibitor of Metalloproteinase-3) SB - IM MH - Animals MH - Animals, Newborn MH - Cell Adhesion Molecules/*physiology MH - Cells, Cultured MH - Embryonic Development MH - Extracellular Matrix/*physiology MH - Gingiva/cytology/growth & development/physiology MH - Immunohistochemistry MH - Mandible/cytology/*embryology/growth & development MH - Mice MH - Stress, Mechanical MH - Tissue Inhibitor of Metalloproteinase-3/*physiology EDAT- 2007/07/03 09:00 MHDA- 2008/02/12 09:00 CRDT- 2007/07/03 09:00 PHST- 2006/11/21 00:00 [received] PHST- 2007/04/27 00:00 [accepted] PHST- 2007/07/03 09:00 [pubmed] PHST- 2008/02/12 09:00 [medline] PHST- 2007/07/03 09:00 [entrez] AID - 10.1007/s00441-007-0439-x [doi] PST - ppublish SO - Cell Tissue Res. 2007 Oct;330(1):133-45. doi: 10.1007/s00441-007-0439-x. Epub 2007 Jun 30. PMID- 28888475 OWN - NLM STAT- MEDLINE DCOM- 20180404 LR - 20180404 IS - 1878-1861 (Electronic) IS - 1878-1861 (Linking) VI - 21 IP - 4 DP - 2018 Apr TI - Promoter methylation status of the TIMP2 and ADAMTS4 genes and patellar tendinopathy. PG - 378-382 LID - S1440-2440(17)31021-6 [pii] LID - 10.1016/j.jsams.2017.08.016 [doi] AB - OBJECTIVES: Patellar tendinopathy (PT) is a debilitating and prevalent condition that tends to affect those who are physically active or engaged in jumping sports. Although tendinopathies are known to have a genetic basis, the role of DNA methylation as an epigenetic factor and risk determinant for human PT has never been described. We sought to determine whether differences existed between the methylation profiles of both the TIMP2 and ADAMTS4 gene promoter sequences in a cohort of males having undergone surgery for patellar tendinopathy compared to controls. DESIGN: Case-control epigenetic study using DNA from 10 males with PT and 10 males with healthy tendons. METHODS: We used PCR and targeted pyrosequencing to interrogate the methylation profiles of CpG sites upstream of both the TIMP2 (4 sites) and ADAMTS4 (6 sites) genes. We compared methylation differences between the two groups using t-tests. RESULTS: We report no significant (p>0.05) methylation differences within the TIMP2 gene promoter between the PT group and controls across the 4 CpG sites investigated. In contrast, we detected a significant (p=0.016) difference in the methylation status of 1 CpG site, approximately 3kb upstream of the ADAMTS4 gene between the PT group and controls. CONCLUSIONS: To our knowledge, this is the first study to investigate how DNA methylation impacts on the risk of human tendinopathy. Our data indicate that the methylation status of the ADAMTS4 gene is altered in patellar tendinopathy and we speculate on how this change might modify the patellar tendon extra-cellular matrix environment. CI - Copyright © 2017 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved. FAU - El Khoury, Louis Y AU - El Khoury LY AD - The Centre for Physical Activity and Chronic Disease, The Institute of Health and Wellbeing, University of Northampton, UK; Department of Biochemistry and Molecular Biology, Mayo Clinic, USA. FAU - Rickaby, Rebecca AU - Rickaby R AD - The Centre for Physical Activity and Chronic Disease, The Institute of Health and Wellbeing, University of Northampton, UK. FAU - Samiric, Tom AU - Samiric T AD - School of Human Biosciences and the Musculoskeletal Research Centre, La Trobe University, Australia. FAU - Raleigh, Stuart M AU - Raleigh SM AD - The Centre for Physical Activity and Chronic Disease, The Institute of Health and Wellbeing, University of Northampton, UK. Electronic address: stuart.raleigh@northampton.ac.uk. LA - eng PT - Journal Article DEP - 20170901 PL - Australia TA - J Sci Med Sport JT - Journal of science and medicine in sport JID - 9812598 RN - 0 (TIMP2 protein, human) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.82 (ADAMTS4 Protein) RN - EC 3.4.24.82 (ADAMTS4 protein, human) SB - IM MH - ADAMTS4 Protein/*genetics MH - Case-Control Studies MH - CpG Islands MH - *DNA Methylation MH - Epigenesis, Genetic MH - Humans MH - Male MH - Patellar Ligament/*physiology MH - Promoter Regions, Genetic MH - Tendinopathy/*genetics MH - Tissue Inhibitor of Metalloproteinase-2/*genetics OTO - NOTNLM OT - Epigenetics OT - Genetics OT - Sports injury OT - Tendinopathy OT - Tendon EDAT- 2017/09/11 06:00 MHDA- 2018/04/05 06:00 CRDT- 2017/09/11 06:00 PHST- 2017/02/08 00:00 [received] PHST- 2017/08/03 00:00 [revised] PHST- 2017/08/22 00:00 [accepted] PHST- 2017/09/11 06:00 [pubmed] PHST- 2018/04/05 06:00 [medline] PHST- 2017/09/11 06:00 [entrez] AID - S1440-2440(17)31021-6 [pii] AID - 10.1016/j.jsams.2017.08.016 [doi] PST - ppublish SO - J Sci Med Sport. 2018 Apr;21(4):378-382. doi: 10.1016/j.jsams.2017.08.016. Epub 2017 Sep 1. PMID- 20925084 OWN - NLM STAT- MEDLINE DCOM- 20110222 LR - 20101108 IS - 1552-4965 (Electronic) IS - 1549-3296 (Linking) VI - 95 IP - 4 DP - 2010 Dec 15 TI - The effect of various denier capillary channel polymer fibers on the alignment of NHDF cells and type I collagen. PG - 1194-202 LID - 10.1002/jbm.a.32941 [doi] AB - If tissue engineers are to successfully repair and regenerate native tendons and ligaments, it will be essential to implement contact guidance to induce cellular and type I collagen alignment to replicate the native structure. Capillary channel polymer (CC-P) fibers fabricated by melt-extrusion have aligned micrometer scale surface channels that may serve the goal of achieving biomimetic, physical templates for ligament growth and regeneration. Previous work characterizing the behavior of normal human dermal fibroblasts (NHDF), on the 19 denier per filament (dpf) CC-P fibers, demonstrated a need for improved cellular and type I collagen alignment. Therefore, 5 and 9 dpf CC-P fibers were manufactured to determine whether their channel dimensions would achieve greater alignment. A 29 dpf CC-P fiber was also examined to determine whether cellular guidance could still be achieved within the larger dimensions of the fiber's channels. The 9 dpf CC-P fiber appeared to approach the topographical constraints necessary to induce the cellular and type I collagen architecture that most closely mirrored that of native ACL tissue. This work demonstrated that the novel cross-section of the CC-P fiber geometry could approach the necessary surface topography to align NHDF cells along the longitudinal axis of each fiber. CI - Copyright © 2010 Wiley Periodicals, Inc. FAU - Sinclair, Kristofer D AU - Sinclair KD AD - Department of Materials Science and Engineering, Clemson University, Clemson, South Carolina 29634-0905, USA. kristofer.sinclair@hsc.utah.edu FAU - Webb, Ken AU - Webb K FAU - Brown, Philip J AU - Brown PJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20101005 PL - United States TA - J Biomed Mater Res A JT - Journal of biomedical materials research. Part A JID - 101234237 RN - 0 (Actins) RN - 0 (Collagen Type I) RN - 0 (Indoles) RN - 0 (Polymers) RN - 47165-04-8 (DAPI) SB - IM MH - Actins/metabolism MH - Biomimetic Materials/*pharmacology MH - Cell Adhesion/drug effects MH - Cell Nucleus/drug effects/metabolism MH - Collagen Type I/*metabolism MH - Dermis/*cytology MH - Fibroblasts/*cytology/*drug effects/ultrastructure MH - Fluorescent Antibody Technique MH - Humans MH - Indoles/metabolism MH - Microscopy, Electron, Scanning MH - Microscopy, Fluorescence MH - Polymers/*pharmacology EDAT- 2010/10/07 06:00 MHDA- 2011/02/23 06:00 CRDT- 2010/10/07 06:00 PHST- 2010/02/22 00:00 [received] PHST- 2010/07/14 00:00 [revised] PHST- 2010/07/22 00:00 [accepted] PHST- 2010/10/07 06:00 [entrez] PHST- 2010/10/07 06:00 [pubmed] PHST- 2011/02/23 06:00 [medline] AID - 10.1002/jbm.a.32941 [doi] PST - ppublish SO - J Biomed Mater Res A. 2010 Dec 15;95(4):1194-202. doi: 10.1002/jbm.a.32941. Epub 2010 Oct 5. PMID- 15223606 OWN - NLM STAT- MEDLINE DCOM- 20050308 LR - 20181113 IS - 0962-9351 (Print) IS - 0962-9351 (Linking) VI - 13 IP - 3 DP - 2004 Jun TI - Single dose of inducible nitric oxide synthase inhibitor induces prolonged inflammatory cell accumulation and fibrosis around injured tendon and synovium. PG - 157-64 AB - The aim of the current study was to investigate the effect of inhibition of nitric oxide (NO) production after injury on inflammatory cell accumulation and fibrosis around digital flexor tendon and synovium. A standard crush injury was applied to the flexor tendons of the middle digit of the hindpaw and the overlying muscle and synovium of female Wistar rats. Thirty animals received an intraperitoneal injection of either isotonic saline or N(G)-nitro-l-arginine methyl ester (L-NAME; 5 mg/kg) immediately following the crush injury, and five animals were then sacrificed at various intervals and the paws processed for histology. Another group of five animals was sacrificed after 3 days for nitrite determinations. The results showed that nitrite production and hence NO synthase activity is doubled at the acute phase of tendon wound healing, and we can prevent this by administering a single dose of L-NAME immediately after injury. The incidence and severity of fibrocellular adhesions between tendon and synovium was much more marked in animals treated with L-NAME. Treatment with L-NAME elicited a chronic inflammatory response characterised by a persistent and extraordinarily severe accumulation of large numbers of inflammatory cells in the subcutaneous tissues, in muscle and in tendon. These findings indicate that in the case of injured tendon and synovium, NO could act to protect the healing tissue from an uncontrolled inflammatory response. FAU - Darmani, Homa AU - Darmani H AD - Department of Applied Biology, Faculty of Science, Jordan University of Science and Technology, Irbid 22110. darmani@just.edu.jo FAU - Crossan, James C AU - Crossan JC FAU - Curtis, Adam AU - Curtis A LA - eng PT - Journal Article PL - United States TA - Mediators Inflamm JT - Mediators of inflammation JID - 9209001 RN - 0 (Anti-Inflammatory Agents) RN - EC 1.14.13.39 (Nitric Oxide Synthase) RN - EC 1.14.13.39 (Nitric Oxide Synthase Type II) RN - EC 1.14.13.39 (Nos2 protein, rat) RN - V55S2QJN2X (NG-Nitroarginine Methyl Ester) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Inflammation/enzymology/*prevention & control MH - Male MH - NG-Nitroarginine Methyl Ester/*pharmacology MH - Nitric Oxide Synthase/*antagonists & inhibitors MH - Nitric Oxide Synthase Type II MH - Rats MH - Rats, Wistar MH - Synovitis/enzymology/*prevention & control MH - Tendon Injuries/*prevention & control MH - Tissue Adhesions/prevention & control MH - Wound Healing/drug effects PMC - PMC1781556 EDAT- 2004/06/30 05:00 MHDA- 2005/03/09 09:00 PMCR- 2004/06/01 CRDT- 2004/06/30 05:00 PHST- 2004/06/30 05:00 [pubmed] PHST- 2005/03/09 09:00 [medline] PHST- 2004/06/30 05:00 [entrez] PHST- 2004/06/01 00:00 [pmc-release] AID - J7RYD8FRG00JVR08 [pii] AID - 10.1080/09511920410001713556 [doi] PST - ppublish SO - Mediators Inflamm. 2004 Jun;13(3):157-64. doi: 10.1080/09511920410001713556. PMID- 7668900 OWN - NLM STAT- MEDLINE DCOM- 19951006 LR - 20250214 IS - 0003-4967 (Print) IS - 1468-2060 (Electronic) IS - 0003-4967 (Linking) VI - 54 IP - 7 DP - 1995 Jul TI - Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases. PG - 571-7 AB - OBJECTIVE: To investigate the production of the matrix metalloproteinase (MMP), collagenase (MMP-1), and its natural inhibitor, the tissue inhibitor of metalloproteinases (TIMP) by diseased human tendon samples in organ culture. METHODS: Portions of tendons were excised from the shoulders of patients undergoing shoulder surgery, classified as either proximal to the lesion (abnormal) or distal to the lesion (normal) according to their macroscopic appearance at surgery, and placed in organ culture for periods of up to 28 days. The release of collagenase and TIMP activity in the conditioned culture medium was measured. RESULTS: Procollagenase and TIMP were both produced by all the tendon samples for an extended period of time. The levels of enzyme and inhibitor varied between patients, but in most of them TIMP levels were greater than collagenase levels. In one sample of calcified tendon, procollagenase levels were greater than those of TIMP. The mean level of collagenase produced by tendon proximal to the lesion and tendon distal to the lesion were not significantly different (95.2 (SD 106.8) U/g and 34.0 (45.3) U/g, respectively), while the corresponding figures for TIMP were 109.7 (62.3) U/g and 53.0 (27.9) U/g (p = < 0.05), although there was considerable variation in some samples. Western blotting and collagen fragment analysis confirmed that the collagenolytic activity detected was attributable to the metalloproteinase fibroblast collagenase (MMP-1). CONCLUSIONS: Tendon tissue can actively secrete procollagenase, an enzyme that, once activated, is capable of remodelling collagen, the major connective tissue component of tendon. Collagenase is produced even in unstimulated cultures, although the concentrations of TIMP are usually greater than that of collagenase in most samples. Some activation of collagenase appeared to have occurred. These results indicate that tendon tissue cells are capable of producing a remodelling response, even in end stage tendon disease. FAU - Dalton, S AU - Dalton S AD - North Sydney Orthopaedic and Sports Medicine Centre, Sydney, NSW, Australia. FAU - Cawston, T E AU - Cawston TE FAU - Riley, G P AU - Riley GP FAU - Bayley, I J AU - Bayley IJ FAU - Hazleman, B L AU - Hazleman BL LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Ann Rheum Dis JT - Annals of the rheumatic diseases JID - 0372355 RN - 0 (Enzyme Precursors) RN - 0 (Glycoproteins) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.- (procollagenase) SB - IM MH - Adult MH - Aged MH - Blotting, Western MH - Chronic Disease MH - Collagenases/*biosynthesis MH - Culture Techniques MH - Enzyme Precursors/*biosynthesis MH - Female MH - Glycoproteins/*biosynthesis MH - Humans MH - Male MH - Middle Aged MH - Muscular Diseases/enzymology MH - Rotator Cuff/*enzymology MH - Shoulder Joint/*enzymology MH - Tissue Inhibitor of Metalloproteinases PMC - PMC1009937 EDAT- 1995/07/01 00:00 MHDA- 1995/07/01 00:01 PMCR- 1998/07/01 CRDT- 1995/07/01 00:00 PHST- 1995/07/01 00:00 [pubmed] PHST- 1995/07/01 00:01 [medline] PHST- 1995/07/01 00:00 [entrez] PHST- 1998/07/01 00:00 [pmc-release] AID - S0003-4967(24)03088-7 [pii] AID - 10.1136/ard.54.7.571 [doi] PST - ppublish SO - Ann Rheum Dis. 1995 Jul;54(7):571-7. doi: 10.1136/ard.54.7.571. PMID- 21186083 OWN - NLM STAT- MEDLINE DCOM- 20110601 LR - 20151119 IS - 1531-6564 (Electronic) IS - 0363-5023 (Linking) VI - 36 IP - 2 DP - 2011 Feb TI - Viability and proliferation of pluripotential cells delivered to tendon repair sites using bioactive sutures--an in vitro study. PG - 252-8 LID - 10.1016/j.jhsa.2010.10.004 [doi] AB - PURPOSE: We evaluated the fate of pluripotential stem cells adherent to a suture carrier after being passed through tendon tissue in vitro. METHODS: FiberWire suture segments were coated with poly-L-lysine (PLL) and a 2 × 10(6) C3H10T1/2 (a mouse embryo pluripotential cell line) cell suspension. The sutures were incubated for 7 days, passed through two 1-cm segments of acellularized rabbit Achilles tendons and tied (horizontal mattress). The repairs were frozen and sectioned (6 μm). The sections were stained with 4',6-diamidino-2-phenylindole and a live/dead viability/cytotoxicity (calcein/ethidium homodimer) kit and examined with fluorescent microscopy to evaluate cell presence and viability. Alamar Blue was used in parallel to assess metabolic activity. RESULTS: PLL-coated sutures showed a 3-fold increase in fluorescence when compared with the phosphate-buffered saline-coated controls. At day 3, fluorescence was 2.2 times greater. At day 5, a 2-fold increase was found, and at day 8 there was no significant difference in values. Furthermore, after delivery of the cells into tendon, fluorescence readings for the samples (n = 19) showed 9450 compared with the positive control at 21,218. At 96 hours the mean was 27,609 compared with 34,850 for the positive control. The difference in fluorescence means at 48 hours and 96 hours were significant (p < .001). Live-dead and DAPI staining confirmed the presence of live cells at the tendon repair site. CONCLUSIONS: Sutures seeded with pluripotential embryonic cells deliver cells to a tendon repair site. The cells deposited at the repair site survive the trauma of passage and remain metabolically active, as seen in staining and metabolic assay studies. Use of bioactive sutures leads to repopulation of the acellular zone surrounding sutures within the tendon. CI - Copyright © 2011 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved. FAU - Yao, Jeffrey AU - Yao J AD - Department of Orthopaedic Surgery, Stanford University Medical Center, Palo Alto, CA 94063, USA. jyao@stanford.edu FAU - Korotkova, Tatiana AU - Korotkova T FAU - Smith, R Lane AU - Smith RL LA - eng PT - Comparative Study PT - Journal Article DEP - 20101224 PL - United States TA - J Hand Surg Am JT - The Journal of hand surgery JID - 7609631 RN - 0 (Coated Materials, Biocompatible) RN - 0 (Fluorescent Dyes) RN - 0 (Indoles) RN - 47165-04-8 (DAPI) SB - IM MH - Achilles Tendon/*surgery MH - Animals MH - *Cell Proliferation MH - Coated Materials, Biocompatible MH - Fluorescent Dyes MH - Indoles MH - Microscopy, Fluorescence MH - Models, Animal MH - Pluripotent Stem Cells/*transplantation MH - Rabbits MH - Stem Cell Transplantation/methods MH - Suture Techniques MH - *Sutures MH - Tensile Strength MH - Tissue and Organ Harvesting EDAT- 2010/12/28 06:00 MHDA- 2011/06/02 06:00 CRDT- 2010/12/28 06:00 PHST- 2010/01/05 00:00 [received] PHST- 2010/09/29 00:00 [revised] PHST- 2010/10/04 00:00 [accepted] PHST- 2010/12/28 06:00 [entrez] PHST- 2010/12/28 06:00 [pubmed] PHST- 2011/06/02 06:00 [medline] AID - S0363-5023(10)01197-4 [pii] AID - 10.1016/j.jhsa.2010.10.004 [doi] PST - ppublish SO - J Hand Surg Am. 2011 Feb;36(2):252-8. doi: 10.1016/j.jhsa.2010.10.004. Epub 2010 Dec 24. PMID- 15146536 OWN - NLM STAT- MEDLINE DCOM- 20050208 LR - 20111117 IS - 0886-1544 (Print) IS - 0886-1544 (Linking) VI - 58 IP - 3 DP - 2004 Jul TI - Molecular dissection of the fibroblast-traction machinery. PG - 175-85 AB - Motile fibroblasts generate forces that can be expressed as cell migration or as traction, the drawing-in of extracellular matrix. Traction by cultured fibroblasts can induce a rapid concerted reorganization of collagen gel, creating a pattern of collagen alignment similar to that seen in tendons and ligaments. In such fibrous connective tissues, after pattern morphogenesis is complete, ongoing traction may be responsible for the maintenance of proper form and function. The molecules that generate and transmit forces have been catalogued; however, how these nanometer-scale molecules contribute to millimeter-scale patterns has not been directly tested. Here, we placed pairs of explants of human periodontal ligament fibroblasts in collagen gels, where ligament-like straps of anisotropic collagen formed on the axes between them. We scrutinized the traction apparatus using electron microscopy, video microscopy, and computer-based pattern analysis, augmented with pharmacologic inhibitors of cytoskeletal function. Patterning was marked by the co-alignment of collagen, fibroblasts, and their actin cytoskeletons, all parallel to the axis between explants. The pattern was diminished by depolymerizing actin filaments or by blocking myosin activity, but was accentuated by depolymerizing microtubules. The plasma membrane also seems to contribute to the traction force. These molecular components combine to exert a sub-maximal traction force on the matrix, suggesting that the force may be regulated to ensure tissue tensional homeostasis. CI - Copyright 2004 Wiley-Liss, Inc. FAU - Sawhney, Ravi K AU - Sawhney RK AD - Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany. FAU - Howard, Jonathon AU - Howard J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Cell Motil Cytoskeleton JT - Cell motility and the cytoskeleton JID - 8605339 RN - 0 (Actins) RN - 22144-77-0 (Cytochalasin D) RN - 9007-34-5 (Collagen) RN - EC 3.6.4.1 (Myosins) SB - IM MH - Actin Cytoskeleton/physiology/ultrastructure MH - Actins/antagonists & inhibitors/metabolism MH - Anisotropy MH - Cell Adhesion/physiology MH - Cell Membrane/*physiology/ultrastructure MH - Cell Movement/*physiology MH - Cells, Cultured MH - Collagen/physiology/ultrastructure MH - Cytochalasin D/pharmacology MH - Cytoskeleton/*physiology/ultrastructure MH - Extracellular Matrix/*metabolism MH - Fibroblasts/*physiology/*ultrastructure MH - Homeostasis/physiology MH - Humans MH - Microscopy, Electron, Transmission MH - Microtubules/physiology/ultrastructure MH - Myosins/antagonists & inhibitors/metabolism MH - Tensile Strength/physiology EDAT- 2004/05/18 05:00 MHDA- 2005/02/09 09:00 CRDT- 2004/05/18 05:00 PHST- 2004/05/18 05:00 [pubmed] PHST- 2005/02/09 09:00 [medline] PHST- 2004/05/18 05:00 [entrez] AID - 10.1002/cm.20004 [doi] PST - ppublish SO - Cell Motil Cytoskeleton. 2004 Jul;58(3):175-85. doi: 10.1002/cm.20004. PMID- 27255933 OWN - NLM STAT- MEDLINE DCOM- 20170116 LR - 20211203 IS - 1752-1947 (Electronic) IS - 1752-1947 (Linking) VI - 10 IP - 1 DP - 2016 Jun 2 TI - Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report. PG - 159 LID - 10.1186/s13256-016-0913-8 [doi] LID - 159 AB - BACKGROUND: Henoch-Schönlein vasculitis is the most common systemic vasculitis in children. Arthritis or arthralgia occurs in 80 % of patients. We believe this to be the first case report to describe the finding of polyarthritis in a fludeoxyglucose positron emission tomography-computed tomography scan in a patient with Henoch-Schönlein vasculitis without clinical signs of arthritis. CASE PRESENTATION: A 4.5-year-old Caucasian boy presented with fever of 4 days' duration followed by debilitating migratory arthralgia and inflammation. He underwent a fludeoxyglucose positron emission tomography-computed tomography scan to exclude a possible malignant cause or to detect any infectious or autoimmune focus of his symptoms. Fludeoxyglucose uptake was observed in multiple large joints and in multiple tendons. These findings suggested active polyarthritis and polytendinitis. However, physical and ultrasound evaluations did not show any signs of arthritis in our patient, despite his evident arthralgia. CONCLUSIONS: Fludeoxyglucose positron emission tomography-computed tomography might be able to detect inflammatory activity in painful joints that cannot yet be detected clinically or with ultrasound evaluation in a patient with Henoch-Schönlein vasculitis. Therefore, fludeoxyglucose positron emission tomography-computed tomography can be of additional value in the diagnostic workup of patients with an unresolved diagnosis of suspected autoimmune disease, especially in patients with unresolved arthralgia and fever of unknown cause. FAU - Mooij, Christiaan F AU - Mooij CF AD - Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. christiaan.mooij@radboudumc.nl. FAU - Hermsen, Rick AU - Hermsen R AD - Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. FAU - Hoppenreijs, Esther P A H AU - Hoppenreijs EP AD - Department of Pediatric Rheumatology, Amalia Children's Hospital, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. FAU - Bleeker-Rovers, Chantal P AU - Bleeker-Rovers CP AD - Department of Internal Medicine, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. FAU - IJland, Marloes M AU - IJland MM AD - Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. FAU - de Geus-Oei, Lioe-Fee AU - de Geus-Oei LF AD - Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. LA - eng PT - Case Reports PT - Journal Article DEP - 20160602 PL - England TA - J Med Case Rep JT - Journal of medical case reports JID - 101293382 RN - 0 (Glucocorticoids) RN - 0 (Radiopharmaceuticals) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) RN - 9PHQ9Y1OLM (Prednisolone) SB - IM MH - Arthritis/*diagnostic imaging/drug therapy/etiology MH - Child, Preschool MH - Disease Progression MH - Fluorodeoxyglucose F18 MH - Glucocorticoids/therapeutic use MH - Humans MH - IgA Vasculitis/complications/*diagnostic imaging/drug therapy MH - Male MH - Positron Emission Tomography Computed Tomography MH - Prednisolone/therapeutic use MH - Radiopharmaceuticals PMC - PMC4890487 OTO - NOTNLM OT - FDG-PET/CT OT - Henoch-Schönlein OT - polyarthritis EDAT- 2016/06/04 06:00 MHDA- 2017/01/17 06:00 PMCR- 2016/06/02 CRDT- 2016/06/04 06:00 PHST- 2015/12/16 00:00 [received] PHST- 2016/04/25 00:00 [accepted] PHST- 2016/06/04 06:00 [entrez] PHST- 2016/06/04 06:00 [pubmed] PHST- 2017/01/17 06:00 [medline] PHST- 2016/06/02 00:00 [pmc-release] AID - 10.1186/s13256-016-0913-8 [pii] AID - 913 [pii] AID - 10.1186/s13256-016-0913-8 [doi] PST - epublish SO - J Med Case Rep. 2016 Jun 2;10(1):159. doi: 10.1186/s13256-016-0913-8. PMID- 22886634 OWN - NLM STAT- MEDLINE DCOM- 20130129 LR - 20211021 IS - 1554-527X (Electronic) IS - 0736-0266 (Print) IS - 0736-0266 (Linking) VI - 31 IP - 1 DP - 2013 Jan TI - The effects of dexamethasone on human patellar tendon stem cells: implications for dexamethasone treatment of tendon injury. PG - 105-10 LID - 10.1002/jor.22193 [doi] AB - Injection of Dexamethasone (Dex) is commonly used in clinics to treat tendon injury such as tendinopathy because of its anti-inflammatory capabilities. However, serious adverse effects have been reported as a result of Dex treatment, such as impaired tendon healing and tendon rupture. Using both in vitro and in vivo approaches, this study was to determine the effects of Dex treatment on the proliferation and differentiation of human tendon stem cells (hTSCs), which can directly impact tendon healing. We found that Dex treatment stimulated cell proliferation at lower concentrations (<1,000 nM), whereas a high concentration (1,000 nM) decreased cell proliferation. Moreover, at all concentrations used (5, 10, 100, and 1,000 nM), Dex treatment induced non-tenocyte differentiation of hTSCs, as evidenced by a change in cell shape, a nearly complete suppression of collagen type I expression, and an upregulation of non-tenocyte related genes (PPARγ and Sox-9), which was especially evident when higher concentrations (>10 nM) of Dex were used. Implantation of Dex-treated hTSCs for a short time (3 weeks) resulted in the extensive formation of fatty tissues, cartilage-like tissues, and bony tissues. These findings suggest that Dex treatment in clinics may cause a paradoxical effect on the injured tendons it is supposed to treat: by inducing non-tenocyte differentiation of hTSCs, Dex treatment depletes the stem cell pool and leads to the formation of non-tendinous tissues (e.g., fatty and cartilage-like tissues), which make tendon susceptible to rupture. CI - Copyright © 2012 Orthopaedic Research Society. FAU - Zhang, Jianying AU - Zhang J AD - MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, 210 Lothrop Street, BST, E1640, Pittsburgh, Pennsylvania 15213, USA. FAU - Keenan, Camille AU - Keenan C FAU - Wang, James H-C AU - Wang JH LA - eng GR - R21 AR060920/AR/NIAMS NIH HHS/United States GR - AR061395/AR/NIAMS NIH HHS/United States GR - R01 AR061395/AR/NIAMS NIH HHS/United States GR - AR049921/AR/NIAMS NIH HHS/United States GR - R01 AR049921/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20120808 PL - United States TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 RN - 0 (Glucocorticoids) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Adult MH - Adult Stem Cells/cytology/*drug effects/transplantation MH - Animals MH - Cell Differentiation/drug effects MH - Cell Proliferation/drug effects MH - Cells, Cultured MH - Dexamethasone/*pharmacology MH - Dose-Response Relationship, Drug MH - Female MH - Glucocorticoids/pharmacology MH - Humans MH - Male MH - Patellar Ligament/*cytology/drug effects MH - Rats MH - Rats, Nude MH - Tendon Injuries/*drug therapy/*pathology MH - Transplantation, Heterologous MH - Wound Healing/drug effects MH - Young Adult PMC - PMC3498577 MID - NIHMS390390 EDAT- 2012/08/14 06:00 MHDA- 2013/01/30 06:00 PMCR- 2014/01/01 CRDT- 2012/08/14 06:00 PHST- 2012/03/27 00:00 [received] PHST- 2012/06/25 00:00 [accepted] PHST- 2012/08/14 06:00 [entrez] PHST- 2012/08/14 06:00 [pubmed] PHST- 2013/01/30 06:00 [medline] PHST- 2014/01/01 00:00 [pmc-release] AID - 10.1002/jor.22193 [doi] PST - ppublish SO - J Orthop Res. 2013 Jan;31(1):105-10. doi: 10.1002/jor.22193. Epub 2012 Aug 8. PMID- 31408279 OWN - NLM STAT- MEDLINE DCOM- 20200707 LR - 20200707 IS - 1521-6551 (Electronic) IS - 1521-6543 (Linking) VI - 71 IP - 12 DP - 2019 Dec TI - MFG-E8 regulates inflammation and apoptosis in tendon healing, and promotes tendon repair: A histological and biochemical evaluation. PG - 1986-1993 LID - 10.1002/iub.2143 [doi] AB - Several studies have identified potential roles for MFG-E8 in promoting tissue repair. However, the effects of MFG-E8 on tendon repair have not yet been investigated. Therefore, we explored the role of MFG-E8 on tendon repair using a rat model of patellar tendon injury. The patellar tendons of Sprague Dawley rats (n = 24/group) received window defects and, after modeling, three groups were randomly assigned: (a) recombinant MFG-E8 (rMFG-E8) group, implantation with MFG-E8 and fibrin glue (400 ng in 10 μl); (b) fibrin group, implantation with fibrin only; and (c) control group, without any treatment. Histopathology, immunohistochemistry, and gene expression analyses were performed at 2 and 4 weeks after healing. Administration of rMFG-E8 in injury sites significantly improved tendon healing histologically at 4 weeks after injury. In addition, numbers of M1 macrophages and M1-stimulator genes, including IFNG, Il-1B, and Il-6, were reduced in the repair sites at 2 weeks by rMFG-E8 administration. In parallel, rMFG-E8 significantly increased the number of M2 macrophages and expression of anti-inflammatory IL-10 and IL-4 at 2 weeks after injury. Treatment with rMFG-E8 markedly decreased tendon cell apoptosis. Moreover, rMFG-E8 significantly enhanced the expression of genes related to tendon matrix formation at 2 weeks after injury, including Col1a1and tenascin-C. We conclude that MFG-E8 could regulate inflammatory responses and apoptotic cell accumulation in tendon repair, and promote the healing process of injured tendon tissue. Thus, exogenous application of MFG-E8 might have therapeutic potential for repair of tendon injuries. CI - © 2019 International Union of Biochemistry and Molecular Biology. FAU - Shi, Zhengzhou AU - Shi Z AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Zhang, Youbo AU - Zhang Y AD - Department of Pediatric Surgery, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, China. FAU - Wang, Qi AU - Wang Q AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Jiang, Dapeng AU - Jiang D AD - Department of Urology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190813 PL - England TA - IUBMB Life JT - IUBMB life JID - 100888706 RN - 0 (Antigens, Surface) RN - 0 (IL10 protein, mouse) RN - 0 (Il4 protein, mouse) RN - 0 (Milk Proteins) RN - 0 (Recombinant Proteins) RN - 130068-27-8 (Interleukin-10) RN - 207137-56-2 (Interleukin-4) SB - IM MH - Animals MH - Antigens, Surface/*pharmacology MH - Apoptosis/drug effects/physiology MH - Gene Expression Regulation/drug effects MH - Interleukin-10/genetics MH - Interleukin-4/genetics MH - Macrophages/drug effects MH - Male MH - Milk Proteins/*pharmacology MH - Rats, Sprague-Dawley MH - Recombinant Proteins/pharmacology MH - Tendinopathy/drug therapy/pathology MH - Tendon Injuries/*drug therapy/*pathology OTO - NOTNLM OT - MFG-E8 OT - apoptosis OT - healing OT - inflammation OT - tendon EDAT- 2019/08/14 06:00 MHDA- 2020/07/08 06:00 CRDT- 2019/08/14 06:00 PHST- 2019/06/12 00:00 [received] PHST- 2019/07/26 00:00 [accepted] PHST- 2019/08/14 06:00 [pubmed] PHST- 2020/07/08 06:00 [medline] PHST- 2019/08/14 06:00 [entrez] AID - 10.1002/iub.2143 [doi] PST - ppublish SO - IUBMB Life. 2019 Dec;71(12):1986-1993. doi: 10.1002/iub.2143. Epub 2019 Aug 13. PMID- 16304529 OWN - NLM STAT- MEDLINE DCOM- 20060124 LR - 20190922 IS - 0740-9303 (Print) IS - 0740-9303 (Linking) VI - 21 IP - 6 DP - 2005 Nov TI - Orbital lymphoma with concomitant sarcoid-like granulomas. PG - 458-61 AB - A 41-year-old man presented with chronic eyelid swelling, conjunctival injection, and decreased ocular motility in all gaze directions. MRI showed bilateral enlarged extraocular muscles, including the tendons. Laboratory tests revealed elevated levels of angiotensin-converting enzyme. An orbital biopsy showed collections of monotonous small lymphocytes, and granulomatous inflammation that included multinucleated giant cells, predominantly Langhans type. Flow cytometric analysis of tissue demonstrated a light chain-restricted clonal population of B cells, a finding that confirmed the morphologic impression of lymphoma. This case demonstrates that elevated angiotensin-converting enzyme and granulomatous inflammation can occur in lymphoma. Careful histopathologic examination and flow cytometric analysis are essential to avoid an erroneous diagnosis that could lead to inappropriate management. FAU - Behbehani, Raed S AU - Behbehani RS AD - Oculoplastic and Orbital Surgery Service, Wills Eye Hospital, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. r_behbehani@hotmail.com FAU - Bilyk, Jurij R AU - Bilyk JR FAU - Haber, Marian M AU - Haber MM FAU - Savino, Peter J AU - Savino PJ LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Ophthalmic Plast Reconstr Surg JT - Ophthalmic plastic and reconstructive surgery JID - 8508431 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Monoclonal, Murine-Derived) RN - 0 (Antineoplastic Agents) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Adult MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Monoclonal, Murine-Derived MH - Antineoplastic Agents/therapeutic use MH - Biopsy MH - Diagnosis, Differential MH - Follow-Up Studies MH - Granuloma, Giant Cell/complications/*diagnosis/drug therapy/radiotherapy MH - Humans MH - Leukemia, Lymphocytic, Chronic, B-Cell/complications/*diagnosis/drug therapy/radiotherapy MH - Magnetic Resonance Imaging MH - Male MH - Orbital Neoplasms/complications/*diagnosis/drug therapy/radiotherapy MH - Positron-Emission Tomography MH - Radiotherapy, Adjuvant MH - Rituximab MH - Sarcoidosis/complications/*diagnosis/drug therapy/radiotherapy EDAT- 2005/11/24 09:00 MHDA- 2006/01/25 09:00 CRDT- 2005/11/24 09:00 PHST- 2005/11/24 09:00 [pubmed] PHST- 2006/01/25 09:00 [medline] PHST- 2005/11/24 09:00 [entrez] AID - 00002341-200511000-00016 [pii] AID - 10.1097/01.iop.0000186125.71845.03 [doi] PST - ppublish SO - Ophthalmic Plast Reconstr Surg. 2005 Nov;21(6):458-61. doi: 10.1097/01.iop.0000186125.71845.03. PMID- 26519383 OWN - NLM STAT- MEDLINE DCOM- 20161220 LR - 20161230 IS - 1944-7876 (Electronic) IS - 1071-1007 (Linking) VI - 37 IP - 3 DP - 2016 Mar TI - Quantitative and Qualitative Change of Collagen of Achilles Tendons in Rats With Systemic Administration of Glucocorticoids. PG - 327-33 LID - 10.1177/1071100715613138 [doi] AB - BACKGROUND: It is unclear whether glucocorticoid (GC) therapy is directly related to Achilles tendon rupture (ATR), because many of the reported patients were receiving long-term GC therapy for underlying diseases. This study aimed to elucidate the mechanism by which systemic GC administration causes weakening of the Achilles tendon by biochemically, mechanically, and morphologically evaluating quantitative and qualitative changes in collagen. METHODS: Male 8-week-old mice were subcutaneously treated with either prednisolone (10 mg/mL/kg; GC group) or saline (1 mL/kg; control group) for 8 weeks and then subjected to the following experiments: (1) a tensile strength test; (2) quantification of the gene expressions of type 1 collagen and lysyl oxidase; (3) quantification of collagen content, enzymatic crosslinks (immature + mature), and senescent crosslinks; and (4) measurement of collagen fiber diameter by electron microscopy. RESULTS: The maximum tensile load and gene expressions of type 1 collagen and lysyl oxidase were decreased in the GC group. Collagen content was significantly decreased in the GC group compared with the control group. The content of enzymatic crosslinks was significantly lower in the GC group than in the control group. The corresponding amount of senescent crosslinks was not significantly different. The mean collagen fiber diameter was significantly smaller in the GC group than in the control group. Histogram analysis showed a decreased number of thick fibers and an increased number of thin fibers in the GC group. CONCLUSION: These observations suggest that systemic GC administration causes decreased strength of the Achilles tendon by decreasing its collagen content, hindering the formation of enzymatic crosslinks and thereby keeping collagen fibers in an immature state with smaller diameters. CLINICAL RELEVANCE: This animal study showed that systemic GC administration directly prevents maturation of tendon collagen fibers and decreases tendon strength, regardless of the presence or absence of underlying disease. CI - © The Author(s) 2015. FAU - Taguchi, Tetsuya AU - Taguchi T AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kubota, Makoto AU - Kubota M AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan. FAU - Saito, Mitsuru AU - Saito M AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan xlink67@gol.com. FAU - Hattori, Hidekazu AU - Hattori H AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan. FAU - Kimura, Tadashi AU - Kimura T AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan. FAU - Marumo, Keishi AU - Marumo K AD - Department of Orthopaedic Surgery, The Jikei University School of Medicine, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20151030 PL - United States TA - Foot Ankle Int JT - Foot & ankle international JID - 9433869 RN - 0 (Collagen Type I) RN - 0 (Glucocorticoids) RN - 9007-34-5 (Collagen) RN - 9PHQ9Y1OLM (Prednisolone) RN - EC 1.4.3.13 (Protein-Lysine 6-Oxidase) SB - IM MH - Achilles Tendon/*metabolism MH - Animals MH - Collagen/*metabolism/ultrastructure MH - Collagen Type I/genetics MH - Gene Expression MH - Glucocorticoids/*pharmacology MH - Injections, Subcutaneous MH - Male MH - Microscopy, Electron MH - Prednisolone/*pharmacology MH - Protein-Lysine 6-Oxidase/genetics MH - Rats, Wistar MH - Real-Time Polymerase Chain Reaction MH - Tensile Strength/drug effects OTO - NOTNLM OT - collagen OT - crosslink OT - electron microscope OT - general administration OT - glucocorticoid OT - rat OT - tensile strength test EDAT- 2015/11/01 06:00 MHDA- 2016/12/21 06:00 CRDT- 2015/11/01 06:00 PHST- 2015/11/01 06:00 [entrez] PHST- 2015/11/01 06:00 [pubmed] PHST- 2016/12/21 06:00 [medline] AID - 1071100715613138 [pii] AID - 10.1177/1071100715613138 [doi] PST - ppublish SO - Foot Ankle Int. 2016 Mar;37(3):327-33. doi: 10.1177/1071100715613138. Epub 2015 Oct 30. PMID- 18425559 OWN - NLM STAT- MEDLINE DCOM- 20080626 LR - 20211020 IS - 1528-1132 (Electronic) IS - 0009-921X (Print) IS - 0009-921X (Linking) VI - 466 IP - 7 DP - 2008 Jul TI - Collagens, proteoglycans, MMP-2, MMP-9 and TIMPs in human achilles tendon rupture. PG - 1577-82 LID - 10.1007/s11999-008-0255-y [doi] AB - Tendon integrity depends on the extracellular matrix (ECM) metabolism which is regulated by proteolytic enzymes. However, it is unclear which enzymes play a role in tendon rupture. We studied the ECM of 19 ruptured human Achilles tendons, comparing the composition of specimens harvested close to the rupture with specimens harvested from an apparently healthy area in the same tendon. We compared gene expression of collagen Type I, decorin, and versican including enzymes involved in their metabolism as matrix metalloproteases (MMP-2 and -9) and tissue inhibitory of metalloproteinase (TIMP-1 and -2) using real-time PCR, zymography and FACE analysis. We found greater gene expression of proteoglycan core protein decorin and versican, collagen Type I, MMPs and TIMPs in the tendon rupture. Zymography analysis, reflecting expression of enzymatic activity, confirmed the gene expression data at protein level. Carbohydrate content was greater in the macroscopically healthy area than in the ruptured area. In the ruptured area, we found increased core protein synthesis but without the normal glycosaminoglycan production. The tissue in the area of rupture undergoes marked rearrangement at molecular levels and supports the role of MMPs in the pathology. FAU - Karousou, Evgenia AU - Karousou E AD - Department of Experimental Biomedical and Clinical Sciences (DSBSC), University of Insubria, Varese, Italy. FAU - Ronga, Mario AU - Ronga M FAU - Vigetti, Davide AU - Vigetti D FAU - Passi, Alberto AU - Passi A FAU - Maffulli, Nicola AU - Maffulli N LA - eng PT - Journal Article DEP - 20080419 PL - United States TA - Clin Orthop Relat Res JT - Clinical orthopaedics and related research JID - 0075674 RN - 0 (Collagen Type I) RN - 0 (DCN protein, human) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Proteoglycans) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 126968-45-4 (Versicans) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.- (Metalloproteases) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Achilles Tendon/*metabolism MH - Adult MH - Collagen Type I/genetics/*metabolism MH - Decorin MH - Extracellular Matrix/genetics/metabolism MH - Extracellular Matrix Proteins/genetics MH - Female MH - Gene Expression MH - Humans MH - Male MH - Matrix Metalloproteinase 2/genetics/metabolism MH - Matrix Metalloproteinase 9/genetics/metabolism MH - Metalloproteases/genetics/*metabolism MH - Middle Aged MH - Proteoglycans/genetics/*metabolism MH - Rupture MH - Tendon Injuries/genetics/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Tissue Inhibitor of Metalloproteinase-2/genetics/metabolism MH - Tissue Inhibitor of Metalloproteinases/genetics/*metabolism MH - Versicans/genetics PMC - PMC2505242 EDAT- 2008/04/22 09:00 MHDA- 2008/06/27 09:00 PMCR- 2009/07/01 CRDT- 2008/04/22 09:00 PHST- 2007/06/13 00:00 [received] PHST- 2008/03/31 00:00 [accepted] PHST- 2008/04/22 09:00 [pubmed] PHST- 2008/06/27 09:00 [medline] PHST- 2008/04/22 09:00 [entrez] PHST- 2009/07/01 00:00 [pmc-release] AID - 255 [pii] AID - 10.1007/s11999-008-0255-y [doi] PST - ppublish SO - Clin Orthop Relat Res. 2008 Jul;466(7):1577-82. doi: 10.1007/s11999-008-0255-y. Epub 2008 Apr 19. PMID- 21030675 OWN - NLM STAT- MEDLINE DCOM- 20110802 LR - 20131121 IS - 1522-1601 (Electronic) IS - 0161-7567 (Linking) VI - 110 IP - 1 DP - 2011 Jan TI - Effect of anti-inflammatory medication on the running-induced rise in patella tendon collagen synthesis in humans. PG - 137-41 LID - 10.1152/japplphysiol.00942.2010 [doi] AB - NSAIDs are widely used in the treatment of inflammatory diseases as well as of tendon diseases associated with pain in sports and labor. However, the effect of NSAID intake, and thus blockade of PGE(2) production, on the tendon tissue adaptation is unknown. The purpose of the present study was to elucidate the possible effects of NSAID intake on healthy tendon collagen turnover in relation to a strenuous bout of endurance exercise. Fifteen healthy young men were randomly assigned into two experimental groups, with one group receiving indomethacin (oral 2 × 100 mg Confortid daily for 7 days; NSAID; n = 7) and a placebo group (n = 8). Both groups were exposed to a prolonged bout of running (36 km). The collagen synthesis NH₂-terminal propeptide of type I (PINP) and PGE₂ concentrations were measured before and 72 h following the run in the patella tendon by microdialysis. The peritendinous concentrations of PINP increased significantly in the placebo group as a result of the run, as shown previously. PGE₂ levels were significantly decreased 72 h after the run compared with basal levels in the subjects treated with NSAID and unchanged in the placebo group. The NSAID intake abolished the adaptive increase in collagen synthesis in the patella tendon found in the placebo group in response to the prolonged exercise (P < 0.05). The present study demonstrates that intake of NSAID decreased interstitial PGE₂ and abolished the exercise-induced adaptive increase in collagen synthesis in human tendons. FAU - Christensen, Britt AU - Christensen B AD - Institute of Sports Medicine Copenhagen, Bispebjerg Hospital, and Center of Healthy Aging, University of Copenhagen, Copenhagen, Denmark. FAU - Dandanell, Sune AU - Dandanell S FAU - Kjaer, Michael AU - Kjaer M FAU - Langberg, Henning AU - Langberg H LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20101028 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 9007-34-5 (Collagen) RN - K7Q1JQR04M (Dinoprostone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Adult MH - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage MH - Collagen/*biosynthesis MH - Dinoprostone/*metabolism MH - Dose-Response Relationship, Drug MH - Female MH - Humans MH - Indomethacin/*administration & dosage MH - Male MH - Patellar Ligament/drug effects/*physiology MH - Physical Endurance/drug effects/*physiology MH - Running/*physiology MH - Up-Regulation/drug effects/physiology EDAT- 2010/10/30 06:00 MHDA- 2011/08/04 06:00 CRDT- 2010/10/30 06:00 PHST- 2010/10/30 06:00 [entrez] PHST- 2010/10/30 06:00 [pubmed] PHST- 2011/08/04 06:00 [medline] AID - japplphysiol.00942.2010 [pii] AID - 10.1152/japplphysiol.00942.2010 [doi] PST - ppublish SO - J Appl Physiol (1985). 2011 Jan;110(1):137-41. doi: 10.1152/japplphysiol.00942.2010. Epub 2010 Oct 28. PMID- 39979391 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20250508 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Feb 20 TI - Retarding human adipose-derived MSCs senescence and promoting tendon repair using cell sheet engineering with a histone methyltransferase inhibitor. PG - 6198 LID - 10.1038/s41598-025-89234-3 [doi] LID - 6198 AB - Mesenchymal stem cell (MSC) holds immense potential as candidates for cell therapy in the treatment of tendon injuries due to their remarkable ability for multiple cell differentiation. However, the proliferative and differentiation capacity of MSCs has been limited by cellular senescence during the process of expanding culture. Therefore, in this study, our aim was to maintain the beneficial properties of MSCs. We found that SETD7, a histone methyltransferase, was upregulated during ex vivo expansion of human adipose-derived mesenchymal stem cells (hAD-MSCs). Pharmacological inhibition of SETD7 with PFI-2 in hAD-MSCs cultures delayed their senescence, as evident by the diminished expression of senescent-associated genes and the maintenance of their proliferation and differentiation capacity. Upon transplantation, cell sheets derived from hAD-MSCs expanded with PFI-2 were better able to accelerate tendon repair. Therefore, the present findings reveal that SETD7 is an important target to improve the expansion of hAD-MSCs by delaying senescence, which is importance for the development of efficient stem cell-based therapeutic approaches. CI - © 2025. The Author(s). FAU - Wang, Junjuan AU - Wang J AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Jian, Ke AU - Jian K AD - Department of Biomedical Engineering, College of Biology, Hunan University, Changsha, 410082, China. FAU - Yang, Qing AU - Yang Q AD - Department of Biomedical Engineering, College of Biology, Hunan University, Changsha, 410082, China. FAU - Gu, Chunyi AU - Gu C AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Sheng, Jiajun AU - Sheng J AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Zhou, Yan AU - Zhou Y AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Yin, Hantian AU - Yin H AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Zhang, Zhihan AU - Zhang Z AD - School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 310000, China. FAU - Hua, Kouzhen AU - Hua K AD - Department of Anatomy, School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, 311300, China. huakzh@163.com. FAU - Zhang, Can AU - Zhang C AD - Department of Biomedical Engineering, College of Biology, Hunan University, Changsha, 410082, China. zc420@hnu.edu.cn. LA - eng GR - LGF20H110001/the Research on Public Welfare Technology Application Projects of Zhejiang Province/ GR - Y202352014/Scientific Research Fund of Zhejiang Provincial Education Department/ GR - 00004ACKYQN202108/Basic Scientific Research Funds of Department of Education of Zhejiang Province/ GR - 82002350/National Natural Science Foundation of China/ GR - 2023JJ30177/Natural Science Foundation of Hunan Province/ PT - Journal Article DEP - 20250220 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase) RN - EC 2.1.1.43 (SETD7 protein, human) RN - 0 (Enzyme Inhibitors) SB - IM MH - Humans MH - *Mesenchymal Stem Cells/cytology/drug effects/metabolism MH - *Cellular Senescence/drug effects MH - Cell Differentiation/drug effects MH - *Histone-Lysine N-Methyltransferase/antagonists & inhibitors/metabolism/genetics MH - Cell Proliferation/drug effects MH - *Adipose Tissue/cytology MH - Cells, Cultured MH - *Tendon Injuries/therapy MH - *Enzyme Inhibitors/pharmacology MH - Tendons MH - Mesenchymal Stem Cell Transplantation MH - Animals PMC - PMC11842574 OTO - NOTNLM OT - Adipose-derived mesenchymal stem cells OT - Cell sheet OT - Histone methyltransferase OT - Senescence OT - Tendon repair COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/02/21 00:21 MHDA- 2025/02/21 00:22 PMCR- 2025/02/20 CRDT- 2025/02/20 23:20 PHST- 2024/10/29 00:00 [received] PHST- 2025/02/04 00:00 [accepted] PHST- 2025/02/21 00:22 [medline] PHST- 2025/02/21 00:21 [pubmed] PHST- 2025/02/20 23:20 [entrez] PHST- 2025/02/20 00:00 [pmc-release] AID - 10.1038/s41598-025-89234-3 [pii] AID - 89234 [pii] AID - 10.1038/s41598-025-89234-3 [doi] PST - epublish SO - Sci Rep. 2025 Feb 20;15(1):6198. doi: 10.1038/s41598-025-89234-3. PMID- 26254227 OWN - NLM STAT- MEDLINE DCOM- 20160920 LR - 20161126 IS - 1864-6433 (Electronic) IS - 0914-7187 (Linking) VI - 29 IP - 10 DP - 2015 Dec TI - ¹⁸F-FPRGD₂ PET/CT imaging of musculoskeletal disorders. PG - 839-47 LID - 10.1007/s12149-015-1011-5 [doi] AB - OBJECTIVE: This work reports on musculoskeletal uptake of ¹⁸F-FPRGD₂, targeting the integrin αvβ3, in patients who had undergone ¹⁸F-FPRGD₂ positron emission tomography combined with computed tomography (PET/CT) for oncologic purposes. METHODS: Whole-body ¹⁸F-FPRGD₂ PET/CT images of 62 cancer patients were retrospectively reviewed to detect foci of musculoskeletal ¹⁸F-FPRGD₂ uptake. For 37 patients, a FDG PET/CT performed in clinical settings was available. In each joint with an abnormal uptake, the maximum standardized uptake value (SUVmax) was estimated. RESULTS: A total of 260 musculoskeletal foci of ¹⁸F-FPRGD₂ uptake were detected. Most common sites of uptake were joints and discs (n = 160; 61.5%), entheses (osteotendinous and osteoligamentous junctions; n = 55; 21.2%) and recent fractures (n = 18; 6.9%). In addition, 27 (10.4%) miscellaneous foci were detected. Out of the 146 lesions for which a FDG PET was available, 63% showed both ¹⁸F-FPRGD₂ and FDG uptake, 33.6% did not show FDG avidity and 3.4% showed only FDG uptake. The uptake intensity of the 92 lesions positive with ¹⁸F-FPRGD₂ and FDG was similar with both radiopharmaceuticals, but the target-to-background (blood pool or muscle) ratios were significantly higher with ¹⁸F-FPRGD₂ than with FDG (p < 0.0001). CONCLUSION: The ¹⁸F-FPRGD₂ uptake in joints, spine degenerative diseases and tendons was highly prevalent in our population. Up to one-third of ¹⁸F-FPRGD₂ foci showed no FDG uptake suggesting that ¹⁸F-FPRGD₂ signal may not be related to inflammatory angiogenesis only. FAU - Withofs, Nadia AU - Withofs N AD - Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU Liege, Liege, Belgium. nwithofs@chu.ulg.ac.be. FAU - Charlier, Edith AU - Charlier E AD - Department and Laboratory of Rheumatology CHU Liege and GIGA-Research, University of Liege, Liege, Belgium. FAU - Simoni, Paolo AU - Simoni P AD - Division of Diagnostic Imaging, Department of Medical Physics, CHU Liege, Liege, Belgium. FAU - Alvarez-Miezentseva, Victoria AU - Alvarez-Miezentseva V AD - Division of Diagnostic Imaging, Department of Medical Physics, CHU Liege, Liege, Belgium. FAU - Mievis, Frédéric AU - Mievis F AD - Cyclotron Research Centre, University of Liege, Liege, Belgium. FAU - Giacomelli, Fabrice AU - Giacomelli F AD - Cyclotron Research Centre, University of Liege, Liege, Belgium. FAU - Mella, Christine AU - Mella C AD - Cyclotron Research Centre, University of Liege, Liege, Belgium. FAU - Gambhir, Sanjiv S AU - Gambhir SS AD - Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University, Stanford, CA, USA. FAU - Malaise, Olivier AU - Malaise O AD - Department and Laboratory of Rheumatology CHU Liege and GIGA-Research, University of Liege, Liege, Belgium. FAU - de Seny, Dominique AU - de Seny D AD - Department and Laboratory of Rheumatology CHU Liege and GIGA-Research, University of Liege, Liege, Belgium. FAU - Malaise, Michel AU - Malaise M AD - Department and Laboratory of Rheumatology CHU Liege and GIGA-Research, University of Liege, Liege, Belgium. FAU - Hustinx, Roland AU - Hustinx R AD - Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU Liege, Liege, Belgium. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20150808 PL - Japan TA - Ann Nucl Med JT - Annals of nuclear medicine JID - 8913398 RN - 0 (FB-mini-PEG-E(c(RGDyK))2) RN - 0 (Oligopeptides) RN - 0 (Peptides, Cyclic) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) SB - IM MH - Adenocarcinoma/complications MH - Adult MH - Aged MH - Aged, 80 and over MH - Biological Transport MH - Cartilage/metabolism MH - Cell Dedifferentiation MH - Chondrocytes/metabolism MH - Cohort Studies MH - Female MH - Gene Expression Regulation, Neoplastic MH - Humans MH - Male MH - Middle Aged MH - *Multimodal Imaging MH - Musculoskeletal Diseases/complications/*diagnostic imaging/metabolism MH - *Oligopeptides MH - Osteoarthritis/pathology MH - *Peptides, Cyclic MH - *Positron-Emission Tomography MH - Radiation Dosage MH - Rectal Neoplasms/complications MH - Retrospective Studies MH - *Tomography, X-Ray Computed OTO - NOTNLM OT - Discopathy OT - Integrin OT - Joint OT - Osteoarthritis OT - PET OT - RGD EDAT- 2015/08/09 06:00 MHDA- 2016/09/22 06:00 CRDT- 2015/08/09 06:00 PHST- 2015/06/02 00:00 [received] PHST- 2015/07/26 00:00 [accepted] PHST- 2015/08/09 06:00 [entrez] PHST- 2015/08/09 06:00 [pubmed] PHST- 2016/09/22 06:00 [medline] AID - 10.1007/s12149-015-1011-5 [pii] AID - 10.1007/s12149-015-1011-5 [doi] PST - ppublish SO - Ann Nucl Med. 2015 Dec;29(10):839-47. doi: 10.1007/s12149-015-1011-5. Epub 2015 Aug 8. PMID- 8467247 OWN - NLM STAT- MEDLINE DCOM- 19930513 LR - 20151119 IS - 1055-9965 (Print) IS - 1055-9965 (Linking) VI - 2 IP - 2 DP - 1993 Mar-Apr TI - Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. PG - 125-9 AB - Collagen type I is the sole collagen type found in bones and tendons. Carboxyterminal propeptide, deriving and cleaved from procollagen type I (PICP) during collagen synthesis, is delivered into the blood, where it can be measured. According to current knowledge, PICP correlates with bone collagen synthesis and bone formation rate. Elevated serum levels of PICP in patients with Paget's disease, compared with normal subjects and correlated with serum alkaline phosphatase (Alk.Ph.), have been previously described. Thus, PICP may be a valuable marker of bone formation. PICP, serum Alk.Ph., serum bone Gla protein and 24-h urinary hydroxyproline:creatinine ratio have been measured in 47 cancer patients: 27 with predominantly osteolytic lesions (5 myeloma, 15 breast, 3 lung, 2 kidney, 1 bladder, 1 thyroid) and 20 with predominantly osteoblastic lesions (18 prostate and 2 breast). The higher levels of PICP were noted in patients with osteoblastic or mixed metastases. In the entire group of patients, a statistically significant correlation between PICP and bone Gla protein (r = 0.57; P < 0.001), PICP and Alk.Ph. (r = 0.80; P < 0.001), and bone Gla protein and Alk.Ph. (r = 0.44; P < 0.01) was noted. In those patients with osteoblastic metastases we observed a significant correlation only between PICP and Alk.Ph. (r = 0.62; P < 0.003). During chemotherapy, 13 of 20 patients with osteoblastic metastases who achieved objective response or stable disease showed a more rapid and significant decrease in PICP with respect to the other bone markers. Serum PICP level could be considered a good marker of osteoblastic activity. FAU - Francini, G AU - Francini G AD - Institute of Medical Pathology, University of Siena, Italy. FAU - Gonnelli, S AU - Gonnelli S FAU - Petrioli, R AU - Petrioli R FAU - Bruni, S AU - Bruni S FAU - Marsili, S AU - Marsili S FAU - Aquino, A AU - Aquino A FAU - Camporeale, A AU - Camporeale A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Epidemiol Biomarkers Prev JT - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JID - 9200608 RN - 0 (Antineoplastic Agents) RN - 0 (Biomarkers, Tumor) RN - 0 (Peptide Fragments) RN - 0 (Procollagen) RN - 0 (procollagen type I carboxy terminal peptide) RN - 104982-03-8 (Osteocalcin) RN - AYI8EX34EU (Creatinine) RN - EC 3.1.3.1 (Alkaline Phosphatase) RN - RMB44WO89X (Hydroxyproline) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Alkaline Phosphatase/blood MH - Antineoplastic Agents/therapeutic use MH - Biomarkers, Tumor/*blood MH - Bone Neoplasms/*blood/drug therapy/enzymology/*secondary/urine MH - Creatinine/urine MH - Female MH - Humans MH - Hydroxyproline/urine MH - Male MH - Middle Aged MH - Osteoblasts MH - Osteocalcin/blood MH - Osteolysis/blood/enzymology/urine MH - Peptide Fragments/*blood MH - Procollagen/*blood EDAT- 1993/03/01 00:00 MHDA- 1993/03/01 00:01 CRDT- 1993/03/01 00:00 PHST- 1993/03/01 00:00 [pubmed] PHST- 1993/03/01 00:01 [medline] PHST- 1993/03/01 00:00 [entrez] PST - ppublish SO - Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):125-9. PMID- 30265844 OWN - NLM STAT- MEDLINE DCOM- 20191010 LR - 20191010 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 46 IP - 13 DP - 2018 Nov TI - Stimulation of Tendon Healing With Delayed Dexamethasone Treatment Is Modified by the Microbiome. PG - 3281-3287 LID - 10.1177/0363546518799442 [doi] AB - BACKGROUND: The immune system reflects the microbiome (microbiota). Modulation of the immune system during early tendon remodeling by dexamethasone treatment can improve rat Achilles tendon healing. The authors tested whether changes in the microbiota could influence the effect of dexamethasone treatment. HYPOTHESIS: A change in microbiome would influence the response to dexamethasone on regenerate remodeling, specifically tendon material properties (peak stress). STUDY DESIGN: Controlled laboratory study. METHODS: Specific opportunist and pathogen-free female rats were housed separately (n = 41) or together with specific pathogen-free rats carrying opportunistic microbes such as Staphylococcus aureus (n = 41). After 6 weeks, all co-housed rats appeared healthy but now carried S aureus. Changes in the gut bacterial flora were tested by API and RapID biochemical tests. All rats (clean and contaminated) underwent Achilles tendon transection under aseptic conditions. Flow cytometry was performed 8 days postoperatively on tendon tissue. Sixty rats received subcutaneous dexamethasone or saline injections on days 5 through 9 after transection. The tendons were tested mechanically on day 12. The predetermined primary outcome was the interaction between contamination and dexamethasone regarding peak stress, tested by 2-way analysis of variance. RESULTS: Dexamethasone increased peak stress in all groups but more in contaminated rats (105%) than in clean rats (53%) (interaction, P = .018). A similar interaction was found for an estimate of elastic modulus ( P = .021). Furthermore, dexamethasone treatment reduced transverse area but had small effects on peak force and stiffness. In rats treated with saline only, contamination reduced peak stress by 16% ( P = .04) and elastic modulus by 35% ( P = .004). Contamination led to changes in the gut bacterial flora and higher levels of T cells (CD3(+)CD4(+)) in the healing tendon ( P < .05). CONCLUSION: Changes in the microbiome influence tendon healing and enhance the positive effects of dexamethasone treatment during the early remodeling phase of tendon healing. CLINICAL RELEVANCE: The positive effect of dexamethasone on early tendon remodeling in rats is strikingly strong. If similar effects could be shown in humans, immune modulation by a few days of systemic corticosteroids, or more specific compounds, could open new approaches to rehabilitation after tendon injury. FAU - Dietrich-Zagonel, Franciele AU - Dietrich-Zagonel F AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Hammerman, Malin AU - Hammerman M AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Tätting, Love AU - Tätting L AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Dietrich, Fabrícia AU - Dietrich F AD - Division of Pediatrics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Kozak Ljunggren, Monika AU - Kozak Ljunggren M AD - Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Blomgran, Parmis AU - Blomgran P AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Eliasson, Pernilla AU - Eliasson P AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. FAU - Aspenberg, Per AU - Aspenberg P AD - Orthopedics, Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20180928 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Anti-Inflammatory Agents) RN - 7S5I7G3JQL (Dexamethasone) SB - IM MH - Achilles Tendon/*injuries MH - Animals MH - Anti-Inflammatory Agents/*pharmacology MH - Dexamethasone/*pharmacology MH - Female MH - *Microbiota MH - Rats MH - Specific Pathogen-Free Organisms MH - Tendon Injuries/*therapy MH - Wound Healing OTO - NOTNLM OT - Achilles tendon OT - biomechanics of the tendon OT - corticosteroids OT - immune system OT - microbiota OT - tendon healing EDAT- 2018/09/29 06:00 MHDA- 2019/10/11 06:00 CRDT- 2018/09/29 06:00 PHST- 2018/09/29 06:00 [pubmed] PHST- 2019/10/11 06:00 [medline] PHST- 2018/09/29 06:00 [entrez] AID - 10.1177/0363546518799442 [doi] PST - ppublish SO - Am J Sports Med. 2018 Nov;46(13):3281-3287. doi: 10.1177/0363546518799442. Epub 2018 Sep 28. PMID- 39805031 OWN - NLM STAT- MEDLINE DCOM- 20250527 LR - 20250527 IS - 1522-1555 (Electronic) IS - 0193-1849 (Linking) VI - 328 IP - 6 DP - 2025 Jun 1 TI - Activation of TFEB protects against diabetic vascular calcification by improving autophagic flux and activating Nrf2 antioxidant system. PG - E924-E939 LID - 10.1152/ajpendo.00161.2023 [doi] AB - Autophagic flux blockade and excessive oxidative stress play important roles in the pathogenesis of diabetic vascular calcification (VC). Transcription factor EB (TFEB) is an important regulator of many autophagy-lysosomal related components, which is mainly involved in promoting autophagy process in cells. Nuclear factor erythroid-2 related factor 2 (Nrf2) antioxidant system is considered as one of the key pathways in response to intracellular oxidative stress. Periostin (POSTN), a matrix protein, is widely involved in regulating the formation and maintenance of organs such as bones, teeth, heart valves, and tendons. We have previously reported that POSTN interfered with autophagic flux in an oxidative stress-dependent manner in vascular smooth muscle cells (VSMCs) to aggravate the development of diabetic VC. However, how POSTN interfered with autophagic flux by regulating oxidative stress has not been clarified. This study aims to further explore the roles of TFEB, POSTN, autophagy, and Nrf2 antioxidant system in the development of diabetic VC. Our experimental results revealed that activation of TFEB attenuated diabetic VC by improving autophagic flux and activating Nrf2 antioxidant system, whereas POSTN reduced the autophagic degradation of Kelch-like ECH-associated protein 1 (KEAP1) by inhibiting lysosomal function, thus inhibiting the activation of the Nrf2 antioxidant system, and ultimately abolishing the protective effect of TFEB against diabetic VC. In conclusion, this study uncovers that TFEB play an important role in alleviating diabetic VC by improving autophagic flux and activating Nrf2 antioxidant system, suggesting that TFEB may be a new target for the prevention and treatment of diabetic VC.NEW & NOTEWORTHY This study is the first to suggest the protective effect of activation of transcription factor EB (TFEB) against diabetic vascular calcification (VC), emphasizing that activation of TFEB alleviated diabetic VC by improving the autophagic flux and activating the Nuclear factor erythroid-2 related factor 2 (Nrf2) antioxidant system in vascular smooth muscle cells (VSMCs), and revealing that periostin (POSTN) partially abolished the protective effect of TFEB on diabetic VC by inhibiting the autophagic degradation of Kelch-like ECH-associated protein 1 (KEAP1). FAU - Sun, Xue-Jiao AU - Sun XJ AUID- ORCID: 0009-0007-3725-3975 AD - Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, People's Republic of China. AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Xiao, Sheng-Jue AU - Xiao SJ AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Ma, Wen-Qi AU - Ma WQ AD - Department of cardiovascular medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. AD - Institute of Cardiovascular Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. FAU - Jin, Hong AU - Jin H AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Ren, Li-Qun AU - Ren LQ AD - Department of Geriatrics, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Yao, Yu-Yu AU - Yao YY AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Chen, Zheng-Dong AU - Chen ZD AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Li, Xiao-Xue AU - Li XX AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Chen, Tian AU - Chen T AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. FAU - Liu, Nai-Feng AU - Liu NF AUID- ORCID: 0000-0001-9998-1889 AD - Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China. LA - eng GR - No. 82170478/the general program of National natural science foundation of china/ GR - No. 81970381/the general program of National natural science foundation of china/ GR - BK20201272/JST | Natural Science Foundation of Jiangsu Province (Jiangsu Natural Science Foundation)/ PT - Journal Article DEP - 20250113 PL - United States TA - Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism JID - 100901226 RN - 0 (NF-E2-Related Factor 2) RN - 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors) RN - 0 (Antioxidants) RN - 0 (Tcfeb protein, mouse) RN - 0 (Kelch-Like ECH-Associated Protein 1) RN - 0 (Nfe2l2 protein, mouse) RN - 0 (Cell Adhesion Molecules) RN - 0 (TFEB protein, rat) SB - IM MH - *NF-E2-Related Factor 2/metabolism MH - *Autophagy/drug effects MH - *Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism MH - Animals MH - Oxidative Stress/drug effects MH - *Vascular Calcification/metabolism/prevention & control/pathology MH - Male MH - Muscle, Smooth, Vascular/metabolism MH - *Antioxidants/metabolism MH - *Diabetes Mellitus, Experimental/metabolism/complications MH - Myocytes, Smooth Muscle/metabolism MH - Rats MH - Kelch-Like ECH-Associated Protein 1/metabolism MH - *Diabetic Angiopathies/metabolism/prevention & control/pathology MH - Mice MH - Cell Adhesion Molecules/metabolism MH - Cells, Cultured MH - Mice, Inbred C57BL MH - Rats, Sprague-Dawley OTO - NOTNLM OT - Nrf2 OT - POSTN OT - TFEB OT - autophagy OT - diabetic vascular calcification EDAT- 2025/01/13 18:21 MHDA- 2025/05/27 12:44 CRDT- 2025/01/13 15:52 PHST- 2025/05/27 12:44 [medline] PHST- 2025/01/13 18:21 [pubmed] PHST- 2025/01/13 15:52 [entrez] AID - 10.1152/ajpendo.00161.2023 [doi] PST - ppublish SO - Am J Physiol Endocrinol Metab. 2025 Jun 1;328(6):E924-E939. doi: 10.1152/ajpendo.00161.2023. Epub 2025 Jan 13. PMID- 3358778 OWN - NLM STAT- MEDLINE DCOM- 19880517 LR - 20190623 IS - 0006-2952 (Print) IS - 0006-2952 (Linking) VI - 37 IP - 8 DP - 1988 Apr 15 TI - Modulation of collagen metabolism by glucocorticoids. Receptor-mediated effects of dexamethasone on collagen biosynthesis in chick embryo fibroblasts and chondrocytes. PG - 1451-62 AB - The steroid modulation of collagen metabolism was studied by injecting chick embryos with dexamethasone in vivo, and collagen synthesis was subsequently assayed by pulse-labeling the tissue with [14C]proline in vitro. The synthesis of [14C]hydroxyproline in tendons and sterna from chick embryos treated with dexamethasone was markedly reduced as compared with untreated controls. The inhibition of [3H]hydroxyproline synthesis was accompanied by a similar reduction in type I and II procollagen mRNA levels, as detected by Northern blot and dot blot hybridizations with chick pro alpha 1(I), pro alpha 2(I) and pro alpha 1(II) sequence specific cDNAs. The reduction in type II procollagen mRNA level was shown to be dose dependent. Control experiments indicated that the post-translational hydroxylation of prolyl residues was only slightly decreased in dexamethasone treated animals, and that the specific activity of the intracellular free proline pool and the intracellular degradation of collagen were unchanged. To address the mechanisms of the inhibition of collagen biosynthesis, specific binding of dexamethasone to glucocorticoid receptors in chick embryo tendon and cartilage cells was studied in a whole cell assay using [3H]dexamethasone as the ligand. Matrix-free tendon and cartilage cells had approximately 19,000 and 15,000 receptor sites per cell, respectively, and the binding affinities (Kd) for dexamethasone in tendon and cartilage cells were 2.9 x 10(-9) and 2.3 x 10(-9) M. Comparable values were obtained using a cytosol binding assay. The nuclear binding of dexamethasone in tendon and cartilage cells were similar. The results suggest that the dexamethasone-induced inhibition of collagen production is primarily due to decreased levels of functional procollagen mRNA, possibly resulting from receptor-mediated inhibition of the gene expression on the transcriptional level. FAU - Oikarinen, A I AU - Oikarinen AI AD - Department of Dermatology, University of Oulu, Finland. FAU - Vuorio, E I AU - Vuorio EI FAU - Zaragoza, E J AU - Zaragoza EJ FAU - Palotie, A AU - Palotie A FAU - Chu, M L AU - Chu ML FAU - Uitto, J AU - Uitto J LA - eng GR - AM-28450/AM/NIADDK NIH HHS/United States GR - AM-35297/AM/NIADDK NIH HHS/United States GR - GM-28833/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - Biochem Pharmacol JT - Biochemical pharmacology JID - 0101032 RN - 0 (Procollagen) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Glucocorticoid) RN - 7S5I7G3JQL (Dexamethasone) RN - 9007-34-5 (Collagen) SB - IM MH - Animals MH - Binding, Competitive MH - Cartilage/*metabolism MH - Cell Nucleus/metabolism MH - Chick Embryo MH - Collagen/*biosynthesis MH - Dexamethasone/*pharmacology MH - Fibroblasts/*metabolism MH - Gene Expression Regulation/drug effects MH - In Vitro Techniques MH - Procollagen/metabolism MH - RNA, Messenger/analysis MH - Receptors, Glucocorticoid/*physiology EDAT- 1988/04/15 00:00 MHDA- 1988/04/15 00:01 CRDT- 1988/04/15 00:00 PHST- 1988/04/15 00:00 [pubmed] PHST- 1988/04/15 00:01 [medline] PHST- 1988/04/15 00:00 [entrez] AID - 0006-2952(88)90006-8 [pii] AID - 10.1016/0006-2952(88)90006-8 [doi] PST - ppublish SO - Biochem Pharmacol. 1988 Apr 15;37(8):1451-62. doi: 10.1016/0006-2952(88)90006-8. PMID- 18236465 OWN - NLM STAT- MEDLINE DCOM- 20080522 LR - 20220309 IS - 0148-639X (Print) IS - 0148-639X (Linking) VI - 37 IP - 4 DP - 2008 Apr TI - Drug-screening platform based on the contractility of tissue-engineered muscle. PG - 438-47 LID - 10.1002/mus.20931 [doi] AB - A tissue-based approach to in vitro drug screening allows for determination of the cumulative positive and negative effects of a drug at the tissue rather than the cellular or subcellular level. Skeletal muscle myoblasts were tissue-engineered into three-dimensional muscle with parallel myofibers generating directed forces. When grown attached to two flexible micro-posts (mu posts) acting as artificial tendons in a 96-well plate format, the miniature bioartificial muscles (mBAMs) generated tetanic (active) forces upon electrical stimulation measured with a novel image-based motion detection system. mBAM myofiber hypertrophy and active force increased in response to insulin-like growth factor 1. In contrast, mBAM deterioration and weakness was observed with a cholesterol-lowering statin. The results described in this study demonstrate the integration of tissue engineering and biomechanical testing into a single platform for the screening of compounds affecting muscle strength. FAU - Vandenburgh, Herman AU - Vandenburgh H AD - Department of Pathology, RISE Research Building, Brown Medical School/Miriam Hospital, Providence, RI 02906, USA. herman_vandenburgh@brown.edu FAU - Shansky, Janet AU - Shansky J FAU - Benesch-Lee, Frank AU - Benesch-Lee F FAU - Barbata, Victoria AU - Barbata V FAU - Reid, Jonathan AU - Reid J FAU - Thorrez, Lieven AU - Thorrez L FAU - Valentini, Robert AU - Valentini R FAU - Crawford, Gregory AU - Crawford G LA - eng GR - R41 AR 053386/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - Muscle Nerve JT - Muscle & nerve JID - 7803146 RN - 0 (Heptanoic Acids) RN - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) RN - 0 (Pyrroles) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - A0JWA85V8F (Atorvastatin) SB - IM MH - Animals MH - Atorvastatin MH - Biological Assay/instrumentation/*methods MH - Cells, Cultured MH - Drug Evaluation, Preclinical/instrumentation/*methods MH - Electric Stimulation MH - Heptanoic Acids/pharmacology MH - Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology MH - Insulin-Like Growth Factor I/pharmacology MH - Male MH - Mice MH - Mice, Inbred C3H MH - Muscle Contraction/*drug effects MH - Muscular Atrophy/*drug therapy/physiopathology MH - Myoblasts/cytology/drug effects MH - Pyrroles/pharmacology MH - Tissue Engineering/instrumentation/*methods EDAT- 2008/02/01 09:00 MHDA- 2008/05/23 09:00 CRDT- 2008/02/01 09:00 PHST- 2008/02/01 09:00 [pubmed] PHST- 2008/05/23 09:00 [medline] PHST- 2008/02/01 09:00 [entrez] AID - 10.1002/mus.20931 [doi] PST - ppublish SO - Muscle Nerve. 2008 Apr;37(4):438-47. doi: 10.1002/mus.20931. PMID- 10089163 OWN - NLM STAT- MEDLINE DCOM- 19990714 LR - 20131121 IS - 1090-7807 (Print) IS - 1090-7807 (Linking) VI - 137 IP - 2 DP - 1999 Apr TI - A study of dipolar interactions and dynamic processes of water molecules in tendon by 1H and 2H homonuclear and heteronuclear multiple-quantum-filtered NMR spectroscopy. PG - 295-310 AB - The effect of proton exchange on the measurement of 1H-1H, 1H-2H, and 2H-2H residual dipolar interactions in water molecules in bovine Achilles tendons was investigated using double-quantum-filtered (DQF) NMR and new pulse sequences based on heteronuclear and homonuclear multiple-quantum filtering (MQF). Derivation of theoretical expressions for these techniques allowed evaluation of the 1H-1H and 1H-2H residual dipolar interactions and the proton exchange rate at a temperature of 24 degrees C and above, where no dipolar splitting is evident. The values obtained for these parameters at 24 degrees C were 300 and 50 Hz and 3000 s-1, respectively. The results for the residual dipolar interactions were verified by repeating the above measurements at a temperature of 1.5 degrees C, where the spectra of the H2O molecules were well resolved, so that the 1H-1H dipolar interaction could be determined directly from the observed splitting. Analysis of the MQF experiments at 1.5 degrees C, where the proton exchange was in the intermediate regime for the 1H-2H dipolar interaction, confirmed the result obtained at 24 degrees C for this interaction. A strong dependence of the intensities of the MQF signals on the proton exchange rate, in the intermediate and the fast exchange regimes, was observed and theoretically interpreted. This leads to the conclusion that the MQF techniques are mostly useful for tissues where the residual dipolar interaction is not significantly smaller than the proton exchange rate. Dependence of the relaxation times and signal intensities of the MQF experiments on the orientation of the tendon with respect to the magnetic field was observed and analyzed. One of the results of the theoretical analysis is that, in the fast exchange regime, the signal decay rates in the MQF experiments as well as in the spin echo or CPMG pulse sequences (T2) depend on the orientation as the square of the second-rank Legendre polynomial. CI - Copyright 1999 Academic Press. FAU - Eliav, U AU - Eliav U AD - School of Chemistry, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel. FAU - Navon, G AU - Navon G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - J Magn Reson JT - Journal of magnetic resonance (San Diego, Calif. : 1997) JID - 9707935 RN - 0 (Protein Sorting Signals) RN - 0 (Protons) RN - 059QF0KO0R (Water) RN - AR09D82C7G (Deuterium) RN - J65BV539M3 (Deuterium Oxide) SB - IM MH - Achilles Tendon/*chemistry/*ultrastructure MH - Animals MH - Binomial Distribution MH - Cattle MH - Deuterium MH - Deuterium Oxide MH - Hydrogen Bonding MH - Models, Biological MH - Molecular Structure MH - *Nuclear Magnetic Resonance, Biomolecular/instrumentation/methods MH - Protein Sorting Signals MH - Protons MH - Signal Processing, Computer-Assisted MH - *Water EDAT- 1999/03/25 00:00 MHDA- 1999/03/25 00:01 CRDT- 1999/03/25 00:00 PHST- 1999/03/25 00:00 [pubmed] PHST- 1999/03/25 00:01 [medline] PHST- 1999/03/25 00:00 [entrez] AID - S1090-7807(98)91681-0 [pii] AID - 10.1006/jmre.1998.1681 [doi] PST - ppublish SO - J Magn Reson. 1999 Apr;137(2):295-310. doi: 10.1006/jmre.1998.1681. PMID- 1918137 OWN - NLM STAT- MEDLINE DCOM- 19911031 LR - 20190508 IS - 0021-9525 (Print) IS - 1540-8140 (Electronic) IS - 0021-9525 (Linking) VI - 115 IP - 1 DP - 1991 Oct TI - The complete primary structure of type XII collagen shows a chimeric molecule with reiterated fibronectin type III motifs, von Willebrand factor A motifs, a domain homologous to a noncollagenous region of type IX collagen, and short collagenous domains with an Arg-Gly-Asp site. PG - 209-21 AB - Extracellular matrix molecules are generally categorized as collagens, elastin, proteoglycans, or other noncollagenous structural/cell interaction proteins. Many of these extracellular proteins contain distinctive repetitive modules, which can sometimes be found in other proteins. We describe the complete primary structure of an alpha 1 chain of type XII collagen from chick embryonic fibroblasts. This large, structurally chimeric molecule identified by cDNA analysis combines previously unrelated molecular domains into a single large protein 3,124 residues long (approximately 340 kD). The deduced chicken type XII collagen sequence starts at the amino terminus with one unit of the type III motif of fibronectin, which is followed by one unit homologous to the von Willebrand factor A domain, then one more fibronectin type III module, a second A domain from von Willebrand factor, 6 units of type III motif and a third A domain, 10 consecutive units of type III motif and a fourth A domain, a domain homologous to the NC4 domain peptide of type IX collagen, and finally two short collagenous regions previously described as part of the partially sequenced collagen type XII molecule; an Arg-Gly-Asp potential cell adhesive recognition sequence is present in a hydrophilic region at the terminus of one collagenous domain. Antibodies raised to type XII collagen synthesized in a bacterial expression system recognized not only previously reported bands (220 kD et cetera) in tendons, but also bands with apparently different molecular sizes in fibroblasts and 4-d embryos. The antibodies stained a wide variety of extracellular matrices in embryos in patterns distinct from those of fibronectin or interstitial collagens. They prominently stained extracellular matrix associated with certain neuronal tissues, such as axons from dorsal root ganglia and neural tube. These studies identify a novel chimeric type of molecule that contains both adhesion molecule and collagen motifs in one protein. Its structure blurs current classification schemes for extracellular proteins and underscores the potentially large diversity possible in these molecules. FAU - Yamagata, M AU - Yamagata M AD - Institute for Molecular Science of Medicine, Aichi Medical University, Japan. FAU - Yamada, K M AU - Yamada KM FAU - Yamada, S S AU - Yamada SS FAU - Shinomura, T AU - Shinomura T FAU - Tanaka, H AU - Tanaka H FAU - Nishida, Y AU - Nishida Y FAU - Obara, M AU - Obara M FAU - Kimata, K AU - Kimata K LA - eng SI - GENBANK/D00824 SI - GENBANK/M60692 SI - GENBANK/M60693 SI - GENBANK/M60694 SI - GENBANK/M60695 SI - GENBANK/M60696 SI - GENBANK/M60697 SI - GENBANK/S56596 SI - GENBANK/S56633 SI - GENBANK/S66765 PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Cell Biol JT - The Journal of cell biology JID - 0375356 RN - 0 (Cell Adhesion Molecules) RN - 0 (Fibronectins) RN - 0 (Oligonucleotides) RN - 0 (Oligopeptides) RN - 0 (Recombinant Proteins) RN - 0 (von Willebrand Factor) RN - 78VO7F77PN (arginyl-glycyl-aspartic acid) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Cell Adhesion MH - Cell Adhesion Molecules/chemistry/ultrastructure MH - Chick Embryo MH - Cloning, Molecular MH - Collagen/*chemistry/genetics/metabolism/ultrastructure MH - DNA/genetics MH - Fibronectins/chemistry/ultrastructure MH - Molecular Sequence Data MH - Oligonucleotides/chemistry MH - Oligopeptides MH - Polymerase Chain Reaction MH - Recombinant Proteins/immunology MH - Sequence Alignment MH - Tissue Distribution MH - von Willebrand Factor/chemistry/ultrastructure PMC - PMC2289926 EDAT- 1991/10/01 00:00 MHDA- 1991/10/01 00:01 PMCR- 1992/04/01 CRDT- 1991/10/01 00:00 PHST- 1991/10/01 00:00 [pubmed] PHST- 1991/10/01 00:01 [medline] PHST- 1991/10/01 00:00 [entrez] PHST- 1992/04/01 00:00 [pmc-release] AID - 92011862 [pii] AID - 10.1083/jcb.115.1.209 [doi] PST - ppublish SO - J Cell Biol. 1991 Oct;115(1):209-21. doi: 10.1083/jcb.115.1.209. PMID- 32046672 OWN - NLM STAT- MEDLINE DCOM- 20210312 LR - 20210312 IS - 1471-2431 (Electronic) IS - 1471-2431 (Linking) VI - 20 IP - 1 DP - 2020 Feb 11 TI - The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan. PG - 64 LID - 10.1186/s12887-020-1962-0 [doi] LID - 64 AB - BACKGROUND: To evaluate the safety of using fluoroquinolones in pediatric population in Taiwan. METHODS: Patients aged 0~18 years old with fluoroquinolones prescriptions ≥5 consecutive days during year 2000 to 2013 were selected from the National Health Insurance Research Database, 4-time case number were selected as controls. We evaluated the patient's outcome after the use of fluoroquinolones by reviewing a newly diagnosis of the following collagen-associated adverse events by International Classification of Diseases, Ninth Revision, Clinical Modification codes, covering tendons rupture, retinal detachments, gastrointestinal tract perforation, aortic aneurysm or dissection. RESULTS: Of the enrolled patients (n = 167,105), collagen-associated adverse effects developed in 85 cases (0.051%) in 6-month tracking, including 0.051% in the fluoroquinolones study cohort (17 in 33,421) and 0.051% (68 in 133,684) in the fluoroquinolones free comparison cohort. The crude hazard ratio for collagen-associated adverse events in the fluoroquinolones group was 0.997 (0.586-1.696; p = 0.990). After adjusting for age, sex, catastrophic illness, low-income household, seasons, levels of urbanization, and healthcare, the corrected hazard ratio in 6-month tracking with FQs was 1.330 (95% CI; 0.778-2.276; p = 0.255). CONCLUSIONS: There is no significant difference of collagen-associated adverse effects between fluoroquinolones group and fluoroquinolones free group from our data. We propose that fluoroquinolones for pediatric population in clinical practice may be not so harmful as previous references reported. FAU - Yu, Pei-Han AU - Yu PH AD - Master Program of Big Data in Biomedicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. AD - Department of Pharmacy, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan. FAU - Hu, Chih-Fen AU - Hu CF AD - Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. FAU - Liu, Jen-Wei AU - Liu JW AD - Department of Pharmacy, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, Taiwan. AD - School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. FAU - Chung, Chi-Hsiang AU - Chung CH AD - School of Public Health, National Defense Medical Center, Taipei, 11490, Taiwan. FAU - Chen, Yong-Chen AU - Chen YC AD - School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan. AD - Big Data Research Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. FAU - Sun, Chien-An AU - Sun CA AD - Big Data Research Center, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. AD - Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. FAU - Chien, Wu-Chien AU - Chien WC AUID- ORCID: 0000-0002-3286-0780 AD - School of Public Health, National Defense Medical Center, Taipei, 11490, Taiwan. chienwu@ndmctsgh.edu.tw. AD - Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, 11490, Taiwan. chienwu@ndmctsgh.edu.tw. AD - Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, No 325, Section 2, Cheng-Kung Road, Taipei, 11490, Taiwan, Republic of China. chienwu@ndmctsgh.edu.tw. LA - eng GR - TSGH-C108-003, TSGH-B-109010/Tri-Service General Hospital/International PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200211 PL - England TA - BMC Pediatr JT - BMC pediatrics JID - 100967804 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) RN - 9007-34-5 (Collagen) SB - IM MH - Adolescent MH - *Anti-Bacterial Agents/adverse effects MH - Child MH - Cohort Studies MH - *Collagen/drug effects MH - Female MH - *Fluoroquinolones/adverse effects MH - Humans MH - Incidence MH - Male MH - Taiwan/epidemiology PMC - PMC7011365 OTO - NOTNLM OT - Collagen-associated adverse effects OT - Fluoroquinolones OT - Pediatric patients OT - Prescription safety issue COIS- The authors declare that they have no competing interests. EDAT- 2020/02/13 06:00 MHDA- 2021/03/13 06:00 PMCR- 2020/02/11 CRDT- 2020/02/13 06:00 PHST- 2019/11/13 00:00 [received] PHST- 2020/02/06 00:00 [accepted] PHST- 2020/02/13 06:00 [entrez] PHST- 2020/02/13 06:00 [pubmed] PHST- 2021/03/13 06:00 [medline] PHST- 2020/02/11 00:00 [pmc-release] AID - 10.1186/s12887-020-1962-0 [pii] AID - 1962 [pii] AID - 10.1186/s12887-020-1962-0 [doi] PST - epublish SO - BMC Pediatr. 2020 Feb 11;20(1):64. doi: 10.1186/s12887-020-1962-0. PMID- 18628360 OWN - NLM STAT- MEDLINE DCOM- 20110701 LR - 20100630 IS - 1473-0480 (Electronic) IS - 0306-3674 (Linking) VI - 44 IP - 9 DP - 2010 Jul TI - Elevation of systemic matrix metalloproteinases 2 and 7 and tissue inhibitor of metalloproteinase 2 in patients with a history of Achilles tendon rupture: pilot study. PG - 669-72 LID - 10.1136/bjsm.2008.049411 [doi] AB - OBJECTIVES: In this study, serum levels of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) between patients with a history of Achilles tendon rupture and blood donor controls were compared, and their relation to mechanical properties of the tendons during healing were studied. METHODS: More than 3 years after injury, serum levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9 and MMP-13, TIMP-1 and TIMP-2 in eight patients who had Achilles tendon rupture were measured. Twelve blood donors served as controls. During the early phase of healing, the tendon modulus of elasticity was calculated from radiostereometric data and tendon cross-sectional area. RESULTS: Patients with a history of Achilles tendon rupture had increased levels of MMP-2 (median difference 10%, p=0.01), MMP-7 (median difference 15%, p=0.02) and TIMP-2 (median difference 36%, p=0.02), compared with controls. Levels of MMP-7, measured 3 years after injury, correlated inversely to tendon modulus of elasticity (r(s)=20.83, p=0.02) and positively to tendon elongation (r(s)=0.74, p=0.05) during the early phase of healing. There was a trend towards positive correlation between MMP-7 and cross-sectional area during the early phase of healing (r(s)=0.67, p=0.08). CONCLUSIONS: Patients with a history of Achilles tendon rupture appear to have elevated levels of MMP-2, MMP-7 and TIMP-2 in serum. In these pilot data, the view that the MMP-TIMP system is involved in tendinopathy is supported and that disturbances in proteolytic control might be generalised are suggested. FAU - Pasternak, B AU - Pasternak B AD - Orthopaedics and Sports Medicine, Department of Clinical and Experimental Medicine, Linköping University, SE-58185 Linköping, Sweden. pasternak@gmail.com FAU - Schepull, T AU - Schepull T FAU - Eliasson, P AU - Eliasson P FAU - Aspenberg, P AU - Aspenberg P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080715 PL - England TA - Br J Sports Med JT - British journal of sports medicine JID - 0432520 RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - EC 3.4.24.23 (Matrix Metalloproteinase 7) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Achilles Tendon/*injuries MH - Adult MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Male MH - Matrix Metalloproteinase 2/*metabolism MH - Matrix Metalloproteinase 7/*metabolism MH - Middle Aged MH - Pilot Projects MH - Prospective Studies MH - Rupture/enzymology MH - Tissue Inhibitor of Metalloproteinase-2/*metabolism MH - Wound Healing/physiology EDAT- 2008/07/17 09:00 MHDA- 2011/07/02 06:00 CRDT- 2008/07/17 09:00 PHST- 2008/07/17 09:00 [pubmed] PHST- 2011/07/02 06:00 [medline] PHST- 2008/07/17 09:00 [entrez] AID - bjsm.2008.049411 [pii] AID - 10.1136/bjsm.2008.049411 [doi] PST - ppublish SO - Br J Sports Med. 2010 Jul;44(9):669-72. doi: 10.1136/bjsm.2008.049411. Epub 2008 Jul 15. PMID- 11128543 OWN - NLM STAT- MEDLINE DCOM- 20010524 LR - 20190910 IS - 0003-1488 (Print) IS - 0003-1488 (Linking) VI - 217 IP - 10 DP - 2000 Nov 15 TI - Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeletal variables in adult horses. PG - 1514-21 AB - OBJECTIVE: To evaluate clinical safety of administration of injectable enrofloxacin. DESIGN: Randomized controlled clinical trial. ANIMALS: 24 adult horses. PROCEDURES: Healthy horses were randomly allocated into 4 equal groups that received placebo injections (control) or IV administration of enrofloxacin (5 mg/kg [2.3 mg/lb], 15 mg/kg [6.8 mg/lb], or 25 mg/kg [11.4 mg/lb] of body weight, q 24 h) for 21 days. Joint angles, cross-sectional area of superficial and deep digital flexor and calcaneal tendons, carpal or tarsal osteophytes or lucency, and midcarpal and tarsocrural articular cartilage lesions were measured. Physical and lameness examinations were performed daily. Measurements were repeated after day 21, and articular cartilage and bone biopsy specimens were examined. RESULTS: Enrofloxacin did not induce changes in most variables during administration or for 7 days after administration. One horse (dosage, 15 mg/kg) developed lameness and cellulitis around the tarsal plantar ligament during the last week of administration. One horse (dosage, 15 mg/kg) developed mild superficial digital flexor tendinitis, and 1 horse (dosage, 25 mg/kg) developed tarsal sheath effusion without lameness 3 days after the last administration. High doses of enrofloxacin (15 and 25 mg/kg) administered by bolus injection intermittently induced transient neurologic signs that completely resolved within 10 minutes without long-term effects. Slower injection and dilution of the dose ameliorated the neurologic signs. Adverse reactions were not detected with a 5 mg/kg dose administered IV as a bolus. CONCLUSIONS AND CLINICAL RELEVANCE: Enrofloxacin administered IV once daily at the rate of 5 mg/kg for 3 weeks is safe in adult horses. FAU - Bertone, A L AU - Bertone AL AD - Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus 43210, USA. FAU - Tremaine, W H AU - Tremaine WH FAU - Macoris, D G AU - Macoris DG FAU - Simmons, E J AU - Simmons EJ FAU - Ewert, K M AU - Ewert KM FAU - Herr, L G AU - Herr LG FAU - Weisbrode, S E AU - Weisbrode SE LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 0 (Anti-Infective Agents) RN - 0 (Fluoroquinolones) RN - 0 (Quinolones) RN - 3DX3XEK1BN (Enrofloxacin) SB - IM MH - Animals MH - Anti-Infective Agents/administration & dosage/adverse effects/*pharmacology MH - Biopsy/veterinary MH - Blood Cell Count MH - Blood Chemical Analysis MH - Bone and Bones/pathology MH - Cartilage, Articular/pathology MH - Enrofloxacin MH - Evaluation Studies as Topic MH - Female MH - *Fluoroquinolones MH - Horses/*physiology MH - Injections/veterinary MH - Joints/diagnostic imaging/physiology MH - Lameness, Animal MH - Male MH - Muscle, Skeletal/*drug effects MH - Quinolones/administration & dosage/adverse effects/*pharmacology MH - Radiography/veterinary MH - Ultrasonography EDAT- 2000/01/11 19:15 MHDA- 2001/05/26 10:01 CRDT- 2000/01/11 19:15 PHST- 2000/01/11 19:15 [pubmed] PHST- 2001/05/26 10:01 [medline] PHST- 2000/01/11 19:15 [entrez] AID - 10.2460/javma.2000.217.1514 [doi] PST - ppublish SO - J Am Vet Med Assoc. 2000 Nov 15;217(10):1514-21. doi: 10.2460/javma.2000.217.1514. PMID- 26711065 OWN - NLM STAT- MEDLINE DCOM- 20160223 LR - 20181202 IS - 0376-2491 (Print) IS - 0376-2491 (Linking) VI - 95 IP - 29 DP - 2015 Aug 4 TI - [Perspective randomized control study on different NSAIDs drugs after rotator cuff repair]. PG - 2337-41 AB - OBJECTIVE: To compare the effectiveness and safety of ibuprofen, celecoxib and flurbiprofen axetil after arthroscopic rotator cuff repair. METHODS: From Dec., 2012 to Dec., 2012, 63 arthroscopy rotator cuff repaired patients in Department of Orthopedics&Traumatology, Beijing Jishuitan Hospital, were selected and divided randomized into 3 groups:flurbiprofen axetil, ibuprofen and celecoxib. Each group had 21 patients. All groups take drugs 5 days continuously after operation. In first five days postoperatively, visual analogue scale (VAS) was used to compare pain alleviation. The side effects were assessed among three groups. VAS, Shoulder evaluation functional score, range of shoulder forward elevation, external rotation and internal rotation were recorded, compared between the same patients preoperatively and postoperatively and compared also among three groups. RESULTS: Pain was relieved postoperatively with time being in all patients. From 4 day postoperatively, flurbiprofen axetil showed significant difference on pain relieving compared with ibuprofen and celecoxib (P<0.05). Side effects of ibuprofen, celecoxib and flurbiprofen axetil was 33.3%, 14.3% and 9.5% separately. No significant difference was found among three groups. Preoperatively, VAS=7.2, SST=6.5, Constant=67.6, UCLA=17; FE=132.6°, ER=37.7°, IR=L1on average. One year postoperatively, in ibuprofen, celecoxib and flurbiprofen axetil group, VAS was 2.0, 2.1, 1.9; SST was 9.2, 8.5, 10.5; Constant was 82.7, 91.2, 90.5; UCLA was 29.9, 33.2, 30.3; FE was 151.2°, 150.0°, 160.3°, ER was 49.2°, 50.7°, 56.7°; IR was ip to T12, T12, T8 level separately. All patients showed significant improvement on VAS, function evaluation score and range of motion one year postoperatively and no significant difference were found among three groups. CONCLUSION: Flurbiprofen axetil showed better result compared with ibuprofen and celecoxib on pain control, although all three COX inhibitors are highly-efficient and safe for rotator cuff repaired patients. There is no significant difference among three groups according to side effects and no delayed on tendon healing. FAU - Lu, Yi AU - Lu Y AD - Department of Orthopedics&Traumatology, Beijing Jishuitan Hospital, Beijing 100035, China. FAU - Li, Yue AU - Li Y AD - Department of Orthopedics&Traumatology, Beijing Jishuitan Hospital, Beijing 100035, China. FAU - Li, Fenglong AU - Li F AD - Department of Orthopedics&Traumatology, Beijing Jishuitan Hospital, Beijing 100035, China. FAU - Jiang, Chunyan AU - Jiang C AD - Department of Orthopedics&Traumatology, Beijing Jishuitan Hospital, Beijing 100035, China; Email: chunyanj@hotmail.com. LA - chi PT - Journal Article PT - Randomized Controlled Trial PL - China TA - Zhonghua Yi Xue Za Zhi JT - Zhonghua yi xue za zhi JID - 7511141 RN - 0 (Anti-Inflammatory Agents, Non-Steroidal) RN - 5GRO578KLP (Flurbiprofen) RN - I0OU31PUI5 (flurbiprofen axetil) SB - IM MH - Anti-Inflammatory Agents, Non-Steroidal MH - Arthroplasty MH - Beijing MH - Flurbiprofen/analogs & derivatives MH - Humans MH - Pain Measurement MH - Pain, Postoperative MH - Range of Motion, Articular MH - *Rotator Cuff MH - Tendons MH - Treatment Outcome EDAT- 2015/12/30 06:00 MHDA- 2016/02/26 06:00 CRDT- 2015/12/30 06:00 PHST- 2015/12/30 06:00 [entrez] PHST- 2015/12/30 06:00 [pubmed] PHST- 2016/02/26 06:00 [medline] PST - ppublish SO - Zhonghua Yi Xue Za Zhi. 2015 Aug 4;95(29):2337-41. PMID- 21063098 OWN - NLM STAT- MEDLINE DCOM- 20110302 LR - 20190212 IS - 1421-9778 (Electronic) IS - 1015-8987 (Linking) VI - 26 IP - 4-5 DP - 2010 TI - Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. PG - 609-18 LID - 10.1159/000322328 [doi] AB - Periplocin is one of cardenolides isolated from cortex periplocae which is used for treatment of rheumatoid arthritis and reinforcement of bones and tendons in traditional medicine. Here, we investigated the anti-tumor activity of periplocin against lung cancer cells bothin vitro and in vivo, and explored its anti-cancer mechanism. Periplocin inhibited the growth of lung cancer cells and induced their apoptosis in time- and dose-dependent manners by cell cycle arrest in G0/G1 phase. Periplocin exhibited anti-tumor activity both in human (A549) and mouse (LL/2) lung cancer xenograft models. Immunohistochemical analysis revealed that intratumoral angiogenesis was significantly suppressed. Furthermore, anti-cancer activity mediated by periplocin was associated with decreased level of phosphorylated AKT and ERK both in vitro and in vivo, which were important for cell growth and survival. Moreover, periplocin induced apoptosis by downregulating Bcl-2 and upregulating Bax, leading to activation of caspase-3 and caspase-9. These findings suggested that periplocin could inhibit the growth of lung cancer both in vitro and in vivo, which could be attributed to the inhibition of proliferation and the induction of apoptosis signaling pathway, such as AKT and ERK. These observations provide further evidence on the anti-tumor effect of periplocin, and it may be of importance to further explore its potential role as a therapeutic agent for cancer. CI - Copyright © 2010 S. Karger AG, Basel. FAU - Lu, Ze J AU - Lu ZJ AD - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. FAU - Zhou, Yan AU - Zhou Y FAU - Song, Qi AU - Song Q FAU - Qin, Zhao AU - Qin Z FAU - Zhang, Hong AU - Zhang H FAU - Zhou, Yong J AU - Zhou YJ FAU - Gou, Lan T AU - Gou LT FAU - Yang, Jin L AU - Yang JL FAU - Luo, Feng AU - Luo F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20101029 PL - Germany TA - Cell Physiol Biochem JT - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology JID - 9113221 RN - 0 (Antineoplastic Agents) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Saponins) RN - 0 (bcl-2-Associated X Protein) RN - 199X940O3K (periplocin) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases) RN - EC 3.4.22.- (Caspase 3) RN - EC 3.4.22.- (Caspase 9) SB - IM MH - Animals MH - Antineoplastic Agents/*therapeutic use MH - Apoptosis MH - Caspase 3/metabolism MH - Caspase 9/metabolism MH - Cell Survival MH - Extracellular Signal-Regulated MAP Kinases/*antagonists & inhibitors/metabolism MH - G1 Phase MH - Humans MH - Lung Neoplasms/*drug therapy/pathology MH - Mice MH - Mice, Nude MH - Proto-Oncogene Proteins c-akt/*antagonists & inhibitors/metabolism MH - Proto-Oncogene Proteins c-bcl-2/metabolism MH - Resting Phase, Cell Cycle MH - Saponins/*therapeutic use MH - Signal Transduction/drug effects MH - Transplantation, Heterologous MH - bcl-2-Associated X Protein/metabolism EDAT- 2010/11/11 06:00 MHDA- 2011/03/03 06:00 CRDT- 2010/11/11 06:00 PHST- 2010/08/17 00:00 [accepted] PHST- 2010/11/11 06:00 [entrez] PHST- 2010/11/11 06:00 [pubmed] PHST- 2011/03/03 06:00 [medline] AID - 000322328 [pii] AID - 10.1159/000322328 [doi] PST - ppublish SO - Cell Physiol Biochem. 2010;26(4-5):609-18. doi: 10.1159/000322328. Epub 2010 Oct 29. PMID- 39498787 OWN - NLM STAT- MEDLINE DCOM- 20250425 LR - 20250630 IS - 1532-950X (Electronic) IS - 0161-3499 (Print) IS - 0161-3499 (Linking) VI - 54 IP - 1 DP - 2025 Jan TI - Intrathecal enalapril reduces adhesion formation in experimentally induced digital flexor tendon sheath injuries in horses. PG - 141-154 LID - 10.1111/vsu.14186 [doi] AB - OBJECTIVE: The objectives of the study were to describe a standing percutaneous adhesion induction model in the digital flexor tendon sheath (DFTS) of horses and to evaluate the effect of intrathecal administration of the angiotensin-converting enzyme (ACE) inhibitor enalapril on tendon healing and adhesion formation. STUDY DESIGN: Randomized, blinded, controlled experimental study. ANIMALS: Eight healthy horses. METHODS: A collagenase-induced adhesion model was implemented in the deep digital flexor tendon (DDFT) of both forelimbs under standing ultrasonographic guidance. Daily intrathecal injections of 5 mg enalapril (the treatment condition) were administered to a randomly assigned forelimb for 5 days, with the contralateral limb receiving an equivalent volume of 0.9% NaCl (the control). Lameness and limb circumference were recorded weekly. Horses were euthanized after 8 weeks and evaluated for gross digital flexor tendon sheath (DFTS) adhesions. Tendons were collected for histopathologic scoring of DDFT healing. Paired data were analyzed using a one-sided alternative sign test and longitudinal regression. RESULTS: Multiple DFTS adhesions were formed in control limbs of all horses. The median number of gross DFTS adhesions in treated limbs was less than in control limbs (p = .0039). The average reduction in limb circumference and lameness scores over time occurred faster in treated versus control limbs (p < .025). There were no differences in DDFT histopathologic scores between groups. CONCLUSION: The standing percutaneous DFTS adhesion induction model demonstrated that intrathecal enalapril reduced DFTS adhesion formation, lameness scores, and limb circumference over time. CLINICAL SIGNIFICANCE: Intrathecal enalapril administration may reduce morbidity in horses with naturally occurring tendon injuries. CI - © 2024 The Author(s). Veterinary Surgery published by Wiley Periodicals LLC on behalf of American College of Veterinary Surgeons. FAU - Willette, Jaclyn A AU - Willette JA AD - Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. FAU - Tsoi, Mayra AU - Tsoi M AD - Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, Lansing, Michigan, USA. FAU - Frobish, Daniel AU - Frobish D AD - Department of Statistics, College of Liberal Arts and Sciences, Grand Valley State University, Allendale, Michigan, USA. FAU - VanderBroek, Ashley R AU - VanderBroek AR AUID- ORCID: 0000-0001-9118-5685 AD - Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA. LA - eng GR - RH082218-VANDE/Robert & Janet Hafner Fund for Animal Health fund via the Endowed Research Funds/ PT - Journal Article PT - Randomized Controlled Trial, Veterinary DEP - 20241105 PL - United States TA - Vet Surg JT - Veterinary surgery : VS JID - 8113214 RN - 69PN84IO1A (Enalapril) RN - 0 (Angiotensin-Converting Enzyme Inhibitors) SB - IM MH - Animals MH - Horses/injuries MH - *Enalapril/administration & dosage/therapeutic use MH - *Horse Diseases/drug therapy/prevention & control MH - Tissue Adhesions/veterinary/prevention & control/drug therapy MH - *Tendon Injuries/veterinary/drug therapy MH - *Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use MH - Injections, Spinal/veterinary MH - Female MH - Male MH - Forelimb PMC - PMC11734880 COIS- The authors declare no conflicts of interest related to this report. EDAT- 2024/11/05 17:02 MHDA- 2025/01/15 18:20 PMCR- 2025/01/15 CRDT- 2024/11/05 06:43 PHST- 2024/09/21 00:00 [revised] PHST- 2024/03/28 00:00 [received] PHST- 2024/10/13 00:00 [accepted] PHST- 2025/01/15 18:20 [medline] PHST- 2024/11/05 17:02 [pubmed] PHST- 2024/11/05 06:43 [entrez] PHST- 2025/01/15 00:00 [pmc-release] AID - VSU14186 [pii] AID - 10.1111/vsu.14186 [doi] PST - ppublish SO - Vet Surg. 2025 Jan;54(1):141-154. doi: 10.1111/vsu.14186. Epub 2024 Nov 5. PMID- 38701045 OWN - NLM STAT- MEDLINE DCOM- 20240503 LR - 20240505 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 5 DP - 2024 TI - Human-Derived collagen hydrogel as an antibiotic vehicle for topical treatment of bacterial biofilms. PG - e0303039 LID - 10.1371/journal.pone.0303039 [doi] LID - e0303039 AB - The complexity of chronic wounds creates difficulty in effective treatments, leading to prolonged care and significant morbidity. Additionally, these wounds are incredibly prone to bacterial biofilm development, further complicating treatment. The current standard treatment of colonized superficial wounds, debridement with intermittent systemic antibiotics, can lead to systemic side-effects and often fails to directly target the bacterial biofilm. Furthermore, standard of care dressings do not directly provide adequate antimicrobial properties. This study aims to assess the capacity of human-derived collagen hydrogel to provide sustained antibiotic release to disrupt bacterial biofilms and decrease bacterial load while maintaining host cell viability and scaffold integrity. Human collagen harvested from flexor tendons underwent processing to yield a gellable liquid, and subsequently was combined with varying concentrations of gentamicin (50-500 mg/L) or clindamycin (10-100 mg/L). The elution kinetics of antibiotics from the hydrogel were analyzed using liquid chromatography-mass spectrometry. The gel was used to topically treat Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium perfringens in established Kirby-Bauer and Crystal Violet models to assess the efficacy of bacterial inhibition. 2D mammalian cell monolayers were topically treated, and cell death was quantified to assess cytotoxicity. Bacteria-enhanced in vitro scratch assays were treated with antibiotic-embedded hydrogel and imaged over time to assess cell death and mobility. Collagen hydrogel embedded with antibiotics (cHG+abx) demonstrated sustained antibiotic release for up to 48 hours with successful inhibition of both MRSA and C. perfringens biofilms, while remaining bioactive up to 72 hours. Administration of cHG+abx with antibiotic concentrations up to 100X minimum inhibitory concentration was found to be non-toxic and facilitated mammalian cell migration in an in vitro scratch model. Collagen hydrogel is a promising pharmaceutical delivery vehicle that allows for safe, precise bacterial targeting for effective bacterial inhibition in a pro-regenerative scaffold. CI - Copyright: © 2024 Jarman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Jarman, Evan AU - Jarman E AUID- ORCID: 0009-0008-4618-2176 AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. FAU - Burgess, Jordan AU - Burgess J AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. FAU - Sharma, Ayushi AU - Sharma A AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. FAU - Hayashigatani, Kate AU - Hayashigatani K AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. FAU - Singh, Amar AU - Singh A AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. FAU - Fox, Paige AU - Fox P AUID- ORCID: 0000-0002-4166-8547 AD - Division of Plastic & Reconstructive Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California, United States of America. AD - Division of Plastic & Reconstructive Surgery, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States of America. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20240503 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Anti-Bacterial Agents) RN - 9007-34-5 (Collagen) RN - 0 (Hydrogels) RN - 3U02EL437C (Clindamycin) RN - 0 (Gentamicins) SB - IM MH - *Biofilms/drug effects MH - *Anti-Bacterial Agents/pharmacology/administration & dosage MH - Humans MH - *Collagen/chemistry MH - *Hydrogels/chemistry MH - *Methicillin-Resistant Staphylococcus aureus/drug effects MH - Clindamycin/pharmacology/administration & dosage MH - Microbial Sensitivity Tests MH - Administration, Topical MH - Gentamicins/pharmacology/administration & dosage PMC - PMC11068178 COIS- The authors have declared that no competing interests exist. EDAT- 2024/05/03 18:47 MHDA- 2024/05/03 18:48 PMCR- 2024/05/03 CRDT- 2024/05/03 13:23 PHST- 2024/02/11 00:00 [received] PHST- 2024/04/13 00:00 [accepted] PHST- 2024/05/03 18:48 [medline] PHST- 2024/05/03 18:47 [pubmed] PHST- 2024/05/03 13:23 [entrez] PHST- 2024/05/03 00:00 [pmc-release] AID - PONE-D-24-03818 [pii] AID - 10.1371/journal.pone.0303039 [doi] PST - epublish SO - PLoS One. 2024 May 3;19(5):e0303039. doi: 10.1371/journal.pone.0303039. eCollection 2024. PMID- 22480275 OWN - NLM STAT- MEDLINE DCOM- 20120808 LR - 20211021 IS - 1471-2474 (Electronic) IS - 1471-2474 (Linking) VI - 13 DP - 2012 Apr 5 TI - Local biochemical and morphological differences in human Achilles tendinopathy: a case control study. PG - 53 LID - 10.1186/1471-2474-13-53 [doi] AB - BACKGROUND: The incidence of Achilles tendinopathy is high and underlying etiology as well as biochemical and morphological pathology associated with the disease is largely unknown. The aim of the present study was to describe biochemical and morphological differences in chronic Achilles tendinopathy. The expressions of growth factors, inflammatory mediators and tendon morphology were determined in both chronically diseased and healthy tendon parts. METHODS: Thirty Achilles tendinopathy patients were randomized to an expression-study (n = 16) or a structural-study (n = 14). Biopsies from two areas in the Achilles tendon were taken and structural parameters: fibril density, fibril size, volume fraction of cells and the nucleus/cytoplasm ratio of cells were determined. Further gene expressions of various genes were analyzed. RESULTS: Significantly smaller collagen fibrils and a higher volume fraction of cells were observed in the tendinopathic region of the tendon. Markers for collagen and its synthesis collagen 1, collagen 3, fibronectin, tenascin-c, transforming growth factor-β fibromodulin, and markers of collagen breakdown matrix metalloproteinase-2, matrix metalloproteinase-9 and metallopeptidase inhibitor-2 were significantly increased in the tendinopathic region. No altered expressions of markers for fibrillogenesis, inflammation or wound healing were observed. CONCLUSION: The present study indicates that an increased expression of factors stimulating the turnover of connective tissue is present in the diseased part of tendinopathic tendons, associated with an increased number of cells in the injured area as well as an increased number of smaller and thinner fibrils in the diseased tendon region. As no fibrillogenesis, inflammation or wound healing could be detected, the present data supports the notion that tendinopathy is an ongoing degenerative process. TRIAL REGISTRATION: Current Controlled Trials ISRCTN20896880. FAU - J, Pingel AU - J P AD - Institute of Sports Medicine, Department of Orthopedic Surgery M, Bispebjerg Hospital and Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. jessica.pingel@gmx.de FAU - U, Fredberg AU - U F FAU - K, Qvortrup AU - K Q FAU - J O, Larsen AU - J O L FAU - P, Schjerling AU - P S FAU - K, Heinemeier AU - K H FAU - M, Kjaer AU - M K FAU - H, Langberg AU - H L LA - eng SI - ISRCTN/ISRCTN20896880 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20120405 PL - England TA - BMC Musculoskelet Disord JT - BMC musculoskeletal disorders JID - 100968565 RN - 0 (Fibrillar Collagens) RN - 0 (Genetic Markers) RN - 0 (Inflammation Mediators) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (RNA, Messenger) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.24.- (Collagenases) SB - IM MH - Achilles Tendon/*chemistry/*pathology/ultrastructure MH - Biopsy MH - Case-Control Studies MH - Chi-Square Distribution MH - Chronic Disease MH - Collagenases/genetics MH - Denmark MH - Fibrillar Collagens/genetics/ultrastructure MH - Gene Expression Regulation MH - Genetic Markers MH - Humans MH - Inflammation Mediators/analysis MH - Intercellular Signaling Peptides and Proteins/genetics MH - Microscopy, Electron, Transmission MH - Polymerase Chain Reaction MH - RNA, Messenger/analysis MH - Tendinopathy/*genetics/*pathology MH - Tissue Inhibitor of Metalloproteinases/genetics PMC - PMC3341204 EDAT- 2012/04/07 06:00 MHDA- 2012/08/09 06:00 PMCR- 2012/04/05 CRDT- 2012/04/07 06:00 PHST- 2011/12/05 00:00 [received] PHST- 2012/04/05 00:00 [accepted] PHST- 2012/04/07 06:00 [entrez] PHST- 2012/04/07 06:00 [pubmed] PHST- 2012/08/09 06:00 [medline] PHST- 2012/04/05 00:00 [pmc-release] AID - 1471-2474-13-53 [pii] AID - 10.1186/1471-2474-13-53 [doi] PST - epublish SO - BMC Musculoskelet Disord. 2012 Apr 5;13:53. doi: 10.1186/1471-2474-13-53. PMID- 7890717 OWN - NLM STAT- MEDLINE DCOM- 19950418 LR - 20220408 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 270 IP - 11 DP - 1995 Mar 17 TI - Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. PG - 5872-6 AB - The 72-kDa gelatinase/type IV collagenase (MMP-2) is a member of the matrix metalloproteinase (MMP) family of enzymes. This enzyme is known to cleave type IV collagen as well as degrade denatured collagens. However, native interstitial collagens are reportedly resistant to MMP-2 and are thought to be susceptible only to the interstitial collagenases MMP-1 and MMP-8. In this study we report that both human and chicken MMP-2, free of tissue inhibitors of metalloproteinases (TIMPs) are capable of cleaving soluble, triple helical type I collagen generating the 3/4- and 1/4-length collagen fragments characteristic of vertebrate interstitial collagenases. MMP-2 cleaves at the same Gly-Ile/Leu bond in the collagen alpha chains as interstitial collagenases with kcat and Km values similar to that of MMP-1. MMP-2 also is capable of degrading reconstituted type I collagen fibrils. The closely related 92-kDa gelatinase/type IV collagenase (MMP-9) is unable to cleave soluble or fibrillar collagen under identical conditions indicating that the specific collagenolytic activity of MMP-2 is not a general property of gelatinases. That MMP-2, a potent gelatinase, also can cleave fibrillar collagen provides an alternative to the proposal that two enzymes, an interstitial collagenase and a gelatinase, are required for the complete dissolution of stromal collagen during cellular invasion. FAU - Aimes, R T AU - Aimes RT AD - Department of Biochemistry and Cell Biology, State University of New York, Stony Brook 11794. FAU - Quigley, J P AU - Quigley JP LA - eng GR - CA 55852/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Glycoproteins) RN - 0 (Peptide Fragments) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.- (Gelatinases) RN - EC 3.4.24.- (Metalloendopeptidases) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.34 (Matrix Metalloproteinase 8) RN - EC 3.4.24.7 (Matrix Metalloproteinase 1) SB - IM MH - Amino Acid Sequence MH - Animals MH - Cattle MH - Chickens MH - Collagen/chemistry/metabolism MH - Collagenases/metabolism MH - Gelatinases/isolation & purification/*metabolism MH - Glycoproteins/isolation & purification MH - Humans MH - Kinetics MH - Matrix Metalloproteinase 1 MH - Matrix Metalloproteinase 2 MH - Matrix Metalloproteinase 8 MH - Metalloendopeptidases/isolation & purification/*metabolism MH - Molecular Sequence Data MH - Peptide Fragments/chemistry/isolation & purification MH - Rats MH - Skin MH - Substrate Specificity MH - Tendons MH - Tissue Inhibitor of Metalloproteinases EDAT- 1995/03/17 00:00 MHDA- 1995/03/17 00:01 CRDT- 1995/03/17 00:00 PHST- 1995/03/17 00:00 [pubmed] PHST- 1995/03/17 00:01 [medline] PHST- 1995/03/17 00:00 [entrez] AID - S0021-9258(18)81437-5 [pii] AID - 10.1074/jbc.270.11.5872 [doi] PST - ppublish SO - J Biol Chem. 1995 Mar 17;270(11):5872-6. doi: 10.1074/jbc.270.11.5872. PMID- 27881671 OWN - NLM STAT- MEDLINE DCOM- 20171220 LR - 20171220 IS - 1522-1601 (Electronic) IS - 0161-7567 (Linking) VI - 122 IP - 2 DP - 2017 Feb 1 TI - Sex-based difference in Achilles peritendinous levels of matrix metalloproteinases and growth factors after acute resistance exercise. PG - 361-367 LID - 10.1152/japplphysiol.00878.2016 [doi] AB - Several recent investigations have demonstrated that the ability of various tendons to alter structural and functional properties in response to exercise are muted in women compared with men. We hypothesize that this disparity between men and women may be due to a reduced tendon production of key mediators of tendon extracellular matrix (ECM) remodeling in response to mechanical loading, e.g., exercise. Using microdialysis before and after an acute bout of resistance exercise, we evaluated Achilles peritendinous levels of insulin-like growth factor-1 (IGF-1) and interleukin-6 (IL-6), which have both been shown to increase tendon collagen synthesis. Additionally, the matrix remodeling enzymes matrix metalloproteinase-2 (MMP-2), MMP-9, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were also evaluated. IGF-1 levels were elevated (P < 0.05) to a similar extent in men and women after 3 h of exercise but remained elevated at 4 h in only women. IL-6 levels were ~4-fold greater after exercise in both men and women (P < 0.05). MMP-2 levels increased to a similar extent (~2-3-fold) in men and women (P < 0.05). In contrast, MMP-9 increased with exercise but only in men (P < 0.05). Last, TIMP-1 levels also increased (P < 0.05) with exercise in men and women but the increase was more prolonged in women. In conclusion, we observed modest sex differences in tendon release of MMP-9, TIMP-1, and IGF-1 after acute resistance exercise. If such differences persist throughout a chronic exercise training, they may contribute to the reduced ability of women to adapt to exercise compared with men.NEW & NOTEWORTHY In this investigation we utilized microdialysis of the peritendinous Achilles to evaluate potential differences between men and women in tendon production of key regulators of extracellular matrix remodeling. We demonstrate that a modest sex-specific difference exists in peritendinous levels of several key extracellular matrix modulators after an acute bout of resistance exercise. CI - Copyright © 2017 the American Physiological Society. FAU - Astill, Broc D AU - Astill BD AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona. FAU - Katsma, Mark S AU - Katsma MS AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona. FAU - Cauthon, David J AU - Cauthon DJ AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona. FAU - Greenlee, Jason AU - Greenlee J AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona. FAU - Murphy, Mark AU - Murphy M AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona. FAU - Curtis, Donald AU - Curtis D AD - Arizona School of Podiatric Medicine, Midwestern University, Glendale, Arizona; and. FAU - Carroll, Chad C AU - Carroll CC AD - Department of Physiology, Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona; carrol71@purdue.edu. AD - Department of Health and Kinesiology, Purdue University, West Lafayette, Indiana. LA - eng PT - Journal Article DEP - 20161123 PL - United States TA - J Appl Physiol (1985) JT - Journal of applied physiology (Bethesda, Md. : 1985) JID - 8502536 RN - 0 (Interleukin-6) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 9007-34-5 (Collagen) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Achilles Tendon/*metabolism MH - Adult MH - Collagen/metabolism MH - Exercise/*physiology MH - Extracellular Matrix/metabolism MH - Female MH - Humans MH - Insulin-Like Growth Factor I/*metabolism MH - Interleukin-6/metabolism MH - Male MH - Matrix Metalloproteinases/*metabolism MH - Resistance Training/methods MH - Sex Characteristics MH - Tissue Inhibitor of Metalloproteinase-1/metabolism OTO - NOTNLM OT - IGF-1 OT - IL-6 OT - MMP OT - TIMP OT - exercise OT - tendon EDAT- 2016/11/25 06:00 MHDA- 2017/12/21 06:00 CRDT- 2016/11/25 06:00 PHST- 2016/09/30 00:00 [received] PHST- 2016/11/15 00:00 [revised] PHST- 2016/11/20 00:00 [accepted] PHST- 2016/11/25 06:00 [pubmed] PHST- 2017/12/21 06:00 [medline] PHST- 2016/11/25 06:00 [entrez] AID - japplphysiol.00878.2016 [pii] AID - 10.1152/japplphysiol.00878.2016 [doi] PST - ppublish SO - J Appl Physiol (1985). 2017 Feb 1;122(2):361-367. doi: 10.1152/japplphysiol.00878.2016. Epub 2016 Nov 23. PMID- 26910699 OWN - NLM STAT- MEDLINE DCOM- 20160708 LR - 20210109 IS - 1529-4242 (Electronic) IS - 0032-1052 (Print) IS - 0032-1052 (Linking) VI - 137 IP - 3 DP - 2016 Mar TI - Low-Dose and Short-Duration Matrix Metalloproteinase 9 Inhibition Does Not Affect Adhesion Formation during Murine Flexor Tendon Healing. PG - 545e-553e LID - 10.1097/01.prs.0000475823.01907.53 [doi] AB - BACKGROUND: After flexor tendon injury and repair, adhesion formation is a substantial concern, as it can result in loss of motion and functional disability. Matrix metalloproteinase 9 (Mmp9) is a gelatinase that contributes to degradation of extracellular matrix and is expressed during flexor tendon healing. Mmp9(-/-) mice have accelerated remodeling of adhesions during flexor tendon healing, relative to wild-type mice. The purpose of this study was to investigate whether Ro 32-3555, an Mmp9 inhibitor, can improve flexor tendon healing by limiting adhesion formation or enhancing remodeling of scar tissue during murine flexor tendon healing. METHODS: Flexor digitorum longus laceration and repair was performed in female C57BL/6J mice. Mice were treated with vehicle or the Mmp9 inhibitor Ro 32-3555 for 8 days. Analysis was performed for digit range of motion and gliding function, biomechanics, gene expression, and Mmp9 activity. RESULTS: An Mmp9 activity assay and zymography confirmed suppression of Mmp9 activity in mice treated with Ro 32-3555. There was no significant difference in tendon gliding or range of motion between vehicle and Ro 32-3555-treated mice. There was also no difference in tendon biomechanical properties between the two groups. CONCLUSION: Local inhibition of Mmp9 gelatinolytic activity at the flexor tendon repair site is insufficient to alter adhesion formation, remodeling of adhesions, or mechanical properties of healing murine flexor tendons. FAU - Orner, Caitlin A AU - Orner CA AD - Rochester, N.Y.; and St. Louis, Mo. From the Center for Musculoskeletal Research and Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center; the University of Rochester School of Medicine and Dentistry; and the Department of Orthopaedic Surgery, Washington University School of Medicine. FAU - Geary, Michael B AU - Geary MB FAU - Hammert, Warren C AU - Hammert WC FAU - O'Keefe, Regis J AU - O'Keefe RJ FAU - Loiselle, Alayna E AU - Loiselle AE LA - eng GR - P50 AR054041/AR/NIAMS NIH HHS/United States GR - P30 AR061307/AR/NIAMS NIH HHS/United States GR - TL1 TR000096/TR/NCATS NIH HHS/United States GR - P30AR061307/AR/NIAMS NIH HHS/United States GR - TL1TR000096/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Plast Reconstr Surg JT - Plastic and reconstructive surgery JID - 1306050 RN - 0 (Imidazoles) RN - 0 (Matrix Metalloproteinase Inhibitors) RN - 0 (Ro 32-3555) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Analysis of Variance MH - Animals MH - Biomechanical Phenomena MH - Disease Models, Animal MH - Dose-Response Relationship, Drug MH - Drug Administration Schedule MH - Female MH - Imidazoles/*administration & dosage MH - Matrix Metalloproteinase 9/*drug effects/metabolism MH - Matrix Metalloproteinase Inhibitors/*administration & dosage MH - Mice MH - Mice, Inbred C57BL MH - Random Allocation MH - Reference Values MH - Tendon Injuries/drug therapy/*surgery MH - Tensile Strength/drug effects MH - Tissue Adhesions/drug therapy/enzymology MH - Wound Healing/*drug effects/physiology PMC - PMC4770830 MID - NIHMS718506 EDAT- 2016/02/26 06:00 MHDA- 2016/07/09 06:00 PMCR- 2017/03/01 CRDT- 2016/02/25 06:00 PHST- 2017/03/01 00:00 [pmc-release] PHST- 2016/02/25 06:00 [entrez] PHST- 2016/02/26 06:00 [pubmed] PHST- 2016/07/09 06:00 [medline] AID - 00006534-201603000-00016 [pii] AID - 10.1097/01.prs.0000475823.01907.53 [doi] PST - ppublish SO - Plast Reconstr Surg. 2016 Mar;137(3):545e-553e. doi: 10.1097/01.prs.0000475823.01907.53. PMID- 29286087 OWN - NLM STAT- MEDLINE DCOM- 20180814 LR - 20211025 IS - 1791-3004 (Electronic) IS - 1791-2997 (Print) IS - 1791-2997 (Linking) VI - 17 IP - 3 DP - 2018 Mar TI - Growth differentiation factor‑5 induces tenomodulin expression via phosphorylation of p38 and promotes viability of murine mesenchymal stem cells from compact bone. PG - 3640-3646 LID - 10.3892/mmr.2017.8325 [doi] AB - Growth differentiation factor (GDF)‑5 serves a role in tissue development and tenomodulin serves an important role in the development of tendons. The effects of GDF‑5 on mesenchymal stem cells (MSCs), particularly with regards to tendon bioengineering, are poorly understood. The present study aimed to investigate the effects of GDF‑5 on cell viability and tenomodulin expression in MSCs from murine compact bone. MSCs were isolated from murine compact bones and confirmed by flow cytometric analysis. In addition, the adipogenic, osteoblastic and chondrocyte differentiation capabilities of the MSCs were determined. MSCs were treated with GDF‑5 and the effects of GDF‑5 on MSC viability were determined. The mRNA and protein expression levels of tenomodulin were detected by reverse transcription‑quantitative polymerase chain reaction and western blotting, respectively. MSCs from murine compact bone were successfully isolated. GDF‑5 had optimal effects on cell viability at 100 ng/ml (+36.9% of control group without GDF‑5 treatment, P<0.01) and its effects peaked after 6 days of treatment (+56.6% of control group, P<0.001). Compared with the control group, treatment with 100 ng/ml GDF‑5 for 4 days enhanced the mRNA expression levels of tenomodulin (3.56±0.94 vs. 1.02±0.25; P<0.05). In addition, p38 was activated by GDF‑5, as determined by enhanced expression levels of phosphorylated p38 (p‑p38). The GDF‑5‑induced protein expression levels of p‑p38 and tenomodulin were markedly inhibited following treatment with SB203580, an inhibitor of p38 mitogen‑activated protein kinase. These results suggested that GDF‑5 treatment may increase tenomodulin protein expression via phosphorylation of p38 in MSCs from murine compact bone. These findings may aid the future development of tendon bioengineering. FAU - Qu, Yanlong AU - Qu Y AD - Department of Orthopedics, The Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China. FAU - Zhou, Li AU - Zhou L AD - Department of Orthopedics, The Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China. FAU - Lv, Bing AU - Lv B AD - Department of Orthopedics, The Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China. FAU - Wang, Chunlei AU - Wang C AD - Department of Orthopedics, The Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China. FAU - Li, Pengwei AU - Li P AD - Department of Orthopedics, The Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China. LA - eng PT - Journal Article DEP - 20171220 PL - Greece TA - Mol Med Rep JT - Molecular medicine reports JID - 101475259 RN - 0 (Growth Differentiation Factor 5) RN - 0 (Imidazoles) RN - 0 (Membrane Proteins) RN - 0 (Pyridines) RN - 0 (Tnmd protein, mouse) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) RN - OU13V1EYWQ (SB 203580) SB - IM MH - Animals MH - Cell Differentiation/*drug effects MH - Cell Survival/drug effects MH - Cells, Cultured MH - Cortical Bone/cytology MH - Female MH - Growth Differentiation Factor 5/*pharmacology MH - Imidazoles/pharmacology MH - Membrane Proteins/genetics/*metabolism MH - Mesenchymal Stem Cells/cytology/metabolism MH - Mice MH - Mice, Inbred C57BL MH - Phosphorylation/drug effects MH - Pyridines/pharmacology MH - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism PMC - PMC5802169 OTO - NOTNLM OT - growth differentiation factor-5 OT - tenomodulin OT - tendon repair OT - bioengineering OT - p38 OT - murine mesenchymal stem cells from compact bone EDAT- 2017/12/30 06:00 MHDA- 2018/08/15 06:00 PMCR- 2017/12/20 CRDT- 2017/12/30 06:00 PHST- 2016/04/29 00:00 [received] PHST- 2017/03/26 00:00 [accepted] PHST- 2017/12/30 06:00 [pubmed] PHST- 2018/08/15 06:00 [medline] PHST- 2017/12/30 06:00 [entrez] PHST- 2017/12/20 00:00 [pmc-release] AID - mmr-17-03-3640 [pii] AID - 10.3892/mmr.2017.8325 [doi] PST - ppublish SO - Mol Med Rep. 2018 Mar;17(3):3640-3646. doi: 10.3892/mmr.2017.8325. Epub 2017 Dec 20. PMID- 33371012 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 10 IP - 12 DP - 2020 Dec 21 TI - Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries. PG - e034844 LID - 10.1136/bmjopen-2019-034844 [doi] LID - e034844 AB - OBJECTIVES: To assess the association of fluoroquinolone use with tendon ruptures compared with no fluoroquinolone and that of the four most commonly prescribed non-fluoroquinolone antibiotics in the USA. DESIGN: Retrospective observational study. SETTING: US seniors enrolled in the federal old-age, survivor's insurance programme. PARTICIPANTS: 1 009 925 Medicare fee-for-service beneficiaries and their inpatient, outpatient, prescription drug records were used. INTERVENTIONS: Seven oral antibiotics, fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) and amoxicillin, amoxicillin-clavulanate, azithromycin and cephalexin. PRIMARY AND SECONDARY OUTCOME MEASURES: All tendon ruptures combined, and three types of tendon ruptures by anatomic site, Achilles tendon rupture, rupture of rotator cuff and other tendon ruptures occurred in 2007-2016. RESULTS: Of three fluoroquinolones, only levofloxacin exhibited a significant increased risk of tendon ruptures-16% (HR=1.16; 95% CI 1.06 to 1.28), and 120% (HR=2.20; 95% CI 1.50 to 3.24) for rotator cuff and Achilles tendon rupture, respectively, in the ≤30 days window. Ciprofloxacin (HR=0.96; 95% CI 0.89 to 1.03) and moxifloxacin (HR=0.59; 95% CI 0.37 to 0.93) exhibited no increased risk of tendon ruptures combined.Among the non-fluoroquinolone antibiotics, cephalexin exhibited increased risk of combined tendon ruptures (HR=1.31; 95% CI 1.22 to 1.41) and modest to large risks across all anatomic rupture sites (HRs 1.19-1.93) at ≤30 days window. Notably, the risk of levofloxacin never exceeded the risk of the non-fluoroquinolone, cephalexin in any comparison. CONCLUSIONS: In our study, fluoroquinolones as a class were not associated with the increased risk of tendon ruptures. Neither ciprofloxacin nor moxifloxacin exhibited any risk for tendon ruptures. Levofloxacin did exhibit significant increased risk. Cephalexin with no reported effect on metalloprotease activity had an equal or greater risk than levofloxacin; so we question whether metalloprotease activity has any relevance to observed associations with tendon rupture. Confounding by indication bias may be more relevant and should be given more consideration as explanation for significant associations in observational studies of tendon rupture. CI - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Baik, Seo AU - Baik S AUID- ORCID: 0000-0002-2077-4316 AD - Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA. FAU - Lau, Jason AU - Lau J AD - Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA. FAU - Huser, Vojtech AU - Huser V AD - Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA. FAU - McDonald, Clement J AU - McDonald CJ AD - Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland, USA ClemMcDonald@mail.nih.gov. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, N.I.H., Intramural PT - Research Support, Non-U.S. Gov't DEP - 20201221 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Anti-Bacterial Agents) RN - 0 (Fluoroquinolones) SB - IM MH - Aged MH - *Anti-Bacterial Agents/adverse effects MH - *Fluoroquinolones/adverse effects MH - Humans MH - Medicare MH - Retrospective Studies MH - Rupture MH - Tendons MH - United States/epidemiology PMC - PMC7754651 OTO - NOTNLM OT - accident & emergency medicine OT - clinical pharmacology OT - epidemiology OT - musculoskeletal disorders OT - oral medicine COIS- Competing interests: None declared. EDAT- 2020/12/30 06:00 MHDA- 2021/05/15 06:00 PMCR- 2020/12/21 CRDT- 2020/12/29 01:02 PHST- 2020/12/29 01:02 [entrez] PHST- 2020/12/30 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/12/21 00:00 [pmc-release] AID - bmjopen-2019-034844 [pii] AID - 10.1136/bmjopen-2019-034844 [doi] PST - epublish SO - BMJ Open. 2020 Dec 21;10(12):e034844. doi: 10.1136/bmjopen-2019-034844. PMID- 15150318 OWN - NLM STAT- MEDLINE DCOM- 20050113 LR - 20191210 IS - 0021-9533 (Print) IS - 0021-9533 (Linking) VI - 117 IP - Pt 13 DP - 2004 Jun 1 TI - Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I. PG - 2731-44 AB - Tenomodulin (TeM) is a type II transmembrane glycoprotein that contains a C-terminal domain with homology to the mature, secreted form of chondromodulin-I (ChM-I), a cartilage-derived angiogenesis inhibitor. TeM transcripts have been found in hypovascular tissues such as tendons and ligaments but the biological activity of TeM has not yet been fully explored. Using an adenovirus expression system, we utilized the forced expression and subsequent secretion of the human TeM C-terminal 116 amino acids (Ad-shTeM) in human umbilical vein endothelial cells (HUVECs) to assess the anti-angiogenic properties of TeM. The C-terminal 120 amino acids of the human ChM-I precursor (Ad-shChM-I) was similarly expressed in HUVECs as a comparison study. Transduction of both Ad-shTeM and Ad-shChM-I resulted in significant impairment of the tube-forming activity of HUVECs, when cultured in Matrigel. Similarly, conditioned medium from COS7 cells, transfected with plasmid DNA encoding shTeM or shChM-I, inhibited tube formation of HUVECs when compared to medium derived from either COS7 cells transfected with control vector or from non-transfected cells. Upon infection of HUVECs with Ad-shTeM or Ad-shChM-I, DNA synthesis stimulated by vascular endothelial growth factor (VEGF) was reduced to 40-50% of normal levels. Additionally, in a modified Boyden chamber assay, migration of HUVECs in response to VEGF was significantly affected following transduction of either Ad-shTeM or Ad-shChM-I and these transduced HUVECs were found to spread well on type I collagen or fibronectin, but not on vitronectin. Furthermore, the transduction of either Ad-shTeM or Ad-shChM-I in human melanoma cells resulted in suppression of tumor growth in association with decreased vessel density in vivo. Hence, we have demonstrated that, similarly to ChM-1, the C-terminal domain of TeM exhibits both anti-angiogenic and anti-tumor activities when expressed in a secreted form. FAU - Oshima, Yusuke AU - Oshima Y AD - Department of Cellular Differentiation, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan. FAU - Sato, Koji AU - Sato K FAU - Tashiro, Fumi AU - Tashiro F FAU - Miyazaki, Jun-ichi AU - Miyazaki J FAU - Nishida, Koji AU - Nishida K FAU - Hiraki, Yuji AU - Hiraki Y FAU - Tano, Yasuo AU - Tano Y FAU - Shukunami, Chisa AU - Shukunami C LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20040518 PL - England TA - J Cell Sci JT - Journal of cell science JID - 0052457 RN - 0 (Angiogenesis Inhibitors) RN - 0 (Cnmd protein, mouse) RN - 0 (Collagen Type I) RN - 0 (Culture Media, Conditioned) RN - 0 (Drug Combinations) RN - 0 (Fibronectins) RN - 0 (Intercellular Signaling Peptides and Proteins) RN - 0 (Laminin) RN - 0 (Membrane Proteins) RN - 0 (Proteoglycans) RN - 0 (TNMD protein, human) RN - 0 (Tnmd protein, mouse) RN - 0 (Vascular Endothelial Growth Factor A) RN - 119978-18-6 (matrigel) RN - 136362-10-2 (CNMD protein, human) RN - 9007-34-5 (Collagen) RN - 9007-49-2 (DNA) SB - IM MH - Adenoviridae/genetics MH - Angiogenesis Inhibitors/*genetics/metabolism/pharmacology MH - Animals MH - COS Cells MH - Cell Line MH - Cell Movement/drug effects MH - Cells, Cultured MH - Chlorocebus aethiops MH - Collagen/metabolism MH - Collagen Type I/metabolism MH - Culture Media, Conditioned/pharmacology MH - DNA/biosynthesis/drug effects MH - Drug Combinations MH - Endothelium, Vascular/cytology/drug effects/metabolism MH - Fibronectins/metabolism MH - Humans MH - Intercellular Signaling Peptides and Proteins/*chemistry/genetics MH - Laminin/metabolism MH - Melanocytes/drug effects/metabolism MH - Melanoma/pathology MH - Melanoma, Experimental/pathology MH - Membrane Proteins/*chemistry/genetics MH - Mice MH - Mice, Inbred C57BL MH - Neoplasm Transplantation MH - Protein Structure, Tertiary MH - Proteoglycans/metabolism MH - Transplantation, Homologous MH - Tumor Cells, Cultured MH - Umbilical Veins/cytology MH - Vascular Endothelial Growth Factor A/pharmacology EDAT- 2004/05/20 05:00 MHDA- 2005/01/14 09:00 CRDT- 2004/05/20 05:00 PHST- 2004/05/20 05:00 [pubmed] PHST- 2005/01/14 09:00 [medline] PHST- 2004/05/20 05:00 [entrez] AID - jcs.01112 [pii] AID - 10.1242/jcs.01112 [doi] PST - ppublish SO - J Cell Sci. 2004 Jun 1;117(Pt 13):2731-44. doi: 10.1242/jcs.01112. Epub 2004 May 18. PMID- 40170767 OWN - NLM STAT- MEDLINE DCOM- 20250402 LR - 20250515 IS - 2005-4408 (Electronic) IS - 2005-291X (Print) IS - 2005-291X (Linking) VI - 17 IP - 2 DP - 2025 Apr TI - A Comparative Study on the Effects of Repeated Subacromial Injections of Parecoxib and Triamcinolone in a Rat Model of Normal Rotator Cuff. PG - 291-299 LID - 10.4055/cios23417 [doi] AB - BACKGROUD: This study aimed to investigate changes after repeated subacromial drug injections in a rat model of normal rotator cuff. METHODS: Thirty-nine male Sprague-Dawley rats were divided into groups 1 (no injection, n = 3), 2 (parecoxib, n = 18; 6 subgroups, n = 3 each; 0.5 mg/kg), and 3 (triamcinolone, n = 18; 6 subgroups, n = 3 each; 0.3 mg/kg). Groups 2 and 3 received subacromial injections 1-6 times once weekly for 6 weeks. The supraspinatus and infraspinatus tendons and muscles were used for biomechanical and histological evaluation. The subacromial bursa was used to analyze the prostaglandin E2 (PEG2) level. RESULTS: In the biomechanical test, load-to-failure and ultimate stress decreased in groups 2 and 3 with repeated injections and the values were significantly lower in group 3 than in group 1 only at the sixth injection (p = 0.007 and p = 0.008, respectively). On the Bonar score, the cellularity, ground substance, and total score were significantly different among the 3 groups at the fifth and sixth injections (cellularity: p = 0.028 and p = 0.033, ground substance: p = 0.018 and p = 0.006, and total score: p = 0.029 and p = 0.027, respectively). The myocyte cross-sectional area of the infraspinatus muscle showed a significant difference among the 3 groups at the third and fourth injections (p = 0.031 and p = 0.020, respectively). The PEG2 level in the subacromial bursa was significantly different among the 3 groups at the third, fifth, and sixth injections (p = 0.019, p = 0.004, and p = 0.004, respectively). CONCLUSIONS: In the rat model of normal rotator cuff, repeated local injections of the cyclooxygenase-2 inhibitor showed fewer negative effects on the biomechanical and histological properties of the normal tendon than triamcinolone. CI - Copyright © 2025 by The Korean Orthopaedic Association. FAU - Yoon, Jong Pil AU - Yoon JP AUID- ORCID: 0000-0001-6446-6254 AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Kim, Dong Hyun AU - Kim DH AUID- ORCID: 0000-0001-9078-5953 AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Park, Sung-Jin AU - Park SJ AUID- ORCID: 0009-0008-6869-0788 AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Choi, Yoon Seong AU - Choi YS AUID- ORCID: 0009-0006-1483-0023 AD - Department of Carbon Hybrid Fiber Science, Kyungpook National University, Daegu, Korea. FAU - Lee, Hyun Joo AU - Lee HJ AUID- ORCID: 0000-0003-2837-3434 AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Chung, Seok Won AU - Chung SW AUID- ORCID: 0000-0002-8221-9289 AD - Department of Orthopedic Surgery, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. FAU - Lee, Kang-San AU - Lee KS AUID- ORCID: 0000-0001-7932-0426 AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. FAU - Lee, Jeoung Wook AU - Lee JW AUID- ORCID: 0009-0003-1216-263X AD - Department of Orthopedic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea. LA - eng PT - Comparative Study PT - Journal Article DEP - 20250102 PL - Korea (South) TA - Clin Orthop Surg JT - Clinics in orthopedic surgery JID - 101505087 RN - 1ZK20VI6TY (Triamcinolone) RN - 9TUW81Y3CE (parecoxib) RN - 0 (Isoxazoles) RN - 0 (Cyclooxygenase 2 Inhibitors) RN - K7Q1JQR04M (Dinoprostone) SB - IM MH - Animals MH - Rats, Sprague-Dawley MH - Male MH - *Rotator Cuff/drug effects MH - Rats MH - *Triamcinolone/administration & dosage/pharmacology MH - *Isoxazoles/administration & dosage/pharmacology MH - Injections, Intra-Articular MH - Biomechanical Phenomena MH - Disease Models, Animal MH - *Cyclooxygenase 2 Inhibitors/administration & dosage/pharmacology MH - Dinoprostone/metabolism PMC - PMC11957830 OTO - NOTNLM OT - Cyclooxygenase 2 inhibitors OT - Injections OT - Rotator cuff OT - Triamcinolone COIS- CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported. EDAT- 2025/04/02 10:55 MHDA- 2025/04/02 10:56 PMCR- 2025/04/01 CRDT- 2025/04/02 04:25 PHST- 2023/12/29 00:00 [received] PHST- 2024/07/15 00:00 [revised] PHST- 2024/07/15 00:00 [accepted] PHST- 2025/04/02 10:56 [medline] PHST- 2025/04/02 10:55 [pubmed] PHST- 2025/04/02 04:25 [entrez] PHST- 2025/04/01 00:00 [pmc-release] AID - 10.4055/cios23417 [doi] PST - ppublish SO - Clin Orthop Surg. 2025 Apr;17(2):291-299. doi: 10.4055/cios23417. Epub 2025 Jan 2. PMID- 17699562 OWN - NLM STAT- MEDLINE DCOM- 20071127 LR - 20200930 IS - 0363-6119 (Print) IS - 0363-6119 (Linking) VI - 293 IP - 4 DP - 2007 Oct TI - Temporal extracellular matrix adaptations in ligament during wound healing and hindlimb unloading. PG - R1552-60 AB - Previous data from spaceflight studies indicate that injured muscle and bone heal slowly and abnormally compared with ground controls, strongly suggesting that ligaments or tendons may not repair optimally as well. Thus the objective of this study was to investigate the biochemical and molecular gene expression of the collagen extracellular matrix in response to medial collateral ligament (MCL) injury repair in hindlimb unloaded (HLU) rodents. Male rats were assigned to 3- and 7-wk treatment groups with three subgroups each: sham control, ambulatory healing (Amb-healing), and HLU-healing groups. Amb- and HLU-healing animals underwent bilateral surgical transection of their MCLs, whereas control animals were subjected to sham surgeries. All surgeries were performed under isoflurane anesthesia. After 3 wk or 7 wk of HLU, rats were euthanized and MCLs were surgically isolated and prepared for molecular or biochemical analyses. Hydroxyproline concentration and hydroxylysylpyridinoline collagen cross-link contents were measured by HPLC and showed a substantial decrement in surgical groups. MCL tissue cellularity, quantified by DNA content, remained significantly elevated in all HLU-healing groups vs. Amb-healing groups. MCL gene expression of collagen type I, collagen type III, collagen type V, fibronectin, decorin, biglycan, lysyl oxidase, matrix metalloproteinase-2, and tissue inhibitor of matrix metalloproteinase-1, measured by real-time quantitative PCR, demonstrated differential expression in the HLU-healing groups compared with Amb-healing groups at both the 3- and 7-wk time points. Together, these data suggest that HLU affects dense fibrous connective tissue wound healing and confirms previous morphological and biomechanical data that HLU inhibits the ligament repair processes. FAU - Martinez, D A AU - Martinez DA AD - Connective Tissue Physiology Laboratory, Department of Health and Human Performance, Univ. of Houston, N207 D Engineering Bldg. 1, Houston, TX 77204-4006, USA. ddam@uh.edu FAU - Vailas, A C AU - Vailas AC FAU - Vanderby, R Jr AU - Vanderby R Jr FAU - Grindeland, R E AU - Grindeland RE LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20070815 PL - United States TA - Am J Physiol Regul Integr Comp Physiol JT - American journal of physiology. Regulatory, integrative and comparative physiology JID - 100901230 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Collagen Type V) RN - 0 (DCN protein, human) RN - 0 (Decorin) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Fibronectins) RN - 0 (Proteoglycans) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - EC 1.4.3.13 (Protein-Lysine 6-Oxidase) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Adaptation, Physiological MH - Animals MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Collagen Type V/genetics/metabolism MH - Decorin MH - Down-Regulation MH - Extracellular Matrix/*metabolism MH - Extracellular Matrix Proteins/genetics/metabolism MH - Fibronectins/genetics/metabolism MH - Gene Expression Regulation/physiology MH - Hindlimb Suspension/*physiology MH - Ligaments/*injuries/metabolism MH - Male MH - Matrix Metalloproteinase 2/genetics/metabolism MH - Protein-Lysine 6-Oxidase/genetics/metabolism MH - Proteoglycans/genetics/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Time Factors MH - Tissue Inhibitor of Metalloproteinase-1/genetics/metabolism MH - Up-Regulation MH - Wound Healing/*physiology EDAT- 2007/08/19 09:00 MHDA- 2007/12/06 09:00 CRDT- 2007/08/19 09:00 PHST- 2007/08/19 09:00 [pubmed] PHST- 2007/12/06 09:00 [medline] PHST- 2007/08/19 09:00 [entrez] AID - 00423.2007 [pii] AID - 10.1152/ajpregu.00423.2007 [doi] PST - ppublish SO - Am J Physiol Regul Integr Comp Physiol. 2007 Oct;293(4):R1552-60. doi: 10.1152/ajpregu.00423.2007. Epub 2007 Aug 15. PMID- 30759353 OWN - NLM STAT- MEDLINE DCOM- 20200219 LR - 20200914 IS - 1552-3365 (Electronic) IS - 0363-5465 (Linking) VI - 47 IP - 4 DP - 2019 Mar TI - Application of a Purified Protein From Natural Latex and the Influence of Suture Type on Achilles Tendon Repair in Rats. PG - 901-914 LID - 10.1177/0363546518822836 [doi] AB - BACKGROUND: The prolonged tendon-healing process, the high costs associated with treatment, the increase in the number of injuries over the past decades, and the lack of consensus on the optimal treatment of tendon injuries are a global problem. Restoring the normal tendon anatomy and decreasing the healing time are key factors for treatment advancement. HYPOTHESIS: Application of a purified protein from natural latex (PPNL) accelerates the healing process, increasing collagen synthesis and decreasing metalloproteinases. PPNL associated with a simpler suture technique should decrease the healing time. STUDY DESIGN: Controlled laboratory study. METHODS: Injury, surgery, and treatment with PPNL were conducted with male Sprague-Dawley rats. Two suture techniques were used: U-suture, a simpler and lesser traumatic technique, and Kessler-Tajima, to avoid strangulation of the microcirculation. Achilles tendons were completely sectioned, and 100 µL of 0.1% PPNL was applied on the tendon during surgery. Tendon morphology, distribution, and quantity of collagen types I and III, as well as expression of TIMP-1, TIMP-2, MMP-2, and MMP-9 and ultrastructural aspects of cells and collagen fibrils, were assessed after 2 and 4 weeks. RESULTS: PPNL treatment improved collagen type I synthesis and reduced MMP-2 expression. All groups showed a 6.8-times increase in tendon weight as compared with the control group after 2 weeks and a 5.2-times increase after 4 weeks. All groups showed an increase in diameter after 4 weeks, except for the ones treated with PPNL, which showed a slight reduction in diameter. The peak of concentration of collagen fibrils with a 80-nm diameter was 27.79% in the control group; all other experimental groups presented fibrils between 50 and 60 nm. However, the best results were observed with Kessler-Tajima suture associated with PPNL. CONCLUSION/CLINICAL RELEVANCE: There are no known medicines or substances capable of aiding the tendon healing process besides surgery. The discovery of a substance able to improve this process and decrease its duration represents an important advancement in orthopaedic medicine. FAU - Cury, Diego Pulzatto AU - Cury DP AD - Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. FAU - Schäfer, Bárbara Tavares AU - Schäfer BT AD - Department of Surgery, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, Brazil. FAU - de Almeida, Sonia Regina Yokomizo AU - de Almeida SRY AD - Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. FAU - Righetti, Marta Maria da Silva AU - Righetti MMDS AD - Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. FAU - Watanabe, Ii-Sei AU - Watanabe IS AD - Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190213 PL - United States TA - Am J Sports Med JT - The American journal of sports medicine JID - 7609541 RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (TIMP1 protein, rat) RN - 0 (Timp2 protein, rat) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2) RN - 9006-04-6 (Rubber) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - EC 3.4.24.24 (Mmp2 protein, rat) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Achilles Tendon/*injuries/*surgery MH - Animals MH - Collagen Type I/metabolism MH - Collagen Type III/metabolism MH - Hevea MH - Male MH - Matrix Metalloproteinase 2/metabolism MH - Matrix Metalloproteinase 9/metabolism MH - Models, Animal MH - Rats MH - Rats, Sprague-Dawley MH - Rubber/*administration & dosage MH - Suture Techniques MH - *Sutures MH - Tissue Inhibitor of Metalloproteinase-1/metabolism MH - Tissue Inhibitor of Metalloproteinase-2/metabolism MH - Wound Healing/*physiology OTO - NOTNLM OT - MMP OT - TIMP OT - collagen OT - musculoskeletal OT - tendon OT - ultrastructure EDAT- 2019/02/14 06:00 MHDA- 2020/02/20 06:00 CRDT- 2019/02/14 06:00 PHST- 2019/02/14 06:00 [pubmed] PHST- 2020/02/20 06:00 [medline] PHST- 2019/02/14 06:00 [entrez] AID - 10.1177/0363546518822836 [doi] PST - ppublish SO - Am J Sports Med. 2019 Mar;47(4):901-914. doi: 10.1177/0363546518822836. Epub 2019 Feb 13. PMID- 3162671 OWN - NLM STAT- MEDLINE DCOM- 19880506 LR - 20190514 IS - 0003-4932 (Print) IS - 1528-1140 (Electronic) IS - 0003-4932 (Linking) VI - 207 IP - 4 DP - 1988 Apr TI - Further evidence that accelerated muscle protein breakdown during sepsis is not mediated by prostaglandin E2. PG - 399-403 AB - Prostaglandin E2 (PGE2) reportedly increases protein break-down in skeletal muscle. The role of PGE2 for accelerated muscle proteolysis during sepsis, however, is controversial. In this study, the effect of the prostaglandin synthesis inhibitor indomethacin on PGE2 release and protein breakdown in skeletal muscle from nonseptic and septic rats was evaluated. Sepsis was induced in male Sprague-Dawley rats (40-60 g) by cecal ligation and puncture (CLP). After 16 hours the extensor digitorum longus (EDL) and soleus (SOL) muscles were dissected with intact tendons and incubated in an oxygenated medium, and the release of tyrosine (protein breakdown) and PGE2 into the incubation medium was determined. Paired muscles were incubated in the absence or presence of indomethacin (3 mumol/L or 6 mumol/L). In some experiments the effect of indomethacin was investigated in the presence of different concentrations of insulin (1, 10, or 100 mU/mL) since previous reports suggested an interaction between insulin and prostaglandins on protein turnover in skeletal muscle. In other experiments muscles were incubated in a flaccid or stretched state, which is known to influence the metabolic response to different substances. Protein breakdown rate was 0.210 +/- 0.013 and 0.492 +/- 0.025 mumol Tyr/g X 2 hours in EDL from nonseptic and septic rats, respectively (p less than 0.01). The corresponding values for SOL were 0.480 +/- 0.037 and 0.712 +/- 0.039 mumol Tyr/g X 2 hours (p less than 0.01). Addition of indomethacin to the incubation medium reduced PGE2 release from 29.1 +/- 3.1 to 6.8 +/- 0.7 ng/g X 2 hours in nonseptic SOL and from 50.6 +/- 10.4 to 5.6 +/- 0.7 ng/g X 2 hours in septic SOL. Protein breakdown rate in SOL and EDL from sham-operated or septic rats was unaffected by indomethacin, both when muscles were incubated in a flaccid or stretched state, and when they were incubated in the presence or absence of insulin. The present results do not suggest a role of PGE2 for accelerated muscle proteolysis in the present experimental septic model. FAU - Hasselgren, P O AU - Hasselgren PO AD - Department of Surgery, University of Cincinnati Medical Center, OH 45267-0558. FAU - Warner, B W AU - Warner BW FAU - Hummel, R P 3rd AU - Hummel RP 3rd FAU - James, J H AU - James JH FAU - Ogle, C K AU - Ogle CK FAU - Fischer, J E AU - Fischer JE LA - eng GR - 1 R01 DK 37908-01/DK/NIDDK NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Ann Surg JT - Annals of surgery JID - 0372354 RN - 0 (Muscle Proteins) RN - 0 (Prostaglandins E) RN - 42HK56048U (Tyrosine) RN - K7Q1JQR04M (Dinoprostone) RN - XXE1CET956 (Indomethacin) SB - IM MH - Animals MH - Bacterial Infections/*metabolism MH - Dinoprostone MH - Indomethacin/*pharmacology MH - Male MH - Muscle Proteins/*metabolism MH - Muscles/drug effects/*metabolism MH - Prostaglandins E/*physiology MH - Rats MH - Rats, Inbred Strains MH - Tyrosine/metabolism PMC - PMC1493441 EDAT- 1988/04/01 00:00 MHDA- 1988/04/01 00:01 PMCR- 1988/10/01 CRDT- 1988/04/01 00:00 PHST- 1988/04/01 00:00 [pubmed] PHST- 1988/04/01 00:01 [medline] PHST- 1988/04/01 00:00 [entrez] PHST- 1988/10/01 00:00 [pmc-release] AID - 10.1097/00000658-198804000-00005 [doi] PST - ppublish SO - Ann Surg. 1988 Apr;207(4):399-403. doi: 10.1097/00000658-198804000-00005. PMID- 15809055 OWN - NLM STAT- MEDLINE DCOM- 20050614 LR - 20131121 IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 330 IP - 3 DP - 2005 May 13 TI - Calcineurin and heat shock protein 72 in functionally overloaded rat plantaris muscle. PG - 706-13 AB - The involvement of calcineurin (CaN) and heat shock protein (Hsp) 72 in the regulation of fiber size and/or phenotype in response to functional overload (FO) was investigated. In one FO group, the plantaris muscle was overloaded by cutting the distal tendons (5-10 mm length) of the soleus and gastrocnemius of 3-week-old male Wistar rats. Cyclosporin A (CsA), a CaN inhibitor, was injected daily (5 mg/kg body weight, i.p.) in a second group of FO rats (FO+CsA group) for a 2-week period. Compared to age-matched controls (Con), the absolute and relative plantaris weights were increased in both FO groups: the hypertrophic response was attenuated in FO+CsA rats. The mean cross-sectional area of each fiber type was increased (approximately 2.0-fold) in the plantaris of FO rats: CsA treatment attenuated this effect, although the fibers were still larger than in Con rats. The percent composition of myosin heavy chain (MHC) IIb decreased from 54% in Con to 19% in FO rats, whereas types I, IIa, and IIx MHC increased in the FO rats. CsA treatment blunted the shifts in MHC isoforms: the FO+CsA group showed a smaller decrease in type IIb and a smaller increase in type IIx MHC than the FO group. The levels of CaN-A and -B proteins were higher (approximately 2.5-fold) in FO than Con rats, whereas these values were similar in Con and FO+CsA rats. Hsp72 protein levels were higher in FO (3.6-fold) and FO+CsA (5.2-fold) than Con rats, with the values being significantly higher in the FO+CsA than FO rats. CsA treatment in Con rats had no effects on muscle mass, fiber size, MHC composition, and Hsp72 or CaN levels. Combined, these results suggest that CaN levels are related to changes in both fiber size and phenotype, and that Hsp72 levels are more related to the levels of stress added to the muscle rather than to increases in the slow fiber phenotype in functionally overloaded rat plantaris muscles. FAU - Oishi, Yasuharu AU - Oishi Y AD - Laboratory of Muscle Physiology, Faculty of Education, Kumamoto University, Kumamoto 860-8555, Japan. oishi@gpo.kumamoto-u.ac.jp FAU - Ogata, Tomonori AU - Ogata T FAU - Ohira, Yoshinobu AU - Ohira Y FAU - Taniguchi, Kohachi AU - Taniguchi K FAU - Roy, Roland R AU - Roy RR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (HSP72 Heat-Shock Proteins) RN - 0 (Heat-Shock Proteins) RN - 0 (Protein Isoforms) RN - 83HN0GTJ6D (Cyclosporine) RN - EC 3.1.3.16 (Calcineurin) RN - EC 3.6.4.1 (Myosin Heavy Chains) SB - IM MH - Animals MH - Calcineurin/*metabolism MH - Cyclosporine/pharmacology MH - HSP72 Heat-Shock Proteins MH - Heat-Shock Proteins/*metabolism MH - Male MH - Muscle Fibers, Fast-Twitch/drug effects/pathology/physiology MH - Muscle Fibers, Slow-Twitch/drug effects/pathology/physiology MH - Muscle, Skeletal/drug effects/pathology/*physiology MH - Myosin Heavy Chains/metabolism MH - Organ Size/drug effects MH - Protein Isoforms/metabolism MH - Rats MH - Rats, Wistar MH - Time Factors MH - Up-Regulation/drug effects MH - Weight-Bearing/*physiology EDAT- 2005/04/06 09:00 MHDA- 2005/06/15 09:00 CRDT- 2005/04/06 09:00 PHST- 2005/03/01 00:00 [received] PHST- 2005/04/06 09:00 [pubmed] PHST- 2005/06/15 09:00 [medline] PHST- 2005/04/06 09:00 [entrez] AID - S0006-291X(05)00509-7 [pii] AID - 10.1016/j.bbrc.2005.03.049 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2005 May 13;330(3):706-13. doi: 10.1016/j.bbrc.2005.03.049. PMID- 26447688 OWN - NLM STAT- MEDLINE DCOM- 20161005 LR - 20220317 IS - 1872-7077 (Electronic) IS - 1382-6689 (Linking) VI - 40 IP - 3 DP - 2015 Nov TI - Estrogen receptor (ER)-α, β and progesterone receptor (PR) mediates changes in relaxin receptor (RXFP1 and RXFP2) expression and passive range of motion of rats' knee. PG - 785-91 LID - S1382-6689(15)30081-8 [pii] LID - 10.1016/j.etap.2015.09.004 [doi] AB - PURPOSE: The high risk of knee injuries in female may be associated with sex-steroid hormone fluctuations during the menstrual cycle by its effect on ligaments and tendons stiffness. This study examined changes in knee range of motion in presence of estrogen and progesterone and investigated the interaction of their antagonists to relaxin receptors. METHOD: Sixty WKY rats were divided into 10 different groups receiving 17β-estradiol (0.2, 2, 20 and 50 μg/kg), progesterone (4 mg/kg), estrogen receptor (ER) antagonist ICI 182/780, ERβ antagonist PHTPP, ERα antagonist MPP, and mifepristone in presence of estrogen and progesterone. Physiologic dose were injected subcutaneously 30 min before of hormone injection for 3 days consequently. Sham group received peanut oil (vehicle) also for 3 consecutive days. Following the treatment administrations, the knee range of motion and RXFP1/RXFP2 mRNA and protein expression were examined in the patellar tendon, lateral collateral ligament, and hamstring muscle. RESULTS: Our data showed that the knee range of motion was significantly increased in progesterone and high doses estrogen treatment but not significantly increased in low doses of estrogen treatment. The range of motion was decreased in the presence of estrogen receptor (ER) antagonist ICI 182/780, ERβ antagonist PHTPP, ERα antagonist MPP, and mifepristone, independently. CONCLUSION: Progesterone and high doses of estrogen treatment resulted in the highest range of knee laxity correlated to expression of both relaxin receptor isoforms in knee tissues. Our findings thus suggested that female subjects are more vulnerable toward non-traumatic knee injury due to estrogen and progesterone fluctuation as compared to male subjects. CI - Copyright © 2015 Elsevier B.V. All rights reserved. FAU - Dehghan, Firouzeh AU - Dehghan F AD - Department of Physiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Department of Exercise Science, Sports Centre, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: fir_dhn@yahoo.com. FAU - Yusof, Ashril AU - Yusof A AD - Department of Exercise Science, Sports Centre, University of Malaya, Kuala Lumpur, Malaysia. FAU - Muniandy, Sekaran AU - Muniandy S AD - Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. FAU - Salleh, Naguib AU - Salleh N AD - Department of Physiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Electronic address: naguib.salleh@yahoo.com. LA - eng PT - Journal Article DEP - 20150908 PL - Netherlands TA - Environ Toxicol Pharmacol JT - Environmental toxicology and pharmacology JID - 9612020 RN - 0 (1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole) RN - 0 (4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol) RN - 0 (Piperidines) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 0 (Receptors, G-Protein-Coupled) RN - 0 (Receptors, Peptide) RN - 0 (Rxfp1 protein, rat) RN - 0 (Rxfp2 protein, rat) RN - 0 (Steroids) RN - 22X328QOC4 (Fulvestrant) RN - 320T6RNW1F (Mifepristone) RN - 4G7DS2Q64Y (Progesterone) RN - 4TI98Z838E (Estradiol) SB - IM MH - Animals MH - Estradiol/administration & dosage/analogs & derivatives/pharmacology MH - Female MH - Fulvestrant MH - Hindlimb/*drug effects/physiology MH - Male MH - Mifepristone/administration & dosage/pharmacology MH - Piperidines/administration & dosage/pharmacology MH - Progesterone/administration & dosage/pharmacology MH - Pyrazoles/administration & dosage/pharmacology MH - Pyrimidines/administration & dosage/pharmacology MH - Range of Motion, Articular/*drug effects MH - Rats MH - Rats, Inbred WKY MH - Receptors, G-Protein-Coupled/*genetics/metabolism MH - Receptors, Peptide/*genetics/metabolism MH - Steroids/*administration & dosage/pharmacology OTO - NOTNLM OT - Estrogen OT - Knee laxity OT - Progesterone OT - Relaxin receptor EDAT- 2015/10/09 06:00 MHDA- 2016/10/07 06:00 CRDT- 2015/10/09 06:00 PHST- 2015/05/27 00:00 [received] PHST- 2015/09/04 00:00 [revised] PHST- 2015/09/05 00:00 [accepted] PHST- 2015/10/09 06:00 [entrez] PHST- 2015/10/09 06:00 [pubmed] PHST- 2016/10/07 06:00 [medline] AID - S1382-6689(15)30081-8 [pii] AID - 10.1016/j.etap.2015.09.004 [doi] PST - ppublish SO - Environ Toxicol Pharmacol. 2015 Nov;40(3):785-91. doi: 10.1016/j.etap.2015.09.004. Epub 2015 Sep 8.